RC
475
P66



THE NATIONAL CLEARINGHOUSE FOR MENTAL HEALTH INFORMATION

NATIONAL INSTITUTE OF MENTAL HEALTH

VOL. 13-Cumulative Index-June 1976

PSYCHOPHARMACOLOGY ABSTRACTS

RALPH BROWN DRAUGHON
AUBURN UNIVERSITY

U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE
PUBLIC HEALTH SERVICE
ALCOHOL, DRUG ABUSE, AND MENTAL HEALTH ADMINISTRATION

PSYCHOPHARMACOLOGY ABSTRACTS is a publication of the National Clearinghouse for Mental Health Information of the National Institute of Mental Health. It is a specialized information medium designed to assist the Institute in meeting its obligation to foster and support laboratory and clinical research into the nature and causes of mental disorders and methods of treatment and prevention. Specifically, this information service is designed to meet the needs of investigators in the field of psychopharmacology for rapid and comprehensive information about new developments and research results. For information or correspondence with the National Institute of Mental Health concerning *Psychopharmacology Abstracts*, changes of address, or removal of names from the mailing list see the inside back cover page.

The Secretary of Health, Education, and Welfare has determined that the publication of this periodical is necessary in the transaction of the public business required by law of this Department. Use of funds for printing this periodical has been approved by the Director of the Office of Management and Budget through December 31, 1976.

NATIONAL CLEARINGHOUSE FOR MENTAL HEALTH INFORMATION
PSYCHOPHARMACOLOGY ABSTRACTS

Volume 13

Cumulative Index

June 1976

	Page
Author Index	A1
Subject Index	S1

Carrie Lee Rothgeb, *Editor*
Bette L. Shannon, *Managing Editor*

U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE
Public Health Service

Alcohol, Drug Abuse and Mental Health Administration
National Institute of Mental Health
National Clearinghouse for Mental Health Information
5600 Fishers Lane
Rockville, Maryland 20852

Publication No. (ADM) 76-150
Printed 1976

For sale by the Superintendent of Documents, U.S. Government Printing Office, Washington, D.C. 20402. Subscription price per year in the United States, Canada, and Mexico: $16.90; other countries, $21.15. Single copy $3.70. Index issue $2.25. The Clearinghouse does not sell copies of *Psychopharmacology Abstracts*. Persons wishing to subscribe by the year or to purchase single copies should send their orders, accompanied by check or money order, directly to the Superindendent of Documents.

AUTHOR INDEX

0The 6-digit number is the abstract accession number. The next two digits are the issue number; digits after hyphen are the category number.

A

AARONS M 204403 02-15
ABBOTT NJ 217662 04-03
ABDALLAH AH 213282 03-03
ABDESSEMED H 219827 04-15
ABDINE H 206460 03-01
ABEL EL 217828 04-04
ABELES RH 205853 03-03, 207857 03-03
ABERNATHY CO 217796 04-03
ABOOD LG 197996 01-04
ABREU LA 200751 02-03
ABREU RR 200751 02-03
ABSAVA GI 198481 02-03, 223016 04-03
ABT K 207140 03-14
ABULADZE GV 206440 03-04
ABUZZAHAB FS 202764 02-15
ACHTE K 197276 01-17, 221989 04-08
ACKENHEIL M 204414 02-13, 206974 03-13
ADAMS PM 225520 04-14
ADAMS RG 206362 03-14
ADLAND ML 224749 04-09
ADLARD BPF 195906 01-04
ADLER R 197861 01-14, 197862 01-13
ADLER S 202921 02-15
ADVANI GB 200922 02-09
AESCHBACHER H 214109 04-03
AGARWAL MK 195448 01-03
AGEEL AM 212963 03-04
AGHAJANIAN GK 202370 02-03, 202464 02-03, 202788 02-04, 221131 04-03, 222805 04-03
AGID Y 210669 03-03, 210699 03-03
AGNOLI A 210213 03-09
AGRANOFF BW 213853 04-04
AGUILAR CL 200170 02-11
AGURELL S 217878 04-13
AHLENIUS S 197987 01-04, 200042 02-04, 202806 02-04, 217656 04-04
AHLFORS UG 221636 04-08
AHTEE L 194744 01-03, 197299 01-03, 204879 02-05, 217964 04-03
AIDA N 216391 04-15
AKATSU M 221741 04-02
AKCASU A 205546 02-03
AKINS F 223093 04-04
AL-SHALTCHI B 207283 03-03
ALOTSHULER RA 223012 04-03
ALBAUGH BJ 213702 04-12
ALBUS K 200078 02-03
ALDOUS FAB 196437 01-01
ALEKSANDROVSKIY YA 201909 02-14, 212431 03-17
ALEKSANDROWICZ MK 194573 01-15
ALEKSEYEVA LP 201888 02-03, 219749 04-03
ALEKSIDZE NG 213469 04-04
ALEXANDER SF 193039 01-15
ALFREDSSON G 215734 04-03
ALHAVA E 197927 01-03, 210891 03-03
ALINO JJL 204408 02-09
ALINO JML 204408 02-09
ALLAIN P 210791 03-03
ALLEN JJ 214833 04-10
ALLEN LE 206808 03-02
ALLEN M 210808 03-14
ALLEN MP 197474 01-03, 211065 03-03
ALLEN RP 209132 03-17, 224379 04-14
ALLEON AM 211998 03-11
ALLEVA FR 193421 01-03
ALLEVA JJ 193421 01-03
ALLIKMETS LK 198483 02-04
ALLSOPP M 201513 02-09, 218556 04-09
ALMAZOV BN 201910 02-08
ALMLI CR 219071 04-04
ALPERN HP 198222 02-04
ALPERT M 221036 04-01
ALTIKHOVA LB 206438 03-02
ALTMAN H 215251 04-17
ALTMAN N 213918 04-09
ALTMANN KP 197295 01-03
ALTSZULER N 215666 04-03
ALVEZ DE SOUZA W 212215 03-17
AMAN MG 218118 04-14
AMBROSINO SV 194511 01-15
AMIN M 198053 01-07
AMIT Z 195113 01-04, 198226 02-04, 202740 02-04
AMMON HL 220951 04-01
ANANTH J 194168 01-09, 200898 02-08, 208918 03-17
ANCONA L 209527 03-14
ANDEN N 195429 01-03, 195439 01-03, 195440 01-03, 198207 02-03, 207299 03-03
ANDERSON D 201843 02-04
ANDERSON JA 215060 04-10
ANDERSON JAD 207486 03-04
ANDERSON PO 213702 04-12
ANDERSON RJ 197989 01-03
ANDERSON TR 210933 03-03
ANDERSSON PG 221561 04-11
ANDREEVA NI 206438 03-02
ANDREOLI V 210213 03-09, 210500 03-08, 210501 03-09
ANDREWS G 205318 02-09
ANDREYEVA NI 219497 04-03
ANGGARD E 217549 04-14
ANGOFF G 197831 01-13
ANGRIST B 207285 03-14, 225065 04-14
ANGST J 196039 01-11, 204899 02-10, 208919 03-17, 217450 04-09, 221822 04-08
ANISMAN H 202203 02-03
ANKIER SI 193446 01-04
ANOKHINA IP 216999 04-12
ANSON JE 198457 02-04
ANTKIEWICZ L 217815 04-03
ANTON AH 210786 03-06
ANTONACCIO MJ 210868 03-05, 215757 04-03
ANTONELLI F 209795 03-10, 209857 03-14
ANTOPOL W 194153 01-03
AOKI N 211304 03-08
AOYAMA K 210241 03-09
APPEL JB 194178 01-04, 201321 02-04
APPELT M 195037 01-11
APPLETON WS 209753 03-17
APRISON MH 225161 04-04
AQLEH KA 215669 04-13
ARAKI Y 215723 04-03
ARAV VI 219110 04-04
ARCHIBALD JT 204185 02-03
ARDIZZONE EC 210288 03-11, 210291 03-14, 210293 03-14, 210296 03-14
AREFOLOV VA 223017 04-03, 224115 04-03
ARELLANO M 207771 03-14
ARESH B 198119 02-07
ARIYANAYAGAM AD 217473 04-03
ARMSTRONG B 194063 01-13
ARNETOLI G 204372 02-07
ARNOLD LE 210809 03-09
ARNOLD OH 204410 02-15
ARNOLD RC 194827 01-14
ARON-ROSA D 209998 03-15
ARONOW WS 215670 04-15
AROYAN AA 219663 04-03
ARROYO GH 205442 02-13
ARSHANYAN EB 219332 04-04
ARTEMENKO GN 223016 04-03
ARUSHANYAN EB 198835 02-03, 200565 02-03, 202598 02-04, 219510 04-13, 223014 04-03, 224467 04-04
ARVELA P 215160 04-05
ASAI K 213293 03-10
ASAKURA T 197211 01-03
ASAMI Y 206780 03-02, 221741 04-02
ASAO H 200009 02-11
ASBERG H 213434 04-04
ASBERG M 224834 04-09
ASBOE-HANSEN G 199897 02-03
ASCHOFF JC 204395 02-16, 221271 04-14
ASHER IM 202788 02-04
ASKAROV AA 224383 04-08
ASKER T 221306 04-09
ASKEVOLD F 206601 03-09
ASKEW WE 194925 01-03
ASNES DP 208575 03-11
ASPER H 217462 04-03, 217543 04-03
ASTIC L 221049 04-04
ASTRADA CA 202722 02-05
ASTRUP C 212238 03-08
ATACK C 195238 01-01
ATKINSON J 214109 04-03
AUBERT C 218953 04-14, 225558 04-03
AUDISIO M 210088 03-14, 212774 03-14
AUGENBRAUN CB 211512 03-04
AURIEL B 206836 03-04
AVAKYAN RM 219332 04-04
AVALLONE DM 213786 04-11
AVANT GR 197951 01-13
AVRUTSKIY GY 201908 02-08, 224083 04-09
AXELROD J 196804 01-03, 224096 04-03
AXELSSON R 221629 04-13
AYD FJ 196674 01-07, 196679 01-09, 201241 02-17, 209901 03-09, 218152 04-17, 225325 04-08
AYHAN IH 197483 01-04
AYLLON T 225455 04-14
AYVAZASHVILI IM 219745 04-04
AYVAZOV KG 198835 02-03
AZARNOFF DL 202662 02-03
AZBEKOYAN SG 201915 02-04
AZCARATE CL 209128 03-11
AZZARO AJ 202191 02-03

B

BAASTRUP PC 224835 04-09
BABBINI M 197453 01-03, 202765 02-03
BABINGTON RG 197459 01-13
BACK G 202796 02-03
BADAWI M 206977 03-14, 221339 04-14
BADER H 197976 01-13
BADSHA H 195618 01-10
BAEZ LA 196370 01-04
BAGADIA VN 196707 01-08
BAGGOT JD 197456 01-03
BAILE CA 206727 03-04
BAILEY EV 213398 04-03
BAILEY PT 212964 03-04
BAILEY RI 214838 04-10, 215158 04-10
BAJGAR J 205632 03-03
BAKER JC 200004 02-03, 210870 03-02, 210922 03-03, 217879 04-03
BAKER SP 197302 01-03
BAKER WW 213601 04-03, 217669 04-03
BAKOUCHE P 207533 03-15
BAKUNYAEVA AG 198479 02-02
BALAKLEEVSKY A 210776 03-03
BALAN G 212161 03-09
BALAVADZE MV 213469 04-04
BALAZS R 197965 01-03, 210780 03-03
BALAZS T 193421 01-03
BALDESSARINI RJ 199788 02-03, 199958 02-04, 204164 02-15, 204340 02-03, 207288 03-03, 211416 03-15, 213401 04-03, 222813 04-03
BALDWIN DM 210662 03-03
BALL JRB 200581 02-09
BALLARD JE 221934 04-11
BALLENTINE RJ 222804 04-03
BALLINGER BR 194409 01-17, 200049 02-13, 210437 03-17, 222603 04-15
BALSAMO A 220951 04-01
BALSTER RL 197863 01-04
BALTER MB 198048 01-17
BALTHAZART J 199461 02-04
BALTZER V 197447 01-03, 218954 04-04
BALZAMO E 199764 02-03
BAMBASOVA E 205606 03-11
BAMONTI F 215681 04-15
BAN TA 194168 01-09, 198053 01-07, 202787 02-08, 206603 03-08, 211432 03-09, 215699 04-09, 216184 04-15, 219537 04-08
BANCROFT J 196958 01-14
BANERJEE U 195430 01-04, 217465 04-04
BANIC B 197581 01-03
BANNA NR 217874 04-03
BANSA AN 200922 02-09
BANT W 204236 02-15, 221650 04-09
BARAM DA 209787 03-07
BARBEAU A 203494 02-15
BARCHAS JD 207496 03-01, 217664 04-03
BARDIN P 194071 01-09
BAREGGI SR 197868 01-03, 221188 04-03
BARFKNECHT CF 202109 02-02, 208593 03-12, 210867 03-05

BARKER JL 213395 04-03
BARKER LA 217869 04-03
BARKOV NK 198488 02-06
BARNES E 204485 02-03
BARNES L 195094 01-03
BARO F 207000 03-14
BARON M 201000 02-09
BARONDES SH 203572 02-04, 215705 04-03
BARRASS BC 196437 01-01
BARRATT ES 197473 01-03, 225520 04-14
BARRETT JE 214013 04-04
BARRETT RJ 206741 03-04
BARRY H 200043 02-04
BARTH N 197277 01-03, 197939 01-03, 217657 04-03
BARTHOLINI E 221659 04-09
BARTHOLINI G 192933 01-03, 197950 01-03, 217685 04-03, 219631 04-06, 223174 04-03
BARTHOLOW RM 222634 04-01
BARTI L 217460 04-10
BARTIZAL F 200064 02-03
BARTLETT P 213387 04-07
BARTOL CR 210680 03-14
BARTOLETTI M 197453 01-03, 202765 02-03
BARTOSOVA M 205579 02-03
BARTOSZEWSKI J 203741 02-15
BARZAGHI F 199912 02-05
BASKER MA 207486 03-04
BASKIN SI 195089 01-04
BASMADJIAN GP 210887 03-03
BASS E 210793 03-03
BASSETT JR 210784 03-04
BASTECKY J 205581 02-08, 205594 02-15, 217204 04-13
BASTIE Y 202514 02-09
BASU P 217880 04-05
BASURAY BN 199870 02-03
BATESON PPG 210667 03-04
BATTEGAY R 207140 03-14
BATTENBERG ELF 217550 04-16
BATTIG K 225559 04-04
BATTISTIN L 217858 04-03
BATURIN VA 224467 04-04
BAUER G 200573 02-15
BAUER M 198048 01-17, 205596 02-15
BAUM M 198226 02-04
BAUM T 215712 04-03
BAUMANN U 196039 01-11
BAUMGARTEN HG 217555 04-03
BAXLEY GB 194655 01-14
BAY KS 223394 04-14
BAZEMORE RP 197815 01-05
BAZHIN EF 224085 04-08
BEATON JM 194929 01-03, 207293 03-08, 213528 04-04, 224353 04-17
BEAUJOUAN JC 210669 03-03, 217658 04-03
BEAULAC-BAILLARGEON L 205169 02-03
BEAUMONT G 215153 04-15
BECH P 205931 03-12
BECHTEL WD 197940 01-03
BECK L 225382 04-14
BECK-FRIIS J 210434 03-10, 221638 04-10
BECKER BA 217694 04-05
BECKER W 197975 01-03, 204395 02-16, 221271 04-14
BECKETT PR 197305 01-03
BECKMANN H 196042 01-09, 206974 03-13, 206985 03-13, 207443 03-13, 221045 04-09
BECKMANN MKF 225529 04-02
BEDNAR J 205611 03-15
BEECHAM IJ 206358 03-04
BEELER GW 210700 03-03
BEHAGEL H 213595 04-16
BEHAVIORAL SCIENCES TAPE LIBRARY CSI 200231 02-17
BEHRENDT WA 199209 02-02
BEIER R 203666 02-08, 208622 03-08
BEIGEL A 199631 02-09
BEIN HJ 197447 01-03, 207099 03-17
BEJ AJ 195560 01-01
BEKERSKY I 200737 02-16
BELAND C 215701 04-08
BELESLIN DB 202780 02-04, 202781 02-04
BELKNAP JK 202983 02-04
BELL JA 197814 01-03
BELL PJ 216462 04-10
BELL RD 195091 01-03
BELL SC 200739 02-01
BELLEZA T 213764 04-08, 217454 04-08
BELLIN JS 204864 02-03
BELLUZZI JD 210671 03-04
BELLVILLE JW 215669 04-13
BELLWINKEL S 215695 04-05
BELOZERTSEV YA 198835 02-03, 202598 02-04
BELSANTI R 195533 01-09
BEN-ARI Y 217872 04-03
BEN-ZVI Z 195114 01-03, 217817 04-03
BENAIM S 209070 03-09
BENEDITO MAC 217829 04-04
BENES V 205604 03-03
BENESOVA O 196776 01-16, 205604 03-03, 205627 03-14, 217258 04-13
BENJAMIN AM 196800 01-03
BENNETT EL 202202 02-04
BENNETT JL 194155 01-03, 202464 02-03
BENNETT R 193423 01-03, 193424 01-03
BENSON R 213783 04-15
BENTE D 203840 02-14, 206805 03-07, 221288 04-16, 221724 04-13
BENTHE HF 221860 04-03
BENTON D 193545 01-04
BENZ M 197941 01-03
BERENDSEN H 197499 01-04
BERFKNECHT CF 210921 03-03
BERG I 201513 02-09
BERGEN JR 195114 01-03, 210897 03-08
BERGENER M 221337 04-10
BERGER P 194827 01-14
BERGER R 213855 04-03
BERGHEIM-IRPS E 197279 01-01
BERGLING R 209790 03-08
BERGMANN K 194244 01-11
BERKALOFF A 199425 02-04
BERL S 195048 01-03, 213602 04-03
BERLIN C 210793 03-03
BERLINER J 212165 03-09
BERMAN W 216339 04-11
BERNARD J 206787 03-04
BERNARDINI B 208981 03-08
BERNER P 196034 01-17
BERNST SF 197278 01-03
BERNSTEIN JE 202824 02-11
BERRY DJ 194854 01-13
BERTELE R 200738 02-01
BERTOGAYEVA VD 218472 04-04
BEST K 203600 02-09
BEUMONT P 218557 04-15
BEVAN P 199961 02-03
BEYER C 217846 04-04
BEYL HH 197942 01-03
BHAGAT B 207333 03-03
BHANDARI DS 207164 03-02
BHARGAVA AK 195249 01-03
BHARGAVA KP 195249 01-03
BHARGAVA V 195548 01-03
BIAMINO G 204400 02-05
BIANCHI P 195931 01-09
BIANCHI S 210668 03-03
BICKEL P 214009 04-09
BIEGER D 202778 02-03
BIENER R 195055 01-13, 224830 04-13
BIGGER JT 215014 04-13
BIGGIO G 215654 04-03
BIGLER ED 201409 02-03, 222644 04-03
BIGNOTTI N 211202 03-11
BILKOVA J 205606 03-11
BILLE U 197945 01-03
BILOTTA M 212277 03-13, 212281 03-14
BILY J 205609 03-09
BIRCH H 224830 04-13
BIRCH NJ 223318 04-09
BIRNBAUM D 196188 01-13
BISHOP G 216188 04-08
BJEGOVIC M 210766 03-03
BJERKENSTEDT L 221639 04-11
BJORUM N 221417 04-15
BLACK D 205315 02-15
BLACK IB 210670 03-03
BLACKER KH 216190 04-08
BLACKMAN DE 195433 01-04, 225149 04-04
BLACKSHEAR MA 193423 01-03, 193424 01-03
BLACKWELL B 211435 03-17, 218154 04-17
BLACKWELL LA 196025 01-03
BLAINE J 224906 04-04
BLANC G 195239 01-03, 210800 03-03, 217687 04-03
BLANC M 208631 03-08
BLASIG J 195246 01-03, 200053 02-03, 206988 03-03
BLEULER-HERZOG M 204899 02-10
BLIZARD DA 225081 04-04
BLOCK C 192988 01-11
BLOMGREN B 216965 04-15
BLONDAUX C 215702 04-03, 215703 04-03
BLONDE L 202922 02-15
BLOOM AS 219288 04-03
BLOOM F 218148 04-03
BLOOM FE 217550 04-16, 217552 04-04, 218300 04-03, 222353 04-06, 225152 04-17
BLOSSER JC 199277 02-03
BLUM RH 202861 02-17
BLUMBERG AG 195916 01-09
BLUMBERG JB 203032 02-03, 210771 03-03
BLUMBERG MZ 200492 02-15
BLUMENKRANTZ N 199897 02-03
BLUMENTHAL DS 193073 01-16
BLUMER D 209131 03-11
BLUNDELL JE 197865 01-04, 210748 03-04, 217883 04-04
BOAKES RJ 197829 01-03
BOARD RD 195053 01-13
BOBON DP 213597 04-17
BOBON J 212162 03-09, 212163 03-10
BOCCI U 211202 03-11
BOCKNIK SE 197454 01-04, 197464 01-03
BODIN N 199621 02-13
BODZENTA A 210872 03-03, 215749 04-04
BOECK V 210892 03-03, 210893 03-03
BOGDAN-PATAKI N 207140 03-14
BOGDANOFF BM 217668 04-15
BOGDANOV KY 198434 02-03
BOGETTO F 225564 04-04
BOGGAN WO 221044 04-12
BOHACEK N 198327 02-17
BOHR WA 213395 04-03
BOHUON C 196593 01-03, 210349 03-04
BOHUS B 197584 01-03
BOIREAU A 217655 04-03
BOISSIER J 197986 01-03, 217477 04-09
BOLIAN GC 196231 01-17
BOLMAN WM 211425 03-15
BOLT AG 195118 01-03, 202312 02-01
BONACCORSI A 221188 04-03
BONCINELLI A 209144 03-09
BOND A 193851 01-14
BOND AJ 195443 01-15, 209079 03-10, 209080 03-10
BOND PA 224424 04-09
BONDARENKO TT 216999 04-12
BONN JA 201896 02-10
BONNAY MM 196593 01-03
BONOLLO L 209701 03-08
BOOKER HE 195494 01-04, 205491 02-03, 225538 04-15
BOONYAVIROJ P 199869 02-03
BOOTH DA 200054 02-04
BORBELY AA 209981 03-14
BORD M 206836 03-04
BORDA RP 199756 02-13
BORDELEAU J 207052 03-17
BOREN JA 217793 04-03
BORENDAL-JANSSON B 192988 01-11
BORG J 221036 04-01
BORG KO 199621 02-13
BORGEN LA 200036 02-04, 215726 04-03
BORISENKO SA 219748 04-04
BORODULINA OV 202925 02-13
BOROWITZ JL 193455 01-03
BORSELLI S 216761 04-09
BORSY J 197570 01-03, 197859 01-04
BORZEIX MG 218164 04-03
BOS ERH 198229 02-09
BOST J 210743 03-04
BOTTICELLI MG 196231 01-17
BOTWINICK CY 206752 03-04
BOUCEK J 205638 03-10
BOUCHARD M 215701 04-08
BOUCHARDY M 216761 04-09
BOUCHER R 213450 04-03
BOUCSEIN W 204405 02-14
BOULIN J 209784 03-11
BOULU R 204220 02-03, 210349 03-04
BOURDOIS PS 211102 03-03
BOURDOUXHE S 212162 03-09, 212163 03-10, 213597 04-17
BOURGOIN S 217655 04-03

BOUSQUET WF 206912 03-03
BOUVIER JB 216464 04-11
BOVET D 202861 02-17
BOVET-NITTI F 221052 04-04
BOWEN FP 222871 04-14
BOWERS MB 195924 01-09, 198210 02-03, 202248 02-09, 204852 02-08, 206336 03-03
BOYARCHUK ZI 202925 02-13
BOYD AE 197831 01-13
BOYD EH 222819 04-03
BOYD ES 222819 04-03
BOYD M 218120 04-09
BOYD WD 223777 04-15
BOYNS AR 223777 04-15
BOZZETTI L 224906 04-04
BOZZOLI A 210506 03-10
BRADLEY RJ 194929 01-03, 213528 04-04
BRADSHAW CM 199961 02-03
BRAGA PC 200045 02-03
BRAILOWSKY S 205443 02-13
BRAITHWAITE RA 202699 02-13
BRAL E 212211 03-09
BRALET J 197461 01-03
BRAMBILLA F 210500 03-08
BRAMWELL GJ 202718 02-03, 210789 03-03
BRANCHEY M 194044 01-08
BRANDAO F 193139 01-03
BRANDLI A 207283 03-03
BRANZEI P 212161 03-09
BRAUDE MC 193417 01-05, 193576 01-04, 217518 04-05, 217519 04-04
BRAUN G 215710 04-13
BRAUN J 222772 04-10
BRAUN M 199640 02-11
BREAKEY WR 202693 02-08
BREESE GR 193304 01-03, 213603 04-03, 215692 04-03, 217218 04-04
BREMER DA 206360 03-14
BRETAS AD 199962 02-03
BREULET M 212162 03-09, 212163 03-10
BREWSTER JM 210739 03-04
BREYER U 200738 02-01, 206976 03-13
BRIDGES SR 210850 03-03
BRIGHT TP 211015 03-05
BRISKIN AI 198479 02-02
BROADHURST PL 217525 04-04
BROEKER H 203704 02-14
BROEKKAMP CLE 210772 03-03, 217530 04-04
BROOK C 210763 03-04
BROOKE SM 213394 04-03, 217854 04-03
BROPHY PD 193434 01-04
BROUSSOLLE P 210126 03-09
BROVERMAN DM 205437 02-03
BROWN BW 210829 03-13
BROWN CC 199518 02-14
BROWN CR 210829 03-13
BROWN DJ 193419 01-03, 211015 03-05
BROWN F 217961 04-03
BROWN IR 220314 04-03
BROWN LE 222819 04-03
BROWN M 219970 04-17
BROWN R 202806 02-04, 217797 04-03
BROWN RM 217459 04-04, 217852 04-03
BROWN WT 219536 04-08
BROWNE RG 201320 02-02
BROWNE TR 201870 02-11
BROWNSTEIN M 210661 03-03
BRUCK J 202785 02-07
BRUDERLEIN FT 208592 03-01
BRUNELLE R 215701 04-08
BRUNK SF 209787 03-07
BRUNO W 211203 03-14
BRUS R 197449 01-03
BRUSCKY SB 205945 03-14
BRUUN RD 224910 04-11
BRUWER J 218557 04-15
BUCCI L 215665 04 04
BUCH HP 193140 01-01
BUCHAR E 200002 02-03
BUCHER M 192936 01-03
BUCHER UM 215159 04-03
BUCHNESS R 197992 01-13
BUCHSBAUM M 201000 02-09
BUCHWALD WF 210850 03-03
BUCKETT WR 221048 04-04
BUCKHOLTZ NS 195226 01-04, 217833 04-04
BUCKLEY JP 199964 02-03
BUCZKO W 217693 04-03, 217890 04-03
BUDA M 215702 04-03
BUDD RD 222829 04-06
BUDINSKA K 205606 03-11
BUEDING E 194155 01-03
BUENO JR 205945 03-14
BUGGE A 221306 04-09
BULOON VV 208973 03-03, 217065 04-03, 219506 04-03
BULAT M 192925 01-03
BULAYEV VM 217649 04-03
BUNNEY BS 202370 02-03, 207294 03-03, 221131 04-03
BUNNEY WE 210602 03-14, 215860 04-16, 216373 04-09
BUNTING PR 222804 04-03
BURCHARD J 205765 03-13
BURGER A 197280 01-03, 197942 01-03
BURGER H 207140 03-14
BURGOYNE RW 224908 04-08
BURKARD WP 192933 01-03, 223174 04-03
BURKE R 193073 01-16
BURKI HR 206973 03-03, 217462 04-03, 217543 04-03
BURKS JS 202919 02-15
BURNS D 207444 03-13
BURNS MM 222871 04-14
BURNS MO 217356 04-13
BURNS TC 220681 04-04
BUROV YV 215789 04-04, 218814 04-04, 219748 04-04, 223064 04-04
BURROWS EP 202417 02-03
BURROWS G 198029 01-09, 209234 03-15
BURSTEIN S 195114 01-03, 217795 04-03, 217817 04-03
BURTON P 216769 04-09
BUSACCA DOLLEO C 210286 03-14, 210288 03-11, 210291 03-14, 210293 03-14, 210296 03-14
BUSCHSENSCHUTZ E 217477 04-09
BUSER P 209728 03-03, 210740 03-03
BUSH MS 217463 04-04
BUSHING JA 208553 03-03
BUSSATO PA 197495 01-03
BUT PG 201909 02-14
BUTCHER LL 193303 01-03, 194152 01-04, 195452 01-04, 197931 01-03, 217670 04-04
BUTTER HJ 208920 03-14
BUXTON DA 196437 01-01
BUYET L 204372 02-07
BUZNIKOV GA 219663 04-03

C

CABIBBE F 210500 03-08, 210501 03-09
CABROL G 217171 04-09
CACCIA S 198211 02-03
CAFFEY EM 193068 01-09, 193291 01-11, 194355 01-09, 196678 01-07, 197531 01-09, 215009 04-11, 224872 04-09
CAHN J 218164 04-03
CAILLARD C 197461 01-03
CAILLEUX A 210791 03-03
CAIRNCROSS KD 210784 03-04
CALANDRA JC 193429 01-03
CALDEIRA MV 205945 03-14
CALDERINI G 197868 01-03
CALDWELL J 198028 01-12, 200007 02-14, 217690 04-03, 217691 04-03
CALHOUN WH 194133 01-04, 202769 02-04
CALIARI S 221723 04-02
CALIL HM 217528 04-06
CALLAGHAN M 214067 04-04
CALLEJA J 205520 02-13
CALO A 195533 01-09
CALVERT A 202966 02-13
CALVO JM 205443 02-13
CALZADA ZJ 205442 02-13
CAMERON BD 206806 03-13
CAMERON JD 218553 04-11
CAMERON R 208325 03-08
CAMPBELL BA 218498 04-04
CAMPBELL M 198061 01-07, 225335 04-15
CANAFAX DM 196227 01-04
CANAL O 194758 01-11
CANDY JM 197829 01-03
CANNON JG 210888 03-03
CANTER A 209787 03-07
CAPOBIANCO S 195992 01-03
CAPPELL H 217765 04-04
CAPPELLETTI SR 219960 04-09
CAPSTICK N 211433 03-10, 214829 04-10, 214834 04-15, 215155 04-10
CARCASSONNE M 218165 04-14
CARDO B 213431 04-04, 220946 04-04
CARENZI A 197124 01-03, 221732 04-13
CAREY MS 209488 03-10
CAREY RJ 195090 01-04, 206733 03-04
CARLE R 204169 02-08
CARLINI EA 197867 01-14, 210325 03-04
CARLSON RH 206745 03-04
CARLSOO B 216968 04-03
CARLSSON A 195950 01-03, 197583 01-03, 207290 03-03, 217797 04-03, 217852 04-03, 221385 04-09
CARLSSON C 192988 01-11
CARLTON PL 195079 01-04, 225158 04-17
CARMAN JS 202886 02-14
CARNEY M 212491 03-08
CAROLI F 216767 04-15
CARPENTER RL 203847 02-14
CARPENTER WT 224790 04-17
CARR JC 225399 04-17
CARRARA S 221304 04-10
CARRAZ G 216761 04-09
CARRIE JRG 199756 02-13
CARRUTHERS-JONES DI 217452 04-11
CARSON VG 208555 03-03
CARTER MF 217557 04-12
CARTWRIGHT C 197811 01-03
CARUSO D 210513 03-11
CARVALHO FV 197463 01-03, 197495 01-03, 217532 04-04
CASACCHIA M 210213 03-09
CASARDI D 205470 02-13
CASE W 216462 04-10
CASH RJ 225566 04-04
CASS J 196958 01-14
CASSANO GB 209701 03-08, 221304 04-10
CASSIDY J 215670 04-15
CASTAIGNE P 199757 02-13
CASTELLANI A 221272 04-14
CASTELLANO C 221032 04-03, 221037 04-03, 221040 04-04, 225557 04-04
CASTELLANOS G 205505 02-13
CASTELLI J 216759 04-08
CASTROGIOVANNI P 209701 03-08, 221304 04-10
CATALANO A 209147 03-08
CATHALA JP 199757 02-13
CATRAVAS GN 199277 02-03
CATS VM 223120 04-15
CATTABENI F 207289 03-06
CAVALCA GG 209144 03-09
CAVERO I 199964 02-03
CAVNESS C 199640 02-11, 215740 04-14
CAWOOD D 204189 02-06
CAZZULLO CL 210500 03-08, 210501 03-09
CELESIA GG 193797 01-03, 195494 01-04, 205491 02-03
CELSEN B 197954 01-03
CELY W 195117 01-03, 198021 01-03, 200035 02-03
CENTA DM 211883 03-04
CERBO R 210213 03-09
CERNY M 215070 04-13
CERONE G 202272 02-11
CERVANTES M 217846 04-04
CERVENKA J 217204 04-13
CESA-BIANCHI M 221269 04-10
CESKOVA E 205582 02-08, 205600 02-09
CHADWICK D 211470 03-14
CHAFIK M 213595 04-16
CHALOUPKA Z 196758 01-04
CHAMBERLAIN A 193039 01-15
CHAN S 210903 03-03
CHAN TL 224831 04-08
CHANCE WT 222638 04-04
CHANDLER BJ 198457 02-04
CHANDRA O 206787 03-04
CHANNABASAVANNA SM 198119 02-07
CHAPMAN LF 221340 04-04
CHAPMAN LJ 208325 03-08
CHAPPELL EB 211069 03-01
CHARALAMPOUS KD 217154 04-08
CHARNESS ME 202740 02-04
CHARTIER J 218564 04-11
CHASE GJ 215690 04-03
CHASE TN 194542 01-13, 215674 04-13
CHASSAN J 221165 04-15
CHASSEAUD LF 206806 03-13

CHATURVEDI AK 225105 04-01
CHAUDHARI A 225105 04-01
CHEADLE J 200636 02-08
CHEN R 193797 01-03
CHENEY DL 202465 02-06, 207500 03-03, 210885 03-06, 213399 04-03
CHENG HC 197481 01-04, 210867 03-05, 210921 03-03
CHERKSEY BD 215666 04-03
CHERNIK DA 195918 01-09, 206333 03-09
CHERPIN MP 216464 04-11
CHESHER GB 206355 03-04
CHETVERIKOV DA 219747 04-03
CHIBRIKIN VM 201909 02-14
CHICHKANOV GG 223018 04-03
CHIHARA K 214885 04-13
CHIN JH 195248 01-03
CHINERMAN J 198612 02-04
CHINNIAN R 195621 01-10
CHIPPENDALE TJ 199805 02-03
CHIUEH CC 195049 01-03, 200313 02-03, 204865 02-02, 214110 04-03, 217456 04-03
CHLOPOCKA M 202786 02-09
CHMELAR M 215065 04-09
CHO AK 222822 04-03
CHO DW 215251 04-17
CHO HW 206332 03-08
CHO JB 193422 01-03
CHOI RL 217551 04-04, 220472 04-03
CHOPRA YM 215664 04-03
CHOU DT 199811 02-03
CHOUDHURY PC 206043 03-10
CHRIST W 197281 01-01
CHRISTENSEN AV 210892 03-03
CHRISTENSEN DE 202356 02-11
CHRISTENSEN JD 210973 03-03
CHRISTENSEN S 210782 03-03, 210833 03-05
CHRISTIAN ST 195054 01-03
CHRISTIANI E 204468 02-17
CHRISTIANSEN J 198209 02-03, 210834 03-03, 215671 04-13
CHRISTIANSEN PA 210819 03-03, 210826 03-03
CHRISTY D 209897 03-04
CHURCHILL L 208555 03-03
CHUTA M 217354 04-09
CHUTE DL 201125 02-04
CICCHETTI V 200445 02-08
CICERO TJ 195091 01-03
CIESIELSKI L 198135 02-03
CIMICA M 209795 03-10
CIRIA MG 217685 04-03
CIRIGNOTTA F 202272 02-11, 208983 03-16
CISIN IH 198105 02-17
CIUREZU T 205585 02-08, 205614 03-10
CLAGHORN JL 194860 01-08
CLANCY JJ 222736 04-04
CLARK EL 194045 01-10
CLARK ML 195039 01-13, 209905 03-08, 217810 04-08
CLARK MSG 199868 02-03
CLARK WG 211436 03-08, 221737 04-03
CLARKE DD 195048 01-03
CLAYTON FG 209789 03-13
CLEMENS J 206354 03-03, 220973 04-13
CLEMENTS TH 210850 03-03
CLINESCHMIDT BV 193546 01-04, 222804 04-03
CLOQUETTE R 212166 03-10
CLOUET DH 195116 01-03
COCCAGNA G 202272 02-11
COCHRANE C 195918 01-09, 195931 01-09
COCKE JG 208325 03-08
COFFIN DL 204862 02-02
COHEN EL 217399 04-03
COHEN G 210882 03-02, 215756 04-03
COHEN GH 206933 03-08
COHEN N 205264 02-14
COHEN NH 201287 02-15
COHEN WJ 201287 02-15
COHEN Y 210788 03-03, 210884 03-03, 220977 04-03
COHN M 193426 01-03, 222814 04-04
COHN ML 193426 01-03, 222814 04-04
COHN RA 197473 01-03
COLDWELL BB 220950 04-05
COLE EN 223777 04-15
COLE JO 193040 01-09, 194834 01-10, 198062 01-07, 207922 03-17, 208574 03-11, 218217 04-11, 221563 04-17
COLE SO 205263 02-14
COLEMAN JH 206941 03-13
COLEMAN M 198423 02-11, 207788 03-08
COLGAN A 214836 04-10
COLLARD KJ 199966 02-03
COLLETTE J 223949 04-17
COLLIER HOJ 202194 02-13
COLLINS P 207446 03-09
COLLU R 209840 03-03
COLON EJ 218957 04-03
COLONNA L 202029 02-17, 221667 04-09
COLPAERT FC 200039 02-04, 210931 03-04
COMAZZI A 209045 03-11
COMSTOCK BS 224719 04-15
COMSTOCK EG 224719 04-15
CONNELLY JF 217470 04-04
CONNELLY JM 217470 04-04
CONNERS CK 198085 02-11
CONNOR JD 214716 04-03
CONROY CA 197474 01-03
CONSBRUCH U 204392 02-09, 204402 02-13
CONSOLO S 210668 03-03
CONSROE PF 223093 04-04
CONSTANTINIDES SM 205851 03-03
CONSTANTINIDIS J 225558 04-03
CONTI L 209701 03-08
CONTRERAS CM 205443 02-13
COOK L 225171 04-04
COOK PG 217531 04-04
COOK TH 194860 01-08
COOLS AR 199864 02-04, 217530 04-04
COON K 202987 02-04
COOPER BR 215692 04-03, 217218 04-04
COOPER JR 225152 04-17
COOPER RM 222265 04-04
COOPER S 202987 02-04
COOPER TB 194758 01-11
COPER H 197858 01-03, 197961 01-03
COPPEN A 203592 02-09
CORBETT L 195054 01-03
CORCORAN ME 195113 01-04, 195907 01-03
CORDERO FUNES JR 205435 02-13
CORRODI H 210857 03-03
CORSO EA 209044 03-11
COSTA E 194541 01-03, 196588 01-03, 196590 01-03, 197124 01-03, 201491 02-06, 202465 02-06, 202717 02-03, 207500 03-03, 207798 03-03, 208636 03-03, 208735 03-03, 210885 03-06, 213399 04-03, 213715 04-17, 213716 04-17, 215688 04-03, 217219 04-06, 217853 04-03, 217873 04-03, 217888 04-03, 218149 04-03, 225058 04-13, 225307 04-03
COSTALL B 193450 01-03, 195250 01-03, 195252 01-03, 197929 01-04, 197930 01-04, 199911 02-04, 202792 02-04, 210754 03-04, 217472 04-03, 217547 04-04, 217660 04-04, 217671 04-04
COSTELLO WH 220510 04-14
COSTILOE JP 209905 03-08
COSYNS P 219961 04-09
COTMAN CW 199805 02-03, 208555 03-03
COTT JM 215692 04-03
COTTEREAU M 216758 04-09, 221667 04-09
COTTRELL GA 217825 04-03
COUNSELL RE 210886 03-04, 210887 03-03
COUTEAUX F 207151 03-11
COVEZZI E 209144 03-09
COVI L 198078 02-10, 209132 03-17, 224767 04-10
COWAN A 210923 03-03
COWARD JK 213604 04-03
COX RH 206808 03-02, 219756 04-17
COX RS 225560 04-04
COX T 192951 01-04, 197995 01-04, 214016 04-04
COYLE IR 225563 04-04
COYLE JT 196804 01-03
CRABBE JC 193581 01-04
CRABTREE JM 220644 04-04
CRABTREE R 220973 04-13
CRAIG SC 198020 01-11
CRAIGMILL AL 196227 01-04
CRAMER H 205446 02-13
CRAMMER J 203546 02-15, 209350 03-13
CRANDALL P 197992 01-13
CRANE AM 225560 04-04
CRANE G 203546 02-15, 207921 03-17
CRANKSHAW DP 195248 01-03
CRAWFOR RD 197742 01-03
CRAWFORD IL 214716 04-03
CRAWFORD R 221657 04-09
CREESE I 202774 02-04, 207794 03-04, 217152 04-04
CRICHLOW EC 197742 01-03
CROFFORD M 210751 03-03
CROLLINI C 209351 03-03
CROOK TH 218770 04-09
CROVATO E 201669 02-08
CROW LT 205335 02-04
CROW TJ 207306 03-04
CROZE S 210743 03-04
CSAKI L 197289 01-03
CSANALOSI I 209486 03-10, 216462 04-10
CUBEDDU LX 204485 02-03
CUCU I 205585 02-08
CUELLO AC 193050 01-03
CUNNINGHAM CPC 195882 01-11
CUNNINGHAM PC 198086 02-07
CURELARU S 205637 03-11
CURRAN CF 202824 02-11
CURRAN DJ 210209 03-13
CURRY SH 209081 03-10
CURTISS FR 196227 01-04
CURZON G 195443 01-15, 219522 04-03
CVEJIC H 205264 02-14

D

DONETTO TB 194311 01-11
DOYAKOVA SD 212432 03-13
DA PRADA M 202665 02-03, 210753 03-03, 223174 04-03
DA RI H 197577 01-03
DAFELDECKER W 210930 03-04
DAFNY N 220975 04-03
DAHL E 199763 02-03
DAHLBERG CC 198092 02-10
DAIGLE L 207043 03-13
DAIGUJI M 225523 04-13
DAKOVIC K 197581 01-03
DALE R 198225 02-04
DALGLISH FW 208555 03-03
DALHOUSE AD 213128 03-03
DALLO J 197579 01-03
DALTON R 207486 03-04
DALY JW 197293 01-03
DALZELL HC 208594 03-02
DAMITZ C 201843 02-04
DAMJANOV I 192925 01-03
DANDIYA PC 201322 02-04, 202803 02-04, 215664 04-03, 221308 04-03
DANDOY J 205882 03-15
DANIEL JR 196252 01-01
DANIELL HB 217659 04-03
DANIELSEN A 199896 02-14, 211070 03-14
DANIELSON U 207580 03-11
DANIELSSON A 216968 04-03
DANKOVA J 213450 04-03
DANNEBERG P 200047 02-04
DANSCHER G 203521 02-04, 210665 03-03
DANTZER R 210530 03-14, 210741 03-04
DARBINYAN TM 198434 02-03
DASBERG H 196191 01-10, 199991 02-10
DASGUPTA D 196088 01-08
DASKALOPOULOS N 221669 04-03
DATTA RK 194153 01-03, 195242 01-03
DAVENPORT YB 224749 04-09
DAVID FG 212677 03-04
DAVID H 210674 03-04
DAVID J 199386 02-07
DAVIDSON C 219517 04-15
DAVIDSON JRT 213919 04-17
DAVIES B 198029 01-09, 205155 02-09
DAVIES JA 199959 02-04
DAVILA D 197582 01-03
DAVILA T 197582 01-03
DAVIS DM 218682 04-09
DAVIS HN 193549 01-04
DAVIS HP 221005 04-04
DAVIS JM 202723 02-03, 207035 03-04, 207286 03-14, 207291 03-17, 208571 03-11, 209753 03-17, 224773 04-13, 224829 04-17, 224833 04-09
DAVIS LE 197456 01-03
DAVIS RS 197452 01-03
DAVIS S 213863 04-08
DAVIS WM 196106 01-05, 200036 02-04, 205889 03-04, 215726 04-03
DAVISON MA 214203 04-03

DAWSEY WJ 213400 04-03
DAWSON RG 199550 02-04
DAY WA 200004 02-03
DE ANGELIS L 213591 04-03
DE CARO G 198224 02-03
DE FORSTER EMC 205505 02-13
DE GAETANO G 217693 04-03
DE GEYTER J 224583 04-10
DE GROOT MHL 202798 02-11
DE IORIO A 210513 03-11
DE JONG W 197584 01-03
DE JONG Y 197866 01-04, 217474 04-04
DE LA TORRE L 217846 04-04
DE LORENZI A 217858 04-03
DE MARCHI F 194956 01-04, 197453 01-03, 202765 02-03, 221735 04-01
DE MARIA R 221735 04-01
DE MARTINO G 210513 03-11
DE MAXIMY B 217171 04-09
DE MORAES S 197463 01-03, 197495 01-03, 211066 03-03
DE NATALE F 210510 03-08
DE NIE LC 217672 04-03
DE OLIVEIRA L 217468 04-04
DE OLVEIRA LF 199962 02-03
DE SILVA JAF 200737 02-16
DE VOSS R 221273 04-06
DE WIED D 213430 04-03, 222820 04-04
DEBERDT R 209487 03-10, 218750 04-10
DEBRAY R 212494 03-11
DEBUS G 206980 03-16
DECSI L 202779 02-04
DEDICOVA A 215066 04-03
DEETS AC 224907 04-04
DEFFEMINIS ROSPIDE HA 205575 02-13
DEGAETANO G 217890 04-03
DEGIOVANNI A 212179 03-10
DEGKWITZ R 204392 02-09, 204402 02-13
DEITCHMAN D 199863 02-03
DEJONG W 210759 03-03
DEKIRMENJIAN H 224773 04-13, 224833 04-09
DEL GIUDICE J 211436 03-08
DEL PORTILLO L 203423 02-11
DEL RIO J 221722 04-02
DELAUNAY J 209533 03-14
DELFINI LF 213131 03-04
DELINI-STULA A 192937 01-03, 221647 04-03
DEMARCQ J 210141 03-15
DEMENT WC 197816 01-11
DEMETRIOU SK 215724 04-03
DEMISCH L 210813 03-03
DEMPSEY GL 213030 03-04
DEMPSEY GM 206146 03-09
DENBER HCB 213392 04-17, 216335 04-10
DENIKER P 216758 04-09, 216767 04-15, 221667 04-09, 221668 04-17, 221672 04-17
DENYS WJ 212164 03-13
DEO VR 194711 01-08
DESANTIS VP 197958 01-03
DESHPANDE SS 210801 03-03
DESOUSA A 196069 01-08, 206043 03-10
DESSAIGNE S 221286 04-03
DETRE TP 207683 03-17
DETTLI L 207155 03-15
DEUTSCH JA 221005 04-04
DEVI SP 194169 01-03
DEVRIENDT A 199214 02-16
DEWSBURY DA 193549 01-04
DEWYNGAERT M 202266 02-03
DEZE J 221885 04-11
DHILLON AK 195615 01-08
DI CHIARA G 210776 03-03
DI PROSPERO B 211219 03-04
DI SANSEVERINO LR 210746 03-01
DIAMOND H 224742 04-17
DIARD J 210791 03-03
DIAZ PM 195093 01-03
DICARA LV 219083 04-04
DIDIER JP 219709 04-03
DIETRICH AP 195452 01-04
DIGREGORIO GJ 193425 01-03
DIMASCIO A 196601 01-08, 198079 02-10, 198080 02-09, 207042 03-16, 209437 03-09, 209438 03-15, 218010 04-11, 218041 04-09
DIMINO JM 225512 04-09
DIMITRAKOUDI M 224424 04-09
DIMITROVA P 219662 04-11
DINGLER RD 214812 04-16
DINI M 215681 04-15
DINOVO E 195055 01-13, 224830 04-13
DIONYSSIOU A 210773 03-01
DIPASQUALE G 196228 01-04
DISTEFANO V 200082 02-03
DITTMER TLJ 217450 04-09
DITTRICH A 202784 02-14, 214009 04-09
DIXON R 222802 04-06
DIXON WR 217666 04-16
DLABAC A 205583 02-03
DO CARMO MM 197463 01-03
DOAMARAL JR 207496 03-01
DOBRZANSKI T 203741 02-15
DODES LM 202725 02-09
DOGGETT NS 197479 01-03, 210761 03-03, 210762 03-04, 222817 04-04
DOI T 210241 03-09
DOLEZALOVA H 210701 03-03, 217840 04-03
DOLEZALOVA V 205589 02-09
DOLL R 194063 01-13
DOLPHIN A 193544 01-03, 217469 04-03
DOLS LCW 198229 02-09, 215454 04-13
DOM R 207000 03-14
DOMAHIDY B 214109 04-03
DOMINGUE D 204169 02-08
DOMINIC JA 217664 04-03
DOMINO EF 193457 01-03, 197467 01-03, 200773 02-13, 210790 03-04, 210876 03-03, 210879 03-14, 215724 04-03
DOMINO LE 193457 01-03
DOMJAN M 223254 04-04
DONALD A 221657 04-09
DONALD JF 207532 03-10
DONALDSON J 193588 01-03
DONLON PT 216190 04-08
DORR M 210351 03-04
DORRIS RL 210862 03-03
DORUS E 194826 01-13, 224833 04-09
DOSTAL T 205601 03-09, 205607 03-09, 205608 03-09
DOTTI A 208970 03-15
DOUST JWL 206337 03-08
DOWDALL MJ 213395 04-03, 217869 04-03
DOWNEY DJ 219020 04-04
DOWNIE RH 220950 04-05
DOWNS DA 202667 02-04, 215968 04-04
DRAGICEVIC D 198394 02-11
DREIFUSS FE 211064 03-13
DRENNEN HD 210708 03-04
DRESSE A 197682 01-03
DREYFUSS L 212213 03-09
DRISCOLL EJ 195949 01-13
DRIVENES A 195444 01-15
DROZDOVA GA 202925 02-13
DRUCKER-COLIN RR 220945 04-03
DRUSE MJ 200168 02-05
DRY J 209998 03-15
DRYDEN WF 193447 01-03
DUBAS TC 222640 04-03
DUBEY L 221648 04-13
DUBINSKAYA GR 200021 02-03, 219606 04-03
DUBINSKY B 197478 01-03
DUBOVA VG 202925 02-13
DUBROVINA NI 219111 04-03
DUBUIS R 207153 03-13
DUCHARME JR 209840 03-03
DUCHENE-MARULLAZ P 199385 02-02
DUFOUR H 216759 04-08
DUFRESNE JJ 207153 03-13
DUGGAN PF 210812 03-03
DULSKA E 199772 02-03
DUMAIS B 204169 02-08
DUMONT E 224583 04-10
DUMONT M 212182 03-03
DUNCAN RJS 193577 01-03
DUNGES W 197279 01-01
DUNLEAVY DLF 206369 03-14
DUNNER DL 207681 03-09, 224873 04-09, 224874 04-09
DUREMAN I 214018 04-14
DUREN DR 223120 04-15
DUSZYK S 205598 02-10
DUTTA SN 199870 02-03
DUVOISIN RC 193544 01-03, 202281 02-03
DVORKIN VY 219747 04-03
DWIVEDI C 213374 04-03
DYBING F 211070 03-14
DYCK DG 224504 04-04
DYER DC 202109 02-02
DYKEN P 211064 03-13
DYKSTRA LA 200055 02-04

E

EARLEY J 217666 04-16
EASTGATE SM 197931 01-03
EASTHAM RD 218553 04-11
EBADI MS 193547 01-03
EBARA T 207718 03-15
EBEN E 204414 02-13
EBERT MH 224749 04-09
EBSTEIN B 217823 04-03
ECKMANN F 204415 02-08, 206978 03-08, 221336 04-15
EDELBROCK C 205335 02-04
EDELFORS S 198026 01-03
EDLUND AH 197035 01-09
EDMONDS DE 222090 04-04
EDMONDS HL 198613 02-03, 222639 04-03
EDWARDS DJ 217356 04-13
EDWARDS K 217548 04-14
EFVAN J 212493 03-15
EGGER GJ 199550 02-04
EGLI M 211355 03-11
EGOROVA EF 217214 04-03
EHRENSING RH 202887 02-14
EHRNEBO M 217878 04-13
EIDE A 221306 04-09
EIDELBERG E 208554 03-03
EISDORFER C 203606 02-11, 207437 03-11
EISENBERG L 203213 02-08
EISENLOHR JJ 220829 04-11
EISENRING J 206834 03-10
EJSING LO 221821 04-13
EKSTROM-JODAL B 197213 01-03, 197214 01-03, 197215 01-03
EL-YOUSEF MK 201327 02-13, 210828 03-03, 224909 04-13
ELAEV NR 202599 02-03
ELAZAR Z 220947 04-03
ELEFTHERIOU BE 221037 04-03, 221042 04-03
ELLENBROEK GA 217464 04-04
ELLINWOOD EH 197863 01-04, 213531 04-04, 224797 04-14
ELLIOTT GR 207496 03-01
ELMAN M 205264 02-14, 207580 03-11
ELMES PC 204306 02-17
ELONEN E 215667 04-14
ELY DL 216494 04-04
EMANUEL CA 221005 04-04
ENDE W 220434 04-09
ENDO S 194509 01-11
ENDO T 214062 04-03
ENDOH M 197943 01-03
ENGEL J 217656 04-04
ENGELHARDT DM 198063 01-07, 214341 04-17, 217181 04-14
ENGELHORN R 197955 01-03
ENGELSHER C 210751 03-03
ENGLE J 202806 02-04
ENGSTRAND E 221306 04-09
ENGSTROM G 193541 01-03
ENGSTROM RG 217653 04-03
ENNA SJ 202665 02-03
ENOKIDO H 196144 01-08
EPLOV L 197928 01-03, 225565 04-03
ERCAN ZS 217651 04-03
ERDELJAN D 197576 01-03
ERDELYI E 207496 03-01
ERDMANN G 217837 04-03
ERDOSOVA R 210348 03-03, 215066 04-03
ERIKSSON JH 217549 04-14
ERILL S 217546 04-14
EROGLU L 193458 01-03
ERSPAMER R 208554 03-03
ERVIN GN 215704 04-04
ESCANDE M 219694 04-15
ESCHER HD 221337 04-10
ESCOBAR JI 225343 04-15
ESCOUSSE A 219709 04-03
ESKAZAN E 205546 02-03
ESTEVEZ V 217154 04-08
ESTLER C 204396 02-03
ETEVENON P 205448 02-08
EUBANKS EE 195087 01-04, 206086 03-04
EVANS MA 211745 03-14
EVENSON RC 215251 04-17
EVERITT BJ 199968 02-04, 217856 04-04, 222263 04-04

EWING JA 202883 02-17
EXTEIN I 206336 03-03
EZHKOV AA 201908 02-08

F

FABER B 205548 02-13
FABER J 215070 04-13, 215071 04-13
FAEDER IR 213474 04-03
FAHNDRICH C 197961 01-03
FAIRCHILD MD 218190 04-03
FALLER DV 200081 02-03
FALTUS F 205584 02-08, 205589 02-09, 205618 03-08
FANCIULLACCI M 211108 03-12
FANELLI O 199211 02-04, 206783 03-05, 221267 04-03
FANN WE 203470 02-11, 203606 02-11, 217523 04-11
FARBER MO 211015 03-05
FARMER C 198042 01-16
FARMER M 197493 01-03, 197494 01-03
FARNEBO L 210857 03-03
FARQUHAR JA 195492 01-04
FARR D 224378 04-13
FARRANT GW 199782 02-13
FARSKA I 205630 03-03
FAULEY JJ 193456 01-03
FAURE H 209784 03-11
FAURE-MARTINET ML 209784 03-11
FAZIO C 210213 03-09
FECHTER LD 202773 02-04
FEDER J 203840 02-14, 221288 04-16
FEDERICO R 197871 01-03
FEDORA O 223394 04-14
FEGER J 204220 02-03
FEINBERG I 195923 01-14, 199640 02-11, 215740 04-14
FEINSTEIN R 218971 04-13
FEKETE M 197580 01-03
FELBER JP 207153 03-13
FELDMAN JM 217695 04-03
FELLER DR 217880 04-05
FENELON B 205504 02-13
FENICHEL GM 216966 04-11
FENNER H 204400 02-05
FENNESSY MR 197480 01-03
FENWICK S 217807 04-04
FERGUSON HC 206808 03-02
FERNANDES M 197282 01-03, 197858 01-03
FERNANDEZ B 219039 04-04
FERNANDEZ-GUARDIOLA A 205443 02-13
FERNANDEZ-TOME MP 221722 04-02
FERNANDO JC 219522 04-03
FERNER U 206784 03-08, 206983 03-08
FERNSTROM JD 200081 02-03
FERRI S 200045 02-03, 206783 03-05
FERRINI R 206785 03-03, 221268 04-02
FIBIGER HC 193578 01-04, 195907 01-03, 202793 02-04, 207302 03-04, 210861 03-04, 213394 04-03, 217842 04-03, 217854 04-03, 223054 04-03
FIELDS RM 194054 01-17
FIEVE RR 194746 01-09, 195933 01-17, 207681 03-09, 218042 04-16, 224873 04-09, 224874 04-09
FIGLER MH 217524 04-04
FILE SE 196206 01-04
FILIP V 205607 03-09
FILIPPINI C 209123 03-11
FINA G 211226 03-11
FINK M 198060 01-07, 205522 02-16, 224795 04-13
FINK Z 205620 03-15
FINNERTY RJ 194834 01-10
FIORINI G 210425 03-15
FIRESTONE P 220523 04-14
FIRSOV VK 223017 04-03
FISCHER E 206809 03-03, 218959 04-09
FISCHER JF 222822 04-03
FISCHER R 215161 04-03
FISCHER-CORNELSSEN K 206784 03-08, 206983 03-08
FISCHMAN MW 225165 04-05
FISHER D 225512 04-09
FISHER S 198106 02-07, 199517 02-14, 207775 03-14, 210738 03-14
FITZPATRICK KW 202980 02-04
FIUTOWSKI J 203741 02-15
FJALLAND B 199622 02-03, 210892 03-03
FJERDINGSTAD E 203521 02-04, 210665 03-03, 210665 03-03
FLAVIN D 217521 04-04
FLEISCHHAUER J 204412 02-14, 207283 03-03
FLEISCHMAN RW 193417 01-05, 217518 04-05
FLEISS J 224836 04-09, 224873 04-09, 224874 04-09
FLEMING DE 201409 02-03
FLEMING JC 217525 04-04
FLOOD JF 202202 02-04
FLOREZ J 196582 01-03
FLORU L 195037 01-11, 195038 01-11, 204409 02-15, 215059 04-14, 217453 04-15
FOG R 196600 01-11, 206359 03-03, 214010 04-15, 217451 04-04
FOLTYN E 210793 03-03
FON LITTROV K 223016 04-03
FONLUPT V 210128 03-09
FONTAINE O 202770 02-04
FONTAINE P 215701 04-08
FONTANY M 210126 03-09
FOOTE SL 217865 04-03
FOOTE W 200052 02-03, 205455 02-03
FOPPEN FH 213987 04-03
FORN J 208300 03-03
FORNEY RB 193419 01-03, 211015 03-05
FORREST A 213387 04-07, 221657 04-09
FORREST APM 223777 04-15
FORREST IS 217553 04-03, 225399 04-17
FORREST JN 209352 03-03
FORREST WA 215058 04-14, 221662 04-09
FORREST WH 210829 03-13
FORSMAN A 221631 04-13
FORSYTHE WI 206058 03-13
FORTI A 208983 03-16
FOSTER FG 194862 01-09, 224769 04-09
FOULON C 199381 02-04
FOURESTIER J 212493 03-15
FOURNEX R 199912 02-05
FOX KA 213605 04-03
FRAM DH 214015 04-14
FRANCHI G 211108 03-12
FRANCK KF 210892 03-03, 210893 03-03
FRANCO R 221188 04-03
FRANCO S 222818 04-04
FRANKEN RE 206187 03-04
FRANKENHEIM JM 195431 01-04
FRANKOVA S 215067 04-04
FRANTIK E 205595 02-15
FRANTZ AG 213527 04-08
FRANZEN G 221518 04-11
FRATTARELLI M 205470 02-13
FRAZER A 194826 01-13, 195930 01-13, 195931 01-09, 202777 02-03, 207444 03-13, 208917 03-09, 211412 03-03
FRAZIER DT 217662 04-03
FRECHE C 224584 04-11
FREDERIKSEN PK 218254 04-08
FREE SM 198058 01-02
FREEDMAN DX 213606 04-03, 217661 04-03, 221044 04-12
FREEDMAN PE 195088 01-04
FREEDMAN R 217865 04-03
FREEMAN JJ 202782 02-03, 210749 03-03, 217551 04-04
FREEMON FR 210828 03-03
FREIDMAN E 200041 02-03
FREISTEIN H 221338 04-08
FRENCH SW 215980 04-03
FREUND G 210737 03-04
FREUNDENTHAL RI 217457 04-03
FREY LG 197450 01-04
FREYHAN FA 207764 03-09
FRICK R 221165 04-15
FRIEDEL J 195443 01-15
FRIEDHOFF AJ 225517 04-16
FRIEDLI P 197468 01-03
FRIEDMAN AS 218769 04-10
FRIEDMAN E 210221 03-13, 217827 04-03, 225081 04-04
FRIEDRICH M 197567 01-03
FRIEL P 211009 03-03
FRIEMERT K 208622 03-08
FRIVIK PT 211070 03-14
FROST JD 199756 02-13
FROST M 216403 04-08
FUCHIMOTO H 200748 02-04
FUENTES JA 221722 04-02
FUJII H 209399 03-11
FUJII K 214304 04-11
FUJII S 215955 04-14
FUJITA C 204428 02-10
FUJIWARA J 197209 01-09, 207554 03-09, 207719 03-09, 210241 03-09
FUJIWARA M 199807 02-03
FUKUDA H 202804 02-03
FUKUDA N 195549 01-03
FUKUDA S 194736 01-04
FUKUDA T 215723 04-03
FUKUHARA T 217114 04-09
FULLER DR 193456 01-03
FULLER RW 195092 01-02, 197870 01-03, 200004 02-03, 203580 02-03, 210870 03-02, 210922 03-03, 211104 03-03, 217696 04-03, 217879 04-03
FUNASAKA K 213294 03-08
FUNDERBURK WH 210676 03-02
FUNFGELD EW 221648 04-13
FURUKAWA T 202800 02-03, 210787 03-03, 221041 04-04
FUSE S 194475 01-11
FUSEK J 205632 03-03
FUSTER P 220271 04-11
FUXE K 199968 02-04, 207305 03-03, 210857 03-03, 222263 04-04
FYRO B 207295 03-08, 210434 03-10, 221638 04-10

G

GABRIEL E 204413 02-15
GACON J 212493 03-15
GADUSEK FJ 223033 04-04
GAERTNER HJ 200738 02-01
GAIARDI M 197453 01-03, 202765 02-03
GAILIS L 211099 03-03
GAILLARD AWK 217533 04-04
GAILLARD J 197468 01-03, 197994 01-03, 206834 03-10, 218953 04-14, 225558 04-03
GAILLARD L 219827 04-15
GAIND R 202699 02-13, 209789 03-13
GAL EM 210819 03-03, 210826 03-03
GALODINOV GV 213491 04-04
GALANTER M 224757 04-14
GALASSI G 200170 02-11
GALATULAS I 200045 02-03
GALETTI G 210211 03-11
GALEY D 220946 04-04
GALLANT DM 198043 01-07, 198064 01-07, 206933 03-08, 216188 04-08
GALLI T 209123 03-11
GALLUP GG 217762 04-03
GALVAN L 198053 01-07
GANONG WF 193050 01-03
GARATTINI S 197868 01-03, 209073 03-15, 217693 04-03, 217890 04-03, 221188 04-03
GARCIA A 217025 04-08
GARDEY-LEVASSORT C 196580 01-03
GARDNER DE 204862 02-02
GARDOS G 202879 02-08
GARELIS E 210796 03-03
GAREY RE 202719 02-03, 218956 04-02
GARGANO MA 209044 03-11
GARNER LL 194749 01-15
GARVER DL 207035 03-04, 224773 04-13, 224829 04-17
GASTALDO G 194071 01-09
GAUCH R 199913 02-13
GAUDIERI V 210513 03-11
GAULT J 202037 02-11
GAURON EF 215685 04-04
GAUSSEL D 219827 04-15
GAUTIER J 213530 04-08
GAY MH 203033 02-03
GAYRAL L 219694 04-15
GEBER WF 217654 04-03
GEBERT A 204415 02-08
GEBHARDT M 213919 04-17
GEBHART GF 195097 01-03
GEERING JM 207155 03-15
GEHLEN W 220829 04-11
GEHRMANN J 204189 02-06
GEIGER PF 204339 02-03
GEISSBUHLER F 225558 04-03
GELLER HM 213279 03-03
GENTILE JR 212811 03-11
GENTILI P 201690 02-11

GEORGE G 210916 03-04
GEORGI H 199785 02-03
GERALD MC 210765 03-03, 210900 03-03
GERARDY J 197682 01-03
GERBER HR 210786 03-06
GERLACH J 200803 02-08, 214010 04-15, 221335 04-15, 221538 04-13, 221637 04-08
GERNA M 217460 04-10
GERSHON ES 201000 02-09
GERSHON S 197470 01-04, 197532 01-09, 198055 01-02, 198065 01-07, 198081 02-07, 198094 02-08, 199965 02-03, 200041 02-03, 207285 03-14, 207446 03-09, 210221 03-13, 213522 04-15, 213592 04-04, 218129 04-09, 221036 04-01, 224831 04-08, 225065 04-14, 225334 04-15
GERSON S 204340 02-03, 213401 04-03
GERVASI A 197862 01-13
GESER CA 207153 03-13
GESSA GL 210776 03-03, 213715 04-17, 213716 04-17
GESSNER PK 193454 01-03, 197448 01-03
GESSNER T 197448 01-03
GEY KF 199785 02-03
GEYER MA 213400 04-03
GHADIALI HN 196707 01-08
GHAFOOR PKA 194554 01-11
GHERARDI G 209147 03-08
GHEZZI D 210668 03-03, 210923 03-03
GHIRARDI P 221269 04-10
GHISELLI WB 206714 03-04
GHOSH JJ 194153 01-03, 210769 03-03
GHOSH PB 202312 02-01
GIACOBINI E 217840 04-03, 220945 04-03
GIACOBINI G 217840 04-03
GIANASI GC 205470 02-13
GIANNELLI A 209122 03-09, 210507 03-09
GIANUTSOS G 210814 03-03, 210899 03-04, 225568 04-04
GIARDINA WJ 200064 02-03, 206768 03-03
GIBB JW 213607 04-03
GIBBONS P 217548 04-14, 218120 04-09
GIFT T 198042 01-16
GILBERT DL 194927 01-03
GILEV AP 219328 04-04
GILINSKIY MA 219111 04-03
GILL EW 198605 02-01
GILLBE C 207306 03-04
GILLIN JC 198230 02-12, 210602 03-14, 214015 04-14, 217219 04-06, 221732 04-13, 225287 04-04
GILLIS CN 195447 01-13
GILYADOVA LA 201920 02-03
GINESTET D 196035 01-17, 216758 04-09, 216767 04-15, 221667 04-09, 221668 04-17, 221672 04-17
GINGRICH RL 209486 03-10
GINSBURG BE 213479 04-03, 225527 04-03
GIORGI-CONCIATO M 210513 03-11
GIOVANNETTI A 203599 02-14
GIRAULT JT 193451 01-03
GIRKE W 215697 04-13
GISSELMANN A 212392 03-09
GITTELMAN-KLEIN R 198045 01-14, 224855 04-11
GIUREZU T 205637 03-11
GIURGEA C 205507 02-03, 213589 04-03
GIVANT Y 210793 03-03
GJERSTAD LI 199763 02-03
GJESSING LR 207292 03-08
GJURIS V 197568 01-03
GLASSMAN A 213918 04-09, 215014 04-13, 224836 04-09
GLATZEL J 206696 03-09
GLENNON RA 195119 01-01
GLICK SD 205432 02-04, 206747 03-04, 209962 03-03, 210926 03-03, 214012 04-04, 225560 04-04
GLIELMI N 211226 03-11
GLINER JA 213275 03-04
GLISSON SN 195094 01-03
GLITSCHKA A 210807 03-09
GLITTERSTAM K 221633 04-15
GLOTZBACH S 213855 04-03
GLOTZNER FL 221307 04-15
GLOW PH 217476 04-03
GLOWINSKI J 195239 01-03, 207296 03-03, 210669 03-03, 210699 03-03, 210800 03-03, 217658 04-03, 217687 04-03
GLUCKMAN MI 218150 04-17
GLUSHCHENKO TS 198485 02-03
GNEGY M 208735 03-03
GOCKA EF 211436 03-08
GOETZ C 203885 02-03, 218213 04-08
GOGERTY JH 217652 04-04, 217653 04-03
GOGOLAK G 210881 03-03
GOLODOVSKAYA IL 201911 02-15
GOLD GJ 195116 01-03
GOLD PE 209951 03-04
GOLDA V 205632 03-03
GOLDBERG AM 210883 03-03
GOLDBERG HL 194834 01-10, 196601 01-08, 218010 04-11
GOLDBERG LI 210902 03-03
GOLDBERG ME 197478 01-03, 197482 01-04, 210792 03-03, 215711 04-03
GOLDBERG S 224831 04-08, 225157 04-04
GOLDBERG SC 199625 02-08, 199626 02-08
GOLDBERGER E 219694 04-15
GOLDFIELD MD 225331 04-15
GOLDMAN H 215161 04-03
GOLDOWITZ D 213855 04-03
GOLDSTEIN BJ 198087 02-10
GOLDSTEIN DB 197821 01-03
GOLDSTEIN FJ 225059 04-03
GOLDSTEIN M 217823 04-03
GOLDSTEIN ML 201843 02-04
GOLDSTEIN S 225337 04-15
GOLOVCHINSKY VB 198434 02-03
GOMEZ R 202883 02-17
GOMITA Y 198733 02-04
GOMOLL AW 199863 02-03
GONZALEZ LOPEZ JL 220267 04-08
GONZALEZ-VEGAS JA 210659 03-03
GOODALL E 195090 01-04, 206733 03-04
GOODE DJ 195450 01-03
GOODELL H 202693 02-08
GOODEN BA 218971 04-13
GOODWIN FK 196042 01-09, 196087 01-13, 199632 02-07, 202886 02-14, 206985 03-13, 207311 03-07, 207443 03-13, 210602 03-14, 221045 04-09, 224749 04-09
GOPINATH PS 196088 01-08
GORDIN S 210793 03-03
GORDON JH 206334 03-03
GORDON PE 194045 01-10
GORKIN VZ 201914 02-02
GORMSEN CA 197035 01-09
GORSKIY GD 224085 04-08
GORTINSKAYA TV 198484 02-01
GOSZTONYI T 197869 01-03
GOTHERT M 197945 01-03, 221860 04-03
GOTTESFELD Z 220947 04-03
GOTTFRIES CG 197035 01-09
GOTTSCHALK H 203701 02-13
GOTTSCHALK LA 195055 01-13, 198095 02-07, 224830 04-13
GOUDIE AJ 210742 03-04
GOUGH AL 210752 03-04
GRABOWSKA M 202771 02-03, 217815 04-03
GRADWELL PB 217856 04-04
GRAEFE KH 197944 01-03
GRAEFF FG 215693 04-04, 217468 04-04
GRAF I 211355 03-11
GRAHAM G 195118 01-03
GRAHAME-SMITH DG 199960 02-04, 210764 03-03
GRAM LF 210834 03-03, 215671 04-13
GRANACHER RP 211416 03-15, 211427 03-15
GRATCH M 209486 03-10
GRAY GD 193549 01-04
GRAY WD 197864 01-03
GRAZ B 201669 02-08
GRBOVIC L 202780 02-04
GREEN AR 199960 02-04, 210764 03-03
GREEN DE 195053 01-13, 217553 04-03
GREEN DM 196437 01-01
GREEN JP 205432 02-04, 213608 04-03
GREEN JR 211009 03-03
GREEN L 217668 04-15
GREEN RA 225287 04-04
GREENBERG D 207298 03-03
GREENBERG I 194178 01-04, 201321 02-04
GREENBERG R 211101 03-03
GREENBLATT DJ 193192 01-17, 198823 02-17, 199515 02-14, 200584 02-09, 203005 02-13, 204851 02-17, 205299 02-17, 207161 03-17, 213920 04-17, 218151 04-17, 218155 04-15
GREENE FE 193428 01-03
GREENGARD P 207297 03-03, 208300 03-03, 213609 04-03
GREENGRASS PM 192943 01-13, 200058 02-03, 221647 04-03
GREENWOOD MH 195443 01-15
GREGER J 200952 02-15, 210807 03-09
GREGOVA L 205594 02-15
GREIG AM 221047 04-04, 223039 04-04
GREIL W 204393 02-13
GREVEN HM 222820 04-04
GREVEN J 197946 01-03
GREWAAL DS 210658 03-03, 217842 04-03
GRIEK BJ 223737 04-04
GRIFFITH JD 198030 01-14
GRIFFITHS K 223777 04-15
GRIMM U 203645 02-13
GRIMSGARD A 212238 03-08
GRINAKER H 221306 04-09
GRINEVA AN 206438 03-02
GRINGRAS M 215150 04-09
GROF P 207043 03-13
GROMOV AI 218471 04-04
GROMOVA VV 224083 04-09
GROSCHEL W 200952 02-15, 210806 03-03, 210807 03-09
GROSS F 202304 02-17
GROSS H 206975 03-08
GROSS MD 211434 03-11
GROSSMANN W 193282 01-04, 197283 01-03
GROTA LJ 225078 04-03
GROTH U 195446 01-13
GROUNDS AD 200581 02-09
GROVES PM 211063 03-03, 217676 04-03
GRUDEN V 198396 02-10
GRUDZINSKA E 197832 01-03
GRUEN PH 213918 04-09
GRUENAU SP 199765 02-03
GRUENBERG EM 195933 01-17
GRUNDER JR 197493 01-03
GRUNER J 194743 01-03
GUARNIERI B 209044 03-11
GUDELSKY GA 204865 02-02, 220974 04-03
GUEDRI HE 210884 03-03
GUERINOT F 196593 01-03
GUERRERO S 210925 03-03
GUERRERO-GIFUEROA R 216188 04-08
GUHA D 197990 01-03
GUIBERT S 209533 03-14
GUIDOTTI A 196588 01-03, 196590 01-03, 197124 01-03, 201491 02-06, 202716 02-03, 202717 02-03, 207798 03-03, 208636 03-03, 215654 04-03, 215688 04-03, 217853 04-03, 217888 04-03, 218149 04-03, 221031 04-03, 221732 04-13, 225058 04-13, 225307 04-03
GUILLAND JC 219709 04-03
GUILLEMINAULT C 197816 01-11, 199757 02-13
GUIMARAES S 193139 01-03
GULATI OD 194156 01-03
GUNGOR M 193458 01-03
GUPTA AK 206461 03-02
GUPTA BS 209260 03-14
GUPTA JD 209351 03-03
GUPTA RK 217969 04-15
GUPTA TK 206461 03-02
GUROVICH IY 201908 02-08
GUSELO VA 219499 04-03
GUSEWELLE BE 215696 04-04
GUSS H 202785 02-07
GUSSELNIKOV VI 201479 02-03
GUSTAFSON LKW 211899 03-04
GUTH M 197945 01-03
GUTMAN Y 199869 02-03
GUTSCHE K 206994 03-02
GUYENET PG 210669 03-03, 217658 04-03
GUZMAN RA 224767 04-10
GYUNTER M 206439 03-04

H

HAASE H 195038 01-11, 210511 03-17
HAASTRUP S 221635 04-08
HABER PA 193291 01-11, 215009 04-11
HABIGER W 221743 04-03
HACHE J 199385 02-02
HADASS H 203841 02-13
HADFIELD MG 222821 04-03
HAEFELY W 197585 01-03, 204183 02-03
HAEUSLER G 197947 01-03
HAFFNER JFW 199896 02-14, 211070 03-14

HAGA M 223182 04-10
HAGGENDAL E 197213 01-03, 197214 01-03, 197215 01-03
HAGITA K 224507 04-15
HAHER EJ 194044 01-08, 213532 04-15
HAHN I 195245 01-03
HAJNSEK F 205548 02-13
HALARIS AE 217661 04-03
HALBREICH U 225486 04-14
HALFON N 213855 04-03
HALKI JJ 194568 01-04
HALL K 213764 04-08, 217454 04-08
HALL R 213764 04-08, 219521 04-09
HALPERN FS 213918 04-09
HAMANKA T 196444 01-02
HAMBERGER B 210857 03-03, 220949 04-03
HAMBURGER-BAR R 222807 04-04
HAMEISTER W 197956 01-13
HAMETOVA M 205609 03-09
HAMILTON JR 223777 04-15
HAMILTON LW 195079 01-04
HAMILTON M 196037 01-17
HAMMERSHLAG R 213277 03-03
HAMON M 217655 04-03
HAMPEL R 204402 02-13
HAMPRECHT B 195254 01-03
HANADA Y 204424 02-04
HANAOKA M 210241 03-09
HANBAUER I 196590 01-03, 215688 04-03, 217853 04-03
HANCEVIC-RAJAKOVIC N 198395 02-11
HANCOCK JC 197445 01-03
HANDLEY SL 206358 03-04, 217473 04-03
HANDRICK GR 208594 03-02
HANIG JP 197457 01-03
HANIKA R 221336 04-15
HANIN I 210885 03-06
HANLEY MR 217825 04-03
HANON E 212213 03-09
HANSEN CE 221630 04-13, 224835 04-09
HANSEN LB 221632 04-13
HANSEN T 195444 01-15, 195445 01-13
HANSEN V 199989 02-14
HANSON HM 225166 04-03
HANUS H 205609 03-09, 205617 03-08
HARA F 204484 02-03
HARA T 196443 01-14, 205464 02-04, 209412 03-10, 218011 04-11, 224644 04-13
HARADA N 204484 02-03
HARAKAL JJ 217577 04-02
HARAZTI J 224829 04-17
HARBISON RD 213374 04-03
HARDING T 206361 03-12
HARIHARASUBRAMANIAN N 194169 01-03
HARLEY JP 210824 03-15
HARMAN N 217544 04-03
HARMATZ JS 194865 01-14, 218155 04-15, 218156 04-14, 218217 04-11
HARNRYD C 221639 04-11
HARRELL LE 219268 04-04
HARRIS JE 207288 03-03, 222813 04-03
HARRIS LS 200055 02-04, 202201 02-04
HARRIS M 209791 03-07
HARRIS ML 193423 01-03, 193424 01-03
HARRIS RA 202201 02-04
HARRIS RT 201320 02-02
HARRISON SD 193590 01-12
HART JL 210877 03-03
HARTMANN EL 213610 04-03
HARTMANN W 200952 02-15, 210806 03-03, 210807 03-09
HARTZ SC 212107 03-15
HARVEY AL 193447 01-03
HARVEY JA 211494 03-05, 213611 04-03, 225159 04-04
HASEGAWA K 209392 03-09
HASEGAWA N 210559 03-14
HASEGAWA S 222158 04-08
HASHIMOTO S 202804 02-03
HASHIZUME Y 204484 02-03
HASKELL DS 199517 02-14, 209437 03-09
HASKOVEC L 215073 04-07
HATA N 215955 04-14
HATTORI T 196146 01-14
HAUBRICH DR 215711 04-03
HAUGSTAD A 197035 01-09
HAUN CK 210662 03-03
HAUSER GA 201694 02-11
HAUSNER M 211596 03-12
HAVARD CWH 209830 03-08
HAVLICEK V 193803 01-03
HAWKINSON R 209488 03-10
HAY J 221657 04-09
HAYA K 194563 01-01
HAYASAKA I 202422 02-03
HAYASHI Y 211360 03-15
HAYES RL 217821 04-12
HEALY JM 213050 03-03
HEATH RG 202719 02-03
HEBNES K 212238 03-08
HEDWALL PR 197298 01-03
HEGEDIC Z 221515 04-15
HEIDBRINK V 221739 04-06
HEIKKILA RE 210882 03-02, 215756 04-03
HEIMANN H 202865 02-17, 221348 04-09
HEINDEL ND 222870 04-02
HEINEMANN H 197279 01-01, 199213 02-04
HEINONEN OP 194064 01-13, 212107 03-15
HEINRICH K 217450 04-09
HEINTZ S 210888 03-03
HEINZL Z 215075 04-08
HEISE A 195237 01-03
HEISE GA 213612 04-04, 225172 04-04
HEISER JF 213708 04-15
HEISS W 210599 03-03
HELD K 197579 01-03
HELLER A 213613 04-03
HELLER B 206809 03-03, 218959 04-09
HELLER S 204394 02-13
HELMCHEN H 203839 02-13, 203840 02-14, 203842 02-13, 203845 02-16, 206971 03-16, 221288 04-16
HELWEG E 200803 02-08
HEMMELER W 197862 01-13
HEMSWORTH BA 197302 01-03
HENDLER N 221718 04-09
HENDLEY ED 210830 03-03
HENDRICKSON MJ 193547 01-03
HENGEVELD CT 224773 04-13
HENINGER GR 195932 01-09, 213614 04-11
HENKIN RI 194927 01-03, 214015 04-14
HENRIK E 222739 04-04
HENRIKSSON BG 195539 01-03, 202720 02-12, 202969 02-04
HENRY BW 209904 03-10
HENRY JP 216494 04-04
HENRY JT 211010 03-06
HEPTNER W 202807 02-03
HERBAULT M 212494 03-11
HERBERG LJ 221030 04-03
HERBERT J 217856 04-04
HERHA J 210810 03-15
HERINK J 205632 03-03
HERKERT B 197994 01-03
HERLING S 217765 04-04
HERLOFSEN H 221306 04-09
HERMAN J 197580 01-03
HERMANN IL 197035 01-09
HERNACKA B 202786 02-09
HEROLD M 218164 04-03
HERR JJ 193745 01-04
HERRMANN WM 213598 04-07
HERTTING G 197288 01-03
HERY F 217655 04-03
HERZ A 195246 01-03, 200053 02-03, 200078 02-03, 206988 03-03, 206989 03-03
HESBACHER P 198049 01-17
HESS ME 202777 02-03
HEUBERS H 197948 01-03
HEUBERS U 197948 01-03
HEWLAND R 224423 04-09
HEYKANTS JJP 213986 04-06
HEYMAN IA 217519 04-04
HEYNDRICKX A 204195 02-15
HIBI S 195923 01-14, 199640 02-11
HICKENBOTTOM JP 196106 01-05
HICKS LE 217762 04-03
HIDAKA H 204484 02-03
HIEB E 194749 01-15
HIEBERT LM 214056 04-04
HIGASHI T 211360 03-15
HIGUCHI M 194509 01-11, 194510 01-11, 199907 02-17, 210559 03-14
HILL D 209905 03-08
HILL DF 204184 02-03, 217355 04-03, 223175 04-03
HILL J 210210 03-14
HILL R 197282 01-03, 197858 01-03
HILLESTAD L 195444 01-15, 195445 01-13
HILLION C 210089 03-13
HILTON BP 196926 01-13
HINE B 199965 02-03, 210221 03-13
HINGTGEN JN 225161 04-04
HINKAMP DL 195089 01-04
HINZEN DH 210664 03-03
HIPPIUS H 196039 01-11, 203839 02-13, 203840 02-14, 203841 02-13, 203845 02-16, 217450 04-09, 221288 04-16
HIRANO M 223049 04-03
HIRATA J 205460 02-13, 207554 03-09
HIROHASHI T 206780 03-02
HIROOKA T 221287 04-02
HIROSE S 222158 04-08
HIROTA N 194476 01-08
HIRSCH J 210800 03-03, 213522 04-15
HIRSCH SR 206044 03-08
HIRSCHHORN ID 206353 03-03, 217821 04-12
HIRVENOJA R 221558 04-08
HISABA K 194457 01-08
HISADA T 219472 04-04
HITNER H 193425 01-03
HITZEMANN RJ 193453 01-03, 197467 01-03
HO AKS 210750 03-05
HO BT 194925 01-03, 199967 02-03, 201320 02-02, 210747 03-03
HO GKW 213685 04-03
HOAKI T 217354 04-09
HOBI V 203784 02-15
HOC J 212495 03-14
HODEL J 203496 02-17
HODGE GK 197931 01-03, 217670 04-04
HOEFKE W 206997 03-03
HOFER MA 218047 04-03
HOFFER A 209002 03-13, 209011 03-17
HOFFER J 208862 03-08
HOFFMAN SP 217181 04-14
HOFFMANN G 206974 03-13
HOFFMANN H 199209 02-02
HOFFMEISTER F 197284 01-04, 202944 02-06, 210889 03-04
HOFMANN HP 197952 01-04
HOGAN EL 200168 02-05
HOGARTY GE 198075 02-08, 199625 02-08, 199626 02-08
HOJO M 202799 02-03
HOKFELT T 199968 02-04, 222263 04-04
HOLCSLAW TL 223562 04-03
HOLLAND JT 205504 02-13
HOLLETT CR 200006 02-01
HOLLINGER MA 198613 02-03
HOLLINGSWORTH CE 205766 03-12
HOLLISTER AS 217218 04-04
HOLLISTER LE 194827 01-14, 195053 01-13, 198066 01-07, 202192 02-02, 210896 03-16, 217556 04-14
HOLLNAGEL P 197035 01-09
HOLLOWAY JA 217522 04-03
HOLLUNGER G 198015 01-03, 217674 04-03
HOLM P 217455 04-10
HOLMAN WL 211512 03-04
HOLMSTEDT BR 202381 02-01
HOLMSTRAND J 217549 04-14
HOLT NF 224486 04-09
HOLT-HANSEN K 205135 02-14
HOLTZMAN SG 198606 02-03, 201319 02-04, 210783 03-04
HOLZER B 197862 01-13
HOMMA M 221859 04-03
HONDA K 224194 04-10
HONECKER H 197292 01-03
HONIG WMM 217461 04-04, 217475 04-04
HONMA T 202862 02-02
HOOD RD 194130 01-04
HOPKINS HK 213764 04-08, 217454 04-08
HORDERN A 202960 02-09
HORI M 221287 04-02
HORIKAWA S 214750 04-14
HORN AS 205029 02-01, 210746 03-01
HORN G 210667 03-04
HORNUM I 221417 04-15
HORNYKIEWICZ O 197286 01-04
HOROVITZ ZP 197459 01-13
HOROWITZ HA 216183 04-11
HORROM BW 211069 03-01
HORST WD 196836 01-13
HORTON RW 210355 03-03
HORVATH M 205595 02-15

HOSHINO K 202422 02-03
HOSLI E 215159 04-03
HOSLI L 215159 04-03
HOSOKAWA K 205460 02-13
HOUSER VP 193157 01-04, 195223 01-04, 195294 01-04, 205418 02-04, 205765 03-13, 219032 04-04, 221766 04-04, 221799 04-04, 223040 04-04, 225566 04-04
HOUSSE J 212213 03-09
HOVAGUIMIAN T 225558 04-03
HOWARD GS 195995 01-04
HOWARD JS 196676 01-14
HOWE D 220951 04-01
HOWELL HG 202109 02-02
HOWES J 202775 02-03, 204866 02-03
HOWES JF 208594 03-02
HOWIE JGH 216948 04-17
HOWLETT DR 224424 04-09
HOYER J 210599 03-03
HOYT WF 225323 04-13
HOYUMPA A 197951 01-13
HRBEK J 205623 03-14, 205624 03-14, 205625 03-03, 217205 04-14
HRDINA V 205632 03-03
HSU LL 206542 03-03, 210760 03-03
HSU SY 210765 03-03, 210900 03-03
HUANG J 199967 02-03, 210747 03-03
HUBER WK 209905 03-08
HUBSCH T 205599 02-13, 205605 03-13, 205616 03-09
HUCK S 210881 03-03
HUCKER HB 209789 03-13
HUEBERS E 197948 01-03
HUEY L 216965 04-15, 224800 04-13
HUFFMAN RD 217816 04-03
HUG R 216902 04-14
HUGHES IE 217882 04-03
HUGHES RN 221047 04-04, 223039 04-04
HUKOVIC S 197576 01-03
HULLIN R 201513 02-09, 218556 04-09
HUMBER LG 208592 03-01
HUNG CY 217654 04-03
HUNT GM 205467 02-03
HUNT PF 210904 03-03
HUNT WA 196805 01-03
HUNTER PR 219521 04-09
HUNTLEY MS 200048 02-14
HURST PM 205223 02-14
HURZELER H 221648 04-13
HUTCHISON JB 210918 03-03
HVIDBERG EF 224835 04-09
HVIZDOSOVA J 205627 03-14
HYNEK K 215070 04-13, 215071 04-13
HYNES MD 210814 03-03
HYUGANO S 224393 04-09

I

ICHIHASHI H 194512 01-08
ICHIMARU S 221209 04-09
ICHINOWATARI N 216391 04-15, 218011 04-11, 224644 04-13
IGISU T 197491 01-03
IGONOKINA SI 207200 03-03
IGONIN AL 194043 01-11, 200072 02-09
IGUCHI K 207718 03-15
IKEDA H 210703 03-03, 224395 04-11
IKEDA K 205175 02-03
IKUZAWA M 224549 04-08
ILOYUCHENOK RY 208971 03-03, 219111 04-03
ILDIKO K 197859 01-04
ILHAN M 210866 03-03, 217578 04-05
ILLING JW 204862 02-02
IMAI S 207720 03-09, 209411 03-10
IMHOF P 221648 04-13
IMURA H 214885 04-13
INABA S 202862 02-02, 206780 03-02, 221741 04-02
INAGAKI T 207643 03-08, 223202 04-08
INANAGA K 211361 03-14, 224394 04-11
INFANTES V 217025 04-08
INGVAR D 218166 04-14
INOUE K 225086 04-09
INOUE T 198608 02-01
INUI M 202178 02-10
INVERNIZZI G 209045 03-11
IONESCU R 205637 03-11
IORDANISHVILI GS 219745 04-04
IORIO LC 217652 04-04
IOVLEV BV 224086 04-11
IPSEN E 197841 01-11
IRMIS F 205628 03-04
IRWIN P 224795 04-13
ISAAC W 210860 03-04, 214014 04-04
ISAACSON RL 203579 02-04
ISHIDA T 200009 02-11
ISHIDA Y 197577 01-03
ISHII K 208789 03-09
ISHII M 196444 01-02
ISHII T 208789 03-09
ISHII Y 221823 04-02, 221859 04-03
ISHIJIMA H 198710 02-08, 207534 03-08
ISHINO H 207719 03-09, 212340 03-09, 218772 04-09, 224588 04-09
ISOZAKI H 211361 03-14
ISRAEL L 202037 02-11
ITAKURA S 209402 03-08
ITIL M 205434 02-13
ITIL T 224955 04-08
ITIL TM 198041 01-07, 203603 02-14, 209127 03-11, 209829 03-16, 210808 03-14, 213594 04-11, 213863 04-08, 225516 04-10
ITO H 209410 03-15, 224507 04-15
ITO I 194460 01-08
ITO K 198710 02-08, 209324 03-15
ITO R 201655 02-09
ITO T 202804 02-03, 221287 04-02
ITONAGA Y 224549 04-08
ITSCHNER L 194860 01-08
ITURRIAN WB 208617 03-04
IVEN H 202796 02-03
IVERSEN LL 199999 02-03, 209098 03-17
IVERSEN SD 202774 02-04, 207794 03-04, 210666 03-04, 210763 03-04, 213433 04-03
IVERSON F 220950 04-05
IVERSON LL 220311 04-17
IWAHARA S 194736 01-04, 201323 02-03, 209866 03-04
IWATA H 195232 01-03
IZEKI K 208789 03-09
IZNAK AF 201479 02-03
IZQUIERDO I 198228 02-04

J

JACKSON AH 202725 02-09
JACKSON DM 206355 03-04, 221742 04-03
JACOB JJ 193451 01-03
JACOB RG 217549 04-14
JACOBI P 195155 01-11
JACOBOWITZ DM 208994 03-03, 210660 03-03, 210919 03-03, 217848 04-03, 218147 04-03
JACOBS BL 193548 01-04, 195087 01-04, 201324 02-03, 206086 03-04, 206108 03-03, 210710 03-03, 217863 04-03, 222816 04-04
JACOBS W 197946 01-03
JACOBSEN P 197841 01-11
JACOBSON RSF 198662 02-11
JACOBSSON L 221633 04-15
JACQUOT C 210884 03-03
JAEGER RJ 197488 01-03
JAEKEL J 221647 04-03
JAHNCHEN E 195446 01-13
JAIM-ETCHEVERRY G 217867 04-03
JAIN NC 222829 04-06
JAKOUBEK B 210348 03-03, 215066 04-03, 215067 04-04, 215068 04-04
JAKUBOVIC A 195112 01-03
JAKUPCEVIC M 192925 01-03, 197573 01-03
JALLING B 206057 03-13
JAMES DC 209079 03-10, 209080 03-10
JAMES DTD 222268 04-04
JAMES KE 210829 03-13
JAMES NM 217041 04-14
JANCAR J 218553 04-11
JANDHYALA BS 199964 02-03
JANICKI RS 202824 02-11
JANKU I 200002 02-03
JANOWSKY DS 224800 04-13, 224906 04-04
JANSEN FH 199214 02-16
JANSSEN H 199864 02-04
JANSSEN PAJ 206786 03-04, 206804 03-02, 213986 04-06
JANZ D 225537 04-15
JANZIK H 204394 02-13
JAQUES LB 214056 04-04
JARAMILLO J 211101 03-03
JARBE TUC 195539 01-03, 202720 02-12, 202969 02-04, 210865 03-03, 225561 04-04
JAROSZ CJ 216494 04-04
JARVIK ME 210739 03-04, 215696 04-04
JASINSKI DR 198030 01-14
JASKARI M 221989 04-08
JASO JJ 219289 04-04
JAVOY F 210669 03-03, 210699 03-03
JEFFERSON JW 199636 02-17
JENDEN DJ 217551 04-04, 218190 04-03
JENKINS BW 194045 01-10
JENNER FA 224424 04-09
JENNER P 193544 01-03, 217469 04-03
JENSEN J 199623 02-03, 213481 04-03, 213482 04-03
JEPSON K 215148 04-09
JERUSSI TP 205432 02-04, 214012 04-04, 220473 04-04
JEZEQUEL AM 215681 04-15
JIMERSON D 222772 04-10
JINDAL MN 206782 03-03
JIRSAK R 215073 04-07
JOAQUIN A 218191 04-03
JOBE PC 204339 02-03
JOFFE JM 218492 04-04
JOFFROY AJ 212182 03-03
JOGAN E 209122 03-09, 210507 03-09
JOHANNESSEN JN 220312 04-03
JOHANSSON JO 195539 01-03, 202969 02-04, 210865 03-03, 225561 04-04
JOHANSSON R 199621 02-13, 221628 04-13
JOHN ER 204189 02-06
JOHNS MW 206450 03-14
JOHNSON A 194827 01-14
JOHNSON AL 224423 04-09
JOHNSON AM 197949 01-04
JOHNSON BE 204233 02-15
JOHNSON C 205504 02-13
JOHNSON DAW 194407 01-17, 222602 04-17
JOHNSON DD 197742 01-03, 199861 02-03
JOHNSON DN 210676 03-02
JOHNSON HD 208617 03-04
JOHNSON JC 195116 01-03
JOHNSON PC 217154 04-08
JOHNSTONE EC 206366 03-09
JOHNSTONE EE 194860 01-08
JOLY H 221668 04-17
JONA G 197574 01-04
JONAS W 197490 01-04
JONAS WZ 201000 02-09
JONES BC 223093 04-04
JONES BE 217541 04-04
JONES C 206985 03-13
JONES EA 202769 02-04
JONES F 224829 04-17
JONES FD 224773 04-13
JONES G 217878 04-13
JONES GL 200481 02-09
JONES JR 210684 03-10
JONES R 215740 04-14
JONSSON G 195449 01-03, 222263 04-04
JONSSON J 217881 04-03
JONSSON JA 205433 02-03
JORI A 198211 02-03
JOSEPH A 207579 03-14
JOSEPH C 217962 04-03
JOSEPH MH 219522 04-03
JOSPE ML 212593 03-17
JOUNELA AJ 204879 02-05
JOUVET M 215703 04-03
JOVANOVIC UJ 205621 03-13
JUKES AM 221656 04-09, 221663 04-15
JULIANO DB 212811 03-11
JUNASOVA D 205639 03-11
JURNA I 193282 01-04
JUS A 213530 04-08, 215701 04-08, 216789 04-13
JUS K 213530 04-08, 215701 04-08, 216789 04-13
JUST WW 217837 04-03
JUSTUS P 197567 01-03
JUVANCZ P 197578 01-04

K

KAARIAINEN I 194744 01-03
KABES J 205601 03-09
KADOTA K 211360 03-15
KADZIELAWA K 210880 03-03

KAFOE WF 197496 01-03
KAHAN E 211071 03-02
KAHN RJ 199517 02-14
KAINULAINEN P 209702 03-11
KAINUMA H 198518 02-14
KAITANI H 209394 03-08
KAIYA H 211365 03-11
KAJARIA SM 194719 01-10
KAJFEZ F 221858 04-01
KAJI S 222158 04-08
KAKIHANA R 197821 01-03
KALANT H 211100 03-03, 211112 03-03, 217672 04-03
KALAT JW 223033 04-04
KALBHEN DA 215710 04-13
KALISH R 208595 03-01
KALISKER A 215691 04-03
KALLMAN WM 214014 04-04
KAMAT KA 197446 01-03
KAMEI C 202802 02-04, 221287 04-02
KAMENICKA V 205600 02-09, 215065 04-09
KAMETA H 213293 03-10, 221209 04-09
KAMEYAMA Y 202422 02-03
KAMIENNY RS 222871 04-14
KAMIYA I 198705 02-11
KAMPMAN R 221558 04-08
KANDEL HJ 225455 04-14
KANE M 202777 02-03
KANEKO H 194509 01-11
KANEKO M 197491 01-03
KANEKO S 224392 04-11
KANEKO Z 202178 02-10
KANIG K 204398 02-13
KANNENGIESSER M 210904 03-03
KANNO T 224195 04-14
KANO R 216391 04-15
KANOWSKI S 203842 02-13, 203845 02-16
KANTER SL 195053 01-13, 210896 03-16
KANTOR SJ 215014 04-13, 224836 04-09
KAPELSKI Z 202786 02-09
KAPLAN J 198230 02-12
KAPLAN JH 215456 04-08
KAPLANSKI J 197498 01-03
KAPLITZ SE 218216 04-11
KAPLUNSKIY GD 201909 02-14
KARACAN I 224719 04-15
KARASAWA T 221287 04-02
KARCZMAR AG 195094 01-03
KARGE E 197469 01-03
KARGER W 206781 03-03
KARLER R 195117 01-03, 198021 01-03, 200035 02-03
KARMELI F 196188 01-13
KARNIOL IG 197867 01-14, 210785 03-04
KAROBATH M 199867 02-03, 206990 03-03, 210856 03-03
KAROUM F 217219 04-06
KASAHARA H 209395 03-11
KASHIMA H 212947 03-09, 217957 04-14
KASINSKI N 197867 01-14
KASL SV 224766 04-09
KASTNER M 203600 02-09
KASTURIRANGAN V 200897 02-08
KATAOKA K 210713 03-03
KATAOKA N 198710 02-08
KATICIC N 198354 02-10
KATO G 210180 03-11
KATO H 194460 01-08, 209394 03-08, 211365 03-11
KATO K 204426 02-17
KATO S 202162 02-11
KATO T 198710 02-08, 207534 03-08, 223182 04-10
KATO Y 214885 04-13
KATORI I 194449 01-08
KATZ RJ 217526 04-04
KATZMAN R 214323 04-03
KAUL PN 197493 01-03, 197494 01-03, 217667 04-06
KAUR A 194276 01-10, 194558 01-10
KAWA A 218364 04-04
KAWAGOE T 202800 02-03
KAWAHARA R 194457 01-08
KAWAI H 211344 03-10
KAWAKAMI K 210559 03-14
KAWANO M 218364 04-04
KAWASAKI T 220904 04-03
KAWASHIMA K 222802 04-06
KAY SR 213726 04-08
KAYAALP SO 210866 03-03
KAYMAKCALAN S 210866 03-03, 210873 03-05, 217651 04-03
KAZAMATSURI H 201241 02-17
KAZDOVA E 205583 02-03
KAZIC T 197575 01-03
KEARLEY RC 202758 02-04
KEARSE BCW 196250 01-03
KEBABIAN JW 224096 04-03
KEEFE WE 220951 04-01
KEHR W 193302 01-03, 195950 01-03, 197583 01-03, 217852 04-03
KELEMENICS K 197580 01-03
KELKAR VV 206782 03-03
KELLAMS J 196675 01-07
KELLAWAY P 199756 02-13
KELLEHER RT 225157 04-04
KELLER HH 197950 01-03
KELLEY DM 217472 04-03
KELLOGG C 202266 02-03, 202715 02-03
KELLY D 196036 01-17, 201897 02-10, 206367 03-10
KELLY DM 193448 01-03
KELLY EA 209486 03-10
KELLY JT 202764 02-15
KELLY LA 217653 04-03
KELLY PH 198225 02-04, 213432 04-04
KELLY SF 211831 03-14
KELSEY JE 206739 03-04
KEMPF E 198135 02-03
KEMPF H 215698 04-11, 221338 04-08
KEMPH JP 194710 01-11
KENDEL K 205446 02-13
KENDIG JJ 195248 01-03
KENNARD O 205029 02-01, 210746 03-01
KENNEDY GL 193429 01-03
KEPLINGER ML 193429 01-03
KERR FWL 210700 03-03
KERRY RJ 202219 02-10
KESSELL A 224486 04-09
KESSLER CM 206933 03-08
KEUP W 210890 03-03
KEY BJ 197829 01-03, 210827 03-03
KEY M 195433 01-04
KEYES JB 204733 02-04
KHALSA JH 211746 03-03
KHALYUTINA LV 198486 02-03
KHANNA JM 217672 04-03
KHARITONOV RA 224086 04-11
KHARKEVICH DA 198435 02-03
KHECHINASHVILI GG 219504 04-03
KHRISTOLYUBOVA NA 216999 04-12
KHURANA AB 194556 01-10
KHVILIVITSKIY TY 220403 04-17
KIDO A 206339 03-04, 210853 03-04
KIDO K 207535 03-09
KIDO R 202122 02-04
KIELHOLZ P 203784 02-15, 207100 03-17, 209332 03-09
KIERKEGAARD-HANSEN A 213483 04-03
KILBEY MM 213531 04-04
KILOH LG 205318 02-09
KIM J 210888 03-03
KIMISHIMA K 204424 02-04
KIMURA S 211304 03-08, 224195 04-14
KIMURA Y 202122 02-04, 213293 03-10
KING PK 210869 03-03
KINZIE JD 196231 01-17
KIPLINGER GF 210871 03-14
KIRAN BK 217965 04-03
KIRBY J 210869 03-03
KIRILYUK AP 206415 03-03
KIRK L 221634 04-14, 221635 04-08, 221821 04-13
KIRKEGAARD A 204406 02-15
KIRKEGAARD G 204406 02-15
KIRSTEN EB 204483 02-03
KISELEV GV 219747 04-03
KISHIDA S 219472 04-04
KISHIMOTO A 207643 03-08, 209411 03-10, 216390 04-11, 217114 04-09, 225086 04-09
KISHIMOTO R 223202 04-08
KISHORE B 194276 01-10, 194558 01-10, 195615 01-08
KITAGAWA S 199910 02-04, 202862 02-02, 221736 04-03, 221741 04-02
KITAJIMA S 213293 03-10, 221209 04-09
KIZER JS 208994 03-03
KJELLBERG B 213590 04-04, 217663 04-03
KLAIBER EL 205437 02-03
KLAPETEK J 209019 03-11
KLAWANS HL 200086 02-13, 200088 02-03, 202282 02-11, 203885 02-03, 218115 04-04, 218213 04-08
KLEBEL E 221738 04-14
KLEIN DF 195916 01-09, 195936 01-17, 198088 02-07, 213705 04-13, 215456 04-08, 218773 04-15, 224855 04-11
KLEIN RH 211258 03-13
KLEIN RM 217524 04-04
KLEIN SB 217807 04-04
KLEINLOGEL H 206972 03-03
KLEPPING J 219709 04-03
KLERMAN GL 209438 03-15, 224766 04-09
KLETT CJ 193068 01-09
KLEYN M 217000 04-14
KLINE NS 193039 01-15, 194758 01-11, 196680 01-09, 216706 04-17
KLINGENSTEIN RJ 197470 01-04
KLINGER A 195940 01-11
KLINGER PD 213853 04-04
KLINGER W 197469 01-03
KLIPEC WD 213153 03-04
KLOTZ J 202037 02-11
KLOTZ U 197951 01-13
KLUGE H 200952 02-15, 210806 03-03, 210807 03-09
KLUWE S 197282 01-03
KLYGULO TA 198482 02-04, 219502 04-04
KNABE J 193140 01-01
KNAEPS AG 213986 04-06
KNAPP A 203645 02-13
KNAPP S 195926 01-17
KNAPPEN F 200047 02-04
KNEE ST 213710 04-15
KNEEN B 217882 04-03
KNOBEL M 196197 01-14
KNOBLOCH LC 210878 03-02, 214017 04-04
KNOLL B 197574 01-04
KNOLL J 197566 01-03, 197571 01-03, 197574 01-04, 197579 01-03
KNOPP W 210809 03-09
KOBAYASHI RM 208994 03-03, 210660 03-03
KOBAYASHI T 200009 02-11
KOBAYASHI Y 205437 02-03
KOCH M 215681 04-15
KOCH-WESER J 203005 02-13, 204851 02-17, 213920 04-17, 218151 04-17
KOCHANSKY GE 194865 01-14, 218155 04-15, 218156 04-14, 218217 04-11
KODAMA H 208789 03-09
KOE BK 220948 04-03
KOELLER DM 206805 03-07
KOEPKE HH 218153 04-13
KOGA I 204430 02-08, 223202 04-08
KOGA T 215723 04-03
KOGA Y 224507 04-15
KOHUT A 196782 01-03
KOIKE K 202500 02-17
KOIZUMI N 211339 03-08
KOKKINIDIS L 202203 02-03
KOLIBAS E 205639 03-11
KOLLER WC 212520 03-03
KOMENDA S 205624 03-14, 217205 04-14
KOMENDANTOVA MV 198479 02-02
KOMISSAROV IV 200566 02-03, 208991 03-04, 218470 04-04
KOMLOS M 197289 01-03
KOMUKU T 223202 04-08
KONIG L 203601 02-14
KOOB GF 221039 04-04
KOPANDA RT 216373 04-09, 224796 04-14
KOPEC J 205631 03-03
KOPIN IJ 207326 03-03, 208994 03-03, 210660 03-03, 213987 04-03, 215655 04-06, 215688 04-03
KOPPELHUS P 200803 02-08
KOPRIVA K 205595 02-15
KORDUBA CA 197813 01-03
KORF J 210193 03-17
KORNERUP H 197841 01-11
KORNHABER A 209488 03-10
KOROLEV VV 212432 03-13
KOSERSKY DS 202201 02-04
KOSHINO Y 196144 01-08, 209324 03-15, 210276 03-13
KOSLOW SH 210766 03-03
KOSS MC 206250 03-03

KOSTERLITZ HW 197304 01-03
KOSTOPOULOS GK 210932 03-03
KOTORII K 198709 02-08
KOTORII M 214750 04-14
KOTORII T 214750 04-14
KOUFEN H 206805 03-07
KOUKKOU M 204899 02-10
KOVACS GL 213422 04-04
KOVACS J 197492 01-03
KOVARIK J 217204 04-13
KOYUNCUOGLU H 193458 01-03
KOZAR MD 199805 02-03
KOZHECHKIN SN 206441 03-03
KOZLOV VP 224086 04-11
KRABILL LF 206727 03-04
KRAGH-SORENSEN P 213782 04-13, 221632 04-13, 224835 04-09
KRAL J 205612 03-15
KRAMER PF 217880 04-05
KRAUS M 210348 03-03, 215066 04-03
KRAUSE RR 200773 02-13
KRAUZ VA 208972 03-03, 215487 04-04
KRAVTSOV AN 198436 02-03
KRAYNACK BJ 193426 01-03
KREBS F 215697 04-13
KREBS G 210809 03-09
KREINICK CJ 206724 03-04
KREISKOTT H 197952 01-04, 202864 02-04, 206970 03-05
KREJCI Z 205623 03-14, 205625 03-03
KRELL RD 210883 03-03
KRIEGLSTEIN G 195245 01-03
KRIEGLSTEIN J 194742 01-03, 194743 01-03, 194928 01-03, 195236 01-03, 195245 01-03, 197296 01-03, 197967 01-06, 200056 02-03, 205492 02-03
KRIGMAN MR 200168 02-05
KRITVITSKAYA GN 222889 04-03
KRIVANEK J 210779 03-03
KRIVDA JF 193412 01-10
KROLEVETS GN 200564 02-02
KRONEBERG G 195237 01-03
KROST K 219073 04-04
KRSIAK M 205588 02-04, 215063 04-04
KRUEGER BK 208300 03-03
KRUG J 221860 04-03
KRUGER E 205264 02-14, 207580 03-11
KRUK ZL 197301 01-03
KRULIK R 205607 03-09, 205629 03-03, 205630 03-03
KRUPP P 215162 04-03
KRUSE H 197953 01-04
KRUSE-JENSEN A 212238 03-08
KRYSPIN-EXNER K 196034 01-17
KRYZHANOVSKIY GN 207200 03-03
KSIR CJ 206109 03-04
KUBAT K 205633 03-17
KUCHEROVA NF 219663 04-03
KUCZENSKI R 203572 02-04, 206335 03-03, 210816 03-03, 210825 03-03, 210859 03-03
KUDO Y 202804 02-03, 213293 03-10, 221209 04-09
KUDRYAVTSEVA NN 219110 04-04
KUECHENMEISTER CA 210895 03-01
KUEHN A 197492 01-03
KUFTINEC J 221858 04-01
KUHAR MJ 210831 03-03, 213480 04-03
KUHN DM 194178 01-04, 201321 02-04
KULIG BM 222815 04-04
KULKARNI AS 197454 01-04, 197464 01-03
KULKARNI SK 201322 02-04, 202803 02-04, 221308 04-03
KUMAR A 194700 01-03
KUMAR R 209076 03-17
KUMASHIRO H 211339 03-08
KUMBAR M 210928 03-03
KUMBARACI T 224874 04-09
KUMPEL Q 205603 03-15
KUPFER DJ 194862 01-09, 207683 03-17, 224769 04-09
KUPFERBERG HJ 211064 03-13
KURAMOTO I 195232 01-03
KURIOKA Y 193828 01-15
KURKJIAN R 217874 04-03
KURLAND AA 198047 01-08
KUROMARU S 214885 04-13
KUSCHINSKY K 197286 01-04, 197954 01-03, 221038 04-03
KUSHIKU K 202800 02-03
KUSUBOV N 215710 04-13
KUZNETSOVA NA 219508 04-03
KVACHADZE DA 217067 04-03
KYRIACOU CP 193545 01-04

L

LOETANG H 196031 01-17
LABORIT H 207204 03-17, 210419 03-13
LACASSIN J 212215 03-17
LACHANCE R 213530 04-08
LACHMAN M 205612 03-15
LACKI M 199772 02-03
LACKOVIC Z 192925 01-03, 197573 01-03
LACOURSIERE RB 199663 02-14
LACY PS 193547 01-03
LADEFOGED O 197484 01-03, 210920 03-05
LADER M 193851 01-14, 195443 01-15, 202783 02-17, 209079 03-10, 209080 03-10
LADINSKY H 210668 03-03
LADISICH W 199773 02-03, 206993 03-03
LADURON P 210811 03-02, 210931 03-04
LAGERGREN K 201328 02-13
LAGUTINA NI 206439 03-04
LAIRD HE 212521 03-03
LAL H 200039 02-04, 205851 03-03, 210814 03-03, 210899 03-04, 210931 03-04, 225562 04-03, 225568 04-04
LAL S 193577 01-03, 197462 01-04, 210796 03-03, 211111 03-03
LALLI N 195532 01-10
LAMANNA JC 210820 03-03, 220944 04-03
LAMARRE Y 212182 03-03
LAMBERT P 202445 02-15, 216761 04-09, 217171 04-09
LAMBLE AP 210770 03-03
LAMBLE JW 210770 03-03
LAMON R 199473 02-11
LAMPUGNANI E 209148 03-09
LANDIS S 218300 04-03, 221031 04-03
LANDIS SC 203573 02-03
LANDO LI 207199 03-03
LANGER SZ 193279 01-02
LANGFORD WS 225382 04-14
LANGNER E 206975 03-08
LANIER LP 203579 02-04
LAPIDUS JB 193456 01-03
LAPIERRE Y 202458 02-17, 208920 03-14
LAPIN IP 201915 02-04, 201919 02-04, 215074 04-17
LAPKIN VA 219501 04-03
LAPPIN F 209070 03-09
LARISON GR 222060 04-14
LARMO-MATTINEN A 221537 04-11
LASAGNA L 224832 04-13
LASSEN JB 217471 04-03, 217663 04-03
LAT J 215066 04-03, 215068 04-04
LATIES VG 225170 04-04
LAU P 221043 04-04
LAUBIE M 221669 04-03
LAUENER H 202863 02-04
LAURAS A 212213 03-09
LAURENT B 211099 03-03
LAURITSEN B 197031 01-09, 221651 04-09
LAVARDA A 209857 03-14
LAVOINE J 208928 03-17
LAVRETSKAYA EF 223015 04-05
LAVYNE M 209839 03-17
LAWRENCE DK 198605 02-01
LAYANI M 199386 02-07
LAYMAN D 200461 02-11, 225455 04-14
LE CORRE A 210089 03-13
LE STER A 212493 03-15
LEANDER JD 215722 04-04, 217458 04-04
LEAROYD BM 202310 02-15
LEATHWOOD PD 217463 04-04
LEBLANC AE 217765 04-04
LEBLONDEL G 210791 03-03
LEBOEUF G 209840 03-03
LEBOVITZ HE 197831 01-13
LECHAT P 196580 01-03
LEE HK 199811 02-03
LEE JF 220312 04-03
LEE JH 194044 01-08
LEE N 200004 02-03
LEFKOWITZ RJ 224096 04-03
LEFKOWITZ SS 217654 04-03
LEFTOFF S 194677 01-04
LEGROS JJ 212162 03-09
LEHMANN A 198135 02-03
LEHMANN HE 194168 01-09, 198053 01-07, 198067 01-07, 215699 04-09, 219537 04-08
LEHMANN K 205042 02-13, 205043 02-13
LEHNE R 194541 01-03, 208735 03-03
LEHR RE 217667 04-06
LEHTI H 221990 04-15
LEIBOWITZ SF 210675 03-03
LEITH NJ 206741 03-04
LEITOLD M 197955 01-03
LELIEVRE-LALLIGIER A 210141 03-15
LEMBERGER L 220973 04-13
LEMMER B 197957 01-03
LEMMINGSON O 221273 04-06
LEMOAL M 220946 04-04
LENARD LG 220674 04-04
LENNINGER S 221518 04-11
LENS F 212167 03-10
LEONARD BE 197496 01-03, 210875 03-03
LEONOV BV 217005 04-03
LEOPOLD G 197956 01-13
LEPPALUOTO J 210858 03-03
LERNER S 218958 04-02
LEROUX AG 219075 04-04
LESCOVELLI M 221272 04-14
LESHEM MB 197865 01-04, 210748 03-04, 217883 04-04
LETARTE J 209840 03-03
LEVANDER S 201328 02-13
LEVI G 197871 01-03
LEVIN BE 215704 04-04
LEVINE J 196040 01-17
LEVINE RR 213616 04-03
LEVINE S 221654 04-09
LEVITT RA 193434 01-04
LEVY RH 195492 01-04, 211009 03-03
LEWANDER T 217881 04-03
LEWIS BF 213919 04-17
LEWIS JA 215668 04-13
LEWIS JD 206806 03-13
LEWIS MF 217545 04-04
LEWIS MJ 211511 03-04
LEWIS SC 193419 01-03
LIBERMAN SS 217214 04-03, 219505 04-03
LIBON P 202770 02-04
LICHTENSTEIGER W 197287 01-03
LID M 212238 03-08
LIEB J 197992 01-13
LIEBLING LI 221660 04-09
LIEBMAN JM 193303 01-03, 193582 01-04, 194152 01-04
LIENERT GA 204415 02-08
LIENHART R 197287 01-03
LIEW CC 220314 04-03
LIKWORNIK V 215734 04-03
LILJEQUIST R 200057 02-14
LIMACHER JJ 210932 03-03
LIMANTSEV AV 217005 04-03
LIN H 221053 04-03
LINDEN KJ 221337 04-10
LINDENBAUM A 210788 03-03, 220977 04-03
LINDHOLM H 221639 04-11
LINDMAR R 197958 01-03
LINDQVIST M 195238 01-01, 195950 01-03, 197583 01-03
LINDSEY CJ 210325 03-04
LINFORD REES W 216463 04-09
LINGJAERDE O 197035 01-09, 221306 04-09
LINKA Z 217001 04-11
LINNOILA M 200057 02-14, 215667 04-14
LINTON PH 210895 03-01
LION J 209126 03-17
LION JR 206939 03-09, 210210 03-14
LION P 202272 02-11
LIPICKY RJ 194927 01-03
LIPMAN RS 222411 04-17, 224767 04-10
LIPP JA 197466 01-03, 204192 02-02
LIPPMANN W 215725 04-03, 217688 04-03
LIPSITT DR 208572 03-11
LIPTON MA 213706 04-15, 215692 04-03
LISSAK K 213422 04-04
LITTERIA M 213478 04-03
LITTLE HJ 194930 01-03
LITTLETON JM 199898 02-05
LITTRE MF 205448 02-08
LITTRE-POIRIER M 216767 04-15
LIU RK 196226 01-04
LIVESEY PJ 199550 02-04
LIVINGSTON K 218191 04-03

LIVINGSTON S 216339 04-11
LJUNGBERG L 221639 04-11
LJUNGBERG T 207304 03-03
LLOYD KG 219631 04-06
LOCKARD JS 195492 01-04, 211009 03-03
LOETZER R 197486 01-03
LOEW DM 197949 01-04
LOFFELHOLZ K 197959 01-03
LOGE O 206994 03-02
LOGSTON DG 196106 01-05
LOGUE G 216485 04-11
LOH HH 193453 01-03, 197467 01-03
LOHMANDER S 195449 01-03
LOIZZO A 217467 04-03
LOKHANDWALA MF 199964 02-03
LOKHOV MI 213491 04-04
LOMAX P 217673 04-03
LOMAZZI F 197861 01-14
LONCHAMP D 212494 03-11
LONEY J 224359 04-17
LONG JP 197481 01-04, 202109 02-02, 210867 03-05, 210888 03-03, 210921 03-03, 217578 04-05
LONGEVIALLE-HENIN R 221668 04-17
LONGO VG 217467 04-03
LOO H 216758 04-09, 221667 04-09
LOPEZ-IBOR ALINO JJ 202854 02-09
LORENS SA 206733 03-04
LORENZ PC 202693 02-08
LORENZO AV 215690 04-03
LOREZ HP 192944 01-03
LORIEDO C 208970 03-15
LOSEV NA 219501 04-03
LOSEY EG 215689 04-04
LOSKOTA WJ 217673 04-03
LOTTI VJ 197471 01-03
LOUCAS K 196958 01-14
LOUGHREY-GROFOVA E 203705 02-07
LOVENBERG W 217555 04-03
LOW NC 221661 04-09
LOWNDES HE 199861 02-03
LOWREY JB 215857 04-14
LOWY K 197996 01-04
LU M 210886 03-04
LUCCIONI H 216759 04-08
LUDIN HP 193800 01-13
LUKOYANOVA SN 223013 04-04
LUKES JJ 203028 02-03
LULLMANN H 195240 01-17, 221273 04-06
LULLMANN-RAUCH R 197960 01-03, 202767 02-03
LUNDBORG P 202806 02-04, 217656 04-04, 217692 04-03
LUNDQUIST GAR 221559 04-09
LUSSIER D 224504 04-04
LUTHRA YK 217519 04-04
LUTTGE WG 221010 04-04
LUTZ EG 219353 04-15, 225338 04-15
LUTZ MP 210790 03-04, 210876 03-03
LUZI T 211202 03-11
LYCKE E 217440 04-04
LYNCH GS 199805 02-03
LYUBCHENKO PN 202925 02-13
LYUBIMOV BI 207163 03-04

M

MAAS JW 207035 03-04
MABRY PD 218498 04-04
MACAKOVA J 205623 03-14, 205624 03-14, 217205 04-14
MACCACARO GA 210077 03-15
MACCHIA B 220951 04-01
MACCHIA F 220951 04-01
MACDONALD R 201513 02-09
MACINTOSH FC 211102 03-03
MACKAY AVP 199999 02-03
MACKAY M 225382 04-14
MACKEN DL 215014 04-13
MACPHAIL RC 225162 04-04
MACSWEENEY DA 224423 04-09
MADDEN DJ 210210 03-14
MADDEN JS 205316 02-11
MADRONERO R 221722 04-02
MADSEN H 197031 01-09
MAEDA K 214885 04-13
MAEDA T 194474 01-08, 210803 03-03
MAGALIF AY 201908 02-08
MAGER M 197831 01-13
MAGNUSSON T 195244 01-03, 195439 01-03, 195440 01-03
MAGOUR S 197961 01-03
MAGYAR K 197571 01-03
MAHESHWARI UR 210903 03-03
MAHLER DL 210829 03-13
MAHNKE JH 218499 04-03
MAICKEL RP 197991 01-03, 213617 04-03
MAIER RD 204196 02-01
MAILLARD M 219836 04-14
MAILLE R 210141 03-15
MAIN VA 217882 04-03
MAITRE L 192943 01-13, 197298 01-03, 197676 01-17, 221647 04-03
MAITRE M 198135 02-03
MAJ J 197572 01-04
MAJCHROWICZ E 196805 01-03
MAKI M 215667 04-14
MAKIMATTILA A 197035 01-09
MAKOWSKA K 216747 04-09
MALAKHOV BB 220403 04-17
MALCOLM MT 205316 02-11
MALETZKY BM 206143 03-14
MALIGNAGGI S 209857 03-14
MALIK MKU 209830 03-08
MALIN J 203843 02-13
MALITZ S 198097 02-07
MALLACH HJ 221739 04-06
MALLAYA UL 196088 01-08
MALLION Y 217171 04-09
MALOBABIC ZS 202781 02-04
MALONEY GJ 197991 01-03
MALSEED RT 217669 04-03
MAMIZU K 209411 03-10
MAMMI I 194554 01-11
MANDEL LR 198230 02-12
MANDEL P 198135 02-03
MANDELL AJ 195926 01-17, 206335 03-03, 206542 03-03, 207307 03-03, 210760 03-03, 210816 03-03, 213400 04-03, 214067 04-04
MANDELL S 208536 03-15
MANDELLI M 215672 04-13
MANEZ J 221286 04-03
MANGIAMELI GC 210418 03-14
MANGONI A 210500 03-08, 210501 03-09
MANHEIMER DI 198105 02-17
MANIAN AA 195096 01-03, 199771 02-03, 210882 03-02
MANIER H 224909 04-13
MANNISTO P 210858 03-03, 221988 04-15
MANNS M 217657 04-03
MANT A 224492 04-17
MANTEGAZZA P 199912 02-05
MANUKHIN BN 219663 04-03
MAO CC 202717 02-03, 207798 03-03, 215654 04-03, 218149 04-03, 221031 04-03, 225058 04-13
MARAMIS WF 196704 01-07
MARASA J 203603 02-14, 213863 04-08, 215455 04-09
MARC V 197868 01-03
MARCH J 215740 04-14
MARCHER K 210788 03-03, 220977 04-03
MARCHETTI G 206785 03-03
MARCY R 195540 01-03
MARGOLIN DI 218115 04-04
MARGOLIS RA 217181 04-14
MARGOLIS RU 213618 04-03
MARGULES DL 211511 03-04
MARHOLD J 205612 03-15
MARIN A 212392 03-09
MARK RF 210708 03-04
MARKIANOS E 206974 03-13
MARKIN VA 198481 02-03, 219498 04-03
MARKLUND S 216968 04-03
MARKOFF RA 196231 01-17
MARKOVITCH VV 217649 04-03
MAROIS G 214055 04-03
MAROIS M 214055 04-03
MARONI JB 217829 04-04
MARQUARDT GM 200082 02-03
MARQUIS WJ 195089 01-04, 219181 04-12
MARRIOTT JG 214205 04-04
MARSANICO RG 206747 03-04, 210926 03-03
MARSDEN CD 193544 01-03, 202281 02-03, 211470 03-14, 217469 04-03
MARSH BD 215700 04-09
MARSH W 206366 03-09
MARSHALL JR 209750 03-11
MARSHALL WK 214835 04-10, 215156 04-10
MARTENSSON E 221629 04-13
MARTIN GI 225336 04-15
MARTIN J 217457 04-03
MARTIN WR 197814 01-03, 210850 03-03
MARTINELLI P 208983 03-16
MARTINI G 210500 03-08
MARTIS L 211009 03-03
MARTYNOV NN 208971 03-03
MARUKO K 211339 03-08
MARUYAMA S 220904 04-03, 224395 04-11
MARX I 210674 03-04
MARZIN D 217477 04-09
MASCIOCCHI A 200445 02-08
MASEK K 200002 02-03
MASER JD 217762 04-03
MASHKOVSKIY MD 198484 02-01, 201914 02-02, 206438 03-02, 219497 04-03, 223012 04-03
MASLOVA AF 212432 03-13
MASON AS 206940 03-17
MASON J 223394 04-14
MASTERS RS 194719 01-10
MASTERTON JP 206450 03-14
MASUDA Y 202802 02-04, 221287 04-02
MASUR J 217829 04-04
MATEJCEK M 205472 02-13, 221724 04-13
MATHUR GN 221653 04-09
MATHUR PP 196107 01-03, 217793 04-03
MATSUMOTO E 213294 03-08
MATSUMOTO K 196144 01-08, 209324 03-15, 212938 03-10
MATSUOKA T 196144 01-08
MATSUSHIMA Y 217114 04-09, 225086 04-09
MATSUSHITA K 212938 03-10
MATSUZAKI S 194509 01-11
MATTHAEI H 197962 01-03
MATTHEWS CG 210824 03-15
MATTHEWS JA 213474 04-03
MATTHIES H 198227 02-04, 210674 03-04
MATTHYSSE S 207300 03-03
MATTILA MJ 197927 01-03, 200057 02-14, 215667 04-14
MATTKE DJ 221307 04-15
MATTSSON B 221310 04-09
MATUSSEK N 204403 02-15, 206787 03-04, 221648 04-13
MATVYEYEV VF 222890 04-03
MAULDING HV 211007 03-06, 211008 03-06
MAUREL H 199386 02-07, 216760 04-09
MAURON J 217463 04-04
MAURUSCHAT W 203840 02-14, 203841 02-13, 203845 02-16
MAXION H 195155 01-11, 206977 03-14, 221339 04-14
MAY PRA 198076 02-08
MAYER O 215069 04-03
MAYSOV NI 224114 04-03
MAYZELIS MY 223063 04-03
MAZIERES H 212774 03-14
MAZZONCINI V 206783 03-05, 221267 04-03
MCBRIDE A 197303 01-03
MCBRIDE WJ 225161 04-04
MCCALL RB 204865 02-02
MCCANDLESS DL 211102 03-03
MCCAUGHRAN JA 195907 01-03
MCCAULLY RJ 200739 02-01
MCCAWLEY A 208536 03-15
MCCLAIN LD 195054 01-03
MCCLURE J 206360 03-14
MCCLURE WO 223051 04-03
MCCOUBRIE M 209082 03-09
MCCOY DJ 220474 04-04
MCDANAL CE 211425 03-15
MCDERMOTT CM 202219 02-10
MCDONALD R 218556 04-09
MCFADIN LS 217816 04-03
MCGAUGH JL 202724 02-04
MCGEER EG 210658 03-03, 217842 04-03
MCGEER PL 195112 01-03, 210658 03-03
MCGLASHAN TH 224790 04-17
MCGLOTHLIN W 206356 03-12
MCGUFFIN JC 193546 01-04, 222804 04-03
MCHOSE JH 195995 01-04
MCHUGH PR 202693 02-08, 217552 04-04
MCKEARNEY JW 213619 04-04
MCKENZIE GM 217523 04-11
MCKIM WA 200046 02-04
MCKINNEY WT 224776 04-04
MCLAUGHLIN JL 202382 02-01

MCLEAN JR 215732 04-04
MCLENNAN H 197993 01-03
MCMAHON EM 217695 04-03
MCMASTER SE 211494 03-05
MCMILLAN DE 200055 02-04, 215722 04-04, 225169 04-04
MCMILLIN WP 215149 04-09
MCNAIR DM 199517 02-14, 210738 03-14
MCNEILL JH 197452 01-03
MCWHIRTER WR 202922 02-15
MEACHAM M 224906 04-04
MEADOW A 216190 04-08
MEANI E 210501 03-09
MEDAKOVIC M 197581 01-03
MEDEK A 205623 03-14, 205624 03-14, 217205 04-14
MEDICI M 205575 02-13
MEDINA MA 197455 01-05
MEDLEWICZ J 194746 01-09
MEDZIHRADSKY F 221053 04-03
MEEKER R 219073 04-04
MEFFERT A 194928 01-03
MEHTA CS 220475 04-03
MEISCH J 217897 04-03
MEISEL W 195940 01-11
MEJTA C 202987 02-04
MEKHEDOVA AY 223013 04-04
MEKHOVA GM 219328 04-04
MELCHIOR CL 217520 04-03
MELDRUM BS 199764 02-03, 210355 03-03
MELE C 211226 03-11
MELGES FT 224755 04-14
MELISKA CJ 202980 02-04
MELLANBY J 210916 03-04
MELLERUP ET 205929 03-09, 221417 04-15
MELLINGER GD 198105 02-17
MELLO NK 202307 02-13, 224753 04-14
MELO JC 215693 04-04
MELSOM H 195444 01-15, 195445 01-13
MELTZER HY 195450 01-03, 206332 03-08, 213527 04-08
MELVIN KB 194130 01-04
MEMBREY J 210088 03-14, 212774 03-14
MENDELS J 194826 01-13, 195918 01-09, 195930 01-13, 195931 01-09, 202777 02-03, 206333 03-09, 207444 03-13, 208917 03-09, 211412 03-03, 224871 04-09
MENDELSON JH 202307 02-13, 224753 04-14
MENDLEWICZ J 218042 04-16
MENGUY A 221286 04-03
MENON MK 221737 04-03
MENON MS 195618 01-10, 200897 02-08
MERCIER J 221286 04-03
MERLET A 202037 02-11
MERLINI L 194071 01-09
MERLIS S 198068 01-07, 198098 02-08, 218153 04-13
MERLO L 206785 03-03
MERRITT JH 197455 01-05
MERTEN K 205043 02-13
MERTENS HW 217545 04-04
MESHVELISHVILI DF 209032 03-03, 213469 04-04
MESSERI P 221052 04-04
MESSERSCHMITT P 212494 03-11
METYS J 205578 02-03, 205579 02-03
METYSOVA J 205578 02-03
MEURICE E 212164 03-13
MEYER DK 197288 01-03, 197963 01-03
MEYER ER 195091 01-03
MEYERHOFF JL 221039 04-04
MEZEY E 204386 02-03
MIANO JD 202417 02-03
MICEV V 214835 04-10
MICHAELIS AF 211008 03-06
MICHALUK J 217815 04-03
MICHELLI FA 202824 02-11
MICHIELS LJM 213986 04-06
MICKEY MR 218190 04-03
MICOSSI LG 198224 02-03
MICZEK KA 202768 02-04, 221043 04-04
MIDDAUGH LD 196025 01-03
MIDDELHOFF HD 203602 02-15
MIDDLETON RSW 221655 04-09
MIELKE D 206933 03-08, 216188 04-08
MIGAS EA 208973 03-03, 217065 04-03
MIGEON C 209131 03-11
MIKAMI Y 209394 03-08
MIKHAILOVA NM 194043 01-11
MIKULKA PJ 217807 04-04
MILOSHTEYN GI 206439 03-04, 223062 04-04
MILES SB 206768 03-03
MILLER F 204862 02-02
MILLER JJ 197993 01-03
MILLER RD 217523 04-11
MILLER RE 224907 04-04
MILLER RP 217694 04-05
MILNER JS 195305 01-04
MILOGRADOVA GP 198479 02-02
MILONE FF 202272 02-11
MINAZZI M 209148 03-09
MINCK K 200047 02-04
MINDE KK 207582 03-11
MINNE H 215695 04-05
MIRAGOLI G 206785 03-03, 221268 04-02
MIRAS CJ 210773 03-01
MIRMAN MJ 209486 03-10
MIRSKY AF 217544 04-03
MISHRA OP 198196 02-03
MISRA CH 207333 03-03
MISSALA K 211111 03-03
MISUREC J 205600 02-09, 205615 03-11, 215064 04-13, 215065 04-09
MITCHELL AS 202966 02-13
MITCHELL CL 197451 01-03
MITCHELL R 193060 01-09
MITCHELL VE 205223 02-14
MITROFANOV VS 219498 04-03
MITTAG TW 217869 04-03
MITYUSHOV MI 219327 04-04
MIURA K 198710 02-08
MIURA S 224507 04-15
MIYA TS 197684 01-04, 206912 03-03
MIYABO S 219472 04-04
MIYAGISHI B 198710 02-08
MIYAMOTO K 207643 03-08, 210713 03-03
MIYAMOTO M 202422 02-03
MIZOGUCHI AH 194564 01-01
MIZRAHI J 219960 04-09
MIZUGUCHI R 218011 04-11
MIZUSHIMA S 211339 03-08
MJORNDAL T 209790 03-08
MLCAKOVA K 205603 03-15
MOCHIZUKI Y 196443 01-14, 209412 03-10
MODEL DG 194854 01-13
MODELL W 206605 03-17
MODESTIN J 199913 02-13, 207196 03-15
MODIGH K 198025 01-03
MOHAN KJ 210209 03-13
MOHLER H 197585 01-03, 197965 01-03, 210780 03-03
MOHR C 224776 04-04
MOLANDER L 198014 01-04
MOLCAN J 205596 02-15, 205613 03-08
MOLDOFSKY H 199473 02-11
MOLGO J 210925 03-03
MOLINE RA 225333 04-15
MOLINEGO L 210065 03-17
MOLINOFF PB 207331 03-17
MOLLA AL 207532 03-10
MOLLOY BB 195092 01-02, 197870 01-03, 200004 02-03, 210870 03-02, 210922 03-03, 211104 03-03
MOLODAVKIN GM 217064 04-04, 217649 04-03
MOMBOUR W 221307 04-15
MONIUSZKO-JAKONIUK J 210744 03-03, 210872 03-03
MONOV A 196923 01-15
MONRAD A 200803 02-08
MONROE RR 209130 03-11
MONTAGUE AF 217041 04-14
MONTAGUE S 205472 02-13
MONTEL H 197295 01-03, 197964 01-03, 202805 02-03
MONTGOMERY S 217969 04-15
MONTI JA 195054 01-03
MOODY JP 222604 04-09
MOORE F 210896 03-16
MOORE J 202861 02-17
MOORE JN 202968 02-04
MOORE KE 195049 01-03, 204865 02-02, 208552 03-03, 213620 04-03, 214110 04-03, 217456 04-03, 217872 04-03, 220974 04-03
MOORE RH 215724 04-03, 215727 04-03
MOORMAN P 210897 03-08
MOOSMAYER A 221739 04-06
MORCELET J 212493 03-15
MOREVA EV 219506 04-03
MORGAN JF 210673 03-03
MORGAN JJ 205435 02-13
MORGAN JP 203034 02-03
MORGAN MJ 210666 03-04
MORGAN R 200636 02-08
MORGAN WW 197465 01-03, 210673 03-03, 217816 04-03
MORGANE PJ 213621 04-03
MORI A 196149 01-09
MORI H 198709 02-08
MORI Y 209405 03-08
MORIARTY JD 218214 04-14
MORIGUCHI Y 200447 02-17
MORIN RD 210352 03-01
MORISHITA H 210787 03-03
MORITA S 207534 03-08
MORITA T 206339 03-04, 210853 03-04
MORLAND J 199896 02-14, 211070 03-14
MORRIS DJ 214337 04-17
MORRIS LA 214228 04-17, 221165 04-15
MORRISON J 222772 04-10
MORRISON RC 209830 03-08
MORSE WH 225157 04-04, 225168 04-06
MORSELLI P 209073 03-15
MORSELLI PL 197868 01-03, 210507 03-09, 215672 04-13, 221188 04-03
MORTIMORE S 210742 03-04
MOSHKOVSKIY YS 223015 04-05
MOSKO S 210710 03-03, 217863 04-03
MOSKOWITZ H 206356 03-12
MOSKOWITZ M 209839 03-17
MOSLY SA 222633 04-01
MOSS DE 199039 02-04
MOSS J 215655 04-06
MOTOIKE M 207643 03-08, 223202 04-08, 225086 04-09
MOTTONEN M 215160 04-05
MOUNIE J 219709 04-03
MOUNT CD 202417 02-03
MOUNTFORD D 195992 01-03
MOUNTJOY CP 219521 04-09
MOYERSOONS F 205507 02-03, 213589 04-03
MRSULJA BB 211106 03-03
MUCCIARDI AN 213863 04-08
MUELLER RA 193304 01-03, 202795 02-03
MUKHAMETOV LM 201479 02-03
MULAS A 200044 02-03
MULAS ML 200044 02-03
MULHALL S 210897 03-08
MULICK JA 218492 04-04
MULLER D 203704 02-14
MULLER E 204413 02-15
MULLER J 203704 02-14
MULLER P 217826 04-04
MULLER W 193278 01-01, 194148 01-01
MULLER WE 200033 02-03, 217686 04-01
MULLER-HESS R 207153 03-13
MULLER-OERLINGHAUSEN B 203841 02-13, 206971 03-16, 215697 04-13
MULLEROVA S 205610 03-09
MULLIGAN BM 195118 01-03
MULLIGAN LT 196107 01-03
MUNARI C 205470 02-13
MUNCH-PETERSEN S 197841 01-11
MUNDO AS 221188 04-03
MUNEKIYO K 210703 03-03
MUNJACK D 193986 01-15, 224984 04-10
MUNKVARD I 207284 03-04, 221335 04-15, 221637 04-08
MUNRO RJK 213784 04-09
MUNSTER G 225559 04-04
MUNTZING J 197291 01-04
MURAYAMA K 217662 04-03
MURAZAKI M 194459 01-12, 196443 01-14, 209412 03-10
MURPHY DL 194397 01-13, 199631 02-09, 215860 04-16, 216373 04-09
MURPHY JE 207532 03-10, 215058 04-14, 215060 04-10, 215152 04-10, 221658 04-09, 225107 04-09
MURPHY S 215161 04-03
MURPHY SD 197488 01-03
MURTHY KSK 210801 03-03
MUSCHOLL E 217657 04-03
MUSTY RE 210785 03-04
MUTALIPASSI LR 211437 03-08
MUUS P 221634 04-14
MYERS RD 200034 02-03, 210672 03-03, 217520 04-03, 219075 04-04
MYLES SB 200064 02-03

MYSLINSKI NR 212522 03-03

N

NABEYAMA T 217354 04-09
NACHON M 218959 04-09
NAGAI H 207535 03-09
NAGANUMA R 224394 04-11
NAGASE F 223053 04-03
NAGASHIMA M 207535 03-09
NAGASWAMI S 210209 03-13
NAGAWA Y 195549 01-03
NAGAYAMA H 206339 03-04, 210853 03-04
NAGY A 221385 04-09, 221628 04-13
NAGY J 202779 02-04
NAHORSKI SR 196808 01-03, 217527 04-03, 217677 04-03
NAHUNEK K 205580 02-09, 205582 02-08, 205591 02-08, 205600 02-09, 205615 03-11, 215064 04-13, 215065 04-09
NAIK N 215654 04-03
NAIK VP 194554 01-11
NAIR NPV 198053 01-07, 200898 02-08
NAIR X 200037 02-03
NAITO Y 202122 02-04
NAKAGAWA F 196144 01-08
NAKAHAMA H 198610 02-04
NAKAJIMA S 206751 03-04, 216391 04-15
NAKAJIMA Y 210241 03-09, 217354 04-09
NAKAMURA K 210794 03-17, 225086 04-09
NAKANE Y 214304 04-11
NAKANISHI M 199210 02-03
NAKANISHI S 224194 04-10
NAKANO M 195235 01-03
NAKANO S 210559 03-14
NAKAO T 209411 03-10, 217114 04-09, 223202 04-08
NAKAOKA K 208789 03-09
NAKASHIMA Y 207718 03-15
NAKATANI H 194509 01-11
NAKAYA K 209413 03-09
NAKAZAWA K 194457 01-08, 209411 03-10, 216390 04-11
NAKAZAWA Y 214750 04-14
NAKRA BRS 202699 02-13, 209789 03-13
NAMBA T 210180 03-11
NAMIKI M 210559 03-14
NAMYSLOWSKA I 207767 03-17
NANNO H 200009 02-11
NAQUET R 199764 02-03
NARAHASHI T 217662 04-03
NARANG RL 195616 01-10
NARANJO C 223921 04-12
NAROD ME 215980 04-03
NASELLO AG 202722 02-05
NASH H 206377 03-17
NASRALLAH H 224832 04-13
NATHAN L 194834 01-10
NATSUGOE K 221823 04-02
NAVRATIL J 205623 03-14, 205624 03-14, 205625 03-03, 217205 04-14
NAYANI GR 196069 01-08
NAYLOR GJ 222604 04-09
NAYLOR RJ 193448 01-03, 193450 01-03, 195250 01-03, 195252 01-03, 197929 01-04, 197930 01-04, 199911 02-04, 202792 02-04, 210754 03-04, 217472 04-03, 217547 04-04, 217660 04-04, 217671 04-04
NAZARENO JP 211008 03-06
NEDERGAARD OA 197966 01-03
NEELEY S 202777 02-03
NEFF NH 199347 02-03, 215600 04-03
NEILSON M 205318 02-09
NEKOLOVA J 215075 04-08
NELL T 193282 01-04
NELSON JJ 213353 03-11
NELSON WL 195561 01-01
NEMEC J 205597 02-15, 205611 03-15
NEMECEK S 205632 03-03
NEMTSOV AV 200021 02-03, 215499 04-03, 219606 04-03
NESTADT A 216485 04-11
NETTER P 206984 03-16
NEU C 207042 03-16
NEUMANN Y 216485 04-11
NEUMEYER JL 210930 03-04
NEUVONEN PJ 193301 01-03
NEWELL LR 200168 02-05
NEWMAN LM 210876 03-03
NEWTON RW 212265 03-15
NEYE J 204400 02-05
NEZIROGLU F 209489 03-10
NIAGUCHI T 198608 02-01
NICA S 205614 03-10, 205637 03-11
NICAK A 196782 01-03
NICHIIKI S 208789 03-09
NICHOLLS J 200054 02-04
NICHOLS DE 202109 02-02, 208593 03-12, 210867 03-05, 210921 03-03, 217578 04-05
NICHOLSON AN 199957 02-04
NICKLAS WJ 195048 01-03
NICOLOV N 215161 04-03
NICOLSCHI L 205637 03-11
NIELSEN IM 210892 03-03, 210893 03-03
NIELSEN M 197928 01-03, 217966 04-03, 225565 04-03
NIEMEGEERS CJE 198223 02-03, 206786 03-04, 206804 03-02, 225562 04-03
NIEMEYER DH 194928 01-03, 197967 01-06
NIEMINEN L 215160 04-05
NIETO D 205505 02-13
NIKOLOVA M 215076 04-03
NIKULINA EM 219110 04-04
NINTEMAN FW 215732 04-04
NIR I 202772 02-04
NISHIDA K 210180 03-11
NISHIKAWA K 212947 03-09, 217957 04-14
NISHIKIORI T 207519 03-15
NISHIURA M 211304 03-08, 220156 04-08
NISHIZAKI H 196444 01-02
NISHIZAWA T 197491 01-03
NISHIZONO M 204427 02-17
NISKANEN P 197276 01-17, 221989 04-08
NISTRI A 193550 01-03
NITURAD A 205585 02-08, 205637 03-11
NOBLE AB 224776 04-04
NOBLE EP 224830 04-13
NOBLE P 201239 02-15
NOBLE RE 225062 04-13
NOGUCHI S 209866 03-04
NORDIO S 215672 04-13
NORRMAN B 214018 04-14
NORTON S 213622 04-04
NOSE T 195234 01-03, 215686 04-03
NOSEDA V 206785 03-03
NOTOSOEDIRDJO M 202390 02-10
NOVAK A 205638 03-10
NOVOTNA J 205610 03-09
NOVOTNY V 205613 03-08, 205639 03-11
NOWACZYK T 197578 01-04
NOWAK H 200573 02-15
NOYES R 206146 03-09, 209787 03-07
NOZAWA A 210180 03-11, 221664 04-14
NUDELMAN A 200739 02-01
NUITE JA 193429 01-03
NUNES JF 217532 04-04
NURIMOTO S 195231 01-04
NUTT JG 198030 01-14
NYAKAS C 197498 01-03
NYBACK H 207295 03-08, 222805 04-03
NYBY J 202983 02-04
NYMARK M 210892 03-03, 210893 03-03
NYRKOVA VG 198484 02-01
NYSTROM I 206974 03-13
NYSTROM M 207305 03-03

O

OOBOYLE M 201153 02-04
OOBRIEN CP 197539 01-15, 225386 04-09
OOBRIEN P 201513 02-09
OOCALLAGHAN MA 210812 03-03
OOCONNOR MF 217794 04-03
OODONNELL SR 199862 02-03
OOREGAN B 202705 02-09
OBE G 210810 03-15
OBIANWU H 199621 02-13
OBRIST R 210753 03-03
OBUKHOV GA 217003 04-14
ODA N 209411 03-10
ODA T 207643 03-08
OELSCHLAGER H 199209 02-02
OELSNER T 206933 03-08, 216188 04-08
OFSTI E 221306 04-09
OGAWA N 195231 01-04, 198733 02-04
OGIHARA M 194509 01-11
OGLE FL 194827 01-14
OGLESBY MW 225162 04-04
OGLETREE AM 218156 04-14
OGREN S 207305 03-03
OGUCHI T 209412 03-10
OGURA C 207643 03-08, 207720 03-09, 209411 03-10, 216390 04-11, 225086 04-09
OH M 205179 02-08
OHARA K 209395 03-11, 224395 04-11
OHARA Y 207554 03-09
OHGO S 214885 04-13
OHMAN R 221631 04-13
OHSHIMA M 214750 04-14
OHTA Y 200009 02-11
OKA M 220903 04-04, 221287 04-02
OKADA F 225523 04-13
OKADA M 223182 04-10
OKAMOTO H 195232 01-03
OKAWA M 224719 04-15
OKSENKRUG GF 201919 02-04, 219503 04-13
OKUMA T 194457 01-08, 207720 03-09, 209411 03-10, 215955 04-14, 216390 04-11, 217114 04-09, 225086 04-09
OLDENDORF WH 206913 03-03
OLDS ME 210704 03-04
OLESEN OV 195042 01-03, 197744 01-03, 199623 02-03, 213481 04-03
OLESHANSKY MA 215600 04-03
OLEYNIK VM 224466 04-04
OLGIATI SG 209485 03-10
OLIVE G 196580 01-03
OLIVERIO A 203520 02-04, 221032 04-03, 221037 04-03, 225557 04-04
OLIVEROS A 205520 02-13
OLIVEROS C 205520 02-13
OLIVIER AP 217865 04-03
OLIVIER-MARTIN R 210334 03-17, 217477 04-09
OLLEY JE 210752 03-04
OLSSON SO 217663 04-03
OMINE S 212947 03-09, 217957 04-14
ONDO JG 219633 04-03
ONO K 202862 02-02
ONO N 221041 04-04
ONO T 213293 03-10, 221209 04-09
ONODERA I 198710 02-08
ONUR R 210866 03-03
OOKAWA T 205459 02-03
ORDONA TT 224359 04-17
ORELAND L 209790 03-08
ORITA N 194457 01-08
ORLANDI F 215681 04-15
ORLANSKY H 215756 04-03
ORLOV IV 198436 02-03
ORME AE 202202 02-04
ORME JE 202219 02-10
ORSULAK P 210927 03-03
ORTH M 204392 02-09
ORTMANN J 197841 01-11
OSE E 199212 02-09, 221306 04-09
OSGOOD P 202775 02-03, 204866 02-03
OSHIMA H 217544 04-03
OSIPOVA SV 201919 02-04
OSSENKOPP K 224504 04-04
OSSOFSKY HJ 195040 01-09
OSTAPTZEFF G 208928 03-17
OSTAPTZEFF M 208928 03-17
OSTERHOLM KC 197473 01-03
OSTOW M 218123 04-09
OSTROUMOVA NG 198484 02-01
OSTROVSKAYA RU 200002 02-03, 205588 02-04, 217064 04-04, 217649 04-03
OTA F 218362 04-09
OTA KY 198047 01-08
OTSUKA K 224194 04-10
OTSUKA M 199910 02-04, 206780 03-02, 221736 04-03, 221741 04-02
OTSUKA N 224507 04-15
OTSUKA R 196144 01-08, 209324 03-15, 210276 03-13
OTSUKA T 211339 03-08
OTSUKI S 197209 01-09, 205460 02-13, 207554 03-09, 207718 03-15, 207719 03-09, 209413 03-09, 212340 03-09, 218772 04-09
OTT JE 202919 02-15
OTT T 198227 02-04
OTTEN U 202795 02-03
OVERALL JE 198059 01-02, 198107 02-17, 209904 03-10
OVERO K 210834 03-03
OVERSTREET DH 197855 01-04, 199956 02-04, 208555 03-03

OVERTON DA 195935 01-17

P

PAALZOW G 193452 01-03, 197926 01-03, 215683 04-03
PAALZOW L 193452 01-03, 197926 01-03, 215683 04-03
PAAVILAINEN MT 209702 03-11
PABRAI PR 197494 01-03
PADJEN A 218148 04-03
PAGE JG 202824 02-11
PAKKENBERG H 196600 01-11, 197841 01-11, 206359 03-03
PALATUCCI DM 193087 01-15
PALERMO NETO J 217532 04-04
PALFREYMAN ES 199868 02-03
PALFREYMAN MG 199868 02-03
PALIDER W 197572 01-04
PALKOVITS M 208994 03-03, 210660 03-03, 210661 03-03, 210919 03-03
PALM U 221633 04-15
PALMER DS 215980 04-03
PALMER GC 195096 01-03, 199771 02-03
PANACCIO L 203204 02-04
PANASYUK LV 223017 04-03, 224115 04-03
PANCHENKO PM 220420 04-11
PANDEY G 194826 01-13, 195930 01-13, 202777 02-03, 211412 03-03, 224773 04-13, 224833 04-09
PANKSEPP J 206253 03-04, 219073 04-04
PAOLETTI R 207289 03-06
PAOLINO RM 206912 03-03
PAPASPIROPOULOS S 225281 04-11
PAPESCHI R 193577 01-03, 197974 01-03, 200053 02-03, 206988 03-03, 206989 03-03, 211068 03-04
PAPPAS BA 225077 04-04
PARDI G 215672 04-13
PARE CMB 203596 02-09
PAREDES A 217810 04-08
PARENT M 212162 03-09, 212163 03-10
PARISH L 216462 04-10
PARISH PA 204306 02-17
PARK GB 194561 01-16
PARKER MD 200310 02-01
PARKER RB 194478 01-04
PARLI CJ 200004 02-03, 210929 03-03
PARMAR SS 206461 03-02, 225105 04-01
PARRY HJ 198105 02-17
PARTYKA RA 202109 02-02
PASCHEN K 203602 02-15
PASS HL 212547 03-03
PASSERAN O 216464 04-11
PATEISKY K 205508 02-13
PATEL A 197965 01-03
PATEL AJ 210780 03-03
PATEL DM 225106 04-01
PATEL GJ 205851 03-03
PATEL SR 194156 01-03
PATEL VK 206782 03-03
PATITO JA 219960 04-09
PATOCKA J 205632 03-03
PATON DM 217889 04-03
PATON WDM 211689 03-17
PAUL C 202037 02-11
PAUL SM 210760 03-03
PAULING L 213703 04-13
PAWLOWSKI L 197572 01-04
PAYKEL ES 218041 04-09
PAYNE RW 198102 02-08
PAZDIREK S 205616 03-09
PEARCE JB 216463 04-09
PEARSON JE 211008 03-06
PEDERSEN V 210893 03-03
PEDROTTI DELLOACQUA LM 210069 03-17
PEGRAM GV 194929 01-03
PEITER E 197469 01-03
PELC I 221035 04-10
PENBERTHY C 217652 04-04
PENNA MW 206939 03-09
PENNING J 221724 04-13
PENRY JK 201870 02-11, 211064 03-13
PENTREATH VW 217638 04-03
PENTTILA A 221990 04-15
PEPEU G 193550 01-03, 200044 02-03
PERAITA MR 205520 02-13
PERALES JA 217025 04-08
PERBELLINI D 221272 04-14
PEREIRA-OGAN JA 216462 04-10
PEREL JM 215014 04-13, 224836 04-09, 225337 04-15
PERNEVI P 217824 04-03
PERON-MAGNAN P 205448 02-08
PERRIS C 220858 04-07, 221310 04-09
PERRY KW 195092 01-02, 197870 01-03, 200004 02-03, 203580 02-03, 210870 03-02, 210922 03-03
PERSIANINOV LS 217005 04-03
PERSSON G 197029 01-15
PERSSON S 198015 01-03, 217674 04-03
PERTWEE RG 198605 02-01
PETERS DAV 199783 02-03
PETERS MA 205467 02-03
PETERSON DW 204482 02-04
PETERSON E 217663 04-03
PETERSON JM 218492 04-04
PETERSSON B 200637 02-04
PETIT TL 203579 02-04
PETITJEAN F 215702 04-03, 215703 04-03
PETKOV V 196923 01-15
PETRANOVA T 205586 02-17, 205592 02-08
PETROVA M 205592 02-08
PETRUCH F 206992 03-13
PETTERSON U 221820 04-09
PETTI TA 225335 04-15
PFEFERMAN A 197867 01-14
PFEIFER AK 197289 01-03
PFEIFER Y 197489 01-03
PFEIFFER CC 213623 04-08
PFLUEGER AB 222804 04-03
PFOLZ H 206975 03-08
PHIFER R 217470 04-04
PHILIPPU A 195441 01-03, 197290 01-03, 197962 01-03
PHILLIPS AG 193578 01-04, 207302 03-04, 210861 03-04, 213394 04-03
PHILLIPS J 198044 01-15
PHILLIPS JM 211781 03-04
PHILLIPS KC 225567 04-03
PHILLIS JW 210932 03-03
PHILPOTT WH 209010 03-17
PIAZZA A 211226 03-11
PICHOT P 203591 02-09, 210334 03-17, 212215 03-17, 217477 04-09
PICKENS R 225156 04-04
PIEPHO RW 217794 04-03
PIERI L 192940 01-03, 204183 02-03
PIERI M 192940 01-03, 204183 02-03
PIETTE LH 213624 04-03
PIETZCKER A 206805 03-07
PIJNENBURG AJJ 217461 04-04, 217475 04-04, 217530 04-04
PIK K 197570 01-03
PILLARD RC 198089 02-11, 207775 03-14, 210738 03-14
PIMSTONE B 218557 04-15
PINAR N 206836 03-04
PINCHARD A 207151 03-11
PINDER RM 196437 01-01, 217671 04-04
PIPER JM 198605 02-01
PIRCH JH 197473 01-03
PIRES P 213530 04-08
PISARZ A 210088 03-14, 212774 03-14
PISL I 205586 02-17, 205592 02-08
PISLOVA J 205586 02-17, 205592 02-08
PLAA GL 225539 04-15
PLANCHE R 216764 04-11
PLANCHE S 216764 04-11
PLEKHOTKINA SI 198434 02-03
PLENGE P 205929 03-09
PLENGE PK 221417 04-15
PLETSCHER A 202665 02-03, 210753 03-03, 223174 04-03
PLEUL O 197968 01-03
PLEVOVA J 205627 03-14
PLOTNIKOFF NP 211069 03-01, 215692 04-03
POELDINGER W 196034 01-17
POHLE W 210674 03-04
POIRIER LJ 194483 01-05, 213450 04-03
POIRIER-LITTRE M 221668 04-17
POITOU P 210349 03-04
POLACKOVA J 205609 03-09
POLACZEK R 200573 02-15
POLC P 197585 01-03
POLDINGER W 215694 04-10
POLESUK J 211007 03-06
POLETAYEVA II 224466 04-04
POLEZHAEVA AI 201914 02-02, 207198 03-03
POLIFKO ML 212523 03-04
POLISHUK WZ 197489 01-03
POLIZOS P 217181 04-14
POLLACK A 219073 04-04
POLLARD HB 213395 04-03
POLTORAKOV AP 201909 02-14
POPE JH 196206 01-04
POPOVA N 218472 04-04, 219110 04-04, 222889 04-03
POPOVICI E 205637 03-11
POPPE W 220434 04-09
PORCEDDU ML 210776 03-03
PORFIROYEVA RP 217064 04-04
PORGES P 210881 03-03
PORRINO LJ 194865 01-14
PORTER CC 197471 01-03
POSCHEL BPH 215732 04-04
POSCHLOVA N 205588 02-04
POSHIVALOV VP 198480 02-04, 218800 04-04
POST GR 204688 02-11
POST ML 205029 02-01, 210746 03-01
POST RM 196087 01-13, 202886 02-14, 210602 03-14, 224796 04-14
POSTMA E 217666 04-16
POSTMA JU 215858 04-11
POTKONJAK D 197569 01-03
POTOCZAK D 215732 04-04
POUPIER G 202037 02-11
PRADA JA 217541 04-04
PRADALIER A 209998 03-15
PRADHAN PV 196707 01-08
PRADHAN SN 197446 01-03, 197990 01-03
PRANGE AJ 195929 01-10, 198082 02-07, 198592 02-14, 215692 04-03
PRASADIO T 196704 01-07
PRAY BJ 221075 04-17
PREDESCU V 205637 03-11
PREININGEROVA O 205617 03-08
PRELLWITZ W 195446 01-13
PREMEL-CABIC A 210791 03-03
PREPAS S 221737 04-03
PRESLEY A 200049 02-13
PRESLEY JM 200405 02-02
PRESSLICH O 204413 02-15
PRICE J 202797 02-17
PRICE JS 219521 04-09
PRICE MTC 202793 02-04, 222265 04-04
PRICHEP LS 222747 04-11
PRIEN RF 193068 01-09, 193291 01-11, 194355 01-09, 196678 01-07, 197531 01-09, 215009 04-11, 224872 04-09
PRINCIPI N 215672 04-13
PRITCHETT T 208325 03-08
PROCTOR CD 193422 01-03, 193423 01-03, 193424 01-03, 210869 03-03
PROKUDIN VN 200104 02-11, 201908 02-08
PROOTER H 221273 04-06
PROSSER TD 197684 01-04
PROUIX P 211012 03-15
PROVOOST AP 197584 01-03, 210759 03-03
PROX A 200738 02-01
PRUNERI C 209045 03-11
PRUSOFF B 198083 02-10, 209437 03-09, 209438 03-15
PRZUNTEK H 195441 01-03, 197290 01-03
PUGLISI CV 200737 02-16
PUGSLEY TA 215725 04-03, 217688 04-03
PUJOL B 216760 04-09
PUJOL J 215702 04-03
PURCHATZKE G 198042 01-16
PURGYI P 221515 04-15
PUSAKULICH RL 196409 01-04
PYCOCK C 217469 04-03

Q

QUADAGNO DM 213685 04-03
QUADRI SK 194571 01-03
QUARTERMAIN D 206752 03-04
QUASTEL JH 196800 01-03
QUENZER LF 219278 04-04
QUERMONNE MA 195540 01-03
QUEST JA 196107 01-03
QUIDU M 202069 02-11, 210089 03-13
QUINN CP 203166 02-04
QUINN P 194397 01-13
QUINN PO 209736 03-11

QUITKIN F 195916 01-09, 215456 04-08, 218773 04-15

R

RAAFLAUB J 206788 03-13, 219630 04-13
RABSZTYN T 205631 03-03
RACAGNI G 202465 02-06, 207289 03-06, 207500 03-03, 213399 04-03
RACINE R 218191 04-03
RACK PH 214833 04-10
RADIVOJEVIC M 197576 01-03
RADMANOVIC BZ 202780 02-04
RADSTAAK D 223394 04-14
RAESE J 204414 02-13, 206974 03-13
RAFAELSEN L 205931 03-12
RAFAELSEN OJ 205929 03-09, 205931 03-12, 221417 04-15
RAFT D 202883 02-17, 213919 04-17
RAHEJA S 194719 01-10
RAHWAN RG 197454 01-04
RAINAUT J 221671 04-11
RAINES A 197989 01-03
RAISKIY VA 200104 02-11
RAITERI M 197871 01-03
RAJ MVJ 213783 04-15
RAJAGOPALAN TG 221648 04-13
RAKICH L 219663 04-03
RAKOW D 197281 01-01
RAMACHANDRA K 194559 01-17
RAMACHANDRAN T 194559 01-17
RAMACHANDRAN V 200897 02-08
RAMANATHAN KB 219517 04-15
RAMASARMA T 221051 04-03
RAMIREZ OA 202722 02-05
RAMSAY AC 222603 04-15
RANDALL LO 198056 01-06
RANDAZZO S 209044 03-11
RANDRUP A 197483 01-04, 198014 01-04, 207284 03-04, 213590 04-04
RANDT CT 225081 04-04
RANJE C 202794 02-04
RANTA T 210858 03-03
RANTY Y 210136 03-15
RAO AV 194169 01-03, 195621 01-10
RAO KB 195617 01-09
RAO VB 196088 01-08
RAPIN J 210884 03-03
RAPIN JR 197461 01-03
RAPOPORT J 194397 01-13, 198090 02-11, 209736 03-11
RAPP W 209790 03-08
RAPPAPORT M 213764 04-08, 217454 04-08
RASCHDORF F 221648 04-13
RASCOL A 199386 02-07
RASKIN A 193093 01-11, 196040 01-17, 197856 01-09, 218770 04-09
RASMUSSEN RR 211069 03-01
RASMUSSEN S 221635 04-08
RASSAERT CL 196228 01-04
RATNER M 195116 01-03
RAUH CE 197864 01-03
RAUWS AG 197969 01-03
RAVACCIA F 221269 04-10
RAVN J 199989 02-14
RAYEVSKIY KS 224114 04-03
RAYKHMAN LM 223015 04-05
RAYNAUD J 210904 03-03
RAZANI J 193986 01-15, 213710 04-15
RAZDAN RK 208594 03-02
REATIG N 197856 01-09
REAVEY-CANTWELL NH 217793 04-03, 225106 04-01
REBEC GV 211063 03-03, 217676 04-03
REDA FA 225343 04-15
REDFERN PH 199959 02-04, 217961 04-03
REDICK JA 207326 03-03
REDMOND A 206058 03-13
REEPMEYER JC 194565 01-01
REES JA 215700 04-09
REES JMH 194930 01-03
REGEZ JL 207549 03-06
REHAN V 205610 03-09
REICH L 224769 04-09
REICHENBERG K 195434 01-04
REID AH 200049 02-13
REID JL 213987 04-03
REID L 202987 02-04, 209897 03-04
REIFFENSTEIN RJ 199769 02-03
REIGLE T 210927 03-03
REIGNIER A 207533 03-15
REIL GH 197960 01-03
REILLY MA 197472 01-03
REILLY TM 223320 04-09
REIMER F 208921 03-17
REIMERDES EH 199208 02-01
REINHOLD K 195246 01-03
REINKE LA 217794 04-03
REIS DJ 210670 03-03
REISCH J 197675 01-01
REITANO S 200445 02-08
REITER RJ 197465 01-03
REMR J 215075 04-08
REMSCHMIDT H 203881 02-14
REMSCHMIDT U 203881 02-14
REMY-SCHMETZ J 212164 03-13
RENFORDT E 203844 02-13
RENNICK PM 205031 02-11
RENO H 210761 03-03, 210762 03-04, 222817 04-04
RENSON J 207496 03-01
RENYI AL 197869 01-03
RENZI P 221032 04-03
REPRINTSEVA VM 206404 03-03
REUNING RH 197456 01-03
REUSE JJ 197477 01-03
REYERO F 205520 02-13
REYNARD CL 219354 04-14
REYNOLDS CF 194862 01-09
REYNOLDS EH 211470 03-14
RIBLET LA 197451 01-03
RICEBERG LJ 205853 03-03
RICH P 196437 01-01
RICHARDSON JS 200980 02-17, 210919 03-03
RICHELLE M 202770 02-04
RICHMAN BW 203470 02-11
RICHOU H 216902 04-14
RICHTER A 217689 04-13
RICHTER M 205622 03-14
RICK JT 193545 01-04
RICKELS K 194045 01-10, 198049 01-17, 198069 01-07, 209486 03-10, 216462 04-10, 224742 04-17, 225386 04-09
RIEGER H 194743 01-03, 195236 01-03, 197296 01-03, 200056 02-03, 205492 02-03
RIESS W 221648 04-13
RIFKIN A 195916 01-09, 215456 04-08, 218773 04-15
RIGTER H 197497 01-03, 222807 04-04
RIJK H 197499 01-04
RIKLAN M 201496 02-11
RIM CS 205031 02-11
RINALDI P 193777 01-03, 218499 04-03
RIOUX P 205448 02-08
RISBERG A 218166 04-14
RISBERG J 218166 04-14
RISNER ME 222806 04-04
RITTER M 219073 04-04
RITTER RC 214206 04-04
RITTER S 211538 03-04
RIVERA-CALIMLIM L 224832 04-13
RIZZO M 209122 03-09, 210507 03-09
RIZZOLA N 209063 03-15
ROBBINS TW 210666 03-04, 217675 04-04
ROBERGE AG 194483 01-05
ROBERGE C 217823 04-03
ROBERT F 193800 01-13
ROBERTS DCS 223054 04-03
ROBERTS MHT 199961 02-03, 199966 02-03
ROBERTS S 204184 02-03, 217355 04-03, 223175 04-03
ROBICHAUD RC 197478 01-03, 210792 03-03
ROBIN A 209081 03-10
ROBINS E 213625 04-03
ROBINSON RG 217552 04-04
ROBSON RD 210868 03-05, 215757 04-03
ROBY DM 213282 03-03
ROCA M 210741 03-04
ROCHUS L 197477 01-03
RODDA BE 210871 03-14
RODIN EA 205031 02-11
RODOVA A 205582 02-08, 205591 02-08, 205600 02-09, 205615 03-11, 215064 04-13
RODRIGUES JMG 199255 02-05
RODUVA A 205580 02-09
ROELANDTS A 212490 03-10
ROELOFS GA 197033 01-09
ROENSBERG W 195441 01-03, 197290 01-03
ROFFLER-TARLOV S 210930 03-04
ROFFMAN M 210927 03-03
ROGER RV 219960 04-09
ROGERS KJ 196808 01-03, 217677 04-03
ROGERS LJ 210708 03-04
ROGINA V 198393 02-17
ROGLIANI G 212277 03-13, 212281 03-14
ROHTE O 197291 01-04
ROIZEN MF 215655 04-06
ROKYTA R 196758 01-04
ROLINSKI Z 210894 03-04
ROLLIN HR 225055 04-17
ROLLS BJ 198225 02-04
ROLLS ET 198225 02-04
ROMAGNOLI C 194071 01-09
ROMAN I 205566 02-13
ROMANO A 221723 04-02
ROMANOV YD 200104 02-11
ROMANOVA LA 201914 02-02
ROMERO JA 215601 04-03, 224096 04-03
ROMMELSPACHER H 197292 01-03, 210831 03-03
RONAI AZ 197566 01-03
ROOS B 197213 01-03, 197215 01-03, 217440 04-04, 217692 04-03, 221385 04-09
ROPERT R 215798 04-04
ROSADINI I 209063 03-15
ROSE CK 194045 01-10
ROSE GH 199765 02-03
ROSE SPR 210667 03-04
ROSE SW 211064 03-13
ROSECRANS JA 206353 03-03, 217821 04-12
ROSEN AJ 195088 01-04
ROSEN HJ 218306 04-11
ROSENBAUM D 211007 03-06
ROSENBERG J 210392 03-04
ROSENBERG L 203841 02-13, 203842 02-13, 203843 02-13, 203844 02-13, 203845 02-16, 221288 04-16, 221289 04-11
ROSENBERG M 225323 04-13
ROSENBLATT JE 210828 03-03
ROSENBLATT JS 219069 04-04, 219070 04-04
ROSENBLATT S 198099 02-10
ROSENFELD H 194045 01-10
ROSENFELD P 197600 01-09
ROSENFELD R 217181 04-14
ROSENKRANTZ H 193417 01-05, 193576 01-04, 217518 04-05, 217519 04-04
ROSENTHAL M 210820 03-03, 220944 04-03
ROSENZWEIG MR 202202 02-04
ROSHCHINA LF 223012 04-03
ROSIC N 211106 03-03
ROSIER YA 210126 03-09
ROSIN AJ 206926 03-14
ROSINE JE 202980 02-04
ROSLOFF BN 202723 02-03
ROSS S 205223 02-14
ROSS SB 197869 01-03
ROSSER RM 203546 02-15
ROSSI A 217840 04-03
ROSSI GV 225059 04-03
ROSSIER J 210669 03-03
ROSSIGNOL P 197461 01-03, 204220 02-03
ROSSNER M 203601 02-14
ROTH JA 195447 01-13, 220972 04-03
ROTH RH 202370 02-03, 202664 02-03, 206336 03-03, 213626 04-03, 222805 04-03, 222813 04-03, 225152 04-17
ROTHFELD B 205765 03-13, 221799 04-04
ROTHWEILER R 196039 01-11
ROTTGER HJ 206807 03-06
ROUBEIN IF 210890 03-03
ROUBI AE 215061 04-10
ROUBICEK J 205472 02-13
ROUEFF E 210128 03-09
ROUFOGALIS BD 210818 03-03
ROUTTENBERG A 210804 03-03
ROWE H 220973 04-13
ROWLES GS 196107 01-03
ROWLEY VN 215685 04-04
ROY PE 211099 03-03
ROZITIS A 198210 02-03
ROZYNOV BV 198484 02-01
RUANGTRAKOOL S 221891 04-10
RUBERG-SCHWEER M 206781 03-03
RUBIO MC 193279 01-02
RUBOVITS R 200086 02-13
RUCART G 219709 04-03
RUCH W 207155 03-15, 217462 04-03, 217543 04-03

RUD C 199989 02-14
RUDY V 201000 02-09
RUFER C 206994 03-02
RUMACK BH 202919 02-15
RUMMEL W 193140 01-01, 197948 01-03
RUMP S 197832 01-03, 205631 03-03
RUSH M 204189 02-06
RUSKIN R 208918 03-17
RUSSELL A 217476 04-03
RUSSELL RL 220687 04-04
RUSSELL RW 197855 01-04, 199956 02-04, 208555 03-03
RUSTERHOLZ DB 210921 03-03
RUTHER E 204414 02-13
RUTLEDGE CO 202191 02-03, 215691 04-03
RYBAKOWSKI J 202786 02-09, 216747 04-09
RYDZYNSKI Z 205598 02-10
RYSANEK K 217258 04-13
RYZHENKOV VY 219504 04-03

S

SAAR N 199862 02-03
SAARINEN A 210858 03-03
SAARMA J 195041 01-09
SAARMA M 195041 01-09
SAARNIVAARA L 204879 02-05
SAAVEDRA JM 196804 01-03, 210661 03-03
SABELLI HC 200064 02-03, 206768 03-03, 213627 04-03, 217521 04-04
SACHAR EJ 213527 04-08, 213918 04-09
SACHS C 195449 01-03
SACK G 203701 02-13, 203704 02-14
SACK RL 199632 02-07, 207311 03-07
SADOVSKY E 197489 01-03
SAELENS JK 197474 01-03, 211065 03-03
SAFER D 209132 03-17, 224379 04-14
SAGALES T 217546 04-14
SAGDUYU H 193458 01-03
SAHAKIAN BJ 210666 03-04, 213433 04-03, 217675 04-04
SAITO A 200447 02-17
SAITO M 213596 04-07, 223049 04-03, 224507 04-15
SAITO T 210180 03-11, 224193 04-14
SAJI Y 195549 01-03
SAKAE K 202799 02-03
SAKAI K 215703 04-03
SAKAI M 200447 02-17
SAKAI T 198608 02-01
SAKALIS G 224831 04-08
SAKAMOTO F 202285 02-14
SAKAMOTO Y 208723 03-11
SAKURADA S 198610 02-04
SALAMA AI 197482 01-04
SALDANA JJ 210673 03-03
SALETU B 203603 02-14, 210808 03-14, 213863 04-08, 215455 04-09, 225516 04-10
SALETU M 215455 04-09, 225516 04-10
SALIMOV RM 218814 04-04, 223064 04-04
SALLER R 197957 01-03
SALPETER MM 213474 04-03
SALVA L 210286 03-14
SALYAEV VN 201917 02-03
SALZMAN C 194865 01-14, 198071 01-07, 208573 03-11, 218155 04-15, 218156 04-14, 224754 04-14
SALZMAN LF 211258 03-13
SALZMANN R 197300 01-03, 197941 01-03
SAMANIN R 210668 03-03, 210923 03-03
SAMARDZIC R 202781 02-04
SAMOYLOVA ZT 198486 02-03
SAMUELLY M 210890 03-03
SANDERS AF 217533 04-04
SANDERS MG 206745 03-04
SANDERS-BUSH E 202417 02-03, 208553 03-03
SANDLER M 206365 03-03, 213715 04-17, 213716 04-17
SANER A 192944 01-03, 223174 04-03
SANGER DJ 195433 01-04, 199866 02-04, 225149 04-04
SANGHVI I 198055 01-02, 213592 04-04
SANGIAH S 193455 01-03
SANKAR DVS 195115 01-08, 210928 03-03
SANO I 210635 03-09
SANSONE M 217466 04-04
SANTAGOSTINO A 200045 02-03
SANTOS CA 196025 01-03
SARACENI C 209527 03-14
SARAMIKOV AS 201888 02-03, 219749 04-03
SARGENT T 215710 04-13
SARKAR C 210769 03-03
SASA M 210703 03-03
SASAJIMA K 202862 02-02
SASAKI K 202121 02-11
SASSENRATH EN 221340 04-04
SASSIN J 213918 04-09
SASTRY BSR 195095 01-03
SATHANANTHAN G 200637 02-04, 207285 03-14, 224831 04-08, 225065 04-14
SATIJA DC 200922 02-09
SATO C 194512 01-08
SATO K 196443 01-14, 209412 03-10, 224392 04-11
SATO M 213294 03-08
SATO S 195494 01-04, 205491 02-03, 211064 03-13
SATTERFIELD J 195940 01-11
SATTERFIELD JH 198100 02-10
SAUCIER D 221049 04-04
SAUNDERS DR 196256 01-03, 206912 03-03
SAVINEL E 210141 03-15
SAVITSKAYA NV 198484 02-01
SAVITSKY E 208576 03-11
SAWLER B 205455 02-03
SAWYER BD 206354 03-03
SAWYER CH 210662 03-03
SAWYNOK J 197480 01-03
SAYERS AC 206972 03-03, 217462 04-03
SCANLAN JM 225343 04-15
SCARABINO R 205575 02-13
SCATTAREGIA F 222814 04-04
SCHABAREK A 197858 01-03
SCHACHT U 202807 02-03
SCHAEFER A 197289 01-03
SCHAEFER JF 197486 01-03
SCHAEFFER JC 222822 04-03
SCHAEFFER LA 222870 04-02
SCHAFER A 215695 04-05
SCHAIN RJ 217885 04-03, 219354 04-14
SCHALLEK W 197492 01-03
SCHALLER JP 218582 04-17
SCHANBERG SM 210933 03-03, 217695 04-03
SCHATZ RP 205851 03-03
SCHAUB RG 196261 01-03
SCHAYER RW 197472 01-03
SCHECHTER MD 199963 02-04, 217531 04-04
SCHEEL-KRUGER J 197490 01-04, 197928 01-03, 210894 03-04, 225565 04-03
SCHEELE G 206769 03-03
SCHENK G 221724 04-13
SCHENKER S 197951 01-13
SCHERRER P 219836 04-14
SCHEUER C 202968 02-04
SCHIAVON M 217460 04-10
SCHIELE BC 198070 01-07, 202764 02-15
SCHIFF AA 215060 04-10
SCHILDKRAUT JJ 202249 02-09, 202380 02-17, 203594 02-09, 210927 03-03, 213628 04-09
SCHIRRMEISTER M 197469 01-03
SCHLAPFER WT 215705 04-03
SCHLEIFER M 205264 02-14
SCHLEMMER RF 207035 03-04
SCHLESINGER K 213629 04-03
SCHLESS AP 211412 03-03
SCHLOSBERG AJ 225159 04-04
SCHLOSSER W 222818 04-04
SCHLUPKOVA L 205613 03-08
SCHMID K 221648 04-13
SCHMIDT B 210929 03-03
SCHMIDT G 197577 01-03
SCHMITT H 221669 04-03
SCHMITZ W 203645 02-13
SCHMUTZ J 221734 04-01
SCHNEIDER E 195155 01-11, 204407 02-15, 206977 03-14, 221339 04-14
SCHNEIDER-AFFELD F 193140 01-01
SCHNELL RC 197684 01-04, 199770 02-03
SCHNELLE K 204393 02-13
SCHNETZLER JP 211998 03-11
SCHOEL WM 213853 04-04
SCHOENER EP 204483 02-03
SCHOENFELD RI 210930 03-04
SCHOLTYSIK G 197300 01-03, 197971 01-03
SCHOOLAR JC 197458 01-03
SCHOOLER N 224831 04-08
SCHOOLER NR 199625 02-08, 199626 02-08
SCHOONHOED L 197986 01-03
SCHORDERET M 192936 01-03
SCHOU M 200568 02-09, 209392 03-09
SCHRODER E 206994 03-02
SCHROLD J 197970 01-03
SCHULTE PW 206805 03-07
SCHULTERBRANDT JG 197856 01-09
SCHULTZ J 195254 01-03, 197293 01-03, 197972 01-03
SCHULTZ O 199208 02-01
SCHULZ J 217193 04-11
SCHULZ M 203645 02-13
SCHULZ R 197811 01-03
SCHULZE B 209018 03-15
SCHUMAN J 211065 03-03
SCHUMANN HJ 197943 01-03
SCHUPPEL RVA 206992 03-13
SCHUSTER CR 225165 04-05
SCHUSTER P 204413 02-15
SCHUT T 215454 04-13
SCHUYLER D 214011 04-13
SCHWALB H 221336 04-15
SCHWARTZ GV 215699 04-09
SCHWARTZ MA 221732 04-13
SCHWARTZ MS 199782 02-13
SCHWARTZ R 225517 04-16
SCHWARTZ RB 200572 02-15
SCHWARTZBAUM JS 206724 03-04
SCHWEBKE R 203742 02-11
SCHWEITZER JW 225517 04-16
SCHYDLO RB 203882 02-15
SCLABASSI R 197992 01-13
SCOGGINS BA 198029 01-09
SCOTT DF 199782 02-13
SCOTTO J 216759 04-08
SCRIBANU N 194397 01-13
SCROLLINI F 221723 04-02
SDINO C 211219 03-04
SEBENS JB 210193 03-17
SECRET P 221672 04-17
SECUNDA SK 208917 03-09
SEDLACEK J 197788 01-03
SEDLACEK S 221647 04-03
SEDVALL G 207295 03-08, 210864 03-03, 213630 04-03, 215734 04-03
SEEDAT YK 195773 01-14
SEEMAN P 217826 04-04
SEGAL AM 207199 03-03
SEGAL DS 206335 03-03, 210816 03-03, 210859 03-03, 214067 04-04
SEGAL M 193449 01-03, 203573 02-03, 223171 04-03
SEGAWA T 195234 01-03, 195235 01-03
SEGAWA Y 208789 03-09
SEIBOLD S 204393 02-13
SEIDEN LS 213631 04-04, 217459 04-04, 225162 04-04
SEIFERT J 200002 02-03
SEIFERTOVA D 205622 03-14
SEIFTER J 197457 01-03
SEILER N 210813 03-03
SELIGER DL 225079 04-04
SELLS CJ 203847 02-14
SEMINARA B 201668 02-09
SEPINWALL J 225171 04-04
SEPPALA T 215667 04-14
SERAFETINIDES EA 195039 01-13
SERCK-HANSSEN G 195591 01-03
SERENI F 215672 04-13
SERKOV FN 199443 02-03
SERRA MT 217553 04-03
SERVIT Z 205635 03-17
SETEKLEIV J 199896 02-14, 211070 03-14
SETHI BB 206014 03-03
SETHI N 206014 03-03
SETHY VH 195046 01-03
SETOGUCHI M 199210 02-03
SEVER PS 198028 01-12, 200007 02-14, 217690 04-03, 217691 04-03
SEXTON K 217548 04-14
SHABSHELOWITZ H 200081 02-03
SHACHNOW NK 208536 03-15
SHAD NS 194156 01-03
SHADER RI 193192 01-17, 194865 01-14, 198051 01-17, 198071 01-07, 198823 02-17, 199515 02-14, 200584 02-09, 202725 02-09, 203005 02-13, 204851 02-17, 205299 02-17, 207161 03-17, 208573 03-11, 213920 04-17, 218151 04-17, 218155 04-15, 218156 04-14, 218217 04-11, 224754 04-14

SHAFFER JW 199518 02-14
SHAGASS C 195935 01-17
SHAH BK 196680 01-09, 208919 03-17
SHAH DK 225064 04-10
SHAH LP 196707 01-08
SHAH UH 206782 03-03
SHANI J 210793 03-03
SHANKAR R 198196 02-03
SHAPERO M 210351 03-04
SHAPIRO AK 193073 01-16, 207957 03-11, 221165 04-15, 224894 04-16, 224910 04-11
SHAPIRO E 207957 03-11, 224894 04-16, 224910 04-11
SHAPIRO S 194064 01-13, 212107 03-15
SHARMA S 194556 01-10
SHAROVA SA 217214 04-03, 219505 04-03
SHARPE J 225323 04-13
SHARPLES D 217891 04-03
SHASHKOVA IA 212432 03-13
SHAW DM 224423 04-09
SHAW JS 221048 04-04
SHAW SG 198225 02-04
SHEARD MH 209129 03-11
SHEARER DE 201409 02-03
SHEFFIELD B 212491 03-08
SHELLENBERGER MK 206334 03-03
SHELLEY EM 194746 01-09
SHERMAN A 195097 01-03
SHERSTNEV VV 198436 02-03
SHERWOOD BE 195561 01-01
SHEYKHON FD 207200 03-03
SHIH T 222641 04-03
SHIMA K 198610 02-04
SHIMABUKURO T 204424 02-04
SHIMIZU H 202603 02-08, 204464 02-10
SHIMIZU M 202802 02-04, 220903 04-04, 221287 04-02
SHIMIZU N 210803 03-03
SHINTOMI K 215682 04-04, 215684 04-04
SHIRAKAWA I 197867 01-14
SHLIAPOCHNIK J 205435 02-13
SHOEMAKER WJ 193050 01-03
SHOEMAN DW 202662 02-03
SHOMORI A 210241 03-09
SHOPSIN B 200637 02-04, 207446 03-09, 213522 04-15, 217827 04-03, 218129 04-09, 225334 04-15
SHORE PA 210862 03-03, 213632 04-03
SHOSTAK M 224836 04-09
SHOULSON I 194542 01-13, 215674 04-13
SHROPSHIRE AT 215712 04-03
SHULGIN AT 215710 04-13, 217557 04-12
SHUMILOVA NY 215498 04-04
SHUSTER L 221042 04-03
SHVEDOV VI 206438 03-02
SICARD JP 207533 03-15
SICHEL J 210128 03-09
SICILIANI O 217460 04-10
SICUTERI F 211108 03-12
SIEBEL I 217450 04-09
SIEGEL HI 219069 04-04, 219070 04-04
SIEGEL L 197600 01-09
SIEGEL LG 223051 04-03
SIEGEL RK 210739 03-04, 215696 04-04
SIEMENS AJ 211100 03-03, 211112 03-03, 217672 04-03
SIGG EB 222818 04-04
SIKORA J 205629 03-03
SILD L 195041 01-09
SILVA MT 217528 04-06
SILVERMAN LB 214719 04-11
SILVERSTONE JT 198046 01-10
SILVERSTONE T 197137 01-11, 201270 02-17, 212888 03-17, 214011 04-13
SIM M 209428 03-17
SIMEON J 213600 04-17, 215455 04-09, 224955 04-08, 225516 04-10
SIMEON S 213600 04-17
SIMKE JP 197474 01-03, 211065 03-03
SIMMELSGARD H 197841 01-11
SIMMONS VJ 193547 01-03
SIMOLA I 204879 02-05
SIMON M 205853 03-03
SIMON P 197986 01-03, 202029 02-17
SIMPSON CW 206727 03-04
SIMPSON E 194409 01-17, 210437 03-17
SIMPSON GM 194044 01-08, 198052 01-08, 198072 01-02, 213532 04-15
SIMPSON JB 210804 03-03
SIMPSON LL 195436 01-03, 197854 01-04, 215687 04-03
SIMS ACP 223165 04-08
SINCLAIR G 202966 02-13
SINCLAIR JG 195095 01-03, 196259 01-03
SINGER G 225563 04-04
SINGH G 196090 01-14
SINGH HK 198227 02-04
SINGH JM 193420 01-04
SINGH KP 207164 03-02, 221740 04-03
SINGH MM 213726 04-08
SINGHABHANDHU A 201003 02-01
SINHA AK 217664 04-03
SINYUKHIN VN 198484 02-01, 201914 02-02, 207198 03-03
SIOMOPOULOS V 221386 04-13
SIROKA A 205623 03-14, 205624 03-14, 217205 04-14
SIRTORI CR 202662 02-03
SISKIND V 212107 03-15
SITARAMAM V 221051 04-03
SIVIL S 210873 03-05
SIWERS B 211071 03-02
SIZARET P 212179 03-10
SJODEN P 223044 04-04
SJOSTRAND I 210434 03-10, 221638 04-10
SKEELS M 196437 01-01
SKLENOVSKY A 205625 03-03
SKLODOWSKI H 205598 02-10
SKOTT A 221385 04-09
SKREDE KK 199763 02-03
SKULA E 205610 03-09
SLADE LT 217795 04-03
SLANSKA J 196776 01-16, 204401 02-16, 205627 03-14
SLATER P 197475 01-03
SLEDGE K 197478 01-03
SLETTEN IW 215251 04-17
SLOAN JW 210850 03-03
SLOAN K 217548 04-14, 218120 04-09
SLONE D 212107 03-15
SLONIM PS 198897 02-04
SLOTKIN TA 205852 03-03
SMALL A 199640 02-11
SMALL JG 196675 01-07
SMALSTIG EB 206354 03-03
SMIRNOVA LB 206439 03-04
SMITH AA 210751 03-03
SMITH AJ 221650 04-09
SMITH DF 198027 01-03
SMITH GP 215704 04-04
SMITH HE 202417 02-03
SMITH K 198084 02-09
SMITH R 207305 03-03
SMITH RC 221044 04-12, 225063 04-09
SMITH RD 193304 01-03
SMITH S 193429 01-03, 217796 04-03
SMITH SE 217689 04-13
SMITH SG 205889 03-04
SMITH TL 219179 04-03
SMITH WL 215857 04-14
SMOLONIKOVA NM 207163 03-04
SMULEVICH AB 194043 01-11, 200072 02-09
SMYTH RD 217793 04-03
SMYTHIES JR 194929 01-03, 207293 03-08, 213528 04-04
SNAITH RP 209082 03-09
SNEATH TC 222829 04-06
SNIDER SR 217797 04-03
SNODDY HD 197870 01-03, 211104 03-03, 217696 04-03
SNYDER BD 202922 02-15, 219621 04-15
SNYDER F 210602 03-14, 214015 04-14
SNYDER RW 199863 02-03
SNYDER SH 195925 01-17, 206437 03-17, 207287 03-04, 207298 03-03, 213480 04-03, 213633 04-03
SOARES JR 193586 01-01
SOAVE OA 217553 04-03
SOBOR A 217000 04-14
SOBOTKA P 196758 01-04
SOBRIAN SK 225077 04-04
SODERBERG U 213434 04-04, 221640 04-03, 223044 04-04
SOFIA RD 197486 01-03, 200043 02-04, 210878 03-02, 214017 04-04, 217577 04-02
SOGA K 222158 04-08
SOHJI Y 221287 04-02
SOKOL G 210871 03-14
SOKOLOVA YV 219327 04-04
SOLIMAN SA 206460 03-01
SOLIS H 205443 02-13
SOLOMATINA ES 219502 04-04
SOLOMON G 224910 04-11
SOLOMON K 205288 02-15
SOLOVYEV LA 200071 02-13
SONNE LM 217455 04-10
SORANZIO MR 213591 04-03
SORIMACHI M 210713 03-03
SORRENTINO GM 204864 02-03
SOUBRIE P 197986 01-03
SOUCEK K 205589 02-09, 205607 03-09, 205608 03-09
SOURKES TL 193577 01-03, 194857 01-13, 197462 01-04, 210796 03-03, 211111 03-03
SOUSSEN G 212492 03-09
SOUTHGATE PJ 197305 01-03
SOWINSKI J 216747 04-09
SPANKOVA H 217258 04-13
SPARBER SB 204482 02-04, 225160 04-04
SPATZ H 218959 04-09
SPECIALE SG 201005 02-03
SPECTOR HB 217668 04-15
SPECTOR NH 221039 04-04
SPECTOR S 222802 04-06
SPEHLMANN R 205510 02-03
SPEIRS CF 199782 02-13
SPEISER-COURVOISIER J 206788 03-13
SPENCER HJ 193803 01-03
SPENCER JW 199765 02-03, 214207 04-04
SPENCER PSJ 210761 03-03, 210762 03-04, 222817 04-04
SPERANSKAYA NP 215789 04-04
SPIEGEL R 207140 03-14
SPIRIDONOVA ZI 201888 02-03, 219749 04-03
SPIRT N 196836 01-13
SPIRTES MA 218956 04-02
SPOHN HE 198103 02-08, 199663 02-14
SPRAGUE RA 217518 04-05
SPRAGUE RL 198091 02-11
SPRINGER AD 213853 04-04
SPRUYT L 212164 03-13
SPYKER JM 225164 04-15
SQUIRE LR 203572 02-04, 221005 04-04
SQUIRES RF 198209 02-03, 210817 03-04, 217471 04-03
SRIDHAR C 195621 01-10
SRINIVASAN V 194169 01-03
SRUTOVA K 215073 04-07
ST. LAURENT J 196042 01-09, 204169 02-08, 221045 04-09
STADLER H 217685 04-03
STAFFORD CR 217668 04-15
STALBY B 193452 01-03
STALINICKIEWICZ G 210141 03-15
STALLONE F 218042 04-16, 224874 04-09
STAMBAUGH JE 199519 02-13
STAMM T 197294 01-03
STANCER HC 217665 04-03
STANDEN SM 210507 03-09
STANDRIDGE RT 202109 02-02
STANISSTREET M 200752 02-03
STARK LG 198613 02-03
STARKE K 197295 01-03, 197973 01-03, 202805 02-03, 214062 04-03
STARLING PB 194130 01-04
STAUFFER H 215710 04-13
STAUFFER SC 209789 03-13
STEEN JA 217545 04-04
STEIN L 210671 03-04, 211538 03-04
STEINBERG H 199866 02-04, 201293 02-04, 210351 03-04
STEINER H 206784 03-08, 206983 03-08
STENBERG VI 206461 03-02
STENIER P 224583 04-10
STEPANEK J 197460 01-03, 197485 01-03
STEPHANOVA D 215076 04-03
STEPHENS DN 221030 04-03
STEPHENS JH 199518 02-14
STEPITA-KLAUCO M 210701 03-03
STEPPE TV 208595 03-01
STERCKX G 197477 01-03
STERN JA 206360 03-14
STERN M 214812 04-16
STERNBACH R 224800 04-13
STERNLICHT M 197600 01-09
STEVENS J 200052 02-03
STEVENS JR 205455 02-03

STEVENS N 194063 01-13
STEVENSON IH 200049 02-13
STEWART MJ 194409 01-17, 210437 03-17
STEWART WJ 223849 04-04
STIGBRAND T 216968 04-03
STIGMAR I 221518 04-11
STIKA L 205633 03-17
STILLE G 202863 02-04, 206998 03-06
STILLMAN IS 194927 01-03
STILLMAN R 198230 02-12, 224756 04-14
STINNETT JL 207444 03-13
STINNETTE MJ 210860 03-04
STINUS L 213431 04-04
STITZER M 202666 02-04, 210879 03-14
STIX AH 195145 01-14, 199609 02-14
STOCK G 195439 01-03, 195440 01-03, 199213 02-04
STOCK R 194742 01-03, 195236 01-03, 197296 01-03
STOHS SJ 217794 04-03
STOKES JW 208917 03-09
STOLK JM 210821 03-03
STOLYAROV GV 200073 02-08, 200565 02-03
STONE GC 206377 03-17
STONE TW 195438 01-03, 213398 04-03
STONIER PD 197475 01-03
STORM-MATHISEN J 211062 03-03
STOYCHEV EG 194208 01-11
STRAIN A 206187 03-04
STRAUMANIS JJ 195935 01-17
STRAUSS JS 224790 04-17, 224832 04-13
STREICHENBERGER G 199385 02-02
STREKALOVA SN 207163 03-04
STRIPLING JS 198222 02-04, 222749 04-04
STRNAD D 205599 02-13, 205616 03-09
STROGONOV YA 207271 03-11
STROMBERG U 217835 04-04
STROMBOM U 195429 01-03
STROMSAETHER CE 199896 02-14, 211070 03-14
STRUENING EL 224894 04-16
STUBING G 204468 02-17
STULL RE 204339 02-03
STUMPF C 210881 03-03
STURGES S 219970 04-17
SUAREZ MV 205505 02-13
SUDA T 200009 02-11
SUGA T 196444 01-02
SUGANO K 194512 01-08
SUGAWARA M 196443 01-14
SUGDEN RF 197305 01-03
SUGERMAN AA 198073 01-07
SULLIVAN JL 217523 04-11
SULMAN FG 197489 01-03, 202772 02-04, 210793 03-03
SULSER F 202417 02-03, 202782 02-03, 208553 03-03, 210749 03-03, 210771 03-03
SULZBACHER SI 221103 04-11
SUM G 225382 04-14
SUMINISHI Y 194509 01-11
SUNAMI Y 207720 03-09, 209411 03-10
SUNJIC V 221858 04-01
SUNSHINE A 215673 04-14
SUPEK Z 197568 01-03
SURIA A 194541 01-03, 217873 04-03, 225058 04-13
SUTKO M 218499 04-03
SUTTER J 216759 04-08
SUVARNA GC 195620 01-10
SUVOROV NN 219663 04-03
SUWA N 225523 04-13
SUZUKI O 223053 04-03
SUZUKI S 194512 01-08
SUZUKI Z 210559 03-14
SVENSSON R 199621 02-13
SVENSSON TH 193541 01-03, 217835 04-04, 221131 04-03
SVESTKA J 205580 02-09, 205582 02-08, 205591 02-08, 205600 02-09, 205615 03-11, 215064 04-13
SWANSON GD 215669 04-13
SWAZEY JP 224972 04-17
SWEET RD 224910 04-11
SWETT C 193072 01-15, 197923 01-01, 198050 01-17, 225332 04-15
SWETT CP 194865 01-14
SWIFT EW 207771 03-14
SWIFT WJ 207771 03-14
SYMCHOWICZ S 197813 01-03
SYME GJ 202721 02-04
SYME LA 202721 02-04
SYNDER T 224742 04-17
SZABADI E 199961 02-03
SZAJNERMAN Z 202786 02-09
SZE PY 213479 04-03, 225527 04-03
SZEKELY JI 197859 01-04

T

TABACHNICK J 217823 04-03
TABERNER PV 193545 01-04
TACCARDI B 221268 04-02
TACKE B 215698 04-11, 221338 04-08
TAGLIAMONTE A 210776 03-03
TAGUCHI K 207718 03-15, 209413 03-09
TAKAGI S 215291 04-17
TAKAHASHI J 208761 03-17
TAKAHASHI R 206339 03-04, 210853 03-04
TAKAHASHI RN 210785 03-04
TAKAHASHI Y 194509 01-11
TAKAKOSU Y 194512 01-08
TAKAORI S 210703 03-03
TAKASAKI K 197491 01-03
TAKEI H 223182 04-10
TAKEMOTO H 215686 04-03
TAKESHITA H 217114 04-09
TAKISHITA S 215723 04-03
TAL A 206745 03-04
TALONOV AN 199443 02-03
TALALAYENKO AN 200566 02-03, 208991 03-04, 218803 04-04
TALBOT JA 197465 01-03
TAMAGNONE GF 194956 01-04, 221735 04-01
TAMAOKI S 210241 03-09
TAMAZAWA A 216391 04-15
TANABE K 204424 02-04
TANAKA K 213293 03-10, 224549 04-08, 225086 04-09
TANAKA M 209394 03-08, 210559 03-14, 222158 04-08
TANAKA T 218011 04-11, 224644 04-13
TANEDA M 209412 03-10
TANGRI KK 195249 01-03
TANIJIKI T 194460 01-08
TANIMUKAI H 202178 02-10, 221209 04-09
TANNER NS 195560 01-01
TANSELLA CZ 217460 04-10
TANSELLA M 217460 04-10
TARPY RM 211512 03-04
TARSY D 193544 01-03, 199958 02-04, 217469 04-03
TASHJIAN AH 207857 03-03
TASKA RJ 197458 01-03
TASSIN JP 210800 03-03, 217687 04-03
TAUBE HD 214062 04-03
TAUBER J 205569 02-13
TAUC L 210664 03-03
TAUSSIGOVA D 205581 02-08, 205601 03-09
TAYLOR FH 222814 04-04
TAYLOR KM 222816 04-04
TAYLOR M 202740 02-04, 210742 03-04
TAYLOR MJ 215680 04-17
TAYLOR RE 210771 03-03
TAYLOR T 206806 03-13
TCHAVDAROV D 215076 04-03
TECCE JJ 198101 02-13, 217544 04-03
TEGLER J 204409 02-15, 217453 04-15
TEHRANI JB 225059 04-03
TEICHMANN H 203742 02-11
TEITELBAUM H 220312 04-03
TEJA JS 225064 04-10
TELEGDY G 213422 04-04
TEMKOV I 220425 04-08
TEN HAM M 197866 01-04, 217474 04-04, 217673 04-03
TENNENT G 196958 01-14
TEPLITZ TA 202886 02-14
TERAI T 222158 04-08
TEREKHOVA NM 219507 04-03
TERNAUX JP 217655 04-03
TERNES JW 219023 04-04, 219031 04-04, 219033 04-04, 219039 04-04
TESSEL RE 193137 01-04, 210886 03-04, 210887 03-03, 223563 04-04
TETENOCHUK EV 219328 04-04
TETREAULT L 203204 02-04
TEUTSCH G 210829 03-13
THEISOHN M 197567 01-03
THEISS P 197974 01-03, 206989 03-03
THEL S 217837 04-03
THEODORIDES M 224585 04-11
THEODORIDES VJ 211412 03-03
THERES C 197297 01-03
THIBAULT P 203495 02-15
THIERRY AM 195239 01-03, 210800 03-03, 217687 04-03
THIESSEN DD 202983 02-04
THOENEN H 202795 02-03
THOMAS E 217526 04-04
THOMAS J 197492 01-03
THOMAS JA 207326 03-03, 217848 04-03, 218147 04-03
THOMAS RJ 217697 04-05
THOMASOVA E 205603 03-15
THOMPSON CS 217524 04-04
THOMPSON DM 215969 04-04
THOMPSON GR 193417 01-05
THOMPSON H 207446 03-09, 225065 04-14
THOMPSON T 225156 04-04
THOMSEN K 195042 01-03, 197744 01-03, 199623 02-03, 210696 03-03, 213481 04-03
THOMSON TD 212524 03-03
THONGSTANG O 221891 04-10
THOR DH 206714 03-04
THORELL L 212241 03-11
THORNBURG JE 208552 03-03, 220974 04-03
THORNER MW 213478 04-03
THORNTON WE 221075 04-17
THORSEN K 214010 04-15, 221335 04-15
THURMOND A 217548 04-14, 218120 04-09
TIKAL K 205627 03-14
TIKHONOV VN 218470 04-04
TIKK P 195041 01-09
TILBURG WV 215858 04-11
TILDERS FJH 197498 01-03
TILSON HA 195089 01-04
TIMAR J 197574 01-04
TIMPERMAN J 204195 02-15
TISLOW R 224742 04-17
TISSOT R 197468 01-03, 197994 01-03, 206834 03-10, 225558 04-03
TITOV NS 201917 02-03
TJIO J 195949 01-13
TOBLER HJ 207549 03-06
TODA N 202799 02-03
TODOROKI S 207535 03-09
TODZY I 197975 01-03
TOGNONI G 215672 04-13
TOHYAMA M 210803 03-03
TOKAR JT 198104 02-08
TOKIZAWA T 224548 04-08
TOLLE R 204404 02-15
TOLPYSHEV BA 200565 02-03, 219500 04-03, 223014 04-03
TOMAS I 220271 04-11
TOMIOKA T 213294 03-08
TOMKIEWICZ M 201293 02-04
TOMLINSON WK 206933 03-08
TOMOSKY TK 194155 01-03
TOMPKINS EC 196066 01-04
TONGE SR 195437 01-03, 200058 02-03, 217962 04-03, 217963 04-03
TONINELLI P 211202 03-11
TORCHIANA ML 197471 01-03
TORCHIO P 221723 04-02
TORRE E 225564 04-04
TORRE M 225564 04-04
TORRELIO M 210221 03-13
TORRIELLI MV 194956 01-04, 197453 01-03, 202765 02-03
TORRITI A 210211 03-11
TORU M 201260 02-15
TOSCHI G 217840 04-03
TOSOVSKY J 215070 04-13, 215071 04-13
TOTHILL A 222803 04-03
TOVI M 207305 03-03
TRABUCCHI M 202465 02-06, 210885 03-06, 213399 04-03, 221732 04-13
TRACY M 198051 01-17
TRALLORI L 221267 04-03
TRAPOLD JH 217652 04-04
TRAVERSA U 213591 04-03
TRAVIS RP 210895 03-01
TRAYLOR TD 200168 02-05
TRELINSKI M 217691 04-03
TREMBLAY JP 215705 04-03
TRENDELENBURG U 197944 01-03
TRETOYAKOVA KA 198486 02-03

TREVOR AJ 210903 03-03
TRICK KLK 221652 04-09
TRICKLEBANK MD 195906 01-04
TRIEBE J 197675 01-01
TRIEZENBERG HJ 215689 04-04
TRIGGLE C 199769 02-03
TRIMBLE M 211470 03-14
TRIPLETT JN 210700 03-03
TRITT J 201843 02-04
TROLIN G 217824 04-03
TROMBETTA N 203599 02-14
TROUPIN AS 215738 04-11
TSAI CS 210750 03-05
TSCHENTSCHER K 195245 01-03
TSUANG MT 221166 04-09
TSUBOI S 222158 04-08
TSUCHIYA T 199910 02-04, 221736 04-03
TSUJIO T 213293 03-10
TSUKADA K 222158 04-08
TSURU N 197211 01-03
TSUSHIMA M 224193 04-14
TSUTSUI S 201655 02-09, 210180 03-11, 224193 04-14
TUCAN-FORETIC M 197568 01-03
TUCK JR 211071 03-02, 220949 04-03
TUDORACHE D 205637 03-11
TULLIS C 199473 02-11
TUOMINEN L 194064 01-13
TUOMISTO J 210858 03-03
TURAYEV RN 202925 02-13
TURECEK LR 198029 01-09
TURKANIS SA 195117 01-03, 198021 01-03, 200035 02-03
TURKER RK 217651 04-03
TURNBULL MJ 197303 01-03
TURNER CE 211010 03-06
TURNER DA 198042 01-16
TURNER M 205435 02-13
TURNER P 201270 02-17, 212888 03-17
TURNS D 195933 01-17
TURUNEN MI 194064 01-13
TURUNEN S 221537 04-11
TUTT KJ 196437 01-01
TYE N 214016 04-04
TYRER P 194066 01-17, 206368 03-10

U

UCHIDA Y 207720 03-09, 217114 04-09
UCHIMURA H 209191 03-04, 218364 04-04, 223049 04-03
UDANGIU L 205614 03-10
UEDA K 213293 03-10
UEKI S 195231 01-04, 199807 02-03, 222801 04-04
UENO F 224194 04-10
UENO K 210559 03-14
UGLESIC B 198394 02-11
UHLENHUTH EH 198042 01-16, 214812 04-16
UHLIR V 195492 01-04
ULISS DB 208594 03-02
ULRICH F 195038 01-11
ULRICH RF 199625 02-08
ULUS IH 217965 04-03
UMEZAWA H 221823 04-02, 221859 04-03
UMINO Y 211339 03-08
UNGERSTEDT U 202794 02-04, 207304 03-03
URBAN I 213430 04-03
URETSKY NJ 215690 04-03
USDIN E 206437 03-17, 225399 04-17
USHIZIMA I 221041 04-04
USKOVA NV 201919 02-04
USUI H 202799 02-03
UTECH C 213600 04-17
UTIAN W 218557 04-15
UXA M 205633 03-17
UZUNOV P 201491 02-06, 208735 03-03

V

VACAFLOR L 194168 01-09
VAISANEN K 209702 03-11
VALIN A 209728 03-03
VALLE G 217025 04-08
VALLILLO R 209071 03-08
VALZELLI L 210099 03-17
VAN ABEELEN JHF 217464 04-04
VAN BUSKIRK R 202724 02-04, 209951 03-04
VAN DELFT AML 197498 01-03
VAN DEN BERGHE H 221270 04-15
VAN DEN BURG W 198229 02-09
VAN DER KOLK B 224754 04-14
VAN DER VELDE CDK 209484 03-08
VAN DUIJN H 225529 04-02
VAN EYS B 197946 01-03
VAN HAM I 210793 03-03
VAN HART DA 193157 01-04, 195223 01-04, 195294 01-04
VAN HOOF F 204195 02-15
VAN LOMMEL R 207000 03-14
VAN NUETEN JM 206786 03-04
VAN ORDEN LS 207326 03-03
VAN PRAAG HM 197534 01-17, 198229 02-09, 199991 02-10, 203593 02-09, 207765 03-17, 215454 04-13
VAN PUTTEN T 205766 03-12, 207768 03-15, 211437 03-08, 219365 04-09
VAN REE JM 210759 03-03
VAN RIEZEN H 197499 01-04, 204412 02-14, 213595 04-16
VAN ROSSUM JM 210772 03-03, 217461 04-04, 217475 04-04, 217530 04-04
VAN VUNAKIS H 205853 03-03
VAN WOERT MH 195046 01-03
VAN ZWIETEN PA 217575 04-03, 220976 04-03
VANDECASTEELE AJA 199993 02-08
VANDENHEUVEL WJA 198230 02-12
VANDERWOLF CH 206742 03-04
VANECEK J 205620 03-15
VANINI M 200445 02-08
VANNOTTI A 207153 03-13
VARADY A 205765 03-13, 221799 04-04
VARANELLI C 217795 04-03
VARGA E 194044 01-08, 194758 01-11, 213532 04-15
VARKONYI B 224347 04-09
VARMA LP 194274 01-15
VARMA SC 194710 01-11
VAROTTO M 217858 04-03
VASKO MR 193457 01-03
VASQUEZ BJ 197855 01-04, 199956 02-04, 208555 03-03
VASSAR HB 214017 04-04
VAUTERIN C 216766 04-15
VAZQUEZ AJ 206768 03-03, 217521 04-04
VAZQUEZ-DEL MERCADO J 205442 02-13
VEALS J 197813 01-03
VEHRESCHILD T 203666 02-08, 208622 03-08
VEILLON F 216766 04-15
VELA A 205520 02-13
VELLEY L 217687 04-03
VENCOVSKY E 196758 01-04, 203705 02-07
VENTSOVSKIY E 220367 04-09
VENTURI F 198224 02-03
VEREECKEN JLTM 199993 02-08
VERGARA L 198053 01-07
VERIMER T 210866 03-03
VERMA HC 196090 01-14
VERMA M 225105 04-01
VERMA RS 194276 01-10, 194558 01-10
VERSTEEG DHG 210759 03-03, 223050 04-03
VERTUA R 213591 04-03
VERZEANO M 218499 04-03
VESCOVINI L 201667 02-09
VETULANI J 195434 01-04
VIALA D 209728 03-03, 210740 03-03
VIAMONTES G 225516 04-10
VICKERS R 205288 02-15
VICTOR SJ 217555 04-03
VIGOURET JM 197949 01-04
VIKHLYAYEV YI 198482 02-04, 207199 03-03, 223016 04-03
VIKULINA NS 219328 04-04
VILLANI F 210501 03-09
VILLENEUVE A 207052 03-17, 213530 04-08
VILLENEUVE R 213530 04-08
VINAR O 205581 02-08, 205601 03-09, 205611 03-15, 205620 03-15, 205622 03-14, 205633 03-17, 205638 03-10
VINAROVA E 205607 03-09, 205608 03-09, 205611 03-15
VINCENT O 205575 02-13
VINIK A 218557 04-15
VIOL GW 207043 03-13
VISHVESHWARA S 203027 02-01
VIUKARI M 209702 03-11
VIZI ES 197566 01-03
VOELKEL A 204411 02-09
VOGEL G 217548 04-14, 218120 04-09
VOGEL W 205437 02-03
VOGEL WH 218958 04-02
VOHRA J 209234 03-15
VOHRA JK 195847 01-15
VOITH K 208592 03-01
VOJTECHOVSKY M 205602 03-09, 205612 03-15
VOLLE RL 197445 01-03
VON ESSEN C 197213 01-03, 197214 01-03, 197215 01-03
VON HUNGEN K 204184 02-03, 217355 04-03, 223175 04-03
VONVOIGTLANDER PF 215689 04-04
VOROBOYEV VS 222890 04-03
VOROBOYEVA TM 215497 04-04
VORONTSOV VV 223019 04-05
VOVIN RY 220403 04-17
VOVINA EN 220403 04-17
VUGMAN I 199255 02-05
VUILLAUME M 199425 02-04
VYNCKE J 203598 02-11

W

WADA JA 195907 01-03, 199764 02-03
WADDELL KJ 222725 04-14
WADE LA 214323 04-03
WADE LH 210869 03-03
WADUD A 209127 03-11, 224955 04-08
WAGNER P 197976 01-13
WAGNER SR 193428 01-03
WAHLIG H 197956 01-13
WAINER IW 199519 02-13
WAIZER J 217181 04-14
WAJSBORT J 205569 02-13
WAKAHARA T 198705 02-11
WAKE A 210241 03-09
WAKO T 209399 03-11
WALCHER W 196038 01-17
WALDECK B 193541 01-03, 217797 04-03, 217897 04-03
WALDMANN KD 200952 02-15, 210807 03-09
WALDMEIER PC 192943 01-13, 197298 01-03, 197676 01-17, 221647 04-03
WALESKI MV 193421 01-03
WALINDER J 221385 04-09
WALKER JE 202919 02-15
WALKER JM 215740 04-14
WALKER M 218120 04-09
WALKER P 204189 02-06
WALKER RW 198230 02-12
WALLACH MB 197470 01-04, 199965 02-03
WALLE T 200740 02-16
WALLER MB 200034 02-03, 210672 03-03
WALLISER C 207549 03-06
WALLS EK 195081 01-04
WALSER A 208595 03-01
WALSH AC 195601 01-14
WALSH BH 195601 01-14
WALTERS JR 202664 02-03, 222805 04-03
WANG C 202465 02-06
WANG CT 210885 03-06
WANG RIH 194749 01-15
WANG SC 199811 02-03, 204483 02-03
WANG YC 195930 01-13, 196260 01-13
WARBURTON DM 192952 01-04
WARD JW 210676 03-02
WARD OB 211511 03-04
WARNKE-SACHS E 206997 03-03
WARSH JJ 217665 04-03
WATANABE A 194157 01-08
WATANABE K 217885 04-03
WATANABE M 198710 02-08
WATANABE S 207718 03-15, 207719 03-09, 209413 03-09, 210241 03-09, 212340 03-09, 217354 04-09, 218772 04-09, 224588 04-09
WATERFIELD AA 197304 01-03
WATERS DH 205432 02-04
WATT DC 224417 04-08
WAUQUIER A 198223 02-03, 225562 04-03
WAXMAN D 214837 04-10, 215157 04-10
WAYMIRE JC 215691 04-03
WAYNE HL 224910 04-11
WEBB SD 223949 04-17
WEBER BA 221103 04-11
WEBER F 197964 01-03
WEBER NE 222821 04-03
WEBSTER GW 221042 04-03
WECKOWICZ TE 223394 04-14

WEEKS JR 225155 04-04
WEEKS P 197142 01-08
WEEMAES AJM 210772 03-03
WEEMAES I 199214 02-16
WEHR KH 204196 02-01
WEICHMANN M 217837 04-03
WEIDMANN KG 197675 01-01
WEIL-MALHERBE H 201002 02-08
WEINBERG ES 214013 04-04
WEINER H 218047 04-03
WEINER N 204485 02-03
WEINER WJ 202282 02-11
WEINERT D 204395 02-16
WEINGARTNER H 224756 04-14
WEINRICH D 213277 03-03
WEINSTEIN D 197489 01-03
WEINSTEIN MR 225331 04-15
WEISE CC 194045 01-10
WEISE V 215655 04-06
WEISKRANTZ L 218954 04-04
WEISS B 197996 01-04, 224769 04-09
WEISS BL 194862 01-09
WEISS CS 219071 04-04
WEISS G 205264 02-14, 207580 03-11
WEISSENSTEIN H 206769 03-03
WEISSMAN A 198057 01-02
WEISSMAN MM 212518 03-09, 224766 04-09
WELAJ P 196228 01-04
WELCH BL 210830 03-03
WELLENS HJ 223120 04-15
WELLER CP 202772 02-04
WELLISH CS 209488 03-10
WELLMAN W 197294 01-03
WELLS B 193498 01-12
WELTMAN M 225077 04-04
WEMEAU J 210141 03-15
WENNER R 201694 02-11
WENNERSTROM G 202715 02-03
WENZEL J 210674 03-04
WEPIERRE J 210788 03-03, 220977 04-03
WERNER AB 193546 01-04
WERNER G 213634 04-04, 217837 04-03
WERRY JS 218118 04-14
WESP M 215162 04-03
WESSELY P 205508 02-13
WESTERMAN G 199640 02-11
WESTERMANN E 193301 01-03
WESTFALL TC 197985 01-03
WESTHEIMER R 200088 02-03, 218213 04-08
WETHE GH 199896 02-14
WHEATLEY D 197269 01-17, 198040 01-10, 201898 02-11, 213599 04-17, 218771 04-10
WHEELER SC 204340 02-03
WHEELER TJ 210742 03-04
WHELESS JC 203470 02-11
WHELPTON R 209081 03-10
WHITE AC 223165 04-08
WHITE BJ 195949 01-13
WHITE HB 210895 03-01
WHITE RP 215727 04-03
WHITE TD 204185 02-03
WHITEHOUSE LW 220950 04-05
WHITLOCK FA 202797 02-17, 224491 04-17
WIDER F 210874 03-17
WIDMAN M 217878 04-13
WIECZOREK V 210806 03-03
WIESEL F 207295 03-08, 210864 03-03, 215734 04-03
WIG NN 225064 04-10
WIGMAN HGAJ 217464 04-04
WILBERT DE 213708 04-15
WILDT S 205579 02-03
WILK S 207285 03-14
WILKINSON GR 197951 01-13
WILKUS RJ 215738 04-11
WILLEY TJ 205467 02-03
WILLIAMS AE 205316 02-11
WILLIAMS B 210684 03-10
WILLIAMS D 207042 03-16
WILLIAMS JGL 210684 03-10
WILLIAMS JM 195079 01-04
WILLIAMS RL 224719 04-15
WILLIAMS RO 199663 02-14
WILLIAMS RT 217690 04-03
WILLINSKY MD 217467 04-03
WILLIS D 195039 01-13
WILMSEN H 217453 04-15
WILSON JR 219083 04-04
WILSON K 200052 02-03, 205455 02-03
WILSON LC 195929 01-10
WILSON MH 200168 02-05
WILSON RA 197816 01-11
WILSON RG 223777 04-15
WINDHEUSER A 221338 04-08
WINDORFER A 206807 03-06
WINN M 211069 03-01
WINOKUR G 221166 04-09
WINSBERG BG 225337 04-15
WINTER JC 197450 01-04, 213635 04-04, 217650 04-03, 221046 04-02
WIRTH PW 223711 04-04
WISE CD 210671 03-04, 211538 03-04
WISE RA 198612 02-04, 213350 03-04
WISE WD 195087 01-04, 222816 04-04
WISHART TB 195081 01-04
WISNIEWSKI K 210744 03-03, 210872 03-03, 215749 04-04
WISZNIOWSKA G 195434 01-04
WITA C 205446 02-13
WITTENBORN JR 198074 01-11
WITTER A 222820 04-04
WLODAVER C 197986 01-03
WODE-HELGODT B 207295 03-08
WOGGON B 202784 02-14, 217450 04-09, 221822 04-08
WOLD S 209790 03-08
WOLF S 218971 04-13
WOLFARTH S 199772 02-03
WOLLERT U 193278 01-01, 194148 01-01, 200033 02-03, 217686 04-01
WOLPERT A 224378 04-13
WOLTERS RJ 195560 01-01
WONG DT 195092 01-02
WOOD F 209905 03-08
WOOD MH 210869 03-03
WOOD RJ 198225 02-04
WOOD RW 222114 04-04
WOOD WG 206745 03-04
WOODRUFF ML 202758 02-04
WOODS JH 193137 01-04, 202667 02-04, 210392 03-04, 210886 03-04, 210887 03-03, 215968 04-04
WOODSON PBJ 215705 04-03
WOODWARD DJ 213279 03-03
WOODWARD JA 209904 03-10
WOODY GE 197539 01-15, 225386 04-09
WOOLLACOTT S 205315 02-15
WOOTTON LW 214838 04-10, 215158 04-10
WORRALL EP 222604 04-09
WORTON E 197829 01-03
WRAY SR 225567 04-03
WREN JC 194758 01-11
WRETMARK G 212241 03-11
WRIGHT CM 199957 02-04
WRIGHT DF 204528 02-11
WRIGHT L 198020 01-11
WU A 222830 04-06
WURTMAN RJ 209839 03-17, 210855 03-03, 217399 04-03, 223050 04-03
WUTTKE W 197284 01-04
WYATT RJ 198230 02-12, 207496 03-01, 210602 03-14, 213704 04-08, 214015 04-14, 217219 04-06, 221732 04-13, 225287 04-04
WYLER AR 215738 04-11
WYNNE-HUGHES I 215151 04-15

X

XHENSEVAL B 220284 04-11

Y

YAGI G 209410 03-15
YAGI K 215291 04-17, 223053 04-03
YAGIL R 210793 03-03
YAMABATA Y 213294 03-08
YAMADA R 194475 01-11
YAMAGUCHI K 200009 02-11, 201323 02-03
YAMAGUCHI N 214885 04-13
YAMAGUCHI S 222158 04-08
YAMAGUCHI T 207535 03-09
YAMAMOTO H 202862 02-02, 206780 03-02, 221741 04-02
YAMAMOTO K 202122 02-04, 224394 04-11
YAMAMOTO M 198610 02-04
YAMAMURA H 202165 02-03
YAMAMURA HI 213480 04-03
YAMAMURA M 215684 04-04
YAMANISHI E 213294 03-08
YAMASAKI M 204424 02-04
YAMASHITA I 202161 02-17, 225523 04-13
YAMATO T 222801 04-04
YAMUMURA HI 207298 03-03
YANAGIDA H 202165 02-03
YANAI J 213479 04-03, 225527 04-03
YANG YT 199347 02-03
YANO M 204484 02-03
YANOVSKY ES 199443 02-03
YARBROUGH GG 215733 04-03
YARYURA-TOBIAS JA 209489 03-10, 219960 04-09
YASUHARA H 202801 02-03
YEHUDA S 209961 03-03, 210855 03-03
YEPES LE 225337 04-15
YHAR MD 222871 04-14
YIM GKW 193455 01-03
YNDO CA 210673 03-03, 217816 04-03
YOGI H 207720 03-09
YOKEL RA 213350 03-04
YONGE KA 223394 04-14
YORK JL 221046 04-02
YORKE C 199788 02-03
YORKSTON NJ 209830 03-08
YOSHIDA H 215291 04-17
YOSHIDA M 194512 01-08, 198709 02-08
YOSHIDA T 224549 04-08
YOSHIKAWA A 221859 04-03
YOSHIMOTO Y 214885 04-13
YOSHIMURA G 194460 01-08
YOSHIMURA H 199807 02-03
YOSHIMURA M 202285 02-14
YOUNG R 215668 04-13
YOUNG S 200492 02-15
YOUNG SN 194857 01-13, 210796 03-03
YU G 221042 04-03
YUNGER LM 210826 03-03, 211494 03-05, 225159 04-04
YUZURU M 224393 04-09

Z

ZABRODIN GD 200013 02-08, 216999 04-12
ZAHLTEN W 200952 02-15, 210806 03-03, 210807 03-09
ZAKHARI NA 206460 03-01
ZAKHAROVA NN 200103 02-09, 201916 02-14
ZAKI SA 209830 03-08
ZAKUSOV VV 198488 02-06, 200564 02-02, 201913 02-03, 217649 04-03
ZALIPSKY JJ 225106 04-01
ZAMRAZIL V 205611 03-15
ZAOSTROVSKIY OV 223062 04-04
ZAPLETALEK M 205599 02-13, 205605 03-13, 205616 03-09, 205617 03-08
ZARIFIAN E 216758 04-09
ZASKALOKO NI 219506 04-03
ZASPRZAK K 202786 02-09
ZATZ M 215601 04-03, 224096 04-03
ZAUG PJ 225336 04-15
ZAUNER J 204478 02-17
ZAVIDOVSKAYA GI 194043 01-11, 200072 02-09
ZAVODSKAYA IS 217065 04-03, 219506 04-03
ZAYTSEV SG 201908 02-08, 224083 04-09
ZEMBILCI N 205546 02-03
ZEMP JW 196025 01-03
ZENATA L 205599 02-13, 205605 03-13
ZERVAS N 209839 03-17
ZETLER G 202796 02-03
ZIANCE RJ 202191 02-03
ZIEGLER A 195240 01-17
ZIEGLER B 195155 01-11, 204407 02-15, 206977 03-14, 221339 04-14
ZIEGLER MG 217848 04-03, 218147 04-03
ZIEGLER R 215695 04-05
ZIEHER LM 217867 04-03
ZIGMOND RE 199999 02-03, 217872 04-03
ZIMANOVA J 205602 03-09, 205612 03-15
ZIMMER D 214009 04-09
ZIMMERMAN HJ 217796 04-03
ZIMMERMANN RL 202764 02-15
ZINOKOVSKAYA LY 208991 03-04, 218470 04-04
ZIS AP 193578 01-04, 210861 03-04, 223054 04-03
ZISKIND D 198226 02-04
ZIVANOVIC D 217669 04-03
ZIVIN JA 213987 04-03

ZIVKOVIC B 196588 01-03, 201491 02-06, 202716 02-03, 208636 03-03, 217888 04-03, 225307 04-03
ZLATNIKOVA J 204402 02-13
ZOCH C 198053 01-07
ZUBIANI A 209071 03-08
ZUBOVSKAYA AM 217064 04-04
ZUCKERMANN EC 197815 01-05
ZVIZDIC E 197576 01-03
ZVOLSKY P 205607 03-09, 205608 03-09

SUBJECT INDEX

0The Subject Index is machine generated. Keywords in the titles of abstracts appear alphabetically in the left hand margin; under each keyword is a list of titles in which the keyword appears. The spelling of words in the titles of abstracts has not been changed; hence, two spellings of the same word may appear in this index – for example, BEHAVIOR and BEHAVIOUR.'

ABERRATION
CHROMOSOMAL ABERRATION RATES AND INTRAVENOUSLY GIVEN DIAZEPAM: A NEGATIVE STUDY.
195949 01-13

ABILITIES
EFFECTS OF DIPHENYLHYDANTOIN ON MENTAL ABILITIES IN THE ELDERLY.
215857 04-14

THE EFFECTS OF METHYLPHENIDATE HYDROCHLORIDE ON PSYCHOLINGUISTIC, MOTOR AND VISUAL PERCEPTUAL ABILITIES OF HYPERKINETIC CHILDREN WITH LEARNING DISABILITIES. (PH.D. DISSERTATION).
222725 04-14

ABILITY
THE EFFECTS OF CORD SECTION UNDER ETHER OR HALOTHANE ON THE ABILITY OF CHLORPROMAZINE TO AFFECT THE JAW-JERK RESPONSE TO TOOTH PULP STIMULATION IN THE ENCEPHALE ISOLE PREPARATION.
197451 01-03

EFFECTS OF MARIJUANA ON FLYING ABILITY.
224906 04-04

ABLATION
PERSISTENT THALAMIC AND CORTICAL BARBITURATE SPINDLE ACTIVITY AFTER ABLATION OF THE ORBITAL CORTEX IN CATS.
199763 02-03

ABLATIONS
EFFECTS OF PSYCHOTROPIC DRUGS ON HYPEREMOTIONALITY OF RATS WITH BILATERAL ABLATIONS OF THE OLFACTORY BULBS AND OLFACTORY TUBERCLES.
195231 01-04

TIME-DEPENDENT CHANGES IN AMPHETAMINE SELF-ADMINISTRATION FOLLOWING FRONTAL CORTEX ABLATIONS IN RATS.
206747 03-04

ABNORMALITIES
CARDIOVASCULAR ABNORMALITIES FOLLOWING TRICYCLIC ANTIDEPRESSANT DRUG OVERDOSAGE.
195847 01-15

SYMPTOMATIC SINUS NODE ABNORMALITIES FOLLOWING LITHIUM CARBONATE THERAPY.
223120 04-15

IMIPRAMINE AND ELECTROCARDIOGRAPHIC ABNORMALITIES IN HYPERACTIVE CHILDREN.
225337 04-15

ABORTION
PREVENTION OF SEROTONIN ABORTION BY SEROTONIN ANTAGONISTS IN RATS.
197489 01-03

ABSENCE
ABSENCE OF TOLERANCE TO THE HYPOTENSIVE EFFECTS OF DELTA9-TETRAHYDROCANNABINOL IN HYPERTENSIVE RATS.
193419 01-03

ACTION OF RESERPINE IN MORPHINE TOLERANT RATS: ABSENCE OF AN ANTAGONISM OF CATECHOLAMINE DEPLETION.
199277 02-03

PRESENCE OF DOPAMINERGIC TERMINALS AND ABSENCE OF DOPAMINERGIC CELL BODIES IN THE CEREBRAL CORTEX OF THE CAT.
210800 03-03

SERUM CLONAZEPAM CONCENTRATIONS IN CHILDREN WITH ABSENCE SEIZURES.
211064 03-13

ABSENCE OF INTERACTION BETWEEN DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) AND CANNABIDIOL (CBD) IN AGGRESSION, MUSCLE CONTROL AND BODY TEMPERATURE EXPERIMENTS IN MICE.
217474 04-04

ABSENT
ABSENT VESTIBULO-OCULAR REFLEXES AND ACUTE SUPRATENTORIAL LESIONS.
225323 04-13

ABSOLUTE
FREE THYROXINE INDEX AND ABSOLUTE FREE THYROXINE IN PATIENTS WITH AFFECTIVE DISORDERS TREATED WITH LITHIUM CARBONATE.
216747 04-09

ABSORPTION
INFLUENCE OF MAO INHIBITORS ON THE INTESTINAL ABSORPTION OF BIOGENIC AMINES.
197948 01-03

ABSORPTION, DISTRIBUTION AND EXCRETION OF ALPRENOLOL IN MAN, DOG, AND RAT.
199621 02-13

ABSORPTION AND EXCRETION OF THIORIDAZINE AND MESORIDAZINE IN MAN.
217154 04-08

ABSTINENCE
ROLE OF CATECHOLAMINERGIC MECHANISMS IN THE EXPRESSION OF THE MORPHINE ABSTINENCE SYNDROME IN RATS.
200053 02-03

PLASMA TESTOSTERONE LEVELS DURING CHRONIC HEROIN USE AND PROTRACTED ABSTINENCE.
202307 02-13

MORPHINE-DEPENDENT RATS: BLOCKADE OF PRECIPITATED ABSTINENCE BY TETRAHYDROCANNABINOL.
210221 03-13

ABUSE
DRUG ABUSE AND DRUG DEPENDENCY. A COMPENDIUM FOR MEDICAL DOCTORS.
204468 02-17

EEG SLEEP PATTERNS AND DRUG ABUSE.
224719 04-15

CHILDHOOD CHEMOTHERAPY AND LATER DRUG ABUSE AND GROWTH CURVE: A FOLLOWUP STUDY OF 30 ADOLESCENTS.
225382 04-14

ABUSED
THE BIOCHEMICAL PHARMACOLOGY OF ABUSED DRUGS: I. AMPHETAMINES, COCAINE, AND LSD.
198028 01-12

THE BIOCHEMICAL PHARMACOLOGY OF ABUSED DRUGS. II. ALCOHOL AND BARBITURATES.
200007 02-14

ACTIONS AND INTERACTIONS OF ABUSED DRUGS OF THE REWARD SYSTEM. (PH.D. DISSERTATION).
212964 03-04

ABUSERS
ANTICHOLINERGIC TOXIC PSYCHOSIS IN DRUG ABUSERS TREATED WITH BENZTROPINE.
197539 01-15

ACADEMIC
A BEHAVIORAL INVESTIGATION: THE EFFECTS OF MEDICATION ON DISRUPTIVE CLASSROOM BEHAVIOR AND ACADEMIC PERFORMANCE. (PH.D. DISSERTATION).
200461 02-11

ACCELERATION
ACCELERATION OF ANTIDEPRESSANTS BY THYROID HORMONE.
198082 02-07

MONOAMINEOXIDASE INHIBITORS ANTAGONIZE THE ACCELERATION OF BRAIN DOPAMINE SYNTHESIS INDUCED BY NEUROLEPTIC DRUGS IN VIVO: IMPLICATIONS FOR THE TREATMENT OF TARDIVE DYSKINESIA.
220948 04-03

ACCELERATOR
INHIBITION OF EFFECTS OF ACCELERATOR NERVE STIMULATION IN CATS AND RABBITS BY BS-100-141 AND GUANABENZ.
197971 01-03

ACCENTUATED
ON THE USE OF SYDNOCARB FOR PSYCHOPHARMACOLOGICAL CORRECTION OF BEHAVIORAL DISORDERS OF THE CYCLOID TYPE OF ACCENTUATED PERSONALITY IN ADOLESCENTS.
207271 03-11

ACCEPTOR
CRYSTAL STRUCTURE DETERMINATIONS OF THE DONOR ACCEPTOR COMPLEXES OF PHENOTHIAZINE AND PHENOXAZINE WITH NICKEL THIETE. (PH.D. DISSERTATION).
201003 02-01

ACCIDENTS
ACCIDENTS AND DRUG TREATMENT IN A PSYCHIATRIC HOSPITAL.
222603 04-15

ACCUMULATION
D,L P-CHLORO-N-METHYLAMPHETAMINE (P) INDUCED ACCUMULATION OF 5-HT IN NONTERMINAL AXONS.
192944 01-03

A COMPARISON OF THE INHIBITORY EFFECTS OF CERTAIN ANTIPARKINSONIAN AGENTS ON DOPAMINE ACCUMULATION INTO THE RAT STRIATUM.
195234 01-03

EFFECT OF PHENCYCLIDINE ON THE ACCUMULATION OF 14C-CATECHOLAMINES FORMED FROM 14C-TYROSINE.
197467 01-03

EFFECT OF ANGIOTENSIN II ON SEROTONIN ACCUMULATION IN THE RAT BRAIN.
197582 01-03

POSTMORTAL ACCUMULATION OF 3-METHOXYTYRAMINE IN BRAIN.
197583 01-03

LONG-TERM EFFECTS OF N-HYDROXY-4-CHLOROAMPHETAMINE ON THE LEVEL AND ACCUMULATION OF 5-HYDROXYTRYPTAMINE IN THE RAT BRAIN.
197869 01-03

THE ACCUMULATION OF NORADRENALINE AND 5-HYDROXYTRYPTAMINE IN THREE REGIONS OF MOUSE BRAIN AFTER TETRABENAZINE AND IPRONIAZID: EFFECTS OF ETHINYLESTRADIOL AND PROGESTERONE.
200058 02-03

ACCUMULATION OF 3H-HOMOVANILLIC ACID IN RABBIT BRAIN AND CEREBROSPINAL FLUID FOLLOWING INTRAVENOUS 3H-L-DOPA.
206336 03-03

CYCLIC-AMP IN CEREBROSPINAL FLUID: ACCUMULATION FOLLOWING PROBENECID AND BIOGENIC AMINES.
210193 03-17

ACCUMULATION OF ACETYLCHOLINE AND AROMATIC MONOAMINES BY INTERACTION WITH ADENOSINE-5-TRIPHOSPHATE.
210753 03-03

ACCUMULATION OF LITHIUM IN THE PARTICULATE FRACTION OF RAT BRAIN FOLLOWING ITS LONG-TERM ADMINISTRATION.
210782 03-03

THE EFFECT OF LSD AND 2-BROMOLSD ON THE DOPA ACCUMULATION AFTER CENTRAL AND PERIPHERAL DECARBOXYLASE INHIBITION.
217674 04-03

THE INFLUENCE OF DESIPRAMINE AND AMITRIPTYLINE ON THE ACCUMULATION OF (3H)NORADRENALINE AND ITS TWO MAJOR METABOLITES FORMED FROM (3H)TYROSINE IN THE RAT BRAIN.
217966 04-03

ACCUMULATION OF 4-HYDROXYAMPHETAMINE BY RAT STRIATAL HOMOGENATES.
222822 04-03

ACCURACY

EFFECTS OF PHYSOSTIGMINE ON THE ACCURACY AND ACTIVITY OF DISCRIMINATION BEHAVIOUR IN RATS.
197995 01-04

ACEPROMETAZINE

ELECTROENCEPHALOGRAPHIC STUDY ON THE ACTION OF THE COMBINATION MEPROBAMATE ACEPROMETAZINE ON VARIOUS CEREBRAL SYSTEMS.
221286 04-03

ACETAMIDE

PILOT STUDY OF 2-PYRROLIDON ACETAMIDE (GENERIC NAME: PIRACETAM).
221338 04-08

ACETAMIDOBENZOATE

TREATMENT OF PHENOTHIAZINE INDUCED BULBAR PERSISTENT DYSKINESIA WITH DEANOL ACETAMIDOBENZOATE.
210209 03-13

ACETATE

EXPERIENCE WITH CYPROTERONE ACETATE INFLUENCE ON HUMAN SEXUALITY.
195037 01-11

INCORPORATION OF ACETATE (C14)(P-32) AND PHOSPHATE INTO THE BRAIN LIPIDS DURING BLOCKAGE OF THE CHOLINORECEPTOR AND ADRENORECEPTORS.
202599 02-03

TREATMENT OF SEXUAL DELINQUENCY WITH ANDROCUR (CYPROTERONE ACETATE).
203496 02-17

ACETYLATION

COMPARATIVE STUDIES ON SYNAPTOSOMES: HIGH-AFFINITY UPTAKE AND ACETYLATION OF N-H3-ME-CHOLINE AND N-H3-ME-HYDROXYETHYLPYRROLIDINIUM.
217869 04-03

LYSERGIC ACID DIETHYLAMIDE: EFFECT ON HISTONE ACETYLATION IN RABBIT BRAIN.
220314 04-03

ACETYLATOR

THE RELATIONSHIP BETWEEN RESPONSE TO PHENELZINE AND ACETYLATOR STATUS IN DEPRESSED PATIENTS.
206366 03-09

ACETYLCHOLINE

DIFFERENTIAL EFFECTS OF D-AMPHETAMINE ON BRAIN ACETYLCHOLINE IN YOUNG, ADULT, AND GERIATRIC RATS.
193457 01-03

ACETYLCHOLINE LEVELS IN THE FROG SPINAL CORD FOLLOWING THE ADMINISTRATION OF DIFFERENT CONVULSANTS.
193550 01-03

ALTERATIONS BY ANESTHETIC AGENTS OF THE RESPONSES OF RAT STRIATAL NEURONS TO IONTOPHORETICALLY APPLIED AMPHETAMINE, ACETYLCHOLINE, NORADRENALINE, AND DOPAMINE.
193803 01-03

BRAIN ACETYLCHOLINE AND CHOLINESTERASE: EFFECT OF PHENOTHIAZINES AND PHYSOSTIGMINE INTERACTION IN RATS.
195046 01-03

EFFECTS OF DIISOPROPYLPHOSPHOFLUORIDATE ON ACETYLCHOLINE, CHOLINESTERASE AND CATECHOLAMINES OF SEVERAL PARTS OF RABBIT BRAIN.
195094 01-03

SOME OF THE DYNAMICS OF CHOLINE AND ACETYLCHOLINE METABOLISM IN RAT BRAIN.
197474 01-03

A COMPARISON OF THE EFFECTS OF (+) AMPHETAMINE, COCAINE AND DENERVATION ON THE RESPONSES OF THE ISOLATED VAS-DEFERENS OF THE GUINEA-PIG TO NOREPINEPHRINE AND ACETYLCHOLINE.
197495 01-03

THE INHIBITORY EFFECT OF DOPAMINE ON ACETYLCHOLINE RELEASE.
197566 01-03

THE RELATIONSHIP BETWEEN RIGIDITY AND CHANGE IN WHOLE BRAIN ACETYLCHOLINE CONCENTRATION PRODUCED BY INJECTION OF RESERPINE IN THE RAT.
197569 01-03

BIOCHEMICAL CORRELATES IN MOUSE-KILLING BEHAVIOR OF THE RAT BRAIN: BRAIN ACETYLCHOLINE AND ACETYLCHOLINESTERASE AFTER ADMINISTRATION OF DELTA9-TETRAHYDROCANNABINOL.
199807 02-03

EFFECT OF LIMBIC SYSTEM LESIONS ON ACETYLCHOLINE RELEASE FROM THE CEREBRAL CORTEX OF THE RAT.
200044 02-03

MEASUREMENT OF ACETYLCHOLINE TURNOVER RATE IN DISCRETE AREAS OF RAT BRAIN.
202465 02-06

AMPHETAMINE-INDUCED CHANGES IN STRIATAL DOPAMINE AND ACETYLCHOLINE LEVELS AND RELATIONSHIP TO ROTATION (CIRCLING BEHAVIOR) IN RATS.
205432 02-04

THE EFFECTS OF ACETYLCHOLINE AND SYNAPTIC STIMULATION ON THE NEURONS IN THE SENSORIMOTOR CORTEX.
205510 02-03

THE EFFECT OF CLOZAPINE AND ACETYLCHOLINE TURNOVER RATE IN RAT STRIATUM. (UNPUBLISHED PAPER).
207500 03-03

INFLUENCE OF NONCHOLINERGIC DRUGS ON RAT STRIATAL ACETYLCHOLINE LEVELS.
210658 03-03

CHOLINERGIC DOPAMINERGIC INTERACTION IN THE STRIATUM: THE EFFECT OF 6-HYDROXYDOPAMINE OR PIMOZIDE TREATMENT ON THE INCREASED STRIATAL ACETYLCHOLINE LEVELS INDUCED BY APOMORPHINE, PIRIBEDIL AND D-AMPHETAMINE.
210668 03-03

ACCUMULATION OF ACETYLCHOLINE AND AROMATIC MONOAMINES BY INTERACTION WITH ADENOSINE-5-TRIPHOSPHATE.
210753 03-03

SOME EFFECTS OF PILOCARPINE AND ACETYLCHOLINE ON THE RESPONSES OF THE GUINEA-PIG VAS-DEFERENS TO HYPOGASTRIC NERVE STIMULATION AND TRANSMURAL STIMULATION AND APPLIED (-) NORADRENALINE.
210770 03-03

SUBFORNICAL ORGAN: ACETYLCHOLINE APPLICATION ELICITS DRINKING.
210804 03-03

EFFECTS OF DOPAMINERGIC DRUGS AND ACUTE MEDIAL FOREBRAIN BUNDLE LESIONS ON STRIATAL ACETYLCHOLINE LEVELS.
210831 03-03

EFFECT OF CHOLINE ACETYLTRANSFERASE INHIBITORS ON MOUSE AND GUINEA-PIG BRAIN CHOLINE AND ACETYLCHOLINE.
210883 03-03

APPLICATION OF PRINCIPLES OF STEADY-STATE KINETICS TO THE IN VIVO ESTIMATION OF ACETYLCHOLINE TURNOVER RATE IN MOUSE BRAIN.
210885 03-06

STUDIES WITH AGENTS WHICH INFLUENCE ACETYLCHOLINE METABOLISM IN MOUSE BRAIN.
211065 03-03

A PROLONGED AFTEREFFECT OF INTENSE SYNAPTIC ACTIVITY ON ACETYLCHOLINE IN A SYMPATHETIC GANGLION.
211102 03-03

IN VIVO INHIBITION OF STRIATAL ACETYLCHOLINE TURNOVER BY L-DOPA, APOMORPHINE AND (+) AMPHETAMINE.
213399 04-03

ACTIONS OF ACETYLCHOLINE AND ATROPINE ON CEREBRAL CORTICAL NEURONS IN CHRONICALLY MORPHINE TREATED RATS.
215733 04-03

KININS AND CENTRAL EFFECTS OF THE ACETYLCHOLINE.
215749 04-04

BRAIN ACETYLCHOLINE: INCREASE AFTER SYSTEMIC CHOLINE ADMINISTRATION.
217399 04-03

THE EFFECT OF HEMICHOLINIUM ON BEHAVIOR AND ON BRAIN ACETYLCHOLINE AND CHOLINE IN THE RAT.
217551 04-04

ACETYLCHOLINE ACTIVITY IN AN IDENTIFIED 5-HYDROXYTRYPTAMINE CONTAINING NEURON.
217825 04-03

6-HYDROXYDOPAMINE AND STRIATAL ACETYLCHOLINE LEVELS.
217842 04-03

ON THE MECHANISM OF THE DEFENSIVE ACTION OF ACETYLCHOLINE AND SEROTONIN AGAINST THEIR CYTOTOXIC ANTAGONISTS.
219663 04-03

THE DISTRIBUTION KINETICS AND TURNOVER OF CHOLINE AND ACETYLCHOLINE IN PLASMA AND BRAIN OF RATS. (PH.D. DISSERTATION).
220472 04-03

ACETYLCHOLINE-INDUCED

EFFECTS OF THEOPHYLLINE AND PROPRANOLOL ON ACETYLCHOLINE-INDUCED RELEASE OF ADRENAL MEDULLARY CATECHOLAMINES.
195591 01-03

THE ACTION OF BICUCULLINE UPON ACETYLCHOLINE-INDUCED EXCITATIONS OF CENTRAL NEURONS.
197993 01-03

ACETYLCHOLINESTERASE

THE EFFECTS OF LITHIUM AND PHYSOSTIGMINE ON RAT BRAIN ACETYLCHOLINESTERASE ACTIVITY.
195436 01-03

ANALYSIS OF ACETYLCHOLINESTERASE SYNTHESIS AND TRANSPORT IN THE RAT HIPPOCAMPUS: RECOVERY OF ACETYLCHOLINESTERASE ACTIVITY IN THE SEPTUM AND HIPPOCAMPUS AFTER ADMINISTRATION OF DIISOPROPYLFLUOROPHOSPHATE.
199805 02-03

BIOCHEMICAL CORRELATES IN MOUSE-KILLING BEHAVIOR OF THE RAT BRAIN: BRAIN ACETYLCHOLINE AND ACETYLCHOLINESTERASE AFTER ADMINISTRATION OF DELTA9-TETRAHYDROCANNABINOL.
199807 02-03

REVERSIBLE INHIBITION OF MAMMALIAN BRAIN ACETYLCHOLINESTERASE AND SODIUM POTASSIUM STIMULATED ADENOSINE-TRIPHOSPHATASE BY CYCLOPROPANE.
210903 03-03

A HISTOCHEMICAL STUDY OF VENTRAL TEGMENTAL ACETYLCHOLINESTERASE CONTAINING PATHWAY FOLLOWING DESTRUCTIVE LESIONS.
210919 03-03

ACETYLTRANSFERASE

REGIONAL AND SUBCELLULAR DISTRIBUTION AND KINETIC PROPERTIES OF RAT BRAIN CHOLINE ACETYLTRANSFERASE -- SOME FUNCTIONAL CONSIDERATIONS.
210816 03-03

EFFECT OF CHOLINE ACETYLTRANSFERASE INHIBITORS ON MOUSE AND GUINEA-PIG BRAIN CHOLINE AND ACETYLCHOLINE.
210883 03-03

HOMOVANILLIC ACID CONCENTRATION IN RAT BRAIN: EFFECT OF A CHOLINE ACETYLTRANSFERASE INHIBITOR AND COMPARISON WITH CHOLINERGIC AND DOPAMINERGIC AGENTS.
215711 04-03

DEVELOPMENTAL VARIATIONS OF CHOLINE ACETYLTRANSFERASE, DOPAMINE-BETA-HYDROXYLASE AND MONOAMINEOXIDASE IN CHICKEN EMBRYO AND CHICKEN SYMPATHETIC GANGLIA.
217840 04-03

ACH

5-HT AND NOREPINEPHRINE-INDUCED RELEASE OF ACH FROM THE THALAMUS AND MESENCEPHALON OF THE MONKEY DURING THERMOREGULATION.
210672 03-03

ACID

THE ANTAGONISTIC EFFECTS OF ASPARTIC ACID ON SOME EFFECTS OF MORPHINE ON RATS.
193453 01-03

BEHAVIOURAL INTERACTIONS BETWEEN IMIDAZOLEACETIC ACID AND GAMMA-HYDROXYBUTYRIC ACID IN RATS AND MICE.
193545 01-04

THE EFFECTS OF DEXTROAMPHETAMINE, DIMETHYLTRYPTAMINE, LYSERGIC ACID DIETHYLAMIDE AND TETRAHYDROCANNABINOL UPON PREGNANCY AND THE OFFSPRING. (PH.D. DISSERTATION).
194568 01-04

INEFFECTIVENESS OF LYSERGIC ACID DIETHYL AMIDE 25 (LSD) ON ALTERING NA-K CURRENTS IN SQUID GIANT AXON.
194927 01-03

INTERACTION OF CATECHOLAMINE AND AMINO ACID METABOLISM IN BRAIN: EFFECT OF PARGYLINE AND L-DOPA.
195048 01-03

CANNABINOL-7-OIC ACID: A METABOLITE OF DELTA1-TETRAHYDROCANNABINOL IN THE RHESUS MONKEY.
195114 01-03

INCREASE IN BRAIN DOPAMINE AFTER AXOTOMY OR TREATMENT WITH GAMMA-HYDROXYBUTYRIC ACID DUE TO ELIMINATION OF THE NERVE IMPULSE FLOW.
195439 01-03

EFFECTS OF DRUGS INFLUENCING MONOAMINE MECHANISMS ON THE INCREASE IN BRAIN DOPAMINE PRODUCED BY AXOTOMY OR TREATMENT WITH GAMMA-HYDROXYBUTYRIC ACID.
195440 01-03

EVIDENCE FOR A PERIPHERAL EFFECT OF FUSARIC ACID, A DOPAMINE-BETA-HYDROXYLASE INHIBITOR, ON SEROTONIN METABOLISM.
196593 01-03

CATALEPSY, STEREOTYPED BEHAVIOUR AND STRIATAL HOMOVANILLIC ACID CONTENT IN RATS TREATED WITH METHADONE.
197299 01-03

THE EFFECT OF BETA-THIAMINOKETONES ON THE AMINOPYRINE-N-DEMETHYLATION IN VITRO AND IN VIVA SUCH AS THE HEXOBARBITAL SLEEPING TIME AND L-ASCORBIC ACID EXCRETION IN THE RAT.
197469 01-03

3,4 DIHYDROXYPHENYLACETIC ACID (DOPAC): A POSSIBLE ENDOGENOUS INHIBITOR OF INDOLEAMINE-N-METHYLATION IN THE RAT BRAIN.
197676 01-17

STUDIES OF TRYPTAMINE AND LYSERGIC ACID DIETHYLAMIDE (LSD) ON CUTANEOUS C-FIBER AND POLYSYNAPTIC REFLEXES IN THE CAT.
197814 01-03

ON THE MECHANISM OF ACTION OF GAMMA-HYDROXYBUTYRIC ACID: LACK OF CONVERSION TO GABA IN MOUSE BRAIN IN VIVO.
197965 01-03

DETERMINATION OF NORADRENALINE, DOPAMINE, SEROTONIN, 5-HYDROXYINDOLEACETIC ACID, TYROSINE AND TRYPTOPHANE IN THE ISOLATED PERFUSED RAT BRAIN.
197967 01-06

REGIONAL DIFFERENCES IN HOMOVANILLIC ACID CONCENTRATIONS AFTER ACUTE AND CHRONIC ADMINISTRATION OF ANTIPSYCHOTIC DRUGS.
198210 02-03

STUDIES ON THE IN VITRO METABOLISM OF COMPOUNDS RELATED TO LYSERGIC ACID DIETHYLAMIDE (LSD).
198608 02-01

INHIBITION OF DOPAMINE-BETA-HYDROXYLASE IN MANIC PATIENTS: A CLINICAL TRIAL WITH FUSARIC ACID.
199632 02-07

CHRONIC LYSERGIC ACID DIETHYLAMIDE ADMINISTRATION AND SEROTONIN TURNOVER IN VARIOUS REGIONS OF RAT BRAIN.
199783 02-03

REACTION OF CATIONIC GROUPS OF CHLORPROMAZINE WITH ANIONIC MACROMOLECULES: COMPLEXES WITH DNA, RNA, HYALURONIC ACID AND HEPARIN.
199897 02-03

EFFECT OF AMINOOXYACETIC ACID ON THE METABOLISM OF PENTOBARBITAL IN MICE.
200002 02-03

IDENTIFICATION AND STRUCTURAL CHARACTERIZATION OF AN INHIBITOR OF CATECHOLAMINE INDUCED FREE FATTY ACID MOBILIZATION FROM THE CALF MIDBRAIN.
200006 02-01

LUMBAR CSF 5-HYDROXYINDOLEACETIC ACID AND HOMOVANILLIC ACID IN AFFECTIVE SYNDROMES.
202248 02-09

THE REGULATION OF CYCLIC GUANOSINE MONOPHOSPHATE IN RAT CEREBELLUM: POSSIBLE INVOLVEMENT OF PUTATIVE AMINO ACID NEUROTRANSMITTERS.
202717 02-03

NEGATIVE FINDINGS WITH NICOTINIC ACID IN THE TREATMENT OF SCHIZOPHRENIAS.
202787 02-08

EFFECTS OF 5-HYDROXYINDOLEACETIC ACID ON ISOLATED CANINE CEREBRAL ARTERIES.
202799 02-03

TRYPTOPHAN METABOLISM EXAMINATIONS IN OLIGOPHRENIC CHILDREN. FIRST REPORT: RESULTS OF THE EXCRETION OF KYNURENINE AND XANTHURENIC ACID AFTER TRYPTOPHAN LOADING AND THEIR DEPENDENCE UPON THE SUPPLY.
203645 02-13

THE INFLUENCE OF ENCEPHALOTROPIC DRUGS ON NUCLEIC ACID METABOLISM IN THE BRAIN.
204398 02-13

SELECTIVE INHIBITION OF DOPAMINE-BETA-HYDROXYLASE IN THE PERIPHERAL TISSUES BY 5-DIMETHYLDITHIOCARBAMYLPICOLINIC ACID; ITS EFFECT ON STRESS INDUCED ULCER, ETHANOL INDUCED SLEEP AND BLOOD PRESSURE.
204484 02-03

CANNABINOID INDUCED CHANGES IN MOUSE STRIATAL HOMOVANILLIC ACID AND DIHYDROXYPHENYLACETIC ACID: THE EFFECTS OF AMPHETAMINE AND L-DOPA.
204866 02-03

EFFECT OF DESIPRAMINE AND PARGYLINE ON BRAIN GAMMA-AMINOBUTYRIC ACID.
205851 03-03

ACCUMULATION OF 3H-HOMOVANILLIC ACID IN RABBIT BRAIN AND CEREBROSPINAL FLUID FOLLOWING INTRAVENOUS 3H-L-DOPA.
206336 03-03

THE EFFECT OF LYSERGIC ACID DIETHYLAMIDE ON SERUM CREATINE KINASE LEVELS.
206361 03-12

THE INFLUENCE OF CHLORPROMAZINE ACTION ON EXPERIMENTAL PSYCHOSIS CAUSED BY LYSERGIC ACID DIETHYLAMIDE.
206439 03-04

MASS FRAGMENTOMETRIC DETERMINATION OF HOMOVANILLIC ACID IN LUMBAR CEREBROSPINAL FLUID OF SCHIZOPHRENIC PATIENTS DURING TREATMENT WITH ANTIPSYCHOTIC DRUGS.
207295 03-08

BEHAVIORAL EFFECTS OF A NEW DOPAMINE-BETA-HYDROXYLASE INHIBITOR (FUSARIC ACID) IN MAN.
207311 03-07

FOUR CASES OF DEPRESSION TREATED BY INDOLEACETIC ACID.
207554 03-09

CORRELATIONS BETWEEN CIRCADIAN CHANGES IN SERUM AMINO ACIDS OR BRAIN TRYPTOPHAN AND THE CONTENTS OF SEROTONIN AND 5-HYDROXYINDOLEACETIC ACID IN REGIONS OF THE RAT BRAIN.
210673 03-03

METABOLIC COMPARTMENTATION IN THE BRAIN: METABOLISM OF A TRICARBOXYLIC ACID CYCLE INTERMEDIATE, (1,4-14C)SUCCINATE, AFTER INTRACEREBRAL ADMINISTRATION.
210780 03-03

SOME EVIDENCE FOR LONG-TERM MEMORY RETENTION BY OROTIC ACID IN RATS BAR PRESSING FOR WATER.
210790 03-04

OXIDATIVE METABOLISM OF MESCALINE IN THE CENTRAL NERVOUS SYSTEM -- V. IN VITRO DEAMINATION OF MESCALINE TO 3,4,5 TRIMETHOXYBENZOIC ACID.
210813 03-03

EFFECT OF ANTIPSYCHOTIC DRUGS ON HOMOVANILLIC ACID LEVELS IN STRIATUM AND OLFACTORY TUBERCLE OF THE RAT.
210864 03-03

HYPERSENSITIVITY TO LYSERGIC ACID DIETHYLAMIDE (LSD-25) AND PSILOCYBIN IN ESSENTIAL HEADACHE.
211108 03-12

GAMMA-AMINOBUTYRIC ACID AND CEREBRAL METABOLISM.
212277 03-13

ANTAGONISM OF NICOTINIC ACID AND OTHER KYNURENINES TO ANTIDEPRESSANTS: ONE OF THE PROBABLE REASONS FOR THE THERAPY-RESISTANCE IN DEPRESSION?.
215074 04-17

LYSERGIC ACID DIETHYLAMIDE AFFECTS BLOOD FLOW TO SPECIFIC AREAS OF THE CONSCIOUS RAT BRAIN.
215161 04-03

HOMOVANILLIC ACID CONCENTRATION IN RAT BRAIN: EFFECT OF A CHOLINE ACETYLTRANSFERASE INHIBITOR AND COMPARISON WITH CHOLINERGIC AND DOPAMINERGIC AGENTS.
215711 04-03

A RELATION BETWEEN DRUG CONCENTRATIONS IN BRAIN AND STRIATAL HOMOVANILLIC ACID LEVELS IN CHLORPROMAZINE TREATED RATS.
215734 04-03

INHIBITION OF CATECHOLAMINE AND 5-HYDROXYTRYPTAMINE INDUCED ENZYME SECRETION FROM THE GUINEA-PIG SUBMANDIBULAR GLAND BY 2-BROMO-D-LYSERGIC ACID DIETHYLAMIDE.
216968 04-03

A RAPID, SIMPLE AND MORE SENSITIVE METHOD FOR THE DEMONSTRATION OF CENTRAL CATECHOLAMINE CONTAINING NEURONS AND AXONS BY GLYOXYLIC ACID INDUCED FLUORESCENCE: I. SPECIFICITY.
217550 04-16

THE ORIGIN OF BLOOD 5-HYDROXYINDOLEACETIC (5-HIAA) ACID FOLLOWING L-HYDRAZINO-ALPHA-METHYLDOPA (MK-486).
217665 04-03

INCREASED CONCENTRATION OF HOMOVANILLIC ACID IN THE BRAINS OF INFANT RABBITS AFTER ADMINISTRATION OF HALOPERIDOL TO THEIR NURSING MOTHERS.
217692 04-03

DISCRIMINATIVE CONTROL OF BEHAVIOR BY ELECTRICAL STIMULATION OF THE DORSAL RAPHE NUCLEUS: GENERALIZATION TO LYSERGIC ACID DIETHYLAMIDE (LSD).
217821 04-12

AMINO ACID UPTAKE IN VIVO BY THE MOUSE BRAIN AND BY VARIOUS REGIONS OF THE RABBIT BRAIN AFTER DRUG-INDUCED CONVULSIONS.
217858 04-03

DEXTROMETHORPHAN INHIBITS 5-HYDROXYTRYPTAMINE UPTAKE BY HUMAN BLOOD PLATELETS AND DECREASES 5-HYDROXYINDOLEACETIC ACID CONTENT IN RAT BRAIN.
217964 04-03

NICOTINIC ACID IN THE TREATMENT OF SCHIZOPHRENIAS: CANADIAN MENTAL HEALTH ASSOCIATION COLLABORATIVE STUDY PROGRESS REPORT II.
219537 04-08

A COMPARATIVE STUDY OF THE EFFECTIVENESS OF ENERBOL AND GLUTAMIC ACID IN OLIGOPHRENIC CHILDREN.
219662 04-11

LYSERGIC ACID DIETHYLAMIDE: EFFECT ON HISTONE ACETYLATION IN RABBIT BRAIN.
220314 04-03

SYNERGISM BETWEEN GAMMA-AMINOBUTYRIC ACID AND BUTYROPHENONES ADMINISTERED MICROELECTROPHORETICALLY IN THE PURKINJE CELLS OF THE CAT CEREBELLUM.
220904 04-03

AVERAGE EVOKED RESPONSES (AER) AND HOMOVANILLIC ACID (HVA) IN CEREBROSPINAL FLUID (CSF) IN A PSYCHOTIC PATIENT WITH ADDISONS DISEASE.
221310 04-09

SOME PECULIARITIES OF THE NEURON ULTRASTRUCTURE IN THE BRAIN-CORTEX MOTOR AREA UNDER THE INFLUENCE OF LYSERGIC ACID DIETHYLAMIDE (LSD) AND HALOPERIDOL.
222890 04-03

LONG-LASTING EFFECTS OF PRENATAL 2,4,5 TRICHLOROPHENOXYACETIC ACID ON OPEN-FIELD BEHAVIOR IN RATS: PRE- AND POSTNATAL MEDIATION.
223044 04-04

LYSERGIC ACID DIETHYLAMIDE: EVIDENCE FOR STIMULATION OF CEREBRAL DOPAMINE RECEPTORS.
223174 04-03

INTERACTIONS BETWEEN LYSERGIC ACID DIETHYLAMIDE AND DOPAMINE SENSITIVE ADENYLCYCLASE SYSTEMS IN RAT BRAIN.
223175 04-03

THE EFFECT OF NEUROLEPTICS AND ANTIDEPRESSANTS ON THE UPTAKE OF 3H-GAMMA-AMINOBUTYRIC ACID BY ISOLATED NERVE ENDINGS OF THE RAT BRAIN.
224114 04-03

EFFECTS OF AMINERGIC DRUGS AND GLUTAMIC ACID ON AUDIOGENIC SEIZURES INDUCED BY EARLY EXPOSURE TO ETHANOL.
225527 04-03

DIPROPYLACETIC ACID (DEPAKINE) IN EXPERIMENTAL EPILEPSY IN THE ALERT CAT.
225529 04-02

ACID-BASE

CHANGES IN ACID-BASE BALANCE, RESPIRATION RATE AND HEART RATE UPON REPEATED ORAL ADMINISTRATION OF BENZOCTAMINE AND DIAZEPAM TO CONSCIOUS DOGS.
197460 01-03

ALTERATIONS IN ACID-BASE BALANCE IN THE DOG AFTER INTRAVENOUS ADMINISTRATION OF BENZOCTAMINE AND DIAZEPAM, COMPARED WITH THOSE INDUCED BY THIOPENTAL.
197485 01-03

ACIDS

EFFECTS OF PSYCHOTROPIC DRUGS ON THE INCORPORATION OF GLUCOSE-14C INTO AMINO ACIDS OF THE RAT BRAIN.
198026 01-03

EFFECT OF NEUROTROPIC AGENTS ON TOTAL PYRIDOXAL PHOSPHATE AND ON THE ACTIVITY OF THE DECARBOXYLASE OF AROMATIC AMINO ACIDS AS WELL AS OF OTHER PYRIDOXAL PHOSPHATE DEPENDENT ENZYMES IN RAT BRAIN.
199785 02-03

UPTAKE AND RELEASE OF POSSIBLE FALSE TRANSMITTER AMINO ACIDS BY RAT BRAIN TISSUE.
199788 02-03

THE INFLUENCE OF CATECHOLAMINES, SEROTONIN, AND SOME AMINO ACIDS ADMINISTERED INTO THE AMYGDALOID COMPLEX ON CONDITIONED REFLEXES OF AVOIDANCE AND MOTOR ACTIVITY IN RATS.
200566 02-03

EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON FREE AMINO ACIDS IN BRAIN.
205625 03-03

CORRELATIONS BETWEEN CIRCADIAN CHANGES IN SERUM AMINO ACIDS OR BRAIN TRYPTOPHAN AND THE CONTENTS OF SEROTONIN AND 5-HYDROXYINDOLEACETIC ACID IN REGIONS OF THE RAT BRAIN.
210673 03-03

NERVE IMPULSE ENHANCED RELEASE OF AMINO ACIDS FROM NONSYNAPTIC REGIONS OF PERIPHERAL AND CENTRAL NERVE TRUNKS OF BULLFROG.
213277 03-03

RESPONSES OF CULTURED CEREBELLAR NEURONS TO IONTOPHORETICALLY APPLIED AMINO ACIDS.
213279 03-03

NONRIGID AMINES AND AMINO ACIDS RELATED TO APOMORPHINE. (PH.D. DISSERTATION).
222634 04-01

ACOUSTIC

THE EFFECTS OF L-DOPA, CLONIDINE, AND APOMORPHINE ON THE ACOUSTIC STARTLE REACTION IN RATS.
202773 02-04

ACQUISITION

THE EFFECTS OF PHYSOSTIGMINE DURING THE ACQUISITION OF AVOIDANCE BEHAVIOUR AS A FUNCTION OF THE INTERSESSION INTERVAL.
192951 01-04

EFFECTS OF D-AMPHETAMINE ON ACQUISITION OF LEVERPRESS SIDMAN AVOIDANCE IN RATS.
195305 01-04

CHANGES IN THE ACQUISITION OF CONDITIONED AVOIDANCE RESPONSES FOLLOWING MIDBRAIN RAPHE LESIONS IN TH
197574 01-04

PATTERNS OF DRUG ACQUISITION AND USE.
198105 02-17

THE EFFECT OF DIFFERENTIAL SALINE AND CYCLOHEXIMIDE STATES ON THE ACQUISITION OF A SPATIAL REVERSAL TASK IN MICE AND RATS. (PH.D. DISSERTATION
198897 02-04

THE INTERACTION OF DOPAMINE ANTAGONISTS AND AMANTADINE HYDROCHLORIDE ON THE ACQUISITION OF THE CONDITIONED AVOIDANCE RESPONSE IN RATS.
199959 02-04

EFFECTS ON THE ACQUISITION OF CONDITIONED AVOIDANCE RESPONSES AND SEIZURE THRESHOLD IN THE OFFSPRING OF AMPHETAMINE TREATED GRAVID RATS.
202722 02-05

DEFICIENT BRIGHTNESS DISCRIMINATION ACQUISITION PRODUCED BY DAILY INTRACRANIAL INJECTIONS OF PENICILLIN IN RATS.
202758 02-04

EFFECTS OF DRUG ALTERED SEROTONIN LEVELS ON THE ACQUISITION OF A SHUTTLEBOX AVOIDANCE TASK. (PH.D. DISSERTATION).
211781 03-04

THE COMPARATIVE EFFECTS OF MORPHINE AND CHLORPROMAZINE ON THE ACQUISITION OF CONDITIONED AVOIDANCE RESPONSE. (PH.D. DISSERTATION).
212963 03-04

REPEATED ACQUISITION OF RESPONSE SEQUENCES: STIMULUS CONTROL AND DRUGS.
215969 04-04

THE EFFECT OF DIFFERENT LEVELS OF PRE-EXPOSURE TO SUCROSE ON THE ACQUISITION AND EXTINCTION OF A CONDITIONED AVERSION.
217807 04-04

THE EFFECT OF AN ADRENAL DEMEDULLATION AND CHEMICAL SYMPATHECTOMY (2,4,5 TRIHYDROXYPHENYLETHYLAMINE) ON THE ACQUISITION OF A ONE-WAY ACTIVE AVOIDANCE RESPONSE. (PH.D. DISSERTATION).
222736 04-04

THE PARTIAL PUNISHMENT EFFECT FOLLOWING MINIMAL ACQUISITION TRAINING: SODIUM AMOBARBITAL AND THE STIMULUS PROPERTIES OF EARLY PUNISHED TRIALS.
224504 04-04

ACQUISITIONS

METHAMPHETAMINES EFFECT ON REPEATED ACQUISITIONS WITH SERIAL DISCRIMINATION REVERSALS.
202769 02-04

ACROLEIN

ALTERATIONS OF BARBITURATE ACTION FOLLOWING 1,1 DICHLOROETHYLENE, CORTICOSTERONE, OR ACROLEIN.
197488 01-03

ACTH

THE EFFECT OF ACTH AND AMPHETAMINE ON ECS PRODUCED AMNESIA. (PH.D. DISSERTATION).
204733 02-04

THE EFFECT OF TWO SYNTHETIC ACTH ANALOGUES ON THE METABOLISM OF BIOGENIC AMINES IN THE RAT BRAIN.
210875 03-03

THE EFFECT OF ACTH AND DIAZEPAM, ADMINISTERED TO INFANT RATS ON THE BODY GROWTH CURVE AND SOME ENDOCRINE PARAMETERS MEASURED IN ADULT AGE.
215066 04-03

LONG-TERM BEHAVIOURAL EFFECTS OF DIAZEPAM AND ACTH, ADMINISTERED EARLY IN LIFE.
215067 04-04

PERMANENT EFFECTS OF REPEATED ADMINISTRATION OF ACTH AND DIAZEPAM IN EARLY POSTNATAL PERIOD UPON THE DYNAMICS OF EXCITATION AND INHIBITION DURING HABITUATION.
215068 04-04

MIDBRAIN RAPHE NEURONS: SENSITIVITY TO GLUCOCORTICOIDS AND ACTH IN THE RAT.
217863 04-03

EFFECTS OF ACTH, DEXAMETHASONE AND DEOXYCORTICOSTERONE ON AVERSIVE THRESHOLD OF RATS.
221766 04-04

BEHAVIOURALLY ACTIVE ACTH ANALOGUES.
222820 04-04

ACTH1-24

EFFECTS OF INTRAVENTRICULAR INFUSIONS OF ACTH1-24 AND ACTH4-10 ON LH RELEASE, OVULATION AND BEHAVIOR IN THE RABBIT.
210662 03-03

ACTH4-10

EFFECTS OF INTRAVENTRICULAR INFUSIONS OF ACTH1-24 AND ACTH4-10 ON LH RELEASE, OVULATION AND BEHAVIOR IN THE RABBIT.
210662 03-03

THE INFLUENCE OF ACTH4-10 ON HIPPOCAMPAL AND THALAMIC SYNCHRONISED ACTIVITY IN RATS.
213430 04-03

SOME EFFECTS OF ACTH4-10 ON PERFORMANCE DURING A SERIAL REACTION TASK.
217533 04-04

EFFECT OF ACTH4-10 ON THE RATE OF SYNTHESIS OF (3H)CATECHOLAMINES IN THE BRAINS OF INTACT, HYPOPHYSECTOMIZED AND ADRENALECTOMIZED RATS.
223050 04-03

ACTING

EFFECT OF CHRONIC ADMINISTRATION OF CENTRALLY ACTING COMPOUNDS ON CHLORAMPHENICOL METABOLISM IN SCHIZOPHRENIC PATIENTS.
194157 01-08

EFFECTS OF CENTRAL ACTING DRUGS AND ERGOT DERIVATIVES ON PROLACTIN AND GROWTH HORMONE SECRETION, ON GROWTH OF PITUITARY AND MAMMARY TUMORS AND ON REPRODUCTION IN OLD RATS. (PH.D. DISSERTATION).
194571 01-03

INTERACTION BETWEEN ANTIDEPRESSANT AND CENTRALLY ACTING ANTIHYPERTENSIVE DRUGS.
197300 01-03

INHIBITION OF BEHAVIOURAL AND EEG ACTIVATION INDUCED BY MORPHINE ACTING ON LOWER BRAINSTEM STRUCTURES.
200078 02-03

EFFECTS OF THYROTROPIN-RELEASING HORMONE (TRH) ON THE ACTIONS OF PENTOBARBITAL AND OTHER CENTRALLY ACTING DRUGS.
215692 04-03

INTERACTION BETWEEN CENTRALLY ACTING HYPOTENSIVE DRUGS AND TRICYCLIC ANTIDEPRESSANTS.
217575 04-03

ACTINOMYCIN-D

THE EFFECT OF CYCLOHEXIMIDE AND ACTINOMYCIN-D ON THE SPONTANEOUS AND OPERATIVE BEHAVIORS OF THE PIGEON. PRELIMINARY NOTE.
199381 02-04

ACTION

MECHANISM OF ACTION OF PHENCYCLIDINE ON THE PERIPHERAL SYMPATHETIC NERVOUS SYSTEM.
193425 01-03

THE ACTION OF DIAZEPAM ON HUMAN SKELETAL MUSCLE.
193800 01-13

POSSIBLE MECHANISM OF ACTION OF BENZODIAZEPINES. (UNPUBLISHED PAPER).
194541 01-03

TRANQUILLIZING ACTION OF A CRYSTALLINE FRACTION OF PASPALUM-SCROBICULATUM EXTRACT IN FOURTEEN PSYCHOTIC PATIENTS.
194711 01-08

ANTIDEPRESSANT ACTION OF TRYPTOPHAN.
194857 01-13

INTERACTION OF PENTYLENETETRAZOL AND TRIMETHADIONE ON THE METABOLISM OF SEROTONIN IN BRAIN AND ITS RELATION TO THE ANTICONVULSANT ACTION OF TRIMETHADIONE.
195093 01-03

CENTRAL NERVOUS SYSTEM ALPHA-ADRENERGIC RECEPTORS AND THE MODE OF ACTION OF ALPHA-METHYLDOPA.
195237 01-03

THE IMPORTANCE OF THE ASCENDING DOPAMINERGIC SYSTEMS TO THE EXTRAPYRAMIDAL AND MESOLIMBIC BRAIN AREAS FOR THE CATALEPTIC ACTION OF THE NEUROLEPTIC AND CHOLINERGIC AGENTS.
195250 01-03

THE SITE OF AND MODE OF ACTION OF ET495 FOR THE MEDIATION OF STEREOTYPED BEHAVIOUR IN THE RAT.
195252 01-03

EFFECTS ON SHOCK-ELICITED AGGRESSION IN MICE OF PREFERENTIALLY PROTECTING BRAIN MONOAMINES AGAINST THE DEPLETING ACTION OF RESERPINE.
195452 01-04

ACTION OF PROBENECID ON THE CENTRAL NERVOUS SYSTEM OF THE RABBIT: II. POTENTIATION OF 5-HYDROXYTRYPTOPHAN-INDUCED HYPERTHERMIA AND SUPPRESSION OF THIS EFFECT BY A DECARBOXYLASE INHIBITOR (RO-4-4602).
196580 01-03

THE SITE OF THE RESPIRATORY STIMULANT ACTION OF IMIDAZOLE IN CATS.
196582 01-03

RELATIONSHIP BETWEEN ANALGESIC ACTION OF PETHIDINE AND ITS EFFECT ON THE BRAIN 5-HYDROXYTRYPTAMINE CONCENTRATION IN THE RATS OF DIFFERENT AGE.
196782 01-03

INVESTIGATIONS ON THE ACTION AND MECHANISM OF ACTION OF DIPHENYLHYDANTOIN AS AN ANTAGONIST OF TETRABENAZINE AND RESERPINE.
197471 01-03

ALTERATIONS OF BARBITURATE ACTION FOLLOWING 1,1 DICHLOROETHYLENE, CORTICOSTERONE, OR ACROLEIN.
197488 01-03

THE MECHANISM OF ACTION OF GYKI-32084, A NEW ANTISEROTONIN AGENT.
197570 01-03

THE ACTION OF PSYCHOSTIMULANT SIDNOKARB ON METABOLISM OF BIOGENIC AMINES IN THE BRAIN.
197573 01-03

CATECHOLAMINE DEPLETING ACTION OF PHYSOSTIGMINE IN THE RAT BRAIN.
197575 01-03

THE EFFECT OF DIAZEPAM ON SPINAL CORD ACTIVITIES: POSSIBLE SITES AND MECHANISMS OF ACTION.
197585 01-03

ACTION OF NEUROLEPTICS ON THE CONTENT OF DOPAMINE AND DOPAC IN THE RAT CAUDATE NUCLEUS.
197682 01-03

THE ANTICONVULSANT ACTION OF THE CARBONIC ANHYDRASE INHIBITOR METHAZOLAMIDE: POSSIBLE INVOLVEMENT OF A NORADRENERGIC MECHANISM.
197864 01-03

CENTRAL ACTION OF ANOREXIC AGENTS: EFFECTS OF AMPHETAMINE AND FENFLURAMINE IN RATS WITH LATERAL HYPOTHALAMIC LESIONS.
197865 01-04

ON THE MECHANISM OF ACTION OF GAMMA-HYDROXYBUTYRIC ACID: LACK OF CONVERSION TO GABA IN MOUSE BRAIN IN VIVO.
197965 01-03

ON THE ACTION OF OXOTREMORINE ON THE CHOLINERGIC SYSTEM OF THE RAT BRAIN.
197968 01-03

COMPARISON OF THE ACTION OF DIAZEPAM AND PHENOBARBITAL USING EEG DERIVED POWER SPECTRA OBTAINED FROM TEMPORAL LOBE EPILEPTICS.
197992 01-13

THE ACTION OF BICUCULLINE UPON ACETYLCHOLINE-INDUCED EXCITATIONS OF CENTRAL NEURONS.
197993 01-03

BEHAVIORAL MECHANISMS OF DRUG ACTION IN SCHIZOPHRENIA.
198103 02-08

ACTION OF RESERPINE IN MORPHINE TOLERANT RATS: ABSENCE OF AN ANTAGONISM OF CATECHOLAMINE DEPLETION.
199277 02-03

LOCUS OF CENTRAL DEPRESSANT ACTION OF FLUNITRAZEPAM.
199811 02-03

ELECTROENCEPHALOGRAPHIC AND BEHAVIORAL STUDIES ON THE CENTRAL ACTION OF NIMETAZEPAM (S-1530) IN CATS.
199910 02-04

COMPARATIVE CHARACTERISTICS OF THE CLINICAL ACTION OF TRANQUILIZERS.
201909 02-14

POTENTIATION WITH TRICYCLIC ANTIDEPRESSANTS OF THE INHIBITORY ACTION OF APOMORPHINE ON THE ATTITUDINAL REFLEX IN FROGS.
201919 02-04

ACTION OF (S)- AND (R) P-SUBSTITUTED AMPHETAMINE HYDROCHLORIDES AND (ALPHA S)- AND (ALPHA R) P-CHLORONOREPHEDRINE AND (ALPHA S)- AND (ALPHA R) P-CHLORONORPSEUDOEPHEDRINE HYDROCHLORIDES ON THE LEVEL OF 5-HYDROXYTRYPTAMINE AND THE ACTIVITY OF TRYPTOPHAN-HYDROXYLASE IN RAT BRAIN.
202417 02-03

ACTION OF A NEW PSYCHOTROPIC DRUG (SULPIRIDE) ON AVOIDANCE BEHAVIOR IN RATS.
202770 02-04

A PRELIMINARY REPORT ON THE ACTION OF IMIPRAMINE AND ANTIPARKINSONIAN AGENTS ON THE OPEN-FIELD BEHAVIOUR OF RATS.
202803 02-04

THE ROLE OF CEREBRAL CYCLIC-AMP IN THE ACTION OF PSYCHOTROPIC DRUGS: IN VIVO AND IN VITRO STUDIES. (PH.D. DISSERTATION).
203032 02-03

THE ACTION OF CHLORDIAZEPOXIDE ON CONDITIONS OF ANXIETY IN A PSYCHOPHYSIOLOGICAL EXPERIMENT.
204405 02-14

BIOCHEMICAL MECHANISMS OF EXTRAPYRAMIDAL MOTORIC ACTION OF HALOPERIDOL IN MAN.
204414 02-13

CENTRAL NERVOUS ACTION OF L-DOPA.
204424 02-04

INCREASED FIXED-RATIO PERFORMANCE AND DIFFERENTIAL D- AND L-AMPHETAMINE ACTION FOLLOWING NOREPINEPHRINE DEPLETION BY INTRAVENTRICULAR 6-HYDROXYDOPAMINE.
204482 02-04

A CONTRIBUTION TO THE STUDY OF MECHANISM OF ACTION OF PHENYLBUTAZONE: THE INFLUENCE OF CATECHOLAMINES ON THE ANTIINFLAMATORY EFFECT OF PHENYLBUTAZONE.
205169 02-03

ELECTROENCEPHALOGRAPHIC FINDINGS ON THE ACTION OF FENTANYL AND DEHYDROBENZOPERIDOL.
205442 02-13

THE INFLUENCE OF CHLORPROMAZINE ACTION ON EXPERIMENTAL PSYCHOSIS CAUSED BY LYSERGIC ACID DIETHYLAMIDE.
206439 03-04

THE ROLE OF THE RETICULAR FORMATION IN ACTION EXERTED BY CHLORPROMAZINE AND BENACTYZINE ON PRIMARY RESPONSES OF THE BRAIN-CORTEX.
206440 03-04

SURVEY ON AND EVALUATION OF THE CONTRIBUTIONS OF METHODOLOGICAL ASPECTS IN THE INVESTIGATION OF LONG-TERM PSYCHOPHARMACOLOGICAL DRUG ACTION.
206984 03-16

NEW DEVELOPMENTS IN THE STUDY OF THE MECHANISM OF ACTION OF NEUROLEPTICS AND AMPHETAMINE.
207296 03-03

THE ACTION OF CHLORIMIPRAMINE IN OBSESSIVE COMPULSIVE NEUROSIS: A PILOT STUDY.
209489 03-10

THERAPEUTIC EFFECTS AND MECHANISM OF ACTION OF S-ADENOSYL-L-METHIONINE (SAM) IN DEPRESSIVE SYNDROMES.
210213 03-09

ACTION AND REACTION: BIOPHYSIOLOGICAL AND NEUROPHYSIOLOGICAL MECHANISMS.
210419 03-13

ANTAGONISM OF DOPAMINE MEDIATED INHIBITION IN THE NIGROSTRIATAL PATHWAY: A MODE OF ACTION OF SOME CATATONIA INDUCING DRUGS.
210659 03-03

AMPHETAMINE: POSSIBLE SITE AND MODE OF ACTION FOR PRODUCING ANOREXIA IN THE RAT.
210675 03-03

INHIBITION OF MEMORY FORMATION IN THE IMPRINTING PERIOD: IRREVERSIBLE ACTION OF CYCLOHEXIMIDE IN YOUNG CHICKENS.
210708 03-04

THE EFFECT OF 5-HYDROXYTRYPTOPHAN ON FOOD INTAKE AND ON THE ANOREXIC ACTION OF AMPHETAMINE AND FENFLURAMINE.
210748 03-04

THE ROLE OF P-HYDROXYLATION OF AMPHETAMINE IN ITS PERIPHERAL MODE OF ACTION.
210749 03-03

BLOCKADE BY PIMOZIDE OF A NORADRENALINE SENSITIVE ADENYLATE-CYCLASE IN THE LIMBIC FOREBRAIN: POSSIBLE ROLE OF LIMBIC NORADRENERGIC MECHANISMS IN THE MODE OF ACTION OF ANTIPSYCHOTICS.
210771 03-03

ACTION OF STRYCHNINE AND CENTRAL DEPRESSANTS ON THE CEREBELLO-RUBRAL SYSTEM.
210881 03-03

EFFECT OF PHENOBARBITAL ON THE METABOLISM AND SEROTONIN DEPLETING ACTION OF 4-CHLORODIFLUOROAMPHETAMINE IN RATS.
210922 03-03

EFFECT OF MIDBRAIN RAPHE LESION AND OF 6-HYDROXYDOPAMINE ON THE ANTINOCICEPTIVE ACTION OF BUPRENORPHINE IN RATS.
210923 03-03

A POTENT DEPRESSANT ACTION OF ADENINE DERIVATIVES ON CEREBRAL CORTICAL NEURONES.
210932 03-03

CLINICAL AND PSYCHOMETRIC EVALUATION OF THE ACTION OF VINCAMIN IN CEREBRAL ARTERIOSCLEROSIS.
211226 03-11

P-CHLOROAMPHETAMINE: SELECTIVE NEUROTOXIC ACTION IN BRAIN.
211494 03-05

PARKINSONIAN TYPE TREMOR AND THE ACTION OF HARMALINE: EXPERIMENTAL FACTS AND HYPOTHETICAL MECHANISMS.
212182 03-03

THE ACTION OF SULPIRIDE IN PURE INTERPRETIVE DELIRIUM.
212492 03-09

EFFECT OF CENTRAL NERVOUS SYSTEM LESIONS ON DRUG ACTION.
213611 04-03

DISPOSITION AND ACTION OF DRUGS AFFECTING BEHAVIOR.
213617 04-03

FREE-RADICALS IN PSYCHOTROPIC DRUG ACTION.
213624 04-03

HALLUCINOGENIC DRUG ACTION ON THE SOMATOSENSORY SYSTEM.
213634 04-04

BIOCHEMICAL VERSUS PSYCHOPATHOLOGICAL ACTION PROFILE OF NEUROLEPTICS: A COMPARATIVE STUDY OF CHLORPROMAZINE AND OXYPERTINE IN ACUTE PSYCHOTIC DISORDERS.
215454 04-13

THE ACTION OF CHLORPROMAZINE AND TRIFTAZINE ON DISCHARGES OF CORTICAL NEURONS IN RABBITS AFTER CHRONIC ADMINISTRATION OF THE DRUGS.
215499 04-03

THE IN VIVO REGULATION OF CGMP CONTENT IN RAT CEREBELLUM: A STUDY OF THE ACTION OF TAURINE.
215654 04-03

ANTINOCICEPTIVE ACTION OF OXOTREMORINE AND REGIONAL TURNOVER OF RAT BRAIN NORADRENALINE, DOPAMINE AND 5-HT.
215683 04-03

AN ATTEMPT TO VERIFY THE ANTIDEPRESSANT ACTION OF THE HYPOTHALAMIC THYROSTIMULIN (THYROTROPIN-RELEASING FACTOR OR TRF) IN MELANCHOLIC STATES.
216758 04-09

SOME GENERAL PRINCIPLES OF THE MECHANISM OF THE CENTRAL ACTION OF PSYCHOTOMIMETICS.
216999 04-12

NEUROLEPTICS OF PROLONGED ACTION (A SURVEY OF FOREIGN LITERATURE).
217003 04-14

THE PROTECTIVE EFFECT OF SEROTONIN AGAINST THE INHIBITORY ACTION OF CHLORPROMAZINE ON THE MEMBRANE POTENTIAL OF STAGE 2 BLASTOMERES OF MOUSE EMBRYOS IN VITRO.
217005 04-03

THE MECHANISM OF ANTICONVULSIVE ACTION OF DIAZEPAM.
217064 04-04

NEUROLEPTIC ACTION OF CLOZAPINE INJECTED INTO VARIOUS BRAIN AREAS IN RATS.
217451 04-04

ELECTROPHYSIOLOGICAL EVIDENCE FOR AN INHIBITORY ACTION OF DIAZEPAM UPON CAT BRAIN CORTEX.
217649 04-03

ANTIHISTAMINIC ACTION OF (-) TRANS-DELTA9-TETRAHYDROCANNABINOL.
217651 04-03

COMPARISON OF THE ACTION OF DIFFERENT BARBITURATES ON SQUID AXON MEMBRANES.
217662 04-03

THE ROLE OF CATECHOLAMINES IN THE ACTION OF AMPHETAMINE AND L-DOPA ON CEREBRAL ENERGY METABOLISM.
217677 04-03

DIFFERENCES BETWEEN (+)- AND (-) AMPHETAMINE IN EFFECTS ON LOCOMOTOR ACTIVITY AND L-DOPA POTENTIATING ACTION IN MICE.
217835 04-04

ACTION OF DIAZEPAM, DIBUTYRYL-CGMP, AND GABA ON PRESYNAPTIC NERVE TERMINALS IN BULLFROG SYMPATHETIC GANGLIA.
217873 04-03

UPTAKE AND DISAPPEARANCE OF 4-METHYL-ALPHA-ETHYLMETATYRAMINE IN RELATION TO ITS RELEASING ACTION ON 5-HYDROXYTRYPTAMINE IN THE BRAIN.
217897 04-03

PROBLEMS IN THE ELECTROPHYSIOLOGICAL ANALYSIS OF THE SITE OF ACTION OF BENZODIAZEPINES. (UNPUBLISHED PAPER).
218148 04-03

A GABA HYPOTHESIS FOR THE ACTION OF BENZODIAZEPINES. (UNPUBLISHED PAPER).
218149 04-03

THE PARTICIPATION OF CEREBRAL CHOLINERGIC MECHANISMS IN THE ACTION OF NEUROLEPTICS.
218471 04-04

SPECIFICITY OF BENZODIAZEPINE ACTION ON HUMAN SLEEP CONFIRMED. ANOTHER CONTRIBUTION OF AUTOMATIC ANALYSIS OF POLYGRAPH RECORDINGS.
218953 04-14

ACTION OF SEROTONIN MICROINJECTED INTO HYPOTHALAMIC SITES AT WHICH ELECTRICAL STIMULATION PRODUCED AVERSIVE RESPONSES IN THE RAT.
219075 04-04

THE ROLE OF THE AMYGDALA IN THE DEPRESSIVE ACTION OF SEROTONIN AND 5-HYDROXYTRYPTOPHAN ON THE CONDITIONED ACTIVITY OF WHITE RATS.
219328 04-04

AN EXPERIMENTAL STUDY OF THE PSYCHOTROPIC ACTION OF PYRAZIDOL.
219497 04-03

A COMPARISON OF THE ACTION OF THE TRICYCLIC ANTIDEPRESSANTS, AZAPHEN AND IMIPRAMINE, ON THE GASTROINTESTINAL TRACT OF TEST ANIMALS.
219505 04-03

TOWARDS THE MECHANISM OF THE ANTIPHLOGISTIC ACTION OF CHLORPROMAZINE.
219507 04-03

THE SPECIFICITY OF ACTION EXERTED BY NEUROTROPIC AGENTS DURING SENSITIZATION.
219508 04-03

NEUROCHEMICAL AND NEUROPHYSIOLOGICAL MECHANISMS OF THE PSYCHOSTIMULATING ACTION OF PHENAMINE.
219510 04-13

ON THE MECHANISM OF THE DEFENSIVE ACTION OF ACETYLCHOLINE AND SEROTONIN AGAINST THEIR CYTOTOXIC ANTAGONISTS.
219663 04-03

THE ACTION OF PIMOZIDE ON ACUTE PSYCHOSIS.
219960 04-09

A BENZODIOXANHYDROXYETHYLPIPERIDINE DERIVATIVE WITH ACUTE CENTRAL HYPOTENSIVE ACTION, DIFFERENT FROM THAT OF CLONIDINE: A COMPARISON WITH NEUROLEPTIC AGENTS.
220976 04-03

INHIBITORY ACTION OF NOREPINEPHRINE ON THE INDUCTION OF TRYPTOPHAN 2,3 DIOXYGENASE BY CORTISOL: MEDIATION BY THE ALPHA-RECEPTOR.
221051 04-03

ELECTROENCEPHALOGRAPHIC STUDY ON THE ACTION OF THE COMBINATION MEPROBAMATE ACEPROMETAZINE ON VARIOUS CEREBRAL SYSTEMS.
221286 04-03

NOXIPTILIN (AGEDAL) -- A NEW TRICYCLIC ANTIDEPRESSANT WITH A FASTER ONSET OF ACTION? A DOUBLE-BLIND, MULTICENTRE COMPARISON WITH AMITRIPTYLINE.
221306 04-09

POTENTIATION OF ANTIDEPRESSANT ACTION OF CLOMIPRAMINE BY TRYPTOPHAN.
221385 04-09

THE ACTION OF DELTA9-TETRAHYDROCANNABINOL ON CENTRAL CARDIOVASCULAR REGULATION: MECHANISM AND LOCALIZATION.
221669 04-03

PHARMACOLOGICAL ACTION OF FD-008, A NEW DOPAMINE-BETA-HYDROXYLASE INHIBITOR: II. EFFECTS ON CENTRAL NERVOUS SYSTEM IN MICE AND RATS.
221823 04-02

PHARMACOLOGICAL ACTION OF FD-008, A NEW DOPAMINE-BETA-HYDROXYLASE INHIBITOR: III. EFFECTS ON ENDOGENOUS BIOGENIC AMINE LEVELS IN RATS.
221859 04-03

THE DOPAMINERGIC COMPONENT IN THE ACTION OF D,L-AMPHETAMINE ON THE INHIBITORY FUNCTION OF THE CAUDATE NUCLEUS.
223014 04-03

A STUDY OF THE RELATIONSHIP BETWEEN CIRCADIAN RHYTHMS IN DRUG ACTION AND METABOLISM IN THE MOUSE. (PH.D. DISSERTATION).
223562 04-03

NEW CONCEPTS ON THE MECHANISM OF ACTION OF BENZODIAZEPINES.
225058 04-13

THE ROLE OF DISCRIMINATIVE STIMULI IN MODULATING DRUG ACTION.
225170 04-04

DISCRETE TRIAL ANALYSIS OF DRUG ACTION.
225172 04-04

ACTIONS

ACTIONS OF GABA, PICROTOXIN AND BICUCULLINE ON ADRENAL MEDULLA.
193455 01-03

ROLE OF MONOAMINES IN THE ANOREXIGENIC ACTIONS OF FENFLURAMINE, AMPHETAMINE AND P-CHLOROMETHAMPHETAMINE.
193546 01-04

TOLERANCE DEVELOPMENT TO THE ANTINOCICEPTIVE ACTIONS OF MORPHINE, AMPHETAMINE, PHYSOSTIGMINE AND 2-AMINOINDANE IN THE MOUSE.
194930 01-03

MODIFICATION OF DELTA9-THC ACTIONS BY CANNABINOL AND CANNABIDIOL IN THE RAT.
197858 01-03

SIMILAR ACTIONS OF INTRAHYPOTHALAMIC 5-6-DHT AND 5-HT IN EVOKING HYPERTHERMIA IN THE MONKEY.
200034 02-03

CENTRAL ACTIONS OF SOME BETA-ADRENOCEPTOR BLOCKING AGENTS.
206782 03-03

EXPERIMENTAL STUDY ON NEUROPHARMACOLOGICAL ACTIONS OF SOME INDOLE DERIVATIVES.
207164 03-02

DOPAMINERGIC MECHANISMS OF OPIATE ACTIONS IN BRAIN.
208554 03-03

SOME PHARMACOLOGICAL ACTIONS OF 2,5 DIMETHOXY-4-ETHYLAMPHETAMINE (DOET) IN RATS AND MICE.
210747 03-03

COMPARATIVE STUDIES ON THE MEMBRANE ACTIONS OF DEPRESSANT DRUGS: THE ROLE OF LIPOPHILICITY IN INHIBITION OF BRAIN SODIUM AND POTASSIUM STIMULATED ATPASE.
210818 03-03

ACTIONS AND INTERACTIONS OF ABUSED DRUGS OF THE REWARD SYSTEM. (PH.D. DISSERTATION).
212964 03-04

THE EFFECT OF PROLONGED LITHIUM INGESTION ON MORPHINE ACTIONS IN THE RAT.
213482 04-03

NEUROCHEMICAL ACTIONS OF PSYCHOTROPIC DRUGS.
213633 04-03

EFFECTS OF THYROTROPIN-RELEASING HORMONE (TRH) ON THE ACTIONS OF PENTOBARBITAL AND OTHER CENTRALLY ACTING DRUGS.
215692 04-03

CENTRAL ANTICHOLINERGIC ACTIONS OF DOXEPIN IN RABBITS.
215727 04-03

ACTIONS OF ACETYLCHOLINE AND ATROPINE ON CEREBRAL CORTICAL NEURONS IN CHRONICALLY MORPHINE TREATED RATS.
215733 04-03

NEUROLEPTICS: RELATION BETWEEN CATALEPTIC AND ANTITURNING ACTIONS, AND ROLE OF THE CHOLINERGIC SYSTEM.
217826 04-04

CENTRAL CATECHOLAMINE RECEPTOR BLOCKING ACTIONS OF BE-2254 (HEAT): COMPARISON WITH CHLORPROMAZINE AND HALOPERIDOL.
222804 04-03

RELATIONSHIPS BETWEEN THE STRUCTURE AND THE CHRONOTROPIC, LOCOMOTOR STIMULANT AND REINFORCING ACTIONS OF SEVERAL FENFLURAMINE ANALOGS. (PH.D. DISSERTATION).
223563 04-04

ACTIVATED
TREATMENT OF EXPERIMENTAL IMIPRAMINE INTOXICATION BY INTERRUPTING ENTERAL CYCLES WITH ACTIVATED CHARCOAL.
197969 01-03

ACTIVATING
NEUROPHARMACOLOGICAL STUDIES OF EFFECT OF NEW CENTRAL DEPRESSANT, 8-CHLOR-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D40TA) ON EEG AND CENTRAL SYMPATHETIC ACTIVATING MECHANISM IN CATS.
195549 01-03

CLINICAL EXPERIENCE WITH FORIT: ITS ACTIVATING EFFECT ON CHRONIC SCHIZOPHRENIA.
198710 02-08

ACTIVATION
CHANGES IN ACTIVATION OF ADENYLATE-CYCLASE AND OF DOPAMINE TURNOVER IN RAT STRIATUM DURING PROLONGED HALOPERIDOL TREATMENT.
192933 01-03

THYROTROPIN-RELEASING HORMONE: ACTIVATION OF CEREBRAL NORADRENALINE TURNOVER.
197950 01-03

INHIBITION OF BEHAVIOURAL AND EEG ACTIVATION INDUCED BY MORPHINE ACTING ON LOWER BRAINSTEM STRUCTURES.
200078 02-03

ACTIVATION OF BRAIN MONOAMINEOXIDASE BY SOME CNS DEPRESSANTS.
204864 02-03

ACTIVATION OF EEG BY GAMMA-HYDROXYBUTYRATE (GHB) IN ORGANIC BRAIN DISORDERS.
205460 02-13

FURTHER EXPERIENCE WITH EPONTOL IN EEG ACTIVATION.
205548 02-13

NEOCORTICAL AND HIPPOCAMPAL ACTIVATION IN RELATION TO BEHAVIOR: EFFECTS OF ATROPINE, ESERINE, PHENOTHIAZINES, AND AMPHETAMINE.
206742 03-04

THE ACTIVATION OF THE KININ FORMING SYSTEM AND THE EFFECTS OF THIOPENTAL.
210744 03-03

EFFECT OF THE ACTIVATION OF THE KININ FORMING SYSTEM ON THE POTENCY OF CHLORPROMAZINE.
210872 03-03

ACTIVATOR
ON THE REGULATION OF CYCLIC-AMP PHOSPHODIESTERASE BY A SPECIFIC PROTEIN ACTIVATOR. (UNPUBLISHED PAPER).
208735 03-03

ACTIVE
STEREOCHEMICAL DEPENDENCE OF PHARMACOLOGICAL ACTIVITY IN A SERIES OF OPTICALLY ACTIVE N-METHYLATED BARBITURATES.
193140 01-01

STEREOCHEMICAL STUDIES ON POTENTIAL CENTRAL NERVOUS SYSTEM ACTIVE AGENTS AND STUDIES ON THE CHEMISTRY OF SOME 3-BENZOYLPIPERIDINES. (PH.D. DISSERTATION).
193586 01-01

A DUAL STUDY. PART I: SYNTHESIS AND STEREOCHEMISTRY OF SOME 1 SUBSTITUTED QUINOLIZIDINES AS ANALOGS OF BIOLOGICALLY ACTIVE COMPOUNDS. PART II: AMINO DERIVATIVES OF THIOPHENE FUSED CYCLIC KETONES AS POTENTIAL CNS. (PH.D. DISSERTATION).
196252 01-01

EFFECTS OF HIPPOCAMPAL MICROINJECTIONS OF D-AMPHETAMINE AND SCOPOLAMINE ON ACTIVE AVOIDANCE BEHAVIOR IN RATS.
206741 03-04

LOSS OF ACTIVE AVOIDANCE RESPONDING AFTER LATERAL HYPOTHALAMIC INJECTIONS OF 6-HYDROXYDOPAMINE.
215704 04-04

CENTRALLY ACTIVE PHENETHYLAMINES.
217557 04-12

STATE-DEPENDENT LEARNING WITH CENTRALLY AND NONCENTRALLY ACTIVE DRUGS.
219020 04-04

THE EFFECT OF AN ADRENAL DEMEDULLATION AND CHEMICAL SYMPATHECTOMY (2,4,5 TRIHYDROXYPHENYLETHYLAMINE) ON THE ACQUISITION OF A ONE-WAY ACTIVE AVOIDANCE RESPONSE. (PH.D. DISSERTATION).
222736 04-04

BEHAVIOURALLY ACTIVE ACTH ANALOGUES.
222820 04-04

ACTIVITIES
NEW HOT PLATE TESTS TO QUANTIFY ANTINOCICEPTIVE AND NARCOTIC ANTAGONIST ACTIVITIES.
193446 01-04

THE INCORPORATION OF GLUCOSE INTO BRAIN GLYCOGEN AND THE ACTIVITIES OF CEREBRAL GLYCOGEN PHOSPHORYLASE AND SYNTHETASE: SOME EFFECTS OF AMPHETAMINE.
196808 01-03

NEUROCHEMICAL BASES FOR THE ANORECTIC ACTIVITIES OF AMPHETAMINE AND FENFLURAMINE.
197301 01-03

CENTRAL PHARMACOLOGICAL ACTIVITIES OF 4-PHENYL-6-CHLORO-1,4-DIHYDRO-2H-3,1 BENZOXAZIN-2-ONE.
197453 01-03

CHLORPROMAZINE METABOLISM VI -- ADRENOLYTIC AND ANTISEROTONERGIC ACTIVITIES OF CHLORPROMAZINE AND ITS VARIOUS METABOLITES.
197494 01-03

THE EFFECT OF DIAZEPAM ON SPINAL CORD ACTIVITIES: POSSIBLE SITES AND MECHANISMS OF ACTION.
197585 01-03

DOPAMINE AGONIST AND ANTAGONIST ACTIVITIES OF PIRIBEDIL (ET495) AND ITS METABOLITES.
197930 01-04

ANXIETY AND ACTIVITIES OF CYCLIC ADENOSINE-MONOPHOSPHATE PHOSPHODIESTERASE.
202161 02-17

STUDIES ON ANTIDIURETIC ACTIVITIES AND ON PORTER-SILBERS CHROMOGENS CONTENT IN PLASMA OF PATIENTS WITH ALCOHOLIC DELIRIUM OR WITH ACUTE PHENOTHIAZINE INTOXICATIONS.
203741 02-15

ANTICONVULSANT ACTIVITIES OF DELTA8-THC AND DELTA9-TETRAHYDROCANNABINOL AND URIDINE.
213374 04-03

CONTRASTING LOCAL EFFECTS OF MAO INHIBITORS ON CAUDATE TREMOR ACTIVITIES.
217669 04-03

DIFFERENTIAL RATES OF INCREASE IN PONTINE TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE ACTIVITIES AFTER RESERPINE.
217854 04-03

ACTIVITY
STEREOCHEMICAL DEPENDENCE OF PHARMACOLOGICAL ACTIVITY IN A SERIES OF OPTICALLY ACTIVE N-METHYLATED BARBITURATES.
193140 01-01

EFFECTS OF THE NORADRENALINE METABOLITES ON TYROSINE-HYDROXYLASE ACTIVITY IN GUINEA-PIG ATRIA.
193279 01-02

MESOLIMBIC INVOLVEMENT WITH BEHAVIOURAL EFFECTS INDICATING ANTIPSYCHOTIC ACTIVITY.
193450 01-03

EFFECTS OF KETAMINE ON EEG ACTIVITY IN CATS AND MONKEYS.
193797 01-03

MOUSE LOCOMOTOR ACTIVITY: EFFECT OF MORPHINE, NARCOTIC ANTAGONISTS, AND THE INTERACTION OF MORPHINE AND NARCOTIC ANTAGONISTS.
194478 01-04

BRAIN DOPA/5-HTP DECARBOXYLASE ACTIVITY AFTER THE CHRONIC ADMINISTRATION OF L-DOPA OR 5-HYDROXY-L-TRYPTOPHAN IN NORMAL AND LESIONED CATS.
194483 01-05

PSYCHOMOTOR ACTIVITY IN MANIA.
194862 01-09

EFFECT OF THIOTHIXENE UPON THE HIGHER NERVOUS ACTIVITY IN CHRONIC SCHIZOPHRENICS.
195041 01-09

EFFECT OF INDOLEALKYLAMINE MANIPULATIONS ON LOCOMOTOR ACTIVITY IN RATS.
195087 01-04

EFFECTS OF TAURINE ON PSYCHOMOTOR ACTIVITY IN THE RAT.
195089 01-04

THE LIPOLYTIC ACTIVITY OF AMPHETAMINE IN THE SPINALISED CAT.
195118 01-03

EFFECTS OF WITHDRAWAL FROM CHRONIC AMPHETAMINE ADMINISTRATION ON ACTIVITY LEVELS OF ALBINO RATS.
195223 01-04

ADRENERGIC RECEPTOR BLOCKING AGENTS: EFFECTS ON CENTRAL NORADRENALINE AND DOPAMINE RECEPTORS AND ON MOTOR ACTIVITY.
195429 01-03

THE EFFECTS OF LITHIUM AND PHYSOSTIGMINE ON RAT BRAIN ACETYLCHOLINESTERASE ACTIVITY.
195436 01-03

EFFECT OF MONOVALENT CATIONS ON HUMAN PLATELET ADENYLCYCLASE ACTIVITY.
195930 01-13

EFFECTS OF D-AMPHETAMINE SULFATE GIVEN TO PREGNANT MICE ON ACTIVITY AND ON CATECHOLAMINES IN THE BRAINS OF OFFSPRING.
196025 01-03

THE USE OF THE IMMOBILITY REFLEX (ANIMAL HYPNOSIS) AS A POSSIBLE PROCEDURE FOR DETECTING SEDATIVE ACTIVITY.
196066 01-04

THE EFFECT OF PSYCHOPHARMACA ON UROPEPTIC ACTIVITY.
196188 01-13

THE INFLUENCE OF CEREBROLYSINE ON HIGHER NERVOUS ACTIVITY IN ADULT RATS.
196758 01-04

A POSSIBLE MECHANISM FOR THE ANTIDEPRESSANT ACTIVITY OF THYROTROPIN-RELEASING HORMONE.
196836 01-13

A SIMPLE AND RAPID SPECTROPHOTOMETRIC DETERMINATION OF MONOAMINEOXIDASE ACTIVITY.
197281 01-01

ON THE INVOLVEMENT OF BRAIN CATECHOLAMINES IN MORPHINE-INDUCED RUNNING ACTIVITY IN MICE.
197286 01-04

EFFECT OF BENZODIAZEPINE DERIVATIVES ON SOMAN INDUCED SEIZURE ACTIVITY AND CONVULSIONS IN THE MONKEY.
197466 01-03

EFFECTS OF THE HIGH DOSES OF L-DOPA ON ELECTRICAL ACTIVITY IN THE BRAIN OF THE RABBIT: INTERACTION WITH THE METABOLISM OF 5-HT.
197468 01-03

ENHANCED LOCOMOTOR ACTIVITY FOLLOWING AMPHETAMINE IN MOUSE-KILLING RATS.
197482 01-04

SYMPATHETIC NERVE ACTIVITY AFTER NORADRENALINE DEPLETION AND ITS ALTERATION BY CLONIDINE.
197947 01-03

THE EFFECT OF BEDREST AND OF PHYSICAL ACTIVITY ON THE BLOOD LEVEL OF GENTAMYCIN AFTER INTRAMUSCULAR APPLICATION.
197956 01-13

EFFECTS OF PHYSOSTIGMINE ON THE ACCURACY AND ACTIVITY OF DISCRIMINATION BEHAVIOUR IN RATS.
197995 01-04

EVALUATION OF CLINICAL PREDICTION OF ANTIDEPRESSANT ACTIVITY USING VARIOUS ANIMAL TEST MODELS.
198055 01-02

EFFECT ON PSEUDOCONDITIONING OF DRUGS WITH KNOWN CENTRAL NERVOUS ACTIVITY.
198228 02-04

THE INFLUENCE OF TYROCALCITONIN ON CONDITIONAL REFLEXES AND THE ELECTRICAL ACTIVITY OF THE BRAIN IN ANIMALS.
198479 02-02

PROTEINASE ACTIVITY OF DIFFERENT SECTIONS OF THE BRAIN DURING CORAZOL (PENTYLENETETRAZOL) INDUCED CONVULSIONS.
198485 02-03

COMPARATIVE EFFECT OF PHENAMINE (AMPHETAMINE) AND CAFFEINE ON THE BACKGROUND ACTIVITY OF CORTICAL SENSORIMOTOR NEURONS AND THEIR REACTIONS DURING STIMULATION OF THE CAUDATE NUCLEUS.
198835 02-03

PERSISTENT THALAMIC AND CORTICAL BARBITURATE SPINDLE ACTIVITY AFTER ABLATION OF THE ORBITAL CORTEX IN CATS.
199763 02-03

EFFECT OF NEUROTROPIC AGENTS ON TOTAL PYRIDOXAL PHOSPHATE AND ON THE ACTIVITY OF THE DECARBOXYLASE OF AROMATIC AMINO ACIDS AS WELL AS OF OTHER PYRIDOXAL PHOSPHATE DEPENDENT ENZYMES IN RAT BRAIN.
199785 02-03

ANALYSIS OF ACETYLCHOLINESTERASE SYNTHESIS AND TRANSPORT IN THE RAT HIPPOCAMPUS: RECOVERY OF ACETYLCHOLINESTERASE ACTIVITY IN THE SEPTUM AND HIPPOCAMPUS AFTER ADMINISTRATION OF DIISOPROPYLFLUOROPHOSPHATE.
199805 02-03

REDUCTION BY DIAZEPAM OF REPETITIVE ELECTRICAL ACTIVITY AND TOXICITY RESULTING FROM SOMAN.
199861 02-03

INHIBITION OF SYMPATHETIC ACTIVITY FOLLOWING CHRONIC ADMINISTRATION OF 2-AMINO-4-(3,4 DICHLOROPHENYL) 2-IMIDAZOLINE (MJ-10459-2).
199863 02-03

INHIBITION OF SCOPOLAMINE INDUCED STIMULATION OF Y-MAZE ACTIVITY BY ALPHA-METHYL-P-TYROSINE AND BY LITHIUM.
199866 02-04

REDUCED BEHAVIOURAL EFFECTS OF INTRAHIPPOCAMPALLY ADMINISTERED CARBACHOL IN RATS WITH LOW CHOLINESTERASE ACTIVITY.
199956 02-04

ANTICONVULSANT ACTIVITY OF DELTA9-TETRAHYDROCANNABINOL AND ITS 11 HYDROXY AND BALPHA,11 DIHYDROXY METABOLITES IN THE FROG.
200035 02-03

THE INFLUENCE OF CATECHOLAMINES, SEROTONIN, AND SOME AMINO ACIDS ADMINISTERED INTO THE AMYGDALOID COMPLEX ON CONDITIONED REFLEXES OF AVOIDANCE AND MOTOR ACTIVITY IN RATS.
200566 02-03

EFFECT OF LONG-TERM LITHIUM TREATMENT ON BRAIN FUMARASE ACTIVITY.
200751 02-03

NEURONAL ACTIVITY OF NUCLEUS CAUDATES AND THALAMUS DURING BARBITURATE SPINDLES IN RATS.
201479 02-03

CLINICAL DOUBLE-BLIND STUDY ON THE ACTIVITY OF A NEW ANTIDEPRESSANT: CAROXAZONE (FI-6654).
201667 02-09

THE EFFECT OF DIAZAPHENOXAZINE DERIVATIVES ON MONOAMINEOXIDASE ACTIVITY.
201914 02-02

NALOXONE PRECIPITATED JUMPING ACTIVITY IN MICE FOLLOWING THE ACUTE ADMINISTRATION OF MORPHINE.
202201 02-04

AMPHETAMINE, L-DOPA AND APOMORPHINE: EFFECTS ON ACTIVITY OF RAT DOPAMINERGIC NEURONS.
202370 02-03

ACTION OF (S)- AND (R) P-SUBSTITUTED AMPHETAMINE HYDROCHLORIDES AND (ALPHA S)- AND (ALPHA R) P-CHLORONOREPHEDRINE AND (ALPHA S)- AND (ALPHA R) P-CHLORONORPSEUDOEPHEDRINE HYDROCHLORIDES ON THE LEVEL OF 5-HYDROXYTRYPTAMINE AND THE ACTIVITY OF TRYPTOPHAN-HYDROXYLASE IN RAT BRAIN.
202417 02-03

THE EFFECT OF INHIBITORS OF CATECHOLAMINE SYNTHESIS (ALPHA-METHYLTYROSINE AND DISULFIRAM) ON THE BACKGROUND ACTIVITY OF SENSORIMOTOR CORTEX NEURONS AND THEIR RESPONSES TO AFFERENT CAUDATE AND RETICULAR STIMULATION.
202598 02-04

DOPAMINERGIC NEURONS: DRUG-INDUCED ANTAGONISM OF THE INCREASE IN TYROSINE-HYDROXYLASE ACTIVITY PRODUCED BY CESSATION OF IMPULSE FLOW.
202664 02-03

FACTORS AFFECTING THE ACTIVITY OF 5-HT CONTAINING NEURONES.
202718 02-03

METHYLDOPA INDUCED DECREASE IN MENTAL ACTIVITY.
202921 02-15

EFFECTS OF NICOTINE ON SPONTANEOUS LOCOMOTOR ACTIVITY IN RATS HAVING HIGH AND LOW BASAL ACTIVITY LEVELS.
202980 02-04

EFFECTS OF PHENOBARBITAL ON ELECTROCORTICOGRAM AND ACTIVITY, ON REGIONAL CNS ENERGY METABOLISM, AND ON PRESYNAPTIC EVENTS IN CEREBRAL CORTEX AND BRAINSTEM. (PH.D. DISSERTATION).
203033 02-03

EFFECT OF DIAZEPAM UPON SOMAN INDUCED SEIZURE ACTIVITY AND CONVULSIONS.
204192 02-02

THE INFLUENCE OF ANTIADRENERGIC AND ANTIDOPAMINERGIC DRUGS ON METHAMPHETAMINE INDUCED CHANGES IN MOTORIC ACTIVITY AND CEREBRAL GLYCOGEN CONTENT IN MICE.
204396 02-03

THE ACTIVITY PROFILE OF PIRACETAM IN PSYCHOSYNDROMES AND SYMPTOMATIC PSYCHOSES.
204411 02-09

THE DIFFERENTIATION OF TWO TYPES OF HYPERACTIVE CHILDREN BY ACTIVITY LEVEL AND TASK PERFORMANCE WITH METHYLPHENIDATE (RITALIN) AND PLACEBO. (PH.D. DISSERTATION).
204688 02-11

MG++ DEPENDENT ADENOSINE-TRIPHOSPHATASE ACTIVITY IN ERYTHROCYTE GHOSTS OF SCHIZOPHRENIC PATIENTS.
206332 03-08

AN INVESTIGATION OF PSYCHOTROPIC ACTIVITY IN A SERIES OF PIPERAZINE (1,2-A) INDOLE DERIVATIVES.
206438 03-02

MICROIONTOPHORETIC STUDIES ON THE EFFECT OF NOREPINEPHRINE ON THE ACTIVITY OF THE VISUAL CORTEX NEURONS IN RABBITS.
206441 03-03

AZAPERONE, A SEDATIVE NEUROLEPTIC OF THE BUTYROPHENONE SERIES WITH PRONOUNCED ANTIAGGRESSIVE AND ANTISHOCK ACTIVITY IN ANIMALS.
206786 03-04

LONG-TERM TRIAL OF FLUPHENAZINE DECANOATE AND FLUPENTHIXOL DECANOATE FOR CATALEPTIC ACTIVITY AND EFFECT ON MOTOR ACTIVITY IN RATS.
206787 03-04

THE EFFECT OF L-DOPA AND L-DOPA COMBINED WITH CHLORPROMAZINE ON SPINAL CORD ACTIVITY DURING DISTURBED INHIBITION BY TETANUS TOXOID.
207200 03-03

COMPARISON OF THE INHIBITORY EFFECTS OF PROPARGYLAMINE AND PARGYLINE ON BRAIN AND LIVER MONOAMINEOXIDASE ACTIVITY.
207857 03-03

NEUROLEPTIC AGENTS OF THE BENZOCYCLOHEPTAPYRIDOISOQUINOLINE SERIES. 1.SYNTHESES AND STEREOCHEMICAL AND STRUCTURAL REQUIREMENTS FOR ACTIVITY OF BUTACLAMOL AND RELATED COMPOUNDS.
208592 03-01

CORRELATION OF PSYCHOTOMIMETIC ACTIVITY OF PHENETHYLAMINES AND AMPHETAMINES WITH 1-OCTANOL WATER PARTITION COEFFICIENTS.
208593 03-12

THE INFLUENCE OF ETHYMISOL ON THE ACTIVITY OF ADENYLCYCLASE AND 3,5 AMP-PHOSPHODIESTERASE OF RATS BRAINS.
208973 03-03

EFFECT OF STRESS ON CATECHOLAMINES AND TYROSINE-HYDROXYLASE ACTIVITY OF INDIVIDUAL HYPOTHALAMIC NUCLEI.
208994 03-03

EFFECT OF STRESS AND DIAZEPAM TREATMENT DURING INFANCY ON THE CORTICOSTERONE REGULATION AND ANDROGENIC ACTIVITY IN ADULT MALE RATS.
210348 03-03

THE EFFECTS OF PSYCHOMOTOR STIMULANTS ON STEREOTYPY AND LOCOMOTOR ACTIVITY IN SOCIALLY DEPRIVED AND CONTROL RATS.
210666 03-04

EFFECTS OF DOPAMINERGIC RECEPTOR AGONISTS AND ANTAGONISTS ON THE ACTIVITY OF THE NEOSTRIATAL CHOLINERGIC SYSTEM.
210669 03-03

EFFECT OF INTRAVENTRICULAR NOREPINEPHRINE ON NEURON ACTIVITY IN THE MEDIAL FOREBRAIN BUNDLE DURING SELF-STIMULATION BEHAVIOR.
210704 03-04

EFFECT OF PERIPHERALLY ADMINISTERED SEROTONIN ON THE NEURONAL ACTIVITY OF MIDBRAIN RAPHE NEURONS.
210710 03-03

EXTRAPINEAL N-ACETYLTRANSFERASE ACTIVITY IN RAT BRAIN.
210760 03-03

POSSIBLE INVOLVEMENT OF 5-HYDROXYTRYPTAMINE IN THE ANTIDEPRESSANT ACTIVITY OF NARCOTIC ANALGESICS.
210761 03-03

THE EFFECT OF DRUGS WITH ANTIDEPRESSANT ACTIVITY UPON THE HYPOTHERMIA AND BEHAVIOURAL DEPRESSION INDUCED IN MICE BY PIMOZIDE OR CENTRALLY ADMINISTERED NORADRENALINE.
210762 03-04

EFFECTS OF NALORPHINE ON AVOIDANCE BEHAVIOR AND LOCOMOTOR ACTIVITY IN THE RAT.
210783 03-04

THE EFFECT OF ANTIDEPRESSANTS ON UNIT ACTIVITY IN THE MIDBRAIN RAPHE OF RATS.
210789 03-03

EVIDENCE FOR REVERSIBLE INHIBITION OF BRAIN DOPAMINE-BETA-HYDROXYLASE ACTIVITY IN VIVO BY AMPHETAMINE ANALOGUES.
210821 03-03

COMPARISON OF THE EFFECTS OF D-AMPHETAMINE AND L-AMPHETAMINE IN REVERSING DEPRESSION OF MOUSE LOCOMOTOR ACTIVITY CAUSED BY RESERPINE.
210869 03-03

STRUCTURE-ACTIVITY RELATIONSHIPS BETWEEN META-SUBSTITUTED N-ETHYLAMPHETAMINES AND LOCOMOTOR ACTIVITY IN MICE.
210886 03-04

THE EFFECT OF DOPAMINE AND NORADRENALINE ANTAGONISTS ON AMPHETAMINE-INDUCED LOCOMOTOR ACTIVITY IN MICE AND RATS.
210894 03-04

EFFECT OF THYROXINE AND CORTISOL ON BRAIN ORNITHINE DECARBOXYLASE ACTIVITY AND SWIMMING BEHAVIOR IN DEVELOPING RAT.
210933 03-03

DIFFERENTIAL EFFECTS OF THE OPTICAL ISOMERS OF AMPHETAMINE ON NEURONAL ACTIVITY IN THE RETICULAR FORMATION AND CAUDATE NUCLEUS OF THE RAT.
211063 03-03

A PROLONGED AFTEREFFECT OF INTENSE SYNAPTIC ACTIVITY ON ACETYLCHOLINE IN A SYMPATHETIC GANGLION.
211102 03-03

THE EFFECTS OF STRAIN, DRUG, AND DOSE LEVEL ON GENERAL ACTIVITY AND EXPLORATORY BEHAVIOR IN MICE. (PH.D. DISSERTATION).
211883 03-04

EVOKED NEURAL ACTIVITY IN THE BASAL GANGLIA OF THE CAT AND ITS MODIFICATION BY CHOLINERGIC AND DOPAMINERGIC AGENTS. (PH.D. DISSERTATION).
212520 03-03

ANTAGONISM OF DEPRESSANT ACTIVITY OF ETHANOL BY DH-524; A COMPARATIVE STUDY WITH BEMEGRIDE, DOXAPRAM AND D-AMPHETAMINE (38640).
213282 03-03

THE INFLUENCE OF ACTH4-10 ON HIPPOCAMPAL AND THALAMIC SYNCHRONISED ACTIVITY IN RATS.
213430 04-03

THE EFFECTS OF PSYCHOMOTOR STIMULATION ON STEREOTYPY AND LOCOMOTOR ACTIVITY IN SOCIALLY DEPRIVED AND CONTROL RATS.
213433 04-03

PSYCHOPHARMACOLOGIC ACTIVITY: QUANTUM CHEMICAL STUDY.
213608 04-03

COMPARATIVE ANALGESIC ACTIVITY OF VARIOUS NATURALLY OCCURRING CANNABINOIDS IN MICE AND RATS.
214017 04-04

PSYCHOTROPIC DRUGS, OVARIAN FUNCTIONS AND MAMMARY ACTIVITY.
214055 04-03

ISOLATION INDUCED TIMIDITY IN MICE AS A MEASURE OF ANXIOLYTIC ACTIVITY OF DRUGS.
215063 04-04

RAT PINEAL CYCLIC ADENOSINE-3-5-MONOPHOSPHATE PHOSPHODIESTERASE ACTIVITY: IN VIVO MODULATION BY A BETA ADRENERGIC RECEPTOR.
215600 04-03

THE BIPHASIC EFFECT OF SMALL DOSES OF TRANYLCYPROMINE ON THE SPONTANEOUS MOTOR ACTIVITY AND LEARNED CONDITIONED BEHAVIOUR IN RATS.
215665 04-04

COMPARISON OF THE HYPNOTIC ACTIVITY OF TRIAZOLAM, FLURAZEPAM HYDROCHLORIDE, AND PLACEBO.
215673 04-14

INHIBITION OF EFFERENT SYMPATHETIC NERVE ACTIVITY BY 5-HYDROXYTRYPTOPHAN AND CENTRALLY ADMINISTERED 5-HYDROXYTRYPTAMINE.
215712 04-03

THE EFFECTS OF SCOPOLAMINE (0.6 MG) AND PHYSOSTIGMINE (1.0 MG) ON HIGHER NERVOUS ACTIVITY IN MAN, FOLLOWED-UP DURING 5 HOURS AFTER APPLICATION.
217205 04-14

SEROTONIN SENSITIVE ADENYLCYCLASE ACTIVITY IN IMMATURE RAT BRAIN.
217355 04-03

INHIBITION OF D-AMPHETAMINE INDUCED LOCOMOTOR ACTIVITY BY INJECTION OF HALOPERIDOL INTO THE NUCLEUS-ACCUMBENS OF THE RAT.
217461 04-04

A COMPARISON OF CIRCLING MODELS FOR THE DETECTION OF PARKINSON ACTIVITY.
217547 04-04

EVALUATION OF KETAMINE HCL FOR ANTIDEPRESSANT ACTIVITY.
217577 04-02

POTENTIATION OF LOCOMOTOR ACTIVITY AND MODIFICATION OF STEREOTYPY BY STARVATION IN APOMORPHINE TREATED RATS.
217675 04-04

ACETYLCHOLINE ACTIVITY IN AN IDENTIFIED 5-HYDROXYTRYPTAMINE CONTAINING NEURON.
217825 04-03

DIFFERENCES BETWEEN (+)- AND (-) AMPHETAMINE IN EFFECTS ON LOCOMOTOR ACTIVITY AND L-DOPA POTENTIATING ACTION IN MICE.
217835 04-04

EFFECTS OF PUTATIVE NEUROTRANSMITTERS ON NEURONAL ACTIVITY IN MONKEY AUDITORY CORTEX.
217865 04-03

METHYLPHENIDATE AND HALOPERIDOL IN CHILDREN: EFFECTS ON ATTENTION, MEMORY, AND ACTIVITY.
218118 04-14

ANTIDEPRESSANT AGENTS AND REVERSAL OF DIURNAL ACTIVITY CYCLES IN THE RAT.
218954 04-04

EFFECTS OF CHRONIC ADMINISTRATION AND WITHDRAWAL OF D-AMPHETAMINE UPON DAILY ACTIVITY LEVELS OF SQUIRREL MONKEYS.
219032 04-04

HIPPOCAMPAL AND PITUITARY ADRENAL INFLUENCES ON ACTIVITY AND AVOIDANCE BEHAVIOR. (PH.D. DISSERTATION).
219289 04-04

THE ROLE OF THE AMYGDALA IN THE DEPRESSIVE ACTION OF SEROTONIN AND 5-HYDROXYTRYPTOPHAN ON THE CONDITIONED ACTIVITY OF WHITE RATS.
219328 04-04

A HISTOCHEMICAL ANALYSIS OF THE INFLUENCE OF SOME PSYCHOTROPIC SUBSTANCES ON THE DEHYDROGENASE ACTIVITY OF VARIOUS BRAIN STRUCTURES.
219498 04-03

THE INFLUENCE OF CHOLINOMIMETICS ON THE AFTEREFFECTS OF TRACE DISCHARGES AND THE ACTIVITY OF EPILEPTOGENIC FOCI IN THE RABBIT HIPPOCAMPUS.
219499 04-03

THE EFFECT OF NEUROLEPTICS OF THE PHENOTHIAZINE SERIES ON PULSE ACTIVITY AND THE ULTRASTRUCTURE OF RABBIT CORTICAL NEURONS.
219606 04-03

EFFECT OF OUABAIN AND PHENOBARBITAL ON OXIDATIVE METABOLIC ACTIVITY ASSOCIATED WITH SPREADING CORTICAL DEPRESSION IN CATS.
220944 04-03

THE PROPOSAL OF AN UNIFIED MODEL FOR THE INTERPRETATION OF THE ACTIVITY OF DIFFERENT CLASSES OF BETA-ADRENERGIC AGENTS.
220951 04-01

CHLORDIAZEPOXIDE EFFECTS ON REACTIONS TO NOVELTY AND ACTIVITY WITH AND WITHOUT PRIOR DRUG EXPERIENCE.
221047 04-04

INHIBITION OF CELLULAR ATP HYDROLYZING ACTIVITY BY TRICYCLIC ANTIDEPRESSANTS AND PHENOTHIAZINE TRANQUILIZERS.
221053 04-03

ANTAGONISM OF PSYCHOSTIMULANT 2 PHENYLDIMETHYLTETRAHYDROOXAZINE HYDROCHLORIDE (G-130) TO CENTRAL NERVOUS SYSTEM DEPRESSING DRUGS:

MONOAMINEOXIDASE INHIBITORY ACTIVITY AND NOREPINEPHRINE AND SEROTONIN INDUCED CHANGES, COMPARISON WITH DL-AMPHETAMINE.
221267 04-03

AN ANIMAL TEST MODEL FOR EVALUATING DRUGS WITH ANTIMASS PSYCHOTIC ACTIVITY.
221273 04-06

A STATISTICAL ANALYSIS OF THE COMPARATIVE DOUBLE-BLIND STUDY OF THE ACTIVITY OF LOXAPINE AND THIORIDAZINE.
221671 04-11

ANTIACCELERATOR AND DECELERATOR ACTIVITY OF ELEVEN PHENOTHIAZINE DERIVATIVES.
221740 04-03

BETA-PHENYLETHYLAMINE AND LOCOMOTOR ACTIVITY IN MICE: INTERACTION WITH CATECHOLAMINERGIC NEURONES AND RECEPTORS.
221742 04-03

CLINICAL STUDY OF FIVE DEPOT NEUROLEPTICS, COMPARISON OF ACTIVITY PROFILES OF FLUPHENAZINE DECANOATE, FLUSPIRILENE, PENFLURIDOL, PERPHENAZINE ENANTHATE AND PIPOTHIAZINE PALMITATE.
221822 04-08

IS THERE A CATECHOLAMINE SEROTONIN INTERACTION IN THE CONTROL OF LOCOMOTOR ACTIVITY?
222816 04-04

COMPARATIVE EFFECTS OF SYDNOCARB AND AMPHETAMINE ON THE BIOELECTRICAL ACTIVITY OF THE BRAIN.
223012 04-03

THE EFFECT OF TRANQUILIZERS (DIAZEPAM AND CHLORDIAZEPOXIDE) ON THE BLOOD SUPPLY AND CARDIAC ACTIVITY.
223018 04-03

REGIONAL DISTRIBUTION OF MONOAMINEOXIDASE ACTIVITY FOR 5-HYDROXYTRYPTAMINE AND TYRAMINE IN THE HYPOTHALAMUS OF THE RAT.
223049 04-03

ASCENDING CATECHOLAMINE PATHWAYS AND AMPHETAMINE-INDUCED LOCOMOTOR ACTIVITY: IMPORTANCE OF DOPAMINE AND APPARENT NONINVOLVEMENT OF NOREPINEPHRINE.
223054 04-03

THE EFFECT OF INTRAVENTRICULAR ADMINISTRATION OF SEROTONIN ON SPONTANEOUS MOTOR ACTIVITY OF RATS. (UNPUBLISHED PAPER).
225287 04-04

ELEVATION OF PLASMA DOPAMINE-BETA-HYDROXYLASE ACTIVITY DURING MECHOLYL TEST.
225523 04-13

ACUTE

EFFECT OF ACUTE AND CHRONIC DIELDRIN EXPOSURE ON BRAIN BIOGENIC AMINES OF MALE AND FEMALE RATS.
193428 01-03

ACUTE, SUBACUTE AND 23-DAY CHRONIC MARIHUANA INHALATION TOXICITIES IN THE RAT.
193576 01-04

THE ACUTE EFFECTS OF INTRAVENOUS INFUSION OF L-TRYPTOPHAN IN NORMAL SUBJECTS.
195443 01-15

CLINICAL MEASUREMENT OF CENTRAL DOPAMINE AND SEROTONIN METABOLISM IN ACUTE PSYCHOTIC DISORDERS.
195924 01-09

ANTAGONISM OF ACUTE AMPHETAMINE INTOXICATION BY HALOPERIDOL AND PROPRANOLOL.
196106 01-05

THE EFFECT OF DAILY ORAL DOSAGE OF DIAZEPAM, PLASMA CONCENTRATIONS AND METABOLIC CLEARANCE OF DIAZEPAM AND DEMETHYLDIAZEPAM ON VARIOUS CONSTITUENTS OF THE ACUTE CLINICAL ANXIETY SYNDROME.
196191 01-10

ACUTE INTOXICATIONS WITH NEUROLEPTICS.
196923 01-15

ACUTE TOLERANCE, AND DEPENDENCE IN GUINEA-PIG ILEUM.
197304 01-03

THE INFLUENCE OF SKF-525A ON THE ACUTE PHARMACOLOGICAL PROPERTIES OF CHLORDIAZEPOXIDE.
197478 01-03

EFFECT OF ACUTE ADMINISTRATION OF L-DOPA ON BODY TEMPERATURE IN MAN.
197831 01-13

INVESTIGATIONS OF THE EFFECTS OF DIAZEPAM IN ACUTE EXPERIMENTAL INTOXICATION WITH FLUOSTIGMINE.
197832 01-03

TURNOVER OF BIOGENIC AMINES AFTER ACUTE AND CHRONIC MORPHINE TREATMENT IN RATS.
197974 01-03

CHLORPROMAZINE METABOLISM IN ACUTE SCHIZOPHRENIA.
198094 02-08

REGIONAL DIFFERENCES IN HOMOVANILLIC ACID CONCENTRATIONS AFTER ACUTE AND CHRONIC ADMINISTRATION OF ANTIPSYCHOTIC DRUGS.
198210 02-03

THE THERAPEUTIC EFFECT OF SHORT-TERM ORAL DIAZEPAM TREATMENT ON ACUTE CLINICAL ANXIETY IN A CRISIS CENTRE.
199991 02-10

ACUTE AND CHRONIC EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON FOOD INTAKE BY RATS.
200043 02-04

THE ROLE OF SEROTONIN IN THE PATHOPHYSIOLOGY OF MYOCLONIC SEIZURES ASSOCIATED WITH ACUTE IMIPRAMINE TOXICITY.
200088 02-03

NALOXONE PRECIPITATED JUMPING ACTIVITY IN MICE FOLLOWING THE ACUTE ADMINISTRATION OF MORPHINE.
202201 02-04

A DOUBLE-BLIND EVALUATION OF DIAZEPAM AND AMYLOBARBITONE IN ACUTE MYOCARDIAL INFARCTION.
202966 02-13

STUDIES ON ANTIDIURETIC ACTIVITIES AND ON PORTER-SILBERS CHROMOGENS CONTENT IN PLASMA OF PATIENTS WITH ALCOHOLIC DELIRIUM OR WITH ACUTE PHENOTHIAZINE INTOXICATIONS.
203741 02-15

ACUTE TOXIC PSYCHOSIS IN TWO CHILDREN TREATED WITH BENZHEXOL HYDROCHLORIDE (ARTANE).
205315 02-15

CARDIOTOXIC EFFECTS OF TRICYCLIC ANTIDEPRESSANTS IMIPRAMINE, AMITRIPTYLINE AND DOSULEPIN (PROTHIADEN-SPOFA) IN AN ACUTE EXPERIMENT IN RATS.
205597 02-15

ATTENUATION OF ACUTE HABITUATION BY SCOPOLAMINE IN THE BLACK-TAILED PRAIRIE DOG (CYNOMYS-LUDOVICIANUS).
206745 03-04

SEROTONIN AND DOPAMINE TURNOVER AFTER ACUTE AND CHRONIC MORPHINE ADMINISTRATION.
206989 03-03

PSYCHOPATHOGENIC ASPECTS IN ACUTE PSYCHOORGANIC SYNDROMES (RELATIONSHIPS BETWEEN DRUG DEPENDENCE AND DELIRIUM-TREMENS TYPE SYNDROMES).
209063 03-15

EFFECTIVENESS OF LOXAPINE SUCCINATE IN ACUTE SCHIZOPHRENIA: A COMPARATIVE STUDY WITH THIOTHIXENE.
209484 03-08

RELATIONSHIP BETWEEN THE LATE REFLEX DISCHARGE AND LOCOMOTOR MOVEMENTS IN ACUTE SPINAL CATS AND RABBITS WITH DOPA.
209728 03-03

TREATMENT OF ACUTE SCHIZOPHRENIA WITH A NEW BUTYROPHENONE - - LENPERONE.
209791 03-07

ACUTE VOLUNTARY POISONING BY DOXEPIN.
210141 03-15

EFFECTS OF DOPAMINERGIC DRUGS AND ACUTE MEDIAL FOREBRAIN BUNDLE LESIONS ON STRIATAL ACETYLCHOLINE LEVELS.
210831 03-03

THE EFFECTS OF ACUTE AND CHRONIC MORPHINE ADMINISTRATION ON THE LEVELS OF 3-METHOXY-4-HYDROXYPHENYLGLYCOL SULFATE IN RAT BRAIN.
210927 03-03

PHYSOSTIGMINE: ITS USE IN ACUTE ANTICHOLINERGIC SYNDROME WITH ANTIDEPRESSANT AND ANTIPARKINSON DRUGS.
211416 03-15

ACUTE ORGANIC BRAIN SYNDROME: A COMPLICATION OF DISULFIRAM THERAPY.
213710 04-15

ACUTE HYPOMANIA.
213784 04-09

BIOCHEMICAL VERSUS PSYCHOPATHOLOGICAL ACTION PROFILE OF NEUROLEPTICS: A COMPARATIVE STUDY OF CHLORPROMAZINE AND OXYPERTINE IN ACUTE PSYCHOTIC DISORDERS.
215454 04-13

TREATMENT OF ACUTE SCHIZOPHRENIA WITH ULTRA-HIGH-DOSE FLUPHENAZINE: A FAILURE AT SHORTENING TIME ON A CRISIS INTERVENTION UNIT.
215456 04-08

A CLINICAL STUDY OF A NEW NEUROLEPTIC EXTRAPYRAMIDAL SYNDROME CORRECTOR WITH ACUTE PSYCHOTIC STATES.
216766 04-15

COMPARATIVE STUDY OF CLOTHIAPINE AND TRIFLUOPERAZINE IN EPISODES OF ACUTE PARANOID SCHIZOPHRENIA.
217025 04-08

PHENOTHIAZINE EFFECTS ON CEREBRAL EVOKED POTENTIALS AND EYE MOVEMENTS IN ACUTE SCHIZOPHRENICS.
217454 04-08

ACUTE AND CHRONIC EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON SEIZURES IN THE GERBIL.
217673 04-03

SOME NEUROCHEMICAL EFFECTS OF N,N DIMETHYLTRYPTAMINE AND THEIR POSSIBLE RELATION TO ACUTE SCHIZOPHRENIA. (PH.D. DISSERTATION).
219179 04-03

THE ACTION OF PIMOZIDE ON ACUTE PSYCHOSIS.
219960 04-09

A BENZODIOXANHYDROXYETHYLPIPERIDINE DERIVATIVE WITH ACUTE CENTRAL HYPOTENSIVE ACTION, DIFFERENT FROM THAT OF CLONIDINE: A COMPARISON WITH NEUROLEPTIC AGENTS.
220976 04-03

THREE ACUTE CASES OF DIPHENYLHYDANTOIN INTOXICATION.
221515 04-15

PSYCHOSOCIAL TREATMENT OF ACUTE SCHIZOPHRENIA.
224790 04-17

ABSENT VESTIBULO-OCULAR REFLEXES AND ACUTE SUPRATENTORIAL LESIONS.
225323 04-13

ACUTE TOXICITY OF ANTIEPILEPTIC DRUGS.
225539 04-15

ACYLATION

RAPID ANALYSIS OF THE CENTRAL NERVOUS SYSTEM STIMULANTS, AMPHETAMINES, VIA GAS CHROMATOGRAPHY MASS SPECTROMETRY: RAPID ACYLATION IN THE PRESENCE OF A MERCURY CATALYST.
222830 04-06

ADAPTED

THE EFFECT OF DIAZEPAM ON THE BEHAVIOR OF RATS ADAPTED TO HIGH ALTITUDE HYPOXIA IN CONFLICTING SITUATIONS.
219502 04-04

ADAPTIVE

THEORETICAL IMPLICATIONS OF DRUG-INDUCED ADAPTIVE REGULATION FOR A BIOGENIC AMINE HYPOTHESIS OF AFFECTIVE DISORDER.
206335 03-03

THE ROLE OF ADAPTIVE REGULATION IN THE PATHOPHYSIOLOGY OF PSYCHIATRIC DISEASE.
207307 03-03

ADDICT

LITHIUM TREATMENT REDUCES MORPHINE SELF-ADMINISTRATION IN ADDICT RATS.
201293 02-04

CASE PRESENTATION OF AN ALTERNATIVE THERAPEUTIC APPROACH FOR THE BORDERLINE PSYCHOTIC HEROIN ADDICT: DIPHENYLHYDANTOIN.
225512 04-09

ADDICTED

CONDITIONED LEARNING IN YOUNG RATS BORN OF DRUG ADDICTED PARENTS AND RAISED ON ADDICTIVE DRUGS.
217465 04-04

ADDICTION

VOLATILE SOLVENT ADDICTION AND TRAFFIC SAFETY.
205596 02-15

ADDICTION AND PSYCHOTROPIC DRUGS.
210069 03-17

SULPIRIDE AND DRUG ADDICTION.
216764 04-11

ANXIETY NEUROSIS, DEPRESSIVE DISORDER AND MEPROBAMATE ADDICTION -- PSYCHIATRIC GRAND-ROUNDS, UNIV. OF CALIFORNIA, SAN-DIEGO.
222772 04-10

ADDICTIVE

PROGRAMMED SELF-ADMINISTRATION OF POTENTIALLY ADDICTIVE DRUGS IN YOUNG RATS AND ITS EFFECTS ON LEARNING.
195430 01-04

CONDITIONED LEARNING IN YOUNG RATS BORN OF DRUG ADDICTED PARENTS AND RAISED ON ADDICTIVE DRUGS.
217465 04-04

ADDICTS

DEPRESSION AND ANXIETY IN HEROIN ADDICTS: A PLACEBO CONTROLLED STUDY OF DOXEPIN IN COMBINATION WITH METHADONE.
225386 04-09

ADDISONS

AVERAGE EVOKED RESPONSES (AER) AND HOMOVANILLIC ACID (HVA) IN CEREBROSPINAL FLUID (CSF) IN A PSYCHOTIC PATIENT WITH ADDISONS DISEASE.
221310 04-09

ADENINE

A POTENT DEPRESSANT ACTION OF ADENINE DERIVATIVES ON CEREBRAL CORTICAL NEURONES.
210932 03-03

ADENOSINE

ADENOSINE 3,5 MONOPHOSPHATE IN CULTURED NEUROBLASTOMA CELLS: EFFECT OF ADENOSINE, PHOSPHODIESTERASE INHIBITORS AND BENZAZEPINES.
195254 01-03

PROTECTIVE EFFECT OF ADENOSINE AND NICOTINAMIDE AGAINST AUDIOGENIC SEIZURE.
198135 02-03

ADENOSINE-MONOPHOSPHATE

ANXIETY AND ACTIVITIES OF CYCLIC ADENOSINE-MONOPHOSPHATE PHOSPHODIESTERASE.
202161 02-17

INDUCTION OF TYROSINE-HYDROXYLASE ELICITED BY BETA ADRENERGIC RECEPTOR AGONISTS IN NORMAL AND DECENTRALIZED SYMPATHETIC GANGLIA: ROLE OF CYCLIC 3,5 ADENOSINE-MONOPHOSPHATE.
215688 04-03

THE EFFECT OF ETHYMIZOL ON THE CONTENT OF CYCLIC 3,5 ADENOSINE-MONOPHOSPHATE IN BRAIN TISSUE.
217065 04-03

ADENOSINE-TRIPHOSPHATASE

MG++ DEPENDENT ADENOSINE-TRIPHOSPHATASE ACTIVITY IN ERYTHROCYTE GHOSTS OF SCHIZOPHRENIC PATIENTS.
206332 03-08

REVERSIBLE INHIBITION OF MAMMALIAN BRAIN ACETYLCHOLINESTERASE AND SODIUM POTASSIUM STIMULATED ADENOSINE-TRIPHOSPHATASE BY CYCLOPROPANE.
210903 03-03

ADENOSINE-3-5-MONOPHOSPHATE

ADENOSINE-3-5-MONOPHOSPHATE IN CEREBRAL CORTICAL SLICES FROM GUINEA-PIG AND RAT: EFFECT OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC COMPOUNDS.
197293 01-03

ADENOSINE-3-5-MONOPHOSPHATE IN CEREBRAL CORTICAL SLICES FROM GUINEA-PIG AND RAT: EFFECT OF BENZODIAZEPINES.
197972 01-03

ADENOSINE-3-5-MONOPHOSPHATE CONTENT IN RAT CAUDATE NUCLEUS: DEMONSTRATION OF DOPAMINERGIC AND ADRENERGIC RECEPTORS.
208300 03-03

RAT PINEAL CYCLIC ADENOSINE-3-5-MONOPHOSPHATE PHOSPHODIESTERASE ACTIVITY: IN VIVO MODULATION BY A BETA ADRENERGIC RECEPTOR.
215600 04-03

POSSIBLE ROLE OF ADENOSINE-3-5-MONOPHOSPHATE AND BIOGENIC AMINES IN MORPHINE AND COCAINE TREATED RATS. (PH.D. DISSERTATION).
220475 04-03

ADENOSINE-5-TRIPHOSPHATE

ACCUMULATION OF ACETYLCHOLINE AND AROMATIC MONOAMINES BY INTERACTION WITH ADENOSINE-5-TRIPHOSPHATE.
210753 03-03

ADENYLATE-CYCLASE

CHANGES IN ACTIVATION OF ADENYLATE-CYCLASE AND OF DOPAMINE TURNOVER IN RAT STRIATUM DURING PROLONGED HALOPERIDOL TREATMENT.
192933 01-03

SELECTIVE STIMULATION BY DOPAMINE OF ADENYLATE-CYCLASE IN HOMOGENATES OF RABBIT RETINA.
192936 01-03

INHIBITION OF THE CATALYTIC SITE OF ADENYLATE-CYCLASE IN THE CENTRAL NERVOUS SYSTEM BY PHENOTHIAZINE DERIVATIVES.
195096 01-03

MODIFICATION OF THE RECEPTOR COMPONENT OF ADENYLATE-CYCLASE IN THE RAT BRAIN BY PHENOTHIAZINE DERIVATIVES.
199771 02-03

AMANTADINE AND D-145, AN AMANTADINE DERIVATIVE, DO NOT EFFECT DOPAMINE SENSITIVE ADENYLATE-CYCLASE FROM THE CAUDATE PUTAMEN OF THE RAT BRAIN.
199867 02-03

BLOCKADE BY PIMOZIDE OF A NORADRENALINE SENSITIVE ADENYLATE-CYCLASE IN THE LIMBIC FOREBRAIN: POSSIBLE ROLE OF LIMBIC NORADRENERGIC MECHANISMS IN THE MODE OF ACTION OF ANTIPSYCHOTICS.
210771 03-03

TRICYCLIC ANTIDEPRESSIVE DRUGS AND DOPAMINE SENSITIVE ADENYLATE-CYCLASE FROM RAT BRAIN STRIATUM.
210856 03-03

ADENYLCYCLASE

EFFECT OF MONOVALENT CATIONS ON HUMAN PLATELET ADENYLCYCLASE ACTIVITY.
195930 01-13

DEPRESSIVE ILLNESS: ADRENERGIC RESPONSIVENESS AND THE EFFECT OF LITHIUM ON PLATELET ADENYLCYCLASE. (PH.D. DISSERTATION).
196260 01-13

ADENYLCYCLASE IN RAT STRIATUM AND NUCLEUS-ACCUMBENS: STIMULATION BY DOPAMINE RECEPTOR AGONISTS. (UNPUBLISHED PAPER).
197124 01-03

TRICYCLIC ANTIDEPRESSANT DRUGS AND DOPAMINE SENSITIVE ADENYLCYCLASE FROM RAT CAUDATE NUCLEI.
206990 03-03

THE INFLUENCE OF ETHYMISOL ON THE ACTIVITY OF ADENYLCYCLASE AND 3,5 AMP-PHOSPHODIESTERASE OF RATS BRAINS.
208973 03-03

SEROTONIN SENSITIVE ADENYLCYCLASE ACTIVITY IN IMMATURE RAT BRAIN.
217355 04-03

DOPAMINE SENSITIVE ADENYLCYCLASE IN HUMAN CAUDATE NUCLEUS: A STUDY IN CONTROL SUBJECTS AND SCHIZOPHRENIC PATIENTS.
221732 04-13

INTERACTIONS BETWEEN LYSERGIC ACID DIETHYLAMIDE AND DOPAMINE SENSITIVE ADENYLCYCLASE SYSTEMS IN RAT BRAIN.
223175 04-03

PINEAL BETA-ADRENERGIC RECEPTOR: CORRELATION OF BINDING OF H3-1-ALPRENOLOL WITH STIMULATION OF ADENYLCYCLASE. (UNPUBLISHED PAPER).
224096 04-03

ADJUNCTIVE
THE EFFECTS OF CHLORDIAZEPOXIDE ON THE DEVELOPMENT OF ADJUNCTIVE DRINKING IN RATS.
225149 04-04

ADJUNCTS
METHODS OF DECONDITIONING PERSISTING AVOIDANCE: AMPHETAMINE, CHLORPROMAZINE, AND CHLORDIAZEPOXIDE AS ADJUNCTS TO RESPONSE PREVENTION.
202987 02-04
METHODS OF DECONDITIONING PERSISTING AVOIDANCE: AMPHETAMINE AND AMOBARBITAL AS ADJUNCTS TO RESPONSE PREVENTION.
209897 03-04

ADJUSTMENT
DRUG AND SOCIOTHERAPY IN THE AFTERCARE OF SCHIZOPHRENIC PATIENTS: III. ADJUSTMENT OF NONRELAPSED PATIENTS.
199626 02-08

ADMINISTERED
THE SUBCELLULAR DISTRIBUTION OF INTRAVENTRICULARLY ADMINISTERED 3H-METARAMINOL IN INTACT AND RAT BRAIN PRETREATED WITH P-CHLOROAMPHETAMINE.
197289 01-03
REDUCED BEHAVIOURAL EFFECTS OF INTRAHIPPOCAMPALLY ADMINISTERED CARBACHOL IN RATS WITH LOW CHOLINESTERASE ACTIVITY.
199956 02-04
THE INFLUENCE OF CATECHOLAMINES, SEROTONIN, AND SOME AMINO ACIDS ADMINISTERED INTO THE AMYGDALOID COMPLEX ON CONDITIONED REFLEXES OF AVOIDANCE AND MOTOR ACTIVITY IN RATS.
200566 02-03
A COMPARISON OF THE LOCOMOTOR EFFECTS OF 5-HYDROXYTRYPTAMINE AND 5-HYDROXYTRYPTOPHAN ADMINISTERED VIA TWO SYSTEMIC ROUTES.
206086 03-04
EFFECT OF PERIPHERALLY ADMINISTERED SEROTONIN ON THE NEURONAL ACTIVITY OF MIDBRAIN RAPHE NEURONS.
210710 03-03
THE EFFECT OF DRUGS WITH ANTIDEPRESSANT ACTIVITY UPON THE HYPOTHERMIA AND BEHAVIOURAL DEPRESSION INDUCED IN MICE BY PIMOZIDE OR CENTRALLY ADMINISTERED NORADRENALINE.
210762 03-04
DECREASED TEMPORAL VARIABILITY IN HIPPOCAMPAL THETA RHYTHMS OF CATS ADMINISTERED METHYLPHENIDATE.
213855 04-03
THE EFFECT OF ACTH AND DIAZEPAM, ADMINISTERED TO INFANT RATS ON THE BODY GROWTH CURVE AND SOME ENDOCRINE PARAMETERS MEASURED IN ADULT AGE.
215066 04-03
LONG-TERM BEHAVIOURAL EFFECTS OF DIAZEPAM AND ACTH, ADMINISTERED EARLY IN LIFE.
215067 04-04
INHIBITION OF EFFERENT SYMPATHETIC NERVE ACTIVITY BY 5-HYDROXYTRYPTOPHAN AND CENTRALLY ADMINISTERED 5-HYDROXYTRYPTAMINE.
215712 04-03
SERUM ERYTHROCYTE AND CNS LEVELS IN RHESUS MONKEYS OF ORALLY AND INTRAVENOUSLY ADMINISTERED RUBIDIUM SALTS.
218956 04-02
SYNERGISM BETWEEN GAMMA-AMINOBUTYRIC ACID AND BUTYROPHENONES ADMINISTERED MICROELECTROPHORETICALLY IN THE PURKINJE CELLS OF THE CAT CEREBELLUM.
220904 04-03

ADMINISTRATION
PSYCHOACTIVE DRUG USE IN ELDERLY PATIENTS WITH PSYCHIATRIC DISORDERS: A SURVEY OF 12 VETERANS ADMINISTRATION HOSPITALS.
193291 01-11
ACETYLCHOLINE LEVELS IN THE FROG SPINAL CORD FOLLOWING THE ADMINISTRATION OF DIFFERENT CONVULSANTS.
193550 01-03
EFFECT OF CHRONIC ADMINISTRATION OF CENTRALLY ACTING COMPOUNDS ON CHLORAMPHENICOL METABOLISM IN SCHIZOPHRENIC PATIENTS.
194157 01-08
AN EVALUATION OF A DRUG ADMINISTRATION SYSTEM IN A PSYCHIATRIC HOSPITAL.
194409 01-17
ADMINISTRATION OF PG-501 FOR THE TREATMENT OF EXTRAPYRAMIDAL SYNDROME CAUSED BY THE ADMINISTRATION OF A PSYCHOTROPIC DRUG.
194475 01-11
TREATMENT OF SCHIZOPHRENIA BY THE ADMINISTRATION OF A SMALL DOSE OF FORIT FOR COMPARATIVELY LONG PERIODS OF TIME.
194476 01-08
BRAIN DOPA/5-HTP DECARBOXYLASE ACTIVITY AFTER THE CHRONIC ADMINISTRATION OF L-DOPA OR 5-HYDROXY-L-TRYPTOPHAN IN NORMAL AND LESIONED CATS.
194483 01-05
COMMENTS ON TREATMENT: EYE CHANGES FOLLOWING PHENOTHIAZINE ADMINISTRATION.
194749 01-15
LONG-TERM LITHIUM ADMINISTRATION TO RATS. LITHIUM AND SODIUM DOSAGE AND ADMINISTRATION, AVOIDANCE OF INTOXICATION, POLYURIC CONTROL RATS.
195042 01-03
EFFECT OF ORAL AND INTRAMUSCULAR ROUTES OF ADMINISTRATION ON SERUM CHLORDIAZEPOXIDE LEVELS AND THE PREDICTION OF THESE LEVELS FROM PREDRUG FASTING SERUM GLUCOSE CONCENTRATIONS.
195055 01-13
REDUCTION OF STIMULUS BOUND FOOD CONSUMPTION IN THE RAT FOLLOWING AMPHETAMINE ADMINISTRATION.
195081 01-04
INTRACELLULAR DISTRIBUTION OF 3H-DELTA8-TETRAHYDROCANNABINOL IN RAT ORGANS AFTER I.V. ADMINISTRATION.
195112 01-03
EFFECTS OF WITHDRAWAL FROM CHRONIC AMPHETAMINE ADMINISTRATION ON ACTIVITY LEVELS OF ALBINO RATS.
195223 01-04
DIAZEPAM METABOLISM IN NORMAL MAN: I. SERUM CONCENTRATIONS AND CLINICAL EFFECTS AFTER INTRAVENOUS, INTRAMUSCULAR, AND ORAL ADMINISTRATION.
195444 01-15
DIAZEPAM METABOLISM IN NORMAL MAN: II. SERUM CONCENTRATION AND CLINICAL EFFECT AFTER ORAL ADMINISTRATION AND CUMULATION.
195445 01-13
THE EFFECTS OF DRUG ADMINISTRATION TO THE LATERAL HYPOTHALAMUS: NEUROCHEMICAL CODING OR NONSPECIFICITY?.
195992 01-03
PLASMA LITHIUM LEVELS AND SIDE-EFFECTS DURING ADMINISTRATION OF A SLOW-RELEASE LITHIUM SULPHATE PREPARATION (LITHIUM LIPETT-C) AND LITHIUM CARBONATE LEVELS.
197029 01-15
THE EFFECTS OF PARENTERAL ADMINISTRATION OF CATECHOLAMINES, SEROTONIN AND HISTAMINE ON BEHAVIOR AND LEVELS OF THESE AMINES IN THE BRAIN OF THE NEONATE CHICK.
197457 01-03
CHANGES IN ACID-BASE BALANCE, RESPIRATION RATE AND HEART RATE UPON REPEATED ORAL ADMINISTRATION OF BENZOCTAMINE AND DIAZEPAM TO CONSCIOUS DOGS.
197460 01-03
ALTERATIONS IN ACID-BASE BALANCE IN THE DOG AFTER INTRAVENOUS ADMINISTRATION OF BENZOCTAMINE AND DIAZEPAM, COMPARED WITH THOSE INDUCED BY THIOPENTAL.
197485 01-03
THE EFFECT OF 6-HYDROXYDOPAMINE ADMINISTRATION TO NEONATAL RATS ON SOME ENDOCRINE AND BEHAVIORAL PARAMETERS.
197498 01-03
MORPHOLOGICAL, BIOCHEMICAL, AND FUNCTIONAL CHANGES IN CHICK EMBRYONIC BRAIN TISSUE AFTER INTRACEREBRAL ADMINISTRATION OF OUABAIN.
197788 01-03
EFFECT OF ACUTE ADMINISTRATION OF L-DOPA ON BODY TEMPERATURE IN MAN.
197831 01-13
EVIDENCE THAT PUNCTUATE INTRACEREBRAL ADMINISTRATION OF 6-HYDROXYDOPAMINE FAILS TO PRODUCE SELECTIVE NEURONAL DEGENERATION: COMPARISON WITH COPPER SULFATE AND FACTORS GOVERNING THE DEPORTMENT OF FLUIDS INJECTED INTO BRAIN.
197931 01-03
THE EFFECT OF NH4CL ON POLYURIA AND POLYDIPSIA DURING PROLONGED LITHIUM ADMINISTRATION IN THE RAT.
198027 01-03
EFFECTS OF DIETHYLPROPION AND D-AMPHETAMINE AFTER SUBCUTANEOUS AND ORAL ADMINISTRATION.
198030 01-14
REGIONAL DIFFERENCES IN HOMOVANILLIC ACID CONCENTRATIONS AFTER ACUTE AND CHRONIC ADMINISTRATION OF ANTIPSYCHOTIC DRUGS.
198210 02-03
RESISTANCE TO EXTINCTION OF AN AVOIDANCE RESPONSE IN RATS FOLLOWING THE ADMINISTRATION OF CHLORDIAZEPOXIDE (LIBRIUM) AND DIAZEPAM (VALIUM).
198226 02-04
BLOOD AND URINE LEVELS OF N,N DIMETHYLTRYPTAMINE FOLLOWING ADMINISTRATION OF PSYCHOACTIVE DOSAGES TO HUMAN SUBJECTS.
198230 02-12
CHRONIC LYSERGIC ACID DIETHYLAMIDE ADMINISTRATION AND SEROTONIN TURNOVER IN VARIOUS REGIONS OF RAT BRAIN.
199783 02-03

ANALYSIS OF ACETYLCHOLINESTERASE SYNTHESIS AND TRANSPORT IN THE RAT HIPPOCAMPUS: RECOVERY OF ACETYLCHOLINESTERASE ACTIVITY IN THE SEPTUM AND HIPPOCAMPUS AFTER ADMINISTRATION OF DIISOPROPYLFLUOROPHOSPHATE.
199805 02-03

BIOCHEMICAL CORRELATES IN MOUSE-KILLING BEHAVIOR OF THE RAT BRAIN: BRAIN ACETYLCHOLINE AND ACETYLCHOLINESTERASE AFTER ADMINISTRATION OF DELTA9-TETRAHYDROCANNABINOL.
199807 02-03

INHIBITION OF SYMPATHETIC ACTIVITY FOLLOWING CHRONIC ADMINISTRATION OF 2-AMINO-4-(3,4 DICHLOROPHENYL) 2-IMIDAZOLINE (MJ-10459-2).
199863 02-03

THE NEURON ULTRASTRUCTURE IN SOME BRAIN AREAS DURING A LONG-TERM ADMINISTRATION OF AMINAZINE AND STELAZINE.
200021 02-03

THE IN VIVO RELEASE OF ENDOGENOUSLY SYNTHESIZED CATECHOLAMINES FROM THE CAT BRAIN BY LATERAL HYPOTHALAMIC STIMULATION AND BY D-AMPHETAMINE ADMINISTRATION. (PH.D. DISSERTATION).
200313 02-03

AGGRESSIVE BEHAVIORS INDUCED BY CHRONIC ADMINISTRATION OF THEOPHYLLINE, WITH PARTICULAR REFERENCE TO ALTERATIONS IN BEHAVIORS OF IMMATURE RATS.
200748 02-04

STIMULUS PROPERTIES OF MESCALINE AND N-METHYLATED DERIVATIVES: DIFFERENCE IN PERIPHERAL AND DIRECT CENTRAL ADMINISTRATION.
201320 02-02

NALOXONE PRECIPITATED JUMPING ACTIVITY IN MICE FOLLOWING THE ACUTE ADMINISTRATION OF MORPHINE.
202201 02-04

EFFECT OF EARLY L-DOPA ADMINISTRATION ON THE ONTOGENY OF MOTOR FUNCTIONS IN THE RAT.
202266 02-03

DEVELOPMENTAL DISTURBANCE OF THE BRAIN IN RAT OFFSPRING FOLLOWING MATERNAL ADMINISTRATION OF 5-FLUOURACIL DURING PREGNANCY.
202422 02-03

FORMATION OF P-HYDROXYNOREPHEDRINE IN BRAIN FOLLOWING INTRAVENTRICULAR ADMINISTRATION OF P-HYDROXYAMPHETAMINE.
202782 02-03

CHANGES IN THE PSYCHODYNAMICS OF MANIC-DEPRESSIVES THROUGH LONG-TERM ADMINISTRATION OF LITHIUM SALTS.
203601 02-14

EFFECT OF PHENOBARBITAL ADMINISTRATION ON ETHANOL OXIDIZING ENZYMES AND ON RATES OF ETHANOL DEGRADATION.
204386 02-03

EFFECTS OF SINGLE AND REPEATED ADMINISTRATION OF MAPROTILINE AND ITS RELATION TO PLASMA LEVELS IN HEALTHY TEST SUBJECTS.
204403 02-15

THE ALTERATION OF AVERSIVE THRESHOLDS AFTER CHRONIC ADMINISTRATION OF TWO TRANQUILIZING AGENTS.
205418 02-04

PHARMACOLOGICAL PROPERTIES OF A POTENTIAL TRANQUILISING AGENT MESYLPHENACYRAZINE: II. CHANGES RELATED TO ITS REPEATED ADMINISTRATION.
205579 02-03

NEUROPHARMACOLOGICAL FINDINGS AFTER CHRONIC ADMINISTRATION OF HALOPERIDOL, LOXAPINE AND CLOZAPINE.
206972 03-03

METABOLISM OF DOPAMINE AND NOREPINEPHRINE IN RAT BRAIN AFTER SINGLE AND REPEATED ADMINISTRATION OF HALOPERIDOL, LOXAPINE AND CLOZAPINE.
206973 03-03

SEROTONIN AND DOPAMINE TURNOVER AFTER ACUTE AND CHRONIC MORPHINE ADMINISTRATION.
206989 03-03

A CROSSOVER STUDY OF ALLOPURINOL ADMINISTRATION TO A SCHIZOPHRENIC CHILD.
207788 03-08

VARIATIONS IN THE AUTONOMIC NERVOUS SYSTEM AFTER ADMINISTRATION OF DIHYDROERGOTAMINE IN PSYCHOSOMATIC PATIENTS.
209045 03-11

ENDOCRINE EFFECTS OF CHRONIC ADMINISTRATION OF PSYCHOACTIVE DRUGS TO PREPUBERAL MALE RATS. I: DELTA9-TETRAHYDROCANNABINOL.
209840 03-03

MEMORY ENHANCEMENT BY CENTRAL ADMINISTRATION OF NOREPINEPHRINE.
210671 03-04

EFFECT OF DELTA9-TETRAHYDROCANNABINOL ADMINISTRATION ON THE LIPID CONSTITUENTS OF RAT BRAIN SUBCELLULAR FRACTIONS.
210769 03-03

METABOLIC COMPARTMENTATION IN THE BRAIN: METABOLISM OF A TRICARBOXYLIC ACID CYCLE INTERMEDIATE, (1,4-14C)SUCCINATE, AFTER INTRACEREBRAL ADMINISTRATION.
210780 03-03

ACCUMULATION OF LITHIUM IN THE PARTICULATE FRACTION OF RAT BRAIN FOLLOWING ITS LONG-TERM ADMINISTRATION.
210782 03-03

BLOOD-BRAIN BARRIER: I. KINETICS OF DISTRIBUTION OF 3H-AMPHETAMINE IN THE RAT BRAIN AFTER INTRAVENOUS ADMINISTRATION.
210788 03-03

EFFECTS OF WATER DEPRIVATION IN RATS WITH POLYDIPSIA AND POLYURIA DUE TO LONG-TERM ADMINISTRATION OF LITHIUM.
210833 03-05

THE EFFECTS OF ACUTE AND CHRONIC MORPHINE ADMINISTRATION ON THE LEVELS OF 3-METHOXY-4-HYDROXYPHENYLGLYCOL SULFATE IN RAT BRAIN.
210927 03-03

PHARMACOKINETICS OF CARBAMAZEPINE IN MONKEYS FOLLOWING INTRAVENOUS AND ORAL ADMINISTRATION.
211009 03-03

THE EFFECTS OF INTRAVENOUS AND SUBCUTANEOUS EPINEPHRINE ADMINISTRATION ON CONDITIONED SUPPRESSION. (PH.D. DISSERTATION).
213131 03-04

THE USE OF PSYCHOACTIVE DRUGS IN ELDERLY PATIENTS WITH PSYCHIATRIC DISORDERS: SURVEY CONDUCTED IN TWELVE VETERANS ADMINISTRATION HOSPITALS.
215009 04-11

PERMANENT EFFECTS OF REPEATED ADMINISTRATION OF ACTH AND DIAZEPAM IN EARLY POSTNATAL PERIOD UPON THE DYNAMICS OF EXCITATION AND INHIBITION DURING HABITUATION.
215068 04-04

THE ACTION OF CHLORPROMAZINE AND TRIFTAZINE ON DISCHARGES OF CORTICAL NEURONS IN RABBITS AFTER CHRONIC ADMINISTRATION OF THE DRUGS.
215499 04-03

POLYGRAPHIC NIGHT SLEEP PATTERN DURING CHRONIC SINGLE AND MULTIPLE NEUROLEPTIC DOSE ADMINISTRATION.
215701 04-08

BRAIN ACETYLCHOLINE: INCREASE AFTER SYSTEMIC CHOLINE ADMINISTRATION.
217399 04-03

EFFECT OF MESORIDAZINE ADMINISTRATION AND WITHDRAWAL ON PERFORMANCE IN AN OLDER AGE GROUP.
217452 04-11

APPARENT FEEDBACK FROM THE CAUDATE NUCLEUS TO THE SUBSTANTIA-NIGRA FOLLOWING AMPHETAMINE ADMINISTRATION.
217676 04-03

INCREASED CONCENTRATION OF HOMOVANILLIC ACID IN THE BRAINS OF INFANT RABBITS AFTER ADMINISTRATION OF HALOPERIDOL TO THEIR NURSING MOTHERS.
217692 04-03

EFFECT OF CHRONIC PHENOBARBITAL ADMINISTRATION UPON BRAIN GROWTH OF THE INFANT RAT.
217885 04-03

CHANGES IN THE CONCENTRATIONS OF 5-HYDROXYTRYPTAMINE AND NORADRENALINE IN SIX AREAS OF RAT BRAIN DURING RECOVERY FROM CHRONIC METHYLAMPHETAMINE ADMINISTRATION.
217963 04-03

EFFECTS OF CHRONIC ADMINISTRATION AND WITHDRAWAL OF D-AMPHETAMINE UPON DAILY ACTIVITY LEVELS OF SQUIRREL MONKEYS.
219032 04-04

BLOCKADE OF ALPHA-METHYLTYROSINE-INDUCED SUPERSENSITIVITY TO APOMORPHINE BY CHRONIC ADMINISTRATION OF L-DOPA.
220974 04-03

THE BLOOD-BRAIN BARRIER II: DISTRIBUTION KINETICS OF H3-P-HYDROXYAMPHETAMINE IN BRAIN STRUCTURES OF THE RAT AFTER INTRAVENOUS ADMINISTRATION.
220977 04-03

THE CORRELATION BETWEEN TRIFTAZINE DISTRIBUTION IN SOME RAT ORGANS AND ITS PHARMACOLOGICAL EFFECTS WITH DIFFERENT TYPES OF ADMINISTRATION.
223016 04-03

THE EFFECT OF INTRAVENTRICULAR ADMINISTRATION OF SEROTONIN ON SPONTANEOUS MOTOR ACTIVITY OF RATS. (UNPUBLISHED PAPER).
225287 04-04

EFFECT OF CHRONIC MARIJUANA ADMINISTRATION ON STAGES OF PRIMATE SLEEP-WAKEFULNESS.
225520 04-14

FORMATION OF NOREPINEPHRINE IN THE BRAIN OF RATS AFTER ADMINISTRATION OF (+) ERYTHRO 3,4 DIHYDROXYPHENYLSERINE.
225558 04-03

THE RELATION BETWEEN CEREBRAL SEROTONIN LEVELS AND CONDITIONED BEHAVIOUR IN THE RAT FOLLOWING THE ADMINISTRATION OF LSD-25 AND UML.
225564 04-04

THE EFFECTS OF CHRONIC MORPHINE ADMINISTRATION UPON A MODIFIED SIDMAN AVOIDANCE SCHEDULE THAT UTILIZES RESPONSE INDEPENDENT SHOCK.
225566 04-04

ADMINISTRATIONS
RELATIONSHIP BETWEEN THE CHANGES ON BLOOD PRESSURE RESPONSE AND THE CARDIAC CATECHOLAMINE LEVEL AFTER SINGLE AND REPEATED ADMINISTRATIONS OF TYRAMINE AND METHAMPHETAMINE IN RATS.
197491 01-03

ADMISSIONS
THE COURSE AND PROGNOSIS OF SCHIZOPHRENIC PSYCHOSES IN HELSINKI: A COMPARATIVE STUDY OF FIRST ADMISSIONS IN 1950, 1960 AND 1965.
197276 01-17

ADMITTED
LOXAPINE IN NEWLY ADMITTED CHRONIC SCHIZOPHRENIC PATIENTS.
217810 04-08

ADOLESCENCE
BIPOLAR MANIC-DEPRESSIVE PSYCHOSIS IN EARLY ADOLESCENCE: A CASE REPORT.
201513 02-09

ADOLESCENTS
ON THE USE OF SYDNOCARB FOR PSYCHOPHARMACOLOGICAL CORRECTION OF BEHAVIORAL DISORDERS OF THE CYCLOID TYPE OF ACCENTUATED PERSONALITY IN ADOLESCENTS.
207271 03-11
STIMULANT DRUG TREATMENT OF HYPERACTIVE ADOLESCENTS.
224379 04-14
CHILDHOOD CHEMOTHERAPY AND LATER DRUG ABUSE AND GROWTH CURVE: A FOLLOWUP STUDY OF 30 ADOLESCENTS.
225382 04-14

ADRENAL
POTENTIATION OF DRUG INITIATED ADRENAL TYROSINE-HYDROXYLASE INDUCTION BY DIAZEPAM.
193304 01-03
ACTIONS OF GABA, PICROTOXIN AND BICUCULLINE ON ADRENAL MEDULLA.
193455 01-03
LITHIUM AND ADRENAL CORTEX.
194169 01-03
EFFECTS OF THEOPHYLLINE AND PROPRANOLOL ON ACETYLCHOLINE-INDUCED RELEASE OF ADRENAL MEDULLARY CATECHOLAMINES.
195591 01-03
SUPPRESSION BY NORADRENALINE OF CATECHOLAMINE SECRETION FROM ADRENAL MEDULLA.
199869 02-03
EVIDENCE AGAINST A CAUSAL RELATIONSHIP BETWEEN INCREASE IN C-AMP AND INDUCTION OF TYROSINE-HYDROXYLASE IN THE RAT ADRENAL MEDULLA.
202795 02-03
THE EFFECTS OF CHRONIC PHENOTHIAZINE TREATMENT ON ADRENAL PITUITARY FUNCTION IN MAN.
205765 03-13
MATURATION OF THE ADRENAL MEDULLA -- III: PRACTICAL AND THEORETICAL CONSIDERATIONS OF AGE DEPENDENT ALTERATIONS IN KINETICS OF INCORPORATION OF CATECHOLAMINES AND NONCATECHOLAMINES.
205852 03-03
POSSIBLE ROLE OF CATECHOLAMINES (CA) IN THE REGULATION OF ADRENAL TYROSINE-HYDROXYLASE (TH).
207333 03-03
ONTOGENY OF THE INDUCTION OF TYROSINE-HYDROXYLASE BY RESERPINE IN THE SUPERIOR CERVICAL GANGLION, NUCLEUS LOCUS-COERULEUS AND ADRENAL GLAND.
210670 03-03
ADRENAL GLUCOCORTICOIDS AS A REQUIRED FACTOR IN THE DEVELOPMENT OF ETHANOL WITHDRAWAL SEIZURES IN MICE.
213479 04-03
STUDIES ON THE SYNTHESIS AND SUBCELLULAR DISTRIBUTION OF DOPAMINE IN THE RAT ADRENAL MEDULLA.
217797 04-03
DEXAMETHASONE INDUCES TYROSINE-HYDROXYLASE IN SYMPATHETIC GANGLIA BUT NOT IN ADRENAL MEDULLA.
217853 04-03
HIPPOCAMPAL AND PITUITARY ADRENAL INFLUENCES ON ACTIVITY AND AVOIDANCE BEHAVIOR. (PH.D. DISSERTATION).
219289 04-04
THE EFFECT OF AN ADRENAL DEMEDULLATION AND CHEMICAL SYMPATHECTOMY (2,4,5 TRIHYDROXYPHENYLETHYLAMINE) ON THE ACQUISITION OF A ONE-WAY ACTIVE AVOIDANCE RESPONSE. (PH.D. DISSERTATION).
222736 04-04

ADRENALECTOMIZED
EFFECT OF ACTH4-10 ON THE RATE OF SYNTHESIS OF (3H)CATECHOLAMINES IN THE BRAINS OF INTACT, HYPOPHYSECTOMIZED AND ADRENALECTOMIZED RATS.
223050 04-03

ADRENALINE
THE SIGNIFICANCE OF NORADRENALINE AND ADRENALINE AS ADRENERGIC TRANSMITTERS IN THE CHICKEN.
197958 01-03
THE EFFECT OF AUTONOMIC AND PSYCHOTROPIC DRUGS ON ADRENALINE REVERSAL IN THE RAT UTERUS.
222803 04-03

ADRENERGIC
SOME STUDIES OF ADRENERGIC AMINES: PART I. ROLE OF THE AROMATIC RING IN RECEPTOR BINDING. PART II. BETA ADRENERGIC BLOCKADE. (PH.D. DISSERTATION).
194564 01-01
ADRENERGIC RECEPTOR BLOCKING AGENTS: EFFECTS ON CENTRAL NORADRENALINE AND DOPAMINE RECEPTORS AND ON MOTOR ACTIVITY.
195429 01-03
EFFECTS OF ADRENERGIC DRUGS ON PRESSOR RESPONSES TO HYPOTHALAMIC STIMULATION.
195441 01-03
DEPRESSIVE ILLNESS: ADRENERGIC RESPONSIVENESS AND THE EFFECT OF LITHIUM ON PLATELET ADENYLCYCLASE. (PH.D. DISSERTATION).
196260 01-13
PRESSOR RESPONSES TO HYPOTHALAMIC STIMULATION AS INFLUENCED BY DRUGS AFFECTING ADRENERGIC RECEPTORS.
197290 01-03
MODIFICATION BY DESIPRAMINE OF THE ADRENERGIC SENSITIVITY OF PYROGALLOL IN THE RAT.
197461 01-03
THE SIGNIFICANCE OF NORADRENALINE AND ADRENALINE AS ADRENERGIC TRANSMITTERS IN THE CHICKEN.
197958 01-03
EFFECT OF NICOTINE AND NICOTINE MONOMETHIODIDE ON VASCULAR ADRENERGIC NEUROEFFECTOR TRANSMISSION.
197966 01-03
THE EFFECTS OF 6-HYDROXYDOPAMINE AND GUANETHIDINE ON PERIPHERAL ADRENERGIC NERVES IN THE GUINEA-PIG.
199862 02-03
EFFECTS OF LITHIUM CHLORIDE ON CARDIOVASCULAR RESPONSES INDUCED BY CHOLINERGIC AND ADRENERGIC STIMULATIONS.
199870 02-03
THE EFFECT OF SEROTONINERGIC AND ADRENERGIC PREPARATIONS UPON ALCOHOL-INDUCED EXCITATION IN MICE.
201915 02-04
EFFECTS OF CENTRAL AND PERIPHERAL ADRENERGIC AND CHOLINERGIC MODIFICATION ON TIME-DEPENDENT PROCESSES IN AVOIDANCE PERFORMANCE.
202203 02-03
THE STRUCTURAL CHEMISTRY OF ADRENERGIC NEURAL TRANSMISSION SYSTEMS. (PH.D. DISSERTATION).
203027 02-01
STUDIES ON THE TIME COURSE AND THE EFFECT OF CHOLINERGIC AND ADRENERGIC RECEPTOR BLOCKERS ON THE STIMULUS EFFECT OF NICOTINE.
206353 03-03
ADENOSINE-3-5-MONOPHOSPHATE CONTENT IN RAT CAUDATE NUCLEUS: DEMONSTRATION OF DOPAMINERGIC AND ADRENERGIC RECEPTORS.
208300 03-03
ADRENERGIC AND CHOLINERGIC DRUG EFFECTS UPON SHORT-TERM MEMORY IN MICE. (PH.D. DISSERTATION).
214205 04-04
RAT PINEAL CYCLIC ADENOSINE-3-5-MONOPHOSPHATE PHOSPHODIESTERASE ACTIVITY: IN VIVO MODULATION BY A BETA ADRENERGIC RECEPTOR.
215600 04-03
INDUCTION OF TYROSINE-HYDROXYLASE ELICITED BY BETA ADRENERGIC RECEPTOR AGONISTS IN NORMAL AND DECENTRALIZED SYMPATHETIC GANGLIA: ROLE OF CYCLIC 3,5 ADENOSINE-MONOPHOSPHATE.
215688 04-03
6-HYDROXYDOPA DURING DEVELOPMENT OF CENTRAL ADRENERGIC NEURONS PRODUCES DIFFERENT LONG-TERM CHANGES IN RAT BRAIN NORADRENALINE.
217867 04-03
EFFECT OF AMPHETAMINE, 3,4 METHYLENEDIOXYAMPHETAMINE, P-METHOXYAMPHETAMINE AND RELATED AMPHETAMINES ON UPTAKE OF METARAMINOL AND EFFLUX OF NORADRENALINE IN ADRENERGIC NERVES OF RABBIT ATRIA.
217889 04-03
IN VIVO BINDING OF ANTIBODY TO DOPAMINE-BETA-HYDROXYLASE IN ADRENERGIC NERVES AND SUBSEQUENT ANTIDROMIC TRANSPORT (UNPUBLISHED PAPER).
218147 04-03
AN ADRENERGIC DRUG IN DEPRESSION.
218771 04-10
INTERACTION OF CYCLOHEXIMIDE AND ADRENERGIC DRUGS WITH BRAIN PROTEIN AND CATECHOLAMINE BIOSYNTHESIS. (PH.D. DISSERTATION).
219288 04-03
NEUROTRANSMITTER CONTENT IN SYNAPTIC VESICLES OF THE ADRENERGIC NERVES OF RATS UNDER PHARMACOLOGICAL INFLUENCE.
223017 04-03
THE EFFECT OF CARBIDINE ON ADRENERGIC TRANSMISSION.
224115 04-03

ADRENOCORTICAL
ROLE OF PITUITARY ADRENOCORTICAL SYSTEM IN MEDIATING AVOIDANCE BEHAVIOR OF RATS WITH SEPTAL LESIONS.
206739 03-04
AMNESIC EFFECT OF CYCLOHEXIMIDE IN THE MOUSE MEDIATED BY ADRENOCORTICAL HORMONES.
206751 03-04
ROLE OF BRAIN SEROTONIN IN THE INTEGRATION OF BEHAVIORAL RESPONSES AND PITUITARY ADRENOCORTICAL FUNCTIONS UNDER EMOTION.
218364 04-04
EFFECTS OF EARLY EXPERIENCE AND DEXAMETHASONE ON ADRENOCORTICAL REACTIVITY.
225078 04-03

ADRENOLYTIC
CHLORPROMAZINE METABOLISM VI -- ADRENOLYTIC AND ANTISEROTONERGIC ACTIVITIES OF CHLORPROMAZINE AND ITS VARIOUS METABOLITES.
197494 01-03

ADRENORECEPTORS
INCORPORATION OF ACETATE (C14)(P-32) AND PHOSPHATE INTO THE BRAIN LIPIDS DURING BLOCKAGE OF THE CHOLINORECEPTOR AND ADRENORECEPTORS.
202599 02-03

ADULT
DIFFERENTIAL EFFECTS OF D-AMPHETAMINE ON BRAIN ACETYLCHOLINE IN YOUNG, ADULT, AND GERIATRIC RATS.
193457 01-03
THE INFLUENCE OF CEREBROLYSINE ON HIGHER NERVOUS ACTIVITY IN ADULT RATS.
196758 01-04
ON THE BIOTRANSFORMATION OF AMPHETAMINE IN ADULT AND OLD RATS.
197292 01-03
DOSE-DEPENDENT DIFFERENCES OF AMPHETAMINE LEVELS IN BRAIN AND HEART OF ADULT AND DEVELOPING MICE.
197927 01-03
BEHAVIOURAL AND ELECTROGRAPHIC OBSERVATIONS DURING EPILEPTIC CONVULSIONS INDUCED BY STRYCHNINE AND PENTYLENETETRAZOL IN CONSCIOUS YOUNG AND ADULT CHICKENS.
205459 02-03
HALOPERIDOL AS A TREATMENT FOR ADULT STUTTERING.
207771 03-14
EFFECT OF STRESS AND DIAZEPAM TREATMENT DURING INFANCY ON THE CORTICOSTERONE REGULATION AND ANDROGENIC ACTIVITY IN ADULT MALE RATS.
210348 03-03
NEONATAL 6-HYDROXYDOPAMINE TREATMENT: NORADRENALINE LEVELS AND IN VITRO 3H-CATECHOLAMINE SYNTHESIS IN DISCRETE BRAIN REGIONS OF ADULT RATS.
210759 03-03
ESTROGEN STIMULATIONS DURING NEONATAL PERIOD AND THEIR EFFECTS ON EMOTIONAL AND OPERATIVE BEHAVIOR IN THE ADULT.
211219 03-04
INHIBITORY EFFECT OF NEONATAL ESTROGENIZATION ON THE INCORPORATION OF (3H)LYSINE IN THE PURKINJE CELLS OF THE ADULT MALE AND FEMALE RAT.
213478 04-03
THE EFFECT OF ACTH AND DIAZEPAM, ADMINISTERED TO INFANT RATS ON THE BODY GROWTH CURVE AND SOME ENDOCRINE PARAMETERS MEASURED IN ADULT AGE.
215066 04-03

ADULTS
FLUPENTHIXOL DECANOATE IN PSYCHOTIC ADULTS -- PILOT STUDY.
209071 03-08
CLINICAL STUDIES OF D-40TA (TRIAZOLOBENZODIAZEPINE) -- CROSSOVER TRIAL ON SLEEP DISTURBANCES AND SLEEP EEG IN NORMAL ADULTS.
209412 03-10
CORRECTION OF AUTONOMIC EFFECTS OF PSYCHOTROPIC DRUGS BY LARGE DOSES OF DIHYDROERGOTAMINE IN ADULTS AND THE ELDERLY.
211998 03-11

ADVERSE
ADVERSE REACTIONS TO CHLORPROMAZINE IN PSYCHIATRIC PATIENTS.
197923 01-01

AER
AVERAGE EVOKED RESPONSES (AER) AND HOMOVANILLIC ACID (HVA) IN CEREBROSPINAL FLUID (CSF) IN A PSYCHOTIC PATIENT WITH ADDISONS DISEASE.
221310 04-09

AF-1161
PSYCHOTHERAPEUTIC PROFILE OF A NEW PSYCHOACTIVE DRUG TRAZODONE (AF-1161).
215699 04-09

AFFECT
THE EFFECTS OF CORD SECTION UNDER ETHER OR HALOTHANE ON THE ABILITY OF CHLORPROMAZINE TO AFFECT THE JAW-JERK RESPONSE TO TOOTH PULP STIMULATION IN THE ENCEPHALE ISOLE PREPARATION.
197451 01-03
L-HISTIDINE: FAILURE TO AFFECT THE SLEEP-WAKING CYCLE IN MAN.
214015 04-14
CHOLINERGIC AGENTS AFFECT TWO RECEPTORS THAT MODULATE TRANSMITTER RELEASE AT A CENTRAL SYNAPSE IN APLYSIA-CALIFORNICA.
215705 04-03
GENOTYPE OR PRENATAL DRUG EXPERIENCE AFFECT BRAIN MATURATION IN THE MOUSE.
221032 04-03

AFFECTIVE
THE EFFECTIVENESS OF LITHIUM IN AFFECTIVE AND SCHIZOAFFECTIVE PSYCHOSES.
194043 01-11
AFFECTIVE DISEASE HEALTH MAINTENANCE ORGANIZATION: PATTERNS OF LITHIUM RESPONSE.
194746 01-09
SODIUM AND LITHIUM ERYTHROCYTE CONCENTRATION IN AFFECTIVE DISORDERS.
195931 01-09
SUBTYPE OF AFFECTIVE PSYCHOSES CLASSIFIED BY RESPONSE ON AMINE PRECURSORS AND MONOAMINE METABOLISM.
197209 01-09
LITHIUM PROPHYLAXIS IN RECURRENT AFFECTIVE DISORDERS.
197532 01-09
THE INFLUENCE OF ANALGESICS AND NEUROLEPTICS ON AFFECTIVE MANIFESTATIONS OF PAIN.
198480 02-04
PSYCHOPHARMACOLOGIC TREATMENT OF AFFECTIVE DISORDERS.
200237 02-09
THE CURRENT STATUS OF LITHIUM RECIDIVISM PROPHYLAXIS IN ENDOGENOUS AFFECTIVE ILLNESSES.
200568 02-09
A CASE OF SEVERE HEADACHE AS AN EQUIVALENT OF AFFECTIVE DISORDER.
201668 02-09
LUMBAR CSF 5-HYDROXYINDOLEACETIC ACID AND HOMOVANILLIC ACID IN AFFECTIVE SYNDROMES.
202248 02-09
AN MAOI SPECIFIC AFFECTIVE DISORDER. THE TOO MUCH SYNDROME.
202705 02-09
RED BLOOD CELL LITHIUM INDEX IN PATIENTS WITH AFFECTIVE DISORDERS IN THE COURSE OF LITHIUM PROPHYLAXIS.
202786 02-09
L-DOPA AND TRICYCLIC ANTIDEPRESSANTS IN AFFECTIVE DISORDERS. A PILOT STUDY.
205601 03-09
THEORETICAL IMPLICATIONS OF DRUG-INDUCED ADAPTIVE REGULATION FOR A BIOGENIC AMINE HYPOTHESIS OF AFFECTIVE DISORDER.
206335 03-03
AFFECTIVE DISORDER: STUDIES WITH AMINE PRECURSORS.
207681 03-09
THE LITHIUM PROPHYLACTIC TREATMENT OF RECURRENT ENDOGENOUS AFFECTIVE DISORDERS.
209392 03-09
COMPARATIVE STUDIES ABOUT SERUM ELECTROLYTES DURING LITHIUM PROPHYLAXIS OF AFFECTIVE DISORDERS.
210807 03-09
LITHIUM ION AND AFFECTIVE PSYCHOSES.
212340 03-09
FREE THYROXINE INDEX AND ABSOLUTE FREE THYROXINE IN PATIENTS WITH AFFECTIVE DISORDERS TREATED WITH LITHIUM CARBONATE.
216747 04-09
FURTHER REPORT ON PROPHYLACTIC LITHIUM IN RECURRENT AFFECTIVE DISORDERS.
218556 04-09
BIPOLAR PRIMARY AFFECTIVE DISORDER.
221166 04-09
AFFECTIVE DISORDERS AND LITHIUM ION.
224588 04-09
GROWTH HORMONE RELEASE AND CATECHOLAMINES IN AFFECTIVE DISEASE.
224773 04-13

AFFERENT
THE EFFECT OF INHIBITORS OF CATECHOLAMINE SYNTHESIS (ALPHA-METHYLTYROSINE AND DISULFIRAM) ON THE BACKGROUND ACTIVITY OF SENSORIMOTOR CORTEX NEURONS AND THEIR RESPONSES TO AFFERENT CAUDATE AND RETICULAR STIMULATION.
202598 02-04

AFFERENTS
AFFERENTS TO THE SEPTAL AREA OF THE RAT STUDIED WITH THE METHOD OF RETROGRADE AXONAL TRANSPORT OF HORSERADISH PEROXIDASE.
203573 02-03
DIFFERENTIAL SENSITIVITY OF PRIMARY AND SECONDARY SPINDLE AFFERENTS TO DEPRESSANT DRUGS.
210801 03-03

AFFINITY

TYROSINE-HYDROXYLASE (TH) IN NUCLEUS-ACCUMBENS AND STRIATUM: EFFECTS OF NEUROLEPTICS ON THE AFFINITY FOR PTERIDINE COFACTOR. (UNPUBLISHED PAPER).
196588 01-03

HYDROCORTISONE-INDUCED SUPERSENSITIVITY TO NORADRENALINE IN THE ISOLATED NICTITATING MEMBRANE AS A CONSEQUENCE OF AN IMPAIRMENT OF AN O-METHYLATING SYSTEM WITH HIGH AFFINITY.
197944 01-03

ANTISCHIZOPHRENIC DRUGS: AFFINITY FOR MUSCARINIC CHOLINERGIC RECEPTOR SITES IN THE BRAIN PREDICTS EXTRAPYRAMIDAL EFFECTS.
207298 03-03

ELECTROCONVULSIVE SHOCK: SUSTAINED DECREASE IN NOREPINEPHRINE UPTAKE AFFINITY IN A RESERPINE MODEL OF DEPRESSION.
210830 03-03

HIGH AFFINITY UPTAKE OF GABA IN PRESUMED GABA-ERGIC NERVE ENDINGS IN RAT BRAIN.
211062 03-03

PRESYNAPTIC AND POSTSYNAPTIC COMPONENTS IN EFFECT OF DRUGS WITH ALPHA-ADRENOCEPTOR AFFINITY.
214062 04-03

AFTERBIRTH

EFFECTS OF ALPHA-METHYLDOPA ON NEWBORN KITTEN SLEEP. BEHAVIORAL EVOLUTION DURING THE FIRST MONTH AFTERBIRTH.
221049 04-04

AFTERCARE

DRUG AND SOCIOTHERAPY IN THE AFTERCARE OF SCHIZOPHRENIC PATIENTS: II. TWO-YEAR RELAPSE RATES.
199625 02-08

DRUG AND SOCIOTHERAPY IN THE AFTERCARE OF SCHIZOPHRENIC PATIENTS: III. ADJUSTMENT OF NONRELAPSED PATIENTS.
199626 02-08

AFTERDISCHARGE

PHARMACOLOGICAL MODULATION OF PHOTICALLY EVOKED AFTERDISCHARGE PATTERNS IN HOODED LONG-EVANS RATS.
201409 02-03

AFTERDISCHARGES

MODULATION OF PHOTICALLY EVOKED AFTERDISCHARGES BY MEANS OF PHARMACOLOGICAL AND BEHAVIORAL AROUSAL. (PH.D. DISSERTATION).
222644 04-03

AFTEREFFECT

A PROLONGED AFTEREFFECT OF INTENSE SYNAPTIC ACTIVITY ON ACETYLCHOLINE IN A SYMPATHETIC GANGLION.
211102 03-03

AFTEREFFECTS

THE INFLUENCE OF CHOLINOMIMETICS ON THE AFTEREFFECTS OF TRACE DISCHARGES AND THE ACTIVITY OF EPILEPTOGENIC FOCI IN THE RABBIT HIPPOCAMPUS.
219499 04-03

AGE

AGE SEX DIFFERENCES IN RESPONSE TO ANTIDEPRESSANT DRUGS.
193093 01-11

SHUTTLE AVOIDANCE LEARNING OF MICE: EFFECTS OF POSTTRIAL PENTYLENETETRAZOL, STRAIN AND AGE.
195226 01-04

AGE RELATED ENHANCED RESPONSIVENESS TO CENTRAL NERVOUS SYSTEM DRUGS IN RATS. (PH.D. DISSERTATION).
196256 01-03

RELATIONSHIP BETWEEN ANALGESIC ACTION OF PETHIDINE AND ITS EFFECT ON THE BRAIN 5-HYDROXYTRYPTAMINE CONCENTRATION IN THE RATS OF DIFFERENT AGE.
196782 01-03

ELIMINATION OF LITHIUM DEPENDENT ON AGE IN HEALTHY PEOPLE AND PATIENTS SUFFERING FROM RENAL INSUFFICIENCY.
205043 02-13

HYDERGINE THIORIDAZINE COMBINATION IN THE TREATMENT OF PSYCHOPATHOLOGICAL STATES IN OLD AGE.
205637 03-11

MATURATION OF THE ADRENAL MEDULLA -- III: PRACTICAL AND THEORETICAL CONSIDERATIONS OF AGE DEPENDENT ALTERATIONS IN KINETICS OF INCORPORATION OF CATECHOLAMINES AND NONCATECHOLAMINES.
205852 03-03

AGE RELATED RESPONSIVENESS OF THE RAT TO DRUGS AFFECTING THE CENTRAL NERVOUS SYSTEM.
206912 03-03

CHANGES IN MENTAL AGE WITH SUBNORMAL CHILDREN TREATED WITH DOSES OF GABA AND NUCLEOTIDES.
210286 03-14

THE EFFECTS OF AGE AND ILLUMINATION ON THE DOSE-RESPONSE CURVES FOR THREE STIMULANTS.
214014 04-04

BLOCKING OF STRESS BY PENTOBARBITAL MORPHINE AS RELATED TO TRAINING AND AGE OF RATS.
214056 04-04

THE EFFECT OF ACTH AND DIAZEPAM, ADMINISTERED TO INFANT RATS ON THE BODY GROWTH CURVE AND SOME ENDOCRINE PARAMETERS MEASURED IN ADULT AGE.
215066 04-03

EFFECT OF MESORIDAZINE ADMINISTRATION AND WITHDRAWAL ON PERFORMANCE IN AN OLDER AGE GROUP.
217452 04-11

AGE DIFFERENCES AFFECTING INDUCTION OF HEPATIC DRUG METABOLIZING ENZYMES BY METHAQUALONE AND PHENOBARBITAL IN THE RAT.
217793 04-03

AGED

OBSERVATIONS OF THE PSYCHOPHARMACOLOGY OF THE AGED.
207437 03-11

PSYCHOPHARMACOLOGY IN THE AGED: USE OF PSYCHOTROPIC DRUGS IN GERIATRIC PATIENTS.
208571 03-11

PSYCHOPHARMACOLOGY IN THE AGED: DISCUSSION.
208572 03-11

PSYCHOPHARMACOLOGY IN THE AGED: RESEARCH CONSIDERATIONS IN GERIATRIC PSYCHOPHARMACOLOGY.
208573 03-11

PSYCHOPHARMACOLOGY IN THE AGED: DISCUSSION.
208574 03-11

PSYCHOPHARMACOLOGY IN THE AGED: USE OF MAJOR PSYCHOTROPIC MEDICATIONS IN TREATMENT OF THE ELDERLY: CASE EXAMPLES.
208575 03-11

PSYCHOPHARMACOLOGY IN THE AGED: DISCUSSION.
208576 03-11

AGEDAL

NOXIPTILIN (AGEDAL) -- A NEW TRICYCLIC ANTIDEPRESSANT WITH A FASTER ONSET OF ACTION? A DOUBLE-BLIND, MULTICENTRE COMPARISON WITH AMITRIPTYLINE.
221306 04-09

AGES

DIFFERENTIAL EFFECTS OF EPINEPHRINE AND PROPRANOLOL ON SHUTTLEBOX AVOIDANCE LEARNING IN RATS OF DIFFERENT AGES. (PH.D. DISSERTATION).
193745 01-04

METHYLPHENIDATE EFFECTS ON AVOIDANCE LEARNING AT TWO AGES IN THE RAT.
215685 04-04

AGGREGATED

PHENOTHIAZINE TRANQUILIZER PD-50S EXERTED AGAINST AMPHETAMINE EFFECT IN AGGREGATED MICE.
193422 01-03

THE INTERACTION OF DELTA9-TETRAHYDROCANNABINOL AND D-AMPHETAMINE IN AGGREGATED MICE.
196227 01-04

AGGRESSION

EFFECTS ON SHOCK-ELICITED AGGRESSION IN MICE OF PREFERENTIALLY PROTECTING BRAIN MONOAMINES AGAINST THE DEPLETING ACTION OF RESERPINE.
195452 01-04

TOLERANCE TO THE HYPOTHERMIC AND AGGRESSION ATTENUATING EFFECT OF DELTA8- AND DELTA9-TETRAHYDROCANNABINOL IN MICE.
197866 01-04

INTRASPECIES AGGRESSION IN RATS: EFFECTS OF D-AMPHETAMINE AND CHLORDIAZEPOXIDE.
202768 02-04

SUPPRESSION OF MOUSE-KILLING AND APOMORPHINE-INDUCED SOCIAL AGGRESSION IN RATS BY LOCAL ANESTHESIA OF THE MYSTACIAL-VIBRISSAE.
206714 03-04

CONCEPTUAL ISSUES IN THE USE OF DRUGS FOR THE TREATMENT OF AGGRESSION IN MAN.
209126 03-17

TREATMENT OF HUMAN AGGRESSION WITH MAJOR TRANQUILIZERS, ANTIDEPRESSANTS, AND NEWER PSYCHOTROPIC DRUGS.
209127 03-11

MINOR TRANQUILIZERS IN THE TREATMENT OF AGGRESSION.
209128 03-11

LITHIUM IN THE TREATMENT OF AGGRESSION.
209129 03-11

ANTICONVULSANTS IN THE TREATMENT OF AGGRESSION.
209130 03-11

HORMONE AND HORMONAL AGENTS IN THE TREATMENT OF AGGRESSION.
209131 03-11

EFFECTS OF PSYCHOSTIMULANTS ON AGGRESSION.
209132 03-17

AGGRESSION AND NEUROTRANSMITTERS.
209191 03-04

LITHIUM CARBONATE AND AGGRESSION: A CASE REPORT.
210210 03-14

TRANQUILIZERS CAUSING AGGRESSION.
210220 03-17

AGGRESSION IN MICE AFTER P-CHLOROAMPHETAMINE.
210899 03-04

EFFECTS OF PSYCHOTROPIC DRUGS ON EXTINCTION INDUCED AGGRESSION. (PH.D. DISSERTATION).
212523 03-04

ABSENCE OF INTERACTION BETWEEN DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) AND CANNABIDIOL (CBD) IN AGGRESSION, MUSCLE CONTROL AND BODY TEMPERATURE EXPERIMENTS IN MICE.
217474 04-04

CATECHOLAMINE CORRELATES OF ISOLATION INDUCED AGGRESSION IN MICE.
217670 04-04

CANNABIS AND AGGRESSION IN ANIMALS.
217828 04-04

ON THE ROLE OF SEROTONIN IN PREDATORY AGGRESSION.
219110 04-04

EXAMINATION OF THE ROLE OF BRAIN AMINES AND CYCLIC-AMP IN BENZODIAZEPINE INDUCED SUPPRESSION OF AGGRESSION. (PH.D. DISSERTATION).
219278 04-04

SCHEDULE INDUCED AGGRESSION IN LABORATORY RATS: DEMONSTRATION AND CONTROL THROUGH SODIUM AMOBARBITAL. (PH.D. DISSERTATION).
220644 04-04

THE EFFECT OF DRUGS ON INTRASPECIES AGGRESSION.
223064 04-04

EARLY LIFE UNDERNUTRITION AND AGGRESSION IN TWO MOUSE STRAINS.
225081 04-04

AGGRESSIVE

AGGRESSIVE BEHAVIORS INDUCED BY CHRONIC ADMINISTRATION OF THEOPHYLLINE, WITH PARTICULAR REFERENCE TO ALTERATIONS IN BEHAVIORS OF IMMATURE RATS.
200748 02-04

PHARMACOLOGICAL MANIPULATIONS OF BRAIN CATECHOLAMINES AND THE AGGRESSIVE BEHAVIOR INDUCED BY MARIHUANA IN REM SLEEP DEPRIVED RATS.
210325 03-04

THE EFFECTS OF CHRONIC CANNABIS TREATMENT UPON BRAIN 5-HYDROXYTRYPTAMINE, PLASMA CORTICOSTERONE AND AGGRESSIVE BEHAVIOR IN FEMALE RATS WITH DIFFERENT HORMONAL STATUS.
217532 04-04

A PHARMACOLOGICAL ANALYSIS OF AGGRESSIVE BEHAVIOR OF MICE INDUCED BY ISOLATION.
218800 04-04

A COMPARISON OF PHENOTHIAZINES IN MANAGING AGGRESSIVE EPISODES IN SCHIZOPHRENIC PATIENTS.
224955 04-08

AGGRESSIVITY

EFFECT OF SODIUM GAMMA-HYDROXYBUTYRATE ON ISOLATION INDUCED AGGRESSIVITY IN MICE.
205588 02-04

AGING

PSYCHOPHARMACOLOGY AND AGING.
203606 02-11

MORE EVIDENCE FAVORS YOUTH DRUG: FIRST DOUBLE-BLIND TRIALS SHOW GEROVITAL HAS SOME EFFECT ON AGING.
221352 04-11

AGITATION

URGENT CHEMICAL TREATMENT OF STATES OF AGITATION.
207151 03-11

AGONIST

DOPAMINE AGONIST AND ANTAGONIST ACTIVITIES OF PIRIBEDIL (ET495) AND ITS METABOLITES.
197930 01-04

LSD AS AN AGONIST OF DOPAMINE RECEPTORS IN THE STRIATUM.
204183 02-03

LSD AS AN AGONIST AND ANTAGONIST AT CENTRAL DOPAMINE RECEPTORS.
204184 02-03

NOMIFENSINE: A POTENT DOPAMINERGIC AGONIST OF ANTIPARKINSON POTENTIAL.
217472 04-03

DOPAMINERGIC DRUGS ANTAGONIZED THE PSYCHOTOMIMETIC EFFECTS OF PARTIAL AGONIST ANALGESICS.
221048 04-04

INHIBITION OF BOTH NORADRENERGIC AND SEROTONERGIC NEURONS IN BRAIN BY THE ALPHA-ADRENERGIC AGONIST CLONIDINE.
221131 04-03

AGONISTS

ADENYLCYCLASE IN RAT STRIATUM AND NUCLEUS-ACCUMBENS: STIMULATION BY DOPAMINE RECEPTOR AGONISTS. (UNPUBLISHED PAPER).
197124 01-03

STEREOTYPED AND CIRCLING BEHAVIOUR INDUCED BY DOPAMINERGIC AGONISTS AFTER LESIONS OF THE MIDBRAIN RAPHE NUCLEI.
202792 02-04

SUPERSENSITIVITY TO DOPAMINE AGONISTS FOLLOWING UNILATERAL, 6-HYDROXYDOPAMINE INDUCED STRIATAL LESIONS IN MICE.
208552 03-03

EFFECTS OF DOPAMINERGIC RECEPTOR AGONISTS AND ANTAGONISTS ON THE ACTIVITY OF THE NEOSTRIATAL CHOLINERGIC SYSTEM.
210669 03-03

INDUCTION OF TYROSINE-HYDROXYLASE ELICITED BY BETA ADRENERGIC RECEPTOR AGONISTS IN NORMAL AND DECENTRALIZED SYMPATHETIC GANGLIA: ROLE OF CYCLIC 3,5 ADENOSINE-MONOPHOSPHATE.
215688 04-03

EFFECT OF WITHDRAWAL FROM CHRONIC ETHANOL INGESTION ON THE CAMP RESPONSE OF CEREBRAL CORTICAL SLICES USING THE AGONISTS HISTAMINE, SEROTONIN, AND OTHER NEUROTRANSMITTERS.
215980 04-03

NARCOTIC AGONISTS AND ANTAGONISTS AS MODELS FOR POTENTIAL ANTIDEPRESSANT DRUGS.
222817 04-04

AGORAPHOBIA

AGORAPHOBIA.
206228 03-10

AGROCLAVINE

EFFECTS OF AGROCLAVINE ON AVOIDANCE BEHAVIOR IN THE HAMSTER.
194130 01-04

AHR-2244

PRECLINICAL EVALUATION OF AHR-2244: A NEW PSYCHOTHERAPEUTIC AGENT.
210676 03-02

AKATHISIA

THE MANY FACES OF AKATHISIA.
207768 03-15

AKINESIA

ROLE OF NORADRENALINE IN LEVODOPA REVERSAL OF RESERPINE AKINESIA.
193544 01-03

CONTRIBUTION OF TREATMENT BY LEVODOPA TO THE NEUROPHARMACOLOGY OF AKINESIA.
203494 02-15

AKINESIA: A POORLY RECOGNIZED DRUG-INDUCED EXTRAPYRAMIDAL BEHAVIORAL DISORDER.
218773 04-15

ALAMON

THE EFFECT OF ALAMON (HYDROXYZINE HYDROCHLORIDE) AND MEDAZEPAM ON NEUROSIS TESTED BY A DOUBLE-BLIND METHOD.
211344 03-10

ALBINO

EFFECTS OF WITHDRAWAL FROM CHRONIC AMPHETAMINE ADMINISTRATION ON ACTIVITY LEVELS OF ALBINO RATS.
195223 01-04

INTRAVENTRICULAR AMPHETAMINE SELF-ADMINISTRATION IN THE ALBINO RAT. (PH.D. DISSERTATION).
211899 03-04

CENTRAL NERVOUS SYSTEM PHARMACOLOGY OF CHOLINERGICALLY ELICITED EATING AND DRINKING BEHAVIOR IN THE ALBINO RAT. (PH.D. DISSERTATION).
222638 04-04

ALBUMIN

CHARACTERIZATION OF THE BINDING OF BENZODIAZEPINES TO HUMAN SERUM ALBUMIN.
193278 01-01

INTERACTIONS OF BENZODIAZEPINES WITH HUMAN SERUM ALBUMIN: CIRCULAR DICHROISM STUDIES.
194148 01-01

BINDING OF D-OXAZEPAM AND L-OXAZEPAM HEMISUCCINATE TO BOVINE SERUM ALBUMIN.
200033 02-03

BENZODIAZEPINES: SPECIFIC COMPETITORS FOR THE BINDING OF L-TRYPTOPHAN TO HUMAN SERUM ALBUMIN.
217686 04-01

ALCOHOL

FAILURE OF DIPHENYLHYDANTOIN TO PREVENT ALCOHOL WITHDRAWAL CONVULSIONS IN MICE.
193454 01-03

ALTERATIONS IN THE TURNOVER OF BRAIN NOREPINEPHRINE AND DOPAMINE IN ALCOHOL DEPENDENT RATS.
196805 01-03

ALCOHOL WITHDRAWAL REACTIONS AND RESERPINE EFFECTS IN INBRED STRAINS OF MICE.
197821 01-03

THE BIOCHEMICAL PHARMACOLOGY OF ABUSED DRUGS. II. ALCOHOL AND BARBITURATES.
200007 02-14

EFFECTS OF ALCOHOL, UNCERTAINTY AND NOVELTY UPON RESPONSE SELECTION.
200048 02-14

EFFECT OF TWO WEEKS TREATMENT WITH CHLORIMIPRAMINE AND NORTRIPTYLINE, ALONE OR IN COMBINATION WITH ALCOHOL, ON LEARNING AND MEMORY.
200057 02-14

EEG VARIATIONS UNDER ANTABUSE (DISULFIRAM) AND ANTABUSE PLUS ALCOHOL EXPOSITION: A STUDY OF PATHOGENESIS FROM ANTABUSE THERAPY COMPLICATIONS.
200572 02-15

THE PENTOBARBITAL TEST DOSE FOR DEPRESSANT DRUG DEPENDENCE: A REEVALUATION IN TERMS OF ALCOHOL CONSUMPTION.
202883 02-17

EFFECT OF COMBINED ALCOHOL AND PROPOXYPHENE ON HUMAN PERFORMANCE.
210871 03-14

EFFECTS OF CHLORDIAZEPOXIDE ON SCHEDULE INDUCED WATER AND ALCOHOL CONSUMPTION IN THE SQUIRREL MONKEY.
214013 04-04

EFFECT OF TRICYCLIC ANTIDEPRESSANTS AND ALCOHOL ON PSYCHOMOTOR SKILLS RELATED TO DRIVING.
215667 04-14

ON THE INFLUENCE OF APROTINIUM (TRASYLOL) IN THE TREATMENT OF ALCOHOL DELIRIUM.
215698 04-11

DIETARY TRYPTOPHAN AND THE SELECTION OF ETHYL ALCOHOL IN DIFFERENT STRAINS OF RATS.
217520 04-03

THE EFFECT OF ALCOHOL AND BARBITURATE ON THE FREQUENCY OF ATRIAL AND VENTRICULAR PREMATURE BEATS DURING SLEEP.
218971 04-13

CROSS-TOLERANCE BETWEEN MORPHINE AND ALCOHOL. (PH.D. DISSERTATION).
223737 04-04

ALCOHOL AND MARIJUANA: COMPARATIVE PSYCHOPHARMACOLOGY.
224753 04-14

MARIJUANA, ALCOHOL AND INTERPERSONAL PERCEPTIONS.
224755 04-14

ALCOHOL-INDUCED

EFFECT OF DELTA8-THC ON ALCOHOL-INDUCED SLEEPING TIME IN THE RAT.
200041 02-03

THE EFFECT OF SEROTONINERGIC AND ADRENERGIC PREPARATIONS UPON ALCOHOL-INDUCED EXCITATION IN MICE.
201915 02-04

ALCOHOLIC

STUDIES ON ANTIDIURETIC ACTIVITIES AND ON PORTER-SILBERS CHROMOGENS CONTENT IN PLASMA OF PATIENTS WITH ALCOHOLIC DELIRIUM OR WITH ACUTE PHENOTHIAZINE INTOXICATIONS.
203741 02-15

ALCOHOLICS

A DOUBLE-BLIND CROSSOVER COMPARISON BETWEEN CLOTHIAPINE AND DIAZEPAM IN THE TREATMENT OF MENTAL SYMPTOMS IN CHRONIC ALCOHOLICS.
192988 01-11

ALCOHOLISM

EVALUATION OF LITHIUM THERAPY IN CHRONIC AND PERIODIC ALCOHOLISM.
194758 01-11

PEYOTE IN THE TREATMENT OF ALCOHOLISM AMONG AMERICAN-INDIANS.
213702 04-12

ALCOHOLISM AND INCISIVE NEUROLEPTICS.
219836 04-14

ALCOHOLS

EFFECT OF ALCOHOLS, CHLORPROMAZINE AND DIPHENYLHYDANTOIN ON (CA2+) ATPASE OF HUMAN RED BLOOD CELLS.
197976 01-13

ALERT

DIPROPYLACETIC ACID (DEPAKINE) IN EXPERIMENTAL EPILEPSY IN THE ALERT CAT.
225529 04-02

ALERTONIC

PSYCHOPHARMACOLOGIC INVESTIGATIONS IN HEALTHY ELDERLY VOLUNTEERS: EFFECTS OF PIPRADROL - VITAMIN (ALERTONIC) ELIXIR AND PLACEBO IN RELATION TO RESEARCH DESIGN.
218217 04-11

ALIMENTARY

COMPARISON OF THE EFFECTS OF ATROPINE AND CANNABIS UPON THE FIXED CONDITIONED ALIMENTARY MOTOR REFLEXES IN CATS AFFECTED BY NICOTINE.
205623 03-14

ALKALOIDS

PHARMACOKINETICS IN THE RAT OF THE HALLUCINOGENIC ALKALOIDS HARMINE AND HARMALINE.
202796 02-03

MENTAL DECLINE IN THE ELDERLY: PHARMACOTHERAPY (ERGOT ALKALOIDS VERSUS PAPAVERINE).
218306 04-11

ALKYLATE

THE INFLUENCE OF ALKYLATE PHERPACET DERIVATIVES ON NEURON POPULATIONS IN THE MIDBRAIN RETICULAR FORMATION.
219501 04-03

ALL-NIGHT

ALL-NIGHT POLYGRAPHIC RECORDINGS ON THE HYPNOTIC EFFECTS OF A NEW BENZODIAZEPINE: FLUNITRAZEPAM (RO-5-4200, ROHYPNOL).
202272 02-11

THE EFFECTS OF MEDAZEPAM (S-804) ON ALL-NIGHT SLEEP.
211361 03-14

INFLUENCE OF RESERPINE ON ALL-NIGHT SLEEP PATTERN IN NONLOBOTOMIZED AND LOBOTOMIZED CHRONIC SCHIZOPHRENIC PATIENTS.
213530 04-08

ALLERGIC

ALLERGIC CONJUNCTIVITIS DUE TO DIAZEPAM.
225338 04-15

ALLEVIATIVE

URBAN ECOLOGICAL AND HOUSEHOLD CORRELATES OF STRESS ALLEVIATIVE DRUG USE.
223949 04-17

ALLOFERIN

BLOCKADE BY ESERINE OF THE CEREBRAL CORTICAL EFFECTS OF ALLOFERIN: A FURTHER EVIDENCE OF CHOLINERGIC INHIBITORY MECHANISM.
195548 01-03

ALLOPURINOL

A CROSSOVER STUDY OF ALLOPURINOL ADMINISTRATION TO A SCHIZOPHRENIC CHILD.
207788 03-08

ALPHA

ACTION OF (S)- AND (R) P-SUBSTITUTED AMPHETAMINE HYDROCHLORIDES AND (ALPHA S)- AND (ALPHA R) P-CHLORONOREPHEDRINE AND (ALPHA S)- AND (ALPHA R) P-CHLORONORPSEUDOEPHEDRINE HYDROCHLORIDES ON THE LEVEL OF 5-HYDROXYTRYPTAMINE AND THE ACTIVITY OF TRYPTOPHAN-HYDROXYLASE IN RAT BRAIN.
202417 02-03

THE ROLE OF 5-HYDROXYTRYPTAMINE IN THE CONTROL OF ALPHA AND GAMMA MOTONEURONS. (PH.D. DISSERTATION).
212522 03-03

ALPHA-ADRENERGIC

CENTRAL NERVOUS SYSTEM ALPHA-ADRENERGIC RECEPTORS AND THE MODE OF ACTION OF ALPHA-METHYLDOPA.
195237 01-03

ADENOSINE-3-5-MONOPHOSPHATE IN CEREBRAL CORTICAL SLICES FROM GUINEA-PIG AND RAT: EFFECT OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC COMPOUNDS.
197293 01-03

PHARMACOLOGIC STUDIES ON PROPYNYL DIBENZAZEPINE, A NEW ALPHA-ADRENERGIC BLOCKER.
197493 01-03

EFFECTS OF ALPHA-ADRENERGIC BLOCKERS ON VISUAL EVOKED RESPONSES IN RABBITS.
200064 02-03

INHIBITION OF BOTH NORADRENERGIC AND SEROTONERGIC NEURONS IN BRAIN BY THE ALPHA-ADRENERGIC AGONIST CLONIDINE.
221131 04-03

ALPHA-ADRENOCEPTOR

PRESYNAPTIC AND POSTSYNAPTIC COMPONENTS IN EFFECT OF DRUGS WITH ALPHA-ADRENOCEPTOR AFFINITY.
214062 04-03

INFLUENCE OF RESERPINE ON THE POTENCY OF ALPHA-ADRENOCEPTOR BLOCKING AGENTS.
221860 04-03

ALPHA-ADRENOCEPTORS

BETA-ADRENOCEPTORS AND/OR ALPHA-ADRENOCEPTORS IN THE VENTRICULAR MUSCLE OF THE RABBIT
197943 01-03

ALPHA-FLUPENTHIXOL

PROLONGED NEUROLEPTIC EFFECT OF ALPHA-FLUPENTHIXOL DECANOATE IN OIL.
210893 03-03

ALPHA-METHYL-P-TYROSINE

A CONDITIONED TASTE AVERSION INDUCED BY ALPHA-METHYL-P-TYROSINE.
195090 01-04

INHIBITION OF SCOPOLAMINE INDUCED STIMULATION OF Y-MAZE ACTIVITY BY ALPHA-METHYL-P-TYROSINE AND BY LITHIUM.
199866 02-04

OPIOID REINFORCED OPERANT BEHAVIOR: SELECTIVE SUPPRESSION BY ALPHA-METHYL-P-TYROSINE.
211511 03-04

EFFECTS OF SCOPOLAMINE AND ALPHA-METHYL-P-TYROSINE UPON PREDATORY ATTACK IN CATS.
217526 04-04

THE EFFECT OF ALPHA-METHYL-P-TYROSINE METHYLESTER ON TEMPORAL SUMMATION IN THE NEURAL SUBSTRATE FOR THE REINFORCEMENT EFFECT IN SELF-STIMULATION. (PH.D. DISSERTATION).
222090 04-04

ALPHA-METHYLDOPA
CENTRAL NERVOUS SYSTEM ALPHA-ADRENERGIC RECEPTORS AND THE MODE OF ACTION OF ALPHA-METHYLDOPA.
195237 01-03
STUDIES ON ALPHA-METHYLDOPA: RELATIONSHIP BETWEEN METABOLISM, BIOGENIC AMINES AND ANTIHYPERTENSIVE EFFECT.
197298 01-03
THE EFFECTS OF EARLY ALPHA-METHYLDOPA TREATMENT ON BEHAVIOUR IN THE RAT.
197578 01-04
REVERSAL OF RESERPINE INDUCED BRADYKINESIA BY ALPHA-METHYLDOPA -- NEW LIGHT ON ITS MODUS-OPERANDI.
202281 02-03
EFFECT OF ALPHA-METHYLDOPA ON DOPAMINE SYNTHESIS AND RELEASE IN RAT STRIATUM IN VITRO.
215690 04-03
EFFECTS OF ALPHA-METHYLDOPA ON NEWBORN KITTEN SLEEP. BEHAVIORAL EVOLUTION DURING THE FIRST MONTH AFTERBIRTH.
221049 04-04

ALPHA-METHYLTRYPTOPHAN
ALPHA-METHYLTRYPTOPHAN: EFFECTS ON CEREBRAL MONOOXYGENASES IN VITRO AND IN VIVO.
210819 03-03

ALPHA-METHYLTYROSINE
EFFECTS OF L-DOPA ON CONDITIONED AVOIDANCE RESPONDING AFTER BEHAVIOURAL SUPPRESSION BY ALPHA-METHYLTYROSINE OR RESERPINE IN MICE.
197987 01-04
THE INFLUENCE OF ALPHA-METHYLTYROSINE AND DISULFIRAM ON THE INHIBITORY FUNCTION OF THE CAUDATE NUCLEUS AND CATECHOLAMINE CONTENT IN THE BRAIN OF CATS.
200565 02-03
THE EFFECT OF INHIBITORS OF CATECHOLAMINE SYNTHESIS (ALPHA-METHYLTYROSINE AND DISULFIRAM) ON THE BACKGROUND ACTIVITY OF SENSORIMOTOR CORTEX NEURONS AND THEIR RESPONSES TO AFFERENT CAUDATE AND RETICULAR STIMULATION.
202598 02-04
THE EFFECTS OF THYROTROPIN-RELEASING HORMONE ON THE BEHAVIOUR OF RATS PRETREATED WITH ALPHA-METHYLTYROSINE.
222815 04-04

ALPHA-METHYLTYROSINE-INDUCED
EFFECTS OF LOW AND HIGH DOSES OF L-DOPA ON THE TETRABENAZINE OR ALPHA-METHYLTYROSINE-INDUCED SUPPRESSION OF BEHAVIOUR IN A SUCCESSIVE DISCRIMINATION TASK.
200042 02-04
BLOCKADE OF ALPHA-METHYLTYROSINE-INDUCED SUPERSENSITIVITY TO APOMORPHINE BY CHRONIC ADMINISTRATION OF L-DOPA.
220974 04-03

ALPHA-NORADRENERGIC
NEUROCHEMICAL REGULATION OF FEEDING IN THE RAT: FACILITATION BY ALPHA-NORADRENERGIC, BUT NOT DOPAMINERGIC RECEPTOR STIMULANTS.
211538 03-04

ALPHA-RECEPTOR
ALPHA-RECEPTOR MEDIATED MODULATION OF TRANSMITTER RELEASE FROM CENTRAL NORADRENERGIC NEURONES.
202805 02-03
INHIBITORY ACTION OF NOREPINEPHRINE ON THE INDUCTION OF TRYPTOPHAN 2,3 DIOXYGENASE BY CORTISOL: MEDIATION BY THE ALPHA-RECEPTOR.
221051 04-03

ALPRENOLOL
ABSORPTION, DISTRIBUTION AND EXCRETION OF ALPRENOLOL IN MAN, DOG, AND RAT.
199621 02-13

ALTERATION
SYMPATHETIC NERVE ACTIVITY AFTER NORADRENALINE DEPLETION AND ITS ALTERATION BY CLONIDINE.
197947 01-03
ALTERATION OF THE EFFECTS AND THE METABOLISM OF D-AMPHETAMINE BY ETHANOL.
197975 01-03
THE ALTERATION OF AVERSIVE THRESHOLDS AFTER CHRONIC ADMINISTRATION OF TWO TRANQUILIZING AGENTS.
205418 02-04
ALTERATION OF PSYCHOSOMATIC REACTIVITY AFTER A SINGLE THERAPEUTIC DOSE OF PENTOBARBITAL IN RELATION TO THE SEX OF PROBANDS.
205627 03-14

ALTERATIONS
ALTERATIONS BY ANESTHETIC AGENTS OF THE RESPONSES OF RAT STRIATAL NEURONS TO IONTOPHORETICALLY APPLIED AMPHETAMINE, ACETYLCHOLINE, NORADRENALINE, AND DOPAMINE.
193803 01-03
ALTERATIONS IN THE TURNOVER OF BRAIN NOREPINEPHRINE AND DOPAMINE IN ALCOHOL DEPENDENT RATS.
196805 01-03
ALTERATIONS IN ACID-BASE BALANCE IN THE DOG AFTER INTRAVENOUS ADMINISTRATION OF BENZOCTAMINE AND DIAZEPAM, COMPARED WITH THOSE INDUCED BY THIOPENTAL.
197485 01-03
ALTERATIONS OF BARBITURATE ACTION FOLLOWING 1,1 DICHLOROETHYLENE, CORTICOSTERONE, OR ACROLEIN.
197488 01-03
DOSE-DEPENDENCE OF CHLORPHENTERMINE-INDUCED ULTRASTRUCTURAL ALTERATIONS IN RAT.
197960 01-03
AGGRESSIVE BEHAVIORS INDUCED BY CHRONIC ADMINISTRATION OF THEOPHYLLINE, WITH PARTICULAR REFERENCE TO ALTERATIONS IN BEHAVIORS OF IMMATURE RATS.
200748 02-04
LIPIDOSIS LIKE ALTERATIONS IN SPINAL CORD AND CEREBELLAR CORTEX OF RATS TREATED WITH CHLORPHENTERMINE OR TRICYCLIC ANTIDEPRESSANTS.
202767 02-03
MATURATION OF THE ADRENAL MEDULLA -- III: PRACTICAL AND THEORETICAL CONSIDERATIONS OF AGE DEPENDENT ALTERATIONS IN KINETICS OF INCORPORATION OF CATECHOLAMINES AND NONCATECHOLAMINES.
205852 03-03
ALTERATIONS IN BEHAVIOUR AND CATECHOLAMINE BIOSYNTHESIS INDUCED BY LITHIUM.
214067 04-04
PSYCHOTROPIC DRUGS AND OVARIAN CYCLE ALTERATIONS.
217204 04-13
AN APPLICATION OF LONG-TERM FREQUENCY ANALYSIS IN MEASURING DRUG SPECIFIC ALTERATIONS IN THE EEG OF THE CAT.
218190 04-03
NEUROTRANSMITTER ALTERATIONS AND CHRONIC PAIN.
224800 04-13

ALTERED
EFFECTS OF DRUG ALTERED SEROTONIN LEVELS ON THE ACQUISITION OF A SHUTTLEBOX AVOIDANCE TASK. (PH.D. DISSERTATION).
211781 03-04

ALTERING
INEFFECTIVENESS OF LYSERGIC ACID DIETHYL AMIDE 25 (LSD) ON ALTERING NA-K CURRENTS IN SQUID GIANT AXON.
194927 01-03
EXPERIENCING AND ALTERING STATES OF INTOXICATION: AN INFORMATION PROCESSING VIEW OF THE HIGH.
224756 04-14

ALTERNATION
ONTOGENETIC ASPECTS OF CENTRAL CHOLINERGIC INVOLVEMENT IN SPONTANEOUS ALTERNATION BEHAVIOR.
199550 02-04
SPONTANEOUS ALTERNATION IN FERRETS FOLLOWING TREATMENT WITH SCOPOLAMINE, CHLORDIAZEPOXIDE, AND CAFFEINE.
223039 04-04

ALTERNATIVE
A BEHAVIORAL EDUCATIONAL ALTERNATIVE TO DRUG CONTROL OF HYPERACTIVE CHILDREN.
225455 04-14
CASE PRESENTATION OF AN ALTERNATIVE THERAPEUTIC APPROACH FOR THE BORDERLINE PSYCHOTIC HEROIN ADDICT: DIPHENYLHYDANTOIN.
225512 04-09

ALTITUDE
EFFECT OF SIMULATED ALTITUDE ON THE DISPOSITION OF CHLORPROMAZINE IN MOUSE BRAIN AND LIVER.
197455 01-05
THE EFFECT OF DIAZEPAM ON THE BEHAVIOR OF RATS ADAPTED TO HIGH ALTITUDE HYPOXIA IN CONFLICTING SITUATIONS.
219502 04-04

AMANTADINE
DEPRESSION BY AMANTADINE OF TREMOR INDUCED BY RESERPINE AND OXOTREMORINE IN THE RAT.
193282 01-04
STUDIES ON THE EFFECT OF AMANTADINE ON NEURONAL MEMBRANES.
197283 01-03
AMANTADINE AND D-145, AN AMANTADINE DERIVATIVE, DO NOT EFFECT DOPAMINE SENSITIVE ADENYLATE-CYCLASE FROM THE CAUDATE PUTAMEN OF THE RAT BRAIN.
199867 02-03
THE INTERACTION OF DOPAMINE ANTAGONISTS AND AMANTADINE HYDROCHLORIDE ON THE ACQUISITION OF THE CONDITIONED AVOIDANCE RESPONSE IN RATS.
199959 02-04
A DOUBLE-BLIND STUDY OF AMANTADINE HYDROCHLORIDE VERSUS BENZTROPINE MESYLATE IN DRUG-INDUCED PARKINSONISM.
202764 02-15
LACK OF EFFECT OF AMANTADINE ON D-AMPHETAMINE INDUCED RELEASE OF DOPAMINE FROM CAT BRAIN IN VIVO.
204865 02-02
RESPONSES OF CENTRAL NEURONES TO AMANTADINE: COMPARISON WITH DOPAMINE AND AMPHETAMINE.
213398 04-03

VISUAL HALLUCINATIONS AND DELIRIUM DURING TREATMENT WITH AMANTADINE (SYMMETREL).
215858 04-11

THE EFFECT OF AMANTADINE ON THE TURNOVER OF CATECHOLAMINES IN THE RAT BRAIN.
217961 04-03

BLOCKADE OF THE CENTRAL EFFECTS OF D-AMPHETAMINE BY AMANTADINE II.
221737 04-03

AMBULATORY

SULPIRIDE IN AMBULATORY TREATMENT OF CHRONIC PSYCHOTICS.
209533 03-14

CLINICAL STUDY OF AN NEW ANTIDEPRESSANT, MELITRACEN, FOR 50 AMBULATORY PATIENTS.
212490 03-10

AMENORRHEA

AMENORRHEA IN ENDOGENOUS DEPRESSION.
195040 01-09

AMENORRHEA AND BEHAVIORAL DISTURBANCES: CLINICAL CASE TREATED WITH A PSYCHOTHERAPEUTIC METHOD BASED ON ELEMENTS OF THE CYBERNETIC THEORY OF G. CIPOLLINA MANGIAMELI.
210418 03-14

AMERICAN

THE DIPHENYLBUTYLPIPERIDINES: FIRST NORTH AMERICAN SYMPOSIUM, 1972.
207052 03-17

AMERICAN-INDIANS

PEYOTE IN THE TREATMENT OF ALCOHOLISM AMONG AMERICAN-INDIANS.
213702 04-12

AMIDE

INEFFECTIVENESS OF LYSERGIC ACID DIETHYL AMIDE 25 (LSD) ON ALTERING NA-K CURRENTS IN SQUID GIANT AXON.
194927 01-03

AMINAZINE

THE NEURON ULTRASTRUCTURE IN SOME BRAIN AREAS DURING A LONG-TERM ADMINISTRATION OF AMINAZINE AND STELAZINE.
200021 02-03

COMPARATIVE RESULTS OF A PHARMACOLOGICAL LOADING WITH AMINAZINE AND HALOPERIDOL IN SCHIZOPHRENIC PATIENTS.
201910 02-08

AMINE

SUBTYPE OF AFFECTIVE PSYCHOSES CLASSIFIED BY RESPONSE ON AMINE PRECURSORS AND MONOAMINE METABOLISM.
197209 01-09

COMPARISON OF THE SPECIFICITY OF 3-(P-TRIFLUOROMETHYLPHENOXY)-N-METHYL-3 PHENYLPROPYLAMINE AND CHLORIMIPRAMINE AS AMINE UPTAKE INHIBITORS IN MICE.
197870 01-03

EFFECTS OF AMINOACETONITRILE, AN AMINE OXIDASE INHIBITOR, ON MESCALINE METABOLISM IN THE RABBIT.
205853 03-03

THEORETICAL IMPLICATIONS OF DRUG-INDUCED ADAPTIVE REGULATION FOR A BIOGENIC AMINE HYPOTHESIS OF AFFECTIVE DISORDER.
206335 03-03

AMINE PRECURSORS AND DEPRESSION.
207444 03-13

AFFECTIVE DISORDER: STUDIES WITH AMINE PRECURSORS.
207681 03-09

A STUDY OF ELECTROLYTE AND BIOGENIC AMINE METABOLISM IN MANIC-DEPRESSIVE ILLNESS.
208917 03-09

BIOCHEMICAL PHARMACOLOGY OF BRAIN AMINE MECHANISMS.
213603 04-03

EXTRAPYRAMIDAL REACTIONS AND AMINE METABOLITES IN CEREBROSPINAL FLUID DURING HALOPERIDOL AND CLOZAPINE TREATMENT OF SCHIZOPHRENIC PATIENTS.
214010 04-15

MASS FRAGMENTOGRAPHY OF PICOMOLE QUANTITIES OF BIOGENIC AMINE METABOLITES IN HUMAN CEREBROSPINAL FLUID AS WELL AS WHOLE RAT BRAINS. (UNPUBLISHED PAPER).
217219 04-06

LOSS OF BODY WEIGHT AS A PREDICTOR OF RESERPINE INDUCED AMINE DEPLETION.
217661 04-03

EFFECT OF BENZODIAZEPINE COMPOUNDS ON BRAIN AMINE METABOLISM.
217664 04-03

CHLORPROMAZINE METABOLISM IV: QUATERNIZATION AS A KEY TO DETERMINATION OF PICOMOLES OF CHLORPROMAZINE AND OTHER TERTIARY AMINE DRUGS.
217667 04-06

PHARMACOLOGICAL ACTION OF FD-008, A NEW DOPAMINE-BETA-HYDROXYLASE INHIBITOR: III. EFFECTS ON ENDOGENOUS BIOGENIC AMINE LEVELS IN RATS.
221859 04-03

AMINERGIC

CORRELATED HISTOCHEMICAL, ELECTRON MICROSCOPICAL, PHARMACOLOGICAL AND PHYSIOLOGICAL OBSERVATION ON AMINERGIC MECHANISMS IN THE CENTRAL NERVOUS SYSTEM. (UNPUBLISHED PAPER).
218300 04-03

EFFECTS OF AMINERGIC DRUGS AND GLUTAMIC ACID ON AUDIOGENIC SEIZURES INDUCED BY EARLY EXPOSURE TO ETHANOL.
225527 04-03

AMINES

BIOGENIC AMINES IN A RETRANSPLANTABLE NEUROGENIC TERATOCARCINOMA.
192925 01-03

EFFECT OF ACUTE AND CHRONIC DIELDRIN EXPOSURE ON BRAIN BIOGENIC AMINES OF MALE AND FEMALE RATS.
193428 01-03

SOME STUDIES OF ADRENERGIC AMINES: PART I. ROLE OF THE AROMATIC RING IN RECEPTOR BINDING. PART II. BETA ADRENERGIC BLOCKADE. (PH.D. DISSERTATION).
194564 01-01

TIME-DEPENDENT, MEMORY RETRIEVAL EFFECTS FOLLOWING PERIPHERAL AND HIPPOCAMPAL TREATMENTS TO INCREASE SYNAPTIC BIOGENIC AMINES. (PH.D. DISSERTATION).
194677 01-04

CHANGES IN BRAIN CONCENTRATION OF BIOGENIC AMINES AND THE ANTINOCICEPTIVE EFFECT OF MORPHINE IN RATS.
195246 01-03

SEIZURES OF CHOREOATHETIC TYPE INDUCED BY SUDDEN MOVEMENT: CORRELATION TO THE BIOGENIC AMINES.
196146 01-14

STUDIES ON ALPHA-METHYLDOPA: RELATIONSHIP BETWEEN METABOLISM, BIOGENIC AMINES AND ANTIHYPERTENSIVE EFFECT.
197298 01-03

THE EFFECTS OF PARENTERAL ADMINISTRATION OF CATECHOLAMINES, SEROTONIN AND HISTAMINE ON BEHAVIOR AND LEVELS OF THESE AMINES IN THE BRAIN OF THE NEONATE CHICK.
197457 01-03

THE ACTION OF PSYCHOSTIMULANT SIDNOKARB ON METABOLISM OF BIOGENIC AMINES IN THE BRAIN.
197573 01-03

CORRELATION OF THE RELEASE OF AMINES AND ANTAGONISTS WITH THEIR EFFECTS.
197829 01-03

INFLUENCE OF MAO INHIBITORS ON THE INTESTINAL ABSORPTION OF BIOGENIC AMINES.
197948 01-03

TURNOVER OF BIOGENIC AMINES AFTER ACUTE AND CHRONIC MORPHINE TREATMENT IN RATS.
197974 01-03

STUDIES ON PSYCHOTROPIC DRUGS: XVII. EFFECTS OF 3-CHLORO-5-(3-(4 PIPERIDINO-4-CARBAMOYL-PIPERIDINO)PROPYL) 10,11-DIHYDRO-5(H) DIBENZAZEPINE DIHYDROCHLORIDE MONOHYDRATE (Y-4153) ON THE METABOLISM OF BIOGENIC AMINES.
199210 02-03

N-ACETYLTRANSFERASE OF BRAIN: POSSIBLE INVOLVEMENT IN THE METABOLISM OF THE BIOGENIC AMINES. (UNPUBLISHED PAPER).
199347 02-03

SYMPATHOMIMETIC AMINES AND GASTRIC SECRETION IN RATS.
199622 02-03

THE IMPORTANCE OF NEURONAL UPTAKE OF AMINES FOR AMPHETAMINE-INDUCED RELEASE OF 3H-NOREPINEPHRINE FROM ISOLATED BRAIN TISSUE.
202191 02-03

ANALYSIS OF PSYCHOACTIVE PHENOLIC AMINES.
202381 02-01

ROLE OF THE BIOGENIC AMINES IN THE REVERSAL OF CYCLOHEXIMIDE INDUCED AMNESIA.
206752 03-04

THE INFLUENCE OF INTRAPERITONEAL INJECTION OF IPRAZIDE AND TRANSAMINE ON THE DISTRIBUTION OF BIOGENIC AMINES IN CORTICAL AND SUBCORTICAL WHITE MATTER OF THE RAT BRAIN.
209032 03-03

CYCLIC-AMP IN CEREBROSPINAL FLUID: ACCUMULATION FOLLOWING PROBENECID AND BIOGENIC AMINES.
210193 03-17

AMINES AND DISORDERS OF THE CENTRAL NERVOUS SYSTEM.
210635 03-09

THE EFFECT OF TWO SYNTHETIC ACTH ANALOGUES ON THE METABOLISM OF BIOGENIC AMINES IN THE RAT BRAIN.
210875 03-03

ON THE PARTICIPATION OF BIOGENIC AMINES AND THEIR SYNTHETIC ENZYMES IN THE MECHANISMS OF IMAGE MEMORY.
213469 04-04

PSYCHOPHARMACOLOGY OF BIOGENIC AMINES IN DEPRESSIONS.
213628 04-09

MECHANISMS OF STORAGE AND RELEASE OF AMINES.
213632 04-03

RELATIONSHIP OF BIOGENIC AMINES TO BEHAVIOR.
217218 04-04

EFFECTS OF CLOZAPINE, THIORIDAZINE, PERLAPINE AND HALOPERIDOL ON THE METABOLISM OF THE BIOGENIC AMINES IN THE BRAIN OF THE RAT.
217543 04-03

INTERACTIONS OF IMIPRAMINE AND SYNTHESIS INHIBITORS ON BIOGENIC AMINES.
217827 04-03

EXAMINATION OF THE ROLE OF BRAIN AMINES AND CYCLIC-AMP IN BENZODIAZEPINE INDUCED SUPPRESSION OF AGGRESSION. (PH.D. DISSERTATION).
219278 04-04

POSSIBLE ROLE OF ADENOSINE-3-5-MONOPHOSPHATE AND BIOGENIC AMINES IN MORPHINE AND COCAINE TREATED RATS. (PH.D. DISSERTATION).
220475 04-03

NONRIGID AMINES AND AMINO ACIDS RELATED TO APOMORPHINE. (PH.D. DISSERTATION).
222634 04-01

AMINO

INTERACTION OF CATECHOLAMINE AND AMINO ACID METABOLISM IN BRAIN: EFFECT OF PARGYLINE AND L-DOPA.
195048 01-03

A DUAL STUDY. PART I: SYNTHESIS AND STEREOCHEMISTRY OF SOME 1 SUBSTITUTED QUINOLIZIDINES AS ANALOGS OF BIOLOGICALLY ACTIVE COMPOUNDS. PART II: AMINO DERIVATIVES OF THIOPHENE FUSED CYCLIC KETONES AS POTENTIAL CNS. (PH.D. DISSERTATION).
196252 01-01

EFFECTS OF PSYCHOTROPIC DRUGS ON THE INCORPORATION OF GLUCOSE-14C INTO AMINO ACIDS OF THE RAT BRAIN.
198026 01-03

EFFECT OF NEUROTROPIC AGENTS ON TOTAL PYRIDOXAL PHOSPHATE AND ON THE ACTIVITY OF THE DECARBOXYLASE OF AROMATIC AMINO ACIDS AS WELL AS OF OTHER PYRIDOXAL PHOSPHATE DEPENDENT ENZYMES IN RAT BRAIN.
199785 02-03

UPTAKE AND RELEASE OF POSSIBLE FALSE TRANSMITTER AMINO ACIDS BY RAT BRAIN TISSUE.
199788 02-03

THE INFLUENCE OF CATECHOLAMINES, SEROTONIN, AND SOME AMINO ACIDS ADMINISTERED INTO THE AMYGDALOID COMPLEX ON CONDITIONED REFLEXES OF AVOIDANCE AND MOTOR ACTIVITY IN RATS.
200566 02-03

THE REGULATION OF CYCLIC GUANOSINE MONOPHOSPHATE IN RAT CEREBELLUM: POSSIBLE INVOLVEMENT OF PUTATIVE AMINO ACID NEUROTRANSMITTERS.
202717 02-03

EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON FREE AMINO ACIDS IN BRAIN.
205625 03-03

CORRELATIONS BETWEEN CIRCADIAN CHANGES IN SERUM AMINO ACIDS OR BRAIN TRYPTOPHAN AND THE CONTENTS OF SEROTONIN AND 5-HYDROXYINDOLEACETIC ACID IN REGIONS OF THE RAT BRAIN.
210673 03-03

NERVE IMPULSE ENHANCED RELEASE OF AMINO ACIDS FROM NONSYNAPTIC REGIONS OF PERIPHERAL AND CENTRAL NERVE TRUNKS OF BULLFROG.
213277 03-03

RESPONSES OF CULTURED CEREBELLAR NEURONS TO IONTOPHORETICALLY APPLIED AMINO ACIDS.
213279 03-03

AMINO ACID UPTAKE IN VIVO BY THE MOUSE BRAIN AND BY VARIOUS REGIONS OF THE RABBIT BRAIN AFTER DRUG-INDUCED CONVULSIONS.
217858 04-03

NONRIGID AMINES AND AMINO ACIDS RELATED TO APOMORPHINE. (PH.D. DISSERTATION).
222634 04-01

AMINOACETONITRILE

EFFECTS OF AMINOACETONITRILE, AN AMINE OXIDASE INHIBITOR, ON MESCALINE METABOLISM IN THE RABBIT.
205853 03-03

AMINOACYL-TRNA

MESCALINE-INDUCED CHANGES OF BRAIN-CORTEX RIBOSOMES: EFFECT OF MESCALINE ON TRNA AND AMINOACYL-TRNA SYNTHETASE.
195242 01-03

AMINOOXYACETIC

EFFECT OF AMINOOXYACETIC ACID ON THE METABOLISM OF PENTOBARBITAL IN MICE.
200002 02-03

AMINOPHYLLINE

POTENTIATION OF JUMPING BEHAVIOR BY AMINOPHYLLINE IN MICE TREATED WITH THRESHOLD DOSES OF AMPHETAMINE AND DOPA.
200039 02-04

AMINOPROPAN-1-OL

PHARMACOLOGICAL EVALUATION OF 3-(N 3,3 DIPHENYLPROPYL-N-METHYL) AMINOPROPAN-1-OL HYDROCHLORIDE (PF-82), A NEW TYPE OF ANTIDEPRESSANT DRUG.
221287 04-02

AMINOPYRINE-N-DEMETHYLATION

THE EFFECT OF BETA-THIAMINOKETONES ON THE AMINOPYRINE-N-DEMETHYLATION IN VITRO AND IN VIVA SUCH AS THE HEXOBARBITAL SLEEPING TIME AND L-ASCORBIC ACID EXCRETION IN THE RAT.
197469 01-03

AMITRIPTYLINE

A MULTINATIONAL, DOUBLE-BLIND TRIAL WITH A NEW ANTIDEPRESSANT MAPROTILINE (LUDIOMIL) AND AMITRIPTYLINE.
197031 01-09

A CONTROLLED OUTPATIENT TRIAL OF PERPHENAZINE AMITRIPTYLINE AND CHLORPROMAZINE.
199517 02-14

A DOUBLE-BLIND COMPARISON OF CLOMIPRAMINE WITH AMITRIPTYLINE IN DEPRESSION.
202178 02-10

STEADY-STATE PLASMA CONCENTRATIONS DURING SINGLE AND MULTIPLE DOSAGE SCHEDULES OF AMITRIPTYLINE.
202699 02-13

REVERSAL OF AMITRIPTYLINE INTOXICATION BY PHYSOSTIGMINE.
202922 02-15

EFFECT OF AMITRIPTYLINE IN LONG-TERM AUTOEXPERIMENTS: PSYCHOPHYSIOLOGIC STUDY AND DURATION OF EXCRETION.
204402 02-13

CARDIOTOXIC EFFECTS OF TRICYCLIC ANTIDEPRESSANTS IMIPRAMINE, AMITRIPTYLINE AND DOSULEPIN (PROTHIADEN-SPOFA) IN AN ACUTE EXPERIMENT IN RATS.
205597 02-15

ANTIDEPRESSANT RESPONSE TO TRICYCLICS AND URINARY MHPG IN UNIPOLAR PATIENTS: CLINICAL RESPONSE TO IMIPRAMINE OR AMITRIPTYLINE.
207443 03-13

SIDE-EFFECTS OF IMIPRAMINE AND AMITRIPTYLINE.
207519 03-15

AMITRIPTYLINE AND DEPRESSIVE STRUCTURES (ON 100 OBSERVATIONS).
207579 03-14

RAPIDITY OF SYMPTOM REDUCTION IN DEPRESSIONS TREATED WITH AMITRIPTYLINE.
209437 03-09

RELATIVE SAFETY OF AMITRIPTYLINE IN MAINTENANCE TREATMENT OF DEPRESSION.
209438 03-15

PLASMA LEVELS OF A NEW PELLETIZED FORM OF AMITRIPTYLINE FOR MAINTENANCE THERAPY.
209789 03-13

EXPERIMENTATION WITH THE INTRAVENOUS FORM OF AMITRIPTYLINE WITH 40 PATIENTS.
210128 03-09

EFFECTS OF AMITRIPTYLINE ON HUMAN REM SLEEP AS EVALUATED BY USING PARTIAL DIFFERENTIAL REM SLEEP DEPRIVATION (PDRD).
214750 04-14

A COMPARISON BETWEEN MAPROTILINE (LUDIOMIL) AND AMITRIPTYLINE IN THE TREATMENT OF DEPRESSIVE REACTION IN GENERAL PRACTICE.
215058 04-14

THE INFLUENCE OF DESIPRAMINE AND AMITRIPTYLINE ON THE ACCUMULATION OF (3H)NORADRENALINE AND ITS TWO MAJOR METABOLITES FORMED FROM (3H)TYROSINE IN THE RAT BRAIN.
217966 04-03

EFFECTS OF MAINTENANCE AMITRIPTYLINE AND PSYCHOTHERAPY ON SYMPTOMS OF DEPRESSION.
218041 04-09

A SINGLE DAILY DOSE OF A SUSTAINED RELEASE FORM OF AMITRIPTYLINE IN DEPRESSIVE ILLNESS.
219961 04-09

NOXIPTILIN (AGEDAL) – A NEW TRICYCLIC ANTIDEPRESSANT WITH A FASTER ONSET OF ACTION? A DOUBLE-BLIND, MULTICENTRE COMPARISON WITH AMITRIPTYLINE.
221306 04-09

AMITRIPTYLINE TREATMENT OF PATIENTS WITH MIGRAINE.
221561 04-11

DOUBLE-BLIND COMPARISON OF MAPROTILINE (LUDIOMIL) WITH AMITRIPTYLINE IN THE TREATMENT OF DEPRESSIVE ILLNESS.
221652 04-09

A DOUBLE-BLIND COMPARATIVE CLINICAL TRIAL OF MAPROTILINE (LUDIOMIL) AND AMITRIPTYLINE.
221653 04-09

A DOUBLE-BLIND GENERAL PRACTICE TRIAL OF MAPROTILINE (LUDIOMIL) AGAINST AMITRIPTYLINE IN THE TREATMENT OF REACTIVE DEPRESSION.
221658 04-09

AN INTERIM REPORT OF A DOUBLE-BLIND STUDY COMPARING A ONCE DAILY DOSAGE OF MAPROTILINE (LUDIOMIL) WITH AMITRIPTYLINE THRICE DAILY.
221661 04-09

A COMPARISON BETWEEN DAILY AND NIGHTLY DOSE REGIMEN OF AMITRIPTYLINE AND MAPROTILINE (LUDIOMIL) IN THE TREATMENT OF REACTIVE DEPRESSION IN GENERAL PRACTICE.
221662 04-09

THE EFFECT OF AMITRIPTYLINE, DESIPRAMINE AND IMIPRAMINE ON THE IN VIVO BRAIN SYNTHESIS OF 3H-NORADRENALINE FROM 3H-L-DOPA IN THE RAT.
225565 04-03

AMITRIPTYLINE-INDUCED
STUDY ON AMITRIPTYLINE-INDUCED SLEEP IN EPILEPTIC PATIENTS.
205470 02-13

AMIZYL
THE EFFECT OF NEUROTROPIC AGENTS ON MOTOR HYPERACTIVITY IN DOGS INDUCED BY AMIZYL.
223062 04-04

AMMONIUM
EEG SEIZURES PRODUCED BY INTRAVENTRICULAR QUATERNARY AMMONIUM COMPOUNDS IN THE RAT.
197475 01-03

AMNESIA
PHARMACOLOGICAL INFLUENCES ON CARBON DIOXIDE INDUCED AMNESIA.
197497 01-03
PENTYLENETETRAZOL INDUCED RETROGRADE AMNESIA AND BRAIN SEIZURES IN MICE.
202724 02-04
THE EFFECT OF ACTH AND AMPHETAMINE ON ECS PRODUCED AMNESIA. (PH.D. DISSERTATION).
204733 02-04
ROLE OF THE BIOGENIC AMINES IN THE REVERSAL OF CYCLOHEXIMIDE INDUCED AMNESIA.
206752 03-04

AMNESIC
TYROSINE-HYDROXYLASE INHIBITION BY CYCLOHEXIMIDE AND ANISOMYCIN IS NOT RESPONSIBLE FOR THEIR AMNESIC EFFECT.
203572 02-04
AMNESIC EFFECT OF CYCLOHEXIMIDE IN THE MOUSE MEDIATED BY ADRENOCORTICAL HORMONES.
206751 03-04
INHIBITORS OF CEREBRAL PROTEIN SYNTHESIS: DISSOCIATION OF AVERSIVE AND AMNESIC EFFECTS.
221005 04-04

AMOBARBITAL
ANTIANESTHETIC EFFECTS OF CYCLIC-AMP AND ANALEPTIC DRUGS AS DETERMINED BY REVERSAL OF AMOBARBITAL INDUCED NARCOSIS.
193426 01-03
THE EFFECTS OF SODIUM AMOBARBITAL ON ODOR-BASED RESPONDING IN RATS.
195995 01-04
METHODS OF DECONDITIONING PERSISTING AVOIDANCE: AMPHETAMINE AND AMOBARBITAL AS ADJUNCTS TO RESPONSE PREVENTION.
209897 03-04
DIFFERENTIAL EFFECTS OF CHLORPROMAZINE, IMIPRAMINE, NITRAZEPAM AND AMOBARBITAL ON REM SLEEP AND REM DENSITY IN MAN.
215955 04-14
SCHEDULE INDUCED AGGRESSION IN LABORATORY RATS: DEMONSTRATION AND CONTROL THROUGH SODIUM AMOBARBITAL. (PH.D. DISSERTATION).
220644 04-04
THE PARTIAL PUNISHMENT EFFECT FOLLOWING MINIMAL ACQUISITION TRAINING: SODIUM AMOBARBITAL AND THE STIMULUS PROPERTIES OF EARLY PUNISHED TRIALS.
224504 04-04

AMOXAPINE
AMOXAPINE, IMIPRAMINE AND PLACEBO IN DEPRESSIVE ILLNESS.
225063 04-09

AMP
MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 2. COMMUNICATION: PSYCHOPATHOLOGICAL COURSE PROFILE AND SOMATIC CHARACTERISTICS (STUDIES WITH THE AMP SYSTEM).
203840 02-14

AMP-PHOSPHODIESTERASE
THE INFLUENCE OF ETHYMISOL ON THE ACTIVITY OF ADENYLCYCLASE AND 3,5 AMP-PHOSPHODIESTERASE OF RATS BRAINS.
208973 03-03

AMPHETAMINE
FENFLURAMINE: AMPHETAMINE CONGENER THAT FAILS TO MAINTAIN DRUG-TAKING BEHAVIOR IN THE RHESUS MONKEY.
193137 01-04
PHENOTHIAZINE TRANQUILIZER PD-50S EXERTED AGAINST AMPHETAMINE EFFECT IN AGGREGATED MICE.
193422 01-03
AN EFFECT OF AMPHETAMINE ON MOUSE BRAIN POLYRIBOSOMES.
193423 01-03
AN EFFECT OF AMPHETAMINE ON INCORPORATION OF LEUCINE INTO MOUSE BRAIN PROTEIN.
193424 01-03
ROLE OF MONOAMINES IN THE ANOREXIGENIC ACTIONS OF FENFLURAMINE, AMPHETAMINE AND P-CHLOROMETHAMPHETAMINE.
193546 01-04
ALTERATIONS BY ANESTHETIC AGENTS OF THE RESPONSES OF RAT STRIATAL NEURONS TO IONTOPHORETICALLY APPLIED AMPHETAMINE, ACETYLCHOLINE, NORADRENALINE, AND DOPAMINE.
193803 01-03
TOLERANCE DEVELOPMENT TO THE ANTINOCICEPTIVE ACTIONS OF MORPHINE, AMPHETAMINE, PHYSOSTIGMINE AND 2-AMINOINDANE IN THE MOUSE.
194930 01-03
REDUCTION OF STIMULUS BOUND FOOD CONSUMPTION IN THE RAT FOLLOWING AMPHETAMINE ADMINISTRATION.
195081 01-04
THE LIPOLYTIC ACTIVITY OF AMPHETAMINE IN THE SPINALISED CAT.
195118 01-03
EFFECTS OF WITHDRAWAL FROM CHRONIC AMPHETAMINE ADMINISTRATION ON ACTIVITY LEVELS OF ALBINO RATS.
195223 01-04
AMPHETAMINE DERIVATIVES: 10(E)- AND 10(A)-AMINO-1,2,3,4,4A,9,10,10A-(TRANS-4A,10A) OCTAHYDROPHENANTHRENE.
195561 01-01
SOME AMPHETAMINE EFFECTS ON REM SLEEP.
195923 01-14
ANTAGONISM OF ACUTE AMPHETAMINE INTOXICATION BY HALOPERIDOL AND PROPRANOLOL.
196106 01-05
THE ROLE OF BRAIN CATECHOLAMINES IN THE ANORECTIC RESPONSE TO AMPHETAMINE. (PH.D. DISSERTATION).
196370 01-04
THE INCORPORATION OF GLUCOSE INTO BRAIN GLYCOGEN AND THE ACTIVITIES OF CEREBRAL GLYCOGEN PHOSPHORYLASE AND SYNTHETASE: SOME EFFECTS OF AMPHETAMINE.
196808 01-03
ON THE BIOTRANSFORMATION OF AMPHETAMINE IN ADULT AND OLD RATS.
197292 01-03
NEUROCHEMICAL BASES FOR THE ANORECTIC ACTIVITIES OF AMPHETAMINE AND FENFLURAMINE.
197301 01-03
THE EFFECTS OF AMPHETAMINE AND A RELATED COMPOUND ON MAO.
197302 01-03
THE DISPOSITION KINETICS OF AMPHETAMINE IN THE RUMINANT ANIMAL.
197456 01-03
ONTOGENY OF STEREOTYPED BEHAVIOUR INDUCED BY APOMORPHINE AND AMPHETAMINE IN THE RAT.
197462 01-04
THE EFFECTS OF AMPHETAMINE AND COCAINE ON THE RESPONSE OF THE ISOLATED GUINEA-PIG VAS-DEFERENS TO NORADRENALINE, TYRAMINE AND NERVE STIMULATION.
197463 01-03
ENHANCED LOCOMOTOR ACTIVITY FOLLOWING AMPHETAMINE IN MOUSE-KILLING RATS.
197482 01-04
INHIBITORY EFFECT OF AMPHETAMINE, L-DOPA AND APOMORPHINE ON MORPHINE-INDUCED BEHAVIOURAL EXCITATION OF RATS.
197483 01-04
THE EFFECTS OF LSD, PSILOCYBIN, HARMALINE AND AMPHETAMINE ON THE BODY TEMPERATURE OF P-CHLOROPHENYLALANINE PRETREATED RATS.
197484 01-03
PHARMACOLOGICAL STUDIES ON TETRABENAZINE-INDUCED EXCITED BEHAVIOUR OF RATS PRETREATED WITH AMPHETAMINE OR NIALAMIDE.
197490 01-04
A COMPARISON OF THE EFFECTS OF (+) AMPHETAMINE, COCAINE AND DENERVATION ON THE RESPONSES OF THE ISOLATED VAS-DEFERENS OF THE GUINEA-PIG TO NOREPINEPHRINE AND ACETYLCHOLINE.
197495 01-03
A STUDY OF THE INTERACTION BETWEEN AMPHETAMINE AND FOOD DEPRIVATION.
197854 01-04
RATING THE BEHAVIORAL EFFECTS OF AMPHETAMINE.
197863 01-04
CENTRAL ACTION OF ANOREXIC AGENTS: EFFECTS OF AMPHETAMINE AND FENFLURAMINE IN RATS WITH LATERAL HYPOTHALAMIC LESIONS.
197865 01-04
DOSE-DEPENDENT DIFFERENCES OF AMPHETAMINE LEVELS IN BRAIN AND HEART OF ADULT AND DEVELOPING MICE.
197927 01-03
A COMPARATIVE STUDY OF AMPHETAMINE, EPHEDRINE ATROPINE MIXTURE, PLACEBO AND BEHAVIORAL CONDITIONING IN THE TREATMENT OF NOCTURNAL ENURESIS.
198020 01-11
DISTRIBUTION OF AMPHETAMINE AND ITS HYDROXYLATED METABOLITES IN VARIOUS AREAS OF THE RAT BRAIN.
198211 02-03
COMPARATIVE EFFECT OF PHENAMINE (AMPHETAMINE) AND CAFFEINE ON THE BACKGROUND ACTIVITY OF CORTICAL SENSORIMOTOR

NEURONS AND THEIR REACTIONS DURING STIMULATION OF THE CAUDATE NUCLEUS.
198835 02-03

SLEEP AMPHETAMINE EFFECTS IN MBDS AND NORMAL SUBJECTS.
199640 02-11

DUAL MECHANISM OF AMPHETAMINE TOXICITY IN MICE: RELATIONSHIP TO BRAIN CATECHOLAMINES.
199898 02-05

EFFECTS OF NIKETHAMIDE, PICROTOXIN AND STRYCHNINE ON AMPHETAMINE STATE.
199967 02-03

POTENTIATION OF JUMPING BEHAVIOR BY AMINOPHYLLINE IN MICE TREATED WITH THRESHOLD DOSES OF AMPHETAMINE AND DOPA.
200039 02-04

AMPHETAMINE, L-DOPA AND APOMORPHINE: EFFECTS ON ACTIVITY OF RAT DOPAMINERGIC NEURONS.
202370 02-03

ACTION OF (S)- AND (R) P-SUBSTITUTED AMPHETAMINE HYDROCHLORIDES AND (ALPHA S)- AND (ALPHA R) P-CHLORONOREPHEDRINE AND (ALPHA S)- AND (ALPHA R) P-CHLORONORPSEUDOEPHEDRINE HYDROCHLORIDES ON THE LEVEL OF 5-HYDROXYTRYPTAMINE AND THE ACTIVITY OF TRYPTOPHAN-HYDROXYLASE IN RAT BRAIN.
202417 02-03

INHIBITION OF AMPHETAMINE TOLERANCE AND METABOLISM BY PROPRANOLOL.
202662 02-03

EFFECTS ON THE ACQUISITION OF CONDITIONED AVOIDANCE RESPONSES AND SEIZURE THRESHOLD IN THE OFFSPRING OF AMPHETAMINE TREATED GRAVID RATS.
202722 02-05

APOMORPHINE AND AMPHETAMINE STEREOTYPY AFTER 6-HYDROXYDOPAMINE LESIONS OF THE SUBSTANTIA-NIGRA.
202793 02-04

CHRONIC AMPHETAMINE TREATMENT: VAST INDIVIDUAL DIFFERENCES IN PERFORMING A LEARNED RESPONSE.
202794 02-04

METHODS OF DECONDITIONING PERSISTING AVOIDANCE: AMPHETAMINE, CHLORPROMAZINE, AND CHLORDIAZEPOXIDE AS ADJUNCTS TO RESPONSE PREVENTION.
202987 02-04

EFFECTS OF AMPHETAMINE AND AND CHLORPROMAZINE UPON OBSERVING RESPONSES IN RATS. (PH.D. DISSERTATION).
203166 02-04

REPORT OF A HUMAN FATALITY DUE TO AMPHETAMINE.
204195 02-15

THE EFFECT OF ACTH AND AMPHETAMINE ON ECS PRODUCED AMNESIA. (PH.D. DISSERTATION).
204733 02-04

CANNABINOID INDUCED CHANGES IN MOUSE STRIATAL HOMOVANILLIC ACID AND DIHYDROXYPHENYLACETIC ACID: THE EFFECTS OF AMPHETAMINE AND L-DOPA.
204866 02-03

HYDROXYLATION OF AMPHETAMINE TO P-HYDROXYAMPHETAMINE BY RAT LIVER MICROSOMES.
205433 02-03

CENTRAL CHOLINERGIC INFLUENCE ON SELF-ADMINISTRATION OF MORPHINE AND AMPHETAMINE.
205889 03-04

SCOPOLAMINE AND AMPHETAMINE EFFECTS ON DISCRIMINATION.
206109 03-04

DIFFERENTIAL EFFECTS OF AMPHETAMINE AND FOOD DEPRIVATION ON SELF-STIMULATION OF THE LATERAL HYPOTHALAMUS AND MEDIAL FRONTAL CORTEX.
206733 03-04

NEOCORTICAL AND HIPPOCAMPAL ACTIVATION IN RELATION TO BEHAVIOR: EFFECTS OF ATROPINE, ESERINE, PHENOTHIAZINES, AND AMPHETAMINE.
206742 03-04

TIME-DEPENDENT CHANGES IN AMPHETAMINE SELF-ADMINISTRATION FOLLOWING FRONTAL CORTEX ABLATIONS IN RATS.
206747 03-04

AMPHETAMINE PSYCHOSIS: BEHAVIORAL AND BIOCHEMICAL ASPECTS.
207285 03-14

A MASS FRAGMENTOGRAPHIC STUDY OF AMPHETAMINE AND METABOLITES IN RAT BRAIN.
207289 03-06

NEW DEVELOPMENTS IN THE STUDY OF THE MECHANISM OF ACTION OF NEUROLEPTICS AND AMPHETAMINE.
207296 03-03

THE PHARMACOLOGICAL AND ANATOMICAL SUBSTRATES OF THE AMPHETAMINE RESPONSE IN THE RAT.
207794 03-04

A CONTRIBUTION TO THE STUDY OF CHRONIC AMPHETAMINE PSYCHOSIS.
208970 03-15

METHODS OF DECONDITIONING PERSISTING AVOIDANCE: AMPHETAMINE AND AMOBARBITAL AS ADJUNCTS TO RESPONSE PREVENTION.
209897 03-04

RECOVERY OF FUNCTION AND CHANGES IN SENSITIVITY TO AMPHETAMINE FOLLOWING CAUDATE LESIONS IN RATS.
209962 03-03

EFFECT OF LITHIUM AND OTHER DRUGS ON THE AMPHETAMINE CHLORDIAZEPOXIDE HYPERACTIVITY IN MICE.
210349 03-04

AMPHETAMINE: POSSIBLE SITE AND MODE OF ACTION FOR PRODUCING ANOREXIA IN THE RAT.
210675 03-03

COMPARISON BETWEEN BEHAVIOURS ELICITED BY HIGH DOSES OF AMPHETAMINE AND FENFLURAMINE: IMPLICATIONS FOR THE CONCEPT OF STEREOTYPY.
210742 03-04

THE EFFECT OF 5-HYDROXYTRYPTOPHAN ON FOOD INTAKE AND ON THE ANOREXIC ACTION OF AMPHETAMINE AND FENFLURAMINE.
210748 03-04

THE ROLE OF P-HYDROXYLATION OF AMPHETAMINE IN ITS PERIPHERAL MODE OF ACTION.
210749 03-03

THE EFFECTS OF AMPHETAMINE ISOMERS ON NEUROMUSCULAR TRANSMISSION.
210765 03-03

AMPHETAMINE TREATMENT OF PARANOID OBSESSIONS: CASE REPORT AND BIOCHEMICAL IMPLICATIONS.
210809 03-09

EVIDENCE FOR REVERSIBLE INHIBITION OF BRAIN DOPAMINE-BETA-HYDROXYLASE ACTIVITY IN VIVO BY AMPHETAMINE ANALOGUES.
210821 03-03

EFFECTS OF AMPHETAMINE AND ITS HYDROXYLATED DERIVATIVES ON NEWLY SYNTHESIZED HYPOTHALAMIC NOREPINEPHRINE; STUDY IN VITRO.
210884 03-03

THE EFFECT OF LSD, PSILOCYBIN, HARMALINE AND AMPHETAMINE ON THE BODY TEMPERATURE OF P-CHLOROPHENYLALANINE PRETREATED RABBITS.
210920 03-05

EFFECTS OF RIGID AMPHETAMINE ANALOGS ON VASCULAR STRIPS: STUDIES OF 2-AMINOTETRAHYDRONAPHTHALENE AND 2-AMINOINDAN DERIVATIVES.
210921 03-03

NARCOTIC WITHDRAWAL LIKE MOUSE JUMPING PRODUCED BY AMPHETAMINE AND L-DOPA.
210931 03-04

DIFFERENTIAL EFFECTS OF THE OPTICAL ISOMERS OF AMPHETAMINE ON NEURONAL ACTIVITY IN THE RETICULAR FORMATION AND CAUDATE NUCLEUS OF THE RAT.
211063 03-03

THE EFFECTS OF (+) AMPHETAMINE ON THE CHRONOTROPIC RESPONSES OF THE ISOLATED GUINEA-PIG PACEMAKER TO NOREPINEPHRINE AND ISOPROTERENOL.
211066 03-03

THE EFFECT OF CERTAIN TRANQUILISERS, CHLORPROMAZINE METABOLITES AND DIETHYLDITHIOCARBAMATE ON TISSUE AMPHETAMINE LEVELS IN THE RAT.
211111 03-03

BEHAVIORAL AND NEUROCHEMICAL EFFECTS OF MORPHINE OR AMPHETAMINE AFTER CHRONIC PRETREATMENT WITH CATECHOLAMINE DEPLETING AGENTS. (PH.D. DISSERTATION).
211746 03-03

INTRAVENTRICULAR AMPHETAMINE SELF-ADMINISTRATION IN THE ALBINO RAT. (PH.D. DISSERTATION).
211899 03-04

INCREASED LEVEL PRESSING FOR AMPHETAMINE AFTER PIMOZIDE IN RATS: IMPLICATIONS FOR A DOPAMINE THEORY OF REWARD.
213350 03-04

EFFECTS OF AMPHETAMINE ISOMERS AND NEUROLEPTICS ON SELF-STIMULATION FROM THE NUCLEUS-ACCUMBENS AND DORSAL NORADRENERGIC BUNDLE.
213394 04-03

RESPONSES OF CENTRAL NEURONES TO AMANTADINE: COMPARISON WITH DOPAMINE AND AMPHETAMINE.
213398 04-03

IN VIVO INHIBITION OF STRIATAL ACETYLCHOLINE TURNOVER BY L-DOPA, APOMORPHINE AND (+) AMPHETAMINE.
213399 04-03

AMPHETAMINE STEREOTYPY: THE INFLUENCE OF ENVIRONMENTAL FACTORS AND PREPOTENT BEHAVIORAL PATTERNS ON ITS TOPOGRAPHY AND DEVELOPMENT.
213531 04-04

PARTIAL RESTORATION BY AN A NEUROLEPTIC (SPIRAMIDE) OF ITEMS OF GROOMING BEHAVIOUR SUPPRESSED BY AMPHETAMINE.
213590 04-04

THE EFFECTS OF AMPHETAMINE, IMIPRAMINE AND ICI-58834 (VIVALAN), A POTENTIAL ANTIDEPRESSANT, ON UNCONDITIONED BEHAVIOUR IN RATS.
214016 04-04

AMPHETAMINE PSYCHOSIS OR PARANOID SCHIZOPHRENIA?
216965 04-15

INTERRESPONSE TIME CHANGES AS A FUNCTION OF WATER DEPRIVATION AND AMPHETAMINE.
217459 04-04

FACILITATION OF AVOIDANCE LEARNING BY CHLORDIAZEPOXIDE AMPHETAMINE COMBINATIONS IN MICE.
217466 04-04

INFLUENCE OF RESPONSE TOPOGRAPHY ON THE EFFECT OF APOMORPHINE AND AMPHETAMINE ON OPERANT BEHAVIOR OF PIGEONS.
217468 04-04

THE EFFECT OF MICROINJECTIONS OF AMPHETAMINE INTO THE NEOSTRIATUM AND THE NUCLEUS-ACCUMBENS ON SELF-STIMULATION BEHAVIOUR.
217530 04-04

MONONEUROPATHY MULTIPLEX AS A COMPLICATION OF AMPHETAMINE ANGIITIS.
217668 04-15

APPARENT FEEDBACK FROM THE CAUDATE NUCLEUS TO THE SUBSTANTIA-NIGRA FOLLOWING AMPHETAMINE ADMINISTRATION.
217676 04-03

THE ROLE OF CATECHOLAMINES IN THE ACTION OF AMPHETAMINE AND L-DOPA ON CEREBRAL ENERGY METABOLISM.
217677 04-03

ON THE MECHANISM OF THE HYPERTHERMIA INDUCED BY AMPHETAMINE IN THE RAT.
217691 04-03

DIFFERENCES BETWEEN (+)- AND (-) AMPHETAMINE IN EFFECTS ON LOCOMOTOR ACTIVITY AND L-DOPA POTENTIATING ACTION IN MICE.
217835 04-04

BINDING OF (+) AMPHETAMINE AND (-) DELTA1-TETRAHYDROCANNABINOLS AND (-) 7-HYDROXY-DELTA1-TETRAHYDROCANNBINOL TO BLOOD CELLS AND PLASMA PROTEINS IN MAN.
217878 04-13

CORRELATION OF (+) AMPHETAMINE LETHALITY AND HEPATIC METABOLISM.
217880 04-05

EFFECTS OF THE DOPAMINE-BETA-HYDROXYLASE INHIBITOR FLA-63 ON THE KINETICS OF ELIMINATION OF AMPHETAMINE IN THE RAT.
217881 04-03

INTERACTIVE EFFECT OF (PLUS/MINUS) FENFLURAMINE AND (+) AMPHETAMINE ON FEEDING IN RATS.
217883 04-04

EFFECT OF AMPHETAMINE, 3,4 METHYLENEDIOXYAMPHETAMINE, P-METHOXYAMPHETAMINE AND RELATED AMPHETAMINES ON UPTAKE OF METARAMINOL AND EFFLUX OF NORADRENALINE IN ADRENERGIC NERVES OF RABBIT ATRIA.
217889 04-03

THE EFFECT OF 6-HYDROXYDOPAMINE ON THE TOLERANCE DEVELOPMENT TO THE HYPERTHERMIC EFFECT OF (+) AMPHETAMINE IN THE RAT.
217965 04-03

EXPERIMENTAL INVESTIGATION OF A NEW AMPHETAMINE DERIVATIVE.
219709 04-03

THE METABOLISM OF INDIVIDUAL PHOSPHOLIPID FRACTIONS IN THE RAT BRAIN DURING THIOPENTAL SLEEP AND AMPHETAMINE EXCITATION.
219747 04-03

DETERMINANTS OF AMPHETAMINE PRODUCED STEREOTYPED BEHAVIOR IN THE RAT. (PH.D. DISSERTATION).
220687 04-04

EFFECT OF ETHANOL ON TOXICITY AND METABOLISM OF AMPHETAMINE IN THE MOUSE.
220950 04-05

COCAINE, AMPHETAMINE, AND TRICYCLIC ANTIDEPRESSANTS AND SYNAPTIC TRANSMISSION.
221386 04-13

ANALYSIS OF AMPHETAMINES AND OTHER PSYCHOACTIVE DRUGS: A COLORIMETRIC ASSAY OF (S)-(+) AMPHETAMINE IN THE SUBMICROGRAM RANGE. (PH.D. DISSERTATION).
222633 04-01

RAPID MASS SCREENING AND CONFIRMATION OF URINARY AMPHETAMINE AND METHAMPHETAMINE BY GAS CHROMATOGRAPHY.
222829 04-06

COMPARATIVE EFFECTS OF SYDNOCARB AND AMPHETAMINE ON THE BIOELECTRICAL ACTIVITY OF THE BRAIN.
223012 04-03

PREPOTENT BEHAVIORS IN AMPHETAMINE MODEL PSYCHOSIS.
224797 04-14

AMPHETAMINE TOXICITY: BEHAVIORAL AND NEUROPATHOLOGICAL INDEXES.
225165 04-05

AMPHETAMINE-INDUCED

A COMPARISON OF PIMOZIDE AND THIORIDAZINE AS ANTAGONISTS OF AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR IN DOGS.
197470 01-04

THE IMPORTANCE OF NEURONAL UPTAKE OF AMINES FOR AMPHETAMINE-INDUCED RELEASE OF 3H-NOREPINEPHRINE FROM ISOLATED BRAIN TISSUE.
202191 02-03

THE ROLE OF FOREBRAIN DOPAMINE SYSTEMS IN AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR IN THE RAT.
202774 02-04

6-HYDROXYDOPAMINE LESIONS OF OLFACTORY TUBERCLES AND CAUDATE NUCLEI: EFFECT ON AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR IN RATS.
202788 02-04

AMPHETAMINE-INDUCED CHANGES IN STRIATAL DOPAMINE AND ACETYLCHOLINE LEVELS AND RELATIONSHIP TO ROTATION (CIRCLING BEHAVIOR) IN RATS.
205432 02-04

CANNABIS AND AMPHETAMINE-INDUCED STEREOTYPY IN RATS.
210752 03-04

MODIFICATION BY L-DOPA METHYLESTER (H-19-61) OF AMPHETAMINE-INDUCED BRAIN CATECHOLAMINE CHANGES, THERMAL RESPONSES AND TOXICITY IN DEVELOPING MICE.
210891 03-03

THE EFFECT OF DOPAMINE AND NORADRENALINE ANTAGONISTS ON AMPHETAMINE-INDUCED LOCOMOTOR ACTIVITY IN MICE AND RATS.
210894 03-04

EFFECTS OF 6-HYDROXYDOPAMINE AND RESERPINE ON AMPHETAMINE-INDUCED RELEASE OF NOREPINEPHRINE IN RAT CEREBRAL CORTEX.
215691 04-03

EVIDENCE AGAINST THE INVOLVEMENT OF FALSE NEUROTRANSMITTERS IN TOLERANCE TO AMPHETAMINE-INDUCED HYPERTHERMIA IN THE RAT.
217690 04-03

AMPHETAMINE-INDUCED DOPAMINERGIC HYPERSENSITIVITY IN GUINEA-PIGS: IMPLICATIONS IN PSYCHOSIS AND HUMAN MOVEMENT DISORDERS.
218115 04-04

POTENTIATION OF AMPHETAMINE-INDUCED AROUSAL BY FOOD DEPRIVATION: EFFECT OF HYPOTHALAMIC LESIONS.
218498 04-04

AMPHETAMINE-INDUCED INHIBITION OF TYROSINE HYDROXYLATION IN HOMOGENATES OF RAT CORPUS-STRIATUM.
222813 04-03

ASCENDING CATECHOLAMINE PATHWAYS AND AMPHETAMINE-INDUCED LOCOMOTOR ACTIVITY: IMPORTANCE OF DOPAMINE AND APPARENT NONINVOLVEMENT OF NOREPINEPHRINE.
223054 04-03

AMPHETAMINES

AMPHETAMINES AND MALIGNANT LYMPHOMA.
193035 01-17

THE EFFECTS OF P-SUBSTITUTED AMPHETAMINES ON THE TRANSMITTER REGULATION IN RAT BRAIN.
197571 01-03

THE BIOCHEMICAL PHARMACOLOGY OF ABUSED DRUGS: I. AMPHETAMINES, COCAINE, AND LSD.
198028 01-12

EFFECTS OF AMPHETAMINES ON THE METABOLISM OF CATECHOLAMINES IN THE RAT BRAIN.
207288 03-03

CORRELATION OF PSYCHOTOMIMETIC ACTIVITY OF PHENETHYLAMINES AND AMPHETAMINES WITH 1-OCTANOL WATER PARTITION COEFFICIENTS.
208593 03-12

A CRYSTALLOGRAPHIC AND THEORETICAL STUDY OF THE CONFORMATION OF DOET AND ITS SIGNIFICANCE FOR THE HALLUCINOGENIC AMPHETAMINES.
210746 03-01

EFFECT OF AMPHETAMINE, 3,4 METHYLENEDIOXYAMPHETAMINE, P-METHOXYAMPHETAMINE AND RELATED AMPHETAMINES ON UPTAKE OF METARAMINOL AND EFFLUX OF NORADRENALINE IN ADRENERGIC NERVES OF RABBIT ATRIA.
217889 04-03

ANALYSIS OF AMPHETAMINES AND OTHER PSYCHOACTIVE DRUGS: A COLORIMETRIC ASSAY OF (S)-(+) AMPHETAMINE IN THE SUBMICROGRAM RANGE. (PH.D. DISSERTATION).
222633 04-01

RAPID ANALYSIS OF THE CENTRAL NERVOUS SYSTEM STIMULANTS, AMPHETAMINES, VIA GAS CHROMATOGRAPHY MASS SPECTROMETRY: RAPID ACYLATION IN THE PRESENCE OF A MERCURY CATALYST.
222830 04-06

AMPLITUDE

SCHIZOPHRENIA AND EVOKED POTENTIALS: MAXIMUM AMPLITUDE, FREQUENCY OF PEAKS, VARIABILITY, AND PHENOTHIAZINE EFFECTS.
213764 04-08

AMYGDALA

BASIC CONCEPTS OF PSYCHOPHARMACOLOGICAL RESEARCH AS APPLIED TO THE PSYCHOPHARMACOLOGICAL ANALYSIS OF THE AMYGDALA.
200980 02-17

CHEMICAL STIMULATION OF THE AMYGDALA WITH SPECIAL REGARD TO INFLUENCE ON THE HYPOTHALAMUS.
202779 02-04

THE ROLE OF THE AMYGDALA IN THE DEPRESSIVE ACTION OF SEROTONIN AND 5-HYDROXYTRYPTOPHAN ON THE CONDITIONED ACTIVITY OF WHITE RATS.
219328 04-04

AMYGDALOID

POTENTIATION OF AMYGDALOID KINDLING AND METRAZOL-INDUCED SEIZURES BY 6-HYDROXYDOPAMINE IN RATS.
195907 01-03

EFFECTS OF DIAZEPAM AND PHENOBARBITAL ON ELECTRICALLY-INDUCED AMYGDALOID SEIZURES AND SEIZURE DEVELOPMENT.
198612 02-04

THE INFLUENCE OF CATECHOLAMINES, SEROTONIN, AND SOME AMINO ACIDS ADMINISTERED INTO THE AMYGDALOID COMPLEX ON CONDITIONED REFLEXES OF AVOIDANCE AND MOTOR ACTIVITY IN RATS.
200566 02-03

A COMPARISON BETWEEN CAUDATE, AMYGDALOID AND HYPOTHALAMIC SELF-STIMULATION IN SQUIRREL MONKEYS (SAIMIRI-SCIUREUS). (PH.D. DISSERTATION).
214207 04-04

REGIONAL DISTRIBUTION OF TYROSINE-HYDROXYLASE, NOREPINEPHRINE AND DOPAMINE WITHIN THE AMYGDALOID COMPLEX OF THE RAT.
217872 04-03

AMYLOBARBITONE

A DOUBLE-BLIND EVALUATION OF DIAZEPAM AND AMYLOBARBITONE IN ACUTE MYOCARDIAL INFARCTION.
202966 02-13

N-DESMETHYLDIAZEPAM AND AMYLOBARBITONE SODIUM AS HYPNOTICS IN ANXIOUS PATIENTS. PLASMA LEVELS, CLINICAL EFFICACY AND RESIDUAL EFFECTS.
217460 04-10

THE EFFECTS OF A DEXAMPHETAMINE AMYLOBARBITONE SODIUM MIXTURE ON THE REWARD VALUE OF DIFFERENT SENSORY CHANGES.
217476 04-03

ANAFRANIL

EXPERIENCE WITH CHLORIMIPRAMINE (ANAFRANIL) IN PSYCHIATRY.
195533 01-09

CLINICAL ELECTROENCEPHALOGRAPHIC DATA IN DEPRESSED PATIENTS TREATED WITH ANAFRANIL.
209148 03-09

A PILOT STUDY OF ANAFRANIL IN THE TREATMENT OF PHOBIC STATES.
214836 04-10

AN INVESTIGATION INTO THE USE OF ANAFRANIL IN PHOBIC AND OBSESSIONAL DISORDERS.
214837 04-10

A COMPARATIVE STUDY OF CLOMIPRAMINE (ANAFRANIL) CAPSULES AND TABLETS.
215148 04-09

A COMPARISON OF A DIVIDED AND A SINGLE DOSE REGIME OF CLOMIPRAMINE (ANAFRANIL).
215149 04-09

A COMPARISON OF A LOW AND HIGH DOSAGE REGIME OF CLOMIPRAMINE (ANAFRANIL).
215150 04-09

ON-GOING STUDIES OF CLOMIPRAMINE (ANAFRANIL) IN GENERAL PRACTICE.
215151 04-15

COMPARATIVE STUDIES WITH CLOMIPRAMINE (ANAFRANIL) AND CLOMIPRAMINE COMBINATIONS.
215152 04-10

SOME PRACTICAL CONSIDERATIONS IN THE USE OF CLOMIPRAMINE (ANAFRANIL) IN GENERAL PRACTICE.
215153 04-15

CLOMIPRAMINE (ANAFRANIL) IN THE TREATMENT OF OBSESSIONAL STATES: A PSYCHIATRISTS VIEW.
215155 04-10

CLOMIPRAMINE (ANAFRANIL) IN THE TREATMENT OF PHOBIC STATES: A PSYCHIATRISTS VIEW.
215156 04-10

A GENERAL PRACTITIONER TRIAL OF CLOMIPRAMINE (ANAFRANIL) IN OBSESSIONS AND PHOBIAS.
215157 04-10

EXPERIENCES WITH CLOMIPRAMINE (ANAFRANIL) IN THE TREATMENT OF THE PHOBIC ANXIETY STATES IN GENERAL PRACTICE.
215158 04-10

ANALEPTIC

ANTIANESTHETIC EFFECTS OF CYCLIC-AMP AND ANALEPTIC DRUGS AS DETERMINED BY REVERSAL OF AMOBARBITAL INDUCED NARCOSIS.
193426 01-03

ANALGESIA

PENTAZOCINE ANALGESIA AND REGIONAL RAT BRAIN CATECHOLAMINES.
193452 01-03

POTENTIATION OF CATALEPSY INDUCED BY NARCOTIC AGENTS DURING HAFFNERS TEST FOR ANALGESIA.
206358 03-04

A GENETIC ANALYSIS OF THE RESPONSE TO MORPHINE IN MICE: ANALGESIA AND RUNNING.
221042 04-03

A GENETIC ANALYSIS OF MORPHINE-INDUCED RUNNING AND ANALGESIA IN THE MOUSE.
225557 04-04

ANALGESIC

RELATIONSHIP BETWEEN ANALGESIC ACTION OF PETHIDINE AND ITS EFFECT ON THE BRAIN 5-HYDROXYTRYPTAMINE CONCENTRATION IN THE RATS OF DIFFERENT AGE.
196782 01-03

THE EFFECT OF BENZODIAZEPINES ON THE ANALGESIC EFFECT OF MORPHINE AND SODIUM SALICYLATE.
197480 01-03

GENOTYPE DEPENDENT ELECTROENCEPHALOGRAPHIC, BEHAVIORAL AND ANALGESIC CORRELATES OF MORPHINE: AN ANALYSIS IN NORMAL MICE AND IN MICE WITH SEPTAL LESIONS.
203520 02-04

UNEXPECTED COMPLICATIONS BY ANTICHOLINERGICS CONTAINED IN SOPORIFICS AND ANALGESIC DRUGS.
204404 02-15

ANALGESIC EFFECT OF DELTA9-TETRAHYDROCANNABINOL.
209787 03-07

COMPARATIVE ANALGESIC ACTIVITY OF VARIOUS NATURALLY OCCURRING CANNABINOIDS IN MICE AND RATS.
214017 04-04

ANALGESICS

CHANGES IN THE DORSAL ROOT POTENTIAL WITH DIAZEPAM AND WITH THE ANALGESICS ASPIRIN, NITROUS OXIDE, MORPHINE AND MEPERIDINE.
195248 01-03

MILD ANALGESICS EVALUATED WITH THE SUBMAXIMUM EFFORT TOURNIQUET TECHNIQUE. I. THE INFLUENCE OF PSYCHOLOGICAL FACTORS ON THEIR EFFECT.
197861 01-14

MILD ANALGESICS EVALUATED WITH THE SUBMAXIMUM EFFORT TOURNIQUET TECHNIQUE: II. THE INFLUENCE OF A TRANQUILLIZER ON THEIR EFFECT.
197862 01-13

THE INFLUENCE OF ANALGESICS AND NEUROLEPTICS ON AFFECTIVE MANIFESTATIONS OF PAIN.
198480 02-04

INTERACTIONS OF SOME ANALGESICS AND ANTIDEPRESSANTS WITH PHENELZINE OR RESERPINE IN THE MOUSE.
204879 02-05

POSSIBLE INVOLVEMENT OF 5-HYDROXYTRYPTAMINE IN THE ANTIDEPRESSANT ACTIVITY OF NARCOTIC ANALGESICS.
210761 03-03

DOPAMINERGIC DRUGS ANTAGONIZED THE PSYCHOTOMIMETIC EFFECTS OF PARTIAL AGONIST ANALGESICS.
221048 04-04

ANALGETICS

THIETANES AS POTENTIAL MAO INHIBITORS AND ANALGETICS. (PH.D. DISSERTATION).
194563 01-01

EFFECTS OF ANALGETICS ON CENTRALLY INDUCED PAIN IN RATS. (PH.D. DISSERTATION).
222640 04-03

ANALOG

6-CHLORO-2-AMINOTETRALIN, A RIGID CONFORMATIONAL ANALOG OF 4-CHLOROAMPHETAMINE: PHARMACOLOGIC PROPERTIES OF IT AND RELATED COMPOUNDS IN RATS.
210870 03-02

ANALOGS

CHEMICAL PHARMACOLOGY OF THE BENZOTHIOPHENE AND 1-METHYLINDOLE ANALOGS OF N,N-DIMETHYLTRYPTAMINE. (PH.D. DISSERTATION).
193590 01-12

CONFORMATIONALLY CONSTRAINED ANALOGS OF MESCALINE.
195560 01-01

A DUAL STUDY. PART I: SYNTHESIS AND STEREOCHEMISTRY OF SOME 1 SUBSTITUTED QUINOLIZIDINES AS ANALOGS OF BIOLOGICALLY ACTIVE COMPOUNDS. PART II: AMINO DERIVATIVES OF THIOPHENE FUSED CYCLIC KETONES AS POTENTIAL CNS. (PH.D. DISSERTATION).
196252 01-01

POTENTIAL PSYCHOTOMIMETICS. 2. RIGID ANALOGS OF 2,5 DIMETHOXY-4-METHYLPHENYLISOPROPYLAMINE (DOM, STP).
202109 02-02

EFFECTS OF RIGID AMPHETAMINE ANALOGS ON VASCULAR STRIPS: STUDIES OF 2-AMINOTETRAHYDRONAPHTHALENE AND 2-AMINOINDAN DERIVATIVES.
210921 03-03

RELATIONSHIPS BETWEEN THE STRUCTURE AND THE CHRONOTROPIC, LOCOMOTOR STIMULANT AND REINFORCING ACTIONS OF SEVERAL FENFLURAMINE ANALOGS. (PH.D. DISSERTATION).
223563 04-04

ANALOGUE

THE USE OF ANALOGUE SCALES IN RATING SUBJECTIVE FEELINGS.
193851 01-14

BRAIN LEVELS AND RELATIVE POTENCY OF THE 1,2 DIMETHYLHEPTYL ANALOGUE OF DELTA1-TETRAHYDROCANNABINOL IN MICE.
198605 02-01

BIOLOGICAL AND PHARMACOKINETIC EVIDENCE FOR GENERIC EQUIVALENCE OF THREE IMIPRAMINE PREPARATIONS: COMPARISON WITH A NEW IMIPRAMINE ANALOGUE.
211071 03-02

ANALOGUES

EVIDENCE FOR REVERSIBLE INHIBITION OF BRAIN DOPAMINE-BETA-HYDROXYLASE ACTIVITY IN VIVO BY AMPHETAMINE ANALOGUES.
210821 03-03

THE EFFECT OF TWO SYNTHETIC ACTH ANALOGUES ON THE METABOLISM OF BIOGENIC AMINES IN THE RAT BRAIN.
210875 03-03

BEHAVIOURALLY ACTIVE ACTH ANALOGUES.
222820 04-04

ANALYSES

GAS CHROMATOGRAPHIC ANALYSES OF BARBITURATES IN SMALL AMOUNTS OF BLOOD.
197279 01-01

INFLUENCE OF MELATONIN ON EEG AND HUMAN SLEEP: AUTOMATIC EEG ANALYSES AND POLYGRAPHIC NIGHT SLEEP INVESTIGATIONS.
205446 02-13

ANALYSIS

A PHARMACOLOGICAL AND NEUROANATOMICAL ANALYSIS OF DOPAMINERGIC AND NORADRENERGIC PATHWAYS INVOLVED IN SELF-STIMULATION IN RATS. (PH. D. DISSERTATION).
193582 01-04

ANALYSIS OF THE INFLUENCE OF SELECTED NEUROTROPIC AGENTS ON HEPATIC METABOLISM IN RELATION TO ENDOTOXICOSIS.
195448 01-03

PATTERN ANALYSIS OF PSYCHIATRIC RESEARCH DATA.
195940 01-11

ANALYSIS OF CUE USE IN STATE-DEPENDENT LEARNING. (PH.D. DISSERTATION).
196409 01-04

HMO ANALYSIS OF STRUCTURE-ACTIVITY RELATIONS IN SEDATIVE AND HYPNOTIC DRUGS AND ANALYSIS OF POTENTIAL SEDATIVES BY MEANS OF HOMOLOGOUS COMPOUNDS.
199208 02-01

DEPRESSION TREATED WITH CHLORIMIPRAMINE WITH SPECIAL ANALYSIS OF CHANGE IN BLOOD PRESSURE BY INFUSION.
199212 02-09

ANALYSIS OF ACETYLCHOLINESTERASE SYNTHESIS AND TRANSPORT IN THE RAT HIPPOCAMPUS: RECOVERY OF ACETYLCHOLINESTERASE ACTIVITY IN THE SEPTUM AND HIPPOCAMPUS AFTER ADMINISTRATION OF DIISOPROPYLFLUOROPHOSPHATE.
199805 02-03

LONG-TERM TREATMENT OF PSYCHIATRIC PATIENTS WITH CLOPENTHIXOL: ANALYSIS OF LABORATORY TESTS WITH A VIEW TO LONG-TERM THERAPY.
199989 02-14

QUANTITATIVE ANALYSIS OF THE EEG EFFECTS PRODUCED BY IMIPRAMINE, DESIPRAMINE, PROMAZINE, AND MONODESMETHYL PROMAZINE IN THE ISOLATED PERFUSED RAT BRAIN.
200056 02-03

BASIC CONCEPTS OF PSYCHOPHARMACOLOGICAL RESEARCH AS APPLIED TO THE PSYCHOPHARMACOLOGICAL ANALYSIS OF THE AMYGDALA.
200980 02-17

SIDE-EFFECTS OF PSYCHOTROPIC DRUGS -- AN ANALYSIS OF DATA OBTAINED FROM DOUBLE-BLIND COMPARATIVE STUDIES IN JAPAN.
201260 02-15

AN ANALYSIS OF SOME DISCRIMINATIVE PROPERTIES OF D-AMPHETAMINE.
201321 02-04

STUDIES OF CONFLICT INDUCED BEHAVIOR IN THE CAT: BEHAVIOR ANALYSIS AND EFFECTS OF PSYCHOTROPIC DRUGS.
202122 02-04

ANALYSIS OF PSYCHOACTIVE PHENOLIC AMINES.
202381 02-01

AN ANALYSIS OF THE GROSS BEHAVIOURAL CHANGES INDUCED BY TETRAETHYLAMMONIUM AND A COMPARISON WITH OTHER SUBSTANCES AFFECTING THE AUTONOMIC AND CENTRAL NERVOUS SYSTEM AFTER INTRAVENTRICULAR INJECTIONS TO CONSCIOUS CATS.
202781 02-04

GENOTYPE DEPENDENT ELECTROENCEPHALOGRAPHIC, BEHAVIORAL AND ANALGESIC CORRELATES OF MORPHINE: AN ANALYSIS IN NORMAL MICE AND IN MICE WITH SEPTAL LESIONS.
203520 02-04

FACTOR ANALYSIS OF EVOKED POTENTIALS.
204189 02-06

EEG STATISTICAL SPECTRAL ANALYSIS OF SCHIZOPHRENIC PATIENTS.
205448 02-08

EEG AND SCHIZOPHRENIA: EXPERIMENTAL STUDIES, SPECTRAL ANALYSIS AND SEPTAL SPIKES.
205455 02-03

COMPUTER ANALYSIS OF METHADONE EFFECTS ON THE ELECTROENCEPHALOGRAM.
205467 02-03

ANALYSIS OF EYE MOVEMENTS AND BLINKS DURING READING: EFFECTS OF VALIUM.
206360 03-14

CENTRAL CATECHOLAMINE NEURONS, BEHAVIOR AND NEUROLEPTIC DRUGS: AN ANALYSIS TO UNDERSTAND THE INVOLVEMENT OF CATECHOLAMINES IN SCHIZOPHRENIA.
207305 03-03

BRAIN DOPAMINE AND BEHAVIOUR: A CRITICAL ANALYSIS OF THE RELATIONSHIP BETWEEN DOPAMINE ANTAGONISM AND THERAPEUTIC EFFICACY OF NEUROLEPTIC DRUGS.
207306 03-04

AN ANALYSIS OF MONOAMINERGIC MECHANISMS OF THE DORSAL HIPPOCAMPUS WHICH MEDIATE THE CONDITIONED ESCAPE REACTION IN RATS.
208991 03-04

LITHIUM GLUCONATE: SYSTEMATIC AND FACTORIAL ANALYSIS OF 104 OBSERVATIONS OVER 2.5-3 YEARS IN PATIENTS PRESENTING CYCLOTHYMIC OR DYSTHYMIC DISORDERS.
210126 03-09

THE PLACEBO EFFECT: AN INTEGRATED ANALYSIS OF THEORETICAL AND RESEARCH PERSPECTIVES. (PH.D. DISSERTATION).
212593 03-17

THE EFFECT OF COMBINATION OF METHYLPHENIDATE AND DIAZEPAM ON THE EEG AND ITS EVALUATION BY MEANS OF DISCRIMINANT ANALYSIS.
215070 04-13

FACTOR ANALYSIS OF EEG OF HEALTHY SUBJECTS GIVEN NO DRUGS AND A COMBINATION OF DIAZEPAM AND METHYLPHENIDATE.
215071 04-13

A NEUROPHARMACOLOGICAL ANALYSIS OF CHOLINERGIC MECHANISMS OF SELF-STIMULATION REACTIONS.
215497 04-04

AN ANALYSIS OF NEUROCHEMICAL MECHANISMS OF ONE FORM OF INTRASPECIES BEHAVIOR.
215789 04-04

EEG SPECTRAL ANALYSIS FOR THE EVALUATION OF THE CENTRAL EFFECTS OF DELTA6-TETRAHYDROCANNABINOL IN RABBITS.
217467 04-03

PHARMACOLOGICAL ANALYSIS OF A NEW ANOREXIC SUBSTANCE: 5-HYDROXY-5-4-CHLOROPHENYL 2,3 DIHYDRO-5H-IMIDAZOISOINDOLE (MAZINDOL).
217652 04-04

ANALYSIS OF VARIOUS FACTORS INVOLVED IN EEG SYNCHRONIZATION DURING MILK DRINKING IN THE CAT.
217846 04-04

PROBLEMS IN THE ELECTROPHYSIOLOGICAL ANALYSIS OF THE SITE OF ACTION OF BENZODIAZEPINES. (UNPUBLISHED PAPER).
218148 04-03

AN APPLICATION OF LONG-TERM FREQUENCY ANALYSIS IN MEASURING DRUG SPECIFIC ALTERATIONS IN THE EEG OF THE CAT.
218190 04-03

A PHARMACOLOGICAL ANALYSIS OF AGGRESSIVE BEHAVIOR OF MICE INDUCED BY ISOLATION.
218800 04-04

SPECIFICITY OF BENZODIAZEPINE ACTION ON HUMAN SLEEP CONFIRMED. ANOTHER CONTRIBUTION OF AUTOMATIC ANALYSIS OF POLYGRAPH RECORDINGS.
218953 04-14

A BEHAVIORAL ANALYSIS OF HALLUCINOGENIC DRUGS. (PH.D. DISSERTATION).
219181 04-12

A HISTOCHEMICAL ANALYSIS OF THE INFLUENCE OF SOME PSYCHOTROPIC SUBSTANCES ON THE DEHYDROGENASE ACTIVITY OF VARIOUS BRAIN STRUCTURES.
219498 04-03

PSYCHOPHARMACOLOGY IN CHILD PSYCHIATRY: LITERATURE ANALYSIS.
220271 04-11

6-HYDROXYDOPAMINE AND AVOIDANCE: A BEHAVIORAL AND PHARMACOLOGICAL ANALYSIS. (PH.D. DISSERTATION).
220674 04-04

A GENETIC ANALYSIS OF THE RESPONSE TO MORPHINE IN MICE: ANALGESIA AND RUNNING.
221042 04-03

A STATISTICAL ANALYSIS OF THE COMPARATIVE DOUBLE-BLIND STUDY OF THE ACTIVITY OF LOXAPINE AND THIORIDAZINE.
221671 04-11

SPECTRAL ANALYSIS OF HUMAN EEG CHANGES INDUCED BY ETIFOXIN.
221724 04-13

ON THE GAS CHROMATOGRAPHIC ANALYSIS OF BENZODIAZEPINES: SECOND COMMUNICATION: DIAZEPAM AND ITS METABOLITES.
221739 04-06

ANALYSIS OF AMPHETAMINES AND OTHER PSYCHOACTIVE DRUGS: A COLORIMETRIC ASSAY OF (S)-(+) AMPHETAMINE IN THE SUBMICROGRAM RANGE. (PH.D. DISSERTATION).
222633 04-01

RAPID ANALYSIS OF THE CENTRAL NERVOUS SYSTEM STIMULANTS, AMPHETAMINES, VIA GAS CHROMATOGRAPHY MASS SPECTROMETRY: RAPID ACYLATION IN THE PRESENCE OF A MERCURY CATALYST.
222830 04-06

AN EXPERIMENTAL ANALYSIS ON THE EFFECTS OF THE PSYCHOSTIMULATOR SYDNOCARB.
223013 04-04

AN EXPERIMENTAL ANALYSIS OF BEHAVIORAL FACTORS IN DRUG DEPENDENCE.
225156 04-04

DISCRETE TRIAL ANALYSIS OF DRUG ACTION.
225172 04-04

A GENETIC ANALYSIS OF MORPHINE-INDUCED RUNNING AND ANALGESIA IN THE MOUSE.
225557 04-04

ANALYTIC

EEG CHANGES AFTER PSYCHOACTIVE DRUGS (SPECTRAL ANALYTIC STUDY).
205472 02-13

PSYCHOLOGICAL EFFECTS OF DRUGS: A FACTOR ANALYTIC APPROACH.
206377 03-17

ANALYTICAL

DIFFERENTIAL EFFECTS OF NEUROLEPTIC DRUGS IN CHRONIC SCHIZOPHRENICS: A CONFIGURATION ANALYTICAL EVOLUTION.
204415 02-08

ANAS-PLATYRHYNCHOS

SHORT-TERM EFFECTS OF TESTOSTERONE PROPIONATE ON THE BEHAVIOUR OF YOUNG INTACT MALE DOMESTIC DUCKS (ANAS-PLATYRHYNCHOS).
199461 02-04

ANATENSOL

TESTING ANATENSOL DECANOATE, A MAJOR NEUROLEPTIC, AT THE IXELLES GUIDANCE CENTER.
212165 03-09

ANATOMICAL

PHARMACOLOGICAL AND ANATOMICAL DISSOCIATION OF TWO TYPES OF HABITUATION.
195079 01-04

FUNCTIONAL ANATOMICAL STUDIES OF THE RAPHE NUCLEI.
206108 03-03

THE PHARMACOLOGICAL AND ANATOMICAL SUBSTRATES OF THE AMPHETAMINE RESPONSE IN THE RAT.
207794 03-04

ANDROCUR

TREATMENT OF SEXUAL DELINQUENCY WITH ANDROCUR (CYPROTERONE ACETATE).
203496 02-17

ANDROGEN

POSTCASTRATION DECLINE IN BEHAVIOURAL RESPONSIVENESS TO INTRAHYPOTHALAMIC ANDROGEN IN DOVES.
210918 03-03

ANDROGENIC

EFFECT OF STRESS AND DIAZEPAM TREATMENT DURING INFANCY ON THE CORTICOSTERONE REGULATION AND ANDROGENIC ACTIVITY IN ADULT MALE RATS.
210348 03-03

ANEJACULATION

THREE CASES OF ANEJACULATION IN PATIENTS TREATED WITH CLOMIPRAMINE.
210136 03-15

ANEMIC

RIGIDITY IN RATS DUE TO ANEMIC DECEREBRATION AND THE EFFECT OF CHLORPROMAZINE.
202804 02-03

ANESTHESIA

A STUDY OF NEUROPHYSIOLOGICAL MECHANISMS OF GENERAL ANESTHESIA WITH KETAMIN.
198434 02-03

MATURATION OF VISUAL ELECTROCORTICAL RESPONSES IN UNANESTHETIZED KITTENS: EFFECTS OF BARBITURATE ANESTHESIA.
199765 02-03

SUPPRESSION OF MOUSE-KILLING AND APOMORPHINE-INDUCED SOCIAL AGGRESSION IN RATS BY LOCAL ANESTHESIA OF THE MYSTACIAL-VIBRISSAE.
206714 03-04

EFFECTS OF HALOTHANE AND NITROUS OXIDE ANESTHESIA ON 5-HT TURN-OVER IN THE RAT BRAIN.
217655 04-03

ANESTHETIC

ALTERATIONS BY ANESTHETIC AGENTS OF THE RESPONSES OF RAT STRIATAL NEURONS TO IONTOPHORETICALLY APPLIED AMPHETAMINE, ACETYLCHOLINE, NORADRENALINE, AND DOPAMINE.
193803 01-03

EFFECT OF ANESTHETIC DOSAGES OF PENTOBARBITAL ON THE CONTENT AND TURNOVER OF SEROTONIN IN BRAIN AREAS.
217816 04-03

A DIRECT EFFECT OF DIBUTYRYL CYCLIC-AMP ON THE DURATION OF NARCOSIS INDUCED BY SEDATIVE, HYPNOTIC, TRANQUILISER AND ANESTHETIC DRUGS IN THE RAT.
222814 04-04

ANESTHETIZED

THE EFFECT OF (-) DELTA9-TRANS-TETRAHYDROCANNABINOL ON MYOCARDIAL CONTRACTILITY AND VENOUS RETURN IN ANESTHETIZED DOGS.
199964 02-03

CARDIOPULMONARY TOXICITY OF DELTA9-TETRAHYDROCANNABINOL IN THE ANESTHETIZED DOG.
211015 03-05

ANGIITIS

MONONEUROPATHY MULTIPLEX AS A COMPLICATION OF AMPHETAMINE ANGIITIS.
217668 04-15

ANGINA-PECTORIS

EFFECT OF SMOKING MARIHUANA AND OF A HIGH NICOTINE CIGARETTE ON ANGINA-PECTORIS.
215670 04-15

ANGIOTENSIN

EFFECTS OF TRANSMITTER MIMICKERS AT SITES OF ANGIOTENSIN INDUCED DRINKING IN THE CAT.
193434 01-04

EFFECT OF ANGIOTENSIN II ON SEROTONIN ACCUMULATION IN THE RAT BRAIN.
197582 01-03

EFFECT OF SEROTONIN ON WATER INTAKE AND RENIN ANGIOTENSIN SYSTEM IN RATS.
197963 01-03

ANGUISH

INJECTABLE TEMESTA, ANXIETY AND ANGUISH.
212163 03-10

ANHYDRASE

THE ANTICONVULSANT ACTION OF THE CARBONIC ANHYDRASE INHIBITOR METHAZOLAMIDE: POSSIBLE INVOLVEMENT OF A NORADRENERGIC MECHANISM.
197864 01-03

ENHANCEMENT OF THE CHLORPROMAZINE-INDUCED SUPPRESSION OF THE CONDITIONED AVOIDANCE RESPONSE BY CARBONIC ANHYDRASE INHIBITION.
199770 02-03

CENTRAL NERVOUS SYSTEM CARBONIC ANHYDRASE INHIBITORS. (PH.D. DISSERTATION).
203028 02-03

ANHYDROTIC

ANHYDROTIC EFFECT OF BENZODIAZEPINES IN MICE.
195540 01-03

ANIMAL

THE USE OF THE IMMOBILITY REFLEX (ANIMAL HYPNOSIS) AS A POSSIBLE PROCEDURE FOR DETECTING SEDATIVE ACTIVITY.
196066 01-04

THE DISPOSITION KINETICS OF AMPHETAMINE IN THE RUMINANT ANIMAL.
197456 01-03

EVALUATION OF CLINICAL PREDICTION OF ANTIDEPRESSANT ACTIVITY USING VARIOUS ANIMAL TEST MODELS.
198055 01-02

MULTIDIMENSIONAL SCALING TO RELATE ANIMAL PHARMACOLOGY AND CLINICAL SYMPTOMS OF PSYCHOPHARMACOLOGIC AGENTS.
198058 01-02

AN EXTENSION OF MULTIDIMENSIONAL SCALING TO FACILITATE CLINICAL INTERPRETATION OF ANIMAL TEST MODELS.
198059 01-02

THE INFLUENCE OF BENZODIAZEPINE SERIES TRANQUILIZERS ON VARIOUS FORMS OF OPERANT ANIMAL BEHAVIOR.
198482 02-04

WAYS OF DEMONSTRATING AND DIFFERENTIATING CENTRAL NERVOUS EFFECTS OF DRUGS IN ANIMAL EXPERIMENTS.
202944 02-06

THERAPY-RESISTANT DEPRESSIONS: METHODOLOGICAL PROBLEMS. CONTRIBUTIONS TO METHODICAL QUESTIONS AND ANIMAL EXPERIMENTAL ASPECTS.
203591 02-09

AN ANIMAL MODEL OF DEPRESSION.
206339 03-04

MICROAUTORADIOGRAPHIC STUDIES AFTER MEDICATION OF C14-FLUPHENAZINE IN THE ANIMAL EXPERIMENT.
206769 03-03

LONGITUDINAL PROFILES OF THE EFFECTS OF PSYCHOTROPIC DRUGS: RESULTS OF AN ANIMAL STUDY.
206970 03-05

ANIMAL MODES FOR EVALUATING PSYCHOTROPIC DRUGS.
209076 03-17

A STUDY OF AN ANIMAL MODEL OF DEPRESSION BY THE CONDITIONED REFLEX TECHNIQUE.
210853 03-04

SUMMARY OF THE ANIMAL PHARMACOLOGY OF OXAZEPAM.
218150 04-17

AN ANIMAL TEST MODEL FOR EVALUATING DRUGS WITH ANTIMASS PSYCHOTIC ACTIVITY.
221273 04-06

ANIMALS

PRESELECTION OF ANIMALS IN STUDIES OF ANTIANXIETY DRUGS.
197986 01-03

THE USE OF DRUG INTERACTIONS IN ANIMALS FOR SELECTING PSYCHOTROPIC DRUGS.
198057 01-02

THE INFLUENCE OF TYROCALCITONIN ON CONDITIONAL REFLEXES AND THE ELECTRICAL ACTIVITY OF THE BRAIN IN ANIMALS.
198479 02-02

BEHAVIORAL CHANGES INDUCED BY PSYCHOTROPIC SUBSTANCES IN EXPERIMENTAL ANIMALS.
202864 02-04

AZAPERONE, A SEDATIVE NEUROLEPTIC OF THE BUTYROPHENONE SERIES WITH PRONOUNCED ANTIAGGRESSIVE AND ANTISHOCK ACTIVITY IN ANIMALS.
206786 03-04

LONGITUDINAL STUDIES ON THE METABOLITE PATTERN OF PERAZINE AND RELATED PHENOTHIAZINES IN HUMANS AND ANIMALS.
206976 03-13

INFLUENCE OF NEUROLEPTIC SUBSTANCE ON NEUROPHYSIOLOGICAL PARAMETERS IN EXPERIMENTAL ANIMALS.
206998 03-06

EFFECTS OF HYPERBARIC CONDITIONS ON THE RESPONSE OF ANIMALS TO CENTRAL NERVOUS SYSTEM STIMULANTS AND DEPRESSANTS.
210877 03-03

CANNABIS AND AGGRESSION IN ANIMALS.
217828 04-04

A COMPARISON OF THE ACTION OF THE TRICYCLIC ANTIDEPRESSANTS, AZAPHEN AND IMIPRAMINE, ON THE GASTROINTESTINAL TRACT OF TEST ANIMALS.
219505 04-03

REINFORCEMENT SCHEDULES AND EXTRAPOLATIONS TO HUMANS FROM ANIMALS IN BEHAVIORAL PHARMACOLOGY.
225171 04-04

ANIONIC

REACTION OF CATIONIC GROUPS OF CHLORPROMAZINE WITH ANIONIC MACROMOLECULES: COMPLEXES WITH DNA, RNA, HYALURONIC ACID AND HEPARIN.
199897 02-03

ANIONS

THE INFLUENCE OF ANIONS ON THE PHYSICAL PROPERTIES OF BUTYROPHENONE-TYPE MOLECULES. (PH.D. DISSERTATION).
200310 02-01

ANISOMYCIN

COMPARISON OF THE EFFECTS OF ANISOMYCIN ON MEMORY ACROSS SIX STRAINS OF MICE.
202202 02-04

TYROSINE-HYDROXYLASE INHIBITION BY CYCLOHEXIMIDE AND ANISOMYCIN IS NOT RESPONSIBLE FOR THEIR AMNESIC EFFECT.
203572 02-04

ANORECTIC

THE ROLE OF BRAIN CATECHOLAMINES IN THE ANORECTIC RESPONSE TO AMPHETAMINE. (PH.D. DISSERTATION).
196370 01-04

INTERMITTENT TREATMENT WITH ANORECTIC DRUGS.
197137 01-11

NEUROCHEMICAL BASES FOR THE ANORECTIC ACTIVITIES OF AMPHETAMINE AND FENFLURAMINE.
197301 01-03

EFFECTS OF ANORECTIC AGENTS ON BLOOD PRESSURE OF THE DOG.
197464 01-03

EFFECT OF SOME ANORECTIC AGENTS ON THE UPTAKE AND RELEASE OF 5-HYDROXYTRYPTAMINE BY BLOOD PLATELETS OF RATS.
217890 04-03

ANOREXIA

AMPHETAMINE: POSSIBLE SITE AND MODE OF ACTION FOR PRODUCING ANOREXIA IN THE RAT.
210675 03-03

ANOREXIC

CENTRAL ACTION OF ANOREXIC AGENTS: EFFECTS OF AMPHETAMINE AND FENFLURAMINE IN RATS WITH LATERAL HYPOTHALAMIC LESIONS.
197865 01-04

THE EFFECT OF 5-HYDROXYTRYPTOPHAN ON FOOD INTAKE AND ON THE ANOREXIC ACTION OF AMPHETAMINE AND FENFLURAMINE.
210748 03-04

PHARMACOLOGICAL ANALYSIS OF A NEW ANOREXIC SUBSTANCE: 5-HYDROXY-5-4-CHLOROPHENYL 2,3 DIHYDRO-5H-IMIDAZOISOINDOLE (MAZINDOL).
217652 04-04

ANOREXIGENIC

ROLE OF MONOAMINES IN THE ANOREXIGENIC ACTIONS OF FENFLURAMINE, AMPHETAMINE AND P-CHLOROMETHAMPHETAMINE.
193546 01-04

ANTABUSE

EEG VARIATIONS UNDER ANTABUSE (DISULFIRAM) AND ANTABUSE PLUS ALCOHOL EXPOSITION: A STUDY OF PATHOGENESIS FROM ANTABUSE THERAPY COMPLICATIONS.
200572 02-15

DIETHYLDITHIOCARBAMATE (ANTABUSE): DECREASE OF BRAIN HEAVY METAL STAINING PATTERN AND IMPROVED CONSOLIDATION OF SHUTTLEBOX AVOIDANCE IN GOLDFISH.
203521 02-04

ANTAGONISM

ANTAGONISM OF ACUTE AMPHETAMINE INTOXICATION BY HALOPERIDOL AND PROPRANOLOL.
196106 01-05

ACTION OF RESERPINE IN MORPHINE TOLERANT RATS: ABSENCE OF AN ANTAGONISM OF CATECHOLAMINE DEPLETION.
199277 02-03

ANTAGONISM OF MORPHINE BY LONG-ACTING NARCOTIC ANTAGONISTS.
200055 02-04

DOPAMINERGIC NEURONS: DRUG-INDUCED ANTAGONISM OF THE INCREASE IN TYROSINE-HYDROXYLASE ACTIVITY PRODUCED BY CESSATION OF IMPULSE FLOW.
202664 02-03

BRAIN DOPAMINE AND BEHAVIOUR: A CRITICAL ANALYSIS OF THE RELATIONSHIP BETWEEN DOPAMINE ANTAGONISM AND THERAPEUTIC EFFICACY OF NEUROLEPTIC DRUGS.
207306 03-04

ANTAGONISM OF DOPAMINE MEDIATED INHIBITION IN THE NIGROSTRIATAL PATHWAY: A MODE OF ACTION OF SOME CATATONIA INDUCING DRUGS.
210659 03-03

DIAZEPAM AS A DISCRIMINATIVE CUE: ITS ANTAGONISM BY BEMEGRIDE.
210865 03-03

ANTAGONISM OF DEPRESSANT ACTIVITY OF ETHANOL BY DH-524; A COMPARATIVE STUDY WITH BEMEGRIDE, DOXAPRAM AND D-AMPHETAMINE (38640).
213282 03-03

DOPAMINE ANTAGONISM BY THIORIDAZINE IN SCHIZOPHRENIA.
213527 04-08

ANTAGONISM OF NICOTINIC ACID AND OTHER KYNURENINES TO ANTIDEPRESSANTS: ONE OF THE PROBABLE REASONS FOR THE THERAPY-RESISTANCE IN DEPRESSION?.
215074 04-17

ANTAGONISM BY D-AMPHETAMINE OF LEARNING DEFICITS IN RATS INDUCED BY EXPOSURE TO ANTIPSYCHOTIC DRUGS DURING EARLY POSTNATAL LIFE.
217656 04-04

ANTAGONISM OF PSYCHOSTIMULANT 2 PHENYLDIMETHYLTETRAHYDROOXAZINE HYDROCHLORIDE (G-130) TO CENTRAL NERVOUS SYSTEM DEPRESSING DRUGS: MONOAMINEOXIDASE INHIBITORY ACTIVITY AND NOREPINEPHRINE AND SEROTONIN INDUCED CHANGES, COMPARISON WITH DL-AMPHETAMINE.
221267 04-03

ANTAGONISM OF PENTOBARBITAL INDUCED DISCRIMINATION IN THE GERBIL.
225561 04-04

DIFFERENTIAL ANTAGONISM BY THE ANTICHOLINERGIC DEXETIMIDE OF INHIBITORY EFFECTS OF HALOPERIDOL AND FENTANYL ON BRAIN SELF-STIMULATION.
225562 04-03

ANTAGONIST

NEW HOT PLATE TESTS TO QUANTIFY ANTINOCICEPTIVE AND NARCOTIC ANTAGONIST ACTIVITIES.
193446 01-04

INVESTIGATIONS ON THE ACTION AND MECHANISM OF ACTION OF DIPHENYLHYDANTOIN AS AN ANTAGONIST OF TETRABENAZINE AND RESERPINE.
197471 01-03

DOPAMINE AGONIST AND ANTAGONIST ACTIVITIES OF PIRIBEDIL (ET495) AND ITS METABOLITES.
197930 01-04

LSD AS AN AGONIST AND ANTAGONIST AT CENTRAL DOPAMINE RECEPTORS.
204184 02-03

BLOCKADE OF THE STIMULUS PROPERTIES OF MESCALINE BY A SEROTONIN ANTAGONIST.
217650 04-03

ANTAGONISTIC

THE ANTAGONISTIC EFFECTS OF ASPARTIC ACID ON SOME EFFECTS OF MORPHINE ON RATS.
193458 01-03

ANTAGONISTIC EFFECTS OF NEUROLEPTICS AND APOMORPHINE ON SYNAPTOSOMAL TYROSINE-HYDROXYLASE IN VITRO.
198209 02-03

SPECIES DIFFERENCES IN ANTAGONISTIC EFFECT OF MORPHINE AGAINST DEPRESSOR RESPONSE TO DOPAMINE.
202800 02-03

ANTAGONISTS

MOUSE LOCOMOTOR ACTIVITY: EFFECT OF MORPHINE, NARCOTIC ANTAGONISTS, AND THE INTERACTION OF MORPHINE AND NARCOTIC ANTAGONISTS.
194478 01-04

NEGATIVE REINFORCING PROPERTIES OF MORPHINE ANTAGONISTS IN NAIVE RHESUS MONKEYS.
197284 01-04

A COMPARISON OF PIMOZIDE AND THIORIDAZINE AS ANTAGONISTS OF AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR IN DOGS.
197470 01-04

PREVENTION OF SEROTONIN ABORTION BY SEROTONIN ANTAGONISTS IN RATS.
197489 01-03

CORRELATION OF THE RELEASE OF AMINES AND ANTAGONISTS WITH THEIR EFFECTS.
197829 01-03

THE INTERACTION OF DOPAMINE ANTAGONISTS AND AMANTADINE HYDROCHLORIDE ON THE ACQUISITION OF THE CONDITIONED AVOIDANCE RESPONSE IN RATS.
199959 02-04

ANTAGONISM OF MORPHINE BY LONG-ACTING NARCOTIC ANTAGONISTS.
200055 02-04

EFFECTS OF DOPAMINERGIC RECEPTOR AGONISTS AND ANTAGONISTS ON THE ACTIVITY OF THE NEOSTRIATAL CHOLINERGIC SYSTEM.
210669 03-03

THE EFFECT OF DOPAMINE AND NORADRENALINE ANTAGONISTS ON AMPHETAMINE-INDUCED LOCOMOTOR ACTIVITY IN MICE AND RATS.
210894 03-04

CENTRALLY MEDIATED CARDIOVASCULAR EFFECTS OF 5-HYDROXYTRYPTOPHAN IN MAO INHIBITED DOGS: MODIFICATION BY AUTONOMIC ANTAGONISTS.
215757 04-03

EFFECTS OF ANTAGONISTS UPON LOCOMOTOR STIMULATION INDUCED BY INJECTION OF DOPAMINE AND NORADRENALINE INTO THE NUCLEUS-ACCUMBENS OF NIALAMIDE PRETREATED RATS.
217475 04-04

ON THE MECHANISM OF THE DEFENSIVE ACTION OF ACETYLCHOLINE AND SEROTONIN AGAINST THEIR CYTOTOXIC ANTAGONISTS.
219663 04-03

NARCOTIC AGONISTS AND ANTAGONISTS AS MODELS FOR POTENTIAL ANTIDEPRESSANT DRUGS.
222817 04-04

ANTAGONIZE

MONOAMINEOXIDASE INHIBITORS ANTAGONIZE THE ACCELERATION OF BRAIN DOPAMINE SYNTHESIS INDUCED BY NEUROLEPTIC DRUGS IN VIVO: IMPLICATIONS FOR THE TREATMENT OF TARDIVE DYSKINESIA.
220948 04-03

ANTAGONIZED

A NOVEL TREMORIGEN ANTAGONIZED BY D-AMPHETAMINE.
217874 04-03

DOPAMINERGIC DRUGS ANTAGONIZED THE PSYCHOTOMIMETIC EFFECTS OF PARTIAL AGONIST ANALGESICS.
221048 04-04

ANTENATAL

ANTENATAL EXPOSURE TO MEPROBAMATE AND CHLORDIAZEPOXIDE IN RELATION TO MALFORMATIONS, MENTAL DEVELOPMENT, AND CHILDHOOD MORTALITY.
212107 03-15

ANTEROGRADE

ANTEROGRADE AND RETROGRADE EFFECTS OF ELECTROCONVULSIVE SHOCK AND OF PUROMYCIN ON MEMORY FORMATION IN THE GOLDFISH.
213853 04-04

ANTIACCELERATOR

ANTIACCELERATOR AND DECELERATOR ACTIVITY OF ELEVEN PHENOTHIAZINE DERIVATIVES.
221740 04-03

ANTIADRENERGIC

THE INFLUENCE OF ANTIADRENERGIC AND ANTIDOPAMINERGIC DRUGS ON METHAMPHETAMINE INDUCED CHANGES IN MOTORIC ACTIVITY AND CEREBRAL GLYCOGEN CONTENT IN MICE.
204396 02-03

ANTIAGGRESSIVE

THE ANTIAGGRESSIVE EFFECTS OF LITHIUM IN MAN.
202725 02-09

AZAPERONE, A SEDATIVE NEUROLEPTIC OF THE BUTYROPHENONE SERIES WITH PRONOUNCED ANTIAGGRESSIVE AND ANTISHOCK ACTIVITY IN ANIMALS.
206786 03-04

LITHIUM IN NONMANIC DEPRESSIVES: ANTIAGGRESSIVE EFFECT AND RED BLOOD CELL LITHIUM VALUES.
222604 04-09

ANTIANDROGENS

THE CONTROL OF DEVIANT SEXUAL BEHAVIOUR BY DRUGS: I. BEHAVIOURAL CHANGES FOLLOWING ESTROGENS AND ANTIANDROGENS.
196958 01-14

ANTIANESTHETIC

ANTIANESTHETIC EFFECTS OF CYCLIC-AMP AND ANALEPTIC DRUGS AS DETERMINED BY REVERSAL OF AMOBARBITAL INDUCED NARCOSIS.
193426 01-03

ANTIANXIETY

RATIONAL USE OF PSYCHOTROPIC DRUGS. II. ANTIANXIETY AGENTS.
193192 01-17

PRESELECTION OF ANIMALS IN STUDIES OF ANTIANXIETY DRUGS.
197986 01-03

ANTIANXIOUS

EFFECT OF CAMAZEPAM (SB-5833), A NEW ANTIANXIOUS DRUG, ON CARDIAC CONTRACTILITY AND CORONARY HEMODYNAMICS.
206785 03-03

ANTIBODY

IN VIVO UPTAKE OF ANTIBODY TO DOPAMINE-BETA-HYDROXYLASE INTO SYMPATHETIC ELEMENTS.
217848 04-03

IN VIVO BINDING OF ANTIBODY TO DOPAMINE-BETA-HYDROXYLASE IN ADRENERGIC NERVES AND SUBSEQUENT ANTIDROMIC TRANSPORT (UNPUBLISHED PAPER).
218147 04-03

ANTICATECHOLAMINERGIC

THE INFLUENCE OF ANTICATECHOLAMINERGIC AGENTS ON THE BEHAVIOURAL EFFECTS OF L-5-HYDROXYTRYPTOPHAN.
197572 01-04

ANTICHOLINERGIC

EFFECTS OF ANTICHOLINERGIC AGENTS ON SELF-STIMULATION.
197446 01-03

ANTICHOLINERGIC TOXIC PSYCHOSIS IN DRUG ABUSERS TREATED WITH BENZTROPINE.
197539 01-15

INFLUENCE OF AN ANTICHOLINERGIC PSYCHOTOMIMETIC AGENT ON BEHAVIOUR IN CATS CONTROLLED BY AN AUDITORY STIMULUS.
197996 01-04

EFFECT OF CHOLINERGIC AND ANTICHOLINERGIC AGENTS ON TARDIVE DYSKINESIA.
200086 02-13

SOME FACTORS DETERMINING THE RESPONSE OF SEPTAL RATS TO ANTICHOLINERGIC DRUGS.
205632 03-03

HALOPERIDOL INDUCED DISRUPTION OF CONDITIONED AVOIDANCE RESPONDING: ATTENUATION BY PRIOR TRAINING OR BY ANTICHOLINERGIC DRUGS.
210861 03-04

PHYSOSTIGMINE: ITS USE IN ACUTE ANTICHOLINERGIC SYNDROME WITH ANTIDEPRESSANT AND ANTIPARKINSON DRUGS.
211416 03-15

THE CENTRAL ANTICHOLINERGIC SYNDROME: MANAGEMENT WITH PHYSOSTIGMINE.
211427 03-15

CENTRAL ANTICHOLINERGIC ACTIONS OF DOXEPIN IN RABBITS.
215727 04-03

PHYSOSTIGMINE -- ANTIDOTE FOR ANTICHOLINERGIC POISONING.
219621 04-15

OBJECTIVE ASSESSMENT OF ANTICHOLINERGIC SIDE-EFFECTS OF TRICYCLIC ANTIDEPRESSANTS A CONTROLLED STUDY OF IMIPRAMINE AND IMIPRAMINE-N-OXIDE.
221633 04-15

DIFFERENTIAL ANTAGONISM BY THE ANTICHOLINERGIC DEXETIMIDE OF INHIBITORY EFFECTS OF HALOPERIDOL AND FENTANYL ON BRAIN SELF-STIMULATION.
225562 04-03

ANTICHOLINERGICS

UNEXPECTED COMPLICATIONS BY ANTICHOLINERGICS CONTAINED IN SOPORIFICS AND ANALGESIC DRUGS.
204404 02-15

ANTICHOLINESTERASE

EXPERIMENTAL TESTS OF HYPOTHESES ABOUT NEUROCHEMICAL MECHANISMS UNDERLYING BEHAVIORAL TOLERANCE TO THE ANTICHOLINESTERASE, DIISOPROPYLFLUOROPHOSPHATE.
208555 03-03

ANTICOAGULANT

PRESENILE DEMENTIA: FURTHER EXPERIENCE WITH AN ANTICOAGULANT PSYCHOTHERAPY REGIMEN.
195601 01-14

ANTICONVULSANT

INTERACTION OF PENTYLENETETRAZOL AND TRIMETHADIONE ON THE METABOLISM OF SEROTONIN IN BRAIN AND ITS RELATION TO THE ANTICONVULSANT ACTION OF TRIMETHADIONE.
195093 01-03

A STUDY OF THE DEVELOPMENT OF TOLERANCE TO AN ANTICONVULSANT EFFECT OF DELTA9-TETRAHYDROCANNABINOL AND CANNABIDIOL.
195117 01-03

EPILEPTIFORM SEIZURES IN DOMESTIC FOWL. IV. THE EFFECTS OF ANTICONVULSANT DRUGS.
197742 01-03

THE ANTICONVULSANT ACTION OF THE CARBONIC ANHYDRASE INHIBITOR METHAZOLAMIDE: POSSIBLE INVOLVEMENT OF A NORADRENERGIC MECHANISM.
197864 01-03

ANTICONVULSANT PROPERTIES OF DELTA9-TETRAHYDROCANNABINOL AND OTHER CANNABINOIDS.
198021 01-03

ANTICONVULSANT ACTIVITY OF DELTA9-TETRAHYDROCANNABINOL AND ITS 11 HYDROXY AND 8ALPHA,11 DIHYDROXY METABOLITES IN THE FROG.
200035 02-03

SYNTHESIS OF SUBSTITUTED BENZYLIDINOHYDRAZINES AND THEIR MONOAMINEOXIDASE INHIBITORY AND ANTICONVULSANT PROPERTIES.
206461 03-02

THE USE OF ANTICONVULSANT TREATMENT OF BEHAVIORALLY DISTURBED CHILDREN WITH BIOELECTRIC EPILEPSY: A CATAMNESTIC STUDY OF 76 CASES.
211355 03-11

ANTICONVULSANT ACTIVITIES OF DELTA8-THC AND DELTA9-TETRAHYDROCANNABINOL AND URIDINE.
213374 04-03

RED CELL FOLATE AND MACROCYTOSIS DURING LONG-TERM ANTICONVULSANT THERAPY IN NONANAEMIC MENTALLY RETARDED EPILEPTICS.
218553 04-11

A NEUROPHARMACOLOGICAL EVALUATION OF SC-13504 -- A NEW ANTICONVULSANT. (PH.D. DISSERTATION).
222639 04-03

MONOAMINEOXIDASE INHIBITORY AND ANTICONVULSANT PROPERTIES OF 1,2,4 TRISUBSTITUTED 5-IMIDAZOLONES.
225105 04-01

ANTICONVULSANTS

PHARMACOKINETIC EVALUATION OF ANTICONVULSANTS PRIOR TO EFFICACY TESTING EXEMPLIFIED BY CARBAMAZEPINE IN EPILEPTIC MONKEY MODEL.
195492 01-04

ANTICONVULSANTS IN THE TREATMENT OF AGGRESSION.
209130 03-11

ANTICONVULSIVE

THE MECHANISM OF ANTICONVULSIVE ACTION OF DIAZEPAM.
217064 04-04

THE EFFECT OF PSYCHOTROPIC AND ANTICONVULSIVE DRUGS ON THE TRANSPORT OF ATPASE IN THE RENAL TUBES OF A GUINEA-PIG.
223015 04-05

ANTIDEPRESSANT

AGE SEX DIFFERENCES IN RESPONSE TO ANTIDEPRESSANT DRUGS.
193093 01-11

A STUDY OF THE USE OF ANTIDEPRESSANT MEDICATION IN GENERAL PRACTICE.
194407 01-17

ANTIDEPRESSANT ACTION OF TRYPTOPHAN.
194857 01-13

CARDIOVASCULAR ABNORMALITIES FOLLOWING TRICYCLIC ANTIDEPRESSANT DRUG OVERDOSAGE.
195847 01-15

MECHANISM OF ANTIDEPRESSANT EFFICACY OF MONOAMINEOXIDASE INHIBITORS: INHIBITION OF MONOAMINE OXIDASE OR OF CATECHOLAMINE REUPTAKE.
195925 01-17

CLINICAL EVALUATION OF NEW ANTIDEPRESSANT, LOPRAMINE.
196443 01-14

ONCE-A-DAY DOSAGE TRICYCLIC ANTIDEPRESSANT DRUG THERAPY: A SURVEY.
196679 01-09

A POSSIBLE MECHANISM FOR THE ANTIDEPRESSANT ACTIVITY OF THYROTROPIN-RELEASING HORMONE.
196836 01-13

A MULTINATIONAL, DOUBLE-BLIND TRIAL WITH A NEW ANTIDEPRESSANT MAPROTILINE (LUDIOMIL) AND AMITRIPTYLINE.
197031 01-09

INTERACTION BETWEEN ANTIDEPRESSANT AND CENTRALLY ACTING ANTIHYPERTENSIVE DRUGS.
197300 01-03

THE PHARMACOLOGY OF WY-23409, A NEW ANTIDEPRESSANT.
197305 01-03

THE EFFECT OF A NEW TETRACYCLIC ANTIDEPRESSANT COMPOUND, ORG-GB94, ON THE TURNOVER OF DOPAMINE, NORADRENALIN AND SEROTONIN IN THE RAT BRAIN.
197496 01-03

EVALUATION OF CLINICAL PREDICTION OF ANTIDEPRESSANT ACTIVITY USING VARIOUS ANIMAL TEST MODELS.
198055 01-02

ON THE METABOLISM OF A NEW ANTIDEPRESSANT, AZAPHEN, IN RATS.
198484 02-01

PHARMACOLOGICAL PROFILE OF A NEW NONTRICYCLIC ANTIDEPRESSANT: OXAFLOZANE (1766-CERM).
199385 02-02

PRELIMINARY CLINICAL RESULTS OF A NEW NONTRICYCLIC ANTIDEPRESSANT: OXAFLOZANE (1766-CERM).
199386 02-07

A DOUBLE-BLIND CLINICAL TRIAL OF NEW ANTIDEPRESSANT, SURMONTIL.
200922 02-09

CLINICAL DOUBLE-BLIND STUDY ON THE ACTIVITY OF A NEW ANTIDEPRESSANT: CAROXAZONE (FI-6654).
201667 02-09

EFFECT OF NOMIFENSINE (HOE-984), A NEW ANTIDEPRESSANT, ON UPTAKE OF NORADRENALINE AND SEROTONIN AND ON RELEASE OF NORADRENALINE IN RAT BRAIN SYNAPTOSOMES.
202807 02-03

DIVALENT CATIONS IN PREDICTING ANTIDEPRESSANT RESPONSE TO LITHIUM.
202886 02-14

TRICYCLIC ANTIDEPRESSANT POISONING: REVERSAL OF COMA, CHOREOATHETOSIS, AND MYOCLONUS BY PHYSOSTIGMINE.
202919 02-15

POSSIBLE PHARMACOLOGICAL AND THEORETICAL IMPLICATIONS OF X-RAY STRUCTURE OF THE TRICYCLIC ANTIDEPRESSANT IMIPRAMINE.
205029 02-01

TRICYCLIC ANTIDEPRESSANT DRUGS AND DOPAMINE SENSITIVE ADENYLCYCLASE FROM RAT CAUDATE NUCLEI.
206990 03-03

REPORT ON A PRELIMINARY CLINICAL STUDY OF MIANSERIN (GB-94), A TETRACYCLIC ANTIDEPRESSANT, AN OPEN TRIAL.
207283 03-03

ANTIDEPRESSANT RESPONSE TO TRICYCLICS AND URINARY MHPG IN UNIPOLAR PATIENTS: CLINICAL RESPONSE TO IMIPRAMINE OR AMITRIPTYLINE.
207443 03-13

COMBINED THYROID (TRIIODOTHYRONINE) TRICYCLIC ANTIDEPRESSANT TREATMENT IN DEPRESSIVE STATES.
207720 03-09

USE OF ANTIDEPRESSANT E-330 (IPRINDOLE).
208789 03-09

CARDIOVASCULAR COMPLICATIONS OF TRICYCLIC ANTIDEPRESSANT OVERDOSAGE.
209234 03-15

POSSIBLE INVOLVEMENT OF 5-HYDROXYTRYPTAMINE IN THE ANTIDEPRESSANT ACTIVITY OF NARCOTIC ANALGESICS.
210761 03-03

THE EFFECT OF DRUGS WITH ANTIDEPRESSANT ACTIVITY UPON THE HYPOTHERMIA AND BEHAVIOURAL DEPRESSION INDUCED IN MICE BY PIMOZIDE OR CENTRALLY ADMINISTERED NORADRENALINE.
210762 03-04

PHYSOSTIGMINE: ITS USE IN ACUTE ANTICHOLINERGIC SYNDROME WITH ANTIDEPRESSANT AND ANTIPARKINSON DRUGS.
211416 03-15

PHYSOSTIGMINE SALICYLATE IN THE TREATMENT OF TRICYCLIC ANTIDEPRESSANT OVERDOSAGE.
212265 03-15

A TRUE ANTIDEPRESSANT: 19560-RP.
212392 03-09

CLINICAL STUDY OF AN NEW ANTIDEPRESSANT, MELITRACEN, FOR 50 AMBULATORY PATIENTS.
212490 03-10

REVERSAL OF DELIRIUM INDUCED BY TRICYCLIC ANTIDEPRESSANT DRUGS WITH PHYSOSTIGMINE.
213708 04-15

THE EFFECTS OF AMPHETAMINE, IMIPRAMINE AND ICI-58834 (VIVALAN), A POTENTIAL ANTIDEPRESSANT, ON UNCONDITIONED BEHAVIOUR IN RATS.
214016 04-04

THE MECHANISM OF THE POTENTIATING EFFECT OF ANTIDEPRESSANT DRUGS ON THE PROTECTIVE INFLUENCE OF DIPHENHYDRAMINE IN EXPERIMENTAL CATATONIA. THE ROLE OF HISTAMINE.
215664 04-03

A DOUBLE-BLIND COMPARISON OF THREE TIMES DAILY AND SINGLE NIGHT DOSAGE OF THE TRICYCLIC ANTIDEPRESSANT DOTHIEPIN.
216463 04-09

AN ATTEMPT TO VERIFY THE ANTIDEPRESSANT ACTION OF THE HYPOTHALAMIC THYROSTIMULIN (THYROTROPIN-RELEASING FACTOR OR TRF) IN MELANCHOLIC STATES.
216758 04-09

PLASMA LEVELS OF IMIPRAMINE AND DESMETHYLIMIPRAMINE AND ANTIDEPRESSANT EFFECT DURING CONTROLLED THERAPY.
217477 04-09

EVALUATION OF KETAMINE HCL FOR ANTIDEPRESSANT ACTIVITY.
217577 04-02

THE INFLUENCE OF APOMORPHINE AND TRICYCLIC ANTIDEPRESSANT DRUGS ON THE LEVEL OF SEROTONIN AND ITS METABOLITE IN RAT BRAIN.
217815 04-03

SOME INTERACTIONS BETWEEN FENFLURAMINE AND ANTIDEPRESSANT DRUGS: EFFECTS ON 5-HYDROXYINDOLE CONCENTRATIONS IN RAT BRAIN.
217962 04-03

ANTIDEPRESSANT AGENTS AND REVERSAL OF DIURNAL ACTIVITY CYCLES IN THE RAT.
218954 04-04

RELATIONSHIPS BETWEEN TRICYCLIC ANTIDEPRESSANT CONCENTRATIONS, 1-3H-NORAFRENALINE UPTAKE AND CHRONOTROPIC EFFECT IN ISOLATED RAT ATRIA.
221188 04-03

PHARMACOLOGICAL EVALUATION OF 3-(N 3,3 DIPHENYLPROPYL-N-METHYL) AMINOPROPAN-1-OL HYDROCHLORIDE (PF-82), A NEW TYPE OF ANTIDEPRESSANT DRUG.
221287 04-02

NOXIPTILIN (AGEDAL) -- A NEW TRICYCLIC ANTIDEPRESSANT WITH A FASTER ONSET OF ACTION? A DOUBLE-BLIND, MULTICENTRE COMPARISON WITH AMITRIPTYLINE.
221306 04-09

POTENTIATION OF ANTIDEPRESSANT ACTION OF CLOMIPRAMINE BY TRYPTOPHAN.
221385 04-09

DESIPRAMINE AS AN ANTIDEPRESSANT IN GENERAL PRACTICE.
221559 04-09

MAPROTILINE -- ITS POSITION AS AN ANTIDEPRESSANT IN THE LIGHT OF RECENT NEUROPHARMACOLOGICAL AND NEUROBIOCHEMICAL FINDINGS.
221647 04-03

NARCOTIC AGONISTS AND ANTAGONISTS AS MODELS FOR POTENTIAL ANTIDEPRESSANT DRUGS.
222817 04-04

ON THE ANTIDEPRESSANT EFFECT OF CIBA-34276-BA (MAPROTILINE).
223182 04-10

A CONTROLLED STUDY OF A TETRACYCLIC ANTIDEPRESSANT -- MAPROTILINE (LUDIOMIL).
224486 04-09

ANTIDEPRESSANTS

INFLUENCE OF THERAPEUTIC AND TOXIC DOSES OF NEUROLEPTICS AND ANTIDEPRESSANTS ON ENERGY METABOLISM OF THE ISOLATED PERFUSED RAT BRAIN.
195236 01-03

THE EFFECT OF LITHIUM CARBONATE IN COMBINATION WITH TRICYCLIC ANTIDEPRESSANTS IN ENDOGENOUS DEPRESSION: A DOUBLE-BLIND, MULTICENTER TRIAL.
197035 01-09

THE EFFECTS OF THE TRICYCLIC ANTIDEPRESSANTS DESMETHYLIMIPRAMINE, DOXEPIN AND IPRINDOLE ON THE ISOLATED PERFUSED RABBIT HEART.
197277 01-03

THE CARDIAC EFFECTS OF COCAINE AND CERTAIN ANTIHISTAMINES AND ANTIDEPRESSANTS.
197452 01-03

ARRHYTHMIAS EVOKED BY INFUSION OF TRICYCLIC ANTIDEPRESSANTS AND NORADRENALINE ON ISOLATED RABBIT HEARTS.
197939 01-03

POTENTIAL CARDIOTOXICITY FROM PHENOTHIAZINES AND TRICYCLIC ANTIDEPRESSANTS.
198044 01-15

ACCELERATION OF ANTIDEPRESSANTS BY THYROID HORMONE.
198082 02-07

THE INFLUENCE OF ANTIDEPRESSANTS AND NEUROLEPTICS ON BEHAVIORAL REACTIONS ELICITED BY LESION AND EXCITATION OF THE HIPPOCAMPUS.
198483 02-04

RATIONAL USE OF PSYCHOTROPIC DRUGS. IV. ANTIDEPRESSANTS.
200584 02-09

THE INFLUENCE OF PROLONGED APPLICATION OF TRANQUILIZERS AND ANTIDEPRESSANTS ON THE SUMMATIONAL CAPACITY OF THE CENTRAL NERVOUS SYSTEM.
201913 02-03

POTENTIATION WITH TRICYCLIC ANTIDEPRESSANTS OF THE INHIBITORY ACTION OF APOMORPHINE ON THE ATTITUDINAL REFLEX IN FROGS.
201919 02-04

LIPIDOSIS LIKE ALTERATIONS IN SPINAL CORD AND CEREBELLAR CORTEX OF RATS TREATED WITH CHLORPHENTERMINE OR TRICYCLIC ANTIDEPRESSANTS.
202767 02-03

NEGATIVE INOTROPIC EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON THE ISOLATED RIGHT VENTRICULAR PAPILLARY MUSCLE OF THE CAT.
204400 02-05

INTERACTIONS OF SOME ANALGESICS AND ANTIDEPRESSANTS WITH PHENELZINE OR RESERPINE IN THE MOUSE.
204879 02-05

CARDIOTOXIC EFFECTS OF TRICYCLIC ANTIDEPRESSANTS IMIPRAMINE, AMITRIPTYLINE AND DOSULEPIN (PROTHIADEN-SPOFA) IN AN ACUTE EXPERIMENT IN RATS.
205597 02-15

L-DOPA AND TRICYCLIC ANTIDEPRESSANTS IN AFFECTIVE DISORDERS. A PILOT STUDY.
205601 03-09

CONFUSIONAL STATES IN ELDERLY MENTAL PATIENTS TREATED WITH ANTIDEPRESSANTS.
205603 03-15

ARE MONOAMINEOXIDASE INHIBITORS ANTIDEPRESSANTS
206368 03-10

ON THE CONTROVERSY OF PROPHYLACTIC ANTIDEPRESSANTS.
207764 03-09

TREATMENT OF HUMAN AGGRESSION WITH MAJOR TRANQUILIZERS, ANTIDEPRESSANTS, AND NEWER PSYCHOTROPIC DRUGS.
209127 03-11

SOME OBSERVATIONS ON THE CORRELATIONS BETWEEN PLASMA LEVELS OF MONOMETHYLATED TRICYCLIC ANTIDEPRESSANTS AND THERAPEUTIC EFFECTS.
210507 03-09

THE EFFECT OF ANTIDEPRESSANTS ON UNIT ACTIVITY IN THE MIDBRAIN RAPHE OF RATS.
210789 03-03

THE EFFECT OF COCA-COLA, CAFFEINE, ANTIDEPRESSANTS AND CHLORPROMAZINE ON OBJECTIVE AND SUBJECTIVE SLEEP PARAMETERS.
210808 03-14

PHARMACOKINETIC INTERACTION BETWEEN NEUROLEPTICS AND TRICYCLIC ANTIDEPRESSANTS IN THE RAT.
210834 03-03

COMPARATIVE PHARMACOLOGICAL STUDIES ON BUTRIPTYLINE AND SOME RELATED STANDARD TRICYCLIC ANTIDEPRESSANTS.
211101 03-03

A FOLLOWUP STUDY OF FEMALE DEPRESSED OUTPATIENTS WHO COMPLETE A RANDOMIZED DOUBLE-BLIND PROPHYLACTIC TRIAL OF ANTIDEPRESSANTS AND HIGH CONTACT. (PH.D. DISSERTATION).
212518 03-09

ANTAGONISM OF NICOTINIC ACID AND OTHER KYNURENINES TO ANTIDEPRESSANTS: ONE OF THE PROBABLE REASONS FOR THE THERAPY-RESISTANCE IN DEPRESSION?.
215074 04-17

EFFECT OF TRICYCLIC ANTIDEPRESSANTS AND ALCOHOL ON PSYCHOMOTOR SKILLS RELATED TO DRIVING.
215667 04-14

THE INFLUENCE OF TRICYCLIC ANTIDEPRESSANTS, AZAPHEN AND IMIZINE ON BLOOD SUGAR CONCENTRATION CHANGES PRODUCED BY EPINEPHRINE AND SEROTONIN.
217214 04-03

COMPARISON OF THE EFFECTS OF TETRACYCLIC AND TRICYCLIC ANTIDEPRESSANTS ON THE SEROTONIN UPTAKE BY HUMAN THROMBOCYTES IN VITRO.
217258 04-13

EFFECTS OF TRICYCLIC ANTIDEPRESSANTS UPON HUMAN PLATELET MONOAMINEOXIDASE.
217356 04-13

INTERACTION BETWEEN CENTRALLY ACTING HYPOTENSIVE DRUGS AND TRICYCLIC ANTIDEPRESSANTS.
217575 04-03

ARRHYTHMIAS AND INHIBITION OF NORADRENALINE UPTAKE CAUSED BY TRICYCLIC ANTIDEPRESSANTS AND CHLORPROMAZINE ON THE ISOLATED PERFUSED RABBIT HEART.
217657 04-03

COMPETITION FOR PLASMA PROTEIN BINDING SITES BETWEEN PHENOTHIAZINE TRANQUILIZERS AND IMINODIBENZYL ANTIDEPRESSANTS.
217891 04-03

ANTIDEPRESSANTS IN BLACK AND WHITE INPATIENTS: DIFFERENTIAL RESPONSE TO A CONTROLLED TRIAL OF CHLORPROMAZINE AND IMIPRAMINE.
218770 04-09

SIMILARITIES OF THE INFLUENCE OF SECONDARY AND TERTIARY TRICYCLIC ANTIDEPRESSANTS ON THE EFFECT OF RESERPINE IN FROGS AND ON THE SEROTONIN UPTAKE OF HUMAN THROMBOCYTES.
219503 04-13

A COMPARISON OF THE ACTION OF THE TRICYCLIC ANTIDEPRESSANTS, AZAPHEN AND IMIPRAMINE, ON THE GASTROINTESTINAL TRACT OF TEST ANIMALS.
219505 04-03

DEPRESSIONS AND ANTIDEPRESSANTS DURING TREATMENT WITH LONG-ACTING NEUROLEPTIC DRUGS: SIDE-EFFECTS AND THE EMERGENT METATHERAPEUTIC SYNDROME.
219694 04-15

INHIBITION OF CELLULAR ATP HYDROLYZING ACTIVITY BY TRICYCLIC ANTIDEPRESSANTS AND PHENOTHIAZINE TRANQUILIZERS.
221053 04-03

DOUBLE-BLIND TEST OF THREE ANTIDEPRESSANTS, THIRD COMMUNICATIONS: METHODOLOGICAL PROBLEMS.
221288 04-16

DOUBLE-BLIND TEST OF THREE ANTIDEPRESSANTS, FOURTH COMMUNICATION; RESULTS WITH THE HAMBURG DEPRESSION SCALE.
221289 04-11

COCAINE, AMPHETAMINE, AND TRICYCLIC ANTIDEPRESSANTS AND SYNAPTIC TRANSMISSION.
221386 04-13

OBJECTIVE ASSESSMENT OF ANTICHOLINERGIC SIDE-EFFECTS OF TRICYCLIC ANTIDEPRESSANTS A CONTROLLED STUDY OF IMIPRAMINE AND IMIPRAMINE-N-OXIDE.
221633 04-15

INTERACTIONS BETWEEN POSTGANGLIONIC SYMPATHETIC BLOCKING DRUGS AND ANTIDEPRESSANTS.
221650 04-09

TRICYCLIC ANTIDEPRESSANTS: EFFECTS ON THE FIRING RATE OF BRAIN NORADRENERGIC NEURONS.
222805 04-03

THE EFFECT OF NEUROLEPTICS AND ANTIDEPRESSANTS ON THE UPTAKE OF 3H-GAMMA-AMINOBUTYRIC ACID BY ISOLATED NERVE ENDINGS OF THE RAT BRAIN.
224114 04-03

TRICYCLIC ANTIDEPRESSANTS AND TRYPTOPHAN IN UNIPOLAR DEPRESSION.
224423 04-09

ANTIDEPRESSIVE

A PATTERN OF ANTIDEPRESSIVE EFFECT OF TRYPTOPHAN & IMIPRAMINE IN MALES & FEMALES.
196680 01-09

SLEEP DEPRIVATION AS A POTENTIATION OF ANTIDEPRESSIVE PHARMACOTHERAPY?
205602 03-09

DIFFERENT URINARY EXCRETIONS OF 3-METHOXY-4-HYDROXYPHENYLGLYCOL AND RESPONSE TO TRICYCLIC ANTIDEPRESSIVE DRUGS.
206985 03-13

THE ANTIDEPRESSIVE EFFECT OF SANDOMIGRAN.
209019 03-11

TRICYCLIC ANTIDEPRESSIVE DRUGS AND DOPAMINE SENSITIVE ADENYLATE-CYCLASE FROM RAT BRAIN STRIATUM.
210856 03-03

INFLUENCE OF AZAPHEN, A NEW ANTIDEPRESSIVE DRUG, ON THE HUMAN EEG.
215065 04-09

INFLUENCE OF SOME TRICYCLIC ANTIDEPRESSIVE DRUGS ON THE UPTAKE OF 5-HYDROXYTRYPTAMINE BY RAT BLOOD PLATELETS.
217693 04-03

ANTIDEPRESSIVE THERAPY IN GENERAL PRACTICE.
221348 04-09

ANTIDIURETIC

STUDIES ON ANTIDIURETIC ACTIVITIES AND ON PORTER-SILBERS CHROMOGENS CONTENT IN PLASMA OF PATIENTS WITH ALCOHOLIC DELIRIUM OR WITH ACUTE PHENOTHIAZINE INTOXICATIONS.
203741 02-15

ANTIDOPAMINERGIC

THE INFLUENCE OF ANTIADRENERGIC AND ANTIDOPAMINERGIC DRUGS ON METHAMPHETAMINE INDUCED CHANGES IN MOTORIC ACTIVITY AND CEREBRAL GLYCOGEN CONTENT IN MICE.
204396 02-03

ANTIDOTE

PHYSOSTIGMINE -- ANTIDOTE FOR ANTICHOLINERGIC POISONING.
219621 04-15

ANTIDROMIC

IN VIVO BINDING OF ANTIBODY TO DOPAMINE-BETA-HYDROXYLASE IN ADRENERGIC NERVES AND SUBSEQUENT ANTIDROMIC TRANSPORT (UNPUBLISHED PAPER).
218147 04-03

ANTIEPILEPTIC

PSYCHOTROPIC AND ANTIEPILEPTIC DRUGS.
205635 03-17

THE TERATOGENIC RISK OF ANTIEPILEPTIC DRUGS.
225537 04-15

IDIOSYNCRATIC REACTIONS TO THE ANTIEPILEPTIC DRUGS.
225538 04-15

ACUTE TOXICITY OF ANTIEPILEPTIC DRUGS.
225539 04-15

ANTIHISTAMINES

THE CARDIAC EFFECTS OF COCAINE AND CERTAIN ANTIHISTAMINES AND ANTIDEPRESSANTS.
197452 01-03

ANTIHISTAMINIC

ANTIHISTAMINIC ACTION OF (-) TRANS-DELTA9-TETRAHYDROCANNABINOL.
217651 04-03

ANTIHYPERTENSIVE

STUDIES ON ALPHA-METHYLDOPA: RELATIONSHIP BETWEEN METABOLISM, BIOGENIC AMINES AND ANTIHYPERTENSIVE EFFECT.
197298 01-03

INTERACTION BETWEEN ANTIDEPRESSANT AND CENTRALLY ACTING ANTIHYPERTENSIVE DRUGS.
197300 01-03

DO ANTIHYPERTENSIVE DRUGS REALLY CAUSE DEPRESSION?
204236 02-15

ANTIHYPERTENSIVE DRUGS AND DEPRESSION.
209082 03-09

ANTIINFLAMATORY

A CONTRIBUTION TO THE STUDY OF MECHANISM OF ACTION OF PHENYLBUTAZONE: THE INFLUENCE OF CATECHOLAMINES ON THE ANTIINFLAMATORY EFFECT OF PHENYLBUTAZONE.
205169 02-03

ANTIMANIC

ANTIMANIC AND PROPHYLACTIC EFFECTS OF CARBAMAZEPINE (TEGRETOL) ON MANIC-DEPRESSIVE PSYCHOSIS.
225086 04-09

ANTIMASS

AN ANIMAL TEST MODEL FOR EVALUATING DRUGS WITH ANTIMASS PSYCHOTIC ACTIVITY.
221273 04-06

ANTINOCICEPTIVE

NEW HOT PLATE TESTS TO QUANTIFY ANTINOCICEPTIVE AND NARCOTIC ANTAGONIST ACTIVITIES.
193446 01-04

TOLERANCE DEVELOPMENT TO THE ANTINOCICEPTIVE ACTIONS OF MORPHINE, AMPHETAMINE, PHYSOSTIGMINE AND 2-AMINOINDANE IN THE MOUSE.
194930 01-03

CHANGES IN BRAIN CONCENTRATION OF BIOGENIC AMINES AND THE ANTINOCICEPTIVE EFFECT OF MORPHINE IN RATS.
195246 01-03

DECREASED ANTINOCICEPTIVE EFFECT OF MORPHINE IN RATS TREATED INTRAVENTRICULARLY WITH PROSTAGLANDIN-E1.
200045 02-03

EFFECT OF MIDBRAIN RAPHE LESION AND OF 6-HYDROXYDOPAMINE ON THE ANTINOCICEPTIVE ACTION OF BUPRENORPHINE IN RATS.
210923 03-03

ANTINOCICEPTIVE ACTION OF OXOTREMORINE AND REGIONAL TURNOVER OF RAT BRAIN NORADRENALINE, DOPAMINE AND 5-HT.
215683 04-03

ANTIPARKINSON

CB-154 (2-BROMO-ALPHA-ERGOKRYPTINE, BROMOCRIPTIN), A POTENTIAL ANTIPARKINSON AGENT.
197949 01-04

EFFECTS OF BENAPRYZINE, A NEW ANTIPARKINSON DRUG, ON DOPAMINE UPTAKE INTO CORPUS-STRIATUM.
199868 02-03

PHYSOSTIGMINE: ITS USE IN ACUTE ANTICHOLINERGIC SYNDROME WITH ANTIDEPRESSANT AND ANTIPARKINSON DRUGS.
211416 03-15

NOMIFENSINE: A POTENT DOPAMINERGIC AGONIST OF ANTIPARKINSON POTENTIAL.
217472 04-03

ANTIPARKINSONIAN

A COMPARISON OF THE INHIBITORY EFFECTS OF CERTAIN ANTIPARKINSONIAN AGENTS ON DOPAMINE ACCUMULATION INTO THE RAT STRIATUM.
195234 01-03

A PRELIMINARY REPORT ON THE ACTION OF IMIPRAMINE AND ANTIPARKINSONIAN AGENTS ON THE OPEN-FIELD BEHAVIOUR OF RATS.
202803 02-04

ANTIPARKINSONIANS

TRIAL INTERRUPTION OF ANTIPARKINSONIANS IN LONG-TERM NEUROLEPTIC TREATMENT.
216767 04-15

ANTIPHLOGISTIC

TOWARDS THE MECHANISM OF THE ANTIPHLOGISTIC ACTION OF CHLORPROMAZINE.
219507 04-03

ANTIPODES

THE EFFECT OF TWO BARBITURATE ANTIPODES ON SPINAL REFLEXES AND SINGLE MOTONEURONS.
197297 01-03

ANTIPSYCHOTIC

MESOLIMBIC INVOLVEMENT WITH BEHAVIOURAL EFFECTS INDICATING ANTIPSYCHOTIC ACTIVITY.
193450 01-03

INHIBITION OF SYNAPTIC VESICULAR MG++ DEPENDENT ATPASE (STENIN) BY ANTIPSYCHOTIC PHENOTHIAZINES.
195054 01-03

REGIONAL DIFFERENCES IN HOMOVANILLIC ACID CONCENTRATIONS AFTER ACUTE AND CHRONIC ADMINISTRATION OF ANTIPSYCHOTIC DRUGS.
198210 02-03

ARE ANTIPSYCHOTIC DRUGS INTERCHANGEABLE?.
202879 02-08

MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 6. COMMUNICATION: RELATIONSHIP BETWEEN NEUROLEPTIC HYPOKINESIS AND ANTIPSYCHOTIC THERAPEUTIC RESULTS.
203844 02-13

THIORIDAZINE: CENTRAL DOPAMINE TURNOVER AND CLINICAL EFFECTS OF ANTIPSYCHOTIC DRUGS.
204852 02-08

ANTIPSYCHOTIC DRUGS STIMULATE PROLACTIN RELEASE.
206354 03-03

ANTIPSYCHOTIC DRUGS AND CATECHOLAMINE SYNAPSES.
207290 03-03

DOSE EQUIVALENCE OF THE ANTIPSYCHOTIC DRUGS.
207291 03-17

CATECHOLAMINES AND ANTIPSYCHOTIC DRUGS IN PERIODIC CATATONIA.
207292 03-08
DOPAMINERGIC BLOCKING EFFECTS OF ANTIPSYCHOTIC DRUGS.
207294 03-03
MASS FRAGMENTOMETRIC DETERMINATION OF HOMOVANILLIC ACID IN LUMBAR CEREBROSPINAL FLUID OF SCHIZOPHRENIC PATIENTS DURING TREATMENT WITH ANTIPSYCHOTIC DRUGS.
207295 03-08
ANTIPSYCHOTIC DRUGS AND CATECHOLAMINE SYNAPSES: SUMMARY OF THE SESSION.
207299 03-03
INFANTILE AUDITORY EXPOSURE AND UNUSUAL RESPONSE TO ANTIPSYCHOTIC DRUGS.
208617 03-04
EFFECT OF ANTIPSYCHOTIC DRUGS ON HOMOVANILLIC ACID LEVELS IN STRIATUM AND OLFACTORY TUBERCLE OF THE RAT.
210864 03-03
ANTIPSYCHOTIC DRUGS: ROLES OF CYCLIC-AMP.
213609 04-03
PIPOTHIAZINE PALMITATE: AN EVALUATION OF A NEW LONG-ACTING INTRAMUSCULAR ANTIPSYCHOTIC AGENT IN SEVERELY ILL SCHIZOPHRENIC PATIENTS.
216188 04-08
ANTAGONISM BY D-AMPHETAMINE OF LEARNING DEFICITS IN RATS INDUCED BY EXPOSURE TO ANTIPSYCHOTIC DRUGS DURING EARLY POSTNATAL LIFE.
217656 04-04
THE USE OF AN ORGAL LONG-ACTING ANTIPSYCHOTIC AGENT, PENFLURIDOL, IN SCHIZOPHRENIA.
223165 04-08

ANTIPSYCHOTICS
ARE AUTORECEPTORS IN DOPAMINERGIC NEURONS INVOLVED IN THE CHANGE OF THE KINETIC STATE OF STRIATAL TYROSINE-HYDROXYLASE ELICITED BY ANTIPSYCHOTICS? (UNPUBLISHED PAPER).
208636 03-03
BLOCKADE BY PIMOZIDE OF A NORADRENALINE SENSITIVE ADENYLATE-CYCLASE IN THE LIMBIC FOREBRAIN: POSSIBLE ROLE OF LIMBIC NORADRENERGIC MECHANISMS IN THE MODE OF ACTION OF ANTIPSYCHOTICS.
210771 03-03

ANTIPYRETICS
MICROMETHODS FOR QUANTITATIVE DETERMINATION OF SEDATIVES AND ANTIPYRETICS BY THERMO-GAS CHROMATOGRAPHY.
206807 03-06

ANTISCHIZOPHRENIC
ANTISCHIZOPHRENIC DRUGS: AFFINITY FOR MUSCARINIC CHOLINERGIC RECEPTOR SITES IN THE BRAIN PREDICTS EXTRAPYRAMIDAL EFFECTS.
207298 03-03

ANTISEROTONERGIC
CHLORPROMAZINE METABOLISM VI -- ADRENOLYTIC AND ANTISEROTONERGIC ACTIVITIES OF CHLORPROMAZINE AND ITS VARIOUS METABOLITES.
197494 01-03
FAILURE OF ANTISEROTONERGIC AGENTS TO MODIFY LEVALLORPHAN INDUCED STEREOTYPY IN RATS.
225567 04-03

ANTISEROTONIN
THE MECHANISM OF ACTION OF GYKI-32084, A NEW ANTISEROTONIN AGENT.
197570 01-03

ANTISERUM
HYPOTHALAMIC SELF-STIMULATION IN RATS FOLLOWING IMMUNOSYMPATHECTOMY OR CENTRAL NERVE GROWTH FACTOR ANTISERUM INJECTION.
211512 03-04

ANTISHOCK
AZAPERONE, A SEDATIVE NEUROLEPTIC OF THE BUTYROPHENONE SERIES WITH PRONOUNCED ANTIAGGRESSIVE AND ANTISHOCK ACTIVITY IN ANIMALS.
206786 03-04

ANTITURNING
NEUROLEPTICS: RELATION BETWEEN CATALEPTIC AND ANTITURNING ACTIONS, AND ROLE OF THE CHOLINERGIC SYSTEM.
217826 04-04

ANXIETY
THIOTHIXENE AND THIORIDAZINE IN ANXIETY.
194045 01-10
A COMPARATIVE STUDY OF DOXEPIN VERSUS TRIFLUOPERAZINE IN ANXIETY NEUROSIS.
194276 01-10
COMPARATIVE STUDY OF DIAZEPAM VS. CHLORDIAZEPOXIDE IN ANXIETY NEUROSIS.
194558 01-10
A CONTROLLED EVALUATION OF LORAZEPAM AND DIAZEPAM IN ANXIETY NEUROSIS.
194719 01-10
LORAZEPAM IN ANXIETY NEUROSIS.
195621 01-10
THE EFFECT OF DAILY ORAL DOSAGE OF DIAZEPAM, PLASMA CONCENTRATIONS AND METABOLIC CLEARANCE OF DIAZEPAM AND DEMETHYLDIAZEPAM ON VARIOUS CONSTITUENTS OF THE ACUTE CLINICAL ANXIETY SYNDROME.
196191 01-10
SOME NEW APPROACHES TO THE TREATMENT OF ANXIETY.
198046 01-10
THE THERAPEUTIC EFFECT OF SHORT-TERM ORAL DIAZEPAM TREATMENT ON ACUTE CLINICAL ANXIETY IN A CRISIS CENTRE.
199991 02-10
PROGRESS IN ANXIETY STATES.
201896 02-10
PROGRESS IN ANXIETY STATES.
201897 02-10
PROGRESS IN ANXIETY STATES.
201898 02-11
ANXIETY AND ACTIVITIES OF CYCLIC ADENOSINE-MONOPHOSPHATE PHOSPHODIESTERASE.
202161 02-17
BROMAZEPAM, MEDAZEPAM, CHLORDIAZEPOXIDE IN TREATMENT OF NEUROTIC ANXIETY.
202219 02-10
THE PERIPHERAL AND CENTRAL ROLE OF THE CATECHOLAMINES IN THE MECHANISMS OF ANXIETY.
202783 02-17
THE ACTION OF CHLORDIAZEPOXIDE ON CONDITIONS OF ANXIETY IN A PSYCHOPHYSIOLOGICAL EXPERIMENT.
204405 02-14
CLINICAL TRIAL OF CLOCAPRAMINE IN NEUROTIC PATIENTS WHO HAD TROUBLES IN EVERYDAY LIFE OWING TO SEVERE ANXIETY, IRRITABILITY AND DEPRESSION.
204464 02-10
A CONTROLLED COMPARISON OF CHLORAZEPATE WITH OXAZEPAM IN NEUROTIC ANXIETY.
205638 03-10
OXYPERTINE IN THE TREATMENT OF MORBID ANXIETY. REPORT OF A NEW LOW DOSAGE SCHEDULE.
207532 03-10
CHLORDIAZEPOXIDE AND PHENOBARBITAL IN A MODEL ANXIETY INDUCING SITUATION.
207775 03-14
CLINICAL ASSESSMENT OF LORAZEPAM IN ANXIETY: A DOUBLE-BLIND STUDY.
209485 03-10
PHENAGLYCODOL IN ANXIETY: A CONTROLLED STUDY.
209486 03-10
THE TREATMENT OF ANXIETY IN THE ELDERLY WITH A NEW TRANQUILIZER COMPOUND.
210211 03-11
A COMPARISON BETWEEN DIAZEPAM AND HALOPERIDOL IN ANXIETY STATES.
210434 03-10
THE CHEMICAL CONTROL OF PREOPERATIVE ANXIETY.
210684 03-10
DOES MARIJUANA ENHANCE EXPERIMENTALLY INDUCED ANXIETY?
210738 03-14
INJECTABLE TEMESTA, ANXIETY AND ANGUISH.
212163 03-10
TENTATIVE DOUBLE-BLIND TREATMENT OF ANXIETY WITH B-5833.
212166 03-10
PATHOPHYSIOLOGICAL STUDIES OF MANIC-DEPRESSIVE PSYCHOSES: RELATIONSHIP BETWEEN ANXIETY AND EXCRETION OF URINARY CATECHOLAMINES.
212938 03-10
NONPHARMACOLOGICAL FACTORS IN DRUG THERAPY: THE INTERACTION OF DOCTOR, PATIENT, AND TABLET APPEARANCE IN THE TREATMENT OF ANXIETY/DEPRESSIVE SYNDROMES.
215060 04-10
EXPERIENCES WITH CLOMIPRAMINE (ANAFRANIL) IN THE TREATMENT OF THE PHOBIC ANXIETY STATES IN GENERAL PRACTICE.
215158 04-10
EFFECTS OF PHENOTHIAZINES ON ANXIETY AND COGNITION IN SCHIZOPHRENIA.
216190 04-08
LORAZEPAM IN ANXIETY: A CONTROLLED STUDY.
216462 04-10
A COMPARISON BETWEEN BROMAZEPAM (RO-5-3350, LEXOTAN) AND DIAZEPAM (VALIUM) IN ANXIETY NEUROSIS: A CONTROLLED, DOUBLE-BLIND CLINICAL TRIAL.
217455 04-10
DOXEPIN I.M. IN THE TREATMENT OF DEPRESSION AND ANXIETY.
221035 04-10
A COMPARISON BETWEEN DIAZEPAM AND HALOPERIDOL IN NEUROTIC ANXIETY AND TENSION STATES IN PATIENTS IN A OPEN WARD.
221638 04-10
ANXIETY NEUROSIS, DEPRESSIVE DISORDER AND MEPROBAMATE ADDICTION -- PSYCHIATRIC GRAND-ROUNDS, UNIV. OF CALIFORNIA, SAN-DIEGO.
222772 04-10

TREATMENT OF ANXIETY BY LORAZEPAM.
224393 04-09

BENZOCTAMINE (TACITIN) VERSUS PLACEBO: A DOUBLE-BLIND CROSSOVER STUDY IN ANXIETY NEUROTICS.
225064 04-10

DEPRESSION AND ANXIETY IN HEROIN ADDICTS: A PLACEBO CONTROLLED STUDY OF DOXEPIN IN COMBINATION WITH METHADONE.
225386 04-09

ANXIOLYTIC

INTENSIVE DESIGN IN EVALUATING ANXIOLYTIC AGENTS.
198042 01-16

CLINICAL COMPARISON OF ANXIOLYTIC DRUG THERAPY.
209080 03-10

RESEARCH ON PSYCHIATRIC INDICATIONS OF A POWERFUL ANXIOLYTIC, LORAZEPAM.
210088 03-14

ISOLATION INDUCED TIMIDITY IN MICE AS A MEASURE OF ANXIOLYTIC ACTIVITY OF DRUGS.
215063 04-04

STUDY OF AN ANXIOLYTIC DRUG, CLOBAZAM, IN ORL WITH PHARYNGEAL PSYCHOSOMATIC MANIFESTATIONS.
224584 04-11

ANXIOUS

TREATMENT OF ANXIOUS PATIENTS WITH NEALBARBITONE -- (CENSEDAL).
194556 01-10

ANXIOUS DENTAL PATIENTS AS MODELS OF PSYCHOPATHOLOGY.
198089 02-11

SEDATIVE EFFECTS ON PHYSIOLOGICAL AND PSYCHOLOGICAL MEASURES IN ANXIOUS PATIENTS.
209079 03-10

PATTERNS OF SYMPTOM CHANGE IN ANXIOUS DEPRESSED OUTPATIENTS TREATED WITH DIFFERENT DRUGS.
209904 03-10

N-DESMETHYLDIAZEPAM AND AMYLOBARBITONE SODIUM AS HYPNOTICS IN ANXIOUS PATIENTS. PLASMA LEVELS, CLINICAL EFFICACY AND RESIDUAL EFFECTS.
217460 04-10

APATHETIC

WITHDRAWN, APATHETIC GERIATRIC PATIENTS RESPONSIVE TO METHYLPHENIDATE.
218216 04-11

APATHY

CLINICAL TRIAL OF FLUPENTHIXOL IN PATIENTS WITH CHRONIC SCHIZOPHRENIA: ESPECIALLY IN PATIENTS HAVING DIFFICULTY IN REHABILITATION OWING TO DECREASED EXPRESSION, APATHY AND DISTURBANCE OF RAPPORT.
202603 02-08

APLYSIA

DOPAMINE RECEPTOR BLOCKADE BY NEUROLEPTIC DRUGS IN APLYSIA NEURONES.
210599 03-03

APLYSIA-CALIFORNICA

CHOLINERGIC AGENTS AFFECT TWO RECEPTORS THAT MODULATE TRANSMITTER RELEASE AT A CENTRAL SYNAPSE IN APLYSIA-CALIFORNICA.
215705 04-03

APOMORPHINE

EFFECT OF APOMORPHINE AND NALLINE ON METHADONE INDUCED BEHAVIORAL CHANGES.
193420 01-04

ONTOGENY OF STEREOTYPED BEHAVIOUR INDUCED BY APOMORPHINE AND AMPHETAMINE IN THE RAT.
197462 01-04

INHIBITORY EFFECT OF AMPHETAMINE, L-DOPA AND APOMORPHINE ON MORPHINE-INDUCED BEHAVIOURAL EXCITATION OF RATS.
197483 01-04

ANTAGONISTIC EFFECTS OF NEUROLEPTICS AND APOMORPHINE ON SYNAPTOSOMAL TYROSINE-HYDROXYLASE IN VITRO.
198209 02-03

BEHAVIOURAL SUPERSENSITIVITY TO APOMORPHINE FOLLOWING CHRONIC TREATMENT WITH DRUGS WHICH INTERFERE WITH THE SYNAPTIC FUNCTION OF CATECHOLAMINES.
199958 02-04

POTENTIATION WITH TRICYCLIC ANTIDEPRESSANTS OF THE INHIBITORY ACTION OF APOMORPHINE ON THE ATTITUDINAL REFLEX IN FROGS.
201919 02-04

AMPHETAMINE, L-DOPA AND APOMORPHINE: EFFECTS ON ACTIVITY OF RAT DOPAMINERGIC NEURONS.
202370 02-03

INFLUENCE OF MIDBRAIN RAPHE LESION ON SOME PHARMACOLOGICAL AND BIOCHEMICAL EFFECTS OF APOMORPHINE IN RATS.
202771 02-03

THE EFFECTS OF L-DOPA, CLONIDINE, AND APOMORPHINE ON THE ACOUSTIC STARTLE REACTION IN RATS.
202773 02-04

APOMORPHINE AND AMPHETAMINE STEREOTYPY AFTER 6-HYDROXYDOPAMINE LESIONS OF THE SUBSTANTIA-NIGRA.
202793 02-04

STUDIES ON THE INTERACTION OF RESERPINE, D-AMPHETAMINE, APOMORPHINE AND 5-HYDROXYTRYPTOPHAN.
203885 02-03

TREATMENT OF WITHDRAWAL SYMPTOMS WITH APOMORPHINE.
204407 02-15

CHOLINERGIC DOPAMINERGIC INTERACTION IN THE STRIATUM: THE EFFECT OF 6-HYDROXYDOPAMINE OR PIMOZIDE TREATMENT ON THE INCREASED STRIATAL ACETYLCHOLINE LEVELS INDUCED BY APOMORPHINE, PIRIBEDIL AND D-AMPHETAMINE.
210668 03-03

INHIBITION BY APOMORPHINE OF DOPAMINE DEAMINATION IN THE RAT BRAIN.
210776 03-03

INHIBITION OF THE SYMPATHETIC NERVOUS SYSTEM BY 5,6 DIHYDROXY-2-DIMETHYLAMINOTETRALIN (M-7), APOMORPHINE AND DOPAMINE.
210888 03-03

COMPARISON OF STRUCTURAL AND STEREOISOMERS OF APOMORPHINE ON STEREOTYPED SNIFFING BEHAVIOUR OF THE RAT.
210930 03-04

IN VIVO INHIBITION OF STRIATAL ACETYLCHOLINE TURNOVER BY L-DOPA, APOMORPHINE AND (+) AMPHETAMINE.
213399 04-03

INFLUENCE OF RESPONSE TOPOGRAPHY ON THE EFFECT OF APOMORPHINE AND AMPHETAMINE ON OPERANT BEHAVIOR OF PIGEONS.
217468 04-04

BEHAVIOURAL SUPERSENSITIVITY TO APOMORPHINE FOLLOWING CEREBRAL DOPAMINERGIC DENERVATION BY 6-HYDROXYDOPAMINE.
217527 04-03

POTENTIATION OF LOCOMOTOR ACTIVITY AND MODIFICATION OF STEREOTYPY BY STARVATION IN APOMORPHINE TREATED RATS.
217675 04-04

THE INFLUENCE OF APOMORPHINE AND TRICYCLIC ANTIDEPRESSANT DRUGS ON THE LEVEL OF SEROTONIN AND ITS METABOLITE IN RAT BRAIN.
217815 04-03

THE EFFECT OF DOPAMINE AND OF APOMORPHINE ON DB-CAMP INDUCED STIMULATION OF SYNAPTOSOMAL TYROSINE-HYDROXYLASE.
217823 04-03

GENETICALLY SELECTED WINNER AND LOSER RATS IN THE TUNNEL COMPETITION: INFLUENCE OF APOMORPHINE AND DOPA.
217829 04-04

BLOCKADE OF ALPHA-METHYLTYROSINE-INDUCED SUPERSENSITIVITY TO APOMORPHINE BY CHRONIC ADMINISTRATION OF L-DOPA.
220974 04-03

NONRIGID AMINES AND AMINO ACIDS RELATED TO APOMORPHINE. (PH.D. DISSERTATION).
222634 04-01

APOMORPHINE: FACILITATION OF SEXUAL BEHAVIOUR IN FEMALE RATS.
222807 04-04

APOMORPHINE-INDUCED

SUPPRESSION OF MOUSE-KILLING AND APOMORPHINE-INDUCED SOCIAL AGGRESSION IN RATS BY LOCAL ANESTHESIA OF THE MYSTACIAL-VIBRISSAE.
206714 03-04

ENHANCEMENT OF APOMORPHINE-INDUCED INHIBITION OF STRIATAL DOPAMINE TURNOVER FOLLOWING CHRONIC HALOPERIDOL.
210814 03-03

APOMORPHINE-INDUCED ROTATION IN NORMAL RATS AND INTERACTION WITH UNILATERAL CAUDATE LESIONS.
214012 04-04

EFFECTS OF PENFLURIDOL AND OTHER DRUGS ON APOMORPHINE-INDUCED STEREOTYPED BEHAVIOR IN MONKEYS.
215684 04-04

APONAL

TACITIN AND APONAL IN THE TREATMENT OF NEUROSES.
198396 02-10

APONEURON

APONEURON TREATMENT OF CHRONIC SCHIZOPHRENICS WITH REDUCED DRIVE.
2C[illegible]666 02-08

APPEARANCE

THE APPEARANCE OF EXOPHTHALMIA IN THE COURSE OF LITHIUM CARBONATE TREATMENT: BIOLOGICAL HYPERTHYROIDISM.
209998 03-15

NONPHARMACOLOGICAL FACTORS IN DRUG THERAPY: THE INTERACTION OF DOCTOR, PATIENT, AND TABLET APPEARANCE IN THE TREATMENT OF ANXIETY/DEPRESSIVE SYNDROMES.
215060 04-10

APPETITIVE

THE EFFECTS OF MEVINPHOS ON APPETITIVE OPERANT BEHAVIOR IN THE GERBIL.
217545 04-04

APPLICATIONS
SALIVA LITHIUM LEVELS: CLINICAL APPLICATIONS.
207042 03-16
MOLECULAR MECHANISMS OF MEMORY AND LEARNING (GENERAL CONSIDERATIONS AND CLINICAL APPLICATIONS).
212281 03-14
PHARMACOLOGY OF CEREBRAL CIRCULATION AND CLINICAL APPLICATIONS. EXPERIMENTAL STUDY OF THE CIRCULATORY AND METABOLIC EFFECTS OF HYDROSARPAN-711.
218164 04-03

APPRAISAL
CLINICAL TRENDS AND PSYCHOMETRIC APPRAISAL OF A GROUP OF SCHIZOPHRENICS TREATED WITH THIOTHIXENE (NAVANE).
208981 03-08

APPROACH
ON THE PROBLEM OF DIPHENYLHYDANTOIN-INDUCED SEIZURES: AN EXPERIMENTAL APPROACH.
197815 01-05
AN ECOLOGICAL APPROACH TO A BEHAVIOR DISORDER: ENURESIS. (PH.D. DISSERTATION).
204528 02-11
PSYCHOLOGICAL EFFECTS OF DRUGS: A FACTOR ANALYTIC APPROACH.
206377 03-17
SEROTONERGIC AND CHOLINERGIC MECHANISMS DURING DISRUPTION OF APPROACH AND AVOIDANCE BEHAVIOR.
225161 04-04
CASE PRESENTATION OF AN ALTERNATIVE THERAPEUTIC APPROACH FOR THE BORDERLINE PSYCHOTIC HEROIN ADDICT: DIPHENYLHYDANTOIN.
225512 04-09

APPROACHES
STEREOCHEMICAL APPROACHES TO TRICYCLIC PSYCHOACTIVE AGENTS. (PH.D. DISSERTATION).
194565 01-01
SOME NEW APPROACHES TO THE TREATMENT OF ANXIETY.
198046 01-10
THE HEALING JOURNEY: NEW APPROACHES TO CONSCIOUSNESS.
223921 04-12

APROTINIUM
ON THE INFLUENCE OF APROTINIUM (TRASYLOL) IN THE TREATMENT OF ALCOHOL DELIRIUM.
215698 04-11

APTITUDE
THE INFLUENCE OF PSYCHOPHARMACA ON THE APTITUDE TO DRIVE.
203784 02-15

ARBITERS
ARBITERS AND SELF-RATING OF MOMENTARY MOOD IN PSYCHOPHARMACOLOGICAL LONGITUDINAL STUDIES.
206980 03-16

AROMATIC
SOME STUDIES OF ADRENERGIC AMINES: PART I. ROLE OF THE AROMATIC RING IN RECEPTOR BINDING. PART II. BETA ADRENERGIC BLOCKADE. (PH.D. DISSERTATION).
194564 01-01
EFFECT OF NEUROTROPIC AGENTS ON TOTAL PYRIDOXAL PHOSPHATE AND ON THE ACTIVITY OF THE DECARBOXYLASE OF AROMATIC AMINO ACIDS AS WELL AS OF OTHER PYRIDOXAL PHOSPHATE DEPENDENT ENZYMES IN RAT BRAIN.
199785 02-03
ACCUMULATION OF ACETYLCHOLINE AND AROMATIC MONOAMINES BY INTERACTION WITH ADENOSINE-5-TRIPHOSPHATE.
210753 03-03

AROUSAL
EFFECT OF INCREASED AROUSAL ON RESPONSE TO STIMULUS CHANGE IN A COMPLEX MAZE.
206187 03-04
THE EFFECT OF CHLORPROMAZINE AND STIMULATION OF THE MESENCEPHALIC RETICULAR FORMATION ON CENTRAL AROUSAL AND ON THE VISUAL EVOKED RESPONSE. (PH.D. DISSERTATION).
212547 03-03
POTENTIATION OF AMPHETAMINE-INDUCED AROUSAL BY FOOD DEPRIVATION: EFFECT OF HYPOTHALAMIC LESIONS.
218498 04-04
MODULATION OF PHOTICALLY EVOKED AFTERDISCHARGES BY MEANS OF PHARMACOLOGICAL AND BEHAVIORAL AROUSAL. (PH.D. DISSERTATION).
222644 04-03

ARRHYTHMIA
CARDIAC ARRHYTHMIA AND IMIPRAMINE THERAPY.
219517 04-15

ARRHYTHMIAS
EFFECT OF DELTA1-TETRAHYDROCANNABINOL AND PROPRANOLOL ON OUABAIN INDUCED ARRHYTHMIAS.
197486 01-03
ARRHYTHMIAS EVOKED BY INFUSION OF TRICYCLIC ANTIDEPRESSANTS AND NORADRENALINE ON ISOLATED RABBIT HEARTS.
197939 01-03
ARRHYTHMIAS AND INHIBITION OF NORADRENALINE UPTAKE CAUSED BY TRICYCLIC ANTIDEPRESSANTS AND CHLORPROMAZINE ON THE ISOLATED PERFUSED RABBIT HEART.
217657 04-03

ARTANE
ACUTE TOXIC PSYCHOSIS IN TWO CHILDREN TREATED WITH BENZHEXOL HYDROCHLORIDE (ARTANE).
205315 02-15

ARTERIAL
PLASMA CATECHOLAMINES: ARTERIAL VENOUS DIFFERENCES AND THE INFLUENCE OF BODY TEMPERATURE.
215655 04-06
THE EFFECT OF SOME NEUROTROPIC DRUGS ON THE PHASIC CHANGES OF ARTERIAL PRESSURE EVOKED BY STIMULATION OF THE CEREBELLAR FASTIGAL NUCLEUS.
217067 04-03

ARTERIES
CONTRACTILE RESPONSES OF GUINEA-PIG UMBILICAL ARTERIES TO VARIOUS HALLUCINOGENIC AGENTS.
200037 02-03
EFFECTS OF 5-HYDROXYINDOLEACETIC ACID ON ISOLATED CANINE CEREBRAL ARTERIES.
202799 02-03

ARTERIOSCLEROSIS
CLINICAL AND PSYCHOMETRIC EVALUATION OF THE ACTION OF VINCAMIN IN CEREBRAL ARTERIOSCLEROSIS.
211226 03-11

ARTIFICIAL
A DOUBLE-BLIND STUDY ON THE EFFECTS OF PIRACETAM UPON PERCEPTUAL AND PSYCHOMOTOR PERFORMANCE AT VARIED HEART RATES IN PATIENTS TREATED WITH ARTIFICIAL PACEMAKERS.
201328 02-13

ASCENDING
THE IMPORTANCE OF THE ASCENDING DOPAMINERGIC SYSTEMS TO THE EXTRAPYRAMIDAL AND MESOLIMBIC BRAIN AREAS FOR THE CATALEPTIC ACTION OF THE NEUROLEPTIC AND CHOLINERGIC AGENTS.
195250 01-03
ASCENDING CATECHOLAMINE PATHWAYS AND AMPHETAMINE-INDUCED LOCOMOTOR ACTIVITY: IMPORTANCE OF DOPAMINE AND APPARENT NONINVOLVEMENT OF NOREPINEPHRINE.
223054 04-03

ASPARTATE
CLINICAL APPLICATION OF LITHIUM ASPARTATE.
204392 02-09

ASPARTIC
THE ANTAGONISTIC EFFECTS OF ASPARTIC ACID ON SOME EFFECTS OF MORPHINE ON RATS.
193458 01-03

ASPIRIN
CHANGES IN THE DORSAL ROOT POTENTIAL WITH DIAZEPAM AND WITH THE ANALGESICS ASPIRIN, NITROUS OXIDE, MORPHINE AND MEPERIDINE.
195248 01-03

ASSAY
ASSAY OF PSYCHOTROPIC SUBSTANCES IN MAN.
202865 02-17
ANALYSIS OF AMPHETAMINES AND OTHER PSYCHOACTIVE DRUGS: A COLORIMETRIC ASSAY OF (S)-(+) AMPHETAMINE IN THE SUBMICROGRAM RANGE. (PH.D. DISSERTATION).
222633 04-01

ASSAYS
CONJOINT NATIVE AND ORTHOPHTHALDIALDEHYDE CONDENSATE ASSAYS FOR THE FLUORIMETRIC DETERMINATION OF 5-HYDROXYINDOLES IN BRAIN.
195238 01-01

ASSESSING
METHODS OF ASSESSING PSYCHOPHARMACOLOGICAL AGENTS IN EXPERIMENTS.
198488 02-06
ASSESSING THE IMPACT OF LOW LEVEL CHEMICALS ON DEVELOPMENT: BEHAVIORAL AND LATENT EFFECTS.
225164 04-15

ASSESSMENT
ASSESSMENT OF THERAPY IN PSYCHOGERIATRIC ILLNESS.
194244 01-11
L-DOPA AND PARKINSONISM: A PSYCHOLOGICAL ASSESSMENT.
201496 02-11
CLINICAL ASSESSMENT OF LORAZEPAM IN ANXIETY: A DOUBLE-BLIND STUDY.
209485 03-10
THE SHAPIRO CARDS SCALE AS A METHOD OF ASSESSMENT OF OBSESSIONAL SYMPTOMS IN CLOMIPRAMINE THERAPY.
214829 04-10
DOUBLE-BLIND PROCEDURE: AN ASSESSMENT IN A STUDY OF LITHIUM PROPHYLAXIS.
218042 04-16

ASSESSMENT OF TOLERANCE TO BARBITAL BY MEANS OF DRUG DISCRIMINATION PROCEDURES.
221046 04-02

THE ASSESSMENT OF NEUROLEPTOGENIC EXTRAPYRAMIDAL SYNDROMES IN PSYCHOPHARMACOLOGICAL RESEARCH.
221307 04-15

OBJECTIVE ASSESSMENT OF ANTICHOLINERGIC SIDE-EFFECTS OF TRICYCLIC ANTIDEPRESSANTS A CONTROLLED STUDY OF IMIPRAMINE AND IMIPRAMINE-N-OXIDE.
221633 04-15

ASSIGNMENT

THE RELATIONSHIP OF DIAGNOSIS AND TARGET SYMPTOMS TO PSYCHOTROPIC DRUG ASSIGNMENT.
215251 04-17

ASSOCIATION

RETROSPECTIVE STUDY OF THE ASSOCIATION BETWEEN USE OF RAUWOLFIA DERIVATIVES AND BREAST CANCER IN ENGLISH WOMEN.
194063 01-13

TARDIVE DYSKINESIA: AN EVALUATION OF THE ETIOLOGIC ASSOCIATION WITH NEUROLEPTIC THERAPY.
204164 02-15

NICOTINIC ACID IN THE TREATMENT OF SCHIZOPHRENIAS: CANADIAN MENTAL HEALTH ASSOCIATION COLLABORATIVE STUDY PROGRESS REPORT II.
219537 04-08

ASSOCIATIVE

TOWARD THE QUESTION OF THE INFLUENCE OF STIMULATION OF THE THALAMIC ASSOCIATIVE NUCLEI ON THE BEHAVIOR OF CATS.
215498 04-04

ASTHMA

DIAZEPAM ASSOCIATED ASTHMA.
200492 02-15

ASYMMETRIC

SPECIFIC ASYMMETRIC BEHAVIOUR INDUCED BY THE DIRECT CHEMICAL STIMULATION OF NEOSTRIATAL DOPAMINERGIC MECHANISMS.
197929 01-04

ATHLETES

THE EFFECTS OF A NEW SEDATIVE (LEXOTAN) ON REACTION TIMES AND ON ATTENTIVE CAPACITY OF A GROUP OF ATHLETES.
209857 03-14

ATP

INHIBITION OF CELLULAR ATP HYDROLYZING ACTIVITY BY TRICYCLIC ANTIDEPRESSANTS AND PHENOTHIAZINE TRANQUILIZERS.
221053 04-03

ATPASE

REGIONAL DISTRIBUTION OF CATIONS AND THEIR RELATION TO THE NEUROCHEMISTRY OF EXPERIMENTAL EPILEPSY, NEUROTRANSMITTERS AND ATPASE IN THE CENTRAL NERVOUS SYSTEM. (PH.D. DISSERTATION).
193588 01-03

INHIBITION OF SYNAPTIC VESICULAR MG++ DEPENDENT ATPASE (STENIN) BY ANTIPSYCHOTIC PHENOTHIAZINES.
195054 01-03

EFFECT OF ALCOHOLS, CHLORPROMAZINE AND DIPHENYLHYDANTOIN ON (CA2+) ATPASE OF HUMAN RED BLOOD CELLS.
197976 01-13

PSYCHOTROPIC DRUGS AND DIFFERENTLY STIMULATED ATPASE IN CNS.
205629 03-03

COMPARATIVE STUDIES ON THE MEMBRANE ACTIONS OF DEPRESSANT DRUGS: THE ROLE OF LIPOPHILICITY IN INHIBITION OF BRAIN SODIUM AND POTASSIUM STIMULATED ATPASE.
210818 03-03

INHIBITION OF DELTA1-TETRAHYDROCANNABINOL OF NA+-K+ TRANSPORT ATPASE FROM RAT ILEUM. PRELIMINARY REPORT.
211099 03-03

THE EFFECT OF PSYCHOTROPIC AND ANTICONVULSIVE DRUGS ON THE TRANSPORT OF ATPASE IN THE RENAL TUBES OF A GUINEA-PIG.
223015 04-05

ATRIA

EFFECTS OF THE NORADRENALINE METABOLITES ON TYROSINE-HYDROXYLASE ACTIVITY IN GUINEA-PIG ATRIA.
193279 01-02

EFFECT OF AMPHETAMINE, 3,4 METHYLENEDIOXYAMPHETAMINE, P-METHOXYAMPHETAMINE AND RELATED AMPHETAMINES ON UPTAKE OF METARAMINOL AND EFFLUX OF NORADRENALINE IN ADRENERGIC NERVES OF RABBIT ATRIA.
217889 04-03

RELATIONSHIPS BETWEEN TRICYCLIC ANTIDEPRESSANT CONCENTRATIONS, 1-3H-NORAFRENALINE UPTAKE AND CHRONOTROPIC EFFECT IN ISOLATED RAT ATRIA.
221188 04-03

ATRIAL

STRUCTURE-ACTIVITY RELATIONSHIPS BETWEEN META-SUBSTITUTED N-ETHYLAMPHETAMINES AND ISOLATED GUINEA-PIG ATRIAL RATE.
210887 03-03

THE EFFECT OF ALCOHOL AND BARBITURATE ON THE FREQUENCY OF ATRIAL AND VENTRICULAR PREMATURE BEATS DURING SLEEP.
218971 04-13

ATROPINE

A COMPARATIVE STUDY OF AMPHETAMINE, EPHEDRINE ATROPINE MIXTURE, PLACEBO AND BEHAVIORAL CONDITIONING IN THE TREATMENT OF NOCTURNAL ENURESIS.
198020 01-11

EFFECT OF INTRAHIPPOCAMPAL INJECTION OF ATROPINE ON DIFFERENT PHASES OF A LEARNING EXPERIMENT.
198227 02-04

THE EFFECTS OF CHLORPROMAZINE, ATROPINE, MORPHINE AND PENTOBARBITAL ON INDUCED GASTRIC ULCERATION IN RATS. (PH.D. DISSERTATION).
200405 02-02

COMPARISON OF THE EFFECTS OF ATROPINE AND CANNABIS UPON THE FIXED CONDITIONED ALIMENTARY MOTOR REFLEXES IN CATS AFFECTED BY NICOTINE.
205623 03-14

NEOCORTICAL AND HIPPOCAMPAL ACTIVATION IN RELATION TO BEHAVIOR: EFFECTS OF ATROPINE, ESERINE, PHENOTHIAZINES, AND AMPHETAMINE.
206742 03-04

ACTIONS OF ACETYLCHOLINE AND ATROPINE ON CEREBRAL CORTICAL NEURONS IN CHRONICALLY MORPHINE TREATED RATS.
215733 04-03

ATROPINE COMA TREATMENT OF SCHIZOPHRENIC PATIENTS WITH A SLUGGISH DEVELOPMENT AND OBSESSIVE SYNDROMES.
224085 04-08

ATTACK

CHLORDIAZEPOXIDE (LIBRIUM) INDUCED CHANGES IN INTRASPECIFIC ATTACK AND SELECTED NONAGONISTIC BEHAVIORS IN MALE SIAMESE FIGHTING FISH.
217524 04-04

EFFECTS OF SCOPOLAMINE AND ALPHA-METHYL-P-TYROSINE UPON PREDATORY ATTACK IN CATS.
217526 04-04

THE EFFECTS OF SHOCK INTENSITY, D-AMPHETAMINE, AND PENTOBARBITAL ON THE FREQUENCY AND RESPONSE DYNAMICS OF BITING ATTACK IN THE SQUIRREL MONKEY. (PH.D. DISSERTATION).
222114 04-04

ATTENTION

EEG CORRELATES OF IMPAIRED ATTENTION PERFORMANCE UNDER SECOBARBITAL AND CHLORPROMAZINE IN THE MONKEY.
217544 04-03

METHYLPHENIDATE AND HALOPERIDOL IN CHILDREN: EFFECTS ON ATTENTION, MEMORY, AND ACTIVITY.
218118 04-14

ATTENTION AND THE AUDITORY EVOKED POTENTIAL IN HYPERKINETIC CHILDREN TREATED WITH METHYLPHENIDATE AND IN NORMAL CHILDREN. (PH.D. DISSERTATION).
222747 04-11

ATTENTIVE

THE EFFECTS OF A NEW SEDATIVE (LEXOTAN) ON REACTION TIMES AND ON ATTENTIVE CAPACITY OF A GROUP OF ATHLETES.
209857 03-14

ATTENUATING

TOLERANCE TO THE HYPOTHERMIC AND AGGRESSION ATTENUATING EFFECT OF DELTA8- AND DELTA9-TETRAHYDROCANNABINOL IN MICE.
197866 01-04

ATTENUATION

PHYSOSTIGMINE ATTENUATION OF DELTA9-TETRAHYDROCANNABINOL INDUCED HYPERTHERMIA IN RATS.
195539 01-03

THE RELATIVE ATTENUATION OF SELF-STIMULATION, EATING AND DRINKING PRODUCED BY DOPAMINE RECEPTOR BLOCKADE.
198225 02-04

ATTENUATION OF ACUTE HABITUATION BY SCOPOLAMINE IN THE BLACK-TAILED PRAIRIE DOG (CYNOMYS-LUDOVICIANUS).
206745 03-04

HALOPERIDOL INDUCED DISRUPTION OF CONDITIONED AVOIDANCE RESPONDING: ATTENUATION BY PRIOR TRAINING OR BY ANTICHOLINERGIC DRUGS.
210861 03-04

DIFFERENTIAL ATTENUATION OF SOMATOVISCERAL AND VISCEROSOMATIC REFLEXES BY DIAZEPAM, PHENOBARBITAL AND DIPHENYLHYDANTOIN.
222818 04-04

ATTITUDES

THE PSYCHIATRIST ATTITUDES AND THERAPEUTIC MEANS WHEN FACED WITH RESISTANT DEPRESSIONS.
196035 01-17

ATTITUDINAL

POTENTIATION WITH TRICYCLIC ANTIDEPRESSANTS OF THE INHIBITORY ACTION OF APOMORPHINE ON THE ATTITUDINAL REFLEX IN FROGS.
201919 02-04

ATYPICAL

ATYPICAL INDICATION OF LITHIUM THERAPY.
212213 03-09

ATYPICAL TARDINE DYSKINESIA.
225333 04-15

AUDIOGENIC
PROTECTIVE EFFECT OF ADENOSINE AND NICOTINAMIDE AGAINST AUDIOGENIC SEIZURE.
198135 02-03
5-HYDROXYTRYPTAMINE AS AN INHIBITORY MODULATOR IN AUDIOGENIC SEIZURE. (PH.D. DISSERTATION).
212521 03-03
THE PSYCHOPHARMACOLOGY OF AUDIOGENIC SEIZURE.
213629 04-03
PRENATAL MATERNAL D-AMPHETAMINE EFFECTS ON EMOTIONALITY AND AUDIOGENIC SEIZURE SUSCEPTIBILITY OF RAT OFFSPRING.
225079 04-04
EFFECTS OF AMINERGIC DRUGS AND GLUTAMIC ACID ON AUDIOGENIC SEIZURES INDUCED BY EARLY EXPOSURE TO ETHANOL.
225527 04-03

AUDIOMETRY
USE OF CNS STIMULANT MEDICATION IN AVERAGED ELECTROENCEPHALIC AUDIOMETRY WITH CHILDREN WITH MBD.
221103 04-11

AUDITORY
SELECTIVE DIPHENYLHYDANTOIN SUPPRESSION OF AUDITORY EVOKED POTENTIALS IN THE CAT CEREBELLAR CORTEX.
197989 01-03
EFFECTS OF MESCALINE, DELTA9-TETRAHYDROCANNABINOL AND PENTOBARBITAL ON THE AUDITORY EVOKED RESPONSES IN THE CAT.
197990 01-03
INFLUENCE OF AN ANTICHOLINERGIC PSYCHOTOMIMETIC AGENT ON BEHAVIOUR IN CATS CONTROLLED BY AN AUDITORY STIMULUS.
197996 01-04
EFFECTS OF MARIHUANA ON AUDITORY SIGNAL DETECTION.
206356 03-12
INFANTILE AUDITORY EXPOSURE AND UNUSUAL RESPONSE TO ANTIPSYCHOTIC DRUGS.
208617 03-04
EFFECTS OF PUTATIVE NEUROTRANSMITTERS ON NEURONAL ACTIVITY IN MONKEY AUDITORY CORTEX.
217865 04-03
ATTENTION AND THE AUDITORY EVOKED POTENTIAL IN HYPERKINETIC CHILDREN TREATED WITH METHYLPHENIDATE AND IN NORMAL CHILDREN. (PH.D. DISSERTATION).
222747 04-11

AUTOEXPERIMENTS
EFFECT OF AMITRIPTYLINE IN LONG-TERM AUTOEXPERIMENTS: PSYCHOPHYSIOLOGIC STUDY AND DURATION OF EXCRETION.
204402 02-13

AUTOMATIC
INFLUENCE OF MELATONIN ON EEG AND HUMAN SLEEP: AUTOMATIC EEG ANALYSES AND POLYGRAPHIC NIGHT SLEEP INVESTIGATIONS.
205446 02-13
SPECIFICITY OF BENZODIAZEPINE ACTION ON HUMAN SLEEP CONFIRMED. ANOTHER CONTRIBUTION OF AUTOMATIC ANALYSIS OF POLYGRAPH RECORDINGS.
218953 04-14

AUTOMATON
FURTHER OBSERVATIONS ON AUTOMATON LIKE EXISTENCE UNDER LONG-TERM LITHIUM THERAPY.
204410 02-15

AUTOMOBILE
NEUROLEPTIC DRUGS AND AUTOMOBILE DRIVING.
205882 03-15

AUTONOMIC
THE EFFECTS OF DRUGS REGULATING AUTONOMIC RESPONSES DURING CONDITIONING ON SUBSEQUENT AVOIDANCE BEHAVIOR. (PH.D. DISSERTATION).
193777 01-03
AN ANALYSIS OF THE GROSS BEHAVIOURAL CHANGES INDUCED BY TETRAETHYLAMMONIUM AND A COMPARISON WITH OTHER SUBSTANCES AFFECTING THE AUTONOMIC AND CENTRAL NERVOUS SYSTEM AFTER INTRAVENTRICULAR INJECTIONS TO CONSCIOUS CATS.
202781 02-04
CARDIOVASCULAR AND AUTONOMIC EFFECTS OF CHLORPROMAZINE. (PH.D. DISSERTATION).
203034 02-03
THE EFFECT OF SYDNOCARB ON SOME PSYCHOLOGICAL AND AUTONOMIC TESTS: A PILOT STUDY.
205599 02-13
THE EFFECT OF MEFEXAMIDE ON SOME AUTONOMIC AND PSYCHOLOGICAL TESTS.
205605 03-13
VARIATIONS IN THE AUTONOMIC NERVOUS SYSTEM AFTER ADMINISTRATION OF DIHYDROERGOTAMINE IN PSYCHOSOMATIC PATIENTS.
209045 03-11
CORRECTION OF AUTONOMIC EFFECTS OF PSYCHOTROPIC DRUGS BY LARGE DOSES OF DIHYDROERGOTAMINE IN ADULTS AND THE ELDERLY.
211998 03-11
CENTRALLY MEDIATED CARDIOVASCULAR EFFECTS OF 5-HYDROXYTRYPTOPHAN IN MAO INHIBITED DOGS: MODIFICATION BY AUTONOMIC ANTAGONISTS.
215757 04-03
THE EFFECT OF AUTONOMIC AND PSYCHOTROPIC DRUGS ON ADRENALINE REVERSAL IN THE RAT UTERUS.
222803 04-03

AUTORADIOGRAPHIC
METABOLISM AND AUTORADIOGRAPHIC DISTRIBUTION OF DELTA8- AND DELTA9-TETRAHYDROCANNABINOL IN SOME ORGANS OF THE MONKEY CALLITHRIX-JACCHUS.
217837 04-03

AUTORECEPTORS
ARE AUTORECEPTORS IN DOPAMINERGIC NEURONS INVOLVED IN THE CHANGE OF THE KINETIC STATE OF STRIATAL TYROSINE-HYDROXYLASE ELICITED BY ANTIPSYCHOTICS? (UNPUBLISHED PAPER).
208636 03-03

AVAILABILITY
INFLUENCE OF EMULSIFIED FAT ON CHLORPROMAZINE AVAILABILITY IN RABBIT BLOOD.
194928 01-03

AVERAGE
LITHIUM RESPONSE IN DEPRESSION AS PREDICTED BY UNIPOLAR/BIPOLAR ILLNESS, AVERAGE EVOKED RESPONSE, CATECHOL-O-METHYLTRANSFERASE AND FAMILY HISTORY. (UNPUBLISHED PAPER).
201000 02-09
AVERAGE EVOKED RESPONSES (AER) AND HOMOVANILLIC ACID (HVA) IN CEREBROSPINAL FLUID (CSF) IN A PSYCHOTIC PATIENT WITH ADDISONS DISEASE.
221310 04-09

AVERAGED
USE OF CNS STIMULANT MEDICATION IN AVERAGED ELECTROENCEPHALIC AUDIOMETRY WITH CHILDREN WITH MBD.
221103 04-11

AVERSION
A CONDITIONED TASTE AVERSION INDUCED BY ALPHA-METHYL-P-TYROSINE.
195090 01-04
THE EFFECT OF DIFFERENT LEVELS OF PRE-EXPOSURE TO SUCROSE ON THE ACQUISITION AND EXTINCTION OF A CONDITIONED AVERSION.
217807 04-04
CONDITIONED AVERSION TO MORPHINE WITH NALOXONE.
219023 04-04
NALOXONE-INDUCED AVERSION TO SUCROSE IN MORPHINE-DEPENDENT RATS.
219031 04-04
CONDITIONED AVERSION TO MORPHINE WITH LITHIUM CHLORIDE IN MORPHINE-DEPENDENT RATS.
219039 04-04
INVESTIGATIONS OF UCS-CS MEDIATION IN RADIATION INDUCED CONDITIONED TASTE AVERSION. (PH.D. DISSERTATION).
220681 04-04
EFFECTS OF SCOPOLAMINE ON RETENTION OF TASTE AVERSION LEARNING IN RATS.
223033 04-04

AVERSIONS
POISON INDUCED NEOPHOBIA IN RATS: ROLE OF STIMULUS GENERALIZATION OF CONDITIONED TASTE AVERSIONS.
223254 04-04

AVERSIVE
SEROTONIN AND THE AVERSIVE THRESHOLD IN RATS.
193157 01-04
THE EFFECT OF CHLORPROMAZINE AND IMIPRAMINE ON THE AVERSIVE THRESHOLD OF RATS.
195294 01-04
THE ALTERATION OF AVERSIVE THRESHOLDS AFTER CHRONIC ADMINISTRATION OF TWO TRANQUILIZING AGENTS.
205418 02-04
EFFECTS OF PSYCHOACTIVE DRUGS ON RESPONSES OF THE RAT TO AVERSIVE STIMULATION.
210784 03-04
DRUG EFFECTS ON BEHAVIOR MAINTAINED BY AVERSIVE EVENTS.
213619 04-04
ACTION OF SEROTONIN MICROINJECTED INTO HYPOTHALAMIC SITES AT WHICH ELECTRICAL STIMULATION PRODUCED AVERSIVE RESPONSES IN THE RAT.
219075 04-04
INHIBITORS OF CEREBRAL PROTEIN SYNTHESIS: DISSOCIATION OF AVERSIVE AND AMNESIC EFFECTS.
221005 04-04
EFFECTS OF ACTH, DEXAMETHASONE AND DEOXYCORTICOSTERONE ON AVERSIVE THRESHOLD OF RATS.
221766 04-04

AVOIDANCE
THE EFFECTS OF PHYSOSTIGMINE DURING THE ACQUISITION OF AVOIDANCE BEHAVIOUR AS A FUNCTION OF THE INTERSESSION INTERVAL.
192951 01-04

DIFFERENTIAL EFFECTS OF EPINEPHRINE AND PROPRANOLOL ON SHUTTLEBOX AVOIDANCE LEARNING IN RATS OF DIFFERENT AGES. (PH.D. DISSERTATION).
193745 01-04

THE EFFECTS OF DRUGS REGULATING AUTONOMIC RESPONSES DURING CONDITIONING ON SUBSEQUENT AVOIDANCE BEHAVIOR. (PH.D. DISSERTATION).
193777 01-03

EFFECTS OF AGROCLAVINE ON AVOIDANCE BEHAVIOR IN THE HAMSTER.
194130 01-04

LONG-TERM LITHIUM ADMINISTRATION TO RATS. LITHIUM AND SODIUM DOSAGE AND ADMINISTRATION, AVOIDANCE OF INTOXICATION, POLYURIC CONTROL RATS.
195042 01-03

SHUTTLE AVOIDANCE LEARNING OF MICE: EFFECTS OF POSTTRIAL PENTYLENETETRAZOL, STRAIN AND AGE.
195226 01-04

EFFECTS OF D-AMPHETAMINE ON ACQUISITION OF LEVERPRESS SIDMAN AVOIDANCE IN RATS.
195305 01-04

CHANGES IN THE ACQUISITION OF CONDITIONED AVOIDANCE RESPONSES FOLLOWING MIDBRAIN RAPHE LESIONS IN TH
197574 01-04

POTENTIATION OF TETRABENAZINE-INDUCED BEHAVIOURAL DEPRESSION BY IMIPRAMINE ON A DISCRETE TRIAL AVOIDANCE ESCAPE SCHEDULE.
197859 01-04

EFFECTS OF L-DOPA ON CONDITIONED AVOIDANCE RESPONDING AFTER BEHAVIOURAL SUPPRESSION BY ALPHA-METHYLTYROSINE OR RESERPINE IN MICE.
197987 01-04

RESISTANCE TO EXTINCTION OF AN AVOIDANCE RESPONSE IN RATS FOLLOWING THE ADMINISTRATION OF CHLORDIAZEPOXIDE (LIBRIUM) AND DIAZEPAM (VALIUM).
198226 02-04

ENHANCEMENT OF THE CHLORPROMAZINE-INDUCED SUPPRESSION OF THE CONDITIONED AVOIDANCE RESPONSE BY CARBONIC ANHYDRASE INHIBITION.
199770 02-03

THE INTERACTION OF DOPAMINE ANTAGONISTS AND AMANTADINE HYDROCHLORIDE ON THE ACQUISITION OF THE CONDITIONED AVOIDANCE RESPONSE IN RATS.
199959 02-04

THE INFLUENCE OF CATECHOLAMINES, SEROTONIN, AND SOME AMINO ACIDS ADMINISTERED INTO THE AMYGDALOID COMPLEX ON CONDITIONED REFLEXES OF AVOIDANCE AND MOTOR ACTIVITY IN RATS.
200566 02-03

TOLERANCE TO THE STIMULANT EFFECTS OF MORPHINE AND PENTAZOCINE ON AVOIDANCE RESPONDING IN THE RAT.
201319 02-04

EFFECTS OF CENTRAL AND PERIPHERAL ADRENERGIC AND CHOLINERGIC MODIFICATION ON TIME-DEPENDENT PROCESSES IN AVOIDANCE PERFORMANCE.
202203 02-03

EFFECTS ON THE ACQUISITION OF CONDITIONED AVOIDANCE RESPONSES AND SEIZURE THRESHOLD IN THE OFFSPRING OF AMPHETAMINE TREATED GRAVID RATS.
202722 02-05

ACTION OF A NEW PSYCHOTROPIC DRUG (SULPIRIDE) ON AVOIDANCE BEHAVIOR IN RATS.
202770 02-04

EFFECTS OF DELTA8-THC ON DISSOCIATION OF CONDITIONED AVOIDANCE RESPONDING IN TOLERANT AND NONTOLERANT RATS.
202969 02-04

METHODS OF DECONDITIONING PERSISTING AVOIDANCE: AMPHETAMINE, CHLORPROMAZINE, AND CHLORDIAZEPOXIDE AS ADJUNCTS TO RESPONSE PREVENTION.
202987 02-04

DIETHYLDITHIOCARBAMATE (ANTABUSE): DECREASE OF BRAIN HEAVY METAL STAINING PATTERN AND IMPROVED CONSOLIDATION OF SHUTTLEBOX AVOIDANCE IN GOLDFISH.
203521 02-04

ROLE OF PITUITARY ADRENOCORTICAL SYSTEM IN MEDIATING AVOIDANCE BEHAVIOR OF RATS WITH SEPTAL LESIONS.
206739 03-04

EFFECTS OF HIPPOCAMPAL MICROINJECTIONS OF D-AMPHETAMINE AND SCOPOLAMINE ON ACTIVE AVOIDANCE BEHAVIOR IN RATS.
206741 03-04

METHODS OF DECONDITIONING PERSISTING AVOIDANCE: AMPHETAMINE AND AMOBARBITAL AS ADJUNCTS TO RESPONSE PREVENTION.
209897 03-04

NORMAL SHUTTLEBOX AVOIDANCE LEARNING AFTER CHRONIC PHENOBARBITAL INTOXICATION IN MICE.
210737 03-04

EFFECTS OF NALORPHINE ON AVOIDANCE BEHAVIOR AND LOCOMOTOR ACTIVITY IN THE RAT.
210783 03-04

HALOPERIDOL INDUCED DISRUPTION OF CONDITIONED AVOIDANCE RESPONDING: ATTENUATION BY PRIOR TRAINING OR BY ANTICHOLINERGIC DRUGS.
210861 03-04

EFFECTS OF DRUG ALTERED SEROTONIN LEVELS ON THE ACQUISITION OF A SHUTTLEBOX AVOIDANCE TASK. (PH.D. DISSERTATION).
211781 03-04

EFFECTS OF D-AMPHETAMINE AND PRESESSION SHOCKS ON SIDMAN AVOIDANCE WITH A TONE IN RATS. (PH.D. DISSERTATION).
212677 03-04

THE COMPARATIVE EFFECTS OF MORPHINE AND CHLORPROMAZINE ON THE ACQUISITION OF CONDITIONED AVOIDANCE RESPONSE. (PH.D. DISSERTATION).
212963 03-04

THE ROLE OF MONOAMINES IN AVOIDANCE BEHAVIOUR IN RATS.
213422 04-04

METHYLPHENIDATE EFFECTS ON AVOIDANCE LEARNING AT TWO AGES IN THE RAT.
215685 04-04

LOSS OF ACTIVE AVOIDANCE RESPONDING AFTER LATERAL HYPOTHALAMIC INJECTIONS OF 6-HYDROXYDOPAMINE.
215704 04-04

FIXED-RATIO ESCAPE AND AVOIDANCE ESCAPE FROM NALOXONE IN MORPHINE-DEPENDENT MONKEYS: EFFECTS OF NALOXONE DOSE AND MORPHINE PRETREATMENT.
215968 04-04

THE EFFECTS OF CHLORDIAZEPOXIDE ON AVOIDANCE PERFORMANCE OF MICE SUBJECTED TO UNDERNUTRITION OR HANDLING STRESS IN EARLY LIFE.
217463 04-04

FACILITATION OF AVOIDANCE LEARNING BY CHLORDIAZEPOXIDE AMPHETAMINE COMBINATIONS IN MICE.
217466 04-04

THE EFFECTS OF NICOTINE ON TWO-WAY AVOIDANCE CONDITIONING IN BIDIRECTIONALLY SELECTED STRAINS OF RATS.
217525 04-04

6-METHOXYTETRAHYDRO-BETA-CARBOLINE PRODUCES A RETENTION DEFICIT FOR ONE-TRIAL PASSIVE AVOIDANCE IN MICE.
217833 04-04

ON NEUROCHEMICAL MECHANISMS OF SEPTUM INFLUENCE ON THE CONDITIONED AVOIDANCE REACTION IN RATS.
218803 04-04

METHYLATED DERIVATIVES OF NOREPINEPHRINE AND THE CONDITIONED AVOIDANCE RESPONSE IN RATS.
218958 04-02

HIPPOCAMPAL AND PITUITARY ADRENAL INFLUENCES ON ACTIVITY AND AVOIDANCE BEHAVIOR. (PH.D. DISSERTATION).
219289 04-04

6-HYDROXYDOPAMINE AND AVOIDANCE: A BEHAVIORAL AND PHARMACOLOGICAL ANALYSIS. (PH.D. DISSERTATION).
220674 04-04

A SIMPLE AVOIDANCE PROCEDURE FOR TESTING PSYCHOTROPIC DRUGS IN MICE.
220903 04-04

THE EFFECT OF AN ADRENAL DEMEDULLATION AND CHEMICAL SYMPATHECTOMY (2,4,5 TRIHYDROXYPHENYLETHYLAMINE) ON THE ACQUISITION OF A ONE-WAY ACTIVE AVOIDANCE RESPONSE. (PH.D. DISSERTATION).
222736 04-04

THE INFLUENCE OF PHENAMINE ON THE AVOIDANCE REACTION IN INTACT AND STRIATECTOMIZED RATS.
224467 04-04

SEROTONERGIC AND CHOLINERGIC MECHANISMS DURING DISRUPTION OF APPROACH AND AVOIDANCE BEHAVIOR.
225161 04-04

THE EFFECTS OF CHRONIC MORPHINE ADMINISTRATION UPON A MODIFIED SIDMAN AVOIDANCE SCHEDULE THAT UTILIZES RESPONSE INDEPENDENT SHOCK.
225566 04-04

AVOIDING

A CONTROLLED COMPARISON OF MAPROTILINE (LUDIOMIL) WITH IMIPRAMINE AVOIDING OBSERVER BIAS.
221654 04-09

AXIS

THYROID AXIS -- DRUGS AND BEHAVIOR.
198592 02-14

AXON

INEFFECTIVENESS OF LYSERGIC ACID DIETHYL AMIDE 25 (LSD) ON ALTERING NA-K CURRENTS IN SQUID GIANT AXON.
194927 01-03

COMPARISON OF THE ACTION OF DIFFERENT BARBITURATES ON SQUID AXON MEMBRANES.
217662 04-03

AXONAL

AFFERENTS TO THE SEPTAL AREA OF THE RAT STUDIED WITH THE METHOD OF RETROGRADE AXONAL TRANSPORT OF HORSERADISH PEROXIDASE.
203573 02-03

AXONS
D,L P-CHLORO-N-METHYLAMPHETAMINE (P) INDUCED ACCUMULATION OF 5-HT IN NONTERMINAL AXONS.
192944 01-03

A RAPID, SIMPLE AND MORE SENSITIVE METHOD FOR THE DEMONSTRATION OF CENTRAL CATECHOLAMINE CONTAINING NEURONS AND AXONS BY GLYOXYLIC ACID INDUCED FLUORESCENCE: I. SPECIFICITY.
217550 04-16

AXOPLASMIC
PUTRESCINE: EFFECT ON AXOPLASMIC TRANSPORT.
223051 04-03

AXOTOMY
INCREASE IN BRAIN DOPAMINE AFTER AXOTOMY OR TREATMENT WITH GAMMA-HYDROXYBUTYRIC ACID DUE TO ELIMINATION OF THE NERVE IMPULSE FLOW.
195439 01-03

EFFECTS OF DRUGS INFLUENCING MONOAMINE MECHANISMS ON THE INCREASE IN BRAIN DOPAMINE PRODUCED BY AXOTOMY OR TREATMENT WITH GAMMA-HYDROXYBUTYRIC ACID.
195440 01-03

AY-22214
EFFECTS OF TACLAMINE (AY-22214), A NEW PSYCHOACTIVE AGENT, ON CATECHOLAMINE AND SEROTONIN METABOLISM.
215725 04-03

AY-23028
BUTACLAMOL HYDROCHLORIDE (AY-23028): AN EARLY EVALUATION IN SEVERELY ILL SCHIZOPHRENICS.
206933 03-08

AZAPERONE
AZAPERONE, A SEDATIVE NEUROLEPTIC OF THE BUTYROPHENONE SERIES WITH PRONOUNCED ANTIAGGRESSIVE AND ANTISHOCK ACTIVITY IN ANIMALS.
206786 03-04

AZAPHEN
ON THE METABOLISM OF A NEW ANTIDEPRESSANT, AZAPHEN, IN RATS.
198484 02-01

INFLUENCE OF AZAPHEN, A NEW ANTIDEPRESSIVE DRUG, ON THE HUMAN EEG.
215065 04-09

THE INFLUENCE OF TRICYCLIC ANTIDEPRESSANTS, AZAPHEN AND IMIZINE ON BLOOD SUGAR CONCENTRATION CHANGES PRODUCED BY EPINEPHRINE AND SEROTONIN.
217214 04-03

A COMPARISON OF THE ACTION OF THE TRICYCLIC ANTIDEPRESSANTS, AZAPHEN AND IMIPRAMINE, ON THE GASTROINTESTINAL TRACT OF TEST ANIMALS.
219505 04-03

B-5833
TENTATIVE DOUBLE-BLIND TREATMENT OF ANXIETY WITH B-5833.
212166 03-10

BABOON
BEHAVIOURAL AND ELECTROGRAPHIC EFFECTS OF L-5-HYDROXYTRYPTOPHAN AND D,L-PARA-CHLOROPHENYLALANINE ON EPILEPTIC SENEGALESE BABOON (PAPIO-PAPIO).
199764 02-03

BACKGROUND
COMPARATIVE EFFECT OF PHENAMINE (AMPHETAMINE) AND CAFFEINE ON THE BACKGROUND ACTIVITY OF CORTICAL SENSORIMOTOR NEURONS AND THEIR REACTIONS DURING STIMULATION OF THE CAUDATE NUCLEUS.
198835 02-03

THE EFFECT OF INHIBITORS OF CATECHOLAMINE SYNTHESIS (ALPHA-METHYLTYROSINE AND DISULFIRAM) ON THE BACKGROUND ACTIVITY OF SENSORIMOTOR CORTEX NEURONS AND THEIR RESPONSES TO AFFERENT CAUDATE AND RETICULAR STIMULATION.
202598 02-04

BIOCHEMICAL BACKGROUND OF MONOAMINEOXIDASE INHIBITORS.
206365 03-03

BACLOFEN
BACLOFEN IN THE TREATMENT OF SCHIZOPHRENIA.
218254 04-08

BACTERIAL
A BACTERIAL MODEL FOR THE EVALUATION OF BARBITURATES.
210786 03-06

BALANCE
CHANGES IN ACID-BASE BALANCE, RESPIRATION RATE AND HEART RATE UPON REPEATED ORAL ADMINISTRATION OF BENZOCTAMINE AND DIAZEPAM TO CONSCIOUS DOGS.
197460 01-03

ALTERATIONS IN ACID-BASE BALANCE IN THE DOG AFTER INTRAVENOUS ADMINISTRATION OF BENZOCTAMINE AND DIAZEPAM, COMPARED WITH THOSE INDUCED BY THIOPENTAL.
197485 01-03

BARBITAL
THE INTERACTION OF BARBITAL AND TESTOSTERONE RELATIVE TO THEIR HYPNOTIC EFFECTS.
197448 01-03

ASSESSMENT OF TOLERANCE TO BARBITAL BY MEANS OF DRUG DISCRIMINATION PROCEDURES.
221046 04-02

BARBITONE
THE SENSITIVITY OF BARBITONE DEPENDENT AND WITHDRAWN RATS TO TREMORGENIC DRUGS.
197303 01-03

BARBITURATE
THE EFFECT OF TWO BARBITURATE ANTIPODES ON SPINAL REFLEXES AND SINGLE MOTONEURONS.
197297 01-03

ALTERATIONS OF BARBITURATE ACTION FOLLOWING 1,1 DICHLOROETHYLENE, CORTICOSTERONE, OR ACROLEIN.
197488 01-03

PERSISTENT THALAMIC AND CORTICAL BARBITURATE SPINDLE ACTIVITY AFTER ABLATION OF THE ORBITAL CORTEX IN CATS.
199763 02-03

MATURATION OF VISUAL ELECTROCORTICAL RESPONSES IN UNANESTHETIZED KITTENS: EFFECTS OF BARBITURATE ANESTHESIA.
199765 02-03

NEURONAL ACTIVITY OF NUCLEUS CAUDATES AND THALAMUS DURING BARBITURATE SPINDLES IN RATS.
201479 02-03

BARBITURATES AND BARBITURATE LIKE DRUGS: CONSIDERATIONS IN THEIR MEDICAL USE.
202923 02-17

EXPERIMENTAL EEG STUDIES ON BARBITURATE INTOXICATION AND PIRACETAM.
205507 02-03

PRACTICAL KINETICS I: QUANTITATION OF BARBITURATE STABILITY BY TLC.
211007 03-06

PROTECTIVE EFFECT OF PIRACETAM IN EXPERIMENTAL BARBITURATE INTOXICATION: EEG AND BEHAVIOURAL STUDIES.
213589 04-03

THE EFFECT OF CAFFEINE ON BARBITURATE SLEEPING TIME AND BRAIN LEVEL.
214109 04-03

CORRELATION OF BRAIN LEVELS OF BARBITURATE ENANTIOMERS WITH REPORTED DIFFERENCES IN DURATION OF SLEEP.
217457 04-03

THE EFFECT OF ALCOHOL AND BARBITURATE ON THE FREQUENCY OF ATRIAL AND VENTRICULAR PREMATURE BEATS DURING SLEEP.
218971 04-13

BARBITURATES
STEREOCHEMICAL DEPENDENCE OF PHARMACOLOGICAL ACTIVITY IN A SERIES OF OPTICALLY ACTIVE N-METHYLATED BARBITURATES.
193140 01-01

GAS CHROMATOGRAPHIC ANALYSES OF BARBITURATES IN SMALL AMOUNTS OF BLOOD.
197279 01-01

THE BIOCHEMICAL PHARMACOLOGY OF ABUSED DRUGS. II. ALCOHOL AND BARBITURATES.
200007 02-14

BARBITURATES AND BARBITURATE LIKE DRUGS: CONSIDERATIONS IN THEIR MEDICAL USE.
202923 02-17

A BACTERIAL MODEL FOR THE EVALUATION OF BARBITURATES.
210786 03-06

COMPARISON OF THE ACTION OF DIFFERENT BARBITURATES ON SQUID AXON MEMBRANES.
217662 04-03

BARPRESS
THE EFFECT OF VARYING THE DOSAGE OF SODIUM PENTOBARBITAL ON THE BARPRESS RATE OF RATS.
201843 02-04

BARRIER
LIPID SOLUBILITY AND DRUG PENETRATION OF THE BLOOD-BRAIN BARRIER.
206913 03-03

BLOOD-BRAIN BARRIER: I. KINETICS OF DISTRIBUTION OF 3H-AMPHETAMINE IN THE RAT BRAIN AFTER INTRAVENOUS ADMINISTRATION.
210788 03-03

THE BLOOD-BRAIN BARRIER II: DISTRIBUTION KINETICS OF H3-P-HYDROXYAMPHETAMINE IN BRAIN STRUCTURES OF THE RAT AFTER INTRAVENOUS ADMINISTRATION.
220977 04-03

BASAL
EFFECTS OF NICOTINE ON SPONTANEOUS LOCOMOTOR ACTIVITY IN RATS HAVING HIGH AND LOW BASAL ACTIVITY LEVELS.
202980 02-04

EVOKED NEURAL ACTIVITY IN THE BASAL GANGLIA OF THE CAT AND ITS MODIFICATION BY CHOLINERGIC AND DOPAMINERGIC AGENTS. (PH.D. DISSERTATION).
212520 03-03

BE-2254
CENTRAL CATECHOLAMINE RECEPTOR BLOCKING ACTIONS OF BE-2254 (HEAT): COMPARISON WITH CHLORPROMAZINE AND HALOPERIDOL.
222804 04-03

BEATS
THE EFFECT OF ALCOHOL AND BARBITURATE ON THE FREQUENCY OF ATRIAL AND VENTRICULAR PREMATURE BEATS DURING SLEEP.
218971 04-13

BEDREST
THE EFFECT OF BEDREST AND OF PHYSICAL ACTIVITY ON THE BLOOD LEVEL OF GENTAMYCIN AFTER INTRAMUSCULAR APPLICATION.
197956 01-13

BEDTIME
DOXEPIN IN A SINGLE BEDTIME DOSE IN PSYCHONEUROTIC OUTPATIENTS.
194834 01-10

BEHAVING
EFFECTS OF RESERPINE AND L-DOPA IN THE GLOBUS-PALLIDUS OF FREELY BEHAVING RATS.
220975 04-03

BEHAVIOR
FENFLURAMINE: AMPHETAMINE CONGENER THAT FAILS TO MAINTAIN DRUG-TAKING BEHAVIOR IN THE RHESUS MONKEY.
193137 01-04
EFFECTS OF L-DOPA ON THE HETEROSEXUAL COPULATORY BEHAVIOR OF MALE RATS.
193549 01-04
THE EFFECTS OF DRUGS REGULATING AUTONOMIC RESPONSES DURING CONDITIONING ON SUBSEQUENT AVOIDANCE BEHAVIOR. (PH.D. DISSERTATION).
193777 01-03
EFFECTS OF AGROCLAVINE ON AVOIDANCE BEHAVIOR IN THE HAMSTER.
194130 01-04
EFFECTS OF SELF-STIMULATION BEHAVIOR OF DRUGS INFLUENCING DOPAMINERGIC NEUROTRANSMISSION MECHANISMS.
194152 01-04
DOSE EFFECTS OF CHLORDIAZEPOXIDE UPON HABITUATION OF OPEN-FIELD BEHAVIOR IN WHITE RATS.
194736 01-04
EFFECTS OF P-ACETYLDEOXYEPHEDRINE ON PUNISHED BEHAVIOR IN THE RAT.
197450 01-04
THE EFFECTS OF PARENTERAL ADMINISTRATION OF CATECHOLAMINES, SEROTONIN AND HISTAMINE ON BEHAVIOR AND LEVELS OF THESE AMINES IN THE BRAIN OF THE NEONATE CHICK.
197457 01-03
A COMPARISON OF PIMOZIDE AND THIORIDAZINE AS ANTAGONISTS OF AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR IN DOGS.
197470 01-04
STIMULATION OF A SPECIFIC DRIVE (PREDATORY BEHAVIOR) BY P-CHLOROPHENYLALANINE (PCPA) IN THE RAT.
197952 01-04
CHLORPROMAZINE EFFECTS ON SELF-PUNITIVE BEHAVIOR.
198457 02-04
THE INFLUENCE OF BENZODIAZEPINE SERIES TRANQUILIZERS ON VARIOUS FORMS OF OPERANT ANIMAL BEHAVIOR.
198482 02-04
THYROID AXIS -- DRUGS AND BEHAVIOR.
198592 02-14
DISSOCIATION OF GENERAL BEHAVIOR PRODUCED BY PSYCHOTROPIC DRUGS IN MICE.
198733 02-04
CHLORDIAZEPOXIDE AND ITS EFFECT ON SLEEP WAKEFULNESS BEHAVIOR IN UNRESTRAINED CATS.
199213 02-04
ONTOGENETIC ASPECTS OF CENTRAL CHOLINERGIC INVOLVEMENT IN SPONTANEOUS ALTERNATION BEHAVIOR.
199550 02-04
CHLORDIAZEPOXIDE (LIBRIUM): THE EFFECTS OF A MINOR TRANQUILIZER ON STRATEGIC CHOICE BEHAVIOR IN THE PRISONERS DILEMMA.
199609 02-14
BIOCHEMICAL CORRELATES IN MOUSE-KILLING BEHAVIOR OF THE RAT BRAIN: BRAIN ACETYLCHOLINE AND ACETYLCHOLINESTERASE AFTER ADMINISTRATION OF DELTA9-TETRAHYDROCANNABINOL.
199807 02-03
EFFECTS OF CANNABIDIOL AND DELTA9-TETRAHYDROCANNABINOL ON OPERANT BEHAVIOR.
200036 02-04
POTENTIATION OF JUMPING BEHAVIOR BY AMINOPHYLLINE IN MICE TREATED WITH THRESHOLD DOSES OF AMPHETAMINE AND DOPA.
200039 02-04
EFFECTS OF PSYCHOTROPIC DRUGS ON EXPLORATORY BEHAVIOR OF MICE.
200047 02-04
A BEHAVIORAL INVESTIGATION: THE EFFECTS OF MEDICATION ON DISRUPTIVE CLASSROOM BEHAVIOR AND ACADEMIC PERFORMANCE. (PH.D. DISSERTATION).
200461 02-11
STUDIES OF CONFLICT INDUCED BEHAVIOR IN THE CAT: BEHAVIOR ANALYSIS AND EFFECTS OF PSYCHOTROPIC DRUGS.
202122 02-04
THE COMBINED EFFECTS OF METHYLPHENIDATE (RITALIN) AND A CLASSROOM BEHAVIOR MODIFICATION PROGRAM IN REDUCING THE HYPERKINETIC BEHAVIORS OF INSTITUTIONALIZED MENTAL RETARDATES. (PH.D. DISSERTATION).
202356 02-11
MORPHINE-INDUCED STEREOTYPIC BEHAVIOR IN RATS.
202740 02-04
ACTION OF A NEW PSYCHOTROPIC DRUG (SULPIRIDE) ON AVOIDANCE BEHAVIOR IN RATS.
202770 02-04
THE ROLE OF FOREBRAIN DOPAMINE SYSTEMS IN AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR IN THE RAT.
202774 02-04
6-HYDROXYDOPAMINE LESIONS OF OLFACTORY TUBERCLES AND CAUDATE NUCLEI: EFFECT ON AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR IN RATS.
202788 02-04
EFFECTS OF PSYCHOTROPIC DRUGS ON HYPOTHALAMIC SELF-STIMULATION BEHAVIOR IN RATS.
202802 02-04
THE EFFECTS OF D- AND L-AMPHETAMINE UPON HOARDING BEHAVIOR AND FEEDING IN THE MONGOLIAN GERBIL (MERIONES-UNGUICULATUS).
202983 02-04
THE TREATMENT OF BEHAVIOR DISORDERS IN IDIOCY AND IMBECILITY WITH CLOZAPINE.
203598 02-11
AN ECOLOGICAL APPROACH TO A BEHAVIOR DISORDER: ENURESIS. (PH.D. DISSERTATION).
204528 02-11
AMPHETAMINE-INDUCED CHANGES IN STRIATAL DOPAMINE AND ACETYLCHOLINE LEVELS AND RELATIONSHIP TO ROTATION (CIRCLING BEHAVIOR) IN RATS.
205432 02-04
ROLE OF PITUITARY ADRENOCORTICAL SYSTEM IN MEDIATING AVOIDANCE BEHAVIOR OF RATS WITH SEPTAL LESIONS.
206739 03-04
EFFECTS OF HIPPOCAMPAL MICROINJECTIONS OF D-AMPHETAMINE AND SCOPOLAMINE ON ACTIVE AVOIDANCE BEHAVIOR IN RATS.
206741 03-04
NEOCORTICAL AND HIPPOCAMPAL ACTIVATION IN RELATION TO BEHAVIOR: EFFECTS OF ATROPINE, ESERINE, PHENOTHIAZINES, AND AMPHETAMINE.
206742 03-04
THE EFFECTS OF DOPA ON THE VISUAL EVOKED POTENTIALS IN RABBIT AND ON MOUSE MOTOR BEHAVIOR FOLLOWING INHIBITION OF DOPAMINE-BETA-HYDROXYLASE.
206768 03-03
BEHAVIOR: BIOLOGY, PHYSIOLOGY, PHARMACOLOGY.
207204 03-17
PHARMACOLOGY AND PHYSIOLOGY OF STEREOTYPED BEHAVIOR.
207284 03-04
CENTRAL CATECHOLAMINE NEURONS, BEHAVIOR AND NEUROLEPTIC DRUGS: AN ANALYSIS TO UNDERSTAND THE INVOLVEMENT OF CATECHOLAMINES IN SCHIZOPHRENIA.
207305 03-03
PHARMACOLOGICAL MANIPULATIONS OF BRAIN CATECHOLAMINES AND THE AGGRESSIVE BEHAVIOR INDUCED BY MARIHUANA IN REM SLEEP DEPRIVED RATS.
210325 03-04
FROM PSYCHOPHARMACOLOGY TO PSYCHOPHARMACOGENETICS: DETERMINANTS OF THE EFFECTS OF DRUGS ON BEHAVIOR, ROLE OF GENETIC FACTORS.
210530 03-14
EFFECTS OF INTRAVENTRICULAR INFUSIONS OF ACTH1-24 AND ACTH4-10 ON LH RELEASE, OVULATION AND BEHAVIOR IN THE RABBIT.
210662 03-03
EFFECT OF INTRAVENTRICULAR NOREPINEPHRINE ON NEURON ACTIVITY IN THE MEDIAL FOREBRAIN BUNDLE DURING SELF-STIMULATION BEHAVIOR.
210704 03-04
AN OBSERVATIONAL STUDY OF HALLUCINOGEN INDUCED BEHAVIOR IN UNRESTRAINED MACACA-MULATTA.
210739 03-04
FEEDING BEHAVIOR IN SHEEP: EFFECTS OF NIALAMIDE AND 6-HYDROXYDOPAMINE.
210743 03-04
EFFECTS OF NALORPHINE ON AVOIDANCE BEHAVIOR AND LOCOMOTOR ACTIVITY IN THE RAT.
210783 03-04
EFFECT OF THYROXINE AND CORTISOL ON BRAIN ORNITHINE DECARBOXYLASE ACTIVITY AND SWIMMING BEHAVIOR IN DEVELOPING RAT.
210933 03-03

ESTROGEN STIMULATIONS DURING NEONATAL PERIOD AND THEIR EFFECTS ON EMOTIONAL AND OPERATIVE BEHAVIOR IN THE ADULT.
211219 03-04

OPIOID REINFORCED OPERANT BEHAVIOR: SELECTIVE SUPPRESSION BY ALPHA-METHYL-P-TYROSINE.
211511 03-04

THE EFFECTS OF STRAIN, DRUG, AND DOSE LEVEL ON GENERAL ACTIVITY AND EXPLORATORY BEHAVIOR IN MICE. (PH.D. DISSERTATION).
211883 03-04

TYPOLOGY OF DEPRESSIONS AND THERAPEUTIC BEHAVIOR OF PSYCHIATRISTS.
212215 03-17

THE ROLE OF SEROTONIN IN THE SEPTAL BEHAVIOR SYNDROME OF RATS. (PH.D. DISSERTATION).
213128 03-03

DISPOSITION AND ACTION OF DRUGS AFFECTING BEHAVIOR.
213617 04-03

DRUG EFFECTS ON BEHAVIOR MAINTAINED BY AVERSIVE EVENTS.
213619 04-04

PSYCHOACTIVE DRUGS AND THE ORGANIZATION OF BEHAVIOR.
213622 04-04

CEREBRAL NEUROHUMORS AND BEHAVIOR.
213623 04-08

BRAIN MONOAMINES AND BEHAVIOR.
213631 04-04

THE REVERSIBLE INHIBITION OF STEROID INDUCED SEXUAL BEHAVIOR BY INTRACRANIAL CYCLOHEXIMIDE.
213685 04-03

TOWARD THE QUESTION OF THE INFLUENCE OF STIMULATION OF THE THALAMIC ASSOCIATIVE NUCLEI ON THE BEHAVIOR OF CATS.
215498 04-04

EFFECTS OF PENFLURIDOL AND OTHER DRUGS ON APOMORPHINE-INDUCED STEREOTYPED BEHAVIOR IN MONKEYS.
215684 04-04

EFFECT OF INTRACEREBROVENTRICULAR BRADYKININ AND RELATED PEPTIDES ON RABBIT OPERANT BEHAVIOR.
215693 04-04

TOLERANCE DEVELOPMENT TO THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON CONDITIONED BEHAVIOR: ROLE OF TREATMENT INTERVAL AND INFLUENCE OF MICROSOMAL METABOLISM.
215726 04-03

AN ANALYSIS OF NEUROCHEMICAL MECHANISMS OF ONE FORM OF INTRASPECIES BEHAVIOR.
215789 04-04

EFFECTS OF MARIHUANA (DELTA9-THC) ON BEHAVIOR PATTERNS AND SOCIAL ROLES IN COLONIES OF CBA MICE.
216494 04-04

RELATIONSHIP OF BIOGENIC AMINES TO BEHAVIOR.
217218 04-04

INFLUENCE OF RESPONSE TOPOGRAPHY ON THE EFFECT OF APOMORPHINE AND AMPHETAMINE ON OPERANT BEHAVIOR OF PIGEONS.
217468 04-04

THE EFFECTS OF CHRONIC CANNABIS TREATMENT UPON BRAIN 5-HYDROXYTRYPTAMINE, PLASMA CORTICOSTERONE AND AGGRESSIVE BEHAVIOR IN FEMALE RATS WITH DIFFERENT HORMONAL STATUS.
217532 04-04

DRUG SEEKING BEHAVIOR DURING METHADONE MAINTENANCE.
217541 04-04

PUNISHED BEHAVIOR: INCREASES IN RESPONDING AFTER D-AMPHETAMINE.
217542 04-04

THE EFFECTS OF MEVINPHOS ON APPETITIVE OPERANT BEHAVIOR IN THE GERBIL.
217545 04-04

THE EFFECT OF HEMICHOLINIUM ON BEHAVIOR AND ON BRAIN ACETYLCHOLINE AND CHOLINE IN THE RAT.
217551 04-04

DISCRIMINATIVE CONTROL OF BEHAVIOR BY ELECTRICAL STIMULATION OF THE DORSAL RAPHE NUCLEUS: GENERALIZATION TO LYSERGIC ACID DIETHYLAMIDE (LSD).
217821 04-12

SEX DIFFERENCES IN THE EFFECTS OF DEXAMETHASONE PHOSPHATE ON BEHAVIOR IN RATS.
218492 04-04

A PHARMACOLOGICAL ANALYSIS OF AGGRESSIVE BEHAVIOR OF MICE INDUCED BY ISOLATION.
218800 04-04

ESTROGEN INDUCED MATERNAL BEHAVIOR IN HYSTERECTOMIZED OVARIECTOMIZED VIRGIN RATS.
219069 04-04

LATENCY AND DURATION OF ESTROGEN INDUCTION OF MATERNAL BEHAVIOR IN HYSTERECTOMIZED OVARIECTOMIZED VIRGIN RATS: EFFECTS OF PUP STIMULATION.
219070 04-04

HIPPOCAMPAL AND PITUITARY ADRENAL INFLUENCES ON ACTIVITY AND AVOIDANCE BEHAVIOR. (PH.D. DISSERTATION).
219289 04-04

THE EFFECT OF CATECHOLAMINERGIC DRUGS ON THE BEHAVIOR AND EEG OF RATS DURING CORAZOL SEIZURES.
219332 04-04

OBSERVATIONS ON EFFECTS OF A CENTRAL STIMULANT DRUG (METHYLPHENIDATE) IN CHILDREN WITH HYPERACTIVE BEHAVIOR.
219354 04-14

THE EFFECT OF DIAZEPAM ON THE BEHAVIOR OF RATS ADAPTED TO HIGH ALTITUDE HYPOXIA IN CONFLICTING SITUATIONS.
219502 04-04

THE EFFECTIVENESS OF RITALIN AND TOKEN ECONOMY IN INCREASING HYPERKINETIC CHILDRENS COLORING BEHAVIOR. (PH.D. DISSERTATION).
220510 04-14

DETERMINANTS OF AMPHETAMINE PRODUCED STEREOTYPED BEHAVIOR IN THE RAT. (PH.D. DISSERTATION).
220687 04-04

STIMULATION OF ESTROGEN INDUCED COPULATORY BEHAVIOR IN CASTRATE MALE RATS WITH THE SEROTONIN BIOSYNTHESIS INHIBITOR P-CHLOROPHENYLALANINE.
221010 04-04

INFLUENCE OF CHEMICAL STIMULATION OF CENTRAL DOPAMINERGIC SYSTEM ON THE OPEN-FIELD BEHAVIOR OF RATS.
221308 04-03

EFFECTS OF CHLORDIAZEPOXIDE UPON FEAR MOTIVATED BEHAVIOR IN DOGS.
221799 04-04

CENTRAL NERVOUS SYSTEM PHARMACOLOGY OF CHOLINERGICALLY ELICITED EATING AND DRINKING BEHAVIOR IN THE ALBINO RAT. (PH.D. DISSERTATION).
222638 04-04

FACILITATORY AND INHIBITORY INFLUENCES OF PROGESTERONE, 20ALPHA-HYDROXYPROGESTERONE AND METHYSERGIDE ON THE RECEPTIVE BEHAVIOR OF THE FEMALE RAT. (PH.D. DISSERTATION).
222739 04-04

THE EFFECTS OF DELTA9-TETRAHYDROCANNABINOL UPON FEAR-MOTIVATED BEHAVIOR IN SQUIRREL MONKEYS.
223040 04-04

LONG-LASTING EFFECTS OF PRENATAL 2,4,5 TRICHLOROPHENOXYACETIC ACID ON OPEN-FIELD BEHAVIOR IN RATS: PRE- AND POSTNATAL MEDIATION.
223044 04-04

RITALIN VERSUS BEHAVIOR THERAPY IN HYPERACTIVE CHILDREN.
224855 04-11

ON NEUROCHEMISTRY AND BEHAVIOR.
225158 04-17

NEUROCHEMICAL CHANGES ASSOCIATED WITH SCHEDULE-CONTROLLED BEHAVIOR.
225160 04-04

SEROTONERGIC AND CHOLINERGIC MECHANISMS DURING DISRUPTION OF APPROACH AND AVOIDANCE BEHAVIOR.
225161 04-04

CATECHOLAMINES AND DRUG BEHAVIOR INTERACTIONS.
225162 04-04

BEHAVIORAL

EFFECT OF APOMORPHINE AND NALLINE ON METHADONE INDUCED BEHAVIORAL CHANGES.
193420 01-04

EFFECT OF TWO DOPAMINE RECEPTOR BLOCKERS ON A SEROTONIN MEDIATED BEHAVIORAL SYNDROME IN RATS.
193548 01-04

NEONATAL BEHAVIORAL PATTERNS AND THEIR RELATION TO OBSTETRICAL MEDICATION. (PH.D. DISSERTATION).
194573 01-15

THE INEFFECTIVENESS OF DESIPRAMINE PRETREATMENT ON BEHAVIORAL EFFECTS OF 6-HYDROXYDOPAMINE IN NIALAMIDE PRETREATED RATS.
195434 01-04

THE EFFECT OF 6-HYDROXYDOPAMINE ADMINISTRATION TO NEONATAL RATS ON SOME ENDOCRINE AND BEHAVIORAL PARAMETERS.
197498 01-03

RATING THE BEHAVIORAL EFFECTS OF AMPHETAMINE.
197863 01-04

A COMPARATIVE STUDY OF AMPHETAMINE, EPHEDRINE ATROPINE MIXTURE, PLACEBO AND BEHAVIORAL CONDITIONING IN THE TREATMENT OF NOCTURNAL ENURESIS.
198020 01-11

BEHAVIORAL MECHANISMS OF DRUG ACTION IN SCHIZOPHRENIA.
198103 02-08

THE INFLUENCE OF ANTIDEPRESSANTS AND NEUROLEPTICS ON BEHAVIORAL REACTIONS ELICITED BY LESION AND EXCITATION OF THE HIPPOCAMPUS.
198483 02-04

ELECTROENCEPHALOGRAPHIC AND BEHAVIORAL STUDIES ON THE CENTRAL ACTION OF NIMETAZEPAM (S-1530) IN CATS.
199910 02-04

BEHAVIORAL SPECIFICITY OF CHLORALOSE INDUCED FEEDING IN THE RAT.
200054 02-04

A BEHAVIORAL INVESTIGATION: THE EFFECTS OF MEDICATION ON DISRUPTIVE CLASSROOM BEHAVIOR AND ACADEMIC PERFORMANCE. (PH.D. DISSERTATION).
200461 02-11

BEHAVIORAL CHANGES INDUCED BY PSYCHOTROPIC SUBSTANCES IN EXPERIMENTAL ANIMALS.
202864 02-04

GENOTYPE DEPENDENT ELECTROENCEPHALOGRAPHIC, BEHAVIORAL AND ANALGESIC CORRELATES OF MORPHINE: AN ANALYSIS IN NORMAL MICE AND IN MICE WITH SEPTAL LESIONS.
203520 02-04

SLEEP - EEG TESTS OF NONSPECIFIC CASES OF PAROXYSM AND EPISODIC BEHAVIORAL DISTURBANCES: A PRELIMINARY REPORT.
203704 02-14

ELECTROPHYSIOLOGICAL AND BEHAVIORAL REACTIVITY TO PHOTIC STIMULI FOLLOWING SEPTAL LESIONS AND PHARMACOLOGICAL TREATMENTS IN RATS.
206724 03-04

A SCHIZOPHRENIFORM BEHAVIORAL PSYCHOSIS MEDIATED BY DOPAMINE.
207035 03-04

ON THE USE OF SYDNOCARB FOR PSYCHOPHARMACOLOGICAL CORRECTION OF BEHAVIORAL DISORDERS OF THE CYCLOID TYPE OF ACCENTUATED PERSONALITY IN ADOLESCENTS.
207271 03-11

AMPHETAMINE PSYCHOSIS: BEHAVIORAL AND BIOCHEMICAL ASPECTS.
207285 03-14

STEREOSELECTIVE FEATURES OF CATECHOLAMINE DISPOSITION AND THEIR BEHAVIORAL IMPLICATIONS.
207287 03-04

BEHAVIORAL EFFECTS OF A NEW DOPAMINE-BETA-HYDROXYLASE INHIBITOR (FUSARIC ACID) IN MAN.
207311 03-07

EXPERIMENTAL TESTS OF HYPOTHESES ABOUT NEUROCHEMICAL MECHANISMS UNDERLYING BEHAVIORAL TOLERANCE TO THE ANTICHOLINESTERASE, DIISOPROPYLFLUOROPHOSPHATE.
208555 03-03

THE BEHAVIORAL EFFECTS OF 2,5 DIMETHOXY-4-ALKYLAMPHETAMINES.
210352 03-01

AMENORRHEA AND BEHAVIORAL DISTURBANCES: CLINICAL CASE TREATED WITH A PSYCHOTHERAPEUTIC METHOD BASED ON ELEMENTS OF THE CYBERNETIC THEORY OF G. CIPOLLINA MANGIAMELI.
210418 03-14

EVIDENCE THAT 5-METHOXYDIMETHYLTRYPTAMINE IS A SPECIFIC SUBSTRATE FOR MAO-A IN THE RAT: IMPLICATIONS FOR THE INDOLEAMINE DEPENDENT BEHAVIORAL SYNDROME.
210817 03-04

BEHAVIORAL EFFECTS OF D-AMPHETAMINE AND CAFFEINE IN THE SQUIRREL MONKEY.
210860 03-04

AN INVESTIGATION ON THE BEHAVIORAL AND HYPOTHERMIC EFFECTS OF YOHIMBINE: INTERACTION WITH DRUGS AFFECTING CENTRAL AND PERIPHERAL MONOAMINES.
211068 03-04

BEHAVIORAL AND NEUROCHEMICAL EFFECTS OF MORPHINE OR AMPHETAMINE AFTER CHRONIC PRETREATMENT WITH CATECHOLAMINE DEPLETING AGENTS. (PH.D. DISSERTATION).
211746 03-03

MELANOCYTE STIMULATING HORMONE: SOME BEHAVIORAL EFFECTS. (PH.D. DISSERTATION).
213030 03-04

THE BEHAVIORAL EFFECTS OF L-METHIONINE AND RELATED COMPOUNDS IN RATS AND MICE.
213528 04-04

AMPHETAMINE STEREOTYPY: THE INFLUENCE OF ENVIRONMENTAL FACTORS AND PREPOTENT BEHAVIORAL PATTERNS ON ITS TOPOGRAPHY AND DEVELOPMENT.
213531 04-04

YOHIMBINE: BEHAVIORAL AND BIOCHEMICAL EFFECTS IN MICE.
213592 04-04

PROGRAM IN BEHAVIORAL PHARMACOLOGY.
213612 04-04

BEHAVIORAL NEUROENDOCRINOLOGY: CHEMICAL CORRELATES.
213625 04-03

THE BEHAVIORAL PHARMACOLOGY OF PSYCHOACTIVE DRUGS.
213635 04-04

SEROTONIN -- NEW VISTAS: BIOCHEMISTRY AND BEHAVIORAL AND CLINICAL STUDIES.
213716 04-17

BEHAVIORAL AND PHYSIOLOGICAL FEEDBACK AS SOURCES OF INFORMATION ABOUT THE EFFECTIVENESS OF A PLACEBO. (PH.D. DISSERTATION).
214228 04-17

EFFECTS OF PSYCHOTROPIC DRUGS ON METHAMPHETAMINE-INDUCED BEHAVIORAL EXCITATION IN GROUPED MICE.
215682 04-04

SLEEP AND BEHAVIORAL CHANGES REFLECTING CENTRAL RECEPTOR HYPERSENSITIVITY FOLLOWING CATECHOLAMINE SYNTHESIS INHIBITION IN MAN. (UNPUBLISHED PAPER).
216373 04-09

BEHAVIORAL AND ELECTROPHYSIOLOGICAL EFFECTS OF PHENYLETHANOLAMINE AND 2-PHENYLETHYLAMINE.
217521 04-04

SCREENING HALLUCINOGENIC DRUGS: SYSTEMIC STUDY OF THREE BEHAVIORAL TESTS.
217528 04-06

ROLE OF BRAIN SEROTONIN IN THE INTEGRATION OF BEHAVIORAL RESPONSES AND PITUITARY ADRENOCORTICAL FUNCTIONS UNDER EMOTION.
218364 04-04

THE PARTICIPATION OF SEROTONIN REACTIVE BRAIN STRUCTURES IN SOME FORMS OF BEHAVIORAL PATTERNS IN HAMSTERS.
218472 04-04

AKINESIA: A POORLY RECOGNIZED DRUG-INDUCED EXTRAPYRAMIDAL BEHAVIORAL DISORDER.
218773 04-15

A BEHAVIORAL ANALYSIS OF HALLUCINOGENIC DRUGS. (PH.D. DISSERTATION).
219181 04-12

STUDIES ON BEHAVIORAL ENDOCRINOLOGY OF CORTICOSTEROIDS.
219472 04-04

PHARMACOLOGICALLY INDUCED BEHAVIORAL CORRELATES OF NIGROSTRIATAL FUNCTION. (PH.D. DISSERTATION).
220473 04-04

6-HYDROXYDOPAMINE AND AVOIDANCE: A BEHAVIORAL AND PHARMACOLOGICAL ANALYSIS. (PH.D. DISSERTATION).
220674 04-04

BEHAVIORAL EFFECTS OF LOCAL INJECTION OF 6-HYDROXYDOPAMINE IN THE MEDIAL VENTRAL TEGMENTUM IN THE RAT. POSSIBLE ROLE OF THE MESOLIMBIC DOPAMINERGIC SYSTEM.
220946 04-04

MODIFICATIONS BY LITHIUM OF BEHAVIORAL RESPONSES TO METHAMPHETAMINE AND TETRABENAZINE.
221041 04-04

EFFECTS OF ALPHA-METHYLDOPA ON NEWBORN KITTEN SLEEP. BEHAVIORAL EVOLUTION DURING THE FIRST MONTH AFTERBIRTH.
221049 04-04

ELECTROPHYSIOLOGICAL AND BEHAVIORAL EFFECTS OF 1-METHYL-5-O-FLUOROPHENYL 7-CHLORODIHYDROBENZODIAZEPIN-2-ONE (ID-540) IN CATS AND RABBITS.
221736 04-03

MODULATION OF PHOTICALLY EVOKED AFTERDISCHARGES BY MEANS OF PHARMACOLOGICAL AND BEHAVIORAL AROUSAL. (PH.D. DISSERTATION).
222644 04-03

BEHAVIORAL EFFECTS OF 2,5 DIMETHOXY-4-METHYLAMPHETAMINE (DOM) IN RATS AND MICE.
222801 04-04

PHYSOSTIGMINE INDUCED REVERSAL OF EEG AND BEHAVIORAL EFFECTS OF DELTA9-TETRAHYDROCANNABINOL.
223093 04-04

NEONATAL LOCOMOTOR AND LONG-TERM BEHAVIORAL EFFECTS OF D-AMPHETAMINE IN THE RAT.
225077 04-04

AN EXPERIMENTAL ANALYSIS OF BEHAVIORAL FACTORS IN DRUG DEPENDENCE.
225156 04-04

BEHAVIORAL CORRELATES OF SEROTONIN DEPLETION.
225159 04-04

ASSESSING THE IMPACT OF LOW LEVEL CHEMICALS ON DEVELOPMENT: BEHAVIORAL AND LATENT EFFECTS.
225164 04-15

AMPHETAMINE TOXICITY: BEHAVIORAL AND NEUROPATHOLOGICAL INDEXES.
225165 04-05

REINFORCEMENT SCHEDULES AND EXTRAPOLATIONS TO HUMANS FROM ANIMALS IN BEHAVIORAL PHARMACOLOGY.
225171 04-04

A BEHAVIORAL EDUCATIONAL ALTERNATIVE TO DRUG CONTROL OF HYPERACTIVE CHILDREN.
225455 04-14

BEHAVIORALLY

THE USE OF ANTICONVULSANT TREATMENT OF BEHAVIORALLY DISTURBED CHILDREN WITH BIOELECTRIC EPILEPSY: A CATAMNESTIC STUDY OF 76 CASES.
211355 03-11

BEHAVIORALLY EVOKED HIPPOCAMPAL THETA WAVES: A CHOLINERGIC RESPONSE.
220312 04-03

BEHAVIORS

THE EFFECT OF CYCLOHEXIMIDE AND ACTINOMYCIN-D ON THE SPONTANEOUS AND OPERATIVE BEHAVIORS OF THE PIGEON. PRELIMINARY NOTE.
199381 02-04

AGGRESSIVE BEHAVIORS INDUCED BY CHRONIC ADMINISTRATION OF THEOPHYLLINE, WITH PARTICULAR REFERENCE TO ALTERATIONS IN BEHAVIORS OF IMMATURE RATS.
200748 02-04

THE COMBINED EFFECTS OF METHYLPHENIDATE (RITALIN) AND A CLASSROOM BEHAVIOR MODIFICATION PROGRAM IN REDUCING THE HYPERKINETIC BEHAVIORS OF INSTITUTIONALIZED MENTAL RETARDATES. (PH.D. DISSERTATION).
202356 02-11

CHLORDIAZEPOXIDE (LIBRIUM) INDUCED CHANGES IN INTRASPECIFIC ATTACK AND SELECTED NONAGONISTIC BEHAVIORS IN MALE SIAMESE FIGHTING FISH.
217524 04-04

PREPOTENT BEHAVIORS IN AMPHETAMINE MODEL PSYCHOSIS.
224797 04-14

SCHEDULE-CONTROLLED BEHAVIORS AS DETERMINANTS OF DRUG RESPONSE.
225168 04-06

BEHAVIOUR

THE EFFECTS OF PHYSOSTIGMINE DURING THE ACQUISITION OF AVOIDANCE BEHAVIOUR AS A FUNCTION OF THE INTERSESSION INTERVAL.
192951 01-04

THE SITE OF AND MODE OF ACTION OF ET495 FOR THE MEDIATION OF STEREOTYPED BEHAVIOUR IN THE RAT.
195252 01-03

THE CONTROL OF DEVIANT SEXUAL BEHAVIOUR BY DRUGS: I. BEHAVIOURAL CHANGES FOLLOWING ESTROGENS AND ANTIANDROGENS.
196958 01-14

EFFECTS OF RESERPINE, 6-HYDROXYDOPAMINE, P-CHLOROPHENYLALANINE AND A COMBINATION OF THESE SUBSTANCES ON THE GROOMING BEHAVIOUR OF MICE.
197291 01-04

CATALEPSY, STEREOTYPED BEHAVIOUR AND STRIATAL HOMOVANILLIC ACID CONTENT IN RATS TREATED WITH METHADONE.
197299 01-03

ONTOGENY OF STEREOTYPED BEHAVIOUR INDUCED BY APOMORPHINE AND AMPHETAMINE IN THE RAT.
197462 01-04

PHARMACOLOGICAL STUDIES ON TETRABENAZINE-INDUCED EXCITED BEHAVIOUR OF RATS PRETREATED WITH AMPHETAMINE OR NIALAMIDE.
197490 01-04

THE EFFECTS OF EARLY ALPHA-METHYLDOPA TREATMENT ON BEHAVIOUR IN THE RAT.
197578 01-04

SPECIFIC ASYMMETRIC BEHAVIOUR INDUCED BY THE DIRECT CHEMICAL STIMULATION OF NEOSTRIATAL DOPAMINERGIC MECHANISMS.
197929 01-04

EFFECTS OF PHYSOSTIGMINE ON THE ACCURACY AND ACTIVITY OF DISCRIMINATION BEHAVIOUR IN RATS.
197995 01-04

INFLUENCE OF AN ANTICHOLINERGIC PSYCHOTOMIMETIC AGENT ON BEHAVIOUR IN CATS CONTROLLED BY AN AUDITORY STIMULUS.
197996 01-04

SHORT-TERM EFFECTS OF TESTOSTERONE PROPIONATE ON THE BEHAVIOUR OF YOUNG INTACT MALE DOMESTIC DUCKS (ANAS-PLATYRHYNCHOS).
199461 02-04

THE NUCLEUS LINEARIS INTERMEDIUS RAPHE AND BEHAVIOUR EVOKED BY DIRECT AND INDIRECT STIMULATION OF DOPAMINE SENSITIVE SITES WITHIN THE CAUDATE NUCLEUS OF CATS.
199864 02-04

INHIBITORY AND DISINHIBITORY EFFECTS OF NITRAZEPAM, DIAZEPAM AND FLURAZEPAM HYDROCHLORIDE ON DELAYED MATCHING BEHAVIOUR IN MONKEYS (MACACA-MULATTA).
199957 02-04

INHIBITORY ROLE OF DOPAMINE AND 5-HYDROXYTRYPTAMINE IN THE SEXUAL BEHAVIOUR OF FEMALE RATS.
199968 02-04

EFFECTS OF LOW AND HIGH DOSES OF L-DOPA ON THE TETRABENAZINE OR ALPHA-METHYLTYROSINE-INDUCED SUPPRESSION OF BEHAVIOUR IN A SUCCESSIVE DISCRIMINATION TASK.
200042 02-04

THE EFFECTS OF SCOPOLAMINE AND PHYSOSTIGMINE ON FIXED-INTERVAL BEHAVIOUR IN THE RAT.
200046 02-04

STEREOTYPED AND CIRCLING BEHAVIOUR INDUCED BY DOPAMINERGIC AGONISTS AFTER LESIONS OF THE MIDBRAIN RAPHE NUCLEI.
202792 02-04

A PRELIMINARY REPORT ON THE ACTION OF IMIPRAMINE AND ANTIPARKINSONIAN AGENTS ON THE OPEN-FIELD BEHAVIOUR OF RATS.
202803 02-04

DRUGS, EEG AND BEHAVIOUR: EEG PROFILES AND BIOAVAILABILITY MEASURES FOR CLINICAL PSYCHOPHARMACOLOGY.
205522 02-16

EFFECTS OF SCOPOLAMINE ON THE EEG OF CORTEX AND HIPPOCAMPUS DURING SPONTANEOUS BEHAVIOUR IN RATS.
205628 03-04

BRAIN DOPAMINE AND BEHAVIOUR: A CRITICAL ANALYSIS OF THE RELATIONSHIP BETWEEN DOPAMINE ANTAGONISM AND THERAPEUTIC EFFICACY OF NEUROLEPTIC DRUGS.
207306 03-04

STIMULATION OF SEXUAL BEHAVIOUR IN RATS BY A BENZODIOXANE DERIVATIVE.
210351 03-04

IMPRINTING: CORRELATIONS BETWEEN BEHAVIOUR AND INCORPORATION OF (14C)URACIL INTO CHICK BRAIN.
210667 03-04

CHANGED EATING AND LOCOMOTOR BEHAVIOUR IN THE RAT AFTER 6-HYDROXYDOPAMINE LESIONS TO THE SUBSTANTIA-NIGRA.
210763 03-04

COMPARISON OF STRUCTURAL AND STEREOISOMERS OF APOMORPHINE ON STEREOTYPED SNIFFING BEHAVIOUR OF THE RAT.
210930 03-04

THE ROLE OF MONOAMINES IN AVOIDANCE BEHAVIOUR IN RATS.
213422 04-04

EFFECT OF VARIOUS INHIBITORS OF TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE ON SELF-STIMULATION BEHAVIOUR.
213431 04-04

THYROXINE-LIKE EFFECTS OF ZINC ON BRAIN AND BEHAVIOUR WITH FIRM DEPENDENCE ON SEVERAL HORMONES.
213434 04-04

PARTIAL RESTORATION BY AN A NEUROLEPTIC (SPIRAMIDE) OF ITEMS OF GROOMING BEHAVIOUR SUPPRESSED BY AMPHETAMINE.
213590 04-04

THE EFFECTS OF AMPHETAMINE, IMIPRAMINE AND ICI-58834 (VIVALAN), A POTENTIAL ANTIDEPRESSANT, ON UNCONDITIONED BEHAVIOUR IN RATS.
214016 04-04

ALTERATIONS IN BEHAVIOUR AND CATECHOLAMINE BIOSYNTHESIS INDUCED BY LITHIUM.
214067 04-04

THE BIPHASIC EFFECT OF SMALL DOSES OF TRANYLCYPROMINE ON THE SPONTANEOUS MOTOR ACTIVITY AND LEARNED CONDITIONED BEHAVIOUR IN RATS.
215665 04-04

THE EFFECTS OF PYRITHIOXINE ON THE BEHAVIOUR AND INTELLECTUAL FUNCTION OF LEARNING DISABLED CHILDREN.
216485 04-11

INFLUENCE OF CHANGES IN BRAIN MONOAMINE METABOLISM ON BEHAVIOUR OF HERPES-SIMPLEX INFECTED MICE.
217440 04-04

EXPLORATORY BEHAVIOUR IN TWO SELECTIVELY BRED LINES OF MICE AFTER INTRAHIPPOCAMPAL INJECTION OF METHYLSCOPOLAMINE.
217464 04-04

THE EFFECT OF MICROINJECTIONS OF AMPHETAMINE INTO THE NEOSTRIATUM AND THE NUCLEUS-ACCUMBENS ON SELF-STIMULATION BEHAVIOUR.
217530 04-04

APOMORPHINE: FACILITATION OF SEXUAL BEHAVIOUR IN FEMALE RATS.
222807 04-04

THE EFFECTS OF THYROTROPIN-RELEASING HORMONE ON THE BEHAVIOUR OF RATS PRETREATED WITH ALPHA-METHYLTYROSINE.
222815 04-04

THE INTERACTION OF POSTWEANING HOUSING CONDITIONS AND PRENATAL DRUG EFFECTS ON BEHAVIOUR.
225563 04-04

THE RELATION BETWEEN CEREBRAL SEROTONIN LEVELS AND CONDITIONED BEHAVIOUR IN THE RAT FOLLOWING THE ADMINISTRATION OF LSD-25 AND UML.
225564 04-04

BEHAVIOURAL

MESOLIMBIC INVOLVEMENT WITH BEHAVIOURAL EFFECTS INDICATING ANTIPSYCHOTIC ACTIVITY.
193450 01-03

BEHAVIOURAL INTERACTIONS BETWEEN IMIDAZOLEACETIC ACID AND GAMMA-HYDROXYBUTYRIC ACID IN RATS AND MICE.
193545 01-04

THE CONTROL OF DEVIANT SEXUAL BEHAVIOUR BY DRUGS: I. BEHAVIOURAL CHANGES FOLLOWING ESTROGENS AND ANTIANDROGENS.
196958 01-14

INHIBITORY EFFECT OF AMPHETAMINE, L-DOPA AND APOMORPHINE ON MORPHINE-INDUCED BEHAVIOURAL EXCITATION OF RATS.
197483 01-04

THE INFLUENCE OF ANTICATECHOLAMINERGIC AGENTS ON THE BEHAVIOURAL EFFECTS OF L-5-HYDROXYTRYPTOPHAN.
197572 01-04

POTENTIATION OF TETRABENAZINE-INDUCED BEHAVIOURAL DEPRESSION BY IMIPRAMINE ON A DISCRETE TRIAL AVOIDANCE ESCAPE SCHEDULE.
197859 01-04

EFFECTS OF L-DOPA ON CONDITIONED AVOIDANCE RESPONDING AFTER BEHAVIOURAL SUPPRESSION BY ALPHA-METHYLTYROSINE OR RESERPINE IN MICE.
197987 01-04

BEHAVIOURAL AND ELECTROCORTICAL MODIFICATIONS INDUCED IN THE RAT BY INTRAVENTRICULAR INJECTION OF PHYSALAEMIN AND ELEDOISIN.
198224 02-03

BEHAVIOURAL AND ELECTROGRAPHIC EFFECTS OF L-5-HYDROXYTRYPTOPHAN AND D,L-PARA-CHLOROPHENYLALANINE ON EPILEPTIC SENEGALESE BABOON (PAPIO-PAPIO).
199764 02-03

REDUCED BEHAVIOURAL EFFECTS OF INTRAHIPPOCAMPALLY ADMINISTERED CARBACHOL IN RATS WITH LOW CHOLINESTERASE ACTIVITY.
199956 02-04

BEHAVIOURAL SUPERSENSITIVITY TO APOMORPHINE FOLLOWING CHRONIC TREATMENT WITH DRUGS WHICH INTERFERE WITH THE SYNAPTIC FUNCTION OF CATECHOLAMINES.
199958 02-04

INHIBITION OF BEHAVIOURAL AND EEG ACTIVATION INDUCED BY MORPHINE ACTING ON LOWER BRAINSTEM STRUCTURES.
200078 02-03

BEHAVIOURAL EFFECT OF INTRAVENTRICULAR APPLICATION OF METHOXYINDOLEALKYLAMINES IN THE RAT.
202772 02-04

THE PHARMACOLOGY OF GROSS BEHAVIOURAL EFFECTS OF CHOLINOMIMETIC SUBSTANCES INJECTED INTO THE CEREBRAL VENTRICLES OF UNANAESTHETIZED CATS: EVIDENCE FOR CENTRAL MUSCARINIC MEDIATION.
202780 02-04

AN ANALYSIS OF THE GROSS BEHAVIOURAL CHANGES INDUCED BY TETRAETHYLAMMONIUM AND A COMPARISON WITH OTHER SUBSTANCES AFFECTING THE AUTONOMIC AND CENTRAL NERVOUS SYSTEM AFTER INTRAVENTRICULAR INJECTIONS TO CONSCIOUS CATS.
202781 02-04

BEHAVIOURAL AND ELECTROGRAPHIC OBSERVATIONS DURING EPILEPTIC CONVULSIONS INDUCED BY STRYCHNINE AND PENTYLENETETRAZOL IN CONSCIOUS YOUNG AND ADULT CHICKENS.
205459 02-03

LITHIUM TREATMENT OF BEHAVIOURAL DISTURBANCES IN PATIENTS WITH DEFECTIVE INTELLECT.
205610 03-09

THE EFFECT OF DRUGS WITH ANTIDEPRESSANT ACTIVITY UPON THE HYPOTHERMIA AND BEHAVIOURAL DEPRESSION INDUCED IN MICE BY PIMOZIDE OR CENTRALLY ADMINISTERED NORADRENALINE.
210762 03-04

POSTCASTRATION DECLINE IN BEHAVIOURAL RESPONSIVENESS TO INTRAHYPOTHALAMIC ANDROGEN IN DOVES.
210918 03-03

PROTECTIVE EFFECT OF PIRACETAM IN EXPERIMENTAL BARBITURATE INTOXICATION: EEG AND BEHAVIOURAL STUDIES.
213589 04-03

LONG-TERM BEHAVIOURAL EFFECTS OF DIAZEPAM AND ACTH, ADMINISTERED EARLY IN LIFE.
215067 04-04

BEHAVIOURAL EVIDENCE OF DOPAMINE RECEPTOR STIMULATION BY PIRIBEDIL (ET495) AND ITS METABOLITE S584.
217152 04-04

THE INHIBITION OF A AND B FORMS OF MAO IN THE PRODUCTION OF A CHARACTERISTIC BEHAVIOURAL SYNDROME IN RATS AFTER L-TRYPTOPHAN LOADING.
217471 04-03

BEHAVIOURAL SUPERSENSITIVITY TO APOMORPHINE FOLLOWING CEREBRAL DOPAMINERGIC DENERVATION BY 6-HYDROXYDOPAMINE.
217527 04-03

THE BEHAVIOURAL EFFECTS OF DOPAMINE APPLIED INTRACEREBRALLY TO AREAS OF THE MESOLIMBIC SYSTEM.
217660 04-04

BEHAVIOURALLY
BEHAVIOURALLY ACTIVE ACTH ANALOGUES.
222820 04-04

BEHAVIOURS
COMPARISON BETWEEN BEHAVIOURS ELICITED BY HIGH DOSES OF AMPHETAMINE AND FENFLURAMINE: IMPLICATIONS FOR THE CONCEPT OF STEREOTYPY.
210742 03-04

BELGIUM
NEW PSYCHOTROPIC DRUG DEVELOPMENTS IN FRANCE AND BELGIUM.
213597 04-17

BEMEGRIDE
DIAZEPAM AS A DISCRIMINATIVE CUE: ITS ANTAGONISM BY BEMEGRIDE.
210865 03-03

ANTAGONISM OF DEPRESSANT ACTIVITY OF ETHANOL BY DH-524; A COMPARATIVE STUDY WITH BEMEGRIDE, DOXAPRAM AND D-AMPHETAMINE (38640).
213282 03-03

BENACTYZINE
THE ROLE OF THE RETICULAR FORMATION IN ACTION EXERTED BY CHLORPROMAZINE AND BENACTYZINE ON PRIMARY RESPONSES OF THE BRAIN-CORTEX.
206440 03-04

BENAPRYZINE
EFFECTS OF BENAPRYZINE, A NEW ANTIPARKINSON DRUG, ON DOPAMINE UPTAKE INTO CORPUS-STRIATUM.
199868 02-03

EVALUATION OF BENAPRYZINE IN PSYCHOTIC PATIENTS TREATED WITH PHENOTHIAZINES.
213387 04-07

BENZAMIDE
THE DISINHIBITING EFFECT OF N(1-ETHYL-2-PYRROLIDINYL-METHYL-2-METHOXY-5-SULFAMIDE BENZAMIDE (SULPIRIDE).
209527 03-14

A NEW SUBSTITUTED BENZAMIDE WITH NEUROLEPTIC EFFECTS: LIN-14-18 OR SULTOPRIDE.
216759 04-08

BENZAZEPINES
ADENOSINE 3,5 MONOPHOSPHATE IN CULTURED NEUROBLASTOMA CELLS: EFFECT OF ADENOSINE, PHOSPHODIESTERASE INHIBITORS AND BENZAZEPINES.
195254 01-03

BENZENESULFONAMIDO
NEW HYPOGLYCEMIC BENZENESULFONAMIDO PYRIMIDINES: N-SUBSTITUTED 4-(N-(2-PYRIMIDINYLSULFONYL-PHENYLACETAMIDES.
206994 03-02

BENZHEXOL
ACUTE TOXIC PSYCHOSIS IN TWO CHILDREN TREATED WITH BENZHEXOL HYDROCHLORIDE (ARTANE).
205315 02-15

BENZOCTAMINE
PHARMACOLOGICAL INVESTIGATIONS WITH BENZOCTAMINE (TACITIN), A NEW PSYCHOACTIVE AGENT.
197447 01-03

CHANGES IN ACID-BASE BALANCE, RESPIRATION RATE AND HEART RATE UPON REPEATED ORAL ADMINISTRATION OF BENZOCTAMINE AND DIAZEPAM TO CONSCIOUS DOGS.
197460 01-03

ALTERATIONS IN ACID-BASE BALANCE IN THE DOG AFTER INTRAVENOUS ADMINISTRATION OF BENZOCTAMINE AND DIAZEPAM, COMPARED WITH THOSE INDUCED BY THIOPENTAL.
197485 01-03

BENZOCTAMINE (TACITIN) VERSUS PLACEBO: A DOUBLE-BLIND CROSSOVER STUDY IN ANXIETY NEUROTICS.
225064 04-10

BENZOCYCLOHEPTAPYRIDOISOQUINOLINE
NEUROLEPTIC AGENTS OF THE BENZOCYCLOHEPTAPYRIDOISOQUINOLINE SERIES. 1.SYNTHESES AND STEREOCHEMICAL AND STRUCTURAL REQUIREMENTS FOR ACTIVITY OF BUTACLAMOL AND RELATED COMPOUNDS.
208592 03-01

BENZODIAZEPIN-2-ONE
A NEW BENZODIAZEPINE: 1-(2 HYDROXYETHYL)-3-HYDROXY-7-CHLORO-1,3 DIHYDRO-5-(O-FLUOROPHENYL)-1H-1,4 BENZODIAZEPIN-2-ONE.
194956 01-04

BENZODIAZEPIN-2-ONES
CHIRAL 1,4 BENZODIAZEPINE: VII. CYCLIZATION RATES OF 2-N-ALPHA-AMMONIUMACYL-AMINO-5-CHLOROBENZOPHENONES IN THE CHIRAL 1,4 BENZODIAZEPIN-2-ONES.
221858 04-01

BENZODIAZEPINE
THE BENZODIAZEPINE BONANZA.
194066 01-17

A NEW BENZODIAZEPINE: 1-(2 HYDROXYETHYL)-3-HYDROXY-7-CHLORO-1,3 DIHYDRO-5-(O-FLUOROPHENYL)-1H-1,4 BENZODIAZEPIN-2-ONE.
194956 01-04

EFFECT OF BENZODIAZEPINE DERIVATIVES ON SOMAN INDUCED SEIZURE ACTIVITY AND CONVULSIONS IN THE MONKEY.
197466 01-03

BLOOD LEVEL, EXCRETION, DISTRIBUTION AND METABOLISM OF 14C-TRIFLUBAZAM, A NEW 1,5 BENZODIAZEPINE, IN MICE AND DOGS.
197940 01-03

THE INFLUENCE OF BENZODIAZEPINE SERIES TRANQUILIZERS ON VARIOUS FORMS OF OPERANT ANIMAL BEHAVIOR.
198482 02-04

PHARMACOLOGICAL AND TOXICOLOGICAL PROPERTIES OF CLOBAZAM (1-PHENYL-5-METHYL-8-CHLORO 1,2,4,5-TETRAHYDRO-2,4-DIKETO-3H-1,5 BENZODIAZEPINE), A NEW PSYCHOTHERAPEUTIC AGENT.
199912 02-05

ALL-NIGHT POLYGRAPHIC RECORDINGS ON THE HYPNOTIC EFFECTS OF A NEW BENZODIAZEPINE: FLUNITRAZEPAM (RO-5-4200, ROHYPNOL).
202272 02-11

THE DETECTION OF PRAZEPAM, A NEW BENZODIAZEPINE TRANQUILIZER.
204196 02-01

THE SYNTHESIS AND PHARMACOLOGY OF A NOVEL BENZODIAZEPINE DERIVATIVE, 1-METHYL-5-O-FLUOROPHENYL 7-CHLORODIHYDROBENZODIAZEPIN-2-ONE (ID-540).
206780 03-02

PRACTICAL KINETICS III: BENZODIAZEPINE HYDROLYSIS.
211008 03-06

A NEW BENZODIAZEPINE, SCREENED BY A PARALLEL DOUBLE-BLIND TEST.
212167 03-10

USE OF A BENZODIAZEPINE AT HIGH DOSAGE LEVELS: A STATEMENT ON 50 OBSERVATIONS.
212179 03-10

EFFECT OF BENZODIAZEPINE COMPOUNDS ON BRAIN AMINE METABOLISM.
217664 04-03

SPECIFICITY OF BENZODIAZEPINE ACTION ON HUMAN SLEEP CONFIRMED. ANOTHER CONTRIBUTION OF AUTOMATIC ANALYSIS OF POLYGRAPH RECORDINGS.
218953 04-14

EXAMINATION OF THE ROLE OF BRAIN AMINES AND CYCLIC-AMP IN BENZODIAZEPINE INDUCED SUPPRESSION OF AGGRESSION. (PH.D. DISSERTATION).
219278 04-04

NEUROPHARMACOLOGICAL STUDIES ON SB-5833, A NEW PSYCHOTHERAPEUTIC AGENT OF THE BENZODIAZEPINE CLASS.
221268 04-02

A PRELIMINARY DOUBLE-BLIND STUDY WITH SB-5833 (CAMAZEPAM), A NEW BENZODIAZEPINE DERIVATIVE.
221269 04-10

THE SYNTHESIS AND PHARMACOLOGY OF A NOVEL BENZODIAZEPINE DERIVATIVE, 1-BETA-METHYLSULFONYLETHYL-5-O-FLUOROPHENYL 7-CHLORODIHYDROBENZODIAZEPIN-2-ONE (ID-622).
221741 04-02

CHIRAL 1,4 BENZODIAZEPINE: VII. CYCLIZATION RATES OF 2-N-ALPHA-AMMONIUMACYL-AMINO-5-CHLOROBENZOPHENONES IN THE CHIRAL 1,4 BENZODIAZEPIN-2-ONES.
221858 04-01

BENZODIAZEPINES

CHARACTERIZATION OF THE BINDING OF BENZODIAZEPINES TO HUMAN SERUM ALBUMIN.
193278 01-01

INTERACTIONS OF BENZODIAZEPINES WITH HUMAN SERUM ALBUMIN: CIRCULAR DICHROISM STUDIES.
194148 01-01

POSSIBLE MECHANISM OF ACTION OF BENZODIAZEPINES. (UNPUBLISHED PAPER).
194541 01-03

ANHYDROTIC EFFECT OF BENZODIAZEPINES IN MICE.
195540 01-03

THE EFFECT OF BENZODIAZEPINES ON THE ANALGESIC EFFECT OF MORPHINE AND SODIUM SALICYLATE.
197480 01-03

STUDIES ON CLONAZEPAM, FLUNITRAZEPAM, AND RELATED BENZODIAZEPINES IN CAT AND MONKEY.
197492 01-03

ADENOSINE-3-5-MONOPHOSPHATE IN CEREBRAL CORTICAL SLICES FROM GUINEA-PIG AND RAT: EFFECT OF BENZODIAZEPINES.
197972 01-03

THE SCREENING OF BENZODIAZEPINES.
198056 01-06

DRUG THERAPY: BENZODIAZEPINES (FIRST OF TWO PARTS).
199515 02-14

WATER SOLUBLE DERIVATIVES OF 3-OXY-SUBSTITUTED 1,4 BENZODIAZEPINES.
200739 02-01

BENZODIAZEPINES IN THE TREATMENT OF EPILEPSY: A REVIEW.
201870 02-11

CENTRAL EFFECTS OF THREE FLUORINATED BENZODIAZEPINES IN COMPARISON WITH DIAZEPAM.
202765 02-03

DRUG THERAPY: BENZODIAZEPINES (SECOND OF TWO PARTS).
205299 02-17

BENZODIAZEPINES IN CLINICAL PRACTICE.
207161 03-17

QUINAZOLINES AND 1,4 BENZODIAZEPINES. 67. 5-FERROCENYLBENZODIAZEPIN-2-ONES.
208595 03-01

BENZODIAZEPINES, REPRODUCTION, AND DEVELOPMENT.
213605 04-03

BENZODIAZEPINES: SPECIFIC COMPETITORS FOR THE BINDING OF L-TRYPTOPHAN TO HUMAN SERUM ALBUMIN.
217686 04-01

PROBLEMS IN THE ELECTROPHYSIOLOGICAL ANALYSIS OF THE SITE OF ACTION OF BENZODIAZEPINES. (UNPUBLISHED PAPER).
218148 04-03

A GABA HYPOTHESIS FOR THE ACTION OF BENZODIAZEPINES. (UNPUBLISHED PAPER).
218149 04-03

PHARMACOKINETICS IN CLINICAL MEDICINE: OXAZEPAM VERSUS OTHER BENZODIAZEPINES.
218151 04-17

BENZODIAZEPINES: SAFETY AND TOXICITY.
218155 04-15

A NEW SERIES OF BENZODIAZEPINES: 1 HYDROXYALKYL DERIVATIVES OF 1,3 DIHYDROBENZODIAZEPIN-2-ONES.
221735 04-01

ON THE GAS CHROMATOGRAPHIC ANALYSIS OF BENZODIAZEPINES: SECOND COMMUNICATION: DIAZEPAM AND ITS METABOLITES.
221739 04-06

NEW CONCEPTS ON THE MECHANISM OF ACTION OF BENZODIAZEPINES.
225058 04-13

BENZODIOXANE

STIMULATION OF SEXUAL BEHAVIOUR IN RATS BY A BENZODIOXANE DERIVATIVE.
210351 03-04

BENZODIOXANHYDROXYETHYLPIPERIDINE

A BENZODIOXANHYDROXYETHYLPIPERIDINE DERIVATIVE WITH ACUTE CENTRAL HYPOTENSIVE ACTION, DIFFERENT FROM THAT OF CLONIDINE: A COMPARISON WITH NEUROLEPTIC AGENTS.
220976 04-03

BENZOOXADIAZOLES

BENZOOXADIAZOLES -- A NOVEL CLASS OF HETEROCYCLIC MONOAMINEOXIDASE INHIBITORS.
202312 02-01

BENZOTHIOPHENE

CHEMICAL PHARMACOLOGY OF THE BENZOTHIOPHENE AND 1-METHYLINDOLE ANALOGS OF N,N-DIMETHYLTRYPTAMINE. (PH.D. DISSERTATION).
193590 01-12

BENZOXAZIN-2-ONE

CENTRAL PHARMACOLOGICAL ACTIVITIES OF 4-PHENYL-6-CHLORO-1,4-DIHYDRO-2H-3,1 BENZOXAZIN-2-ONE.
197453 01-03

BENZTROPINE

ANTICHOLINERGIC TOXIC PSYCHOSIS IN DRUG ABUSERS TREATED WITH BENZTROPINE.
197539 01-15

A DOUBLE-BLIND STUDY OF AMANTADINE HYDROCHLORIDE VERSUS BENZTROPINE MESYLATE IN DRUG-INDUCED PARKINSONISM.
202764 02-15

THERAPEUTIC REVERSAL WITH BENZTROPINE IN SCHIZOPHRENICS: PRACTICAL AND THEORETICAL SIGNIFICANCE.
213726 04-08

BENZYLIDINOHYDRAZINES

SYNTHESIS OF SUBSTITUTED BENZYLIDINOHYDRAZINES AND THEIR MONOAMINEOXIDASE INHIBITORY AND ANTICONVULSANT PROPERTIES.
206461 03-02

BETA-ADRENERGIC

ADENOSINE-3-5-MONOPHOSPHATE IN CEREBRAL CORTICAL SLICES FROM GUINEA-PIG AND RAT: EFFECT OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC COMPOUNDS.
197293 01-03

GLUCOSE RELEASE OF THE RAT KIDNEY IN VIVO AFTER BETA-ADRENERGIC STIMULATION AND BLOCKADE.
197946 01-03

BETA-ADRENERGIC RECEPTOR BLOCKING DRUGS IN PSYCHIATRY.
199636 02-17

USE OF BETA-ADRENERGIC RECEPTOR BLOCKING DRUGS IN PSYCHIATRY.
202797 02-17

BETA-ADRENERGIC STIMULATION OF PINEAL N-ACETYLTRANSFERASE: CYCLIC-AMP STIMULATES BOTH RNA AND PROTEIN SYNTHESIS.
215601 04-03

THE PROPOSAL OF AN UNIFIED MODEL FOR THE INTERPRETATION OF THE ACTIVITY OF DIFFERENT CLASSES OF BETA-ADRENERGIC AGENTS.
220951 04-01

PINEAL BETA-ADRENERGIC RECEPTOR: CORRELATION OF BINDING OF H3-1-ALPRENOLOL WITH STIMULATION OF ADENYLCYCLASE. (UNPUBLISHED PAPER).
224096 04-03

BETA-ADRENOCEPTOR

CENTRAL ACTIONS OF SOME BETA-ADRENOCEPTOR BLOCKING AGENTS.
206782 03-03

BETA-ADRENOCEPTORS

BETA-ADRENOCEPTORS AND/OR ALPHA-ADRENOCEPTORS IN THE VENTRICULAR MUSCLE OF THE RABBIT
197943 01-03

BETA-BLOCKER

PRELIMINARY STUDY OF A BETA-BLOCKER (PINDOLOL) IN THREE SCHIZOPHRENICS AND THREE NONPSYCHOTIC PSYCHIATRIC PATIENTS: DIFFERENTIAL SENSITIVITY IN HEART RATE.
212164 03-13

BETA-BLOCKING

GLC DETERMINATION OF PROPRANOLOL, OTHER BETA-BLOCKING DRUGS, AND METABOLITES IN BIOLOGICAL FLUIDS AND TISSUES.
200740 02-16

BETA-HYDROXYLASE
SCOPE AND LIMITATION IN DOPAMINE BETA-HYDROXYLASE MEASUREMENT.
210811 03-02

BETA-HYDROXYLATED
ON THE PHARMACOLOGY OF SOME BETA-HYDROXYLATED TRYPTAMINES.
197568 01-03

BETA-PHENETHYLAMINE
INHIBITION OF HUMAN PLATELET 5-HYDROXYTRYPTAMINE UPTAKE BY BETA-PHENETHYLAMINE DERIVATIVES.
217689 04-13

BETA-PHENYLETHYLAMINE
DEAMINATION OF BETA-PHENYLETHYLAMINE BY MONOAMINEOXIDASE -- INHIBITION BY IMIPRAMINE.
195447 01-13

COMPARISON OF THE EFFECTS OF LITHIUM, BETA-PHENYLETHYLAMINE AND TYROSINE ON XENOPUS EMBRYOS.
200752 02-03

BETA-PHENYLETHYLAMINE AND LOCOMOTOR ACTIVITY IN MICE: INTERACTION WITH CATECHOLAMINERGIC NEURONES AND RECEPTORS.
221742 04-03

BETA-RECEPTOR
EFFECT OF BETA-RECEPTOR BLOCKERS (PINDOLOL AND PRACTOLOL) ON LITHIUM INDUCED TREMOR -- CLINICAL TRIAL AND THEORETICAL CONSIDERATIONS.
204409 02-15

BETA-THIAMINOKETONES
THE EFFECT OF BETA-THIAMINOKETONES ON THE AMINOPYRINE-N-DEMETHYLATION IN VITRO AND IN VIVA SUCH AS THE HEXOBARBITAL SLEEPING TIME AND L-ASCORBIC ACID EXCRETION IN THE RAT.
197469 01-03

BIAS
A CONTROLLED COMPARISON OF MAPROTILINE (LUDIOMIL) WITH IMIPRAMINE AVOIDING OBSERVER BIAS.
221654 04-09

BICUCULLINE
ACTIONS OF GABA, PICROTOXIN AND BICUCULLINE ON ADRENAL MEDULLA.
193455 01-03

THE ACTION OF BICUCULLINE UPON ACETYLCHOLINE-INDUCED EXCITATIONS OF CENTRAL NEURONS.
197993 01-03

BIDIRECTIONALLY
THE EFFECTS OF NICOTINE ON TWO-WAY AVOIDANCE CONDITIONING IN BIDIRECTIONALLY SELECTED STRAINS OF RATS.
217525 04-04

BILATERAL
EFFECTS OF PSYCHOTROPIC DRUGS ON HYPEREMOTIONALITY OF RATS WITH BILATERAL ABLATIONS OF THE OLFACTORY BULBS AND OLFACTORY TUBERCLES.
195231 01-04

BINDING
CHARACTERIZATION OF THE BINDING OF BENZODIAZEPINES TO HUMAN SERUM ALBUMIN.
193278 01-01

SOME STUDIES OF ADRENERGIC AMINES: PART I. ROLE OF THE AROMATIC RING IN RECEPTOR BINDING. PART II. BETA ADRENERGIC BLOCKADE. (PH.D. DISSERTATION).
194564 01-01

BINDING OF D-OXAZEPAM AND L-OXAZEPAM HEMISUCCINATE TO BOVINE SERUM ALBUMIN.
200033 02-03

D-LSD BINDING TO BRAIN HOMOGENATES: POSSIBLE RELATIONSHIP TO SEROTONIN RECEPTORS.
202464 02-03

BINDING OF LITHIUM AND CALCIUM BY CEREBRAL MEMBRANE FRACTIONS.
210806 03-03

THE NATURE OF (3H)IMIPRAMINE BINDING TO SYNAPTOSOMES.
210904 03-03

IN VIVO IDENTIFICATION OF MUSCARINIC CHOLINERGIC RECEPTOR BINDING IN RAT BRAIN.
213480 04-03

BENZODIAZEPINES: SPECIFIC COMPETITORS FOR THE BINDING OF L-TRYPTOPHAN TO HUMAN SERUM ALBUMIN.
217686 04-01

BINDING OF (+) AMPHETAMINE AND (-) DELTA1-TETRAHYDROCANNABINOLS AND (-) 7-HYDROXY-DELTA1-TETRAHYDROCANNBINOL TO BLOOD CELLS AND PLASMA PROTEINS IN MAN.
217878 04-13

COMPETITION FOR PLASMA PROTEIN BINDING SITES BETWEEN PHENOTHIAZINE TRANQUILIZERS AND IMINODIBENZYL ANTIDEPRESSANTS.
217891 04-03

IN VIVO BINDING OF ANTIBODY TO DOPAMINE-BETA-HYDROXYLASE IN ADRENERGIC NERVES AND SUBSEQUENT ANTIDROMIC TRANSPORT (UNPUBLISHED PAPER).
218147 04-03

3H-NORTRIPTYLINE UPTAKE AND TISSUE BINDING IN VITRO AND ITS EFFECT ON 3H-NORADRENALINE UPTAKE.
220949 04-03

PINEAL BETA-ADRENERGIC RECEPTOR: CORRELATION OF BINDING OF H3-1-ALPRENOLOL WITH STIMULATION OF ADENYLCYCLASE. (UNPUBLISHED PAPER).
224096 04-03

BIOAVAILABILITY
THE BIOAVAILABILITY OF MEPERIDINE.
199519 02-13

DRUGS, EEG AND BEHAVIOUR: EEG PROFILES AND BIOAVAILABILITY MEASURES FOR CLINICAL PSYCHOPHARMACOLOGY.
205522 02-16

BIOCHEMICAL
THE APPLICATION OF ELECTROANALYTICAL TECHNIQUES TO BIOCHEMICAL SYSTEMS. (PH.D. DISSERTATION).
194561 01-16

PHYSIOLOGIC, BIOCHEMICAL, AND CLINICAL EFFECTS OF KETAMINE HYDROCHLORIDE IN GOATS (CAPRA-HIRCUS) WITH AND WITHOUT PREMEDICATION. (PH.D. DISSERTATION).
194700 01-03

MORPHOLOGICAL, BIOCHEMICAL, AND FUNCTIONAL CHANGES IN CHICK EMBRYONIC BRAIN TISSUE AFTER INTRACEREBRAL ADMINISTRATION OF OUABAIN.
197788 01-03

THE BIOCHEMICAL PHARMACOLOGY OF ABUSED DRUGS: I. AMPHETAMINES, COCAINE, AND LSD.
198028 01-12

BIOCHEMICAL MONITORING IN THE THERAPY OF DEPRESSIONS.
198099 02-10

ON THE INFLUENCE OF NEUROLEPTICS ON THE CORTICORETICULAR SYSTEM OF THE BRAIN (HISTOCHEMICAL AND BIOCHEMICAL INVESTIGATION).
198481 02-03

BIOCHEMICAL CORRELATES IN MOUSE-KILLING BEHAVIOR OF THE RAT BRAIN: BRAIN ACETYLCHOLINE AND ACETYLCHOLINESTERASE AFTER ADMINISTRATION OF DELTA9-TETRAHYDROCANNABINOL.
199807 02-03

THE BIOCHEMICAL PHARMACOLOGY OF ABUSED DRUGS. II. ALCOHOL AND BARBITURATES.
200007 02-14

CLOZAPINE AND HALOPERIDOL IN A SINGLE-BLIND CROSSOVER TRIAL: THERAPEUTIC AND BIOCHEMICAL ASPECTS IN THE TREATMENT OF SCHIZOPHRENIA.
200803 02-08

INFLUENCE OF MIDBRAIN RAPHE LESION ON SOME PHARMACOLOGICAL AND BIOCHEMICAL EFFECTS OF APOMORPHINE IN RATS.
202771 02-03

THERAPY-RESISTANT DEPRESSIONS. BIOCHEMICAL AND PHARMACOLOGICAL CONSIDERATIONS: CONTRIBUTIONS TO BIOCHEMISTRY.
203593 02-09

BIOCHEMICAL CRITERIA FOR CLASSIFYING DEPRESSIVE DISORDERS AND PREDICTING RESPONSES TO PHARMACOTHERAPY: PRELIMINARY FINDINGS FROM STUDIES OF NOREPINEPHRINE METABOLISM. CONTRIBUTIONS TO BIOCHEMISTRY.
203594 02-09

BIOCHEMICAL EFFECTS OF DIHYDROXYLATED TRYPTAMINES ON CENTRAL INDOLEAMINE NEURONES.
204340 02-03

BIOCHEMICAL MECHANISMS OF EXTRAPYRAMIDAL MOTORIC ACTION OF HALOPERIDOL IN MAN.
204414 02-13

BIOCHEMICAL BACKGROUND OF MONOAMINEOXIDASE INHIBITORS.
206365 03-03

A TWO-FACTOR BIOCHEMICAL THEORY OF SCHIZOPHRENIA.
206542 03-03

AMPHETAMINE PSYCHOSIS: BEHAVIORAL AND BIOCHEMICAL ASPECTS.
207285 03-14

BIOCHEMICAL CHARACTERIZATION OF THE DOPAMINE RECEPTOR IN THE MAMMALIAN CAUDATE NUCLEUS.
207297 03-03

CLINICAL AND BIOCHEMICAL COMPARISON OF CHLORAZEPATE AND DIAZEPAM.
209081 03-10

AMPHETAMINE TREATMENT OF PARANOID OBSESSIONS: CASE REPORT AND BIOCHEMICAL IMPLICATIONS.
210809 03-09

YOHIMBINE: BEHAVIORAL AND BIOCHEMICAL EFFECTS IN MICE.
213592 04-04

BIOCHEMICAL PHARMACOLOGY OF BRAIN AMINE MECHANISMS.
213603 04-03

BIOCHEMICAL VERSUS PSYCHOPATHOLOGICAL ACTION PROFILE OF NEUROLEPTICS: A COMPARATIVE STUDY OF CHLORPROMAZINE AND OXYPERTINE IN ACUTE PSYCHOTIC DISORDERS.
215454 04-13

THE BIOCHEMICAL BASES OF PSYCHOPHARMACOLOGY.
216789 04-13

FUNCTIONAL AND BIOCHEMICAL ASPECTS OF CATECHOLAMINE METABOLISM IN BRAIN UNDER HYPOXIA.
217852 04-03

CLOZAPINE AND HALOPERIDOL: CLINICAL AND BIOCHEMICAL ASPECTS IN THE TREATMENT OF SCHIZOPHRENIA.
221637 04-08

GENETIC, BIOCHEMICAL, AND ENVIRONMENTAL VARIABLES IN THE EXPRESSION OF SHORT-TERM MEMORY IN THE MOUSE. (PH.D. DISSERTATION).
222749 04-04

THE BIOCHEMICAL BASIS OF NEUROPHARMACOLOGY.
225152 04-17

PHENOTHIAZINES AND STRUCTURALLY RELATED DRUGS. ADVANCES IN BIOCHEMICAL PSYCHOPHARMACOLOGY.
225399 04-17

BIOCHEMISTRY

THE BIOCHEMISTRY OF THERAPY-RESISTANT DEPRESSION: CONTRIBUTIONS TO BIOCHEMISTRY.
203592 02-09

THERAPY-RESISTANT DEPRESSIONS. BIOCHEMICAL AND PHARMACOLOGICAL CONSIDERATIONS: CONTRIBUTIONS TO BIOCHEMISTRY.
203593 02-09

BIOCHEMICAL CRITERIA FOR CLASSIFYING DEPRESSIVE DISORDERS AND PREDICTING RESPONSES TO PHARMACOTHERAPY: PRELIMINARY FINDINGS FROM STUDIES OF NOREPINEPHRINE METABOLISM. CONTRIBUTIONS TO BIOCHEMISTRY.
203594 02-09

SEROTONIN -- NEW VISTAS: BIOCHEMISTRY AND BEHAVIORAL AND CLINICAL STUDIES.
213716 04-17

CLOZAPINE: PHARMACOLOGY, BIOCHEMISTRY AND CLINICAL USE.
221538 04-13

BIOCLINICAL

DRUG-RESISTANCE AND BIOCLINICAL FACTORS IN THE RESPONSE OF SCHIZOPHRENIC PATIENTS TO CHLORPROMAZINE.
210500 03-08

BIOELECTRIC

THE USE OF ANTICONVULSANT TREATMENT OF BEHAVIORALLY DISTURBED CHILDREN WITH BIOELECTRIC EPILEPSY: A CATAMNESTIC STUDY OF 76 CASES.
211355 03-11

BIOELECTRICAL

COMPARATIVE EFFECTS OF SYDNOCARB AND AMPHETAMINE ON THE BIOELECTRICAL ACTIVITY OF THE BRAIN.
223012 04-03

BIOGENIC

BIOGENIC AMINES IN A RETRANSPLANTABLE NEUROGENIC TERATOCARCINOMA.
192925 01-03

EFFECT OF ACUTE AND CHRONIC DIELDRIN EXPOSURE ON BRAIN BIOGENIC AMINES OF MALE AND FEMALE RATS.
193428 01-03

TIME-DEPENDENT, MEMORY RETRIEVAL EFFECTS FOLLOWING PERIPHERAL AND HIPPOCAMPAL TREATMENTS TO INCREASE SYNAPTIC BIOGENIC AMINES. (PH.D. DISSERTATION).
194677 01-04

CHANGES IN BRAIN CONCENTRATION OF BIOGENIC AMINES AND THE ANTINOCICEPTIVE EFFECT OF MORPHINE IN RATS.
195246 01-03

SEIZURES OF CHOREOATHETIC TYPE INDUCED BY SUDDEN MOVEMENT: CORRELATION TO THE BIOGENIC AMINES.
196146 01-14

STUDIES ON ALPHA-METHYLDOPA: RELATIONSHIP BETWEEN METABOLISM, BIOGENIC AMINES AND ANTIHYPERTENSIVE EFFECT.
197298 01-03

THE ACTION OF PSYCHOSTIMULANT SIDNOKARB ON METABOLISM OF BIOGENIC AMINES IN THE BRAIN.
197573 01-03

INFLUENCE OF MAO INHIBITORS ON THE INTESTINAL ABSORPTION OF BIOGENIC AMINES.
197948 01-03

TURNOVER OF BIOGENIC AMINES AFTER ACUTE AND CHRONIC MORPHINE TREATMENT IN RATS.
197974 01-03

STUDIES ON PSYCHOTROPIC DRUGS: XVII. EFFECTS OF 3-CHLORO-5-(3-(4 PIPERIDINO-4-CARBAMOYL-PIPERIDINO)PROPYL) 10,11-DIHYDRO-5(H) DIBENZAZEPINE DIHYDROCHLORIDE MONOHYDRATE (Y-4153) ON THE METABOLISM OF BIOGENIC AMINES.
199210 02-03

N-ACETYLTRANSFERASE OF BRAIN: POSSIBLE INVOLVEMENT IN THE METABOLISM OF THE BIOGENIC AMINES. (UNPUBLISHED PAPER).
199347 02-03

THEORETICAL IMPLICATIONS OF DRUG-INDUCED ADAPTIVE REGULATION FOR A BIOGENIC AMINE HYPOTHESIS OF AFFECTIVE DISORDER.
206335 03-03

ROLE OF THE BIOGENIC AMINES IN THE REVERSAL OF CYCLOHEXIMIDE INDUCED AMNESIA.
206752 03-04

A STUDY OF ELECTROLYTE AND BIOGENIC AMINE METABOLISM IN MANIC-DEPRESSIVE ILLNESS.
208917 03-09

THE INFLUENCE OF INTRAPERITONEAL INJECTION OF IPRAZIDE AND TRANSAMINE ON THE DISTRIBUTION OF BIOGENIC AMINES IN CORTICAL AND SUBCORTICAL WHITE MATTER OF THE RAT BRAIN.
209032 03-03

CYCLIC-AMP IN CEREBROSPINAL FLUID: ACCUMULATION FOLLOWING PROBENECID AND BIOGENIC AMINES.
210193 03-17

THE EFFECT OF TWO SYNTHETIC ACTH ANALOGUES ON THE METABOLISM OF BIOGENIC AMINES IN THE RAT BRAIN.
210875 03-03

ON THE PARTICIPATION OF BIOGENIC AMINES AND THEIR SYNTHETIC ENZYMES IN THE MECHANISMS OF IMAGE MEMORY.
213469 04-04

PSYCHOPHARMACOLOGY OF BIOGENIC AMINES IN DEPRESSIONS.
213628 04-09

RELATIONSHIP OF BIOGENIC AMINES TO BEHAVIOR.
217218 04-04

MASS FRAGMENTOGRAPHY OF PICOMOLE QUANTITIES OF BIOGENIC AMINE METABOLITES IN HUMAN CEREBROSPINAL FLUID AS WELL AS WHOLE RAT BRAINS. (UNPUBLISHED PAPER).
217219 04-06

EFFECTS OF CLOZAPINE, THIORIDAZINE, PERLAPINE AND HALOPERIDOL ON THE METABOLISM OF THE BIOGENIC AMINES IN THE BRAIN OF THE RAT.
217543 04-03

INTERACTIONS OF IMIPRAMINE AND SYNTHESIS INHIBITORS ON BIOGENIC AMINES.
217827 04-03

POSSIBLE ROLE OF ADENOSINE-3-5-MONOPHOSPHATE AND BIOGENIC AMINES IN MORPHINE AND COCAINE TREATED RATS. (PH.D. DISSERTATION).
220475 04-03

PHARMACOLOGICAL ACTION OF FD-008, A NEW DOPAMINE-BETA-HYDROXYLASE INHIBITOR: III. EFFECTS ON ENDOGENOUS BIOGENIC AMINE LEVELS IN RATS.
221859 04-03

BIOGRAPHIC

INFLUENCE OF SOME BIOGRAPHIC FACTORS ON THE THERAPEUTIC DRUG RESPONSE.
205622 03-14

BIOLOGICAL

MULTIPLE TIC SYNDROME (GILLES-DE-LA-TOURETTES SYNDROME): CLINICAL, BIOLOGICAL, AND PSYCHOSOCIAL VARIABLES AND THEIR INFLUENCE WITH HALOPERIDOL.
199473 02-11

GLC DETERMINATION OF PROPRANOLOL, OTHER BETA-BLOCKING DRUGS, AND METABOLITES IN BIOLOGICAL FLUIDS AND TISSUES.
200740 02-16

THE CURRENT STATUS OF BIOLOGICAL CRITERIA FOR CLASSIFYING THE DEPRESSIVE DISORDERS AND PREDICTING RESPONSES TO TREATMENT.
202380 02-17

NEUROLEPTICS AS A GUIDELINE TO BIOLOGICAL RESEARCH IN PSYCHOTIC DISORDERS.
207765 03-17

THE APPEARANCE OF EXOPHTHALMIA IN THE COURSE OF LITHIUM CARBONATE TREATMENT: BIOLOGICAL HYPERTHYROIDISM.
209998 03-15

CLINICAL BIOLOGICAL CORRELATIONS IN SCHIZOAFFECTIVE PATIENTS TREATED WITH LITHIUM CARBONATE AND HALOPERIDOL.
210501 03-09

BIOLOGICAL AND PHARMACOKINETIC EVIDENCE FOR GENERIC EQUIVALENCE OF THREE IMIPRAMINE PREPARATIONS: COMPARISON WITH A NEW IMIPRAMINE ANALOGUE.
211071 03-02

A MECHANISTIC STUDY OF BIOLOGICAL TRANSMETHYLATION.
213604 04-03

AN ASPECT OF BIOLOGICAL THERAPY IN THE SYSTEM OF REHABILITATING EPILEPTIC PATIENTS WITH MENTAL DISORDERS.
220420 04-11

BIOLOGICALLY

A DUAL STUDY. PART I: SYNTHESIS AND STEREOCHEMISTRY OF SOME 1 SUBSTITUTED QUINOLIZIDINES AS ANALOGS OF BIOLOGICALLY ACTIVE COMPOUNDS. PART II: AMINO DERIVATIVES OF THIOPHENE FUSED CYCLIC KETONES AS POTENTIAL CNS. (PH.D. DISSERTATION).
196252 01-01

BIOLOGY

BEHAVIOR: BIOLOGY, PHYSIOLOGY, PHARMACOLOGY.
207204 03-17

BIOPHYSIOLOGICAL
ACTION AND REACTION: BIOPHYSIOLOGICAL AND NEUROPHYSIOLOGICAL MECHANISMS.
210419 03-13

BIOPOTENTIALS
COMPUTERIZED CEREBRAL BIOPOTENTIALS IN THE DISCOVERY OF PSYCHOTROPIC DRUGS.
205434 02-13

BIOSYNTHESIS
INFLUENCE OF HEXOBARBITAL ON THE BIOSYNTHESIS OF CATECHOLAMINES AND THEIR PRECURSORS IN THE BRAIN.
201917 02-03
EFFECTS OF CATECHOLAMINE RELEASING AGENTS ON SYNAPTOSOMAL DOPAMINE BIOSYNTHESIS: MULTIPLE POOLS OF DOPAMINE OR MULTIPLE FORMS OF TYROSINE-HYDROXYLASE?.
210825 03-03
DIFFERENTIAL EFFECTS OF D- AND L-AMPHETAMINE AND METHYLPHENIDATE ON RAT STRIATAL DOPAMINE BIOSYNTHESIS.
210859 03-03
ALTERATIONS IN BEHAVIOUR AND CATECHOLAMINE BIOSYNTHESIS INDUCED BY LITHIUM.
214067 04-04
PROSTAGLANDINS AND CANNABIS -- III. INHIBITION OF BIOSYNTHESIS BY ESSENTIAL OIL COMPONENTS OF MARIHUANA.
217795 04-03
INTERACTION OF CYCLOHEXIMIDE AND ADRENERGIC DRUGS WITH BRAIN PROTEIN AND CATECHOLAMINE BIOSYNTHESIS. (PH.D. DISSERTATION).
219288 04-03
STIMULATION OF ESTROGEN INDUCED COPULATORY BEHAVIOR IN CASTRATE MALE RATS WITH THE SEROTONIN BIOSYNTHESIS INHIBITOR P-CHLOROPHENYLALANINE.
221010 04-04

BIOSYNTHETIC
THE MULTIPLICITY OF INTERACTIONS OF PSYCHOTROPIC DRUGS WITH THE BRAIN SEROTONIN BIOSYNTHETIC UNIT.
195926 01-17

BIOTRANSFORMATION
ON THE BIOTRANSFORMATION OF AMPHETAMINE IN ADULT AND OLD RATS.
197292 01-03

BIPHASIC
THE BIPHASIC EFFECT OF SMALL DOSES OF TRANYLCYPROMINE ON THE SPONTANEOUS MOTOR ACTIVITY AND LEARNED CONDITIONED BEHAVIOUR IN RATS.
215665 04-04

BIPOLAR
THE EFFECT OF LITHIUM ON URINARY MHPG IN UNIPOLAR AND BIPOLAR DEPRESSED PATIENTS. (UNPUBLISHED PAPER).
196042 01-09
LITHIUM RESPONSE IN DEPRESSION AS PREDICTED BY UNIPOLAR/BIPOLAR ILLNESS, AVERAGE EVOKED RESPONSE, CATECHOL-O-METHYLTRANSFERASE AND FAMILY HISTORY. (UNPUBLISHED PAPER).
201000 02-09
BIPOLAR MANIC-DEPRESSIVE PSYCHOSIS IN EARLY ADOLESCENCE: A CASE REPORT.
201513 02-09
THE EFFECT OF LITHIUM ON URINARY MHPG IN UNIPOLAR AND BIPOLAR DEPRESSED PATIENTS.
221045 04-09
BIPOLAR PRIMARY AFFECTIVE DISORDER.
221166 04-09

BITING
THE EFFECTS OF SHOCK INTENSITY, D-AMPHETAMINE, AND PENTOBARBITAL ON THE FREQUENCY AND RESPONSE DYNAMICS OF BITING ATTACK IN THE SQUIRREL MONKEY. (PH.D. DISSERTATION).
222114 04-04

BLACK
ANTIDEPRESSANTS IN BLACK AND WHITE INPATIENTS: DIFFERENTIAL RESPONSE TO A CONTROLLED TRIAL OF CHLORPROMAZINE AND IMIPRAMINE.
218770 04-09

BLACK-TAILED
ATTENUATION OF ACUTE HABITUATION BY SCOPOLAMINE IN THE BLACK-TAILED PRAIRIE DOG (CYNOMYS-LUDOVICIANUS).
206745 03-04

BLASTOMERES
THE PROTECTIVE EFFECT OF SEROTONIN AGAINST THE INHIBITORY ACTION OF CHLORPROMAZINE ON THE MEMBRANE POTENTIAL OF STAGE 2 BLASTOMERES OF MOUSE EMBRYOS IN VITRO.
217005 04-03

BLINK
THE BLINK REFLEX TO LIGHT: ITS COURSE AND ITS FACILITATION BY RESERPINE.
204220 02-03

BLINKS
ANALYSIS OF EYE MOVEMENTS AND BLINKS DURING READING: EFFECTS OF VALIUM.
206360 03-14

BLOCK
MURICIDAL BLOCK INDUCED BY 5-HYDROXYTRYPTOPHAN IN THE RAT.
197454 01-04
IMIPRAMINE-INDUCED HEART BLOCK: A LONGITUDINAL CASE STUDY.
215014 04-13

BLOCKADE
SOME STUDIES OF ADRENERGIC AMINES: PART I. ROLE OF THE AROMATIC RING IN RECEPTOR BINDING. PART II. BETA ADRENERGIC BLOCKADE. (PH.D. DISSERTATION).
194564 01-01
THE BLOCKADE OF BULBOSPINAL INHIBITION BY IMIPRAMINE, DESIPRAMINE AND PARGYLINE.
195095 01-03
BLOCKADE BY ESERINE OF THE CEREBRAL CORTICAL EFFECTS OF ALLOFERIN: A FURTHER EVIDENCE OF CHOLINERGIC INHIBITORY MECHANISM.
195548 01-03
GLUCOSE RELEASE OF THE RAT KIDNEY IN VIVO AFTER BETA-ADRENERGIC STIMULATION AND BLOCKADE.
197946 01-03
THE RELATIVE ATTENUATION OF SELF-STIMULATION, EATING AND DRINKING PRODUCED BY DOPAMINE RECEPTOR BLOCKADE.
198225 02-04
GABA BLOCKADE, DOPAMINE AND SCHIZOPHRENIA: EXPERIMENTAL STUDIES IN THE CAT.
200052 02-03
INFLUENCE OF STRIATAL DOPAMINE RECEPTOR BLOCKADE ON A BULBAR MOTOR REACTION.
202778 02-03
CONCEPTS IN BETA BLOCKADE.
206941 03-13
MORPHINE-DEPENDENT RATS: BLOCKADE OF PRECIPITATED ABSTINENCE BY TETRAHYDROCANNABINOL.
210221 03-13
DOPAMINE RECEPTOR BLOCKADE BY NEUROLEPTIC DRUGS IN APLYSIA NEURONES.
210599 03-03
BLOCKADE BY PIMOZIDE OF A NORADRENALINE SENSITIVE ADENYLATE-CYCLASE IN THE LIMBIC FOREBRAIN: POSSIBLE ROLE OF LIMBIC NORADRENERGIC MECHANISMS IN THE MODE OF ACTION OF ANTIPSYCHOTICS.
210771 03-03
BLOCKADE OF RESERPINE OF METHYLPHENIDATE-INDUCED RELEASE OF BRAIN DOPAMINE.
217456 04-03
PHARMACOLOGICAL EVIDENCE FOR CEREBRAL DOPAMINE RECEPTOR BLOCKADE BY METOCLOPRAMIDE IN RODENTS.
217469 04-03
EFFECTS OF CENTRAL DOPAMINERGIC BLOCKADE WITH PIMOZIDE UPON THE EEG STAGES OF SLEEP IN MAN.
217546 04-14
BLOCKADE OF THE STIMULUS PROPERTIES OF MESCALINE BY A SEROTONIN ANTAGONIST.
217650 04-03
BLOCKADE OF ALPHA-METHYLTYROSINE-INDUCED SUPERSENSITIVITY TO APOMORPHINE BY CHRONIC ADMINISTRATION OF L-DOPA.
220974 04-03
BLOCKADE OF THE CENTRAL EFFECTS OF D-AMPHETAMINE BY AMANTADINE II.
221737 04-03

BLOCKAGE
INCORPORATION OF ACETATE (C14)(P-32) AND PHOSPHATE INTO THE BRAIN LIPIDS DURING BLOCKAGE OF THE CHOLINORECEPTOR AND ADRENORECEPTORS.
202599 02-03

BLOCKER
PHARMACOLOGIC STUDIES ON PROPYNYL DIBENZAZEPINE, A NEW ALPHA-ADRENERGIC BLOCKER.
197493 01-03

BLOCKERS
EFFECT OF TWO DOPAMINE RECEPTOR BLOCKERS ON A SEROTONIN MEDIATED BEHAVIORAL SYNDROME IN RATS.
193548 01-04
EFFECTS OF ALPHA-ADRENERGIC BLOCKERS ON VISUAL EVOKED RESPONSES IN RABBITS.
200064 02-03
EFFECT OF BETA-RECEPTOR BLOCKERS (PINDOLOL AND PRACTOLOL) ON LITHIUM INDUCED TREMOR -- CLINICAL TRIAL AND THEORETICAL CONSIDERATIONS.
204409 02-15
STUDIES ON THE TIME COURSE AND THE EFFECT OF CHOLINERGIC AND ADRENERGIC RECEPTOR BLOCKERS ON THE STIMULUS EFFECT OF NICOTINE.
206353 03-03

BLOCKING

ADRENERGIC RECEPTOR BLOCKING AGENTS: EFFECTS ON CENTRAL NORADRENALINE AND DOPAMINE RECEPTORS AND ON MOTOR ACTIVITY.
195429 01-03

INFLUENCE OF CATECHOLAMINE UPTAKE BLOCKING DRUGS ON THE INCREASE IN WATER INTAKE AND PLASMA RENIN CONCENTRATION INDUCED BY SOME HYPOTENSIVE DRUGS.
197288 01-03

BETA-ADRENERGIC RECEPTOR BLOCKING DRUGS IN PSYCHIATRY.
199636 02-17

COMPARISON OF THE EFFECTS OF THE INTRANIGRAL INJECTIONS OF CHOLINOMIMETICS WITH SYSTEMIC INJECTIONS OF THE DOPAMINE RECEPTOR STIMULATING AND BLOCKING AGENTS IN THE RABBIT.
199772 02-03

USE OF BETA-ADRENERGIC RECEPTOR BLOCKING DRUGS IN PSYCHIATRY.
202797 02-17

CENTRAL ACTIONS OF SOME BETA-ADRENOCEPTOR BLOCKING AGENTS.
206782 03-03

DOPAMINERGIC BLOCKING EFFECTS OF ANTIPSYCHOTIC DRUGS.
207294 03-03

BLOCKING OF STRESS BY PENTOBARBITAL MORPHINE AS RELATED TO TRAINING AND AGE OF RATS.
214056 04-04

INTERACTIONS BETWEEN POSTGANGLIONIC SYMPATHETIC BLOCKING DRUGS AND ANTIDEPRESSANTS.
221650 04-09

INFLUENCE OF RESERPINE ON THE POTENCY OF ALPHA-ADRENOCEPTOR BLOCKING AGENTS.
221860 04-03

CENTRAL CATECHOLAMINE RECEPTOR BLOCKING ACTIONS OF BE-2254 (HEAT): COMPARISON WITH CHLORPROMAZINE AND HALOPERIDOL.
222804 04-03

BLOOD

INFLUENCE OF EMULSIFIED FAT ON CHLORPROMAZINE AVAILABILITY IN RABBIT BLOOD.
194928 01-03

DISTRIBUTION OF CHLORPROMAZINE IN A SIMPLIFIED BLOOD INFLUENCED BY VARIOUS DRUGS.
195245 01-03

EFFECTS OF L-DOPA AND L-TRYPTOPHAN ON THE CEREBRAL BLOOD FLOW IN THE DOG.
197213 01-03

EFFECTS OF NORADRENALINE ON THE CEREBRAL BLOOD FLOW IN THE DOG.
197214 01-03

EFFECTS OF 5-HYDROXYTRYPTAMINE ON THE CEREBRAL BLOOD FLOW IN THE DOG.
197215 01-03

GAS CHROMATOGRAPHIC ANALYSES OF BARBITURATES IN SMALL AMOUNTS OF BLOOD.
197279 01-01

EFFECTS OF ANORECTIC AGENTS ON BLOOD PRESSURE OF THE DOG.
197464 01-03

RELATIONSHIP BETWEEN THE CHANGES ON BLOOD PRESSURE RESPONSE AND THE CARDIAC CATECHOLAMINE LEVEL AFTER SINGLE AND REPEATED ADMINISTRATIONS OF TYRAMINE AND METHAMPHETAMINE IN RATS.
197491 01-03

BLOOD LEVEL, EXCRETION, DISTRIBUTION AND METABOLISM OF 14C-TRIFLUBAZAM, A NEW 1,5 BENZODIAZEPINE, IN MICE AND DOGS.
197940 01-03

THE EFFECT OF BEDREST AND OF PHYSICAL ACTIVITY ON THE BLOOD LEVEL OF GENTAMYCIN AFTER INTRAMUSCULAR APPLICATION.
197956 01-13

EFFECT OF ALCOHOLS, CHLORPROMAZINE AND DIPHENYLHYDANTOIN ON (CA2+) ATPASE OF HUMAN RED BLOOD CELLS.
197976 01-13

PSYCHOACTIVE DRUG BLOOD LEVELS AND CLINICAL RESPONSE.
198095 02-07

BLOOD AND URINE LEVELS OF N,N DIMETHYLTRYPTAMINE FOLLOWING ADMINISTRATION OF PSYCHOACTIVE DOSAGES TO HUMAN SUBJECTS.
198230 02-12

DEPRESSION TREATED WITH CHLORIMIPRAMINE WITH SPECIAL ANALYSIS OF CHANGE IN BLOOD PRESSURE BY INFUSION.
199212 02-09

SPECTROFLUORODENSITOMETRIC DETERMINATION OF FLURAZEPAM AND ITS MAJOR METABOLITES IN BLOOD.
200737 02-16

SUBCELLULAR DISTRIBUTION OF RESERPINE IN BLOOD PLATELETS: EVIDENCE FOR MULTIPLE POOLS.
202665 02-03

RED BLOOD CELL LITHIUM INDEX IN PATIENTS WITH AFFECTIVE DISORDERS IN THE COURSE OF LITHIUM PROPHYLAXIS.
202786 02-09

BLOOD LEVELS AND MANAGEMENT OF LITHIUM TREATMENT.
203546 02-15

MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 3. COMMUNICATION: PERAZINE CONCENTRATION IN BLOOD AND CLINICAL EFFICACY.
203841 02-13

MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 4. COMMUNICATION: CONNECTION BETWEEN EEG CHANGES, CONCENTRATION IN BLOOD, AND OTHER CLINICAL VARIABLES.
203842 02-13

SELECTIVE INHIBITION OF DOPAMINE-BETA-HYDROXYLASE IN THE PERIPHERAL TISSUES BY 5-DIMETHYLDITHIOCARBAMYLPICOLINIC ACID; ITS EFFECT ON STRESS INDUCED ULCER, ETHANOL INDUCED SLEEP AND BLOOD PRESSURE.
204484 02-03

THE LEVELS OF LITHIUM IN SERUM AND IN RED BLOOD CELLS AND ITS RATIOS IN MANIC-DEPRESSIVE PATIENTS.
205607 03-09

BRAIN CATECHOLAMINES AND CEREBRAL BLOOD FLOW.
209839 03-17

PIPERIDINE CONCENTRATION CHANGES IN THE BRAIN AND BLOOD OF DORMANT MICE.
210701 03-03

THE LEVEL OF BLOOD NEUROMEDIATORS AFTER THE USE OF SEDUXEN AS AN INDEX OF NERVOUS SYSTEM REACTIVITY.
212432 03-13

THE EFFECT OF LITHIUM ON BLOOD PRESSURE AND ON PLASMA RENIN SUBSTRATE AND RENIN IN RATS.
213483 04-03

LYSERGIC ACID DIETHYLAMIDE AFFECTS BLOOD FLOW TO SPECIFIC AREAS OF THE CONSCIOUS RAT BRAIN.
215161 04-03

BLOOD PRESSURE AND HEART RATE RESPONSES EVOKED BY D- AND L-AMPHETAMINE IN THE PITHED RAT PREPARATION.
215687 04-03

EFFECTS OF IPRONIAZID, CHLORPROMAZINE AND METHIOTHEPIN ON DMT INDUCED CHANGES IN BODY TEMPERATURE, PUPILLARY DILATATION, BLOOD PRESSURE AND EEG IN THE RABBIT.
215724 04-03

THE INFLUENCE OF TRICYCLIC ANTIDEPRESSANTS, AZAPHEN AND IMIZINE ON BLOOD SUGAR CONCENTRATION CHANGES PRODUCED BY EPINEPHRINE AND SEROTONIN.
217214 04-03

THE ORIGIN OF BLOOD 5-HYDROXYINDOLEACETIC (5-HIAA) ACID FOLLOWING L-HYDRAZINO-ALPHA-METHYLDOPA (MK-486).
217665 04-03

INFLUENCE OF SOME TRICYCLIC ANTIDEPRESSIVE DRUGS ON THE UPTAKE OF 5-HYDROXYTRYPTAMINE BY RAT BLOOD PLATELETS.
217693 04-03

BINDING OF (+) AMPHETAMINE AND (-) DELTA1-TETRAHYDROCANNABINOLS AND (-) 7-HYDROXY-DELTA1-TETRAHYDROCANNBINOL TO BLOOD CELLS AND PLASMA PROTEINS IN MAN.
217878 04-13

EFFECT OF SOME ANORECTIC AGENTS ON THE UPTAKE AND RELEASE OF 5-HYDROXYTRYPTAMINE BY BLOOD PLATELETS OF RATS.
217890 04-03

DEXTROMETHORPHAN INHIBITS 5-HYDROXYTRYPTAMINE UPTAKE BY HUMAN BLOOD PLATELETS AND DECREASES 5-HYDROXYINDOLEACETIC ACID CONTENT IN RAT BRAIN.
217964 04-03

STATUS OF LITHIUM PATIENTS AS BLOOD DONORS.
217969 04-15

LITHIUM IN NONMANIC DEPRESSIVES: ANTIAGGRESSIVE EFFECT AND RED BLOOD CELL LITHIUM VALUES.
222604 04-09

THE EFFECT OF TRANQUILIZERS (DIAZEPAM AND CHLORDIAZEPOXIDE) ON THE BLOOD SUPPLY AND CARDIAC ACTIVITY.
223018 04-03

EEG AND BLOOD LEVEL RELATIONS OF PSYCHOACTIVE DRUGS.
224795 04-13

BLOOD-BRAIN

LIPID SOLUBILITY AND DRUG PENETRATION OF THE BLOOD-BRAIN BARRIER.
206913 03-03

BLOOD-BRAIN BARRIER: I. KINETICS OF DISTRIBUTION OF 3H-AMPHETAMINE IN THE RAT BRAIN AFTER INTRAVENOUS ADMINISTRATION.
210788 03-03

THE BLOOD-BRAIN BARRIER II: DISTRIBUTION KINETICS OF H3-P-HYDROXYAMPHETAMINE IN BRAIN STRUCTURES OF THE RAT AFTER INTRAVENOUS ADMINISTRATION.
220977 04-03

BODIES

PRESENCE OF DOPAMINERGIC TERMINALS AND ABSENCE OF DOPAMINERGIC CELL BODIES IN THE CEREBRAL CORTEX OF THE CAT.
210800 03-03

BODY
THE EFFECTS OF LSD, PSILOCYBIN, HARMALINE AND AMPHETAMINE ON THE BODY TEMPERATURE OF P-CHLOROPHENYLALANINE PRETREATED RATS.
197484 01-03
EFFECT OF ACUTE ADMINISTRATION OF L-DOPA ON BODY TEMPERATURE IN MAN.
197831 01-13
LITHIUM INDUCED LOSS OF BODY SODIUM AND THE DEVELOPMENT OF SEVERE INTOXICATION IN RATS.
199623 02-03
THE EFFECT OF LSD, PSILOCYBIN, HARMALINE AND AMPHETAMINE ON THE BODY TEMPERATURE OF P-CHLOROPHENYLALANINE PRETREATED RABBITS.
210920 03-05
THE EFFECT OF CYPROHEPTADINE ON HUNGER, CALORIE INTAKE AND BODY WEIGHT IN MAN.
214011 04-13
THE EFFECT OF ACTH AND DIAZEPAM, ADMINISTERED TO INFANT RATS ON THE BODY GROWTH CURVE AND SOME ENDOCRINE PARAMETERS MEASURED IN ADULT AGE.
215066 04-03
PLASMA CATECHOLAMINES: ARTERIAL VENOUS DIFFERENCES AND THE INFLUENCE OF BODY TEMPERATURE.
215655 04-06
EFFECTS OF IPRONIAZID, CHLORPROMAZINE AND METHIOTHEPIN ON DMT INDUCED CHANGES IN BODY TEMPERATURE, PUPILLARY DILATATION, BLOOD PRESSURE AND EEG IN THE RABBIT.
215724 04-03
ABSENCE OF INTERACTION BETWEEN DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) AND CANNABIDIOL (CBD) IN AGGRESSION, MUSCLE CONTROL AND BODY TEMPERATURE EXPERIMENTS IN MICE.
217474 04-04
LOSS OF BODY WEIGHT AS A PREDICTOR OF RESERPINE INDUCED AMINE DEPLETION.
217661 04-03

BONANZA
THE BENZODIAZEPINE BONANZA.
194066 01-17

BONE
THE EFFECT OF CHRONIC LITHIUM APPLICATION ON THE MINERAL CONTENT OF RAT BONE AND SOFT TISSUES.
215695 04-05

BORDERLINE
PSYCHOPHARMACOLOGICAL THERAPY AND THE PROBLEMS OF DELINEATING BORDERLINE FORMS OF NEUROPSYCHIC DISORDERS.
212431 03-17
CASE PRESENTATION OF AN ALTERNATIVE THERAPEUTIC APPROACH FOR THE BORDERLINE PSYCHOTIC HEROIN ADDICT: DIPHENYLHYDANTOIN.
225512 04-09

BORN
CONDITIONED LEARNING IN YOUNG RATS BORN OF DRUG ADDICTED PARENTS AND RAISED ON ADDICTIVE DRUGS.
217465 04-04

BOSTON
DROWSINESS DUE TO CHLORPROMAZINE IN RELATION TO CIGARETTE SMOKING: A REPORT FROM THE BOSTON COLLABORATIVE DRUG SURVEILLANCE PROGRAM.
193072 01-15
PSYCHOTROPIC DRUG USE IN THE BOSTON AREA: A REPORT FROM THE BOSTON COLLABORATIVE DRUG SURVEILLANCE PROGRAM.
213920 04-17

BOUND
REDUCTION OF STIMULUS BOUND FOOD CONSUMPTION IN THE RAT FOLLOWING AMPHETAMINE ADMINISTRATION.
195081 01-04
FREE AND MEMBRANE BOUND RIBOSOMES AND POLYSOMES IN HIPPOCAMPAL NEURONS DURING A LEARNING EXPERIMENT.
210674 03-04

BOVINE
BINDING OF D-OXAZEPAM AND L-OXAZEPAM HEMISUCCINATE TO BOVINE SERUM ALBUMIN.
200033 02-03

BOYS
PLATELET SEROTONIN OF HYPERACTIVE SCHOOL-AGE BOYS.
194397 01-13
ONE-YEAR FOLLOWUP OF HYPERACTIVE BOYS TREATED WITH IMIPRAMINE OR METHYLPHENIDATE.
209736 03-11
MNEMONIC CAPACITY OF MENTALLY RETARDED BOYS TREATED WITH HIGH DOSES OF NUCLEOTIDES AND GABA.
210291 03-14

BRADYCARDIC
LACK OF TOLERANCE TO THE BRADYCARDIC EFFECT OF DELTA9-TRANS-TETRAHYDROCANNABINOL IN RATS.
210873 03-05

BRADYKINESIA
REVERSAL OF RESERPINE INDUCED BRADYKINESIA BY ALPHA-METHYLDOPA -- NEW LIGHT ON ITS MODUS-OPERANDI.
202281 02-03

BRADYKININ
EFFECT OF INTRACEREBROVENTRICULAR BRADYKININ AND RELATED PEPTIDES ON RABBIT OPERANT BEHAVIOR.
215693 04-04

BRAIN
A METHOD FOR THE ISOLATION AND DETERMINATION OF 3-METHOXYTYRAMINE IN BRAIN TISSUE.
193302 01-03
AN EFFECT OF AMPHETAMINE ON MOUSE BRAIN POLYRIBOSOMES.
193423 01-03
AN EFFECT OF AMPHETAMINE ON INCORPORATION OF LEUCINE INTO MOUSE BRAIN PROTEIN.
193424 01-03
EFFECT OF ACUTE AND CHRONIC DIELDRIN EXPOSURE ON BRAIN BIOGENIC AMINES OF MALE AND FEMALE RATS.
193428 01-03
PENTAZOCINE ANALGESIA AND REGIONAL RAT BRAIN CATECHOLAMINES.
193452 01-03
FURTHER STUDIES ON THE EFFECT OF P-HYDROXYNOREPHEDRINE (PONE) ON NOREPINEPHRINE METABOLISM IN THE RAT BRAIN.
193453 01-03
DIFFERENTIAL EFFECTS OF D-AMPHETAMINE ON BRAIN ACETYLCHOLINE IN YOUNG, ADULT, AND GERIATRIC RATS.
193457 01-03
THYROXINE AND BRAIN CATECHOLAMINES: INCREASED TRANSMITTER SYNTHESIS AND INCREASED RECEPTOR SENSITIVITY.
193541 01-03
PHARMACOKINETICS OF LITHIUM AND ITS REGIONAL DISTRIBUTION IN RAT BRAIN.
193547 01-03
EFFECT OF COPPER LOADING ON VARIOUS TISSUE ENZYMES AND BRAIN MONOAMINES IN THE RAT.
193577 01-03
MESCALINE-INDUCED CHANGES OF BRAIN CORTEX RIBOSOMES: EFFECT OF MESCALINE ON RIBOSOMAL SYNTHESIS OF POLYURIDINE DIRECTED POLYPHENYLALANINE.
194153 01-03
BRAIN DOPA/5-HTP DECARBOXYLASE ACTIVITY AFTER THE CHRONIC ADMINISTRATION OF L-DOPA OR 5-HYDROXY-L-TRYPTOPHAN IN NORMAL AND LESIONED CATS.
194483 01-05
COMPARISON OF THE EFFECTS OF CHLORAL HYDRATE AND TRICHLOROETHANOL ON THE EEG OF THE ISOLATED PERFUSED RAT BRAIN.
194743 01-03
5-HYDROXYTRYPTAMINE IN PLATELETS AND BRAIN OF RABBITS TREATED CHRONICALLY WITH IMIPRAMINE, MORPHINE OR METHADONE.
194744 01-03
EFFECTS OF TETRAHYDROCANNABINOLS ON CYCLIC-AMP LEVELS IN RAT BRAIN AREAS.
194925 01-03
BRAIN ACETYLCHOLINE AND CHOLINESTERASE: EFFECT OF PHENOTHIAZINES AND PHYSOSTIGMINE INTERACTION IN RATS.
195046 01-03
INTERACTION OF CATECHOLAMINE AND AMINO ACID METABOLISM IN BRAIN: EFFECT OF PARGYLINE AND L-DOPA.
195048 01-03
IN VIVO RELEASE OF ENDOGENOUSLY SYNTHESIZED CATECHOLAMINES FROM THE CAT BRAIN EVOKED BY ELECTRICAL STIMULATION AND BY D-AMPHETAMINE.
195049 01-03
EFFECTS OF SOME HOMOLOGUES OF 4-CHLOROAMPHETAMINE ON BRAIN SEROTONIN METABOLISM.
195092 01-02
INTERACTION OF PENTYLENETETRAZOL AND TRIMETHADIONE ON THE METABOLISM OF SEROTONIN IN BRAIN AND ITS RELATION TO THE ANTICONVULSANT ACTION OF TRIMETHADIONE.
195093 01-03
EFFECTS OF DIISOPROPYLPHOSPHOFLUORIDATE ON ACETYLCHOLINE, CHOLINESTERASE AND CATECHOLAMINES OF SEVERAL PARTS OF RABBIT BRAIN.
195094 01-03
REGIONAL LEVELS OF GABA AND GLUTAMATE IN MOUSE BRAIN FOLLOWING EXPOSURE TO PAIN.
195097 01-03
MORPHINE EFFECTS ON THE LEVELS AND TURNOVER OF CATECHOLAMINES IN RAT BRAIN.
195116 01-03
EFFECT OF LITHIUM ON SERUM TRYPTOPHAN AND BRAIN SEROTONIN IN RATS.
195232 01-03
BRAIN SEROTONIN METABOLISM IN LITHIUM TREATED RATS.
195235 01-03

INFLUENCE OF THERAPEUTIC AND TOXIC DOSES OF NEUROLEPTICS AND ANTIDEPRESSANTS ON ENERGY METABOLISM OF THE ISOLATED PERFUSED RAT BRAIN.
195236 01-03

CONJOINT NATIVE AND ORTHOPHTHALDIALDEHYDE CONDENSATE ASSAYS FOR THE FLUORIMETRIC DETERMINATION OF 5-HYDROXYINDOLES IN BRAIN.
195238 01-01

CHANGES IN BRAIN CONCENTRATION OF BIOGENIC AMINES AND THE ANTINOCICEPTIVE EFFECT OF MORPHINE IN RATS.
195246 01-03

THE IMPORTANCE OF THE ASCENDING DOPAMINERGIC SYSTEMS TO THE EXTRAPYRAMIDAL AND MESOLIMBIC BRAIN AREAS FOR THE CATALEPTIC ACTION OF THE NEUROLEPTIC AND CHOLINERGIC AGENTS.
195250 01-03

THE EFFECTS OF LITHIUM AND PHYSOSTIGMINE ON RAT BRAIN ACETYLCHOLINESTERASE ACTIVITY.
195436 01-03

NORADRENALINE AND 5-HYDROXYTRYPTAMINE METABOLISM IN SIX AREAS OF RAT BRAIN DURING POST-AMPHETAMINE DEPRESSION.
195437 01-03

INCREASE IN BRAIN DOPAMINE AFTER AXOTOMY OR TREATMENT WITH GAMMA-HYDROXYBUTYRIC ACID DUE TO ELIMINATION OF THE NERVE IMPULSE FLOW.
195439 01-03

EFFECTS OF DRUGS INFLUENCING MONOAMINE MECHANISMS ON THE INCREASE IN BRAIN DOPAMINE PRODUCED BY AXOTOMY OR TREATMENT WITH GAMMA-HYDROXYBUTYRIC ACID.
195440 01-03

EFFECTS ON SHOCK-ELICITED AGGRESSION IN MICE OF PREFERENTIALLY PROTECTING BRAIN MONOAMINES AGAINST THE DEPLETING ACTION OF RESERPINE.
195452 01-04

BRAIN AND SERUM CONCENTRATIONS OF DIAZEPAM IN EXPERIMENTAL EPILEPSY.
195494 01-04

THE MULTIPLICITY OF INTERACTIONS OF PSYCHOTROPIC DRUGS WITH THE BRAIN SEROTONIN BIOSYNTHETIC UNIT.
195926 01-17

EFFECT OF PENTOBARBITONE AND DIETHYL ETHER ON THE SYNTHESIS OF MONOAMINES IN RAT BRAIN.
195950 01-03

THE ROLE OF BRAIN CATECHOLAMINES IN THE ANORECTIC RESPONSE TO AMPHETAMINE. (PH.D. DISSERTATION).
196370 01-04

RELATIONSHIP BETWEEN ANALGESIC ACTION OF PETHIDINE AND ITS EFFECT ON THE BRAIN 5-HYDROXYTRYPTAMINE CONCENTRATION IN THE RATS OF DIFFERENT AGE.
196782 01-03

FATE OF L-GLUTAMATE IN THE BRAIN.
196800 01-03

DEVELOPMENTAL CHARACTERISTICS OF PHENYLETHANOLAMINE AND OCTOPAMINE IN THE RAT BRAIN.
196804 01-03

ALTERATIONS IN THE TURNOVER OF BRAIN NOREPINEPHRINE AND DOPAMINE IN ALCOHOL DEPENDENT RATS.
196805 01-03

THE INCORPORATION OF GLUCOSE INTO BRAIN GLYCOGEN AND THE ACTIVITIES OF CEREBRAL GLYCOGEN PHOSPHORYLASE AND SYNTHETASE: SOME EFFECTS OF AMPHETAMINE.
196808 01-03

EFFECTS OF LITHIUM ON CYCLIC-3-5-AMP METABOLISM IN RAT BRAIN.
197278 01-03

ON THE INVOLVEMENT OF BRAIN CATECHOLAMINES IN MORPHINE-INDUCED RUNNING ACTIVITY IN MICE.
197286 01-04

THE SUBCELLULAR DISTRIBUTION OF INTRAVENTRICULARLY ADMINISTERED 3H-METARAMINOL IN INTACT AND RAT BRAIN PRETREATED WITH P-CHLOROAMPHETAMINE.
197289 01-03

EFFECTS OF CATECHOLAMINES AND PROSTAGLANDINS ON CYCLIC-AMP LEVELS IN BRAIN IN VIVO.
197294 01-03

THE EFFECTS OF IMIPRAMINE AND PROMAZINE ON ENERGY METABOLISM AND EEG OF THE ISOLATED PERFUSED RAT BRAIN.
197296 01-03

EFFECT OF 6-HYDROXYDOPAMINE ON THE LEVEL OF THE CATECHOLAMINES IN THE BRAIN OF DEVELOPING RATS.
197449 01-03

EFFECT OF SIMULATED ALTITUDE ON THE DISPOSITION OF CHLORPROMAZINE IN MOUSE BRAIN AND LIVER.
197455 01-05

THE EFFECTS OF PARENTERAL ADMINISTRATION OF CATECHOLAMINES, SEROTONIN AND HISTAMINE ON BEHAVIOR AND LEVELS OF THESE AMINES IN THE BRAIN OF THE NEONATE CHICK.
197457 01-03

PERIPHERAL TISSUE DISTRIBUTION, BRAIN DISTRIBUTION AND METABOLISM OF MESCALINE-14C IN MONKEYS.
197458 01-03

EFFECTS OF THE HIGH DOSES OF L-DOPA ON ELECTRICAL ACTIVITY IN THE BRAIN OF THE RABBIT: INTERACTION WITH THE METABOLISM OF 5-HT.
197468 01-03

EFFECT OF PSYCHOACTIVE DRUGS ON IN VIVO METABOLISM OF 14C-HISTAMINE IN MOUSE BRAIN.
197472 01-03

SOME OF THE DYNAMICS OF CHOLINE AND ACETYLCHOLINE METABOLISM IN RAT BRAIN.
197474 01-03

THE EFFECT OF A NEW TETRACYCLIC ANTIDEPRESSANT COMPOUND, ORG-GB94, ON THE TURNOVER OF DOPAMINE, NORADRENALIN AND SEROTONIN IN THE RAT BRAIN.
197496 01-03

THE RELATIONSHIP BETWEEN RIGIDITY AND CHANGE IN WHOLE BRAIN ACETYLCHOLINE CONCENTRATION PRODUCED BY INJECTION OF RESERPINE IN THE RAT.
197569 01-03

THE EFFECTS OF P-SUBSTITUTED AMPHETAMINES ON THE TRANSMITTER REGULATION IN RAT BRAIN.
197571 01-03

THE ACTION OF PSYCHOSTIMULANT SIDNOKARB ON METABOLISM OF BIOGENIC AMINES IN THE BRAIN.
197573 01-03

CATECHOLAMINE DEPLETING ACTION OF PHYSOSTIGMINE IN THE RAT BRAIN.
197575 01-03

EFFECT OF ANGIOTENSIN II ON SEROTONIN ACCUMULATION IN THE RAT BRAIN.
197582 01-03

POSTMORTAL ACCUMULATION OF 3-METHOXYTYRAMINE IN BRAIN.
197583 01-03

3,4 DIHYDROXYPHENYLACETIC ACID (DOPAC): A POSSIBLE ENDOGENOUS INHIBITOR OF INDOLEAMINE-N-METHYLATION IN THE RAT BRAIN.
197676 01-17

MORPHOLOGICAL, BIOCHEMICAL, AND FUNCTIONAL CHANGES IN CHICK EMBRYONIC BRAIN TISSUE AFTER INTRACEREBRAL ADMINISTRATION OF OUABAIN.
197788 01-03

EFFECTS OF 5-(N-BUTYL) PICOLINAMIDE (SCH-10595), A DOPAMINE-BETA-HYDROXYLASE INHIBITOR, ON SEROTONIN AND CATECHOLAMINE METABOLITES IN BRAIN.
197813 01-03

EFFECTS OF PIRIBEDIL ON NORADRENALINE AND MOPEG-SO4 LEVELS IN THE RAT BRAIN.
197868 01-03

LONG-TERM EFFECTS OF N-HYDROXY-4-CHLOROAMPHETAMINE ON THE LEVEL AND ACCUMULATION OF 5-HYDROXYTRYPTAMINE IN THE RAT BRAIN.
197869 01-03

THEOPHYLLINE INCREASED SENSITIVITY TO NOCICEPTIVE STIMULATION AND REGIONAL TURNOVER OF RAT BRAIN 5-HT, NORADRENALINE AND DOPAMINE.
197926 01-03

DOSE-DEPENDENT DIFFERENCES OF AMPHETAMINE LEVELS IN BRAIN AND HEART OF ADULT AND DEVELOPING MICE.
197927 01-03

PROTRIPTYLINE INDUCED INHIBITION OF THE IN VIVO 3H-NORADRENALINE SYNTHESIS FROM 3H-L-DOPA IN THE RAT BRAIN.
197928 01-03

EVIDENCE THAT PUNCTUATE INTRACEREBRAL ADMINISTRATION OF 6-HYDROXYDOPAMINE FAILS TO PRODUCE SELECTIVE NEURONAL DEGENERATION: COMPARISON WITH COPPER SULFATE AND FACTORS GOVERNING THE DEPORTMENT OF FLUIDS INJECTED INTO BRAIN.
197931 01-03

INFLUENCE OF MORPHINE ON THE RELEASE OF NORADRENALINE FROM BRAIN SLICES.
197964 01-03

ON THE MECHANISM OF ACTION OF GAMMA-HYDROXYBUTYRIC ACID: LACK OF CONVERSION TO GABA IN MOUSE BRAIN IN VIVO.
197965 01-03

DETERMINATION OF NORADRENALINE, DOPAMINE, SEROTONIN, 5-HYDROXYINDOLEACETIC ACID, TYROSINE AND TRYPTOPHANE IN THE ISOLATED PERFUSED RAT BRAIN.
197967 01-06

ON THE ACTION OF OXOTREMORINE ON THE CHOLINERGIC SYSTEM OF THE RAT BRAIN.
197968 01-03

EFFECT OF NICOTINE AND OTHER DRUGS ON THE RELEASE OF 3H-NOREPINEPHRINE AND 3H-DOPAMINE FROM RAT BRAIN SLICES.
197985 01-03

EFFECTS OF SOCIAL STRESS ON THE TURNOVER OF BRAIN CATECHOLAMINES AND 5-HYDROXYTRYPTAMINE IN MICE.
198025 01-03

EFFECTS OF PSYCHOTROPIC DRUGS ON THE INCORPORATION OF GLUCOSE-14C INTO AMINO ACIDS OF THE RAT BRAIN.
198026 01-03

EFFECT OF RESERPINE ON CATIONIC CONTENTS OF RAT BRAIN.
198196 02-03

DISTRIBUTION OF AMPHETAMINE AND ITS HYDROXYLATED METABOLITES IN VARIOUS AREAS OF THE RAT BRAIN.
198211 02-03

ON THE SPECIFICITY OF NEUROCHEMICAL MECHANISMS DEALING WITH NOCICEPTIVE STIMULATION OF NEURONS IN VARIOUS BRAIN FORMATIONS OF RABBITS.
198436 02-03

THE INFLUENCE OF TYROCALCITONIN ON CONDITIONAL REFLEXES AND THE ELECTRICAL ACTIVITY OF THE BRAIN IN ANIMALS.
198479 02-02

ON THE INFLUENCE OF NEUROLEPTICS ON THE CORTICORETICULAR SYSTEM OF THE BRAIN (HISTOCHEMICAL AND BIOCHEMICAL INVESTIGATION).
198481 02-03

PROTEINASE ACTIVITY OF DIFFERENT SECTIONS OF THE BRAIN DURING CORAZOL (PENTYLENETETRAZOL) INDUCED CONVULSIONS.
198485 02-03

BRAIN LEVELS AND RELATIVE POTENCY OF THE 1,2 DIMETHYLHEPTYL ANALOGUE OF DELTA1-TETRAHYDROCANNABINOL IN MICE.
198605 02-01

INTERACTIONS OF PENTAZOCINE AND NALOXONE ON THE MONOAMINE CONTENT OF DISCRETE REGIONS OF THE RAT BRAIN.
198606 02-03

N-ACETYLTRANSFERASE OF BRAIN: POSSIBLE INVOLVEMENT IN THE METABOLISM OF THE BIOGENIC AMINES. (UNPUBLISHED PAPER).
199347 02-03

MODIFICATION OF THE RECEPTOR COMPONENT OF ADENYLATE-CYCLASE IN THE RAT BRAIN BY PHENOTHIAZINE DERIVATIVES.
199771 02-03

EFFECT OF PROGESTERONE ON REGIONAL 5-HYDROXYTRYPTAMINE METABOLISM IN THE RAT BRAIN.
199773 02-03

CHRONIC LYSERGIC ACID DIETHYLAMIDE ADMINISTRATION AND SEROTONIN TURNOVER IN VARIOUS REGIONS OF RAT BRAIN.
199783 02-03

EFFECT OF NEUROTROPIC AGENTS ON TOTAL PYRIDOXAL PHOSPHATE AND ON THE ACTIVITY OF THE DECARBOXYLASE OF AROMATIC AMINO ACIDS AS WELL AS OF OTHER PYRIDOXAL PHOSPHATE DEPENDENT ENZYMES IN RAT BRAIN.
199785 02-03

UPTAKE AND RELEASE OF POSSIBLE FALSE TRANSMITTER AMINO ACIDS BY RAT BRAIN TISSUE.
199788 02-03

BIOCHEMICAL CORRELATES IN MOUSE-KILLING BEHAVIOR OF THE RAT BRAIN: BRAIN ACETYLCHOLINE AND ACETYLCHOLINESTERASE AFTER ADMINISTRATION OF DELTA9-TETRAHYDROCANNABINOL.
199807 02-03

AMANTADINE AND D-145, AN AMANTADINE DERIVATIVE, DO NOT EFFECT DOPAMINE SENSITIVE ADENYLATE-CYCLASE FROM THE CAUDATE PUTAMEN OF THE RAT BRAIN.
199867 02-03

DUAL MECHANISM OF AMPHETAMINE TOXICITY IN MICE: RELATIONSHIP TO BRAIN CATECHOLAMINES.
199898 02-05

THE ROLE OF BRAIN DOPAMINE IN THE HYPERACTIVITY SYNDROME PRODUCED BY INCREASED 5-HYDROXYTRYPTAMINE SYNTHESIS IN RATS.
199960 02-04

COMPARISON OF THE OXIME AND THE HYDROXYLAMINE DERIVATIVES OF 4-CHLOROAMPHETAMINE AS DEPLETORS OF BRAIN 5-HYDROXYINDOLES.
200004 02-03

THE NEURON ULTRASTRUCTURE IN SOME BRAIN AREAS DURING A LONG-TERM ADMINISTRATION OF AMINAZINE AND STELAZINE.
200021 02-03

QUANTITATIVE ANALYSIS OF THE EEG EFFECTS PRODUCED BY IMIPRAMINE, DESIPRAMINE, PROMAZINE, AND MONODESMETHYL PROMAZINE IN THE ISOLATED PERFUSED RAT BRAIN.
200056 02-03

THE ACCUMULATION OF NORADRENALINE AND 5-HYDROXYTRYPTAMINE IN THREE REGIONS OF MOUSE BRAIN AFTER TETRABENAZINE AND IPRONIAZID: EFFECTS OF ETHINYLESTRADIOL AND PROGESTERONE.
200058 02-03

DIAZEPAM INCREASES 5-HYDROXYINDOLE CONCENTRATIONS IN RAT BRAIN AND SPINAL CORD.
200081 02-03

THE IN VIVO RELEASE OF ENDOGENOUSLY SYNTHESIZED CATECHOLAMINES FROM THE CAT BRAIN BY LATERAL HYPOTHALAMIC STIMULATION AND BY D-AMPHETAMINE ADMINISTRATION. (PH.D. DISSERTATION).
200313 02-03

THE INFLUENCE OF ALPHA-METHYLTYROSINE AND DISULFIRAM ON THE INHIBITORY FUNCTION OF THE CAUDATE NUCLEUS AND CATECHOLAMINE CONTENT IN THE BRAIN OF CATS.
200565 02-03

EFFECT OF LONG-TERM LITHIUM TREATMENT ON BRAIN FUMARASE ACTIVITY.
200751 02-03

LITHIUM CARBONATE, HALOPERIDOL, AND IRREVERSIBLE BRAIN DAMAGE.
201287 02-15

EFFECT OF LITHIUM ON THE EEG AND SEROTONIN CONTENT IN THE BRAIN.
201888 02-03

INFLUENCE OF HEXOBARBITAL ON THE BIOSYNTHESIS OF CATECHOLAMINES AND THEIR PRECURSORS IN THE BRAIN.
201917 02-03

ELECTROENCEPHALOGRAPHIC STUDY OF THE LOCAL TRANSPORT OF CENTRAL NERVOUS STIMULANTS INTO THE BRAIN.
202165 02-03

THE IMPORTANCE OF NEURONAL UPTAKE OF AMINES FOR AMPHETAMINE-INDUCED RELEASE OF 3H-NOREPINEPHRINE FROM ISOLATED BRAIN TISSUE.
202191 02-03

ACTION OF (S)- AND (R) P-SUBSTITUTED AMPHETAMINE HYDROCHLORIDES AND (ALPHA S)- AND (ALPHA R) P-CHLORONOREPHEDRINE AND (ALPHA S)- AND (ALPHA R) P-CHLORONORPSEUDOEPHEDRINE HYDROCHLORIDES ON THE LEVEL OF 5-HYDROXYTRYPTAMINE AND THE ACTIVITY OF TRYPTOPHAN-HYDROXYLASE IN RAT BRAIN.
202417 02-03

DEVELOPMENTAL DISTURBANCE OF THE BRAIN IN RAT OFFSPRING FOLLOWING MATERNAL ADMINISTRATION OF 5-FLUOURACIL DURING PREGNANCY.
202422 02-03

D-LSD BINDING TO BRAIN HOMOGENATES: POSSIBLE RELATIONSHIP TO SEROTONIN RECEPTORS.
202464 02-03

MEASUREMENT OF ACETYLCHOLINE TURNOVER RATE IN DISCRETE AREAS OF RAT BRAIN.
202465 02-06

INCORPORATION OF ACETATE (C14)(P-32) AND PHOSPHATE INTO THE BRAIN LIPIDS DURING BLOCKAGE OF THE CHOLINORECEPTOR AND ADRENORECEPTORS.
202599 02-03

AN ONTOGENIC STUDY ON THE EFFECT OF CATECHOLAMINE RECEPTOR STIMULATING AGENTS ON THE TURNOVER OF NORADRENALINE AND DOPAMINE IN THE BRAIN.
202715 02-03

PENTYLENETETRAZOL INDUCED RETROGRADE AMNESIA AND BRAIN SEIZURES IN MICE.
202724 02-04

FORMATION OF P-HYDROXYNOREPHEDRINE IN BRAIN FOLLOWING INTRAVENTRICULAR ADMINISTRATION OF P-HYDROXYAMPHETAMINE.
202782 02-03

EFFECT OF NOMIFENSINE (HOE-984), A NEW ANTIDEPRESSANT, ON UPTAKE OF NORADRENALINE AND SEROTONIN AND ON RELEASE OF NORADRENALINE IN RAT BRAIN SYNAPTOSOMES.
202807 02-03

DIETHYLDITHIOCARBAMATE (ANTABUSE): DECREASE OF BRAIN HEAVY METAL STAINING PATTERN AND IMPROVED CONSOLIDATION OF SHUTTLEBOX AVOIDANCE IN GOLDFISH.
203521 02-04

PROTECTION AGAINST EFFECTS OF BRAIN DAMAGE BY CATECHOLAMINE DEPLETION IS TEST DEPENDENT.
203579 02-04

LONG-LASTING DEPLETION OF BRAIN SEROTONIN BY 4-CHLOROAMPHETAMINE IN GUINEA-PIGS.
203580 02-03

THE INFLUENCE OF ENCEPHALOTROPIC DRUGS ON NUCLEIC ACID METABOLISM IN THE BRAIN.
204398 02-13

ACTIVATION OF BRAIN MONOAMINEOXIDASE BY SOME CNS DEPRESSANTS.
204864 02-03

LACK OF EFFECT OF AMANTADINE ON D-AMPHETAMINE INDUCED RELEASE OF DOPAMINE FROM CAT BRAIN IN VIVO.
204865 02-02

ACTIVATION OF EEG BY GAMMA-HYDROXYBUTYRATE (GHB) IN ORGANIC BRAIN DISORDERS.
205460 02-13

EFFECTS OF PSYCHOACTIVE TRICYCLIC DRUGS ON THE EEG OF THE ISOLATED PERFUSED RAT BRAIN.
205492 02-03

THE EFFECT OF MAPROTILIN ON BRAIN SEROTONIN METABOLISM IN RATS.
205604 03-03

EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON FREE AMINO ACIDS IN BRAIN.
205625 03-03

EFFECT OF DESIPRAMINE AND PARGYLINE ON BRAIN GAMMA-AMINOBUTYRIC ACID.
205851 03-03

REGIONAL DIFFERENCES IN RESPONSE TO DISPLACEMENT AND INHIBITION OF SYNTHESIS OF CATECHOLAMINES IN THE CAT BRAIN.
206334 03-03

ACCUMULATION OF 3H-HOMOVANILLIC ACID IN RABBIT BRAIN AND CEREBROSPINAL FLUID FOLLOWING INTRAVENOUS 3H-L-DOPA.
206336 03-03

SHORT-TERM EFFECT OF PERPHENAZINE ENANTHATE ON THE RAT BRAIN.
206359 03-03

INFLUENCE OF IPRONIAZID ON THE CONTENT OF NORADRENALINE IN VARIOUS PARTS OF THE RAT BRAIN BEFORE AND AFTER STIMULATION OF THE RECEPTORS.
206404 03-03

METABOLISM OF DOPAMINE AND NOREPINEPHRINE IN RAT BRAIN AFTER SINGLE AND REPEATED ADMINISTRATION OF HALOPERIDOL, LOXAPINE AND CLOZAPINE.
206973 03-03

EFFECT OF STRESS UPON SEROTONIN METABOLISM IN VARIOUS REGIONS OF THE RAT BRAIN.
206993 03-03

EFFECTS OF AMPHETAMINES ON THE METABOLISM OF CATECHOLAMINES IN THE RAT BRAIN.
207288 03-03

A MASS FRAGMENTOGRAPHIC STUDY OF AMPHETAMINE AND METABOLITES IN RAT BRAIN.
207289 03-06

ANTISCHIZOPHRENIC DRUGS: AFFINITY FOR MUSCARINIC CHOLINERGIC RECEPTOR SITES IN THE BRAIN PREDICTS EXTRAPYRAMIDAL EFFECTS.
207298 03-03

BRAIN DOPAMINE AND BEHAVIOUR: A CRITICAL ANALYSIS OF THE RELATIONSHIP BETWEEN DOPAMINE ANTAGONISM AND THERAPEUTIC EFFICACY OF NEUROLEPTIC DRUGS.
207306 03-04

COMPARISON OF THE INHIBITORY EFFECTS OF PROPARGYLAMINE AND PARGYLINE ON BRAIN AND LIVER MONOAMINEOXIDASE ACTIVITY.
207857 03-03

DOPAMINERGIC MECHANISMS OF OPIATE ACTIONS IN BRAIN.
208554 03-03

THE INFLUENCE OF INTRAPERITONEAL INJECTION OF IPRAZIDE AND TRANSAMINE ON THE DISTRIBUTION OF BIOGENIC AMINES IN CORTICAL AND SUBCORTICAL WHITE MATTER OF THE RAT BRAIN.
209032 03-03

BRAIN CATECHOLAMINES AND CEREBRAL BLOOD FLOW.
209839 03-17

D-AMPHETAMINE AND THE SENSORY ROLE OF A RATS TAIL IN THERMOREGULATION OR WHAT THE RATS TAIL TELLS THE RATS BRAIN.
209961 03-03

PHARMACOLOGICAL MANIPULATIONS OF BRAIN CATECHOLAMINES AND THE AGGRESSIVE BEHAVIOR INDUCED BY MARIHUANA IN REM SLEEP DEPRIVED RATS.
210325 03-04

QUANTITATIVE RELATIONSHIP OF CATECHOLAMINE CONTENT AND HISTOFLUORESCENCE IN BRAIN OF RATS.
210660 03-03

HIPPOCAMPUS: SELECTIVE CONCENTRATIONS OF LEAD IN THE NORMAL RAT BRAIN.
210665 03-03

IMPRINTING: CORRELATIONS BETWEEN BEHAVIOUR AND INCORPORATION OF (14C)URACIL INTO CHICK BRAIN.
210667 03-04

CORRELATIONS BETWEEN CIRCADIAN CHANGES IN SERUM AMINO ACIDS OR BRAIN TRYPTOPHAN AND THE CONTENTS OF SEROTONIN AND 5-HYDROXYINDOLEACETIC ACID IN REGIONS OF THE RAT BRAIN.
210673 03-03

PIPERIDINE CONCENTRATION CHANGES IN THE BRAIN AND BLOOD OF DORMANT MICE.
210701 03-03

POSTNATAL DEVELOPMENT OF CHOLINE UPTAKE BY CHOLINERGIC TERMINALS IN RAT BRAIN.
210713 03-03

NEONATAL 6-HYDROXYDOPAMINE TREATMENT: NORADRENALINE LEVELS AND IN VITRO 3H-CATECHOLAMINE SYNTHESIS IN DISCRETE BRAIN REGIONS OF ADULT RATS.
210759 03-03

EXTRAPINEAL N-ACETYLTRANSFERASE ACTIVITY IN RAT BRAIN.
210760 03-03

THE EFFECT OF DIPHENYLHYDANTOIN ON BRAIN 5-HYDROXYTRYPTAMINE METABOLISM AND FUNCTION.
210764 03-03

EFFECT OF DELTA9-TETRAHYDROCANNABINOL ADMINISTRATION ON THE LIPID CONSTITUENTS OF RAT BRAIN SUBCELLULAR FRACTIONS.
210769 03-03

INHIBITION BY APOMORPHINE OF DOPAMINE DEAMINATION IN THE RAT BRAIN.
210776 03-03

METABOLIC COMPARTMENTATION IN THE BRAIN: METABOLISM OF A TRICARBOXYLIC ACID CYCLE INTERMEDIATE, (1,4-14C)SUCCINATE, AFTER INTRACEREBRAL ADMINISTRATION.
210780 03-03

ACCUMULATION OF LITHIUM IN THE PARTICULATE FRACTION OF RAT BRAIN FOLLOWING ITS LONG-TERM ADMINISTRATION.
210782 03-03

BLOOD-BRAIN BARRIER: I. KINETICS OF DISTRIBUTION OF 3H-AMPHETAMINE IN THE RAT BRAIN AFTER INTRAVENOUS ADMINISTRATION.
210788 03-03

REGIONAL AND SUBCELLULAR DISTRIBUTION AND KINETIC PROPERTIES OF RAT BRAIN CHOLINE ACETYLTRANSFERASE -- SOME FUNCTIONAL CONSIDERATIONS.
210816 03-03

COMPARATIVE STUDIES ON THE MEMBRANE ACTIONS OF DEPRESSANT DRUGS: THE ROLE OF LIPOPHILICITY IN INHIBITION OF BRAIN SODIUM AND POTASSIUM STIMULATED ATPASE.
210818 03-03

EVIDENCE FOR REVERSIBLE INHIBITION OF BRAIN DOPAMINE-BETA-HYDROXYLASE ACTIVITY IN VIVO BY AMPHETAMINE ANALOGUES.
210821 03-03

FACTORS INFLUENCING BRAIN AND TISSUE LEVELS OF TRYPTAMINE: SPECIES, DRUGS AND LESIONS.
210850 03-03

TRICYCLIC ANTIDEPRESSIVE DRUGS AND DOPAMINE SENSITIVE ADENYLATE-CYCLASE FROM RAT BRAIN STRIATUM.
210856 03-03

THE EFFECT OF TWO SYNTHETIC ACTH ANALOGUES ON THE METABOLISM OF BIOGENIC AMINES IN THE RAT BRAIN.
210875 03-03

EFFECT OF CHOLINE ACETYLTRANSFERASE INHIBITORS ON MOUSE AND GUINEA-PIG BRAIN CHOLINE AND ACETYLCHOLINE.
210883 03-03

APPLICATION OF PRINCIPLES OF STEADY-STATE KINETICS TO THE IN VIVO ESTIMATION OF ACETYLCHOLINE TURNOVER RATE IN MOUSE BRAIN.
210885 03-06

MODIFICATION BY L-DOPA METHYLESTER (H-19-61) OF AMPHETAMINE-INDUCED BRAIN CATECHOLAMINE CHANGES, THERMAL RESPONSES AND TOXICITY IN DEVELOPING MICE.
210891 03-03

REVERSIBLE INHIBITION OF MAMMALIAN BRAIN ACETYLCHOLINESTERASE AND SODIUM POTASSIUM STIMULATED ADENOSINE-TRIPHOSPHATASE BY CYCLOPROPANE.
210903 03-03

THE EFFECTS OF ACUTE AND CHRONIC MORPHINE ADMINISTRATION ON THE LEVELS OF 3-METHOXY-4-HYDROXYPHENYLGLYCOL SULFATE IN RAT BRAIN.
210927 03-03

EFFECT OF THYROXINE AND CORTISOL ON BRAIN ORNITHINE DECARBOXYLASE ACTIVITY AND SWIMMING BEHAVIOR IN DEVELOPING RAT.
210933 03-03

HIGH AFFINITY UPTAKE OF GABA IN PRESUMED GABA-ERGIC NERVE ENDINGS IN RAT BRAIN.
211062 03-03

STUDIES WITH AGENTS WHICH INFLUENCE ACETYLCHOLINE METABOLISM IN MOUSE BRAIN.
211065 03-03

THE EFFECT OF RESERPINE AND CHLORIMIPRAMINE ON GLYCOGEN CONTENT IN DIFFERENT BRAIN STRUCTURES OF RAT.
211106 03-03

CAFFEINE IN THE TREATMENT OF CHILDREN WITH MINIMAL BRAIN DYSFUNCTION OR HYPERKINETIC SYNDROME.
211434 03-11

P-CHLOROAMPHETAMINE: SELECTIVE NEUROTOXIC ACTION IN BRAIN.
211494 03-05

CHLORPROMAZINE: SPECIFIC INHIBITION OF L-NORADRENALINE AND 5-HYDROXYTRYPTAMINE UPTAKE IN SYNAPTOSOMES FROM SQUID BRAIN.
213395 04-03

THYROXINE-LIKE EFFECTS OF ZINC ON BRAIN AND BEHAVIOUR WITH FIRM DEPENDENCE ON SEVERAL HORMONES.
213434 04-04

IN VIVO IDENTIFICATION OF MUSCARINIC CHOLINERGIC RECEPTOR BINDING IN RAT BRAIN.
213480 04-03

NEUROPHARMACOLOGIC STUDIES OF LOCAL BRAIN FUNCTION.
213601 04-03

BIOCHEMICAL PHARMACOLOGY OF BRAIN AMINE MECHANISMS.
213603 04-03

LSD, PSYCHOTOGENIC PROCEDURES, AND BRAIN NEUROHUMORS.
213606 04-03

THE ROLE OF TYROSINE TRANSAMINASE IN BRAIN FUNCTION.
213607 04-03

LIMBIC SYSTEM LESIONS AND BRAIN NEUROHUMORS.
213613 04-03

STUDIES ON MUCOPOLYSACCHARIDES IN BRAIN.
213618 04-03

CHLORPROMAZINE AND BRAIN CATECHOLAMINE SYNTHESIS.
213630 04-03

BRAIN MONOAMINES AND BEHAVIOR.
213631 04-04

ACUTE ORGANIC BRAIN SYNDROME: A COMPLICATION OF DISULFIRAM THERAPY.
213710 04-15

THE EFFECT OF CAFFEINE ON BARBITURATE SLEEPING TIME AND BRAIN LEVEL.
214109 04-03

RAT BRAIN REGIONAL UPTAKE AND DECARBOXYLATION OF L-DOPA FOLLOWING CAROTID INJECTION.
214323 04-03

ORTHOMOLECULAR TREATMENT IN DISTURBANCES INVOLVING BRAIN FUNCTION.
214719 04-11

LYSERGIC ACID DIETHYLAMIDE AFFECTS BLOOD FLOW TO SPECIFIC AREAS OF THE CONSCIOUS RAT BRAIN.
215161 04-03

ANTINOCICEPTIVE ACTION OF OXOTREMORINE AND REGIONAL TURNOVER OF RAT BRAIN NORADRENALINE, DOPAMINE AND 5-HT.
215683 04-03

HOMOVANILLIC ACID CONCENTRATION IN RAT BRAIN: EFFECT OF A CHOLINE ACETYLTRANSFERASE INHIBITOR AND COMPARISON WITH CHOLINERGIC AND DOPAMINERGIC AGENTS.
215711 04-03

CORRELATION BETWEEN BRAIN MONOAMINE LEVELS AND POSTICTAL COMA FOLLOWING ELECTROSHOCK.
215723 04-03

A RELATION BETWEEN DRUG CONCENTRATIONS IN BRAIN AND STRIATAL HOMOVANILLIC ACID LEVELS IN CHLORPROMAZINE TREATED RATS.
215734 04-03

STUDIES ON THE DISTINCTION BETWEEN UPTAKE INHIBITION AND RELEASE OF H3-DOPAMINE IN RAT BRAIN TISSUE SLICES.
215756 04-03

THE EFFECT OF ETHYMIZOL ON THE CONTENT OF CYCLIC 3,5 ADENOSINE-MONOPHOSPHATE IN BRAIN TISSUE.
217065 04-03

SEROTONIN SENSITIVE ADENYLCYCLASE ACTIVITY IN IMMATURE RAT BRAIN.
217355 04-03

BRAIN ACETYLCHOLINE: INCREASE AFTER SYSTEMIC CHOLINE ADMINISTRATION.
217399 04-03

INFLUENCE OF CHANGES IN BRAIN MONOAMINE METABOLISM ON BEHAVIOUR OF HERPES-SIMPLEX INFECTED MICE.
217440 04-04

NEUROLEPTIC ACTION OF CLOZAPINE INJECTED INTO VARIOUS BRAIN AREAS IN RATS.
217451 04-04

BLOCKADE OF RESERPINE OF METHYLPHENIDATE-INDUCED RELEASE OF BRAIN DOPAMINE.
217456 04-03

CORRELATION OF BRAIN LEVELS OF BARBITURATE ENANTIOMERS WITH REPORTED DIFFERENCES IN DURATION OF SLEEP.
217457 04-03

NOREPINEPHRINE AND SEROTONIN: SPECIFICITY OF RELEASE WITH REWARDING ELECTRICAL STIMULATION OF THE BRAIN.
217522 04-03

THE EFFECTS OF CHRONIC CANNABIS TREATMENT UPON BRAIN 5-HYDROXYTRYPTAMINE, PLASMA CORTICOSTERONE AND AGGRESSIVE BEHAVIOR IN FEMALE RATS WITH DIFFERENT HORMONAL STATUS.
217532 04-04

EFFECTS OF CLOZAPINE, THIORIDAZINE, PERLAPINE AND HALOPERIDOL ON THE METABOLISM OF THE BIOGENIC AMINES IN THE BRAIN OF THE RAT.
217543 04-03

THE EFFECT OF HEMICHOLINIUM ON BEHAVIOR AND ON BRAIN ACETYLCHOLINE AND CHOLINE IN THE RAT.
217551 04-04

A DEVELOPMENTAL STUDY OF THE EFFECTS OF 5,7 DIHYDROXYTRYPTAMINE ON REGIONAL TRYPTOPHAN-HYDROXYLASE IN RAT BRAIN.
217555 04-03

ELECTROPHYSIOLOGICAL EVIDENCE FOR AN INHIBITORY ACTION OF DIAZEPAM UPON CAT BRAIN CORTEX.
217649 04-03

THE EFFECTS OF 5-HYDROXY-5-4-CHLOROPHENYL 2,3 DIHYDRO-5H-IMIDAZOISOINDOLE (MAZINDOL, SAH-42-548) ON THE METABOLISM OF BRAIN NOREPINEPHRINE.
217653 04-03

EFFECTS OF HALOTHANE AND NITROUS OXIDE ANESTHESIA ON 5-HT TURN-OVER IN THE RAT BRAIN.
217655 04-03

EFFECT OF BENZODIAZEPINE COMPOUNDS ON BRAIN AMINE METABOLISM.
217664 04-03

EFFECT OF BUTRIPTYLINE ON THE BRAIN UPTAKE MECHANISMS FOR NORADRENALINE AND 5-HYDROXYTRYPTAMINE.
217688 04-03

THE INFLUENCE OF APOMORPHINE AND TRICYCLIC ANTIDEPRESSANT DRUGS ON THE LEVEL OF SEROTONIN AND ITS METABOLITE IN RAT BRAIN.
217815 04-03

EFFECT OF ANESTHETIC DOSAGES OF PENTOBARBITAL ON THE CONTENT AND TURNOVER OF SEROTONIN IN BRAIN AREAS.
217816 04-03

FUNCTIONAL AND BIOCHEMICAL ASPECTS OF CATECHOLAMINE METABOLISM IN BRAIN UNDER HYPOXIA.
217852 04-03

AMINO ACID UPTAKE IN VIVO BY THE MOUSE BRAIN AND BY VARIOUS REGIONS OF THE RABBIT BRAIN AFTER DRUG-INDUCED CONVULSIONS.
217858 04-03

6-HYDROXYDOPA DURING DEVELOPMENT OF CENTRAL ADRENERGIC NEURONS PRODUCES DIFFERENT LONG-TERM CHANGES IN RAT BRAIN NORADRENALINE.
217867 04-03

LONG-LASTING REDUCTION OF BRAIN 5-HYDROXYTRYPTAMINE CONCENTRATION BY 3-CHLOROAMPHETAMINE AND 4-CHLOROAMPHETAMINE IN IPRINDOLE TREATED RATS.
217879 04-03

EFFECT OF CHRONIC PHENOBARBITAL ADMINISTRATION UPON BRAIN GROWTH OF THE INFANT RAT.
217885 04-03

UPTAKE AND DISAPPEARANCE OF 4-METHYL-ALPHA-ETHYLMETATYRAMINE IN RELATION TO ITS RELEASING ACTION ON 5-HYDROXYTRYPTAMINE IN THE BRAIN.
217897 04-03

THE EFFECT OF AMANTADINE ON THE TURNOVER OF CATECHOLAMINES IN THE RAT BRAIN.
217961 04-03

SOME INTERACTIONS BETWEEN FENFLURAMINE AND ANTIDEPRESSANT DRUGS: EFFECTS ON 5-HYDROXYINDOLE CONCENTRATIONS IN RAT BRAIN.
217962 04-03

CHANGES IN THE CONCENTRATIONS OF 5-HYDROXYTRYPTAMINE AND NORADRENALINE IN SIX AREAS OF RAT BRAIN DURING RECOVERY FROM CHRONIC METHYLAMPHETAMINE ADMINISTRATION.
217963 04-03

DEXTROMETHORPHAN INHIBITS 5-HYDROXYTRYPTAMINE UPTAKE BY HUMAN BLOOD PLATELETS AND DECREASES 5-HYDROXYINDOLEACETIC ACID CONTENT IN RAT BRAIN.
217964 04-03

THE INFLUENCE OF DESIPRAMINE AND AMITRIPTYLINE ON THE ACCUMULATION OF (3H)NORADRENALINE AND ITS TWO MAJOR METABOLITES FORMED FROM (3H)TYROSINE IN THE RAT BRAIN.
217966 04-03

ROLE OF BRAIN SEROTONIN IN THE INTEGRATION OF BEHAVIORAL RESPONSES AND PITUITARY ADRENOCORTICAL FUNCTIONS UNDER EMOTION.
218364 04-04

THE PARTICIPATION OF SEROTONIN REACTIVE BRAIN STRUCTURES IN SOME FORMS OF BEHAVIORAL PATTERNS IN HAMSTERS.
218472 04-04

EXAMINATION OF THE ROLE OF BRAIN AMINES AND CYCLIC-AMP IN BENZODIAZEPINE INDUCED SUPPRESSION OF AGGRESSION. (PH.D. DISSERTATION).
219278 04-04

INTERACTION OF CYCLOHEXIMIDE AND ADRENERGIC DRUGS WITH BRAIN PROTEIN AND CATECHOLAMINE BIOSYNTHESIS. (PH.D. DISSERTATION).
219288 04-03

A HISTOCHEMICAL ANALYSIS OF THE INFLUENCE OF SOME PSYCHOTROPIC SUBSTANCES ON THE DEHYDROGENASE ACTIVITY OF VARIOUS BRAIN STRUCTURES.
219498 04-03

THE EFFECT OF DRUGS ON THE RELEASE OF ENDOGENOUS CATECHOLAMINES INTO THE PERFUSATE OF DISCRETE BRAIN AREAS OF THE CAT IN VIVO.
219631 04-06

THE METABOLISM OF INDIVIDUAL PHOSPHOLIPID FRACTIONS IN THE RAT BRAIN DURING THIOPENTAL SLEEP AND AMPHETAMINE EXCITATION.
219747 04-03

THE EFFECT OF LITHIUM ON THE CONTENT OF CATECHOLAMINES IN THE BRAIN OF RABBITS AND RATS.
219749 04-03

DOPAMINE RECEPTORS IN THE BRAIN.
220311 04-17

LYSERGIC ACID DIETHYLAMIDE: EFFECT ON HISTONE ACETYLATION IN RABBIT BRAIN.
220314 04-03

THE DISTRIBUTION KINETICS AND TURNOVER OF CHOLINE AND ACETYLCHOLINE IN PLASMA AND BRAIN OF RATS. (PH.D. DISSERTATION).
220472 04-03

EFFECT OF DRUG-INDUCED INCREASE OF BRAIN GABA LEVELS ON PENICILLIN FOCUS.
220947 04-03

MONOAMINEOXIDASE INHIBITORS ANTAGONIZE THE ACCELERATION OF BRAIN DOPAMINE SYNTHESIS INDUCED BY NEUROLEPTIC DRUGS IN VIVO: IMPLICATIONS FOR THE TREATMENT OF TARDIVE DYSKINESIA.
220948 04-03

THE BLOOD-BRAIN BARRIER II: DISTRIBUTION KINETICS OF H3-P-HYDROXYAMPHETAMINE IN BRAIN STRUCTURES OF THE RAT AFTER INTRAVENOUS ADMINISTRATION.
220977 04-03

GENOTYPE OR PRENATAL DRUG EXPERIENCE AFFECT BRAIN MATURATION IN THE MOUSE.
221032 04-03

DOES CHRONIC MORPHINE TREATMENT INDUCE A SUPERSENSITIVITY OF DOPAMINE RECEPTORS IN RAT BRAIN
221038 04-03

EFFECTS OF SINGLE AND MULTIPLE DOSE LSD ON ENDOGENOUS LEVELS OF BRAIN TYROSINE-HYDROXYLASE AND CATECHOLAMINES.
221044 04-12

INHIBITION OF BOTH NORADRENERGIC AND SEROTONERGIC NEURONS IN BRAIN BY THE ALPHA-ADRENERGIC AGONIST CLONIDINE.
221131 04-03

TRICYCLIC ANTIDEPRESSANTS: EFFECTS ON THE FIRING RATE OF BRAIN NORADRENERGIC NEURONS.
222805 04-03

THE INFLUENCE OF SEVERAL PSYCHOTROPIC DRUGS ON THE STRUCTURE OF THE BRAIN.
222889 04-03

COMPARATIVE EFFECTS OF SYDNOCARB AND AMPHETAMINE ON THE BIOELECTRICAL ACTIVITY OF THE BRAIN.
223012 04-03

TRYPTOPHAN METABOLISM IN DEVELOPING CHICK BRAIN.
223053 04-03

THE EFFECT OF THE PSYCHOTROPIC AGENTS (CHLORPROMAZINE, MAJEPTIL, TRICEDIL) ON PROTEIN SYNTHESIS IN VARIOUS PORTIONS OF THE RAT BRAIN.
223063 04-03

INTERACTIONS BETWEEN LYSERGIC ACID DIETHYLAMIDE AND DOPAMINE SENSITIVE ADENYLCYCLASE SYSTEMS IN RAT BRAIN.
223175 04-03

THE EFFECT OF NEUROLEPTICS AND ANTIDEPRESSANTS ON THE UPTAKE OF 3H-GAMMA-AMINOBUTYRIC ACID BY ISOLATED NERVE ENDINGS OF THE RAT BRAIN.
224114 04-03

FORMATION OF NOREPINEPHRINE IN THE BRAIN OF RATS AFTER ADMINISTRATION OF (+) ERYTHRO 3,4 DIHYDROXYPHENYLSERINE.
225558 04-03

DIFFERENTIAL ANTAGONISM BY THE ANTICHOLINERGIC DEXETIMIDE OF INHIBITORY EFFECTS OF HALOPERIDOL AND FENTANYL ON BRAIN SELF-STIMULATION.
225562 04-03

THE EFFECT OF AMITRIPTYLINE, DESIPRAMINE AND IMIPRAMINE ON THE IN VIVO BRAIN SYNTHESIS OF 3H-NORADRENALINE FROM 3H-L-DOPA IN THE RAT.
225565 04-03

BRAIN-CORTEX

MESCALINE-INDUCED CHANGES OF BRAIN-CORTEX RIBOSOMES: EFFECT OF MESCALINE ON TRNA AND AMINOACYL-TRNA SYNTHETASE.
195242 01-03

THE ROLE OF THE RETICULAR FORMATION IN ACTION EXERTED BY CHLORPROMAZINE AND BENACTYZINE ON PRIMARY RESPONSES OF THE BRAIN-CORTEX.
206440 03-04

SOME PECULIARITIES OF THE NEURON ULTRASTRUCTURE IN THE BRAIN-CORTEX MOTOR AREA UNDER THE INFLUENCE OF LYSERGIC ACID DIETHYLAMIDE (LSD) AND HALOPERIDOL.
222890 04-03

BRAINS

EFFECTS OF D-AMPHETAMINE SULFATE GIVEN TO PREGNANT MICE ON ACTIVITY AND ON CATECHOLAMINES IN THE BRAINS OF OFFSPRING.
196025 01-03

THE EFFECT OF DIAZEPAM AND NITRAZEPAM ON INTRACELLULAR AND EXTRACELLULAR DISTRIBUTION OF SODIUM AND POTASSIUM IONS IN INDIVIDUAL STRUCTURES OF RATS BRAINS.
207199 03-03

THE INFLUENCE OF ETHYMISOL ON THE ACTIVITY OF ADENYLCYCLASE AND 3,5 AMP-PHOSPHODIESTERASE OF RATS BRAINS.
208973 03-03

MASS FRAGMENTOGRAPHY OF PICOMOLE QUANTITIES OF BIOGENIC AMINE METABOLITES IN HUMAN CEREBROSPINAL FLUID AS WELL AS WHOLE RAT BRAINS. (UNPUBLISHED PAPER).
217219 04-06

INCREASED CONCENTRATION OF HOMOVANILLIC ACID IN THE BRAINS OF INFANT RABBITS AFTER ADMINISTRATION OF HALOPERIDOL TO THEIR NURSING MOTHERS.
217692 04-03

EFFECT OF ACTH4-10 ON THE RATE OF SYNTHESIS OF (3H)CATECHOLAMINES IN THE BRAINS OF INTACT, HYPOPHYSECTOMIZED AND ADRENALECTOMIZED RATS.
223050 04-03

BRAINSTEM

EFFECTS OF 5-HYDROXYTRYPTOPHAN ON SLEEP OF A PATIENT WITH A BRAINSTEM LESION.
199757 02-13

INHIBITION OF BEHAVIOURAL AND EEG ACTIVATION INDUCED BY MORPHINE ACTING ON LOWER BRAINSTEM STRUCTURES.
200078 02-03

EFFECTS OF PHENOBARBITAL ON ELECTROCORTICOGRAM AND ACTIVITY, ON REGIONAL CNS ENERGY METABOLISM, AND ON PRESYNAPTIC EVENTS IN CEREBRAL CORTEX AND BRAINSTEM. (PH.D. DISSERTATION).
203033 02-03

REACTIVE BRAINSTEM LOCI FOR ELICITING ELECTRODERMAL RESPONSES.
206250 03-03

SEROTONIN CONTENT OF THE BRAINSTEM NUCLEI IN THE RAT.
210661 03-03

ELECTROCORTICAL CHANGES INDUCED BY PERFUSION OF CATECHOLAMINES INTO THE BRAINSTEM RETICULAR FORMATION.
210827 03-03

THE EEG EFFECTS OF DOPA IN THE RABBIT DEPENDING UPON THE LEVEL OF BRAINSTEM SECTION.
210880 03-03

UPTAKE OF 3H-NORADRENALINE AND 3H-5-HYDROXYTRYPTAMINE IN CULTURED RAT BRAINSTEM.
215159 04-03

BREAKDOWN

BREAKDOWN OF STIMULUS CONTROL BY D-AMPHETAMINE.
202968 02-04

BREAST

RESERPINE AND BREAST CANCER.
194062 01-13

RETROSPECTIVE STUDY OF THE ASSOCIATION BETWEEN USE OF RAUWOLFIA DERIVATIVES AND BREAST CANCER IN ENGLISH WOMEN.
194063 01-13

RESERPINE USE IN RELATION TO BREAST CANCER.
194064 01-13

BRED

EXPLORATORY BEHAVIOUR IN TWO SELECTIVELY BRED LINES OF MICE AFTER INTRAHIPPOCAMPAL INJECTION OF METHYLSCOPOLAMINE.
217464 04-04

BREEDING

EFFECT OF FIGHTING AND DIPHENYLHYDANTOIN ON THE UPTAKE OF H3-L-NOREPINEPHRINE IN VITRO IN SYNAPTOSOMES ISOLATED FROM RETIRED MALE BREEDING MICE.
222821 04-03

BREVITAL

SIDE-EFFECTS OF BREVITAL AIDED DESENSITIZATION: SOME CLINICAL IMPRESSIONS.
193986 01-15

OVERCOMING OBSTACLES TO DESENSITIZATION USING IN VIVO STIMULI AND BREVITAL.
224984 04-10

BRIGHTNESS

DEFICIENT BRIGHTNESS DISCRIMINATION ACQUISITION PRODUCED BY DAILY INTRACRANIAL INJECTIONS OF PENICILLIN IN RATS.
202758 02-04

BRISBANE

SUICIDE IN BRISBANE, 1956 TO 1973: THE DRUG DEATH EPIDEMIC.
224491 04-17

BROM-ERGOCRYPTINE

BROM-ERGOCRYPTINE IN THE TREATMENT OF PHENOTHIAZINE INDUCED GALACTORRHOEA.
218557 04-15

BROMAZEPAM

BROMAZEPAM IN TREATING DYSTHYMIC ELDERLY PATIENTS.
201690 02-11

BROMAZEPAM, MEDAZEPAM, CHLORDIAZEPOXIDE IN TREATMENT OF NEUROTIC ANXIETY.
202219 02-10

ON THE PHARMACOKINETICS OF BROMAZEPAM IN MAN.
206788 03-13

A DOUBLE-BLIND CONTROLLED COMPARISON OF BROMAZEPAM AND DIAZEPAM.
209411 03-10

CLINICAL EXPERIMENTS WITH BROMAZEPAM ON PSYCHONEUROTIC AND PSYCHOSOMATIC PATIENTS WITH PSYCHOTHERAPY.
209795 03-10

DOUBLE-BLIND EXAMINATION OF BROMAZEPAM (RO-5-3350) FOR THE TREATMENT OF PSYCHONEUROSIS.
213293 03-10

A COMPARISON BETWEEN BROMAZEPAM (RO-5-3350, LEXOTAN) AND DIAZEPAM (VALIUM) IN ANXIETY NEUROSIS: A CONTROLLED, DOUBLE-BLIND CLINICAL TRIAL.
217455 04-10

BROMAZEPAM VERSUS DIAZEPAM IN PSYCHONEUROTIC INPATIENTS.
221304 04-10

BROMOCRIPTIN
CB-154 (2-BROMO-ALPHA-ERGOKRYPTINE, BROMOCRIPTIN), A POTENTIAL ANTIPARKINSON AGENT.
197949 01-04

BROMOPERIDOL
BROMOPERIDOL, A NEW POTENT NEUROLEPTIC OF THE BUTYROPHENONE SERIES; COMPARATIVE PHARMACOLOGY OF BROMOPERIDOL AND HALOPERIDOL.
206804 03-02

BRONCHITIS
EFFECTS OF CHLORDIAZEPOXIDE IN RESPIRATORY FAILURE DUE TO CHRONIC BRONCHITIS.
194854 01-13

BS-100-141
INHIBITION OF EFFECTS OF ACCELERATOR NERVE STIMULATION IN CATS AND RABBITS BY BS-100-141 AND GUANABENZ.
197971 01-03

BULBAR
INFLUENCE OF STRIATAL DOPAMINE RECEPTOR BLOCKADE ON A BULBAR MOTOR REACTION.
202778 02-03

TREATMENT OF PHENOTHIAZINE INDUCED BULBAR PERSISTENT DYSKINESIA WITH DEANOL ACETAMIDOBENZOATE.
210209 03-13

BULBOSPINAL
THE BLOCKADE OF BULBOSPINAL INHIBITION BY IMIPRAMINE, DESIPRAMINE AND PARGYLINE.
195095 01-03

BULBS
EFFECTS OF PSYCHOTROPIC DRUGS ON HYPEREMOTIONALITY OF RATS WITH BILATERAL ABLATIONS OF THE OLFACTORY BULBS AND OLFACTORY TUBERCLES.
195231 01-04

BULLFROG
NERVE IMPULSE ENHANCED RELEASE OF AMINO ACIDS FROM NONSYNAPTIC REGIONS OF PERIPHERAL AND CENTRAL NERVE TRUNKS OF BULLFROG.
213277 03-03

ACTION OF DIAZEPAM, DIBUTYRYL-CGMP, AND GABA ON PRESYNAPTIC NERVE TERMINALS IN BULLFROG SYMPATHETIC GANGLIA.
217873 04-03

BUNDLE
INTRACRANIAL SELF-STIMULATION IN RATS AS A FUNCTION OF VARIOUS STIMULUS PARAMETERS: V. INFLUENCE OF COCAINE ON MEDIAL FOREBRAIN BUNDLE STIMULATION WITH MONOPOLAR ELECTRODES.
198223 02-03

EFFECT OF INTRAVENTRICULAR NOREPINEPHRINE ON NEURON ACTIVITY IN THE MEDIAL FOREBRAIN BUNDLE DURING SELF-STIMULATION BEHAVIOR.
210704 03-04

EFFECTS OF DOPAMINERGIC DRUGS AND ACUTE MEDIAL FOREBRAIN BUNDLE LESIONS ON STRIATAL ACETYLCHOLINE LEVELS.
210831 03-03

EFFECTS OF AMPHETAMINE ISOMERS AND NEUROLEPTICS ON SELF-STIMULATION FROM THE NUCLEUS-ACCUMBENS AND DORSAL NORADRENERGIC BUNDLE.
213394 04-03

BUPRENORPHINE
EFFECT OF MIDBRAIN RAPHE LESION AND OF 6-HYDROXYDOPAMINE ON THE ANTINOCICEPTIVE ACTION OF BUPRENORPHINE IN RATS.
210923 03-03

BURONIL
CLINICAL EVALUATION OF METYLPERONE (BURONIL) WITH EPILEPTICS.
221518 04-11

A CONTROLLED CLINICAL EXPERIMENT WITH BURONIL AND HALOPERIDOL IN DISORIENTATION AMONG ELDERLY PATIENTS.
221639 04-11

BUTACLAMOL
BUTACLAMOL HYDROCHLORIDE (AY-23028): AN EARLY EVALUATION IN SEVERELY ILL SCHIZOPHRENICS.
206933 03-08

NEUROLEPTIC AGENTS OF THE BENZOCYCLOHEPTAPYRIDOISOQUINOLINE SERIES. 1.SYNTHESES AND STEREOCHEMICAL AND STRUCTURAL REQUIREMENTS FOR ACTIVITY OF BUTACLAMOL AND RELATED COMPOUNDS.
208592 03-01

BUTAPERAZINE
EFFECTS OF CONJUGATED ESTROGENS ON PLASMA BUTAPERAZINE LEVELS.
201327 02-13

TRICYCLIC EFFECT ON BUTAPERAZINE PLASMA LEVEL.
224909 04-13

BUTRIPTYLINE
THE DISPOSITION OF BUTRIPTYLINE IN RATS, DOGS AND MAN.
206806 03-13

COMPARATIVE PHARMACOLOGICAL STUDIES ON BUTRIPTYLINE AND SOME RELATED STANDARD TRICYCLIC ANTIDEPRESSANTS.
211101 03-03

EFFECT OF BUTRIPTYLINE ON THE BRAIN UPTAKE MECHANISMS FOR NORADRENALINE AND 5-HYDROXYTRYPTAMINE.
217688 04-03

BUTYROPHENONE
SYNTHESIS AND PRELIMINARY PHARMACOLOGY OF A NOVEL BUTYROPHENONE DERIVATIVE, ID-4708.
202862 02-02

AZAPERONE, A SEDATIVE NEUROLEPTIC OF THE BUTYROPHENONE SERIES WITH PRONOUNCED ANTIAGGRESSIVE AND ANTISHOCK ACTIVITY IN ANIMALS.
206786 03-04

BROMOPERIDOL, A NEW POTENT NEUROLEPTIC OF THE BUTYROPHENONE SERIES; COMPARATIVE PHARMACOLOGY OF BROMOPERIDOL AND HALOPERIDOL.
206804 03-02

TREATMENT OF ACUTE SCHIZOPHRENIA WITH A NEW BUTYROPHENONE - - LENPERONE.
209791 03-07

BUTYROPHENONE-TYPE
THE INFLUENCE OF ANIONS ON THE PHYSICAL PROPERTIES OF BUTYROPHENONE-TYPE MOLECULES. (PH.D. DISSERTATION).
200310 02-01

BUTYROPHENONES
SYNERGISM BETWEEN GAMMA-AMINOBUTYRIC ACID AND BUTYROPHENONES ADMINISTERED MICROELECTROPHORETICALLY IN THE PURKINJE CELLS OF THE CAT CEREBELLUM.
220904 04-03

C-AMP
EVIDENCE AGAINST A CAUSAL RELATIONSHIP BETWEEN INCREASE IN C-AMP AND INDUCTION OF TYROSINE-HYDROXYLASE IN THE RAT ADRENAL MEDULLA.
202795 02-03

C-FIBER
STUDIES OF TRYPTAMINE AND LYSERGIC ACID DIETHYLAMIDE (LSD) ON CUTANEOUS C-FIBER AND POLYSYNAPTIC REFLEXES IN THE CAT.
197814 01-03

CACTI
SEARCH FOR NEW HALLUCINOGENIC CACTI.
202382 02-01

CADMIUM-INDUCED
CADMIUM-INDUCED POTENTIATION OF HEXOBARBITAL SLEEP TIME IN RATS.
197684 01-04

CAFFEINE
NICOTINE AND CAFFEINE: DISRUPTION OF THE LONG-TERM STORE MEMORY AND PROACTIVE FACILITATION OF LEARNING IN MICE.
198222 02-04

COMPARATIVE EFFECT OF PHENAMINE (AMPHETAMINE) AND CAFFEINE ON THE BACKGROUND ACTIVITY OF CORTICAL SENSORIMOTOR NEURONS AND THEIR REACTIONS DURING STIMULATION OF THE CAUDATE NUCLEUS.
198835 02-03

EFFECTS OF PROPRANOLOL, D-AMPHETAMINE AND CAFFEINE ON ETHANOL AS A DISCRIMINATIVE CUE.
199963 02-04

DRUGS AND PLACEBOS: EFFECTS OF CAFFEINE ON COGNITIVE PERFORMANCE.
205223 02-14

THE EFFECT OF COCA-COLA, CAFFEINE, ANTIDEPRESSANTS AND CHLORPROMAZINE ON OBJECTIVE AND SUBJECTIVE SLEEP PARAMETERS.
210808 03-14

BEHAVIORAL EFFECTS OF D-AMPHETAMINE AND CAFFEINE IN THE SQUIRREL MONKEY.
210860 03-04

PARADOXICAL EFFECTS OF CAFFEINE.
211258 03-13

CAFFEINE IN THE TREATMENT OF CHILDREN WITH MINIMAL BRAIN DYSFUNCTION OR HYPERKINETIC SYNDROME.
211434 03-11

DIFFERENTIAL EFFECTS OF CAFFEINE, D-AMPHETAMINE AND METHYLPHENIDATE ON INDIVIDUAL RAPHE CELL FLUORESCENCE: A MICROSPECTROFLUORIMETRIC DEMONSTRATION.
213400 04-03

THE EFFECT OF CAFFEINE ON BARBITURATE SLEEPING TIME AND BRAIN LEVEL.
214109 04-03

EFFECT OF MORPHINE, HYDROMORPHONE, METHADONE, MESCALINE, TRYPAN-BLUE, VITAMIN-A, SODIUM SALICYLATE AND CAFFEINE ON THE SERUM INTERFERON LEVEL IN RESPONSE TO VIRAL INFECTION.
217654 04-03

THE EFFECTS OF REINFORCEMENT CONTINGENCIES AND CAFFEINE ON HYPERACTIVE CHILDREN. (PH.D. DISSERTATION).
220523 04-14

SPONTANEOUS ALTERNATION IN FERRETS FOLLOWING TREATMENT WITH SCOPOLAMINE, CHLORDIAZEPOXIDE, AND CAFFEINE.
223039 04-04

THE INFLUENCE OF PHENAMINE AND CAFFEINE ON THE CAPACITY FOR EXTRAPOLATION IN RATS.
224466 04-04

CALCIUM

LITHIUM, CALCIUM, AND MENTAL ILLNESS.
209350 03-13

BINDING OF LITHIUM AND CALCIUM BY CEREBRAL MEMBRANE FRACTIONS.
210806 03-03

DIFFERENTIAL EFFECTS OF CHLORPROMAZINE AND CHLORPROMAZINE FREE-RADICAL ON CALCIUM TRANSPORT IN SARCOPLASMIC RETICULUM VESICLES.
210812 03-03

LITHIUM, CALCIUM, AND PHOSPHATE.
221417 04-15

CALF

IDENTIFICATION AND STRUCTURAL CHARACTERIZATION OF AN INHIBITOR OF CATECHOLAMINE INDUCED FREE FATTY ACID MOBILIZATION FROM THE CALF MIDBRAIN.
200006 02-01

CALIFORNIA

ANXIETY NEUROSIS, DEPRESSIVE DISORDER AND MEPROBAMATE ADDICTION -- PSYCHIATRIC GRAND-ROUNDS, UNIV. OF CALIFORNIA, SAN-DIEGO.
222772 04-10

CALLITHRIX-JACCHUS

METABOLISM AND AUTORADIOGRAPHIC DISTRIBUTION OF DELTA8- AND DELTA9-TETRAHYDROCANNABINOL IN SOME ORGANS OF THE MONKEY CALLITHRIX-JACCHUS.
217837 04-03

CALORIE

THE EFFECT OF CYPROHEPTADINE ON HUNGER, CALORIE INTAKE AND BODY WEIGHT IN MAN.
214011 04-13

CAMAZEPAM

EFFECT OF CAMAZEPAM (SB-5833), A NEW ANTIANXIOUS DRUG, ON CARDIAC CONTRACTILITY AND CORONARY HEMODYNAMICS.
206785 03-03

CAMAZEPAM VERSUS DIAZEPAM: A DOUBLE-BLIND TRIAL ON PSYCHONEUROTIC PATIENTS.
209487 03-10

A PRELIMINARY DOUBLE-BLIND STUDY WITH SB-5833 (CAMAZEPAM), A NEW BENZODIAZEPINE DERIVATIVE.
221269 04-10

CAMP

EFFECT OF WITHDRAWAL FROM CHRONIC ETHANOL INGESTION ON THE CAMP RESPONSE OF CEREBRAL CORTICAL SLICES USING THE AGONISTS HISTAMINE, SEROTONIN, AND OTHER NEUROTRANSMITTERS.
215980 04-03

CAMP-MEDIATED

LITHIUM INHIBITION OF CAMP-MEDIATED HORMONES: A CAUTION.
209352 03-03

CANADIAN

NICOTINIC ACID IN THE TREATMENT OF SCHIZOPHRENIAS: CANADIAN MENTAL HEALTH ASSOCIATION COLLABORATIVE STUDY PROGRESS REPORT II.
219537 04-08

CANCER

RESERPINE AND BREAST CANCER.
194062 01-13

RETROSPECTIVE STUDY OF THE ASSOCIATION BETWEEN USE OF RAUWOLFIA DERIVATIVES AND BREAST CANCER IN ENGLISH WOMEN.
194063 01-13

RESERPINE USE IN RELATION TO BREAST CANCER.
194064 01-13

RAUWOLFIA DERIVATIVES AND CANCER.
194065 01-13

CANINE

EFFECTS OF 5-HYDROXYINDOLEACETIC ACID ON ISOLATED CANINE CEREBRAL ARTERIES.
202799 02-03

CANNABIDIOL

A STUDY OF THE DEVELOPMENT OF TOLERANCE TO AN ANTICONVULSANT EFFECT OF DELTA9-TETRAHYDROCANNABINOL AND CANNABIDIOL.
195117 01-03

MODIFICATION OF DELTA9-THC ACTIONS BY CANNABINOL AND CANNABIDIOL IN THE RAT.
197858 01-03

CANNABIDIOL INTERFERES WITH THE EFFECTS OF DELTA9-TETRAHYDROCANNABINOL IN MAN.
197867 01-14

EFFECTS OF CANNABIDIOL AND DELTA9-TETRAHYDROCANNABINOL ON OPERANT BEHAVIOR.
200036 02-04

ABSENCE OF INTERACTION BETWEEN DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) AND CANNABIDIOL (CBD) IN AGGRESSION, MUSCLE CONTROL AND BODY TEMPERATURE EXPERIMENTS IN MICE.
217474 04-04

THE COMBINED EFFECTS OF CANNABIDIOL AND DELTA9-TETRAHYDROCANNABINOL. (PH.D. DISSERTATION).
220474 04-04

CANNABINOID

THE EFFECT OF CHRONIC CANNABIS AND CANNABINOID APPLICATION ON THE HEPATIC DRUG METABOLIZING SYSTEM OF THE RAT.
197282 01-03

CANNABINOID INDUCED CHANGES IN MOUSE STRIATAL HOMOVANILLIC ACID AND DIHYDROXYPHENYLACETIC ACID: THE EFFECTS OF AMPHETAMINE AND L-DOPA.
204866 02-03

CANNABINOIDS

CHRONIC ORAL TOXICITY OF CANNABINOIDS IN MONKEYS.
193417 01-05

CENTRAL IMPLANTATION OF CANNABINOIDS: INDUCTION OF EPILEPTIFORM DISCHARGES.
193449 01-03

ANTICONVULSANT PROPERTIES OF DELTA9-TETRAHYDROCANNABINOL AND OTHER CANNABINOIDS.
198021 01-03

FLUORESCENCE OF CANNABINOIDS.
210773 03-01

CONSTITUENTS OF CANNABIS-SATIVA L. IX: STABILITY OF SYNTHETIC AND NATURALLY OCCURRING CANNABINOIDS IN CHLOROFORM.
211010 03-06

COMPARATIVE ANALGESIC ACTIVITY OF VARIOUS NATURALLY OCCURRING CANNABINOIDS IN MICE AND RATS.
214017 04-04

CANNABINOL

MODIFICATION OF DELTA9-THC ACTIONS BY CANNABINOL AND CANNABIDIOL IN THE RAT.
197858 01-03

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL AND CANNABINOL ON OPERANT PERFORMANCE IN RATS.
210785 03-04

CANNABINOL-7-OIC

CANNABINOL-7-OIC ACID: A METABOLITE OF DELTA1-TETRAHYDROCANNABINOL IN THE RHESUS MONKEY.
195114 01-03

CANNABIS

THE EFFECT OF CHRONIC CANNABIS AND CANNABINOID APPLICATION ON THE HEPATIC DRUG METABOLIZING SYSTEM OF THE RAT.
197282 01-03

STRUCTURE-ACTIVITY RELATIONSHIPS IN MAN OF CANNABIS CONSTITUENTS, AND HOMOLOGS AND METABOLITES OF DELTA9-TETRAHYDROCANNABINOL.
202192 02-02

SUBJECTIVE CHANGES IN VOLUNTEERS WITHOUT PRIOR EXPERIENCE OF CANNABIS INDUCED BY (-)DELTA9-TRANS-TETRAHYDROCANNABINOL.
202784 02-14

COMPARISON OF THE EFFECTS OF ATROPINE AND CANNABIS UPON THE FIXED CONDITIONED ALIMENTARY MOTOR REFLEXES IN CATS AFFECTED BY NICOTINE.
205623 03-14

CANNABIS: A PSYCHOPHARMACOLOGICAL REVIEW.
205931 03-12

THE EFFECT OF WITHDRAWAL FROM CANNABIS ON PENTYLENETETRAZOL CONVULSIVE THRESHOLD IN MICE.
206355 03-04

CANNABIS AND AMPHETAMINE-INDUCED STEREOTYPY IN RATS.
210752 03-04

CHROMOSOMAL DAMAGE IN CHRONICAL USERS OF CANNABIS: IN VIVO INVESTIGATION WITH TWO-DAY LEUKOCYTE CULTURES.
210810 03-15

SOME EFFECTS OF CANNABIS.
210998 03-17

METABOLISM OF DELTA1-TETRAHYDROCANNABINOL BY RATS TOLERANT TO CANNABIS.
211100 03-03

THE EFFECTS OF CANNABIS INTOXICATION ON PRIMARY SUGGESTIBILITY. (PH.D. DISSERTATION).
211831 03-14

THE EFFECTS OF CHRONIC CANNABIS TREATMENT UPON BRAIN 5-HYDROXYTRYPTAMINE, PLASMA CORTICOSTERONE AND AGGRESSIVE BEHAVIOR IN FEMALE RATS WITH DIFFERENT HORMONAL STATUS.
217532 04-04

PROSTAGLANDINS AND CANNABIS -- III. INHIBITION OF BIOSYNTHESIS BY ESSENTIAL OIL COMPONENTS OF MARIHUANA.
217795 04-03

CANNABIS AND AGGRESSION IN ANIMALS.
217828 04-04

CANNABIS-SATIVA

CONSTITUENTS OF CANNABIS-SATIVA L. IX: STABILITY OF SYNTHETIC AND NATURALLY OCCURRING CANNABINOIDS IN CHLOROFORM.
211010 03-06

CAPABILITY
WORK CAPABILITY AND TREATMENT OF REACTIVE DEPRESSIONS.
198354 02-10

CAPACITY
THE INFLUENCE OF PROLONGED APPLICATION OF TRANQUILIZERS AND ANTIDEPRESSANTS ON THE SUMMATIONAL CAPACITY OF THE CENTRAL NERVOUS SYSTEM.
201913 02-03

THE INFLUENCE OF HALOPERIDOL AND PENFLURIDOL ON THE LEARNING CAPACITY OF THE SCHIZOPHRENIC.
207000 03-14

THE EFFECTS OF A NEW SEDATIVE (LEXOTAN) ON REACTION TIMES AND ON ATTENTIVE CAPACITY OF A GROUP OF ATHLETES.
209857 03-14

MNEMONIC CAPACITY OF MENTALLY RETARDED BOYS TREATED WITH HIGH DOSES OF NUCLEOTIDES AND GABA.
210291 03-14

THE EFFECT OF PSYCHOTROPIC AGENTS ON THE MENTAL AND PHYSICAL WORKING CAPACITY IN RATS.
219748 04-04

THE INFLUENCE OF PHENAMINE AND CAFFEINE ON THE CAPACITY FOR EXTRAPOLATION IN RATS.
224466 04-04

CAPRA-HIRCUS
PHYSIOLOGIC, BIOCHEMICAL, AND CLINICAL EFFECTS OF KETAMINE HYDROCHLORIDE IN GOATS (CAPRA-HIRCUS) WITH AND WITHOUT PREMEDICATION. (PH.D. DISSERTATION).
194700 01-03

CAPSULES
A COMPARATIVE STUDY OF CLOMIPRAMINE (ANAFRANIL) CAPSULES AND TABLETS.
215148 04-09

CARBACHOL
REDUCED BEHAVIOURAL EFFECTS OF INTRAHIPPOCAMPALLY ADMINISTERED CARBACHOL IN RATS WITH LOW CHOLINESTERASE ACTIVITY.
199956 02-04

CARBAMAZEPINE
PHARMACOKINETIC EVALUATION OF ANTICONVULSANTS PRIOR TO EFFICACY TESTING EXEMPLIFIED BY CARBAMAZEPINE IN EPILEPTIC MONKEY MODEL.
195492 01-04

THE EFFECTS OF CARBAMAZEPINE ON PATIENTS WITH PSYCHOMOTOR EPILEPSY: RESULTS OF A DOUBLE-BLIND STUDY.
205031 02-11

PHARMACOKINETICS OF CARBAMAZEPINE IN MONKEYS FOLLOWING INTRAVENOUS AND ORAL ADMINISTRATION.
211009 03-03

ANTIMANIC AND PROPHYLACTIC EFFECTS OF CARBAMAZEPINE (TEGRETOL) ON MANIC-DEPRESSIVE PSYCHOSIS.
225086 04-09

CARBIDINE
THE INFLUENCE OF TRIFLUOPERAZINE, CARBIDINE AND IMIZINE ON EVOKED POTENTIALS IN DIFFERENT STRUCTURES OF THE LIMBIC RETICULAR COMPLEX.
200564 02-02

THE EFFECT OF CARBIDINE ON ADRENERGIC TRANSMISSION.
224115 04-03

CARBOHYDRATE
LITHIUM AND INSULIN: EFFECTS ON CARBOHYDRATE AND ELECTROLYTE METABOLISM.
205929 03-09

EFFECT OF L-DOPA ON PITUITARY HORMONES AND ON CARBOHYDRATE AND FAT METABOLISM IN NORMALS AND IN PARKINSONS DISEASE.
207153 03-13

CARBOHYDRATES
THE EFFECT OF 6-HYDROXYDOPAMINE AND RESERPINE ON THE MOBILIZATION OF CARBOHYDRATES AND FATS IN STIMULATED RATS.
219504 04-03

CARBON
PHARMACOLOGICAL INFLUENCES ON CARBON DIOXIDE INDUCED AMNESIA.
197497 01-03

CARBONATE
FACTORS ASSOCIATED WITH TREATMENT SUCCESS IN LITHIUM CARBONATE PROPHYLAXIS: REPORT OF THE NIMH-VA COLLABORATIVE STUDY GROUP.
193068 01-09

EFFECTS OF LITHIUM CARBONATE ON SLEEP.
195918 01-09

PLASMA LITHIUM LEVELS AND SIDE-EFFECTS DURING ADMINISTRATION OF A SLOW-RELEASE LITHIUM SULPHATE PREPARATION (LITHIUM LIPETT-C) AND LITHIUM CARBONATE LEVELS.
197029 01-15

THE EFFECT OF LITHIUM CARBONATE IN COMBINATION WITH TRICYCLIC ANTIDEPRESSANTS IN ENDOGENOUS DEPRESSION: A DOUBLE-BLIND, MULTICENTER TRIAL.
197035 01-09

DEPRESSION, ELATION, AND LITHIUM CARBONATE RESPONSES IN MANIC PATIENT SUBGROUPS.
199631 02-09

THE EFFECTS OF LITHIUM CARBONATE ON SERUM GASTRIN IN PSYCHIATRIC PATIENTS.
200637 02-04

LITHIUM CARBONATE, HALOPERIDOL, AND IRREVERSIBLE BRAIN DAMAGE.
201287 02-15

LABORATORY AND CLINICAL STUDIES OF LITHIUM CARBONATE.
205175 02-03

DYSARTHRIA RESULTING FROM LITHIUM CARBONATE: A CASE REPORT.
205288 02-15

THE EFFECTS OF LITHIUM CARBONATE ON SLEEP AND WAKEFULNESS IN THE CAT.
205546 02-03

LONGITUDINAL STUDY OF THE EFFECTS OF LITHIUM CARBONATE ON THE SLEEP OF HOSPITALIZED DEPRESSED PATIENTS.
206333 03-09

PSYCHOACTIVE DRUGS IN MANIA: A CONTROLLED COMPARISON OF LITHIUM CARBONATE, CHLORPROMAZINE AND HALOPERIDOL.
207446 03-09

RELATIONSHIP BETWEEN SERUM LITHIUM LEVEL AND CLINICAL RESPONSE TO DEPRESSION TREATED WITH LITHIUM CARBONATE.
207719 03-09

CLINICAL EFFECTS OF LITHIUM CARBONATE ON DEPRESSIVE STATES.
209413 03-09

THE APPEARANCE OF EXOPHTHALMIA IN THE COURSE OF LITHIUM CARBONATE TREATMENT: BIOLOGICAL HYPERTHYROIDISM.
209998 03-15

LITHIUM CARBONATE AND AGGRESSION: A CASE REPORT.
210210 03-14

A DOUBLE-BLIND COMPARISON OF LITHIUM CARBONATE AND IMIPRAMINE IN THE TREATMENT OF DEPRESSION.
210241 03-09

CLINICAL BIOLOGICAL CORRELATIONS IN SCHIZOAFFECTIVE PATIENTS TREATED WITH LITHIUM CARBONATE AND HALOPERIDOL.
210501 03-09

CONTRIBUTIONS TO THE STUDY OF THE INFLUENCE OF LITHIUM CARBONATE ON THE EVOLUTION OF HYPERTHYMIC PSYCHOSES.
212161 03-09

A CASE OF NARCOLEPSY IMPROVED BY LITHIUM CARBONATE.
216390 04-11

FREE THYROXINE INDEX AND ABSOLUTE FREE THYROXINE IN PATIENTS WITH AFFECTIVE DISORDERS TREATED WITH LITHIUM CARBONATE.
216747 04-09

CLINICAL EXPERIMENTATION WITH A SUSTAINED RELEASE LITHIUM CARBONATE.
216769 04-09

THE EFFECT OF LITHIUM CARBONATE ON THE ELECTROENCEPHALOGRAM OF MANIC-DEPRESSIVE PSYCHOTICS.
217114 04-09

RELATIONSHIP BETWEEN SERUM LITHIUM LEVEL AND CLINICAL RESPONSE ON DEPRESSION TREATED WITH LITHIUM CARBONATE.
217354 04-09

TREATING DEPRESSION WITH TRANQUILIZERS: WITH DISSENTING VIEW OF LITHIUM CARBONATE THERAPY.
218123 04-09

EXPERIENCE WITH 20 PATIENTS TREATED WITH LITHIUM CARBONATE.
218682 04-09

DOUBLE-BLIND COMPARISON OF LITHIUM CARBONATE AND IMIPRAMINE IN TREATMENT OF DEPRESSION.
218772 04-09

SIMILARITIES IN THE EFFECTS OF LITHIUM CARBONATE, LITAREX AND LITHIONITE DURETTER: PRELIMINARY STUDY.
221634 04-14

SYMPTOMATIC SINUS NODE ABNORMALITIES FOLLOWING LITHIUM CARBONATE THERAPY.
223120 04-15

LITHIUM CARBONATE PROPHYLAXIS FAILURE.
224873 04-09

LITHIUM CARBONATE IN THE TREATMENT OF TARDIVE DYSKINESIA.
225343 04-15

CARBONIC
THE ANTICONVULSANT ACTION OF THE CARBONIC ANHYDRASE INHIBITOR METHAZOLAMIDE: POSSIBLE INVOLVEMENT OF A NORADRENERGIC MECHANISM.
197864 01-03

ENHANCEMENT OF THE CHLORPROMAZINE-INDUCED SUPPRESSION OF THE CONDITIONED AVOIDANCE RESPONSE BY CARBONIC ANHYDRASE INHIBITION.
199770 02-03

CENTRAL NERVOUS SYSTEM CARBONIC ANHYDRASE INHIBITORS. (PH.D. DISSERTATION).
203028 02-03

CARBROMAL
HEAVY INTOXICATION AS A SIDE-EFFECT OF CARBROMAL IN TWO CHILDREN.
203882 02-15

CARD
ATTEMPTS TO CLASSIFY AND ORIENT PRESCRIPTION OF PSYCHOTROPIC DRUGS BY MEANS OF A COMPUTER CARD INDEX.
221668 04-17

CARDIAC
THE CARDIAC EFFECTS OF COCAINE AND CERTAIN ANTIHISTAMINES AND ANTIDEPRESSANTS.
197452 01-03
RELATIONSHIP BETWEEN THE CHANGES ON BLOOD PRESSURE RESPONSE AND THE CARDIAC CATECHOLAMINE LEVEL AFTER SINGLE AND REPEATED ADMINISTRATIONS OF TYRAMINE AND METHAMPHETAMINE IN RATS.
197491 01-03
EFFECT OF CAMAZEPAM (SB-5833), A NEW ANTIANXIOUS DRUG, ON CARDIAC CONTRACTILITY AND CORONARY HEMODYNAMICS.
206785 03-03
REPORT ON THREE CASES OF CARDIAC CHANGES DURING TREATMENT WITH FLOROPIPAMIDE (PROPITAN).
216391 04-15
PHYSIOLOGICAL MECHANISMS FOR CARDIAC CONTROL BY NUTRITIONAL INTAKE AFTER EARLY MATERNAL SEPARATION IN THE YOUNG RAT.
218047 04-03
CARDIAC ARRHYTHMIA AND IMIPRAMINE THERAPY.
219517 04-15
THE EFFECT OF TRANQUILIZERS (DIAZEPAM AND CHLORDIAZEPOXIDE) ON THE BLOOD SUPPLY AND CARDIAC ACTIVITY.
223018 04-03

CARDIOPULMONARY
CARDIOPULMONARY TOXICITY OF DELTA9-TETRAHYDROCANNABINOL IN THE ANESTHETIZED DOG.
211015 03-05

CARDIOTOXIC
CARDIOTOXIC EFFECTS OF TRICYCLIC ANTIDEPRESSANTS IMIPRAMINE, AMITRIPTYLINE AND DOSULEPIN (PROTHIADEN-SPOFA) IN AN ACUTE EXPERIMENT IN RATS.
205597 02-15

CARDIOTOXICITY
POTENTIAL CARDIOTOXICITY FROM PHENOTHIAZINES AND TRICYCLIC ANTIDEPRESSANTS.
198044 01-15

CARDIOVASCULAR
CARDIOVASCULAR ABNORMALITIES FOLLOWING TRICYCLIC ANTIDEPRESSANT DRUG OVERDOSAGE.
195847 01-15
EFFECTS OF LITHIUM CHLORIDE ON CARDIOVASCULAR RESPONSES INDUCED BY CHOLINERGIC AND ADRENERGIC STIMULATIONS.
199870 02-03
CARDIOVASCULAR AND AUTONOMIC EFFECTS OF CHLORPROMAZINE. (PH.D. DISSERTATION).
203034 02-03
CARDIOVASCULAR COMPLICATIONS OF TRICYCLIC ANTIDEPRESSANT OVERDOSAGE.
209234 03-15
EFFECTS OF P-METHOXYAMPHETAMINE (PMA) ON THE CARDIOVASCULAR SYSTEM OF THE DOG.
210867 03-05
CENTRALLY MEDIATED CARDIOVASCULAR EFFECTS OF 5-HYDROXYTRYPTOPHAN IN MAO INHIBITED DOGS: MODIFICATION BY AUTONOMIC ANTAGONISTS.
215757 04-03
COMPARISON OF CARDIOVASCULAR, HYPERTHERMIC, AND TOXIC EFFECTS OF P-METHOXYAMPHETAMINE (PMA) AND 3,4 METHYLENEDIOXYAMPHETAMINE (MDA).
217578 04-05
CARDIOVASCULAR EFFECTS OF DIAZEPAM AND CHLORDIAZEPOXIDE.
217659 04-03
THE ACTION OF DELTA9-TETRAHYDROCANNABINOL ON CENTRAL CARDIOVASCULAR REGULATION: MECHANISM AND LOCALIZATION.
221669 04-03
CARDIOVASCULAR MALFORMATIONS WITH LITHIUM USE DURING PREGNANCY.
225331 04-15

CARDS
THE SHAPIRO CARDS SCALE AS A METHOD OF ASSESSMENT OF OBSESSIONAL SYMPTOMS IN CLOMIPRAMINE THERAPY.
214829 04-10

CARISPRODOL
INFLUENCE OF MEPROBAMATE, CARISPRODOL, OXAZEPAM AND PHENOBARBITAL ON NA+ TRANSPORT IN THE ISOLATED FROG SKIN.
206781 03-03

CAROTID
RAT BRAIN REGIONAL UPTAKE AND DECARBOXYLATION OF L-DOPA FOLLOWING CAROTID INJECTION.
214323 04-03

CAROXAZONE
CLINICAL DOUBLE-BLIND STUDY ON THE ACTIVITY OF A NEW ANTIDEPRESSANT: CAROXAZONE (FI-6654).
201667 02-09

CARPIPRAMINE
CLINICAL EXPERIENCE WITH CARPIPRAMINE (DEFEKTON).
205592 02-08

CASTRATE
STIMULATION OF ESTROGEN INDUCED COPULATORY BEHAVIOR IN CASTRATE MALE RATS WITH THE SEROTONIN BIOSYNTHESIS INHIBITOR P-CHLOROPHENYLALANINE.
221010 04-04

CAT
EFFECTS OF TRANSMITTER MIMICKERS AT SITES OF ANGIOTENSIN INDUCED DRINKING IN THE CAT.
193434 01-04
IN VIVO RELEASE OF ENDOGENOUSLY SYNTHESIZED CATECHOLAMINES FROM THE CAT BRAIN EVOKED BY ELECTRICAL STIMULATION AND BY D-AMPHETAMINE.
195049 01-03
THE LIPOLYTIC ACTIVITY OF AMPHETAMINE IN THE SPINALISED CAT.
195118 01-03
MECHANISM OF THE HYPOTENSIVE EFFECT OF INTRAVENOUS METHAQUALONE IN THE CAT.
196107 01-03
STUDIES ON CLONAZEPAM, FLUNITRAZEPAM, AND RELATED BENZODIAZEPINES IN CAT AND MONKEY.
197492 01-03
STUDIES OF TRYPTAMINE AND LYSERGIC ACID DIETHYLAMIDE (LSD) ON CUTANEOUS C-FIBER AND POLYSYNAPTIC REFLEXES IN THE CAT.
197814 01-03
SELECTIVE DIPHENYLHYDANTOIN SUPPRESSION OF AUDITORY EVOKED POTENTIALS IN THE CAT CEREBELLAR CORTEX.
197989 01-03
EFFECTS OF MESCALINE, DELTA9-TETRAHYDROCANNABINOL AND PENTOBARBITAL ON THE AUDITORY EVOKED RESPONSES IN THE CAT.
197990 01-03
GABA BLOCKADE, DOPAMINE AND SCHIZOPHRENIA: EXPERIMENTAL STUDIES IN THE CAT.
200052 02-03
THE IN VIVO RELEASE OF ENDOGENOUSLY SYNTHESIZED CATECHOLAMINES FROM THE CAT BRAIN BY LATERAL HYPOTHALAMIC STIMULATION AND BY D-AMPHETAMINE ADMINISTRATION. (PH.D. DISSERTATION).
200313 02-03
STUDIES OF CONFLICT INDUCED BEHAVIOR IN THE CAT: BEHAVIOR ANALYSIS AND EFFECTS OF PSYCHOTROPIC DRUGS.
202122 02-04
NEGATIVE INOTROPIC EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON THE ISOLATED RIGHT VENTRICULAR PAPILLARY MUSCLE OF THE CAT.
204400 02-05
LACK OF EFFECT OF AMANTADINE ON D-AMPHETAMINE INDUCED RELEASE OF DOPAMINE FROM CAT BRAIN IN VIVO.
204865 02-02
THE EFFECTS OF LITHIUM CARBONATE ON SLEEP AND WAKEFULNESS IN THE CAT.
205546 02-03
REGIONAL DIFFERENCES IN RESPONSE TO DISPLACEMENT AND INHIBITION OF SYNTHESIS OF CATECHOLAMINES IN THE CAT BRAIN.
206334 03-03
PRESENCE OF DOPAMINERGIC TERMINALS AND ABSENCE OF DOPAMINERGIC CELL BODIES IN THE CEREBRAL CORTEX OF THE CAT.
210800 03-03
EVOKED NEURAL ACTIVITY IN THE BASAL GANGLIA OF THE CAT AND ITS MODIFICATION BY CHOLINERGIC AND DOPAMINERGIC AGENTS. (PH.D. DISSERTATION).
212520 03-03
HYPERSOMNIA BY ISTHMIC LESION IN THE CAT. I. STUDY OF THE METABOLISM OF CEREBRAL MONOAMINES.
215702 04-03
HYPERSOMNIA BY ISTHMIC LESION IN THE CAT. II. NEUROPHYSIOLOGICAL AND PHARMACOLOGICAL STUDY.
215703 04-03
ELECTROPHYSIOLOGICAL EVIDENCE FOR AN INHIBITORY ACTION OF DIAZEPAM UPON CAT BRAIN CORTEX.
217649 04-03
IN VIVO RELEASE OF ENDOGENOUS NEUROTRANSMITTERS IN CAT LIMBIC REGIONS: EFFECT OF CHLORPROMAZINE AND OF ELECTRICAL STIMULATION.
217685 04-03
ANALYSIS OF VARIOUS FACTORS INVOLVED IN EEG SYNCHRONIZATION DURING MILK DRINKING IN THE CAT.
217846 04-04
AN APPLICATION OF LONG-TERM FREQUENCY ANALYSIS IN MEASURING DRUG SPECIFIC ALTERATIONS IN THE EEG OF THE CAT.
218190 04-03
THE EFFECT OF DRUGS ON THE RELEASE OF ENDOGENOUS CATECHOLAMINES INTO THE PERFUSATE OF DISCRETE BRAIN AREAS OF THE CAT IN VIVO.
219631 04-06

SYNERGISM BETWEEN GAMMA-AMINOBUTYRIC ACID AND BUTYROPHENONES ADMINISTERED MICROELECTROPHORETICALLY IN THE PURKINJE CELLS OF THE CAT CEREBELLUM.
220904 04-03

DIPROPYLACETIC ACID (DEPAKINE) IN EXPERIMENTAL EPILEPSY IN THE ALERT CAT.
225529 04-02

CATALEPSY

CATALEPSY, STEREOTYPED BEHAVIOUR AND STRIATAL HOMOVANILLIC ACID CONTENT IN RATS TREATED WITH METHADONE.
197299 01-03

NEUROLEPTIC AND NON-NEUROLEPTIC CATALEPSY.
199911 02-04

POTENTIATION OF CATALEPSY INDUCED BY NARCOTIC AGENTS DURING HAFFNERS TEST FOR ANALGESIA.
206358 03-04

SEROTONERGIC INVOLVEMENT WITH THE STEREOTYPY/CATALEPSY INDUCED BY MORPHINE-LIKE AGENTS IN THE RAT.
210754 03-04

CATALEPTIC

THE IMPORTANCE OF THE ASCENDING DOPAMINERGIC SYSTEMS TO THE EXTRAPYRAMIDAL AND MESOLIMBIC BRAIN AREAS FOR THE CATALEPTIC ACTION OF THE NEUROLEPTIC AND CHOLINERGIC AGENTS.
195250 01-03

LONG-TERM TRIAL OF FLUPHENAZINE DECANOATE AND FLUPENTHIXOL DECANOATE FOR CATALEPTIC ACTIVITY AND EFFECT ON MOTOR ACTIVITY IN RATS.
206787 03-04

NEUROLEPTICS: RELATION BETWEEN CATALEPTIC AND ANTITURNING ACTIONS, AND ROLE OF THE CHOLINERGIC SYSTEM.
217826 04-04

CATALEPTOGENS

EFFECT OF SENSORY STIMULATION ON THE POTENCY OF CATALEPTOGENS.
217473 04-03

CATALYST

RAPID ANALYSIS OF THE CENTRAL NERVOUS SYSTEM STIMULANTS, AMPHETAMINES, VIA GAS CHROMATOGRAPHY MASS SPECTROMETRY: RAPID ACYLATION IN THE PRESENCE OF A MERCURY CATALYST.
222830 04-06

CATALYTIC

INHIBITION OF THE CATALYTIC SITE OF ADENYLATE-CYCLASE IN THE CENTRAL NERVOUS SYSTEM BY PHENOTHIAZINE DERIVATIVES.
195096 01-03

CATAMNESTIC

THE USE OF ANTICONVULSANT TREATMENT OF BEHAVIORALLY DISTURBED CHILDREN WITH BIOELECTRIC EPILEPSY: A CATAMNESTIC STUDY OF 76 CASES.
211355 03-11

CATAPLEXY

A STUDY ON CATAPLEXY.
197816 01-11

CATATONIA

CATECHOLAMINES AND ANTIPSYCHOTIC DRUGS IN PERIODIC CATATONIA.
207292 03-08

ANTAGONISM OF DOPAMINE MEDIATED INHIBITION IN THE NIGROSTRIATAL PATHWAY: A MODE OF ACTION OF SOME CATATONIA INDUCING DRUGS.
210659 03-03

THE MECHANISM OF THE POTENTIATING EFFECT OF ANTIDEPRESSANT DRUGS ON THE PROTECTIVE INFLUENCE OF DIPHENHYDRAMINE IN EXPERIMENTAL CATATONIA. THE ROLE OF HISTAMINE.
215664 04-03

CATECHOL-O-METHYLTRANSFERASE

LITHIUM RESPONSE IN DEPRESSION AS PREDICTED BY UNIPOLAR/BIPOLAR ILLNESS, AVERAGE EVOKED RESPONSE, CATECHOL-O-METHYLTRANSFERASE AND FAMILY HISTORY. (UNPUBLISHED PAPER).
201000 02-09

CATECHOLAMINE

INTERACTION OF CATECHOLAMINE AND AMINO ACID METABOLISM IN BRAIN: EFFECT OF PARGYLINE AND L-DOPA.
195048 01-03

MECHANISM OF ANTIDEPRESSANT EFFICACY OF MONOAMINEOXIDASE INHIBITORS: INHIBITION OF MONOAMINE OXIDASE OR OF CATECHOLAMINE REUPTAKE.
195925 01-17

INFLUENCE OF CATECHOLAMINE UPTAKE BLOCKING DRUGS ON THE INCREASE IN WATER INTAKE AND PLASMA RENIN CONCENTRATION INDUCED BY SOME HYPOTENSIVE DRUGS.
197288 01-03

RELATIONSHIP BETWEEN THE CHANGES ON BLOOD PRESSURE RESPONSE AND THE CARDIAC CATECHOLAMINE LEVEL AFTER SINGLE AND REPEATED ADMINISTRATIONS OF TYRAMINE AND METHAMPHETAMINE IN RATS.
197491 01-03

CATECHOLAMINE DEPLETING ACTION OF PHYSOSTIGMINE IN THE RAT BRAIN.
197575 01-03

EFFECTS OF 5-(N-BUTYL) PICOLINAMIDE (SCH-10595), A DOPAMINE-BETA-HYDROXYLASE INHIBITOR, ON SEROTONIN AND CATECHOLAMINE METABOLITES IN BRAIN.
197813 01-03

THE EFFECT OF L-DOPA ON THE DEVELOPMENT OF RESERPINE INDUCED PARKINSONISM AND CATECHOLAMINE METABOLISM IN RATS.
198486 02-03

ACTION OF RESERPINE IN MORPHINE TOLERANT RATS: ABSENCE OF AN ANTAGONISM OF CATECHOLAMINE DEPLETION.
199277 02-03

SUPPRESSION BY NORADRENALINE OF CATECHOLAMINE SECRETION FROM ADRENAL MEDULLA.
199869 02-03

IDENTIFICATION AND STRUCTURAL CHARACTERIZATION OF AN INHIBITOR OF CATECHOLAMINE INDUCED FREE FATTY ACID MOBILIZATION FROM THE CALF MIDBRAIN.
200006 02-01

THE INFLUENCE OF NEUROLEPTICAL DRUGS ON CATECHOLAMINE EXCRETION.
200073 02-08

THE INFLUENCE OF ALPHA-METHYLTYROSINE AND DISULFIRAM ON THE INHIBITORY FUNCTION OF THE CAUDATE NUCLEUS AND CATECHOLAMINE CONTENT IN THE BRAIN OF CATS.
200565 02-03

THE EFFECT OF INHIBITORS OF CATECHOLAMINE SYNTHESIS (ALPHA-METHYLTYROSINE AND DISULFIRAM) ON THE BACKGROUND ACTIVITY OF SENSORIMOTOR CORTEX NEURONS AND THEIR RESPONSES TO AFFERENT CAUDATE AND RETICULAR STIMULATION.
202598 02-04

AN ONTOGENIC STUDY ON THE EFFECT OF CATECHOLAMINE RECEPTOR STIMULATING AGENTS ON THE TURNOVER OF NORADRENALINE AND DOPAMINE IN THE BRAIN.
202715 02-03

PROTECTION AGAINST EFFECTS OF BRAIN DAMAGE BY CATECHOLAMINE DEPLETION IS TEST DEPENDENT.
203579 02-04

FRONTIERS IN CATECHOLAMINE RESEARCH. PROCEEDINGS OF THE THIRD INTERNATIONAL CATECHOLAMINE SYMPOSIUM.
206437 03-17

STEREOSELECTIVE FEATURES OF CATECHOLAMINE DISPOSITION AND THEIR BEHAVIORAL IMPLICATIONS.
207287 03-04

ANTIPSYCHOTIC DRUGS AND CATECHOLAMINE SYNAPSES.
207290 03-03

ANTIPSYCHOTIC DRUGS AND CATECHOLAMINE SYNAPSES: SUMMARY OF THE SESSION.
207299 03-03

CENTRAL CATECHOLAMINE NEURONS, BEHAVIOR AND NEUROLEPTIC DRUGS: AN ANALYSIS TO UNDERSTAND THE INVOLVEMENT OF CATECHOLAMINES IN SCHIZOPHRENIA.
207305 03-03

QUANTITATIVE RELATIONSHIP OF CATECHOLAMINE CONTENT AND HISTOFLUORESCENCE IN BRAIN OF RATS.
210660 03-03

EFFECTS OF CATECHOLAMINE RELEASING AGENTS ON SYNAPTOSOMAL DOPAMINE BIOSYNTHESIS: MULTIPLE POOLS OF DOPAMINE OR MULTIPLE FORMS OF TYROSINE-HYDROXYLASE?.
210825 03-03

MODIFICATION BY L-DOPA METHYLESTER (H-19-61) OF AMPHETAMINE-INDUCED BRAIN CATECHOLAMINE CHANGES, THERMAL RESPONSES AND TOXICITY IN DEVELOPING MICE.
210891 03-03

BEHAVIORAL AND NEUROCHEMICAL EFFECTS OF MORPHINE OR AMPHETAMINE AFTER CHRONIC PRETREATMENT WITH CATECHOLAMINE DEPLETING AGENTS. (PH.D. DISSERTATION).
211746 03-03

CHLORPROMAZINE AND BRAIN CATECHOLAMINE SYNTHESIS.
213630 04-03

CATECHOLAMINE NEUROTRANSMITTERS AND SYNTHETIC ENZYMES IN THE SPINAL CORD OF THE RAT.
213987 04-03

ALTERATIONS IN BEHAVIOUR AND CATECHOLAMINE BIOSYNTHESIS INDUCED BY LITHIUM.
214067 04-04

EFFECTS OF TACLAMINE (AY-22214), A NEW PSYCHOACTIVE AGENT, ON CATECHOLAMINE AND SEROTONIN METABOLISM.
215725 04-03

SLEEP AND BEHAVIORAL CHANGES REFLECTING CENTRAL RECEPTOR HYPERSENSITIVITY FOLLOWING CATECHOLAMINE SYNTHESIS INHIBITION IN MAN. (UNPUBLISHED PAPER).
216373 04-09

INHIBITION OF CATECHOLAMINE AND 5-HYDROXYTRYPTAMINE INDUCED ENZYME SECRETION FROM THE GUINEA-PIG SUBMANDIBULAR GLAND BY 2-BROMO-D-LYSERGIC ACID DIETHYLAMIDE.
216968 04-03

A RAPID, SIMPLE AND MORE SENSITIVE METHOD FOR THE DEMONSTRATION OF CENTRAL CATECHOLAMINE CONTAINING NEURONS AND AXONS BY GLYOXYLIC ACID INDUCED FLUORESCENCE: I. SPECIFICITY.
217550 04-16

CATECHOLAMINE CORRELATES OF ISOLATION INDUCED AGGRESSION IN MICE.
217670 04-04

FUNCTIONAL AND BIOCHEMICAL ASPECTS OF CATECHOLAMINE METABOLISM IN BRAIN UNDER HYPOXIA.
217852 04-03

MOOD AND CATECHOLAMINE -- NONSIMPLICITY OF THEIR RELATIONSHIP.
218362 04-09

INTERACTION OF CYCLOHEXIMIDE AND ADRENERGIC DRUGS WITH BRAIN PROTEIN AND CATECHOLAMINE BIOSYNTHESIS. (PH.D. DISSERTATION).
219288 04-03

CENTRAL CATECHOLAMINE RECEPTOR BLOCKING ACTIONS OF BE-2254 (HEAT): COMPARISON WITH CHLORPROMAZINE AND HALOPERIDOL.
222804 04-03

IS THERE A CATECHOLAMINE SEROTONIN INTERACTION IN THE CONTROL OF LOCOMOTOR ACTIVITY?
222816 04-04

ASCENDING CATECHOLAMINE PATHWAYS AND AMPHETAMINE-INDUCED LOCOMOTOR ACTIVITY: IMPORTANCE OF DOPAMINE AND APPARENT NONINVOLVEMENT OF NOREPINEPHRINE.
223054 04-03

DOXEPIN AND IMIPRAMINE: EFFECT ON CATECHOLAMINE INHIBITION OF GANGLIONIC TRANSMISSION.
225059 04-03

CATECHOLAMINERGIC

ROLE OF CATECHOLAMINERGIC MECHANISMS IN THE EXPRESSION OF THE MORPHINE ABSTINENCE SYNDROME IN RATS.
200053 02-03

THE EFFECT OF CATECHOLAMINERGIC DRUGS ON THE BEHAVIOR AND EEG OF RATS DURING CORAZOL SEIZURES.
219332 04-04

BETA-PHENYLETHYLAMINE AND LOCOMOTOR ACTIVITY IN MICE: INTERACTION WITH CATECHOLAMINERGIC NEURONES AND RECEPTORS.
221742 04-03

CATECHOLAMINES

PENTAZOCINE ANALGESIA AND REGIONAL RAT BRAIN CATECHOLAMINES.
193452 01-03

THYROXINE AND BRAIN CATECHOLAMINES: INCREASED TRANSMITTER SYNTHESIS AND INCREASED RECEPTOR SENSITIVITY.
193541 01-03

IN VIVO RELEASE OF ENDOGENOUSLY SYNTHESIZED CATECHOLAMINES FROM THE CAT BRAIN EVOKED BY ELECTRICAL STIMULATION AND BY D-AMPHETAMINE.
195049 01-03

EFFECTS OF DIISOPROPYLPHOSPHOFLUORIDATE ON ACETYLCHOLINE, CHOLINESTERASE AND CATECHOLAMINES OF SEVERAL PARTS OF RABBIT BRAIN.
195094 01-03

MORPHINE EFFECTS ON THE LEVELS AND TURNOVER OF CATECHOLAMINES IN RAT BRAIN.
195116 01-03

EFFECTS OF THEOPHYLLINE AND PROPRANOLOL ON ACETYLCHOLINE-INDUCED RELEASE OF ADRENAL MEDULLARY CATECHOLAMINES.
195591 01-03

EFFECTS OF D-AMPHETAMINE SULFATE GIVEN TO PREGNANT MICE ON ACTIVITY AND ON CATECHOLAMINES IN THE BRAINS OF OFFSPRING.
196025 01-03

THE ROLE OF BRAIN CATECHOLAMINES IN THE ANORECTIC RESPONSE TO AMPHETAMINE. (PH.D. DISSERTATION).
196370 01-04

ON THE INVOLVEMENT OF BRAIN CATECHOLAMINES IN MORPHINE-INDUCED RUNNING ACTIVITY IN MICE.
197286 01-04

EFFECTS OF CATECHOLAMINES AND PROSTAGLANDINS ON CYCLIC-AMP LEVELS IN BRAIN IN VIVO.
197294 01-03

RESPONSES OF MOLLUSCAN NEURONS TO CATECHOLAMINES.
197445 01-03

EFFECT OF 6-HYDROXYDOPAMINE ON THE LEVEL OF THE CATECHOLAMINES IN THE BRAIN OF DEVELOPING RATS.
197449 01-03

THE EFFECTS OF PARENTERAL ADMINISTRATION OF CATECHOLAMINES, SEROTONIN AND HISTAMINE ON BEHAVIOR AND LEVELS OF THESE AMINES IN THE BRAIN OF THE NEONATE CHICK.
197457 01-03

EFFECTS OF SOCIAL STRESS ON THE TURNOVER OF BRAIN CATECHOLAMINES AND 5-HYDROXYTRYPTAMINE IN MICE.
198025 01-03

DUAL MECHANISM OF AMPHETAMINE TOXICITY IN MICE: RELATIONSHIP TO BRAIN CATECHOLAMINES.
199898 02-05

BEHAVIOURAL SUPERSENSITIVITY TO APOMORPHINE FOLLOWING CHRONIC TREATMENT WITH DRUGS WHICH INTERFERE WITH THE SYNAPTIC FUNCTION OF CATECHOLAMINES.
199958 02-04

THE IN VIVO RELEASE OF ENDOGENOUSLY SYNTHESIZED CATECHOLAMINES FROM THE CAT BRAIN BY LATERAL HYPOTHALAMIC STIMULATION AND BY D-AMPHETAMINE ADMINISTRATION. (PH.D. DISSERTATION).
200313 02-03

THE INFLUENCE OF CATECHOLAMINES, SEROTONIN, AND SOME AMINO ACIDS ADMINISTERED INTO THE AMYGDALOID COMPLEX ON CONDITIONED REFLEXES OF AVOIDANCE AND MOTOR ACTIVITY IN RATS.
200566 02-03

INFLUENCE OF HEXOBARBITAL ON THE BIOSYNTHESIS OF CATECHOLAMINES AND THEIR PRECURSORS IN THE BRAIN.
201917 02-03

UPTAKE OF CATECHOLAMINES BY HUMAN SYNAPTOSOMES.
202719 02-03

THE PERIPHERAL AND CENTRAL ROLE OF THE CATECHOLAMINES IN THE MECHANISMS OF ANXIETY.
202783 02-17

A CONTRIBUTION TO THE STUDY OF MECHANISM OF ACTION OF PHENYLBUTAZONE: THE INFLUENCE OF CATECHOLAMINES ON THE ANTIINFLAMATORY EFFECT OF PHENYLBUTAZONE.
205169 02-03

MATURATION OF THE ADRENAL MEDULLA -- III: PRACTICAL AND THEORETICAL CONSIDERATIONS OF AGE DEPENDENT ALTERATIONS IN KINETICS OF INCORPORATION OF CATECHOLAMINES AND NONCATECHOLAMINES.
205852 03-03

REGIONAL DIFFERENCES IN RESPONSE TO DISPLACEMENT AND INHIBITION OF SYNTHESIS OF CATECHOLAMINES IN THE CAT BRAIN.
206334 03-03

SIGNIFICANCE OF CATECHOLAMINES FOR THE MANIFESTATION OF MORPHINE WITHDRAWAL IN THE RAT.
206988 03-03

EFFECTS OF AMPHETAMINES ON THE METABOLISM OF CATECHOLAMINES IN THE RAT BRAIN.
207288 03-03

CATECHOLAMINES AND ANTIPSYCHOTIC DRUGS IN PERIODIC CATATONIA.
207292 03-08

CENTRAL CATECHOLAMINE NEURONS, BEHAVIOR AND NEUROLEPTIC DRUGS: AN ANALYSIS TO UNDERSTAND THE INVOLVEMENT OF CATECHOLAMINES IN SCHIZOPHRENIA.
207305 03-03

POSSIBLE ROLE OF CATECHOLAMINES (CA) IN THE REGULATION OF ADRENAL TYROSINE-HYDROXYLASE (TH).
207333 03-03

EFFECT OF STRESS ON CATECHOLAMINES AND TYROSINE-HYDROXYLASE ACTIVITY OF INDIVIDUAL HYPOTHALAMIC NUCLEI.
208994 03-03

CATECHOLAMINES.
209098 03-17

BRAIN CATECHOLAMINES AND CEREBRAL BLOOD FLOW.
209839 03-17

PHARMACOLOGICAL MANIPULATIONS OF BRAIN CATECHOLAMINES AND THE AGGRESSIVE BEHAVIOR INDUCED BY MARIHUANA IN REM SLEEP DEPRIVED RATS.
210325 03-04

CATECHOLAMINES IN SYMPATHETIC GANGLIA OF RAT: EFFECTS OF DEXAMETHASONE AND RESERPINE.
210766 03-03

ELECTROCORTICAL CHANGES INDUCED BY PERFUSION OF CATECHOLAMINES INTO THE BRAINSTEM RETICULAR FORMATION.
210827 03-03

PATHOPHYSIOLOGICAL STUDIES OF MANIC-DEPRESSIVE PSYCHOSES: RELATIONSHIP BETWEEN ANXIETY AND EXCRETION OF URINARY CATECHOLAMINES.
212938 03-10

DRUGS, CATECHOLAMINES AND KREBS CYCLE INTERACTION (CNS).
213602 04-03

CATECHOLAMINES AS CENTRAL NERVOUS TRANSMITTERS.
213620 04-03

PLASMA CATECHOLAMINES: ARTERIAL VENOUS DIFFERENCES AND THE INFLUENCE OF BODY TEMPERATURE.
215655 04-06

THE ROLE OF CATECHOLAMINES IN THE ACTION OF AMPHETAMINE AND L-DOPA ON CEREBRAL ENERGY METABOLISM.
217677 04-03

THE EFFECT OF AMANTADINE ON THE TURNOVER OF CATECHOLAMINES IN THE RAT BRAIN.
217961 04-03

THE INFLUENCE OF LITHIUM AND CESIUM IONS ON THE EFFECTS OF CATECHOLAMINES AND SEROTONIN INTRODUCED INTO THE HIPPOCAMPUS OF RATS.
218470 04-04

THE EFFECT OF CATECHOLAMINES ON THE NOREPINEPHRINE LEVEL IN THE TISSUES.
219506 04-03

THE EFFECT OF DRUGS ON THE RELEASE OF ENDOGENOUS CATECHOLAMINES INTO THE PERFUSATE OF DISCRETE BRAIN AREAS OF THE CAT IN VIVO.
219631 04-06

THE EFFECT OF LITHIUM ON THE CONTENT OF CATECHOLAMINES IN THE BRAIN OF RABBITS AND RATS.
219749 04-03

CATECHOLAMINES AND SELF-STIMULATION: PHARMACOLOGICAL DIFFERENCES BETWEEN NEAR-LATERAL AND FAR-LATERAL HYPOTHALAMIC SITES.
221030 04-03

EFFECTS OF SINGLE AND MULTIPLE DOSE LSD ON ENDOGENOUS LEVELS OF BRAIN TYROSINE-HYDROXYLASE AND CATECHOLAMINES.
221044 04-12

EFFECT OF ACTH4-10 ON THE RATE OF SYNTHESIS OF (3H)CATECHOLAMINES IN THE BRAINS OF INTACT, HYPOPHYSECTOMIZED AND ADRENALECTOMIZED RATS.
223050 04-03

GROWTH HORMONE RELEASE AND CATECHOLAMINES IN AFFECTIVE DISEASE.
224773 04-13

CATECHOLAMINES AND DRUG BEHAVIOR INTERACTIONS.
225162 04-04

CATEGORIES

CATEGORIES OF PSYCHOTROPIC DRUG EFFECTS ON SLEEP EEG AND EOG.
205621 03-13

CATIONIC

EFFECT OF RESERPINE ON CATIONIC CONTENTS OF RAT BRAIN.
198196 02-03

REACTION OF CATIONIC GROUPS OF CHLORPROMAZINE WITH ANIONIC MACROMOLECULES: COMPLEXES WITH DNA, RNA, HYALURONIC ACID AND HEPARIN.
199897 02-03

CATIONS

REGIONAL DISTRIBUTION OF CATIONS AND THEIR RELATION TO THE NEUROCHEMISTRY OF EXPERIMENTAL EPILEPSY, NEUROTRANSMITTERS AND ATPASE IN THE CENTRAL NERVOUS SYSTEM. (PH.D. DISSERTATION).
193588 01-03

EFFECT OF MONOVALENT CATIONS ON HUMAN PLATELET ADENYLCYCLASE ACTIVITY.
195930 01-13

DIVALENT CATIONS IN PREDICTING ANTIDEPRESSANT RESPONSE TO LITHIUM.
202886 02-14

CATS

EFFECTS OF KETAMINE ON EEG ACTIVITY IN CATS AND MONKEYS.
193797 01-03

BRAIN DOPA/5-HTP DECARBOXYLASE ACTIVITY AFTER THE CHRONIC ADMINISTRATION OF L-DOPA OR 5-HYDROXY-L-TRYPTOPHAN IN NORMAL AND LESIONED CATS.
194483 01-05

NEUROPHARMACOLOGICAL STUDIES OF EFFECT OF NEW CENTRAL DEPRESSANT, 8-CHLOR-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D40TA) ON EEG AND CENTRAL SYMPATHETIC ACTIVATING MECHANISM IN CATS.
195549 01-03

THE SITE OF THE RESPIRATORY STIMULANT ACTION OF IMIDAZOLE IN CATS.
196582 01-03

INHIBITION OF EFFECTS OF ACCELERATOR NERVE STIMULATION IN CATS AND RABBITS BY BS-100-141 AND GUANABENZ.
197971 01-03

INFLUENCE OF AN ANTICHOLINERGIC PSYCHOTOMIMETIC AGENT ON BEHAVIOUR IN CATS CONTROLLED BY AN AUDITORY STIMULUS.
197996 01-04

EFFECTS OF CYTIDINE DIPHOSPHATE CHOLINE ON THE NERVOUS SYSTEM IN CATS.
198610 02-04

CHLORDIAZEPOXIDE AND ITS EFFECT ON SLEEP WAKEFULNESS BEHAVIOR IN UNRESTRAINED CATS.
199213 02-04

PERSISTENT THALAMIC AND CORTICAL BARBITURATE SPINDLE ACTIVITY AFTER ABLATION OF THE ORBITAL CORTEX IN CATS.
199763 02-03

THE NUCLEUS LINEARIS INTERMEDIUS RAPHE AND BEHAVIOUR EVOKED BY DIRECT AND INDIRECT STIMULATION OF DOPAMINE SENSITIVE SITES WITHIN THE CAUDATE NUCLEUS OF CATS.
199864 02-04

ELECTROENCEPHALOGRAPHIC AND BEHAVIORAL STUDIES ON THE CENTRAL ACTION OF NIMETAZEPAM (S-1530) IN CATS.
199910 02-04

CROSS-TOLERANCE OR TACHYPHYLAXIS AMONG VARIOUS PSYCHOTOMIMETIC AGENTS ON CATS.
199965 02-03

THE INFLUENCE OF ALPHA-METHYLTYROSINE AND DISULFIRAM ON THE INHIBITORY FUNCTION OF THE CAUDATE NUCLEUS AND CATECHOLAMINE CONTENT IN THE BRAIN OF CATS.
200565 02-03

THE PHARMACOLOGY OF GROSS BEHAVIOURAL EFFECTS OF CHOLINOMIMETIC SUBSTANCES INJECTED INTO THE CEREBRAL VENTRICLES OF UNANAESTHETIZED CATS: EVIDENCE FOR CENTRAL MUSCARINIC MEDIATION.
202780 02-04

AN ANALYSIS OF THE GROSS BEHAVIOURAL CHANGES INDUCED BY TETRAETHYLAMMONIUM AND A COMPARISON WITH OTHER SUBSTANCES AFFECTING THE AUTONOMIC AND CENTRAL NERVOUS SYSTEM AFTER INTRAVENTRICULAR INJECTIONS TO CONSCIOUS CATS.
202781 02-04

COMPARISON OF THE EFFECTS OF ATROPINE AND CANNABIS UPON THE FIXED CONDITIONED ALIMENTARY MOTOR REFLEXES IN CATS AFFECTED BY NICOTINE.
205623 03-14

RELATIONSHIP BETWEEN THE LATE REFLEX DISCHARGE AND LOCOMOTOR MOVEMENTS IN ACUTE SPINAL CATS AND RABBITS WITH DOPA.
209728 03-03

ROLE OF THE STRIO-PALLIDAL SYSTEM AND MOTOR CORTEX IN INDUCED CIRCUS MOVEMENTS IN RATS AND CATS.
213450 04-03

DECREASED TEMPORAL VARIABILITY IN HIPPOCAMPAL THETA RHYTHMS OF CATS ADMINISTERED METHYLPHENIDATE.
213855 04-03

INFLUENCE OF TEMPIDON ON THE EEG OF CATS AT A SINGLE AND REPEATED APPLICATION.
215076 04-03

TOWARD THE QUESTION OF THE INFLUENCE OF STIMULATION OF THE THALAMIC ASSOCIATIVE NUCLEI ON THE BEHAVIOR OF CATS.
215498 04-04

EFFECTS OF SCOPOLAMINE AND ALPHA-METHYL-P-TYROSINE UPON PREDATORY ATTACK IN CATS.
217526 04-04

THE INFLUENCE OF PHARMACOLOGICAL AGENTS ON THE CONSEQUENCES OF EMOTIONAL EXCITATION IN CATS.
218814 04-04

EFFECT OF OUABAIN AND PHENOBARBITAL ON OXIDATIVE METABOLIC ACTIVITY ASSOCIATED WITH SPREADING CORTICAL DEPRESSION IN CATS.
220944 04-03

ELECTROPHYSIOLOGICAL AND BEHAVIORAL EFFECTS OF 1-METHYL-5-O-FLUOROPHENYL 7-CHLORODIHYDROBENZODIAZEPIN-2-ONE (ID-540) IN CATS AND RABBITS.
221736 04-03

CAUDATE

ACTION OF NEUROLEPTICS ON THE CONTENT OF DOPAMINE AND DOPAC IN THE RAT CAUDATE NUCLEUS.
197682 01-03

UPTAKE OF NEUROTRANSMITTERS INTO SUBCELLULAR PARTICLES OF THE CAUDATE NUCLEUS.
197962 01-03

COMPARATIVE EFFECT OF PHENAMINE (AMPHETAMINE) AND CAFFEINE ON THE BACKGROUND ACTIVITY OF CORTICAL SENSORIMOTOR NEURONS AND THEIR REACTIONS DURING STIMULATION OF THE CAUDATE NUCLEUS.
198835 02-03

THE NUCLEUS LINEARIS INTERMEDIUS RAPHE AND BEHAVIOUR EVOKED BY DIRECT AND INDIRECT STIMULATION OF DOPAMINE SENSITIVE SITES WITHIN THE CAUDATE NUCLEUS OF CATS.
199864 02-04

AMANTADINE AND D-145, AN AMANTADINE DERIVATIVE, DO NOT EFFECT DOPAMINE SENSITIVE ADENYLATE-CYCLASE FROM THE CAUDATE PUTAMEN OF THE RAT BRAIN.
199867 02-03

THE INFLUENCE OF ALPHA-METHYLTYROSINE AND DISULFIRAM ON THE INHIBITORY FUNCTION OF THE CAUDATE NUCLEUS AND CATECHOLAMINE CONTENT IN THE BRAIN OF CATS.
200565 02-03

THE EFFECT OF INHIBITORS OF CATECHOLAMINE SYNTHESIS (ALPHA-METHYLTYROSINE AND DISULFIRAM) ON THE BACKGROUND ACTIVITY OF SENSORIMOTOR CORTEX NEURONS AND THEIR RESPONSES TO AFFERENT CAUDATE AND RETICULAR STIMULATION.
202598 02-04

6-HYDROXYDOPAMINE LESIONS OF OLFACTORY TUBERCLES AND CAUDATE NUCLEI: EFFECT ON AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR IN RATS.
202788 02-04

TRICYCLIC ANTIDEPRESSANT DRUGS AND DOPAMINE SENSITIVE ADENYLCYCLASE FROM RAT CAUDATE NUCLEI.
206990 03-03

BIOCHEMICAL CHARACTERIZATION OF THE DOPAMINE RECEPTOR IN THE MAMMALIAN CAUDATE NUCLEUS.
207297 03-03

ADENOSINE-3-5-MONOPHOSPHATE CONTENT IN RAT CAUDATE NUCLEUS: DEMONSTRATION OF DOPAMINERGIC AND ADRENERGIC RECEPTORS.
208300 03-03

RECOVERY OF FUNCTION AND CHANGES IN SENSITIVITY TO AMPHETAMINE FOLLOWING CAUDATE LESIONS IN RATS.
209962 03-03

COMPARATIVE TIME-DEPENDENT CHANGES IN SENSITIVITY TO LOCOMOTOR EFFECTS OF D-AMPHETAMINE IN MICE WITH CAUDATE, HIPPOCAMPAL OR FRONTAL CORTICAL LESIONS.
210926 03-03

DIFFERENTIAL EFFECTS OF THE OPTICAL ISOMERS OF AMPHETAMINE ON NEURONAL ACTIVITY IN THE RETICULAR FORMATION AND CAUDATE NUCLEUS OF THE RAT.
211063 03-03

APOMORPHINE-INDUCED ROTATION IN NORMAL RATS AND INTERACTION WITH UNILATERAL CAUDATE LESIONS.
214012 04-04

D-AMPHETAMINE INDUCED RELEASE OF NEWLY SYNTHESIZED AND STORED DOPAMINE FROM THE CAUDATE NUCLEUS IN VIVO.
214110 04-03

A COMPARISON BETWEEN CAUDATE, AMYGDALOID AND HYPOTHALAMIC SELF-STIMULATION IN SQUIRREL MONKEYS (SAIMIRI-SCIUREUS). (PH.D. DISSERTATION).
214207 04-04

CONTRASTING LOCAL EFFECTS OF MAO INHIBITORS ON CAUDATE TREMOR ACTIVITIES.
217669 04-03

APPARENT FEEDBACK FROM THE CAUDATE NUCLEUS TO THE SUBSTANTIA-NIGRA FOLLOWING AMPHETAMINE ADMINISTRATION.
217676 04-03

THE EFFECT OF PSYCHOTROPIC AGENTS ON THE ELECTROENCEPHALOGRAPHIC CHARACTERISTICS OF THE INHIBITORY FUNCTION OF THE CAUDATE NUCLEUS.
219500 04-03

DOPAMINE SENSITIVE ADENYLCYCLASE IN HUMAN CAUDATE NUCLEUS: A STUDY IN CONTROL SUBJECTS AND SCHIZOPHRENIC PATIENTS.
221732 04-13

THE DOPAMINERGIC COMPONENT IN THE ACTION OF D,L-AMPHETAMINE ON THE INHIBITORY FUNCTION OF THE CAUDATE NUCLEUS.
223014 04-03

CHANGES IN MORPHINE SELF-ADMINISTRATION AND MORPHINE-DEPENDENCE AFTER LESIONS OF THE CAUDATE NUCLEUS IN RATS.
225560 04-04

CAUDATES

NEURONAL ACTIVITY OF NUCLEUS CAUDATES AND THALAMUS DURING BARBITURATE SPINDLES IN RATS.
201479 02-03

CAUSAL

EVIDENCE AGAINST A CAUSAL RELATIONSHIP BETWEEN INCREASE IN C-AMP AND INDUCTION OF TYROSINE-HYDROXYLASE IN THE RAT ADRENAL MEDULLA.
202795 02-03

CAUTION

LITHIUM INHIBITION OF CAMP-MEDIATED HORMONES: A CAUTION.
209352 03-03

CA2+

EFFECT OF ALCOHOLS, CHLORPROMAZINE AND DIPHENYLHYDANTOIN ON (CA2+) ATPASE OF HUMAN RED BLOOD CELLS.
197976 01-13

CB-154

CB-154 (2-BROMO-ALPHA-ERGOKRYPTINE, BROMOCRIPTIN), A POTENTIAL ANTIPARKINSON AGENT.
197949 01-04

CBD

ABSENCE OF INTERACTION BETWEEN DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) AND CANNABIDIOL (CBD) IN AGGRESSION, MUSCLE CONTROL AND BODY TEMPERATURE EXPERIMENTS IN MICE.
217474 04-04

CELL

THE INHIBITORY EFFECT OF TOLUIDINE BLUE AND METHYLENE BLUE ON RAT MAST CELL DAMAGE BY PROMETHAZINE, CHLORPROMETHAZINE AND CHLORPROMAZINE. ITS REVERSAL BY GLUCOSE.
199255 02-05

RED BLOOD CELL LITHIUM INDEX IN PATIENTS WITH AFFECTIVE DISORDERS IN THE COURSE OF LITHIUM PROPHYLAXIS.
202786 02-09

PRESENCE OF DOPAMINERGIC TERMINALS AND ABSENCE OF DOPAMINERGIC CELL BODIES IN THE CEREBRAL CORTEX OF THE CAT.
210800 03-03

DIFFERENTIAL EFFECTS OF CAFFEINE, D-AMPHETAMINE AND METHYLPHENIDATE ON INDIVIDUAL RAPHE CELL FLUORESCENCE: A MICROSPECTROFLUORIMETRIC DEMONSTRATION.
213400 04-03

RED CELL FOLATE AND MACROCYTOSIS DURING LONG-TERM ANTICONVULSANT THERAPY IN NONANAEMIC MENTALLY RETARDED EPILEPTICS.
218553 04-11

LITHIUM IN NONMANIC DEPRESSIVES: ANTIAGGRESSIVE EFFECT AND RED BLOOD CELL LITHIUM VALUES.
222604 04-09

CELLS

ADENOSINE 3,5 MONOPHOSPHATE IN CULTURED NEUROBLASTOMA CELLS: EFFECT OF ADENOSINE, PHOSPHODIESTERASE INHIBITORS AND BENZAZEPINES.
195254 01-03

PHARMACOLOGY OF PYRAMIDAL TRACT CELLS IN THE CEREBRAL CORTEX: NORADRENALINE AND RELATED SUBSTANCES.
195438 01-03

EFFECTS OF MORPHINE, CHOLINERGIC AGENTS AND COLD EXPOSURE ON MIDBRAIN DOPAMINE (DA) NERVE CELLS OF MORPHINE TOLERANT AND NONTOLERANT MICE.
197287 01-03

EFFECT OF ALCOHOLS, CHLORPROMAZINE AND DIPHENYLHYDANTOIN ON (CA2+) ATPASE OF HUMAN RED BLOOD CELLS.
197976 01-13

THE LEVELS OF LITHIUM IN SERUM AND IN RED BLOOD CELLS AND ITS RATIOS IN MANIC-DEPRESSIVE PATIENTS.
205607 03-09

THE TOXICITY OF CHLORPROMAZINE AND MESCALINE ON MOUSE CEREBELLUM AND FIBROBLAST CELLS IN CULTURE.
210890 03-03

INHIBITORY EFFECT OF NEONATAL ESTROGENIZATION ON THE INCORPORATION OF (3H)LYSINE IN THE PURKINJE CELLS OF THE ADULT MALE AND FEMALE RAT.
213478 04-03

BINDING OF (+) AMPHETAMINE AND (-) DELTA1-TETRAHYDROCANNABINOLS AND (-) 7-HYDROXY-DELTA1-TETRAHYDROCANNBINOL TO BLOOD CELLS AND PLASMA PROTEINS IN MAN.
217878 04-13

SYNERGISM BETWEEN GAMMA-AMINOBUTYRIC ACID AND BUTYROPHENONES ADMINISTERED MICROELECTROPHORETICALLY IN THE PURKINJE CELLS OF THE CAT CEREBELLUM.
220904 04-03

CELLULAR

CELLULAR MECHANISMS OF CHLORPROMAZINE PHOTOSENSITIVITY.
204233 02-15

INHIBITION OF CELLULAR ATP HYDROLYZING ACTIVITY BY TRICYCLIC ANTIDEPRESSANTS AND PHENOTHIAZINE TRANQUILIZERS.
221053 04-03

CENSEDAL

TREATMENT OF ANXIOUS PATIENTS WITH NEALBARBITONE -- (CENSEDAL).
194556 01-10

CENTRAL

COMPARATIVE INVOLVEMENT OF DOPAMINE AND NORADRENALINE IN RATE-FREE SELF-STIMULATION IN SUBSTANTIA-NIGRA, LATERAL HYPOTHALAMUS, AND MESENCEPHALIC CENTRAL GRAY.
193303 01-03

CENTRAL IMPLANTATION OF CANNABINOIDS: INDUCTION OF EPILEPTIFORM DISCHARGES.
193449 01-03

STEREOCHEMICAL STUDIES ON POTENTIAL CENTRAL NERVOUS SYSTEM ACTIVE AGENTS AND STUDIES ON THE CHEMISTRY OF SOME 3-BENZOYLPIPERIDINES. (PH.D. DISSERTATION).
193586 01-01

REGIONAL DISTRIBUTION OF CATIONS AND THEIR RELATION TO THE NEUROCHEMISTRY OF EXPERIMENTAL EPILEPSY, NEUROTRANSMITTERS AND ATPASE IN THE CENTRAL NERVOUS SYSTEM. (PH.D. DISSERTATION).
193588 01-03

EFFECTS OF CENTRAL ACTING DRUGS AND ERGOT DERIVATIVES ON PROLACTIN AND GROWTH HORMONE SECRETION, ON GROWTH OF PITUITARY AND MAMMARY TUMORS AND ON REPRODUCTION IN OLD RATS. (PH.D. DISSERTATION).
194571 01-03

INHIBITION OF THE CATALYTIC SITE OF ADENYLATE-CYCLASE IN THE CENTRAL NERVOUS SYSTEM BY PHENOTHIAZINE DERIVATIVES.
195096 01-03

CENTRAL NERVOUS SYSTEM ALPHA-ADRENERGIC RECEPTORS AND THE MODE OF ACTION OF ALPHA-METHYLDOPA.
195237 01-03

FURTHER EVIDENCE FOR THE HETEROGENEOUS STORAGE OF NORADRENALINE IN CENTRAL NORADRENERGIC TERMINALS.
195239 01-03

ADRENERGIC RECEPTOR BLOCKING AGENTS: EFFECTS ON CENTRAL NORADRENALINE AND DOPAMINE RECEPTORS AND ON MOTOR ACTIVITY.
195429 01-03

NEUROPHARMACOLOGICAL STUDIES OF EFFECT OF NEW CENTRAL DEPRESSANT, 8-CHLOR-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D40TA) ON EEG AND CENTRAL SYMPATHETIC ACTIVATING MECHANISM IN CATS.
195549 01-03

CLINICAL MEASUREMENT OF CENTRAL DOPAMINE AND SEROTONIN METABOLISM IN ACUTE PSYCHOTIC DISORDERS.
195924 01-09

AGE RELATED ENHANCED RESPONSIVENESS TO CENTRAL NERVOUS SYSTEM DRUGS IN RATS. (PH.D. DISSERTATION).
196256 01-03

ACTION OF PROBENECID ON THE CENTRAL NERVOUS SYSTEM OF THE RABBIT: II. POTENTIATION OF 5-HYDROXYTRYPTOPHAN-INDUCED HYPERTHERMIA AND SUPPRESSION OF THIS EFFECT BY A DECARBOXYLASE INHIBITOR (RO-4-4602).
196580 01-03

ON THE INHIBITION OF PERIPHERAL AND CENTRAL NORADRENERGIC NEUROTRANSMISSION BY CLONIDINE.
197295 01-03

CENTRAL PHARMACOLOGICAL ACTIVITIES OF 4-PHENYL-6-CHLORO-1,4-DIHYDRO-2H-3,1 BENZOXAZIN-2-ONE.
197453 01-03

CENTRAL ACTION OF ANOREXIC AGENTS: EFFECTS OF AMPHETAMINE AND FENFLURAMINE IN RATS WITH LATERAL HYPOTHALAMIC LESIONS.
197865 01-04

THE ACTION OF BICUCULLINE UPON ACETYLCHOLINE-INDUCED EXCITATIONS OF CENTRAL NEURONS.
197993 01-03

EFFECT ON PSEUDOCONDITIONING OF DRUGS WITH KNOWN CENTRAL NERVOUS ACTIVITY.
198228 02-04

THE INFLUENCE OF SODIUM OXYBUTYRATE ON INTERNEURONAL TRANSMISSION OF EXCITATION AT VARIOUS LEVELS OF THE CENTRAL NERVOUS SYSTEM.
198435 02-03

ONTOGENETIC ASPECTS OF CENTRAL CHOLINERGIC INVOLVEMENT IN SPONTANEOUS ALTERNATION BEHAVIOR.
199550 02-04

LOCUS OF CENTRAL DEPRESSANT ACTION OF FLUNITRAZEPAM.
199811 02-03

ELECTROENCEPHALOGRAPHIC AND BEHAVIORAL STUDIES ON THE CENTRAL ACTION OF NIMETAZEPAM (S-1530) IN CATS.
199910 02-04

THE RELATIONSHIP OF CENTRAL MONOAMINES TO DRUG-INDUCED SLEEP IN THE RAT, EXAMINED ON A 24-HOUR BASIS. (PH.D. DISSERTATION).
201005 02-03

STIMULUS PROPERTIES OF MESCALINE AND N-METHYLATED DERIVATIVES: DIFFERENCE IN PERIPHERAL AND DIRECT CENTRAL ADMINISTRATION.
201320 02-02

EVIDENCE FOR THE FUNCTIONAL INTERACTION OF TWO CENTRAL NEUROTRANSMITTERS.
201324 02-03

THE INFLUENCE OF PROLONGED APPLICATION OF TRANQUILIZERS AND ANTIDEPRESSANTS ON THE SUMMATIONAL CAPACITY OF THE CENTRAL NERVOUS SYSTEM.
201913 02-03

THE EFFECT OF SEDUXEN ON THE PERCEPTIVE AND SOME OTHER FUNCTIONS OF THE CENTRAL NERVOUS SYSTEM UNDER EMOTIONAL STRESS IN MAN.
201916 02-14

ELECTROENCEPHALOGRAPHIC STUDY OF THE LOCAL TRANSPORT OF CENTRAL NERVOUS STIMULANTS INTO THE BRAIN.
202165 02-03

EFFECTS OF CENTRAL AND PERIPHERAL ADRENERGIC AND CHOLINERGIC MODIFICATION ON TIME-DEPENDENT PROCESSES IN AVOIDANCE PERFORMANCE.
202203 02-03

CENTRAL EFFECTS OF THREE FLUORINATED BENZODIAZEPINES IN COMPARISON WITH DIAZEPAM.
202765 02-03

THE PHARMACOLOGY OF GROSS BEHAVIOURAL EFFECTS OF CHOLINOMIMETIC SUBSTANCES INJECTED INTO THE CEREBRAL VENTRICLES OF UNANAESTHETIZED CATS: EVIDENCE FOR CENTRAL MUSCARINIC MEDIATION.
202780 02-04

AN ANALYSIS OF THE GROSS BEHAVIOURAL CHANGES INDUCED BY TETRAETHYLAMMONIUM AND A COMPARISON WITH OTHER SUBSTANCES AFFECTING THE AUTONOMIC AND CENTRAL NERVOUS SYSTEM AFTER INTRAVENTRICULAR INJECTIONS TO CONSCIOUS CATS.
202781 02-04

THE PERIPHERAL AND CENTRAL ROLE OF THE CATECHOLAMINES IN THE MECHANISMS OF ANXIETY.
202783 02-17

ALPHA-RECEPTOR MEDIATED MODULATION OF TRANSMITTER RELEASE FROM CENTRAL NORADRENERGIC NEURONES.
202805 02-03

WAYS OF DEMONSTRATING AND DIFFERENTIATING CENTRAL NERVOUS EFFECTS OF DRUGS IN ANIMAL EXPERIMENTS.
202944 02-06

CENTRAL NERVOUS SYSTEM CARBONIC ANHYDRASE INHIBITORS. (PH.D. DISSERTATION).
203028 02-03

LSD AS AN AGONIST AND ANTAGONIST AT CENTRAL DOPAMINE RECEPTORS.
204184 02-03

BIOCHEMICAL EFFECTS OF DIHYDROXYLATED TRYPTAMINES ON CENTRAL INDOLEAMINE NEURONES.
204340 02-03

CENTRAL NERVOUS ACTION OF L-DOPA.
204424 02-04

THIORIDAZINE: CENTRAL DOPAMINE TURNOVER AND CLINICAL EFFECTS OF ANTIPSYCHOTIC DRUGS.
204852 02-08

CENTRAL CHOLINERGIC INFLUENCE ON SELF-ADMINISTRATION OF MORPHINE AND AMPHETAMINE.
205889 03-04

CENTRAL ACTIONS OF SOME BETA-ADRENOCEPTOR BLOCKING AGENTS.
206782 03-03

AGE RELATED RESPONSIVENESS OF THE RAT TO DRUGS AFFECTING THE CENTRAL NERVOUS SYSTEM.
206912 03-03

CENTRAL DOPAMINE NEURONS AND SENSORY PROCESSING.
207304 03-03

CENTRAL CATECHOLAMINE NEURONS, BEHAVIOR AND NEUROLEPTIC DRUGS: AN ANALYSIS TO UNDERSTAND THE INVOLVEMENT OF CATECHOLAMINES IN SCHIZOPHRENIA.
207305 03-03

LONG-TERM EFFECTS OF P-CHLOROAMPHETAMINE AND RELATED DRUGS ON CENTRAL SEROTONERGIC MECHANISMS.
208553 03-03

AMINES AND DISORDERS OF THE CENTRAL NERVOUS SYSTEM.
210635 03-09

MEMORY ENHANCEMENT BY CENTRAL ADMINISTRATION OF NOREPINEPHRINE.
210671 03-04

OXIDATIVE METABOLISM OF MESCALINE IN THE CENTRAL NERVOUS SYSTEM -- V. IN VITRO DEAMINATION OF MESCALINE TO 3,4,5 TRIMETHOXYBENZOIC ACID.
210813 03-03

EFFECT OF ERGOT DRUGS ON CENTRAL 5-HYDROXYTRYPTAMINE NEURONS: EVIDENCE FOR 5-HYDROXYTRYPTAMINE RELEASE OR 5-HYDROXYTRYPTAMINE RECEPTOR STIMULATION.
210857 03-03

EFFECTS OF HYPERBARIC CONDITIONS ON THE RESPONSE OF ANIMALS TO CENTRAL NERVOUS SYSTEM STIMULANTS AND DEPRESSANTS.
210877 03-03

ACTION OF STRYCHNINE AND CENTRAL DEPRESSANTS ON THE CEREBELLO-RUBRAL SYSTEM.
210881 03-03

AN INVESTIGATION ON THE BEHAVIORAL AND HYPOTHERMIC EFFECTS OF YOHIMBINE: INTERACTION WITH DRUGS AFFECTING CENTRAL AND PERIPHERAL MONOAMINES.
211068 03-04

THE CENTRAL ANTICHOLINERGIC SYNDROME: MANAGEMENT WITH PHYSOSTIGMINE.
211427 03-15

HYPOTHALAMIC SELF-STIMULATION IN RATS FOLLOWING IMMUNOSYMPATHECTOMY OR CENTRAL NERVE GROWTH FACTOR ANTISERUM INJECTION.
211512 03-04

THE EFFECT OF CHLORPROMAZINE AND STIMULATION OF THE MESENCEPHALIC RETICULAR FORMATION ON CENTRAL AROUSAL AND ON THE VISUAL EVOKED RESPONSE. (PH.D. DISSERTATION).
212547 03-03

NERVE IMPULSE ENHANCED RELEASE OF AMINO ACIDS FROM NONSYNAPTIC REGIONS OF PERIPHERAL AND CENTRAL NERVE TRUNKS OF BULLFROG.
213277 03-03

RESPONSES OF CENTRAL NEURONES TO AMANTADINE: COMPARISON WITH DOPAMINE AND AMPHETAMINE.
213398 04-03

EFFECT OF CENTRAL NERVOUS SYSTEM LESIONS ON DRUG ACTION.
213611 04-03

CENTRAL NEUROPHYSIOLOGY OF THE FUNCTIONAL PSYCHOSES.
213614 04-11

CATECHOLAMINES AS CENTRAL NERVOUS TRANSMITTERS.
213620 04-03

THE EFFECT OF PENFLURIDOL AND SOME PSYCHOTROPIC DRUGS ON MONOAMINE METABOLISM IN CENTRAL NERVOUS SYSTEM.
215686 04-03

CHOLINERGIC AGENTS AFFECT TWO RECEPTORS THAT MODULATE TRANSMITTER RELEASE AT A CENTRAL SYNAPSE IN APLYSIA-CALIFORNICA.
215705 04-03

CENTRAL ANTICHOLINERGIC ACTIONS OF DOXEPIN IN RABBITS.
215727 04-03

KININS AND CENTRAL EFFECTS OF THE ACETYLCHOLINE.
215749 04-04

SLEEP AND BEHAVIORAL CHANGES REFLECTING CENTRAL RECEPTOR HYPERSENSITIVITY FOLLOWING CATECHOLAMINE SYNTHESIS INHIBITION IN MAN. (UNPUBLISHED PAPER).
216373 04-09

SOME GENERAL PRINCIPLES OF THE MECHANISM OF THE CENTRAL ACTION OF PSYCHOTOMIMETICS.
216999 04-12

EEG SPECTRAL ANALYSIS FOR THE EVALUATION OF THE CENTRAL EFFECTS OF DELTA6-TETRAHYDROCANNABINOL IN RABBITS.
217467 04-03

EFFECTS OF CENTRAL DOPAMINERGIC BLOCKADE WITH PIMOZIDE UPON THE EEG STAGES OF SLEEP IN MAN.
217546 04-14

A RAPID, SIMPLE AND MORE SENSITIVE METHOD FOR THE DEMONSTRATION OF CENTRAL CATECHOLAMINE CONTAINING NEURONS AND AXONS BY GLYOXYLIC ACID INDUCED FLUORESCENCE: I. SPECIFICITY.
217550 04-16

THE EFFECT OF LSD AND 2-BROMOLSD ON THE DOPA ACCUMULATION AFTER CENTRAL AND PERIPHERAL DECARBOXYLASE INHIBITION.
217674 04-03

5-HYDROXYTRYPTAMINE IN THE CENTRAL NERVOUS SYSTEM AND SEXUAL RECEPTIVITY OF FEMALE RHESUS MONKEYS.
217856 04-04

6-HYDROXYDOPA DURING DEVELOPMENT OF CENTRAL ADRENERGIC NEURONS PRODUCES DIFFERENT LONG-TERM CHANGES IN RAT BRAIN NORADRENALINE.
217867 04-03

CORRELATED HISTOCHEMICAL, ELECTRON MICROSCOPICAL, PHARMACOLOGICAL AND PHYSIOLOGICAL OBSERVATION ON AMINERGIC MECHANISMS IN THE CENTRAL NERVOUS SYSTEM. (UNPUBLISHED PAPER).
218300 04-03

OBSERVATIONS ON EFFECTS OF A CENTRAL STIMULANT DRUG (METHYLPHENIDATE) IN CHILDREN WITH HYPERACTIVE BEHAVIOR.
219354 04-14

A BENZODIOXANHYDROXYETHYLPIPERIDINE DERIVATIVE WITH ACUTE CENTRAL HYPOTENSIVE ACTION, DIFFERENT FROM THAT OF CLONIDINE: A COMPARISON WITH NEUROLEPTIC AGENTS.
220976 04-03

CENTRAL STIMULATING AGENTS AND POPULATION GROWTH IN MICE.
221052 04-04

ANTAGONISM OF PSYCHOSTIMULANT 2 PHENYLDIMETHYLTETRAHYDROOXAZINE HYDROCHLORIDE (G-130) TO CENTRAL NERVOUS SYSTEM DEPRESSING DRUGS: MONOAMINEOXIDASE INHIBITORY ACTIVITY AND NOREPINEPHRINE AND SEROTONIN INDUCED CHANGES, COMPARISON WITH DL-AMPHETAMINE.
221267 04-03

INFLUENCE OF CHEMICAL STIMULATION OF CENTRAL DOPAMINERGIC SYSTEM ON THE OPEN-FIELD BEHAVIOR OF RATS.
221308 04-03

THE ACTION OF DELTA9-TETRAHYDROCANNABINOL ON CENTRAL CARDIOVASCULAR REGULATION: MECHANISM AND LOCALIZATION.
221669 04-03

BLOCKADE OF THE CENTRAL EFFECTS OF D-AMPHETAMINE BY AMANTADINE II.
221737 04-03

PHARMACOLOGICAL ACTION OF FD-008, A NEW DOPAMINE-BETA-HYDROXYLASE INHIBITOR: II. EFFECTS ON CENTRAL NERVOUS SYSTEM IN MICE AND RATS.
221823 04-02

CENTRAL NERVOUS SYSTEM PHARMACOLOGY OF CHOLINERGICALLY ELICITED EATING AND DRINKING BEHAVIOR IN THE ALBINO RAT. (PH.D. DISSERTATION).
222638 04-04

EFFECTS OF METHYLPHENIDATE HYDROCHLORIDE ON THE CENTRAL NERVOUS SYSTEM. (PH.D. DISSERTATION).
222641 04-03

CENTRAL CATECHOLAMINE RECEPTOR BLOCKING ACTIONS OF BE-2254 (HEAT): COMPARISON WITH CHLORPROMAZINE AND HALOPERIDOL.
222804 04-03

RAPID ANALYSIS OF THE CENTRAL NERVOUS SYSTEM STIMULANTS, AMPHETAMINES, VIA GAS CHROMATOGRAPHY MASS SPECTROMETRY: RAPID ACYLATION IN THE PRESENCE OF A MERCURY CATALYST.
222830 04-06

CENTRALLY

EFFECT OF CHRONIC ADMINISTRATION OF CENTRALLY ACTING COMPOUNDS ON CHLORAMPHENICOL METABOLISM IN SCHIZOPHRENIC PATIENTS.
194157 01-08

INTERACTION BETWEEN ANTIDEPRESSANT AND CENTRALLY ACTING ANTIHYPERTENSIVE DRUGS.
197300 01-03

THE EFFECT OF DRUGS WITH ANTIDEPRESSANT ACTIVITY UPON THE HYPOTHERMIA AND BEHAVIOURAL DEPRESSION INDUCED IN MICE BY PIMOZIDE OR CENTRALLY ADMINISTERED NORADRENALINE.
210762 03-04

EFFECTS OF THYROTROPIN-RELEASING HORMONE (TRH) ON THE ACTIONS OF PENTOBARBITAL AND OTHER CENTRALLY ACTING DRUGS.
215692 04-03

INHIBITION OF EFFERENT SYMPATHETIC NERVE ACTIVITY BY 5-HYDROXYTRYPTOPHAN AND CENTRALLY ADMINISTERED 5-HYDROXYTRYPTAMINE.
215712 04-03

CENTRALLY MEDIATED CARDIOVASCULAR EFFECTS OF 5-HYDROXYTRYPTOPHAN IN MAO INHIBITED DOGS: MODIFICATION BY AUTONOMIC ANTAGONISTS.
215757 04-03

CENTRALLY ACTIVE PHENETHYLAMINES.
217557 04-12

INTERACTION BETWEEN CENTRALLY ACTING HYPOTENSIVE DRUGS AND TRICYCLIC ANTIDEPRESSANTS.
217575 04-03

STATE-DEPENDENT LEARNING WITH CENTRALLY AND NONCENTRALLY ACTIVE DRUGS.
219020 04-04

EFFECTS OF ANALGETICS ON CENTRALLY INDUCED PAIN IN RATS. (PH.D. DISSERTATION).
222640 04-03

CEREBELLAR

THE EFFECTS OF DIPHENYLAMINOETHANOL (DPAE) AND LIDOCAINE ON CEREBELLAR INHIBITION DEITERS NEURONS. (PH.D. DISSERTATION).
196259 01-03

SELECTIVE DIPHENYLHYDANTOIN SUPPRESSION OF AUDITORY EVOKED POTENTIALS IN THE CAT CEREBELLAR CORTEX.
197989 01-03

LIPIDOSIS LIKE ALTERATIONS IN SPINAL CORD AND CEREBELLAR CORTEX OF RATS TREATED WITH CHLORPHENTERMINE OR TRICYCLIC ANTIDEPRESSANTS.
202767 02-03

INHIBITION BY DIAZEPAM OF THE TREMOR AND THE INCREASE OF CEREBELLAR CGMP CONTENT ELICITED BY HARMALINE.
207798 03-03

RESPONSES OF CULTURED CEREBELLAR NEURONS TO IONTOPHORETICALLY APPLIED AMINO ACIDS.
213279 03-03

THE EFFECT OF SOME NEUROTROPIC DRUGS ON THE PHASIC CHANGES OF ARTERIAL PRESSURE EVOKED BY STIMULATION OF THE CEREBELLAR FASTIGAL NUCLEUS.
217067 04-03

CYCLIC-GMP: REDUCTION OF CEREBELLAR CONCENTRATIONS IN NERVOUS MUTANT MICE.
221031 04-03

CEREBELLO-RUBRAL

ACTION OF STRYCHNINE AND CENTRAL DEPRESSANTS ON THE CEREBELLO-RUBRAL SYSTEM.
210881 03-03

CEREBELLUM

THE REGULATION OF CYCLIC GUANOSINE MONOPHOSPHATE IN RAT CEREBELLUM: POSSIBLE INVOLVEMENT OF PUTATIVE AMINO ACID NEUROTRANSMITTERS.
202717 02-03

THE TOXICITY OF CHLORPROMAZINE AND MESCALINE ON MOUSE CEREBELLUM AND FIBROBLAST CELLS IN CULTURE.
210890 03-03

THE IN VIVO REGULATION OF CGMP CONTENT IN RAT CEREBELLUM: A STUDY OF THE ACTION OF TAURINE.
215654 04-03

SYNERGISM BETWEEN GAMMA-AMINOBUTYRIC ACID AND BUTYROPHENONES ADMINISTERED MICROELECTROPHORETICALLY IN THE PURKINJE CELLS OF THE CAT CEREBELLUM.
220904 04-03

CEREBRAL

COMPARATIVE STUDY OF THE EFFECTS OF CHLORAL HYDRATE AND TRICHLOROETHANOL ON CEREBRAL METABOLISM.
194742 01-03

PHARMACOLOGY OF PYRAMIDAL TRACT CELLS IN THE CEREBRAL CORTEX: NORADRENALINE AND RELATED SUBSTANCES.
195438 01-03

BLOCKADE BY ESERINE OF THE CEREBRAL CORTICAL EFFECTS OF ALLOFERIN: A FURTHER EVIDENCE OF CHOLINERGIC INHIBITORY MECHANISM.
195548 01-03

THE INCORPORATION OF GLUCOSE INTO BRAIN GLYCOGEN AND THE ACTIVITIES OF CEREBRAL GLYCOGEN PHOSPHORYLASE AND SYNTHETASE: SOME EFFECTS OF AMPHETAMINE.
196808 01-03

EFFECTS OF L-DOPA AND L-TRYPTOPHAN ON THE CEREBRAL BLOOD FLOW IN THE DOG.
197213 01-03

EFFECTS OF NORADRENALINE ON THE CEREBRAL BLOOD FLOW IN THE DOG.
197214 01-03

EFFECTS OF 5-HYDROXYTRYPTAMINE ON THE CEREBRAL BLOOD FLOW IN THE DOG.
197215 01-03

ADENOSINE-3-5-MONOPHOSPHATE IN CEREBRAL CORTICAL SLICES FROM GUINEA-PIG AND RAT: EFFECT OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC COMPOUNDS.
197293 01-03

THE INFLUENCE OF CHLORPROMAZINE AND RESERPINE ON THE METABOLISM OF CEREBRAL PHOSPHOLIPIDS IN THE RAT IN VIVO.
197477 01-03

THYROTROPIN-RELEASING HORMONE: ACTIVATION OF CEREBRAL NORADRENALINE TURNOVER.
197950 01-03

STUDIES ON THE UPTAKE OF D-AMPHETAMINE BY RAT CEREBRAL CORTEX SLICES.
197961 01-03

ADENOSINE-3-5-MONOPHOSPHATE IN CEREBRAL CORTICAL SLICES FROM GUINEA-PIG AND RAT: EFFECT OF BENZODIAZEPINES.
197972 01-03

SENSITIVITY OF DENERVATED CEREBRAL CORTEX TO CHOLINOMIMETICS.
199769 02-03

EFFECT OF LIMBIC SYSTEM LESIONS ON ACETYLCHOLINE RELEASE FROM THE CEREBRAL CORTEX OF THE RAT.
200044 02-03

DPAM AND CEREBRAL FUNCTION (SECOND REPORT): PSYCHOPHARMACOLOGICAL IMPLICATIONS.
202162 02-11

THE EFFECT OF TRIIODOTHYRONINE IN COMBINATION WITH IMIPRAMINE ON (3H) CYCLIC-AMP PRODUCTION IN SLICES OF RAT CEREBRAL CORTEX.
202777 02-03

THE PHARMACOLOGY OF GROSS BEHAVIOURAL EFFECTS OF CHOLINOMIMETIC SUBSTANCES INJECTED INTO THE CEREBRAL VENTRICLES OF UNANAESTHETIZED CATS: EVIDENCE FOR CENTRAL MUSCARINIC MEDIATION.
202780 02-04

EFFECTS OF 5-HYDROXYINDOLEACETIC ACID ON ISOLATED CANINE CEREBRAL ARTERIES.
202799 02-03

THE ROLE OF CEREBRAL CYCLIC-AMP IN THE ACTION OF PSYCHOTROPIC DRUGS: IN VIVO AND IN VITRO STUDIES. (PH.D. DISSERTATION).
203032 02-03

EFFECTS OF PHENOBARBITAL ON ELECTROCORTICOGRAM AND ACTIVITY, ON REGIONAL CNS ENERGY METABOLISM, AND ON PRESYNAPTIC EVENTS IN CEREBRAL CORTEX AND BRAINSTEM. (PH.D. DISSERTATION).
203033 02-03

THE INFLUENCE OF ANTIADRENERGIC AND ANTIDOPAMINERGIC DRUGS ON METHAMPHETAMINE INDUCED CHANGES IN MOTORIC ACTIVITY AND CEREBRAL GLYCOGEN CONTENT IN MICE.
204396 02-03

COMPUTERIZED CEREBRAL BIOPOTENTIALS IN THE DISCOVERY OF PSYCHOTROPIC DRUGS.
205434 02-13

CEREBRAL HEMODYNAMIC EFFECTS OF CHRONIC TRYPTOPHAN FEEDING IN MAN AS MEASURED BY QUANTIFIED CEREBRAL IMPEDANCE PLETHYSMOGRAPHY.
206337 03-08

CEREBRAL AND PERIPHERAL CONSUMPTION OF L-5-HTP BY PATIENTS SUFFERING FROM MANIACAL, DEPRESSIVE OR PSYCHOTIC SYMPTOMS.
206834 03-10

BRAIN CATECHOLAMINES AND CEREBRAL BLOOD FLOW.
209839 03-17

CEREBRAL FUNCTIONAL EFFECTS OF 2-DEOXY-D-GLUCOSE AND 3-O-METHYLGLUCOSE IN RHESUS MONKEYS.
210355 03-03

PRESENCE OF DOPAMINERGIC TERMINALS AND ABSENCE OF DOPAMINERGIC CELL BODIES IN THE CEREBRAL CORTEX OF THE CAT.
210800 03-03

DETAILED NORADRENALINE PATHWAYS OF LOCUS-COERULEUS NEURON TO THE CEREBRAL CORTEX WITH THE USE OF 5-HYDROXYDOPA.
210803 03-03

BINDING OF LITHIUM AND CALCIUM BY CEREBRAL MEMBRANE FRACTIONS.
210806 03-03

ALPHA-METHYLTRYPTOPHAN: EFFECTS ON CEREBRAL MONOOXYGENASES IN VITRO AND IN VIVO.
210819 03-03

EFFECT OF P-CHLOROAMPHETAMINE ON CEREBRAL TRYPTOPHAN-5-HYDROXYLASE IN VIVO: A REEXAMINATION.
210826 03-03

A POTENT DEPRESSANT ACTION OF ADENINE DERIVATIVES ON CEREBRAL CORTICAL NEURONES.
210932 03-03

CLINICAL AND PSYCHOMETRIC EVALUATION OF THE ACTION OF VINCAMIN IN CEREBRAL ARTERIOSCLEROSIS.
211226 03-11

GAMMA-AMINOBUTYRIC ACID AND CEREBRAL METABOLISM.
212277 03-13

CEREBRAL NEUROHUMORS AND BEHAVIOR.
213623 04-08

EFFECTS OF 6-HYDROXYDOPAMINE AND RESERPINE ON AMPHETAMINE-INDUCED RELEASE OF NOREPINEPHRINE IN RAT CEREBRAL CORTEX.
215691 04-03

HYPERSOMNIA BY ISTHMIC LESION IN THE CAT. I. STUDY OF THE METABOLISM OF CEREBRAL MONOAMINES.
215702 04-03

ACTIONS OF ACETYLCHOLINE AND ATROPINE ON CEREBRAL CORTICAL NEURONS IN CHRONICALLY MORPHINE TREATED RATS.
215733 04-03

EFFECT OF WITHDRAWAL FROM CHRONIC ETHANOL INGESTION ON THE CAMP RESPONSE OF CEREBRAL CORTICAL SLICES USING THE AGONISTS HISTAMINE, SEROTONIN, AND OTHER NEUROTRANSMITTERS.
215980 04-03

PHENOTHIAZINE EFFECTS ON CEREBRAL EVOKED POTENTIALS AND EYE MOVEMENTS IN ACUTE SCHIZOPHRENICS.
217454 04-08

PHARMACOLOGICAL EVIDENCE FOR CEREBRAL DOPAMINE RECEPTOR BLOCKADE BY METOCLOPRAMIDE IN RODENTS.
217469 04-03

BEHAVIOURAL SUPERSENSITIVITY TO APOMORPHINE FOLLOWING CEREBRAL DOPAMINERGIC DENERVATION BY 6-HYDROXYDOPAMINE.
217527 04-03

THE ROLE OF CATECHOLAMINES IN THE ACTION OF AMPHETAMINE AND L-DOPA ON CEREBRAL ENERGY METABOLISM.
217677 04-03

PHARMACOLOGY OF CEREBRAL CIRCULATION AND CLINICAL APPLICATIONS. EXPERIMENTAL STUDY OF THE CIRCULATORY AND METABOLIC EFFECTS OF HYDROSARPAN-711.
218164 04-03

THE PARTICIPATION OF CEREBRAL CHOLINERGIC MECHANISMS IN THE ACTION OF NEUROLEPTICS.
218471 04-04

LONG-LASTING CHANGES IN CEREBRAL NEURONS INDUCED BY DRUGS.
218957 04-03

INHIBITORS OF CEREBRAL PROTEIN SYNTHESIS: DISSOCIATION OF AVERSIVE AND AMNESIC EFFECTS.
221005 04-04

ELECTROENCEPHALOGRAPHIC STUDY ON THE ACTION OF THE COMBINATION MEPROBAMATE ACEPROMETAZINE ON VARIOUS CEREBRAL SYSTEMS.
221286 04-03

DIFFERENTIAL EFFECTS OF A TETRAHYDROCANNABINOL AND PENTOBARBITAL ON CEREBRAL CORTICAL NEURONES.
222819 04-03

LYSERGIC ACID DIETHYLAMIDE: EVIDENCE FOR STIMULATION OF CEREBRAL DOPAMINE RECEPTORS.
223174 04-03

USING CEREBRAL STIMULANTS TO TREAT MINIMAL-BRAIN-DYSFUNCTION.
224359 04-17

THE RELATION BETWEEN CEREBRAL SEROTONIN LEVELS AND CONDITIONED BEHAVIOUR IN THE RAT FOLLOWING THE ADMINISTRATION OF LSD-25 AND UML.
225564 04-04

CEREBROLYSINE

THE INFLUENCE OF CEREBROLYSINE ON HIGHER NERVOUS ACTIVITY IN ADULT RATS.
196758 01-04

CEREBROORGANIC

PERFORMANCES UNDER CERUTIL OF NORMALLY INTELLIGENT CHILDREN AFFECTED BY CEREBROORGANIC REDUCTIONS IN EFFICIENCY.
203742 02-11

CEREBROSPINAL

PLASMA AND CEREBROSPINAL FLUID CONCENTRATIONS OF PHENOBARBITAL IN INFANTS GIVEN SINGLE DOSES.
206057 03-13

ACCUMULATION OF 3H-HOMOVANILLIC ACID IN RABBIT BRAIN AND CEREBROSPINAL FLUID FOLLOWING INTRAVENOUS 3H-L-DOPA.
206336 03-03

THE INFLUENCE OF CLOZAPINE ON THE EXCRETION OF MHPG, HVA, AND 5-HIAA IN URINE AND CEREBROSPINAL FLUID.
206974 03-13

MASS FRAGMENTOMETRIC DETERMINATION OF HOMOVANILLIC ACID IN LUMBAR CEREBROSPINAL FLUID OF SCHIZOPHRENIC PATIENTS DURING TREATMENT WITH ANTIPSYCHOTIC DRUGS.
207295 03-08

CYCLIC-AMP IN CEREBROSPINAL FLUID: ACCUMULATION FOLLOWING PROBENECID AND BIOGENIC AMINES.
210193 03-17

EXTRAPYRAMIDAL REACTIONS AND AMINE METABOLITES IN CEREBROSPINAL FLUID DURING HALOPERIDOL AND CLOZAPINE TREATMENT OF SCHIZOPHRENIC PATIENTS.
214010 04-15

MASS FRAGMENTOGRAPHY OF PICOMOLE QUANTITIES OF BIOGENIC AMINE METABOLITES IN HUMAN CEREBROSPINAL FLUID AS WELL AS WHOLE RAT BRAINS. (UNPUBLISHED PAPER).
217219 04-06

AVERAGE EVOKED RESPONSES (AER) AND HOMOVANILLIC ACID (HVA) IN CEREBROSPINAL FLUID (CSF) IN A PSYCHOTIC PATIENT WITH ADDISONS DISEASE.
221310 04-09

CERUTIL

PERFORMANCES UNDER CERUTIL OF NORMALLY INTELLIGENT CHILDREN AFFECTED BY CEREBROORGANIC REDUCTIONS IN EFFICIENCY.
203742 02-11

CERVICAL

MINIMUM DURATION OF TRANS-SYNAPTIC STIMULATION REQUIRED FOR THE INDUCTION OF TYROSINE-HYDROXYLASE BY RESERPINE IN THE RAT SUPERIOR CERVICAL GANGLION.
199999 02-03

ONTOGENY OF THE INDUCTION OF TYROSINE-HYDROXYLASE BY RESERPINE IN THE SUPERIOR CERVICAL GANGLION, NUCLEUS LOCUS-COERULEUS AND ADRENAL GLAND.
210670 03-03

CESIUM

THE INFLUENCE OF LITHIUM AND CESIUM IONS ON THE EFFECTS OF CATECHOLAMINES AND SEROTONIN INTRODUCED INTO THE HIPPOCAMPUS OF RATS.
218470 04-04

CESSATION

DOPAMINERGIC NEURONS: DRUG-INDUCED ANTAGONISM OF THE INCREASE IN TYROSINE-HYDROXYLASE ACTIVITY PRODUCED BY CESSATION OF IMPULSE FLOW.
202664 02-03

CGMP

INHIBITION BY DIAZEPAM OF THE TREMOR AND THE INCREASE OF CEREBELLAR CGMP CONTENT ELICITED BY HARMALINE.
207798 03-03

THE IN VIVO REGULATION OF CGMP CONTENT IN RAT CEREBELLUM: A STUDY OF THE ACTION OF TAURINE.
215654 04-03

CHAIN

MARKOV CHAIN AS A MODEL OF VERBAL LEARNING.
205624 03-14

CHANGE

INTERACTIVE PREDICTION OF DRUG-INDUCED CHANGE.
195936 01-17

THE RELATIONSHIP BETWEEN RIGIDITY AND CHANGE IN WHOLE BRAIN ACETYLCHOLINE CONCENTRATION PRODUCED BY INJECTION OF RESERPINE IN THE RAT.
197569 01-03

DEPRESSION TREATED WITH CHLORIMIPRAMINE WITH SPECIAL ANALYSIS OF CHANGE IN BLOOD PRESSURE BY INFUSION.
199212 02-09

EFFECT OF INCREASED AROUSAL ON RESPONSE TO STIMULUS CHANGE IN A COMPLEX MAZE.
206187 03-04

ARE AUTORECEPTORS IN DOPAMINERGIC NEURONS INVOLVED IN THE CHANGE OF THE KINETIC STATE OF STRIATAL TYROSINE-HYDROXYLASE ELICITED BY ANTIPSYCHOTICS? (UNPUBLISHED PAPER).
208636 03-03

PATTERNS OF SYMPTOM CHANGE IN ANXIOUS DEPRESSED OUTPATIENTS TREATED WITH DIFFERENT DRUGS.
209904 03-10

CHANGED

CHANGED EATING AND LOCOMOTOR BEHAVIOUR IN THE RAT AFTER 6-HYDROXYDOPAMINE LESIONS TO THE SUBSTANTIA-NIGRA.
210763 03-04

CHANGES

CHANGES IN ACTIVATION OF ADENYLATE-CYCLASE AND OF DOPAMINE TURNOVER IN RAT STRIATUM DURING PROLONGED HALOPERIDOL TREATMENT.
192933 01-03

EFFECT OF APOMORPHINE AND NALLINE ON METHADONE INDUCED BEHAVIORAL CHANGES.
193420 01-04

MESCALINE-INDUCED CHANGES OF BRAIN CORTEX RIBOSOMES: EFFECT OF MESCALINE ON RIBOSOMAL SYNTHESIS OF POLYURIDINE DIRECTED POLYPHENYLALANINE.
194153 01-03

COMMENTS ON TREATMENT: EYE CHANGES FOLLOWING PHENOTHIAZINE ADMINISTRATION.
194749 01-15

MESCALINE-INDUCED CHANGES OF BRAIN-CORTEX RIBOSOMES: EFFECT OF MESCALINE ON TRNA AND AMINOACYL-TRNA SYNTHETASE.
195242 01-03

CHANGES IN BRAIN CONCENTRATION OF BIOGENIC AMINES AND THE ANTINOCICEPTIVE EFFECT OF MORPHINE IN RATS.
195246 01-03

CHANGES IN THE DORSAL ROOT POTENTIAL WITH DIAZEPAM AND WITH THE ANALGESICS ASPIRIN, NITROUS OXIDE, MORPHINE AND MEPERIDINE.
195248 01-03

THE CONTROL OF DEVIANT SEXUAL BEHAVIOUR BY DRUGS: I. BEHAVIOURAL CHANGES FOLLOWING ESTROGENS AND ANTIANDROGENS.
196958 01-14

CHANGES IN ACID-BASE BALANCE, RESPIRATION RATE AND HEART RATE UPON REPEATED ORAL ADMINISTRATION OF BENZOCTAMINE AND DIAZEPAM TO CONSCIOUS DOGS.
197460 01-03

RELATIONSHIP BETWEEN THE CHANGES ON BLOOD PRESSURE RESPONSE AND THE CARDIAC CATECHOLAMINE LEVEL AFTER SINGLE AND REPEATED ADMINISTRATIONS OF TYRAMINE AND METHAMPHETAMINE IN RATS.
197491 01-03

CHANGES IN THE ACQUISITION OF CONDITIONED AVOIDANCE RESPONSES FOLLOWING MIDBRAIN RAPHE LESIONS IN TH
197574 01-04

MORPHOLOGICAL, BIOCHEMICAL, AND FUNCTIONAL CHANGES IN CHICK EMBRYONIC BRAIN TISSUE AFTER INTRACEREBRAL ADMINISTRATION OF OUABAIN.
197788 01-03

EEG CHANGES WITH LITHIUM IN DEPRESSED PATIENTS.
198100 02-10

EFFECTS OF CHLORIMIPRAMINE ON EXPERIMENTALLY INDUCED CHANGES IN FOREBRAIN 5-HYDROXYINDOLES.
199966 02-03

CHANGES OF KINETIC CONSTANT OF STRIATAL TYROSINE-HYDROXYLASE ELICITED BY NEUROLEPTICS THAT IMPAIR THE FUNCTION OF DOPAMINE RECEPTORS.
202716 02-03

AN ANALYSIS OF THE GROSS BEHAVIOURAL CHANGES INDUCED BY TETRAETHYLAMMONIUM AND A COMPARISON WITH OTHER SUBSTANCES AFFECTING THE AUTONOMIC AND CENTRAL NERVOUS SYSTEM AFTER INTRAVENTRICULAR INJECTIONS TO CONSCIOUS CATS.
202781 02-04

SUBJECTIVE CHANGES IN VOLUNTEERS WITHOUT PRIOR EXPERIENCE OF CANNABIS INDUCED BY (-)DELTA9-TRANS-TETRAHYDROCANNABINOL.
202784 02-14

BEHAVIORAL CHANGES INDUCED BY PSYCHOTROPIC SUBSTANCES IN EXPERIMENTAL ANIMALS.
202864 02-04

CHANGES IN THE PSYCHODYNAMICS OF MANIC-DEPRESSIVES THROUGH LONG-TERM ADMINISTRATION OF LITHIUM SALTS.
203601 02-14

DETERMINATION OF DRUG-INDUCED CHANGES IN SLEEP QUALITY BASED ON DIGITAL COMPUTER SLEEP PRINTS.
203603 02-14

MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 4. COMMUNICATION: CONNECTION BETWEEN EEG CHANGES, CONCENTRATION IN BLOOD, AND OTHER CLINICAL VARIABLES.
203842 02-13

COMPUTER NYSTAGMOGRAPHY, A NEW METHOD OF DETERMINING CHANGES IN VIGILANCE AS A RESPONSE TO PSYCHOTROPIC DRUGS.
204395 02-16

THE INFLUENCE OF ANTIADRENERGIC AND ANTIDOPAMINERGIC DRUGS ON METHAMPHETAMINE INDUCED CHANGES IN MOTORIC ACTIVITY AND CEREBRAL GLYCOGEN CONTENT IN MICE.
204396 02-03

CANNABINOID INDUCED CHANGES IN MOUSE STRIATAL HOMOVANILLIC ACID AND DIHYDROXYPHENYLACETIC ACID: THE EFFECTS OF AMPHETAMINE AND L-DOPA.
204866 02-03

AMPHETAMINE-INDUCED CHANGES IN STRIATAL DOPAMINE AND ACETYLCHOLINE LEVELS AND RELATIONSHIP TO ROTATION (CIRCLING BEHAVIOR) IN RATS.
205432 02-04

EEG CHANGES AFTER PSYCHOACTIVE DRUGS (SPECTRAL ANALYTIC STUDY).
205472 02-13

EEG CHANGES BEFORE AND AFTER L-DOPA THERAPY IN PARKINSON PATIENTS.
205569 02-13

PHARMACOLOGICAL PROPERTIES OF A POTENTIAL TRANQUILISING AGENT MESYLPHENACYRAZINE: II. CHANGES RELATED TO ITS REPEATED ADMINISTRATION.
205579 02-03

MOOD AND SLEEP CHANGES WITH MONOAMINEOXIDASE INHIBITORS.
206369 03-14

TIME-DEPENDENT CHANGES IN AMPHETAMINE SELF-ADMINISTRATION FOLLOWING FRONTAL CORTEX ABLATIONS IN RATS.
206747 03-04

RECOVERY OF FUNCTION AND CHANGES IN SENSITIVITY TO AMPHETAMINE FOLLOWING CAUDATE LESIONS IN RATS.
209962 03-03

CHANGES IN MENTAL AGE WITH SUBNORMAL CHILDREN TREATED WITH DOSES OF GABA AND NUCLEOTIDES.
210286 03-14

CORRELATIONS BETWEEN CIRCADIAN CHANGES IN SERUM AMINO ACIDS OR BRAIN TRYPTOPHAN AND THE CONTENTS OF SEROTONIN AND 5-HYDROXYINDOLEACETIC ACID IN REGIONS OF THE RAT BRAIN.
210673 03-03

PIPERIDINE CONCENTRATION CHANGES IN THE BRAIN AND BLOOD OF DORMANT MICE.
210701 03-03

EFFECTS OF A DECARBOXYLASE INHIBITOR ON THE DOPA AND 5-HTP INDUCED CHANGES IN THE LOCOMOTOR LIKE DISCHARGE PATTERN OF RABBIT HIND LIMB NERVES.
210740 03-03

CHANGES IN THE NEURONAL PROTEIN LABELLING INDUCED BY POTASSIUM IONS IN VIVO (SPREADING DEPRESSION).
210779 03-03

ELECTROCORTICAL CHANGES INDUCED BY PERFUSION OF CATECHOLAMINES INTO THE BRAINSTEM RETICULAR FORMATION.
210827 03-03

MODIFICATION BY L-DOPA METHYLESTER (H-19-61) OF AMPHETAMINE-INDUCED BRAIN CATECHOLAMINE CHANGES, THERMAL RESPONSES AND TOXICITY IN DEVELOPING MICE.
210891 03-03

COMPARATIVE TIME-DEPENDENT CHANGES IN SENSITIVITY TO LOCOMOTOR EFFECTS OF D-AMPHETAMINE IN MICE WITH CAUDATE, HIPPOCAMPAL OR FRONTAL CORTICAL LESIONS.
210926 03-03

OPERANT CONDITIONING OF HEART RATE IN CURARIZED RATS: HEMODYNAMIC CHANGES.
213275 03-04

CHANGES IN OBSESSIVE/COMPULSIVE PATIENTS AS MEASURED BY THE LEYTON INVENTORY BEFORE AND AFTER TREATMENT WITH CLOMIPRAMINE.
214833 04-10

EEG CHANGES IN THE TREATMENT WITH OCTOCLOTHEPINE IN VERY HIGH DOSES.
215064 04-13

EFFECTS OF IPRONIAZID, CHLORPROMAZINE AND METHIOTHEPIN ON DMT INDUCED CHANGES IN BODY TEMPERATURE, PUPILLARY DILATATION, BLOOD PRESSURE AND EEG IN THE RABBIT.
215724 04-03

SLEEP AND BEHAVIORAL CHANGES REFLECTING CENTRAL RECEPTOR HYPERSENSITIVITY FOLLOWING CATECHOLAMINE SYNTHESIS INHIBITION IN MAN. (UNPUBLISHED PAPER).
216373 04-09

REPORT ON THREE CASES OF CARDIAC CHANGES DURING TREATMENT WITH FLOROPIPAMIDE (PROPITAN).
216391 04-15

THE EFFECT OF SOME NEUROTROPIC DRUGS ON THE PHASIC CHANGES OF ARTERIAL PRESSURE EVOKED BY STIMULATION OF THE CEREBELLAR FASTIGAL NUCLEUS.
217067 04-03

THE INFLUENCE OF TRICYCLIC ANTIDEPRESSANTS, AZAPHEN AND IMIZINE ON BLOOD SUGAR CONCENTRATION CHANGES PRODUCED BY EPINEPHRINE AND SEROTONIN.
217214 04-03

INFLUENCE OF CHANGES IN BRAIN MONOAMINE METABOLISM ON BEHAVIOUR OF HERPES-SIMPLEX INFECTED MICE.
217440 04-04

INTERRESPONSE TIME CHANGES AS A FUNCTION OF WATER DEPRIVATION AND AMPHETAMINE.
217459 04-04

THE EFFECTS OF A DEXAMPHETAMINE AMYLOBARBITONE SODIUM MIXTURE ON THE REWARD VALUE OF DIFFERENT SENSORY CHANGES.
217476 04-03

CHLORDIAZEPOXIDE (LIBRIUM) INDUCED CHANGES IN INTRASPECIFIC ATTACK AND SELECTED NONAGONISTIC BEHAVIORS IN MALE SIAMESE FIGHTING FISH.
217524 04-04

6-HYDROXYDOPA DURING DEVELOPMENT OF CENTRAL ADRENERGIC NEURONS PRODUCES DIFFERENT LONG-TERM CHANGES IN RAT BRAIN NORADRENALINE.
217867 04-03

CHANGES IN THE CONCENTRATIONS OF 5-HYDROXYTRYPTAMINE AND NORADRENALINE IN SIX AREAS OF RAT BRAIN DURING RECOVERY FROM CHRONIC METHYLAMPHETAMINE ADMINISTRATION.
217963 04-03

LONG-LASTING CHANGES IN CEREBRAL NEURONS INDUCED BY DRUGS.
218957 04-03

ANTAGONISM OF PSYCHOSTIMULANT 2 PHENYLDIMETHYLTETRAHYDROOXAZINE HYDROCHLORIDE (G-130) TO CENTRAL NERVOUS SYSTEM DEPRESSING DRUGS: MONOAMINEOXIDASE INHIBITORY ACTIVITY AND NOREPINEPHRINE AND SEROTONIN INDUCED CHANGES, COMPARISON WITH DL-AMPHETAMINE.
221267 04-03

PSYCHOTROPIC AGENTS AND PATHOLOGICAL ECG CHANGES.
221336 04-15

SPECTRAL ANALYSIS OF HUMAN EEG CHANGES INDUCED BY ETIFOXIN.
221724 04-13

EEG SLEEP CHANGES AS PREDICTORS IN DEPRESSION.
224769 04-09

EFFECT OF DRUG RITUAL CHANGES ON SCHIZOPHRENICS.
224908 04-08

NEUROCHEMICAL CHANGES ASSOCIATED WITH SCHEDULE-CONTROLLED BEHAVIOR.
225160 04-04

CHANGES IN MORPHINE SELF-ADMINISTRATION AND MORPHINE-DEPENDENCE AFTER LESIONS OF THE CAUDATE NUCLEUS IN RATS.
225560 04-04

CHANGING

THE ROLE OF DOPAMINE AND NOREPINEPHRINE IN CHANGING THE DIRECT CORTICAL RESPONSE TO PHENAMINE.
208971 03-03

CHARACTERISTIC

THE INHIBITION OF A AND B FORMS OF MAO IN THE PRODUCTION OF A CHARACTERISTIC BEHAVIOURAL SYNDROME IN RATS AFTER L-TRYPTOPHAN LOADING.
217471 04-03

CHARACTERISTICS

DEVELOPMENTAL CHARACTERISTICS OF PHENYLETHANOLAMINE AND OCTOPAMINE IN THE RAT BRAIN.
196804 01-03

THE EFFECTS OF DALMANE (FLURAZEPAM HYDROCHLORIDE) ON HUMAN EEG CHARACTERISTICS.
199756 02-13

SOME CHARACTERISTICS OF PATHOLOGY IN SCHIZOPHRENIA DURING THE TWO STAGES OF PSYCHOPHARMACOLOGICAL DEVELOPMENT.
201908 02-08

COMPARATIVE CHARACTERISTICS OF THE CLINICAL ACTION OF TRANQUILIZERS.
201909 02-14

MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 2. COMMUNICATION: PSYCHOPATHOLOGICAL COURSE PROFILE AND SOMATIC CHARACTERISTICS (STUDIES WITH THE AMP SYSTEM).
203840 02-14

CLINICAL APPLICATION OF OXYPERTINE -- ITS CHARACTERISTICS AS A STRONG TRANQUILIZER.
209394 03-08

MARIHUANA METABOLITES IN URINE OF MAN: V. CHARACTERISTICS AND SEPARATION OF POLAR METABOLITES OF DELTA9-TETRAHYDROCANNABINOL.
210896 03-16

THE ELECTRODERMAL RESPONSE: NEUROPHYSIOLOGICAL AND NEUROPHARMACOLOGICAL CHARACTERISTICS. (PH.D. DISSERTATION).
214203 04-03

THE EFFECT OF PSYCHOTROPIC AGENTS ON THE ELECTROENCEPHALOGRAPHIC CHARACTERISTICS OF THE INHIBITORY FUNCTION OF THE CAUDATE NUCLEUS.
219500 04-03

CHARACTERIZATION

CHARACTERIZATION OF THE BINDING OF BENZODIAZEPINES TO HUMAN SERUM ALBUMIN.
193278 01-01

IDENTIFICATION AND STRUCTURAL CHARACTERIZATION OF AN INHIBITOR OF CATECHOLAMINE INDUCED FREE FATTY ACID MOBILIZATION FROM THE CALF MIDBRAIN.
200006 02-01

BIOCHEMICAL CHARACTERIZATION OF THE DOPAMINE RECEPTOR IN THE MAMMALIAN CAUDATE NUCLEUS.
207297 03-03

CHARCOAL

TREATMENT OF EXPERIMENTAL IMIPRAMINE INTOXICATION BY INTERRUPTING ENTERAL CYCLES WITH ACTIVATED CHARCOAL.
197969 01-03

CHEATERS

SIMPLE METHOD FOR DETECTION OF THE DRUG CHEATERS IN PSYCHIATRY.
205586 02-17

CHEMICAL

CHEMICAL PHARMACOLOGY OF THE BENZOTHIOPHENE AND 1-METHYLINDOLE ANALOGS OF N,N-DIMETHYLTRYPTAMINE. (PH.D. DISSERTATION).
193590 01-12

A QUANTUM CHEMICAL INVESTIGATION OF THE PI-ELECTRONIC STRUCTURE OF THE HALLUCINOGENIC N,N-DIMETHYLTRYPTAMINES.
195119 01-01

NEONATAL CHEMICAL SYMPATHECTOMY: FUNCTIONAL CONTROL OF DENERVATION OF THE VASCULAR SYSTEM AND TISSUE NORADRENALINE LEVEL IN THE RAT AFTER 6-HYDROXYDOPAMINE.
197584 01-03

SPECIFIC ASYMMETRIC BEHAVIOUR INDUCED BY THE DIRECT CHEMICAL STIMULATION OF NEOSTRIATAL DOPAMINERGIC MECHANISMS.
197929 01-04

CLINICAL CHEMICAL CORRELATES OF CPZ THERAPY.
198098 02-08

CHEMICAL STIMULATION OF THE AMYGDALA WITH SPECIAL REGARD TO INFLUENCE ON THE HYPOTHALAMUS.
202779 02-04

URGENT CHEMICAL TREATMENT OF STATES OF AGITATION.
207151 03-11

THE CHEMICAL CONTROL OF PREOPERATIVE ANXIETY.
210684 03-10

CHEMICAL OR ELECTROLYTIC LESION OF THE SUBSTANTIA-NIGRA: EARLY EFFECTS ON NEOSTRIATAL DOPAMINE METABOLISM.
210699 03-03

PSYCHOPHARMACOLOGIC ACTIVITY: QUANTUM CHEMICAL STUDY.
213608 04-03

BEHAVIORAL NEUROENDOCRINOLOGY: CHEMICAL CORRELATES.
213625 04-03

INFLUENCE OF CHEMICAL STIMULATION OF CENTRAL DOPAMINERGIC SYSTEM ON THE OPEN-FIELD BEHAVIOR OF RATS.
221308 04-03

THE EFFECT OF AN ADRENAL DEMEDULLATION AND CHEMICAL SYMPATHECTOMY (2,4,5 TRIHYDROXYPHENYLETHYLAMINE) ON THE ACQUISITION OF A ONE-WAY ACTIVE AVOIDANCE RESPONSE. (PH.D. DISSERTATION).
222736 04-04

CHEMICALS

ASSESSING THE IMPACT OF LOW LEVEL CHEMICALS ON DEVELOPMENT: BEHAVIORAL AND LATENT EFFECTS.
225164 04-15

CHEMISTRY

STEREOCHEMICAL STUDIES ON POTENTIAL CENTRAL NERVOUS SYSTEM ACTIVE AGENTS AND STUDIES ON THE CHEMISTRY OF SOME 3-BENZOYLPIPERIDINES. (PH.D. DISSERTATION).
193586 01-01

THE STRUCTURAL CHEMISTRY OF ADRENERGIC NEURAL TRANSMISSION SYSTEMS. (PH.D. DISSERTATION).
203027 02-01

CHEMISTRY OF NONAQUEOUS TITRATION OF CHLORPROMAZINE.
206460 03-01

ROLE OF DOPAMINE AND NOREPINEPHRINE IN THE CHEMISTRY OF REWARD.
207302 03-04

NEUROLEPTIC PIPERAZINYLDIBENZOAZEPINES: CHEMISTRY AND STRUCTURE-ACTIVITY RELATIONSHIPS.
221734 04-01

CHEMOTHERAPEUTIC

CLINICAL EVALUATION OF NEW CHEMOTHERAPEUTIC AGENTS.
198064 01-07

CHEMOTHERAPY

MONTHLY INTERMITTENT CHEMOTHERAPY OF CHRONIC SCHIZOPHRENIC OUTPATIENTS WITH PIPOTHIAZINE PALMITATE.
204169 02-08

MANAGING DISTURBED GERIATRIC PATIENTS WITH CHEMOTHERAPY.
218010 04-11

CHILDHOOD CHEMOTHERAPY AND LATER DRUG ABUSE AND GROWTH CURVE: A FOLLOWUP STUDY OF 30 ADOLESCENTS.
225382 04-14

CHICK

THE EFFECTS OF PARENTERAL ADMINISTRATION OF CATECHOLAMINES, SEROTONIN AND HISTAMINE ON BEHAVIOR AND LEVELS OF THESE AMINES IN THE BRAIN OF THE NEONATE CHICK.
197457 01-03

MORPHOLOGICAL, BIOCHEMICAL, AND FUNCTIONAL CHANGES IN CHICK EMBRYONIC BRAIN TISSUE AFTER INTRACEREBRAL ADMINISTRATION OF OUABAIN.
197788 01-03

IMPRINTING: CORRELATIONS BETWEEN BEHAVIOUR AND INCORPORATION OF (14C)URACIL INTO CHICK BRAIN.
210667 03-04

TRYPTOPHAN METABOLISM IN DEVELOPING CHICK BRAIN.
223053 04-03

CHICKEN

THE SIGNIFICANCE OF NORADRENALINE AND ADRENALINE AS ADRENERGIC TRANSMITTERS IN THE CHICKEN.
197958 01-03

DEVELOPMENTAL VARIATIONS OF CHOLINE ACETYLTRANSFERASE, DOPAMINE-BETA-HYDROXYLASE AND MONOAMINEOXIDASE IN CHICKEN EMBRYO AND CHICKEN SYMPATHETIC GANGLIA.
217840 04-03

CHICKENS

BEHAVIOURAL AND ELECTROGRAPHIC OBSERVATIONS DURING EPILEPTIC CONVULSIONS INDUCED BY STRYCHNINE AND PENTYLENETETRAZOL IN CONSCIOUS YOUNG AND ADULT CHICKENS.
205459 02-03

INHIBITION OF MEMORY FORMATION IN THE IMPRINTING PERIOD: IRREVERSIBLE ACTION OF CYCLOHEXIMIDE IN YOUNG CHICKENS.
210708 03-04

TONIC IMMOBILITY IN CHICKENS: POSSIBLE INVOLVEMENT OF MONOAMINES.
217762 04-03

CHILD

THE USE OF HALOPERIDOL IN THE TREATMENT OF A PSYCHOTIC CHILD WITH MULTIPLE TICS: A CASE REPORT.
194710 01-11

THE PRESENT CONDITIONS OF PSYCHOPHARMACOLOGICAL TREATMENT FOR CHILDREN IN JAPAN: OPINIONS FROM THIRTY-SEVEN WELL-KNOWN CHILD NEUROPSYCHIATRISTS AND NEUROPSYCHIATRIC PEDIATRICIANS.
202500 02-17

MEASURING EFFECTS OF PSYCHOACTIVE MEDICATION IN A CHILD WITH A LEARNING DISABILITY.
203847 02-14

THE HYPERACTIVE CHILD.
207582 03-11

A CROSSOVER STUDY OF ALLOPURINOL ADMINISTRATION TO A SCHIZOPHRENIC CHILD.
207788 03-08

A YEAR OF INVESTIGATIONS ON 1035-MD IN CHILD AND JUVENILE NEUROPSYCHIATRY: CLINICAL AND EEG FINDINGS FROM 46 CASES.
209784 03-11

WILL THE REAL HYPERACTIVE CHILD PLEASE SIT DOWN? PROBLEMS OF DIAGNOSIS AND REMEDIATION.
212811 03-11

FLUPHENAZINE TREATMENT IN THE PSYCHOTIC CHILD: CLINICAL EVOKED POTENTIAL CORRELATIONS.
215455 04-09

PROS AND CONS OF DRUG THERAPY IN THE MANAGEMENT OF THE HYPERACTIVE CHILD.
216966 04-11

THE USE OF SIDNOCARB IN CHILD PSYCHIATRY.
217001 04-11

LITHIUM SALT POISONING IN AN 8-YEAR-OLD CHILD.
219827 04-15

PSYCHOPHARMACOLOGY IN CHILD PSYCHIATRY: LITERATURE ANALYSIS.
220271 04-11

SULPIRIDE TRIAL IN CHILD PSYCHIATRY.
224585 04-11

CHILDHOOD

PEMOLINE (CYLERT) IN THE TREATMENT OF CHILDHOOD HYPERKINESIS.
202824 02-11

ANTENATAL EXPOSURE TO MEPROBAMATE AND CHLORDIAZEPOXIDE IN RELATION TO MALFORMATIONS, MENTAL DEVELOPMENT, AND CHILDHOOD MORTALITY.
212107 03-15

CHILDHOOD CHEMOTHERAPY AND LATER DRUG ABUSE AND GROWTH CURVE: A FOLLOWUP STUDY OF 30 ADOLESCENTS.
225382 04-14

CHILDREN

RESULTS OF TREATING CHILDREN WITH NOCTURNAL ENURESIS WITH IMIPRAMINE (PSYCHOFORIN).
194208 01-11

PYRITHIOXINE (ENCEPHABOL) IN MENTALLY DEFICIENT CHILDREN (A TRIAL ON 50 CASES).
194554 01-11

EFFECTS OF PSYCHOTROPIC DRUGS ON THE SHORT-TERM MEMORY OF RETARDED CHILDREN. (PH.D. DISSERTATION).
194655 01-14

THE EFFECTS OF PABENOL COMPLEX ON CHILDREN WITH LEARNING PROBLEMS.
196704 01-07

METHYLPHENIDATE EFFECTS IN LEARNING DISABILITIES OF CHILDREN.
198045 01-14

DRUG AND COGNITION STUDIES IN DISTURBED CHILDREN.
198085 02-11

COMPARATIVE DRUG EFFECTS IN HYPERKINETIC CHILDREN.
198088 02-07

COMPARATIVE DRUG TREATMENT OF HYPERACTIVE CHILDREN.
198090 02-11

A COMPARISON OF THE RELATIVE EFFICACY OF SPECIAL CLASS EDUCATION AND DRUG THERAPY FOR CHILDREN WITH SELECTED LEARNING DISABILITIES. (ED.D. DISSERTATION).
198662 02-11

THE PRESENT CONDITIONS OF PSYCHOPHARMACOLOGICAL TREATMENT FOR CHILDREN IN JAPAN: OPINIONS FROM THIRTY-SEVEN WELL-KNOWN CHILD NEUROPSYCHIATRISTS AND NEUROPSYCHIATRIC PEDIATRICIANS.
202500 02-17

TRYPTOPHAN METABOLISM EXAMINATIONS IN OLIGOPHRENIC CHILDREN. FIRST REPORT: RESULTS OF THE EXCRETION OF KYNURENINE AND XANTHURENIC ACID AFTER TRYPTOPHAN LOADING AND THEIR DEPENDENCE UPON THE SUPPLY.
203645 02-13

PERFORMANCES UNDER CERUTIL OF NORMALLY INTELLIGENT CHILDREN AFFECTED BY CEREBROORGANIC REDUCTIONS IN EFFICIENCY.
203742 02-11

SIGNS, COURSE AND PROGNOSIS OF TICS IN CHILDREN AND JUVENILES.
203881 02-14

HEAVY INTOXICATION AS A SIDE-EFFECT OF CARBROMAL IN TWO CHILDREN.
203882 02-15

THE DIFFERENTIATION OF TWO TYPES OF HYPERACTIVE CHILDREN BY ACTIVITY LEVEL AND TASK PERFORMANCE WITH METHYLPHENIDATE (RITALIN) AND PLACEBO. (PH.D. DISSERTATION).
204688 02-11

HYPERKINETIC CHILDREN: THE USE OF STIMULANT DRUGS EVALUATED.
205263 02-14

ACUTE TOXIC PSYCHOSIS IN TWO CHILDREN TREATED WITH BENZHEXOL HYDROCHLORIDE (ARTANE).
205315 02-15

SPATIAL DISTRIBUTION OF THE EEG OF DYSLEXIC CHILDREN.
205504 02-13

TWO CONTROLLED TRIALS OF TYRAMINE IN CHILDREN WITH MIGRAINE.
206058 03-13

EFFECT OF LONG-TERM TREATMENT OF HYPERACTIVE CHILDREN WITH METHYLPHENIDATE.
207580 03-11

THE EFFECT OF METHYLPHENIDATE ON SENSORY PERCEPTION AND INTEGRATION IN HYPERACTIVE CHILDREN.
208920 03-14

CHANGES IN MENTAL AGE WITH SUBNORMAL CHILDREN TREATED WITH DOSES OF GABA AND NUCLEOTIDES.
210286 03-14

SERUM CLONAZEPAM CONCENTRATIONS IN CHILDREN WITH ABSENCE SEIZURES.
211064 03-13

THE USE OF ANTICONVULSANT TREATMENT OF BEHAVIORALLY DISTURBED CHILDREN WITH BIOELECTRIC EPILEPSY: A CATAMNESTIC STUDY OF 76 CASES.
211355 03-11

CAFFEINE IN THE TREATMENT OF CHILDREN WITH MINIMAL BRAIN DYSFUNCTION OR HYPERKINETIC SYNDROME.
211434 03-11

TWENTY-THREE PSYCHOTROPIC DRUGS USED IN CHILDREN ABROAD WHICH ARE NOT RECOMMENDED IN THE UNITED-STATES.
213600 04-17

MEDICATION FOR HYPERKINETIC CHILDREN.
213988 04-11

THE EFFECTS OF PYRITHIOXINE ON THE BEHAVIOUR AND INTELLECTUAL FUNCTION OF LEARNING DISABLED CHILDREN.
216485 04-11

RESPONSE TO METHYLPHENIDATE IN LOW SOCIOECONOMIC HYPERACTIVE CHILDREN.
217181 04-14

METHYLPHENIDATE AND HALOPERIDOL IN CHILDREN: EFFECTS ON ATTENTION, MEMORY, AND ACTIVITY.
218118 04-14

OBSERVATIONS ON EFFECTS OF A CENTRAL STIMULANT DRUG (METHYLPHENIDATE) IN CHILDREN WITH HYPERACTIVE BEHAVIOR.
219354 04-14

A COMPARATIVE STUDY OF THE EFFECTIVENESS OF ENERBOL AND GLUTAMIC ACID IN OLIGOPHRENIC CHILDREN.
219662 04-11

THE EFFECTS OF REINFORCEMENT CONTINGENCIES AND CAFFEINE ON HYPERACTIVE CHILDREN. (PH.D. DISSERTATION).
220523 04-14

USE OF CNS STIMULANT MEDICATION IN AVERAGED ELECTROENCEPHALIC AUDIOMETRY WITH CHILDREN WITH MBD.
221103 04-11

THE EFFECTS OF METHYLPHENIDATE DURING REST, EXERCISE, AND RECOVERY UPON THE CIRCULORESPIRATORY RESPONSES OF HYPERACTIVE CHILDREN. (PH.D. DISSERTATION).
221934 04-11

THE EFFECTS OF METHYLPHENIDATE HYDROCHLORIDE ON PSYCHOLINGUISTIC, MOTOR AND VISUAL PERCEPTUAL ABILITIES OF HYPERKINETIC CHILDREN WITH LEARNING DISABILITIES. (PH.D. DISSERTATION).
222725 04-14

ATTENTION AND THE AUDITORY EVOKED POTENTIAL IN HYPERKINETIC CHILDREN TREATED WITH METHYLPHENIDATE AND IN NORMAL CHILDREN. (PH.D. DISSERTATION).
222747 04-11

PSYCHOTROPICS AND THEIR EFFECT ON THE EKG IN CHILDREN.
224378 04-13

RITALIN VERSUS BEHAVIOR THERAPY IN HYPERACTIVE CHILDREN.
224855 04-11

ELECTROCARDIOGRAPHIC MONITORING OF ENURETIC CHILDREN RECEIVING THERAPEUTIC DOSES OF IMIPRAMINE.
225336 04-15

IMIPRAMINE AND ELECTROCARDIOGRAPHIC ABNORMALITIES IN HYPERACTIVE CHILDREN.
225337 04-15

A BEHAVIORAL EDUCATIONAL ALTERNATIVE TO DRUG CONTROL OF HYPERACTIVE CHILDREN.
225455 04-14

COMPARATIVE SYMPTOMATOLOGICAL AND EVOKED POTENTIAL STUDIES WITH D-AMPHETAMINE, THIORIDAZINE, AND PLACEBO IN HYPERKINETIC CHILDREN.
225516 04-10

CHILDRENS

CHILDRENS PSYCHOPHARMACOLOGY UNIT.
198061 01-07

REVIBOL IN CHILDRENS PSYCHIATRY.
198395 02-11

THE EFFECTIVENESS OF RITALIN AND TOKEN ECONOMY IN INCREASING HYPERKINETIC CHILDRENS COLORING BEHAVIOR. (PH.D. DISSERTATION).
220510 04-14

CHIRAL

CHIRAL 1,4 BENZODIAZEPINE: VII. CYCLIZATION RATES OF 2-N-ALPHA-AMMONIUMACYL-AMINO-5-CHLOROBENZOPHENONES IN THE CHIRAL 1,4 BENZODIAZEPIN-2-ONES.
221858 04-01

CHLORAL

COMPARATIVE STUDY OF THE EFFECTS OF CHLORAL HYDRATE AND TRICHLOROETHANOL ON CEREBRAL METABOLISM.
194742 01-03

COMPARISON OF THE EFFECTS OF CHLORAL HYDRATE AND TRICHLOROETHANOL ON THE EEG OF THE ISOLATED PERFUSED RAT BRAIN.
194743 01-03

CHLORALOSE

THE INFLUENCE OF NEMBUTAL, CHLORALOSE AND URETHANE ON INHIBITORY POSTSYNAPTIC POTENTIALS OF CORTICAL NEURONS.
199443 02-03

BEHAVIORAL SPECIFICITY OF CHLORALOSE INDUCED FEEDING IN THE RAT.
200054 02-04

CHLORAMPHENICOL

EFFECT OF CHRONIC ADMINISTRATION OF CENTRALLY ACTING COMPOUNDS ON CHLORAMPHENICOL METABOLISM IN SCHIZOPHRENIC PATIENTS.
194157 01-08

CHLORAZEPATE

A CONTROLLED COMPARISON OF CHLORAZEPATE WITH OXAZEPAM IN NEUROTIC ANXIETY.
205638 03-10

CLINICAL AND BIOCHEMICAL COMPARISON OF CHLORAZEPATE AND DIAZEPAM.
209081 03-10

CLINICAL AND EXPERIMENTAL COMPARISON OF DIAZEPAM, CHLORAZEPATE AND PLACEBO.
214018 04-14

CHLORDIAZEPOXIDE

COMPARATIVE STUDY OF DIAZEPAM VS. CHLORDIAZEPOXIDE IN ANXIETY NEUROSIS.
194558 01-10

DOSE EFFECTS OF CHLORDIAZEPOXIDE UPON HABITUATION OF OPEN-FIELD BEHAVIOR IN WHITE RATS.
194736 01-04

EFFECTS OF CHLORDIAZEPOXIDE IN RESPIRATORY FAILURE DUE TO CHRONIC BRONCHITIS.
194854 01-13

EFFECT OF ORAL AND INTRAMUSCULAR ROUTES OF ADMINISTRATION ON SERUM CHLORDIAZEPOXIDE LEVELS AND THE PREDICTION OF THESE LEVELS FROM PREDRUG FASTING SERUM GLUCOSE CONCENTRATIONS.
195055 01-13

A CONTROLLED SERIES OF EXPERIMENTS INVESTIGATING SOME SOCIOLOGICAL EFFECTS OF TWO DOSAGES OF CHLORDIAZEPOXIDE (LIBRIUM) UPON INDIVIDUALS AND SMALL GROUPS. (PH.D. DISSERTATION).
195145 01-14

DIFFERENTIAL EFFECTS OF CHLORDIAZEPOXIDE AND D-AMPHETAMINE ON RESPONDING MAINTAINED BY A DRL SCHEDULE OF REINFORCEMENT.
195433 01-04

SEIZURES IN RATS INDUCED BY PINEALECTOMY: INFLUENCE OF DIAZEPAM, CHLORDIAZEPOXIDE, AND DIPHENYLHYDANTOIN AND PINEAL SUBSTANCES.
197465 01-03

THE INFLUENCE OF SKF-525A ON THE ACUTE PHARMACOLOGICAL PROPERTIES OF CHLORDIAZEPOXIDE.
197478 01-03

RESISTANCE TO EXTINCTION OF AN AVOIDANCE RESPONSE IN RATS FOLLOWING THE ADMINISTRATION OF CHLORDIAZEPOXIDE (LIBRIUM) AND DIAZEPAM (VALIUM).
198226 02-04

CHLORDIAZEPOXIDE AND ITS EFFECT ON SLEEP WAKEFULNESS BEHAVIOR IN UNRESTRAINED CATS.
199213 02-04

CHLORDIAZEPOXIDE (LIBRIUM): THE EFFECTS OF A MINOR TRANQUILIZER ON STRATEGIC CHOICE BEHAVIOR IN THE PRISONERS DILEMMA.
199609 02-14

EFFECTS OF CHLORDIAZEPOXIDE UPON DIFFERENTIAL HEART RATE CONDITIONING IN RATS.
201323 02-03

BROMAZEPAM, MEDAZEPAM, CHLORDIAZEPOXIDE IN TREATMENT OF NEUROTIC ANXIETY.
202219 02-10

INTRASPECIES AGGRESSION IN RATS: EFFECTS OF D-AMPHETAMINE AND CHLORDIAZEPOXIDE.
202768 02-04

METHODS OF DECONDITIONING PERSISTING AVOIDANCE: AMPHETAMINE, CHLORPROMAZINE, AND CHLORDIAZEPOXIDE AS ADJUNCTS TO RESPONSE PREVENTION.
202987 02-04

PHARMACOKINETIC DETERMINANTS OF THE RESPONSE TO SINGLE DOSES OF CHLORDIAZEPOXIDE.
203005 02-13

THE ACTION OF CHLORDIAZEPOXIDE ON CONDITIONS OF ANXIETY IN A PSYCHOPHYSIOLOGICAL EXPERIMENT.
204405 02-14

COMPARATIVE STUDIES OF VERBAL INTERACTIONS IN A GROUP OF HEALTHY SUBJECTS UNDER THE INFLUENCE OF PSYCHOPHARMACOLOGICAL AGENTS: WITH SPECIAL CONSIDERATION OF YG-19256, CHLORDIAZEPOXIDE AND PLACEBO.
207140 03-14

CHLORDIAZEPOXIDE AND PHENOBARBITAL IN A MODEL ANXIETY INDUCING SITUATION.
207775 03-14

EFFECT OF LITHIUM AND OTHER DRUGS ON THE AMPHETAMINE CHLORDIAZEPOXIDE HYPERACTIVITY IN MICE.
210349 03-04

PHARMACOLOGICAL PROPERTIES OF TWO CHLORDIAZEPOXIDE METABOLITES FOLLOWING MICROSOMAL ENZYME INHIBITION.
210792 03-03

TOLERANCE DEVELOPMENT WITH CHLORDIAZEPOXIDE IN RELATION TO THE PLASMA LEVELS OF THE PARENT COMPOUND AND ITS MAIN METABOLITES IN MICE.
210973 03-03

THREE CASES OF CHRONIC CHLORDIAZEPOXIDE INTOXICATION AND THEIR WITHDRAWAL SYMPTOMS.
211360 03-15

ANTENATAL EXPOSURE TO MEPROBAMATE AND CHLORDIAZEPOXIDE IN RELATION TO MALFORMATIONS, MENTAL DEVELOPMENT, AND CHILDHOOD MORTALITY.
212107 03-15

EFFECTS OF CHLORDIAZEPOXIDE ON SCHEDULE INDUCED WATER AND ALCOHOL CONSUMPTION IN THE SQUIRREL MONKEY.
214013 04-04

THE EFFECTS OF CHLORDIAZEPOXIDE ON AVOIDANCE PERFORMANCE OF MICE SUBJECTED TO UNDERNUTRITION OR HANDLING STRESS IN EARLY LIFE.
217463 04-04

FACILITATION OF AVOIDANCE LEARNING BY CHLORDIAZEPOXIDE AMPHETAMINE COMBINATIONS IN MICE.
217466 04-04

CHLORDIAZEPOXIDE (LIBRIUM) INDUCED CHANGES IN INTRASPECIFIC ATTACK AND SELECTED NONAGONISTIC BEHAVIORS IN MALE SIAMESE FIGHTING FISH.
217524 04-04

CARDIOVASCULAR EFFECTS OF DIAZEPAM AND CHLORDIAZEPOXIDE.
217659 04-03

RADIOIMMUNOASSAY OF CHLORDIAZEPOXIDE IN PLASMA.
217666 04-16

THE EFFECT OF CHLORDIAZEPOXIDE HYDROCHLORIDE ON THE ISOLATED PERFUSED RAT LIVER (38786).
217796 04-03

EFFECTS OF SCOPOLAMINE, PHYSOSTIGMINE AND CHLORDIAZEPOXIDE ON PUNISHED AND EXTINGUISHED WATER CONSUMPTION IN RATS.
221043 04-04

CHLORDIAZEPOXIDE EFFECTS ON REACTIONS TO NOVELTY AND ACTIVITY WITH AND WITHOUT PRIOR DRUG EXPERIENCE.
221047 04-04

EFFECTS OF CHLORDIAZEPOXIDE UPON FEAR MOTIVATED BEHAVIOR IN DOGS.
221799 04-04

THE EFFECT OF TRANQUILIZERS (DIAZEPAM AND CHLORDIAZEPOXIDE) ON THE BLOOD SUPPLY AND CARDIAC ACTIVITY.
223018 04-03

SPONTANEOUS ALTERNATION IN FERRETS FOLLOWING TREATMENT WITH SCOPOLAMINE, CHLORDIAZEPOXIDE, AND CAFFEINE.
223039 04-04

PHARMACOKINETICS OF CHLORDIAZEPOXIDE, MEPERIDINE, THIORIDAZINE, AND MESORIDAZINE AND CLINICAL RESPONSE.
224830 04-13

THE EFFECTS OF CHLORDIAZEPOXIDE ON THE DEVELOPMENT OF ADJUNCTIVE DRINKING IN RATS.
225149 04-04

CHLORDIAZEPOXIDE-INDUCED

CHLORDIAZEPOXIDE-INDUCED HOSTILITY IN A SMALL GROUP SETTING.
194865 01-14

CHLORIDE

EFFECTS OF LITHIUM CHLORIDE ON CARDIOVASCULAR RESPONSES INDUCED BY CHOLINERGIC AND ADRENERGIC STIMULATIONS.
199870 02-03

CONDITIONED SUPPRESSION OF MOUSE-KILLING IN RATS FOLLOWING RADIATION OR LITHIUM CHLORIDE INJECTIONS. (PH.D. DISSERTATION).
201153 02-04

THE ROLE OF SEX AND NOVELTY IN DETERMINING THE SOCIAL RESPONSE TO LITHIUM CHLORIDE.
202721 02-04

THE EFFECT OF SODIUM CHLORIDE ON KIDNEY FUNCTION IN RATS WITH LITHIUM INTOXICATION.
210696 03-03

CONDITIONED AVERSION TO MORPHINE WITH LITHIUM CHLORIDE IN MORPHINE-DEPENDENT RATS.
219039 04-04

CHLORIMIPRAMINE

EXPERIENCE WITH CHLORIMIPRAMINE (ANAFRANIL) IN PSYCHIATRY.
195533 01-09

COMPARISON OF THE SPECIFICITY OF 3-(P-TRIFLUOROMETHYLPHENOXY)-N-METHYL-3 PHENYLPROPYLAMINE AND CHLORIMIPRAMINE AS AMINE UPTAKE INHIBITORS IN MICE.
197870 01-03

DEPRESSION TREATED WITH CHLORIMIPRAMINE WITH SPECIAL ANALYSIS OF CHANGE IN BLOOD PRESSURE BY INFUSION.
199212 02-09

EFFECTS OF CHLORIMIPRAMINE ON EXPERIMENTALLY INDUCED CHANGES IN FOREBRAIN 5-HYDROXYINDOLES.
199966 02-03

EFFECT OF TWO WEEKS TREATMENT WITH CHLORIMIPRAMINE AND NORTRIPTYLINE, ALONE OR IN COMBINATION WITH ALCOHOL, ON LEARNING AND MEMORY.
200057 02-14

PRELIMINARY RESULTS OF A CONTROLLED TRIAL WITH SULPIRIDE VERSUS CHLORIMIPRAMINE IN CHRONIC SCHIZOPHRENIC PATIENTS WITH MARKED IDEO-EMOTIONAL POVERTY.
200445 02-08

THE ACTION OF CHLORIMIPRAMINE IN OBSESSIVE COMPULSIVE NEUROSIS: A PILOT STUDY.
209489 03-10

THE EFFECT OF RESERPINE AND CHLORIMIPRAMINE ON GLYCOGEN CONTENT IN DIFFERENT BRAIN STRUCTURES OF RAT.
211106 03-03

CHLORIMIPRAMINE IN SCHIZOPHRENIA.
220267 04-08

CHLOROFORM

CONSTITUENTS OF CANNABIS-SATIVA L. IX: STABILITY OF SYNTHETIC AND NATURALLY OCCURRING CANNABINOIDS IN CHLOROFORM.
211010 03-06

CHLORPHENTERMINE

LIPIDOSIS LIKE ALTERATIONS IN SPINAL CORD AND CEREBELLAR CORTEX OF RATS TREATED WITH CHLORPHENTERMINE OR TRICYCLIC ANTIDEPRESSANTS.
202767 02-03

CHLORPHENTERMINE-INDUCED

DOSE-DEPENDENCE OF CHLORPHENTERMINE-INDUCED ULTRASTRUCTURAL ALTERATIONS IN RAT.
197960 01-03

CHLORPROMAZINE

DROWSINESS DUE TO CHLORPROMAZINE IN RELATION TO CIGARETTE SMOKING: A REPORT FROM THE BOSTON COLLABORATIVE DRUG SURVEILLANCE PROGRAM.
193072 01-15

A CLINICAL TRIAL WITH THIOPROPERAZINE (MAJEPTIL M & B) -- A COMPARISON WITH CHLORPROMAZINE.
194311 01-11

INFLUENCE OF EMULSIFIED FAT ON CHLORPROMAZINE AVAILABILITY IN RABBIT BLOOD.
194928 01-03

DISTRIBUTION OF CHLORPROMAZINE IN A SIMPLIFIED BLOOD INFLUENCED BY VARIOUS DRUGS.
195245 01-03

THE EFFECT OF CHLORPROMAZINE AND IMIPRAMINE ON THE AVERSIVE THRESHOLD OF RATS.
195294 01-04

HYPOTHERMIC EFFECTS OF MARIHUANA, MARIHUANA DERIVATIVES AND CHLORPROMAZINE IN LABORATORY MICE.
196226 01-04

EFFECTS OF RESERPINE AND CHLORPROMAZINE ON 5-HYDROXYTRYPTAMINE UPTAKE OF PLATELETS FROM MIGRAINOUS AND CONTROL SUBJECTS.
196926 01-13

THE EFFECTS OF CORD SECTION UNDER ETHER OR HALOTHANE ON THE ABILITY OF CHLORPROMAZINE TO AFFECT THE JAW-JERK RESPONSE TO TOOTH PULP STIMULATION IN THE ENCEPHALE ISOLE PREPARATION.
197451 01-03

EFFECT OF SIMULATED ALTITUDE ON THE DISPOSITION OF CHLORPROMAZINE IN MOUSE BRAIN AND LIVER.
197455 01-05

THE INFLUENCE OF CHLORPROMAZINE AND RESERPINE ON THE METABOLISM OF CEREBRAL PHOSPHOLIPIDS IN THE RAT IN VIVO.
197477 01-03

CHLORPROMAZINE METABOLISM VI -- ADRENOLYTIC AND ANTISEROTONERGIC ACTIVITIES OF CHLORPROMAZINE AND ITS VARIOUS METABOLITES.
197494 01-03

TRUE AND APPARENT SIDE-EFFECTS IN A CONTROLLED TRIAL OF CHLORPROMAZINE AND IMIPRAMINE IN DEPRESSION.
197856 01-09

ADVERSE REACTIONS TO CHLORPROMAZINE IN PSYCHIATRIC PATIENTS.
197923 01-01

EFFECT OF ALCOHOLS, CHLORPROMAZINE AND DIPHENYLHYDANTOIN ON (CA2+) ATPASE OF HUMAN RED BLOOD CELLS.
197976 01-13

PATTERNS OF CHLORPROMAZINE USE IN GENERAL AND PSYCHIATRIC HOSPITALS.
198050 01-17

CHLORPROMAZINE METABOLISM IN ACUTE SCHIZOPHRENIA.
198094 02-08

CHLORPROMAZINE EFFECTS ON SELF-PUNITIVE BEHAVIOR.
198457 02-04

THE INHIBITORY EFFECT OF TOLUIDINE BLUE AND METHYLENE BLUE ON RAT MAST CELL DAMAGE BY PROMETHAZINE, CHLORPROMETHAZINE AND CHLORPROMAZINE. ITS REVERSAL BY GLUCOSE.
199255 02-05

A CONTROLLED OUTPATIENT TRIAL OF PERPHENAZINE AMITRIPTYLINE AND CHLORPROMAZINE.
199517 02-14

THE EFFECT OF CHLORPROMAZINE ON VISUAL INFORMATION PROCESSING IN NORMAL SUBJECTS.
199663 02-14

REACTION OF CATIONIC GROUPS OF CHLORPROMAZINE WITH ANIONIC MACROMOLECULES: COMPLEXES WITH DNA, RNA, HYALURONIC ACID AND HEPARIN.
199897 02-03

THE EFFECTS OF CHLORPROMAZINE, ATROPINE, MORPHINE AND PENTOBARBITAL ON INDUCED GASTRIC ULCERATION IN RATS. (PH.D. DISSERTATION).
200405 02-02

EXPERIMENTAL STUDY INTO IMMUNOLOGICAL FACTORS OF RESISTANCE TO CHLORPROMAZINE.
201920 02-03

COMPARISON OF MORPHINE AND CHLORPROMAZINE EFFECTS ON MODERATELY AND SEVERELY SUPPRESSED PUNISHED RESPONDING IN THE PIGEON.
202666 02-04

RIGIDITY IN RATS DUE TO ANEMIC DECEREBRATION AND THE EFFECT OF CHLORPROMAZINE.
202804 02-03

LIVER FUNCTION IN WORKERS OCCUPATIONALLY DEALING WITH CHLORPROMAZINE AND SOME OTHER COMPOUNDS.
202925 02-13

METHODS OF DECONDITIONING PERSISTING AVOIDANCE: AMPHETAMINE, CHLORPROMAZINE, AND CHLORDIAZEPOXIDE AS ADJUNCTS TO RESPONSE PREVENTION.
202987 02-04

CARDIOVASCULAR AND AUTONOMIC EFFECTS OF CHLORPROMAZINE. (PH.D. DISSERTATION).
203034 02-03

EFFECTS OF AMPHETAMINE AND AND CHLORPROMAZINE UPON OBSERVING RESPONSES IN RATS. (PH.D. DISSERTATION).
203166 02-04

CELLULAR MECHANISMS OF CHLORPROMAZINE PHOTOSENSITIVITY.
204233 02-15

A POLYGRAPHIC STUDY OF TOLERANCE OF SCHIZOPHRENICS TO CHLORPROMAZINE.
204430 02-08

PRIAPISM AS A POSSIBLE COMPLICATION OF THE CHLORPROMAZINE TREATMENT.
205594 02-15

THE INFLUENCE OF CHLORPROMAZINE ACTION ON EXPERIMENTAL PSYCHOSIS CAUSED BY LYSERGIC ACID DIETHYLAMIDE.
206439 03-04

THE ROLE OF THE RETICULAR FORMATION IN ACTION EXERTED BY CHLORPROMAZINE AND BENACTYZINE ON PRIMARY RESPONSES OF THE BRAIN-CORTEX.
206440 03-04

CHEMISTRY OF NONAQUEOUS TITRATION OF CHLORPROMAZINE.
206460 03-01

THE EFFECT OF L-DOPA AND L-DOPA COMBINED WITH CHLORPROMAZINE ON SPINAL CORD ACTIVITY DURING DISTURBED INHIBITION BY TETANUS TOXOID.
207200 03-03

PSYCHOACTIVE DRUGS IN MANIA: A CONTROLLED COMPARISON OF LITHIUM CARBONATE, CHLORPROMAZINE AND HALOPERIDOL.
207446 03-09

SULPIRIDE VERSUS CHLORPROMAZINE AND PLACEBO IN THE TREATMENT OF RESTLESS MENTALLY SUBNORMAL PATIENTS -- A DOUBLE-BLIND CROSSOVER STUDY.
209702 03-11

DRUG-RESISTANCE AND BIOCLINICAL FACTORS IN THE RESPONSE OF SCHIZOPHRENIC PATIENTS TO CHLORPROMAZINE.
210500 03-08

THE EFFECTS OF CHLORPROMAZINE AND D-AMPHETAMINE SULFATE ON THE VISUAL STIMULATION PREFERENCE OF EXTRAVERTS AND INTROVERTS.
210680 03-14

THE EFFECT OF COCA-COLA, CAFFEINE, ANTIDEPRESSANTS AND CHLORPROMAZINE ON OBJECTIVE AND SUBJECTIVE SLEEP PARAMETERS.
210808 03-14

DIFFERENTIAL EFFECTS OF CHLORPROMAZINE AND CHLORPROMAZINE FREE-RADICAL ON CALCIUM TRANSPORT IN SARCOPLASMIC RETICULUM VESICLES.
210812 03-03

EFFECT OF THE ACTIVATION OF THE KININ FORMING SYSTEM ON THE POTENCY OF CHLORPROMAZINE.
210872 03-03

THE TOXICITY OF CHLORPROMAZINE AND MESCALINE ON MOUSE CEREBELLUM AND FIBROBLAST CELLS IN CULTURE.
210890 03-03

THE EFFECT OF CERTAIN TRANQUILISERS, CHLORPROMAZINE METABOLITES AND DIETHYLDITHIOCARBAMATE ON TISSUE AMPHETAMINE LEVELS IN THE RAT.
211111 03-03

THE EFFECT OF CHLORPROMAZINE AND STIMULATION OF THE MESENCEPHALIC RETICULAR FORMATION ON CENTRAL AROUSAL AND ON THE VISUAL EVOKED RESPONSE. (PH.D. DISSERTATION).
212547 03-03

THE COMPARATIVE EFFECTS OF MORPHINE AND CHLORPROMAZINE ON THE ACQUISITION OF CONDITIONED AVOIDANCE RESPONSE. (PH.D. DISSERTATION).
212963 03-04

CHLORPROMAZINE: SPECIFIC INHIBITION OF L-NORADRENALINE AND 5-HYDROXYTRYPTAMINE UPTAKE IN SYNAPTOSOMES FROM SQUID BRAIN.
213395 04-03

(3H)GLUTAMATE UPTAKE AT INSECT NEUROMUSCULAR JUNCTIONS: EFFECT OF CHLORPROMAZINE.
213474 04-03

CHLORPROMAZINE AND BRAIN CATECHOLAMINE SYNTHESIS.
213630 04-03

BIOCHEMICAL VERSUS PSYCHOPATHOLOGICAL ACTION PROFILE OF NEUROLEPTICS: A COMPARATIVE STUDY OF CHLORPROMAZINE AND OXYPERTINE IN ACUTE PSYCHOTIC DISORDERS.
215454 04-13

THE ACTION OF CHLORPROMAZINE AND TRIFTAZINE ON DISCHARGES OF CORTICAL NEURONS IN RABBITS AFTER CHRONIC ADMINISTRATION OF THE DRUGS.
215499 04-03

EFFECTS OF IPRONIAZID, CHLORPROMAZINE AND METHIOTHEPIN ON DMT INDUCED CHANGES IN BODY TEMPERATURE, PUPILLARY DILATATION, BLOOD PRESSURE AND EEG IN THE RABBIT.
215724 04-03

A RELATION BETWEEN DRUG CONCENTRATIONS IN BRAIN AND STRIATAL HOMOVANILLIC ACID LEVELS IN CHLORPROMAZINE TREATED RATS.
215734 04-03

DIFFERENTIAL EFFECTS OF CHLORPROMAZINE, IMIPRAMINE, NITRAZEPAM AND AMOBARBITAL ON REM SLEEP AND REM DENSITY IN MAN.
215955 04-14

THE PROTECTIVE EFFECT OF SEROTONIN AGAINST THE INHIBITORY ACTION OF CHLORPROMAZINE ON THE MEMBRANE POTENTIAL OF STAGE 2 BLASTOMERES OF MOUSE EMBRYOS IN VITRO.
217005 04-03

NEUROLEPTIC-INDUCED HYPERSENSITIVITY OF STRIATAL DOPAMINE RECEPTORS IN THE RAT AS A MODEL OF TARDIVE DYSKINESIAS. EFFECTS OF CLOZAPINE, HALOPERIDOL, LOXAPINE AND CHLORPROMAZINE.
217462 04-03

EEG CORRELATES OF IMP\IRED ATTENTION PERFORMANCE UNDER SECOBARBITAL AND CHLORPROMAZINE IN THE MONKEY.
217544 04-03

CHLORPROMAZINE EXCRETION IN CHRONICALLY DOSED PRIMATES. I. OCCURRENCE OF A PREVIOUSLY UNREPORTED CLASS OF CHLORPROMAZINE CONJUGATES.
217553 04-03

ARRHYTHMIAS AND INHIBITION OF NORADRENALINE UPTAKE CAUSED BY TRICYCLIC ANTIDEPRESSANTS AND CHLORPROMAZINE ON THE ISOLATED PERFUSED RABBIT HEART.
217657 04-03

CHLORPROMAZINE METABOLISM IV: QUATERNIZATION AS A KEY TO DETERMINATION OF PICOMOLES OF CHLORPROMAZINE AND OTHER TERTIARY AMINE DRUGS.
217667 04-06

IN VIVO RELEASE OF ENDOGENOUS NEUROTRANSMITTERS IN CAT LIMBIC REGIONS: EFFECT OF CHLORPROMAZINE AND OF ELECTRICAL STIMULATION.
217685 04-03

ANTIDEPRESSANTS IN BLACK AND WHITE INPATIENTS: DIFFERENTIAL RESPONSE TO A CONTROLLED TRIAL OF CHLORPROMAZINE AND IMIPRAMINE.
218770 04-09

TOWARDS THE MECHANISM OF THE ANTIPHLOGISTIC ACTION OF CHLORPROMAZINE.
219507 04-03

RESULTS OF A COMPARATIVE DOUBLE-BLIND STUDY WITH CLOZAPINE AND CHLORPROMAZINE IN THE TREATMENT OF SCHIZOPHRENIC PATIENTS.
221989 04-08

DEVELOPMENT OF RADIOIMMUNOASSAY FOR CHLORPROMAZINE.
222802 04-06

CENTRAL CATECHOLAMINE RECEPTOR BLOCKING ACTIONS OF BE-2254 (HEAT): COMPARISON WITH CHLORPROMAZINE AND HALOPERIDOL.
222804 04-03

THE EFFECT OF THE PSYCHOTROPIC AGENTS (CHLORPROMAZINE, MAJEPTIL, TRICEDIL) ON PROTEIN SYNTHESIS IN VARIOUS PORTIONS OF THE RAT BRAIN.
223063 04-03

SIGNIFICANCE OF PLASMA CHLORPROMAZINE IN MANAGEMENT OF PSYCHIATRIC PATIENTS.
224832 04-13

CHLORPROMAZINE-INDUCED

ENHANCEMENT OF THE CHLORPROMAZINE-INDUCED SUPPRESSION OF THE CONDITIONED AVOIDANCE RESPONSE BY CARBONIC ANHYDRASE INHIBITION.
199770 02-03

CHLORPROMAZINE-INDUCED HYPERPHAGIA IN THE RAT.
217552 04-04

CHLORPROMETHAZINE

THE INHIBITORY EFFECT OF TOLUIDINE BLUE AND METHYLENE BLUE ON RAT MAST CELL DAMAGE BY PROMETHAZINE, CHLORPROMETHAZINE AND CHLORPROMAZINE. ITS REVERSAL BY GLUCOSE.
199255 02-05

CHLORPROTHIXENE

ON THE PHARMACOKINETICS OF CHLORPROTHIXENE IN MAN.
219630 04-13

CHOICE

DIFFERENTIAL EFFECTS ON LEVER CHOICE AND RESPONSE RATE PRODUCED BY D-AMPHETAMINE.
194178 01-04

CHLORDIAZEPOXIDE (LIBRIUM): THE EFFECTS OF A MINOR TRANQUILIZER ON STRATEGIC CHOICE BEHAVIOR IN THE PRISONERS DILEMMA.
199609 02-14

1974 DRUGS OF CHOICE 1975.
206605 03-17

CHOLESTEROL

HEPATIC CHOLESTEROL SYNTHESIS IN MAN: EFFECT OF DIAZEPAM AND OTHER DRUGS.
215681 04-15

CHOLINE

SOME OF THE DYNAMICS OF CHOLINE AND ACETYLCHOLINE METABOLISM IN RAT BRAIN.
197474 01-03

EFFECTS OF CYTIDINE DIPHOSPHATE CHOLINE ON THE NERVOUS SYSTEM IN CATS.
198610 02-04

POSTNATAL DEVELOPMENT OF CHOLINE UPTAKE BY CHOLINERGIC TERMINALS IN RAT BRAIN.
210713 03-03

REGIONAL AND SUBCELLULAR DISTRIBUTION AND KINETIC PROPERTIES OF RAT BRAIN CHOLINE ACETYLTRANSFERASE -- SOME FUNCTIONAL CONSIDERATIONS.
210816 03-03

EFFECT OF CHOLINE ACETYLTRANSFERASE INHIBITORS ON MOUSE AND GUINEA-PIG BRAIN CHOLINE AND ACETYLCHOLINE.
210883 03-03

METABOLISM OF 4-CHLOROAMPHETAMINE TO 3-CHLORO-4-HYDROXYAMPHETAMINE IN RAT: EVIDENCE FOR AN IN VIVO NIH SHIFT OF CHOLINE.
210929 03-03

HOMOVANILLIC ACID CONCENTRATION IN RAT BRAIN: EFFECT OF A CHOLINE ACETYLTRANSFERASE INHIBITOR AND COMPARISON WITH CHOLINERGIC AND DOPAMINERGIC AGENTS.
215711 04-03

BRAIN ACETYLCHOLINE: INCREASE AFTER SYSTEMIC CHOLINE ADMINISTRATION.
217399 04-03

THE EFFECT OF HEMICHOLINIUM ON BEHAVIOR AND ON BRAIN ACETYLCHOLINE AND CHOLINE IN THE RAT.
217551 04-04

DEVELOPMENTAL VARIATIONS OF CHOLINE ACETYLTRANSFERASE, DOPAMINE-BETA-HYDROXYLASE AND MONOAMINEOXIDASE IN CHICKEN EMBRYO AND CHICKEN SYMPATHETIC GANGLIA.
217840 04-03

THE DISTRIBUTION KINETICS AND TURNOVER OF CHOLINE AND ACETYLCHOLINE IN PLASMA AND BRAIN OF RATS. (PH.D. DISSERTATION).
220472 04-03

CHOLINERGIC

INTERRELATION BETWEEN MONOAMINERGIC AND CHOLINERGIC MECHANISMS IN THE HYPOTHALAMIC THERMOREGULATORY CENTRE OF RABBITS.
195249 01-03

THE IMPORTANCE OF THE ASCENDING DOPAMINERGIC SYSTEMS TO THE EXTRAPYRAMIDAL AND MESOLIMBIC BRAIN AREAS FOR THE CATALEPTIC ACTION OF THE NEUROLEPTIC AND CHOLINERGIC AGENTS.
195250 01-03

BLOCKADE BY ESERINE OF THE CEREBRAL CORTICAL EFFECTS OF ALLOFERIN: A FURTHER EVIDENCE OF CHOLINERGIC INHIBITORY MECHANISM.
195548 01-03

EFFECTS OF MORPHINE, CHOLINERGIC AGENTS AND COLD EXPOSURE ON MIDBRAIN DOPAMINE (DA) NERVE CELLS OF MORPHINE TOLERANT AND NONTOLERANT MICE.
197287 01-03

ON THE ACTION OF OXOTREMORINE ON THE CHOLINERGIC SYSTEM OF THE RAT BRAIN.
197968 01-03

ONTOGENETIC ASPECTS OF CENTRAL CHOLINERGIC INVOLVEMENT IN SPONTANEOUS ALTERNATION BEHAVIOR.
199550 02-04

EFFECTS OF LITHIUM CHLORIDE ON CARDIOVASCULAR RESPONSES INDUCED BY CHOLINERGIC AND ADRENERGIC STIMULATIONS.
199870 02-03

EFFECT OF CHOLINERGIC AND ANTICHOLINERGIC AGENTS ON TARDIVE DYSKINESIA.
200086 02-13

EFFECTS OF CENTRAL AND PERIPHERAL ADRENERGIC AND CHOLINERGIC MODIFICATION ON TIME-DEPENDENT PROCESSES IN AVOIDANCE PERFORMANCE.
202203 02-03

CENTRAL CHOLINERGIC INFLUENCE ON SELF-ADMINISTRATION OF MORPHINE AND AMPHETAMINE.
205889 03-04

STUDIES ON THE TIME COURSE AND THE EFFECT OF CHOLINERGIC AND ADRENERGIC RECEPTOR BLOCKERS ON THE STIMULUS EFFECT OF NICOTINE.
206353 03-03

ANTISCHIZOPHRENIC DRUGS: AFFINITY FOR MUSCARINIC CHOLINERGIC RECEPTOR SITES IN THE BRAIN PREDICTS EXTRAPYRAMIDAL EFFECTS.
207298 03-03

CHOLINERGIC DOPAMINERGIC INTERACTION IN THE STRIATUM: THE EFFECT OF 6-HYDROXYDOPAMINE OR PIMOZIDE TREATMENT ON THE INCREASED STRIATAL ACETYLCHOLINE LEVELS INDUCED BY APOMORPHINE, PIRIBEDIL AND D-AMPHETAMINE.
210668 03-03

EFFECTS OF DOPAMINERGIC RECEPTOR AGONISTS AND ANTAGONISTS ON THE ACTIVITY OF THE NEOSTRIATAL CHOLINERGIC SYSTEM.
210669 03-03

POSTNATAL DEVELOPMENT OF CHOLINE UPTAKE BY CHOLINERGIC TERMINALS IN RAT BRAIN.
210713 03-03

EVOKED NEURAL ACTIVITY IN THE BASAL GANGLIA OF THE CAT AND ITS MODIFICATION BY CHOLINERGIC AND DOPAMINERGIC AGENTS. (PH.D. DISSERTATION).
212520 03-03

IN VIVO IDENTIFICATION OF MUSCARINIC CHOLINERGIC RECEPTOR BINDING IN RAT BRAIN.
213480 04-03

ADRENERGIC AND CHOLINERGIC DRUG EFFECTS UPON SHORT-TERM MEMORY IN MICE. (PH.D. DISSERTATION).
214205 04-04

A NEUROPHARMACOLOGICAL ANALYSIS OF CHOLINERGIC MECHANISMS OF SELF-STIMULATION REACTIONS.
215497 04-04

CHOLINERGIC AGENTS AFFECT TWO RECEPTORS THAT MODULATE TRANSMITTER RELEASE AT A CENTRAL SYNAPSE IN APLYSIA-CALIFORNICA.
215705 04-03

HOMOVANILLIC ACID CONCENTRATION IN RAT BRAIN: EFFECT OF A CHOLINE ACETYLTRANSFERASE INHIBITOR AND COMPARISON WITH CHOLINERGIC AND DOPAMINERGIC AGENTS.
215711 04-03

ONTOGENESIS OF NEOSTRIATAL CHOLINERGIC NEURONES IN THE RAT AND DEVELOPMENT OF THEIR SENSITIVITY TO NEUROLEPTIC DRUGS.
217658 04-03

NEUROLEPTICS: RELATION BETWEEN CATALEPTIC AND ANTITURNING ACTIONS, AND ROLE OF THE CHOLINERGIC SYSTEM.
217826 04-04

THE PARTICIPATION OF CEREBRAL CHOLINERGIC MECHANISMS IN THE ACTION OF NEUROLEPTICS.
218471 04-04

BEHAVIORALLY EVOKED HIPPOCAMPAL THETA WAVES: A CHOLINERGIC RESPONSE.
220312 04-03

SEROTONERGIC AND CHOLINERGIC MECHANISMS DURING DISRUPTION OF APPROACH AND AVOIDANCE BEHAVIOR.
225161 04-04

CHOLINERGICALLY

CENTRAL NERVOUS SYSTEM PHARMACOLOGY OF CHOLINERGICALLY ELICITED EATING AND DRINKING BEHAVIOR IN THE ALBINO RAT. (PH.D. DISSERTATION).
222638 04-04

CHOLINERGICS

THE EFFECT OF CHOLINERGICS ON SHORT-TERM MEMORY AND THE EXCITABILITY LEVEL OF HIPPOCAMPUS CIRCLE STRUCTURES.
208972 03-03

CHOLINESTERASE

BRAIN ACETYLCHOLINE AND CHOLINESTERASE: EFFECT OF PHENOTHIAZINES AND PHYSOSTIGMINE INTERACTION IN RATS.
195046 01-03

EFFECTS OF DIISOPROPYLPHOSPHOFLUORIDATE ON ACETYLCHOLINE, CHOLINESTERASE AND CATECHOLAMINES OF SEVERAL PARTS OF RABBIT BRAIN.
195094 01-03

REDUCED BEHAVIOURAL EFFECTS OF INTRAHIPPOCAMPALLY ADMINISTERED CARBACHOL IN RATS WITH LOW CHOLINESTERASE ACTIVITY.
199956 02-04

EFFECTS OF CHOLINESTERASE INHIBITION ON THE VISUAL EVOKED POTENTIALS IN THE RABBIT AND THEIR MODIFICATION WITH VARIOUS DRUGS.
205631 03-03

CHOLINOMIMETIC

THE PHARMACOLOGY OF GROSS BEHAVIOURAL EFFECTS OF CHOLINOMIMETIC SUBSTANCES INJECTED INTO THE CEREBRAL VENTRICLES OF UNANAESTHETIZED CATS: EVIDENCE FOR CENTRAL MUSCARINIC MEDIATION.
202780 02-04

CHOLINOMIMETICS

SENSITIVITY OF DENERVATED CEREBRAL CORTEX TO CHOLINOMIMETICS.
199769 02-03

COMPARISON OF THE EFFECTS OF THE INTRANIGRAL INJECTIONS OF CHOLINOMIMETICS WITH SYSTEMIC INJECTIONS OF THE DOPAMINE RECEPTOR STIMULATING AND BLOCKING AGENTS IN THE RABBIT.
199772 02-03

THE INFLUENCE OF CHOLINOMIMETICS ON THE AFTEREFFECTS OF TRACE DISCHARGES AND THE ACTIVITY OF EPILEPTOGENIC FOCI IN THE RABBIT HIPPOCAMPUS.
219499 04-03

CHOLINORECEPTOR

INCORPORATION OF ACETATE (C14)(P-32) AND PHOSPHATE INTO THE BRAIN LIPIDS DURING BLOCKAGE OF THE CHOLINORECEPTOR AND ADRENORECEPTORS.
202599 02-03

CHOREIFORM

THE EFFECT OF D-AMPHETAMINE ON CHOREIFORM MOVEMENT DISORDERS.
202282 02-11

CHOREOATHETIC

SEIZURES OF CHOREOATHETIC TYPE INDUCED BY SUDDEN MOVEMENT: CORRELATION TO THE BIOGENIC AMINES.
196146 01-14

CHOREOATHETOSIS

TRICYCLIC ANTIDEPRESSANT POISONING: REVERSAL OF COMA, CHOREOATHETOSIS, AND MYOCLONUS BY PHYSOSTIGMINE.
202919 02-15

CHROMAFFIN

IMMUNOLOGICAL LOCALIZATION OF DOPAMINE-BETA-HYDROXYLASE ON THE CHROMAFFIN GRANULE MEMBRANE.
207326 03-03

CHROMATOGRAPHIC

GAS CHROMATOGRAPHIC ANALYSES OF BARBITURATES IN SMALL AMOUNTS OF BLOOD.
197279 01-01

ON THE GAS CHROMATOGRAPHIC ANALYSIS OF BENZODIAZEPINES: SECOND COMMUNICATION: DIAZEPAM AND ITS METABOLITES.
221739 04-06

CHROMATOGRAPHY

MICROMETHODS FOR QUANTITATIVE DETERMINATION OF SEDATIVES AND ANTIPYRETICS BY THERMO-GAS CHROMATOGRAPHY.
206807 03-06

RAPID MASS SCREENING AND CONFIRMATION OF URINARY AMPHETAMINE AND METHAMPHETAMINE BY GAS CHROMATOGRAPHY.
222829 04-06

RAPID ANALYSIS OF THE CENTRAL NERVOUS SYSTEM STIMULANTS, AMPHETAMINES, VIA GAS CHROMATOGRAPHY MASS SPECTROMETRY: RAPID ACYLATION IN THE PRESENCE OF A MERCURY CATALYST.
222830 04-06

CHROMOGENS

STUDIES ON ANTIDIURETIC ACTIVITIES AND ON PORTER-SILBERS CHROMOGENS CONTENT IN PLASMA OF PATIENTS WITH ALCOHOLIC DELIRIUM OR WITH ACUTE PHENOTHIAZINE INTOXICATIONS.
203741 02-15

CHROMOSOMAL

CHROMOSOMAL ABERRATION RATES AND INTRAVENOUSLY GIVEN DIAZEPAM: A NEGATIVE STUDY.
195949 01-13

CHROMOSOMAL DAMAGE IN CHRONICAL USERS OF CANNABIS: IN VIVO INVESTIGATION WITH TWO-DAY LEUKOCYTE CULTURES.
210810 03-15

CHROMOSOMES

THE EFFECT OF PSYCHOPHARMACOLOGICAL DRUGS ON PUFFING AND ON RNA AND DNA SYNTHESES IN THE SALIVARY GLAND CHROMOSOMES OF DROSOPHILA-MELANOGASTER. (PH.D. DISSERTATION).
196250 01-03

CHRONIC

A DOUBLE-BLIND CROSSOVER COMPARISON BETWEEN CLOTHIAPINE AND DIAZEPAM IN THE TREATMENT OF MENTAL SYMPTOMS IN CHRONIC ALCOHOLICS.
192988 01-11

COMPARISON BETWEEN THE EFFECTS PRODUCED BY CHRONIC DENERVATION AND BY COCAINE ON THE SENSITIVITY TO, AND ON THE DISPOSITION OF, NORADRENALINE IN ISOLATED SPLEEN STRIPS.
193139 01-03

CHRONIC ORAL TOXICITY OF CANNABINOIDS IN MONKEYS.
193417 01-05

EFFECT OF ACUTE AND CHRONIC DIELDRIN EXPOSURE ON BRAIN BIOGENIC AMINES OF MALE AND FEMALE RATS.
193428 01-03

ACUTE, SUBACUTE AND 23-DAY CHRONIC MARIHUANA INHALATION TOXICITIES IN THE RAT.
193576 01-04

EFFECT OF CHRONIC ADMINISTRATION OF CENTRALLY ACTING COMPOUNDS ON CHLORAMPHENICOL METABOLISM IN SCHIZOPHRENIC PATIENTS.
194157 01-08

BRAIN DOPA/5-HTP DECARBOXYLASE ACTIVITY AFTER THE CHRONIC ADMINISTRATION OF L-DOPA OR 5-HYDROXY-L-TRYPTOPHAN IN NORMAL AND LESIONED CATS.
194483 01-05

EVALUATION OF LITHIUM THERAPY IN CHRONIC AND PERIODIC ALCOHOLISM.
194758 01-11

EFFECTS OF CHLORDIAZEPOXIDE IN RESPIRATORY FAILURE DUE TO CHRONIC BRONCHITIS.
194854 01-13

EFFECT OF THIOTHIXENE UPON THE HIGHER NERVOUS ACTIVITY IN CHRONIC SCHIZOPHRENICS.
195041 01-09

EFFECTS OF WITHDRAWAL FROM CHRONIC AMPHETAMINE ADMINISTRATION ON ACTIVITY LEVELS OF ALBINO RATS.
195223 01-04

EFFECT OF CHRONIC TRANSECTION ON DOPAMINE, NORADRENALINE AND 5-HYDROXYTRYPTAMINE IN THE RAT SPINAL CORD.
195244 01-03

CLINICAL EFFICACY OF PIMOZIDE IN HOSPITALISED CHRONIC SCHIZOPHRENICS.
195615 01-08

EFFECTS IN THE SUCKLING RAT OF CHRONIC TREATMENT WITH TRYPTOPHAN AND A MONOAMINE OXIDASE INHIBITOR.
195906 01-04

DRUG TREATMENT OF CHRONIC INTRACTABLE PAIN IN PATIENTS REFERRED TO A PSYCHIATRY CLINIC.
196090 01-14

DIAGNOSING AND TREATING CHRONIC SCHIZOPHRENIA.
196601 01-08

PENFLURIDOL (R-16341) AS A MAINTENANCE THERAPY IN CHRONIC PSYCHOTIC PATIENTS: A DOUBLE-BLIND CLINICAL EVALUATION.
197033 01-09

THE EFFECT OF CHRONIC CANNABIS AND CANNABINOID APPLICATION ON THE HEPATIC DRUG METABOLIZING SYSTEM OF THE RAT.
197282 01-03

PSYCHOPHARMACOLOGICAL EVIDENCE FOR INCREASE IN RECEPTOR SENSITIVITY FOLLOWING CHRONIC MORPHINE TREATMENT.
197855 01-04

TURNOVER OF BIOGENIC AMINES AFTER ACUTE AND CHRONIC MORPHINE TREATMENT IN RATS.
197974 01-03

REGIONAL DIFFERENCES IN HOMOVANILLIC ACID CONCENTRATIONS AFTER ACUTE AND CHRONIC ADMINISTRATION OF ANTIPSYCHOTIC DRUGS.
198210 02-03

CLINICAL EXPERIENCE WITH FORIT: ITS ACTIVATING EFFECT ON CHRONIC SCHIZOPHRENIA.
198710 02-08

CHRONIC LYSERGIC ACID DIETHYLAMIDE ADMINISTRATION AND SEROTONIN TURNOVER IN VARIOUS REGIONS OF RAT BRAIN.
199783 02-03

INHIBITION OF SYMPATHETIC ACTIVITY FOLLOWING CHRONIC ADMINISTRATION OF 2-AMINO-4-(3,4 DICHLOROPHENYL) 2-IMIDAZOLINE (MJ-10459-2).
199863 02-03

BEHAVIOURAL SUPERSENSITIVITY TO APOMORPHINE FOLLOWING CHRONIC TREATMENT WITH DRUGS WHICH INTERFERE WITH THE SYNAPTIC FUNCTION OF CATECHOLAMINES.
199958 02-04

ACUTE AND CHRONIC EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON FOOD INTAKE BY RATS.
200043 02-04

PRELIMINARY RESULTS OF A CONTROLLED TRIAL WITH SULPIRIDE VERSUS CHLORIMIPRAMINE IN CHRONIC SCHIZOPHRENIC PATIENTS WITH MARKED IDEO-EMOTIONAL POVERTY.
200445 02-08

MAINTENANCE TREATMENT OF CHRONIC SCHIZOPHRENIA WITH NEUROLEPTIC DRUGS.
200636 02-08

AGGRESSIVE BEHAVIORS INDUCED BY CHRONIC ADMINISTRATION OF THEOPHYLLINE, WITH PARTICULAR REFERENCE TO ALTERATIONS IN BEHAVIORS OF IMMATURE RATS.
200748 02-04

REMARKS ON THE USE OF FLUPENTHIXOL IN TREATING CHRONIC SCHIZOPHRENIA.
201669 02-08

PLASMA TESTOSTERONE LEVELS DURING CHRONIC HEROIN USE AND PROTRACTED ABSTINENCE.
202307 02-13

EVENTUAL DEVELOPMENTS OF 64 CHRONIC PSYCHOTICS ON MODITEN RETARD OR MODECATE TREATMENT.
202514 02-09

CLINICAL TRIAL OF FLUPENTHIXOL IN PATIENTS WITH CHRONIC SCHIZOPHRENIA: ESPECIALLY IN PATIENTS HAVING DIFFICULTY IN REHABILITATION OWING TO DECREASED EXPRESSION, APATHY AND DISTURBANCE OF RAPPORT.
202603 02-08

CHRONIC AMPHETAMINE TREATMENT: VAST INDIVIDUAL DIFFERENCES IN PERFORMING A LEARNED RESPONSE.
202794 02-04

THE EFFECTS OF NEUROLEPTIC AGENTS IN THE CHRONIC PHARMACOLOGICAL EXPERIMENT.
202863 02-04

APONEURON TREATMENT OF CHRONIC SCHIZOPHRENICS WITH REDUCED DRIVE.
203666 02-08

MONTHLY INTERMITTENT CHEMOTHERAPY OF CHRONIC SCHIZOPHRENIC OUTPATIENTS WITH PIPOTHIAZINE PALMITATE.
204169 02-08

DIFFERENTIAL EFFECTS OF NEUROLEPTIC DRUGS IN CHRONIC SCHIZOPHRENICS: A CONFIGURATION ANALYTICAL EVOLUTION.
204415 02-08

THE ALTERATION OF AVERSIVE THRESHOLDS AFTER CHRONIC ADMINISTRATION OF TWO TRANQUILIZING AGENTS.
205418 02-04

THE EFFECTS OF CHRONIC PHENOTHIAZINE TREATMENT ON ADRENAL PITUITARY FUNCTION IN MAN.
205765 03-13

CEREBRAL HEMODYNAMIC EFFECTS OF CHRONIC TRYPTOPHAN FEEDING IN MAN AS MEASURED BY QUANTIFIED CEREBRAL IMPEDANCE PLETHYSMOGRAPHY.
206337 03-08

NEUROPHARMACOLOGICAL FINDINGS AFTER CHRONIC ADMINISTRATION OF HALOPERIDOL, LOXAPINE AND CLOZAPINE.
206972 03-03

CLOZAPINE IN LONG-TERM THERAPY OF CHRONIC SCHIZOPHRENIA.
206975 03-08

SEROTONIN AND DOPAMINE TURNOVER AFTER ACUTE AND CHRONIC MORPHINE ADMINISTRATION.
206989 03-03

CLINICAL USE OF CLOCAPRAMINE FOR THE TREATMENT OF CHRONIC SCHIZOPHRENIA -- SPECIAL EMPHASIS ON ITS COMPARISON WITH PERPHENAZINE.
207534 03-08

EFFECTS OF PHENOTHIAZINE WITHDRAWAL ON PROVERB INTERPRETATION BY CHRONIC SCHIZOPHRENICS.
208325 03-08

A CONTRIBUTION TO THE STUDY OF CHRONIC AMPHETAMINE PSYCHOSIS.
208970 03-15

SULPIRIDE IN AMBULATORY TREATMENT OF CHRONIC PSYCHOTICS.
209533 03-14

ENDOCRINE EFFECTS OF CHRONIC ADMINISTRATION OF PSYCHOACTIVE DRUGS TO PREPUBERAL MALE RATS. I: DELTA9-TETRAHYDROCANNABINOL.
209840 03-03

PIMOZIDE IN CHRONIC SCHIZOPHRENIC OUTPATIENTS.
209905 03-08

A CLINICAL EXPERIMENTAL STUDY ON THE USE OF SULPIRIDE IN A GROUP OF CHRONIC SCHIZOPHRENICS (FIRST NOTE).
210510 03-08

NORMAL SHUTTLEBOX AVOIDANCE LEARNING AFTER CHRONIC PHENOBARBITAL INTOXICATION IN MICE.
210737 03-04

ENHANCEMENT OF APOMORPHINE-INDUCED INHIBITION OF STRIATAL DOPAMINE TURNOVER FOLLOWING CHRONIC HALOPERIDOL.
210814 03-03

COMPARISON OF 3,4 DIMETHOXYPHENYLETHYLAMINE TREATED PLASMA FROM CHRONIC SCHIZOPHRENICS AND CONTROLS.
210897 03-08

THE EFFECTS OF ACUTE AND CHRONIC MORPHINE ADMINISTRATION ON THE LEVELS OF 3-METHOXY-4-HYDROXYPHENYLGLYCOL SULFATE IN RAT BRAIN.
210927 03-03

USE OF A NEW PSYCHOTROPIC DRUG, CLOFLUPEROL FOR THE TREATMENT OF CHRONIC SCHIZOPHRENIC PATIENTS.
211304 03-08

THREE CASES OF CHRONIC CHLORDIAZEPOXIDE INTOXICATION AND THEIR WITHDRAWAL SYMPTOMS.
211360 03-15

BEHAVIORAL AND NEUROCHEMICAL EFFECTS OF MORPHINE OR AMPHETAMINE AFTER CHRONIC PRETREATMENT WITH CATECHOLAMINE DEPLETING AGENTS. (PH.D. DISSERTATION).
211746 03-03

INFLUENCE OF RESERPINE ON ALL-NIGHT SLEEP PATTERN IN NONLOBOTOMIZED AND LOBOTOMIZED CHRONIC SCHIZOPHRENIC PATIENTS.
213530 04-08

A COMPARISON OF THE THERAPEUTIC EFFECT OF OXYPERTINE AND THIORIDAZINE IN CHRONIC SCHIZOPHRENIA (A CONTROLLED TRIAL).
215075 04-08

THE ACTION OF CHLORPROMAZINE AND TRIFTAZINE ON DISCHARGES OF CORTICAL NEURONS IN RABBITS AFTER CHRONIC ADMINISTRATION OF THE DRUGS.
215499 04-03

INCREASED SENSITIVITY TO DOPAMINERGIC AGENTS AFTER CHRONIC NEUROLEPTIC TREATMENT.
215689 04-04

THE EFFECT OF CHRONIC LITHIUM APPLICATION ON THE MINERAL CONTENT OF RAT BONE AND SOFT TISSUES.
215695 04-05

POLYGRAPHIC NIGHT SLEEP PATTERN DURING CHRONIC SINGLE AND MULTIPLE NEUROLEPTIC DOSE ADMINISTRATION.
215701 04-08

EFFECT OF WITHDRAWAL FROM CHRONIC ETHANOL INGESTION ON THE CAMP RESPONSE OF CEREBRAL CORTICAL SLICES USING THE AGONISTS HISTAMINE, SEROTONIN, AND OTHER NEUROTRANSMITTERS.
215980 04-03

THE EFFECTS OF CHRONIC CANNABIS TREATMENT UPON BRAIN 5-HYDROXYTRYPTAMINE, PLASMA CORTICOSTERONE AND AGGRESSIVE BEHAVIOR IN FEMALE RATS WITH DIFFERENT HORMONAL STATUS.
217532 04-04

ACUTE AND CHRONIC EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON SEIZURES IN THE GERBIL.
217673 04-03

LOXAPINE IN NEWLY ADMITTED CHRONIC SCHIZOPHRENIC PATIENTS.
217810 04-08

EFFECT OF CHRONIC PHENOBARBITAL ADMINISTRATION UPON BRAIN GROWTH OF THE INFANT RAT.
217885 04-03

CHANGES IN THE CONCENTRATIONS OF 5-HYDROXYTRYPTAMINE AND NORADRENALINE IN SIX AREAS OF RAT BRAIN DURING RECOVERY FROM CHRONIC METHYLAMPHETAMINE ADMINISTRATION.
217963 04-03

EFFECTS OF CHRONIC ADMINISTRATION AND WITHDRAWAL OF D-AMPHETAMINE UPON DAILY ACTIVITY LEVELS OF SQUIRREL MONKEYS.
219032 04-04

BLOCKADE OF ALPHA-METHYLTYROSINE-INDUCED SUPERSENSITIVITY TO APOMORPHINE BY CHRONIC ADMINISTRATION OF L-DOPA.
220974 04-03

DOES CHRONIC MORPHINE TREATMENT INDUCE A SUPERSENSITIVITY OF DOPAMINE RECEPTORS IN RAT BRAIN
221038 04-03

PERPHENAZINE ENANTHATE IN TREATING CHRONIC SCHIZOPHRENIA.
221558 04-08

COMPARATIVE STUDY OF CLOCAPRAMINE AND PERPHENAZINE ON CHRONIC SCHIZOPHRENIA BY A DOUBLE-BLIND METHOD.
222158 04-08

TREATMENT EXPERIENCE OF CHRONIC SCHIZOPHRENIA WITH PENFLURIDOL.
224548 04-08

NEUROTRANSMITTER ALTERATIONS AND CHRONIC PAIN.
224800 04-13

THE MISUSE OF DRUGS IN THE TREATMENT OF THE CHRONIC PSYCHOSES.
225055 04-17

EFFECT OF CHRONIC MARIJUANA ADMINISTRATION ON STAGES OF PRIMATE SLEEP-WAKEFULNESS.
225520 04-14

THE EFFECTS OF CHRONIC MORPHINE ADMINISTRATION UPON A MODIFIED SIDMAN AVOIDANCE SCHEDULE THAT UTILIZES RESPONSE INDEPENDENT SHOCK.
225566 04-04

CHRONICAL

CHROMOSOMAL DAMAGE IN CHRONICAL USERS OF CANNABIS: IN VIVO INVESTIGATION WITH TWO-DAY LEUKOCYTE CULTURES.
210810 03-15

CHRONICALLY

5-HYDROXYTRYPTAMINE IN PLATELETS AND BRAIN OF RABBITS TREATED CHRONICALLY WITH IMIPRAMINE, MORPHINE OR METHADONE.
194744 01-03

HALOPERIDOL FOR CHRONICALLY HOSPITALIZED PSYCHOTICS: A DOUBLE-BLIND COMPARISON WITH THIOTHIXENE AND PLACEBO: A FOLLOWUP OPEN EVALUATION.
196676 01-14

ACTIONS OF ACETYLCHOLINE AND ATROPINE ON CEREBRAL CORTICAL NEURONS IN CHRONICALLY MORPHINE TREATED RATS.
215733 04-03

CHLORPROMAZINE EXCRETION IN CHRONICALLY DOSED PRIMATES. I. OCCURRENCE OF A PREVIOUSLY UNREPORTED CLASS OF CHLORPROMAZINE CONJUGATES.
217553 04-03

INHIBITION OF STRIATAL DOPAMINE SYNTHESIS IN RATS INJECTED CHRONICALLY WITH NEUROLEPTICS IN THEIR EARLY LIFE.
217687 04-03

CHRONOTROPIC

THE EFFECTS OF (+) AMPHETAMINE ON THE CHRONOTROPIC RESPONSES OF THE ISOLATED GUINEA-PIG PACEMAKER TO NOREPINEPHRINE AND ISOPROTERENOL.
211066 03-03

RELATIONSHIPS BETWEEN TRICYCLIC ANTIDEPRESSANT CONCENTRATIONS, 1-3H-NORAFRENALINE UPTAKE AND CHRONOTROPIC EFFECT IN ISOLATED RAT ATRIA.
221188 04-03

RELATIONSHIPS BETWEEN THE STRUCTURE AND THE CHRONOTROPIC, LOCOMOTOR STIMULANT AND REINFORCING ACTIONS OF SEVERAL FENFLURAMINE ANALOGS. (PH.D. DISSERTATION).
223563 04-04

CIBA-34276-BA

ON THE ANTIDEPRESSANT EFFECT OF CIBA-34276-BA (MAPROTILINE).
223182 04-10

CIGARETTE

DROWSINESS DUE TO CHLORPROMAZINE IN RELATION TO CIGARETTE SMOKING: A REPORT FROM THE BOSTON COLLABORATIVE DRUG SURVEILLANCE PROGRAM.
193072 01-15

EFFECT OF SMOKING MARIHUANA AND OF A HIGH NICOTINE CIGARETTE ON ANGINA-PECTORIS.
215670 04-15

CIRCADIAN

CORRELATIONS BETWEEN CIRCADIAN CHANGES IN SERUM AMINO ACIDS OR BRAIN TRYPTOPHAN AND THE CONTENTS OF SEROTONIN AND 5-HYDROXYINDOLEACETIC ACID IN REGIONS OF THE RAT BRAIN.
210673 03-03

A STUDY OF THE RELATIONSHIP BETWEEN CIRCADIAN RHYTHMS IN DRUG ACTION AND METABOLISM IN THE MOUSE. (PH.D. DISSERTATION).
223562 04-03

CIRCLE

THE EFFECT OF CHOLINERGICS ON SHORT-TERM MEMORY AND THE EXCITABILITY LEVEL OF HIPPOCAMPUS CIRCLE STRUCTURES.
208972 03-03

CIRCLING

STEREOTYPED AND CIRCLING BEHAVIOUR INDUCED BY DOPAMINERGIC AGONISTS AFTER LESIONS OF THE MIDBRAIN RAPHE NUCLEI.
202792 02-04

AMPHETAMINE-INDUCED CHANGES IN STRIATAL DOPAMINE AND ACETYLCHOLINE LEVELS AND RELATIONSHIP TO ROTATION (CIRCLING BEHAVIOR) IN RATS.
205432 02-04

A COMPARISON OF CIRCLING MODELS FOR THE DETECTION OF PARKINSON ACTIVITY.
217547 04-04

CIRCULAR

INTERACTIONS OF BENZODIAZEPINES WITH HUMAN SERUM ALBUMIN: CIRCULAR DICHROISM STUDIES.
194148 01-01

CIRCULATION

PHARMACOLOGY OF CEREBRAL CIRCULATION AND CLINICAL APPLICATIONS. EXPERIMENTAL STUDY OF THE CIRCULATORY AND METABOLIC EFFECTS OF HYDROSARPAN-711.
218164 04-03

CIRCULATORY

PHARMACOLOGY OF CEREBRAL CIRCULATION AND CLINICAL APPLICATIONS. EXPERIMENTAL STUDY OF THE CIRCULATORY AND METABOLIC EFFECTS OF HYDROSARPAN-711.
218164 04-03

CIRCULORESPIRATORY

THE EFFECTS OF METHYLPHENIDATE DURING REST, EXERCISE, AND RECOVERY UPON THE CIRCULORESPIRATORY RESPONSES OF HYPERACTIVE CHILDREN. (PH.D. DISSERTATION).
221934 04-11

CIRCUMCISION

HEAD INJURY, HYPOPITUITARISM AND PARANOID PSYCHOSIS: CIRCUMCISION FOR THE SINGAPORE VIRUS.
200581 02-09

CIRCUS

ROLE OF THE STRIO-PALLIDAL SYSTEM AND MOTOR CORTEX IN INDUCED CIRCUS MOVEMENTS IN RATS AND CATS.
213450 04-03

CLASS

A COMPARISON OF THE RELATIVE EFFICACY OF SPECIAL CLASS EDUCATION AND DRUG THERAPY FOR CHILDREN WITH SELECTED LEARNING DISABILITIES. (ED.D. DISSERTATION).
198662 02-11

BENZOOXADIAZOLES -- A NOVEL CLASS OF HETEROCYCLIC MONOAMINEOXIDASE INHIBITORS.
202312 02-01

CHLORPROMAZINE EXCRETION IN CHRONICALLY DOSED PRIMATES. I. OCCURRENCE OF A PREVIOUSLY UNREPORTED CLASS OF CHLORPROMAZINE CONJUGATES.
217553 04-03

NEUROPHARMACOLOGICAL STUDIES ON SB-5833, A NEW PSYCHOTHERAPEUTIC AGENT OF THE BENZODIAZEPINE CLASS.
221268 04-02

CLASSES

THE PROPOSAL OF AN UNIFIED MODEL FOR THE INTERPRETATION OF THE ACTIVITY OF DIFFERENT CLASSES OF BETA-ADRENERGIC AGENTS.
220951 04-01

CLASSIFICATION

EEG PROFILES AS PREDICTORS OF PSYCHOTROPIC DRUG CLASSIFICATION.
198060 01-07

CONTROLLING DRUGS: INTERNATIONAL HANDBOOK FOR PSYCHOACTIVE DRUG CLASSIFICATION.
202861 02-17

CLASSIFIED

SUBTYPE OF AFFECTIVE PSYCHOSES CLASSIFIED BY RESPONSE ON AMINE PRECURSORS AND MONOAMINE METABOLISM.
197209 01-09

CLASSIFY

AN ATTEMPT TO CLASSIFY NEUROLEPTIC DRUGS ON THE BASIS OF SHORT-TERM CLINICAL COMPARATIVE STUDIES.
205591 02-08

AN ATTEMPT TO CLASSIFY SULTOPRIDE AMONG CURRENT NEUROLEPTICS.
216760 04-09

ATTEMPTS TO CLASSIFY AND ORIENT PRESCRIPTION OF PSYCHOTROPIC DRUGS BY MEANS OF A COMPUTER CARD INDEX.
221668 04-17

CLASSIFYING

THE CURRENT STATUS OF BIOLOGICAL CRITERIA FOR CLASSIFYING THE DEPRESSIVE DISORDERS AND PREDICTING RESPONSES TO TREATMENT.
202380 02-17

BIOCHEMICAL CRITERIA FOR CLASSIFYING DEPRESSIVE DISORDERS AND PREDICTING RESPONSES TO PHARMACOTHERAPY: PRELIMINARY FINDINGS FROM STUDIES OF NOREPINEPHRINE METABOLISM. CONTRIBUTIONS TO BIOCHEMISTRY.
203594 02-09

CLASSROOM

A BEHAVIORAL INVESTIGATION: THE EFFECTS OF MEDICATION ON DISRUPTIVE CLASSROOM BEHAVIOR AND ACADEMIC PERFORMANCE. (PH.D. DISSERTATION).
200461 02-11

THE COMBINED EFFECTS OF METHYLPHENIDATE (RITALIN) AND A CLASSROOM BEHAVIOR MODIFICATION PROGRAM IN REDUCING THE HYPERKINETIC BEHAVIORS OF INSTITUTIONALIZED MENTAL RETARDATES. (PH.D. DISSERTATION).
202356 02-11

CLASTOGENIC
CLASTOGENIC EFFECTS OF HALOPERIDOL IN VIVO AND OF HALOPERIDOL, DROPERIDOL, AND PIPAMPERONE IN VITRO: A NEGATIVE STUDY.
221270 04-15

CLEARANCE
THE EFFECT OF DAILY ORAL DOSAGE OF DIAZEPAM, PLASMA CONCENTRATIONS AND METABOLIC CLEARANCE OF DIAZEPAM AND DEMETHYLDIAZEPAM ON VARIOUS CONSTITUENTS OF THE ACUTE CLINICAL ANXIETY SYNDROME.
196191 01-10

CLINIC
DRUG TREATMENT OF CHRONIC INTRACTABLE PAIN IN PATIENTS REFERRED TO A PSYCHIATRY CLINIC.
196090 01-14
A CLINICAL TRIAL OF MAPROTILINE (LUDIOMIL) IN THE TREATMENT OF DEPRESSIVE PATIENTS IN GENERAL PRACTICE AND THE PSYCHIATRIC CLINIC.
221657 04-09

CLINICAL
SIDE-EFFECTS OF BREVITAL AIDED DESENSITIZATION: SOME CLINICAL IMPRESSIONS.
193986 01-15
A CLINICAL TRIAL WITH THIOPROPERAZINE (MAJEPTIL M & B) -- A COMPARISON WITH CHLORPROMAZINE.
194311 01-11
CLINICAL EXPERIENCE OF THE USE OF PENFLURIDOL (TLP-609) FOR THE TREATMENT OF SCHIZOPHRENIA.
194457 01-08
PHYSIOLOGIC, BIOCHEMICAL, AND CLINICAL EFFECTS OF KETAMINE HYDROCHLORIDE IN GOATS (CAPRA-HIRCUS) WITH AND WITHOUT PREMEDICATION. (PH.D. DISSERTATION).
194700 01-03
A CLINICAL NEUROLEPTIC INVESTIGATION OF N-(1-ETHYL-PYRROLIDIN-2-YL) 2-METHOXY-5-SULFAMOYL-BENZAMIDE NEUROLEPTIC SULPIRIDE (DOGMATIL) IN ACUTELY ILL SCHIZOPHRENICS.
195038 01-11
DIAZEPAM METABOLISM IN NORMAL MAN: I. SERUM CONCENTRATIONS AND CLINICAL EFFECTS AFTER INTRAVENOUS, INTRAMUSCULAR, AND ORAL ADMINISTRATION.
195444 01-15
DIAZEPAM METABOLISM IN NORMAL MAN: II. SERUM CONCENTRATION AND CLINICAL EFFECT AFTER ORAL ADMINISTRATION AND CUMULATION.
195445 01-13
CLINICAL EFFICACY OF PIMOZIDE IN HOSPITALISED CHRONIC SCHIZOPHRENICS.
195615 01-08
TRIMIPRAMINE (SURMONTIL) -- CLINICAL EVALUATION IN DEPRESSION.
195617 01-09
CONTROLLED CLINICAL TRIAL WITH DIAZEPAM.
195618 01-10
SURMONTIL (TRIMIPRAMINE) -- A CLINICAL TRIAL.
195620 01-10
CLINICAL MEASUREMENT OF CENTRAL DOPAMINE AND SEROTONIN METABOLISM IN ACUTE PSYCHOTIC DISORDERS.
195924 01-09
CLINICAL ASPECTS OF RESISTANCE TO IMIPRAMINE THERAPY.
196039 01-11
THE EFFECT OF DAILY ORAL DOSAGE OF DIAZEPAM, PLASMA CONCENTRATIONS AND METABOLIC CLEARANCE OF DIAZEPAM AND DEMETHYLDIAZEPAM ON VARIOUS CONSTITUENTS OF THE ACUTE CLINICAL ANXIETY SYNDROME.
196191 01-10
CLINICAL EVALUATION OF NEW ANTIDEPRESSANT, LOPRAMINE.
196443 01-14
PENFLURIDOL (R-16341) AS A MAINTENANCE THERAPY IN CHRONIC PSYCHOTIC PATIENTS: A DOUBLE-BLIND CLINICAL EVALUATION.
197033 01-09
PLASMA NORTRIPTYLINE AND CLINICAL RESPONSE.
198029 01-09
REPORT OF EARLY CLINICAL DRUG EVALUATION UNIT '11.
198041 01-07
REPORT ON THE EARLY CLINICAL DRUG EVALUATION UNIT.
198043 01-07
SYSTEMATIC CLINICAL STUDIES WITH TRAZODONE.
198053 01-07
EVALUATION OF CLINICAL PREDICTION OF ANTIDEPRESSANT ACTIVITY USING VARIOUS ANIMAL TEST MODELS.
198055 01-02
MULTIDIMENSIONAL SCALING TO RELATE ANIMAL PHARMACOLOGY AND CLINICAL SYMPTOMS OF PSYCHOPHARMACOLOGIC AGENTS.
198058 01-02
AN EXTENSION OF MULTIDIMENSIONAL SCALING TO FACILITATE CLINICAL INTERPRETATION OF ANIMAL TEST MODELS.
198059 01-02
EARLY CLINICAL DRUG EVALUATION UNIT.
198062 01-07
CLINICAL EVALUATION OF NEW CHEMOTHERAPEUTIC AGENTS.
198064 01-07
COOPERATIVE CLINICAL SCREENING OF PSYCHOTROPIC DRUGS.
198066 01-07
COMPREHENSIVE CLINICAL STUDIES OF PSYCHOACTIVE DRUGS.
198067 01-07
NIMH-PRB EARLY CLINICAL DRUG EVALUATION UNIT.
198068 01-07
EARLY CLINICAL DRUG EVALUATION UNIT.
198070 01-07
NIMH-PRB EARLY CLINICAL DRUG EVALUATION UNIT.
198073 01-07
PSYCHOACTIVE DRUG BLOOD LEVELS AND CLINICAL RESPONSE.
198095 02-07
PLASMA LEVELS OF IMIPRAMINE AND CLINICAL OUTCOME.
198097 02-07
CLINICAL CHEMICAL CORRELATES OF CPZ THERAPY.
198098 02-08
CLINICAL TRIAL OF TRIMIPRAMINE (SURMONTIL).
198119 02-07
CLINICAL EXPERIENCE WITH CLOCAPRAMINE (CLOFEKTON) FOR THE TREATMENT OF SCHIZOPHRENIC PATIENTS.
198709 02-08
CLINICAL EXPERIENCE WITH FORIT: ITS ACTIVATING EFFECT ON CHRONIC SCHIZOPHRENIA.
198710 02-08
PRELIMINARY CLINICAL RESULTS OF A NEW NONTRICYCLIC ANTIDEPRESSANT: OXAFLOZANE (1766-CERM).
199386 02-07
MULTIPLE TIC SYNDROME (GILLES-DE-LA-TOURETTES SYNDROME): CLINICAL, BIOLOGICAL, AND PSYCHOSOCIAL VARIABLES AND THEIR INFLUENCE WITH HALOPERIDOL.
199473 02-11
INHIBITION OF DOPAMINE-BETA-HYDROXYLASE IN MANIC PATIENTS: A CLINICAL TRIAL WITH FUSARIC ACID.
199632 02-07
THE THERAPEUTIC EFFECT OF SHORT-TERM ORAL DIAZEPAM TREATMENT ON ACUTE CLINICAL ANXIETY IN A CRISIS CENTRE.
199991 02-10
A DOUBLE-BLIND CLINICAL EVALUATION OF PENFLURIDOL (R-16341) AS A MAINTENANCE THERAPY IN SCHIZOPHRENIA.
199993 02-08
CLINICAL PHARMACOLOGICAL STUDY OF A HYPNOTIC DRUG, TRICLORYL.
200009 02-11
PROBLEMS OF CLINICAL EFFECTIVENESS AND USE OF LITHIUM SALTS IN PSYCHIATRIC PRACTICE.
200072 02-09
CLINICAL OBSERVATIONS ON SULPIRIDE TREATMENT IN PSYCHIATRY.
200170 02-11
A CONTROLLED CLINICAL TRIAL OF PIMOZIDE (R-6238) -- A NEW NEUROLEPTIC.
200897 02-08
A DOUBLE-BLIND CLINICAL TRIAL OF NEW ANTIDEPRESSANT, SURMONTIL.
200922 02-09
CLINICAL DOUBLE-BLIND STUDY ON THE ACTIVITY OF A NEW ANTIDEPRESSANT: CAROXAZONE (FI-6654).
201667 02-09
COMPARATIVE CHARACTERISTICS OF THE CLINICAL ACTION OF TRANQUILIZERS.
201909 02-14
CLINICAL STUDY OF GERDAXYL 10MG WITH 40 PATIENTS TREATED IN A PSYCHIATRIC OUTPATIENT FACILITY.
202037 02-11
THE EFFECTS OF LITHIUM ON NOREPINEPHRINE TURNOVER AND METABOLISM: BASIC AND CLINICAL STUDIES.
202249 02-09
TREATMENT AND COUNTERMEASURES FOR PATIENTS WITH INSOMNIA IN THE DEPARTMENT OF INTERNAL MEDICINE -- SPECIAL EMPHASIS ON THE CLINICAL APPLICATION OF FLURAZEPAM.
202285 02-14
CLINICAL TRIAL OF FLUPENTHIXOL IN PATIENTS WITH CHRONIC SCHIZOPHRENIA: ESPECIALLY IN PATIENTS HAVING DIFFICULTY IN REHABILITATION OWING TO DECREASED EXPRESSION, APATHY AND DISTURBANCE OF RAPPORT.
202603 02-08
ASPECTS OF NEUROLEPTIC DEPOT THERAPY WITH SPECIAL CONSIDERATION OF CLINICAL EXPERIENCE WITH THE PERORAL DEPOT PREPARATION PENFLURIDOL (R-16341 - JANSSEN).
202785 02-07
THE CLINICAL USE OF PSYCHOTHERAPEUTIC DRUGS IN THE ELDERLY.
202798 02-11
MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 3. COMMUNICATION: PERAZINE CONCENTRATION IN BLOOD AND CLINICAL EFFICACY.
203841 02-13
MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 4. COMMUNICATION: CONNECTION BETWEEN

EEG CHANGES, CONCENTRATION IN BLOOD, AND OTHER CLINICAL VARIABLES.
203842 02-13

CLINICAL APPLICATION OF LITHIUM ASPARTATE.
204392 02-09

INTRA-EXTRACELLULAR LITHIUM RATIO: CLINICAL AND EXPERIMENTAL FINDINGS ON THROMBOCYTES AND ERYTHROCYTES.
204393 02-13

EFFECT OF BETA-RECEPTOR BLOCKERS (PINDOLOL AND PRACTOLOL) ON LITHIUM INDUCED TREMOR -- CLINICAL TRIAL AND THEORETICAL CONSIDERATIONS.
204409 02-15

STUDIES ON CLINICAL AND PHARMACOLOGICAL SPECTRA OF THE TETRACYCLIC COMPOUND MIANSERIN.
204412 02-14

CLINICAL TRIAL OF CLOCAPRAMINE IN NEUROTIC PATIENTS WHO HAD TROUBLES IN EVERYDAY LIFE OWING TO SEVERE ANXIETY, IRRITABILITY AND DEPRESSION.
204464 02-10

PSYCHOPHARMACEUTICS AND CLINICAL PSYCHOTHERAPY.
204478 02-17

THIORIDAZINE: CENTRAL DOPAMINE TURNOVER AND CLINICAL EFFECTS OF ANTIPSYCHOTIC DRUGS.
204852 02-08

LABORATORY AND CLINICAL STUDIES OF LITHIUM CARBONATE.
205175 02-03

SCHNEIDERIAN FIRST RANK SYMPTOMS AND CLINICAL FEATURES OF SCHIZOPHRENIA.
205179 02-08

CLONAZEPAM (RO-5-4023). FOUR YEARS OF CLINICAL RESEARCH.
205505 02-13

DRUGS, EEG AND BEHAVIOUR: EEG PROFILES AND BIOAVAILABILITY MEASURES FOR CLINICAL PSYCHOPHARMACOLOGY.
205522 02-16

THE DEPOT COMPOUNDS MODITEN (FLUPHENAZINE) AND IMAP (FLUSPIRILENE) IN CLINICAL PRACTICE.
205584 02-08

PILOT CLINICAL STUDY WITH TRIFLUPERIDOL (TRISEDYL) THERAPY IN PSYCHOTIC PATIENTS.
205589 02-09

AN ATTEMPT TO CLASSIFY NEUROLEPTIC DRUGS ON THE BASIS OF SHORT-TERM CLINICAL COMPARATIVE STUDIES.
205591 02-08

CLINICAL EXPERIENCE WITH CARPIPRAMINE (DEFEKTON).
205592 02-08

CLINICAL EXPERIENCE WITH DOXEPIN.
205600 02-09

FAMILY HISTORY OF MANIC-DEPRESSIVE AND ENDOGENOUS DEPRESSIVE PATIENTS AND CLINICAL EFFECT OF TREATMENT WITH LITHIUM.
205608 03-09

FURTHER CLINICAL AND EEG EXPERIENCE WITH CLOZAPINE.
205615 03-11

CLINICAL EXPERIENCE WITH CLOZAPINE IN PSYCHOSES.
205616 03-09

CLINICAL TRIAL WITH SULPIRIDE.
205945 03-14

CLINICAL FEATURES, ETIOLOGY AND TREATMENT OF FACIAL DYSKINESIAS IN THE ELDERLY.
206926 03-14

CLINICAL STUDY ON SULPIRIDE IN LONG-TERM HOSPITALIZED SCHIZOPHRENIC PATIENTS.
206978 03-08

SALIVA LITHIUM LEVELS: CLINICAL APPLICATIONS.
207042 03-16

BENZODIAZEPINES IN CLINICAL PRACTICE.
207161 03-17

REPORT ON A PRELIMINARY CLINICAL STUDY OF MIANSERIN (GB-94), A TETRACYCLIC ANTIDEPRESSANT, AN OPEN TRIAL.
207283 03-03

ANTIDEPRESSANT RESPONSE TO TRICYCLICS AND URINARY MHPG IN UNIPOLAR PATIENTS: CLINICAL RESPONSE TO IMIPRAMINE OR AMITRIPTYLINE.
207443 03-13

CLINICAL USE OF CLOCAPRAMINE FOR THE TREATMENT OF CHRONIC SCHIZOPHRENIA -- SPECIAL EMPHASIS ON ITS COMPARISON WITH PERPHENAZINE.
207534 03-08

INVESTIGATION OF CLINICAL EFFECTS OF FK-880 (SULPIRIDE) ON MANIC-DEPRESSIVE ILLNESS.
207535 03-09

DOSE LEVEL AND EFFECTS OF TRIFLUPERIDOL IN CLINICAL USE FOR SCHIZOPHRENIA.
207643 03-08

RELATIONSHIP BETWEEN SERUM LITHIUM LEVEL AND CLINICAL RESPONSE TO DEPRESSION TREATED WITH LITHIUM CARBONATE.
207719 03-09

CLINICAL TRENDS AND PSYCHOMETRIC APPRAISAL OF A GROUP OF SCHIZOPHRENICS TREATED WITH THIOTHIXENE (NAVANE).
208981 03-08

THE CLINICAL RELEVANCE OF PHOTOSENSITIVITY IN PSYCHIATRIC EEG DIAGNOSIS.
209018 03-15

CLINICAL COMPARISON OF ANXIOLYTIC DRUG THERAPY.
209080 03-10

CLINICAL AND BIOCHEMICAL COMPARISON OF CHLORAZEPATE AND DIAZEPAM.
209081 03-10

PRELIMINARY RESULTS ON THE CLINICAL USE OF A SLOW-RELEASE PREPARATION OF LITHIUM SALTS.
209122 03-09

CLINICAL EXPERIENCES IN TREATING DEPRESSED PATIENTS WITH A COMBINATION OF TRICYCLIC DRUGS AND THYROID EXTRACT.
209144 03-09

CLINICAL ELECTROENCEPHALOGRAPHIC DATA IN DEPRESSED PATIENTS TREATED WITH ANAFRANIL.
209148 03-09

CLINICAL APPLICATION OF OXYPERTINE -- ITS CHARACTERISTICS AS A STRONG TRANQUILIZER.
209394 03-08

CLINICAL STUDIES OF D-40TA (TRIAZOLOBENZODIAZEPINE) -- CROSSOVER TRIAL ON SLEEP DISTURBANCES AND SLEEP EEG IN NORMAL ADULTS.
209412 03-10

CLINICAL EFFECTS OF LITHIUM CARBONATE ON DEPRESSIVE STATES.
209413 03-09

CLINICAL ASSESSMENT OF LORAZEPAM IN ANXIETY: A DOUBLE-BLIND STUDY.
209485 03-10

PRACTICAL CLINICAL PSYCHOPHARMACOLOGY.
209753 03-17

A YEAR OF INVESTIGATIONS ON 1035-MD IN CHILD AND JUVENILE NEUROPSYCHIATRY: CLINICAL AND EEG FINDINGS FROM 46 CASES.
209784 03-11

PLASMA LEVELS AND CLINICAL EFFECTS OF THIORIDAZINE AND THIOTHIXENE.
209790 03-08

CLINICAL EXPERIMENTS WITH BROMAZEPAM ON PSYCHONEUROTIC AND PSYCHOSOMATIC PATIENTS WITH PSYCHOTHERAPY.
209795 03-10

HEPTAMINOL AND TENSION DISTURBANCES INDUCED BY PSYCHOTROPIC DRUG THERAPY: CLINICAL STUDY.
210089 03-13

PSYCHOPHARMACOLOGY: AN INTRODUCTION TO EXPERIMENTAL AND CLINICAL PRINCIPLES.
210099 03-17

AMENORRHEA AND BEHAVIORAL DISTURBANCES: CLINICAL CASE TREATED WITH A PSYCHOTHERAPEUTIC METHOD BASED ON ELEMENTS OF THE CYBERNETIC THEORY OF G. CIPOLLINA MANGIAMELI.
210418 03-14

CLINICAL BIOLOGICAL CORRELATIONS IN SCHIZOAFFECTIVE PATIENTS TREATED WITH LITHIUM CARBONATE AND HALOPERIDOL.
210501 03-09

A CLINICAL EXPERIMENTAL STUDY ON THE USE OF SULPIRIDE IN A GROUP OF CHRONIC SCHIZOPHRENICS (FIRST NOTE).
210510 03-08

MONOAMINE METABOLITES IN LUMBAR CSF: THE QUESTION OF THEIR ORIGIN IN RELATION TO CLINICAL STUDIES.
210796 03-03

CLINICAL EXPERIMENTS WITH A NEW PSYCHOTROPIC DRUG (SULPIRIDE).
211203 03-14

CLINICAL AND PSYCHOMETRIC EVALUATION OF THE ACTION OF VINCAMIN IN CEREBRAL ARTERIOSCLEROSIS.
211226 03-11

CLINICAL STUDIES WITH MARIHUANA AND D-AMPHETAMINE COMBINATION.
211745 03-14

CLINICAL AND NEUROENDOCRINOLOGICAL STUDY OF TRH IN MELANCHOLIA.
212162 03-09

MOLECULAR MECHANISMS OF MEMORY AND LEARNING (GENERAL CONSIDERATIONS AND CLINICAL APPLICATIONS).
212281 03-14

CLINICAL STUDY OF AN NEW ANTIDEPRESSANT, MELITRACEN, FOR 50 AMBULATORY PATIENTS.
212490 03-10

CLINICAL STUDY AND FOLLOWUP OF 40 PSYCHOTIC PATIENTS ON PERPHENAZINE ENANTHATE.
212495 03-14

CLINICAL EXPERIENCE OF FLUPHENAZINE ENANTHATE IN TREATMENT OF SCHIZOPHRENIC PATIENTS.
213294 03-08

SEROTONIN -- NEW VISTAS: BIOCHEMISTRY AND BEHAVIORAL AND CLINICAL STUDIES.
213716 04-17

THE RELATIONSHIP BETWEEN NORTRIPTYLINE PLASMA LEVELS AND CLINICAL EFFECTS.
213782 04-13

CLINICAL AND EXPERIMENTAL COMPARISON OF DIAZEPAM, CHLORAZEPATE AND PLACEBO.
214018 04-14

ETHICS IN MEDICAL RESEARCH AS VIEWED BY THE CLINICAL INVESTIGATOR.
214341 04-17

FLUPHENAZINE TREATMENT IN THE PSYCHOTIC CHILD: CLINICAL EVOKED POTENTIAL CORRELATIONS.
215455 04-09

CLINICAL TRIAL OF 3-METHYL-5-BETA-N-N-M-CHLOROPHENYLPIPERAZINOETHYL PYRAZOLE DIHYDROCHLORIDE (MEPIPRAZOL) IN THE THERAPY OF PSYCHOVEGETATIVE DISORDERS.
215694 04-10

A CLINICAL STUDY OF A NEW NEUROLEPTIC EXTRAPYRAMIDAL SYNDROME CORRECTOR WITH ACUTE PSYCHOTIC STATES.
216766 04-15

CLINICAL EXPERIMENTATION WITH A SUSTAINED RELEASE LITHIUM CARBONATE.
216769 04-09

CLINICAL STUDY OF PIMOZIDE.
217171 04-09

RELATIONSHIP BETWEEN SERUM LITHIUM LEVEL AND CLINICAL RESPONSE ON DEPRESSION TREATED WITH LITHIUM CARBONATE.
217354 04-09

CLINICAL TRIAL OF LOFEPRAMIN VERSUS IMIPRAMINE.
217450 04-09

A COMPARISON BETWEEN BROMAZEPAM (RO-5-3350, LEXOTAN) AND DIAZEPAM (VALIUM) IN ANXIETY NEUROSIS: A CONTROLLED, DOUBLE-BLIND CLINICAL TRIAL.
217455 04-10

N-DESMETHYLDIAZEPAM AND AMYLOBARBITONE SODIUM AS HYPNOTICS IN ANXIOUS PATIENTS. PLASMA LEVELS, CLINICAL EFFICACY AND RESIDUAL EFFECTS.
217460 04-10

CLINICAL EXPERIENCE OF HALOPERIDOL INJECTION ON PSYCHIATRIC CASES.
217957 04-14

PHARMACOKINETICS IN CLINICAL MEDICINE: OXAZEPAM VERSUS OTHER BENZODIAZEPINES.
218151 04-17

PHARMACOLOGY OF CEREBRAL CIRCULATION AND CLINICAL APPLICATIONS. EXPERIMENTAL STUDY OF THE CIRCULATORY AND METABOLIC EFFECTS OF HYDROSARPAN-711.
218164 04-03

EFFECTS OF D-PHENYLALANINE ON CLINICAL PICTURE AND PHENETHYLAMINURIA IN DEPRESSION.
218959 04-09

CLINICAL STUDY OF HALOPERIDOL. I. TECHNIQUES AND THEORY OF PARENTERAL THERAPY.
220156 04-08

CLINICAL - PSYCHOPATHOLOGICAL CRITERIA FOR THE SELECTION OF PSYCHOTROPIC DRUGS ACCORDING TO THE STAGE OF ILLNESS AND THE EFFECTIVENESS OF REHABILITATING SCHIZOPHRENICS.
220403 04-17

CLINICAL EVALUATION OF METYLPERONE (BURONIL) WITH EPILEPTICS.
221518 04-11

CLOZAPINE: PHARMACOLOGY, BIOCHEMISTRY AND CLINICAL USE.
221538 04-13

RESEARCH INTO THE INTERACTION BETWEEN NORTRIPTYLINE AND PERPHENAZINE -- CLINICAL EVALUATION.
221632 04-13

CLOZAPINE AND HALOPERIDOL: CLINICAL AND BIOCHEMICAL ASPECTS IN THE TREATMENT OF SCHIZOPHRENIA.
221637 04-08

A CONTROLLED CLINICAL EXPERIMENT WITH BURONIL AND HALOPERIDOL IN DISORIENTATION AMONG ELDERLY PATIENTS.
221639 04-11

A DOUBLE-BLIND COMPARATIVE CLINICAL TRIAL OF MAPROTILINE (LUDIOMIL) AND AMITRIPTYLINE.
221653 04-09

A CLINICAL TRIAL OF MAPROTILINE (LUDIOMIL) IN THE TREATMENT OF DEPRESSIVE PATIENTS IN GENERAL PRACTICE AND THE PSYCHIATRIC CLINIC.
221657 04-09

STUDIES ON MICROVIBRATION OF UNIDENTIFIED CLINICAL SYNDROME.
221664 04-14

PHARMACOLOGICAL - CLINICAL INTEREST IN THE STUDY OF 24 HOUR LITHIUM RATE CYCLES.
221667 04-09

CLINICAL STUDY OF FIVE DEPOT NEUROLEPTICS, COMPARISON OF ACTIVITY PROFILES OF FLUPHENAZINE DECANOATE, FLUSPIRILENE, PENFLURIDOL, PERPHENAZINE ENANTHATE AND PIPOTHIAZINE PALMITATE.
221822 04-08

CLINICAL TRIAL OF OXYPERTINE IN THE TREATMENT OF PSYCHOSOMATIC DISORDERS, NEUROSIS AND DEPRESSION.
224193 04-14

CLINICAL TRAILS OF SULPIRIDE WITH EMPHASIS ON NEUROTIC OUTPATIENTS.
224194 04-10

CLINICAL EXPERIENCE OF THE USE OF FK-880 (SULPIRIDE) FOR DEPRESSION AND NEUROSIS.
224195 04-14

CLINICAL STUDY OF A NEW TRANQUILIZER, LEXOTAN, IN NEUROTIC DISTURBANCES.
224583 04-10

A CLINICAL STUDY OF SERUM CONCENTRATION LEVELS OF PHENOBARBITAL DERIVED FROM PRIMIDONE (MUSOLINE).
224644 04-13

CLINICAL PHARMACOLOGY IN PSYCHIATRY.
224829 04-17

PHARMACOKINETICS OF CHLORDIAZEPOXIDE, MEPERIDINE, THIORIDAZINE, AND MESORIDAZINE AND CLINICAL RESPONSE.
224830 04-13

RELATIONSHIPS AMONG CLINICAL RESPONSE, EPS, AND PLASMA CPZ AND CPZ METABOLITE RATIOS.
224831 04-08

PLASMA LEVEL, DEPRESSIVE TYPOLOGY, CLINICAL OUTCOME.
224836 04-09

A CLINICAL TRIAL OF A STRUCTURALLY UNIQUE NEUROLEPTIC (SU-23397).
225065 04-14

A COMPARATIVE CLINICAL TRIAL OF ORG-GB-94 AND IMIPRAMINE IN THE TREATMENT OF DEPRESSION IN GENERAL PRACTICE.
225107 04-09

CLINICAL TRIAL WITH FLUPENTHIXOL (FLUANXOL) IN THE TREATMENT OF SENILE DEMENTIA.
225281 04-11

THE DEPOT FLUPHENAZINES: A REAPPRAISAL AFTER 10 YEARS CLINICAL EXPERIENCE.
225325 04-08

CLINICOMETHODOLOGICAL

LONGITUDINAL PROFILES OF THE EFFECTS OF PSYCHOTROPIC DRUGS FROM CLINICOMETHODOLOGICAL VIEWPOINTS.
206971 03-16

CLINICOSTATISTICAL

CLINICOSTATISTICAL STUDY OF THE EFFECTS OF SULPIRIDE, A NEW NEUROLEPTIC DRUG.
206805 03-07

CLOBAZAM

PHARMACOLOGICAL AND TOXICOLOGICAL PROPERTIES OF CLOBAZAM (1-PHENYL-5-METHYL-8-CHLORO 1,2,4,5-TETRAHYDRO-2,4-DIKETO-3H-1,5 BENZODIAZEPINE), A NEW PSYCHOTHERAPEUTIC AGENT.
199912 02-05

STUDY OF AN ANXIOLYTIC DRUG, CLOBAZAM, IN ORL WITH PHARYNGEAL PSYCHOSOMATIC MANIFESTATIONS.
224584 04-11

CLOCAPRAMINE

CLINICAL EXPERIENCE WITH CLOCAPRAMINE (CLOFEKTON) FOR THE TREATMENT OF SCHIZOPHRENIC PATIENTS.
198709 02-08

CLINICAL TRIAL OF CLOCAPRAMINE IN NEUROTIC PATIENTS WHO HAD TROUBLES IN EVERYDAY LIFE OWING TO SEVERE ANXIETY, IRRITABILITY AND DEPRESSION.
204464 02-10

CLINICAL USE OF CLOCAPRAMINE FOR THE TREATMENT OF CHRONIC SCHIZOPHRENIA -- SPECIAL EMPHASIS ON ITS COMPARISON WITH PERPHENAZINE.
207534 03-08

COMPARATIVE STUDY OF CLOCAPRAMINE AND PERPHENAZINE ON CHRONIC SCHIZOPHRENIA BY A DOUBLE-BLIND METHOD.
222158 04-08

CLOFEKTON

CLINICAL EXPERIENCE WITH CLOCAPRAMINE (CLOFEKTON) FOR THE TREATMENT OF SCHIZOPHRENIC PATIENTS.
198709 02-08

CLOFLUPEROL

USE OF A NEW PSYCHOTROPIC DRUG, CLOFLUPEROL FOR THE TREATMENT OF CHRONIC SCHIZOPHRENIC PATIENTS.
211304 03-08

COMPARISON OF THE REMEDIAL RESULTS OF CLOFLUPEROL AND HALOPERIDOL FOR SCHIZOPHRENIA BY DOUBLE-BLIND TEST METHOD.
224549 04-08

CLOMIPRAMINE

5-HYDROXYTRYPTOPHAN IN COMBINATION WITH CLOMIPRAMINE IN THERAPY RESISTANT DEPRESSIONS.
198229 02-09

A DOUBLE-BLIND COMPARISON OF CLOMIPRAMINE WITH AMITRIPTYLINE IN DEPRESSION.
202178 02-10

THE USE OF CLOMIPRAMINE IN PHOBIC PATIENTS; PRELIMINARY RESEARCH REPORT.
209488 03-10

THREE CASES OF ANEJACULATION IN PATIENTS TREATED WITH CLOMIPRAMINE.
210136 03-15

CLOMIPRAMINE IN THE TREATMENT OF THE TRUE OBSESSIONAL STATE: A REPORT ON FOUR PATIENTS.
211433 03-10

THE SHAPIRO CARDS SCALE AS A METHOD OF ASSESSMENT OF OBSESSIONAL SYMPTOMS IN CLOMIPRAMINE THERAPY.
214829 04-10

CHANGES IN OBSESSIVE/COMPULSIVE PATIENTS AS MEASURED BY THE LEYTON INVENTORY BEFORE AND AFTER TREATMENT WITH CLOMIPRAMINE.
214833 04-10

DEPRESSIVE REACTIONS IN THE COURSE OF CLOMIPRAMINE THERAPY USED IN THE TREATMENT OF OBSESSIONAL CONDITIONS.
214834 04-15

THE ROLE OF INTRAVENOUS CLOMIPRAMINE IN THE TREATMENT OF OBSESSIONAL AND PHOBIC DISORDERS.
214835 04-10

A PRELIMINARY REPORT ON THE USE OF CLOMIPRAMINE IN GENERAL PRACTICE.
214838 04-10

A COMPARATIVE STUDY OF CLOMIPRAMINE (ANAFRANIL) CAPSULES AND TABLETS.
215148 04-09

A COMPARISON OF A DIVIDED AND A SINGLE DOSE REGIME OF CLOMIPRAMINE (ANAFRANIL).
215149 04-09

A COMPARISON OF A LOW AND HIGH DOSAGE REGIME OF CLOMIPRAMINE (ANAFRANIL).
215150 04-09

ON-GOING STUDIES OF CLOMIPRAMINE (ANAFRANIL) IN GENERAL PRACTICE.
215151 04-15

COMPARATIVE STUDIES WITH CLOMIPRAMINE (ANAFRANIL) AND CLOMIPRAMINE COMBINATIONS.
215152 04-10

SOME PRACTICAL CONSIDERATIONS IN THE USE OF CLOMIPRAMINE (ANAFRANIL) IN GENERAL PRACTICE.
215153 04-15

CLOMIPRAMINE (ANAFRANIL) IN THE TREATMENT OF OBSESSIONAL STATES: A PSYCHIATRISTS VIEW.
215155 04-10

CLOMIPRAMINE (ANAFRANIL) IN THE TREATMENT OF PHOBIC STATES: A PSYCHIATRISTS VIEW.
215156 04-10

A GENERAL PRACTITIONER TRIAL OF CLOMIPRAMINE (ANAFRANIL) IN OBSESSIONS AND PHOBIAS.
215157 04-10

EXPERIENCES WITH CLOMIPRAMINE (ANAFRANIL) IN THE TREATMENT OF THE PHOBIC ANXIETY STATES IN GENERAL PRACTICE.
215158 04-10

POTENTIATION OF ANTIDEPRESSANT ACTION OF CLOMIPRAMINE BY TRYPTOPHAN.
221385 04-09

CLONAZEPAM

STUDIES ON CLONAZEPAM, FLUNITRAZEPAM, AND RELATED BENZODIAZEPINES IN CAT AND MONKEY.
197492 01-03

CLONAZEPAM (RO-5-4023). FOUR YEARS OF CLINICAL RESEARCH.
205505 02-13

SERUM CLONAZEPAM CONCENTRATIONS IN CHILDREN WITH ABSENCE SEIZURES.
211064 03-13

DOSE RANGING STUDIES OF CLONAZEPAM IN MAN.
217556 04-14

CLONIDINE

ON THE INHIBITION OF PERIPHERAL AND CENTRAL NORADRENERGIC NEUROTRANSMISSION BY CLONIDINE.
197295 01-03

SYMPATHETIC NERVE ACTIVITY AFTER NORADRENALINE DEPLETION AND ITS ALTERATION BY CLONIDINE.
197947 01-03

THE EFFECTS OF L-DOPA, CLONIDINE, AND APOMORPHINE ON THE ACOUSTIC STARTLE REACTION IN RATS.
202773 02-04

INFLUENCE OF DESMETHYLIMIPRAMINE ON THE HYPOTENSIVE EFFECT OF CLONIDINE.
206997 03-03

A BENZODIOXANHYDROXYETHYLPIPERIDINE DERIVATIVE WITH ACUTE CENTRAL HYPOTENSIVE ACTION, DIFFERENT FROM THAT OF CLONIDINE: A COMPARISON WITH NEUROLEPTIC AGENTS.
220976 04-03

INHIBITION OF BOTH NORADRENERGIC AND SEROTONERGIC NEURONS IN BRAIN BY THE ALPHA-ADRENERGIC AGONIST CLONIDINE.
221131 04-03

CLOPENTHIXOL

LONG-TERM TREATMENT OF PSYCHIATRIC PATIENTS WITH CLOPENTHIXOL: ANALYSIS OF LABORATORY TESTS WITH A VIEW TO LONG-TERM THERAPY.
199989 02-14

CLOTHIAPINE

A DOUBLE-BLIND CROSSOVER COMPARISON BETWEEN CLOTHIAPINE AND DIAZEPAM IN THE TREATMENT OF MENTAL SYMPTOMS IN CHRONIC ALCOHOLICS.
192988 01-11

COMPARATIVE STUDY OF CLOTHIAPINE AND TRIFLUOPERAZINE IN EPISODES OF ACUTE PARANOID SCHIZOPHRENIA.
217025 04-08

CLOXAZOLAM

EXAMINATION OF THE EFFECTS OF CLOXAZOLAM BY A DOUBLE-BLIND STUDY OF MENTAL PATIENTS BEFORE REHABILITATION.
194474 01-08

CLOZAPINE

CLOZAPINE AND HALOPERIDOL IN A SINGLE-BLIND CROSSOVER TRIAL: THERAPEUTIC AND BIOCHEMICAL ASPECTS IN THE TREATMENT OF SCHIZOPHRENIA.
200803 02-08

THE TREATMENT OF BEHAVIOR DISORDERS IN IDIOCY AND IMBECILITY WITH CLOZAPINE.
203598 02-11

PRETREATMENT OF PROBLEM YOUTHS WITH CLOZAPINE IN PREPARATION FOR GROUP PSYCHOTHERAPY.
203599 02-14

OUR EXPERIENCE WITH CLOZAPINE TREATMENT.
205613 03-08

RESULTS ACHIEVED WITH CLOZAPINE (LEPONEX) IN THE TREATMENT OF NEUROSES.
205614 03-10

FURTHER CLINICAL AND EEG EXPERIENCE WITH CLOZAPINE.
205615 03-11

CLINICAL EXPERIENCE WITH CLOZAPINE IN PSYCHOSES.
205616 03-09

CLOZAPINE IN OUTPATIENT PRACTICE.
205617 03-08

CLOZAPINE IN THE MAINTENANCE THERAPY OF SCHIZOPHRENIA.
205618 03-08

NEUROPHARMACOLOGICAL FINDINGS AFTER CHRONIC ADMINISTRATION OF HALOPERIDOL, LOXAPINE AND CLOZAPINE.
206972 03-03

METABOLISM OF DOPAMINE AND NOREPINEPHRINE IN RAT BRAIN AFTER SINGLE AND REPEATED ADMINISTRATION OF HALOPERIDOL, LOXAPINE AND CLOZAPINE.
206973 03-03

THE INFLUENCE OF CLOZAPINE ON THE EXCRETION OF MHPG, HVA, AND 5-HIAA IN URINE AND CEREBROSPINAL FLUID.
206974 03-13

CLOZAPINE IN LONG-TERM THERAPY OF CHRONIC SCHIZOPHRENIA.
206975 03-08

THE EFFECT OF CLOZAPINE AND ACETYLCHOLINE TURNOVER RATE IN RAT STRIATUM. (UNPUBLISHED PAPER).
207500 03-03

EXTRAPYRAMIDAL REACTIONS AND AMINE METABOLITES IN CEREBROSPINAL FLUID DURING HALOPERIDOL AND CLOZAPINE TREATMENT OF SCHIZOPHRENIC PATIENTS.
214010 04-15

NEUROLEPTIC ACTION OF CLOZAPINE INJECTED INTO VARIOUS BRAIN AREAS IN RATS.
217451 04-04

NEUROLEPTIC-INDUCED HYPERSENSITIVITY OF STRIATAL DOPAMINE RECEPTORS IN THE RAT AS A MODEL OF TARDIVE DYSKINESIAS. EFFECTS OF CLOZAPINE, HALOPERIDOL, LOXAPINE AND CHLORPROMAZINE.
217462 04-03

EFFECTS OF CLOZAPINE, THIORIDAZINE, PERLAPINE AND HALOPERIDOL ON THE METABOLISM OF THE BIOGENIC AMINES IN THE BRAIN OF THE RAT.
217543 04-03

CLOZAPINE AS A SEDATIVE.
221537 04-11

CLOZAPINE: PHARMACOLOGY, BIOCHEMISTRY AND CLINICAL USE.
221538 04-13

CLOZAPINE AND HALOPERIDOL: CLINICAL AND BIOCHEMICAL ASPECTS IN THE TREATMENT OF SCHIZOPHRENIA.
221637 04-08

RESULTS OF A COMPARATIVE DOUBLE-BLIND STUDY WITH CLOZAPINE AND CHLORPROMAZINE IN THE TREATMENT OF SCHIZOPHRENIC PATIENTS.
221989 04-08

CMHC

PEER REVIEW OF PRESCRIBING PATTERNS IN A CMHC.
224742 04-17

CNS

A DUAL STUDY. PART I: SYNTHESIS AND STEREOCHEMISTRY OF SOME 1 SUBSTITUTED QUINOLIZIDINES AS ANALOGS OF BIOLOGICALLY ACTIVE COMPOUNDS. PART II: AMINO DERIVATIVES OF THIOPHENE FUSED CYCLIC KETONES AS POTENTIAL CNS. (PH.D. DISSERTATION).
196252 01-01

THE EFFECTS OF SOME CNS DEPRESSANTS ON RATS EXPOSED TO IONIZING IRRADIATION.
197581 01-03

BASIC DERIVATIVES OF DIPHENYLMETHANE WITH A DEPRESSIVE EFFECT ON THE CNS.
199209 02-02

EFFECTS OF PHENOBARBITAL ON ELECTROCORTICOGRAM AND ACTIVITY, ON REGIONAL CNS ENERGY METABOLISM, AND ON PRESYNAPTIC EVENTS IN CEREBRAL CORTEX AND BRAINSTEM. (PH.D. DISSERTATION).
203033 02-03

ACTIVATION OF BRAIN MONOAMINEOXIDASE BY SOME CNS DEPRESSANTS.
204864 02-03

PSYCHOTROPIC DRUGS AND DIFFERENTLY STIMULATED ATPASE IN CNS.
205629 03-03

DELTA9-TETRAHYDROCANNABINOL AND SOME CNS DEPRESSANTS: EVIDENCE FOR CROSS-TOLERANCE IN THE RAT.
210876 03-03

DRUGS, CATECHOLAMINES AND KREBS CYCLE INTERACTION (CNS).
213602 04-03

THE EFFECT OF SODIUM GAMMA-HYDROXYBUTYRATE ON THE CNS OF RATS AND MICE.
215069 04-03

SERUM ERYTHROCYTE AND CNS LEVELS IN RHESUS MONKEYS OF ORALLY AND INTRAVENOUSLY ADMINISTERED RUBIDIUM SALTS.
218956 04-02

USE OF CNS STIMULANT MEDICATION IN AVERAGED ELECTROENCEPHALIC AUDIOMETRY WITH CHILDREN WITH MBD.
221103 04-11

CYANOGEN CONDENSATIONS AS A ROUTE TO 3-AMINO-2-IMINOBENZOTHIAZIN-4-ONES WITH CNS DEPRESSANT POTENTIAL.
222870 04-02

COCA-COLA

THE EFFECT OF COCA-COLA, CAFFEINE, ANTIDEPRESSANTS AND CHLORPROMAZINE ON OBJECTIVE AND SUBJECTIVE SLEEP PARAMETERS.
210808 03-14

COCAINE

COMPARISON BETWEEN THE EFFECTS PRODUCED BY CHRONIC DENERVATION AND BY COCAINE ON THE SENSITIVITY TO, AND ON THE DISPOSITION OF, NORADRENALINE IN ISOLATED SPLEEN STRIPS.
193139 01-03

POTENTIATION BY 3,4 DIMETHOXYPHENYLETHYLAMINE (DMPEA) AND COCAINE OF NOREPINEPHRINE-INDUCED CONTRACTION OF GUINEA-PIG VAS-DEFERENS.
194156 01-03

THE CARDIAC EFFECTS OF COCAINE AND CERTAIN ANTIHISTAMINES AND ANTIDEPRESSANTS.
197452 01-03

THE EFFECTS OF AMPHETAMINE AND COCAINE ON THE RESPONSE OF THE ISOLATED GUINEA-PIG VAS-DEFERENS TO NORADRENALINE, TYRAMINE AND NERVE STIMULATION.
197463 01-03

A COMPARISON OF THE EFFECTS OF (+) AMPHETAMINE, COCAINE AND DENERVATION ON THE RESPONSES OF THE ISOLATED VAS-DEFERENS OF THE GUINEA-PIG TO NOREPINEPHRINE AND ACETYLCHOLINE.
197495 01-03

THE BIOCHEMICAL PHARMACOLOGY OF ABUSED DRUGS: I. AMPHETAMINES, COCAINE, AND LSD.
198028 01-12

INTRACRANIAL SELF-STIMULATION IN RATS AS A FUNCTION OF VARIOUS STIMULUS PARAMETERS: V. INFLUENCE OF COCAINE ON MEDIAL FOREBRAIN BUNDLE STIMULATION WITH MONOPOLAR ELECTRODES.
198223 02-03

CODEINE AND COCAINE REINFORCED RESPONDING IN RHESUS MONKEYS: EFFECTS OF DOSE ON RESPONSE RATES UNDER A FIXED-RATIO SCHEDULE.
202667 02-04

POSSIBLE ROLE OF ADENOSINE-3-5-MONOPHOSPHATE AND BIOGENIC AMINES IN MORPHINE AND COCAINE TREATED RATS. (PH.D. DISSERTATION).
220475 04-03

COCAINE, AMPHETAMINE, AND TRICYCLIC ANTIDEPRESSANTS AND SYNAPTIC TRANSMISSION.
221386 04-13

COCAINE, KINDLING, AND PSYCHOSIS.
224796 04-14

CODEINE

CODEINE AND COCAINE REINFORCED RESPONDING IN RHESUS MONKEYS: EFFECTS OF DOSE ON RESPONSE RATES UNDER A FIXED-RATIO SCHEDULE.
202667 02-04

CODING

THE EFFECTS OF DRUG ADMINISTRATION TO THE LATERAL HYPOTHALAMUS: NEUROCHEMICAL CODING OR NONSPECIFICITY?.
195992 01-03

NEUROCHEMICAL CODING FOR FEEDING IN SHEEP AND STEERS.
206727 03-04

COEFFICIENTS

CORRELATION OF PSYCHOTOMIMETIC ACTIVITY OF PHENETHYLAMINES AND AMPHETAMINES WITH 1-OCTANOL WATER PARTITION COEFFICIENTS.
208593 03-12

COFACTOR

TYROSINE-HYDROXYLASE (TH) IN NUCLEUS-ACCUMBENS AND STRIATUM: EFFECTS OF NEUROLEPTICS ON THE AFFINITY FOR PTERIDINE COFACTOR. (UNPUBLISHED PAPER).
196588 01-03

COGNITION

DRUG AND COGNITION STUDIES IN DISTURBED CHILDREN.
198085 02-11

EFFECTS OF PHENOTHIAZINES ON ANXIETY AND COGNITION IN SCHIZOPHRENIA.
216190 04-08

COGNITIVE

DRUGS AND PLACEBOS: EFFECTS OF CAFFEINE ON COGNITIVE PERFORMANCE.
205223 02-14

COGNITIVE AND MOTOR SENSORY PERFORMANCES IN TOXIC AND NONTOXIC EPILEPTIC SUBJECTS.
210824 03-15

DOSE EFFECTS OF SMOKED MARIHUANA ON HUMAN COGNITIVE AND MOTOR FUNCTIONS.
221036 04-01

EFFECT OF MARIJUANA ON DIVERGENT AND CONVERGENT PRODUCTION COGNITIVE TESTS.
223394 04-14

COGWHEEL

COGWHEEL RIGIDITY RELATED TO LITHIUM MAINTENANCE.
225334 04-15

COLD

EFFECTS OF MORPHINE, CHOLINERGIC AGENTS AND COLD EXPOSURE ON MIDBRAIN DOPAMINE (DA) NERVE CELLS OF MORPHINE TOLERANT AND NONTOLERANT MICE.
197287 01-03

THE EFFECT OF COLD AND DIAZEPAM ON THE TOXICITY OF FENFLURAMINE IN MICE.
215160 04-05

COLLABORATIVE

FACTORS ASSOCIATED WITH TREATMENT SUCCESS IN LITHIUM CARBONATE PROPHYLAXIS: REPORT OF THE NIMH-VA COLLABORATIVE STUDY GROUP.
193068 01-09

DROWSINESS DUE TO CHLORPROMAZINE IN RELATION TO CIGARETTE SMOKING: A REPORT FROM THE BOSTON COLLABORATIVE DRUG SURVEILLANCE PROGRAM.
193072 01-15

NIMH-PRB COLLABORATIVE OUTPATIENT SCHIZOPHRENIC STUDY.
198075 02-08

NIMH-VA LITHIUM COLLABORATIVE STUDY.
198080 02-09

PSYCHOTROPIC DRUG USE IN THE BOSTON AREA: A REPORT FROM THE BOSTON COLLABORATIVE DRUG SURVEILLANCE PROGRAM.
213920 04-17

NICOTINIC ACID IN THE TREATMENT OF SCHIZOPHRENIAS: CANADIAN MENTAL HEALTH ASSOCIATION COLLABORATIVE STUDY PROGRESS REPORT II.
219537 04-08

COLONIES

EFFECTS OF MARIHUANA (DELTA9-THC) ON BEHAVIOR PATTERNS AND SOCIAL ROLES IN COLONIES OF CBA MICE.
216494 04-04

COLORIMETRIC

COLORIMETRIC, ULTRAVIOLET SPECTROPHOTOMETRIC, AND SPECTROPHOTOFLUOROMETRIC DETERMINATION OF DOXEPIN AND SOME OF ITS METABOLITES IN SERUM AND IN URINE.
199214 02-16

ANALYSIS OF AMPHETAMINES AND OTHER PSYCHOACTIVE DRUGS: A COLORIMETRIC ASSAY OF (S)-(+) AMPHETAMINE IN THE SUBMICROGRAM RANGE. (PH.D. DISSERTATION).
222633 04-01

COLORING

THE EFFECTIVENESS OF RITALIN AND TOKEN ECONOMY IN INCREASING HYPERKINETIC CHILDRENS COLORING BEHAVIOR. (PH.D. DISSERTATION).
220510 04-14

COMA

TRICYCLIC ANTIDEPRESSANT POISONING: REVERSAL OF COMA, CHOREOATHETOSIS, AND MYOCLONUS BY PHYSOSTIGMINE.
202919 02-15

SURVIVAL IN LITHIUM INTOXICATION, STATUS-EPILEPTICUS, AND PROLONGED COMA.
208536 03-15

CORRELATION BETWEEN BRAIN MONOAMINE LEVELS AND POSTICTAL COMA FOLLOWING ELECTROSHOCK.
215723 04-03

ATROPINE COMA TREATMENT OF SCHIZOPHRENIC PATIENTS WITH A SLUGGISH DEVELOPMENT AND OBSESSIVE SYNDROMES.
224085 04-08

COMBINATION

THE EFFECT OF LITHIUM CARBONATE IN COMBINATION WITH TRICYCLIC ANTIDEPRESSANTS IN ENDOGENOUS DEPRESSION: A DOUBLE-BLIND, MULTICENTER TRIAL.
197035 01-09

EFFECTS OF RESERPINE, 6-HYDROXYDOPAMINE, P-CHLOROPHENYLALANINE AND A COMBINATION OF THESE SUBSTANCES ON THE GROOMING BEHAVIOUR OF MICE.
197291 01-04

5-HYDROXYTRYPTOPHAN IN COMBINATION WITH CLOMIPRAMINE IN THERAPY RESISTANT DEPRESSIONS.
198229 02-09

EFFECT OF TWO WEEKS TREATMENT WITH CHLORIMIPRAMINE AND NORTRIPTYLINE, ALONE OR IN COMBINATION WITH ALCOHOL, ON LEARNING AND MEMORY.
200057 02-14

THE EFFECT OF TRIIODOTHYRONINE IN COMBINATION WITH IMIPRAMINE ON (3H) CYCLIC-AMP PRODUCTION IN SLICES OF RAT CEREBRAL CORTEX.
202777 02-03

HYDERGINE THIORIDAZINE COMBINATION IN THE TREATMENT OF PSYCHOPATHOLOGICAL STATES IN OLD AGE.
205637 03-11

CLINICAL EXPERIENCES IN TREATING DEPRESSED PATIENTS WITH A COMBINATION OF TRICYCLIC DRUGS AND THYROID EXTRACT.
209144 03-09

CLINICAL STUDIES WITH MARIHUANA AND D-AMPHETAMINE COMBINATION.
211745 03-14

THE EFFECT OF COMBINATION OF METHYLPHENIDATE AND DIAZEPAM ON THE EEG AND ITS EVALUATION BY MEANS OF DISCRIMINANT ANALYSIS.
215070 04-13

FACTOR ANALYSIS OF EEG OF HEALTHY SUBJECTS GIVEN NO DRUGS AND A COMBINATION OF DIAZEPAM AND METHYLPHENIDATE.
215071 04-13

QUANTITATIVE MEASUREMENT OF PARKINSON DISEASE RIGOR. MYOINTEGRATIVE DRUG TRIAL IN COMBINATION WITH THE DECARBOXYLASE INHIBITING DRUG RO-8-0576.
220829 04-11

COMBINATION DRUG THERAPY IN PSYCHOPHARMACOLOGY.
221075 04-17

ELECTROENCEPHALOGRAPHIC STUDY ON THE ACTION OF THE COMBINATION MEPROBAMATE ACEPROMETAZINE ON VARIOUS CEREBRAL SYSTEMS.
221286 04-03

EXPERIMENTAL PSYCHOLOGICAL STUDY ON THE EFFECT OF A COMBINATION OF HEXOBENDINE, ETHAMIVAN AND ETOFYLLINE.
221738 04-14

DEPRESSION AND ANXIETY IN HEROIN ADDICTS: A PLACEBO CONTROLLED STUDY OF DOXEPIN IN COMBINATION WITH METHADONE.
225386 04-09

COMBINATIONS

PSYCHOACTIVE DRUGS: INCLUDING COMBINATIONS.
210874 03-17

COMPARATIVE STUDIES WITH CLOMIPRAMINE (ANAFRANIL) AND CLOMIPRAMINE COMBINATIONS.
215152 04-10

FACILITATION OF AVOIDANCE LEARNING BY CHLORDIAZEPOXIDE AMPHETAMINE COMBINATIONS IN MICE.
217466 04-04

COMBINED

COMBINED EFFECTS OF DIAZEPAM AND ETHANOL ON MENTAL AND PSYCHOMOTOR FUNCTIONS.
199896 02-14

THE COMBINED EFFECTS OF METHYLPHENIDATE (RITALIN) AND A CLASSROOM BEHAVIOR MODIFICATION PROGRAM IN REDUCING THE HYPERKINETIC BEHAVIORS OF INSTITUTIONALIZED MENTAL RETARDATES. (PH.D. DISSERTATION).
202356 02-11

THE EFFECT OF L-DOPA AND L-DOPA COMBINED WITH CHLORPROMAZINE ON SPINAL CORD ACTIVITY DURING DISTURBED INHIBITION BY TETANUS TOXOID.
207200 03-03

COMBINED THYROID (TRIIODOTHYRONINE) TRICYCLIC ANTIDEPRESSANT TREATMENT IN DEPRESSIVE STATES.
207720 03-09

EFFECT OF COMBINED ALCOHOL AND PROPOXYPHENE ON HUMAN PERFORMANCE.
210871 03-14

THE COMBINED EFFECTS OF CANNABIDIOL AND DELTA9-TETRAHYDROCANNABINOL. (PH.D. DISSERTATION).
220474 04-04

COMBINING

TREATMENT OF PARKINSONS DISEASE BY COMBINING L-DOPA WITH A DECARBOXYLASE INHIBITOR.
204372 02-07

COMMISSURAL

COMMISSURAL AND SENSORY EVOKED POTENTIALS OF THE HIPPOCAMPUS FOLLOWING MICROIONTOPHORESIS OF SOME DRUGS.
219111 04-03

COMMUNICATION

EFFECTS OF LSD-25 ON PSYCHOTHERAPEUTIC COMMUNICATION.
198092 02-10

MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 1. COMMUNICATION: SETTING A GOAL AND METHODOLOGICAL GROUND RULES.
203839 02-13

MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 2. COMMUNICATION: PSYCHOPATHOLOGICAL COURSE PROFILE AND SOMATIC CHARACTERISTICS (STUDIES WITH THE AMP SYSTEM).
203840 02-14

MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 3. COMMUNICATION: PERAZINE CONCENTRATION IN BLOOD AND CLINICAL EFFICACY.
203841 02-13

MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 4. COMMUNICATION: CONNECTION BETWEEN EEG CHANGES, CONCENTRATION IN BLOOD, AND OTHER CLINICAL VARIABLES.
203842 02-13

MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 5. COMMUNICATION: INFLUENCE ON VENTRICULAR EXCITATION IN THE ELECTROCARDIOGRAM.
203843 02-13

MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 6. COMMUNICATION: RELATIONSHIP BETWEEN NEUROLEPTIC HYPOKINESIS AND ANTIPSYCHOTIC THERAPEUTIC RESULTS.
203844 02-13

MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 7. COMMUNICATION: METHODOLOGICAL OUTCOME.
203845 02-16

DOUBLE-BLIND TEST OF THREE ANTIDEPRESSANTS, FOURTH COMMUNICATION; RESULTS WITH THE HAMBURG DEPRESSION SCALE.
221289 04-11

ON THE GAS CHROMATOGRAPHIC ANALYSIS OF BENZODIAZEPINES: SECOND COMMUNICATION: DIAZEPAM AND ITS METABOLITES.
221739 04-06

DELTA9-THC AND NONVERBAL COMMUNICATION IN MONKEYS.
224907 04-04

COMMUNICATIONS

DOUBLE-BLIND TEST OF THREE ANTIDEPRESSANTS, THIRD COMMUNICATIONS: METHODOLOGICAL PROBLEMS.
221288 04-16

COMMUNITY

TWO DECADES OF PSYCHOPHARMACOLOGY AND COMMUNITY MENTAL HEALTH: OLD AND NEW PROBLEMS OF THE SCHIZOPHRENIC PATIENT.
207921 03-17

PSYCHOPHARMACOLOGY, COMMUNITY MENTAL HEALTH AND THE SCHIZOPHRENIC PATIENT.
207922 03-17

FROM HOSPITAL TREATMENT TO COMMUNITY PSYCHIATRY -- SECOND REPORT -- OUTPATIENT EMERGENCY TREATMENT OF MENTAL PATIENTS WITH THE USE OF HALOPERIDOL.
208723 03-11

COMPARATIVELY

TREATMENT OF SCHIZOPHRENIA BY THE ADMINISTRATION OF A SMALL DOSE OF FORIT FOR COMPARATIVELY LONG PERIODS OF TIME.
194476 01-08

COMPARED

ALTERATIONS IN ACID-BASE BALANCE IN THE DOG AFTER INTRAVENOUS ADMINISTRATION OF BENZOCTAMINE AND DIAZEPAM, COMPARED WITH THOSE INDUCED BY THIOPENTAL.
197485 01-03

EFFECT OF LITHIUM ON NEUROLEPTIC-INDUCED TARDIVE DYSKINESIA COMPARED WITH PLACEBO IN A DOUBLE-BLIND CROSSOVER TRIAL.
221335 04-15

COMPARING

AN INTERIM REPORT OF A DOUBLE-BLIND STUDY COMPARING A ONCE DAILY DOSAGE OF MAPROTILINE (LUDIOMIL) WITH AMITRIPTYLINE THRICE DAILY.
221661 04-09

COMPARISON

A DOUBLE-BLIND CROSSOVER COMPARISON BETWEEN CLOTHIAPINE AND DIAZEPAM IN THE TREATMENT OF MENTAL SYMPTOMS IN CHRONIC ALCOHOLICS.
192988 01-11

COMPARISON BETWEEN THE EFFECTS PRODUCED BY CHRONIC DENERVATION AND BY COCAINE ON THE SENSITIVITY TO, AND ON THE DISPOSITION OF, NORADRENALINE IN ISOLATED SPLEEN STRIPS.
193139 01-03

A CLINICAL TRIAL WITH THIOPROPERAZINE (MAJEPTIL M & B) -- A COMPARISON WITH CHLORPROMAZINE.
194311 01-11

COMPARISON OF THE EFFECTS OF CHLORAL HYDRATE AND TRICHLOROETHANOL ON THE EEG OF THE ISOLATED PERFUSED RAT BRAIN.
194743 01-03

A COMPARISON OF THE INHIBITORY EFFECTS OF CERTAIN ANTIPARKINSONIAN AGENTS ON DOPAMINE ACCUMULATION INTO THE RAT STRIATUM.
195234 01-03

HALOPERIDOL FOR CHRONICALLY HOSPITALIZED PSYCHOTICS: A DOUBLE-BLIND COMPARISON WITH THIOTHIXENE AND PLACEBO: A FOLLOWUP OPEN EVALUATION.
196676 01-14

A COMPARISON OF PIMOZIDE AND THIORIDAZINE AS ANTAGONISTS OF AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR IN DOGS.
197470 01-04

A COMPARISON OF THE EFFECTS OF (+) AMPHETAMINE, COCAINE AND DENERVATION ON THE RESPONSES OF THE ISOLATED VAS-DEFERENS OF THE GUINEA-PIG TO NOREPINEPHRINE AND ACETYLCHOLINE.
197495 01-03

COMPARISON OF THE SPECIFICITY OF 3-(P-TRIFLUOROMETHYLPHENOXY)-N-METHYL-3 PHENYLPROPYLAMINE AND CHLORIMIPRAMINE AS AMINE UPTAKE INHIBITORS IN MICE.
197870 01-03

EVIDENCE THAT PUNCTUATE INTRACEREBRAL ADMINISTRATION OF 6-HYDROXYDOPAMINE FAILS TO PRODUCE SELECTIVE NEURONAL DEGENERATION: COMPARISON WITH COPPER SULFATE AND FACTORS GOVERNING THE DEPORTMENT OF FLUIDS INJECTED INTO BRAIN.
197931 01-03

COMPARISON OF THE ACTION OF DIAZEPAM AND PHENOBARBITAL USING EEG DERIVED POWER SPECTRA OBTAINED FROM TEMPORAL LOBE EPILEPTICS.
197992 01-13

A COMPARISON OF THE RELATIVE EFFICACY OF SPECIAL CLASS EDUCATION AND DRUG THERAPY FOR CHILDREN WITH SELECTED LEARNING DISABILITIES. (ED.D. DISSERTATION).
198662 02-11

PHARMACOLOGICAL AND TOXICOLOGICAL STUDY OF A NEW PSYCHOTROPIC STIMULANT: THE 2-PHENYLDIMETHYL-TETRAHYDROOXAZINE, IN COMPARISON WITH D,L-AMPHETAMINE, PHENMETRAZINE AND PEMOLINE-MG.
199211 02-04

A CONTROLLED COMPARISON OF THE EFFECTS OF DIPHENYLHYDANTOIN AND PLACEBO ON MOOD AND PSYCHOMOTOR FUNCTIONING IN NORMAL VOLUNTEERS.
199518 02-14

COMPARISON OF THE EFFECTS OF THE INTRANIGRAL INJECTIONS OF CHOLINOMIMETICS WITH SYSTEMIC INJECTIONS OF THE DOPAMINE RECEPTOR STIMULATING AND BLOCKING AGENTS IN THE RABBIT.
199772 02-03

COMPARISON OF THE OXIME AND THE HYDROXYLAMINE DERIVATIVES OF 4-CHLOROAMPHETAMINE AS DEPLETORS OF BRAIN 5-HYDROXYINDOLES.
200004 02-03

COMPARISON OF THE EFFECTS OF LITHIUM, BETA-PHENYLETHYLAMINE AND TYROSINE ON XENOPUS EMBRYOS.
200752 02-03

A DOUBLE-BLIND COMPARISON OF CLOMIPRAMINE WITH AMITRIPTYLINE IN DEPRESSION.
202178 02-10

COMPARISON OF THE EFFECTS OF ANISOMYCIN ON MEMORY ACROSS SIX STRAINS OF MICE.
202202 02-04

COMPARISON OF MORPHINE AND CHLORPROMAZINE EFFECTS ON MODERATELY AND SEVERELY SUPPRESSED PUNISHED RESPONDING IN THE PIGEON.
202666 02-04

CENTRAL EFFECTS OF THREE FLUORINATED BENZODIAZEPINES IN COMPARISON WITH DIAZEPAM.
202765 02-03

AN ANALYSIS OF THE GROSS BEHAVIOURAL CHANGES INDUCED BY TETRAETHYLAMMONIUM AND A COMPARISON WITH OTHER SUBSTANCES AFFECTING THE AUTONOMIC AND CENTRAL NERVOUS SYSTEM AFTER INTRAVENTRICULAR INJECTIONS TO CONSCIOUS CATS.
202781 02-04

RESULTS OF AN OPEN AND A DOUBLE-BLIND STUDY OF NOMIFENSINE IN COMPARISON TO IMIPRAMINE.
204899 02-10

A CONTROLLED COMPARISON OF OXYPERTINE AND PERPHENAZINE IN SCHIZOPHRENIC PSYCHOSES.
205582 02-08

COMPARISON OF THE EFFECTS OF ATROPINE AND CANNABIS UPON THE FIXED CONDITIONED ALIMENTARY MOTOR REFLEXES IN CATS AFFECTED BY NICOTINE.
205623 03-14

A CONTROLLED COMPARISON OF CHLORAZEPATE WITH OXAZEPAM IN NEUROTIC ANXIETY.
205638 03-10

A COMPARISON OF THE LOCOMOTOR EFFECTS OF 5-HYDROXYTRYPTAMINE AND 5-HYDROXYTRYPTOPHAN ADMINISTERED VIA TWO SYSTEMIC ROUTES.
206086 03-04

PSYCHOACTIVE DRUGS IN MANIA: A CONTROLLED COMPARISON OF LITHIUM CARBONATE, CHLORPROMAZINE AND HALOPERIDOL.
207446 03-09

CLINICAL USE OF CLOCAPRAMINE FOR THE TREATMENT OF CHRONIC SCHIZOPHRENIA -- SPECIAL EMPHASIS ON ITS COMPARISON WITH PERPHENAZINE.
207534 03-08

COMPARISON OF THE INHIBITORY EFFECTS OF PROPARGYLAMINE AND PARGYLINE ON BRAIN AND LIVER MONOAMINEOXIDASE ACTIVITY.
207857 03-03

CLINICAL COMPARISON OF ANXIOLYTIC DRUG THERAPY.
209080 03-10

CLINICAL AND BIOCHEMICAL COMPARISON OF CHLORAZEPATE AND DIAZEPAM.
209081 03-10

COMPARISON OF NEUROLEPTICS IN CONTROLLED EXPERIMENTAL CONDITIONS: METHOPHENAZINE VS PERPHENAZINE.
209147 03-08

A DOUBLE-BLIND CONTROLLED COMPARISON OF BROMAZEPAM AND DIAZEPAM.
209411 03-10

A COMPARISON OF A NEW TRANQUILIZER, SULPIRIDE AND OXAZOLAM ON PSYCHOSOMATIC DISEASES, NEUROSIS AND MASKED DEPRESSION USING DOUBLE-BLIND METHOD.
210180 03-11

A DOUBLE-BLIND COMPARISON OF LITHIUM CARBONATE AND IMIPRAMINE IN THE TREATMENT OF DEPRESSION.
210241 03-09

A COMPARISON BETWEEN DIAZEPAM AND HALOPERIDOL IN ANXIETY STATES.
210434 03-10

COMPARISON BETWEEN BEHAVIOURS ELICITED BY HIGH DOSES OF AMPHETAMINE AND FENFLURAMINE: IMPLICATIONS FOR THE CONCEPT OF STEREOTYPY.
210742 03-04

COMPARISON OF THE EFFECTS OF D-AMPHETAMINE AND L-AMPHETAMINE IN REVERSING DEPRESSION OF MOUSE LOCOMOTOR ACTIVITY CAUSED BY RESERPINE.
210869 03-03

COMPARISON OF 3,4 DIMETHOXYPHENYLETHYLAMINE TREATED PLASMA FROM CHRONIC SCHIZOPHRENICS AND CONTROLS.
210897 03-08

COMPARISON OF STRUCTURAL AND STEREOISOMERS OF APOMORPHINE ON STEREOTYPED SNIFFING BEHAVIOUR OF THE RAT.
210930 03-04

BIOLOGICAL AND PHARMACOKINETIC EVIDENCE FOR GENERIC EQUIVALENCE OF THREE IMIPRAMINE PREPARATIONS: COMPARISON WITH A NEW IMIPRAMINE ANALOGUE.
211071 03-02

RESPONSES OF CENTRAL NEURONES TO AMANTADINE: COMPARISON WITH DOPAMINE AND AMPHETAMINE.
213398 04-03

CLINICAL AND EXPERIMENTAL COMPARISON OF DIAZEPAM, CHLORAZEPATE AND PLACEBO.
214018 04-14

A COMPARISON BETWEEN CAUDATE, AMYGDALOID AND HYPOTHALAMIC SELF-STIMULATION IN SQUIRREL MONKEYS (SAIMIRI-SCIUREUS). (PH.D. DISSERTATION).
214207 04-04

A COMPARISON BETWEEN MAPROTILINE (LUDIOMIL) AND AMITRIPTYLINE IN THE TREATMENT OF DEPRESSIVE REACTION IN GENERAL PRACTICE.
215058 04-14

A COMPARISON OF THE THERAPEUTIC EFFECT OF OXYPERTINE AND THIORIDAZINE IN CHRONIC SCHIZOPHRENIA (A CONTROLLED TRIAL).
215075 04-08

A COMPARISON OF A DIVIDED AND A SINGLE DOSE REGIME OF CLOMIPRAMINE (ANAFRANIL).
215149 04-09

A COMPARISON OF A LOW AND HIGH DOSAGE REGIME OF CLOMIPRAMINE (ANAFRANIL).
215150 04-09

COMPARISON OF THE HYPNOTIC ACTIVITY OF TRIAZOLAM, FLURAZEPAM HYDROCHLORIDE, AND PLACEBO.
215673 04-14

HOMOVANILLIC ACID CONCENTRATION IN RAT BRAIN: EFFECT OF A CHOLINE ACETYLTRANSFERASE INHIBITOR AND COMPARISON WITH CHOLINERGIC AND DOPAMINERGIC AGENTS.
215711 04-03

A DOUBLE-BLIND COMPARISON OF THREE TIMES DAILY AND SINGLE NIGHT DOSAGE OF THE TRICYCLIC ANTIDEPRESSANT DOTHIEPIN.
216463 04-09

COMPARISON OF THE EFFECTS OF TETRACYCLIC AND TRICYCLIC ANTIDEPRESSANTS ON THE SEROTONIN UPTAKE BY HUMAN THROMBOCYTES IN VITRO.
217258 04-13

A COMPARISON BETWEEN BROMAZEPAM (RO-5-3350, LEXOTAN) AND DIAZEPAM (VALIUM) IN ANXIETY NEUROSIS: A CONTROLLED, DOUBLE-BLIND CLINICAL TRIAL.
217455 04-10

A COMPARISON OF CIRCLING MODELS FOR THE DETECTION OF PARKINSON ACTIVITY.
217547 04-04

COMPARISON OF CARDIOVASCULAR, HYPERTHERMIC, AND TOXIC EFFECTS OF P-METHOXYAMPHETAMINE (PMA) AND 3,4 METHYLENEDIOXYAMPHETAMINE (MDA).
217578 04-05

COMPARISON OF THE ACTION OF DIFFERENT BARBITURATES ON SQUID AXON MEMBRANES.
217662 04-03

A COMPARISON OF THE INDUCTIVE EFFECTS OF PHENOBARBITAL, METHAQUALONE, AND METHYPRYLON ON HEPATIC MIXED FUNCTION OXIDASE ENZYMES IN THE RAT.
217794 04-03

DOUBLE-BLIND COMPARISON OF LITHIUM CARBONATE AND IMIPRAMINE IN TREATMENT OF DEPRESSION.
218772 04-09

A COMPARISON OF THE ACTION OF THE TRICYCLIC ANTIDEPRESSANTS, AZAPHEN AND IMIPRAMINE, ON THE GASTROINTESTINAL TRACT OF TEST ANIMALS.
219505 04-03

A BENZODIOXANHYDROXYETHYLPIPERIDINE DERIVATIVE WITH ACUTE CENTRAL HYPOTENSIVE ACTION, DIFFERENT FROM THAT OF CLONIDINE: A COMPARISON WITH NEUROLEPTIC AGENTS.
220976 04-03

ANTAGONISM OF PSYCHOSTIMULANT 2 PHENYLDIMETHYLTETRAHYDROOXAZINE HYDROCHLORIDE (G-130) TO CENTRAL NERVOUS SYSTEM DEPRESSING DRUGS: MONOAMINEOXIDASE INHIBITORY ACTIVITY AND NOREPINEPHRINE AND SEROTONIN INDUCED CHANGES, COMPARISON WITH DL-AMPHETAMINE.
221267 04-03

NOXIPTILIN (AGEDAL) -- A NEW TRICYCLIC ANTIDEPRESSANT WITH A FASTER ONSET OF ACTION? A DOUBLE-BLIND, MULTICENTRE COMPARISON WITH AMITRIPTYLINE.
221306 04-09

A COMPARISON BETWEEN DIAZEPAM AND HALOPERIDOL IN NEUROTIC ANXIETY AND TENSION STATES IN PATIENTS IN A OPEN WARD.
221638 04-10

DOUBLE-BLIND COMPARISON OF MAPROTILINE (LUDIOMIL) WITH AMITRIPTYLINE IN THE TREATMENT OF DEPRESSIVE ILLNESS.
221652 04-09

A CONTROLLED COMPARISON OF MAPROTILINE (LUDIOMIL) WITH IMIPRAMINE AVOIDING OBSERVER BIAS.
221654 04-09

A COMPARISON BETWEEN MAPROTILINE (LUDIOMIL) AND IMIPRAMINE IN THE TREATMENT OF DEPRESSIVE ILLNESS IN THE ELDERLY.
221655 04-09

A COMPARISON OF MAPROTILINE (LUDIOMIL) AND PLACEBO IN THE TREATMENT OF DEPRESSION.
221656 04-09

A COMPARISON BETWEEN DAILY AND NIGHTLY DOSE REGIMEN OF AMITRIPTYLINE AND MAPROTILINE (LUDIOMIL) IN THE TREATMENT OF REACTIVE DEPRESSION IN GENERAL PRACTICE.
221662 04-09

CLINICAL STUDY OF FIVE DEPOT NEUROLEPTICS, COMPARISON OF ACTIVITY PROFILES OF FLUPHENAZINE DECANOATE, FLUSPIRILENE, PENFLURIDOL, PERPHENAZINE ENANTHATE AND PIPOTHIAZINE PALMITATE.
221822 04-08

CENTRAL CATECHOLAMINE RECEPTOR BLOCKING ACTIONS OF BE-2254 (HEAT): COMPARISON WITH CHLORPROMAZINE AND HALOPERIDOL.
222804 04-03

COMPARISON OF THE REMEDIAL RESULTS OF CLOFLUPEROL AND HALOPERIDOL FOR SCHIZOPHRENIA BY DOUBLE-BLIND TEST METHOD.
224549 04-08

A COMPARISON OF PHENOTHIAZINES IN MANAGING AGGRESSIVE EPISODES IN SCHIZOPHRENIC PATIENTS.
224955 04-08

COMPARTMENTATION

METABOLIC COMPARTMENTATION IN THE BRAIN: METABOLISM OF A TRICARBOXYLIC ACID CYCLE INTERMEDIATE, (1,4-14C)SUCCINATE, AFTER INTRACEREBRAL ADMINISTRATION.
210780 03-03

COMPENDIUM

DRUG ABUSE AND DRUG DEPENDENCY. A COMPENDIUM FOR MEDICAL DOCTORS.
204468 02-17

COMPENSATORY

PENTOBARBITAL EFFECT ON PERFORMANCE IN MONOTONOUS CONDITIONS NOT PREVENTED BY COMPENSATORY EFFORT.
205595 02-15

COMPETITION

GENETICALLY SELECTED WINNER AND LOSER RATS IN THE TUNNEL COMPETITION: INFLUENCE OF APOMORPHINE AND DOPA.
217829 04-04

COMPETITION FOR PLASMA PROTEIN BINDING SITES BETWEEN PHENOTHIAZINE TRANQUILIZERS AND IMINODIBENZYL ANTIDEPRESSANTS.
217891 04-03

COMPETITORS

BENZODIAZEPINES: SPECIFIC COMPETITORS FOR THE BINDING OF L-TRYPTOPHAN TO HUMAN SERUM ALBUMIN.
217686 04-01

COMPLEX

THE EFFECTS OF PABENOL COMPLEX ON CHILDREN WITH LEARNING PROBLEMS.
196704 01-07

THE INFLUENCE OF TRIFLUOPERAZINE, CARBIDINE AND IMIZINE ON EVOKED POTENTIALS IN DIFFERENT STRUCTURES OF THE LIMBIC RETICULAR COMPLEX.
200564 02-02

THE INFLUENCE OF CATECHOLAMINES, SEROTONIN, AND SOME AMINO ACIDS ADMINISTERED INTO THE AMYGDALOID COMPLEX ON CONDITIONED REFLEXES OF AVOIDANCE AND MOTOR ACTIVITY IN RATS.
200566 02-03

EFFECT OF INCREASED AROUSAL ON RESPONSE TO STIMULUS CHANGE IN A COMPLEX MAZE.
206187 03-04

REGIONAL DISTRIBUTION OF TYROSINE-HYDROXYLASE, NOREPINEPHRINE AND DOPAMINE WITHIN THE AMYGDALOID COMPLEX OF THE RAT.
217872 04-03

COMPLEXES

REACTION OF CATIONIC GROUPS OF CHLORPROMAZINE WITH ANIONIC MACROMOLECULES: COMPLEXES WITH DNA, RNA, HYALURONIC ACID AND HEPARIN.
199897 02-03

CRYSTAL STRUCTURE DETERMINATIONS OF THE DONOR ACCEPTOR COMPLEXES OF PHENOTHIAZINE AND PHENOXAZINE WITH NICKEL THIETE. (PH.D. DISSERTATION).
201003 02-01

COMPLICATION

PRIAPISM AS A POSSIBLE COMPLICATION OF THE CHLORPROMAZINE TREATMENT.
205594 02-15

ACUTE ORGANIC BRAIN SYNDROME: A COMPLICATION OF DISULFIRAM THERAPY.
213710 04-15

MONONEUROPATHY MULTIPLEX AS A COMPLICATION OF AMPHETAMINE ANGIITIS.
217668 04-15

COMPLICATIONS

EEG VARIATIONS UNDER ANTABUSE (DISULFIRAM) AND ANTABUSE PLUS ALCOHOL EXPOSITION: A STUDY OF PATHOGENESIS FROM ANTABUSE THERAPY COMPLICATIONS.
200572 02-15

UNEXPECTED COMPLICATIONS BY ANTICHOLINERGICS CONTAINED IN SOPORIFICS AND ANALGESIC DRUGS.
204404 02-15

CARDIOVASCULAR COMPLICATIONS OF TRICYCLIC ANTIDEPRESSANT OVERDOSAGE.
209234 03-15

COMPREHENSIVE

COMPREHENSIVE CLINICAL STUDIES OF PSYCHOACTIVE DRUGS.
198067 01-07

COMPREHENSIVE MANAGEMENT OF EPILEPSY.
216339 04-11

COMPULSIVE

THE ACTION OF CHLORIMIPRAMINE IN OBSESSIVE COMPULSIVE NEUROSIS: A PILOT STUDY.
209489 03-10

CHANGES IN OBSESSIVE/COMPULSIVE PATIENTS AS MEASURED BY THE LEYTON INVENTORY BEFORE AND AFTER TREATMENT WITH CLOMIPRAMINE.
214833 04-10

COMPUTER

PSYCHOPHARMACOLOGY COMPUTER RESEARCH.
198107 02-17

DETERMINATION OF DRUG-INDUCED CHANGES IN SLEEP QUALITY BASED ON DIGITAL COMPUTER SLEEP PRINTS.
203603 02-14

COMPUTER NYSTAGMOGRAPHY, A NEW METHOD OF DETERMINING CHANGES IN VIGILANCE AS A RESPONSE TO PSYCHOTROPIC DRUGS.
204395 02-16

COMPUTER ANALYSIS OF METHADONE EFFECTS ON THE ELECTROENCEPHALOGRAM.
205467 02-03

ATTEMPTS TO CLASSIFY AND ORIENT PRESCRIPTION OF PSYCHOTROPIC DRUGS BY MEANS OF A COMPUTER CARD INDEX.
221668 04-17

COMPUTERIZED

COMPUTERIZED CEREBRAL BIOPOTENTIALS IN THE DISCOVERY OF PSYCHOTROPIC DRUGS.
205434 02-13

COMPUTERIZED EEG: PREDICTOR OF OUTCOME IN SCHIZOPHRENIA.
213863 04-08

CONCENTRATION

DOES MAPROTILINE (LUDIOMIL) INFLUENCE SEROTONIN UPTAKE AND FREE TRYPTOPHAN CONCENTRATION IN HUMAN PLASMA
192943 01-13

CHANGES IN BRAIN CONCENTRATION OF BIOGENIC AMINES AND THE ANTINOCICEPTIVE EFFECT OF MORPHINE IN RATS.
195246 01-03

DIAZEPAM METABOLISM IN NORMAL MAN: II. SERUM CONCENTRATION AND CLINICAL EFFECT AFTER ORAL ADMINISTRATION AND CUMULATION.
195445 01-13

SODIUM AND LITHIUM ERYTHROCYTE CONCENTRATION IN AFFECTIVE DISORDERS.
195931 01-09

RELATIONSHIP BETWEEN ANALGESIC ACTION OF PETHIDINE AND ITS EFFECT ON THE BRAIN 5-HYDROXYTRYPTAMINE CONCENTRATION IN THE RATS OF DIFFERENT AGE.
196782 01-03

INFLUENCE OF CATECHOLAMINE UPTAKE BLOCKING DRUGS ON THE INCREASE IN WATER INTAKE AND PLASMA RENIN CONCENTRATION INDUCED BY SOME HYPOTENSIVE DRUGS.
197288 01-03

THE RELATIONSHIP BETWEEN RIGIDITY AND CHANGE IN WHOLE BRAIN ACETYLCHOLINE CONCENTRATION PRODUCED BY INJECTION OF RESERPINE IN THE RAT.
197569 01-03

STUDY OF LITHIUM INTOXICATION UNDER THERAPEUTIC LITHIUM SERUM CONCENTRATION.
200952 02-15

MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 3. COMMUNICATION: PERAZINE CONCENTRATION IN BLOOD AND CLINICAL EFFICACY.
203841 02-13

MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 4. COMMUNICATION: CONNECTION BETWEEN EEG CHANGES, CONCENTRATION IN BLOOD, AND OTHER CLINICAL VARIABLES.
203842 02-13

EFFECTS OF DIAZEPAM ON EXPERIMENTALLY INDUCED CORTICAL EPILEPSY AND THEIR CORRELATION WITH DRUG CONCENTRATION.
205491 02-03

PIPERIDINE CONCENTRATION CHANGES IN THE BRAIN AND BLOOD OF DORMANT MICE.
210701 03-03

HUMAN GROWTH HORMONE RESPONSE TO LEVODOPA: RELATION TO MENOPAUSE, DEPRESSION, AND PLASMA DOPA CONCENTRATION.
213918 04-09

HOMOVANILLIC ACID CONCENTRATION IN RAT BRAIN: EFFECT OF A CHOLINE ACETYLTRANSFERASE INHIBITOR AND COMPARISON WITH CHOLINERGIC AND DOPAMINERGIC AGENTS.
215711 04-03

THE INFLUENCE OF TRICYCLIC ANTIDEPRESSANTS, AZAPHEN AND IMIZINE ON BLOOD SUGAR CONCENTRATION CHANGES PRODUCED BY EPINEPHRINE AND SEROTONIN.
217214 04-03

INCREASED CONCENTRATION OF HOMOVANILLIC ACID IN THE BRAINS OF INFANT RABBITS AFTER ADMINISTRATION OF HALOPERIDOL TO THEIR NURSING MOTHERS.
217692 04-03

LONG-LASTING REDUCTION OF BRAIN 5-HYDROXYTRYPTAMINE CONCENTRATION BY 3-CHLOROAMPHETAMINE AND 4-CHLOROAMPHETAMINE IN IPRINDOLE TREATED RATS.
217879 04-03

A CLINICAL STUDY OF SERUM CONCENTRATION LEVELS OF PHENOBARBITAL DERIVED FROM PRIMIDONE (MUSOLINE).
224644 04-13

CONCENTRATIONS

EFFECT OF ORAL AND INTRAMUSCULAR ROUTES OF ADMINISTRATION ON SERUM CHLORDIAZEPOXIDE LEVELS AND THE PREDICTION OF THESE LEVELS FROM PREDRUG FASTING SERUM GLUCOSE CONCENTRATIONS.
195055 01-13

DIAZEPAM METABOLISM IN NORMAL MAN: I. SERUM CONCENTRATIONS AND CLINICAL EFFECTS AFTER INTRAVENOUS, INTRAMUSCULAR, AND ORAL ADMINISTRATION.
195444 01-15

BRAIN AND SERUM CONCENTRATIONS OF DIAZEPAM IN EXPERIMENTAL EPILEPSY.
195494 01-04

THE EFFECT OF DAILY ORAL DOSAGE OF DIAZEPAM, PLASMA CONCENTRATIONS AND METABOLIC CLEARANCE OF DIAZEPAM AND DEMETHYLDIAZEPAM ON VARIOUS CONSTITUENTS OF THE ACUTE CLINICAL ANXIETY SYNDROME.
196191 01-10

REGIONAL DIFFERENCES IN HOMOVANILLIC ACID CONCENTRATIONS AFTER ACUTE AND CHRONIC ADMINISTRATION OF ANTIPSYCHOTIC DRUGS.
198210 02-03

DIAZEPAM INCREASES 5-HYDROXYINDOLE CONCENTRATIONS IN RAT BRAIN AND SPINAL CORD.
200081 02-03

STEADY-STATE PLASMA CONCENTRATIONS DURING SINGLE AND MULTIPLE DOSAGE SCHEDULES OF AMITRIPTYLINE.
202699 02-13

PLASMA AND CEREBROSPINAL FLUID CONCENTRATIONS OF PHENOBARBITAL IN INFANTS GIVEN SINGLE DOSES.
206057 03-13

HIPPOCAMPUS: SELECTIVE CONCENTRATIONS OF LEAD IN THE NORMAL RAT BRAIN.
210665 03-03

SERUM CLONAZEPAM CONCENTRATIONS IN CHILDREN WITH ABSENCE SEIZURES.
211064 03-13

A RELATION BETWEEN DRUG CONCENTRATIONS IN BRAIN AND STRIATAL HOMOVANILLIC ACID LEVELS IN CHLORPROMAZINE TREATED RATS.
215734 04-03

SOME INTERACTIONS BETWEEN FENFLURAMINE AND ANTIDEPRESSANT DRUGS: EFFECTS ON 5-HYDROXYINDOLE CONCENTRATIONS IN RAT BRAIN.
217962 04-03

CHANGES IN THE CONCENTRATIONS OF 5-HYDROXYTRYPTAMINE AND NORADRENALINE IN SIX AREAS OF RAT BRAIN DURING RECOVERY FROM CHRONIC METHYLAMPHETAMINE ADMINISTRATION.
217963 04-03

SERUM CONCENTRATIONS OF PHENOBARBITAL AND DIPHENYLHYDANTOIN (PRELIMINARY REPORT).
218011 04-11

CYCLIC-GMP: REDUCTION OF CEREBELLAR CONCENTRATIONS IN NERVOUS MUTANT MICE.
221031 04-03

RELATIONSHIPS BETWEEN TRICYCLIC ANTIDEPRESSANT CONCENTRATIONS, 1-3H-NORAFRENALINE UPTAKE AND CHRONOTROPIC EFFECT IN ISOLATED RAT ATRIA.
221188 04-03

CONCEPT

A TRANSIENT STATE CONCEPT OF DRUG RECEPTOR INTERACTION.
195240 01-17

THE CONCEPT OF THE QUASI-ABSTINENCE EFFECT AND ITS USE IN THE INVESTIGATION OF DEPENDENCE MECHANISMS.
202194 02-13

CRITICAL REMARKS ON TELLENBACHS CONCEPT OF TYPUS-MELANCHOLICUS.
206696 03-09

COMPARISON BETWEEN BEHAVIOURS ELICITED BY HIGH DOSES OF AMPHETAMINE AND FENFLURAMINE: IMPLICATIONS FOR THE CONCEPT OF STEREOTYPY.
210742 03-04

PARKINSONISM: EFFECTS OF LEVODOPA TREATMENT ON CONCEPT FORMATION.
222871 04-14

CONCEPTS

BASIC CONCEPTS OF PSYCHOPHARMACOLOGICAL RESEARCH AS APPLIED TO THE PSYCHOPHARMACOLOGICAL ANALYSIS OF THE AMYGDALA.
200980 02-17

CONCEPTS IN BETA BLOCKADE.
206941 03-13

NEW CONCEPTS ON THE MECHANISM OF ACTION OF BENZODIAZEPINES.
225058 04-13

CONCEPTUAL

CONCEPTUAL ISSUES IN THE USE OF DRUGS FOR THE TREATMENT OF AGGRESSION IN MAN.
209126 03-17

CONDENSATE

CONJOINT NATIVE AND ORTHOPHTHALDIALDEHYDE CONDENSATE ASSAYS FOR THE FLUORIMETRIC DETERMINATION OF 5-HYDROXYINDOLES IN BRAIN.
195238 01-01

CONDENSATIONS

CYANOGEN CONDENSATIONS AS A ROUTE TO 3-AMINO-2-IMINOBENZOTHIAZIN-4-ONES WITH CNS DEPRESSANT POTENTIAL.
222870 04-02

CONDITION
DEPRESSIVE CONDITION. PERCEPTION, EVALUATION, TREATMENT.
209332 03-09

CONDITIONAL
THE INFLUENCE OF TYROCALCITONIN ON CONDITIONAL REFLEXES AND THE ELECTRICAL ACTIVITY OF THE BRAIN IN ANIMALS.
198479 02-02

CONDITIONED
SUPPRESSION OF CONDITIONED HYPERTHERMIC RESPONSE BY L- AND D-OXPRENOLOL IN RATS.
192937 01-03

A CONDITIONED TASTE AVERSION INDUCED BY ALPHA-METHYL-P-TYROSINE.
195090 01-04

CHANGES IN THE ACQUISITION OF CONDITIONED AVOIDANCE RESPONSES FOLLOWING MIDBRAIN RAPHE LESIONS IN TH
197574 01-04

EFFECTS OF L-DOPA ON CONDITIONED AVOIDANCE RESPONDING AFTER BEHAVIOURAL SUPPRESSION BY ALPHA-METHYLTYROSINE OR RESERPINE IN MICE.
197987 01-04

ENHANCEMENT OF THE CHLORPROMAZINE-INDUCED SUPPRESSION OF THE CONDITIONED AVOIDANCE RESPONSE BY CARBONIC ANHYDRASE INHIBITION.
199770 02-03

THE INTERACTION OF DOPAMINE ANTAGONISTS AND AMANTADINE HYDROCHLORIDE ON THE ACQUISITION OF THE CONDITIONED AVOIDANCE RESPONSE IN RATS.
199959 02-04

THE INFLUENCE OF CATECHOLAMINES, SEROTONIN, AND SOME AMINO ACIDS ADMINISTERED INTO THE AMYGDALOID COMPLEX ON CONDITIONED REFLEXES OF AVOIDANCE AND MOTOR ACTIVITY IN RATS.
200566 02-03

CONDITIONED SUPPRESSION OF MOUSE-KILLING IN RATS FOLLOWING RADIATION OR LITHIUM CHLORIDE INJECTIONS. (PH.D. DISSERTATION).
201153 02-04

EFFECTS ON THE ACQUISITION OF CONDITIONED AVOIDANCE RESPONSES AND SEIZURE THRESHOLD IN THE OFFSPRING OF AMPHETAMINE TREATED GRAVID RATS.
202722 02-05

EFFECTS OF DELTA8-THC ON DISSOCIATION OF CONDITIONED AVOIDANCE RESPONDING IN TOLERANT AND NONTOLERANT RATS.
202969 02-04

COMPARISON OF THE EFFECTS OF ATROPINE AND CANNABIS UPON THE FIXED CONDITIONED ALIMENTARY MOTOR REFLEXES IN CATS AFFECTED BY NICOTINE.
205623 03-14

AN ANALYSIS OF MONOAMINERGIC MECHANISMS OF THE DORSAL HIPPOCAMPUS WHICH MEDIATE THE CONDITIONED ESCAPE REACTION IN RATS.
208991 03-04

A STUDY OF AN ANIMAL MODEL OF DEPRESSION BY THE CONDITIONED REFLEX TECHNIQUE.
210853 03-04

HALOPERIDOL INDUCED DISRUPTION OF CONDITIONED AVOIDANCE RESPONDING: ATTENUATION BY PRIOR TRAINING OR BY ANTICHOLINERGIC DRUGS.
210861 03-04

THE COMPARATIVE EFFECTS OF MORPHINE AND CHLORPROMAZINE ON THE ACQUISITION OF CONDITIONED AVOIDANCE RESPONSE. (PH.D. DISSERTATION).
212963 03-04

THE EFFECTS OF INTRAVENOUS AND SUBCUTANEOUS EPINEPHRINE ADMINISTRATION ON CONDITIONED SUPPRESSION. (PH.D. DISSERTATION).
213131 03-04

THE BIPHASIC EFFECT OF SMALL DOSES OF TRANYLCYPROMINE ON THE SPONTANEOUS MOTOR ACTIVITY AND LEARNED CONDITIONED BEHAVIOUR IN RATS.
215665 04-04

TOLERANCE DEVELOPMENT TO THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON CONDITIONED BEHAVIOR: ROLE OF TREATMENT INTERVAL AND INFLUENCE OF MICROSOMAL METABOLISM.
215726 04-03

CONDITIONED LEARNING IN YOUNG RATS BORN OF DRUG ADDICTED PARENTS AND RAISED ON ADDICTIVE DRUGS.
217465 04-04

THE EFFECT OF DIFFERENT LEVELS OF PRE-EXPOSURE TO SUCROSE ON THE ACQUISITION AND EXTINCTION OF A CONDITIONED AVERSION.
217807 04-04

ON NEUROCHEMICAL MECHANISMS OF SEPTUM INFLUENCE ON THE CONDITIONED AVOIDANCE REACTION IN RATS.
218803 04-04

METHYLATED DERIVATIVES OF NOREPINEPHRINE AND THE CONDITIONED AVOIDANCE RESPONSE IN RATS.
218958 04-02

CONDITIONED AVERSION TO MORPHINE WITH NALOXONE.
219023 04-04

CONDITIONED AVERSION TO MORPHINE WITH LITHIUM CHLORIDE IN MORPHINE-DEPENDENT RATS.
219039 04-04

EFFECTS OF PREVIOUS CURARE IMMOBILIZATION ON PAVLOVIAN CONDITIONED HEART DECELERATIONS IN THE CURARIZED RAT.
219083 04-04

THE ROLE OF THE AMYGDALA IN THE DEPRESSIVE ACTION OF SEROTONIN AND 5-HYDROXYTRYPTOPHAN ON THE CONDITIONED ACTIVITY OF WHITE RATS.
219328 04-04

THE EFFECT OF TRANSAMINE ON PSYCHONERVOUS AND CONDITIONED MEMORY IN RATS.
219745 04-04

INVESTIGATIONS OF UCS-CS MEDIATION IN RADIATION INDUCED CONDITIONED TASTE AVERSION. (PH.D. DISSERTATION).
220681 04-04

POISON INDUCED NEOPHOBIA IN RATS: ROLE OF STIMULUS GENERALIZATION OF CONDITIONED TASTE AVERSIONS.
223254 04-04

THE RELATION BETWEEN CEREBRAL SEROTONIN LEVELS AND CONDITIONED BEHAVIOUR IN THE RAT FOLLOWING THE ADMINISTRATION OF LSD-25 AND UML.
225564 04-04

CONDITIONING
THE EFFECTS OF DRUGS REGULATING AUTONOMIC RESPONSES DURING CONDITIONING ON SUBSEQUENT AVOIDANCE BEHAVIOR. (PH.D. DISSERTATION).
193777 01-03

THE EFFECTS OF P-CHLOROAMPHETAMINE ON INSTRUMENTAL CONDITIONING IN THE RAT.
195088 01-04

A COMPARATIVE STUDY OF AMPHETAMINE, EPHEDRINE ATROPINE MIXTURE, PLACEBO AND BEHAVIORAL CONDITIONING IN THE TREATMENT OF NOCTURNAL ENURESIS.
198020 01-11

EFFECTS OF CHLORDIAZEPOXIDE UPON DIFFERENTIAL HEART RATE CONDITIONING IN RATS.
201323 02-03

THE EFFECTS OF STIMULANT AND DEPRESSANT DRUGS ON VERBAL CONDITIONING.
209260 03-14

OPERANT CONDITIONING OF HEART RATE IN CURARIZED RATS: HEMODYNAMIC CHANGES.
213275 03-04

THE EFFECTS OF NICOTINE ON TWO-WAY AVOIDANCE CONDITIONING IN BIDIRECTIONALLY SELECTED STRAINS OF RATS.
217525 04-04

CONDITIONS
THE INFLUENCE OF RESERPINE ON THE SEROTONIN METABOLISM IN PATIENTS WITH SCHIZOPHRENIA AND REACTIVE CONDITIONS.
200013 02-08

THE PRESENT CONDITIONS OF PSYCHOPHARMACOLOGICAL TREATMENT FOR CHILDREN IN JAPAN: OPINIONS FROM THIRTY-SEVEN WELL-KNOWN CHILD NEUROPSYCHIATRISTS AND NEUROPSYCHIATRIC PEDIATRICIANS.
202500 02-17

THE ACTION OF CHLORDIAZEPOXIDE ON CONDITIONS OF ANXIETY IN A PSYCHOPHYSIOLOGICAL EXPERIMENT.
204405 02-14

PENTOBARBITAL EFFECT ON PERFORMANCE IN MONOTONOUS CONDITIONS NOT PREVENTED BY COMPENSATORY EFFORT.
205595 02-15

COMPARISON OF NEUROLEPTICS IN CONTROLLED EXPERIMENTAL CONDITIONS: METHOPHENAZINE VS PERPHENAZINE.
209147 03-08

EFFECTS OF HYPERBARIC CONDITIONS ON THE RESPONSE OF ANIMALS TO CENTRAL NERVOUS SYSTEM STIMULANTS AND DEPRESSANTS.
210877 03-03

DEPRESSIVE REACTIONS IN THE COURSE OF CLOMIPRAMINE THERAPY USED IN THE TREATMENT OF OBSESSIONAL CONDITIONS.
214834 04-15

THE INTERACTION OF POSTWEANING HOUSING CONDITIONS AND PRENATAL DRUG EFFECTS ON BEHAVIOUR.
225563 04-04

CONDUCTED
THE USE OF PSYCHOACTIVE DRUGS IN ELDERLY PATIENTS WITH PSYCHIATRIC DISORDERS: SURVEY CONDUCTED IN TWELVE VETERANS ADMINISTRATION HOSPITALS.
215009 04-11

CONDUCTION
EFFECTS OF IMIPRAMINE UPON FROG NERVE EXCITABILITY AND CONDUCTION.
210925 03-03

CONFIGURATION
DIFFERENTIAL EFFECTS OF NEUROLEPTIC DRUGS IN CHRONIC SCHIZOPHRENICS: A CONFIGURATION ANALYTICAL EVOLUTION.
204415 02-08

CONFIRMATION
RAPID MASS SCREENING AND CONFIRMATION OF URINARY AMPHETAMINE AND METHAMPHETAMINE BY GAS CHROMATOGRAPHY.
222829 04-06

CONFIRMED
SPECIFICITY OF BENZODIAZEPINE ACTION ON HUMAN SLEEP CONFIRMED. ANOTHER CONTRIBUTION OF AUTOMATIC ANALYSIS OF POLYGRAPH RECORDINGS.
218953 04-14

CONFLICT
STUDIES OF CONFLICT INDUCED BEHAVIOR IN THE CAT: BEHAVIOR ANALYSIS AND EFFECTS OF PSYCHOTROPIC DRUGS.
202122 02-04

CONFLICTING
THE EFFECT OF DIAZEPAM ON THE BEHAVIOR OF RATS ADAPTED TO HIGH ALTITUDE HYPOXIA IN CONFLICTING SITUATIONS.
219502 04-04

CONFORMATION
A CRYSTALLOGRAPHIC AND THEORETICAL STUDY OF THE CONFORMATION OF DOET AND ITS SIGNIFICANCE FOR THE HALLUCINOGENIC AMPHETAMINES.
210746 03-01

CONFORMATIONAL
6-CHLORO-2-AMINOTETRALIN, A RIGID CONFORMATIONAL ANALOG OF 4-CHLOROAMPHETAMINE: PHARMACOLOGIC PROPERTIES OF IT AND RELATED COMPOUNDS IN RATS.
210870 03-02

CONFORMATIONALLY
CONFORMATIONALLY CONSTRAINED ANALOGS OF MESCALINE.
195560 01-01

CONFORMATIONS
PREFERRED CONFORMATIONS OF SEROTONIN IN RELATION TO RECEPTOR SITES.
210928 03-03

CONFRONTATION
THE DYNAMIC CONFRONTATION MODEL AS AN INTEGRATION OF PSYCHOTHERAPY.
211596 03-12

CONFUSIONAL
CONFUSIONAL STATES IN ELDERLY MENTAL PATIENTS TREATED WITH ANTIDEPRESSANTS.
205603 03-15

CONGENER
FENFLURAMINE: AMPHETAMINE CONGENER THAT FAILS TO MAINTAIN DRUG-TAKING BEHAVIOR IN THE RHESUS MONKEY.
193137 01-04

CONJOINT
CONJOINT NATIVE AND ORTHOPHTHALDIALDEHYDE CONDENSATE ASSAYS FOR THE FLUORIMETRIC DETERMINATION OF 5-HYDROXYINDOLES IN BRAIN.
195238 01-01

CONJUGATED
EFFECTS OF CONJUGATED ESTROGENS ON PLASMA BUTAPERAZINE LEVELS.
201327 02-13

CONJUGATES
CHLORPROMAZINE EXCRETION IN CHRONICALLY DOSED PRIMATES. I. OCCURRENCE OF A PREVIOUSLY UNREPORTED CLASS OF CHLORPROMAZINE CONJUGATES.
217553 04-03

CONJUNCTIVITIS
ALLERGIC CONJUNCTIVITIS DUE TO DIAZEPAM.
225338 04-15

CONSCIOUS
THE INFLUENCE OF CYPROHEPTADINE AND OF D-LYSERGAMIDE ON THE RISE IN TEMPERATURE INDUCED BY INTRACEREBROVENTRICULAR 5-HYDROXYTRYPTAMINE, NORADRENALINE AND DOPAMINE IN CONSCIOUS RABBITS.
193451 01-03

CHANGES IN ACID-BASE BALANCE, RESPIRATION RATE AND HEART RATE UPON REPEATED ORAL ADMINISTRATION OF BENZOCTAMINE AND DIAZEPAM TO CONSCIOUS DOGS.
197460 01-03

AN ANALYSIS OF THE GROSS BEHAVIOURAL CHANGES INDUCED BY TETRAETHYLAMMONIUM AND A COMPARISON WITH OTHER SUBSTANCES AFFECTING THE AUTONOMIC AND CENTRAL NERVOUS SYSTEM AFTER INTRAVENTRICULAR INJECTIONS TO CONSCIOUS CATS.
202781 02-04

BEHAVIOURAL AND ELECTROGRAPHIC OBSERVATIONS DURING EPILEPTIC CONVULSIONS INDUCED BY STRYCHNINE AND PENTYLENETETRAZOL IN CONSCIOUS YOUNG AND ADULT CHICKENS.
205459 02-03

LYSERGIC ACID DIETHYLAMIDE AFFECTS BLOOD FLOW TO SPECIFIC AREAS OF THE CONSCIOUS RAT BRAIN.
215161 04-03

CONSCIOUSNESS
THE HEALING JOURNEY: NEW APPROACHES TO CONSCIOUSNESS.
223921 04-12

THE INTOXICATION: STATE OF CONSCIOUSNESS.
224757 04-14

CONSEQUENCE
HYDROCORTISONE-INDUCED SUPERSENSITIVITY TO NORADRENALINE IN THE ISOLATED NICTITATING MEMBRANE AS A CONSEQUENCE OF AN IMPAIRMENT OF AN O-METHYLATING SYSTEM WITH HIGH AFFINITY.
197944 01-03

CONSOLIDATION
DIETHYLDITHIOCARBAMATE (ANTABUSE): DECREASE OF BRAIN HEAVY METAL STAINING PATTERN AND IMPROVED CONSOLIDATION OF SHUTTLEBOX AVOIDANCE IN GOLDFISH.
203521 02-04

EFFECTS OF MORPHINE AND HEROIN ON DISCRIMINATION LEARNING AND CONSOLIDATION IN MICE.
221040 04-04

CONSTANT
CHANGES OF KINETIC CONSTANT OF STRIATAL TYROSINE-HYDROXYLASE ELICITED BY NEUROLEPTICS THAT IMPAIR THE FUNCTION OF DOPAMINE RECEPTORS.
202716 02-03

CONSTANTS
EXPLICIT SOLUTION TO PHARMACOKINETIC FIRST-ORDER RATE CONSTANTS OF MAPROTILIN.
208919 03-17

CONSTITUENTS
THE EFFECT OF DAILY ORAL DOSAGE OF DIAZEPAM, PLASMA CONCENTRATIONS AND METABOLIC CLEARANCE OF DIAZEPAM AND DEMETHYLDIAZEPAM ON VARIOUS CONSTITUENTS OF THE ACUTE CLINICAL ANXIETY SYNDROME.
196191 01-10

STRUCTURE-ACTIVITY RELATIONSHIPS IN MAN OF CANNABIS CONSTITUENTS, AND HOMOLOGS AND METABOLITES OF DELTA9-TETRAHYDROCANNABINOL.
202192 02-02

EFFECT OF DELTA9-TETRAHYDROCANNABINOL ADMINISTRATION ON THE LIPID CONSTITUENTS OF RAT BRAIN SUBCELLULAR FRACTIONS.
210769 03-03

CONSTITUENTS OF CANNABIS-SATIVA L. IX: STABILITY OF SYNTHETIC AND NATURALLY OCCURRING CANNABINOIDS IN CHLOROFORM.
211010 03-06

CONSTRAINED
CONFORMATIONALLY CONSTRAINED ANALOGS OF MESCALINE.
195560 01-01

CONSUMPTION
REDUCTION OF STIMULUS BOUND FOOD CONSUMPTION IN THE RAT FOLLOWING AMPHETAMINE ADMINISTRATION.
195081 01-04

HEAT PRODUCTION AND OXYGEN CONSUMPTION OF THE ISOLATED RABBIT HEART UNDER THE INFLUENCE OF STROPHANTHIN VERAPAMIL, AND GLYCERYL TRINITRATE.
197567 01-03

TASTE PHENOMENA INFLUENCES ON STIMULATION OF DEPRIVATION INDUCED FLUID CONSUMPTION OF RATS.
197991 01-03

THE PENTOBARBITAL TEST DOSE FOR DEPRESSANT DRUG DEPENDENCE: A REEVALUATION IN TERMS OF ALCOHOL CONSUMPTION.
202883 02-17

CEREBRAL AND PERIPHERAL CONSUMPTION OF L-5-HTP BY PATIENTS SUFFERING FROM MANIACAL, DEPRESSIVE OR PSYCHOTIC SYMPTOMS.
206834 03-10

EFFECTS OF CHLORDIAZEPOXIDE ON SCHEDULE INDUCED WATER AND ALCOHOL CONSUMPTION IN THE SQUIRREL MONKEY.
214013 04-04

EFFECTS OF SCOPOLAMINE, PHYSOSTIGMINE AND CHLORDIAZEPOXIDE ON PUNISHED AND EXTINGUISHED WATER CONSUMPTION IN RATS.
221043 04-04

CONTACT
A FOLLOWUP STUDY OF FEMALE DEPRESSED OUTPATIENTS WHO COMPLETE A RANDOMIZED DOUBLE-BLIND PROPHYLACTIC TRIAL OF ANTIDEPRESSANTS AND HIGH CONTACT. (PH.D. DISSERTATION).
212518 03-09

CONTAINED
UNEXPECTED COMPLICATIONS BY ANTICHOLINERGICS CONTAINED IN SOPORIFICS AND ANALGESIC DRUGS.
204404 02-15

CONTINENTAL
CONTINENTAL HOSPITAL STUDIES WITH MAPROTILINE (LUDIOMIL).
221651 04-09

CONTINGENCIES
THE EFFECTS OF REINFORCEMENT CONTINGENCIES AND CAFFEINE ON HYPERACTIVE CHILDREN. (PH.D. DISSERTATION).
220523 04-14

CONTRACEPTION
ORAL CONTRACEPTION AND INDUCED DEPRESSIVE STATES.
216902 04-14

CONTRACEPTIVES
DEPRESSIONS CAUSED BY ORAL CONTRACEPTIVES AND THEIR TREATMENT WITH ORIGEN.
224347 04-09

CONTRACTILE
CONTRACTILE RESPONSES OF GUINEA-PIG UMBILICAL ARTERIES TO VARIOUS HALLUCINOGENIC AGENTS.
200037 02-03

CONTRACTILITY
THE EFFECT OF (-) DELTA9-TRANS-TETRAHYDROCANNABINOL ON MYOCARDIAL CONTRACTILITY AND VENOUS RETURN IN ANESTHETIZED DOGS.
199964 02-03
EFFECT OF CAMAZEPAM (SB-5833), A NEW ANTIANXIOUS DRUG, ON CARDIAC CONTRACTILITY AND CORONARY HEMODYNAMICS.
206785 03-03

CONTRACTION
POTENTIATION BY 3,4 DIMETHOXYPHENYLETHYLAMINE (DMPEA) AND COCAINE OF NOREPINEPHRINE-INDUCED CONTRACTION OF GUINEA-PIG VAS-DEFERENS.
194156 01-03

CONTRASTING
CONTRASTING LOCAL EFFECTS OF MAO INHIBITORS ON CAUDATE TREMOR ACTIVITIES.
217669 04-03

CONTROL
LONG-TERM LITHIUM ADMINISTRATION TO RATS. LITHIUM AND SODIUM DOSAGE AND ADMINISTRATION, AVOIDANCE OF INTOXICATION, POLYURIC CONTROL RATS.
195042 01-03
EFFECTS OF RESERPINE AND CHLORPROMAZINE ON 5-HYDROXYTRYPTAMINE UPTAKE OF PLATELETS FROM MIGRAINOUS AND CONTROL SUBJECTS.
196926 01-13
THE CONTROL OF DEVIANT SEXUAL BEHAVIOUR BY DRUGS: I. BEHAVIOURAL CHANGES FOLLOWING ESTROGENS AND ANTIANDROGENS.
196958 01-14
NEONATAL CHEMICAL SYMPATHECTOMY: FUNCTIONAL CONTROL OF DENERVATION OF THE VASCULAR SYSTEM AND TISSUE NORADRENALINE LEVEL IN THE RAT AFTER 6-HYDROXYDOPAMINE.
197584 01-03
DISCRIMINATIVE RESPONSE CONTROL PRODUCED WITH HASHISH, TETRAHYDROCANNABINOLS (DELTA8-THC AND DELTA9-THC), AND OTHER DRUGS.
202720 02-12
BREAKDOWN OF STIMULUS CONTROL BY D-AMPHETAMINE.
202968 02-04
PROPRANOLOL IN THE CONTROL OF SCHIZOPHRENIC SYMPTOMS.
209830 03-08
THE EFFECTS OF PSYCHOMOTOR STIMULANTS ON STEREOTYPY AND LOCOMOTOR ACTIVITY IN SOCIALLY DEPRIVED AND CONTROL RATS.
210666 03-04
THE CHEMICAL CONTROL OF PREOPERATIVE ANXIETY.
210684 03-10
NEUROTRANSMITTER CONTROL OF THYROTROPIN SECRETION IN THE RAT.
210858 03-03
THE ROLE OF 5-HYDROXYTRYPTAMINE IN THE CONTROL OF ALPHA AND GAMMA MOTONEURONS. (PH.D. DISSERTATION).
212522 03-03
THE EFFECTS OF PSYCHOMOTOR STIMULATION ON STEREOTYPY AND LOCOMOTOR ACTIVITY IN SOCIALLY DEPRIVED AND CONTROL RATS.
213433 04-03
GAMMA-HYDROXYBUTYRATE AND CONTROL OF DOPAMINERGIC NEURONS.
213626 04-03
NORADRENERGIC CONTROL OF SPONTANEOUS MEAL SIZE IN THE RAT. (PH.D. DISSERTATION).
214206 04-04
NALOXONE-INDUCED JUMPING IN MORPHINE-DEPENDENT MICE: STIMULUS CONTROL AND MOTIVATION.
215696 04-04
REPEATED ACQUISITION OF RESPONSE SEQUENCES: STIMULUS CONTROL AND DRUGS.
215969 04-04
ABSENCE OF INTERACTION BETWEEN DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) AND CANNABIDIOL (CBD) IN AGGRESSION, MUSCLE CONTROL AND BODY TEMPERATURE EXPERIMENTS IN MICE.
217474 04-04
DISCRIMINATIVE CONTROL OF BEHAVIOR BY ELECTRICAL STIMULATION OF THE DORSAL RAPHE NUCLEUS: GENERALIZATION TO LYSERGIC ACID DIETHYLAMIDE (LSD).
217821 04-12
PHYSIOLOGICAL MECHANISMS FOR CARDIAC CONTROL BY NUTRITIONAL INTAKE AFTER EARLY MATERNAL SEPARATION IN THE YOUNG RAT.
218047 04-03
SCHEDULE INDUCED AGGRESSION IN LABORATORY RATS: DEMONSTRATION AND CONTROL THROUGH SODIUM AMOBARBITAL. (PH.D. DISSERTATION).
220644 04-04
DOPAMINE SENSITIVE ADENYLCYCLASE IN HUMAN CAUDATE NUCLEUS: A STUDY IN CONTROL SUBJECTS AND SCHIZOPHRENIC PATIENTS.
221732 04-13
ROLE OF MONOAMINES IN THE CONTROL BY HORMONES OF SEXUAL RECEPTIVITY IN THE FEMALE RAT.
222263 04-04
IS THERE A CATECHOLAMINE SEROTONIN INTERACTION IN THE CONTROL OF LOCOMOTOR ACTIVITY?
222816 04-04
GENETIC CONTROL OF LITHIUM ION DISTRIBUTION.
224833 04-09
A BEHAVIORAL EDUCATIONAL ALTERNATIVE TO DRUG CONTROL OF HYPERACTIVE CHILDREN.
225455 04-14

CONTROLLED
A CONTROLLED EVALUATION OF LORAZEPAM AND DIAZEPAM IN ANXIETY NEUROSIS.
194719 01-10
A CONTROLLED SERIES OF EXPERIMENTS INVESTIGATING SOME SOCIOLOGICAL EFFECTS OF TWO DOSAGES OF CHLORDIAZEPOXIDE (LIBRIUM) UPON INDIVIDUALS AND SMALL GROUPS. (PH.D. DISSERTATION).
195145 01-14
CONTROLLED CLINICAL TRIAL WITH DIAZEPAM.
195618 01-10
THE EFFECT OF LITHIUM ON THYROID FUNCTIONING: A CONTROLLED STUDY.
195916 01-09
A CONTROLLED TRIAL OF TRIFLUPERIDOL WITH TRIFLUOPERAZINE.
196069 01-08
TRUE AND APPARENT SIDE-EFFECTS IN A CONTROLLED TRIAL OF CHLORPROMAZINE AND IMIPRAMINE IN DEPRESSION.
197856 01-09
INFLUENCE OF AN ANTICHOLINERGIC PSYCHOTOMIMETIC AGENT ON BEHAVIOUR IN CATS CONTROLLED BY AN AUDITORY STIMULUS.
197996 01-04
CONTROLLED DRUG EVALUATIONS.
198065 01-07
SCHIZOPHRENIA FOLLOWUP: A CONTROLLED TREATMENT STUDY.
198076 02-08
A CONTROLLED OUTPATIENT TRIAL OF PERPHENAZINE AMITRIPTYLINE AND CHLORPROMAZINE.
199517 02-14
A CONTROLLED COMPARISON OF THE EFFECTS OF DIPHENYLHYDANTOIN AND PLACEBO ON MOOD AND PSYCHOMOTOR FUNCTIONING IN NORMAL VOLUNTEERS.
199518 02-14
PRELIMINARY RESULTS OF A CONTROLLED TRIAL WITH SULPIRIDE VERSUS CHLORIMIPRAMINE IN CHRONIC SCHIZOPHRENIC PATIENTS WITH MARKED IDEO-EMOTIONAL POVERTY.
200445 02-08
A CONTROLLED CLINICAL TRIAL OF PIMOZIDE (R-6238) -- A NEW NEUROLEPTIC.
200897 02-08
A CONTROLLED COMPARISON OF OXYPERTINE AND PERPHENAZINE IN SCHIZOPHRENIC PSYCHOSES.
205582 02-08
A CONTROLLED COMPARISON OF CHLORAZEPATE WITH OXAZEPAM IN NEUROTIC ANXIETY.
205638 03-10
TWO CONTROLLED TRIALS OF TYRAMINE IN CHILDREN WITH MIGRAINE.
206058 03-13
PSYCHOACTIVE DRUGS IN MANIA: A CONTROLLED COMPARISON OF LITHIUM CARBONATE, CHLORPROMAZINE AND HALOPERIDOL.
207446 03-09
COMPARISON OF NEUROLEPTICS IN CONTROLLED EXPERIMENTAL CONDITIONS: METHOPHENAZINE VS PERPHENAZINE.
209147 03-08
A DOUBLE-BLIND CONTROLLED COMPARISON OF BROMAZEPAM AND DIAZEPAM.
209411 03-10
PHENAGLYCODOL IN ANXIETY: A CONTROLLED STUDY.
209486 03-10
A DOUBLE-BLIND CONTROLLED STUDY OF THE THIENODIAZEPINE DERIVATIVE (Y-6047) ON NEUROTICS AND PSYCHOSOMATIC DISORDERS.
210559 03-14
A COMPARISON OF THE THERAPEUTIC EFFECT OF OXYPERTINE AND THIORIDAZINE IN CHRONIC SCHIZOPHRENIA (A CONTROLLED TRIAL).
215075 04-08
LORAZEPAM IN ANXIETY: A CONTROLLED STUDY.
216462 04-10

A COMPARISON BETWEEN BROMAZEPAM (RO-5-3350, LEXOTAN) AND DIAZEPAM (VALIUM) IN ANXIETY NEUROSIS: A CONTROLLED, DOUBLE-BLIND CLINICAL TRIAL.
217455 04-10

PLASMA LEVELS OF IMIPRAMINE AND DESMETHYLIMIPRAMINE AND ANTIDEPRESSANT EFFECT DURING CONTROLLED THERAPY.
217477 04-09

PROPRANOLOL IN THE TREATMENT OF OPIATE DEPENDENCE -- A CONTROLLED STUDY.
217549 04-14

ANTIDEPRESSANTS IN BLACK AND WHITE INPATIENTS: DIFFERENTIAL RESPONSE TO A CONTROLLED TRIAL OF CHLORPROMAZINE AND IMIPRAMINE.
218770 04-09

OBJECTIVE ASSESSMENT OF ANTICHOLINERGIC SIDE-EFFECTS OF TRICYCLIC ANTIDEPRESSANTS A CONTROLLED STUDY OF IMIPRAMINE AND IMIPRAMINE-N-OXIDE.
221633 04-15

LITHIUM TREATMENT OF SCHIZOPHRENIA: A CONTROLLED EXPERIMENT.
221635 04-08

CROSS-ANALYSIS OF A CONTROLLED EXPERIMENT WITH PIPOTHIAZINE AND FLUPHENAZINE ENANTHATE.
221636 04-08

A CONTROLLED CLINICAL EXPERIMENT WITH BURONIL AND HALOPERIDOL IN DISORIENTATION AMONG ELDERLY PATIENTS.
221639 04-11

A CONTROLLED COMPARISON OF MAPROTILINE (LUDIOMIL) WITH IMIPRAMINE AVOIDING OBSERVER BIAS.
221654 04-09

A CONTROLLED STUDY OF A TETRACYCLIC ANTIDEPRESSANT -- MAPROTILINE (LUDIOMIL).
224486 04-09

DEPRESSION AND ANXIETY IN HEROIN ADDICTS: A PLACEBO CONTROLLED STUDY OF DOXEPIN IN COMBINATION WITH METHADONE.
225386 04-09

CONTROLLING

CONTROLLING DRUGS: INTERNATIONAL HANDBOOK FOR PSYCHOACTIVE DRUG CLASSIFICATION.
202861 02-17

CONTROLS

PLASMA TRYPTOPHAN TOLERANCE CURVES IN DRUG-FREE NORMAL CONTROLS, SCHIZOPHRENIC PATIENTS AND PRISONER VOLUNTEERS.
200773 02-13

COMPARISON OF 3,4 DIMETHOXYPHENYLETHYLAMINE TREATED PLASMA FROM CHRONIC SCHIZOPHRENICS AND CONTROLS.
210897 03-08

CONTROVERSY

ON THE CONTROVERSY OF PROPHYLACTIC ANTIDEPRESSANTS.
207764 03-09

THE CONTROVERSY OVER ORTHOMOLECULAR THERAPY.
208862 03-08

THE ORTHOMOLECULAR CONTROVERSY.
209011 03-17

CONVERGENT

EFFECT OF MARIJUANA ON DIVERGENT AND CONVERGENT PRODUCTION COGNITIVE TESTS.
223394 04-14

CONVERSION

ON THE MECHANISM OF ACTION OF GAMMA-HYDROXYBUTYRIC ACID: LACK OF CONVERSION TO GABA IN MOUSE BRAIN IN VIVO.
197965 01-03

CONVULSANTS

ACETYLCHOLINE LEVELS IN THE FROG SPINAL CORD FOLLOWING THE ADMINISTRATION OF DIFFERENT CONVULSANTS.
193550 01-03

CONVULSIONS

FAILURE OF DIPHENYLHYDANTOIN TO PREVENT ALCOHOL WITHDRAWAL CONVULSIONS IN MICE.
193454 01-03

EFFECT OF BENZODIAZEPINE DERIVATIVES ON SOMAN INDUCED SEIZURE ACTIVITY AND CONVULSIONS IN THE MONKEY.
197466 01-03

PROTEINASE ACTIVITY OF DIFFERENT SECTIONS OF THE BRAIN DURING CORAZOL (PENTYLENETETRAZOL) INDUCED CONVULSIONS.
198485 02-03

EFFECT OF DIAZEPAM UPON SOMAN INDUCED SEIZURE ACTIVITY AND CONVULSIONS.
204192 02-02

BEHAVIOURAL AND ELECTROGRAPHIC OBSERVATIONS DURING EPILEPTIC CONVULSIONS INDUCED BY STRYCHNINE AND PENTYLENETETRAZOL IN CONSCIOUS YOUNG AND ADULT CHICKENS.
205459 02-03

AMINO ACID UPTAKE IN VIVO BY THE MOUSE BRAIN AND BY VARIOUS REGIONS OF THE RABBIT BRAIN AFTER DRUG-INDUCED CONVULSIONS.
217858 04-03

CONVULSIVE

THE EFFECT OF WITHDRAWAL FROM CANNABIS ON PENTYLENETETRAZOL CONVULSIVE THRESHOLD IN MICE.
206355 03-04

A CASE OF NONSPECIFIC PSYCHOSES WHICH MANIFESTED CONVULSIVE SEIZURES DURING LITHIUM THERAPY.
209324 03-15

COPPER

EFFECT OF COPPER LOADING ON VARIOUS TISSUE ENZYMES AND BRAIN MONOAMINES IN THE RAT.
193577 01-03

EVIDENCE THAT PUNCTUATE INTRACEREBRAL ADMINISTRATION OF 6-HYDROXYDOPAMINE FAILS TO PRODUCE SELECTIVE NEURONAL DEGENERATION: COMPARISON WITH COPPER SULFATE AND FACTORS GOVERNING THE DEPORTMENT OF FLUIDS INJECTED INTO BRAIN.
197931 01-03

COPULATORY

EFFECTS OF L-DOPA ON THE HETEROSEXUAL COPULATORY BEHAVIOR OF MALE RATS.
193549 01-04

STIMULATION OF ESTROGEN INDUCED COPULATORY BEHAVIOR IN CASTRATE MALE RATS WITH THE SEROTONIN BIOSYNTHESIS INHIBITOR P-CHLOROPHENYLALANINE.
221010 04-04

CORAZOL

PROTEINASE ACTIVITY OF DIFFERENT SECTIONS OF THE BRAIN DURING CORAZOL (PENTYLENETETRAZOL) INDUCED CONVULSIONS.
198485 02-03

THE EFFECT OF CATECHOLAMINERGIC DRUGS ON THE BEHAVIOR AND EEG OF RATS DURING CORAZOL SEIZURES.
219332 04-04

CORD

ACETYLCHOLINE LEVELS IN THE FROG SPINAL CORD FOLLOWING THE ADMINISTRATION OF DIFFERENT CONVULSANTS.
193550 01-03

EFFECT OF CHRONIC TRANSECTION ON DOPAMINE, NORADRENALINE AND 5-HYDROXYTRYPTAMINE IN THE RAT SPINAL CORD.
195244 01-03

THE EFFECTS OF CORD SECTION UNDER ETHER OR HALOTHANE ON THE ABILITY OF CHLORPROMAZINE TO AFFECT THE JAW-JERK RESPONSE TO TOOTH PULP STIMULATION IN THE ENCEPHALE ISOLE PREPARATION.
197451 01-03

THE EFFECT OF DIAZEPAM ON SPINAL CORD ACTIVITIES: POSSIBLE SITES AND MECHANISMS OF ACTION.
197585 01-03

DIAZEPAM INCREASES 5-HYDROXYINDOLE CONCENTRATIONS IN RAT BRAIN AND SPINAL CORD.
200081 02-03

LIPIDOSIS LIKE ALTERATIONS IN SPINAL CORD AND CEREBELLAR CORTEX OF RATS TREATED WITH CHLORPHENTERMINE OR TRICYCLIC ANTIDEPRESSANTS.
202767 02-03

THE EFFECT OF L-DOPA AND L-DOPA COMBINED WITH CHLORPROMAZINE ON SPINAL CORD ACTIVITY DURING DISTURBED INHIBITION BY TETANUS TOXOID.
207200 03-03

CATECHOLAMINE NEUROTRANSMITTERS AND SYNTHETIC ENZYMES IN THE SPINAL CORD OF THE RAT.
213987 04-03

LACK OF EFFECT OF PROTRIPTYLINE ON THE 6-HYDROXYDOPAMINE INDUCED NORADRENALINE DEPLETION IN THE RAT SPINAL CORD.
217824 04-03

CORONARY

EFFECT OF CAMAZEPAM (SB-5833), A NEW ANTIANXIOUS DRUG, ON CARDIAC CONTRACTILITY AND CORONARY HEMODYNAMICS.
206785 03-03

CORPUS-STRIATUM

EFFECTS OF OXOTREMORINE AND PHYSOSTIGMINE ON THE TURNOVER OF DOPAMINE IN THE CORPUS-STRIATUM AND THE LIMBIC SYSTEM.
198207 02-03

EFFECTS OF BENAPRYZINE, A NEW ANTIPARKINSON DRUG, ON DOPAMINE UPTAKE INTO CORPUS-STRIATUM.
199868 02-03

AMPHETAMINE-INDUCED INHIBITION OF TYROSINE HYDROXYLATION IN HOMOGENATES OF RAT CORPUS-STRIATUM.
222813 04-03

CORRECTION

ON THE USE OF SYDNOCARB FOR PSYCHOPHARMACOLOGICAL CORRECTION OF BEHAVIORAL DISORDERS OF THE CYCLOID TYPE OF ACCENTUATED PERSONALITY IN ADOLESCENTS.
207271 03-11

CORRECTION OF AUTONOMIC EFFECTS OF PSYCHOTROPIC DRUGS BY LARGE DOSES OF DIHYDROERGOTAMINE IN ADULTS AND THE ELDERLY.
211998 03-11

CORRECTOR
A CLINICAL STUDY OF A NEW NEUROLEPTIC EXTRAPYRAMIDAL SYNDROME CORRECTOR WITH ACUTE PSYCHOTIC STATES.
216766 04-15

CORRELATED
CORRELATED HISTOCHEMICAL, ELECTRON MICROSCOPICAL, PHARMACOLOGICAL AND PHYSIOLOGICAL OBSERVATION ON AMINERGIC MECHANISMS IN THE CENTRAL NERVOUS SYSTEM. (UNPUBLISHED PAPER).
218300 04-03

CORRELATES
LONG-TERM CORRELATES OF DRUG USE IN HYPERKINESIS.
198086 02-07
CLINICAL CHEMICAL CORRELATES OF CPZ THERAPY.
198098 02-08
BIOCHEMICAL CORRELATES IN MOUSE-KILLING BEHAVIOR OF THE RAT BRAIN: BRAIN ACETYLCHOLINE AND ACETYLCHOLINESTERASE AFTER ADMINISTRATION OF DELTA9-TETRAHYDROCANNABINOL.
199807 02-03
GENOTYPE DEPENDENT ELECTROENCEPHALOGRAPHIC, BEHAVIORAL AND ANALGESIC CORRELATES OF MORPHINE: AN ANALYSIS IN NORMAL MICE AND IN MICE WITH SEPTAL LESIONS.
203520 02-04
BEHAVIORAL NEUROENDOCRINOLOGY: CHEMICAL CORRELATES.
213625 04-03
EEG CORRELATES OF IMPAIRED ATTENTION PERFORMANCE UNDER SECOBARBITAL AND CHLORPROMAZINE IN THE MONKEY.
217544 04-03
CATECHOLAMINE CORRELATES OF ISOLATION INDUCED AGGRESSION IN MICE.
217670 04-04
PHARMACOLOGICALLY INDUCED BEHAVIORAL CORRELATES OF NIGROSTRIATAL FUNCTION. (PH.D. DISSERTATION).
220473 04-04
URBAN ECOLOGICAL AND HOUSEHOLD CORRELATES OF STRESS ALLEVIATIVE DRUG USE.
223949 04-17
BEHAVIORAL CORRELATES OF SEROTONIN DEPLETION.
225159 04-04

CORRELATION
SEIZURES OF CHOREOATHETIC TYPE INDUCED BY SUDDEN MOVEMENT: CORRELATION TO THE BIOGENIC AMINES.
196146 01-14
CORRELATION OF THE RELEASE OF AMINES AND ANTAGONISTS WITH THEIR EFFECTS.
197829 01-03
A CORRELATION BETWEEN THE INFLUENCE OF PSYCHOTROPIC DRUGS AND EMOTIONAL STRESS.
200103 02-09
EFFECTS OF DIAZEPAM ON EXPERIMENTALLY INDUCED CORTICAL EPILEPSY AND THEIR CORRELATION WITH DRUG CONCENTRATION.
205491 02-03
LEUKOCYTOSIS DURING LITHIUM TREATMENT AND ITS CORRELATION TO SERUM LITHIUM LEVEL.
207718 03-15
CORRELATION OF PSYCHOTOMIMETIC ACTIVITY OF PHENETHYLAMINES AND AMPHETAMINES WITH 1-OCTANOL WATER PARTITION COEFFICIENTS.
208593 03-12
THE CORRELATION BETWEEN THE VENTRAL AND DORSAL HIPPOCAMPUS DURING IMPROVEMENT OR DETERIORATION OF SHORT-TERM MEMORY.
215487 04-04
CORRELATION BETWEEN BRAIN MONOAMINE LEVELS AND POSTICTAL COMA FOLLOWING ELECTROSHOCK.
215723 04-03
CORRELATION OF BRAIN LEVELS OF BARBITURATE ENANTIOMERS WITH REPORTED DIFFERENCES IN DURATION OF SLEEP.
217457 04-03
CORRELATION OF (+) AMPHETAMINE LETHALITY AND HEPATIC METABOLISM.
217880 04-05
THE CORRELATION BETWEEN TRIFTAZINE DISTRIBUTION IN SOME RAT ORGANS AND ITS PHARMACOLOGICAL EFFECTS WITH DIFFERENT TYPES OF ADMINISTRATION.
223016 04-03
PINEAL BETA-ADRENERGIC RECEPTOR: CORRELATION OF BINDING OF H3-1-ALPRENOLOL WITH STIMULATION OF ADENYLCYCLASE. (UNPUBLISHED PAPER).
224096 04-03

CORRELATIONS
CLINICAL BIOLOGICAL CORRELATIONS IN SCHIZOAFFECTIVE PATIENTS TREATED WITH LITHIUM CARBONATE AND HALOPERIDOL.
210501 03-09
SOME OBSERVATIONS ON THE CORRELATIONS BETWEEN PLASMA LEVELS OF MONOMETHYLATED TRICYCLIC ANTIDEPRESSANTS AND THERAPEUTIC EFFECTS.
210507 03-09
IMPRINTING: CORRELATIONS BETWEEN BEHAVIOUR AND INCORPORATION OF (14C)URACIL INTO CHICK BRAIN.
210667 03-04
CORRELATIONS BETWEEN CIRCADIAN CHANGES IN SERUM AMINO ACIDS OR BRAIN TRYPTOPHAN AND THE CONTENTS OF SEROTONIN AND 5-HYDROXYINDOLEACETIC ACID IN REGIONS OF THE RAT BRAIN.
210673 03-03
FLUPHENAZINE TREATMENT IN THE PSYCHOTIC CHILD: CLINICAL EVOKED POTENTIAL CORRELATIONS.
215455 04-09

CORTEX
MESCALINE-INDUCED CHANGES OF BRAIN CORTEX RIBOSOMES: EFFECT OF MESCALINE ON RIBOSOMAL SYNTHESIS OF POLYURIDINE DIRECTED POLYPHENYLALANINE.
194153 01-03
LITHIUM AND ADRENAL CORTEX.
194169 01-03
PHARMACOLOGY OF PYRAMIDAL TRACT CELLS IN THE CEREBRAL CORTEX: NORADRENALINE AND RELATED SUBSTANCES.
195438 01-03
STUDIES ON THE UPTAKE OF D-AMPHETAMINE BY RAT CEREBRAL CORTEX SLICES.
197961 01-03
SELECTIVE DIPHENYLHYDANTOIN SUPPRESSION OF AUDITORY EVOKED POTENTIALS IN THE CAT CEREBELLAR CORTEX.
197989 01-03
PERSISTENT THALAMIC AND CORTICAL BARBITURATE SPINDLE ACTIVITY AFTER ABLATION OF THE ORBITAL CORTEX IN CATS.
199763 02-03
SENSITIVITY OF DENERVATED CEREBRAL CORTEX TO CHOLINOMIMETICS.
199769 02-03
EFFECT OF LIMBIC SYSTEM LESIONS ON ACETYLCHOLINE RELEASE FROM THE CEREBRAL CORTEX OF THE RAT.
200044 02-03
THE EFFECT OF INHIBITORS OF CATECHOLAMINE SYNTHESIS (ALPHA-METHYLTYROSINE AND DISULFIRAM) ON THE BACKGROUND ACTIVITY OF SENSORIMOTOR CORTEX NEURONS AND THEIR RESPONSES TO AFFERENT CAUDATE AND RETICULAR STIMULATION.
202598 02-04
LIPIDOSIS LIKE ALTERATIONS IN SPINAL CORD AND CEREBELLAR CORTEX OF RATS TREATED WITH CHLORPHENTERMINE OR TRICYCLIC ANTIDEPRESSANTS.
202767 02-03
THE EFFECT OF TRIIODOTHYRONINE IN COMBINATION WITH IMIPRAMINE ON (3H) CYCLIC-AMP PRODUCTION IN SLICES OF RAT CEREBRAL CORTEX.
202777 02-03
EFFECTS OF PHENOBARBITAL ON ELECTROCORTICOGRAM AND ACTIVITY, ON REGIONAL CNS ENERGY METABOLISM, AND ON PRESYNAPTIC EVENTS IN CEREBRAL CORTEX AND BRAINSTEM. (PH.D. DISSERTATION).
203033 02-03
THE EFFECTS OF ACETYLCHOLINE AND SYNAPTIC STIMULATION ON THE NEURONS IN THE SENSORIMOTOR CORTEX.
205510 02-03
EFFECTS OF SCOPOLAMINE ON THE EEG OF CORTEX AND HIPPOCAMPUS DURING SPONTANEOUS BEHAVIOUR IN RATS.
205628 03-04
MICROIONTOPHORETIC STUDIES ON THE EFFECT OF NOREPINEPHRINE ON THE ACTIVITY OF THE VISUAL CORTEX NEURONS IN RABBITS.
206441 03-03
DIFFERENTIAL EFFECTS OF AMPHETAMINE AND FOOD DEPRIVATION ON SELF-STIMULATION OF THE LATERAL HYPOTHALAMUS AND MEDIAL FRONTAL CORTEX.
206733 03-04
TIME-DEPENDENT CHANGES IN AMPHETAMINE SELF-ADMINISTRATION FOLLOWING FRONTAL CORTEX ABLATIONS IN RATS.
206747 03-04
PRESENCE OF DOPAMINERGIC TERMINALS AND ABSENCE OF DOPAMINERGIC CELL BODIES IN THE CEREBRAL CORTEX OF THE CAT.
210800 03-03
DETAILED NORADRENALINE PATHWAYS OF LOCUS-COERULEUS NEURON TO THE CEREBRAL CORTEX WITH THE USE OF 5-HYDROXYDOPA.
210803 03-03
ROLE OF THE STRIO-PALLIDAL SYSTEM AND MOTOR CORTEX IN INDUCED CIRCUS MOVEMENTS IN RATS AND CATS.
213450 04-03
EFFECTS OF 6-HYDROXYDOPAMINE AND RESERPINE ON AMPHETAMINE-INDUCED RELEASE OF NOREPINEPHRINE IN RAT CEREBRAL CORTEX.
215691 04-03
ELECTROPHYSIOLOGICAL EVIDENCE FOR AN INHIBITORY ACTION OF DIAZEPAM UPON CAT BRAIN CORTEX.
217649 04-03
EFFECTS OF PUTATIVE NEUROTRANSMITTERS ON NEURONAL ACTIVITY IN MONKEY AUDITORY CORTEX.
217865 04-03

CORTICAL
BLOCKADE BY ESERINE OF THE CEREBRAL CORTICAL EFFECTS OF ALLOFERIN: A FURTHER EVIDENCE OF CHOLINERGIC INHIBITORY MECHANISM.
195548 01-03
ADENOSINE-3-5-MONOPHOSPHATE IN CEREBRAL CORTICAL SLICES FROM GUINEA-PIG AND RAT: EFFECT OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC COMPOUNDS.
197293 01-03
ADENOSINE-3-5-MONOPHOSPHATE IN CEREBRAL CORTICAL SLICES FROM GUINEA-PIG AND RAT: EFFECT OF BENZODIAZEPINES.
197972 01-03
COMPARATIVE EFFECT OF PHENAMINE (AMPHETAMINE) AND CAFFEINE ON THE BACKGROUND ACTIVITY OF CORTICAL SENSORIMOTOR NEURONS AND THEIR REACTIONS DURING STIMULATION OF THE CAUDATE NUCLEUS.
198835 02-03
THE INFLUENCE OF NEMBUTAL, CHLORALOSE AND URETHANE ON INHIBITORY POSTSYNAPTIC POTENTIALS OF CORTICAL NEURONS.
199443 02-03
PERSISTENT THALAMIC AND CORTICAL BARBITURATE SPINDLE ACTIVITY AFTER ABLATION OF THE ORBITAL CORTEX IN CATS.
199763 02-03
THE EFFECT OF MICROELECTROPHORETICALLY APPLIED MESCALINE ON CORTICAL NEURONES.
199961 02-03
LEAD ENCEPHALOPATHY IN THE DEVELOPING RAT: EFFECT ON CORTICAL ONTOGENESIS.
200168 02-05
EFFECTS OF DIAZEPAM ON EXPERIMENTALLY INDUCED CORTICAL EPILEPSY AND THEIR CORRELATION WITH DRUG CONCENTRATION.
205491 02-03
THE ROLE OF DOPAMINE AND NOREPINEPHRINE IN CHANGING THE DIRECT CORTICAL RESPONSE TO PHENAMINE.
208971 03-03
THE INFLUENCE OF INTRAPERITONEAL INJECTION OF IPRAZIDE AND TRANSAMINE ON THE DISTRIBUTION OF BIOGENIC AMINES IN CORTICAL AND SUBCORTICAL WHITE MATTER OF THE RAT BRAIN.
209032 03-03
EFFECT OF OUABAIN AND PHENOBARBITAL ON THE KINETICS OF CORTICAL METABOLIC TRANSIENTS ASSOCIATED WITH EVOKED POTENTIALS.
210820 03-03
COMPARATIVE TIME-DEPENDENT CHANGES IN SENSITIVITY TO LOCOMOTOR EFFECTS OF D-AMPHETAMINE IN MICE WITH CAUDATE, HIPPOCAMPAL OR FRONTAL CORTICAL LESIONS.
210926 03-03
A POTENT DEPRESSANT ACTION OF ADENINE DERIVATIVES ON CEREBRAL CORTICAL NEURONES.
210932 03-03
THE ACTION OF CHLORPROMAZINE AND TRIFTAZINE ON DISCHARGES OF CORTICAL NEURONS IN RABBITS AFTER CHRONIC ADMINISTRATION OF THE DRUGS.
215499 04-03
ACTIONS OF ACETYLCHOLINE AND ATROPINE ON CEREBRAL CORTICAL NEURONS IN CHRONICALLY MORPHINE TREATED RATS.
215733 04-03
EFFECT OF WITHDRAWAL FROM CHRONIC ETHANOL INGESTION ON THE CAMP RESPONSE OF CEREBRAL CORTICAL SLICES USING THE AGONISTS HISTAMINE, SEROTONIN, AND OTHER NEUROTRANSMITTERS.
215980 04-03
EFFECTS OF PROCAINE HYDROCHLORIDE, DIAZEPAM, AND DIPHENYLHYDANTOIN ON SEIZURE DEVELOPMENT IN CORTICAL AND SUBCORTICAL STRUCTURES IN RATS.
218191 04-03
THE EFFECT OF NEUROLEPTICS OF THE PHENOTHIAZINE SERIES ON PULSE ACTIVITY AND THE ULTRASTRUCTURE OF RABBIT CORTICAL NEURONS.
219606 04-03
EFFECT OF OUABAIN AND PHENOBARBITAL ON OXIDATIVE METABOLIC ACTIVITY ASSOCIATED WITH SPREADING CORTICAL DEPRESSION IN CATS.
220944 04-03
DIFFERENTIAL EFFECTS OF A TETRAHYDROCANNABINOL AND PENTOBARBITAL ON CEREBRAL CORTICAL NEURONES.
222819 04-03

CORTICORETICULAR
ON THE INFLUENCE OF NEUROLEPTICS ON THE CORTICORETICULAR SYSTEM OF THE BRAIN (HISTOCHEMICAL AND BIOCHEMICAL INVESTIGATION).
198481 02-03

CORTICOSTEROIDS
STUDIES ON BEHAVIORAL ENDOCRINOLOGY OF CORTICOSTEROIDS.
219472 04-04

CORTICOSTERONE
EFFECT OF 6-HYDROXYDOPAMINE ON HYPOTHALAMIC NOREPINEPHRINE AND DOPAMINE CONTENT, ULTRASTRUCTURE OF THE MEDIAN EMINENCE, AND PLASMA CORTICOSTERONE.
193050 01-03
ALTERATIONS OF BARBITURATE ACTION FOLLOWING 1,1 DICHLOROETHYLENE, CORTICOSTERONE, OR ACROLEIN.
197488 01-03
EFFECT OF STRESS AND DIAZEPAM TREATMENT DURING INFANCY ON THE CORTICOSTERONE REGULATION AND ANDROGENIC ACTIVITY IN ADULT MALE RATS.
210348 03-03
POTENTIATION OF THE L-5-HYDROXYTRYPTOPHAN INDUCED ELEVATION OF PLASMA CORTICOSTERONE LEVELS IN RATS BY A SPECIFIC INHIBITOR OF SEROTONIN UPTAKE.
211104 03-03
THE EFFECTS OF CHRONIC CANNABIS TREATMENT UPON BRAIN 5-HYDROXYTRYPTAMINE, PLASMA CORTICOSTERONE AND AGGRESSIVE BEHAVIOR IN FEMALE RATS WITH DIFFERENT HORMONAL STATUS.
217532 04-04

CORTISOL
EFFECT OF THYROXINE AND CORTISOL ON BRAIN ORNITHINE DECARBOXYLASE ACTIVITY AND SWIMMING BEHAVIOR IN DEVELOPING RAT.
210933 03-03
INHIBITORY ACTION OF NOREPINEPHRINE ON THE INDUCTION OF TRYPTOPHAN 2,3 DIOXYGENASE BY CORTISOL: MEDIATION BY THE ALPHA-RECEPTOR.
221051 04-03

COUNTERMEASURES
TREATMENT AND COUNTERMEASURES FOR PATIENTS WITH INSOMNIA IN THE DEPARTMENT OF INTERNAL MEDICINE -- SPECIAL EMPHASIS ON THE CLINICAL APPLICATION OF FLURAZEPAM.
202285 02-14

COUNTRIES
NEW PSYCHOTROPIC DRUG DEVELOPMENTS IN THE USSR AND OTHER EASTERN EUROPEAN COUNTRIES.
213598 04-07

COUPLES
LITHIUM PROPHYLAXIS: THE MARRIED COUPLES GROUP.
224749 04-09

COURT
SUIT AGAINST RECOMMENDING DOCTOR AND PSYCHIATRIST -- REJECTED. STOVALL V. HARMS, 522 P.2D 353, (KANSAS) SUPREME COURT OF KANSAS. MAY 11, 1974.
200438 02-17

CPZ
CLINICAL CHEMICAL CORRELATES OF CPZ THERAPY.
198098 02-08
RELATIONSHIPS AMONG CLINICAL RESPONSE, EPS, AND PLASMA CPZ AND CPZ METABOLITE RATIOS.
224831 04-08

CREATINE
THE EFFECT OF LYSERGIC ACID DIETHYLAMIDE ON SERUM CREATINE KINASE LEVELS.
206361 03-12

CRISIS
THE THERAPEUTIC EFFECT OF SHORT-TERM ORAL DIAZEPAM TREATMENT ON ACUTE CLINICAL ANXIETY IN A CRISIS CENTRE.
199991 02-10
TREATMENT OF ACUTE SCHIZOPHRENIA WITH ULTRA-HIGH-DOSE FLUPHENAZINE: A FAILURE AT SHORTENING TIME ON A CRISIS INTERVENTION UNIT.
215456 04-08

CRITERIA
THE CURRENT STATUS OF BIOLOGICAL CRITERIA FOR CLASSIFYING THE DEPRESSIVE DISORDERS AND PREDICTING RESPONSES TO TREATMENT.
202380 02-17
BIOCHEMICAL CRITERIA FOR CLASSIFYING DEPRESSIVE DISORDERS AND PREDICTING RESPONSES TO PHARMACOTHERAPY: PRELIMINARY FINDINGS FROM STUDIES OF NOREPINEPHRINE METABOLISM. CONTRIBUTIONS TO BIOCHEMISTRY.
203594 02-09
POLYGRAPHIC EVALUATION OF HYPNOTIC DRUGS: METHODOLOGICAL CRITERIA.
208983 03-16
CLINICAL - PSYCHOPATHOLOGICAL CRITERIA FOR THE SELECTION OF PSYCHOTROPIC DRUGS ACCORDING TO THE STAGE OF ILLNESS AND THE EFFECTIVENESS OF REHABILITATING SCHIZOPHRENICS.
220403 04-17

CRITICALLY
DISULFIRAM IMPLANTATION CRITICALLY EVALUATED.
205316 02-11

CROSS-ANALYSIS
CROSS-ANALYSIS OF A CONTROLLED EXPERIMENT WITH PIPOTHIAZINE AND FLUPHENAZINE ENANTHATE.
221636 04-08

CROSS-TOLERANCE
CROSS-TOLERANCE OR TACHYPHYLAXIS AMONG VARIOUS PSYCHOTOMIMETIC AGENTS ON CATS.
199965 02-03
DELTA9-TETRAHYDROCANNABINOL AND SOME CNS DEPRESSANTS: EVIDENCE FOR CROSS-TOLERANCE IN THE RAT.
210876 03-03
CROSS-TOLERANCE BETWEEN MORPHINE AND ALCOHOL. (PH.D. DISSERTATION).
223737 04-04

CROSSOVER
A DOUBLE-BLIND CROSSOVER COMPARISON BETWEEN CLOTHIAPINE AND DIAZEPAM IN THE TREATMENT OF MENTAL SYMPTOMS IN CHRONIC ALCOHOLICS.
192988 01-11
CLOZAPINE AND HALOPERIDOL IN A SINGLE-BLIND CROSSOVER TRIAL: THERAPEUTIC AND BIOCHEMICAL ASPECTS IN THE TREATMENT OF SCHIZOPHRENIA.
200803 02-08
A CROSSOVER STUDY OF ALLOPURINOL ADMINISTRATION TO A SCHIZOPHRENIC CHILD.
207788 03-08
CLINICAL STUDIES OF D-40TA (TRIAZOLOBENZODIAZEPINE) -- CROSSOVER TRIAL ON SLEEP DISTURBANCES AND SLEEP EEG IN NORMAL ADULTS.
209412 03-10
SULPIRIDE VERSUS CHLORPROMAZINE AND PLACEBO IN THE TREATMENT OF RESTLESS MENTALLY SUBNORMAL PATIENTS -- A DOUBLE-BLIND CROSSOVER STUDY.
209702 03-11
EFFECT OF LITHIUM ON NEUROLEPTIC-INDUCED TARDIVE DYSKINESIA COMPARED WITH PLACEBO IN A DOUBLE-BLIND CROSSOVER TRIAL.
221335 04-15
BENZOCTAMINE (TACITIN) VERSUS PLACEBO: A DOUBLE-BLIND CROSSOVER STUDY IN ANXIETY NEUROTICS.
225064 04-10

CRUDE
THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON THE UPTAKE AND RELEASE OF 14C-DOPAMINE FROM CRUDE STRIATAL SYNAPTOSOMAL PREPARATIONS.
202775 02-03

CRYSTAL
CRYSTAL STRUCTURE DETERMINATIONS OF THE DONOR ACCEPTOR COMPLEXES OF PHENOTHIAZINE AND PHENOXAZINE WITH NICKEL THIETE. (PH.D. DISSERTATION).
201003 02-01

CRYSTALLINE
TRANQUILLIZING ACTION OF A CRYSTALLINE FRACTION OF PASPALUM-SCROBICULATUM EXTRACT IN FOURTEEN PSYCHOTIC PATIENTS.
194711 01-08

CRYSTALLOGRAPHIC
A CRYSTALLOGRAPHIC AND THEORETICAL STUDY OF THE CONFORMATION OF DOET AND ITS SIGNIFICANCE FOR THE HALLUCINOGENIC AMPHETAMINES.
210746 03-01

CSF
LUMBAR CSF 5-HYDROXYINDOLEACETIC ACID AND HOMOVANILLIC ACID IN AFFECTIVE SYNDROMES.
202248 02-09
MONOAMINE METABOLITES IN LUMBAR CSF: THE QUESTION OF THEIR ORIGIN IN RELATION TO CLINICAL STUDIES.
210796 03-03
AVERAGE EVOKED RESPONSES (AER) AND HOMOVANILLIC ACID (HVA) IN CEREBROSPINAL FLUID (CSF) IN A PSYCHOTIC PATIENT WITH ADDISONS DISEASE.
221310 04-09

CT-1341
THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL PRETREATMENT ON KETAMINE, THIOPENTAL OR CT-1341 -- INDUCED LOSS OF RIGHTING REFLEX IN MICE.
210878 03-02

CUE
ANALYSIS OF CUE USE IN STATE-DEPENDENT LEARNING. (PH.D. DISSERTATION).
196409 01-04
EFFECTS OF PROPRANOLOL, D-AMPHETAMINE AND CAFFEINE ON ETHANOL AS A DISCRIMINATIVE CUE.
199963 02-04
DIAZEPAM AS A DISCRIMINATIVE CUE: ITS ANTAGONISM BY BEMEGRIDE.
210865 03-03
DOPAMINERGIC MEDIATION OF THE INTEROCEPTIVE CUE PRODUCED BY D-AMPHETAMINE IN RATS.
217531 04-04

CULTURE
THE TOXICITY OF CHLORPROMAZINE AND MESCALINE ON MOUSE CEREBELLUM AND FIBROBLAST CELLS IN CULTURE.
210890 03-03

CULTURED
DEPOLARIZATION, DESENSITIZATION AND THE EFFECTS OF TUBOCURARINE AND NEOSTIGMINE IN CULTURED SKELETAL MUSCLE.
193447 01-03
ADENOSINE 3,5 MONOPHOSPHATE IN CULTURED NEUROBLASTOMA CELLS: EFFECT OF ADENOSINE, PHOSPHODIESTERASE INHIBITORS AND BENZAZEPINES.
195254 01-03
RESPONSES OF CULTURED CEREBELLAR NEURONS TO IONTOPHORETICALLY APPLIED AMINO ACIDS.
213279 03-03
UPTAKE OF 3H-NORADRENALINE AND 3H-5-HYDROXYTRYPTAMINE IN CULTURED RAT BRAINSTEM.
215159 04-03

CULTURES
CHROMOSOMAL DAMAGE IN CHRONICAL USERS OF CANNABIS: IN VIVO INVESTIGATION WITH TWO-DAY LEUKOCYTE CULTURES.
210810 03-15

CUMULATION
DIAZEPAM METABOLISM IN NORMAL MAN: II. SERUM CONCENTRATION AND CLINICAL EFFECT AFTER ORAL ADMINISTRATION AND CUMULATION.
195445 01-13

CURARE
EFFECTS OF PREVIOUS CURARE IMMOBILIZATION ON PAVLOVIAN CONDITIONED HEART DECELERATIONS IN THE CURARIZED RAT.
219083 04-04

CURARIZED
OPERANT CONDITIONING OF HEART RATE IN CURARIZED RATS: HEMODYNAMIC CHANGES.
213275 03-04
EFFECTS OF PREVIOUS CURARE IMMOBILIZATION ON PAVLOVIAN CONDITIONED HEART DECELERATIONS IN THE CURARIZED RAT.
219083 04-04

CURED
DOSAGE OF A PSYCHOTROPIC DRUG TO PREVENT RELAPSE IN A CURED SCHIZOPHRENIC PATIENT.
209402 03-08

CURRENTS
INEFFECTIVENESS OF LYSERGIC ACID DIETHYL AMIDE 25 (LSD) ON ALTERING NA-K CURRENTS IN SQUID GIANT AXON.
194927 01-03

CURVE
THE EFFECT OF ACTH AND DIAZEPAM, ADMINISTERED TO INFANT RATS ON THE BODY GROWTH CURVE AND SOME ENDOCRINE PARAMETERS MEASURED IN ADULT AGE.
215066 04-03
CHILDHOOD CHEMOTHERAPY AND LATER DRUG ABUSE AND GROWTH CURVE: A FOLLOWUP STUDY OF 30 ADOLESCENTS.
225382 04-14

CURVES
PLASMA TRYPTOPHAN TOLERANCE CURVES IN DRUG-FREE NORMAL CONTROLS, SCHIZOPHRENIC PATIENTS AND PRISONER VOLUNTEERS.
200773 02-13
THE EFFECTS OF AGE AND ILLUMINATION ON THE DOSE-RESPONSE CURVES FOR THREE STIMULANTS.
214014 04-04

CUTANEOUS
STUDIES OF TRYPTAMINE AND LYSERGIC ACID DIETHYLAMIDE (LSD) ON CUTANEOUS C-FIBER AND POLYSYNAPTIC REFLEXES IN THE CAT.
197814 01-03

CYAMEPROMAZINE
THE USE OF CYAMEPROMAZINE IN SMALL DOSES IN TREATMENT OF NONPSYCHOTIC DISTURBANCES.
215798 04-04

CYANOGEN
CYANOGEN CONDENSATIONS AS A ROUTE TO 3-AMINO-2-IMINOBENZOTHIAZIN-4-ONES WITH CNS DEPRESSANT POTENTIAL.
222870 04-02

CYBERNETIC
AMENORRHEA AND BEHAVIORAL DISTURBANCES: CLINICAL CASE TREATED WITH A PSYCHOTHERAPEUTIC METHOD BASED ON ELEMENTS OF THE CYBERNETIC THEORY OF G. CIPOLLINA MANGIAMELI.
210418 03-14

CYCLAZOCINE
TERATOLOGIC AND REPRODUCTION STUDIES WITH CYCLAZOCINE.
193429 01-03

CYCLE
METABOLIC COMPARTMENTATION IN THE BRAIN: METABOLISM OF A TRICARBOXYLIC ACID CYCLE INTERMEDIATE, (1,4-14C)SUCCINATE, AFTER INTRACEREBRAL ADMINISTRATION.
210780 03-03
DRUGS, CATECHOLAMINES AND KREBS CYCLE INTERACTION (CNS).
213602 04-03
L-HISTIDINE: FAILURE TO AFFECT THE SLEEP-WAKING CYCLE IN MAN.
214015 04-14
PSYCHOTROPIC DRUGS AND OVARIAN CYCLE ALTERATIONS.
217204 04-13

CYCLES
TREATMENT OF EXPERIMENTAL IMIPRAMINE INTOXICATION BY INTERRUPTING ENTERAL CYCLES WITH ACTIVATED CHARCOAL.
197969 01-03
ANTIDEPRESSANT AGENTS AND REVERSAL OF DIURNAL ACTIVITY CYCLES IN THE RAT.
218954 04-04
PHARMACOLOGICAL - CLINICAL INTEREST IN THE STUDY OF 24 HOUR LITHIUM RATE CYCLES.
221667 04-09

CYCLIC
A DUAL STUDY. PART I: SYNTHESIS AND STEREOCHEMISTRY OF SOME 1 SUBSTITUTED QUINOLIZIDINES AS ANALOGS OF BIOLOGICALLY ACTIVE COMPOUNDS. PART II: AMINO DERIVATIVES OF THIOPHENE FUSED CYCLIC KETONES AS POTENTIAL CNS. (PH.D. DISSERTATION).
196252 01-01
INVOLVEMENT OF CYCLIC NUCLEOTIDES IN THE LONG-TERM INDUCTION OF TYROSINE-HYDROXYLASE. (UNPUBLISHED PAPER).
196590 01-03
METHODS TO STUDY THE IN VIVO REGULATION OF CYCLIC NUCLEOTIDES IN HYPOTHALAMIC NUCLEI, PITUITARY AND PINEAL. (UNPUBLISHED PAPER).
201491 02-06
ANXIETY AND ACTIVITIES OF CYCLIC ADENOSINE-MONOPHOSPHATE PHOSPHODIESTERASE.
202161 02-17
THE REGULATION OF CYCLIC GUANOSINE MONOPHOSPHATE IN RAT CEREBELLUM: POSSIBLE INVOLVEMENT OF PUTATIVE AMINO ACID NEUROTRANSMITTERS.
202717 02-03
RAT PINEAL CYCLIC ADENOSINE-3-5-MONOPHOSPHATE PHOSPHODIESTERASE ACTIVITY: IN VIVO MODULATION BY A BETA ADRENERGIC RECEPTOR.
215600 04-03
INDUCTION OF TYROSINE-HYDROXYLASE ELICITED BY BETA ADRENERGIC RECEPTOR AGONISTS IN NORMAL AND DECENTRALIZED SYMPATHETIC GANGLIA: ROLE OF CYCLIC 3,5 ADENOSINE-MONOPHOSPHATE.
215688 04-03
THE EFFECT OF ETHYMIZOL ON THE CONTENT OF CYCLIC 3,5 ADENOSINE-MONOPHOSPHATE IN BRAIN TISSUE.
217065 04-03

CYCLIC-AMP
ANTIANESTHETIC EFFECTS OF CYCLIC-AMP AND ANALEPTIC DRUGS AS DETERMINED BY REVERSAL OF AMOBARBITAL INDUCED NARCOSIS.
193426 01-03
EFFECTS OF TETRAHYDROCANNABINOLS ON CYCLIC-AMP LEVELS IN RAT BRAIN AREAS.
194925 01-03
EFFECTS OF CATECHOLAMINES AND PROSTAGLANDINS ON CYCLIC-AMP LEVELS IN BRAIN IN VIVO.
197294 01-03
THE EFFECT OF TRIIODOTHYRONINE IN COMBINATION WITH IMIPRAMINE ON (3H) CYCLIC-AMP PRODUCTION IN SLICES OF RAT CEREBRAL CORTEX.
202777 02-03
THE ROLE OF CEREBRAL CYCLIC-AMP IN THE ACTION OF PSYCHOTROPIC DRUGS: IN VIVO AND IN VITRO STUDIES. (PH.D. DISSERTATION).
203032 02-03
ON THE REGULATION OF CYCLIC-AMP PHOSPHODIESTERASE BY A SPECIFIC PROTEIN ACTIVATOR. (UNPUBLISHED PAPER).
208735 03-03
CYCLIC-AMP IN CEREBROSPINAL FLUID: ACCUMULATION FOLLOWING PROBENECID AND BIOGENIC AMINES.
210193 03-17
EFFECT OF LITHIUM ON GLUCAGON STIMULATED CYCLIC-AMP EXCRETION IN RATS.
213481 04-03
ANTIPSYCHOTIC DRUGS: ROLES OF CYCLIC-AMP.
213609 04-03
BETA-ADRENERGIC STIMULATION OF PINEAL N-ACETYLTRANSFERASE: CYCLIC-AMP STIMULATES BOTH RNA AND PROTEIN SYNTHESIS.
215601 04-03
EXAMINATION OF THE ROLE OF BRAIN AMINES AND CYCLIC-AMP IN BENZODIAZEPINE INDUCED SUPPRESSION OF AGGRESSION. (PH.D. DISSERTATION).
219278 04-04
A DIRECT EFFECT OF DIBUTYRYL CYCLIC-AMP ON THE DURATION OF NARCOSIS INDUCED BY SEDATIVE, HYPNOTIC, TRANQUILISER AND ANESTHETIC DRUGS IN THE RAT.
222814 04-04

CYCLIC-GMP
CYCLIC-GMP: REDUCTION OF CEREBELLAR CONCENTRATIONS IN NERVOUS MUTANT MICE.
221031 04-03

CYCLIC-3-5-AMP
EFFECTS OF LITHIUM ON CYCLIC-3-5-AMP METABOLISM IN RAT BRAIN.
197278 01-03

CYCLIZATION
CHIRAL 1,4 BENZODIAZEPINE: VII. CYCLIZATION RATES OF 2-N-ALPHA-AMMONIUMACYL-AMINO-5-CHLOROBENZOPHENONES IN THE CHIRAL 1,4 BENZODIAZEPIN-2-ONES.
221858 04-01

CYCLOHEXIMIDE
THE EFFECT OF DIFFERENTIAL SALINE AND CYCLOHEXIMIDE STATES ON THE ACQUISITION OF A SPATIAL REVERSAL TASK IN MICE AND RATS. (PH.D. DISSERTATION
198897 02-04
THE EFFECT OF CYCLOHEXIMIDE AND ACTINOMYCIN-D ON THE SPONTANEOUS AND OPERATIVE BEHAVIORS OF THE PIGEON. PRELIMINARY NOTE.
199381 02-04
TYROSINE-HYDROXYLASE INHIBITION BY CYCLOHEXIMIDE AND ANISOMYCIN IS NOT RESPONSIBLE FOR THEIR AMNESIC EFFECT.
203572 02-04
AMNESIC EFFECT OF CYCLOHEXIMIDE IN THE MOUSE MEDIATED BY ADRENOCORTICAL HORMONES.
206751 03-04
ROLE OF THE BIOGENIC AMINES IN THE REVERSAL OF CYCLOHEXIMIDE INDUCED AMNESIA.
206752 03-04
INHIBITION OF MEMORY FORMATION IN THE IMPRINTING PERIOD: IRREVERSIBLE ACTION OF CYCLOHEXIMIDE IN YOUNG CHICKENS.
210708 03-04
THE REVERSIBLE INHIBITION OF STEROID INDUCED SEXUAL BEHAVIOR BY INTRACRANIAL CYCLOHEXIMIDE.
213685 04-03
INTERACTION OF CYCLOHEXIMIDE AND ADRENERGIC DRUGS WITH BRAIN PROTEIN AND CATECHOLAMINE BIOSYNTHESIS. (PH.D. DISSERTATION).
219288 04-03

CYCLOID
ON THE USE OF SYDNOCARB FOR PSYCHOPHARMACOLOGICAL CORRECTION OF BEHAVIORAL DISORDERS OF THE CYCLOID TYPE OF ACCENTUATED PERSONALITY IN ADOLESCENTS.
207271 03-11

CYCLOPROPANE
REVERSIBLE INHIBITION OF MAMMALIAN BRAIN ACETYLCHOLINESTERASE AND SODIUM POTASSIUM STIMULATED ADENOSINE-TRIPHOSPHATASE BY CYCLOPROPANE.
210903 03-03

CYCLOTHYMIA
LITHIUM THERAPY IN CYCLOTHYMIA.
203600 02-09

CYCLOTHYMIC
LITHIUM GLUCONATE: SYSTEMATIC AND FACTORIAL ANALYSIS OF 104 OBSERVATIONS OVER 2.5-3 YEARS IN PATIENTS PRESENTING CYCLOTHYMIC OR DYSTHYMIC DISORDERS.
210126 03-09

CYLERT
PEMOLINE (CYLERT) IN THE TREATMENT OF CHILDHOOD HYPERKINESIS.
202824 02-11

CYNOMYS-LUDOVICIANUS
ATTENUATION OF ACUTE HABITUATION BY SCOPOLAMINE IN THE BLACK-TAILED PRAIRIE DOG (CYNOMYS-LUDOVICIANUS).
206745 03-04

CYPROHEPTADINE
THE INFLUENCE OF CYPROHEPTADINE AND OF D-LYSERGAMIDE ON THE RISE IN TEMPERATURE INDUCED BY INTRACEREBROVENTRICULAR 5-HYDROXYTRYPTAMINE, NORADRENALINE AND DOPAMINE IN CONSCIOUS RABBITS.
193451 01-03
THE EFFECT OF CYPROHEPTADINE ON HUNGER, CALORIE INTAKE AND BODY WEIGHT IN MAN.
214011 04-13

CYPROTERONE
EXPERIENCE WITH CYPROTERONE ACETATE INFLUENCE ON HUMAN SEXUALITY.
195037 01-11
TREATMENT OF SEXUAL DELINQUENCY WITH ANDROCUR (CYPROTERONE ACETATE).
203496 02-17

CYTIDINE
EFFECTS OF CYTIDINE DIPHOSPHATE CHOLINE ON THE NERVOUS SYSTEM IN CATS.
198610 02-04

CYTOTOXIC
CYTOTOXIC EFFECTS OF IMIPRAMINE ON PLATELETS.
195450 01-03
ON THE MECHANISM OF THE DEFENSIVE ACTION OF ACETYLCHOLINE AND SEROTONIN AGAINST THEIR CYTOTOXIC ANTAGONISTS.
219663 04-03

C14
INCORPORATION OF ACETATE (C14)(P-32) AND PHOSPHATE INTO THE BRAIN LIPIDS DURING BLOCKAGE OF THE CHOLINORECEPTOR AND ADRENORECEPTORS.
202599 02-03

C14-FLUPHENAZINE
MICROAUTORADIOGRAPHIC STUDIES AFTER MEDICATION OF C14-FLUPHENAZINE IN THE ANIMAL EXPERIMENT.
206769 03-03

D-AMPHETAMINE
DIFFERENTIAL EFFECTS OF D-AMPHETAMINE ON BRAIN ACETYLCHOLINE IN YOUNG, ADULT, AND GERIATRIC RATS.
193457 01-03
EFFECTS OF D-AMPHETAMINE ON LEARNING AND MEMORY IN INBRED AND HYBRID MICE. (PH.D. DISSERTATION).
193581 01-04
DIFFERENTIAL EFFECTS ON LEVER CHOICE AND RESPONSE RATE PRODUCED BY D-AMPHETAMINE.
194178 01-04
IN VIVO RELEASE OF ENDOGENOUSLY SYNTHESIZED CATECHOLAMINES FROM THE CAT BRAIN EVOKED BY ELECTRICAL STIMULATION AND BY D-AMPHETAMINE.
195049 01-03
EFFECTS OF D-AMPHETAMINE ON ACQUISITION OF LEVERPRESS SIDMAN AVOIDANCE IN RATS.
195305 01-04
DIFFERENTIAL EFFECTS OF CHLORDIAZEPOXIDE AND D-AMPHETAMINE ON RESPONDING MAINTAINED BY A DRL SCHEDULE OF REINFORCEMENT.
195433 01-04
EFFECTS OF D-AMPHETAMINE SULFATE GIVEN TO PREGNANT MICE ON ACTIVITY AND ON CATECHOLAMINES IN THE BRAINS OF OFFSPRING.
196025 01-03
THE INTERACTION OF DELTA9-TETRAHYDROCANNABINOL AND D-AMPHETAMINE IN AGGREGATED MICE.
196227 01-04
D-AMPHETAMINE AND THE RELEASE OF 3H-NOREPINEPHRINE FROM SYNAPTOSOMES.
197871 01-03
STUDIES ON THE UPTAKE OF D-AMPHETAMINE BY RAT CEREBRAL CORTEX SLICES.
197961 01-03
ALTERATION OF THE EFFECTS AND THE METABOLISM OF D-AMPHETAMINE BY ETHANOL.
197975 01-03
EFFECTS OF DIETHYLPROPION AND D-AMPHETAMINE AFTER SUBCUTANEOUS AND ORAL ADMINISTRATION.
198030 01-14
EFFECTS OF PROPRANOLOL, D-AMPHETAMINE AND CAFFEINE ON ETHANOL AS A DISCRIMINATIVE CUE.
199963 02-04
THE IN VIVO RELEASE OF ENDOGENOUSLY SYNTHESIZED CATECHOLAMINES FROM THE CAT BRAIN BY LATERAL HYPOTHALAMIC STIMULATION AND BY D-AMPHETAMINE ADMINISTRATION. (PH.D. DISSERTATION).
200313 02-03
AN ANALYSIS OF SOME DISCRIMINATIVE PROPERTIES OF D-AMPHETAMINE.
201321 02-04
THE EFFECT OF D-AMPHETAMINE ON CHOREIFORM MOVEMENT DISORDERS.
202282 02-11
INTRASPECIES AGGRESSION IN RATS: EFFECTS OF D-AMPHETAMINE AND CHLORDIAZEPOXIDE.
202768 02-04
BREAKDOWN OF STIMULUS CONTROL BY D-AMPHETAMINE.
202968 02-04
STUDIES ON THE INTERACTION OF RESERPINE, D-AMPHETAMINE, APOMORPHINE AND 5-HYDROXYTRYPTOPHAN.
203885 02-03
EFFECTS OF D-AMPHETAMINE ON SINGLE VESTIBULAR NEURONS.
204483 02-03
LACK OF EFFECT OF AMANTADINE ON D-AMPHETAMINE INDUCED RELEASE OF DOPAMINE FROM CAT BRAIN IN VIVO.
204865 02-02
D-AMPHETAMINE AND DELINQUENCY: HYPERKINESIS PERSISTING
206143 03-14
EFFECTS OF HIPPOCAMPAL MICROINJECTIONS OF D-AMPHETAMINE AND SCOPOLAMINE ON ACTIVE AVOIDANCE BEHAVIOR IN RATS.
206741 03-04
D-AMPHETAMINE AND THE SENSORY ROLE OF A RATS TAIL IN THERMOREGULATION OR WHAT THE RATS TAIL TELLS THE RATS BRAIN.
209961 03-03
CHOLINERGIC DOPAMINERGIC INTERACTION IN THE STRIATUM: THE EFFECT OF 6-HYDROXYDOPAMINE OR PIMOZIDE TREATMENT ON THE INCREASED STRIATAL ACETYLCHOLINE LEVELS INDUCED BY APOMORPHINE, PIRIBEDIL AND D-AMPHETAMINE.
210668 03-03
THE EFFECTS OF CHLORPROMAZINE AND D-AMPHETAMINE SULFATE ON THE VISUAL STIMULATION PREFERENCE OF EXTRAVERTS AND INTROVERTS.
210680 03-14
DOPAMINERGIC NEURONS IN THE NIGROSTRIATAL AND MESOLIMBIC PATHWAYS: MEDIATION OF SPECIFIC EFFECTS OF D-AMPHETAMINE.
210855 03-03
BEHAVIORAL EFFECTS OF D-AMPHETAMINE AND CAFFEINE IN THE SQUIRREL MONKEY.
210860 03-04
COMPARISON OF THE EFFECTS OF D-AMPHETAMINE AND L-AMPHETAMINE IN REVERSING DEPRESSION OF MOUSE LOCOMOTOR ACTIVITY CAUSED BY RESERPINE.
210869 03-03
EFFECTS OF D-AMPHETAMINE AND SECOBARBITAL ON KEY PRESS RATES IN NORMAL HUMANS.
210879 03-14
COMPARATIVE TIME-DEPENDENT CHANGES IN SENSITIVITY TO LOCOMOTOR EFFECTS OF D-AMPHETAMINE IN MICE WITH CAUDATE, HIPPOCAMPAL OR FRONTAL CORTICAL LESIONS.
210926 03-03
CLINICAL STUDIES WITH MARIHUANA AND D-AMPHETAMINE COMBINATION.
211745 03-14
EFFECTS OF D-AMPHETAMINE AND PRESESSION SHOCKS ON SIDMAN AVOIDANCE WITH A TONE IN RATS. (PH.D. DISSERTATION).
212677 03-04
THE EFFECTS OF D-AMPHETAMINE MONOPHOSPHATE ON THE PEAK SHIFT. (PH.D. DISSERTATION).
213153 03-04
ANTAGONISM OF DEPRESSANT ACTIVITY OF ETHANOL BY DH-524; A COMPARATIVE STUDY WITH BEMEGRIDE, DOXAPRAM AND D-AMPHETAMINE (38640).
213282 03-03
DIFFERENTIAL EFFECTS OF CAFFEINE, D-AMPHETAMINE AND METHYLPHENIDATE ON INDIVIDUAL RAPHE CELL FLUORESCENCE: A MICROSPECTROFLUORIMETRIC DEMONSTRATION.
213400 04-03
D-AMPHETAMINE INDUCED RELEASE OF NEWLY SYNTHESIZED AND STORED DOPAMINE FROM THE CAUDATE NUCLEUS IN VIVO.
214110 04-03
INHIBITION OF D-AMPHETAMINE INDUCED LOCOMOTOR ACTIVITY BY INJECTION OF HALOPERIDOL INTO THE NUCLEUS-ACCUMBENS OF THE RAT.
217461 04-04
DOPAMINERGIC MEDIATION OF THE INTEROCEPTIVE CUE PRODUCED BY D-AMPHETAMINE IN RATS.
217531 04-04
PUNISHED BEHAVIOR: INCREASES IN RESPONDING AFTER D-AMPHETAMINE.
217542 04-04
ANTAGONISM BY D-AMPHETAMINE OF LEARNING DEFICITS IN RATS INDUCED BY EXPOSURE TO ANTIPSYCHOTIC DRUGS DURING EARLY POSTNATAL LIFE.
217656 04-04
A NOVEL TREMORIGEN ANTAGONIZED BY D-AMPHETAMINE.
217874 04-03
EFFECTS OF CHRONIC ADMINISTRATION AND WITHDRAWAL OF D-AMPHETAMINE UPON DAILY ACTIVITY LEVELS OF SQUIRREL MONKEYS.
219032 04-04
BLOCKADE OF THE CENTRAL EFFECTS OF D-AMPHETAMINE BY AMANTADINE II.
221737 04-03
THE EFFECTS OF SHOCK INTENSITY, D-AMPHETAMINE, AND PENTOBARBITAL ON THE FREQUENCY AND RESPONSE DYNAMICS OF BITING ATTACK IN THE SQUIRREL MONKEY. (PH.D. DISSERTATION).
222114 04-04
POSTTRIAL D-AMPHETAMINE SULFATE AND ONE-TRIAL LEARNING IN MICE.
222268 04-04
INTRAVENOUS SELF-ADMINISTRATION OF D-AMPHETAMINE AND L-AMPHETAMINE BY DOG.
222806 04-04
GALVANIC SKIN RESISTANCE (GSR) MEASUREMENTS ON VOLUNTEERS RECEIVING FENFLURAMINE OR D-AMPHETAMINE.
225062 04-13
NEONATAL LOCOMOTOR AND LONG-TERM BEHAVIORAL EFFECTS OF D-AMPHETAMINE IN THE RAT.
225077 04-04
PRENATAL MATERNAL D-AMPHETAMINE EFFECTS ON EMOTIONALITY AND AUDIOGENIC SEIZURE SUSCEPTIBILITY OF RAT OFFSPRING.
225079 04-04
COMPARATIVE SYMPTOMATOLOGICAL AND EVOKED POTENTIAL STUDIES WITH D-AMPHETAMINE, THIORIDAZINE, AND PLACEBO IN HYPERKINETIC CHILDREN.
225516 04-10

D-ISOMERS
EFFECTS OF D-ISOMERS AND L-AMPHETAMINE ON 5-HYDROXYTRYPTAMINE RECEPTORS.
197481 01-04

D-LSD
D-LSD BINDING TO BRAIN HOMOGENATES: POSSIBLE RELATIONSHIP TO SEROTONIN RECEPTORS.
202464 02-03

D-LYSERGAMIDE
THE INFLUENCE OF CYPROHEPTADINE AND OF D-LYSERGAMIDE ON THE RISE IN TEMPERATURE INDUCED BY INTRACEREBROVENTRICULAR 5-HYDROXYTRYPTAMINE, NORADRENALINE AND DOPAMINE IN CONSCIOUS RABBITS.
193451 01-03

D-OXAZEPAM
BINDING OF D-OXAZEPAM AND L-OXAZEPAM HEMISUCCINATE TO BOVINE SERUM ALBUMIN.
200033 02-03

D-OXPRENOLOL
SUPPRESSION OF CONDITIONED HYPERTHERMIC RESPONSE BY L- AND D-OXPRENOLOL IN RATS.
192937 01-03

D-PHENYLALANINE
EFFECTS OF D-PHENYLALANINE ON CLINICAL PICTURE AND PHENETHYLAMINURIA IN DEPRESSION.
218959 04-09

D-145
AMANTADINE AND D-145, AN AMANTADINE DERIVATIVE, DO NOT EFFECT DOPAMINE SENSITIVE ADENYLATE-CYCLASE FROM THE CAUDATE PUTAMEN OF THE RAT BRAIN.
199867 02-03

D-40TA
CLINICAL STUDIES OF D-40TA (TRIAZOLOBENZODIAZEPINE) -- CROSSOVER TRIAL ON SLEEP DISTURBANCES AND SLEEP EEG IN NORMAL ADULTS.
209412 03-10

DAILY
EFFECT OF SINGLE AND DAILY INJECTIONS OF PHENOBARBITAL ON OVULATION IN HAMSTERS.
193421 01-03

ONCE VERSUS THRICE DAILY THIOTHIXENE IN THE TREATMENT OF SCHIZOPHRENIC INPATIENTS.
194044 01-08

THE EFFECT OF DAILY ORAL DOSAGE OF DIAZEPAM, PLASMA CONCENTRATIONS AND METABOLIC CLEARANCE OF DIAZEPAM AND DEMETHYLDIAZEPAM ON VARIOUS CONSTITUENTS OF THE ACUTE CLINICAL ANXIETY SYNDROME.
196191 01-10

DEFICIENT BRIGHTNESS DISCRIMINATION ACQUISITION PRODUCED BY DAILY INTRACRANIAL INJECTIONS OF PENICILLIN IN RATS.
202758 02-04

A DOUBLE-BLIND COMPARISON OF THREE TIMES DAILY AND SINGLE NIGHT DOSAGE OF THE TRICYCLIC ANTIDEPRESSANT DOTHIEPIN.
216463 04-09

EFFECTS OF CHRONIC ADMINISTRATION AND WITHDRAWAL OF D-AMPHETAMINE UPON DAILY ACTIVITY LEVELS OF SQUIRREL MONKEYS.
219032 04-04

A SINGLE DAILY DOSE OF A SUSTAINED RELEASE FORM OF AMITRIPTYLINE IN DEPRESSIVE ILLNESS.
219961 04-09

ONCE DAILY DOSAGE WITH MAPROTILINE (LUDIOMIL).
221659 04-09

ONCE DAILY DOSAGE STUDY WITH MAPROTILINE (LUDIOMIL).
221660 04-09

AN INTERIM REPORT OF A DOUBLE-BLIND STUDY COMPARING A ONCE DAILY DOSAGE OF MAPROTILINE (LUDIOMIL) WITH AMITRIPTYLINE THRICE DAILY.
221661 04-09

A COMPARISON BETWEEN DAILY AND NIGHTLY DOSE REGIMEN OF AMITRIPTYLINE AND MAPROTILINE (LUDIOMIL) IN THE TREATMENT OF REACTIVE DEPRESSION IN GENERAL PRACTICE.
221662 04-09

DALMANE
THE EFFECTS OF DALMANE (FLURAZEPAM HYDROCHLORIDE) ON HUMAN EEG CHARACTERISTICS.
199756 02-13

DAMAGE
THE INHIBITORY EFFECT OF TOLUIDINE BLUE AND METHYLENE BLUE ON RAT MAST CELL DAMAGE BY PROMETHAZINE, CHLORPROMETHAZINE AND CHLORPROMAZINE. ITS REVERSAL BY GLUCOSE.
199255 02-05

LITHIUM CARBONATE, HALOPERIDOL, AND IRREVERSIBLE BRAIN DAMAGE.
201287 02-15

PROTECTION AGAINST EFFECTS OF BRAIN DAMAGE BY CATECHOLAMINE DEPLETION IS TEST DEPENDENT.
203579 02-04

CHROMOSOMAL DAMAGE IN CHRONICAL USERS OF CANNABIS: IN VIVO INVESTIGATION WITH TWO-DAY LEUKOCYTE CULTURES.
210810 03-15

DATA
PATTERN ANALYSIS OF PSYCHIATRIC RESEARCH DATA.
195940 01-11

SIDE-EFFECTS OF PSYCHOTROPIC DRUGS -- AN ANALYSIS OF DATA OBTAINED FROM DOUBLE-BLIND COMPARATIVE STUDIES IN JAPAN.
201260 02-15

CLINICAL ELECTROENCEPHALOGRAPHIC DATA IN DEPRESSED PATIENTS TREATED WITH ANAFRANIL.
209148 03-09

DB-CAMP
THE EFFECT OF DOPAMINE AND OF APOMORPHINE ON DB-CAMP INDUCED STIMULATION OF SYNAPTOSOMAL TYROSINE-HYDROXYLASE.
217823 04-03

DB-2182
APPLICATION OF LOPRAMINE (DB-2182) FOR THE TREATMENT OF DEPRESSIVE STATE.
209395 03-11

DEAMINATION
DEAMINATION OF BETA-PHENYLETHYLAMINE BY MONOAMINEOXIDASE -- INHIBITION BY IMIPRAMINE.
195447 01-13

INHIBITION BY APOMORPHINE OF DOPAMINE DEAMINATION IN THE RAT BRAIN.
210776 03-03

OXIDATIVE METABOLISM OF MESCALINE IN THE CENTRAL NERVOUS SYSTEM -- V. IN VITRO DEAMINATION OF MESCALINE TO 3,4,5 TRIMETHOXYBENZOIC ACID.
210813 03-03

DEANOL
TREATMENT OF PHENOTHIAZINE INDUCED BULBAR PERSISTENT DYSKINESIA WITH DEANOL ACETAMIDOBENZOATE.
210209 03-13

DEANOL AND METHYLPHENIDATE IN MINIMAL-BRAIN-DYSFUNCTION.
215668 04-13

DEANOL IN TARDIVE DYSKINESIA: A PRELIMINARY REPORT.
217523 04-11

DEATH
SUICIDE IN BRISBANE, 1956 TO 1973: THE DRUG DEATH EPIDEMIC.
224491 04-17

DECADES
TWO DECADES OF PSYCHOPHARMACOLOGY AND COMMUNITY MENTAL HEALTH: OLD AND NEW PROBLEMS OF THE SCHIZOPHRENIC PATIENT.
207921 03-17

DECANOATE
EARLY HOSPITAL EXPERIENCES WITH FLUPHENAZINE DECANOATE.
196675 01-07

LONG-ACTING NEUROLEPTICS OF PERATHIEPINE GROUP: VUFB-9977 (OXYPROTHEPINE DECANOATE).
205583 02-03

LONG-TERM TRIAL OF FLUPHENAZINE DECANOATE AND FLUPENTHIXOL DECANOATE FOR CATALEPTIC ACTIVITY AND EFFECT ON MOTOR ACTIVITY IN RATS.
206787 03-04

FLUPENTHIXOL DECANOATE IN PSYCHOTIC ADULTS -- PILOT STUDY.
209071 03-08

PROLONGED NEUROLEPTIC EFFECT OF ALPHA-FLUPENTHIXOL DECANOATE IN OIL.
210893 03-03

TESTING ANATENSOL DECANOATE, A MAJOR NEUROLEPTIC, AT THE IXELLES GUIDANCE CENTER.
212165 03-09

A STUDY OF FLUPENTHIXOL DECANOATE AND PIPOTIAZINE UNDECYLENATE IN SCHIZOPHRENICS.
212238 03-08

CLINICAL STUDY OF FIVE DEPOT NEUROLEPTICS, COMPARISON OF ACTIVITY PROFILES OF FLUPHENAZINE DECANOATE, FLUSPIRILENE, PENFLURIDOL, PERPHENAZINE ENANTHATE AND PIPOTHIAZINE PALMITATE.
221822 04-08

OBSERVATIONS ON THE DOSE REGIME OF FLUPHENAZINE DECANOATE IN MAINTENANCE THERAPY OF SCHIZOPHRENIA.
222602 04-17

DECARBOXYLASE
BRAIN DOPA/5-HTP DECARBOXYLASE ACTIVITY AFTER THE CHRONIC ADMINISTRATION OF L-DOPA OR 5-HYDROXY-L-TRYPTOPHAN IN NORMAL AND LESIONED CATS.
194483 01-05

ACTION OF PROBENECID ON THE CENTRAL NERVOUS SYSTEM OF THE RABBIT: II. POTENTIATION OF 5-HYDROXYTRYPTOPHAN-INDUCED HYPERTHERMIA AND SUPPRESSION OF THIS EFFECT BY A DECARBOXYLASE INHIBITOR (RO-4-4602).
196580 01-03

EFFECT OF NEUROTROPIC AGENTS ON TOTAL PYRIDOXAL PHOSPHATE AND ON THE ACTIVITY OF THE DECARBOXYLASE OF AROMATIC AMINO ACIDS AS WELL AS OF OTHER PYRIDOXAL PHOSPHATE DEPENDENT ENZYMES IN RAT BRAIN.
199785 02-03

TREATMENT OF PARKINSONS DISEASE BY COMBINING L-DOPA WITH A DECARBOXYLASE INHIBITOR.
204372 02-07

EFFECTS OF A DECARBOXYLASE INHIBITOR ON THE DOPA AND 5-HTP INDUCED CHANGES IN THE LOCOMOTOR LIKE DISCHARGE PATTERN OF RABBIT HIND LIMB NERVES.
210740 03-03

EFFECT OF THYROXINE AND CORTISOL ON BRAIN ORNITHINE DECARBOXYLASE ACTIVITY AND SWIMMING BEHAVIOR IN DEVELOPING RAT.
210933 03-03

THE EFFECT OF LSD AND 2-BROMOLSD ON THE DOPA ACCUMULATION AFTER CENTRAL AND PERIPHERAL DECARBOXYLASE INHIBITION.
217674 04-03

QUANTITATIVE MEASUREMENT OF PARKINSON DISEASE RIGOR. MYOINTEGRATIVE DRUG TRIAL IN COMBINATION WITH THE DECARBOXYLASE INHIBITING DRUG RO-8-0576.
220829 04-11

DECARBOXYLATION
RAT BRAIN REGIONAL UPTAKE AND DECARBOXYLATION OF L-DOPA FOLLOWING CAROTID INJECTION.
214323 04-03

DECELERATIONS
EFFECTS OF PREVIOUS CURARE IMMOBILIZATION ON PAVLOVIAN CONDITIONED HEART DECELERATIONS IN THE CURARIZED RAT.
219083 04-04

DECELERATOR
ANTIACCELERATOR AND DECELERATOR ACTIVITY OF ELEVEN PHENOTHIAZINE DERIVATIVES.
221740 04-03

DECENTRALIZED
INDUCTION OF TYROSINE-HYDROXYLASE ELICITED BY BETA ADRENERGIC RECEPTOR AGONISTS IN NORMAL AND DECENTRALIZED SYMPATHETIC GANGLIA: ROLE OF CYCLIC 3,5 ADENOSINE-MONOPHOSPHATE.
215688 04-03

DECEREBRATION
RIGIDITY IN RATS DUE TO ANEMIC DECEREBRATION AND THE EFFECT OF CHLORPROMAZINE.
202804 02-03

DECISIONS
PSYCHOPHARMACOLOGIC MANAGEMENT OF PATIENTS: A METHOD FOR RECORDING TREATMENT DECISIONS.
207683 03-17

DECLINE
POSTCASTRATION DECLINE IN BEHAVIOURAL RESPONSIVENESS TO INTRAHYPOTHALAMIC ANDROGEN IN DOVES.
210918 03-03

MENTAL DECLINE IN THE ELDERLY: PHARMACOTHERAPY (ERGOT ALKALOIDS VERSUS PAPAVERINE).
218306 04-11

DECOMPENSATIONS
FLUPHENAZINE ENANTHATE INDUCED DECOMPENSATIONS.
211437 03-08

DECONDITIONING
METHODS OF DECONDITIONING PERSISTING AVOIDANCE: AMPHETAMINE, CHLORPROMAZINE, AND CHLORDIAZEPOXIDE AS ADJUNCTS TO RESPONSE PREVENTION.
202987 02-04

METHODS OF DECONDITIONING PERSISTING AVOIDANCE: AMPHETAMINE AND AMOBARBITAL AS ADJUNCTS TO RESPONSE PREVENTION.
209897 03-04

DEFECTIVE
LITHIUM TREATMENT OF BEHAVIOURAL DISTURBANCES IN PATIENTS WITH DEFECTIVE INTELLECT.
205610 03-09

DEFEKTON
CLINICAL EXPERIENCE WITH CARPIPRAMINE (DEFEKTON).
205592 02-08

DEFENSIVE
ON THE MECHANISM OF THE DEFENSIVE ACTION OF ACETYLCHOLINE AND SEROTONIN AGAINST THEIR CYTOTOXIC ANTAGONISTS.
219663 04-03

DEFICIENT
PYRITHIOXINE (ENCEPHABOL) IN MENTALLY DEFICIENT CHILDREN (A TRIAL ON 50 CASES).
194554 01-11

DEFICIENT BRIGHTNESS DISCRIMINATION ACQUISITION PRODUCED BY DAILY INTRACRANIAL INJECTIONS OF PENICILLIN IN RATS.
202758 02-04

DEFICIT
6-METHOXYTETRAHYDRO-BETA-CARBOLINE PRODUCES A RETENTION DEFICIT FOR ONE-TRIAL PASSIVE AVOIDANCE IN MICE.
217833 04-04

DEFICITS
LEARNING DEFICITS IN 4 WEEKS OLD OFFSPRING OF THE NURSING MOTHERS TREATED WITH THE NEUROLEPTIC DRUG PENFLURIDOL.
202806 02-04

ANTAGONISM BY D-AMPHETAMINE OF LEARNING DEFICITS IN RATS INDUCED BY EXPOSURE TO ANTIPSYCHOTIC DRUGS DURING EARLY POSTNATAL LIFE.
217656 04-04

DEFINITION
WHATS IN A WORD? OR GUILT BY DEFINITION.
221563 04-17

DEGENERATION
6-HYDROXYDOPAMINE INDUCED DEGENERATION OF NORADRENALINE NEURONS IN THE SCORBUTIC GUINEA-PIG.
195449 01-03

EVIDENCE THAT PUNCTUATE INTRACEREBRAL ADMINISTRATION OF 6-HYDROXYDOPAMINE FAILS TO PRODUCE SELECTIVE NEURONAL DEGENERATION: COMPARISON WITH COPPER SULFATE AND FACTORS GOVERNING THE DEPORTMENT OF FLUIDS INJECTED INTO BRAIN.
197931 01-03

DEGRADATION
EFFECT OF PHENOBARBITAL ADMINISTRATION ON ETHANOL OXIDIZING ENZYMES AND ON RATES OF ETHANOL DEGRADATION.
204386 02-03

HYDROLYTIC DEGRADATION OF METHAQUALONE.
225106 04-01

DEHYDROBENZOPERIDOL
ELECTROENCEPHALOGRAPHIC FINDINGS ON THE ACTION OF FENTANYL AND DEHYDROBENZOPERIDOL.
205442 02-13

DEHYDROGENASE
A HISTOCHEMICAL ANALYSIS OF THE INFLUENCE OF SOME PSYCHOTROPIC SUBSTANCES ON THE DEHYDROGENASE ACTIVITY OF VARIOUS BRAIN STRUCTURES.
219498 04-03

DEITERS
THE EFFECTS OF DIPHENYLAMINOETHANOL (DPAE) AND LIDOCAINE ON CEREBELLAR INHIBITION DEITERS NEURONS. (PH.D. DISSERTATION).
196259 01-03

DELAYED
INHIBITORY AND DISINHIBITORY EFFECTS OF NITRAZEPAM, DIAZEPAM AND FLURAZEPAM HYDROCHLORIDE ON DELAYED MATCHING BEHAVIOUR IN MONKEYS (MACACA-MULATTA).
199957 02-04

DELAYED IDIOSYNCRATIC PSYCHOSIS WITH DIPHENYLHYDANTOIN.
211425 03-15

DELINEATING
PSYCHOPHARMACOLOGICAL THERAPY AND THE PROBLEMS OF DELINEATING BORDERLINE FORMS OF NEUROPSYCHIC DISORDERS.
212431 03-17

DELINQUENCY
TREATMENT OF SEXUAL DELINQUENCY WITH ANDROCUR (CYPROTERONE ACETATE).
203496 02-17

D-AMPHETAMINE AND DELINQUENCY: HYPERKINESIS PERSISTING
206143 03-14

DELIRIOUS
ON THE PATHOGENESIS OF DELIRIOUS STATES.
207196 03-15

DELIRIUM
STUDIES ON ANTIDIURETIC ACTIVITIES AND ON PORTER-SILBERS CHROMOGENS CONTENT IN PLASMA OF PATIENTS WITH ALCOHOLIC DELIRIUM OR WITH ACUTE PHENOTHIAZINE INTOXICATIONS.
203741 02-15

THE ACTION OF SULPIRIDE IN PURE INTERPRETIVE DELIRIUM.
212492 03-09

REVERSAL OF DELIRIUM INDUCED BY TRICYCLIC ANTIDEPRESSANT DRUGS WITH PHYSOSTIGMINE.
213708 04-15

ON THE INFLUENCE OF APROTINIUM (TRASYLOL) IN THE TREATMENT OF ALCOHOL DELIRIUM.
215698 04-11

VISUAL HALLUCINATIONS AND DELIRIUM DURING TREATMENT WITH AMANTADINE (SYMMETREL).
215858 04-11

DELIRIUM-TREMENS
OUR EXPERIENCE WITH THE TREATMENT OF DELIRIUM-TREMENS WITH DIAZEPAM.
205639 03-11

PSYCHOPATHOGENIC ASPECTS IN ACUTE PSYCHOORGANIC SYNDROMES (RELATIONSHIPS BETWEEN DRUG DEPENDENCE AND DELIRIUM-TREMENS TYPE SYNDROMES).
209063 03-15

DELTA1-TETRAHYDROCANNABINOL
CANNABINOL-7-OIC ACID: A METABOLITE OF DELTA1-TETRAHYDROCANNABINOL IN THE RHESUS MONKEY.
195114 01-03

EFFECT OF DELTA1-TETRAHYDROCANNABINOL AND PROPRANOLOL ON OUABAIN INDUCED ARRHYTHMIAS.
197486 01-03

BRAIN LEVELS AND RELATIVE POTENCY OF THE 1,2 DIMETHYLHEPTYL ANALOGUE OF DELTA1-TETRAHYDROCANNABINOL IN MICE.
198605 02-01

INHIBITION OF DELTA1-TETRAHYDROCANNABINOL OF NA+-K+ TRANSPORT ATPASE FROM RAT ILEUM. PRELIMINARY REPORT.
211099 03-03

METABOLISM OF DELTA1-TETRAHYDROCANNABINOL BY RATS TOLERANT TO CANNABIS.
211100 03-03

METABOLISM OF DELTA1-TETRAHYDROCANNABINOL BY THE RAT IN VIVO AND IN VITRO.
211112 03-03

EFFECTS OF VARIOUS PSYCHOACTIVE DRUGS ON THE METABOLISM OF DELTA1-TETRAHYDROCANNABINOL BY RATS IN VITRO AND IN VIVO.
217672 04-03

TRANSFORMATION OF DELTA1-TETRAHYDROCANNABINOL (THC) BY RABBIT LIVER MICROSOMES.
217817 04-03

DELTA1-TETRAHYDROCANNABINOLS

BINDING OF (+) AMPHETAMINE AND (-) DELTA1-TETRAHYDROCANNABINOLS AND (-) 7-HYDROXY-DELTA1-TETRAHYDROCANNBINOL TO BLOOD CELLS AND PLASMA PROTEINS IN MAN.
217878 04-13

DELTA6-TETRAHYDROCANNABINOL

EEG SPECTRAL ANALYSIS FOR THE EVALUATION OF THE CENTRAL EFFECTS OF DELTA6-TETRAHYDROCANNABINOL IN RABBITS.
217467 04-03

DELTA8-THC

EFFECT OF DELTA8-THC ON ALCOHOL-INDUCED SLEEPING TIME IN THE RAT.
200041 02-03

DISCRIMINATIVE RESPONSE CONTROL PRODUCED WITH HASHISH, TETRAHYDROCANNABINOLS (DELTA8-THC AND DELTA9-THC), AND OTHER DRUGS.
202720 02-12

EFFECTS OF DELTA8-THC ON DISSOCIATION OF CONDITIONED AVOIDANCE RESPONDING IN TOLERANT AND NONTOLERANT RATS.
202969 02-04

ANTICONVULSANT ACTIVITIES OF DELTA8-THC AND DELTA9-TETRAHYDROCANNABINOL AND URIDINE.
213374 04-03

DELTA9-TETRAHYDROCANNABINOL

ABSENCE OF TOLERANCE TO THE HYPOTENSIVE EFFECTS OF DELTA9-TETRAHYDROCANNABINOL IN HYPERTENSIVE RATS.
193419 01-03

MARIHUANA METABOLITES IN URINE OF MAN: III. UNCHANGED DELTA9-TETRAHYDROCANNABINOL.
195053 01-13

A STUDY OF THE DEVELOPMENT OF TOLERANCE TO AN ANTICONVULSANT EFFECT OF DELTA9-TETRAHYDROCANNABINOL AND CANNABIDIOL.
195117 01-03

PHYSOSTIGMINE ATTENUATION OF DELTA9-TETRAHYDROCANNABINOL INDUCED HYPERTHERMIA IN RATS.
195539 01-03

THE INTERACTION OF DELTA9-TETRAHYDROCANNABINOL AND D-AMPHETAMINE IN AGGREGATED MICE.
196227 01-04

TOLERANCE TO THE HYPOTHERMIC AND AGGRESSION ATTENUATING EFFECT OF DELTA8- AND DELTA9-TETRAHYDROCANNABINOL IN MICE.
197866 01-04

CANNABIDIOL INTERFERES WITH THE EFFECTS OF DELTA9-TETRAHYDROCANNABINOL IN MAN.
197867 01-14

EFFECTS OF MESCALINE, DELTA9-TETRAHYDROCANNABINOL AND PENTOBARBITAL ON THE AUDITORY EVOKED RESPONSES IN THE CAT.
197990 01-03

ANTICONVULSANT PROPERTIES OF DELTA9-TETRAHYDROCANNABINOL AND OTHER CANNABINOIDS.
198021 01-03

BIOCHEMICAL CORRELATES IN MOUSE-KILLING BEHAVIOR OF THE RAT BRAIN: BRAIN ACETYLCHOLINE AND ACETYLCHOLINESTERASE AFTER ADMINISTRATION OF DELTA9-TETRAHYDROCANNABINOL.
199807 02-03

ANTICONVULSANT ACTIVITY OF DELTA9-TETRAHYDROCANNABINOL AND ITS 11 HYDROXY AND 8ALPHA,11 DIHYDROXY METABOLITES IN THE FROG.
200035 02-03

EFFECTS OF CANNABIDIOL AND DELTA9-TETRAHYDROCANNABINOL ON OPERANT BEHAVIOR.
200036 02-04

ACUTE AND CHRONIC EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON FOOD INTAKE BY RATS.
200043 02-04

STRUCTURE-ACTIVITY RELATIONSHIPS IN MAN OF CANNABIS CONSTITUENTS, AND HOMOLOGS AND METABOLITES OF DELTA9-TETRAHYDROCANNABINOL.
202192 02-02

THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON THE UPTAKE AND RELEASE OF 14C-DOPAMINE FROM CRUDE STRIATAL SYNAPTOSOMAL PREPARATIONS.
202775 02-03

EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON FREE AMINO ACIDS IN BRAIN.
205625 03-03

ANALGESIC EFFECT OF DELTA9-TETRAHYDROCANNABINOL.
209787 03-07

ENDOCRINE EFFECTS OF CHRONIC ADMINISTRATION OF PSYCHOACTIVE DRUGS TO PREPUBERAL MALE RATS. I: DELTA9-TETRAHYDROCANNABINOL.
209840 03-03

EFFECT OF DELTA9-TETRAHYDROCANNABINOL ADMINISTRATION ON THE LIPID CONSTITUENTS OF RAT BRAIN SUBCELLULAR FRACTIONS.
210769 03-03

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL AND CANNABINOL ON OPERANT PERFORMANCE IN RATS.
210785 03-04

INTERACTION OF PHYSOSTIGMINE AND DELTA9-TETRAHYDROCANNABINOL IN MAN.
210828 03-03

IN VITRO NEUROMUSCULAR EFFECTS OF DELTA9-TETRAHYDROCANNABINOL (THC).
210866 03-03

DELTA9-TETRAHYDROCANNABINOL AND SOME CNS DEPRESSANTS: EVIDENCE FOR CROSS-TOLERANCE IN THE RAT.
210876 03-03

THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL PRETREATMENT ON KETAMINE, THIOPENTAL OR CT-1341 -- INDUCED LOSS OF RIGHTING REFLEX IN MICE.
210878 03-02

MARIHUANA METABOLITES IN URINE OF MAN: V. CHARACTERISTICS AND SEPARATION OF POLAR METABOLITES OF DELTA9-TETRAHYDROCANNABINOL.
210896 03-16

CARDIOPULMONARY TOXICITY OF DELTA9-TETRAHYDROCANNABINOL IN THE ANESTHETIZED DOG.
211015 03-05

ANTICONVULSANT ACTIVITIES OF DELTA8-THC AND DELTA9-TETRAHYDROCANNABINOL AND URIDINE.
213374 04-03

RESPIRATORY EFFECTS OF DELTA9-TETRAHYDROCANNABINOL.
215669 04-13

TOLERANCE DEVELOPMENT TO THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON CONDITIONED BEHAVIOR: ROLE OF TREATMENT INTERVAL AND INFLUENCE OF MICROSOMAL METABOLISM.
215726 04-03

EFFECTS OF HIGH DOSAGE DELTA9-TETRAHYDROCANNABINOL ON SLEEP PATTERNS IN MAN.
215740 04-14

ABSENCE OF INTERACTION BETWEEN DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) AND CANNABIDIOL (CBD) IN AGGRESSION, MUSCLE CONTROL AND BODY TEMPERATURE EXPERIMENTS IN MICE.
217474 04-04

ORAL DELTA9-TETRAHYDROCANNABINOL TOXICITY IN RATS TREATED UP TO SIX MONTHS.
217518 04-05

DIFFERENTIAL NEUROCHEMISTRY AND TEMPORAL PATTERN IN RATS TREATED ORALLY WITH DELTA9-TETRAHYDROCANNABINOL FOR PERIODS UP TO SIX MONTHS.
217519 04-04

ACUTE AND CHRONIC EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON SEIZURES IN THE GERBIL.
217673 04-03

THE TOXICOLOGIC AND TERATOLOGIC EFFECTS OF DELTA9-TETRAHYDROCANNABINOL IN THE ZEBRAFISH EMBRYO.
217697 04-05

METABOLISM AND AUTORADIOGRAPHIC DISTRIBUTION OF DELTA8- AND DELTA9-TETRAHYDROCANNABINOL IN SOME ORGANS OF THE MONKEY CALLITHRIX-JACCHUS.
217837 04-03

THE COMBINED EFFECTS OF CANNABIDIOL AND DELTA9-TETRAHYDROCANNABINOL. (PH.D. DISSERTATION).
220474 04-04

THE ACTION OF DELTA9-TETRAHYDROCANNABINOL ON CENTRAL CARDIOVASCULAR REGULATION: MECHANISM AND LOCALIZATION.
221669 04-03

THE EFFECTS OF DELTA9-TETRAHYDROCANNABINOL UPON FEAR-MOTIVATED BEHAVIOR IN SQUIRREL MONKEYS.
223040 04-04

PHYSOSTIGMINE INDUCED REVERSAL OF EEG AND BEHAVIORAL EFFECTS OF DELTA9-TETRAHYDROCANNABINOL.
223093 04-04

DELTA9-THC

MODIFICATION OF DELTA9-THC ACTIONS BY CANNABINOL AND CANNABIDIOL IN THE RAT.
197858 01-03

DISCRIMINATIVE RESPONSE CONTROL PRODUCED WITH HASHISH, TETRAHYDROCANNABINOLS (DELTA8-THC AND DELTA9-THC), AND OTHER DRUGS.
202720 02-12

EFFECTS OF (-)DELTA9-TRANS-TETRAHYDROCANNABINOL (DELTA9-THC) ON TESTS OF PSYCHOTICISM: A STUDY OF EYSENCKS DRUG POSTULATE ON THE EFFECTS OF HALLUCINOGENS IN RELATION TO PSYCHOTICISM.
214009 04-09

EFFECTS OF MARIHUANA (DELTA9-THC) ON BEHAVIOR PATTERNS AND SOCIAL ROLES IN COLONIES OF CBA MICE.
216494 04-04

ABSENCE OF INTERACTION BETWEEN DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) AND CANNABIDIOL (CBD) IN AGGRESSION, MUSCLE CONTROL AND BODY TEMPERATURE EXPERIMENTS IN MICE.
217474 04-04

DELTA9-THC AND NONVERBAL COMMUNICATION IN MONKEYS.
224907 04-04

DELTA9-TRANS-TETRAHYDROCANNABINOL

THE EFFECT OF (-) DELTA9-TRANS-TETRAHYDROCANNABINOL ON MYOCARDIAL CONTRACTILITY AND VENOUS RETURN IN ANESTHETIZED DOGS.
199964 02-03

SUBJECTIVE CHANGES IN VOLUNTEERS WITHOUT PRIOR EXPERIENCE OF CANNABIS INDUCED BY (-)DELTA9-TRANS-TETRAHYDROCANNABINOL.
202784 02-14

LACK OF TOLERANCE TO THE BRADYCARDIC EFFECT OF DELTA9-TRANS-TETRAHYDROCANNABINOL IN RATS.
210873 03-05

EFFECTS OF (-)DELTA9-TRANS-TETRAHYDROCANNABINOL (DELTA9-THC) ON TESTS OF PSYCHOTICISM: A STUDY OF EYSENCKS DRUG POSTULATE ON THE EFFECTS OF HALLUCINOGENS IN RELATION TO PSYCHOTICISM.
214009 04-09

DEMEDULLATION

THE EFFECT OF AN ADRENAL DEMEDULLATION AND CHEMICAL SYMPATHECTOMY (2,4,5 TRIHYDROXYPHENYLETHYLAMINE) ON THE ACQUISITION OF A ONE-WAY ACTIVE AVOIDANCE RESPONSE. (PH.D. DISSERTATION).
222736 04-04

DEMENTIA

PRESENILE DEMENTIA: FURTHER EXPERIENCE WITH AN ANTICOAGULANT PSYCHOTHERAPY REGIMEN.
195601 01-14

RNA TREATMENT OF DEMENTIA: A DOUBLE-BLIND STUDY.
197841 01-11

CLINICAL TRIAL WITH FLUPENTHIXOL (FLUANXOL) IN THE TREATMENT OF SENILE DEMENTIA.
225281 04-11

DEMETHYLDIAZEPAM

THE EFFECT OF DAILY ORAL DOSAGE OF DIAZEPAM, PLASMA CONCENTRATIONS AND METABOLIC CLEARANCE OF DIAZEPAM AND DEMETHYLDIAZEPAM ON VARIOUS CONSTITUENTS OF THE ACUTE CLINICAL ANXIETY SYNDROME.
196191 01-10

DEMONSTRATING

WAYS OF DEMONSTRATING AND DIFFERENTIATING CENTRAL NERVOUS EFFECTS OF DRUGS IN ANIMAL EXPERIMENTS.
202944 02-06

DEMONSTRATION

ADENOSINE-3-5-MONOPHOSPHATE CONTENT IN RAT CAUDATE NUCLEUS: DEMONSTRATION OF DOPAMINERGIC AND ADRENERGIC RECEPTORS.
208300 03-03

DIFFERENTIAL EFFECTS OF CAFFEINE, D-AMPHETAMINE AND METHYLPHENIDATE ON INDIVIDUAL RAPHE CELL FLUORESCENCE: A MICROSPECTROFLUORIMETRIC DEMONSTRATION.
213400 04-03

A RAPID, SIMPLE AND MORE SENSITIVE METHOD FOR THE DEMONSTRATION OF CENTRAL CATECHOLAMINE CONTAINING NEURONS AND AXONS BY GLYOXYLIC ACID INDUCED FLUORESCENCE: I. SPECIFICITY.
217550 04-16

SCHEDULE INDUCED AGGRESSION IN LABORATORY RATS: DEMONSTRATION AND CONTROL THROUGH SODIUM AMOBARBITAL. (PH.D. DISSERTATION).
220644 04-04

DENERVATED

SENSITIVITY OF DENERVATED CEREBRAL CORTEX TO CHOLINOMIMETICS.
199769 02-03

DENERVATION

COMPARISON BETWEEN THE EFFECTS PRODUCED BY CHRONIC DENERVATION AND BY COCAINE ON THE SENSITIVITY TO, AND ON THE DISPOSITION OF, NORADRENALINE IN ISOLATED SPLEEN STRIPS.
193139 01-03

A COMPARISON OF THE EFFECTS OF (+) AMPHETAMINE, COCAINE AND DENERVATION ON THE RESPONSES OF THE ISOLATED VAS-DEFERENS OF THE GUINEA-PIG TO NOREPINEPHRINE AND ACETYLCHOLINE.
197495 01-03

NEONATAL CHEMICAL SYMPATHECTOMY: FUNCTIONAL CONTROL OF DENERVATION OF THE VASCULAR SYSTEM AND TISSUE NORADRENALINE LEVEL IN THE RAT AFTER 6-HYDROXYDOPAMINE.
197584 01-03

BEHAVIOURAL SUPERSENSITIVITY TO APOMORPHINE FOLLOWING CEREBRAL DOPAMINERGIC DENERVATION BY 6-HYDROXYDOPAMINE.
217527 04-03

DENSITY

DIFFERENTIAL EFFECTS OF CHLORPROMAZINE, IMIPRAMINE, NITRAZEPAM AND AMOBARBITAL ON REM SLEEP AND REM DENSITY IN MAN.
215955 04-14

DENTAL

ANXIOUS DENTAL PATIENTS AS MODELS OF PSYCHOPATHOLOGY.
198089 02-11

DEOXYCORTICOSTERONE

EFFECTS OF ACTH, DEXAMETHASONE AND DEOXYCORTICOSTERONE ON AVERSIVE THRESHOLD OF RATS.
221766 04-04

DEPAKINE

DIPROPYLACETIC ACID (DEPAKINE) IN EXPERIMENTAL EPILEPSY IN THE ALERT CAT.
225529 04-02

DEPENDENCE

STEREOCHEMICAL DEPENDENCE OF PHARMACOLOGICAL ACTIVITY IN A SERIES OF OPTICALLY ACTIVE N-METHYLATED BARBITURATES.
193140 01-01

ACUTE TOLERANCE, AND DEPENDENCE IN GUINEA-PIG ILEUM.
197304 01-03

THE CONCEPT OF THE QUASI-ABSTINENCE EFFECT AND ITS USE IN THE INVESTIGATION OF DEPENDENCE MECHANISMS.
202194 02-13

THE PENTOBARBITAL TEST DOSE FOR DEPRESSANT DRUG DEPENDENCE: A REEVALUATION IN TERMS OF ALCOHOL CONSUMPTION.
202883 02-17

TRYPTOPHAN METABOLISM EXAMINATIONS IN OLIGOPHRENIC CHILDREN. FIRST REPORT: RESULTS OF THE EXCRETION OF KYNURENINE AND XANTHURENIC ACID AFTER TRYPTOPHAN LOADING AND THEIR DEPENDENCE UPON THE SUPPLY.
203645 02-13

PSYCHIATRIC INVESTIGATION OF DRUG DEPENDENCE.
208761 03-17

PSYCHOPATHOGENIC ASPECTS IN ACUTE PSYCHOORGANIC SYNDROMES (RELATIONSHIPS BETWEEN DRUG DEPENDENCE AND DELIRIUM-TREMENS TYPE SYNDROMES).
209063 03-15

THYROXINE-LIKE EFFECTS OF ZINC ON BRAIN AND BEHAVIOUR WITH FIRM DEPENDENCE ON SEVERAL HORMONES.
213434 04-04

PROPRANOLOL IN THE TREATMENT OF OPIATE DEPENDENCE -- A CONTROLLED STUDY.
217549 04-14

AN EXPERIMENTAL ANALYSIS OF BEHAVIORAL FACTORS IN DRUG DEPENDENCE.
225156 04-04

DEPENDENCY

DRUG ABUSE AND DRUG DEPENDENCY. A COMPENDIUM FOR MEDICAL DOCTORS.
204468 02-17

EFFECTS OF OVERTRAINING UPON DRUG STATE DEPENDENCY IN DISCRIMINATION LEARNING IN WHITE RATS.
209866 03-04

TEGRETOL DEPENDENCY AND DIVERSION OF THE SENSE OF TASTE.
225486 04-14

DEPENDENT

INHIBITION OF SYNAPTIC VESICULAR MG++ DEPENDENT ATPASE (STENIN) BY ANTIPSYCHOTIC PHENOTHIAZINES.
195054 01-03

ALTERATIONS IN THE TURNOVER OF BRAIN NOREPINEPHRINE AND DOPAMINE IN ALCOHOL DEPENDENT RATS.
196805 01-03

THE SENSITIVITY OF BARBITONE DEPENDENT AND WITHDRAWN RATS TO TREMORGENIC DRUGS.
197303 01-03

EFFECT OF NEUROTROPIC AGENTS ON TOTAL PYRIDOXAL PHOSPHATE AND ON THE ACTIVITY OF THE DECARBOXYLASE OF AROMATIC AMINO ACIDS AS WELL AS OF OTHER PYRIDOXAL PHOSPHATE DEPENDENT ENZYMES IN RAT BRAIN.
199785 02-03

GENOTYPE DEPENDENT ELECTROENCEPHALOGRAPHIC, BEHAVIORAL AND ANALGESIC CORRELATES OF MORPHINE: AN ANALYSIS IN NORMAL MICE AND IN MICE WITH SEPTAL LESIONS.
203520 02-04

PROTECTION AGAINST EFFECTS OF BRAIN DAMAGE BY CATECHOLAMINE DEPLETION IS TEST DEPENDENT.
203579 02-04

ELIMINATION OF LITHIUM DEPENDENT ON AGE IN HEALTHY PEOPLE AND PATIENTS SUFFERING FROM RENAL INSUFFICIENCY.
205043 02-13

MATURATION OF THE ADRENAL MEDULLA -- III: PRACTICAL AND THEORETICAL CONSIDERATIONS OF AGE DEPENDENT ALTERATIONS IN KINETICS OF INCORPORATION OF CATECHOLAMINES AND NONCATECHOLAMINES.
205852 03-03

MG++ DEPENDENT ADENOSINE-TRIPHOSPHATASE ACTIVITY IN ERYTHROCYTE GHOSTS OF SCHIZOPHRENIC PATIENTS.
206332 03-08

EFFECT OF LITHIUM ON MAGNESIUM DEPENDENT ENZYMES.
209351 03-03

EVIDENCE THAT 5-METHOXYDIMETHYLTRYPTAMINE IS A SPECIFIC SUBSTRATE FOR MAO-A IN THE RAT: IMPLICATIONS FOR THE INDOLEAMINE DEPENDENT BEHAVIORAL SYNDROME.
210817 03-04

DRUGS AND PUNISHED RESPONDING. V. EFFECTS OF DRUGS ON RESPONDING SUPPRESSED BY RESPONSE DEPENDENT AND RESPONSE INDEPENDENT ELECTRIC SHOCK.
215722 04-04

RATE DEPENDENT EFFECTS OF DRUGS. II. EFFECTS OF SOME MAJOR TRANQUILIZERS ON MULTIPLE FIXED-RATIO, FIXED-INTERVAL SCHEDULE PERFORMANCE.
217458 04-04

LITHIUM AND MAGNESIUM DEPENDENT PROCESSES.
223318 04-09

DEPLETING

EFFECTS ON SHOCK-ELICITED AGGRESSION IN MICE OF PREFERENTIALLY PROTECTING BRAIN MONOAMINES AGAINST THE DEPLETING ACTION OF RESERPINE.
195452 01-04

CATECHOLAMINE DEPLETING ACTION OF PHYSOSTIGMINE IN THE RAT BRAIN.
197575 01-03

EFFECT OF PHENOBARBITAL ON THE METABOLISM AND SEROTONIN DEPLETING ACTION OF 4-CHLORODIFLUOROAMPHETAMINE IN RATS.
210922 03-03

BEHAVIORAL AND NEUROCHEMICAL EFFECTS OF MORPHINE OR AMPHETAMINE AFTER CHRONIC PRETREATMENT WITH CATECHOLAMINE DEPLETING AGENTS. (PH.D. DISSERTATION).
211746 03-03

DEPLETION

SYMPATHETIC NERVE ACTIVITY AFTER NORADRENALINE DEPLETION AND ITS ALTERATION BY CLONIDINE.
197947 01-03

ACTION OF RESERPINE IN MORPHINE TOLERANT RATS: ABSENCE OF AN ANTAGONISM OF CATECHOLAMINE DEPLETION.
199277 02-03

PROTECTION AGAINST EFFECTS OF BRAIN DAMAGE BY CATECHOLAMINE DEPLETION IS TEST DEPENDENT.
203579 02-04

LONG-LASTING DEPLETION OF BRAIN SEROTONIN BY 4-CHLOROAMPHETAMINE IN GUINEA-PIGS.
203580 02-03

INCREASED FIXED-RATIO PERFORMANCE AND DIFFERENTIAL D- AND L-AMPHETAMINE ACTION FOLLOWING NOREPINEPHRINE DEPLETION BY INTRAVENTRICULAR 6-HYDROXYDOPAMINE.
204482 02-04

LOSS OF BODY WEIGHT AS A PREDICTOR OF RESERPINE INDUCED AMINE DEPLETION.
217661 04-03

LACK OF EFFECT OF PROTRIPTYLINE ON THE 6-HYDROXYDOPAMINE INDUCED NORADRENALINE DEPLETION IN THE RAT SPINAL CORD.
217824 04-03

BEHAVIORAL CORRELATES OF SEROTONIN DEPLETION.
225159 04-04

DEPLETORS

COMPARISON OF THE OXIME AND THE HYDROXYLAMINE DERIVATIVES OF 4-CHLOROAMPHETAMINE AS DEPLETORS OF BRAIN 5-HYDROXYINDOLES.
200004 02-03

DEPOLARIZATION

DEPOLARIZATION, DESENSITIZATION AND THE EFFECTS OF TUBOCURARINE AND NEOSTIGMINE IN CULTURED SKELETAL MUSCLE.
193447 01-03

DEPORTMENT

EVIDENCE THAT PUNCTUATE INTRACEREBRAL ADMINISTRATION OF 6-HYDROXYDOPAMINE FAILS TO PRODUCE SELECTIVE NEURONAL DEGENERATION: COMPARISON WITH COPPER SULFATE AND FACTORS GOVERNING THE DEPORTMENT OF FLUIDS INJECTED INTO BRAIN.
197931 01-03

DEPOT

ASPECTS OF NEUROLEPTIC DEPOT THERAPY WITH SPECIAL CONSIDERATION OF CLINICAL EXPERIENCE WITH THE PERORAL DEPOT PREPARATION PENFLURIDOL (R-16341 - JANSSEN).
202785 02-07

THE DEPOT COMPOUNDS MODITEN (FLUPHENAZINE) AND IMAP (FLUSPIRILENE) IN CLINICAL PRACTICE.
205584 02-08

RESULTS OF THERAPY WITH LYOGEN DEPOT IN SCHIZOPHRENIC ILLNESS.
208622 03-08

THE LONG-TERM MAINTENANCE TREATMENT OF SCHIZOPHRENIC OUTPATIENTS WITH DEPOT FLUPENTHIXOL.
212491 03-08

CLINICAL STUDY OF FIVE DEPOT NEUROLEPTICS, COMPARISON OF ACTIVITY PROFILES OF FLUPHENAZINE DECANOATE, FLUSPIRILENE, PENFLURIDOL, PERPHENAZINE ENANTHATE AND PIPOTHIAZINE PALMITATE.
221822 04-08

THE DEPOT FLUPHENAZINES: A REAPPRAISAL AFTER 10 YEARS CLINICAL EXPERIENCE.
225325 04-08

DEPRENIL

ENHANCEMENT OF SELF-STIMULATION BY DEPRENIL: EVIDENCE FOR A ROLE OF DOPAMINE NEURONES IN REWARD.
213432 04-04

DEPRESSANT

NEUROPHARMACOLOGICAL STUDIES OF EFFECT OF NEW CENTRAL DEPRESSANT, 8-CHLOR-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D40TA) ON EEG AND CENTRAL SYMPATHETIC ACTIVATING MECHANISM IN CATS.
195549 01-03

LOCUS OF CENTRAL DEPRESSANT ACTION OF FLUNITRAZEPAM.
199811 02-03

THE PENTOBARBITAL TEST DOSE FOR DEPRESSANT DRUG DEPENDENCE: A REEVALUATION IN TERMS OF ALCOHOL CONSUMPTION.
202883 02-17

THE EFFECTS OF STIMULANT AND DEPRESSANT DRUGS ON VERBAL CONDITIONING.
209260 03-14

MODULATION OF THE RESPIRATORY DEPRESSANT EFFECT OF ETHANOL BY 5-HYDROXYTRYPTAMINE.
210751 03-03

DIFFERENTIAL SENSITIVITY OF PRIMARY AND SECONDARY SPINDLE AFFERENTS TO DEPRESSANT DRUGS.
210801 03-03

COMPARATIVE STUDIES ON THE MEMBRANE ACTIONS OF DEPRESSANT DRUGS: THE ROLE OF LIPOPHILICITY IN INHIBITION OF BRAIN SODIUM AND POTASSIUM STIMULATED ATPASE.
210818 03-03

A POTENT DEPRESSANT ACTION OF ADENINE DERIVATIVES ON CEREBRAL CORTICAL NEURONES.
210932 03-03

ANTAGONISM OF DEPRESSANT ACTIVITY OF ETHANOL BY DH-524; A COMPARATIVE STUDY WITH BEMEGRIDE, DOXAPRAM AND D-AMPHETAMINE (38640).
213282 03-03

CYANOGEN CONDENSATIONS AS A ROUTE TO 3-AMINO-2-IMINOBENZOTHIAZIN-4-OHES WITH CNS DEPRESSANT POTENTIAL.
222870 04-02

DEPRESSANTS

THE EFFECTS OF SOME CNS DEPRESSANTS ON RATS EXPOSED TO IONIZING IRRADIATION.
197581 01-03

ACTIVATION OF BRAIN MONOAMINEOXIDASE BY SOME CNS DEPRESSANTS.
204864 02-03

DELTA9-TETRAHYDROCANNABINOL AND SOME CNS DEPRESSANTS: EVIDENCE FOR CROSS-TOLERANCE IN THE RAT.
210876 03-03

EFFECTS OF HYPERBARIC CONDITIONS ON THE RESPONSE OF ANIMALS TO CENTRAL NERVOUS SYSTEM STIMULANTS AND DEPRESSANTS.
210877 03-03

ACTION OF STRYCHNINE AND CENTRAL DEPRESSANTS ON THE CEREBELLO-RUBRAL SYSTEM.
210881 03-03

DEPRESSED

PREDICTING TREATMENT RESPONSIVENESS RESISTIVENESS IN A POPULATION OF DEPRESSED PATIENTS.
196040 01-17

THE EFFECT OF LITHIUM ON URINARY MHPG IN UNIPOLAR AND BIPOLAR DEPRESSED PATIENTS. (UNPUBLISHED PAPER).
196042 01-09

DRUG THERAPY OF DEPRESSED OUTPATIENTS.
198079 02-10

DRUG TREATMENT OF DEPRESSED OUTPATIENTS.
198083 02-10

EEG CHANGES WITH LITHIUM IN DEPRESSED PATIENTS.
198100 02-10

RESPONSE OF DEPRESSED PATIENTS TO METHYLAMPHETAMINE.
205318 02-09

LONGITUDINAL STUDY OF THE EFFECTS OF LITHIUM CARBONATE ON THE SLEEP OF HOSPITALIZED DEPRESSED PATIENTS.
206333 03-09

THE RELATIONSHIP BETWEEN RESPONSE TO PHENELZINE AND ACETYLATOR STATUS IN DEPRESSED PATIENTS.
206366 03-09

CLINICAL EXPERIENCES IN TREATING DEPRESSED PATIENTS WITH A COMBINATION OF TRICYCLIC DRUGS AND THYROID EXTRACT.
209144 03-09

CLINICAL ELECTROENCEPHALOGRAPHIC DATA IN DEPRESSED PATIENTS TREATED WITH ANAFRANIL.
209148 03-09

PATTERNS OF SYMPTOM CHANGE IN ANXIOUS DEPRESSED OUTPATIENTS TREATED WITH DIFFERENT DRUGS.
209904 03-10

A FOLLOWUP STUDY OF FEMALE DEPRESSED OUTPATIENTS WHO COMPLETE A RANDOMIZED DOUBLE-BLIND PROPHYLACTIC TRIAL OF ANTIDEPRESSANTS AND HIGH CONTACT. (PH.D. DISSERTATION).
212518 03-09

THE OUTCOME OF DOTHIEPIN TREATMENT IN 1,900 DEPRESSED PATIENTS.
215700 04-09

THE EFFECT OF LITHIUM ON URINARY MHPG IN UNIPOLAR AND BIPOLAR DEPRESSED PATIENTS.
221045 04-09

DEPRESSED WOMEN ONE YEAR AFTER MAINTENANCE THERAPY.
224766 04-09

DEPRESSING

ANTAGONISM OF PSYCHOSTIMULANT 2 PHENYLDIMETHYLTETRAHYDROOXAZINE HYDROCHLORIDE (G-130) TO CENTRAL NERVOUS SYSTEM DEPRESSING DRUGS: MONOAMINEOXIDASE INHIBITORY ACTIVITY AND NOREPINEPHRINE AND SEROTONIN INDUCED CHANGES, COMPARISON WITH DL-AMPHETAMINE.
221267 04-03

DEPRESSION

DEPRESSION BY AMANTADINE OF TREMOR INDUCED BY RESERPINE AND OXOTREMORINE IN THE RAT.
193282 01-04

PROTIRELIN (TRH) IN DEPRESSION.
194827 01-14

AMENORRHEA IN ENDOGENOUS DEPRESSION.
195040 01-09

NORADRENALINE AND 5-HYDROXYTRYPTAMINE METABOLISM IN SIX AREAS OF RAT BRAIN DURING POST-AMPHETAMINE DEPRESSION.
195437 01-03

SURMONTIL -- IN DEPRESSION
195616 01-10

TRIMIPRAMINE (SURMONTIL) -- CLINICAL EVALUATION IN DEPRESSION.
195617 01-09

THYROTROPIN-RELEASING HORMONE (TRH) IN DEPRESSION: A PRELIMINARY REPORT.
195929 01-10

TREATMENT OF RESISTANT DEPRESSION.
196036 01-17

RECENT THERAPEUTIC ASPECTS OF DEPRESSION ESPECIALLY ON THE DRUG THERAPY.
196149 01-09

THE EFFECT OF LITHIUM CARBONATE IN COMBINATION WITH TRICYCLIC ANTIDEPRESSANTS IN ENDOGENOUS DEPRESSION: A DOUBLE-BLIND, MULTICENTER TRIAL.
197035 01-09

TRUE AND APPARENT SIDE-EFFECTS IN A CONTROLLED TRIAL OF CHLORPROMAZINE AND IMIPRAMINE IN DEPRESSION.
197856 01-09

POTENTIATION OF TETRABENAZINE-INDUCED BEHAVIOURAL DEPRESSION BY IMIPRAMINE ON A DISCRETE TRIAL AVOIDANCE ESCAPE SCHEDULE.
197859 01-04

NIMH-PRB OUTPATIENT TREATMENT OF DEPRESSION.
198078 02-10

DRUG THERAPY IN DEPRESSION.
198084 02-09

DEPRESSION TREATED WITH CHLORIMIPRAMINE WITH SPECIAL ANALYSIS OF CHANGE IN BLOOD PRESSURE BY INFUSION.
199212 02-09

DEPRESSION, ELATION, AND LITHIUM CARBONATE RESPONSES IN MANIC PATIENT SUBGROUPS.
199631 02-09

LITHIUM RESPONSE IN DEPRESSION AS PREDICTED BY UNIPOLAR/BIPOLAR ILLNESS, AVERAGE EVOKED RESPONSE, CATECHOL-O-METHYLTRANSFERASE AND FAMILY HISTORY. (UNPUBLISHED PAPER).
201000 02-09

TREATMENT OF MASKED DEPRESSION.
201655 02-09

A DOUBLE-BLIND COMPARISON OF CLOMIPRAMINE WITH AMITRIPTYLINE IN DEPRESSION.
202178 02-10

RECENT ADVANCES IN THE TREATMENT OF DEPRESSION.
202390 02-10

THE BIOCHEMISTRY OF THERAPY-RESISTANT DEPRESSION: CONTRIBUTIONS TO BIOCHEMISTRY.
203592 02-09

TREATMENT OF RESISTANT DEPRESSION: CONTRIBUTIONS TO GENETIC ASPECTS.
203596 02-09

DO ANTIHYPERTENSIVE DRUGS REALLY CAUSE DEPRESSION?
204236 02-15

CLINICAL TRIAL OF CLOCAPRAMINE IN NEUROTIC PATIENTS WHO HAD TROUBLES IN EVERYDAY LIFE OWING TO SEVERE ANXIETY, IRRITABILITY AND DEPRESSION.
204464 02-10

RECENT ADVANCES IN THE TREATMENT OF DEPRESSION.
205155 02-09

DOUBLE-BLIND TRIAL OF SINTAMIL IN DEPRESSION.
206043 03-10

LITHIUM TREATMENT OF DEPRESSION.
206146 03-09

AN ANIMAL MODEL OF DEPRESSION.
206339 03-04

GILLES-DE-LA-TOURETTES SYNDROME AND DEPRESSION: A CASE REPORT.
206939 03-09

AMINE PRECURSORS AND DEPRESSION.
207444 03-13

FOUR CASES OF DEPRESSION TREATED BY INDOLEACETIC ACID.
207554 03-09

RELATIONSHIP BETWEEN SERUM LITHIUM LEVEL AND CLINICAL RESPONSE TO DEPRESSION TREATED WITH LITHIUM CARBONATE.
207719 03-09

TREATMENT OF INTRACTABLE DEPRESSION.
208918 03-17

ANTIHYPERTENSIVE DRUGS AND DEPRESSION.
209082 03-09

RELATIVE SAFETY OF AMITRIPTYLINE IN MAINTENANCE TREATMENT OF DEPRESSION.
209438 03-15

A COMPARISON OF A NEW TRANQUILIZER, SULPIRIDE AND OXAZOLAM ON PSYCHOSOMATIC DISEASES, NEUROSIS AND MASKED DEPRESSION USING DOUBLE-BLIND METHOD.
210180 03-11

A DOUBLE-BLIND COMPARISON OF LITHIUM CARBONATE AND IMIPRAMINE IN THE TREATMENT OF DEPRESSION.
210241 03-09

THE EFFECT OF DRUGS WITH ANTIDEPRESSANT ACTIVITY UPON THE HYPOTHERMIA AND BEHAVIOURAL DEPRESSION INDUCED IN MICE BY PIMOZIDE OR CENTRALLY ADMINISTERED NORADRENALINE.
210762 03-04

CHANGES IN THE NEURONAL PROTEIN LABELLING INDUCED BY POTASSIUM IONS IN VIVO (SPREADING DEPRESSION).
210779 03-03

ELECTROCONVULSIVE SHOCK: SUSTAINED DECREASE IN NOREPINEPHRINE UPTAKE AFFINITY IN A RESERPINE MODEL OF DEPRESSION.
210830 03-03

A STUDY OF AN ANIMAL MODEL OF DEPRESSION BY THE CONDITIONED REFLEX TECHNIQUE.
210853 03-04

COMPARISON OF THE EFFECTS OF D-AMPHETAMINE AND L-AMPHETAMINE IN REVERSING DEPRESSION OF MOUSE LOCOMOTOR ACTIVITY CAUSED BY RESERPINE.
210869 03-03

PHARMACOTHERAPY OF DEPRESSION -- A CRITICAL REVIEW.
211432 03-09

STUDY OF 220 OBSERVATIONS OF LITHIUM THERAPY IN DEPRESSION CASES IN TEHERAN.
212211 03-09

THERAPEUTIC STUDIES OF DEPRESSION WITH L-DOPA.
212947 03-09

HUMAN GROWTH HORMONE RESPONSE TO LEVODOPA: RELATION TO MENOPAUSE, DEPRESSION, AND PLASMA DOPA CONCENTRATION.
213918 04-09

GROWTH HORMONE AND PROLACTIN RELEASE AFTER INJECTION OF THYROTROPIN-RELEASING HORMONE IN PATIENTS WITH DEPRESSION.
214885 04-13

ANTAGONISM OF NICOTINIC ACID AND OTHER KYNURENINES TO ANTIDEPRESSANTS: ONE OF THE PROBABLE REASONS FOR THE THERAPY-RESISTANCE IN DEPRESSION?.
215074 04-17

FROM SAD TO GLAD: KLINE ON DEPRESSION.
216706 04-17

RELATIONSHIP BETWEEN SERUM LITHIUM LEVEL AND CLINICAL RESPONSE ON DEPRESSION TREATED WITH LITHIUM CARBONATE.
217354 04-09

EFFECTS OF MAINTENANCE AMITRIPTYLINE AND PSYCHOTHERAPY ON SYMPTOMS OF DEPRESSION.
218041 04-09

REM SLEEP REDUCTION EFFECTS ON DEPRESSION SYNDROMES.
218120 04-09

TREATING DEPRESSION WITH TRANQUILIZERS: WITH DISSENTING VIEW OF LITHIUM CARBONATE THERAPY.
218123 04-09

AN ADRENERGIC DRUG IN DEPRESSION.
218771 04-10

DOUBLE-BLIND COMPARISON OF LITHIUM CARBONATE AND IMIPRAMINE IN TREATMENT OF DEPRESSION.
218772 04-09

EFFECTS OF D-PHENYLALANINE ON CLINICAL PICTURE AND PHENETHYLAMINURIA IN DEPRESSION.
218959 04-09

THYROTROPIN-RELEASING HORMONE IN DEPRESSION.
219521 04-09

TRYPTOPHAN PLUS A PYRROLASE INHIBITOR FOR DEPRESSION?.
219522 04-03

EFFECT OF OUABAIN AND PHENOBARBITAL ON OXIDATIVE METABOLIC ACTIVITY ASSOCIATED WITH SPREADING CORTICAL DEPRESSION IN CATS.
220944 04-03

DOXEPIN I.M. IN THE TREATMENT OF DEPRESSION AND ANXIETY.
221035 04-10

DOUBLE-BLIND TEST OF THREE ANTIDEPRESSANTS, FOURTH COMMUNICATION; RESULTS WITH THE HAMBURG DEPRESSION SCALE.
221289 04-11

A COMPARISON OF MAPROTILINE (LUDIOMIL) AND PLACEBO IN THE TREATMENT OF DEPRESSION.
221656 04-09

A DOUBLE-BLIND GENERAL PRACTICE TRIAL OF MAPROTILINE (LUDIOMIL) AGAINST AMITRIPTYLINE IN THE TREATMENT OF REACTIVE DEPRESSION.
221658 04-09

A COMPARISON BETWEEN DAILY AND NIGHTLY DOSE REGIMEN OF AMITRIPTYLINE AND MAPROTILINE (LUDIOMIL) IN THE TREATMENT OF REACTIVE DEPRESSION IN GENERAL PRACTICE.
221662 04-09

TREATMENT OF DEPRESSION WITH PIRAZIDOL.
224083 04-09

CLINICAL TRIAL OF OXYPERTINE IN THE TREATMENT OF PSYCHOSOMATIC DISORDERS, NEUROSIS AND DEPRESSION.
224193 04-14

CLINICAL EXPERIENCE OF THE USE OF FK-880 (SULPIRIDE) FOR DEPRESSION AND NEUROSIS.
224195 04-14

TRICYCLIC ANTIDEPRESSANTS AND TRYPTOPHAN IN UNIPOLAR DEPRESSION.
224423 04-09

DRUG PSYCHOTHERAPY INTERACTIONS IN DEPRESSION.
224767 04-10

EEG SLEEP CHANGES AS PREDICTORS IN DEPRESSION.
224769 04-09

DOSE-RESPONSE RELATIONSHIP FOR NORTRIPTYLINE IN ENDOGENOUS DEPRESSION.
224835 04-09

LITHIUM IN THE TREATMENT OF DEPRESSION.
224871 04-09

RELATIONSHIP BETWEEN DOSAGE AND RESPONSE TO LITHIUM PROPHYLAXIS IN RECURRENT DEPRESSION.
224872 04-09

LITHIUM PROPHYLAXIS OF THREE DEPRESSION SUBTYPES.
224874 04-09

A COMPARATIVE CLINICAL TRIAL OF ORG-GB-94 AND IMIPRAMINE IN THE TREATMENT OF DEPRESSION IN GENERAL PRACTICE.
225107 04-09

DEPRESSION AND ANXIETY IN HEROIN ADDICTS: A PLACEBO CONTROLLED STUDY OF DOXEPIN IN COMBINATION WITH METHADONE.
225386 04-09

DEPRESSIONS

THERAPY POSSIBILITIES FOR THERAPY-RESISTANT DEPRESSIONS.
196034 01-17

THE PSYCHIATRIST ATTITUDES AND THERAPEUTIC MEANS WHEN FACED WITH RESISTANT DEPRESSIONS.
196035 01-17

DRUG-RESISTANT DEPRESSIONS: RESPONSE TO ECT.
196037 01-17

INFLUENCE POSSIBILITIES ON THERAPY-RESISTANT LATE DEPRESSIONS.
196038 01-17

BIOCHEMICAL MONITORING IN THE THERAPY OF DEPRESSIONS.
198099 02-10

5-HYDROXYTRYPTOPHAN IN COMBINATION WITH CLOMIPRAMINE IN THERAPY RESISTANT DEPRESSIONS.
198229 02-09

WORK CAPABILITY AND TREATMENT OF REACTIVE DEPRESSIONS.
198354 02-10

OBSERVATIONS ON THE TREATMENT OF DEPRESSIONS.
200481 02-09

THERAPEUTIC-RESISTANT DEPRESSIONS: SYMPTOMS, RESISTANCE AND THERAPY.
202854 02-09

THERAPY-RESISTANT DEPRESSIONS: METHODOLOGICAL PROBLEMS. CONTRIBUTIONS TO METHODICAL QUESTIONS AND ANIMAL EXPERIMENTAL ASPECTS.
203591 02-09

THERAPY-RESISTANT DEPRESSIONS. BIOCHEMICAL AND PHARMACOLOGICAL CONSIDERATIONS: CONTRIBUTIONS TO BIOCHEMISTRY.
203593 02-09

RAPIDITY OF SYMPTOM REDUCTION IN DEPRESSIONS TREATED WITH AMITRIPTYLINE.
209437 03-09

TYPOLOGY OF DEPRESSIONS AND THERAPEUTIC BEHAVIOR OF PSYCHIATRISTS.
212215 03-17

PSYCHOPHARMACOLOGY OF BIOGENIC AMINES IN DEPRESSIONS.
213628 04-09

PHARMACOTHERAPY OF DEPRESSIONS.
216335 04-10

DEPRESSIONS AND ANTIDEPRESSANTS DURING TREATMENT WITH LONG-ACTING NEUROLEPTIC DRUGS: SIDE-EFFECTS AND THE EMERGENT METATHERAPEUTIC SYNDROME.
219694 04-15

DEPRESSIONS CAUSED BY ORAL CONTRACEPTIVES AND THEIR TREATMENT WITH ORIGEN.
224347 04-09

DEPRESSIVE

DEPRESSIVE REACTIONS ASSOCIATED WITH RESERPINE.
194511 01-15

DEPRESSIVE ILLNESS: ADRENERGIC RESPONSIVENESS AND THE EFFECT OF LITHIUM ON PLATELET ADENYLCYCLASE. (PH.D. DISSERTATION).
196260 01-13

BASIC DERIVATIVES OF DIPHENYLMETHANE WITH A DEPRESSIVE EFFECT ON THE CNS.
199209 02-02

DEPRESSIVE ILLNESS AND HYPERPARATHYROIDISM.
201239 02-15

THE CURRENT STATUS OF BIOLOGICAL CRITERIA FOR CLASSIFYING THE DEPRESSIVE DISORDERS AND PREDICTING RESPONSES TO TREATMENT.
202380 02-17

DEPRESSIVE DISORDERS.
202960 02-09

BIOCHEMICAL CRITERIA FOR CLASSIFYING DEPRESSIVE DISORDERS AND PREDICTING RESPONSES TO PHARMACOTHERAPY: PRELIMINARY FINDINGS FROM STUDIES OF NOREPINEPHRINE METABOLISM. CONTRIBUTIONS TO BIOCHEMISTRY.
203594 02-09

EXPERIMENTAL PSYCHOLOGIC AND PSYCHOPHYSIOLOGIC LONGITUDINAL PROFILE STUDIES ON DEPRESSIVE PATIENTS UNDER THYMOLEPTIC MEDICATION.
204413 02-15

FAMILY HISTORY OF MANIC-DEPRESSIVE AND ENDOGENOUS DEPRESSIVE PATIENTS AND CLINICAL EFFECT OF TREATMENT WITH LITHIUM.
205608 03-09

CEREBRAL AND PERIPHERAL CONSUMPTION OF L-5-HTP BY PATIENTS SUFFERING FROM MANIACAL, DEPRESSIVE OR PSYCHOTIC SYMPTOMS.
206834 03-10

AMITRIPTYLINE AND DEPRESSIVE STRUCTURES (ON 100 OBSERVATIONS).
207579 03-14

COMBINED THYROID (TRIIODOTHYRONINE) TRICYCLIC ANTIDEPRESSANT TREATMENT IN DEPRESSIVE STATES.
207720 03-09

DEPRESSIVE CONDITION. PERCEPTION, EVALUATION, TREATMENT.
209332 03-09

APPLICATION OF LOPRAMINE (DB-2182) FOR THE TREATMENT OF DEPRESSIVE STATE.
209395 03-11

CLINICAL EFFECTS OF LITHIUM CARBONATE ON DEPRESSIVE STATES.
209413 03-09

MAINTENANCE DOXEPIN (SINEQUAN) THERAPY FOR DEPRESSIVE ILLNESS.
209901 03-09

THERAPEUTIC EFFECTS AND MECHANISM OF ACTION OF S-ADENOSYL-L-METHIONINE (SAM) IN DEPRESSIVE SYNDROMES.
210213 03-09

A COMPARATIVE STUDY OF N-7001 (METRISIL) AND IMIPRAMINE ON A SERIES OF DEPRESSIVE PATIENTS.
212241 03-11

DEPRESSIVE REACTIONS IN THE COURSE OF CLOMIPRAMINE THERAPY USED IN THE TREATMENT OF OBSESSIONAL CONDITIONS.
214834 04-15

A COMPARISON BETWEEN MAPROTILINE (LUDIOMIL) AND AMITRIPTYLINE IN THE TREATMENT OF DEPRESSIVE REACTION IN GENERAL PRACTICE.
215058 04-14

NONPHARMACOLOGICAL FACTORS IN DRUG THERAPY: THE INTERACTION OF DOCTOR, PATIENT, AND TABLET APPEARANCE IN THE TREATMENT OF ANXIETY/DEPRESSIVE SYNDROMES.
215060 04-10

ORAL CONTRACEPTION AND INDUCED DEPRESSIVE STATES.
216902 04-14

INTERACTION OF DRUG THERAPY WITH MARITAL THERAPY IN DEPRESSIVE PATIENTS.
218769 04-10

THE ROLE OF THE AMYGDALA IN THE DEPRESSIVE ACTION OF SEROTONIN AND 5-HYDROXYTRYPTOPHAN ON THE CONDITIONED ACTIVITY OF WHITE RATS.
219328 04-04

A SINGLE DAILY DOSE OF A SUSTAINED RELEASE FORM OF AMITRIPTYLINE IN DEPRESSIVE ILLNESS.
219961 04-09

EXPERIENCE WITH IMIPRAMINE-N-OXIDE (IPNO) IN TREATING DEPRESSIVE STATES.
221209 04-09

DOUBLE-BLIND COMPARISON OF MAPROTILINE (LUDIOMIL) WITH AMITRIPTYLINE IN THE TREATMENT OF DEPRESSIVE ILLNESS.
221652 04-09

A COMPARISON BETWEEN MAPROTILINE (LUDIOMIL) AND IMIPRAMINE IN THE TREATMENT OF DEPRESSIVE ILLNESS IN THE ELDERLY.
221655 04-09

A CLINICAL TRIAL OF MAPROTILINE (LUDIOMIL) IN THE TREATMENT OF DEPRESSIVE PATIENTS IN GENERAL PRACTICE AND THE PSYCHIATRIC CLINIC.
221657 04-09

MILD DEPRESSIVE ILLNESS.
221891 04-10

ANXIETY NEUROSIS, DEPRESSIVE DISORDER AND MEPROBAMATE ADDICTION -- PSYCHIATRIC GRAND-ROUNDS, UNIV. OF CALIFORNIA, SAN-DIEGO.
222772 04-10

PLASMA LEVEL, DEPRESSIVE TYPOLOGY, CLINICAL OUTCOME.
224836 04-09

AMOXAPINE, IMIPRAMINE AND PLACEBO IN DEPRESSIVE ILLNESS.
225063 04-09

DEPRESSIVES

LITHIUM IN NONMANIC DEPRESSIVES: ANTIAGGRESSIVE EFFECT AND RED BLOOD CELL LITHIUM VALUES.
222604 04-09

DEPRESSOR

SPECIES DIFFERENCES IN ANTAGONISTIC EFFECT OF MORPHINE AGAINST DEPRESSOR RESPONSE TO DOPAMINE.
202800 02-03

POSSIBLE MECHANISMS INVOLVED IN THE DEPRESSOR RESPONSE TO DOPAMINE.
210787 03-03

DEPRIVATION

A STUDY OF THE INTERACTION BETWEEN AMPHETAMINE AND FOOD DEPRIVATION.
197854 01-04

TASTE PHENOMENA INFLUENCES ON STIMULATION OF DEPRIVATION INDUCED FLUID CONSUMPTION OF RATS.
197991 01-03

SLEEP DEPRIVATION AS A POTENTIATION OF ANTIDEPRESSIVE PHARMACOTHERAPY?
205602 03-09

DIFFERENTIAL EFFECTS OF AMPHETAMINE AND FOOD DEPRIVATION ON SELF-STIMULATION OF THE LATERAL HYPOTHALAMUS AND MEDIAL FRONTAL CORTEX.
206733 03-04

EFFECTS OF WATER DEPRIVATION IN RATS WITH POLYDIPSIA AND POLYURIA DUE TO LONG-TERM ADMINISTRATION OF LITHIUM.
210833 03-05

EFFECTS OF AMITRIPTYLINE ON HUMAN REM SLEEP AS EVALUATED BY USING PARTIAL DIFFERENTIAL REM SLEEP DEPRIVATION (PDRD).
214750 04-14

INTERRESPONSE TIME CHANGES AS A FUNCTION OF WATER DEPRIVATION AND AMPHETAMINE.
217459 04-04

POTENTIATION OF AMPHETAMINE-INDUCED AROUSAL BY FOOD DEPRIVATION: EFFECT OF HYPOTHALAMIC LESIONS.
218498 04-04

DEPRIVED

PHARMACOLOGICAL MANIPULATIONS OF BRAIN CATECHOLAMINES AND THE AGGRESSIVE BEHAVIOR INDUCED BY MARIHUANA IN REM SLEEP DEPRIVED RATS.
210325 03-04

THE EFFECTS OF PSYCHOMOTOR STIMULANTS ON STEREOTYPY AND LOCOMOTOR ACTIVITY IN SOCIALLY DEPRIVED AND CONTROL RATS.
210666 03-04

THE EFFECTS OF PSYCHOMOTOR STIMULATION ON STEREOTYPY AND LOCOMOTOR ACTIVITY IN SOCIALLY DEPRIVED AND CONTROL RATS.
213433 04-03

NICOTINE INDUCED HYPOPHAGIA AND HYPODIPSIA IN DEPRIVED AND IN HYPOTHALAMICALLY STIMULATED RATS.
225559 04-04

DERIVATIVE

A CRITICAL EVALUATION OR MOLINDONE (MOBAN): A NEW INDOLE DERIVATIVE NEUROLEPTIC.
196674 01-07

AMANTADINE AND D-145, AN AMANTADINE DERIVATIVE, DO NOT EFFECT DOPAMINE SENSITIVE ADENYLATE-CYCLASE FROM THE CAUDATE PUTAMEN OF THE RAT BRAIN.
199867 02-03

SYNTHESIS AND PRELIMINARY PHARMACOLOGY OF A NOVEL BUTYROPHENONE DERIVATIVE, ID-4708.
202862 02-02

THE SYNTHESIS AND PHARMACOLOGY OF A NOVEL BENZODIAZEPINE DERIVATIVE, 1-METHYL-5-O-FLUOROPHENYL 7-CHLORODIHYDROBENZODIAZEPIN-2-ONE (ID-540).
206780 03-02

STIMULATION OF SEXUAL BEHAVIOUR IN RATS BY A BENZODIOXANE DERIVATIVE.
210351 03-04

A DOUBLE-BLIND CONTROLLED STUDY OF THE THIENODIAZEPINE DERIVATIVE (Y-6047) ON NEUROTICS AND PSYCHOSOMATIC DISORDERS.
210559 03-14

EXPERIMENTAL INVESTIGATION OF A NEW AMPHETAMINE DERIVATIVE.
219709 04-03

A BENZODIOXANHYDROXYETHYLPIPERIDINE DERIVATIVE WITH ACUTE CENTRAL HYPOTENSIVE ACTION, DIFFERENT FROM THAT OF CLONIDINE: A COMPARISON WITH NEUROLEPTIC AGENTS.
220976 04-03

A PRELIMINARY DOUBLE-BLIND STUDY WITH SB-5833 (CAMAZEPAM), A NEW BENZODIAZEPINE DERIVATIVE.
221269 04-10

THE SYNTHESIS AND PHARMACOLOGY OF A NOVEL BENZODIAZEPINE DERIVATIVE, 1-BETA-METHYLSULFONYLETHYL-5-O-FLUOROPHENYL 7-CHLORODIHYDROBENZODIAZEPIN-2-ONE (ID-622).
221741 04-02

DERIVATIVES

RETROSPECTIVE STUDY OF THE ASSOCIATION BETWEEN USE OF RAUWOLFIA DERIVATIVES AND BREAST CANCER IN ENGLISH WOMEN.
194063 01-13

RAUWOLFIA DERIVATIVES AND CANCER.
194065 01-13

EFFECTS OF CENTRAL ACTING DRUGS AND ERGOT DERIVATIVES ON PROLACTIN AND GROWTH HORMONE SECRETION, ON GROWTH OF PITUITARY AND MAMMARY TUMORS AND ON REPRODUCTION IN OLD RATS. (PH.D. DISSERTATION).
194571 01-03

INHIBITION OF THE CATALYTIC SITE OF ADENYLATE-CYCLASE IN THE CENTRAL NERVOUS SYSTEM BY PHENOTHIAZINE DERIVATIVES.
195096 01-03

AMPHETAMINE DERIVATIVES: 10(E)- AND 10(A)-AMINO-1,2,3,4,4A,9,10,10A-(TRANS-4A,10A) OCTAHYDROPHENANTHRENE.
195561 01-01

HYPOTHERMIC EFFECTS OF MARIHUANA, MARIHUANA DERIVATIVES AND CHLORPROMAZINE IN LABORATORY MICE.
196226 01-04

A DUAL STUDY. PART I: SYNTHESIS AND STEREOCHEMISTRY OF SOME 1 SUBSTITUTED QUINOLIZIDINES AS ANALOGS OF BIOLOGICALLY ACTIVE COMPOUNDS. PART II: AMINO DERIVATIVES OF THIOPHENE FUSED CYCLIC KETONES AS POTENTIAL CNS. (PH.D. DISSERTATION).
196252 01-01

EFFECT OF BENZODIAZEPINE DERIVATIVES ON SOMAN INDUCED SEIZURE ACTIVITY AND CONVULSIONS IN THE MONKEY.
197466 01-03

BASIC DERIVATIVES OF DIPHENYLMETHANE WITH A DEPRESSIVE EFFECT ON THE CNS.
199209 02-02

MODIFICATION OF THE RECEPTOR COMPONENT OF ADENYLATE-CYCLASE IN THE RAT BRAIN BY PHENOTHIAZINE DERIVATIVES.
199771 02-03

COMPARISON OF THE OXIME AND THE HYDROXYLAMINE DERIVATIVES OF 4-CHLOROAMPHETAMINE AS DEPLETORS OF BRAIN 5-HYDROXYINDOLES.
200004 02-03

WATER SOLUBLE DERIVATIVES OF 3-OXY-SUBSTITUTED 1,4 BENZODIAZEPINES.
200739 02-01

STIMULUS PROPERTIES OF MESCALINE AND N-METHYLATED DERIVATIVES: DIFFERENCE IN PERIPHERAL AND DIRECT CENTRAL ADMINISTRATION.
201320 02-02

THE EFFECT OF DIAZAPHENOXAZINE DERIVATIVES ON MONOAMINEOXIDASE ACTIVITY.
201914 02-02

AN INVESTIGATION OF PSYCHOTROPIC ACTIVITY IN A SERIES OF PIPERAZINE (1,2-A) INDOLE DERIVATIVES.
206438 03-02

EXPERIMENTAL STUDY ON NEUROPHARMACOLOGICAL ACTIONS OF SOME INDOLE DERIVATIVES.
207164 03-02

ON THE PHARMACOLOGY OF DESMETHYLAZAPHEN DERIVATIVES.
207198 03-03

1 N-METHYLATED TRYPTAMINE DERIVATIVES: SYNTHESIS AND PROPERTIES.
207496 03-01

REACTIVITY OF VARIOUS PHENOTHIAZINE DERIVATIVES WITH OXYGEN AND OXYGEN RADICALS.
210882 03-02

EFFECTS OF AMPHETAMINE AND ITS HYDROXYLATED DERIVATIVES ON NEWLY SYNTHESIZED HYPOTHALAMIC NOREPINEPHRINE; STUDY IN VITRO.
210884 03-03

EFFECTS OF RIGID AMPHETAMINE ANALOGS ON VASCULAR STRIPS: STUDIES OF 2-AMINOTETRAHYDRONAPHTHALENE AND 2-AMINOINDAN DERIVATIVES.
210921 03-03

A POTENT DEPRESSANT ACTION OF ADENINE DERIVATIVES ON CEREBRAL CORTICAL NEURONES.
210932 03-03

DYSKINETIC PHENOMENA CAUSED BY THE INTRASTRIATAL INJECTION OF PHENYLETHYLAMINE, PHENYLPIPERAZINE, TETRAHYDROISOQUINOLINE AND TETRAHYDRONAPTHALENE DERIVATIVES IN THE GUINEA-PIG.
217671 04-04

INHIBITION OF HUMAN PLATELET 5-HYDROXYTRYPTAMINE UPTAKE BY BETA-PHENETHYLAMINE DERIVATIVES.
217689 04-13

METHYLATED DERIVATIVES OF NOREPINEPHRINE AND THE CONDITIONED AVOIDANCE RESPONSE IN RATS.
218958 04-02

THE INFLUENCE OF ALKYLATE PHERPACET DERIVATIVES ON NEURON POPULATIONS IN THE MIDBRAIN RETICULAR FORMATION.
219501 04-03

A NEW SERIES OF BENZODIAZEPINES: 1 HYDROXYALKYL DERIVATIVES OF 1,3 DIHYDROBENZODIAZEPIN-2-ONES.
221735 04-01

ANTIACCELERATOR AND DECELERATOR ACTIVITY OF ELEVEN PHENOTHIAZINE DERIVATIVES.
221740 04-03

THE INFLUENCE OF SOME PHENOTHIAZINE DERIVATIVES ON RENAL FUNCTION.
223019 04-05

DERIVED

COMPARISON OF THE ACTION OF DIAZEPAM AND PHENOBARBITAL USING EEG DERIVED POWER SPECTRA OBTAINED FROM TEMPORAL LOBE EPILEPTICS.
197992 01-13

A CLINICAL STUDY OF SERUM CONCENTRATION LEVELS OF PHENOBARBITAL DERIVED FROM PRIMIDONE (MUSOLINE).
224644 04-13

DESENSITIZATION

DEPOLARIZATION, DESENSITIZATION AND THE EFFECTS OF TUBOCURARINE AND NEOSTIGMINE IN CULTURED SKELETAL MUSCLE.
193447 01-03

SIDE-EFFECTS OF BREVITAL AIDED DESENSITIZATION: SOME CLINICAL IMPRESSIONS.
193986 01-15

OVERCOMING OBSTACLES TO DESENSITIZATION USING IN VIVO STIMULI AND BREVITAL.
224984 04-10

DESIGN

INTENSIVE DESIGN IN EVALUATING ANXIOLYTIC AGENTS.
198042 01-16

PSYCHOPHARMACOLOGIC INVESTIGATIONS IN HEALTHY ELDERLY VOLUNTEERS: EFFECTS OF PIPRADROL - VITAMIN (ALERTONIC) ELIXIR AND PLACEBO IN RELATION TO RESEARCH DESIGN.
218217 04-11

DESIPRAMINE

THE BLOCKADE OF BULBOSPINAL INHIBITION BY IMIPRAMINE, DESIPRAMINE AND PARGYLINE.
195095 01-03

THE INEFFECTIVENESS OF DESIPRAMINE PRETREATMENT ON BEHAVIORAL EFFECTS OF 6-HYDROXYDOPAMINE IN NIALAMIDE PRETREATED RATS.
195434 01-04

MODIFICATION BY DESIPRAMINE OF THE ADRENERGIC SENSITIVITY OF PYROGALLOL IN THE RAT.
197461 01-03

QUANTITATIVE ANALYSIS OF THE EEG EFFECTS PRODUCED BY IMIPRAMINE, DESIPRAMINE, PROMAZINE, AND MONODESMETHYL PROMAZINE IN THE ISOLATED PERFUSED RAT BRAIN.
200056 02-03

EFFECT OF DESIPRAMINE AND PARGYLINE ON BRAIN GAMMA-AMINOBUTYRIC ACID.
205851 03-03

THE USE OF DESIPRAMINE IN STUDIES OF NORADRENERGIC NERVE FUNCTION.
217882 04-03

THE INFLUENCE OF DESIPRAMINE AND AMITRIPTYLINE ON THE ACCUMULATION OF (3H)NORADRENALINE AND ITS TWO MAJOR METABOLITES FORMED FROM (3H)TYROSINE IN THE RAT BRAIN.
217966 04-03

DESIPRAMINE AS AN ANTIDEPRESSANT IN GENERAL PRACTICE.
221559 04-09

THE EFFECT OF AMITRIPTYLINE, DESIPRAMINE AND IMIPRAMINE ON THE IN VIVO BRAIN SYNTHESIS OF 3H-NORADRENALINE FROM 3H-L-DOPA IN THE RAT.
225565 04-03

DESMETHYLAZAPHEN

ON THE PHARMACOLOGY OF DESMETHYLAZAPHEN DERIVATIVES.
207198 03-03

DESMETHYLIMIPRAMINE

THE EFFECTS OF THE TRICYCLIC ANTIDEPRESSANTS DESMETHYLIMIPRAMINE, DOXEPIN AND IPRINDOLE ON THE ISOLATED PERFUSED RABBIT HEART.
197277 01-03

INFLUENCE OF DESMETHYLIMIPRAMINE ON THE HYPOTENSIVE EFFECT OF CLONIDINE.
206997 03-03

PLASMA LEVELS OF IMIPRAMINE AND DESMETHYLIMIPRAMINE AND ANTIDEPRESSANT EFFECT DURING CONTROLLED THERAPY.
217477 04-09

DESMETHYLOXAPINE

THE SIGNIFICANCE OF STANDARDIZED EVALUATION SCALES IN PSYCHIATRIC DIAGNOSIS AS EXEMPLIFIED BY THE THERAPEUTIC INTERVENTION WITH DESMETHYLOXAPINE.
221337 04-10

DESTRUCTION

REVERSAL BY L-DOPA OF IMPAIRED LEARNING DUE TO DESTRUCTION OF THE DOPAMINERGIC NIGRO-NEOSTRIATAL PROJECTION.
193578 01-04

SELECTIVE DESTRUCTION OF SEROTONIN TERMINALS IN RAT FOREBRAIN BY HIGH DOSES OF 5,7 DIHYDROXYTRYPTAMINE.
213401 04-03

DESTRUCTIVE

A HISTOCHEMICAL STUDY OF VENTRAL TEGMENTAL ACETYLCHOLINESTERASE CONTAINING PATHWAY FOLLOWING DESTRUCTIVE LESIONS.
210919 03-03

DETECTING

THE USE OF THE IMMOBILITY REFLEX (ANIMAL HYPNOSIS) AS A POSSIBLE PROCEDURE FOR DETECTING SEDATIVE ACTIVITY.
196066 01-04

DETECTION

THE DETECTION OF PRAZEPAM, A NEW BENZODIAZEPINE TRANQUILIZER.
204196 02-01

SIMPLE METHOD FOR DETECTION OF THE DRUG CHEATERS IN PSYCHIATRY.
205586 02-17

EFFECTS OF MARIHUANA ON AUDITORY SIGNAL DETECTION.
206356 03-12

A COMPARISON OF CIRCLING MODELS FOR THE DETECTION OF PARKINSON ACTIVITY.
217547 04-04

DETERIORATION

THE CORRELATION BETWEEN THE VENTRAL AND DORSAL HIPPOCAMPUS DURING IMPROVEMENT OR DETERIORATION OF SHORT-TERM MEMORY.
215487 04-04

DETERIORATION SYNDROMES IN THE ELDERLY.
220284 04-11

DETERMINANT

GENETIC DETERMINANT OF LITHIUM ION DISTRIBUTION. I. AN IN VITRO MONOZYGOTIC DIZYGOTIC TWIN STUDY.
194826 01-13

GENETIC DETERMINANT OF LITHIUM ION METABOLISM: II. AN IN VIVO STUDY OF LITHIUM ION DISTRIBUTION ACROSS ERYTHROCYTE MEMBRANES.
211412 03-03

DETERMINANTS

PHARMACOKINETIC DETERMINANTS OF THE RESPONSE TO SINGLE DOSES OF CHLORDIAZEPOXIDE.
203005 02-13

FROM PSYCHOPHARMACOLOGY TO PSYCHOPHARMACOGENETICS: DETERMINANTS OF THE EFFECTS OF DRUGS ON BEHAVIOR, ROLE OF GENETIC FACTORS.
210530 03-14

DETERMINANTS OF AMPHETAMINE PRODUCED STEREOTYPED BEHAVIOR IN THE RAT. (PH.D. DISSERTATION).
220687 04-04

DETERMINANTS OF PRESCRIBING OF PSYCHOACTIVE DRUGS BY GENERAL PRACTITIONERS.
224492 04-17

SCHEDULE-CONTROLLED BEHAVIORS AS DETERMINANTS OF DRUG RESPONSE.
225168 04-06

DETERMINANTS OF DRUG EFFECTS ON PUNISHED RESPONDING.
225169 04-04

DETERMINATION

A METHOD FOR THE ISOLATION AND DETERMINATION OF 3-METHOXYTYRAMINE IN BRAIN TISSUE.
193302 01-03

CONJOINT NATIVE AND ORTHOPHTHALDIALDEHYDE CONDENSATE ASSAYS FOR THE FLUORIMETRIC DETERMINATION OF 5-HYDROXYINDOLES IN BRAIN.
195238 01-01

A SIMPLE AND RAPID SPECTROPHOTOMETRIC DETERMINATION OF MONOAMINEOXIDASE ACTIVITY.
197281 01-01

DETERMINATION OF NORADRENALINE, DOPAMINE, SEROTONIN, 5-HYDROXYINDOLEACETIC ACID, TYROSINE AND TRYPTOPHANE IN THE ISOLATED PERFUSED RAT BRAIN.
197967 01-06

COLORIMETRIC, ULTRAVIOLET SPECTROPHOTOMETRIC, AND SPECTROPHOTOFLUOROMETRIC DETERMINATION OF DOXEPIN AND SOME OF ITS METABOLITES IN SERUM AND IN URINE.
199214 02-16

SPECTROFLUORODENSITOMETRIC DETERMINATION OF FLURAZEPAM AND ITS MAJOR METABOLITES IN BLOOD.
200737 02-16

GLC DETERMINATION OF PROPRANOLOL, OTHER BETA-BLOCKING DRUGS, AND METABOLITES IN BIOLOGICAL FLUIDS AND TISSUES.
200740 02-16

DETERMINATION OF DRUG-INDUCED CHANGES IN SLEEP QUALITY BASED ON DIGITAL COMPUTER SLEEP PRINTS.
203603 02-14

MICROMETHODS FOR QUANTITATIVE DETERMINATION OF SEDATIVES AND ANTIPYRETICS BY THERMO-GAS CHROMATOGRAPHY.
206807 03-06

MASS FRAGMENTOMETRIC DETERMINATION OF HOMOVANILLIC ACID IN LUMBAR CEREBROSPINAL FLUID OF SCHIZOPHRENIC PATIENTS DURING TREATMENT WITH ANTIPSYCHOTIC DRUGS.
207295 03-08

CHLORPROMAZINE METABOLISM IV: QUATERNIZATION AS A KEY TO DETERMINATION OF PICOMOLES OF CHLORPROMAZINE AND OTHER TERTIARY AMINE DRUGS.
217667 04-06

DETERMINATIONS

CRYSTAL STRUCTURE DETERMINATIONS OF THE DONOR ACCEPTOR COMPLEXES OF PHENOTHIAZINE AND PHENOXAZINE WITH NICKEL THIETE. (PH.D. DISSERTATION).
201003 02-01

DETERMINED

ANTIANESTHETIC EFFECTS OF CYCLIC-AMP AND ANALEPTIC DRUGS AS DETERMINED BY REVERSAL OF AMOBARBITAL INDUCED NARCOSIS.
193426 01-03

DETERMINER

SIZE OF THE ENVIRONMENT AS A DETERMINER OF EFFECTS OF SCOPOLAMINE.
223849 04-04

DEVELOPING

EFFECT OF 6-HYDROXYDOPAMINE ON THE LEVEL OF THE CATECHOLAMINES IN THE BRAIN OF DEVELOPING RATS.
197449 01-03

DOSE-DEPENDENT DIFFERENCES OF AMPHETAMINE LEVELS IN BRAIN AND HEART OF ADULT AND DEVELOPING MICE.
197927 01-03

LEAD ENCEPHALOPATHY IN THE DEVELOPING RAT: EFFECT ON CORTICAL ONTOGENESIS.
200168 02-05

MODIFICATION BY L-DOPA METHYLESTER (H-19-61) OF AMPHETAMINE-INDUCED BRAIN CATECHOLAMINE CHANGES, THERMAL RESPONSES AND TOXICITY IN DEVELOPING MICE.
210891 03-03

EFFECT OF THYROXINE AND CORTISOL ON BRAIN ORNITHINE DECARBOXYLASE ACTIVITY AND SWIMMING BEHAVIOR IN DEVELOPING RAT.
210933 03-03

TRYPTOPHAN METABOLISM IN DEVELOPING CHICK BRAIN.
223053 04-03

DEVELOPMENT

TOLERANCE DEVELOPMENT TO THE ANTINOCICEPTIVE ACTIONS OF MORPHINE, AMPHETAMINE, PHYSOSTIGMINE AND 2-AMINOINDANE IN THE MOUSE.
194930 01-03

A STUDY OF THE DEVELOPMENT OF TOLERANCE TO AN ANTICONVULSANT EFFECT OF DELTA9-TETRAHYDROCANNABINOL AND CANNABIDIOL.
195117 01-03

THE EFFECT OF L-DOPA ON THE DEVELOPMENT OF RESERPINE INDUCED PARKINSONISM AND CATECHOLAMINE METABOLISM IN RATS.
198486 02-03

EFFECTS OF DIAZEPAM AND PHENOBARBITAL ON ELECTRICALLY-INDUCED AMYGDALOID SEIZURES AND SEIZURE DEVELOPMENT.
198612 02-04

LITHIUM INDUCED LOSS OF BODY SODIUM AND THE DEVELOPMENT OF SEVERE INTOXICATION IN RATS.
199623 02-03

SOME CHARACTERISTICS OF PATHOLOGY IN SCHIZOPHRENIA DURING THE TWO STAGES OF PSYCHOPHARMACOLOGICAL DEVELOPMENT.
201908 02-08

FUTURE DEVELOPMENT OF PHARMACOTHERAPY AND TOXICOMANIA.
207100 03-17

THE EFFECT OF DIAZEPAM ON THE DEVELOPMENT OF PROGENY.
207163 03-04

POSTNATAL DEVELOPMENT OF CHOLINE UPTAKE BY CHOLINERGIC TERMINALS IN RAT BRAIN.
210713 03-03

TOLERANCE DEVELOPMENT WITH CHLORDIAZEPOXIDE IN RELATION TO THE PLASMA LEVELS OF THE PARENT COMPOUND AND ITS MAIN METABOLITES IN MICE.
210973 03-03

ANTENATAL EXPOSURE TO MEPROBAMATE AND CHLORDIAZEPOXIDE IN RELATION TO MALFORMATIONS, MENTAL DEVELOPMENT, AND CHILDHOOD MORTALITY.
212107 03-15

ADRENAL GLUCOCORTICOIDS AS A REQUIRED FACTOR IN THE DEVELOPMENT OF ETHANOL WITHDRAWAL SEIZURES IN MICE.
213479 04-03

AMPHETAMINE STEREOTYPY: THE INFLUENCE OF ENVIRONMENTAL FACTORS AND PREPOTENT BEHAVIORAL PATTERNS ON ITS TOPOGRAPHY AND DEVELOPMENT.
213531 04-04

DEVELOPMENT OF PSYCHOTROPIC DRUGS.
213595 04-16

BENZODIAZEPINES, REPRODUCTION, AND DEVELOPMENT.
213605 04-03

TOLERANCE DEVELOPMENT TO THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON CONDITIONED BEHAVIOR: ROLE OF TREATMENT INTERVAL AND INFLUENCE OF MICROSOMAL METABOLISM.
215726 04-03

ONTOGENESIS OF NEOSTRIATAL CHOLINERGIC NEURONES IN THE RAT AND DEVELOPMENT OF THEIR SENSITIVITY TO NEUROLEPTIC DRUGS.
217658 04-03

6-HYDROXYDOPA DURING DEVELOPMENT OF CENTRAL ADRENERGIC NEURONS PRODUCES DIFFERENT LONG-TERM CHANGES IN RAT BRAIN NORADRENALINE.
217867 04-03

THE EFFECT OF 6-HYDROXYDOPAMINE ON THE TOLERANCE DEVELOPMENT TO THE HYPERTHERMIC EFFECT OF (+) AMPHETAMINE IN THE RAT.
217965 04-03

EFFECTS OF PROCAINE HYDROCHLORIDE, DIAZEPAM, AND DIPHENYLHYDANTOIN ON SEIZURE DEVELOPMENT IN CORTICAL AND SUBCORTICAL STRUCTURES IN RATS.
218191 04-03

DEVELOPMENT OF RADIOIMMUNOASSAY FOR CHLORPROMAZINE.
222802 04-06

ATROPINE COMA TREATMENT OF SCHIZOPHRENIC PATIENTS WITH A SLUGGISH DEVELOPMENT AND OBSESSIVE SYNDROMES.
224085 04-08

THE EFFECTS OF CHLORDIAZEPOXIDE ON THE DEVELOPMENT OF ADJUNCTIVE DRINKING IN RATS.
225149 04-04

ASSESSING THE IMPACT OF LOW LEVEL CHEMICALS ON DEVELOPMENT: BEHAVIORAL AND LATENT EFFECTS.
225164 04-15

DEVELOPMENTAL

DEVELOPMENTAL CHARACTERISTICS OF PHENYLETHANOLAMINE AND OCTOPAMINE IN THE RAT BRAIN.
196804 01-03

DEVELOPMENTAL DISTURBANCE OF THE BRAIN IN RAT OFFSPRING FOLLOWING MATERNAL ADMINISTRATION OF 5-FLUOURACIL DURING PREGNANCY.
202422 02-03

A DEVELOPMENTAL STUDY OF THE EFFECTS OF 5,7 DIHYDROXYTRYPTAMINE ON REGIONAL TRYPTOPHAN-HYDROXYLASE IN RAT BRAIN.
217555 04-03

DEVELOPMENTAL VARIATIONS OF CHOLINE ACETYLTRANSFERASE, DOPAMINE-BETA-HYDROXYLASE AND MONOAMINEOXIDASE IN CHICKEN EMBRYO AND CHICKEN SYMPATHETIC GANGLIA.
217840 04-03

DEVELOPMENTS

NEW DEVELOPMENTS IN HUMAN PSYCHOPHARMACOLOGY.
197534 01-17

EVENTUAL DEVELOPMENTS OF 64 CHRONIC PSYCHOTICS ON MODITEN RETARD OR MODECATE TREATMENT.
202514 02-09

NEW DEVELOPMENTS IN THE STUDY OF THE MECHANISM OF ACTION OF NEUROLEPTICS AND AMPHETAMINE.
207296 03-03

NEW PSYCHOTROPIC DRUG DEVELOPMENTS IN FRANCE AND BELGIUM.
213597 04-17

NEW PSYCHOTROPIC DRUG DEVELOPMENTS IN THE USSR AND OTHER EASTERN EUROPEAN COUNTRIES.
213598 04-07

NEW PSYCHOTROPIC DRUG DEVELOPMENTS IN GREAT-BRITAIN.
213599 04-17

DEVIANT
THE CONTROL OF DEVIANT SEXUAL BEHAVIOUR BY DRUGS: I. BEHAVIOURAL CHANGES FOLLOWING ESTROGENS AND ANTIANDROGENS.
196958 01-14

DEXAMETHASONE
CATECHOLAMINES IN SYMPATHETIC GANGLIA OF RAT: EFFECTS OF DEXAMETHASONE AND RESERPINE.
210766 03-03
DEXAMETHASONE INDUCES TYROSINE-HYDROXYLASE IN SYMPATHETIC GANGLIA BUT NOT IN ADRENAL MEDULLA.
217853 04-03
SEX DIFFERENCES IN THE EFFECTS OF DEXAMETHASONE PHOSPHATE ON BEHAVIOR IN RATS.
218492 04-04
EFFECTS OF ACTH, DEXAMETHASONE AND DEOXYCORTICOSTERONE ON AVERSIVE THRESHOLD OF RATS.
221766 04-04
EFFECTS OF EARLY EXPERIENCE AND DEXAMETHASONE ON ADRENOCORTICAL REACTIVITY.
225078 04-03

DEXAMPHETAMINE
THE EFFECTS OF A DEXAMPHETAMINE AMYLOBARBITONE SODIUM MIXTURE ON THE REWARD VALUE OF DIFFERENT SENSORY CHANGES.
217476 04-03

DEXAMPHETAMINE-14C
5-HYDROXYTRYPTAMINE-14C AND DEXAMPHETAMINE-14C UPTAKE BY FUNDAL SARCOLEMMA PREPARATIONS AND THE PROBLEM OF THE COMMON RECEPTOR.
213591 04-03

DEXETIMIDE
DIFFERENTIAL ANTAGONISM BY THE ANTICHOLINERGIC DEXETIMIDE OF INHIBITORY EFFECTS OF HALOPERIDOL AND FENTANYL ON BRAIN SELF-STIMULATION.
225562 04-03

DEXTROAMPHETAMINE
THE EFFECTS OF DEXTROAMPHETAMINE, DIMETHYLTRYPTAMINE, LYSERGIC ACID DIETHYLAMIDE AND TETRAHYDROCANNABINOL UPON PREGNANCY AND THE OFFSPRING. (PH.D. DISSERTATION).
194568 01-04

DEXTROMETHORPHAN
DEXTROMETHORPHAN INHIBITS 5-HYDROXYTRYPTAMINE UPTAKE BY HUMAN BLOOD PLATELETS AND DECREASES 5-HYDROXYINDOLEACETIC ACID CONTENT IN RAT BRAIN.
217964 04-03

DH-524
ANTAGONISM OF DEPRESSANT ACTIVITY OF ETHANOL BY DH-524; A COMPARATIVE STUDY WITH BEMEGRIDE, DOXAPRAM AND D-AMPHETAMINE (38640).
213282 03-03

DIAGNOSING
DIAGNOSING AND TREATING CHRONIC SCHIZOPHRENIA.
196601 01-08

DIAGNOSIS
SOMATOSENSORY EVOKED RESPONSE WAVE SHAPE STABILITY: RELATIONSHIPS TO PSYCHIATRIC DIAGNOSIS AND EFFECTS OF PSYCHOACTIVE DRUGS.
195935 01-17
THE CLINICAL RELEVANCE OF PHOTOSENSITIVITY IN PSYCHIATRIC EEG DIAGNOSIS.
209018 03-15
WILL THE REAL HYPERACTIVE CHILD PLEASE SIT DOWN? PROBLEMS OF DIAGNOSIS AND REMEDIATION.
212811 03-11
THE RELATIONSHIP OF DIAGNOSIS AND TARGET SYMPTOMS TO PSYCHOTROPIC DRUG ASSIGNMENT.
215251 04-17
DIFFERENTIAL DIAGNOSIS AND THERAPY OF SLEEP DISTURBANCES.
217193 04-11
THE SIGNIFICANCE OF STANDARDIZED EVALUATION SCALES IN PSYCHIATRIC DIAGNOSIS AS EXEMPLIFIED BY THE THERAPEUTIC INTERVENTION WITH DESMETHYLOXAPINE.
221337 04-10

DIAGNOSTIC
RETESTING WITH GRAPHIC PRODUCTION: RESOLUTION OF A DIAGNOSTIC DILEMMA.
197600 01-09

DIAPHRAM
EFFECTS OF METHAMPHETAMINE ON THE ISOLATED RAT PHRENIC NERVE DIAPHRAM PREPARATION.
210900 03-03

DIAZAPHENOXAZINE
THE EFFECT OF DIAZAPHENOXAZINE DERIVATIVES ON MONOAMINEOXIDASE ACTIVITY.
201914 02-02

DIAZEPAM
A DOUBLE-BLIND CROSSOVER COMPARISON BETWEEN CLOTHIAPINE AND DIAZEPAM IN THE TREATMENT OF MENTAL SYMPTOMS IN CHRONIC ALCOHOLICS.
192988 01-11
POTENTIATION OF DRUG INITIATED ADRENAL TYROSINE-HYDROXYLASE INDUCTION BY DIAZEPAM.
193304 01-03
THE ACTION OF DIAZEPAM ON HUMAN SKELETAL MUSCLE.
193800 01-13
COMPARATIVE STUDY OF DIAZEPAM VS. CHLORDIAZEPOXIDE IN ANXIETY NEUROSIS.
194558 01-10
A CONTROLLED EVALUATION OF LORAZEPAM AND DIAZEPAM IN ANXIETY NEUROSIS.
194719 01-10
CHANGES IN THE DORSAL ROOT POTENTIAL WITH DIAZEPAM AND WITH THE ANALGESICS ASPIRIN, NITROUS OXIDE, MORPHINE AND MEPERIDINE.
195248 01-03
DIAZEPAM METABOLISM IN NORMAL MAN: I. SERUM CONCENTRATIONS AND CLINICAL EFFECTS AFTER INTRAVENOUS, INTRAMUSCULAR, AND ORAL ADMINISTRATION.
195444 01-15
DIAZEPAM METABOLISM IN NORMAL MAN: II. SERUM CONCENTRATION AND CLINICAL EFFECT AFTER ORAL ADMINISTRATION AND CUMULATION.
195445 01-13
BRAIN AND SERUM CONCENTRATIONS OF DIAZEPAM IN EXPERIMENTAL EPILEPSY.
195494 01-04
CONTROLLED CLINICAL TRIAL WITH DIAZEPAM.
195618 01-10
CHROMOSOMAL ABERRATION RATES AND INTRAVENOUSLY GIVEN DIAZEPAM: A NEGATIVE STUDY.
195949 01-13
THE EFFECT OF DAILY ORAL DOSAGE OF DIAZEPAM, PLASMA CONCENTRATIONS AND METABOLIC CLEARANCE OF DIAZEPAM AND DEMETHYLDIAZEPAM ON VARIOUS CONSTITUENTS OF THE ACUTE CLINICAL ANXIETY SYNDROME.
196191 01-10
CHANGES IN ACID-BASE BALANCE, RESPIRATION RATE AND HEART RATE UPON REPEATED ORAL ADMINISTRATION OF BENZOCTAMINE AND DIAZEPAM TO CONSCIOUS DOGS.
197460 01-03
SEIZURES IN RATS INDUCED BY PINEALECTOMY: INFLUENCE OF DIAZEPAM, CHLORDIAZEPOXIDE, AND DIPHENYLHYDANTOIN AND PINEAL SUBSTANCES.
197465 01-03
ALTERATIONS IN ACID-BASE BALANCE IN THE DOG AFTER INTRAVENOUS ADMINISTRATION OF BENZOCTAMINE AND DIAZEPAM, COMPARED WITH THOSE INDUCED BY THIOPENTAL.
197485 01-03
EFFECTS OF DIAZEPAM ON DISCHARGE PATTERN IN SINGLE FIBRES OF PHRENIC NERVE.
197577 01-03
THE EFFECT OF DIAZEPAM ON SPINAL CORD ACTIVITIES: POSSIBLE SITES AND MECHANISMS OF ACTION.
197585 01-03
INVESTIGATIONS OF THE EFFECTS OF DIAZEPAM IN ACUTE EXPERIMENTAL INTOXICATION WITH FLUOSTIGMINE.
197832 01-03
PHARMACOKINETICS OF DIAZEPAM IN MAN.
197951 01-13
COMPARISON OF THE ACTION OF DIAZEPAM AND PHENOBARBITAL USING EEG DERIVED POWER SPECTRA OBTAINED FROM TEMPORAL LOBE EPILEPTICS.
197992 01-13
RESISTANCE TO EXTINCTION OF AN AVOIDANCE RESPONSE IN RATS FOLLOWING THE ADMINISTRATION OF CHLORDIAZEPOXIDE (LIBRIUM) AND DIAZEPAM (VALIUM).
198226 02-04
EFFECTS OF DIAZEPAM AND PHENOBARBITAL ON ELECTRICALLY-INDUCED AMYGDALOID SEIZURES AND SEIZURE DEVELOPMENT.
198612 02-04
THE EFFECTS OF DIPHENYLHYDANTOIN, PHENOBARBITAL, AND DIAZEPAM ON THE PENICILLIN INDUCED EPILEPTOGENIC FOCUS IN THE RAT.
198613 02-03
COMPARATIVE STUDY OF Y-6047 AND DIAZEPAM BY A DOUBLE-BLIND METHOD FOR THE TREATMENT OF PSYCHOSOMATIC DISEASES AND NEUROSIS.
198705 02-11
REDUCTION BY DIAZEPAM OF REPETITIVE ELECTRICAL ACTIVITY AND TOXICITY RESULTING FROM SOMAN.
199861 02-03
COMBINED EFFECTS OF DIAZEPAM AND ETHANOL ON MENTAL AND PSYCHOMOTOR FUNCTIONS.
199896 02-14

INHIBITORY AND DISINHIBITORY EFFECTS OF NITRAZEPAM, DIAZEPAM AND FLURAZEPAM HYDROCHLORIDE ON DELAYED MATCHING BEHAVIOUR IN MONKEYS (MACACA-MULATTA).
199957 02-04

THE THERAPEUTIC EFFECT OF SHORT-TERM ORAL DIAZEPAM TREATMENT ON ACUTE CLINICAL ANXIETY IN A CRISIS CENTRE.
199991 02-10

DIAZEPAM INCREASES 5-HYDROXYINDOLE CONCENTRATIONS IN RAT BRAIN AND SPINAL CORD.
200081 02-03

DIAZEPAM ASSOCIATED ASTHMA.
200492 02-15

CENTRAL EFFECTS OF THREE FLUORINATED BENZODIAZEPINES IN COMPARISON WITH DIAZEPAM.
202765 02-03

A DOUBLE-BLIND EVALUATION OF DIAZEPAM AND AMYLOBARBITONE IN ACUTE MYOCARDIAL INFARCTION.
202966 02-13

EFFECT OF DIAZEPAM UPON SOMAN INDUCED SEIZURE ACTIVITY AND CONVULSIONS.
204192 02-02

EFFECTS OF DIAZEPAM ON EXPERIMENTALLY INDUCED CORTICAL EPILEPSY AND THEIR CORRELATION WITH DRUG CONCENTRATION.
205491 02-03

POLYGRAPHIC EXAMINATION DURING FAST AND SLOW INTRAVENOUS INJECTION OF THE SAME DOSE OF DIAZEPAM.
205508 02-13

A COMPARATIVE STUDY ON THE EFFECT OF INTRAVENOUS DIAZEPAM AND RO-5-3350 ON PYRAMIDAL SPASTICITY.
205575 02-13

OUR EXPERIENCE WITH THE TREATMENT OF DELIRIUM-TREMENS WITH DIAZEPAM.
205639 03-11

THE EFFECT OF DIAZEPAM ON THE DEVELOPMENT OF PROGENY.
207163 03-04

THE EFFECT OF DIAZEPAM AND NITRAZEPAM ON INTRACELLULAR AND EXTRACELLULAR DISTRIBUTION OF SODIUM AND POTASSIUM IONS IN INDIVIDUAL STRUCTURES OF RATS BRAINS.
207199 03-03

INHIBITION BY DIAZEPAM OF THE TREMOR AND THE INCREASE OF CEREBELLAR CGMP CONTENT ELICITED BY HARMALINE.
207798 03-03

CLINICAL AND BIOCHEMICAL COMPARISON OF CHLORAZEPATE AND DIAZEPAM.
209081 03-10

A DOUBLE-BLIND CONTROLLED COMPARISON OF BROMAZEPAM AND DIAZEPAM.
209411 03-10

CAMAZEPAM VERSUS DIAZEPAM: A DOUBLE-BLIND TRIAL ON PSYCHONEUROTIC PATIENTS.
209487 03-10

EFFECT OF STRESS AND DIAZEPAM TREATMENT DURING INFANCY ON THE CORTICOSTERONE REGULATION AND ANDROGENIC ACTIVITY IN ADULT MALE RATS.
210348 03-03

A COMPARISON BETWEEN DIAZEPAM AND HALOPERIDOL IN ANXIETY STATES.
210434 03-10

TRANQUILIZING EFFECTS OF DIAZEPAM IN PIGS SUBJECTED TO A PUNISHMENT PROCEDURE.
210741 03-04

DIAZEPAM AS A DISCRIMINATIVE CUE: ITS ANTAGONISM BY BEMEGRIDE.
210865 03-03

MENTAL AND PSYCHOMOTOR EFFECTS OF DIAZEPAM AND ETHANOL.
211070 03-14

CLINICAL AND EXPERIMENTAL COMPARISON OF DIAZEPAM, CHLORAZEPATE AND PLACEBO.
214018 04-14

THE EFFECT OF ACTH AND DIAZEPAM, ADMINISTERED TO INFANT RATS ON THE BODY GROWTH CURVE AND SOME ENDOCRINE PARAMETERS MEASURED IN ADULT AGE.
215066 04-03

LONG-TERM BEHAVIOURAL EFFECTS OF DIAZEPAM AND ACTH, ADMINISTERED EARLY IN LIFE.
215067 04-04

PERMANENT EFFECTS OF REPEATED ADMINISTRATION OF ACTH AND DIAZEPAM IN EARLY POSTNATAL PERIOD UPON THE DYNAMICS OF EXCITATION AND INHIBITION DURING HABITUATION.
215068 04-04

THE EFFECT OF COMBINATION OF METHYLPHENIDATE AND DIAZEPAM ON THE EEG AND ITS EVALUATION BY MEANS OF DISCRIMINANT ANALYSIS.
215070 04-13

FACTOR ANALYSIS OF EEG OF HEALTHY SUBJECTS GIVEN NO DRUGS AND A COMBINATION OF DIAZEPAM AND METHYLPHENIDATE.
215071 04-13

THE EFFECT OF COLD AND DIAZEPAM ON THE TOXICITY OF FENFLURAMINE IN MICE.
215160 04-05

PLACENTAL TRANSFER OF DIAZEPAM AND ITS DISPOSITION IN THE NEWBORN.
215672 04-13

HEPATIC CHOLESTEROL SYNTHESIS IN MAN: EFFECT OF DIAZEPAM AND OTHER DRUGS.
215681 04-15

THE MECHANISM OF ANTICONVULSIVE ACTION OF DIAZEPAM.
217064 04-04

A COMPARISON BETWEEN BROMAZEPAM (RO-5-3350, LEXOTAN) AND DIAZEPAM (VALIUM) IN ANXIETY NEUROSIS: A CONTROLLED, DOUBLE-BLIND CLINICAL TRIAL.
217455 04-10

ELECTROPHYSIOLOGICAL EVIDENCE FOR AN INHIBITORY ACTION OF DIAZEPAM UPON CAT BRAIN CORTEX.
217649 04-03

CARDIOVASCULAR EFFECTS OF DIAZEPAM AND CHLORDIAZEPOXIDE.
217659 04-03

TERATOGENICITY OF ORAL DIAZEPAM AND DIPHENYLHYDANTOIN IN MICE.
217694 04-05

ACTION OF DIAZEPAM, DIBUTYRYL-CGMP, AND GABA ON PRESYNAPTIC NERVE TERMINALS IN BULLFROG SYMPATHETIC GANGLIA.
217873 04-03

EFFECTS OF PROCAINE HYDROCHLORIDE, DIAZEPAM, AND DIPHENYLHYDANTOIN ON SEIZURE DEVELOPMENT IN CORTICAL AND SUBCORTICAL STRUCTURES IN RATS.
218191 04-03

THE EFFECT OF DIAZEPAM ON THE BEHAVIOR OF RATS ADAPTED TO HIGH ALTITUDE HYPOXIA IN CONFLICTING SITUATIONS.
219502 04-04

BROMAZEPAM VERSUS DIAZEPAM IN PSYCHONEUROTIC INPATIENTS.
221304 04-10

A COMPARISON BETWEEN DIAZEPAM AND HALOPERIDOL IN NEUROTIC ANXIETY AND TENSION STATES IN PATIENTS IN A OPEN WARD.
221638 04-10

ON THE GAS CHROMATOGRAPHIC ANALYSIS OF BENZODIAZEPINES: SECOND COMMUNICATION: DIAZEPAM AND ITS METABOLITES.
221739 04-06

DIFFERENTIAL ATTENUATION OF SOMATOVISCERAL AND VISCEROSOMATIC REFLEXES BY DIAZEPAM, PHENOBARBITAL AND DIPHENYLHYDANTOIN.
222818 04-04

THE EFFECT OF TRANQUILIZERS (DIAZEPAM AND CHLORDIAZEPOXIDE) ON THE BLOOD SUPPLY AND CARDIAC ACTIVITY.
223018 04-03

DIAZEPAM TREATMENT OF SOCIALLY ISOLATED MONKEYS.
224776 04-04

ALLERGIC CONJUNCTIVITIS DUE TO DIAZEPAM.
225338 04-15

DIBENZAZEPINE

PHARMACOLOGIC STUDIES ON PROPYNYL DIBENZAZEPINE, A NEW ALPHA-ADRENERGIC BLOCKER.
197493 01-03

STUDIES ON PSYCHOTROPIC DRUGS: XVII. EFFECTS OF 3-CHLORO-5-(3-(4 PIPERIDINO-4-CARBAMOYL-PIPERIDINO)PROPYL) 10,11-DIHYDRO-5(H) DIBENZAZEPINE DIHYDROCHLORIDE MONOHYDRATE (Y-4153) ON THE METABOLISM OF BIOGENIC AMINES.
199210 02-03

DIBENZEPINE

ON THE PHARMACOKINETICS OF DIBENZEPINE.
199913 02-13

DIBUTYRYL

A DIRECT EFFECT OF DIBUTYRYL CYCLIC-AMP ON THE DURATION OF NARCOSIS INDUCED BY SEDATIVE, HYPNOTIC, TRANQUILISER AND ANESTHETIC DRUGS IN THE RAT.
222814 04-04

DIBUTYRYL-CGMP

ACTION OF DIAZEPAM, DIBUTYRYL-CGMP, AND GABA ON PRESYNAPTIC NERVE TERMINALS IN BULLFROG SYMPATHETIC GANGLIA.
217873 04-03

DICHLOROETHYLENE

ALTERATIONS OF BARBITURATE ACTION FOLLOWING 1,1 DICHLOROETHYLENE, CORTICOSTERONE, OR ACROLEIN.
197488 01-03

DICHLOROPHENYL

INHIBITION OF SYMPATHETIC ACTIVITY FOLLOWING CHRONIC ADMINISTRATION OF 2-AMINO-4-(3,4 DICHLOROPHENYL) 2-IMIDAZOLINE (MJ-10459-2).
199863 02-03

DICHROISM

INTERACTIONS OF BENZODIAZEPINES WITH HUMAN SERUM ALBUMIN: CIRCULAR DICHROISM STUDIES.
194148 01-01

DIELDRIN
EFFECT OF ACUTE AND CHRONIC DIELDRIN EXPOSURE ON BRAIN BIOGENIC AMINES OF MALE AND FEMALE RATS.
193428 01-03

DIETARY
DIETARY TRYPTOPHAN AND THE SELECTION OF ETHYL ALCOHOL IN DIFFERENT STRAINS OF RATS.
217520 04-03

DIETHYL
INEFFECTIVENESS OF LYSERGIC ACID DIETHYL AMIDE 25 (LSD) ON ALTERING NA-K CURRENTS IN SQUID GIANT AXON.
194927 01-03
EFFECT OF PENTOBARBITONE AND DIETHYL ETHER ON THE SYNTHESIS OF MONOAMINES IN RAT BRAIN.
195950 01-03

DIETHYLAMIDE
THE EFFECTS OF DEXTROAMPHETAMINE, DIMETHYLTRYPTAMINE, LYSERGIC ACID DIETHYLAMIDE AND TETRAHYDROCANNABINOL UPON PREGNANCY AND THE OFFSPRING. (PH.D. DISSERTATION).
194568 01-04
STUDIES OF TRYPTAMINE AND LYSERGIC ACID DIETHYLAMIDE (LSD) ON CUTANEOUS C-FIBER AND POLYSYNAPTIC REFLEXES IN THE CAT.
197814 01-03
STUDIES ON THE IN VITRO METABOLISM OF COMPOUNDS RELATED TO LYSERGIC ACID DIETHYLAMIDE (LSD).
198608 02-01
CHRONIC LYSERGIC ACID DIETHYLAMIDE ADMINISTRATION AND SEROTONIN TURNOVER IN VARIOUS REGIONS OF RAT BRAIN.
199783 02-03
THE EFFECT OF LYSERGIC ACID DIETHYLAMIDE ON SERUM CREATINE KINASE LEVELS.
206361 03-12
THE INFLUENCE OF CHLORPROMAZINE ACTION ON EXPERIMENTAL PSYCHOSIS CAUSED BY LYSERGIC ACID DIETHYLAMIDE.
206439 03-04
HYPERSENSITIVITY TO LYSERGIC ACID DIETHYLAMIDE (LSD-25) AND PSILOCYBIN IN ESSENTIAL HEADACHE.
211108 03-12
LYSERGIC ACID DIETHYLAMIDE AFFECTS BLOOD FLOW TO SPECIFIC AREAS OF THE CONSCIOUS RAT BRAIN.
215161 04-03
INHIBITION OF CATECHOLAMINE AND 5-HYDROXYTRYPTAMINE INDUCED ENZYME SECRETION FROM THE GUINEA-PIG SUBMANDIBULAR GLAND BY 2-BROMO-D-LYSERGIC ACID DIETHYLAMIDE.
216968 04-03
DISCRIMINATIVE CONTROL OF BEHAVIOR BY ELECTRICAL STIMULATION OF THE DORSAL RAPHE NUCLEUS: GENERALIZATION TO LYSERGIC ACID DIETHYLAMIDE (LSD).
217821 04-12
LYSERGIC ACID DIETHYLAMIDE: EFFECT ON HISTONE ACETYLATION IN RABBIT BRAIN.
220314 04-03
SOME PECULIARITIES OF THE NEURON ULTRASTRUCTURE IN THE BRAIN-CORTEX MOTOR AREA UNDER THE INFLUENCE OF LYSERGIC ACID DIETHYLAMIDE (LSD) AND HALOPERIDOL.
222890 04-03
LYSERGIC ACID DIETHYLAMIDE: EVIDENCE FOR STIMULATION OF CEREBRAL DOPAMINE RECEPTORS.
223174 04-03
INTERACTIONS BETWEEN LYSERGIC ACID DIETHYLAMIDE AND DOPAMINE SENSITIVE ADENYLCYCLASE SYSTEMS IN RAT BRAIN.
223175 04-03

DIETHYLDITHIOCARBAMATE
DIETHYLDITHIOCARBAMATE (ANTABUSE): DECREASE OF BRAIN HEAVY METAL STAINING PATTERN AND IMPROVED CONSOLIDATION OF SHUTTLEBOX AVOIDANCE IN GOLDFISH.
203521 02-04
THE EFFECT OF CERTAIN TRANQUILISERS, CHLORPROMAZINE METABOLITES AND DIETHYLDITHIOCARBAMATE ON TISSUE AMPHETAMINE LEVELS IN THE RAT.
211111 03-03

DIETHYLPROPION
EFFECTS OF DIETHYLPROPION AND D-AMPHETAMINE AFTER SUBCUTANEOUS AND ORAL ADMINISTRATION.
198030 01-14

DIFFERENCE
STIMULUS PROPERTIES OF MESCALINE AND N-METHYLATED DERIVATIVES: DIFFERENCE IN PERIPHERAL AND DIRECT CENTRAL ADMINISTRATION.
201320 02-02

DIFFERENTIATED
A DIFFERENTIATED USE OF ELENIUM AND SEDUXEN IN YOUNG PATIENTS IN THE POST-INFARCTIONAL PERIOD.
200104 02-11

DIFFERENTIATING
WAYS OF DEMONSTRATING AND DIFFERENTIATING CENTRAL NERVOUS EFFECTS OF DRUGS IN ANIMAL EXPERIMENTS.
202944 02-06

DIFFERENTIATION
THE DIFFERENTIATION OF TWO TYPES OF HYPERACTIVE CHILDREN BY ACTIVITY LEVEL AND TASK PERFORMANCE WITH METHYLPHENIDATE (RITALIN) AND PLACEBO. (PH.D. DISSERTATION).
204688 02-11

DIGITAL
DETERMINATION OF DRUG-INDUCED CHANGES IN SLEEP QUALITY BASED ON DIGITAL COMPUTER SLEEP PRINTS.
203603 02-14

DIHYDRO-5-
A NEW BENZODIAZEPINE: 1-(2 HYDROXYETHYL)-3-HYDROXY-7-CHLORO-1,3 DIHYDRO-5-(O-FLUOROPHENYL)-1H-1,4 BENZODIAZEPIN-2-ONE.
194956 01-04

DIHYDRO-5H-IMIDAZOISOINDOLE
PHARMACOLOGICAL ANALYSIS OF A NEW ANOREXIC SUBSTANCE: 5-HYDROXY-5-4-CHLOROPHENYL 2,3 DIHYDRO-5H-IMIDAZOISOINDOLE (MAZINDOL).
217652 04-04
THE EFFECTS OF 5-HYDROXY-5-4-CHLOROPHENYL 2,3 DIHYDRO-5H-IMIDAZOISOINDOLE (MAZINDOL, SAH-42-548) ON THE METABOLISM OF BRAIN NOREPINEPHRINE.
217653 04-03

DIHYDROBENZODIAZEPIN-2-ONES
A NEW SERIES OF BENZODIAZEPINES: 1 HYDROXYALKYL DERIVATIVES OF 1,3 DIHYDROBENZODIAZEPIN-2-ONES.
221735 04-01

DIHYDROCHLORIDE
STUDIES ON PSYCHOTROPIC DRUGS: XVII. EFFECTS OF 3-CHLORO-5-(3-(4 PIPERIDINO-4-CARBAMOYL-PIPERIDINO)PROPYL) 10,11-DIHYDRO-5(H) DIBENZAZEPINE DIHYDROCHLORIDE MONOHYDRATE (Y-4153) ON THE METABOLISM OF BIOGENIC AMINES.
199210 02-03
CLINICAL TRIAL OF 3-METHYL-5-BETA-N-N-M-CHLOROPHENYLPIPERAZINOETHYL PYRAZOLE DIHYDROCHLORIDE (MEPIPRAZOL) IN THE THERAPY OF PSYCHOVEGETATIVE DISORDERS.
215694 04-10

DIHYDROERGOTAMINE
VARIATIONS IN THE AUTONOMIC NERVOUS SYSTEM AFTER ADMINISTRATION OF DIHYDROERGOTAMINE IN PSYCHOSOMATIC PATIENTS.
209045 03-11
CORRECTION OF AUTONOMIC EFFECTS OF PSYCHOTROPIC DRUGS BY LARGE DOSES OF DIHYDROERGOTAMINE IN ADULTS AND THE ELDERLY.
211998 03-11

DIHYDROXY
ANTICONVULSANT ACTIVITY OF DELTA9-TETRAHYDROCANNABINOL AND ITS 11 HYDROXY AND 8ALPHA,11 DIHYDROXY METABOLITES IN THE FROG.
200035 02-03

DIHYDROXY-2-DIMETHYLAMINOTETRALIN
INHIBITION OF THE SYMPATHETIC NERVOUS SYSTEM BY 5,6 DIHYDROXY-2-DIMETHYLAMINOTETRALIN (M-7), APOMORPHINE AND DOPAMINE.
210888 03-03

DIHYDROXYLATED
BIOCHEMICAL EFFECTS OF DIHYDROXYLATED TRYPTAMINES ON CENTRAL INDOLEAMINE NEURONES.
204340 02-03

DIHYDROXYPHENYLACETIC
3,4 DIHYDROXYPHENYLACETIC ACID (DOPAC): A POSSIBLE ENDOGENOUS INHIBITOR OF INDOLEAMINE-N-METHYLATION IN THE RAT BRAIN.
197676 01-17
CANNABINOID INDUCED CHANGES IN MOUSE STRIATAL HOMOVANILLIC ACID AND DIHYDROXYPHENYLACETIC ACID: THE EFFECTS OF AMPHETAMINE AND L-DOPA.
204866 02-03

DIHYDROXYPHENYLALANINE
THE FORMATION IN VIVO OF 3,4 DIHYDROXYPHENYLALANINE (DOPA) FROM 3-HYDROXY-DL-PHENYLALANINE (M-TYROSINE).
198015 01-03

DIHYDROXYPHENYLSERINE
PROFILE-BASED-THERAPY (PBT) IN SCHIZOPHRENIAS: A PRECLINICAL INDICATION FOR THE USE OF DIHYDROXYPHENYLSERINE (DOPS).
195115 01-08
FORMATION OF NOREPINEPHRINE IN THE BRAIN OF RATS AFTER ADMINISTRATION OF (+) ERYTHRO 3,4 DIHYDROXYPHENYLSERINE.
225558 04-03

DIHYDROXYTRYPTAMINE
DRUG-INDUCED ROTATION IN RATS AFTER UNILATERAL INTRACEREBRAL INJECTION OF 5,6 DIHYDROXYTRYPTAMINE (5-6-DHT).
192940 01-03
SELECTIVE DESTRUCTION OF SEROTONIN TERMINALS IN RAT FOREBRAIN BY HIGH DOSES OF 5,7 DIHYDROXYTRYPTAMINE.
213401 04-03
INTRACRANIAL REWARD AFTER 5,6 DIHYDROXYTRYPTAMINE: FURTHER EVIDENCE FOR SEROTONINS INHIBITORY ROLE.
215732 04-04

A DEVELOPMENTAL STUDY OF THE EFFECTS OF 5,7 DIHYDROXYTRYPTAMINE ON REGIONAL TRYPTOPHAN-HYDROXYLASE IN RAT BRAIN.
217555 04-03

EFFECTS OF 5,7 DIHYDROXYTRYPTAMINE ON TRANSMISSION AT SEROTONERGIC SYNAPSE.
217638 04-03

DIISOPROPYLFLUOROPHOSPHATE

ANALYSIS OF ACETYLCHOLINESTERASE SYNTHESIS AND TRANSPORT IN THE RAT HIPPOCAMPUS: RECOVERY OF ACETYLCHOLINESTERASE ACTIVITY IN THE SEPTUM AND HIPPOCAMPUS AFTER ADMINISTRATION OF DIISOPROPYLFLUOROPHOSPHATE.
199805 02-03

EXPERIMENTAL TESTS OF HYPOTHESES ABOUT NEUROCHEMICAL MECHANISMS UNDERLYING BEHAVIORAL TOLERANCE TO THE ANTICHOLINESTERASE, DIISOPROPYLFLUOROPHOSPHATE.
208555 03-03

DIISOPROPYLPHOSPHOFLUORIDATE

EFFECTS OF DIISOPROPYLPHOSPHOFLUORIDATE ON ACETYLCHOLINE, CHOLINESTERASE AND CATECHOLAMINES OF SEVERAL PARTS OF RABBIT BRAIN.
195094 01-03

DILATATION

EFFECTS OF IPRONIAZID, CHLORPROMAZINE AND METHIOTHEPIN ON DMT INDUCED CHANGES IN BODY TEMPERATURE, PUPILLARY DILATATION, BLOOD PRESSURE AND EEG IN THE RABBIT.
215724 04-03

DILEMMA

RETESTING WITH GRAPHIC PRODUCTION: RESOLUTION OF A DIAGNOSTIC DILEMMA.
197600 01-09

CHLORDIAZEPOXIDE (LIBRIUM): THE EFFECTS OF A MINOR TRANQUILIZER ON STRATEGIC CHOICE BEHAVIOR IN THE PRISONERS DILEMMA.
199609 02-14

DIMETHOXY-4-ALKYLAMPHETAMINES

THE BEHAVIORAL EFFECTS OF 2,5 DIMETHOXY-4-ALKYLAMPHETAMINES.
210352 03-01

DIMETHOXY-4-ETHYLAMPHETAMINE

SOME PHARMACOLOGICAL ACTIONS OF 2,5 DIMETHOXY-4-ETHYLAMPHETAMINE (DOET) IN RATS AND MICE.
210747 03-03

DIMETHOXY-4-METHYLAMPHETAMINE

BEHAVIORAL EFFECTS OF 2,5 DIMETHOXY-4-METHYLAMPHETAMINE (DOM) IN RATS AND MICE.
222801 04-04

DIMETHOXY-4-METHYLPHENYLISOPROPYLAMINE

POTENTIAL PSYCHOTOMIMETICS. 2. RIGID ANALOGS OF 2,5 DIMETHOXY-4-METHYLPHENYLISOPROPYLAMINE (DOM, STP).
202109 02-02

DIMETHOXYPHENYLETHYLAMINE

POTENTIATION BY 3,4 DIMETHOXYPHENYLETHYLAMINE (DMPEA) AND COCAINE OF NOREPINEPHRINE-INDUCED CONTRACTION OF GUINEA-PIG VAS-DEFERENS.
194156 01-03

COMPARISON OF 3,4 DIMETHOXYPHENYLETHYLAMINE TREATED PLASMA FROM CHRONIC SCHIZOPHRENICS AND CONTROLS.
210897 03-08

DIMETHYLHEPTYL

BRAIN LEVELS AND RELATIVE POTENCY OF THE 1,2 DIMETHYLHEPTYL ANALOGUE OF DELTA1-TETRAHYDROCANNABINOL IN MICE.
198605 02-01

DIMETHYLPHENYLPIPERAZINE

INFLUENCE OF OXYMETAZOLINE AND PHENTOLAMINE ON NORADRENALINE (NA) RELEASE CAUSED BY ELECTRICAL STIMULATION, POTASSIUM, TYRAMINE AND DIMETHYLPHENYLPIPERAZINE (DMPP).
197973 01-03

DIMETHYLTRYPTAMINE

THE EFFECTS OF DEXTROAMPHETAMINE, DIMETHYLTRYPTAMINE, LYSERGIC ACID DIETHYLAMIDE AND TETRAHYDROCANNABINOL UPON PREGNANCY AND THE OFFSPRING. (PH.D. DISSERTATION).
194568 01-04

BLOOD AND URINE LEVELS OF N,N DIMETHYLTRYPTAMINE FOLLOWING ADMINISTRATION OF PSYCHOACTIVE DOSAGES TO HUMAN SUBJECTS.
198230 02-12

SOME NEUROCHEMICAL EFFECTS OF N,N DIMETHYLTRYPTAMINE AND THEIR POSSIBLE RELATION TO ACUTE SCHIZOPHRENIA. (PH.D. DISSERTATION).
219179 04-03

DIMINISHED

FENFLURAMINE IN MAN: HYPOPHAGIA ASSOCIATED WITH DIMINISHED SEROTONIN TURNOVER.
215674 04-13

DIOXIDE

PHARMACOLOGICAL INFLUENCES ON CARBON DIOXIDE INDUCED AMNESIA.
197497 01-03

DIOXYGENASE

INHIBITORY ACTION OF NOREPINEPHRINE ON THE INDUCTION OF TRYPTOPHAN 2,3 DIOXYGENASE BY CORTISOL: MEDIATION BY THE ALPHA-RECEPTOR.
221051 04-03

DIPHENHYDRAMINE

HYPNOTIC EFFICACY OF DIPHENHYDRAMINE, METHAPYRILENE, AND PENTOBARBITAL.
210829 03-13

THE MECHANISM OF THE POTENTIATING EFFECT OF ANTIDEPRESSANT DRUGS ON THE PROTECTIVE INFLUENCE OF DIPHENHYDRAMINE IN EXPERIMENTAL CATATONIA. THE ROLE OF HISTAMINE.
215664 04-03

DIPHENYL-4-N-BUTYLPYRAZOLIDINE

LIGHT INDUCED FRAGMENTATION OF 3,5-DIOXO-1,2 DIPHENYL-4-N-BUTYLPYRAZOLIDINE (PHENYLBUTAZONE) WITH NUCLEOPHILIC AGENTS.
197675 01-01

DIPHENYLAMINOETHANOL

THE EFFECTS OF DIPHENYLAMINOETHANOL (DPAE) AND LIDOCAINE ON CEREBELLAR INHIBITION DEITERS NEURONS. (PH.D. DISSERTATION).
196259 01-03

DIPHENYLBUTYLPIPERIDINES

THE DIPHENYLBUTYLPIPERIDINES: FIRST NORTH AMERICAN SYMPOSIUM, 1972.
207052 03-17

DIPHENYLHYDANTOIN

FAILURE OF DIPHENYLHYDANTOIN TO PREVENT ALCOHOL WITHDRAWAL CONVULSIONS IN MICE.
193454 01-03

SEIZURES IN RATS INDUCED BY PINEALECTOMY: INFLUENCE OF DIAZEPAM, CHLORDIAZEPOXIDE, AND DIPHENYLHYDANTOIN AND PINEAL SUBSTANCES.
197465 01-03

INVESTIGATIONS ON THE ACTION AND MECHANISM OF ACTION OF DIPHENYLHYDANTOIN AS AN ANTAGONIST OF TETRABENAZINE AND RESERPINE.
197471 01-03

EFFECT OF ALCOHOLS, CHLORPROMAZINE AND DIPHENYLHYDANTOIN ON (CA2+) ATPASE OF HUMAN RED BLOOD CELLS.
197976 01-13

SELECTIVE DIPHENYLHYDANTOIN SUPPRESSION OF AUDITORY EVOKED POTENTIALS IN THE CAT CEREBELLAR CORTEX.
197989 01-03

THE EFFECTS OF DIPHENYLHYDANTOIN, PHENOBARBITAL, AND DIAZEPAM ON THE PENICILLIN INDUCED EPILEPTOGENIC FOCUS IN THE RAT.
198613 02-03

A CONTROLLED COMPARISON OF THE EFFECTS OF DIPHENYLHYDANTOIN AND PLACEBO ON MOOD AND PSYCHOMOTOR FUNCTIONING IN NORMAL VOLUNTEERS.
199518 02-14

POLYNEUROPATHY AS A RESULT OF DIPHENYLHYDANTOIN OVERDOSE.
200573 02-15

DIPHENYLHYDANTOIN IN THE TREATMENT OF LSD FLASHBACKS: A CASE STUDY.
205766 03-12

ENHANCED DRUG HYDROXYLATION IN MAN UNDER DIPHENYLHYDANTOIN THERAPY.
206992 03-13

DIPHENYLHYDANTOIN INTOXICATION DUE TO DIPHENYLHYDANTOIN ISONIAZID INTERACTION.
207155 03-15

THE EFFECT OF DIPHENYLHYDANTOIN ON BRAIN 5-HYDROXYTRYPTAMINE METABOLISM AND FUNCTION.
210764 03-03

DELAYED IDIOSYNCRATIC PSYCHOSIS WITH DIPHENYLHYDANTOIN.
211425 03-15

EFFECTS OF DIPHENYLHYDANTOIN ON MENTAL ABILITIES IN THE ELDERLY.
215857 04-14

TERATOGENICITY OF ORAL DIAZEPAM AND DIPHENYLHYDANTOIN IN MICE.
217694 04-05

SERUM CONCENTRATIONS OF PHENOBARBITAL AND DIPHENYLHYDANTOIN (PRELIMINARY REPORT).
218011 04-11

EFFECTS OF PROCAINE HYDROCHLORIDE, DIAZEPAM, AND DIPHENYLHYDANTOIN ON SEIZURE DEVELOPMENT IN CORTICAL AND SUBCORTICAL STRUCTURES IN RATS.
218191 04-03

THREE ACUTE CASES OF DIPHENYLHYDANTOIN INTOXICATION.
221515 04-15

DIFFERENTIAL ATTENUATION OF SOMATOVISCERAL AND VISCEROSOMATIC REFLEXES BY DIAZEPAM, PHENOBARBITAL AND DIPHENYLHYDANTOIN.
222818 04-04

EFFECT OF FIGHTING AND DIPHENYLHYDANTOIN ON THE UPTAKE OF H3-L-NOREPINEPHRINE IN VITRO IN SYNAPTOSOMES ISOLATED FROM RETIRED MALE BREEDING MICE.
222821 04-03

CASE PRESENTATION OF AN ALTERNATIVE THERAPEUTIC APPROACH FOR THE BORDERLINE PSYCHOTIC HEROIN ADDICT: DIPHENYLHYDANTOIN.
225512 04-09

DIPHENYLHYDANTOIN-INDUCED
ON THE PROBLEM OF DIPHENYLHYDANTOIN-INDUCED SEIZURES: AN EXPERIMENTAL APPROACH.
197815 01-05

DIPHENYLMETHANE
BASIC DERIVATIVES OF DIPHENYLMETHANE WITH A DEPRESSIVE EFFECT ON THE CNS.
199209 02-02

DIPHENYLPROPYL-N-METHYL
PHARMACOLOGICAL EVALUATION OF 3-(N 3,3 DIPHENYLPROPYL-N-METHYL) AMINOPROPAN-1-OL HYDROCHLORIDE (PF-82), A NEW TYPE OF ANTIDEPRESSANT DRUG.
221287 04-02

DIPHOSPHATE
EFFECTS OF CYTIDINE DIPHOSPHATE CHOLINE ON THE NERVOUS SYSTEM IN CATS.
198610 02-04

DIPROPYLACETAMIDE
DIPROPYLACETAMIDE IN TREATING MANIC-DEPRESSIVE PSYCHOSIS.
216761 04-09

DIPROPYLACETIC
DIPROPYLACETIC ACID (DEPAKINE) IN EXPERIMENTAL EPILEPSY IN THE ALERT CAT.
225529 04-02

DIPYRIDAMOLE
THE EFFECT OF DIPYRIDAMOLE ON THE NORADRENALINE TRANSPORT INTO NERVE GRANULES.
197942 01-03

DIRECT
SPECIFIC ASYMMETRIC BEHAVIOUR INDUCED BY THE DIRECT CHEMICAL STIMULATION OF NEOSTRIATAL DOPAMINERGIC MECHANISMS.
197929 01-04

THE NUCLEUS LINEARIS INTERMEDIUS RAPHE AND BEHAVIOUR EVOKED BY DIRECT AND INDIRECT STIMULATION OF DOPAMINE SENSITIVE SITES WITHIN THE CAUDATE NUCLEUS OF CATS.
199864 02-04

STIMULUS PROPERTIES OF MESCALINE AND N-METHYLATED DERIVATIVES: DIFFERENCE IN PERIPHERAL AND DIRECT CENTRAL ADMINISTRATION.
201320 02-02

THE ROLE OF DOPAMINE AND NOREPINEPHRINE IN CHANGING THE DIRECT CORTICAL RESPONSE TO PHENAMINE.
208971 03-03

A DIRECT EFFECT OF DIBUTYRYL CYCLIC-AMP ON THE DURATION OF NARCOSIS INDUCED BY SEDATIVE, HYPNOTIC, TRANQUILISER AND ANESTHETIC DRUGS IN THE RAT.
222814 04-04

DIRECTED
MESCALINE-INDUCED CHANGES OF BRAIN CORTEX RIBOSOMES: EFFECT OF MESCALINE ON RIBOSOMAL SYNTHESIS OF POLYURIDINE DIRECTED POLYPHENYLALANINE.
194153 01-03

DISABILITIES
METHYLPHENIDATE EFFECTS IN LEARNING DISABILITIES OF CHILDREN.
198045 01-14

A COMPARISON OF THE RELATIVE EFFICACY OF SPECIAL CLASS EDUCATION AND DRUG THERAPY FOR CHILDREN WITH SELECTED LEARNING DISABILITIES. (ED.D. DISSERTATION).
198662 02-11

THE EFFECTS OF METHYLPHENIDATE HYDROCHLORIDE ON PSYCHOLINGUISTIC, MOTOR AND VISUAL PERCEPTUAL ABILITIES OF HYPERKINETIC CHILDREN WITH LEARNING DISABILITIES. (PH.D. DISSERTATION).
222725 04-14

DISABILITY
MEASURING EFFECTS OF PSYCHOACTIVE MEDICATION IN A CHILD WITH A LEARNING DISABILITY.
203847 02-14

DISABLED
THE EFFECTS OF PYRITHIOXINE ON THE BEHAVIOUR AND INTELLECTUAL FUNCTION OF LEARNING DISABLED CHILDREN.
216485 04-11

DISCHARGE
EFFECTS OF DIAZEPAM ON DISCHARGE PATTERN IN SINGLE FIBRES OF PHRENIC NERVE.
197577 01-03

RELATIONSHIP BETWEEN THE LATE REFLEX DISCHARGE AND LOCOMOTOR MOVEMENTS IN ACUTE SPINAL CATS AND RABBITS WITH DOPA.
209728 03-03

EFFECTS OF A DECARBOXYLASE INHIBITOR ON THE DOPA AND 5-HTP INDUCED CHANGES IN THE LOCOMOTOR LIKE DISCHARGE PATTERN OF RABBIT HIND LIMB NERVES.
210740 03-03

DISCHARGES
CENTRAL IMPLANTATION OF CANNABINOIDS: INDUCTION OF EPILEPTIFORM DISCHARGES.
193449 01-03

THE ACTION OF CHLORPROMAZINE AND TRIFTAZINE ON DISCHARGES OF CORTICAL NEURONS IN RABBITS AFTER CHRONIC ADMINISTRATION OF THE DRUGS.
215499 04-03

THE INFLUENCE OF CHOLINOMIMETICS ON THE AFTEREFFECTS OF TRACE DISCHARGES AND THE ACTIVITY OF EPILEPTOGENIC FOCI IN THE RABBIT HIPPOCAMPUS.
219499 04-03

DISCOVERY
COMPUTERIZED CEREBRAL BIOPOTENTIALS IN THE DISCOVERY OF PSYCHOTROPIC DRUGS.
205434 02-13

DISCRIMINANT
THE EFFECT OF COMBINATION OF METHYLPHENIDATE AND DIAZEPAM ON THE EEG AND ITS EVALUATION BY MEANS OF DISCRIMINANT ANALYSIS.
215070 04-13

DISCRIMINATE
EFFECT OF LOPERAMIDE, HALOPERIDOL AND METHADONE IN RATS TRAINED TO DISCRIMINATE MORPHINE FROM SALINE.
225568 04-04

DISCRIMINATION
THE EFFECTS OF SCOPOLAMINE ON A TWO-CUE DISCRIMINATION.
192952 01-04

EFFECTS OF PHYSOSTIGMINE ON THE ACCURACY AND ACTIVITY OF DISCRIMINATION BEHAVIOUR IN RATS.
197995 01-04

EFFECTS OF LOW AND HIGH DOSES OF L-DOPA ON THE TETRABENAZINE OR ALPHA-METHYLTYROSINE-INDUCED SUPPRESSION OF BEHAVIOUR IN A SUCCESSIVE DISCRIMINATION TASK.
200042 02-04

DEFICIENT BRIGHTNESS DISCRIMINATION ACQUISITION PRODUCED BY DAILY INTRACRANIAL INJECTIONS OF PENICILLIN IN RATS.
202758 02-04

METHAMPHETAMINES EFFECT ON REPEATED ACQUISITIONS WITH SERIAL DISCRIMINATION REVERSALS.
202769 02-04

SCOPOLAMINE AND AMPHETAMINE EFFECTS ON DISCRIMINATION.
206109 03-04

EFFECTS OF OVERTRAINING UPON DRUG STATE DEPENDENCY IN DISCRIMINATION LEARNING IN WHITE RATS.
209866 03-04

TEMPORAL DISCRIMINATION TESTS IN MENTAL RETARDATES TREATED WITH NUCLEOTIDES AND GABA IN HIGH DOSES.
210293 03-14

EFFECTS OF PENTOBARBITAL ON FIXED-RATIO DISCRIMINATION.
210392 03-04

EFFECTS OF MORPHINE AND HEROIN ON DISCRIMINATION LEARNING AND CONSOLIDATION IN MICE.
221040 04-04

ASSESSMENT OF TOLERANCE TO BARBITAL BY MEANS OF DRUG DISCRIMINATION PROCEDURES.
221046 04-02

ANTAGONISM OF PENTOBARBITAL INDUCED DISCRIMINATION IN THE GERBIL.
225561 04-04

DISCRIMINATIVE
EFFECTS OF PROPRANOLOL, D-AMPHETAMINE AND CAFFEINE ON ETHANOL AS A DISCRIMINATIVE CUE.
199963 02-04

AN ANALYSIS OF SOME DISCRIMINATIVE PROPERTIES OF D-AMPHETAMINE.
201321 02-04

DISCRIMINATIVE RESPONSE CONTROL PRODUCED WITH HASHISH, TETRAHYDROCANNABINOLS (DELTA8-THC AND DELTA9-THC), AND OTHER DRUGS.
202720 02-12

DIAZEPAM AS A DISCRIMINATIVE CUE: ITS ANTAGONISM BY BEMEGRIDE.
210865 03-03

DISCRIMINATIVE CONTROL OF BEHAVIOR BY ELECTRICAL STIMULATION OF THE DORSAL RAPHE NUCLEUS: GENERALIZATION TO LYSERGIC ACID DIETHYLAMIDE (LSD).
217821 04-12

THE ROLE OF DISCRIMINATIVE STIMULI IN MODULATING DRUG ACTION.
225170 04-04

DISEASE
DOPAMINERGIC MECHANISMS IN PATIENTS WITH EXTRAPYRAMIDAL DISEASE. (UNPUBLISHED PAPER).
194542 01-13

AFFECTIVE DISEASE HEALTH MAINTENANCE ORGANIZATION: PATTERNS OF LITHIUM RESPONSE.
194746 01-09

SLEEP IN PATIENTS WITH PARKINSONS DISEASE AND ITS INFLUENCE BY L-DOPA.
195155 01-11

TREATMENT OF PARKINSONS DISEASE BY COMBINING L-DOPA WITH A DECARBOXYLASE INHIBITOR.
204372 02-07

EFFECT OF L-DOPA ON PITUITARY HORMONES AND ON CARBOHYDRATE AND FAT METABOLISM IN NORMALS AND IN PARKINSONS DISEASE.
207153 03-13

THE ROLE OF ADAPTIVE REGULATION IN THE PATHOPHYSIOLOGY OF PSYCHIATRIC DISEASE.
207307 03-03

AFFECTS OF L-DOPA ON THE PSYCHOLOGICAL SYMPTOMS OF PICKS DISEASE.
211365 03-11

QUANTITATIVE MEASUREMENT OF PARKINSON DISEASE RIGOR. MYOINTEGRATIVE DRUG TRIAL IN COMBINATION WITH THE DECARBOXYLASE INHIBITING DRUG RO-8-0576.
220829 04-11

AVERAGE EVOKED RESPONSES (AER) AND HOMOVANILLIC ACID (HVA) IN CEREBROSPINAL FLUID (CSF) IN A PSYCHOTIC PATIENT WITH ADDISONS DISEASE.
221310 04-09

NEW PROSPECTS OF TREATMENT OF PARKINSONS DISEASE WITH PARKS-PLUS.
221885 04-11

GROWTH HORMONE RELEASE AND CATECHOLAMINES IN AFFECTIVE DISEASE.
224773 04-13

DISEASES

USE OF THE MAUDSLEY PERSONALITY INVENTORY IN EVALUATING THE EFFECTIVENESS OF A MINOR TRANQUILIZER IN PSYCHOSOMATIC DISEASES (THE FIRST REPORT).
198518 02-14

COMPARATIVE STUDY OF Y-6047 AND DIAZEPAM BY A DOUBLE-BLIND METHOD FOR THE TREATMENT OF PSYCHOSOMATIC DISEASES AND NEUROSIS.
198705 02-11

ON THE USE OF SULPIRIDE WITH SOME SKIN DISEASES.
209044 03-11

A COMPARISON OF A NEW TRANQUILIZER, SULPIRIDE AND OXAZOLAM ON PSYCHOSOMATIC DISEASES, NEUROSIS AND MASKED DEPRESSION USING DOUBLE-BLIND METHOD.
210180 03-11

DISINHIBITING

THE DISINHIBITING EFFECT OF N(1-ETHYL-2-PYRROLIDINYL-METHYL-2-METHOXY-5-SULFAMIDE BENZAMIDE (SULPIRIDE).
209527 03-14

DISINHIBITORY

INHIBITORY AND DISINHIBITORY EFFECTS OF NITRAZEPAM, DIAZEPAM AND FLURAZEPAM HYDROCHLORIDE ON DELAYED MATCHING BEHAVIOUR IN MONKEYS (MACACA-MULATTA).
199957 02-04

DISORDER

DOES LITHIUM IN DRINKING WATER PREVENT MENTAL DISORDER?
195933 01-17

PHENOTHIAZINE AND SCHIZOPHRENIC THOUGHT DISORDER.
198102 02-08

A CASE OF SEVERE HEADACHE AS AN EQUIVALENT OF AFFECTIVE DISORDER.
201668 02-09

AN MAOI SPECIFIC AFFECTIVE DISORDER. THE TOO MUCH SYNDROME.
202705 02-09

AN ECOLOGICAL APPROACH TO A BEHAVIOR DISORDER: ENURESIS. (PH.D. DISSERTATION).
204528 02-11

THEORETICAL IMPLICATIONS OF DRUG-INDUCED ADAPTIVE REGULATION FOR A BIOGENIC AMINE HYPOTHESIS OF AFFECTIVE DISORDER.
206335 03-03

AFFECTIVE DISORDER: STUDIES WITH AMINE PRECURSORS.
207681 03-09

AKINESIA: A POORLY RECOGNIZED DRUG-INDUCED EXTRAPYRAMIDAL BEHAVIORAL DISORDER.
218773 04-15

BIPOLAR PRIMARY AFFECTIVE DISORDER.
221166 04-09

ANXIETY NEUROSIS, DEPRESSIVE DISORDER AND MEPROBAMATE ADDICTION -- PSYCHIATRIC GRAND-ROUNDS, UNIV. OF CALIFORNIA, SAN-DIEGO.
222772 04-10

DISORDERS

PSYCHOACTIVE DRUG USE IN ELDERLY PATIENTS WITH PSYCHIATRIC DISORDERS: A SURVEY OF 12 VETERANS ADMINISTRATION HOSPITALS.
193291 01-11

CLINICAL MEASUREMENT OF CENTRAL DOPAMINE AND SEROTONIN METABOLISM IN ACUTE PSYCHOTIC DISORDERS.
195924 01-09

SODIUM AND LITHIUM ERYTHROCYTE CONCENTRATION IN AFFECTIVE DISORDERS.
195931 01-09

LITHIUM PROPHYLAXIS IN RECURRENT AFFECTIVE DISORDERS.
197532 01-09

PSYCHOPHARMACOLOGIC TREATMENT OF AFFECTIVE DISORDERS.
200237 02-09

THE EFFECT OF D-AMPHETAMINE ON CHOREIFORM MOVEMENT DISORDERS.
202282 02-11

THE CURRENT STATUS OF BIOLOGICAL CRITERIA FOR CLASSIFYING THE DEPRESSIVE DISORDERS AND PREDICTING RESPONSES TO TREATMENT.
202380 02-17

RED BLOOD CELL LITHIUM INDEX IN PATIENTS WITH AFFECTIVE DISORDERS IN THE COURSE OF LITHIUM PROPHYLAXIS.
202786 02-09

DEPRESSIVE DISORDERS.
202960 02-09

PSYCHOPHARMACOLOGICAL TREATMENT OF DISORDERS OF SENESCENCE.
203470 02-11

BIOCHEMICAL CRITERIA FOR CLASSIFYING DEPRESSIVE DISORDERS AND PREDICTING RESPONSES TO PHARMACOTHERAPY: PRELIMINARY FINDINGS FROM STUDIES OF NOREPINEPHRINE METABOLISM. CONTRIBUTIONS TO BIOCHEMISTRY.
203594 02-09

THE TREATMENT OF BEHAVIOR DISORDERS IN IDIOCY AND IMBECILITY WITH CLOZAPINE.
203598 02-11

ACTIVATION OF EEG BY GAMMA-HYDROXYBUTYRATE (GHB) IN ORGANIC BRAIN DISORDERS.
205460 02-13

L-DOPA AND TRICYCLIC ANTIDEPRESSANTS IN AFFECTIVE DISORDERS. A PILOT STUDY.
205601 03-09

ON THE USE OF SYDNOCARB FOR PSYCHOPHARMACOLOGICAL CORRECTION OF BEHAVIORAL DISORDERS OF THE CYCLOID TYPE OF ACCENTUATED PERSONALITY IN ADOLESCENTS.
207271 03-11

NEUROLEPTICS AS A GUIDELINE TO BIOLOGICAL RESEARCH IN PSYCHOTIC DISORDERS.
207765 03-17

THOUGHT DISORDERS IN SCHIZOPHRENIA BEFORE AND AFTER PHARMACOLOGICAL TREATMENT.
207767 03-17

THE LITHIUM PROPHYLACTIC TREATMENT OF RECURRENT ENDOGENOUS AFFECTIVE DISORDERS.
209392 03-09

LITHIUM GLUCONATE: SYSTEMATIC AND FACTORIAL ANALYSIS OF 104 OBSERVATIONS OVER 2.5-3 YEARS IN PATIENTS PRESENTING CYCLOTHYMIC OR DYSTHYMIC DISORDERS.
210126 03-09

TREATMENT OF PSYCHOSOMATIC GASTROINTESTINAL DISORDERS IN OUTPATIENTS.
210513 03-11

A DOUBLE-BLIND CONTROLLED STUDY OF THE THIENODIAZEPINE DERIVATIVE (Y-6047) ON NEUROTICS AND PSYCHOSOMATIC DISORDERS.
210559 03-14

AMINES AND DISORDERS OF THE CENTRAL NERVOUS SYSTEM.
210635 03-09

COMPARATIVE STUDIES ABOUT SERUM ELECTROLYTES DURING LITHIUM PROPHYLAXIS OF AFFECTIVE DISORDERS.
210807 03-09

PSYCHOPHARMACOLOGICAL THERAPY AND THE PROBLEMS OF DELINEATING BORDERLINE FORMS OF NEUROPSYCHIC DISORDERS.
212431 03-17

MENTAL DISORDERS SEEN AFTER OPEN HEART SURGERY.
214304 04-11

THE ROLE OF INTRAVENOUS CLOMIPRAMINE IN THE TREATMENT OF OBSESSIONAL AND PHOBIC DISORDERS.
214835 04-10

AN INVESTIGATION INTO THE USE OF ANAFRANIL IN PHOBIC AND OBSESSIONAL DISORDERS.
214837 04-10

THE USE OF PSYCHOACTIVE DRUGS IN ELDERLY PATIENTS WITH PSYCHIATRIC DISORDERS: SURVEY CONDUCTED IN TWELVE VETERANS ADMINISTRATION HOSPITALS.
215009 04-11

BIOCHEMICAL VERSUS PSYCHOPATHOLOGICAL ACTION PROFILE OF NEUROLEPTICS: A COMPARATIVE STUDY OF CHLORPROMAZINE AND OXYPERTINE IN ACUTE PSYCHOTIC DISORDERS.
215454 04-13

CLINICAL TRIAL OF 3-METHYL-5-BETA-N-N-M-CHLOROPHENYLPIPERAZINOETHYL PYRAZOLE DIHYDROCHLORIDE (MEPIPRAZOL) IN THE THERAPY OF PSYCHOVEGETATIVE DISORDERS.
215694 04-10

FREE THYROXINE INDEX AND ABSOLUTE FREE THYROXINE IN PATIENTS WITH AFFECTIVE DISORDERS TREATED WITH LITHIUM CARBONATE.
216747 04-09

AMPHETAMINE-INDUCED DOPAMINERGIC HYPERSENSITIVITY IN GUINEA-PIGS: IMPLICATIONS IN PSYCHOSIS AND HUMAN MOVEMENT DISORDERS.
218115 04-04

FURTHER REPORT ON PROPHYLACTIC LITHIUM IN RECURRENT AFFECTIVE DISORDERS.
218556 04-09

AN ASPECT OF BIOLOGICAL THERAPY IN THE SYSTEM OF REHABILITATING EPILEPTIC PATIENTS WITH MENTAL DISORDERS.
220420 04-11

CLINICAL TRIAL OF OXYPERTINE IN THE TREATMENT OF PSYCHOSOMATIC DISORDERS, NEUROSIS AND DEPRESSION.
224193 04-14

AFFECTIVE DISORDERS AND LITHIUM ION.
224588 04-09

DISORIENTATION

A CONTROLLED CLINICAL EXPERIMENT WITH BURONIL AND HALOPERIDOL IN DISORIENTATION AMONG ELDERLY PATIENTS.
221639 04-11

DISPLACEMENT

REGIONAL DIFFERENCES IN RESPONSE TO DISPLACEMENT AND INHIBITION OF SYNTHESIS OF CATECHOLAMINES IN THE CAT BRAIN.
206334 03-03

DISPOSITION

COMPARISON BETWEEN THE EFFECTS PRODUCED BY CHRONIC DENERVATION AND BY COCAINE ON THE SENSITIVITY TO, AND ON THE DISPOSITION OF, NORADRENALINE IN ISOLATED SPLEEN STRIPS.
193139 01-03

EFFECT OF SIMULATED ALTITUDE ON THE DISPOSITION OF CHLORPROMAZINE IN MOUSE BRAIN AND LIVER.
197455 01-05

THE DISPOSITION KINETICS OF AMPHETAMINE IN THE RUMINANT ANIMAL.
197456 01-03

THE DISPOSITION OF BUTRIPTYLINE IN RATS, DOGS AND MAN.
206806 03-13

STEREOSELECTIVE FEATURES OF CATECHOLAMINE DISPOSITION AND THEIR BEHAVIORAL IMPLICATIONS.
207287 03-04

DISPOSITION AND ACTION OF DRUGS AFFECTING BEHAVIOR.
213617 04-03

PLACENTAL TRANSFER OF DIAZEPAM AND ITS DISPOSITION IN THE NEWBORN.
215672 04-13

DISRUPTION

NICOTINE AND CAFFEINE: DISRUPTION OF THE LONG-TERM STORE MEMORY AND PROACTIVE FACILITATION OF LEARNING IN MICE.
198222 02-04

HALOPERIDOL INDUCED DISRUPTION OF CONDITIONED AVOIDANCE RESPONDING: ATTENUATION BY PRIOR TRAINING OR BY ANTICHOLINERGIC DRUGS.
210861 03-04

DISRUPTION OF STATE-DEPENDENT LEARNING (MEMORY RETRIEVAL) BY EMOTIONALLY IMPORTANT STIMULI.
217470 04-04

SEROTONERGIC AND CHOLINERGIC MECHANISMS DURING DISRUPTION OF APPROACH AND AVOIDANCE BEHAVIOR.
225161 04-04

DISRUPTIVE

A BEHAVIORAL INVESTIGATION: THE EFFECTS OF MEDICATION ON DISRUPTIVE CLASSROOM BEHAVIOR AND ACADEMIC PERFORMANCE. (PH.D. DISSERTATION).
200461 02-11

DISSENTING

TREATING DEPRESSION WITH TRANQUILIZERS: WITH DISSENTING VIEW OF LITHIUM CARBONATE THERAPY.
218123 04-09

DISSOCIATION

PHARMACOLOGICAL AND ANATOMICAL DISSOCIATION OF TWO TYPES OF HABITUATION.
195079 01-04

DISSOCIATION OF GENERAL BEHAVIOR PRODUCED BY PSYCHOTROPIC DRUGS IN MICE.
198733 02-04

EFFECTS OF DELTA8-THC ON DISSOCIATION OF CONDITIONED AVOIDANCE RESPONDING IN TOLERANT AND NONTOLERANT RATS.
202969 02-04

INHIBITORS OF CEREBRAL PROTEIN SYNTHESIS: DISSOCIATION OF AVERSIVE AND AMNESIC EFFECTS.
221005 04-04

DISTRIBUTION

PHARMACOKINETICS OF LITHIUM AND ITS REGIONAL DISTRIBUTION IN RAT BRAIN.
193547 01-03

REGIONAL DISTRIBUTION OF CATIONS AND THEIR RELATION TO THE NEUROCHEMISTRY OF EXPERIMENTAL EPILEPSY, NEUROTRANSMITTERS AND ATPASE IN THE CENTRAL NERVOUS SYSTEM. (PH.D. DISSERTATION).
193588 01-03

GENETIC DETERMINANT OF LITHIUM ION DISTRIBUTION. I. AN IN VITRO MONOZYGOTIC DIZYGOTIC TWIN STUDY.
194826 01-13

INTRACELLULAR DISTRIBUTION OF 3H-DELTA8-TETRAHYDROCANNABINOL IN RAT ORGANS AFTER I.V. ADMINISTRATION.
195112 01-03

DISTRIBUTION OF CHLORPROMAZINE IN A SIMPLIFIED BLOOD INFLUENCED BY VARIOUS DRUGS.
195245 01-03

THE SUBCELLULAR DISTRIBUTION OF INTRAVENTRICULARLY ADMINISTERED 3H-METARAMINOL IN INTACT AND RAT BRAIN PRETREATED WITH P-CHLOROAMPHETAMINE.
197289 01-03

PERIPHERAL TISSUE DISTRIBUTION, BRAIN DISTRIBUTION AND METABOLISM OF MESCALINE-14C IN MONKEYS.
197458 01-03

BLOOD LEVEL, EXCRETION, DISTRIBUTION AND METABOLISM OF 14C-TRIFLUBAZAM, A NEW 1,5 BENZODIAZEPINE, IN MICE AND DOGS.
197940 01-03

DISTRIBUTION OF AMPHETAMINE AND ITS HYDROXYLATED METABOLITES IN VARIOUS AREAS OF THE RAT BRAIN.
198211 02-03

ABSORPTION, DISTRIBUTION AND EXCRETION OF ALPRENOLOL IN MAN, DOG, AND RAT.
199621 02-13

SUBCELLULAR DISTRIBUTION OF RESERPINE IN BLOOD PLATELETS: EVIDENCE FOR MULTIPLE POOLS.
202665 02-03

SPATIAL DISTRIBUTION OF THE EEG OF DYSLEXIC CHILDREN.
205504 02-13

THE EFFECT OF DIAZEPAM AND NITRAZEPAM ON INTRACELLULAR AND EXTRACELLULAR DISTRIBUTION OF SODIUM AND POTASSIUM IONS IN INDIVIDUAL STRUCTURES OF RATS BRAINS.
207199 03-03

THE INFLUENCE OF INTRAPERITONEAL INJECTION OF IPRAZIDE AND TRANSAMINE ON THE DISTRIBUTION OF BIOGENIC AMINES IN CORTICAL AND SUBCORTICAL WHITE MATTER OF THE RAT BRAIN.
209032 03-03

BLOOD-BRAIN BARRIER: I. KINETICS OF DISTRIBUTION OF 3H-AMPHETAMINE IN THE RAT BRAIN AFTER INTRAVENOUS ADMINISTRATION.
210788 03-03

REGIONAL AND SUBCELLULAR DISTRIBUTION AND KINETIC PROPERTIES OF RAT BRAIN CHOLINE ACETYLTRANSFERASE -- SOME FUNCTIONAL CONSIDERATIONS.
210816 03-03

GENETIC DETERMINANT OF LITHIUM ION METABOLISM: II. AN IN VIVO STUDY OF LITHIUM ION DISTRIBUTION ACROSS ERYTHROCYTE MEMBRANES.
211412 03-03

STUDIES ON THE SYNTHESIS AND SUBCELLULAR DISTRIBUTION OF DOPAMINE IN THE RAT ADRENAL MEDULLA.
217797 04-03

METABOLISM AND AUTORADIOGRAPHIC DISTRIBUTION OF DELTA8- AND DELTA9-TETRAHYDROCANNABINOL IN SOME ORGANS OF THE MONKEY CALLITHRIX-JACCHUS.
217837 04-03

REGIONAL DISTRIBUTION OF TYROSINE-HYDROXYLASE, NOREPINEPHRINE AND DOPAMINE WITHIN THE AMYGDALOID COMPLEX OF THE RAT.
217872 04-03

THE DISTRIBUTION KINETICS AND TURNOVER OF CHOLINE AND ACETYLCHOLINE IN PLASMA AND BRAIN OF RATS. (PH.D. DISSERTATION).
220472 04-03

THE BLOOD-BRAIN BARRIER II: DISTRIBUTION KINETICS OF H3-P-HYDROXYAMPHETAMINE IN BRAIN STRUCTURES OF THE RAT AFTER INTRAVENOUS ADMINISTRATION.
220977 04-03

THE CORRELATION BETWEEN TRIFTAZINE DISTRIBUTION IN SOME RAT ORGANS AND ITS PHARMACOLOGICAL EFFECTS WITH DIFFERENT TYPES OF ADMINISTRATION.
223016 04-03

REGIONAL DISTRIBUTION OF MONOAMINEOXIDASE ACTIVITY FOR 5-HYDROXYTRYPTAMINE AND TYRAMINE IN THE HYPOTHALAMUS OF THE RAT.
223049 04-03

GENETIC CONTROL OF LITHIUM ION DISTRIBUTION.
224833 04-09

DISTURBANCE
DEVELOPMENTAL DISTURBANCE OF THE BRAIN IN RAT OFFSPRING FOLLOWING MATERNAL ADMINISTRATION OF 5-FLUOURACIL DURING PREGNANCY.
202422 02-03
CLINICAL TRIAL OF FLUPENTHIXOL IN PATIENTS WITH CHRONIC SCHIZOPHRENIA: ESPECIALLY IN PATIENTS HAVING DIFFICULTY IN REHABILITATION OWING TO DECREASED EXPRESSION, APATHY AND DISTURBANCE OF RAPPORT.
202603 02-08

DISTURBANCES
INTEREST OF SULPIRIDE IN KINETIC DISTURBANCES.
202069 02-11
SLEEP - EEG TESTS OF NONSPECIFIC CASES OF PAROXYSM AND EPISODIC BEHAVIORAL DISTURBANCES: A PRELIMINARY REPORT.
203704 02-14
LITHIUM TREATMENT OF BEHAVIOURAL DISTURBANCES IN PATIENTS WITH DEFECTIVE INTELLECT.
205610 03-09
CLINICAL STUDIES OF D-40TA (TRIAZOLOBENZODIAZEPINE) -- CROSSOVER TRIAL ON SLEEP DISTURBANCES AND SLEEP EEG IN NORMAL ADULTS.
209412 03-10
HEPTAMINOL AND TENSION DISTURBANCES INDUCED BY PSYCHOTROPIC DRUG THERAPY: CLINICAL STUDY.
210089 03-13
AMENORRHEA AND BEHAVIORAL DISTURBANCES: CLINICAL CASE TREATED WITH A PSYCHOTHERAPEUTIC METHOD BASED ON ELEMENTS OF THE CYBERNETIC THEORY OF G. CIPOLLINA MANGIAMELI.
210418 03-14
ORTHOMOLECULAR TREATMENT IN DISTURBANCES INVOLVING BRAIN FUNCTION.
214719 04-11
THE USE OF CYAMEPROMAZINE IN SMALL DOSES IN TREATMENT OF NONPSYCHOTIC DISTURBANCES.
215798 04-04
DIFFERENTIAL DIAGNOSIS AND THERAPY OF SLEEP DISTURBANCES.
217193 04-11
ELECTROENCEPHALOGRAPHIC STUDY FOR THE EVALUATION OF THE EFFECTS OF 7-CHLORO-5-PHENYLBENZODIAZEPIN-2-ONE (N-DEMETHYLDIAZEPAM) ON SLEEP DISTURBANCES IN A GROUP OF MENTAL PATIENTS.
221272 04-14
NYSTAGMUS AND DISTURBANCES IN PSYCHOMOTOR FUNCTIONS INDUCED BY PSYCHOTROPIC DRUG THERAPY.
221990 04-15
CLINICAL STUDY OF A NEW TRANQUILIZER, LEXOTAN, IN NEUROTIC DISTURBANCES.
224583 04-10

DISTURBED
DRUG AND COGNITION STUDIES IN DISTURBED CHILDREN.
198085 02-11
THE EFFECT OF L-DOPA AND L-DOPA COMBINED WITH CHLORPROMAZINE ON SPINAL CORD ACTIVITY DURING DISTURBED INHIBITION BY TETANUS TOXOID.
207200 03-03
THE USE OF ANTICONVULSANT TREATMENT OF BEHAVIORALLY DISTURBED CHILDREN WITH BIOELECTRIC EPILEPSY: A CATAMNESTIC STUDY OF 76 CASES.
211355 03-11
MANAGING DISTURBED GERIATRIC PATIENTS WITH CHEMOTHERAPY.
218010 04-11

DISULFIRAM
THE INFLUENCE OF ALPHA-METHYLTYROSINE AND DISULFIRAM ON THE INHIBITORY FUNCTION OF THE CAUDATE NUCLEUS AND CATECHOLAMINE CONTENT IN THE BRAIN OF CATS.
200565 02-03
EEG VARIATIONS UNDER ANTABUSE (DISULFIRAM) AND ANTABUSE PLUS ALCOHOL EXPOSITION: A STUDY OF PATHOGENESIS FROM ANTABUSE THERAPY COMPLICATIONS.
200572 02-15
THE EFFECT OF INHIBITORS OF CATECHOLAMINE SYNTHESIS (ALPHA-METHYLTYROSINE AND DISULFIRAM) ON THE BACKGROUND ACTIVITY OF SENSORIMOTOR CORTEX NEURONS AND THEIR RESPONSES TO AFFERENT CAUDATE AND RETICULAR STIMULATION.
202598 02-04
DISULFIRAM IMPLANTATION CRITICALLY EVALUATED.
205316 02-11
ACUTE ORGANIC BRAIN SYNDROME: A COMPLICATION OF DISULFIRAM THERAPY.
213710 04-15

DIURETICS
LITHIUM TOXICITY PRECIPITATED BY DIURETICS.
219353 04-15

DIURNAL
ANTIDEPRESSANT AGENTS AND REVERSAL OF DIURNAL ACTIVITY CYCLES IN THE RAT.
218954 04-04

DIVALENT
DIVALENT CATIONS IN PREDICTING ANTIDEPRESSANT RESPONSE TO LITHIUM.
202886 02-14

DIVERGENT
EFFECT OF MARIJUANA ON DIVERGENT AND CONVERGENT PRODUCTION COGNITIVE TESTS.
223394 04-14

DIVERSION
TEGRETOL DEPENDENCY AND DIVERSION OF THE SENSE OF TASTE.
225486 04-14

DIVIDED
A COMPARISON OF A DIVIDED AND A SINGLE DOSE REGIME OF CLOMIPRAMINE (ANAFRANIL).
215149 04-09

DIZYGOTIC
GENETIC DETERMINANT OF LITHIUM ION DISTRIBUTION. I. AN IN VITRO MONOZYGOTIC DIZYGOTIC TWIN STUDY.
194826 01-13

DL-AMPHETAMINE
ANTAGONISM OF PSYCHOSTIMULANT 2 PHENYLDIMETHYLTETRAHYDROOXAZINE HYDROCHLORIDE (G-130) TO CENTRAL NERVOUS SYSTEM DEPRESSING DRUGS: MONOAMINEOXIDASE INHIBITORY ACTIVITY AND NOREPINEPHRINE AND SEROTONIN INDUCED CHANGES, COMPARISON WITH DL-AMPHETAMINE.
221267 04-03

DMPEA
POTENTIATION BY 3,4 DIMETHOXYPHENYLETHYLAMINE (DMPEA) AND COCAINE OF NOREPINEPHRINE-INDUCED CONTRACTION OF GUINEA-PIG VAS-DEFERENS.
194156 01-03

DMPP
EFFECTS OF SODIUM, OUABAIN AND DMPP ON THE NEURONAL EFFLUX OF NORADRENALINE.
197959 01-03
INFLUENCE OF OXYMETAZOLINE AND PHENTOLAMINE ON NORADRENALINE (NA) RELEASE CAUSED BY ELECTRICAL STIMULATION, POTASSIUM, TYRAMINE AND DIMETHYLPHENYLPIPERAZINE (DMPP).
197973 01-03

DMT
EFFECTS OF IPRONIAZID, CHLORPROMAZINE AND METHIOTHEPIN ON DMT INDUCED CHANGES IN BODY TEMPERATURE, PUPILLARY DILATATION, BLOOD PRESSURE AND EEG IN THE RABBIT.
215724 04-03

DNA
THE EFFECT OF PSYCHOPHARMACOLOGICAL DRUGS ON PUFFING AND ON RNA AND DNA SYNTHESES IN THE SALIVARY GLAND CHROMOSOMES OF DROSOPHILA-MELANOGASTER. (PH.D. DISSERTATION).
196250 01-03
REACTION OF CATIONIC GROUPS OF CHLORPROMAZINE WITH ANIONIC MACROMOLECULES: COMPLEXES WITH DNA, RNA, HYALURONIC ACID AND HEPARIN.
199897 02-03

DOCTOR
SUIT AGAINST RECOMMENDING DOCTOR AND PSYCHIATRIST -- REJECTED. STOVALL V. HARMS, 522 P.2D 353, (KANSAS) SUPREME COURT OF KANSAS. MAY 11, 1974.
200438 02-17
NONPHARMACOLOGICAL FACTORS IN DRUG THERAPY: THE INTERACTION OF DOCTOR, PATIENT, AND TABLET APPEARANCE IN THE TREATMENT OF ANXIETY/DEPRESSIVE SYNDROMES.
215060 04-10

DOCTORS
DRUG ABUSE AND DRUG DEPENDENCY. A COMPENDIUM FOR MEDICAL DOCTORS.
204468 02-17

DOET
A CRYSTALLOGRAPHIC AND THEORETICAL STUDY OF THE CONFORMATION OF DOET AND ITS SIGNIFICANCE FOR THE HALLUCINOGENIC AMPHETAMINES.
210746 03-01
SOME PHARMACOLOGICAL ACTIONS OF 2,5 DIMETHOXY-4-ETHYLAMPHETAMINE (DOET) IN RATS AND MICE.
210747 03-03

DOG
EFFECTS OF L-DOPA AND L-TRYPTOPHAN ON THE CEREBRAL BLOOD FLOW IN THE DOG.
197213 01-03
EFFECTS OF NORADRENALINE ON THE CEREBRAL BLOOD FLOW IN THE DOG.
197214 01-03
EFFECTS OF 5-HYDROXYTRYPTAMINE ON THE CEREBRAL BLOOD FLOW IN THE DOG.
197215 01-03
EFFECTS OF ANORECTIC AGENTS ON BLOOD PRESSURE OF THE DOG.
197464 01-03

ALTERATIONS IN ACID-BASE BALANCE IN THE DOG AFTER INTRAVENOUS ADMINISTRATION OF BENZOCTAMINE AND DIAZEPAM, COMPARED WITH THOSE INDUCED BY THIOPENTAL.
197485 01-03

ABSORPTION, DISTRIBUTION AND EXCRETION OF ALPRENOLOL IN MAN, DOG, AND RAT.
199621 02-13

ATTENUATION OF ACUTE HABITUATION BY SCOPOLAMINE IN THE BLACK-TAILED PRAIRIE DOG (CYNOMYS-LUDOVICIANUS).
206745 03-04

EFFECTS OF P-METHOXYAMPHETAMINE (PMA) ON THE CARDIOVASCULAR SYSTEM OF THE DOG.
210867 03-05

CARDIOPULMONARY TOXICITY OF DELTA9-TETRAHYDROCANNABINOL IN THE ANESTHETIZED DOG.
211015 03-05

INTRAVENOUS SELF-ADMINISTRATION OF D-AMPHETAMINE AND L-AMPHETAMINE BY DOG.
222806 04-04

DOGMATIL

A CLINICAL NEUROLEPTIC INVESTIGATION OF N-(1-ETHYL-PYRROLIDIN-2-YL) 2-METHOXY-5-SULFAMOYL-BENZAMIDE NEUROLEPTIC SULPIRIDE (DOGMATIL) IN ACUTELY ILL SCHIZOPHRENICS.
195038 01-11

REFLECTIONS ON THE EFFICACY OF NEW DRUG THERAPIES ON THE OCCASION OF USING AN ORIGINAL MEDICATION: SULPIRIDE (DOGMATIL).
209123 03-11

ESSENTIAL INFANTILE ENURESIS AND DOGMATIL.
218165 04-14

DOGMATYL

EXAMINATION OF THE NEW PSYCHOTROPIC DRUG, DOGMATYL (FK-880 SULPIRIDE).
194509 01-11

DOGS

INVOLVEMENT OF SEROTONIN IN HYPERKINETIC EPISODES IN SCOTTISH TERRIER DOGS. (PH.D. DISSERTATION).
196261 01-03

CHANGES IN ACID-BASE BALANCE, RESPIRATION RATE AND HEART RATE UPON REPEATED ORAL ADMINISTRATION OF BENZOCTAMINE AND DIAZEPAM TO CONSCIOUS DOGS.
197460 01-03

A COMPARISON OF PIMOZIDE AND THIORIDAZINE AS ANTAGONISTS OF AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR IN DOGS.
197470 01-04

BLOOD LEVEL, EXCRETION, DISTRIBUTION AND METABOLISM OF 14C-TRIFLUBAZAM, A NEW 1,5 BENZODIAZEPINE, IN MICE AND DOGS.
197940 01-03

THE EFFECT OF (-) DELTA9-TRANS-TETRAHYDROCANNABINOL ON MYOCARDIAL CONTRACTILITY AND VENOUS RETURN IN ANESTHETIZED DOGS.
199964 02-03

INFLUENCE OF RESERPINE ON HEMODYNAMICS IN DOGS.
206415 03-03

THE DISPOSITION OF BUTRIPTYLINE IN RATS, DOGS AND MAN.
206806 03-13

L-DOPA HYPOTENSION IN DOGS: EVIDENCE FOR MEDIATION THROUGH 5-HT RELEASE.
210868 03-05

CENTRALLY MEDIATED CARDIOVASCULAR EFFECTS OF 5-HYDROXYTRYPTOPHAN IN MAO INHIBITED DOGS: MODIFICATION BY AUTONOMIC ANTAGONISTS.
215757 04-03

EFFECTS OF CHLORDIAZEPOXIDE UPON FEAR MOTIVATED BEHAVIOR IN DOGS.
221799 04-04

THE EFFECT OF NEUROTROPIC AGENTS ON MOTOR HYPERACTIVITY IN DOGS INDUCED BY AMIZYL.
223062 04-04

DOMESTIC

EPILEPTIFORM SEIZURES IN DOMESTIC FOWL. IV. THE EFFECTS OF ANTICONVULSANT DRUGS.
197742 01-03

SHORT-TERM EFFECTS OF TESTOSTERONE PROPIONATE ON THE BEHAVIOUR OF YOUNG INTACT MALE DOMESTIC DUCKS (ANAS-PLATYRHYNCHOS).
199461 02-04

DONOR

CRYSTAL STRUCTURE DETERMINATIONS OF THE DONOR ACCEPTOR COMPLEXES OF PHENOTHIAZINE AND PHENOXAZINE WITH NICKEL THIETE. (PH.D. DISSERTATION).
201003 02-01

DONORS

STATUS OF LITHIUM PATIENTS AS BLOOD DONORS.
217969 04-15

DOPA

STUDIES ON SOME METABOLIC EFFECTS OF DOPA AND DOPAMINE IN THE RAT.
193301 01-03

BRAIN DOPA/5-HTP DECARBOXYLASE ACTIVITY AFTER THE CHRONIC ADMINISTRATION OF L-DOPA OR 5-HYDROXY-L-TRYPTOPHAN IN NORMAL AND LESIONED CATS.
194483 01-05

THE FORMATION IN VIVO OF 3,4 DIHYDROXYPHENYLALANINE (DOPA) FROM 3-HYDROXY-DL-PHENYLALANINE (M-TYROSINE).
198015 01-03

POTENTIATION OF JUMPING BEHAVIOR BY AMINOPHYLLINE IN MICE TREATED WITH THRESHOLD DOSES OF AMPHETAMINE AND DOPA.
200039 02-04

THE EFFECTS OF DOPA ON THE VISUAL EVOKED POTENTIALS IN RABBIT AND ON MOUSE MOTOR BEHAVIOR FOLLOWING INHIBITION OF DOPAMINE-BETA-HYDROXYLASE.
206768 03-03

RELATIONSHIP BETWEEN THE LATE REFLEX DISCHARGE AND LOCOMOTOR MOVEMENTS IN ACUTE SPINAL CATS AND RABBITS WITH DOPA.
209728 03-03

EFFECTS OF A DECARBOXYLASE INHIBITOR ON THE DOPA AND 5-HTP INDUCED CHANGES IN THE LOCOMOTOR LIKE DISCHARGE PATTERN OF RABBIT HIND LIMB NERVES.
210740 03-03

THE EEG EFFECTS OF DOPA IN THE RABBIT DEPENDING UPON THE LEVEL OF BRAINSTEM SECTION.
210880 03-03

HUMAN GROWTH HORMONE RESPONSE TO LEVODOPA: RELATION TO MENOPAUSE, DEPRESSION, AND PLASMA DOPA CONCENTRATION.
213918 04-09

THE EFFECT OF LSD AND 2-BROMOLSD ON THE DOPA ACCUMULATION AFTER CENTRAL AND PERIPHERAL DECARBOXYLASE INHIBITION.
217674 04-03

GENETICALLY SELECTED WINNER AND LOSER RATS IN THE TUNNEL COMPETITION: INFLUENCE OF APOMORPHINE AND DOPA.
217829 04-04

DOPAC

3,4 DIHYDROXYPHENYLACETIC ACID (DOPAC): A POSSIBLE ENDOGENOUS INHIBITOR OF INDOLEAMINE-N-METHYLATION IN THE RAT BRAIN.
197676 01-17

ACTION OF NEUROLEPTICS ON THE CONTENT OF DOPAMINE AND DOPAC IN THE RAT CAUDATE NUCLEUS.
197682 01-03

DOPAMINE

CHANGES IN ACTIVATION OF ADENYLATE-CYCLASE AND OF DOPAMINE TURNOVER IN RAT STRIATUM DURING PROLONGED HALOPERIDOL TREATMENT.
192933 01-03

SELECTIVE STIMULATION BY DOPAMINE OF ADENYLATE-CYCLASE IN HOMOGENATES OF RABBIT RETINA.
192936 01-03

EFFECT OF 6-HYDROXYDOPAMINE ON HYPOTHALAMIC NOREPINEPHRINE AND DOPAMINE CONTENT, ULTRASTRUCTURE OF THE MEDIAN EMINENCE, AND PLASMA CORTICOSTERONE.
193050 01-03

STUDIES ON SOME METABOLIC EFFECTS OF DOPA AND DOPAMINE IN THE RAT.
193301 01-03

COMPARATIVE INVOLVEMENT OF DOPAMINE AND NORADRENALINE IN RATE-FREE SELF-STIMULATION IN SUBSTANTIA-NIGRA, LATERAL HYPOTHALAMUS, AND MESENCEPHALIC CENTRAL GRAY.
193303 01-03

THE INFLUENCE OF CYPROHEPTADINE AND OF D-LYSERGAMIDE ON THE RISE IN TEMPERATURE INDUCED BY INTRACEREBROVENTRICULAR 5-HYDROXYTRYPTAMINE, NORADRENALINE AND DOPAMINE IN CONSCIOUS RABBITS.
193451 01-03

EFFECT OF TWO DOPAMINE RECEPTOR BLOCKERS ON A SEROTONIN MEDIATED BEHAVIORAL SYNDROME IN RATS.
193548 01-04

ALTERATIONS BY ANESTHETIC AGENTS OF THE RESPONSES OF RAT STRIATAL NEURONS TO IONTOPHORETICALLY APPLIED AMPHETAMINE, ACETYLCHOLINE, NORADRENALINE, AND DOPAMINE.
193803 01-03

A COMPARISON OF THE INHIBITORY EFFECTS OF CERTAIN ANTIPARKINSONIAN AGENTS ON DOPAMINE ACCUMULATION INTO THE RAT STRIATUM.
195234 01-03

EFFECT OF CHRONIC TRANSECTION ON DOPAMINE, NORADRENALINE AND 5-HYDROXYTRYPTAMINE IN THE RAT SPINAL CORD.
195244 01-03

ADRENERGIC RECEPTOR BLOCKING AGENTS: EFFECTS ON CENTRAL NORADRENALINE AND DOPAMINE RECEPTORS AND ON MOTOR ACTIVITY.
195429 01-03

INCREASE IN BRAIN DOPAMINE AFTER AXOTOMY OR TREATMENT WITH GAMMA-HYDROXYBUTYRIC ACID DUE TO ELIMINATION OF THE NERVE IMPULSE FLOW.
195439 01-03

EFFECTS OF DRUGS INFLUENCING MONOAMINE MECHANISMS ON THE INCREASE IN BRAIN DOPAMINE PRODUCED BY AXOTOMY OR TREATMENT WITH GAMMA-HYDROXYBUTYRIC ACID.
195440 01-03

CLINICAL MEASUREMENT OF CENTRAL DOPAMINE AND SEROTONIN METABOLISM IN ACUTE PSYCHOTIC DISORDERS.
195924 01-09

TIME-DEPENDENT EFFECTS OF PHENOTHIAZINES ON DOPAMINE TURNOVER IN PSYCHIATRIC PATIENTS. (UNPUBLISHED PAPER).
196087 01-13

ALTERATIONS IN THE TURNOVER OF BRAIN NOREPINEPHRINE AND DOPAMINE IN ALCOHOL DEPENDENT RATS.
196805 01-03

ADENYLCYCLASE IN RAT STRIATUM AND NUCLEUS-ACCUMBENS: STIMULATION BY DOPAMINE RECEPTOR AGONISTS. (UNPUBLISHED PAPER).
197124 01-03

EFFECTS OF MORPHINE, CHOLINERGIC AGENTS AND COLD EXPOSURE ON MIDBRAIN DOPAMINE (DA) NERVE CELLS OF MORPHINE TOLERANT AND NONTOLERANT MICE.
197287 01-03

THE EFFECT OF A NEW TETRACYCLIC ANTIDEPRESSANT COMPOUND, ORG-GB94, ON THE TURNOVER OF DOPAMINE, NORADRENALIN AND SEROTONIN IN THE RAT BRAIN.
197496 01-03

THE INHIBITORY EFFECT OF DOPAMINE ON ACETYLCHOLINE RELEASE.
197566 01-03

ACTION OF NEUROLEPTICS ON THE CONTENT OF DOPAMINE AND DOPAC IN THE RAT CAUDATE NUCLEUS.
197682 01-03

THEOPHYLLINE INCREASED SENSITIVITY TO NOCICEPTIVE STIMULATION AND REGIONAL TURNOVER OF RAT BRAIN 5-HT, NORADRENALINE AND DOPAMINE.
197926 01-03

DOPAMINE AGONIST AND ANTAGONIST ACTIVITIES OF PIRIBEDIL (ET495) AND ITS METABOLITES.
197930 01-04

DETERMINATION OF NORADRENALINE, DOPAMINE, SEROTONIN, 5-HYDROXYINDOLEACETIC ACID, TYROSINE AND TRYPTOPHANE IN THE ISOLATED PERFUSED RAT BRAIN.
197967 01-06

EFFECTS OF OXOTREMORINE AND PHYSOSTIGMINE ON THE TURNOVER OF DOPAMINE IN THE CORPUS-STRIATUM AND THE LIMBIC SYSTEM.
198207 02-03

THE RELATIVE ATTENUATION OF SELF-STIMULATION, EATING AND DRINKING PRODUCED BY DOPAMINE RECEPTOR BLOCKADE.
198225 02-04

COMPARISON OF THE EFFECTS OF THE INTRANIGRAL INJECTIONS OF CHOLINOMIMETICS WITH SYSTEMIC INJECTIONS OF THE DOPAMINE RECEPTOR STIMULATING AND BLOCKING AGENTS IN THE RABBIT.
199772 02-03

THE NUCLEUS LINEARIS INTERMEDIUS RAPHE AND BEHAVIOUR EVOKED BY DIRECT AND INDIRECT STIMULATION OF DOPAMINE SENSITIVE SITES WITHIN THE CAUDATE NUCLEUS OF CATS.
199864 02-04

AMANTADINE AND D-145, AN AMANTADINE DERIVATIVE, DO NOT EFFECT DOPAMINE SENSITIVE ADENYLATE-CYCLASE FROM THE CAUDATE PUTAMEN OF THE RAT BRAIN.
199867 02-03

EFFECTS OF BENAPRYZINE, A NEW ANTIPARKINSON DRUG, ON DOPAMINE UPTAKE INTO CORPUS-STRIATUM.
199868 02-03

THE INTERACTION OF DOPAMINE ANTAGONISTS AND AMANTADINE HYDROCHLORIDE ON THE ACQUISITION OF THE CONDITIONED AVOIDANCE RESPONSE IN RATS.
199959 02-04

THE ROLE OF BRAIN DOPAMINE IN THE HYPERACTIVITY SYNDROME PRODUCED BY INCREASED 5-HYDROXYTRYPTAMINE SYNTHESIS IN RATS.
199960 02-04

INHIBITORY ROLE OF DOPAMINE AND 5-HYDROXYTRYPTAMINE IN THE SEXUAL BEHAVIOUR OF FEMALE RATS.
199968 02-04

GABA BLOCKADE, DOPAMINE AND SCHIZOPHRENIA: EXPERIMENTAL STUDIES IN THE CAT.
200052 02-03

AN ONTOGENIC STUDY ON THE EFFECT OF CATECHOLAMINE RECEPTOR STIMULATING AGENTS ON THE TURNOVER OF NORADRENALINE AND DOPAMINE IN THE BRAIN.
202715 02-03

CHANGES OF KINETIC CONSTANT OF STRIATAL TYROSINE-HYDROXYLASE ELICITED BY NEUROLEPTICS THAT IMPAIR THE FUNCTION OF DOPAMINE RECEPTORS.
202716 02-03

THE ROLE OF FOREBRAIN DOPAMINE SYSTEMS IN AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR IN THE RAT.
202774 02-04

INFLUENCE OF STRIATAL DOPAMINE RECEPTOR BLOCKADE ON A BULBAR MOTOR REACTION.
202778 02-03

SPECIES DIFFERENCES IN ANTAGONISTIC EFFECT OF MORPHINE AGAINST DEPRESSOR RESPONSE TO DOPAMINE.
202800 02-03

LSD AS AN AGONIST OF DOPAMINE RECEPTORS IN THE STRIATUM.
204183 02-03

LSD AS AN AGONIST AND ANTAGONIST AT CENTRAL DOPAMINE RECEPTORS.
204184 02-03

THE RELATIVE SIGNIFICANCE OF NOREPINEPHRINE DOPAMINE AND 5-HYDROXYTRYPTAMINE IN THE ELECTROSHOCK SEIZURE IN THE RAT.
204339 02-03

THIORIDAZINE: CENTRAL DOPAMINE TURNOVER AND CLINICAL EFFECTS OF ANTIPSYCHOTIC DRUGS.
204852 02-08

LACK OF EFFECT OF AMANTADINE ON D-AMPHETAMINE INDUCED RELEASE OF DOPAMINE FROM CAT BRAIN IN VIVO.
204865 02-02

AMPHETAMINE-INDUCED CHANGES IN STRIATAL DOPAMINE AND ACETYLCHOLINE LEVELS AND RELATIONSHIP TO ROTATION (CIRCLING BEHAVIOR) IN RATS.
205432 02-04

METABOLISM OF DOPAMINE AND NOREPINEPHRINE IN RAT BRAIN AFTER SINGLE AND REPEATED ADMINISTRATION OF HALOPERIDOL, LOXAPINE AND CLOZAPINE.
206973 03-03

SEROTONIN AND DOPAMINE TURNOVER AFTER ACUTE AND CHRONIC MORPHINE ADMINISTRATION.
206989 03-03

TRICYCLIC ANTIDEPRESSANT DRUGS AND DOPAMINE SENSITIVE ADENYLCYCLASE FROM RAT CAUDATE NUCLEI.
206990 03-03

A SCHIZOPHRENIFORM BEHAVIORAL PSYCHOSIS MEDIATED BY DOPAMINE.
207035 03-04

BIOCHEMICAL CHARACTERIZATION OF THE DOPAMINE RECEPTOR IN THE MAMMALIAN CAUDATE NUCLEUS.
207297 03-03

DOPAMINE AND THE PHARMACOLOGY OF SCHIZOPHRENIA: THE STATE OF THE EVIDENCE.
207300 03-03

ROLE OF DOPAMINE AND NOREPINEPHRINE IN THE CHEMISTRY OF REWARD.
207302 03-04

CENTRAL DOPAMINE NEURONS AND SENSORY PROCESSING.
207304 03-03

BRAIN DOPAMINE AND BEHAVIOUR: A CRITICAL ANALYSIS OF THE RELATIONSHIP BETWEEN DOPAMINE ANTAGONISM AND THERAPEUTIC EFFICACY OF NEUROLEPTIC DRUGS.
207306 03-04

SUPERSENSITIVITY TO DOPAMINE AGONISTS FOLLOWING UNILATERAL, 6-HYDROXYDOPAMINE INDUCED STRIATAL LESIONS IN MICE.
208552 03-03

THE ROLE OF DOPAMINE AND NOREPINEPHRINE IN CHANGING THE DIRECT CORTICAL RESPONSE TO PHENAMINE.
208971 03-03

DOPAMINE RECEPTOR BLOCKADE BY NEUROLEPTIC DRUGS IN APLYSIA NEURONES.
210599 03-03

ANTAGONISM OF DOPAMINE MEDIATED INHIBITION IN THE NIGROSTRIATAL PATHWAY: A MODE OF ACTION OF SOME CATATONIA INDUCING DRUGS.
210659 03-03

CHEMICAL OR ELECTROLYTIC LESION OF THE SUBSTANTIA-NIGRA: EARLY EFFECTS ON NEOSTRIATAL DOPAMINE METABOLISM.
210699 03-03

INHIBITION BY APOMORPHINE OF DOPAMINE DEAMINATION IN THE RAT BRAIN.
210776 03-03

POSSIBLE MECHANISMS INVOLVED IN THE DEPRESSOR RESPONSE TO DOPAMINE.
210787 03-03

SCOPE AND LIMITATION IN DOPAMINE BETA-HYDROXYLASE MEASUREMENT.
210811 03-02

ENHANCEMENT OF APOMORPHINE-INDUCED INHIBITION OF STRIATAL DOPAMINE TURNOVER FOLLOWING CHRONIC HALOPERIDOL.
210814 03-03

EFFECTS OF CATECHOLAMINE RELEASING AGENTS ON SYNAPTOSOMAL DOPAMINE BIOSYNTHESIS: MULTIPLE POOLS OF DOPAMINE OR MULTIPLE FORMS OF TYROSINE-HYDROXYLASE?.
210825 03-03

TRICYCLIC ANTIDEPRESSIVE DRUGS AND DOPAMINE SENSITIVE ADENYLATE-CYCLASE FROM RAT BRAIN STRIATUM.
210856 03-03

DIFFERENTIAL EFFECTS OF D- AND L-AMPHETAMINE AND METHYLPHENIDATE ON RAT STRIATAL DOPAMINE BIOSYNTHESIS.
210859 03-03

ON A PRIME ROLE FOR NEWLY SYNTHESIZED DOPAMINE IN STRIATAL FUNCTION.
210862 03-03

INHIBITION OF THE SYMPATHETIC NERVOUS SYSTEM BY 5,6 DIHYDROXY-2-DIMETHYLAMINOTETRALIN (M-7), APOMORPHINE AND DOPAMINE.
210888 03-03

THE EFFECT OF DOPAMINE AND NORADRENALINE ANTAGONISTS ON AMPHETAMINE-INDUCED LOCOMOTOR ACTIVITY IN MICE AND RATS.
210894 03-04

THE DOPAMINE VASCULAR RECEPTOR.
210902 03-03

INCREASED LEVEL PRESSING FOR AMPHETAMINE AFTER PIMOZIDE IN RATS: IMPLICATIONS FOR A DOPAMINE THEORY OF REWARD.
213350 03-04

RESPONSES OF CENTRAL NEURONES TO AMANTADINE: COMPARISON WITH DOPAMINE AND AMPHETAMINE.
213398 04-03

ENHANCEMENT OF SELF-STIMULATION BY DEPRENIL: EVIDENCE FOR A ROLE OF DOPAMINE NEURONES IN REWARD.
213432 04-04

DOPAMINE ANTAGONISM BY THIORIDAZINE IN SCHIZOPHRENIA.
213527 04-08

D-AMPHETAMINE INDUCED RELEASE OF NEWLY SYNTHESIZED AND STORED DOPAMINE FROM THE CAUDATE NUCLEUS IN VIVO.
214110 04-03

ANTINOCICEPTIVE ACTION OF OXOTREMORINE AND REGIONAL TURNOVER OF RAT BRAIN NORADRENALINE, DOPAMINE AND 5-HT.
215683 04-03

EFFECT OF ALPHA-METHYLDOPA ON DOPAMINE SYNTHESIS AND RELEASE IN RAT STRIATUM IN VITRO.
215690 04-03

BEHAVIOURAL EVIDENCE OF DOPAMINE RECEPTOR STIMULATION BY PIRIBEDIL (ET495) AND ITS METABOLITE S584.
217152 04-04

BLOCKADE OF RESERPINE OF METHYLPHENIDATE-INDUCED RELEASE OF BRAIN DOPAMINE.
217456 04-03

NEUROLEPTIC-INDUCED HYPERSENSITIVITY OF STRIATAL DOPAMINE RECEPTORS IN THE RAT AS A MODEL OF TARDIVE DYSKINESIAS. EFFECTS OF CLOZAPINE, HALOPERIDOL, LOXAPINE AND CHLORPROMAZINE.
217462 04-03

PHARMACOLOGICAL EVIDENCE FOR CEREBRAL DOPAMINE RECEPTOR BLOCKADE BY METOCLOPRAMIDE IN RODENTS.
217469 04-03

EFFECTS OF ANTAGONISTS UPON LOCOMOTOR STIMULATION INDUCED BY INJECTION OF DOPAMINE AND NORADRENALINE INTO THE NUCLEUS-ACCUMBENS OF NIALAMIDE PRETREATED RATS.
217475 04-04

THE BEHAVIOURAL EFFECTS OF DOPAMINE APPLIED INTRACEREBRALLY TO AREAS OF THE MESOLIMBIC SYSTEM.
217660 04-04

INHIBITION OF STRIATAL DOPAMINE SYNTHESIS IN RATS INJECTED CHRONICALLY WITH NEUROLEPTICS IN THEIR EARLY LIFE.
217687 04-03

STUDIES ON THE SYNTHESIS AND SUBCELLULAR DISTRIBUTION OF DOPAMINE IN THE RAT ADRENAL MEDULLA.
217797 04-03

THE EFFECT OF DOPAMINE AND OF APOMORPHINE ON DB-CAMP INDUCED STIMULATION OF SYNAPTOSOMAL TYROSINE-HYDROXYLASE.
217823 04-03

REGIONAL DISTRIBUTION OF TYROSINE-HYDROXYLASE, NOREPINEPHRINE AND DOPAMINE WITHIN THE AMYGDALOID COMPLEX OF THE RAT.
217872 04-03

STEREOSPECIFICITY OF DOPAMINE RECEPTORS INVOLVED IN THE REGULATION OF THE KINETIC STATE OF TYROSINE-HYDROXYLASE IN STRIATUM AND NUCLEUS-ACCUMBENS.
217888 04-03

DOPAMINE RECEPTORS IN THE BRAIN.
220311 04-17

MONOAMINEOXIDASE INHIBITORS ANTAGONIZE THE ACCELERATION OF BRAIN DOPAMINE SYNTHESIS INDUCED BY NEUROLEPTIC DRUGS IN VIVO: IMPLICATIONS FOR THE TREATMENT OF TARDIVE DYSKINESIA.
220948 04-03

DOES CHRONIC MORPHINE TREATMENT INDUCE A SUPERSENSITIVITY OF DOPAMINE RECEPTORS IN RAT BRAIN
221038 04-03

DOPAMINE SENSITIVE ADENYLCYCLASE IN HUMAN CAUDATE NUCLEUS: A STUDY IN CONTROL SUBJECTS AND SCHIZOPHRENIC PATIENTS.
221732 04-13

ASCENDING CATECHOLAMINE PATHWAYS AND AMPHETAMINE-INDUCED LOCOMOTOR ACTIVITY: IMPORTANCE OF DOPAMINE AND APPARENT NONINVOLVEMENT OF NOREPINEPHRINE.
223054 04-03

LYSERGIC ACID DIETHYLAMIDE: EVIDENCE FOR STIMULATION OF CEREBRAL DOPAMINE RECEPTORS.
223174 04-03

INTERACTIONS BETWEEN LYSERGIC ACID DIETHYLAMIDE AND DOPAMINE SENSITIVE ADENYLCYCLASE SYSTEMS IN RAT BRAIN.
223175 04-03

ROLE FOR POSTSYNAPTIC DOPAMINE RECEPTORS IN THE REGULATION OF THE KINETIC STATE OF STRIATAL TYROSINE-HYDROXYLASE. (UNPUBLISHED PAPER).
225307 04-03

DOPAMINE-BETA-HYDROXYLASE

EVIDENCE FOR A PERIPHERAL EFFECT OF FUSARIC ACID, A DOPAMINE-BETA-HYDROXYLASE INHIBITOR, ON SEROTONIN METABOLISM.
196593 01-03

EFFECTS OF 5-(N-BUTYL) PICOLINAMIDE (SCH-10595), A DOPAMINE-BETA-HYDROXYLASE INHIBITOR, ON SEROTONIN AND CATECHOLAMINE METABOLITES IN BRAIN.
197813 01-03

INHIBITION OF DOPAMINE-BETA-HYDROXYLASE IN MANIC PATIENTS: A CLINICAL TRIAL WITH FUSARIC ACID.
199632 02-07

SELECTIVE INHIBITION OF DOPAMINE-BETA-HYDROXYLASE IN THE PERIPHERAL TISSUES BY 5-DIMETHYLDITHIOCARBAMYLPICOLINIC ACID; ITS EFFECT ON STRESS INDUCED ULCER, ETHANOL INDUCED SLEEP AND BLOOD PRESSURE.
204484 02-03

RELEASE OF NOREPINEPHRINE AND DOPAMINE-BETA-HYDROXYLASE BY NERVE STIMULATION: II. EFFECTS OF PAPAVERINE.
204485 02-03

THE EFFECTS OF DOPA ON THE VISUAL EVOKED POTENTIALS IN RABBIT AND ON MOUSE MOTOR BEHAVIOR FOLLOWING INHIBITION OF DOPAMINE-BETA-HYDROXYLASE.
206768 03-03

BEHAVIORAL EFFECTS OF A NEW DOPAMINE-BETA-HYDROXYLASE INHIBITOR (FUSARIC ACID) IN MAN.
207311 03-07

IMMUNOLOGICAL LOCALIZATION OF DOPAMINE-BETA-HYDROXYLASE ON THE CHROMAFFIN GRANULE MEMBRANE.
207326 03-03

EVIDENCE FOR REVERSIBLE INHIBITION OF BRAIN DOPAMINE-BETA-HYDROXYLASE ACTIVITY IN VIVO BY AMPHETAMINE ANALOGUES.
210821 03-03

EFFECT OF VARIOUS INHIBITORS OF TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE ON SELF-STIMULATION BEHAVIOUR.
213431 04-04

DEVELOPMENTAL VARIATIONS OF CHOLINE ACETYLTRANSFERASE, DOPAMINE-BETA-HYDROXYLASE AND MONOAMINEOXIDASE IN CHICKEN EMBRYO AND CHICKEN SYMPATHETIC GANGLIA.
217840 04-03

IN VIVO UPTAKE OF ANTIBODY TO DOPAMINE-BETA-HYDROXYLASE INTO SYMPATHETIC ELEMENTS.
217848 04-03

DIFFERENTIAL RATES OF INCREASE IN PONTINE TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE ACTIVITIES AFTER RESERPINE.
217854 04-03

EFFECTS OF THE DOPAMINE-BETA-HYDROXYLASE INHIBITOR FLA-63 ON THE KINETICS OF ELIMINATION OF AMPHETAMINE IN THE RAT.
217881 04-03

IN VIVO BINDING OF ANTIBODY TO DOPAMINE-BETA-HYDROXYLASE IN ADRENERGIC NERVES AND SUBSEQUENT ANTIDROMIC TRANSPORT (UNPUBLISHED PAPER).
218147 04-03

PHARMACOLOGICAL ACTION OF FD-008, A NEW DOPAMINE-BETA-HYDROXYLASE INHIBITOR: II. EFFECTS ON CENTRAL NERVOUS SYSTEM IN MICE AND RATS.
221823 04-02

PHARMACOLOGICAL ACTION OF FD-008, A NEW DOPAMINE-BETA-HYDROXYLASE INHIBITOR: III. EFFECTS ON ENDOGENOUS BIOGENIC AMINE LEVELS IN RATS.
221859 04-03

ELEVATION OF PLASMA DOPAMINE-BETA-HYDROXYLASE ACTIVITY DURING MECHOLYL TEST.
225523 04-13

DOPAMINERGIC

REVERSAL BY L-DOPA OF IMPAIRED LEARNING DUE TO DESTRUCTION OF THE DOPAMINERGIC NIGRO-NEOSTRIATAL PROJECTION.
193578 01-04

A PHARMACOLOGICAL AND NEUROANATOMICAL ANALYSIS OF DOPAMINERGIC AND NORADRENERGIC PATHWAYS INVOLVED IN SELF-STIMULATION IN RATS. (PH. D. DISSERTATION).
193582 01-04

EFFECTS OF SELF-STIMULATION BEHAVIOR OF DRUGS INFLUENCING DOPAMINERGIC NEUROTRANSMISSION MECHANISMS.
194152 01-04

TRYPTAMINERGIC AND DOPAMINERGIC RESPONSES OF SCHISTOSOMA-MANSONI.
194155 01-03

DOPAMINERGIC MECHANISMS IN PATIENTS WITH EXTRAPYRAMIDAL DISEASE. (UNPUBLISHED PAPER).
194542 01-13

THE IMPORTANCE OF THE ASCENDING DOPAMINERGIC SYSTEMS TO THE EXTRAPYRAMIDAL AND MESOLIMBIC BRAIN AREAS FOR THE CATALEPTIC ACTION OF THE NEUROLEPTIC AND CHOLINERGIC AGENTS.
195250 01-03

SPECIFIC ASYMMETRIC BEHAVIOUR INDUCED BY THE DIRECT CHEMICAL STIMULATION OF NEOSTRIATAL DOPAMINERGIC MECHANISMS.
197929 01-04

AMPHETAMINE, L-DOPA AND APOMORPHINE: EFFECTS ON ACTIVITY OF RAT DOPAMINERGIC NEURONS.
202370 02-03

DOPAMINERGIC NEURONS: DRUG-INDUCED ANTAGONISM OF THE INCREASE IN TYROSINE-HYDROXYLASE ACTIVITY PRODUCED BY CESSATION OF IMPULSE FLOW.
202664 02-03

STEREOTYPED AND CIRCLING BEHAVIOUR INDUCED BY DOPAMINERGIC AGONISTS AFTER LESIONS OF THE MIDBRAIN RAPHE NUCLEI.
202792 02-04

DOPAMINERGIC BLOCKING EFFECTS OF ANTIPSYCHOTIC DRUGS.
207294 03-03

ADENOSINE-3-5-MONOPHOSPHATE CONTENT IN RAT CAUDATE NUCLEUS: DEMONSTRATION OF DOPAMINERGIC AND ADRENERGIC RECEPTORS.
208300 03-03

DOPAMINERGIC MECHANISMS OF OPIATE ACTIONS IN BRAIN.
208554 03-03

ARE AUTORECEPTORS IN DOPAMINERGIC NEURONS INVOLVED IN THE CHANGE OF THE KINETIC STATE OF STRIATAL TYROSINE-HYDROXYLASE ELICITED BY ANTIPSYCHOTICS? (UNPUBLISHED PAPER).
208636 03-03

CHOLINERGIC DOPAMINERGIC INTERACTION IN THE STRIATUM: THE EFFECT OF 6-HYDROXYDOPAMINE OR PIMOZIDE TREATMENT ON THE INCREASED STRIATAL ACETYLCHOLINE LEVELS INDUCED BY APOMORPHINE, PIRIBEDIL AND D-AMPHETAMINE.
210668 03-03

EFFECTS OF DOPAMINERGIC RECEPTOR AGONISTS AND ANTAGONISTS ON THE ACTIVITY OF THE NEOSTRIATAL CHOLINERGIC SYSTEM.
210669 03-03

PRESENCE OF DOPAMINERGIC TERMINALS AND ABSENCE OF DOPAMINERGIC CELL BODIES IN THE CEREBRAL CORTEX OF THE CAT.
210800 03-03

EFFECTS OF DOPAMINERGIC DRUGS AND ACUTE MEDIAL FOREBRAIN BUNDLE LESIONS ON STRIATAL ACETYLCHOLINE LEVELS.
210831 03-03

DOPAMINERGIC NEURONS IN THE NIGROSTRIATAL AND MESOLIMBIC PATHWAYS: MEDIATION OF SPECIFIC EFFECTS OF D-AMPHETAMINE.
210855 03-03

NEUROCHEMICAL REGULATION OF FEEDING IN THE RAT: FACILITATION BY ALPHA-NORADRENERGIC, BUT NOT DOPAMINERGIC RECEPTOR STIMULANTS.
211538 03-04

EVOKED NEURAL ACTIVITY IN THE BASAL GANGLIA OF THE CAT AND ITS MODIFICATION BY CHOLINERGIC AND DOPAMINERGIC AGENTS. (PH.D. DISSERTATION).
212520 03-03

GAMMA-HYDROXYBUTYRATE AND CONTROL OF DOPAMINERGIC NEURONS.
213626 04-03

INCREASED SENSITIVITY TO DOPAMINERGIC AGENTS AFTER CHRONIC NEUROLEPTIC TREATMENT.
215689 04-04

HOMOVANILLIC ACID CONCENTRATION IN RAT BRAIN: EFFECT OF A CHOLINE ACETYLTRANSFERASE INHIBITOR AND COMPARISON WITH CHOLINERGIC AND DOPAMINERGIC AGENTS.
215711 04-03

NOMIFENSINE: A POTENT DOPAMINERGIC AGONIST OF ANTIPARKINSON POTENTIAL.
217472 04-03

BEHAVIOURAL SUPERSENSITIVITY TO APOMORPHINE FOLLOWING CEREBRAL DOPAMINERGIC DENERVATION BY 6-HYDROXYDOPAMINE.
217527 04-03

DOPAMINERGIC MEDIATION OF THE INTEROCEPTIVE CUE PRODUCED BY D-AMPHETAMINE IN RATS.
217531 04-04

EFFECTS OF CENTRAL DOPAMINERGIC BLOCKADE WITH PIMOZIDE UPON THE EEG STAGES OF SLEEP IN MAN.
217546 04-14

AMPHETAMINE-INDUCED DOPAMINERGIC HYPERSENSITIVITY IN GUINEA-PIGS: IMPLICATIONS IN PSYCHOSIS AND HUMAN MOVEMENT DISORDERS.
218115 04-04

BEHAVIORAL EFFECTS OF LOCAL INJECTION OF 6-HYDROXYDOPAMINE IN THE MEDIAL VENTRAL TEGMENTUM IN THE RAT. POSSIBLE ROLE OF THE MESOLIMBIC DOPAMINERGIC SYSTEM.
220946 04-04

DOPAMINERGIC DRUGS ANTAGONIZED THE PSYCHOTOMIMETIC EFFECTS OF PARTIAL AGONIST ANALGESICS.
221048 04-04

INFLUENCE OF CHEMICAL STIMULATION OF CENTRAL DOPAMINERGIC SYSTEM ON THE OPEN-FIELD BEHAVIOR OF RATS.
221308 04-03

THE DOPAMINERGIC COMPONENT IN THE ACTION OF D,L-AMPHETAMINE ON THE INHIBITORY FUNCTION OF THE CAUDATE NUCLEUS.
223014 04-03

DOPS

PROFILE-BASED-THERAPY (PBT) IN SCHIZOPHRENIAS: A PRECLINICAL INDICATION FOR THE USE OF DIHYDROXYPHENYLSERINE (DOPS).
195115 01-08

DORMANT

PIPERIDINE CONCENTRATION CHANGES IN THE BRAIN AND BLOOD OF DORMANT MICE.
210701 03-03

DORSAL

CHANGES IN THE DORSAL ROOT POTENTIAL WITH DIAZEPAM AND WITH THE ANALGESICS ASPIRIN, NITROUS OXIDE, MORPHINE AND MEPERIDINE.
195248 01-03

AN ANALYSIS OF MONOAMINERGIC MECHANISMS OF THE DORSAL HIPPOCAMPUS WHICH MEDIATE THE CONDITIONED ESCAPE REACTION IN RATS.
208991 03-04

EFFECTS OF AMPHETAMINE ISOMERS AND NEUROLEPTICS ON SELF-STIMULATION FROM THE NUCLEUS-ACCUMBENS AND DORSAL NORADRENERGIC BUNDLE.
213394 04-03

THE CORRELATION BETWEEN THE VENTRAL AND DORSAL HIPPOCAMPUS DURING IMPROVEMENT OR DETERIORATION OF SHORT-TERM MEMORY.
215487 04-04

DISCRIMINATIVE CONTROL OF BEHAVIOR BY ELECTRICAL STIMULATION OF THE DORSAL RAPHE NUCLEUS: GENERALIZATION TO LYSERGIC ACID DIETHYLAMIDE (LSD).
217821 04-12

DOSAGE

LONG-TERM LITHIUM ADMINISTRATION TO RATS. LITHIUM AND SODIUM DOSAGE AND ADMINISTRATION, AVOIDANCE OF INTOXICATION, POLYURIC CONTROL RATS.
195042 01-03

THE EFFECT OF DAILY ORAL DOSAGE OF DIAZEPAM, PLASMA CONCENTRATIONS AND METABOLIC CLEARANCE OF DIAZEPAM AND DEMETHYLDIAZEPAM ON VARIOUS CONSTITUENTS OF THE ACUTE CLINICAL ANXIETY SYNDROME.
196191 01-10

ONCE-A-DAY DOSAGE TRICYCLIC ANTIDEPRESSANT DRUG THERAPY: A SURVEY.
196679 01-09

THE EFFECT OF VARYING THE DOSAGE OF SODIUM PENTOBARBITAL ON THE BARPRESS RATE OF RATS.
201843 02-04

STEADY-STATE PLASMA CONCENTRATIONS DURING SINGLE AND MULTIPLE DOSAGE SCHEDULES OF AMITRIPTYLINE.
202699 02-13

OXYPERTINE IN THE TREATMENT OF MORBID ANXIETY. REPORT OF A NEW LOW DOSAGE SCHEDULE.
207532 03-10

DOSAGE OF A PSYCHOTROPIC DRUG TO PREVENT RELAPSE IN A CURED SCHIZOPHRENIC PATIENT.
209402 03-08

USE OF A BENZODIAZEPINE AT HIGH DOSAGE LEVELS: A STATEMENT ON 50 OBSERVATIONS.
212179 03-10

A COMPARISON OF A LOW AND HIGH DOSAGE REGIME OF CLOMIPRAMINE (ANAFRANIL).
215150 04-09

EFFECTS OF HIGH DOSAGE DELTA9-TETRAHYDROCANNABINOL ON SLEEP PATTERNS IN MAN.
215740 04-14

A DOUBLE-BLIND COMPARISON OF THREE TIMES DAILY AND SINGLE NIGHT DOSAGE OF THE TRICYCLIC ANTIDEPRESSANT DOTHIEPIN.
216463 04-09

ONCE DAILY DOSAGE WITH MAPROTILINE (LUDIOMIL).
221659 04-09

ONCE DAILY DOSAGE STUDY WITH MAPROTILINE (LUDIOMIL).
221660 04-09

AN INTERIM REPORT OF A DOUBLE-BLIND STUDY COMPARING A ONCE DAILY DOSAGE OF MAPROTILINE (LUDIOMIL) WITH AMITRIPTYLINE THRICE DAILY.
221661 04-09

RELATIONSHIP BETWEEN DOSAGE AND RESPONSE TO LITHIUM PROPHYLAXIS IN RECURRENT DEPRESSION.
224872 04-09

DOSAGES
A CONTROLLED SERIES OF EXPERIMENTS INVESTIGATING SOME SOCIOLOGICAL EFFECTS OF TWO DOSAGES OF CHLORDIAZEPOXIDE (LIBRIUM) UPON INDIVIDUALS AND SMALL GROUPS. (PH.D. DISSERTATION).
195145 01-14
BLOOD AND URINE LEVELS OF N,N DIMETHYLTRYPTAMINE FOLLOWING ADMINISTRATION OF PSYCHOACTIVE DOSAGES TO HUMAN SUBJECTS.
198230 02-12
EFFECT OF ANESTHETIC DOSAGES OF PENTOBARBITAL ON THE CONTENT AND TURNOVER OF SEROTONIN IN BRAIN AREAS.
217816 04-03

DOSE
TREATMENT OF SCHIZOPHRENIA BY THE ADMINISTRATION OF A SMALL DOSE OF FORIT FOR COMPARATIVELY LONG PERIODS OF TIME.
194476 01-08
DOSE EFFECTS OF CHLORDIAZEPOXIDE UPON HABITUATION OF OPEN-FIELD BEHAVIOR IN WHITE RATS.
194736 01-04
DOXEPIN IN A SINGLE BEDTIME DOSE IN PSYCHONEUROTIC OUTPATIENTS.
194834 01-10
CODEINE AND COCAINE REINFORCED RESPONDING IN RHESUS MONKEYS: EFFECTS OF DOSE ON RESPONSE RATES UNDER A FIXED-RATIO SCHEDULE.
202667 02-04
THE PENTOBARBITAL TEST DOSE FOR DEPRESSANT DRUG DEPENDENCE: A REEVALUATION IN TERMS OF ALCOHOL CONSUMPTION.
202883 02-17
POLYGRAPHIC EXAMINATION DURING FAST AND SLOW INTRAVENOUS INJECTION OF THE SAME DOSE OF DIAZEPAM.
205508 02-13
ALTERATION OF PSYCHOSOMATIC REACTIVITY AFTER A SINGLE THERAPEUTIC DOSE OF PENTOBARBITAL IN RELATION TO THE SEX OF PROBANDS.
205627 03-14
DOSE EQUIVALENCE OF THE ANTIPSYCHOTIC DRUGS.
207291 03-17
DOSE LEVEL AND EFFECTS OF TRIFLUPERIDOL IN CLINICAL USE FOR SCHIZOPHRENIA.
207643 03-08
THE EFFECTS OF STRAIN, DRUG, AND DOSE LEVEL ON GENERAL ACTIVITY AND EXPLORATORY BEHAVIOR IN MICE. (PH.D. DISSERTATION).
211883 03-04
A COMPARISON OF A DIVIDED AND A SINGLE DOSE REGIME OF CLOMIPRAMINE (ANAFRANIL).
215149 04-09
POLYGRAPHIC NIGHT SLEEP PATTERN DURING CHRONIC SINGLE AND MULTIPLE NEUROLEPTIC DOSE ADMINISTRATION.
215701 04-08
FIXED-RATIO ESCAPE AND AVOIDANCE ESCAPE FROM NALOXONE IN MORPHINE-DEPENDENT MONKEYS: EFFECTS OF NALOXONE DOSE AND MORPHINE PRETREATMENT.
215968 04-04
DOSE RANGING STUDIES OF CLONAZEPAM IN MAN.
217556 04-14
A SINGLE DAILY DOSE OF A SUSTAINED RELEASE FORM OF AMITRIPTYLINE IN DEPRESSIVE ILLNESS.
219961 04-09
DOSE EFFECTS OF SMOKED MARIHUANA ON HUMAN COGNITIVE AND MOTOR FUNCTIONS.
221036 04-01
EFFECTS OF SINGLE AND MULTIPLE DOSE LSD ON ENDOGENOUS LEVELS OF BRAIN TYROSINE-HYDROXYLASE AND CATECHOLAMINES.
221044 04-12
A COMPARISON BETWEEN DAILY AND NIGHTLY DOSE REGIMEN OF AMITRIPTYLINE AND MAPROTILINE (LUDIOMIL) IN THE TREATMENT OF REACTIVE DEPRESSION IN GENERAL PRACTICE.
221662 04-09
OBSERVATIONS ON THE DOSE REGIME OF FLUPHENAZINE DECANOATE IN MAINTENANCE THERAPY OF SCHIZOPHRENIA.
222602 04-17

DOSE-DEPENDENCE
DOSE-DEPENDENCE OF CHLORPHENTERMINE-INDUCED ULTRASTRUCTURAL ALTERATIONS IN RAT.
197960 01-03

DOSE-DEPENDENT
DOSE-DEPENDENT DIFFERENCES OF AMPHETAMINE LEVELS IN BRAIN AND HEART OF ADULT AND DEVELOPING MICE.
197927 01-03

DOSE-RESPONSE
THE EFFECTS OF AGE AND ILLUMINATION ON THE DOSE-RESPONSE CURVES FOR THREE STIMULANTS.
214014 04-04
DOSE-RESPONSE RELATIONSHIP FOR NORTRIPTYLINE IN ENDOGENOUS DEPRESSION.
224835 04-09

DOSED
CHLORPROMAZINE EXCRETION IN CHRONICALLY DOSED PRIMATES. I. OCCURRENCE OF A PREVIOUSLY UNREPORTED CLASS OF CHLORPROMAZINE CONJUGATES.
217553 04-03

DOSES
SMALL DOSES OF SULPIRIDE IN THE TREATMENT OF PSYCHONEUROTIC SYNDROMES.
194071 01-09
INFLUENCE OF THERAPEUTIC AND TOXIC DOSES OF NEUROLEPTICS AND ANTIDEPRESSANTS ON ENERGY METABOLISM OF THE ISOLATED PERFUSED RAT BRAIN.
195236 01-03
EFFECTS OF REPEATED DOSES OF 1-DELTA8-TRANS-TETRAHYDROCANNABINOL ON SCHEDULE-CONTROLLED TEMPORALLY SPACED RESPONDING OF RATS.
195431 01-04
EFFECTS OF THE HIGH DOSES OF L-DOPA ON ELECTRICAL ACTIVITY IN THE BRAIN OF THE RABBIT: INTERACTION WITH THE METABOLISM OF 5-HT.
197468 01-03
POTENTIATION OF JUMPING BEHAVIOR BY AMINOPHYLLINE IN MICE TREATED WITH THRESHOLD DOSES OF AMPHETAMINE AND DOPA.
200039 02-04
EFFECTS OF LOW AND HIGH DOSES OF L-DOPA ON THE TETRABENAZINE OR ALPHA-METHYLTYROSINE-INDUCED SUPPRESSION OF BEHAVIOUR IN A SUCCESSIVE DISCRIMINATION TASK.
200042 02-04
PHARMACOKINETIC DETERMINANTS OF THE RESPONSE TO SINGLE DOSES OF CHLORDIAZEPOXIDE.
203005 02-13
PLASMA AND CEREBROSPINAL FLUID CONCENTRATIONS OF PHENOBARBITAL IN INFANTS GIVEN SINGLE DOSES.
206057 03-13
CHANGES IN MENTAL AGE WITH SUBNORMAL CHILDREN TREATED WITH DOSES OF GABA AND NUCLEOTIDES.
210286 03-14
THE PASSATIZATION INDEX OF RETARDATES TREATED WITH HIGH DOSES OF GABA AND NUCLEOTIDES.
210288 03-11
MNEMONIC CAPACITY OF MENTALLY RETARDED BOYS TREATED WITH HIGH DOSES OF NUCLEOTIDES AND GABA.
210291 03-14
TEMPORAL DISCRIMINATION TESTS IN MENTAL RETARDATES TREATED WITH NUCLEOTIDES AND GABA IN HIGH DOSES.
210293 03-14
THE EFFECTS OF NUCLEOTIDES AND GABA IN LARGE DOSES ON THE RESPONSE TO A PAINFUL STIMULUS WITH RETARDATES.
210296 03-14
COMPARISON BETWEEN BEHAVIOURS ELICITED BY HIGH DOSES OF AMPHETAMINE AND FENFLURAMINE: IMPLICATIONS FOR THE CONCEPT OF STEREOTYPY.
210742 03-04
CORRECTION OF AUTONOMIC EFFECTS OF PSYCHOTROPIC DRUGS BY LARGE DOSES OF DIHYDROERGOTAMINE IN ADULTS AND THE ELDERLY.
211998 03-11
SELECTIVE DESTRUCTION OF SEROTONIN TERMINALS IN RAT FOREBRAIN BY HIGH DOSES OF 5,7 DIHYDROXYTRYPTAMINE.
213401 04-03
EEG CHANGES IN THE TREATMENT WITH OCTOCLOTHEPINE IN VERY HIGH DOSES.
215064 04-13
THE BIPHASIC EFFECT OF SMALL DOSES OF TRANYLCYPROMINE ON THE SPONTANEOUS MOTOR ACTIVITY AND LEARNED CONDITIONED BEHAVIOUR IN RATS.
215665 04-04
THE USE OF CYAMEPROMAZINE IN SMALL DOSES IN TREATMENT OF NONPSYCHOTIC DISTURBANCES.
215798 04-04
ELECTROCARDIOGRAPHIC MONITORING OF ENURETIC CHILDREN RECEIVING THERAPEUTIC DOSES OF IMIPRAMINE.
225336 04-15

DOSULEPIN
CARDIOTOXIC EFFECTS OF TRICYCLIC ANTIDEPRESSANTS IMIPRAMINE, AMITRIPTYLINE AND DOSULEPIN (PROTHIADEN-SPOFA) IN AN ACUTE EXPERIMENT IN RATS.
205597 02-15

DOTHIEPIN
THE OUTCOME OF DOTHIEPIN TREATMENT IN 1,900 DEPRESSED PATIENTS.
215700 04-09
A DOUBLE-BLIND COMPARISON OF THREE TIMES DAILY AND SINGLE NIGHT DOSAGE OF THE TRICYCLIC ANTIDEPRESSANT DOTHIEPIN.
216463 04-09

DOUBLE-BLIND

A DOUBLE-BLIND CROSSOVER COMPARISON BETWEEN CLOTHIAPINE AND DIAZEPAM IN THE TREATMENT OF MENTAL SYMPTOMS IN CHRONIC ALCOHOLICS.
192988 01-11

EXAMINATION OF THE EFFECTS OF CLOXAZOLAM BY A DOUBLE-BLIND STUDY OF MENTAL PATIENTS BEFORE REHABILITATION.
194474 01-08

HALOPERIDOL FOR CHRONICALLY HOSPITALIZED PSYCHOTICS: A DOUBLE-BLIND COMPARISON WITH THIOTHIXENE AND PLACEBO: A FOLLOWUP OPEN EVALUATION.
196676 01-14

A MULTINATIONAL, DOUBLE-BLIND TRIAL WITH A NEW ANTIDEPRESSANT MAPROTILINE (LUDIOMIL) AND AMITRIPTYLINE.
197031 01-09

PENFLURIDOL (R-16341) AS A MAINTENANCE THERAPY IN CHRONIC PSYCHOTIC PATIENTS: A DOUBLE-BLIND CLINICAL EVALUATION.
197033 01-09

THE EFFECT OF LITHIUM CARBONATE IN COMBINATION WITH TRICYCLIC ANTIDEPRESSANTS IN ENDOGENOUS DEPRESSION: A DOUBLE-BLIND, MULTICENTER TRIAL.
197035 01-09

RNA TREATMENT OF DEMENTIA: A DOUBLE-BLIND STUDY.
197841 01-11

COMPARATIVE STUDY OF Y-6047 AND DIAZEPAM BY A DOUBLE-BLIND METHOD FOR THE TREATMENT OF PSYCHOSOMATIC DISEASES AND NEUROSIS.
198705 02-11

A DOUBLE-BLIND CLINICAL EVALUATION OF PENFLURIDOL (R-16341) AS A MAINTENANCE THERAPY IN SCHIZOPHRENIA.
199993 02-08

A DOUBLE-BLIND CLINICAL TRIAL OF NEW ANTIDEPRESSANT, SURMONTIL.
200922 02-09

SIDE-EFFECTS OF PSYCHOTROPIC DRUGS -- AN ANALYSIS OF DATA OBTAINED FROM DOUBLE-BLIND COMPARATIVE STUDIES IN JAPAN.
201260 02-15

A DOUBLE-BLIND STUDY ON THE EFFECTS OF PIRACETAM UPON PERCEPTUAL AND PSYCHOMOTOR PERFORMANCE AT VARIED HEART RATES IN PATIENTS TREATED WITH ARTIFICIAL PACEMAKERS.
201328 02-13

CLINICAL DOUBLE-BLIND STUDY ON THE ACTIVITY OF A NEW ANTIDEPRESSANT: CAROXAZONE (FI-6654).
201667 02-09

A DOUBLE-BLIND COMPARISON OF CLOMIPRAMINE WITH AMITRIPTYLINE IN DEPRESSION.
202178 02-10

A DOUBLE-BLIND STUDY OF AMANTADINE HYDROCHLORIDE VERSUS BENZTROPINE MESYLATE IN DRUG-INDUCED PARKINSONISM.
202764 02-15

A DOUBLE-BLIND EVALUATION OF DIAZEPAM AND AMYLOBARBITONE IN ACUTE MYOCARDIAL INFARCTION.
202966 02-13

RESULTS OF AN OPEN AND A DOUBLE-BLIND STUDY OF NOMIFENSINE IN COMPARISON TO IMIPRAMINE.
204899 02-10

THE EFFECTS OF CARBAMAZEPINE ON PATIENTS WITH PSYCHOMOTOR EPILEPSY: RESULTS OF A DOUBLE-BLIND STUDY.
205031 02-11

EEG EVALUATION OF HYPNOTIC DRUGS: MOGADON V. RO-5-4200, USING THE DOUBLE-BLIND METHOD.
205435 02-13

DOUBLE-BLIND TRIAL OF SINTAMIL IN DEPRESSION.
206043 03-10

A DOUBLE-BLIND CONTROLLED COMPARISON OF BROMAZEPAM AND DIAZEPAM.
209411 03-10

CLINICAL ASSESSMENT OF LORAZEPAM IN ANXIETY: A DOUBLE-BLIND STUDY.
209485 03-10

CAMAZEPAM VERSUS DIAZEPAM: A DOUBLE-BLIND TRIAL ON PSYCHONEUROTIC PATIENTS.
209487 03-10

SULPIRIDE VERSUS HALOPERIDOL IN SCHIZOPHRENIA: A DOUBLE-BLIND COMPARATIVE TRIAL.
209701 03-08

SULPIRIDE VERSUS CHLORPROMAZINE AND PLACEBO IN THE TREATMENT OF RESTLESS MENTALLY SUBNORMAL PATIENTS -- A DOUBLE-BLIND CROSSOVER STUDY.
209702 03-11

A COMPARISON OF A NEW TRANQUILIZER, SULPIRIDE AND OXAZOLAM ON PSYCHOSOMATIC DISEASES, NEUROSIS AND MASKED DEPRESSION USING DOUBLE-BLIND METHOD.
210180 03-11

A DOUBLE-BLIND COMPARISON OF LITHIUM CARBONATE AND IMIPRAMINE IN THE TREATMENT OF DEPRESSION.
210241 03-09

A DOUBLE-BLIND CONTROLLED STUDY OF THE THIENODIAZEPINE DERIVATIVE (Y-6047) ON NEUROTICS AND PSYCHOSOMATIC DISORDERS.
210559 03-14

THE EFFECT OF ALAMON (HYDROXYZINE HYDROCHLORIDE) AND MEDAZEPAM ON NEUROSIS TESTED BY A DOUBLE-BLIND METHOD.
211344 03-10

TENTATIVE DOUBLE-BLIND TREATMENT OF ANXIETY WITH B-5833.
212166 03-10

A NEW BENZODIAZEPINE, SCREENED BY A PARALLEL DOUBLE-BLIND TEST.
212167 03-10

A FOLLOWUP STUDY OF FEMALE DEPRESSED OUTPATIENTS WHO COMPLETE A RANDOMIZED DOUBLE-BLIND PROPHYLACTIC TRIAL OF ANTIDEPRESSANTS AND HIGH CONTACT. (PH.D. DISSERTATION).
212518 03-09

DOUBLE-BLIND EXAMINATION OF BROMAZEPAM (RO-5-3350) FOR THE TREATMENT OF PSYCHONEUROSIS.
213293 03-10

A DOUBLE-BLIND COMPARISON OF THREE TIMES DAILY AND SINGLE NIGHT DOSAGE OF THE TRICYCLIC ANTIDEPRESSANT DOTHIEPIN.
216463 04-09

A DOUBLE-BLIND TRIAL OF NITRAZEPAM AND FLURAZEPAM AS SEDATIVES.
217041 04-14

A COMPARISON BETWEEN BROMAZEPAM (RO-5-3350, LEXOTAN) AND DIAZEPAM (VALIUM) IN ANXIETY NEUROSIS: A CONTROLLED, DOUBLE-BLIND CLINICAL TRIAL.
217455 04-10

DOUBLE-BLIND PROCEDURE: AN ASSESSMENT IN A STUDY OF LITHIUM PROPHYLAXIS.
218042 04-16

DOUBLE-BLIND COMPARISON OF LITHIUM CARBONATE AND IMIPRAMINE IN TREATMENT OF DEPRESSION.
218772 04-09

A PRELIMINARY DOUBLE-BLIND STUDY WITH SB-5833 (CAMAZEPAM), A NEW BENZODIAZEPINE DERIVATIVE.
221269 04-10

DOUBLE-BLIND TEST OF THREE ANTIDEPRESSANTS, THIRD COMMUNICATIONS: METHODOLOGICAL PROBLEMS.
221288 04-16

DOUBLE-BLIND TEST OF THREE ANTIDEPRESSANTS, FOURTH COMMUNICATION; RESULTS WITH THE HAMBURG DEPRESSION SCALE.
221289 04-11

NOXIPTILIN (AGEDAL) -- A NEW TRICYCLIC ANTIDEPRESSANT WITH A FASTER ONSET OF ACTION? A DOUBLE-BLIND, MULTICENTRE COMPARISON WITH AMITRIPTYLINE.
221306 04-09

EFFECT OF LITHIUM ON NEUROLEPTIC-INDUCED TARDIVE DYSKINESIA COMPARED WITH PLACEBO IN A DOUBLE-BLIND CROSSOVER TRIAL.
221335 04-15

MORE EVIDENCE FAVORS YOUTH DRUG: FIRST DOUBLE-BLIND TRIALS SHOW GEROVITAL HAS SOME EFFECT ON AGING.
221352 04-11

DOUBLE-BLIND COMPARISON OF MAPROTILINE (LUDIOMIL) WITH AMITRIPTYLINE IN THE TREATMENT OF DEPRESSIVE ILLNESS.
221652 04-09

A DOUBLE-BLIND COMPARATIVE CLINICAL TRIAL OF MAPROTILINE (LUDIOMIL) AND AMITRIPTYLINE.
221653 04-09

A DOUBLE-BLIND GENERAL PRACTICE TRIAL OF MAPROTILINE (LUDIOMIL) AGAINST AMITRIPTYLINE IN THE TREATMENT OF REACTIVE DEPRESSION.
221658 04-09

AN INTERIM REPORT OF A DOUBLE-BLIND STUDY COMPARING A ONCE DAILY DOSAGE OF MAPROTILINE (LUDIOMIL) WITH AMITRIPTYLINE THRICE DAILY.
221661 04-09

A STATISTICAL ANALYSIS OF THE COMPARATIVE DOUBLE-BLIND STUDY OF THE ACTIVITY OF LOXAPINE AND THIORIDAZINE.
221671 04-11

RESULTS OF A COMPARATIVE DOUBLE-BLIND STUDY WITH CLOZAPINE AND CHLORPROMAZINE IN THE TREATMENT OF SCHIZOPHRENIC PATIENTS.
221989 04-08

COMPARATIVE STUDY OF CLOCAPRAMINE AND PERPHENAZINE ON CHRONIC SCHIZOPHRENIA BY A DOUBLE-BLIND METHOD.
222158 04-08

COMPARISON OF THE REMEDIAL RESULTS OF CLOFLUPEROL AND HALOPERIDOL FOR SCHIZOPHRENIA BY DOUBLE-BLIND TEST METHOD.
224549 04-08

BENZOCTAMINE (TACITIN) VERSUS PLACEBO: A DOUBLE-BLIND CROSSOVER STUDY IN ANXIETY NEUROTICS.
225064 04-10

DOVES

POSTCASTRATION DECLINE IN BEHAVIOURAL RESPONSIVENESS TO INTRAHYPOTHALAMIC ANDROGEN IN DOVES.
210918 03-03

DOWNS
SEROTONIN IN DOWNS SYNDROME.
198423 02-11

DOXAPRAM
ANTAGONISM OF DEPRESSANT ACTIVITY OF ETHANOL BY DH-524; A COMPARATIVE STUDY WITH BEMEGRIDE, DOXAPRAM AND D-AMPHETAMINE (38640).
213282 03-03

DOXEPIN
A COMPARATIVE STUDY OF DOXEPIN VERSUS TRIFLUOPERAZINE IN ANXIETY NEUROSIS.
194276 01-10

DOXEPIN IN A SINGLE BEDTIME DOSE IN PSYCHONEUROTIC OUTPATIENTS.
194834 01-10

THE EFFECTS OF THE TRICYCLIC ANTIDEPRESSANTS DESMETHYLIMIPRAMINE, DOXEPIN AND IPRINDOLE ON THE ISOLATED PERFUSED RABBIT HEART.
197277 01-03

COLORIMETRIC, ULTRAVIOLET SPECTROPHOTOMETRIC, AND SPECTROPHOTOFLUOROMETRIC DETERMINATION OF DOXEPIN AND SOME OF ITS METABOLITES IN SERUM AND IN URINE.
199214 02-16

CLINICAL EXPERIENCE WITH DOXEPIN.
205600 02-09

MAINTENANCE DOXEPIN (SINEQUAN) THERAPY FOR DEPRESSIVE ILLNESS.
209901 03-09

ACUTE VOLUNTARY POISONING BY DOXEPIN.
210141 03-15

CENTRAL ANTICHOLINERGIC ACTIONS OF DOXEPIN IN RABBITS.
215727 04-03

INHIBITION OF RABBIT MONOAMINEOXIDASE BY DOXEPIN AND RELATED DRUGS.
220972 04-03

DOXEPIN I.M. IN THE TREATMENT OF DEPRESSION AND ANXIETY.
221035 04-10

DOXEPIN AND IMIPRAMINE: EFFECT ON CATECHOLAMINE INHIBITION OF GANGLIONIC TRANSMISSION.
225059 04-03

DEPRESSION AND ANXIETY IN HEROIN ADDICTS: A PLACEBO CONTROLLED STUDY OF DOXEPIN IN COMBINATION WITH METHADONE.
225386 04-09

DPAE
THE EFFECTS OF DIPHENYLAMINOETHANOL (DPAE) AND LIDOCAINE ON CEREBELLAR INHIBITION DEITERS NEURONS. (PH.D. DISSERTATION).
196259 01-03

DPAM
DPAM AND CEREBRAL FUNCTION (SECOND REPORT): PSYCHOPHARMACOLOGICAL IMPLICATIONS.
202162 02-11

DRINKING
EFFECTS OF TRANSMITTER MIMICKERS AT SITES OF ANGIOTENSIN INDUCED DRINKING IN THE CAT.
193434 01-04

THE EFFECTS OF HASHISH INJECTIONS ON FEEDING AND DRINKING IN RATS.
195113 01-04

DOES LITHIUM IN DRINKING WATER PREVENT MENTAL DISORDER?
195933 01-17

THE RELATIVE ATTENUATION OF SELF-STIMULATION, EATING AND DRINKING PRODUCED BY DOPAMINE RECEPTOR BLOCKADE.
198225 02-04

SUBFORNICAL ORGAN: ACETYLCHOLINE APPLICATION ELICITS DRINKING.
210804 03-03

ANALYSIS OF VARIOUS FACTORS INVOLVED IN EEG SYNCHRONIZATION DURING MILK DRINKING IN THE CAT.
217846 04-04

CENTRAL NERVOUS SYSTEM PHARMACOLOGY OF CHOLINERGICALLY ELICITED EATING AND DRINKING BEHAVIOR IN THE ALBINO RAT. (PH.D. DISSERTATION).
222638 04-04

THE EFFECTS OF CHLORDIAZEPOXIDE ON THE DEVELOPMENT OF ADJUNCTIVE DRINKING IN RATS.
225149 04-04

DRIVE
STIMULATION OF A SPECIFIC DRIVE (PREDATORY BEHAVIOR) BY P-CHLOROPHENYLALANINE (PCPA) IN THE RAT.
197952 01-04

APONEURON TREATMENT OF CHRONIC SCHIZOPHRENICS WITH REDUCED DRIVE.
203666 02-08

THE INFLUENCE OF PSYCHOPHARMACA ON THE APTITUDE TO DRIVE.
203784 02-15

DRIVING
THE RELATIONSHIP BETWEEN THE EEG DRIVING RESPONSE TO LIGHT AND PLASMA MONOAMINEOXIDASE (MAO) LEVELS.
205437 02-03

NEUROLEPTIC DRUGS AND AUTOMOBILE DRIVING.
205882 03-15

EFFECT OF TRICYCLIC ANTIDEPRESSANTS AND ALCOHOL ON PSYCHOMOTOR SKILLS RELATED TO DRIVING.
215667 04-14

DRL
DIFFERENTIAL EFFECTS OF CHLORDIAZEPOXIDE AND D-AMPHETAMINE ON RESPONDING MAINTAINED BY A DRL SCHEDULE OF REINFORCEMENT.
195433 01-04

DROPERIDOL
CLASTOGENIC EFFECTS OF HALOPERIDOL IN VIVO AND OF HALOPERIDOL, DROPERIDOL, AND PIPAMPERONE IN VITRO: A NEGATIVE STUDY.
221270 04-15

DROSOPHILA-MELANOGASTER
THE EFFECT OF PSYCHOPHARMACOLOGICAL DRUGS ON PUFFING AND ON RNA AND DNA SYNTHESES IN THE SALIVARY GLAND CHROMOSOMES OF DROSOPHILA-MELANOGASTER. (PH.D. DISSERTATION).
196250 01-03

DROWSINESS
DROWSINESS DUE TO CHLORPROMAZINE IN RELATION TO CIGARETTE SMOKING: A REPORT FROM THE BOSTON COLLABORATIVE DRUG SURVEILLANCE PROGRAM.
193072 01-15

DRUG
DROWSINESS DUE TO CHLORPROMAZINE IN RELATION TO CIGARETTE SMOKING: A REPORT FROM THE BOSTON COLLABORATIVE DRUG SURVEILLANCE PROGRAM.
193072 01-15

PSYCHOACTIVE DRUG USE IN ELDERLY PATIENTS WITH PSYCHIATRIC DISORDERS: A SURVEY OF 12 VETERANS ADMINISTRATION HOSPITALS.
193291 01-11

POTENTIATION OF DRUG INITIATED ADRENAL TYROSINE-HYDROXYLASE INDUCTION BY DIAZEPAM.
193304 01-03

AN EVALUATION OF A DRUG ADMINISTRATION SYSTEM IN A PSYCHIATRIC HOSPITAL.
194409 01-17

ADMINISTRATION OF PG-501 FOR THE TREATMENT OF EXTRAPYRAMIDAL SYNDROME CAUSED BY THE ADMINISTRATION OF A PSYCHOTROPIC DRUG.
194475 01-11

EXAMINATION OF THE NEW PSYCHOTROPIC DRUG, DOGMATYL (FK-880 SULPIRIDE).
194509 01-11

A TRANSIENT STATE CONCEPT OF DRUG RECEPTOR INTERACTION.
195240 01-17

CARDIOVASCULAR ABNORMALITIES FOLLOWING TRICYCLIC ANTIDEPRESSANT DRUG OVERDOSAGE.
195847 01-15

AN EXPLORATORY STUDY OF THE LONG-TERM EFFECTS OF DRUG USE IN HYPERKINESIS. (PH.D. DISSERTATION).
195882 01-11

THE EFFECTS OF DRUG ADMINISTRATION TO THE LATERAL HYPOTHALAMUS: NEUROCHEMICAL CODING OR NONSPECIFICITY?.
195992 01-03

DRUG TREATMENT OF CHRONIC INTRACTABLE PAIN IN PATIENTS REFERRED TO A PSYCHIATRY CLINIC.
196090 01-14

SERIAL EEG RECORDINGS IN PSYCHOTROPIC DRUG TREATMENT.
196144 01-08

RECENT THERAPEUTIC ASPECTS OF DEPRESSION ESPECIALLY ON THE DRUG THERAPY.
196149 01-09

ONCE-A-DAY DOSAGE TRICYCLIC ANTIDEPRESSANT DRUG THERAPY: A SURVEY.
196679 01-09

THE EFFECT OF CHRONIC CANNABIS AND CANNABINOID APPLICATION ON THE HEPATIC DRUG METABOLIZING SYSTEM OF THE RAT.
197282 01-03

ANTICHOLINERGIC TOXIC PSYCHOSIS IN DRUG ABUSERS TREATED WITH BENZTROPINE.
197539 01-15

REPORT OF EARLY CLINICAL DRUG EVALUATION UNIT '11.
198041 01-07

REPORT ON THE EARLY CLINICAL DRUG EVALUATION UNIT.
198043 01-07

DRUG USE PATTERNS AMONG THE ELDERLY.
198051 01-17

PATTERNS OF PSYCHOTROPIC DRUG USE FOR SCHIZOPHRENIA.
198052 01-08

THE USE OF DRUG INTERACTIONS IN ANIMALS FOR SELECTING PSYCHOTROPIC DRUGS.
198057 01-02

EEG PROFILES AS PREDICTORS OF PSYCHOTROPIC DRUG CLASSIFICATION.
198060 01-07

EARLY CLINICAL DRUG EVALUATION UNIT.
198062 01-07

CONTROLLED DRUG EVALUATIONS. 198065 01-07

NIMH-PRB EARLY CLINICAL DRUG EVALUATION UNIT. 198068 01-07

EARLY DRUG EVALUATION IN NEUROTIC OUTPATIENTS. 198069 01-07

EARLY CLINICAL DRUG EVALUATION UNIT. 198070 01-07

DRUG STUDIES IN NORMAL FEMALES, SENIOR CITIZENS, AND IN EXPERIMENTAL GROUPS. 198071 01-07

NIMH-PRB EARLY CLINICAL DRUG EVALUATION UNIT. 198073 01-07

DRUG THERAPY OF DEPRESSED OUTPATIENTS. 198079 02-10

DRUG TREATMENT OF DEPRESSED OUTPATIENTS. 198083 02-10

DRUG THERAPY IN DEPRESSION. 198084 02-09

DRUG AND COGNITION STUDIES IN DISTURBED CHILDREN. 198085 02-11

LONG-TERM CORRELATES OF DRUG USE IN HYPERKINESIS. 198086 02-07

COMPARATIVE DRUG EFFECTS IN HYPERKINETIC CHILDREN. 198088 02-07

COMPARATIVE DRUG TREATMENT OF HYPERACTIVE CHILDREN. 198090 02-11

PSYCHOACTIVE DRUG BLOOD LEVELS AND CLINICAL RESPONSE. 198095 02-07

BEHAVIORAL MECHANISMS OF DRUG ACTION IN SCHIZOPHRENIA. 198103 02-08

PATTERNS OF DRUG ACQUISITION AND USE. 198105 02-17

METHODOLOGY OF OUTPATIENT DRUG RESEARCH. 198106 02-07

A COMPARISON OF THE RELATIVE EFFICACY OF SPECIAL CLASS EDUCATION AND DRUG THERAPY FOR CHILDREN WITH SELECTED LEARNING DISABILITIES. (ED.D. DISSERTATION). 198662 02-11

DRUG THERAPY: BENZODIAZEPINES (FIRST OF TWO PARTS). 199515 02-14

DRUG AND SOCIOTHERAPY IN THE AFTERCARE OF SCHIZOPHRENIC PATIENTS: II. TWO-YEAR RELAPSE RATES. 199625 02-08

DRUG AND SOCIOTHERAPY IN THE AFTERCARE OF SCHIZOPHRENIC PATIENTS: III. ADJUSTMENT OF NONRELAPSED PATIENTS. 199626 02-08

THE IMPORTANCE OF METHODOLOGY IN DRUG STUDIES USING EEG. 199782 02-13

EFFECTS OF BENAPRYZINE, A NEW ANTIPARKINSON DRUG, ON DOPAMINE UPTAKE INTO CORPUS-STRIATUM. 199868 02-03

CLINICAL PHARMACOLOGICAL STUDY OF A HYPNOTIC DRUG, TRICLORYL. 200009 02-11

A SURVEY OF DRUG TREATMENT IN PSYCHIATRY: SPECIAL EMPHASIS ON INPATIENTS ON MEDICAL WELFARE SUPPORTED BY YOKOHAMA CITY. 200447 02-17

SOCIAL AND PSYCHOLOGICAL ASPECTS OF MEDICAL PRACTICE: DRUG TREATMENT IN PSYCHIATRY. 201270 02-17

KETAMIN HYDROCHLORIDE AS A PREANESTHESIA DRUG FOR AN ELECTROSHOCK TREATMENT. 202121 02-11

ACTION OF A NEW PSYCHOTROPIC DRUG (SULPIRIDE) ON AVOIDANCE BEHAVIOR IN RATS. 202770 02-04

LEARNING DEFICITS IN 4 WEEKS OLD OFFSPRING OF THE NURSING MOTHERS TREATED WITH THE NEUROLEPTIC DRUG PENFLURIDOL. 202806 02-04

CONTROLLING DRUGS: INTERNATIONAL HANDBOOK FOR PSYCHOACTIVE DRUG CLASSIFICATION. 202861 02-17

THE PENTOBARBITAL TEST DOSE FOR DEPRESSANT DRUG DEPENDENCE: A REEVALUATION IN TERMS OF ALCOHOL CONSUMPTION. 202883 02-17

DRUG ABUSE AND DRUG DEPENDENCY. A COMPENDIUM FOR MEDICAL DOCTORS. 204468 02-17

DRUG THERAPY: BENZODIAZEPINES (SECOND OF TWO PARTS). 205299 02-17

EFFECTS OF DIAZEPAM ON EXPERIMENTALLY INDUCED CORTICAL EPILEPSY AND THEIR CORRELATION WITH DRUG CONCENTRATION. 205491 02-03

SIMPLE METHOD FOR DETECTION OF THE DRUG CHEATERS IN PSYCHIATRY. 205586 02-17

CATEGORIES OF PSYCHOTROPIC DRUG EFFECTS ON SLEEP EEG AND EOG. 205621 03-13

INFLUENCE OF SOME BIOGRAPHIC FACTORS ON THE THERAPEUTIC DRUG RESPONSE. 205622 03-14

TOXICOLOGICAL AND TERATOLOGICAL STUDY OF 2-PHENYLDIMETHYLTETRAHYDROOXAZINE HYDROCHLORIDE (G-130), A PSYCHOSTIMULANT DRUG. 206783 03-05

EFFECT OF CAMAZEPAM (SB-5833), A NEW ANTIANXIOUS DRUG, ON CARDIAC CONTRACTILITY AND CORONARY HEMODYNAMICS. 206785 03-03

CLINICOSTATISTICAL STUDY OF THE EFFECTS OF SULPIRIDE, A NEW NEUROLEPTIC DRUG. 206805 03-07

PINDOLOL: A NEW PSYCHOTROPIC DRUG. 206836 03-04

LIPID SOLUBILITY AND DRUG PENETRATION OF THE BLOOD-BRAIN BARRIER. 206913 03-03

THE PSYCHOTROPIC DRUG SUMMARY. 206940 03-17

SURVEY ON AND EVALUATION OF THE CONTRIBUTIONS OF METHODOLOGICAL ASPECTS IN THE INVESTIGATION OF LONG-TERM PSYCHOPHARMACOLOGICAL DRUG ACTION. 206984 03-16

ENHANCED DRUG HYDROXYLATION IN MAN UNDER DIPHENYLHYDANTOIN THERAPY. 206992 03-13

PSYCHIATRIC INVESTIGATION OF DRUG DEPENDENCE. 208761 03-17

PSYCHOPATHOGENIC ASPECTS IN ACUTE PSYCHOORGANIC SYNDROMES (RELATIONSHIPS BETWEEN DRUG DEPENDENCE AND DELIRIUM-TREMENS TYPE SYNDROMES). 209063 03-15

CLINICAL COMPARISON OF ANXIOLYTIC DRUG THERAPY. 209080 03-10

REFLECTIONS ON THE EFFICACY OF NEW DRUG THERAPIES ON THE OCCASION OF USING AN ORIGINAL MEDICATION: SULPIRIDE (DOGMATIL). 209123 03-11

DOSAGE OF A PSYCHOTROPIC DRUG TO PREVENT RELAPSE IN A CURED SCHIZOPHRENIC PATIENT. 209402 03-08

EFFECTS OF OVERTRAINING UPON DRUG STATE DEPENDENCY IN DISCRIMINATION LEARNING IN WHITE RATS. 209866 03-04

HEPTAMINOL AND TENSION DISTURBANCES INDUCED BY PSYCHOTROPIC DRUG THERAPY: CLINICAL STUDY. 210089 03-13

NEGATIVE REINFORCING PROPERTIES OF SOME PSYCHOTROPIC DRUGS IN DRUG NAIVE RHESUS MONKEYS. 210889 03-04

CLINICAL EXPERIMENTS WITH A NEW PSYCHOTROPIC DRUG (SULPIRIDE). 211203 03-14

USE OF A NEW PSYCHOTROPIC DRUG, CLOFLUPEROL FOR THE TREATMENT OF CHRONIC SCHIZOPHRENIC PATIENTS. 211304 03-08

EFFECTS OF DRUG ALTERED SEROTONIN LEVELS ON THE ACQUISITION OF A SHUTTLEBOX AVOIDANCE TASK. (PH.D. DISSERTATION). 211781 03-04

THE EFFECTS OF STRAIN, DRUG, AND DOSE LEVEL ON GENERAL ACTIVITY AND EXPLORATORY BEHAVIOR IN MICE. (PH.D. DISSERTATION). 211883 03-04

DRUG TREATMENT IN PSYCHIATRY. 212888 03-17

NEW PSYCHOTROPIC DRUG TRIALS IN TURKEY. 213594 04-11

NEW PSYCHOTROPIC DRUG RESEARCH IN JAPAN. 213596 04-07

NEW PSYCHOTROPIC DRUG DEVELOPMENTS IN FRANCE AND BELGIUM. 213597 04-17

NEW PSYCHOTROPIC DRUG DEVELOPMENTS IN THE USSR AND OTHER EASTERN EUROPEAN COUNTRIES. 213598 04-07

NEW PSYCHOTROPIC DRUG DEVELOPMENTS IN GREAT-BRITAIN. 213599 04-17

EFFECT OF CENTRAL NERVOUS SYSTEM LESIONS ON DRUG ACTION. 213611 04-03

PHYSIOLOGIC FACTORS IN PSYCHOTROPIC DRUG THERAPY. 213616 04-03

DRUG EFFECTS ON BEHAVIOR MAINTAINED BY AVERSIVE EVENTS. 213619 04-04

FREE-RADICALS IN PSYCHOTROPIC DRUG ACTION. 213624 04-03

HALLUCINOGENIC DRUG ACTION ON THE SOMATOSENSORY SYSTEM. 213634 04-04

DRUG THERAPY FOR STUTTERERS: A REVIEW OF RESEARCH. 213786 04-11

PSYCHOTROPIC DRUG USE IN THE BOSTON AREA: A REPORT FROM THE BOSTON COLLABORATIVE DRUG SURVEILLANCE PROGRAM.
213920 04-17

RADIOIMMUNOASSAY OF THE NEUROLEPTIC DRUG PIMOZIDE.
213986 04-06

EFFECTS OF (-)DELTA9-TRANS-TETRAHYDROCANNABINOL (DELTA9-THC) ON TESTS OF PSYCHOTICISM: A STUDY OF EYSENCKS DRUG POSTULATE ON THE EFFECTS OF HALLUCINOGENS IN RELATION TO PSYCHOTICISM.
214009 04-09

ADRENERGIC AND CHOLINERGIC DRUG EFFECTS UPON SHORT-TERM MEMORY IN MICE. (PH.D. DISSERTATION).
214205 04-04

DRUG METABOLISM AND THERAPEUTIC MONITORING.
214337 04-17

NONPHARMACOLOGICAL FACTORS IN DRUG THERAPY: THE INTERACTION OF DOCTOR, PATIENT, AND TABLET APPEARANCE IN THE TREATMENT OF ANXIETY/DEPRESSIVE SYNDROMES.
215060 04-10

INFLUENCE OF AZAPHEN, A NEW ANTIDEPRESSIVE DRUG, ON THE HUMAN EEG.
215065 04-09

THE RELATIONSHIP OF DIAGNOSIS AND TARGET SYMPTOMS TO PSYCHOTROPIC DRUG ASSIGNMENT.
215251 04-17

PSYCHOTROPIC DRUG THERAPY IN A MENTAL HOSPITAL.
215291 04-17

PSYCHOTHERAPEUTIC PROFILE OF A NEW PSYCHOACTIVE DRUG TRAZODONE (AF-1161).
215699 04-09

A RELATION BETWEEN DRUG CONCENTRATIONS IN BRAIN AND STRIATAL HOMOVANILLIC ACID LEVELS IN CHLORPROMAZINE TREATED RATS.
215734 04-03

DRUG INTERACTIONS WITH PSYCHOACTIVE DRUGS.
216184 04-15

SULPIRIDE AND DRUG ADDICTION.
216764 04-11

PROS AND CONS OF DRUG THERAPY IN THE MANAGEMENT OF THE HYPERACTIVE CHILD.
216966 04-11

CONDITIONED LEARNING IN YOUNG RATS BORN OF DRUG ADDICTED PARENTS AND RAISED ON ADDICTIVE DRUGS.
217465 04-04

DRUG SEEKING BEHAVIOR DURING METHADONE MAINTENANCE.
217541 04-04

MODIFICATION OF THE PUNISHING EFFECTS OF PSYCHOACTIVE DRUGS IN RATS BY PREVIOUS DRUG EXPERIENCE.
217765 04-04

AGE DIFFERENCES AFFECTING INDUCTION OF HEPATIC DRUG METABOLIZING ENZYMES BY METHAQUALONE AND PHENOBARBITAL IN THE RAT.
217793 04-03

AN APPLICATION OF LONG-TERM FREQUENCY ANALYSIS IN MEASURING DRUG SPECIFIC ALTERATIONS IN THE EEG OF THE CAT.
218190 04-03

INTERACTION OF DRUG THERAPY WITH MARITAL THERAPY IN DEPRESSIVE PATIENTS.
218769 04-10

AN ADRENERGIC DRUG IN DEPRESSION.
218771 04-10

OBSERVATIONS ON EFFECTS OF A CENTRAL STIMULANT DRUG (METHYLPHENIDATE) IN CHILDREN WITH HYPERACTIVE BEHAVIOR.
219354 04-14

QUANTITATIVE MEASUREMENT OF PARKINSON DISEASE RIGOR. MYOINTEGRATIVE DRUG TRIAL IN COMBINATION WITH THE DECARBOXYLASE INHIBITING DRUG RO-8-0576.
220829 04-11

GENOTYPE OR PRENATAL DRUG EXPERIENCE AFFECT BRAIN MATURATION IN THE MOUSE.
221032 04-03

ASSESSMENT OF TOLERANCE TO BARBITAL BY MEANS OF DRUG DISCRIMINATION PROCEDURES.
221046 04-02

CHLORDIAZEPOXIDE EFFECTS ON REACTIONS TO NOVELTY AND ACTIVITY WITH AND WITHOUT PRIOR DRUG EXPERIENCE.
221047 04-04

COMBINATION DRUG THERAPY IN PSYCHOPHARMACOLOGY.
221075 04-17

PHARMACOLOGICAL EVALUATION OF 3-(N 3,3 DIPHENYLPROPYL-N-METHYL) AMINOPROPAN-1-OL HYDROCHLORIDE (PF-82), A NEW TYPE OF ANTIDEPRESSANT DRUG.
221287 04-02

MORE EVIDENCE FAVORS YOUTH DRUG: FIRST DOUBLE-BLIND TRIALS SHOW GEROVITAL HAS SOME EFFECT ON AGING.
221352 04-11

PHARMACOLOGICAL PROPERTIES OF 6,7 TETRAMETHYLENE-5-PHENYL-1-2-DIHYDRO 3H THIENODIAZEPIN-2-ONE (QM-6008), THIADIPONE), A NEW PSYCHOTROPIC DRUG.
221722 04-02

NYSTAGMUS AND DISTURBANCES IN PSYCHOMOTOR FUNCTIONS INDUCED BY PSYCHOTROPIC DRUG THERAPY.
221990 04-15

RESULTS OF A SURVEY (1966-1967) OF DRUG USAGE IN INSTITUTIONS FOR THE MENTALLY RETARDED. (UNPUBLISHED PAPER).
222411 04-17

ACCIDENTS AND DRUG TREATMENT IN A PSYCHIATRIC HOSPITAL.
222603 04-15

A STUDY OF THE RELATIONSHIP BETWEEN CIRCADIAN RHYTHMS IN DRUG ACTION AND METABOLISM IN THE MOUSE. (PH.D. DISSERTATION).
223562 04-03

URBAN ECOLOGICAL AND HOUSEHOLD CORRELATES OF STRESS ALLEVIATIVE DRUG USE.
223949 04-17

STIMULANT DRUG TREATMENT OF HYPERACTIVE ADOLESCENTS.
224379 04-14

SUICIDE IN BRISBANE, 1956 TO 1973: THE DRUG DEATH EPIDEMIC.
224491 04-17

STUDY OF AN ANXIOLYTIC DRUG, CLOBAZAM, IN ORL WITH PHARYNGEAL PSYCHOSOMATIC MANIFESTATIONS.
224584 04-11

EEG SLEEP PATTERNS AND DRUG ABUSE.
224719 04-15

DRUG PSYCHOTHERAPY INTERACTIONS IN DEPRESSION.
224767 04-10

NORTRIPTYLINE PLASMA LEVELS: RELATIONSHIP TO DRUG EFFECTS.
224834 04-09

EFFECT OF DRUG RITUAL CHANGES ON SCHIZOPHRENICS.
224908 04-08

AN EXPERIMENTAL ANALYSIS OF BEHAVIORAL FACTORS IN DRUG DEPENDENCE.
225156 04-04

SECOND-ORDER SCHEDULES OF DRUG INJECTION.
225157 04-04

CATECHOLAMINES AND DRUG BEHAVIOR INTERACTIONS.
225162 04-04

SCHEDULE-CONTROLLED BEHAVIORS AS DETERMINANTS OF DRUG RESPONSE.
225168 04-06

DETERMINANTS OF DRUG EFFECTS ON PUNISHED RESPONDING.
225169 04-04

THE ROLE OF DISCRIMINATIVE STIMULI IN MODULATING DRUG ACTION.
225170 04-04

DISCRETE TRIAL ANALYSIS OF DRUG ACTION.
225172 04-04

CHILDHOOD CHEMOTHERAPY AND LATER DRUG ABUSE AND GROWTH CURVE: A FOLLOWUP STUDY OF 30 ADOLESCENTS.
225382 04-14

A BEHAVIORAL EDUCATIONAL ALTERNATIVE TO DRUG CONTROL OF HYPERACTIVE CHILDREN.
225455 04-14

THE INTERACTION OF POSTWEANING HOUSING CONDITIONS AND PRENATAL DRUG EFFECTS ON BEHAVIOUR.
225563 04-04

DRUG-FREE

PLASMA TRYPTOPHAN TOLERANCE CURVES IN DRUG-FREE NORMAL CONTROLS, SCHIZOPHRENIC PATIENTS AND PRISONER VOLUNTEERS.
200773 02-13

DRUG-INDUCED

DRUG-INDUCED ROTATION IN RATS AFTER UNILATERAL INTRACEREBRAL INJECTION OF 5,6 DIHYDROXYTRYPTAMINE (5-6-DHT).
192940 01-03

INTERACTIVE PREDICTION OF DRUG-INDUCED CHANGE.
195936 01-17

THE RELATIONSHIP OF CENTRAL MONOAMINES TO DRUG-INDUCED SLEEP IN THE RAT, EXAMINED ON A 24-HOUR BASIS. (PH.D. DISSERTATION).
201005 02-03

DOPAMINERGIC NEURONS: DRUG-INDUCED ANTAGONISM OF THE INCREASE IN TYROSINE-HYDROXYLASE ACTIVITY PRODUCED BY CESSATION OF IMPULSE FLOW.
202664 02-03

A DOUBLE-BLIND STUDY OF AMANTADINE HYDROCHLORIDE VERSUS BENZTROPINE MESYLATE IN DRUG-INDUCED PARKINSONISM.
202764 02-15

DETERMINATION OF DRUG-INDUCED CHANGES IN SLEEP QUALITY BASED ON DIGITAL COMPUTER SLEEP PRINTS.
203603 02-14

THEORETICAL IMPLICATIONS OF DRUG-INDUCED ADAPTIVE REGULATION FOR A BIOGENIC AMINE HYPOTHESIS OF AFFECTIVE DISORDER.
206335 03-03

THE USE OF LITHIUM IN THE TREATMENT OF THE DRUG-INDUCED PSYCHOTIC REACTION.
216183 04-11

AMINO ACID UPTAKE IN VIVO BY THE MOUSE BRAIN AND BY VARIOUS REGIONS OF THE RABBIT BRAIN AFTER DRUG-INDUCED CONVULSIONS.
217858 04-03

AKINESIA: A POORLY RECOGNIZED DRUG-INDUCED EXTRAPYRAMIDAL BEHAVIORAL DISORDER.
218773 04-15

EFFECT OF DRUG-INDUCED INCREASE OF BRAIN GABA LEVELS ON PENICILLIN FOCUS.
220947 04-03

METFORMIN (GLUCOPHAGE) IN THE TREATMENT OF DRUG-INDUCED OBESITY.
221821 04-13

DRUG-INDUCED DYSTONIA.
225332 04-15

DRUG-RESISTANCE

DRUG-RESISTANCE AND BIOCLINICAL FACTORS IN THE RESPONSE OF SCHIZOPHRENIC PATIENTS TO CHLORPROMAZINE.
210500 03-08

DRUG-RESISTANT

DRUG-RESISTANT DEPRESSIONS: RESPONSE TO ECT.
196037 01-17

DRUG-SCREENING PROGRAM FOR DRUG-RESISTANT SCHIZOPHRENICS.
198072 01-02

DRUG-SCREENING

DRUG-SCREENING PROGRAM FOR DRUG-RESISTANT SCHIZOPHRENICS.
198072 01-02

DRUG-TAKING

FENFLURAMINE: AMPHETAMINE CONGENER THAT FAILS TO MAINTAIN DRUG-TAKING BEHAVIOR IN THE RHESUS MONKEY.
193137 01-04

DRUGGED

SOCIAL INTERACTION BETWEEN DRUGGED AND UNDRUGGED RATS.
196206 01-04

DRUGS

PSYCHOTROPIC DRUGS: A MANUAL FOR EMERGENCY MANAGEMENT OF OVERDOSAGE.
193039 01-15

AGE SEX DIFFERENCES IN RESPONSE TO ANTIDEPRESSANT DRUGS.
193093 01-11

RATIONAL USE OF PSYCHOTROPIC DRUGS. II. ANTIANXIETY AGENTS.
193192 01-17

ANTIANESTHETIC EFFECTS OF CYCLIC-AMP AND ANALEPTIC DRUGS AS DETERMINED BY REVERSAL OF AMOBARBITAL INDUCED NARCOSIS.
193426 01-03

PSYCHEDELIC DRUGS.
193498 01-12

THE EFFECTS OF DRUGS REGULATING AUTONOMIC RESPONSES DURING CONDITIONING ON SUBSEQUENT AVOIDANCE BEHAVIOR. (PH.D. DISSERTATION).
193777 01-03

EFFECTS OF SELF-STIMULATION BEHAVIOR OF DRUGS INFLUENCING DOPAMINERGIC NEUROTRANSMISSION MECHANISMS.
194152 01-04

DRUGS IN PSYCHIATRY.
194274 01-15

PSYCHOTROPIC DRUGS.
194559 01-17

EFFECTS OF CENTRAL ACTING DRUGS AND ERGOT DERIVATIVES ON PROLACTIN AND GROWTH HORMONE SECRETION, ON GROWTH OF PITUITARY AND MAMMARY TUMORS AND ON REPRODUCTION IN OLD RATS. (PH.D. DISSERTATION).
194571 01-03

EFFECTS OF PSYCHOTROPIC DRUGS ON THE SHORT-TERM MEMORY OF RETARDED CHILDREN. (PH.D. DISSERTATION).
194655 01-14

EFFECTS OF PSYCHOTROPIC DRUGS ON HYPEREMOTIONALITY OF RATS WITH BILATERAL ABLATIONS OF THE OLFACTORY BULBS AND OLFACTORY TUBERCLES.
195231 01-04

DISTRIBUTION OF CHLORPROMAZINE IN A SIMPLIFIED BLOOD INFLUENCED BY VARIOUS DRUGS.
195245 01-03

PROGRAMMED SELF-ADMINISTRATION OF POTENTIALLY ADDICTIVE DRUGS IN YOUNG RATS AND ITS EFFECTS ON LEARNING.
195430 01-04

EFFECTS OF DRUGS INFLUENCING MONOAMINE MECHANISMS ON THE INCREASE IN BRAIN DOPAMINE PRODUCED BY AXOTOMY OR TREATMENT WITH GAMMA-HYDROXYBUTYRIC ACID.
195440 01-03

EFFECTS OF ADRENERGIC DRUGS ON PRESSOR RESPONSES TO HYPOTHALAMIC STIMULATION.
195441 01-03

THE MULTIPLICITY OF INTERACTIONS OF PSYCHOTROPIC DRUGS WITH THE BRAIN SEROTONIN BIOSYNTHETIC UNIT.
195926 01-17

SOMATOSENSORY EVOKED RESPONSE WAVE SHAPE STABILITY: RELATIONSHIPS TO PSYCHIATRIC DIAGNOSIS AND EFFECTS OF PSYCHOACTIVE DRUGS.
195935 01-17

A SIMPLIFIED GUIDE TO THE RATIONAL USE OF PSYCHOTROPIC DRUGS.
196231 01-17

THE EFFECT OF PSYCHOPHARMACOLOGICAL DRUGS ON PUFFING AND ON RNA AND DNA SYNTHESES IN THE SALIVARY GLAND CHROMOSOMES OF DROSOPHILA-MELANOGASTER. (PH.D. DISSERTATION).
196250 01-03

AGE RELATED ENHANCED RESPONSIVENESS TO CENTRAL NERVOUS SYSTEM DRUGS IN RATS. (PH.D. DISSERTATION).
196256 01-03

THE CONTROL OF DEVIANT SEXUAL BEHAVIOUR BY DRUGS: I. BEHAVIOURAL CHANGES FOLLOWING ESTROGENS AND ANTIANDROGENS.
196958 01-14

INTERMITTENT TREATMENT WITH ANORECTIC DRUGS.
197137 01-11

INFLUENCE OF CATECHOLAMINE UPTAKE BLOCKING DRUGS ON THE INCREASE IN WATER INTAKE AND PLASMA RENIN CONCENTRATION INDUCED BY SOME HYPOTENSIVE DRUGS.
197288 01-03

PRESSOR RESPONSES TO HYPOTHALAMIC STIMULATION AS INFLUENCED BY DRUGS AFFECTING ADRENERGIC RECEPTORS.
197290 01-03

INTERACTION BETWEEN ANTIDEPRESSANT AND CENTRALLY ACTING ANTIHYPERTENSIVE DRUGS.
197300 01-03

THE SENSITIVITY OF BARBITONE DEPENDENT AND WITHDRAWN RATS TO TREMORGENIC DRUGS.
197303 01-03

EFFECT OF PSYCHOACTIVE DRUGS ON IN VIVO METABOLISM OF 14C-HISTAMINE IN MOUSE BRAIN.
197472 01-03

EFFECTS OF PSYCHOTROPIC DRUGS ON THE EMOTIONAL REACTIVITY OF RATS.
197499 01-04

EPILEPTIFORM SEIZURES IN DOMESTIC FOWL. IV. THE EFFECTS OF ANTICONVULSANT DRUGS.
197742 01-03

EFFECT OF NICOTINE AND OTHER DRUGS ON THE RELEASE OF 3H-NOREPINEPHRINE AND 3H-DOPAMINE FROM RAT BRAIN SLICES.
197985 01-03

PRESELECTION OF ANIMALS IN STUDIES OF ANTIANXIETY DRUGS.
197986 01-03

EFFECTS OF PSYCHOTROPIC DRUGS ON THE INCORPORATION OF GLUCOSE-14C INTO AMINO ACIDS OF THE RAT BRAIN.
198026 01-03

THE BIOCHEMICAL PHARMACOLOGY OF ABUSED DRUGS: I. AMPHETAMINES, COCAINE, AND LSD.
198028 01-12

PSYCHOTHERAPEUTIC DRUGS: STUDIES OF USAGE PATTERNS AND STUDIES OF PRESCRIBING PRACTICES.
198048 01-17

THE USE OF DRUG INTERACTIONS IN ANIMALS FOR SELECTING PSYCHOTROPIC DRUGS.
198057 01-02

COOPERATIVE CLINICAL SCREENING OF PSYCHOTROPIC DRUGS.
198066 01-07

COMPREHENSIVE CLINICAL STUDIES OF PSYCHOACTIVE DRUGS.
198067 01-07

PATIENT PROFILES AND DIFFERENTIAL RESPONSE TO DRUGS.
198087 02-10

PSYCHOTROPIC DRUGS AND SLOW POTENTIALS IN MAN.
198101 02-13

REGIONAL DIFFERENCES IN HOMOVANILLIC ACID CONCENTRATIONS AFTER ACUTE AND CHRONIC ADMINISTRATION OF ANTIPSYCHOTIC DRUGS.
198210 02-03

EFFECT ON PSEUDOCONDITIONING OF DRUGS WITH KNOWN CENTRAL NERVOUS ACTIVITY.
198228 02-04

THYROID AXIS -- DRUGS AND BEHAVIOR.
198592 02-14

DISSOCIATION OF GENERAL BEHAVIOR PRODUCED BY PSYCHOTROPIC DRUGS IN MICE.
198733 02-04

RATIONAL USE OF PSYCHOTROPIC DRUGS. III. MAJOR TRANQUILIZERS.
198823 02-17

HMO ANALYSIS OF STRUCTURE-ACTIVITY RELATIONS IN SEDATIVE AND HYPNOTIC DRUGS AND ANALYSIS OF POTENTIAL SEDATIVES BY MEANS OF HOMOLOGOUS COMPOUNDS.
199208 02-01

STUDIES ON PSYCHOTROPIC DRUGS: XVII. EFFECTS OF 3-CHLORO-5-(3-(4 PIPERIDINO-4-CARBAMOYL-PIPERIDINO)PROPYL) 10,11-DIHYDRO-5(H) DIBENZAZEPINE DIHYDROCHLORIDE MONOHYDRATE (Y-4153) ON THE METABOLISM OF BIOGENIC AMINES.
199210 02-03

BETA-ADRENERGIC RECEPTOR BLOCKING DRUGS IN PSYCHIATRY.
199636 02-17

PSYCHOTHERAPY AND DRUGS FROM THE STANDPOINT OF INTERNAL MEDICINE.
199907 02-17

BEHAVIOURAL SUPERSENSITIVITY TO APOMORPHINE FOLLOWING CHRONIC TREATMENT WITH DRUGS WHICH INTERFERE WITH THE SYNAPTIC FUNCTION OF CATECHOLAMINES.
199958 02-04

THE BIOCHEMICAL PHARMACOLOGY OF ABUSED DRUGS. II. ALCOHOL AND BARBITURATES.
200007 02-14

EFFECTS OF PSYCHOTROPIC DRUGS ON EXPLORATORY BEHAVIOR OF MICE.
200047 02-04

THE INFLUENCE OF NEUROLEPTICAL DRUGS ON CATECHOLAMINE EXCRETION.
200073 02-08

A CORRELATION BETWEEN THE INFLUENCE OF PSYCHOTROPIC DRUGS AND EMOTIONAL STRESS.
200103 02-09

USES OF PSYCHOTROPIC DRUGS.
200238 02-10

RATIONAL USE OF PSYCHOTROPIC DRUGS. IV. ANTIDEPRESSANTS.
200584 02-09

MAINTENANCE TREATMENT OF CHRONIC SCHIZOPHRENIA WITH NEUROLEPTIC DRUGS.
200636 02-08

GLC DETERMINATION OF PROPRANOLOL, OTHER BETA-BLOCKING DRUGS, AND METABOLITES IN BIOLOGICAL FLUIDS AND TISSUES.
200740 02-16

SIDE-EFFECTS OF PSYCHOTROPIC DRUGS -- AN ANALYSIS OF DATA OBTAINED FROM DOUBLE-BLIND COMPARATIVE STUDIES IN JAPAN.
201260 02-15

TO BETTER KNOW AND BETTER PRESCRIBE PSYCHOTROPIC DRUGS.
202029 02-17

STUDIES OF CONFLICT INDUCED BEHAVIOR IN THE CAT: BEHAVIOR ANALYSIS AND EFFECTS OF PSYCHOTROPIC DRUGS.
202122 02-04

PSYCHOTROPIC DRUGS -- ARE THEY JUSTIFIED?
202310 02-15

HALLUCINOGENIC DRUGS AS PRECIPITANTS OF SCHIZOPHRENIA.
202693 02-08

DISCRIMINATIVE RESPONSE CONTROL PRODUCED WITH HASHISH, TETRAHYDROCANNABINOLS (DELTA8-THC AND DELTA9-THC), AND OTHER DRUGS.
202720 02-12

USE OF BETA-ADRENERGIC RECEPTOR BLOCKING DRUGS IN PSYCHIATRY.
202797 02-17

THE CLINICAL USE OF PSYCHOTHERAPEUTIC DRUGS IN THE ELDERLY.
202798 02-11

EFFECTS OF PSYCHOTROPIC DRUGS ON HYPOTHALAMIC SELF-STIMULATION BEHAVIOR IN RATS.
202802 02-04

CONTROLLING DRUGS: INTERNATIONAL HANDBOOK FOR PSYCHOACTIVE DRUG CLASSIFICATION.
202861 02-17

ARE ANTIPSYCHOTIC DRUGS INTERCHANGEABLE?.
202879 02-08

BARBITURATES AND BARBITURATE LIKE DRUGS: CONSIDERATIONS IN THEIR MEDICAL USE.
202923 02-17

WAYS OF DEMONSTRATING AND DIFFERENTIATING CENTRAL NERVOUS EFFECTS OF DRUGS IN ANIMAL EXPERIMENTS.
202944 02-06

THE ROLE OF CEREBRAL CYCLIC-AMP IN THE ACTION OF PSYCHOTROPIC DRUGS: IN VIVO AND IN VITRO STUDIES. (PH.D. DISSERTATION).
203032 02-03

DO ANTIHYPERTENSIVE DRUGS REALLY CAUSE DEPRESSION?
204236 02-15

THE MEDICAL USE OF PSYCHOTROPIC DRUGS.
204306 02-17

COMPUTER NYSTAGMOGRAPHY, A NEW METHOD OF DETERMINING CHANGES IN VIGILANCE AS A RESPONSE TO PSYCHOTROPIC DRUGS.
204395 02-16

THE INFLUENCE OF ANTIADRENERGIC AND ANTIDOPAMINERGIC DRUGS ON METHAMPHETAMINE INDUCED CHANGES IN MOTORIC ACTIVITY AND CEREBRAL GLYCOGEN CONTENT IN MICE.
204396 02-03

THE INFLUENCE OF ENCEPHALOTROPIC DRUGS ON NUCLEIC ACID METABOLISM IN THE BRAIN.
204398 02-13

ASPECTS OF USING PSYCHOLOGICAL METHODS IN STUDYING THE EFFECTS OF PSYCHOTROPIC DRUGS.
204401 02-16

UNEXPECTED COMPLICATIONS BY ANTICHOLINERGICS CONTAINED IN SOPORIFICS AND ANALGESIC DRUGS.
204404 02-15

DIFFERENTIAL EFFECTS OF NEUROLEPTIC DRUGS IN CHRONIC SCHIZOPHRENICS: A CONFIGURATION ANALYTICAL EVOLUTION.
204415 02-08

SIGNIFICANCE OF PSYCHOTHERAPY USED WITH DRUGS.
204426 02-17

DRUGS AND PHARMACOTHERAPY.
204427 02-17

THERAPEUTIC ROLES OF DRUGS AND MORITA THERAPY PROCESS.
204428 02-10

THIORIDAZINE: CENTRAL DOPAMINE TURNOVER AND CLINICAL EFFECTS OF ANTIPSYCHOTIC DRUGS.
204852 02-08

DRUGS AND PLACEBOS: EFFECTS OF CAFFEINE ON COGNITIVE PERFORMANCE.
205223 02-14

HYPERKINETIC CHILDREN: THE USE OF STIMULANT DRUGS EVALUATED.
205263 02-14

STIMULUS PROPERTIES OF SYMPATHOMIMETIC AND SYMPATHOLYTIC DRUGS.
205335 02-04

COMPUTERIZED CEREBRAL BIOPOTENTIALS IN THE DISCOVERY OF PSYCHOTROPIC DRUGS.
205434 02-13

EEG EVALUATION OF HYPNOTIC DRUGS: MOGADON V. RO-5-4200, USING THE DOUBLE-BLIND METHOD.
205435 02-13

EEG CHANGES AFTER PSYCHOACTIVE DRUGS (SPECTRAL ANALYTIC STUDY).
205472 02-13

EFFECTS OF PSYCHOACTIVE TRICYCLIC DRUGS ON THE EEG OF THE ISOLATED PERFUSED RAT BRAIN.
205492 02-03

COMPARATIVE STUDY OF THE ELECTRONEUROPHYSIOLOGICAL PARAMETERS OF SLEEP INDUCED BY SEVERAL HYPNOTIC DRUGS.
205520 02-13

DRUGS, EEG AND BEHAVIOUR: EEG PROFILES AND BIOAVAILABILITY MEASURES FOR CLINICAL PSYCHOPHARMACOLOGY.
205522 02-16

PHARMACOLOGICAL PROPERTIES OF A POTENTIAL TRANQUILISING AGENT MESYLPHENACYRAZINE: I. INTERACTION WITH DRUGS INFLUENCING THE NERVOUS SYSTEM.
205578 02-03

AN ATTEMPT TO CLASSIFY NEUROLEPTIC DRUGS ON THE BASIS OF SHORT-TERM CLINICAL COMPARATIVE STUDIES.
205591 02-08

PSYCHOTROPIC DRUGS AND DIFFERENTLY STIMULATED ATPASE IN CNS.
205629 03-03

PSYCHOTROPIC DRUGS AND SOME ENZYMES OF ENERGY METABOLISM.
205630 03-03

EFFECTS OF CHOLINESTERASE INHIBITION ON THE VISUAL EVOKED POTENTIALS IN THE RABBIT AND THEIR MODIFICATION WITH VARIOUS DRUGS.
205631 03-03

SOME FACTORS DETERMINING THE RESPONSE OF SEPTAL RATS TO ANTICHOLINERGIC DRUGS.
205632 03-03

LONGITUDINAL TREND IN PRESCRIBING PSYCHOTROPIC DRUGS.
205633 03-17

PSYCHOTROPIC AND ANTIEPILEPTIC DRUGS.
205635 03-17

NEUROLEPTIC DRUGS AND AUTOMOBILE DRIVING.
205882 03-15

ANTIPSYCHOTIC DRUGS STIMULATE PROLACTIN RELEASE.
206354 03-03

PRESLEEP INGESTION OF TWO HYPNOTIC DRUGS AND SUBSEQUENT PERFORMANCE.
206362 03-14

PSYCHOLOGICAL EFFECTS OF DRUGS: A FACTOR ANALYTIC APPROACH.
206377 03-17

1974 DRUGS OF CHOICE 1975.
206605 03-17

MULTIFOCAL TRIAL OF PSYCHOTROPIC DRUGS (MULTIHOSPITAL TRIAL).
206784 03-08

AGE RELATED RESPONSIVENESS OF THE RAT TO DRUGS AFFECTING THE CENTRAL NERVOUS SYSTEM.
206912 03-03

LONGITUDINAL PROFILES OF THE EFFECTS OF PSYCHOTROPIC DRUGS: RESULTS OF AN ANIMAL STUDY.
206970 03-05

LONGITUDINAL PROFILES OF THE EFFECTS OF PSYCHOTROPIC DRUGS FROM CLINICOMETHODOLOGICAL VIEWPOINTS.
206971 03-16

MULTISPECTRAL INVESTIGATION OF PSYCHOTROPIC DRUGS.
206983 03-08

DIFFERENT URINARY EXCRETIONS OF 3-METHOXY-4-HYDROXYPHENYLGLYCOL AND RESPONSE TO TRICYCLIC ANTIDEPRESSIVE DRUGS.
206985 03-13

TRICYCLIC ANTIDEPRESSANT DRUGS AND DOPAMINE SENSITIVE ADENYLCYCLASE FROM RAT CAUDATE NUCLEI.
206990 03-03

ANTIPSYCHOTIC DRUGS AND CATECHOLAMINE SYNAPSES.
207290 03-03

DOSE EQUIVALENCE OF THE ANTIPSYCHOTIC DRUGS.
207291 03-17

CATECHOLAMINES AND ANTIPSYCHOTIC DRUGS IN PERIODIC CATATONIA.
207292 03-08

DOPAMINERGIC BLOCKING EFFECTS OF ANTIPSYCHOTIC DRUGS.
207294 03-03

MASS FRAGMENTOMETRIC DETERMINATION OF HOMOVANILLIC ACID IN LUMBAR CEREBROSPINAL FLUID OF SCHIZOPHRENIC PATIENTS DURING TREATMENT WITH ANTIPSYCHOTIC DRUGS.
207295 03-08

ANTISCHIZOPHRENIC DRUGS: AFFINITY FOR MUSCARINIC CHOLINERGIC RECEPTOR SITES IN THE BRAIN PREDICTS EXTRAPYRAMIDAL EFFECTS.
207298 03-03

ANTIPSYCHOTIC DRUGS AND CATECHOLAMINE SYNAPSES: SUMMARY OF THE SESSION.
207299 03-03

CENTRAL CATECHOLAMINE NEURONS, BEHAVIOR AND NEUROLEPTIC DRUGS: AN ANALYSIS TO UNDERSTAND THE INVOLVEMENT OF CATECHOLAMINES IN SCHIZOPHRENIA.
207305 03-03

BRAIN DOPAMINE AND BEHAVIOUR: A CRITICAL ANALYSIS OF THE RELATIONSHIP BETWEEN DOPAMINE ANTAGONISM AND THERAPEUTIC EFFICACY OF NEUROLEPTIC DRUGS.
207306 03-04

PSYCHOACTIVE DRUGS IN MANIA: A CONTROLLED COMPARISON OF LITHIUM CARBONATE, CHLORPROMAZINE AND HALOPERIDOL.
207446 03-09

LONG-TERM EFFECTS OF P-CHLOROAMPHETAMINE AND RELATED DRUGS ON CENTRAL SEROTONERGIC MECHANISMS.
208553 03-03

PSYCHOPHARMACOLOGY IN THE AGED: USE OF PSYCHOTROPIC DRUGS IN GERIATRIC PATIENTS.
208571 03-11

INFANTILE AUDITORY EXPOSURE AND UNUSUAL RESPONSE TO ANTIPSYCHOTIC DRUGS.
208617 03-04

DRUGS, MEDIATORS, AND SCHIZOPHRENIA.
208631 03-08

POLYGRAPHIC EVALUATION OF HYPNOTIC DRUGS: METHODOLOGICAL CRITERIA.
208983 03-16

INTERACTIONS BETWEEN DRUGS.
209073 03-15

ANIMAL MODES FOR EVALUATING PSYCHOTROPIC DRUGS.
209076 03-17

ANTIHYPERTENSIVE DRUGS AND DEPRESSION.
209082 03-09

CONCEPTUAL ISSUES IN THE USE OF DRUGS FOR THE TREATMENT OF AGGRESSION IN MAN.
209126 03-17

TREATMENT OF HUMAN AGGRESSION WITH MAJOR TRANQUILIZERS, ANTIDEPRESSANTS, AND NEWER PSYCHOTROPIC DRUGS.
209127 03-11

CLINICAL EXPERIENCES IN TREATING DEPRESSED PATIENTS WITH A COMBINATION OF TRICYCLIC DRUGS AND THYROID EXTRACT.
209144 03-09

THE EFFECTS OF STIMULANT AND DEPRESSANT DRUGS ON VERBAL CONDITIONING.
209260 03-14

A CASE OF IRREVERSIBLE EXTRAPYRAMIDAL HYPERKINESIA INDUCED BY NEUROLEPTIC DRUGS.
209410 03-15

PSYCHOTROPIC DRUGS AND THE HUMAN EEG.
209829 03-16

ENDOCRINE EFFECTS OF CHRONIC ADMINISTRATION OF PSYCHOACTIVE DRUGS TO PREPUBERAL MALE RATS. I: DELTA9-TETRAHYDROCANNABINOL.
209840 03-03

PATTERNS OF SYMPTOM CHANGE IN ANXIOUS DEPRESSED OUTPATIENTS TREATED WITH DIFFERENT DRUGS.
209904 03-10

THE EFFECTS OF HYPNOTIC DRUGS ON SLEEP.
209981 03-14

ADDICTION AND PSYCHOTROPIC DRUGS.
210069 03-17

PSYCHOTROPIC DRUGS AND ELECTROENCEPHALOGRAPHY: THIRD REPORT.
210276 03-13

EFFECT OF LITHIUM AND OTHER DRUGS ON THE AMPHETAMINE CHLORDIAZEPOXIDE HYPERACTIVITY IN MICE.
210349 03-04

URINARY SCREENING FOR DRUGS IN A HOSPITAL FOR THE MENTALLY SUBNORMAL.
210437 03-17

THERAPY WITH PSYCHOPHARMACEUTIC AND OTHER PSYCHOTROPIC DRUGS.
210511 03-17

FROM PSYCHOPHARMACOLOGY TO PSYCHOPHARMACOGENETICS: DETERMINANTS OF THE EFFECTS OF DRUGS ON BEHAVIOR, ROLE OF GENETIC FACTORS.
210530 03-14

DOPAMINE RECEPTOR BLOCKADE BY NEUROLEPTIC DRUGS IN APLYSIA NEURONES.
210599 03-03

INFLUENCE OF NONCHOLINERGIC DRUGS ON RAT STRIATAL ACETYLCHOLINE LEVELS.
210658 03-03

ANTAGONISM OF DOPAMINE MEDIATED INHIBITION IN THE NIGROSTRIATAL PATHWAY: A MODE OF ACTION OF SOME CATATONIA INDUCING DRUGS.
210659 03-03

THE EFFECT OF DRUGS WITH ANTIDEPRESSANT ACTIVITY UPON THE HYPOTHERMIA AND BEHAVIOURAL DEPRESSION INDUCED IN MICE BY PIMOZIDE OR CENTRALLY ADMINISTERED NORADRENALINE.
210762 03-04

EFFECTS OF PSYCHOACTIVE DRUGS ON RESPONSES OF THE RAT TO AVERSIVE STIMULATION.
210784 03-04

DIFFERENTIAL SENSITIVITY OF PRIMARY AND SECONDARY SPINDLE AFFERENTS TO DEPRESSANT DRUGS.
210801 03-03

COMPARATIVE STUDIES ON THE MEMBRANE ACTIONS OF DEPRESSANT DRUGS: THE ROLE OF LIPOPHILICITY IN INHIBITION OF BRAIN SODIUM AND POTASSIUM STIMULATED ATPASE.
210818 03-03

EFFECTS OF DOPAMINERGIC DRUGS AND ACUTE MEDIAL FOREBRAIN BUNDLE LESIONS ON STRIATAL ACETYLCHOLINE LEVELS.
210831 03-03

FACTORS INFLUENCING BRAIN AND TISSUE LEVELS OF TRYPTAMINE: SPECIES, DRUGS AND LESIONS.
210850 03-03

TRICYCLIC ANTIDEPRESSIVE DRUGS AND DOPAMINE SENSITIVE ADENYLATE-CYCLASE FROM RAT BRAIN STRIATUM.
210856 03-03

EFFECT OF ERGOT DRUGS ON CENTRAL 5-HYDROXYTRYPTAMINE NEURONS: EVIDENCE FOR 5-HYDROXYTRYPTAMINE RELEASE OR 5-HYDROXYTRYPTAMINE RECEPTOR STIMULATION.
210857 03-03

HALOPERIDOL INDUCED DISRUPTION OF CONDITIONED AVOIDANCE RESPONDING: ATTENUATION BY PRIOR TRAINING OR BY ANTICHOLINERGIC DRUGS.
210861 03-04

EFFECT OF ANTIPSYCHOTIC DRUGS ON HOMOVANILLIC ACID LEVELS IN STRIATUM AND OLFACTORY TUBERCLE OF THE RAT.
210864 03-03

PSYCHOACTIVE DRUGS: INCLUDING COMBINATIONS.
210874 03-17

NEGATIVE REINFORCING PROPERTIES OF SOME PSYCHOTROPIC DRUGS IN DRUG NAIVE RHESUS MONKEYS.
210889 03-04

AN INVESTIGATION ON THE BEHAVIORAL AND HYPOTHERMIC EFFECTS OF YOHIMBINE: INTERACTION WITH DRUGS AFFECTING CENTRAL AND PERIPHERAL MONOAMINES.
211068 03-04

PHYSOSTIGMINE: ITS USE IN ACUTE ANTICHOLINERGIC SYNDROME WITH ANTIDEPRESSANT AND ANTIPARKINSON DRUGS.
211416 03-15

CORRECTION OF AUTONOMIC EFFECTS OF PSYCHOTROPIC DRUGS BY LARGE DOSES OF DIHYDROERGOTAMINE IN ADULTS AND THE ELDERLY.
211998 03-11

EFFECTS OF PSYCHOTROPIC DRUGS ON EXTINCTION INDUCED AGGRESSION. (PH.D. DISSERTATION).
212523 03-04

ACTIONS AND INTERACTIONS OF ABUSED DRUGS OF THE REWARD SYSTEM. (PH.D. DISSERTATION).
212964 03-04

DEVELOPMENT OF PSYCHOTROPIC DRUGS.
213595 04-16

TWENTY-THREE PSYCHOTROPIC DRUGS USED IN CHILDREN ABROAD WHICH ARE NOT RECOMMENDED IN THE UNITED-STATES.
213600 04-17

DRUGS, CATECHOLAMINES AND KREBS CYCLE INTERACTION (CNS).
213602 04-03

ANTIPSYCHOTIC DRUGS: ROLES OF CYCLIC-AMP.
213609 04-03

DISPOSITION AND ACTION OF DRUGS AFFECTING BEHAVIOR.
213617 04-03

PSYCHOACTIVE DRUGS AND THE ORGANIZATION OF BEHAVIOR.
213622 04-04

NEUROCHEMICAL ACTIONS OF PSYCHOTROPIC DRUGS.
213633 04-03

THE BEHAVIORAL PHARMACOLOGY OF PSYCHOACTIVE DRUGS.
213635 04-04

REVERSAL OF DELIRIUM INDUCED BY TRICYCLIC ANTIDEPRESSANT DRUGS WITH PHYSOSTIGMINE.
213708 04-15

PSYCHOTROPIC DRUGS ON GENERAL MEDICAL AND SURGICAL WARDS OF A TEACHING HOSPITAL.
213919 04-17

PSYCHOTROPIC DRUGS, OVARIAN FUNCTIONS AND MAMMARY ACTIVITY.
214055 04-03

PRESYNAPTIC AND POSTSYNAPTIC COMPONENTS IN EFFECT OF DRUGS WITH ALPHA-ADRENOCEPTOR AFFINITY.
214062 04-03

THE USE OF PSYCHOACTIVE DRUGS IN ELDERLY PATIENTS WITH PSYCHIATRIC DISORDERS: SURVEY CONDUCTED IN TWELVE VETERANS ADMINISTRATION HOSPITALS.
215009 04-11

ISOLATION INDUCED TIMIDITY IN MICE AS A MEASURE OF ANXIOLYTIC ACTIVITY OF DRUGS.
215063 04-04

FACTOR ANALYSIS OF EEG OF HEALTHY SUBJECTS GIVEN NO DRUGS AND A COMBINATION OF DIAZEPAM AND METHYLPHENIDATE.
215071 04-13

INHIBITION OF PROSTAGLANDIN-SYNTHETASE BY PSYCHOTROPIC DRUGS.
215162 04-03

THE ACTION OF CHLORPROMAZINE AND TRIFTAZINE ON DISCHARGES OF CORTICAL NEURONS IN RABBITS AFTER CHRONIC ADMINISTRATION OF THE DRUGS.
215499 04-03

THE MECHANISM OF THE POTENTIATING EFFECT OF ANTIDEPRESSANT DRUGS ON THE PROTECTIVE INFLUENCE OF DIPHENHYDRAMINE IN EXPERIMENTAL CATATONIA. THE ROLE OF HISTAMINE.
215664 04-03

HEPATIC CHOLESTEROL SYNTHESIS IN MAN: EFFECT OF DIAZEPAM AND OTHER DRUGS.
215681 04-15

EFFECTS OF PSYCHOTROPIC DRUGS ON METHAMPHETAMINE-INDUCED BEHAVIORAL EXCITATION IN GROUPED MICE.
215682 04-04

EFFECTS OF PENFLURIDOL AND OTHER DRUGS ON APOMORPHINE-INDUCED STEREOTYPED BEHAVIOR IN MONKEYS.
215684 04-04

THE EFFECT OF PENFLURIDOL AND SOME PSYCHOTROPIC DRUGS ON MONOAMINE METABOLISM IN CENTRAL NERVOUS SYSTEM.
215686 04-03

EFFECTS OF THYROTROPIN-RELEASING HORMONE (TRH) ON THE ACTIONS OF PENTOBARBITAL AND OTHER CENTRALLY ACTING DRUGS.
215692 04-03

DRUGS AND PUNISHED RESPONDING. V. EFFECTS OF DRUGS ON RESPONDING SUPPRESSED BY RESPONSE DEPENDENT AND RESPONSE INDEPENDENT ELECTRIC SHOCK.
215722 04-04

REPEATED ACQUISITION OF RESPONSE SEQUENCES: STIMULUS CONTROL AND DRUGS.
215969 04-04

DRUG INTERACTIONS WITH PSYCHOACTIVE DRUGS.
216184 04-15

SCHIZOPHRENIA -- 5: PHYSICAL TREATMENTS AND DRUGS.
216403 04-08

PSYCHOLOGICAL MEDICINE: PSYCHOTROPIC DRUGS IN GENERAL PRACTICE.
216948 04-17

THE EFFECT OF SOME NEUROTROPIC DRUGS ON THE PHASIC CHANGES OF ARTERIAL PRESSURE EVOKED BY STIMULATION OF THE CEREBELLAR FASTIGAL NUCLEUS.
217067 04-03

PSYCHOTROPIC DRUGS AND OVARIAN CYCLE ALTERATIONS.
217204 04-13

RATE DEPENDENT EFFECTS OF DRUGS. II. EFFECTS OF SOME MAJOR TRANQUILIZERS ON MULTIPLE FIXED-RATIO, FIXED-INTERVAL SCHEDULE PERFORMANCE.
217458 04-04

CONDITIONED LEARNING IN YOUNG RATS BORN OF DRUG ADDICTED PARENTS AND RAISED ON ADDICTIVE DRUGS.
217465 04-04

SCREENING HALLUCINOGENIC DRUGS: SYSTEMIC STUDY OF THREE BEHAVIORAL TESTS.
217528 04-06

INTERACTION BETWEEN CENTRALLY ACTING HYPOTENSIVE DRUGS AND TRICYCLIC ANTIDEPRESSANTS.
217575 04-03

ANTAGONISM BY D-AMPHETAMINE OF LEARNING DEFICITS IN RATS INDUCED BY EXPOSURE TO ANTIPSYCHOTIC DRUGS DURING EARLY POSTNATAL LIFE.
217656 04-04

ONTOGENESIS OF NEOSTRIATAL CHOLINERGIC NEURONES IN THE RAT AND DEVELOPMENT OF THEIR SENSITIVITY TO NEUROLEPTIC DRUGS.
217658 04-03

CHLORPROMAZINE METABOLISM IV: QUATERNIZATION AS A KEY TO DETERMINATION OF PICOMOLES OF CHLORPROMAZINE AND OTHER TERTIARY AMINE DRUGS.
217667 04-06

EFFECTS OF VARIOUS PSYCHOACTIVE DRUGS ON THE METABOLISM OF DELTA1-TETRAHYDROCANNABINOL BY RATS IN VITRO AND IN VIVO.
217672 04-03

INFLUENCE OF SOME TRICYCLIC ANTIDEPRESSIVE DRUGS ON THE UPTAKE OF 5-HYDROXYTRYPTAMINE BY RAT BLOOD PLATELETS.
217693 04-03

MODIFICATION OF THE PUNISHING EFFECTS OF PSYCHOACTIVE DRUGS IN RATS BY PREVIOUS DRUG EXPERIENCE.
217765 04-04

THE INFLUENCE OF APOMORPHINE AND TRICYCLIC ANTIDEPRESSANT DRUGS ON THE LEVEL OF SEROTONIN AND ITS METABOLITE IN RAT BRAIN.
217815 04-03

SOME INTERACTIONS BETWEEN FENFLURAMINE AND ANTIDEPRESSANT DRUGS: EFFECTS ON 5-HYDROXYINDOLE CONCENTRATIONS IN RAT BRAIN.
217962 04-03

LONG-LASTING CHANGES IN CEREBRAL NEURONS INDUCED BY DRUGS.
218957 04-03

STATE-DEPENDENT LEARNING WITH CENTRALLY AND NONCENTRALLY ACTIVE DRUGS.
219020 04-04

COMMISSURAL AND SENSORY EVOKED POTENTIALS OF THE HIPPOCAMPUS FOLLOWING MICROIONTOPHORESIS OF SOME DRUGS.
219111 04-03

A BEHAVIORAL ANALYSIS OF HALLUCINOGENIC DRUGS. (PH.D. DISSERTATION).
219181 04-12

INTERACTION OF CYCLOHEXIMIDE AND ADRENERGIC DRUGS WITH BRAIN PROTEIN AND CATECHOLAMINE BIOSYNTHESIS. (PH.D. DISSERTATION).
219288 04-03

THE EFFECT OF CATECHOLAMINERGIC DRUGS ON THE BEHAVIOR AND EEG OF RATS DURING CORAZOL SEIZURES.
219332 04-04

THE EFFECT OF DRUGS ON THE RELEASE OF ENDOGENOUS CATECHOLAMINES INTO THE PERFUSATE OF DISCRETE BRAIN AREAS OF THE CAT IN VIVO.
219631 04-06

DEPRESSIONS AND ANTIDEPRESSANTS DURING TREATMENT WITH LONG-ACTING NEUROLEPTIC DRUGS: SIDE-EFFECTS AND THE EMERGENT METATHERAPEUTIC SYNDROME.
219694 04-15

CLINICAL - PSYCHOPATHOLOGICAL CRITERIA FOR THE SELECTION OF PSYCHOTROPIC DRUGS ACCORDING TO THE STAGE OF ILLNESS AND THE EFFECTIVENESS OF REHABILITATING SCHIZOPHRENICS.
220403 04-17

A MULTICENTER MULTIDIMENSIONAL STUDY OF SOME NEW LONG-ACTING NEUROLEPTIC DRUGS.
220858 04-07

A SIMPLE AVOIDANCE PROCEDURE FOR TESTING PSYCHOTROPIC DRUGS IN MICE.
220903 04-04

MONOAMINEOXIDASE INHIBITORS ANTAGONIZE THE ACCELERATION OF BRAIN DOPAMINE SYNTHESIS INDUCED BY NEUROLEPTIC DRUGS IN VIVO: IMPLICATIONS FOR THE TREATMENT OF TARDIVE DYSKINESIA.
220948 04-03

INHIBITION OF RABBIT MONOAMINEOXIDASE BY DOXEPIN AND RELATED DRUGS.
220972 04-03

DOPAMINERGIC DRUGS ANTAGONIZED THE PSYCHOTOMIMETIC EFFECTS OF PARTIAL AGONIST ANALGESICS.
221048 04-04

ANTAGONISM OF PSYCHOSTIMULANT 2 PHENYLDIMETHYLTETRAHYDROOXAZINE HYDROCHLORIDE (G-130) TO CENTRAL NERVOUS SYSTEM DEPRESSING DRUGS: MONOAMINEOXIDASE INHIBITORY ACTIVITY AND NOREPINEPHRINE AND SEROTONIN INDUCED CHANGES, COMPARISON WITH DL-AMPHETAMINE.
221267 04-03

AN ANIMAL TEST MODEL FOR EVALUATING DRUGS WITH ANTIMASS PSYCHOTIC ACTIVITY.
221273 04-06

INTERACTIONS BETWEEN POSTGANGLIONIC SYMPATHETIC BLOCKING DRUGS AND ANTIDEPRESSANTS.
221650 04-09

ATTEMPTS TO CLASSIFY AND ORIENT PRESCRIPTION OF PSYCHOTROPIC DRUGS BY MEANS OF A COMPUTER CARD INDEX.
221668 04-17

LONG-ACTING DRUGS IN PSYCHIATRIC TREATMENT: LACUNAE AND NEEDS.
221672 04-17

THE USE OF FREE IMAGERY, NONDIRECTIVE INTERVIEWING, AND SELECTED DRUGS TO LIFT POSTHYPNOTIC REPRESSION. (PH.D. DISSERTATION).
222060 04-14

ANALYSIS OF AMPHETAMINES AND OTHER PSYCHOACTIVE DRUGS: A COLORIMETRIC ASSAY OF (S)-(+) AMPHETAMINE IN THE SUBMICROGRAM RANGE. (PH.D. DISSERTATION).
222633 04-01

THE EFFECT OF AUTONOMIC AND PSYCHOTROPIC DRUGS ON ADRENALINE REVERSAL IN THE RAT UTERUS.
222803 04-03

A DIRECT EFFECT OF DIBUTYRYL CYCLIC-AMP ON THE DURATION OF NARCOSIS INDUCED BY SEDATIVE, HYPNOTIC, TRANQUILISER AND ANESTHETIC DRUGS IN THE RAT.
222814 04-04

NARCOTIC AGONISTS AND ANTAGONISTS AS MODELS FOR POTENTIAL ANTIDEPRESSANT DRUGS.
222817 04-04

THE INFLUENCE OF SEVERAL PSYCHOTROPIC DRUGS ON THE STRUCTURE OF THE BRAIN.
222889 04-03

THE EFFECT OF PSYCHOTROPIC AND ANTICONVULSIVE DRUGS ON THE TRANSPORT OF ATPASE IN THE RENAL TUBES OF A GUINEA-PIG.
223015 04-05

THE EFFECT OF DRUGS ON INTRASPECIES AGGRESSION.
223064 04-04

DETERMINANTS OF PRESCRIBING OF PSYCHOACTIVE DRUGS BY GENERAL PRACTITIONERS.
224492 04-17

EEG AND BLOOD LEVEL RELATIONS OF PSYCHOACTIVE DRUGS.
224795 04-13

THE MISUSE OF DRUGS IN THE TREATMENT OF THE CHRONIC PSYCHOSES.
225055 04-17

ENVIRONMENTAL INFLUENCES AFFECTING THE VOLUNTARY INTAKE OF DRUGS: AN OVERVIEW.
225155 04-04

PHENOTHIAZINES AND STRUCTURALLY RELATED DRUGS. ADVANCES IN BIOCHEMICAL PSYCHOPHARMACOLOGY.
225399 04-17

EFFECTS OF AMINERGIC DRUGS AND GLUTAMIC ACID ON AUDIOGENIC SEIZURES INDUCED BY EARLY EXPOSURE TO ETHANOL.
225527 04-03

THE TERATOGENIC RISK OF ANTIEPILEPTIC DRUGS.
225537 04-15

IDIOSYNCRATIC REACTIONS TO THE ANTIEPILEPTIC DRUGS.
225538 04-15

ACUTE TOXICITY OF ANTIEPILEPTIC DRUGS.
225539 04-15

DRY

SALIVARY SCINTOGRAPHY: INTEREST IN TREATMENT OF DRY MOUTH PROVOKED BY PSYCHOTROPIC MEDICATION.
212493 03-15

DUAL

A DUAL STUDY. PART I: SYNTHESIS AND STEREOCHEMISTRY OF SOME 1 SUBSTITUTED QUINOLIZIDINES AS ANALOGS OF BIOLOGICALLY ACTIVE COMPOUNDS. PART II: AMINO DERIVATIVES OF THIOPHENE FUSED CYCLIC KETONES AS POTENTIAL CNS. (PH.D. DISSERTATION).
196252 01-01

DUAL MECHANISM OF AMPHETAMINE TOXICITY IN MICE: RELATIONSHIP TO BRAIN CATECHOLAMINES.
199898 02-05

POLYETHYLENE GLYCOL INDUCED THIRST: A DUAL STIMULATORY MECHANISM?
219071 04-04

DUCKS

SHORT-TERM EFFECTS OF TESTOSTERONE PROPIONATE ON THE BEHAVIOUR OF YOUNG INTACT MALE DOMESTIC DUCKS (ANAS-PLATYRHYNCHOS).
199461 02-04

DURATION

MINIMUM DURATION OF TRANS-SYNAPTIC STIMULATION REQUIRED FOR THE INDUCTION OF TYROSINE-HYDROXYLASE BY RESERPINE IN THE RAT SUPERIOR CERVICAL GANGLION.
199999 02-03

EFFECT OF AMITRIPTYLINE IN LONG-TERM AUTOEXPERIMENTS: PSYCHOPHYSIOLOGIC STUDY AND DURATION OF EXCRETION.
204402 02-13

DURATION OF EXPERIENCED LENGTHENING AND SHORTENING OF STRAIGHT LINES.
205135 02-14

THE EFFECTS OF RUBIDIUM ON THE DURATION OF SLEEP ELICITED BY PENTOBARBITAL IN THE RAT.
210791 03-03

CORRELATION OF BRAIN LEVELS OF BARBITURATE ENANTIOMERS WITH REPORTED DIFFERENCES IN DURATION OF SLEEP.
217457 04-03

LATENCY AND DURATION OF ESTROGEN INDUCTION OF MATERNAL BEHAVIOR IN HYSTERECTOMIZED OVARIECTOMIZED VIRGIN RATS: EFFECTS OF PUP STIMULATION.
219070 04-04

A DIRECT EFFECT OF DIBUTYRYL CYCLIC-AMP ON THE DURATION OF NARCOSIS INDUCED BY SEDATIVE, HYPNOTIC, TRANQUILISER AND ANESTHETIC DRUGS IN THE RAT.
222814 04-04

DURETTER

SIMILARITIES IN THE EFFECTS OF LITHIUM CARBONATE, LITAREX AND LITHIONITE DURETTER: PRELIMINARY STUDY.
221634 04-14

DYNAMIC

THE DYNAMIC CONFRONTATION MODEL AS AN INTEGRATION OF PSYCHOTHERAPY.
211596 03-12

DYNAMICS

SOME OF THE DYNAMICS OF CHOLINE AND ACETYLCHOLINE METABOLISM IN RAT BRAIN.
197474 01-03

PERMANENT EFFECTS OF REPEATED ADMINISTRATION OF ACTH AND DIAZEPAM IN EARLY POSTNATAL PERIOD UPON THE DYNAMICS OF EXCITATION AND INHIBITION DURING HABITUATION.
215068 04-04

THE EFFECTS OF SHOCK INTENSITY, D-AMPHETAMINE, AND PENTOBARBITAL ON THE FREQUENCY AND RESPONSE DYNAMICS OF BITING ATTACK IN THE SQUIRREL MONKEY. (PH.D. DISSERTATION).
222114 04-04

DYSARTHRIA

DYSARTHRIA RESULTING FROM LITHIUM CARBONATE: A CASE REPORT.
205288 02-15

DYSFUNCTION

CAFFEINE IN THE TREATMENT OF CHILDREN WITH MINIMAL BRAIN DYSFUNCTION OR HYPERKINETIC SYNDROME.
211434 03-11

DYSKINESIA

IATROGENIC DYSKINESIA: A UNIQUE REACTION TO PARENTERAL METHYLPHENIDATE.
193087 01-15

SPONTANEOUS ORAL DYSKINESIA: RESULTS OF TREATMENT WITH TETRABENAZINE, PIMOZIDE, OR BOTH.
196600 01-11

EFFECT OF CHOLINERGIC AND ANTICHOLINERGIC AGENTS ON TARDIVE DYSKINESIA.
200086 02-13

LITHIUM AND MRIH IN TARDIVE DYSKINESIA.
202887 02-14

TARDIVE DYSKINESIA: AN EVALUATION OF THE ETIOLOGIC ASSOCIATION WITH NEUROLEPTIC THERAPY.
204164 02-15

TREATMENT OF PHENOTHIAZINE INDUCED BULBAR PERSISTENT DYSKINESIA WITH DEANOL ACETAMIDOBENZOATE.
210209 03-13

DEANOL IN TARDIVE DYSKINESIA: A PRELIMINARY REPORT.
217523 04-11

MONOAMINEOXIDASE INHIBITORS ANTAGONIZE THE ACCELERATION OF BRAIN DOPAMINE SYNTHESIS INDUCED BY NEUROLEPTIC DRUGS IN VIVO: IMPLICATIONS FOR THE TREATMENT OF TARDIVE DYSKINESIA.
220948 04-03

EFFECT OF LITHIUM ON NEUROLEPTIC-INDUCED TARDIVE DYSKINESIA COMPARED WITH PLACEBO IN A DOUBLE-BLIND CROSSOVER TRIAL.
221335 04-15

ATYPICAL TARDINE DYSKINESIA.
225333 04-15

LITHIUM CARBONATE IN THE TREATMENT OF TARDIVE DYSKINESIA.
225343 04-15

DYSKINESIAS

CLINICAL FEATURES, ETIOLOGY AND TREATMENT OF FACIAL DYSKINESIAS IN THE ELDERLY.
206926 03-14

NEUROLEPTIC-INDUCED HYPERSENSITIVITY OF STRIATAL DOPAMINE RECEPTORS IN THE RAT AS A MODEL OF TARDIVE DYSKINESIAS. EFFECTS OF CLOZAPINE, HALOPERIDOL, LOXAPINE AND CHLORPROMAZINE.
217462 04-03

DYSKINETIC

DYSKINETIC PHENOMENA CAUSED BY THE INTRASTRIATAL INJECTION OF PHENYLETHYLAMINE, PHENYLPIPERAZINE, TETRAHYDROISOQUINOLINE AND TETRAHYDRONAPTHALENE DERIVATIVES IN THE GUINEA-PIG.
217671 04-04

DYSLEXIC

SPATIAL DISTRIBUTION OF THE EEG OF DYSLEXIC CHILDREN.
205504 02-13

DYSPHORIC

RESPONSES OF DYSPHORIC PATIENTS TO PHARMACOTHERAPIES.
198074 01-11

DYSTHYMIC

BROMAZEPAM IN TREATING DYSTHYMIC ELDERLY PATIENTS.
201690 02-11

LITHIUM GLUCONATE: SYSTEMATIC AND FACTORIAL ANALYSIS OF 104 OBSERVATIONS OVER 2.5-3 YEARS IN PATIENTS PRESENTING CYCLOTHYMIC OR DYSTHYMIC DISORDERS.
210126 03-09

DYSTONIA
DRUG-INDUCED DYSTONIA.
225332 04-15

D40TA
NEUROPHARMACOLOGICAL STUDIES OF EFFECT OF NEW CENTRAL DEPRESSANT, 8-CHLOR-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D40TA) ON EEG AND CENTRAL SYMPATHETIC ACTIVATING MECHANISM IN CATS.
195549 01-03

E-330
USE OF ANTIDEPRESSANT E-330 (IPRINDOLE).
208789 03-09

EASTERN
NEW PSYCHOTROPIC DRUG DEVELOPMENTS IN THE USSR AND OTHER EASTERN EUROPEAN COUNTRIES.
213598 04-07

EATING
THE RELATIVE ATTENUATION OF SELF-STIMULATION, EATING AND DRINKING PRODUCED BY DOPAMINE RECEPTOR BLOCKADE.
198225 02-04
CHANGED EATING AND LOCOMOTOR BEHAVIOUR IN THE RAT AFTER 6-HYDROXYDOPAMINE LESIONS TO THE SUBSTANTIA-NIGRA.
210763 03-04
CENTRAL NERVOUS SYSTEM PHARMACOLOGY OF CHOLINERGICALLY ELICITED EATING AND DRINKING BEHAVIOR IN THE ALBINO RAT. (PH.D. DISSERTATION).
222638 04-04

ECG
PSYCHOTROPIC AGENTS AND PATHOLOGICAL ECG CHANGES.
221336 04-15

ECOLOGICAL
AN ECOLOGICAL APPROACH TO A BEHAVIOR DISORDER: ENURESIS. (PH.D. DISSERTATION).
204528 02-11
URBAN ECOLOGICAL AND HOUSEHOLD CORRELATES OF STRESS ALLEVIATIVE DRUG USE.
223949 04-17

ECONOMY
THE EFFECTIVENESS OF RITALIN AND TOKEN ECONOMY IN INCREASING HYPERKINETIC CHILDRENS COLORING BEHAVIOR. (PH.D. DISSERTATION).
220510 04-14

ECS
THE EFFECT OF ACTH AND AMPHETAMINE ON ECS PRODUCED AMNESIA. (PH.D. DISSERTATION).
204733 02-04

ECT
DRUG-RESISTANT DEPRESSIONS: RESPONSE TO ECT.
196037 01-17

EDUCATION
A COMPARISON OF THE RELATIVE EFFICACY OF SPECIAL CLASS EDUCATION AND DRUG THERAPY FOR CHILDREN WITH SELECTED LEARNING DISABILITIES. (ED.D. DISSERTATION).
198662 02-11

EDUCATIONAL
A BEHAVIORAL EDUCATIONAL ALTERNATIVE TO DRUG CONTROL OF HYPERACTIVE CHILDREN.
225455 04-14

EEG
EFFECTS OF KETAMINE ON EEG ACTIVITY IN CATS AND MONKEYS.
193797 01-03
COMPARISON OF THE EFFECTS OF CHLORAL HYDRATE AND TRICHLOROETHANOL ON THE EEG OF THE ISOLATED PERFUSED RAT BRAIN.
194743 01-03
THE EEG EFFECTS OF ZINC IN GERIATRIC PSYCHIATRIC PATIENTS.
195039 01-13
NEUROPHARMACOLOGICAL STUDIES OF EFFECT OF NEW CENTRAL DEPRESSANT, 8-CHLOR-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D40TA) ON EEG AND CENTRAL SYMPATHETIC ACTIVATING MECHANISM IN CATS.
195549 01-03
SERIAL EEG RECORDINGS IN PSYCHOTROPIC DRUG TREATMENT.
196144 01-08
THE EFFECTS OF IMIPRAMINE AND PROMAZINE ON ENERGY METABOLISM AND EEG OF THE ISOLATED PERFUSED RAT BRAIN.
197296 01-03
STUDIES ON EEG TOLERANCE TO MARIJUANA IN THE RAT.
197473 01-03
EEG SEIZURES PRODUCED BY INTRAVENTRICULAR QUATERNARY AMMONIUM COMPOUNDS IN THE RAT.
197475 01-03
COMPARISON OF THE ACTION OF DIAZEPAM AND PHENOBARBITAL USING EEG DERIVED POWER SPECTRA OBTAINED FROM TEMPORAL LOBE EPILEPTICS.
197992 01-13
EEG PROFILES AS PREDICTORS OF PSYCHOTROPIC DRUG CLASSIFICATION.
198060 01-07
EEG CHANGES WITH LITHIUM IN DEPRESSED PATIENTS.
198100 02-10
THE EFFECTS OF DALMANE (FLURAZEPAM HYDROCHLORIDE) ON HUMAN EEG CHARACTERISTICS.
199756 02-13
THE IMPORTANCE OF METHODOLOGY IN DRUG STUDIES USING EEG.
199782 02-13
QUANTITATIVE ANALYSIS OF THE EEG EFFECTS PRODUCED BY IMIPRAMINE, DESIPRAMINE, PROMAZINE, AND MONODESMETHYL PROMAZINE IN THE ISOLATED PERFUSED RAT BRAIN.
200056 02-03
INHIBITION OF BEHAVIOURAL AND EEG ACTIVATION INDUCED BY MORPHINE ACTING ON LOWER BRAINSTEM STRUCTURES.
200078 02-03
EEG VARIATIONS UNDER ANTABUSE (DISULFIRAM) AND ANTABUSE PLUS ALCOHOL EXPOSITION: A STUDY OF PATHOGENESIS FROM ANTABUSE THERAPY COMPLICATIONS.
200572 02-15
EFFECT OF LITHIUM ON THE EEG AND SEROTONIN CONTENT IN THE BRAIN.
201888 02-03
EEG EXAMINATIONS DURING LITHIUM TREATMENT.
203701 02-13
SLEEP - EEG TESTS OF NONSPECIFIC CASES OF PAROXYSM AND EPISODIC BEHAVIORAL DISTURBANCES: A PRELIMINARY REPORT.
203704 02-14
MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 4. COMMUNICATION: CONNECTION BETWEEN EEG CHANGES, CONCENTRATION IN BLOOD, AND OTHER CLINICAL VARIABLES.
203842 02-13
EEG EVALUATION OF HYPNOTIC DRUGS: MOGADON V. RO-5-4200, USING THE DOUBLE-BLIND METHOD.
205435 02-13
THE RELATIONSHIP BETWEEN THE EEG DRIVING RESPONSE TO LIGHT AND PLASMA MONOAMINEOXIDASE (MAO) LEVELS.
205437 02-03
INFLUENCE OF MELATONIN ON EEG AND HUMAN SLEEP: AUTOMATIC EEG ANALYSES AND POLYGRAPHIC NIGHT SLEEP INVESTIGATIONS.
205446 02-13
EEG STATISTICAL SPECTRAL ANALYSIS OF SCHIZOPHRENIC PATIENTS.
205448 02-08
EEG AND SCHIZOPHRENIA: EXPERIMENTAL STUDIES, SPECTRAL ANALYSIS AND SEPTAL SPIKES.
205455 02-03
ACTIVATION OF EEG BY GAMMA-HYDROXYBUTYRATE (GHB) IN ORGANIC BRAIN DISORDERS.
205460 02-13
EEG CHANGES AFTER PSYCHOACTIVE DRUGS (SPECTRAL ANALYTIC STUDY).
205472 02-13
EFFECTS OF PSYCHOACTIVE TRICYCLIC DRUGS ON THE EEG OF THE ISOLATED PERFUSED RAT BRAIN.
205492 02-03
SPATIAL DISTRIBUTION OF THE EEG OF DYSLEXIC CHILDREN.
205504 02-13
EXPERIMENTAL EEG STUDIES ON BARBITURATE INTOXICATION AND PIRACETAM.
205507 02-03
DRUGS, EEG AND BEHAVIOUR: EEG PROFILES AND BIOAVAILABILITY MEASURES FOR CLINICAL PSYCHOPHARMACOLOGY.
205522 02-16
FURTHER EXPERIENCE WITH EPONTOL IN EEG ACTIVATION.
205548 02-13
THE USE OF MEGIMIDE IN FUNCTIONAL EEG.
205566 02-13
EEG CHANGES BEFORE AND AFTER L-DOPA THERAPY IN PARKINSON PATIENTS.
205569 02-13
FURTHER CLINICAL AND EEG EXPERIENCE WITH CLOZAPINE.
205615 03-11
CATEGORIES OF PSYCHOTROPIC DRUG EFFECTS ON SLEEP EEG AND EOG.
205621 03-13
EFFECTS OF SCOPOLAMINE ON THE EEG OF CORTEX AND HIPPOCAMPUS DURING SPONTANEOUS BEHAVIOUR IN RATS.
205628 03-04
LONG-TERM AND SHORT-TERM EFFECTS OF SULPIRIDE ON SLEEP EEG IN MAN.
206977 03-14
THE CLINICAL RELEVANCE OF PHOTOSENSITIVITY IN PSYCHIATRIC EEG DIAGNOSIS.
209018 03-15

CLINICAL STUDIES OF D-40TA (TRIAZOLOBENZODIAZEPINE) -- CROSSOVER TRIAL ON SLEEP DISTURBANCES AND SLEEP EEG IN NORMAL ADULTS.
209412 03-10

A YEAR OF INVESTIGATIONS ON 1035-MD IN CHILD AND JUVENILE NEUROPSYCHIATRY: CLINICAL AND EEG FINDINGS FROM 46 CASES.
209784 03-11

PSYCHOTROPIC DRUGS AND THE HUMAN EEG.
209829 03-16

THE EEG EFFECTS OF DOPA IN THE RABBIT DEPENDING UPON THE LEVEL OF BRAINSTEM SECTION.
210880 03-03

MARIJUANA: HEART RATE AND EEG RESPONSE.
210895 03-01

PROTECTIVE EFFECT OF PIRACETAM IN EXPERIMENTAL BARBITURATE INTOXICATION: EEG AND BEHAVIOURAL STUDIES.
213589 04-03

COMPUTERIZED EEG: PREDICTOR OF OUTCOME IN SCHIZOPHRENIA.
213863 04-08

EEG CHANGES IN THE TREATMENT WITH OCTOCLOTHEPINE IN VERY HIGH DOSES.
215064 04-13

INFLUENCE OF AZAPHEN, A NEW ANTIDEPRESSIVE DRUG, ON THE HUMAN EEG.
215065 04-09

THE EFFECT OF COMBINATION OF METHYLPHENIDATE AND DIAZEPAM ON THE EEG AND ITS EVALUATION BY MEANS OF DISCRIMINANT ANALYSIS.
215070 04-13

FACTOR ANALYSIS OF EEG OF HEALTHY SUBJECTS GIVEN NO DRUGS AND A COMBINATION OF DIAZEPAM AND METHYLPHENIDATE.
215071 04-13

INFLUENCE OF TEMPIDON ON THE EEG OF CATS AT A SINGLE AND REPEATED APPLICATION.
215076 04-03

EFFECTS OF IPRONIAZID, CHLORPROMAZINE AND METHIOTHEPIN ON DMT INDUCED CHANGES IN BODY TEMPERATURE, PUPILLARY DILATATION, BLOOD PRESSURE AND EEG IN THE RABBIT.
215724 04-03

EEG SPECTRAL ANALYSIS FOR THE EVALUATION OF THE CENTRAL EFFECTS OF DELTA6-TETRAHYDROCANNABINOL IN RABBITS.
217467 04-03

EEG CORRELATES OF IMPAIRED ATTENTION PERFORMANCE UNDER SECOBARBITAL AND CHLORPROMAZINE IN THE MONKEY.
217544 04-03

EFFECTS OF CENTRAL DOPAMINERGIC BLOCKADE WITH PIMOZIDE UPON THE EEG STAGES OF SLEEP IN MAN.
217546 04-14

ANALYSIS OF VARIOUS FACTORS INVOLVED IN EEG SYNCHRONIZATION DURING MILK DRINKING IN THE CAT.
217846 04-04

AN APPLICATION OF LONG-TERM FREQUENCY ANALYSIS IN MEASURING DRUG SPECIFIC ALTERATIONS IN THE EEG OF THE CAT.
218190 04-03

THE EFFECT OF CATECHOLAMINERGIC DRUGS ON THE BEHAVIOR AND EEG OF RATS DURING CORAZOL SEIZURES.
219332 04-04

SPECTRAL ANALYSIS OF HUMAN EEG CHANGES INDUCED BY ETIFOXIN.
221724 04-13

PHYSOSTIGMINE INDUCED REVERSAL OF EEG AND BEHAVIORAL EFFECTS OF DELTA9-TETRAHYDROCANNABINOL.
223093 04-04

EEG SLEEP PATTERNS AND DRUG ABUSE.
224719 04-15

EEG SLEEP CHANGES AS PREDICTORS IN DEPRESSION.
224769 04-09

EEG AND BLOOD LEVEL RELATIONS OF PSYCHOACTIVE DRUGS.
224795 04-13

EFFECTIVENESS

THE EFFECTIVENESS OF LITHIUM IN AFFECTIVE AND SCHIZOAFFECTIVE PSYCHOSES.
194043 01-11

USE OF THE MAUDSLEY PERSONALITY INVENTORY IN EVALUATING THE EFFECTIVENESS OF A MINOR TRANQUILIZER IN PSYCHOSOMATIC DISEASES (THE FIRST REPORT).
198518 02-14

PROBLEMS OF CLINICAL EFFECTIVENESS AND USE OF LITHIUM SALTS IN PSYCHIATRIC PRACTICE.
200072 02-09

EFFECTIVENESS OF LOXAPINE SUCCINATE IN ACUTE SCHIZOPHRENIA: A COMPARATIVE STUDY WITH THIOTHIXENE.
209484 03-08

BEHAVIORAL AND PHYSIOLOGICAL FEEDBACK AS SOURCES OF INFORMATION ABOUT THE EFFECTIVENESS OF A PLACEBO. (PH.D. DISSERTATION).
214228 04-17

A COMPARATIVE STUDY OF THE EFFECTIVENESS OF ENERBOL AND GLUTAMIC ACID IN OLIGOPHRENIC CHILDREN.
219662 04-11

CLINICAL - PSYCHOPATHOLOGICAL CRITERIA FOR THE SELECTION OF PSYCHOTROPIC DRUGS ACCORDING TO THE STAGE OF ILLNESS AND THE EFFECTIVENESS OF REHABILITATING SCHIZOPHRENICS.
220403 04-17

THE EFFECTIVENESS OF RITALIN AND TOKEN ECONOMY IN INCREASING HYPERKINETIC CHILDRENS COLORING BEHAVIOR. (PH.D. DISSERTATION).
220510 04-14

EFFERENT

INHIBITION OF EFFERENT SYMPATHETIC NERVE ACTIVITY BY 5-HYDROXYTRYPTOPHAN AND CENTRALLY ADMINISTERED 5-HYDROXYTRYPTAMINE.
215712 04-03

EFFICIENCY

PERFORMANCES UNDER CERUTIL OF NORMALLY INTELLIGENT CHILDREN AFFECTED BY CEREBROORGANIC REDUCTIONS IN EFFICIENCY.
203742 02-11

EFFLUX

EFFECTS OF SODIUM, OUABAIN AND DMPP ON THE NEURONAL EFFLUX OF NORADRENALINE.
197959 01-03

EFFECT OF AMPHETAMINE, 3,4 METHYLENEDIOXYAMPHETAMINE, P-METHOXYAMPHETAMINE AND RELATED AMPHETAMINES ON UPTAKE OF METARAMINOL AND EFFLUX OF NORADRENALINE IN ADRENERGIC NERVES OF RABBIT ATRIA.
217889 04-03

EFFORT

MILD ANALGESICS EVALUATED WITH THE SUBMAXIMUM EFFORT TOURNIQUET TECHNIQUE. I. THE INFLUENCE OF PSYCHOLOGICAL FACTORS ON THEIR EFFECT.
197861 01-14

MILD ANALGESICS EVALUATED WITH THE SUBMAXIMUM EFFORT TOURNIQUET TECHNIQUE: II. THE INFLUENCE OF A TRANQUILLIZER ON THEIR EFFECT.
197862 01-13

PENTOBARBITAL EFFECT ON PERFORMANCE IN MONOTONOUS CONDITIONS NOT PREVENTED BY COMPENSATORY EFFORT.
205595 02-15

EKG

THE EFFECTS OF LITHIUM ON THE EKG.
203602 02-15

PSYCHOTROPICS AND THEIR EFFECT ON THE EKG IN CHILDREN.
224378 04-13

ELABORATION

THE INFLUENCE OF HYDROCORTISONE ON THE ELABORATION OF EXTINCTION INHIBITION IN RATS.
219327 04-04

ELATION

DEPRESSION, ELATION, AND LITHIUM CARBONATE RESPONSES IN MANIC PATIENT SUBGROUPS.
199631 02-09

ELDERLY

PSYCHOACTIVE DRUG USE IN ELDERLY PATIENTS WITH PSYCHIATRIC DISORDERS: A SURVEY OF 12 VETERANS ADMINISTRATION HOSPITALS.
193291 01-11

DRUG USE PATTERNS AMONG THE ELDERLY.
198051 01-17

BROMAZEPAM IN TREATING DYSTHYMIC ELDERLY PATIENTS.
201690 02-11

THE CLINICAL USE OF PSYCHOTHERAPEUTIC DRUGS IN THE ELDERLY.
202798 02-11

CONFUSIONAL STATES IN ELDERLY MENTAL PATIENTS TREATED WITH ANTIDEPRESSANTS.
205603 03-15

CLINICAL FEATURES, ETIOLOGY AND TREATMENT OF FACIAL DYSKINESIAS IN THE ELDERLY.
206926 03-14

PSYCHOPHARMACOLOGY IN THE AGED: USE OF MAJOR PSYCHOTROPIC MEDICATIONS IN TREATMENT OF THE ELDERLY: CASE EXAMPLES.
208575 03-11

THE TREATMENT OF ANXIETY IN THE ELDERLY WITH A NEW TRANQUILIZER COMPOUND.
210211 03-11

CORRECTION OF AUTONOMIC EFFECTS OF PSYCHOTROPIC DRUGS BY LARGE DOSES OF DIHYDROERGOTAMINE IN ADULTS AND THE ELDERLY.
211998 03-11

RELIEVING SELECT SYMPTOMS OF THE ELDERLY.
213353 03-11

THE USE OF PSYCHOACTIVE DRUGS IN ELDERLY PATIENTS WITH PSYCHIATRIC DISORDERS: SURVEY CONDUCTED IN TWELVE VETERANS ADMINISTRATION HOSPITALS.
215009 04-11

EFFECTS OF DIPHENYLHYDANTOIN ON MENTAL ABILITIES IN THE ELDERLY.
215857 04-14

THE USE OF OXAZEPAM IN ELDERLY PATIENTS.
218153 04-13

PSYCHOPHARMACOLOGIC INVESTIGATIONS IN HEALTHY ELDERLY VOLUNTEERS: EFFECTS OF PIPRADROL - VITAMIN (ALERTONIC) ELIXIR AND PLACEBO IN RELATION TO RESEARCH DESIGN.
218217 04-11

MENTAL DECLINE IN THE ELDERLY: PHARMACOTHERAPY (ERGOT ALKALOIDS VERSUS PAPAVERINE).
218306 04-11

DETERIORATION SYNDROMES IN THE ELDERLY.
220284 04-11

PREVENTIVE USE OF LITHIUM IN ELDERLY PATIENTS.
220434 04-09

A CONTROLLED CLINICAL EXPERIMENT WITH BURONIL AND HALOPERIDOL IN DISORIENTATION AMONG ELDERLY PATIENTS.
221639 04-11

A COMPARISON BETWEEN MAPROTILINE (LUDIOMIL) AND IMIPRAMINE IN THE TREATMENT OF DEPRESSIVE ILLNESS IN THE ELDERLY.
221655 04-09

ELECTRIC

DRUGS AND PUNISHED RESPONDING. V. EFFECTS OF DRUGS ON RESPONDING SUPPRESSED BY RESPONSE DEPENDENT AND RESPONSE INDEPENDENT ELECTRIC SHOCK.
215722 04-04

ELECTRICAL

IN VIVO RELEASE OF ENDOGENOUSLY SYNTHESIZED CATECHOLAMINES FROM THE CAT BRAIN EVOKED BY ELECTRICAL STIMULATION AND BY D-AMPHETAMINE.
195049 01-03

EFFECTS OF THE HIGH DOSES OF L-DOPA ON ELECTRICAL ACTIVITY IN THE BRAIN OF THE RABBIT: INTERACTION WITH THE METABOLISM OF 5-HT.
197468 01-03

INFLUENCE OF OXYMETAZOLINE AND PHENTOLAMINE ON NORADRENALINE (NA) RELEASE CAUSED BY ELECTRICAL STIMULATION, POTASSIUM, TYRAMINE AND DIMETHYLPHENYLPIPERAZINE (DMPP).
197973 01-03

THE INFLUENCE OF TYROCALCITONIN ON CONDITIONAL REFLEXES AND THE ELECTRICAL ACTIVITY OF THE BRAIN IN ANIMALS.
198479 02-02

REDUCTION BY DIAZEPAM OF REPETITIVE ELECTRICAL ACTIVITY AND TOXICITY RESULTING FROM SOMAN.
199861 02-03

NOREPINEPHRINE AND SEROTONIN: SPECIFICITY OF RELEASE WITH REWARDING ELECTRICAL STIMULATION OF THE BRAIN.
217522 04-03

IN VIVO RELEASE OF ENDOGENOUS NEUROTRANSMITTERS IN CAT LIMBIC REGIONS: EFFECT OF CHLORPROMAZINE AND OF ELECTRICAL STIMULATION.
217685 04-03

DISCRIMINATIVE CONTROL OF BEHAVIOR BY ELECTRICAL STIMULATION OF THE DORSAL RAPHE NUCLEUS: GENERALIZATION TO LYSERGIC ACID DIETHYLAMIDE (LSD).
217821 04-12

ACTION OF SEROTONIN MICROINJECTED INTO HYPOTHALAMIC SITES AT WHICH ELECTRICAL STIMULATION PRODUCED AVERSIVE RESPONSES IN THE RAT.
219075 04-04

ELECTRICALLY-INDUCED

EFFECTS OF DIAZEPAM AND PHENOBARBITAL ON ELECTRICALLY-INDUCED AMYGDALOID SEIZURES AND SEIZURE DEVELOPMENT.
198612 02-04

ELECTROANALYTICAL

THE APPLICATION OF ELECTROANALYTICAL TECHNIQUES TO BIOCHEMICAL SYSTEMS. (PH.D. DISSERTATION).
194561 01-16

ELECTROCARDIOGRAM

MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 5. COMMUNICATION: INFLUENCE ON VENTRICULAR EXCITATION IN THE ELECTROCARDIOGRAM.
203843 02-13

PHENOTHIAZINES AND THE ELECTROCARDIOGRAM.
213783 04-15

ELECTROCARDIOGRAPHIC

ELECTROCARDIOGRAPHIC MONITORING OF ENURETIC CHILDREN RECEIVING THERAPEUTIC DOSES OF IMIPRAMINE.
225336 04-15

IMIPRAMINE AND ELECTROCARDIOGRAPHIC ABNORMALITIES IN HYPERACTIVE CHILDREN.
225337 04-15

ELECTROCONVULSIVE

INTERACTION BETWEEN MASSED ELECTROCONVULSIVE SHOCK AND P-BROMOMETHYLAMPHETAMINE (V-111) TREATMENT.
197579 01-03

THE SPARING TECHNIQUE IN ELECTROCONVULSIVE THERAPY.
200071 02-13

ELECTROCONVULSIVE SHOCK: SUSTAINED DECREASE IN NOREPINEPHRINE UPTAKE AFFINITY IN A RESERPINE MODEL OF DEPRESSION.
210830 03-03

ANTEROGRADE AND RETROGRADE EFFECTS OF ELECTROCONVULSIVE SHOCK AND OF PUROMYCIN ON MEMORY FORMATION IN THE GOLDFISH.
213853 04-04

ELECTROCORTICAL

BEHAVIOURAL AND ELECTROCORTICAL MODIFICATIONS INDUCED IN THE RAT BY INTRAVENTRICULAR INJECTION OF PHYSALAEMIN AND ELEDOISIN.
198224 02-03

MATURATION OF VISUAL ELECTROCORTICAL RESPONSES IN UNANESTHETIZED KITTENS: EFFECTS OF BARBITURATE ANESTHESIA.
199765 02-03

ELECTROCORTICAL CHANGES INDUCED BY PERFUSION OF CATECHOLAMINES INTO THE BRAINSTEM RETICULAR FORMATION.
210827 03-03

ELECTROCORTICOGRAM

EFFECTS OF PHENOBARBITAL ON ELECTROCORTICOGRAM AND ACTIVITY, ON REGIONAL CNS ENERGY METABOLISM, AND ON PRESYNAPTIC EVENTS IN CEREBRAL CORTEX AND BRAINSTEM. (PH.D. DISSERTATION).
203033 02-03

ELECTRODERMAL

REACTIVE BRAINSTEM LOCI FOR ELICITING ELECTRODERMAL RESPONSES.
206250 03-03

THE ELECTRODERMAL RESPONSE: NEUROPHYSIOLOGICAL AND NEUROPHARMACOLOGICAL CHARACTERISTICS. (PH.D. DISSERTATION).
214203 04-03

ELECTRODES

INTRACRANIAL SELF-STIMULATION IN RATS AS A FUNCTION OF VARIOUS STIMULUS PARAMETERS: V. INFLUENCE OF COCAINE ON MEDIAL FOREBRAIN BUNDLE STIMULATION WITH MONOPOLAR ELECTRODES.
198223 02-03

ELECTROENCEPHALIC

USE OF CNS STIMULANT MEDICATION IN AVERAGED ELECTROENCEPHALIC AUDIOMETRY WITH CHILDREN WITH MBD.
221103 04-11

ELECTROENCEPHALOGRAM

COMPUTER ANALYSIS OF METHADONE EFFECTS ON THE ELECTROENCEPHALOGRAM.
205467 02-03

THE ELECTROENCEPHALOGRAM AS A PHYSIOLOGICAL AND PHARMACOLOGICAL OBSERVABLE.
207549 03-06

THE EFFECT OF LITHIUM CARBONATE ON THE ELECTROENCEPHALOGRAM OF MANIC-DEPRESSIVE PSYCHOTICS.
217114 04-09

ELECTROENCEPHALOGRAPHIC

REVERSAL OF THE RESERPINE ELECTROENCEPHALOGRAPHIC SYNCHRONIZATION IN THE RABBIT BY P-CHLOROPHENYLALANINE.
197994 01-03

ELECTROENCEPHALOGRAPHIC AND BEHAVIORAL STUDIES ON THE CENTRAL ACTION OF NIMETAZEPAM (S-1530) IN CATS.
199910 02-04

ELECTROENCEPHALOGRAPHIC STUDY OF THE LOCAL TRANSPORT OF CENTRAL NERVOUS STIMULANTS INTO THE BRAIN.
202165 02-03

GENOTYPE DEPENDENT ELECTROENCEPHALOGRAPHIC, BEHAVIORAL AND ANALGESIC CORRELATES OF MORPHINE: AN ANALYSIS IN NORMAL MICE AND IN MICE WITH SEPTAL LESIONS.
203520 02-04

ELECTROENCEPHALOGRAPHIC FINDINGS ON THE ACTION OF FENTANYL AND DEHYDROBENZOPERIDOL.
205442 02-13

CLINICAL ELECTROENCEPHALOGRAPHIC DATA IN DEPRESSED PATIENTS TREATED WITH ANAFRANIL.
209148 03-09

THE EFFECT OF PSYCHOTROPIC AGENTS ON THE ELECTROENCEPHALOGRAPHIC CHARACTERISTICS OF THE INHIBITORY FUNCTION OF THE CAUDATE NUCLEUS.
219500 04-03

ELECTROENCEPHALOGRAPHIC STUDY FOR THE EVALUATION OF THE EFFECTS OF 7-CHLORO-5-PHENYLBENZODIAZEPIN-2-ONE (N-DEMETHYLDIAZEPAM) ON SLEEP DISTURBANCES IN A GROUP OF MENTAL PATIENTS.
221272 04-14

ELECTROENCEPHALOGRAPHIC STUDY ON THE ACTION OF THE COMBINATION MEPROBAMATE ACEPROMETAZINE ON VARIOUS CEREBRAL SYSTEMS.
221286 04-03

ELECTROENCEPHALOGRAPHY

PSYCHOTROPIC DRUGS AND ELECTROENCEPHALOGRAPHY: THIRD REPORT.
210276 03-13

ELECTROGRAPHIC

BEHAVIOURAL AND ELECTROGRAPHIC EFFECTS OF L-5-HYDROXYTRYPTOPHAN AND D,L-PARA-CHLOROPHENYLALANINE ON EPILEPTIC SENEGALESE BABOON (PAPIO-PAPIO).
199764 02-03

BEHAVIOURAL AND ELECTROGRAPHIC OBSERVATIONS DURING EPILEPTIC CONVULSIONS INDUCED BY STRYCHNINE AND PENTYLENETETRAZOL IN CONSCIOUS YOUNG AND ADULT CHICKENS.
205459 02-03

ELECTROLYTE
LITHIUM AND INSULIN: EFFECTS ON CARBOHYDRATE AND ELECTROLYTE METABOLISM.
205929 03-09

A STUDY OF ELECTROLYTE AND BIOGENIC AMINE METABOLISM IN MANIC-DEPRESSIVE ILLNESS.
208917 03-09

ELECTROLYTES
COMPARATIVE STUDIES ABOUT SERUM ELECTROLYTES DURING LITHIUM PROPHYLAXIS OF AFFECTIVE DISORDERS.
210807 03-09

ELECTROLYTIC
CHEMICAL OR ELECTROLYTIC LESION OF THE SUBSTANTIA-NIGRA: EARLY EFFECTS ON NEOSTRIATAL DOPAMINE METABOLISM.
210699 03-03

ELECTROMYOGRAPHIC
EFFECTS OF LITHIUM ON ELECTROMYOGRAPHIC RECORDINGS IN MAN: STUDIES IN MANIC-DEPRESSIVE PATIENTS AND NORMAL VOLUNTEERS.
215697 04-13

ELECTRON
CORRELATED HISTOCHEMICAL, ELECTRON MICROSCOPICAL, PHARMACOLOGICAL AND PHYSIOLOGICAL OBSERVATION ON AMINERGIC MECHANISMS IN THE CENTRAL NERVOUS SYSTEM. (UNPUBLISHED PAPER).
218300 04-03

ELECTRONEUROPHYSIOLOGICAL
COMPARATIVE STUDY OF THE ELECTRONEUROPHYSIOLOGICAL PARAMETERS OF SLEEP INDUCED BY SEVERAL HYPNOTIC DRUGS.
205520 02-13

ELECTROPHYSIOLOGICAL
ELECTROPHYSIOLOGICAL AND BEHAVIORAL REACTIVITY TO PHOTIC STIMULI FOLLOWING SEPTAL LESIONS AND PHARMACOLOGICAL TREATMENTS IN RATS.
206724 03-04

BEHAVIORAL AND ELECTROPHYSIOLOGICAL EFFECTS OF PHENYLETHANOLAMINE AND 2-PHENYLETHYLAMINE.
217521 04-04

ELECTROPHYSIOLOGICAL EVIDENCE FOR AN INHIBITORY ACTION OF DIAZEPAM UPON CAT BRAIN CORTEX.
217649 04-03

PROBLEMS IN THE ELECTROPHYSIOLOGICAL ANALYSIS OF THE SITE OF ACTION OF BENZODIAZEPINES. (UNPUBLISHED PAPER).
218148 04-03

ELECTROPHYSIOLOGICAL AND BEHAVIORAL EFFECTS OF 1-METHYL-5-O-FLUOROPHENYL 7-CHLORODIHYDROBENZODIAZEPIN-2-ONE (ID-540) IN CATS AND RABBITS.
221736 04-03

ELECTROSHOCK
KETAMIN HYDROCHLORIDE AS A PREANESTHESIA DRUG FOR AN ELECTROSHOCK TREATMENT.
202121 02-11

THE RELATIVE SIGNIFICANCE OF NOREPINEPHRINE DOPAMINE AND 5-HYDROXYTRYPTAMINE IN THE ELECTROSHOCK SEIZURE IN THE RAT.
204339 02-03

CORRELATION BETWEEN BRAIN MONOAMINE LEVELS AND POSTICTAL COMA FOLLOWING ELECTROSHOCK.
215723 04-03

ELEDOISIN
BEHAVIOURAL AND ELECTROCORTICAL MODIFICATIONS INDUCED IN THE RAT BY INTRAVENTRICULAR INJECTION OF PHYSALAEMIN AND ELEDOISIN.
198224 02-03

ELENIUM
A DIFFERENTIATED USE OF ELENIUM AND SEDUXEN IN YOUNG PATIENTS IN THE POST-INFARCTIONAL PERIOD.
200104 02-11

ELEVATION
POTENTIATION OF THE L-5-HYDROXYTRYPTOPHAN INDUCED ELEVATION OF PLASMA CORTICOSTERONE LEVELS IN RATS BY A SPECIFIC INHIBITOR OF SEROTONIN UPTAKE.
211104 03-03

ELEVATION OF PLASMA DOPAMINE-BETA-HYDROXYLASE ACTIVITY DURING MECHOLYL TEST.
225523 04-13

ELICITING
REACTIVE BRAINSTEM LOCI FOR ELICITING ELECTRODERMAL RESPONSES.
206250 03-03

ELICITS
SUBFORNICAL ORGAN: ACETYLCHOLINE APPLICATION ELICITS DRINKING.
210804 03-03

ELIMINATION
INCREASE IN BRAIN DOPAMINE AFTER AXOTOMY OR TREATMENT WITH GAMMA-HYDROXYBUTYRIC ACID DUE TO ELIMINATION OF THE NERVE IMPULSE FLOW.
195439 01-03

ELIMINATION OF LITHIUM DEPENDENT ON AGE IN HEALTHY PEOPLE AND PATIENTS SUFFERING FROM RENAL INSUFFICIENCY.
205043 02-13

EFFECTS OF THE DOPAMINE-BETA-HYDROXYLASE INHIBITOR FLA-63 ON THE KINETICS OF ELIMINATION OF AMPHETAMINE IN THE RAT.
217881 04-03

ELIXIR
PSYCHOPHARMACOLOGIC INVESTIGATIONS IN HEALTHY ELDERLY VOLUNTEERS: EFFECTS OF PIPRADROL - VITAMIN (ALERTONIC) ELIXIR AND PLACEBO IN RELATION TO RESEARCH DESIGN.
218217 04-11

EMBRYO
THE TOXICOLOGIC AND TERATOLOGIC EFFECTS OF DELTA9-TETRAHYDROCANNABINOL IN THE ZEBRAFISH EMBRYO.
217697 04-05

DEVELOPMENTAL VARIATIONS OF CHOLINE ACETYLTRANSFERASE, DOPAMINE-BETA-HYDROXYLASE AND MONOAMINEOXIDASE IN CHICKEN EMBRYO AND CHICKEN SYMPATHETIC GANGLIA.
217840 04-03

EMBRYONIC
MORPHOLOGICAL, BIOCHEMICAL, AND FUNCTIONAL CHANGES IN CHICK EMBRYONIC BRAIN TISSUE AFTER INTRACEREBRAL ADMINISTRATION OF OUABAIN.
197788 01-03

EMBRYOS
COMPARISON OF THE EFFECTS OF LITHIUM, BETA-PHENYLETHYLAMINE AND TYROSINE ON XENOPUS EMBRYOS.
200752 02-03

THE PROTECTIVE EFFECT OF SEROTONIN AGAINST THE INHIBITORY ACTION OF CHLORPROMAZINE ON THE MEMBRANE POTENTIAL OF STAGE 2 BLASTOMERES OF MOUSE EMBRYOS IN VITRO.
217005 04-03

EMERGENCY
PSYCHOTROPIC DRUGS: A MANUAL FOR EMERGENCY MANAGEMENT OF OVERDOSAGE.
193039 01-15

FROM HOSPITAL TREATMENT TO COMMUNITY PSYCHIATRY -- SECOND REPORT -- OUTPATIENT EMERGENCY TREATMENT OF MENTAL PATIENTS WITH THE USE OF HALOPERIDOL.
208723 03-11

EMERGENT
DEPRESSIONS AND ANTIDEPRESSANTS DURING TREATMENT WITH LONG-ACTING NEUROLEPTIC DRUGS: SIDE-EFFECTS AND THE EMERGENT METATHERAPEUTIC SYNDROME.
219694 04-15

EMINENCE
EFFECT OF 6-HYDROXYDOPAMINE ON HYPOTHALAMIC NOREPINEPHRINE AND DOPAMINE CONTENT, ULTRASTRUCTURE OF THE MEDIAN EMINENCE, AND PLASMA CORTICOSTERONE.
193050 01-03

EMOTION
ROLE OF BRAIN SEROTONIN IN THE INTEGRATION OF BEHAVIORAL RESPONSES AND PITUITARY ADRENOCORTICAL FUNCTIONS UNDER EMOTION.
218364 04-04

EMOTIONAL
EFFECTS OF PSYCHOTROPIC DRUGS ON THE EMOTIONAL REACTIVITY OF RATS.
197499 01-04

A CORRELATION BETWEEN THE INFLUENCE OF PSYCHOTROPIC DRUGS AND EMOTIONAL STRESS.
200103 02-09

THE EFFECT OF SEDUXEN ON THE PERCEPTIVE AND SOME OTHER FUNCTIONS OF THE CENTRAL NERVOUS SYSTEM UNDER EMOTIONAL STRESS IN MAN.
201916 02-14

ESTROGEN STIMULATIONS DURING NEONATAL PERIOD AND THEIR EFFECTS ON EMOTIONAL AND OPERATIVE BEHAVIOR IN THE ADULT.
211219 03-04

THE INFLUENCE OF PHARMACOLOGICAL AGENTS ON THE CONSEQUENCES OF EMOTIONAL EXCITATION IN CATS.
218814 04-04

EMOTIONALITY
PRENATAL MATERNAL D-AMPHETAMINE EFFECTS ON EMOTIONALITY AND AUDIOGENIC SEIZURE SUSCEPTIBILITY OF RAT OFFSPRING.
225079 04-04

EMOTIONALLY
DISRUPTION OF STATE-DEPENDENT LEARNING (MEMORY RETRIEVAL) BY EMOTIONALLY IMPORTANT STIMULI.
217470 04-04

EMPHASIS
A SURVEY OF DRUG TREATMENT IN PSYCHIATRY: SPECIAL EMPHASIS ON INPATIENTS ON MEDICAL WELFARE SUPPORTED BY YOKOHAMA CITY.
200447 02-17

TREATMENT AND COUNTERMEASURES FOR PATIENTS WITH INSOMNIA IN THE DEPARTMENT OF INTERNAL MEDICINE -- SPECIAL EMPHASIS ON THE CLINICAL APPLICATION OF FLURAZEPAM.
202285 02-14

CLINICAL USE OF CLOCAPRAMINE FOR THE TREATMENT OF CHRONIC SCHIZOPHRENIA -- SPECIAL EMPHASIS ON ITS COMPARISON WITH PERPHENAZINE.
207534 03-08

CLINICAL TRAILS OF SULPIRIDE WITH EMPHASIS ON NEUROTIC OUTPATIENTS.
224194 04-10

EMULSIFIED
INFLUENCE OF EMULSIFIED FAT ON CHLORPROMAZINE AVAILABILITY IN RABBIT BLOOD.
194928 01-03

ENANTHATE
OUTPATIENT TREATMENT OF SCHIZOPHRENIA BY A LONG-LASTING STRONG TRANQUILIZER: USE OF FLUPHENAZINE ENANTHATE.
194460 01-08

SHORT-TERM EFFECT OF PERPHENAZINE ENANTHATE ON THE RAT BRAIN.
206359 03-03

PREVENTION OF RECIDIVISM OF SCHIZOPHRENICS TREATED WITH FLUPHENAZINE ENANTHATE.
211436 03-08

FLUPHENAZINE ENANTHATE INDUCED DECOMPENSATIONS.
211437 03-08

CLINICAL STUDY AND FOLLOWUP OF 40 PSYCHOTIC PATIENTS ON PERPHENAZINE ENANTHATE.
212495 03-14

CLINICAL EXPERIENCE OF FLUPHENAZINE ENANTHATE IN TREATMENT OF SCHIZOPHRENIC PATIENTS.
213294 03-08

PERPHENAZINE ENANTHATE IN TREATING CHRONIC SCHIZOPHRENIA.
221558 04-08

CROSS-ANALYSIS OF A CONTROLLED EXPERIMENT WITH PIPOTHIAZINE AND FLUPHENAZINE ENANTHATE.
221636 04-08

CLINICAL STUDY OF FIVE DEPOT NEUROLEPTICS, COMPARISON OF ACTIVITY PROFILES OF FLUPHENAZINE DECANOATE, FLUSPIRILENE, PENFLURIDOL, PERPHENAZINE ENANTHATE AND PIPOTHIAZINE PALMITATE.
221822 04-08

ENANTIOMERS
CORRELATION OF BRAIN LEVELS OF BARBITURATE ENANTIOMERS WITH REPORTED DIFFERENCES IN DURATION OF SLEEP.
217457 04-03

ENCEPHABOL
PYRITHIOXINE (ENCEPHABOL) IN MENTALLY DEFICIENT CHILDREN (A TRIAL ON 50 CASES).
194554 01-11

ENCEPHABOL IN PATIENTS WITH ORGANIC-BRAIN-SYNDROME.
215073 04-07

ENCEPHALE
THE EFFECTS OF CORD SECTION UNDER ETHER OR HALOTHANE ON THE ABILITY OF CHLORPROMAZINE TO AFFECT THE JAW-JERK RESPONSE TO TOOTH PULP STIMULATION IN THE ENCEPHALE ISOLE PREPARATION.
197451 01-03

ENCEPHALOPATHY
LEAD ENCEPHALOPATHY IN THE DEVELOPING RAT: EFFECT ON CORTICAL ONTOGENESIS.
200168 02-05

ENCEPHALOTROPIC
THE INFLUENCE OF ENCEPHALOTROPIC DRUGS ON NUCLEIC ACID METABOLISM IN THE BRAIN.
204398 02-13

ENDINGS
HIGH AFFINITY UPTAKE OF GABA IN PRESUMED GABA-ERGIC NERVE ENDINGS IN RAT BRAIN.
211062 03-03

THE EFFECT OF NEUROLEPTICS AND ANTIDEPRESSANTS ON THE UPTAKE OF 3H-GAMMA-AMINOBUTYRIC ACID BY ISOLATED NERVE ENDINGS OF THE RAT BRAIN.
224114 04-03

ENDOCRINE
THE EFFECT OF 6-HYDROXYDOPAMINE ADMINISTRATION TO NEONATAL RATS ON SOME ENDOCRINE AND BEHAVIORAL PARAMETERS.
197498 01-03

ENDOCRINE EFFECTS OF CHRONIC ADMINISTRATION OF PSYCHOACTIVE DRUGS TO PREPUBERAL MALE RATS. I: DELTA9-TETRAHYDROCANNABINOL.
209840 03-03

THE EFFECT OF ACTH AND DIAZEPAM, ADMINISTERED TO INFANT RATS ON THE BODY GROWTH CURVE AND SOME ENDOCRINE PARAMETERS MEASURED IN ADULT AGE.
215066 04-03

ENDOCRINOLOGY
STUDIES ON BEHAVIORAL ENDOCRINOLOGY OF CORTICOSTEROIDS.
219472 04-04

ENDOGENOUS
AMENORRHEA IN ENDOGENOUS DEPRESSION.
195040 01-09

THE EFFECT OF LITHIUM CARBONATE IN COMBINATION WITH TRICYCLIC ANTIDEPRESSANTS IN ENDOGENOUS DEPRESSION: A DOUBLE-BLIND, MULTICENTER TRIAL.
197035 01-09

3,4 DIHYDROXYPHENYLACETIC ACID (DOPAC): A POSSIBLE ENDOGENOUS INHIBITOR OF INDOLEAMINE-N-METHYLATION IN THE RAT BRAIN.
197676 01-17

THE CURRENT STATUS OF LITHIUM RECIDIVISM PROPHYLAXIS IN ENDOGENOUS AFFECTIVE ILLNESSES.
200568 02-09

FAMILY HISTORY OF MANIC-DEPRESSIVE AND ENDOGENOUS DEPRESSIVE PATIENTS AND CLINICAL EFFECT OF TREATMENT WITH LITHIUM.
205608 03-09

THE LITHIUM PROPHYLACTIC TREATMENT OF RECURRENT ENDOGENOUS AFFECTIVE DISORDERS.
209392 03-09

IN VIVO RELEASE OF ENDOGENOUS NEUROTRANSMITTERS IN CAT LIMBIC REGIONS: EFFECT OF CHLORPROMAZINE AND OF ELECTRICAL STIMULATION.
217685 04-03

THE EFFECT OF DRUGS ON THE RELEASE OF ENDOGENOUS CATECHOLAMINES INTO THE PERFUSATE OF DISCRETE BRAIN AREAS OF THE CAT IN VIVO.
219631 04-06

EFFECTS OF SINGLE AND MULTIPLE DOSE LSD ON ENDOGENOUS LEVELS OF BRAIN TYROSINE-HYDROXYLASE AND CATECHOLAMINES.
221044 04-12

PHARMACOLOGICAL ACTION OF FD-008, A NEW DOPAMINE-BETA-HYDROXYLASE INHIBITOR: III. EFFECTS ON ENDOGENOUS BIOGENIC AMINE LEVELS IN RATS.
221859 04-03

DOSE-RESPONSE RELATIONSHIP FOR NORTRIPTYLINE IN ENDOGENOUS DEPRESSION.
224835 04-09

ENDOGENOUSLY
IN VIVO RELEASE OF ENDOGENOUSLY SYNTHESIZED CATECHOLAMINES FROM THE CAT BRAIN EVOKED BY ELECTRICAL STIMULATION AND BY D-AMPHETAMINE.
195049 01-03

THE IN VIVO RELEASE OF ENDOGENOUSLY SYNTHESIZED CATECHOLAMINES FROM THE CAT BRAIN BY LATERAL HYPOTHALAMIC STIMULATION AND BY D-AMPHETAMINE ADMINISTRATION. (PH.D. DISSERTATION).
200313 02-03

ENDOTOXICOSIS
ANALYSIS OF THE INFLUENCE OF SELECTED NEUROTROPIC AGENTS ON HEPATIC METABOLISM IN RELATION TO ENDOTOXICOSIS.
195448 01-03

ENERBOL
A COMPARATIVE STUDY OF THE EFFECTIVENESS OF ENERBOL AND GLUTAMIC ACID IN OLIGOPHRENIC CHILDREN.
219662 04-11

ENERGY
INFLUENCE OF THERAPEUTIC AND TOXIC DOSES OF NEUROLEPTICS AND ANTIDEPRESSANTS ON ENERGY METABOLISM OF THE ISOLATED PERFUSED RAT BRAIN.
195236 01-03

THE EFFECTS OF IMIPRAMINE AND PROMAZINE ON ENERGY METABOLISM AND EEG OF THE ISOLATED PERFUSED RAT BRAIN.
197296 01-03

EFFECTS OF PHENOBARBITAL ON ELECTROCORTICOGRAM AND ACTIVITY, ON REGIONAL CNS ENERGY METABOLISM, AND ON PRESYNAPTIC EVENTS IN CEREBRAL CORTEX AND BRAINSTEM. (PH.D. DISSERTATION).
203033 02-03

PSYCHOTROPIC DRUGS AND SOME ENZYMES OF ENERGY METABOLISM.
205630 03-03

THE ROLE OF CATECHOLAMINES IN THE ACTION OF AMPHETAMINE AND L-DOPA ON CEREBRAL ENERGY METABOLISM.
217677 04-03

ENGLISH
RETROSPECTIVE STUDY OF THE ASSOCIATION BETWEEN USE OF RAUWOLFIA DERIVATIVES AND BREAST CANCER IN ENGLISH WOMEN.
194063 01-13

ENGRAM
THE ENGRAM, LOST AND FOUND. (PH.D. DISSERTATION).
201125 02-04

ENHANCEMENT
ENHANCEMENT OF THE CHLORPROMAZINE-INDUCED SUPPRESSION OF THE CONDITIONED AVOIDANCE RESPONSE BY CARBONIC ANHYDRASE INHIBITION.
199770 02-03

MEMORY ENHANCEMENT BY CENTRAL ADMINISTRATION OF NOREPINEPHRINE.
210671 03-04

ENHANCEMENT OF APOMORPHINE-INDUCED INHIBITION OF STRIATAL DOPAMINE TURNOVER FOLLOWING CHRONIC HALOPERIDOL.
210814 03-03

ENHANCEMENT OF SELF-STIMULATION BY DEPRENIL: EVIDENCE FOR A ROLE OF DOPAMINE NEURONES IN REWARD.
213432 04-04

ENTERAL
TREATMENT OF EXPERIMENTAL IMIPRAMINE INTOXICATION BY INTERRUPTING ENTERAL CYCLES WITH ACTIVATED CHARCOAL.
197969 01-03

ENURESIS
RESULTS OF TREATING CHILDREN WITH NOCTURNAL ENURESIS WITH IMIPRAMINE (PSYCHOFORIN).
194208 01-11

A COMPARATIVE STUDY OF AMPHETAMINE, EPHEDRINE ATROPINE MIXTURE, PLACEBO AND BEHAVIORAL CONDITIONING IN THE TREATMENT OF NOCTURNAL ENURESIS.
198020 01-11

AN ECOLOGICAL APPROACH TO A BEHAVIOR DISORDER: ENURESIS. (PH.D. DISSERTATION).
204528 02-11

ESSENTIAL INFANTILE ENURESIS AND DOGMATIL.
218165 04-14

ENURETIC
ELECTROCARDIOGRAPHIC MONITORING OF ENURETIC CHILDREN RECEIVING THERAPEUTIC DOSES OF IMIPRAMINE.
225336 04-15

ENVIRONMENT
ON THE ORTHOMOLECULAR ENVIRONMENT OF THE MIND: ORTHOMOLECULAR THEORY.
213703 04-13

SIZE OF THE ENVIRONMENT AS A DETERMINER OF EFFECTS OF SCOPOLAMINE.
223849 04-04

ENVIRONMENTAL
AMPHETAMINE STEREOTYPY: THE INFLUENCE OF ENVIRONMENTAL FACTORS AND PREPOTENT BEHAVIORAL PATTERNS ON ITS TOPOGRAPHY AND DEVELOPMENT.
213531 04-04

GENETIC, BIOCHEMICAL, AND ENVIRONMENTAL VARIABLES IN THE EXPRESSION OF SHORT-TERM MEMORY IN THE MOUSE. (PH.D. DISSERTATION).
222749 04-04

ENVIRONMENTAL INFLUENCES AFFECTING THE VOLUNTARY INTAKE OF DRUGS: AN OVERVIEW.
225155 04-04

ENZYME
PHARMACOLOGICAL PROPERTIES OF TWO CHLORDIAZEPOXIDE METABOLITES FOLLOWING MICROSOMAL ENZYME INHIBITION.
210792 03-03

INHIBITION OF CATECHOLAMINE AND 5-HYDROXYTRYPTAMINE INDUCED ENZYME SECRETION FROM THE GUINEA-PIG SUBMANDIBULAR GLAND BY 2-BROMO-D-LYSERGIC ACID DIETHYLAMIDE.
216968 04-03

ENZYMES
EFFECT OF COPPER LOADING ON VARIOUS TISSUE ENZYMES AND BRAIN MONOAMINES IN THE RAT.
193577 01-03

EFFECT OF NEUROTROPIC AGENTS ON TOTAL PYRIDOXAL PHOSPHATE AND ON THE ACTIVITY OF THE DECARBOXYLASE OF AROMATIC AMINO ACIDS AS WELL AS OF OTHER PYRIDOXAL PHOSPHATE DEPENDENT ENZYMES IN RAT BRAIN.
199785 02-03

EFFECT OF PHENOBARBITAL ADMINISTRATION ON ETHANOL OXIDIZING ENZYMES AND ON RATES OF ETHANOL DEGRADATION.
204386 02-03

PSYCHOTROPIC DRUGS AND SOME ENZYMES OF ENERGY METABOLISM.
205630 03-03

EFFECT OF LITHIUM ON MAGNESIUM DEPENDENT ENZYMES.
209351 03-03

ON THE PARTICIPATION OF BIOGENIC AMINES AND THEIR SYNTHETIC ENZYMES IN THE MECHANISMS OF IMAGE MEMORY.
213469 04-04

CATECHOLAMINE NEUROTRANSMITTERS AND SYNTHETIC ENZYMES IN THE SPINAL CORD OF THE RAT.
213987 04-03

AGE DIFFERENCES AFFECTING INDUCTION OF HEPATIC DRUG METABOLIZING ENZYMES BY METHAQUALONE AND PHENOBARBITAL IN THE RAT.
217793 04-03

A COMPARISON OF THE INDUCTIVE EFFECTS OF PHENOBARBITAL, METHAQUALONE, AND METHYPRYLON ON HEPATIC MIXED FUNCTION OXIDASE ENZYMES IN THE RAT.
217794 04-03

EOG
CATEGORIES OF PSYCHOTROPIC DRUG EFFECTS ON SLEEP EEG AND EOG.
205621 03-13

EPHEDRINE
A COMPARATIVE STUDY OF AMPHETAMINE, EPHEDRINE ATROPINE MIXTURE, PLACEBO AND BEHAVIORAL CONDITIONING IN THE TREATMENT OF NOCTURNAL ENURESIS.
198020 01-11

EPIDEMIC
SUICIDE IN BRISBANE, 1956 TO 1973: THE DRUG DEATH EPIDEMIC.
224491 04-17

EPILEPSY
REGIONAL DISTRIBUTION OF CATIONS AND THEIR RELATION TO THE NEUROCHEMISTRY OF EXPERIMENTAL EPILEPSY, NEUROTRANSMITTERS AND ATPASE IN THE CENTRAL NERVOUS SYSTEM. (PH.D. DISSERTATION).
193588 01-03

BRAIN AND SERUM CONCENTRATIONS OF DIAZEPAM IN EXPERIMENTAL EPILEPSY.
195494 01-04

BENZODIAZEPINES IN THE TREATMENT OF EPILEPSY: A REVIEW.
201870 02-11

THE EFFECTS OF CARBAMAZEPINE ON PATIENTS WITH PSYCHOMOTOR EPILEPSY: RESULTS OF A DOUBLE-BLIND STUDY.
205031 02-11

EXPERIMENTAL STUDIES ON THE PSYCHICAL EPISODES OF EPILEPSY.
205464 02-04

EFFECTS OF DIAZEPAM ON EXPERIMENTALLY INDUCED CORTICAL EPILEPSY AND THEIR CORRELATION WITH DRUG CONCENTRATION.
205491 02-03

THE USE OF ANTICONVULSANT TREATMENT OF BEHAVIORALLY DISTURBED CHILDREN WITH BIOELECTRIC EPILEPSY: A CATAMNESTIC STUDY OF 76 CASES.
211355 03-11

COMPREHENSIVE MANAGEMENT OF EPILEPSY.
216339 04-11

DIPROPYLACETIC ACID (DEPAKINE) IN EXPERIMENTAL EPILEPSY IN THE ALERT CAT.
225529 04-02

EPILEPTIC
PHARMACOKINETIC EVALUATION OF ANTICONVULSANTS PRIOR TO EFFICACY TESTING EXEMPLIFIED BY CARBAMAZEPINE IN EPILEPTIC MONKEY MODEL.
195492 01-04

BEHAVIOURAL AND ELECTROGRAPHIC EFFECTS OF L-5-HYDROXYTRYPTOPHAN AND D,L-PARA-CHLOROPHENYLALANINE ON EPILEPTIC SENEGALESE BABOON (PAPIO-PAPIO).
199764 02-03

BEHAVIOURAL AND ELECTROGRAPHIC OBSERVATIONS DURING EPILEPTIC CONVULSIONS INDUCED BY STRYCHNINE AND PENTYLENETETRAZOL IN CONSCIOUS YOUNG AND ADULT CHICKENS.
205459 02-03

STUDY ON AMITRIPTYLINE-INDUCED SLEEP IN EPILEPTIC PATIENTS.
205470 02-13

COGNITIVE AND MOTOR SENSORY PERFORMANCES IN TOXIC AND NONTOXIC EPILEPTIC SUBJECTS.
210824 03-15

AN ASPECT OF BIOLOGICAL THERAPY IN THE SYSTEM OF REHABILITATING EPILEPTIC PATIENTS WITH MENTAL DISORDERS.
220420 04-11

EPILEPTICS
COMPARISON OF THE ACTION OF DIAZEPAM AND PHENOBARBITAL USING EEG DERIVED POWER SPECTRA OBTAINED FROM TEMPORAL LOBE EPILEPTICS.
197992 01-13

RED CELL FOLATE AND MACROCYTOSIS DURING LONG-TERM ANTICONVULSANT THERAPY IN NONANAEMIC MENTALLY RETARDED EPILEPTICS.
218553 04-11

CLINICAL EVALUATION OF METYLPERONE (BURONIL) WITH EPILEPTICS.
221518 04-11

EPILEPTIFORM
CENTRAL IMPLANTATION OF CANNABINOIDS: INDUCTION OF EPILEPTIFORM DISCHARGES.
193449 01-03

EPILEPTIFORM SEIZURES IN DOMESTIC FOWL. IV. THE EFFECTS OF ANTICONVULSANT DRUGS.
197742 01-03

EPILEPTOGENIC
EXPERIMENTAL STUDIES ON FACILITATIVE AND INHIBITORY FACTORS FOR EPILEPTOGENIC FOCUS FORMATION.
197211 01-03

THE EFFECTS OF DIPHENYLHYDANTOIN, PHENOBARBITAL, AND DIAZEPAM ON THE PENICILLIN INDUCED EPILEPTOGENIC FOCUS IN THE RAT.
198613 02-03

THE INFLUENCE OF CHOLINOMIMETICS ON THE AFTEREFFECTS OF TRACE DISCHARGES AND THE ACTIVITY OF EPILEPTOGENIC FOCI IN THE RABBIT HIPPOCAMPUS.
219499 04-03

EPINEPHRINE
DIFFERENTIAL EFFECTS OF EPINEPHRINE AND PROPRANOLOL ON SHUTTLEBOX AVOIDANCE LEARNING IN RATS OF DIFFERENT AGES. (PH.D. DISSERTATION).
193745 01-04

FACILITATION OF TIME-DEPENDENT MEMORY PROCESSES WITH POSTTRIAL EPINEPHRINE INJECTIONS.
209951 03-04
THE EFFECTS OF INTRAVENOUS AND SUBCUTANEOUS EPINEPHRINE ADMINISTRATION ON CONDITIONED SUPPRESSION. (PH.D. DISSERTATION).
213131 03-04
THE INFLUENCE OF TRICYCLIC ANTIDEPRESSANTS, AZAPHEN AND IMIZINE ON BLOOD SUGAR CONCENTRATION CHANGES PRODUCED BY EPINEPHRINE AND SEROTONIN.
217214 04-03

EPISODES
INVOLVEMENT OF SEROTONIN IN HYPERKINETIC EPISODES IN SCOTTISH TERRIER DOGS. (PH.D. DISSERTATION).
196261 01-03
EXPERIMENTAL STUDIES ON THE PSYCHICAL EPISODES OF EPILEPSY.
205464 02-04
COMPARATIVE STUDY OF CLOTHIAPINE AND TRIFLUOPERAZINE IN EPISODES OF ACUTE PARANOID SCHIZOPHRENIA.
217025 04-08
A COMPARISON OF PHENOTHIAZINES IN MANAGING AGGRESSIVE EPISODES IN SCHIZOPHRENIC PATIENTS.
224955 04-08

EPISODIC
SLEEP - EEG TESTS OF NONSPECIFIC CASES OF PAROXYSM AND EPISODIC BEHAVIORAL DISTURBANCES: A PRELIMINARY REPORT.
203704 02-14

EPONTOL
FURTHER EXPERIENCE WITH EPONTOL IN EEG ACTIVATION.
205548 02-13

EPS
RELATIONSHIPS AMONG CLINICAL RESPONSE, EPS, AND PLASMA CPZ AND CPZ METABOLITE RATIOS.
224831 04-08

EQUIVALENCE
DOSE EQUIVALENCE OF THE ANTIPSYCHOTIC DRUGS.
207291 03-17
BIOLOGICAL AND PHARMACOKINETIC EVIDENCE FOR GENERIC EQUIVALENCE OF THREE IMIPRAMINE PREPARATIONS: COMPARISON WITH A NEW IMIPRAMINE ANALOGUE.
211071 03-02

EQUIVALENT
A CASE OF SEVERE HEADACHE AS AN EQUIVALENT OF AFFECTIVE DISORDER.
201668 02-09

ERGOT
EFFECTS OF CENTRAL ACTING DRUGS AND ERGOT DERIVATIVES ON PROLACTIN AND GROWTH HORMONE SECRETION, ON GROWTH OF PITUITARY AND MAMMARY TUMORS AND ON REPRODUCTION IN OLD RATS. (PH.D. DISSERTATION).
194571 01-03
EFFECT OF ERGOT DRUGS ON CENTRAL 5-HYDROXYTRYPTAMINE NEURONS: EVIDENCE FOR 5-HYDROXYTRYPTAMINE RELEASE OR 5-HYDROXYTRYPTAMINE RECEPTOR STIMULATION.
210857 03-03
MENTAL DECLINE IN THE ELDERLY: PHARMACOTHERAPY (ERGOT ALKALOIDS VERSUS PAPAVERINE).
218306 04-11

ERYTHRO
FORMATION OF NOREPINEPHRINE IN THE BRAIN OF RATS AFTER ADMINISTRATION OF (+) ERYTHRO 3,4 DIHYDROXYPHENYLSERINE.
225558 04-03

ERYTHROCYTE
SODIUM AND LITHIUM ERYTHROCYTE CONCENTRATION IN AFFECTIVE DISORDERS.
195931 01-09
MG++ DEPENDENT ADENOSINE-TRIPHOSPHATASE ACTIVITY IN ERYTHROCYTE GHOSTS OF SCHIZOPHRENIC PATIENTS.
206332 03-08
GENETIC DETERMINANT OF LITHIUM ION METABOLISM: II. AN IN VIVO STUDY OF LITHIUM ION DISTRIBUTION ACROSS ERYTHROCYTE MEMBRANES.
211412 03-03
SERUM ERYTHROCYTE AND CNS LEVELS IN RHESUS MONKEYS OF ORALLY AND INTRAVENOUSLY ADMINISTERED RUBIDIUM SALTS.
218956 04-02

ERYTHROCYTES
INTRA-EXTRACELLULAR LITHIUM RATIO: CLINICAL AND EXPERIMENTAL FINDINGS ON THROMBOCYTES AND ERYTHROCYTES.
204393 02-13

ESCAPE
POTENTIATION OF TETRABENAZINE-INDUCED BEHAVIOURAL DEPRESSION BY IMIPRAMINE ON A DISCRETE TRIAL AVOIDANCE ESCAPE SCHEDULE.
197859 01-04
AN ANALYSIS OF MONOAMINERGIC MECHANISMS OF THE DORSAL HIPPOCAMPUS WHICH MEDIATE THE CONDITIONED ESCAPE REACTION IN RATS.
208991 03-04
FIXED-RATIO ESCAPE AND AVOIDANCE ESCAPE FROM NALOXONE IN MORPHINE-DEPENDENT MONKEYS: EFFECTS OF NALOXONE DOSE AND MORPHINE PRETREATMENT.
215968 04-04
U-SHAPED FUNCTIONS IN A SHOCK ESCAPE TASK.
222265 04-04

ESERINE
BLOCKADE BY ESERINE OF THE CEREBRAL CORTICAL EFFECTS OF ALLOFERIN: A FURTHER EVIDENCE OF CHOLINERGIC INHIBITORY MECHANISM.
195548 01-03
NEOCORTICAL AND HIPPOCAMPAL ACTIVATION IN RELATION TO BEHAVIOR: EFFECTS OF ATROPINE, ESERINE, PHENOTHIAZINES, AND AMPHETAMINE.
206742 03-04

ESTIMATION
ESTIMATION OF PHARMACOKINETIC PARAMETERS OF LITHIUM FROM SALIVA AND URINE.
195446 01-13
APPLICATION OF PRINCIPLES OF STEADY-STATE KINETICS TO THE IN VIVO ESTIMATION OF ACETYLCHOLINE TURNOVER RATE IN MOUSE BRAIN.
210885 03-06

ESTROGEN
ESTROGEN STIMULATIONS DURING NEONATAL PERIOD AND THEIR EFFECTS ON EMOTIONAL AND OPERATIVE BEHAVIOR IN THE ADULT.
211219 03-04
ESTROGEN INDUCED MATERNAL BEHAVIOR IN HYSTERECTOMIZED OVARIECTOMIZED VIRGIN RATS.
219069 04-04
LATENCY AND DURATION OF ESTROGEN INDUCTION OF MATERNAL BEHAVIOR IN HYSTERECTOMIZED OVARIECTOMIZED VIRGIN RATS: EFFECTS OF PUP STIMULATION.
219070 04-04
STIMULATION OF ESTROGEN INDUCED COPULATORY BEHAVIOR IN CASTRATE MALE RATS WITH THE SEROTONIN BIOSYNTHESIS INHIBITOR P-CHLOROPHENYLALANINE.
221010 04-04

ESTROGENIZATION
INHIBITORY EFFECT OF NEONATAL ESTROGENIZATION ON THE INCORPORATION OF (3H)LYSINE IN THE PURKINJE CELLS OF THE ADULT MALE AND FEMALE RAT.
213478 04-03

ESTROGENS
THE CONTROL OF DEVIANT SEXUAL BEHAVIOUR BY DRUGS: I. BEHAVIOURAL CHANGES FOLLOWING ESTROGENS AND ANTIANDROGENS.
196958 01-14
EFFECTS OF CONJUGATED ESTROGENS ON PLASMA BUTAPERAZINE LEVELS.
201327 02-13

ETHAMIVAN
EXPERIMENTAL PSYCHOLOGICAL STUDY ON THE EFFECT OF A COMBINATION OF HEXOBENDINE, ETHAMIVAN AND ETOFYLLINE.
221738 04-14

ETHANOL
ALTERATION OF THE EFFECTS AND THE METABOLISM OF D-AMPHETAMINE BY ETHANOL.
197975 01-03
COMBINED EFFECTS OF DIAZEPAM AND ETHANOL ON MENTAL AND PSYCHOMOTOR FUNCTIONS.
199896 02-14
EFFECTS OF PROPRANOLOL, D-AMPHETAMINE AND CAFFEINE ON ETHANOL AS A DISCRIMINATIVE CUE.
199963 02-04
EFFECT OF PHENOBARBITAL ADMINISTRATION ON ETHANOL OXIDIZING ENZYMES AND ON RATES OF ETHANOL DEGRADATION.
204386 02-03
SELECTIVE INHIBITION OF DOPAMINE-BETA-HYDROXYLASE IN THE PERIPHERAL TISSUES BY 5-DIMETHYLDITHIOCARBAMYLPICOLINIC ACID; ITS EFFECT ON STRESS INDUCED ULCER, ETHANOL INDUCED SLEEP AND BLOOD PRESSURE.
204484 02-03
LITHIUM AND ETHANOL PREFERENCE.
210750 03-05
MODULATION OF THE RESPIRATORY DEPRESSANT EFFECT OF ETHANOL BY 5-HYDROXYTRYPTAMINE.
210751 03-03
MENTAL AND PSYCHOMOTOR EFFECTS OF DIAZEPAM AND ETHANOL.
211070 03-14
ANTAGONISM OF DEPRESSANT ACTIVITY OF ETHANOL BY DH-524; A COMPARATIVE STUDY WITH BEMEGRIDE, DOXAPRAM AND D-AMPHETAMINE (38640).
213282 03-03
ADRENAL GLUCOCORTICOIDS AS A REQUIRED FACTOR IN THE DEVELOPMENT OF ETHANOL WITHDRAWAL SEIZURES IN MICE.
213479 04-03

EFFECT OF WITHDRAWAL FROM CHRONIC ETHANOL INGESTION ON THE CAMP RESPONSE OF CEREBRAL CORTICAL SLICES USING THE AGONISTS HISTAMINE, SEROTONIN, AND OTHER NEUROTRANSMITTERS.
215980 04-03

EFFECT OF ETHANOL ON TOXICITY AND METABOLISM OF AMPHETAMINE IN THE MOUSE.
220950 04-05

EFFECTS OF AMINERGIC DRUGS AND GLUTAMIC ACID ON AUDIOGENIC SEIZURES INDUCED BY EARLY EXPOSURE TO ETHANOL.
225527 04-03

ETHER

EFFECT OF PENTOBARBITONE AND DIETHYL ETHER ON THE SYNTHESIS OF MONOAMINES IN RAT BRAIN.
195950 01-03

THE EFFECTS OF CORD SECTION UNDER ETHER OR HALOTHANE ON THE ABILITY OF CHLORPROMAZINE TO AFFECT THE JAW-JERK RESPONSE TO TOOTH PULP STIMULATION IN THE ENCEPHALE ISOLE PREPARATION.
197451 01-03

ETHICS

ETHICS IN MEDICAL RESEARCH AS VIEWED BY THE CLINICAL INVESTIGATOR.
214341 04-17

ETHINYLESTRADIOL

THE ACCUMULATION OF NORADRENALINE AND 5-HYDROXYTRYPTAMINE IN THREE REGIONS OF MOUSE BRAIN AFTER TETRABENAZINE AND IPRONIAZID: EFFECTS OF ETHINYLESTRADIOL AND PROGESTERONE.
200058 02-03

ETHYL

DIETARY TRYPTOPHAN AND THE SELECTION OF ETHYL ALCOHOL IN DIFFERENT STRAINS OF RATS.
217520 04-03

ETHYMISOL

THE INFLUENCE OF ETHYMISOL ON THE ACTIVITY OF ADENYLCYCLASE AND 3,5 AMP-PHOSPHODIESTERASE OF RATS BRAINS.
208973 03-03

ETHYMIZOL

THE EFFECT OF ETHYMIZOL ON THE CONTENT OF CYCLIC 3,5 ADENOSINE-MONOPHOSPHATE IN BRAIN TISSUE.
217065 04-03

ETIFOXIN

SPECTRAL ANALYSIS OF HUMAN EEG CHANGES INDUCED BY ETIFOXIN.
221724 04-13

ETIOLOGIC

TARDIVE DYSKINESIA: AN EVALUATION OF THE ETIOLOGIC ASSOCIATION WITH NEUROLEPTIC THERAPY.
204164 02-15

ETIOLOGY

CLINICAL FEATURES, ETIOLOGY AND TREATMENT OF FACIAL DYSKINESIAS IN THE ELDERLY.
206926 03-14

ETOFYLLINE

EXPERIMENTAL PSYCHOLOGICAL STUDY ON THE EFFECT OF A COMBINATION OF HEXOBENDINE, ETHAMIVAN AND ETOFYLLINE.
221738 04-14

ET495

THE SITE OF AND MODE OF ACTION OF ET495 FOR THE MEDIATION OF STEREOTYPED BEHAVIOUR IN THE RAT.
195252 01-03

DOPAMINE AGONIST AND ANTAGONIST ACTIVITIES OF PIRIBEDIL (ET495) AND ITS METABOLITES.
197930 01-04

BEHAVIOURAL EVIDENCE OF DOPAMINE RECEPTOR STIMULATION BY PIRIBEDIL (ET495) AND ITS METABOLITE S584.
217152 04-04

EUROPEAN

NEW PSYCHOTROPIC DRUG DEVELOPMENTS IN THE USSR AND OTHER EASTERN EUROPEAN COUNTRIES.
213598 04-07

EVALUATE

TIME TO EVALUATE LONG-ACTING NEUROLEPTICS?
224417 04-08

EVALUATED

MILD ANALGESICS EVALUATED WITH THE SUBMAXIMUM EFFORT TOURNIQUET TECHNIQUE. I. THE INFLUENCE OF PSYCHOLOGICAL FACTORS ON THEIR EFFECT.
197861 01-14

MILD ANALGESICS EVALUATED WITH THE SUBMAXIMUM EFFORT TOURNIQUET TECHNIQUE: II. THE INFLUENCE OF A TRANQUILLIZER ON THEIR EFFECT.
197862 01-13

HYPERKINETIC CHILDREN: THE USE OF STIMULANT DRUGS EVALUATED.
205263 02-14

DISULFIRAM IMPLANTATION CRITICALLY EVALUATED.
205316 02-11

EFFECTS OF AMITRIPTYLINE ON HUMAN REM SLEEP AS EVALUATED BY USING PARTIAL DIFFERENTIAL REM SLEEP DEPRIVATION (PDRD).
214750 04-14

EVALUATING

INTENSIVE DESIGN IN EVALUATING ANXIOLYTIC AGENTS.
198042 01-16

USE OF THE MAUDSLEY PERSONALITY INVENTORY IN EVALUATING THE EFFECTIVENESS OF A MINOR TRANQUILIZER IN PSYCHOSOMATIC DISEASES (THE FIRST REPORT).
198518 02-14

ANIMAL MODES FOR EVALUATING PSYCHOTROPIC DRUGS.
209076 03-17

AN ANIMAL TEST MODEL FOR EVALUATING DRUGS WITH ANTIMASS PSYCHOTIC ACTIVITY.
221273 04-06

EVALUATION

AN EVALUATION OF A DRUG ADMINISTRATION SYSTEM IN A PSYCHIATRIC HOSPITAL.
194409 01-17

A CONTROLLED EVALUATION OF LORAZEPAM AND DIAZEPAM IN ANXIETY NEUROSIS.
194719 01-10

EVALUATION OF LITHIUM THERAPY IN CHRONIC AND PERIODIC ALCOHOLISM.
194758 01-11

PHARMACOKINETIC EVALUATION OF ANTICONVULSANTS PRIOR TO EFFICACY TESTING EXEMPLIFIED BY CARBAMAZEPINE IN EPILEPTIC MONKEY MODEL.
195492 01-04

TRIMIPRAMINE (SURMONTIL) -- CLINICAL EVALUATION IN DEPRESSION.
195617 01-09

CLINICAL EVALUATION OF NEW ANTIDEPRESSANT, LOPRAMINE.
196443 01-14

A CRITICAL EVALUATION OR MOLINDONE (MOBAN): A NEW INDOLE DERIVATIVE NEUROLEPTIC.
196674 01-07

HALOPERIDOL FOR CHRONICALLY HOSPITALIZED PSYCHOTICS: A DOUBLE-BLIND COMPARISON WITH THIOTHIXENE AND PLACEBO: A FOLLOWUP OPEN EVALUATION.
196676 01-14

PENFLURIDOL (R-16341) AS A MAINTENANCE THERAPY IN CHRONIC PSYCHOTIC PATIENTS: A DOUBLE-BLIND CLINICAL EVALUATION.
197033 01-09

REPORT OF EARLY CLINICAL DRUG EVALUATION UNIT '11.
198041 01-07

REPORT ON THE EARLY CLINICAL DRUG EVALUATION UNIT.
198043 01-07

SAFETY EVALUATION OF PENFLURIDOL.
198047 01-08

EVALUATION OF CLINICAL PREDICTION OF ANTIDEPRESSANT ACTIVITY USING VARIOUS ANIMAL TEST MODELS.
198055 01-02

EARLY CLINICAL DRUG EVALUATION UNIT.
198062 01-07

CLINICAL EVALUATION OF NEW CHEMOTHERAPEUTIC AGENTS.
198064 01-07

NIMH-PRB EARLY CLINICAL DRUG EVALUATION UNIT.
198068 01-07

EARLY DRUG EVALUATION IN NEUROTIC OUTPATIENTS.
198069 01-07

EARLY CLINICAL DRUG EVALUATION UNIT.
198070 01-07

NIMH-PRB EARLY CLINICAL DRUG EVALUATION UNIT.
198073 01-07

A DOUBLE-BLIND CLINICAL EVALUATION OF PENFLURIDOL (R-16341) AS A MAINTENANCE THERAPY IN SCHIZOPHRENIA.
199993 02-08

A DOUBLE-BLIND EVALUATION OF DIAZEPAM AND AMYLOBARBITONE IN ACUTE MYOCARDIAL INFARCTION.
202966 02-13

TARDIVE DYSKINESIA: AN EVALUATION OF THE ETIOLOGIC ASSOCIATION WITH NEUROLEPTIC THERAPY.
204164 02-15

EEG EVALUATION OF HYPNOTIC DRUGS: MOGADON V. RO-5-4200, USING THE DOUBLE-BLIND METHOD.
205435 02-13

BUTACLAMOL HYDROCHLORIDE (AY-23028): AN EARLY EVALUATION IN SEVERELY ILL SCHIZOPHRENICS.
206933 03-08

SURVEY ON AND EVALUATION OF THE CONTRIBUTIONS OF METHODOLOGICAL ASPECTS IN THE INVESTIGATION OF LONG-TERM PSYCHOPHARMACOLOGICAL DRUG ACTION.
206984 03-16

POLYGRAPHIC EVALUATION OF HYPNOTIC DRUGS: METHODOLOGICAL CRITERIA.
208983 03-16

DEPRESSIVE CONDITION. PERCEPTION, EVALUATION, TREATMENT.
209332 03-09

PRECLINICAL EVALUATION OF AHR-2244: A NEW PSYCHOTHERAPEUTIC AGENT.
210676 03-02

A BACTERIAL MODEL FOR THE EVALUATION OF BARBITURATES.
210786 03-06
CLINICAL AND PSYCHOMETRIC EVALUATION OF THE ACTION OF VINCAMIN IN CEREBRAL ARTERIOSCLEROSIS.
211226 03-11
EVALUATION OF BENAPRYZINE IN PSYCHOTIC PATIENTS TREATED WITH PHENOTHIAZINES.
213387 04-07
THE EFFECT OF COMBINATION OF METHYLPHENIDATE AND DIAZEPAM ON THE EEG AND ITS EVALUATION BY MEANS OF DISCRIMINANT ANALYSIS.
215070 04-13
PIPOTHIAZINE PALMITATE: AN EVALUATION OF A NEW LONG-ACTING INTRAMUSCULAR ANTIPSYCHOTIC AGENT IN SEVERELY ILL SCHIZOPHRENIC PATIENTS.
216188 04-08
EEG SPECTRAL ANALYSIS FOR THE EVALUATION OF THE CENTRAL EFFECTS OF DELTA6-TETRAHYDROCANNABINOL IN RABBITS.
217467 04-03
EVALUATION OF KETAMINE HCL FOR ANTIDEPRESSANT ACTIVITY.
217577 04-02
A MULTICENTRIC EVALUATION OF PIMOZIDE (ORAP) IN PATIENTS WHO USUALLY WOULD TAKE TRANQUILIZERS.
218750 04-10
ELECTROENCEPHALOGRAPHIC STUDY FOR THE EVALUATION OF THE EFFECTS OF 7-CHLORO-5-PHENYLBENZODIAZEPIN-2-ONE (N-DEMETHYLDIAZEPAM) ON SLEEP DISTURBANCES IN A GROUP OF MENTAL PATIENTS.
221272 04-14
PHARMACOLOGICAL EVALUATION OF 3-(N 3,3 DIPHENYLPROPYL-N-METHYL) AMINOPROPAN-1-OL HYDROCHLORIDE (PF-82), A NEW TYPE OF ANTIDEPRESSANT DRUG.
221287 04-02
THE SIGNIFICANCE OF STANDARDIZED EVALUATION SCALES IN PSYCHIATRIC DIAGNOSIS AS EXEMPLIFIED BY THE THERAPEUTIC INTERVENTION WITH DESMETHYLOXAPINE.
221337 04-10
CLINICAL EVALUATION OF METYLPERONE (BURONIL) WITH EPILEPTICS.
221518 04-11
RESEARCH INTO THE INTERACTION BETWEEN NORTRIPTYLINE AND PERPHENAZINE -- CLINICAL EVALUATION.
221632 04-13
A NEUROPHARMACOLOGICAL EVALUATION OF SC-13504 -- A NEW ANTICONVULSANT. (PH.D. DISSERTATION).
222639 04-03
PSYCHOPHYSICAL EVALUATION OF TOXIC EFFECTS ON SENSORY SYSTEMS.
225166 04-03

EVALUATIONS
CONTROLLED DRUG EVALUATIONS.
198065 01-07

EVENTS
EFFECTS OF PHENOBARBITAL ON ELECTROCORTICOGRAM AND ACTIVITY, ON REGIONAL CNS ENERGY METABOLISM, AND ON PRESYNAPTIC EVENTS IN CEREBRAL CORTEX AND BRAINSTEM. (PH.D. DISSERTATION).
203033 02-03
DRUG EFFECTS ON BEHAVIOR MAINTAINED BY AVERSIVE EVENTS.
213619 04-04

EVENTUAL
EVENTUAL DEVELOPMENTS OF 64 CHRONIC PSYCHOTICS ON MODITEN RETARD OR MODECATE TREATMENT.
202514 02-09

EVIDENCE
FURTHER EVIDENCE FOR THE HETEROGENEOUS STORAGE OF NORADRENALINE IN CENTRAL NORADRENERGIC TERMINALS.
195239 01-03
BLOCKADE BY ESERINE OF THE CEREBRAL CORTICAL EFFECTS OF ALLOFERIN: A FURTHER EVIDENCE OF CHOLINERGIC INHIBITORY MECHANISM.
195548 01-03
EVIDENCE FOR A PERIPHERAL EFFECT OF FUSARIC ACID, A DOPAMINE-BETA-HYDROXYLASE INHIBITOR, ON SEROTONIN METABOLISM.
196593 01-03
PSYCHOPHARMACOLOGICAL EVIDENCE FOR INCREASE IN RECEPTOR SENSITIVITY FOLLOWING CHRONIC MORPHINE TREATMENT.
197855 01-04
EVIDENCE THAT PUNCTUATE INTRACEREBRAL ADMINISTRATION OF 6-HYDROXYDOPAMINE FAILS TO PRODUCE SELECTIVE NEURONAL DEGENERATION: COMPARISON WITH COPPER SULFATE AND FACTORS GOVERNING THE DEPORTMENT OF FLUIDS INJECTED INTO BRAIN.
197931 01-03
EVIDENCE FOR THE FUNCTIONAL INTERACTION OF TWO CENTRAL NEUROTRANSMITTERS.
201324 02-03
SUBCELLULAR DISTRIBUTION OF RESERPINE IN BLOOD PLATELETS: EVIDENCE FOR MULTIPLE POOLS.
202665 02-03
THE PHARMACOLOGY OF GROSS BEHAVIOURAL EFFECTS OF CHOLINOMIMETIC SUBSTANCES INJECTED INTO THE CEREBRAL VENTRICLES OF UNANAESTHETIZED CATS: EVIDENCE FOR CENTRAL MUSCARINIC MEDIATION.
202780 02-04
EVIDENCE AGAINST A CAUSAL RELATIONSHIP BETWEEN INCREASE IN C-AMP AND INDUCTION OF TYROSINE-HYDROXYLASE IN THE RAT ADRENAL MEDULLA.
202795 02-03
DOPAMINE AND THE PHARMACOLOGY OF SCHIZOPHRENIA: THE STATE OF THE EVIDENCE.
207300 03-03
SOME EVIDENCE FOR LONG-TERM MEMORY RETENTION BY OROTIC ACID IN RATS BAR PRESSING FOR WATER.
210790 03-04
EVIDENCE THAT 5-METHOXYDIMETHYLTRYPTAMINE IS A SPECIFIC SUBSTRATE FOR MAO-A IN THE RAT: IMPLICATIONS FOR THE INDOLEAMINE DEPENDENT BEHAVIORAL SYNDROME.
210817 03-04
EVIDENCE FOR REVERSIBLE INHIBITION OF BRAIN DOPAMINE-BETA-HYDROXYLASE ACTIVITY IN VIVO BY AMPHETAMINE ANALOGUES.
210821 03-03
EFFECT OF ERGOT DRUGS ON CENTRAL 5-HYDROXYTRYPTAMINE NEURONS: EVIDENCE FOR 5-HYDROXYTRYPTAMINE RELEASE OR 5-HYDROXYTRYPTAMINE RECEPTOR STIMULATION.
210857 03-03
L-DOPA HYPOTENSION IN DOGS: EVIDENCE FOR MEDIATION THROUGH 5-HT RELEASE.
210868 03-05
DELTA9-TETRAHYDROCANNABINOL AND SOME CNS DEPRESSANTS: EVIDENCE FOR CROSS-TOLERANCE IN THE RAT.
210876 03-03
METABOLISM OF 4-CHLOROAMPHETAMINE TO 3-CHLORO-4-HYDROXYAMPHETAMINE IN RAT: EVIDENCE FOR AN IN VIVO NIH SHIFT OF CHOLINE.
210929 03-03
BIOLOGICAL AND PHARMACOKINETIC EVIDENCE FOR GENERIC EQUIVALENCE OF THREE IMIPRAMINE PREPARATIONS: COMPARISON WITH A NEW IMIPRAMINE ANALOGUE.
211071 03-02
ENHANCEMENT OF SELF-STIMULATION BY DEPRENIL: EVIDENCE FOR A ROLE OF DOPAMINE NEURONES IN REWARD.
213432 04-04
INTRACRANIAL REWARD AFTER 5,6 DIHYDROXYTRYPTAMINE: FURTHER EVIDENCE FOR SEROTONINS INHIBITORY ROLE.
215732 04-04
BEHAVIOURAL EVIDENCE OF DOPAMINE RECEPTOR STIMULATION BY PIRIBEDIL (ET495) AND ITS METABOLITE S584.
217152 04-04
PHARMACOLOGICAL EVIDENCE FOR CEREBRAL DOPAMINE RECEPTOR BLOCKADE BY METOCLOPRAMIDE IN RODENTS.
217469 04-03
ELECTROPHYSIOLOGICAL EVIDENCE FOR AN INHIBITORY ACTION OF DIAZEPAM UPON CAT BRAIN CORTEX.
217649 04-03
EVIDENCE AGAINST THE INVOLVEMENT OF FALSE NEUROTRANSMITTERS IN TOLERANCE TO AMPHETAMINE-INDUCED HYPERTHERMIA IN THE RAT.
217690 04-03
MORE EVIDENCE FAVORS YOUTH DRUG: FIRST DOUBLE-BLIND TRIALS SHOW GEROVITAL HAS SOME EFFECT ON AGING.
221352 04-11
PHYSIOLOGICAL AND PHARMACOLOGICAL EVIDENCE FOR A SEROTONERGIC PROJECTION TO THE HIPPOCAMPUS.
223171 04-03
LYSERGIC ACID DIETHYLAMIDE: EVIDENCE FOR STIMULATION OF CEREBRAL DOPAMINE RECEPTORS.
223174 04-03

EVOKED
IN VIVO RELEASE OF ENDOGENOUSLY SYNTHESIZED CATECHOLAMINES FROM THE CAT BRAIN EVOKED BY ELECTRICAL STIMULATION AND BY D-AMPHETAMINE.
195049 01-03
SOMATOSENSORY EVOKED RESPONSE WAVE SHAPE STABILITY: RELATIONSHIPS TO PSYCHIATRIC DIAGNOSIS AND EFFECTS OF PSYCHOACTIVE DRUGS.
195935 01-17
ARRHYTHMIAS EVOKED BY INFUSION OF TRICYCLIC ANTIDEPRESSANTS AND NORADRENALINE ON ISOLATED RABBIT HEARTS.
197939 01-03
SELECTIVE DIPHENYLHYDANTOIN SUPPRESSION OF AUDITORY EVOKED POTENTIALS IN THE CAT CEREBELLAR CORTEX.
197989 01-03
EFFECTS OF MESCALINE, DELTA9-TETRAHYDROCANNABINOL AND PENTOBARBITAL ON THE AUDITORY EVOKED RESPONSES IN THE CAT.
197990 01-03

THE NUCLEUS LINEARIS INTERMEDIUS RAPHE AND BEHAVIOUR EVOKED BY DIRECT AND INDIRECT STIMULATION OF DOPAMINE SENSITIVE SITES WITHIN THE CAUDATE NUCLEUS OF CATS.
199864 02-04

EFFECTS OF ALPHA-ADRENERGIC BLOCKERS ON VISUAL EVOKED RESPONSES IN RABBITS.
200064 02-03

THE INFLUENCE OF TRIFLUOPERAZINE, CARBIDINE AND IMIZINE ON EVOKED POTENTIALS IN DIFFERENT STRUCTURES OF THE LIMBIC RETICULAR COMPLEX.
200564 02-02

LITHIUM RESPONSE IN DEPRESSION AS PREDICTED BY UNIPOLAR/BIPOLAR ILLNESS, AVERAGE EVOKED RESPONSE, CATECHOL-O-METHYLTRANSFERASE AND FAMILY HISTORY. (UNPUBLISHED PAPER).
201000 02-09

PHARMACOLOGICAL MODULATION OF PHOTICALLY EVOKED AFTERDISCHARGE PATTERNS IN HOODED LONG-EVANS RATS.
201409 02-03

FACTOR ANALYSIS OF EVOKED POTENTIALS.
204189 02-06

EFFECTS OF CHOLINESTERASE INHIBITION ON THE VISUAL EVOKED POTENTIALS IN THE RABBIT AND THEIR MODIFICATION WITH VARIOUS DRUGS.
205631 03-03

THE EFFECTS OF DOPA ON THE VISUAL EVOKED POTENTIALS IN RABBIT AND ON MOUSE MOTOR BEHAVIOR FOLLOWING INHIBITION OF DOPAMINE-BETA-HYDROXYLASE.
206768 03-03

EFFECT OF OUABAIN AND PHENOBARBITAL ON THE KINETICS OF CORTICAL METABOLIC TRANSIENTS ASSOCIATED WITH EVOKED POTENTIALS.
210820 03-03

EVOKED NEURAL ACTIVITY IN THE BASAL GANGLIA OF THE CAT AND ITS MODIFICATION BY CHOLINERGIC AND DOPAMINERGIC AGENTS. (PH.D. DISSERTATION).
212520 03-03

THE EFFECT OF CHLORPROMAZINE AND STIMULATION OF THE MESENCEPHALIC RETICULAR FORMATION ON CENTRAL AROUSAL AND ON THE VISUAL EVOKED RESPONSE. (PH.D. DISSERTATION).
212547 03-03

SCHIZOPHRENIA AND EVOKED POTENTIALS: MAXIMUM AMPLITUDE, FREQUENCY OF PEAKS, VARIABILITY, AND PHENOTHIAZINE EFFECTS.
213764 04-08

FLUPHENAZINE TREATMENT IN THE PSYCHOTIC CHILD: CLINICAL EVOKED POTENTIAL CORRELATIONS.
215455 04-09

BLOOD PRESSURE AND HEART RATE RESPONSES EVOKED BY D- AND L-AMPHETAMINE IN THE PITHED RAT PREPARATION.
215687 04-03

THE EFFECT OF SOME NEUROTROPIC DRUGS ON THE PHASIC CHANGES OF ARTERIAL PRESSURE EVOKED BY STIMULATION OF THE CEREBELLAR FASTIGAL NUCLEUS.
217067 04-03

PHENOTHIAZINE EFFECTS ON CEREBRAL EVOKED POTENTIALS AND EYE MOVEMENTS IN ACUTE SCHIZOPHRENICS.
217454 04-08

COMMISSURAL AND SENSORY EVOKED POTENTIALS OF THE HIPPOCAMPUS FOLLOWING MICROIONTOPHORESIS OF SOME DRUGS.
219111 04-03

BEHAVIORALLY EVOKED HIPPOCAMPAL THETA WAVES: A CHOLINERGIC RESPONSE.
220312 04-03

AVERAGE EVOKED RESPONSES (AER) AND HOMOVANILLIC ACID (HVA) IN CEREBROSPINAL FLUID (CSF) IN A PSYCHOTIC PATIENT WITH ADDISONS DISEASE.
221310 04-09

MODULATION OF PHOTICALLY EVOKED AFTERDISCHARGES BY MEANS OF PHARMACOLOGICAL AND BEHAVIORAL AROUSAL. (PH.D. DISSERTATION).
222644 04-03

ATTENTION AND THE AUDITORY EVOKED POTENTIAL IN HYPERKINETIC CHILDREN TREATED WITH METHYLPHENIDATE AND IN NORMAL CHILDREN. (PH.D. DISSERTATION).
222747 04-11

COMPARATIVE SYMPTOMATOLOGICAL AND EVOKED POTENTIAL STUDIES WITH D-AMPHETAMINE, THIORIDAZINE, AND PLACEBO IN HYPERKINETIC CHILDREN.
225516 04-10

EVOKING

SIMILAR ACTIONS OF INTRAHYPOTHALAMIC 5-6-DHT AND 5-HT IN EVOKING HYPERTHERMIA IN THE MONKEY.
200034 02-03

EVOLUTION

DIFFERENTIAL EFFECTS OF NEUROLEPTIC DRUGS IN CHRONIC SCHIZOPHRENICS: A CONFIGURATION ANALYTICAL EVOLUTION.
204415 02-08

CONTRIBUTIONS TO THE STUDY OF THE INFLUENCE OF LITHIUM CARBONATE ON THE EVOLUTION OF HYPERTHYMIC PSYCHOSES.
212161 03-09

EFFECTS OF ALPHA-METHYLDOPA ON NEWBORN KITTEN SLEEP. BEHAVIORAL EVOLUTION DURING THE FIRST MONTH AFTERBIRTH.
221049 04-04

EXAMINATION

EXAMINATION OF THE EFFECTS OF CLOXAZOLAM BY A DOUBLE-BLIND STUDY OF MENTAL PATIENTS BEFORE REHABILITATION.
194474 01-08

EXAMINATION OF THE NEW PSYCHOTROPIC DRUG, DOGMATYL (FK-880 SULPIRIDE).
194509 01-11

POLYGRAPHIC EXAMINATION DURING FAST AND SLOW INTRAVENOUS INJECTION OF THE SAME DOSE OF DIAZEPAM.
205508 02-13

DOUBLE-BLIND EXAMINATION OF BROMAZEPAM (RO-5-3350) FOR THE TREATMENT OF PSYCHONEUROSIS.
213293 03-10

EXAMINATION OF THE ROLE OF BRAIN AMINES AND CYCLIC-AMP IN BENZODIAZEPINE INDUCED SUPPRESSION OF AGGRESSION. (PH.D. DISSERTATION).
219278 04-04

EXAMINATIONS

PHARMACOLOGICAL EXAMINATIONS BY AN ULCUS INHIBITING AGENT (L-S-519).
197955 01-03

TRYPTOPHAN METABOLISM EXAMINATIONS IN OLIGOPHRENIC CHILDREN. FIRST REPORT: RESULTS OF THE EXCRETION OF KYNURENINE AND XANTHURENIC ACID AFTER TRYPTOPHAN LOADING AND THEIR DEPENDENCE UPON THE SUPPLY.
203645 02-13

EEG EXAMINATIONS DURING LITHIUM TREATMENT.
203701 02-13

EXAMINED

THE RELATIONSHIP OF CENTRAL MONOAMINES TO DRUG-INDUCED SLEEP IN THE RAT, EXAMINED ON A 24-HOUR BASIS. (PH.D. DISSERTATION).
201005 02-03

EXAMPLES

PSYCHOPHARMACOLOGY IN THE AGED: USE OF MAJOR PSYCHOTROPIC MEDICATIONS IN TREATMENT OF THE ELDERLY: CASE EXAMPLES.
208575 03-11

EXCITABILITY

THE EFFECT OF CHOLINERGICS ON SHORT-TERM MEMORY AND THE EXCITABILITY LEVEL OF HIPPOCAMPUS CIRCLE STRUCTURES.
208972 03-03

EFFECTS OF IMIPRAMINE UPON FROG NERVE EXCITABILITY AND CONDUCTION.
210925 03-03

EXCITATION

INHIBITORY EFFECT OF AMPHETAMINE, L-DOPA AND APOMORPHINE ON MORPHINE-INDUCED BEHAVIOURAL EXCITATION OF RATS.
197483 01-04

THE INFLUENCE OF SODIUM OXYBUTYRATE ON INTERNEURONAL TRANSMISSION OF EXCITATION AT VARIOUS LEVELS OF THE CENTRAL NERVOUS SYSTEM.
198435 02-03

THE INFLUENCE OF ANTIDEPRESSANTS AND NEUROLEPTICS ON BEHAVIORAL REACTIONS ELICITED BY LESION AND EXCITATION OF THE HIPPOCAMPUS.
198483 02-04

THE EFFECT OF SEROTONINERGIC AND ADRENERGIC PREPARATIONS UPON ALCOHOL-INDUCED EXCITATION IN MICE.
201915 02-04

MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 5. COMMUNICATION: INFLUENCE ON VENTRICULAR EXCITATION IN THE ELECTROCARDIOGRAM.
203843 02-13

PERMANENT EFFECTS OF REPEATED ADMINISTRATION OF ACTH AND DIAZEPAM IN EARLY POSTNATAL PERIOD UPON THE DYNAMICS OF EXCITATION AND INHIBITION DURING HABITUATION.
215068 04-04

EFFECTS OF PSYCHOTROPIC DRUGS ON METHAMPHETAMINE-INDUCED BEHAVIORAL EXCITATION IN GROUPED MICE.
215682 04-04

THE INFLUENCE OF PHARMACOLOGICAL AGENTS ON THE CONSEQUENCES OF EMOTIONAL EXCITATION IN CATS.
218814 04-04

THE METABOLISM OF INDIVIDUAL PHOSPHOLIPID FRACTIONS IN THE RAT BRAIN DURING THIOPENTAL SLEEP AND AMPHETAMINE EXCITATION.
219747 04-03

EXCITATIONS

THE ACTION OF BICUCULLINE UPON ACETYLCHOLINE-INDUCED EXCITATIONS OF CENTRAL NEURONS.
197993 01-03

EXCITED
PHARMACOLOGICAL STUDIES ON TETRABENAZINE-INDUCED EXCITED BEHAVIOUR OF RATS PRETREATED WITH AMPHETAMINE OR NIALAMIDE.
197490 01-04

EXCRETION
THE EFFECT OF BETA-THIAMINOKETONES ON THE AMINOPYRINE-N-DEMETHYLATION IN VITRO AND IN VIVA SUCH AS THE HEXOBARBITAL SLEEPING TIME AND L-ASCORBIC ACID EXCRETION IN THE RAT.
197469 01-03
BLOOD LEVEL, EXCRETION, DISTRIBUTION AND METABOLISM OF 14C-TRIFLUBAZAM, A NEW 1,5 BENZODIAZEPINE, IN MICE AND DOGS.
197940 01-03
ABSORPTION, DISTRIBUTION AND EXCRETION OF ALPRENOLOL IN MAN, DOG, AND RAT.
199621 02-13
THE INFLUENCE OF NEUROLEPTICAL DRUGS ON CATECHOLAMINE EXCRETION.
200073 02-08
TRYPTOPHAN METABOLISM EXAMINATIONS IN OLIGOPHRENIC CHILDREN. FIRST REPORT: RESULTS OF THE EXCRETION OF KYNURENINE AND XANTHURENIC ACID AFTER TRYPTOPHAN LOADING AND THEIR DEPENDENCE UPON THE SUPPLY.
203645 02-13
EFFECT OF AMITRIPTYLINE IN LONG-TERM AUTOEXPERIMENTS: PSYCHOPHYSIOLOGIC STUDY AND DURATION OF EXCRETION.
204402 02-13
THE INFLUENCE OF CLOZAPINE ON THE EXCRETION OF MHPG, HVA, AND 5-HIAA IN URINE AND CEREBROSPINAL FLUID.
206974 03-13
PATHOPHYSIOLOGICAL STUDIES OF MANIC-DEPRESSIVE PSYCHOSES: RELATIONSHIP BETWEEN ANXIETY AND EXCRETION OF URINARY CATECHOLAMINES.
212938 03-10
EFFECT OF LITHIUM ON GLUCAGON STIMULATED CYCLIC-AMP EXCRETION IN RATS.
213481 04-03
ABSORPTION AND EXCRETION OF THIORIDAZINE AND MESORIDAZINE IN MAN.
217154 04-08
CHLORPROMAZINE EXCRETION IN CHRONICALLY DOSED PRIMATES. I. OCCURRENCE OF A PREVIOUSLY UNREPORTED CLASS OF CHLORPROMAZINE CONJUGATES.
217553 04-03
URINARY EXCRETION OF THE SULPHATE AND GLUCURONIDE OF 3-METHOXY-4-HYDROXYPHENYLETHYLENEGLYCOL IN A MANIC-DEPRESSIVE PATIENT.
224424 04-09

EXCRETIONS
DIFFERENT URINARY EXCRETIONS OF 3-METHOXY-4-HYDROXYPHENYLGLYCOL AND RESPONSE TO TRICYCLIC ANTIDEPRESSIVE DRUGS.
206985 03-13

EXERCISE
THE EFFECTS OF METHYLPHENIDATE DURING REST, EXERCISE, AND RECOVERY UPON THE CIRCULORESPIRATORY RESPONSES OF HYPERACTIVE CHILDREN. (PH.D. DISSERTATION).
221934 04-11

EXISTENCE
FURTHER OBSERVATIONS ON AUTOMATON LIKE EXISTENCE UNDER LONG-TERM LITHIUM THERAPY.
204410 02-15

EXOPHTHALMIA
THE APPEARANCE OF EXOPHTHALMIA IN THE COURSE OF LITHIUM CARBONATE TREATMENT: BIOLOGICAL HYPERTHYROIDISM.
209998 03-15

EXPERIENCE
CLINICAL EXPERIENCE OF THE USE OF PENFLURIDOL (TLP-609) FOR THE TREATMENT OF SCHIZOPHRENIA.
194457 01-08
MY EXPERIENCE WITH THE USE OF A TRANQUILIZER, NORITREN, IN THE DEPARTMENT OF INTERNAL MEDICINE PSYCHOSOMATICS.
194510 01-11
EXPERIENCE WITH CYPROTERONE ACETATE INFLUENCE ON HUMAN SEXUALITY.
195037 01-11
EXPERIENCE WITH CHLORIMIPRAMINE (ANAFRANIL) IN PSYCHIATRY.
195533 01-09
PRESENILE DEMENTIA: FURTHER EXPERIENCE WITH AN ANTICOAGULANT PSYCHOTHERAPY REGIMEN.
195601 01-14
CLINICAL EXPERIENCE WITH CLOCAPRAMINE (CLOFEKTON) FOR THE TREATMENT OF SCHIZOPHRENIC PATIENTS.
198709 02-08
CLINICAL EXPERIENCE WITH FORIT: ITS ACTIVATING EFFECT ON CHRONIC SCHIZOPHRENIA.
198710 02-08
SUBJECTIVE CHANGES IN VOLUNTEERS WITHOUT PRIOR EXPERIENCE OF CANNABIS INDUCED BY (-)DELTA9-TRANS-TETRAHYDROCANNABINOL.
202784 02-14
ASPECTS OF NEUROLEPTIC DEPOT THERAPY WITH SPECIAL CONSIDERATION OF CLINICAL EXPERIENCE WITH THE PERORAL DEPOT PREPARATION PENFLURIDOL (R-16341 - JANSSEN).
202785 02-07
FURTHER EXPERIENCE WITH EPONTOL IN EEG ACTIVATION.
205548 02-13
EXPERIENCE WITH OXYPROTHEPINE IN THE TREATMENT OF MANIC SYNDROMES.
205580 02-09
CLINICAL EXPERIENCE WITH CARPIPRAMINE (DEFEKTON).
205592 02-08
CLINICAL EXPERIENCE WITH DOXEPIN.
205600 02-09
OUR EXPERIENCE WITH CLOZAPINE TREATMENT.
205613 03-08
FURTHER CLINICAL AND EEG EXPERIENCE WITH CLOZAPINE.
205615 03-11
CLINICAL EXPERIENCE WITH CLOZAPINE IN PSYCHOSES.
205616 03-09
OUR EXPERIENCE WITH THE TREATMENT OF DELIRIUM-TREMENS WITH DIAZEPAM.
205639 03-11
EXPERIENCE WITH LONG-ACTING PHENOTHIAZINES IN A PSYCHIATRIC HOSPITAL.
208921 03-17
PERSONAL EXPERIENCE IN THE USE OF SULPIRIDE (FK-880) ON SCHIZOPHRENIA.
209405 03-08
CLINICAL EXPERIENCE OF FLUPHENAZINE ENANTHATE IN TREATMENT OF SCHIZOPHRENIC PATIENTS.
213294 03-08
ASPECTS OF LONG-TERM TREATMENT WITH NEUROLEPTICS: HISTORICAL AND LITERATURE REVIEW -- PERSONAL EXPERIENCE WITH FLUSPIRILENE AND PENFLURIDOL.
215059 04-14
MODIFICATION OF THE PUNISHING EFFECTS OF PSYCHOACTIVE DRUGS IN RATS BY PREVIOUS DRUG EXPERIENCE.
217765 04-04
CLINICAL EXPERIENCE OF HALOPERIDOL INJECTION ON PSYCHIATRIC CASES.
217957 04-14
EXPERIENCE WITH 20 PATIENTS TREATED WITH LITHIUM CARBONATE.
218682 04-09
GENOTYPE OR PRENATAL DRUG EXPERIENCE AFFECT BRAIN MATURATION IN THE MOUSE.
221032 04-03
CHLORDIAZEPOXIDE EFFECTS ON REACTIONS TO NOVELTY AND ACTIVITY WITH AND WITHOUT PRIOR DRUG EXPERIENCE.
221047 04-04
EXPERIENCE WITH IMIPRAMINE-N-OXIDE (IPNO) IN TREATING DEPRESSIVE STATES.
221209 04-09
CLINICAL EXPERIENCE OF THE USE OF FK-880 (SULPIRIDE) FOR DEPRESSION AND NEUROSIS.
224195 04-14
TRIAL EXPERIENCE OF NEOPROSERIN IN THE PSYCHIATRIC AREA.
224392 04-11
EXPERIENCE OF USING LORAZEPAM, A NEW TRANQUILIZER.
224394 04-11
EXPERIENCE OF USING LORAZEPAM (WY-4036) IN PSYCHIATRY.
224395 04-11
TREATMENT EXPERIENCE OF CHRONIC SCHIZOPHRENIA WITH PENFLURIDOL.
224548 04-08
EFFECTS OF EARLY EXPERIENCE AND DEXAMETHASONE ON ADRENOCORTICAL REACTIVITY.
225078 04-03
THE DEPOT FLUPHENAZINES: A REAPPRAISAL AFTER 10 YEARS CLINICAL EXPERIENCE.
225325 04-08

EXPERIENCED
DURATION OF EXPERIENCED LENGTHENING AND SHORTENING OF STRAIGHT LINES.
205135 02-14

EXPERIENCES
EARLY HOSPITAL EXPERIENCES WITH FLUPHENAZINE DECANOATE.
196675 01-07
CLINICAL EXPERIENCES IN TREATING DEPRESSED PATIENTS WITH A COMBINATION OF TRICYCLIC DRUGS AND THYROID EXTRACT.
209144 03-09
EXPERIENCES OF A GENERAL PRACTITIONER AMONG PSYCHIATRIC PATIENTS.
211012 03-15
EXPERIENCES WITH CLOMIPRAMINE (ANAFRANIL) IN THE TREATMENT OF THE PHOBIC ANXIETY STATES IN GENERAL PRACTICE.
215158 04-10

EXPERIENCING
EXPERIENCING AND ALTERING STATES OF INTOXICATION: AN INFORMATION PROCESSING VIEW OF THE HIGH.
224756 04-14

EXPERIMENT
EFFECT OF INTRAHIPPOCAMPAL INJECTION OF ATROPINE ON DIFFERENT PHASES OF A LEARNING EXPERIMENT.
198227 02-04

THE EFFECTS OF NEUROLEPTIC AGENTS IN THE CHRONIC PHARMACOLOGICAL EXPERIMENT.
202863 02-04

THE ACTION OF CHLORDIAZEPOXIDE ON CONDITIONS OF ANXIETY IN A PSYCHOPHYSIOLOGICAL EXPERIMENT.
204405 02-14

CARDIOTOXIC EFFECTS OF TRICYCLIC ANTIDEPRESSANTS IMIPRAMINE, AMITRIPTYLINE AND DOSULEPIN (PROTHIADEN-SPOFA) IN AN ACUTE EXPERIMENT IN RATS.
205597 02-15

MICROAUTORADIOGRAPHIC STUDIES AFTER MEDICATION OF C14-FLUPHENAZINE IN THE ANIMAL EXPERIMENT.
206769 03-03

FREE AND MEMBRANE BOUND RIBOSOMES AND POLYSOMES IN HIPPOCAMPAL NEURONS DURING A LEARNING EXPERIMENT.
210674 03-04

LITHIUM TREATMENT OF SCHIZOPHRENIA: A CONTROLLED EXPERIMENT.
221635 04-08

CROSS-ANALYSIS OF A CONTROLLED EXPERIMENT WITH PIPOTHIAZINE AND FLUPHENAZINE ENANTHATE.
221636 04-08

A CONTROLLED CLINICAL EXPERIMENT WITH BURONIL AND HALOPERIDOL IN DISORIENTATION AMONG ELDERLY PATIENTS.
221639 04-11

EXPERIMENTAL
REGIONAL DISTRIBUTION OF CATIONS AND THEIR RELATION TO THE NEUROCHEMISTRY OF EXPERIMENTAL EPILEPSY, NEUROTRANSMITTERS AND ATPASE IN THE CENTRAL NERVOUS SYSTEM. (PH.D. DISSERTATION).
193588 01-03

BRAIN AND SERUM CONCENTRATIONS OF DIAZEPAM IN EXPERIMENTAL EPILEPSY.
195494 01-04

EXPERIMENTAL STUDIES ON FACILITATIVE AND INHIBITORY FACTORS FOR EPILEPTOGENIC FOCUS FORMATION.
197211 01-03

ON THE PROBLEM OF DIPHENYLHYDANTOIN-INDUCED SEIZURES: AN EXPERIMENTAL APPROACH.
197815 01-05

INVESTIGATIONS OF THE EFFECTS OF DIAZEPAM IN ACUTE EXPERIMENTAL INTOXICATION WITH FLUOSTIGMINE.
197832 01-03

TREATMENT OF EXPERIMENTAL IMIPRAMINE INTOXICATION BY INTERRUPTING ENTERAL CYCLES WITH ACTIVATED CHARCOAL.
197969 01-03

DRUG STUDIES IN NORMAL FEMALES, SENIOR CITIZENS, AND IN EXPERIMENTAL GROUPS.
198071 01-07

GABA BLOCKADE, DOPAMINE AND SCHIZOPHRENIA: EXPERIMENTAL STUDIES IN THE CAT.
200052 02-03

EXPERIMENTAL STUDY INTO IMMUNOLOGICAL FACTORS OF RESISTANCE TO CHLORPROMAZINE.
201920 02-03

BEHAVIORAL CHANGES INDUCED BY PSYCHOTROPIC SUBSTANCES IN EXPERIMENTAL ANIMALS.
202864 02-04

THERAPY-RESISTANT DEPRESSIONS: METHODOLOGICAL PROBLEMS. CONTRIBUTIONS TO METHODICAL QUESTIONS AND ANIMAL EXPERIMENTAL ASPECTS.
203591 02-09

INTRA-EXTRACELLULAR LITHIUM RATIO: CLINICAL AND EXPERIMENTAL FINDINGS ON THROMBOCYTES AND ERYTHROCYTES.
204393 02-13

EXPERIMENTAL PSYCHOLOGIC AND PSYCHOPHYSIOLOGIC LONGITUDINAL PROFILE STUDIES ON DEPRESSIVE PATIENTS UNDER THYMOLEPTIC MEDICATION.
204413 02-15

EEG AND SCHIZOPHRENIA: EXPERIMENTAL STUDIES, SPECTRAL ANALYSIS AND SEPTAL SPIKES.
205455 02-03

EXPERIMENTAL STUDIES ON THE PSYCHICAL EPISODES OF EPILEPSY.
205464 02-04

EXPERIMENTAL EEG STUDIES ON BARBITURATE INTOXICATION AND PIRACETAM.
205507 02-03

THE INFLUENCE OF CHLORPROMAZINE ACTION ON EXPERIMENTAL PSYCHOSIS CAUSED BY LYSERGIC ACID DIETHYLAMIDE.
206439 03-04

INFLUENCE OF NEUROLEPTIC SUBSTANCE ON NEUROPHYSIOLOGICAL PARAMETERS IN EXPERIMENTAL ANIMALS.
206998 03-06

EXPERIMENTAL STUDY ON NEUROPHARMACOLOGICAL ACTIONS OF SOME INDOLE DERIVATIVES.
207164 03-02

EXPERIMENTAL TESTS OF HYPOTHESES ABOUT NEUROCHEMICAL MECHANISMS UNDERLYING BEHAVIORAL TOLERANCE TO THE ANTICHOLINESTERASE, DIISOPROPYLFLUOROPHOSPHATE.
208555 03-03

COMPARISON OF NEUROLEPTICS IN CONTROLLED EXPERIMENTAL CONDITIONS: METHOPHENAZINE VS PERPHENAZINE.
209147 03-08

PSYCHOPHARMACOLOGY: AN INTRODUCTION TO EXPERIMENTAL AND CLINICAL PRINCIPLES.
210099 03-17

A CLINICAL EXPERIMENTAL STUDY ON THE USE OF SULPIRIDE IN A GROUP OF CHRONIC SCHIZOPHRENICS (FIRST NOTE).
210510 03-08

PARKINSONIAN TYPE TREMOR AND THE ACTION OF HARMALINE: EXPERIMENTAL FACTS AND HYPOTHETICAL MECHANISMS.
212182 03-03

PROTECTIVE EFFECT OF PIRACETAM IN EXPERIMENTAL BARBITURATE INTOXICATION: EEG AND BEHAVIOURAL STUDIES.
213589 04-03

CLINICAL AND EXPERIMENTAL COMPARISON OF DIAZEPAM, CHLORAZEPATE AND PLACEBO.
214018 04-14

THE MECHANISM OF THE POTENTIATING EFFECT OF ANTIDEPRESSANT DRUGS ON THE PROTECTIVE INFLUENCE OF DIPHENHYDRAMINE IN EXPERIMENTAL CATATONIA. THE ROLE OF HISTAMINE.
215664 04-03

PHARMACOLOGY OF CEREBRAL CIRCULATION AND CLINICAL APPLICATIONS. EXPERIMENTAL STUDY OF THE CIRCULATORY AND METABOLIC EFFECTS OF HYDROSARPAN-711.
218164 04-03

AN EXPERIMENTAL STUDY OF THE PSYCHOTROPIC ACTION OF PYRAZIDOL.
219497 04-03

EXPERIMENTAL INVESTIGATION OF A NEW AMPHETAMINE DERIVATIVE.
219709 04-03

EXPERIMENTAL PSYCHOLOGICAL STUDY ON THE EFFECT OF A COMBINATION OF HEXOBENDINE, ETHAMIVAN AND ETOFYLLINE.
221738 04-14

AN EXPERIMENTAL ANALYSIS ON THE EFFECTS OF THE PSYCHOSTIMULATOR SYDNOCARB.
223013 04-04

AN EXPERIMENTAL ANALYSIS OF BEHAVIORAL FACTORS IN DRUG DEPENDENCE.
225156 04-04

DIPROPYLACETIC ACID (DEPAKINE) IN EXPERIMENTAL EPILEPSY IN THE ALERT CAT.
225529 04-02

EXPERIMENTALLY
EFFECTS OF CHLORIMIPRAMINE ON EXPERIMENTALLY INDUCED CHANGES IN FOREBRAIN 5-HYDROXYINDOLES.
199966 02-03

EFFECTS OF DIAZEPAM ON EXPERIMENTALLY INDUCED CORTICAL EPILEPSY AND THEIR CORRELATION WITH DRUG CONCENTRATION.
205491 02-03

DOES MARIJUANA ENHANCE EXPERIMENTALLY INDUCED ANXIETY?
210738 03-14

EXPERIMENTATION
EXPERIMENTATION WITH SULPIRIDE IN CASES OF PSYCHONEUROSIS.
195532 01-10

EXPERIMENTATION WITH THE INTRAVENOUS FORM OF AMITRIPTYLINE WITH 40 PATIENTS.
210128 03-09

CLINICAL EXPERIMENTATION WITH A SUSTAINED RELEASE LITHIUM CARBONATE.
216769 04-09

EXPERIMENTS
A CONTROLLED SERIES OF EXPERIMENTS INVESTIGATING SOME SOCIOLOGICAL EFFECTS OF TWO DOSAGES OF CHLORDIAZEPOXIDE (LIBRIUM) UPON INDIVIDUALS AND SMALL GROUPS. (PH.D. DISSERTATION).
195145 01-14

METHODS OF ASSESSING PSYCHOPHARMACOLOGICAL AGENTS IN EXPERIMENTS.
198488 02-06

WAYS OF DEMONSTRATING AND DIFFERENTIATING CENTRAL NERVOUS EFFECTS OF DRUGS IN ANIMAL EXPERIMENTS.
202944 02-06

CLINICAL EXPERIMENTS WITH BROMAZEPAM ON PSYCHONEUROTIC AND PSYCHOSOMATIC PATIENTS WITH PSYCHOTHERAPY.
209795 03-10

CLINICAL EXPERIMENTS WITH A NEW PSYCHOTROPIC DRUG (SULPIRIDE).
211203 03-14

ABSENCE OF INTERACTION BETWEEN DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) AND CANNABIDIOL (CBD) IN AGGRESSION, MUSCLE CONTROL AND BODY TEMPERATURE EXPERIMENTS IN MICE.
217474 04-04

EXPLICIT
EXPLICIT SOLUTION TO PHARMACOKINETIC FIRST-ORDER RATE CONSTANTS OF MAPROTILIN.
208919 03-17

EXPLORATORY
AN EXPLORATORY STUDY OF THE LONG-TERM EFFECTS OF DRUG USE IN HYPERKINESIS. (PH.D. DISSERTATION).
195882 01-11

EFFECTS OF PSYCHOTROPIC DRUGS ON EXPLORATORY BEHAVIOR OF MICE.
200047 02-04

THE EFFECTS OF STRAIN, DRUG, AND DOSE LEVEL ON GENERAL ACTIVITY AND EXPLORATORY BEHAVIOR IN MICE. (PH.D. DISSERTATION).
211883 03-04

EXPLORATORY BEHAVIOUR IN TWO SELECTIVELY BRED LINES OF MICE AFTER INTRAHIPPOCAMPAL INJECTION OF METHYLSCOPOLAMINE.
217464 04-04

EXPOSED
THE EFFECTS OF SOME CNS DEPRESSANTS ON RATS EXPOSED TO IONIZING IRRADIATION.
197581 01-03

EXPOSITION
EEG VARIATIONS UNDER ANTABUSE (DISULFIRAM) AND ANTABUSE PLUS ALCOHOL EXPOSITION: A STUDY OF PATHOGENESIS FROM ANTABUSE THERAPY COMPLICATIONS.
200572 02-15

EXPOSURE
EFFECT OF ACUTE AND CHRONIC DIELDRIN EXPOSURE ON BRAIN BIOGENIC AMINES OF MALE AND FEMALE RATS.
193428 01-03

REGIONAL LEVELS OF GABA AND GLUTAMATE IN MOUSE BRAIN FOLLOWING EXPOSURE TO PAIN.
195097 01-03

EFFECTS OF MORPHINE, CHOLINERGIC AGENTS AND COLD EXPOSURE ON MIDBRAIN DOPAMINE (DA) NERVE CELLS OF MORPHINE TOLERANT AND NONTOLERANT MICE.
197287 01-03

INFANTILE AUDITORY EXPOSURE AND UNUSUAL RESPONSE TO ANTIPSYCHOTIC DRUGS.
208617 03-04

ANTENATAL EXPOSURE TO MEPROBAMATE AND CHLORDIAZEPOXIDE IN RELATION TO MALFORMATIONS, MENTAL DEVELOPMENT, AND CHILDHOOD MORTALITY.
212107 03-15

ANTAGONISM BY D-AMPHETAMINE OF LEARNING DEFICITS IN RATS INDUCED BY EXPOSURE TO ANTIPSYCHOTIC DRUGS DURING EARLY POSTNATAL LIFE.
217656 04-04

EFFECTS OF AMINERGIC DRUGS AND GLUTAMIC ACID ON AUDIOGENIC SEIZURES INDUCED BY EARLY EXPOSURE TO ETHANOL.
225527 04-03

EXPRESSION
ROLE OF CATECHOLAMINERGIC MECHANISMS IN THE EXPRESSION OF THE MORPHINE ABSTINENCE SYNDROME IN RATS.
200053 02-03

CLINICAL TRIAL OF FLUPENTHIXOL IN PATIENTS WITH CHRONIC SCHIZOPHRENIA: ESPECIALLY IN PATIENTS HAVING DIFFICULTY IN REHABILITATION OWING TO DECREASED EXPRESSION, APATHY AND DISTURBANCE OF RAPPORT.
202603 02-08

GENETIC, BIOCHEMICAL, AND ENVIRONMENTAL VARIABLES IN THE EXPRESSION OF SHORT-TERM MEMORY IN THE MOUSE. (PH.D. DISSERTATION).
222749 04-04

EXTENSION
METHAMPHETAMINES EFFECT ON SDR: REPLICATION AND EXTENSION.
194133 01-04

AN EXTENSION OF MULTIDIMENSIONAL SCALING TO FACILITATE CLINICAL INTERPRETATION OF ANIMAL TEST MODELS.
198059 01-02

EXTINCTION
RESISTANCE TO EXTINCTION OF AN AVOIDANCE RESPONSE IN RATS FOLLOWING THE ADMINISTRATION OF CHLORDIAZEPOXIDE (LIBRIUM) AND DIAZEPAM (VALIUM).
198226 02-04

EFFECTS OF PSYCHOTROPIC DRUGS ON EXTINCTION INDUCED AGGRESSION. (PH.D. DISSERTATION).
212523 03-04

THE EFFECT OF DIFFERENT LEVELS OF PRE-EXPOSURE TO SUCROSE ON THE ACQUISITION AND EXTINCTION OF A CONDITIONED AVERSION.
217807 04-04

THE INFLUENCE OF HYDROCORTISONE ON THE ELABORATION OF EXTINCTION INHIBITION IN RATS.
219327 04-04

EXTINGUISHED
EFFECTS OF SCOPOLAMINE, PHYSOSTIGMINE AND CHLORDIAZEPOXIDE ON PUNISHED AND EXTINGUISHED WATER CONSUMPTION IN RATS.
221043 04-04

EXTRACELLULAR
THE EFFECT OF DIAZEPAM AND NITRAZEPAM ON INTRACELLULAR AND EXTRACELLULAR DISTRIBUTION OF SODIUM AND POTASSIUM IONS IN INDIVIDUAL STRUCTURES OF RATS BRAINS.
207199 03-03

EXTRACT
TRANQUILLIZING ACTION OF A CRYSTALLINE FRACTION OF PASPALUM-SCROBICULATUM EXTRACT IN FOURTEEN PSYCHOTIC PATIENTS.
194711 01-08

CLINICAL EXPERIENCES IN TREATING DEPRESSED PATIENTS WITH A COMBINATION OF TRICYCLIC DRUGS AND THYROID EXTRACT.
209144 03-09

EXTRAPINEAL
EXTRAPINEAL N-ACETYLTRANSFERASE ACTIVITY IN RAT BRAIN.
210760 03-03

EXTRAPOLATION
THE INFLUENCE OF PHENAMINE AND CAFFEINE ON THE CAPACITY FOR EXTRAPOLATION IN RATS.
224466 04-04

EXTRAPOLATIONS
REINFORCEMENT SCHEDULES AND EXTRAPOLATIONS TO HUMANS FROM ANIMALS IN BEHAVIORAL PHARMACOLOGY.
225171 04-04

EXTRAPYRAMIDAL
ADMINISTRATION OF PG-501 FOR THE TREATMENT OF EXTRAPYRAMIDAL SYNDROME CAUSED BY THE ADMINISTRATION OF A PSYCHOTROPIC DRUG.
194475 01-11

DOPAMINERGIC MECHANISMS IN PATIENTS WITH EXTRAPYRAMIDAL DISEASE. (UNPUBLISHED PAPER).
194542 01-13

THE IMPORTANCE OF THE ASCENDING DOPAMINERGIC SYSTEMS TO THE EXTRAPYRAMIDAL AND MESOLIMBIC BRAIN AREAS FOR THE CATALEPTIC ACTION OF THE NEUROLEPTIC AND CHOLINERGIC AGENTS.
195250 01-03

THE EXTRAPYRAMIDAL SYNDROME INDUCED BY NEUROLEPTICS.
202445 02-15

BIOCHEMICAL MECHANISMS OF EXTRAPYRAMIDAL MOTORIC ACTION OF HALOPERIDOL IN MAN.
204414 02-13

ANTISCHIZOPHRENIC DRUGS: AFFINITY FOR MUSCARINIC CHOLINERGIC RECEPTOR SITES IN THE BRAIN PREDICTS EXTRAPYRAMIDAL EFFECTS.
207298 03-03

EXTRAPYRAMIDAL MANIFESTATIONS DUE TO METOCLOPRAMIDE IN SIX CASE STUDIES.
207533 03-15

A CASE OF IRREVERSIBLE EXTRAPYRAMIDAL HYPERKINESIA INDUCED BY NEUROLEPTIC DRUGS.
209410 03-15

EXTRAPYRAMIDAL REACTIONS AND AMINE METABOLITES IN CEREBROSPINAL FLUID DURING HALOPERIDOL AND CLOZAPINE TREATMENT OF SCHIZOPHRENIC PATIENTS.
214010 04-15

A CLINICAL STUDY OF A NEW NEUROLEPTIC EXTRAPYRAMIDAL SYNDROME CORRECTOR WITH ACUTE PSYCHOTIC STATES.
216766 04-15

AKINESIA: A POORLY RECOGNIZED DRUG-INDUCED EXTRAPYRAMIDAL BEHAVIORAL DISORDER.
218773 04-15

THE ASSESSMENT OF NEUROLEPTOGENIC EXTRAPYRAMIDAL SYNDROMES IN PSYCHOPHARMACOLOGICAL RESEARCH.
221307 04-15

EXTRAVERTS
THE EFFECTS OF CHLORPROMAZINE AND D-AMPHETAMINE SULFATE ON THE VISUAL STIMULATION PREFERENCE OF EXTRAVERTS AND INTROVERTS.
210680 03-14

EYE
COMMENTS ON TREATMENT: EYE CHANGES FOLLOWING PHENOTHIAZINE ADMINISTRATION.
194749 01-15

ANALYSIS OF EYE MOVEMENTS AND BLINKS DURING READING: EFFECTS OF VALIUM.
206360 03-14

PHENOTHIAZINE EFFECTS ON CEREBRAL EVOKED POTENTIALS AND EYE MOVEMENTS IN ACUTE SCHIZOPHRENICS.
217454 04-08

EYSENCKS
EFFECTS OF (-)DELTA9-TRANS-TETRAHYDROCANNABINOL (DELTA9-THC) ON TESTS OF PSYCHOTICISM: A STUDY OF EYSENCKS DRUG POSTULATE ON THE EFFECTS OF HALLUCINOGENS IN RELATION TO PSYCHOTICISM.
214009 04-09

FACES
THE MANY FACES OF AKATHISIA.
207768 03-15

FACIAL
CLINICAL FEATURES, ETIOLOGY AND TREATMENT OF FACIAL DYSKINESIAS IN THE ELDERLY.
206926 03-14

FACILITATE
AN EXTENSION OF MULTIDIMENSIONAL SCALING TO FACILITATE CLINICAL INTERPRETATION OF ANIMAL TEST MODELS.
198059 01-02

FACILITATION
NICOTINE AND CAFFEINE: DISRUPTION OF THE LONG-TERM STORE MEMORY AND PROACTIVE FACILITATION OF LEARNING IN MICE.
198222 02-04
THE BLINK REFLEX TO LIGHT: ITS COURSE AND ITS FACILITATION BY RESERPINE.
204220 02-03
FACILITATION OF TIME-DEPENDENT MEMORY PROCESSES WITH POSTTRIAL EPINEPHRINE INJECTIONS.
209951 03-04
NEUROCHEMICAL REGULATION OF FEEDING IN THE RAT: FACILITATION BY ALPHA-NORADRENERGIC, BUT NOT DOPAMINERGIC RECEPTOR STIMULANTS.
211538 03-04
FACILITATION OF AVOIDANCE LEARNING BY CHLORDIAZEPOXIDE AMPHETAMINE COMBINATIONS IN MICE.
217466 04-04
APOMORPHINE: FACILITATION OF SEXUAL BEHAVIOUR IN FEMALE RATS.
222807 04-04

FACILITATORY
FACILITATORY AND INHIBITORY INFLUENCES OF PROGESTERONE, 20ALPHA-HYDROXYPROGESTERONE AND METHYSERGIDE ON THE RECEPTIVE BEHAVIOR OF THE FEMALE RAT. (PH.D. DISSERTATION).
222739 04-04

FACILITY
CLINICAL STUDY OF GERDAXYL 10MG WITH 40 PATIENTS TREATED IN A PSYCHIATRIC OUTPATIENT FACILITY.
202037 02-11

FACTORIAL
LITHIUM GLUCONATE: SYSTEMATIC AND FACTORIAL ANALYSIS OF 104 OBSERVATIONS OVER 2.5-3 YEARS IN PATIENTS PRESENTING CYCLOTHYMIC OR DYSTHYMIC DISORDERS.
210126 03-09

FADDISM
THE ROAD TO SHANGRI-LA IS PAVED WITH VITAMIN AND PSYCHOTHERAPEUTIC FADDISM.
209010 03-17

FAILS
FENFLURAMINE: AMPHETAMINE CONGENER THAT FAILS TO MAINTAIN DRUG-TAKING BEHAVIOR IN THE RHESUS MONKEY.
193137 01-04
EVIDENCE THAT PUNCTUATE INTRACEREBRAL ADMINISTRATION OF 6-HYDROXYDOPAMINE FAILS TO PRODUCE SELECTIVE NEURONAL DEGENERATION: COMPARISON WITH COPPER SULFATE AND FACTORS GOVERNING THE DEPORTMENT OF FLUIDS INJECTED INTO BRAIN.
197931 01-03

FAILURE
FAILURE OF DIPHENYLHYDANTOIN TO PREVENT ALCOHOL WITHDRAWAL CONVULSIONS IN MICE.
193454 01-03
EFFECTS OF CHLORDIAZEPOXIDE IN RESPIRATORY FAILURE DUE TO CHRONIC BRONCHITIS.
194854 01-13
L-HISTIDINE: FAILURE TO AFFECT THE SLEEP-WAKING CYCLE IN MAN.
214015 04-14
TREATMENT OF ACUTE SCHIZOPHRENIA WITH ULTRA-HIGH-DOSE FLUPHENAZINE: A FAILURE AT SHORTENING TIME ON A CRISIS INTERVENTION UNIT.
215456 04-08
LITHIUM CARBONATE PROPHYLAXIS FAILURE.
224873 04-09
PHENETHYLAMINE IN NORMAL URINE: FAILURE TO VERIFY HIGH VALUES.
225517 04-16
FAILURE OF ANTISEROTONERGIC AGENTS TO MODIFY LEVALLORPHAN INDUCED STEREOTYPY IN RATS.
225567 04-03

FAMILY
SURVEY OF HEALTH AND ILLNESS IN FAMILY PRACTICE.
198049 01-17
LITHIUM RESPONSE IN DEPRESSION AS PREDICTED BY UNIPOLAR/BIPOLAR ILLNESS, AVERAGE EVOKED RESPONSE, CATECHOL-O-METHYLTRANSFERASE AND FAMILY HISTORY. (UNPUBLISHED PAPER).
201000 02-09
FAMILY HISTORY OF MANIC-DEPRESSIVE AND ENDOGENOUS DEPRESSIVE PATIENTS AND CLINICAL EFFECT OF TREATMENT WITH LITHIUM.
205608 03-09

FAR-LATERAL
CATECHOLAMINES AND SELF-STIMULATION: PHARMACOLOGICAL DIFFERENCES BETWEEN NEAR-LATERAL AND FAR-LATERAL HYPOTHALAMIC SITES.
221030 04-03

FAST
POLYGRAPHIC EXAMINATION DURING FAST AND SLOW INTRAVENOUS INJECTION OF THE SAME DOSE OF DIAZEPAM.
205508 02-13

FASTER
NOXIPTILIN (AGEDAL) -- A NEW TRICYCLIC ANTIDEPRESSANT WITH A FASTER ONSET OF ACTION? A DOUBLE-BLIND, MULTICENTRE COMPARISON WITH AMITRIPTYLINE.
221306 04-09

FASTIGAL
THE EFFECT OF SOME NEUROTROPIC DRUGS ON THE PHASIC CHANGES OF ARTERIAL PRESSURE EVOKED BY STIMULATION OF THE CEREBELLAR FASTIGAL NUCLEUS.
217067 04-03

FASTING
EFFECT OF ORAL AND INTRAMUSCULAR ROUTES OF ADMINISTRATION ON SERUM CHLORDIAZEPOXIDE LEVELS AND THE PREDICTION OF THESE LEVELS FROM PREDRUG FASTING SERUM GLUCOSE CONCENTRATIONS.
195055 01-13

FAT
INFLUENCE OF EMULSIFIED FAT ON CHLORPROMAZINE AVAILABILITY IN RABBIT BLOOD.
194928 01-03
EFFECT OF L-DOPA ON PITUITARY HORMONES AND ON CARBOHYDRATE AND FAT METABOLISM IN NORMALS AND IN PARKINSONS DISEASE.
207153 03-13

FATALITY
REPORT OF A HUMAN FATALITY DUE TO AMPHETAMINE.
204195 02-15

FATE
FATE OF L-GLUTAMATE IN THE BRAIN.
196800 01-03

FATS
THE EFFECT OF 6-HYDROXYDOPAMINE AND RESERPINE ON THE MOBILIZATION OF CARBOHYDRATES AND FATS IN STIMULATED RATS.
219504 04-03

FATTY
IDENTIFICATION AND STRUCTURAL CHARACTERIZATION OF AN INHIBITOR OF CATECHOLAMINE INDUCED FREE FATTY ACID MOBILIZATION FROM THE CALF MIDBRAIN.
200006 02-01

FAVORS
MORE EVIDENCE FAVORS YOUTH DRUG: FIRST DOUBLE-BLIND TRIALS SHOW GEROVITAL HAS SOME EFFECT ON AGING.
221352 04-11

FD-008
PHARMACOLOGICAL ACTION OF FD-008, A NEW DOPAMINE-BETA-HYDROXYLASE INHIBITOR: II. EFFECTS ON CENTRAL NERVOUS SYSTEM IN MICE AND RATS.
221823 04-02
PHARMACOLOGICAL ACTION OF FD-008, A NEW DOPAMINE-BETA-HYDROXYLASE INHIBITOR: III. EFFECTS ON ENDOGENOUS BIOGENIC AMINE LEVELS IN RATS.
221859 04-03

FEAR
EFFECTS OF CHLORDIAZEPOXIDE UPON FEAR MOTIVATED BEHAVIOR IN DOGS.
221799 04-04

FEAR-MOTIVATED
THE EFFECTS OF DELTA9-TETRAHYDROCANNABINOL UPON FEAR-MOTIVATED BEHAVIOR IN SQUIRREL MONKEYS.
223040 04-04

FEARS
THE FUTURE: HOPES AND FEARS.
202304 02-17

FEEDBACK
BEHAVIORAL AND PHYSIOLOGICAL FEEDBACK AS SOURCES OF INFORMATION ABOUT THE EFFECTIVENESS OF A PLACEBO. (PH.D. DISSERTATION).
214228 04-17
APPARENT FEEDBACK FROM THE CAUDATE NUCLEUS TO THE SUBSTANTIA-NIGRA FOLLOWING AMPHETAMINE ADMINISTRATION.
217676 04-03

FEEDING
THE EFFECTS OF HASHISH INJECTIONS ON FEEDING AND DRINKING IN RATS.
195113 01-04
BEHAVIORAL SPECIFICITY OF CHLORALOSE INDUCED FEEDING IN THE RAT.
200054 02-04

THE EFFECTS OF D- AND L-AMPHETAMINE UPON HOARDING BEHAVIOR AND FEEDING IN THE MONGOLIAN GERBIL (MERIONES-UNGUICULATUS).
202983 02-04

CEREBRAL HEMODYNAMIC EFFECTS OF CHRONIC TRYPTOPHAN FEEDING IN MAN AS MEASURED BY QUANTIFIED CEREBRAL IMPEDANCE PLETHYSMOGRAPHY.
206337 03-08

NEUROCHEMICAL CODING FOR FEEDING IN SHEEP AND STEERS.
206727 03-04

FEEDING BEHAVIOR IN SHEEP: EFFECTS OF NIALAMIDE AND 6-HYDROXYDOPAMINE.
210743 03-04

NEUROCHEMICAL REGULATION OF FEEDING IN THE RAT: FACILITATION BY ALPHA-NORADRENERGIC, BUT NOT DOPAMINERGIC RECEPTOR STIMULANTS.
211538 03-04

INTERACTIVE EFFECT OF (PLUS/MINUS) FENFLURAMINE AND (+) AMPHETAMINE ON FEEDING IN RATS.
217883 04-04

FEEDING IN RESPONSE TO REPEATED PROTAMINE ZINC INSULIN INJECTIONS.
219073 04-04

FEELINGS

THE USE OF ANALOGUE SCALES IN RATING SUBJECTIVE FEELINGS.
193851 01-14

FEMALE

EFFECT OF ACUTE AND CHRONIC DIELDRIN EXPOSURE ON BRAIN BIOGENIC AMINES OF MALE AND FEMALE RATS.
193428 01-03

INHIBITORY ROLE OF DOPAMINE AND 5-HYDROXYTRYPTAMINE IN THE SEXUAL BEHAVIOUR OF FEMALE RATS.
199968 02-04

A FOLLOWUP STUDY OF FEMALE DEPRESSED OUTPATIENTS WHO COMPLETE A RANDOMIZED DOUBLE-BLIND PROPHYLACTIC TRIAL OF ANTIDEPRESSANTS AND HIGH CONTACT. (PH.D. DISSERTATION).
212518 03-09

INHIBITORY EFFECT OF NEONATAL ESTROGENIZATION ON THE INCORPORATION OF (3H)LYSINE IN THE PURKINJE CELLS OF THE ADULT MALE AND FEMALE RAT.
213478 04-03

THE EFFECTS OF CHRONIC CANNABIS TREATMENT UPON BRAIN 5-HYDROXYTRYPTAMINE, PLASMA CORTICOSTERONE AND AGGRESSIVE BEHAVIOR IN FEMALE RATS WITH DIFFERENT HORMONAL STATUS.
217532 04-04

5-HYDROXYTRYPTAMINE IN THE CENTRAL NERVOUS SYSTEM AND SEXUAL RECEPTIVITY OF FEMALE RHESUS MONKEYS.
217856 04-04

ROLE OF MONOAMINES IN THE CONTROL BY HORMONES OF SEXUAL RECEPTIVITY IN THE FEMALE RAT.
222263 04-04

FACILITATORY AND INHIBITORY INFLUENCES OF PROGESTERONE, 20ALPHA-HYDROXYPROGESTERONE AND METHYSERGIDE ON THE RECEPTIVE BEHAVIOR OF THE FEMALE RAT. (PH.D. DISSERTATION).
222739 04-04

APOMORPHINE: FACILITATION OF SEXUAL BEHAVIOUR IN FEMALE RATS.
222807 04-04

FEMALES

A PATTERN OF ANTIDEPRESSIVE EFFECT OF TRYPTOPHAN & IMIPRAMINE IN MALES & FEMALES.
196680 01-09

DRUG STUDIES IN NORMAL FEMALES, SENIOR CITIZENS, AND IN EXPERIMENTAL GROUPS.
198071 01-07

FENFLURAMINE

FENFLURAMINE: AMPHETAMINE CONGENER THAT FAILS TO MAINTAIN DRUG-TAKING BEHAVIOR IN THE RHESUS MONKEY.
193137 01-04

ROLE OF MONOAMINES IN THE ANOREXIGENIC ACTIONS OF FENFLURAMINE, AMPHETAMINE AND P-CHLOROMETHAMPHETAMINE.
193546 01-04

NEUROCHEMICAL BASES FOR THE ANORECTIC ACTIVITIES OF AMPHETAMINE AND FENFLURAMINE.
197301 01-03

CENTRAL ACTION OF ANOREXIC AGENTS: EFFECTS OF AMPHETAMINE AND FENFLURAMINE IN RATS WITH LATERAL HYPOTHALAMIC LESIONS.
197865 01-04

COMPARISON BETWEEN BEHAVIOURS ELICITED BY HIGH DOSES OF AMPHETAMINE AND FENFLURAMINE: IMPLICATIONS FOR THE CONCEPT OF STEREOTYPY.
210742 03-04

THE EFFECT OF 5-HYDROXYTRYPTOPHAN ON FOOD INTAKE AND ON THE ANOREXIC ACTION OF AMPHETAMINE AND FENFLURAMINE.
210748 03-04

DOES FENFLURAMINE ACT VIA NORFENFLURAMINE?
210772 03-03

THE EFFECT OF COLD AND DIAZEPAM ON THE TOXICITY OF FENFLURAMINE IN MICE.
215160 04-05

FENFLURAMINE IN MAN: HYPOPHAGIA ASSOCIATED WITH DIMINISHED SEROTONIN TURNOVER.
215674 04-13

INTERACTIVE EFFECT OF (PLUS/MINUS) FENFLURAMINE AND (+) AMPHETAMINE ON FEEDING IN RATS.
217883 04-04

SOME INTERACTIONS BETWEEN FENFLURAMINE AND ANTIDEPRESSANT DRUGS: EFFECTS ON 5-HYDROXYINDOLE CONCENTRATIONS IN RAT BRAIN.
217962 04-03

RELATIONSHIPS BETWEEN THE STRUCTURE AND THE CHRONOTROPIC, LOCOMOTOR STIMULANT AND REINFORCING ACTIONS OF SEVERAL FENFLURAMINE ANALOGS. (PH.D. DISSERTATION).
223563 04-04

GALVANIC SKIN RESISTANCE (GSR) MEASUREMENTS ON VOLUNTEERS RECEIVING FENFLURAMINE OR D-AMPHETAMINE.
225062 04-13

FENTANYL

ELECTROENCEPHALOGRAPHIC FINDINGS ON THE ACTION OF FENTANYL AND DEHYDROBENZOPERIDOL.
205442 02-13

DIFFERENTIAL ANTAGONISM BY THE ANTICHOLINERGIC DEXETIMIDE OF INHIBITORY EFFECTS OF HALOPERIDOL AND FENTANYL ON BRAIN SELF-STIMULATION.
225562 04-03

FERRETS

SPONTANEOUS ALTERNATION IN FERRETS FOLLOWING TREATMENT WITH SCOPOLAMINE, CHLORDIAZEPOXIDE, AND CAFFEINE.
223039 04-04

FETAL

THE EFFECT OF SEROTONIN ON THE FETUS AND FETAL MATERNAL RELATIONS IN THE RAT.
221743 04-03

FETUS

THE EFFECT OF SEROTONIN ON THE FETUS AND FETAL MATERNAL RELATIONS IN THE RAT.
221743 04-03

FI-6654

CLINICAL DOUBLE-BLIND STUDY ON THE ACTIVITY OF A NEW ANTIDEPRESSANT: CAROXAZONE (FI-6654).
201667 02-09

FIBRES

EFFECTS OF DIAZEPAM ON DISCHARGE PATTERN IN SINGLE FIBRES OF PHRENIC NERVE.
197577 01-03

FIBROBLAST

THE TOXICITY OF CHLORPROMAZINE AND MESCALINE ON MOUSE CEREBELLUM AND FIBROBLAST CELLS IN CULTURE.
210890 03-03

FIGHTING

CHLORDIAZEPOXIDE (LIBRIUM) INDUCED CHANGES IN INTRASPECIFIC ATTACK AND SELECTED NONAGONISTIC BEHAVIORS IN MALE SIAMESE FIGHTING FISH.
217524 04-04

EFFECT OF FIGHTING AND DIPHENYLHYDANTOIN ON THE UPTAKE OF H3-L-NOREPINEPHRINE IN VITRO IN SYNAPTOSOMES ISOLATED FROM RETIRED MALE BREEDING MICE.
222821 04-03

FIRING

TRICYCLIC ANTIDEPRESSANTS: EFFECTS ON THE FIRING RATE OF BRAIN NORADRENERGIC NEURONS.
222805 04-03

FIRM

THYROXINE-LIKE EFFECTS OF ZINC ON BRAIN AND BEHAVIOUR WITH FIRM DEPENDENCE ON SEVERAL HORMONES.
213434 04-04

FIRST-ORDER

EXPLICIT SOLUTION TO PHARMACOKINETIC FIRST-ORDER RATE CONSTANTS OF MAPROTILIN.
208919 03-17

FIRST-PASS

FIRST-PASS METABOLISM OF IMIPRAMINE IN MAN.
215671 04-13

FISH

CHLORDIAZEPOXIDE (LIBRIUM) INDUCED CHANGES IN INTRASPECIFIC ATTACK AND SELECTED NONAGONISTIC BEHAVIORS IN MALE SIAMESE FIGHTING FISH.
217524 04-04

FIXED

COMPARISON OF THE EFFECTS OF ATROPINE AND CANNABIS UPON THE FIXED CONDITIONED ALIMENTARY MOTOR REFLEXES IN CATS AFFECTED BY NICOTINE.
205623 03-14

FIXED-INTERVAL
THE EFFECTS OF SCOPOLAMINE AND PHYSOSTIGMINE ON FIXED-INTERVAL BEHAVIOUR IN THE RAT.
200046 02-04
RATE DEPENDENT EFFECTS OF DRUGS. II. EFFECTS OF SOME MAJOR TRANQUILIZERS ON MULTIPLE FIXED-RATIO, FIXED-INTERVAL SCHEDULE PERFORMANCE.
217458 04-04

FIXED-RATIO
CODEINE AND COCAINE REINFORCED RESPONDING IN RHESUS MONKEYS: EFFECTS OF DOSE ON RESPONSE RATES UNDER A FIXED-RATIO SCHEDULE.
202667 02-04
INCREASED FIXED-RATIO PERFORMANCE AND DIFFERENTIAL D- AND L-AMPHETAMINE ACTION FOLLOWING NOREPINEPHRINE DEPLETION BY INTRAVENTRICULAR 6-HYDROXYDOPAMINE.
204482 02-04
EFFECTS OF PENTOBARBITAL ON FIXED-RATIO DISCRIMINATION.
210392 03-04
FIXED-RATIO ESCAPE AND AVOIDANCE ESCAPE FROM NALOXONE IN MORPHINE-DEPENDENT MONKEYS: EFFECTS OF NALOXONE DOSE AND MORPHINE PRETREATMENT.
215968 04-04
RATE DEPENDENT EFFECTS OF DRUGS. II. EFFECTS OF SOME MAJOR TRANQUILIZERS ON MULTIPLE FIXED-RATIO, FIXED-INTERVAL SCHEDULE PERFORMANCE.
217458 04-04

FK-880
EXAMINATION OF THE NEW PSYCHOTROPIC DRUG, DOGMATYL (FK-880 SULPIRIDE).
194509 01-11
INVESTIGATION OF CLINICAL EFFECTS OF FK-880 (SULPIRIDE) ON MANIC-DEPRESSIVE ILLNESS.
207535 03-09
PERSONAL EXPERIENCE IN THE USE OF SULPIRIDE (FK-880) ON SCHIZOPHRENIA.
209405 03-08
CLINICAL EXPERIENCE OF THE USE OF FK-880 (SULPIRIDE) FOR DEPRESSION AND NEUROSIS.
224195 04-14

FLA-63
EFFECTS OF THE DOPAMINE-BETA-HYDROXYLASE INHIBITOR FLA-63 ON THE KINETICS OF ELIMINATION OF AMPHETAMINE IN THE RAT.
217881 04-03

FLASHBACKS
DIPHENYLHYDANTOIN IN THE TREATMENT OF LSD FLASHBACKS: A CASE STUDY.
205766 03-12

FLOROPIPAMIDE
REPORT ON THREE CASES OF CARDIAC CHANGES DURING TREATMENT WITH FLOROPIPAMIDE (PROPITAN).
216391 04-15

FLOW
INCREASE IN BRAIN DOPAMINE AFTER AXOTOMY OR TREATMENT WITH GAMMA-HYDROXYBUTYRIC ACID DUE TO ELIMINATION OF THE NERVE IMPULSE FLOW.
195439 01-03
EFFECTS OF L-DOPA AND L-TRYPTOPHAN ON THE CEREBRAL BLOOD FLOW IN THE DOG.
197213 01-03
EFFECTS OF NORADRENALINE ON THE CEREBRAL BLOOD FLOW IN THE DOG.
197214 01-03
EFFECTS OF 5-HYDROXYTRYPTAMINE ON THE CEREBRAL BLOOD FLOW IN THE DOG.
197215 01-03
DOPAMINERGIC NEURONS: DRUG-INDUCED ANTAGONISM OF THE INCREASE IN TYROSINE-HYDROXYLASE ACTIVITY PRODUCED BY CESSATION OF IMPULSE FLOW.
202664 02-03
BRAIN CATECHOLAMINES AND CEREBRAL BLOOD FLOW.
209839 03-17
LYSERGIC ACID DIETHYLAMIDE AFFECTS BLOOD FLOW TO SPECIFIC AREAS OF THE CONSCIOUS RAT BRAIN.
215161 04-03

FLUANXOL
CLINICAL TRIAL WITH FLUPENTHIXOL (FLUANXOL) IN THE TREATMENT OF SENILE DEMENTIA.
225281 04-11

FLUID
TASTE PHENOMENA INFLUENCES ON STIMULATION OF DEPRIVATION INDUCED FLUID CONSUMPTION OF RATS.
197991 01-03
PLASMA AND CEREBROSPINAL FLUID CONCENTRATIONS OF PHENOBARBITAL IN INFANTS GIVEN SINGLE DOSES.
206057 03-13
ACCUMULATION OF 3H-HOMOVANILLIC ACID IN RABBIT BRAIN AND CEREBROSPINAL FLUID FOLLOWING INTRAVENOUS 3H-L-DOPA.
206336 03-03
THE INFLUENCE OF CLOZAPINE ON THE EXCRETION OF MHPG, HVA, AND 5-HIAA IN URINE AND CEREBROSPINAL FLUID.
206974 03-13
MASS FRAGMENTOMETRIC DETERMINATION OF HOMOVANILLIC ACID IN LUMBAR CEREBROSPINAL FLUID OF SCHIZOPHRENIC PATIENTS DURING TREATMENT WITH ANTIPSYCHOTIC DRUGS.
207295 03-08
CYCLIC-AMP IN CEREBROSPINAL FLUID: ACCUMULATION FOLLOWING PROBENECID AND BIOGENIC AMINES.
210193 03-17
EXTRAPYRAMIDAL REACTIONS AND AMINE METABOLITES IN CEREBROSPINAL FLUID DURING HALOPERIDOL AND CLOZAPINE TREATMENT OF SCHIZOPHRENIC PATIENTS.
214010 04-15
MASS FRAGMENTOGRAPHY OF PICOMOLE QUANTITIES OF BIOGENIC AMINE METABOLITES IN HUMAN CEREBROSPINAL FLUID AS WELL AS WHOLE RAT BRAINS. (UNPUBLISHED PAPER).
217219 04-06
AVERAGE EVOKED RESPONSES (AER) AND HOMOVANILLIC ACID (HVA) IN CEREBROSPINAL FLUID (CSF) IN A PSYCHOTIC PATIENT WITH ADDISONS DISEASE.
221310 04-09

FLUIDS
EVIDENCE THAT PUNCTUATE INTRACEREBRAL ADMINISTRATION OF 6-HYDROXYDOPAMINE FAILS TO PRODUCE SELECTIVE NEURONAL DEGENERATION: COMPARISON WITH COPPER SULFATE AND FACTORS GOVERNING THE DEPORTMENT OF FLUIDS INJECTED INTO BRAIN.
197931 01-03
GLC DETERMINATION OF PROPRANOLOL, OTHER BETA-BLOCKING DRUGS, AND METABOLITES IN BIOLOGICAL FLUIDS AND TISSUES.
200740 02-16

FLUNITRAZEPAM
STUDIES ON CLONAZEPAM, FLUNITRAZEPAM, AND RELATED BENZODIAZEPINES IN CAT AND MONKEY.
197492 01-03
LOCUS OF CENTRAL DEPRESSANT ACTION OF FLUNITRAZEPAM.
199811 02-03
ALL-NIGHT POLYGRAPHIC RECORDINGS ON THE HYPNOTIC EFFECTS OF A NEW BENZODIAZEPINE: FLUNITRAZEPAM (RO-5-4200, ROHYPNOL).
202272 02-11

FLUORESCENCE
FLUORESCENCE OF CANNABINOIDS.
210773 03-01
DIFFERENTIAL EFFECTS OF CAFFEINE, D-AMPHETAMINE AND METHYLPHENIDATE ON INDIVIDUAL RAPHE CELL FLUORESCENCE: A MICROSPECTROFLUORIMETRIC DEMONSTRATION.
213400 04-03
A RAPID, SIMPLE AND MORE SENSITIVE METHOD FOR THE DEMONSTRATION OF CENTRAL CATECHOLAMINE CONTAINING NEURONS AND AXONS BY GLYOXYLIC ACID INDUCED FLUORESCENCE: I. SPECIFICITY.
217550 04-16

FLUORIMETRIC
CONJOINT NATIVE AND ORTHOPHTHALDIALDEHYDE CONDENSATE ASSAYS FOR THE FLUORIMETRIC DETERMINATION OF 5-HYDROXYINDOLES IN BRAIN.
195238 01-01

FLUORINATED
CENTRAL EFFECTS OF THREE FLUORINATED BENZODIAZEPINES IN COMPARISON WITH DIAZEPAM.
202765 02-03

FLUOSTIGMINE
INVESTIGATIONS OF THE EFFECTS OF DIAZEPAM IN ACUTE EXPERIMENTAL INTOXICATION WITH FLUOSTIGMINE.
197832 01-03

FLUPENTHIXOL
USE OF METAMIN (FLUPENTHIXOL) IN THE DEPARTMENT OF PSYCHIATRY.
194449 01-08
REMARKS ON THE USE OF FLUPENTHIXOL IN TREATING CHRONIC SCHIZOPHRENIA.
201669 02-08
CLINICAL TRIAL OF FLUPENTHIXOL IN PATIENTS WITH CHRONIC SCHIZOPHRENIA: ESPECIALLY IN PATIENTS HAVING DIFFICULTY IN REHABILITATION OWING TO DECREASED EXPRESSION, APATHY AND DISTURBANCE OF RAPPORT.
202603 02-08
LONG-TERM TRIAL OF FLUPHENAZINE DECANOATE AND FLUPENTHIXOL DECANOATE FOR CATALEPTIC ACTIVITY AND EFFECT ON MOTOR ACTIVITY IN RATS.
206787 03-04
FLUPENTHIXOL DECANOATE IN PSYCHOTIC ADULTS -- PILOT STUDY.
209071 03-08
THE COMPARATIVE PHARMACOLOGY OF FLUPENTHIXOL AND SOME REFERENCE NEUROLEPTICS.
210892 03-03
A STUDY OF FLUPENTHIXOL DECANOATE AND PIPOTIAZINE UNDECYLENATE IN SCHIZOPHRENICS.
212238 03-08

THE LONG-TERM MAINTENANCE TREATMENT OF SCHIZOPHRENIC OUTPATIENTS WITH DEPOT FLUPENTHIXOL.
212491 03-08

CLINICAL TRIAL WITH FLUPENTHIXOL (FLUANXOL) IN THE TREATMENT OF SENILE DEMENTIA.
225281 04-11

FLUPHENAZINE

OUTPATIENT TREATMENT OF SCHIZOPHRENIA BY A LONG-LASTING STRONG TRANQUILIZER: USE OF FLUPHENAZINE ENANTHATE.
194460 01-08

EARLY HOSPITAL EXPERIENCES WITH FLUPHENAZINE DECANOATE.
196675 01-07

TISSUE METABOLITES OF TRIFLUOPERAZINE, FLUPHENAZINE, PROCHLORPERAZINE, AND PERPHENAZINE IN THE RAT: IDENTIFICATION AND SYNTHESIS.
200738 02-01

THE DEPOT COMPOUNDS MODITEN (FLUPHENAZINE) AND IMAP (FLUSPIRILENE) IN CLINICAL PRACTICE.
205584 02-08

MAINTENANCE TREATMENT OF SCHIZOPHRENIA WITH LONG-ACTING FLUPHENAZINE.
205585 02-08

LONG-TERM TRIAL OF FLUPHENAZINE DECANOATE AND FLUPENTHIXOL DECANOATE FOR CATALEPTIC ACTIVITY AND EFFECT ON MOTOR ACTIVITY IN RATS.
206787 03-04

PREVENTION OF RECIDIVISM OF SCHIZOPHRENICS TREATED WITH FLUPHENAZINE ENANTHATE.
211436 03-08

FLUPHENAZINE ENANTHATE INDUCED DECOMPENSATIONS.
211437 03-08

CLINICAL EXPERIENCE OF FLUPHENAZINE ENANTHATE IN TREATMENT OF SCHIZOPHRENIC PATIENTS.
213294 03-08

FLUPHENAZINE TREATMENT IN THE PSYCHOTIC CHILD: CLINICAL EVOKED POTENTIAL CORRELATIONS.
215455 04-09

TREATMENT OF ACUTE SCHIZOPHRENIA WITH ULTRA-HIGH-DOSE FLUPHENAZINE: A FAILURE AT SHORTENING TIME ON A CRISIS INTERVENTION UNIT.
215456 04-08

CROSS-ANALYSIS OF A CONTROLLED EXPERIMENT WITH PIPOTHIAZINE AND FLUPHENAZINE ENANTHATE.
221636 04-08

CLINICAL STUDY OF FIVE DEPOT NEUROLEPTICS, COMPARISON OF ACTIVITY PROFILES OF FLUPHENAZINE DECANOATE, FLUSPIRILENE, PENFLURIDOL, PERPHENAZINE ENANTHATE AND PIPOTHIAZINE PALMITATE.
221822 04-08

OBSERVATIONS ON THE DOSE REGIME OF FLUPHENAZINE DECANOATE IN MAINTENANCE THERAPY OF SCHIZOPHRENIA.
222602 04-17

FLUPHENAZINES

THE DEPOT FLUPHENAZINES: A REAPPRAISAL AFTER 10 YEARS CLINICAL EXPERIENCE.
225325 04-08

FLURAZEPAM

THE EFFECTS OF DALMANE (FLURAZEPAM HYDROCHLORIDE) ON HUMAN EEG CHARACTERISTICS.
199756 02-13

INHIBITORY AND DISINHIBITORY EFFECTS OF NITRAZEPAM, DIAZEPAM AND FLURAZEPAM HYDROCHLORIDE ON DELAYED MATCHING BEHAVIOUR IN MONKEYS (MACACA-MULATTA).
199957 02-04

SPECTROFLUORODENSITOMETRIC DETERMINATION OF FLURAZEPAM AND ITS MAJOR METABOLITES IN BLOOD.
200737 02-16

TREATMENT AND COUNTERMEASURES FOR PATIENTS WITH INSOMNIA IN THE DEPARTMENT OF INTERNAL MEDICINE -- SPECIAL EMPHASIS ON THE CLINICAL APPLICATION OF FLURAZEPAM.
202285 02-14

A COMPARATIVE STUDY OF THE HYPNOTIC PROPERTIES OF FLURAZEPAM (30 MG), SECOBARBITAL (100 MG), AND OF PLACEBO AMONG FOUR TYPES OF PSYCHOTIC INSOMNIACS.
203204 02-04

FLURAZEPAM HYDROCHLORIDE.
204851 02-17

EFFECT OF FLURAZEPAM ON SLEEP IN THE LABORATORY.
206450 03-14

COMPARISON OF THE HYPNOTIC ACTIVITY OF TRIAZOLAM, FLURAZEPAM HYDROCHLORIDE, AND PLACEBO.
215673 04-14

A DOUBLE-BLIND TRIAL OF NITRAZEPAM AND FLURAZEPAM AS SEDATIVES.
217041 04-14

FLUSPIRILENE

THE DEPOT COMPOUNDS MODITEN (FLUPHENAZINE) AND IMAP (FLUSPIRILENE) IN CLINICAL PRACTICE.
205584 02-08

ASPECTS OF LONG-TERM TREATMENT WITH NEUROLEPTICS: HISTORICAL AND LITERATURE REVIEW -- PERSONAL EXPERIENCE WITH FLUSPIRILENE AND PENFLURIDOL.
215059 04-14

CLINICAL STUDY OF FIVE DEPOT NEUROLEPTICS, COMPARISON OF ACTIVITY PROFILES OF FLUPHENAZINE DECANOATE, FLUSPIRILENE, PENFLURIDOL, PERPHENAZINE ENANTHATE AND PIPOTHIAZINE PALMITATE.
221822 04-08

FLUXES

EFFECTS OF RESERPINE AND PRENYLAMINE ON THE NORADRENALINE FLUXES OF ISOLATED SPLENIC NERVE GRANULES.
197280 01-03

FLYING

EFFECTS OF MARIJUANA ON FLYING ABILITY.
224906 04-04

FOCI

THE INFLUENCE OF CHOLINOMIMETICS ON THE AFTEREFFECTS OF TRACE DISCHARGES AND THE ACTIVITY OF EPILEPTOGENIC FOCI IN THE RABBIT HIPPOCAMPUS.
219499 04-03

FOCUS

EXPERIMENTAL STUDIES ON FACILITATIVE AND INHIBITORY FACTORS FOR EPILEPTOGENIC FOCUS FORMATION.
197211 01-03

THE EFFECTS OF DIPHENYLHYDANTOIN, PHENOBARBITAL, AND DIAZEPAM ON THE PENICILLIN INDUCED EPILEPTOGENIC FOCUS IN THE RAT.
198613 02-03

EFFECT OF DRUG-INDUCED INCREASE OF BRAIN GABA LEVELS ON PENICILLIN FOCUS.
220947 04-03

FOLATE

RED CELL FOLATE AND MACROCYTOSIS DURING LONG-TERM ANTICONVULSANT THERAPY IN NONANAEMIC MENTALLY RETARDED EPILEPTICS.
218553 04-11

FOLLOWED-UP

THE EFFECTS OF SCOPOLAMINE (0.6 MG) AND PHYSOSTIGMINE (1.0 MG) ON HIGHER NERVOUS ACTIVITY IN MAN, FOLLOWED-UP DURING 5 HOURS AFTER APPLICATION.
217205 04-14

FOLLOWUP

HALOPERIDOL FOR CHRONICALLY HOSPITALIZED PSYCHOTICS: A DOUBLE-BLIND COMPARISON WITH THIOTHIXENE AND PLACEBO: A FOLLOWUP OPEN EVALUATION.
196676 01-14

SCHIZOPHRENIA FOLLOWUP: A CONTROLLED TREATMENT STUDY.
198076 02-08

ONE-YEAR FOLLOWUP OF HYPERACTIVE BOYS TREATED WITH IMIPRAMINE OR METHYLPHENIDATE.
209736 03-11

CLINICAL STUDY AND FOLLOWUP OF 40 PSYCHOTIC PATIENTS ON PERPHENAZINE ENANTHATE.
212495 03-14

A FOLLOWUP STUDY OF FEMALE DEPRESSED OUTPATIENTS WHO COMPLETE A RANDOMIZED DOUBLE-BLIND PROPHYLACTIC TRIAL OF ANTIDEPRESSANTS AND HIGH CONTACT. (PH.D. DISSERTATION).
212518 03-09

A FOLLOWUP OF TOURETTES SYNDROME IN SEVENTY-SEVEN PATIENTS.
224910 04-11

CHILDHOOD CHEMOTHERAPY AND LATER DRUG ABUSE AND GROWTH CURVE: A FOLLOWUP STUDY OF 30 ADOLESCENTS.
225382 04-14

FOOD

REDUCTION OF STIMULUS BOUND FOOD CONSUMPTION IN THE RAT FOLLOWING AMPHETAMINE ADMINISTRATION.
195081 01-04

A STUDY OF THE INTERACTION BETWEEN AMPHETAMINE AND FOOD DEPRIVATION.
197854 01-04

ACUTE AND CHRONIC EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON FOOD INTAKE BY RATS.
200043 02-04

DIFFERENTIAL EFFECTS OF AMPHETAMINE AND FOOD DEPRIVATION ON SELF-STIMULATION OF THE LATERAL HYPOTHALAMUS AND MEDIAL FRONTAL CORTEX.
206733 03-04

THE EFFECT OF 5-HYDROXYTRYPTOPHAN ON FOOD INTAKE AND ON THE ANOREXIC ACTION OF AMPHETAMINE AND FENFLURAMINE.
210748 03-04

POTENTIATION OF AMPHETAMINE-INDUCED AROUSAL BY FOOD DEPRIVATION: EFFECT OF HYPOTHALAMIC LESIONS.
218498 04-04

EFFECTS OF HEROIN ON LEVER PRESSING FOR INTRACRANIAL SELF-STIMULATION, FOOD AND WATER IN THE RAT.
221039 04-04

FOREBRAIN
INTRACRANIAL SELF-STIMULATION IN RATS AS A FUNCTION OF VARIOUS STIMULUS PARAMETERS: V. INFLUENCE OF COCAINE ON MEDIAL FOREBRAIN BUNDLE STIMULATION WITH MONOPOLAR ELECTRODES.
198223 02-03
EFFECTS OF CHLORIMIPRAMINE ON EXPERIMENTALLY INDUCED CHANGES IN FOREBRAIN 5-HYDROXYINDOLES.
199966 02-03
THE ROLE OF FOREBRAIN DOPAMINE SYSTEMS IN AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR IN THE RAT.
202774 02-04
EFFECT OF INTRAVENTRICULAR NOREPINEPHRINE ON NEURON ACTIVITY IN THE MEDIAL FOREBRAIN BUNDLE DURING SELF-STIMULATION BEHAVIOR.
210704 03-04
BLOCKADE BY PIMOZIDE OF A NORADRENALINE SENSITIVE ADENYLATE-CYCLASE IN THE LIMBIC FOREBRAIN: POSSIBLE ROLE OF LIMBIC NORADRENERGIC MECHANISMS IN THE MODE OF ACTION OF ANTIPSYCHOTICS.
210771 03-03
EFFECTS OF DOPAMINERGIC DRUGS AND ACUTE MEDIAL FOREBRAIN BUNDLE LESIONS ON STRIATAL ACETYLCHOLINE LEVELS.
210831 03-03
SELECTIVE DESTRUCTION OF SEROTONIN TERMINALS IN RAT FOREBRAIN BY HIGH DOSES OF 5,7 DIHYDROXYTRYPTAMINE.
213401 04-03

FOREIGN
NEUROLEPTICS OF PROLONGED ACTION (A SURVEY OF FOREIGN LITERATURE).
217003 04-14

FORIT
TREATMENT OF SCHIZOPHRENIA BY THE ADMINISTRATION OF A SMALL DOSE OF FORIT FOR COMPARATIVELY LONG PERIODS OF TIME.
194476 01-08
CLINICAL EXPERIENCE WITH FORIT: ITS ACTIVATING EFFECT ON CHRONIC SCHIZOPHRENIA.
198710 02-08

FORMATION
EXPERIMENTAL STUDIES ON FACILITATIVE AND INHIBITORY FACTORS FOR EPILEPTOGENIC FOCUS FORMATION.
197211 01-03
THE FORMATION IN VIVO OF 3,4 DIHYDROXYPHENYLALANINE (DOPA) FROM 3-HYDROXY-DL-PHENYLALANINE (M-TYROSINE).
198015 01-03
FORMATION OF P-HYDROXYNOREPHEDRINE IN BRAIN FOLLOWING INTRAVENTRICULAR ADMINISTRATION OF P-HYDROXYAMPHETAMINE.
202782 02-03
THE ROLE OF THE RETICULAR FORMATION IN ACTION EXERTED BY CHLORPROMAZINE AND BENACTYZINE ON PRIMARY RESPONSES OF THE BRAIN-CORTEX.
206440 03-04
INHIBITION OF MEMORY FORMATION IN THE IMPRINTING PERIOD: IRREVERSIBLE ACTION OF CYCLOHEXIMIDE IN YOUNG CHICKENS.
210708 03-04
ELECTROCORTICAL CHANGES INDUCED BY PERFUSION OF CATECHOLAMINES INTO THE BRAINSTEM RETICULAR FORMATION.
210827 03-03
DIFFERENTIAL EFFECTS OF THE OPTICAL ISOMERS OF AMPHETAMINE ON NEURONAL ACTIVITY IN THE RETICULAR FORMATION AND CAUDATE NUCLEUS OF THE RAT.
211063 03-03
THE EFFECT OF CHLORPROMAZINE AND STIMULATION OF THE MESENCEPHALIC RETICULAR FORMATION ON CENTRAL AROUSAL AND ON THE VISUAL EVOKED RESPONSE. (PH.D. DISSERTATION).
212547 03-03
ANTEROGRADE AND RETROGRADE EFFECTS OF ELECTROCONVULSIVE SHOCK AND OF PUROMYCIN ON MEMORY FORMATION IN THE GOLDFISH.
213853 04-04
THE INFLUENCE OF ALKYLATE PHERPACET DERIVATIVES ON NEURON POPULATIONS IN THE MIDBRAIN RETICULAR FORMATION.
219501 04-03
PARKINSONISM: EFFECTS OF LEVODOPA TREATMENT ON CONCEPT FORMATION.
222871 04-14
FORMATION OF NOREPINEPHRINE IN THE BRAIN OF RATS AFTER ADMINISTRATION OF (+) ERYTHRO 3,4 DIHYDROXYPHENYLSERINE.
225558 04-03

FORMATIONS
ON THE SPECIFICITY OF NEUROCHEMICAL MECHANISMS DEALING WITH NOCICEPTIVE STIMULATION OF NEURONS IN VARIOUS BRAIN FORMATIONS OF RABBITS.
198436 02-03

FORMING
THE ACTIVATION OF THE KININ FORMING SYSTEM AND THE EFFECTS OF THIOPENTAL.
210744 03-03
EFFECT OF THE ACTIVATION OF THE KININ FORMING SYSTEM ON THE POTENCY OF CHLORPROMAZINE.
210872 03-03

FOWL
EPILEPTIFORM SEIZURES IN DOMESTIC FOWL. IV. THE EFFECTS OF ANTICONVULSANT DRUGS.
197742 01-03

FRACTION
TRANQUILLIZING ACTION OF A CRYSTALLINE FRACTION OF PASPALUM-SCROBICULATUM EXTRACT IN FOURTEEN PSYCHOTIC PATIENTS.
194711 01-08
ACCUMULATION OF LITHIUM IN THE PARTICULATE FRACTION OF RAT BRAIN FOLLOWING ITS LONG-TERM ADMINISTRATION.
210782 03-03

FRACTIONS
EFFECT OF DELTA9-TETRAHYDROCANNABINOL ADMINISTRATION ON THE LIPID CONSTITUENTS OF RAT BRAIN SUBCELLULAR FRACTIONS.
210769 03-03
BINDING OF LITHIUM AND CALCIUM BY CEREBRAL MEMBRANE FRACTIONS.
210806 03-03
THE METABOLISM OF INDIVIDUAL PHOSPHOLIPID FRACTIONS IN THE RAT BRAIN DURING THIOPENTAL SLEEP AND AMPHETAMINE EXCITATION.
219747 04-03

FRAGMENTATION
LIGHT INDUCED FRAGMENTATION OF 3,5-DIOXO-1,2 DIPHENYL-4-N-BUTYLPYRAZOLIDINE (PHENYLBUTAZONE) WITH NUCLEOPHILIC AGENTS.
197675 01-01

FRAGMENTOGRAPHIC
A MASS FRAGMENTOGRAPHIC STUDY OF AMPHETAMINE AND METABOLITES IN RAT BRAIN.
207289 03-06

FRAGMENTOGRAPHY
MASS FRAGMENTOGRAPHY OF PICOMOLE QUANTITIES OF BIOGENIC AMINE METABOLITES IN HUMAN CEREBROSPINAL FLUID AS WELL AS WHOLE RAT BRAINS. (UNPUBLISHED PAPER).
217219 04-06

FRAGMENTOMETRIC
MASS FRAGMENTOMETRIC DETERMINATION OF HOMOVANILLIC ACID IN LUMBAR CEREBROSPINAL FLUID OF SCHIZOPHRENIC PATIENTS DURING TREATMENT WITH ANTIPSYCHOTIC DRUGS.
207295 03-08

FRANCE
NEW PSYCHOTROPIC DRUG DEVELOPMENTS IN FRANCE AND BELGIUM.
213597 04-17

FREE
DOES MAPROTILINE (LUDIOMIL) INFLUENCE SEROTONIN UPTAKE AND FREE TRYPTOPHAN CONCENTRATION IN HUMAN PLASMA
192943 01-13
IDENTIFICATION AND STRUCTURAL CHARACTERIZATION OF AN INHIBITOR OF CATECHOLAMINE INDUCED FREE FATTY ACID MOBILIZATION FROM THE CALF MIDBRAIN.
200006 02-01
EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON FREE AMINO ACIDS IN BRAIN.
205625 03-03
FREE AND MEMBRANE BOUND RIBOSOMES AND POLYSOMES IN HIPPOCAMPAL NEURONS DURING A LEARNING EXPERIMENT.
210674 03-04
FREE THYROXINE INDEX AND ABSOLUTE FREE THYROXINE IN PATIENTS WITH AFFECTIVE DISORDERS TREATED WITH LITHIUM CARBONATE.
216747 04-09
THE USE OF FREE IMAGERY, NONDIRECTIVE INTERVIEWING, AND SELECTED DRUGS TO LIFT POSTHYPNOTIC REPRESSION. (PH.D. DISSERTATION).
222060 04-14

FREE-RADICAL
DIFFERENTIAL EFFECTS OF CHLORPROMAZINE AND CHLORPROMAZINE FREE-RADICAL ON CALCIUM TRANSPORT IN SARCOPLASMIC RETICULUM VESICLES.
210812 03-03

FREE-RADICALS
FREE-RADICALS IN PSYCHOTROPIC DRUG ACTION.
213624 04-03

FREEDOM
MEDICINE FOR FREEDOM OR THE FREEDOM OF MEDICINE.
208928 03-17

FREQUENCY
SCHIZOPHRENIA AND EVOKED POTENTIALS: MAXIMUM AMPLITUDE, FREQUENCY OF PEAKS, VARIABILITY, AND PHENOTHIAZINE EFFECTS.
213764 04-08
AN APPLICATION OF LONG-TERM FREQUENCY ANALYSIS IN MEASURING DRUG SPECIFIC ALTERATIONS IN THE EEG OF THE CAT.
218190 04-03
THE EFFECT OF ALCOHOL AND BARBITURATE ON THE FREQUENCY OF ATRIAL AND VENTRICULAR PREMATURE BEATS DURING SLEEP.
218971 04-13

THE EFFECTS OF SHOCK INTENSITY, D-AMPHETAMINE, AND PENTOBARBITAL ON THE FREQUENCY AND RESPONSE DYNAMICS OF BITING ATTACK IN THE SQUIRREL MONKEY. (PH.D. DISSERTATION).
222114 04-04

FROG

ACETYLCHOLINE LEVELS IN THE FROG SPINAL CORD FOLLOWING THE ADMINISTRATION OF DIFFERENT CONVULSANTS.
193550 01-03

ANTICONVULSANT ACTIVITY OF DELTA9-TETRAHYDROCANNABINOL AND ITS 11 HYDROXY AND 8ALPHA,11 DIHYDROXY METABOLITES IN THE FROG.
200035 02-03

INFLUENCE OF MEPROBAMATE, CARISPRODOL, OXAZEPAM AND PHENOBARBITAL ON NA+ TRANSPORT IN THE ISOLATED FROG SKIN.
206781 03-03

EFFECTS OF IMIPRAMINE UPON FROG NERVE EXCITABILITY AND CONDUCTION.
210925 03-03

FROGS

POTENTIATION WITH TRICYCLIC ANTIDEPRESSANTS OF THE INHIBITORY ACTION OF APOMORPHINE ON THE ATTITUDINAL REFLEX IN FROGS.
201919 02-04

SIMILARITIES OF THE INFLUENCE OF SECONDARY AND TERTIARY TRICYCLIC ANTIDEPRESSANTS ON THE EFFECT OF RESERPINE IN FROGS AND ON THE SEROTONIN UPTAKE OF HUMAN THROMBOCYTES.
219503 04-13

FRONTAL

DIFFERENTIAL EFFECTS OF AMPHETAMINE AND FOOD DEPRIVATION ON SELF-STIMULATION OF THE LATERAL HYPOTHALAMUS AND MEDIAL FRONTAL CORTEX.
206733 03-04

TIME-DEPENDENT CHANGES IN AMPHETAMINE SELF-ADMINISTRATION FOLLOWING FRONTAL CORTEX ABLATIONS IN RATS.
206747 03-04

COMPARATIVE TIME-DEPENDENT CHANGES IN SENSITIVITY TO LOCOMOTOR EFFECTS OF D-AMPHETAMINE IN MICE WITH CAUDATE, HIPPOCAMPAL OR FRONTAL CORTICAL LESIONS.
210926 03-03

FRONTIERS

FRONTIERS IN CATECHOLAMINE RESEARCH. PROCEEDINGS OF THE THIRD INTERNATIONAL CATECHOLAMINE SYMPOSIUM.
206437 03-17

FUMARASE

EFFECT OF LONG-TERM LITHIUM TREATMENT ON BRAIN FUMARASE ACTIVITY.
200751 02-03

FUNCTION

THE EFFECTS OF PHYSOSTIGMINE DURING THE ACQUISITION OF AVOIDANCE BEHAVIOUR AS A FUNCTION OF THE INTERSESSION INTERVAL.
192951 01-04

INTRACRANIAL SELF-STIMULATION IN RATS AS A FUNCTION OF VARIOUS STIMULUS PARAMETERS: V. INFLUENCE OF COCAINE ON MEDIAL FOREBRAIN BUNDLE STIMULATION WITH MONOPOLAR ELECTRODES.
198223 02-03

BEHAVIOURAL SUPERSENSITIVITY TO APOMORPHINE FOLLOWING CHRONIC TREATMENT WITH DRUGS WHICH INTERFERE WITH THE SYNAPTIC FUNCTION OF CATECHOLAMINES.
199958 02-04

THE INFLUENCE OF ALPHA-METHYLTYROSINE AND DISULFIRAM ON THE INHIBITORY FUNCTION OF THE CAUDATE NUCLEUS AND CATECHOLAMINE CONTENT IN THE BRAIN OF CATS.
200565 02-03

DPAM AND CEREBRAL FUNCTION (SECOND REPORT): PSYCHOPHARMACOLOGICAL IMPLICATIONS.
202162 02-11

CHANGES OF KINETIC CONSTANT OF STRIATAL TYROSINE-HYDROXYLASE ELICITED BY NEUROLEPTICS THAT IMPAIR THE FUNCTION OF DOPAMINE RECEPTORS.
202716 02-03

LIVER FUNCTION IN WORKERS OCCUPATIONALLY DEALING WITH CHLORPROMAZINE AND SOME OTHER COMPOUNDS.
202925 02-13

LITHIUM TREATMENT AND THYROID FUNCTION IN MAN.
205611 03-15

THE EFFECTS OF CHRONIC PHENOTHIAZINE TREATMENT ON ADRENAL PITUITARY FUNCTION IN MAN.
205765 03-13

RENAL TUBULAR FUNCTION IN PATIENTS ON LONG-TERM LITHIUM THERAPY.
207043 03-13

RECOVERY OF FUNCTION AND CHANGES IN SENSITIVITY TO AMPHETAMINE FOLLOWING CAUDATE LESIONS IN RATS.
209962 03-03

THE EFFECT OF SODIUM CHLORIDE ON KIDNEY FUNCTION IN RATS WITH LITHIUM INTOXICATION.
210696 03-03

THE EFFECT OF DIPHENYLHYDANTOIN ON BRAIN 5-HYDROXYTRYPTAMINE METABOLISM AND FUNCTION.
210764 03-03

ON A PRIME ROLE FOR NEWLY SYNTHESIZED DOPAMINE IN STRIATAL FUNCTION.
210862 03-03

NEUROPHARMACOLOGIC STUDIES OF LOCAL BRAIN FUNCTION.
213601 04-03

THE ROLE OF TYROSINE TRANSAMINASE IN BRAIN FUNCTION.
213607 04-03

ZINC AND HIPPOCAMPAL FUNCTION.
214716 04-03

ORTHOMOLECULAR TREATMENT IN DISTURBANCES INVOLVING BRAIN FUNCTION.
214719 04-11

STRATEGIES FOR THE SYSTEMATIC STUDY OF NEUROTRANSMITTER RECEPTOR FUNCTION IN MAN.
215860 04-16

THE EFFECTS OF PYRITHIOXINE ON THE BEHAVIOUR AND INTELLECTUAL FUNCTION OF LEARNING DISABLED CHILDREN.
216485 04-11

INTERRESPONSE TIME CHANGES AS A FUNCTION OF WATER DEPRIVATION AND AMPHETAMINE.
217459 04-04

A COMPARISON OF THE INDUCTIVE EFFECTS OF PHENOBARBITAL, METHAQUALONE, AND METHYPRYLON ON HEPATIC MIXED FUNCTION OXIDASE ENZYMES IN THE RAT.
217794 04-03

THE USE OF DESIPRAMINE IN STUDIES OF NORADRENERGIC NERVE FUNCTION.
217882 04-03

RECOVERY OF FUNCTION: SOME NEW THOUGHTS ON AN OLD PROBLEM. (PH.D. DISSERTATION).
219268 04-04

THE EFFECT OF PSYCHOTROPIC AGENTS ON THE ELECTROENCEPHALOGRAPHIC CHARACTERISTICS OF THE INHIBITORY FUNCTION OF THE CAUDATE NUCLEUS.
219500 04-03

PHARMACOLOGICALLY INDUCED BEHAVIORAL CORRELATES OF NIGROSTRIATAL FUNCTION. (PH.D. DISSERTATION).
220473 04-04

THE DOPAMINERGIC COMPONENT IN THE ACTION OF D,L-AMPHETAMINE ON THE INHIBITORY FUNCTION OF THE CAUDATE NUCLEUS.
223014 04-03

THE INFLUENCE OF SOME PHENOTHIAZINE DERIVATIVES ON RENAL FUNCTION.
223019 04-05

FUNCTIONAL

NEONATAL CHEMICAL SYMPATHECTOMY: FUNCTIONAL CONTROL OF DENERVATION OF THE VASCULAR SYSTEM AND TISSUE NORADRENALINE LEVEL IN THE RAT AFTER 6-HYDROXYDOPAMINE.
197584 01-03

MORPHOLOGICAL, BIOCHEMICAL, AND FUNCTIONAL CHANGES IN CHICK EMBRYONIC BRAIN TISSUE AFTER INTRACEREBRAL ADMINISTRATION OF OUABAIN.
197788 01-03

EVIDENCE FOR THE FUNCTIONAL INTERACTION OF TWO CENTRAL NEUROTRANSMITTERS.
201324 02-03

THE USE OF MEGIMIDE IN FUNCTIONAL EEG.
205566 02-13

FUNCTIONAL ANATOMICAL STUDIES OF THE RAPHE NUCLEI.
206108 03-03

CEREBRAL FUNCTIONAL EFFECTS OF 2-DEOXY-D-GLUCOSE AND 3-O-METHYLGLUCOSE IN RHESUS MONKEYS.
210355 03-03

REGIONAL AND SUBCELLULAR DISTRIBUTION AND KINETIC PROPERTIES OF RAT BRAIN CHOLINE ACETYLTRANSFERASE -- SOME FUNCTIONAL CONSIDERATIONS.
210816 03-03

CENTRAL NEUROPHYSIOLOGY OF THE FUNCTIONAL PSYCHOSES.
213614 04-11

FUNCTIONAL AND BIOCHEMICAL ASPECTS OF CATECHOLAMINE METABOLISM IN BRAIN UNDER HYPOXIA.
217852 04-03

FUNCTIONING

THE EFFECT OF LITHIUM ON THYROID FUNCTIONING: A CONTROLLED STUDY.
195916 01-09

A CONTROLLED COMPARISON OF THE EFFECTS OF DIPHENYLHYDANTOIN AND PLACEBO ON MOOD AND PSYCHOMOTOR FUNCTIONING IN NORMAL VOLUNTEERS.
199518 02-14

FUNCTIONS

COMBINED EFFECTS OF DIAZEPAM AND ETHANOL ON MENTAL AND PSYCHOMOTOR FUNCTIONS.
199896 02-14

THE EFFECT OF SEDUXEN ON THE PERCEPTIVE AND SOME OTHER FUNCTIONS OF THE CENTRAL NERVOUS SYSTEM UNDER EMOTIONAL STRESS IN MAN.
201916 02-14

EFFECT OF EARLY L-DOPA ADMINISTRATION ON THE ONTOGENY OF MOTOR FUNCTIONS IN THE RAT.
202266 02-03

PSYCHOTROPIC DRUGS, OVARIAN FUNCTIONS AND MAMMARY ACTIVITY.
214055 04-03

ROLE OF BRAIN SEROTONIN IN THE INTEGRATION OF BEHAVIORAL RESPONSES AND PITUITARY ADRENOCORTICAL FUNCTIONS UNDER EMOTION.
218364 04-04

DOSE EFFECTS OF SMOKED MARIHUANA ON HUMAN COGNITIVE AND MOTOR FUNCTIONS.
221036 04-01

NYSTAGMUS AND DISTURBANCES IN PSYCHOMOTOR FUNCTIONS INDUCED BY PSYCHOTROPIC DRUG THERAPY.
221990 04-15

U-SHAPED FUNCTIONS IN A SHOCK ESCAPE TASK.
222265 04-04

FUNDAL

5-HYDROXYTRYPTAMINE-14C AND DEXAMPHETAMINE-14C UPTAKE BY FUNDAL SARCOLEMMA PREPARATIONS AND THE PROBLEM OF THE COMMON RECEPTOR.
213591 04-03

FUSARIC

EVIDENCE FOR A PERIPHERAL EFFECT OF FUSARIC ACID, A DOPAMINE-BETA-HYDROXYLASE INHIBITOR, ON SEROTONIN METABOLISM.
196593 01-03

INHIBITION OF DOPAMINE-BETA-HYDROXYLASE IN MANIC PATIENTS: A CLINICAL TRIAL WITH FUSARIC ACID.
199632 02-07

BEHAVIORAL EFFECTS OF A NEW DOPAMINE-BETA-HYDROXYLASE INHIBITOR (FUSARIC ACID) IN MAN.
207311 03-07

FUSED

A DUAL STUDY. PART I: SYNTHESIS AND STEREOCHEMISTRY OF SOME 1 SUBSTITUTED QUINOLIZIDINES AS ANALOGS OF BIOLOGICALLY ACTIVE COMPOUNDS. PART II: AMINO DERIVATIVES OF THIOPHENE FUSED CYCLIC KETONES AS POTENTIAL CNS. (PH.D. DISSERTATION).
196252 01-01

G-130

TOXICOLOGICAL AND TERATOLOGICAL STUDY OF 2-PHENYLDIMETHYLTETRAHYDROOXAZINE HYDROCHLORIDE (G-130), A PSYCHOSTIMULANT DRUG.
206783 03-05

ANTAGONISM OF PSYCHOSTIMULANT 2 PHENYLDIMETHYLTETRAHYDROOXAZINE HYDROCHLORIDE (G-130) TO CENTRAL NERVOUS SYSTEM DEPRESSING DRUGS: MONOAMINEOXIDASE INHIBITORY ACTIVITY AND NOREPINEPHRINE AND SEROTONIN INDUCED CHANGES, COMPARISON WITH DL-AMPHETAMINE.
221267 04-03

GABA

ACTIONS OF GABA, PICROTOXIN AND BICUCULLINE ON ADRENAL MEDULLA.
193455 01-03

REGIONAL LEVELS OF GABA AND GLUTAMATE IN MOUSE BRAIN FOLLOWING EXPOSURE TO PAIN.
195097 01-03

ON THE MECHANISM OF ACTION OF GAMMA-HYDROXYBUTYRIC ACID: LACK OF CONVERSION TO GABA IN MOUSE BRAIN IN VIVO.
197965 01-03

GABA BLOCKADE, DOPAMINE AND SCHIZOPHRENIA: EXPERIMENTAL STUDIES IN THE CAT.
200052 02-03

CHANGES IN MENTAL AGE WITH SUBNORMAL CHILDREN TREATED WITH DOSES OF GABA AND NUCLEOTIDES.
210286 03-14

THE PASSATIZATION INDEX OF RETARDATES TREATED WITH HIGH DOSES OF GABA AND NUCLEOTIDES.
210288 03-11

MNEMONIC CAPACITY OF MENTALLY RETARDED BOYS TREATED WITH HIGH DOSES OF NUCLEOTIDES AND GABA.
210291 03-14

TEMPORAL DISCRIMINATION TESTS IN MENTAL RETARDATES TREATED WITH NUCLEOTIDES AND GABA IN HIGH DOSES.
210293 03-14

THE EFFECTS OF NUCLEOTIDES AND GABA IN LARGE DOSES ON THE RESPONSE TO A PAINFUL STIMULUS WITH RETARDATES.
210296 03-14

HIGH AFFINITY UPTAKE OF GABA IN PRESUMED GABA-ERGIC NERVE ENDINGS IN RAT BRAIN.
211062 03-03

INHIBITION OF SACRAL PARASYMPATHETIC PREGANGLIONIC NEURONS BY GABA, GLYCIN, 5-HYDROXYTRYPTAMINE AND NOREPINEPHRINE. (PH.D. DISSERTATION).
212524 03-03

ACTION OF DIAZEPAM, DIBUTYRYL-CGMP, AND GABA ON PRESYNAPTIC NERVE TERMINALS IN BULLFROG SYMPATHETIC GANGLIA.
217873 04-03

A GABA HYPOTHESIS FOR THE ACTION OF BENZODIAZEPINES. (UNPUBLISHED PAPER).
218149 04-03

EFFECT OF DRUG-INDUCED INCREASE OF BRAIN GABA LEVELS ON PENICILLIN FOCUS.
220947 04-03

GABA-ERGIC

HIGH AFFINITY UPTAKE OF GABA IN PRESUMED GABA-ERGIC NERVE ENDINGS IN RAT BRAIN.
211062 03-03

GALACTORRHOEA

BROM-ERGOCRYPTINE IN THE TREATMENT OF PHENOTHIAZINE INDUCED GALACTORRHOEA.
218557 04-15

GALVANIC

HEART RATE AND GALVANIC SKIN RESPONSE VARIATIONS DURING THE REM AND NON-REM SLEEP PHASES IN MAN.
205443 02-13

GALVANIC SKIN RESISTANCE (GSR) MEASUREMENTS ON VOLUNTEERS RECEIVING FENFLURAMINE OR D-AMPHETAMINE.
225062 04-13

GAMMA

THE ROLE OF 5-HYDROXYTRYPTAMINE IN THE CONTROL OF ALPHA AND GAMMA MOTONEURONS. (PH.D. DISSERTATION).
212522 03-03

GAMMA-AMINOBUTYRIC

EFFECT OF DESIPRAMINE AND PARGYLINE ON BRAIN GAMMA-AMINOBUTYRIC ACID.
205851 03-03

GAMMA-AMINOBUTYRIC ACID AND CEREBRAL METABOLISM.
212277 03-13

SYNERGISM BETWEEN GAMMA-AMINOBUTYRIC ACID AND BUTYROPHENONES ADMINISTERED MICROELECTROPHORETICALLY IN THE PURKINJE CELLS OF THE CAT CEREBELLUM.
220904 04-03

GAMMA-HYDROXYBUTYRATE

ACTIVATION OF EEG BY GAMMA-HYDROXYBUTYRATE (GHB) IN ORGANIC BRAIN DISORDERS.
205460 02-13

EFFECT OF SODIUM GAMMA-HYDROXYBUTYRATE ON ISOLATION INDUCED AGGRESSIVITY IN MICE.
205588 02-04

GAMMA-HYDROXYBUTYRATE AND CONTROL OF DOPAMINERGIC NEURONS.
213626 04-03

THE EFFECT OF SODIUM GAMMA-HYDROXYBUTYRATE ON THE CNS OF RATS AND MICE.
215069 04-03

GAMMA-HYDROXYBUTYRIC

BEHAVIOURAL INTERACTIONS BETWEEN IMIDAZOLEACETIC ACID AND GAMMA-HYDROXYBUTYRIC ACID IN RATS AND MICE.
193545 01-04

INCREASE IN BRAIN DOPAMINE AFTER AXOTOMY OR TREATMENT WITH GAMMA-HYDROXYBUTYRIC ACID DUE TO ELIMINATION OF THE NERVE IMPULSE FLOW.
195439 01-03

EFFECTS OF DRUGS INFLUENCING MONOAMINE MECHANISMS ON THE INCREASE IN BRAIN DOPAMINE PRODUCED BY AXOTOMY OR TREATMENT WITH GAMMA-HYDROXYBUTYRIC ACID.
195440 01-03

ON THE MECHANISM OF ACTION OF GAMMA-HYDROXYBUTYRIC ACID: LACK OF CONVERSION TO GABA IN MOUSE BRAIN IN VIVO.
197965 01-03

GANGLIA

CATECHOLAMINES IN SYMPATHETIC GANGLIA OF RAT: EFFECTS OF DEXAMETHASONE AND RESERPINE.
210766 03-03

EVOKED NEURAL ACTIVITY IN THE BASAL GANGLIA OF THE CAT AND ITS MODIFICATION BY CHOLINERGIC AND DOPAMINERGIC AGENTS. (PH.D. DISSERTATION).
212520 03-03

INDUCTION OF TYROSINE-HYDROXYLASE ELICITED BY BETA ADRENERGIC RECEPTOR AGONISTS IN NORMAL AND DECENTRALIZED SYMPATHETIC GANGLIA: ROLE OF CYCLIC 3,5 ADENOSINE-MONOPHOSPHATE.
215688 04-03

DEVELOPMENTAL VARIATIONS OF CHOLINE ACETYLTRANSFERASE, DOPAMINE-BETA-HYDROXYLASE AND MONOAMINEOXIDASE IN CHICKEN EMBRYO AND CHICKEN SYMPATHETIC GANGLIA.
217840 04-03

DEXAMETHASONE INDUCES TYROSINE-HYDROXYLASE IN SYMPATHETIC GANGLIA BUT NOT IN ADRENAL MEDULLA.
217853 04-03

ACTION OF DIAZEPAM, DIBUTYRYL-CGMP, AND GABA ON PRESYNAPTIC NERVE TERMINALS IN BULLFROG SYMPATHETIC GANGLIA.
217873 04-03

GANGLION
MINIMUM DURATION OF TRANS-SYNAPTIC STIMULATION REQUIRED FOR THE INDUCTION OF TYROSINE-HYDROXYLASE BY RESERPINE IN THE RAT SUPERIOR CERVICAL GANGLION.
199999 02-03
ONTOGENY OF THE INDUCTION OF TYROSINE-HYDROXYLASE BY RESERPINE IN THE SUPERIOR CERVICAL GANGLION, NUCLEUS LOCUS-COERULEUS AND ADRENAL GLAND.
210670 03-03
A PROLONGED AFTEREFFECT OF INTENSE SYNAPTIC ACTIVITY ON ACETYLCHOLINE IN A SYMPATHETIC GANGLION.
211102 03-03

GANGLIONIC
DOXEPIN AND IMIPRAMINE: EFFECT ON CATECHOLAMINE INHIBITION OF GANGLIONIC TRANSMISSION.
225059 04-03

GAS
GAS CHROMATOGRAPHIC ANALYSES OF BARBITURATES IN SMALL AMOUNTS OF BLOOD.
197279 01-01
ON THE GAS CHROMATOGRAPHIC ANALYSIS OF BENZODIAZEPINES: SECOND COMMUNICATION: DIAZEPAM AND ITS METABOLITES.
221739 04-06
RAPID MASS SCREENING AND CONFIRMATION OF URINARY AMPHETAMINE AND METHAMPHETAMINE BY GAS CHROMATOGRAPHY.
222829 04-06
RAPID ANALYSIS OF THE CENTRAL NERVOUS SYSTEM STIMULANTS, AMPHETAMINES, VIA GAS CHROMATOGRAPHY MASS SPECTROMETRY: RAPID ACYLATION IN THE PRESENCE OF A MERCURY CATALYST.
222830 04-06

GASTRIC
SYMPATHOMIMETIC AMINES AND GASTRIC SECRETION IN RATS.
199622 02-03
THE EFFECTS OF CHLORPROMAZINE, ATROPINE, MORPHINE AND PENTOBARBITAL ON INDUCED GASTRIC ULCERATION IN RATS. (PH.D. DISSERTATION).
200405 02-02

GASTRIN
THE EFFECTS OF LITHIUM CARBONATE ON SERUM GASTRIN IN PSYCHIATRIC PATIENTS.
200637 02-04

GASTROINTESTINAL
TREATMENT OF PSYCHOSOMATIC GASTROINTESTINAL DISORDERS IN OUTPATIENTS.
210513 03-11
LORAZEPAM IN THE MANAGEMENT OF GASTROINTESTINAL NEUROSES.
215061 04-10
A COMPARISON OF THE ACTION OF THE TRICYCLIC ANTIDEPRESSANTS, AZAPHEN AND IMIPRAMINE, ON THE GASTROINTESTINAL TRACT OF TEST ANIMALS.
219505 04-03

GB-94
REPORT ON A PRELIMINARY CLINICAL STUDY OF MIANSERIN (GB-94), A TETRACYCLIC ANTIDEPRESSANT, AN OPEN TRIAL.
207283 03-03

GENERALIZATION
DISCRIMINATIVE CONTROL OF BEHAVIOR BY ELECTRICAL STIMULATION OF THE DORSAL RAPHE NUCLEUS: GENERALIZATION TO LYSERGIC ACID DIETHYLAMIDE (LSD).
217821 04-12
POISON INDUCED NEOPHOBIA IN RATS: ROLE OF STIMULUS GENERALIZATION OF CONDITIONED TASTE AVERSIONS.
223254 04-04

GENERIC
BIOLOGICAL AND PHARMACOKINETIC EVIDENCE FOR GENERIC EQUIVALENCE OF THREE IMIPRAMINE PREPARATIONS: COMPARISON WITH A NEW IMIPRAMINE ANALOGUE.
211071 03-02
PILOT STUDY OF 2-PYRROLIDON ACETAMIDE (GENERIC NAME: PIRACETAM).
221338 04-08

GENETIC
GENETIC DETERMINANT OF LITHIUM ION DISTRIBUTION. I. AN IN VITRO MONOZYGOTIC DIZYGOTIC TWIN STUDY.
194826 01-13
TREATMENT OF RESISTANT DEPRESSION: CONTRIBUTIONS TO GENETIC ASPECTS.
203596 02-09
FROM PSYCHOPHARMACOLOGY TO PSYCHOPHARMACOGENETICS: DETERMINANTS OF THE EFFECTS OF DRUGS ON BEHAVIOR, ROLE OF GENETIC FACTORS.
210530 03-14
GENETIC DETERMINANT OF LITHIUM ION METABOLISM: II. AN IN VIVO STUDY OF LITHIUM ION DISTRIBUTION ACROSS ERYTHROCYTE MEMBRANES.
211412 03-03
MORPHINE SENSITIVITY AND TOLERANCE: A GENETIC INVESTIGATION IN THE MOUSE.
221037 04-03
A GENETIC ANALYSIS OF THE RESPONSE TO MORPHINE IN MICE: ANALGESIA AND RUNNING.
221042 04-03
GENETIC, BIOCHEMICAL, AND ENVIRONMENTAL VARIABLES IN THE EXPRESSION OF SHORT-TERM MEMORY IN THE MOUSE. (PH.D. DISSERTATION).
222749 04-04
GENETIC CONTROL OF LITHIUM ION DISTRIBUTION.
224833 04-09
A GENETIC ANALYSIS OF MORPHINE-INDUCED RUNNING AND ANALGESIA IN THE MOUSE.
225557 04-04

GENETICALLY
GENETICALLY SELECTED WINNER AND LOSER RATS IN THE TUNNEL COMPETITION: INFLUENCE OF APOMORPHINE AND DOPA.
217829 04-04

GENICULATE
SEROTONIN IN THE LATERAL GENICULATE.
218499 04-03

GENOTYPE
GENOTYPE DEPENDENT ELECTROENCEPHALOGRAPHIC, BEHAVIORAL AND ANALGESIC CORRELATES OF MORPHINE: AN ANALYSIS IN NORMAL MICE AND IN MICE WITH SEPTAL LESIONS.
203520 02-04
GENOTYPE OR PRENATAL DRUG EXPERIENCE AFFECT BRAIN MATURATION IN THE MOUSE.
221032 04-03

GENTAMYCIN
THE EFFECT OF BEDREST AND OF PHYSICAL ACTIVITY ON THE BLOOD LEVEL OF GENTAMYCIN AFTER INTRAMUSCULAR APPLICATION.
197956 01-13

GERBIL
THE EFFECTS OF D- AND L-AMPHETAMINE UPON HOARDING BEHAVIOR AND FEEDING IN THE MONGOLIAN GERBIL (MERIONES-UNGUICULATUS).
202983 02-04
THE EFFECTS OF MEVINPHOS ON APPETITIVE OPERANT BEHAVIOR IN THE GERBIL.
217545 04-04
ACUTE AND CHRONIC EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON SEIZURES IN THE GERBIL.
217673 04-03
ANTAGONISM OF PENTOBARBITAL INDUCED DISCRIMINATION IN THE GERBIL.
225561 04-04

GERDAXYL
CLINICAL STUDY OF GERDAXYL 10MG WITH 40 PATIENTS TREATED IN A PSYCHIATRIC OUTPATIENT FACILITY.
202037 02-11

GERIATRIC
DIFFERENTIAL EFFECTS OF D-AMPHETAMINE ON BRAIN ACETYLCHOLINE IN YOUNG, ADULT, AND GERIATRIC RATS.
193457 01-03
THE EEG EFFECTS OF ZINC IN GERIATRIC PSYCHIATRIC PATIENTS.
195039 01-13
PAPAVERIN IN THE TREATMENT OF GERIATRIC PATIENTS.
205606 03-11
PSYCHOPHARMACOLOGY IN THE AGED: USE OF PSYCHOTROPIC DRUGS IN GERIATRIC PATIENTS.
208571 03-11
PSYCHOPHARMACOLOGY IN THE AGED: RESEARCH CONSIDERATIONS IN GERIATRIC PSYCHOPHARMACOLOGY.
208573 03-11
MANAGING DISTURBED GERIATRIC PATIENTS WITH CHEMOTHERAPY.
218010 04-11
WITHDRAWN, APATHETIC GERIATRIC PATIENTS RESPONSIVE TO METHYLPHENIDATE.
218216 04-11

GERIATRICS
SOCIOPSYCHIATRIC SIGNIFICANCE OF THE APPLICATION OF PSYCHOTROPICS IN GERIATRICS.
198394 02-11

GEROVITAL
MORE EVIDENCE FAVORS YOUTH DRUG: FIRST DOUBLE-BLIND TRIALS SHOW GEROVITAL HAS SOME EFFECT ON AGING.
221352 04-11

GHB
ACTIVATION OF EEG BY GAMMA-HYDROXYBUTYRATE (GHB) IN ORGANIC BRAIN DISORDERS.
205460 02-13

GHOSTS
MG+ + DEPENDENT ADENOSINE-TRIPHOSPHATASE ACTIVITY IN ERYTHROCYTE GHOSTS OF SCHIZOPHRENIC PATIENTS.
206332 03-08

GIANT
INEFFECTIVENESS OF LYSERGIC ACID DIETHYL AMIDE 25 (LSD) ON ALTERING NA-K CURRENTS IN SQUID GIANT AXON.
194927 01-03

GILLES-DE-LA-TOURETTES
MULTIPLE TIC SYNDROME (GILLES-DE-LA-TOURETTES SYNDROME): CLINICAL, BIOLOGICAL, AND PSYCHOSOCIAL VARIABLES AND THEIR INFLUENCE WITH HALOPERIDOL.
199473 02-11
GILLES-DE-LA-TOURETTES SYNDROME AND DEPRESSION: A CASE REPORT.
206939 03-09
SEXUALITY AND GILLES-DE-LA-TOURETTES SYNDROME.
207957 03-11

GLAD
FROM SAD TO GLAD: KLINE ON DEPRESSION.
216706 04-17

GLAND
THE EFFECT OF PSYCHOPHARMACOLOGICAL DRUGS ON PUFFING AND ON RNA AND DNA SYNTHESES IN THE SALIVARY GLAND CHROMOSOMES OF DROSOPHILA-MELANOGASTER. (PH.D. DISSERTATION).
196250 01-03
ONTOGENY OF THE INDUCTION OF TYROSINE-HYDROXYLASE BY RESERPINE IN THE SUPERIOR CERVICAL GANGLION, NUCLEUS LOCUS-COERULEUS AND ADRENAL GLAND.
210670 03-03
INHIBITION OF CATECHOLAMINE AND 5-HYDROXYTRYPTAMINE INDUCED ENZYME SECRETION FROM THE GUINEA-PIG SUBMANDIBULAR GLAND BY 2-BROMO-D-LYSERGIC ACID DIETHYLAMIDE.
216968 04-03

GLAUCOMA
POSSIBILITIES AND LIMITATIONS OF PSYCHOTROPIC THERAPY IN PATIENTS WITH GLAUCOMA.
201911 02-15

GLC
GLC DETERMINATION OF PROPRANOLOL, OTHER BETA-BLOCKING DRUGS, AND METABOLITES IN BIOLOGICAL FLUIDS AND TISSUES.
200740 02-16

GLOBUS-PALLIDUS
EFFECTS OF RESERPINE AND L-DOPA IN THE GLOBUS-PALLIDUS OF FREELY BEHAVING RATS.
220975 04-03

GLUCAGON
EFFECT OF PROLONGED LITHIUM INGESTION ON GLUCAGON AND PARATHYROID HORMONE RESPONSES IN RATS.
197744 01-03
EFFECT OF LITHIUM ON GLUCAGON STIMULATED CYCLIC-AMP EXCRETION IN RATS.
213481 04-03

GLUCOCORTICOIDS
ADRENAL GLUCOCORTICOIDS AS A REQUIRED FACTOR IN THE DEVELOPMENT OF ETHANOL WITHDRAWAL SEIZURES IN MICE.
213479 04-03
MIDBRAIN RAPHE NEURONS: SENSITIVITY TO GLUCOCORTICOIDS AND ACTH IN THE RAT.
217863 04-03

GLUCONATE
LITHIUM GLUCONATE: SYSTEMATIC AND FACTORIAL ANALYSIS OF 104 OBSERVATIONS OVER 2.5-3 YEARS IN PATIENTS PRESENTING CYCLOTHYMIC OR DYSTHYMIC DISORDERS.
210126 03-09

GLUCOPHAGE
METFORMIN (GLUCOPHAGE) IN THE TREATMENT OF DRUG-INDUCED OBESITY.
221821 04-13

GLUCOSE
EFFECT OF ORAL AND INTRAMUSCULAR ROUTES OF ADMINISTRATION ON SERUM CHLORDIAZEPOXIDE LEVELS AND THE PREDICTION OF THESE LEVELS FROM PREDRUG FASTING SERUM GLUCOSE CONCENTRATIONS.
195055 01-13
THE INCORPORATION OF GLUCOSE INTO BRAIN GLYCOGEN AND THE ACTIVITIES OF CEREBRAL GLYCOGEN PHOSPHORYLASE AND SYNTHETASE: SOME EFFECTS OF AMPHETAMINE.
196808 01-03
GLUCOSE RELEASE OF THE RAT KIDNEY IN VIVO AFTER BETA-ADRENERGIC STIMULATION AND BLOCKADE.
197946 01-03
THE INHIBITORY EFFECT OF TOLUIDINE BLUE AND METHYLENE BLUE ON RAT MAST CELL DAMAGE BY PROMETHAZINE, CHLORPROMETHAZINE AND CHLORPROMAZINE. ITS REVERSAL BY GLUCOSE.
199255 02-05

GLUCOSE-14C
EFFECTS OF PSYCHOTROPIC DRUGS ON THE INCORPORATION OF GLUCOSE-14C INTO AMINO ACIDS OF THE RAT BRAIN.
198026 01-03

GLUCURONIDE
URINARY EXCRETION OF THE SULPHATE AND GLUCURONIDE OF 3-METHOXY-4-HYDROXYPHENYLETHYLENEGLYCOL IN A MANIC-DEPRESSIVE PATIENT.
224424 04-09

GLUTAMATE
REGIONAL LEVELS OF GABA AND GLUTAMATE IN MOUSE BRAIN FOLLOWING EXPOSURE TO PAIN.
195097 01-03
PHARMACOLOGY OF MAGNESIUM GLUTAMATE HYDROBROMIDE (PS-042), A NEW TRANQUILIZER: THIRD PART, PSYCHOPHARMACOLOGICAL STUDIES.
196444 01-02
(3H)GLUTAMATE UPTAKE AT INSECT NEUROMUSCULAR JUNCTIONS: EFFECT OF CHLORPROMAZINE.
213474 04-03

GLUTAMIC
A COMPARATIVE STUDY OF THE EFFECTIVENESS OF ENERBOL AND GLUTAMIC ACID IN OLIGOPHRENIC CHILDREN.
219662 04-11
EFFECTS OF AMINERGIC DRUGS AND GLUTAMIC ACID ON AUDIOGENIC SEIZURES INDUCED BY EARLY EXPOSURE TO ETHANOL.
225527 04-03

GLYCERYL
HEAT PRODUCTION AND OXYGEN CONSUMPTION OF THE ISOLATED RABBIT HEART UNDER THE INFLUENCE OF STROPHANTHIN VERAPAMIL, AND GLYCERYL TRINITRATE.
197567 01-03

GLYCIN
INHIBITION OF SACRAL PARASYMPATHETIC PREGANGLIONIC NEURONS BY GABA, GLYCIN, 5-HYDROXYTRYPTAMINE AND NOREPINEPHRINE. (PH.D. DISSERTATION).
212524 03-03

GLYCOGEN
THE INCORPORATION OF GLUCOSE INTO BRAIN GLYCOGEN AND THE ACTIVITIES OF CEREBRAL GLYCOGEN PHOSPHORYLASE AND SYNTHETASE: SOME EFFECTS OF AMPHETAMINE.
196808 01-03
THE INFLUENCE OF ANTIADRENERGIC AND ANTIDOPAMINERGIC DRUGS ON METHAMPHETAMINE INDUCED CHANGES IN MOTORIC ACTIVITY AND CEREBRAL GLYCOGEN CONTENT IN MICE.
204396 02-03
THE EFFECT OF RESERPINE AND CHLORIMIPRAMINE ON GLYCOGEN CONTENT IN DIFFERENT BRAIN STRUCTURES OF RAT.
211106 03-03

GLYCOL
POLYETHYLENE GLYCOL INDUCED THIRST: A DUAL STIMULATORY MECHANISM?
219071 04-04

GLYOXYLIC
A RAPID, SIMPLE AND MORE SENSITIVE METHOD FOR THE DEMONSTRATION OF CENTRAL CATECHOLAMINE CONTAINING NEURONS AND AXONS BY GLYOXYLIC ACID INDUCED FLUORESCENCE: I. SPECIFICITY.
217550 04-16

GNAWING
INVESTIGATION OF THE MECHANISM BY WHICH L-DOPA INDUCES GNAWING IN MICE.
198014 01-04

GOAL
MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 1. COMMUNICATION: SETTING A GOAL AND METHODOLOGICAL GROUND RULES.
203839 02-13

GOATS
PHYSIOLOGIC, BIOCHEMICAL, AND CLINICAL EFFECTS OF KETAMINE HYDROCHLORIDE IN GOATS (CAPRA-HIRCUS) WITH AND WITHOUT PREMEDICATION. (PH.D. DISSERTATION).
194700 01-03

GOLDFISH
DIETHYLDITHIOCARBAMATE (ANTABUSE): DECREASE OF BRAIN HEAVY METAL STAINING PATTERN AND IMPROVED CONSOLIDATION OF SHUTTLEBOX AVOIDANCE IN GOLDFISH.
203521 02-04
ANTEROGRADE AND RETROGRADE EFFECTS OF ELECTROCONVULSIVE SHOCK AND OF PUROMYCIN ON MEMORY FORMATION IN THE GOLDFISH.
213853 04-04

GONADOTROPIN
THE SERUM GONADOTROPIN LEVEL UNDER THE MEDICATION OF L-DOPA.
204394 02-13

GRAND-ROUNDS
ANXIETY NEUROSIS, DEPRESSIVE DISORDER AND MEPROBAMATE ADDICTION -- PSYCHIATRIC GRAND-ROUNDS, UNIV. OF CALIFORNIA, SAN-DIEGO.
222772 04-10

GRANULE
IMMUNOLOGICAL LOCALIZATION OF DOPAMINE-BETA-HYDROXYLASE ON THE CHROMAFFIN GRANULE MEMBRANE.
207326 03-03

GRANULES
EFFECTS OF RESERPINE AND PRENYLAMINE ON THE NORADRENALINE FLUXES OF ISOLATED SPLENIC NERVE GRANULES.
197280 01-03
THE EFFECT OF DIPYRIDAMOLE ON THE NORADRENALINE TRANSPORT INTO NERVE GRANULES.
197942 01-03

GRAPHIC
RETESTING WITH GRAPHIC PRODUCTION: RESOLUTION OF A DIAGNOSTIC DILEMMA.
197600 01-09

GRAVID
EFFECTS ON THE ACQUISITION OF CONDITIONED AVOIDANCE RESPONSES AND SEIZURE THRESHOLD IN THE OFFSPRING OF AMPHETAMINE TREATED GRAVID RATS.
202722 02-05

GRAY
COMPARATIVE INVOLVEMENT OF DOPAMINE AND NORADRENALINE IN RATE-FREE SELF-STIMULATION IN SUBSTANTIA-NIGRA, LATERAL HYPOTHALAMUS, AND MESENCEPHALIC CENTRAL GRAY.
193303 01-03

GREAT-BRITAIN
NEW PSYCHOTROPIC DRUG DEVELOPMENTS IN GREAT-BRITAIN.
213599 04-17

GROOMING
EFFECTS OF RESERPINE, 6-HYDROXYDOPAMINE, P-CHLOROPHENYLALANINE AND A COMBINATION OF THESE SUBSTANCES ON THE GROOMING BEHAVIOUR OF MICE.
197291 01-04
PARTIAL RESTORATION BY AN A NEUROLEPTIC (SPIRAMIDE) OF ITEMS OF GROOMING BEHAVIOUR SUPPRESSED BY AMPHETAMINE.
213590 04-04

GROUND
MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 1. COMMUNICATION: SETTING A GOAL AND METHODOLOGICAL GROUND RULES.
203839 02-13

GROUP
FACTORS ASSOCIATED WITH TREATMENT SUCCESS IN LITHIUM CARBONATE PROPHYLAXIS: REPORT OF THE NIMH-VA COLLABORATIVE STUDY GROUP.
193068 01-09
GROUP THERAPY AND MAINTENANCE TREATMENT OF SCHIZOPHRENICS.
194860 01-08
CHLORDIAZEPOXIDE-INDUCED HOSTILITY IN A SMALL GROUP SETTING.
194865 01-14
PRETREATMENT OF PROBLEM YOUTHS WITH CLOZAPINE IN PREPARATION FOR GROUP PSYCHOTHERAPY.
203599 02-14
LONG-ACTING NEUROLEPTICS OF PERATHIEPINE GROUP: VUFB-9977 (OXYPROTHEPINE DECANOATE).
205583 02-03
COMPARATIVE STUDIES OF VERBAL INTERACTIONS IN A GROUP OF HEALTHY SUBJECTS UNDER THE INFLUENCE OF PSYCHOPHARMACOLOGICAL AGENTS: WITH SPECIAL CONSIDERATION OF YG-19256, CHLORDIAZEPOXIDE AND PLACEBO.
207140 03-14
HASHISH. IMPORTANCE OF THE PHENOLIC HYDROXYL GROUP IN TETRAHYDROCANNABINOLS.
208594 03-02
CLINICAL TRENDS AND PSYCHOMETRIC APPRAISAL OF A GROUP OF SCHIZOPHRENICS TREATED WITH THIOTHIXENE (NAVANE).
208981 03-08
THE EFFECTS OF A NEW SEDATIVE (LEXOTAN) ON REACTION TIMES AND ON ATTENTIVE CAPACITY OF A GROUP OF ATHLETES.
209857 03-14
A CLINICAL EXPERIMENTAL STUDY ON THE USE OF SULPIRIDE IN A GROUP OF CHRONIC SCHIZOPHRENICS (FIRST NOTE).
210510 03-08
EFFECT OF MESORIDAZINE ADMINISTRATION AND WITHDRAWAL ON PERFORMANCE IN AN OLDER AGE GROUP.
217452 04-11
ELECTROENCEPHALOGRAPHIC STUDY FOR THE EVALUATION OF THE EFFECTS OF 7-CHLORO-5-PHENYLBENZODIAZEPIN-2-ONE (N-DEMETHYLDIAZEPAM) ON SLEEP DISTURBANCES IN A GROUP OF MENTAL PATIENTS.
221272 04-14
TETRAHYDROCANNABINOL INDUCED MANIFESTATIONS OF THE MARIHUANA SYNDROME IN GROUP LIVING MACAQUES.
221340 04-04
LITHIUM PROPHYLAXIS: THE MARRIED COUPLES GROUP.
224749 04-09
MARIJUANA AND HOSTILITY IN A SMALL GROUP SETTING.
224754 04-14

GROUPED
EFFECTS OF PSYCHOTROPIC DRUGS ON METHAMPHETAMINE-INDUCED BEHAVIORAL EXCITATION IN GROUPED MICE.
215682 04-04

GROUPS
A CONTROLLED SERIES OF EXPERIMENTS INVESTIGATING SOME SOCIOLOGICAL EFFECTS OF TWO DOSAGES OF CHLORDIAZEPOXIDE (LIBRIUM) UPON INDIVIDUALS AND SMALL GROUPS. (PH.D. DISSERTATION).
195145 01-14
DRUG STUDIES IN NORMAL FEMALES, SENIOR CITIZENS, AND IN EXPERIMENTAL GROUPS.
198071 01-07
REACTION OF CATIONIC GROUPS OF CHLORPROMAZINE WITH ANIONIC MACROMOLECULES: COMPLEXES WITH DNA, RNA, HYALURONIC ACID AND HEPARIN.
199897 02-03

GROWTH
EFFECTS OF CENTRAL ACTING DRUGS AND ERGOT DERIVATIVES ON PROLACTIN AND GROWTH HORMONE SECRETION, ON GROWTH OF PITUITARY AND MAMMARY TUMORS AND ON REPRODUCTION IN OLD RATS. (PH.D. DISSERTATION).
194571 01-03
HYPOTHALAMIC SELF-STIMULATION IN RATS FOLLOWING IMMUNOSYMPATHECTOMY OR CENTRAL NERVE GROWTH FACTOR ANTISERUM INJECTION.
211512 03-04
HUMAN GROWTH HORMONE RESPONSE TO LEVODOPA: RELATION TO MENOPAUSE, DEPRESSION, AND PLASMA DOPA CONCENTRATION.
213918 04-09
GROWTH HORMONE AND PROLACTIN RELEASE AFTER INJECTION OF THYROTROPIN-RELEASING HORMONE IN PATIENTS WITH DEPRESSION.
214885 04-13
THE EFFECT OF ACTH AND DIAZEPAM, ADMINISTERED TO INFANT RATS ON THE BODY GROWTH CURVE AND SOME ENDOCRINE PARAMETERS MEASURED IN ADULT AGE.
215066 04-03
EFFECT OF CHRONIC PHENOBARBITAL ADMINISTRATION UPON BRAIN GROWTH OF THE INFANT RAT.
217885 04-03
CENTRAL STIMULATING AGENTS AND POPULATION GROWTH IN MICE.
221052 04-04
GROWTH HORMONE RELEASE AND CATECHOLAMINES IN AFFECTIVE DISEASE.
224773 04-13
CHILDHOOD CHEMOTHERAPY AND LATER DRUG ABUSE AND GROWTH CURVE: A FOLLOWUP STUDY OF 30 ADOLESCENTS.
225382 04-14

GSR
GALVANIC SKIN RESISTANCE (GSR) MEASUREMENTS ON VOLUNTEERS RECEIVING FENFLURAMINE OR D-AMPHETAMINE.
225062 04-13

GUANABENZ
INHIBITION OF EFFECTS OF ACCELERATOR NERVE STIMULATION IN CATS AND RABBITS BY BS-100-141 AND GUANABENZ.
197971 01-03

GUANETHIDINE
THE EFFECTS OF 6-HYDROXYDOPAMINE AND GUANETHIDINE ON PERIPHERAL ADRENERGIC NERVES IN THE GUINEA-PIG.
199862 02-03

GUANOSINE
THE REGULATION OF CYCLIC GUANOSINE MONOPHOSPHATE IN RAT CEREBELLUM: POSSIBLE INVOLVEMENT OF PUTATIVE AMINO ACID NEUROTRANSMITTERS.
202717 02-03

GUIDANCE
TESTING ANATENSOL DECANOATE, A MAJOR NEUROLEPTIC, AT THE IXELLES GUIDANCE CENTER.
212165 03-09

GUIDE
A SIMPLIFIED GUIDE TO THE RATIONAL USE OF PSYCHOTROPIC DRUGS.
196231 01-17
GUIDE TO PSYCHIATRY.
209428 03-17

GUIDELINE
NEUROLEPTICS AS A GUIDELINE TO BIOLOGICAL RESEARCH IN PSYCHOTIC DISORDERS.
207765 03-17

GUILT
WHATS IN A WORD? OR GUILT BY DEFINITION.
221563 04-17

GUINEA-PIG
EFFECTS OF THE NORADRENALINE METABOLITES ON TYROSINE-HYDROXYLASE ACTIVITY IN GUINEA-PIG ATRIA.
193279 01-02
POTENTIATION BY 3,4 DIMETHOXYPHENYLETHYLAMINE (DMPEA) AND COCAINE OF NOREPINEPHRINE-INDUCED CONTRACTION OF GUINEA-PIG VAS-DEFERENS.
194156 01-03

6-HYDROXYDOPAMINE INDUCED DEGENERATION OF NORADRENALINE NEURONS IN THE SCORBUTIC GUINEA-PIG.
195449 01-03

ADENOSINE-3-5-MONOPHOSPHATE IN CEREBRAL CORTICAL SLICES FROM GUINEA-PIG AND RAT: EFFECT OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC COMPOUNDS.
197293 01-03

ACUTE TOLERANCE, AND DEPENDENCE IN GUINEA-PIG ILEUM.
197304 01-03

THE EFFECTS OF AMPHETAMINE AND COCAINE ON THE RESPONSE OF THE ISOLATED GUINEA-PIG VAS-DEFERENS TO NORADRENALINE, TYRAMINE AND NERVE STIMULATION.
197463 01-03

A COMPARISON OF THE EFFECTS OF (+) AMPHETAMINE, COCAINE AND DENERVATION ON THE RESPONSES OF THE ISOLATED VAS-DEFERENS OF THE GUINEA-PIG TO NOREPINEPHRINE AND ACETYLCHOLINE.
197495 01-03

EFFECT OF MORPHINE ON SEROTONIN RELEASE FROM MYENTERIC PLEXUS OF THE GUINEA-PIG.
197811 01-03

ADENOSINE-3-5-MONOPHOSPHATE IN CEREBRAL CORTICAL SLICES FROM GUINEA-PIG AND RAT: EFFECT OF BENZODIAZEPINES.
197972 01-03

THE EFFECTS OF 6-HYDROXYDOPAMINE AND GUANETHIDINE ON PERIPHERAL ADRENERGIC NERVES IN THE GUINEA-PIG.
199862 02-03

CONTRACTILE RESPONSES OF GUINEA-PIG UMBILICAL ARTERIES TO VARIOUS HALLUCINOGENIC AGENTS.
200037 02-03

SOME EFFECTS OF PILOCARPINE AND ACETYLCHOLINE ON THE RESPONSES OF THE GUINEA-PIG VAS-DEFERENS TO HYPOGASTRIC NERVE STIMULATION AND TRANSMURAL STIMULATION AND APPLIED (-) NORADRENALINE.
210770 03-03

EFFECT OF CHOLINE ACETYLTRANSFERASE INHIBITORS ON MOUSE AND GUINEA-PIG BRAIN CHOLINE AND ACETYLCHOLINE.
210883 03-03

STRUCTURE-ACTIVITY RELATIONSHIPS BETWEEN META-SUBSTITUTED N-ETHYLAMPHETAMINES AND ISOLATED GUINEA-PIG ATRIAL RATE.
210887 03-03

THE EFFECTS OF (+) AMPHETAMINE ON THE CHRONOTROPIC RESPONSES OF THE ISOLATED GUINEA-PIG PACEMAKER TO NOREPINEPHRINE AND ISOPROTERENOL.
211066 03-03

INHIBITION OF CATECHOLAMINE AND 5-HYDROXYTRYPTAMINE INDUCED ENZYME SECRETION FROM THE GUINEA-PIG SUBMANDIBULAR GLAND BY 2-BROMO-D-LYSERGIC ACID DIETHYLAMIDE.
216968 04-03

DYSKINETIC PHENOMENA CAUSED BY THE INTRASTRIATAL INJECTION OF PHENYLETHYLAMINE, PHENYLPIPERAZINE, TETRAHYDROISOQUINOLINE AND TETRAHYDRONAPTHALENE DERIVATIVES IN THE GUINEA-PIG.
217671 04-04

THE EFFECT OF PSYCHOTROPIC AND ANTICONVULSIVE DRUGS ON THE TRANSPORT OF ATPASE IN THE RENAL TUBES OF A GUINEA-PIG.
223015 04-05

GUINEA-PIGS

LONG-LASTING DEPLETION OF BRAIN SEROTONIN BY 4-CHLOROAMPHETAMINE IN GUINEA-PIGS.
203580 02-03

AMPHETAMINE-INDUCED DOPAMINERGIC HYPERSENSITIVITY IN GUINEA-PIGS: IMPLICATIONS IN PSYCHOSIS AND HUMAN MOVEMENT DISORDERS.
218115 04-04

GYKI-32084

THE MECHANISM OF ACTION OF GYKI-32084, A NEW ANTISEROTONIN AGENT.
197570 01-03

H-19-61

MODIFICATION BY L-DOPA METHYLESTER (H-19-61) OF AMPHETAMINE-INDUCED BRAIN CATECHOLAMINE CHANGES, THERMAL RESPONSES AND TOXICITY IN DEVELOPING MICE.
210891 03-03

HABITUATION

DOSE EFFECTS OF CHLORDIAZEPOXIDE UPON HABITUATION OF OPEN-FIELD BEHAVIOR IN WHITE RATS.
194736 01-04

PHARMACOLOGICAL AND ANATOMICAL DISSOCIATION OF TWO TYPES OF HABITUATION.
195079 01-04

ATTENUATION OF ACUTE HABITUATION BY SCOPOLAMINE IN THE BLACK-TAILED PRAIRIE DOG (CYNOMYS-LUDOVICIANUS).
206745 03-04

PERMANENT EFFECTS OF REPEATED ADMINISTRATION OF ACTH AND DIAZEPAM IN EARLY POSTNATAL PERIOD UPON THE DYNAMICS OF EXCITATION AND INHIBITION DURING HABITUATION.
215068 04-04

HAFFNERS

POTENTIATION OF CATALEPSY INDUCED BY NARCOTIC AGENTS DURING HAFFNERS TEST FOR ANALGESIA.
206358 03-04

HALLUCINATIONS

VISUAL HALLUCINATIONS AND PROPRANOLOL.
213522 04-15

VISUAL HALLUCINATIONS AND DELIRIUM DURING TREATMENT WITH AMANTADINE (SYMMETREL).
215858 04-11

HALLUCINOGEN

HALLUCINOGEN.
194459 01-12

AN OBSERVATIONAL STUDY OF HALLUCINOGEN INDUCED BEHAVIOR IN UNRESTRAINED MACACA-MULATTA.
210739 03-04

HALLUCINOGENIC

A QUANTUM CHEMICAL INVESTIGATION OF THE PI-ELECTRONIC STRUCTURE OF THE HALLUCINOGENIC N,N-DIMETHYLTRYPTAMINES.
195119 01-01

CONTRACTILE RESPONSES OF GUINEA-PIG UMBILICAL ARTERIES TO VARIOUS HALLUCINOGENIC AGENTS.
200037 02-03

SEARCH FOR NEW HALLUCINOGENIC CACTI.
202382 02-01

HALLUCINOGENIC DRUGS AS PRECIPITANTS OF SCHIZOPHRENIA.
202693 02-08

PHARMACOKINETICS IN THE RAT OF THE HALLUCINOGENIC ALKALOIDS HARMINE AND HARMALINE.
202796 02-03

A CRYSTALLOGRAPHIC AND THEORETICAL STUDY OF THE CONFORMATION OF DOET AND ITS SIGNIFICANCE FOR THE HALLUCINOGENIC AMPHETAMINES.
210746 03-01

HALLUCINOGENIC DRUG ACTION ON THE SOMATOSENSORY SYSTEM.
213634 04-04

SCREENING HALLUCINOGENIC DRUGS: SYSTEMIC STUDY OF THREE BEHAVIORAL TESTS.
217528 04-06

A BEHAVIORAL ANALYSIS OF HALLUCINOGENIC DRUGS. (PH.D. DISSERTATION).
219181 04-12

HALLUCINOGENS

EFFECTS OF (-)DELTA9-TRANS-TETRAHYDROCANNABINOL (DELTA9-THC) ON TESTS OF PSYCHOTICISM: A STUDY OF EYSENCKS DRUG POSTULATE ON THE EFFECTS OF HALLUCINOGENS IN RELATION TO PSYCHOTICISM.
214009 04-09

HALOPERIDOL

CHANGES IN ACTIVATION OF ADENYLATE-CYCLASE AND OF DOPAMINE TURNOVER IN RAT STRIATUM DURING PROLONGED HALOPERIDOL TREATMENT.
192933 01-03

THE USE OF HALOPERIDOL IN THE TREATMENT OF A PSYCHOTIC CHILD WITH MULTIPLE TICS: A CASE REPORT.
194710 01-11

ANTAGONISM OF ACUTE AMPHETAMINE INTOXICATION BY HALOPERIDOL AND PROPRANOLOL.
196106 01-05

HALOPERIDOL FOR CHRONICALLY HOSPITALIZED PSYCHOTICS: A DOUBLE-BLIND COMPARISON WITH THIOTHIXENE AND PLACEBO: A FOLLOWUP OPEN EVALUATION.
196676 01-14

MULTIPLE TIC SYNDROME (GILLES-DE-LA-TOURETTES SYNDROME): CLINICAL, BIOLOGICAL, AND PSYCHOSOCIAL VARIABLES AND THEIR INFLUENCE WITH HALOPERIDOL.
199473 02-11

CLOZAPINE AND HALOPERIDOL IN A SINGLE-BLIND CROSSOVER TRIAL: THERAPEUTIC AND BIOCHEMICAL ASPECTS IN THE TREATMENT OF SCHIZOPHRENIA.
200803 02-08

LITHIUM CARBONATE, HALOPERIDOL, AND IRREVERSIBLE BRAIN DAMAGE.
201287 02-15

COMPARATIVE RESULTS OF A PHARMACOLOGICAL LOADING WITH AMINAZINE AND HALOPERIDOL IN SCHIZOPHRENIC PATIENTS.
201910 02-08

BIOCHEMICAL MECHANISMS OF EXTRAPYRAMIDAL MOTORIC ACTION OF HALOPERIDOL IN MAN.
204414 02-13

TO THE INCOMPATIBILITY OF HALOPERIDOL WITH LITHIUM SALTS.
205612 03-15

A TERATOGENIC STUDY OF HALOPERIDOL.
206014 03-03

BROMOPERIDOL, A NEW POTENT NEUROLEPTIC OF THE BUTYROPHENONE SERIES; COMPARATIVE PHARMACOLOGY OF BROMOPERIDOL AND HALOPERIDOL.
206804 03-02

NEUROPHARMACOLOGICAL FINDINGS AFTER CHRONIC ADMINISTRATION OF HALOPERIDOL, LOXAPINE AND CLOZAPINE.
206972 03-03
METABOLISM OF DOPAMINE AND NOREPINEPHRINE IN RAT BRAIN AFTER SINGLE AND REPEATED ADMINISTRATION OF HALOPERIDOL, LOXAPINE AND CLOZAPINE.
206973 03-03
THE INFLUENCE OF HALOPERIDOL AND PENFLURIDOL ON THE LEARNING CAPACITY OF THE SCHIZOPHRENIC.
207000 03-14
PSYCHOACTIVE DRUGS IN MANIA: A CONTROLLED COMPARISON OF LITHIUM CARBONATE, CHLORPROMAZINE AND HALOPERIDOL.
207446 03-09
HALOPERIDOL AS A TREATMENT FOR ADULT STUTTERING.
207771 03-14
FROM HOSPITAL TREATMENT TO COMMUNITY PSYCHIATRY -- SECOND REPORT -- OUTPATIENT EMERGENCY TREATMENT OF MENTAL PATIENTS WITH THE USE OF HALOPERIDOL.
208723 03-11
SULPIRIDE VERSUS HALOPERIDOL IN SCHIZOPHRENIA: A DOUBLE-BLIND COMPARATIVE TRIAL.
209701 03-08
A COMPARISON BETWEEN DIAZEPAM AND HALOPERIDOL IN ANXIETY STATES.
210434 03-10
CLINICAL BIOLOGICAL CORRELATIONS IN SCHIZOAFFECTIVE PATIENTS TREATED WITH LITHIUM CARBONATE AND HALOPERIDOL.
210501 03-09
ENHANCEMENT OF APOMORPHINE-INDUCED INHIBITION OF STRIATAL DOPAMINE TURNOVER FOLLOWING CHRONIC HALOPERIDOL.
210814 03-03
HALOPERIDOL INDUCED DISRUPTION OF CONDITIONED AVOIDANCE RESPONDING: ATTENUATION BY PRIOR TRAINING OR BY ANTICHOLINERGIC DRUGS.
210861 03-04
EXTRAPYRAMIDAL REACTIONS AND AMINE METABOLITES IN CEREBROSPINAL FLUID DURING HALOPERIDOL AND CLOZAPINE TREATMENT OF SCHIZOPHRENIC PATIENTS.
214010 04-15
INHIBITION OF D-AMPHETAMINE INDUCED LOCOMOTOR ACTIVITY BY INJECTION OF HALOPERIDOL INTO THE NUCLEUS-ACCUMBENS OF THE RAT.
217461 04-04
NEUROLEPTIC-INDUCED HYPERSENSITIVITY OF STRIATAL DOPAMINE RECEPTORS IN THE RAT AS A MODEL OF TARDIVE DYSKINESIAS. EFFECTS OF CLOZAPINE, HALOPERIDOL, LOXAPINE AND CHLORPROMAZINE.
217462 04-03
EFFECTS OF CLOZAPINE, THIORIDAZINE, PERLAPINE AND HALOPERIDOL ON THE METABOLISM OF THE BIOGENIC AMINES IN THE BRAIN OF THE RAT.
217543 04-03
INCREASED CONCENTRATION OF HOMOVANILLIC ACID IN THE BRAINS OF INFANT RABBITS AFTER ADMINISTRATION OF HALOPERIDOL TO THEIR NURSING MOTHERS.
217692 04-03
CLINICAL EXPERIENCE OF HALOPERIDOL INJECTION ON PSYCHIATRIC CASES.
217957 04-14
METHYLPHENIDATE AND HALOPERIDOL IN CHILDREN: EFFECTS ON ATTENTION, MEMORY, AND ACTIVITY.
218118 04-14
CLINICAL STUDY OF HALOPERIDOL. I. TECHNIQUES AND THEORY OF PARENTERAL THERAPY.
220156 04-08
CLASTOGENIC EFFECTS OF HALOPERIDOL IN VIVO AND OF HALOPERIDOL, DROPERIDOL, AND PIPAMPERONE IN VITRO: A NEGATIVE STUDY.
221270 04-15
ON THE PHARMACOKINETICS OF HALOPERIDOL.
221631 04-13
CLOZAPINE AND HALOPERIDOL: CLINICAL AND BIOCHEMICAL ASPECTS IN THE TREATMENT OF SCHIZOPHRENIA.
221637 04-08
A COMPARISON BETWEEN DIAZEPAM AND HALOPERIDOL IN NEUROTIC ANXIETY AND TENSION STATES IN PATIENTS IN A OPEN WARD.
221638 04-10
A CONTROLLED CLINICAL EXPERIMENT WITH BURONIL AND HALOPERIDOL IN DISORIENTATION AMONG ELDERLY PATIENTS.
221639 04-11
CENTRAL CATECHOLAMINE RECEPTOR BLOCKING ACTIONS OF BE-2254 (HEAT): COMPARISON WITH CHLORPROMAZINE AND HALOPERIDOL.
222804 04-03
SOME PECULIARITIES OF THE NEURON ULTRASTRUCTURE IN THE BRAIN-CORTEX MOTOR AREA UNDER THE INFLUENCE OF LYSERGIC ACID DIETHYLAMIDE (LSD) AND HALOPERIDOL.
222890 04-03
COMPARISON OF THE REMEDIAL RESULTS OF CLOFLUPEROL AND HALOPERIDOL FOR SCHIZOPHRENIA BY DOUBLE-BLIND TEST METHOD.
224549 04-08
DIFFERENTIAL ANTAGONISM BY THE ANTICHOLINERGIC DEXETIMIDE OF INHIBITORY EFFECTS OF HALOPERIDOL AND FENTANYL ON BRAIN SELF-STIMULATION.
225562 04-03
EFFECT OF LOPERAMIDE, HALOPERIDOL AND METHADONE IN RATS TRAINED TO DISCRIMINATE MORPHINE FROM SALINE.
225568 04-04

HALOTHANE
THE EFFECTS OF CORD SECTION UNDER ETHER OR HALOTHANE ON THE ABILITY OF CHLORPROMAZINE TO AFFECT THE JAW-JERK RESPONSE TO TOOTH PULP STIMULATION IN THE ENCEPHALE ISOLE PREPARATION.
197451 01-03
INFLUENCE OF HALOTHANE ON PERIPHERAL SYMPATHETIC NERVES AND ON THE EFFECTS OF NORADRENALINE ON MYOCARDIUM.
197945 01-03
EFFECTS OF HALOTHANE AND NITROUS OXIDE ANESTHESIA ON 5-HT TURN-OVER IN THE RAT BRAIN.
217655 04-03

HAMBURG
DOUBLE-BLIND TEST OF THREE ANTIDEPRESSANTS, FOURTH COMMUNICATION; RESULTS WITH THE HAMBURG DEPRESSION SCALE.
221289 04-11

HAMSTER
EFFECTS OF AGROCLAVINE ON AVOIDANCE BEHAVIOR IN THE HAMSTER.
194130 01-04

HAMSTERS
EFFECT OF SINGLE AND DAILY INJECTIONS OF PHENOBARBITAL ON OVULATION IN HAMSTERS.
193421 01-03
THE PARTICIPATION OF SEROTONIN REACTIVE BRAIN STRUCTURES IN SOME FORMS OF BEHAVIORAL PATTERNS IN HAMSTERS.
218472 04-04

HANDBOOK
CONTROLLING DRUGS: INTERNATIONAL HANDBOOK FOR PSYCHOACTIVE DRUG CLASSIFICATION.
202861 02-17

HANDLING
THE EFFECTS OF CHLORDIAZEPOXIDE ON AVOIDANCE PERFORMANCE OF MICE SUBJECTED TO UNDERNUTRITION OR HANDLING STRESS IN EARLY LIFE.
217463 04-04

HARMALINE
THE EFFECTS OF LSD, PSILOCYBIN, HARMALINE AND AMPHETAMINE ON THE BODY TEMPERATURE OF P-CHLOROPHENYLALANINE PRETREATED RATS.
197484 01-03
PHARMACOKINETICS IN THE RAT OF THE HALLUCINOGENIC ALKALOIDS HARMINE AND HARMALINE.
202796 02-03
INHIBITION BY DIAZEPAM OF THE TREMOR AND THE INCREASE OF CEREBELLAR CGMP CONTENT ELICITED BY HARMALINE.
207798 03-03
THE EFFECT OF LSD, PSILOCYBIN, HARMALINE AND AMPHETAMINE ON THE BODY TEMPERATURE OF P-CHLOROPHENYLALANINE PRETREATED RABBITS.
210920 03-05
PARKINSONIAN TYPE TREMOR AND THE ACTION OF HARMALINE: EXPERIMENTAL FACTS AND HYPOTHETICAL MECHANISMS.
212182 03-03

HARMINE
MECHANISMS OF TREMOR INDUCTION BY HARMINE.
193448 01-03
PHARMACOKINETICS IN THE RAT OF THE HALLUCINOGENIC ALKALOIDS HARMINE AND HARMALINE.
202796 02-03
STUDIES ON MONOAMINEOXIDASE (REPORT XXIV) EFFECT OF HARMINE ON MONOAMINE OXIDASE.
202801 02-03

HARMS
SUIT AGAINST RECOMMENDING DOCTOR AND PSYCHIATRIST -- REJECTED. STOVALL V. HARMS, 522 P.2D 353, (KANSAS) SUPREME COURT OF KANSAS. MAY 11, 1974.
200438 02-17

HASHISH
THE EFFECTS OF HASHISH INJECTIONS ON FEEDING AND DRINKING IN RATS.
195113 01-04
DISCRIMINATIVE RESPONSE CONTROL PRODUCED WITH HASHISH, TETRAHYDROCANNABINOLS (DELTA8-THC AND DELTA9-THC), AND OTHER DRUGS.
202720 02-12
HASHISH. IMPORTANCE OF THE PHENOLIC HYDROXYL GROUP IN TETRAHYDROCANNABINOLS.
208594 03-02

HEAD
HEAD INJURY, HYPOPITUITARISM AND PARANOID PSYCHOSIS: CIRCUMCISION FOR THE SINGAPORE VIRUS.
200581 02-09

HEADACHE
A CASE OF SEVERE HEADACHE AS AN EQUIVALENT OF AFFECTIVE DISORDER.
201668 02-09
HYPERSENSITIVITY TO LYSERGIC ACID DIETHYLAMIDE (LSD-25) AND PSILOCYBIN IN ESSENTIAL HEADACHE.
211108 03-12

HEALING
THE HEALING JOURNEY: NEW APPROACHES TO CONSCIOUSNESS.
223921 04-12

HEALTH
AFFECTIVE DISEASE HEALTH MAINTENANCE ORGANIZATION: PATTERNS OF LITHIUM RESPONSE.
194746 01-09
SURVEY OF HEALTH AND ILLNESS IN FAMILY PRACTICE.
198049 01-17
TWO DECADES OF PSYCHOPHARMACOLOGY AND COMMUNITY MENTAL HEALTH: OLD AND NEW PROBLEMS OF THE SCHIZOPHRENIC PATIENT.
207921 03-17
PSYCHOPHARMACOLOGY, COMMUNITY MENTAL HEALTH AND THE SCHIZOPHRENIC PATIENT.
207922 03-17
NICOTINIC ACID IN THE TREATMENT OF SCHIZOPHRENIAS: CANADIAN MENTAL HEALTH ASSOCIATION COLLABORATIVE STUDY PROGRESS REPORT II.
219537 04-08

HEALTHY
EFFECTS OF SINGLE AND REPEATED ADMINISTRATION OF MAPROTILINE AND ITS RELATION TO PLASMA LEVELS IN HEALTHY TEST SUBJECTS.
204403 02-15
ELIMINATION OF LITHIUM DEPENDENT ON AGE IN HEALTHY PEOPLE AND PATIENTS SUFFERING FROM RENAL INSUFFICIENCY.
205043 02-13
COMPARATIVE STUDIES OF VERBAL INTERACTIONS IN A GROUP OF HEALTHY SUBJECTS UNDER THE INFLUENCE OF PSYCHOPHARMACOLOGICAL AGENTS: WITH SPECIAL CONSIDERATION OF YG-19256, CHLORDIAZEPOXIDE AND PLACEBO.
207140 03-14
FACTOR ANALYSIS OF EEG OF HEALTHY SUBJECTS GIVEN NO DRUGS AND A COMBINATION OF DIAZEPAM AND METHYLPHENIDATE.
215071 04-13
PSYCHOPHARMACOLOGIC INVESTIGATIONS IN HEALTHY ELDERLY VOLUNTEERS: EFFECTS OF PIPRADROL - VITAMIN (ALERTONIC) ELIXIR AND PLACEBO IN RELATION TO RESEARCH DESIGN.
218217 04-11

HEART
THE EFFECTS OF THE TRICYCLIC ANTIDEPRESSANTS DESMETHYLIMIPRAMINE, DOXEPIN AND IPRINDOLE ON THE ISOLATED PERFUSED RABBIT HEART.
197277 01-03
CHANGES IN ACID-BASE BALANCE, RESPIRATION RATE AND HEART RATE UPON REPEATED ORAL ADMINISTRATION OF BENZOCTAMINE AND DIAZEPAM TO CONSCIOUS DOGS.
197460 01-03
HEAT PRODUCTION AND OXYGEN CONSUMPTION OF THE ISOLATED RABBIT HEART UNDER THE INFLUENCE OF STROPHANTHIN VERAPAMIL, AND GLYCERYL TRINITRATE.
197567 01-03
DOSE-DEPENDENT DIFFERENCES OF AMPHETAMINE LEVELS IN BRAIN AND HEART OF ADULT AND DEVELOPING MICE.
197927 01-03
INFLUENCE OF PROPRANOLOL AND PRACTOLOL ON THE TURNOVER OF NORADRENALINE IN THE RAT HEART.
197957 01-03
EFFECTS OF CHLORDIAZEPOXIDE UPON DIFFERENTIAL HEART RATE CONDITIONING IN RATS.
201323 02-03
A DOUBLE-BLIND STUDY ON THE EFFECTS OF PIRACETAM UPON PERCEPTUAL AND PSYCHOMOTOR PERFORMANCE AT VARIED HEART RATES IN PATIENTS TREATED WITH ARTIFICIAL PACEMAKERS.
201328 02-13
HEART RATE AND GALVANIC SKIN RESPONSE VARIATIONS DURING THE REM AND NON-REM SLEEP PHASES IN MAN.
205443 02-13
MARIJUANA: HEART RATE AND EEG RESPONSE.
210895 03-01
PRELIMINARY STUDY OF A BETA-BLOCKER (PINDOLOL) IN THREE SCHIZOPHRENICS AND THREE NONPSYCHOTIC PSYCHIATRIC PATIENTS: DIFFERENTIAL SENSITIVITY IN HEART RATE.
212164 03-13
OPERANT CONDITIONING OF HEART RATE IN CURARIZED RATS: HEMODYNAMIC CHANGES.
213275 03-04
MENTAL DISORDERS SEEN AFTER OPEN HEART SURGERY.
214304 04-11
IMIPRAMINE-INDUCED HEART BLOCK: A LONGITUDINAL CASE STUDY.
215014 04-13
BLOOD PRESSURE AND HEART RATE RESPONSES EVOKED BY D- AND L-AMPHETAMINE IN THE PITHED RAT PREPARATION.
215687 04-03
ARRHYTHMIAS AND INHIBITION OF NORADRENALINE UPTAKE CAUSED BY TRICYCLIC ANTIDEPRESSANTS AND CHLORPROMAZINE ON THE ISOLATED PERFUSED RABBIT HEART.
217657 04-03
EFFECTS OF PREVIOUS CURARE IMMOBILIZATION ON PAVLOVIAN CONDITIONED HEART DECELERATIONS IN THE CURARIZED RAT.
219083 04-04

HEARTS
ARRHYTHMIAS EVOKED BY INFUSION OF TRICYCLIC ANTIDEPRESSANTS AND NORADRENALINE ON ISOLATED RABBIT HEARTS.
197939 01-03

HEAT
HEAT PRODUCTION AND OXYGEN CONSUMPTION OF THE ISOLATED RABBIT HEART UNDER THE INFLUENCE OF STROPHANTHIN VERAPAMIL, AND GLYCERYL TRINITRATE.
197567 01-03
CENTRAL CATECHOLAMINE RECEPTOR BLOCKING ACTIONS OF BE-2254 (HEAT): COMPARISON WITH CHLORPROMAZINE AND HALOPERIDOL.
222804 04-03

HELSINKI
THE COURSE AND PROGNOSIS OF SCHIZOPHRENIC PSYCHOSES IN HELSINKI: A COMPARATIVE STUDY OF FIRST ADMISSIONS IN 1950, 1960 AND 1965.
197276 01-17

HEMICHOLINIUM
THE EFFECT OF HEMICHOLINIUM ON BEHAVIOR AND ON BRAIN ACETYLCHOLINE AND CHOLINE IN THE RAT.
217551 04-04

HEMISUCCINATE
BINDING OF D-OXAZEPAM AND L-OXAZEPAM HEMISUCCINATE TO BOVINE SERUM ALBUMIN.
200033 02-03

HEMODYNAMIC
CEREBRAL HEMODYNAMIC EFFECTS OF CHRONIC TRYPTOPHAN FEEDING IN MAN AS MEASURED BY QUANTIFIED CEREBRAL IMPEDANCE PLETHYSMOGRAPHY.
206337 03-08
OPERANT CONDITIONING OF HEART RATE IN CURARIZED RATS: HEMODYNAMIC CHANGES.
213275 03-04

HEMODYNAMICS
INFLUENCE OF RESERPINE ON HEMODYNAMICS IN DOGS.
206415 03-03
EFFECT OF CAMAZEPAM (SB-5833), A NEW ANTIANXIOUS DRUG, ON CARDIAC CONTRACTILITY AND CORONARY HEMODYNAMICS.
206785 03-03

HEPARIN
REACTION OF CATIONIC GROUPS OF CHLORPROMAZINE WITH ANIONIC MACROMOLECULES: COMPLEXES WITH DNA, RNA, HYALURONIC ACID AND HEPARIN.
199897 02-03

HEPATIC
ANALYSIS OF THE INFLUENCE OF SELECTED NEUROTROPIC AGENTS ON HEPATIC METABOLISM IN RELATION TO ENDOTOXICOSIS.
195448 01-03
THE EFFECT OF CHRONIC CANNABIS AND CANNABINOID APPLICATION ON THE HEPATIC DRUG METABOLIZING SYSTEM OF THE RAT.
197282 01-03
THE HEPATIC MICROSOMAL METABOLISM OF BETA 3,4 METHYLENEDIOXYAMPHETAMINE (MDA).
200082 02-03
HEPATIC CHOLESTEROL SYNTHESIS IN MAN: EFFECT OF DIAZEPAM AND OTHER DRUGS.
215681 04-15
AGE DIFFERENCES AFFECTING INDUCTION OF HEPATIC DRUG METABOLIZING ENZYMES BY METHAQUALONE AND PHENOBARBITAL IN THE RAT.
217793 04-03
A COMPARISON OF THE INDUCTIVE EFFECTS OF PHENOBARBITAL, METHAQUALONE, AND METHYPRYLON ON HEPATIC MIXED FUNCTION OXIDASE ENZYMES IN THE RAT.
217794 04-03
CORRELATION OF (+) AMPHETAMINE LETHALITY AND HEPATIC METABOLISM.
217880 04-05

HEPTAMINOL
HEPTAMINOL AND TENSION DISTURBANCES INDUCED BY PSYCHOTROPIC DRUG THERAPY: CLINICAL STUDY.
210089 03-13

HEROIN
PLASMA TESTOSTERONE LEVELS DURING CHRONIC HEROIN USE AND PROTRACTED ABSTINENCE.
202307 02-13
EFFECTS OF HEROIN ON LEVER PRESSING FOR INTRACRANIAL SELF-STIMULATION, FOOD AND WATER IN THE RAT.
221039 04-04

EFFECTS OF MORPHINE AND HEROIN ON DISCRIMINATION LEARNING AND CONSOLIDATION IN MICE.
221040 04-04

DEPRESSION AND ANXIETY IN HEROIN ADDICTS: A PLACEBO CONTROLLED STUDY OF DOXEPIN IN COMBINATION WITH METHADONE.
225386 04-09

CASE PRESENTATION OF AN ALTERNATIVE THERAPEUTIC APPROACH FOR THE BORDERLINE PSYCHOTIC HEROIN ADDICT: DIPHENYLHYDANTOIN.
225512 04-09

HERPES-SIMPLEX
INFLUENCE OF CHANGES IN BRAIN MONOAMINE METABOLISM ON BEHAVIOUR OF HERPES-SIMPLEX INFECTED MICE.
217440 04-04

HETEROCYCLIC
BENZOOXADIAZOLES -- A NOVEL CLASS OF HETEROCYCLIC MONOAMINEOXIDASE INHIBITORS.
202312 02-01

HETEROGENEOUS
FURTHER EVIDENCE FOR THE HETEROGENEOUS STORAGE OF NORADRENALINE IN CENTRAL NORADRENERGIC TERMINALS.
195239 01-03

HETEROSEXUAL
EFFECTS OF L-DOPA ON THE HETEROSEXUAL COPULATORY BEHAVIOR OF MALE RATS.
193549 01-04

HEXAPROPYMATE
EFFECTS OF HEXAPROPYMATE ON THE SLEEP OF THE NORMAL MAN MEASURED BY A POLYGRAPHIC METHOD.
218166 04-14

HEXOBARBITAL
THE EFFECT OF BETA-THIAMINOKETONES ON THE AMINOPYRINE-N-DEMETHYLATION IN VITRO AND IN VIVA SUCH AS THE HEXOBARBITAL SLEEPING TIME AND L-ASCORBIC ACID EXCRETION IN THE RAT.
197469 01-03

CADMIUM-INDUCED POTENTIATION OF HEXOBARBITAL SLEEP TIME IN RATS.
197684 01-04

INFLUENCE OF HEXOBARBITAL ON THE BIOSYNTHESIS OF CATECHOLAMINES AND THEIR PRECURSORS IN THE BRAIN.
201917 02-03

HEXOBENDINE
EXPERIMENTAL PSYCHOLOGICAL STUDY ON THE EFFECT OF A COMBINATION OF HEXOBENDINE, ETHAMIVAN AND ETOFYLLINE.
221738 04-14

HIGH-AFFINITY
COMPARATIVE STUDIES ON SYNAPTOSOMES: HIGH-AFFINITY UPTAKE AND ACETYLATION OF N-H3-ME-CHOLINE AND N-H3-ME-HYDROXYETHYLPYRROLIDINIUM.
217869 04-03

HIND
EFFECTS OF A DECARBOXYLASE INHIBITOR ON THE DOPA AND 5-HTP INDUCED CHANGES IN THE LOCOMOTOR LIKE DISCHARGE PATTERN OF RABBIT HIND LIMB NERVES.
210740 03-03

HIPPOCAMPAL
TIME-DEPENDENT, MEMORY RETRIEVAL EFFECTS FOLLOWING PERIPHERAL AND HIPPOCAMPAL TREATMENTS TO INCREASE SYNAPTIC BIOGENIC AMINES. (PH.D. DISSERTATION).
194677 01-04

EFFECTS OF HIPPOCAMPAL MICROINJECTIONS OF D-AMPHETAMINE AND SCOPOLAMINE ON ACTIVE AVOIDANCE BEHAVIOR IN RATS.
206741 03-04

NEOCORTICAL AND HIPPOCAMPAL ACTIVATION IN RELATION TO BEHAVIOR: EFFECTS OF ATROPINE, ESERINE, PHENOTHIAZINES, AND AMPHETAMINE.
206742 03-04

FREE AND MEMBRANE BOUND RIBOSOMES AND POLYSOMES IN HIPPOCAMPAL NEURONS DURING A LEARNING EXPERIMENT.
210674 03-04

COMPARATIVE TIME-DEPENDENT CHANGES IN SENSITIVITY TO LOCOMOTOR EFFECTS OF D-AMPHETAMINE IN MICE WITH CAUDATE, HIPPOCAMPAL OR FRONTAL CORTICAL LESIONS.
210926 03-03

THE INFLUENCE OF ACTH4-10 ON HIPPOCAMPAL AND THALAMIC SYNCHRONISED ACTIVITY IN RATS.
213430 04-03

DECREASED TEMPORAL VARIABILITY IN HIPPOCAMPAL THETA RHYTHMS OF CATS ADMINISTERED METHYLPHENIDATE.
213855 04-03

ZINC AND HIPPOCAMPAL FUNCTION.
214716 04-03

HIPPOCAMPAL AND PITUITARY ADRENAL INFLUENCES ON ACTIVITY AND AVOIDANCE BEHAVIOR. (PH.D. DISSERTATION).
219289 04-04

BEHAVIORALLY EVOKED HIPPOCAMPAL THETA WAVES: A CHOLINERGIC RESPONSE.
220312 04-03

HIPPOCAMPUS
THE INFLUENCE OF ANTIDEPRESSANTS AND NEUROLEPTICS ON BEHAVIORAL REACTIONS ELICITED BY LESION AND EXCITATION OF THE HIPPOCAMPUS.
198483 02-04

ANALYSIS OF ACETYLCHOLINESTERASE SYNTHESIS AND TRANSPORT IN THE RAT HIPPOCAMPUS: RECOVERY OF ACETYLCHOLINESTERASE ACTIVITY IN THE SEPTUM AND HIPPOCAMPUS AFTER ADMINISTRATION OF DIISOPROPYLFLUOROPHOSPHATE.
199805 02-03

EFFECTS OF SCOPOLAMINE ON THE EEG OF CORTEX AND HIPPOCAMPUS DURING SPONTANEOUS BEHAVIOUR IN RATS.
205628 03-04

THE EFFECT OF CHOLINERGICS ON SHORT-TERM MEMORY AND THE EXCITABILITY LEVEL OF HIPPOCAMPUS CIRCLE STRUCTURES.
208972 03-03

AN ANALYSIS OF MONOAMINERGIC MECHANISMS OF THE DORSAL HIPPOCAMPUS WHICH MEDIATE THE CONDITIONED ESCAPE REACTION IN RATS.
208991 03-04

HIPPOCAMPUS: SELECTIVE CONCENTRATIONS OF LEAD IN THE NORMAL RAT BRAIN.
210665 03-03

THE CORRELATION BETWEEN THE VENTRAL AND DORSAL HIPPOCAMPUS DURING IMPROVEMENT OR DETERIORATION OF SHORT-TERM MEMORY.
215487 04-04

THE INFLUENCE OF LITHIUM AND CESIUM IONS ON THE EFFECTS OF CATECHOLAMINES AND SEROTONIN INTRODUCED INTO THE HIPPOCAMPUS OF RATS.
218470 04-04

COMMISSURAL AND SENSORY EVOKED POTENTIALS OF THE HIPPOCAMPUS FOLLOWING MICROIONTOPHORESIS OF SOME DRUGS.
219111 04-03

THE INFLUENCE OF CHOLINOMIMETICS ON THE AFTEREFFECTS OF TRACE DISCHARGES AND THE ACTIVITY OF EPILEPTOGENIC FOCI IN THE RABBIT HIPPOCAMPUS.
219499 04-03

PHYSIOLOGICAL AND PHARMACOLOGICAL EVIDENCE FOR A SEROTONERGIC PROJECTION TO THE HIPPOCAMPUS.
223171 04-03

HISTAMINE
THE EFFECTS OF PARENTERAL ADMINISTRATION OF CATECHOLAMINES, SEROTONIN AND HISTAMINE ON BEHAVIOR AND LEVELS OF THESE AMINES IN THE BRAIN OF THE NEONATE CHICK.
197457 01-03

THE MECHANISM OF THE POTENTIATING EFFECT OF ANTIDEPRESSANT DRUGS ON THE PROTECTIVE INFLUENCE OF DIPHENHYDRAMINE IN EXPERIMENTAL CATATONIA. THE ROLE OF HISTAMINE.
215664 04-03

EFFECT OF WITHDRAWAL FROM CHRONIC ETHANOL INGESTION ON THE CAMP RESPONSE OF CEREBRAL CORTICAL SLICES USING THE AGONISTS HISTAMINE, SEROTONIN, AND OTHER NEUROTRANSMITTERS.
215980 04-03

HISTOCHEMICAL
ON THE INFLUENCE OF NEUROLEPTICS ON THE CORTICORETICULAR SYSTEM OF THE BRAIN (HISTOCHEMICAL AND BIOCHEMICAL INVESTIGATION).
198481 02-03

A HISTOCHEMICAL STUDY OF VENTRAL TEGMENTAL ACETYLCHOLINESTERASE CONTAINING PATHWAY FOLLOWING DESTRUCTIVE LESIONS.
210919 03-03

CORRELATED HISTOCHEMICAL, ELECTRON MICROSCOPICAL, PHARMACOLOGICAL AND PHYSIOLOGICAL OBSERVATION ON AMINERGIC MECHANISMS IN THE CENTRAL NERVOUS SYSTEM. (UNPUBLISHED PAPER).
218300 04-03

A HISTOCHEMICAL ANALYSIS OF THE INFLUENCE OF SOME PSYCHOTROPIC SUBSTANCES ON THE DEHYDROGENASE ACTIVITY OF VARIOUS BRAIN STRUCTURES.
219498 04-03

HISTOCHEMISTRY
SEROTONIN -- NEW VISTAS: HISTOCHEMISTRY AND PHARMACOLOGY.
213715 04-17

HISTOFLUORESCENCE
QUANTITATIVE RELATIONSHIP OF CATECHOLAMINE CONTENT AND HISTOFLUORESCENCE IN BRAIN OF RATS.
210660 03-03

HISTONE
LYSERGIC ACID DIETHYLAMIDE: EFFECT ON HISTONE ACETYLATION IN RABBIT BRAIN.
220314 04-03

HISTORICAL
ASPECTS OF LONG-TERM TREATMENT WITH NEUROLEPTICS: HISTORICAL AND LITERATURE REVIEW -- PERSONAL EXPERIENCE WITH FLUSPIRILENE AND PENFLURIDOL.
215059 04-14

HISTORY
LITHIUM RESPONSE IN DEPRESSION AS PREDICTED BY UNIPOLAR/BIPOLAR ILLNESS, AVERAGE EVOKED RESPONSE, CATECHOL-O-METHYLTRANSFERASE AND FAMILY HISTORY. (UNPUBLISHED PAPER).
201000 02-09
FAMILY HISTORY OF MANIC-DEPRESSIVE AND ENDOGENOUS DEPRESSIVE PATIENTS AND CLINICAL EFFECT OF TREATMENT WITH LITHIUM.
205608 03-09

HMO
HMO ANALYSIS OF STRUCTURE-ACTIVITY RELATIONS IN SEDATIVE AND HYPNOTIC DRUGS AND ANALYSIS OF POTENTIAL SEDATIVES BY MEANS OF HOMOLOGOUS COMPOUNDS.
199208 02-01

HOARDING
THE EFFECTS OF D- AND L-AMPHETAMINE UPON HOARDING BEHAVIOR AND FEEDING IN THE MONGOLIAN GERBIL (MERIONES-UNGUICULATUS).
202983 02-04

HOE-984
EFFECT OF NOMIFENSINE (HOE-984), A NEW ANTIDEPRESSANT, ON UPTAKE OF NORADRENALINE AND SEROTONIN AND ON RELEASE OF NORADRENALINE IN RAT BRAIN SYNAPTOSOMES.
202807 02-03

HOMOGENATES
SELECTIVE STIMULATION BY DOPAMINE OF ADENYLATE-CYCLASE IN HOMOGENATES OF RABBIT RETINA.
192936 01-03
D-LSD BINDING TO BRAIN HOMOGENATES: POSSIBLE RELATIONSHIP TO SEROTONIN RECEPTORS.
202464 02-03
AMPHETAMINE-INDUCED INHIBITION OF TYROSINE HYDROXYLATION IN HOMOGENATES OF RAT CORPUS-STRIATUM.
222813 04-03
ACCUMULATION OF 4-HYDROXYAMPHETAMINE BY RAT STRIATAL HOMOGENATES.
222822 04-03

HOMOLOGOUS
HMO ANALYSIS OF STRUCTURE-ACTIVITY RELATIONS IN SEDATIVE AND HYPNOTIC DRUGS AND ANALYSIS OF POTENTIAL SEDATIVES BY MEANS OF HOMOLOGOUS COMPOUNDS.
199208 02-01

HOMOLOGS
STRUCTURE-ACTIVITY RELATIONSHIPS IN MAN OF CANNABIS CONSTITUENTS, AND HOMOLOGS AND METABOLITES OF DELTA9-TETRAHYDROCANNABINOL.
202192 02-02

HOMOLOGUES
EFFECTS OF SOME HOMOLOGUES OF 4-CHLOROAMPHETAMINE ON BRAIN SEROTONIN METABOLISM.
195092 01-02

HOMOVANILLIC
CATALEPSY, STEREOTYPED BEHAVIOUR AND STRIATAL HOMOVANILLIC ACID CONTENT IN RATS TREATED WITH METHADONE.
197299 01-03
REGIONAL DIFFERENCES IN HOMOVANILLIC ACID CONCENTRATIONS AFTER ACUTE AND CHRONIC ADMINISTRATION OF ANTIPSYCHOTIC DRUGS.
198210 02-03
LUMBAR CSF 5-HYDROXYINDOLEACETIC ACID AND HOMOVANILLIC ACID IN AFFECTIVE SYNDROMES.
202248 02-09
CANNABINOID INDUCED CHANGES IN MOUSE STRIATAL HOMOVANILLIC ACID AND DIHYDROXYPHENYLACETIC ACID: THE EFFECTS OF AMPHETAMINE AND L-DOPA.
204866 02-03
MASS FRAGMENTOMETRIC DETERMINATION OF HOMOVANILLIC ACID IN LUMBAR CEREBROSPINAL FLUID OF SCHIZOPHRENIC PATIENTS DURING TREATMENT WITH ANTIPSYCHOTIC DRUGS.
207295 03-08
EFFECT OF ANTIPSYCHOTIC DRUGS ON HOMOVANILLIC ACID LEVELS IN STRIATUM AND OLFACTORY TUBERCLE OF THE RAT.
210864 03-03
HOMOVANILLIC ACID CONCENTRATION IN RAT BRAIN: EFFECT OF A CHOLINE ACETYLTRANSFERASE INHIBITOR AND COMPARISON WITH CHOLINERGIC AND DOPAMINERGIC AGENTS.
215711 04-03
A RELATION BETWEEN DRUG CONCENTRATIONS IN BRAIN AND STRIATAL HOMOVANILLIC ACID LEVELS IN CHLORPROMAZINE TREATED RATS.
215734 04-03
INCREASED CONCENTRATION OF HOMOVANILLIC ACID IN THE BRAINS OF INFANT RABBITS AFTER ADMINISTRATION OF HALOPERIDOL TO THEIR NURSING MOTHERS.
217692 04-03
AVERAGE EVOKED RESPONSES (AER) AND HOMOVANILLIC ACID (HVA) IN CEREBROSPINAL FLUID (CSF) IN A PSYCHOTIC PATIENT WITH ADDISONS DISEASE.
221310 04-09

HOODED
PHARMACOLOGICAL MODULATION OF PHOTICALLY EVOKED AFTERDISCHARGE PATTERNS IN HOODED LONG-EVANS RATS.
201409 02-03

HOPES
THE FUTURE: HOPES AND FEARS.
202304 02-17

HORMONAL
HORMONE AND HORMONAL AGENTS IN THE TREATMENT OF AGGRESSION.
209131 03-11
THE EFFECTS OF CHRONIC CANNABIS TREATMENT UPON BRAIN 5-HYDROXYTRYPTAMINE, PLASMA CORTICOSTERONE AND AGGRESSIVE BEHAVIOR IN FEMALE RATS WITH DIFFERENT HORMONAL STATUS.
217532 04-04

HORMONE
EFFECTS OF CENTRAL ACTING DRUGS AND ERGOT DERIVATIVES ON PROLACTIN AND GROWTH HORMONE SECRETION, ON GROWTH OF PITUITARY AND MAMMARY TUMORS AND ON REPRODUCTION IN OLD RATS. (PH.D. DISSERTATION).
194571 01-03
THYROTROPIN-RELEASING HORMONE (TRH) IN DEPRESSION: A PRELIMINARY REPORT.
195929 01-10
A POSSIBLE MECHANISM FOR THE ANTIDEPRESSANT ACTIVITY OF THYROTROPIN-RELEASING HORMONE.
196836 01-13
EFFECT OF PROLONGED LITHIUM INGESTION ON GLUCAGON AND PARATHYROID HORMONE RESPONSES IN RATS.
197744 01-03
THYROTROPIN-RELEASING HORMONE: ACTIVATION OF CEREBRAL NORADRENALINE TURNOVER.
197950 01-03
NEUROTROPIC EFFECTS OF THYROTROPIN-RELEASING HORMONE (TRH).
197953 01-04
ACCELERATION OF ANTIDEPRESSANTS BY THYROID HORMONE.
198082 02-07
HORMONE AND HORMONAL AGENTS IN THE TREATMENT OF AGGRESSION.
209131 03-11
MELANOCYTE STIMULATING HORMONE: SOME BEHAVIORAL EFFECTS. (PH.D. DISSERTATION).
213030 03-04
HUMAN GROWTH HORMONE RESPONSE TO LEVODOPA: RELATION TO MENOPAUSE, DEPRESSION, AND PLASMA DOPA CONCENTRATION.
213918 04-09
GROWTH HORMONE AND PROLACTIN RELEASE AFTER INJECTION OF THYROTROPIN-RELEASING HORMONE IN PATIENTS WITH DEPRESSION.
214885 04-13
EFFECTS OF THYROTROPIN-RELEASING HORMONE (TRH) ON THE ACTIONS OF PENTOBARBITAL AND OTHER CENTRALLY ACTING DRUGS.
215692 04-03
THYROTROPIN-RELEASING HORMONE IN DEPRESSION.
219521 04-09
NEUROTRANSMITTERS AFFECTING PITUITARY HORMONE RELEASE. (UNPUBLISHED PAPER).
219633 04-03
HORMONE INDUCED EFFECTS ON LITHIUMS PHARMACOKINETICS.
221640 04-03
THE EFFECTS OF THYROTROPIN-RELEASING HORMONE ON THE BEHAVIOUR OF RATS PRETREATED WITH ALPHA-METHYLTYROSINE.
222815 04-04
GROWTH HORMONE RELEASE AND CATECHOLAMINES IN AFFECTIVE DISEASE.
224773 04-13

HORMONES
AMNESIC EFFECT OF CYCLOHEXIMIDE IN THE MOUSE MEDIATED BY ADRENOCORTICAL HORMONES.
206751 03-04
EFFECT OF L-DOPA ON PITUITARY HORMONES AND ON CARBOHYDRATE AND FAT METABOLISM IN NORMALS AND IN PARKINSONS DISEASE.
207153 03-13
LITHIUM INHIBITION OF CAMP-MEDIATED HORMONES: A CAUTION.
209352 03-03
THYROXINE-LIKE EFFECTS OF ZINC ON BRAIN AND BEHAVIOUR WITH FIRM DEPENDENCE ON SEVERAL HORMONES.
213434 04-04
ROLE OF MONOAMINES IN THE CONTROL BY HORMONES OF SEXUAL RECEPTIVITY IN THE FEMALE RAT.
222263 04-04

HORSERADISH
AFFERENTS TO THE SEPTAL AREA OF THE RAT STUDIED WITH THE METHOD OF RETROGRADE AXONAL TRANSPORT OF HORSERADISH PEROXIDASE.
203573 02-03

HOSPITAL
AN EVALUATION OF A DRUG ADMINISTRATION SYSTEM IN A PSYCHIATRIC HOSPITAL.
194409 01-17

EARLY HOSPITAL EXPERIENCES WITH FLUPHENAZINE DECANOATE.
196675 01-07

PIPERACETAZINE STUDY IN STATE HOSPITAL PATIENTS.
203423 02-11

THE MANAGEMENT OF SCHIZOPHRENIA OUTSIDE THE HOSPITAL: RESEARCH FINDINGS AND UNDERLYING PRINCIPLES.
206044 03-08

FROM HOSPITAL TREATMENT TO COMMUNITY PSYCHIATRY -- SECOND REPORT -- OUTPATIENT EMERGENCY TREATMENT OF MENTAL PATIENTS WITH THE USE OF HALOPERIDOL.
208723 03-11

EXPERIENCE WITH LONG-ACTING PHENOTHIAZINES IN A PSYCHIATRIC HOSPITAL.
208921 03-17

URINARY SCREENING FOR DRUGS IN A HOSPITAL FOR THE MENTALLY SUBNORMAL.
210437 03-17

PSYCHOTROPIC DRUGS ON GENERAL MEDICAL AND SURGICAL WARDS OF A TEACHING HOSPITAL.
213919 04-17

PSYCHOTROPIC DRUG THERAPY IN A MENTAL HOSPITAL.
215291 04-17

CONTINENTAL HOSPITAL STUDIES WITH MAPROTILINE (LUDIOMIL).
221651 04-09

ACCIDENTS AND DRUG TREATMENT IN A PSYCHIATRIC HOSPITAL.
222603 04-15

HOSPITALISED

CLINICAL EFFICACY OF PIMOZIDE IN HOSPITALISED CHRONIC SCHIZOPHRENICS.
195615 01-08

HOSPITALIZED

HALOPERIDOL FOR CHRONICALLY HOSPITALIZED PSYCHOTICS: A DOUBLE-BLIND COMPARISON WITH THIOTHIXENE AND PLACEBO: A FOLLOWUP OPEN EVALUATION.
196676 01-14

LONGITUDINAL STUDY OF THE EFFECTS OF LITHIUM CARBONATE ON THE SLEEP OF HOSPITALIZED DEPRESSED PATIENTS.
206333 03-09

CLINICAL STUDY ON SULPIRIDE IN LONG-TERM HOSPITALIZED SCHIZOPHRENIC PATIENTS.
206978 03-08

PHYSIOLOGICAL MANAGEMENT OF HOSPITALIZED PSYCHIATRIC PATIENTS.
209399 03-11

HOSPITALS

PSYCHOACTIVE DRUG USE IN ELDERLY PATIENTS WITH PSYCHIATRIC DISORDERS: A SURVEY OF 12 VETERANS ADMINISTRATION HOSPITALS.
193291 01-11

PATTERNS OF CHLORPROMAZINE USE IN GENERAL AND PSYCHIATRIC HOSPITALS.
198050 01-17

THE USE OF PSYCHOACTIVE DRUGS IN ELDERLY PATIENTS WITH PSYCHIATRIC DISORDERS: SURVEY CONDUCTED IN TWELVE VETERANS ADMINISTRATION HOSPITALS.
215009 04-11

HOSTILITY

CHLORDIAZEPOXIDE-INDUCED HOSTILITY IN A SMALL GROUP SETTING.
194865 01-14

IS OXAZEPAM ASSOCIATED WITH HOSTILITY?
218156 04-14

MARIJUANA AND HOSTILITY IN A SMALL GROUP SETTING.
224754 04-14

HOUSEHOLD

URBAN ECOLOGICAL AND HOUSEHOLD CORRELATES OF STRESS ALLEVIATIVE DRUG USE.
223949 04-17

HOUSING

THE INTERACTION OF POSTWEANING HOUSING CONDITIONS AND PRENATAL DRUG EFFECTS ON BEHAVIOUR.
225563 04-04

HUMAN

DOES MAPROTILINE (LUDIOMIL) INFLUENCE SEROTONIN UPTAKE AND FREE TRYPTOPHAN CONCENTRATION IN HUMAN PLASMA
192943 01-13

CHARACTERIZATION OF THE BINDING OF BENZODIAZEPINES TO HUMAN SERUM ALBUMIN.
193278 01-01

THE ACTION OF DIAZEPAM ON HUMAN SKELETAL MUSCLE.
193800 01-13

INTERACTIONS OF BENZODIAZEPINES WITH HUMAN SERUM ALBUMIN: CIRCULAR DICHROISM STUDIES.
194148 01-01

EXPERIENCE WITH CYPROTERONE ACETATE INFLUENCE ON HUMAN SEXUALITY.
195037 01-11

EFFECT OF MONOVALENT CATIONS ON HUMAN PLATELET ADENYLCYCLASE ACTIVITY.
195930 01-13

NEW DEVELOPMENTS IN HUMAN PSYCHOPHARMACOLOGY.
197534 01-17

EFFECT OF ALCOHOLS, CHLORPROMAZINE AND DIPHENYLHYDANTOIN ON (CA2+) ATPASE OF HUMAN RED BLOOD CELLS.
197976 01-13

BLOOD AND URINE LEVELS OF N,N DIMETHYLTRYPTAMINE FOLLOWING ADMINISTRATION OF PSYCHOACTIVE DOSAGES TO HUMAN SUBJECTS.
198230 02-12

THE EFFECTS OF DALMANE (FLURAZEPAM HYDROCHLORIDE) ON HUMAN EEG CHARACTERISTICS.
199756 02-13

UPTAKE OF CATECHOLAMINES BY HUMAN SYNAPTOSOMES.
202719 02-03

REPORT OF A HUMAN FATALITY DUE TO AMPHETAMINE.
204195 02-15

THE KINETICS OF LITHIUM IN THE HUMAN ORGANISM.
205042 02-13

INFLUENCE OF MELATONIN ON EEG AND HUMAN SLEEP: AUTOMATIC EEG ANALYSES AND POLYGRAPHIC NIGHT SLEEP INVESTIGATIONS.
205446 02-13

TREATMENT OF HUMAN AGGRESSION WITH MAJOR TRANQUILIZERS, ANTIDEPRESSANTS, AND NEWER PSYCHOTROPIC DRUGS.
209127 03-11

PSYCHOTROPIC DRUGS AND THE HUMAN EEG.
209829 03-16

REM INHIBITORY EFFECT OF L-DOPA INFUSION DURING HUMAN SLEEP.
210602 03-14

EFFECT OF COMBINED ALCOHOL AND PROPOXYPHENE ON HUMAN PERFORMANCE.
210871 03-14

HUMAN GROWTH HORMONE RESPONSE TO LEVODOPA: RELATION TO MENOPAUSE, DEPRESSION, AND PLASMA DOPA CONCENTRATION.
213918 04-09

EFFECTS OF AMITRIPTYLINE ON HUMAN REM SLEEP AS EVALUATED BY USING PARTIAL DIFFERENTIAL REM SLEEP DEPRIVATION (PDRD).
214750 04-14

INFLUENCE OF AZAPHEN, A NEW ANTIDEPRESSIVE DRUG, ON THE HUMAN EEG.
215065 04-09

IN VIVO HUMAN PHARMACODYNAMICS OF THE PSYCHODYSLEPTIC 4-BR-DIMETHOXYPHENYLISOPROPYLAMINE LABELLED WITH 82BR OR 77BR.
215710 04-13

MASS FRAGMENTOGRAPHY OF PICOMOLE QUANTITIES OF BIOGENIC AMINE METABOLITES IN HUMAN CEREBROSPINAL FLUID AS WELL AS WHOLE RAT BRAINS. (UNPUBLISHED PAPER).
217219 04-06

COMPARISON OF THE EFFECTS OF TETRACYCLIC AND TRICYCLIC ANTIDEPRESSANTS ON THE SEROTONIN UPTAKE BY HUMAN THROMBOCYTES IN VITRO.
217258 04-13

EFFECTS OF TRICYCLIC ANTIDEPRESSANTS UPON HUMAN PLATELET MONOAMINEOXIDASE.
217356 04-13

BENZODIAZEPINES: SPECIFIC COMPETITORS FOR THE BINDING OF L-TRYPTOPHAN TO HUMAN SERUM ALBUMIN.
217686 04-01

INHIBITION OF HUMAN PLATELET 5-HYDROXYTRYPTAMINE UPTAKE BY BETA-PHENETHYLAMINE DERIVATIVES.
217689 04-13

DEXTROMETHORPHAN INHIBITS 5-HYDROXYTRYPTAMINE UPTAKE BY HUMAN BLOOD PLATELETS AND DECREASES 5-HYDROXYINDOLEACETIC ACID CONTENT IN RAT BRAIN.
217964 04-03

AMPHETAMINE-INDUCED DOPAMINERGIC HYPERSENSITIVITY IN GUINEA-PIGS: IMPLICATIONS IN PSYCHOSIS AND HUMAN MOVEMENT DISORDERS.
218115 04-04

SPECIFICITY OF BENZODIAZEPINE ACTION ON HUMAN SLEEP CONFIRMED. ANOTHER CONTRIBUTION OF AUTOMATIC ANALYSIS OF POLYGRAPH RECORDINGS.
218953 04-14

SIMILARITIES OF THE INFLUENCE OF SECONDARY AND TERTIARY TRICYCLIC ANTIDEPRESSANTS ON THE EFFECT OF RESERPINE IN FROGS AND ON THE SEROTONIN UPTAKE OF HUMAN THROMBOCYTES.
219503 04-13

DOSE EFFECTS OF SMOKED MARIHUANA ON HUMAN COGNITIVE AND MOTOR FUNCTIONS.
221036 04-01

SPECTRAL ANALYSIS OF HUMAN EEG CHANGES INDUCED BY ETIFOXIN.
221724 04-13

DOPAMINE SENSITIVE ADENYLCYCLASE IN HUMAN CAUDATE NUCLEUS: A STUDY IN CONTROL SUBJECTS AND SCHIZOPHRENIC PATIENTS.
221732 04-13

HUMANS

LONGITUDINAL STUDIES ON THE METABOLITE PATTERN OF PERAZINE AND RELATED PHENOTHIAZINES IN HUMANS AND ANIMALS.
206976 03-13

EFFECTS OF D-AMPHETAMINE AND SECOBARBITAL ON KEY PRESS RATES IN NORMAL HUMANS.
210879 03-14

REINFORCEMENT SCHEDULES AND EXTRAPOLATIONS TO HUMANS FROM ANIMALS IN BEHAVIORAL PHARMACOLOGY.
225171 04-04

HUNGER
THE EFFECT OF CYPROHEPTADINE ON HUNGER, CALORIE INTAKE AND BODY WEIGHT IN MAN.
214011 04-13

HVA
THE INFLUENCE OF CLOZAPINE ON THE EXCRETION OF MHPG, HVA, AND 5-HIAA IN URINE AND CEREBROSPINAL FLUID.
206974 03-13

AVERAGE EVOKED RESPONSES (AER) AND HOMOVANILLIC ACID (HVA) IN CEREBROSPINAL FLUID (CSF) IN A PSYCHOTIC PATIENT WITH ADDISONS DISEASE.
221310 04-09

HYALURONIC
REACTION OF CATIONIC GROUPS OF CHLORPROMAZINE WITH ANIONIC MACROMOLECULES: COMPLEXES WITH DNA, RNA, HYALURONIC ACID AND HEPARIN.
199897 02-03

HYBRID
EFFECTS OF D-AMPHETAMINE ON LEARNING AND MEMORY IN INBRED AND HYBRID MICE. (PH.D. DISSERTATION).
193581 01-04

HYDERGINE
HYDERGINE THIORIDAZINE COMBINATION IN THE TREATMENT OF PSYCHOPATHOLOGICAL STATES IN OLD AGE.
205637 03-11

HYDRATE
COMPARATIVE STUDY OF THE EFFECTS OF CHLORAL HYDRATE AND TRICHLOROETHANOL ON CEREBRAL METABOLISM.
194742 01-03

COMPARISON OF THE EFFECTS OF CHLORAL HYDRATE AND TRICHLOROETHANOL ON THE EEG OF THE ISOLATED PERFUSED RAT BRAIN.
194743 01-03

HYDROCHLORIDES
ACTION OF (S)- AND (R) P-SUBSTITUTED AMPHETAMINE HYDROCHLORIDES AND (ALPHA S)- AND (ALPHA R) P-CHLORONOREPHEDRINE AND (ALPHA S)- AND (ALPHA R) P-CHLORONORPSEUDOEPHEDRINE HYDROCHLORIDES ON THE LEVEL OF 5-HYDROXYTRYPTAMINE AND THE ACTIVITY OF TRYPTOPHAN-HYDROXYLASE IN RAT BRAIN.
202417 02-03

HYDROCORTISONE
THE INFLUENCE OF HYDROCORTISONE ON THE ELABORATION OF EXTINCTION INHIBITION IN RATS.
219327 04-04

HYDROCORTISONE-INDUCED
HYDROCORTISONE-INDUCED SUPERSENSITIVITY TO NORADRENALINE IN THE ISOLATED NICTITATING MEMBRANE AS A CONSEQUENCE OF AN IMPAIRMENT OF AN O-METHYLATING SYSTEM WITH HIGH AFFINITY.
197944 01-03

HYDROLYSIS
PRACTICAL KINETICS III: BENZODIAZEPINE HYDROLYSIS.
211008 03-06

HYDROLYTIC
HYDROLYTIC DEGRADATION OF METHAQUALONE.
225106 04-01

HYDROLYZING
INHIBITION OF CELLULAR ATP HYDROLYZING ACTIVITY BY TRICYCLIC ANTIDEPRESSANTS AND PHENOTHIAZINE TRANQUILIZERS.
221053 04-03

HYDROMORPHONE
EFFECT OF MORPHINE, HYDROMORPHONE, METHADONE, MESCALINE, TRYPAN-BLUE, VITAMIN-A, SODIUM SALICYLATE AND CAFFEINE ON THE SERUM INTERFERON LEVEL IN RESPONSE TO VIRAL INFECTION.
217654 04-03

HYDROSARPAN-711
PHARMACOLOGY OF CEREBRAL CIRCULATION AND CLINICAL APPLICATIONS. EXPERIMENTAL STUDY OF THE CIRCULATORY AND METABOLIC EFFECTS OF HYDROSARPAN-711.
218164 04-03

HYDROXY
ANTICONVULSANT ACTIVITY OF DELTA9-TETRAHYDROCANNABINOL AND ITS 11 HYDROXY AND 8ALPHA,11 DIHYDROXY METABOLITES IN THE FROG.
200035 02-03

HYDROXYALKYL
A NEW SERIES OF BENZODIAZEPINES: 1 HYDROXYALKYL DERIVATIVES OF 1,3 DIHYDROBENZODIAZEPIN-2-ONES.
221735 04-01

HYDROXYETHYL
A NEW BENZODIAZEPINE: 1-(2 HYDROXYETHYL)-3-HYDROXY-7-CHLORO-1,3 DIHYDRO-5-(O-FLUOROPHENYL)-1H-1,4 BENZODIAZEPIN-2-ONE.
194956 01-04

HYDROXYL
HASHISH. IMPORTANCE OF THE PHENOLIC HYDROXYL GROUP IN TETRAHYDROCANNABINOLS.
208594 03-02

HYDROXYLAMINE
COMPARISON OF THE OXIME AND THE HYDROXYLAMINE DERIVATIVES OF 4-CHLOROAMPHETAMINE AS DEPLETORS OF BRAIN 5-HYDROXYINDOLES.
200004 02-03

HYDROXYLATED
DISTRIBUTION OF AMPHETAMINE AND ITS HYDROXYLATED METABOLITES IN VARIOUS AREAS OF THE RAT BRAIN.
198211 02-03

EFFECTS OF AMPHETAMINE AND ITS HYDROXYLATED DERIVATIVES ON NEWLY SYNTHESIZED HYPOTHALAMIC NOREPINEPHRINE; STUDY IN VITRO.
210884 03-03

HYDROXYLATION
HYDROXYLATION OF AMPHETAMINE TO P-HYDROXYAMPHETAMINE BY RAT LIVER MICROSOMES.
205433 02-03

ENHANCED DRUG HYDROXYLATION IN MAN UNDER DIPHENYLHYDANTOIN THERAPY.
206992 03-13

AMPHETAMINE-INDUCED INHIBITION OF TYROSINE HYDROXYLATION IN HOMOGENATES OF RAT CORPUS-STRIATUM.
222813 04-03

HYDROXYZINE
THE EFFECT OF ALAMON (HYDROXYZINE HYDROCHLORIDE) AND MEDAZEPAM ON NEUROSIS TESTED BY A DOUBLE-BLIND METHOD.
211344 03-10

HYPERACTIVE
PLATELET SEROTONIN OF HYPERACTIVE SCHOOL-AGE BOYS.
194397 01-13

COMPARATIVE DRUG TREATMENT OF HYPERACTIVE CHILDREN.
198090 02-11

THE DIFFERENTIATION OF TWO TYPES OF HYPERACTIVE CHILDREN BY ACTIVITY LEVEL AND TASK PERFORMANCE WITH METHYLPHENIDATE (RITALIN) AND PLACEBO. (PH.D. DISSERTATION).
204688 02-11

EFFECT OF LONG-TERM TREATMENT OF HYPERACTIVE CHILDREN WITH METHYLPHENIDATE.
207580 03-11

THE HYPERACTIVE CHILD.
207582 03-11

THE EFFECT OF METHYLPHENIDATE ON SENSORY PERCEPTION AND INTEGRATION IN HYPERACTIVE CHILDREN.
208920 03-14

ONE-YEAR FOLLOWUP OF HYPERACTIVE BOYS TREATED WITH IMIPRAMINE OR METHYLPHENIDATE.
209736 03-11

WILL THE REAL HYPERACTIVE CHILD PLEASE SIT DOWN? PROBLEMS OF DIAGNOSIS AND REMEDIATION.
212811 03-11

PROS AND CONS OF DRUG THERAPY IN THE MANAGEMENT OF THE HYPERACTIVE CHILD.
216966 04-11

RESPONSE TO METHYLPHENIDATE IN LOW SOCIOECONOMIC HYPERACTIVE CHILDREN.
217181 04-14

OBSERVATIONS ON EFFECTS OF A CENTRAL STIMULANT DRUG (METHYLPHENIDATE) IN CHILDREN WITH HYPERACTIVE BEHAVIOR.
219354 04-14

THE EFFECTS OF REINFORCEMENT CONTINGENCIES AND CAFFEINE ON HYPERACTIVE CHILDREN. (PH.D. DISSERTATION).
220523 04-14

THE EFFECTS OF METHYLPHENIDATE DURING REST, EXERCISE, AND RECOVERY UPON THE CIRCULORESPIRATORY RESPONSES OF HYPERACTIVE CHILDREN. (PH.D. DISSERTATION).
221934 04-11

STIMULANT DRUG TREATMENT OF HYPERACTIVE ADOLESCENTS.
224379 04-14

RITALIN VERSUS BEHAVIOR THERAPY IN HYPERACTIVE CHILDREN.
224855 04-11

IMIPRAMINE AND ELECTROCARDIOGRAPHIC ABNORMALITIES IN HYPERACTIVE CHILDREN.
225337 04-15

A BEHAVIORAL EDUCATIONAL ALTERNATIVE TO DRUG CONTROL OF HYPERACTIVE CHILDREN.
225455 04-14

HYPERACTIVITY
THE ROLE OF BRAIN DOPAMINE IN THE HYPERACTIVITY SYNDROME PRODUCED BY INCREASED 5-HYDROXYTRYPTAMINE SYNTHESIS IN RATS.
199960 02-04

HYPERACTIVITY IN PRESCHOOLERS AND THE EFFECT OF METHYLPHENIDATE.
205264 02-14

EFFECT OF LITHIUM AND OTHER DRUGS ON THE AMPHETAMINE CHLORDIAZEPOXIDE HYPERACTIVITY IN MICE.
210349 03-04

THE EFFECT OF NEUROTROPIC AGENTS ON MOTOR HYPERACTIVITY IN DOGS INDUCED BY AMIZYL.
223062 04-04

HYPERALDOSTERONISM
LITHIUM RESPONSIVE HYPERALDOSTERONISM IN MANIC PATIENTS.
221718 04-09

HYPERBARIC
EFFECTS OF HYPERBARIC CONDITIONS ON THE RESPONSE OF ANIMALS TO CENTRAL NERVOUS SYSTEM STIMULANTS AND DEPRESSANTS.
210877 03-03

HYPEREMOTIONALITY
EFFECTS OF PSYCHOTROPIC DRUGS ON HYPEREMOTIONALITY OF RATS WITH BILATERAL ABLATIONS OF THE OLFACTORY BULBS AND OLFACTORY TUBERCLES.
195231 01-04

HYPERKINESIA
A CASE OF IRREVERSIBLE EXTRAPYRAMIDAL HYPERKINESIA INDUCED BY NEUROLEPTIC DRUGS.
209410 03-15

HYPERKINESIS
AN EXPLORATORY STUDY OF THE LONG-TERM EFFECTS OF DRUG USE IN HYPERKINESIS. (PH.D. DISSERTATION).
195882 01-11

LONG-TERM CORRELATES OF DRUG USE IN HYPERKINESIS.
198086 02-07

PEMOLINE (CYLERT) IN THE TREATMENT OF CHILDHOOD HYPERKINESIS.
202824 02-11

D-AMPHETAMINE AND DELINQUENCY: HYPERKINESIS PERSISTING
206143 03-14

HYPERKINETIC
INVOLVEMENT OF SEROTONIN IN HYPERKINETIC EPISODES IN SCOTTISH TERRIER DOGS. (PH.D. DISSERTATION).
196261 01-03

COMPARATIVE DRUG EFFECTS IN HYPERKINETIC CHILDREN.
198088 02-07

THE COMBINED EFFECTS OF METHYLPHENIDATE (RITALIN) AND A CLASSROOM BEHAVIOR MODIFICATION PROGRAM IN REDUCING THE HYPERKINETIC BEHAVIORS OF INSTITUTIONALIZED MENTAL RETARDATES. (PH.D. DISSERTATION).
202356 02-11

HYPERKINETIC CHILDREN: THE USE OF STIMULANT DRUGS EVALUATED.
205263 02-14

CAFFEINE IN THE TREATMENT OF CHILDREN WITH MINIMAL BRAIN DYSFUNCTION OR HYPERKINETIC SYNDROME.
211434 03-11

MEDICATION FOR HYPERKINETIC CHILDREN.
213988 04-11

SULPIRIDE AND HYPERKINETIC SYNDROMES.
218564 04-11

THE EFFECTIVENESS OF RITALIN AND TOKEN ECONOMY IN INCREASING HYPERKINETIC CHILDRENS COLORING BEHAVIOR. (PH.D. DISSERTATION).
220510 04-14

THE EFFECTS OF METHYLPHENIDATE HYDROCHLORIDE ON PSYCHOLINGUISTIC, MOTOR AND VISUAL PERCEPTUAL ABILITIES OF HYPERKINETIC CHILDREN WITH LEARNING DISABILITIES. (PH.D. DISSERTATION).
222725 04-14

ATTENTION AND THE AUDITORY EVOKED POTENTIAL IN HYPERKINETIC CHILDREN TREATED WITH METHYLPHENIDATE AND IN NORMAL CHILDREN. (PH.D. DISSERTATION).
222747 04-11

COMPARATIVE SYMPTOMATOLOGICAL AND EVOKED POTENTIAL STUDIES WITH D-AMPHETAMINE, THIORIDAZINE, AND PLACEBO IN HYPERKINETIC CHILDREN.
225516 04-10

HYPERPARATHYROIDISM
DEPRESSIVE ILLNESS AND HYPERPARATHYROIDISM.
201239 02-15

HYPERPHAGIA
CHLORPROMAZINE-INDUCED HYPERPHAGIA IN THE RAT.
217552 04-04

HYPERSENSITIVITY
HYPERSENSITIVITY TO LYSERGIC ACID DIETHYLAMIDE (LSD-25) AND PSILOCYBIN IN ESSENTIAL HEADACHE.
211108 03-12

SLEEP AND BEHAVIORAL CHANGES REFLECTING CENTRAL RECEPTOR HYPERSENSITIVITY FOLLOWING CATECHOLAMINE SYNTHESIS INHIBITION IN MAN. (UNPUBLISHED PAPER).
216373 04-09

NEUROLEPTIC-INDUCED HYPERSENSITIVITY OF STRIATAL DOPAMINE RECEPTORS IN THE RAT AS A MODEL OF TARDIVE DYSKINESIAS. EFFECTS OF CLOZAPINE, HALOPERIDOL, LOXAPINE AND CHLORPROMAZINE.
217462 04-03

AMPHETAMINE-INDUCED DOPAMINERGIC HYPERSENSITIVITY IN GUINEA-PIGS: IMPLICATIONS IN PSYCHOSIS AND HUMAN MOVEMENT DISORDERS.
218115 04-04

HYPERSOMNIA
HYPERSOMNIA BY ISTHMIC LESION IN THE CAT. I. STUDY OF THE METABOLISM OF CEREBRAL MONOAMINES.
215702 04-03

HYPERSOMNIA BY ISTHMIC LESION IN THE CAT. II. NEUROPHYSIOLOGICAL AND PHARMACOLOGICAL STUDY.
215703 04-03

HYPERTENSION
PRINDOLOL IN THE MANAGEMENT OF HYPERTENSION.
195773 01-14

PSYCHIATRIC ASPECTS OF HYPERTENSION.
198040 01-10

HYPERTENSIVE
ABSENCE OF TOLERANCE TO THE HYPOTENSIVE EFFECTS OF DELTA9-TETRAHYDROCANNABINOL IN HYPERTENSIVE RATS.
193419 01-03

HYPERTHERMIA
PHYSOSTIGMINE ATTENUATION OF DELTA9-TETRAHYDROCANNABINOL INDUCED HYPERTHERMIA IN RATS.
195539 01-03

ACTION OF PROBENECID ON THE CENTRAL NERVOUS SYSTEM OF THE RABBIT: II. POTENTIATION OF 5-HYDROXYTRYPTOPHAN-INDUCED HYPERTHERMIA AND SUPPRESSION OF THIS EFFECT BY A DECARBOXYLASE INHIBITOR (RO-4-4602).
196580 01-03

SIMILAR ACTIONS OF INTRAHYPOTHALAMIC 5-6-DHT AND 5-HT IN EVOKING HYPERTHERMIA IN THE MONKEY.
200034 02-03

EVIDENCE AGAINST THE INVOLVEMENT OF FALSE NEUROTRANSMITTERS IN TOLERANCE TO AMPHETAMINE-INDUCED HYPERTHERMIA IN THE RAT.
217690 04-03

ON THE MECHANISM OF THE HYPERTHERMIA INDUCED BY AMPHETAMINE IN THE RAT.
217691 04-03

HYPERTHERMIC
SUPPRESSION OF CONDITIONED HYPERTHERMIC RESPONSE BY L- AND D-OXPRENOLOL IN RATS.
192937 01-03

COMPARISON OF CARDIOVASCULAR, HYPERTHERMIC, AND TOXIC EFFECTS OF P-METHOXYAMPHETAMINE (PMA) AND 3,4 METHYLENEDIOXYAMPHETAMINE (MDA).
217578 04-05

THE EFFECT OF 6-HYDROXYDOPAMINE ON THE TOLERANCE DEVELOPMENT TO THE HYPERTHERMIC EFFECT OF (+) AMPHETAMINE IN THE RAT.
217965 04-03

HYPERTHYMIC
CONTRIBUTIONS TO THE STUDY OF THE INFLUENCE OF LITHIUM CARBONATE ON THE EVOLUTION OF HYPERTHYMIC PSYCHOSES.
212161 03-09

HYPERTHYROIDISM
THE APPEARANCE OF EXOPHTHALMIA IN THE COURSE OF LITHIUM CARBONATE TREATMENT: BIOLOGICAL HYPERTHYROIDISM.
209998 03-15

HYPNOSIS
THE USE OF THE IMMOBILITY REFLEX (ANIMAL HYPNOSIS) AS A POSSIBLE PROCEDURE FOR DETECTING SEDATIVE ACTIVITY.
196066 01-04

HYPNOTHERAPY
MIGRAINE AND HYPNOTHERAPY.
207486 03-04

HYPNOTIC
THE INTERACTION OF BARBITAL AND TESTOSTERONE RELATIVE TO THEIR HYPNOTIC EFFECTS.
197448 01-03

HMO ANALYSIS OF STRUCTURE-ACTIVITY RELATIONS IN SEDATIVE AND HYPNOTIC DRUGS AND ANALYSIS OF POTENTIAL SEDATIVES BY MEANS OF HOMOLOGOUS COMPOUNDS.
199208 02-01

CLINICAL PHARMACOLOGICAL STUDY OF A HYPNOTIC DRUG, TRICLORYL.
200009 02-11

ALL-NIGHT POLYGRAPHIC RECORDINGS ON THE HYPNOTIC EFFECTS OF A NEW BENZODIAZEPINE: FLUNITRAZEPAM (RO-5-4200, ROHYPNOL).
202272 02-11

A COMPARATIVE STUDY OF THE HYPNOTIC PROPERTIES OF FLURAZEPAM (30 MG), SECOBARBITAL (100 MG), AND OF PLACEBO AMONG FOUR TYPES OF PSYCHOTIC INSOMNIACS.
203204 02-04

EEG EVALUATION OF HYPNOTIC DRUGS: MOGADON V. RO-5-4200, USING THE DOUBLE-BLIND METHOD.
205435 02-13

COMPARATIVE STUDY OF THE ELECTRONEUROPHYSIOLOGICAL PARAMETERS OF SLEEP INDUCED BY SEVERAL HYPNOTIC DRUGS.
205520 02-13

PRESLEEP INGESTION OF TWO HYPNOTIC DRUGS AND SUBSEQUENT PERFORMANCE.
206362 03-14

POLYGRAPHIC EVALUATION OF HYPNOTIC DRUGS: METHODOLOGICAL CRITERIA.
208983 03-16

THE EFFECTS OF HYPNOTIC DRUGS ON SLEEP.
209981 03-14

HYPNOTIC EFFICACY OF DIPHENHYDRAMINE, METHAPYRILENE, AND PENTOBARBITAL.
210829 03-13

COMPARISON OF THE HYPNOTIC ACTIVITY OF TRIAZOLAM, FLURAZEPAM HYDROCHLORIDE, AND PLACEBO.
215673 04-14

A DIRECT EFFECT OF DIBUTYRYL CYCLIC-AMP ON THE DURATION OF NARCOSIS INDUCED BY SEDATIVE, HYPNOTIC, TRANQUILISER AND ANESTHETIC DRUGS IN THE RAT.
222814 04-04

HYPNOTICS

THE EFFECTS OF HYPNOTICS ON IMIPRAMINE TREATMENT.
200049 02-13

SEDATIVES, HYPNOTICS AND TRANQUILLIZERS.
202458 02-17

N-DESMETHYLDIAZEPAM AND AMYLOBARBITONE SODIUM AS HYPNOTICS IN ANXIOUS PATIENTS. PLASMA LEVELS, CLINICAL EFFICACY AND RESIDUAL EFFECTS.
217460 04-10

HYPODIPSIA

NICOTINE INDUCED HYPOPHAGIA AND HYPODIPSIA IN DEPRIVED AND IN HYPOTHALAMICALLY STIMULATED RATS.
225559 04-04

HYPOGASTRIC

SOME EFFECTS OF PILOCARPINE AND ACETYLCHOLINE ON THE RESPONSES OF THE GUINEA-PIG VAS-DEFERENS TO HYPOGASTRIC NERVE STIMULATION AND TRANSMURAL STIMULATION AND APPLIED (-) NORADRENALINE.
210770 03-03

HYPOGLYCEMIC

NEW HYPOGLYCEMIC BENZENESULFONAMIDO PYRIMIDINES: N-SUBSTITUTED 4-(N-(2-PYRIMIDINYLSULFONYL-PHENYLACETAMIDES.
206994 03-02

HYPOKINESIS

MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 6. COMMUNICATION: RELATIONSHIP BETWEEN NEUROLEPTIC HYPOKINESIS AND ANTIPSYCHOTIC THERAPEUTIC RESULTS.
203844 02-13

HYPOMANIA

ACUTE HYPOMANIA.
213784 04-09

HYPOPHAGIA

FENFLURAMINE IN MAN: HYPOPHAGIA ASSOCIATED WITH DIMINISHED SEROTONIN TURNOVER.
215674 04-13

NICOTINE INDUCED HYPOPHAGIA AND HYPODIPSIA IN DEPRIVED AND IN HYPOTHALAMICALLY STIMULATED RATS.
225559 04-04

HYPOPHYSECTOMIZED

EFFECT OF ACTH4-10 ON THE RATE OF SYNTHESIS OF (3H)CATECHOLAMINES IN THE BRAINS OF INTACT, HYPOPHYSECTOMIZED AND ADRENALECTOMIZED RATS.
223050 04-03

HYPOPITUITARISM

HEAD INJURY, HYPOPITUITARISM AND PARANOID PSYCHOSIS: CIRCUMCISION FOR THE SINGAPORE VIRUS.
200581 02-09

HYPOTENSION

L-DOPA HYPOTENSION IN DOGS: EVIDENCE FOR MEDIATION THROUGH 5-HT RELEASE.
210868 03-05

HYPOTENSIVE

ABSENCE OF TOLERANCE TO THE HYPOTENSIVE EFFECTS OF DELTA9-TETRAHYDROCANNABINOL IN HYPERTENSIVE RATS.
193419 01-03

MECHANISM OF THE HYPOTENSIVE EFFECT OF INTRAVENOUS METHAQUALONE IN THE CAT.
196107 01-03

INFLUENCE OF CATECHOLAMINE UPTAKE BLOCKING DRUGS ON THE INCREASE IN WATER INTAKE AND PLASMA RENIN CONCENTRATION INDUCED BY SOME HYPOTENSIVE DRUGS.
197288 01-03

INFLUENCE OF DESMETHYLIMIPRAMINE ON THE HYPOTENSIVE EFFECT OF CLONIDINE.
206997 03-03

INTERACTION BETWEEN CENTRALLY ACTING HYPOTENSIVE DRUGS AND TRICYCLIC ANTIDEPRESSANTS.
217575 04-03

A BENZODIOXANHYDROXYETHYLPIPERIDINE DERIVATIVE WITH ACUTE CENTRAL HYPOTENSIVE ACTION, DIFFERENT FROM THAT OF CLONIDINE: A COMPARISON WITH NEUROLEPTIC AGENTS.
220976 04-03

HYPOTHALAMIC

EFFECT OF 6-HYDROXYDOPAMINE ON HYPOTHALAMIC NOREPINEPHRINE AND DOPAMINE CONTENT, ULTRASTRUCTURE OF THE MEDIAN EMINENCE, AND PLASMA CORTICOSTERONE.
193050 01-03

INTERRELATION BETWEEN MONOAMINERGIC AND CHOLINERGIC MECHANISMS IN THE HYPOTHALAMIC THERMOREGULATORY CENTRE OF RABBITS.
195249 01-03

EFFECTS OF ADRENERGIC DRUGS ON PRESSOR RESPONSES TO HYPOTHALAMIC STIMULATION.
195441 01-03

PRESSOR RESPONSES TO HYPOTHALAMIC STIMULATION AS INFLUENCED BY DRUGS AFFECTING ADRENERGIC RECEPTORS.
197290 01-03

CENTRAL ACTION OF ANOREXIC AGENTS: EFFECTS OF AMPHETAMINE AND FENFLURAMINE IN RATS WITH LATERAL HYPOTHALAMIC LESIONS.
197865 01-04

THE IN VIVO RELEASE OF ENDOGENOUSLY SYNTHESIZED CATECHOLAMINES FROM THE CAT BRAIN BY LATERAL HYPOTHALAMIC STIMULATION AND BY D-AMPHETAMINE ADMINISTRATION. (PH.D. DISSERTATION).
200313 02-03

METHODS TO STUDY THE IN VIVO REGULATION OF CYCLIC NUCLEOTIDES IN HYPOTHALAMIC NUCLEI, PITUITARY AND PINEAL. (UNPUBLISHED PAPER).
201491 02-06

EFFECTS OF PSYCHOTROPIC DRUGS ON HYPOTHALAMIC SELF-STIMULATION BEHAVIOR IN RATS.
202802 02-04

EFFECT OF STRESS ON CATECHOLAMINES AND TYROSINE-HYDROXYLASE ACTIVITY OF INDIVIDUAL HYPOTHALAMIC NUCLEI.
208994 03-03

EFFECTS OF AMPHETAMINE AND ITS HYDROXYLATED DERIVATIVES ON NEWLY SYNTHESIZED HYPOTHALAMIC NOREPINEPHRINE; STUDY IN VITRO.
210884 03-03

HYPOTHALAMIC SELF-STIMULATION IN RATS FOLLOWING IMMUNOSYMPATHECTOMY OR CENTRAL NERVE GROWTH FACTOR ANTISERUM INJECTION.
211512 03-04

A COMPARISON BETWEEN CAUDATE, AMYGDALOID AND HYPOTHALAMIC SELF-STIMULATION IN SQUIRREL MONKEYS (SAIMIRI-SCIUREUS). (PH.D. DISSERTATION).
214207 04-04

LOSS OF ACTIVE AVOIDANCE RESPONDING AFTER LATERAL HYPOTHALAMIC INJECTIONS OF 6-HYDROXYDOPAMINE.
215704 04-04

AN ATTEMPT TO VERIFY THE ANTIDEPRESSANT ACTION OF THE HYPOTHALAMIC THYROSTIMULIN (THYROTROPIN-RELEASING FACTOR OR TRF) IN MELANCHOLIC STATES.
216758 04-09

POTENTIATION OF AMPHETAMINE-INDUCED AROUSAL BY FOOD DEPRIVATION: EFFECT OF HYPOTHALAMIC LESIONS.
218498 04-04

ACTION OF SEROTONIN MICROINJECTED INTO HYPOTHALAMIC SITES AT WHICH ELECTRICAL STIMULATION PRODUCED AVERSIVE RESPONSES IN THE RAT.
219075 04-04

CATECHOLAMINES AND SELF-STIMULATION: PHARMACOLOGICAL DIFFERENCES BETWEEN NEAR-LATERAL AND FAR-LATERAL HYPOTHALAMIC SITES.
221030 04-03

HYPOTHALAMICALLY

NICOTINE INDUCED HYPOPHAGIA AND HYPODIPSIA IN DEPRIVED AND IN HYPOTHALAMICALLY STIMULATED RATS.
225559 04-04

HYPOTHALAMUS

COMPARATIVE INVOLVEMENT OF DOPAMINE AND NORADRENALINE IN RATE-FREE SELF-STIMULATION IN SUBSTANTIA-NIGRA, LATERAL HYPOTHALAMUS, AND MESENCEPHALIC CENTRAL GRAY.
193303 01-03

THE EFFECTS OF DRUG ADMINISTRATION TO THE LATERAL HYPOTHALAMUS: NEUROCHEMICAL CODING OR NONSPECIFICITY?.
195992 01-03

CHEMICAL STIMULATION OF THE AMYGDALA WITH SPECIAL REGARD TO INFLUENCE ON THE HYPOTHALAMUS.
202779 02-04

DIFFERENTIAL EFFECTS OF AMPHETAMINE AND FOOD DEPRIVATION ON SELF-STIMULATION OF THE LATERAL HYPOTHALAMUS AND MEDIAL FRONTAL CORTEX.
206733 03-04

RECIPROCAL (PUSH-PULL) EFFECTS OF MORPHINE ON SINGLE UNITS IN THE VENTROMEDIAN AND LATERAL HYPOTHALAMUS AND INFLUENCES ON OTHER NUCLEI: WITH COMMENT ON METHADONE EFFECTS DURING WITHDRAWAL FROM MORPHINE.
210700 03-03

REGIONAL DISTRIBUTION OF MONOAMINEOXIDASE ACTIVITY FOR 5-HYDROXYTRYPTAMINE AND TYRAMINE IN THE HYPOTHALAMUS OF THE RAT.
223049 04-03

HYPOTHERMIA
THE EFFECT OF DRUGS WITH ANTIDEPRESSANT ACTIVITY UPON THE HYPOTHERMIA AND BEHAVIOURAL DEPRESSION INDUCED IN MICE BY PIMOZIDE OR CENTRALLY ADMINISTERED NORADRENALINE.
210762 03-04

HYPOTHERMIC
HYPOTHERMIC EFFECTS OF MARIHUANA, MARIHUANA DERIVATIVES AND CHLORPROMAZINE IN LABORATORY MICE.
196226 01-04

TOLERANCE TO THE HYPOTHERMIC AND AGGRESSION ATTENUATING EFFECT OF DELTAB- AND DELTA9-TETRAHYDROCANNABINOL IN MICE.
197866 01-04

AN INVESTIGATION ON THE BEHAVIORAL AND HYPOTHERMIC EFFECTS OF YOHIMBINE: INTERACTION WITH DRUGS AFFECTING CENTRAL AND PERIPHERAL MONOAMINES.
211068 03-04

HYPOTHESES
PHARMACOTHERAPY OF SCHIZOPHRENIA: FACTS, SPECULATIONS, HYPOTHESES AND THEORIES.
206603 03-08

EXPERIMENTAL TESTS OF HYPOTHESES ABOUT NEUROCHEMICAL MECHANISMS UNDERLYING BEHAVIORAL TOLERANCE TO THE ANTICHOLINESTERASE, DIISOPROPYLFLUOROPHOSPHATE.
208555 03-03

HYPOTHESIS
THEORETICAL IMPLICATIONS OF DRUG-INDUCED ADAPTIVE REGULATION FOR A BIOGENIC AMINE HYPOTHESIS OF AFFECTIVE DISORDER.
206335 03-03

A GABA HYPOTHESIS FOR THE ACTION OF BENZODIAZEPINES. (UNPUBLISHED PAPER).
218149 04-03

HYPOTHETICAL
PARKINSONIAN TYPE TREMOR AND THE ACTION OF HARMALINE: EXPERIMENTAL FACTS AND HYPOTHETICAL MECHANISMS.
212182 03-03

HYPOTHYROIDISM
HYPOTHYROIDISM DURING LITHIUM TREATMENT: A REVIEW OF 49 CASES.
221988 04-15

HYPOXIA
FUNCTIONAL AND BIOCHEMICAL ASPECTS OF CATECHOLAMINE METABOLISM IN BRAIN UNDER HYPOXIA.
217852 04-03

THE EFFECT OF DIAZEPAM ON THE BEHAVIOR OF RATS ADAPTED TO HIGH ALTITUDE HYPOXIA IN CONFLICTING SITUATIONS.
219502 04-04

HYSTERECTOMIZED
ESTROGEN INDUCED MATERNAL BEHAVIOR IN HYSTERECTOMIZED OVARIECTOMIZED VIRGIN RATS.
219069 04-04

LATENCY AND DURATION OF ESTROGEN INDUCTION OF MATERNAL BEHAVIOR IN HYSTERECTOMIZED OVARIECTOMIZED VIRGIN RATS: EFFECTS OF PUP STIMULATION.
219070 04-04

H3-DOPAMINE
STUDIES ON THE DISTINCTION BETWEEN UPTAKE INHIBITION AND RELEASE OF H3-DOPAMINE IN RAT BRAIN TISSUE SLICES.
215756 04-03

H3-L-NOREPINEPHRINE
EFFECT OF FIGHTING AND DIPHENYLHYDANTOIN ON THE UPTAKE OF H3-L-NOREPINEPHRINE IN VITRO IN SYNAPTOSOMES ISOLATED FROM RETIRED MALE BREEDING MICE.
222821 04-03

H3-P-HYDROXYAMPHETAMINE
THE BLOOD-BRAIN BARRIER II: DISTRIBUTION KINETICS OF H3-P-HYDROXYAMPHETAMINE IN BRAIN STRUCTURES OF THE RAT AFTER INTRAVENOUS ADMINISTRATION.
220977 04-03

H3-1-ALPRENOLOL
PINEAL BETA-ADRENERGIC RECEPTOR: CORRELATION OF BINDING OF H3-1-ALPRENOLOL WITH STIMULATION OF ADENYLCYCLASE. (UNPUBLISHED PAPER).
224096 04-03

IATROGENIC
IATROGENIC DYSKINESIA: A UNIQUE REACTION TO PARENTERAL METHYLPHENIDATE.
193087 01-15

ICI-58834
THE EFFECTS OF AMPHETAMINE, IMIPRAMINE AND ICI-58834 (VIVALAN), A POTENTIAL ANTIDEPRESSANT, ON UNCONDITIONED BEHAVIOUR IN RATS.
214016 04-04

ID-4708
SYNTHESIS AND PRELIMINARY PHARMACOLOGY OF A NOVEL BUTYROPHENONE DERIVATIVE, ID-4708.
202862 02-02

ID-540
THE SYNTHESIS AND PHARMACOLOGY OF A NOVEL BENZODIAZEPINE DERIVATIVE, 1-METHYL-5-O-FLUOROPHENYL 7-CHLORODIHYDROBENZODIAZEPIN-2-ONE (ID-540).
206780 03-02

ELECTROPHYSIOLOGICAL AND BEHAVIORAL EFFECTS OF 1-METHYL-5-O-FLUOROPHENYL 7-CHLORODIHYDROBENZODIAZEPIN-2-ONE (ID-540) IN CATS AND RABBITS.
221736 04-03

ID-622
THE SYNTHESIS AND PHARMACOLOGY OF A NOVEL BENZODIAZEPINE DERIVATIVE, 1-BETA-METHYLSULFONYLETHYL-5-O-FLUOROPHENYL 7-CHLORODIHYDROBENZODIAZEPIN-2-ONE (ID-622).
221741 04-02

IDENTICAL
THE VALIDITY OF IDENTICAL MATCHING PLACEBOS.
193073 01-16

IDENTIFICATION
IDENTIFICATION AND STRUCTURAL CHARACTERIZATION OF AN INHIBITOR OF CATECHOLAMINE INDUCED FREE FATTY ACID MOBILIZATION FROM THE CALF MIDBRAIN.
200006 02-01

TISSUE METABOLITES OF TRIFLUOPERAZINE, FLUPHENAZINE, PROCHLORPERAZINE, AND PERPHENAZINE IN THE RAT: IDENTIFICATION AND SYNTHESIS.
200738 02-01

IN VIVO IDENTIFICATION OF MUSCARINIC CHOLINERGIC RECEPTOR BINDING IN RAT BRAIN.
213480 04-03

IDENTIFIED
ACETYLCHOLINE ACTIVITY IN AN IDENTIFIED 5-HYDROXYTRYPTAMINE CONTAINING NEURON.
217825 04-03

IDEO-EMOTIONAL
PRELIMINARY RESULTS OF A CONTROLLED TRIAL WITH SULPIRIDE VERSUS CHLORIMIPRAMINE IN CHRONIC SCHIZOPHRENIC PATIENTS WITH MARKED IDEO-EMOTIONAL POVERTY.
200445 02-08

IDIOCY
THE TREATMENT OF BEHAVIOR DISORDERS IN IDIOCY AND IMBECILITY WITH CLOZAPINE.
203598 02-11

IDIOSYNCRATIC
DELAYED IDIOSYNCRATIC PSYCHOSIS WITH DIPHENYLHYDANTOIN.
211425 03-15

IDIOSYNCRATIC REACTIONS TO THE ANTIEPILEPTIC DRUGS.
225538 04-15

ILEUM
ACUTE TOLERANCE, AND DEPENDENCE IN GUINEA-PIG ILEUM.
197304 01-03

INHIBITION OF DELTA1-TETRAHYDROCANNABINOL OF NA+-K+ TRANSPORT ATPASE FROM RAT ILEUM. PRELIMINARY REPORT.
211099 03-03

ILEUS
A CASE OF PHENOTHIAZINE ILEUS RECOVERED FROM SHOCK.
193828 01-15

ILL
A CLINICAL NEUROLEPTIC INVESTIGATION OF N-(1-ETHYL-PYRROLIDIN-2-YL) 2-METHOXY-5-SULFAMOYL-BENZAMIDE NEUROLEPTIC SULPIRIDE (DOGMATIL) IN ACUTELY ILL SCHIZOPHRENICS.
195038 01-11

BUTACLAMOL HYDROCHLORIDE (AY-23028): AN EARLY EVALUATION IN SEVERELY ILL SCHIZOPHRENICS.
206933 03-08

PIPOTHIAZINE PALMITATE: AN EVALUATION OF A NEW LONG-ACTING INTRAMUSCULAR ANTIPSYCHOTIC AGENT IN SEVERELY ILL SCHIZOPHRENIC PATIENTS.
216188 04-08

ILLNESS
ASSESSMENT OF THERAPY IN PSYCHOGERIATRIC ILLNESS.
194244 01-11

PSYCHIATRIC ILLNESS AND THE FUTURE OF NATIONS.
196031 01-17

DEPRESSIVE ILLNESS: ADRENERGIC RESPONSIVENESS AND THE EFFECT OF LITHIUM ON PLATELET ADENYLCYCLASE. (PH.D. DISSERTATION).
196260 01-13

SURVEY OF HEALTH AND ILLNESS IN FAMILY PRACTICE.
198049 01-17

LITHIUM RESPONSE IN DEPRESSION AS PREDICTED BY UNIPOLAR/BIPOLAR ILLNESS, AVERAGE EVOKED RESPONSE, CATECHOL-O-METHYLTRANSFERASE AND FAMILY HISTORY. (UNPUBLISHED PAPER).
201000 02-09

DEPRESSIVE ILLNESS AND HYPERPARATHYROIDISM.
201239 02-15

INVESTIGATION OF CLINICAL EFFECTS OF FK-880 (SULPIRIDE) ON MANIC-DEPRESSIVE ILLNESS.
207535 03-09

RESULTS OF THERAPY WITH LYOGEN DEPOT IN SCHIZOPHRENIC ILLNESS.
208622 03-08

A STUDY OF ELECTROLYTE AND BIOGENIC AMINE METABOLISM IN MANIC-DEPRESSIVE ILLNESS.
208917 03-09

LITHIUM, CALCIUM, AND MENTAL ILLNESS.
209350 03-13

MAINTENANCE DOXEPIN (SINEQUAN) THERAPY FOR DEPRESSIVE ILLNESS.
209901 03-09

LITHIUM USE IN MANIC-DEPRESSIVE ILLNESS: PRACTICAL ASPECTS.
215680 04-17

WHY DO PATIENTS WITH MANIC-DEPRESSIVE ILLNESS STOP THEIR LITHIUM?
219365 04-09

A SINGLE DAILY DOSE OF A SUSTAINED RELEASE FORM OF AMITRIPTYLINE IN DEPRESSIVE ILLNESS.
219961 04-09

CLINICAL - PSYCHOPATHOLOGICAL CRITERIA FOR THE SELECTION OF PSYCHOTROPIC DRUGS ACCORDING TO THE STAGE OF ILLNESS AND THE EFFECTIVENESS OF REHABILITATING SCHIZOPHRENICS.
220403 04-17

DOUBLE-BLIND COMPARISON OF MAPROTILINE (LUDIOMIL) WITH AMITRIPTYLINE IN THE TREATMENT OF DEPRESSIVE ILLNESS.
221652 04-09

A COMPARISON BETWEEN MAPROTILINE (LUDIOMIL) AND IMIPRAMINE IN THE TREATMENT OF DEPRESSIVE ILLNESS IN THE ELDERLY.
221655 04-09

MANIC-DEPRESSIVE ILLNESS.
221820 04-09

MILD DEPRESSIVE ILLNESS.
221891 04-10

AMOXAPINE, IMIPRAMINE AND PLACEBO IN DEPRESSIVE ILLNESS.
225063 04-09

ILLNESSES

THE CURRENT STATUS OF LITHIUM RECIDIVISM PROPHYLAXIS IN ENDOGENOUS AFFECTIVE ILLNESSES.
200568 02-09

THERAPY WITH LITHIUM SALTS IN MANIC-DEPRESSIVE ILLNESSES.
209070 03-09

ILLUMINATION

THE EFFECTS OF AGE AND ILLUMINATION ON THE DOSE-RESPONSE CURVES FOR THREE STIMULANTS.
214014 04-04

IMAGE

ON THE PARTICIPATION OF BIOGENIC AMINES AND THEIR SYNTHETIC ENZYMES IN THE MECHANISMS OF IMAGE MEMORY.
213469 04-04

IMAGERY

THE USE OF FREE IMAGERY, NONDIRECTIVE INTERVIEWING, AND SELECTED DRUGS TO LIFT POSTHYPNOTIC REPRESSION. (PH.D. DISSERTATION).
222060 04-14

IMAP

THE DEPOT COMPOUNDS MODITEN (FLUPHENAZINE) AND IMAP (FLUSPIRILENE) IN CLINICAL PRACTICE.
205584 02-08

IMBECILITY

THE TREATMENT OF BEHAVIOR DISORDERS IN IDIOCY AND IMBECILITY WITH CLOZAPINE.
203598 02-11

IMIDAZOLE

THE SITE OF THE RESPIRATORY STIMULANT ACTION OF IMIDAZOLE IN CATS.
196582 01-03

IMIDAZOLEACETIC

BEHAVIOURAL INTERACTIONS BETWEEN IMIDAZOLEACETIC ACID AND GAMMA-HYDROXYBUTYRIC ACID IN RATS AND MICE.
193545 01-04

IMINODIBENZYL

COMPETITION FOR PLASMA PROTEIN BINDING SITES BETWEEN PHENOTHIAZINE TRANQUILIZERS AND IMINODIBENZYL ANTIDEPRESSANTS.
217891 04-03

IMIPRAMINE

RESULTS OF TREATING CHILDREN WITH NOCTURNAL ENURESIS WITH IMIPRAMINE (PSYCHOFORIN).
194208 01-11

5-HYDROXYTRYPTAMINE IN PLATELETS AND BRAIN OF RABBITS TREATED CHRONICALLY WITH IMIPRAMINE, MORPHINE OR METHADONE.
194744 01-03

THE BLOCKADE OF BULBOSPINAL INHIBITION BY IMIPRAMINE, DESIPRAMINE AND PARGYLINE.
195095 01-03

THE EFFECT OF CHLORPROMAZINE AND IMIPRAMINE ON THE AVERSIVE THRESHOLD OF RATS.
195294 01-04

DEAMINATION OF BETA-PHENYLETHYLAMINE BY MONOAMINEOXIDASE -- INHIBITION BY IMIPRAMINE.
195447 01-13

CYTOTOXIC EFFECTS OF IMIPRAMINE ON PLATELETS.
195450 01-03

CLINICAL ASPECTS OF RESISTANCE TO IMIPRAMINE THERAPY.
196039 01-11

A PATTERN OF ANTIDEPRESSIVE EFFECT OF TRYPTOPHAN & IMIPRAMINE IN MALES & FEMALES.
196680 01-09

THE EFFECTS OF IMIPRAMINE AND PROMAZINE ON ENERGY METABOLISM AND EEG OF THE ISOLATED PERFUSED RAT BRAIN.
197296 01-03

TRUE AND APPARENT SIDE-EFFECTS IN A CONTROLLED TRIAL OF CHLORPROMAZINE AND IMIPRAMINE IN DEPRESSION.
197856 01-09

POTENTIATION OF TETRABENAZINE-INDUCED BEHAVIOURAL DEPRESSION BY IMIPRAMINE ON A DISCRETE TRIAL AVOIDANCE ESCAPE SCHEDULE.
197859 01-04

TREATMENT OF EXPERIMENTAL IMIPRAMINE INTOXICATION BY INTERRUPTING ENTERAL CYCLES WITH ACTIVATED CHARCOAL.
197969 01-03

PLASMA LEVELS OF IMIPRAMINE AND CLINICAL OUTCOME.
198097 02-07

THE EFFECTS OF HYPNOTICS ON IMIPRAMINE TREATMENT.
200049 02-13

QUANTITATIVE ANALYSIS OF THE EEG EFFECTS PRODUCED BY IMIPRAMINE, DESIPRAMINE, PROMAZINE, AND MONODESMETHYL PROMAZINE IN THE ISOLATED PERFUSED RAT BRAIN.
200056 02-03

THE ROLE OF SEROTONIN IN THE PATHOPHYSIOLOGY OF MYOCLONIC SEIZURES ASSOCIATED WITH ACUTE IMIPRAMINE TOXICITY.
200088 02-03

THE EFFECT OF TRIIODOTHYRONINE IN COMBINATION WITH IMIPRAMINE ON (3H) CYCLIC-AMP PRODUCTION IN SLICES OF RAT CEREBRAL CORTEX.
202777 02-03

A PRELIMINARY REPORT ON THE ACTION OF IMIPRAMINE AND ANTIPARKINSONIAN AGENTS ON THE OPEN-FIELD BEHAVIOUR OF RATS.
202803 02-04

RESULTS OF AN OPEN AND A DOUBLE-BLIND STUDY OF NOMIFENSINE IN COMPARISON TO IMIPRAMINE.
204899 02-10

POSSIBLE PHARMACOLOGICAL AND THEORETICAL IMPLICATIONS OF X-RAY STRUCTURE OF THE TRICYCLIC ANTIDEPRESSANT IMIPRAMINE.
205029 02-01

CARDIOTOXIC EFFECTS OF TRICYCLIC ANTIDEPRESSANTS IMIPRAMINE, AMITRIPTYLINE AND DOSULEPIN (PROTHIADEN-SPOFA) IN AN ACUTE EXPERIMENT IN RATS.
205597 02-15

ANTIDEPRESSANT RESPONSE TO TRICYCLICS AND URINARY MHPG IN UNIPOLAR PATIENTS: CLINICAL RESPONSE TO IMIPRAMINE OR AMITRIPTYLINE.
207443 03-13

SIDE-EFFECTS OF IMIPRAMINE AND AMITRIPTYLINE.
207519 03-15

ONE-YEAR FOLLOWUP OF HYPERACTIVE BOYS TREATED WITH IMIPRAMINE OR METHYLPHENIDATE.
209736 03-11

A DOUBLE-BLIND COMPARISON OF LITHIUM CARBONATE AND IMIPRAMINE IN THE TREATMENT OF DEPRESSION.
210241 03-09

THE NATURE OF (3H)IMIPRAMINE BINDING TO SYNAPTOSOMES.
210904 03-03

EFFECTS OF IMIPRAMINE UPON FROG NERVE EXCITABILITY AND CONDUCTION.
210925 03-03

BIOLOGICAL AND PHARMACOKINETIC EVIDENCE FOR GENERIC EQUIVALENCE OF THREE IMIPRAMINE PREPARATIONS: COMPARISON WITH A NEW IMIPRAMINE ANALOGUE.
211071 03-02

A COMPARATIVE STUDY OF N-7001 (METRISIL) AND IMIPRAMINE ON A SERIES OF DEPRESSIVE PATIENTS.
212241 03-11

THE EFFECTS OF AMPHETAMINE, IMIPRAMINE AND ICI-58834 (VIVALAN), A POTENTIAL ANTIDEPRESSANT, ON UNCONDITIONED BEHAVIOUR IN RATS.
214016 04-04

FIRST-PASS METABOLISM OF IMIPRAMINE IN MAN.
215671 04-13
DIFFERENTIAL EFFECTS OF CHLORPROMAZINE, IMIPRAMINE, NITRAZEPAM AND AMOBARBITAL ON REM SLEEP AND REM DENSITY IN MAN.
215955 04-14
CLINICAL TRIAL OF LOFEPRAMIN VERSUS IMIPRAMINE.
217450 04-09
PLASMA LEVELS OF IMIPRAMINE AND DESMETHYLIMIPRAMINE AND ANTIDEPRESSANT EFFECT DURING CONTROLLED THERAPY.
217477 04-09
INTERACTIONS OF IMIPRAMINE AND SYNTHESIS INHIBITORS ON BIOGENIC AMINES.
217827 04-03
ANTIDEPRESSANTS IN BLACK AND WHITE INPATIENTS: DIFFERENTIAL RESPONSE TO A CONTROLLED TRIAL OF CHLORPROMAZINE AND IMIPRAMINE.
218770 04-09
DOUBLE-BLIND COMPARISON OF LITHIUM CARBONATE AND IMIPRAMINE IN TREATMENT OF DEPRESSION.
218772 04-09
A COMPARISON OF THE ACTION OF THE TRICYCLIC ANTIDEPRESSANTS, AZAPHEN AND IMIPRAMINE, ON THE GASTROINTESTINAL TRACT OF TEST ANIMALS.
219505 04-03
CARDIAC ARRHYTHMIA AND IMIPRAMINE THERAPY.
219517 04-15
PHARMACOKINETICS OF IMIPRAMINE.
221628 04-13
OBJECTIVE ASSESSMENT OF ANTICHOLINERGIC SIDE-EFFECTS OF TRICYCLIC ANTIDEPRESSANTS A CONTROLLED STUDY OF IMIPRAMINE AND IMIPRAMINE-N-OXIDE.
221633 04-15
A CONTROLLED COMPARISON OF MAPROTILINE (LUDIOMIL) WITH IMIPRAMINE AVOIDING OBSERVER BIAS.
221654 04-09
A COMPARISON BETWEEN MAPROTILINE (LUDIOMIL) AND IMIPRAMINE IN THE TREATMENT OF DEPRESSIVE ILLNESS IN THE ELDERLY.
221655 04-09
DOXEPIN AND IMIPRAMINE: EFFECT ON CATECHOLAMINE INHIBITION OF GANGLIONIC TRANSMISSION.
225059 04-03
AMOXAPINE, IMIPRAMINE AND PLACEBO IN DEPRESSIVE ILLNESS.
225063 04-09
A COMPARATIVE CLINICAL TRIAL OF ORG-GB-94 AND IMIPRAMINE IN THE TREATMENT OF DEPRESSION IN GENERAL PRACTICE.
225107 04-09
IMIPRAMINE AND SEIZURES.
225335 04-15
ELECTROCARDIOGRAPHIC MONITORING OF ENURETIC CHILDREN RECEIVING THERAPEUTIC DOSES OF IMIPRAMINE.
225336 04-15
IMIPRAMINE AND ELECTROCARDIOGRAPHIC ABNORMALITIES IN HYPERACTIVE CHILDREN.
225337 04-15
THE EFFECT OF AMITRIPTYLINE, DESIPRAMINE AND IMIPRAMINE ON THE IN VIVO BRAIN SYNTHESIS OF 3H-NORADRENALINE FROM 3H-L-DOPA IN THE RAT.
225565 04-03

IMIPRAMINE-INDUCED
IMIPRAMINE-INDUCED HEART BLOCK: A LONGITUDINAL CASE STUDY.
215014 04-13

IMIPRAMINE-N-OXIDE
EXPERIENCE WITH IMIPRAMINE-N-OXIDE (IPNO) IN TREATING DEPRESSIVE STATES.
221209 04-09
OBJECTIVE ASSESSMENT OF ANTICHOLINERGIC SIDE-EFFECTS OF TRICYCLIC ANTIDEPRESSANTS A CONTROLLED STUDY OF IMIPRAMINE AND IMIPRAMINE-N-OXIDE.
221633 04-15

IMIZINE
THE INFLUENCE OF TRIFLUOPERAZINE, CARBIDINE AND IMIZINE ON EVOKED POTENTIALS IN DIFFERENT STRUCTURES OF THE LIMBIC RETICULAR COMPLEX.
200564 02-02
THE INFLUENCE OF TRICYCLIC ANTIDEPRESSANTS, AZAPHEN AND IMIZINE ON BLOOD SUGAR CONCENTRATION CHANGES PRODUCED BY EPINEPHRINE AND SEROTONIN.
217214 04-03

IMMATURE
AGGRESSIVE BEHAVIORS INDUCED BY CHRONIC ADMINISTRATION OF THEOPHYLLINE, WITH PARTICULAR REFERENCE TO ALTERATIONS IN BEHAVIORS OF IMMATURE RATS.
200748 02-04
SEROTONIN SENSITIVE ADENYLCYCLASE ACTIVITY IN IMMATURE RAT BRAIN.
217355 04-03

IMMOBILITY
THE USE OF THE IMMOBILITY REFLEX (ANIMAL HYPNOSIS) AS A POSSIBLE PROCEDURE FOR DETECTING SEDATIVE ACTIVITY.
196066 01-04
TONIC IMMOBILITY IN CHICKENS: POSSIBLE INVOLVEMENT OF MONOAMINES.
217762 04-03

IMMOBILIZATION
EFFECTS OF PREVIOUS CURARE IMMOBILIZATION ON PAVLOVIAN CONDITIONED HEART DECELERATIONS IN THE CURARIZED RAT.
219083 04-04

IMMUNOLOGICAL
EXPERIMENTAL STUDY INTO IMMUNOLOGICAL FACTORS OF RESISTANCE TO CHLORPROMAZINE.
201920 02-03
IMMUNOLOGICAL LOCALIZATION OF DOPAMINE-BETA-HYDROXYLASE ON THE CHROMAFFIN GRANULE MEMBRANE.
207326 03-03

IMMUNOSYMPATHECTOMY
HYPOTHALAMIC SELF-STIMULATION IN RATS FOLLOWING IMMUNOSYMPATHECTOMY OR CENTRAL NERVE GROWTH FACTOR ANTISERUM INJECTION.
211512 03-04

IMPACT
ASSESSING THE IMPACT OF LOW LEVEL CHEMICALS ON DEVELOPMENT: BEHAVIORAL AND LATENT EFFECTS.
225164 04-15

IMPAIR
CHANGES OF KINETIC CONSTANT OF STRIATAL TYROSINE-HYDROXYLASE ELICITED BY NEUROLEPTICS THAT IMPAIR THE FUNCTION OF DOPAMINE RECEPTORS.
202716 02-03

IMPAIRED
REVERSAL BY L-DOPA OF IMPAIRED LEARNING DUE TO DESTRUCTION OF THE DOPAMINERGIC NIGRO-NEOSTRIATAL PROJECTION.
193578 01-04
EEG CORRELATES OF IMPAIRED ATTENTION PERFORMANCE UNDER SECOBARBITAL AND CHLORPROMAZINE IN THE MONKEY.
217544 04-03

IMPAIRMENT
HYDROCORTISONE-INDUCED SUPERSENSITIVITY TO NORADRENALINE IN THE ISOLATED NICTITATING MEMBRANE AS A CONSEQUENCE OF AN IMPAIRMENT OF AN O-METHYLATING SYSTEM WITH HIGH AFFINITY.
197944 01-03

IMPEDANCE
CEREBRAL HEMODYNAMIC EFFECTS OF CHRONIC TRYPTOPHAN FEEDING IN MAN AS MEASURED BY QUANTIFIED CEREBRAL IMPEDANCE PLETHYSMOGRAPHY.
206337 03-08

IMPLANTATION
CENTRAL IMPLANTATION OF CANNABINOIDS: INDUCTION OF EPILEPTIFORM DISCHARGES.
193449 01-03
DISULFIRAM IMPLANTATION CRITICALLY EVALUATED.
205316 02-11

IMPORTANT
DISRUPTION OF STATE-DEPENDENT LEARNING (MEMORY RETRIEVAL) BY EMOTIONALLY IMPORTANT STIMULI.
217470 04-04

IMPRESSIONS
SIDE-EFFECTS OF BREVITAL AIDED DESENSITIZATION: SOME CLINICAL IMPRESSIONS.
193986 01-15

IMPRINTING
IMPRINTING: CORRELATIONS BETWEEN BEHAVIOUR AND INCORPORATION OF (14C)URACIL INTO CHICK BRAIN.
210667 03-04
INHIBITION OF MEMORY FORMATION IN THE IMPRINTING PERIOD: IRREVERSIBLE ACTION OF CYCLOHEXIMIDE IN YOUNG CHICKENS.
210708 03-04

IMPROVEMENT
THE CORRELATION BETWEEN THE VENTRAL AND DORSAL HIPPOCAMPUS DURING IMPROVEMENT OR DETERIORATION OF SHORT-TERM MEMORY.
215487 04-04

IMPULSE
INCREASE IN BRAIN DOPAMINE AFTER AXOTOMY OR TREATMENT WITH GAMMA-HYDROXYBUTYRIC ACID DUE TO ELIMINATION OF THE NERVE IMPULSE FLOW.
195439 01-03
DOPAMINERGIC NEURONS: DRUG-INDUCED ANTAGONISM OF THE INCREASE IN TYROSINE-HYDROXYLASE ACTIVITY PRODUCED BY CESSATION OF IMPULSE FLOW.
202664 02-03
NERVE IMPULSE ENHANCED RELEASE OF AMINO ACIDS FROM NONSYNAPTIC REGIONS OF PERIPHERAL AND CENTRAL NERVE TRUNKS OF BULLFROG.
213277 03-03

INBRED
EFFECTS OF D-AMPHETAMINE ON LEARNING AND MEMORY IN INBRED AND HYBRID MICE. (PH.D. DISSERTATION).
193581 01-04

ALCOHOL WITHDRAWAL REACTIONS AND RESERPINE EFFECTS IN INBRED STRAINS OF MICE.
197821 01-03

INCISIVE
ALCOHOLISM AND INCISIVE NEUROLEPTICS.
219836 04-14

INCOMPATIBILITY
TO THE INCOMPATIBILITY OF HALOPERIDOL WITH LITHIUM SALTS.
205612 03-15

INCREASE
TIME-DEPENDENT, MEMORY RETRIEVAL EFFECTS FOLLOWING PERIPHERAL AND HIPPOCAMPAL TREATMENTS TO INCREASE SYNAPTIC BIOGENIC AMINES. (PH.D. DISSERTATION).
194677 01-04

INCREASE IN BRAIN DOPAMINE AFTER AXOTOMY OR TREATMENT WITH GAMMA-HYDROXYBUTYRIC ACID DUE TO ELIMINATION OF THE NERVE IMPULSE FLOW.
195439 01-03

EFFECTS OF DRUGS INFLUENCING MONOAMINE MECHANISMS ON THE INCREASE IN BRAIN DOPAMINE PRODUCED BY AXOTOMY OR TREATMENT WITH GAMMA-HYDROXYBUTYRIC ACID.
195440 01-03

INFLUENCE OF CATECHOLAMINE UPTAKE BLOCKING DRUGS ON THE INCREASE IN WATER INTAKE AND PLASMA RENIN CONCENTRATION INDUCED BY SOME HYPOTENSIVE DRUGS.
197288 01-03

PSYCHOPHARMACOLOGICAL EVIDENCE FOR INCREASE IN RECEPTOR SENSITIVITY FOLLOWING CHRONIC MORPHINE TREATMENT.
197855 01-04

DOPAMINERGIC NEURONS: DRUG-INDUCED ANTAGONISM OF THE INCREASE IN TYROSINE-HYDROXYLASE ACTIVITY PRODUCED BY CESSATION OF IMPULSE FLOW.
202664 02-03

EVIDENCE AGAINST A CAUSAL RELATIONSHIP BETWEEN INCREASE IN C-AMP AND INDUCTION OF TYROSINE-HYDROXYLASE IN THE RAT ADRENAL MEDULLA.
202795 02-03

INHIBITION BY DIAZEPAM OF THE TREMOR AND THE INCREASE OF CEREBELLAR CGMP CONTENT ELICITED BY HARMALINE.
207798 03-03

BRAIN ACETYLCHOLINE: INCREASE AFTER SYSTEMIC CHOLINE ADMINISTRATION.
217399 04-03

DIFFERENTIAL RATES OF INCREASE IN PONTINE TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE ACTIVITIES AFTER RESERPINE.
217854 04-03

EFFECT OF DRUG-INDUCED INCREASE OF BRAIN GABA LEVELS ON PENICILLIN FOCUS.
220947 04-03

INCREASES
DIAZEPAM INCREASES 5-HYDROXYINDOLE CONCENTRATIONS IN RAT BRAIN AND SPINAL CORD.
200081 02-03

PUNISHED BEHAVIOR: INCREASES IN RESPONDING AFTER D-AMPHETAMINE.
217542 04-04

INCREASING
THE EFFECTIVENESS OF RITALIN AND TOKEN ECONOMY IN INCREASING HYPERKINETIC CHILDRENS COLORING BEHAVIOR. (PH.D. DISSERTATION).
220510 04-14

INDEPENDENT
DRUGS AND PUNISHED RESPONDING. V. EFFECTS OF DRUGS ON RESPONDING SUPPRESSED BY RESPONSE DEPENDENT AND RESPONSE INDEPENDENT ELECTRIC SHOCK.
215722 04-04

THE EFFECTS OF CHRONIC MORPHINE ADMINISTRATION UPON A MODIFIED SIDMAN AVOIDANCE SCHEDULE THAT UTILIZES RESPONSE INDEPENDENT SHOCK.
225566 04-04

INDEXES
AMPHETAMINE TOXICITY: BEHAVIORAL AND NEUROPATHOLOGICAL INDEXES.
225165 04-05

INDICATING
MESOLIMBIC INVOLVEMENT WITH BEHAVIOURAL EFFECTS INDICATING ANTIPSYCHOTIC ACTIVITY.
193450 01-03

INDICATION
PROFILE-BASED-THERAPY (PBT) IN SCHIZOPHRENIAS: A PRECLINICAL INDICATION FOR THE USE OF DIHYDROXYPHENYLSERINE (DOPS).
195115 01-08

ATYPICAL INDICATION OF LITHIUM THERAPY.
212213 03-09

INDIRECT
THE NUCLEUS LINEARIS INTERMEDIUS RAPHE AND BEHAVIOUR EVOKED BY DIRECT AND INDIRECT STIMULATION OF DOPAMINE SENSITIVE SITES WITHIN THE CAUDATE NUCLEUS OF CATS.
199864 02-04

INDIVIDUAL
CHRONIC AMPHETAMINE TREATMENT: VAST INDIVIDUAL DIFFERENCES IN PERFORMING A LEARNED RESPONSE.
202794 02-04

THE EFFECT OF DIAZEPAM AND NITRAZEPAM ON INTRACELLULAR AND EXTRACELLULAR DISTRIBUTION OF SODIUM AND POTASSIUM IONS IN INDIVIDUAL STRUCTURES OF RATS BRAINS.
207199 03-03

EFFECT OF STRESS ON CATECHOLAMINES AND TYROSINE-HYDROXYLASE ACTIVITY OF INDIVIDUAL HYPOTHALAMIC NUCLEI.
208994 03-03

DIFFERENTIAL EFFECTS OF CAFFEINE, D-AMPHETAMINE AND METHYLPHENIDATE ON INDIVIDUAL RAPHE CELL FLUORESCENCE: A MICROSPECTROFLUORIMETRIC DEMONSTRATION.
213400 04-03

THE METABOLISM OF INDIVIDUAL PHOSPHOLIPID FRACTIONS IN THE RAT BRAIN DURING THIOPENTAL SLEEP AND AMPHETAMINE EXCITATION.
219747 04-03

INDIVIDUALS
A CONTROLLED SERIES OF EXPERIMENTS INVESTIGATING SOME SOCIOLOGICAL EFFECTS OF TWO DOSAGES OF CHLORDIAZEPOXIDE (LIBRIUM) UPON INDIVIDUALS AND SMALL GROUPS. (PH.D. DISSERTATION).
195145 01-14

INDOLE
A CRITICAL EVALUATION OR MOLINDONE (MOBAN): A NEW INDOLE DERIVATIVE NEUROLEPTIC.
196674 01-07

AN INVESTIGATION OF PSYCHOTROPIC ACTIVITY IN A SERIES OF PIPERAZINE (1,2-A) INDOLE DERIVATIVES.
206438 03-02

EXPERIMENTAL STUDY ON NEUROPHARMACOLOGICAL ACTIONS OF SOME INDOLE DERIVATIVES.
207164 03-02

INDOLEACETIC
FOUR CASES OF DEPRESSION TREATED BY INDOLEACETIC ACID.
207554 03-09

INDOLEALKYLAMINE
EFFECT OF INDOLEALKYLAMINE MANIPULATIONS ON LOCOMOTOR ACTIVITY IN RATS.
195087 01-04

INDOLEAMINE
BIOCHEMICAL EFFECTS OF DIHYDROXYLATED TRYPTAMINES ON CENTRAL INDOLEAMINE NEURONES.
204340 02-03

EVIDENCE THAT 5-METHOXYDIMETHYLTRYPTAMINE IS A SPECIFIC SUBSTRATE FOR MAO-A IN THE RAT: IMPLICATIONS FOR THE INDOLEAMINE DEPENDENT BEHAVIORAL SYNDROME.
210817 03-04

INDOLEAMINE-N-METHYLATION
3,4 DIHYDROXYPHENYLACETIC ACID (DOPAC): A POSSIBLE ENDOGENOUS INHIBITOR OF INDOLEAMINE-N-METHYLATION IN THE RAT BRAIN.
197676 01-17

INDUCE
DOES CHRONIC MORPHINE TREATMENT INDUCE A SUPERSENSITIVITY OF DOPAMINE RECEPTORS IN RAT BRAIN
221038 04-03

INDUCED
D,L P-CHLORO-N-METHYLAMPHETAMINE (P) INDUCED ACCUMULATION OF 5-HT IN NONTERMINAL AXONS.
192944 01-03

DEPRESSION BY AMANTADINE OF TREMOR INDUCED BY RESERPINE AND OXOTREMORINE IN THE RAT.
193282 01-04

EFFECT OF APOMORPHINE AND NALLINE ON METHADONE INDUCED BEHAVIORAL CHANGES.
193420 01-04

ANTIANESTHETIC EFFECTS OF CYCLIC-AMP AND ANALEPTIC DRUGS AS DETERMINED BY REVERSAL OF AMOBARBITAL INDUCED NARCOSIS.
193426 01-03

EFFECTS OF TRANSMITTER MIMICKERS AT SITES OF ANGIOTENSIN INDUCED DRINKING IN THE CAT.
193434 01-04

THE INFLUENCE OF CYPROHEPTADINE AND OF D-LYSERGAMIDE ON THE RISE IN TEMPERATURE INDUCED BY INTRACEREBROVENTRICULAR 5-HYDROXYTRYPTAMINE, NORADRENALINE AND DOPAMINE IN CONSCIOUS RABBITS.
193451 01-03

A CONDITIONED TASTE AVERSION INDUCED BY ALPHA-METHYL-P-TYROSINE.
195090 01-04

6-HYDROXYDOPAMINE INDUCED DEGENERATION OF NORADRENALINE NEURONS IN THE SCORBUTIC GUINEA-PIG.
195449 01-03

PHYSOSTIGMINE ATTENUATION OF DELTA9-TETRAHYDROCANNABINOL INDUCED HYPERTHERMIA IN RATS.
195539 01-03

SEIZURES OF CHOREOATHETIC TYPE INDUCED BY SUDDEN MOVEMENT: CORRELATION TO THE BIOGENIC AMINES.
196146 01-14

PROLONGED PENTOBARBITAL SLEEPING TIME IN ADJUVANT INDUCED POLYARTHRITIC RATS.
196228 01-04

INFLUENCE OF CATECHOLAMINE UPTAKE BLOCKING DRUGS ON THE INCREASE IN WATER INTAKE AND PLASMA RENIN CONCENTRATION INDUCED BY SOME HYPOTENSIVE DRUGS.
197288 01-03

MURICIDAL BLOCK INDUCED BY 5-HYDROXYTRYPTOPHAN IN THE RAT.
197454 01-04

ONTOGENY OF STEREOTYPED BEHAVIOUR INDUCED BY APOMORPHINE AND AMPHETAMINE IN THE RAT.
197462 01-04

SEIZURES IN RATS INDUCED BY PINEALECTOMY: INFLUENCE OF DIAZEPAM, CHLORDIAZEPOXIDE, AND DIPHENYLHYDANTOIN AND PINEAL SUBSTANCES.
197465 01-03

EFFECT OF BENZODIAZEPINE DERIVATIVES ON SOMAN INDUCED SEIZURE ACTIVITY AND CONVULSIONS IN THE MONKEY.
197466 01-03

ALTERATIONS IN ACID-BASE BALANCE IN THE DOG AFTER INTRAVENOUS ADMINISTRATION OF BENZOCTAMINE AND DIAZEPAM, COMPARED WITH THOSE INDUCED BY THIOPENTAL.
197485 01-03

EFFECT OF DELTA1-TETRAHYDROCANNABINOL AND PROPRANOLOL ON OUABAIN INDUCED ARRHYTHMIAS.
197486 01-03

PHARMACOLOGICAL INFLUENCES ON CARBON DIOXIDE INDUCED AMNESIA.
197497 01-03

LIGHT INDUCED FRAGMENTATION OF 3,5-DIOXO-1,2 DIPHENYL-4-N-BUTYLPYRAZOLIDINE (PHENYLBUTAZONE) WITH NUCLEOPHILIC AGENTS.
197675 01-01

PROTRIPTYLINE INDUCED INHIBITION OF THE IN VIVO 3H-NORADRENALINE SYNTHESIS FROM 3H-L-DOPA IN THE RAT BRAIN.
197928 01-03

SPECIFIC ASYMMETRIC BEHAVIOUR INDUCED BY THE DIRECT CHEMICAL STIMULATION OF NEOSTRIATAL DOPAMINERGIC MECHANISMS.
197929 01-04

TASTE PHENOMENA INFLUENCES ON STIMULATION OF DEPRIVATION INDUCED FLUID CONSUMPTION OF RATS.
197991 01-03

BEHAVIOURAL AND ELECTROCORTICAL MODIFICATIONS INDUCED IN THE RAT BY INTRAVENTRICULAR INJECTION OF PHYSALAEMIN AND ELEDOISIN.
198224 02-03

PROTEINASE ACTIVITY OF DIFFERENT SECTIONS OF THE BRAIN DURING CORAZOL (PENTYLENETETRAZOL) INDUCED CONVULSIONS.
198485 02-03

THE EFFECT OF L-DOPA ON THE DEVELOPMENT OF RESERPINE INDUCED PARKINSONISM AND CATECHOLAMINE METABOLISM IN RATS.
198486 02-03

THE EFFECTS OF DIPHENYLHYDANTOIN, PHENOBARBITAL, AND DIAZEPAM ON THE PENICILLIN INDUCED EPILEPTOGENIC FOCUS IN THE RAT.
198613 02-03

LITHIUM INDUCED LOSS OF BODY SODIUM AND THE DEVELOPMENT OF SEVERE INTOXICATION IN RATS.
199623 02-03

INHIBITION OF SCOPOLAMINE INDUCED STIMULATION OF Y-MAZE ACTIVITY BY ALPHA-METHYL-P-TYROSINE AND BY LITHIUM.
199866 02-04

EFFECTS OF LITHIUM CHLORIDE ON CARDIOVASCULAR RESPONSES INDUCED BY CHOLINERGIC AND ADRENERGIC STIMULATIONS.
199870 02-03

EFFECTS OF CHLORIMIPRAMINE ON EXPERIMENTALLY INDUCED CHANGES IN FOREBRAIN 5-HYDROXYINDOLES.
199966 02-03

IDENTIFICATION AND STRUCTURAL CHARACTERIZATION OF AN INHIBITOR OF CATECHOLAMINE INDUCED FREE FATTY ACID MOBILIZATION FROM THE CALF MIDBRAIN.
200006 02-01

BEHAVIORAL SPECIFICITY OF CHLORALOSE INDUCED FEEDING IN THE RAT.
200054 02-04

INHIBITION OF BEHAVIOURAL AND EEG ACTIVATION INDUCED BY MORPHINE ACTING ON LOWER BRAINSTEM STRUCTURES.
200078 02-03

THE EFFECTS OF CHLORPROMAZINE, ATROPINE, MORPHINE AND PENTOBARBITAL ON INDUCED GASTRIC ULCERATION IN RATS. (PH.D. DISSERTATION).
200405 02-02

AGGRESSIVE BEHAVIORS INDUCED BY CHRONIC ADMINISTRATION OF THEOPHYLLINE, WITH PARTICULAR REFERENCE TO ALTERATIONS IN BEHAVIORS OF IMMATURE RATS.
200748 02-04

STUDIES OF CONFLICT INDUCED BEHAVIOR IN THE CAT: BEHAVIOR ANALYSIS AND EFFECTS OF PSYCHOTROPIC DRUGS.
202122 02-04

REVERSAL OF RESERPINE INDUCED BRADYKINESIA BY ALPHA-METHYLDOPA -- NEW LIGHT ON ITS MODUS-OPERANDI.
202281 02-03

THE EXTRAPYRAMIDAL SYNDROME INDUCED BY NEUROLEPTICS.
202445 02-15

PENTYLENETETRAZOL INDUCED RETROGRADE AMNESIA AND BRAIN SEIZURES IN MICE.
202724 02-04

AN ANALYSIS OF THE GROSS BEHAVIOURAL CHANGES INDUCED BY TETRAETHYLAMMONIUM AND A COMPARISON WITH OTHER SUBSTANCES AFFECTING THE AUTONOMIC AND CENTRAL NERVOUS SYSTEM AFTER INTRAVENTRICULAR INJECTIONS TO CONSCIOUS CATS.
202781 02-04

SUBJECTIVE CHANGES IN VOLUNTEERS WITHOUT PRIOR EXPERIENCE OF CANNABIS INDUCED BY (-)DELTA9-TRANS-TETRAHYDROCANNABINOL.
202784 02-14

STEREOTYPED AND CIRCLING BEHAVIOUR INDUCED BY DOPAMINERGIC AGONISTS AFTER LESIONS OF THE MIDBRAIN RAPHE NUCLEI.
202792 02-04

BEHAVIORAL CHANGES INDUCED BY PSYCHOTROPIC SUBSTANCES IN EXPERIMENTAL ANIMALS.
202864 02-04

METHYLDOPA INDUCED DECREASE IN MENTAL ACTIVITY.
202921 02-15

EFFECT OF DIAZEPAM UPON SOMAN INDUCED SEIZURE ACTIVITY AND CONVULSIONS.
204192 02-02

THE INFLUENCE OF ANTIADRENERGIC AND ANTIDOPAMINERGIC DRUGS ON METHAMPHETAMINE INDUCED CHANGES IN MOTORIC ACTIVITY AND CEREBRAL GLYCOGEN CONTENT IN MICE.
204396 02-03

EFFECT OF BETA-RECEPTOR BLOCKERS (PINDOLOL AND PRACTOLOL) ON LITHIUM INDUCED TREMOR -- CLINICAL TRIAL AND THEORETICAL CONSIDERATIONS.
204409 02-15

SELECTIVE INHIBITION OF DOPAMINE-BETA-HYDROXYLASE IN THE PERIPHERAL TISSUES BY 5-DIMETHYLDITHIOCARBAMYLPICOLINIC ACID; ITS EFFECT ON STRESS INDUCED ULCER, ETHANOL INDUCED SLEEP AND BLOOD PRESSURE.
204484 02-03

LACK OF EFFECT OF AMANTADINE ON D-AMPHETAMINE INDUCED RELEASE OF DOPAMINE FROM CAT BRAIN IN VIVO.
204865 02-02

CANNABINOID INDUCED CHANGES IN MOUSE STRIATAL HOMOVANILLIC ACID AND DIHYDROXYPHENYLACETIC ACID: THE EFFECTS OF AMPHETAMINE AND L-DOPA.
204866 02-03

BEHAVIOURAL AND ELECTROGRAPHIC OBSERVATIONS DURING EPILEPTIC CONVULSIONS INDUCED BY STRYCHNINE AND PENTYLENETETRAZOL IN CONSCIOUS YOUNG AND ADULT CHICKENS.
205459 02-03

EFFECTS OF DIAZEPAM ON EXPERIMENTALLY INDUCED CORTICAL EPILEPSY AND THEIR CORRELATION WITH DRUG CONCENTRATION.
205491 02-03

COMPARATIVE STUDY OF THE ELECTRONEUROPHYSIOLOGICAL PARAMETERS OF SLEEP INDUCED BY SEVERAL HYPNOTIC DRUGS.
205520 02-13

EFFECT OF SODIUM GAMMA-HYDROXYBUTYRATE ON ISOLATION INDUCED AGGRESSIVITY IN MICE.
205588 02-04

POTENTIATION OF CATALEPSY INDUCED BY NARCOTIC AGENTS DURING HAFFNERS TEST FOR ANALGESIA.
206358 03-04

ROLE OF THE BIOGENIC AMINES IN THE REVERSAL OF CYCLOHEXIMIDE INDUCED AMNESIA.
206752 03-04

SUPERSENSITIVITY TO DOPAMINE AGONISTS FOLLOWING UNILATERAL, 6-HYDROXYDOPAMINE INDUCED STRIATAL LESIONS IN MICE.
208552 03-03

A CASE OF IRREVERSIBLE EXTRAPYRAMIDAL HYPERKINESIA INDUCED BY NEUROLEPTIC DRUGS.
209410 03-15

HEPTAMINOL AND TENSION DISTURBANCES INDUCED BY PSYCHOTROPIC DRUG THERAPY: CLINICAL STUDY.
210089 03-13

TREATMENT OF PHENOTHIAZINE INDUCED BULBAR PERSISTENT DYSKINESIA WITH DEANOL ACETAMIDOBENZOATE.
210209 03-13

PHARMACOLOGICAL MANIPULATIONS OF BRAIN CATECHOLAMINES AND THE AGGRESSIVE BEHAVIOR INDUCED BY MARIHUANA IN REM SLEEP DEPRIVED RATS.
210325 03-04

CHOLINERGIC DOPAMINERGIC INTERACTION IN THE STRIATUM: THE EFFECT OF 6-HYDROXYDOPAMINE OR PIMOZIDE TREATMENT ON THE INCREASED STRIATAL ACETYLCHOLINE LEVELS INDUCED BY APOMORPHINE, PIRIBEDIL AND D-AMPHETAMINE.
210668 03-03

DOES MARIJUANA ENHANCE EXPERIMENTALLY INDUCED ANXIETY?
210738 03-14

AN OBSERVATIONAL STUDY OF HALLUCINOGEN INDUCED BEHAVIOR IN UNRESTRAINED MACACA-MULATTA.
210739 03-04

EFFECTS OF A DECARBOXYLASE INHIBITOR ON THE DOPA AND 5-HTP INDUCED CHANGES IN THE LOCOMOTOR LIKE DISCHARGE PATTERN OF RABBIT HIND LIMB NERVES.
210740 03-03

SEROTONERGIC INVOLVEMENT WITH THE STEREOTYPY/CATALEPSY INDUCED BY MORPHINE-LIKE AGENTS IN THE RAT.
210754 03-04

THE EFFECT OF DRUGS WITH ANTIDEPRESSANT ACTIVITY UPON THE HYPOTHERMIA AND BEHAVIOURAL DEPRESSION INDUCED IN MICE BY PIMOZIDE OR CENTRALLY ADMINISTERED NORADRENALINE.
210762 03-04

CHANGES IN THE NEURONAL PROTEIN LABELLING INDUCED BY POTASSIUM IONS IN VIVO (SPREADING DEPRESSION).
210779 03-03

ELECTROCORTICAL CHANGES INDUCED BY PERFUSION OF CATECHOLAMINES INTO THE BRAINSTEM RETICULAR FORMATION.
210827 03-03

HALOPERIDOL INDUCED DISRUPTION OF CONDITIONED AVOIDANCE RESPONDING: ATTENUATION BY PRIOR TRAINING OR BY ANTICHOLINERGIC DRUGS.
210861 03-04

THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL PRETREATMENT ON KETAMINE, THIOPENTAL OR CT-1341 -- INDUCED LOSS OF RIGHTING REFLEX IN MICE.
210878 03-02

POTENTIATION OF THE L-5-HYDROXYTRYPTOPHAN INDUCED ELEVATION OF PLASMA CORTICOSTERONE LEVELS IN RATS BY A SPECIFIC INHIBITOR OF SEROTONIN UPTAKE.
211104 03-03

FLUPHENAZINE ENANTHATE INDUCED DECOMPENSATIONS.
211437 03-08

EFFECTS OF PSYCHOTROPIC DRUGS ON EXTINCTION INDUCED AGGRESSION. (PH.D. DISSERTATION).
212523 03-04

ROLE OF THE STRIO-PALLIDAL SYSTEM AND MOTOR CORTEX IN INDUCED CIRCUS MOVEMENTS IN RATS AND CATS.
213450 04-03

THE REVERSIBLE INHIBITION OF STEROID INDUCED SEXUAL BEHAVIOR BY INTRACRANIAL CYCLOHEXIMIDE.
213685 04-03

REVERSAL OF DELIRIUM INDUCED BY TRICYCLIC ANTIDEPRESSANT DRUGS WITH PHYSOSTIGMINE.
213708 04-15

EFFECTS OF CHLORDIAZEPOXIDE ON SCHEDULE INDUCED WATER AND ALCOHOL CONSUMPTION IN THE SQUIRREL MONKEY.
214013 04-04

ALTERATIONS IN BEHAVIOUR AND CATECHOLAMINE BIOSYNTHESIS INDUCED BY LITHIUM.
214067 04-04

D-AMPHETAMINE INDUCED RELEASE OF NEWLY SYNTHESIZED AND STORED DOPAMINE FROM THE CAUDATE NUCLEUS IN VIVO.
214110 04-03

ISOLATION INDUCED TIMIDITY IN MICE AS A MEASURE OF ANXIOLYTIC ACTIVITY OF DRUGS.
215063 04-04

EFFECTS OF IPRONIAZID, CHLORPROMAZINE AND METHIOTHEPIN ON DMT INDUCED CHANGES IN BODY TEMPERATURE, PUPILLARY DILATATION, BLOOD PRESSURE AND EEG IN THE RABBIT.
215724 04-03

ORAL CONTRACEPTION AND INDUCED DEPRESSIVE STATES.
216902 04-14

INHIBITION OF CATECHOLAMINE AND 5-HYDROXYTRYPTAMINE INDUCED ENZYME SECRETION FROM THE GUINEA-PIG SUBMANDIBULAR GLAND BY 2-BROMO-D-LYSERGIC ACID DIETHYLAMIDE.
216968 04-03

STUDIES OF LITHIUM INDUCED TREMOR BY MEANS OF DIFFERENT MEASUREMENT METHODS.
217453 04-15

INHIBITION OF D-AMPHETAMINE INDUCED LOCOMOTOR ACTIVITY BY INJECTION OF HALOPERIDOL INTO THE NUCLEUS-ACCUMBENS OF THE RAT.
217461 04-04

EFFECTS OF ANTAGONISTS UPON LOCOMOTOR STIMULATION INDUCED BY INJECTION OF DOPAMINE AND NORADRENALINE INTO THE NUCLEUS-ACCUMBENS OF NIALAMIDE PRETREATED RATS.
217475 04-04

CHLORDIAZEPOXIDE (LIBRIUM) INDUCED CHANGES IN INTRASPECIFIC ATTACK AND SELECTED NONAGONISTIC BEHAVIORS IN MALE SIAMESE FIGHTING FISH.
217524 04-04

A RAPID, SIMPLE AND MORE SENSITIVE METHOD FOR THE DEMONSTRATION OF CENTRAL CATECHOLAMINE CONTAINING NEURONS AND AXONS BY GLYOXYLIC ACID INDUCED FLUORESCENCE: I. SPECIFICITY.
217550 04-16

ANTAGONISM BY D-AMPHETAMINE OF LEARNING DEFICITS IN RATS INDUCED BY EXPOSURE TO ANTIPSYCHOTIC DRUGS DURING EARLY POSTNATAL LIFE.
217656 04-04

LOSS OF BODY WEIGHT AS A PREDICTOR OF RESERPINE INDUCED AMINE DEPLETION.
217661 04-03

CATECHOLAMINE CORRELATES OF ISOLATION INDUCED AGGRESSION IN MICE.
217670 04-04

ON THE MECHANISM OF THE HYPERTHERMIA INDUCED BY AMPHETAMINE IN THE RAT.
217691 04-03

THE EFFECT OF DOPAMINE AND OF APOMORPHINE ON DB-CAMP INDUCED STIMULATION OF SYNAPTOSOMAL TYROSINE-HYDROXYLASE.
217823 04-03

LACK OF EFFECT OF PROTRIPTYLINE ON THE 6-HYDROXYDOPAMINE INDUCED NORADRENALINE DEPLETION IN THE RAT SPINAL CORD.
217824 04-03

BROM-ERGOCRYPTINE IN THE TREATMENT OF PHENOTHIAZINE INDUCED GALACTORRHOEA.
218557 04-15

A PHARMACOLOGICAL ANALYSIS OF AGGRESSIVE BEHAVIOR OF MICE INDUCED BY ISOLATION.
218800 04-04

LONG-LASTING CHANGES IN CEREBRAL NEURONS INDUCED BY DRUGS.
218957 04-03

INDUCED PREFERENCE FOR MORPHINE IN RATS.
219033 04-04

ESTROGEN INDUCED MATERNAL BEHAVIOR IN HYSTERECTOMIZED OVARIECTOMIZED VIRGIN RATS.
219069 04-04

POLYETHYLENE GLYCOL INDUCED THIRST: A DUAL STIMULATORY MECHANISM?
219071 04-04

EXAMINATION OF THE ROLE OF BRAIN AMINES AND CYCLIC-AMP IN BENZODIAZEPINE INDUCED SUPPRESSION OF AGGRESSION. (PH.D. DISSERTATION).
219278 04-04

PHARMACOLOGICALLY INDUCED BEHAVIORAL CORRELATES OF NIGROSTRIATAL FUNCTION. (PH.D. DISSERTATION).
220473 04-04

SCHEDULE INDUCED AGGRESSION IN LABORATORY RATS: DEMONSTRATION AND CONTROL THROUGH SODIUM AMOBARBITAL. (PH.D. DISSERTATION).
220644 04-04

INVESTIGATIONS OF UCS-CS MEDIATION IN RADIATION INDUCED CONDITIONED TASTE AVERSION. (PH.D. DISSERTATION).
220681 04-04

MONOAMINEOXIDASE INHIBITORS ANTAGONIZE THE ACCELERATION OF BRAIN DOPAMINE SYNTHESIS INDUCED BY NEUROLEPTIC DRUGS IN VIVO: IMPLICATIONS FOR THE TREATMENT OF TARDIVE DYSKINESIA.
220948 04-03

STIMULATION OF ESTROGEN INDUCED COPULATORY BEHAVIOR IN CASTRATE MALE RATS WITH THE SEROTONIN BIOSYNTHESIS INHIBITOR P-CHLOROPHENYLALANINE.
221010 04-04

PLACEBO INDUCED SIDE-EFFECTS.
221165 04-15

ANTAGONISM OF PSYCHOSTIMULANT 2 PHENYLDIMETHYLTETRAHYDROOXAZINE HYDROCHLORIDE (G-130) TO CENTRAL NERVOUS SYSTEM DEPRESSING DRUGS: MONOAMINEOXIDASE INHIBITORY ACTIVITY AND NOREPINEPHRINE AND SEROTONIN INDUCED CHANGES, COMPARISON WITH DL-AMPHETAMINE.
221267 04-03

TETRAHYDROCANNABINOL INDUCED MANIFESTATIONS OF THE MARIHUANA SYNDROME IN GROUP LIVING MACAQUES.
221340 04-04

HORMONE INDUCED EFFECTS ON LITHIUMS PHARMACOKINETICS.
221640 04-03

SPECTRAL ANALYSIS OF HUMAN EEG CHANGES INDUCED BY ETIFOXIN.
221724 04-13

NYSTAGMUS AND DISTURBANCES IN PSYCHOMOTOR FUNCTIONS INDUCED BY PSYCHOTROPIC DRUG THERAPY.
221990 04-15

EFFECTS OF ANALGETICS ON CENTRALLY INDUCED PAIN IN RATS. (PH.D. DISSERTATION).
222640 04-03

A DIRECT EFFECT OF DIBUTYRYL CYCLIC-AMP ON THE DURATION OF NARCOSIS INDUCED BY SEDATIVE, HYPNOTIC, TRANQUILISER AND ANESTHETIC DRUGS IN THE RAT.
222814 04-04

THE EFFECT OF NEUROTROPIC AGENTS ON MOTOR HYPERACTIVITY IN DOGS INDUCED BY AMIZYL.
223062 04-04

PHYSOSTIGMINE INDUCED REVERSAL OF EEG AND BEHAVIORAL EFFECTS OF DELTA9-TETRAHYDROCANNABINOL.
223093 04-04

POISON INDUCED NEOPHOBIA IN RATS: ROLE OF STIMULUS GENERALIZATION OF CONDITIONED TASTE AVERSIONS.
223254 04-04

ON SYNDROME MALIN INDUCED BY NEUROLEPTICS.
224507 04-15

EFFECTS OF AMINERGIC DRUGS AND GLUTAMIC ACID ON AUDIOGENIC SEIZURES INDUCED BY EARLY EXPOSURE TO ETHANOL.
225527 04-03

NICOTINE INDUCED HYPOPHAGIA AND HYPODIPSIA IN DEPRIVED AND IN HYPOTHALAMICALLY STIMULATED RATS.
225559 04-04

ANTAGONISM OF PENTOBARBITAL INDUCED DISCRIMINATION IN THE GERBIL.
225561 04-04

FAILURE OF ANTISEROTONERGIC AGENTS TO MODIFY LEVALLORPHAN INDUCED STEREOTYPY IN RATS.
225567 04-03

INDUCES

INVESTIGATION OF THE MECHANISM BY WHICH L-DOPA INDUCES GNAWING IN MICE.
198014 01-04

DEXAMETHASONE INDUCES TYROSINE-HYDROXYLASE IN SYMPATHETIC GANGLIA BUT NOT IN ADRENAL MEDULLA.
217853 04-03

INDUCING

CHLORDIAZEPOXIDE AND PHENOBARBITAL IN A MODEL ANXIETY INDUCING SITUATION.
207775 03-14

ANTAGONISM OF DOPAMINE MEDIATED INHIBITION IN THE NIGROSTRIATAL PATHWAY: A MODE OF ACTION OF SOME CATATONIA INDUCING DRUGS.
210659 03-03

SLEEP INDUCING EFFECT OF PIPERIDINE.
220945 04-03

INDUCTION

POTENTIATION OF DRUG INITIATED ADRENAL TYROSINE-HYDROXYLASE INDUCTION BY DIAZEPAM.
193304 01-03

MECHANISMS OF TREMOR INDUCTION BY HARMINE.
193448 01-03

CENTRAL IMPLANTATION OF CANNABINOIDS: INDUCTION OF EPILEPTIFORM DISCHARGES.
193449 01-03

INVOLVEMENT OF CYCLIC NUCLEOTIDES IN THE LONG-TERM INDUCTION OF TYROSINE-HYDROXYLASE. (UNPUBLISHED PAPER).
196590 01-03

MINIMUM DURATION OF TRANS-SYNAPTIC STIMULATION REQUIRED FOR THE INDUCTION OF TYROSINE-HYDROXYLASE BY RESERPINE IN THE RAT SUPERIOR CERVICAL GANGLION.
199999 02-03

EVIDENCE AGAINST A CAUSAL RELATIONSHIP BETWEEN INCREASE IN C-AMP AND INDUCTION OF TYROSINE-HYDROXYLASE IN THE RAT ADRENAL MEDULLA.
202795 02-03

ONTOGENY OF THE INDUCTION OF TYROSINE-HYDROXYLASE BY RESERPINE IN THE SUPERIOR CERVICAL GANGLION, NUCLEUS LOCUS-COERULEUS AND ADRENAL GLAND.
210670 03-03

INDUCTION OF TYROSINE-HYDROXYLASE ELICITED BY BETA ADRENERGIC RECEPTOR AGONISTS IN NORMAL AND DECENTRALIZED SYMPATHETIC GANGLIA: ROLE OF CYCLIC 3,5 ADENOSINE-MONOPHOSPHATE.
215688 04-03

AGE DIFFERENCES AFFECTING INDUCTION OF HEPATIC DRUG METABOLIZING ENZYMES BY METHAQUALONE AND PHENOBARBITAL IN THE RAT.
217793 04-03

LATENCY AND DURATION OF ESTROGEN INDUCTION OF MATERNAL BEHAVIOR IN HYSTERECTOMIZED OVARIECTOMIZED VIRGIN RATS: EFFECTS OF PUP STIMULATION.
219070 04-04

INHIBITORY ACTION OF NOREPINEPHRINE ON THE INDUCTION OF TRYPTOPHAN 2,3 DIOXYGENASE BY CORTISOL: MEDIATION BY THE ALPHA-RECEPTOR.
221051 04-03

INDUCTIVE

A COMPARISON OF THE INDUCTIVE EFFECTS OF PHENOBARBITAL, METHAQUALONE, AND METHYPRYLON ON HEPATIC MIXED FUNCTION OXIDASE ENZYMES IN THE RAT.
217794 04-03

INDUSTRY

THALIDOMIDE AND THE POWER OF THE PHARMACEUTICAL INDUSTRY.
210077 03-15

INEFFECTIVENESS

INEFFECTIVENESS OF LYSERGIC ACID DIETHYL AMIDE 25 (LSD) ON ALTERING NA-K CURRENTS IN SQUID GIANT AXON.
194927 01-03

THE INEFFECTIVENESS OF DESIPRAMINE PRETREATMENT ON BEHAVIORAL EFFECTS OF 6-HYDROXYDOPAMINE IN NIALAMIDE PRETREATED RATS.
195434 01-04

INFANCY

EFFECT OF STRESS AND DIAZEPAM TREATMENT DURING INFANCY ON THE CORTICOSTERONE REGULATION AND ANDROGENIC ACTIVITY IN ADULT MALE RATS.
210348 03-03

INFANT

THE EFFECT OF ACTH AND DIAZEPAM, ADMINISTERED TO INFANT RATS ON THE BODY GROWTH CURVE AND SOME ENDOCRINE PARAMETERS MEASURED IN ADULT AGE.
215066 04-03

INCREASED CONCENTRATION OF HOMOVANILLIC ACID IN THE BRAINS OF INFANT RABBITS AFTER ADMINISTRATION OF HALOPERIDOL TO THEIR NURSING MOTHERS.
217692 04-03

EFFECT OF CHRONIC PHENOBARBITAL ADMINISTRATION UPON BRAIN GROWTH OF THE INFANT RAT.
217885 04-03

INFANTILE

INFANTILE AUDITORY EXPOSURE AND UNUSUAL RESPONSE TO ANTIPSYCHOTIC DRUGS.
208617 03-04

ESSENTIAL INFANTILE ENURESIS AND DOGMATIL.
218165 04-14

INFANTS

PLASMA AND CEREBROSPINAL FLUID CONCENTRATIONS OF PHENOBARBITAL IN INFANTS GIVEN SINGLE DOSES.
206057 03-13

INFARCTION

A DOUBLE-BLIND EVALUATION OF DIAZEPAM AND AMYLOBARBITONE IN ACUTE MYOCARDIAL INFARCTION.
202966 02-13

INFECTED

INFLUENCE OF CHANGES IN BRAIN MONOAMINE METABOLISM ON BEHAVIOUR OF HERPES-SIMPLEX INFECTED MICE.
217440 04-04

INFECTION

EFFECT OF MORPHINE, HYDROMORPHONE, METHADONE, MESCALINE, TRYPAN-BLUE, VITAMIN-A, SODIUM SALICYLATE AND CAFFEINE ON THE SERUM INTERFERON LEVEL IN RESPONSE TO VIRAL INFECTION.
217654 04-03

INFLUENCE

DOES MAPROTILINE (LUDIOMIL) INFLUENCE SEROTONIN UPTAKE AND FREE TRYPTOPHAN CONCENTRATION IN HUMAN PLASMA
192943 01-13

THE INFLUENCE OF CYPROHEPTADINE AND OF D-LYSERGAMIDE ON THE RISE IN TEMPERATURE INDUCED BY INTRACEREBROVENTRICULAR 5-HYDROXYTRYPTAMINE, NORADRENALINE AND DOPAMINE IN CONSCIOUS RABBITS.
193451 01-03

INFLUENCE OF EMULSIFIED FAT ON CHLORPROMAZINE AVAILABILITY IN RABBIT BLOOD.
194928 01-03

EXPERIENCE WITH CYPROTERONE ACETATE INFLUENCE ON HUMAN SEXUALITY.
195037 01-11

SLEEP IN PATIENTS WITH PARKINSONS DISEASE AND ITS INFLUENCE BY L-DOPA.
195155 01-11

INFLUENCE OF THERAPEUTIC AND TOXIC DOSES OF NEUROLEPTICS AND ANTIDEPRESSANTS ON ENERGY METABOLISM OF THE ISOLATED PERFUSED RAT BRAIN.
195236 01-03

ANALYSIS OF THE INFLUENCE OF SELECTED NEUROTROPIC AGENTS ON HEPATIC METABOLISM IN RELATION TO ENDOTOXICOSIS.
195448 01-03

INFLUENCE POSSIBILITIES ON THERAPY-RESISTANT LATE DEPRESSIONS.
196038 01-17

THE INFLUENCE OF CEREBROLYSINE ON HIGHER NERVOUS ACTIVITY IN ADULT RATS.
196758 01-04

INFLUENCE OF CATECHOLAMINE UPTAKE BLOCKING DRUGS ON THE INCREASE IN WATER INTAKE AND PLASMA RENIN CONCENTRATION INDUCED BY SOME HYPOTENSIVE DRUGS.
197288 01-03

SEIZURES IN RATS INDUCED BY PINEALECTOMY: INFLUENCE OF DIAZEPAM, CHLORDIAZEPOXIDE, AND DIPHENYLHYDANTOIN AND PINEAL SUBSTANCES.
197465 01-03

THE INFLUENCE OF CHLORPROMAZINE AND RESERPINE ON THE METABOLISM OF CEREBRAL PHOSPHOLIPIDS IN THE RAT IN VIVO.
197477 01-03

THE INFLUENCE OF SKF-525A ON THE ACUTE PHARMACOLOGICAL PROPERTIES OF CHLORDIAZEPOXIDE.
197478 01-03

HEAT PRODUCTION AND OXYGEN CONSUMPTION OF THE ISOLATED RABBIT HEART UNDER THE INFLUENCE OF STROPHANTHIN VERAPAMIL, AND GLYCERYL TRINITRATE.
197567 01-03

THE INFLUENCE OF ANTICATECHOLAMINERGIC AGENTS ON THE BEHAVIOURAL EFFECTS OF L-5-HYDROXYTRYPTOPHAN.
197572 01-04

MILD ANALGESICS EVALUATED WITH THE SUBMAXIMUM EFFORT TOURNIQUET TECHNIQUE. I. THE INFLUENCE OF PSYCHOLOGICAL FACTORS ON THEIR EFFECT.
197861 01-14

MILD ANALGESICS EVALUATED WITH THE SUBMAXIMUM EFFORT TOURNIQUET TECHNIQUE: II. THE INFLUENCE OF A TRANQUILLIZER ON THEIR EFFECT.
197862 01-13

INFLUENCE OF HALOTHANE ON PERIPHERAL SYMPATHETIC NERVES AND ON THE EFFECTS OF NORADRENALINE ON MYOCARDIUM.
197945 01-03

INFLUENCE OF MAO INHIBITORS ON THE INTESTINAL ABSORPTION OF BIOGENIC AMINES.
197948 01-03

KINETICS OF 14C-DOPAMINE IN ISOLATED RAT STRIATAL TISSUE UNDER THE INFLUENCE OF MORPHINE.
197954 01-03

INFLUENCE OF PROPRANOLOL AND PRACTOLOL ON THE TURNOVER OF NORADRENALINE IN THE RAT HEART.
197957 01-03

INFLUENCE OF MORPHINE ON THE RELEASE OF NORADRENALINE FROM BRAIN SLICES.
197964 01-03

INFLUENCE OF OXYMETAZOLINE AND PHENTOLAMINE ON NORADRENALINE (NA) RELEASE CAUSED BY ELECTRICAL STIMULATION, POTASSIUM, TYRAMINE AND DIMETHYLPHENYLPIPERAZINE (DMPP).
197973 01-03

INFLUENCE OF AN ANTICHOLINERGIC PSYCHOTOMIMETIC AGENT ON BEHAVIOUR IN CATS CONTROLLED BY AN AUDITORY STIMULUS.
197996 01-04

INTRACRANIAL SELF-STIMULATION IN RATS AS A FUNCTION OF VARIOUS STIMULUS PARAMETERS: V. INFLUENCE OF COCAINE ON MEDIAL FOREBRAIN BUNDLE STIMULATION WITH MONOPOLAR ELECTRODES.
198223 02-03

THE INFLUENCE OF SODIUM OXYBUTYRATE ON INTERNEURONAL TRANSMISSION OF EXCITATION AT VARIOUS LEVELS OF THE CENTRAL NERVOUS SYSTEM.
198435 02-03

THE INFLUENCE OF TYROCALCITONIN ON CONDITIONAL REFLEXES AND THE ELECTRICAL ACTIVITY OF THE BRAIN IN ANIMALS.
198479 02-02

THE INFLUENCE OF ANALGESICS AND NEUROLEPTICS ON AFFECTIVE MANIFESTATIONS OF PAIN.
198480 02-04

ON THE INFLUENCE OF NEUROLEPTICS ON THE CORTICORETICULAR SYSTEM OF THE BRAIN (HISTOCHEMICAL AND BIOCHEMICAL INVESTIGATION).
198481 02-03

THE INFLUENCE OF BENZODIAZEPINE SERIES TRANQUILIZERS ON VARIOUS FORMS OF OPERANT ANIMAL BEHAVIOR.
198482 02-04

THE INFLUENCE OF ANTIDEPRESSANTS AND NEUROLEPTICS ON BEHAVIORAL REACTIONS ELICITED BY LESION AND EXCITATION OF THE HIPPOCAMPUS.
198483 02-04

THE INFLUENCE OF NEMBUTAL, CHLORALOSE AND URETHANE ON INHIBITORY POSTSYNAPTIC POTENTIALS OF CORTICAL NEURONS.
199443 02-03

MULTIPLE TIC SYNDROME (GILLES-DE-LA-TOURETTES SYNDROME): CLINICAL, BIOLOGICAL, AND PSYCHOSOCIAL VARIABLES AND THEIR INFLUENCE WITH HALOPERIDOL.
199473 02-11

THE INFLUENCE OF RESERPINE ON THE SEROTONIN METABOLISM IN PATIENTS WITH SCHIZOPHRENIA AND REACTIVE CONDITIONS.
200013 02-08

THE INFLUENCE OF NEUROLEPTICAL DRUGS ON CATECHOLAMINE EXCRETION.
200073 02-08

A CORRELATION BETWEEN THE INFLUENCE OF PSYCHOTROPIC DRUGS AND EMOTIONAL STRESS.
200103 02-09

THE INFLUENCE OF ANIONS ON THE PHYSICAL PROPERTIES OF BUTYROPHENONE-TYPE MOLECULES. (PH.D. DISSERTATION).
200310 02-01

THE INFLUENCE OF TRIFLUOPERAZINE, CARBIDINE AND IMIZINE ON EVOKED POTENTIALS IN DIFFERENT STRUCTURES OF THE LIMBIC RETICULAR COMPLEX.
200564 02-02

THE INFLUENCE OF ALPHA-METHYLTYROSINE AND DISULFIRAM ON THE INHIBITORY FUNCTION OF THE CAUDATE NUCLEUS AND CATECHOLAMINE CONTENT IN THE BRAIN OF CATS.
200565 02-03

THE INFLUENCE OF CATECHOLAMINES, SEROTONIN, AND SOME AMINO ACIDS ADMINISTERED INTO THE AMYGDALOID COMPLEX ON CONDITIONED REFLEXES OF AVOIDANCE AND MOTOR ACTIVITY IN RATS.
200566 02-03

THE INFLUENCE OF PROLONGED APPLICATION OF TRANQUILIZERS AND ANTIDEPRESSANTS ON THE SUMMATIONAL CAPACITY OF THE CENTRAL NERVOUS SYSTEM.
201913 02-03

INFLUENCE OF HEXOBARBITAL ON THE BIOSYNTHESIS OF CATECHOLAMINES AND THEIR PRECURSORS IN THE BRAIN.
201917 02-03

INFLUENCE OF MIDBRAIN RAPHE LESION ON SOME PHARMACOLOGICAL AND BIOCHEMICAL EFFECTS OF APOMORPHINE IN RATS.
202771 02-03

INFLUENCE OF STRIATAL DOPAMINE RECEPTOR BLOCKADE ON A BULBAR MOTOR REACTION.
202778 02-03

CHEMICAL STIMULATION OF THE AMYGDALA WITH SPECIAL REGARD TO INFLUENCE ON THE HYPOTHALAMUS.
202779 02-04

THE INFLUENCE OF PSYCHOPHARMACA ON THE APTITUDE TO DRIVE.
203784 02-15

MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 5. COMMUNICATION: INFLUENCE ON VENTRICULAR EXCITATION IN THE ELECTROCARDIOGRAM.
203843 02-13

THE INFLUENCE OF ANTIADRENERGIC AND ANTIDOPAMINERGIC DRUGS ON METHAMPHETAMINE INDUCED CHANGES IN MOTORIC ACTIVITY AND CEREBRAL GLYCOGEN CONTENT IN MICE.
204396 02-03

THE INFLUENCE OF ENCEPHALOTROPIC DRUGS ON NUCLEIC ACID METABOLISM IN THE BRAIN.
204398 02-13

A CONTRIBUTION TO THE STUDY OF MECHANISM OF ACTION OF PHENYLBUTAZONE: THE INFLUENCE OF CATECHOLAMINES ON THE ANTIINFLAMATORY EFFECT OF PHENYLBUTAZONE.
205169 02-03

INFLUENCE OF MELATONIN ON EEG AND HUMAN SLEEP: AUTOMATIC EEG ANALYSES AND POLYGRAPHIC NIGHT SLEEP INVESTIGATIONS.
205446 02-13

INFLUENCE OF SOME BIOGRAPHIC FACTORS ON THE THERAPEUTIC DRUG RESPONSE.
205622 03-14

CENTRAL CHOLINERGIC INFLUENCE ON SELF-ADMINISTRATION OF MORPHINE AND AMPHETAMINE.
205889 03-04

INFLUENCE OF IPRONIAZID ON THE CONTENT OF NORADRENALINE IN VARIOUS PARTS OF THE RAT BRAIN BEFORE AND AFTER STIMULATION OF THE RECEPTORS.
206404 03-03

INFLUENCE OF RESERPINE ON HEMODYNAMICS IN DOGS.
206415 03-03

THE INFLUENCE OF CHLORPROMAZINE ACTION ON EXPERIMENTAL PSYCHOSIS CAUSED BY LYSERGIC ACID DIETHYLAMIDE.
206439 03-04

INFLUENCE OF MEPROBAMATE, CARISPRODOL, OXAZEPAM AND PHENOBARBITAL ON NA+ TRANSPORT IN THE ISOLATED FROG SKIN.
206781 03-03

THE INFLUENCE OF CLOZAPINE ON THE EXCRETION OF MHPG, HVA, AND 5-HIAA IN URINE AND CEREBROSPINAL FLUID.
206974 03-13

INFLUENCE OF DESMETHYLIMIPRAMINE ON THE HYPOTENSIVE EFFECT OF CLONIDINE.
206997 03-03

INFLUENCE OF NEUROLEPTIC SUBSTANCE ON NEUROPHYSIOLOGICAL PARAMETERS IN EXPERIMENTAL ANIMALS.
206998 03-06

THE INFLUENCE OF HALOPERIDOL AND PENFLURIDOL ON THE LEARNING CAPACITY OF THE SCHIZOPHRENIC.
207000 03-14

COMPARATIVE STUDIES OF VERBAL INTERACTIONS IN A GROUP OF HEALTHY SUBJECTS UNDER THE INFLUENCE OF PSYCHOPHARMACOLOGICAL AGENTS: WITH SPECIAL CONSIDERATION OF YG-19256, CHLORDIAZEPOXIDE AND PLACEBO.
207140 03-14

THE INFLUENCE OF ETHYMISOL ON THE ACTIVITY OF ADENYLCYCLASE AND 3,5 AMP-PHOSPHODIESTERASE OF RATS BRAINS.
208973 03-03

THE INFLUENCE OF INTRAPERITONEAL INJECTION OF IPRAZIDE AND TRANSAMINE ON THE DISTRIBUTION OF BIOGENIC AMINES IN CORTICAL AND SUBCORTICAL WHITE MATTER OF THE RAT BRAIN.
209032 03-03

INFLUENCE OF NONCHOLINERGIC DRUGS ON RAT STRIATAL ACETYLCHOLINE LEVELS.
210658 03-03

STUDIES WITH AGENTS WHICH INFLUENCE ACETYLCHOLINE METABOLISM IN MOUSE BRAIN.
211065 03-03

CONTRIBUTIONS TO THE STUDY OF THE INFLUENCE OF LITHIUM CARBONATE ON THE EVOLUTION OF HYPERTHYMIC PSYCHOSES.
212161 03-09

THE INFLUENCE OF ACTH4-10 ON HIPPOCAMPAL AND THALAMIC SYNCHRONISED ACTIVITY IN RATS.
213430 04-03

ON THE PHYSIOLOGICAL MECHANISMS OF THE INFLUENCE OF PHENAMINE AND MICROPOLARIZATION ON LONG-TERM MEMORY PROCESSES.
213491 04-04

INFLUENCE OF RESERPINE ON ALL-NIGHT SLEEP PATTERN IN NONLOBOTOMIZED AND LOBOTOMIZED CHRONIC SCHIZOPHRENIC PATIENTS.
213530 04-08

AMPHETAMINE STEREOTYPY: THE INFLUENCE OF ENVIRONMENTAL FACTORS AND PREPOTENT BEHAVIORAL PATTERNS ON ITS TOPOGRAPHY AND DEVELOPMENT.
213531 04-04

INFLUENCE OF AZAPHEN, A NEW ANTIDEPRESSIVE DRUG, ON THE HUMAN EEG.
215065 04-09

INFLUENCE OF TEMPIDON ON THE EEG OF CATS AT A SINGLE AND REPEATED APPLICATION.
215076 04-03

TOWARD THE QUESTION OF THE INFLUENCE OF STIMULATION OF THE THALAMIC ASSOCIATIVE NUCLEI ON THE BEHAVIOR OF CATS.
215498 04-04

PLASMA CATECHOLAMINES: ARTERIAL VENOUS DIFFERENCES AND THE INFLUENCE OF BODY TEMPERATURE.
215655 04-06

THE MECHANISM OF THE POTENTIATING EFFECT OF ANTIDEPRESSANT DRUGS ON THE PROTECTIVE INFLUENCE OF DIPHENHYDRAMINE IN EXPERIMENTAL CATATONIA. THE ROLE OF HISTAMINE.
215664 04-03

ON THE INFLUENCE OF APROTINIUM (TRASYLOL) IN THE TREATMENT OF ALCOHOL DELIRIUM.
215698 04-11

TOLERANCE DEVELOPMENT TO THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON CONDITIONED BEHAVIOR: ROLE OF TREATMENT INTERVAL AND INFLUENCE OF MICROSOMAL METABOLISM.
215726 04-03

THE INFLUENCE OF TRICYCLIC ANTIDEPRESSANTS, AZAPHEN AND IMIZINE ON BLOOD SUGAR CONCENTRATION CHANGES PRODUCED BY EPINEPHRINE AND SEROTONIN.
217214 04-03

INFLUENCE OF CHANGES IN BRAIN MONOAMINE METABOLISM ON BEHAVIOUR OF HERPES-SIMPLEX INFECTED MICE.
217440 04-04

INFLUENCE OF RESPONSE TOPOGRAPHY ON THE EFFECT OF APOMORPHINE AND AMPHETAMINE ON OPERANT BEHAVIOR OF PIGEONS.
217468 04-04

INFLUENCE OF SOME TRICYCLIC ANTIDEPRESSIVE DRUGS ON THE UPTAKE OF 5-HYDROXYTRYPTAMINE BY RAT BLOOD PLATELETS.
217693 04-03

THE INFLUENCE OF APOMORPHINE AND TRICYCLIC ANTIDEPRESSANT DRUGS ON THE LEVEL OF SEROTONIN AND ITS METABOLITE IN RAT BRAIN.
217815 04-03

GENETICALLY SELECTED WINNER AND LOSER RATS IN THE TUNNEL COMPETITION: INFLUENCE OF APOMORPHINE AND DOPA.
217829 04-04

THE INFLUENCE OF DESIPRAMINE AND AMITRIPTYLINE ON THE ACCUMULATION OF (3H)NORADRENALINE AND ITS TWO MAJOR METABOLITES FORMED FROM (3H)TYROSINE IN THE RAT BRAIN.
217966 04-03

THE INFLUENCE OF LITHIUM AND CESIUM IONS ON THE EFFECTS OF CATECHOLAMINES AND SEROTONIN INTRODUCED INTO THE HIPPOCAMPUS OF RATS.
218470 04-04

ON NEUROCHEMICAL MECHANISMS OF SEPTUM INFLUENCE ON THE CONDITIONED AVOIDANCE REACTION IN RATS.
218803 04-04

THE INFLUENCE OF PHARMACOLOGICAL AGENTS ON THE CONSEQUENCES OF EMOTIONAL EXCITATION IN CATS.
218814 04-04

THE INFLUENCE OF HYDROCORTISONE ON THE ELABORATION OF EXTINCTION INHIBITION IN RATS.
219327 04-04

A HISTOCHEMICAL ANALYSIS OF THE INFLUENCE OF SOME PSYCHOTROPIC SUBSTANCES ON THE DEHYDROGENASE ACTIVITY OF VARIOUS BRAIN STRUCTURES.
219498 04-03

THE INFLUENCE OF CHOLINOMIMETICS ON THE AFTEREFFECTS OF TRACE DISCHARGES AND THE ACTIVITY OF EPILEPTOGENIC FOCI IN THE RABBIT HIPPOCAMPUS.
219499 04-03

THE INFLUENCE OF ALKYLATE PHERPACET DERIVATIVES ON NEURON POPULATIONS IN THE MIDBRAIN RETICULAR FORMATION.
219501 04-03

SIMILARITIES OF THE INFLUENCE OF SECONDARY AND TERTIARY TRICYCLIC ANTIDEPRESSANTS ON THE EFFECT OF RESERPINE IN FROGS AND ON THE SEROTONIN UPTAKE OF HUMAN THROMBOCYTES.
219503 04-13

THE INFLUENCE OF SULPIRIDE ON VIGILANCE: OBJECTIVE MEASUREMENTS OF THE VISUOMOTOR SYSTEM.
221271 04-14

INFLUENCE OF CHEMICAL STIMULATION OF CENTRAL DOPAMINERGIC SYSTEM ON THE OPEN-FIELD BEHAVIOR OF RATS.
221308 04-03

THE INFLUENCE OF SULPIRIDE ON SLEEP: RESULTS OF POLYGRAPHIC NIGHT SLEEP RECORDINGS.
221339 04-14

INFLUENCE OF RESERPINE ON THE POTENCY OF ALPHA-ADRENOCEPTOR BLOCKING AGENTS.
221860 04-03

THE INFLUENCE OF SEVERAL PSYCHOTROPIC DRUGS ON THE STRUCTURE OF THE BRAIN.
222889 04-03

SOME PECULIARITIES OF THE NEURON ULTRASTRUCTURE IN THE BRAIN-CORTEX MOTOR AREA UNDER THE INFLUENCE OF LYSERGIC ACID DIETHYLAMIDE (LSD) AND HALOPERIDOL.
222890 04-03

NEUROTRANSMITTER CONTENT IN SYNAPTIC VESICLES OF THE ADRENERGIC NERVES OF RATS UNDER PHARMACOLOGICAL INFLUENCE.
223017 04-03

THE INFLUENCE OF SOME PHENOTHIAZINE DERIVATIVES ON RENAL FUNCTION.
223019 04-05

THE INFLUENCE OF PHENAMINE AND CAFFEINE ON THE CAPACITY FOR EXTRAPOLATION IN RATS.
224466 04-04

THE INFLUENCE OF PHENAMINE ON THE AVOIDANCE REACTION IN INTACT AND STRIATECTOMIZED RATS.
224467 04-04

INFLUENCED

DISTRIBUTION OF CHLORPROMAZINE IN A SIMPLIFIED BLOOD INFLUENCED BY VARIOUS DRUGS.
195245 01-03

PRESSOR RESPONSES TO HYPOTHALAMIC STIMULATION AS INFLUENCED BY DRUGS AFFECTING ADRENERGIC RECEPTORS.
197290 01-03

INFLUENCES

PHARMACOLOGICAL INFLUENCES ON CARBON DIOXIDE INDUCED AMNESIA.
197497 01-03

TASTE PHENOMENA INFLUENCES ON STIMULATION OF DEPRIVATION INDUCED FLUID CONSUMPTION OF RATS.
197991 01-03

RECIPROCAL (PUSH-PULL) EFFECTS OF MORPHINE ON SINGLE UNITS IN THE VENTROMEDIAN AND LATERAL HYPOTHALAMUS AND INFLUENCES ON OTHER NUCLEI: WITH COMMENT ON METHADONE EFFECTS DURING WITHDRAWAL FROM MORPHINE.
210700 03-03

HIPPOCAMPAL AND PITUITARY ADRENAL INFLUENCES ON ACTIVITY AND AVOIDANCE BEHAVIOR. (PH.D. DISSERTATION).
219289 04-04

FACILITATORY AND INHIBITORY INFLUENCES OF PROGESTERONE, 20ALPHA-HYDROXYPROGESTERONE AND METHYSERGIDE ON THE RECEPTIVE BEHAVIOR OF THE FEMALE RAT. (PH.D. DISSERTATION).
222739 04-04

ENVIRONMENTAL INFLUENCES AFFECTING THE VOLUNTARY INTAKE OF DRUGS: AN OVERVIEW.
225155 04-04

INFLUENCING

EFFECTS OF SELF-STIMULATION BEHAVIOR OF DRUGS INFLUENCING DOPAMINERGIC NEUROTRANSMISSION MECHANISMS.
194152 01-04

EFFECTS OF DRUGS INFLUENCING MONOAMINE MECHANISMS ON THE INCREASE IN BRAIN DOPAMINE PRODUCED BY AXOTOMY OR TREATMENT WITH GAMMA-HYDROXYBUTYRIC ACID.
195440 01-03

PHARMACOLOGICAL PROPERTIES OF A POTENTIAL TRANQUILISING AGENT MESYLPHENACYRAZINE: I. INTERACTION WITH DRUGS INFLUENCING THE NERVOUS SYSTEM.
205578 02-03

FACTORS INFLUENCING BRAIN AND TISSUE LEVELS OF TRYPTAMINE: SPECIES, DRUGS AND LESIONS.
210850 03-03

INFORMATION

THE EFFECT OF CHLORPROMAZINE ON VISUAL INFORMATION PROCESSING IN NORMAL SUBJECTS.
199663 02-14

BEHAVIORAL AND PHYSIOLOGICAL FEEDBACK AS SOURCES OF INFORMATION ABOUT THE EFFECTIVENESS OF A PLACEBO. (PH.D. DISSERTATION).
214228 04-17

EXPERIENCING AND ALTERING STATES OF INTOXICATION: AN INFORMATION PROCESSING VIEW OF THE HIGH.
224756 04-14

INFUSION

THE ACUTE EFFECTS OF INTRAVENOUS INFUSION OF L-TRYPTOPHAN IN NORMAL SUBJECTS.
195443 01-15

ARRHYTHMIAS EVOKED BY INFUSION OF TRICYCLIC ANTIDEPRESSANTS AND NORADRENALINE ON ISOLATED RABBIT HEARTS.
197939 01-03

DEPRESSION TREATED WITH CHLORIMIPRAMINE WITH SPECIAL ANALYSIS OF CHANGE IN BLOOD PRESSURE BY INFUSION.
199212 02-09

REM INHIBITORY EFFECT OF L-DOPA INFUSION DURING HUMAN SLEEP.
210602 03-14

INFUSIONS

EFFECTS OF INTRAVENTRICULAR INFUSIONS OF ACTH1-24 AND ACTH4-10 ON LH RELEASE, OVULATION AND BEHAVIOR IN THE RABBIT.
210662 03-03

INGESTION

EFFECT OF PROLONGED LITHIUM INGESTION ON GLUCAGON AND PARATHYROID HORMONE RESPONSES IN RATS.
197744 01-03

PRESLEEP INGESTION OF TWO HYPNOTIC DRUGS AND SUBSEQUENT PERFORMANCE.
206362 03-14

THE EFFECT OF PROLONGED LITHIUM INGESTION ON MORPHINE ACTIONS IN THE RAT.
213482 04-03

EFFECT OF WITHDRAWAL FROM CHRONIC ETHANOL INGESTION ON THE CAMP RESPONSE OF CEREBRAL CORTICAL SLICES USING THE AGONISTS HISTAMINE, SEROTONIN, AND OTHER NEUROTRANSMITTERS.
215980 04-03

INHALATION

ACUTE, SUBACUTE AND 23-DAY CHRONIC MARIHUANA INHALATION TOXICITIES IN THE RAT.
193576 01-04

INHIBITED

CENTRALLY MEDIATED CARDIOVASCULAR EFFECTS OF 5-HYDROXYTRYPTOPHAN IN MAO INHIBITED DOGS: MODIFICATION BY AUTONOMIC ANTAGONISTS.
215757 04-03

INHIBITING

PHARMACOLOGICAL EXAMINATIONS BY AN ULCUS INHIBITING AGENT (L-S-519).
197955 01-03

QUANTITATIVE MEASUREMENT OF PARKINSON DISEASE RIGOR. MYOINTEGRATIVE DRUG TRIAL IN COMBINATION WITH THE DECARBOXYLASE INHIBITING DRUG RO-8-0576.
220829 04-11

INHIBITION

THE STEREOSELECTIVE INHIBITION OF LIPOLYSIS BY NONPHENOLIC PHENETHYLAMINES.
193456 01-03

INHIBITION OF SYNAPTIC VESICULAR MG++ DEPENDENT ATPASE (STENIN) BY ANTIPSYCHOTIC PHENOTHIAZINES.
195054 01-03

THE BLOCKADE OF BULBOSPINAL INHIBITION BY IMIPRAMINE, DESIPRAMINE AND PARGYLINE.
195095 01-03

INHIBITION OF THE CATALYTIC SITE OF ADENYLATE-CYCLASE IN THE CENTRAL NERVOUS SYSTEM BY PHENOTHIAZINE DERIVATIVES.
195096 01-03

DEAMINATION OF BETA-PHENYLETHYLAMINE BY MONOAMINEOXIDASE -- INHIBITION BY IMIPRAMINE.
195447 01-13

MECHANISM OF ANTIDEPRESSANT EFFICACY OF MONOAMINEOXIDASE INHIBITORS: INHIBITION OF MONOAMINE OXIDASE OR OF CATECHOLAMINE REUPTAKE.
195925 01-17

THE EFFECTS OF DIPHENYLAMINOETHANOL (DPAE) AND LIDOCAINE ON CEREBELLAR INHIBITION DEITERS NEURONS. (PH.D. DISSERTATION).
196259 01-03

ON THE INHIBITION OF PERIPHERAL AND CENTRAL NORADRENERGIC NEUROTRANSMISSION BY CLONIDINE.
197295 01-03

THE INHIBITION OF THE EFFECT OF NERVE STIMULATION BY PHENOTHIAZINES ON ISOLATED INNERVATED ORGANS.
197576 01-03

PROTRIPTYLINE INDUCED INHIBITION OF THE IN VIVO 3H-NORADRENALINE SYNTHESIS FROM 3H-L-DOPA IN THE RAT BRAIN.
197928 01-03

INHIBITION OF EFFECTS OF ACCELERATOR NERVE STIMULATION IN CATS AND RABBITS BY BS-100-141 AND GUANABENZ.
197971 01-03

INHIBITION OF DOPAMINE-BETA-HYDROXYLASE IN MANIC PATIENTS: A CLINICAL TRIAL WITH FUSARIC ACID.
199632 02-07

ENHANCEMENT OF THE CHLORPROMAZINE-INDUCED SUPPRESSION OF THE CONDITIONED AVOIDANCE RESPONSE BY CARBONIC ANHYDRASE INHIBITION.
199770 02-03

INHIBITION OF SYMPATHETIC ACTIVITY FOLLOWING CHRONIC ADMINISTRATION OF 2-AMINO-4-(3,4 DICHLOROPHENYL) 2-IMIDAZOLINE (MJ-10459-2).
199863 02-03

INHIBITION OF SCOPOLAMINE INDUCED STIMULATION OF Y-MAZE ACTIVITY BY ALPHA-METHYL-P-TYROSINE AND BY LITHIUM.
199866 02-04

INHIBITION OF BEHAVIOURAL AND EEG ACTIVATION INDUCED BY MORPHINE ACTING ON LOWER BRAINSTEM STRUCTURES.
200078 02-03

INHIBITION OF AMPHETAMINE TOLERANCE AND METABOLISM BY PROPRANOLOL.
202662 02-03

TYROSINE-HYDROXYLASE INHIBITION BY CYCLOHEXIMIDE AND ANISOMYCIN IS NOT RESPONSIBLE FOR THEIR AMNESIC EFFECT.
203572 02-04

SELECTIVE INHIBITION OF DOPAMINE-BETA-HYDROXYLASE IN THE PERIPHERAL TISSUES BY 5-DIMETHYLDITHIOCARBAMYLPICOLINIC ACID; ITS EFFECT ON STRESS INDUCED ULCER, ETHANOL INDUCED SLEEP AND BLOOD PRESSURE.
204484 02-03

EFFECTS OF CHOLINESTERASE INHIBITION ON THE VISUAL EVOKED POTENTIALS IN THE RABBIT AND THEIR MODIFICATION WITH VARIOUS DRUGS.
205631 03-03

REGIONAL DIFFERENCES IN RESPONSE TO DISPLACEMENT AND INHIBITION OF SYNTHESIS OF CATECHOLAMINES IN THE CAT BRAIN.
206334 03-03

THE EFFECTS OF DOPA ON THE VISUAL EVOKED POTENTIALS IN RABBIT AND ON MOUSE MOTOR BEHAVIOR FOLLOWING INHIBITION OF DOPAMINE-BETA-HYDROXYLASE.
206768 03-03

THE EFFECT OF L-DOPA AND L-DOPA COMBINED WITH CHLORPROMAZINE ON SPINAL CORD ACTIVITY DURING DISTURBED INHIBITION BY TETANUS TOXOID.
207200 03-03

INHIBITION BY DIAZEPAM OF THE TREMOR AND THE INCREASE OF CEREBELLAR CGMP CONTENT ELICITED BY HARMALINE.
207798 03-03

LITHIUM INHIBITION OF CAMP-MEDIATED HORMONES: A CAUTION.
209352 03-03

ANTAGONISM OF DOPAMINE MEDIATED INHIBITION IN THE NIGROSTRIATAL PATHWAY: A MODE OF ACTION OF SOME CATATONIA INDUCING DRUGS.
210659 03-03

NORADRENALINE MEDIATED INHIBITION BY LOCUS-COERULEUS OF SPINAL TRIGEMINAL NEURONS.
210703 03-03

INHIBITION OF MEMORY FORMATION IN THE IMPRINTING PERIOD: IRREVERSIBLE ACTION OF CYCLOHEXIMIDE IN YOUNG CHICKENS.
210708 03-04

INHIBITION BY APOMORPHINE OF DOPAMINE DEAMINATION IN THE RAT BRAIN.
210776 03-03

PHARMACOLOGICAL PROPERTIES OF TWO CHLORDIAZEPOXIDE METABOLITES FOLLOWING MICROSOMAL ENZYME INHIBITION.
210792 03-03

ENHANCEMENT OF APOMORPHINE-INDUCED INHIBITION OF STRIATAL DOPAMINE TURNOVER FOLLOWING CHRONIC HALOPERIDOL.
210814 03-03

COMPARATIVE STUDIES ON THE MEMBRANE ACTIONS OF DEPRESSANT DRUGS: THE ROLE OF LIPOPHILICITY IN INHIBITION OF BRAIN SODIUM AND POTASSIUM STIMULATED ATPASE.
210818 03-03

EVIDENCE FOR REVERSIBLE INHIBITION OF BRAIN DOPAMINE-BETA-HYDROXYLASE ACTIVITY IN VIVO BY AMPHETAMINE ANALOGUES.
210821 03-03

INHIBITION OF THE SYMPATHETIC NERVOUS SYSTEM BY 5,6 DIHYDROXY-2-DIMETHYLAMINOTETRALIN (M-7), APOMORPHINE AND DOPAMINE.
210888 03-03

REVERSIBLE INHIBITION OF MAMMALIAN BRAIN ACETYLCHOLINESTERASE AND SODIUM POTASSIUM STIMULATED ADENOSINE-TRIPHOSPHATASE BY CYCLOPROPANE.
210903 03-03

INHIBITION OF DELTA1-TETRAHYDROCANNABINOL OF NA+-K+ TRANSPORT ATPASE FROM RAT ILEUM. PRELIMINARY REPORT.
211099 03-03

INHIBITION OF SACRAL PARASYMPATHETIC PREGANGLIONIC NEURONS BY GABA, GLYCIN, 5-HYDROXYTRYPTAMINE AND NOREPINEPHRINE. (PH.D. DISSERTATION).
212524 03-03

CHLORPROMAZINE: SPECIFIC INHIBITION OF L-NORADRENALINE AND 5-HYDROXYTRYPTAMINE UPTAKE IN SYNAPTOSOMES FROM SQUID BRAIN.
213395 04-03

IN VIVO INHIBITION OF STRIATAL ACETYLCHOLINE TURNOVER BY L-DOPA, APOMORPHINE AND (+) AMPHETAMINE.
213399 04-03

THE REVERSIBLE INHIBITION OF STEROID INDUCED SEXUAL BEHAVIOR BY INTRACRANIAL CYCLOHEXIMIDE.
213685 04-03

PERMANENT EFFECTS OF REPEATED ADMINISTRATION OF ACTH AND DIAZEPAM IN EARLY POSTNATAL PERIOD UPON THE DYNAMICS OF EXCITATION AND INHIBITION DURING HABITUATION.
215068 04-04

INHIBITION OF PROSTAGLANDIN-SYNTHETASE BY PSYCHOTROPIC DRUGS.
215162 04-03

INHIBITION OF EFFERENT SYMPATHETIC NERVE ACTIVITY BY 5-HYDROXYTRYPTOPHAN AND CENTRALLY ADMINISTERED 5-HYDROXYTRYPTAMINE.
215712 04-03

STUDIES ON THE DISTINCTION BETWEEN UPTAKE INHIBITION AND RELEASE OF H3-DOPAMINE IN RAT BRAIN TISSUE SLICES.
215756 04-03

SLEEP AND BEHAVIORAL CHANGES REFLECTING CENTRAL RECEPTOR HYPERSENSITIVITY FOLLOWING CATECHOLAMINE SYNTHESIS INHIBITION IN MAN. (UNPUBLISHED PAPER).
216373 04-09

INHIBITION OF CATECHOLAMINE AND 5-HYDROXYTRYPTAMINE INDUCED ENZYME SECRETION FROM THE GUINEA-PIG SUBMANDIBULAR GLAND BY 2-BROMO-D-LYSERGIC ACID DIETHYLAMIDE.
216968 04-03

INHIBITION OF D-AMPHETAMINE INDUCED LOCOMOTOR ACTIVITY BY INJECTION OF HALOPERIDOL INTO THE NUCLEUS-ACCUMBENS OF THE RAT.
217461 04-04

THE INHIBITION OF A AND B FORMS OF MAO IN THE PRODUCTION OF A CHARACTERISTIC BEHAVIOURAL SYNDROME IN RATS AFTER L-TRYPTOPHAN LOADING.
217471 04-03

ARRHYTHMIAS AND INHIBITION OF NORADRENALINE UPTAKE CAUSED BY TRICYCLIC ANTIDEPRESSANTS AND CHLORPROMAZINE ON THE ISOLATED PERFUSED RABBIT HEART.
217657 04-03

THE EFFECT OF LSD AND 2-BROMOLSD ON THE DOPA ACCUMULATION AFTER CENTRAL AND PERIPHERAL DECARBOXYLASE INHIBITION.
217674 04-03

INHIBITION OF STRIATAL DOPAMINE SYNTHESIS IN RATS INJECTED CHRONICALLY WITH NEUROLEPTICS IN THEIR EARLY LIFE.
217687 04-03

INHIBITION OF HUMAN PLATELET 5-HYDROXYTRYPTAMINE UPTAKE BY BETA-PHENETHYLAMINE DERIVATIVES.
217689 04-13

INHIBITION OF SEROTONIN UPTAKE AND THE TOXIC INTERACTION BETWEEN MEPERIDINE AND MONOAMINEOXIDASE INHIBITORS.
217696 04-03

PROSTAGLANDINS AND CANNABIS -- III. INHIBITION OF BIOSYNTHESIS BY ESSENTIAL OIL COMPONENTS OF MARIHUANA.
217795 04-03

THE INFLUENCE OF HYDROCORTISONE ON THE ELABORATION OF EXTINCTION INHIBITION IN RATS.
219327 04-04

INHIBITION OF RABBIT MONOAMINEOXIDASE BY DOXEPIN AND RELATED DRUGS.
220972 04-03

INHIBITION OF CELLULAR ATP HYDROLYZING ACTIVITY BY TRICYCLIC ANTIDEPRESSANTS AND PHENOTHIAZINE TRANQUILIZERS.
221053 04-03

INHIBITION OF BOTH NORADRENERGIC AND SEROTONERGIC NEURONS IN BRAIN BY THE ALPHA-ADRENERGIC AGONIST CLONIDINE.
221131 04-03

AMPHETAMINE-INDUCED INHIBITION OF TYROSINE HYDROXYLATION IN HOMOGENATES OF RAT CORPUS-STRIATUM.
222813 04-03

DOXEPIN AND IMIPRAMINE: EFFECT ON CATECHOLAMINE INHIBITION OF GANGLIONIC TRANSMISSION.
225059 04-03

INHIBITOR

EFFECTS IN THE SUCKLING RAT OF CHRONIC TREATMENT WITH TRYPTOPHAN AND A MONOAMINE OXIDASE INHIBITOR.
195906 01-04

ACTION OF PROBENECID ON THE CENTRAL NERVOUS SYSTEM OF THE RABBIT: II. POTENTIATION OF 5-HYDROXYTRYPTOPHAN-INDUCED HYPERTHERMIA AND SUPPRESSION OF THIS EFFECT BY A DECARBOXYLASE INHIBITOR (RO-4-4602).
196580 01-03

EVIDENCE FOR A PERIPHERAL EFFECT OF FUSARIC ACID, A DOPAMINE-BETA-HYDROXYLASE INHIBITOR, ON SEROTONIN METABOLISM.
196593 01-03

3,4 DIHYDROXYPHENYLACETIC ACID (DOPAC): A POSSIBLE ENDOGENOUS INHIBITOR OF INDOLEAMINE-N-METHYLATION IN THE RAT BRAIN.
197676 01-17

EFFECTS OF 5-(N-BUTYL) PICOLINAMIDE (SCH-10595), A DOPAMINE-BETA-HYDROXYLASE INHIBITOR, ON SEROTONIN AND CATECHOLAMINE METABOLITES IN BRAIN.
197813 01-03

THE ANTICONVULSANT ACTION OF THE CARBONIC ANHYDRASE INHIBITOR METHAZOLAMIDE: POSSIBLE INVOLVEMENT OF A NORADRENERGIC MECHANISM.
197864 01-03

IDENTIFICATION AND STRUCTURAL CHARACTERIZATION OF AN INHIBITOR OF CATECHOLAMINE INDUCED FREE FATTY ACID MOBILIZATION FROM THE CALF MIDBRAIN.
200006 02-01

TREATMENT OF PARKINSONS DISEASE BY COMBINING L-DOPA WITH A DECARBOXYLASE INHIBITOR.
204372 02-07

EFFECTS OF AMINOACETONITRILE, AN AMINE OXIDASE INHIBITOR, ON MESCALINE METABOLISM IN THE RABBIT.
205853 03-03

BEHAVIORAL EFFECTS OF A NEW DOPAMINE-BETA-HYDROXYLASE INHIBITOR (FUSARIC ACID) IN MAN.
207311 03-07

EFFECTS OF A DECARBOXYLASE INHIBITOR ON THE DOPA AND 5-HTP INDUCED CHANGES IN THE LOCOMOTOR LIKE DISCHARGE PATTERN OF RABBIT HIND LIMB NERVES.
210740 03-03

POTENTIATION OF THE L-5-HYDROXYTRYPTOPHAN INDUCED ELEVATION OF PLASMA CORTICOSTERONE LEVELS IN RATS BY A SPECIFIC INHIBITOR OF SEROTONIN UPTAKE.
211104 03-03

HOMOVANILLIC ACID CONCENTRATION IN RAT BRAIN: EFFECT OF A CHOLINE ACETYLTRANSFERASE INHIBITOR AND COMPARISON WITH CHOLINERGIC AND DOPAMINERGIC AGENTS.
215711 04-03

COMPARATIVE STUDIES OF A NEW 5-HT UPTAKE INHIBITOR AND SOME TRICYCLIC THYMOLEPTICS.
217663 04-03

EFFECTS OF THE DOPAMINE-BETA-HYDROXYLASE INHIBITOR FLA-63 ON THE KINETICS OF ELIMINATION OF AMPHETAMINE IN THE RAT.
217881 04-03

TRYPTOPHAN PLUS A PYRROLASE INHIBITOR FOR DEPRESSION?.
219522 04-03

STIMULATION OF ESTROGEN INDUCED COPULATORY BEHAVIOR IN CASTRATE MALE RATS WITH THE SEROTONIN BIOSYNTHESIS INHIBITOR P-CHLOROPHENYLALANINE.
221010 04-04

PHARMACOLOGICAL ACTION OF FD-008, A NEW DOPAMINE-BETA-HYDROXYLASE INHIBITOR: II. EFFECTS ON CENTRAL NERVOUS SYSTEM IN MICE AND RATS.
221823 04-02

PHARMACOLOGICAL ACTION OF FD-008, A NEW DOPAMINE-BETA-HYDROXYLASE INHIBITOR: III. EFFECTS ON ENDOGENOUS BIOGENIC AMINE LEVELS IN RATS.
221859 04-03

INHIBITORS

THIETANES AS POTENTIAL MAO INHIBITORS AND ANALGETICS. (PH.D. DISSERTATION).
194563 01-01

ADENOSINE 3,5 MONOPHOSPHATE IN CULTURED NEUROBLASTOMA CELLS: EFFECT OF ADENOSINE, PHOSPHODIESTERASE INHIBITORS AND BENZAZEPINES.
195254 01-03

MECHANISM OF ANTIDEPRESSANT EFFICACY OF MONOAMINEOXIDASE INHIBITORS: INHIBITION OF MONOAMINE OXIDASE OR OF CATECHOLAMINE REUPTAKE.
195925 01-17

MEASUREMENT OF SEROTONIN TURNOVER IN RATS WITH THE HELP OF MONOAMINEOXIDASE INHIBITORS.
197580 01-03

COMPARISON OF THE SPECIFICITY OF 3-(P-TRIFLUOROMETHYLPHENOXY)-N-METHYL-3 PHENYLPROPYLAMINE AND CHLORIMIPRAMINE AS AMINE UPTAKE INHIBITORS IN MICE.
197870 01-03

INFLUENCE OF MAO INHIBITORS ON THE INTESTINAL ABSORPTION OF BIOGENIC AMINES.
197948 01-03

BENZOOXADIAZOLES -- A NOVEL CLASS OF HETEROCYCLIC MONOAMINEOXIDASE INHIBITORS.
202312 02-01

THE EFFECT OF INHIBITORS OF CATECHOLAMINE SYNTHESIS (ALPHA-METHYLTYROSINE AND DISULFIRAM) ON THE BACKGROUND ACTIVITY OF SENSORIMOTOR CORTEX NEURONS AND THEIR RESPONSES TO AFFERENT CAUDATE AND RETICULAR STIMULATION.
202598 02-04

CENTRAL NERVOUS SYSTEM CARBONIC ANHYDRASE INHIBITORS. (PH.D. DISSERTATION).
203028 02-03

BIOCHEMICAL BACKGROUND OF MONOAMINEOXIDASE INHIBITORS.
206365 03-03

ARE MONOAMINEOXIDASE INHIBITORS ANTIDEPRESSANTS
206368 03-10

MOOD AND SLEEP CHANGES WITH MONOAMINEOXIDASE INHIBITORS.
206369 03-14

EFFECT OF CHOLINE ACETYLTRANSFERASE INHIBITORS ON MOUSE AND GUINEA-PIG BRAIN CHOLINE AND ACETYLCHOLINE.
210883 03-03

N-CYCLOPROPYLTRYPTAMINES, POTENT MONOAMINEOXIDASE INHIBITORS.
211069 03-01

EFFECT OF VARIOUS INHIBITORS OF TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE ON SELF-STIMULATION BEHAVIOUR.
213431 04-04

CONTRASTING LOCAL EFFECTS OF MAO INHIBITORS ON CAUDATE TREMOR ACTIVITIES.
217669 04-03

INHIBITION OF SEROTONIN UPTAKE AND THE TOXIC INTERACTION BETWEEN MEPERIDINE AND MONOAMINEOXIDASE INHIBITORS.
217696 04-03

INTERACTIONS OF IMIPRAMINE AND SYNTHESIS INHIBITORS ON BIOGENIC AMINES.
217827 04-03

MONOAMINEOXIDASE INHIBITORS ANTAGONIZE THE ACCELERATION OF BRAIN DOPAMINE SYNTHESIS INDUCED BY NEUROLEPTIC DRUGS IN VIVO: IMPLICATIONS FOR THE TREATMENT OF TARDIVE DYSKINESIA.
220948 04-03

INHIBITORS OF CEREBRAL PROTEIN SYNTHESIS: DISSOCIATION OF AVERSIVE AND AMNESIC EFFECTS.
221005 04-04

INHIBITORY

A COMPARISON OF THE INHIBITORY EFFECTS OF CERTAIN ANTIPARKINSONIAN AGENTS ON DOPAMINE ACCUMULATION INTO THE RAT STRIATUM.
195234 01-03

BLOCKADE BY ESERINE OF THE CEREBRAL CORTICAL EFFECTS OF ALLOFERIN: A FURTHER EVIDENCE OF CHOLINERGIC INHIBITORY MECHANISM.
195548 01-03

EXPERIMENTAL STUDIES ON FACILITATIVE AND INHIBITORY FACTORS FOR EPILEPTOGENIC FOCUS FORMATION.
197211 01-03

INHIBITORY EFFECT OF AMPHETAMINE, L-DOPA AND APOMORPHINE ON MORPHINE-INDUCED BEHAVIOURAL EXCITATION OF RATS.
197483 01-04

THE INHIBITORY EFFECT OF DOPAMINE ON ACETYLCHOLINE RELEASE.
197566 01-03

THE INHIBITORY EFFECT OF TOLUIDINE BLUE AND METHYLENE BLUE ON RAT MAST CELL DAMAGE BY PROMETHAZINE, CHLORPROMETHAZINE AND CHLORPROMAZINE. ITS REVERSAL BY GLUCOSE.
199255 02-05

THE INFLUENCE OF NEMBUTAL, CHLORALOSE AND URETHANE ON INHIBITORY POSTSYNAPTIC POTENTIALS OF CORTICAL NEURONS.
199443 02-03

INHIBITORY AND DISINHIBITORY EFFECTS OF NITRAZEPAM, DIAZEPAM AND FLURAZEPAM HYDROCHLORIDE ON DELAYED MATCHING BEHAVIOUR IN MONKEYS (MACACA-MULATTA).
199957 02-04

INHIBITORY ROLE OF DOPAMINE AND 5-HYDROXYTRYPTAMINE IN THE SEXUAL BEHAVIOUR OF FEMALE RATS.
199968 02-04

THE INFLUENCE OF ALPHA-METHYLTYROSINE AND DISULFIRAM ON THE INHIBITORY FUNCTION OF THE CAUDATE NUCLEUS AND CATECHOLAMINE CONTENT IN THE BRAIN OF CATS.
200565 02-03

POTENTIATION WITH TRICYCLIC ANTIDEPRESSANTS OF THE INHIBITORY ACTION OF APOMORPHINE ON THE ATTITUDINAL REFLEX IN FROGS.
201919 02-04

SYNTHESIS OF SUBSTITUTED BENZYLIDINOHYDRAZINES AND THEIR MONOAMINEOXIDASE INHIBITORY AND ANTICONVULSANT PROPERTIES.
206461 03-02

COMPARISON OF THE INHIBITORY EFFECTS OF PROPARGYLAMINE AND PARGYLINE ON BRAIN AND LIVER MONOAMINEOXIDASE ACTIVITY.
207857 03-03

REM INHIBITORY EFFECT OF L-DOPA INFUSION DURING HUMAN SLEEP.
210602 03-14

5-HYDROXYTRYPTAMINE AS AN INHIBITORY MODULATOR IN AUDIOGENIC SEIZURE. (PH.D. DISSERTATION).
212521 03-03

INHIBITORY EFFECT OF NEONATAL ESTROGENIZATION ON THE INCORPORATION OF (3H)LYSINE IN THE PURKINJE CELLS OF THE ADULT MALE AND FEMALE RAT.
213478 04-03

INTRACRANIAL REWARD AFTER 5,6 DIHYDROXYTRYPTAMINE: FURTHER EVIDENCE FOR SEROTONINS INHIBITORY ROLE.
215732 04-04

THE PROTECTIVE EFFECT OF SEROTONIN AGAINST THE INHIBITORY ACTION OF CHLORPROMAZINE ON THE MEMBRANE POTENTIAL OF STAGE 2 BLASTOMERES OF MOUSE EMBRYOS IN VITRO.
217005 04-03

ELECTROPHYSIOLOGICAL EVIDENCE FOR AN INHIBITORY ACTION OF DIAZEPAM UPON CAT BRAIN CORTEX.
217649 04-03

THE EFFECT OF PSYCHOTROPIC AGENTS ON THE ELECTROENCEPHALOGRAPHIC CHARACTERISTICS OF THE INHIBITORY FUNCTION OF THE CAUDATE NUCLEUS.
219500 04-03

INHIBITORY ACTION OF NOREPINEPHRINE ON THE INDUCTION OF TRYPTOPHAN 2,3 DIOXYGENASE BY CORTISOL: MEDIATION BY THE ALPHA-RECEPTOR.
221051 04-03

ANTAGONISM OF PSYCHOSTIMULANT 2 PHENYLDIMETHYLTETRAHYDROOXAZINE HYDROCHLORIDE (G-130) TO CENTRAL NERVOUS SYSTEM DEPRESSING DRUGS: MONOAMINEOXIDASE INHIBITORY ACTIVITY AND NOREPINEPHRINE AND SEROTONIN INDUCED CHANGES, COMPARISON WITH DL-AMPHETAMINE.
221267 04-03

FACILITATORY AND INHIBITORY INFLUENCES OF PROGESTERONE, 20ALPHA-HYDROXYPROGESTERONE AND METHYSERGIDE ON THE RECEPTIVE BEHAVIOR OF THE FEMALE RAT. (PH.D. DISSERTATION).
222739 04-04

THE DOPAMINERGIC COMPONENT IN THE ACTION OF D,L-AMPHETAMINE ON THE INHIBITORY FUNCTION OF THE CAUDATE NUCLEUS.
223014 04-03

MONOAMINEOXIDASE INHIBITORY AND ANTICONVULSANT PROPERTIES OF 1,2,4 TRISUBSTITUTED 5-IMIDAZOLONES.
225105 04-01

DIFFERENTIAL ANTAGONISM BY THE ANTICHOLINERGIC DEXETIMIDE OF INHIBITORY EFFECTS OF HALOPERIDOL AND FENTANYL ON BRAIN SELF-STIMULATION.
225562 04-03

INHIBITS

DEXTROMETHORPHAN INHIBITS 5-HYDROXYTRYPTAMINE UPTAKE BY HUMAN BLOOD PLATELETS AND DECREASES 5-HYDROXYINDOLEACETIC ACID CONTENT IN RAT BRAIN.
217964 04-03

INITIATED

POTENTIATION OF DRUG INITIATED ADRENAL TYROSINE-HYDROXYLASE INDUCTION BY DIAZEPAM.
193304 01-03

INJECTABLE

INJECTABLE TEMESTA, ANXIETY AND ANGUISH.
212163 03-10

INJECTED

EVIDENCE THAT PUNCTUATE INTRACEREBRAL ADMINISTRATION OF 6-HYDROXYDOPAMINE FAILS TO PRODUCE SELECTIVE NEURONAL DEGENERATION: COMPARISON WITH COPPER SULFATE AND FACTORS GOVERNING THE DEPORTMENT OF FLUIDS INJECTED INTO BRAIN.
197931 01-03

THE PHARMACOLOGY OF GROSS BEHAVIOURAL EFFECTS OF CHOLINOMIMETIC SUBSTANCES INJECTED INTO THE CEREBRAL VENTRICLES OF UNANAESTHETIZED CATS: EVIDENCE FOR CENTRAL MUSCARINIC MEDIATION.
202780 02-04

NEUROLEPTIC ACTION OF CLOZAPINE INJECTED INTO VARIOUS BRAIN AREAS IN RATS.
217451 04-04

INHIBITION OF STRIATAL DOPAMINE SYNTHESIS IN RATS INJECTED CHRONICALLY WITH NEUROLEPTICS IN THEIR EARLY LIFE.
217687 04-03

INJECTION
DRUG-INDUCED ROTATION IN RATS AFTER UNILATERAL INTRACEREBRAL INJECTION OF 5,6 DIHYDROXYTRYPTAMINE (5-6-DHT).
192940 01-03
THE RELATIONSHIP BETWEEN RIGIDITY AND CHANGE IN WHOLE BRAIN ACETYLCHOLINE CONCENTRATION PRODUCED BY INJECTION OF RESERPINE IN THE RAT.
197569 01-03
BEHAVIOURAL AND ELECTROCORTICAL MODIFICATIONS INDUCED IN THE RAT BY INTRAVENTRICULAR INJECTION OF PHYSALAEMIN AND ELEDOISIN.
198224 02-03
EFFECT OF INTRAHIPPOCAMPAL INJECTION OF ATROPINE ON DIFFERENT PHASES OF A LEARNING EXPERIMENT.
198227 02-04
POLYGRAPHIC EXAMINATION DURING FAST AND SLOW INTRAVENOUS INJECTION OF THE SAME DOSE OF DIAZEPAM.
205508 02-13
THE INFLUENCE OF INTRAPERITONEAL INJECTION OF IPRAZIDE AND TRANSAMINE ON THE DISTRIBUTION OF BIOGENIC AMINES IN CORTICAL AND SUBCORTICAL WHITE MATTER OF THE RAT BRAIN.
209032 03-03
HYPOTHALAMIC SELF-STIMULATION IN RATS FOLLOWING IMMUNOSYMPATHECTOMY OR CENTRAL NERVE GROWTH FACTOR ANTISERUM INJECTION.
211512 03-04
RAT BRAIN REGIONAL UPTAKE AND DECARBOXYLATION OF L-DOPA FOLLOWING CAROTID INJECTION.
214323 04-03
GROWTH HORMONE AND PROLACTIN RELEASE AFTER INJECTION OF THYROTROPIN-RELEASING HORMONE IN PATIENTS WITH DEPRESSION.
214885 04-13
INHIBITION OF D-AMPHETAMINE INDUCED LOCOMOTOR ACTIVITY BY INJECTION OF HALOPERIDOL INTO THE NUCLEUS-ACCUMBENS OF THE RAT.
217461 04-04
EXPLORATORY BEHAVIOUR IN TWO SELECTIVELY BRED LINES OF MICE AFTER INTRAHIPPOCAMPAL INJECTION OF METHYLSCOPOLAMINE.
217464 04-04
EFFECTS OF ANTAGONISTS UPON LOCOMOTOR STIMULATION INDUCED BY INJECTION OF DOPAMINE AND NORADRENALINE INTO THE NUCLEUS-ACCUMBENS OF NIALAMIDE PRETREATED RATS.
217475 04-04
DYSKINETIC PHENOMENA CAUSED BY THE INTRASTRIATAL INJECTION OF PHENYLETHYLAMINE, PHENYLPIPERAZINE, TETRAHYDROISOQUINOLINE AND TETRAHYDRONAPTHALENE DERIVATIVES IN THE GUINEA-PIG.
217671 04-04
CLINICAL EXPERIENCE OF HALOPERIDOL INJECTION ON PSYCHIATRIC CASES.
217957 04-14
BEHAVIORAL EFFECTS OF LOCAL INJECTION OF 6-HYDROXYDOPAMINE IN THE MEDIAL VENTRAL TEGMENTUM IN THE RAT. POSSIBLE ROLE OF THE MESOLIMBIC DOPAMINERGIC SYSTEM.
220946 04-04
SECOND-ORDER SCHEDULES OF DRUG INJECTION.
225157 04-04

INJECTIONS
EFFECT OF SINGLE AND DAILY INJECTIONS OF PHENOBARBITAL ON OVULATION IN HAMSTERS.
193421 01-03
THE EFFECTS OF HASHISH INJECTIONS ON FEEDING AND DRINKING IN RATS.
195113 01-04
COMPARISON OF THE EFFECTS OF THE INTRANIGRAL INJECTIONS OF CHOLINOMIMETICS WITH SYSTEMIC INJECTIONS OF THE DOPAMINE RECEPTOR STIMULATING AND BLOCKING AGENTS IN THE RABBIT.
199772 02-03
CONDITIONED SUPPRESSION OF MOUSE-KILLING IN RATS FOLLOWING RADIATION OR LITHIUM CHLORIDE INJECTIONS. (PH.D. DISSERTATION).
201153 02-04
DEFICIENT BRIGHTNESS DISCRIMINATION ACQUISITION PRODUCED BY DAILY INTRACRANIAL INJECTIONS OF PENICILLIN IN RATS.
202758 02-04
AN ANALYSIS OF THE GROSS BEHAVIOURAL CHANGES INDUCED BY TETRAETHYLAMMONIUM AND A COMPARISON WITH OTHER SUBSTANCES AFFECTING THE AUTONOMIC AND CENTRAL NERVOUS SYSTEM AFTER INTRAVENTRICULAR INJECTIONS TO CONSCIOUS CATS.
202781 02-04
FACILITATION OF TIME-DEPENDENT MEMORY PROCESSES WITH POSTTRIAL EPINEPHRINE INJECTIONS.
209951 03-04
LOSS OF ACTIVE AVOIDANCE RESPONDING AFTER LATERAL HYPOTHALAMIC INJECTIONS OF 6-HYDROXYDOPAMINE.
215704 04-04
FEEDING IN RESPONSE TO REPEATED PROTAMINE ZINC INSULIN INJECTIONS.
219073 04-04

INJURY
HEAD INJURY, HYPOPITUITARISM AND PARANOID PSYCHOSIS: CIRCUMCISION FOR THE SINGAPORE VIRUS.
200581 02-09

INNERVATED
THE INHIBITION OF THE EFFECT OF NERVE STIMULATION BY PHENOTHIAZINES ON ISOLATED INNERVATED ORGANS.
197576 01-03

INNOVATION
A STUDY OF THERAPEUTIC INNOVATION.
224972 04-17

INOTROPIC
NEGATIVE INOTROPIC EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON THE ISOLATED RIGHT VENTRICULAR PAPILLARY MUSCLE OF THE CAT.
204400 02-05

INPATIENTS
ONCE VERSUS THRICE DAILY THIOTHIXENE IN THE TREATMENT OF SCHIZOPHRENIC INPATIENTS.
194044 01-08
A SURVEY OF DRUG TREATMENT IN PSYCHIATRY: SPECIAL EMPHASIS ON INPATIENTS ON MEDICAL WELFARE SUPPORTED BY YOKOHAMA CITY.
200447 02-17
LIMBITROL IN OUTPATIENTS AND INPATIENTS PRACTICE.
205598 02-10
ANTIDEPRESSANTS IN BLACK AND WHITE INPATIENTS: DIFFERENTIAL RESPONSE TO A CONTROLLED TRIAL OF CHLORPROMAZINE AND IMIPRAMINE.
218770 04-09
BROMAZEPAM VERSUS DIAZEPAM IN PSYCHONEUROTIC INPATIENTS.
221304 04-10

INSECT
(3H)GLUTAMATE UPTAKE AT INSECT NEUROMUSCULAR JUNCTIONS: EFFECT OF CHLORPROMAZINE.
213474 04-03

INSOMNIA
TREATMENT AND COUNTERMEASURES FOR PATIENTS WITH INSOMNIA IN THE DEPARTMENT OF INTERNAL MEDICINE -- SPECIAL EMPHASIS ON THE CLINICAL APPLICATION OF FLURAZEPAM.
202285 02-14
INSOMNIA: OFTEN A THERAPEUTIC CHALLENGE.
218214 04-14

INSOMNIACS
A COMPARATIVE STUDY OF THE HYPNOTIC PROPERTIES OF FLURAZEPAM (30 MG), SECOBARBITAL (100 MG), AND OF PLACEBO AMONG FOUR TYPES OF PSYCHOTIC INSOMNIACS.
203204 02-04
THE EFFECT OF TRIAZOLAM ON THE SLEEP OF INSOMNIACS.
217548 04-14

INSTITUTIONALIZED
THE COMBINED EFFECTS OF METHYLPHENIDATE (RITALIN) AND A CLASSROOM BEHAVIOR MODIFICATION PROGRAM IN REDUCING THE HYPERKINETIC BEHAVIORS OF INSTITUTIONALIZED MENTAL RETARDATES. (PH.D. DISSERTATION).
202356 02-11

INSTITUTIONS
RESULTS OF A SURVEY (1966-1967) OF DRUG USAGE IN INSTITUTIONS FOR THE MENTALLY RETARDED. (UNPUBLISHED PAPER).
222411 04-17

INSTRUMENTAL
THE EFFECTS OF P-CHLOROAMPHETAMINE ON INSTRUMENTAL CONDITIONING IN THE RAT.
195088 01-04

INSUFFICIENCY
ELIMINATION OF LITHIUM DEPENDENT ON AGE IN HEALTHY PEOPLE AND PATIENTS SUFFERING FROM RENAL INSUFFICIENCY.
205043 02-13

INSULIN
LITHIUM AND INSULIN: EFFECTS ON CARBOHYDRATE AND ELECTROLYTE METABOLISM.
205929 03-09
FURTHER STUDIES OF METHAMPHETAMINE-INDUCED INSULIN RELEASE.
217695 04-03
FEEDING IN RESPONSE TO REPEATED PROTAMINE ZINC INSULIN INJECTIONS.
219073 04-04

INTACT
THE SUBCELLULAR DISTRIBUTION OF INTRAVENTRICULARLY ADMINISTERED 3H-METARAMINOL IN INTACT AND RAT BRAIN PRETREATED WITH P-CHLOROAMPHETAMINE.
197289 01-03
SHORT-TERM EFFECTS OF TESTOSTERONE PROPIONATE ON THE BEHAVIOUR OF YOUNG INTACT MALE DOMESTIC DUCKS (ANAS-PLATYRHYNCHOS).
199461 02-04
EFFECT OF ACTH4-10 ON THE RATE OF SYNTHESIS OF (3H)CATECHOLAMINES IN THE BRAINS OF INTACT, HYPOPHYSECTOMIZED AND ADRENALECTOMIZED RATS.
223050 04-03

THE INFLUENCE OF PHENAMINE ON THE AVOIDANCE REACTION IN INTACT AND STRIATECTOMIZED RATS.
224467 04-04

INTAKE

INFLUENCE OF CATECHOLAMINE UPTAKE BLOCKING DRUGS ON THE INCREASE IN WATER INTAKE AND PLASMA RENIN CONCENTRATION INDUCED BY SOME HYPOTENSIVE DRUGS.
197288 01-03

EFFECT OF SEROTONIN ON WATER INTAKE AND RENIN ANGIOTENSIN SYSTEM IN RATS.
197963 01-03

ACUTE AND CHRONIC EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON FOOD INTAKE BY RATS.
200043 02-04

THE EFFECT OF 5-HYDROXYTRYPTOPHAN ON FOOD INTAKE AND ON THE ANOREXIC ACTION OF AMPHETAMINE AND FENFLURAMINE.
210748 03-04

THE EFFECT OF CYPROHEPTADINE ON HUNGER, CALORIE INTAKE AND BODY WEIGHT IN MAN.
214011 04-13

PHYSIOLOGICAL MECHANISMS FOR CARDIAC CONTROL BY NUTRITIONAL INTAKE AFTER EARLY MATERNAL SEPARATION IN THE YOUNG RAT.
218047 04-03

ENVIRONMENTAL INFLUENCES AFFECTING THE VOLUNTARY INTAKE OF DRUGS: AN OVERVIEW.
225155 04-04

INTEGRATED

THE PLACEBO EFFECT: AN INTEGRATED ANALYSIS OF THEORETICAL AND RESEARCH PERSPECTIVES. (PH.D. DISSERTATION).
212593 03-17

INTEGRATION

THE EFFECT OF METHYLPHENIDATE ON SENSORY PERCEPTION AND INTEGRATION IN HYPERACTIVE CHILDREN.
208920 03-14

THE DYNAMIC CONFRONTATION MODEL AS AN INTEGRATION OF PSYCHOTHERAPY.
211596 03-12

ROLE OF BRAIN SEROTONIN IN THE INTEGRATION OF BEHAVIORAL RESPONSES AND PITUITARY ADRENOCORTICAL FUNCTIONS UNDER EMOTION.
218364 04-04

INTELLECT

LITHIUM TREATMENT OF BEHAVIOURAL DISTURBANCES IN PATIENTS WITH DEFECTIVE INTELLECT.
205610 03-09

INTELLECTUAL

THE EFFECTS OF PYRITHIOXINE ON THE BEHAVIOUR AND INTELLECTUAL FUNCTION OF LEARNING DISABLED CHILDREN.
216485 04-11

INTELLIGENT

PERFORMANCES UNDER CERUTIL OF NORMALLY INTELLIGENT CHILDREN AFFECTED BY CEREBROORGANIC REDUCTIONS IN EFFICIENCY.
203742 02-11

INTENSE

A PROLONGED AFTEREFFECT OF INTENSE SYNAPTIC ACTIVITY ON ACETYLCHOLINE IN A SYMPATHETIC GANGLION.
211102 03-03

INTENSITY

THE EFFECTS OF SHOCK INTENSITY, D-AMPHETAMINE, AND PENTOBARBITAL ON THE FREQUENCY AND RESPONSE DYNAMICS OF BITING ATTACK IN THE SQUIRREL MONKEY. (PH.D. DISSERTATION).
222114 04-04

INTENSIVE

INTENSIVE DESIGN IN EVALUATING ANXIOLYTIC AGENTS.
198042 01-16

INTERACTION

MOUSE LOCOMOTOR ACTIVITY: EFFECT OF MORPHINE, NARCOTIC ANTAGONISTS, AND THE INTERACTION OF MORPHINE AND NARCOTIC ANTAGONISTS.
194478 01-04

BRAIN ACETYLCHOLINE AND CHOLINESTERASE: EFFECT OF PHENOTHIAZINES AND PHYSOSTIGMINE INTERACTION IN RATS.
195046 01-03

INTERACTION OF CATECHOLAMINE AND AMINO ACID METABOLISM IN BRAIN: EFFECT OF PARGYLINE AND L-DOPA.
195048 01-03

INTERACTION OF PENTYLENETETRAZOL AND TRIMETHADIONE ON THE METABOLISM OF SEROTONIN IN BRAIN AND ITS RELATION TO THE ANTICONVULSANT ACTION OF TRIMETHADIONE.
195093 01-03

A TRANSIENT STATE CONCEPT OF DRUG RECEPTOR INTERACTION.
195240 01-17

SOCIAL INTERACTION BETWEEN DRUGGED AND UNDRUGGED RATS.
196206 01-04

THE INTERACTION OF DELTA9-TETRAHYDROCANNABINOL AND D-AMPHETAMINE IN AGGREGATED MICE.
196227 01-04

INTERACTION BETWEEN ANTIDEPRESSANT AND CENTRALLY ACTING ANTIHYPERTENSIVE DRUGS.
197300 01-03

THE INTERACTION OF BARBITAL AND TESTOSTERONE RELATIVE TO THEIR HYPNOTIC EFFECTS.
197448 01-03

EFFECTS OF THE HIGH DOSES OF L-DOPA ON ELECTRICAL ACTIVITY IN THE BRAIN OF THE RABBIT: INTERACTION WITH THE METABOLISM OF 5-HT.
197468 01-03

INTERACTION OF OUABAIN WITH PENTOBARBITONE IN THE MOUSE.
197479 01-03

INTERACTION BETWEEN MASSED ELECTROCONVULSIVE SHOCK AND P-BROMOMETHYLAMPHETAMINE (V-111) TREATMENT.
197579 01-03

A STUDY OF THE INTERACTION BETWEEN AMPHETAMINE AND FOOD DEPRIVATION.
197854 01-04

THE INTERACTION OF DOPAMINE ANTAGONISTS AND AMANTADINE HYDROCHLORIDE ON THE ACQUISITION OF THE CONDITIONED AVOIDANCE RESPONSE IN RATS.
199959 02-04

EVIDENCE FOR THE FUNCTIONAL INTERACTION OF TWO CENTRAL NEUROTRANSMITTERS.
201324 02-03

STUDIES ON THE INTERACTION OF RESERPINE, D-AMPHETAMINE, APOMORPHINE AND 5-HYDROXYTRYPTOPHAN.
203885 02-03

PHARMACOLOGICAL PROPERTIES OF A POTENTIAL TRANQUILISING AGENT MESYLPHENACYRAZINE: I. INTERACTION WITH DRUGS INFLUENCING THE NERVOUS SYSTEM.
205578 02-03

DIPHENYLHYDANTOIN INTOXICATION DUE TO DIPHENYLHYDANTOIN ISONIAZID INTERACTION.
207155 03-15

CHOLINERGIC DOPAMINERGIC INTERACTION IN THE STRIATUM: THE EFFECT OF 6-HYDROXYDOPAMINE OR PIMOZIDE TREATMENT ON THE INCREASED STRIATAL ACETYLCHOLINE LEVELS INDUCED BY APOMORPHINE, PIRIBEDIL AND D-AMPHETAMINE.
210668 03-03

ACCUMULATION OF ACETYLCHOLINE AND AROMATIC MONOAMINES BY INTERACTION WITH ADENOSINE-5-TRIPHOSPHATE.
210753 03-03

INTERACTION OF PHYSOSTIGMINE AND DELTA9-TETRAHYDROCANNABINOL IN MAN.
210828 03-03

PHARMACOKINETIC INTERACTION BETWEEN NEUROLEPTICS AND TRICYCLIC ANTIDEPRESSANTS IN THE RAT.
210834 03-03

AN INVESTIGATION ON THE BEHAVIORAL AND HYPOTHERMIC EFFECTS OF YOHIMBINE: INTERACTION WITH DRUGS AFFECTING CENTRAL AND PERIPHERAL MONOAMINES.
211068 03-04

DRUGS, CATECHOLAMINES AND KREBS CYCLE INTERACTION (CNS).
213602 04-03

APOMORPHINE-INDUCED ROTATION IN NORMAL RATS AND INTERACTION WITH UNILATERAL CAUDATE LESIONS.
214012 04-04

NONPHARMACOLOGICAL FACTORS IN DRUG THERAPY: THE INTERACTION OF DOCTOR, PATIENT, AND TABLET APPEARANCE IN THE TREATMENT OF ANXIETY/DEPRESSIVE SYNDROMES.
215060 04-10

ABSENCE OF INTERACTION BETWEEN DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) AND CANNABIDIOL (CBD) IN AGGRESSION, MUSCLE CONTROL AND BODY TEMPERATURE EXPERIMENTS IN MICE.
217474 04-04

INTERACTION BETWEEN CENTRALLY ACTING HYPOTENSIVE DRUGS AND TRICYCLIC ANTIDEPRESSANTS.
217575 04-03

INHIBITION OF SEROTONIN UPTAKE AND THE TOXIC INTERACTION BETWEEN MEPERIDINE AND MONOAMINEOXIDASE INHIBITORS.
217696 04-03

INTERACTION OF DRUG THERAPY WITH MARITAL THERAPY IN DEPRESSIVE PATIENTS.
218769 04-10

INTERACTION OF CYCLOHEXIMIDE AND ADRENERGIC DRUGS WITH BRAIN PROTEIN AND CATECHOLAMINE BIOSYNTHESIS. (PH.D. DISSERTATION).
219288 04-03

RESEARCH INTO THE INTERACTION BETWEEN NORTRIPTYLINE AND PERPHENAZINE -- CLINICAL EVALUATION.
221632 04-13

BETA-PHENYLETHYLAMINE AND LOCOMOTOR ACTIVITY IN MICE: INTERACTION WITH CATECHOLAMINERGIC NEURONES AND RECEPTORS.
221742 04-03

IS THERE A CATECHOLAMINE SEROTONIN INTERACTION IN THE CONTROL OF LOCOMOTOR ACTIVITY?
222816 04-04

THE INTERACTION OF POSTWEANING HOUSING CONDITIONS AND PRENATAL DRUG EFFECTS ON BEHAVIOUR.
225563 04-04

INTERACTIONS
BEHAVIOURAL INTERACTIONS BETWEEN IMIDAZOLEACETIC ACID AND GAMMA-HYDROXYBUTYRIC ACID IN RATS AND MICE.
193545 01-04
INTERACTIONS OF BENZODIAZEPINES WITH HUMAN SERUM ALBUMIN: CIRCULAR DICHROISM STUDIES.
194148 01-01
THE MULTIPLICITY OF INTERACTIONS OF PSYCHOTROPIC DRUGS WITH THE BRAIN SEROTONIN BIOSYNTHETIC UNIT.
195926 01-17
THE USE OF DRUG INTERACTIONS IN ANIMALS FOR SELECTING PSYCHOTROPIC DRUGS.
198057 01-02
INTERACTIONS OF PENTAZOCINE AND NALOXONE ON THE MONOAMINE CONTENT OF DISCRETE REGIONS OF THE RAT BRAIN.
198606 02-03
INTERACTIONS OF SOME ANALGESICS AND ANTIDEPRESSANTS WITH PHENELZINE OR RESERPINE IN THE MOUSE.
204879 02-05
COMPARATIVE STUDIES OF VERBAL INTERACTIONS IN A GROUP OF HEALTHY SUBJECTS UNDER THE INFLUENCE OF PSYCHOPHARMACOLOGICAL AGENTS: WITH SPECIAL CONSIDERATION OF YG-19256, CHLORDIAZEPOXIDE AND PLACEBO.
207140 03-14
INTERACTIONS BETWEEN DRUGS.
209073 03-15
ACTIONS AND INTERACTIONS OF ABUSED DRUGS OF THE REWARD SYSTEM. (PH.D. DISSERTATION).
212964 03-04
DRUG INTERACTIONS WITH PSYCHOACTIVE DRUGS.
216184 04-15
INTERACTIONS OF IMIPRAMINE AND SYNTHESIS INHIBITORS ON BIOGENIC AMINES.
217827 04-03
SOME INTERACTIONS BETWEEN FENFLURAMINE AND ANTIDEPRESSANT DRUGS: EFFECTS ON 5-HYDROXYINDOLE CONCENTRATIONS IN RAT BRAIN.
217962 04-03
INTERACTIONS BETWEEN POSTGANGLIONIC SYMPATHETIC BLOCKING DRUGS AND ANTIDEPRESSANTS.
221650 04-09
INTERACTIONS BETWEEN LYSERGIC ACID DIETHYLAMIDE AND DOPAMINE SENSITIVE ADENYLCYCLASE SYSTEMS IN RAT BRAIN.
223175 04-03
DRUG PSYCHOTHERAPY INTERACTIONS IN DEPRESSION.
224767 04-10
CATECHOLAMINES AND DRUG BEHAVIOR INTERACTIONS.
225162 04-04

INTERACTIVE
INTERACTIVE PREDICTION OF DRUG-INDUCED CHANGE.
195936 01-17
INTERACTIVE EFFECT OF (PLUS/MINUS) FENFLURAMINE AND (+) AMPHETAMINE ON FEEDING IN RATS.
217883 04-04

INTERCHANGEABLE
ARE ANTIPSYCHOTIC DRUGS INTERCHANGEABLE?.
202879 02-08

INTERFERE
BEHAVIOURAL SUPERSENSITIVITY TO APOMORPHINE FOLLOWING CHRONIC TREATMENT WITH DRUGS WHICH INTERFERE WITH THE SYNAPTIC FUNCTION OF CATECHOLAMINES.
199958 02-04

INTERFERES
CANNABIDIOL INTERFERES WITH THE EFFECTS OF DELTA9-TETRAHYDROCANNABINOL IN MAN.
197867 01-14

INTERFERON
EFFECT OF MORPHINE, HYDROMORPHONE, METHADONE, MESCALINE, TRYPAN-BLUE, VITAMIN-A, SODIUM SALICYLATE AND CAFFEINE ON THE SERUM INTERFERON LEVEL IN RESPONSE TO VIRAL INFECTION.
217654 04-03

INTERMEDIATE
METABOLIC COMPARTMENTATION IN THE BRAIN: METABOLISM OF A TRICARBOXYLIC ACID CYCLE INTERMEDIATE, (1,4-14C)SUCCINATE, AFTER INTRACEREBRAL ADMINISTRATION.
210780 03-03

INTERMEDIUS
THE NUCLEUS LINEARIS INTERMEDIUS RAPHE AND BEHAVIOUR EVOKED BY DIRECT AND INDIRECT STIMULATION OF DOPAMINE SENSITIVE SITES WITHIN THE CAUDATE NUCLEUS OF CATS.
199864 02-04

INTERMITTENT
INTERMITTENT TREATMENT WITH ANORECTIC DRUGS.
197137 01-11
MONTHLY INTERMITTENT CHEMOTHERAPY OF CHRONIC SCHIZOPHRENIC OUTPATIENTS WITH PIPOTHIAZINE PALMITATE.
204169 02-08

INTERNAL
MY EXPERIENCE WITH THE USE OF A TRANQUILIZER, NORITREN, IN THE DEPARTMENT OF INTERNAL MEDICINE PSYCHOSOMATICS.
194510 01-11
PSYCHOTHERAPY AND DRUGS FROM THE STANDPOINT OF INTERNAL MEDICINE.
199907 02-17
TREATMENT AND COUNTERMEASURES FOR PATIENTS WITH INSOMNIA IN THE DEPARTMENT OF INTERNAL MEDICINE -- SPECIAL EMPHASIS ON THE CLINICAL APPLICATION OF FLURAZEPAM.
202285 02-14
RAPID REVERSAL OF INTERNAL NA+ AND K+ CONTENTS OF SYNAPTOSOMES BY OUABAIN.
204185 02-03

INTERNATIONAL
CONTROLLING DRUGS: INTERNATIONAL HANDBOOK FOR PSYCHOACTIVE DRUG CLASSIFICATION.
202861 02-17
FRONTIERS IN CATECHOLAMINE RESEARCH. PROCEEDINGS OF THE THIRD INTERNATIONAL CATECHOLAMINE SYMPOSIUM.
206437 03-17

INTERNEURONAL
THE INFLUENCE OF SODIUM OXYBUTYRATE ON INTERNEURONAL TRANSMISSION OF EXCITATION AT VARIOUS LEVELS OF THE CENTRAL NERVOUS SYSTEM.
198435 02-03

INTEROCEPTIVE
DOPAMINERGIC MEDIATION OF THE INTEROCEPTIVE CUE PRODUCED BY D-AMPHETAMINE IN RATS.
217531 04-04

INTERPERSONAL
MARIJUANA, ALCOHOL AND INTERPERSONAL PERCEPTIONS.
224755 04-14

INTERPRETATION
AN EXTENSION OF MULTIDIMENSIONAL SCALING TO FACILITATE CLINICAL INTERPRETATION OF ANIMAL TEST MODELS.
198059 01-02
EFFECTS OF PHENOTHIAZINE WITHDRAWAL ON PROVERB INTERPRETATION BY CHRONIC SCHIZOPHRENICS.
208325 03-08
THE PROPOSAL OF AN UNIFIED MODEL FOR THE INTERPRETATION OF THE ACTIVITY OF DIFFERENT CLASSES OF BETA-ADRENERGIC AGENTS.
220951 04-01

INTERPRETIVE
THE ACTION OF SULPIRIDE IN PURE INTERPRETIVE DELIRIUM.
212492 03-09

INTERRELATION
INTERRELATION BETWEEN MONOAMINERGIC AND CHOLINERGIC MECHANISMS IN THE HYPOTHALAMIC THERMOREGULATORY CENTRE OF RABBITS.
195249 01-03

INTERRESPONSE
INTERRESPONSE TIME CHANGES AS A FUNCTION OF WATER DEPRIVATION AND AMPHETAMINE.
217459 04-04

INTERRUPTING
TREATMENT OF EXPERIMENTAL IMIPRAMINE INTOXICATION BY INTERRUPTING ENTERAL CYCLES WITH ACTIVATED CHARCOAL.
197969 01-03

INTERRUPTION
TRIAL INTERRUPTION OF ANTIPARKINSONIANS IN LONG-TERM NEUROLEPTIC TREATMENT.
216767 04-15

INTERSESSION
THE EFFECTS OF PHYSOSTIGMINE DURING THE ACQUISITION OF AVOIDANCE BEHAVIOUR AS A FUNCTION OF THE INTERSESSION INTERVAL.
192951 01-04

INTERVAL
THE EFFECTS OF PHYSOSTIGMINE DURING THE ACQUISITION OF AVOIDANCE BEHAVIOUR AS A FUNCTION OF THE INTERSESSION INTERVAL.
192951 01-04
TOLERANCE DEVELOPMENT TO THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON CONDITIONED BEHAVIOR: ROLE OF TREATMENT INTERVAL AND INFLUENCE OF MICROSOMAL METABOLISM.
215726 04-03

INTERVENTION
TREATMENT OF ACUTE SCHIZOPHRENIA WITH ULTRA-HIGH-DOSE FLUPHENAZINE: A FAILURE AT SHORTENING TIME ON A CRISIS INTERVENTION UNIT.
215456 04-08

THE SIGNIFICANCE OF STANDARDIZED EVALUATION SCALES IN PSYCHIATRIC DIAGNOSIS AS EXEMPLIFIED BY THE THERAPEUTIC INTERVENTION WITH DESMETHYLOXAPINE.
221337 04-10

INTERVIEWING
THE USE OF FREE IMAGERY, NONDIRECTIVE INTERVIEWING, AND SELECTED DRUGS TO LIFT POSTHYPNOTIC REPRESSION. (PH.D. DISSERTATION).
222060 04-14

INTESTINAL
INFLUENCE OF MAO INHIBITORS ON THE INTESTINAL ABSORPTION OF BIOGENIC AMINES.
197948 01-03

INTOXICATION
LONG-TERM LITHIUM ADMINISTRATION TO RATS. LITHIUM AND SODIUM DOSAGE AND ADMINISTRATION, AVOIDANCE OF INTOXICATION, POLYURIC CONTROL RATS.
195042 01-03
ANTAGONISM OF ACUTE AMPHETAMINE INTOXICATION BY HALOPERIDOL AND PROPRANOLOL.
196106 01-05
INVESTIGATIONS OF THE EFFECTS OF DIAZEPAM IN ACUTE EXPERIMENTAL INTOXICATION WITH FLUOSTIGMINE.
197832 01-03
TREATMENT OF EXPERIMENTAL IMIPRAMINE INTOXICATION BY INTERRUPTING ENTERAL CYCLES WITH ACTIVATED CHARCOAL.
197969 01-03
LITHIUM INDUCED LOSS OF BODY SODIUM AND THE DEVELOPMENT OF SEVERE INTOXICATION IN RATS.
199623 02-03
STUDY OF LITHIUM INTOXICATION UNDER THERAPEUTIC LITHIUM SERUM CONCENTRATION.
200952 02-15
REVERSAL OF AMITRIPTYLINE INTOXICATION BY PHYSOSTIGMINE.
202922 02-15
HEAVY INTOXICATION AS A SIDE-EFFECT OF CARBROMAL IN TWO CHILDREN.
203882 02-15
EXPERIMENTAL EEG STUDIES ON BARBITURATE INTOXICATION AND PIRACETAM.
205507 02-03
DIPHENYLHYDANTOIN INTOXICATION DUE TO DIPHENYLHYDANTOIN ISONIAZID INTERACTION.
207155 03-15
SURVIVAL IN LITHIUM INTOXICATION, STATUS-EPILEPTICUS, AND PROLONGED COMA.
208536 03-15
THE EFFECT OF SODIUM CHLORIDE ON KIDNEY FUNCTION IN RATS WITH LITHIUM INTOXICATION.
210696 03-03
NORMAL SHUTTLEBOX AVOIDANCE LEARNING AFTER CHRONIC PHENOBARBITAL INTOXICATION IN MICE.
210737 03-04
THREE CASES OF CHRONIC CHLORDIAZEPOXIDE INTOXICATION AND THEIR WITHDRAWAL SYMPTOMS.
211360 03-15
THE EFFECTS OF CANNABIS INTOXICATION ON PRIMARY SUGGESTIBILITY. (PH.D. DISSERTATION).
211831 03-14
PROTECTIVE EFFECT OF PIRACETAM IN EXPERIMENTAL BARBITURATE INTOXICATION: EEG AND BEHAVIOURAL STUDIES.
213589 04-03
THREE ACUTE CASES OF DIPHENYLHYDANTOIN INTOXICATION.
221515 04-15
EXPERIENCING AND ALTERING STATES OF INTOXICATION: AN INFORMATION PROCESSING VIEW OF THE HIGH.
224756 04-14
THE INTOXICATION: STATE OF CONSCIOUSNESS.
224757 04-14

INTOXICATIONS
ACUTE INTOXICATIONS WITH NEUROLEPTICS.
196923 01-15
STUDIES ON ANTIDIURETIC ACTIVITIES AND ON PORTER-SILBERS CHROMOGENS CONTENT IN PLASMA OF PATIENTS WITH ALCOHOLIC DELIRIUM OR WITH ACUTE PHENOTHIAZINE INTOXICATIONS.
203741 02-15

INTRA-EXTRACELLULAR
INTRA-EXTRACELLULAR LITHIUM RATIO: CLINICAL AND EXPERIMENTAL FINDINGS ON THROMBOCYTES AND ERYTHROCYTES.
204393 02-13

INTRACELLULAR
INTRACELLULAR DISTRIBUTION OF 3H-DELTA8-TETRAHYDROCANNABINOL IN RAT ORGANS AFTER I.V. ADMINISTRATION.
195112 01-03
THE EFFECT OF DIAZEPAM AND NITRAZEPAM ON INTRACELLULAR AND EXTRACELLULAR DISTRIBUTION OF SODIUM AND POTASSIUM IONS IN INDIVIDUAL STRUCTURES OF RATS BRAINS.
207199 03-03

INTRACEREBRAL
DRUG-INDUCED ROTATION IN RATS AFTER UNILATERAL INTRACEREBRAL INJECTION OF 5,6 DIHYDROXYTRYPTAMINE (5-6-DHT).
192940 01-03
MORPHOLOGICAL, BIOCHEMICAL, AND FUNCTIONAL CHANGES IN CHICK EMBRYONIC BRAIN TISSUE AFTER INTRACEREBRAL ADMINISTRATION OF OUABAIN.
197788 01-03
EVIDENCE THAT PUNCTUATE INTRACEREBRAL ADMINISTRATION OF 6-HYDROXYDOPAMINE FAILS TO PRODUCE SELECTIVE NEURONAL DEGENERATION: COMPARISON WITH COPPER SULFATE AND FACTORS GOVERNING THE DEPORTMENT OF FLUIDS INJECTED INTO BRAIN.
197931 01-03
METABOLIC COMPARTMENTATION IN THE BRAIN: METABOLISM OF A TRICARBOXYLIC ACID CYCLE INTERMEDIATE, (1,4-14C)SUCCINATE, AFTER INTRACEREBRAL ADMINISTRATION.
210780 03-03

INTRACEREBRALLY
THE BEHAVIOURAL EFFECTS OF DOPAMINE APPLIED INTRACEREBRALLY TO AREAS OF THE MESOLIMBIC SYSTEM.
217660 04-04

INTRACEREBROVENTRICULAR
THE INFLUENCE OF CYPROHEPTADINE AND OF D-LYSERGAMIDE ON THE RISE IN TEMPERATURE INDUCED BY INTRACEREBROVENTRICULAR 5-HYDROXYTRYPTAMINE, NORADRENALINE AND DOPAMINE IN CONSCIOUS RABBITS.
193451 01-03
EFFECT OF INTRACEREBROVENTRICULAR BRADYKININ AND RELATED PEPTIDES ON RABBIT OPERANT BEHAVIOR.
215693 04-04

INTRACRANIAL
INTRACRANIAL SELF-STIMULATION IN RATS AS A FUNCTION OF VARIOUS STIMULUS PARAMETERS: V. INFLUENCE OF COCAINE ON MEDIAL FOREBRAIN BUNDLE STIMULATION WITH MONOPOLAR ELECTRODES.
198223 02-03
DEFICIENT BRIGHTNESS DISCRIMINATION ACQUISITION PRODUCED BY DAILY INTRACRANIAL INJECTIONS OF PENICILLIN IN RATS.
202758 02-04
THE REVERSIBLE INHIBITION OF STEROID INDUCED SEXUAL BEHAVIOR BY INTRACRANIAL CYCLOHEXIMIDE.
213685 04-03
INTRACRANIAL REWARD AFTER 5,6 DIHYDROXYTRYPTAMINE: FURTHER EVIDENCE FOR SEROTONINS INHIBITORY ROLE.
215732 04-04
EFFECTS OF HEROIN ON LEVER PRESSING FOR INTRACRANIAL SELF-STIMULATION, FOOD AND WATER IN THE RAT.
221039 04-04

INTRACTABLE
DRUG TREATMENT OF CHRONIC INTRACTABLE PAIN IN PATIENTS REFERRED TO A PSYCHIATRY CLINIC.
196090 01-14
TREATMENT OF INTRACTABLE DEPRESSION.
208918 03-17

INTRAHIPPOCAMPAL
EFFECT OF INTRAHIPPOCAMPAL INJECTION OF ATROPINE ON DIFFERENT PHASES OF A LEARNING EXPERIMENT.
198227 02-04
EXPLORATORY BEHAVIOUR IN TWO SELECTIVELY BRED LINES OF MICE AFTER INTRAHIPPOCAMPAL INJECTION OF METHYLSCOPOLAMINE.
217464 04-04

INTRAHIPPOCAMPALLY
REDUCED BEHAVIOURAL EFFECTS OF INTRAHIPPOCAMPALLY ADMINISTERED CARBACHOL IN RATS WITH LOW CHOLINESTERASE ACTIVITY.
199956 02-04

INTRAHYPOTHALAMIC
SIMILAR ACTIONS OF INTRAHYPOTHALAMIC 5-6-DHT AND 5-HT IN EVOKING HYPERTHERMIA IN THE MONKEY.
200034 02-03
POSTCASTRATION DECLINE IN BEHAVIOURAL RESPONSIVENESS TO INTRAHYPOTHALAMIC ANDROGEN IN DOVES.
210918 03-03

INTRAMUSCULAR
EFFECT OF ORAL AND INTRAMUSCULAR ROUTES OF ADMINISTRATION ON SERUM CHLORDIAZEPOXIDE LEVELS AND THE PREDICTION OF THESE LEVELS FROM PREDRUG FASTING SERUM GLUCOSE CONCENTRATIONS.
195055 01-13
DIAZEPAM METABOLISM IN NORMAL MAN: I. SERUM CONCENTRATIONS AND CLINICAL EFFECTS AFTER INTRAVENOUS, INTRAMUSCULAR, AND ORAL ADMINISTRATION.
195444 01-15
THE EFFECT OF BEDREST AND OF PHYSICAL ACTIVITY ON THE BLOOD LEVEL OF GENTAMYCIN AFTER INTRAMUSCULAR APPLICATION.
197956 01-13

PIPOTHIAZINE PALMITATE: AN EVALUATION OF A NEW LONG-ACTING INTRAMUSCULAR ANTIPSYCHOTIC AGENT IN SEVERELY ILL SCHIZOPHRENIC PATIENTS.
216188 04-08

INTRANIGRAL
COMPARISON OF THE EFFECTS OF THE INTRANIGRAL INJECTIONS OF CHOLINOMIMETICS WITH SYSTEMIC INJECTIONS OF THE DOPAMINE RECEPTOR STIMULATING AND BLOCKING AGENTS IN THE RABBIT.
199772 02-03

INTRAPERITONEAL
THE INFLUENCE OF INTRAPERITONEAL INJECTION OF IPRAZIDE AND TRANSAMINE ON THE DISTRIBUTION OF BIOGENIC AMINES IN CORTICAL AND SUBCORTICAL WHITE MATTER OF THE RAT BRAIN.
209032 03-03

INTRASPECIES
INTRASPECIES AGGRESSION IN RATS: EFFECTS OF D-AMPHETAMINE AND CHLORDIAZEPOXIDE.
202768 02-04
AN ANALYSIS OF NEUROCHEMICAL MECHANISMS OF ONE FORM OF INTRASPECIES BEHAVIOR.
215789 04-04
THE EFFECT OF DRUGS ON INTRASPECIES AGGRESSION.
223064 04-04

INTRASPECIFIC
CHLORDIAZEPOXIDE (LIBRIUM) INDUCED CHANGES IN INTRASPECIFIC ATTACK AND SELECTED NONAGONISTIC BEHAVIORS IN MALE SIAMESE FIGHTING FISH.
217524 04-04

INTRASTRIATAL
DYSKINETIC PHENOMENA CAUSED BY THE INTRASTRIATAL INJECTION OF PHENYLETHYLAMINE, PHENYLPIPERAZINE, TETRAHYDROISOQUINOLINE AND TETRAHYDRONAPTHALENE DERIVATIVES IN THE GUINEA-PIG.
217671 04-04

INTRAVENOUS
THE ACUTE EFFECTS OF INTRAVENOUS INFUSION OF L-TRYPTOPHAN IN NORMAL SUBJECTS.
195443 01-15
DIAZEPAM METABOLISM IN NORMAL MAN: I. SERUM CONCENTRATIONS AND CLINICAL EFFECTS AFTER INTRAVENOUS, INTRAMUSCULAR, AND ORAL ADMINISTRATION.
195444 01-15
MECHANISM OF THE HYPOTENSIVE EFFECT OF INTRAVENOUS METHAQUALONE IN THE CAT.
196107 01-03
ALTERATIONS IN ACID-BASE BALANCE IN THE DOG AFTER INTRAVENOUS ADMINISTRATION OF BENZOCTAMINE AND DIAZEPAM, COMPARED WITH THOSE INDUCED BY THIOPENTAL.
197485 01-03
POLYGRAPHIC EXAMINATION DURING FAST AND SLOW INTRAVENOUS INJECTION OF THE SAME DOSE OF DIAZEPAM.
205508 02-13
A COMPARATIVE STUDY ON THE EFFECT OF INTRAVENOUS DIAZEPAM AND RO-5-3350 ON PYRAMIDAL SPASTICITY.
205575 02-13
ACCUMULATION OF 3H-HOMOVANILLIC ACID IN RABBIT BRAIN AND CEREBROSPINAL FLUID FOLLOWING INTRAVENOUS 3H-L-DOPA.
206336 03-03
EXPERIMENTATION WITH THE INTRAVENOUS FORM OF AMITRIPTYLINE WITH 40 PATIENTS.
210128 03-09
BLOOD-BRAIN BARRIER: I. KINETICS OF DISTRIBUTION OF 3H-AMPHETAMINE IN THE RAT BRAIN AFTER INTRAVENOUS ADMINISTRATION.
210788 03-03
PHARMACOKINETICS OF CARBAMAZEPINE IN MONKEYS FOLLOWING INTRAVENOUS AND ORAL ADMINISTRATION.
211009 03-03
THE EFFECTS OF INTRAVENOUS AND SUBCUTANEOUS EPINEPHRINE ADMINISTRATION ON CONDITIONED SUPPRESSION. (PH.D. DISSERTATION).
213131 03-04
THE ROLE OF INTRAVENOUS CLOMIPRAMINE IN THE TREATMENT OF OBSESSIONAL AND PHOBIC DISORDERS.
214835 04-10
THE BLOOD-BRAIN BARRIER II: DISTRIBUTION KINETICS OF H3-P-HYDROXYAMPHETAMINE IN BRAIN STRUCTURES OF THE RAT AFTER INTRAVENOUS ADMINISTRATION.
220977 04-03
INTRAVENOUS SELF-ADMINISTRATION OF D-AMPHETAMINE AND L-AMPHETAMINE BY DOG.
222806 04-04

INTRAVENOUSLY
CHROMOSOMAL ABERRATION RATES AND INTRAVENOUSLY GIVEN DIAZEPAM: A NEGATIVE STUDY.
195949 01-13
SERUM ERYTHROCYTE AND CNS LEVELS IN RHESUS MONKEYS OF ORALLY AND INTRAVENOUSLY ADMINISTERED RUBIDIUM SALTS.
218956 04-02

INTRAVENTRICULAR
EEG SEIZURES PRODUCED BY INTRAVENTRICULAR QUATERNARY AMMONIUM COMPOUNDS IN THE RAT.
197475 01-03
BEHAVIOURAL AND ELECTROCORTICAL MODIFICATIONS INDUCED IN THE RAT BY INTRAVENTRICULAR INJECTION OF PHYSALAEMIN AND ELEDOISIN.
198224 02-03
BEHAVIOURAL EFFECT OF INTRAVENTRICULAR APPLICATION OF METHOXYINDOLEALKYLAMINES IN THE RAT.
202772 02-04
AN ANALYSIS OF THE GROSS BEHAVIOURAL CHANGES INDUCED BY TETRAETHYLAMMONIUM AND A COMPARISON WITH OTHER SUBSTANCES AFFECTING THE AUTONOMIC AND CENTRAL NERVOUS SYSTEM AFTER INTRAVENTRICULAR INJECTIONS TO CONSCIOUS CATS.
202781 02-04
FORMATION OF P-HYDROXYNOREPHEDRINE IN BRAIN FOLLOWING INTRAVENTRICULAR ADMINISTRATION OF P-HYDROXYAMPHETAMINE.
202782 02-03
INCREASED FIXED-RATIO PERFORMANCE AND DIFFERENTIAL D- AND L-AMPHETAMINE ACTION FOLLOWING NOREPINEPHRINE DEPLETION BY INTRAVENTRICULAR 6-HYDROXYDOPAMINE.
204482 02-04
EFFECTS OF INTRAVENTRICULAR INFUSIONS OF ACTH1-24 AND ACTH4-10 ON LH RELEASE, OVULATION AND BEHAVIOR IN THE RABBIT.
210662 03-03
EFFECT OF INTRAVENTRICULAR NOREPINEPHRINE ON NEURON ACTIVITY IN THE MEDIAL FOREBRAIN BUNDLE DURING SELF-STIMULATION BEHAVIOR.
210704 03-04
INTRAVENTRICULAR AMPHETAMINE SELF-ADMINISTRATION IN THE ALBINO RAT. (PH.D. DISSERTATION).
211899 03-04
THE EFFECT OF INTRAVENTRICULAR ADMINISTRATION OF SEROTONIN ON SPONTANEOUS MOTOR ACTIVITY OF RATS. (UNPUBLISHED PAPER).
225287 04-04

INTRAVENTRICULARLY
THE SUBCELLULAR DISTRIBUTION OF INTRAVENTRICULARLY ADMINISTERED 3H-METARAMINOL IN INTACT AND RAT BRAIN PRETREATED WITH P-CHLOROAMPHETAMINE.
197289 01-03
DECREASED ANTINOCICEPTIVE EFFECT OF MORPHINE IN RATS TREATED INTRAVENTRICULARLY WITH PROSTAGLANDIN-E1.
200045 02-03

INTROVERTS
THE EFFECTS OF CHLORPROMAZINE AND D-AMPHETAMINE SULFATE ON THE VISUAL STIMULATION PREFERENCE OF EXTRAVERTS AND INTROVERTS.
210680 03-14

INVENTORY
USE OF THE MAUDSLEY PERSONALITY INVENTORY IN EVALUATING THE EFFECTIVENESS OF A MINOR TRANQUILIZER IN PSYCHOSOMATIC DISEASES (THE FIRST REPORT).
198518 02-14
CHANGES IN OBSESSIVE/COMPULSIVE PATIENTS AS MEASURED BY THE LEYTON INVENTORY BEFORE AND AFTER TREATMENT WITH CLOMIPRAMINE.
214833 04-10

INVESTIGATING
A CONTROLLED SERIES OF EXPERIMENTS INVESTIGATING SOME SOCIOLOGICAL EFFECTS OF TWO DOSAGES OF CHLORDIAZEPOXIDE (LIBRIUM) UPON INDIVIDUALS AND SMALL GROUPS. (PH.D. DISSERTATION).
195145 01-14

INVESTIGATION
A CLINICAL NEUROLEPTIC INVESTIGATION OF N-(1-ETHYL-PYRROLIDIN-2-YL) 2-METHOXY-5-SULFAMOYL-BENZAMIDE NEUROLEPTIC SULPIRIDE (DOGMATIL) IN ACUTELY ILL SCHIZOPHRENICS.
195038 01-11
A QUANTUM CHEMICAL INVESTIGATION OF THE PI-ELECTRONIC STRUCTURE OF THE HALLUCINOGENIC N,N-DIMETHYLTRYPTAMINES.
195119 01-01
INVESTIGATION OF THE MECHANISM BY WHICH L-DOPA INDUCES GNAWING IN MICE.
198014 01-04
ON THE INFLUENCE OF NEUROLEPTICS ON THE CORTICORETICULAR SYSTEM OF THE BRAIN (HISTOCHEMICAL AND BIOCHEMICAL INVESTIGATION).
198481 02-03
A BEHAVIORAL INVESTIGATION: THE EFFECTS OF MEDICATION ON DISRUPTIVE CLASSROOM BEHAVIOR AND ACADEMIC PERFORMANCE. (PH.D. DISSERTATION).
200461 02-11
THE CONCEPT OF THE QUASI-ABSTINENCE EFFECT AND ITS USE IN THE INVESTIGATION OF DEPENDENCE MECHANISMS.
202194 02-13
AN INVESTIGATION OF PSYCHOTROPIC ACTIVITY IN A SERIES OF PIPERAZINE (1,2-A) INDOLE DERIVATIVES.
206438 03-02

MULTISPECTRAL INVESTIGATION OF PSYCHOTROPIC DRUGS.
206983 03-08

SURVEY ON AND EVALUATION OF THE CONTRIBUTIONS OF METHODOLOGICAL ASPECTS IN THE INVESTIGATION OF LONG-TERM PSYCHOPHARMACOLOGICAL DRUG ACTION.
206984 03-16

INVESTIGATION OF CLINICAL EFFECTS OF FK-880 (SULPIRIDE) ON MANIC-DEPRESSIVE ILLNESS.
207535 03-09

PSYCHIATRIC INVESTIGATION OF DRUG DEPENDENCE.
208761 03-17

CHROMOSOMAL DAMAGE IN CHRONICAL USERS OF CANNABIS: IN VIVO INVESTIGATION WITH TWO-DAY LEUKOCYTE CULTURES.
210810 03-15

AN INVESTIGATION ON THE BEHAVIORAL AND HYPOTHERMIC EFFECTS OF YOHIMBINE: INTERACTION WITH DRUGS AFFECTING CENTRAL AND PERIPHERAL MONOAMINES.
211068 03-04

AN INVESTIGATION INTO THE USE OF ANAFRANIL IN PHOBIC AND OBSESSIONAL DISORDERS.
214837 04-10

EXPERIMENTAL INVESTIGATION OF A NEW AMPHETAMINE DERIVATIVE.
219709 04-03

MORPHINE SENSITIVITY AND TOLERANCE: A GENETIC INVESTIGATION IN THE MOUSE.
221037 04-03

INVESTIGATIONS

PHARMACOLOGICAL INVESTIGATIONS WITH BENZOCTAMINE (TACITIN), A NEW PSYCHOACTIVE AGENT.
197447 01-03

INVESTIGATIONS ON THE ACTION AND MECHANISM OF ACTION OF DIPHENYLHYDANTOIN AS AN ANTAGONIST OF TETRABENAZINE AND RESERPINE.
197471 01-03

INVESTIGATIONS OF THE EFFECTS OF DIAZEPAM IN ACUTE EXPERIMENTAL INTOXICATION WITH FLUOSTIGMINE.
197832 01-03

INFLUENCE OF MELATONIN ON EEG AND HUMAN SLEEP: AUTOMATIC EEG ANALYSES AND POLYGRAPHIC NIGHT SLEEP INVESTIGATIONS.
205446 02-13

A YEAR OF INVESTIGATIONS ON 1035-MD IN CHILD AND JUVENILE NEUROPSYCHIATRY: CLINICAL AND EEG FINDINGS FROM 46 CASES.
209784 03-11

PSYCHOPHARMACOLOGIC INVESTIGATIONS IN HEALTHY ELDERLY VOLUNTEERS: EFFECTS OF PIPRADROL - VITAMIN (ALERTONIC) ELIXIR AND PLACEBO IN RELATION TO RESEARCH DESIGN.
218217 04-11

INVESTIGATIONS OF UCS-CS MEDIATION IN RADIATION INDUCED CONDITIONED TASTE AVERSION. (PH.D. DISSERTATION).
220681 04-04

TOXICOLOGICAL AND PHARMACOLOGICAL INVESTIGATIONS OF PINAZEPAM (7-CHLORO-1-PROPARGYL-5-PHENYLBENZODIAZEPIN-2-ONE): A NEW THERAPEUTIC AGENT.
221723 04-02

INVESTIGATOR

ETHICS IN MEDICAL RESEARCH AS VIEWED BY THE CLINICAL INVESTIGATOR.
214341 04-17

INVOLUTIONAL

INVOLUTIONAL MELANCHOLIA IN MALES?
206601 03-09

INVOLVED

A PHARMACOLOGICAL AND NEUROANATOMICAL ANALYSIS OF DOPAMINERGIC AND NORADRENERGIC PATHWAYS INVOLVED IN SELF-STIMULATION IN RATS. (PH. D. DISSERTATION).
193582 01-04

ARE AUTORECEPTORS IN DOPAMINERGIC NEURONS INVOLVED IN THE CHANGE OF THE KINETIC STATE OF STRIATAL TYROSINE-HYDROXYLASE ELICITED BY ANTIPSYCHOTICS? (UNPUBLISHED PAPER).
208636 03-03

POSSIBLE MECHANISMS INVOLVED IN THE DEPRESSOR RESPONSE TO DOPAMINE.
210787 03-03

ANALYSIS OF VARIOUS FACTORS INVOLVED IN EEG SYNCHRONIZATION DURING MILK DRINKING IN THE CAT.
217846 04-04

STEREOSPECIFICITY OF DOPAMINE RECEPTORS INVOLVED IN THE REGULATION OF THE KINETIC STATE OF TYROSINE-HYDROXYLASE IN STRIATUM AND NUCLEUS-ACCUMBENS.
217888 04-03

INVOLVEMENT

COMPARATIVE INVOLVEMENT OF DOPAMINE AND NORADRENALINE IN RATE-FREE SELF-STIMULATION IN SUBSTANTIA-NIGRA, LATERAL HYPOTHALAMUS, AND MESENCEPHALIC CENTRAL GRAY.
193303 01-03

MESOLIMBIC INVOLVEMENT WITH BEHAVIOURAL EFFECTS INDICATING ANTIPSYCHOTIC ACTIVITY.
193450 01-03

INVOLVEMENT OF SEROTONIN IN HYPERKINETIC EPISODES IN SCOTTISH TERRIER DOGS. (PH.D. DISSERTATION).
196261 01-03

INVOLVEMENT OF CYCLIC NUCLEOTIDES IN THE LONG-TERM INDUCTION OF TYROSINE-HYDROXYLASE. (UNPUBLISHED PAPER).
196590 01-03

ON THE INVOLVEMENT OF BRAIN CATECHOLAMINES IN MORPHINE-INDUCED RUNNING ACTIVITY IN MICE.
197286 01-04

THE ANTICONVULSANT ACTION OF THE CARBONIC ANHYDRASE INHIBITOR METHAZOLAMIDE: POSSIBLE INVOLVEMENT OF A NORADRENERGIC MECHANISM.
197864 01-03

N-ACETYLTRANSFERASE OF BRAIN: POSSIBLE INVOLVEMENT IN THE METABOLISM OF THE BIOGENIC AMINES. (UNPUBLISHED PAPER).
199347 02-03

ONTOGENETIC ASPECTS OF CENTRAL CHOLINERGIC INVOLVEMENT IN SPONTANEOUS ALTERNATION BEHAVIOR.
199550 02-04

THE REGULATION OF CYCLIC GUANOSINE MONOPHOSPHATE IN RAT CEREBELLUM: POSSIBLE INVOLVEMENT OF PUTATIVE AMINO ACID NEUROTRANSMITTERS.
202717 02-03

CENTRAL CATECHOLAMINE NEURONS, BEHAVIOR AND NEUROLEPTIC DRUGS: AN ANALYSIS TO UNDERSTAND THE INVOLVEMENT OF CATECHOLAMINES IN SCHIZOPHRENIA.
207305 03-03

SEROTONERGIC INVOLVEMENT WITH THE STEREOTYPY/CATALEPSY INDUCED BY MORPHINE-LIKE AGENTS IN THE RAT.
210754 03-04

POSSIBLE INVOLVEMENT OF 5-HYDROXYTRYPTAMINE IN THE ANTIDEPRESSANT ACTIVITY OF NARCOTIC ANALGESICS.
210761 03-03

EVIDENCE AGAINST THE INVOLVEMENT OF FALSE NEUROTRANSMITTERS IN TOLERANCE TO AMPHETAMINE-INDUCED HYPERTHERMIA IN THE RAT.
217690 04-03

TONIC IMMOBILITY IN CHICKENS: POSSIBLE INVOLVEMENT OF MONOAMINES.
217762 04-03

ION

GENETIC DETERMINANT OF LITHIUM ION DISTRIBUTION. I. AN IN VITRO MONOZYGOTIC DIZYGOTIC TWIN STUDY.
194826 01-13

PSYCHOPHARMACOLOGY OF THE LITHIUM ION.
198081 02-07

GENETIC DETERMINANT OF LITHIUM ION METABOLISM: II. AN IN VIVO STUDY OF LITHIUM ION DISTRIBUTION ACROSS ERYTHROCYTE MEMBRANES.
211412 03-03

LITHIUM ION AND AFFECTIVE PSYCHOSES.
212340 03-09

AFFECTIVE DISORDERS AND LITHIUM ION.
224588 04-09

GENETIC CONTROL OF LITHIUM ION DISTRIBUTION.
224833 04-09

IONIZING

THE EFFECTS OF SOME CNS DEPRESSANTS ON RATS EXPOSED TO IONIZING IRRADIATION.
197581 01-03

IONS

THE EFFECT OF DIAZEPAM AND NITRAZEPAM ON INTRACELLULAR AND EXTRACELLULAR DISTRIBUTION OF SODIUM AND POTASSIUM IONS IN INDIVIDUAL STRUCTURES OF RATS BRAINS.
207199 03-03

CHANGES IN THE NEURONAL PROTEIN LABELLING INDUCED BY POTASSIUM IONS IN VIVO (SPREADING DEPRESSION).
210779 03-03

THE INFLUENCE OF LITHIUM AND CESIUM IONS ON THE EFFECTS OF CATECHOLAMINES AND SEROTONIN INTRODUCED INTO THE HIPPOCAMPUS OF RATS.
218470 04-04

IONTOPHORETICALLY

ALTERATIONS BY ANESTHETIC AGENTS OF THE RESPONSES OF RAT STRIATAL NEURONS TO IONTOPHORETICALLY APPLIED AMPHETAMINE, ACETYLCHOLINE, NORADRENALINE, AND DOPAMINE.
193803 01-03

RESPONSES OF CULTURED CEREBELLAR NEURONS TO IONTOPHORETICALLY APPLIED AMINO ACIDS.
213279 03-03

IPNO

EXPERIENCE WITH IMIPRAMINE-N-OXIDE (IPNO) IN TREATING DEPRESSIVE STATES.
221209 04-09

IPRAZIDE

THE INFLUENCE OF INTRAPERITONEAL INJECTION OF IPRAZIDE AND TRANSAMINE ON THE DISTRIBUTION OF BIOGENIC AMINES IN CORTICAL AND SUBCORTICAL WHITE MATTER OF THE RAT BRAIN.
209032 03-03

IPRINDOLE
THE EFFECTS OF THE TRICYCLIC ANTIDEPRESSANTS DESMETHYLIMIPRAMINE, DOXEPIN AND IPRINDOLE ON THE ISOLATED PERFUSED RABBIT HEART.
197277 01-03
EFFECT OF IPRINDOLE ON NOREPINEPHRINE TURNOVER AND TRANSPORT.
202723 02-03
USE OF ANTIDEPRESSANT E-330 (IPRINDOLE).
208789 03-09
LONG-LASTING REDUCTION OF BRAIN 5-HYDROXYTRYPTAMINE CONCENTRATION BY 3-CHLOROAMPHETAMINE AND 4-CHLOROAMPHETAMINE IN IPRINDOLE TREATED RATS.
217879 04-03

IPRONIAZID
EFFECTS OF 5-HYDROXYTRYPTOPHAN, IPRONIAZID AND P-CHLOROPHENYLALANINE ON LIDOCAINE SEIZURE THRESHOLD OF MICE.
199962 02-03
THE ACCUMULATION OF NORADRENALINE AND 5-HYDROXYTRYPTAMINE IN THREE REGIONS OF MOUSE BRAIN AFTER TETRABENAZINE AND IPRONIAZID: EFFECTS OF ETHINYLESTRADIOL AND PROGESTERONE.
200058 02-03
INFLUENCE OF IPRONIAZID ON THE CONTENT OF NORADRENALINE IN VARIOUS PARTS OF THE RAT BRAIN BEFORE AND AFTER STIMULATION OF THE RECEPTORS.
206404 03-03
EFFECTS OF IPRONIAZID, CHLORPROMAZINE AND METHIOTHEPIN ON DMT INDUCED CHANGES IN BODY TEMPERATURE, PUPILLARY DILATATION, BLOOD PRESSURE AND EEG IN THE RABBIT.
215724 04-03

IRRADIATION
THE EFFECTS OF SOME CNS DEPRESSANTS ON RATS EXPOSED TO IONIZING IRRADIATION.
197581 01-03

IRREVERSIBLE
LITHIUM CARBONATE, HALOPERIDOL, AND IRREVERSIBLE BRAIN DAMAGE.
201287 02-15
A CASE OF IRREVERSIBLE EXTRAPYRAMIDAL HYPERKINESIA INDUCED BY NEUROLEPTIC DRUGS.
209410 03-15
INHIBITION OF MEMORY FORMATION IN THE IMPRINTING PERIOD: IRREVERSIBLE ACTION OF CYCLOHEXIMIDE IN YOUNG CHICKENS.
210708 03-04

IRRITABILITY
CLINICAL TRIAL OF CLOCAPRAMINE IN NEUROTIC PATIENTS WHO HAD TROUBLES IN EVERYDAY LIFE OWING TO SEVERE ANXIETY, IRRITABILITY AND DEPRESSION.
204464 02-10

ISOLATED
COMPARISON BETWEEN THE EFFECTS PRODUCED BY CHRONIC DENERVATION AND BY COCAINE ON THE SENSITIVITY TO, AND ON THE DISPOSITION OF, NORADRENALINE IN ISOLATED SPLEEN STRIPS.
193139 01-03
COMPARISON OF THE EFFECTS OF CHLORAL HYDRATE AND TRICHLOROETHANOL ON THE EEG OF THE ISOLATED PERFUSED RAT BRAIN.
194743 01-03
INFLUENCE OF THERAPEUTIC AND TOXIC DOSES OF NEUROLEPTICS AND ANTIDEPRESSANTS ON ENERGY METABOLISM OF THE ISOLATED PERFUSED RAT BRAIN.
195236 01-03
THE EFFECTS OF THE TRICYCLIC ANTIDEPRESSANTS DESMETHYLIMIPRAMINE, DOXEPIN AND IPRINDOLE ON THE ISOLATED PERFUSED RABBIT HEART.
197277 01-03
EFFECTS OF RESERPINE AND PRENYLAMINE ON THE NORADRENALINE FLUXES OF ISOLATED SPLENIC NERVE GRANULES.
197280 01-03
THE EFFECTS OF IMIPRAMINE AND PROMAZINE ON ENERGY METABOLISM AND EEG OF THE ISOLATED PERFUSED RAT BRAIN.
197296 01-03
THE EFFECTS OF AMPHETAMINE AND COCAINE ON THE RESPONSE OF THE ISOLATED GUINEA-PIG VAS-DEFERENS TO NORADRENALINE, TYRAMINE AND NERVE STIMULATION.
197463 01-03
A COMPARISON OF THE EFFECTS OF (+) AMPHETAMINE, COCAINE AND DENERVATION ON THE RESPONSES OF THE ISOLATED VAS-DEFERENS OF THE GUINEA-PIG TO NOREPINEPHRINE AND ACETYLCHOLINE.
197495 01-03
HEAT PRODUCTION AND OXYGEN CONSUMPTION OF THE ISOLATED RABBIT HEART UNDER THE INFLUENCE OF STROPHANTHIN VERAPAMIL, AND GLYCERYL TRINITRATE.
197567 01-03
THE INHIBITION OF THE EFFECT OF NERVE STIMULATION BY PHENOTHIAZINES ON ISOLATED INNERVATED ORGANS.
197576 01-03
ARRHYTHMIAS EVOKED BY INFUSION OF TRICYCLIC ANTIDEPRESSANTS AND NORADRENALINE ON ISOLATED RABBIT HEARTS.
197939 01-03
HYDROCORTISONE-INDUCED SUPERSENSITIVITY TO NORADRENALINE IN THE ISOLATED NICTITATING MEMBRANE AS A CONSEQUENCE OF AN IMPAIRMENT OF AN O-METHYLATING SYSTEM WITH HIGH AFFINITY.
197944 01-03
KINETICS OF 14C-DOPAMINE IN ISOLATED RAT STRIATAL TISSUE UNDER THE INFLUENCE OF MORPHINE.
197954 01-03
DETERMINATION OF NORADRENALINE, DOPAMINE, SEROTONIN, 5-HYDROXYINDOLEACETIC ACID, TYROSINE AND TRYPTOPHANE IN THE ISOLATED PERFUSED RAT BRAIN.
197967 01-06
QUANTITATIVE ANALYSIS OF THE EEG EFFECTS PRODUCED BY IMIPRAMINE, DESIPRAMINE, PROMAZINE, AND MONODESMETHYL PROMAZINE IN THE ISOLATED PERFUSED RAT BRAIN.
200056 02-03
THE IMPORTANCE OF NEURONAL UPTAKE OF AMINES FOR AMPHETAMINE-INDUCED RELEASE OF 3H-NOREPINEPHRINE FROM ISOLATED BRAIN TISSUE.
202191 02-03
EFFECTS OF 5-HYDROXYINDOLEACETIC ACID ON ISOLATED CANINE CEREBRAL ARTERIES.
202799 02-03
NEGATIVE INOTROPIC EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON THE ISOLATED RIGHT VENTRICULAR PAPILLARY MUSCLE OF THE CAT.
204400 02-05
EFFECTS OF PSYCHOACTIVE TRICYCLIC DRUGS ON THE EEG OF THE ISOLATED PERFUSED RAT BRAIN.
205492 02-03
INFLUENCE OF MEPROBAMATE, CARISPRODOL, OXAZEPAM AND PHENOBARBITAL ON NA+ TRANSPORT IN THE ISOLATED FROG SKIN.
206781 03-03
STRUCTURE-ACTIVITY RELATIONSHIPS BETWEEN META-SUBSTITUTED N-ETHYLAMPHETAMINES AND ISOLATED GUINEA-PIG ATRIAL RATE.
210887 03-03
EFFECTS OF METHAMPHETAMINE ON THE ISOLATED RAT PHRENIC NERVE DIAPHRAM PREPARATION.
210900 03-03
THE EFFECTS OF (+) AMPHETAMINE ON THE CHRONOTROPIC RESPONSES OF THE ISOLATED GUINEA-PIG PACEMAKER TO NOREPINEPHRINE AND ISOPROTERENOL.
211066 03-03
ARRHYTHMIAS AND INHIBITION OF NORADRENALINE UPTAKE CAUSED BY TRICYCLIC ANTIDEPRESSANTS AND CHLORPROMAZINE ON THE ISOLATED PERFUSED RABBIT HEART.
217657 04-03
THE EFFECT OF CHLORDIAZEPOXIDE HYDROCHLORIDE ON THE ISOLATED PERFUSED RAT LIVER (38786).
217796 04-03
RELATIONSHIPS BETWEEN TRICYCLIC ANTIDEPRESSANT CONCENTRATIONS, 1-3H-NORAFRENALINE UPTAKE AND CHRONOTROPIC EFFECT IN ISOLATED RAT ATRIA.
221188 04-03
EFFECT OF FIGHTING AND DIPHENYLHYDANTOIN ON THE UPTAKE OF H3-L-NOREPINEPHRINE IN VITRO IN SYNAPTOSOMES ISOLATED FROM RETIRED MALE BREEDING MICE.
222821 04-03
THE EFFECT OF NEUROLEPTICS AND ANTIDEPRESSANTS ON THE UPTAKE OF 3H-GAMMA-AMINOBUTYRIC ACID BY ISOLATED NERVE ENDINGS OF THE RAT BRAIN.
224114 04-03
DIAZEPAM TREATMENT OF SOCIALLY ISOLATED MONKEYS.
224776 04-04

ISOLATION
A METHOD FOR THE ISOLATION AND DETERMINATION OF 3-METHOXYTYRAMINE IN BRAIN TISSUE.
193302 01-03
EFFECT OF SODIUM GAMMA-HYDROXYBUTYRATE ON ISOLATION INDUCED AGGRESSIVITY IN MICE.
205588 02-04
ISOLATION INDUCED TIMIDITY IN MICE AS A MEASURE OF ANXIOLYTIC ACTIVITY OF DRUGS.
215063 04-04
CATECHOLAMINE CORRELATES OF ISOLATION INDUCED AGGRESSION IN MICE.
217670 04-04
A PHARMACOLOGICAL ANALYSIS OF AGGRESSIVE BEHAVIOR OF MICE INDUCED BY ISOLATION.
218800 04-04

ISOLE
THE EFFECTS OF CORD SECTION UNDER ETHER OR HALOTHANE ON THE ABILITY OF CHLORPROMAZINE TO AFFECT THE JAW-JERK RESPONSE TO TOOTH PULP STIMULATION IN THE ENCEPHALE ISOLE PREPARATION.
197451 01-03

ISOMERS
THE EFFECTS OF AMPHETAMINE ISOMERS ON NEUROMUSCULAR TRANSMISSION.
210765 03-03

DIFFERENTIAL EFFECTS OF THE OPTICAL ISOMERS OF AMPHETAMINE ON NEURONAL ACTIVITY IN THE RETICULAR FORMATION AND CAUDATE NUCLEUS OF THE RAT.
211063 03-03

EFFECTS OF AMPHETAMINE ISOMERS AND NEUROLEPTICS ON SELF-STIMULATION FROM THE NUCLEUS-ACCUMBENS AND DORSAL NORADRENERGIC BUNDLE.
213394 04-03

ISONIAZID
DIPHENYLHYDANTOIN INTOXICATION DUE TO DIPHENYLHYDANTOIN ISONIAZID INTERACTION.
207155 03-15

ISONIAZIDE
UNUSUAL REACTIONS TO ISONIAZIDE.
203495 02-15

ISOPROTERENOL
THE EFFECTS OF (+) AMPHETAMINE ON THE CHRONOTROPIC RESPONSES OF THE ISOLATED GUINEA-PIG PACEMAKER TO NOREPINEPHRINE AND ISOPROTERENOL.
211066 03-03

ISTHMIC
HYPERSOMNIA BY ISTHMIC LESION IN THE CAT. I. STUDY OF THE METABOLISM OF CEREBRAL MONOAMINES.
215702 04-03

HYPERSOMNIA BY ISTHMIC LESION IN THE CAT. II. NEUROPHYSIOLOGICAL AND PHARMACOLOGICAL STUDY.
215703 04-03

ITEMS
PARTIAL RESTORATION BY AN A NEUROLEPTIC (SPIRAMIDE) OF ITEMS OF GROOMING BEHAVIOUR SUPPRESSED BY AMPHETAMINE.
213590 04-04

IXELLES
TESTING ANATENSOL DECANOATE, A MAJOR NEUROLEPTIC, AT THE IXELLES GUIDANCE CENTER.
212165 03-09

JANSSEN
ASPECTS OF NEUROLEPTIC DEPOT THERAPY WITH SPECIAL CONSIDERATION OF CLINICAL EXPERIENCE WITH THE PERORAL DEPOT PREPARATION PENFLURIDOL (R-16341 - JANSSEN).
202785 02-07

JAPAN
SIDE-EFFECTS OF PSYCHOTROPIC DRUGS -- AN ANALYSIS OF DATA OBTAINED FROM DOUBLE-BLIND COMPARATIVE STUDIES IN JAPAN.
201260 02-15

THE PRESENT CONDITIONS OF PSYCHOPHARMACOLOGICAL TREATMENT FOR CHILDREN IN JAPAN: OPINIONS FROM THIRTY-SEVEN WELL-KNOWN CHILD NEUROPSYCHIATRISTS AND NEUROPSYCHIATRIC PEDIATRICIANS.
202500 02-17

NEW PSYCHOTROPIC DRUG RESEARCH IN JAPAN.
213596 04-07

JAW-JERK
THE EFFECTS OF CORD SECTION UNDER ETHER OR HALOTHANE ON THE ABILITY OF CHLORPROMAZINE TO AFFECT THE JAW-JERK RESPONSE TO TOOTH PULP STIMULATION IN THE ENCEPHALE ISOLE PREPARATION.
197451 01-03

JOURNEY
THE HEALING JOURNEY: NEW APPROACHES TO CONSCIOUSNESS.
223921 04-12

JUMPING
POTENTIATION OF JUMPING BEHAVIOR BY AMINOPHYLLINE IN MICE TREATED WITH THRESHOLD DOSES OF AMPHETAMINE AND DOPA.
200039 02-04

NALOXONE PRECIPITATED JUMPING ACTIVITY IN MICE FOLLOWING THE ACUTE ADMINISTRATION OF MORPHINE.
202201 02-04

NARCOTIC WITHDRAWAL LIKE MOUSE JUMPING PRODUCED BY AMPHETAMINE AND L-DOPA.
210931 03-04

NALOXONE-INDUCED JUMPING IN MORPHINE-DEPENDENT MICE: STIMULUS CONTROL AND MOTIVATION.
215696 04-04

JUNCTIONS
(3H)GLUTAMATE UPTAKE AT INSECT NEUROMUSCULAR JUNCTIONS: EFFECT OF CHLORPROMAZINE.
213474 04-03

JUVENILE
A YEAR OF INVESTIGATIONS ON 1035-MD IN CHILD AND JUVENILE NEUROPSYCHIATRY: CLINICAL AND EEG FINDINGS FROM 46 CASES.
209784 03-11

JUVENILES
SIGNS, COURSE AND PROGNOSIS OF TICS IN CHILDREN AND JUVENILES.
203881 02-14

K+
RAPID REVERSAL OF INTERNAL NA+ AND K+ CONTENTS OF SYNAPTOSOMES BY OUABAIN.
204185 02-03

KANSAS
SUIT AGAINST RECOMMENDING DOCTOR AND PSYCHIATRIST -- REJECTED. STOVALL V. HARMS, 522 P.2D 353, (KANSAS) SUPREME COURT OF KANSAS. MAY 11, 1974.
200438 02-17

KETAMIN
A STUDY OF NEUROPHYSIOLOGICAL MECHANISMS OF GENERAL ANESTHESIA WITH KETAMIN.
198434 02-03

KETAMIN HYDROCHLORIDE AS A PREANESTHESIA DRUG FOR AN ELECTROSHOCK TREATMENT.
202121 02-11

KETAMINE
EFFECTS OF KETAMINE ON EEG ACTIVITY IN CATS AND MONKEYS.
193797 01-03

PHYSIOLOGIC, BIOCHEMICAL, AND CLINICAL EFFECTS OF KETAMINE HYDROCHLORIDE IN GOATS (CAPRA-HIRCUS) WITH AND WITHOUT PREMEDICATION. (PH.D. DISSERTATION).
194700 01-03

THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL PRETREATMENT ON KETAMINE, THIOPENTAL OR CT-1341 -- INDUCED LOSS OF RIGHTING REFLEX IN MICE.
210878 03-02

EVALUATION OF KETAMINE HCL FOR ANTIDEPRESSANT ACTIVITY.
217577 04-02

KETONES
A DUAL STUDY. PART I: SYNTHESIS AND STEREOCHEMISTRY OF SOME 1 SUBSTITUTED QUINOLIZIDINES AS ANALOGS OF BIOLOGICALLY ACTIVE COMPOUNDS. PART II: AMINO DERIVATIVES OF THIOPHENE FUSED CYCLIC KETONES AS POTENTIAL CNS. (PH.D. DISSERTATION).
196252 01-01

KEY
EFFECTS OF D-AMPHETAMINE AND SECOBARBITAL ON KEY PRESS RATES IN NORMAL HUMANS.
210879 03-14

CHLORPROMAZINE METABOLISM IV: QUATERNIZATION AS A KEY TO DETERMINATION OF PICOMOLES OF CHLORPROMAZINE AND OTHER TERTIARY AMINE DRUGS.
217667 04-06

KIDNEY
GLUCOSE RELEASE OF THE RAT KIDNEY IN VIVO AFTER BETA-ADRENERGIC STIMULATION AND BLOCKADE.
197946 01-03

THE EFFECT OF SODIUM CHLORIDE ON KIDNEY FUNCTION IN RATS WITH LITHIUM INTOXICATION.
210696 03-03

KINASE
THE EFFECT OF LYSERGIC ACID DIETHYLAMIDE ON SERUM CREATINE KINASE LEVELS.
206361 03-12

KINDLING
POTENTIATION OF AMYGDALOID KINDLING AND METRAZOL-INDUCED SEIZURES BY 6-HYDROXYDOPAMINE IN RATS.
195907 01-03

COCAINE, KINDLING, AND PSYCHOSIS.
224796 04-14

KINETIC
INTEREST OF SULPIRIDE IN KINETIC DISTURBANCES.
202069 02-11

CHANGES OF KINETIC CONSTANT OF STRIATAL TYROSINE-HYDROXYLASE ELICITED BY NEUROLEPTICS THAT IMPAIR THE FUNCTION OF DOPAMINE RECEPTORS.
202716 02-03

ARE AUTORECEPTORS IN DOPAMINERGIC NEURONS INVOLVED IN THE CHANGE OF THE KINETIC STATE OF STRIATAL TYROSINE-HYDROXYLASE ELICITED BY ANTIPSYCHOTICS? (UNPUBLISHED PAPER).
208636 03-03

REGIONAL AND SUBCELLULAR DISTRIBUTION AND KINETIC PROPERTIES OF RAT BRAIN CHOLINE ACETYLTRANSFERASE -- SOME FUNCTIONAL CONSIDERATIONS.
210816 03-03

STEREOSPECIFICITY OF DOPAMINE RECEPTORS INVOLVED IN THE REGULATION OF THE KINETIC STATE OF TYROSINE-HYDROXYLASE IN STRIATUM AND NUCLEUS-ACCUMBENS.
217888 04-03

ROLE FOR POSTSYNAPTIC DOPAMINE RECEPTORS IN THE REGULATION OF THE KINETIC STATE OF STRIATAL TYROSINE-HYDROXYLASE. (UNPUBLISHED PAPER).
225307 04-03

KINETICS
THE DISPOSITION KINETICS OF AMPHETAMINE IN THE RUMINANT ANIMAL.
197456 01-03

KINETICS OF 14C-DOPAMINE IN ISOLATED RAT STRIATAL TISSUE UNDER THE INFLUENCE OF MORPHINE.
197954 01-03

THE KINETICS OF LITHIUM IN THE HUMAN ORGANISM.
205042 02-13

MATURATION OF THE ADRENAL MEDULLA -- III: PRACTICAL AND THEORETICAL CONSIDERATIONS OF AGE DEPENDENT ALTERATIONS IN KINETICS OF INCORPORATION OF CATECHOLAMINES AND NONCATECHOLAMINES.
205852 03-03

BLOOD-BRAIN BARRIER: I. KINETICS OF DISTRIBUTION OF 3H-AMPHETAMINE IN THE RAT BRAIN AFTER INTRAVENOUS ADMINISTRATION.
210788 03-03

EFFECT OF OUABAIN AND PHENOBARBITAL ON THE KINETICS OF CORTICAL METABOLIC TRANSIENTS ASSOCIATED WITH EVOKED POTENTIALS.
210820 03-03

APPLICATION OF PRINCIPLES OF STEADY-STATE KINETICS TO THE IN VIVO ESTIMATION OF ACETYLCHOLINE TURNOVER RATE IN MOUSE BRAIN.
210885 03-06

PRACTICAL KINETICS I: QUANTITATION OF BARBITURATE STABILITY BY TLC.
211007 03-06

PRACTICAL KINETICS III: BENZODIAZEPINE HYDROLYSIS.
211008 03-06

EFFECTS OF THE DOPAMINE-BETA-HYDROXYLASE INHIBITOR FLA-63 ON THE KINETICS OF ELIMINATION OF AMPHETAMINE IN THE RAT.
217881 04-03

THE DISTRIBUTION KINETICS AND TURNOVER OF CHOLINE AND ACETYLCHOLINE IN PLASMA AND BRAIN OF RATS. (PH.D. DISSERTATION).
220472 04-03

THE BLOOD-BRAIN BARRIER II: DISTRIBUTION KINETICS OF H3-P-HYDROXYAMPHETAMINE IN BRAIN STRUCTURES OF THE RAT AFTER INTRAVENOUS ADMINISTRATION.
220977 04-03

KININ

THE ACTIVATION OF THE KININ FORMING SYSTEM AND THE EFFECTS OF THIOPENTAL.
210744 03-03

EFFECT OF THE ACTIVATION OF THE KININ FORMING SYSTEM ON THE POTENCY OF CHLORPROMAZINE.
210872 03-03

KININS

KININS AND CENTRAL EFFECTS OF THE ACETYLCHOLINE.
215749 04-04

KITTEN

EFFECTS OF ALPHA-METHYLDOPA ON NEWBORN KITTEN SLEEP. BEHAVIORAL EVOLUTION DURING THE FIRST MONTH AFTERBIRTH.
221049 04-04

KITTENS

MATURATION OF VISUAL ELECTROCORTICAL RESPONSES IN UNANESTHETIZED KITTENS: EFFECTS OF BARBITURATE ANESTHESIA.
199765 02-03

KLINE

FROM SAD TO GLAD: KLINE ON DEPRESSION.
216706 04-17

KLUVER-BUCY

NEUROLEPTIC-INDUCED KLUVER-BUCY SYNDROME.
213532 04-15

KREBS

DRUGS, CATECHOLAMINES AND KREBS CYCLE INTERACTION (CNS).
213602 04-03

KYNURENINE

TRYPTOPHAN METABOLISM EXAMINATIONS IN OLIGOPHRENIC CHILDREN. FIRST REPORT: RESULTS OF THE EXCRETION OF KYNURENINE AND XANTHURENIC ACID AFTER TRYPTOPHAN LOADING AND THEIR DEPENDENCE UPON THE SUPPLY.
203645 02-13

KYNURENINES

ANTAGONISM OF NICOTINIC ACID AND OTHER KYNURENINES TO ANTIDEPRESSANTS: ONE OF THE PROBABLE REASONS FOR THE THERAPY-RESISTANCE IN DEPRESSION?.
215074 04-17

L-AMPHETAMINE

EFFECTS OF D-ISOMERS AND L-AMPHETAMINE ON 5-HYDROXYTRYPTAMINE RECEPTORS.
197481 01-04

PHARMACOLOGICAL AND TOXICOLOGICAL STUDY OF A NEW PSYCHOTROPIC STIMULANT: THE 2-PHENYLDIMETHYL-TETRAHYDROOXAZINE, IN COMPARISON WITH D,L-AMPHETAMINE, PHENMETRAZINE AND PEMOLINE-MG.
199211 02-04

A COMPARATIVE STUDY OF D- AND L-AMPHETAMINE ON THE OPEN-FIELD PERFORMANCE OF RATS.
201322 02-04

THE EFFECTS OF D- AND L-AMPHETAMINE UPON HOARDING BEHAVIOR AND FEEDING IN THE MONGOLIAN GERBIL (MERIONES-UNGUICULATUS).
202983 02-04

INCREASED FIXED-RATIO PERFORMANCE AND DIFFERENTIAL D- AND L-AMPHETAMINE ACTION FOLLOWING NOREPINEPHRINE DEPLETION BY INTRAVENTRICULAR 6-HYDROXYDOPAMINE.
204482 02-04

DIFFERENTIAL EFFECTS OF D- AND L-AMPHETAMINE AND METHYLPHENIDATE ON RAT STRIATAL DOPAMINE BIOSYNTHESIS.
210859 03-03

COMPARISON OF THE EFFECTS OF D-AMPHETAMINE AND L-AMPHETAMINE IN REVERSING DEPRESSION OF MOUSE LOCOMOTOR ACTIVITY CAUSED BY RESERPINE.
210869 03-03

BLOOD PRESSURE AND HEART RATE RESPONSES EVOKED BY D- AND L-AMPHETAMINE IN THE PITHED RAT PREPARATION.
215687 04-03

INTRAVENOUS SELF-ADMINISTRATION OF D-AMPHETAMINE AND L-AMPHETAMINE BY DOG.
222806 04-04

THE DOPAMINERGIC COMPONENT IN THE ACTION OF D,L-AMPHETAMINE ON THE INHIBITORY FUNCTION OF THE CAUDATE NUCLEUS.
223014 04-03

L-ASCORBIC

THE EFFECT OF BETA-THIAMINOKETONES ON THE AMINOPYRINE-N-DEMETHYLATION IN VITRO AND IN VIVA SUCH AS THE HEXOBARBITAL SLEEPING TIME AND L-ASCORBIC ACID EXCRETION IN THE RAT.
197469 01-03

L-DOPA

EFFECTS OF L-DOPA ON THE HETEROSEXUAL COPULATORY BEHAVIOR OF MALE RATS.
193549 01-04

REVERSAL BY L-DOPA OF IMPAIRED LEARNING DUE TO DESTRUCTION OF THE DOPAMINERGIC NIGRO-NEOSTRIATAL PROJECTION.
193578 01-04

BRAIN DOPA/5-HTP DECARBOXYLASE ACTIVITY AFTER THE CHRONIC ADMINISTRATION OF L-DOPA OR 5-HYDROXY-L-TRYPTOPHAN IN NORMAL AND LESIONED CATS.
194483 01-05

INTERACTION OF CATECHOLAMINE AND AMINO ACID METABOLISM IN BRAIN: EFFECT OF PARGYLINE AND L-DOPA.
195048 01-03

SLEEP IN PATIENTS WITH PARKINSONS DISEASE AND ITS INFLUENCE BY L-DOPA.
195155 01-11

EFFECTS OF L-DOPA AND L-TRYPTOPHAN ON THE CEREBRAL BLOOD FLOW IN THE DOG.
197213 01-03

EFFECTS OF THE HIGH DOSES OF L-DOPA ON ELECTRICAL ACTIVITY IN THE BRAIN OF THE RABBIT: INTERACTION WITH THE METABOLISM OF 5-HT.
197468 01-03

INHIBITORY EFFECT OF AMPHETAMINE, L-DOPA AND APOMORPHINE ON MORPHINE-INDUCED BEHAVIOURAL EXCITATION OF RATS.
197483 01-04

EFFECT OF ACUTE ADMINISTRATION OF L-DOPA ON BODY TEMPERATURE IN MAN.
197831 01-13

EFFECTS OF L-DOPA ON CONDITIONED AVOIDANCE RESPONDING AFTER BEHAVIOURAL SUPPRESSION BY ALPHA-METHYLTYROSINE OR RESERPINE IN MICE.
197987 01-04

INVESTIGATION OF THE MECHANISM BY WHICH L-DOPA INDUCES GNAWING IN MICE.
198014 01-04

THE EFFECT OF L-DOPA ON THE DEVELOPMENT OF RESERPINE INDUCED PARKINSONISM AND CATECHOLAMINE METABOLISM IN RATS.
198486 02-03

EFFECTS OF LOW AND HIGH DOSES OF L-DOPA ON THE TETRABENAZINE OR ALPHA-METHYLTYROSINE-INDUCED SUPPRESSION OF BEHAVIOUR IN A SUCCESSIVE DISCRIMINATION TASK.
200042 02-04

L-DOPA AND PARKINSONISM: A PSYCHOLOGICAL ASSESSMENT.
201496 02-11

EFFECT OF EARLY L-DOPA ADMINISTRATION ON THE ONTOGENY OF MOTOR FUNCTIONS IN THE RAT.
202266 02-03

AMPHETAMINE, L-DOPA AND APOMORPHINE: EFFECTS ON ACTIVITY OF RAT DOPAMINERGIC NEURONS.
202370 02-03

THE EFFECTS OF L-DOPA, CLONIDINE, AND APOMORPHINE ON THE ACOUSTIC STARTLE REACTION IN RATS.
202773 02-04

TREATMENT OF PARKINSONS DISEASE BY COMBINING L-DOPA WITH A DECARBOXYLASE INHIBITOR.
204372 02-07

THE SERUM GONADOTROPIN LEVEL UNDER THE MEDICATION OF L-DOPA.
204394 02-13

CENTRAL NERVOUS ACTION OF L-DOPA.
204424 02-04

CANNABINOID INDUCED CHANGES IN MOUSE STRIATAL HOMOVANILLIC ACID AND DIHYDROXYPHENYLACETIC ACID: THE EFFECTS OF AMPHETAMINE AND L-DOPA.
204866 02-03

EEG CHANGES BEFORE AND AFTER L-DOPA THERAPY IN PARKINSON PATIENTS.
205569 02-13

L-DOPA AND TRICYCLIC ANTIDEPRESSANTS IN AFFECTIVE DISORDERS. A PILOT STUDY.
205601 03-09

EFFECT OF L-DOPA ON PITUITARY HORMONES AND ON CARBOHYDRATE AND FAT METABOLISM IN NORMALS AND IN PARKINSONS DISEASE.
207153 03-13

THE EFFECT OF L-DOPA AND L-DOPA COMBINED WITH CHLORPROMAZINE ON SPINAL CORD ACTIVITY DURING DISTURBED INHIBITION BY TETANUS TOXOID.
207200 03-03

REM INHIBITORY EFFECT OF L-DOPA INFUSION DURING HUMAN SLEEP.
210602 03-14

L-DOPA HYPOTENSION IN DOGS: EVIDENCE FOR MEDIATION THROUGH 5-HT RELEASE.
210868 03-05

MODIFICATION BY L-DOPA METHYLESTER (H-19-61) OF AMPHETAMINE-INDUCED BRAIN CATECHOLAMINE CHANGES, THERMAL RESPONSES AND TOXICITY IN DEVELOPING MICE.
210891 03-03

NARCOTIC WITHDRAWAL LIKE MOUSE JUMPING PRODUCED BY AMPHETAMINE AND L-DOPA.
210931 03-04

THE EFFECT OF L-DOPA ON SCHIZOPHRENIA.
211339 03-08

AFFECTS OF L-DOPA ON THE PSYCHOLOGICAL SYMPTOMS OF PICKS DISEASE.
211365 03-11

THERAPEUTIC STUDIES OF DEPRESSION WITH L-DOPA.
212947 03-09

IN VIVO INHIBITION OF STRIATAL ACETYLCHOLINE TURNOVER BY L-DOPA, APOMORPHINE AND (+) AMPHETAMINE.
213399 04-03

RAT BRAIN REGIONAL UPTAKE AND DECARBOXYLATION OF L-DOPA FOLLOWING CAROTID INJECTION.
214323 04-03

THE ROLE OF CATECHOLAMINES IN THE ACTION OF AMPHETAMINE AND L-DOPA ON CEREBRAL ENERGY METABOLISM.
217677 04-03

DIFFERENCES BETWEEN (+)- AND (-) AMPHETAMINE IN EFFECTS ON LOCOMOTOR ACTIVITY AND L-DOPA POTENTIATING ACTION IN MICE.
217835 04-04

BLOCKADE OF ALPHA-METHYLTYROSINE-INDUCED SUPERSENSITIVITY TO APOMORPHINE BY CHRONIC ADMINISTRATION OF L-DOPA.
220974 04-03

EFFECTS OF RESERPINE AND L-DOPA IN THE GLOBUS-PALLIDUS OF FREELY BEHAVING RATS.
220975 04-03

TREATMENT RESULTS OF L-DOPA ON SCHIZOPHRENIA.
223202 04-08

L-GLUTAMATE
FATE OF L-GLUTAMATE IN THE BRAIN.
196800 01-03

L-HISTIDINE
L-HISTIDINE: FAILURE TO AFFECT THE SLEEP-WAKING CYCLE IN MAN.
214015 04-14

L-HYDRAZINO-ALPHA-METHYLDOPA
THE ORIGIN OF BLOOD 5-HYDROXYINDOLEACETIC (5-HIAA) ACID FOLLOWING L-HYDRAZINO-ALPHA-METHYLDOPA (MK-486).
217665 04-03

L-METHIONINE
THE BEHAVIORAL EFFECTS OF L-METHIONINE AND RELATED COMPOUNDS IN RATS AND MICE.
213528 04-04

L-NORADRENALINE
CHLORPROMAZINE: SPECIFIC INHIBITION OF L-NORADRENALINE AND 5-HYDROXYTRYPTAMINE UPTAKE IN SYNAPTOSOMES FROM SQUID BRAIN.
213395 04-03

L-OXAZEPAM
BINDING OF D-OXAZEPAM AND L-OXAZEPAM HEMISUCCINATE TO BOVINE SERUM ALBUMIN.
200033 02-03

L-PARA-CHLOROPHENYLALANINE
BEHAVIOURAL AND ELECTROGRAPHIC EFFECTS OF L-5-HYDROXYTRYPTOPHAN AND D,L-PARA-CHLOROPHENYLALANINE ON EPILEPTIC SENEGALESE BABOON (PAPIO-PAPIO).
199764 02-03

L-S-519
PHARMACOLOGICAL EXAMINATIONS BY AN ULCUS INHIBITING AGENT (L-S-519).
197955 01-03

L-TRYPTOPHAN
THE ACUTE EFFECTS OF INTRAVENOUS INFUSION OF L-TRYPTOPHAN IN NORMAL SUBJECTS.
195443 01-15

EFFECTS OF L-DOPA AND L-TRYPTOPHAN ON THE CEREBRAL BLOOD FLOW IN THE DOG.
197213 01-03

THE INHIBITION OF A AND B FORMS OF MAO IN THE PRODUCTION OF A CHARACTERISTIC BEHAVIOURAL SYNDROME IN RATS AFTER L-TRYPTOPHAN LOADING.
217471 04-03

BENZODIAZEPINES: SPECIFIC COMPETITORS FOR THE BINDING OF L-TRYPTOPHAN TO HUMAN SERUM ALBUMIN.
217686 04-01

L-5-HTP
CEREBRAL AND PERIPHERAL CONSUMPTION OF L-5-HTP BY PATIENTS SUFFERING FROM MANIACAL, DEPRESSIVE OR PSYCHOTIC SYMPTOMS.
206834 03-10

L-5-HYDROXYTRYPTOPHAN
THE INFLUENCE OF ANTICATECHOLAMINERGIC AGENTS ON THE BEHAVIOURAL EFFECTS OF L-5-HYDROXYTRYPTOPHAN.
197572 01-04

BEHAVIOURAL AND ELECTROGRAPHIC EFFECTS OF L-5-HYDROXYTRYPTOPHAN AND D,L-PARA-CHLOROPHENYLALANINE ON EPILEPTIC SENEGALESE BABOON (PAPIO-PAPIO).
199764 02-03

POTENTIATION OF THE L-5-HYDROXYTRYPTOPHAN INDUCED ELEVATION OF PLASMA CORTICOSTERONE LEVELS IN RATS BY A SPECIFIC INHIBITOR OF SEROTONIN UPTAKE.
211104 03-03

L-5-HYDROXYTRYPTOPHAN AND MOOD.
211470 03-14

LABELLED
IN VIVO HUMAN PHARMACODYNAMICS OF THE PSYCHODYSLEPTIC 4-BR-DIMETHOXYPHENYLISOPROPYLAMINE LABELLED WITH 82BR OR 77BR.
215710 04-13

LABELLING
CHANGES IN THE NEURONAL PROTEIN LABELLING INDUCED BY POTASSIUM IONS IN VIVO (SPREADING DEPRESSION).
210779 03-03

LABILITY
PERSONALITY TRAIT STABILITY LABILITY AND ITS SIGNIFICANCE FOR PHARMACOLOGICAL RESEARCH.
196776 01-16

LABORATORY
HYPOTHERMIC EFFECTS OF MARIHUANA, MARIHUANA DERIVATIVES AND CHLORPROMAZINE IN LABORATORY MICE.
196226 01-04

LONG-TERM TREATMENT OF PSYCHIATRIC PATIENTS WITH CLOPENTHIXOL: ANALYSIS OF LABORATORY TESTS WITH A VIEW TO LONG-TERM THERAPY.
199989 02-14

LABORATORY AND CLINICAL STUDIES OF LITHIUM CARBONATE.
205175 02-03

EFFECT OF FLURAZEPAM ON SLEEP IN THE LABORATORY.
206450 03-14

SCHEDULE INDUCED AGGRESSION IN LABORATORY RATS: DEMONSTRATION AND CONTROL THROUGH SODIUM AMOBARBITAL. (PH.D. DISSERTATION).
220644 04-04

LACTATION
THE EFFECT OF PSYCHOPHARMACOLOGIC PROLACTIN RELEASERS ON LACTATION IN SHEEP.
210793 03-03

LACUNAE
LONG-ACTING DRUGS IN PSYCHIATRIC TREATMENT: LACUNAE AND NEEDS.
221672 04-17

LANGUAGE
THE EFFECTS OF THIORIDAZINE ON LANGUAGE AND THINKING.
198104 02-08

LATENCY
LATENCY AND DURATION OF ESTROGEN INDUCTION OF MATERNAL BEHAVIOR IN HYSTERECTOMIZED OVARIECTOMIZED VIRGIN RATS: EFFECTS OF PUP STIMULATION.
219070 04-04

LATENT
ASSESSING THE IMPACT OF LOW LEVEL CHEMICALS ON DEVELOPMENT: BEHAVIORAL AND LATENT EFFECTS.
225164 04-15

LATERAL
COMPARATIVE INVOLVEMENT OF DOPAMINE AND NORADRENALINE IN RATE-FREE SELF-STIMULATION IN SUBSTANTIA-NIGRA, LATERAL HYPOTHALAMUS, AND MESENCEPHALIC CENTRAL GRAY.
193303 01-03

THE EFFECTS OF DRUG ADMINISTRATION TO THE LATERAL HYPOTHALAMUS: NEUROCHEMICAL CODING OR NONSPECIFICITY?.
195992 01-03

CENTRAL ACTION OF ANOREXIC AGENTS: EFFECTS OF AMPHETAMINE AND FENFLURAMINE IN RATS WITH LATERAL HYPOTHALAMIC LESIONS.
197865 01-04

THE IN VIVO RELEASE OF ENDOGENOUSLY SYNTHESIZED CATECHOLAMINES FROM THE CAT BRAIN BY LATERAL HYPOTHALAMIC STIMULATION AND BY D-AMPHETAMINE ADMINISTRATION. (PH.D. DISSERTATION).
200313 02-03

DIFFERENTIAL EFFECTS OF AMPHETAMINE AND FOOD DEPRIVATION ON SELF-STIMULATION OF THE LATERAL HYPOTHALAMUS AND MEDIAL FRONTAL CORTEX.
206733 03-04

RECIPROCAL (PUSH-PULL) EFFECTS OF MORPHINE ON SINGLE UNITS IN THE VENTROMEDIAN AND LATERAL HYPOTHALAMUS AND INFLUENCES ON OTHER NUCLEI: WITH COMMENT ON METHADONE EFFECTS DURING WITHDRAWAL FROM MORPHINE.
210700 03-03

LOSS OF ACTIVE AVOIDANCE RESPONDING AFTER LATERAL HYPOTHALAMIC INJECTIONS OF 6-HYDROXYDOPAMINE.
215704 04-04

SEROTONIN IN THE LATERAL GENICULATE.
218499 04-03

LEAD

LEAD ENCEPHALOPATHY IN THE DEVELOPING RAT: EFFECT ON CORTICAL ONTOGENESIS.
200168 02-05

HIPPOCAMPUS: SELECTIVE CONCENTRATIONS OF LEAD IN THE NORMAL RAT BRAIN.
210665 03-03

LEARNED

CHRONIC AMPHETAMINE TREATMENT: VAST INDIVIDUAL DIFFERENCES IN PERFORMING A LEARNED RESPONSE.
202794 02-04

THE BIPHASIC EFFECT OF SMALL DOSES OF TRANYLCYPROMINE ON THE SPONTANEOUS MOTOR ACTIVITY AND LEARNED CONDITIONED BEHAVIOUR IN RATS.
215665 04-04

LEARNING

REVERSAL BY L-DOPA OF IMPAIRED LEARNING DUE TO DESTRUCTION OF THE DOPAMINERGIC NIGRO-NEOSTRIATAL PROJECTION.
193578 01-04

EFFECTS OF D-AMPHETAMINE ON LEARNING AND MEMORY IN INBRED AND HYBRID MICE. (PH.D. DISSERTATION).
193581 01-04

DIFFERENTIAL EFFECTS OF EPINEPHRINE AND PROPRANOLOL ON SHUTTLEBOX AVOIDANCE LEARNING IN RATS OF DIFFERENT AGES. (PH.D. DISSERTATION).
193745 01-04

SHUTTLE AVOIDANCE LEARNING OF MICE: EFFECTS OF POSTTRIAL PENTYLENETETRAZOL, STRAIN AND AGE.
195226 01-04

PROGRAMMED SELF-ADMINISTRATION OF POTENTIALLY ADDICTIVE DRUGS IN YOUNG RATS AND ITS EFFECTS ON LEARNING.
195430 01-04

ANALYSIS OF CUE USE IN STATE-DEPENDENT LEARNING. (PH.D. DISSERTATION).
196409 01-04

THE EFFECTS OF PABENOL COMPLEX ON CHILDREN WITH LEARNING PROBLEMS.
196704 01-07

METHYLPHENIDATE EFFECTS IN LEARNING DISABILITIES OF CHILDREN.
198045 01-14

NICOTINE AND CAFFEINE: DISRUPTION OF THE LONG-TERM STORE MEMORY AND PROACTIVE FACILITATION OF LEARNING IN MICE.
198222 02-04

EFFECT OF INTRAHIPPOCAMPAL INJECTION OF ATROPINE ON DIFFERENT PHASES OF A LEARNING EXPERIMENT.
198227 02-04

A COMPARISON OF THE RELATIVE EFFICACY OF SPECIAL CLASS EDUCATION AND DRUG THERAPY FOR CHILDREN WITH SELECTED LEARNING DISABILITIES. (ED.D. DISSERTATION).
198662 02-11

EFFECT OF TWO WEEKS TREATMENT WITH CHLORIMIPRAMINE AND NORTRIPTYLINE, ALONE OR IN COMBINATION WITH ALCOHOL, ON LEARNING AND MEMORY.
200057 02-14

LEARNING DEFICITS IN 4 WEEKS OLD OFFSPRING OF THE NURSING MOTHERS TREATED WITH THE NEUROLEPTIC DRUG PENFLURIDOL.
202806 02-04

MEASURING EFFECTS OF PSYCHOACTIVE MEDICATION IN A CHILD WITH A LEARNING DISABILITY.
203847 02-14

MARKOV CHAIN AS A MODEL OF VERBAL LEARNING.
205624 03-14

THE INFLUENCE OF HALOPERIDOL AND PENFLURIDOL ON THE LEARNING CAPACITY OF THE SCHIZOPHRENIC.
207000 03-14

EFFECTS OF OVERTRAINING UPON DRUG STATE DEPENDENCY IN DISCRIMINATION LEARNING IN WHITE RATS.
209866 03-04

FREE AND MEMBRANE BOUND RIBOSOMES AND POLYSOMES IN HIPPOCAMPAL NEURONS DURING A LEARNING EXPERIMENT.
210674 03-04

NORMAL SHUTTLEBOX AVOIDANCE LEARNING AFTER CHRONIC PHENOBARBITAL INTOXICATION IN MICE.
210737 03-04

MOLECULAR MECHANISMS OF MEMORY AND LEARNING (GENERAL CONSIDERATIONS AND CLINICAL APPLICATIONS).
212281 03-14

METHYLPHENIDATE EFFECTS ON AVOIDANCE LEARNING AT TWO AGES IN THE RAT.
215685 04-04

THE EFFECTS OF PYRITHIOXINE ON THE BEHAVIOUR AND INTELLECTUAL FUNCTION OF LEARNING DISABLED CHILDREN.
216485 04-11

CONDITIONED LEARNING IN YOUNG RATS BORN OF DRUG ADDICTED PARENTS AND RAISED ON ADDICTIVE DRUGS.
217465 04-04

FACILITATION OF AVOIDANCE LEARNING BY CHLORDIAZEPOXIDE AMPHETAMINE COMBINATIONS IN MICE.
217466 04-04

DISRUPTION OF STATE-DEPENDENT LEARNING (MEMORY RETRIEVAL) BY EMOTIONALLY IMPORTANT STIMULI.
217470 04-04

ANTAGONISM BY D-AMPHETAMINE OF LEARNING DEFICITS IN RATS INDUCED BY EXPOSURE TO ANTIPSYCHOTIC DRUGS DURING EARLY POSTNATAL LIFE.
217656 04-04

STATE-DEPENDENT LEARNING WITH CENTRALLY AND NONCENTRALLY ACTIVE DRUGS.
219020 04-04

EFFECTS OF MORPHINE AND HEROIN ON DISCRIMINATION LEARNING AND CONSOLIDATION IN MICE.
221040 04-04

POSTTRIAL D-AMPHETAMINE SULFATE AND ONE-TRIAL LEARNING IN MICE.
222268 04-04

THE EFFECTS OF METHYLPHENIDATE HYDROCHLORIDE ON PSYCHOLINGUISTIC, MOTOR AND VISUAL PERCEPTUAL ABILITIES OF HYPERKINETIC CHILDREN WITH LEARNING DISABILITIES. (PH.D. DISSERTATION).
222725 04-14

EFFECTS OF SCOPOLAMINE ON RETENTION OF TASTE AVERSION LEARNING IN RATS.
223033 04-04

LENGTHENING

DURATION OF EXPERIENCED LENGTHENING AND SHORTENING OF STRAIGHT LINES.
205135 02-14

LENPERONE

TREATMENT OF ACUTE SCHIZOPHRENIA WITH A NEW BUTYROPHENONE - - LENPERONE.
209791 03-07

LEPONEX

RESULTS ACHIEVED WITH CLOZAPINE (LEPONEX) IN THE TREATMENT OF NEUROSES.
205614 03-10

LESION

THE INFLUENCE OF ANTIDEPRESSANTS AND NEUROLEPTICS ON BEHAVIORAL REACTIONS ELICITED BY LESION AND EXCITATION OF THE HIPPOCAMPUS.
198483 02-04

EFFECTS OF 5-HYDROXYTRYPTOPHAN ON SLEEP OF A PATIENT WITH A BRAINSTEM LESION.
199757 02-13

INFLUENCE OF MIDBRAIN RAPHE LESION ON SOME PHARMACOLOGICAL AND BIOCHEMICAL EFFECTS OF APOMORPHINE IN RATS.
202771 02-03

CHEMICAL OR ELECTROLYTIC LESION OF THE SUBSTANTIA-NIGRA: EARLY EFFECTS ON NEOSTRIATAL DOPAMINE METABOLISM.
210699 03-03

EFFECT OF MIDBRAIN RAPHE LESION AND OF 6-HYDROXYDOPAMINE ON THE ANTINOCICEPTIVE ACTION OF BUPRENORPHINE IN RATS.
210923 03-03

HYPERSOMNIA BY ISTHMIC LESION IN THE CAT. I. STUDY OF THE METABOLISM OF CEREBRAL MONOAMINES.
215702 04-03

HYPERSOMNIA BY ISTHMIC LESION IN THE CAT. II. NEUROPHYSIOLOGICAL AND PHARMACOLOGICAL STUDY.
215703 04-03

LESIONED

BRAIN DOPA/5-HTP DECARBOXYLASE ACTIVITY AFTER THE CHRONIC ADMINISTRATION OF L-DOPA OR 5-HYDROXY-L-TRYPTOPHAN IN NORMAL AND LESIONED CATS.
194483 01-05

LESIONS

CHANGES IN THE ACQUISITION OF CONDITIONED AVOIDANCE RESPONSES FOLLOWING MIDBRAIN RAPHE LESIONS IN TH
197574 01-04

CENTRAL ACTION OF ANOREXIC AGENTS: EFFECTS OF AMPHETAMINE AND FENFLURAMINE IN RATS WITH LATERAL HYPOTHALAMIC LESIONS.
197865 01-04

EFFECT OF LIMBIC SYSTEM LESIONS ON ACETYLCHOLINE RELEASE FROM THE CEREBRAL CORTEX OF THE RAT.
200044 02-03

6-HYDROXYDOPAMINE LESIONS OF OLFACTORY TUBERCLES AND CAUDATE NUCLEI: EFFECT ON AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR IN RATS.
202788 02-04

STEREOTYPED AND CIRCLING BEHAVIOUR INDUCED BY DOPAMINERGIC AGONISTS AFTER LESIONS OF THE MIDBRAIN RAPHE NUCLEI.
202792 02-04

APOMORPHINE AND AMPHETAMINE STEREOTYPY AFTER 6-HYDROXYDOPAMINE LESIONS OF THE SUBSTANTIA-NIGRA.
202793 02-04

GENOTYPE DEPENDENT ELECTROENCEPHALOGRAPHIC, BEHAVIORAL AND ANALGESIC CORRELATES OF MORPHINE: AN ANALYSIS IN NORMAL MICE AND IN MICE WITH SEPTAL LESIONS.
203520 02-04

ELECTROPHYSIOLOGICAL AND BEHAVIORAL REACTIVITY TO PHOTIC STIMULI FOLLOWING SEPTAL LESIONS AND PHARMACOLOGICAL TREATMENTS IN RATS.
206724 03-04

ROLE OF PITUITARY ADRENOCORTICAL SYSTEM IN MEDIATING AVOIDANCE BEHAVIOR OF RATS WITH SEPTAL LESIONS.
206739 03-04

SUPERSENSITIVITY TO DOPAMINE AGONISTS FOLLOWING UNILATERAL, 6-HYDROXYDOPAMINE INDUCED STRIATAL LESIONS IN MICE.
208552 03-03

RECOVERY OF FUNCTION AND CHANGES IN SENSITIVITY TO AMPHETAMINE FOLLOWING CAUDATE LESIONS IN RATS.
209962 03-03

CHANGED EATING AND LOCOMOTOR BEHAVIOUR IN THE RAT AFTER 6-HYDROXYDOPAMINE LESIONS TO THE SUBSTANTIA-NIGRA.
210763 03-04

EFFECTS OF DOPAMINERGIC DRUGS AND ACUTE MEDIAL FOREBRAIN BUNDLE LESIONS ON STRIATAL ACETYLCHOLINE LEVELS.
210831 03-03

FACTORS INFLUENCING BRAIN AND TISSUE LEVELS OF TRYPTAMINE: SPECIES, DRUGS AND LESIONS.
210850 03-03

A HISTOCHEMICAL STUDY OF VENTRAL TEGMENTAL ACETYLCHOLINESTERASE CONTAINING PATHWAY FOLLOWING DESTRUCTIVE LESIONS.
210919 03-03

COMPARATIVE TIME-DEPENDENT CHANGES IN SENSITIVITY TO LOCOMOTOR EFFECTS OF D-AMPHETAMINE IN MICE WITH CAUDATE, HIPPOCAMPAL OR FRONTAL CORTICAL LESIONS.
210926 03-03

EFFECT OF CENTRAL NERVOUS SYSTEM LESIONS ON DRUG ACTION.
213611 04-03

LIMBIC SYSTEM LESIONS AND BRAIN NEUROHUMORS.
213613 04-03

APOMORPHINE-INDUCED ROTATION IN NORMAL RATS AND INTERACTION WITH UNILATERAL CAUDATE LESIONS.
214012 04-04

POTENTIATION OF AMPHETAMINE-INDUCED AROUSAL BY FOOD DEPRIVATION: EFFECT OF HYPOTHALAMIC LESIONS.
218498 04-04

ABSENT VESTIBULO-OCULAR REFLEXES AND ACUTE SUPRATENTORIAL LESIONS.
225323 04-13

CHANGES IN MORPHINE SELF-ADMINISTRATION AND MORPHINE-DEPENDENCE AFTER LESIONS OF THE CAUDATE NUCLEUS IN RATS.
225560 04-04

LETHALITY

CORRELATION OF (+) AMPHETAMINE LETHALITY AND HEPATIC METABOLISM.
217880 04-05

LEUCINE

AN EFFECT OF AMPHETAMINE ON INCORPORATION OF LEUCINE INTO MOUSE BRAIN PROTEIN.
193424 01-03

LEUKOCYTE

CHROMOSOMAL DAMAGE IN CHRONICAL USERS OF CANNABIS: IN VIVO INVESTIGATION WITH TWO-DAY LEUKOCYTE CULTURES.
210810 03-15

LEUKOCYTOSIS

LEUKOCYTOSIS DURING LITHIUM TREATMENT AND ITS CORRELATION TO SERUM LITHIUM LEVEL.
207718 03-15

LEVALLORPHAN

FAILURE OF ANTISEROTONERGIC AGENTS TO MODIFY LEVALLORPHAN INDUCED STEREOTYPY IN RATS.
225567 04-03

LEVEL

EFFECT OF 6-HYDROXYDOPAMINE ON THE LEVEL OF THE CATECHOLAMINES IN THE BRAIN OF DEVELOPING RATS.
197449 01-03

RELATIONSHIP BETWEEN THE CHANGES ON BLOOD PRESSURE RESPONSE AND THE CARDIAC CATECHOLAMINE LEVEL AFTER SINGLE AND REPEATED ADMINISTRATIONS OF TYRAMINE AND METHAMPHETAMINE IN RATS.
197491 01-03

NEONATAL CHEMICAL SYMPATHECTOMY: FUNCTIONAL CONTROL OF DENERVATION OF THE VASCULAR SYSTEM AND TISSUE NORADRENALINE LEVEL IN THE RAT AFTER 6-HYDROXYDOPAMINE.
197584 01-03

LONG-TERM EFFECTS OF N-HYDROXY-4-CHLOROAMPHETAMINE ON THE LEVEL AND ACCUMULATION OF 5-HYDROXYTRYPTAMINE IN THE RAT BRAIN.
197869 01-03

BLOOD LEVEL, EXCRETION, DISTRIBUTION AND METABOLISM OF 14C-TRIFLUBAZAM, A NEW 1,5 BENZODIAZEPINE, IN MICE AND DOGS.
197940 01-03

THE EFFECT OF BEDREST AND OF PHYSICAL ACTIVITY ON THE BLOOD LEVEL OF GENTAMYCIN AFTER INTRAMUSCULAR APPLICATION.
197956 01-13

ACTION OF (S)- AND (R) P-SUBSTITUTED AMPHETAMINE HYDROCHLORIDES AND (ALPHA S)- AND (ALPHA R) P-CHLORONOREPHEDRINE AND (ALPHA S)- AND (ALPHA R) P-CHLORONORPSEUDOEPHEDRINE HYDROCHLORIDES ON THE LEVEL OF 5-HYDROXYTRYPTAMINE AND THE ACTIVITY OF TRYPTOPHAN-HYDROXYLASE IN RAT BRAIN.
202417 02-03

THE SERUM GONADOTROPIN LEVEL UNDER THE MEDICATION OF L-DOPA.
204394 02-13

THE DIFFERENTIATION OF TWO TYPES OF HYPERACTIVE CHILDREN BY ACTIVITY LEVEL AND TASK PERFORMANCE WITH METHYLPHENIDATE (RITALIN) AND PLACEBO. (PH.D. DISSERTATION).
204688 02-11

DOSE LEVEL AND EFFECTS OF TRIFLUPERIDOL IN CLINICAL USE FOR SCHIZOPHRENIA.
207643 03-08

LEUKOCYTOSIS DURING LITHIUM TREATMENT AND ITS CORRELATION TO SERUM LITHIUM LEVEL.
207718 03-15

RELATIONSHIP BETWEEN SERUM LITHIUM LEVEL AND CLINICAL RESPONSE TO DEPRESSION TREATED WITH LITHIUM CARBONATE.
207719 03-09

THE EFFECT OF CHOLINERGICS ON SHORT-TERM MEMORY AND THE EXCITABILITY LEVEL OF HIPPOCAMPUS CIRCLE STRUCTURES.
208972 03-03

THE EEG EFFECTS OF DOPA IN THE RABBIT DEPENDING UPON THE LEVEL OF BRAINSTEM SECTION.
210880 03-03

THE EFFECTS OF STRAIN, DRUG, AND DOSE LEVEL ON GENERAL ACTIVITY AND EXPLORATORY BEHAVIOR IN MICE. (PH.D. DISSERTATION).
211883 03-04

THE LEVEL OF BLOOD NEUROMEDIATORS AFTER THE USE OF SEDUXEN AS AN INDEX OF NERVOUS SYSTEM REACTIVITY.
212432 03-13

INCREASED LEVEL PRESSING FOR AMPHETAMINE AFTER PIMOZIDE IN RATS: IMPLICATIONS FOR A DOPAMINE THEORY OF REWARD.
213350 03-04

THE EFFECT OF CAFFEINE ON BARBITURATE SLEEPING TIME AND BRAIN LEVEL.
214109 04-03

RELATIONSHIP BETWEEN SERUM LITHIUM LEVEL AND CLINICAL RESPONSE ON DEPRESSION TREATED WITH LITHIUM CARBONATE.
217354 04-09

EFFECT OF MORPHINE, HYDROMORPHONE, METHADONE, MESCALINE, TRYPAN-BLUE, VITAMIN-A, SODIUM SALICYLATE AND CAFFEINE ON THE SERUM INTERFERON LEVEL IN RESPONSE TO VIRAL INFECTION.
217654 04-03

THE INFLUENCE OF APOMORPHINE AND TRICYCLIC ANTIDEPRESSANT DRUGS ON THE LEVEL OF SEROTONIN AND ITS METABOLITE IN RAT BRAIN.
217815 04-03

THE EFFECT OF CATECHOLAMINES ON THE NOREPINEPHRINE LEVEL IN THE TISSUES.
219506 04-03

EEG AND BLOOD LEVEL RELATIONS OF PSYCHOACTIVE DRUGS.
224795 04-13

PLASMA LEVEL, DEPRESSIVE TYPOLOGY, CLINICAL OUTCOME.
224836 04-09

TRICYCLIC EFFECT ON BUTAPERAZINE PLASMA LEVEL.
224909 04-13

ASSESSING THE IMPACT OF LOW LEVEL CHEMICALS ON DEVELOPMENT: BEHAVIORAL AND LATENT EFFECTS.
225164 04-15

LEVELS

ACETYLCHOLINE LEVELS IN THE FROG SPINAL CORD FOLLOWING THE ADMINISTRATION OF DIFFERENT CONVULSANTS.
193550 01-03

EFFECTS OF TETRAHYDROCANNABINOLS ON CYCLIC-AMP LEVELS IN RAT BRAIN AREAS.
194925 01-03

EFFECT OF ORAL AND INTRAMUSCULAR ROUTES OF ADMINISTRATION ON SERUM CHLORDIAZEPOXIDE LEVELS AND THE PREDICTION OF THESE LEVELS FROM PREDRUG FASTING SERUM GLUCOSE CONCENTRATIONS.
195055 01-13

REGIONAL LEVELS OF GABA AND GLUTAMATE IN MOUSE BRAIN FOLLOWING EXPOSURE TO PAIN.
195097 01-03

MORPHINE EFFECTS ON THE LEVELS AND TURNOVER OF CATECHOLAMINES IN RAT BRAIN.
195116 01-03

EFFECTS OF WITHDRAWAL FROM CHRONIC AMPHETAMINE ADMINISTRATION ON ACTIVITY LEVELS OF ALBINO RATS.
195223 01-04

PLASMA LITHIUM LEVELS AND SIDE-EFFECTS DURING ADMINISTRATION OF A SLOW-RELEASE LITHIUM SULPHATE PREPARATION (LITHIUM LIPETT-C) AND LITHIUM CARBONATE LEVELS.
197029 01-15

EFFECTS OF CATECHOLAMINES AND PROSTAGLANDINS ON CYCLIC-AMP LEVELS IN BRAIN IN VIVO.
197294 01-03

THE EFFECTS OF PARENTERAL ADMINISTRATION OF CATECHOLAMINES, SEROTONIN AND HISTAMINE ON BEHAVIOR AND LEVELS OF THESE AMINES IN THE BRAIN OF THE NEONATE CHICK.
197457 01-03

EFFECTS OF PIRIBEDIL ON NORADRENALINE AND MOPEG-SO4 LEVELS IN THE RAT BRAIN.
197868 01-03

DOSE-DEPENDENT DIFFERENCES OF AMPHETAMINE LEVELS IN BRAIN AND HEART OF ADULT AND DEVELOPING MICE.
197927 01-03

PSYCHOACTIVE DRUG BLOOD LEVELS AND CLINICAL RESPONSE.
198095 02-07

PLASMA LEVELS OF IMIPRAMINE AND CLINICAL OUTCOME.
198097 02-07

BLOOD AND URINE LEVELS OF N,N DIMETHYLTRYPTAMINE FOLLOWING ADMINISTRATION OF PSYCHOACTIVE DOSAGES TO HUMAN SUBJECTS.
198230 02-12

THE INFLUENCE OF SODIUM OXYBUTYRATE ON INTERNEURONAL TRANSMISSION OF EXCITATION AT VARIOUS LEVELS OF THE CENTRAL NERVOUS SYSTEM.
198435 02-03

BRAIN LEVELS AND RELATIVE POTENCY OF THE 1,2 DIMETHYLHEPTYL ANALOGUE OF DELTA1-TETRAHYDROCANNABINOL IN MICE.
198605 02-01

EFFECTS OF CONJUGATED ESTROGENS ON PLASMA BUTAPERAZINE LEVELS.
201327 02-13

PLASMA TESTOSTERONE LEVELS DURING CHRONIC HEROIN USE AND PROTRACTED ABSTINENCE.
202307 02-13

EFFECTS OF NICOTINE ON SPONTANEOUS LOCOMOTOR ACTIVITY IN RATS HAVING HIGH AND LOW BASAL ACTIVITY LEVELS.
202980 02-04

BLOOD LEVELS AND MANAGEMENT OF LITHIUM TREATMENT.
203546 02-15

EFFECTS OF SINGLE AND REPEATED ADMINISTRATION OF MAPROTILINE AND ITS RELATION TO PLASMA LEVELS IN HEALTHY TEST SUBJECTS.
204403 02-15

AMPHETAMINE-INDUCED CHANGES IN STRIATAL DOPAMINE AND ACETYLCHOLINE LEVELS AND RELATIONSHIP TO ROTATION (CIRCLING BEHAVIOR) IN RATS.
205432 02-04

THE RELATIONSHIP BETWEEN THE EEG DRIVING RESPONSE TO LIGHT AND PLASMA MONOAMINEOXIDASE (MAO) LEVELS.
205437 02-03

THE LEVELS OF LITHIUM IN SERUM AND IN RED BLOOD CELLS AND ITS RATIOS IN MANIC-DEPRESSIVE PATIENTS.
205607 03-09

THE EFFECT OF LYSERGIC ACID DIETHYLAMIDE ON SERUM CREATINE KINASE LEVELS.
206361 03-12

SALIVA LITHIUM LEVELS: CLINICAL APPLICATIONS.
207042 03-16

PLASMA LEVELS OF A NEW PELLETIZED FORM OF AMITRIPTYLINE FOR MAINTENANCE THERAPY.
209789 03-13

PLASMA LEVELS AND CLINICAL EFFECTS OF THIORIDAZINE AND THIOTHIXENE.
209790 03-08

SOME OBSERVATIONS ON THE CORRELATIONS BETWEEN PLASMA LEVELS OF MONOMETHYLATED TRICYCLIC ANTIDEPRESSANTS AND THERAPEUTIC EFFECTS.
210507 03-09

INFLUENCE OF NONCHOLINERGIC DRUGS ON RAT STRIATAL ACETYLCHOLINE LEVELS.
210658 03-03

CHOLINERGIC DOPAMINERGIC INTERACTION IN THE STRIATUM: THE EFFECT OF 6-HYDROXYDOPAMINE OR PIMOZIDE TREATMENT ON THE INCREASED STRIATAL ACETYLCHOLINE LEVELS INDUCED BY APOMORPHINE, PIRIBEDIL AND D-AMPHETAMINE.
210668 03-03

NEONATAL 6-HYDROXYDOPAMINE TREATMENT: NORADRENALINE LEVELS AND IN VITRO 3H-CATECHOLAMINE SYNTHESIS IN DISCRETE BRAIN REGIONS OF ADULT RATS.
210759 03-03

EFFECTS OF DOPAMINERGIC DRUGS AND ACUTE MEDIAL FOREBRAIN BUNDLE LESIONS ON STRIATAL ACETYLCHOLINE LEVELS.
210831 03-03

FACTORS INFLUENCING BRAIN AND TISSUE LEVELS OF TRYPTAMINE: SPECIES, DRUGS AND LESIONS.
210850 03-03

EFFECT OF ANTIPSYCHOTIC DRUGS ON HOMOVANILLIC ACID LEVELS IN STRIATUM AND OLFACTORY TUBERCLE OF THE RAT.
210864 03-03

THE EFFECTS OF ACUTE AND CHRONIC MORPHINE ADMINISTRATION ON THE LEVELS OF 3-METHOXY-4-HYDROXYPHENYLGLYCOL SULFATE IN RAT BRAIN.
210927 03-03

TOLERANCE DEVELOPMENT WITH CHLORDIAZEPOXIDE IN RELATION TO THE PLASMA LEVELS OF THE PARENT COMPOUND AND ITS MAIN METABOLITES IN MICE.
210973 03-03

POTENTIATION OF THE L-5-HYDROXYTRYPTOPHAN INDUCED ELEVATION OF PLASMA CORTICOSTERONE LEVELS IN RATS BY A SPECIFIC INHIBITOR OF SEROTONIN UPTAKE.
211104 03-03

THE EFFECT OF CERTAIN TRANQUILISERS, CHLORPROMAZINE METABOLITES AND DIETHYLDITHIOCARBAMATE ON TISSUE AMPHETAMINE LEVELS IN THE RAT.
211111 03-03

EFFECTS OF DRUG ALTERED SEROTONIN LEVELS ON THE ACQUISITION OF A SHUTTLEBOX AVOIDANCE TASK. (PH.D. DISSERTATION).
211781 03-04

USE OF A BENZODIAZEPINE AT HIGH DOSAGE LEVELS: A STATEMENT ON 50 OBSERVATIONS.
212179 03-10

THE RELATIONSHIP BETWEEN NORTRIPTYLINE PLASMA LEVELS AND CLINICAL EFFECTS.
213782 04-13

CORRELATION BETWEEN BRAIN MONOAMINE LEVELS AND POSTICTAL COMA FOLLOWING ELECTROSHOCK.
215723 04-03

A RELATION BETWEEN DRUG CONCENTRATIONS IN BRAIN AND STRIATAL HOMOVANILLIC ACID LEVELS IN CHLORPROMAZINE TREATED RATS.
215734 04-03

CORRELATION OF BRAIN LEVELS OF BARBITURATE ENANTIOMERS WITH REPORTED DIFFERENCES IN DURATION OF SLEEP.
217457 04-03

N-DESMETHYLDIAZEPAM AND AMYLOBARBITONE SODIUM AS HYPNOTICS IN ANXIOUS PATIENTS. PLASMA LEVELS, CLINICAL EFFICACY AND RESIDUAL EFFECTS.
217460 04-10

PLASMA LEVELS OF IMIPRAMINE AND DESMETHYLIMIPRAMINE AND ANTIDEPRESSANT EFFECT DURING CONTROLLED THERAPY.
217477 04-09

THE EFFECT OF DIFFERENT LEVELS OF PRE-EXPOSURE TO SUCROSE ON THE ACQUISITION AND EXTINCTION OF A CONDITIONED AVERSION.
217807 04-04

6-HYDROXYDOPAMINE AND STRIATAL ACETYLCHOLINE LEVELS.
217842 04-03

SERUM ERYTHROCYTE AND CNS LEVELS IN RHESUS MONKEYS OF ORALLY AND INTRAVENOUSLY ADMINISTERED RUBIDIUM SALTS.
218956 04-02

EFFECTS OF CHRONIC ADMINISTRATION AND WITHDRAWAL OF D-AMPHETAMINE UPON DAILY ACTIVITY LEVELS OF SQUIRREL MONKEYS.
219032 04-04

EFFECT OF DRUG-INDUCED INCREASE OF BRAIN GABA LEVELS ON PENICILLIN FOCUS.
220947 04-03

TETRAHYDROCANNABINOLS AND SERUM PROLACTIN LEVELS IN MAN.
220973 04-13

EFFECTS OF SINGLE AND MULTIPLE DOSE LSD ON ENDOGENOUS LEVELS OF BRAIN TYROSINE-HYDROXYLASE AND CATECHOLAMINES.
221044 04-12

PHARMACOLOGICAL ACTION OF FD-008, A NEW DOPAMINE-BETA-HYDROXYLASE INHIBITOR: III. EFFECTS ON ENDOGENOUS BIOGENIC AMINE LEVELS IN RATS.
221859 04-03

A CLINICAL STUDY OF SERUM CONCENTRATION LEVELS OF PHENOBARBITAL DERIVED FROM PRIMIDONE (MUSOLINE).
224644 04-13

NORTRIPTYLINE PLASMA LEVELS: RELATIONSHIP TO DRUG EFFECTS.
224834 04-09

THE RELATION BETWEEN CEREBRAL SEROTONIN LEVELS AND CONDITIONED BEHAVIOUR IN THE RAT FOLLOWING THE ADMINISTRATION OF LSD-25 AND UML.
225564 04-04

LEVER

DIFFERENTIAL EFFECTS ON LEVER CHOICE AND RESPONSE RATE PRODUCED BY D-AMPHETAMINE.
194178 01-04

EFFECTS OF HEROIN ON LEVER PRESSING FOR INTRACRANIAL SELF-STIMULATION, FOOD AND WATER IN THE RAT.
221039 04-04

LEVERPRESS

EFFECTS OF D-AMPHETAMINE ON ACQUISITION OF LEVERPRESS SIDMAN AVOIDANCE IN RATS.
195305 01-04

LEVODOPA

ROLE OF NORADRENALINE IN LEVODOPA REVERSAL OF RESERPINE AKINESIA.
193544 01-03

CONTRIBUTION OF TREATMENT BY LEVODOPA TO THE NEUROPHARMACOLOGY OF AKINESIA.
203494 02-15

HUMAN GROWTH HORMONE RESPONSE TO LEVODOPA: RELATION TO MENOPAUSE, DEPRESSION, AND PLASMA DOPA CONCENTRATION.
213918 04-09

PARKINSONISM: EFFECTS OF LEVODOPA TREATMENT ON CONCEPT FORMATION.
222871 04-14

LEXOTAN

THE EFFECTS OF A NEW SEDATIVE (LEXOTAN) ON REACTION TIMES AND ON ATTENTIVE CAPACITY OF A GROUP OF ATHLETES.
209857 03-14

A COMPARISON BETWEEN BROMAZEPAM (RO-5-3350, LEXOTAN) AND DIAZEPAM (VALIUM) IN ANXIETY NEUROSIS: A CONTROLLED, DOUBLE-BLIND CLINICAL TRIAL.
217455 04-10

CLINICAL STUDY OF A NEW TRANQUILIZER, LEXOTAN, IN NEUROTIC DISTURBANCES.
224583 04-10

LEYTON

CHANGES IN OBSESSIVE/COMPULSIVE PATIENTS AS MEASURED BY THE LEYTON INVENTORY BEFORE AND AFTER TREATMENT WITH CLOMIPRAMINE.
214833 04-10

LH

EFFECTS OF INTRAVENTRICULAR INFUSIONS OF ACTH1-24 AND ACTH4-10 ON LH RELEASE, OVULATION AND BEHAVIOR IN THE RABBIT.
210662 03-03

LIBRIUM

A CONTROLLED SERIES OF EXPERIMENTS INVESTIGATING SOME SOCIOLOGICAL EFFECTS OF TWO DOSAGES OF CHLORDIAZEPOXIDE (LIBRIUM) UPON INDIVIDUALS AND SMALL GROUPS. (PH.D. DISSERTATION).
195145 01-14

RESISTANCE TO EXTINCTION OF AN AVOIDANCE RESPONSE IN RATS FOLLOWING THE ADMINISTRATION OF CHLORDIAZEPOXIDE (LIBRIUM) AND DIAZEPAM (VALIUM).
198226 02-04

CHLORDIAZEPOXIDE (LIBRIUM): THE EFFECTS OF A MINOR TRANQUILIZER ON STRATEGIC CHOICE BEHAVIOR IN THE PRISONERS DILEMMA.
199609 02-14

CHLORDIAZEPOXIDE (LIBRIUM) INDUCED CHANGES IN INTRASPECIFIC ATTACK AND SELECTED NONAGONISTIC BEHAVIORS IN MALE SIAMESE FIGHTING FISH.
217524 04-04

LIDOCAINE

THE EFFECTS OF DIPHENYLAMINOETHANOL (DPAE) AND LIDOCAINE ON CEREBELLAR INHIBITION DEITERS NEURONS. (PH.D. DISSERTATION).
196259 01-03

EFFECTS OF 5-HYDROXYTRYPTOPHAN, IPRONIAZID AND P-CHLOROPHENYLALANINE ON LIDOCAINE SEIZURE THRESHOLD OF MICE.
199962 02-03

LIFE

CLINICAL TRIAL OF CLOCAPRAMINE IN NEUROTIC PATIENTS WHO HAD TROUBLES IN EVERYDAY LIFE OWING TO SEVERE ANXIETY, IRRITABILITY AND DEPRESSION.
204464 02-10

LONG-TERM BEHAVIOURAL EFFECTS OF DIAZEPAM AND ACTH, ADMINISTERED EARLY IN LIFE.
215067 04-04

THE EFFECTS OF CHLORDIAZEPOXIDE ON AVOIDANCE PERFORMANCE OF MICE SUBJECTED TO UNDERNUTRITION OR HANDLING STRESS IN EARLY LIFE.
217463 04-04

ANTAGONISM BY D-AMPHETAMINE OF LEARNING DEFICITS IN RATS INDUCED BY EXPOSURE TO ANTIPSYCHOTIC DRUGS DURING EARLY POSTNATAL LIFE.
217656 04-04

INHIBITION OF STRIATAL DOPAMINE SYNTHESIS IN RATS INJECTED CHRONICALLY WITH NEUROLEPTICS IN THEIR EARLY LIFE.
217687 04-03

EARLY LIFE UNDERNUTRITION AND AGGRESSION IN TWO MOUSE STRAINS.
225081 04-04

LIFT

THE USE OF FREE IMAGERY, NONDIRECTIVE INTERVIEWING, AND SELECTED DRUGS TO LIFT POSTHYPNOTIC REPRESSION. (PH.D. DISSERTATION).
222060 04-14

LIGHT

LIGHT INDUCED FRAGMENTATION OF 3,5-DIOXO-1,2 DIPHENYL-4-N-BUTYLPYRAZOLIDINE (PHENYLBUTAZONE) WITH NUCLEOPHILIC AGENTS.
197675 01-01

REVERSAL OF RESERPINE INDUCED BRADYKINESIA BY ALPHA-METHYLDOPA -- NEW LIGHT ON ITS MODUS-OPERANDI.
202281 02-03

THE BLINK REFLEX TO LIGHT: ITS COURSE AND ITS FACILITATION BY RESERPINE.
204220 02-03

THE RELATIONSHIP BETWEEN THE EEG DRIVING RESPONSE TO LIGHT AND PLASMA MONOAMINEOXIDASE (MAO) LEVELS.
205437 02-03

MAPROTILINE -- ITS POSITION AS AN ANTIDEPRESSANT IN THE LIGHT OF RECENT NEUROPHARMACOLOGICAL AND NEUROBIOCHEMICAL FINDINGS.
221647 04-03

LIMB

EFFECTS OF A DECARBOXYLASE INHIBITOR ON THE DOPA AND 5-HTP INDUCED CHANGES IN THE LOCOMOTOR LIKE DISCHARGE PATTERN OF RABBIT HIND LIMB NERVES.
210740 03-03

LIMBIC

EFFECTS OF OXOTREMORINE AND PHYSOSTIGMINE ON THE TURNOVER OF DOPAMINE IN THE CORPUS-STRIATUM AND THE LIMBIC SYSTEM.
198207 02-03

EFFECT OF LIMBIC SYSTEM LESIONS ON ACETYLCHOLINE RELEASE FROM THE CEREBRAL CORTEX OF THE RAT.
200044 02-03

THE INFLUENCE OF TRIFLUOPERAZINE, CARBIDINE AND IMIZINE ON EVOKED POTENTIALS IN DIFFERENT STRUCTURES OF THE LIMBIC RETICULAR COMPLEX.
200564 02-02

BLOCKADE BY PIMOZIDE OF A NORADRENALINE SENSITIVE ADENYLATE-CYCLASE IN THE LIMBIC FOREBRAIN: POSSIBLE ROLE OF LIMBIC NORADRENERGIC MECHANISMS IN THE MODE OF ACTION OF ANTIPSYCHOTICS.
210771 03-03

LIMBIC SYSTEM LESIONS AND BRAIN NEUROHUMORS.
213613 04-03

IN VIVO RELEASE OF ENDOGENOUS NEUROTRANSMITTERS IN CAT LIMBIC REGIONS: EFFECT OF CHLORPROMAZINE AND OF ELECTRICAL STIMULATION.
217685 04-03

LIMBITROL

LIMBITROL IN OUTPATIENTS AND INPATIENTS PRACTICE.
205598 02-10

LIMITATION

SCOPE AND LIMITATION IN DOPAMINE BETA-HYDROXYLASE MEASUREMENT.
210811 03-02

LIMITATIONS

POSSIBILITIES AND LIMITATIONS OF PSYCHOTROPIC THERAPY IN PATIENTS WITH GLAUCOMA.
201911 02-15

LIN-14-18

A NEW SUBSTITUTED BENZAMIDE WITH NEUROLEPTIC EFFECTS: LIN-14-18 OR SULTOPRIDE.
216759 04-08

LINEARIS

THE NUCLEUS LINEARIS INTERMEDIUS RAPHE AND BEHAVIOUR EVOKED BY DIRECT AND INDIRECT STIMULATION OF DOPAMINE SENSITIVE SITES WITHIN THE CAUDATE NUCLEUS OF CATS.
199864 02-04

LIPETT-C

PLASMA LITHIUM LEVELS AND SIDE-EFFECTS DURING ADMINISTRATION OF A SLOW-RELEASE LITHIUM SULPHATE PREPARATION (LITHIUM LIPETT-C) AND LITHIUM CARBONATE LEVELS.
197029 01-15

LIPID
LIPID SOLUBILITY AND DRUG PENETRATION OF THE BLOOD-BRAIN BARRIER.
206913 03-03
EFFECT OF DELTA9-TETRAHYDROCANNABINOL ADMINISTRATION ON THE LIPID CONSTITUENTS OF RAT BRAIN SUBCELLULAR FRACTIONS.
210769 03-03

LIPIDOSIS
LIPIDOSIS LIKE ALTERATIONS IN SPINAL CORD AND CEREBELLAR CORTEX OF RATS TREATED WITH CHLORPHENTERMINE OR TRICYCLIC ANTIDEPRESSANTS.
202767 02-03

LIPIDS
INCORPORATION OF ACETATE (C14)(P-32) AND PHOSPHATE INTO THE BRAIN LIPIDS DURING BLOCKAGE OF THE CHOLINORECEPTOR AND ADRENORECEPTORS.
202599 02-03

LIPOLYSIS
THE STEREOSELECTIVE INHIBITION OF LIPOLYSIS BY NONPHENOLIC PHENETHYLAMINES.
193456 01-03

LIPOLYTIC
THE LIPOLYTIC ACTIVITY OF AMPHETAMINE IN THE SPINALISED CAT.
195118 01-03

LIPOPHILICITY
COMPARATIVE STUDIES ON THE MEMBRANE ACTIONS OF DEPRESSANT DRUGS: THE ROLE OF LIPOPHILICITY IN INHIBITION OF BRAIN SODIUM AND POTASSIUM STIMULATED ATPASE.
210818 03-03

LITAREX
SIMILARITIES IN THE EFFECTS OF LITHIUM CARBONATE, LITAREX AND LITHIONITE DURETTER: PRELIMINARY STUDY.
221634 04-14

LITERATURE
ASPECTS OF LONG-TERM TREATMENT WITH NEUROLEPTICS: HISTORICAL AND LITERATURE REVIEW -- PERSONAL EXPERIENCE WITH FLUSPIRILENE AND PENFLURIDOL.
215059 04-14
NEUROLEPTICS OF PROLONGED ACTION (A SURVEY OF FOREIGN LITERATURE).
217003 04-14
PSYCHOPHARMACOLOGY IN CHILD PSYCHIATRY: LITERATURE ANALYSIS.
220271 04-11

LITHIONITE
SIMILARITIES IN THE EFFECTS OF LITHIUM CARBONATE, LITAREX AND LITHIONITE DURETTER: PRELIMINARY STUDY.
221634 04-14

LITHIUM
THE CURRENT STATUS OF LITHIUM TREATMENT.
193040 01-09
FACTORS ASSOCIATED WITH TREATMENT SUCCESS IN LITHIUM CARBONATE PROPHYLAXIS: REPORT OF THE NIMH-VA COLLABORATIVE STUDY GROUP.
193068 01-09
PHARMACOKINETICS OF LITHIUM AND ITS REGIONAL DISTRIBUTION IN RAT BRAIN.
193547 01-03
THE EFFECTIVENESS OF LITHIUM IN AFFECTIVE AND SCHIZOAFFECTIVE PSYCHOSES.
194043 01-11
PROPHYLACTIC USE OF LITHIUM.
194168 01-09
LITHIUM AND ADRENAL CORTEX.
194169 01-03
LITHIUM PROPHYLAXIS -- A CRITICAL REVIEW.
194355 01-09
AFFECTIVE DISEASE HEALTH MAINTENANCE ORGANIZATION: PATTERNS OF LITHIUM RESPONSE.
194746 01-09
EVALUATION OF LITHIUM THERAPY IN CHRONIC AND PERIODIC ALCOHOLISM.
194758 01-11
GENETIC DETERMINANT OF LITHIUM ION DISTRIBUTION. I. AN IN VITRO MONOZYGOTIC DIZYGOTIC TWIN STUDY.
194826 01-13
LONG-TERM LITHIUM ADMINISTRATION TO RATS. LITHIUM AND SODIUM DOSAGE AND ADMINISTRATION, AVOIDANCE OF INTOXICATION, POLYURIC CONTROL RATS.
195042 01-03
EFFECT OF LITHIUM ON SERUM TRYPTOPHAN AND BRAIN SEROTONIN IN RATS.
195232 01-03
BRAIN SEROTONIN METABOLISM IN LITHIUM TREATED RATS.
195235 01-03
THE EFFECTS OF LITHIUM AND PHYSOSTIGMINE ON RAT BRAIN ACETYLCHOLINESTERASE ACTIVITY.
195436 01-03
ESTIMATION OF PHARMACOKINETIC PARAMETERS OF LITHIUM FROM SALIVA AND URINE.
195446 01-13
THE EFFECT OF LITHIUM ON THYROID FUNCTIONING: A CONTROLLED STUDY.
195916 01-09
EFFECTS OF LITHIUM CARBONATE ON SLEEP.
195918 01-09
SODIUM AND LITHIUM ERYTHROCYTE CONCENTRATION IN AFFECTIVE DISORDERS.
195931 01-09
NEUROPSYCHOLOGIC MECHANISMS OF LITHIUM THERAPY.
195932 01-09
DOES LITHIUM IN DRINKING WATER PREVENT MENTAL DISORDER?
195933 01-17
THE EFFECT OF LITHIUM ON URINARY MHPG IN UNIPOLAR AND BIPOLAR DEPRESSED PATIENTS. (UNPUBLISHED PAPER).
196042 01-09
DEPRESSIVE ILLNESS: ADRENERGIC RESPONSIVENESS AND THE EFFECT OF LITHIUM ON PLATELET ADENYLCYCLASE. (PH.D. DISSERTATION).
196260 01-13
THE CURRENT STATUS OF LITHIUM PROPHYLAXIS.
196678 01-07
PLASMA LITHIUM LEVELS AND SIDE-EFFECTS DURING ADMINISTRATION OF A SLOW-RELEASE LITHIUM SULPHATE PREPARATION (LITHIUM LIPETT-C) AND LITHIUM CARBONATE LEVELS.
197029 01-15
THE EFFECT OF LITHIUM CARBONATE IN COMBINATION WITH TRICYCLIC ANTIDEPRESSANTS IN ENDOGENOUS DEPRESSION: A DOUBLE-BLIND, MULTICENTER TRIAL.
197035 01-09
EFFECTS OF LITHIUM ON CYCLIC-3-5-AMP METABOLISM IN RAT BRAIN.
197278 01-03
LITHIUM PROPHYLAXIS: A CRITICAL REVIEW.
197531 01-09
LITHIUM PROPHYLAXIS IN RECURRENT AFFECTIVE DISORDERS.
197532 01-09
EFFECT OF PROLONGED LITHIUM INGESTION ON GLUCAGON AND PARATHYROID HORMONE RESPONSES IN RATS.
197744 01-03
THE EFFECT OF NH4CL ON POLYURIA AND POLYDIPSIA DURING PROLONGED LITHIUM ADMINISTRATION IN THE RAT.
198027 01-03
NIMH-VA LITHIUM COLLABORATIVE STUDY.
198080 02-09
PSYCHOPHARMACOLOGY OF THE LITHIUM ION.
198081 02-07
EEG CHANGES WITH LITHIUM IN DEPRESSED PATIENTS.
198100 02-10
LITHIUM INDUCED LOSS OF BODY SODIUM AND THE DEVELOPMENT OF SEVERE INTOXICATION IN RATS.
199623 02-03
DEPRESSION, ELATION, AND LITHIUM CARBONATE RESPONSES IN MANIC PATIENT SUBGROUPS.
199631 02-09
INHIBITION OF SCOPOLAMINE INDUCED STIMULATION OF Y-MAZE ACTIVITY BY ALPHA-METHYL-P-TYROSINE AND BY LITHIUM.
199866 02-04
EFFECTS OF LITHIUM CHLORIDE ON CARDIOVASCULAR RESPONSES INDUCED BY CHOLINERGIC AND ADRENERGIC STIMULATIONS.
199870 02-03
PROBLEMS OF CLINICAL EFFECTIVENESS AND USE OF LITHIUM SALTS IN PSYCHIATRIC PRACTICE.
200072 02-09
THE CURRENT STATUS OF LITHIUM RECIDIVISM PROPHYLAXIS IN ENDOGENOUS AFFECTIVE ILLNESSES.
200568 02-09
THE EFFECTS OF LITHIUM CARBONATE ON SERUM GASTRIN IN PSYCHIATRIC PATIENTS.
200637 02-04
EFFECT OF LONG-TERM LITHIUM TREATMENT ON BRAIN FUMARASE ACTIVITY.
200751 02-03
COMPARISON OF THE EFFECTS OF LITHIUM, BETA-PHENYLETHYLAMINE AND TYROSINE ON XENOPUS EMBRYOS.
200752 02-03
STUDY OF LITHIUM INTOXICATION UNDER THERAPEUTIC LITHIUM SERUM CONCENTRATION.
200952 02-15
LITHIUM RESPONSE IN DEPRESSION AS PREDICTED BY UNIPOLAR/BIPOLAR ILLNESS, AVERAGE EVOKED RESPONSE, CATECHOL-O-METHYLTRANSFERASE AND FAMILY HISTORY. (UNPUBLISHED PAPER).
201000 02-09
CONDITIONED SUPPRESSION OF MOUSE-KILLING IN RATS FOLLOWING RADIATION OR LITHIUM CHLORIDE INJECTIONS. (PH.D. DISSERTATION).
201153 02-04

LITHIUM CARBONATE, HALOPERIDOL, AND IRREVERSIBLE BRAIN DAMAGE.
201287 02-15

LITHIUM TREATMENT REDUCES MORPHINE SELF-ADMINISTRATION IN ADDICT RATS.
201293 02-04

EFFECT OF LITHIUM ON THE EEG AND SEROTONIN CONTENT IN THE BRAIN.
201888 02-03

THE EFFECTS OF LITHIUM ON NOREPINEPHRINE TURNOVER AND METABOLISM: BASIC AND CLINICAL STUDIES.
202249 02-09

THE ROLE OF SEX AND NOVELTY IN DETERMINING THE SOCIAL RESPONSE TO LITHIUM CHLORIDE.
202721 02-04

THE ANTIAGGRESSIVE EFFECTS OF LITHIUM IN MAN.
202725 02-09

RED BLOOD CELL LITHIUM INDEX IN PATIENTS WITH AFFECTIVE DISORDERS IN THE COURSE OF LITHIUM PROPHYLAXIS.
202786 02-09

DIVALENT CATIONS IN PREDICTING ANTIDEPRESSANT RESPONSE TO LITHIUM.
202886 02-14

LITHIUM AND MRIH IN TARDIVE DYSKINESIA.
202887 02-14

BLOOD LEVELS AND MANAGEMENT OF LITHIUM TREATMENT.
203546 02-15

LITHIUM THERAPY IN CYCLOTHYMIA.
203600 02-09

CHANGES IN THE PSYCHODYNAMICS OF MANIC-DEPRESSIVES THROUGH LONG-TERM ADMINISTRATION OF LITHIUM SALTS.
203601 02-14

THE EFFECTS OF LITHIUM ON THE EKG.
203602 02-15

EEG EXAMINATIONS DURING LITHIUM TREATMENT.
203701 02-13

CLINICAL APPLICATION OF LITHIUM ASPARTATE.
204392 02-09

INTRA-EXTRACELLULAR LITHIUM RATIO: CLINICAL AND EXPERIMENTAL FINDINGS ON THROMBOCYTES AND ERYTHROCYTES.
204393 02-13

EFFECT OF BETA-RECEPTOR BLOCKERS (PINDOLOL AND PRACTOLOL) ON LITHIUM INDUCED TREMOR -- CLINICAL TRIAL AND THEORETICAL CONSIDERATIONS.
204409 02-15

FURTHER OBSERVATIONS ON AUTOMATON LIKE EXISTENCE UNDER LONG-TERM LITHIUM THERAPY.
204410 02-15

THE KINETICS OF LITHIUM IN THE HUMAN ORGANISM.
205042 02-13

ELIMINATION OF LITHIUM DEPENDENT ON AGE IN HEALTHY PEOPLE AND PATIENTS SUFFERING FROM RENAL INSUFFICIENCY.
205043 02-13

LABORATORY AND CLINICAL STUDIES OF LITHIUM CARBONATE.
205175 02-03

DYSARTHRIA RESULTING FROM LITHIUM CARBONATE: A CASE REPORT.
205288 02-15

THE EFFECTS OF LITHIUM CARBONATE ON SLEEP AND WAKEFULNESS IN THE CAT.
205546 02-03

THE LEVELS OF LITHIUM IN SERUM AND IN RED BLOOD CELLS AND ITS RATIOS IN MANIC-DEPRESSIVE PATIENTS.
205607 03-09

FAMILY HISTORY OF MANIC-DEPRESSIVE AND ENDOGENOUS DEPRESSIVE PATIENTS AND CLINICAL EFFECT OF TREATMENT WITH LITHIUM.
205608 03-09

SOME SPECIFICITIES IN THE COURSE OF MANIOMELANCHOLIC PSYCHOSIS DURING LITHIUM THERAPY.
205609 03-09

LITHIUM TREATMENT OF BEHAVIOURAL DISTURBANCES IN PATIENTS WITH DEFECTIVE INTELLECT.
205610 03-09

LITHIUM TREATMENT AND THYROID FUNCTION IN MAN.
205611 03-15

TO THE INCOMPATIBILITY OF HALOPERIDOL WITH LITHIUM SALTS.
205612 03-15

LITHIUM AND INSULIN: EFFECTS ON CARBOHYDRATE AND ELECTROLYTE METABOLISM.
205929 03-09

LITHIUM TREATMENT OF DEPRESSION.
206146 03-09

LONGITUDINAL STUDY OF THE EFFECTS OF LITHIUM CARBONATE ON THE SLEEP OF HOSPITALIZED DEPRESSED PATIENTS.
206333 03-09

SALIVA LITHIUM LEVELS: CLINICAL APPLICATIONS.
207042 03-16

RENAL TUBULAR FUNCTION IN PATIENTS ON LONG-TERM LITHIUM THERAPY.
207043 03-13

PSYCHOACTIVE DRUGS IN MANIA: A CONTROLLED COMPARISON OF LITHIUM CARBONATE, CHLORPROMAZINE AND HALOPERIDOL.
207446 03-09

LEUKOCYTOSIS DURING LITHIUM TREATMENT AND ITS CORRELATION TO SERUM LITHIUM LEVEL.
207718 03-15

RELATIONSHIP BETWEEN SERUM LITHIUM LEVEL AND CLINICAL RESPONSE TO DEPRESSION TREATED WITH LITHIUM CARBONATE.
207719 03-09

SURVIVAL IN LITHIUM INTOXICATION, STATUS-EPILEPTICUS, AND PROLONGED COMA.
208536 03-15

THERAPY WITH LITHIUM SALTS IN MANIC-DEPRESSIVE ILLNESSES.
209070 03-09

PRELIMINARY RESULTS ON THE CLINICAL USE OF A SLOW-RELEASE PREPARATION OF LITHIUM SALTS.
209122 03-09

LITHIUM IN THE TREATMENT OF AGGRESSION.
209129 03-11

A CASE OF NONSPECIFIC PSYCHOSES WHICH MANIFESTED CONVULSIVE SEIZURES DURING LITHIUM THERAPY.
209324 03-15

LITHIUM, CALCIUM, AND MENTAL ILLNESS.
209350 03-13

EFFECT OF LITHIUM ON MAGNESIUM DEPENDENT ENZYMES.
209351 03-03

LITHIUM INHIBITION OF CAMP-MEDIATED HORMONES: A CAUTION.
209352 03-03

THE LITHIUM PROPHYLACTIC TREATMENT OF RECURRENT ENDOGENOUS AFFECTIVE DISORDERS.
209392 03-09

CLINICAL EFFECTS OF LITHIUM CARBONATE ON DEPRESSIVE STATES.
209413 03-09

THE APPEARANCE OF EXOPHTHALMIA IN THE COURSE OF LITHIUM CARBONATE TREATMENT: BIOLOGICAL HYPERTHYROIDISM.
209998 03-15

LITHIUM GLUCONATE: SYSTEMATIC AND FACTORIAL ANALYSIS OF 104 OBSERVATIONS OVER 2.5-3 YEARS IN PATIENTS PRESENTING CYCLOTHYMIC OR DYSTHYMIC DISORDERS.
210126 03-09

LITHIUM CARBONATE AND AGGRESSION: A CASE REPORT.
210210 03-14

A DOUBLE-BLIND COMPARISON OF LITHIUM CARBONATE AND IMIPRAMINE IN THE TREATMENT OF DEPRESSION.
210241 03-09

EFFECT OF LITHIUM AND OTHER DRUGS ON THE AMPHETAMINE CHLORDIAZEPOXIDE HYPERACTIVITY IN MICE.
210349 03-04

LITHIUM.
210425 03-15

CLINICAL BIOLOGICAL CORRELATIONS IN SCHIZOAFFECTIVE PATIENTS TREATED WITH LITHIUM CARBONATE AND HALOPERIDOL.
210501 03-09

THE EFFECT OF SODIUM CHLORIDE ON KIDNEY FUNCTION IN RATS WITH LITHIUM INTOXICATION.
210696 03-03

LITHIUM AND ETHANOL PREFERENCE.
210750 03-05

ACCUMULATION OF LITHIUM IN THE PARTICULATE FRACTION OF RAT BRAIN FOLLOWING ITS LONG-TERM ADMINISTRATION.
210782 03-03

BINDING OF LITHIUM AND CALCIUM BY CEREBRAL MEMBRANE FRACTIONS.
210806 03-03

COMPARATIVE STUDIES ABOUT SERUM ELECTROLYTES DURING LITHIUM PROPHYLAXIS OF AFFECTIVE DISORDERS.
210807 03-09

EFFECTS OF WATER DEPRIVATION IN RATS WITH POLYDIPSIA AND POLYURIA DUE TO LONG-TERM ADMINISTRATION OF LITHIUM.
210833 03-05

GENETIC DETERMINANT OF LITHIUM ION METABOLISM: II. AN IN VIVO STUDY OF LITHIUM ION DISTRIBUTION ACROSS ERYTHROCYTE MEMBRANES.
211412 03-03

CONTRIBUTIONS TO THE STUDY OF THE INFLUENCE OF LITHIUM CARBONATE ON THE EVOLUTION OF HYPERTHYMIC PSYCHOSES.
212161 03-09

STUDY OF 220 OBSERVATIONS OF LITHIUM THERAPY IN DEPRESSION CASES IN TEHERAN.
212211 03-09

ATYPICAL INDICATION OF LITHIUM THERAPY.
212213 03-09

LITHIUM ION AND AFFECTIVE PSYCHOSES.
212340 03-09

EFFECT OF LITHIUM ON GLUCAGON STIMULATED CYCLIC-AMP EXCRETION IN RATS.
213481 04-03

THE EFFECT OF PROLONGED LITHIUM INGESTION ON MORPHINE ACTIONS IN THE RAT.
213482 04-03
THE EFFECT OF LITHIUM ON BLOOD PRESSURE AND ON PLASMA RENIN SUBSTRATE AND RENIN IN RATS.
213483 04-03
ALTERATIONS IN BEHAVIOUR AND CATECHOLAMINE BIOSYNTHESIS INDUCED BY LITHIUM.
214067 04-04
LITHIUM USE IN MANIC-DEPRESSIVE ILLNESS: PRACTICAL ASPECTS.
215680 04-17
THE EFFECT OF CHRONIC LITHIUM APPLICATION ON THE MINERAL CONTENT OF RAT BONE AND SOFT TISSUES.
215695 04-05
EFFECTS OF LITHIUM ON ELECTROMYOGRAPHIC RECORDINGS IN MAN: STUDIES IN MANIC-DEPRESSIVE PATIENTS AND NORMAL VOLUNTEERS.
215697 04-13
THE USE OF LITHIUM IN THE TREATMENT OF THE DRUG-INDUCED PSYCHOTIC REACTION.
216183 04-11
A CASE OF NARCOLEPSY IMPROVED BY LITHIUM CARBONATE.
216390 04-11
FREE THYROXINE INDEX AND ABSOLUTE FREE THYROXINE IN PATIENTS WITH AFFECTIVE DISORDERS TREATED WITH LITHIUM CARBONATE.
216747 04-09
CLINICAL EXPERIMENTATION WITH A SUSTAINED RELEASE LITHIUM CARBONATE.
216769 04-09
THE EFFECT OF LITHIUM CARBONATE ON THE ELECTROENCEPHALOGRAM OF MANIC-DEPRESSIVE PSYCHOTICS.
217114 04-09
RELATIONSHIP BETWEEN SERUM LITHIUM LEVEL AND CLINICAL RESPONSE ON DEPRESSION TREATED WITH LITHIUM CARBONATE.
217354 04-09
STUDIES OF LITHIUM INDUCED TREMOR BY MEANS OF DIFFERENT MEASUREMENT METHODS.
217453 04-15
STATUS OF LITHIUM PATIENTS AS BLOOD DONORS.
217969 04-15
DOUBLE-BLIND PROCEDURE: AN ASSESSMENT IN A STUDY OF LITHIUM PROPHYLAXIS.
218042 04-16
TREATING DEPRESSION WITH TRANQUILIZERS: WITH DISSENTING VIEW OF LITHIUM CARBONATE THERAPY.
218123 04-09
THE CURRENT STATUS OF LITHIUM IN PSYCHIATRY.
218129 04-09
THE INFLUENCE OF LITHIUM AND CESIUM IONS ON THE EFFECTS OF CATECHOLAMINES AND SEROTONIN INTRODUCED INTO THE HIPPOCAMPUS OF RATS.
218470 04-04
FURTHER REPORT ON PROPHYLACTIC LITHIUM IN RECURRENT AFFECTIVE DISORDERS.
218556 04-09
EXPERIENCE WITH 20 PATIENTS TREATED WITH LITHIUM CARBONATE.
218682 04-09
DOUBLE-BLIND COMPARISON OF LITHIUM CARBONATE AND IMIPRAMINE IN TREATMENT OF DEPRESSION.
218772 04-09
CONDITIONED AVERSION TO MORPHINE WITH LITHIUM CHLORIDE IN MORPHINE-DEPENDENT RATS.
219039 04-04
LITHIUM TOXICITY PRECIPITATED BY DIURETICS.
219353 04-15
WHY DO PATIENTS WITH MANIC-DEPRESSIVE ILLNESS STOP THEIR LITHIUM?
219365 04-09
THE EFFECT OF LITHIUM ON THE CONTENT OF CATECHOLAMINES IN THE BRAIN OF RABBITS AND RATS.
219749 04-03
LITHIUM SALT POISONING IN AN 8-YEAR-OLD CHILD.
219827 04-15
PREVENTIVE USE OF LITHIUM IN ELDERLY PATIENTS.
220434 04-09
MODIFICATIONS BY LITHIUM OF BEHAVIORAL RESPONSES TO METHAMPHETAMINE AND TETRABENAZINE.
221041 04-04
THE EFFECT OF LITHIUM ON URINARY MHPG IN UNIPOLAR AND BIPOLAR DEPRESSED PATIENTS.
221045 04-09
EFFECT OF LITHIUM ON NEUROLEPTIC-INDUCED TARDIVE DYSKINESIA COMPARED WITH PLACEBO IN A DOUBLE-BLIND CROSSOVER TRIAL.
221335 04-15
LITHIUM, CALCIUM, AND PHOSPHATE.
221417 04-15
SIMILARITIES IN THE EFFECTS OF LITHIUM CARBONATE, LITAREX AND LITHIONITE DURETTER: PRELIMINARY STUDY.
221634 04-14
LITHIUM TREATMENT OF SCHIZOPHRENIA: A CONTROLLED EXPERIMENT.
221635 04-08
PHARMACOLOGICAL - CLINICAL INTEREST IN THE STUDY OF 24 HOUR LITHIUM RATE CYCLES.
221667 04-09
LITHIUM RESPONSIVE HYPERALDOSTERONISM IN MANIC PATIENTS.
221718 04-09
HYPOTHYROIDISM DURING LITHIUM TREATMENT: A REVIEW OF 49 CASES.
221988 04-15
LITHIUM IN NONMANIC DEPRESSIVES: ANTIAGGRESSIVE EFFECT AND RED BLOOD CELL LITHIUM VALUES.
222604 04-09
SYMPTOMATIC SINUS NODE ABNORMALITIES FOLLOWING LITHIUM CARBONATE THERAPY.
223120 04-15
LITHIUM AND MAGNESIUM DEPENDENT PROCESSES.
223318 04-09
AFFECTIVE DISORDERS AND LITHIUM ION.
224588 04-09
LITHIUM PROPHYLAXIS: THE MARRIED COUPLES GROUP.
224749 04-09
GENETIC CONTROL OF LITHIUM ION DISTRIBUTION.
224833 04-09
LITHIUM IN THE TREATMENT OF DEPRESSION.
224871 04-09
RELATIONSHIP BETWEEN DOSAGE AND RESPONSE TO LITHIUM PROPHYLAXIS IN RECURRENT DEPRESSION.
224872 04-09
LITHIUM CARBONATE PROPHYLAXIS FAILURE.
224873 04-09
LITHIUM PROPHYLAXIS OF THREE DEPRESSION SUBTYPES.
224874 04-09
CARDIOVASCULAR MALFORMATIONS WITH LITHIUM USE DURING PREGNANCY.
225331 04-15
COGWHEEL RIGIDITY RELATED TO LITHIUM MAINTENANCE.
225334 04-15
LITHIUM CARBONATE IN THE TREATMENT OF TARDIVE DYSKINESIA.
225343 04-15

LITHIUMS
HORMONE INDUCED EFFECTS ON LITHIUMS PHARMACOKINETICS.
221640 04-03

LIVER
EFFECT OF SIMULATED ALTITUDE ON THE DISPOSITION OF CHLORPROMAZINE IN MOUSE BRAIN AND LIVER.
197455 01-05
LIVER FUNCTION IN WORKERS OCCUPATIONALLY DEALING WITH CHLORPROMAZINE AND SOME OTHER COMPOUNDS.
202925 02-13
HYDROXYLATION OF AMPHETAMINE TO P-HYDROXYAMPHETAMINE BY RAT LIVER MICROSOMES.
205433 02-03
COMPARISON OF THE INHIBITORY EFFECTS OF PROPARGYLAMINE AND PARGYLINE ON BRAIN AND LIVER MONOAMINEOXIDASE ACTIVITY.
207857 03-03
THE EFFECT OF CHLORDIAZEPOXIDE HYDROCHLORIDE ON THE ISOLATED PERFUSED RAT LIVER (38786).
217796 04-03
TRANSFORMATION OF DELTA1-TETRAHYDROCANNABINOL (THC) BY RABBIT LIVER MICROSOMES.
217817 04-03

LIVING
TETRAHYDROCANNABINOL INDUCED MANIFESTATIONS OF THE MARIHUANA SYNDROME IN GROUP LIVING MACAQUES.
221340 04-04

LOADING
EFFECT OF COPPER LOADING ON VARIOUS TISSUE ENZYMES AND BRAIN MONOAMINES IN THE RAT.
193577 01-03
COMPARATIVE RESULTS OF A PHARMACOLOGICAL LOADING WITH AMINAZINE AND HALOPERIDOL IN SCHIZOPHRENIC PATIENTS.
201910 02-08
TRYPTOPHAN METABOLISM EXAMINATIONS IN OLIGOPHRENIC CHILDREN. FIRST REPORT: RESULTS OF THE EXCRETION OF KYNURENINE AND XANTHURENIC ACID AFTER TRYPTOPHAN LOADING AND THEIR DEPENDENCE UPON THE SUPPLY.
203645 02-13
THE INHIBITION OF A AND B FORMS OF MAO IN THE PRODUCTION OF A CHARACTERISTIC BEHAVIOURAL SYNDROME IN RATS AFTER L-TRYPTOPHAN LOADING.
217471 04-03

LOBE
COMPARISON OF THE ACTION OF DIAZEPAM AND PHENOBARBITAL USING EEG DERIVED POWER SPECTRA OBTAINED FROM TEMPORAL LOBE EPILEPTICS.
197992 01-13

LOBOTOMIZED
INFLUENCE OF RESERPINE ON ALL-NIGHT SLEEP PATTERN IN NONLOBOTOMIZED AND LOBOTOMIZED CHRONIC SCHIZOPHRENIC PATIENTS.
213530 04-08

LOCAL
ELECTROENCEPHALOGRAPHIC STUDY OF THE LOCAL TRANSPORT OF CENTRAL NERVOUS STIMULANTS INTO THE BRAIN.
202165 02-03

SUPPRESSION OF MOUSE-KILLING AND APOMORPHINE-INDUCED SOCIAL AGGRESSION IN RATS BY LOCAL ANESTHESIA OF THE MYSTACIAL-VIBRISSAE.
206714 03-04

NEUROPHARMACOLOGIC STUDIES OF LOCAL BRAIN FUNCTION.
213601 04-03

CONTRASTING LOCAL EFFECTS OF MAO INHIBITORS ON CAUDATE TREMOR ACTIVITIES.
217669 04-03

BEHAVIORAL EFFECTS OF LOCAL INJECTION OF 6-HYDROXYDOPAMINE IN THE MEDIAL VENTRAL TEGMENTUM IN THE RAT. POSSIBLE ROLE OF THE MESOLIMBIC DOPAMINERGIC SYSTEM.
220946 04-04

LOCALIZATION
IMMUNOLOGICAL LOCALIZATION OF DOPAMINE-BETA-HYDROXYLASE ON THE CHROMAFFIN GRANULE MEMBRANE.
207326 03-03

THE ACTION OF DELTA9-TETRAHYDROCANNABINOL ON CENTRAL CARDIOVASCULAR REGULATION: MECHANISM AND LOCALIZATION.
221669 04-03

LOCI
REACTIVE BRAINSTEM LOCI FOR ELICITING ELECTRODERMAL RESPONSES.
206250 03-03

LOCOMOTOR
MOUSE LOCOMOTOR ACTIVITY: EFFECT OF MORPHINE, NARCOTIC ANTAGONISTS, AND THE INTERACTION OF MORPHINE AND NARCOTIC ANTAGONISTS.
194478 01-04

EFFECT OF INDOLEALKYLAMINE MANIPULATIONS ON LOCOMOTOR ACTIVITY IN RATS.
195087 01-04

ENHANCED LOCOMOTOR ACTIVITY FOLLOWING AMPHETAMINE IN MOUSE-KILLING RATS.
197482 01-04

EFFECTS OF NICOTINE ON SPONTANEOUS LOCOMOTOR ACTIVITY IN RATS HAVING HIGH AND LOW BASAL ACTIVITY LEVELS.
202980 02-04

A COMPARISON OF THE LOCOMOTOR EFFECTS OF 5-HYDROXYTRYPTAMINE AND 5-HYDROXYTRYPTOPHAN ADMINISTERED VIA TWO SYSTEMIC ROUTES.
206086 03-04

RELATIONSHIP BETWEEN THE LATE REFLEX DISCHARGE AND LOCOMOTOR MOVEMENTS IN ACUTE SPINAL CATS AND RABBITS WITH DOPA.
209728 03-03

THE EFFECTS OF PSYCHOMOTOR STIMULANTS ON STEREOTYPY AND LOCOMOTOR ACTIVITY IN SOCIALLY DEPRIVED AND CONTROL RATS.
210666 03-04

EFFECTS OF A DECARBOXYLASE INHIBITOR ON THE DOPA AND 5-HTP INDUCED CHANGES IN THE LOCOMOTOR LIKE DISCHARGE PATTERN OF RABBIT HIND LIMB NERVES.
210740 03-03

CHANGED EATING AND LOCOMOTOR BEHAVIOUR IN THE RAT AFTER 6-HYDROXYDOPAMINE LESIONS TO THE SUBSTANTIA-NIGRA.
210763 03-04

EFFECTS OF NALORPHINE ON AVOIDANCE BEHAVIOR AND LOCOMOTOR ACTIVITY IN THE RAT.
210783 03-04

COMPARISON OF THE EFFECTS OF D-AMPHETAMINE AND L-AMPHETAMINE IN REVERSING DEPRESSION OF MOUSE LOCOMOTOR ACTIVITY CAUSED BY RESERPINE.
210869 03-03

STRUCTURE-ACTIVITY RELATIONSHIPS BETWEEN META-SUBSTITUTED N-ETHYLAMPHETAMINES AND LOCOMOTOR ACTIVITY IN MICE.
210886 03-04

THE EFFECT OF DOPAMINE AND NORADRENALINE ANTAGONISTS ON AMPHETAMINE-INDUCED LOCOMOTOR ACTIVITY IN MICE AND RATS.
210894 03-04

COMPARATIVE TIME-DEPENDENT CHANGES IN SENSITIVITY TO LOCOMOTOR EFFECTS OF D-AMPHETAMINE IN MICE WITH CAUDATE, HIPPOCAMPAL OR FRONTAL CORTICAL LESIONS.
210926 03-03

THE EFFECTS OF PSYCHOMOTOR STIMULATION ON STEREOTYPY AND LOCOMOTOR ACTIVITY IN SOCIALLY DEPRIVED AND CONTROL RATS.
213433 04-03

INHIBITION OF D-AMPHETAMINE INDUCED LOCOMOTOR ACTIVITY BY INJECTION OF HALOPERIDOL INTO THE NUCLEUS-ACCUMBENS OF THE RAT.
217461 04-04

EFFECTS OF ANTAGONISTS UPON LOCOMOTOR STIMULATION INDUCED BY INJECTION OF DOPAMINE AND NORADRENALINE INTO THE NUCLEUS-ACCUMBENS OF NIALAMIDE PRETREATED RATS.
217475 04-04

POTENTIATION OF LOCOMOTOR ACTIVITY AND MODIFICATION OF STEREOTYPY BY STARVATION IN APOMORPHINE TREATED RATS.
217675 04-04

DIFFERENCES BETWEEN (+)- AND (-) AMPHETAMINE IN EFFECTS ON LOCOMOTOR ACTIVITY AND L-DOPA POTENTIATING ACTION IN MICE.
217835 04-04

BETA-PHENYLETHYLAMINE AND LOCOMOTOR ACTIVITY IN MICE: INTERACTION WITH CATECHOLAMINERGIC NEURONES AND RECEPTORS.
221742 04-03

IS THERE A CATECHOLAMINE SEROTONIN INTERACTION IN THE CONTROL OF LOCOMOTOR ACTIVITY?
222816 04-04

ASCENDING CATECHOLAMINE PATHWAYS AND AMPHETAMINE-INDUCED LOCOMOTOR ACTIVITY: IMPORTANCE OF DOPAMINE AND APPARENT NONINVOLVEMENT OF NOREPINEPHRINE.
223054 04-03

RELATIONSHIPS BETWEEN THE STRUCTURE AND THE CHRONOTROPIC, LOCOMOTOR STIMULANT AND REINFORCING ACTIONS OF SEVERAL FENFLURAMINE ANALOGS. (PH.D. DISSERTATION).
223563 04-04

NEONATAL LOCOMOTOR AND LONG-TERM BEHAVIORAL EFFECTS OF D-AMPHETAMINE IN THE RAT.
225077 04-04

LOCUS
LOCUS OF CENTRAL DEPRESSANT ACTION OF FLUNITRAZEPAM.
199811 02-03

LOCUS-COERULEUS
ONTOGENY OF THE INDUCTION OF TYROSINE-HYDROXYLASE BY RESERPINE IN THE SUPERIOR CERVICAL GANGLION, NUCLEUS LOCUS-COERULEUS AND ADRENAL GLAND.
210670 03-03

NORADRENALINE MEDIATED INHIBITION BY LOCUS-COERULEUS OF SPINAL TRIGEMINAL NEURONS.
210703 03-03

DETAILED NORADRENALINE PATHWAYS OF LOCUS-COERULEUS NEURON TO THE CEREBRAL CORTEX WITH THE USE OF 5-HYDROXYDOPA.
210803 03-03

LOFEPRAMIN
CLINICAL TRIAL OF LOFEPRAMIN VERSUS IMIPRAMINE.
217450 04-09

LONG
TREATMENT OF SCHIZOPHRENIA BY THE ADMINISTRATION OF A SMALL DOSE OF FORIT FOR COMPARATIVELY LONG PERIODS OF TIME.
194476 01-08

LONG-ACTING
ANTAGONISM OF MORPHINE BY LONG-ACTING NARCOTIC ANTAGONISTS.
200055 02-04

LONG-ACTING NEUROLEPTICS OF PERATHIEPINE GROUP: VUFB-9977 (OXYPROTHEPINE DECANOATE).
205583 02-03

MAINTENANCE TREATMENT OF SCHIZOPHRENIA WITH LONG-ACTING FLUPHENAZINE.
205585 02-08

EXPERIENCE WITH LONG-ACTING PHENOTHIAZINES IN A PSYCHIATRIC HOSPITAL.
208921 03-17

THERAPY AND LONG-ACTING NEUROLEPTICS.
212774 03-14

PIPOTHIAZINE PALMITATE: AN EVALUATION OF A NEW LONG-ACTING INTRAMUSCULAR ANTIPSYCHOTIC AGENT IN SEVERELY ILL SCHIZOPHRENIC PATIENTS.
216188 04-08

DEPRESSIONS AND ANTIDEPRESSANTS DURING TREATMENT WITH LONG-ACTING NEUROLEPTIC DRUGS: SIDE-EFFECTS AND THE EMERGENT METATHERAPEUTIC SYNDROME.
219694 04-15

A MULTICENTER MULTIDIMENSIONAL STUDY OF SOME NEW LONG-ACTING NEUROLEPTIC DRUGS.
220858 04-07

LONG-ACTING DRUGS IN PSYCHIATRIC TREATMENT: LACUNAE AND NEEDS.
221672 04-17

THE USE OF AN ORGAL LONG-ACTING ANTIPSYCHOTIC AGENT, PENFLURIDOL, IN SCHIZOPHRENIA.
223165 04-08

TIME TO EVALUATE LONG-ACTING NEUROLEPTICS?
224417 04-08

LONG-EVANS
PHARMACOLOGICAL MODULATION OF PHOTICALLY EVOKED AFTERDISCHARGE PATTERNS IN HOODED LONG-EVANS RATS.
201409 02-03

LONG-LASTING
OUTPATIENT TREATMENT OF SCHIZOPHRENIA BY A LONG-LASTING STRONG TRANQUILIZER: USE OF FLUPHENAZINE ENANTHATE.
194460 01-08
LONG-LASTING DEPLETION OF BRAIN SEROTONIN BY 4-CHLOROAMPHETAMINE IN GUINEA-PIGS.
203580 02-03
LONG-LASTING REDUCTION OF BRAIN 5-HYDROXYTRYPTAMINE CONCENTRATION BY 3-CHLOROAMPHETAMINE AND 4-CHLOROAMPHETAMINE IN IPRINDOLE TREATED RATS.
217879 04-03
LONG-LASTING CHANGES IN CEREBRAL NEURONS INDUCED BY DRUGS.
218957 04-03
LONG-LASTING EFFECTS OF PRENATAL 2,4,5 TRICHLOROPHENOXYACETIC ACID ON OPEN-FIELD BEHAVIOR IN RATS: PRE- AND POSTNATAL MEDIATION.
223044 04-04

LONG-TERM
LONG-TERM LITHIUM ADMINISTRATION TO RATS. LITHIUM AND SODIUM DOSAGE AND ADMINISTRATION, AVOIDANCE OF INTOXICATION, POLYURIC CONTROL RATS.
195042 01-03
AN EXPLORATORY STUDY OF THE LONG-TERM EFFECTS OF DRUG USE IN HYPERKINESIS. (PH.D. DISSERTATION).
195882 01-11
INVOLVEMENT OF CYCLIC NUCLEOTIDES IN THE LONG-TERM INDUCTION OF TYROSINE-HYDROXYLASE. (UNPUBLISHED PAPER).
196590 01-03
LONG-TERM EFFECTS OF N-HYDROXY-4-CHLOROAMPHETAMINE ON THE LEVEL AND ACCUMULATION OF 5-HYDROXYTRYPTAMINE IN THE RAT BRAIN.
197869 01-03
LONG-TERM CORRELATES OF DRUG USE IN HYPERKINESIS.
198086 02-07
NICOTINE AND CAFFEINE: DISRUPTION OF THE LONG-TERM STORE MEMORY AND PROACTIVE FACILITATION OF LEARNING IN MICE.
198222 02-04
LONG-TERM TREATMENT OF PSYCHIATRIC PATIENTS WITH CLOPENTHIXOL: ANALYSIS OF LABORATORY TESTS WITH A VIEW TO LONG-TERM THERAPY.
199989 02-14
THE NEURON ULTRASTRUCTURE IN SOME BRAIN AREAS DURING A LONG-TERM ADMINISTRATION OF AMINAZINE AND STELAZINE.
200021 02-03
EFFECT OF LONG-TERM LITHIUM TREATMENT ON BRAIN FUMARASE ACTIVITY.
200751 02-03
CHANGES IN THE PSYCHODYNAMICS OF MANIC-DEPRESSIVES THROUGH LONG-TERM ADMINISTRATION OF LITHIUM SALTS.
203601 02-14
EFFECT OF AMITRIPTYLINE IN LONG-TERM AUTOEXPERIMENTS: PSYCHOPHYSIOLOGIC STUDY AND DURATION OF EXCRETION.
204402 02-13
SIDE-EFFECTS OF METHYLPERONE IN LONG-TERM THERAPY UP TO 8 YEARS.
204406 02-15
FURTHER OBSERVATIONS ON AUTOMATON LIKE EXISTENCE UNDER LONG-TERM LITHIUM THERAPY.
204410 02-15
LONG-TERM TRIAL OF FLUPHENAZINE DECANOATE AND FLUPENTHIXOL DECANOATE FOR CATALEPTIC ACTIVITY AND EFFECT ON MOTOR ACTIVITY IN RATS.
206787 03-04
CLOZAPINE IN LONG-TERM THERAPY OF CHRONIC SCHIZOPHRENIA.
206975 03-08
LONG-TERM AND SHORT-TERM EFFECTS OF SULPIRIDE ON SLEEP EEG IN MAN.
206977 03-14
CLINICAL STUDY ON SULPIRIDE IN LONG-TERM HOSPITALIZED SCHIZOPHRENIC PATIENTS.
206978 03-08
SURVEY ON AND EVALUATION OF THE CONTRIBUTIONS OF METHODOLOGICAL ASPECTS IN THE INVESTIGATION OF LONG-TERM PSYCHOPHARMACOLOGICAL DRUG ACTION.
206984 03-16
RENAL TUBULAR FUNCTION IN PATIENTS ON LONG-TERM LITHIUM THERAPY.
207043 03-13
EFFECT OF LONG-TERM TREATMENT OF HYPERACTIVE CHILDREN WITH METHYLPHENIDATE.
207580 03-11
LONG-TERM EFFECTS OF P-CHLOROAMPHETAMINE AND RELATED DRUGS ON CENTRAL SEROTONERGIC MECHANISMS.
208553 03-03
ACCUMULATION OF LITHIUM IN THE PARTICULATE FRACTION OF RAT BRAIN FOLLOWING ITS LONG-TERM ADMINISTRATION.
210782 03-03
SOME EVIDENCE FOR LONG-TERM MEMORY RETENTION BY OROTIC ACID IN RATS BAR PRESSING FOR WATER.
210790 03-04
EFFECTS OF WATER DEPRIVATION IN RATS WITH POLYDIPSIA AND POLYURIA DUE TO LONG-TERM ADMINISTRATION OF LITHIUM.
210833 03-05
THE LONG-TERM MAINTENANCE TREATMENT OF SCHIZOPHRENIC OUTPATIENTS WITH DEPOT FLUPENTHIXOL.
212491 03-08
ON THE PHYSIOLOGICAL MECHANISMS OF THE INFLUENCE OF PHENAMINE AND MICROPOLARIZATION ON LONG-TERM MEMORY PROCESSES.
213491 04-04
ASPECTS OF LONG-TERM TREATMENT WITH NEUROLEPTICS: HISTORICAL AND LITERATURE REVIEW -- PERSONAL EXPERIENCE WITH FLUSPIRILENE AND PENFLURIDOL.
215059 04-14
LONG-TERM BEHAVIOURAL EFFECTS OF DIAZEPAM AND ACTH, ADMINISTERED EARLY IN LIFE.
215067 04-04
TRIAL INTERRUPTION OF ANTIPARKINSONIANS IN LONG-TERM NEUROLEPTIC TREATMENT.
216767 04-15
6-HYDROXYDOPA DURING DEVELOPMENT OF CENTRAL ADRENERGIC NEURONS PRODUCES DIFFERENT LONG-TERM CHANGES IN RAT BRAIN NORADRENALINE.
217867 04-03
AN APPLICATION OF LONG-TERM FREQUENCY ANALYSIS IN MEASURING DRUG SPECIFIC ALTERATIONS IN THE EEG OF THE CAT.
218190 04-03
RED CELL FOLATE AND MACROCYTOSIS DURING LONG-TERM ANTICONVULSANT THERAPY IN NONANAEMIC MENTALLY RETARDED EPILEPTICS.
218553 04-11
THE EFFECT OF LONG-TERM PHENOTHIAZINE THERAPY ON PLASMA PROLACTIN.
223777 04-15
NEONATAL LOCOMOTOR AND LONG-TERM BEHAVIORAL EFFECTS OF D-AMPHETAMINE IN THE RAT.
225077 04-04

LONGITUDINAL
EXPERIMENTAL PSYCHOLOGIC AND PSYCHOPHYSIOLOGIC LONGITUDINAL PROFILE STUDIES ON DEPRESSIVE PATIENTS UNDER THYMOLEPTIC MEDICATION.
204413 02-15
LONGITUDINAL TREND IN PRESCRIBING PSYCHOTROPIC DRUGS.
205633 03-17
LONGITUDINAL STUDY OF THE EFFECTS OF LITHIUM CARBONATE ON THE SLEEP OF HOSPITALIZED DEPRESSED PATIENTS.
206333 03-09
LONGITUDINAL PROFILES OF THE EFFECTS OF PSYCHOTROPIC DRUGS: RESULTS OF AN ANIMAL STUDY.
206970 03-05
LONGITUDINAL PROFILES OF THE EFFECTS OF PSYCHOTROPIC DRUGS FROM CLINICOMETHODOLOGICAL VIEWPOINTS.
206971 03-16
LONGITUDINAL STUDIES ON THE METABOLITE PATTERN OF PERAZINE AND RELATED PHENOTHIAZINES IN HUMANS AND ANIMALS.
206976 03-13
ARBITERS AND SELF-RATING OF MOMENTARY MOOD IN PSYCHOPHARMACOLOGICAL LONGITUDINAL STUDIES.
206980 03-16
IMIPRAMINE-INDUCED HEART BLOCK: A LONGITUDINAL CASE STUDY.
215014 04-13

LOPERAMIDE
EFFECT OF LOPERAMIDE, HALOPERIDOL AND METHADONE IN RATS TRAINED TO DISCRIMINATE MORPHINE FROM SALINE.
225568 04-04

LOPRAMINE
CLINICAL EVALUATION OF NEW ANTIDEPRESSANT, LOPRAMINE.
196443 01-14
APPLICATION OF LOPRAMINE (DB-2182) FOR THE TREATMENT OF DEPRESSIVE STATE.
209395 03-11

LORAZEPAM
A CONTROLLED EVALUATION OF LORAZEPAM AND DIAZEPAM IN ANXIETY NEUROSIS.
194719 01-10
LORAZEPAM IN ANXIETY NEUROSIS.
195621 01-10
CLINICAL ASSESSMENT OF LORAZEPAM IN ANXIETY: A DOUBLE-BLIND STUDY.
209485 03-10
RESEARCH ON PSYCHIATRIC INDICATIONS OF A POWERFUL ANXIOLYTIC, LORAZEPAM.
210088 03-14
LORAZEPAM IN THE MANAGEMENT OF GASTROINTESTINAL NEUROSES.
215061 04-10

LORAZEPAM IN ANXIETY: A CONTROLLED STUDY.
216462 04-10

TREATMENT OF ANXIETY BY LORAZEPAM.
224393 04-09

EXPERIENCE OF USING LORAZEPAM, A NEW TRANQUILIZER.
224394 04-11

EXPERIENCE OF USING LORAZEPAM (WY-4036) IN PSYCHIATRY.
224395 04-11

LOSER

GENETICALLY SELECTED WINNER AND LOSER RATS IN THE TUNNEL COMPETITION: INFLUENCE OF APOMORPHINE AND DOPA.
217829 04-04

LOSS

LITHIUM INDUCED LOSS OF BODY SODIUM AND THE DEVELOPMENT OF SEVERE INTOXICATION IN RATS.
199623 02-03

THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL PRETREATMENT ON KETAMINE, THIOPENTAL OR CT-1341 -- INDUCED LOSS OF RIGHTING REFLEX IN MICE.
210878 03-02

LOSS OF ACTIVE AVOIDANCE RESPONDING AFTER LATERAL HYPOTHALAMIC INJECTIONS OF 6-HYDROXYDOPAMINE.
215704 04-04

LOSS OF BODY WEIGHT AS A PREDICTOR OF RESERPINE INDUCED AMINE DEPLETION.
217661 04-03

LOST

THE ENGRAM, LOST AND FOUND. (PH.D. DISSERTATION).
201125 02-04

LOXAPINE

NEUROPHARMACOLOGICAL FINDINGS AFTER CHRONIC ADMINISTRATION OF HALOPERIDOL, LOXAPINE AND CLOZAPINE.
206972 03-03

METABOLISM OF DOPAMINE AND NOREPINEPHRINE IN RAT BRAIN AFTER SINGLE AND REPEATED ADMINISTRATION OF HALOPERIDOL, LOXAPINE AND CLOZAPINE.
206973 03-03

EFFECTIVENESS OF LOXAPINE SUCCINATE IN ACUTE SCHIZOPHRENIA: A COMPARATIVE STUDY WITH THIOTHIXENE.
209484 03-08

NEUROLEPTIC-INDUCED HYPERSENSITIVITY OF STRIATAL DOPAMINE RECEPTORS IN THE RAT AS A MODEL OF TARDIVE DYSKINESIAS. EFFECTS OF CLOZAPINE, HALOPERIDOL, LOXAPINE AND CHLORPROMAZINE.
217462 04-03

LOXAPINE IN NEWLY ADMITTED CHRONIC SCHIZOPHRENIC PATIENTS.
217810 04-08

A STATISTICAL ANALYSIS OF THE COMPARATIVE DOUBLE-BLIND STUDY OF THE ACTIVITY OF LOXAPINE AND THIORIDAZINE.
221671 04-11

LSD

INEFFECTIVENESS OF LYSERGIC ACID DIETHYL AMIDE 25 (LSD) ON ALTERING NA-K CURRENTS IN SQUID GIANT AXON.
194927 01-03

THE EFFECTS OF LSD, PSILOCYBIN, HARMALINE AND AMPHETAMINE ON THE BODY TEMPERATURE OF P-CHLOROPHENYLALANINE PRETREATED RATS.
197484 01-03

STUDIES OF TRYPTAMINE AND LYSERGIC ACID DIETHYLAMIDE (LSD) ON CUTANEOUS C-FIBER AND POLYSYNAPTIC REFLEXES IN THE CAT.
197814 01-03

THE BIOCHEMICAL PHARMACOLOGY OF ABUSED DRUGS: I. AMPHETAMINES, COCAINE, AND LSD.
198028 01-12

STUDIES ON THE IN VITRO METABOLISM OF COMPOUNDS RELATED TO LYSERGIC ACID DIETHYLAMIDE (LSD).
198608 02-01

LSD TREATMENT OF PIERIS-BRASSICAE AND CONSEQUENCES ON THE PROGENY.
199425 02-04

LSD AS AN AGONIST OF DOPAMINE RECEPTORS IN THE STRIATUM.
204183 02-03

LSD AS AN AGONIST AND ANTAGONIST AT CENTRAL DOPAMINE RECEPTORS.
204184 02-03

DIPHENYLHYDANTOIN IN THE TREATMENT OF LSD FLASHBACKS: A CASE STUDY.
205766 03-12

THE EFFECT OF LSD, PSILOCYBIN, HARMALINE AND AMPHETAMINE ON THE BODY TEMPERATURE OF P-CHLOROPHENYLALANINE PRETREATED RABBITS.
210920 03-05

LSD, PSYCHOTOGENIC PROCEDURES, AND BRAIN NEUROHUMORS.
213606 04-03

THE EFFECT OF LSD AND 2-BROMOLSD ON THE DOPA ACCUMULATION AFTER CENTRAL AND PERIPHERAL DECARBOXYLASE INHIBITION.
217674 04-03

DISCRIMINATIVE CONTROL OF BEHAVIOR BY ELECTRICAL STIMULATION OF THE DORSAL RAPHE NUCLEUS: GENERALIZATION TO LYSERGIC ACID DIETHYLAMIDE (LSD).
217821 04-12

EFFECTS OF SINGLE AND MULTIPLE DOSE LSD ON ENDOGENOUS LEVELS OF BRAIN TYROSINE-HYDROXYLASE AND CATECHOLAMINES.
221044 04-12

SOME PECULIARITIES OF THE NEURON ULTRASTRUCTURE IN THE BRAIN-CORTEX MOTOR AREA UNDER THE INFLUENCE OF LYSERGIC ACID DIETHYLAMIDE (LSD) AND HALOPERIDOL.
222890 04-03

LSD-25

EFFECTS OF LSD-25 ON PSYCHOTHERAPEUTIC COMMUNICATION.
198092 02-10

HYPERSENSITIVITY TO LYSERGIC ACID DIETHYLAMIDE (LSD-25) AND PSILOCYBIN IN ESSENTIAL HEADACHE.
211108 03-12

THE RELATION BETWEEN CEREBRAL SEROTONIN LEVELS AND CONDITIONED BEHAVIOUR IN THE RAT FOLLOWING THE ADMINISTRATION OF LSD-25 AND UML.
225564 04-04

LUDIOMIL

DOES MAPROTILINE (LUDIOMIL) INFLUENCE SEROTONIN UPTAKE AND FREE TRYPTOPHAN CONCENTRATION IN HUMAN PLASMA
192943 01-13

A MULTINATIONAL, DOUBLE-BLIND TRIAL WITH A NEW ANTIDEPRESSANT MAPROTILINE (LUDIOMIL) AND AMITRIPTYLINE.
197031 01-09

A COMPARISON BETWEEN MAPROTILINE (LUDIOMIL) AND AMITRIPTYLINE IN THE TREATMENT OF DEPRESSIVE REACTION IN GENERAL PRACTICE.
215058 04-14

THE PHARMACOKINETIC PROPERTIES OF MAPROTILINE (LUDIOMIL) IN MAN.
221648 04-13

CONTINENTAL HOSPITAL STUDIES WITH MAPROTILINE (LUDIOMIL).
221651 04-09

DOUBLE-BLIND COMPARISON OF MAPROTILINE (LUDIOMIL) WITH AMITRIPTYLINE IN THE TREATMENT OF DEPRESSIVE ILLNESS.
221652 04-09

A DOUBLE-BLIND COMPARATIVE CLINICAL TRIAL OF MAPROTILINE (LUDIOMIL) AND AMITRIPTYLINE.
221653 04-09

A CONTROLLED COMPARISON OF MAPROTILINE (LUDIOMIL) WITH IMIPRAMINE AVOIDING OBSERVER BIAS.
221654 04-09

A COMPARISON BETWEEN MAPROTILINE (LUDIOMIL) AND IMIPRAMINE IN THE TREATMENT OF DEPRESSIVE ILLNESS IN THE ELDERLY.
221655 04-09

A COMPARISON OF MAPROTILINE (LUDIOMIL) AND PLACEBO IN THE TREATMENT OF DEPRESSION.
221656 04-09

A CLINICAL TRIAL OF MAPROTILINE (LUDIOMIL) IN THE TREATMENT OF DEPRESSIVE PATIENTS IN GENERAL PRACTICE AND THE PSYCHIATRIC CLINIC.
221657 04-09

A DOUBLE-BLIND GENERAL PRACTICE TRIAL OF MAPROTILINE (LUDIOMIL) AGAINST AMITRIPTYLINE IN THE TREATMENT OF REACTIVE DEPRESSION.
221658 04-09

ONCE DAILY DOSAGE WITH MAPROTILINE (LUDIOMIL).
221659 04-09

ONCE DAILY DOSAGE STUDY WITH MAPROTILINE (LUDIOMIL).
221660 04-09

AN INTERIM REPORT OF A DOUBLE-BLIND STUDY COMPARING A ONCE DAILY DOSAGE OF MAPROTILINE (LUDIOMIL) WITH AMITRIPTYLINE THRICE DAILY.
221661 04-09

A COMPARISON BETWEEN DAILY AND NIGHTLY DOSE REGIMEN OF AMITRIPTYLINE AND MAPROTILINE (LUDIOMIL) IN THE TREATMENT OF REACTIVE DEPRESSION IN GENERAL PRACTICE.
221662 04-09

MAPROTILINE (LUDIOMIL): SIDE-EFFECTS AND OVERDOSAGE.
221663 04-15

A CONTROLLED STUDY OF A TETRACYCLIC ANTIDEPRESSANT -- MAPROTILINE (LUDIOMIL).
224486 04-09

LUMBAR

LUMBAR CSF 5-HYDROXYINDOLEACETIC ACID AND HOMOVANILLIC ACID IN AFFECTIVE SYNDROMES.
202248 02-09

MASS FRAGMENTOMETRIC DETERMINATION OF HOMOVANILLIC ACID IN LUMBAR CEREBROSPINAL FLUID OF SCHIZOPHRENIC PATIENTS DURING TREATMENT WITH ANTIPSYCHOTIC DRUGS.
207295 03-08

MONOAMINE METABOLITES IN LUMBAR CSF: THE QUESTION OF THEIR ORIGIN IN RELATION TO CLINICAL STUDIES.
210796 03-03

LUPUS-ERYTHEMATOSUS
PSYCHOSIS IN SYSTEMIC LUPUS-ERYTHEMATOSUS.
196088 01-08

LYMPHOMA
AMPHETAMINES AND MALIGNANT LYMPHOMA.
193035 01-17

LYOGEN
RESULTS OF THERAPY WITH LYOGEN DEPOT IN SCHIZOPHRENIC ILLNESS.
208622 03-08

LYSERGIC
THE EFFECTS OF DEXTROAMPHETAMINE, DIMETHYLTRYPTAMINE, LYSERGIC ACID DIETHYLAMIDE AND TETRAHYDROCANNABINOL UPON PREGNANCY AND THE OFFSPRING. (PH.D. DISSERTATION).
194568 01-04

INEFFECTIVENESS OF LYSERGIC ACID DIETHYL AMIDE 25 (LSD) ON ALTERING NA-K CURRENTS IN SQUID GIANT AXON.
194927 01-03

STUDIES OF TRYPTAMINE AND LYSERGIC ACID DIETHYLAMIDE (LSD) ON CUTANEOUS C-FIBER AND POLYSYNAPTIC REFLEXES IN THE CAT.
197814 01-03

STUDIES ON THE IN VITRO METABOLISM OF COMPOUNDS RELATED TO LYSERGIC ACID DIETHYLAMIDE (LSD).
198608 02-01

CHRONIC LYSERGIC ACID DIETHYLAMIDE ADMINISTRATION AND SEROTONIN TURNOVER IN VARIOUS REGIONS OF RAT BRAIN.
199783 02-03

THE EFFECT OF LYSERGIC ACID DIETHYLAMIDE ON SERUM CREATINE KINASE LEVELS.
206361 03-12

THE INFLUENCE OF CHLORPROMAZINE ACTION ON EXPERIMENTAL PSYCHOSIS CAUSED BY LYSERGIC ACID DIETHYLAMIDE.
206439 03-04

HYPERSENSITIVITY TO LYSERGIC ACID DIETHYLAMIDE (LSD-25) AND PSILOCYBIN IN ESSENTIAL HEADACHE.
211108 03-12

LYSERGIC ACID DIETHYLAMIDE AFFECTS BLOOD FLOW TO SPECIFIC AREAS OF THE CONSCIOUS RAT BRAIN.
215161 04-03

DISCRIMINATIVE CONTROL OF BEHAVIOR BY ELECTRICAL STIMULATION OF THE DORSAL RAPHE NUCLEUS: GENERALIZATION TO LYSERGIC ACID DIETHYLAMIDE (LSD).
217821 04-12

LYSERGIC ACID DIETHYLAMIDE: EFFECT ON HISTONE ACETYLATION IN RABBIT BRAIN.
220314 04-03

SOME PECULIARITIES OF THE NEURON ULTRASTRUCTURE IN THE BRAIN-CORTEX MOTOR AREA UNDER THE INFLUENCE OF LYSERGIC ACID DIETHYLAMIDE (LSD) AND HALOPERIDOL.
222890 04-03

LYSERGIC ACID DIETHYLAMIDE: EVIDENCE FOR STIMULATION OF CEREBRAL DOPAMINE RECEPTORS.
223174 04-03

INTERACTIONS BETWEEN LYSERGIC ACID DIETHYLAMIDE AND DOPAMINE SENSITIVE ADENYLCYCLASE SYSTEMS IN RAT BRAIN.
223175 04-03

LYSINE
INHIBITORY EFFECT OF NEONATAL ESTROGENIZATION ON THE INCORPORATION OF (3H)LYSINE IN THE PURKINJE CELLS OF THE ADULT MALE AND FEMALE RAT.
213478 04-03

M-TYROSINE
THE FORMATION IN VIVO OF 3,4 DIHYDROXYPHENYLALANINE (DOPA) FROM 3-HYDROXY-DL-PHENYLALANINE (M-TYROSINE).
198015 01-03

M-7
INHIBITION OF THE SYMPATHETIC NERVOUS SYSTEM BY 5,6 DIHYDROXY-2-DIMETHYLAMINOTETRALIN (M-7), APOMORPHINE AND DOPAMINE.
210888 03-03

MACACA-MULATTA
INHIBITORY AND DISINHIBITORY EFFECTS OF NITRAZEPAM, DIAZEPAM AND FLURAZEPAM HYDROCHLORIDE ON DELAYED MATCHING BEHAVIOUR IN MONKEYS (MACACA-MULATTA).
199957 02-04

AN OBSERVATIONAL STUDY OF HALLUCINOGEN INDUCED BEHAVIOR IN UNRESTRAINED MACACA-MULATTA.
210739 03-04

MACAQUES
TETRAHYDROCANNABINOL INDUCED MANIFESTATIONS OF THE MARIHUANA SYNDROME IN GROUP LIVING MACAQUES.
221340 04-04

MACROCYTOSIS
RED CELL FOLATE AND MACROCYTOSIS DURING LONG-TERM ANTICONVULSANT THERAPY IN NONANAEMIC MENTALLY RETARDED EPILEPTICS.
218553 04-11

MACROMOLECULES
REACTION OF CATIONIC GROUPS OF CHLORPROMAZINE WITH ANIONIC MACROMOLECULES: COMPLEXES WITH DNA, RNA, HYALURONIC ACID AND HEPARIN.
199897 02-03

MAGNESIUM
PHARMACOLOGY OF MAGNESIUM GLUTAMATE HYDROBROMIDE (PS-042), A NEW TRANQUILIZER: THIRD PART, PSYCHOPHARMACOLOGICAL STUDIES.
196444 01-02

EFFECT OF LITHIUM ON MAGNESIUM DEPENDENT ENZYMES.
209351 03-03

LITHIUM AND MAGNESIUM DEPENDENT PROCESSES.
223318 04-09

MAINTAIN
FENFLURAMINE: AMPHETAMINE CONGENER THAT FAILS TO MAINTAIN DRUG-TAKING BEHAVIOR IN THE RHESUS MONKEY.
193137 01-04

MAINTAINED
DIFFERENTIAL EFFECTS OF CHLORDIAZEPOXIDE AND D-AMPHETAMINE ON RESPONDING MAINTAINED BY A DRL SCHEDULE OF REINFORCEMENT.
195433 01-04

DRUG EFFECTS ON BEHAVIOR MAINTAINED BY AVERSIVE EVENTS.
213619 04-04

MAINTENANCE
AFFECTIVE DISEASE HEALTH MAINTENANCE ORGANIZATION: PATTERNS OF LITHIUM RESPONSE.
194746 01-09

GROUP THERAPY AND MAINTENANCE TREATMENT OF SCHIZOPHRENICS.
194860 01-08

PENFLURIDOL (R-16341) AS A MAINTENANCE THERAPY IN CHRONIC PSYCHOTIC PATIENTS: A DOUBLE-BLIND CLINICAL EVALUATION.
197033 01-09

A DOUBLE-BLIND CLINICAL EVALUATION OF PENFLURIDOL (R-16341) AS A MAINTENANCE THERAPY IN SCHIZOPHRENIA.
199993 02-08

MAINTENANCE TREATMENT OF CHRONIC SCHIZOPHRENIA WITH NEUROLEPTIC DRUGS.
200636 02-08

MAINTENANCE TREATMENT OF SCHIZOPHRENIA WITH LONG-ACTING FLUPHENAZINE.
205585 02-08

CLOZAPINE IN THE MAINTENANCE THERAPY OF SCHIZOPHRENIA.
205618 03-08

RELATIVE SAFETY OF AMITRIPTYLINE IN MAINTENANCE TREATMENT OF DEPRESSION.
209438 03-15

PLASMA LEVELS OF A NEW PELLETIZED FORM OF AMITRIPTYLINE FOR MAINTENANCE THERAPY.
209789 03-13

MAINTENANCE DOXEPIN (SINEQUAN) THERAPY FOR DEPRESSIVE ILLNESS.
209901 03-09

THE LONG-TERM MAINTENANCE TREATMENT OF SCHIZOPHRENIC OUTPATIENTS WITH DEPOT FLUPENTHIXOL.
212491 03-08

DRUG SEEKING BEHAVIOR DURING METHADONE MAINTENANCE.
217541 04-04

EFFECTS OF MAINTENANCE AMITRIPTYLINE AND PSYCHOTHERAPY ON SYMPTOMS OF DEPRESSION.
218041 04-09

OBSERVATIONS ON THE DOSE REGIME OF FLUPHENAZINE DECANOATE IN MAINTENANCE THERAPY OF SCHIZOPHRENIA.
222602 04-17

DEPRESSED WOMEN ONE YEAR AFTER MAINTENANCE THERAPY.
224766 04-09

COGWHEEL RIGIDITY RELATED TO LITHIUM MAINTENANCE.
225334 04-15

MAJEPTIL
A CLINICAL TRIAL WITH THIOPROPERAZINE (MAJEPTIL M & B) -- A COMPARISON WITH CHLORPROMAZINE.
194311 01-11

THE EFFECT OF THE PSYCHOTROPIC AGENTS (CHLORPROMAZINE, MAJEPTIL, TRICEDIL) ON PROTEIN SYNTHESIS IN VARIOUS PORTIONS OF THE RAT BRAIN.
223063 04-03

MAJOR
MAJOR OR MINOR TRANQUILIZERS FOR RELIEF OF COMMON SYMPTOMS OF PSYCHONEUROSIS
193412 01-10

RATIONAL USE OF PSYCHOTROPIC DRUGS. III. MAJOR TRANQUILIZERS.
198823 02-17

SPECTROFLUORODENSITOMETRIC DETERMINATION OF FLURAZEPAM AND ITS MAJOR METABOLITES IN BLOOD.
200737 02-16

PSYCHOPHARMACOLOGY IN THE AGED: USE OF MAJOR PSYCHOTROPIC MEDICATIONS IN TREATMENT OF THE ELDERLY: CASE EXAMPLES.
208575 03-11

TREATMENT OF HUMAN AGGRESSION WITH MAJOR TRANQUILIZERS, ANTIDEPRESSANTS, AND NEWER PSYCHOTROPIC DRUGS.
209127 03-11

TESTING ANATENSOL DECANOATE, A MAJOR NEUROLEPTIC, AT THE IXELLES GUIDANCE CENTER.
212165 03-09

RATE DEPENDENT EFFECTS OF DRUGS. II. EFFECTS OF SOME MAJOR TRANQUILIZERS ON MULTIPLE FIXED-RATIO, FIXED-INTERVAL SCHEDULE PERFORMANCE.
217458 04-04

THE INFLUENCE OF DESIPRAMINE AND AMITRIPTYLINE ON THE ACCUMULATION OF (3H)NORADRENALINE AND ITS TWO MAJOR METABOLITES FORMED FROM (3H)TYROSINE IN THE RAT BRAIN.
217966 04-03

MALE

EFFECT OF ACUTE AND CHRONIC DIELDRIN EXPOSURE ON BRAIN BIOGENIC AMINES OF MALE AND FEMALE RATS.
193428 01-03

EFFECTS OF L-DOPA ON THE HETEROSEXUAL COPULATORY BEHAVIOR OF MALE RATS.
193549 01-04

SHORT-TERM EFFECTS OF TESTOSTERONE PROPIONATE ON THE BEHAVIOUR OF YOUNG INTACT MALE DOMESTIC DUCKS (ANAS-PLATYRHYNCHOS).
199461 02-04

ENDOCRINE EFFECTS OF CHRONIC ADMINISTRATION OF PSYCHOACTIVE DRUGS TO PREPUBERAL MALE RATS. I: DELTA9-TETRAHYDROCANNABINOL.
209840 03-03

EFFECT OF STRESS AND DIAZEPAM TREATMENT DURING INFANCY ON THE CORTICOSTERONE REGULATION AND ANDROGENIC ACTIVITY IN ADULT MALE RATS.
210348 03-03

INHIBITORY EFFECT OF NEONATAL ESTROGENIZATION ON THE INCORPORATION OF (3H)LYSINE IN THE PURKINJE CELLS OF THE ADULT MALE AND FEMALE RAT.
213478 04-03

CHLORDIAZEPOXIDE (LIBRIUM) INDUCED CHANGES IN INTRASPECIFIC ATTACK AND SELECTED NONAGONISTIC BEHAVIORS IN MALE SIAMESE FIGHTING FISH.
217524 04-04

STIMULATION OF ESTROGEN INDUCED COPULATORY BEHAVIOR IN CASTRATE MALE RATS WITH THE SEROTONIN BIOSYNTHESIS INHIBITOR P-CHLOROPHENYLALANINE.
221010 04-04

EFFECT OF FIGHTING AND DIPHENYLHYDANTOIN ON THE UPTAKE OF H3-L-NOREPINEPHRINE IN VITRO IN SYNAPTOSOMES ISOLATED FROM RETIRED MALE BREEDING MICE.
222821 04-03

MALES

A PATTERN OF ANTIDEPRESSIVE EFFECT OF TRYPTOPHAN & IMIPRAMINE IN MALES & FEMALES.
196680 01-09

INVOLUTIONAL MELANCHOLIA IN MALES?
206601 03-09

MALFORMATIONS

ANTENATAL EXPOSURE TO MEPROBAMATE AND CHLORDIAZEPOXIDE IN RELATION TO MALFORMATIONS, MENTAL DEVELOPMENT, AND CHILDHOOD MORTALITY.
212107 03-15

CARDIOVASCULAR MALFORMATIONS WITH LITHIUM USE DURING PREGNANCY.
225331 04-15

MALIGNANT

AMPHETAMINES AND MALIGNANT LYMPHOMA.
193035 01-17

MALIN

ON SYNDROME MALIN INDUCED BY NEUROLEPTICS.
224507 04-15

MAMMALIAN

BIOCHEMICAL CHARACTERIZATION OF THE DOPAMINE RECEPTOR IN THE MAMMALIAN CAUDATE NUCLEUS.
207297 03-03

REVERSIBLE INHIBITION OF MAMMALIAN BRAIN ACETYLCHOLINESTERASE AND SODIUM POTASSIUM STIMULATED ADENOSINE-TRIPHOSPHATASE BY CYCLOPROPANE.
210903 03-03

MAMMARY

EFFECTS OF CENTRAL ACTING DRUGS AND ERGOT DERIVATIVES ON PROLACTIN AND GROWTH HORMONE SECRETION, ON GROWTH OF PITUITARY AND MAMMARY TUMORS AND ON REPRODUCTION IN OLD RATS. (PH.D. DISSERTATION).
194571 01-03

PSYCHOTROPIC DRUGS, OVARIAN FUNCTIONS AND MAMMARY ACTIVITY.
214055 04-03

MAN

MARIHUANA METABOLITES IN URINE OF MAN: III. UNCHANGED DELTA9-TETRAHYDROCANNABINOL.
195053 01-13

DIAZEPAM METABOLISM IN NORMAL MAN: I. SERUM CONCENTRATIONS AND CLINICAL EFFECTS AFTER INTRAVENOUS, INTRAMUSCULAR, AND ORAL ADMINISTRATION.
195444 01-15

DIAZEPAM METABOLISM IN NORMAL MAN: II. SERUM CONCENTRATION AND CLINICAL EFFECT AFTER ORAL ADMINISTRATION AND CUMULATION.
195445 01-13

EFFECT OF ACUTE ADMINISTRATION OF L-DOPA ON BODY TEMPERATURE IN MAN.
197831 01-13

CANNABIDIOL INTERFERES WITH THE EFFECTS OF DELTA9-TETRAHYDROCANNABINOL IN MAN.
197867 01-14

PHARMACOKINETICS OF DIAZEPAM IN MAN.
197951 01-13

PSYCHOTROPIC DRUGS AND SLOW POTENTIALS IN MAN.
198101 02-13

ABSORPTION, DISTRIBUTION AND EXCRETION OF ALPRENOLOL IN MAN, DOG, AND RAT.
199621 02-13

THE EFFECT OF SEDUXEN ON THE PERCEPTIVE AND SOME OTHER FUNCTIONS OF THE CENTRAL NERVOUS SYSTEM UNDER EMOTIONAL STRESS IN MAN.
201916 02-14

STRUCTURE-ACTIVITY RELATIONSHIPS IN MAN OF CANNABIS CONSTITUENTS, AND HOMOLOGS AND METABOLITES OF DELTA9-TETRAHYDROCANNABINOL.
202192 02-02

THE ANTIAGGRESSIVE EFFECTS OF LITHIUM IN MAN.
202725 02-09

ASSAY OF PSYCHOTROPIC SUBSTANCES IN MAN.
202865 02-17

BIOCHEMICAL MECHANISMS OF EXTRAPYRAMIDAL MOTORIC ACTION OF HALOPERIDOL IN MAN.
204414 02-13

HEART RATE AND GALVANIC SKIN RESPONSE VARIATIONS DURING THE REM AND NQN-REM SLEEP PHASES IN MAN.
205443 02-13

LITHIUM TREATMENT AND THYROID FUNCTION IN MAN.
205611 03-15

THE EFFECTS OF CHRONIC PHENOTHIAZINE TREATMENT ON ADRENAL PITUITARY FUNCTION IN MAN.
205765 03-13

CEREBRAL HEMODYNAMIC EFFECTS OF CHRONIC TRYPTOPHAN FEEDING IN MAN AS MEASURED BY QUANTIFIED CEREBRAL IMPEDANCE PLETHYSMOGRAPHY.
206337 03-08

ON THE PHARMACOKINETICS OF BROMAZEPAM IN MAN.
206788 03-13

THE DISPOSITION OF BUTRIPTYLINE IN RATS, DOGS AND MAN.
206806 03-13

LONG-TERM AND SHORT-TERM EFFECTS OF SULPIRIDE ON SLEEP EEG IN MAN.
206977 03-14

ENHANCED DRUG HYDROXYLATION IN MAN UNDER DIPHENYLHYDANTOIN THERAPY.
206992 03-13

BEHAVIORAL EFFECTS OF A NEW DOPAMINE-BETA-HYDROXYLASE INHIBITOR (FUSARIC ACID) IN MAN.
207311 03-07

CONCEPTUAL ISSUES IN THE USE OF DRUGS FOR THE TREATMENT OF AGGRESSION IN MAN.
209126 03-17

INTERACTION OF PHYSOSTIGMINE AND DELTA9-TETRAHYDROCANNABINOL IN MAN.
210828 03-03

MARIHUANA METABOLITES IN URINE OF MAN: V. CHARACTERISTICS AND SEPARATION OF POLAR METABOLITES OF DELTA9-TETRAHYDROCANNABINOL.
210896 03-16

THE EFFECT OF CYPROHEPTADINE ON HUNGER, CALORIE INTAKE AND BODY WEIGHT IN MAN.
214011 04-13

L-HISTIDINE: FAILURE TO AFFECT THE SLEEP-WAKING CYCLE IN MAN.
214015 04-14

FIRST-PASS METABOLISM OF IMIPRAMINE IN MAN.
215671 04-13

FENFLURAMINE IN MAN: HYPOPHAGIA ASSOCIATED WITH DIMINISHED SEROTONIN TURNOVER.
215674 04-13

HEPATIC CHOLESTEROL SYNTHESIS IN MAN: EFFECT OF DIAZEPAM AND OTHER DRUGS.
215681 04-15

EFFECTS OF LITHIUM ON ELECTROMYOGRAPHIC RECORDINGS IN MAN: STUDIES IN MANIC-DEPRESSIVE PATIENTS AND NORMAL VOLUNTEERS.
215697 04-13

EFFECTS OF HIGH DOSAGE DELTA9-TETRAHYDROCANNABINOL ON SLEEP PATTERNS IN MAN.
215740 04-14

STRATEGIES FOR THE SYSTEMATIC STUDY OF NEUROTRANSMITTER RECEPTOR FUNCTION IN MAN.
215860 04-16

DIFFERENTIAL EFFECTS OF CHLORPROMAZINE, IMIPRAMINE, NITRAZEPAM AND AMOBARBITAL ON REM SLEEP AND REM DENSITY IN MAN.
215955 04-14

SLEEP AND BEHAVIORAL CHANGES REFLECTING CENTRAL RECEPTOR HYPERSENSITIVITY FOLLOWING CATECHOLAMINE SYNTHESIS INHIBITION IN MAN. (UNPUBLISHED PAPER).
216373 04-09

ABSORPTION AND EXCRETION OF THIORIDAZINE AND MESORIDAZINE IN MAN.
217154 04-08

THE EFFECTS OF SCOPOLAMINE (0.6 MG) AND PHYSOSTIGMINE (1.0 MG) ON HIGHER NERVOUS ACTIVITY IN MAN, FOLLOWED-UP DURING 5 HOURS AFTER APPLICATION.
217205 04-14

EFFECTS OF CENTRAL DOPAMINERGIC BLOCKADE WITH PIMOZIDE UPON THE EEG STAGES OF SLEEP IN MAN.
217546 04-14

DOSE RANGING STUDIES OF CLONAZEPAM IN MAN.
217556 04-14

BINDING OF (+) AMPHETAMINE AND (-) DELTA1-TETRAHYDROCANNABINOLS AND (-) 7-HYDROXY-DELTA1-TETRAHYDROCANNBINOL TO BLOOD CELLS AND PLASMA PROTEINS IN MAN.
217878 04-13

EFFECTS OF HEXAPROPYMATE ON THE SLEEP OF THE NORMAL MAN MEASURED BY A POLYGRAPHIC METHOD.
218166 04-14

ON THE PHARMACOKINETICS OF CHLORPROTHIXENE IN MAN.
219630 04-13

TETRAHYDROCANNABINOLS AND SERUM PROLACTIN LEVELS IN MAN.
220973 04-13

THE PHARMACOKINETIC PROPERTIES OF MAPROTILINE (LUDIOMIL) IN MAN.
221648 04-13

MANAGEMENT

PSYCHOTROPIC DRUGS: A MANUAL FOR EMERGENCY MANAGEMENT OF OVERDOSAGE.
193039 01-15

PRINDOLOL IN THE MANAGEMENT OF HYPERTENSION.
195773 01-14

BLOOD LEVELS AND MANAGEMENT OF LITHIUM TREATMENT.
203546 02-15

THE MANAGEMENT OF SCHIZOPHRENIA OUTSIDE THE HOSPITAL: RESEARCH FINDINGS AND UNDERLYING PRINCIPLES.
206044 03-08

PSYCHOPHARMACOLOGIC MANAGEMENT OF PATIENTS: A METHOD FOR RECORDING TREATMENT DECISIONS.
207683 03-17

PHYSIOLOGICAL MANAGEMENT OF HOSPITALIZED PSYCHIATRIC PATIENTS.
209399 03-11

THE CENTRAL ANTICHOLINERGIC SYNDROME: MANAGEMENT WITH PHYSOSTIGMINE.
211427 03-15

LORAZEPAM IN THE MANAGEMENT OF GASTROINTESTINAL NEUROSES.
215061 04-10

COMPREHENSIVE MANAGEMENT OF EPILEPSY.
216339 04-11

PROS AND CONS OF DRUG THERAPY IN THE MANAGEMENT OF THE HYPERACTIVE CHILD.
216966 04-11

SIGNIFICANCE OF PLASMA CHLORPROMAZINE IN MANAGEMENT OF PSYCHIATRIC PATIENTS.
224832 04-13

MANAGING

MANAGING DISTURBED GERIATRIC PATIENTS WITH CHEMOTHERAPY.
218010 04-11

A COMPARISON OF PHENOTHIAZINES IN MANAGING AGGRESSIVE EPISODES IN SCHIZOPHRENIC PATIENTS.
224955 04-08

MANGIAMELI

AMENORRHEA AND BEHAVIORAL DISTURBANCES: CLINICAL CASE TREATED WITH A PSYCHOTHERAPEUTIC METHOD BASED ON ELEMENTS OF THE CYBERNETIC THEORY OF G. CIPOLLINA MANGIAMELI.
210418 03-14

MANIA

PSYCHOMOTOR ACTIVITY IN MANIA.
194862 01-09

PSYCHOACTIVE DRUGS IN MANIA: A CONTROLLED COMPARISON OF LITHIUM CARBONATE, CHLORPROMAZINE AND HALOPERIDOL.
207446 03-09

MANIACAL

CEREBRAL AND PERIPHERAL CONSUMPTION OF L-5-HTP BY PATIENTS SUFFERING FROM MANIACAL, DEPRESSIVE OR PSYCHOTIC SYMPTOMS.
206834 03-10

MANIC

DEPRESSION, ELATION, AND LITHIUM CARBONATE RESPONSES IN MANIC PATIENT SUBGROUPS.
199631 02-09

INHIBITION OF DOPAMINE-BETA-HYDROXYLASE IN MANIC PATIENTS: A CLINICAL TRIAL WITH FUSARIC ACID.
199632 02-07

EXPERIENCE WITH OXYPROTHEPINE IN THE TREATMENT OF MANIC SYNDROMES.
205580 02-09

LITHIUM RESPONSIVE HYPERALDOSTERONISM IN MANIC PATIENTS.
221718 04-09

MANIC-DEPRESSION

MANIC-DEPRESSION.
193060 01-09

MANIC-DEPRESSIVE

BIPOLAR MANIC-DEPRESSIVE PSYCHOSIS IN EARLY ADOLESCENCE: A CASE REPORT.
201513 02-09

THE LEVELS OF LITHIUM IN SERUM AND IN RED BLOOD CELLS AND ITS RATIOS IN MANIC-DEPRESSIVE PATIENTS.
205607 03-09

FAMILY HISTORY OF MANIC-DEPRESSIVE AND ENDOGENOUS DEPRESSIVE PATIENTS AND CLINICAL EFFECT OF TREATMENT WITH LITHIUM.
205608 03-09

INVESTIGATION OF CLINICAL EFFECTS OF FK-880 (SULPIRIDE) ON MANIC-DEPRESSIVE ILLNESS.
207535 03-09

A STUDY OF ELECTROLYTE AND BIOGENIC AMINE METABOLISM IN MANIC-DEPRESSIVE ILLNESS.
208917 03-09

THERAPY WITH LITHIUM SALTS IN MANIC-DEPRESSIVE ILLNESSES.
209070 03-09

PATHOPHYSIOLOGICAL STUDIES OF MANIC-DEPRESSIVE PSYCHOSES: RELATIONSHIP BETWEEN ANXIETY AND EXCRETION OF URINARY CATECHOLAMINES.
212938 03-10

LITHIUM USE IN MANIC-DEPRESSIVE ILLNESS: PRACTICAL ASPECTS.
215680 04-17

EFFECTS OF LITHIUM ON ELECTROMYOGRAPHIC RECORDINGS IN MAN: STUDIES IN MANIC-DEPRESSIVE PATIENTS AND NORMAL VOLUNTEERS.
215697 04-13

DIPROPYLACETAMIDE IN TREATING MANIC-DEPRESSIVE PSYCHOSIS.
216761 04-09

THE EFFECT OF LITHIUM CARBONATE ON THE ELECTROENCEPHALOGRAM OF MANIC-DEPRESSIVE PSYCHOTICS.
217114 04-09

WHY DO PATIENTS WITH MANIC-DEPRESSIVE ILLNESS STOP THEIR LITHIUM?
219365 04-09

MANIC-DEPRESSIVE ILLNESS.
221820 04-09

URINARY EXCRETION OF THE SULPHATE AND GLUCURONIDE OF 3-METHOXY-4-HYDROXYPHENYLETHYLENEGLYCOL IN A MANIC-DEPRESSIVE PATIENT.
224424 04-09

ANTIMANIC AND PROPHYLACTIC EFFECTS OF CARBAMAZEPINE (TEGRETOL) ON MANIC-DEPRESSIVE PSYCHOSIS.
225086 04-09

MANIC-DEPRESSIVES

CHANGES IN THE PSYCHODYNAMICS OF MANIC-DEPRESSIVES THROUGH LONG-TERM ADMINISTRATION OF LITHIUM SALTS.
203601 02-14

MANIFESTATION

SIGNIFICANCE OF CATECHOLAMINES FOR THE MANIFESTATION OF MORPHINE WITHDRAWAL IN THE RAT.
206988 03-03

MANIFESTATIONS

THE INFLUENCE OF ANALGESICS AND NEUROLEPTICS ON AFFECTIVE MANIFESTATIONS OF PAIN.
198480 02-04

EXTRAPYRAMIDAL MANIFESTATIONS DUE TO METOCLOPRAMIDE IN SIX CASE STUDIES.
207533 03-15

TETRAHYDROCANNABINOL INDUCED MANIFESTATIONS OF THE MARIHUANA SYNDROME IN GROUP LIVING MACAQUES.
221340 04-04

STUDY OF AN ANXIOLYTIC DRUG, CLOBAZAM, IN ORL WITH PHARYNGEAL PSYCHOSOMATIC MANIFESTATIONS.
224584 04-11

MANIFESTED
A CASE OF NONSPECIFIC PSYCHOSES WHICH MANIFESTED CONVULSIVE SEIZURES DURING LITHIUM THERAPY.
209324 03-15

MANIOMELANCHOLIC
SOME SPECIFICITIES IN THE COURSE OF MANIOMELANCHOLIC PSYCHOSIS DURING LITHIUM THERAPY.
205609 03-09

MANIPULATIONS
EFFECT OF INDOLEALKYLAMINE MANIPULATIONS ON LOCOMOTOR ACTIVITY IN RATS.
195087 01-04
PHARMACOLOGICAL MANIPULATIONS OF BRAIN CATECHOLAMINES AND THE AGGRESSIVE BEHAVIOR INDUCED BY MARIHUANA IN REM SLEEP DEPRIVED RATS.
210325 03-04

MANUAL
PSYCHOTROPIC DRUGS: A MANUAL FOR EMERGENCY MANAGEMENT OF OVERDOSAGE.
193039 01-15

MAO
THIETANES AS POTENTIAL MAO INHIBITORS AND ANALGETICS. (PH.D. DISSERTATION).
194563 01-01
THE EFFECTS OF AMPHETAMINE AND A RELATED COMPOUND ON MAO.
197302 01-03
INFLUENCE OF MAO INHIBITORS ON THE INTESTINAL ABSORPTION OF BIOGENIC AMINES.
197948 01-03
THE RELATIONSHIP BETWEEN THE EEG DRIVING RESPONSE TO LIGHT AND PLASMA MONOAMINEOXIDASE (MAO) LEVELS.
205437 02-03
CENTRALLY MEDIATED CARDIOVASCULAR EFFECTS OF 5-HYDROXYTRYPTOPHAN IN MAO INHIBITED DOGS: MODIFICATION BY AUTONOMIC ANTAGONISTS.
215757 04-03
THE INHIBITION OF A AND B FORMS OF MAO IN THE PRODUCTION OF A CHARACTERISTIC BEHAVIOURAL SYNDROME IN RATS AFTER L-TRYPTOPHAN LOADING.
217471 04-03
CONTRASTING LOCAL EFFECTS OF MAO INHIBITORS ON CAUDATE TREMOR ACTIVITIES.
217669 04-03

MAO-A
EVIDENCE THAT 5-METHOXYDIMETHYLTRYPTAMINE IS A SPECIFIC SUBSTRATE FOR MAO-A IN THE RAT: IMPLICATIONS FOR THE INDOLEAMINE DEPENDENT BEHAVIORAL SYNDROME.
210817 03-04

MAOI
AN MAOI SPECIFIC AFFECTIVE DISORDER. THE TOO MUCH SYNDROME.
202705 02-09

MAPROTILIN
THE EFFECT OF MAPROTILIN ON BRAIN SEROTONIN METABOLISM IN RATS.
205604 03-03
EXPLICIT SOLUTION TO PHARMACOKINETIC FIRST-ORDER RATE CONSTANTS OF MAPROTILIN.
208919 03-17

MAPROTILINE
DOES MAPROTILINE (LUDIOMIL) INFLUENCE SEROTONIN UPTAKE AND FREE TRYPTOPHAN CONCENTRATION IN HUMAN PLASMA
192943 01-13
A MULTINATIONAL, DOUBLE-BLIND TRIAL WITH A NEW ANTIDEPRESSANT MAPROTILINE (LUDIOMIL) AND AMITRIPTYLINE.
197031 01-09
EFFECTS OF SINGLE AND REPEATED ADMINISTRATION OF MAPROTILINE AND ITS RELATION TO PLASMA LEVELS IN HEALTHY TEST SUBJECTS.
204403 02-15
A COMPARISON BETWEEN MAPROTILINE (LUDIOMIL) AND AMITRIPTYLINE IN THE TREATMENT OF DEPRESSIVE REACTION IN GENERAL PRACTICE.
215058 04-14
MAPROTILINE -- ITS POSITION AS AN ANTIDEPRESSANT IN THE LIGHT OF RECENT NEUROPHARMACOLOGICAL AND NEUROBIOCHEMICAL FINDINGS.
221647 04-03
THE PHARMACOKINETIC PROPERTIES OF MAPROTILINE (LUDIOMIL) IN MAN.
221648 04-13
CONTINENTAL HOSPITAL STUDIES WITH MAPROTILINE (LUDIOMIL).
221651 04-09
DOUBLE-BLIND COMPARISON OF MAPROTILINE (LUDIOMIL) WITH AMITRIPTYLINE IN THE TREATMENT OF DEPRESSIVE ILLNESS.
221652 04-09
A DOUBLE-BLIND COMPARATIVE CLINICAL TRIAL OF MAPROTILINE (LUDIOMIL) AND AMITRIPTYLINE.
221653 04-09
A CONTROLLED COMPARISON OF MAPROTILINE (LUDIOMIL) WITH IMIPRAMINE AVOIDING OBSERVER BIAS.
221654 04-09
A COMPARISON BETWEEN MAPROTILINE (LUDIOMIL) AND IMIPRAMINE IN THE TREATMENT OF DEPRESSIVE ILLNESS IN THE ELDERLY.
221655 04-09
A COMPARISON OF MAPROTILINE (LUDIOMIL) AND PLACEBO IN THE TREATMENT OF DEPRESSION.
221656 04-09
A CLINICAL TRIAL OF MAPROTILINE (LUDIOMIL) IN THE TREATMENT OF DEPRESSIVE PATIENTS IN GENERAL PRACTICE AND THE PSYCHIATRIC CLINIC.
221657 04-09
A DOUBLE-BLIND GENERAL PRACTICE TRIAL OF MAPROTILINE (LUDIOMIL) AGAINST AMITRIPTYLINE IN THE TREATMENT OF REACTIVE DEPRESSION.
221658 04-09
ONCE DAILY DOSAGE WITH MAPROTILINE (LUDIOMIL).
221659 04-09
ONCE DAILY DOSAGE STUDY WITH MAPROTILINE (LUDIOMIL).
221660 04-09
AN INTERIM REPORT OF A DOUBLE-BLIND STUDY COMPARING A ONCE DAILY DOSAGE OF MAPROTILINE (LUDIOMIL) WITH AMITRIPTYLINE THRICE DAILY.
221661 04-09
A COMPARISON BETWEEN DAILY AND NIGHTLY DOSE REGIMEN OF AMITRIPTYLINE AND MAPROTILINE (LUDIOMIL) IN THE TREATMENT OF REACTIVE DEPRESSION IN GENERAL PRACTICE.
221662 04-09
MAPROTILINE (LUDIOMIL): SIDE-EFFECTS AND OVERDOSAGE.
221663 04-15
ON THE ANTIDEPRESSANT EFFECT OF CIBA-34276-BA (MAPROTILINE).
223182 04-10
A CONTROLLED STUDY OF A TETRACYCLIC ANTIDEPRESSANT -- MAPROTILINE (LUDIOMIL).
224486 04-09

MARIHUANA
ACUTE, SUBACUTE AND 23-DAY CHRONIC MARIHUANA INHALATION TOXICITIES IN THE RAT.
193576 01-04
MARIHUANA METABOLITES IN URINE OF MAN: III. UNCHANGED DELTA9-TETRAHYDROCANNABINOL.
195053 01-13
HYPOTHERMIC EFFECTS OF MARIHUANA, MARIHUANA DERIVATIVES AND CHLORPROMAZINE IN LABORATORY MICE.
196226 01-04
EFFECTS OF MARIHUANA ON AUDITORY SIGNAL DETECTION.
206356 03-12
PHARMACOLOGICAL MANIPULATIONS OF BRAIN CATECHOLAMINES AND THE AGGRESSIVE BEHAVIOR INDUCED BY MARIHUANA IN REM SLEEP DEPRIVED RATS.
210325 03-04
MARIHUANA METABOLITES IN URINE OF MAN: V. CHARACTERISTICS AND SEPARATION OF POLAR METABOLITES OF DELTA9-TETRAHYDROCANNABINOL.
210896 03-16
CLINICAL STUDIES WITH MARIHUANA AND D-AMPHETAMINE COMBINATION.
211745 03-14
EFFECT OF SMOKING MARIHUANA AND OF A HIGH NICOTINE CIGARETTE ON ANGINA-PECTORIS.
215670 04-15
EFFECTS OF MARIHUANA (DELTA9-THC) ON BEHAVIOR PATTERNS AND SOCIAL ROLES IN COLONIES OF CBA MICE.
216494 04-04
PROSTAGLANDINS AND CANNABIS -- III. INHIBITION OF BIOSYNTHESIS BY ESSENTIAL OIL COMPONENTS OF MARIHUANA.
217795 04-03
DOSE EFFECTS OF SMOKED MARIHUANA ON HUMAN COGNITIVE AND MOTOR FUNCTIONS.
221036 04-01
TETRAHYDROCANNABINOL INDUCED MANIFESTATIONS OF THE MARIHUANA SYNDROME IN GROUP LIVING MACAQUES.
221340 04-04

MARIJUANA
STUDIES ON EEG TOLERANCE TO MARIJUANA IN THE RAT.
197473 01-03
DOES MARIJUANA ENHANCE EXPERIMENTALLY INDUCED ANXIETY?
210738 03-14
MARIJUANA: HEART RATE AND EEG RESPONSE.
210895 03-01
PHARMACOLOGY OF MARIJUANA.
211689 03-17
EFFECT OF MARIJUANA ON DIVERGENT AND CONVERGENT PRODUCTION COGNITIVE TESTS.
223394 04-14
ALCOHOL AND MARIJUANA: COMPARATIVE PSYCHOPHARMACOLOGY.
224753 04-14

MARIJUANA AND HOSTILITY IN A SMALL GROUP SETTING.
224754 04-14
MARIJUANA, ALCOHOL AND INTERPERSONAL PERCEPTIONS.
224755 04-14
EFFECTS OF MARIJUANA ON FLYING ABILITY.
224906 04-04
EFFECT OF CHRONIC MARIJUANA ADMINISTRATION ON STAGES OF PRIMATE SLEEP-WAKEFULNESS.
225520 04-14

MARITAL
INTERACTION OF DRUG THERAPY WITH MARITAL THERAPY IN DEPRESSIVE PATIENTS.
218769 04-10

MARKED
PRELIMINARY RESULTS OF A CONTROLLED TRIAL WITH SULPIRIDE VERSUS CHLORIMIPRAMINE IN CHRONIC SCHIZOPHRENIC PATIENTS WITH MARKED IDEO-EMOTIONAL POVERTY.
200445 02-08

MARKOV
MARKOV CHAIN AS A MODEL OF VERBAL LEARNING.
205624 03-14

MARRIED
LITHIUM PROPHYLAXIS: THE MARRIED COUPLES GROUP.
224749 04-09

MASKED
TREATMENT OF MASKED DEPRESSION.
201655 02-09
A COMPARISON OF A NEW TRANQUILIZER, SULPIRIDE AND OXAZOLAM ON PSYCHOSOMATIC DISEASES, NEUROSIS AND MASKED DEPRESSION USING DOUBLE-BLIND METHOD.
210180 03-11

MASSED
INTERACTION BETWEEN MASSED ELECTROCONVULSIVE SHOCK AND P-BROMOMETHYLAMPHETAMINE (V-111) TREATMENT.
197579 01-03

MAST
THE INHIBITORY EFFECT OF TOLUIDINE BLUE AND METHYLENE BLUE ON RAT MAST CELL DAMAGE BY PROMETHAZINE, CHLORPROMETHAZINE AND CHLORPROMAZINE. ITS REVERSAL BY GLUCOSE.
199255 02-05

MATCHING
THE VALIDITY OF IDENTICAL MATCHING PLACEBOS.
193073 01-16
INHIBITORY AND DISINHIBITORY EFFECTS OF NITRAZEPAM, DIAZEPAM AND FLURAZEPAM HYDROCHLORIDE ON DELAYED MATCHING BEHAVIOUR IN MONKEYS (MACACA-MULATTA).
199957 02-04

MATERNAL
DEVELOPMENTAL DISTURBANCE OF THE BRAIN IN RAT OFFSPRING FOLLOWING MATERNAL ADMINISTRATION OF 5-FLUOURACIL DURING PREGNANCY.
202422 02-03
PHYSIOLOGICAL MECHANISMS FOR CARDIAC CONTROL BY NUTRITIONAL INTAKE AFTER EARLY MATERNAL SEPARATION IN THE YOUNG RAT.
218047 04-03
ESTROGEN INDUCED MATERNAL BEHAVIOR IN HYSTERECTOMIZED OVARIECTOMIZED VIRGIN RATS.
219069 04-04
LATENCY AND DURATION OF ESTROGEN INDUCTION OF MATERNAL BEHAVIOR IN HYSTERECTOMIZED OVARIECTOMIZED VIRGIN RATS: EFFECTS OF PUP STIMULATION.
219070 04-04
THE EFFECT OF SEROTONIN ON THE FETUS AND FETAL MATERNAL RELATIONS IN THE RAT.
221743 04-03
PRENATAL MATERNAL D-AMPHETAMINE EFFECTS ON EMOTIONALITY AND AUDIOGENIC SEIZURE SUSCEPTIBILITY OF RAT OFFSPRING.
225079 04-04

MATTER
THE INFLUENCE OF INTRAPERITONEAL INJECTION OF IPRAZIDE AND TRANSAMINE ON THE DISTRIBUTION OF BIOGENIC AMINES IN CORTICAL AND SUBCORTICAL WHITE MATTER OF THE RAT BRAIN.
209032 03-03

MATURATION
MATURATION OF VISUAL ELECTROCORTICAL RESPONSES IN UNANESTHETIZED KITTENS: EFFECTS OF BARBITURATE ANESTHESIA.
199765 02-03
MATURATION OF THE ADRENAL MEDULLA -- III: PRACTICAL AND THEORETICAL CONSIDERATIONS OF AGE DEPENDENT ALTERATIONS IN KINETICS OF INCORPORATION OF CATECHOLAMINES AND NONCATECHOLAMINES.
205852 03-03
GENOTYPE OR PRENATAL DRUG EXPERIENCE AFFECT BRAIN MATURATION IN THE MOUSE.
221032 04-03

MAUDSLEY
USE OF THE MAUDSLEY PERSONALITY INVENTORY IN EVALUATING THE EFFECTIVENESS OF A MINOR TRANQUILIZER IN PSYCHOSOMATIC DISEASES (THE FIRST REPORT).
198518 02-14

MAXIMUM
SCHIZOPHRENIA AND EVOKED POTENTIALS: MAXIMUM AMPLITUDE, FREQUENCY OF PEAKS, VARIABILITY, AND PHENOTHIAZINE EFFECTS.
213764 04-08

MAZE
EFFECT OF INCREASED AROUSAL ON RESPONSE TO STIMULUS CHANGE IN A COMPLEX MAZE.
206187 03-04

MAZINDOL
PHARMACOLOGICAL ANALYSIS OF A NEW ANOREXIC SUBSTANCE: 5-HYDROXY-5-4-CHLOROPHENYL 2,3 DIHYDRO-5H-IMIDAZOISOINDOLE (MAZINDOL).
217652 04-04
THE EFFECTS OF 5-HYDROXY-5-4-CHLOROPHENYL 2,3 DIHYDRO-5H-IMIDAZOISOINDOLE (MAZINDOL, SAH-42-548) ON THE METABOLISM OF BRAIN NOREPINEPHRINE.
217653 04-03

MBD
USE OF CNS STIMULANT MEDICATION IN AVERAGED ELECTROENCEPHALIC AUDIOMETRY WITH CHILDREN WITH MBD.
221103 04-11

MBDS
SLEEP AMPHETAMINE EFFECTS IN MBDS AND NORMAL SUBJECTS.
199640 02-11

MDA
THE HEPATIC MICROSOMAL METABOLISM OF BETA 3,4 METHYLENEDIOXYAMPHETAMINE (MDA).
200082 02-03
COMPARISON OF CARDIOVASCULAR, HYPERTHERMIC, AND TOXIC EFFECTS OF P-METHOXYAMPHETAMINE (PMA) AND 3,4 METHYLENEDIOXYAMPHETAMINE (MDA).
217578 04-05

MEAL
NORADRENERGIC CONTROL OF SPONTANEOUS MEAL SIZE IN THE RAT. (PH.D. DISSERTATION).
214206 04-04

MEASURE
ISOLATION INDUCED TIMIDITY IN MICE AS A MEASURE OF ANXIOLYTIC ACTIVITY OF DRUGS.
215063 04-04

MEASURED
CEREBRAL HEMODYNAMIC EFFECTS OF CHRONIC TRYPTOPHAN FEEDING IN MAN AS MEASURED BY QUANTIFIED CEREBRAL IMPEDANCE PLETHYSMOGRAPHY.
206337 03-08
CHANGES IN OBSESSIVE/COMPULSIVE PATIENTS AS MEASURED BY THE LEYTON INVENTORY BEFORE AND AFTER TREATMENT WITH CLOMIPRAMINE.
214833 04-10
THE EFFECT OF ACTH AND DIAZEPAM, ADMINISTERED TO INFANT RATS ON THE BODY GROWTH CURVE AND SOME ENDOCRINE PARAMETERS MEASURED IN ADULT AGE.
215066 04-03
EFFECTS OF HEXAPROPYMATE ON THE SLEEP OF THE NORMAL MAN MEASURED BY A POLYGRAPHIC METHOD.
218166 04-14

MEASUREMENT
CLINICAL MEASUREMENT OF CENTRAL DOPAMINE AND SEROTONIN METABOLISM IN ACUTE PSYCHOTIC DISORDERS.
195924 01-09
MEASUREMENT OF SEROTONIN TURNOVER IN RATS WITH THE HELP OF MONOAMINEOXIDASE INHIBITORS.
197580 01-03
MEASUREMENT OF ACETYLCHOLINE TURNOVER RATE IN DISCRETE AREAS OF RAT BRAIN.
202465 02-06
SCOPE AND LIMITATION IN DOPAMINE BETA-HYDROXYLASE MEASUREMENT.
210811 03-02
STUDIES OF LITHIUM INDUCED TREMOR BY MEANS OF DIFFERENT MEASUREMENT METHODS.
217453 04-15
QUANTITATIVE MEASUREMENT OF PARKINSON DISEASE RIGOR. MYOINTEGRATIVE DRUG TRIAL IN COMBINATION WITH THE DECARBOXYLASE INHIBITING DRUG RO-8-0576.
220829 04-11

MEASUREMENTS
PSYCHOLOGICAL MEASUREMENTS IN PSYCHOPHARMACOLOGY VOL. 7.
210334 03-17
THE INFLUENCE OF SULPIRIDE ON VIGILANCE: OBJECTIVE MEASUREMENTS OF THE VISUOMOTOR SYSTEM.
221271 04-14

GALVANIC SKIN RESISTANCE (GSR) MEASUREMENTS ON VOLUNTEERS RECEIVING FENFLURAMINE OR D-AMPHETAMINE.
225062 04-13

MEASURES

DRUGS, EEG AND BEHAVIOUR: EEG PROFILES AND BIOAVAILABILITY MEASURES FOR CLINICAL PSYCHOPHARMACOLOGY.
205522 02-16

SEDATIVE EFFECTS ON PHYSIOLOGICAL AND PSYCHOLOGICAL MEASURES IN ANXIOUS PATIENTS.
209079 03-10

MEASURING

MEASURING EFFECTS OF PSYCHOACTIVE MEDICATION IN A CHILD WITH A LEARNING DISABILITY.
203847 02-14

AN APPLICATION OF LONG-TERM FREQUENCY ANALYSIS IN MEASURING DRUG SPECIFIC ALTERATIONS IN THE EEG OF THE CAT.
218190 04-03

MECHANISM

MECHANISM OF ACTION OF PHENCYCLIDINE ON THE PERIPHERAL SYMPATHETIC NERVOUS SYSTEM.
193425 01-03

POSSIBLE MECHANISM OF ACTION OF BENZODIAZEPINES. (UNPUBLISHED PAPER).
194541 01-03

BLOCKADE BY ESERINE OF THE CEREBRAL CORTICAL EFFECTS OF ALLOFERIN: A FURTHER EVIDENCE OF CHOLINERGIC INHIBITORY MECHANISM.
195548 01-03

NEUROPHARMACOLOGICAL STUDIES OF EFFECT OF NEW CENTRAL DEPRESSANT, 8-CHLOR-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D40TA) ON EEG AND CENTRAL SYMPATHETIC ACTIVATING MECHANISM IN CATS.
195549 01-03

MECHANISM OF ANTIDEPRESSANT EFFICACY OF MONOAMINEOXIDASE INHIBITORS: INHIBITION OF MONOAMINE OXIDASE OR OF CATECHOLAMINE REUPTAKE.
195925 01-17

MECHANISM OF THE HYPOTENSIVE EFFECT OF INTRAVENOUS METHAQUALONE IN THE CAT.
196107 01-03

A POSSIBLE MECHANISM FOR THE ANTIDEPRESSANT ACTIVITY OF THYROTROPIN-RELEASING HORMONE.
196836 01-13

INVESTIGATIONS ON THE ACTION AND MECHANISM OF ACTION OF DIPHENYLHYDANTOIN AS AN ANTAGONIST OF TETRABENAZINE AND RESERPINE.
197471 01-03

THE MECHANISM OF ACTION OF GYKI-32084, A NEW ANTISEROTONIN AGENT.
197570 01-03

THE ANTICONVULSANT ACTION OF THE CARBONIC ANHYDRASE INHIBITOR METHAZOLAMIDE: POSSIBLE INVOLVEMENT OF A NORADRENERGIC MECHANISM.
197864 01-03

ON THE MECHANISM OF ACTION OF GAMMA-HYDROXYBUTYRIC ACID: LACK OF CONVERSION TO GABA IN MOUSE BRAIN IN VIVO.
197965 01-03

INVESTIGATION OF THE MECHANISM BY WHICH L-DOPA INDUCES GNAWING IN MICE.
198014 01-04

DUAL MECHANISM OF AMPHETAMINE TOXICITY IN MICE: RELATIONSHIP TO BRAIN CATECHOLAMINES.
199898 02-05

A CONTRIBUTION TO THE STUDY OF MECHANISM OF ACTION OF PHENYLBUTAZONE: THE INFLUENCE OF CATECHOLAMINES ON THE ANTIINFLAMATORY EFFECT OF PHENYLBUTAZONE.
205169 02-03

NEW DEVELOPMENTS IN THE STUDY OF THE MECHANISM OF ACTION OF NEUROLEPTICS AND AMPHETAMINE.
207296 03-03

THERAPEUTIC EFFECTS AND MECHANISM OF ACTION OF S-ADENOSYL-L-METHIONINE (SAM) IN DEPRESSIVE SYNDROMES.
210213 03-09

THE MECHANISM OF THE POTENTIATING EFFECT OF ANTIDEPRESSANT DRUGS ON THE PROTECTIVE INFLUENCE OF DIPHENHYDRAMINE IN EXPERIMENTAL CATATONIA. THE ROLE OF HISTAMINE.
215664 04-03

ON THE MECHANISM OF POTENTIATION BY MORPHINE OF THIOPENTAL SLEEPING TIME.
215666 04-03

SOME GENERAL PRINCIPLES OF THE MECHANISM OF THE CENTRAL ACTION OF PSYCHOTOMIMETICS.
216999 04-12

THE MECHANISM OF ANTICONVULSIVE ACTION OF DIAZEPAM.
217064 04-04

ON THE MECHANISM OF THE HYPERTHERMIA INDUCED BY AMPHETAMINE IN THE RAT.
217691 04-03

POLYETHYLENE GLYCOL INDUCED THIRST: A DUAL STIMULATORY MECHANISM?
219071 04-04

TOWARDS THE MECHANISM OF THE ANTIPHLOGISTIC ACTION OF CHLORPROMAZINE.
219507 04-03

ON THE MECHANISM OF THE DEFENSIVE ACTION OF ACETYLCHOLINE AND SEROTONIN AGAINST THEIR CYTOTOXIC ANTAGONISTS.
219663 04-03

THE ACTION OF DELTA9-TETRAHYDROCANNABINOL ON CENTRAL CARDIOVASCULAR REGULATION: MECHANISM AND LOCALIZATION.
221669 04-03

NEW CONCEPTS ON THE MECHANISM OF ACTION OF BENZODIAZEPINES.
225058 04-13

MECHANISMS

MECHANISMS OF TREMOR INDUCTION BY HARMINE.
193448 01-03

EFFECTS OF SELF-STIMULATION BEHAVIOR OF DRUGS INFLUENCING DOPAMINERGIC NEUROTRANSMISSION MECHANISMS.
194152 01-04

DOPAMINERGIC MECHANISMS IN PATIENTS WITH EXTRAPYRAMIDAL DISEASE. (UNPUBLISHED PAPER).
194542 01-13

INTERRELATION BETWEEN MONOAMINERGIC AND CHOLINERGIC MECHANISMS IN THE HYPOTHALAMIC THERMOREGULATORY CENTRE OF RABBITS.
195249 01-03

EFFECTS OF DRUGS INFLUENCING MONOAMINE MECHANISMS ON THE INCREASE IN BRAIN DOPAMINE PRODUCED BY AXOTOMY OR TREATMENT WITH GAMMA-HYDROXYBUTYRIC ACID.
195440 01-03

NEUROPSYCHOLOGIC MECHANISMS OF LITHIUM THERAPY.
195932 01-09

THE EFFECT OF DIAZEPAM ON SPINAL CORD ACTIVITIES: POSSIBLE SITES AND MECHANISMS OF ACTION.
197585 01-03

SPECIFIC ASYMMETRIC BEHAVIOUR INDUCED BY THE DIRECT CHEMICAL STIMULATION OF NEOSTRIATAL DOPAMINERGIC MECHANISMS.
197929 01-04

BEHAVIORAL MECHANISMS OF DRUG ACTION IN SCHIZOPHRENIA.
198103 02-08

A STUDY OF NEUROPHYSIOLOGICAL MECHANISMS OF GENERAL ANESTHESIA WITH KETAMIN.
198434 02-03

ON THE SPECIFICITY OF NEUROCHEMICAL MECHANISMS DEALING WITH NOCICEPTIVE STIMULATION OF NEURONS IN VARIOUS BRAIN FORMATIONS OF RABBITS.
198436 02-03

ROLE OF CATECHOLAMINERGIC MECHANISMS IN THE EXPRESSION OF THE MORPHINE ABSTINENCE SYNDROME IN RATS.
200053 02-03

THE CONCEPT OF THE QUASI-ABSTINENCE EFFECT AND ITS USE IN THE INVESTIGATION OF DEPENDENCE MECHANISMS.
202194 02-13

THE PERIPHERAL AND CENTRAL ROLE OF THE CATECHOLAMINES IN THE MECHANISMS OF ANXIETY.
202783 02-17

CELLULAR MECHANISMS OF CHLORPROMAZINE PHOTOSENSITIVITY.
204233 02-15

BIOCHEMICAL MECHANISMS OF EXTRAPYRAMIDAL MOTORIC ACTION OF HALOPERIDOL IN MAN.
204414 02-13

LONG-TERM EFFECTS OF P-CHLOROAMPHETAMINE AND RELATED DRUGS ON CENTRAL SEROTONERGIC MECHANISMS.
208553 03-03

DOPAMINERGIC MECHANISMS OF OPIATE ACTIONS IN BRAIN.
208554 03-03

EXPERIMENTAL TESTS OF HYPOTHESES ABOUT NEUROCHEMICAL MECHANISMS UNDERLYING BEHAVIORAL TOLERANCE TO THE ANTICHOLINESTERASE, DIISOPROPYLFLUOROPHOSPHATE.
208555 03-03

AN ANALYSIS OF MONOAMINERGIC MECHANISMS OF THE DORSAL HIPPOCAMPUS WHICH MEDIATE THE CONDITIONED ESCAPE REACTION IN RATS.
208991 03-04

ACTION AND REACTION: BIOPHYSIOLOGICAL AND NEUROPHYSIOLOGICAL MECHANISMS.
210419 03-13

BLOCKADE BY PIMOZIDE OF A NORADRENALINE SENSITIVE ADENYLATE-CYCLASE IN THE LIMBIC FOREBRAIN: POSSIBLE ROLE OF LIMBIC NORADRENERGIC MECHANISMS IN THE MODE OF ACTION OF ANTIPSYCHOTICS.
210771 03-03

POSSIBLE MECHANISMS INVOLVED IN THE DEPRESSOR RESPONSE TO DOPAMINE.
210787 03-03

PARKINSONIAN TYPE TREMOR AND THE ACTION OF HARMALINE: EXPERIMENTAL FACTS AND HYPOTHETICAL MECHANISMS.
212182 03-03

MOLECULAR MECHANISMS OF MEMORY AND LEARNING (GENERAL CONSIDERATIONS AND CLINICAL APPLICATIONS).
212281 03-14
ON THE PARTICIPATION OF BIOGENIC AMINES AND THEIR SYNTHETIC ENZYMES IN THE MECHANISMS OF IMAGE MEMORY.
213469 04-04
ON THE PHYSIOLOGICAL MECHANISMS OF THE INFLUENCE OF PHENAMINE AND MICROPOLARIZATION ON LONG-TERM MEMORY PROCESSES.
213491 04-04
BIOCHEMICAL PHARMACOLOGY OF BRAIN AMINE MECHANISMS.
213603 04-03
MECHANISMS OF STORAGE AND RELEASE OF AMINES.
213632 04-03
A NEUROPHARMACOLOGICAL ANALYSIS OF CHOLINERGIC MECHANISMS OF SELF-STIMULATION REACTIONS.
215497 04-04
AN ANALYSIS OF NEUROCHEMICAL MECHANISMS OF ONE FORM OF INTRASPECIES BEHAVIOR.
215789 04-04
EFFECT OF BUTRIPTYLINE ON THE BRAIN UPTAKE MECHANISMS FOR NORADRENALINE AND 5-HYDROXYTRYPTAMINE.
217688 04-03
PHYSIOLOGICAL MECHANISMS FOR CARDIAC CONTROL BY NUTRITIONAL INTAKE AFTER EARLY MATERNAL SEPARATION IN THE YOUNG RAT.
218047 04-03
CORRELATED HISTOCHEMICAL, ELECTRON MICROSCOPICAL, PHARMACOLOGICAL AND PHYSIOLOGICAL OBSERVATION ON AMINERGIC MECHANISMS IN THE CENTRAL NERVOUS SYSTEM. (UNPUBLISHED PAPER).
218300 04-03
THE PARTICIPATION OF CEREBRAL CHOLINERGIC MECHANISMS IN THE ACTION OF NEUROLEPTICS.
218471 04-04
ON NEUROCHEMICAL MECHANISMS OF SEPTUM INFLUENCE ON THE CONDITIONED AVOIDANCE REACTION IN RATS.
218803 04-04
NEUROCHEMICAL AND NEUROPHYSIOLOGICAL MECHANISMS OF THE PSYCHOSTIMULATING ACTION OF PHENAMINE.
219510 04-13
SEROTONERGIC AND CHOLINERGIC MECHANISMS DURING DISRUPTION OF APPROACH AND AVOIDANCE BEHAVIOR.
225161 04-04

MECHANISTIC
A MECHANISTIC STUDY OF BIOLOGICAL TRANSMETHYLATION.
213604 04-03

MECHOLYL
ELEVATION OF PLASMA DOPAMINE-BETA-HYDROXYLASE ACTIVITY DURING MECHOLYL TEST.
225523 04-13

MEDAZEPAM
BROMAZEPAM, MEDAZEPAM, CHLORDIAZEPOXIDE IN TREATMENT OF NEUROTIC ANXIETY.
202219 02-10
POSSIBLE TREATMENT OF PSYCHONEUROSES WITH MEDAZEPAM (NOBRIUM).
203705 02-07
THE EFFECT OF ALAMON (HYDROXYZINE HYDROCHLORIDE) AND MEDAZEPAM ON NEUROSIS TESTED BY A DOUBLE-BLIND METHOD.
211344 03-10
THE EFFECTS OF MEDAZEPAM (S-804) ON ALL-NIGHT SLEEP.
211361 03-14

MEDIAL
INTRACRANIAL SELF-STIMULATION IN RATS AS A FUNCTION OF VARIOUS STIMULUS PARAMETERS: V. INFLUENCE OF COCAINE ON MEDIAL FOREBRAIN BUNDLE STIMULATION WITH MONOPOLAR ELECTRODES.
198223 02-03
DIFFERENTIAL EFFECTS OF AMPHETAMINE AND FOOD DEPRIVATION ON SELF-STIMULATION OF THE LATERAL HYPOTHALAMUS AND MEDIAL FRONTAL CORTEX.
206733 03-04
EFFECT OF INTRAVENTRICULAR NOREPINEPHRINE ON NEURON ACTIVITY IN THE MEDIAL FOREBRAIN BUNDLE DURING SELF-STIMULATION BEHAVIOR.
210704 03-04
EFFECTS OF DOPAMINERGIC DRUGS AND ACUTE MEDIAL FOREBRAIN BUNDLE LESIONS ON STRIATAL ACETYLCHOLINE LEVELS.
210831 03-03
BEHAVIORAL EFFECTS OF LOCAL INJECTION OF 6-HYDROXYDOPAMINE IN THE MEDIAL VENTRAL TEGMENTUM IN THE RAT. POSSIBLE ROLE OF THE MESOLIMBIC DOPAMINERGIC SYSTEM.
220946 04-04

MEDIAN
EFFECT OF 6-HYDROXYDOPAMINE ON HYPOTHALAMIC NOREPINEPHRINE AND DOPAMINE CONTENT, ULTRASTRUCTURE OF THE MEDIAN EMINENCE, AND PLASMA CORTICOSTERONE.
193050 01-03

MEDIATE
AN ANALYSIS OF MONOAMINERGIC MECHANISMS OF THE DORSAL HIPPOCAMPUS WHICH MEDIATE THE CONDITIONED ESCAPE REACTION IN RATS.
208991 03-04

MEDIATED
EFFECT OF TWO DOPAMINE RECEPTOR BLOCKERS ON A SEROTONIN MEDIATED BEHAVIORAL SYNDROME IN RATS.
193548 01-04
ALPHA-RECEPTOR MEDIATED MODULATION OF TRANSMITTER RELEASE FROM CENTRAL NORADRENERGIC NEURONES.
202805 02-03
AMNESIC EFFECT OF CYCLOHEXIMIDE IN THE MOUSE MEDIATED BY ADRENOCORTICAL HORMONES.
206751 03-04
A SCHIZOPHRENIFORM BEHAVIORAL PSYCHOSIS MEDIATED BY DOPAMINE.
207035 03-04
ANTAGONISM OF DOPAMINE MEDIATED INHIBITION IN THE NIGROSTRIATAL PATHWAY: A MODE OF ACTION OF SOME CATATONIA INDUCING DRUGS.
210659 03-03
NORADRENALINE MEDIATED INHIBITION BY LOCUS-COERULEUS OF SPINAL TRIGEMINAL NEURONS.
210703 03-03
CENTRALLY MEDIATED CARDIOVASCULAR EFFECTS OF 5-HYDROXYTRYPTOPHAN IN MAO INHIBITED DOGS: MODIFICATION BY AUTONOMIC ANTAGONISTS.
215757 04-03

MEDIATING
ROLE OF PITUITARY ADRENOCORTICAL SYSTEM IN MEDIATING AVOIDANCE BEHAVIOR OF RATS WITH SEPTAL LESIONS.
206739 03-04

MEDIATION
THE SITE OF AND MODE OF ACTION OF ET495 FOR THE MEDIATION OF STEREOTYPED BEHAVIOUR IN THE RAT.
195252 01-03
THE PHARMACOLOGY OF GROSS BEHAVIOURAL EFFECTS OF CHOLINOMIMETIC SUBSTANCES INJECTED INTO THE CEREBRAL VENTRICLES OF UNANAESTHETIZED CATS: EVIDENCE FOR CENTRAL MUSCARINIC MEDIATION.
202780 02-04
DOPAMINERGIC NEURONS IN THE NIGROSTRIATAL AND MESOLIMBIC PATHWAYS: MEDIATION OF SPECIFIC EFFECTS OF D-AMPHETAMINE.
210855 03-03
L-DOPA HYPOTENSION IN DOGS: EVIDENCE FOR MEDIATION THROUGH 5-HT RELEASE.
210868 03-05
DOPAMINERGIC MEDIATION OF THE INTEROCEPTIVE CUE PRODUCED BY D-AMPHETAMINE IN RATS.
217531 04-04
INVESTIGATIONS OF UCS-CS MEDIATION IN RADIATION INDUCED CONDITIONED TASTE AVERSION. (PH.D. DISSERTATION).
220681 04-04
INHIBITORY ACTION OF NOREPINEPHRINE ON THE INDUCTION OF TRYPTOPHAN 2,3 DIOXYGENASE BY CORTISOL: MEDIATION BY THE ALPHA-RECEPTOR.
221051 04-03
LONG-LASTING EFFECTS OF PRENATAL 2,4,5 TRICHLOROPHENOXYACETIC ACID ON OPEN-FIELD BEHAVIOR IN RATS: PRE- AND POSTNATAL MEDIATION.
223044 04-04

MEDIATORS
DRUGS, MEDIATORS, AND SCHIZOPHRENIA.
208631 03-08

MEDICAL
PSYCHOPHARMACOLOGY IN MEDICAL PRACTICE.
197269 01-17
A SURVEY OF DRUG TREATMENT IN PSYCHIATRY: SPECIAL EMPHASIS ON INPATIENTS ON MEDICAL WELFARE SUPPORTED BY YOKOHAMA CITY.
200447 02-17
SOCIAL AND PSYCHOLOGICAL ASPECTS OF MEDICAL PRACTICE: DRUG TREATMENT IN PSYCHIATRY.
201270 02-17
BARBITURATES AND BARBITURATE LIKE DRUGS: CONSIDERATIONS IN THEIR MEDICAL USE.
202923 02-17
THE MEDICAL USE OF PSYCHOTROPIC DRUGS.
204306 02-17
DRUG ABUSE AND DRUG DEPENDENCY. A COMPENDIUM FOR MEDICAL DOCTORS.
204468 02-17
PSYCHOTROPIC DRUGS ON GENERAL MEDICAL AND SURGICAL WARDS OF A TEACHING HOSPITAL.
213919 04-17
ETHICS IN MEDICAL RESEARCH AS VIEWED BY THE CLINICAL INVESTIGATOR.
214341 04-17

MEDICATION
A STUDY OF THE USE OF ANTIDEPRESSANT MEDICATION IN GENERAL PRACTICE.
194407 01-17
NEONATAL BEHAVIORAL PATTERNS AND THEIR RELATION TO OBSTETRICAL MEDICATION. (PH.D. DISSERTATION).
194573 01-15
A BEHAVIORAL INVESTIGATION: THE EFFECTS OF MEDICATION ON DISRUPTIVE CLASSROOM BEHAVIOR AND ACADEMIC PERFORMANCE. (PH.D. DISSERTATION).
200461 02-11
MEASURING EFFECTS OF PSYCHOACTIVE MEDICATION IN A CHILD WITH A LEARNING DISABILITY.
203847 02-14
THE SERUM GONADOTROPIN LEVEL UNDER THE MEDICATION OF L-DOPA.
204394 02-13
EXPERIMENTAL PSYCHOLOGIC AND PSYCHOPHYSIOLOGIC LONGITUDINAL PROFILE STUDIES ON DEPRESSIVE PATIENTS UNDER THYMOLEPTIC MEDICATION.
204413 02-15
MICROAUTORADIOGRAPHIC STUDIES AFTER MEDICATION OF C14-FLUPHENAZINE IN THE ANIMAL EXPERIMENT.
206769 03-03
REFLECTIONS ON THE EFFICACY OF NEW DRUG THERAPIES ON THE OCCASION OF USING AN ORIGINAL MEDICATION: SULPIRIDE (DOGMATIL).
209123 03-11
SALIVARY SCINTOGRAPHY: INTEREST IN TREATMENT OF DRY MOUTH PROVOKED BY PSYCHOTROPIC MEDICATION.
212493 03-15
MEDICATION FOR HYPERKINETIC CHILDREN.
213988 04-11
USE OF CNS STIMULANT MEDICATION IN AVERAGED ELECTROENCEPHALIC AUDIOMETRY WITH CHILDREN WITH MBD.
221103 04-11

MEDICATIONS
PSYCHOPHARMACOLOGY IN THE AGED: USE OF MAJOR PSYCHOTROPIC MEDICATIONS IN TREATMENT OF THE ELDERLY: CASE EXAMPLES.
208575 03-11

MEDICINE
MY EXPERIENCE WITH THE USE OF A TRANQUILIZER, NORITREN, IN THE DEPARTMENT OF INTERNAL MEDICINE PSYCHOSOMATICS.
194510 01-11
THE USE OF TRAZODONE IN PSYCHOSOMATIC MEDICINE.
196197 01-14
PSYCHOTHERAPY AND DRUGS FROM THE STANDPOINT OF INTERNAL MEDICINE.
199907 02-17
TREATMENT AND COUNTERMEASURES FOR PATIENTS WITH INSOMNIA IN THE DEPARTMENT OF INTERNAL MEDICINE -- SPECIAL EMPHASIS ON THE CLINICAL APPLICATION OF FLURAZEPAM.
202285 02-14
MEDICINE FOR FREEDOM OR THE FREEDOM OF MEDICINE.
208928 03-17
PSYCHOLOGICAL MEDICINE: PSYCHOTROPIC DRUGS IN GENERAL PRACTICE.
216948 04-17
PHARMACOKINETICS IN CLINICAL MEDICINE: OXAZEPAM VERSUS OTHER BENZODIAZEPINES.
218151 04-17

MEDULLA
ACTIONS OF GABA, PICROTOXIN AND BICUCULLINE ON ADRENAL MEDULLA.
193455 01-03
SUPPRESSION BY NORADRENALINE OF CATECHOLAMINE SECRETION FROM ADRENAL MEDULLA.
199869 02-03
EVIDENCE AGAINST A CAUSAL RELATIONSHIP BETWEEN INCREASE IN C-AMP AND INDUCTION OF TYROSINE-HYDROXYLASE IN THE RAT ADRENAL MEDULLA.
202795 02-03
MATURATION OF THE ADRENAL MEDULLA -- III: PRACTICAL AND THEORETICAL CONSIDERATIONS OF AGE DEPENDENT ALTERATIONS IN KINETICS OF INCORPORATION OF CATECHOLAMINES AND NONCATECHOLAMINES.
205852 03-03
STUDIES ON THE SYNTHESIS AND SUBCELLULAR DISTRIBUTION OF DOPAMINE IN THE RAT ADRENAL MEDULLA.
217797 04-03
DEXAMETHASONE INDUCES TYROSINE-HYDROXYLASE IN SYMPATHETIC GANGLIA BUT NOT IN ADRENAL MEDULLA.
217853 04-03

MEDULLARY
EFFECTS OF THEOPHYLLINE AND PROPRANOLOL ON ACETYLCHOLINE-INDUCED RELEASE OF ADRENAL MEDULLARY CATECHOLAMINES.
195591 01-03

MEFEXAMIDE
THE EFFECT OF MEFEXAMIDE ON SOME AUTONOMIC AND PSYCHOLOGICAL TESTS.
205605 03-13

MEGAVITAMIN
MEGAVITAMIN AND ORTHOMOLECULAR THERAPY OF SCHIZOPHRENIA.
219536 04-08

MEGIMIDE
THE USE OF MEGIMIDE IN FUNCTIONAL EEG.
205566 02-13

MELANCHOLIA
INVOLUTIONAL MELANCHOLIA IN MALES?
206601 03-09
CLINICAL AND NEUROENDOCRINOLOGICAL STUDY OF TRH IN MELANCHOLIA.
212162 03-09

MELANCHOLIC
AN ATTEMPT TO VERIFY THE ANTIDEPRESSANT ACTION OF THE HYPOTHALAMIC THYROSTIMULIN (THYROTROPIN-RELEASING FACTOR OR TRF) IN MELANCHOLIC STATES.
216758 04-09

MELANOCYTE
MELANOCYTE STIMULATING HORMONE: SOME BEHAVIORAL EFFECTS. (PH.D. DISSERTATION).
213030 03-04

MELATONIN
INFLUENCE OF MELATONIN ON EEG AND HUMAN SLEEP: AUTOMATIC EEG ANALYSES AND POLYGRAPHIC NIGHT SLEEP INVESTIGATIONS.
205446 02-13

MELITRACEN
CLINICAL STUDY OF AN NEW ANTIDEPRESSANT, MELITRACEN, FOR 50 AMBULATORY PATIENTS.
212490 03-10

MEMBRANE
HYDROCORTISONE-INDUCED SUPERSENSITIVITY TO NORADRENALINE IN THE ISOLATED NICTITATING MEMBRANE AS A CONSEQUENCE OF AN IMPAIRMENT OF AN O-METHYLATING SYSTEM WITH HIGH AFFINITY.
197944 01-03
IMMUNOLOGICAL LOCALIZATION OF DOPAMINE-BETA-HYDROXYLASE ON THE CHROMAFFIN GRANULE MEMBRANE.
207326 03-03
FREE AND MEMBRANE BOUND RIBOSOMES AND POLYSOMES IN HIPPOCAMPAL NEURONS DURING A LEARNING EXPERIMENT.
210674 03-04
BINDING OF LITHIUM AND CALCIUM BY CEREBRAL MEMBRANE FRACTIONS.
210806 03-03
COMPARATIVE STUDIES ON THE MEMBRANE ACTIONS OF DEPRESSANT DRUGS: THE ROLE OF LIPOPHILICITY IN INHIBITION OF BRAIN SODIUM AND POTASSIUM STIMULATED ATPASE.
210818 03-03
THE PROTECTIVE EFFECT OF SEROTONIN AGAINST THE INHIBITORY ACTION OF CHLORPROMAZINE ON THE MEMBRANE POTENTIAL OF STAGE 2 BLASTOMERES OF MOUSE EMBRYOS IN VITRO.
217005 04-03

MEMBRANES
STUDIES ON THE EFFECT OF AMANTADINE ON NEURONAL MEMBRANES.
197283 01-03
GENETIC DETERMINANT OF LITHIUM ION METABOLISM: II. AN IN VIVO STUDY OF LITHIUM ION DISTRIBUTION ACROSS ERYTHROCYTE MEMBRANES.
211412 03-03
COMPARISON OF THE ACTION OF DIFFERENT BARBITURATES ON SQUID AXON MEMBRANES.
217662 04-03

MEMORY
EFFECTS OF D-AMPHETAMINE ON LEARNING AND MEMORY IN INBRED AND HYBRID MICE. (PH.D. DISSERTATION).
193581 01-04
EFFECTS OF PSYCHOTROPIC DRUGS ON THE SHORT-TERM MEMORY OF RETARDED CHILDREN. (PH.D. DISSERTATION).
194655 01-14
TIME-DEPENDENT, MEMORY RETRIEVAL EFFECTS FOLLOWING PERIPHERAL AND HIPPOCAMPAL TREATMENTS TO INCREASE SYNAPTIC BIOGENIC AMINES. (PH.D. DISSERTATION).
194677 01-04
NICOTINE AND CAFFEINE: DISRUPTION OF THE LONG-TERM STORE MEMORY AND PROACTIVE FACILITATION OF LEARNING IN MICE.
198222 02-04
PUROMYCIN AND MEMORY. (PH.D. DISSERTATION).
199039 02-04
EFFECT OF TWO WEEKS TREATMENT WITH CHLORIMIPRAMINE AND NORTRIPTYLINE, ALONE OR IN COMBINATION WITH ALCOHOL, ON LEARNING AND MEMORY.
200057 02-14
COMPARISON OF THE EFFECTS OF ANISOMYCIN ON MEMORY ACROSS SIX STRAINS OF MICE.
202202 02-04

THE EFFECT OF CHOLINERGICS ON SHORT-TERM MEMORY AND THE EXCITABILITY LEVEL OF HIPPOCAMPUS CIRCLE STRUCTURES.
208972 03-03
FACILITATION OF TIME-DEPENDENT MEMORY PROCESSES WITH POSTTRIAL EPINEPHRINE INJECTIONS.
209951 03-04
MEMORY ENHANCEMENT BY CENTRAL ADMINISTRATION OF NOREPINEPHRINE.
210671 03-04
INHIBITION OF MEMORY FORMATION IN THE IMPRINTING PERIOD: IRREVERSIBLE ACTION OF CYCLOHEXIMIDE IN YOUNG CHICKENS.
210708 03-04
SOME EVIDENCE FOR LONG-TERM MEMORY RETENTION BY OROTIC ACID IN RATS BAR PRESSING FOR WATER.
210790 03-04
A FURTHER STUDY ON THE EFFECT OF PHYSOSTIGMINE ON MEMORY IN RATS.
210916 03-04
MOLECULAR MECHANISMS OF MEMORY AND LEARNING (GENERAL CONSIDERATIONS AND CLINICAL APPLICATIONS).
212281 03-14
ON THE PARTICIPATION OF BIOGENIC AMINES AND THEIR SYNTHETIC ENZYMES IN THE MECHANISMS OF IMAGE MEMORY.
213469 04-04
ON THE PHYSIOLOGICAL MECHANISMS OF THE INFLUENCE OF PHENAMINE AND MICROPOLARIZATION ON LONG-TERM MEMORY PROCESSES.
213491 04-04
ANTEROGRADE AND RETROGRADE EFFECTS OF ELECTROCONVULSIVE SHOCK AND OF PUROMYCIN ON MEMORY FORMATION IN THE GOLDFISH.
213853 04-04
ADRENERGIC AND CHOLINERGIC DRUG EFFECTS UPON SHORT-TERM MEMORY IN MICE. (PH.D. DISSERTATION).
214205 04-04
THE CORRELATION BETWEEN THE VENTRAL AND DORSAL HIPPOCAMPUS DURING IMPROVEMENT OR DETERIORATION OF SHORT-TERM MEMORY.
215487 04-04
DISRUPTION OF STATE-DEPENDENT LEARNING (MEMORY RETRIEVAL) BY EMOTIONALLY IMPORTANT STIMULI.
217470 04-04
METHYLPHENIDATE AND HALOPERIDOL IN CHILDREN: EFFECTS ON ATTENTION, MEMORY, AND ACTIVITY.
218118 04-14
THE EFFECT OF TRANSAMINE ON PSYCHONERVOUS AND CONDITIONED MEMORY IN RATS.
219745 04-04
GENETIC, BIOCHEMICAL, AND ENVIRONMENTAL VARIABLES IN THE EXPRESSION OF SHORT-TERM MEMORY IN THE MOUSE. (PH.D. DISSERTATION).
222749 04-04

MENOPAUSAL
RESERPINE THERAPY FOR MENOPAUSAL TROUBLE.
201694 02-11

MENOPAUSE
HUMAN GROWTH HORMONE RESPONSE TO LEVODOPA: RELATION TO MENOPAUSE, DEPRESSION, AND PLASMA DOPA CONCENTRATION.
213918 04-09

MENTAL
A DOUBLE-BLIND CROSSOVER COMPARISON BETWEEN CLOTHIAPINE AND DIAZEPAM IN THE TREATMENT OF MENTAL SYMPTOMS IN CHRONIC ALCOHOLICS.
192988 01-11
EXAMINATION OF THE EFFECTS OF CLOXAZOLAM BY A DOUBLE-BLIND STUDY OF MENTAL PATIENTS BEFORE REHABILITATION.
194474 01-08
DOES LITHIUM IN DRINKING WATER PREVENT MENTAL DISORDER?
195933 01-17
COMBINED EFFECTS OF DIAZEPAM AND ETHANOL ON MENTAL AND PSYCHOMOTOR FUNCTIONS.
199896 02-14
THE COMBINED EFFECTS OF METHYLPHENIDATE (RITALIN) AND A CLASSROOM BEHAVIOR MODIFICATION PROGRAM IN REDUCING THE HYPERKINETIC BEHAVIORS OF INSTITUTIONALIZED MENTAL RETARDATES. (PH.D. DISSERTATION).
202356 02-11
METHYLDOPA INDUCED DECREASE IN MENTAL ACTIVITY.
202921 02-15
CONFUSIONAL STATES IN ELDERLY MENTAL PATIENTS TREATED WITH ANTIDEPRESSANTS.
205603 03-15
TWO DECADES OF PSYCHOPHARMACOLOGY AND COMMUNITY MENTAL HEALTH: OLD AND NEW PROBLEMS OF THE SCHIZOPHRENIC PATIENT.
207921 03-17
PSYCHOPHARMACOLOGY, COMMUNITY MENTAL HEALTH AND THE SCHIZOPHRENIC PATIENT.
207922 03-17
FROM HOSPITAL TREATMENT TO COMMUNITY PSYCHIATRY -- SECOND REPORT -- OUTPATIENT EMERGENCY TREATMENT OF MENTAL PATIENTS WITH THE USE OF HALOPERIDOL.
208723 03-11
LITHIUM, CALCIUM, AND MENTAL ILLNESS.
209350 03-13
CHANGES IN MENTAL AGE WITH SUBNORMAL CHILDREN TREATED WITH DOSES OF GABA AND NUCLEOTIDES.
210286 03-14
TEMPORAL DISCRIMINATION TESTS IN MENTAL RETARDATES TREATED WITH NUCLEOTIDES AND GABA IN HIGH DOSES.
210293 03-14
MENTAL AND PSYCHOMOTOR EFFECTS OF DIAZEPAM AND ETHANOL.
211070 03-14
ANTENATAL EXPOSURE TO MEPROBAMATE AND CHLORDIAZEPOXIDE IN RELATION TO MALFORMATIONS, MENTAL DEVELOPMENT, AND CHILDHOOD MORTALITY.
212107 03-15
MENTAL DISORDERS SEEN AFTER OPEN HEART SURGERY.
214304 04-11
PSYCHOTROPIC DRUG THERAPY IN A MENTAL HOSPITAL.
215291 04-17
EFFECTS OF DIPHENYLHYDANTOIN ON MENTAL ABILITIES IN THE ELDERLY.
215857 04-14
MENTAL DECLINE IN THE ELDERLY: PHARMACOTHERAPY (ERGOT ALKALOIDS VERSUS PAPAVERINE).
218306 04-11
NICOTINIC ACID IN THE TREATMENT OF SCHIZOPHRENIAS: CANADIAN MENTAL HEALTH ASSOCIATION COLLABORATIVE STUDY PROGRESS REPORT II.
219537 04-08
THE EFFECT OF PSYCHOTROPIC AGENTS ON THE MENTAL AND PHYSICAL WORKING CAPACITY IN RATS.
219748 04-04
AN ASPECT OF BIOLOGICAL THERAPY IN THE SYSTEM OF REHABILITATING EPILEPTIC PATIENTS WITH MENTAL DISORDERS.
220420 04-11
PSYCHOPHARMACOLOGICAL PRINCIPLES OF REHABILITATING MENTAL PATIENTS.
220425 04-08
ELECTROENCEPHALOGRAPHIC STUDY FOR THE EVALUATION OF THE EFFECTS OF 7-CHLORO-5-PHENYLBENZODIAZEPIN-2-ONE (N-DEMETHYLDIAZEPAM) ON SLEEP DISTURBANCES IN A GROUP OF MENTAL PATIENTS.
221272 04-14

MENTALLY
PYRITHIOXINE (ENCEPHABOL) IN MENTALLY DEFICIENT CHILDREN (A TRIAL ON 50 CASES).
194554 01-11
SULPIRIDE VERSUS CHLORPROMAZINE AND PLACEBO IN THE TREATMENT OF RESTLESS MENTALLY SUBNORMAL PATIENTS -- A DOUBLE-BLIND CROSSOVER STUDY.
209702 03-11
MNEMONIC CAPACITY OF MENTALLY RETARDED BOYS TREATED WITH HIGH DOSES OF NUCLEOTIDES AND GABA.
210291 03-14
URINARY SCREENING FOR DRUGS IN A HOSPITAL FOR THE MENTALLY SUBNORMAL.
210437 03-17
RED CELL FOLATE AND MACROCYTOSIS DURING LONG-TERM ANTICONVULSANT THERAPY IN NONANAEMIC MENTALLY RETARDED EPILEPTICS.
218553 04-11
RESULTS OF A SURVEY (1966-1967) OF DRUG USAGE IN INSTITUTIONS FOR THE MENTALLY RETARDED. (UNPUBLISHED PAPER).
222411 04-17

MEPERIDINE
CHANGES IN THE DORSAL ROOT POTENTIAL WITH DIAZEPAM AND WITH THE ANALGESICS ASPIRIN, NITROUS OXIDE, MORPHINE AND MEPERIDINE.
195248 01-03
THE BIOAVAILABILITY OF MEPERIDINE.
199519 02-13
INHIBITION OF SEROTONIN UPTAKE AND THE TOXIC INTERACTION BETWEEN MEPERIDINE AND MONOAMINEOXIDASE INHIBITORS.
217696 04-03
PHARMACOKINETICS OF CHLORDIAZEPOXIDE, MEPERIDINE, THIORIDAZINE, AND MESORIDAZINE AND CLINICAL RESPONSE.
224830 04-13

MEPIPRAZOL
CLINICAL TRIAL OF 3-METHYL-5-BETA-N-N-M-CHLOROPHENYLPIPERAZINOETHYL PYRAZOLE DIHYDROCHLORIDE (MEPIPRAZOL) IN THE THERAPY OF PSYCHOVEGETATIVE DISORDERS.
215694 04-10

MEPROBAMATE
INFLUENCE OF MEPROBAMATE, CARISPRODOL, OXAZEPAM AND PHENOBARBITAL ON NA+ TRANSPORT IN THE ISOLATED FROG SKIN.
206781 03-03

ANTENATAL EXPOSURE TO MEPROBAMATE AND CHLORDIAZEPOXIDE IN RELATION TO MALFORMATIONS, MENTAL DEVELOPMENT, AND CHILDHOOD MORTALITY.
212107 03-15

ELECTROENCEPHALOGRAPHIC STUDY ON THE ACTION OF THE COMBINATION MEPROBAMATE ACEPROMETAZINE ON VARIOUS CEREBRAL SYSTEMS.
221286 04-03

ANXIETY NEUROSIS, DEPRESSIVE DISORDER AND MEPROBAMATE ADDICTION -- PSYCHIATRIC GRAND-ROUNDS, UNIV. OF CALIFORNIA, SAN-DIEGO.
222772 04-10

MERCURY

RAPID ANALYSIS OF THE CENTRAL NERVOUS SYSTEM STIMULANTS, AMPHETAMINES, VIA GAS CHROMATOGRAPHY MASS SPECTROMETRY: RAPID ACYLATION IN THE PRESENCE OF A MERCURY CATALYST.
222830 04-06

MERIONES-UNGUICULATUS

THE EFFECTS OF D- AND L-AMPHETAMINE UPON HOARDING BEHAVIOR AND FEEDING IN THE MONGOLIAN GERBIL (MERIONES-UNGUICULATUS).
202983 02-04

MESCALINE

MESCALINE-INDUCED CHANGES OF BRAIN CORTEX RIBOSOMES: EFFECT OF MESCALINE ON RIBOSOMAL SYNTHESIS OF POLYURIDINE DIRECTED POLYPHENYLALANINE.
194153 01-03

MESCALINE-INDUCED CHANGES OF BRAIN-CORTEX RIBOSOMES: EFFECT OF MESCALINE ON TRNA AND AMINOACYL-TRNA SYNTHETASE.
195242 01-03

CONFORMATIONALLY CONSTRAINED ANALOGS OF MESCALINE.
195560 01-01

EFFECTS OF MESCALINE, DELTA9-TETRAHYDROCANNABINOL AND PENTOBARBITAL ON THE AUDITORY EVOKED RESPONSES IN THE CAT.
197990 01-03

THE EFFECT OF MICROELECTROPHORETICALLY APPLIED MESCALINE ON CORTICAL NEURONES.
199961 02-03

STIMULUS PROPERTIES OF MESCALINE AND N-METHYLATED DERIVATIVES: DIFFERENCE IN PERIPHERAL AND DIRECT CENTRAL ADMINISTRATION.
201320 02-02

EFFECTS OF AMINOACETONITRILE, AN AMINE OXIDASE INHIBITOR, ON MESCALINE METABOLISM IN THE RABBIT.
205853 03-03

OXIDATIVE METABOLISM OF MESCALINE IN THE CENTRAL NERVOUS SYSTEM -- V. IN VITRO DEAMINATION OF MESCALINE TO 3,4,5 TRIMETHOXYBENZOIC ACID.
210813 03-03

THE TOXICITY OF CHLORPROMAZINE AND MESCALINE ON MOUSE CEREBELLUM AND FIBROBLAST CELLS IN CULTURE.
210890 03-03

BLOCKADE OF THE STIMULUS PROPERTIES OF MESCALINE BY A SEROTONIN ANTAGONIST.
217650 04-03

EFFECT OF MORPHINE, HYDROMORPHONE, METHADONE, MESCALINE, TRYPAN-BLUE, VITAMIN-A, SODIUM SALICYLATE AND CAFFEINE ON THE SERUM INTERFERON LEVEL IN RESPONSE TO VIRAL INFECTION.
217654 04-03

MESCALINE-INDUCED

MESCALINE-INDUCED CHANGES OF BRAIN CORTEX RIBOSOMES: EFFECT OF MESCALINE ON RIBOSOMAL SYNTHESIS OF POLYURIDINE DIRECTED POLYPHENYLALANINE.
194153 01-03

MESCALINE-INDUCED CHANGES OF BRAIN-CORTEX RIBOSOMES: EFFECT OF MESCALINE ON TRNA AND AMINOACYL-TRNA SYNTHETASE.
195242 01-03

MESCALINE-14C

PERIPHERAL TISSUE DISTRIBUTION, BRAIN DISTRIBUTION AND METABOLISM OF MESCALINE-14C IN MONKEYS.
197458 01-03

MESENCEPHALIC

COMPARATIVE INVOLVEMENT OF DOPAMINE AND NORADRENALINE IN RATE-FREE SELF-STIMULATION IN SUBSTANTIA-NIGRA, LATERAL HYPOTHALAMUS, AND MESENCEPHALIC CENTRAL GRAY.
193303 01-03

THE EFFECT OF CHLORPROMAZINE AND STIMULATION OF THE MESENCEPHALIC RETICULAR FORMATION ON CENTRAL AROUSAL AND ON THE VISUAL EVOKED RESPONSE. (PH.D. DISSERTATION).
212547 03-03

MESENCEPHALON

5-HT AND NOREPINEPHRINE-INDUCED RELEASE OF ACH FROM THE THALAMUS AND MESENCEPHALON OF THE MONKEY DURING THERMOREGULATION.
210672 03-03

MESOLIMBIC

MESOLIMBIC INVOLVEMENT WITH BEHAVIOURAL EFFECTS INDICATING ANTIPSYCHOTIC ACTIVITY.
193450 01-03

THE IMPORTANCE OF THE ASCENDING DOPAMINERGIC SYSTEMS TO THE EXTRAPYRAMIDAL AND MESOLIMBIC BRAIN AREAS FOR THE CATALEPTIC ACTION OF THE NEUROLEPTIC AND CHOLINERGIC AGENTS.
195250 01-03

DOPAMINERGIC NEURONS IN THE NIGROSTRIATAL AND MESOLIMBIC PATHWAYS: MEDIATION OF SPECIFIC EFFECTS OF D-AMPHETAMINE.
210855 03-03

THE BEHAVIOURAL EFFECTS OF DOPAMINE APPLIED INTRACEREBRALLY TO AREAS OF THE MESOLIMBIC SYSTEM.
217660 04-04

BEHAVIORAL EFFECTS OF LOCAL INJECTION OF 6-HYDROXYDOPAMINE IN THE MEDIAL VENTRAL TEGMENTUM IN THE RAT. POSSIBLE ROLE OF THE MESOLIMBIC DOPAMINERGIC SYSTEM.
220946 04-04

MESORIDAZINE

ABSORPTION AND EXCRETION OF THIORIDAZINE AND MESORIDAZINE IN MAN.
217154 04-08

EFFECT OF MESORIDAZINE ADMINISTRATION AND WITHDRAWAL ON PERFORMANCE IN AN OLDER AGE GROUP.
217452 04-11

PHARMACOKINETICS OF CHLORDIAZEPOXIDE, MEPERIDINE, THIORIDAZINE, AND MESORIDAZINE AND CLINICAL RESPONSE.
224830 04-13

MESYLATE

A DOUBLE-BLIND STUDY OF AMANTADINE HYDROCHLORIDE VERSUS BENZTROPINE MESYLATE IN DRUG-INDUCED PARKINSONISM.
202764 02-15

MESYLPHENACYRAZINE

PHARMACOLOGICAL PROPERTIES OF A POTENTIAL TRANQUILISING AGENT MESYLPHENACYRAZINE: I. INTERACTION WITH DRUGS INFLUENCING THE NERVOUS SYSTEM.
205578 02-03

PHARMACOLOGICAL PROPERTIES OF A POTENTIAL TRANQUILISING AGENT MESYLPHENACYRAZINE: II. CHANGES RELATED TO ITS REPEATED ADMINISTRATION.
205579 02-03

META-SUBSTITUTED

STRUCTURE-ACTIVITY RELATIONSHIPS BETWEEN META-SUBSTITUTED N-ETHYLAMPHETAMINES AND LOCOMOTOR ACTIVITY IN MICE.
210886 03-04

STRUCTURE-ACTIVITY RELATIONSHIPS BETWEEN META-SUBSTITUTED N-ETHYLAMPHETAMINES AND ISOLATED GUINEA-PIG ATRIAL RATE.
210887 03-03

METABOLIC

STUDIES ON SOME METABOLIC EFFECTS OF DOPA AND DOPAMINE IN THE RAT.
193301 01-03

THE EFFECT OF DAILY ORAL DOSAGE OF DIAZEPAM, PLASMA CONCENTRATIONS AND METABOLIC CLEARANCE OF DIAZEPAM AND DEMETHYLDIAZEPAM ON VARIOUS CONSTITUENTS OF THE ACUTE CLINICAL ANXIETY SYNDROME.
196191 01-10

METABOLIC COMPARTMENTATION IN THE BRAIN: METABOLISM OF A TRICARBOXYLIC ACID CYCLE INTERMEDIATE, (1,4-14C)SUCCINATE, AFTER INTRACEREBRAL ADMINISTRATION.
210780 03-03

EFFECT OF OUABAIN AND PHENOBARBITAL ON THE KINETICS OF CORTICAL METABOLIC TRANSIENTS ASSOCIATED WITH EVOKED POTENTIALS.
210820 03-03

PHARMACOLOGY OF CEREBRAL CIRCULATION AND CLINICAL APPLICATIONS. EXPERIMENTAL STUDY OF THE CIRCULATORY AND METABOLIC EFFECTS OF HYDROSARPAN-711.
218164 04-03

EFFECT OF OUABAIN AND PHENOBARBITAL ON OXIDATIVE METABOLIC ACTIVITY ASSOCIATED WITH SPREADING CORTICAL DEPRESSION IN CATS.
220944 04-03

METABOLISM

FURTHER STUDIES ON THE EFFECT OF P-HYDROXYNOREPHEDRINE (PONE) ON NOREPINEPHRINE METABOLISM IN THE RAT BRAIN.
193453 01-03

EFFECT OF CHRONIC ADMINISTRATION OF CENTRALLY ACTING COMPOUNDS ON CHLORAMPHENICOL METABOLISM IN SCHIZOPHRENIC PATIENTS.
194157 01-08

COMPARATIVE STUDY OF THE EFFECTS OF CHLORAL HYDRATE AND TRICHLOROETHANOL ON CEREBRAL METABOLISM.
194742 01-03

INTERACTION OF CATECHOLAMINE AND AMINO ACID METABOLISM IN BRAIN: EFFECT OF PARGYLINE AND L-DOPA.
195048 01-03

EFFECTS OF SOME HOMOLOGUES OF 4-CHLOROAMPHETAMINE ON BRAIN SEROTONIN METABOLISM.
195092 01-02

INTERACTION OF PENTYLENETETRAZOL AND TRIMETHADIONE ON THE METABOLISM OF SEROTONIN IN BRAIN AND ITS RELATION TO THE ANTICONVULSANT ACTION OF TRIMETHADIONE.
195093 01-03

BRAIN SEROTONIN METABOLISM IN LITHIUM TREATED RATS.
195235 01-03

INFLUENCE OF THERAPEUTIC AND TOXIC DOSES OF NEUROLEPTICS AND ANTIDEPRESSANTS ON ENERGY METABOLISM OF THE ISOLATED PERFUSED RAT BRAIN.
195236 01-03

NORADRENALINE AND 5-HYDROXYTRYPTAMINE METABOLISM IN SIX AREAS OF RAT BRAIN DURING POST-AMPHETAMINE DEPRESSION.
195437 01-03

DIAZEPAM METABOLISM IN NORMAL MAN: I. SERUM CONCENTRATIONS AND CLINICAL EFFECTS AFTER INTRAVENOUS, INTRAMUSCULAR, AND ORAL ADMINISTRATION.
195444 01-15

DIAZEPAM METABOLISM IN NORMAL MAN: II. SERUM CONCENTRATION AND CLINICAL EFFECT AFTER ORAL ADMINISTRATION AND CUMULATION.
195445 01-13

ANALYSIS OF THE INFLUENCE OF SELECTED NEUROTROPIC AGENTS ON HEPATIC METABOLISM IN RELATION TO ENDOTOXICOSIS.
195448 01-03

CLINICAL MEASUREMENT OF CENTRAL DOPAMINE AND SEROTONIN METABOLISM IN ACUTE PSYCHOTIC DISORDERS.
195924 01-09

EVIDENCE FOR A PERIPHERAL EFFECT OF FUSARIC ACID, A DOPAMINE-BETA-HYDROXYLASE INHIBITOR, ON SEROTONIN METABOLISM.
196593 01-03

SUBTYPE OF AFFECTIVE PSYCHOSES CLASSIFIED BY RESPONSE ON AMINE PRECURSORS AND MONOAMINE METABOLISM.
197209 01-09

EFFECTS OF LITHIUM ON CYCLIC-3-5-AMP METABOLISM IN RAT BRAIN.
197278 01-03

THE EFFECTS OF IMIPRAMINE AND PROMAZINE ON ENERGY METABOLISM AND EEG OF THE ISOLATED PERFUSED RAT BRAIN.
197296 01-03

STUDIES ON ALPHA-METHYLDOPA: RELATIONSHIP BETWEEN METABOLISM, BIOGENIC AMINES AND ANTIHYPERTENSIVE EFFECT.
197298 01-03

PERIPHERAL TISSUE DISTRIBUTION, BRAIN DISTRIBUTION AND METABOLISM OF MESCALINE-14C IN MONKEYS.
197458 01-03

EFFECTS OF THE HIGH DOSES OF L-DOPA ON ELECTRICAL ACTIVITY IN THE BRAIN OF THE RABBIT: INTERACTION WITH THE METABOLISM OF 5-HT.
197468 01-03

EFFECT OF PSYCHOACTIVE DRUGS ON IN VIVO METABOLISM OF 14C-HISTAMINE IN MOUSE BRAIN.
197472 01-03

SOME OF THE DYNAMICS OF CHOLINE AND ACETYLCHOLINE METABOLISM IN RAT BRAIN.
197474 01-03

THE INFLUENCE OF CHLORPROMAZINE AND RESERPINE ON THE METABOLISM OF CEREBRAL PHOSPHOLIPIDS IN THE RAT IN VIVO.
197477 01-03

CHLORPROMAZINE METABOLISM VI -- ADRENOLYTIC AND ANTISEROTONERGIC ACTIVITIES OF CHLORPROMAZINE AND ITS VARIOUS METABOLITES.
197494 01-03

THE ACTION OF PSYCHOSTIMULANT SIDNOKARB ON METABOLISM OF BIOGENIC AMINES IN THE BRAIN.
197573 01-03

BLOOD LEVEL, EXCRETION, DISTRIBUTION AND METABOLISM OF 14C-TRIFLUBAZAM, A NEW 1,5 BENZODIAZEPINE, IN MICE AND DOGS.
197940 01-03

ALTERATION OF THE EFFECTS AND THE METABOLISM OF D-AMPHETAMINE BY ETHANOL.
197975 01-03

CHLORPROMAZINE METABOLISM IN ACUTE SCHIZOPHRENIA.
198094 02-08

ON THE METABOLISM OF A NEW ANTIDEPRESSANT, AZAPHEN, IN RATS.
198484 02-01

THE EFFECT OF L-DOPA ON THE DEVELOPMENT OF RESERPINE INDUCED PARKINSONISM AND CATECHOLAMINE METABOLISM IN RATS.
198486 02-03

STUDIES ON THE IN VITRO METABOLISM OF COMPOUNDS RELATED TO LYSERGIC ACID DIETHYLAMIDE (LSD).
198608 02-01

STUDIES ON PSYCHOTROPIC DRUGS: XVII. EFFECTS OF 3-CHLORO-5-(3-(4 PIPERIDINO-4-CARBAMOYL-PIPERIDINO)PROPYL) 10,11-DIHYDRO-5(H) DIBENZAZEPINE DIHYDROCHLORIDE MONOHYDRATE (Y-4153) ON THE METABOLISM OF BIOGENIC AMINES.
199210 02-03

N-ACETYLTRANSFERASE OF BRAIN: POSSIBLE INVOLVEMENT IN THE METABOLISM OF THE BIOGENIC AMINES. (UNPUBLISHED PAPER).
199347 02-03

EFFECT OF PROGESTERONE ON REGIONAL 5-HYDROXYTRYPTAMINE METABOLISM IN THE RAT BRAIN.
199773 02-03

EFFECT OF AMINOOXYACETIC ACID ON THE METABOLISM OF PENTOBARBITAL IN MICE.
200002 02-03

THE INFLUENCE OF RESERPINE ON THE SEROTONIN METABOLISM IN PATIENTS WITH SCHIZOPHRENIA AND REACTIVE CONDITIONS.
200013 02-08

THE HEPATIC MICROSOMAL METABOLISM OF BETA 3,4 METHYLENEDIOXYAMPHETAMINE (MDA).
200082 02-03

THE EFFECTS OF LITHIUM ON NOREPINEPHRINE TURNOVER AND METABOLISM: BASIC AND CLINICAL STUDIES.
202249 02-09

INHIBITION OF AMPHETAMINE TOLERANCE AND METABOLISM BY PROPRANOLOL.
202662 02-03

EFFECTS OF PHENOBARBITAL ON ELECTROCORTICOGRAM AND ACTIVITY, ON REGIONAL CNS ENERGY METABOLISM, AND ON PRESYNAPTIC EVENTS IN CEREBRAL CORTEX AND BRAINSTEM. (PH.D. DISSERTATION).
203033 02-03

BIOCHEMICAL CRITERIA FOR CLASSIFYING DEPRESSIVE DISORDERS AND PREDICTING RESPONSES TO PHARMACOTHERAPY: PRELIMINARY FINDINGS FROM STUDIES OF NOREPINEPHRINE METABOLISM. CONTRIBUTIONS TO BIOCHEMISTRY.
203594 02-09

TRYPTOPHAN METABOLISM EXAMINATIONS IN OLIGOPHRENIC CHILDREN. FIRST REPORT: RESULTS OF THE EXCRETION OF KYNURENINE AND XANTHURENIC ACID AFTER TRYPTOPHAN LOADING AND THEIR DEPENDENCE UPON THE SUPPLY.
203645 02-13

THE INFLUENCE OF ENCEPHALOTROPIC DRUGS ON NUCLEIC ACID METABOLISM IN THE BRAIN.
204398 02-13

THE EFFECT OF MAPROTILIN ON BRAIN SEROTONIN METABOLISM IN RATS.
205604 03-03

PSYCHOTROPIC DRUGS AND SOME ENZYMES OF ENERGY METABOLISM.
205630 03-03

EFFECTS OF AMINOACETONITRILE, AN AMINE OXIDASE INHIBITOR, ON MESCALINE METABOLISM IN THE RABBIT.
205853 03-03

LITHIUM AND INSULIN: EFFECTS ON CARBOHYDRATE AND ELECTROLYTE METABOLISM.
205929 03-09

METABOLISM OF DOPAMINE AND NOREPINEPHRINE IN RAT BRAIN AFTER SINGLE AND REPEATED ADMINISTRATION OF HALOPERIDOL, LOXAPINE AND CLOZAPINE.
206973 03-03

EFFECT OF STRESS UPON SEROTONIN METABOLISM IN VARIOUS REGIONS OF THE RAT BRAIN.
206993 03-03

EFFECT OF L-DOPA ON PITUITARY HORMONES AND ON CARBOHYDRATE AND FAT METABOLISM IN NORMALS AND IN PARKINSONS DISEASE.
207153 03-13

EFFECTS OF AMPHETAMINES ON THE METABOLISM OF CATECHOLAMINES IN THE RAT BRAIN.
207288 03-03

A STUDY OF ELECTROLYTE AND BIOGENIC AMINE METABOLISM IN MANIC-DEPRESSIVE ILLNESS.
208917 03-09

CHEMICAL OR ELECTROLYTIC LESION OF THE SUBSTANTIA-NIGRA: EARLY EFFECTS ON NEOSTRIATAL DOPAMINE METABOLISM.
210699 03-03

THE EFFECT OF DIPHENYLHYDANTOIN ON BRAIN 5-HYDROXYTRYPTAMINE METABOLISM AND FUNCTION.
210764 03-03

METABOLIC COMPARTMENTATION IN THE BRAIN: METABOLISM OF A TRICARBOXYLIC ACID CYCLE INTERMEDIATE, (1,4-14C)SUCCINATE, AFTER INTRACEREBRAL ADMINISTRATION.
210780 03-03

OXIDATIVE METABOLISM OF MESCALINE IN THE CENTRAL NERVOUS SYSTEM -- V. IN VITRO DEAMINATION OF MESCALINE TO 3,4,5 TRIMETHOXYBENZOIC ACID.
210813 03-03

THE EFFECT OF TWO SYNTHETIC ACTH ANALOGUES ON THE METABOLISM OF BIOGENIC AMINES IN THE RAT BRAIN.
210875 03-03

EFFECT OF PHENOBARBITAL ON THE METABOLISM AND SEROTONIN DEPLETING ACTION OF 4-CHLORODIFLUOROAMPHETAMINE IN RATS.
210922 03-03

METABOLISM OF 4-CHLOROAMPHETAMINE TO 3-CHLORO-4-HYDROXYAMPHETAMINE IN RAT: EVIDENCE FOR AN IN VIVO NIH SHIFT OF CHOLINE.
210929 03-03

STUDIES WITH AGENTS WHICH INFLUENCE ACETYLCHOLINE METABOLISM IN MOUSE BRAIN.
211065 03-03

METABOLISM OF DELTA1-TETRAHYDROCANNABINOL BY RATS TOLERANT TO CANNABIS.
211100 03-03

METABOLISM OF DELTA1-TETRAHYDROCANNABINOL BY THE RAT IN VIVO AND IN VITRO.
211112 03-03

GENETIC DETERMINANT OF LITHIUM ION METABOLISM: II. AN IN VIVO STUDY OF LITHIUM ION DISTRIBUTION ACROSS ERYTHROCYTE MEMBRANES.
211412 03-03

GAMMA-AMINOBUTYRIC ACID AND CEREBRAL METABOLISM.
212277 03-13

DRUG METABOLISM AND THERAPEUTIC MONITORING.
214337 04-17

FIRST-PASS METABOLISM OF IMIPRAMINE IN MAN.
215671 04-13

THE EFFECT OF PENFLURIDOL AND SOME PSYCHOTROPIC DRUGS ON MONOAMINE METABOLISM IN CENTRAL NERVOUS SYSTEM.
215686 04-03

HYPERSOMNIA BY ISTHMIC LESION IN THE CAT. I. STUDY OF THE METABOLISM OF CEREBRAL MONOAMINES.
215702 04-03

EFFECTS OF TACLAMINE (AY-22214), A NEW PSYCHOACTIVE AGENT, ON CATECHOLAMINE AND SEROTONIN METABOLISM.
215725 04-03

TOLERANCE DEVELOPMENT TO THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON CONDITIONED BEHAVIOR: ROLE OF TREATMENT INTERVAL AND INFLUENCE OF MICROSOMAL METABOLISM.
215726 04-03

INFLUENCE OF CHANGES IN BRAIN MONOAMINE METABOLISM ON BEHAVIOUR OF HERPES-SIMPLEX INFECTED MICE.
217440 04-04

EFFECTS OF CLOZAPINE, THIORIDAZINE, PERLAPINE AND HALOPERIDOL ON THE METABOLISM OF THE BIOGENIC AMINES IN THE BRAIN OF THE RAT.
217543 04-03

THE EFFECTS OF 5-HYDROXY-5-4-CHLOROPHENYL 2,3 DIHYDRO-5H-IMIDAZOISOINDOLE (MAZINDOL, SAH-42-548) ON THE METABOLISM OF BRAIN NOREPINEPHRINE.
217653 04-03

EFFECT OF BENZODIAZEPINE COMPOUNDS ON BRAIN AMINE METABOLISM.
217664 04-03

CHLORPROMAZINE METABOLISM IV: QUATERNIZATION AS A KEY TO DETERMINATION OF PICOMOLES OF CHLORPROMAZINE AND OTHER TERTIARY AMINE DRUGS.
217667 04-06

EFFECTS OF VARIOUS PSYCHOACTIVE DRUGS ON THE METABOLISM OF DELTA1-TETRAHYDROCANNABINOL BY RATS IN VITRO AND IN VIVO.
217672 04-03

THE ROLE OF CATECHOLAMINES IN THE ACTION OF AMPHETAMINE AND L-DOPA ON CEREBRAL ENERGY METABOLISM.
217677 04-03

METABOLISM AND AUTORADIOGRAPHIC DISTRIBUTION OF DELTA8- AND DELTA9-TETRAHYDROCANNABINOL IN SOME ORGANS OF THE MONKEY CALLITHRIX-JACCHUS.
217837 04-03

FUNCTIONAL AND BIOCHEMICAL ASPECTS OF CATECHOLAMINE METABOLISM IN BRAIN UNDER HYPOXIA.
217852 04-03

CORRELATION OF (+) AMPHETAMINE LETHALITY AND HEPATIC METABOLISM.
217880 04-05

THE METABOLISM OF INDIVIDUAL PHOSPHOLIPID FRACTIONS IN THE RAT BRAIN DURING THIOPENTAL SLEEP AND AMPHETAMINE EXCITATION.
219747 04-03

EFFECT OF ETHANOL ON TOXICITY AND METABOLISM OF AMPHETAMINE IN THE MOUSE.
220950 04-05

TRYPTOPHAN METABOLISM IN DEVELOPING CHICK BRAIN.
223053 04-03

A STUDY OF THE RELATIONSHIP BETWEEN CIRCADIAN RHYTHMS IN DRUG ACTION AND METABOLISM IN THE MOUSE. (PH.D. DISSERTATION).
223562 04-03

METABOLITE

CANNABINOL-7-OIC ACID: A METABOLITE OF DELTA1-TETRAHYDROCANNABINOL IN THE RHESUS MONKEY.
195114 01-03

LONGITUDINAL STUDIES ON THE METABOLITE PATTERN OF PERAZINE AND RELATED PHENOTHIAZINES IN HUMANS AND ANIMALS.
206976 03-13

BEHAVIOURAL EVIDENCE OF DOPAMINE RECEPTOR STIMULATION BY PIRIBEDIL (ET495) AND ITS METABOLITE S584.
217152 04-04

THE INFLUENCE OF APOMORPHINE AND TRICYCLIC ANTIDEPRESSANT DRUGS ON THE LEVEL OF SEROTONIN AND ITS METABOLITE IN RAT BRAIN.
217815 04-03

RELATIONSHIPS AMONG CLINICAL RESPONSE, EPS, AND PLASMA CPZ AND CPZ METABOLITE RATIOS.
224831 04-08

METABOLITES

EFFECTS OF THE NORADRENALINE METABOLITES ON TYROSINE-HYDROXYLASE ACTIVITY IN GUINEA-PIG ATRIA.
193279 01-02

MARIHUANA METABOLITES IN URINE OF MAN: III. UNCHANGED DELTA9-TETRAHYDROCANNABINOL.
195053 01-13

CHLORPROMAZINE METABOLISM VI -- ADRENOLYTIC AND ANTISEROTONERGIC ACTIVITIES OF CHLORPROMAZINE AND ITS VARIOUS METABOLITES.
197494 01-03

EFFECTS OF 5-(N-BUTYL) PICOLINAMIDE (SCH-10595), A DOPAMINE-BETA-HYDROXYLASE INHIBITOR, ON SEROTONIN AND CATECHOLAMINE METABOLITES IN BRAIN.
197813 01-03

DOPAMINE AGONIST AND ANTAGONIST ACTIVITIES OF PIRIBEDIL (ET495) AND ITS METABOLITES.
197930 01-04

DISTRIBUTION OF AMPHETAMINE AND ITS HYDROXYLATED METABOLITES IN VARIOUS AREAS OF THE RAT BRAIN.
198211 02-03

COLORIMETRIC, ULTRAVIOLET SPECTROPHOTOMETRIC, AND SPECTROPHOTOFLUOROMETRIC DETERMINATION OF DOXEPIN AND SOME OF ITS METABOLITES IN SERUM AND IN URINE.
199214 02-16

ANTICONVULSANT ACTIVITY OF DELTA9-TETRAHYDROCANNABINOL AND ITS 11 HYDROXY AND 8ALPHA,11 DIHYDROXY METABOLITES IN THE FROG.
200035 02-03

SPECTROFLUORODENSITOMETRIC DETERMINATION OF FLURAZEPAM AND ITS MAJOR METABOLITES IN BLOOD.
200737 02-16

TISSUE METABOLITES OF TRIFLUOPERAZINE, FLUPHENAZINE, PROCHLORPERAZINE, AND PERPHENAZINE IN THE RAT: IDENTIFICATION AND SYNTHESIS.
200738 02-01

GLC DETERMINATION OF PROPRANOLOL, OTHER BETA-BLOCKING DRUGS, AND METABOLITES IN BIOLOGICAL FLUIDS AND TISSUES.
200740 02-16

STRUCTURE-ACTIVITY RELATIONSHIPS IN MAN OF CANNABIS CONSTITUENTS, AND HOMOLOGS AND METABOLITES OF DELTA9-TETRAHYDROCANNABINOL.
202192 02-02

A MASS FRAGMENTOGRAPHIC STUDY OF AMPHETAMINE AND METABOLITES IN RAT BRAIN.
207289 03-06

PHARMACOLOGICAL PROPERTIES OF TWO CHLORDIAZEPOXIDE METABOLITES FOLLOWING MICROSOMAL ENZYME INHIBITION.
210792 03-03

MONOAMINE METABOLITES IN LUMBAR CSF: THE QUESTION OF THEIR ORIGIN IN RELATION TO CLINICAL STUDIES.
210796 03-03

MARIHUANA METABOLITES IN URINE OF MAN: V. CHARACTERISTICS AND SEPARATION OF POLAR METABOLITES OF DELTA9-TETRAHYDROCANNABINOL.
210896 03-16

TOLERANCE DEVELOPMENT WITH CHLORDIAZEPOXIDE IN RELATION TO THE PLASMA LEVELS OF THE PARENT COMPOUND AND ITS MAIN METABOLITES IN MICE.
210973 03-03

THE EFFECT OF CERTAIN TRANQUILISERS, CHLORPROMAZINE METABOLITES AND DIETHYLDITHIOCARBAMATE ON TISSUE AMPHETAMINE LEVELS IN THE RAT.
211111 03-03

EXTRAPYRAMIDAL REACTIONS AND AMINE METABOLITES IN CEREBROSPINAL FLUID DURING HALOPERIDOL AND CLOZAPINE TREATMENT OF SCHIZOPHRENIC PATIENTS.
214010 04-15

MASS FRAGMENTOGRAPHY OF PICOMOLE QUANTITIES OF BIOGENIC AMINE METABOLITES IN HUMAN CEREBROSPINAL FLUID AS WELL AS WHOLE RAT BRAINS. (UNPUBLISHED PAPER).
217219 04-06

THE INFLUENCE OF DESIPRAMINE AND AMITRIPTYLINE ON THE ACCUMULATION OF (3H)NORADRENALINE AND ITS TWO MAJOR METABOLITES FORMED FROM (3H)TYROSINE IN THE RAT BRAIN.
217966 04-03

ON THE GAS CHROMATOGRAPHIC ANALYSIS OF BENZODIAZEPINES: SECOND COMMUNICATION: DIAZEPAM AND ITS METABOLITES.
221739 04-06

METABOLIZING
THE EFFECT OF CHRONIC CANNABIS AND CANNABINOID APPLICATION ON THE HEPATIC DRUG METABOLIZING SYSTEM OF THE RAT.
197282 01-03
AGE DIFFERENCES AFFECTING INDUCTION OF HEPATIC DRUG METABOLIZING ENZYMES BY METHAQUALONE AND PHENOBARBITAL IN THE RAT.
217793 04-03

METAL
DIETHYLDITHIOCARBAMATE (ANTABUSE): DECREASE OF BRAIN HEAVY METAL STAINING PATTERN AND IMPROVED CONSOLIDATION OF SHUTTLEBOX AVOIDANCE IN GOLDFISH.
203521 02-04

METAMIN
USE OF METAMIN (FLUPENTHIXOL) IN THE DEPARTMENT OF PSYCHIATRY.
194449 01-08

METARAMINOL
EFFECT OF AMPHETAMINE, 3,4 METHYLENEDIOXYAMPHETAMINE, P-METHOXYAMPHETAMINE AND RELATED AMPHETAMINES ON UPTAKE OF METARAMINOL AND EFFLUX OF NORADRENALINE IN ADRENERGIC NERVES OF RABBIT ATRIA.
217889 04-03

METATHERAPEUTIC
DEPRESSIONS AND ANTIDEPRESSANTS DURING TREATMENT WITH LONG-ACTING NEUROLEPTIC DRUGS: SIDE-EFFECTS AND THE EMERGENT METATHERAPEUTIC SYNDROME.
219694 04-15

METFORMIN
METFORMIN (GLUCOPHAGE) IN THE TREATMENT OF DRUG-INDUCED OBESITY.
221821 04-13

METHADONE
EFFECT OF APOMORPHINE AND NALLINE ON METHADONE INDUCED BEHAVIORAL CHANGES.
193420 01-04
5-HYDROXYTRYPTAMINE IN PLATELETS AND BRAIN OF RABBITS TREATED CHRONICALLY WITH IMIPRAMINE, MORPHINE OR METHADONE.
194744 01-03
CATALEPSY, STEREOTYPED BEHAVIOUR AND STRIATAL HOMOVANILLIC ACID CONTENT IN RATS TREATED WITH METHADONE.
197299 01-03
COMPUTER ANALYSIS OF METHADONE EFFECTS ON THE ELECTROENCEPHALOGRAM.
205467 02-03
RECIPROCAL (PUSH-PULL) EFFECTS OF MORPHINE ON SINGLE UNITS IN THE VENTROMEDIAN AND LATERAL HYPOTHALAMUS AND INFLUENCES ON OTHER NUCLEI: WITH COMMENT ON METHADONE EFFECTS DURING WITHDRAWAL FROM MORPHINE.
210700 03-03
DRUG SEEKING BEHAVIOR DURING METHADONE MAINTENANCE.
217541 04-04
EFFECT OF MORPHINE, HYDROMORPHONE, METHADONE, MESCALINE, TRYPAN-BLUE, VITAMIN-A, SODIUM SALICYLATE AND CAFFEINE ON THE SERUM INTERFERON LEVEL IN RESPONSE TO VIRAL INFECTION.
217654 04-03
DEPRESSION AND ANXIETY IN HEROIN ADDICTS: A PLACEBO CONTROLLED STUDY OF DOXEPIN IN COMBINATION WITH METHADONE.
225386 04-09
EFFECT OF LOPERAMIDE, HALOPERIDOL AND METHADONE IN RATS TRAINED TO DISCRIMINATE MORPHINE FROM SALINE.
225568 04-04

METHAMPHETAMINE
RELATIONSHIP BETWEEN THE CHANGES ON BLOOD PRESSURE RESPONSE AND THE CARDIAC CATECHOLAMINE LEVEL AFTER SINGLE AND REPEATED ADMINISTRATIONS OF TYRAMINE AND METHAMPHETAMINE IN RATS.
197491 01-03
THE INFLUENCE OF ANTIADRENERGIC AND ANTIDOPAMINERGIC DRUGS ON METHAMPHETAMINE INDUCED CHANGES IN MOTORIC ACTIVITY AND CEREBRAL GLYCOGEN CONTENT IN MICE.
204396 02-03
METHAMPHETAMINE AND PHENETHYLAMINE.
206809 03-03
EFFECTS OF METHAMPHETAMINE ON THE ISOLATED RAT PHRENIC NERVE DIAPHRAM PREPARATION.
210900 03-03
MODIFICATIONS BY LITHIUM OF BEHAVIORAL RESPONSES TO METHAMPHETAMINE AND TETRABENAZINE.
221041 04-04
RAPID MASS SCREENING AND CONFIRMATION OF URINARY AMPHETAMINE AND METHAMPHETAMINE BY GAS CHROMATOGRAPHY.
222829 04-06

METHAMPHETAMINE-INDUCED
EFFECTS OF PSYCHOTROPIC DRUGS ON METHAMPHETAMINE-INDUCED BEHAVIORAL EXCITATION IN GROUPED MICE.
215682 04-04
FURTHER STUDIES OF METHAMPHETAMINE-INDUCED INSULIN RELEASE.
217695 04-03

METHAMPHETAMINES
METHAMPHETAMINES EFFECT ON SDR: REPLICATION AND EXTENSION.
194133 01-04
METHAMPHETAMINES EFFECT ON REPEATED ACQUISITIONS WITH SERIAL DISCRIMINATION REVERSALS.
202769 02-04

METHAPYRILENE
HYPNOTIC EFFICACY OF DIPHENHYDRAMINE, METHAPYRILENE, AND PENTOBARBITAL.
210829 03-13

METHAQUALONE
MECHANISM OF THE HYPOTENSIVE EFFECT OF INTRAVENOUS METHAQUALONE IN THE CAT.
196107 01-03
AGE DIFFERENCES AFFECTING INDUCTION OF HEPATIC DRUG METABOLIZING ENZYMES BY METHAQUALONE AND PHENOBARBITAL IN THE RAT.
217793 04-03
A COMPARISON OF THE INDUCTIVE EFFECTS OF PHENOBARBITAL, METHAQUALONE, AND METHYPRYLON ON HEPATIC MIXED FUNCTION OXIDASE ENZYMES IN THE RAT.
217794 04-03
HYDROLYTIC DEGRADATION OF METHAQUALONE.
225106 04-01

METHAZOLAMIDE
THE ANTICONVULSANT ACTION OF THE CARBONIC ANHYDRASE INHIBITOR METHAZOLAMIDE: POSSIBLE INVOLVEMENT OF A NORADRENERGIC MECHANISM.
197864 01-03

METHIOTHEPIN
EFFECTS OF IPRONIAZID, CHLORPROMAZINE AND METHIOTHEPIN ON DMT INDUCED CHANGES IN BODY TEMPERATURE, PUPILLARY DILATATION, BLOOD PRESSURE AND EEG IN THE RABBIT.
215724 04-03

METHOD
A METHOD FOR THE ISOLATION AND DETERMINATION OF 3-METHOXYTYRAMINE IN BRAIN TISSUE.
193302 01-03
COMPARATIVE STUDY OF Y-6047 AND DIAZEPAM BY A DOUBLE-BLIND METHOD FOR THE TREATMENT OF PSYCHOSOMATIC DISEASES AND NEUROSIS.
198705 02-11
AFFERENTS TO THE SEPTAL AREA OF THE RAT STUDIED WITH THE METHOD OF RETROGRADE AXONAL TRANSPORT OF HORSERADISH PEROXIDASE.
203573 02-03
COMPUTER NYSTAGMOGRAPHY, A NEW METHOD OF DETERMINING CHANGES IN VIGILANCE AS A RESPONSE TO PSYCHOTROPIC DRUGS.
204395 02-16
EEG EVALUATION OF HYPNOTIC DRUGS: MOGADON V. RO-5-4200, USING THE DOUBLE-BLIND METHOD.
205435 02-13
SIMPLE METHOD FOR DETECTION OF THE DRUG CHEATERS IN PSYCHIATRY.
205586 02-17
PSYCHOPHARMACOLOGIC MANAGEMENT OF PATIENTS: A METHOD FOR RECORDING TREATMENT DECISIONS.
207683 03-17
A COMPARISON OF A NEW TRANQUILIZER, SULPIRIDE AND OXAZOLAM ON PSYCHOSOMATIC DISEASES, NEUROSIS AND MASKED DEPRESSION USING DOUBLE-BLIND METHOD.
210180 03-11
AMENORRHEA AND BEHAVIORAL DISTURBANCES: CLINICAL CASE TREATED WITH A PSYCHOTHERAPEUTIC METHOD BASED ON ELEMENTS OF THE CYBERNETIC THEORY OF G. CIPOLLINA MANGIAMELI.
210418 03-14
THE EFFECT OF ALAMON (HYDROXYZINE HYDROCHLORIDE) AND MEDAZEPAM ON NEUROSIS TESTED BY A DOUBLE-BLIND METHOD.
211344 03-10
THE SHAPIRO CARDS SCALE AS A METHOD OF ASSESSMENT OF OBSESSIONAL SYMPTOMS IN CLOMIPRAMINE THERAPY.
214829 04-10
A RAPID, SIMPLE AND MORE SENSITIVE METHOD FOR THE DEMONSTRATION OF CENTRAL CATECHOLAMINE CONTAINING NEURONS AND AXONS BY GLYOXYLIC ACID INDUCED FLUORESCENCE: I. SPECIFICITY.
217550 04-16
EFFECTS OF HEXAPROPYMATE ON THE SLEEP OF THE NORMAL MAN MEASURED BY A POLYGRAPHIC METHOD.
218166 04-14
COMPARATIVE STUDY OF CLOCAPRAMINE AND PERPHENAZINE ON CHRONIC SCHIZOPHRENIA BY A DOUBLE-BLIND METHOD.
222158 04-08
COMPARISON OF THE REMEDIAL RESULTS OF CLOFLUPEROL AND HALOPERIDOL FOR SCHIZOPHRENIA BY DOUBLE-BLIND TEST METHOD.
224549 04-08

METHODICAL
THERAPY-RESISTANT DEPRESSIONS: METHODOLOGICAL PROBLEMS. CONTRIBUTIONS TO METHODICAL QUESTIONS AND ANIMAL EXPERIMENTAL ASPECTS.
203591 02-09

METHODOLOGICAL
THERAPY-RESISTANT DEPRESSIONS: METHODOLOGICAL PROBLEMS. CONTRIBUTIONS TO METHODICAL QUESTIONS AND ANIMAL EXPERIMENTAL ASPECTS.
203591 02-09
MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 1. COMMUNICATION: SETTING A GOAL AND METHODOLOGICAL GROUND RULES.
203839 02-13
MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 7. COMMUNICATION: METHODOLOGICAL OUTCOME.
203845 02-16
SURVEY ON AND EVALUATION OF THE CONTRIBUTIONS OF METHODOLOGICAL ASPECTS IN THE INVESTIGATION OF LONG-TERM PSYCHOPHARMACOLOGICAL DRUG ACTION.
206984 03-16
POLYGRAPHIC EVALUATION OF HYPNOTIC DRUGS: METHODOLOGICAL CRITERIA.
208983 03-16
DOUBLE-BLIND TEST OF THREE ANTIDEPRESSANTS, THIRD COMMUNICATIONS: METHODOLOGICAL PROBLEMS.
221288 04-16

METHODOLOGY
METHODOLOGY OF OUTPATIENT DRUG RESEARCH.
198106 02-07
THE IMPORTANCE OF METHODOLOGY IN DRUG STUDIES USING EEG.
199782 02-13

METHODS
METHODS OF ASSESSING PSYCHOPHARMACOLOGICAL AGENTS IN EXPERIMENTS.
198488 02-06
METHODS TO STUDY THE IN VIVO REGULATION OF CYCLIC NUCLEOTIDES IN HYPOTHALAMIC NUCLEI, PITUITARY AND PINEAL. (UNPUBLISHED PAPER).
201491 02-06
METHODS OF DECONDITIONING PERSISTING AVOIDANCE: AMPHETAMINE, CHLORPROMAZINE, AND CHLORDIAZEPOXIDE AS ADJUNCTS TO RESPONSE PREVENTION.
202987 02-04
ASPECTS OF USING PSYCHOLOGICAL METHODS IN STUDYING THE EFFECTS OF PSYCHOTROPIC DRUGS.
204401 02-16
METHODS OF DECONDITIONING PERSISTING AVOIDANCE: AMPHETAMINE AND AMOBARBITAL AS ADJUNCTS TO RESPONSE PREVENTION.
209897 03-04
STUDIES OF LITHIUM INDUCED TREMOR BY MEANS OF DIFFERENT MEASUREMENT METHODS.
217453 04-15

METHOPHENAZINE
COMPARISON OF NEUROLEPTICS IN CONTROLLED EXPERIMENTAL CONDITIONS: METHOPHENAZINE VS PERPHENAZINE.
209147 03-08

METHOXYINDOLEALKYLAMINES
BEHAVIOURAL EFFECT OF INTRAVENTRICULAR APPLICATION OF METHOXYINDOLEALKYLAMINES IN THE RAT.
202772 02-04

METHYLAMPHETAMINE
RESPONSE OF DEPRESSED PATIENTS TO METHYLAMPHETAMINE.
205318 02-09
CHANGES IN THE CONCENTRATIONS OF 5-HYDROXYTRYPTAMINE AND NORADRENALINE IN SIX AREAS OF RAT BRAIN DURING RECOVERY FROM CHRONIC METHYLAMPHETAMINE ADMINISTRATION.
217963 04-03

METHYLATED
METHYLATED DERIVATIVES OF NOREPINEPHRINE AND THE CONDITIONED AVOIDANCE RESPONSE IN RATS.
218958 04-02

METHYLATION
METHYLATION & SCHIZOPHRENIA.
224353 04-17

METHYLDOPA
METHYLDOPA INDUCED DECREASE IN MENTAL ACTIVITY.
202921 02-15

METHYLENE
THE INHIBITORY EFFECT OF TOLUIDINE BLUE AND METHYLENE BLUE ON RAT MAST CELL DAMAGE BY PROMETHAZINE, CHLORPROMETHAZINE AND CHLORPROMAZINE. ITS REVERSAL BY GLUCOSE.
199255 02-05

METHYLENEDIOXYAMPHETAMINE
THE HEPATIC MICROSOMAL METABOLISM OF BETA 3,4 METHYLENEDIOXYAMPHETAMINE (MDA).
200082 02-03
COMPARISON OF CARDIOVASCULAR, HYPERTHERMIC, AND TOXIC EFFECTS OF P-METHOXYAMPHETAMINE (PMA) AND 3,4 METHYLENEDIOXYAMPHETAMINE (MDA).
217578 04-05
EFFECT OF AMPHETAMINE, 3,4 METHYLENEDIOXYAMPHETAMINE, P-METHOXYAMPHETAMINE AND RELATED AMPHETAMINES ON UPTAKE OF METARAMINOL AND EFFLUX OF NORADRENALINE IN ADRENERGIC NERVES OF RABBIT ATRIA.
217889 04-03

METHYLESTER
MODIFICATION BY L-DOPA METHYLESTER (H-19-61) OF AMPHETAMINE-INDUCED BRAIN CATECHOLAMINE CHANGES, THERMAL RESPONSES AND TOXICITY IN DEVELOPING MICE.
210891 03-03
THE EFFECT OF ALPHA-METHYL-P-TYROSINE METHYLESTER ON TEMPORAL SUMMATION IN THE NEURAL SUBSTRATE FOR THE REINFORCEMENT EFFECT IN SELF-STIMULATION. (PH.D. DISSERTATION).
222090 04-04

METHYLPERONE
SIDE-EFFECTS OF METHYLPERONE IN LONG-TERM THERAPY UP TO 8 YEARS.
204406 02-15

METHYLPHENIDATE
IATROGENIC DYSKINESIA: A UNIQUE REACTION TO PARENTERAL METHYLPHENIDATE.
193087 01-15
METHYLPHENIDATE EFFECTS IN LEARNING DISABILITIES OF CHILDREN.
198045 01-14
THE COMBINED EFFECTS OF METHYLPHENIDATE (RITALIN) AND A CLASSROOM BEHAVIOR MODIFICATION PROGRAM IN REDUCING THE HYPERKINETIC BEHAVIORS OF INSTITUTIONALIZED MENTAL RETARDATES. (PH.D. DISSERTATION).
202356 02-11
THE DIFFERENTIATION OF TWO TYPES OF HYPERACTIVE CHILDREN BY ACTIVITY LEVEL AND TASK PERFORMANCE WITH METHYLPHENIDATE (RITALIN) AND PLACEBO. (PH.D. DISSERTATION).
204688 02-11
HYPERACTIVITY IN PRESCHOOLERS AND THE EFFECT OF METHYLPHENIDATE.
205264 02-14
EFFECT OF LONG-TERM TREATMENT OF HYPERACTIVE CHILDREN WITH METHYLPHENIDATE.
207580 03-11
THE EFFECT OF METHYLPHENIDATE ON SENSORY PERCEPTION AND INTEGRATION IN HYPERACTIVE CHILDREN.
208920 03-14
ONE-YEAR FOLLOWUP OF HYPERACTIVE BOYS TREATED WITH IMIPRAMINE OR METHYLPHENIDATE.
209736 03-11
DIFFERENTIAL EFFECTS OF D- AND L-AMPHETAMINE AND METHYLPHENIDATE ON RAT STRIATAL DOPAMINE BIOSYNTHESIS.
210859 03-03
DIFFERENTIAL EFFECTS OF CAFFEINE, D-AMPHETAMINE AND METHYLPHENIDATE ON INDIVIDUAL RAPHE CELL FLUORESCENCE: A MICROSPECTROFLUORIMETRIC DEMONSTRATION.
213400 04-03
DECREASED TEMPORAL VARIABILITY IN HIPPOCAMPAL THETA RHYTHMS OF CATS ADMINISTERED METHYLPHENIDATE.
213855 04-03
THE EFFECT OF COMBINATION OF METHYLPHENIDATE AND DIAZEPAM ON THE EEG AND ITS EVALUATION BY MEANS OF DISCRIMINANT ANALYSIS.
215070 04-13
FACTOR ANALYSIS OF EEG OF HEALTHY SUBJECTS GIVEN NO DRUGS AND A COMBINATION OF DIAZEPAM AND METHYLPHENIDATE.
215071 04-13
DEANOL AND METHYLPHENIDATE IN MINIMAL-BRAIN-DYSFUNCTION.
215668 04-13
METHYLPHENIDATE EFFECTS ON AVOIDANCE LEARNING AT TWO AGES IN THE RAT.
215685 04-04
RESPONSE TO METHYLPHENIDATE IN LOW SOCIOECONOMIC HYPERACTIVE CHILDREN.
217181 04-14
METHYLPHENIDATE AND HALOPERIDOL IN CHILDREN: EFFECTS ON ATTENTION, MEMORY, AND ACTIVITY.
218118 04-14
WITHDRAWN, APATHETIC GERIATRIC PATIENTS RESPONSIVE TO METHYLPHENIDATE.
218216 04-11
OBSERVATIONS ON EFFECTS OF A CENTRAL STIMULANT DRUG (METHYLPHENIDATE) IN CHILDREN WITH HYPERACTIVE BEHAVIOR.
219354 04-14
THE EFFECTS OF METHYLPHENIDATE DURING REST, EXERCISE, AND RECOVERY UPON THE CIRCULORESPIRATORY RESPONSES OF HYPERACTIVE CHILDREN. (PH.D. DISSERTATION).
221934 04-11

EFFECTS OF METHYLPHENIDATE HYDROCHLORIDE ON THE CENTRAL NERVOUS SYSTEM. (PH.D. DISSERTATION).
222641 04-03

THE EFFECTS OF METHYLPHENIDATE HYDROCHLORIDE ON PSYCHOLINGUISTIC, MOTOR AND VISUAL PERCEPTUAL ABILITIES OF HYPERKINETIC CHILDREN WITH LEARNING DISABILITIES. (PH.D. DISSERTATION).
222725 04-14

ATTENTION AND THE AUDITORY EVOKED POTENTIAL IN HYPERKINETIC CHILDREN TREATED WITH METHYLPHENIDATE AND IN NORMAL CHILDREN. (PH.D. DISSERTATION).
222747 04-11

METHYLPHENIDATE-INDUCED
BLOCKADE OF RESERPINE OF METHYLPHENIDATE-INDUCED RELEASE OF BRAIN DOPAMINE.
217456 04-03

METHYLSCOPOLAMINE
EXPLORATORY BEHAVIOUR IN TWO SELECTIVELY BRED LINES OF MICE AFTER INTRAHIPPOCAMPAL INJECTION OF METHYLSCOPOLAMINE.
217464 04-04

METHYPRYLON
A COMPARISON OF THE INDUCTIVE EFFECTS OF PHENOBARBITAL, METHAQUALONE, AND METHYPRYLON ON HEPATIC MIXED FUNCTION OXIDASE ENZYMES IN THE RAT.
217794 04-03

METHYSERGIDE
METHYSERGIDE IN THE TREATMENT OF NARCOLEPSY.
215738 04-11

FACILITATORY AND INHIBITORY INFLUENCES OF PROGESTERONE, 20ALPHA-HYDROXYPROGESTERONE AND METHYSERGIDE ON THE RECEPTIVE BEHAVIOR OF THE FEMALE RAT. (PH.D. DISSERTATION).
222739 04-04

METOCLOPRAMIDE
EXTRAPYRAMIDAL MANIFESTATIONS DUE TO METOCLOPRAMIDE IN SIX CASE STUDIES.
207533 03-15

PHARMACOLOGICAL EVIDENCE FOR CEREBRAL DOPAMINE RECEPTOR BLOCKADE BY METOCLOPRAMIDE IN RODENTS.
217469 04-03

METRAZOL-INDUCED
POTENTIATION OF AMYGDALOID KINDLING AND METRAZOL-INDUCED SEIZURES BY 6-HYDROXYDOPAMINE IN RATS.
195907 01-03

METRISIL
A COMPARATIVE STUDY OF N-7001 (METRISIL) AND IMIPRAMINE ON A SERIES OF DEPRESSIVE PATIENTS.
212241 03-11

METYLPERONE
CLINICAL EVALUATION OF METYLPERONE (BURONIL) WITH EPILEPTICS.
221518 04-11

MEVINPHOS
THE EFFECTS OF MEVINPHOS ON APPETITIVE OPERANT BEHAVIOR IN THE GERBIL.
217545 04-04

MG++
INHIBITION OF SYNAPTIC VESICULAR MG++ DEPENDENT ATPASE (STENIN) BY ANTIPSYCHOTIC PHENOTHIAZINES.
195054 01-03

MG++ DEPENDENT ADENOSINE-TRIPHOSPHATASE ACTIVITY IN ERYTHROCYTE GHOSTS OF SCHIZOPHRENIC PATIENTS.
206332 03-08

MH-9022-1
PHARMACOLOGIC EFFECTS OF MH-9022-1, A POTENTIAL TRANQUILIZING AGENT.
206808 03-02

MHPG
THE EFFECT OF LITHIUM ON URINARY MHPG IN UNIPOLAR AND BIPOLAR DEPRESSED PATIENTS. (UNPUBLISHED PAPER).
196042 01-09

THE INFLUENCE OF CLOZAPINE ON THE EXCRETION OF MHPG, HVA, AND 5-HIAA IN URINE AND CEREBROSPINAL FLUID.
206974 03-13

ANTIDEPRESSANT RESPONSE TO TRICYCLICS AND URINARY MHPG IN UNIPOLAR PATIENTS: CLINICAL RESPONSE TO IMIPRAMINE OR AMITRIPTYLINE.
207443 03-13

THE EFFECT OF LITHIUM ON URINARY MHPG IN UNIPOLAR AND BIPOLAR DEPRESSED PATIENTS.
221045 04-09

MIANSERIN
STUDIES ON CLINICAL AND PHARMACOLOGICAL SPECTRA OF THE TETRACYCLIC COMPOUND MIANSERIN.
204412 02-14

REPORT ON A PRELIMINARY CLINICAL STUDY OF MIANSERIN (GB-94), A TETRACYCLIC ANTIDEPRESSANT, AN OPEN TRIAL.
207283 03-03

MICE
PHENOTHIAZINE TRANQUILIZER PD-50S EXERTED AGAINST AMPHETAMINE EFFECT IN AGGREGATED MICE.
193422 01-03

FAILURE OF DIPHENYLHYDANTOIN TO PREVENT ALCOHOL WITHDRAWAL CONVULSIONS IN MICE.
193454 01-03

BEHAVIOURAL INTERACTIONS BETWEEN IMIDAZOLEACETIC ACID AND GAMMA-HYDROXYBUTYRIC ACID IN RATS AND MICE.
193545 01-04

EFFECTS OF D-AMPHETAMINE ON LEARNING AND MEMORY IN INBRED AND HYBRID MICE. (PH.D. DISSERTATION).
193581 01-04

SHUTTLE AVOIDANCE LEARNING OF MICE: EFFECTS OF POSTTRIAL PENTYLENETETRAZOL, STRAIN AND AGE.
195226 01-04

EFFECTS ON SHOCK-ELICITED AGGRESSION IN MICE OF PREFERENTIALLY PROTECTING BRAIN MONOAMINES AGAINST THE DEPLETING ACTION OF RESERPINE.
195452 01-04

ANHYDROTIC EFFECT OF BENZODIAZEPINES IN MICE.
195540 01-03

EFFECTS OF D-AMPHETAMINE SULFATE GIVEN TO PREGNANT MICE ON ACTIVITY AND ON CATECHOLAMINES IN THE BRAINS OF OFFSPRING.
196025 01-03

HYPOTHERMIC EFFECTS OF MARIHUANA, MARIHUANA DERIVATIVES AND CHLORPROMAZINE IN LABORATORY MICE.
196226 01-04

THE INTERACTION OF DELTA9-TETRAHYDROCANNABINOL AND D-AMPHETAMINE IN AGGREGATED MICE.
196227 01-04

ON THE INVOLVEMENT OF BRAIN CATECHOLAMINES IN MORPHINE-INDUCED RUNNING ACTIVITY IN MICE.
197286 01-04

EFFECTS OF MORPHINE, CHOLINERGIC AGENTS AND COLD EXPOSURE ON MIDBRAIN DOPAMINE (DA) NERVE CELLS OF MORPHINE TOLERANT AND NONTOLERANT MICE.
197287 01-03

EFFECTS OF RESERPINE, 6-HYDROXYDOPAMINE, P-CHLOROPHENYLALANINE AND A COMBINATION OF THESE SUBSTANCES ON THE GROOMING BEHAVIOUR OF MICE.
197291 01-04

ALCOHOL WITHDRAWAL REACTIONS AND RESERPINE EFFECTS IN INBRED STRAINS OF MICE.
197821 01-03

TOLERANCE TO THE HYPOTHERMIC AND AGGRESSION ATTENUATING EFFECT OF DELTA8- AND DELTA9-TETRAHYDROCANNABINOL IN MICE.
197866 01-04

COMPARISON OF THE SPECIFICITY OF 3-(P-TRIFLUOROMETHYLPHENOXY)-N-METHYL-3 PHENYLPROPYLAMINE AND CHLORIMIPRAMINE AS AMINE UPTAKE INHIBITORS IN MICE.
197870 01-03

DOSE-DEPENDENT DIFFERENCES OF AMPHETAMINE LEVELS IN BRAIN AND HEART OF ADULT AND DEVELOPING MICE.
197927 01-03

BLOOD LEVEL, EXCRETION, DISTRIBUTION AND METABOLISM OF 14C-TRIFLUBAZAM, A NEW 1,5 BENZODIAZEPINE, IN MICE AND DOGS.
197940 01-03

EFFECTS OF L-DOPA ON CONDITIONED AVOIDANCE RESPONDING AFTER BEHAVIOURAL SUPPRESSION BY ALPHA-METHYLTYROSINE OR RESERPINE IN MICE.
197987 01-04

INVESTIGATION OF THE MECHANISM BY WHICH L-DOPA INDUCES GNAWING IN MICE.
198014 01-04

EFFECTS OF SOCIAL STRESS ON THE TURNOVER OF BRAIN CATECHOLAMINES AND 5-HYDROXYTRYPTAMINE IN MICE.
198025 01-03

NICOTINE AND CAFFEINE: DISRUPTION OF THE LONG-TERM STORE MEMORY AND PROACTIVE FACILITATION OF LEARNING IN MICE.
198222 02-04

BRAIN LEVELS AND RELATIVE POTENCY OF THE 1,2 DIMETHYLHEPTYL ANALOGUE OF DELTA1-TETRAHYDROCANNABINOL IN MICE.
198605 02-01

DISSOCIATION OF GENERAL BEHAVIOR PRODUCED BY PSYCHOTROPIC DRUGS IN MICE.
198733 02-04

THE EFFECT OF DIFFERENTIAL SALINE AND CYCLOHEXIMIDE STATES ON THE ACQUISITION OF A SPATIAL REVERSAL TASK IN MICE AND RATS. (PH.D. DISSERTATION
198897 02-04

DUAL MECHANISM OF AMPHETAMINE TOXICITY IN MICE: RELATIONSHIP TO BRAIN CATECHOLAMINES.
199898 02-05

EFFECTS OF 5-HYDROXYTRYPTOPHAN, IPRONIAZID AND P-CHLOROPHENYLALANINE ON LIDOCAINE SEIZURE THRESHOLD OF MICE.
199962 02-03

EFFECT OF AMINOOXYACETIC ACID ON THE METABOLISM OF PENTOBARBITAL IN MICE.
200002 02-03

POTENTIATION OF JUMPING BEHAVIOR BY AMINOPHYLLINE IN MICE TREATED WITH THRESHOLD DOSES OF AMPHETAMINE AND DOPA.
200039 02-04

EFFECTS OF PSYCHOTROPIC DRUGS ON EXPLORATORY BEHAVIOR OF MICE.
200047 02-04

THE EFFECT OF SEROTONINERGIC AND ADRENERGIC PREPARATIONS UPON ALCOHOL-INDUCED EXCITATION IN MICE.
201915 02-04

NALOXONE PRECIPITATED JUMPING ACTIVITY IN MICE FOLLOWING THE ACUTE ADMINISTRATION OF MORPHINE.
202201 02-04

COMPARISON OF THE EFFECTS OF ANISOMYCIN ON MEMORY ACROSS SIX STRAINS OF MICE.
202202 02-04

PENTYLENETETRAZOL INDUCED RETROGRADE AMNESIA AND BRAIN SEIZURES IN MICE.
202724 02-04

GENOTYPE DEPENDENT ELECTROENCEPHALOGRAPHIC, BEHAVIORAL AND ANALGESIC CORRELATES OF MORPHINE: AN ANALYSIS IN NORMAL MICE AND IN MICE WITH SEPTAL LESIONS.
203520 02-04

THE INFLUENCE OF ANTIADRENERGIC AND ANTIDOPAMINERGIC DRUGS ON METHAMPHETAMINE INDUCED CHANGES IN MOTORIC ACTIVITY AND CEREBRAL GLYCOGEN CONTENT IN MICE.
204396 02-03

THE EFFECT OF OZONE ON PENTOBARBITAL SLEEPING TIME IN MICE.
204862 02-02

EFFECT OF SODIUM GAMMA-HYDROXYBUTYRATE ON ISOLATION INDUCED AGGRESSIVITY IN MICE.
205588 02-04

THE EFFECT OF WITHDRAWAL FROM CANNABIS ON PENTYLENETETRAZOL CONVULSIVE THRESHOLD IN MICE.
206355 03-04

SUPERSENSITIVITY TO DOPAMINE AGONISTS FOLLOWING UNILATERAL, 6-HYDROXYDOPAMINE INDUCED STRIATAL LESIONS IN MICE.
208552 03-03

EFFECT OF LITHIUM AND OTHER DRUGS ON THE AMPHETAMINE CHLORDIAZEPOXIDE HYPERACTIVITY IN MICE.
210349 03-04

PIPERIDINE CONCENTRATION CHANGES IN THE BRAIN AND BLOOD OF DORMANT MICE.
210701 03-03

NORMAL SHUTTLEBOX AVOIDANCE LEARNING AFTER CHRONIC PHENOBARBITAL INTOXICATION IN MICE.
210737 03-04

SOME PHARMACOLOGICAL ACTIONS OF 2,5 DIMETHOXY-4-ETHYLAMPHETAMINE (DOET) IN RATS AND MICE.
210747 03-03

THE EFFECT OF DRUGS WITH ANTIDEPRESSANT ACTIVITY UPON THE HYPOTHERMIA AND BEHAVIOURAL DEPRESSION INDUCED IN MICE BY PIMOZIDE OR CENTRALLY ADMINISTERED NORADRENALINE.
210762 03-04

THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL PRETREATMENT ON KETAMINE, THIOPENTAL OR CT-1341 -- INDUCED LOSS OF RIGHTING REFLEX IN MICE.
210878 03-02

STRUCTURE-ACTIVITY RELATIONSHIPS BETWEEN META-SUBSTITUTED N-ETHYLAMPHETAMINES AND LOCOMOTOR ACTIVITY IN MICE.
210886 03-04

MODIFICATION BY L-DOPA METHYLESTER (H-19-61) OF AMPHETAMINE-INDUCED BRAIN CATECHOLAMINE CHANGES, THERMAL RESPONSES AND TOXICITY IN DEVELOPING MICE.
210891 03-03

THE EFFECT OF DOPAMINE AND NORADRENALINE ANTAGONISTS ON AMPHETAMINE-INDUCED LOCOMOTOR ACTIVITY IN MICE AND RATS.
210894 03-04

AGGRESSION IN MICE AFTER P-CHLOROAMPHETAMINE.
210899 03-04

COMPARATIVE TIME-DEPENDENT CHANGES IN SENSITIVITY TO LOCOMOTOR EFFECTS OF D-AMPHETAMINE IN MICE WITH CAUDATE, HIPPOCAMPAL OR FRONTAL CORTICAL LESIONS.
210926 03-03

TOLERANCE DEVELOPMENT WITH CHLORDIAZEPOXIDE IN RELATION TO THE PLASMA LEVELS OF THE PARENT COMPOUND AND ITS MAIN METABOLITES IN MICE.
210973 03-03

THE EFFECTS OF STRAIN, DRUG, AND DOSE LEVEL ON GENERAL ACTIVITY AND EXPLORATORY BEHAVIOR IN MICE. (PH.D. DISSERTATION).
211883 03-04

PSYCHOTOMIMETIC SUBSTANCES DURING PREGNANCY AND SEX OF OFFSPRING MICE. (PH.D. DISSERTATION).
213050 03-03

ADRENAL GLUCOCORTICOIDS AS A REQUIRED FACTOR IN THE DEVELOPMENT OF ETHANOL WITHDRAWAL SEIZURES IN MICE.
213479 04-03

THE BEHAVIORAL EFFECTS OF L-METHIONINE AND RELATED COMPOUNDS IN RATS AND MICE.
213528 04-04

YOHIMBINE: BEHAVIORAL AND BIOCHEMICAL EFFECTS IN MICE.
213592 04-04

COMPARATIVE ANALGESIC ACTIVITY OF VARIOUS NATURALLY OCCURRING CANNABINOIDS IN MICE AND RATS.
214017 04-04

ADRENERGIC AND CHOLINERGIC DRUG EFFECTS UPON SHORT-TERM MEMORY IN MICE. (PH.D. DISSERTATION).
214205 04-04

ISOLATION INDUCED TIMIDITY IN MICE AS A MEASURE OF ANXIOLYTIC ACTIVITY OF DRUGS.
215063 04-04

THE EFFECT OF SODIUM GAMMA-HYDROXYBUTYRATE ON THE CNS OF RATS AND MICE.
215069 04-03

THE EFFECT OF COLD AND DIAZEPAM ON THE TOXICITY OF FENFLURAMINE IN MICE.
215160 04-05

EFFECTS OF PSYCHOTROPIC DRUGS ON METHAMPHETAMINE-INDUCED BEHAVIORAL EXCITATION IN GROUPED MICE.
215682 04-04

NALOXONE-INDUCED JUMPING IN MORPHINE-DEPENDENT MICE: STIMULUS CONTROL AND MOTIVATION.
215696 04-04

EFFECTS OF MARIHUANA (DELTA9-THC) ON BEHAVIOR PATTERNS AND SOCIAL ROLES IN COLONIES OF CBA MICE.
216494 04-04

INFLUENCE OF CHANGES IN BRAIN MONOAMINE METABOLISM ON BEHAVIOUR OF HERPES-SIMPLEX INFECTED MICE.
217440 04-04

THE EFFECTS OF CHLORDIAZEPOXIDE ON AVOIDANCE PERFORMANCE OF MICE SUBJECTED TO UNDERNUTRITION OR HANDLING STRESS IN EARLY LIFE.
217463 04-04

EXPLORATORY BEHAVIOUR IN TWO SELECTIVELY BRED LINES OF MICE AFTER INTRAHIPPOCAMPAL INJECTION OF METHYLSCOPOLAMINE.
217464 04-04

FACILITATION OF AVOIDANCE LEARNING BY CHLORDIAZEPOXIDE AMPHETAMINE COMBINATIONS IN MICE.
217466 04-04

ABSENCE OF INTERACTION BETWEEN DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) AND CANNABIDIOL (CBD) IN AGGRESSION, MUSCLE CONTROL AND BODY TEMPERATURE EXPERIMENTS IN MICE.
217474 04-04

CATECHOLAMINE CORRELATES OF ISOLATION INDUCED AGGRESSION IN MICE.
217670 04-04

TERATOGENICITY OF ORAL DIAZEPAM AND DIPHENYLHYDANTOIN IN MICE.
217694 04-05

6-METHOXYTETRAHYDRO-BETA-CARBOLINE PRODUCES A RETENTION DEFICIT FOR ONE-TRIAL PASSIVE AVOIDANCE IN MICE.
217833 04-04

DIFFERENCES BETWEEN (+)- AND (-) AMPHETAMINE IN EFFECTS ON LOCOMOTOR ACTIVITY AND L-DOPA POTENTIATING ACTION IN MICE.
217835 04-04

A PHARMACOLOGICAL ANALYSIS OF AGGRESSIVE BEHAVIOR OF MICE INDUCED BY ISOLATION.
218800 04-04

A SIMPLE AVOIDANCE PROCEDURE FOR TESTING PSYCHOTROPIC DRUGS IN MICE.
220903 04-04

CYCLIC-GMP: REDUCTION OF CEREBELLAR CONCENTRATIONS IN NERVOUS MUTANT MICE.
221031 04-03

EFFECTS OF MORPHINE AND HEROIN ON DISCRIMINATION LEARNING AND CONSOLIDATION IN MICE.
221040 04-04

A GENETIC ANALYSIS OF THE RESPONSE TO MORPHINE IN MICE: ANALGESIA AND RUNNING.
221042 04-03

CENTRAL STIMULATING AGENTS AND POPULATION GROWTH IN MICE.
221052 04-04

BETA-PHENYLETHYLAMINE AND LOCOMOTOR ACTIVITY IN MICE: INTERACTION WITH CATECHOLAMINERGIC NEURONES AND RECEPTORS.
221742 04-03

PHARMACOLOGICAL ACTION OF FD-008, A NEW DOPAMINE-BETA-HYDROXYLASE INHIBITOR: II. EFFECTS ON CENTRAL NERVOUS SYSTEM IN MICE AND RATS.
221823 04-02

POSTTRIAL D-AMPHETAMINE SULFATE AND ONE-TRIAL LEARNING IN MICE.
222268 04-04

BEHAVIORAL EFFECTS OF 2,5 DIMETHOXY-4-METHYLAMPHETAMINE (DOM) IN RATS AND MICE.
222801 04-04

EFFECT OF FIGHTING AND DIPHENYLHYDANTOIN ON THE UPTAKE OF H3-L-NOREPINEPHRINE IN VITRO IN SYNAPTOSOMES ISOLATED FROM RETIRED MALE BREEDING MICE.
222821 04-03

MICROAUTORADIOGRAPHIC
MICROAUTORADIOGRAPHIC STUDIES AFTER MEDICATION OF C14-FLUPHENAZINE IN THE ANIMAL EXPERIMENT.
206769 03-03

MICROELECTROPHORETICALLY
THE EFFECT OF MICROELECTROPHORETICALLY APPLIED MESCALINE ON CORTICAL NEURONES.
199961 02-03

SYNERGISM BETWEEN GAMMA-AMINOBUTYRIC ACID AND BUTYROPHENONES ADMINISTERED MICROELECTROPHORETICALLY IN THE PURKINJE CELLS OF THE CAT CEREBELLUM.
220904 04-03

MICROINJECTED
ACTION OF SEROTONIN MICROINJECTED INTO HYPOTHALAMIC SITES AT WHICH ELECTRICAL STIMULATION PRODUCED AVERSIVE RESPONSES IN THE RAT.
219075 04-04

MICROINJECTIONS
EFFECTS OF HIPPOCAMPAL MICROINJECTIONS OF D-AMPHETAMINE AND SCOPOLAMINE ON ACTIVE AVOIDANCE BEHAVIOR IN RATS.
206741 03-04

THE EFFECT OF MICROINJECTIONS OF AMPHETAMINE INTO THE NEOSTRIATUM AND THE NUCLEUS-ACCUMBENS ON SELF-STIMULATION BEHAVIOUR.
217530 04-04

MICROIONTOPHORESIS
COMMISSURAL AND SENSORY EVOKED POTENTIALS OF THE HIPPOCAMPUS FOLLOWING MICROIONTOPHORESIS OF SOME DRUGS.
219111 04-03

MICROIONTOPHORETIC
MICROIONTOPHORETIC STUDIES ON THE EFFECT OF NOREPINEPHRINE ON THE ACTIVITY OF THE VISUAL CORTEX NEURONS IN RABBITS.
206441 03-03

MICROMETHODS
MICROMETHODS FOR QUANTITATIVE DETERMINATION OF SEDATIVES AND ANTIPYRETICS BY THERMO-GAS CHROMATOGRAPHY.
206807 03-06

MICROPOLARIZATION
ON THE PHYSIOLOGICAL MECHANISMS OF THE INFLUENCE OF PHENAMINE AND MICROPOLARIZATION ON LONG-TERM MEMORY PROCESSES.
213491 04-04

MICROSCOPICAL
CORRELATED HISTOCHEMICAL, ELECTRON MICROSCOPICAL, PHARMACOLOGICAL AND PHYSIOLOGICAL OBSERVATION ON AMINERGIC MECHANISMS IN THE CENTRAL NERVOUS SYSTEM. (UNPUBLISHED PAPER).
218300 04-03

MICROSOMAL
THE HEPATIC MICROSOMAL METABOLISM OF BETA 3,4 METHYLENEDIOXYAMPHETAMINE (MDA).
200082 02-03

PHARMACOLOGICAL PROPERTIES OF TWO CHLORDIAZEPOXIDE METABOLITES FOLLOWING MICROSOMAL ENZYME INHIBITION.
210792 03-03

TOLERANCE DEVELOPMENT TO THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON CONDITIONED BEHAVIOR: ROLE OF TREATMENT INTERVAL AND INFLUENCE OF MICROSOMAL METABOLISM.
215726 04-03

MICROSOMES
HYDROXYLATION OF AMPHETAMINE TO P-HYDROXYAMPHETAMINE BY RAT LIVER MICROSOMES.
205433 02-03

TRANSFORMATION OF DELTA1-TETRAHYDROCANNABINOL (THC) BY RABBIT LIVER MICROSOMES.
217817 04-03

MICROSPECTROFLUORIMETRIC
DIFFERENTIAL EFFECTS OF CAFFEINE, D-AMPHETAMINE AND METHYLPHENIDATE ON INDIVIDUAL RAPHE CELL FLUORESCENCE: A MICROSPECTROFLUORIMETRIC DEMONSTRATION.
213400 04-03

MICROVIBRATION
STUDIES ON MICROVIBRATION OF UNIDENTIFIED CLINICAL SYNDROME.
221664 04-14

MIDBRAIN
EFFECTS OF MORPHINE, CHOLINERGIC AGENTS AND COLD EXPOSURE ON MIDBRAIN DOPAMINE (DA) NERVE CELLS OF MORPHINE TOLERANT AND NONTOLERANT MICE.
197287 01-03

CHANGES IN THE ACQUISITION OF CONDITIONED AVOIDANCE RESPONSES FOLLOWING MIDBRAIN RAPHE LESIONS IN TH
197574 01-04

IDENTIFICATION AND STRUCTURAL CHARACTERIZATION OF AN INHIBITOR OF CATECHOLAMINE INDUCED FREE FATTY ACID MOBILIZATION FROM THE CALF MIDBRAIN.
200006 02-01

INFLUENCE OF MIDBRAIN RAPHE LESION ON SOME PHARMACOLOGICAL AND BIOCHEMICAL EFFECTS OF APOMORPHINE IN RATS.
202771 02-03

STEREOTYPED AND CIRCLING BEHAVIOUR INDUCED BY DOPAMINERGIC AGONISTS AFTER LESIONS OF THE MIDBRAIN RAPHE NUCLEI.
202792 02-04

EFFECT OF PERIPHERALLY ADMINISTERED SEROTONIN ON THE NEURONAL ACTIVITY OF MIDBRAIN RAPHE NEURONS.
210710 03-03

THE EFFECT OF ANTIDEPRESSANTS ON UNIT ACTIVITY IN THE MIDBRAIN RAPHE OF RATS.
210789 03-03

EFFECT OF MIDBRAIN RAPHE LESION AND OF 6-HYDROXYDOPAMINE ON THE ANTINOCICEPTIVE ACTION OF BUPRENORPHINE IN RATS.
210923 03-03

MIDBRAIN RAPHE NEURONS: SENSITIVITY TO GLUCOCORTICOIDS AND ACTH IN THE RAT.
217863 04-03

THE INFLUENCE OF ALKYLATE PHERPACET DERIVATIVES ON NEURON POPULATIONS IN THE MIDBRAIN RETICULAR FORMATION.
219501 04-03

MIGRAINE
TWO CONTROLLED TRIALS OF TYRAMINE IN CHILDREN WITH MIGRAINE.
206058 03-13

MIGRAINE AND HYPNOTHERAPY.
207486 03-04

AMITRIPTYLINE TREATMENT OF PATIENTS WITH MIGRAINE.
221561 04-11

MIGRAINOUS
EFFECTS OF RESERPINE AND CHLORPROMAZINE ON 5-HYDROXYTRYPTAMINE UPTAKE OF PLATELETS FROM MIGRAINOUS AND CONTROL SUBJECTS.
196926 01-13

MILK
ANALYSIS OF VARIOUS FACTORS INVOLVED IN EEG SYNCHRONIZATION DURING MILK DRINKING IN THE CAT.
217846 04-04

MIMICKERS
EFFECTS OF TRANSMITTER MIMICKERS AT SITES OF ANGIOTENSIN INDUCED DRINKING IN THE CAT.
193434 01-04

MIND
ON THE ORTHOMOLECULAR ENVIRONMENT OF THE MIND: ORTHOMOLECULAR THEORY.
213703 04-13

MINERAL
THE EFFECT OF CHRONIC LITHIUM APPLICATION ON THE MINERAL CONTENT OF RAT BONE AND SOFT TISSUES.
215695 04-05

MINIMAL
CAFFEINE IN THE TREATMENT OF CHILDREN WITH MINIMAL BRAIN DYSFUNCTION OR HYPERKINETIC SYNDROME.
211434 03-11

THE PARTIAL PUNISHMENT EFFECT FOLLOWING MINIMAL ACQUISITION TRAINING: SODIUM AMOBARBITAL AND THE STIMULUS PROPERTIES OF EARLY PUNISHED TRIALS.
224504 04-04

MINIMAL-BRAIN-DYSFUNCTION
DEANOL AND METHYLPHENIDATE IN MINIMAL-BRAIN-DYSFUNCTION.
215668 04-13

USING CEREBRAL STIMULANTS TO TREAT MINIMAL-BRAIN-DYSFUNCTION.
224359 04-17

MINIMUM
MINIMUM DURATION OF TRANS-SYNAPTIC STIMULATION REQUIRED FOR THE INDUCTION OF TYROSINE-HYDROXYLASE BY RESERPINE IN THE RAT SUPERIOR CERVICAL GANGLION.
199999 02-03

MINOR
MAJOR OR MINOR TRANQUILIZERS FOR RELIEF OF COMMON SYMPTOMS OF PSYCHONEUROSIS
193412 01-10

USE OF THE MAUDSLEY PERSONALITY INVENTORY IN EVALUATING THE EFFECTIVENESS OF A MINOR TRANQUILIZER IN PSYCHOSOMATIC DISEASES (THE FIRST REPORT).
198518 02-14

CHLORDIAZEPOXIDE (LIBRIUM): THE EFFECTS OF A MINOR TRANQUILIZER ON STRATEGIC CHOICE BEHAVIOR IN THE PRISONERS DILEMMA.
199609 02-14

MINOR TRANQUILIZERS IN THE TREATMENT OF AGGRESSION.
209128 03-11

MINOR TRANQUILIZERS: USE, MISUSE OR OVERUSE
211435 03-17

MISUSE
MINOR TRANQUILIZERS: USE, MISUSE OR OVERUSE
211435 03-17
THE MISUSE OF DRUGS IN THE TREATMENT OF THE CHRONIC PSYCHOSES.
225055 04-17

MIXED
A COMPARISON OF THE INDUCTIVE EFFECTS OF PHENOBARBITAL, METHAQUALONE, AND METHYPRYLON ON HEPATIC MIXED FUNCTION OXIDASE ENZYMES IN THE RAT.
217794 04-03

MIXTURE
A COMPARATIVE STUDY OF AMPHETAMINE, EPHEDRINE ATROPINE MIXTURE, PLACEBO AND BEHAVIORAL CONDITIONING IN THE TREATMENT OF NOCTURNAL ENURESIS.
198020 01-11
THE EFFECTS OF A DEXAMPHETAMINE AMYLOBARBITONE SODIUM MIXTURE ON THE REWARD VALUE OF DIFFERENT SENSORY CHANGES.
217476 04-03

MJ-10459-2
INHIBITION OF SYMPATHETIC ACTIVITY FOLLOWING CHRONIC ADMINISTRATION OF 2-AMINO-4-(3,4 DICHLOROPHENYL) 2-IMIDAZOLINE (MJ-10459-2).
199863 02-03

MK-486
THE ORIGIN OF BLOOD 5-HYDROXYINDOLEACETIC (5-HIAA) ACID FOLLOWING L-HYDRAZINO-ALPHA-METHYLDOPA (MK-486).
217665 04-03

MNEMONIC
MNEMONIC CAPACITY OF MENTALLY RETARDED BOYS TREATED WITH HIGH DOSES OF NUCLEOTIDES AND GABA.
210291 03-14

MOBAN
A CRITICAL EVALUATION OR MOLINDONE (MOBAN): A NEW INDOLE DERIVATIVE NEUROLEPTIC.
196674 01-07

MOBILIZATION
IDENTIFICATION AND STRUCTURAL CHARACTERIZATION OF AN INHIBITOR OF CATECHOLAMINE INDUCED FREE FATTY ACID MOBILIZATION FROM THE CALF MIDBRAIN.
200006 02-01
THE EFFECT OF 6-HYDROXYDOPAMINE AND RESERPINE ON THE MOBILIZATION OF CARBOHYDRATES AND FATS IN STIMULATED RATS.
219504 04-03

MODE
CENTRAL NERVOUS SYSTEM ALPHA-ADRENERGIC RECEPTORS AND THE MODE OF ACTION OF ALPHA-METHYLDOPA.
195237 01-03
THE SITE OF AND MODE OF ACTION OF ET495 FOR THE MEDIATION OF STEREOTYPED BEHAVIOUR IN THE RAT.
195252 01-03
ANTAGONISM OF DOPAMINE MEDIATED INHIBITION IN THE NIGROSTRIATAL PATHWAY: A MODE OF ACTION OF SOME CATATONIA INDUCING DRUGS.
210659 03-03
AMPHETAMINE: POSSIBLE SITE AND MODE OF ACTION FOR PRODUCING ANOREXIA IN THE RAT.
210675 03-03
THE ROLE OF P-HYDROXYLATION OF AMPHETAMINE IN ITS PERIPHERAL MODE OF ACTION.
210749 03-03
BLOCKADE BY PIMOZIDE OF A NORADRENALINE SENSITIVE ADENYLATE-CYCLASE IN THE LIMBIC FOREBRAIN: POSSIBLE ROLE OF LIMBIC NORADRENERGIC MECHANISMS IN THE MODE OF ACTION OF ANTIPSYCHOTICS.
210771 03-03

MODECATE
EVENTUAL DEVELOPMENTS OF 64 CHRONIC PSYCHOTICS ON MODITEN RETARD OR MODECATE TREATMENT.
202514 02-09

MODEL
PHARMACOKINETIC EVALUATION OF ANTICONVULSANTS PRIOR TO EFFICACY TESTING EXEMPLIFIED BY CARBAMAZEPINE IN EPILEPTIC MONKEY MODEL.
195492 01-04
MARKOV CHAIN AS A MODEL OF VERBAL LEARNING.
205624 03-14
AN ANIMAL MODEL OF DEPRESSION.
206339 03-04
CHLORDIAZEPOXIDE AND PHENOBARBITAL IN A MODEL ANXIETY INDUCING SITUATION.
207775 03-14
A BACTERIAL MODEL FOR THE EVALUATION OF BARBITURATES.
210786 03-06
ELECTROCONVULSIVE SHOCK: SUSTAINED DECREASE IN NOREPINEPHRINE UPTAKE AFFINITY IN A RESERPINE MODEL OF DEPRESSION.
210830 03-03
A STUDY OF AN ANIMAL MODEL OF DEPRESSION BY THE CONDITIONED REFLEX TECHNIQUE.
210853 03-04
THE DYNAMIC CONFRONTATION MODEL AS AN INTEGRATION OF PSYCHOTHERAPY.
211596 03-12
NEUROLEPTIC-INDUCED HYPERSENSITIVITY OF STRIATAL DOPAMINE RECEPTORS IN THE RAT AS A MODEL OF TARDIVE DYSKINESIAS. EFFECTS OF CLOZAPINE, HALOPERIDOL, LOXAPINE AND CHLORPROMAZINE.
217462 04-03
A PHARMACOLOGICAL MODEL OF THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA.
218213 04-08
THE PROPOSAL OF AN UNIFIED MODEL FOR THE INTERPRETATION OF THE ACTIVITY OF DIFFERENT CLASSES OF BETA-ADRENERGIC AGENTS.
220951 04-01
AN ANIMAL TEST MODEL FOR EVALUATING DRUGS WITH ANTIMASS PSYCHOTIC ACTIVITY.
221273 04-06
PREPOTENT BEHAVIORS IN AMPHETAMINE MODEL PSYCHOSIS.
224797 04-14

MODELS
EVALUATION OF CLINICAL PREDICTION OF ANTIDEPRESSANT ACTIVITY USING VARIOUS ANIMAL TEST MODELS.
198055 01-02
AN EXTENSION OF MULTIDIMENSIONAL SCALING TO FACILITATE CLINICAL INTERPRETATION OF ANIMAL TEST MODELS.
198059 01-02
ANXIOUS DENTAL PATIENTS AS MODELS OF PSYCHOPATHOLOGY.
198089 02-11
A COMPARISON OF CIRCLING MODELS FOR THE DETECTION OF PARKINSON ACTIVITY.
217547 04-04
NARCOTIC AGONISTS AND ANTAGONISTS AS MODELS FOR POTENTIAL ANTIDEPRESSANT DRUGS.
222817 04-04

MODERATELY
COMPARISON OF MORPHINE AND CHLORPROMAZINE EFFECTS ON MODERATELY AND SEVERELY SUPPRESSED PUNISHED RESPONDING IN THE PIGEON.
202666 02-04

MODES
ANIMAL MODES FOR EVALUATING PSYCHOTROPIC DRUGS.
209076 03-17

MODIFICATION
MODIFICATION BY DESIPRAMINE OF THE ADRENERGIC SENSITIVITY OF PYROGALLOL IN THE RAT.
197461 01-03
MODIFICATION OF DELTA9-THC ACTIONS BY CANNABINOL AND CANNABIDIOL IN THE RAT.
197858 01-03
MODIFICATION OF THE RECEPTOR COMPONENT OF ADENYLATE-CYCLASE IN THE RAT BRAIN BY PHENOTHIAZINE DERIVATIVES.
199771 02-03
EFFECTS OF CENTRAL AND PERIPHERAL ADRENERGIC AND CHOLINERGIC MODIFICATION ON TIME-DEPENDENT PROCESSES IN AVOIDANCE PERFORMANCE.
202203 02-03
THE COMBINED EFFECTS OF METHYLPHENIDATE (RITALIN) AND A CLASSROOM BEHAVIOR MODIFICATION PROGRAM IN REDUCING THE HYPERKINETIC BEHAVIORS OF INSTITUTIONALIZED MENTAL RETARDATES. (PH.D. DISSERTATION).
202356 02-11
EFFECTS OF CHOLINESTERASE INHIBITION ON THE VISUAL EVOKED POTENTIALS IN THE RABBIT AND THEIR MODIFICATION WITH VARIOUS DRUGS.
205631 03-03
MODIFICATION BY L-DOPA METHYLESTER (H-19-61) OF AMPHETAMINE-INDUCED BRAIN CATECHOLAMINE CHANGES, THERMAL RESPONSES AND TOXICITY IN DEVELOPING MICE.
210891 03-03
EVOKED NEURAL ACTIVITY IN THE BASAL GANGLIA OF THE CAT AND ITS MODIFICATION BY CHOLINERGIC AND DOPAMINERGIC AGENTS. (PH.D. DISSERTATION).
212520 03-03
CENTRALLY MEDIATED CARDIOVASCULAR EFFECTS OF 5-HYDROXYTRYPTOPHAN IN MAO INHIBITED DOGS: MODIFICATION BY AUTONOMIC ANTAGONISTS.
215757 04-03
POTENTIATION OF LOCOMOTOR ACTIVITY AND MODIFICATION OF STEREOTYPY BY STARVATION IN APOMORPHINE TREATED RATS.
217675 04-04
MODIFICATION OF THE PUNISHING EFFECTS OF PSYCHOACTIVE DRUGS IN RATS BY PREVIOUS DRUG EXPERIENCE.
217765 04-04

MODIFICATIONS
BEHAVIOURAL AND ELECTROCORTICAL MODIFICATIONS INDUCED IN THE RAT BY INTRAVENTRICULAR INJECTION OF PHYSALAEMIN AND ELEDOISIN.
198224 02-03
MODIFICATIONS BY LITHIUM OF BEHAVIORAL RESPONSES TO METHAMPHETAMINE AND TETRABENAZINE.
221041 04-04

MODIFIED
SKED PROGRAM FOR A MODIFIED STERNBERG PROCEDURE.
214812 04-16
THE EFFECTS OF CHRONIC MORPHINE ADMINISTRATION UPON A MODIFIED SIDMAN AVOIDANCE SCHEDULE THAT UTILIZES RESPONSE INDEPENDENT SHOCK.
225566 04-04

MODIFY
FAILURE OF ANTISEROTONERGIC AGENTS TO MODIFY LEVALLORPHAN INDUCED STEREOTYPY IN RATS.
225567 04-03

MODITEN
EVENTUAL DEVELOPMENTS OF 64 CHRONIC PSYCHOTICS ON MODITEN RETARD OR MODECATE TREATMENT.
202514 02-09
THE DEPOT COMPOUNDS MODITEN (FLUPHENAZINE) AND IMAP (FLUSPIRILENE) IN CLINICAL PRACTICE.
205584 02-08

MODULATE
CHOLINERGIC AGENTS AFFECT TWO RECEPTORS THAT MODULATE TRANSMITTER RELEASE AT A CENTRAL SYNAPSE IN APLYSIA-CALIFORNICA.
215705 04-03

MODULATING
THE ROLE OF DISCRIMINATIVE STIMULI IN MODULATING DRUG ACTION.
225170 04-04

MODULATION
PHARMACOLOGICAL MODULATION OF PHOTICALLY EVOKED AFTERDISCHARGE PATTERNS IN HOODED LONG-EVANS RATS.
201409 02-03
ALPHA-RECEPTOR MEDIATED MODULATION OF TRANSMITTER RELEASE FROM CENTRAL NORADRENERGIC NEURONES.
202805 02-03
MODULATION OF THE RESPIRATORY DEPRESSANT EFFECT OF ETHANOL BY 5-HYDROXYTRYPTAMINE.
210751 03-03
PHARMACOLOGY OF NEURAL MODULATION AND TRANSMISSION.
213627 04-03
RAT PINEAL CYCLIC ADENOSINE-3-5-MONOPHOSPHATE PHOSPHODIESTERASE ACTIVITY: IN VIVO MODULATION BY A BETA ADRENERGIC RECEPTOR.
215600 04-03
MODULATION OF PHOTICALLY EVOKED AFTERDISCHARGES BY MEANS OF PHARMACOLOGICAL AND BEHAVIORAL AROUSAL. (PH.D. DISSERTATION).
222644 04-03

MODULATOR
5-HYDROXYTRYPTAMINE AS AN INHIBITORY MODULATOR IN AUDIOGENIC SEIZURE. (PH.D. DISSERTATION).
212521 03-03

MODUS-OPERANDI
REVERSAL OF RESERPINE INDUCED BRADYKINESIA BY ALPHA-METHYLDOPA -- NEW LIGHT ON ITS MODUS-OPERANDI.
202281 02-03

MOGADON
EEG EVALUATION OF HYPNOTIC DRUGS: MOGADON V. RO-5-4200, USING THE DOUBLE-BLIND METHOD.
205435 02-13

MOLECULAR
MOLECULAR MECHANISMS OF MEMORY AND LEARNING (GENERAL CONSIDERATIONS AND CLINICAL APPLICATIONS).
212281 03-14

MOLECULES
THE INFLUENCE OF ANIONS ON THE PHYSICAL PROPERTIES OF BUTYROPHENONE-TYPE MOLECULES. (PH.D. DISSERTATION).
200310 02-01

MOLINDONE
A CRITICAL EVALUATION OR MOLINDONE (MOBAN): A NEW INDOLE DERIVATIVE NEUROLEPTIC.
196674 01-07

MOLLUSCAN
RESPONSES OF MOLLUSCAN NEURONS TO CATECHOLAMINES.
197445 01-03

MOMENTARY
ARBITERS AND SELF-RATING OF MOMENTARY MOOD IN PSYCHOPHARMACOLOGICAL LONGITUDINAL STUDIES.
206980 03-16

MONGOLIAN
THE EFFECTS OF D- AND L-AMPHETAMINE UPON HOARDING BEHAVIOR AND FEEDING IN THE MONGOLIAN GERBIL (MERIONES-UNGUICULATUS).
202983 02-04

MONITORING
BIOCHEMICAL MONITORING IN THE THERAPY OF DEPRESSIONS.
198099 02-10
DRUG METABOLISM AND THERAPEUTIC MONITORING.
214337 04-17
ELECTROCARDIOGRAPHIC MONITORING OF ENURETIC CHILDREN RECEIVING THERAPEUTIC DOSES OF IMIPRAMINE.
225336 04-15

MONKEY
FENFLURAMINE: AMPHETAMINE CONGENER THAT FAILS TO MAINTAIN DRUG-TAKING BEHAVIOR IN THE RHESUS MONKEY.
193137 01-04
CANNABINOL-7-OIC ACID: A METABOLITE OF DELTA1-TETRAHYDROCANNABINOL IN THE RHESUS MONKEY.
195114 01-03
PHARMACOKINETIC EVALUATION OF ANTICONVULSANTS PRIOR TO EFFICACY TESTING EXEMPLIFIED BY CARBAMAZEPINE IN EPILEPTIC MONKEY MODEL.
195492 01-04
EFFECT OF BENZODIAZEPINE DERIVATIVES ON SOMAN INDUCED SEIZURE ACTIVITY AND CONVULSIONS IN THE MONKEY.
197466 01-03
STUDIES ON CLONAZEPAM, FLUNITRAZEPAM, AND RELATED BENZODIAZEPINES IN CAT AND MONKEY.
197492 01-03
SIMILAR ACTIONS OF INTRAHYPOTHALAMIC 5-6-DHT AND 5-HT IN EVOKING HYPERTHERMIA IN THE MONKEY.
200034 02-03
5-HT AND NOREPINEPHRINE-INDUCED RELEASE OF ACH FROM THE THALAMUS AND MESENCEPHALON OF THE MONKEY DURING THERMOREGULATION.
210672 03-03
BEHAVIORAL EFFECTS OF D-AMPHETAMINE AND CAFFEINE IN THE SQUIRREL MONKEY.
210860 03-04
EFFECTS OF CHLORDIAZEPOXIDE ON SCHEDULE INDUCED WATER AND ALCOHOL CONSUMPTION IN THE SQUIRREL MONKEY.
214013 04-04
EEG CORRELATES OF IMPAIRED ATTENTION PERFORMANCE UNDER SECOBARBITAL AND CHLORPROMAZINE IN THE MONKEY.
217544 04-03
METABOLISM AND AUTORADIOGRAPHIC DISTRIBUTION OF DELTA8- AND DELTA9-TETRAHYDROCANNABINOL IN SOME ORGANS OF THE MONKEY CALLITHRIX-JACCHUS.
217837 04-03
EFFECTS OF PUTATIVE NEUROTRANSMITTERS ON NEURONAL ACTIVITY IN MONKEY AUDITORY CORTEX.
217865 04-03
THE EFFECTS OF SHOCK INTENSITY, D-AMPHETAMINE, AND PENTOBARBITAL ON THE FREQUENCY AND RESPONSE DYNAMICS OF BITING ATTACK IN THE SQUIRREL MONKEY. (PH.D. DISSERTATION).
222114 04-04

MONKEYS
CHRONIC ORAL TOXICITY OF CANNABINOIDS IN MONKEYS.
193417 01-05
EFFECTS OF KETAMINE ON EEG ACTIVITY IN CATS AND MONKEYS.
193797 01-03
NEGATIVE REINFORCING PROPERTIES OF MORPHINE ANTAGONISTS IN NAIVE RHESUS MONKEYS.
197284 01-04
PERIPHERAL TISSUE DISTRIBUTION, BRAIN DISTRIBUTION AND METABOLISM OF MESCALINE-14C IN MONKEYS.
197458 01-03
INHIBITORY AND DISINHIBITORY EFFECTS OF NITRAZEPAM, DIAZEPAM AND FLURAZEPAM HYDROCHLORIDE ON DELAYED MATCHING BEHAVIOUR IN MONKEYS (MACACA-MULATTA).
199957 02-04
CODEINE AND COCAINE REINFORCED RESPONDING IN RHESUS MONKEYS: EFFECTS OF DOSE ON RESPONSE RATES UNDER A FIXED-RATIO SCHEDULE.
202667 02-04
CEREBRAL FUNCTIONAL EFFECTS OF 2-DEOXY-D-GLUCOSE AND 3-O-METHYLGLUCOSE IN RHESUS MONKEYS.
210355 03-03
NEGATIVE REINFORCING PROPERTIES OF SOME PSYCHOTROPIC DRUGS IN DRUG NAIVE RHESUS MONKEYS.
210889 03-04
PHARMACOKINETICS OF CARBAMAZEPINE IN MONKEYS FOLLOWING INTRAVENOUS AND ORAL ADMINISTRATION.
211009 03-03
A COMPARISON BETWEEN CAUDATE, AMYGDALOID AND HYPOTHALAMIC SELF-STIMULATION IN SQUIRREL MONKEYS (SAIMIRI-SCIUREUS). (PH.D. DISSERTATION).
214207 04-04

EFFECTS OF PENFLURIDOL AND OTHER DRUGS ON APOMORPHINE-INDUCED STEREOTYPED BEHAVIOR IN MONKEYS.
215684 04-04

FIXED-RATIO ESCAPE AND AVOIDANCE ESCAPE FROM NALOXONE IN MORPHINE-DEPENDENT MONKEYS: EFFECTS OF NALOXONE DOSE AND MORPHINE PRETREATMENT.
215968 04-04

5-HYDROXYTRYPTAMINE IN THE CENTRAL NERVOUS SYSTEM AND SEXUAL RECEPTIVITY OF FEMALE RHESUS MONKEYS.
217856 04-04

SERUM ERYTHROCYTE AND CNS LEVELS IN RHESUS MONKEYS OF ORALLY AND INTRAVENOUSLY ADMINISTERED RUBIDIUM SALTS.
218956 04-02

EFFECTS OF CHRONIC ADMINISTRATION AND WITHDRAWAL OF D-AMPHETAMINE UPON DAILY ACTIVITY LEVELS OF SQUIRREL MONKEYS.
219032 04-04

THE EFFECTS OF DELTA9-TETRAHYDROCANNABINOL UPON FEAR-MOTIVATED BEHAVIOR IN SQUIRREL MONKEYS.
223040 04-04

DIAZEPAM TREATMENT OF SOCIALLY ISOLATED MONKEYS.
224776 04-04

DELTA9-THC AND NONVERBAL COMMUNICATION IN MONKEYS.
224907 04-04

MONOAMINE

EFFECTS OF DRUGS INFLUENCING MONOAMINE MECHANISMS ON THE INCREASE IN BRAIN DOPAMINE PRODUCED BY AXOTOMY OR TREATMENT WITH GAMMA-HYDROXYBUTYRIC ACID.
195440 01-03

EFFECTS IN THE SUCKLING RAT OF CHRONIC TREATMENT WITH TRYPTOPHAN AND A MONOAMINE OXIDASE INHIBITOR.
195906 01-04

MECHANISM OF ANTIDEPRESSANT EFFICACY OF MONOAMINEOXIDASE INHIBITORS: INHIBITION OF MONOAMINE OXIDASE OR OF CATECHOLAMINE REUPTAKE.
195925 01-17

SUBTYPE OF AFFECTIVE PSYCHOSES CLASSIFIED BY RESPONSE ON AMINE PRECURSORS AND MONOAMINE METABOLISM.
197209 01-09

INTERACTIONS OF PENTAZOCINE AND NALOXONE ON THE MONOAMINE CONTENT OF DISCRETE REGIONS OF THE RAT BRAIN.
198606 02-03

STUDIES ON MONOAMINEOXIDASE (REPORT XXIV) EFFECT OF HARMINE ON MONOAMINE OXIDASE.
202801 02-03

MONOAMINE METABOLITES IN LUMBAR CSF: THE QUESTION OF THEIR ORIGIN IN RELATION TO CLINICAL STUDIES.
210796 03-03

THE EFFECT OF PENFLURIDOL AND SOME PSYCHOTROPIC DRUGS ON MONOAMINE METABOLISM IN CENTRAL NERVOUS SYSTEM.
215686 04-03

CORRELATION BETWEEN BRAIN MONOAMINE LEVELS AND POSTICTAL COMA FOLLOWING ELECTROSHOCK.
215723 04-03

INFLUENCE OF CHANGES IN BRAIN MONOAMINE METABOLISM ON BEHAVIOUR OF HERPES-SIMPLEX INFECTED MICE.
217440 04-04

MONOAMINEOXIDASE

DEAMINATION OF BETA-PHENYLETHYLAMINE BY MONOAMINEOXIDASE -- INHIBITION BY IMIPRAMINE.
195447 01-13

MECHANISM OF ANTIDEPRESSANT EFFICACY OF MONOAMINEOXIDASE INHIBITORS: INHIBITION OF MONOAMINE OXIDASE OR OF CATECHOLAMINE REUPTAKE.
195925 01-17

A SIMPLE AND RAPID SPECTROPHOTOMETRIC DETERMINATION OF MONOAMINEOXIDASE ACTIVITY.
197281 01-01

MEASUREMENT OF SEROTONIN TURNOVER IN RATS WITH THE HELP OF MONOAMINEOXIDASE INHIBITORS.
197580 01-03

THE EFFECT OF DIAZAPHENOXAZINE DERIVATIVES ON MONOAMINEOXIDASE ACTIVITY.
201914 02-02

BENZOOXADIAZOLES -- A NOVEL CLASS OF HETEROCYCLIC MONOAMINEOXIDASE INHIBITORS.
202312 02-01

STUDIES ON MONOAMINEOXIDASE (REPORT XXIV) EFFECT OF HARMINE ON MONOAMINE OXIDASE.
202801 02-03

ACTIVATION OF BRAIN MONOAMINEOXIDASE BY SOME CNS DEPRESSANTS.
204864 02-03

THE RELATIONSHIP BETWEEN THE EEG DRIVING RESPONSE TO LIGHT AND PLASMA MONOAMINEOXIDASE (MAO) LEVELS.
205437 02-03

BIOCHEMICAL BACKGROUND OF MONOAMINEOXIDASE INHIBITORS.
206365 03-03

ARE MONOAMINEOXIDASE INHIBITORS ANTIDEPRESSANTS
206368 03-10

MOOD AND SLEEP CHANGES WITH MONOAMINEOXIDASE INHIBITORS.
206369 03-14

SYNTHESIS OF SUBSTITUTED BENZYLIDINOHYDRAZINES AND THEIR MONOAMINEOXIDASE INHIBITORY AND ANTICONVULSANT PROPERTIES.
206461 03-02

COMPARISON OF THE INHIBITORY EFFECTS OF PROPARGYLAMINE AND PARGYLINE ON BRAIN AND LIVER MONOAMINEOXIDASE ACTIVITY.
207857 03-03

N-CYCLOPROPYLTRYPTAMINES, POTENT MONOAMINEOXIDASE INHIBITORS.
211069 03-01

EFFECTS OF TRICYCLIC ANTIDEPRESSANTS UPON HUMAN PLATELET MONOAMINEOXIDASE.
217356 04-13

INHIBITION OF SEROTONIN UPTAKE AND THE TOXIC INTERACTION BETWEEN MEPERIDINE AND MONOAMINEOXIDASE INHIBITORS.
217696 04-03

DEVELOPMENTAL VARIATIONS OF CHOLINE ACETYLTRANSFERASE, DOPAMINE-BETA-HYDROXYLASE AND MONOAMINEOXIDASE IN CHICKEN EMBRYO AND CHICKEN SYMPATHETIC GANGLIA.
217840 04-03

MONOAMINEOXIDASE INHIBITORS ANTAGONIZE THE ACCELERATION OF BRAIN DOPAMINE SYNTHESIS INDUCED BY NEUROLEPTIC DRUGS IN VIVO: IMPLICATIONS FOR THE TREATMENT OF TARDIVE DYSKINESIA.
220948 04-03

INHIBITION OF RABBIT MONOAMINEOXIDASE BY DOXEPIN AND RELATED DRUGS.
220972 04-03

ANTAGONISM OF PSYCHOSTIMULANT 2 PHENYLDIMETHYLTETRAHYDROOXAZINE HYDROCHLORIDE (G-130) TO CENTRAL NERVOUS SYSTEM DEPRESSING DRUGS: MONOAMINEOXIDASE INHIBITORY ACTIVITY AND NOREPINEPHRINE AND SEROTONIN INDUCED CHANGES, COMPARISON WITH DL-AMPHETAMINE.
221267 04-03

REGIONAL DISTRIBUTION OF MONOAMINEOXIDASE ACTIVITY FOR 5-HYDROXYTRYPTAMINE AND TYRAMINE IN THE HYPOTHALAMUS OF THE RAT.
223049 04-03

MONOAMINEOXIDASE INHIBITORY AND ANTICONVULSANT PROPERTIES OF 1,2,4 TRISUBSTITUTED 5-IMIDAZOLONES.
225105 04-01

MONOAMINERGIC

INTERRELATION BETWEEN MONOAMINERGIC AND CHOLINERGIC MECHANISMS IN THE HYPOTHALAMIC THERMOREGULATORY CENTRE OF RABBITS.
195249 01-03

AN ANALYSIS OF MONOAMINERGIC MECHANISMS OF THE DORSAL HIPPOCAMPUS WHICH MEDIATE THE CONDITIONED ESCAPE REACTION IN RATS.
208991 03-04

MONOAMINERGIC NEUROTOXINS: ARE THEY SELECTIVE? SOME PERSPECTIVES ON THE SYMPOSIUM HELD AT THE FOURTH ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, OCTOBER, 1974. (UNPUBLISHED PAPER).
222353 04-06

MONOAMINES

ROLE OF MONOAMINES IN THE ANOREXIGENIC ACTIONS OF FENFLURAMINE, AMPHETAMINE AND P-CHLOROMETHAMPHETAMINE.
193546 01-04

EFFECT OF COPPER LOADING ON VARIOUS TISSUE ENZYMES AND BRAIN MONOAMINES IN THE RAT.
193577 01-03

EFFECTS ON SHOCK-ELICITED AGGRESSION IN MICE OF PREFERENTIALLY PROTECTING BRAIN MONOAMINES AGAINST THE DEPLETING ACTION OF RESERPINE.
195452 01-04

EFFECT OF PENTOBARBITONE AND DIETHYL ETHER ON THE SYNTHESIS OF MONOAMINES IN RAT BRAIN.
195950 01-03

THE RELATIONSHIP OF CENTRAL MONOAMINES TO DRUG-INDUCED SLEEP IN THE RAT, EXAMINED ON A 24-HOUR BASIS. (PH.D. DISSERTATION).
201005 02-03

ACCUMULATION OF ACETYLCHOLINE AND AROMATIC MONOAMINES BY INTERACTION WITH ADENOSINE-5-TRIPHOSPHATE.
210753 03-03

AN INVESTIGATION ON THE BEHAVIORAL AND HYPOTHERMIC EFFECTS OF YOHIMBINE: INTERACTION WITH DRUGS AFFECTING CENTRAL AND PERIPHERAL MONOAMINES.
211068 03-04

THE ROLE OF MONOAMINES IN AVOIDANCE BEHAVIOUR IN RATS.
213422 04-04

BRAIN MONOAMINES AND BEHAVIOR.
213631 04-04

HYPERSOMNIA BY ISTHMIC LESION IN THE CAT. I. STUDY OF THE METABOLISM OF CEREBRAL MONOAMINES.
215702 04-03
TONIC IMMOBILITY IN CHICKENS: POSSIBLE INVOLVEMENT OF MONOAMINES.
217762 04-03
ROLE OF MONOAMINES IN THE CONTROL BY HORMONES OF SEXUAL RECEPTIVITY IN THE FEMALE RAT.
222263 04-04

MONODESMETHYL
QUANTITATIVE ANALYSIS OF THE EEG EFFECTS PRODUCED BY IMIPRAMINE, DESIPRAMINE, PROMAZINE, AND MONODESMETHYL PROMAZINE IN THE ISOLATED PERFUSED RAT BRAIN.
200056 02-03

MONOHYDRATE
STUDIES ON PSYCHOTROPIC DRUGS: XVII. EFFECTS OF 3-CHLORO-5-(3-(4 PIPERIDINO-4-CARBAMOYL-PIPERIDINO)PROPYL) 10,11-DIHYDRO-5(H) DIBENZAZEPINE DIHYDROCHLORIDE MONOHYDRATE (Y-4153) ON THE METABOLISM OF BIOGENIC AMINES.
199210 02-03

MONOMETHIODIDE
EFFECT OF NICOTINE AND NICOTINE MONOMETHIODIDE ON VASCULAR ADRENERGIC NEUROEFFECTOR TRANSMISSION.
197966 01-03

MONOMETHYLATED
SOME OBSERVATIONS ON THE CORRELATIONS BETWEEN PLASMA LEVELS OF MONOMETHYLATED TRICYCLIC ANTIDEPRESSANTS AND THERAPEUTIC EFFECTS.
210507 03-09

MONONEUROPATHY
MONONEUROPATHY MULTIPLEX AS A COMPLICATION OF AMPHETAMINE ANGIITIS.
217668 04-15

MONOOXYGENASES
ALPHA-METHYLTRYPTOPHAN: EFFECTS ON CEREBRAL MONOOXYGENASES IN VITRO AND IN VIVO.
210819 03-03

MONOPHOSPHATE
ADENOSINE 3,5 MONOPHOSPHATE IN CULTURED NEUROBLASTOMA CELLS: EFFECT OF ADENOSINE, PHOSPHODIESTERASE INHIBITORS AND BENZAZEPINES.
195254 01-03
THE REGULATION OF CYCLIC GUANOSINE MONOPHOSPHATE IN RAT CEREBELLUM: POSSIBLE INVOLVEMENT OF PUTATIVE AMINO ACID NEUROTRANSMITTERS.
202717 02-03
THE EFFECTS OF D-AMPHETAMINE MONOPHOSPHATE ON THE PEAK SHIFT. (PH.D. DISSERTATION).
213153 03-04

MONOPOLAR
INTRACRANIAL SELF-STIMULATION IN RATS AS A FUNCTION OF VARIOUS STIMULUS PARAMETERS: V. INFLUENCE OF COCAINE ON MEDIAL FOREBRAIN BUNDLE STIMULATION WITH MONOPOLAR ELECTRODES.
198223 02-03

MONOSYMPTOMATIC
PIMOZIDE IN MONOSYMPTOMATIC PSYCHOSIS.
223320 04-09

MONOTONOUS
PENTOBARBITAL EFFECT ON PERFORMANCE IN MONOTONOUS CONDITIONS NOT PREVENTED BY COMPENSATORY EFFORT.
205595 02-15

MONOVALENT
EFFECT OF MONOVALENT CATIONS ON HUMAN PLATELET ADENYLCYCLASE ACTIVITY.
195930 01-13

MONOZYGOTIC
GENETIC DETERMINANT OF LITHIUM ION DISTRIBUTION. I. AN IN VITRO MONOZYGOTIC DIZYGOTIC TWIN STUDY.
194826 01-13

MONTHLY
MONTHLY INTERMITTENT CHEMOTHERAPY OF CHRONIC SCHIZOPHRENIC OUTPATIENTS WITH PIPOTHIAZINE PALMITATE.
204169 02-08

MOOD
A CONTROLLED COMPARISON OF THE EFFECTS OF DIPHENYLHYDANTOIN AND PLACEBO ON MOOD AND PSYCHOMOTOR FUNCTIONING IN NORMAL VOLUNTEERS.
199518 02-14
MOOD AND SLEEP CHANGES WITH MONOAMINEOXIDASE INHIBITORS.
206369 03-14
ARBITERS AND SELF-RATING OF MOMENTARY MOOD IN PSYCHOPHARMACOLOGICAL LONGITUDINAL STUDIES.
206980 03-16
L-5-HYDROXYTRYPTOPHAN AND MOOD.
211470 03-14
MOOD AND CATECHOLAMINE -- NONSIMPLICITY OF THEIR RELATIONSHIP.
218362 04-09

MOPEG-SO4
EFFECTS OF PIRIBEDIL ON NORADRENALINE AND MOPEG-SO4 LEVELS IN THE RAT BRAIN.
197868 01-03

MORALS
PSYCHOPHARMACOLOGY AND MORALS.
218582 04-17

MORBID
OXYPERTINE IN THE TREATMENT OF MORBID ANXIETY. REPORT OF A NEW LOW DOSAGE SCHEDULE.
207532 03-10

MORITA
THERAPEUTIC ROLES OF DRUGS AND MORITA THERAPY PROCESS.
204428 02-10

MORPHINE
THE ANTAGONISTIC EFFECTS OF ASPARTIC ACID ON SOME EFFECTS OF MORPHINE ON RATS.
193458 01-03
MOUSE LOCOMOTOR ACTIVITY: EFFECT OF MORPHINE, NARCOTIC ANTAGONISTS, AND THE INTERACTION OF MORPHINE AND NARCOTIC ANTAGONISTS.
194478 01-04
5-HYDROXYTRYPTAMINE IN PLATELETS AND BRAIN OF RABBITS TREATED CHRONICALLY WITH IMIPRAMINE, MORPHINE OR METHADONE.
194744 01-03
TOLERANCE DEVELOPMENT TO THE ANTINOCICEPTIVE ACTIONS OF MORPHINE, AMPHETAMINE, PHYSOSTIGMINE AND 2-AMINOINDANE IN THE MOUSE.
194930 01-03
MORPHINE EFFECTS ON THE LEVELS AND TURNOVER OF CATECHOLAMINES IN RAT BRAIN.
195116 01-03
CHANGES IN BRAIN CONCENTRATION OF BIOGENIC AMINES AND THE ANTINOCICEPTIVE EFFECT OF MORPHINE IN RATS.
195246 01-03
CHANGES IN THE DORSAL ROOT POTENTIAL WITH DIAZEPAM AND WITH THE ANALGESICS ASPIRIN, NITROUS OXIDE, MORPHINE AND MEPERIDINE.
195248 01-03
NEGATIVE REINFORCING PROPERTIES OF MORPHINE ANTAGONISTS IN NAIVE RHESUS MONKEYS.
197284 01-04
EFFECTS OF MORPHINE, CHOLINERGIC AGENTS AND COLD EXPOSURE ON MIDBRAIN DOPAMINE (DA) NERVE CELLS OF MORPHINE TOLERANT AND NONTOLERANT MICE.
197287 01-03
THE EFFECT OF BENZODIAZEPINES ON THE ANALGESIC EFFECT OF MORPHINE AND SODIUM SALICYLATE.
197480 01-03
EFFECT OF MORPHINE ON SEROTONIN RELEASE FROM MYENTERIC PLEXUS OF THE GUINEA-PIG.
197811 01-03
PSYCHOPHARMACOLOGICAL EVIDENCE FOR INCREASE IN RECEPTOR SENSITIVITY FOLLOWING CHRONIC MORPHINE TREATMENT.
197855 01-04
KINETICS OF 14C-DOPAMINE IN ISOLATED RAT STRIATAL TISSUE UNDER THE INFLUENCE OF MORPHINE.
197954 01-03
INFLUENCE OF MORPHINE ON THE RELEASE OF NORADRENALINE FROM BRAIN SLICES.
197964 01-03
TURNOVER OF BIOGENIC AMINES AFTER ACUTE AND CHRONIC MORPHINE TREATMENT IN RATS.
197974 01-03
ACTION OF RESERPINE IN MORPHINE TOLERANT RATS: ABSENCE OF AN ANTAGONISM OF CATECHOLAMINE DEPLETION.
199277 02-03
DECREASED ANTINOCICEPTIVE EFFECT OF MORPHINE IN RATS TREATED INTRAVENTRICULARLY WITH PROSTAGLANDIN-E1.
200045 02-03
ROLE OF CATECHOLAMINERGIC MECHANISMS IN THE EXPRESSION OF THE MORPHINE ABSTINENCE SYNDROME IN RATS.
200053 02-03
ANTAGONISM OF MORPHINE BY LONG-ACTING NARCOTIC ANTAGONISTS.
200055 02-04
INHIBITION OF BEHAVIOURAL AND EEG ACTIVATION INDUCED BY MORPHINE ACTING ON LOWER BRAINSTEM STRUCTURES.
200078 02-03
THE EFFECTS OF CHLORPROMAZINE, ATROPINE, MORPHINE AND PENTOBARBITAL ON INDUCED GASTRIC ULCERATION IN RATS. (PH.D. DISSERTATION).
200405 02-02
LITHIUM TREATMENT REDUCES MORPHINE SELF-ADMINISTRATION IN ADDICT RATS.
201293 02-04
TOLERANCE TO THE STIMULANT EFFECTS OF MORPHINE AND PENTAZOCINE ON AVOIDANCE RESPONDING IN THE RAT.
201319 02-04

NALOXONE PRECIPITATED JUMPING ACTIVITY IN MICE FOLLOWING THE ACUTE ADMINISTRATION OF MORPHINE.
202201 02-04

COMPARISON OF MORPHINE AND CHLORPROMAZINE EFFECTS ON MODERATELY AND SEVERELY SUPPRESSED PUNISHED RESPONDING IN THE PIGEON.
202666 02-04

SPECIES DIFFERENCES IN ANTAGONISTIC EFFECT OF MORPHINE AGAINST DEPRESSOR RESPONSE TO DOPAMINE.
202800 02-03

GENOTYPE DEPENDENT ELECTROENCEPHALOGRAPHIC, BEHAVIORAL AND ANALGESIC CORRELATES OF MORPHINE: AN ANALYSIS IN NORMAL MICE AND IN MICE WITH SEPTAL LESIONS.
203520 02-04

CENTRAL CHOLINERGIC INFLUENCE ON SELF-ADMINISTRATION OF MORPHINE AND AMPHETAMINE.
205889 03-04

SIGNIFICANCE OF CATECHOLAMINES FOR THE MANIFESTATION OF MORPHINE WITHDRAWAL IN THE RAT.
206988 03-03

SEROTONIN AND DOPAMINE TURNOVER AFTER ACUTE AND CHRONIC MORPHINE ADMINISTRATION.
206989 03-03

RECIPROCAL (PUSH-PULL) EFFECTS OF MORPHINE ON SINGLE UNITS IN THE VENTROMEDIAN AND LATERAL HYPOTHALAMUS AND INFLUENCES ON OTHER NUCLEI: WITH COMMENT ON METHADONE EFFECTS DURING WITHDRAWAL FROM MORPHINE.
210700 03-03

THE EFFECTS OF ACUTE AND CHRONIC MORPHINE ADMINISTRATION ON THE LEVELS OF 3-METHOXY-4-HYDROXYPHENYLGLYCOL SULFATE IN RAT BRAIN.
210927 03-03

BEHAVIORAL AND NEUROCHEMICAL EFFECTS OF MORPHINE OR AMPHETAMINE AFTER CHRONIC PRETREATMENT WITH CATECHOLAMINE DEPLETING AGENTS. (PH.D. DISSERTATION).
211746 03-03

THE COMPARATIVE EFFECTS OF MORPHINE AND CHLORPROMAZINE ON THE ACQUISITION OF CONDITIONED AVOIDANCE RESPONSE. (PH.D. DISSERTATION).
212963 03-04

THE EFFECT OF PROLONGED LITHIUM INGESTION ON MORPHINE ACTIONS IN THE RAT.
213482 04-03

BLOCKING OF STRESS BY PENTOBARBITAL MORPHINE AS RELATED TO TRAINING AND AGE OF RATS.
214056 04-04

ON THE MECHANISM OF POTENTIATION BY MORPHINE OF THIOPENTAL SLEEPING TIME.
215666 04-03

ACTIONS OF ACETYLCHOLINE AND ATROPINE ON CEREBRAL CORTICAL NEURONS IN CHRONICALLY MORPHINE TREATED RATS.
215733 04-03

FIXED-RATIO ESCAPE AND AVOIDANCE ESCAPE FROM NALOXONE IN MORPHINE-DEPENDENT MONKEYS: EFFECTS OF NALOXONE DOSE AND MORPHINE PRETREATMENT.
215968 04-04

EFFECT OF MORPHINE, HYDROMORPHONE, METHADONE, MESCALINE, TRYPAN-BLUE, VITAMIN-A, SODIUM SALICYLATE AND CAFFEINE ON THE SERUM INTERFERON LEVEL IN RESPONSE TO VIRAL INFECTION.
217654 04-03

CONDITIONED AVERSION TO MORPHINE WITH NALOXONE.
219023 04-04

INDUCED PREFERENCE FOR MORPHINE IN RATS.
219033 04-04

CONDITIONED AVERSION TO MORPHINE WITH LITHIUM CHLORIDE IN MORPHINE-DEPENDENT RATS.
219039 04-04

POSSIBLE ROLE OF ADENOSINE-3-5-MONOPHOSPHATE AND BIOGENIC AMINES IN MORPHINE AND COCAINE TREATED RATS. (PH.D. DISSERTATION).
220475 04-03

MORPHINE SENSITIVITY AND TOLERANCE: A GENETIC INVESTIGATION IN THE MOUSE.
221037 04-03

DOES CHRONIC MORPHINE TREATMENT INDUCE A SUPERSENSITIVITY OF DOPAMINE RECEPTORS IN RAT BRAIN
221038 04-03

EFFECTS OF MORPHINE AND HEROIN ON DISCRIMINATION LEARNING AND CONSOLIDATION IN MICE.
221040 04-04

A GENETIC ANALYSIS OF THE RESPONSE TO MORPHINE IN MICE: ANALGESIA AND RUNNING.
221042 04-03

CROSS-TOLERANCE BETWEEN MORPHINE AND ALCOHOL. (PH.D. DISSERTATION).
223737 04-04

CHANGES IN MORPHINE SELF-ADMINISTRATION AND MORPHINE-DEPENDENCE AFTER LESIONS OF THE CAUDATE NUCLEUS IN RATS.
225560 04-04

THE EFFECTS OF CHRONIC MORPHINE ADMINISTRATION UPON A MODIFIED SIDMAN AVOIDANCE SCHEDULE THAT UTILIZES RESPONSE INDEPENDENT SHOCK.
225566 04-04

EFFECT OF LOPERAMIDE, HALOPERIDOL AND METHADONE IN RATS TRAINED TO DISCRIMINATE MORPHINE FROM SALINE.
225568 04-04

MORPHINE-DEPENDENCE

CHANGES IN MORPHINE SELF-ADMINISTRATION AND MORPHINE-DEPENDENCE AFTER LESIONS OF THE CAUDATE NUCLEUS IN RATS.
225560 04-04

MORPHINE-DEPENDENT

MORPHINE-DEPENDENT RATS: BLOCKADE OF PRECIPITATED ABSTINENCE BY TETRAHYDROCANNABINOL.
210221 03-13

NALOXONE-INDUCED JUMPING IN MORPHINE-DEPENDENT MICE: STIMULUS CONTROL AND MOTIVATION.
215696 04-04

FIXED-RATIO ESCAPE AND AVOIDANCE ESCAPE FROM NALOXONE IN MORPHINE-DEPENDENT MONKEYS: EFFECTS OF NALOXONE DOSE AND MORPHINE PRETREATMENT.
215968 04-04

NALOXONE-INDUCED AVERSION TO SUCROSE IN MORPHINE-DEPENDENT RATS.
219031 04-04

CONDITIONED AVERSION TO MORPHINE WITH LITHIUM CHLORIDE IN MORPHINE-DEPENDENT RATS.
219039 04-04

MORPHINE-INDUCED

ON THE INVOLVEMENT OF BRAIN CATECHOLAMINES IN MORPHINE-INDUCED RUNNING ACTIVITY IN MICE.
197286 01-04

INHIBITORY EFFECT OF AMPHETAMINE, L-DOPA AND APOMORPHINE ON MORPHINE-INDUCED BEHAVIOURAL EXCITATION OF RATS.
197483 01-04

MORPHINE-INDUCED STEREOTYPIC BEHAVIOR IN RATS.
202740 02-04

A GENETIC ANALYSIS OF MORPHINE-INDUCED RUNNING AND ANALGESIA IN THE MOUSE.
225557 04-04

MORPHINE-LIKE

SEROTONERGIC INVOLVEMENT WITH THE STEREOTYPY/CATALEPSY INDUCED BY MORPHINE-LIKE AGENTS IN THE RAT.
210754 03-04

MORPHOLOGICAL

MORPHOLOGICAL, BIOCHEMICAL, AND FUNCTIONAL CHANGES IN CHICK EMBRYONIC BRAIN TISSUE AFTER INTRACEREBRAL ADMINISTRATION OF OUABAIN.
197788 01-03

MORTALITY

ANTENATAL EXPOSURE TO MEPROBAMATE AND CHLORDIAZEPOXIDE IN RELATION TO MALFORMATIONS, MENTAL DEVELOPMENT, AND CHILDHOOD MORTALITY.
212107 03-15

MOTHERS

LEARNING DEFICITS IN 4 WEEKS OLD OFFSPRING OF THE NURSING MOTHERS TREATED WITH THE NEUROLEPTIC DRUG PENFLURIDOL.
202806 02-04

INCREASED CONCENTRATION OF HOMOVANILLIC ACID IN THE BRAINS OF INFANT RABBITS AFTER ADMINISTRATION OF HALOPERIDOL TO THEIR NURSING MOTHERS.
217692 04-03

MOTIVATED

EFFECTS OF CHLORDIAZEPOXIDE UPON FEAR MOTIVATED BEHAVIOR IN DOGS.
221799 04-04

MOTIVATION

NALOXONE-INDUCED JUMPING IN MORPHINE-DEPENDENT MICE: STIMULUS CONTROL AND MOTIVATION.
215696 04-04

MOTONEURONS

THE EFFECT OF TWO BARBITURATE ANTIPODES ON SPINAL REFLEXES AND SINGLE MOTONEURONS.
197297 01-03

THE ROLE OF 5-HYDROXYTRYPTAMINE IN THE CONTROL OF ALPHA AND GAMMA MOTONEURONS. (PH.D. DISSERTATION).
212522 03-03

MOTOR

ADRENERGIC RECEPTOR BLOCKING AGENTS: EFFECTS ON CENTRAL NORADRENALINE AND DOPAMINE RECEPTORS AND ON MOTOR ACTIVITY.
195429 01-03

THE INFLUENCE OF CATECHOLAMINES, SEROTONIN, AND SOME AMINO ACIDS ADMINISTERED INTO THE AMYGDALOID COMPLEX ON CONDITIONED REFLEXES OF AVOIDANCE AND MOTOR ACTIVITY IN RATS.
200566 02-03

EFFECT OF EARLY L-DOPA ADMINISTRATION ON THE ONTOGENY OF MOTOR FUNCTIONS IN THE RAT.
202266 02-03

INFLUENCE OF STRIATAL DOPAMINE RECEPTOR BLOCKADE ON A BULBAR MOTOR REACTION.
202778 02-03

COMPARISON OF THE EFFECTS OF ATROPINE AND CANNABIS UPON THE FIXED CONDITIONED ALIMENTARY MOTOR REFLEXES IN CATS AFFECTED BY NICOTINE.
205623 03-14

THE EFFECTS OF DOPA ON THE VISUAL EVOKED POTENTIALS IN RABBIT AND ON MOUSE MOTOR BEHAVIOR FOLLOWING INHIBITION OF DOPAMINE-BETA-HYDROXYLASE.
206768 03-03

LONG-TERM TRIAL OF FLUPHENAZINE DECANOATE AND FLUPENTHIXOL DECANOATE FOR CATALEPTIC ACTIVITY AND EFFECT ON MOTOR ACTIVITY IN RATS.
206787 03-04

COGNITIVE AND MOTOR SENSORY PERFORMANCES IN TOXIC AND NONTOXIC EPILEPTIC SUBJECTS.
210824 03-15

ROLE OF THE STRIO-PALLIDAL SYSTEM AND MOTOR CORTEX IN INDUCED CIRCUS MOVEMENTS IN RATS AND CATS.
213450 04-03

THE BIPHASIC EFFECT OF SMALL DOSES OF TRANYLCYPROMINE ON THE SPONTANEOUS MOTOR ACTIVITY AND LEARNED CONDITIONED BEHAVIOUR IN RATS.
215665 04-04

DOSE EFFECTS OF SMOKED MARIHUANA ON HUMAN COGNITIVE AND MOTOR FUNCTIONS.
221036 04-01

THE EFFECTS OF METHYLPHENIDATE HYDROCHLORIDE ON PSYCHOLINGUISTIC, MOTOR AND VISUAL PERCEPTUAL ABILITIES OF HYPERKINETIC CHILDREN WITH LEARNING DISABILITIES. (PH.D. DISSERTATION).
222725 04-14

SOME PECULIARITIES OF THE NEURON ULTRASTRUCTURE IN THE BRAIN-CORTEX MOTOR AREA UNDER THE INFLUENCE OF LYSERGIC ACID DIETHYLAMIDE (LSD) AND HALOPERIDOL.
222890 04-03

THE EFFECT OF NEUROTROPIC AGENTS ON MOTOR HYPERACTIVITY IN DOGS INDUCED BY AMIZYL.
223062 04-04

THE EFFECT OF INTRAVENTRICULAR ADMINISTRATION OF SEROTONIN ON SPONTANEOUS MOTOR ACTIVITY OF RATS. (UNPUBLISHED PAPER).
225287 04-04

MOTORIC

THE INFLUENCE OF ANTIADRENERGIC AND ANTIDOPAMINERGIC DRUGS ON METHAMPHETAMINE INDUCED CHANGES IN MOTORIC ACTIVITY AND CEREBRAL GLYCOGEN CONTENT IN MICE.
204396 02-03

BIOCHEMICAL MECHANISMS OF EXTRAPYRAMIDAL MOTORIC ACTION OF HALOPERIDOL IN MAN.
204414 02-13

MOUSE

AN EFFECT OF AMPHETAMINE ON MOUSE BRAIN POLYRIBOSOMES.
193423 01-03

AN EFFECT OF AMPHETAMINE ON INCORPORATION OF LEUCINE INTO MOUSE BRAIN PROTEIN.
193424 01-03

MOUSE LOCOMOTOR ACTIVITY: EFFECT OF MORPHINE, NARCOTIC ANTAGONISTS, AND THE INTERACTION OF MORPHINE AND NARCOTIC ANTAGONISTS.
194478 01-04

THE EFFECTS OF NICOTINAMIDE ON MOUSE SLEEP.
194929 01-03

TOLERANCE DEVELOPMENT TO THE ANTINOCICEPTIVE ACTIONS OF MORPHINE, AMPHETAMINE, PHYSOSTIGMINE AND 2-AMINOINDANE IN THE MOUSE.
194930 01-03

REGIONAL LEVELS OF GABA AND GLUTAMATE IN MOUSE BRAIN FOLLOWING EXPOSURE TO PAIN.
195097 01-03

EFFECT OF SIMULATED ALTITUDE ON THE DISPOSITION OF CHLORPROMAZINE IN MOUSE BRAIN AND LIVER.
197455 01-05

EFFECT OF PSYCHOACTIVE DRUGS ON IN VIVO METABOLISM OF 14C-HISTAMINE IN MOUSE BRAIN.
197472 01-03

INTERACTION OF OUABAIN WITH PENTOBARBITONE IN THE MOUSE.
197479 01-03

ON THE MECHANISM OF ACTION OF GAMMA-HYDROXYBUTYRIC ACID: LACK OF CONVERSION TO GABA IN MOUSE BRAIN IN VIVO.
197965 01-03

THE ACCUMULATION OF NORADRENALINE AND 5-HYDROXYTRYPTAMINE IN THREE REGIONS OF MOUSE BRAIN AFTER TETRABENAZINE AND IPRONIAZID: EFFECTS OF ETHINYLESTRADIOL AND PROGESTERONE.
200058 02-03

CANNABINOID INDUCED CHANGES IN MOUSE STRIATAL HOMOVANILLIC ACID AND DIHYDROXYPHENYLACETIC ACID: THE EFFECTS OF AMPHETAMINE AND L-DOPA.
204866 02-03

INTERACTIONS OF SOME ANALGESICS AND ANTIDEPRESSANTS WITH PHENELZINE OR RESERPINE IN THE MOUSE.
204879 02-05

AMNESIC EFFECT OF CYCLOHEXIMIDE IN THE MOUSE MEDIATED BY ADRENOCORTICAL HORMONES.
206751 03-04

THE EFFECTS OF DOPA ON THE VISUAL EVOKED POTENTIALS IN RABBIT AND ON MOUSE MOTOR BEHAVIOR FOLLOWING INHIBITION OF DOPAMINE-BETA-HYDROXYLASE.
206768 03-03

COMPARISON OF THE EFFECTS OF D-AMPHETAMINE AND L-AMPHETAMINE IN REVERSING DEPRESSION OF MOUSE LOCOMOTOR ACTIVITY CAUSED BY RESERPINE.
210869 03-03

EFFECT OF CHOLINE ACETYLTRANSFERASE INHIBITORS ON MOUSE AND GUINEA-PIG BRAIN CHOLINE AND ACETYLCHOLINE.
210883 03-03

APPLICATION OF PRINCIPLES OF STEADY-STATE KINETICS TO THE IN VIVO ESTIMATION OF ACETYLCHOLINE TURNOVER RATE IN MOUSE BRAIN.
210885 03-06

THE TOXICITY OF CHLORPROMAZINE AND MESCALINE ON MOUSE CEREBELLUM AND FIBROBLAST CELLS IN CULTURE.
210890 03-03

NARCOTIC WITHDRAWAL LIKE MOUSE JUMPING PRODUCED BY AMPHETAMINE AND L-DOPA.
210931 03-04

STUDIES WITH AGENTS WHICH INFLUENCE ACETYLCHOLINE METABOLISM IN MOUSE BRAIN.
211065 03-03

THE PROTECTIVE EFFECT OF SEROTONIN AGAINST THE INHIBITORY ACTION OF CHLORPROMAZINE ON THE MEMBRANE POTENTIAL OF STAGE 2 BLASTOMERES OF MOUSE EMBRYOS IN VITRO.
217005 04-03

AMINO ACID UPTAKE IN VIVO BY THE MOUSE BRAIN AND BY VARIOUS REGIONS OF THE RABBIT BRAIN AFTER DRUG-INDUCED CONVULSIONS.
217858 04-03

EFFECT OF ETHANOL ON TOXICITY AND METABOLISM OF AMPHETAMINE IN THE MOUSE.
220950 04-05

GENOTYPE OR PRENATAL DRUG EXPERIENCE AFFECT BRAIN MATURATION IN THE MOUSE.
221032 04-03

MORPHINE SENSITIVITY AND TOLERANCE: A GENETIC INVESTIGATION IN THE MOUSE.
221037 04-03

GENETIC, BIOCHEMICAL, AND ENVIRONMENTAL VARIABLES IN THE EXPRESSION OF SHORT-TERM MEMORY IN THE MOUSE. (PH.D. DISSERTATION).
222749 04-04

A STUDY OF THE RELATIONSHIP BETWEEN CIRCADIAN RHYTHMS IN DRUG ACTION AND METABOLISM IN THE MOUSE. (PH.D. DISSERTATION).
223562 04-03

EARLY LIFE UNDERNUTRITION AND AGGRESSION IN TWO MOUSE STRAINS.
225081 04-04

A GENETIC ANALYSIS OF MORPHINE-INDUCED RUNNING AND ANALGESIA IN THE MOUSE.
225557 04-04

MOUSE-KILLING

ENHANCED LOCOMOTOR ACTIVITY FOLLOWING AMPHETAMINE IN MOUSE-KILLING RATS.
197482 01-04

BIOCHEMICAL CORRELATES IN MOUSE-KILLING BEHAVIOR OF THE RAT BRAIN: BRAIN ACETYLCHOLINE AND ACETYLCHOLINESTERASE AFTER ADMINISTRATION OF DELTA9-TETRAHYDROCANNABINOL.
199807 02-03

CONDITIONED SUPPRESSION OF MOUSE-KILLING IN RATS FOLLOWING RADIATION OR LITHIUM CHLORIDE INJECTIONS. (PH.D. DISSERTATION).
201153 02-04

SUPPRESSION OF MOUSE-KILLING AND APOMORPHINE-INDUCED SOCIAL AGGRESSION IN RATS BY LOCAL ANESTHESIA OF THE MYSTACIAL-VIBRISSAE.
206714 03-04

MOUTH

SALIVARY SCINTOGRAPHY: INTEREST IN TREATMENT OF DRY MOUTH PROVOKED BY PSYCHOTROPIC MEDICATION.
212493 03-15

MOVEMENT

SEIZURES OF CHOREOATHETIC TYPE INDUCED BY SUDDEN MOVEMENT: CORRELATION TO THE BIOGENIC AMINES.
196146 01-14

THE EFFECT OF D-AMPHETAMINE ON CHOREIFORM MOVEMENT DISORDERS.
202282 02-11

AMPHETAMINE-INDUCED DOPAMINERGIC HYPERSENSITIVITY IN GUINEA-PIGS: IMPLICATIONS IN PSYCHOSIS AND HUMAN MOVEMENT DISORDERS.
218115 04-04

MOVEMENTS

ANALYSIS OF EYE MOVEMENTS AND BLINKS DURING READING: EFFECTS OF VALIUM.
206360 03-14

RELATIONSHIP BETWEEN THE LATE REFLEX DISCHARGE AND LOCOMOTOR MOVEMENTS IN ACUTE SPINAL CATS AND RABBITS WITH DOPA.
209728 03-03

ROLE OF THE STRIO-PALLIDAL SYSTEM AND MOTOR CORTEX IN INDUCED CIRCUS MOVEMENTS IN RATS AND CATS.
213450 04-03

PHENOTHIAZINE EFFECTS ON CEREBRAL EVOKED POTENTIALS AND EYE MOVEMENTS IN ACUTE SCHIZOPHRENICS.
217454 04-08

MRIH

LITHIUM AND MRIH IN TARDIVE DYSKINESIA.
202887 02-14

MUCOPOLYSACCHARIDES

STUDIES ON MUCOPOLYSACCHARIDES IN BRAIN.
213618 04-03

MULTICENTER

THE EFFECT OF LITHIUM CARBONATE IN COMBINATION WITH TRICYCLIC ANTIDEPRESSANTS IN ENDOGENOUS DEPRESSION: A DOUBLE-BLIND, MULTICENTER TRIAL.
197035 01-09

A MULTICENTER MULTIDIMENSIONAL STUDY OF SOME NEW LONG-ACTING NEUROLEPTIC DRUGS.
220858 04-07

MULTICENTRE

NOXIPTILIN (AGEDAL) – A NEW TRICYCLIC ANTIDEPRESSANT WITH A FASTER ONSET OF ACTION? A DOUBLE-BLIND, MULTICENTRE COMPARISON WITH AMITRIPTYLINE.
221306 04-09

MULTICENTRIC

A MULTICENTRIC EVALUATION OF PIMOZIDE (ORAP) IN PATIENTS WHO USUALLY WOULD TAKE TRANQUILIZERS.
218750 04-10

MULTIDIMENSIONAL

MULTIDIMENSIONAL SCALING TO RELATE ANIMAL PHARMACOLOGY AND CLINICAL SYMPTOMS OF PSYCHOPHARMACOLOGIC AGENTS.
198058 01-02

AN EXTENSION OF MULTIDIMENSIONAL SCALING TO FACILITATE CLINICAL INTERPRETATION OF ANIMAL TEST MODELS.
198059 01-02

MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 1. COMMUNICATION: SETTING A GOAL AND METHODOLOGICAL GROUND RULES.
203839 02-13

MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 2. COMMUNICATION: PSYCHOPATHOLOGICAL COURSE PROFILE AND SOMATIC CHARACTERISTICS (STUDIES WITH THE AMP SYSTEM).
203840 02-14

MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 3. COMMUNICATION: PERAZINE CONCENTRATION IN BLOOD AND CLINICAL EFFICACY.
203841 02-13

MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 4. COMMUNICATION: CONNECTION BETWEEN EEG CHANGES, CONCENTRATION IN BLOOD, AND OTHER CLINICAL VARIABLES.
203842 02-13

MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 5. COMMUNICATION: INFLUENCE ON VENTRICULAR EXCITATION IN THE ELECTROCARDIOGRAM.
203843 02-13

MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 6. COMMUNICATION: RELATIONSHIP BETWEEN NEUROLEPTIC HYPOKINESIS AND ANTIPSYCHOTIC THERAPEUTIC RESULTS.
203844 02-13

MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 7. COMMUNICATION: METHODOLOGICAL OUTCOME.
203845 02-16

A MULTICENTER MULTIDIMENSIONAL STUDY OF SOME NEW LONG-ACTING NEUROLEPTIC DRUGS.
220858 04-07

MULTIFOCAL

MULTIFOCAL TRIAL OF PSYCHOTROPIC DRUGS (MULTIHOSPITAL TRIAL).
206784 03-08

MULTIHOSPITAL

MULTIFOCAL TRIAL OF PSYCHOTROPIC DRUGS (MULTIHOSPITAL TRIAL).
206784 03-08

MULTINATIONAL

A MULTINATIONAL, DOUBLE-BLIND TRIAL WITH A NEW ANTIDEPRESSANT MAPROTILINE (LUDIOMIL) AND AMITRIPTYLINE.
197031 01-09

MULTIPLE

THE USE OF HALOPERIDOL IN THE TREATMENT OF A PSYCHOTIC CHILD WITH MULTIPLE TICS: A CASE REPORT.
194710 01-11

MULTIPLE TIC SYNDROME (GILLES-DE-LA-TOURETTES SYNDROME): CLINICAL, BIOLOGICAL, AND PSYCHOSOCIAL VARIABLES AND THEIR INFLUENCE WITH HALOPERIDOL.
199473 02-11

SUBCELLULAR DISTRIBUTION OF RESERPINE IN BLOOD PLATELETS: EVIDENCE FOR MULTIPLE POOLS.
202665 02-03

STEADY-STATE PLASMA CONCENTRATIONS DURING SINGLE AND MULTIPLE DOSAGE SCHEDULES OF AMITRIPTYLINE.
202699 02-13

EFFECTS OF CATECHOLAMINE RELEASING AGENTS ON SYNAPTOSOMAL DOPAMINE BIOSYNTHESIS: MULTIPLE POOLS OF DOPAMINE OR MULTIPLE FORMS OF TYROSINE-HYDROXYLASE?.
210825 03-03

POLYGRAPHIC NIGHT SLEEP PATTERN DURING CHRONIC SINGLE AND MULTIPLE NEUROLEPTIC DOSE ADMINISTRATION.
215701 04-08

RATE DEPENDENT EFFECTS OF DRUGS. II. EFFECTS OF SOME MAJOR TRANQUILIZERS ON MULTIPLE FIXED-RATIO, FIXED-INTERVAL SCHEDULE PERFORMANCE.
217458 04-04

EFFECTS OF SINGLE AND MULTIPLE DOSE LSD ON ENDOGENOUS LEVELS OF BRAIN TYROSINE-HYDROXYLASE AND CATECHOLAMINES.
221044 04-12

MULTIPLEX

MONONEUROPATHY MULTIPLEX AS A COMPLICATION OF AMPHETAMINE ANGIITIS.
217668 04-15

MULTIPLICITY

THE MULTIPLICITY OF INTERACTIONS OF PSYCHOTROPIC DRUGS WITH THE BRAIN SEROTONIN BIOSYNTHETIC UNIT.
195926 01-17

MULTISPECTRAL

MULTISPECTRAL INVESTIGATION OF PSYCHOTROPIC DRUGS.
206983 03-08

MURICIDAL

MURICIDAL BLOCK INDUCED BY 5-HYDROXYTRYPTOPHAN IN THE RAT.
197454 01-04

MUSCARINIC

THE PHARMACOLOGY OF GROSS BEHAVIOURAL EFFECTS OF CHOLINOMIMETIC SUBSTANCES INJECTED INTO THE CEREBRAL VENTRICLES OF UNANAESTHETIZED CATS: EVIDENCE FOR CENTRAL MUSCARINIC MEDIATION.
202780 02-04

ANTISCHIZOPHRENIC DRUGS: AFFINITY FOR MUSCARINIC CHOLINERGIC RECEPTOR SITES IN THE BRAIN PREDICTS EXTRAPYRAMIDAL EFFECTS.
207298 03-03

IN VIVO IDENTIFICATION OF MUSCARINIC CHOLINERGIC RECEPTOR BINDING IN RAT BRAIN.
213480 04-03

MUSCLE

DEPOLARIZATION, DESENSITIZATION AND THE EFFECTS OF TUBOCURARINE AND NEOSTIGMINE IN CULTURED SKELETAL MUSCLE.
193447 01-03

THE ACTION OF DIAZEPAM ON HUMAN SKELETAL MUSCLE.
193800 01-13

BETA-ADRENOCEPTORS AND/OR ALPHA-ADRENOCEPTORS IN THE VENTRICULAR MUSCLE OF THE RABBIT
197943 01-03

NEGATIVE INOTROPIC EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON THE ISOLATED RIGHT VENTRICULAR PAPILLARY MUSCLE OF THE CAT.
204400 02-05

ABSENCE OF INTERACTION BETWEEN DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) AND CANNABIDIOL (CBD) IN AGGRESSION, MUSCLE CONTROL AND BODY TEMPERATURE EXPERIMENTS IN MICE.
217474 04-04

MUSOLINE

A CLINICAL STUDY OF SERUM CONCENTRATION LEVELS OF PHENOBARBITAL DERIVED FROM PRIMIDONE (MUSOLINE).
224644 04-13

MUTANT

CYCLIC-GMP: REDUCTION OF CEREBELLAR CONCENTRATIONS IN NERVOUS MUTANT MICE.
221031 04-03

MYENTERIC

EFFECT OF MORPHINE ON SEROTONIN RELEASE FROM MYENTERIC PLEXUS OF THE GUINEA-PIG.
197811 01-03

MYOCARDIAL
THE EFFECT OF (-) DELTA9-TRANS-TETRAHYDROCANNABINOL ON MYOCARDIAL CONTRACTILITY AND VENOUS RETURN IN ANESTHETIZED DOGS.
199964 02-03
A DOUBLE-BLIND EVALUATION OF DIAZEPAM AND AMYLOBARBITONE IN ACUTE MYOCARDIAL INFARCTION.
202966 02-13

MYOCARDIUM
INFLUENCE OF HALOTHANE ON PERIPHERAL SYMPATHETIC NERVES AND ON THE EFFECTS OF NORADRENALINE ON MYOCARDIUM.
197945 01-03

MYOCLONIC
THE ROLE OF SEROTONIN IN THE PATHOPHYSIOLOGY OF MYOCLONIC SEIZURES ASSOCIATED WITH ACUTE IMIPRAMINE TOXICITY.
200088 02-03

MYOCLONUS
TRICYCLIC ANTIDEPRESSANT POISONING: REVERSAL OF COMA, CHOREOATHETOSIS, AND MYOCLONUS BY PHYSOSTIGMINE.
202919 02-15

MYOINTEGRATIVE
QUANTITATIVE MEASUREMENT OF PARKINSON DISEASE RIGOR. MYOINTEGRATIVE DRUG TRIAL IN COMBINATION WITH THE DECARBOXYLASE INHIBITING DRUG RO-8-0576.
220829 04-11

MYSTACIAL-VIBRISSAE
SUPPRESSION OF MOUSE-KILLING AND APOMORPHINE-INDUCED SOCIAL AGGRESSION IN RATS BY LOCAL ANESTHESIA OF THE MYSTACIAL-VIBRISSAE.
206714 03-04

N-ACETYLTRANSFERASE
N-ACETYLTRANSFERASE OF BRAIN: POSSIBLE INVOLVEMENT IN THE METABOLISM OF THE BIOGENIC AMINES. (UNPUBLISHED PAPER).
199347 02-03
EXTRAPINEAL N-ACETYLTRANSFERASE ACTIVITY IN RAT BRAIN.
210760 03-03
BETA-ADRENERGIC STIMULATION OF PINEAL N-ACETYLTRANSFERASE: CYCLIC-AMP STIMULATES BOTH RNA AND PROTEIN SYNTHESIS.
215601 04-03

N-BUTYL
EFFECTS OF 5-(N-BUTYL) PICOLINAMIDE (SCH-10595), A DOPAMINE-BETA-HYDROXYLASE INHIBITOR, ON SEROTONIN AND CATECHOLAMINE METABOLITES IN BRAIN.
197813 01-03

N-CYCLOPROPYLTRYPTAMINES
N-CYCLOPROPYLTRYPTAMINES, POTENT MONOAMINEOXIDASE INHIBITORS.
211069 03-01

N-DEMETHYLDIAZEPAM
ELECTROENCEPHALOGRAPHIC STUDY FOR THE EVALUATION OF THE EFFECTS OF 7-CHLORO-5-PHENYLBENZODIAZEPIN-2-ONE (N-DEMETHYLDIAZEPAM) ON SLEEP DISTURBANCES IN A GROUP OF MENTAL PATIENTS.
221272 04-14

N-DESMETHYLDIAZEPAM
N-DESMETHYLDIAZEPAM AND AMYLOBARBITONE SODIUM AS HYPNOTICS IN ANXIOUS PATIENTS. PLASMA LEVELS, CLINICAL EFFICACY AND RESIDUAL EFFECTS.
217460 04-10

N-DIMETHYLTRYPTAMINE
CHEMICAL PHARMACOLOGY OF THE BENZOTHIOPHENE AND 1-METHYLINDOLE ANALOGS OF N,N-DIMETHYLTRYPTAMINE. (PH.D. DISSERTATION).
193590 01-12

N-DIMETHYLTRYPTAMINES
A QUANTUM CHEMICAL INVESTIGATION OF THE PI-ELECTRONIC STRUCTURE OF THE HALLUCINOGENIC N,N-DIMETHYLTRYPTAMINES.
195119 01-01

N-ETHYLAMPHETAMINES
STRUCTURE-ACTIVITY RELATIONSHIPS BETWEEN META-SUBSTITUTED N-ETHYLAMPHETAMINES AND LOCOMOTOR ACTIVITY IN MICE.
210886 03-04
STRUCTURE-ACTIVITY RELATIONSHIPS BETWEEN META-SUBSTITUTED N-ETHYLAMPHETAMINES AND ISOLATED GUINEA-PIG ATRIAL RATE.
210887 03-03

N-HYDROXY-4-CHLOROAMPHETAMINE
LONG-TERM EFFECTS OF N-HYDROXY-4-CHLOROAMPHETAMINE ON THE LEVEL AND ACCUMULATION OF 5-HYDROXYTRYPTAMINE IN THE RAT BRAIN.
197869 01-03

N-H3-ME-CHOLINE
COMPARATIVE STUDIES ON SYNAPTOSOMES: HIGH-AFFINITY UPTAKE AND ACETYLATION OF N-H3-ME-CHOLINE AND N-H3-ME-HYDROXYETHYLPYRROLIDINIUM.
217869 04-03

N-H3-ME-HYDROXYETHYLPYRROLIDINIUM
COMPARATIVE STUDIES ON SYNAPTOSOMES: HIGH-AFFINITY UPTAKE AND ACETYLATION OF N-H3-ME-CHOLINE AND N-H3-ME-HYDROXYETHYLPYRROLIDINIUM.
217869 04-03

N-METHYLATED
STEREOCHEMICAL DEPENDENCE OF PHARMACOLOGICAL ACTIVITY IN A SERIES OF OPTICALLY ACTIVE N-METHYLATED BARBITURATES.
193140 01-01
STIMULUS PROPERTIES OF MESCALINE AND N-METHYLATED DERIVATIVES: DIFFERENCE IN PERIPHERAL AND DIRECT CENTRAL ADMINISTRATION.
201320 02-02
1 N-METHYLATED TRYPTAMINE DERIVATIVES: SYNTHESIS AND PROPERTIES.
207496 03-01

N-SUBSTITUTED
NEW HYPOGLYCEMIC BENZENESULFONAMIDO PYRIMIDINES: N-SUBSTITUTED 4-(N-(2-PYRIMIDINYLSULFONYL-PHENYLACETAMIDES.
206994 03-02

N-7001
A COMPARATIVE STUDY OF N-7001 (METRISIL) AND IMIPRAMINE ON A SERIES OF DEPRESSIVE PATIENTS.
212241 03-11

NA+
RAPID REVERSAL OF INTERNAL NA+ AND K+ CONTENTS OF SYNAPTOSOMES BY OUABAIN.
204185 02-03
INFLUENCE OF MEPROBAMATE, CARISPRODOL, OXAZEPAM AND PHENOBARBITAL ON NA+ TRANSPORT IN THE ISOLATED FROG SKIN.
206781 03-03

NA+-K+
INHIBITION OF DELTA1-TETRAHYDROCANNABINOL OF NA+-K+ TRANSPORT ATPASE FROM RAT ILEUM. PRELIMINARY REPORT.
211099 03-03

NA-K
INEFFECTIVENESS OF LYSERGIC ACID DIETHYL AMIDE 25 (LSD) ON ALTERING NA-K CURRENTS IN SQUID GIANT AXON.
194927 01-03

NAIVE
NEGATIVE REINFORCING PROPERTIES OF MORPHINE ANTAGONISTS IN NAIVE RHESUS MONKEYS.
197284 01-04
NEGATIVE REINFORCING PROPERTIES OF SOME PSYCHOTROPIC DRUGS IN DRUG NAIVE RHESUS MONKEYS.
210889 03-04

NALLINE
EFFECT OF APOMORPHINE AND NALLINE ON METHADONE INDUCED BEHAVIORAL CHANGES.
193420 01-04

NALORPHINE
EFFECTS OF NALORPHINE ON AVOIDANCE BEHAVIOR AND LOCOMOTOR ACTIVITY IN THE RAT.
210783 03-04

NALOXONE
INTERACTIONS OF PENTAZOCINE AND NALOXONE ON THE MONOAMINE CONTENT OF DISCRETE REGIONS OF THE RAT BRAIN.
198606 02-03
NALOXONE PRECIPITATED JUMPING ACTIVITY IN MICE FOLLOWING THE ACUTE ADMINISTRATION OF MORPHINE.
202201 02-04
FIXED-RATIO ESCAPE AND AVOIDANCE ESCAPE FROM NALOXONE IN MORPHINE-DEPENDENT MONKEYS: EFFECTS OF NALOXONE DOSE AND MORPHINE PRETREATMENT.
215968 04-04
CONDITIONED AVERSION TO MORPHINE WITH NALOXONE.
219023 04-04

NALOXONE-INDUCED
NALOXONE-INDUCED JUMPING IN MORPHINE-DEPENDENT MICE: STIMULUS CONTROL AND MOTIVATION.
215696 04-04
NALOXONE-INDUCED AVERSION TO SUCROSE IN MORPHINE-DEPENDENT RATS.
219031 04-04

NAME
PILOT STUDY OF 2-PYRROLIDON ACETAMIDE (GENERIC NAME: PIRACETAM).
221338 04-08

NARCOLEPSY
METHYSERGIDE IN THE TREATMENT OF NARCOLEPSY.
215738 04-11
A CASE OF NARCOLEPSY IMPROVED BY LITHIUM CARBONATE.
216390 04-11

NARCOSIS
ANTIANESTHETIC EFFECTS OF CYCLIC-AMP AND ANALEPTIC DRUGS AS DETERMINED BY REVERSAL OF AMOBARBITAL INDUCED NARCOSIS.
193426 01-03

A DIRECT EFFECT OF DIBUTYRYL CYCLIC-AMP ON THE DURATION OF NARCOSIS INDUCED BY SEDATIVE, HYPNOTIC, TRANQUILISER AND ANESTHETIC DRUGS IN THE RAT.
222814 04-04

NARCOTIC
NEW HOT PLATE TESTS TO QUANTIFY ANTINOCICEPTIVE AND NARCOTIC ANTAGONIST ACTIVITIES.
193446 01-04
MOUSE LOCOMOTOR ACTIVITY: EFFECT OF MORPHINE, NARCOTIC ANTAGONISTS, AND THE INTERACTION OF MORPHINE AND NARCOTIC ANTAGONISTS.
194478 01-04
EFFECTS OF PHENOXYBENZAMINE ON THE NARCOTIC WITHDRAWAL SYNDROME IN THE RAT.
195091 01-03
ANTAGONISM OF MORPHINE BY LONG-ACTING NARCOTIC ANTAGONISTS.
200055 02-04
POTENTIATION OF CATALEPSY INDUCED BY NARCOTIC AGENTS DURING HAFFNERS TEST FOR ANALGESIA.
206358 03-04
POSSIBLE INVOLVEMENT OF 5-HYDROXYTRYPTAMINE IN THE ANTIDEPRESSANT ACTIVITY OF NARCOTIC ANALGESICS.
210761 03-03
NARCOTIC WITHDRAWAL LIKE MOUSE JUMPING PRODUCED BY AMPHETAMINE AND L-DOPA.
210931 03-04
NARCOTIC AGONISTS AND ANTAGONISTS AS MODELS FOR POTENTIAL ANTIDEPRESSANT DRUGS.
222817 04-04

NATIONS
PSYCHIATRIC ILLNESS AND THE FUTURE OF NATIONS.
196031 01-17

NATIVE
CONJOINT NATIVE AND ORTHOPHTHALDIALDEHYDE CONDENSATE ASSAYS FOR THE FLUORIMETRIC DETERMINATION OF 5-HYDROXYINDOLES IN BRAIN.
195238 01-01

NATURE
THE NATURE OF (3H)IMIPRAMINE BINDING TO SYNAPTOSOMES.
210904 03-03

NAVANE
CLINICAL TRENDS AND PSYCHOMETRIC APPRAISAL OF A GROUP OF SCHIZOPHRENICS TREATED WITH THIOTHIXENE (NAVANE).
208981 03-08

NEALBARBITONE
TREATMENT OF ANXIOUS PATIENTS WITH NEALBARBITONE -- (CENSEDAL).
194556 01-10

NEAR-LATERAL
CATECHOLAMINES AND SELF-STIMULATION: PHARMACOLOGICAL DIFFERENCES BETWEEN NEAR-LATERAL AND FAR-LATERAL HYPOTHALAMIC SITES.
221030 04-03

NEEDS
LONG-ACTING DRUGS IN PSYCHIATRIC TREATMENT: LACUNAE AND NEEDS.
221672 04-17

NEGATIVE
CHROMOSOMAL ABERRATION RATES AND INTRAVENOUSLY GIVEN DIAZEPAM: A NEGATIVE STUDY.
195949 01-13
NEGATIVE REINFORCING PROPERTIES OF MORPHINE ANTAGONISTS IN NAIVE RHESUS MONKEYS.
197284 01-04
NEGATIVE FINDINGS WITH NICOTINIC ACID IN THE TREATMENT OF SCHIZOPHRENIAS.
202787 02-08
NEGATIVE INOTROPIC EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON THE ISOLATED RIGHT VENTRICULAR PAPILLARY MUSCLE OF THE CAT.
204400 02-05
NEGATIVE REINFORCING PROPERTIES OF SOME PSYCHOTROPIC DRUGS IN DRUG NAIVE RHESUS MONKEYS.
210889 03-04
CLASTOGENIC EFFECTS OF HALOPERIDOL IN VIVO AND OF HALOPERIDOL, DROPERIDOL, AND PIPAMPERONE IN VITRO: A NEGATIVE STUDY.
221270 04-15

NEMBUTAL
THE INFLUENCE OF NEMBUTAL, CHLORALOSE AND URETHANE ON INHIBITORY POSTSYNAPTIC POTENTIALS OF CORTICAL NEURONS.
199443 02-03

NEOCORTICAL
NEOCORTICAL AND HIPPOCAMPAL ACTIVATION IN RELATION TO BEHAVIOR: EFFECTS OF ATROPINE, ESERINE, PHENOTHIAZINES, AND AMPHETAMINE.
206742 03-04

NEONATAL
NEONATAL BEHAVIORAL PATTERNS AND THEIR RELATION TO OBSTETRICAL MEDICATION. (PH.D. DISSERTATION).
194573 01-15
THE EFFECT OF 6-HYDROXYDOPAMINE ADMINISTRATION TO NEONATAL RATS ON SOME ENDOCRINE AND BEHAVIORAL PARAMETERS.
197498 01-03
NEONATAL CHEMICAL SYMPATHECTOMY: FUNCTIONAL CONTROL OF DENERVATION OF THE VASCULAR SYSTEM AND TISSUE NORADRENALINE LEVEL IN THE RAT AFTER 6-HYDROXYDOPAMINE.
197584 01-03
NEONATAL 6-HYDROXYDOPAMINE TREATMENT: NORADRENALINE LEVELS AND IN VITRO 3H-CATECHOLAMINE SYNTHESIS IN DISCRETE BRAIN REGIONS OF ADULT RATS.
210759 03-03
ESTROGEN STIMULATIONS DURING NEONATAL PERIOD AND THEIR EFFECTS ON EMOTIONAL AND OPERATIVE BEHAVIOR IN THE ADULT.
211219 03-04
INHIBITORY EFFECT OF NEONATAL ESTROGENIZATION ON THE INCORPORATION OF (3H)LYSINE IN THE PURKINJE CELLS OF THE ADULT MALE AND FEMALE RAT.
213478 04-03
NEONATAL LOCOMOTOR AND LONG-TERM BEHAVIORAL EFFECTS OF D-AMPHETAMINE IN THE RAT.
225077 04-04

NEONATE
THE EFFECTS OF PARENTERAL ADMINISTRATION OF CATECHOLAMINES, SEROTONIN AND HISTAMINE ON BEHAVIOR AND LEVELS OF THESE AMINES IN THE BRAIN OF THE NEONATE CHICK.
197457 01-03

NEOPHOBIA
POISON INDUCED NEOPHOBIA IN RATS: ROLE OF STIMULUS GENERALIZATION OF CONDITIONED TASTE AVERSIONS.
223254 04-04

NEOPROSERIN
TRIAL EXPERIENCE OF NEOPROSERIN IN THE PSYCHIATRIC AREA.
224392 04-11

NEOSTIGMINE
DEPOLARIZATION, DESENSITIZATION AND THE EFFECTS OF TUBOCURARINE AND NEOSTIGMINE IN CULTURED SKELETAL MUSCLE.
193447 01-03

NEOSTRIATAL
SPECIFIC ASYMMETRIC BEHAVIOUR INDUCED BY THE DIRECT CHEMICAL STIMULATION OF NEOSTRIATAL DOPAMINERGIC MECHANISMS.
197929 01-04
EFFECTS OF DOPAMINERGIC RECEPTOR AGONISTS AND ANTAGONISTS ON THE ACTIVITY OF THE NEOSTRIATAL CHOLINERGIC SYSTEM.
210669 03-03
CHEMICAL OR ELECTROLYTIC LESION OF THE SUBSTANTIA-NIGRA: EARLY EFFECTS ON NEOSTRIATAL DOPAMINE METABOLISM.
210699 03-03
ONTOGENESIS OF NEOSTRIATAL CHOLINERGIC NEURONES IN THE RAT AND DEVELOPMENT OF THEIR SENSITIVITY TO NEUROLEPTIC DRUGS.
217658 04-03

NEOSTRIATUM
THE EFFECT OF MICROINJECTIONS OF AMPHETAMINE INTO THE NEOSTRIATUM AND THE NUCLEUS-ACCUMBENS ON SELF-STIMULATION BEHAVIOUR.
217530 04-04

NERVE
INCREASE IN BRAIN DOPAMINE AFTER AXOTOMY OR TREATMENT WITH GAMMA-HYDROXYBUTYRIC ACID DUE TO ELIMINATION OF THE NERVE IMPULSE FLOW.
195439 01-03
EFFECTS OF RESERPINE AND PRENYLAMINE ON THE NORADRENALINE FLUXES OF ISOLATED SPLENIC NERVE GRANULES.
197280 01-03
EFFECTS OF MORPHINE, CHOLINERGIC AGENTS AND COLD EXPOSURE ON MIDBRAIN DOPAMINE (DA) NERVE CELLS OF MORPHINE TOLERANT AND NONTOLERANT MICE.
197287 01-03
THE EFFECTS OF AMPHETAMINE AND COCAINE ON THE RESPONSE OF THE ISOLATED GUINEA-PIG VAS-DEFERENS TO NORADRENALINE, TYRAMINE AND NERVE STIMULATION.
197463 01-03
THE INHIBITION OF THE EFFECT OF NERVE STIMULATION BY PHENOTHIAZINES ON ISOLATED INNERVATED ORGANS.
197576 01-03
EFFECTS OF DIAZEPAM ON DISCHARGE PATTERN IN SINGLE FIBRES OF PHRENIC NERVE.
197577 01-03
THE EFFECT OF DIPYRIDAMOLE ON THE NORADRENALINE TRANSPORT INTO NERVE GRANULES.
197942 01-03
SYMPATHETIC NERVE ACTIVITY AFTER NORADRENALINE DEPLETION AND ITS ALTERATION BY CLONIDINE.
197947 01-03

INHIBITION OF EFFECTS OF ACCELERATOR NERVE STIMULATION IN CATS AND RABBITS BY BS-100-141 AND GUANABENZ.
197971 01-03

RELEASE OF NOREPINEPHRINE AND DOPAMINE-BETA-HYDROXYLASE BY NERVE STIMULATION: II. EFFECTS OF PAPAVERINE.
204485 02-03

SOME EFFECTS OF PILOCARPINE AND ACETYLCHOLINE ON THE RESPONSES OF THE GUINEA-PIG VAS-DEFERENS TO HYPOGASTRIC NERVE STIMULATION AND TRANSMURAL STIMULATION AND APPLIED (-) NORADRENALINE.
210770 03-03

EFFECTS OF METHAMPHETAMINE ON THE ISOLATED RAT PHRENIC NERVE DIAPHRAM PREPARATION.
210900 03-03

EFFECTS OF IMIPRAMINE UPON FROG NERVE EXCITABILITY AND CONDUCTION.
210925 03-03

HIGH AFFINITY UPTAKE OF GABA IN PRESUMED GABA-ERGIC NERVE ENDINGS IN RAT BRAIN.
211062 03-03

HYPOTHALAMIC SELF-STIMULATION IN RATS FOLLOWING IMMUNOSYMPATHECTOMY OR CENTRAL NERVE GROWTH FACTOR ANTISERUM INJECTION.
211512 03-04

NERVE IMPULSE ENHANCED RELEASE OF AMINO ACIDS FROM NONSYNAPTIC REGIONS OF PERIPHERAL AND CENTRAL NERVE TRUNKS OF BULLFROG.
213277 03-03

INHIBITION OF EFFERENT SYMPATHETIC NERVE ACTIVITY BY 5-HYDROXYTRYPTOPHAN AND CENTRALLY ADMINISTERED 5-HYDROXYTRYPTAMINE.
215712 04-03

ACTION OF DIAZEPAM, DIBUTYRYL-CGMP, AND GABA ON PRESYNAPTIC NERVE TERMINALS IN BULLFROG SYMPATHETIC GANGLIA.
217873 04-03

THE USE OF DESIPRAMINE IN STUDIES OF NORADRENERGIC NERVE FUNCTION.
217882 04-03

THE EFFECT OF NEUROLEPTICS AND ANTIDEPRESSANTS ON THE UPTAKE OF 3H-GAMMA-AMINOBUTYRIC ACID BY ISOLATED NERVE ENDINGS OF THE RAT BRAIN.
224114 04-03

NERVES

INFLUENCE OF HALOTHANE ON PERIPHERAL SYMPATHETIC NERVES AND ON THE EFFECTS OF NORADRENALINE ON MYOCARDIUM.
197945 01-03

THE EFFECTS OF 6-HYDROXYDOPAMINE AND GUANETHIDINE ON PERIPHERAL ADRENERGIC NERVES IN THE GUINEA-PIG.
199862 02-03

EFFECTS OF A DECARBOXYLASE INHIBITOR ON THE DOPA AND 5-HTP INDUCED CHANGES IN THE LOCOMOTOR LIKE DISCHARGE PATTERN OF RABBIT HIND LIMB NERVES.
210740 03-03

EFFECT OF AMPHETAMINE, 3,4 METHYLENEDIOXYAMPHETAMINE, P-METHOXYAMPHETAMINE AND RELATED AMPHETAMINES ON UPTAKE OF METARAMINOL AND EFFLUX OF NORADRENALINE IN ADRENERGIC NERVES OF RABBIT ATRIA.
217889 04-03

IN VIVO BINDING OF ANTIBODY TO DOPAMINE-BETA-HYDROXYLASE IN ADRENERGIC NERVES AND SUBSEQUENT ANTIDROMIC TRANSPORT (UNPUBLISHED PAPER).
218147 04-03

NEUROTRANSMITTER CONTENT IN SYNAPTIC VESICLES OF THE ADRENERGIC NERVES OF RATS UNDER PHARMACOLOGICAL INFLUENCE.
223017 04-03

NERVOUS

MECHANISM OF ACTION OF PHENCYCLIDINE ON THE PERIPHERAL SYMPATHETIC NERVOUS SYSTEM.
193425 01-03

STEREOCHEMICAL STUDIES ON POTENTIAL CENTRAL NERVOUS SYSTEM ACTIVE AGENTS AND STUDIES ON THE CHEMISTRY OF SOME 3-BENZOYLPIPERIDINES. (PH.D. DISSERTATION).
193586 01-01

REGIONAL DISTRIBUTION OF CATIONS AND THEIR RELATION TO THE NEUROCHEMISTRY OF EXPERIMENTAL EPILEPSY, NEUROTRANSMITTERS AND ATPASE IN THE CENTRAL NERVOUS SYSTEM. (PH.D. DISSERTATION).
193588 01-03

EFFECT OF THIOTHIXENE UPON THE HIGHER NERVOUS ACTIVITY IN CHRONIC SCHIZOPHRENICS.
195041 01-09

INHIBITION OF THE CATALYTIC SITE OF ADENYLATE-CYCLASE IN THE CENTRAL NERVOUS SYSTEM BY PHENOTHIAZINE DERIVATIVES.
195096 01-03

CENTRAL NERVOUS SYSTEM ALPHA-ADRENERGIC RECEPTORS AND THE MODE OF ACTION OF ALPHA-METHYLDOPA.
195237 01-03

AGE RELATED ENHANCED RESPONSIVENESS TO CENTRAL NERVOUS SYSTEM DRUGS IN RATS. (PH.D. DISSERTATION).
196256 01-03

ACTION OF PROBENECID ON THE CENTRAL NERVOUS SYSTEM OF THE RABBIT: II. POTENTIATION OF 5-HYDROXYTRYPTOPHAN-INDUCED HYPERTHERMIA AND SUPPRESSION OF THIS EFFECT BY A DECARBOXYLASE INHIBITOR (RO-4-4602).
196580 01-03

THE INFLUENCE OF CEREBROLYSINE ON HIGHER NERVOUS ACTIVITY IN ADULT RATS.
196758 01-04

EFFECT ON PSEUDOCONDITIONING OF DRUGS WITH KNOWN CENTRAL NERVOUS ACTIVITY.
198228 02-04

THE INFLUENCE OF SODIUM OXYBUTYRATE ON INTERNEURONAL TRANSMISSION OF EXCITATION AT VARIOUS LEVELS OF THE CENTRAL NERVOUS SYSTEM.
198435 02-03

EFFECTS OF CYTIDINE DIPHOSPHATE CHOLINE ON THE NERVOUS SYSTEM IN CATS.
198610 02-04

THE INFLUENCE OF PROLONGED APPLICATION OF TRANQUILIZERS AND ANTIDEPRESSANTS ON THE SUMMATIONAL CAPACITY OF THE CENTRAL NERVOUS SYSTEM.
201913 02-03

THE EFFECT OF SEDUXEN ON THE PERCEPTIVE AND SOME OTHER FUNCTIONS OF THE CENTRAL NERVOUS SYSTEM UNDER EMOTIONAL STRESS IN MAN.
201916 02-14

ELECTROENCEPHALOGRAPHIC STUDY OF THE LOCAL TRANSPORT OF CENTRAL NERVOUS STIMULANTS INTO THE BRAIN.
202165 02-03

AN ANALYSIS OF THE GROSS BEHAVIOURAL CHANGES INDUCED BY TETRAETHYLAMMONIUM AND A COMPARISON WITH OTHER SUBSTANCES AFFECTING THE AUTONOMIC AND CENTRAL NERVOUS SYSTEM AFTER INTRAVENTRICULAR INJECTIONS TO CONSCIOUS CATS.
202781 02-04

WAYS OF DEMONSTRATING AND DIFFERENTIATING CENTRAL NERVOUS EFFECTS OF DRUGS IN ANIMAL EXPERIMENTS.
202944 02-06

CENTRAL NERVOUS SYSTEM CARBONIC ANHYDRASE INHIBITORS. (PH.D. DISSERTATION).
203028 02-03

CENTRAL NERVOUS ACTION OF L-DOPA.
204424 02-04

PHARMACOLOGICAL PROPERTIES OF A POTENTIAL TRANQUILISING AGENT MESYLPHENACYRAZINE: I. INTERACTION WITH DRUGS INFLUENCING THE NERVOUS SYSTEM.
205578 02-03

AGE RELATED RESPONSIVENESS OF THE RAT TO DRUGS AFFECTING THE CENTRAL NERVOUS SYSTEM.
206912 03-03

VARIATIONS IN THE AUTONOMIC NERVOUS SYSTEM AFTER ADMINISTRATION OF DIHYDROERGOTAMINE IN PSYCHOSOMATIC PATIENTS.
209045 03-11

AMINES AND DISORDERS OF THE CENTRAL NERVOUS SYSTEM.
210635 03-09

OXIDATIVE METABOLISM OF MESCALINE IN THE CENTRAL NERVOUS SYSTEM – V. IN VITRO DEAMINATION OF MESCALINE TO 3,4,5 TRIMETHOXYBENZOIC ACID.
210813 03-03

EFFECTS OF HYPERBARIC CONDITIONS ON THE RESPONSE OF ANIMALS TO CENTRAL NERVOUS SYSTEM STIMULANTS AND DEPRESSANTS.
210877 03-03

INHIBITION OF THE SYMPATHETIC NERVOUS SYSTEM BY 5,6 DIHYDROXY-2-DIMETHYLAMINOTETRALIN (M-7), APOMORPHINE AND DOPAMINE.
210888 03-03

THE LEVEL OF BLOOD NEUROMEDIATORS AFTER THE USE OF SEDUXEN AS AN INDEX OF NERVOUS SYSTEM REACTIVITY.
212432 03-13

EFFECT OF CENTRAL NERVOUS SYSTEM LESIONS ON DRUG ACTION.
213611 04-03

CATECHOLAMINES AS CENTRAL NERVOUS TRANSMITTERS.
213620 04-03

THE EFFECT OF PENFLURIDOL AND SOME PSYCHOTROPIC DRUGS ON MONOAMINE METABOLISM IN CENTRAL NERVOUS SYSTEM.
215686 04-03

THE EFFECTS OF SCOPOLAMINE (0.6 MG) AND PHYSOSTIGMINE (1.0 MG) ON HIGHER NERVOUS ACTIVITY IN MAN, FOLLOWED-UP DURING 5 HOURS AFTER APPLICATION.
217205 04-14

5-HYDROXYTRYPTAMINE IN THE CENTRAL NERVOUS SYSTEM AND SEXUAL RECEPTIVITY OF FEMALE RHESUS MONKEYS.
217856 04-04

CORRELATED HISTOCHEMICAL, ELECTRON MICROSCOPICAL, PHARMACOLOGICAL AND PHYSIOLOGICAL OBSERVATION ON

AMINERGIC MECHANISMS IN THE CENTRAL NERVOUS SYSTEM. (UNPUBLISHED PAPER).
218300 04-03

CYCLIC-GMP: REDUCTION OF CEREBELLAR CONCENTRATIONS IN NERVOUS MUTANT MICE.
221031 04-03

ANTAGONISM OF PSYCHOSTIMULANT 2 PHENYLDIMETHYLTETRAHYDROOXAZINE HYDROCHLORIDE (G-130) TO CENTRAL NERVOUS SYSTEM DEPRESSING DRUGS: MONOAMINEOXIDASE INHIBITORY ACTIVITY AND NOREPINEPHRINE AND SEROTONIN INDUCED CHANGES, COMPARISON WITH DL-AMPHETAMINE.
221267 04-03

PHARMACOLOGICAL ACTION OF FD-008, A NEW DOPAMINE-BETA-HYDROXYLASE INHIBITOR: II. EFFECTS ON CENTRAL NERVOUS SYSTEM IN MICE AND RATS.
221823 04-02

CENTRAL NERVOUS SYSTEM PHARMACOLOGY OF CHOLINERGICALLY ELICITED EATING AND DRINKING BEHAVIOR IN THE ALBINO RAT. (PH.D. DISSERTATION).
222638 04-04

EFFECTS OF METHYLPHENIDATE HYDROCHLORIDE ON THE CENTRAL NERVOUS SYSTEM. (PH.D. DISSERTATION).
222641 04-03

RAPID ANALYSIS OF THE CENTRAL NERVOUS SYSTEM STIMULANTS, AMPHETAMINES, VIA GAS CHROMATOGRAPHY MASS SPECTROMETRY: RAPID ACYLATION IN THE PRESENCE OF A MERCURY CATALYST.
222830 04-06

NEURAL

THE STRUCTURAL CHEMISTRY OF ADRENERGIC NEURAL TRANSMISSION SYSTEMS. (PH.D. DISSERTATION).
203027 02-01

EVOKED NEURAL ACTIVITY IN THE BASAL GANGLIA OF THE CAT AND ITS MODIFICATION BY CHOLINERGIC AND DOPAMINERGIC AGENTS. (PH.D. DISSERTATION).
212520 03-03

PHARMACOLOGY OF NEURAL MODULATION AND TRANSMISSION.
213627 04-03

THE EFFECT OF ALPHA-METHYL-P-TYROSINE METHYLESTER ON TEMPORAL SUMMATION IN THE NEURAL SUBSTRATE FOR THE REINFORCEMENT EFFECT IN SELF-STIMULATION. (PH.D. DISSERTATION).
222090 04-04

NEURAMINIDASE

NEURAMINIDASE: ITS EFFECT ON SYNAPTIC TRANSMISSION.
210664 03-03

NEUROANATOMICAL

A PHARMACOLOGICAL AND NEUROANATOMICAL ANALYSIS OF DOPAMINERGIC AND NORADRENERGIC PATHWAYS INVOLVED IN SELF-STIMULATION IN RATS. (PH. D. DISSERTATION).
193582 01-04

NEUROBIOCHEMICAL

MAPROTILINE -- ITS POSITION AS AN ANTIDEPRESSANT IN THE LIGHT OF RECENT NEUROPHARMACOLOGICAL AND NEUROBIOCHEMICAL FINDINGS.
221647 04-03

NEUROBLASTOMA

ADENOSINE 3,5 MONOPHOSPHATE IN CULTURED NEUROBLASTOMA CELLS: EFFECT OF ADENOSINE, PHOSPHODIESTERASE INHIBITORS AND BENZAZEPINES.
195254 01-03

NEUROCHEMICAL

THE EFFECTS OF DRUG ADMINISTRATION TO THE LATERAL HYPOTHALAMUS: NEUROCHEMICAL CODING OR NONSPECIFICITY?.
195992 01-03

NEUROCHEMICAL BASES FOR THE ANORECTIC ACTIVITIES OF AMPHETAMINE AND FENFLURAMINE.
197301 01-03

ON THE SPECIFICITY OF NEUROCHEMICAL MECHANISMS DEALING WITH NOCICEPTIVE STIMULATION OF NEURONS IN VARIOUS BRAIN FORMATIONS OF RABBITS.
198436 02-03

NEUROCHEMICAL CODING FOR FEEDING IN SHEEP AND STEERS.
206727 03-04

EXPERIMENTAL TESTS OF HYPOTHESES ABOUT NEUROCHEMICAL MECHANISMS UNDERLYING BEHAVIORAL TOLERANCE TO THE ANTICHOLINESTERASE, DIISOPROPYLFLUOROPHOSPHATE.
208555 03-03

NEUROCHEMICAL REGULATION OF FEEDING IN THE RAT: FACILITATION BY ALPHA-NORADRENERGIC, BUT NOT DOPAMINERGIC RECEPTOR STIMULANTS.
211538 03-04

BEHAVIORAL AND NEUROCHEMICAL EFFECTS OF MORPHINE OR AMPHETAMINE AFTER CHRONIC PRETREATMENT WITH CATECHOLAMINE DEPLETING AGENTS. (PH.D. DISSERTATION).
211746 03-03

NEUROCHEMICAL ACTIONS OF PSYCHOTROPIC DRUGS.
213633 04-03

AN ANALYSIS OF NEUROCHEMICAL MECHANISMS OF ONE FORM OF INTRASPECIES BEHAVIOR.
215789 04-04

ON NEUROCHEMICAL MECHANISMS OF SEPTUM INFLUENCE ON THE CONDITIONED AVOIDANCE REACTION IN RATS.
218803 04-04

SOME NEUROCHEMICAL EFFECTS OF N,N DIMETHYLTRYPTAMINE AND THEIR POSSIBLE RELATION TO ACUTE SCHIZOPHRENIA. (PH.D. DISSERTATION).
219179 04-03

NEUROCHEMICAL AND NEUROPHYSIOLOGICAL MECHANISMS OF THE PSYCHOSTIMULATING ACTION OF PHENAMINE.
219510 04-13

NEUROCHEMICAL CHANGES ASSOCIATED WITH SCHEDULE-CONTROLLED BEHAVIOR.
225160 04-04

NEUROCHEMISTRY

REGIONAL DISTRIBUTION OF CATIONS AND THEIR RELATION TO THE NEUROCHEMISTRY OF EXPERIMENTAL EPILEPSY, NEUROTRANSMITTERS AND ATPASE IN THE CENTRAL NERVOUS SYSTEM. (PH.D. DISSERTATION).
193588 01-03

DIFFERENTIAL NEUROCHEMISTRY AND TEMPORAL PATTERN IN RATS TREATED ORALLY WITH DELTA9-TETRAHYDROCANNABINOL FOR PERIODS UP TO SIX MONTHS.
217519 04-04

ON NEUROCHEMISTRY AND BEHAVIOR.
225158 04-17

NEUROEFFECTOR

EFFECT OF NICOTINE AND NICOTINE MONOMETHIODIDE ON VASCULAR ADRENERGIC NEUROEFFECTOR TRANSMISSION.
197966 01-03

EFFECT OF TROPOLONE ON VASCULAR SYMPATHETIC NEUROEFFECTOR TRANSMISSION.
197970 01-03

NEUROENDOCRINOLOGICAL

CLINICAL AND NEUROENDOCRINOLOGICAL STUDY OF TRH IN MELANCHOLIA.
212162 03-09

NEUROENDOCRINOLOGY

BEHAVIORAL NEUROENDOCRINOLOGY: CHEMICAL CORRELATES.
213625 04-03

NEUROGENIC

BIOGENIC AMINES IN A RETRANSPLANTABLE NEUROGENIC TERATOCARCINOMA.
192925 01-03

NEUROHUMORS

LSD, PSYCHOTOGENIC PROCEDURES, AND BRAIN NEUROHUMORS.
213606 04-03

LIMBIC SYSTEM LESIONS AND BRAIN NEUROHUMORS.
213613 04-03

CEREBRAL NEUROHUMORS AND BEHAVIOR.
213623 04-08

NEUROLEPTIC

A CLINICAL NEUROLEPTIC INVESTIGATION OF N-(1-ETHYL-PYRROLIDIN-2-YL) 2-METHOXY-5-SULFAMOYL-BENZAMIDE NEUROLEPTIC SULPIRIDE (DOGMATIL) IN ACUTELY ILL SCHIZOPHRENICS.
195038 01-11

THE IMPORTANCE OF THE ASCENDING DOPAMINERGIC SYSTEMS TO THE EXTRAPYRAMIDAL AND MESOLIMBIC BRAIN AREAS FOR THE CATALEPTIC ACTION OF THE NEUROLEPTIC AND CHOLINERGIC AGENTS.
195250 01-03

A CRITICAL EVALUATION OR MOLINDONE (MOBAN): A NEW INDOLE DERIVATIVE NEUROLEPTIC.
196674 01-07

NEUROLEPTIC AND NON-NEUROLEPTIC CATALEPSY.
199911 02-04

MAINTENANCE TREATMENT OF CHRONIC SCHIZOPHRENIA WITH NEUROLEPTIC DRUGS.
200636 02-06

A CONTROLLED CLINICAL TRIAL OF PIMOZIDE (R-6238) -- A NEW NEUROLEPTIC.
200897 02-08

ASPECTS OF NEUROLEPTIC DEPOT THERAPY WITH SPECIAL CONSIDERATION OF CLINICAL EXPERIENCE WITH THE PERORAL DEPOT PREPARATION PENFLURIDOL (R-16341 - JANSSEN).
202785 02-07

LEARNING DEFICITS IN 4 WEEKS OLD OFFSPRING OF THE NURSING MOTHERS TREATED WITH THE NEUROLEPTIC DRUG PENFLURIDOL.
202806 02-04

THE EFFECTS OF NEUROLEPTIC AGENTS IN THE CHRONIC PHARMACOLOGICAL EXPERIMENT.
202863 02-04

MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 1. COMMUNICATION: SETTING A GOAL AND METHODOLOGICAL GROUND RULES.
203839 02-13

MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 2. COMMUNICATION: PSYCHOPATHOLOGICAL COURSE PROFILE AND SOMATIC CHARACTERISTICS (STUDIES WITH THE AMP SYSTEM).
203840 02-14
MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 3. COMMUNICATION: PERAZINE CONCENTRATION IN BLOOD AND CLINICAL EFFICACY.
203841 02-13
MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 4. COMMUNICATION: CONNECTION BETWEEN EEG CHANGES, CONCENTRATION IN BLOOD, AND OTHER CLINICAL VARIABLES.
203842 02-13
MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 5. COMMUNICATION: INFLUENCE ON VENTRICULAR EXCITATION IN THE ELECTROCARDIOGRAM.
203843 02-13
MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 6. COMMUNICATION: RELATIONSHIP BETWEEN NEUROLEPTIC HYPOKINESIS AND ANTIPSYCHOTIC THERAPEUTIC RESULTS.
203844 02-13
MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 7. COMMUNICATION: METHODOLOGICAL OUTCOME.
203845 02-16
TARDIVE DYSKINESIA: AN EVALUATION OF THE ETIOLOGIC ASSOCIATION WITH NEUROLEPTIC THERAPY.
204164 02-15
DIFFERENTIAL EFFECTS OF NEUROLEPTIC DRUGS IN CHRONIC SCHIZOPHRENICS: A CONFIGURATION ANALYTICAL EVOLUTION.
204415 02-08
AN ATTEMPT TO CLASSIFY NEUROLEPTIC DRUGS ON THE BASIS OF SHORT-TERM CLINICAL COMPARATIVE STUDIES.
205591 02-08
NEUROLEPTIC DRUGS AND AUTOMOBILE DRIVING.
205882 03-15
AZAPERONE, A SEDATIVE NEUROLEPTIC OF THE BUTYROPHENONE SERIES WITH PRONOUNCED ANTIAGGRESSIVE AND ANTISHOCK ACTIVITY IN ANIMALS.
206786 03-04
BROMOPERIDOL, A NEW POTENT NEUROLEPTIC OF THE BUTYROPHENONE SERIES; COMPARATIVE PHARMACOLOGY OF BROMOPERIDOL AND HALOPERIDOL.
206804 03-02
CLINICOSTATISTICAL STUDY OF THE EFFECTS OF SULPIRIDE, A NEW NEUROLEPTIC DRUG.
206805 03-07
INFLUENCE OF NEUROLEPTIC SUBSTANCE ON NEUROPHYSIOLOGICAL PARAMETERS IN EXPERIMENTAL ANIMALS.
206998 03-06
CENTRAL CATECHOLAMINE NEURONS, BEHAVIOR AND NEUROLEPTIC DRUGS: AN ANALYSIS TO UNDERSTAND THE INVOLVEMENT OF CATECHOLAMINES IN SCHIZOPHRENIA.
207305 03-03
BRAIN DOPAMINE AND BEHAVIOUR: A CRITICAL ANALYSIS OF THE RELATIONSHIP BETWEEN DOPAMINE ANTAGONISM AND THERAPEUTIC EFFICACY OF NEUROLEPTIC DRUGS.
207306 03-04
NEUROLEPTIC AGENTS OF THE BENZOCYCLOHEPTAPYRIDOISOQUINOLINE SERIES. 1.SYNTHESES AND STEREOCHEMICAL AND STRUCTURAL REQUIREMENTS FOR ACTIVITY OF BUTACLAMOL AND RELATED COMPOUNDS.
208592 03-01
A CASE OF IRREVERSIBLE EXTRAPYRAMIDAL HYPERKINESIA INDUCED BY NEUROLEPTIC DRUGS.
209410 03-15
DOPAMINE RECEPTOR BLOCKADE BY NEUROLEPTIC DRUGS IN APLYSIA NEURONES.
210599 03-03
PROLONGED NEUROLEPTIC EFFECT OF ALPHA-FLUPENTHIXOL DECANOATE IN OIL.
210893 03-03
TESTING ANATENSOL DECANOATE, A MAJOR NEUROLEPTIC, AT THE IXELLES GUIDANCE CENTER.
212165 03-09
PARTIAL RESTORATION BY AN A NEUROLEPTIC (SPIRAMIDE) OF ITEMS OF GROOMING BEHAVIOUR SUPPRESSED BY AMPHETAMINE.
213590 04-04
RADIOIMMUNOASSAY OF THE NEUROLEPTIC DRUG PIMOZIDE.
213986 04-06
INCREASED SENSITIVITY TO DOPAMINERGIC AGENTS AFTER CHRONIC NEUROLEPTIC TREATMENT.
215689 04-04
POLYGRAPHIC NIGHT SLEEP PATTERN DURING CHRONIC SINGLE AND MULTIPLE NEUROLEPTIC DOSE ADMINISTRATION.
215701 04-08
A NEW SUBSTITUTED BENZAMIDE WITH NEUROLEPTIC EFFECTS: LIN-14-18 OR SULTOPRIDE.
216759 04-08
A CLINICAL STUDY OF A NEW NEUROLEPTIC EXTRAPYRAMIDAL SYNDROME CORRECTOR WITH ACUTE PSYCHOTIC STATES.
216766 04-15
TRIAL INTERRUPTION OF ANTIPARKINSONIANS IN LONG-TERM NEUROLEPTIC TREATMENT.
216767 04-15
NEUROLEPTIC ACTION OF CLOZAPINE INJECTED INTO VARIOUS BRAIN AREAS IN RATS.
217451 04-04
ONTOGENESIS OF NEOSTRIATAL CHOLINERGIC NEURONES IN THE RAT AND DEVELOPMENT OF THEIR SENSITIVITY TO NEUROLEPTIC DRUGS.
217658 04-03
DEPRESSIONS AND ANTIDEPRESSANTS DURING TREATMENT WITH LONG-ACTING NEUROLEPTIC DRUGS: SIDE-EFFECTS AND THE EMERGENT METATHERAPEUTIC SYNDROME.
219694 04-15
A MULTICENTER MULTIDIMENSIONAL STUDY OF SOME NEW LONG-ACTING NEUROLEPTIC DRUGS.
220858 04-07
MONOAMINEOXIDASE INHIBITORS ANTAGONIZE THE ACCELERATION OF BRAIN DOPAMINE SYNTHESIS INDUCED BY NEUROLEPTIC DRUGS IN VIVO: IMPLICATIONS FOR THE TREATMENT OF TARDIVE DYSKINESIA.
220948 04-03
A BENZODIOXANHYDROXYETHYLPIPERIDINE DERIVATIVE WITH ACUTE CENTRAL HYPOTENSIVE ACTION, DIFFERENT FROM THAT OF CLONIDINE: A COMPARISON WITH NEUROLEPTIC AGENTS.
220976 04-03
NEUROLEPTIC PIPERAZINYLDIBENZOAZEPINES: CHEMISTRY AND STRUCTURE-ACTIVITY RELATIONSHIPS.
221734 04-01
A CLINICAL TRIAL OF A STRUCTURALLY UNIQUE NEUROLEPTIC (SU-23397).
225065 04-14

NEUROLEPTIC-INDUCED
NEUROLEPTIC-INDUCED KLUVER-BUCY SYNDROME.
213532 04-15
NEUROLEPTIC-INDUCED HYPERSENSITIVITY OF STRIATAL DOPAMINE RECEPTORS IN THE RAT AS A MODEL OF TARDIVE DYSKINESIAS. EFFECTS OF CLOZAPINE, HALOPERIDOL, LOXAPINE AND CHLORPROMAZINE.
217462 04-03
EFFECT OF LITHIUM ON NEUROLEPTIC-INDUCED TARDIVE DYSKINESIA COMPARED WITH PLACEBO IN A DOUBLE-BLIND CROSSOVER TRIAL.
221335 04-15

NEUROLEPTICAL
THE INFLUENCE OF NEUROLEPTICAL DRUGS ON CATECHOLAMINE EXCRETION.
200073 02-08

NEUROLEPTICS
INFLUENCE OF THERAPEUTIC AND TOXIC DOSES OF NEUROLEPTICS AND ANTIDEPRESSANTS ON ENERGY METABOLISM OF THE ISOLATED PERFUSED RAT BRAIN.
195236 01-03
TYROSINE-HYDROXYLASE (TH) IN NUCLEUS-ACCUMBENS AND STRIATUM: EFFECTS OF NEUROLEPTICS ON THE AFFINITY FOR PTERIDINE COFACTOR. (UNPUBLISHED PAPER).
196588 01-03
ACUTE INTOXICATIONS WITH NEUROLEPTICS.
196923 01-15
ACTION OF NEUROLEPTICS ON THE CONTENT OF DOPAMINE AND DOPAC IN THE RAT CAUDATE NUCLEUS.
197682 01-03
ANTAGONISTIC EFFECTS OF NEUROLEPTICS AND APOMORPHINE ON SYNAPTOSOMAL TYROSINE-HYDROXYLASE IN VITRO.
198209 02-03
THE INFLUENCE OF ANALGESICS AND NEUROLEPTICS ON AFFECTIVE MANIFESTATIONS OF PAIN.
198480 02-04
ON THE INFLUENCE OF NEUROLEPTICS ON THE CORTICORETICULAR SYSTEM OF THE BRAIN (HISTOCHEMICAL AND BIOCHEMICAL INVESTIGATION).
198481 02-03
THE INFLUENCE OF ANTIDEPRESSANTS AND NEUROLEPTICS ON BEHAVIORAL REACTIONS ELICITED BY LESION AND EXCITATION OF THE HIPPOCAMPUS.
198483 02-04
THE EXTRAPYRAMIDAL SYNDROME INDUCED BY NEUROLEPTICS.
202445 02-15
CHANGES OF KINETIC CONSTANT OF STRIATAL TYROSINE-HYDROXYLASE ELICITED BY NEUROLEPTICS THAT IMPAIR THE FUNCTION OF DOPAMINE RECEPTORS.
202716 02-03
LONG-ACTING NEUROLEPTICS OF PERATHIEPINE GROUP: VUFB-9977 (OXYPROTHEPINE DECANOATE).
205583 02-03

NEW DEVELOPMENTS IN THE STUDY OF THE MECHANISM OF ACTION OF NEUROLEPTICS AND AMPHETAMINE.
207296 03-03

NEUROLEPTICS AS A GUIDELINE TO BIOLOGICAL RESEARCH IN PSYCHOTIC DISORDERS.
207765 03-17

COMPARISON OF NEUROLEPTICS IN CONTROLLED EXPERIMENTAL CONDITIONS: METHOPHENAZINE VS PERPHENAZINE.
209147 03-08

PHARMACOKINETIC INTERACTION BETWEEN NEUROLEPTICS AND TRICYCLIC ANTIDEPRESSANTS IN THE RAT.
210834 03-03

THE COMPARATIVE PHARMACOLOGY OF FLUPENTHIXOL AND SOME REFERENCE NEUROLEPTICS.
210892 03-03

THERAPY AND LONG-ACTING NEUROLEPTICS.
212774 03-14

EFFECTS OF AMPHETAMINE ISOMERS AND NEUROLEPTICS ON SELF-STIMULATION FROM THE NUCLEUS-ACCUMBENS AND DORSAL NORADRENERGIC BUNDLE.
213394 04-03

ASPECTS OF LONG-TERM TREATMENT WITH NEUROLEPTICS: HISTORICAL AND LITERATURE REVIEW -- PERSONAL EXPERIENCE WITH FLUSPIRILENE AND PENFLURIDOL.
215059 04-14

BIOCHEMICAL VERSUS PSYCHOPATHOLOGICAL ACTION PROFILE OF NEUROLEPTICS: A COMPARATIVE STUDY OF CHLORPROMAZINE AND OXYPERTINE IN ACUTE PSYCHOTIC DISORDERS.
215454 04-13

AN ATTEMPT TO CLASSIFY SULTOPRIDE AMONG CURRENT NEUROLEPTICS.
216760 04-09

NEUROLEPTICS OF PROLONGED ACTION (A SURVEY OF FOREIGN LITERATURE).
217003 04-14

INHIBITION OF STRIATAL DOPAMINE SYNTHESIS IN RATS INJECTED CHRONICALLY WITH NEUROLEPTICS IN THEIR EARLY LIFE.
217687 04-03

NEUROLEPTICS: RELATION BETWEEN CATALEPTIC AND ANTITURNING ACTIONS, AND ROLE OF THE CHOLINERGIC SYSTEM.
217826 04-04

THE PARTICIPATION OF CEREBRAL CHOLINERGIC MECHANISMS IN THE ACTION OF NEUROLEPTICS.
218471 04-04

THE EFFECT OF NEUROLEPTICS OF THE PHENOTHIAZINE SERIES ON PULSE ACTIVITY AND THE ULTRASTRUCTURE OF RABBIT CORTICAL NEURONS.
219606 04-03

ALCOHOLISM AND INCISIVE NEUROLEPTICS.
219836 04-14

CLINICAL STUDY OF FIVE DEPOT NEUROLEPTICS, COMPARISON OF ACTIVITY PROFILES OF FLUPHENAZINE DECANOATE, FLUSPIRILENE, PENFLURIDOL, PERPHENAZINE ENANTHATE AND PIPOTHIAZINE PALMITATE.
221822 04-08

THE EFFECT OF NEUROLEPTICS AND ANTIDEPRESSANTS ON THE UPTAKE OF 3H-GAMMA-AMINOBUTYRIC ACID BY ISOLATED NERVE ENDINGS OF THE RAT BRAIN.
224114 04-03

TIME TO EVALUATE LONG-ACTING NEUROLEPTICS?
224417 04-08

ON SYNDROME MALIN INDUCED BY NEUROLEPTICS.
224507 04-15

NEUROLEPTOGENIC

THE ASSESSMENT OF NEUROLEPTOGENIC EXTRAPYRAMIDAL SYNDROMES IN PSYCHOPHARMACOLOGICAL RESEARCH.
221307 04-15

NEUROMEDIATORS

THE LEVEL OF BLOOD NEUROMEDIATORS AFTER THE USE OF SEDUXEN AS AN INDEX OF NERVOUS SYSTEM REACTIVITY.
212432 03-13

NEUROMUSCULAR

THE EFFECTS OF AMPHETAMINE ISOMERS ON NEUROMUSCULAR TRANSMISSION.
210765 03-03

IN VITRO NEUROMUSCULAR EFFECTS OF DELTA9-TETRAHYDROCANNABINOL (THC).
210866 03-03

(3H)GLUTAMATE UPTAKE AT INSECT NEUROMUSCULAR JUNCTIONS: EFFECT OF CHLORPROMAZINE.
213474 04-03

NEURON

THE NEURON ULTRASTRUCTURE IN SOME BRAIN AREAS DURING A LONG-TERM ADMINISTRATION OF AMINAZINE AND STELAZINE.
200021 02-03

THE REGULATION OF THE NORADRENERGIC NEURON.
207331 03-17

EFFECT OF INTRAVENTRICULAR NOREPINEPHRINE ON NEURON ACTIVITY IN THE MEDIAL FOREBRAIN BUNDLE DURING SELF-STIMULATION BEHAVIOR.
210704 03-04

DETAILED NORADRENALINE PATHWAYS OF LOCUS-COERULEUS NEURON TO THE CEREBRAL CORTEX WITH THE USE OF 5-HYDROXYDOPA.
210803 03-03

ACETYLCHOLINE ACTIVITY IN AN IDENTIFIED 5-HYDROXYTRYPTAMINE CONTAINING NEURON.
217825 04-03

THE INFLUENCE OF ALKYLATE PHERPACET DERIVATIVES ON NEURON POPULATIONS IN THE MIDBRAIN RETICULAR FORMATION.
219501 04-03

SOME PECULIARITIES OF THE NEURON ULTRASTRUCTURE IN THE BRAIN-CORTEX MOTOR AREA UNDER THE INFLUENCE OF LYSERGIC ACID DIETHYLAMIDE (LSD) AND HALOPERIDOL.
222890 04-03

NEURONAL

STUDIES ON THE EFFECT OF AMANTADINE ON NEURONAL MEMBRANES.
197283 01-03

EVIDENCE THAT PUNCTUATE INTRACEREBRAL ADMINISTRATION OF 6-HYDROXYDOPAMINE FAILS TO PRODUCE SELECTIVE NEURONAL DEGENERATION: COMPARISON WITH COPPER SULFATE AND FACTORS GOVERNING THE DEPORTMENT OF FLUIDS INJECTED INTO BRAIN.
197931 01-03

EFFECTS OF SODIUM, OUABAIN AND DMPP ON THE NEURONAL EFFLUX OF NORADRENALINE.
197959 01-03

NEURONAL ACTIVITY OF NUCLEUS CAUDATES AND THALAMUS DURING BARBITURATE SPINDLES IN RATS.
201479 02-03

THE IMPORTANCE OF NEURONAL UPTAKE OF AMINES FOR AMPHETAMINE-INDUCED RELEASE OF 3H-NOREPINEPHRINE FROM ISOLATED BRAIN TISSUE.
202191 02-03

EFFECT OF PERIPHERALLY ADMINISTERED SEROTONIN ON THE NEURONAL ACTIVITY OF MIDBRAIN RAPHE NEURONS.
210710 03-03

CHANGES IN THE NEURONAL PROTEIN LABELLING INDUCED BY POTASSIUM IONS IN VIVO (SPREADING DEPRESSION).
210779 03-03

DIFFERENTIAL EFFECTS OF THE OPTICAL ISOMERS OF AMPHETAMINE ON NEURONAL ACTIVITY IN THE RETICULAR FORMATION AND CAUDATE NUCLEUS OF THE RAT.
211063 03-03

EFFECTS OF PUTATIVE NEUROTRANSMITTERS ON NEURONAL ACTIVITY IN MONKEY AUDITORY CORTEX.
217865 04-03

NEURONES

THE EFFECT OF MICROELECTROPHORETICALLY APPLIED MESCALINE ON CORTICAL NEURONES.
199961 02-03

FACTORS AFFECTING THE ACTIVITY OF 5-HT CONTAINING NEURONES.
202718 02-03

ALPHA-RECEPTOR MEDIATED MODULATION OF TRANSMITTER RELEASE FROM CENTRAL NORADRENERGIC NEURONES.
202805 02-03

BIOCHEMICAL EFFECTS OF DIHYDROXYLATED TRYPTAMINES ON CENTRAL INDOLEAMINE NEURONES.
204340 02-03

DOPAMINE RECEPTOR BLOCKADE BY NEUROLEPTIC DRUGS IN APLYSIA NEURONES.
210599 03-03

A POTENT DEPRESSANT ACTION OF ADENINE DERIVATIVES ON CEREBRAL CORTICAL NEURONES.
210932 03-03

RESPONSES OF CENTRAL NEURONES TO AMANTADINE: COMPARISON WITH DOPAMINE AND AMPHETAMINE.
213398 04-03

ENHANCEMENT OF SELF-STIMULATION BY DEPRENIL: EVIDENCE FOR A ROLE OF DOPAMINE NEURONES IN REWARD.
213432 04-04

ONTOGENESIS OF NEOSTRIATAL CHOLINERGIC NEURONES IN THE RAT AND DEVELOPMENT OF THEIR SENSITIVITY TO NEUROLEPTIC DRUGS.
217658 04-03

BETA-PHENYLETHYLAMINE AND LOCOMOTOR ACTIVITY IN MICE: INTERACTION WITH CATECHOLAMINERGIC NEURONES AND RECEPTORS.
221742 04-03

DIFFERENTIAL EFFECTS OF A TETRAHYDROCANNABINOL AND PENTOBARBITAL ON CEREBRAL CORTICAL NEURONES.
222819 04-03

NEURONS

ALTERATIONS BY ANESTHETIC AGENTS OF THE RESPONSES OF RAT STRIATAL NEURONS TO IONTOPHORETICALLY APPLIED AMPHETAMINE, ACETYLCHOLINE, NORADRENALINE, AND DOPAMINE.
193803 01-03

6-HYDROXYDOPAMINE INDUCED DEGENERATION OF NORADRENALINE NEURONS IN THE SCORBUTIC GUINEA-PIG.
195449 01-03

THE EFFECTS OF DIPHENYLAMINOETHANOL (DPAE) AND LIDOCAINE ON CEREBELLAR INHIBITION DEITERS NEURONS. (PH.D. DISSERTATION).
196259 01-03

RESPONSES OF MOLLUSCAN NEURONS TO CATECHOLAMINES.
197445 01-03

THE ACTION OF BICUCULLINE UPON ACETYLCHOLINE-INDUCED EXCITATIONS OF CENTRAL NEURONS.
197993 01-03

ON THE SPECIFICITY OF NEUROCHEMICAL MECHANISMS DEALING WITH NOCICEPTIVE STIMULATION OF NEURONS IN VARIOUS BRAIN FORMATIONS OF RABBITS.
198436 02-03

COMPARATIVE EFFECT OF PHENAMINE (AMPHETAMINE) AND CAFFEINE ON THE BACKGROUND ACTIVITY OF CORTICAL SENSORIMOTOR NEURONS AND THEIR REACTIONS DURING STIMULATION OF THE CAUDATE NUCLEUS.
198835 02-03

THE INFLUENCE OF NEMBUTAL, CHLORALOSE AND URETHANE ON INHIBITORY POSTSYNAPTIC POTENTIALS OF CORTICAL NEURONS.
199443 02-03

AMPHETAMINE, L-DOPA AND APOMORPHINE: EFFECTS ON ACTIVITY OF RAT DOPAMINERGIC NEURONS.
202370 02-03

THE EFFECT OF INHIBITORS OF CATECHOLAMINE SYNTHESIS (ALPHA-METHYLTYROSINE AND DISULFIRAM) ON THE BACKGROUND ACTIVITY OF SENSORIMOTOR CORTEX NEURONS AND THEIR RESPONSES TO AFFERENT CAUDATE AND RETICULAR STIMULATION.
202598 02-04

DOPAMINERGIC NEURONS: DRUG-INDUCED ANTAGONISM OF THE INCREASE IN TYROSINE-HYDROXYLASE ACTIVITY PRODUCED BY CESSATION OF IMPULSE FLOW.
202664 02-03

EFFECTS OF D-AMPHETAMINE ON SINGLE VESTIBULAR NEURONS.
204483 02-03

THE EFFECTS OF ACETYLCHOLINE AND SYNAPTIC STIMULATION ON THE NEURONS IN THE SENSORIMOTOR CORTEX.
205510 02-03

MICROIONTOPHORETIC STUDIES ON THE EFFECT OF NOREPINEPHRINE ON THE ACTIVITY OF THE VISUAL CORTEX NEURONS IN RABBITS.
206441 03-03

CENTRAL DOPAMINE NEURONS AND SENSORY PROCESSING.
207304 03-03

CENTRAL CATECHOLAMINE NEURONS, BEHAVIOR AND NEUROLEPTIC DRUGS: AN ANALYSIS TO UNDERSTAND THE INVOLVEMENT OF CATECHOLAMINES IN SCHIZOPHRENIA.
207305 03-03

ARE AUTORECEPTORS IN DOPAMINERGIC NEURONS INVOLVED IN THE CHANGE OF THE KINETIC STATE OF STRIATAL TYROSINE-HYDROXYLASE ELICITED BY ANTIPSYCHOTICS? (UNPUBLISHED PAPER).
208636 03-03

FREE AND MEMBRANE BOUND RIBOSOMES AND POLYSOMES IN HIPPOCAMPAL NEURONS DURING A LEARNING EXPERIMENT.
210674 03-04

NORADRENALINE MEDIATED INHIBITION BY LOCUS-COERULEUS OF SPINAL TRIGEMINAL NEURONS.
210703 03-03

EFFECT OF PERIPHERALLY ADMINISTERED SEROTONIN ON THE NEURONAL ACTIVITY OF MIDBRAIN RAPHE NEURONS.
210710 03-03

DOPAMINERGIC NEURONS IN THE NIGROSTRIATAL AND MESOLIMBIC PATHWAYS: MEDIATION OF SPECIFIC EFFECTS OF D-AMPHETAMINE.
210855 03-03

EFFECT OF ERGOT DRUGS ON CENTRAL 5-HYDROXYTRYPTAMINE NEURONS: EVIDENCE FOR 5-HYDROXYTRYPTAMINE RELEASE OR 5-HYDROXYTRYPTAMINE RECEPTOR STIMULATION.
210857 03-03

INHIBITION OF SACRAL PARASYMPATHETIC PREGANGLIONIC NEURONS BY GABA, GLYCIN, 5-HYDROXYTRYPTAMINE AND NOREPINEPHRINE. (PH.D. DISSERTATION).
212524 03-03

RESPONSES OF CULTURED CEREBELLAR NEURONS TO IONTOPHORETICALLY APPLIED AMINO ACIDS.
213279 03-03

GAMMA-HYDROXYBUTYRATE AND CONTROL OF DOPAMINERGIC NEURONS.
213626 04-03

THE ACTION OF CHLORPROMAZINE AND TRIFTAZINE ON DISCHARGES OF CORTICAL NEURONS IN RABBITS AFTER CHRONIC ADMINISTRATION OF THE DRUGS.
215499 04-03

ACTIONS OF ACETYLCHOLINE AND ATROPINE ON CEREBRAL CORTICAL NEURONS IN CHRONICALLY MORPHINE TREATED RATS.
215733 04-03

A RAPID, SIMPLE AND MORE SENSITIVE METHOD FOR THE DEMONSTRATION OF CENTRAL CATECHOLAMINE CONTAINING NEURONS AND AXONS BY GLYOXYLIC ACID INDUCED FLUORESCENCE: I. SPECIFICITY.
217550 04-16

MIDBRAIN RAPHE NEURONS: SENSITIVITY TO GLUCOCORTICOIDS AND ACTH IN THE RAT.
217863 04-03

6-HYDROXYDOPA DURING DEVELOPMENT OF CENTRAL ADRENERGIC NEURONS PRODUCES DIFFERENT LONG-TERM CHANGES IN RAT BRAIN NORADRENALINE.
217867 04-03

LONG-LASTING CHANGES IN CEREBRAL NEURONS INDUCED BY DRUGS.
218957 04-03

THE EFFECT OF NEUROLEPTICS OF THE PHENOTHIAZINE SERIES ON PULSE ACTIVITY AND THE ULTRASTRUCTURE OF RABBIT CORTICAL NEURONS.
219606 04-03

INHIBITION OF BOTH NORADRENERGIC AND SEROTONERGIC NEURONS IN BRAIN BY THE ALPHA-ADRENERGIC AGONIST CLONIDINE.
221131 04-03

TRICYCLIC ANTIDEPRESSANTS: EFFECTS ON THE FIRING RATE OF BRAIN NORADRENERGIC NEURONS.
222805 04-03

NEUROPATHOLOGICAL

AMPHETAMINE TOXICITY: BEHAVIORAL AND NEUROPATHOLOGICAL INDEXES.
225165 04-05

NEUROPHARMACOLOGIC

NEUROPHARMACOLOGIC STUDIES OF LOCAL BRAIN FUNCTION.
213601 04-03

NEUROPHARMACOLOGICAL

NEUROPHARMACOLOGICAL STUDIES OF EFFECT OF NEW CENTRAL DEPRESSANT, 8-CHLOR-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D40TA) ON EEG AND CENTRAL SYMPATHETIC ACTIVATING MECHANISM IN CATS.
195549 01-03

NEUROPHARMACOLOGICAL FINDINGS AFTER CHRONIC ADMINISTRATION OF HALOPERIDOL, LOXAPINE AND CLOZAPINE.
206972 03-03

EXPERIMENTAL STUDY ON NEUROPHARMACOLOGICAL ACTIONS OF SOME INDOLE DERIVATIVES.
207164 03-02

THE ELECTRODERMAL RESPONSE: NEUROPHYSIOLOGICAL AND NEUROPHARMACOLOGICAL CHARACTERISTICS. (PH.D. DISSERTATION).
214203 04-03

A NEUROPHARMACOLOGICAL ANALYSIS OF CHOLINERGIC MECHANISMS OF SELF-STIMULATION REACTIONS.
215497 04-04

NEUROPHARMACOLOGICAL STUDIES ON SB-5833, A NEW PSYCHOTHERAPEUTIC AGENT OF THE BENZODIAZEPINE CLASS.
221268 04-02

MAPROTILINE -- ITS POSITION AS AN ANTIDEPRESSANT IN THE LIGHT OF RECENT NEUROPHARMACOLOGICAL AND NEUROBIOCHEMICAL FINDINGS.
221647 04-03

A NEUROPHARMACOLOGICAL EVALUATION OF SC-13504 -- A NEW ANTICONVULSANT. (PH.D. DISSERTATION).
222639 04-03

NEUROPHARMACOLOGY

NEUROPHARMACOLOGY OF SQ-10996, A COMPOUND WITH SEVERAL THERAPEUTIC INDICATIONS.
197459 01-13

CONTRIBUTION OF TREATMENT BY LEVODOPA TO THE NEUROPHARMACOLOGY OF AKINESIA.
203494 02-15

THE BIOCHEMICAL BASIS OF NEUROPHARMACOLOGY.
225152 04-17

NEUROPHYSIOLOGICAL

A STUDY OF NEUROPHYSIOLOGICAL MECHANISMS OF GENERAL ANESTHESIA WITH KETAMIN.
198434 02-03

INFLUENCE OF NEUROLEPTIC SUBSTANCE ON NEUROPHYSIOLOGICAL PARAMETERS IN EXPERIMENTAL ANIMALS.
206998 03-06

ACTION AND REACTION: BIOPHYSIOLOGICAL AND NEUROPHYSIOLOGICAL MECHANISMS.
210419 03-13

NEUROPHYSIOLOGICAL ROLE OF SEROTONIN.
213621 04-03

THE ELECTRODERMAL RESPONSE: NEUROPHYSIOLOGICAL AND NEUROPHARMACOLOGICAL CHARACTERISTICS. (PH.D. DISSERTATION).
214203 04-03

HYPERSOMNIA BY ISTHMIC LESION IN THE CAT. II. NEUROPHYSIOLOGICAL AND PHARMACOLOGICAL STUDY.
215703 04-03

NEUROCHEMICAL AND NEUROPHYSIOLOGICAL MECHANISMS OF THE PSYCHOSTIMULATING ACTION OF PHENAMINE.
219510 04-13

NEUROPHYSIOLOGY
CENTRAL NEUROPHYSIOLOGY OF THE FUNCTIONAL PSYCHOSES.
213614 04-11

NEUROPSYCHIATRIC
THE PRESENT CONDITIONS OF PSYCHOPHARMACOLOGICAL TREATMENT FOR CHILDREN IN JAPAN: OPINIONS FROM THIRTY-SEVEN WELL-KNOWN CHILD NEUROPSYCHIATRISTS AND NEUROPSYCHIATRIC PEDIATRICIANS.
202500 02-17

NEUROPSYCHIATRISTS
THE PRESENT CONDITIONS OF PSYCHOPHARMACOLOGICAL TREATMENT FOR CHILDREN IN JAPAN: OPINIONS FROM THIRTY-SEVEN WELL-KNOWN CHILD NEUROPSYCHIATRISTS AND NEUROPSYCHIATRIC PEDIATRICIANS.
202500 02-17

NEUROPSYCHIATRY
A YEAR OF INVESTIGATIONS ON 1035-MD IN CHILD AND JUVENILE NEUROPSYCHIATRY: CLINICAL AND EEG FINDINGS FROM 46 CASES.
209784 03-11

NEUROPSYCHIC
PSYCHOPHARMACOLOGICAL THERAPY AND THE PROBLEMS OF DELINEATING BORDERLINE FORMS OF NEUROPSYCHIC DISORDERS.
212431 03-17

NEUROPSYCHOLOGIC
NEUROPSYCHOLOGIC MECHANISMS OF LITHIUM THERAPY.
195932 01-09

NEUROSCIENCE
MONOAMINERGIC NEUROTOXINS: ARE THEY SELECTIVE? SOME PERSPECTIVES ON THE SYMPOSIUM HELD AT THE FOURTH ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, OCTOBER, 1974. (UNPUBLISHED PAPER).
222353 04-06

NEUROSES
TACITIN AND APONAL IN THE TREATMENT OF NEUROSES.
198396 02-10
RESULTS ACHIEVED WITH CLOZAPINE (LEPONEX) IN THE TREATMENT OF NEUROSES.
205614 03-10
LORAZEPAM IN THE MANAGEMENT OF GASTROINTESTINAL NEUROSES.
215061 04-10

NEUROSIS
A COMPARATIVE STUDY OF DOXEPIN VERSUS TRIFLUOPERAZINE IN ANXIETY NEUROSIS.
194276 01-10
COMPARATIVE STUDY OF DIAZEPAM VS. CHLORDIAZEPOXIDE IN ANXIETY NEUROSIS.
194558 01-10
A CONTROLLED EVALUATION OF LORAZEPAM AND DIAZEPAM IN ANXIETY NEUROSIS.
194719 01-10
LORAZEPAM IN ANXIETY NEUROSIS.
195621 01-10
COMPARATIVE STUDY OF Y-6047 AND DIAZEPAM BY A DOUBLE-BLIND METHOD FOR THE TREATMENT OF PSYCHOSOMATIC DISEASES AND NEUROSIS.
198705 02-11
THE ACTION OF CHLORIMIPRAMINE IN OBSESSIVE COMPULSIVE NEUROSIS: A PILOT STUDY.
209489 03-10
A COMPARISON OF A NEW TRANQUILIZER, SULPIRIDE AND OXAZOLAM ON PSYCHOSOMATIC DISEASES, NEUROSIS AND MASKED DEPRESSION USING DOUBLE-BLIND METHOD.
210180 03-11
THE EFFECT OF ALAMON (HYDROXYZINE HYDROCHLORIDE) AND MEDAZEPAM ON NEUROSIS TESTED BY A DOUBLE-BLIND METHOD.
211344 03-10
A COMPARISON BETWEEN BROMAZEPAM (RO-5-3350, LEXOTAN) AND DIAZEPAM (VALIUM) IN ANXIETY NEUROSIS: A CONTROLLED, DOUBLE-BLIND CLINICAL TRIAL.
217455 04-10
ANXIETY NEUROSIS, DEPRESSIVE DISORDER AND MEPROBAMATE ADDICTION -- PSYCHIATRIC GRAND-ROUNDS, UNIV. OF CALIFORNIA, SAN-DIEGO.
222772 04-10
CLINICAL TRIAL OF OXYPERTINE IN THE TREATMENT OF PSYCHOSOMATIC DISORDERS, NEUROSIS AND DEPRESSION.
224193 04-14
CLINICAL EXPERIENCE OF THE USE OF FK-880 (SULPIRIDE) FOR DEPRESSION AND NEUROSIS.
224195 04-14

NEUROTIC
EARLY DRUG EVALUATION IN NEUROTIC OUTPATIENTS.
198069 01-07
BROMAZEPAM, MEDAZEPAM, CHLORDIAZEPOXIDE IN TREATMENT OF NEUROTIC ANXIETY.
202219 02-10
CLINICAL TRIAL OF CLOCAPRAMINE IN NEUROTIC PATIENTS WHO HAD TROUBLES IN EVERYDAY LIFE OWING TO SEVERE ANXIETY, IRRITABILITY AND DEPRESSION.
204464 02-10
A CONTROLLED COMPARISON OF CHLORAZEPATE WITH OXAZEPAM IN NEUROTIC ANXIETY.
205638 03-10
A COMPARISON BETWEEN DIAZEPAM AND HALOPERIDOL IN NEUROTIC ANXIETY AND TENSION STATES IN PATIENTS IN A OPEN WARD.
221638 04-10
CLINICAL TRAILS OF SULPIRIDE WITH EMPHASIS ON NEUROTIC OUTPATIENTS.
224194 04-10
CLINICAL STUDY OF A NEW TRANQUILIZER, LEXOTAN, IN NEUROTIC DISTURBANCES.
224583 04-10

NEUROTICS
A DOUBLE-BLIND CONTROLLED STUDY OF THE THIENODIAZEPINE DERIVATIVE (Y-6047) ON NEUROTICS AND PSYCHOSOMATIC DISORDERS.
210559 03-14
BENZOCTAMINE (TACITIN) VERSUS PLACEBO: A DOUBLE-BLIND CROSSOVER STUDY IN ANXIETY NEUROTICS.
225064 04-10

NEUROTOXIC
P-CHLOROAMPHETAMINE: SELECTIVE NEUROTOXIC ACTION IN BRAIN.
211494 03-05

NEUROTOXINS
MONOAMINERGIC NEUROTOXINS: ARE THEY SELECTIVE? SOME PERSPECTIVES ON THE SYMPOSIUM HELD AT THE FOURTH ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, OCTOBER, 1974. (UNPUBLISHED PAPER).
222353 04-06

NEUROTRANSMISSION
EFFECTS OF SELF-STIMULATION BEHAVIOR OF DRUGS INFLUENCING DOPAMINERGIC NEUROTRANSMISSION MECHANISMS.
194152 01-04
ON THE INHIBITION OF PERIPHERAL AND CENTRAL NORADRENERGIC NEUROTRANSMISSION BY CLONIDINE.
197295 01-03

NEUROTRANSMITTER
NEUROTRANSMITTER CONTROL OF THYROTROPIN SECRETION IN THE RAT.
210858 03-03
STRATEGIES FOR THE SYSTEMATIC STUDY OF NEUROTRANSMITTER RECEPTOR FUNCTION IN MAN.
215860 04-16
NEUROTRANSMITTER CONTENT IN SYNAPTIC VESICLES OF THE ADRENERGIC NERVES OF RATS UNDER PHARMACOLOGICAL INFLUENCE.
223017 04-03
NEUROTRANSMITTER ALTERATIONS AND CHRONIC PAIN.
224800 04-13

NEUROTRANSMITTERS
REGIONAL DISTRIBUTION OF CATIONS AND THEIR RELATION TO THE NEUROCHEMISTRY OF EXPERIMENTAL EPILEPSY, NEUROTRANSMITTERS AND ATPASE IN THE CENTRAL NERVOUS SYSTEM. (PH.D. DISSERTATION).
193588 01-03
UPTAKE OF NEUROTRANSMITTERS INTO SUBCELLULAR PARTICLES OF THE CAUDATE NUCLEUS.
197962 01-03
EVIDENCE FOR THE FUNCTIONAL INTERACTION OF TWO CENTRAL NEUROTRANSMITTERS.
201324 02-03
THE REGULATION OF CYCLIC GUANOSINE MONOPHOSPHATE IN RAT CEREBELLUM: POSSIBLE INVOLVEMENT OF PUTATIVE AMINO ACID NEUROTRANSMITTERS.
202717 02-03
AGGRESSION AND NEUROTRANSMITTERS.
209191 03-04
CATECHOLAMINE NEUROTRANSMITTERS AND SYNTHETIC ENZYMES IN THE SPINAL CORD OF THE RAT.
213987 04-03
EFFECT OF WITHDRAWAL FROM CHRONIC ETHANOL INGESTION ON THE CAMP RESPONSE OF CEREBRAL CORTICAL SLICES USING THE AGONISTS HISTAMINE, SEROTONIN, AND OTHER NEUROTRANSMITTERS.
215980 04-03
IN VIVO RELEASE OF ENDOGENOUS NEUROTRANSMITTERS IN CAT LIMBIC REGIONS: EFFECT OF CHLORPROMAZINE AND OF ELECTRICAL STIMULATION.
217685 04-03
EVIDENCE AGAINST THE INVOLVEMENT OF FALSE NEUROTRANSMITTERS IN TOLERANCE TO AMPHETAMINE-INDUCED HYPERTHERMIA IN THE RAT.
217690 04-03

EFFECTS OF PUTATIVE NEUROTRANSMITTERS ON NEURONAL ACTIVITY IN MONKEY AUDITORY CORTEX.
217865 04-03
NEUROTRANSMITTERS AFFECTING PITUITARY HORMONE RELEASE. (UNPUBLISHED PAPER).
219633 04-03

NEUROTROPIC
ANALYSIS OF THE INFLUENCE OF SELECTED NEUROTROPIC AGENTS ON HEPATIC METABOLISM IN RELATION TO ENDOTOXICOSIS.
195448 01-03
NEUROTROPIC EFFECTS OF THYROTROPIN-RELEASING HORMONE (TRH).
197953 01-04
EFFECT OF NEUROTROPIC AGENTS ON TOTAL PYRIDOXAL PHOSPHATE AND ON THE ACTIVITY OF THE DECARBOXYLASE OF AROMATIC AMINO ACIDS AS WELL AS OF OTHER PYRIDOXAL PHOSPHATE DEPENDENT ENZYMES IN RAT BRAIN.
199785 02-03
THE EFFECT OF SOME NEUROTROPIC DRUGS ON THE PHASIC CHANGES OF ARTERIAL PRESSURE EVOKED BY STIMULATION OF THE CEREBELLAR FASTIGAL NUCLEUS.
217067 04-03
THE SPECIFICITY OF ACTION EXERTED BY NEUROTROPIC AGENTS DURING SENSITIZATION.
219508 04-03
THE EFFECT OF NEUROTROPIC AGENTS ON MOTOR HYPERACTIVITY IN DOGS INDUCED BY AMIZYL.
223062 04-04

NEW
NEW HOT PLATE TESTS TO QUANTIFY ANTINOCICEPTIVE AND NARCOTIC ANTAGONIST ACTIVITIES.
193446 01-04
EXAMINATION OF THE NEW PSYCHOTROPIC DRUG, DOGMATYL (FK-880 SULPIRIDE).
194509 01-11
A NEW BENZODIAZEPINE: 1-(2 HYDROXYETHYL)-3-HYDROXY-7-CHLORO-1,3 DIHYDRO-5-(O-FLUOROPHENYL)-1H-1,4 BENZODIAZEPIN-2-ONE.
194956 01-04
NEUROPHARMACOLOGICAL STUDIES OF EFFECT OF NEW CENTRAL DEPRESSANT, 8-CHLOR-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D40TA) ON EEG AND CENTRAL SYMPATHETIC ACTIVATING MECHANISM IN CATS.
195549 01-03
CLINICAL EVALUATION OF NEW ANTIDEPRESSANT, LOPRAMINE.
196443 01-14
PHARMACOLOGY OF MAGNESIUM GLUTAMATE HYDROBROMIDE (PS-042), A NEW TRANQUILIZER: THIRD PART, PSYCHOPHARMACOLOGICAL STUDIES.
196444 01-02
A CRITICAL EVALUATION OR MOLINDONE (MOBAN): A NEW INDOLE DERIVATIVE NEUROLEPTIC.
196674 01-07
A MULTINATIONAL, DOUBLE-BLIND TRIAL WITH A NEW ANTIDEPRESSANT MAPROTILINE (LUDIOMIL) AND AMITRIPTYLINE.
197031 01-09
THE PHARMACOLOGY OF WY-23409, A NEW ANTIDEPRESSANT.
197305 01-03
PHARMACOLOGICAL INVESTIGATIONS WITH BENZOCTAMINE (TACITIN), A NEW PSYCHOACTIVE AGENT.
197447 01-03
PHARMACOLOGIC STUDIES ON PROPYNYL DIBENZAZEPINE, A NEW ALPHA-ADRENERGIC BLOCKER.
197493 01-03
THE EFFECT OF A NEW TETRACYCLIC ANTIDEPRESSANT COMPOUND, ORG-GB94, ON THE TURNOVER OF DOPAMINE, NORADRENALIN AND SEROTONIN IN THE RAT BRAIN.
197496 01-03
NEW DEVELOPMENTS IN HUMAN PSYCHOPHARMACOLOGY.
197534 01-17
THE MECHANISM OF ACTION OF GYKI-32084, A NEW ANTISEROTONIN AGENT.
197570 01-03
BLOOD LEVEL, EXCRETION, DISTRIBUTION AND METABOLISM OF 14C-TRIFLUBAZAM, A NEW 1,5 BENZODIAZEPINE, IN MICE AND DOGS.
197940 01-03
SOME NEW APPROACHES TO THE TREATMENT OF ANXIETY.
198046 01-10
CLINICAL EVALUATION OF NEW CHEMOTHERAPEUTIC AGENTS.
198064 01-07
ON THE METABOLISM OF A NEW ANTIDEPRESSANT, AZAPHEN, IN RATS.
198484 02-01
PHARMACOLOGICAL AND TOXICOLOGICAL STUDY OF A NEW PSYCHOTROPIC STIMULANT: THE 2-PHENYLDIMETHYL-TETRAHYDROOXAZINE, IN COMPARISON WITH D,L-AMPHETAMINE, PHENMETRAZINE AND PEMOLINE-MG.
199211 02-04
PHARMACOLOGICAL PROFILE OF A NEW NONTRICYCLIC ANTIDEPRESSANT: OXAFLOZANE (1766-CERM).
199385 02-02
PRELIMINARY CLINICAL RESULTS OF A NEW NONTRICYCLIC ANTIDEPRESSANT: OXAFLOZANE (1766-CERM).
199386 02-07
EFFECTS OF BENAPRYZINE, A NEW ANTIPARKINSON DRUG, ON DOPAMINE UPTAKE INTO CORPUS-STRIATUM.
199868 02-03
PHARMACOLOGICAL AND TOXICOLOGICAL PROPERTIES OF CLOBAZAM (1-PHENYL-5-METHYL-8-CHLORO 1,2,4,5-TETRAHYDRO-2,4-DIKETO-3H-1,5 BENZODIAZEPINE), A NEW PSYCHOTHERAPEUTIC AGENT.
199912 02-05
A CONTROLLED CLINICAL TRIAL OF PIMOZIDE (R-6238) -- A NEW NEUROLEPTIC.
200897 02-08
A DOUBLE-BLIND CLINICAL TRIAL OF NEW ANTIDEPRESSANT, SURMONTIL.
200922 02-09
CLINICAL DOUBLE-BLIND STUDY ON THE ACTIVITY OF A NEW ANTIDEPRESSANT: CAROXAZONE (FI-6654).
201667 02-09
ALL-NIGHT POLYGRAPHIC RECORDINGS ON THE HYPNOTIC EFFECTS OF A NEW BENZODIAZEPINE: FLUNITRAZEPAM (RO-5-4200, ROHYPNOL).
202272 02-11
REVERSAL OF RESERPINE INDUCED BRADYKINESIA BY ALPHA-METHYLDOPA -- NEW LIGHT ON ITS MODUS-OPERANDI.
202281 02-03
SEARCH FOR NEW HALLUCINOGENIC CACTI.
202382 02-01
ACTION OF A NEW PSYCHOTROPIC DRUG (SULPIRIDE) ON AVOIDANCE BEHAVIOR IN RATS.
202770 02-04
EFFECT OF NOMIFENSINE (HOE-984), A NEW ANTIDEPRESSANT, ON UPTAKE OF NORADRENALINE AND SEROTONIN AND ON RELEASE OF NORADRENALINE IN RAT BRAIN SYNAPTOSOMES.
202807 02-03
THE DETECTION OF PRAZEPAM, A NEW BENZODIAZEPINE TRANQUILIZER.
204196 02-01
COMPUTER NYSTAGMOGRAPHY, A NEW METHOD OF DETERMINING CHANGES IN VIGILANCE AS A RESPONSE TO PSYCHOTROPIC DRUGS.
204395 02-16
EFFECT OF CAMAZEPAM (SB-5833), A NEW ANTIANXIOUS DRUG, ON CARDIAC CONTRACTILITY AND CORONARY HEMODYNAMICS.
206785 03-03
BROMOPERIDOL, A NEW POTENT NEUROLEPTIC OF THE BUTYROPHENONE SERIES; COMPARATIVE PHARMACOLOGY OF BROMOPERIDOL AND HALOPERIDOL.
206804 03-02
CLINICOSTATISTICAL STUDY OF THE EFFECTS OF SULPIRIDE, A NEW NEUROLEPTIC DRUG.
206805 03-07
PINDOLOL: A NEW PSYCHOTROPIC DRUG.
206836 03-04
NEW HYPOGLYCEMIC BENZENESULFONAMIDO PYRIMIDINES: N-SUBSTITUTED 4-(N-(2-PYRIMIDINYLSULFONYL-PHENYLACETAMIDES.
206994 03-02
NEW DEVELOPMENTS IN THE STUDY OF THE MECHANISM OF ACTION OF NEUROLEPTICS AND AMPHETAMINE.
207296 03-03
BEHAVIORAL EFFECTS OF A NEW DOPAMINE-BETA-HYDROXYLASE INHIBITOR (FUSARIC ACID) IN MAN.
207311 03-07
OXYPERTINE IN THE TREATMENT OF MORBID ANXIETY. REPORT OF A NEW LOW DOSAGE SCHEDULE.
207532 03-10
TWO DECADES OF PSYCHOPHARMACOLOGY AND COMMUNITY MENTAL HEALTH: OLD AND NEW PROBLEMS OF THE SCHIZOPHRENIC PATIENT.
207921 03-17
REFLECTIONS ON THE EFFICACY OF NEW DRUG THERAPIES ON THE OCCASION OF USING AN ORIGINAL MEDICATION: SULPIRIDE (DOGMATIL).
209123 03-11
PLASMA LEVELS OF A NEW PELLETIZED FORM OF AMITRIPTYLINE FOR MAINTENANCE THERAPY.
209789 03-13
TREATMENT OF ACUTE SCHIZOPHRENIA WITH A NEW BUTYROPHENONE - - LENPERONE.
209791 03-07
THE EFFECTS OF A NEW SEDATIVE (LEXOTAN) ON REACTION TIMES AND ON ATTENTIVE CAPACITY OF A GROUP OF ATHLETES.
209857 03-14
A COMPARISON OF A NEW TRANQUILIZER, SULPIRIDE AND OXAZOLAM ON PSYCHOSOMATIC DISEASES, NEUROSIS AND MASKED DEPRESSION USING DOUBLE-BLIND METHOD.
210180 03-11
THE TREATMENT OF ANXIETY IN THE ELDERLY WITH A NEW TRANQUILIZER COMPOUND.
210211 03-11
PRECLINICAL EVALUATION OF AHR-2244: A NEW PSYCHOTHERAPEUTIC AGENT.
210676 03-02

BIOLOGICAL AND PHARMACOKINETIC EVIDENCE FOR GENERIC EQUIVALENCE OF THREE IMIPRAMINE PREPARATIONS: COMPARISON WITH A NEW IMIPRAMINE ANALOGUE.
211071 03-02

CLINICAL EXPERIMENTS WITH A NEW PSYCHOTROPIC DRUG (SULPIRIDE).
211203 03-14

USE OF A NEW PSYCHOTROPIC DRUG, CLOFLUPEROL FOR THE TREATMENT OF CHRONIC SCHIZOPHRENIC PATIENTS.
211304 03-08

A NEW BENZODIAZEPINE, SCREENED BY A PARALLEL DOUBLE-BLIND TEST.
212167 03-10

CLINICAL STUDY OF AN NEW ANTIDEPRESSANT, MELITRACEN, FOR 50 AMBULATORY PATIENTS.
212490 03-10

NEW PSYCHOTROPIC DRUG TRIALS IN TURKEY.
213594 04-11

NEW PSYCHOTROPIC DRUG RESEARCH IN JAPAN.
213596 04-07

NEW PSYCHOTROPIC DRUG DEVELOPMENTS IN FRANCE AND BELGIUM.
213597 04-17

NEW PSYCHOTROPIC DRUG DEVELOPMENTS IN THE USSR AND OTHER EASTERN EUROPEAN COUNTRIES.
213598 04-07

NEW PSYCHOTROPIC DRUG DEVELOPMENTS IN GREAT-BRITAIN.
213599 04-17

SEROTONIN -- NEW VISTAS: HISTOCHEMISTRY AND PHARMACOLOGY.
213715 04-17

SEROTONIN -- NEW VISTAS: BIOCHEMISTRY AND BEHAVIORAL AND CLINICAL STUDIES.
213716 04-17

INFLUENCE OF AZAPHEN, A NEW ANTIDEPRESSIVE DRUG, ON THE HUMAN EEG.
215065 04-09

PSYCHOTHERAPEUTIC PROFILE OF A NEW PSYCHOACTIVE DRUG TRAZODONE (AF-1161).
215699 04-09

EFFECTS OF TACLAMINE (AY-22214), A NEW PSYCHOACTIVE AGENT, ON CATECHOLAMINE AND SEROTONIN METABOLISM.
215725 04-03

PIPOTHIAZINE PALMITATE: AN EVALUATION OF A NEW LONG-ACTING INTRAMUSCULAR ANTIPSYCHOTIC AGENT IN SEVERELY ILL SCHIZOPHRENIC PATIENTS.
216188 04-08

A NEW SUBSTITUTED BENZAMIDE WITH NEUROLEPTIC EFFECTS: LIN-14-18 OR SULTOPRIDE.
216759 04-08

A CLINICAL STUDY OF A NEW NEUROLEPTIC EXTRAPYRAMIDAL SYNDROME CORRECTOR WITH ACUTE PSYCHOTIC STATES.
216766 04-15

PHARMACOLOGICAL ANALYSIS OF A NEW ANOREXIC SUBSTANCE: 5-HYDROXY-5-4-CHLOROPHENYL 2,3 DIHYDRO-5H-IMIDAZOISOINDOLE (MAZINDOL).
217652 04-04

COMPARATIVE STUDIES OF A NEW 5-HT UPTAKE INHIBITOR AND SOME TRICYCLIC THYMOLEPTICS.
217663 04-03

RECOVERY OF FUNCTION: SOME NEW THOUGHTS ON AN OLD PROBLEM. (PH.D. DISSERTATION).
219268 04-04

EXPERIMENTAL INVESTIGATION OF A NEW AMPHETAMINE DERIVATIVE.
219709 04-03

A MULTICENTER MULTIDIMENSIONAL STUDY OF SOME NEW LONG-ACTING NEUROLEPTIC DRUGS.
220858 04-07

NEUROPHARMACOLOGICAL STUDIES ON SB-5833, A NEW PSYCHOTHERAPEUTIC AGENT OF THE BENZODIAZEPINE CLASS.
221268 04-02

A PRELIMINARY DOUBLE-BLIND STUDY WITH SB-5833 (CAMAZEPAM), A NEW BENZODIAZEPINE DERIVATIVE.
221269 04-10

PHARMACOLOGICAL EVALUATION OF 3-(N 3,3 DIPHENYLPROPYL-N-METHYL) AMINOPROPAN-1-OL HYDROCHLORIDE (PF-82), A NEW TYPE OF ANTIDEPRESSANT DRUG.
221287 04-02

NOXIPTILIN (AGEDAL) -- A NEW TRICYCLIC ANTIDEPRESSANT WITH A FASTER ONSET OF ACTION? A DOUBLE-BLIND, MULTICENTRE COMPARISON WITH AMITRIPTYLINE.
221306 04-09

PHARMACOLOGICAL PROPERTIES OF 6,7 TETRAMETHYLENE-5-PHENYL-1-2-DIHYDRO 3H THIENODIAZEPIN-2-ONE (QM-6008), THIADIPONE), A NEW PSYCHOTROPIC DRUG.
221722 04-02

TOXICOLOGICAL AND PHARMACOLOGICAL INVESTIGATIONS OF PINAZEPAM (7-CHLORO-1-PROPARGYL-5-PHENYLBENZODIAZEPIN-2-ONE): A NEW THERAPEUTIC AGENT.
221723 04-02

A NEW SERIES OF BENZODIAZEPINES: 1 HYDROXYALKYL DERIVATIVES OF 1,3 DIHYDROBENZODIAZEPIN-2-ONES.
221735 04-01

PHARMACOLOGICAL ACTION OF FD-008, A NEW DOPAMINE-BETA-HYDROXYLASE INHIBITOR: II. EFFECTS ON CENTRAL NERVOUS SYSTEM IN MICE AND RATS.
221823 04-02

PHARMACOLOGICAL ACTION OF FD-008, A NEW DOPAMINE-BETA-HYDROXYLASE INHIBITOR: III. EFFECTS ON ENDOGENOUS BIOGENIC AMINE LEVELS IN RATS.
221859 04-03

NEW PROSPECTS OF TREATMENT OF PARKINSONS DISEASE WITH PARKS-PLUS.
221885 04-11

A NEUROPHARMACOLOGICAL EVALUATION OF SC-13504 -- A NEW ANTICONVULSANT. (PH.D. DISSERTATION).
222639 04-03

THE HEALING JOURNEY: NEW APPROACHES TO CONSCIOUSNESS.
223921 04-12

EXPERIENCE OF USING LORAZEPAM, A NEW TRANQUILIZER.
224394 04-11

CLINICAL STUDY OF A NEW TRANQUILIZER, LEXOTAN, IN NEUROTIC DISTURBANCES.
224583 04-10

NEW CONCEPTS ON THE MECHANISM OF ACTION OF BENZODIAZEPINES.
225058 04-13

NEWBORN

PLACENTAL TRANSFER OF DIAZEPAM AND ITS DISPOSITION IN THE NEWBORN.
215672 04-13

EFFECTS OF ALPHA-METHYLDOPA ON NEWBORN KITTEN SLEEP. BEHAVIORAL EVOLUTION DURING THE FIRST MONTH AFTERBIRTH.
221049 04-04

NH4CL

THE EFFECT OF NH4CL ON POLYURIA AND POLYDIPSIA DURING PROLONGED LITHIUM ADMINISTRATION IN THE RAT.
198027 01-03

NIACIN

NIACIN THERAPY IN SCHIZOPHRENIA: A REVIEW.
200898 02-08

NIALAMIDE

THE INEFFECTIVENESS OF DESIPRAMINE PRETREATMENT ON BEHAVIORAL EFFECTS OF 6-HYDROXYDOPAMINE IN NIALAMIDE PRETREATED RATS.
195434 01-04

PHARMACOLOGICAL STUDIES ON TETRABENAZINE-INDUCED EXCITED BEHAVIOUR OF RATS PRETREATED WITH AMPHETAMINE OR NIALAMIDE.
197490 01-04

FEEDING BEHAVIOR IN SHEEP: EFFECTS OF NIALAMIDE AND 6-HYDROXYDOPAMINE.
210743 03-04

EFFECTS OF ANTAGONISTS UPON LOCOMOTOR STIMULATION INDUCED BY INJECTION OF DOPAMINE AND NORADRENALINE INTO THE NUCLEUS-ACCUMBENS OF NIALAMIDE PRETREATED RATS.
217475 04-04

NICKEL

CRYSTAL STRUCTURE DETERMINATIONS OF THE DONOR ACCEPTOR COMPLEXES OF PHENOTHIAZINE AND PHENOXAZINE WITH NICKEL THIETE. (PH.D. DISSERTATION).
201003 02-01

NICOTINAMIDE

THE EFFECTS OF NICOTINAMIDE ON MOUSE SLEEP.
194929 01-03

PROTECTIVE EFFECT OF ADENOSINE AND NICOTINAMIDE AGAINST AUDIOGENIC SEIZURE.
198135 02-03

NICOTINE

EFFECT OF NICOTINE AND NICOTINE MONOMETHIODIDE ON VASCULAR ADRENERGIC NEUROEFFECTOR TRANSMISSION.
197966 01-03

EFFECT OF NICOTINE AND OTHER DRUGS ON THE RELEASE OF 3H-NOREPINEPHRINE AND 3H-DOPAMINE FROM RAT BRAIN SLICES.
197985 01-03

NICOTINE AND CAFFEINE: DISRUPTION OF THE LONG-TERM STORE MEMORY AND PROACTIVE FACILITATION OF LEARNING IN MICE.
198222 02-04

EFFECTS OF NICOTINE ON SPONTANEOUS LOCOMOTOR ACTIVITY IN RATS HAVING HIGH AND LOW BASAL ACTIVITY LEVELS.
202980 02-04

COMPARISON OF THE EFFECTS OF ATROPINE AND CANNABIS UPON THE FIXED CONDITIONED ALIMENTARY MOTOR REFLEXES IN CATS AFFECTED BY NICOTINE.
205623 03-14

STUDIES ON THE TIME COURSE AND THE EFFECT OF CHOLINERGIC AND ADRENERGIC RECEPTOR BLOCKERS ON THE STIMULUS EFFECT OF NICOTINE.
206353 03-03

EFFECT OF SMOKING MARIHUANA AND OF A HIGH NICOTINE CIGARETTE ON ANGINA-PECTORIS.
215670 04-15
THE EFFECTS OF NICOTINE ON TWO-WAY AVOIDANCE CONDITIONING IN BIDIRECTIONALLY SELECTED STRAINS OF RATS.
217525 04-04
NICOTINE INDUCED HYPOPHAGIA AND HYPODIPSIA IN DEPRIVED AND IN HYPOTHALAMICALLY STIMULATED RATS.
225559 04-04

NICOTINIC
NEGATIVE FINDINGS WITH NICOTINIC ACID IN THE TREATMENT OF SCHIZOPHRENIAS.
202787 02-08
ANTAGONISM OF NICOTINIC ACID AND OTHER KYNURENINES TO ANTIDEPRESSANTS: ONE OF THE PROBABLE REASONS FOR THE THERAPY-RESISTANCE IN DEPRESSION?.
215074 04-17
NICOTINIC ACID IN THE TREATMENT OF SCHIZOPHRENIAS: CANADIAN MENTAL HEALTH ASSOCIATION COLLABORATIVE STUDY PROGRESS REPORT II.
219537 04-08

NICTITATING
HYDROCORTISONE-INDUCED SUPERSENSITIVITY TO NORADRENALINE IN THE ISOLATED NICTITATING MEMBRANE AS A CONSEQUENCE OF AN IMPAIRMENT OF AN O-METHYLATING SYSTEM WITH HIGH AFFINITY.
197944 01-03

NIGHT
INFLUENCE OF MELATONIN ON EEG AND HUMAN SLEEP: AUTOMATIC EEG ANALYSES AND POLYGRAPHIC NIGHT SLEEP INVESTIGATIONS.
205446 02-13
THE TREATMENT OF NIGHT TERRORS ASSOCIATED WITH THE POSTTRAUMATIC SYNDROME.
209750 03-11
POLYGRAPHIC NIGHT SLEEP PATTERN DURING CHRONIC SINGLE AND MULTIPLE NEUROLEPTIC DOSE ADMINISTRATION.
215701 04-08
A DOUBLE-BLIND COMPARISON OF THREE TIMES DAILY AND SINGLE NIGHT DOSAGE OF THE TRICYCLIC ANTIDEPRESSANT DOTHIEPIN.
216463 04-09
THE INFLUENCE OF SULPIRIDE ON SLEEP: RESULTS OF POLYGRAPHIC NIGHT SLEEP RECORDINGS.
221339 04-14

NIGHTLY
A COMPARISON BETWEEN DAILY AND NIGHTLY DOSE REGIMEN OF AMITRIPTYLINE AND MAPROTILINE (LUDIOMIL) IN THE TREATMENT OF REACTIVE DEPRESSION IN GENERAL PRACTICE.
221662 04-09

NIGRO-NEOSTRIATAL
REVERSAL BY L-DOPA OF IMPAIRED LEARNING DUE TO DESTRUCTION OF THE DOPAMINERGIC NIGRO-NEOSTRIATAL PROJECTION.
193578 01-04

NIGROSTRIATAL
ANTAGONISM OF DOPAMINE MEDIATED INHIBITION IN THE NIGROSTRIATAL PATHWAY: A MODE OF ACTION OF SOME CATATONIA INDUCING DRUGS.
210659 03-03
DOPAMINERGIC NEURONS IN THE NIGROSTRIATAL AND MESOLIMBIC PATHWAYS: MEDIATION OF SPECIFIC EFFECTS OF D-AMPHETAMINE.
210855 03-03
PHARMACOLOGICALLY INDUCED BEHAVIORAL CORRELATES OF NIGROSTRIATAL FUNCTION. (PH.D. DISSERTATION).
220473 04-04

NIH
METABOLISM OF 4-CHLOROAMPHETAMINE TO 3-CHLORO-4-HYDROXYAMPHETAMINE IN RAT: EVIDENCE FOR AN IN VIVO NIH SHIFT OF CHOLINE.
210929 03-03

NIKETHAMIDE
EFFECTS OF NIKETHAMIDE, PICROTOXIN AND STRYCHNINE ON AMPHETAMINE STATE.
199967 02-03

NIMETAZEPAM
ELECTROENCEPHALOGRAPHIC AND BEHAVIORAL STUDIES ON THE CENTRAL ACTION OF NIMETAZEPAM (S-1530) IN CATS.
199910 02-04

NIMH-PRB
NIMH-PRB EARLY CLINICAL DRUG EVALUATION UNIT.
198068 01-07
NIMH-PRB EARLY CLINICAL DRUG EVALUATION UNIT.
198073 01-07
NIMH-PRB COLLABORATIVE OUTPATIENT SCHIZOPHRENIC STUDY.
198075 02-08
NIMH-PRB OUTPATIENT TREATMENT OF DEPRESSION.
198078 02-10

NIMH-VA
FACTORS ASSOCIATED WITH TREATMENT SUCCESS IN LITHIUM CARBONATE PROPHYLAXIS: REPORT OF THE NIMH-VA COLLABORATIVE STUDY GROUP.
193068 01-09
NIMH-VA LITHIUM COLLABORATIVE STUDY.
198080 02-09

NITRAZEPAM
INHIBITORY AND DISINHIBITORY EFFECTS OF NITRAZEPAM, DIAZEPAM AND FLURAZEPAM HYDROCHLORIDE ON DELAYED MATCHING BEHAVIOUR IN MONKEYS (MACACA-MULATTA).
199957 02-04
THE EFFECT OF DIAZEPAM AND NITRAZEPAM ON INTRACELLULAR AND EXTRACELLULAR DISTRIBUTION OF SODIUM AND POTASSIUM IONS IN INDIVIDUAL STRUCTURES OF RATS BRAINS.
207199 03-03
DIFFERENTIAL EFFECTS OF CHLORPROMAZINE, IMIPRAMINE, NITRAZEPAM AND AMOBARBITAL ON REM SLEEP AND REM DENSITY IN MAN.
215955 04-14
A DOUBLE-BLIND TRIAL OF NITRAZEPAM AND FLURAZEPAM AS SEDATIVES.
217041 04-14

NITROUS
CHANGES IN THE DORSAL ROOT POTENTIAL WITH DIAZEPAM AND WITH THE ANALGESICS ASPIRIN, NITROUS OXIDE, MORPHINE AND MEPERIDINE.
195248 01-03
EFFECTS OF HALOTHANE AND NITROUS OXIDE ANESTHESIA ON 5-HT TURN-OVER IN THE RAT BRAIN.
217655 04-03

NOBRIUM
POSSIBLE TREATMENT OF PSYCHONEUROSES WITH MEDAZEPAM (NOBRIUM).
203705 02-07

NOCICEPTIVE
THEOPHYLLINE INCREASED SENSITIVITY TO NOCICEPTIVE STIMULATION AND REGIONAL TURNOVER OF RAT BRAIN 5-HT, NORADRENALINE AND DOPAMINE.
197926 01-03
ON THE SPECIFICITY OF NEUROCHEMICAL MECHANISMS DEALING WITH NOCICEPTIVE STIMULATION OF NEURONS IN VARIOUS BRAIN FORMATIONS OF RABBITS.
198436 02-03

NOCTURNAL
RESULTS OF TREATING CHILDREN WITH NOCTURNAL ENURESIS WITH IMIPRAMINE (PSYCHOFORIN).
194208 01-11
A COMPARATIVE STUDY OF AMPHETAMINE, EPHEDRINE ATROPINE MIXTURE, PLACEBO AND BEHAVIORAL CONDITIONING IN THE TREATMENT OF NOCTURNAL ENURESIS.
198020 01-11

NODE
SYMPTOMATIC SINUS NODE ABNORMALITIES FOLLOWING LITHIUM CARBONATE THERAPY.
223120 04-15

NOMIFENSINE
EFFECT OF NOMIFENSINE (HOE-984), A NEW ANTIDEPRESSANT, ON UPTAKE OF NORADRENALINE AND SEROTONIN AND ON RELEASE OF NORADRENALINE IN RAT BRAIN SYNAPTOSOMES.
202807 02-03
RESULTS OF AN OPEN AND A DOUBLE-BLIND STUDY OF NOMIFENSINE IN COMPARISON TO IMIPRAMINE.
204899 02-10
NOMIFENSINE: A POTENT DOPAMINERGIC AGONIST OF ANTIPARKINSON POTENTIAL.
217472 04-03

NON-NEUROLEPTIC
NEUROLEPTIC AND NON-NEUROLEPTIC CATALEPSY.
199911 02-04

NON-REM
HEART RATE AND GALVANIC SKIN RESPONSE VARIATIONS DURING THE REM AND NON-REM SLEEP PHASES IN MAN.
205443 02-13

NONAGONISTIC
CHLORDIAZEPOXIDE (LIBRIUM) INDUCED CHANGES IN INTRASPECIFIC ATTACK AND SELECTED NONAGONISTIC BEHAVIORS IN MALE SIAMESE FIGHTING FISH.
217524 04-04

NONANAEMIC
RED CELL FOLATE AND MACROCYTOSIS DURING LONG-TERM ANTICONVULSANT THERAPY IN NONANAEMIC MENTALLY RETARDED EPILEPTICS.
218553 04-11

NONAQUEOUS
CHEMISTRY OF NONAQUEOUS TITRATION OF CHLORPROMAZINE.
206460 03-01

NONCATECHOLAMINES
MATURATION OF THE ADRENAL MEDULLA -- III: PRACTICAL AND THEORETICAL CONSIDERATIONS OF AGE DEPENDENT ALTERATIONS IN KINETICS OF INCORPORATION OF CATECHOLAMINES AND NONCATECHOLAMINES.
205852 03-03

NONCENTRALLY
STATE-DEPENDENT LEARNING WITH CENTRALLY AND NONCENTRALLY ACTIVE DRUGS.
219020 04-04

NONCHOLINERGIC
INFLUENCE OF NONCHOLINERGIC DRUGS ON RAT STRIATAL ACETYLCHOLINE LEVELS.
210658 03-03

NONDIRECTIVE
THE USE OF FREE IMAGERY, NONDIRECTIVE INTERVIEWING, AND SELECTED DRUGS TO LIFT POSTHYPNOTIC REPRESSION. (PH.D. DISSERTATION).
222060 04-14

NONINVOLVEMENT
ASCENDING CATECHOLAMINE PATHWAYS AND AMPHETAMINE-INDUCED LOCOMOTOR ACTIVITY: IMPORTANCE OF DOPAMINE AND APPARENT NONINVOLVEMENT OF NOREPINEPHRINE.
223054 04-03

NONLOBOTOMIZED
INFLUENCE OF RESERPINE ON ALL-NIGHT SLEEP PATTERN IN NONLOBOTOMIZED AND LOBOTOMIZED CHRONIC SCHIZOPHRENIC PATIENTS.
213530 04-08

NONMANIC
LITHIUM IN NONMANIC DEPRESSIVES: ANTIAGGRESSIVE EFFECT AND RED BLOOD CELL LITHIUM VALUES.
222604 04-09

NONMEDICAL
II. PSYCHOPHARMACOLOGY AND THE NONMEDICAL PRACTITIONER.
219756 04-17

NONPHARMACOLOGICAL
NONPHARMACOLOGICAL FACTORS IN DRUG THERAPY: THE INTERACTION OF DOCTOR, PATIENT, AND TABLET APPEARANCE IN THE TREATMENT OF ANXIETY/DEPRESSIVE SYNDROMES.
215060 04-10

NONPHENOLIC
THE STEREOSELECTIVE INHIBITION OF LIPOLYSIS BY NONPHENOLIC PHENETHYLAMINES.
193456 01-03

NONPSYCHOTIC
PRELIMINARY STUDY OF A BETA-BLOCKER (PINDOLOL) IN THREE SCHIZOPHRENICS AND THREE NONPSYCHOTIC PSYCHIATRIC PATIENTS: DIFFERENTIAL SENSITIVITY IN HEART RATE.
212164 03-13

THE USE OF CYAMEPROMAZINE IN SMALL DOSES IN TREATMENT OF NONPSYCHOTIC DISTURBANCES.
215798 04-04

NONRELAPSED
DRUG AND SOCIOTHERAPY IN THE AFTERCARE OF SCHIZOPHRENIC PATIENTS: III. ADJUSTMENT OF NONRELAPSED PATIENTS.
199626 02-08

NONRIGID
NONRIGID AMINES AND AMINO ACIDS RELATED TO APOMORPHINE. (PH.D. DISSERTATION).
222634 04-01

NONSIMPLICITY
MOOD AND CATECHOLAMINE -- NONSIMPLICITY OF THEIR RELATIONSHIP.
218362 04-09

NONSPECIFIC
SLEEP - EEG TESTS OF NONSPECIFIC CASES OF PAROXYSM AND EPISODIC BEHAVIORAL DISTURBANCES: A PRELIMINARY REPORT.
203704 02-14

A CASE OF NONSPECIFIC PSYCHOSES WHICH MANIFESTED CONVULSIVE SEIZURES DURING LITHIUM THERAPY.
209324 03-15

NONSPECIFICITY
THE EFFECTS OF DRUG ADMINISTRATION TO THE LATERAL HYPOTHALAMUS: NEUROCHEMICAL CODING OR NONSPECIFICITY?.
195992 01-03

NONSYNAPTIC
NERVE IMPULSE ENHANCED RELEASE OF AMINO ACIDS FROM NONSYNAPTIC REGIONS OF PERIPHERAL AND CENTRAL NERVE TRUNKS OF BULLFROG.
213277 03-03

NONTERMINAL
D,L P-CHLORO-N-METHYLAMPHETAMINE (P) INDUCED ACCUMULATION OF 5-HT IN NONTERMINAL AXONS.
192944 01-03

NONTOLERANT
EFFECTS OF MORPHINE, CHOLINERGIC AGENTS AND COLD EXPOSURE ON MIDBRAIN DOPAMINE (DA) NERVE CELLS OF MORPHINE TOLERANT AND NONTOLERANT MICE.
197287 01-03

EFFECTS OF DELTA8-THC ON DISSOCIATION OF CONDITIONED AVOIDANCE RESPONDING IN TOLERANT AND NONTOLERANT RATS.
202969 02-04

NONTOXIC
COGNITIVE AND MOTOR SENSORY PERFORMANCES IN TOXIC AND NONTOXIC EPILEPTIC SUBJECTS.
210824 03-15

NONTRICYCLIC
PHARMACOLOGICAL PROFILE OF A NEW NONTRICYCLIC ANTIDEPRESSANT: OXAFLOZANE (1766-CERM).
199385 02-02

PRELIMINARY CLINICAL RESULTS OF A NEW NONTRICYCLIC ANTIDEPRESSANT: OXAFLOZANE (1766-CERM).
199386 02-07

NONVERBAL
DELTA9-THC AND NONVERBAL COMMUNICATION IN MONKEYS.
224907 04-04

NORADRENALIN
THE EFFECT OF A NEW TETRACYCLIC ANTIDEPRESSANT COMPOUND, ORG-GB94, ON THE TURNOVER OF DOPAMINE, NORADRENALIN AND SEROTONIN IN THE RAT BRAIN.
197496 01-03

NORADRENALINE
COMPARISON BETWEEN THE EFFECTS PRODUCED BY CHRONIC DENERVATION AND BY COCAINE ON THE SENSITIVITY TO, AND ON THE DISPOSITION OF, NORADRENALINE IN ISOLATED SPLEEN STRIPS.
193139 01-03

EFFECTS OF THE NORADRENALINE METABOLITES ON TYROSINE-HYDROXYLASE ACTIVITY IN GUINEA-PIG ATRIA.
193279 01-02

COMPARATIVE INVOLVEMENT OF DOPAMINE AND NORADRENALINE IN RATE-FREE SELF-STIMULATION IN SUBSTANTIA-NIGRA, LATERAL HYPOTHALAMUS, AND MESENCEPHALIC CENTRAL GRAY.
193303 01-03

THE INFLUENCE OF CYPROHEPTADINE AND OF D-LYSERGAMIDE ON THE RISE IN TEMPERATURE INDUCED BY INTRACEREBROVENTRICULAR 5-HYDROXYTRYPTAMINE, NORADRENALINE AND DOPAMINE IN CONSCIOUS RABBITS.
193451 01-03

ROLE OF NORADRENALINE IN LEVODOPA REVERSAL OF RESERPINE AKINESIA.
193544 01-03

ALTERATIONS BY ANESTHETIC AGENTS OF THE RESPONSES OF RAT STRIATAL NEURONS TO IONTOPHORETICALLY APPLIED AMPHETAMINE, ACETYLCHOLINE, NORADRENALINE, AND DOPAMINE.
193803 01-03

FURTHER EVIDENCE FOR THE HETEROGENEOUS STORAGE OF NORADRENALINE IN CENTRAL NORADRENERGIC TERMINALS.
195239 01-03

EFFECT OF CHRONIC TRANSECTION ON DOPAMINE, NORADRENALINE AND 5-HYDROXYTRYPTAMINE IN THE RAT SPINAL CORD.
195244 01-03

ADRENERGIC RECEPTOR BLOCKING AGENTS: EFFECTS ON CENTRAL NORADRENALINE AND DOPAMINE RECEPTORS AND ON MOTOR ACTIVITY.
195429 01-03

NORADRENALINE AND 5-HYDROXYTRYPTAMINE METABOLISM IN SIX AREAS OF RAT BRAIN DURING POST-AMPHETAMINE DEPRESSION.
195437 01-03

PHARMACOLOGY OF PYRAMIDAL TRACT CELLS IN THE CEREBRAL CORTEX: NORADRENALINE AND RELATED SUBSTANCES.
195438 01-03

6-HYDROXYDOPAMINE INDUCED DEGENERATION OF NORADRENALINE NEURONS IN THE SCORBUTIC GUINEA-PIG.
195449 01-03

EFFECTS OF NORADRENALINE ON THE CEREBRAL BLOOD FLOW IN THE DOG.
197214 01-03

EFFECTS OF RESERPINE AND PRENYLAMINE ON THE NORADRENALINE FLUXES OF ISOLATED SPLENIC NERVE GRANULES.
197280 01-03

THE EFFECTS OF AMPHETAMINE AND COCAINE ON THE RESPONSE OF THE ISOLATED GUINEA-PIG VAS-DEFERENS TO NORADRENALINE, TYRAMINE AND NERVE STIMULATION.
197463 01-03

NEONATAL CHEMICAL SYMPATHECTOMY: FUNCTIONAL CONTROL OF DENERVATION OF THE VASCULAR SYSTEM AND TISSUE NORADRENALINE LEVEL IN THE RAT AFTER 6-HYDROXYDOPAMINE.
197584 01-03

EFFECTS OF PIRIBEDIL ON NORADRENALINE AND MOPEG-SO4 LEVELS IN THE RAT BRAIN.
197868 01-03

THEOPHYLLINE INCREASED SENSITIVITY TO NOCICEPTIVE STIMULATION AND REGIONAL TURNOVER OF RAT BRAIN 5-HT, NORADRENALINE AND DOPAMINE.
197926 01-03

ARRHYTHMIAS EVOKED BY INFUSION OF TRICYCLIC ANTIDEPRESSANTS AND NORADRENALINE ON ISOLATED RABBIT HEARTS.
197939 01-03

THE EFFECT OF DIPYRIDAMOLE ON THE NORADRENALINE TRANSPORT INTO NERVE GRANULES.
197942 01-03

HYDROCORTISONE-INDUCED SUPERSENSITIVITY TO NORADRENALINE IN THE ISOLATED NICTITATING MEMBRANE AS A CONSEQUENCE OF AN IMPAIRMENT OF AN O-METHYLATING SYSTEM WITH HIGH AFFINITY.
197944 01-03

INFLUENCE OF HALOTHANE ON PERIPHERAL SYMPATHETIC NERVES AND ON THE EFFECTS OF NORADRENALINE ON MYOCARDIUM.
197945 01-03

SYMPATHETIC NERVE ACTIVITY AFTER NORADRENALINE DEPLETION AND ITS ALTERATION BY CLONIDINE.
197947 01-03

THYROTROPIN-RELEASING HORMONE: ACTIVATION OF CEREBRAL NORADRENALINE TURNOVER.
197950 01-03

INFLUENCE OF PROPRANOLOL AND PRACTOLOL ON THE TURNOVER OF NORADRENALINE IN THE RAT HEART.
197957 01-03

THE SIGNIFICANCE OF NORADRENALINE AND ADRENALINE AS ADRENERGIC TRANSMITTERS IN THE CHICKEN.
197958 01-03

EFFECTS OF SODIUM, OUABAIN AND DMPP ON THE NEURONAL EFFLUX OF NORADRENALINE.
197959 01-03

INFLUENCE OF MORPHINE ON THE RELEASE OF NORADRENALINE FROM BRAIN SLICES.
197964 01-03

DETERMINATION OF NORADRENALINE, DOPAMINE, SEROTONIN, 5-HYDROXYINDOLEACETIC ACID, TYROSINE AND TRYPTOPHANE IN THE ISOLATED PERFUSED RAT BRAIN.
197967 01-06

INFLUENCE OF OXYMETAZOLINE AND PHENTOLAMINE ON NORADRENALINE (NA) RELEASE CAUSED BY ELECTRICAL STIMULATION, POTASSIUM, TYRAMINE AND DIMETHYLPHENYLPIPERAZINE (DMPP).
197973 01-03

SUPPRESSION BY NORADRENALINE OF CATECHOLAMINE SECRETION FROM ADRENAL MEDULLA.
199869 02-03

THE ACCUMULATION OF NORADRENALINE AND 5-HYDROXYTRYPTAMINE IN THREE REGIONS OF MOUSE BRAIN AFTER TETRABENAZINE AND IPRONIAZID: EFFECTS OF ETHINYLESTRADIOL AND PROGESTERONE.
200058 02-03

AN ONTOGENIC STUDY ON THE EFFECT OF CATECHOLAMINE RECEPTOR STIMULATING AGENTS ON THE TURNOVER OF NORADRENALINE AND DOPAMINE IN THE BRAIN.
202715 02-03

EFFECT OF NOMIFENSINE (HOE-984), A NEW ANTIDEPRESSANT, ON UPTAKE OF NORADRENALINE AND SEROTONIN AND ON RELEASE OF NORADRENALINE IN RAT BRAIN SYNAPTOSOMES.
202807 02-03

INFLUENCE OF IPRONIAZID ON THE CONTENT OF NORADRENALINE IN VARIOUS PARTS OF THE RAT BRAIN BEFORE AND AFTER STIMULATION OF THE RECEPTORS.
206404 03-03

NORADRENALINE MEDIATED INHIBITION BY LOCUS-COERULEUS OF SPINAL TRIGEMINAL NEURONS.
210703 03-03

NEONATAL 6-HYDROXYDOPAMINE TREATMENT: NORADRENALINE LEVELS AND IN VITRO 3H-CATECHOLAMINE SYNTHESIS IN DISCRETE BRAIN REGIONS OF ADULT RATS.
210759 03-03

THE EFFECT OF DRUGS WITH ANTIDEPRESSANT ACTIVITY UPON THE HYPOTHERMIA AND BEHAVIOURAL DEPRESSION INDUCED IN MICE BY PIMOZIDE OR CENTRALLY ADMINISTERED NORADRENALINE.
210762 03-04

SOME EFFECTS OF PILOCARPINE AND ACETYLCHOLINE ON THE RESPONSES OF THE GUINEA-PIG VAS-DEFERENS TO HYPOGASTRIC NERVE STIMULATION AND TRANSMURAL STIMULATION AND APPLIED (-) NORADRENALINE.
210770 03-03

BLOCKADE BY PIMOZIDE OF A NORADRENALINE SENSITIVE ADENYLATE-CYCLASE IN THE LIMBIC FOREBRAIN: POSSIBLE ROLE OF LIMBIC NORADRENERGIC MECHANISMS IN THE MODE OF ACTION OF ANTIPSYCHOTICS.
210771 03-03

DETAILED NORADRENALINE PATHWAYS OF LOCUS-COERULEUS NEURON TO THE CEREBRAL CORTEX WITH THE USE OF 5-HYDROXYDOPA.
210803 03-03

THE EFFECT OF DOPAMINE AND NORADRENALINE ANTAGONISTS ON AMPHETAMINE-INDUCED LOCOMOTOR ACTIVITY IN MICE AND RATS.
210894 03-04

ANTINOCICEPTIVE ACTION OF OXOTREMORINE AND REGIONAL TURNOVER OF RAT BRAIN NORADRENALINE, DOPAMINE AND 5-HT.
215683 04-03

EFFECTS OF ANTAGONISTS UPON LOCOMOTOR STIMULATION INDUCED BY INJECTION OF DOPAMINE AND NORADRENALINE INTO THE NUCLEUS-ACCUMBENS OF NIALAMIDE PRETREATED RATS.
217475 04-04

ARRHYTHMIAS AND INHIBITION OF NORADRENALINE UPTAKE CAUSED BY TRICYCLIC ANTIDEPRESSANTS AND CHLORPROMAZINE ON THE ISOLATED PERFUSED RABBIT HEART.
217657 04-03

EFFECT OF BUTRIPTYLINE ON THE BRAIN UPTAKE MECHANISMS FOR NORADRENALINE AND 5-HYDROXYTRYPTAMINE.
217688 04-03

LACK OF EFFECT OF PROTRIPTYLINE ON THE 6-HYDROXYDOPAMINE INDUCED NORADRENALINE DEPLETION IN THE RAT SPINAL CORD.
217824 04-03

6-HYDROXYDOPA DURING DEVELOPMENT OF CENTRAL ADRENERGIC NEURONS PRODUCES DIFFERENT LONG-TERM CHANGES IN RAT BRAIN NORADRENALINE.
217867 04-03

EFFECT OF AMPHETAMINE, 3,4 METHYLENEDIOXYAMPHETAMINE, P-METHOXYAMPHETAMINE AND RELATED AMPHETAMINES ON UPTAKE OF METARAMINOL AND EFFLUX OF NORADRENALINE IN ADRENERGIC NERVES OF RABBIT ATRIA.
217889 04-03

CHANGES IN THE CONCENTRATIONS OF 5-HYDROXYTRYPTAMINE AND NORADRENALINE IN SIX AREAS OF RAT BRAIN DURING RECOVERY FROM CHRONIC METHYLAMPHETAMINE ADMINISTRATION.
217963 04-03

THE INFLUENCE OF DESIPRAMINE AND AMITRIPTYLINE ON THE ACCUMULATION OF (3H)NORADRENALINE AND ITS TWO MAJOR METABOLITES FORMED FROM (3H)TYROSINE IN THE RAT BRAIN.
217966 04-03

NORADRENERGIC

A PHARMACOLOGICAL AND NEUROANATOMICAL ANALYSIS OF DOPAMINERGIC AND NORADRENERGIC PATHWAYS INVOLVED IN SELF-STIMULATION IN RATS. (PH. D. DISSERTATION).
193582 01-04

FURTHER EVIDENCE FOR THE HETEROGENEOUS STORAGE OF NORADRENALINE IN CENTRAL NORADRENERGIC TERMINALS.
195239 01-03

ON THE INHIBITION OF PERIPHERAL AND CENTRAL NORADRENERGIC NEUROTRANSMISSION BY CLONIDINE.
197295 01-03

THE ANTICONVULSANT ACTION OF THE CARBONIC ANHYDRASE INHIBITOR METHAZOLAMIDE: POSSIBLE INVOLVEMENT OF A NORADRENERGIC MECHANISM.
197864 01-03

ALPHA-RECEPTOR MEDIATED MODULATION OF TRANSMITTER RELEASE FROM CENTRAL NORADRENERGIC NEURONES.
202805 02-03

THE REGULATION OF THE NORADRENERGIC NEURON.
207331 03-17

BLOCKADE BY PIMOZIDE OF A NORADRENALINE SENSITIVE ADENYLATE-CYCLASE IN THE LIMBIC FOREBRAIN: POSSIBLE ROLE OF LIMBIC NORADRENERGIC MECHANISMS IN THE MODE OF ACTION OF ANTIPSYCHOTICS.
210771 03-03

EFFECTS OF AMPHETAMINE ISOMERS AND NEUROLEPTICS ON SELF-STIMULATION FROM THE NUCLEUS-ACCUMBENS AND DORSAL NORADRENERGIC BUNDLE.
213394 04-03

NORADRENERGIC CONTROL OF SPONTANEOUS MEAL SIZE IN THE RAT. (PH.D. DISSERTATION).
214206 04-04

THE USE OF DESIPRAMINE IN STUDIES OF NORADRENERGIC NERVE FUNCTION.
217882 04-03

INHIBITION OF BOTH NORADRENERGIC AND SEROTONERGIC NEURONS IN BRAIN BY THE ALPHA-ADRENERGIC AGONIST CLONIDINE.
221131 04-03

TRICYCLIC ANTIDEPRESSANTS: EFFECTS ON THE FIRING RATE OF BRAIN NORADRENERGIC NEURONS.
222805 04-03

NOREPINEPHRINE

EFFECT OF 6-HYDROXYDOPAMINE ON HYPOTHALAMIC NOREPINEPHRINE AND DOPAMINE CONTENT, ULTRASTRUCTURE OF THE MEDIAN EMINENCE, AND PLASMA CORTICOSTERONE.
193050 01-03

FURTHER STUDIES ON THE EFFECT OF P-HYDROXYNOREPHEDRINE (PONE) ON NOREPINEPHRINE METABOLISM IN THE RAT BRAIN.
193453 01-03

ALTERATIONS IN THE TURNOVER OF BRAIN NOREPINEPHRINE AND DOPAMINE IN ALCOHOL DEPENDENT RATS.
196805 01-03

A COMPARISON OF THE EFFECTS OF (+) AMPHETAMINE, COCAINE AND DENERVATION ON THE RESPONSES OF THE ISOLATED VAS-DEFERENS OF THE GUINEA-PIG TO NOREPINEPHRINE AND ACETYLCHOLINE.
197495 01-03

THE EFFECTS OF LITHIUM ON NOREPINEPHRINE TURNOVER AND METABOLISM: BASIC AND CLINICAL STUDIES.
202249 02-09

EFFECT OF IPRINDOLE ON NOREPINEPHRINE TURNOVER AND TRANSPORT.
202723 02-03

BIOCHEMICAL CRITERIA FOR CLASSIFYING DEPRESSIVE DISORDERS AND PREDICTING RESPONSES TO PHARMACOTHERAPY: PRELIMINARY FINDINGS FROM STUDIES OF NOREPINEPHRINE METABOLISM. CONTRIBUTIONS TO BIOCHEMISTRY.
203594 02-09

THE RELATIVE SIGNIFICANCE OF NOREPINEPHRINE DOPAMINE AND 5-HYDROXYTRYPTAMINE IN THE ELECTROSHOCK SEIZURE IN THE RAT.
204339 02-03

INCREASED FIXED-RATIO PERFORMANCE AND DIFFERENTIAL D- AND L-AMPHETAMINE ACTION FOLLOWING NOREPINEPHRINE DEPLETION BY INTRAVENTRICULAR 6-HYDROXYDOPAMINE.
204482 02-04

RELEASE OF NOREPINEPHRINE AND DOPAMINE-BETA-HYDROXYLASE BY NERVE STIMULATION: II. EFFECTS OF PAPAVERINE.
204485 02-03

MICROIONTOPHORETIC STUDIES ON THE EFFECT OF NOREPINEPHRINE ON THE ACTIVITY OF THE VISUAL CORTEX NEURONS IN RABBITS.
206441 03-03

METABOLISM OF DOPAMINE AND NOREPINEPHRINE IN RAT BRAIN AFTER SINGLE AND REPEATED ADMINISTRATION OF HALOPERIDOL, LOXAPINE AND CLOZAPINE.
206973 03-03

ROLE OF DOPAMINE AND NOREPINEPHRINE IN THE CHEMISTRY OF REWARD.
207302 03-04

THE ROLE OF DOPAMINE AND NOREPINEPHRINE IN CHANGING THE DIRECT CORTICAL RESPONSE TO PHENAMINE.
208971 03-03

MEMORY ENHANCEMENT BY CENTRAL ADMINISTRATION OF NOREPINEPHRINE.
210671 03-04

EFFECT OF INTRAVENTRICULAR NOREPINEPHRINE ON NEURON ACTIVITY IN THE MEDIAL FOREBRAIN BUNDLE DURING SELF-STIMULATION BEHAVIOR.
210704 03-04

ELECTROCONVULSIVE SHOCK: SUSTAINED DECREASE IN NOREPINEPHRINE UPTAKE AFFINITY IN A RESERPINE MODEL OF DEPRESSION.
210830 03-03

EFFECTS OF AMPHETAMINE AND ITS HYDROXYLATED DERIVATIVES ON NEWLY SYNTHESIZED HYPOTHALAMIC NOREPINEPHRINE; STUDY IN VITRO.
210884 03-03

THE EFFECTS OF (+) AMPHETAMINE ON THE CHRONOTROPIC RESPONSES OF THE ISOLATED GUINEA-PIG PACEMAKER TO NOREPINEPHRINE AND ISOPROTERENOL.
211066 03-03

INHIBITION OF SACRAL PARASYMPATHETIC PREGANGLIONIC NEURONS BY GABA, GLYCIN, 5-HYDROXYTRYPTAMINE AND NOREPINEPHRINE. (PH.D. DISSERTATION).
212524 03-03

EFFECTS OF 6-HYDROXYDOPAMINE AND RESERPINE ON AMPHETAMINE-INDUCED RELEASE OF NOREPINEPHRINE IN RAT CEREBRAL CORTEX.
215691 04-03

NOREPINEPHRINE AND SEROTONIN: SPECIFICITY OF RELEASE WITH REWARDING ELECTRICAL STIMULATION OF THE BRAIN.
217522 04-03

THE EFFECTS OF 5-HYDROXY-5-4-CHLOROPHENYL 2,3 DIHYDRO-5H-IMIDAZOISOINDOLE (MAZINDOL, SAH-42-548) ON THE METABOLISM OF BRAIN NOREPINEPHRINE.
217653 04-03

REGIONAL DISTRIBUTION OF TYROSINE-HYDROXYLASE, NOREPINEPHRINE AND DOPAMINE WITHIN THE AMYGDALOID COMPLEX OF THE RAT.
217872 04-03

METHYLATED DERIVATIVES OF NOREPINEPHRINE AND THE CONDITIONED AVOIDANCE RESPONSE IN RATS.
218958 04-02

THE EFFECT OF CATECHOLAMINES ON THE NOREPINEPHRINE LEVEL IN THE TISSUES.
219506 04-03

INHIBITORY ACTION OF NOREPINEPHRINE ON THE INDUCTION OF TRYPTOPHAN 2,3 DIOXYGENASE BY CORTISOL: MEDIATION BY THE ALPHA-RECEPTOR.
221051 04-03

ANTAGONISM OF PSYCHOSTIMULANT 2 PHENYLDIMETHYLTETRAHYDROOXAZINE HYDROCHLORIDE (G-130) TO CENTRAL NERVOUS SYSTEM DEPRESSING DRUGS: MONOAMINEOXIDASE INHIBITORY ACTIVITY AND NOREPINEPHRINE AND SEROTONIN INDUCED CHANGES, COMPARISON WITH DL-AMPHETAMINE.
221267 04-03

ASCENDING CATECHOLAMINE PATHWAYS AND AMPHETAMINE-INDUCED LOCOMOTOR ACTIVITY: IMPORTANCE OF DOPAMINE AND APPARENT NONINVOLVEMENT OF NOREPINEPHRINE.
223054 04-03

FORMATION OF NOREPINEPHRINE IN THE BRAIN OF RATS AFTER ADMINISTRATION OF (+) ERYTHRO 3,4 DIHYDROXYPHENYLSERINE.
225558 04-03

NOREPINEPHRINE-INDUCED

POTENTIATION BY 3,4 DIMETHOXYPHENYLETHYLAMINE (DMPEA) AND COCAINE OF NOREPINEPHRINE-INDUCED CONTRACTION OF GUINEA-PIG VAS-DEFERENS.
194156 01-03

5-HT AND NOREPINEPHRINE-INDUCED RELEASE OF ACH FROM THE THALAMUS AND MESENCEPHALON OF THE MONKEY DURING THERMOREGULATION.
210672 03-03

NORFENFLURAMINE

DOES FENFLURAMINE ACT VIA NORFENFLURAMINE?
210772 03-03

NORITREN

MY EXPERIENCE WITH THE USE OF A TRANQUILIZER, NORITREN, IN THE DEPARTMENT OF INTERNAL MEDICINE PSYCHOSOMATICS.
194510 01-11

NORMAL

BRAIN DOPA/5-HTP DECARBOXYLASE ACTIVITY AFTER THE CHRONIC ADMINISTRATION OF L-DOPA OR 5-HYDROXY-L-TRYPTOPHAN IN NORMAL AND LESIONED CATS.
194483 01-05

THE ACUTE EFFECTS OF INTRAVENOUS INFUSION OF L-TRYPTOPHAN IN NORMAL SUBJECTS.
195443 01-15

DIAZEPAM METABOLISM IN NORMAL MAN: I. SERUM CONCENTRATIONS AND CLINICAL EFFECTS AFTER INTRAVENOUS, INTRAMUSCULAR, AND ORAL ADMINISTRATION.
195444 01-15

DIAZEPAM METABOLISM IN NORMAL MAN: II. SERUM CONCENTRATION AND CLINICAL EFFECT AFTER ORAL ADMINISTRATION AND CUMULATION.
195445 01-13

DRUG STUDIES IN NORMAL FEMALES, SENIOR CITIZENS, AND IN EXPERIMENTAL GROUPS.
198071 01-07

A CONTROLLED COMPARISON OF THE EFFECTS OF DIPHENYLHYDANTOIN AND PLACEBO ON MOOD AND PSYCHOMOTOR FUNCTIONING IN NORMAL VOLUNTEERS.
199518 02-14

SLEEP AMPHETAMINE EFFECTS IN MBDS AND NORMAL SUBJECTS.
199640 02-11

THE EFFECT OF CHLORPROMAZINE ON VISUAL INFORMATION PROCESSING IN NORMAL SUBJECTS.
199663 02-14

PLASMA TRYPTOPHAN TOLERANCE CURVES IN DRUG-FREE NORMAL CONTROLS, SCHIZOPHRENIC PATIENTS AND PRISONER VOLUNTEERS.
200773 02-13

GENOTYPE DEPENDENT ELECTROENCEPHALOGRAPHIC, BEHAVIORAL AND ANALGESIC CORRELATES OF MORPHINE: AN ANALYSIS IN NORMAL MICE AND IN MICE WITH SEPTAL LESIONS.
203520 02-04

CLINICAL STUDIES OF D-40TA (TRIAZOLOBENZODIAZEPINE) -- CROSSOVER TRIAL ON SLEEP DISTURBANCES AND SLEEP EEG IN NORMAL ADULTS.
209412 03-10

HIPPOCAMPUS: SELECTIVE CONCENTRATIONS OF LEAD IN THE NORMAL RAT BRAIN.
210665 03-03

NORMAL SHUTTLEBOX AVOIDANCE LEARNING AFTER CHRONIC PHENOBARBITAL INTOXICATION IN MICE.
210737 03-04

EFFECTS OF D-AMPHETAMINE AND SECOBARBITAL ON KEY PRESS RATES IN NORMAL HUMANS.
210879 03-14

APOMORPHINE-INDUCED ROTATION IN NORMAL RATS AND INTERACTION WITH UNILATERAL CAUDATE LESIONS.
214012 04-04

INDUCTION OF TYROSINE-HYDROXYLASE ELICITED BY BETA ADRENERGIC RECEPTOR AGONISTS IN NORMAL AND DECENTRALIZED SYMPATHETIC GANGLIA: ROLE OF CYCLIC 3,5 ADENOSINE-MONOPHOSPHATE.
215688 04-03

EFFECTS OF LITHIUM ON ELECTROMYOGRAPHIC RECORDINGS IN MAN: STUDIES IN MANIC-DEPRESSIVE PATIENTS AND NORMAL VOLUNTEERS.
215697 04-13

EFFECTS OF HEXAPROPYMATE ON THE SLEEP OF THE NORMAL MAN MEASURED BY A POLYGRAPHIC METHOD.
218166 04-14

ATTENTION AND THE AUDITORY EVOKED POTENTIAL IN HYPERKINETIC CHILDREN TREATED WITH METHYLPHENIDATE AND IN NORMAL CHILDREN. (PH.D. DISSERTATION).
222747 04-11

PHENETHYLAMINE IN NORMAL URINE: FAILURE TO VERIFY HIGH VALUES.
225517 04-16

NORMALS

EFFECT OF L-DOPA ON PITUITARY HORMONES AND ON CARBOHYDRATE AND FAT METABOLISM IN NORMALS AND IN PARKINSONS DISEASE.
207153 03-13

NORTHERN-IRELAND
A SOCIETY ON THE RUN: A PSYCHOLOGY OF NORTHERN-IRELAND.
194054 01-17

NORTRIPTYLINE
PLASMA NORTRIPTYLINE AND CLINICAL RESPONSE.
198029 01-09
EFFECT OF TWO WEEKS TREATMENT WITH CHLORIMIPRAMINE AND NORTRIPTYLINE, ALONE OR IN COMBINATION WITH ALCOHOL, ON LEARNING AND MEMORY.
200057 02-14
THE RELATIONSHIP BETWEEN NORTRIPTYLINE PLASMA LEVELS AND CLINICAL EFFECTS.
213782 04-13
RESEARCH INTO THE INTERACTION BETWEEN NORTRIPTYLINE AND PERPHENAZINE -- CLINICAL EVALUATION.
221632 04-13
NORTRIPTYLINE PLASMA LEVELS: RELATIONSHIP TO DRUG EFFECTS.
224834 04-09
DOSE-RESPONSE RELATIONSHIP FOR NORTRIPTYLINE IN ENDOGENOUS DEPRESSION.
224835 04-09

NOVELTY
EFFECTS OF ALCOHOL, UNCERTAINTY AND NOVELTY UPON RESPONSE SELECTION.
200048 02-14
THE ROLE OF SEX AND NOVELTY IN DETERMINING THE SOCIAL RESPONSE TO LITHIUM CHLORIDE.
202721 02-04
CHLORDIAZEPOXIDE EFFECTS ON REACTIONS TO NOVELTY AND ACTIVITY WITH AND WITHOUT PRIOR DRUG EXPERIENCE.
221047 04-04

NOXIPTILIN
NOXIPTILIN (AGEDAL) -- A NEW TRICYCLIC ANTIDEPRESSANT WITH A FASTER ONSET OF ACTION? A DOUBLE-BLIND, MULTICENTRE COMPARISON WITH AMITRIPTYLINE.
221306 04-09

NUCLEI
METHODS TO STUDY THE IN VIVO REGULATION OF CYCLIC NUCLEOTIDES IN HYPOTHALAMIC NUCLEI, PITUITARY AND PINEAL. (UNPUBLISHED PAPER).
201491 02-06
6-HYDROXYDOPAMINE LESIONS OF OLFACTORY TUBERCLES AND CAUDATE NUCLEI: EFFECT ON AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR IN RATS.
202788 02-04
STEREOTYPED AND CIRCLING BEHAVIOUR INDUCED BY DOPAMINERGIC AGONISTS AFTER LESIONS OF THE MIDBRAIN RAPHE NUCLEI.
202792 02-04
FUNCTIONAL ANATOMICAL STUDIES OF THE RAPHE NUCLEI.
206108 03-03
TRICYCLIC ANTIDEPRESSANT DRUGS AND DOPAMINE SENSITIVE ADENYLCYCLASE FROM RAT CAUDATE NUCLEI.
206990 03-03
EFFECT OF STRESS ON CATECHOLAMINES AND TYROSINE-HYDROXYLASE ACTIVITY OF INDIVIDUAL HYPOTHALAMIC NUCLEI.
208994 03-03
SEROTONIN CONTENT OF THE BRAINSTEM NUCLEI IN THE RAT.
210661 03-03
RECIPROCAL (PUSH-PULL) EFFECTS OF MORPHINE ON SINGLE UNITS IN THE VENTROMEDIAN AND LATERAL HYPOTHALAMUS AND INFLUENCES ON OTHER NUCLEI: WITH COMMENT ON METHADONE EFFECTS DURING WITHDRAWAL FROM MORPHINE.
210700 03-03
TOWARD THE QUESTION OF THE INFLUENCE OF STIMULATION OF THE THALAMIC ASSOCIATIVE NUCLEI ON THE BEHAVIOR OF CATS.
215498 04-04

NUCLEIC
THE INFLUENCE OF ENCEPHALOTROPIC DRUGS ON NUCLEIC ACID METABOLISM IN THE BRAIN.
204398 02-13

NUCLEOPHILIC
LIGHT INDUCED FRAGMENTATION OF 3,5-DIOXO-1,2 DIPHENYL-4-N-BUTYLPYRAZOLIDINE (PHENYLBUTAZONE) WITH NUCLEOPHILIC AGENTS.
197675 01-01

NUCLEOTIDES
INVOLVEMENT OF CYCLIC NUCLEOTIDES IN THE LONG-TERM INDUCTION OF TYROSINE-HYDROXYLASE. (UNPUBLISHED PAPER).
196590 01-03
METHODS TO STUDY THE IN VIVO REGULATION OF CYCLIC NUCLEOTIDES IN HYPOTHALAMIC NUCLEI, PITUITARY AND PINEAL. (UNPUBLISHED PAPER).
201491 02-06
CHANGES IN MENTAL AGE WITH SUBNORMAL CHILDREN TREATED WITH DOSES OF GABA AND NUCLEOTIDES.
210286 03-14
THE PASSATIZATION INDEX OF RETARDATES TREATED WITH HIGH DOSES OF GABA AND NUCLEOTIDES.
210288 03-11
MNEMONIC CAPACITY OF MENTALLY RETARDED BOYS TREATED WITH HIGH DOSES OF NUCLEOTIDES AND GABA.
210291 03-14
TEMPORAL DISCRIMINATION TESTS IN MENTAL RETARDATES TREATED WITH NUCLEOTIDES AND GABA IN HIGH DOSES.
210293 03-14
THE EFFECTS OF NUCLEOTIDES AND GABA IN LARGE DOSES ON THE RESPONSE TO A PAINFUL STIMULUS WITH RETARDATES.
210296 03-14

NUCLEUS
ACTION OF NEUROLEPTICS ON THE CONTENT OF DOPAMINE AND DOPAC IN THE RAT CAUDATE NUCLEUS.
197682 01-03
UPTAKE OF NEUROTRANSMITTERS INTO SUBCELLULAR PARTICLES OF THE CAUDATE NUCLEUS.
197962 01-03
COMPARATIVE EFFECT OF PHENAMINE (AMPHETAMINE) AND CAFFEINE ON THE BACKGROUND ACTIVITY OF CORTICAL SENSORIMOTOR NEURONS AND THEIR REACTIONS DURING STIMULATION OF THE CAUDATE NUCLEUS.
198835 02-03
THE NUCLEUS LINEARIS INTERMEDIUS RAPHE AND BEHAVIOUR EVOKED BY DIRECT AND INDIRECT STIMULATION OF DOPAMINE SENSITIVE SITES WITHIN THE CAUDATE NUCLEUS OF CATS.
199864 02-04
THE INFLUENCE OF ALPHA-METHYLTYROSINE AND DISULFIRAM ON THE INHIBITORY FUNCTION OF THE CAUDATE NUCLEUS AND CATECHOLAMINE CONTENT IN THE BRAIN OF CATS.
200565 02-03
NEURONAL ACTIVITY OF NUCLEUS CAUDATES AND THALAMUS DURING BARBITURATE SPINDLES IN RATS.
201479 02-03
BIOCHEMICAL CHARACTERIZATION OF THE DOPAMINE RECEPTOR IN THE MAMMALIAN CAUDATE NUCLEUS.
207297 03-03
ADENOSINE-3-5-MONOPHOSPHATE CONTENT IN RAT CAUDATE NUCLEUS: DEMONSTRATION OF DOPAMINERGIC AND ADRENERGIC RECEPTORS.
208300 03-03
ONTOGENY OF THE INDUCTION OF TYROSINE-HYDROXYLASE BY RESERPINE IN THE SUPERIOR CERVICAL GANGLION, NUCLEUS LOCUS-COERULEUS AND ADRENAL GLAND.
210670 03-03
DIFFERENTIAL EFFECTS OF THE OPTICAL ISOMERS OF AMPHETAMINE ON NEURONAL ACTIVITY IN THE RETICULAR FORMATION AND CAUDATE NUCLEUS OF THE RAT.
211063 03-03
D-AMPHETAMINE INDUCED RELEASE OF NEWLY SYNTHESIZED AND STORED DOPAMINE FROM THE CAUDATE NUCLEUS IN VIVO.
214110 04-03
THE EFFECT OF SOME NEUROTROPIC DRUGS ON THE PHASIC CHANGES OF ARTERIAL PRESSURE EVOKED BY STIMULATION OF THE CEREBELLAR FASTIGAL NUCLEUS.
217067 04-03
APPARENT FEEDBACK FROM THE CAUDATE NUCLEUS TO THE SUBSTANTIA-NIGRA FOLLOWING AMPHETAMINE ADMINISTRATION.
217676 04-03
DISCRIMINATIVE CONTROL OF BEHAVIOR BY ELECTRICAL STIMULATION OF THE DORSAL RAPHE NUCLEUS: GENERALIZATION TO LYSERGIC ACID DIETHYLAMIDE (LSD).
217821 04-12
THE EFFECT OF PSYCHOTROPIC AGENTS ON THE ELECTROENCEPHALOGRAPHIC CHARACTERISTICS OF THE INHIBITORY FUNCTION OF THE CAUDATE NUCLEUS.
219500 04-03
DOPAMINE SENSITIVE ADENYLCYCLASE IN HUMAN CAUDATE NUCLEUS: A STUDY IN CONTROL SUBJECTS AND SCHIZOPHRENIC PATIENTS.
221732 04-13
THE DOPAMINERGIC COMPONENT IN THE ACTION OF D,L-AMPHETAMINE ON THE INHIBITORY FUNCTION OF THE CAUDATE NUCLEUS.
223014 04-03
CHANGES IN MORPHINE SELF-ADMINISTRATION AND MORPHINE-DEPENDENCE AFTER LESIONS OF THE CAUDATE NUCLEUS IN RATS.
225560 04-04

NUCLEUS-ACCUMBENS
TYROSINE-HYDROXYLASE (TH) IN NUCLEUS-ACCUMBENS AND STRIATUM: EFFECTS OF NEUROLEPTICS ON THE AFFINITY FOR PTERIDINE COFACTOR. (UNPUBLISHED PAPER).
196588 01-03
ADENYLCYCLASE IN RAT STRIATUM AND NUCLEUS-ACCUMBENS: STIMULATION BY DOPAMINE RECEPTOR AGONISTS. (UNPUBLISHED PAPER).
197124 01-03
EFFECTS OF AMPHETAMINE ISOMERS AND NEUROLEPTICS ON SELF-STIMULATION FROM THE NUCLEUS-ACCUMBENS AND DORSAL NORADRENERGIC BUNDLE.
213394 04-03

INHIBITION OF D-AMPHETAMINE INDUCED LOCOMOTOR ACTIVITY BY INJECTION OF HALOPERIDOL INTO THE NUCLEUS-ACCUMBENS OF THE RAT.
217461 04-04

EFFECTS OF ANTAGONISTS UPON LOCOMOTOR STIMULATION INDUCED BY INJECTION OF DOPAMINE AND NORADRENALINE INTO THE NUCLEUS-ACCUMBENS OF NIALAMIDE PRETREATED RATS.
217475 04-04

THE EFFECT OF MICROINJECTIONS OF AMPHETAMINE INTO THE NEOSTRIATUM AND THE NUCLEUS-ACCUMBENS ON SELF-STIMULATION BEHAVIOUR.
217530 04-04

STEREOSPECIFICITY OF DOPAMINE RECEPTORS INVOLVED IN THE REGULATION OF THE KINETIC STATE OF TYROSINE-HYDROXYLASE IN STRIATUM AND NUCLEUS-ACCUMBENS.
217888 04-03

NURSING
LEARNING DEFICITS IN 4 WEEKS OLD OFFSPRING OF THE NURSING MOTHERS TREATED WITH THE NEUROLEPTIC DRUG PENFLURIDOL.
202806 02-04

INCREASED CONCENTRATION OF HOMOVANILLIC ACID IN THE BRAINS OF INFANT RABBITS AFTER ADMINISTRATION OF HALOPERIDOL TO THEIR NURSING MOTHERS.
217692 04-03

NUTRITIONAL
PHYSIOLOGICAL MECHANISMS FOR CARDIAC CONTROL BY NUTRITIONAL INTAKE AFTER EARLY MATERNAL SEPARATION IN THE YOUNG RAT.
218047 04-03

NYSTAGMOGRAPHY
COMPUTER NYSTAGMOGRAPHY, A NEW METHOD OF DETERMINING CHANGES IN VIGILANCE AS A RESPONSE TO PSYCHOTROPIC DRUGS.
204395 02-16

NYSTAGMUS
NYSTAGMUS AND DISTURBANCES IN PSYCHOMOTOR FUNCTIONS INDUCED BY PSYCHOTROPIC DRUG THERAPY.
221990 04-15

O-FLUOROPHENYL
A NEW BENZODIAZEPINE: 1-(2 HYDROXYETHYL)-3-HYDROXY-7-CHLORO-1,3 DIHYDRO-5-(O-FLUOROPHENYL)-1H-1,4 BENZODIAZEPIN-2-ONE.
194956 01-04

O-METHYLATING
HYDROCORTISONE-INDUCED SUPERSENSITIVITY TO NORADRENALINE IN THE ISOLATED NICTITATING MEMBRANE AS A CONSEQUENCE OF AN IMPAIRMENT OF AN O-METHYLATING SYSTEM WITH HIGH AFFINITY.
197944 01-03

OBESITY
METFORMIN (GLUCOPHAGE) IN THE TREATMENT OF DRUG-INDUCED OBESITY.
221821 04-13

OBJECTIVE
THE EFFECT OF COCA-COLA, CAFFEINE, ANTIDEPRESSANTS AND CHLORPROMAZINE ON OBJECTIVE AND SUBJECTIVE SLEEP PARAMETERS.
210808 03-14

THE INFLUENCE OF SULPIRIDE ON VIGILANCE: OBJECTIVE MEASUREMENTS OF THE VISUOMOTOR SYSTEM.
221271 04-14

OBJECTIVE ASSESSMENT OF ANTICHOLINERGIC SIDE-EFFECTS OF TRICYCLIC ANTIDEPRESSANTS A CONTROLLED STUDY OF IMIPRAMINE AND IMIPRAMINE-N-OXIDE.
221633 04-15

OBSERVABLE
THE ELECTROENCEPHALOGRAM AS A PHYSIOLOGICAL AND PHARMACOLOGICAL OBSERVABLE.
207549 03-06

OBSERVATION
CORRELATED HISTOCHEMICAL, ELECTRON MICROSCOPICAL, PHARMACOLOGICAL AND PHYSIOLOGICAL OBSERVATION ON AMINERGIC MECHANISMS IN THE CENTRAL NERVOUS SYSTEM. (UNPUBLISHED PAPER).
218300 04-03

OBSERVATIONAL
AN OBSERVATIONAL STUDY OF HALLUCINOGEN INDUCED BEHAVIOR IN UNRESTRAINED MACACA-MULATTA.
210739 03-04

OBSERVATIONS
CLINICAL OBSERVATIONS ON SULPIRIDE TREATMENT IN PSYCHIATRY.
200170 02-11

OBSERVATIONS ON THE TREATMENT OF DEPRESSIONS.
200481 02-09

FURTHER OBSERVATIONS ON AUTOMATON LIKE EXISTENCE UNDER LONG-TERM LITHIUM THERAPY.
204410 02-15

BEHAVIOURAL AND ELECTROGRAPHIC OBSERVATIONS DURING EPILEPTIC CONVULSIONS INDUCED BY STRYCHNINE AND PENTYLENETETRAZOL IN CONSCIOUS YOUNG AND ADULT CHICKENS.
205459 02-03

OBSERVATIONS OF THE PSYCHOPHARMACOLOGY OF THE AGED.
207437 03-11

AMITRIPTYLINE AND DEPRESSIVE STRUCTURES (ON 100 OBSERVATIONS).
207579 03-14

LITHIUM GLUCONATE: SYSTEMATIC AND FACTORIAL ANALYSIS OF 104 OBSERVATIONS OVER 2.5-3 YEARS IN PATIENTS PRESENTING CYCLOTHYMIC OR DYSTHYMIC DISORDERS.
210126 03-09

SOME OBSERVATIONS ON THE CORRELATIONS BETWEEN PLASMA LEVELS OF MONOMETHYLATED TRICYCLIC ANTIDEPRESSANTS AND THERAPEUTIC EFFECTS.
210507 03-09

USE OF A BENZODIAZEPINE AT HIGH DOSAGE LEVELS: A STATEMENT ON 50 OBSERVATIONS.
212179 03-10

STUDY OF 220 OBSERVATIONS OF LITHIUM THERAPY IN DEPRESSION CASES IN TEHERAN.
212211 03-09

OBSERVATIONS ON EFFECTS OF A CENTRAL STIMULANT DRUG (METHYLPHENIDATE) IN CHILDREN WITH HYPERACTIVE BEHAVIOR.
219354 04-14

OBSERVATIONS ON THE DOSE REGIME OF FLUPHENAZINE DECANOATE IN MAINTENANCE THERAPY OF SCHIZOPHRENIA.
222602 04-17

OBSERVER
A CONTROLLED COMPARISON OF MAPROTILINE (LUDIOMIL) WITH IMIPRAMINE AVOIDING OBSERVER BIAS.
221654 04-09

OBSERVING
EFFECTS OF AMPHETAMINE AND AND CHLORPROMAZINE UPON OBSERVING RESPONSES IN RATS. (PH.D. DISSERTATION).
203166 02-04

OBSESSIONAL
CLOMIPRAMINE IN THE TREATMENT OF THE TRUE OBSESSIONAL STATE: A REPORT ON FOUR PATIENTS.
211433 03-10

THE SHAPIRO CARDS SCALE AS A METHOD OF ASSESSMENT OF OBSESSIONAL SYMPTOMS IN CLOMIPRAMINE THERAPY.
214829 04-10

DEPRESSIVE REACTIONS IN THE COURSE OF CLOMIPRAMINE THERAPY USED IN THE TREATMENT OF OBSESSIONAL CONDITIONS.
214834 04-15

THE ROLE OF INTRAVENOUS CLOMIPRAMINE IN THE TREATMENT OF OBSESSIONAL AND PHOBIC DISORDERS.
214835 04-10

AN INVESTIGATION INTO THE USE OF ANAFRANIL IN PHOBIC AND OBSESSIONAL DISORDERS.
214837 04-10

CLOMIPRAMINE (ANAFRANIL) IN THE TREATMENT OF OBSESSIONAL STATES: A PSYCHIATRISTS VIEW.
215155 04-10

OBSESSIONS
AMPHETAMINE TREATMENT OF PARANOID OBSESSIONS: CASE REPORT AND BIOCHEMICAL IMPLICATIONS.
210809 03-09

A GENERAL PRACTITIONER TRIAL OF CLOMIPRAMINE (ANAFRANIL) IN OBSESSIONS AND PHOBIAS.
215157 04-10

OBSESSIVE
PSYCHOPHARMACOLOGICAL TREATMENT OF OBSESSIVE SYNDROME.
204408 02-09

THE ACTION OF CHLORIMIPRAMINE IN OBSESSIVE COMPULSIVE NEUROSIS: A PILOT STUDY.
209489 03-10

PHARMACOLOGICAL TREATMENT OF PHOBIC - OBSESSIVE PSYCHONEUROSES: PSYCHODYNAMIC AND SYMPTOMATOLOGICAL ASPECTS.
210506 03-10

CHANGES IN OBSESSIVE/COMPULSIVE PATIENTS AS MEASURED BY THE LEYTON INVENTORY BEFORE AND AFTER TREATMENT WITH CLOMIPRAMINE.
214833 04-10

ATROPINE COMA TREATMENT OF SCHIZOPHRENIC PATIENTS WITH A SLUGGISH DEVELOPMENT AND OBSESSIVE SYNDROMES.
224085 04-08

OBSTACLES
OVERCOMING OBSTACLES TO DESENSITIZATION USING IN VIVO STIMULI AND BREVITAL.
224984 04-10

OBSTETRICAL
NEONATAL BEHAVIORAL PATTERNS AND THEIR RELATION TO OBSTETRICAL MEDICATION. (PH.D. DISSERTATION).
194573 01-15

OCCUPATIONALLY
LIVER FUNCTION IN WORKERS OCCUPATIONALLY DEALING WITH CHLORPROMAZINE AND SOME OTHER COMPOUNDS.
202925 02-13

OCTAHYDROPHENANTHRENE
AMPHETAMINE DERIVATIVES: 10(E)- AND 10(A)-AMINO-1,2,3,4,4A,9,10,10A-(TRANS-4A,10A) OCTAHYDROPHENANTHRENE.
195561 01-01

OCTOCLOTHEPINE
EEG CHANGES IN THE TREATMENT WITH OCTOCLOTHEPINE IN VERY HIGH DOSES.
215064 04-13

OCTOPAMINE
DEVELOPMENTAL CHARACTERISTICS OF PHENYLETHANOLAMINE AND OCTOPAMINE IN THE RAT BRAIN.
196804 01-03

ODOR-BASED
THE EFFECTS OF SODIUM AMOBARBITAL ON ODOR-BASED RESPONDING IN RATS.
195995 01-04

OFFSPRING
THE EFFECTS OF DEXTROAMPHETAMINE, DIMETHYLTRYPTAMINE, LYSERGIC ACID DIETHYLAMIDE AND TETRAHYDROCANNABINOL UPON PREGNANCY AND THE OFFSPRING. (PH.D. DISSERTATION).
194568 01-04

EFFECTS OF D-AMPHETAMINE SULFATE GIVEN TO PREGNANT MICE ON ACTIVITY AND ON CATECHOLAMINES IN THE BRAINS OF OFFSPRING.
196025 01-03

DEVELOPMENTAL DISTURBANCE OF THE BRAIN IN RAT OFFSPRING FOLLOWING MATERNAL ADMINISTRATION OF 5-FLUOURACIL DURING PREGNANCY.
202422 02-03

EFFECTS ON THE ACQUISITION OF CONDITIONED AVOIDANCE RESPONSES AND SEIZURE THRESHOLD IN THE OFFSPRING OF AMPHETAMINE TREATED GRAVID RATS.
202722 02-05

LEARNING DEFICITS IN 4 WEEKS OLD OFFSPRING OF THE NURSING MOTHERS TREATED WITH THE NEUROLEPTIC DRUG PENFLURIDOL.
202806 02-04

PSYCHOTOMIMETIC SUBSTANCES DURING PREGNANCY AND SEX OF OFFSPRING MICE. (PH.D. DISSERTATION).
213050 03-03

PRENATAL MATERNAL D-AMPHETAMINE EFFECTS ON EMOTIONALITY AND AUDIOGENIC SEIZURE SUSCEPTIBILITY OF RAT OFFSPRING.
225079 04-04

OIL
PROLONGED NEUROLEPTIC EFFECT OF ALPHA-FLUPENTHIXOL DECANOATE IN OIL.
210893 03-03

PROSTAGLANDINS AND CANNABIS -- III. INHIBITION OF BIOSYNTHESIS BY ESSENTIAL OIL COMPONENTS OF MARIHUANA.
217795 04-03

OLDER
EFFECT OF MESORIDAZINE ADMINISTRATION AND WITHDRAWAL ON PERFORMANCE IN AN OLDER AGE GROUP.
217452 04-11

OLFACTORY
EFFECTS OF PSYCHOTROPIC DRUGS ON HYPEREMOTIONALITY OF RATS WITH BILATERAL ABLATIONS OF THE OLFACTORY BULBS AND OLFACTORY TUBERCLES.
195231 01-04

6-HYDROXYDOPAMINE LESIONS OF OLFACTORY TUBERCLES AND CAUDATE NUCLEI: EFFECT ON AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR IN RATS.
202788 02-04

EFFECT OF ANTIPSYCHOTIC DRUGS ON HOMOVANILLIC ACID LEVELS IN STRIATUM AND OLFACTORY TUBERCLE OF THE RAT.
210864 03-03

OLIGOPHRENIC
TRYPTOPHAN METABOLISM EXAMINATIONS IN OLIGOPHRENIC CHILDREN. FIRST REPORT: RESULTS OF THE EXCRETION OF KYNURENINE AND XANTHURENIC ACID AFTER TRYPTOPHAN LOADING AND THEIR DEPENDENCE UPON THE SUPPLY.
203645 02-13

A COMPARATIVE STUDY OF THE EFFECTIVENESS OF ENERBOL AND GLUTAMIC ACID IN OLIGOPHRENIC CHILDREN.
219662 04-11

ON-GOING
ON-GOING STUDIES OF CLOMIPRAMINE (ANAFRANIL) IN GENERAL PRACTICE.
215151 04-15

ONCE-A-DAY
ONCE-A-DAY DOSAGE TRICYCLIC ANTIDEPRESSANT DRUG THERAPY: A SURVEY.
196679 01-09

ONE-WAY
THE EFFECT OF AN ADRENAL DEMEDULLATION AND CHEMICAL SYMPATHECTOMY (2,4,5 TRIHYDROXYPHENYLETHYLAMINE) ON THE ACQUISITION OF A ONE-WAY ACTIVE AVOIDANCE RESPONSE. (PH.D. DISSERTATION).
222736 04-04

ONTOGENESIS
LEAD ENCEPHALOPATHY IN THE DEVELOPING RAT: EFFECT ON CORTICAL ONTOGENESIS.
200168 02-05

ONTOGENESIS OF NEOSTRIATAL CHOLINERGIC NEURONES IN THE RAT AND DEVELOPMENT OF THEIR SENSITIVITY TO NEUROLEPTIC DRUGS.
217658 04-03

ONTOGENETIC
ONTOGENETIC ASPECTS OF CENTRAL CHOLINERGIC INVOLVEMENT IN SPONTANEOUS ALTERNATION BEHAVIOR.
199550 02-04

ONTOGENIC
AN ONTOGENIC STUDY ON THE EFFECT OF CATECHOLAMINE RECEPTOR STIMULATING AGENTS ON THE TURNOVER OF NORADRENALINE AND DOPAMINE IN THE BRAIN.
202715 02-03

ONTOGENY
ONTOGENY OF STEREOTYPED BEHAVIOUR INDUCED BY APOMORPHINE AND AMPHETAMINE IN THE RAT.
197462 01-04

EFFECT OF EARLY L-DOPA ADMINISTRATION ON THE ONTOGENY OF MOTOR FUNCTIONS IN THE RAT.
202266 02-03

ONTOGENY OF THE INDUCTION OF TYROSINE-HYDROXYLASE BY RESERPINE IN THE SUPERIOR CERVICAL GANGLION, NUCLEUS LOCUS-COERULEUS AND ADRENAL GLAND.
210670 03-03

OPEN
HALOPERIDOL FOR CHRONICALLY HOSPITALIZED PSYCHOTICS: A DOUBLE-BLIND COMPARISON WITH THIOTHIXENE AND PLACEBO: A FOLLOWUP OPEN EVALUATION.
196676 01-14

RESULTS OF AN OPEN AND A DOUBLE-BLIND STUDY OF NOMIFENSINE IN COMPARISON TO IMIPRAMINE.
204899 02-10

REPORT ON A PRELIMINARY CLINICAL STUDY OF MIANSERIN (GB-94), A TETRACYCLIC ANTIDEPRESSANT, AN OPEN TRIAL.
207283 03-03

MENTAL DISORDERS SEEN AFTER OPEN HEART SURGERY.
214304 04-11

A COMPARISON BETWEEN DIAZEPAM AND HALOPERIDOL IN NEUROTIC ANXIETY AND TENSION STATES IN PATIENTS IN A OPEN WARD.
221638 04-10

OPEN-FIELD
DOSE EFFECTS OF CHLORDIAZEPOXIDE UPON HABITUATION OF OPEN-FIELD BEHAVIOR IN WHITE RATS.
194736 01-04

A COMPARATIVE STUDY OF D- AND L-AMPHETAMINE ON THE OPEN-FIELD PERFORMANCE OF RATS.
201322 02-04

A PRELIMINARY REPORT ON THE ACTION OF IMIPRAMINE AND ANTIPARKINSONIAN AGENTS ON THE OPEN-FIELD BEHAVIOUR OF RATS.
202803 02-04

INFLUENCE OF CHEMICAL STIMULATION OF CENTRAL DOPAMINERGIC SYSTEM ON THE OPEN-FIELD BEHAVIOR OF RATS.
221308 04-03

LONG-LASTING EFFECTS OF PRENATAL 2,4,5 TRICHLOROPHENOXYACETIC ACID ON OPEN-FIELD BEHAVIOR IN RATS: PRE- AND POSTNATAL MEDIATION.
223044 04-04

OPERANT
THE INFLUENCE OF BENZODIAZEPINE SERIES TRANQUILIZERS ON VARIOUS FORMS OF OPERANT ANIMAL BEHAVIOR.
198482 02-04

EFFECTS OF CANNABIDIOL AND DELTA9-TETRAHYDROCANNABINOL ON OPERANT BEHAVIOR.
200036 02-04

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL AND CANNABINOL ON OPERANT PERFORMANCE IN RATS.
210785 03-04

OPIOID REINFORCED OPERANT BEHAVIOR: SELECTIVE SUPPRESSION BY ALPHA-METHYL-P-TYROSINE.
211511 03-04

OPERANT CONDITIONING OF HEART RATE IN CURARIZED RATS: HEMODYNAMIC CHANGES.
213275 03-04

EFFECT OF INTRACEREBROVENTRICULAR BRADYKININ AND RELATED PEPTIDES ON RABBIT OPERANT BEHAVIOR.
215693 04-04

INFLUENCE OF RESPONSE TOPOGRAPHY ON THE EFFECT OF APOMORPHINE AND AMPHETAMINE ON OPERANT BEHAVIOR OF PIGEONS.
217468 04-04

THE EFFECTS OF MEVINPHOS ON APPETITIVE OPERANT BEHAVIOR IN THE GERBIL.
217545 04-04

OPERATIVE
THE EFFECT OF CYCLOHEXIMIDE AND ACTINOMYCIN-D ON THE SPONTANEOUS AND OPERATIVE BEHAVIORS OF THE PIGEON. PRELIMINARY NOTE.
199381 02-04

ESTROGEN STIMULATIONS DURING NEONATAL PERIOD AND THEIR EFFECTS ON EMOTIONAL AND OPERATIVE BEHAVIOR IN THE ADULT.
211219 03-04

OPIATE
DOPAMINERGIC MECHANISMS OF OPIATE ACTIONS IN BRAIN.
208554 03-03

PROPRANOLOL IN THE TREATMENT OF OPIATE DEPENDENCE -- A CONTROLLED STUDY.
217549 04-14

OPINIONS
THE PRESENT CONDITIONS OF PSYCHOPHARMACOLOGICAL TREATMENT FOR CHILDREN IN JAPAN: OPINIONS FROM THIRTY-SEVEN WELL-KNOWN CHILD NEUROPSYCHIATRISTS AND NEUROPSYCHIATRIC PEDIATRICIANS.
202500 02-17

OPIOID
OPIOID REINFORCED OPERANT BEHAVIOR: SELECTIVE SUPPRESSION BY ALPHA-METHYL-P-TYROSINE.
211511 03-04

OPIOIDS
THE EFFECT OF STIMULANTS AND OPIOIDS ON SENSORY REINFORCEMENT IN RATS. (PH.D. DISSERTATION).
223711 04-04

OPTICAL
DIFFERENTIAL EFFECTS OF THE OPTICAL ISOMERS OF AMPHETAMINE ON NEURONAL ACTIVITY IN THE RETICULAR FORMATION AND CAUDATE NUCLEUS OF THE RAT.
211063 03-03

OPTICALLY
STEREOCHEMICAL DEPENDENCE OF PHARMACOLOGICAL ACTIVITY IN A SERIES OF OPTICALLY ACTIVE N-METHYLATED BARBITURATES.
193140 01-01

ORAL
CHRONIC ORAL TOXICITY OF CANNABINOIDS IN MONKEYS.
193417 01-05

EFFECT OF ORAL AND INTRAMUSCULAR ROUTES OF ADMINISTRATION ON SERUM CHLORDIAZEPOXIDE LEVELS AND THE PREDICTION OF THESE LEVELS FROM PREDRUG FASTING SERUM GLUCOSE CONCENTRATIONS.
195055 01-13

DIAZEPAM METABOLISM IN NORMAL MAN: I. SERUM CONCENTRATIONS AND CLINICAL EFFECTS AFTER INTRAVENOUS, INTRAMUSCULAR, AND ORAL ADMINISTRATION.
195444 01-15

DIAZEPAM METABOLISM IN NORMAL MAN: II. SERUM CONCENTRATION AND CLINICAL EFFECT AFTER ORAL ADMINISTRATION AND CUMULATION.
195445 01-13

THE EFFECT OF DAILY ORAL DOSAGE OF DIAZEPAM, PLASMA CONCENTRATIONS AND METABOLIC CLEARANCE OF DIAZEPAM AND DEMETHYLDIAZEPAM ON VARIOUS CONSTITUENTS OF THE ACUTE CLINICAL ANXIETY SYNDROME.
196191 01-10

SPONTANEOUS ORAL DYSKINESIA: RESULTS OF TREATMENT WITH TETRABENAZINE, PIMOZIDE, OR BOTH.
196600 01-11

CHANGES IN ACID-BASE BALANCE, RESPIRATION RATE AND HEART RATE UPON REPEATED ORAL ADMINISTRATION OF BENZOCTAMINE AND DIAZEPAM TO CONSCIOUS DOGS.
197460 01-03

EFFECTS OF DIETHYLPROPION AND D-AMPHETAMINE AFTER SUBCUTANEOUS AND ORAL ADMINISTRATION.
198030 01-14

THE THERAPEUTIC EFFECT OF SHORT-TERM ORAL DIAZEPAM TREATMENT ON ACUTE CLINICAL ANXIETY IN A CRISIS CENTRE.
199991 02-10

PHARMACOKINETICS OF CARBAMAZEPINE IN MONKEYS FOLLOWING INTRAVENOUS AND ORAL ADMINISTRATION.
211009 03-03

ORAL CONTRACEPTION AND INDUCED DEPRESSIVE STATES.
216902 04-14

ORAL DELTA9-TETRAHYDROCANNABINOL TOXICITY IN RATS TREATED UP TO SIX MONTHS.
217518 04-05

TERATOGENICITY OF ORAL DIAZEPAM AND DIPHENYLHYDANTOIN IN MICE.
217694 04-05

DEPRESSIONS CAUSED BY ORAL CONTRACEPTIVES AND THEIR TREATMENT WITH ORIGEN.
224347 04-09

ORALLY
DIFFERENTIAL NEUROCHEMISTRY AND TEMPORAL PATTERN IN RATS TREATED ORALLY WITH DELTA9-TETRAHYDROCANNABINOL FOR PERIODS UP TO SIX MONTHS.
217519 04-04

SERUM ERYTHROCYTE AND CNS LEVELS IN RHESUS MONKEYS OF ORALLY AND INTRAVENOUSLY ADMINISTERED RUBIDIUM SALTS.
218956 04-02

ORAP
A MULTICENTRIC EVALUATION OF PIMOZIDE (ORAP) IN PATIENTS WHO USUALLY WOULD TAKE TRANQUILIZERS.
218750 04-10

ORBITAL
PERSISTENT THALAMIC AND CORTICAL BARBITURATE SPINDLE ACTIVITY AFTER ABLATION OF THE ORBITAL CORTEX IN CATS.
199763 02-03

ORG-GB-94
A COMPARATIVE CLINICAL TRIAL OF ORG-GB-94 AND IMIPRAMINE IN THE TREATMENT OF DEPRESSION IN GENERAL PRACTICE.
225107 04-09

ORG-GB94
THE EFFECT OF A NEW TETRACYCLIC ANTIDEPRESSANT COMPOUND, ORG-GB94, ON THE TURNOVER OF DOPAMINE, NORADRENALIN AND SEROTONIN IN THE RAT BRAIN.
197496 01-03

ORGAL
THE USE OF AN ORGAL LONG-ACTING ANTIPSYCHOTIC AGENT, PENFLURIDOL, IN SCHIZOPHRENIA.
223165 04-08

ORGAN
SUBFORNICAL ORGAN: ACETYLCHOLINE APPLICATION ELICITS DRINKING.
210804 03-03

ORGANIC
ACTIVATION OF EEG BY GAMMA-HYDROXYBUTYRATE (GHB) IN ORGANIC BRAIN DISORDERS.
205460 02-13

ACUTE ORGANIC BRAIN SYNDROME: A COMPLICATION OF DISULFIRAM THERAPY.
213710 04-15

ORGANIC-BRAIN-SYNDROME
ENCEPHABOL IN PATIENTS WITH ORGANIC-BRAIN-SYNDROME.
215073 04-07

ORGANISM
THE KINETICS OF LITHIUM IN THE HUMAN ORGANISM.
205042 02-13

ORGANIZATION
AFFECTIVE DISEASE HEALTH MAINTENANCE ORGANIZATION: PATTERNS OF LITHIUM RESPONSE.
194746 01-09

PSYCHOACTIVE DRUGS AND THE ORGANIZATION OF BEHAVIOR.
213622 04-04

ORGANS
INTRACELLULAR DISTRIBUTION OF 3H-DELTA8-TETRAHYDROCANNABINOL IN RAT ORGANS AFTER I.V. ADMINISTRATION.
195112 01-03

THE INHIBITION OF THE EFFECT OF NERVE STIMULATION BY PHENOTHIAZINES ON ISOLATED INNERVATED ORGANS.
197576 01-03

METABOLISM AND AUTORADIOGRAPHIC DISTRIBUTION OF DELTA8- AND DELTA9-TETRAHYDROCANNABINOL IN SOME ORGANS OF THE MONKEY CALLITHRIX-JACCHUS.
217837 04-03

THE CORRELATION BETWEEN TRIFTAZINE DISTRIBUTION IN SOME RAT ORGANS AND ITS PHARMACOLOGICAL EFFECTS WITH DIFFERENT TYPES OF ADMINISTRATION.
223016 04-03

ORIENT
ATTEMPTS TO CLASSIFY AND ORIENT PRESCRIPTION OF PSYCHOTROPIC DRUGS BY MEANS OF A COMPUTER CARD INDEX.
221668 04-17

ORIGEN
DEPRESSIONS CAUSED BY ORAL CONTRACEPTIVES AND THEIR TREATMENT WITH ORIGEN.
224347 04-09

ORIGIN
MONOAMINE METABOLITES IN LUMBAR CSF: THE QUESTION OF THEIR ORIGIN IN RELATION TO CLINICAL STUDIES.
210796 03-03

THE ORIGIN OF BLOOD 5-HYDROXYINDOLEACETIC (5-HIAA) ACID FOLLOWING L-HYDRAZINO-ALPHA-METHYLDOPA (MK-486).
217665 04-03

ORIGINAL
REFLECTIONS ON THE EFFICACY OF NEW DRUG THERAPIES ON THE OCCASION OF USING AN ORIGINAL MEDICATION: SULPIRIDE (DOGMATIL).
209123 03-11

ORL
STUDY OF AN ANXIOLYTIC DRUG, CLOBAZAM, IN ORL WITH PHARYNGEAL PSYCHOSOMATIC MANIFESTATIONS.
224584 04-11

ORNITHINE
EFFECT OF THYROXINE AND CORTISOL ON BRAIN ORNITHINE DECARBOXYLASE ACTIVITY AND SWIMMING BEHAVIOR IN DEVELOPING RAT.
210933 03-03

OROTIC
SOME EVIDENCE FOR LONG-TERM MEMORY RETENTION BY OROTIC ACID IN RATS BAR PRESSING FOR WATER.
210790 03-04

ORTHOMOLECULAR
THE CONTROVERSY OVER ORTHOMOLECULAR THERAPY.
208862 03-08
THE ORTHOMOLECULAR CONTROVERSY.
209011 03-17
ON THE ORTHOMOLECULAR ENVIRONMENT OF THE MIND: ORTHOMOLECULAR THEORY.
213703 04-13
COMMENT ON LINUS PAULINGS THEORY OF ORTHOMOLECULAR PSYCHIATRY.
213704 04-08
COMMENT ON LINUS PAULINGS THEORY OF ORTHOMOLECULAR PSYCHIATRY.
213705 04-13
COMMENT ON LINUS PAULINGS THEORY OF ORTHOMOLECULAR PSYCHIATRY.
213706 04-15
ORTHOMOLECULAR TREATMENT IN DISTURBANCES INVOLVING BRAIN FUNCTION.
214719 04-11
MEGAVITAMIN AND ORTHOMOLECULAR THERAPY OF SCHIZOPHRENIA.
219536 04-08

ORTHOPHTHALDIALDEHYDE
CONJOINT NATIVE AND ORTHOPHTHALDIALDEHYDE CONDENSATE ASSAYS FOR THE FLUORIMETRIC DETERMINATION OF 5-HYDROXYINDOLES IN BRAIN.
195238 01-01

OUABAIN
INTERACTION OF OUABAIN WITH PENTOBARBITONE IN THE MOUSE.
197479 01-03
EFFECT OF DELTA1-TETRAHYDROCANNABINOL AND PROPRANOLOL ON OUABAIN INDUCED ARRHYTHMIAS.
197486 01-03
MORPHOLOGICAL, BIOCHEMICAL, AND FUNCTIONAL CHANGES IN CHICK EMBRYONIC BRAIN TISSUE AFTER INTRACEREBRAL ADMINISTRATION OF OUABAIN.
197788 01-03
EFFECTS OF SODIUM, OUABAIN AND DMPP ON THE NEURONAL EFFLUX OF NORADRENALINE.
197959 01-03
RAPID REVERSAL OF INTERNAL NA+ AND K+ CONTENTS OF SYNAPTOSOMES BY OUABAIN.
204185 02-03
EFFECT OF OUABAIN AND PHENOBARBITAL ON THE KINETICS OF CORTICAL METABOLIC TRANSIENTS ASSOCIATED WITH EVOKED POTENTIALS.
210820 03-03
EFFECT OF OUABAIN AND PHENOBARBITAL ON OXIDATIVE METABOLIC ACTIVITY ASSOCIATED WITH SPREADING CORTICAL DEPRESSION IN CATS.
220944 04-03

OUTCOME
PLASMA LEVELS OF IMIPRAMINE AND CLINICAL OUTCOME.
198097 02-07
MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 7. COMMUNICATION: METHODOLOGICAL OUTCOME.
203845 02-16
COMPUTERIZED EEG: PREDICTOR OF OUTCOME IN SCHIZOPHRENIA.
213863 04-08
THE OUTCOME OF DOTHIEPIN TREATMENT IN 1,900 DEPRESSED PATIENTS.
215700 04-09
PLASMA LEVEL, DEPRESSIVE TYPOLOGY, CLINICAL OUTCOME.
224836 04-09

OUTPATIENT
OUTPATIENT TREATMENT OF SCHIZOPHRENIA BY A LONG-LASTING STRONG TRANQUILIZER: USE OF FLUPHENAZINE ENANTHATE.
194460 01-08
OUTPATIENT PEDIATRIC PSYCHOPHARMACOLOGY.
198063 01-07
NIMH-PRB COLLABORATIVE OUTPATIENT SCHIZOPHRENIC STUDY.
198075 02-08
NIMH-PRB OUTPATIENT TREATMENT OF DEPRESSION.
198078 02-10
METHODOLOGY OF OUTPATIENT DRUG RESEARCH.
198106 02-07
A CONTROLLED OUTPATIENT TRIAL OF PERPHENAZINE AMITRIPTYLINE AND CHLORPROMAZINE.
199517 02-14
CLINICAL STUDY OF GERDAXYL 10MG WITH 40 PATIENTS TREATED IN A PSYCHIATRIC OUTPATIENT FACILITY.
202037 02-11
CLOZAPINE IN OUTPATIENT PRACTICE.
205617 03-08
FROM HOSPITAL TREATMENT TO COMMUNITY PSYCHIATRY -- SECOND REPORT -- OUTPATIENT EMERGENCY TREATMENT OF MENTAL PATIENTS WITH THE USE OF HALOPERIDOL.
208723 03-11

OUTPATIENTS
DOXEPIN IN A SINGLE BEDTIME DOSE IN PSYCHONEUROTIC OUTPATIENTS.
194834 01-10
EARLY DRUG EVALUATION IN NEUROTIC OUTPATIENTS.
198069 01-07
DRUG THERAPY OF DEPRESSED OUTPATIENTS.
198079 02-10
DRUG TREATMENT OF DEPRESSED OUTPATIENTS.
198083 02-10
MONTHLY INTERMITTENT CHEMOTHERAPY OF CHRONIC SCHIZOPHRENIC OUTPATIENTS WITH PIPOTHIAZINE PALMITATE.
204169 02-08
LIMBITROL IN OUTPATIENTS AND INPATIENTS PRACTICE.
205598 02-10
PATTERNS OF SYMPTOM CHANGE IN ANXIOUS DEPRESSED OUTPATIENTS TREATED WITH DIFFERENT DRUGS.
209904 03-10
PIMOZIDE IN CHRONIC SCHIZOPHRENIC OUTPATIENTS.
209905 03-08
TREATMENT OF PSYCHOSOMATIC GASTROINTESTINAL DISORDERS IN OUTPATIENTS.
210513 03-11
THE LONG-TERM MAINTENANCE TREATMENT OF SCHIZOPHRENIC OUTPATIENTS WITH DEPOT FLUPENTHIXOL.
212491 03-08
A FOLLOWUP STUDY OF FEMALE DEPRESSED OUTPATIENTS WHO COMPLETE A RANDOMIZED DOUBLE-BLIND PROPHYLACTIC TRIAL OF ANTIDEPRESSANTS AND HIGH CONTACT. (PH.D. DISSERTATION).
212518 03-09
CLINICAL TRAILS OF SULPIRIDE WITH EMPHASIS ON NEUROTIC OUTPATIENTS.
224194 04-10

OVARIAN
PSYCHOTROPIC DRUGS, OVARIAN FUNCTIONS AND MAMMARY ACTIVITY.
214055 04-03
PSYCHOTROPIC DRUGS AND OVARIAN CYCLE ALTERATIONS.
217204 04-13

OVARIECTOMIZED
ESTROGEN INDUCED MATERNAL BEHAVIOR IN HYSTERECTOMIZED OVARIECTOMIZED VIRGIN RATS.
219069 04-04
LATENCY AND DURATION OF ESTROGEN INDUCTION OF MATERNAL BEHAVIOR IN HYSTERECTOMIZED OVARIECTOMIZED VIRGIN RATS: EFFECTS OF PUP STIMULATION.
219070 04-04

OVERDOSAGE
PSYCHOTROPIC DRUGS: A MANUAL FOR EMERGENCY MANAGEMENT OF OVERDOSAGE.
193039 01-15
CARDIOVASCULAR ABNORMALITIES FOLLOWING TRICYCLIC ANTIDEPRESSANT DRUG OVERDOSAGE.
195847 01-15
CARDIOVASCULAR COMPLICATIONS OF TRICYCLIC ANTIDEPRESSANT OVERDOSAGE.
209234 03-15
PHYSOSTIGMINE SALICYLATE IN THE TREATMENT OF TRICYCLIC ANTIDEPRESSANT OVERDOSAGE.
212265 03-15
MAPROTILINE (LUDIOMIL): SIDE-EFFECTS AND OVERDOSAGE.
221663 04-15

OVERDOSE
POLYNEUROPATHY AS A RESULT OF DIPHENYLHYDANTOIN OVERDOSE.
200573 02-15

OVERTRAINING
EFFECTS OF OVERTRAINING UPON DRUG STATE DEPENDENCY IN DISCRIMINATION LEARNING IN WHITE RATS.
209866 03-04

OVERUSE
MINOR TRANQUILIZERS: USE, MISUSE OR OVERUSE
211435 03-17

OVERVIEW
OXAZEPAM: AN OVERVIEW.
218152 04-17
ENVIRONMENTAL INFLUENCES AFFECTING THE VOLUNTARY INTAKE OF DRUGS: AN OVERVIEW.
225155 04-04

OVULATION
EFFECT OF SINGLE AND DAILY INJECTIONS OF PHENOBARBITAL ON OVULATION IN HAMSTERS.
193421 01-03
EFFECTS OF INTRAVENTRICULAR INFUSIONS OF ACTH1-24 AND ACTH4-10 ON LH RELEASE, OVULATION AND BEHAVIOR IN THE RABBIT.
210662 03-03

OWING
CLINICAL TRIAL OF FLUPENTHIXOL IN PATIENTS WITH CHRONIC SCHIZOPHRENIA: ESPECIALLY IN PATIENTS HAVING DIFFICULTY IN REHABILITATION OWING TO DECREASED EXPRESSION, APATHY AND DISTURBANCE OF RAPPORT.
202603 02-08
CLINICAL TRIAL OF CLOCAPRAMINE IN NEUROTIC PATIENTS WHO HAD TROUBLES IN EVERYDAY LIFE OWING TO SEVERE ANXIETY, IRRITABILITY AND DEPRESSION.
204464 02-10

OXAFLOZANE
PHARMACOLOGICAL PROFILE OF A NEW NONTRICYCLIC ANTIDEPRESSANT: OXAFLOZANE (1766-CERM).
199385 02-02
PRELIMINARY CLINICAL RESULTS OF A NEW NONTRICYCLIC ANTIDEPRESSANT: OXAFLOZANE (1766-CERM).
199386 02-07

OXAZEPAM
A CONTROLLED COMPARISON OF CHLORAZEPATE WITH OXAZEPAM IN NEUROTIC ANXIETY.
205638 03-10
INFLUENCE OF MEPROBAMATE, CARISPRODOL, OXAZEPAM AND PHENOBARBITAL ON NA+ TRANSPORT IN THE ISOLATED FROG SKIN.
206781 03-03
SUMMARY OF THE ANIMAL PHARMACOLOGY OF OXAZEPAM.
218150 04-17
PHARMACOKINETICS IN CLINICAL MEDICINE: OXAZEPAM VERSUS OTHER BENZODIAZEPINES.
218151 04-17
OXAZEPAM: AN OVERVIEW.
218152 04-17
THE USE OF OXAZEPAM IN ELDERLY PATIENTS.
218153 04-13
A CRITICAL REVIEW OF OXAZEPAM: EFFICACY AND SPECIFICITY.
218154 04-17
IS OXAZEPAM ASSOCIATED WITH HOSTILITY?
218156 04-14

OXAZOLAM
A COMPARISON OF A NEW TRANQUILIZER, SULPIRIDE AND OXAZOLAM ON PSYCHOSOMATIC DISEASES, NEUROSIS AND MASKED DEPRESSION USING DOUBLE-BLIND METHOD.
210180 03-11

OXIDASE
EFFECTS IN THE SUCKLING RAT OF CHRONIC TREATMENT WITH TRYPTOPHAN AND A MONOAMINE OXIDASE INHIBITOR.
195906 01-04
MECHANISM OF ANTIDEPRESSANT EFFICACY OF MONOAMINEOXIDASE INHIBITORS: INHIBITION OF MONOAMINE OXIDASE OR OF CATECHOLAMINE REUPTAKE.
195925 01-17
STUDIES ON MONOAMINEOXIDASE (REPORT XXIV) EFFECT OF HARMINE ON MONOAMINE OXIDASE.
202801 02-03
EFFECTS OF AMINOACETONITRILE, AN AMINE OXIDASE INHIBITOR, ON MESCALINE METABOLISM IN THE RABBIT.
205853 03-03
A COMPARISON OF THE INDUCTIVE EFFECTS OF PHENOBARBITAL, METHAQUALONE, AND METHYPRYLON ON HEPATIC MIXED FUNCTION OXIDASE ENZYMES IN THE RAT.
217794 04-03

OXIDATIVE
OXIDATIVE METABOLISM OF MESCALINE IN THE CENTRAL NERVOUS SYSTEM -- V. IN VITRO DEAMINATION OF MESCALINE TO 3,4,5 TRIMETHOXYBENZOIC ACID.
210813 03-03
EFFECT OF OUABAIN AND PHENOBARBITAL ON OXIDATIVE METABOLIC ACTIVITY ASSOCIATED WITH SPREADING CORTICAL DEPRESSION IN CATS.
220944 04-03

OXIDE
CHANGES IN THE DORSAL ROOT POTENTIAL WITH DIAZEPAM AND WITH THE ANALGESICS ASPIRIN, NITROUS OXIDE, MORPHINE AND MEPERIDINE.
195248 01-03
EFFECTS OF HALOTHANE AND NITROUS OXIDE ANESTHESIA ON 5-HT TURN-OVER IN THE RAT BRAIN.
217655 04-03

OXIDIZING
EFFECT OF PHENOBARBITAL ADMINISTRATION ON ETHANOL OXIDIZING ENZYMES AND ON RATES OF ETHANOL DEGRADATION.
204386 02-03

OXIME
COMPARISON OF THE OXIME AND THE HYDROXYLAMINE DERIVATIVES OF 4-CHLOROAMPHETAMINE AS DEPLETORS OF BRAIN 5-HYDROXYINDOLES.
200004 02-03

OXOTREMORINE
DEPRESSION BY AMANTADINE OF TREMOR INDUCED BY RESERPINE AND OXOTREMORINE IN THE RAT.
193282 01-04
ON THE ACTION OF OXOTREMORINE ON THE CHOLINERGIC SYSTEM OF THE RAT BRAIN.
197968 01-03
EFFECTS OF OXOTREMORINE AND PHYSOSTIGMINE ON THE TURNOVER OF DOPAMINE IN THE CORPUS-STRIATUM AND THE LIMBIC SYSTEM.
198207 02-03
ANTINOCICEPTIVE ACTION OF OXOTREMORINE AND REGIONAL TURNOVER OF RAT BRAIN NORADRENALINE, DOPAMINE AND 5-HT.
215683 04-03

OXYBUTYRATE
THE INFLUENCE OF SODIUM OXYBUTYRATE ON INTERNEURONAL TRANSMISSION OF EXCITATION AT VARIOUS LEVELS OF THE CENTRAL NERVOUS SYSTEM.
198435 02-03

OXYGEN
HEAT PRODUCTION AND OXYGEN CONSUMPTION OF THE ISOLATED RABBIT HEART UNDER THE INFLUENCE OF STROPHANTHIN VERAPAMIL, AND GLYCERYL TRINITRATE.
197567 01-03
REACTIVITY OF VARIOUS PHENOTHIAZINE DERIVATIVES WITH OXYGEN AND OXYGEN RADICALS.
210882 03-02

OXYMETAZOLINE
INFLUENCE OF OXYMETAZOLINE AND PHENTOLAMINE ON NORADRENALINE (NA) RELEASE CAUSED BY ELECTRICAL STIMULATION, POTASSIUM, TYRAMINE AND DIMETHYLPHENYLPIPERAZINE (DMPP).
197973 01-03

OXYPERTINE
A CONTROLLED COMPARISON OF OXYPERTINE AND PERPHENAZINE IN SCHIZOPHRENIC PSYCHOSES.
205582 02-08
OXYPERTINE IN THE TREATMENT OF MORBID ANXIETY. REPORT OF A NEW LOW DOSAGE SCHEDULE.
207532 03-10
CLINICAL APPLICATION OF OXYPERTINE -- ITS CHARACTERISTICS AS A STRONG TRANQUILIZER.
209394 03-08
A COMPARISON OF THE THERAPEUTIC EFFECT OF OXYPERTINE AND THIORIDAZINE IN CHRONIC SCHIZOPHRENIA (A CONTROLLED TRIAL).
215075 04-08
BIOCHEMICAL VERSUS PSYCHOPATHOLOGICAL ACTION PROFILE OF NEUROLEPTICS: A COMPARATIVE STUDY OF CHLORPROMAZINE AND OXYPERTINE IN ACUTE PSYCHOTIC DISORDERS.
215454 04-13
CLINICAL TRIAL OF OXYPERTINE IN THE TREATMENT OF PSYCHOSOMATIC DISORDERS, NEUROSIS AND DEPRESSION.
224193 04-14

OXYPROTHEPINE
EXPERIENCE WITH OXYPROTHEPINE IN THE TREATMENT OF MANIC SYNDROMES.
205580 02-09
OXYPROTHEPINE IN SCHIZOPHRENIA.
205581 02-08
LONG-ACTING NEUROLEPTICS OF PERATHIEPINE GROUP: VUFB-9977 (OXYPROTHEPINE DECANOATE).
205583 02-03

OZONE
THE EFFECT OF OZONE ON PENTOBARBITAL SLEEPING TIME IN MICE.
204862 02-02

P-ACETYLDEOXYEPHEDRINE
EFFECTS OF P-ACETYLDEOXYEPHEDRINE ON PUNISHED BEHAVIOR IN THE RAT.
197450 01-04

P-BROMOMETHYLAMPHETAMINE
INTERACTION BETWEEN MASSED ELECTROCONVULSIVE SHOCK AND P-BROMOMETHYLAMPHETAMINE (V-111) TREATMENT.
197579 01-03

P-CHLORO-N-METHYLAMPHETAMINE
D,L P-CHLORO-N-METHYLAMPHETAMINE (P) INDUCED ACCUMULATION OF 5-HT IN NONTERMINAL AXONS.
192944 01-03

P-CHLOROAMPHETAMINE
THE EFFECTS OF P-CHLOROAMPHETAMINE ON INSTRUMENTAL CONDITIONING IN THE RAT.
195088 01-04
THE SUBCELLULAR DISTRIBUTION OF INTRAVENTRICULARLY ADMINISTERED 3H-METARAMINOL IN INTACT AND RAT BRAIN PRETREATED WITH P-CHLOROAMPHETAMINE.
197289 01-03
LONG-TERM EFFECTS OF P-CHLOROAMPHETAMINE AND RELATED DRUGS ON CENTRAL SEROTONERGIC MECHANISMS.
208553 03-03
EFFECT OF P-CHLOROAMPHETAMINE ON CEREBRAL TRYPTOPHAN-5-HYDROXYLASE IN VIVO: A REEXAMINATION.
210826 03-03

AGGRESSION IN MICE AFTER P-CHLOROAMPHETAMINE.
210899 03-04
P-CHLOROAMPHETAMINE: SELECTIVE NEUROTOXIC ACTION IN BRAIN.
211494 03-05

P-CHLOROMETHAMPHETAMINE
ROLE OF MONOAMINES IN THE ANOREXIGENIC ACTIONS OF FENFLURAMINE, AMPHETAMINE AND P-CHLOROMETHAMPHETAMINE.
193546 01-04

P-CHLORONOREPHEDRINE
ACTION OF (S)- AND (R) P-SUBSTITUTED AMPHETAMINE HYDROCHLORIDES AND (ALPHA S)- AND (ALPHA R) P-CHLORONOREPHEDRINE AND (ALPHA S)- AND (ALPHA R) P-CHLORONORPSEUDOEPHEDRINE HYDROCHLORIDES ON THE LEVEL OF 5-HYDROXYTRYPTAMINE AND THE ACTIVITY OF TRYPTOPHAN-HYDROXYLASE IN RAT BRAIN.
202417 02-03

P-CHLORONORPSEUDOEPHEDRINE
ACTION OF (S)- AND (R) P-SUBSTITUTED AMPHETAMINE HYDROCHLORIDES AND (ALPHA S)- AND (ALPHA R) P-CHLORONOREPHEDRINE AND (ALPHA S)- AND (ALPHA R) P-CHLORONORPSEUDOEPHEDRINE HYDROCHLORIDES ON THE LEVEL OF 5-HYDROXYTRYPTAMINE AND THE ACTIVITY OF TRYPTOPHAN-HYDROXYLASE IN RAT BRAIN.
202417 02-03

P-CHLOROPHENYLALANINE
EFFECTS OF RESERPINE, 6-HYDROXYDOPAMINE, P-CHLOROPHENYLALANINE AND A COMBINATION OF THESE SUBSTANCES ON THE GROOMING BEHAVIOUR OF MICE.
197291 01-04
THE EFFECTS OF LSD, PSILOCYBIN, HARMALINE AND AMPHETAMINE ON THE BODY TEMPERATURE OF P-CHLOROPHENYLALANINE PRETREATED RATS.
197484 01-03
STIMULATION OF A SPECIFIC DRIVE (PREDATORY BEHAVIOR) BY P-CHLOROPHENYLALANINE (PCPA) IN THE RAT.
197952 01-04
REVERSAL OF THE RESERPINE ELECTROENCEPHALOGRAPHIC SYNCHRONIZATION IN THE RABBIT BY P-CHLOROPHENYLALANINE.
197994 01-03
EFFECTS OF 5-HYDROXYTRYPTOPHAN, IPRONIAZID AND P-CHLOROPHENYLALANINE ON LIDOCAINE SEIZURE THRESHOLD OF MICE.
199962 02-03
THE EFFECT OF LSD, PSILOCYBIN, HARMALINE AND AMPHETAMINE ON THE BODY TEMPERATURE OF P-CHLOROPHENYLALANINE PRETREATED RABBITS.
210920 03-05
STIMULATION OF ESTROGEN INDUCED COPULATORY BEHAVIOR IN CASTRATE MALE RATS WITH THE SEROTONIN BIOSYNTHESIS INHIBITOR P-CHLOROPHENYLALANINE.
221010 04-04

P-HYDROXYAMPHETAMINE
FORMATION OF P-HYDROXYNOREPHEDRINE IN BRAIN FOLLOWING INTRAVENTRICULAR ADMINISTRATION OF P-HYDROXYAMPHETAMINE.
202782 02-03
HYDROXYLATION OF AMPHETAMINE TO P-HYDROXYAMPHETAMINE BY RAT LIVER MICROSOMES.
205433 02-03

P-HYDROXYLATION
THE ROLE OF P-HYDROXYLATION OF AMPHETAMINE IN ITS PERIPHERAL MODE OF ACTION.
210749 03-03

P-HYDROXYNOREPHEDRINE
FURTHER STUDIES ON THE EFFECT OF P-HYDROXYNOREPHEDRINE (PONE) ON NOREPINEPHRINE METABOLISM IN THE RAT BRAIN.
193453 01-03
FORMATION OF P-HYDROXYNOREPHEDRINE IN BRAIN FOLLOWING INTRAVENTRICULAR ADMINISTRATION OF P-HYDROXYAMPHETAMINE.
202782 02-03

P-METHOXYAMPHETAMINE
EFFECTS OF P-METHOXYAMPHETAMINE (PMA) ON THE CARDIOVASCULAR SYSTEM OF THE DOG.
210867 03-05
COMPARISON OF CARDIOVASCULAR, HYPERTHERMIC, AND TOXIC EFFECTS OF P-METHOXYAMPHETAMINE (PMA) AND 3,4 METHYLENEDIOXYAMPHETAMINE (MDA).
217578 04-05
EFFECT OF AMPHETAMINE, 3,4 METHYLENEDIOXYAMPHETAMINE, P-METHOXYAMPHETAMINE AND RELATED AMPHETAMINES ON UPTAKE OF METARAMINOL AND EFFLUX OF NORADRENALINE IN ADRENERGIC NERVES OF RABBIT ATRIA.
217889 04-03

P-SUBSTITUTED
THE EFFECTS OF P-SUBSTITUTED AMPHETAMINES ON THE TRANSMITTER REGULATION IN RAT BRAIN.
197571 01-03
ACTION OF (S)- AND (R) P-SUBSTITUTED AMPHETAMINE HYDROCHLORIDES AND (ALPHA S)- AND (ALPHA R) P-CHLORONOREPHEDRINE AND (ALPHA S)- AND (ALPHA R) P-CHLORONORPSEUDOEPHEDRINE HYDROCHLORIDES ON THE LEVEL OF 5-HYDROXYTRYPTAMINE AND THE ACTIVITY OF TRYPTOPHAN-HYDROXYLASE IN RAT BRAIN.
202417 02-03

P-TRIFLUOROMETHYLPHENOXY
COMPARISON OF THE SPECIFICITY OF 3-(P-TRIFLUOROMETHYLPHENOXY)-N-METHYL-3 PHENYLPROPYLAMINE AND CHLORIMIPRAMINE AS AMINE UPTAKE INHIBITORS IN MICE.
197870 01-03

P-32
INCORPORATION OF ACETATE (C14)(P-32) AND PHOSPHATE INTO THE BRAIN LIPIDS DURING BLOCKAGE OF THE CHOLINORECEPTOR AND ADRENORECEPTORS.
202599 02-03

PABENOL
THE EFFECTS OF PABENOL COMPLEX ON CHILDREN WITH LEARNING PROBLEMS.
196704 01-07

PACE
THE PACE OF PROGRESS.
203213 02-08

PACEMAKER
THE EFFECTS OF (+) AMPHETAMINE ON THE CHRONOTROPIC RESPONSES OF THE ISOLATED GUINEA-PIG PACEMAKER TO NOREPINEPHRINE AND ISOPROTERENOL.
211066 03-03

PACEMAKERS
A DOUBLE-BLIND STUDY ON THE EFFECTS OF PIRACETAM UPON PERCEPTUAL AND PSYCHOMOTOR PERFORMANCE AT VARIED HEART RATES IN PATIENTS TREATED WITH ARTIFICIAL PACEMAKERS.
201328 02-13

PAIN
REGIONAL LEVELS OF GABA AND GLUTAMATE IN MOUSE BRAIN FOLLOWING EXPOSURE TO PAIN.
195097 01-03
DRUG TREATMENT OF CHRONIC INTRACTABLE PAIN IN PATIENTS REFERRED TO A PSYCHIATRY CLINIC.
196090 01-14
THE INFLUENCE OF ANALGESICS AND NEUROLEPTICS ON AFFECTIVE MANIFESTATIONS OF PAIN.
198480 02-04
EFFECTS OF ANALGETICS ON CENTRALLY INDUCED PAIN IN RATS. (PH.D. DISSERTATION).
222640 04-03
NEUROTRANSMITTER ALTERATIONS AND CHRONIC PAIN.
224800 04-13

PAINFUL
THE EFFECTS OF NUCLEOTIDES AND GABA IN LARGE DOSES ON THE RESPONSE TO A PAINFUL STIMULUS WITH RETARDATES.
210296 03-14

PALMITATE
MONTHLY INTERMITTENT CHEMOTHERAPY OF CHRONIC SCHIZOPHRENIC OUTPATIENTS WITH PIPOTHIAZINE PALMITATE.
204169 02-08
PIPOTHIAZINE PALMITATE: AN EVALUATION OF A NEW LONG-ACTING INTRAMUSCULAR ANTIPSYCHOTIC AGENT IN SEVERELY ILL SCHIZOPHRENIC PATIENTS.
216188 04-08
CLINICAL STUDY OF FIVE DEPOT NEUROLEPTICS, COMPARISON OF ACTIVITY PROFILES OF FLUPHENAZINE DECANOATE, FLUSPIRILENE, PENFLURIDOL, PERPHENAZINE ENANTHATE AND PIPOTHIAZINE PALMITATE.
221822 04-08

PAMELA
PAMELA -- A PARANOID SCHIZOPHRENIC.
197142 01-08

PAPAVERIN
PAPAVERIN IN THE TREATMENT OF GERIATRIC PATIENTS.
205606 03-11

PAPAVERINE
RELEASE OF NOREPINEPHRINE AND DOPAMINE-BETA-HYDROXYLASE BY NERVE STIMULATION: II. EFFECTS OF PAPAVERINE.
204485 02-03
MENTAL DECLINE IN THE ELDERLY: PHARMACOTHERAPY (ERGOT ALKALOIDS VERSUS PAPAVERINE).
218306 04-11

PAPILLARY
NEGATIVE INOTROPIC EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON THE ISOLATED RIGHT VENTRICULAR PAPILLARY MUSCLE OF THE CAT.
204400 02-05

PAPIO-PAPIO
BEHAVIOURAL AND ELECTROGRAPHIC EFFECTS OF L-5-HYDROXYTRYPTOPHAN AND D,L-PARA-CHLOROPHENYLALANINE ON EPILEPTIC SENEGALESE BABOON (PAPIO-PAPIO).
199764 02-03

PARADOXICAL
PARADOXICAL EFFECTS OF CAFFEINE.
211258 03-13

PARALLEL
A NEW BENZODIAZEPINE, SCREENED BY A PARALLEL DOUBLE-BLIND TEST.
212167 03-10

PARAMETERS
ESTIMATION OF PHARMACOKINETIC PARAMETERS OF LITHIUM FROM SALIVA AND URINE.
195446 01-13
THE EFFECT OF 6-HYDROXYDOPAMINE ADMINISTRATION TO NEONATAL RATS ON SOME ENDOCRINE AND BEHAVIORAL PARAMETERS.
197498 01-03
INTRACRANIAL SELF-STIMULATION IN RATS AS A FUNCTION OF VARIOUS STIMULUS PARAMETERS: V. INFLUENCE OF COCAINE ON MEDIAL FOREBRAIN BUNDLE STIMULATION WITH MONOPOLAR ELECTRODES.
198223 02-03
COMPARATIVE STUDY OF THE ELECTRONEUROPHYSIOLOGICAL PARAMETERS OF SLEEP INDUCED BY SEVERAL HYPNOTIC DRUGS.
205520 02-13
INFLUENCE OF NEUROLEPTIC SUBSTANCE ON NEUROPHYSIOLOGICAL PARAMETERS IN EXPERIMENTAL ANIMALS.
206998 03-06
THE EFFECT OF COCA-COLA, CAFFEINE, ANTIDEPRESSANTS AND CHLORPROMAZINE ON OBJECTIVE AND SUBJECTIVE SLEEP PARAMETERS.
210808 03-14
THE EFFECT OF ACTH AND DIAZEPAM, ADMINISTERED TO INFANT RATS ON THE BODY GROWTH CURVE AND SOME ENDOCRINE PARAMETERS MEASURED IN ADULT AGE.
215066 04-03

PARANOID
PAMELA -- A PARANOID SCHIZOPHRENIC.
197142 01-08
HEAD INJURY, HYPOPITUITARISM AND PARANOID PSYCHOSIS: CIRCUMCISION FOR THE SINGAPORE VIRUS.
200581 02-09
AMPHETAMINE TREATMENT OF PARANOID OBSESSIONS: CASE REPORT AND BIOCHEMICAL IMPLICATIONS.
210809 03-09
AMPHETAMINE PSYCHOSIS OR PARANOID SCHIZOPHRENIA?
216965 04-15
COMPARATIVE STUDY OF CLOTHIAPINE AND TRIFLUOPERAZINE IN EPISODES OF ACUTE PARANOID SCHIZOPHRENIA.
217025 04-08

PARASYMPATHETIC
THE EFFECT OF PGE1, PGE2 AND PGF2ALPHA ON PARASYMPATHETIC TRANSMISSION.
197941 01-03
INHIBITION OF SACRAL PARASYMPATHETIC PREGANGLIONIC NEURONS BY GABA, GLYCIN, 5-HYDROXYTRYPTAMINE AND NOREPINEPHRINE. (PH.D. DISSERTATION).
212524 03-03

PARATHYROID
EFFECT OF PROLONGED LITHIUM INGESTION ON GLUCAGON AND PARATHYROID HORMONE RESPONSES IN RATS.
197744 01-03

PARENT
TOLERANCE DEVELOPMENT WITH CHLORDIAZEPOXIDE IN RELATION TO THE PLASMA LEVELS OF THE PARENT COMPOUND AND ITS MAIN METABOLITES IN MICE.
210973 03-03

PARENTERAL
IATROGENIC DYSKINESIA: A UNIQUE REACTION TO PARENTERAL METHYLPHENIDATE.
193087 01-15
THE EFFECTS OF PARENTERAL ADMINISTRATION OF CATECHOLAMINES, SEROTONIN AND HISTAMINE ON BEHAVIOR AND LEVELS OF THESE AMINES IN THE BRAIN OF THE NEONATE CHICK.
197457 01-03
CLINICAL STUDY OF HALOPERIDOL. I. TECHNIQUES AND THEORY OF PARENTERAL THERAPY.
220156 04-08

PARENTS
CONDITIONED LEARNING IN YOUNG RATS BORN OF DRUG ADDICTED PARENTS AND RAISED ON ADDICTIVE DRUGS.
217465 04-04

PARGYLINE
INTERACTION OF CATECHOLAMINE AND AMINO ACID METABOLISM IN BRAIN: EFFECT OF PARGYLINE AND L-DOPA.
195048 01-03
THE BLOCKADE OF BULBOSPINAL INHIBITION BY IMIPRAMINE, DESIPRAMINE AND PARGYLINE.
195095 01-03
EFFECT OF DESIPRAMINE AND PARGYLINE ON BRAIN GAMMA-AMINOBUTYRIC ACID.
205851 03-03
COMPARISON OF THE INHIBITORY EFFECTS OF PROPARGYLAMINE AND PARGYLINE ON BRAIN AND LIVER MONOAMINEOXIDASE ACTIVITY.
207857 03-03

PARKINSON
EEG CHANGES BEFORE AND AFTER L-DOPA THERAPY IN PARKINSON PATIENTS.
205569 02-13
A COMPARISON OF CIRCLING MODELS FOR THE DETECTION OF PARKINSON ACTIVITY.
217547 04-04
QUANTITATIVE MEASUREMENT OF PARKINSON DISEASE RIGOR. MYOINTEGRATIVE DRUG TRIAL IN COMBINATION WITH THE DECARBOXYLASE INHIBITING DRUG RO-8-0576.
220829 04-11

PARKINSONIAN
PARKINSONIAN TYPE TREMOR AND THE ACTION OF HARMALINE: EXPERIMENTAL FACTS AND HYPOTHETICAL MECHANISMS.
212182 03-03

PARKINSONISM
THE EFFECT OF L-DOPA ON THE DEVELOPMENT OF RESERPINE INDUCED PARKINSONISM AND CATECHOLAMINE METABOLISM IN RATS.
198486 02-03
L-DOPA AND PARKINSONISM: A PSYCHOLOGICAL ASSESSMENT.
201496 02-11
A DOUBLE-BLIND STUDY OF AMANTADINE HYDROCHLORIDE VERSUS BENZTROPINE MESYLATE IN DRUG-INDUCED PARKINSONISM.
202764 02-15
PARKINSONISM: EFFECTS OF LEVODOPA TREATMENT ON CONCEPT FORMATION.
222871 04-14

PARKINSONS
SLEEP IN PATIENTS WITH PARKINSONS DISEASE AND ITS INFLUENCE BY L-DOPA.
195155 01-11
TREATMENT OF PARKINSONS DISEASE BY COMBINING L-DOPA WITH A DECARBOXYLASE INHIBITOR.
204372 02-07
EFFECT OF L-DOPA ON PITUITARY HORMONES AND ON CARBOHYDRATE AND FAT METABOLISM IN NORMALS AND IN PARKINSONS DISEASE.
207153 03-13
NEW PROSPECTS OF TREATMENT OF PARKINSONS DISEASE WITH PARKS-PLUS.
221885 04-11

PARKS-PLUS
NEW PROSPECTS OF TREATMENT OF PARKINSONS DISEASE WITH PARKS-PLUS.
221885 04-11

PAROXYSM
SLEEP - EEG TESTS OF NONSPECIFIC CASES OF PAROXYSM AND EPISODIC BEHAVIORAL DISTURBANCES: A PRELIMINARY REPORT.
203704 02-14

PARTIAL
PARTIAL RESTORATION BY AN A NEUROLEPTIC (SPIRAMIDE) OF ITEMS OF GROOMING BEHAVIOUR SUPPRESSED BY AMPHETAMINE.
213590 04-04
EFFECTS OF AMITRIPTYLINE ON HUMAN REM SLEEP AS EVALUATED BY USING PARTIAL DIFFERENTIAL REM SLEEP DEPRIVATION (PDRD).
214750 04-14
DOPAMINERGIC DRUGS ANTAGONIZED THE PSYCHOTOMIMETIC EFFECTS OF PARTIAL AGONIST ANALGESICS.
221048 04-04
THE PARTIAL PUNISHMENT EFFECT FOLLOWING MINIMAL ACQUISITION TRAINING: SODIUM AMOBARBITAL AND THE STIMULUS PROPERTIES OF EARLY PUNISHED TRIALS.
224504 04-04

PARTICIPATION
ON THE PARTICIPATION OF BIOGENIC AMINES AND THEIR SYNTHETIC ENZYMES IN THE MECHANISMS OF IMAGE MEMORY.
213469 04-04
THE PARTICIPATION OF CEREBRAL CHOLINERGIC MECHANISMS IN THE ACTION OF NEUROLEPTICS.
218471 04-04
THE PARTICIPATION OF SEROTONIN REACTIVE BRAIN STRUCTURES IN SOME FORMS OF BEHAVIORAL PATTERNS IN HAMSTERS.
218472 04-04

PARTICLES
UPTAKE OF NEUROTRANSMITTERS INTO SUBCELLULAR PARTICLES OF THE CAUDATE NUCLEUS.
197962 01-03

PARTICULATE
ACCUMULATION OF LITHIUM IN THE PARTICULATE FRACTION OF RAT BRAIN FOLLOWING ITS LONG-TERM ADMINISTRATION.
210782 03-03

PARTITION
CORRELATION OF PSYCHOTOMIMETIC ACTIVITY OF PHENETHYLAMINES AND AMPHETAMINES WITH 1-OCTANOL WATER PARTITION COEFFICIENTS.
208593 03-12

PASPALUM-SCROBICULATUM
TRANQUILLIZING ACTION OF A CRYSTALLINE FRACTION OF PASPALUM-SCROBICULATUM EXTRACT IN FOURTEEN PSYCHOTIC PATIENTS.
194711 01-08

PASSATIZATION
THE PASSATIZATION INDEX OF RETARDATES TREATED WITH HIGH DOSES OF GABA AND NUCLEOTIDES.
210288 03-11

PASSIVE
6-METHOXYTETRAHYDRO-BETA-CARBOLINE PRODUCES A RETENTION DEFICIT FOR ONE-TRIAL PASSIVE AVOIDANCE IN MICE.
217833 04-04

PATHOGENESIS
EEG VARIATIONS UNDER ANTABUSE (DISULFIRAM) AND ANTABUSE PLUS ALCOHOL EXPOSITION: A STUDY OF PATHOGENESIS FROM ANTABUSE THERAPY COMPLICATIONS.
200572 02-15
ON THE PATHOGENESIS OF DELIRIOUS STATES.
207196 03-15

PATHOLOGICAL
PSYCHOTROPIC AGENTS AND PATHOLOGICAL ECG CHANGES.
221336 04-15

PATHOLOGY
SOME CHARACTERISTICS OF PATHOLOGY IN SCHIZOPHRENIA DURING THE TWO STAGES OF PSYCHOPHARMACOLOGICAL DEVELOPMENT.
201908 02-08

PATHOPHYSIOLOGICAL
PATHOPHYSIOLOGICAL STUDIES OF MANIC-DEPRESSIVE PSYCHOSES: RELATIONSHIP BETWEEN ANXIETY AND EXCRETION OF URINARY CATECHOLAMINES.
212938 03-10

PATHOPHYSIOLOGY
THE ROLE OF SEROTONIN IN THE PATHOPHYSIOLOGY OF MYOCLONIC SEIZURES ASSOCIATED WITH ACUTE IMIPRAMINE TOXICITY.
200088 02-03
THE ROLE OF ADAPTIVE REGULATION IN THE PATHOPHYSIOLOGY OF PSYCHIATRIC DISEASE.
207307 03-03
A PHARMACOLOGICAL MODEL OF THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA.
218213 04-08

PATHWAY
ANTAGONISM OF DOPAMINE MEDIATED INHIBITION IN THE NIGROSTRIATAL PATHWAY: A MODE OF ACTION OF SOME CATATONIA INDUCING DRUGS.
210659 03-03
A HISTOCHEMICAL STUDY OF VENTRAL TEGMENTAL ACETYLCHOLINESTERASE CONTAINING PATHWAY FOLLOWING DESTRUCTIVE LESIONS.
210919 03-03

PATHWAYS
A PHARMACOLOGICAL AND NEUROANATOMICAL ANALYSIS OF DOPAMINERGIC AND NORADRENERGIC PATHWAYS INVOLVED IN SELF-STIMULATION IN RATS. (PH. D. DISSERTATION).
193582 01-04
DETAILED NORADRENALINE PATHWAYS OF LOCUS-COERULEUS NEURON TO THE CEREBRAL CORTEX WITH THE USE OF 5-HYDROXYDOPA.
210803 03-03
DOPAMINERGIC NEURONS IN THE NIGROSTRIATAL AND MESOLIMBIC PATHWAYS: MEDIATION OF SPECIFIC EFFECTS OF D-AMPHETAMINE.
210855 03-03
ASCENDING CATECHOLAMINE PATHWAYS AND AMPHETAMINE-INDUCED LOCOMOTOR ACTIVITY: IMPORTANCE OF DOPAMINE AND APPARENT NONINVOLVEMENT OF NOREPINEPHRINE.
223054 04-03

PATIENT
PATIENT PROFILES AND DIFFERENTIAL RESPONSE TO DRUGS.
198087 02-10
DEPRESSION, ELATION, AND LITHIUM CARBONATE RESPONSES IN MANIC PATIENT SUBGROUPS.
199631 02-09
EFFECTS OF 5-HYDROXYTRYPTOPHAN ON SLEEP OF A PATIENT WITH A BRAINSTEM LESION.
199757 02-13
TWO DECADES OF PSYCHOPHARMACOLOGY AND COMMUNITY MENTAL HEALTH: OLD AND NEW PROBLEMS OF THE SCHIZOPHRENIC PATIENT.
207921 03-17
PSYCHOPHARMACOLOGY, COMMUNITY MENTAL HEALTH AND THE SCHIZOPHRENIC PATIENT.
207922 03-17
DOSAGE OF A PSYCHOTROPIC DRUG TO PREVENT RELAPSE IN A CURED SCHIZOPHRENIC PATIENT.
209402 03-08
NONPHARMACOLOGICAL FACTORS IN DRUG THERAPY: THE INTERACTION OF DOCTOR, PATIENT, AND TABLET APPEARANCE IN THE TREATMENT OF ANXIETY/DEPRESSIVE SYNDROMES.
215060 04-10
AVERAGE EVOKED RESPONSES (AER) AND HOMOVANILLIC ACID (HVA) IN CEREBROSPINAL FLUID (CSF) IN A PSYCHOTIC PATIENT WITH ADDISONS DISEASE.
221310 04-09
URINARY EXCRETION OF THE SULPHATE AND GLUCURONIDE OF 3-METHOXY-4-HYDROXYPHENYLETHYLENEGLYCOL IN A MANIC-DEPRESSIVE PATIENT.
224424 04-09

PATIENTS
PSYCHOACTIVE DRUG USE IN ELDERLY PATIENTS WITH PSYCHIATRIC DISORDERS: A SURVEY OF 12 VETERANS ADMINISTRATION HOSPITALS.
193291 01-11
EFFECT OF CHRONIC ADMINISTRATION OF CENTRALLY ACTING COMPOUNDS ON CHLORAMPHENICOL METABOLISM IN SCHIZOPHRENIC PATIENTS.
194157 01-08
EXAMINATION OF THE EFFECTS OF CLOXAZOLAM BY A DOUBLE-BLIND STUDY OF MENTAL PATIENTS BEFORE REHABILITATION.
194474 01-08
DOPAMINERGIC MECHANISMS IN PATIENTS WITH EXTRAPYRAMIDAL DISEASE. (UNPUBLISHED PAPER).
194542 01-13
TREATMENT OF ANXIOUS PATIENTS WITH NEALBARBITONE -- (CENSEDAL).
194556 01-10
TRANQUILLIZING ACTION OF A CRYSTALLINE FRACTION OF PASPALUM-SCROBICULATUM EXTRACT IN FOURTEEN PSYCHOTIC PATIENTS.
194711 01-08
THE EEG EFFECTS OF ZINC IN GERIATRIC PSYCHIATRIC PATIENTS.
195039 01-13
SLEEP IN PATIENTS WITH PARKINSONS DISEASE AND ITS INFLUENCE BY L-DOPA.
195155 01-11
PREDICTING TREATMENT RESPONSIVENESS RESISTIVENESS IN A POPULATION OF DEPRESSED PATIENTS.
196040 01-17
THE EFFECT OF LITHIUM ON URINARY MHPG IN UNIPOLAR AND BIPOLAR DEPRESSED PATIENTS. (UNPUBLISHED PAPER).
196042 01-09
TIME-DEPENDENT EFFECTS OF PHENOTHIAZINES ON DOPAMINE TURNOVER IN PSYCHIATRIC PATIENTS. (UNPUBLISHED PAPER).
196087 01-13
DRUG TREATMENT OF CHRONIC INTRACTABLE PAIN IN PATIENTS REFERRED TO A PSYCHIATRY CLINIC.
196090 01-14
PENFLURIDOL (R-16341) AS A MAINTENANCE THERAPY IN CHRONIC PSYCHOTIC PATIENTS: A DOUBLE-BLIND CLINICAL EVALUATION.
197033 01-09
ADVERSE REACTIONS TO CHLORPROMAZINE IN PSYCHIATRIC PATIENTS.
197923 01-01
RESPONSES OF DYSPHORIC PATIENTS TO PHARMACOTHERAPIES.
198074 01-11
ANXIOUS DENTAL PATIENTS AS MODELS OF PSYCHOPATHOLOGY.
198089 02-11
EEG CHANGES WITH LITHIUM IN DEPRESSED PATIENTS.
198100 02-10
CLINICAL EXPERIENCE WITH CLOCAPRAMINE (CLOFEKTON) FOR THE TREATMENT OF SCHIZOPHRENIC PATIENTS.
198709 02-08
DRUG AND SOCIOTHERAPY IN THE AFTERCARE OF SCHIZOPHRENIC PATIENTS: II. TWO-YEAR RELAPSE RATES.
199625 02-08
DRUG AND SOCIOTHERAPY IN THE AFTERCARE OF SCHIZOPHRENIC PATIENTS: III. ADJUSTMENT OF NONRELAPSED PATIENTS.
199626 02-08
INHIBITION OF DOPAMINE-BETA-HYDROXYLASE IN MANIC PATIENTS: A CLINICAL TRIAL WITH FUSARIC ACID.
199632 02-07
LONG-TERM TREATMENT OF PSYCHIATRIC PATIENTS WITH CLOPENTHIXOL: ANALYSIS OF LABORATORY TESTS WITH A VIEW TO LONG-TERM THERAPY.
199989 02-14
THE INFLUENCE OF RESERPINE ON THE SEROTONIN METABOLISM IN PATIENTS WITH SCHIZOPHRENIA AND REACTIVE CONDITIONS.
200013 02-08
A DIFFERENTIATED USE OF ELENIUM AND SEDUXEN IN YOUNG PATIENTS IN THE POST-INFARCTIONAL PERIOD.
200104 02-11
PRELIMINARY RESULTS OF A CONTROLLED TRIAL WITH SULPIRIDE VERSUS CHLORIMIPRAMINE IN CHRONIC SCHIZOPHRENIC PATIENTS WITH MARKED IDEO-EMOTIONAL POVERTY.
200445 02-08
THE EFFECTS OF LITHIUM CARBONATE ON SERUM GASTRIN IN PSYCHIATRIC PATIENTS.
200637 02-04
PLASMA TRYPTOPHAN TOLERANCE CURVES IN DRUG-FREE NORMAL CONTROLS, SCHIZOPHRENIC PATIENTS AND PRISONER VOLUNTEERS.
200773 02-13
A DOUBLE-BLIND STUDY ON THE EFFECTS OF PIRACETAM UPON PERCEPTUAL AND PSYCHOMOTOR PERFORMANCE AT VARIED HEART RATES IN PATIENTS TREATED WITH ARTIFICIAL PACEMAKERS.
201328 02-13

BROMAZEPAM IN TREATING DYSTHYMIC ELDERLY PATIENTS.
201690 02-11

COMPARATIVE RESULTS OF A PHARMACOLOGICAL LOADING WITH AMINAZINE AND HALOPERIDOL IN SCHIZOPHRENIC PATIENTS.
201910 02-08

POSSIBILITIES AND LIMITATIONS OF PSYCHOTROPIC THERAPY IN PATIENTS WITH GLAUCOMA.
201911 02-15

CLINICAL STUDY OF GERDAXYL 10MG WITH 40 PATIENTS TREATED IN A PSYCHIATRIC OUTPATIENT FACILITY.
202037 02-11

TREATMENT AND COUNTERMEASURES FOR PATIENTS WITH INSOMNIA IN THE DEPARTMENT OF INTERNAL MEDICINE -- SPECIAL EMPHASIS ON THE CLINICAL APPLICATION OF FLURAZEPAM.
202285 02-14

CLINICAL TRIAL OF FLUPENTHIXOL IN PATIENTS WITH CHRONIC SCHIZOPHRENIA: ESPECIALLY IN PATIENTS HAVING DIFFICULTY IN REHABILITATION OWING TO DECREASED EXPRESSION, APATHY AND DISTURBANCE OF RAPPORT.
202603 02-08

RED BLOOD CELL LITHIUM INDEX IN PATIENTS WITH AFFECTIVE DISORDERS IN THE COURSE OF LITHIUM PROPHYLAXIS.
202786 02-09

PIPERACETAZINE STUDY IN STATE HOSPITAL PATIENTS.
203423 02-11

STUDIES ON ANTIDIURETIC ACTIVITIES AND ON PORTER-SILBERS CHROMOGENS CONTENT IN PLASMA OF PATIENTS WITH ALCOHOLIC DELIRIUM OR WITH ACUTE PHENOTHIAZINE INTOXICATIONS.
203741 02-15

EXPERIMENTAL PSYCHOLOGIC AND PSYCHOPHYSIOLOGIC LONGITUDINAL PROFILE STUDIES ON DEPRESSIVE PATIENTS UNDER THYMOLEPTIC MEDICATION.
204413 02-15

CLINICAL TRIAL OF CLOCAPRAMINE IN NEUROTIC PATIENTS WHO HAD TROUBLES IN EVERYDAY LIFE OWING TO SEVERE ANXIETY, IRRITABILITY AND DEPRESSION.
204464 02-10

THE EFFECTS OF CARBAMAZEPINE ON PATIENTS WITH PSYCHOMOTOR EPILEPSY: RESULTS OF A DOUBLE-BLIND STUDY.
205031 02-11

ELIMINATION OF LITHIUM DEPENDENT ON AGE IN HEALTHY PEOPLE AND PATIENTS SUFFERING FROM RENAL INSUFFICIENCY.
205043 02-13

RESPONSE OF DEPRESSED PATIENTS TO METHYLAMPHETAMINE.
205318 02-09

EEG STATISTICAL SPECTRAL ANALYSIS OF SCHIZOPHRENIC PATIENTS.
205448 02-08

STUDY ON AMITRIPTYLINE-INDUCED SLEEP IN EPILEPTIC PATIENTS.
205470 02-13

EEG CHANGES BEFORE AND AFTER L-DOPA THERAPY IN PARKINSON PATIENTS.
205569 02-13

PILOT CLINICAL STUDY WITH TRIFLUPERIDOL (TRISEDYL) THERAPY IN PSYCHOTIC PATIENTS.
205589 02-09

CONFUSIONAL STATES IN ELDERLY MENTAL PATIENTS TREATED WITH ANTIDEPRESSANTS.
205603 03-15

PAPAVERIN IN THE TREATMENT OF GERIATRIC PATIENTS.
205606 03-11

THE LEVELS OF LITHIUM IN SERUM AND IN RED BLOOD CELLS AND ITS RATIOS IN MANIC-DEPRESSIVE PATIENTS.
205607 03-09

FAMILY HISTORY OF MANIC-DEPRESSIVE AND ENDOGENOUS DEPRESSIVE PATIENTS AND CLINICAL EFFECT OF TREATMENT WITH LITHIUM.
205608 03-09

LITHIUM TREATMENT OF BEHAVIOURAL DISTURBANCES IN PATIENTS WITH DEFECTIVE INTELLECT.
205610 03-09

MG++ DEPENDENT ADENOSINE-TRIPHOSPHATASE ACTIVITY IN ERYTHROCYTE GHOSTS OF SCHIZOPHRENIC PATIENTS.
206332 03-08

LONGITUDINAL STUDY OF THE EFFECTS OF LITHIUM CARBONATE ON THE SLEEP OF HOSPITALIZED DEPRESSED PATIENTS.
206333 03-09

THE RELATIONSHIP BETWEEN RESPONSE TO PHENELZINE AND ACETYLATOR STATUS IN DEPRESSED PATIENTS.
206366 03-09

CEREBRAL AND PERIPHERAL CONSUMPTION OF L-5-HTP BY PATIENTS SUFFERING FROM MANIACAL, DEPRESSIVE OR PSYCHOTIC SYMPTOMS.
206834 03-10

CLINICAL STUDY ON SULPIRIDE IN LONG-TERM HOSPITALIZED SCHIZOPHRENIC PATIENTS.
206978 03-08

RENAL TUBULAR FUNCTION IN PATIENTS ON LONG-TERM LITHIUM THERAPY.
207043 03-13

MASS FRAGMENTOMETRIC DETERMINATION OF HOMOVANILLIC ACID IN LUMBAR CEREBROSPINAL FLUID OF SCHIZOPHRENIC PATIENTS DURING TREATMENT WITH ANTIPSYCHOTIC DRUGS.
207295 03-08

ANTIDEPRESSANT RESPONSE TO TRICYCLICS AND URINARY MHPG IN UNIPOLAR PATIENTS: CLINICAL RESPONSE TO IMIPRAMINE OR AMITRIPTYLINE.
207443 03-13

PSYCHOPHARMACOLOGIC MANAGEMENT OF PATIENTS: A METHOD FOR RECORDING TREATMENT DECISIONS.
207683 03-17

PSYCHOPHARMACOLOGY IN THE AGED: USE OF PSYCHOTROPIC DRUGS IN GERIATRIC PATIENTS.
208571 03-11

FROM HOSPITAL TREATMENT TO COMMUNITY PSYCHIATRY -- SECOND REPORT -- OUTPATIENT EMERGENCY TREATMENT OF MENTAL PATIENTS WITH THE USE OF HALOPERIDOL.
208723 03-11

VARIATIONS IN THE AUTONOMIC NERVOUS SYSTEM AFTER ADMINISTRATION OF DIHYDROERGOTAMINE IN PSYCHOSOMATIC PATIENTS.
209045 03-11

SEDATIVE EFFECTS ON PHYSIOLOGICAL AND PSYCHOLOGICAL MEASURES IN ANXIOUS PATIENTS.
209079 03-10

CLINICAL EXPERIENCES IN TREATING DEPRESSED PATIENTS WITH A COMBINATION OF TRICYCLIC DRUGS AND THYROID EXTRACT.
209144 03-09

CLINICAL ELECTROENCEPHALOGRAPHIC DATA IN DEPRESSED PATIENTS TREATED WITH ANAFRANIL.
209148 03-09

PHYSIOLOGICAL MANAGEMENT OF HOSPITALIZED PSYCHIATRIC PATIENTS.
209399 03-11

CAMAZEPAM VERSUS DIAZEPAM: A DOUBLE-BLIND TRIAL ON PSYCHONEUROTIC PATIENTS.
209487 03-10

THE USE OF CLOMIPRAMINE IN PHOBIC PATIENTS; PRELIMINARY RESEARCH REPORT.
209488 03-10

SULPIRIDE VERSUS CHLORPROMAZINE AND PLACEBO IN THE TREATMENT OF RESTLESS MENTALLY SUBNORMAL PATIENTS -- A DOUBLE-BLIND CROSSOVER STUDY.
209702 03-11

CLINICAL EXPERIMENTS WITH BROMAZEPAM ON PSYCHONEUROTIC AND PSYCHOSOMATIC PATIENTS WITH PSYCHOTHERAPY.
209795 03-10

LITHIUM GLUCONATE: SYSTEMATIC AND FACTORIAL ANALYSIS OF 104 OBSERVATIONS OVER 2.5-3 YEARS IN PATIENTS PRESENTING CYCLOTHYMIC OR DYSTHYMIC DISORDERS.
210126 03-09

EXPERIMENTATION WITH THE INTRAVENOUS FORM OF AMITRIPTYLINE WITH 40 PATIENTS.
210128 03-09

THREE CASES OF ANEJACULATION IN PATIENTS TREATED WITH CLOMIPRAMINE.
210136 03-15

DRUG-RESISTANCE AND BIOCLINICAL FACTORS IN THE RESPONSE OF SCHIZOPHRENIC PATIENTS TO CHLORPROMAZINE.
210500 03-08

CLINICAL BIOLOGICAL CORRELATIONS IN SCHIZOAFFECTIVE PATIENTS TREATED WITH LITHIUM CARBONATE AND HALOPERIDOL.
210501 03-09

EXPERIENCES OF A GENERAL PRACTITIONER AMONG PSYCHIATRIC PATIENTS.
211012 03-15

USE OF A NEW PSYCHOTROPIC DRUG, CLOFLUPEROL FOR THE TREATMENT OF CHRONIC SCHIZOPHRENIC PATIENTS.
211304 03-08

CLOMIPRAMINE IN THE TREATMENT OF THE TRUE OBSESSIONAL STATE: A REPORT ON FOUR PATIENTS.
211433 03-10

PRELIMINARY STUDY OF A BETA-BLOCKER (PINDOLOL) IN THREE SCHIZOPHRENICS AND THREE NONPSYCHOTIC PSYCHIATRIC PATIENTS: DIFFERENTIAL SENSITIVITY IN HEART RATE.
212164 03-13

A COMPARATIVE STUDY OF N-7001 (METRISIL) AND IMIPRAMINE ON A SERIES OF DEPRESSIVE PATIENTS.
212241 03-11

CLINICAL STUDY OF AN NEW ANTIDEPRESSANT, MELITRACEN, FOR 50 AMBULATORY PATIENTS.
212490 03-10

CLINICAL STUDY AND FOLLOWUP OF 40 PSYCHOTIC PATIENTS ON PERPHENAZINE ENANTHATE.
212495 03-14

CLINICAL EXPERIENCE OF FLUPHENAZINE ENANTHATE IN TREATMENT OF SCHIZOPHRENIC PATIENTS.
213294 03-08

EVALUATION OF BENAPRYZINE IN PSYCHOTIC PATIENTS TREATED WITH PHENOTHIAZINES.
213387 04-07

INFLUENCE OF RESERPINE ON ALL-NIGHT SLEEP PATTERN IN NONLOBOTOMIZED AND LOBOTOMIZED CHRONIC SCHIZOPHRENIC PATIENTS.
213530 04-08

EXTRAPYRAMIDAL REACTIONS AND AMINE METABOLITES IN CEREBROSPINAL FLUID DURING HALOPERIDOL AND CLOZAPINE TREATMENT OF SCHIZOPHRENIC PATIENTS.
214010 04-15

CHANGES IN OBSESSIVE/COMPULSIVE PATIENTS AS MEASURED BY THE LEYTON INVENTORY BEFORE AND AFTER TREATMENT WITH CLOMIPRAMINE.
214833 04-10

GROWTH HORMONE AND PROLACTIN RELEASE AFTER INJECTION OF THYROTROPIN-RELEASING HORMONE IN PATIENTS WITH DEPRESSION.
214885 04-13

THE USE OF PSYCHOACTIVE DRUGS IN ELDERLY PATIENTS WITH PSYCHIATRIC DISORDERS: SURVEY CONDUCTED IN TWELVE VETERANS ADMINISTRATION HOSPITALS.
215009 04-11

ENCEPHABOL IN PATIENTS WITH ORGANIC-BRAIN-SYNDROME.
215073 04-07

EFFECTS OF LITHIUM ON ELECTROMYOGRAPHIC RECORDINGS IN MAN: STUDIES IN MANIC-DEPRESSIVE PATIENTS AND NORMAL VOLUNTEERS.
215697 04-13

THE OUTCOME OF DOTHIEPIN TREATMENT IN 1,900 DEPRESSED PATIENTS.
215700 04-09

PIPOTHIAZINE PALMITATE: AN EVALUATION OF A NEW LONG-ACTING INTRAMUSCULAR ANTIPSYCHOTIC AGENT IN SEVERELY ILL SCHIZOPHRENIC PATIENTS.
216188 04-08

FREE THYROXINE INDEX AND ABSOLUTE FREE THYROXINE IN PATIENTS WITH AFFECTIVE DISORDERS TREATED WITH LITHIUM CARBONATE.
216747 04-09

N-DESMETHYLDIAZEPAM AND AMYLOBARBITONE SODIUM AS HYPNOTICS IN ANXIOUS PATIENTS. PLASMA LEVELS, CLINICAL EFFICACY AND RESIDUAL EFFECTS.
217460 04-10

LOXAPINE IN NEWLY ADMITTED CHRONIC SCHIZOPHRENIC PATIENTS.
217810 04-08

STATUS OF LITHIUM PATIENTS AS BLOOD DONORS.
217969 04-15

MANAGING DISTURBED GERIATRIC PATIENTS WITH CHEMOTHERAPY.
218010 04-11

THE USE OF OXAZEPAM IN ELDERLY PATIENTS.
218153 04-13

WITHDRAWN, APATHETIC GERIATRIC PATIENTS RESPONSIVE TO METHYLPHENIDATE.
218216 04-11

EXPERIENCE WITH 20 PATIENTS TREATED WITH LITHIUM CARBONATE.
218682 04-09

A MULTICENTRIC EVALUATION OF PIMOZIDE (ORAP) IN PATIENTS WHO USUALLY WOULD TAKE TRANQUILIZERS.
218750 04-10

INTERACTION OF DRUG THERAPY WITH MARITAL THERAPY IN DEPRESSIVE PATIENTS.
218769 04-10

WHY DO PATIENTS WITH MANIC-DEPRESSIVE ILLNESS STOP THEIR LITHIUM?
219365 04-09

AN ASPECT OF BIOLOGICAL THERAPY IN THE SYSTEM OF REHABILITATING EPILEPTIC PATIENTS WITH MENTAL DISORDERS.
220420 04-11

PSYCHOPHARMACOLOGICAL PRINCIPLES OF REHABILITATING MENTAL PATIENTS.
220425 04-08

PREVENTIVE USE OF LITHIUM IN ELDERLY PATIENTS.
220434 04-09

THE EFFECT OF LITHIUM ON URINARY MHPG IN UNIPOLAR AND BIPOLAR DEPRESSED PATIENTS.
221045 04-09

ELECTROENCEPHALOGRAPHIC STUDY FOR THE EVALUATION OF THE EFFECTS OF 7-CHLORO-5-PHENYLBENZODIAZEPIN-2-ONE (N-DEMETHYLDIAZEPAM) ON SLEEP DISTURBANCES IN A GROUP OF MENTAL PATIENTS.
221272 04-14

AMITRIPTYLINE TREATMENT OF PATIENTS WITH MIGRAINE.
221561 04-11

A COMPARISON BETWEEN DIAZEPAM AND HALOPERIDOL IN NEUROTIC ANXIETY AND TENSION STATES IN PATIENTS IN A OPEN WARD.
221638 04-10

A CONTROLLED CLINICAL EXPERIMENT WITH BURONIL AND HALOPERIDOL IN DISORIENTATION AMONG ELDERLY PATIENTS.
221639 04-11

A CLINICAL TRIAL OF MAPROTILINE (LUDIOMIL) IN THE TREATMENT OF DEPRESSIVE PATIENTS IN GENERAL PRACTICE AND THE PSYCHIATRIC CLINIC.
221657 04-09

LITHIUM RESPONSIVE HYPERALDOSTERONISM IN MANIC PATIENTS.
221718 04-09

DOPAMINE SENSITIVE ADENYLCYCLASE IN HUMAN CAUDATE NUCLEUS: A STUDY IN CONTROL SUBJECTS AND SCHIZOPHRENIC PATIENTS.
221732 04-13

RESULTS OF A COMPARATIVE DOUBLE-BLIND STUDY WITH CLOZAPINE AND CHLORPROMAZINE IN THE TREATMENT OF SCHIZOPHRENIC PATIENTS.
221989 04-08

ATROPINE COMA TREATMENT OF SCHIZOPHRENIC PATIENTS WITH A SLUGGISH DEVELOPMENT AND OBSESSIVE SYNDROMES.
224085 04-08

TREATING PATIENTS WITH A SLUGGISH FORM OF SCHIZOPHRENIA.
224383 04-08

SIGNIFICANCE OF PLASMA CHLORPROMAZINE IN MANAGEMENT OF PSYCHIATRIC PATIENTS.
224832 04-13

A FOLLOWUP OF TOURETTES SYNDROME IN SEVENTY-SEVEN PATIENTS.
224910 04-11

A COMPARISON OF PHENOTHIAZINES IN MANAGING AGGRESSIVE EPISODES IN SCHIZOPHRENIC PATIENTS.
224955 04-08

PATTERN

PATTERN ANALYSIS OF PSYCHIATRIC RESEARCH DATA.
195940 01-11

A PATTERN OF ANTIDEPRESSIVE EFFECT OF TRYPTOPHAN & IMIPRAMINE IN MALES & FEMALES.
196680 01-09

EFFECTS OF DIAZEPAM ON DISCHARGE PATTERN IN SINGLE FIBRES OF PHRENIC NERVE.
197577 01-03

DIETHYLDITHIOCARBAMATE (ANTABUSE): DECREASE OF BRAIN HEAVY METAL STAINING PATTERN AND IMPROVED CONSOLIDATION OF SHUTTLEBOX AVOIDANCE IN GOLDFISH.
203521 02-04

LONGITUDINAL STUDIES ON THE METABOLITE PATTERN OF PERAZINE AND RELATED PHENOTHIAZINES IN HUMANS AND ANIMALS.
206976 03-13

EFFECTS OF A DECARBOXYLASE INHIBITOR ON THE DOPA AND 5-HTP INDUCED CHANGES IN THE LOCOMOTOR LIKE DISCHARGE PATTERN OF RABBIT HIND LIMB NERVES.
210740 03-03

INFLUENCE OF RESERPINE ON ALL-NIGHT SLEEP PATTERN IN NONLOBOTOMIZED AND LOBOTOMIZED CHRONIC SCHIZOPHRENIC PATIENTS.
213530 04-08

POLYGRAPHIC NIGHT SLEEP PATTERN DURING CHRONIC SINGLE AND MULTIPLE NEUROLEPTIC DOSE ADMINISTRATION.
215701 04-08

DIFFERENTIAL NEUROCHEMISTRY AND TEMPORAL PATTERN IN RATS TREATED ORALLY WITH DELTA9-TETRAHYDROCANNABINOL FOR PERIODS UP TO SIX MONTHS.
217519 04-04

PATTERNS

NEONATAL BEHAVIORAL PATTERNS AND THEIR RELATION TO OBSTETRICAL MEDICATION. (PH.D. DISSERTATION).
194573 01-15

AFFECTIVE DISEASE HEALTH MAINTENANCE ORGANIZATION: PATTERNS OF LITHIUM RESPONSE.
194746 01-09

PSYCHOTHERAPEUTIC DRUGS: STUDIES OF USAGE PATTERNS AND STUDIES OF PRESCRIBING PRACTICES.
198048 01-17

PATTERNS OF CHLORPROMAZINE USE IN GENERAL AND PSYCHIATRIC HOSPITALS.
198050 01-17

DRUG USE PATTERNS AMONG THE ELDERLY.
198051 01-17

PATTERNS OF PSYCHOTROPIC DRUG USE FOR SCHIZOPHRENIA.
198052 01-08

PATTERNS OF DRUG ACQUISITION AND USE.
198105 02-17

PHARMACOLOGICAL MODULATION OF PHOTICALLY EVOKED AFTERDISCHARGE PATTERNS IN HOODED LONG-EVANS RATS.
201409 02-03

EFFECTS OF 2-DEOXY-D-GLUCOSE ON SLEEP-WAKING PATTERNS.
206253 03-04

PATTERNS OF SYMPTOM CHANGE IN ANXIOUS DEPRESSED OUTPATIENTS TREATED WITH DIFFERENT DRUGS.
209904 03-10

AMPHETAMINE STEREOTYPY: THE INFLUENCE OF ENVIRONMENTAL FACTORS AND PREPOTENT BEHAVIORAL PATTERNS ON ITS TOPOGRAPHY AND DEVELOPMENT.
213531 04-04

EFFECTS OF HIGH DOSAGE DELTA9-TETRAHYDROCANNABINOL ON SLEEP PATTERNS IN MAN.
215740 04-14

EFFECTS OF MARIHUANA (DELTA9-THC) ON BEHAVIOR PATTERNS AND SOCIAL ROLES IN COLONIES OF CBA MICE.
216494 04-04

THE PARTICIPATION OF SEROTONIN REACTIVE BRAIN STRUCTURES IN SOME FORMS OF BEHAVIORAL PATTERNS IN HAMSTERS.
218472 04-04

EEG SLEEP PATTERNS AND DRUG ABUSE.
224719 04-15

PEER REVIEW OF PRESCRIBING PATTERNS IN A CMHC.
224742 04-17

PAULINGS

COMMENT ON LINUS PAULINGS THEORY OF ORTHOMOLECULAR PSYCHIATRY.
213704 04-08

COMMENT ON LINUS PAULINGS THEORY OF ORTHOMOLECULAR PSYCHIATRY.
213705 04-13

COMMENT ON LINUS PAULINGS THEORY OF ORTHOMOLECULAR PSYCHIATRY.
213706 04-15

PAVED

THE ROAD TO SHANGRI-LA IS PAVED WITH VITAMIN AND PSYCHOTHERAPEUTIC FADDISM.
209010 03-17

PAVLOVIAN

EFFECTS OF PREVIOUS CURARE IMMOBILIZATION ON PAVLOVIAN CONDITIONED HEART DECELERATIONS IN THE CURARIZED RAT.
219083 04-04

PBT

PROFILE-BASED-THERAPY (PBT) IN SCHIZOPHRENIAS: A PRECLINICAL INDICATION FOR THE USE OF DIHYDROXYPHENYLSERINE (DOPS).
195115 01-08

PCPA

STIMULATION OF A SPECIFIC DRIVE (PREDATORY BEHAVIOR) BY P-CHLOROPHENYLALANINE (PCPA) IN THE RAT.
197952 01-04

PD-50S

PHENOTHIAZINE TRANQUILIZER PD-50S EXERTED AGAINST AMPHETAMINE EFFECT IN AGGREGATED MICE.
193422 01-03

PDRD

EFFECTS OF AMITRIPTYLINE ON HUMAN REM SLEEP AS EVALUATED BY USING PARTIAL DIFFERENTIAL REM SLEEP DEPRIVATION (PDRD).
214750 04-14

PEAK

THE EFFECTS OF D-AMPHETAMINE MONOPHOSPHATE ON THE PEAK SHIFT. (PH.D. DISSERTATION).
213153 03-04

PEAKS

SCHIZOPHRENIA AND EVOKED POTENTIALS: MAXIMUM AMPLITUDE, FREQUENCY OF PEAKS, VARIABILITY, AND PHENOTHIAZINE EFFECTS.
213764 04-08

PECULIARITIES

SOME PECULIARITIES OF THE NEURON ULTRASTRUCTURE IN THE BRAIN-CORTEX MOTOR AREA UNDER THE INFLUENCE OF LYSERGIC ACID DIETHYLAMIDE (LSD) AND HALOPERIDOL.
222890 04-03

PEDIATRIC

OUTPATIENT PEDIATRIC PSYCHOPHARMACOLOGY.
198063 01-07

PEDIATRIC PSYCHOPHARMACOLOGY.
198091 02-11

PEDIATRICIANS

THE PRESENT CONDITIONS OF PSYCHOPHARMACOLOGICAL TREATMENT FOR CHILDREN IN JAPAN: OPINIONS FROM THIRTY-SEVEN WELL-KNOWN CHILD NEUROPSYCHIATRISTS AND NEUROPSYCHIATRIC PEDIATRICIANS.
202500 02-17

PEDOPSYCHIATRY

THE USE OF PIMOZIDE IN PEDOPSYCHIATRY.
212494 03-11

PEER

PEER REVIEW OF PRESCRIBING PATTERNS IN A CMHC.
224742 04-17

PELLETIZED

PLASMA LEVELS OF A NEW PELLETIZED FORM OF AMITRIPTYLINE FOR MAINTENANCE THERAPY.
209789 03-13

PEMOLINE

PEMOLINE (CYLERT) IN THE TREATMENT OF CHILDHOOD HYPERKINESIS.
202824 02-11

PEMOLINE-MG

PHARMACOLOGICAL AND TOXICOLOGICAL STUDY OF A NEW PSYCHOTROPIC STIMULANT: THE 2-PHENYLDIMETHYL-TETRAHYDROOXAZINE, IN COMPARISON WITH D,L-AMPHETAMINE, PHENMETRAZINE AND PEMOLINE-MG.
199211 02-04

PENETRATION

LIPID SOLUBILITY AND DRUG PENETRATION OF THE BLOOD-BRAIN BARRIER.
206913 03-03

PENFLURIDOL

CLINICAL EXPERIENCE OF THE USE OF PENFLURIDOL (TLP-609) FOR THE TREATMENT OF SCHIZOPHRENIA.
194457 01-08

PENFLURIDOL (R-16341) AS A MAINTENANCE THERAPY IN CHRONIC PSYCHOTIC PATIENTS: A DOUBLE-BLIND CLINICAL EVALUATION.
197033 01-09

SAFETY EVALUATION OF PENFLURIDOL.
198047 01-08

A DOUBLE-BLIND CLINICAL EVALUATION OF PENFLURIDOL (R-16341) AS A MAINTENANCE THERAPY IN SCHIZOPHRENIA.
199993 02-08

ASPECTS OF NEUROLEPTIC DEPOT THERAPY WITH SPECIAL CONSIDERATION OF CLINICAL EXPERIENCE WITH THE PERORAL DEPOT PREPARATION PENFLURIDOL (R-16341 - JANSSEN).
202785 02-07

LEARNING DEFICITS IN 4 WEEKS OLD OFFSPRING OF THE NURSING MOTHERS TREATED WITH THE NEUROLEPTIC DRUG PENFLURIDOL.
202806 02-04

THE INFLUENCE OF HALOPERIDOL AND PENFLURIDOL ON THE LEARNING CAPACITY OF THE SCHIZOPHRENIC.
207000 03-14

ASPECTS OF LONG-TERM TREATMENT WITH NEUROLEPTICS: HISTORICAL AND LITERATURE REVIEW -- PERSONAL EXPERIENCE WITH FLUSPIRILENE AND PENFLURIDOL.
215059 04-14

EFFECTS OF PENFLURIDOL AND OTHER DRUGS ON APOMORPHINE-INDUCED STEREOTYPED BEHAVIOR IN MONKEYS.
215684 04-04

THE EFFECT OF PENFLURIDOL AND SOME PSYCHOTROPIC DRUGS ON MONOAMINE METABOLISM IN CENTRAL NERVOUS SYSTEM.
215686 04-03

CLINICAL STUDY OF FIVE DEPOT NEUROLEPTICS, COMPARISON OF ACTIVITY PROFILES OF FLUPHENAZINE DECANOATE, FLUSPIRILENE, PENFLURIDOL, PERPHENAZINE ENANTHATE AND PIPOTHIAZINE PALMITATE.
221822 04-08

THE USE OF AN ORGAL LONG-ACTING ANTIPSYCHOTIC AGENT, PENFLURIDOL, IN SCHIZOPHRENIA.
223165 04-08

TREATMENT EXPERIENCE OF CHRONIC SCHIZOPHRENIA WITH PENFLURIDOL.
224548 04-08

PENICILLIN

THE EFFECTS OF DIPHENYLHYDANTOIN, PHENOBARBITAL, AND DIAZEPAM ON THE PENICILLIN INDUCED EPILEPTOGENIC FOCUS IN THE RAT.
198613 02-03

DEFICIENT BRIGHTNESS DISCRIMINATION ACQUISITION PRODUCED BY DAILY INTRACRANIAL INJECTIONS OF PENICILLIN IN RATS.
202758 02-04

EFFECT OF DRUG-INDUCED INCREASE OF BRAIN GABA LEVELS ON PENICILLIN FOCUS.
220947 04-03

PENTAZOCINE

PENTAZOCINE ANALGESIA AND REGIONAL RAT BRAIN CATECHOLAMINES.
193452 01-03

INTERACTIONS OF PENTAZOCINE AND NALOXONE ON THE MONOAMINE CONTENT OF DISCRETE REGIONS OF THE RAT BRAIN.
198606 02-03

TOLERANCE TO THE STIMULANT EFFECTS OF MORPHINE AND PENTAZOCINE ON AVOIDANCE RESPONDING IN THE RAT.
201319 02-04

PENTOBARBITAL

PROLONGED PENTOBARBITAL SLEEPING TIME IN ADJUVANT INDUCED POLYARTHRITIC RATS.
196228 01-04

EFFECTS OF MESCALINE, DELTA9-TETRAHYDROCANNABINOL AND PENTOBARBITAL ON THE AUDITORY EVOKED RESPONSES IN THE CAT.
197990 01-03

EFFECT OF AMINOOXYACETIC ACID ON THE METABOLISM OF PENTOBARBITAL IN MICE.
200002 02-03

THE EFFECTS OF CHLORPROMAZINE, ATROPINE, MORPHINE AND PENTOBARBITAL ON INDUCED GASTRIC ULCERATION IN RATS. (PH.D. DISSERTATION).
200405 02-02

THE EFFECT OF VARYING THE DOSAGE OF SODIUM PENTOBARBITAL ON THE BARPRESS RATE OF RATS.
201843 02-04

THE PENTOBARBITAL TEST DOSE FOR DEPRESSANT DRUG DEPENDENCE: A REEVALUATION IN TERMS OF ALCOHOL CONSUMPTION.
202883 02-17
THE EFFECT OF OZONE ON PENTOBARBITAL SLEEPING TIME IN MICE.
204862 02-02
PENTOBARBITAL EFFECT ON PERFORMANCE IN MONOTONOUS CONDITIONS NOT PREVENTED BY COMPENSATORY EFFORT.
205595 02-15
ALTERATION OF PSYCHOSOMATIC REACTIVITY AFTER A SINGLE THERAPEUTIC DOSE OF PENTOBARBITAL IN RELATION TO THE SEX OF PROBANDS.
205627 03-14
EFFECTS OF PENTOBARBITAL ON FIXED-RATIO DISCRIMINATION.
210392 03-04
THE EFFECTS OF RUBIDIUM ON THE DURATION OF SLEEP ELICITED BY PENTOBARBITAL IN THE RAT.
210791 03-03
HYPNOTIC EFFICACY OF DIPHENHYDRAMINE, METHAPYRILENE, AND PENTOBARBITAL.
210829 03-13
BLOCKING OF STRESS BY PENTOBARBITAL MORPHINE AS RELATED TO TRAINING AND AGE OF RATS.
214056 04-04
EFFECTS OF THYROTROPIN-RELEASING HORMONE (TRH) ON THE ACTIONS OF PENTOBARBITAL AND OTHER CENTRALLY ACTING DRUGS.
215692 04-03
EFFECT OF ANESTHETIC DOSAGES OF PENTOBARBITAL ON THE CONTENT AND TURNOVER OF SEROTONIN IN BRAIN AREAS.
217816 04-03
THE EFFECTS OF SHOCK INTENSITY, D-AMPHETAMINE, AND PENTOBARBITAL ON THE FREQUENCY AND RESPONSE DYNAMICS OF BITING ATTACK IN THE SQUIRREL MONKEY. (PH.D. DISSERTATION).
222114 04-04
DIFFERENTIAL EFFECTS OF A TETRAHYDROCANNABINOL AND PENTOBARBITAL ON CEREBRAL CORTICAL NEURONES.
222819 04-03
ANTAGONISM OF PENTOBARBITAL INDUCED DISCRIMINATION IN THE GERBIL.
225561 04-04

PENTOBARBITONE
EFFECT OF PENTOBARBITONE AND DIETHYL ETHER ON THE SYNTHESIS OF MONOAMINES IN RAT BRAIN.
195950 01-03
INTERACTION OF OUABAIN WITH PENTOBARBITONE IN THE MOUSE.
197479 01-03

PENTYLENETETRAZOL
INTERACTION OF PENTYLENETETRAZOL AND TRIMETHADIONE ON THE METABOLISM OF SEROTONIN IN BRAIN AND ITS RELATION TO THE ANTICONVULSANT ACTION OF TRIMETHADIONE.
195093 01-03
SHUTTLE AVOIDANCE LEARNING OF MICE: EFFECTS OF POSTTRIAL PENTYLENETETRAZOL, STRAIN AND AGE.
195226 01-04
PROTEINASE ACTIVITY OF DIFFERENT SECTIONS OF THE BRAIN DURING CORAZOL (PENTYLENETETRAZOL) INDUCED CONVULSIONS.
198485 02-03
PENTYLENETETRAZOL INDUCED RETROGRADE AMNESIA AND BRAIN SEIZURES IN MICE.
202724 02-04
BEHAVIOURAL AND ELECTROGRAPHIC OBSERVATIONS DURING EPILEPTIC CONVULSIONS INDUCED BY STRYCHNINE AND PENTYLENETETRAZOL IN CONSCIOUS YOUNG AND ADULT CHICKENS.
205459 02-03
THE EFFECT OF WITHDRAWAL FROM CANNABIS ON PENTYLENETETRAZOL CONVULSIVE THRESHOLD IN MICE.
206355 03-04

PEOPLE
ELIMINATION OF LITHIUM DEPENDENT ON AGE IN HEALTHY PEOPLE AND PATIENTS SUFFERING FROM RENAL INSUFFICIENCY.
205043 02-13

PEPTIDES
EFFECT OF INTRACEREBROVENTRICULAR BRADYKININ AND RELATED PEPTIDES ON RABBIT OPERANT BEHAVIOR.
215693 04-04

PERATHIEPINE
LONG-ACTING NEUROLEPTICS OF PERATHIEPINE GROUP: VUFB-9977 (OXYPROTHEPINE DECANOATE).
205583 02-03

PERAZINE
MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 1. COMMUNICATION: SETTING A GOAL AND METHODOLOGICAL GROUND RULES.
203839 02-13
MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 2. COMMUNICATION: PSYCHOPATHOLOGICAL COURSE PROFILE AND SOMATIC CHARACTERISTICS (STUDIES WITH THE AMP SYSTEM).
203840 02-14
MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 3. COMMUNICATION: PERAZINE CONCENTRATION IN BLOOD AND CLINICAL EFFICACY.
203841 02-13
MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 4. COMMUNICATION: CONNECTION BETWEEN EEG CHANGES, CONCENTRATION IN BLOOD, AND OTHER CLINICAL VARIABLES.
203842 02-13
MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 5. COMMUNICATION: INFLUENCE ON VENTRICULAR EXCITATION IN THE ELECTROCARDIOGRAM.
203843 02-13
MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 6. COMMUNICATION: RELATIONSHIP BETWEEN NEUROLEPTIC HYPOKINESIS AND ANTIPSYCHOTIC THERAPEUTIC RESULTS.
203844 02-13
MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 7. COMMUNICATION: METHODOLOGICAL OUTCOME.
203845 02-16
LONGITUDINAL STUDIES ON THE METABOLITE PATTERN OF PERAZINE AND RELATED PHENOTHIAZINES IN HUMANS AND ANIMALS.
206976 03-13

PERCEPTION
THE EFFECT OF METHYLPHENIDATE ON SENSORY PERCEPTION AND INTEGRATION IN HYPERACTIVE CHILDREN.
208920 03-14
DEPRESSIVE CONDITION. PERCEPTION, EVALUATION, TREATMENT.
209332 03-09

PERCEPTIONS
MARIJUANA, ALCOHOL AND INTERPERSONAL PERCEPTIONS.
224755 04-14

PERCEPTIVE
THE EFFECT OF SEDUXEN ON THE PERCEPTIVE AND SOME OTHER FUNCTIONS OF THE CENTRAL NERVOUS SYSTEM UNDER EMOTIONAL STRESS IN MAN.
201916 02-14

PERCEPTUAL
A DOUBLE-BLIND STUDY ON THE EFFECTS OF PIRACETAM UPON PERCEPTUAL AND PSYCHOMOTOR PERFORMANCE AT VARIED HEART RATES IN PATIENTS TREATED WITH ARTIFICIAL PACEMAKERS.
201328 02-13
THE EFFECTS OF METHYLPHENIDATE HYDROCHLORIDE ON PSYCHOLINGUISTIC, MOTOR AND VISUAL PERCEPTUAL ABILITIES OF HYPERKINETIC CHILDREN WITH LEARNING DISABILITIES. (PH.D. DISSERTATION).
222725 04-14

PERFORMANCE
A BEHAVIORAL INVESTIGATION: THE EFFECTS OF MEDICATION ON DISRUPTIVE CLASSROOM BEHAVIOR AND ACADEMIC PERFORMANCE. (PH.D. DISSERTATION).
200461 02-11
A COMPARATIVE STUDY OF D- AND L-AMPHETAMINE ON THE OPEN-FIELD PERFORMANCE OF RATS.
201322 02-04
A DOUBLE-BLIND STUDY ON THE EFFECTS OF PIRACETAM UPON PERCEPTUAL AND PSYCHOMOTOR PERFORMANCE AT VARIED HEART RATES IN PATIENTS TREATED WITH ARTIFICIAL PACEMAKERS.
201328 02-13
EFFECTS OF CENTRAL AND PERIPHERAL ADRENERGIC AND CHOLINERGIC MODIFICATION ON TIME-DEPENDENT PROCESSES IN AVOIDANCE PERFORMANCE.
202203 02-03
INCREASED FIXED-RATIO PERFORMANCE AND DIFFERENTIAL D- AND L-AMPHETAMINE ACTION FOLLOWING NOREPINEPHRINE DEPLETION BY INTRAVENTRICULAR 6-HYDROXYDOPAMINE.
204482 02-04
THE DIFFERENTIATION OF TWO TYPES OF HYPERACTIVE CHILDREN BY ACTIVITY LEVEL AND TASK PERFORMANCE WITH METHYLPHENIDATE (RITALIN) AND PLACEBO. (PH.D. DISSERTATION).
204688 02-11
DRUGS AND PLACEBOS: EFFECTS OF CAFFEINE ON COGNITIVE PERFORMANCE.
205223 02-14
PENTOBARBITAL EFFECT ON PERFORMANCE IN MONOTONOUS CONDITIONS NOT PREVENTED BY COMPENSATORY EFFORT.
205595 02-15
PRESLEEP INGESTION OF TWO HYPNOTIC DRUGS AND SUBSEQUENT PERFORMANCE.
206362 03-14
EFFECTS OF DELTA9-TETRAHYDROCANNABINOL AND CANNABINOL ON OPERANT PERFORMANCE IN RATS.
210785 03-04
EFFECT OF COMBINED ALCOHOL AND PROPOXYPHENE ON HUMAN PERFORMANCE.
210871 03-14

EFFECT OF MESORIDAZINE ADMINISTRATION AND WITHDRAWAL ON PERFORMANCE IN AN OLDER AGE GROUP.
217452 04-11

RATE DEPENDENT EFFECTS OF DRUGS. II. EFFECTS OF SOME MAJOR TRANQUILIZERS ON MULTIPLE FIXED-RATIO, FIXED-INTERVAL SCHEDULE PERFORMANCE.
217458 04-04

THE EFFECTS OF CHLORDIAZEPOXIDE ON AVOIDANCE PERFORMANCE OF MICE SUBJECTED TO UNDERNUTRITION OR HANDLING STRESS IN EARLY LIFE.
217463 04-04

SOME EFFECTS OF ACTH4-10 ON PERFORMANCE DURING A SERIAL REACTION TASK.
217533 04-04

EEG CORRELATES OF IMPAIRED ATTENTION PERFORMANCE UNDER SECOBARBITAL AND CHLORPROMAZINE IN THE MONKEY.
217544 04-03

PERFORMANCES

PERFORMANCES UNDER CERUTIL OF NORMALLY INTELLIGENT CHILDREN AFFECTED BY CEREBROORGANIC REDUCTIONS IN EFFICIENCY.
203742 02-11

COGNITIVE AND MOTOR SENSORY PERFORMANCES IN TOXIC AND NONTOXIC EPILEPTIC SUBJECTS.
210824 03-15

PERFORMING

CHRONIC AMPHETAMINE TREATMENT: VAST INDIVIDUAL DIFFERENCES IN PERFORMING A LEARNED RESPONSE.
202794 02-04

PERFUSATE

THE EFFECT OF DRUGS ON THE RELEASE OF ENDOGENOUS CATECHOLAMINES INTO THE PERFUSATE OF DISCRETE BRAIN AREAS OF THE CAT IN VIVO.
219631 04-06

PERFUSED

COMPARISON OF THE EFFECTS OF CHLORAL HYDRATE AND TRICHLOROETHANOL ON THE EEG OF THE ISOLATED PERFUSED RAT BRAIN.
194743 01-03

INFLUENCE OF THERAPEUTIC AND TOXIC DOSES OF NEUROLEPTICS AND ANTIDEPRESSANTS ON ENERGY METABOLISM OF THE ISOLATED PERFUSED RAT BRAIN.
195236 01-03

THE EFFECTS OF THE TRICYCLIC ANTIDEPRESSANTS DESMETHYLIMIPRAMINE, DOXEPIN AND IPRINDOLE ON THE ISOLATED PERFUSED RABBIT HEART.
197277 01-03

THE EFFECTS OF IMIPRAMINE AND PROMAZINE ON ENERGY METABOLISM AND EEG OF THE ISOLATED PERFUSED RAT BRAIN.
197296 01-03

DETERMINATION OF NORADRENALINE, DOPAMINE, SEROTONIN, 5-HYDROXYINDOLEACETIC ACID, TYROSINE AND TRYPTOPHANE IN THE ISOLATED PERFUSED RAT BRAIN.
197967 01-06

QUANTITATIVE ANALYSIS OF THE EEG EFFECTS PRODUCED BY IMIPRAMINE, DESIPRAMINE, PROMAZINE, AND MONODESMETHYL PROMAZINE IN THE ISOLATED PERFUSED RAT BRAIN.
200056 02-03

EFFECTS OF PSYCHOACTIVE TRICYCLIC DRUGS ON THE EEG OF THE ISOLATED PERFUSED RAT BRAIN.
205492 02-03

ARRHYTHMIAS AND INHIBITION OF NORADRENALINE UPTAKE CAUSED BY TRICYCLIC ANTIDEPRESSANTS AND CHLORPROMAZINE ON THE ISOLATED PERFUSED RABBIT HEART.
217657 04-03

THE EFFECT OF CHLORDIAZEPOXIDE HYDROCHLORIDE ON THE ISOLATED PERFUSED RAT LIVER (38786).
217796 04-03

PERFUSION

ELECTROCORTICAL CHANGES INDUCED BY PERFUSION OF CATECHOLAMINES INTO THE BRAINSTEM RETICULAR FORMATION.
210827 03-03

PERIODIC

EVALUATION OF LITHIUM THERAPY IN CHRONIC AND PERIODIC ALCOHOLISM.
194758 01-11

CATECHOLAMINES AND ANTIPSYCHOTIC DRUGS IN PERIODIC CATATONIA.
207292 03-08

PERIODS

TREATMENT OF SCHIZOPHRENIA BY THE ADMINISTRATION OF A SMALL DOSE OF FORIT FOR COMPARATIVELY LONG PERIODS OF TIME.
194476 01-08

DIFFERENTIAL NEUROCHEMISTRY AND TEMPORAL PATTERN IN RATS TREATED ORALLY WITH DELTA9-TETRAHYDROCANNABINOL FOR PERIODS UP TO SIX MONTHS.
217519 04-04

PERIPHERAL

MECHANISM OF ACTION OF PHENCYCLIDINE ON THE PERIPHERAL SYMPATHETIC NERVOUS SYSTEM.
193425 01-03

TIME-DEPENDENT, MEMORY RETRIEVAL EFFECTS FOLLOWING PERIPHERAL AND HIPPOCAMPAL TREATMENTS TO INCREASE SYNAPTIC BIOGENIC AMINES. (PH.D. DISSERTATION).
194677 01-04

EVIDENCE FOR A PERIPHERAL EFFECT OF FUSARIC ACID, A DOPAMINE-BETA-HYDROXYLASE INHIBITOR, ON SEROTONIN METABOLISM.
196593 01-03

ON THE INHIBITION OF PERIPHERAL AND CENTRAL NORADRENERGIC NEUROTRANSMISSION BY CLONIDINE.
197295 01-03

PERIPHERAL TISSUE DISTRIBUTION, BRAIN DISTRIBUTION AND METABOLISM OF MESCALINE-14C IN MONKEYS.
197458 01-03

INFLUENCE OF HALOTHANE ON PERIPHERAL SYMPATHETIC NERVES AND ON THE EFFECTS OF NORADRENALINE ON MYOCARDIUM.
197945 01-03

THE EFFECTS OF 6-HYDROXYDOPAMINE AND GUANETHIDINE ON PERIPHERAL ADRENERGIC NERVES IN THE GUINEA-PIG.
199862 02-03

STIMULUS PROPERTIES OF MESCALINE AND N-METHYLATED DERIVATIVES: DIFFERENCE IN PERIPHERAL AND DIRECT CENTRAL ADMINISTRATION.
201320 02-02

EFFECTS OF CENTRAL AND PERIPHERAL ADRENERGIC AND CHOLINERGIC MODIFICATION ON TIME-DEPENDENT PROCESSES IN AVOIDANCE PERFORMANCE.
202203 02-03

THE PERIPHERAL AND CENTRAL ROLE OF THE CATECHOLAMINES IN THE MECHANISMS OF ANXIETY.
202783 02-17

SELECTIVE INHIBITION OF DOPAMINE-BETA-HYDROXYLASE IN THE PERIPHERAL TISSUES BY 5-DIMETHYLDITHIOCARBAMYLPICOLINIC ACID; ITS EFFECT ON STRESS INDUCED ULCER, ETHANOL INDUCED SLEEP AND BLOOD PRESSURE.
204484 02-03

CEREBRAL AND PERIPHERAL CONSUMPTION OF L-5-HTP BY PATIENTS SUFFERING FROM MANIACAL, DEPRESSIVE OR PSYCHOTIC SYMPTOMS.
206834 03-10

THE ROLE OF P-HYDROXYLATION OF AMPHETAMINE IN ITS PERIPHERAL MODE OF ACTION.
210749 03-03

AN INVESTIGATION ON THE BEHAVIORAL AND HYPOTHERMIC EFFECTS OF YOHIMBINE: INTERACTION WITH DRUGS AFFECTING CENTRAL AND PERIPHERAL MONOAMINES.
211068 03-04

NERVE IMPULSE ENHANCED RELEASE OF AMINO ACIDS FROM NONSYNAPTIC REGIONS OF PERIPHERAL AND CENTRAL NERVE TRUNKS OF BULLFROG.
213277 03-03

THE EFFECT OF LSD AND 2-BROMOLSD ON THE DOPA ACCUMULATION AFTER CENTRAL AND PERIPHERAL DECARBOXYLASE INHIBITION.
217674 04-03

PERIPHERALLY

EFFECT OF PERIPHERALLY ADMINISTERED SEROTONIN ON THE NEURONAL ACTIVITY OF MIDBRAIN RAPHE NEURONS.
210710 03-03

PERLAPINE

EFFECTS OF CLOZAPINE, THIORIDAZINE, PERLAPINE AND HALOPERIDOL ON THE METABOLISM OF THE BIOGENIC AMINES IN THE BRAIN OF THE RAT.
217543 04-03

PERMANENT

PERMANENT EFFECTS OF REPEATED ADMINISTRATION OF ACTH AND DIAZEPAM IN EARLY POSTNATAL PERIOD UPON THE DYNAMICS OF EXCITATION AND INHIBITION DURING HABITUATION.
215068 04-04

PERORAL

ASPECTS OF NEUROLEPTIC DEPOT THERAPY WITH SPECIAL CONSIDERATION OF CLINICAL EXPERIENCE WITH THE PERORAL DEPOT PREPARATION PENFLURIDOL (R-16341 - JANSSEN).
202785 02-07

PEROXIDASE

AFFERENTS TO THE SEPTAL AREA OF THE RAT STUDIED WITH THE METHOD OF RETROGRADE AXONAL TRANSPORT OF HORSERADISH PEROXIDASE.
203573 02-03

PERPHENAZINE

A CONTROLLED OUTPATIENT TRIAL OF PERPHENAZINE AMITRIPTYLINE AND CHLORPROMAZINE.
199517 02-14

TISSUE METABOLITES OF TRIFLUOPERAZINE, FLUPHENAZINE, PROCHLORPERAZINE, AND PERPHENAZINE IN THE RAT: IDENTIFICATION AND SYNTHESIS.
200738 02-01

A CONTROLLED COMPARISON OF OXYPERTINE AND PERPHENAZINE IN SCHIZOPHRENIC PSYCHOSES.
205582 02-08
SHORT-TERM EFFECT OF PERPHENAZINE ENANTHATE ON THE RAT BRAIN.
206359 03-03
CLINICAL USE OF CLOCAPRAMINE FOR THE TREATMENT OF CHRONIC SCHIZOPHRENIA -- SPECIAL EMPHASIS ON ITS COMPARISON WITH PERPHENAZINE.
207534 03-08
COMPARISON OF NEUROLEPTICS IN CONTROLLED EXPERIMENTAL CONDITIONS: METHOPHENAZINE VS PERPHENAZINE.
209147 03-08
CLINICAL STUDY AND FOLLOWUP OF 40 PSYCHOTIC PATIENTS ON PERPHENAZINE ENANTHATE.
212495 03-14
PERPHENAZINE ENANTHATE IN TREATING CHRONIC SCHIZOPHRENIA.
221558 04-08
PHARMACOKINETICS OF PERPHENAZINE.
221630 04-13
RESEARCH INTO THE INTERACTION BETWEEN NORTRIPTYLINE AND PERPHENAZINE -- CLINICAL EVALUATION.
221632 04-13
CLINICAL STUDY OF FIVE DEPOT NEUROLEPTICS, COMPARISON OF ACTIVITY PROFILES OF FLUPHENAZINE DECANOATE, FLUSPIRILENE, PENFLURIDOL, PERPHENAZINE ENANTHATE AND PIPOTHIAZINE PALMITATE.
221822 04-08
COMPARATIVE STUDY OF CLOCAPRAMINE AND PERPHENAZINE ON CHRONIC SCHIZOPHRENIA BY A DOUBLE-BLIND METHOD.
222158 04-08

PERSISTENT
PERSISTENT THALAMIC AND CORTICAL BARBITURATE SPINDLE ACTIVITY AFTER ABLATION OF THE ORBITAL CORTEX IN CATS.
199763 02-03
TREATMENT OF PHENOTHIAZINE INDUCED BULBAR PERSISTENT DYSKINESIA WITH DEANOL ACETAMIDOBENZOATE.
210209 03-13

PERSISTING
METHODS OF DECONDITIONING PERSISTING AVOIDANCE: AMPHETAMINE, CHLORPROMAZINE, AND CHLORDIAZEPOXIDE AS ADJUNCTS TO RESPONSE PREVENTION.
202987 02-04
D-AMPHETAMINE AND DELINQUENCY: HYPERKINESIS PERSISTING
206143 03-14
METHODS OF DECONDITIONING PERSISTING AVOIDANCE: AMPHETAMINE AND AMOBARBITAL AS ADJUNCTS TO RESPONSE PREVENTION.
209897 03-04

PERSONAL
PERSONAL EXPERIENCE IN THE USE OF SULPIRIDE (FK-880) ON SCHIZOPHRENIA.
209405 03-08
ASPECTS OF LONG-TERM TREATMENT WITH NEUROLEPTICS: HISTORICAL AND LITERATURE REVIEW -- PERSONAL EXPERIENCE WITH FLUSPIRILENE AND PENFLURIDOL.
215059 04-14

PERSONALITY
PERSONALITY TRAIT STABILITY LABILITY AND ITS SIGNIFICANCE FOR PHARMACOLOGICAL RESEARCH.
196776 01-16
USE OF THE MAUDSLEY PERSONALITY INVENTORY IN EVALUATING THE EFFECTIVENESS OF A MINOR TRANQUILIZER IN PSYCHOSOMATIC DISEASES (THE FIRST REPORT).
198518 02-14
ON THE USE OF SYDNOCARB FOR PSYCHOPHARMACOLOGICAL CORRECTION OF BEHAVIORAL DISORDERS OF THE CYCLOID TYPE OF ACCENTUATED PERSONALITY IN ADOLESCENTS.
207271 03-11

PERSPECTIVES
THE PLACEBO EFFECT: AN INTEGRATED ANALYSIS OF THEORETICAL AND RESEARCH PERSPECTIVES. (PH.D. DISSERTATION).
212593 03-17
MONOAMINERGIC NEUROTOXINS: ARE THEY SELECTIVE? SOME PERSPECTIVES ON THE SYMPOSIUM HELD AT THE FOURTH ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, OCTOBER, 1974. (UNPUBLISHED PAPER).
222353 04-06

PETHIDINE
RELATIONSHIP BETWEEN ANALGESIC ACTION OF PETHIDINE AND ITS EFFECT ON THE BRAIN 5-HYDROXYTRYPTAMINE CONCENTRATION IN THE RATS OF DIFFERENT AGE.
196782 01-03

PEYOTE
PEYOTE IN THE TREATMENT OF ALCOHOLISM AMONG AMERICAN-INDIANS.
213702 04-12

PF-82
PHARMACOLOGICAL EVALUATION OF 3-(N 3,3 DIPHENYLPROPYL-N-METHYL) AMINOPROPAN-1-OL HYDROCHLORIDE (PF-82), A NEW TYPE OF ANTIDEPRESSANT DRUG.
221287 04-02

PG-501
ADMINISTRATION OF PG-501 FOR THE TREATMENT OF EXTRAPYRAMIDAL SYNDROME CAUSED BY THE ADMINISTRATION OF A PSYCHOTROPIC DRUG.
194475 01-11

PGE1
THE EFFECT OF PGE1, PGE2 AND PGF2ALPHA ON PARASYMPATHETIC TRANSMISSION.
197941 01-03

PGE2
THE EFFECT OF PGE1, PGE2 AND PGF2ALPHA ON PARASYMPATHETIC TRANSMISSION.
197941 01-03

PGF2ALPHA
THE EFFECT OF PGE1, PGE2 AND PGF2ALPHA ON PARASYMPATHETIC TRANSMISSION.
197941 01-03

PHARMACEUTICAL
THALIDOMIDE AND THE POWER OF THE PHARMACEUTICAL INDUSTRY.
210077 03-15

PHARMACODYNAMICS
IN VIVO HUMAN PHARMACODYNAMICS OF THE PSYCHODYSLEPTIC 4-BR-DIMETHOXYPHENYLISOPROPYLAMINE LABELLED WITH 82BR OR 77BR.
215710 04-13

PHARMACOKINETIC
ESTIMATION OF PHARMACOKINETIC PARAMETERS OF LITHIUM FROM SALIVA AND URINE.
195446 01-13
PHARMACOKINETIC EVALUATION OF ANTICONVULSANTS PRIOR TO EFFICACY TESTING EXEMPLIFIED BY CARBAMAZEPINE IN EPILEPTIC MONKEY MODEL.
195492 01-04
PHARMACOKINETIC DETERMINANTS OF THE RESPONSE TO SINGLE DOSES OF CHLORDIAZEPOXIDE.
203005 02-13
EXPLICIT SOLUTION TO PHARMACOKINETIC FIRST-ORDER RATE CONSTANTS OF MAPROTILIN.
208919 03-17
PHARMACOKINETIC INTERACTION BETWEEN NEUROLEPTICS AND TRICYCLIC ANTIDEPRESSANTS IN THE RAT.
210834 03-03
BIOLOGICAL AND PHARMACOKINETIC EVIDENCE FOR GENERIC EQUIVALENCE OF THREE IMIPRAMINE PREPARATIONS: COMPARISON WITH A NEW IMIPRAMINE ANALOGUE.
211071 03-02
THE PHARMACOKINETIC PROPERTIES OF MAPROTILINE (LUDIOMIL) IN MAN.
221648 04-13

PHARMACOKINETICS
PHARMACOKINETICS OF LITHIUM AND ITS REGIONAL DISTRIBUTION IN RAT BRAIN.
193547 01-03
PHARMACOKINETICS OF DIAZEPAM IN MAN.
197951 01-13
ON THE PHARMACOKINETICS OF DIBENZEPINE.
199913 02-13
PHARMACOKINETICS IN THE RAT OF THE HALLUCINOGENIC ALKALOIDS HARMINE AND HARMALINE.
202796 02-03
ON THE PHARMACOKINETICS OF BROMAZEPAM IN MAN.
206788 03-13
PHARMACOKINETICS OF CARBAMAZEPINE IN MONKEYS FOLLOWING INTRAVENOUS AND ORAL ADMINISTRATION.
211009 03-03
PHARMACOKINETICS IN CLINICAL MEDICINE: OXAZEPAM VERSUS OTHER BENZODIAZEPINES.
218151 04-17
ON THE PHARMACOKINETICS OF CHLORPROTHIXENE IN MAN.
219630 04-13
PHARMACOKINETICS OF IMIPRAMINE.
221628 04-13
ON THE PHARMACOKINETICS OF THIORIDAZINE.
221629 04-13
PHARMACOKINETICS OF PERPHENAZINE.
221630 04-13
ON THE PHARMACOKINETICS OF HALOPERIDOL.
221631 04-13
HORMONE INDUCED EFFECTS ON LITHIUMS PHARMACOKINETICS.
221640 04-03
PHARMACOKINETICS OF CHLORDIAZEPOXIDE, MEPERIDINE, THIORIDAZINE, AND MESORIDAZINE AND CLINICAL RESPONSE.
224830 04-13

PHARMACOLOGIC

PHARMACOLOGIC STUDIES ON PROPYNYL DIBENZAZEPINE, A NEW ALPHA-ADRENERGIC BLOCKER.
197493 01-03

PHARMACOLOGIC EFFECTS OF MH-9022-1, A POTENTIAL TRANQUILIZING AGENT.
206808 03-02

6-CHLORO-2-AMINOTETRALIN, A RIGID CONFORMATIONAL ANALOG OF 4-CHLOROAMPHETAMINE: PHARMACOLOGIC PROPERTIES OF IT AND RELATED COMPOUNDS IN RATS.
210870 03-02

PHARMACOLOGICAL

STEREOCHEMICAL DEPENDENCE OF PHARMACOLOGICAL ACTIVITY IN A SERIES OF OPTICALLY ACTIVE N-METHYLATED BARBITURATES.
193140 01-01

A PHARMACOLOGICAL AND NEUROANATOMICAL ANALYSIS OF DOPAMINERGIC AND NORADRENERGIC PATHWAYS INVOLVED IN SELF-STIMULATION IN RATS. (PH. D. DISSERTATION).
193582 01-04

PHARMACOLOGICAL AND ANATOMICAL DISSOCIATION OF TWO TYPES OF HABITUATION.
195079 01-04

PERSONALITY TRAIT STABILITY LABILITY AND ITS SIGNIFICANCE FOR PHARMACOLOGICAL RESEARCH.
196776 01-16

PHARMACOLOGICAL INVESTIGATIONS WITH BENZOCTAMINE (TACITIN), A NEW PSYCHOACTIVE AGENT.
197447 01-03

CENTRAL PHARMACOLOGICAL ACTIVITIES OF 4-PHENYL-6-CHLORO-1,4-DIHYDRO-2H-3,1 BENZOXAZIN-2-ONE.
197453 01-03

THE INFLUENCE OF SKF-525A ON THE ACUTE PHARMACOLOGICAL PROPERTIES OF CHLORDIAZEPOXIDE.
197478 01-03

PHARMACOLOGICAL STUDIES ON TETRABENAZINE-INDUCED EXCITED BEHAVIOUR OF RATS PRETREATED WITH AMPHETAMINE OR NIALAMIDE.
197490 01-04

PHARMACOLOGICAL INFLUENCES ON CARBON DIOXIDE INDUCED AMNESIA.
197497 01-03

PHARMACOLOGICAL EXAMINATIONS BY AN ULCUS INHIBITING AGENT (L-S-519).
197955 01-03

PHARMACOLOGICAL AND TOXICOLOGICAL STUDY OF A NEW PSYCHOTROPIC STIMULANT: THE 2-PHENYLDIMETHYL-TETRAHYDROOXAZINE, IN COMPARISON WITH D,L-AMPHETAMINE, PHENMETRAZINE AND PEMOLINE-MG.
199211 02-04

PHARMACOLOGICAL PROFILE OF A NEW NONTRICYCLIC ANTIDEPRESSANT: OXAFLOZANE (1766-CERM).
199385 02-02

PHARMACOLOGICAL AND TOXICOLOGICAL PROPERTIES OF CLOBAZAM (1-PHENYL-5-METHYL-8-CHLORO 1,2,4,5-TETRAHYDRO-2,4-DIKETO-3H-1,5 BENZODIAZEPINE), A NEW PSYCHOTHERAPEUTIC AGENT.
199912 02-05

CLINICAL PHARMACOLOGICAL STUDY OF A HYPNOTIC DRUG, TRICLORYL.
200009 02-11

PHARMACOLOGICAL MODULATION OF PHOTICALLY EVOKED AFTERDISCHARGE PATTERNS IN HOODED LONG-EVANS RATS.
201409 02-03

COMPARATIVE RESULTS OF A PHARMACOLOGICAL LOADING WITH AMINAZINE AND HALOPERIDOL IN SCHIZOPHRENIC PATIENTS.
201910 02-08

INFLUENCE OF MIDBRAIN RAPHE LESION ON SOME PHARMACOLOGICAL AND BIOCHEMICAL EFFECTS OF APOMORPHINE IN RATS.
202771 02-03

THE EFFECTS OF NEUROLEPTIC AGENTS IN THE CHRONIC PHARMACOLOGICAL EXPERIMENT.
202863 02-04

THERAPY-RESISTANT DEPRESSIONS. BIOCHEMICAL AND PHARMACOLOGICAL CONSIDERATIONS: CONTRIBUTIONS TO BIOCHEMISTRY.
203593 02-09

STUDIES ON CLINICAL AND PHARMACOLOGICAL SPECTRA OF THE TETRACYCLIC COMPOUND MIANSERIN.
204412 02-14

POSSIBLE PHARMACOLOGICAL AND THEORETICAL IMPLICATIONS OF X-RAY STRUCTURE OF THE TRICYCLIC ANTIDEPRESSANT IMIPRAMINE.
205029 02-01

PHARMACOLOGICAL PROPERTIES OF A POTENTIAL TRANQUILISING AGENT MESYLPHENACYRAZINE: I. INTERACTION WITH DRUGS INFLUENCING THE NERVOUS SYSTEM.
205578 02-03

PHARMACOLOGICAL PROPERTIES OF A POTENTIAL TRANQUILISING AGENT MESYLPHENACYRAZINE: II. CHANGES RELATED TO ITS REPEATED ADMINISTRATION.
205579 02-03

ELECTROPHYSIOLOGICAL AND BEHAVIORAL REACTIVITY TO PHOTIC STIMULI FOLLOWING SEPTAL LESIONS AND PHARMACOLOGICAL TREATMENTS IN RATS.
206724 03-04

THE ELECTROENCEPHALOGRAM AS A PHYSIOLOGICAL AND PHARMACOLOGICAL OBSERVABLE.
207549 03-06

THOUGHT DISORDERS IN SCHIZOPHRENIA BEFORE AND AFTER PHARMACOLOGICAL TREATMENT.
207767 03-17

THE PHARMACOLOGICAL AND ANATOMICAL SUBSTRATES OF THE AMPHETAMINE RESPONSE IN THE RAT.
207794 03-04

PHARMACOLOGICAL MANIPULATIONS OF BRAIN CATECHOLAMINES AND THE AGGRESSIVE BEHAVIOR INDUCED BY MARIHUANA IN REM SLEEP DEPRIVED RATS.
210325 03-04

PHARMACOLOGICAL TREATMENT OF PHOBIC - OBSESSIVE PSYCHONEUROSES: PSYCHODYNAMIC AND SYMPTOMATOLOGICAL ASPECTS.
210506 03-10

SOME PHARMACOLOGICAL ACTIONS OF 2,5 DIMETHOXY-4-ETHYLAMPHETAMINE (DOET) IN RATS AND MICE.
210747 03-03

PHARMACOLOGICAL PROPERTIES OF TWO CHLORDIAZEPOXIDE METABOLITES FOLLOWING MICROSOMAL ENZYME INHIBITION.
210792 03-03

COMPARATIVE PHARMACOLOGICAL STUDIES ON BUTRIPTYLINE AND SOME RELATED STANDARD TRICYCLIC ANTIDEPRESSANTS.
211101 03-03

PHARMACOLOGICAL STUDIES OF SLEEP.
213610 04-03

HYPERSOMNIA BY ISTHMIC LESION IN THE CAT. II. NEUROPHYSIOLOGICAL AND PHARMACOLOGICAL STUDY.
215703 04-03

PHARMACOLOGICAL EVIDENCE FOR CEREBRAL DOPAMINE RECEPTOR BLOCKADE BY METOCLOPRAMIDE IN RODENTS.
217469 04-03

PHARMACOLOGICAL ANALYSIS OF A NEW ANOREXIC SUBSTANCE: 5-HYDROXY-5-4-CHLOROPHENYL 2,3 DIHYDRO-5H-IMIDAZOISOINDOLE (MAZINDOL).
217652 04-04

A PHARMACOLOGICAL MODEL OF THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA.
218213 04-08

CORRELATED HISTOCHEMICAL, ELECTRON MICROSCOPICAL, PHARMACOLOGICAL AND PHYSIOLOGICAL OBSERVATION ON AMINERGIC MECHANISMS IN THE CENTRAL NERVOUS SYSTEM. (UNPUBLISHED PAPER).
218300 04-03

A PHARMACOLOGICAL ANALYSIS OF AGGRESSIVE BEHAVIOR OF MICE INDUCED BY ISOLATION.
218800 04-04

THE INFLUENCE OF PHARMACOLOGICAL AGENTS ON THE CONSEQUENCES OF EMOTIONAL EXCITATION IN CATS.
218814 04-04

6-HYDROXYDOPAMINE AND AVOIDANCE: A BEHAVIORAL AND PHARMACOLOGICAL ANALYSIS. (PH.D. DISSERTATION).
220674 04-04

CATECHOLAMINES AND SELF-STIMULATION: PHARMACOLOGICAL DIFFERENCES BETWEEN NEAR-LATERAL AND FAR-LATERAL HYPOTHALAMIC SITES.
221030 04-03

PHARMACOLOGICAL EVALUATION OF 3-(N 3,3 DIPHENYLPROPYL-N-METHYL) AMINOPROPAN-1-OL HYDROCHLORIDE (PF-82), A NEW TYPE OF ANTIDEPRESSANT DRUG.
221287 04-02

PHARMACOLOGICAL - CLINICAL INTEREST IN THE STUDY OF 24 HOUR LITHIUM RATE CYCLES.
221667 04-09

PHARMACOLOGICAL PROPERTIES OF 6,7 TETRAMETHYLENE-5-PHENYL-1-2-DIHYDRO 3H THIENODIAZEPIN-2-ONE (QM-6008), THIADIPONE), A NEW PSYCHOTROPIC DRUG.
221722 04-02

TOXICOLOGICAL AND PHARMACOLOGICAL INVESTIGATIONS OF PINAZEPAM (7-CHLORO-1-PROPARGYL-5-PHENYLBENZODIAZEPIN-2-ONE): A NEW THERAPEUTIC AGENT.
221723 04-02

PHARMACOLOGICAL ACTION OF FD-008, A NEW DOPAMINE-BETA-HYDROXYLASE INHIBITOR: II. EFFECTS ON CENTRAL NERVOUS SYSTEM IN MICE AND RATS.
221823 04-02

PHARMACOLOGICAL ACTION OF FD-008, A NEW DOPAMINE-BETA-HYDROXYLASE INHIBITOR: III. EFFECTS ON ENDOGENOUS BIOGENIC AMINE LEVELS IN RATS.
221859 04-03

MODULATION OF PHOTICALLY EVOKED AFTERDISCHARGES BY MEANS OF PHARMACOLOGICAL AND BEHAVIORAL AROUSAL. (PH.D. DISSERTATION).
222644 04-03

THE CORRELATION BETWEEN TRIFTAZINE DISTRIBUTION IN SOME RAT ORGANS AND ITS PHARMACOLOGICAL EFFECTS WITH DIFFERENT TYPES OF ADMINISTRATION.
223016 04-03

NEUROTRANSMITTER CONTENT IN SYNAPTIC VESICLES OF THE ADRENERGIC NERVES OF RATS UNDER PHARMACOLOGICAL INFLUENCE.
223017 04-03

PHYSIOLOGICAL AND PHARMACOLOGICAL EVIDENCE FOR A SEROTONERGIC PROJECTION TO THE HIPPOCAMPUS.
223171 04-03

PHARMACOLOGICALLY

PHARMACOLOGICALLY INDUCED BEHAVIORAL CORRELATES OF NIGROSTRIATAL FUNCTION. (PH.D. DISSERTATION).
220473 04-04

PHARMACOLOGY

CHEMICAL PHARMACOLOGY OF THE BENZOTHIOPHENE AND 1-METHYLINDOLE ANALOGS OF N,N-DIMETHYLTRYPTAMINE. (PH.D. DISSERTATION).
193590 01-12

PHARMACOLOGY OF PYRAMIDAL TRACT CELLS IN THE CEREBRAL CORTEX: NORADRENALINE AND RELATED SUBSTANCES.
195438 01-03

PHARMACOLOGY OF MAGNESIUM GLUTAMATE HYDROBROMIDE (PS-042), A NEW TRANQUILIZER: THIRD PART, PSYCHOPHARMACOLOGICAL STUDIES.
196444 01-02

THE PHARMACOLOGY OF WY-23409, A NEW ANTIDEPRESSANT.
197305 01-03

ON THE PHARMACOLOGY OF SOME BETA-HYDROXYLATED TRYPTAMINES.
197568 01-03

THE BIOCHEMICAL PHARMACOLOGY OF ABUSED DRUGS: I. AMPHETAMINES, COCAINE, AND LSD.
198028 01-12

MULTIDIMENSIONAL SCALING TO RELATE ANIMAL PHARMACOLOGY AND CLINICAL SYMPTOMS OF PSYCHOPHARMACOLOGIC AGENTS.
198058 01-02

THE BIOCHEMICAL PHARMACOLOGY OF ABUSED DRUGS. II. ALCOHOL AND BARBITURATES.
200007 02-14

THE PHARMACOLOGY OF GROSS BEHAVIOURAL EFFECTS OF CHOLINOMIMETIC SUBSTANCES INJECTED INTO THE CEREBRAL VENTRICLES OF UNANAESTHETIZED CATS: EVIDENCE FOR CENTRAL MUSCARINIC MEDIATION.
202780 02-04

SYNTHESIS AND PRELIMINARY PHARMACOLOGY OF A NOVEL BUTYROPHENONE DERIVATIVE, iD-4708.
202862 02-02

THE SYNTHESIS AND PHARMACOLOGY OF A NOVEL BENZODIAZEPINE DERIVATIVE, 1-METHYL-5-O-FLUOROPHENYL 7-CHLORODIHYDROBENZODIAZEPIN-2-ONE (ID-540).
206780 03-02

BROMOPERIDOL, A NEW POTENT NEUROLEPTIC OF THE BUTYROPHENONE SERIES; COMPARATIVE PHARMACOLOGY OF BROMOPERIDOL AND HALOPERIDOL.
206804 03-02

ON THE PHARMACOLOGY OF DESMETHYLAZAPHEN DERIVATIVES.
207198 03-03

BEHAVIOR: BIOLOGY, PHYSIOLOGY, PHARMACOLOGY.
207204 03-17

PHARMACOLOGY AND PHYSIOLOGY OF STEREOTYPED BEHAVIOR.
207284 03-04

DOPAMINE AND THE PHARMACOLOGY OF SCHIZOPHRENIA: THE STATE OF THE EVIDENCE.
207300 03-03

THE COMPARATIVE PHARMACOLOGY OF FLUPENTHIXOL AND SOME REFERENCE NEUROLEPTICS.
210892 03-03

PHARMACOLOGY OF MARIJUANA.
211689 03-17

BIOCHEMICAL PHARMACOLOGY OF BRAIN AMINE MECHANISMS.
213603 04-03

PROGRAM IN BEHAVIORAL PHARMACOLOGY.
213612 04-04

PHARMACOLOGY OF NEURAL MODULATION AND TRANSMISSION.
213627 04-03

THE BEHAVIORAL PHARMACOLOGY OF PSYCHOACTIVE DRUGS.
213635 04-04

SEROTONIN -- NEW VISTAS: HISTOCHEMISTRY AND PHARMACOLOGY.
213715 04-17

SUMMARY OF THE ANIMAL PHARMACOLOGY OF OXAZEPAM.
218150 04-17

PHARMACOLOGY OF CEREBRAL CIRCULATION AND CLINICAL APPLICATIONS. EXPERIMENTAL STUDY OF THE CIRCULATORY AND METABOLIC EFFECTS OF HYDROSARPAN-711.
218164 04-03

CLOZAPINE: PHARMACOLOGY, BIOCHEMISTRY AND CLINICAL USE.
221538 04-13

THE SYNTHESIS AND PHARMACOLOGY OF A NOVEL BENZODIAZEPINE DERIVATIVE, 1-BETA-METHYLSULFONYLETHYL-5-O-FLUOROPHENYL 7-CHLORODIHYDROBENZODIAZEPIN-2-ONE (ID-622).
221741 04-02

CENTRAL NERVOUS SYSTEM PHARMACOLOGY OF CHOLINERGICALLY ELICITED EATING AND DRINKING BEHAVIOR IN THE ALBINO RAT. (PH.D. DISSERTATION).
222638 04-04

CLINICAL PHARMACOLOGY IN PSYCHIATRY.
224829 04-17

REINFORCEMENT SCHEDULES AND EXTRAPOLATIONS TO HUMANS FROM ANIMALS IN BEHAVIORAL PHARMACOLOGY.
225171 04-04

PHARMACOTHERAPIES

RESPONSES OF DYSPHORIC PATIENTS TO PHARMACOTHERAPIES.
198074 01-11

PHARMACOTHERAPY

PHARMACOTHERAPY OF THE PSYCHOSES.
200231 02-17

BIOCHEMICAL CRITERIA FOR CLASSIFYING DEPRESSIVE DISORDERS AND PREDICTING RESPONSES TO PHARMACOTHERAPY: PRELIMINARY FINDINGS FROM STUDIES OF NOREPINEPHRINE METABOLISM. CONTRIBUTIONS TO BIOCHEMISTRY.
203594 02-09

DRUGS AND PHARMACOTHERAPY.
204427 02-17

SLEEP DEPRIVATION AS A POTENTIATION OF ANTIDEPRESSIVE PHARMACOTHERAPY?
205602 03-09

PHARMACOTHERAPY OF SCHIZOPHRENIA: FACTS, SPECULATIONS, HYPOTHESES AND THEORIES.
206603 03-08

FUTURE DEVELOPMENT OF PHARMACOTHERAPY AND TOXICOMANIA.
207100 03-17

PHARMACOTHERAPY OF DEPRESSION -- A CRITICAL REVIEW.
211432 03-09

PHARMACOTHERAPY OF DEPRESSIONS.
216335 04-10

MENTAL DECLINE IN THE ELDERLY: PHARMACOTHERAPY (ERGOT ALKALOIDS VERSUS PAPAVERINE).
218306 04-11

PHARYNGEAL

STUDY OF AN ANXIOLYTIC DRUG, CLOBAZAM, IN ORL WITH PHARYNGEAL PSYCHOSOMATIC MANIFESTATIONS.
224584 04-11

PHASES

EFFECT OF INTRAHIPPOCAMPAL INJECTION OF ATROPINE ON DIFFERENT PHASES OF A LEARNING EXPERIMENT.
198227 02-04

HEART RATE AND GALVANIC SKIN RESPONSE VARIATIONS DURING THE REM AND NON-REM SLEEP PHASES IN MAN.
205443 02-13

PHASIC

THE EFFECT OF SOME NEUROTROPIC DRUGS ON THE PHASIC CHANGES OF ARTERIAL PRESSURE EVOKED BY STIMULATION OF THE CEREBELLAR FASTIGAL NUCLEUS.
217067 04-03

PHENAGLYCODOL

PHENAGLYCODOL IN ANXIETY: A CONTROLLED STUDY.
209486 03-10

PHENAMINE

COMPARATIVE EFFECT OF PHENAMINE (AMPHETAMINE) AND CAFFEINE ON THE BACKGROUND ACTIVITY OF CORTICAL SENSORIMOTOR NEURONS AND THEIR REACTIONS DURING STIMULATION OF THE CAUDATE NUCLEUS.
198835 02-03

THE ROLE OF DOPAMINE AND NOREPINEPHRINE IN CHANGING THE DIRECT CORTICAL RESPONSE TO PHENAMINE.
208971 03-03

ON THE PHYSIOLOGICAL MECHANISMS OF THE INFLUENCE OF PHENAMINE AND MICROPOLARIZATION ON LONG-TERM MEMORY PROCESSES.
213491 04-04

NEUROCHEMICAL AND NEUROPHYSIOLOGICAL MECHANISMS OF THE PSYCHOSTIMULATING ACTION OF PHENAMINE.
219510 04-13

THE INFLUENCE OF PHENAMINE AND CAFFEINE ON THE CAPACITY FOR EXTRAPOLATION IN RATS.
224466 04-04

THE INFLUENCE OF PHENAMINE ON THE AVOIDANCE REACTION IN INTACT AND STRIATECTOMIZED RATS.
224467 04-04

PHENCYCLIDINE
MECHANISM OF ACTION OF PHENCYCLIDINE ON THE PERIPHERAL SYMPATHETIC NERVOUS SYSTEM.
193425 01-03
EFFECT OF PHENCYCLIDINE ON THE ACCUMULATION OF 14C-CATECHOLAMINES FORMED FROM 14C-TYROSINE.
197467 01-03

PHENELZINE
INTERACTIONS OF SOME ANALGESICS AND ANTIDEPRESSANTS WITH PHENELZINE OR RESERPINE IN THE MOUSE.
204879 02-05
THE RELATIONSHIP BETWEEN RESPONSE TO PHENELZINE AND ACETYLATOR STATUS IN DEPRESSED PATIENTS.
206366 03-09
PHENELZINE IN PHOBIC STATES.
206367 03-10

PHENETHYLAMINE
METHAMPHETAMINE AND PHENETHYLAMINE.
206809 03-03
PHENETHYLAMINE IN NORMAL URINE: FAILURE TO VERIFY HIGH VALUES.
225517 04-16

PHENETHYLAMINES
THE STEREOSELECTIVE INHIBITION OF LIPOLYSIS BY NONPHENOLIC PHENETHYLAMINES.
193456 01-03
CORRELATION OF PSYCHOTOMIMETIC ACTIVITY OF PHENETHYLAMINES AND AMPHETAMINES WITH 1-OCTANOL WATER PARTITION COEFFICIENTS.
208593 03-12
CENTRALLY ACTIVE PHENETHYLAMINES.
217557 04-12

PHENETHYLAMINURIA
EFFECTS OF D-PHENYLALANINE ON CLINICAL PICTURE AND PHENETHYLAMINURIA IN DEPRESSION.
218959 04-09

PHENMETRAZINE
PHARMACOLOGICAL AND TOXICOLOGICAL STUDY OF A NEW PSYCHOTROPIC STIMULANT: THE 2-PHENYLDIMETHYL-TETRAHYDROOXAZINE, IN COMPARISON WITH D,L-AMPHETAMINE, PHENMETRAZINE AND PEMOLINE-MG.
199211 02-04

PHENOBARBITAL
EFFECT OF SINGLE AND DAILY INJECTIONS OF PHENOBARBITAL ON OVULATION IN HAMSTERS.
193421 01-03
COMPARISON OF THE ACTION OF DIAZEPAM AND PHENOBARBITAL USING EEG DERIVED POWER SPECTRA OBTAINED FROM TEMPORAL LOBE EPILEPTICS.
197992 01-13
EFFECTS OF DIAZEPAM AND PHENOBARBITAL ON ELECTRICALLY-INDUCED AMYGDALOID SEIZURES AND SEIZURE DEVELOPMENT.
198612 02-04
THE EFFECTS OF DIPHENYLHYDANTOIN, PHENOBARBITAL, AND DIAZEPAM ON THE PENICILLIN INDUCED EPILEPTOGENIC FOCUS IN THE RAT.
198613 02-03
EFFECTS OF PHENOBARBITAL ON ELECTROCORTICOGRAM AND ACTIVITY, ON REGIONAL CNS ENERGY METABOLISM, AND ON PRESYNAPTIC EVENTS IN CEREBRAL CORTEX AND BRAINSTEM. (PH.D. DISSERTATION).
203033 02-03
EFFECT OF PHENOBARBITAL ADMINISTRATION ON ETHANOL OXIDIZING ENZYMES AND ON RATES OF ETHANOL DEGRADATION.
204386 02-03
PLASMA AND CEREBROSPINAL FLUID CONCENTRATIONS OF PHENOBARBITAL IN INFANTS GIVEN SINGLE DOSES.
206057 03-13
INFLUENCE OF MEPROBAMATE, CARISPRODOL, OXAZEPAM AND PHENOBARBITAL ON NA+ TRANSPORT IN THE ISOLATED FROG SKIN.
206781 03-03
CHLORDIAZEPOXIDE AND PHENOBARBITAL IN A MODEL ANXIETY INDUCING SITUATION.
207775 03-14
NORMAL SHUTTLEBOX AVOIDANCE LEARNING AFTER CHRONIC PHENOBARBITAL INTOXICATION IN MICE.
210737 03-04
EFFECT OF OUABAIN AND PHENOBARBITAL ON THE KINETICS OF CORTICAL METABOLIC TRANSIENTS ASSOCIATED WITH EVOKED POTENTIALS.
210820 03-03
EFFECT OF PHENOBARBITAL ON THE METABOLISM AND SEROTONIN DEPLETING ACTION OF 4-CHLORODIFLUOROAMPHETAMINE IN RATS.
210922 03-03
AGE DIFFERENCES AFFECTING INDUCTION OF HEPATIC DRUG METABOLIZING ENZYMES BY METHAQUALONE AND PHENOBARBITAL IN THE RAT.
217793 04-03
A COMPARISON OF THE INDUCTIVE EFFECTS OF PHENOBARBITAL, METHAQUALONE, AND METHYPRYLON ON HEPATIC MIXED FUNCTION OXIDASE ENZYMES IN THE RAT.
217794 04-03
EFFECT OF CHRONIC PHENOBARBITAL ADMINISTRATION UPON BRAIN GROWTH OF THE INFANT RAT.
217885 04-03
SERUM CONCENTRATIONS OF PHENOBARBITAL AND DIPHENYLHYDANTOIN (PRELIMINARY REPORT).
218011 04-11
EFFECT OF OUABAIN AND PHENOBARBITAL ON OXIDATIVE METABOLIC ACTIVITY ASSOCIATED WITH SPREADING CORTICAL DEPRESSION IN CATS.
220944 04-03
DIFFERENTIAL ATTENUATION OF SOMATOVISCERAL AND VISCEROSOMATIC REFLEXES BY DIAZEPAM, PHENOBARBITAL AND DIPHENYLHYDANTOIN.
222818 04-04
A CLINICAL STUDY OF SERUM CONCENTRATION LEVELS OF PHENOBARBITAL DERIVED FROM PRIMIDONE (MUSOLINE).
224644 04-13

PHENOLIC
ANALYSIS OF PSYCHOACTIVE PHENOLIC AMINES.
202381 02-01
HASHISH. IMPORTANCE OF THE PHENOLIC HYDROXYL GROUP IN TETRAHYDROCANNABINOLS.
208594 03-02

PHENOMENA
TASTE PHENOMENA INFLUENCES ON STIMULATION OF DEPRIVATION INDUCED FLUID CONSUMPTION OF RATS.
197991 01-03
DYSKINETIC PHENOMENA CAUSED BY THE INTRASTRIATAL INJECTION OF PHENYLETHYLAMINE, PHENYLPIPERAZINE, TETRAHYDROISOQUINOLINE AND TETRAHYDRONAPTHALENE DERIVATIVES IN THE GUINEA-PIG.
217671 04-04

PHENOTHIAZINE
PHENOTHIAZINE TRANQUILIZER PD-50S EXERTED AGAINST AMPHETAMINE EFFECT IN AGGREGATED MICE.
193422 01-03
A CASE OF PHENOTHIAZINE ILEUS RECOVERED FROM SHOCK.
193828 01-15
COMMENTS ON TREATMENT: EYE CHANGES FOLLOWING PHENOTHIAZINE ADMINISTRATION.
194749 01-15
INHIBITION OF THE CATALYTIC SITE OF ADENYLATE-CYCLASE IN THE CENTRAL NERVOUS SYSTEM BY PHENOTHIAZINE DERIVATIVES.
195096 01-03
PHENOTHIAZINE AND SCHIZOPHRENIC THOUGHT DISORDER.
198102 02-08
MODIFICATION OF THE RECEPTOR COMPONENT OF ADENYLATE-CYCLASE IN THE RAT BRAIN BY PHENOTHIAZINE DERIVATIVES.
199771 02-03
CRYSTAL STRUCTURE DETERMINATIONS OF THE DONOR ACCEPTOR COMPLEXES OF PHENOTHIAZINE AND PHENOXAZINE WITH NICKEL THIETE. (PH.D. DISSERTATION).
201003 02-01
STUDIES ON ANTIDIURETIC ACTIVITIES AND ON PORTER-SILBERS CHROMOGENS CONTENT IN PLASMA OF PATIENTS WITH ALCOHOLIC DELIRIUM OR WITH ACUTE PHENOTHIAZINE INTOXICATIONS.
203741 02-15
THE EFFECTS OF CHRONIC PHENOTHIAZINE TREATMENT ON ADRENAL PITUITARY FUNCTION IN MAN.
205765 03-13
EFFECTS OF PHENOTHIAZINE WITHDRAWAL ON PROVERB INTERPRETATION BY CHRONIC SCHIZOPHRENICS.
208325 03-08
TREATMENT OF PHENOTHIAZINE INDUCED BULBAR PERSISTENT DYSKINESIA WITH DEANOL ACETAMIDOBENZOATE.
210209 03-13
REACTIVITY OF VARIOUS PHENOTHIAZINE DERIVATIVES WITH OXYGEN AND OXYGEN RADICALS.
210882 03-02
SCHIZOPHRENIA AND EVOKED POTENTIALS: MAXIMUM AMPLITUDE, FREQUENCY OF PEAKS, VARIABILITY, AND PHENOTHIAZINE EFFECTS.
213764 04-08
PHENOTHIAZINE EFFECTS ON CEREBRAL EVOKED POTENTIALS AND EYE MOVEMENTS IN ACUTE SCHIZOPHRENICS.
217454 04-08
COMPETITION FOR PLASMA PROTEIN BINDING SITES BETWEEN PHENOTHIAZINE TRANQUILIZERS AND IMINODIBENZYL ANTIDEPRESSANTS.
217891 04-03
BROM-ERGOCRYPTINE IN THE TREATMENT OF PHENOTHIAZINE INDUCED GALACTORRHOEA.
218557 04-15
THE EFFECT OF NEUROLEPTICS OF THE PHENOTHIAZINE SERIES ON PULSE ACTIVITY AND THE ULTRASTRUCTURE OF RABBIT CORTICAL NEURONS.
219606 04-03

INHIBITION OF CELLULAR ATP HYDROLYZING ACTIVITY BY TRICYCLIC ANTIDEPRESSANTS AND PHENOTHIAZINE TRANQUILIZERS.
221053 04-03

ANTIACCELERATOR AND DECELERATOR ACTIVITY OF ELEVEN PHENOTHIAZINE DERIVATIVES.
221740 04-03

THE INFLUENCE OF SOME PHENOTHIAZINE DERIVATIVES ON RENAL FUNCTION.
223019 04-05

THE EFFECT OF LONG-TERM PHENOTHIAZINE THERAPY ON PLASMA PROLACTIN.
223777 04-15

PHENOTHIAZINES

BRAIN ACETYLCHOLINE AND CHOLINESTERASE: EFFECT OF PHENOTHIAZINES AND PHYSOSTIGMINE INTERACTION IN RATS.
195046 01-03

INHIBITION OF SYNAPTIC VESICULAR MG++ DEPENDENT ATPASE (STENIN) BY ANTIPSYCHOTIC PHENOTHIAZINES.
195054 01-03

TIME-DEPENDENT EFFECTS OF PHENOTHIAZINES ON DOPAMINE TURNOVER IN PSYCHIATRIC PATIENTS. (UNPUBLISHED PAPER).
196087 01-13

THE INHIBITION OF THE EFFECT OF NERVE STIMULATION BY PHENOTHIAZINES ON ISOLATED INNERVATED ORGANS.
197576 01-03

POTENTIAL CARDIOTOXICITY FROM PHENOTHIAZINES AND TRICYCLIC ANTIDEPRESSANTS.
198044 01-15

NEOCORTICAL AND HIPPOCAMPAL ACTIVATION IN RELATION TO BEHAVIOR: EFFECTS OF ATROPINE, ESERINE, PHENOTHIAZINES, AND AMPHETAMINE.
206742 03-04

LONGITUDINAL STUDIES ON THE METABOLITE PATTERN OF PERAZINE AND RELATED PHENOTHIAZINES IN HUMANS AND ANIMALS.
206976 03-13

EXPERIENCE WITH LONG-ACTING PHENOTHIAZINES IN A PSYCHIATRIC HOSPITAL.
208921 03-17

EVALUATION OF BENAPRYZINE IN PSYCHOTIC PATIENTS TREATED WITH PHENOTHIAZINES.
213387 04-07

PHENOTHIAZINES AND THE ELECTROCARDIOGRAM.
213783 04-15

EFFECTS OF PHENOTHIAZINES ON ANXIETY AND COGNITION IN SCHIZOPHRENIA.
216190 04-08

A COMPARISON OF PHENOTHIAZINES IN MANAGING AGGRESSIVE EPISODES IN SCHIZOPHRENIC PATIENTS.
224955 04-08

PHENOTHIAZINES AND STRUCTURALLY RELATED DRUGS. ADVANCES IN BIOCHEMICAL PSYCHOPHARMACOLOGY.
225399 04-17

PHENOXAZINE

CRYSTAL STRUCTURE DETERMINATIONS OF THE DONOR ACCEPTOR COMPLEXES OF PHENOTHIAZINE AND PHENOXAZINE WITH NICKEL THIETE. (PH.D. DISSERTATION).
201003 02-01

PHENOXYBENZAMINE

EFFECTS OF PHENOXYBENZAMINE ON THE NARCOTIC WITHDRAWAL SYNDROME IN THE RAT.
195091 01-03

PHENTOLAMINE

INFLUENCE OF OXYMETAZOLINE AND PHENTOLAMINE ON NORADRENALINE (NA) RELEASE CAUSED BY ELECTRICAL STIMULATION, POTASSIUM, TYRAMINE AND DIMETHYLPHENYLPIPERAZINE (DMPP).
197973 01-03

PHENYLALKYLAMINES

STRUCTURE-ACTIVITY RELATIONSHIPS IN PSYCHOTOMIMETIC PHENYLALKYLAMINES.
196437 01-01

PHENYLBUTAZONE

LIGHT INDUCED FRAGMENTATION OF 3,5-DIOXO-1,2 DIPHENYL-4-N-BUTYLPYRAZOLIDINE (PHENYLBUTAZONE) WITH NUCLEOPHILIC AGENTS.
197675 01-01

A CONTRIBUTION TO THE STUDY OF MECHANISM OF ACTION OF PHENYLBUTAZONE: THE INFLUENCE OF CATECHOLAMINES ON THE ANTIINFLAMATORY EFFECT OF PHENYLBUTAZONE.
205169 02-03

PHENYLDIMETHYLTETRAHYDROOXAZINE

ANTAGONISM OF PSYCHOSTIMULANT 2 PHENYLDIMETHYLTETRAHYDROOXAZINE HYDROCHLORIDE (G-130) TO CENTRAL NERVOUS SYSTEM DEPRESSING DRUGS: MONOAMINEOXIDASE INHIBITORY ACTIVITY AND NOREPINEPHRINE AND SEROTONIN INDUCED CHANGES, COMPARISON WITH DL-AMPHETAMINE.
221267 04-03

PHENYLETHANOLAMINE

DEVELOPMENTAL CHARACTERISTICS OF PHENYLETHANOLAMINE AND OCTOPAMINE IN THE RAT BRAIN.
196804 01-03

BEHAVIORAL AND ELECTROPHYSIOLOGICAL EFFECTS OF PHENYLETHANOLAMINE AND 2-PHENYLETHYLAMINE.
217521 04-04

PHENYLETHYLAMINE

DYSKINETIC PHENOMENA CAUSED BY THE INTRASTRIATAL INJECTION OF PHENYLETHYLAMINE, PHENYLPIPERAZINE, TETRAHYDROISOQUINOLINE AND TETRAHYDRONAPTHALENE DERIVATIVES IN THE GUINEA-PIG.
217671 04-04

PHENYLPIPERAZINE

DYSKINETIC PHENOMENA CAUSED BY THE INTRASTRIATAL INJECTION OF PHENYLETHYLAMINE, PHENYLPIPERAZINE, TETRAHYDROISOQUINOLINE AND TETRAHYDRONAPTHALENE DERIVATIVES IN THE GUINEA-PIG.
217671 04-04

PHENYLPROPYLAMINE

COMPARISON OF THE SPECIFICITY OF 3-(P-TRIFLUOROMETHYLPHENOXY)-N-METHYL-3 PHENYLPROPYLAMINE AND CHLORIMIPRAMINE AS AMINE UPTAKE INHIBITORS IN MICE.
197870 01-03

PHEOCHROMOCYTOMA

A CASE OF PHEOCHROMOCYTOMA WITH SCHIZOPHRENIA LIKE SYMPTOMS.
210794 03-17

PHERPACET

THE INFLUENCE OF ALKYLATE PHERPACET DERIVATIVES ON NEURON POPULATIONS IN THE MIDBRAIN RETICULAR FORMATION.
219501 04-03

PHOBIAS

A GENERAL PRACTITIONER TRIAL OF CLOMIPRAMINE (ANAFRANIL) IN OBSESSIONS AND PHOBIAS.
215157 04-10

PHOBIC

PHENELZINE IN PHOBIC STATES.
206367 03-10

THE USE OF CLOMIPRAMINE IN PHOBIC PATIENTS; PRELIMINARY RESEARCH REPORT.
209488 03-10

PHARMACOLOGICAL TREATMENT OF PHOBIC - OBSESSIVE PSYCHONEUROSES: PSYCHODYNAMIC AND SYMPTOMATOLOGICAL ASPECTS.
210506 03-10

THE ROLE OF INTRAVENOUS CLOMIPRAMINE IN THE TREATMENT OF OBSESSIONAL AND PHOBIC DISORDERS.
214835 04-10

A PILOT STUDY OF ANAFRANIL IN THE TREATMENT OF PHOBIC STATES.
214836 04-10

AN INVESTIGATION INTO THE USE OF ANAFRANIL IN PHOBIC AND OBSESSIONAL DISORDERS.
214837 04-10

CLOMIPRAMINE (ANAFRANIL) IN THE TREATMENT OF PHOBIC STATES: A PSYCHIATRISTS VIEW.
215156 04-10

EXPERIENCES WITH CLOMIPRAMINE (ANAFRANIL) IN THE TREATMENT OF THE PHOBIC ANXIETY STATES IN GENERAL PRACTICE.
215158 04-10

PHOSPHATE

EFFECT OF NEUROTROPIC AGENTS ON TOTAL PYRIDOXAL PHOSPHATE AND ON THE ACTIVITY OF THE DECARBOXYLASE OF AROMATIC AMINO ACIDS AS WELL AS OF OTHER PYRIDOXAL PHOSPHATE DEPENDENT ENZYMES IN RAT BRAIN.
199785 02-03

INCORPORATION OF ACETATE (C14)(P-32) AND PHOSPHATE INTO THE BRAIN LIPIDS DURING BLOCKAGE OF THE CHOLINORECEPTOR AND ADRENORECEPTORS.
202599 02-03

SEX DIFFERENCES IN THE EFFECTS OF DEXAMETHASONE PHOSPHATE ON BEHAVIOR IN RATS.
218492 04-04

LITHIUM, CALCIUM, AND PHOSPHATE.
221417 04-15

PHOSPHODIESTERASE

ADENOSINE 3,5 MONOPHOSPHATE IN CULTURED NEUROBLASTOMA CELLS: EFFECT OF ADENOSINE, PHOSPHODIESTERASE INHIBITORS AND BENZAZEPINES.
195254 01-03

ANXIETY AND ACTIVITIES OF CYCLIC ADENOSINE-MONOPHOSPHATE PHOSPHODIESTERASE.
202161 02-17

ON THE REGULATION OF CYCLIC-AMP PHOSPHODIESTERASE BY A SPECIFIC PROTEIN ACTIVATOR. (UNPUBLISHED PAPER).
208735 03-03

RAT PINEAL CYCLIC ADENOSINE-3-5-MONOPHOSPHATE PHOSPHODIESTERASE ACTIVITY: IN VIVO MODULATION BY A BETA ADRENERGIC RECEPTOR.
215600 04-03

PHOSPHOLIPID
THE METABOLISM OF INDIVIDUAL PHOSPHOLIPID FRACTIONS IN THE RAT BRAIN DURING THIOPENTAL SLEEP AND AMPHETAMINE EXCITATION.
219747 04-03

PHOSPHOLIPIDS
THE INFLUENCE OF CHLORPROMAZINE AND RESERPINE ON THE METABOLISM OF CEREBRAL PHOSPHOLIPIDS IN THE RAT IN VIVO.
197477 01-03

PHOSPHORYLASE
THE INCORPORATION OF GLUCOSE INTO BRAIN GLYCOGEN AND THE ACTIVITIES OF CEREBRAL GLYCOGEN PHOSPHORYLASE AND SYNTHETASE: SOME EFFECTS OF AMPHETAMINE.
196808 01-03

PHOTIC
ELECTROPHYSIOLOGICAL AND BEHAVIORAL REACTIVITY TO PHOTIC STIMULI FOLLOWING SEPTAL LESIONS AND PHARMACOLOGICAL TREATMENTS IN RATS.
206724 03-04

PHOTICALLY
PHARMACOLOGICAL MODULATION OF PHOTICALLY EVOKED AFTERDISCHARGE PATTERNS IN HOODED LONG-EVANS RATS.
201409 02-03
MODULATION OF PHOTICALLY EVOKED AFTERDISCHARGES BY MEANS OF PHARMACOLOGICAL AND BEHAVIORAL AROUSAL. (PH.D. DISSERTATION).
222644 04-03

PHOTOSENSITIVITY
CELLULAR MECHANISMS OF CHLORPROMAZINE PHOTOSENSITIVITY.
204233 02-15
THE CLINICAL RELEVANCE OF PHOTOSENSITIVITY IN PSYCHIATRIC EEG DIAGNOSIS.
209018 03-15

PHRENIC
EFFECTS OF DIAZEPAM ON DISCHARGE PATTERN IN SINGLE FIBRES OF PHRENIC NERVE.
197577 01-03
EFFECTS OF METHAMPHETAMINE ON THE ISOLATED RAT PHRENIC NERVE DIAPHRAM PREPARATION.
210900 03-03

PHYSALAEMIN
BEHAVIOURAL AND ELECTROCORTICAL MODIFICATIONS INDUCED IN THE RAT BY INTRAVENTRICULAR INJECTION OF PHYSALAEMIN AND ELEDOISIN.
198224 02-03

PHYSICAL
THE EFFECT OF BEDREST AND OF PHYSICAL ACTIVITY ON THE BLOOD LEVEL OF GENTAMYCIN AFTER INTRAMUSCULAR APPLICATION.
197956 01-13
THE INFLUENCE OF ANIONS ON THE PHYSICAL PROPERTIES OF BUTYROPHENONE-TYPE MOLECULES. (PH.D. DISSERTATION).
200310 02-01
SCHIZOPHRENIA -- 5: PHYSICAL TREATMENTS AND DRUGS.
216403 04-08
THE EFFECT OF PSYCHOTROPIC AGENTS ON THE MENTAL AND PHYSICAL WORKING CAPACITY IN RATS.
219748 04-04

PHYSIOLOGIC
PHYSIOLOGIC, BIOCHEMICAL, AND CLINICAL EFFECTS OF KETAMINE HYDROCHLORIDE IN GOATS (CAPRA-HIRCUS) WITH AND WITHOUT PREMEDICATION. (PH.D. DISSERTATION).
194700 01-03
PHYSIOLOGIC FACTORS IN PSYCHOTROPIC DRUG THERAPY.
213616 04-03

PHYSIOLOGICAL
THE ELECTROENCEPHALOGRAM AS A PHYSIOLOGICAL AND PHARMACOLOGICAL OBSERVABLE.
207549 03-06
SEDATIVE EFFECTS ON PHYSIOLOGICAL AND PSYCHOLOGICAL MEASURES IN ANXIOUS PATIENTS.
209079 03-10
PHYSIOLOGICAL MANAGEMENT OF HOSPITALIZED PSYCHIATRIC PATIENTS.
209399 03-11
ON THE PHYSIOLOGICAL MECHANISMS OF THE INFLUENCE OF PHENAMINE AND MICROPOLARIZATION ON LONG-TERM MEMORY PROCESSES.
213491 04-04
BEHAVIORAL AND PHYSIOLOGICAL FEEDBACK AS SOURCES OF INFORMATION ABOUT THE EFFECTIVENESS OF A PLACEBO. (PH.D. DISSERTATION).
214228 04-17
PHYSIOLOGICAL MECHANISMS FOR CARDIAC CONTROL BY NUTRITIONAL INTAKE AFTER EARLY MATERNAL SEPARATION IN THE YOUNG RAT.
218047 04-03
CORRELATED HISTOCHEMICAL, ELECTRON MICROSCOPICAL, PHARMACOLOGICAL AND PHYSIOLOGICAL OBSERVATION ON AMINERGIC MECHANISMS IN THE CENTRAL NERVOUS SYSTEM. (UNPUBLISHED PAPER).
218300 04-03
PHYSIOLOGICAL AND PHARMACOLOGICAL EVIDENCE FOR A SEROTONERGIC PROJECTION TO THE HIPPOCAMPUS.
223171 04-03

PHYSIOLOGY
BEHAVIOR: BIOLOGY, PHYSIOLOGY, PHARMACOLOGY.
207204 03-17
PHARMACOLOGY AND PHYSIOLOGY OF STEREOTYPED BEHAVIOR.
207284 03-04

PHYSOSTIGMINE
THE EFFECTS OF PHYSOSTIGMINE DURING THE ACQUISITION OF AVOIDANCE BEHAVIOUR AS A FUNCTION OF THE INTERSESSION INTERVAL.
192951 01-04
TOLERANCE DEVELOPMENT TO THE ANTINOCICEPTIVE ACTIONS OF MORPHINE, AMPHETAMINE, PHYSOSTIGMINE AND 2-AMINOINDANE IN THE MOUSE.
194930 01-03
BRAIN ACETYLCHOLINE AND CHOLINESTERASE: EFFECT OF PHENOTHIAZINES AND PHYSOSTIGMINE INTERACTION IN RATS.
195046 01-03
THE EFFECTS OF LITHIUM AND PHYSOSTIGMINE ON RAT BRAIN ACETYLCHOLINESTERASE ACTIVITY.
195436 01-03
PHYSOSTIGMINE ATTENUATION OF DELTA9-TETRAHYDROCANNABINOL INDUCED HYPERTHERMIA IN RATS.
195539 01-03
CATECHOLAMINE DEPLETING ACTION OF PHYSOSTIGMINE IN THE RAT BRAIN.
197575 01-03
EFFECTS OF PHYSOSTIGMINE ON THE ACCURACY AND ACTIVITY OF DISCRIMINATION BEHAVIOUR IN RATS.
197995 01-04
EFFECTS OF OXOTREMORINE AND PHYSOSTIGMINE ON THE TURNOVER OF DOPAMINE IN THE CORPUS-STRIATUM AND THE LIMBIC SYSTEM.
198207 02-03
THE EFFECTS OF SCOPOLAMINE AND PHYSOSTIGMINE ON FIXED-INTERVAL BEHAVIOUR IN THE RAT.
200046 02-04
TRICYCLIC ANTIDEPRESSANT POISONING: REVERSAL OF COMA, CHOREOATHETOSIS, AND MYOCLONUS BY PHYSOSTIGMINE.
202919 02-15
REVERSAL OF AMITRIPTYLINE INTOXICATION BY PHYSOSTIGMINE.
202922 02-15
INTERACTION OF PHYSOSTIGMINE AND DELTA9-TETRAHYDROCANNABINOL IN MAN.
210828 03-03
A FURTHER STUDY ON THE EFFECT OF PHYSOSTIGMINE ON MEMORY IN RATS.
210916 03-04
PHYSOSTIGMINE: ITS USE IN ACUTE ANTICHOLINERGIC SYNDROME WITH ANTIDEPRESSANT AND ANTIPARKINSON DRUGS.
211416 03-15
THE CENTRAL ANTICHOLINERGIC SYNDROME: MANAGEMENT WITH PHYSOSTIGMINE.
211427 03-15
PHYSOSTIGMINE SALICYLATE IN THE TREATMENT OF TRICYCLIC ANTIDEPRESSANT OVERDOSAGE.
212265 03-15
REVERSAL OF DELIRIUM INDUCED BY TRICYCLIC ANTIDEPRESSANT DRUGS WITH PHYSOSTIGMINE.
213708 04-15
THE EFFECTS OF SCOPOLAMINE (0.6 MG) AND PHYSOSTIGMINE (1.0 MG) ON HIGHER NERVOUS ACTIVITY IN MAN, FOLLOWED-UP DURING 5 HOURS AFTER APPLICATION.
217205 04-14
PHYSOSTIGMINE -- ANTIDOTE FOR ANTICHOLINERGIC POISONING.
219621 04-15
EFFECTS OF SCOPOLAMINE, PHYSOSTIGMINE AND CHLORDIAZEPOXIDE ON PUNISHED AND EXTINGUISHED WATER CONSUMPTION IN RATS.
221043 04-04
PHYSOSTIGMINE INDUCED REVERSAL OF EEG AND BEHAVIORAL EFFECTS OF DELTA9-TETRAHYDROCANNABINOL.
223093 04-04

PI-ELECTRONIC
A QUANTUM CHEMICAL INVESTIGATION OF THE PI-ELECTRONIC STRUCTURE OF THE HALLUCINOGENIC N,N-DIMETHYLTRYPTAMINES.
195119 01-01

PICKS
AFFECTS OF L-DOPA ON THE PSYCHOLOGICAL SYMPTOMS OF PICKS DISEASE.
211365 03-11

PICOLINAMIDE
EFFECTS OF 5-(N-BUTYL) PICOLINAMIDE (SCH-10595), A DOPAMINE-BETA-HYDROXYLASE INHIBITOR, ON SEROTONIN AND CATECHOLAMINE METABOLITES IN BRAIN.
197813 01-03

PICOMOLE
MASS FRAGMENTOGRAPHY OF PICOMOLE QUANTITIES OF BIOGENIC AMINE METABOLITES IN HUMAN CEREBROSPINAL FLUID AS WELL AS WHOLE RAT BRAINS. (UNPUBLISHED PAPER).
217219 04-06

PICOMOLES
CHLORPROMAZINE METABOLISM IV: QUATERNIZATION AS A KEY TO DETERMINATION OF PICOMOLES OF CHLORPROMAZINE AND OTHER TERTIARY AMINE DRUGS.
217667 04-06

PICROTOXIN
ACTIONS OF GABA, PICROTOXIN AND BICUCULLINE ON ADRENAL MEDULLA.
193455 01-03
EFFECTS OF NIKETHAMIDE, PICROTOXIN AND STRYCHNINE ON AMPHETAMINE STATE.
199967 02-03

PIERIS-BRASSICAE
LSD TREATMENT OF PIERIS-BRASSICAE AND CONSEQUENCES ON THE PROGENY.
199425 02-04

PIGEON
THE EFFECT OF CYCLOHEXIMIDE AND ACTINOMYCIN-D ON THE SPONTANEOUS AND OPERATIVE BEHAVIORS OF THE PIGEON. PRELIMINARY NOTE.
199381 02-04
COMPARISON OF MORPHINE AND CHLORPROMAZINE EFFECTS ON MODERATELY AND SEVERELY SUPPRESSED PUNISHED RESPONDING IN THE PIGEON.
202666 02-04

PIGEONS
INFLUENCE OF RESPONSE TOPOGRAPHY ON THE EFFECT OF APOMORPHINE AND AMPHETAMINE ON OPERANT BEHAVIOR OF PIGEONS.
217468 04-04

PIGS
TRANQUILIZING EFFECTS OF DIAZEPAM IN PIGS SUBJECTED TO A PUNISHMENT PROCEDURE.
210741 03-04

PILOCARPINE
SOME EFFECTS OF PILOCARPINE AND ACETYLCHOLINE ON THE RESPONSES OF THE GUINEA-PIG VAS-DEFERENS TO HYPOGASTRIC NERVE STIMULATION AND TRANSMURAL STIMULATION AND APPLIED (-) NORADRENALINE.
210770 03-03

PILOT
PIMOZIDE (R-6238) IN SCHIZOPHRENIA (A PILOT STUDY).
196707 01-08
PILOT CLINICAL STUDY WITH TRIFLUPERIDOL (TRISEDYL) THERAPY IN PSYCHOTIC PATIENTS.
205589 02-09
THE EFFECT OF SYDNOCARB ON SOME PSYCHOLOGICAL AND AUTONOMIC TESTS: A PILOT STUDY.
205599 02-13
L-DOPA AND TRICYCLIC ANTIDEPRESSANTS IN AFFECTIVE DISORDERS. A PILOT STUDY.
205601 03-09
A PILOT STUDY OF PIMOZIDE IN SCHIZOPHRENIA.
207293 03-08
FLUPENTHIXOL DECANOATE IN PSYCHOTIC ADULTS -- PILOT STUDY.
209071 03-08
THE ACTION OF CHLORIMIPRAMINE IN OBSESSIVE COMPULSIVE NEUROSIS: A PILOT STUDY.
209489 03-10
A PILOT STUDY OF ANAFRANIL IN THE TREATMENT OF PHOBIC STATES.
214836 04-10
PILOT STUDY OF 2-PYRROLIDON ACETAMIDE (GENERIC NAME: PIRACETAM).
221338 04-08

PIMOZIDE
CLINICAL EFFICACY OF PIMOZIDE IN HOSPITALISED CHRONIC SCHIZOPHRENICS.
195615 01-08
SPONTANEOUS ORAL DYSKINESIA: RESULTS OF TREATMENT WITH TETRABENAZINE, PIMOZIDE, OR BOTH.
196600 01-11
PIMOZIDE (R-6238) IN SCHIZOPHRENIA (A PILOT STUDY).
196707 01-08
A COMPARISON OF PIMOZIDE AND THIORIDAZINE AS ANTAGONISTS OF AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR IN DOGS.
197470 01-04
A CONTROLLED CLINICAL TRIAL OF PIMOZIDE (R-6238) -- A NEW NEUROLEPTIC.
200897 02-08
A PILOT STUDY OF PIMOZIDE IN SCHIZOPHRENIA.
207293 03-08
PIMOZIDE IN CHRONIC SCHIZOPHRENIC OUTPATIENTS.
209905 03-08
CHOLINERGIC DOPAMINERGIC INTERACTION IN THE STRIATUM: THE EFFECT OF 6-HYDROXYDOPAMINE OR PIMOZIDE TREATMENT ON THE INCREASED STRIATAL ACETYLCHOLINE LEVELS INDUCED BY APOMORPHINE, PIRIBEDIL AND D-AMPHETAMINE.
210668 03-03
THE EFFECT OF DRUGS WITH ANTIDEPRESSANT ACTIVITY UPON THE HYPOTHERMIA AND BEHAVIOURAL DEPRESSION INDUCED IN MICE BY PIMOZIDE OR CENTRALLY ADMINISTERED NORADRENALINE.
210762 03-04
BLOCKADE BY PIMOZIDE OF A NORADRENALINE SENSITIVE ADENYLATE-CYCLASE IN THE LIMBIC FOREBRAIN: POSSIBLE ROLE OF LIMBIC NORADRENERGIC MECHANISMS IN THE MODE OF ACTION OF ANTIPSYCHOTICS.
210771 03-03
THE USE OF PIMOZIDE IN PEDOPSYCHIATRY.
212494 03-11
INCREASED LEVEL PRESSING FOR AMPHETAMINE AFTER PIMOZIDE IN RATS: IMPLICATIONS FOR A DOPAMINE THEORY OF REWARD.
213350 03-04
RADIOIMMUNOASSAY OF THE NEUROLEPTIC DRUG PIMOZIDE.
213986 04-06
CLINICAL STUDY OF PIMOZIDE.
217171 04-09
EFFECTS OF CENTRAL DOPAMINERGIC BLOCKADE WITH PIMOZIDE UPON THE EEG STAGES OF SLEEP IN MAN.
217546 04-14
A MULTICENTRIC EVALUATION OF PIMOZIDE (ORAP) IN PATIENTS WHO USUALLY WOULD TAKE TRANQUILIZERS.
218750 04-10
THE ACTION OF PIMOZIDE ON ACUTE PSYCHOSIS.
219960 04-09
PIMOZIDE IN MONOSYMPTOMATIC PSYCHOSIS.
223320 04-09

PINAZEPAM
TOXICOLOGICAL AND PHARMACOLOGICAL INVESTIGATIONS OF PINAZEPAM (7-CHLORO-1-PROPARGYL-5-PHENYLBENZODIAZEPIN-2-ONE): A NEW THERAPEUTIC AGENT.
221723 04-02

PINDOLOL
EFFECT OF BETA-RECEPTOR BLOCKERS (PINDOLOL AND PRACTOLOL) ON LITHIUM INDUCED TREMOR -- CLINICAL TRIAL AND THEORETICAL CONSIDERATIONS.
204409 02-15
PINDOLOL: A NEW PSYCHOTROPIC DRUG.
206836 03-04
PRELIMINARY STUDY OF A BETA-BLOCKER (PINDOLOL) IN THREE SCHIZOPHRENICS AND THREE NONPSYCHOTIC PSYCHIATRIC PATIENTS: DIFFERENTIAL SENSITIVITY IN HEART RATE.
212164 03-13

PINEAL
SEIZURES IN RATS INDUCED BY PINEALECTOMY: INFLUENCE OF DIAZEPAM, CHLORDIAZEPOXIDE, AND DIPHENYLHYDANTOIN AND PINEAL SUBSTANCES.
197465 01-03
METHODS TO STUDY THE IN VIVO REGULATION OF CYCLIC NUCLEOTIDES IN HYPOTHALAMIC NUCLEI, PITUITARY AND PINEAL. (UNPUBLISHED PAPER).
201491 02-06
RAT PINEAL CYCLIC ADENOSINE-3-5-MONOPHOSPHATE PHOSPHODIESTERASE ACTIVITY: IN VIVO MODULATION BY A BETA ADRENERGIC RECEPTOR.
215600 04-03
BETA-ADRENERGIC STIMULATION OF PINEAL N-ACETYLTRANSFERASE: CYCLIC-AMP STIMULATES BOTH RNA AND PROTEIN SYNTHESIS.
215601 04-03
PINEAL BETA-ADRENERGIC RECEPTOR: CORRELATION OF BINDING OF H3-1-ALPRENOLOL WITH STIMULATION OF ADENYLCYCLASE. (UNPUBLISHED PAPER).
224096 04-03

PINEALECTOMY
SEIZURES IN RATS INDUCED BY PINEALECTOMY: INFLUENCE OF DIAZEPAM, CHLORDIAZEPOXIDE, AND DIPHENYLHYDANTOIN AND PINEAL SUBSTANCES.
197465 01-03

PIPAMPERONE
CLASTOGENIC EFFECTS OF HALOPERIDOL IN VIVO AND OF HALOPERIDOL, DROPERIDOL, AND PIPAMPERONE IN VITRO: A NEGATIVE STUDY.
221270 04-15

PIPERACETAZINE
PIPERACETAZINE STUDY IN STATE HOSPITAL PATIENTS.
203423 02-11

PIPERAZINE
AN INVESTIGATION OF PSYCHOTROPIC ACTIVITY IN A SERIES OF PIPERAZINE (1,2-A) INDOLE DERIVATIVES.
206438 03-02

PIPERAZINYLDIBENZOAZEPINES
NEUROLEPTIC PIPERAZINYLDIBENZOAZEPINES: CHEMISTRY AND STRUCTURE-ACTIVITY RELATIONSHIPS.
221734 04-01

PIPERIDINE
PIPERIDINE CONCENTRATION CHANGES IN THE BRAIN AND BLOOD OF DORMANT MICE.
210701 03-03
SLEEP INDUCING EFFECT OF PIPERIDINE.
220945 04-03

PIPERIDINO-4-CARBAMOYL-PIPERIDINO
STUDIES ON PSYCHOTROPIC DRUGS: XVII. EFFECTS OF 3-CHLORO-5-(3-(4 PIPERIDINO-4-CARBAMOYL-PIPERIDINO)PROPYL) 10,11-DIHYDRO-5(H) DIBENZAZEPINE DIHYDROCHLORIDE MONOHYDRATE (Y-4153) ON THE METABOLISM OF BIOGENIC AMINES.
199210 02-03

PIPOTHIAZINE
MONTHLY INTERMITTENT CHEMOTHERAPY OF CHRONIC SCHIZOPHRENIC OUTPATIENTS WITH PIPOTHIAZINE PALMITATE.
204169 02-08
PIPOTHIAZINE PALMITATE: AN EVALUATION OF A NEW LONG-ACTING INTRAMUSCULAR ANTIPSYCHOTIC AGENT IN SEVERELY ILL SCHIZOPHRENIC PATIENTS.
216188 04-08
CROSS-ANALYSIS OF A CONTROLLED EXPERIMENT WITH PIPOTHIAZINE AND FLUPHENAZINE ENANTHATE.
221636 04-08
CLINICAL STUDY OF FIVE DEPOT NEUROLEPTICS, COMPARISON OF ACTIVITY PROFILES OF FLUPHENAZINE DECANOATE, FLUSPIRILENE, PENFLURIDOL, PERPHENAZINE ENANTHATE AND PIPOTHIAZINE PALMITATE.
221822 04-08

PIPOTIAZINE
A STUDY OF FLUPENTHIXOL DECANOATE AND PIPOTIAZINE UNDECYLENATE IN SCHIZOPHRENICS.
212238 03-08

PIPRADROL
PSYCHOPHARMACOLOGIC INVESTIGATIONS IN HEALTHY ELDERLY VOLUNTEERS: EFFECTS OF PIPRADROL - VITAMIN (ALERTONIC) ELIXIR AND PLACEBO IN RELATION TO RESEARCH DESIGN.
218217 04-11

PIRACETAM
A DOUBLE-BLIND STUDY ON THE EFFECTS OF PIRACETAM UPON PERCEPTUAL AND PSYCHOMOTOR PERFORMANCE AT VARIED HEART RATES IN PATIENTS TREATED WITH ARTIFICIAL PACEMAKERS.
201328 02-13
THE ACTIVITY PROFILE OF PIRACETAM IN PSYCHOSYNDROMES AND SYMPTOMATIC PSYCHOSES.
204411 02-09
EXPERIMENTAL EEG STUDIES ON BARBITURATE INTOXICATION AND PIRACETAM.
205507 02-03
PROTECTIVE EFFECT OF PIRACETAM IN EXPERIMENTAL BARBITURATE INTOXICATION: EEG AND BEHAVIOURAL STUDIES.
213589 04-03
PILOT STUDY OF 2-PYRROLIDON ACETAMIDE (GENERIC NAME: PIRACETAM).
221338 04-08

PIRAZIDOL
TREATMENT OF DEPRESSION WITH PIRAZIDOL.
224083 04-09

PIRIBEDIL
EFFECTS OF PIRIBEDIL ON NORADRENALINE AND MOPEG-SO4 LEVELS IN THE RAT BRAIN.
197868 01-03
DOPAMINE AGONIST AND ANTAGONIST ACTIVITIES OF PIRIBEDIL (ET495) AND ITS METABOLITES.
197930 01-04
CHOLINERGIC DOPAMINERGIC INTERACTION IN THE STRIATUM: THE EFFECT OF 6-HYDROXYDOPAMINE OR PIMOZIDE TREATMENT ON THE INCREASED STRIATAL ACETYLCHOLINE LEVELS INDUCED BY APOMORPHINE, PIRIBEDIL AND D-AMPHETAMINE.
210668 03-03
BEHAVIOURAL EVIDENCE OF DOPAMINE RECEPTOR STIMULATION BY PIRIBEDIL (ET495) AND ITS METABOLITE S584.
217152 04-04

PITHED
BLOOD PRESSURE AND HEART RATE RESPONSES EVOKED BY D- AND L-AMPHETAMINE IN THE PITHED RAT PREPARATION.
215687 04-03

PITUITARY
EFFECTS OF CENTRAL ACTING DRUGS AND ERGOT DERIVATIVES ON PROLACTIN AND GROWTH HORMONE SECRETION, ON GROWTH OF PITUITARY AND MAMMARY TUMORS AND ON REPRODUCTION IN OLD RATS. (PH.D. DISSERTATION).
194571 01-03
METHODS TO STUDY THE IN VIVO REGULATION OF CYCLIC NUCLEOTIDES IN HYPOTHALAMIC NUCLEI, PITUITARY AND PINEAL. (UNPUBLISHED PAPER).
201491 02-06
THE EFFECTS OF CHRONIC PHENOTHIAZINE TREATMENT ON ADRENAL PITUITARY FUNCTION IN MAN.
205765 03-13
ROLE OF PITUITARY ADRENOCORTICAL SYSTEM IN MEDIATING AVOIDANCE BEHAVIOR OF RATS WITH SEPTAL LESIONS.
206739 03-04
EFFECT OF L-DOPA ON PITUITARY HORMONES AND ON CARBOHYDRATE AND FAT METABOLISM IN NORMALS AND IN PARKINSONS DISEASE.
207153 03-13
ROLE OF BRAIN SEROTONIN IN THE INTEGRATION OF BEHAVIORAL RESPONSES AND PITUITARY ADRENOCORTICAL FUNCTIONS UNDER EMOTION.
218364 04-04
HIPPOCAMPAL AND PITUITARY ADRENAL INFLUENCES ON ACTIVITY AND AVOIDANCE BEHAVIOR. (PH.D. DISSERTATION).
219289 04-04
NEUROTRANSMITTERS AFFECTING PITUITARY HORMONE RELEASE. (UNPUBLISHED PAPER).
219633 04-03

PLACEBO
HALOPERIDOL FOR CHRONICALLY HOSPITALIZED PSYCHOTICS: A DOUBLE-BLIND COMPARISON WITH THIOTHIXENE AND PLACEBO: A FOLLOWUP OPEN EVALUATION.
196676 01-14
A COMPARATIVE STUDY OF AMPHETAMINE, EPHEDRINE ATROPINE MIXTURE, PLACEBO AND BEHAVIORAL CONDITIONING IN THE TREATMENT OF NOCTURNAL ENURESIS.
198020 01-11
A CONTROLLED COMPARISON OF THE EFFECTS OF DIPHENYLHYDANTOIN AND PLACEBO ON MOOD AND PSYCHOMOTOR FUNCTIONING IN NORMAL VOLUNTEERS.
199518 02-14
A COMPARATIVE STUDY OF THE HYPNOTIC PROPERTIES OF FLURAZEPAM (30 MG), SECOBARBITAL (100 MG), AND OF PLACEBO AMONG FOUR TYPES OF PSYCHOTIC INSOMNIACS.
203204 02-04
THE DIFFERENTIATION OF TWO TYPES OF HYPERACTIVE CHILDREN BY ACTIVITY LEVEL AND TASK PERFORMANCE WITH METHYLPHENIDATE (RITALIN) AND PLACEBO. (PH.D. DISSERTATION).
204688 02-11
COMPARATIVE STUDIES OF VERBAL INTERACTIONS IN A GROUP OF HEALTHY SUBJECTS UNDER THE INFLUENCE OF PSYCHOPHARMACOLOGICAL AGENTS: WITH SPECIAL CONSIDERATION OF YG-19256, CHLORDIAZEPOXIDE AND PLACEBO.
207140 03-14
SULPIRIDE VERSUS CHLORPROMAZINE AND PLACEBO IN THE TREATMENT OF RESTLESS MENTALLY SUBNORMAL PATIENTS -- A DOUBLE-BLIND CROSSOVER STUDY.
209702 03-11
THE PLACEBO EFFECT: AN INTEGRATED ANALYSIS OF THEORETICAL AND RESEARCH PERSPECTIVES. (PH.D. DISSERTATION).
212593 03-17
CLINICAL AND EXPERIMENTAL COMPARISON OF DIAZEPAM, CHLORAZEPATE AND PLACEBO.
214018 04-14
BEHAVIORAL AND PHYSIOLOGICAL FEEDBACK AS SOURCES OF INFORMATION ABOUT THE EFFECTIVENESS OF A PLACEBO. (PH.D. DISSERTATION).
214228 04-17
COMPARISON OF THE HYPNOTIC ACTIVITY OF TRIAZOLAM, FLURAZEPAM HYDROCHLORIDE, AND PLACEBO.
215673 04-14
PSYCHOPHARMACOLOGIC INVESTIGATIONS IN HEALTHY ELDERLY VOLUNTEERS: EFFECTS OF PIPRADROL - VITAMIN (ALERTONIC) ELIXIR AND PLACEBO IN RELATION TO RESEARCH DESIGN.
218217 04-11
PLACEBO INDUCED SIDE-EFFECTS.
221165 04-15
EFFECT OF LITHIUM ON NEUROLEPTIC-INDUCED TARDIVE DYSKINESIA COMPARED WITH PLACEBO IN A DOUBLE-BLIND CROSSOVER TRIAL.
221335 04-15
A COMPARISON OF MAPROTILINE (LUDIOMIL) AND PLACEBO IN THE TREATMENT OF DEPRESSION.
221656 04-09
RELIABILITY AND VALIDITY OF A PLACEBO TEST.
224894 04-16
AMOXAPINE, IMIPRAMINE AND PLACEBO IN DEPRESSIVE ILLNESS.
225063 04-09
BENZOCTAMINE (TACITIN) VERSUS PLACEBO: A DOUBLE-BLIND CROSSOVER STUDY IN ANXIETY NEUROTICS.
225064 04-10
DEPRESSION AND ANXIETY IN HEROIN ADDICTS: A PLACEBO CONTROLLED STUDY OF DOXEPIN IN COMBINATION WITH METHADONE.
225386 04-09
COMPARATIVE SYMPTOMATOLOGICAL AND EVOKED POTENTIAL STUDIES WITH D-AMPHETAMINE, THIORIDAZINE, AND PLACEBO IN HYPERKINETIC CHILDREN.
225516 04-10

PLACEBOS
THE VALIDITY OF IDENTICAL MATCHING PLACEBOS.
193073 01-16

DRUGS AND PLACEBOS: EFFECTS OF CAFFEINE ON COGNITIVE PERFORMANCE.
205223 02-14

PLACENTAL

PLACENTAL TRANSFER OF DIAZEPAM AND ITS DISPOSITION IN THE NEWBORN.
215672 04-13

PLASMA

DOES MAPROTILINE (LUDIOMIL) INFLUENCE SEROTONIN UPTAKE AND FREE TRYPTOPHAN CONCENTRATION IN HUMAN PLASMA
192943 01-13

EFFECT OF 6-HYDROXYDOPAMINE ON HYPOTHALAMIC NOREPINEPHRINE AND DOPAMINE CONTENT, ULTRASTRUCTURE OF THE MEDIAN EMINENCE, AND PLASMA CORTICOSTERONE.
193050 01-03

THE EFFECT OF DAILY ORAL DOSAGE OF DIAZEPAM, PLASMA CONCENTRATIONS AND METABOLIC CLEARANCE OF DIAZEPAM AND DEMETHYLDIAZEPAM ON VARIOUS CONSTITUENTS OF THE ACUTE CLINICAL ANXIETY SYNDROME.
196191 01-10

PLASMA LITHIUM LEVELS AND SIDE-EFFECTS DURING ADMINISTRATION OF A SLOW-RELEASE LITHIUM SULPHATE PREPARATION (LITHIUM LIPETT-C) AND LITHIUM CARBONATE LEVELS.
197029 01-15

INFLUENCE OF CATECHOLAMINE UPTAKE BLOCKING DRUGS ON THE INCREASE IN WATER INTAKE AND PLASMA RENIN CONCENTRATION INDUCED BY SOME HYPOTENSIVE DRUGS.
197288 01-03

PLASMA NORTRIPTYLINE AND CLINICAL RESPONSE.
198029 01-09

PLASMA LEVELS OF IMIPRAMINE AND CLINICAL OUTCOME.
198097 02-07

PLASMA TRYPTOPHAN TOLERANCE CURVES IN DRUG-FREE NORMAL CONTROLS, SCHIZOPHRENIC PATIENTS AND PRISONER VOLUNTEERS.
200773 02-13

EFFECTS OF CONJUGATED ESTROGENS ON PLASMA BUTAPERAZINE LEVELS.
201327 02-13

PLASMA TESTOSTERONE LEVELS DURING CHRONIC HEROIN USE AND PROTRACTED ABSTINENCE.
202307 02-13

STEADY-STATE PLASMA CONCENTRATIONS DURING SINGLE AND MULTIPLE DOSAGE SCHEDULES OF AMITRIPTYLINE.
202699 02-13

STUDIES ON ANTIDIURETIC ACTIVITIES AND ON PORTER-SILBERS CHROMOGENS CONTENT IN PLASMA OF PATIENTS WITH ALCOHOLIC DELIRIUM OR WITH ACUTE PHENOTHIAZINE INTOXICATIONS.
203741 02-15

EFFECTS OF SINGLE AND REPEATED ADMINISTRATION OF MAPROTILINE AND ITS RELATION TO PLASMA LEVELS IN HEALTHY TEST SUBJECTS.
204403 02-15

THE RELATIONSHIP BETWEEN THE EEG DRIVING RESPONSE TO LIGHT AND PLASMA MONOAMINEOXIDASE (MAO) LEVELS.
205437 02-03

PLASMA AND CEREBROSPINAL FLUID CONCENTRATIONS OF PHENOBARBITAL IN INFANTS GIVEN SINGLE DOSES.
206057 03-13

PLASMA LEVELS OF A NEW PELLETIZED FORM OF AMITRIPTYLINE FOR MAINTENANCE THERAPY.
209789 03-13

PLASMA LEVELS AND CLINICAL EFFECTS OF THIORIDAZINE AND THIOTHIXENE.
209790 03-08

SOME OBSERVATIONS ON THE CORRELATIONS BETWEEN PLASMA LEVELS OF MONOMETHYLATED TRICYCLIC ANTIDEPRESSANTS AND THERAPEUTIC EFFECTS.
210507 03-09

COMPARISON OF 3,4 DIMETHOXYPHENYLETHYLAMINE TREATED PLASMA FROM CHRONIC SCHIZOPHRENICS AND CONTROLS.
210897 03-08

TOLERANCE DEVELOPMENT WITH CHLORDIAZEPOXIDE IN RELATION TO THE PLASMA LEVELS OF THE PARENT COMPOUND AND ITS MAIN METABOLITES IN MICE.
210973 03-03

POTENTIATION OF THE L-5-HYDROXYTRYPTOPHAN INDUCED ELEVATION OF PLASMA CORTICOSTERONE LEVELS IN RATS BY A SPECIFIC INHIBITOR OF SEROTONIN UPTAKE.
211104 03-03

THE EFFECT OF LITHIUM ON BLOOD PRESSURE AND ON PLASMA RENIN SUBSTRATE AND RENIN IN RATS.
213483 04-03

THE RELATIONSHIP BETWEEN NORTRIPTYLINE PLASMA LEVELS AND CLINICAL EFFECTS.
213782 04-13

HUMAN GROWTH HORMONE RESPONSE TO LEVODOPA: RELATION TO MENOPAUSE, DEPRESSION, AND PLASMA DOPA CONCENTRATION.
213918 04-09

PLASMA CATECHOLAMINES: ARTERIAL VENOUS DIFFERENCES AND THE INFLUENCE OF BODY TEMPERATURE.
215655 04-06

N-DESMETHYLDIAZEPAM AND AMYLOBARBITONE SODIUM AS HYPNOTICS IN ANXIOUS PATIENTS. PLASMA LEVELS, CLINICAL EFFICACY AND RESIDUAL EFFECTS.
217460 04-10

PLASMA LEVELS OF IMIPRAMINE AND DESMETHYLIMIPRAMINE AND ANTIDEPRESSANT EFFECT DURING CONTROLLED THERAPY.
217477 04-09

THE EFFECTS OF CHRONIC CANNABIS TREATMENT UPON BRAIN 5-HYDROXYTRYPTAMINE, PLASMA CORTICOSTERONE AND AGGRESSIVE BEHAVIOR IN FEMALE RATS WITH DIFFERENT HORMONAL STATUS.
217532 04-04

RADIOIMMUNOASSAY OF CHLORDIAZEPOXIDE IN PLASMA.
217666 04-16

BINDING OF (+) AMPHETAMINE AND (-) DELTA1-TETRAHYDROCANNABINOLS AND (-) 7-HYDROXY-DELTA1-TETRAHYDROCANNBINOL TO BLOOD CELLS AND PLASMA PROTEINS IN MAN.
217878 04-13

COMPETITION FOR PLASMA PROTEIN BINDING SITES BETWEEN PHENOTHIAZINE TRANQUILIZERS AND IMINODIBENZYL ANTIDEPRESSANTS.
217891 04-03

THE DISTRIBUTION KINETICS AND TURNOVER OF CHOLINE AND ACETYLCHOLINE IN PLASMA AND BRAIN OF RATS. (PH.D. DISSERTATION).
220472 04-03

THE EFFECT OF LONG-TERM PHENOTHIAZINE THERAPY ON PLASMA PROLACTIN.
223777 04-15

RELATIONSHIPS AMONG CLINICAL RESPONSE, EPS, AND PLASMA CPZ AND CPZ METABOLITE RATIOS.
224831 04-08

SIGNIFICANCE OF PLASMA CHLORPROMAZINE IN MANAGEMENT OF PSYCHIATRIC PATIENTS.
224832 04-13

NORTRIPTYLINE PLASMA LEVELS: RELATIONSHIP TO DRUG EFFECTS.
224834 04-09

PLASMA LEVEL, DEPRESSIVE TYPOLOGY, CLINICAL OUTCOME.
224836 04-09

TRICYCLIC EFFECT ON BUTAPERAZINE PLASMA LEVEL.
224909 04-13

ELEVATION OF PLASMA DOPAMINE-BETA-HYDROXYLASE ACTIVITY DURING MECHOLYL TEST.
225523 04-13

PLATE

NEW HOT PLATE TESTS TO QUANTIFY ANTINOCICEPTIVE AND NARCOTIC ANTAGONIST ACTIVITIES.
193446 01-04

PLATELET

PLATELET SEROTONIN OF HYPERACTIVE SCHOOL-AGE BOYS.
194397 01-13

EFFECT OF MONOVALENT CATIONS ON HUMAN PLATELET ADENYLCYCLASE ACTIVITY.
195930 01-13

DEPRESSIVE ILLNESS: ADRENERGIC RESPONSIVENESS AND THE EFFECT OF LITHIUM ON PLATELET ADENYLCYCLASE. (PH.D. DISSERTATION).
196260 01-13

EFFECTS OF TRICYCLIC ANTIDEPRESSANTS UPON HUMAN PLATELET MONOAMINEOXIDASE.
217356 04-13

INHIBITION OF HUMAN PLATELET 5-HYDROXYTRYPTAMINE UPTAKE BY BETA-PHENETHYLAMINE DERIVATIVES.
217689 04-13

PLATELETS

5-HYDROXYTRYPTAMINE IN PLATELETS AND BRAIN OF RABBITS TREATED CHRONICALLY WITH IMIPRAMINE, MORPHINE OR METHADONE.
194744 01-03

CYTOTOXIC EFFECTS OF IMIPRAMINE ON PLATELETS.
195450 01-03

EFFECTS OF RESERPINE AND CHLORPROMAZINE ON 5-HYDROXYTRYPTAMINE UPTAKE OF PLATELETS FROM MIGRAINOUS AND CONTROL SUBJECTS.
196926 01-13

SUBCELLULAR DISTRIBUTION OF RESERPINE IN BLOOD PLATELETS: EVIDENCE FOR MULTIPLE POOLS.
202665 02-03

INFLUENCE OF SOME TRICYCLIC ANTIDEPRESSIVE DRUGS ON THE UPTAKE OF 5-HYDROXYTRYPTAMINE BY RAT BLOOD PLATELETS.
217693 04-03

EFFECT OF SOME ANORECTIC AGENTS ON THE UPTAKE AND RELEASE OF 5-HYDROXYTRYPTAMINE BY BLOOD PLATELETS OF RATS.
217890 04-03

DEXTROMETHORPHAN INHIBITS 5-HYDROXYTRYPTAMINE UPTAKE BY HUMAN BLOOD PLATELETS AND DECREASES 5-HYDROXYINDOLEACETIC ACID CONTENT IN RAT BRAIN.
217964 04-03

PLETHYSMOGRAPHY
CEREBRAL HEMODYNAMIC EFFECTS OF CHRONIC TRYPTOPHAN FEEDING IN MAN AS MEASURED BY QUANTIFIED CEREBRAL IMPEDANCE PLETHYSMOGRAPHY.
206337 03-08

PLEXUS
EFFECT OF MORPHINE ON SEROTONIN RELEASE FROM MYENTERIC PLEXUS OF THE GUINEA-PIG.
197811 01-03

PMA
EFFECTS OF P-METHOXYAMPHETAMINE (PMA) ON THE CARDIOVASCULAR SYSTEM OF THE DOG.
210867 03-05
COMPARISON OF CARDIOVASCULAR, HYPERTHERMIC, AND TOXIC EFFECTS OF P-METHOXYAMPHETAMINE (PMA) AND 3,4 METHYLENEDIOXYAMPHETAMINE (MDA).
217578 04-05

POISON
POISON INDUCED NEOPHOBIA IN RATS: ROLE OF STIMULUS GENERALIZATION OF CONDITIONED TASTE AVERSIONS.
223254 04-04

POISONING
TRICYCLIC ANTIDEPRESSANT POISONING: REVERSAL OF COMA, CHOREOATHETOSIS, AND MYOCLONUS BY PHYSOSTIGMINE.
202919 02-15
ACUTE VOLUNTARY POISONING BY DOXEPIN.
210141 03-15
PHYSOSTIGMINE -- ANTIDOTE FOR ANTICHOLINERGIC POISONING.
219621 04-15
LITHIUM SALT POISONING IN AN 8-YEAR-OLD CHILD.
219827 04-15

POLAR
MARIHUANA METABOLITES IN URINE OF MAN: V. CHARACTERISTICS AND SEPARATION OF POLAR METABOLITES OF DELTA9-TETRAHYDROCANNABINOL.
210896 03-16

POLYARTHRITIC
PROLONGED PENTOBARBITAL SLEEPING TIME IN ADJUVANT INDUCED POLYARTHRITIC RATS.
196228 01-04

POLYDIPSIA
THE EFFECT OF NH4CL ON POLYURIA AND POLYDIPSIA DURING PROLONGED LITHIUM ADMINISTRATION IN THE RAT.
198027 01-03
EFFECTS OF WATER DEPRIVATION IN RATS WITH POLYDIPSIA AND POLYURIA DUE TO LONG-TERM ADMINISTRATION OF LITHIUM.
210833 03-05

POLYETHYLENE
POLYETHYLENE GLYCOL INDUCED THIRST: A DUAL STIMULATORY MECHANISM?
219071 04-04

POLYGRAPH
SPECIFICITY OF BENZODIAZEPINE ACTION ON HUMAN SLEEP CONFIRMED. ANOTHER CONTRIBUTION OF AUTOMATIC ANALYSIS OF POLYGRAPH RECORDINGS.
218953 04-14

POLYGRAPHIC
ALL-NIGHT POLYGRAPHIC RECORDINGS ON THE HYPNOTIC EFFECTS OF A NEW BENZODIAZEPINE: FLUNITRAZEPAM (RO-5-4200, ROHYPNOL).
202272 02-11
A POLYGRAPHIC STUDY OF TOLERANCE OF SCHIZOPHRENICS TO CHLORPROMAZINE.
204430 02-08
INFLUENCE OF MELATONIN ON EEG AND HUMAN SLEEP: AUTOMATIC EEG ANALYSES AND POLYGRAPHIC NIGHT SLEEP INVESTIGATIONS.
205446 02-13
POLYGRAPHIC EXAMINATION DURING FAST AND SLOW INTRAVENOUS INJECTION OF THE SAME DOSE OF DIAZEPAM.
205508 02-13
POLYGRAPHIC EVALUATION OF HYPNOTIC DRUGS: METHODOLOGICAL CRITERIA.
208983 03-16
POLYGRAPHIC NIGHT SLEEP PATTERN DURING CHRONIC SINGLE AND MULTIPLE NEUROLEPTIC DOSE ADMINISTRATION.
215701 04-08
EFFECTS OF HEXAPROPYMATE ON THE SLEEP OF THE NORMAL MAN MEASURED BY A POLYGRAPHIC METHOD.
218166 04-14
THE INFLUENCE OF SULPIRIDE ON SLEEP: RESULTS OF POLYGRAPHIC NIGHT SLEEP RECORDINGS.
221339 04-14

POLYNEUROPATHY
POLYNEUROPATHY AS A RESULT OF DIPHENYLHYDANTOIN OVERDOSE.
200573 02-15

POLYPHENYLALANINE
MESCALINE-INDUCED CHANGES OF BRAIN CORTEX RIBOSOMES: EFFECT OF MESCALINE ON RIBOSOMAL SYNTHESIS OF POLYURIDINE DIRECTED POLYPHENYLALANINE.
194153 01-03

POLYPSYCHOPHARMACY
POLYPSYCHOPHARMACY.
219970 04-17

POLYRIBOSOMES
AN EFFECT OF AMPHETAMINE ON MOUSE BRAIN POLYRIBOSOMES.
193423 01-03

POLYSOMES
FREE AND MEMBRANE BOUND RIBOSOMES AND POLYSOMES IN HIPPOCAMPAL NEURONS DURING A LEARNING EXPERIMENT.
210674 03-04

POLYSYNAPTIC
STUDIES OF TRYPTAMINE AND LYSERGIC ACID DIETHYLAMIDE (LSD) ON CUTANEOUS C-FIBER AND POLYSYNAPTIC REFLEXES IN THE CAT.
197814 01-03

POLYURIA
THE EFFECT OF NH4CL ON POLYURIA AND POLYDIPSIA DURING PROLONGED LITHIUM ADMINISTRATION IN THE RAT.
198027 01-03
EFFECTS OF WATER DEPRIVATION IN RATS WITH POLYDIPSIA AND POLYURIA DUE TO LONG-TERM ADMINISTRATION OF LITHIUM.
210833 03-05

POLYURIC
LONG-TERM LITHIUM ADMINISTRATION TO RATS. LITHIUM AND SODIUM DOSAGE AND ADMINISTRATION, AVOIDANCE OF INTOXICATION, POLYURIC CONTROL RATS.
195042 01-03

POLYURIDINE
MESCALINE-INDUCED CHANGES OF BRAIN CORTEX RIBOSOMES: EFFECT OF MESCALINE ON RIBOSOMAL SYNTHESIS OF POLYURIDINE DIRECTED POLYPHENYLALANINE.
194153 01-03

PONE
FURTHER STUDIES ON THE EFFECT OF P-HYDROXYNOREPHEDRINE (PONE) ON NOREPINEPHRINE METABOLISM IN THE RAT BRAIN.
193453 01-03

PONTINE
DIFFERENTIAL RATES OF INCREASE IN PONTINE TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE ACTIVITIES AFTER RESERPINE.
217854 04-03

POOLS
SUBCELLULAR DISTRIBUTION OF RESERPINE IN BLOOD PLATELETS: EVIDENCE FOR MULTIPLE POOLS.
202665 02-03
EFFECTS OF CATECHOLAMINE RELEASING AGENTS ON SYNAPTOSOMAL DOPAMINE BIOSYNTHESIS: MULTIPLE POOLS OF DOPAMINE OR MULTIPLE FORMS OF TYROSINE-HYDROXYLASE?.
210825 03-03

POPULATION
PREDICTING TREATMENT RESPONSIVENESS RESISTIVENESS IN A POPULATION OF DEPRESSED PATIENTS.
196040 01-17
CENTRAL STIMULATING AGENTS AND POPULATION GROWTH IN MICE.
221052 04-04

POPULATIONS
THE INFLUENCE OF ALKYLATE PHERPACET DERIVATIVES ON NEURON POPULATIONS IN THE MIDBRAIN RETICULAR FORMATION.
219501 04-03

PORTER-SILBERS
STUDIES ON ANTIDIURETIC ACTIVITIES AND ON PORTER-SILBERS CHROMOGENS CONTENT IN PLASMA OF PATIENTS WITH ALCOHOLIC DELIRIUM OR WITH ACUTE PHENOTHIAZINE INTOXICATIONS.
203741 02-15

PORTIONS
THE EFFECT OF THE PSYCHOTROPIC AGENTS (CHLORPROMAZINE, MAJEPTIL, TRICEDIL) ON PROTEIN SYNTHESIS IN VARIOUS PORTIONS OF THE RAT BRAIN.
223063 04-03

POSITION
MAPROTILINE -- ITS POSITION AS AN ANTIDEPRESSANT IN THE LIGHT OF RECENT NEUROPHARMACOLOGICAL AND NEUROBIOCHEMICAL FINDINGS.
221647 04-03

POST-AMPHETAMINE
NORADRENALINE AND 5-HYDROXYTRYPTAMINE METABOLISM IN SIX AREAS OF RAT BRAIN DURING POST-AMPHETAMINE DEPRESSION.
195437 01-03

POST-INFARCTIONAL
A DIFFERENTIATED USE OF ELENIUM AND SEDUXEN IN YOUNG PATIENTS IN THE POST-INFARCTIONAL PERIOD.
200104 02-11

POSTCASTRATION
POSTCASTRATION DECLINE IN BEHAVIOURAL RESPONSIVENESS TO INTRAHYPOTHALAMIC ANDROGEN IN DOVES.
210918 03-03

POSTGANGLIONIC
INTERACTIONS BETWEEN POSTGANGLIONIC SYMPATHETIC BLOCKING DRUGS AND ANTIDEPRESSANTS.
221650 04-09

POSTHYPNOTIC
THE USE OF FREE IMAGERY, NONDIRECTIVE INTERVIEWING, AND SELECTED DRUGS TO LIFT POSTHYPNOTIC REPRESSION. (PH.D. DISSERTATION).
222060 04-14

POSTICTAL
CORRELATION BETWEEN BRAIN MONOAMINE LEVELS AND POSTICTAL COMA FOLLOWING ELECTROSHOCK.
215723 04-03

POSTMORTAL
POSTMORTAL ACCUMULATION OF 3-METHOXYTYRAMINE IN BRAIN.
197583 01-03

POSTNATAL
POSTNATAL DEVELOPMENT OF CHOLINE UPTAKE BY CHOLINERGIC TERMINALS IN RAT BRAIN.
210713 03-03
PERMANENT EFFECTS OF REPEATED ADMINISTRATION OF ACTH AND DIAZEPAM IN EARLY POSTNATAL PERIOD UPON THE DYNAMICS OF EXCITATION AND INHIBITION DURING HABITUATION.
215068 04-04
ANTAGONISM BY D-AMPHETAMINE OF LEARNING DEFICITS IN RATS INDUCED BY EXPOSURE TO ANTIPSYCHOTIC DRUGS DURING EARLY POSTNATAL LIFE.
217656 04-04
LONG-LASTING EFFECTS OF PRENATAL 2,4,5 TRICHLOROPHENOXYACETIC ACID ON OPEN-FIELD BEHAVIOR IN RATS: PRE- AND POSTNATAL MEDIATION.
223044 04-04

POSTSYNAPTIC
THE INFLUENCE OF NEMBUTAL, CHLORALOSE AND URETHANE ON INHIBITORY POSTSYNAPTIC POTENTIALS OF CORTICAL NEURONS.
199443 02-03
PRESYNAPTIC AND POSTSYNAPTIC COMPONENTS IN EFFECT OF DRUGS WITH ALPHA-ADRENOCEPTOR AFFINITY.
214062 04-03
ROLE FOR POSTSYNAPTIC DOPAMINE RECEPTORS IN THE REGULATION OF THE KINETIC STATE OF STRIATAL TYROSINE-HYDROXYLASE. (UNPUBLISHED PAPER).
225307 04-03

POSTTRAUMATIC
THE TREATMENT OF NIGHT TERRORS ASSOCIATED WITH THE POSTTRAUMATIC SYNDROME.
209750 03-11

POSTTRIAL
SHUTTLE AVOIDANCE LEARNING OF MICE: EFFECTS OF POSTTRIAL PENTYLENETETRAZOL, STRAIN AND AGE.
195226 01-04
FACILITATION OF TIME-DEPENDENT MEMORY PROCESSES WITH POSTTRIAL EPINEPHRINE INJECTIONS.
209951 03-04
POSTTRIAL D-AMPHETAMINE SULFATE AND ONE-TRIAL LEARNING IN MICE.
222268 04-04

POSTULATE
EFFECTS OF (-)DELTA9-TRANS-TETRAHYDROCANNABINOL (DELTA9-THC) ON TESTS OF PSYCHOTICISM: A STUDY OF EYSENCKS DRUG POSTULATE ON THE EFFECTS OF HALLUCINOGENS IN RELATION TO PSYCHOTICISM.
214009 04-09

POSTWEANING
THE INTERACTION OF POSTWEANING HOUSING CONDITIONS AND PRENATAL DRUG EFFECTS ON BEHAVIOUR.
225563 04-04

POTASSIUM
INFLUENCE OF OXYMETAZOLINE AND PHENTOLAMINE ON NORADRENALINE (NA) RELEASE CAUSED BY ELECTRICAL STIMULATION, POTASSIUM, TYRAMINE AND DIMETHYLPHENYLPIPERAZINE (DMPP).
197973 01-03
THE EFFECT OF DIAZEPAM AND NITRAZEPAM ON INTRACELLULAR AND EXTRACELLULAR DISTRIBUTION OF SODIUM AND POTASSIUM IONS IN INDIVIDUAL STRUCTURES OF RATS BRAINS.
207199 03-03
CHANGES IN THE NEURONAL PROTEIN LABELLING INDUCED BY POTASSIUM IONS IN VIVO (SPREADING DEPRESSION).
210779 03-03
COMPARATIVE STUDIES ON THE MEMBRANE ACTIONS OF DEPRESSANT DRUGS: THE ROLE OF LIPOPHILICITY IN INHIBITION OF BRAIN SODIUM AND POTASSIUM STIMULATED ATPASE.
210818 03-03
REVERSIBLE INHIBITION OF MAMMALIAN BRAIN ACETYLCHOLINESTERASE AND SODIUM POTASSIUM STIMULATED ADENOSINE-TRIPHOSPHATASE BY CYCLOPROPANE.
210903 03-03

POTENCY
BRAIN LEVELS AND RELATIVE POTENCY OF THE 1,2 DIMETHYLHEPTYL ANALOGUE OF DELTA1-TETRAHYDROCANNABINOL IN MICE.
198605 02-01
EFFECT OF THE ACTIVATION OF THE KININ FORMING SYSTEM ON THE POTENCY OF CHLORPROMAZINE.
210872 03-03
EFFECT OF SENSORY STIMULATION ON THE POTENCY OF CATALEPTOGENS.
217473 04-03
INFLUENCE OF RESERPINE ON THE POTENCY OF ALPHA-ADRENOCEPTOR BLOCKING AGENTS.
221860 04-03

POTENT
BROMOPERIDOL, A NEW POTENT NEUROLEPTIC OF THE BUTYROPHENONE SERIES; COMPARATIVE PHARMACOLOGY OF BROMOPERIDOL AND HALOPERIDOL.
206804 03-02
A POTENT DEPRESSANT ACTION OF ADENINE DERIVATIVES ON CEREBRAL CORTICAL NEURONES.
210932 03-03
N-CYCLOPROPYLTRYPTAMINES, POTENT MONOAMINEOXIDASE INHIBITORS.
211069 03-01
NOMIFENSINE: A POTENT DOPAMINERGIC AGONIST OF ANTIPARKINSON POTENTIAL.
217472 04-03

POTENTIAL
STEREOCHEMICAL STUDIES ON POTENTIAL CENTRAL NERVOUS SYSTEM ACTIVE AGENTS AND STUDIES ON THE CHEMISTRY OF SOME 3-BENZOYLPIPERIDINES. (PH.D. DISSERTATION).
193586 01-01
THIETANES AS POTENTIAL MAO INHIBITORS AND ANALGETICS. (PH.D. DISSERTATION).
194563 01-01
CHANGES IN THE DORSAL ROOT POTENTIAL WITH DIAZEPAM AND WITH THE ANALGESICS ASPIRIN, NITROUS OXIDE, MORPHINE AND MEPERIDINE.
195248 01-03
A DUAL STUDY. PART I: SYNTHESIS AND STEREOCHEMISTRY OF SOME 1 SUBSTITUTED QUINOLIZIDINES AS ANALOGS OF BIOLOGICALLY ACTIVE COMPOUNDS. PART II: AMINO DERIVATIVES OF THIOPHENE FUSED CYCLIC KETONES AS POTENTIAL CNS. (PH.D. DISSERTATION).
196252 01-01
CB-154 (2-BROMO-ALPHA-ERGOKRYPTINE, BROMOCRIPTIN), A POTENTIAL ANTIPARKINSON AGENT.
197949 01-04
POTENTIAL CARDIOTOXICITY FROM PHENOTHIAZINES AND TRICYCLIC ANTIDEPRESSANTS.
198044 01-15
HMO ANALYSIS OF STRUCTURE-ACTIVITY RELATIONS IN SEDATIVE AND HYPNOTIC DRUGS AND ANALYSIS OF POTENTIAL SEDATIVES BY MEANS OF HOMOLOGOUS COMPOUNDS.
199208 02-01
POTENTIAL PSYCHOTOMIMETICS. 2. RIGID ANALOGS OF 2,5 DIMETHOXY-4-METHYLPHENYLISOPROPYLAMINE (DOM, STP).
202109 02-02
PHARMACOLOGICAL PROPERTIES OF A POTENTIAL TRANQUILISING AGENT MESYLPHENACYRAZINE: I. INTERACTION WITH DRUGS INFLUENCING THE NERVOUS SYSTEM.
205578 02-03
PHARMACOLOGICAL PROPERTIES OF A POTENTIAL TRANQUILISING AGENT MESYLPHENACYRAZINE: II. CHANGES RELATED TO ITS REPEATED ADMINISTRATION.
205579 02-03
PHARMACOLOGIC EFFECTS OF MH-9022-1, A POTENTIAL TRANQUILIZING AGENT.
206808 03-02
THE EFFECTS OF AMPHETAMINE, IMIPRAMINE AND ICI-58834 (VIVALAN), A POTENTIAL ANTIDEPRESSANT, ON UNCONDITIONED BEHAVIOUR IN RATS.
214016 04-04
FLUPHENAZINE TREATMENT IN THE PSYCHOTIC CHILD: CLINICAL EVOKED POTENTIAL CORRELATIONS.
215455 04-09
THE PROTECTIVE EFFECT OF SEROTONIN AGAINST THE INHIBITORY ACTION OF CHLORPROMAZINE ON THE MEMBRANE POTENTIAL OF STAGE 2 BLASTOMERES OF MOUSE EMBRYOS IN VITRO.
217005 04-03
NOMIFENSINE: A POTENT DOPAMINERGIC AGONIST OF ANTIPARKINSON POTENTIAL.
217472 04-03
ATTENTION AND THE AUDITORY EVOKED POTENTIAL IN HYPERKINETIC CHILDREN TREATED WITH METHYLPHENIDATE AND IN NORMAL CHILDREN. (PH.D. DISSERTATION).
222747 04-11
NARCOTIC AGONISTS AND ANTAGONISTS AS MODELS FOR POTENTIAL ANTIDEPRESSANT DRUGS.
222817 04-04
CYANOGEN CONDENSATIONS AS A ROUTE TO 3-AMINO-2-IMINOBENZOTHIAZIN-4-ONES WITH CNS DEPRESSANT POTENTIAL.
222870 04-02

COMPARATIVE SYMPTOMATOLOGICAL AND EVOKED POTENTIAL STUDIES WITH DtAMPHETAMINE, THIORIDAZINE, AND PLACEBO IN HYPERKINETIC CHILDREN.
225516 04-10

POTENTIALLY
PROGRAMMED SELF-ADMINISTRATION OF POTENTIALLY ADDICTIVE DRUGS IN YOUNG RATS AND ITS EFFECTS ON LEARNING.
195430 01-04

POTENTIALS
SELECTIVE DIPHENYLHYDANTOIN SUPPRESSION OF AUDITORY EVOKED POTENTIALS IN THE CAT CEREBELLAR CORTEX.
197989 01-03

PSYCHOTROPIC DRUGS AND SLOW POTENTIALS IN MAN.
198101 02-13

THE INFLUENCE OF NEMBUTAL, CHLORALOSE AND URETHANE ON INHIBITORY POSTSYNAPTIC POTENTIALS OF CORTICAL NEURONS.
199443 02-03

THE INFLUENCE OF TRIFLUOPERAZINE, CARBIDINE AND IMIZINE ON EVOKED POTENTIALS IN DIFFERENT STRUCTURES OF THE LIMBIC RETICULAR COMPLEX.
200564 02-02

FACTOR ANALYSIS OF EVOKED POTENTIALS.
204189 02-06

EFFECTS OF CHOLINESTERASE INHIBITION ON THE VISUAL EVOKED POTENTIALS IN THE RABBIT AND THEIR MODIFICATION WITH VARIOUS DRUGS.
205631 03-03

THE EFFECTS OF DOPA ON THE VISUAL EVOKED POTENTIALS IN RABBIT AND ON MOUSE MOTOR BEHAVIOR FOLLOWING INHIBITION OF DOPAMINE-BETA-HYDROXYLASE.
206768 03-03

EFFECT OF OUABAIN AND PHENOBARBITAL ON THE KINETICS OF CORTICAL METABOLIC TRANSIENTS ASSOCIATED WITH EVOKED POTENTIALS.
210820 03-03

SCHIZOPHRENIA AND EVOKED POTENTIALS: MAXIMUM AMPLITUDE, FREQUENCY OF PEAKS, VARIABILITY, AND PHENOTHIAZINE EFFECTS.
213764 04-08

PHENOTHIAZINE EFFECTS ON CEREBRAL EVOKED POTENTIALS AND EYE MOVEMENTS IN ACUTE SCHIZOPHRENICS.
217454 04-08

COMMISSURAL AND SENSORY EVOKED POTENTIALS OF THE HIPPOCAMPUS FOLLOWING MICROIONTOPHORESIS OF SOME DRUGS.
219111 04-03

POTENTIATING
THE MECHANISM OF THE POTENTIATING EFFECT OF ANTIDEPRESSANT DRUGS ON THE PROTECTIVE INFLUENCE OF DIPHENHYDRAMINE IN EXPERIMENTAL CATATONIA. THE ROLE OF HISTAMINE.
215664 04-03

DIFFERENCES BETWEEN (+)- AND (-) AMPHETAMINE IN EFFECTS ON LOCOMOTOR ACTIVITY AND L-DOPA POTENTIATING ACTION IN MICE.
217835 04-04

POTENTIATION
POTENTIATION OF DRUG INITIATED ADRENAL TYROSINE-HYDROXYLASE INDUCTION BY DIAZEPAM.
193304 01-03

POTENTIATION BY 3,4 DIMETHOXYPHENYLETHYLAMINE (DMPEA) AND COCAINE OF NOREPINEPHRINE-INDUCED CONTRACTION OF GUINEA-PIG VAS-DEFERENS.
194156 01-03

POTENTIATION OF AMYGDALOID KINDLING AND METRAZOL-INDUCED SEIZURES BY 6-HYDROXYDOPAMINE IN RATS.
195907 01-03

ACTION OF PROBENECID ON THE CENTRAL NERVOUS SYSTEM OF THE RABBIT: II. POTENTIATION OF 5-HYDROXYTRYPTOPHAN-INDUCED HYPERTHERMIA AND SUPPRESSION OF THIS EFFECT BY A DECARBOXYLASE INHIBITOR (RO-4-4602).
196580 01-03

CADMIUM-INDUCED POTENTIATION OF HEXOBARBITAL SLEEP TIME IN RATS.
197684 01-04

POTENTIATION OF TETRABENAZINE-INDUCED BEHAVIOURAL DEPRESSION BY IMIPRAMINE ON A DISCRETE TRIAL AVOIDANCE ESCAPE SCHEDULE.
197859 01-04

POTENTIATION OF JUMPING BEHAVIOR BY AMINOPHYLLINE IN MICE TREATED WITH THRESHOLD DOSES OF AMPHETAMINE AND DOPA.
200039 02-04

POTENTIATION WITH TRICYCLIC ANTIDEPRESSANTS OF THE INHIBITORY ACTION OF APOMORPHINE ON THE ATTITUDINAL REFLEX IN FROGS.
201919 02-04

SLEEP DEPRIVATION AS A POTENTIATION OF ANTIDEPRESSIVE PHARMACOTHERAPY?
205602 03-09

POTENTIATION OF CATALEPSY INDUCED BY NARCOTIC AGENTS DURING HAFFNERS TEST FOR ANALGESIA.
206358 03-04

POTENTIATION OF THE L-5-HYDROXYTRYPTOPHAN INDUCED ELEVATION OF PLASMA CORTICOSTERONE LEVELS IN RATS BY A SPECIFIC INHIBITOR OF SEROTONIN UPTAKE.
211104 03-03

ON THE MECHANISM OF POTENTIATION BY MORPHINE OF THIOPENTAL SLEEPING TIME.
215666 04-03

POTENTIATION OF LOCOMOTOR ACTIVITY AND MODIFICATION OF STEREOTYPY BY STARVATION IN APOMORPHINE TREATED RATS.
217675 04-04

POTENTIATION OF AMPHETAMINE-INDUCED AROUSAL BY FOOD DEPRIVATION: EFFECT OF HYPOTHALAMIC LESIONS.
218498 04-04

POTENTIATION OF ANTIDEPRESSANT ACTION OF CLOMIPRAMINE BY TRYPTOPHAN.
221385 04-09

POVERTY
PRELIMINARY RESULTS OF A CONTROLLED TRIAL WITH SULPIRIDE VERSUS CHLORIMIPRAMINE IN CHRONIC SCHIZOPHRENIC PATIENTS WITH MARKED IDEO-EMOTIONAL POVERTY.
200445 02-08

POWER
COMPARISON OF THE ACTION OF DIAZEPAM AND PHENOBARBITAL USING EEG DERIVED POWER SPECTRA OBTAINED FROM TEMPORAL LOBE EPILEPTICS.
197992 01-13

THALIDOMIDE AND THE POWER OF THE PHARMACEUTICAL INDUSTRY.
210077 03-15

POWERFUL
RESEARCH ON PSYCHIATRIC INDICATIONS OF A POWERFUL ANXIOLYTIC, LORAZEPAM.
210088 03-14

PRACTITIONER
EXPERIENCES OF A GENERAL PRACTITIONER AMONG PSYCHIATRIC PATIENTS.
211012 03-15

A GENERAL PRACTITIONER TRIAL OF CLOMIPRAMINE (ANAFRANIL) IN OBSESSIONS AND PHOBIAS.
215157 04-10

II. PSYCHOPHARMACOLOGY AND THE NONMEDICAL PRACTITIONER.
219756 04-17

PRACTITIONERS
DETERMINANTS OF PRESCRIBING OF PSYCHOACTIVE DRUGS BY GENERAL PRACTITIONERS.
224492 04-17

PRACTOLOL
INFLUENCE OF PROPRANOLOL AND PRACTOLOL ON THE TURNOVER OF NORADRENALINE IN THE RAT HEART.
197957 01-03

EFFECT OF BETA-RECEPTOR BLOCKERS (PINDOLOL AND PRACTOLOL) ON LITHIUM INDUCED TREMOR -- CLINICAL TRIAL AND THEORETICAL CONSIDERATIONS.
204409 02-15

PRAIRIE
ATTENUATION OF ACUTE HABITUATION BY SCOPOLAMINE IN THE BLACK-TAILED PRAIRIE DOG (CYNOMYS-LUDOVICIANUS).
206745 03-04

PRAXILENE
PSYCHOMETRIC STUDY OF PRAXILENE.
216464 04-11

PRAZEPAM
THE DETECTION OF PRAZEPAM, A NEW BENZODIAZEPINE TRANQUILIZER.
204196 02-01

PRE-EXPOSURE
THE EFFECT OF DIFFERENT LEVELS OF PRE-EXPOSURE TO SUCROSE ON THE ACQUISITION AND EXTINCTION OF A CONDITIONED AVERSION.
217807 04-04

PREANESTHESIA
KETAMIN HYDROCHLORIDE AS A PREANESTHESIA DRUG FOR AN ELECTROSHOCK TREATMENT.
202121 02-11

PRECIPITANTS
HALLUCINOGENIC DRUGS AS PRECIPITANTS OF SCHIZOPHRENIA.
202693 02-08

PRECIPITATED
NALOXONE PRECIPITATED JUMPING ACTIVITY IN MICE FOLLOWING THE ACUTE ADMINISTRATION OF MORPHINE.
202201 02-04

MORPHINE-DEPENDENT RATS: BLOCKADE OF PRECIPITATED ABSTINENCE BY TETRAHYDROCANNABINOL.
210221 03-13

LITHIUM TOXICITY PRECIPITATED BY DIURETICS.
219353 04-15

PRECLINICAL
PROFILE-BASED-THERAPY (PBT) IN SCHIZOPHRENIAS: A PRECLINICAL INDICATION FOR THE USE OF DIHYDROXYPHENYLSERINE (DOPS).
195115 01-08

PRECLINICAL EVALUATION OF AHR-2244: A NEW PSYCHOTHERAPEUTIC AGENT.
210676 03-02

PRECURSORS
SUBTYPE OF AFFECTIVE PSYCHOSES CLASSIFIED BY RESPONSE ON AMINE PRECURSORS AND MONOAMINE METABOLISM.
197209 01-09
INFLUENCE OF HEXOBARBITAL ON THE BIOSYNTHESIS OF CATECHOLAMINES AND THEIR PRECURSORS IN THE BRAIN.
201917 02-03
AMINE PRECURSORS AND DEPRESSION.
207444 03-13
AFFECTIVE DISORDER: STUDIES WITH AMINE PRECURSORS.
207681 03-09

PREDATORY
STIMULATION OF A SPECIFIC DRIVE (PREDATORY BEHAVIOR) BY P-CHLOROPHENYLALANINE (PCPA) IN THE RAT.
197952 01-04
EFFECTS OF SCOPOLAMINE AND ALPHA-METHYL-P-TYROSINE UPON PREDATORY ATTACK IN CATS.
217526 04-04
ON THE ROLE OF SEROTONIN IN PREDATORY AGGRESSION.
219110 04-04

PREDICTED
LITHIUM RESPONSE IN DEPRESSION AS PREDICTED BY UNIPOLAR/BIPOLAR ILLNESS, AVERAGE EVOKED RESPONSE, CATECHOL-O-METHYLTRANSFERASE AND FAMILY HISTORY. (UNPUBLISHED PAPER).
201000 02-09

PREDICTING
PREDICTING TREATMENT RESPONSIVENESS RESISTIVENESS IN A POPULATION OF DEPRESSED PATIENTS.
196040 01-17
THE CURRENT STATUS OF BIOLOGICAL CRITERIA FOR CLASSIFYING THE DEPRESSIVE DISORDERS AND PREDICTING RESPONSES TO TREATMENT.
202380 02-17
DIVALENT CATIONS IN PREDICTING ANTIDEPRESSANT RESPONSE TO LITHIUM.
202886 02-14
BIOCHEMICAL CRITERIA FOR CLASSIFYING DEPRESSIVE DISORDERS AND PREDICTING RESPONSES TO PHARMACOTHERAPY: PRELIMINARY FINDINGS FROM STUDIES OF NOREPINEPHRINE METABOLISM. CONTRIBUTIONS TO BIOCHEMISTRY.
203594 02-09

PREDICTION
EFFECT OF ORAL AND INTRAMUSCULAR ROUTES OF ADMINISTRATION ON SERUM CHLORDIAZEPOXIDE LEVELS AND THE PREDICTION OF THESE LEVELS FROM PREDRUG FASTING SERUM GLUCOSE CONCENTRATIONS.
195055 01-13
INTERACTIVE PREDICTION OF DRUG-INDUCED CHANGE.
195936 01-17
EVALUATION OF CLINICAL PREDICTION OF ANTIDEPRESSANT ACTIVITY USING VARIOUS ANIMAL TEST MODELS.
198055 01-02

PREDICTOR
COMPUTERIZED EEG: PREDICTOR OF OUTCOME IN SCHIZOPHRENIA.
213863 04-08
LOSS OF BODY WEIGHT AS A PREDICTOR OF RESERPINE INDUCED AMINE DEPLETION.
217661 04-03

PREDICTORS
EEG PROFILES AS PREDICTORS OF PSYCHOTROPIC DRUG CLASSIFICATION.
198060 01-07
EEG SLEEP CHANGES AS PREDICTORS IN DEPRESSION.
224769 04-09

PREDICTS
ANTISCHIZOPHRENIC DRUGS: AFFINITY FOR MUSCARINIC CHOLINERGIC RECEPTOR SITES IN THE BRAIN PREDICTS EXTRAPYRAMIDAL EFFECTS.
207298 03-03

PREDRUG
EFFECT OF ORAL AND INTRAMUSCULAR ROUTES OF ADMINISTRATION ON SERUM CHLORDIAZEPOXIDE LEVELS AND THE PREDICTION OF THESE LEVELS FROM PREDRUG FASTING SERUM GLUCOSE CONCENTRATIONS.
195055 01-13

PREFERENCE
THE EFFECTS OF CHLORPROMAZINE AND D-AMPHETAMINE SULFATE ON THE VISUAL STIMULATION PREFERENCE OF EXTRAVERTS AND INTROVERTS.
210680 03-14
LITHIUM AND ETHANOL PREFERENCE.
210750 03-05
INDUCED PREFERENCE FOR MORPHINE IN RATS.
219033 04-04

PREFERENTIALLY
EFFECTS ON SHOCK-ELICITED AGGRESSION IN MICE OF PREFERENTIALLY PROTECTING BRAIN MONOAMINES AGAINST THE DEPLETING ACTION OF RESERPINE.
195452 01-04

PREGANGLIONIC
INHIBITION OF SACRAL PARASYMPATHETIC PREGANGLIONIC NEURONS BY GABA, GLYCIN, 5-HYDROXYTRYPTAMINE AND NOREPINEPHRINE. (PH.D. DISSERTATION).
212524 03-03

PREGNANCY
THE EFFECTS OF DEXTROAMPHETAMINE, DIMETHYLTRYPTAMINE, LYSERGIC ACID DIETHYLAMIDE AND TETRAHYDROCANNABINOL UPON PREGNANCY AND THE OFFSPRING. (PH.D. DISSERTATION).
194568 01-04
DEVELOPMENTAL DISTURBANCE OF THE BRAIN IN RAT OFFSPRING FOLLOWING MATERNAL ADMINISTRATION OF 5-FLUOURACIL DURING PREGNANCY.
202422 02-03
PSYCHOTOMIMETIC SUBSTANCES DURING PREGNANCY AND SEX OF OFFSPRING MICE. (PH.D. DISSERTATION).
213050 03-03
CARDIOVASCULAR MALFORMATIONS WITH LITHIUM USE DURING PREGNANCY.
225331 04-15

PREGNANT
EFFECTS OF D-AMPHETAMINE SULFATE GIVEN TO PREGNANT MICE ON ACTIVITY AND ON CATECHOLAMINES IN THE BRAINS OF OFFSPRING.
196025 01-03

PREMATURE
THE EFFECT OF ALCOHOL AND BARBITURATE ON THE FREQUENCY OF ATRIAL AND VENTRICULAR PREMATURE BEATS DURING SLEEP.
218971 04-13

PREMEDICATION
PHYSIOLOGIC, BIOCHEMICAL, AND CLINICAL EFFECTS OF KETAMINE HYDROCHLORIDE IN GOATS (CAPRA-HIRCUS) WITH AND WITHOUT PREMEDICATION. (PH.D. DISSERTATION).
194700 01-03

PRENATAL
GENOTYPE OR PRENATAL DRUG EXPERIENCE AFFECT BRAIN MATURATION IN THE MOUSE.
221032 04-03
LONG-LASTING EFFECTS OF PRENATAL 2,4,5 TRICHLOROPHENOXYACETIC ACID ON OPEN-FIELD BEHAVIOR IN RATS: PRE- AND POSTNATAL MEDIATION.
223044 04-04
PRENATAL MATERNAL D-AMPHETAMINE EFFECTS ON EMOTIONALITY AND AUDIOGENIC SEIZURE SUSCEPTIBILITY OF RAT OFFSPRING.
225079 04-04
THE INTERACTION OF POSTWEANING HOUSING CONDITIONS AND PRENATAL DRUG EFFECTS ON BEHAVIOUR.
225563 04-04

PRENYLAMINE
EFFECTS OF RESERPINE AND PRENYLAMINE ON THE NORADRENALINE FLUXES OF ISOLATED SPLENIC NERVE GRANULES.
197280 01-03

PREOPERATIVE
THE CHEMICAL CONTROL OF PREOPERATIVE ANXIETY.
210684 03-10

PREPOTENT
AMPHETAMINE STEREOTYPY: THE INFLUENCE OF ENVIRONMENTAL FACTORS AND PREPOTENT BEHAVIORAL PATTERNS ON ITS TOPOGRAPHY AND DEVELOPMENT.
213531 04-04
PREPOTENT BEHAVIORS IN AMPHETAMINE MODEL PSYCHOSIS.
224797 04-14

PREPUBERAL
ENDOCRINE EFFECTS OF CHRONIC ADMINISTRATION OF PSYCHOACTIVE DRUGS TO PREPUBERAL MALE RATS. I: DELTA9-TETRAHYDROCANNABINOL.
209840 03-03

PRESCHOOLERS
HYPERACTIVITY IN PRESCHOOLERS AND THE EFFECT OF METHYLPHENIDATE.
205264 02-14

PRESCRIBE
TO BETTER KNOW AND BETTER PRESCRIBE PSYCHOTROPIC DRUGS.
202029 02-17

PRESCRIBING
PSYCHOTHERAPEUTIC DRUGS: STUDIES OF USAGE PATTERNS AND STUDIES OF PRESCRIBING PRACTICES.
198048 01-17
LONGITUDINAL TREND IN PRESCRIBING PSYCHOTROPIC DRUGS.
205633 03-17
DETERMINANTS OF PRESCRIBING OF PSYCHOACTIVE DRUGS BY GENERAL PRACTITIONERS.
224492 04-17
PEER REVIEW OF PRESCRIBING PATTERNS IN A CMHC.
224742 04-17

PRESCRIPTION
ATTEMPTS TO CLASSIFY AND ORIENT PRESCRIPTION OF PSYCHOTROPIC DRUGS BY MEANS OF A COMPUTER CARD INDEX.
221668 04-17

PRESELECTION
PRESELECTION OF ANIMALS IN STUDIES OF ANTIANXIETY DRUGS.
197986 01-03

PRESENILE
PRESENILE DEMENTIA: FURTHER EXPERIENCE WITH AN ANTICOAGULANT PSYCHOTHERAPY REGIMEN.
195601 01-14

PRESESSION
EFFECTS OF D-AMPHETAMINE AND PRESESSION SHOCKS ON SIDMAN AVOIDANCE WITH A TONE IN RATS. (PH.D. DISSERTATION).
212677 03-04

PRESLEEP
PRESLEEP INGESTION OF TWO HYPNOTIC DRUGS AND SUBSEQUENT PERFORMANCE.
206362 03-14

PRESS
EFFECTS OF D-AMPHETAMINE AND SECOBARBITAL ON KEY PRESS RATES IN NORMAL HUMANS.
210879 03-14

PRESSING
SOME EVIDENCE FOR LONG-TERM MEMORY RETENTION BY OROTIC ACID IN RATS BAR PRESSING FOR WATER.
210790 03-04

INCREASED LEVEL PRESSING FOR AMPHETAMINE AFTER PIMOZIDE IN RATS: IMPLICATIONS FOR A DOPAMINE THEORY OF REWARD.
213350 03-04

EFFECTS OF HEROIN ON LEVER PRESSING FOR INTRACRANIAL SELF-STIMULATION, FOOD AND WATER IN THE RAT.
221039 04-04

PRESSOR
EFFECTS OF ADRENERGIC DRUGS ON PRESSOR RESPONSES TO HYPOTHALAMIC STIMULATION.
195441 01-03

PRESSOR RESPONSES TO HYPOTHALAMIC STIMULATION AS INFLUENCED BY DRUGS AFFECTING ADRENERGIC RECEPTORS.
197290 01-03

PRESSURE
EFFECTS OF ANORECTIC AGENTS ON BLOOD PRESSURE OF THE DOG.
197464 01-03

RELATIONSHIP BETWEEN THE CHANGES ON BLOOD PRESSURE RESPONSE AND THE CARDIAC CATECHOLAMINE LEVEL AFTER SINGLE AND REPEATED ADMINISTRATIONS OF TYRAMINE AND METHAMPHETAMINE IN RATS.
197491 01-03

DEPRESSION TREATED WITH CHLORIMIPRAMINE WITH SPECIAL ANALYSIS OF CHANGE IN BLOOD PRESSURE BY INFUSION.
199212 02-09

SELECTIVE INHIBITION OF DOPAMINE-BETA-HYDROXYLASE IN THE PERIPHERAL TISSUES BY 5-DIMETHYLDITHIOCARBAMYLPICOLINIC ACID; ITS EFFECT ON STRESS INDUCED ULCER, ETHANOL INDUCED SLEEP AND BLOOD PRESSURE.
204484 02-03

THE EFFECT OF LITHIUM ON BLOOD PRESSURE AND ON PLASMA RENIN SUBSTRATE AND RENIN IN RATS.
213483 04-03

BLOOD PRESSURE AND HEART RATE RESPONSES EVOKED BY D- AND L-AMPHETAMINE IN THE PITHED RAT PREPARATION.
215687 04-03

EFFECTS OF IPRONIAZID, CHLORPROMAZINE AND METHIOTHEPIN ON DMT INDUCED CHANGES IN BODY TEMPERATURE, PUPILLARY DILATATION, BLOOD PRESSURE AND EEG IN THE RABBIT.
215724 04-03

THE EFFECT OF SOME NEUROTROPIC DRUGS ON THE PHASIC CHANGES OF ARTERIAL PRESSURE EVOKED BY STIMULATION OF THE CEREBELLAR FASTIGAL NUCLEUS.
217067 04-03

PRESUMED
HIGH AFFINITY UPTAKE OF GABA IN PRESUMED GABA-ERGIC NERVE ENDINGS IN RAT BRAIN.
211062 03-03

PRESYNAPTIC
EFFECTS OF PHENOBARBITAL ON ELECTROCORTICOGRAM AND ACTIVITY, ON REGIONAL CNS ENERGY METABOLISM, AND ON PRESYNAPTIC EVENTS IN CEREBRAL CORTEX AND BRAINSTEM. (PH.D. DISSERTATION).
203033 02-03

PRESYNAPTIC AND POSTSYNAPTIC COMPONENTS IN EFFECT OF DRUGS WITH ALPHA-ADRENOCEPTOR AFFINITY.
214062 04-03

ACTION OF DIAZEPAM, DIBUTYRYL-CGMP, AND GABA ON PRESYNAPTIC NERVE TERMINALS IN BULLFROG SYMPATHETIC GANGLIA.
217873 04-03

PRETREATED
THE INEFFECTIVENESS OF DESIPRAMINE PRETREATMENT ON BEHAVIORAL EFFECTS OF 6-HYDROXYDOPAMINE IN NIALAMIDE PRETREATED RATS.
195434 01-04

THE SUBCELLULAR DISTRIBUTION OF INTRAVENTRICULARLY ADMINISTERED 3H-METARAMINOL IN INTACT AND RAT BRAIN PRETREATED WITH P-CHLOROAMPHETAMINE.
197289 01-03

THE EFFECTS OF LSD, PSILOCYBIN, HARMALINE AND AMPHETAMINE ON THE BODY TEMPERATURE OF P-CHLOROPHENYLALANINE PRETREATED RATS.
197484 01-03

PHARMACOLOGICAL STUDIES ON TETRABENAZINE-INDUCED EXCITED BEHAVIOUR OF RATS PRETREATED WITH AMPHETAMINE OR NIALAMIDE.
197490 01-04

THE EFFECT OF LSD, PSILOCYBIN, HARMALINE AND AMPHETAMINE ON THE BODY TEMPERATURE OF P-CHLOROPHENYLALANINE PRETREATED RABBITS.
210920 03-05

EFFECTS OF ANTAGONISTS UPON LOCOMOTOR STIMULATION INDUCED BY INJECTION OF DOPAMINE AND NORADRENALINE INTO THE NUCLEUS-ACCUMBENS OF NIALAMIDE PRETREATED RATS.
217475 04-04

THE EFFECTS OF THYROTROPIN-RELEASING HORMONE ON THE BEHAVIOUR OF RATS PRETREATED WITH ALPHA-METHYLTYROSINE.
222815 04-04

PRETREATMENT
THE INEFFECTIVENESS OF DESIPRAMINE PRETREATMENT ON BEHAVIORAL EFFECTS OF 6-HYDROXYDOPAMINE IN NIALAMIDE PRETREATED RATS.
195434 01-04

PRETREATMENT OF PROBLEM YOUTHS WITH CLOZAPINE IN PREPARATION FOR GROUP PSYCHOTHERAPY.
203599 02-14

THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL PRETREATMENT ON KETAMINE, THIOPENTAL OR CT-1341 -- INDUCED LOSS OF RIGHTING REFLEX IN MICE.
210878 03-02

BEHAVIORAL AND NEUROCHEMICAL EFFECTS OF MORPHINE OR AMPHETAMINE AFTER CHRONIC PRETREATMENT WITH CATECHOLAMINE DEPLETING AGENTS. (PH.D. DISSERTATION).
211746 03-03

FIXED-RATIO ESCAPE AND AVOIDANCE ESCAPE FROM NALOXONE IN MORPHINE-DEPENDENT MONKEYS: EFFECTS OF NALOXONE DOSE AND MORPHINE PRETREATMENT.
215968 04-04

PREVENT
FAILURE OF DIPHENYLHYDANTOIN TO PREVENT ALCOHOL WITHDRAWAL CONVULSIONS IN MICE.
193454 01-03

DOES LITHIUM IN DRINKING WATER PREVENT MENTAL DISORDER?
195933 01-17

DOSAGE OF A PSYCHOTROPIC DRUG TO PREVENT RELAPSE IN A CURED SCHIZOPHRENIC PATIENT.
209402 03-08

PREVENTED
PENTOBARBITAL EFFECT ON PERFORMANCE IN MONOTONOUS CONDITIONS NOT PREVENTED BY COMPENSATORY EFFORT.
205595 02-15

PREVENTION
PREVENTION OF SEROTONIN ABORTION BY SEROTONIN ANTAGONISTS IN RATS.
197489 01-03

METHODS OF DECONDITIONING PERSISTING AVOIDANCE: AMPHETAMINE, CHLORPROMAZINE, AND CHLORDIAZEPOXIDE AS ADJUNCTS TO RESPONSE PREVENTION.
202987 02-04

METHODS OF DECONDITIONING PERSISTING AVOIDANCE: AMPHETAMINE AND AMOBARBITAL AS ADJUNCTS TO RESPONSE PREVENTION.
209897 03-04

PREVENTION OF RECIDIVISM OF SCHIZOPHRENICS TREATED WITH FLUPHENAZINE ENANTHATE.
211436 03-08

PREVENTIVE
PREVENTIVE USE OF LITHIUM IN ELDERLY PATIENTS.
220434 04-09

PRIAPISM
PRIAPISM AS A POSSIBLE COMPLICATION OF THE CHLORPROMAZINE TREATMENT.
205594 02-15

PRIMARY
THE ROLE OF THE RETICULAR FORMATION IN ACTION EXERTED BY CHLORPROMAZINE AND BENACTYZINE ON PRIMARY RESPONSES OF THE BRAIN-CORTEX.
206440 03-04

DIFFERENTIAL SENSITIVITY OF PRIMARY AND SECONDARY SPINDLE AFFERENTS TO DEPRESSANT DRUGS.
210801 03-03

THE EFFECTS OF CANNABIS INTOXICATION ON PRIMARY SUGGESTIBILITY. (PH.D. DISSERTATION).
211831 03-14

BIPOLAR PRIMARY AFFECTIVE DISORDER.
221166 04-09

PRIMATE
EFFECT OF CHRONIC MARIJUANA ADMINISTRATION ON STAGES OF PRIMATE SLEEP-WAKEFULNESS.
225520 04-14

PRIMATES
CHLORPROMAZINE EXCRETION IN CHRONICALLY DOSED PRIMATES. I. OCCURRENCE OF A PREVIOUSLY UNREPORTED CLASS OF CHLORPROMAZINE CONJUGATES.
217553 04-03

PRIMIDONE
A CLINICAL STUDY OF SERUM CONCENTRATION LEVELS OF PHENOBARBITAL DERIVED FROM PRIMIDONE (MUSOLINE).
224644 04-13

PRINDOLOL
PRINDOLOL IN THE MANAGEMENT OF HYPERTENSION.
195773 01-14

PRINTS
DETERMINATION OF DRUG-INDUCED CHANGES IN SLEEP QUALITY BASED ON DIGITAL COMPUTER SLEEP PRINTS.
203603 02-14

PRISONER
PLASMA TRYPTOPHAN TOLERANCE CURVES IN DRUG-FREE NORMAL CONTROLS, SCHIZOPHRENIC PATIENTS AND PRISONER VOLUNTEERS.
200773 02-13

PRISONERS
CHLORDIAZEPOXIDE (LIBRIUM): THE EFFECTS OF A MINOR TRANQUILIZER ON STRATEGIC CHOICE BEHAVIOR IN THE PRISONERS DILEMMA.
199609 02-14

PROACTIVE
NICOTINE AND CAFFEINE: DISRUPTION OF THE LONG-TERM STORE MEMORY AND PROACTIVE FACILITATION OF LEARNING IN MICE.
198222 02-04

PROBANDS
ALTERATION OF PSYCHOSOMATIC REACTIVITY AFTER A SINGLE THERAPEUTIC DOSE OF PENTOBARBITAL IN RELATION TO THE SEX OF PROBANDS.
205627 03-14

PROBENECID
ACTION OF PROBENECID ON THE CENTRAL NERVOUS SYSTEM OF THE RABBIT: II. POTENTIATION OF 5-HYDROXYTRYPTOPHAN-INDUCED HYPERTHERMIA AND SUPPRESSION OF THIS EFFECT BY A DECARBOXYLASE INHIBITOR (RO-4-4602).
196580 01-03

CYCLIC-AMP IN CEREBROSPINAL FLUID: ACCUMULATION FOLLOWING PROBENECID AND BIOGENIC AMINES.
210193 03-17

PROBLEM
ON THE PROBLEM OF DIPHENYLHYDANTOIN-INDUCED SEIZURES: AN EXPERIMENTAL APPROACH.
197815 01-05

PRETREATMENT OF PROBLEM YOUTHS WITH CLOZAPINE IN PREPARATION FOR GROUP PSYCHOTHERAPY.
203599 02-14

THE PROBLEM OF SIDE-EFFECTS OF THYMOLEPTICS.
205620 03-15

5-HYDROXYTRYPTAMINE-14C AND DEXAMPHETAMINE-14C UPTAKE BY FUNDAL SARCOLEMMA PREPARATIONS AND THE PROBLEM OF THE COMMON RECEPTOR.
213591 04-03

RECOVERY OF FUNCTION: SOME NEW THOUGHTS ON AN OLD PROBLEM. (PH.D. DISSERTATION).
219268 04-04

PROBLEMS
THE EFFECTS OF PABENOL COMPLEX ON CHILDREN WITH LEARNING PROBLEMS.
196704 01-07

PROBLEMS OF CLINICAL EFFECTIVENESS AND USE OF LITHIUM SALTS IN PSYCHIATRIC PRACTICE.
200072 02-09

THERAPY-RESISTANT DEPRESSIONS: METHODOLOGICAL PROBLEMS. CONTRIBUTIONS TO METHODICAL QUESTIONS AND ANIMAL EXPERIMENTAL ASPECTS.
203591 02-09

TWO DECADES OF PSYCHOPHARMACOLOGY AND COMMUNITY MENTAL HEALTH: OLD AND NEW PROBLEMS OF THE SCHIZOPHRENIC PATIENT.
207921 03-17

PSYCHOPHARMACOLOGICAL THERAPY AND THE PROBLEMS OF DELINEATING BORDERLINE FORMS OF NEUROPSYCHIC DISORDERS.
212431 03-17

WILL THE REAL HYPERACTIVE CHILD PLEASE SIT DOWN? PROBLEMS OF DIAGNOSIS AND REMEDIATION.
212811 03-11

PROBLEMS IN THE ELECTROPHYSIOLOGICAL ANALYSIS OF THE SITE OF ACTION OF BENZODIAZEPINES. (UNPUBLISHED PAPER).
218148 04-03

DOUBLE-BLIND TEST OF THREE ANTIDEPRESSANTS, THIRD COMMUNICATIONS: METHODOLOGICAL PROBLEMS.
221288 04-16

PROCAINE
EFFECTS OF PROCAINE HYDROCHLORIDE, DIAZEPAM, AND DIPHENYLHYDANTOIN ON SEIZURE DEVELOPMENT IN CORTICAL AND SUBCORTICAL STRUCTURES IN RATS.
218191 04-03

PROCEDURE
THE USE OF THE IMMOBILITY REFLEX (ANIMAL HYPNOSIS) AS A POSSIBLE PROCEDURE FOR DETECTING SEDATIVE ACTIVITY.
196066 01-04

TRANQUILIZING EFFECTS OF DIAZEPAM IN PIGS SUBJECTED TO A PUNISHMENT PROCEDURE.
210741 03-04

SKED PROGRAM FOR A MODIFIED STERNBERG PROCEDURE.
214812 04-16

DOUBLE-BLIND PROCEDURE: AN ASSESSMENT IN A STUDY OF LITHIUM PROPHYLAXIS.
218042 04-16

A SIMPLE AVOIDANCE PROCEDURE FOR TESTING PSYCHOTROPIC DRUGS IN MICE.
220903 04-04

PROGNOSIS OF THE THERAPEUTIC EFFECT OF SUXILEP AND TRIMETIN USING A SUCCESSIONAL STATISTICAL PROCEDURE.
224086 04-11

PROCEDURES
LSD, PSYCHOTOGENIC PROCEDURES, AND BRAIN NEUROHUMORS.
213606 04-03

ASSESSMENT OF TOLERANCE TO BARBITAL BY MEANS OF DRUG DISCRIMINATION PROCEDURES.
221046 04-02

PROCEEDINGS
FRONTIERS IN CATECHOLAMINE RESEARCH. PROCEEDINGS OF THE THIRD INTERNATIONAL CATECHOLAMINE SYMPOSIUM.
206437 03-17

PROCESSING
THE EFFECT OF CHLORPROMAZINE ON VISUAL INFORMATION PROCESSING IN NORMAL SUBJECTS.
199663 02-14

CENTRAL DOPAMINE NEURONS AND SENSORY PROCESSING.
207304 03-03

EXPERIENCING AND ALTERING STATES OF INTOXICATION: AN INFORMATION PROCESSING VIEW OF THE HIGH.
224756 04-14

PROCHLORPERAZINE
TISSUE METABOLITES OF TRIFLUOPERAZINE, FLUPHENAZINE, PROCHLORPERAZINE, AND PERPHENAZINE IN THE RAT: IDENTIFICATION AND SYNTHESIS.
200738 02-01

PRODUCE
EVIDENCE THAT PUNCTUATE INTRACEREBRAL ADMINISTRATION OF 6-HYDROXYDOPAMINE FAILS TO PRODUCE SELECTIVE NEURONAL DEGENERATION: COMPARISON WITH COPPER SULFATE AND FACTORS GOVERNING THE DEPORTMENT OF FLUIDS INJECTED INTO BRAIN.
197931 01-03

PRODUCING
AMPHETAMINE: POSSIBLE SITE AND MODE OF ACTION FOR PRODUCING ANOREXIA IN THE RAT.
210675 03-03

PRODUCTION
HEAT PRODUCTION AND OXYGEN CONSUMPTION OF THE ISOLATED RABBIT HEART UNDER THE INFLUENCE OF STROPHANTHIN VERAPAMIL, AND GLYCERYL TRINITRATE.
197567 01-03

RETESTING WITH GRAPHIC PRODUCTION: RESOLUTION OF A DIAGNOSTIC DILEMMA.
197600 01-09

THE EFFECT OF TRIIODOTHYRONINE IN COMBINATION WITH IMIPRAMINE ON (3H) CYCLIC-AMP PRODUCTION IN SLICES OF RAT CEREBRAL CORTEX.
202777 02-03

THE INHIBITION OF A AND B FORMS OF MAO IN THE PRODUCTION OF A CHARACTERISTIC BEHAVIOURAL SYNDROME IN RATS AFTER L-TRYPTOPHAN LOADING.
217471 04-03

EFFECT OF MARIJUANA ON DIVERGENT AND CONVERGENT PRODUCTION COGNITIVE TESTS.
223394 04-14

PROFILE
PHARMACOLOGICAL PROFILE OF A NEW NONTRICYCLIC ANTIDEPRESSANT: OXAFLOZANE (1766-CERM).
199385 02-02

MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 2. COMMUNICATION: PSYCHOPATHOLOGICAL

COURSE PROFILE AND SOMATIC CHARACTERISTICS (STUDIES WITH THE AMP SYSTEM).
203840 02-14

THE ACTIVITY PROFILE OF PIRACETAM IN PSYCHOSYNDROMES AND SYMPTOMATIC PSYCHOSES.
204411 02-09

EXPERIMENTAL PSYCHOLOGIC AND PSYCHOPHYSIOLOGIC LONGITUDINAL PROFILE STUDIES ON DEPRESSIVE PATIENTS UNDER THYMOLEPTIC MEDICATION.
204413 02-15

BIOCHEMICAL VERSUS PSYCHOPATHOLOGICAL ACTION PROFILE OF NEUROLEPTICS: A COMPARATIVE STUDY OF CHLORPROMAZINE AND OXYPERTINE IN ACUTE PSYCHOTIC DISORDERS.
215454 04-13

PSYCHOTHERAPEUTIC PROFILE OF A NEW PSYCHOACTIVE DRUG TRAZODONE (AF-1161).
215699 04-09

PROFILE-BASED-THERAPY

PROFILE-BASED-THERAPY (PBT) IN SCHIZOPHRENIAS: A PRECLINICAL INDICATION FOR THE USE OF DIHYDROXYPHENYLSERINE (DOPS).
195115 01-08

PROFILES

EEG PROFILES AS PREDICTORS OF PSYCHOTROPIC DRUG CLASSIFICATION.
198060 01-07

PATIENT PROFILES AND DIFFERENTIAL RESPONSE TO DRUGS.
198087 02-10

DRUGS, EEG AND BEHAVIOUR: EEG PROFILES AND BIOAVAILABILITY MEASURES FOR CLINICAL PSYCHOPHARMACOLOGY.
205522 02-16

LONGITUDINAL PROFILES OF THE EFFECTS OF PSYCHOTROPIC DRUGS: RESULTS OF AN ANIMAL STUDY.
206970 03-05

LONGITUDINAL PROFILES OF THE EFFECTS OF PSYCHOTROPIC DRUGS FROM CLINICOMETHODOLOGICAL VIEWPOINTS.
206971 03-16

CLINICAL STUDY OF FIVE DEPOT NEUROLEPTICS, COMPARISON OF ACTIVITY PROFILES OF FLUPHENAZINE DECANOATE, FLUSPIRILENE, PENFLURIDOL, PERPHENAZINE ENANTHATE AND PIPOTHIAZINE PALMITATE.
221822 04-08

PROGENY

LSD TREATMENT OF PIERIS-BRASSICAE AND CONSEQUENCES ON THE PROGENY.
199425 02-04

THE EFFECT OF DIAZEPAM ON THE DEVELOPMENT OF PROGENY.
207163 03-04

PROGESTERONE

EFFECT OF PROGESTERONE ON REGIONAL 5-HYDROXYTRYPTAMINE METABOLISM IN THE RAT BRAIN.
199773 02-03

THE ACCUMULATION OF NORADRENALINE AND 5-HYDROXYTRYPTAMINE IN THREE REGIONS OF MOUSE BRAIN AFTER TETRABENAZINE AND IPRONIAZID: EFFECTS OF ETHINYLESTRADIOL AND PROGESTERONE.
200058 02-03

FACILITATORY AND INHIBITORY INFLUENCES OF PROGESTERONE, 20ALPHA-HYDROXYPROGESTERONE AND METHYSERGIDE ON THE RECEPTIVE BEHAVIOR OF THE FEMALE RAT. (PH.D. DISSERTATION).
222739 04-04

PROGNOSIS

THE COURSE AND PROGNOSIS OF SCHIZOPHRENIC PSYCHOSES IN HELSINKI: A COMPARATIVE STUDY OF FIRST ADMISSIONS IN 1950, 1960 AND 1965.
197276 01-17

SIGNS, COURSE AND PROGNOSIS OF TICS IN CHILDREN AND JUVENILES.
203881 02-14

PROGNOSIS OF THE THERAPEUTIC EFFECT OF SUXILEP AND TRIMETIN USING A SUCCESSIONAL STATISTICAL PROCEDURE.
224086 04-11

PROGRAM

DROWSINESS DUE TO CHLORPROMAZINE IN RELATION TO CIGARETTE SMOKING: A REPORT FROM THE BOSTON COLLABORATIVE DRUG SURVEILLANCE PROGRAM.
193072 01-15

DRUG-SCREENING PROGRAM FOR DRUG-RESISTANT SCHIZOPHRENICS.
198072 01-02

THE COMBINED EFFECTS OF METHYLPHENIDATE (RITALIN) AND A CLASSROOM BEHAVIOR MODIFICATION PROGRAM IN REDUCING THE HYPERKINETIC BEHAVIORS OF INSTITUTIONALIZED MENTAL RETARDATES. (PH.D. DISSERTATION).
202356 02-11

PROGRAM IN BEHAVIORAL PHARMACOLOGY.
213612 04-04

PSYCHOTROPIC DRUG USE IN THE BOSTON AREA: A REPORT FROM THE BOSTON COLLABORATIVE DRUG SURVEILLANCE PROGRAM.
213920 04-17

SKED PROGRAM FOR A MODIFIED STERNBERG PROCEDURE.
214812 04-16

PROGRAMMED

PROGRAMMED SELF-ADMINISTRATION OF POTENTIALLY ADDICTIVE DRUGS IN YOUNG RATS AND ITS EFFECTS ON LEARNING.
195430 01-04

PROGRESS

PROGRESS IN ANXIETY STATES.
201896 02-10

PROGRESS IN ANXIETY STATES.
201897 02-10

PROGRESS IN ANXIETY STATES.
201898 02-11

THE PACE OF PROGRESS.
203213 02-08

NICOTINIC ACID IN THE TREATMENT OF SCHIZOPHRENIAS: CANADIAN MENTAL HEALTH ASSOCIATION COLLABORATIVE STUDY PROGRESS REPORT II.
219537 04-08

PROJECTION

REVERSAL BY L-DOPA OF IMPAIRED LEARNING DUE TO DESTRUCTION OF THE DOPAMINERGIC NIGRO-NEOSTRIATAL PROJECTION.
193578 01-04

PHYSIOLOGICAL AND PHARMACOLOGICAL EVIDENCE FOR A SEROTONERGIC PROJECTION TO THE HIPPOCAMPUS.
223171 04-03

PROLACTIN

EFFECTS OF CENTRAL ACTING DRUGS AND ERGOT DERIVATIVES ON PROLACTIN AND GROWTH HORMONE SECRETION, ON GROWTH OF PITUITARY AND MAMMARY TUMORS AND ON REPRODUCTION IN OLD RATS. (PH.D. DISSERTATION).
194571 01-03

ANTIPSYCHOTIC DRUGS STIMULATE PROLACTIN RELEASE.
206354 03-03

THE EFFECT OF PSYCHOPHARMACOLOGIC PROLACTIN RELEASERS ON LACTATION IN SHEEP.
210793 03-03

GROWTH HORMONE AND PROLACTIN RELEASE AFTER INJECTION OF THYROTROPIN-RELEASING HORMONE IN PATIENTS WITH DEPRESSION.
214885 04-13

TETRAHYDROCANNABINOLS AND SERUM PROLACTIN LEVELS IN MAN.
220973 04-13

THE EFFECT OF LONG-TERM PHENOTHIAZINE THERAPY ON PLASMA PROLACTIN.
223777 04-15

PROLONGED

CHANGES IN ACTIVATION OF ADENYLATE-CYCLASE AND OF DOPAMINE TURNOVER IN RAT STRIATUM DURING PROLONGED HALOPERIDOL TREATMENT.
192933 01-03

PROLONGED PENTOBARBITAL SLEEPING TIME IN ADJUVANT INDUCED POLYARTHRITIC RATS.
196228 01-04

EFFECT OF PROLONGED LITHIUM INGESTION ON GLUCAGON AND PARATHYROID HORMONE RESPONSES IN RATS.
197744 01-03

THE EFFECT OF NH4CL ON POLYURIA AND POLYDIPSIA DURING PROLONGED LITHIUM ADMINISTRATION IN THE RAT.
198027 01-03

THE INFLUENCE OF PROLONGED APPLICATION OF TRANQUILIZERS AND ANTIDEPRESSANTS ON THE SUMMATIONAL CAPACITY OF THE CENTRAL NERVOUS SYSTEM.
201913 02-03

SURVIVAL IN LITHIUM INTOXICATION, STATUS-EPILEPTICUS, AND PROLONGED COMA.
208536 03-15

PROLONGED NEUROLEPTIC EFFECT OF ALPHA-FLUPENTHIXOL DECANOATE IN OIL.
210893 03-03

A PROLONGED AFTEREFFECT OF INTENSE SYNAPTIC ACTIVITY ON ACETYLCHOLINE IN A SYMPATHETIC GANGLION.
211102 03-03

THE EFFECT OF PROLONGED LITHIUM INGESTION ON MORPHINE ACTIONS IN THE RAT.
213482 04-03

NEUROLEPTICS OF PROLONGED ACTION (A SURVEY OF FOREIGN LITERATURE).
217003 04-14

PROMAZINE

THE EFFECTS OF IMIPRAMINE AND PROMAZINE ON ENERGY METABOLISM AND EEG OF THE ISOLATED PERFUSED RAT BRAIN.
197296 01-03

QUANTITATIVE ANALYSIS OF THE EEG EFFECTS PRODUCED BY IMIPRAMINE, DESIPRAMINE, PROMAZINE, AND MONODESMETHYL PROMAZINE IN THE ISOLATED PERFUSED RAT BRAIN.
200056 02-03

PROMETHAZINE

THE INHIBITORY EFFECT OF TOLUIDINE BLUE AND METHYLENE BLUE ON RAT MAST CELL DAMAGE BY PROMETHAZINE, CHLORPROMETHAZINE AND CHLORPROMAZINE. ITS REVERSAL BY GLUCOSE.
199255 02-05

PRONOUNCED
AZAPERONE, A SEDATIVE NEUROLEPTIC OF THE BUTYROPHENONE SERIES WITH PRONOUNCED ANTIAGGRESSIVE AND ANTISHOCK ACTIVITY IN ANIMALS.
206786 03-04

PROPARGYLAMINE
COMPARISON OF THE INHIBITORY EFFECTS OF PROPARGYLAMINE AND PARGYLINE ON BRAIN AND LIVER MONOAMINEOXIDASE ACTIVITY.
207857 03-03

PROPHYLACTIC
PROPHYLACTIC USE OF LITHIUM.
194168 01-09
ON THE CONTROVERSY OF PROPHYLACTIC ANTIDEPRESSANTS.
207764 03-09
THE LITHIUM PROPHYLACTIC TREATMENT OF RECURRENT ENDOGENOUS AFFECTIVE DISORDERS.
209392 03-09
A FOLLOWUP STUDY OF FEMALE DEPRESSED OUTPATIENTS WHO COMPLETE A RANDOMIZED DOUBLE-BLIND PROPHYLACTIC TRIAL OF ANTIDEPRESSANTS AND HIGH CONTACT. (PH.D. DISSERTATION).
212518 03-09
FURTHER REPORT ON PROPHYLACTIC LITHIUM IN RECURRENT AFFECTIVE DISORDERS.
218556 04-09
ANTIMANIC AND PROPHYLACTIC EFFECTS OF CARBAMAZEPINE (TEGRETOL) ON MANIC-DEPRESSIVE PSYCHOSIS.
225086 04-09

PROPHYLAXIS
FACTORS ASSOCIATED WITH TREATMENT SUCCESS IN LITHIUM CARBONATE PROPHYLAXIS: REPORT OF THE NIMH-VA COLLABORATIVE STUDY GROUP.
193068 01-09
LITHIUM PROPHYLAXIS -- A CRITICAL REVIEW.
194355 01-09
THE CURRENT STATUS OF LITHIUM PROPHYLAXIS.
196678 01-07
LITHIUM PROPHYLAXIS: A CRITICAL REVIEW.
197531 01-09
LITHIUM PROPHYLAXIS IN RECURRENT AFFECTIVE DISORDERS.
197532 01-09
THE CURRENT STATUS OF LITHIUM RECIDIVISM PROPHYLAXIS IN ENDOGENOUS AFFECTIVE ILLNESSES.
200568 02-09
RED BLOOD CELL LITHIUM INDEX IN PATIENTS WITH AFFECTIVE DISORDERS IN THE COURSE OF LITHIUM PROPHYLAXIS.
202786 02-09
COMPARATIVE STUDIES ABOUT SERUM ELECTROLYTES DURING LITHIUM PROPHYLAXIS OF AFFECTIVE DISORDERS.
210807 03-09
DOUBLE-BLIND PROCEDURE: AN ASSESSMENT IN A STUDY OF LITHIUM PROPHYLAXIS.
218042 04-16
LITHIUM PROPHYLAXIS: THE MARRIED COUPLES GROUP.
224749 04-09
RELATIONSHIP BETWEEN DOSAGE AND RESPONSE TO LITHIUM PROPHYLAXIS IN RECURRENT DEPRESSION.
224872 04-09
LITHIUM CARBONATE PROPHYLAXIS FAILURE.
224873 04-09
LITHIUM PROPHYLAXIS OF THREE DEPRESSION SUBTYPES.
224874 04-09

PROPIONATE
SHORT-TERM EFFECTS OF TESTOSTERONE PROPIONATE ON THE BEHAVIOUR OF YOUNG INTACT MALE DOMESTIC DUCKS (ANAS-PLATYRHYNCHOS).
199461 02-04

PROPITAN
REPORT ON THREE CASES OF CARDIAC CHANGES DURING TREATMENT WITH FLOROPIPAMIDE (PROPITAN).
216391 04-15

PROPOSAL
THE PROPOSAL OF AN UNIFIED MODEL FOR THE INTERPRETATION OF THE ACTIVITY OF DIFFERENT CLASSES OF BETA-ADRENERGIC AGENTS.
220951 04-01

PROPOXYPHENE
EFFECT OF COMBINED ALCOHOL AND PROPOXYPHENE ON HUMAN PERFORMANCE.
210871 03-14

PROPRANOLOL
DIFFERENTIAL EFFECTS OF EPINEPHRINE AND PROPRANOLOL ON SHUTTLEBOX AVOIDANCE LEARNING IN RATS OF DIFFERENT AGES. (PH.D. DISSERTATION).
193745 01-04
EFFECTS OF THEOPHYLLINE AND PROPRANOLOL ON ACETYLCHOLINE-INDUCED RELEASE OF ADRENAL MEDULLARY CATECHOLAMINES.
195591 01-03
ANTAGONISM OF ACUTE AMPHETAMINE INTOXICATION BY HALOPERIDOL AND PROPRANOLOL.
196106 01-05
EFFECT OF DELTA1-TETRAHYDROCANNABINOL AND PROPRANOLOL ON OUABAIN INDUCED ARRHYTHMIAS.
197486 01-03
INFLUENCE OF PROPRANOLOL AND PRACTOLOL ON THE TURNOVER OF NORADRENALINE IN THE RAT HEART.
197957 01-03
EFFECTS OF PROPRANOLOL, D-AMPHETAMINE AND CAFFEINE ON ETHANOL AS A DISCRIMINATIVE CUE.
199963 02-04
GLC DETERMINATION OF PROPRANOLOL, OTHER BETA-BLOCKING DRUGS, AND METABOLITES IN BIOLOGICAL FLUIDS AND TISSUES.
200740 02-16
INHIBITION OF AMPHETAMINE TOLERANCE AND METABOLISM BY PROPRANOLOL.
202662 02-03
PROPRANOLOL IN THE CONTROL OF SCHIZOPHRENIC SYMPTOMS.
209830 03-08
VISUAL HALLUCINATIONS AND PROPRANOLOL.
213522 04-15
PROPRANOLOL IN THE TREATMENT OF OPIATE DEPENDENCE -- A CONTROLLED STUDY.
217549 04-14

PROPYL
STUDIES ON PSYCHOTROPIC DRUGS: XVII. EFFECTS OF 3-CHLORO-5-(3-(4 PIPERIDINO-4-CARBAMOYL-PIPERIDINO)PROPYL) 10,11-DIHYDRO-5(H) DIBENZAZEPINE DIHYDROCHLORIDE MONOHYDRATE (Y-4153) ON THE METABOLISM OF BIOGENIC AMINES.
199210 02-03

PROPYNYL
PHARMACOLOGIC STUDIES ON PROPYNYL DIBENZAZEPINE, A NEW ALPHA-ADRENERGIC BLOCKER.
197493 01-03

PROS
PROS AND CONS OF DRUG THERAPY IN THE MANAGEMENT OF THE HYPERACTIVE CHILD.
216966 04-11

PROSPECTS
NEW PROSPECTS OF TREATMENT OF PARKINSONS DISEASE WITH PARKS-PLUS.
221885 04-11

PROSTAGLANDIN-E1
DECREASED ANTINOCICEPTIVE EFFECT OF MORPHINE IN RATS TREATED INTRAVENTRICULARLY WITH PROSTAGLANDIN-E1.
200045 02-03

PROSTAGLANDIN-SYNTHETASE
INHIBITION OF PROSTAGLANDIN-SYNTHETASE BY PSYCHOTROPIC DRUGS.
215162 04-03

PROSTAGLANDINS
EFFECTS OF CATECHOLAMINES AND PROSTAGLANDINS ON CYCLIC-AMP LEVELS IN BRAIN IN VIVO.
197294 01-03
PROSTAGLANDINS AND CANNABIS -- III. INHIBITION OF BIOSYNTHESIS BY ESSENTIAL OIL COMPONENTS OF MARIHUANA.
217795 04-03

PROTAMINE
FEEDING IN RESPONSE TO REPEATED PROTAMINE ZINC INSULIN INJECTIONS.
219073 04-04

PROTECTING
EFFECTS ON SHOCK-ELICITED AGGRESSION IN MICE OF PREFERENTIALLY PROTECTING BRAIN MONOAMINES AGAINST THE DEPLETING ACTION OF RESERPINE.
195452 01-04

PROTECTION
PROTECTION AGAINST EFFECTS OF BRAIN DAMAGE BY CATECHOLAMINE DEPLETION IS TEST DEPENDENT.
203579 02-04

PROTECTIVE
PROTECTIVE EFFECT OF ADENOSINE AND NICOTINAMIDE AGAINST AUDIOGENIC SEIZURE.
198135 02-03
PROTECTIVE EFFECT OF PIRACETAM IN EXPERIMENTAL BARBITURATE INTOXICATION: EEG AND BEHAVIOURAL STUDIES.
213589 04-03
THE MECHANISM OF THE POTENTIATING EFFECT OF ANTIDEPRESSANT DRUGS ON THE PROTECTIVE INFLUENCE OF DIPHENHYDRAMINE IN EXPERIMENTAL CATATONIA. THE ROLE OF HISTAMINE.
215664 04-03
THE PROTECTIVE EFFECT OF SEROTONIN AGAINST THE INHIBITORY ACTION OF CHLORPROMAZINE ON THE MEMBRANE POTENTIAL OF STAGE 2 BLASTOMERES OF MOUSE EMBRYOS IN VITRO.
217005 04-03

PROTEIN
AN EFFECT OF AMPHETAMINE ON INCORPORATION OF LEUCINE INTO MOUSE BRAIN PROTEIN.
193424 01-03
ON THE REGULATION OF CYCLIC-AMP PHOSPHODIESTERASE BY A SPECIFIC PROTEIN ACTIVATOR. (UNPUBLISHED PAPER).
208735 03-03

CHANGES IN THE NEURONAL PROTEIN LABELLING INDUCED BY POTASSIUM IONS IN VIVO (SPREADING DEPRESSION).
210779 03-03

BETA-ADRENERGIC STIMULATION OF PINEAL N-ACETYLTRANSFERASE: CYCLIC-AMP STIMULATES BOTH RNA AND PROTEIN SYNTHESIS.
215601 04-03

COMPETITION FOR PLASMA PROTEIN BINDING SITES BETWEEN PHENOTHIAZINE TRANQUILIZERS AND IMINODIBENZYL ANTIDEPRESSANTS.
217891 04-03

INTERACTION OF CYCLOHEXIMIDE AND ADRENERGIC DRUGS WITH BRAIN PROTEIN AND CATECHOLAMINE BIOSYNTHESIS. (PH.D. DISSERTATION).
219288 04-03

INHIBITORS OF CEREBRAL PROTEIN SYNTHESIS: DISSOCIATION OF AVERSIVE AND AMNESIC EFFECTS.
221005 04-04

THE EFFECT OF THE PSYCHOTROPIC AGENTS (CHLORPROMAZINE, MAJEPTIL, TRICEDIL) ON PROTEIN SYNTHESIS IN VARIOUS PORTIONS OF THE RAT BRAIN.
223063 04-03

PROTEINASE

PROTEINASE ACTIVITY OF DIFFERENT SECTIONS OF THE BRAIN DURING CORAZOL (PENTYLENETETRAZOL) INDUCED CONVULSIONS.
198485 02-03

PROTEINS

BINDING OF (+) AMPHETAMINE AND (-) DELTA1-TETRAHYDROCANNABINOLS AND (-) 7-HYDROXY-DELTA1-TETRAHYDROCANNBINOL TO BLOOD CELLS AND PLASMA PROTEINS IN MAN.
217878 04-13

PROTHIADEN-SPOFA

CARDIOTOXIC EFFECTS OF TRICYCLIC ANTIDEPRESSANTS IMIPRAMINE, AMITRIPTYLINE AND DOSULEPIN (PROTHIADEN-SPOFA) IN AN ACUTE EXPERIMENT IN RATS.
205597 02-15

PROTIRELIN

PROTIRELIN (TRH) IN DEPRESSION.
194827 01-14

PROTRACTED

PLASMA TESTOSTERONE LEVELS DURING CHRONIC HEROIN USE AND PROTRACTED ABSTINENCE.
202307 02-13

PROTRIPTYLINE

PROTRIPTYLINE INDUCED INHIBITION OF THE IN VIVO 3H-NORADRENALINE SYNTHESIS FROM 3H-L-DOPA IN THE RAT BRAIN.
197928 01-03

LACK OF EFFECT OF PROTRIPTYLINE ON THE 6-HYDROXYDOPAMINE INDUCED NORADRENALINE DEPLETION IN THE RAT SPINAL CORD.
217824 04-03

PROVERB

EFFECTS OF PHENOTHIAZINE WITHDRAWAL ON PROVERB INTERPRETATION BY CHRONIC SCHIZOPHRENICS.
208325 03-08

PROVOKED

SALIVARY SCINTOGRAPHY: INTEREST IN TREATMENT OF DRY MOUTH PROVOKED BY PSYCHOTROPIC MEDICATION.
212493 03-15

PS-042

PHARMACOLOGY OF MAGNESIUM GLUTAMATE HYDROBROMIDE (PS-042), A NEW TRANQUILIZER: THIRD PART, PSYCHOPHARMACOLOGICAL STUDIES.
196444 01-02

PSEUDOCONDITIONING

EFFECT ON PSEUDOCONDITIONING OF DRUGS WITH KNOWN CENTRAL NERVOUS ACTIVITY.
198228 02-04

PSILOCYBIN

THE EFFECTS OF LSD, PSILOCYBIN, HARMALINE AND AMPHETAMINE ON THE BODY TEMPERATURE OF P-CHLOROPHENYLALANINE PRETREATED RATS.
197484 01-03

THE EFFECT OF LSD, PSILOCYBIN, HARMALINE AND AMPHETAMINE ON THE BODY TEMPERATURE OF P-CHLOROPHENYLALANINE PRETREATED RABBITS.
210920 03-05

HYPERSENSITIVITY TO LYSERGIC ACID DIETHYLAMIDE (LSD-25) AND PSILOCYBIN IN ESSENTIAL HEADACHE.
211108 03-12

PSYCHEDELIC

PSYCHEDELIC DRUGS.
193498 01-12

PSYCHIATRIC

PSYCHOACTIVE DRUG USE IN ELDERLY PATIENTS WITH PSYCHIATRIC DISORDERS: A SURVEY OF 12 VETERANS ADMINISTRATION HOSPITALS.
193291 01-11

AN EVALUATION OF A DRUG ADMINISTRATION SYSTEM IN A PSYCHIATRIC HOSPITAL.
194409 01-17

THE EEG EFFECTS OF ZINC IN GERIATRIC PSYCHIATRIC PATIENTS.
195039 01-13

SOMATOSENSORY EVOKED RESPONSE WAVE SHAPE STABILITY: RELATIONSHIPS TO PSYCHIATRIC DIAGNOSIS AND EFFECTS OF PSYCHOACTIVE DRUGS.
195935 01-17

PATTERN ANALYSIS OF PSYCHIATRIC RESEARCH DATA.
195940 01-11

PSYCHIATRIC ILLNESS AND THE FUTURE OF NATIONS.
196031 01-17

TIME-DEPENDENT EFFECTS OF PHENOTHIAZINES ON DOPAMINE TURNOVER IN PSYCHIATRIC PATIENTS. (UNPUBLISHED PAPER).
196087 01-13

ADVERSE REACTIONS TO CHLORPROMAZINE IN PSYCHIATRIC PATIENTS.
197923 01-01

PSYCHIATRIC ASPECTS OF HYPERTENSION.
198040 01-10

PATTERNS OF CHLORPROMAZINE USE IN GENERAL AND PSYCHIATRIC HOSPITALS.
198050 01-17

LONG-TERM TREATMENT OF PSYCHIATRIC PATIENTS WITH CLOPENTHIXOL: ANALYSIS OF LABORATORY TESTS WITH A VIEW TO LONG-TERM THERAPY.
199989 02-14

PROBLEMS OF CLINICAL EFFECTIVENESS AND USE OF LITHIUM SALTS IN PSYCHIATRIC PRACTICE.
200072 02-09

THE EFFECTS OF LITHIUM CARBONATE ON SERUM GASTRIN IN PSYCHIATRIC PATIENTS.
200637 02-04

CLINICAL STUDY OF GERDAXYL 10MG WITH 40 PATIENTS TREATED IN A PSYCHIATRIC OUTPATIENT FACILITY.
202037 02-11

THE ROLE OF ADAPTIVE REGULATION IN THE PATHOPHYSIOLOGY OF PSYCHIATRIC DISEASE.
207307 03-03

PSYCHIATRIC INVESTIGATION OF DRUG DEPENDENCE.
208761 03-17

EXPERIENCE WITH LONG-ACTING PHENOTHIAZINES IN A PSYCHIATRIC HOSPITAL.
208921 03-17

THE CLINICAL RELEVANCE OF PHOTOSENSITIVITY IN PSYCHIATRIC EEG DIAGNOSIS.
209018 03-15

PHYSIOLOGICAL MANAGEMENT OF HOSPITALIZED PSYCHIATRIC PATIENTS.
209399 03-11

RESEARCH ON PSYCHIATRIC INDICATIONS OF A POWERFUL ANXIOLYTIC, LORAZEPAM.
210088 03-14

EXPERIENCES OF A GENERAL PRACTITIONER AMONG PSYCHIATRIC PATIENTS.
211012 03-15

PRELIMINARY STUDY OF A BETA-BLOCKER (PINDOLOL) IN THREE SCHIZOPHRENICS AND THREE NONPSYCHOTIC PSYCHIATRIC PATIENTS: DIFFERENTIAL SENSITIVITY IN HEART RATE.
212164 03-13

THE USE OF PSYCHOACTIVE DRUGS IN ELDERLY PATIENTS WITH PSYCHIATRIC DISORDERS: SURVEY CONDUCTED IN TWELVE VETERANS ADMINISTRATION HOSPITALS.
215009 04-11

CLINICAL EXPERIENCE OF HALOPERIDOL INJECTION ON PSYCHIATRIC CASES.
217957 04-14

THE SIGNIFICANCE OF PSYCHOPHARMACOLOGY FOR PSYCHIATRIC REHABILITATION.
220367 04-09

THE SIGNIFICANCE OF STANDARDIZED EVALUATION SCALES IN PSYCHIATRIC DIAGNOSIS AS EXEMPLIFIED BY THE THERAPEUTIC INTERVENTION WITH DESMETHYLOXAPINE.
221337 04-10

A CLINICAL TRIAL OF MAPROTILINE (LUDIOMIL) IN THE TREATMENT OF DEPRESSIVE PATIENTS IN GENERAL PRACTICE AND THE PSYCHIATRIC CLINIC.
221657 04-09

LONG-ACTING DRUGS IN PSYCHIATRIC TREATMENT: LACUNAE AND NEEDS.
221672 04-17

ACCIDENTS AND DRUG TREATMENT IN A PSYCHIATRIC HOSPITAL.
222603 04-15

ANXIETY NEUROSIS, DEPRESSIVE DISORDER AND MEPROBAMATE ADDICTION -- PSYCHIATRIC GRAND-ROUNDS, UNIV. OF CALIFORNIA, SAN-DIEGO.
222772 04-10

TRIAL EXPERIENCE OF NEOPROSERIN IN THE PSYCHIATRIC AREA.
224392 04-11

SIGNIFICANCE OF PLASMA CHLORPROMAZINE IN MANAGEMENT OF PSYCHIATRIC PATIENTS.
224832 04-13

PSYCHIATRIST
THE PSYCHIATRIST ATTITUDES AND THERAPEUTIC MEANS WHEN FACED WITH RESISTANT DEPRESSIONS.
196035 01-17
SUIT AGAINST RECOMMENDING DOCTOR AND PSYCHIATRIST -- REJECTED. STOVALL V. HARMS, 522 P.2D 353, (KANSAS) SUPREME COURT OF KANSAS. MAY 11, 1974.
200438 02-17

PSYCHIATRISTS
TYPOLOGY OF DEPRESSIONS AND THERAPEUTIC BEHAVIOR OF PSYCHIATRISTS.
212215 03-17
CLOMIPRAMINE (ANAFRANIL) IN THE TREATMENT OF OBSESSIONAL STATES: A PSYCHIATRISTS VIEW.
215155 04-10
CLOMIPRAMINE (ANAFRANIL) IN THE TREATMENT OF PHOBIC STATES: A PSYCHIATRISTS VIEW.
215156 04-10

PSYCHIATRY
DRUGS IN PSYCHIATRY.
194274 01-15
USE OF METAMIN (FLUPENTHIXOL) IN THE DEPARTMENT OF PSYCHIATRY.
194449 01-08
EXPERIENCE WITH CHLORIMIPRAMINE (ANAFRANIL) IN PSYCHIATRY.
195533 01-09
DRUG TREATMENT OF CHRONIC INTRACTABLE PAIN IN PATIENTS REFERRED TO A PSYCHIATRY CLINIC.
196090 01-14
REVIBOL IN CHILDRENS PSYCHIATRY.
198395 02-11
BETA-ADRENERGIC RECEPTOR BLOCKING DRUGS IN PSYCHIATRY.
199636 02-17
CLINICAL OBSERVATIONS ON SULPIRIDE TREATMENT IN PSYCHIATRY.
200170 02-11
A SURVEY OF DRUG TREATMENT IN PSYCHIATRY: SPECIAL EMPHASIS ON INPATIENTS ON MEDICAL WELFARE SUPPORTED BY YOKOHAMA CITY.
200447 02-17
SOCIAL AND PSYCHOLOGICAL ASPECTS OF MEDICAL PRACTICE: DRUG TREATMENT IN PSYCHIATRY.
201270 02-17
USE OF BETA-ADRENERGIC RECEPTOR BLOCKING DRUGS IN PSYCHIATRY.
202797 02-17
SIMPLE METHOD FOR DETECTION OF THE DRUG CHEATERS IN PSYCHIATRY.
205586 02-17
FROM HOSPITAL TREATMENT TO COMMUNITY PSYCHIATRY -- SECOND REPORT -- OUTPATIENT EMERGENCY TREATMENT OF MENTAL PATIENTS WITH THE USE OF HALOPERIDOL.
208723 03-11
GUIDE TO PSYCHIATRY.
209428 03-17
DRUG TREATMENT IN PSYCHIATRY.
212888 03-17
COMMENT ON LINUS PAULINGS THEORY OF ORTHOMOLECULAR PSYCHIATRY.
213704 04-08
COMMENT ON LINUS PAULINGS THEORY OF ORTHOMOLECULAR PSYCHIATRY.
213705 04-13
COMMENT ON LINUS PAULINGS THEORY OF ORTHOMOLECULAR PSYCHIATRY.
213706 04-15
THE USE OF SIDNOCARB IN CHILD PSYCHIATRY.
217001 04-11
THE CURRENT STATUS OF LITHIUM IN PSYCHIATRY.
218129 04-09
PSYCHOPHARMACOLOGY IN CHILD PSYCHIATRY: LITERATURE ANALYSIS.
220271 04-11
EXPERIENCE OF USING LORAZEPAM (WY-4036) IN PSYCHIATRY.
224395 04-11
SULPIRIDE TRIAL IN CHILD PSYCHIATRY.
224585 04-11
CLINICAL PHARMACOLOGY IN PSYCHIATRY.
224829 04-17

PSYCHICAL
EXPERIMENTAL STUDIES ON THE PSYCHICAL EPISODES OF EPILEPSY.
205464 02-04

PSYCHOACTIVE
PSYCHOACTIVE DRUG USE IN ELDERLY PATIENTS WITH PSYCHIATRIC DISORDERS: A SURVEY OF 12 VETERANS ADMINISTRATION HOSPITALS.
193291 01-11
STEREOCHEMICAL APPROACHES TO TRICYCLIC PSYCHOACTIVE AGENTS. (PH.D. DISSERTATION).
194565 01-01
SOMATOSENSORY EVOKED RESPONSE WAVE SHAPE STABILITY: RELATIONSHIPS TO PSYCHIATRIC DIAGNOSIS AND EFFECTS OF PSYCHOACTIVE DRUGS.
195935 01-17
PHARMACOLOGICAL INVESTIGATIONS WITH BENZOCTAMINE (TACITIN), A NEW PSYCHOACTIVE AGENT.
197447 01-03
EFFECT OF PSYCHOACTIVE DRUGS ON IN VIVO METABOLISM OF 14C-HISTAMINE IN MOUSE BRAIN.
197472 01-03
COMPREHENSIVE CLINICAL STUDIES OF PSYCHOACTIVE DRUGS.
198067 01-07
PSYCHOACTIVE DRUG BLOOD LEVELS AND CLINICAL RESPONSE.
198095 02-07
BLOOD AND URINE LEVELS OF N,N DIMETHYLTRYPTAMINE FOLLOWING ADMINISTRATION OF PSYCHOACTIVE DOSAGES TO HUMAN SUBJECTS.
198230 02-12
ANALYSIS OF PSYCHOACTIVE PHENOLIC AMINES.
202381 02-01
CONTROLLING DRUGS: INTERNATIONAL HANDBOOK FOR PSYCHOACTIVE DRUG CLASSIFICATION.
202861 02-17
MEASURING EFFECTS OF PSYCHOACTIVE MEDICATION IN A CHILD WITH A LEARNING DISABILITY.
203847 02-14
EEG CHANGES AFTER PSYCHOACTIVE DRUGS (SPECTRAL ANALYTIC STUDY).
205472 02-13
EFFECTS OF PSYCHOACTIVE TRICYCLIC DRUGS ON THE EEG OF THE ISOLATED PERFUSED RAT BRAIN.
205492 02-03
PSYCHOACTIVE DRUGS IN MANIA: A CONTROLLED COMPARISON OF LITHIUM CARBONATE, CHLORPROMAZINE AND HALOPERIDOL.
207446 03-09
ENDOCRINE EFFECTS OF CHRONIC ADMINISTRATION OF PSYCHOACTIVE DRUGS TO PREPUBERAL MALE RATS. I: DELTA9-TETRAHYDROCANNABINOL.
209840 03-03
EFFECTS OF PSYCHOACTIVE DRUGS ON RESPONSES OF THE RAT TO AVERSIVE STIMULATION.
210784 03-04
PSYCHOACTIVE DRUGS: INCLUDING COMBINATIONS.
210874 03-17
PSYCHOACTIVE DRUGS AND THE ORGANIZATION OF BEHAVIOR.
213622 04-04
THE BEHAVIORAL PHARMACOLOGY OF PSYCHOACTIVE DRUGS.
213635 04-04
THE USE OF PSYCHOACTIVE DRUGS IN ELDERLY PATIENTS WITH PSYCHIATRIC DISORDERS: SURVEY CONDUCTED IN TWELVE VETERANS ADMINISTRATION HOSPITALS.
215009 04-11
PSYCHOTHERAPEUTIC PROFILE OF A NEW PSYCHOACTIVE DRUG TRAZODONE (AF-1161).
215699 04-09
EFFECTS OF TACLAMINE (AY-22214), A NEW PSYCHOACTIVE AGENT, ON CATECHOLAMINE AND SEROTONIN METABOLISM.
215725 04-03
DRUG INTERACTIONS WITH PSYCHOACTIVE DRUGS.
216184 04-15
EFFECTS OF VARIOUS PSYCHOACTIVE DRUGS ON THE METABOLISM OF DELTA1-TETRAHYDROCANNABINOL BY RATS IN VITRO AND IN VIVO.
217672 04-03
MODIFICATION OF THE PUNISHING EFFECTS OF PSYCHOACTIVE DRUGS IN RATS BY PREVIOUS DRUG EXPERIENCE.
217765 04-04
ANALYSIS OF AMPHETAMINES AND OTHER PSYCHOACTIVE DRUGS: A COLORIMETRIC ASSAY OF (S)-(+) AMPHETAMINE IN THE SUBMICROGRAM RANGE. (PH.D. DISSERTATION).
222633 04-01
DETERMINANTS OF PRESCRIBING OF PSYCHOACTIVE DRUGS BY GENERAL PRACTITIONERS.
224492 04-17
EEG AND BLOOD LEVEL RELATIONS OF PSYCHOACTIVE DRUGS.
224795 04-13

PSYCHODYNAMIC
PHARMACOLOGICAL TREATMENT OF PHOBIC - OBSESSIVE PSYCHONEUROSES: PSYCHODYNAMIC AND SYMPTOMATOLOGICAL ASPECTS.
210506 03-10

PSYCHODYNAMICS
CHANGES IN THE PSYCHODYNAMICS OF MANIC-DEPRESSIVES THROUGH LONG-TERM ADMINISTRATION OF LITHIUM SALTS.
203601 02-14

PSYCHODYSLEPTIC
IN VIVO HUMAN PHARMACODYNAMICS OF THE PSYCHODYSLEPTIC 4-BR-DIMETHOXYPHENYLISOPROPYLAMINE LABELLED WITH 82BR OR 77BR.
215710 04-13

PSYCHOFORIN
RESULTS OF TREATING CHILDREN WITH NOCTURNAL ENURESIS WITH IMIPRAMINE (PSYCHOFORIN).
194208 01-11

PSYCHOGERIATRIC
ASSESSMENT OF THERAPY IN PSYCHOGERIATRIC ILLNESS.
194244 01-11

PSYCHOLINGUISTIC
THE EFFECTS OF METHYLPHENIDATE HYDROCHLORIDE ON PSYCHOLINGUISTIC, MOTOR AND VISUAL PERCEPTUAL ABILITIES OF HYPERKINETIC CHILDREN WITH LEARNING DISABILITIES. (PH.D. DISSERTATION).
222725 04-14

PSYCHOLOGIC
EXPERIMENTAL PSYCHOLOGIC AND PSYCHOPHYSIOLOGIC LONGITUDINAL PROFILE STUDIES ON DEPRESSIVE PATIENTS UNDER THYMOLEPTIC MEDICATION.
204413 02-15

PSYCHOLOGICAL
MILD ANALGESICS EVALUATED WITH THE SUBMAXIMUM EFFORT TOURNIQUET TECHNIQUE. I. THE INFLUENCE OF PSYCHOLOGICAL FACTORS ON THEIR EFFECT.
197861 01-14
SOCIAL AND PSYCHOLOGICAL ASPECTS OF MEDICAL PRACTICE: DRUG TREATMENT IN PSYCHIATRY.
201270 02-17
L-DOPA AND PARKINSONISM: A PSYCHOLOGICAL ASSESSMENT.
201496 02-11
ASPECTS OF USING PSYCHOLOGICAL METHODS IN STUDYING THE EFFECTS OF PSYCHOTROPIC DRUGS.
204401 02-16
THE EFFECT OF SYDNOCARB ON SOME PSYCHOLOGICAL AND AUTONOMIC TESTS: A PILOT STUDY.
205599 02-13
THE EFFECT OF MEFEXAMIDE ON SOME AUTONOMIC AND PSYCHOLOGICAL TESTS.
205605 03-13
PSYCHOLOGICAL EFFECTS OF DRUGS: A FACTOR ANALYTIC APPROACH.
206377 03-17
SEDATIVE EFFECTS ON PHYSIOLOGICAL AND PSYCHOLOGICAL MEASURES IN ANXIOUS PATIENTS.
209079 03-10
PSYCHOLOGICAL MEASUREMENTS IN PSYCHOPHARMACOLOGY VOL. 7.
210334 03-17
AFFECTS OF L-DOPA ON THE PSYCHOLOGICAL SYMPTOMS OF PICKS DISEASE.
211365 03-11
PSYCHOLOGICAL MEDICINE: PSYCHOTROPIC DRUGS IN GENERAL PRACTICE.
216948 04-17
EXPERIMENTAL PSYCHOLOGICAL STUDY ON THE EFFECT OF A COMBINATION OF HEXOBENDINE, ETHAMIVAN AND ETOFYLLINE.
221738 04-14

PSYCHOLOGY
A SOCIETY ON THE RUN: A PSYCHOLOGY OF NORTHERN-IRELAND.
194054 01-17

PSYCHOMETRIC
CLINICAL TRENDS AND PSYCHOMETRIC APPRAISAL OF A GROUP OF SCHIZOPHRENICS TREATED WITH THIOTHIXENE (NAVANE).
208981 03-08
CLINICAL AND PSYCHOMETRIC EVALUATION OF THE ACTION OF VINCAMIN IN CEREBRAL ARTERIOSCLEROSIS.
211226 03-11
PSYCHOMETRIC STUDY OF PRAXILENE.
216464 04-11

PSYCHOMOTOR
PSYCHOMOTOR ACTIVITY IN MANIA.
194862 01-09
EFFECTS OF TAURINE ON PSYCHOMOTOR ACTIVITY IN THE RAT.
195089 01-04
A CONTROLLED COMPARISON OF THE EFFECTS OF DIPHENYLHYDANTOIN AND PLACEBO ON MOOD AND PSYCHOMOTOR FUNCTIONING IN NORMAL VOLUNTEERS.
199518 02-14
COMBINED EFFECTS OF DIAZEPAM AND ETHANOL ON MENTAL AND PSYCHOMOTOR FUNCTIONS.
199896 02-14
A DOUBLE-BLIND STUDY ON THE EFFECTS OF PIRACETAM UPON PERCEPTUAL AND PSYCHOMOTOR PERFORMANCE AT VARIED HEART RATES IN PATIENTS TREATED WITH ARTIFICIAL PACEMAKERS.
201328 02-13
THE EFFECTS OF CARBAMAZEPINE ON PATIENTS WITH PSYCHOMOTOR EPILEPSY: RESULTS OF A DOUBLE-BLIND STUDY.
205031 02-11
THE EFFECTS OF PSYCHOMOTOR STIMULANTS ON STEREOTYPY AND LOCOMOTOR ACTIVITY IN SOCIALLY DEPRIVED AND CONTROL RATS.
210666 03-04
MENTAL AND PSYCHOMOTOR EFFECTS OF DIAZEPAM AND ETHANOL.
211070 03-14
THE EFFECTS OF PSYCHOMOTOR STIMULATION ON STEREOTYPY AND LOCOMOTOR ACTIVITY IN SOCIALLY DEPRIVED AND CONTROL RATS.
213433 04-03
EFFECT OF TRICYCLIC ANTIDEPRESSANTS AND ALCOHOL ON PSYCHOMOTOR SKILLS RELATED TO DRIVING.
215667 04-14
NYSTAGMUS AND DISTURBANCES IN PSYCHOMOTOR FUNCTIONS INDUCED BY PSYCHOTROPIC DRUG THERAPY.
221990 04-15

PSYCHONERVOUS
THE EFFECT OF TRANSAMINE ON PSYCHONERVOUS AND CONDITIONED MEMORY IN RATS.
219745 04-04

PSYCHONEUROSES
POSSIBLE TREATMENT OF PSYCHONEUROSES WITH MEDAZEPAM (NOBRIUM).
203705 02-07
PHARMACOLOGICAL TREATMENT OF PHOBIC - OBSESSIVE PSYCHONEUROSES: PSYCHODYNAMIC AND SYMPTOMATOLOGICAL ASPECTS.
210506 03-10

PSYCHONEUROSIS
MAJOR OR MINOR TRANQUILIZERS FOR RELIEF OF COMMON SYMPTOMS OF PSYCHONEUROSIS
193412 01-10
EXPERIMENTATION WITH SULPIRIDE IN CASES OF PSYCHONEUROSIS.
195532 01-10
DOUBLE-BLIND EXAMINATION OF BROMAZEPAM (RO-5-3350) FOR THE TREATMENT OF PSYCHONEUROSIS.
213293 03-10

PSYCHONEUROTIC
SMALL DOSES OF SULPIRIDE IN THE TREATMENT OF PSYCHONEUROTIC SYNDROMES.
194071 01-09
DOXEPIN IN A SINGLE BEDTIME DOSE IN PSYCHONEUROTIC OUTPATIENTS.
194834 01-10
CAMAZEPAM VERSUS DIAZEPAM: A DOUBLE-BLIND TRIAL ON PSYCHONEUROTIC PATIENTS.
209487 03-10
CLINICAL EXPERIMENTS WITH BROMAZEPAM ON PSYCHONEUROTIC AND PSYCHOSOMATIC PATIENTS WITH PSYCHOTHERAPY.
209795 03-10
BROMAZEPAM VERSUS DIAZEPAM IN PSYCHONEUROTIC INPATIENTS.
221304 04-10

PSYCHOORGANIC
PSYCHOPATHOGENIC ASPECTS IN ACUTE PSYCHOORGANIC SYNDROMES (RELATIONSHIPS BETWEEN DRUG DEPENDENCE AND DELIRIUM-TREMENS TYPE SYNDROMES).
209063 03-15

PSYCHOPATHOGENIC
PSYCHOPATHOGENIC ASPECTS IN ACUTE PSYCHOORGANIC SYNDROMES (RELATIONSHIPS BETWEEN DRUG DEPENDENCE AND DELIRIUM-TREMENS TYPE SYNDROMES).
209063 03-15

PSYCHOPATHOLOGICAL
MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 2. COMMUNICATION: PSYCHOPATHOLOGICAL COURSE PROFILE AND SOMATIC CHARACTERISTICS (STUDIES WITH THE AMP SYSTEM).
203840 02-14
HYDERGINE THIORIDAZINE COMBINATION IN THE TREATMENT OF PSYCHOPATHOLOGICAL STATES IN OLD AGE.
205637 03-11
BIOCHEMICAL VERSUS PSYCHOPATHOLOGICAL ACTION PROFILE OF NEUROLEPTICS: A COMPARATIVE STUDY OF CHLORPROMAZINE AND OXYPERTINE IN ACUTE PSYCHOTIC DISORDERS.
215454 04-13
CLINICAL - PSYCHOPATHOLOGICAL CRITERIA FOR THE SELECTION OF PSYCHOTROPIC DRUGS ACCORDING TO THE STAGE OF ILLNESS AND THE EFFECTIVENESS OF REHABILITATING SCHIZOPHRENICS.
220403 04-17

PSYCHOPATHOLOGY
ANXIOUS DENTAL PATIENTS AS MODELS OF PSYCHOPATHOLOGY.
198089 02-11

PSYCHOPHARMACA
THE EFFECT OF PSYCHOPHARMACA ON UROPEPTIC ACTIVITY.
196188 01-13
THE INFLUENCE OF PSYCHOPHARMACA ON THE APTITUDE TO DRIVE.
203784 02-15

PSYCHOPHARMACEUTIC
THERAPY WITH PSYCHOPHARMACEUTIC AND OTHER PSYCHOTROPIC DRUGS.
210511 03-17

PSYCHOPHARMACEUTICS
PSYCHOPHARMACEUTICS AND CLINICAL PSYCHOTHERAPY.
204478 02-17

PSYCHOPHARMACOGENETICS
FROM PSYCHOPHARMACOLOGY TO PSYCHOPHARMACOGENETICS: DETERMINANTS OF THE EFFECTS OF DRUGS ON BEHAVIOR, ROLE OF GENETIC FACTORS.
210530 03-14

PSYCHOPHARMACOLOGIC
MULTIDIMENSIONAL SCALING TO RELATE ANIMAL PHARMACOLOGY AND CLINICAL SYMPTOMS OF PSYCHOPHARMACOLOGIC AGENTS.
198058 01-02
PSYCHOPHARMACOLOGIC TREATMENT OF AFFECTIVE DISORDERS.
200237 02-09
PSYCHOPHARMACOLOGIC MANAGEMENT OF PATIENTS: A METHOD FOR RECORDING TREATMENT DECISIONS.
207683 03-17
THE EFFECT OF PSYCHOPHARMACOLOGIC PROLACTIN RELEASERS ON LACTATION IN SHEEP.
210793 03-03
PSYCHOPHARMACOLOGIC ACTIVITY: QUANTUM CHEMICAL STUDY.
213608 04-03
PSYCHOPHARMACOLOGIC INVESTIGATIONS IN HEALTHY ELDERLY VOLUNTEERS: EFFECTS OF PIPRADROL - VITAMIN (ALERTONIC) ELIXIR AND PLACEBO IN RELATION TO RESEARCH DESIGN.
218217 04-11

PSYCHOPHARMACOLOGICAL
THE EFFECT OF PSYCHOPHARMACOLOGICAL DRUGS ON PUFFING AND ON RNA AND DNA SYNTHESES IN THE SALIVARY GLAND CHROMOSOMES OF DROSOPHILA-MELANOGASTER. (PH.D. DISSERTATION).
196250 01-03
PHARMACOLOGY OF MAGNESIUM GLUTAMATE HYDROBROMIDE (PS-042), A NEW TRANQUILIZER: THIRD PART, PSYCHOPHARMACOLOGICAL STUDIES.
196444 01-02
PSYCHOPHARMACOLOGICAL EVIDENCE FOR INCREASE IN RECEPTOR SENSITIVITY FOLLOWING CHRONIC MORPHINE TREATMENT.
197855 01-04
METHODS OF ASSESSING PSYCHOPHARMACOLOGICAL AGENTS IN EXPERIMENTS.
198488 02-06
BASIC CONCEPTS OF PSYCHOPHARMACOLOGICAL RESEARCH AS APPLIED TO THE PSYCHOPHARMACOLOGICAL ANALYSIS OF THE AMYGDALA.
200980 02-17
SOME CHARACTERISTICS OF PATHOLOGY IN SCHIZOPHRENIA DURING THE TWO STAGES OF PSYCHOPHARMACOLOGICAL DEVELOPMENT.
201908 02-08
DPAM AND CEREBRAL FUNCTION (SECOND REPORT): PSYCHOPHARMACOLOGICAL IMPLICATIONS.
202162 02-11
THE PRESENT CONDITIONS OF PSYCHOPHARMACOLOGICAL TREATMENT FOR CHILDREN IN JAPAN: OPINIONS FROM THIRTY-SEVEN WELL-KNOWN CHILD NEUROPSYCHIATRISTS AND NEUROPSYCHIATRIC PEDIATRICIANS.
202500 02-17
PSYCHOPHARMACOLOGICAL TREATMENT OF DISORDERS OF SENESCENCE.
203470 02-11
PSYCHOPHARMACOLOGICAL TREATMENT OF OBSESSIVE SYNDROME.
204408 02-09
CANNABIS: A PSYCHOPHARMACOLOGICAL REVIEW.
205931 03-12
ARBITERS AND SELF-RATING OF MOMENTARY MOOD IN PSYCHOPHARMACOLOGICAL LONGITUDINAL STUDIES.
206980 03-16
SURVEY ON AND EVALUATION OF THE CONTRIBUTIONS OF METHODOLOGICAL ASPECTS IN THE INVESTIGATION OF LONG-TERM PSYCHOPHARMACOLOGICAL DRUG ACTION.
206984 03-16
COMPARATIVE STUDIES OF VERBAL INTERACTIONS IN A GROUP OF HEALTHY SUBJECTS UNDER THE INFLUENCE OF PSYCHOPHARMACOLOGICAL AGENTS: WITH SPECIAL CONSIDERATION OF YG-19256, CHLORDIAZEPOXIDE AND PLACEBO.
207140 03-14
ON THE USE OF SYDNOCARB FOR PSYCHOPHARMACOLOGICAL CORRECTION OF BEHAVIORAL DISORDERS OF THE CYCLOID TYPE OF ACCENTUATED PERSONALITY IN ADOLESCENTS.
207271 03-11
PSYCHOPHARMACOLOGICAL THERAPY AND THE PROBLEMS OF DELINEATING BORDERLINE FORMS OF NEUROPSYCHIC DISORDERS.
212431 03-17
PSYCHOPHARMACOLOGICAL TREATMENT: THEORY AND PRACTICE.
213392 04-17
PSYCHOPHARMACOLOGICAL PRINCIPLES OF REHABILITATING MENTAL PATIENTS.
220425 04-08
THE ASSESSMENT OF NEUROLEPTOGENIC EXTRAPYRAMIDAL SYNDROMES IN PSYCHOPHARMACOLOGICAL RESEARCH.
221307 04-15

PSYCHOPHARMACOLOGY
PSYCHOPHARMACOLOGY IN MEDICAL PRACTICE.
197269 01-17
NEW DEVELOPMENTS IN HUMAN PSYCHOPHARMACOLOGY.
197534 01-17
CHILDRENS PSYCHOPHARMACOLOGY UNIT.
198061 01-07
OUTPATIENT PEDIATRIC PSYCHOPHARMACOLOGY.
198063 01-07
PSYCHOPHARMACOLOGY OF THE LITHIUM ION.
198081 02-07
PEDIATRIC PSYCHOPHARMACOLOGY.
198091 02-11
PSYCHOPHARMACOLOGY COMPUTER RESEARCH.
198107 02-17
SOCIOPSYCHIATRIC ASPECTS OF PSYCHOPHARMACOLOGY.
198393 02-17
THE ART OF PSYCHOPHARMACOLOGY.
201241 02-17
PSYCHOPHARMACOLOGY AND AGING.
203606 02-11
DRUGS, EEG AND BEHAVIOUR: EEG PROFILES AND BIOAVAILABILITY MEASURES FOR CLINICAL PSYCHOPHARMACOLOGY.
205522 02-16
PSYCHOPHARMACOLOGY -- QUO VADIS.
207099 03-17
OBSERVATIONS OF THE PSYCHOPHARMACOLOGY OF THE AGED.
207437 03-11
TWO DECADES OF PSYCHOPHARMACOLOGY AND COMMUNITY MENTAL HEALTH: OLD AND NEW PROBLEMS OF THE SCHIZOPHRENIC PATIENT.
207921 03-17
PSYCHOPHARMACOLOGY, COMMUNITY MENTAL HEALTH AND THE SCHIZOPHRENIC PATIENT.
207922 03-17
PSYCHOPHARMACOLOGY IN THE AGED: USE OF PSYCHOTROPIC DRUGS IN GERIATRIC PATIENTS.
208571 03-11
PSYCHOPHARMACOLOGY IN THE AGED: DISCUSSION.
208572 03-11
PSYCHOPHARMACOLOGY IN THE AGED: RESEARCH CONSIDERATIONS IN GERIATRIC PSYCHOPHARMACOLOGY.
208573 03-11
PSYCHOPHARMACOLOGY IN THE AGED: DISCUSSION.
208574 03-11
PSYCHOPHARMACOLOGY IN THE AGED: USE OF MAJOR PSYCHOTROPIC MEDICATIONS IN TREATMENT OF THE ELDERLY: CASE EXAMPLES.
208575 03-11
PSYCHOPHARMACOLOGY IN THE AGED: DISCUSSION.
208576 03-11
PRACTICAL CLINICAL PSYCHOPHARMACOLOGY.
209753 03-17
INTRODUCTION TO PSYCHOPHARMACOLOGY.
210065 03-17
PSYCHOPHARMACOLOGY: AN INTRODUCTION TO EXPERIMENTAL AND CLINICAL PRINCIPLES.
210099 03-17
PSYCHOLOGICAL MEASUREMENTS IN PSYCHOPHARMACOLOGY VOL. 7.
210334 03-17
FROM PSYCHOPHARMACOLOGY TO PSYCHOPHARMACOGENETICS: DETERMINANTS OF THE EFFECTS OF DRUGS ON BEHAVIOR, ROLE OF GENETIC FACTORS.
210530 03-14
PSYCHOPHARMACOLOGY OF BIOGENIC AMINES IN DEPRESSIONS.
213628 04-09
THE PSYCHOPHARMACOLOGY OF AUDIOGENIC SEIZURE.
213629 04-03
THE BIOCHEMICAL BASES OF PSYCHOPHARMACOLOGY.
216789 04-13
PSYCHOPHARMACOLOGY AND MORALS.
218582 04-17
II. PSYCHOPHARMACOLOGY AND THE NONMEDICAL PRACTITIONER.
219756 04-17
PSYCHOPHARMACOLOGY IN CHILD PSYCHIATRY: LITERATURE ANALYSIS.
220271 04-11
THE SIGNIFICANCE OF PSYCHOPHARMACOLOGY FOR PSYCHIATRIC REHABILITATION.
220367 04-09
COMBINATION DRUG THERAPY IN PSYCHOPHARMACOLOGY.
221075 04-17
ALCOHOL AND MARIJUANA: COMPARATIVE PSYCHOPHARMACOLOGY.
224753 04-14
PHENOTHIAZINES AND STRUCTURALLY RELATED DRUGS. ADVANCES IN BIOCHEMICAL PSYCHOPHARMACOLOGY.
225399 04-17

PSYCHOPHARMACOTHERAPEUTIC
MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 1. COMMUNICATION: SETTING A GOAL AND METHODOLOGICAL GROUND RULES.
203839 02-13
MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 2. COMMUNICATION: PSYCHOPATHOLOGICAL

COURSE PROFILE AND SOMATIC CHARACTERISTICS (STUDIES WITH THE AMP SYSTEM).
203840 02-14

MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 3. COMMUNICATION: PERAZINE CONCENTRATION IN BLOOD AND CLINICAL EFFICACY.
203841 02-13

MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 4. COMMUNICATION: CONNECTION BETWEEN EEG CHANGES, CONCENTRATION IN BLOOD, AND OTHER CLINICAL VARIABLES.
203842 02-13

MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 5. COMMUNICATION: INFLUENCE ON VENTRICULAR EXCITATION IN THE ELECTROCARDIOGRAM.
203843 02-13

MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 6. COMMUNICATION: RELATIONSHIP BETWEEN NEUROLEPTIC HYPOKINESIS AND ANTIPSYCHOTIC THERAPEUTIC RESULTS.
203844 02-13

MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 7. COMMUNICATION: METHODOLOGICAL OUTCOME.
203845 02-16

PSYCHOPHARMACOTHERAPY

SOCIAL ASPECTS OF PSYCHOPHARMACOTHERAPY.
198327 02-17

PSYCHOPHYSICAL

PSYCHOPHYSICAL EVALUATION OF TOXIC EFFECTS ON SENSORY SYSTEMS.
225166 04-03

PSYCHOPHYSIOLOGIC

EFFECT OF AMITRIPTYLINE IN LONG-TERM AUTOEXPERIMENTS: PSYCHOPHYSIOLOGIC STUDY AND DURATION OF EXCRETION.
204402 02-13

EXPERIMENTAL PSYCHOLOGIC AND PSYCHOPHYSIOLOGIC LONGITUDINAL PROFILE STUDIES ON DEPRESSIVE PATIENTS UNDER THYMOLEPTIC MEDICATION.
204413 02-15

PSYCHOPHYSIOLOGICAL

THE ACTION OF CHLORDIAZEPOXIDE ON CONDITIONS OF ANXIETY IN A PSYCHOPHYSIOLOGICAL EXPERIMENT.
204405 02-14

PSYCHOSES

THE EFFECTIVENESS OF LITHIUM IN AFFECTIVE AND SCHIZOAFFECTIVE PSYCHOSES.
194043 01-11

SUBTYPE OF AFFECTIVE PSYCHOSES CLASSIFIED BY RESPONSE ON AMINE PRECURSORS AND MONOAMINE METABOLISM.
197209 01-09

THE COURSE AND PROGNOSIS OF SCHIZOPHRENIC PSYCHOSES IN HELSINKI: A COMPARATIVE STUDY OF FIRST ADMISSIONS IN 1950, 1960 AND 1965.
197276 01-17

PHARMACOTHERAPY OF THE PSYCHOSES.
200231 02-17

THE ACTIVITY PROFILE OF PIRACETAM IN PSYCHOSYNDROMES AND SYMPTOMATIC PSYCHOSES.
204411 02-09

A CONTROLLED COMPARISON OF OXYPERTINE AND PERPHENAZINE IN SCHIZOPHRENIC PSYCHOSES.
205582 02-08

CLINICAL EXPERIENCE WITH CLOZAPINE IN PSYCHOSES.
205616 03-09

A CASE OF NONSPECIFIC PSYCHOSES WHICH MANIFESTED CONVULSIVE SEIZURES DURING LITHIUM THERAPY.
209324 03-15

CONTRIBUTIONS TO THE STUDY OF THE INFLUENCE OF LITHIUM CARBONATE ON THE EVOLUTION OF HYPERTHYMIC PSYCHOSES.
212161 03-09

LITHIUM ION AND AFFECTIVE PSYCHOSES.
212340 03-09

PATHOPHYSIOLOGICAL STUDIES OF MANIC-DEPRESSIVE PSYCHOSES: RELATIONSHIP BETWEEN ANXIETY AND EXCRETION OF URINARY CATECHOLAMINES.
212938 03-10

CENTRAL NEUROPHYSIOLOGY OF THE FUNCTIONAL PSYCHOSES.
213614 04-11

THE MISUSE OF DRUGS IN THE TREATMENT OF THE CHRONIC PSYCHOSES.
225055 04-17

PSYCHOSIS

PSYCHOSIS IN SYSTEMIC LUPUS-ERYTHEMATOSUS.
196088 01-08

ANTICHOLINERGIC TOXIC PSYCHOSIS IN DRUG ABUSERS TREATED WITH BENZTROPINE.
197539 01-15

HEAD INJURY, HYPOPITUITARISM AND PARANOID PSYCHOSIS: CIRCUMCISION FOR THE SINGAPORE VIRUS.
200581 02-09

BIPOLAR MANIC-DEPRESSIVE PSYCHOSIS IN EARLY ADOLESCENCE: A CASE REPORT.
201513 02-09

ACUTE TOXIC PSYCHOSIS IN TWO CHILDREN TREATED WITH BENZHEXOL HYDROCHLORIDE (ARTANE).
205315 02-15

SOME SPECIFICITIES IN THE COURSE OF MANIOMELANCHOLIC PSYCHOSIS DURING LITHIUM THERAPY.
205609 03-09

THE INFLUENCE OF CHLORPROMAZINE ACTION ON EXPERIMENTAL PSYCHOSIS CAUSED BY LYSERGIC ACID DIETHYLAMIDE.
206439 03-04

A SCHIZOPHRENIFORM BEHAVIORAL PSYCHOSIS MEDIATED BY DOPAMINE.
207035 03-04

AMPHETAMINE PSYCHOSIS: BEHAVIORAL AND BIOCHEMICAL ASPECTS.
207285 03-14

A CONTRIBUTION TO THE STUDY OF CHRONIC AMPHETAMINE PSYCHOSIS.
208970 03-15

DELAYED IDIOSYNCRATIC PSYCHOSIS WITH DIPHENYLHYDANTOIN.
211425 03-15

DIPROPYLACETAMIDE IN TREATING MANIC-DEPRESSIVE PSYCHOSIS.
216761 04-09

AMPHETAMINE PSYCHOSIS OR PARANOID SCHIZOPHRENIA?
216965 04-15

AMPHETAMINE-INDUCED DOPAMINERGIC HYPERSENSITIVITY IN GUINEA-PIGS: IMPLICATIONS IN PSYCHOSIS AND HUMAN MOVEMENT DISORDERS.
218115 04-04

THE ACTION OF PIMOZIDE ON ACUTE PSYCHOSIS.
219960 04-09

PIMOZIDE IN MONOSYMPTOMATIC PSYCHOSIS.
223320 04-09

COCAINE, KINDLING, AND PSYCHOSIS.
224796 04-14

PREPOTENT BEHAVIORS IN AMPHETAMINE MODEL PSYCHOSIS.
224797 04-14

ANTIMANIC AND PROPHYLACTIC EFFECTS OF CARBAMAZEPINE (TEGRETOL) ON MANIC-DEPRESSIVE PSYCHOSIS.
225086 04-09

PSYCHOSOCIAL

MULTIPLE TIC SYNDROME (GILLES-DE-LA-TOURETTES SYNDROME): CLINICAL, BIOLOGICAL, AND PSYCHOSOCIAL VARIABLES AND THEIR INFLUENCE WITH HALOPERIDOL.
199473 02-11

PSYCHOSOCIAL TREATMENT OF ACUTE SCHIZOPHRENIA.
224790 04-17

PSYCHOSOMATIC

THE USE OF TRAZODONE IN PSYCHOSOMATIC MEDICINE.
196197 01-14

USE OF THE MAUDSLEY PERSONALITY INVENTORY IN EVALUATING THE EFFECTIVENESS OF A MINOR TRANQUILIZER IN PSYCHOSOMATIC DISEASES (THE FIRST REPORT).
198518 02-14

COMPARATIVE STUDY OF Y-6047 AND DIAZEPAM BY A DOUBLE-BLIND METHOD FOR THE TREATMENT OF PSYCHOSOMATIC DISEASES AND NEUROSIS.
198705 02-11

ALTERATION OF PSYCHOSOMATIC REACTIVITY AFTER A SINGLE THERAPEUTIC DOSE OF PENTOBARBITAL IN RELATION TO THE SEX OF PROBANDS.
205627 03-14

VARIATIONS IN THE AUTONOMIC NERVOUS SYSTEM AFTER ADMINISTRATION OF DIHYDROERGOTAMINE IN PSYCHOSOMATIC PATIENTS.
209045 03-11

CLINICAL EXPERIMENTS WITH BROMAZEPAM ON PSYCHONEUROTIC AND PSYCHOSOMATIC PATIENTS WITH PSYCHOTHERAPY.
209795 03-10

A COMPARISON OF A NEW TRANQUILIZER, SULPIRIDE AND OXAZOLAM ON PSYCHOSOMATIC DISEASES, NEUROSIS AND MASKED DEPRESSION USING DOUBLE-BLIND METHOD.
210180 03-11

TREATMENT OF PSYCHOSOMATIC GASTROINTESTINAL DISORDERS IN OUTPATIENTS.
210513 03-11

A DOUBLE-BLIND CONTROLLED STUDY OF THE THIENODIAZEPINE DERIVATIVE (Y-6047) ON NEUROTICS AND PSYCHOSOMATIC DISORDERS.
210559 03-14

CLINICAL TRIAL OF OXYPERTINE IN THE TREATMENT OF PSYCHOSOMATIC DISORDERS, NEUROSIS AND DEPRESSION.
224193 04-14

STUDY OF AN ANXIOLYTIC DRUG, CLOBAZAM, IN ORL WITH PHARYNGEAL PSYCHOSOMATIC MANIFESTATIONS.
224584 04-11

PSYCHOSOMATICS
MY EXPERIENCE WITH THE USE OF A TRANQUILIZER, NORITREN, IN THE DEPARTMENT OF INTERNAL MEDICINE PSYCHOSOMATICS.
194510 01-11

PSYCHOSTIMULANT
THE ACTION OF PSYCHOSTIMULANT SIDNOKARB ON METABOLISM OF BIOGENIC AMINES IN THE BRAIN.
197573 01-03

TOXICOLOGICAL AND TERATOLOGICAL STUDY OF 2-PHENYLDIMETHYLTETRAHYDROOXAZINE HYDROCHLORIDE (G-130), A PSYCHOSTIMULANT DRUG.
206783 03-05

ANTAGONISM OF PSYCHOSTIMULANT 2 PHENYLDIMETHYLTETRAHYDROOXAZINE HYDROCHLORIDE (G-130) TO CENTRAL NERVOUS SYSTEM DEPRESSING DRUGS: MONOAMINEOXIDASE INHIBITORY ACTIVITY AND NOREPINEPHRINE AND SEROTONIN INDUCED CHANGES, COMPARISON WITH DL-AMPHETAMINE.
221267 04-03

PSYCHOSTIMULANTS
EFFECTS OF PSYCHOSTIMULANTS ON AGGRESSION.
209132 03-17

PSYCHOSTIMULATING
NEUROCHEMICAL AND NEUROPHYSIOLOGICAL MECHANISMS OF THE PSYCHOSTIMULATING ACTION OF PHENAMINE.
219510 04-13

PSYCHOSTIMULATOR
AN EXPERIMENTAL ANALYSIS ON THE EFFECTS OF THE PSYCHOSTIMULATOR SYDNOCARB.
223013 04-04

PSYCHOSYNDROMES
THE ACTIVITY PROFILE OF PIRACETAM IN PSYCHOSYNDROMES AND SYMPTOMATIC PSYCHOSES.
204411 02-09

PSYCHOTHERAPEUTIC
PSYCHOTHERAPEUTIC DRUGS: STUDIES OF USAGE PATTERNS AND STUDIES OF PRESCRIBING PRACTICES.
198048 01-17

EFFECTS OF LSD-25 ON PSYCHOTHERAPEUTIC COMMUNICATION.
198092 02-10

PHARMACOLOGICAL AND TOXICOLOGICAL PROPERTIES OF CLOBAZAM (1-PHENYL-5-METHYL-8-CHLORO 1,2,4,5-TETRAHYDRO-2,4-DIKETO-3H-1,5 BENZODIAZEPINE), A NEW PSYCHOTHERAPEUTIC AGENT.
199912 02-05

THE CLINICAL USE OF PSYCHOTHERAPEUTIC DRUGS IN THE ELDERLY.
202798 02-11

THE ROAD TO SHANGRI-LA IS PAVED WITH VITAMIN AND PSYCHOTHERAPEUTIC FADDISM.
209010 03-17

AMENORRHEA AND BEHAVIORAL DISTURBANCES: CLINICAL CASE TREATED WITH A PSYCHOTHERAPEUTIC METHOD BASED ON ELEMENTS OF THE CYBERNETIC THEORY OF G. CIPOLLINA MANGIAMELI.
210418 03-14

PRECLINICAL EVALUATION OF AHR-2244: A NEW PSYCHOTHERAPEUTIC AGENT.
210676 03-02

PSYCHOTHERAPEUTIC PROFILE OF A NEW PSYCHOACTIVE DRUG TRAZODONE (AF-1161).
215699 04-09

NEUROPHARMACOLOGICAL STUDIES ON SB-5833, A NEW PSYCHOTHERAPEUTIC AGENT OF THE BENZODIAZEPINE CLASS.
221268 04-02

PSYCHOTHERAPY
PRESENILE DEMENTIA: FURTHER EXPERIENCE WITH AN ANTICOAGULANT PSYCHOTHERAPY REGIMEN.
195601 01-14

PSYCHOTHERAPY AND DRUGS FROM THE STANDPOINT OF INTERNAL MEDICINE.
199907 02-17

PRETREATMENT OF PROBLEM YOUTHS WITH CLOZAPINE IN PREPARATION FOR GROUP PSYCHOTHERAPY.
203599 02-14

SIGNIFICANCE OF PSYCHOTHERAPY USED WITH DRUGS.
204426 02-17

PSYCHOPHARMACEUTICS AND CLINICAL PSYCHOTHERAPY.
204478 02-17

CLINICAL EXPERIMENTS WITH BROMAZEPAM ON PSYCHONEUROTIC AND PSYCHOSOMATIC PATIENTS WITH PSYCHOTHERAPY.
209795 03-10

THE DYNAMIC CONFRONTATION MODEL AS AN INTEGRATION OF PSYCHOTHERAPY.
211596 03-12

EFFECTS OF MAINTENANCE AMITRIPTYLINE AND PSYCHOTHERAPY ON SYMPTOMS OF DEPRESSION.
218041 04-09

DRUG PSYCHOTHERAPY INTERACTIONS IN DEPRESSION.
224767 04-10

PSYCHOTIC
THE USE OF HALOPERIDOL IN THE TREATMENT OF A PSYCHOTIC CHILD WITH MULTIPLE TICS: A CASE REPORT.
194710 01-11

TRANQUILLIZING ACTION OF A CRYSTALLINE FRACTION OF PASPALUM-SCROBICULATUM EXTRACT IN FOURTEEN PSYCHOTIC PATIENTS.
194711 01-08

CLINICAL MEASUREMENT OF CENTRAL DOPAMINE AND SEROTONIN METABOLISM IN ACUTE PSYCHOTIC DISORDERS.
195924 01-09

PENFLURIDOL (R-16341) AS A MAINTENANCE THERAPY IN CHRONIC PSYCHOTIC PATIENTS: A DOUBLE-BLIND CLINICAL EVALUATION.
197033 01-09

A COMPARATIVE STUDY OF THE HYPNOTIC PROPERTIES OF FLURAZEPAM (30 MG), SECOBARBITAL (100 MG), AND OF PLACEBO AMONG FOUR TYPES OF PSYCHOTIC INSOMNIACS.
203204 02-04

PILOT CLINICAL STUDY WITH TRIFLUPERIDOL (TRISEDYL) THERAPY IN PSYCHOTIC PATIENTS.
205589 02-09

CEREBRAL AND PERIPHERAL CONSUMPTION OF L-5-HTP BY PATIENTS SUFFERING FROM MANIACAL, DEPRESSIVE OR PSYCHOTIC SYMPTOMS.
206834 03-10

NEUROLEPTICS AS A GUIDELINE TO BIOLOGICAL RESEARCH IN PSYCHOTIC DISORDERS.
207765 03-17

FLUPENTHIXOL DECANOATE IN PSYCHOTIC ADULTS -- PILOT STUDY.
209071 03-08

CLINICAL STUDY AND FOLLOWUP OF 40 PSYCHOTIC PATIENTS ON PERPHENAZINE ENANTHATE.
212495 03-14

EVALUATION OF BENAPRYZINE IN PSYCHOTIC PATIENTS TREATED WITH PHENOTHIAZINES.
213387 04-07

BIOCHEMICAL VERSUS PSYCHOPATHOLOGICAL ACTION PROFILE OF NEUROLEPTICS: A COMPARATIVE STUDY OF CHLORPROMAZINE AND OXYPERTINE IN ACUTE PSYCHOTIC DISORDERS.
215454 04-13

FLUPHENAZINE TREATMENT IN THE PSYCHOTIC CHILD: CLINICAL EVOKED POTENTIAL CORRELATIONS.
215455 04-09

THE USE OF LITHIUM IN THE TREATMENT OF THE DRUG-INDUCED PSYCHOTIC REACTION.
216183 04-11

A CLINICAL STUDY OF A NEW NEUROLEPTIC EXTRAPYRAMIDAL SYNDROME CORRECTOR WITH ACUTE PSYCHOTIC STATES.
216766 04-15

AN ANIMAL TEST MODEL FOR EVALUATING DRUGS WITH ANTIMASS PSYCHOTIC ACTIVITY.
221273 04-06

AVERAGE EVOKED RESPONSES (AER) AND HOMOVANILLIC ACID (HVA) IN CEREBROSPINAL FLUID (CSF) IN A PSYCHOTIC PATIENT WITH ADDISONS DISEASE.
221310 04-09

CASE PRESENTATION OF AN ALTERNATIVE THERAPEUTIC APPROACH FOR THE BORDERLINE PSYCHOTIC HEROIN ADDICT: DIPHENYLHYDANTOIN.
225512 04-09

PSYCHOTICISM
EFFECTS OF (-)DELTA9-TRANS-TETRAHYDROCANNABINOL (DELTA9-THC) ON TESTS OF PSYCHOTICISM: A STUDY OF EYSENCKS DRUG POSTULATE ON THE EFFECTS OF HALLUCINOGENS IN RELATION TO PSYCHOTICISM.
214009 04-09

PSYCHOTICS
HALOPERIDOL FOR CHRONICALLY HOSPITALIZED PSYCHOTICS: A DOUBLE-BLIND COMPARISON WITH THIOTHIXENE AND PLACEBO: A FOLLOWUP OPEN EVALUATION.
196676 01-14

EVENTUAL DEVELOPMENTS OF 64 CHRONIC PSYCHOTICS ON MODITEN RETARD OR MODECATE TREATMENT.
202514 02-09

SULPIRIDE IN AMBULATORY TREATMENT OF CHRONIC PSYCHOTICS.
209533 03-14

THE EFFECT OF LITHIUM CARBONATE ON THE ELECTROENCEPHALOGRAM OF MANIC-DEPRESSIVE PSYCHOTICS.
217114 04-09

PSYCHOTOGENIC
LSD, PSYCHOTOGENIC PROCEDURES, AND BRAIN NEUROHUMORS.
213606 04-03

PSYCHOTOMIMETIC
STRUCTURE-ACTIVITY RELATIONSHIPS IN PSYCHOTOMIMETIC PHENYLALKYLAMINES.
196437 01-01

INFLUENCE OF AN ANTICHOLINERGIC PSYCHOTOMIMETIC AGENT ON BEHAVIOUR IN CATS CONTROLLED BY AN AUDITORY STIMULUS.
197996 01-04

CROSS-TOLERANCE OR TACHYPHYLAXIS AMONG VARIOUS PSYCHOTOMIMETIC AGENTS ON CATS.
199965 02-03

CORRELATION OF PSYCHOTOMIMETIC ACTIVITY OF PHENETHYLAMINES AND AMPHETAMINES WITH 1-OCTANOL WATER PARTITION COEFFICIENTS.
208593 03-12

PSYCHOTOMIMETIC SUBSTANCES DURING PREGNANCY AND SEX OF OFFSPRING MICE. (PH.D. DISSERTATION).
213050 03-03

DOPAMINERGIC DRUGS ANTAGONIZED THE PSYCHOTOMIMETIC EFFECTS OF PARTIAL AGONIST ANALGESICS.
221048 04-04

PSYCHOTOMIMETICS

POTENTIAL PSYCHOTOMIMETICS. 2. RIGID ANALOGS OF 2,5 DIMETHOXY-4-METHYLPHENYLISOPROPYLAMINE (DOM, STP).
202109 02-02

SOME GENERAL PRINCIPLES OF THE MECHANISM OF THE CENTRAL ACTION OF PSYCHOTOMIMETICS.
216999 04-12

PSYCHOTROPIC

PSYCHOTROPIC DRUGS: A MANUAL FOR EMERGENCY MANAGEMENT OF OVERDOSAGE.
193039 01-15

RATIONAL USE OF PSYCHOTROPIC DRUGS. II. ANTIANXIETY AGENTS.
193192 01-17

ADMINISTRATION OF PG-501 FOR THE TREATMENT OF EXTRAPYRAMIDAL SYNDROME CAUSED BY THE ADMINISTRATION OF A PSYCHOTROPIC DRUG.
194475 01-11

EXAMINATION OF THE NEW PSYCHOTROPIC DRUG, DOGMATYL (FK-880 SULPIRIDE).
194509 01-11

PSYCHOTROPIC DRUGS.
194559 01-17

EFFECTS OF PSYCHOTROPIC DRUGS ON THE SHORT-TERM MEMORY OF RETARDED CHILDREN. (PH.D. DISSERTATION).
194655 01-14

EFFECTS OF PSYCHOTROPIC DRUGS ON HYPEREMOTIONALITY OF RATS WITH BILATERAL ABLATIONS OF THE OLFACTORY BULBS AND OLFACTORY TUBERCLES.
195231 01-04

THE MULTIPLICITY OF INTERACTIONS OF PSYCHOTROPIC DRUGS WITH THE BRAIN SEROTONIN BIOSYNTHETIC UNIT.
195926 01-17

SERIAL EEG RECORDINGS IN PSYCHOTROPIC DRUG TREATMENT.
196144 01-08

A SIMPLIFIED GUIDE TO THE RATIONAL USE OF PSYCHOTROPIC DRUGS.
196231 01-17

EFFECTS OF PSYCHOTROPIC DRUGS ON THE EMOTIONAL REACTIVITY OF RATS.
197499 01-04

EFFECTS OF PSYCHOTROPIC DRUGS ON THE INCORPORATION OF GLUCOSE-14C INTO AMINO ACIDS OF THE RAT BRAIN.
198026 01-03

PATTERNS OF PSYCHOTROPIC DRUG USE FOR SCHIZOPHRENIA.
198052 01-08

THE USE OF DRUG INTERACTIONS IN ANIMALS FOR SELECTING PSYCHOTROPIC DRUGS.
198057 01-02

EEG PROFILES AS PREDICTORS OF PSYCHOTROPIC DRUG CLASSIFICATION.
198060 01-07

COOPERATIVE CLINICAL SCREENING OF PSYCHOTROPIC DRUGS.
198066 01-07

PSYCHOTROPIC DRUGS AND SLOW POTENTIALS IN MAN.
198101 02-13

DISSOCIATION OF GENERAL BEHAVIOR PRODUCED BY PSYCHOTROPIC DRUGS IN MICE.
198733 02-04

RATIONAL USE OF PSYCHOTROPIC DRUGS. III. MAJOR TRANQUILIZERS.
198823 02-17

STUDIES ON PSYCHOTROPIC DRUGS: XVII. EFFECTS OF 3-CHLORO-5-(3-(4 PIPERIDINO-4-CARBAMOYL-PIPERIDINO)PROPYL) 10,11-DIHYDRO-5(H) DIBENZAZEPINE DIHYDROCHLORIDE MONOHYDRATE (Y-4153) ON THE METABOLISM OF BIOGENIC AMINES.
199210 02-03

PHARMACOLOGICAL AND TOXICOLOGICAL STUDY OF A NEW PSYCHOTROPIC STIMULANT: THE 2-PHENYLDIMETHYL-TETRAHYDROOXAZINE, IN COMPARISON WITH D,L-AMPHETAMINE, PHENMETRAZINE AND PEMOLINE-MG.
199211 02-04

EFFECTS OF PSYCHOTROPIC DRUGS ON EXPLORATORY BEHAVIOR OF MICE.
200047 02-04

A CORRELATION BETWEEN THE INFLUENCE OF PSYCHOTROPIC DRUGS AND EMOTIONAL STRESS.
200103 02-09

USES OF PSYCHOTROPIC DRUGS.
200238 02-10

RATIONAL USE OF PSYCHOTROPIC DRUGS. IV. ANTIDEPRESSANTS.
200584 02-09

SIDE-EFFECTS OF PSYCHOTROPIC DRUGS -- AN ANALYSIS OF DATA OBTAINED FROM DOUBLE-BLIND COMPARATIVE STUDIES IN JAPAN.
201260 02-15

POSSIBILITIES AND LIMITATIONS OF PSYCHOTROPIC THERAPY IN PATIENTS WITH GLAUCOMA.
201911 02-15

TO BETTER KNOW AND BETTER PRESCRIBE PSYCHOTROPIC DRUGS.
202029 02-17

STUDIES OF CONFLICT INDUCED BEHAVIOR IN THE CAT: BEHAVIOR ANALYSIS AND EFFECTS OF PSYCHOTROPIC DRUGS.
202122 02-04

PSYCHOTROPIC DRUGS -- ARE THEY JUSTIFIED?
202310 02-15

ACTION OF A NEW PSYCHOTROPIC DRUG (SULPIRIDE) ON AVOIDANCE BEHAVIOR IN RATS.
202770 02-04

EFFECTS OF PSYCHOTROPIC DRUGS ON HYPOTHALAMIC SELF-STIMULATION BEHAVIOR IN RATS.
202802 02-04

BEHAVIORAL CHANGES INDUCED BY PSYCHOTROPIC SUBSTANCES IN EXPERIMENTAL ANIMALS.
202864 02-04

ASSAY OF PSYCHOTROPIC SUBSTANCES IN MAN.
202865 02-17

THE ROLE OF CEREBRAL CYCLIC-AMP IN THE ACTION OF PSYCHOTROPIC DRUGS: IN VIVO AND IN VITRO STUDIES. (PH.D. DISSERTATION).
203032 02-03

THE MEDICAL USE OF PSYCHOTROPIC DRUGS.
204306 02-17

COMPUTER NYSTAGMOGRAPHY, A NEW METHOD OF DETERMINING CHANGES IN VIGILANCE AS A RESPONSE TO PSYCHOTROPIC DRUGS.
204395 02-16

ASPECTS OF USING PSYCHOLOGICAL METHODS IN STUDYING THE EFFECTS OF PSYCHOTROPIC DRUGS.
204401 02-16

COMPUTERIZED CEREBRAL BIOPOTENTIALS IN THE DISCOVERY OF PSYCHOTROPIC DRUGS.
205434 02-13

CATEGORIES OF PSYCHOTROPIC DRUG EFFECTS ON SLEEP EEG AND EOG.
205621 03-13

PSYCHOTROPIC DRUGS AND DIFFERENTLY STIMULATED ATPASE IN CNS.
205629 03-03

PSYCHOTROPIC DRUGS AND SOME ENZYMES OF ENERGY METABOLISM.
205630 03-03

LONGITUDINAL TREND IN PRESCRIBING PSYCHOTROPIC DRUGS.
205633 03-17

PSYCHOTROPIC AND ANTIEPILEPTIC DRUGS.
205635 03-17

AN INVESTIGATION OF PSYCHOTROPIC ACTIVITY IN A SERIES OF PIPERAZINE (1,2-A) INDOLE DERIVATIVES.
206438 03-02

MULTIFOCAL TRIAL OF PSYCHOTROPIC DRUGS (MULTIHOSPITAL TRIAL).
206784 03-08

PINDOLOL: A NEW PSYCHOTROPIC DRUG.
206836 03-04

THE PSYCHOTROPIC DRUG SUMMARY.
206940 03-17

LONGITUDINAL PROFILES OF THE EFFECTS OF PSYCHOTROPIC DRUGS: RESULTS OF AN ANIMAL STUDY.
206970 03-05

LONGITUDINAL PROFILES OF THE EFFECTS OF PSYCHOTROPIC DRUGS FROM CLINICOMETHODOLOGICAL VIEWPOINTS.
206971 03-16

MULTISPECTRAL INVESTIGATION OF PSYCHOTROPIC DRUGS.
206983 03-08

PSYCHOPHARMACOLOGY IN THE AGED: USE OF PSYCHOTROPIC DRUGS IN GERIATRIC PATIENTS.
208571 03-11

PSYCHOPHARMACOLOGY IN THE AGED: USE OF MAJOR PSYCHOTROPIC MEDICATIONS IN TREATMENT OF THE ELDERLY: CASE EXAMPLES.
208575 03-11

ANIMAL MODES FOR EVALUATING PSYCHOTROPIC DRUGS.
209076 03-17

TREATMENT OF HUMAN AGGRESSION WITH MAJOR TRANQUILIZERS, ANTIDEPRESSANTS, AND NEWER PSYCHOTROPIC DRUGS.
209127 03-11

DOSAGE OF A PSYCHOTROPIC DRUG TO PREVENT RELAPSE IN A CURED SCHIZOPHRENIC PATIENT.
209402 03-08

PSYCHOTROPIC DRUGS AND THE HUMAN EEG.
209829 03-16

ADDICTION AND PSYCHOTROPIC DRUGS.
210069 03-17

HEPTAMINOL AND TENSION DISTURBANCES INDUCED BY PSYCHOTROPIC DRUG THERAPY: CLINICAL STUDY.
210089 03-13
PSYCHOTROPIC DRUGS AND ELECTROENCEPHALOGRAPHY: THIRD REPORT.
210276 03-13
THERAPY WITH PSYCHOPHARMACEUTIC AND OTHER PSYCHOTROPIC DRUGS.
210511 03-17
NEGATIVE REINFORCING PROPERTIES OF SOME PSYCHOTROPIC DRUGS IN DRUG NAIVE RHESUS MONKEYS.
210889 03-04
CLINICAL EXPERIMENTS WITH A NEW PSYCHOTROPIC DRUG (SULPIRIDE).
211203 03-14
USE OF A NEW PSYCHOTROPIC DRUG, CLOFLUPEROL FOR THE TREATMENT OF CHRONIC SCHIZOPHRENIC PATIENTS.
211304 03-08
CORRECTION OF AUTONOMIC EFFECTS OF PSYCHOTROPIC DRUGS BY LARGE DOSES OF DIHYDROERGOTAMINE IN ADULTS AND THE ELDERLY.
211998 03-11
SALIVARY SCINTOGRAPHY: INTEREST IN TREATMENT OF DRY MOUTH PROVOKED BY PSYCHOTROPIC MEDICATION.
212493 03-15
EFFECTS OF PSYCHOTROPIC DRUGS ON EXTINCTION INDUCED AGGRESSION. (PH.D. DISSERTATION).
212523 03-04
NEW PSYCHOTROPIC DRUG TRIALS IN TURKEY.
213594 04-11
DEVELOPMENT OF PSYCHOTROPIC DRUGS.
213595 04-16
NEW PSYCHOTROPIC DRUG RESEARCH IN JAPAN.
213596 04-07
NEW PSYCHOTROPIC DRUG DEVELOPMENTS IN FRANCE AND BELGIUM.
213597 04-17
NEW PSYCHOTROPIC DRUG DEVELOPMENTS IN THE USSR AND OTHER EASTERN EUROPEAN COUNTRIES.
213598 04-07
NEW PSYCHOTROPIC DRUG DEVELOPMENTS IN GREAT-BRITAIN.
213599 04-17
TWENTY-THREE PSYCHOTROPIC DRUGS USED IN CHILDREN ABROAD WHICH ARE NOT RECOMMENDED IN THE UNITED-STATES.
213600 04-17
PHYSIOLOGIC FACTORS IN PSYCHOTROPIC DRUG THERAPY.
213616 04-03
FREE-RADICALS IN PSYCHOTROPIC DRUG ACTION.
213624 04-03
NEUROCHEMICAL ACTIONS OF PSYCHOTROPIC DRUGS.
213633 04-03
PSYCHOTROPIC DRUGS ON GENERAL MEDICAL AND SURGICAL WARDS OF A TEACHING HOSPITAL.
213919 04-17
PSYCHOTROPIC DRUG USE IN THE BOSTON AREA: A REPORT FROM THE BOSTON COLLABORATIVE DRUG SURVEILLANCE PROGRAM.
213920 04-17
PSYCHOTROPIC DRUGS, OVARIAN FUNCTIONS AND MAMMARY ACTIVITY.
214055 04-03
INHIBITION OF PROSTAGLANDIN-SYNTHETASE BY PSYCHOTROPIC DRUGS.
215162 04-03
THE RELATIONSHIP OF DIAGNOSIS AND TARGET SYMPTOMS TO PSYCHOTROPIC DRUG ASSIGNMENT.
215251 04-17
PSYCHOTROPIC DRUG THERAPY IN A MENTAL HOSPITAL.
215291 04-17
EFFECTS OF PSYCHOTROPIC DRUGS ON METHAMPHETAMINE-INDUCED BEHAVIORAL EXCITATION IN GROUPED MICE.
215682 04-04
THE EFFECT OF PENFLURIDOL AND SOME PSYCHOTROPIC DRUGS ON MONOAMINE METABOLISM IN CENTRAL NERVOUS SYSTEM.
215686 04-03
PSYCHOLOGICAL MEDICINE: PSYCHOTROPIC DRUGS IN GENERAL PRACTICE.
216948 04-17
PSYCHOTROPIC DRUGS AND OVARIAN CYCLE ALTERATIONS.
217204 04-13
AN EXPERIMENTAL STUDY OF THE PSYCHOTROPIC ACTION OF PYRAZIDOL.
219497 04-03
A HISTOCHEMICAL ANALYSIS OF THE INFLUENCE OF SOME PSYCHOTROPIC SUBSTANCES ON THE DEHYDROGENASE ACTIVITY OF VARIOUS BRAIN STRUCTURES.
219498 04-03
THE EFFECT OF PSYCHOTROPIC AGENTS ON THE ELECTROENCEPHALOGRAPHIC CHARACTERISTICS OF THE INHIBITORY FUNCTION OF THE CAUDATE NUCLEUS.
219500 04-03
THE EFFECT OF PSYCHOTROPIC AGENTS ON THE MENTAL AND PHYSICAL WORKING CAPACITY IN RATS.
219748 04-04
CLINICAL - PSYCHOPATHOLOGICAL CRITERIA FOR THE SELECTION OF PSYCHOTROPIC DRUGS ACCORDING TO THE STAGE OF ILLNESS AND THE EFFECTIVENESS OF REHABILITATING SCHIZOPHRENICS.
220403 04-17
A SIMPLE AVOIDANCE PROCEDURE FOR TESTING PSYCHOTROPIC DRUGS IN MICE.
220903 04-04
PSYCHOTROPIC AGENTS AND PATHOLOGICAL ECG CHANGES.
221336 04-15
ATTEMPTS TO CLASSIFY AND ORIENT PRESCRIPTION OF PSYCHOTROPIC DRUGS BY MEANS OF A COMPUTER CARD INDEX.
221668 04-17
PHARMACOLOGICAL PROPERTIES OF 6,7 TETRAMETHYLENE-5-PHENYL-1-2-DIHYDRO 3H THIENODIAZEPIN-2-ONE (QM-6008), THIADIPONE), A NEW PSYCHOTROPIC DRUG.
221722 04-02
NYSTAGMUS AND DISTURBANCES IN PSYCHOMOTOR FUNCTIONS INDUCED BY PSYCHOTROPIC DRUG THERAPY.
221990 04-15
THE EFFECT OF AUTONOMIC AND PSYCHOTROPIC DRUGS ON ADRENALINE REVERSAL IN THE RAT UTERUS.
222803 04-03
THE INFLUENCE OF SEVERAL PSYCHOTROPIC DRUGS ON THE STRUCTURE OF THE BRAIN.
222889 04-03
THE EFFECT OF PSYCHOTROPIC AND ANTICONVULSIVE DRUGS ON THE TRANSPORT OF ATPASE IN THE RENAL TUBES OF A GUINEA-PIG.
223015 04-05
THE EFFECT OF THE PSYCHOTROPIC AGENTS (CHLORPROMAZINE, MAJEPTIL, TRICEDIL) ON PROTEIN SYNTHESIS IN VARIOUS PORTIONS OF THE RAT BRAIN.
223063 04-03

PSYCHOTROPICS
SOCIOPSYCHIATRIC SIGNIFICANCE OF THE APPLICATION OF PSYCHOTROPICS IN GERIATRICS.
198394 02-11
PSYCHOTROPICS AND THEIR EFFECT ON THE EKG IN CHILDREN.
224378 04-13

PSYCHOVEGETATIVE
CLINICAL TRIAL OF 3-METHYL-5-BETA-N-N-M-CHLOROPHENYLPIPERAZINOETHYL PYRAZOLE DIHYDROCHLORIDE (MEPIPRAZOL) IN THE THERAPY OF PSYCHOVEGETATIVE DISORDERS.
215694 04-10

PTERIDINE
TYROSINE-HYDROXYLASE (TH) IN NUCLEUS-ACCUMBENS AND STRIATUM: EFFECTS OF NEUROLEPTICS ON THE AFFINITY FOR PTERIDINE COFACTOR. (UNPUBLISHED PAPER).
196588 01-03

PUFFING
THE EFFECT OF PSYCHOPHARMACOLOGICAL DRUGS ON PUFFING AND ON RNA AND DNA SYNTHESES IN THE SALIVARY GLAND CHROMOSOMES OF DROSOPHILA-MELANOGASTER. (PH.D. DISSERTATION).
196250 01-03

PULP
THE EFFECTS OF CORD SECTION UNDER ETHER OR HALOTHANE ON THE ABILITY OF CHLORPROMAZINE TO AFFECT THE JAW-JERK RESPONSE TO TOOTH PULP STIMULATION IN THE ENCEPHALE ISOLE PREPARATION.
197451 01-03

PULSE
THE EFFECT OF NEUROLEPTICS OF THE PHENOTHIAZINE SERIES ON PULSE ACTIVITY AND THE ULTRASTRUCTURE OF RABBIT CORTICAL NEURONS.
219606 04-03

PUNCTUATE
EVIDENCE THAT PUNCTUATE INTRACEREBRAL ADMINISTRATION OF 6-HYDROXYDOPAMINE FAILS TO PRODUCE SELECTIVE NEURONAL DEGENERATION: COMPARISON WITH COPPER SULFATE AND FACTORS GOVERNING THE DEPORTMENT OF FLUIDS INJECTED INTO BRAIN.
197931 01-03

PUNISHED
EFFECTS OF P-ACETYLDEOXYEPHEDRINE ON PUNISHED BEHAVIOR IN THE RAT.
197450 01-04
COMPARISON OF MORPHINE AND CHLORPROMAZINE EFFECTS ON MODERATELY AND SEVERELY SUPPRESSED PUNISHED RESPONDING IN THE PIGEON.
202666 02-04
DRUGS AND PUNISHED RESPONDING. V. EFFECTS OF DRUGS ON RESPONDING SUPPRESSED BY RESPONSE DEPENDENT AND RESPONSE INDEPENDENT ELECTRIC SHOCK.
215722 04-04
PUNISHED BEHAVIOR: INCREASES IN RESPONDING AFTER D-AMPHETAMINE.
217542 04-04

EFFECTS OF SCOPOLAMINE, PHYSOSTIGMINE AND CHLORDIAZEPOXIDE ON PUNISHED AND EXTINGUISHED WATER CONSUMPTION IN RATS.
221043 04-04
THE PARTIAL PUNISHMENT EFFECT FOLLOWING MINIMAL ACQUISITION TRAINING: SODIUM AMOBARBITAL AND THE STIMULUS PROPERTIES OF EARLY PUNISHED TRIALS.
224504 04-04
DETERMINANTS OF DRUG EFFECTS ON PUNISHED RESPONDING.
225169 04-04

PUNISHING
MODIFICATION OF THE PUNISHING EFFECTS OF PSYCHOACTIVE DRUGS IN RATS BY PREVIOUS DRUG EXPERIENCE.
217765 04-04

PUNISHMENT
TRANQUILIZING EFFECTS OF DIAZEPAM IN PIGS SUBJECTED TO A PUNISHMENT PROCEDURE.
210741 03-04
THE PARTIAL PUNISHMENT EFFECT FOLLOWING MINIMAL ACQUISITION TRAINING: SODIUM AMOBARBITAL AND THE STIMULUS PROPERTIES OF EARLY PUNISHED TRIALS.
224504 04-04

PUP
LATENCY AND DURATION OF ESTROGEN INDUCTION OF MATERNAL BEHAVIOR IN HYSTERECTOMIZED OVARIECTOMIZED VIRGIN RATS: EFFECTS OF PUP STIMULATION.
219070 04-04

PUPILLARY
EFFECTS OF IPRONIAZID, CHLORPROMAZINE AND METHIOTHEPIN ON DMT INDUCED CHANGES IN BODY TEMPERATURE, PUPILLARY DILATATION, BLOOD PRESSURE AND EEG IN THE RABBIT.
215724 04-03

PURE
THE ACTION OF SULPIRIDE IN PURE INTERPRETIVE DELIRIUM.
212492 03-09

PURKINJE
INHIBITORY EFFECT OF NEONATAL ESTROGENIZATION ON THE INCORPORATION OF (3H)LYSINE IN THE PURKINJE CELLS OF THE ADULT MALE AND FEMALE RAT.
213478 04-03
SYNERGISM BETWEEN GAMMA-AMINOBUTYRIC ACID AND BUTYROPHENONES ADMINISTERED MICROELECTROPHORETICALLY IN THE PURKINJE CELLS OF THE CAT CEREBELLUM.
220904 04-03

PUROMYCIN
PUROMYCIN AND MEMORY. (PH.D. DISSERTATION).
199039 02-04
ANTEROGRADE AND RETROGRADE EFFECTS OF ELECTROCONVULSIVE SHOCK AND OF PUROMYCIN ON MEMORY FORMATION IN THE GOLDFISH.
213853 04-04

PUSH-PULL
RECIPROCAL (PUSH-PULL) EFFECTS OF MORPHINE ON SINGLE UNITS IN THE VENTROMEDIAN AND LATERAL HYPOTHALAMUS AND INFLUENCES ON OTHER NUCLEI: WITH COMMENT ON METHADONE EFFECTS DURING WITHDRAWAL FROM MORPHINE.
210700 03-03

PUTAMEN
AMANTADINE AND D-145, AN AMANTADINE DERIVATIVE, DO NOT EFFECT DOPAMINE SENSITIVE ADENYLATE-CYCLASE FROM THE CAUDATE PUTAMEN OF THE RAT BRAIN.
199867 02-03

PUTATIVE
THE REGULATION OF CYCLIC GUANOSINE MONOPHOSPHATE IN RAT CEREBELLUM: POSSIBLE INVOLVEMENT OF PUTATIVE AMINO ACID NEUROTRANSMITTERS.
202717 02-03
EFFECTS OF PUTATIVE NEUROTRANSMITTERS ON NEURONAL ACTIVITY IN MONKEY AUDITORY CORTEX.
217865 04-03

PUTRESCINE
PUTRESCINE: EFFECT ON AXOPLASMIC TRANSPORT.
223051 04-03

PYRAMIDAL
PHARMACOLOGY OF PYRAMIDAL TRACT CELLS IN THE CEREBRAL CORTEX: NORADRENALINE AND RELATED SUBSTANCES.
195438 01-03
A COMPARATIVE STUDY ON THE EFFECT OF INTRAVENOUS DIAZEPAM AND RO-5-3350 ON PYRAMIDAL SPASTICITY.
205575 02-13

PYRAZIDOL
AN EXPERIMENTAL STUDY OF THE PSYCHOTROPIC ACTION OF PYRAZIDOL.
219497 04-03

PYRAZOLE
CLINICAL TRIAL OF 3-METHYL-5-BETA-N-N-M-CHLOROPHENYLPIPERAZINOETHYL PYRAZOLE DIHYDROCHLORIDE (MEPIPRAZOL) IN THE THERAPY OF PSYCHOVEGETATIVE DISORDERS.
215694 04-10

PYRIDOXAL
EFFECT OF NEUROTROPIC AGENTS ON TOTAL PYRIDOXAL PHOSPHATE AND ON THE ACTIVITY OF THE DECARBOXYLASE OF AROMATIC AMINO ACIDS AS WELL AS OF OTHER PYRIDOXAL PHOSPHATE DEPENDENT ENZYMES IN RAT BRAIN.
199785 02-03

PYRIMIDINES
NEW HYPOGLYCEMIC BENZENESULFONAMIDO PYRIMIDINES: N-SUBSTITUTED 4-(N-(2-PYRIMIDINYLSULFONYL-PHENYLACETAMIDES.
206994 03-02

PYRITHIOXINE
PYRITHIOXINE (ENCEPHABOL) IN MENTALLY DEFICIENT CHILDREN (A TRIAL ON 50 CASES).
194554 01-11
THE EFFECTS OF PYRITHIOXINE ON THE BEHAVIOUR AND INTELLECTUAL FUNCTION OF LEARNING DISABLED CHILDREN.
216485 04-11

PYROGALLOL
MODIFICATION BY DESIPRAMINE OF THE ADRENERGIC SENSITIVITY OF PYROGALLOL IN THE RAT.
197461 01-03

PYRROLASE
TRYPTOPHAN PLUS A PYRROLASE INHIBITOR FOR DEPRESSION?.
219522 04-03

QM-6008
PHARMACOLOGICAL PROPERTIES OF 6,7 TETRAMETHYLENE-5-PHENYL-1-2-DIHYDRO 3H THIENODIAZEPIN-2-ONE (QM-6008), THIADIPONE), A NEW PSYCHOTROPIC DRUG.
221722 04-02

QUANTIFIED
CEREBRAL HEMODYNAMIC EFFECTS OF CHRONIC TRYPTOPHAN FEEDING IN MAN AS MEASURED BY QUANTIFIED CEREBRAL IMPEDANCE PLETHYSMOGRAPHY.
206337 03-08

QUANTIFY
NEW HOT PLATE TESTS TO QUANTIFY ANTINOCICEPTIVE AND NARCOTIC ANTAGONIST ACTIVITIES.
193446 01-04

QUANTITATION
PRACTICAL KINETICS I: QUANTITATION OF BARBITURATE STABILITY BY TLC.
211007 03-06

QUANTITATIVE
QUANTITATIVE ANALYSIS OF THE EEG EFFECTS PRODUCED BY IMIPRAMINE, DESIPRAMINE, PROMAZINE, AND MONODESMETHYL PROMAZINE IN THE ISOLATED PERFUSED RAT BRAIN.
200056 02-03
MICROMETHODS FOR QUANTITATIVE DETERMINATION OF SEDATIVES AND ANTIPYRETICS BY THERMO-GAS CHROMATOGRAPHY.
206807 03-06
QUANTITATIVE RELATIONSHIP OF CATECHOLAMINE CONTENT AND HISTOFLUORESCENCE IN BRAIN OF RATS.
210660 03-03
QUANTITATIVE MEASUREMENT OF PARKINSON DISEASE RIGOR. MYOINTEGRATIVE DRUG TRIAL IN COMBINATION WITH THE DECARBOXYLASE INHIBITING DRUG RO-8-0576.
220829 04-11

QUANTITIES
MASS FRAGMENTOGRAPHY OF PICOMOLE QUANTITIES OF BIOGENIC AMINE METABOLITES IN HUMAN CEREBROSPINAL FLUID AS WELL AS WHOLE RAT BRAINS. (UNPUBLISHED PAPER).
217219 04-06

QUANTUM
A QUANTUM CHEMICAL INVESTIGATION OF THE PI-ELECTRONIC STRUCTURE OF THE HALLUCINOGENIC N,N-DIMETHYLTRYPTAMINES.
195119 01-01
PSYCHOPHARMACOLOGIC ACTIVITY: QUANTUM CHEMICAL STUDY.
213608 04-03

QUASI-ABSTINENCE
THE CONCEPT OF THE QUASI-ABSTINENCE EFFECT AND ITS USE IN THE INVESTIGATION OF DEPENDENCE MECHANISMS.
202194 02-13

QUATERNARY
EEG SEIZURES PRODUCED BY INTRAVENTRICULAR QUATERNARY AMMONIUM COMPOUNDS IN THE RAT.
197475 01-03

QUATERNIZATION
CHLORPROMAZINE METABOLISM IV: QUATERNIZATION AS A KEY TO DETERMINATION OF PICOMOLES OF CHLORPROMAZINE AND OTHER TERTIARY AMINE DRUGS.
217667 04-06

QUESTION
MONOAMINE METABOLITES IN LUMBAR CSF: THE QUESTION OF THEIR ORIGIN IN RELATION TO CLINICAL STUDIES.
210796 03-03
TOWARD THE QUESTION OF THE INFLUENCE OF STIMULATION OF THE THALAMIC ASSOCIATIVE NUCLEI ON THE BEHAVIOR OF CATS.
215498 04-04

QUINAZOLINES
QUINAZOLINES AND 1,4 BENZODIAZEPINES. 67. 5-FERROCENYLBENZODIAZEPIN-2-ONES.
208595 03-01

QUINOLIZIDINES
A DUAL STUDY. PART I: SYNTHESIS AND STEREOCHEMISTRY OF SOME 1 SUBSTITUTED QUINOLIZIDINES AS ANALOGS OF BIOLOGICALLY ACTIVE COMPOUNDS. PART II: AMINO DERIVATIVES OF THIOPHENE FUSED CYCLIC KETONES AS POTENTIAL CNS. (PH.D. DISSERTATION).
196252 01-01

R-16341
PENFLURIDOL (R-16341) AS A MAINTENANCE THERAPY IN CHRONIC PSYCHOTIC PATIENTS: A DOUBLE-BLIND CLINICAL EVALUATION.
197033 01-09
A DOUBLE-BLIND CLINICAL EVALUATION OF PENFLURIDOL (R-16341) AS A MAINTENANCE THERAPY IN SCHIZOPHRENIA.
199993 02-08
ASPECTS OF NEUROLEPTIC DEPOT THERAPY WITH SPECIAL CONSIDERATION OF CLINICAL EXPERIENCE WITH THE PERORAL DEPOT PREPARATION PENFLURIDOL (R-16341 - JANSSEN).
202785 02-07

R-6238
PIMOZIDE (R-6238) IN SCHIZOPHRENIA (A PILOT STUDY).
196707 01-08
A CONTROLLED CLINICAL TRIAL OF PIMOZIDE (R-6238) -- A NEW NEUROLEPTIC.
200897 02-08

RABBIT
SELECTIVE STIMULATION BY DOPAMINE OF ADENYLATE-CYCLASE IN HOMOGENATES OF RABBIT RETINA.
192936 01-03
INFLUENCE OF EMULSIFIED FAT ON CHLORPROMAZINE AVAILABILITY IN RABBIT BLOOD.
194928 01-03
EFFECTS OF DIISOPROPYLPHOSPHOFLUORIDATE ON ACETYLCHOLINE, CHOLINESTERASE AND CATECHOLAMINES OF SEVERAL PARTS OF RABBIT BRAIN.
195094 01-03
ACTION OF PROBENECID ON THE CENTRAL NERVOUS SYSTEM OF THE RABBIT: II. POTENTIATION OF 5-HYDROXYTRYPTOPHAN-INDUCED HYPERTHERMIA AND SUPPRESSION OF THIS EFFECT BY A DECARBOXYLASE INHIBITOR (RO-4-4602).
196580 01-03
THE EFFECTS OF THE TRICYCLIC ANTIDEPRESSANTS DESMETHYLIMIPRAMINE, DOXEPIN AND IPRINDOLE ON THE ISOLATED PERFUSED RABBIT HEART.
197277 01-03
EFFECTS OF THE HIGH DOSES OF L-DOPA ON ELECTRICAL ACTIVITY IN THE BRAIN OF THE RABBIT: INTERACTION WITH THE METABOLISM OF 5-HT.
197468 01-03
HEAT PRODUCTION AND OXYGEN CONSUMPTION OF THE ISOLATED RABBIT HEART UNDER THE INFLUENCE OF STROPHANTHIN VERAPAMIL, AND GLYCERYL TRINITRATE.
197567 01-03
ARRHYTHMIAS EVOKED BY INFUSION OF TRICYCLIC ANTIDEPRESSANTS AND NORADRENALINE ON ISOLATED RABBIT HEARTS.
197939 01-03
BETA-ADRENOCEPTORS AND/OR ALPHA-ADRENOCEPTORS IN THE VENTRICULAR MUSCLE OF THE RABBIT
197943 01-03
REVERSAL OF THE RESERPINE ELECTROENCEPHALOGRAPHIC SYNCHRONIZATION IN THE RABBIT BY P-CHLOROPHENYLALANINE.
197994 01-03
COMPARISON OF THE EFFECTS OF THE INTRANIGRAL INJECTIONS OF CHOLINOMIMETICS WITH SYSTEMIC INJECTIONS OF THE DOPAMINE RECEPTOR STIMULATING AND BLOCKING AGENTS IN THE RABBIT.
199772 02-03
EFFECTS OF CHOLINESTERASE INHIBITION ON THE VISUAL EVOKED POTENTIALS IN THE RABBIT AND THEIR MODIFICATION WITH VARIOUS DRUGS.
205631 03-03
EFFECTS OF AMINOACETONITRILE, AN AMINE OXIDASE INHIBITOR, ON MESCALINE METABOLISM IN THE RABBIT.
205853 03-03
ACCUMULATION OF 3H-HOMOVANILLIC ACID IN RABBIT BRAIN AND CEREBROSPINAL FLUID FOLLOWING INTRAVENOUS 3H-L-DOPA.
206336 03-03
THE EFFECTS OF DOPA ON THE VISUAL EVOKED POTENTIALS IN RABBIT AND ON MOUSE MOTOR BEHAVIOR FOLLOWING INHIBITION OF DOPAMINE-BETA-HYDROXYLASE.
206768 03-03
EFFECTS OF INTRAVENTRICULAR INFUSIONS OF ACTH1-24 AND ACTH4-10 ON LH RELEASE, OVULATION AND BEHAVIOR IN THE RABBIT.
210662 03-03
EFFECTS OF A DECARBOXYLASE INHIBITOR ON THE DOPA AND 5-HTP INDUCED CHANGES IN THE LOCOMOTOR LIKE DISCHARGE PATTERN OF RABBIT HIND LIMB NERVES.
210740 03-03
THE EEG EFFECTS OF DOPA IN THE RABBIT DEPENDING UPON THE LEVEL OF BRAINSTEM SECTION.
210880 03-03
EFFECT OF INTRACEREBROVENTRICULAR BRADYKININ AND RELATED PEPTIDES ON RABBIT OPERANT BEHAVIOR.
215693 04-04
EFFECTS OF IPRONIAZID, CHLORPROMAZINE AND METHIOTHEPIN ON DMT INDUCED CHANGES IN BODY TEMPERATURE, PUPILLARY DILATATION, BLOOD PRESSURE AND EEG IN THE RABBIT.
215724 04-03
ARRHYTHMIAS AND INHIBITION OF NORADRENALINE UPTAKE CAUSED BY TRICYCLIC ANTIDEPRESSANTS AND CHLORPROMAZINE ON THE ISOLATED PERFUSED RABBIT HEART.
217657 04-03
TRANSFORMATION OF DELTA1-TETRAHYDROCANNABINOL (THC) BY RABBIT LIVER MICROSOMES.
217817 04-03
AMINO ACID UPTAKE IN VIVO BY THE MOUSE BRAIN AND BY VARIOUS REGIONS OF THE RABBIT BRAIN AFTER DRUG-INDUCED CONVULSIONS.
217858 04-03
EFFECT OF AMPHETAMINE, 3,4 METHYLENEDIOXYAMPHETAMINE, P-METHOXYAMPHETAMINE AND RELATED AMPHETAMINES ON UPTAKE OF METARAMINOL AND EFFLUX OF NORADRENALINE IN ADRENERGIC NERVES OF RABBIT ATRIA.
217889 04-03
THE INFLUENCE OF CHOLINOMIMETICS ON THE AFTEREFFECTS OF TRACE DISCHARGES AND THE ACTIVITY OF EPILEPTOGENIC FOCI IN THE RABBIT HIPPOCAMPUS.
219499 04-03
THE EFFECT OF NEUROLEPTICS OF THE PHENOTHIAZINE SERIES ON PULSE ACTIVITY AND THE ULTRASTRUCTURE OF RABBIT CORTICAL NEURONS.
219606 04-03
LYSERGIC ACID DIETHYLAMIDE: EFFECT ON HISTONE ACETYLATION IN RABBIT BRAIN.
220314 04-03
INHIBITION OF RABBIT MONOAMINEOXIDASE BY DOXEPIN AND RELATED DRUGS.
220972 04-03

RABBITS
THE INFLUENCE OF CYPROHEPTADINE AND OF D-LYSERGAMIDE ON THE RISE IN TEMPERATURE INDUCED BY INTRACEREBROVENTRICULAR 5-HYDROXYTRYPTAMINE, NORADRENALINE AND DOPAMINE IN CONSCIOUS RABBITS.
193451 01-03
5-HYDROXYTRYPTAMINE IN PLATELETS AND BRAIN OF RABBITS TREATED CHRONICALLY WITH IMIPRAMINE, MORPHINE OR METHADONE.
194744 01-03
INTERRELATION BETWEEN MONOAMINERGIC AND CHOLINERGIC MECHANISMS IN THE HYPOTHALAMIC THERMOREGULATORY CENTRE OF RABBITS.
195249 01-03
INHIBITION OF EFFECTS OF ACCELERATOR NERVE STIMULATION IN CATS AND RABBITS BY BS-100-141 AND GUANABENZ.
197971 01-03
ON THE SPECIFICITY OF NEUROCHEMICAL MECHANISMS DEALING WITH NOCICEPTIVE STIMULATION OF NEURONS IN VARIOUS BRAIN FORMATIONS OF RABBITS.
198436 02-03
EFFECTS OF ALPHA-ADRENERGIC BLOCKERS ON VISUAL EVOKED RESPONSES IN RABBITS.
200064 02-03
MICROIONTOPHORETIC STUDIES ON THE EFFECT OF NOREPINEPHRINE ON THE ACTIVITY OF THE VISUAL CORTEX NEURONS IN RABBITS.
206441 03-03
RELATIONSHIP BETWEEN THE LATE REFLEX DISCHARGE AND LOCOMOTOR MOVEMENTS IN ACUTE SPINAL CATS AND RABBITS WITH DOPA.
209728 03-03
THE EFFECT OF LSD, PSILOCYBIN, HARMALINE AND AMPHETAMINE ON THE BODY TEMPERATURE OF P-CHLOROPHENYLALANINE PRETREATED RABBITS.
210920 03-05
THE ACTION OF CHLORPROMAZINE AND TRIFTAZINE ON DISCHARGES OF CORTICAL NEURONS IN RABBITS AFTER CHRONIC ADMINISTRATION OF THE DRUGS.
215499 04-03
CENTRAL ANTICHOLINERGIC ACTIONS OF DOXEPIN IN RABBITS.
215727 04-03
EEG SPECTRAL ANALYSIS FOR THE EVALUATION OF THE CENTRAL EFFECTS OF DELTA6-TETRAHYDROCANNABINOL IN RABBITS.
217467 04-03
INCREASED CONCENTRATION OF HOMOVANILLIC ACID IN THE BRAINS OF INFANT RABBITS AFTER ADMINISTRATION OF HALOPERIDOL TO THEIR NURSING MOTHERS.
217692 04-03
THE EFFECT OF LITHIUM ON THE CONTENT OF CATECHOLAMINES IN THE BRAIN OF RABBITS AND RATS.
219749 04-03

ELECTROPHYSIOLOGICAL AND BEHAVIORAL EFFECTS OF 1-METHYL-5-O-FLUOROPHENYL 7cCHLORODIHYDROBENZODIAZEPIN-2-ONE (ID-540) IN CATS AND RABBITS.
221736 04-03

RADIATION
CONDITIONED SUPPRESSION OF MOUSE-KILLING IN RATS FOLLOWING RADIATION OR LITHIUM CHLORIDE INJECTIONS. (PH.D. DISSERTATION).
201153 02-04

INVESTIGATIONS OF UCS-CS MEDIATION IN RADIATION INDUCED CONDITIONED TASTE AVERSION. (PH.D. DISSERTATION).
220681 04-04

RADICALS
REACTIVITY OF VARIOUS PHENOTHIAZINE DERIVATIVES WITH OXYGEN AND OXYGEN RADICALS.
210882 03-02

RADIOIMMUNOASSAY
RADIOIMMUNOASSAY OF THE NEUROLEPTIC DRUG PIMOZIDE.
213986 04-06

RADIOIMMUNOASSAY OF CHLORDIAZEPOXIDE IN PLASMA.
217666 04-16

DEVELOPMENT OF RADIOIMMUNOASSAY FOR CHLORPROMAZINE.
222802 04-06

RAISED
CONDITIONED LEARNING IN YOUNG RATS BORN OF DRUG ADDICTED PARENTS AND RAISED ON ADDICTIVE DRUGS.
217465 04-04

RANDOMIZED
A FOLLOWUP STUDY OF FEMALE DEPRESSED OUTPATIENTS WHO COMPLETE A RANDOMIZED DOUBLE-BLIND PROPHYLACTIC TRIAL OF ANTIDEPRESSANTS AND HIGH CONTACT. (PH.D. DISSERTATION).
212518 03-09

RANGE
ANALYSIS OF AMPHETAMINES AND OTHER PSYCHOACTIVE DRUGS: A COLORIMETRIC ASSAY OF (S)-(+) AMPHETAMINE IN THE SUBMICROGRAM RANGE. (PH.D. DISSERTATION).
222633 04-01

RANGING
DOSE RANGING STUDIES OF CLONAZEPAM IN MAN.
217556 04-14

RANK
SCHNEIDERIAN FIRST RANK SYMPTOMS AND CLINICAL FEATURES OF SCHIZOPHRENIA.
205179 02-08

RAPHE
CHANGES IN THE ACQUISITION OF CONDITIONED AVOIDANCE RESPONSES FOLLOWING MIDBRAIN RAPHE LESIONS IN TH
197574 01-04

THE NUCLEUS LINEARIS INTERMEDIUS RAPHE AND BEHAVIOUR EVOKED BY DIRECT AND INDIRECT STIMULATION OF DOPAMINE SENSITIVE SITES WITHIN THE CAUDATE NUCLEUS OF CATS.
199864 02-04

INFLUENCE OF MIDBRAIN RAPHE LESION ON SOME PHARMACOLOGICAL AND BIOCHEMICAL EFFECTS OF APOMORPHINE IN RATS.
202771 02-03

STEREOTYPED AND CIRCLING BEHAVIOUR INDUCED BY DOPAMINERGIC AGONISTS AFTER LESIONS OF THE MIDBRAIN RAPHE NUCLEI.
202792 02-04

FUNCTIONAL ANATOMICAL STUDIES OF THE RAPHE NUCLEI.
206108 03-03

EFFECT OF PERIPHERALLY ADMINISTERED SEROTONIN ON THE NEURONAL ACTIVITY OF MIDBRAIN RAPHE NEURONS.
210710 03-03

THE EFFECT OF ANTIDEPRESSANTS ON UNIT ACTIVITY IN THE MIDBRAIN RAPHE OF RATS.
210789 03-03

EFFECT OF MIDBRAIN RAPHE LESION AND OF 6-HYDROXYDOPAMINE ON THE ANTINOCICEPTIVE ACTION OF BUPRENORPHINE IN RATS.
210923 03-03

DIFFERENTIAL EFFECTS OF CAFFEINE, D-AMPHETAMINE AND METHYLPHENIDATE ON INDIVIDUAL RAPHE CELL FLUORESCENCE: A MICROSPECTROFLUORIMETRIC DEMONSTRATION.
213400 04-03

DISCRIMINATIVE CONTROL OF BEHAVIOR BY ELECTRICAL STIMULATION OF THE DORSAL RAPHE NUCLEUS: GENERALIZATION TO LYSERGIC ACID DIETHYLAMIDE (LSD).
217821 04-12

MIDBRAIN RAPHE NEURONS: SENSITIVITY TO GLUCOCORTICOIDS AND ACTH IN THE RAT.
217863 04-03

RAPID
A SIMPLE AND RAPID SPECTROPHOTOMETRIC DETERMINATION OF MONOAMINEOXIDASE ACTIVITY.
197281 01-01

RAPID REVERSAL OF INTERNAL NA+ AND K+ CONTENTS OF SYNAPTOSOMES BY OUABAIN.
204185 02-03

A RAPID, SIMPLE AND MORE SENSITIVE METHOD FOR THE DEMONSTRATION OF CENTRAL CATECHOLAMINE CONTAINING NEURONS AND AXONS BY GLYOXYLIC ACID INDUCED FLUORESCENCE: I. SPECIFICITY.
217550 04-16

RAPID MASS SCREENING AND CONFIRMATION OF URINARY AMPHETAMINE AND METHAMPHETAMINE BY GAS CHROMATOGRAPHY.
222829 04-06

RAPID ANALYSIS OF THE CENTRAL NERVOUS SYSTEM STIMULANTS, AMPHETAMINES, VIA GAS CHROMATOGRAPHY MASS SPECTROMETRY: RAPID ACYLATION IN THE PRESENCE OF A MERCURY CATALYST.
222830 04-06

RAPIDITY
RAPIDITY OF SYMPTOM REDUCTION IN DEPRESSIONS TREATED WITH AMITRIPTYLINE.
209437 03-09

RAPPORT
CLINICAL TRIAL OF FLUPENTHIXOL IN PATIENTS WITH CHRONIC SCHIZOPHRENIA: ESPECIALLY IN PATIENTS HAVING DIFFICULTY IN REHABILITATION OWING TO DECREASED EXPRESSION, APATHY AND DISTURBANCE OF RAPPORT.
202603 02-08

RAT
CHANGES IN ACTIVATION OF ADENYLATE-CYCLASE AND OF DOPAMINE TURNOVER IN RAT STRIATUM DURING PROLONGED HALOPERIDOL TREATMENT.
192933 01-03

DEPRESSION BY AMANTADINE OF TREMOR INDUCED BY RESERPINE AND OXOTREMORINE IN THE RAT.
193282 01-04

STUDIES ON SOME METABOLIC EFFECTS OF DOPA AND DOPAMINE IN THE RAT.
193301 01-03

PENTAZOCINE ANALGESIA AND REGIONAL RAT BRAIN CATECHOLAMINES.
193452 01-03

FURTHER STUDIES ON THE EFFECT OF P-HYDROXYNOREPHEDRINE (PONE) ON NOREPINEPHRINE METABOLISM IN THE RAT BRAIN.
193453 01-03

PHARMACOKINETICS OF LITHIUM AND ITS REGIONAL DISTRIBUTION IN RAT BRAIN.
193547 01-03

ACUTE, SUBACUTE AND 23-DAY CHRONIC MARIHUANA INHALATION TOXICITIES IN THE RAT.
193576 01-04

EFFECT OF COPPER LOADING ON VARIOUS TISSUE ENZYMES AND BRAIN MONOAMINES IN THE RAT.
193577 01-03

ALTERATIONS BY ANESTHETIC AGENTS OF THE RESPONSES OF RAT STRIATAL NEURONS TO IONTOPHORETICALLY APPLIED AMPHETAMINE, ACETYLCHOLINE, NORADRENALINE, AND DOPAMINE.
193803 01-03

COMPARISON OF THE EFFECTS OF CHLORAL HYDRATE AND TRICHLOROETHANOL ON THE EEG OF THE ISOLATED PERFUSED RAT BRAIN.
194743 01-03

EFFECTS OF TETRAHYDROCANNABINOLS ON CYCLIC-AMP LEVELS IN RAT BRAIN AREAS.
194925 01-03

REDUCTION OF STIMULUS BOUND FOOD CONSUMPTION IN THE RAT FOLLOWING AMPHETAMINE ADMINISTRATION.
195081 01-04

THE EFFECTS OF P-CHLOROAMPHETAMINE ON INSTRUMENTAL CONDITIONING IN THE RAT.
195088 01-04

EFFECTS OF TAURINE ON PSYCHOMOTOR ACTIVITY IN THE RAT.
195089 01-04

EFFECTS OF PHENOXYBENZAMINE ON THE NARCOTIC WITHDRAWAL SYNDROME IN THE RAT.
195091 01-03

INTRACELLULAR DISTRIBUTION OF 3H-DELTA8-TETRAHYDROCANNABINOL IN RAT ORGANS AFTER I.V. ADMINISTRATION.
195112 01-03

MORPHINE EFFECTS ON THE LEVELS AND TURNOVER OF CATECHOLAMINES IN RAT BRAIN.
195116 01-03

A COMPARISON OF THE INHIBITORY EFFECTS OF CERTAIN ANTIPARKINSONIAN AGENTS ON DOPAMINE ACCUMULATION INTO THE RAT STRIATUM.
195234 01-03

INFLUENCE OF THERAPEUTIC AND TOXIC DOSES OF NEUROLEPTICS AND ANTIDEPRESSANTS ON ENERGY METABOLISM OF THE ISOLATED PERFUSED RAT BRAIN.
195236 01-03

EFFECT OF CHRONIC TRANSECTION ON DOPAMINE, NORADRENALINE AND 5-HYDROXYTRYPTAMINE IN THE RAT SPINAL CORD.
195244 01-03

THE SITE OF AND MODE OF ACTION OF ET495 FOR THE MEDIATION OF STEREOTYPED BEHAVIOUR IN THE RAT.
195252 01-03

THE EFFECTS OF LITHIUM AND PHYSOSTIGMINE ON RAT BRAIN ACETYLCHOLINESTERASE ACTIVITY.
195436 01-03

NORADRENALINE AND 5-HYDROXYTRYPTAMINE METABOLISM IN SIX AREAS OF RAT BRAIN DURING POST-AMPHETAMINE DEPRESSION.
195437 01-03

EFFECTS IN THE SUCKLING RAT OF CHRONIC TREATMENT WITH TRYPTOPHAN AND A MONOAMINE OXIDASE INHIBITOR.
195906 01-04

EFFECT OF PENTOBARBITONE AND DIETHYL ETHER ON THE SYNTHESIS OF MONOAMINES IN RAT BRAIN.
195950 01-03

DEVELOPMENTAL CHARACTERISTICS OF PHENYLETHANOLAMINE AND OCTOPAMINE IN THE RAT BRAIN.
196804 01-03

ADENYLCYCLASE IN RAT STRIATUM AND NUCLEUS-ACCUMBENS: STIMULATION BY DOPAMINE RECEPTOR AGONISTS. (UNPUBLISHED PAPER).
197124 01-03

EFFECTS OF LITHIUM ON CYCLIC-3-5-AMP METABOLISM IN RAT BRAIN.
197278 01-03

THE EFFECT OF CHRONIC CANNABIS AND CANNABINOID APPLICATION ON THE HEPATIC DRUG METABOLIZING SYSTEM OF THE RAT.
197282 01-03

THE SUBCELLULAR DISTRIBUTION OF INTRAVENTRICULARLY ADMINISTERED 3H-METARAMINOL IN INTACT AND RAT BRAIN PRETREATED WITH P-CHLOROAMPHETAMINE.
197289 01-03

ADENOSINE-3-5-MONOPHOSPHATE IN CEREBRAL CORTICAL SLICES FROM GUINEA-PIG AND RAT: EFFECT OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC COMPOUNDS.
197293 01-03

THE EFFECTS OF IMIPRAMINE AND PROMAZINE ON ENERGY METABOLISM AND EEG OF THE ISOLATED PERFUSED RAT BRAIN.
197296 01-03

EFFECTS OF P-ACETYLDEOXYEPHEDRINE ON PUNISHED BEHAVIOR IN THE RAT.
197450 01-04

MURICIDAL BLOCK INDUCED BY 5-HYDROXYTRYPTOPHAN IN THE RAT.
197454 01-04

MODIFICATION BY DESIPRAMINE OF THE ADRENERGIC SENSITIVITY OF PYROGALLOL IN THE RAT.
197461 01-03

ONTOGENY OF STEREOTYPED BEHAVIOUR INDUCED BY APOMORPHINE AND AMPHETAMINE IN THE RAT.
197462 01-04

THE EFFECT OF BETA-THIAMINOKETONES ON THE AMINOPYRINE-N-DEMETHYLATION IN VITRO AND IN VIVA SUCH AS THE HEXOBARBITAL SLEEPING TIME AND L-ASCORBIC ACID EXCRETION IN THE RAT.
197469 01-03

STUDIES ON EEG TOLERANCE TO MARIJUANA IN THE RAT.
197473 01-03

SOME OF THE DYNAMICS OF CHOLINE AND ACETYLCHOLINE METABOLISM IN RAT BRAIN.
197474 01-03

EEG SEIZURES PRODUCED BY INTRAVENTRICULAR QUATERNARY AMMONIUM COMPOUNDS IN THE RAT.
197475 01-03

THE INFLUENCE OF CHLORPROMAZINE AND RESERPINE ON THE METABOLISM OF CEREBRAL PHOSPHOLIPIDS IN THE RAT IN VIVO.
197477 01-03

THE EFFECT OF A NEW TETRACYCLIC ANTIDEPRESSANT COMPOUND, ORG-GB94, ON THE TURNOVER OF DOPAMINE, NORADRENALIN AND SEROTONIN IN THE RAT BRAIN.
197496 01-03

THE RELATIONSHIP BETWEEN RIGIDITY AND CHANGE IN WHOLE BRAIN ACETYLCHOLINE CONCENTRATION PRODUCED BY INJECTION OF RESERPINE IN THE RAT.
197569 01-03

THE EFFECTS OF P-SUBSTITUTED AMPHETAMINES ON THE TRANSMITTER REGULATION IN RAT BRAIN.
197571 01-03

CATECHOLAMINE DEPLETING ACTION OF PHYSOSTIGMINE IN THE RAT BRAIN.
197575 01-03

THE EFFECTS OF EARLY ALPHA-METHYLDOPA TREATMENT ON BEHAVIOUR IN THE RAT.
197578 01-04

EFFECT OF ANGIOTENSIN II ON SEROTONIN ACCUMULATION IN THE RAT BRAIN.
197582 01-03

NEONATAL CHEMICAL SYMPATHECTOMY: FUNCTIONAL CONTROL OF DENERVATION OF THE VASCULAR SYSTEM AND TISSUE NORADRENALINE LEVEL IN THE RAT AFTER 6-HYDROXYDOPAMINE.
197584 01-03

3,4 DIHYDROXYPHENYLACETIC ACID (DOPAC): A POSSIBLE ENDOGENOUS INHIBITOR OF INDOLEAMINE-N-METHYLATION IN THE RAT BRAIN.
197676 01-17

ACTION OF NEUROLEPTICS ON THE CONTENT OF DOPAMINE AND DOPAC IN THE RAT CAUDATE NUCLEUS.
197682 01-03

MODIFICATION OF DELTA9-THC ACTIONS BY CANNABINOL AND CANNABIDIOL IN THE RAT.
197858 01-03

EFFECTS OF PIRIBEDIL ON NORADRENALINE AND MOPEG-SO4 LEVELS IN THE RAT BRAIN.
197868 01-03

LONG-TERM EFFECTS OF N-HYDROXY-4-CHLOROAMPHETAMINE ON THE LEVEL AND ACCUMULATION OF 5-HYDROXYTRYPTAMINE IN THE RAT BRAIN.
197869 01-03

THEOPHYLLINE INCREASED SENSITIVITY TO NOCICEPTIVE STIMULATION AND REGIONAL TURNOVER OF RAT BRAIN 5-HT, NORADRENALINE AND DOPAMINE.
197926 01-03

PROTRIPTYLINE INDUCED INHIBITION OF THE IN VIVO 3H-NORADRENALINE SYNTHESIS FROM 3H-L-DOPA IN THE RAT BRAIN.
197928 01-03

GLUCOSE RELEASE OF THE RAT KIDNEY IN VIVO AFTER BETA-ADRENERGIC STIMULATION AND BLOCKADE.
197946 01-03

STIMULATION OF A SPECIFIC DRIVE (PREDATORY BEHAVIOR) BY P-CHLOROPHENYLALANINE (PCPA) IN THE RAT.
197952 01-04

KINETICS OF 14C-DOPAMINE IN ISOLATED RAT STRIATAL TISSUE UNDER THE INFLUENCE OF MORPHINE.
197954 01-03

INFLUENCE OF PROPRANOLOL AND PRACTOLOL ON THE TURNOVER OF NORADRENALINE IN THE RAT HEART.
197957 01-03

DOSE-DEPENDENCE OF CHLORPHENTERMINE-INDUCED ULTRASTRUCTURAL ALTERATIONS IN RAT.
197960 01-03

STUDIES ON THE UPTAKE OF D-AMPHETAMINE BY RAT CEREBRAL CORTEX SLICES.
197961 01-03

DETERMINATION OF NORADRENALINE, DOPAMINE, SEROTONIN, 5-HYDROXYINDOLEACETIC ACID, TYROSINE AND TRYPTOPHANE IN THE ISOLATED PERFUSED RAT BRAIN.
197967 01-06

ON THE ACTION OF OXOTREMORINE ON THE CHOLINERGIC SYSTEM OF THE RAT BRAIN.
197968 01-03

ADENOSINE-3-5-MONOPHOSPHATE IN CEREBRAL CORTICAL SLICES FROM GUINEA-PIG AND RAT: EFFECT OF BENZODIAZEPINES.
197972 01-03

EFFECT OF NICOTINE AND OTHER DRUGS ON THE RELEASE OF 3H-NOREPINEPHRINE AND 3H-DOPAMINE FROM RAT BRAIN SLICES.
197985 01-03

EFFECTS OF PSYCHOTROPIC DRUGS ON THE INCORPORATION OF GLUCOSE-14C INTO AMINO ACIDS OF THE RAT BRAIN.
198026 01-03

THE EFFECT OF NH4CL ON POLYURIA AND POLYDIPSIA DURING PROLONGED LITHIUM ADMINISTRATION IN THE RAT.
198027 01-03

EFFECT OF RESERPINE ON CATIONIC CONTENTS OF RAT BRAIN.
198196 02-03

DISTRIBUTION OF AMPHETAMINE AND ITS HYDROXYLATED METABOLITES IN VARIOUS AREAS OF THE RAT BRAIN.
198211 02-03

BEHAVIOURAL AND ELECTROCORTICAL MODIFICATIONS INDUCED IN THE RAT BY INTRAVENTRICULAR INJECTION OF PHYSALAEMIN AND ELEDOISIN.
198224 02-03

INTERACTIONS OF PENTAZOCINE AND NALOXONE ON THE MONOAMINE CONTENT OF DISCRETE REGIONS OF THE RAT BRAIN.
198606 02-03

THE EFFECTS OF DIPHENYLHYDANTOIN, PHENOBARBITAL, AND DIAZEPAM ON THE PENICILLIN INDUCED EPILEPTOGENIC FOCUS IN THE RAT.
198613 02-03

THE INHIBITORY EFFECT OF TOLUIDINE BLUE AND METHYLENE BLUE ON RAT MAST CELL DAMAGE BY PROMETHAZINE, CHLORPROMETHAZINE AND CHLORPROMAZINE. ITS REVERSAL BY GLUCOSE.
199255 02-05

ABSORPTION, DISTRIBUTION AND EXCRETION OF ALPRENOLOL IN MAN, DOG, AND RAT.
199621 02-13

MODIFICATION OF THE RECEPTOR COMPONENT OF ADENYLATE-CYCLASE IN THE RAT BRAIN BY PHENOTHIAZINE DERIVATIVES.
199771 02-03

EFFECT OF PROGESTERONE ON REGIONAL 5-HYDROXYTRYPTAMINE METABOLISM IN THE RAT BRAIN.
199773 02-03

CHRONIC LYSERGIC ACID DIETHYLAMIDE ADMINISTRATION AND SEROTONIN TURNOVER IN VARIOUS REGIONS OF RAT BRAIN.
199783 02-03

EFFECT OF NEUROTROPIC AGENTS ON TOTAL PYRIDOXAL PHOSPHATE AND ON THE ACTIVITY OF THE DECARBOXYLASE OF AROMATIC AMINO ACIDS AS WELL AS OF OTHER PYRIDOXAL PHOSPHATE DEPENDENT ENZYMES IN RAT BRAIN.
199785 02-03

UPTAKE AND RELEASE OF POSSIBLE FALSE TRANSMITTER AMINO ACIDS BY RAT BRAIN TISSUE.
199788 02-03

ANALYSIS OF ACETYLCHOLINESTERASE SYNTHESIS AND TRANSPORT IN THE RAT HIPPOCAMPUS: RECOVERY OF ACETYLCHOLINESTERASE ACTIVITY IN THE SEPTUM AND HIPPOCAMPUS AFTER ADMINISTRATION OF DIISOPROPYLFLUOROPHOSPHATE.
199805 02-03

BIOCHEMICAL CORRELATES IN MOUSE-KILLING BEHAVIOR OF THE RAT BRAIN: BRAIN ACETYLCHOLINE AND ACETYLCHOLINESTERASE AFTER ADMINISTRATION OF DELTA9-TETRAHYDROCANNABINOL.
199807 02-03

AMANTADINE AND D-145, AN AMANTADINE DERIVATIVE, DO NOT EFFECT DOPAMINE SENSITIVE ADENYLATE-CYCLASE FROM THE CAUDATE PUTAMEN OF THE RAT BRAIN.
199867 02-03

MINIMUM DURATION OF TRANS-SYNAPTIC STIMULATION REQUIRED FOR THE INDUCTION OF TYROSINE-HYDROXYLASE BY RESERPINE IN THE RAT SUPERIOR CERVICAL GANGLION.
199999 02-03

EFFECT OF DELTA8-THC ON ALCOHOL-INDUCED SLEEPING TIME IN THE RAT.
200041 02-03

EFFECT OF LIMBIC SYSTEM LESIONS ON ACETYLCHOLINE RELEASE FROM THE CEREBRAL CORTEX OF THE RAT.
200044 02-03

THE EFFECTS OF SCOPOLAMINE AND PHYSOSTIGMINE ON FIXED-INTERVAL BEHAVIOUR IN THE RAT.
200046 02-04

BEHAVIORAL SPECIFICITY OF CHLORALOSE INDUCED FEEDING IN THE RAT.
200054 02-04

QUANTITATIVE ANALYSIS OF THE EEG EFFECTS PRODUCED BY IMIPRAMINE, DESIPRAMINE, PROMAZINE, AND MONODESMETHYL PROMAZINE IN THE ISOLATED PERFUSED RAT BRAIN.
200056 02-03

DIAZEPAM INCREASES 5-HYDROXYINDOLE CONCENTRATIONS IN RAT BRAIN AND SPINAL CORD.
200081 02-03

LEAD ENCEPHALOPATHY IN THE DEVELOPING RAT: EFFECT ON CORTICAL ONTOGENESIS.
200168 02-05

TISSUE METABOLITES OF TRIFLUOPERAZINE, FLUPHENAZINE, PROCHLORPERAZINE, AND PERPHENAZINE IN THE RAT: IDENTIFICATION AND SYNTHESIS.
200738 02-01

THE RELATIONSHIP OF CENTRAL MONOAMINES TO DRUG-INDUCED SLEEP IN THE RAT, EXAMINED ON A 24-HOUR BASIS. (PH.D. DISSERTATION).
201005 02-03

TOLERANCE TO THE STIMULANT EFFECTS OF MORPHINE AND PENTAZOCINE ON AVOIDANCE RESPONDING IN THE RAT.
201319 02-04

EFFECT OF EARLY L-DOPA ADMINISTRATION ON THE ONTOGENY OF MOTOR FUNCTIONS IN THE RAT.
202266 02-03

AMPHETAMINE, L-DOPA AND APOMORPHINE: EFFECTS ON ACTIVITY OF RAT DOPAMINERGIC NEURONS.
202370 02-03

ACTION OF (S)- AND (R) P-SUBSTITUTED AMPHETAMINE HYDROCHLORIDES AND (ALPHA S)- AND (ALPHA R) P-CHLORONOREPHEDRINE AND (ALPHA S)- AND (ALPHA R) P-CHLORONORPSEUDOEPHEDRINE HYDROCHLORIDES ON THE LEVEL OF 5-HYDROXYTRYPTAMINE AND THE ACTIVITY OF TRYPTOPHAN-HYDROXYLASE IN RAT BRAIN.
202417 02-03

DEVELOPMENTAL DISTURBANCE OF THE BRAIN IN RAT OFFSPRING FOLLOWING MATERNAL ADMINISTRATION OF 5-FLUOURACIL DURING PREGNANCY.
202422 02-03

MEASUREMENT OF ACETYLCHOLINE TURNOVER RATE IN DISCRETE AREAS OF RAT BRAIN.
202465 02-06

THE REGULATION OF CYCLIC GUANOSINE MONOPHOSPHATE IN RAT CEREBELLUM: POSSIBLE INVOLVEMENT OF PUTATIVE AMINO ACID NEUROTRANSMITTERS.
202717 02-03

BEHAVIOURAL EFFECT OF INTRAVENTRICULAR APPLICATION OF METHOXYINDOLEALKYLAMINES IN THE RAT.
202772 02-04

THE ROLE OF FOREBRAIN DOPAMINE SYSTEMS IN AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR IN THE RAT.
202774 02-04

THE EFFECT OF TRIIODOTHYRONINE IN COMBINATION WITH IMIPRAMINE ON (3H) CYCLIC-AMP PRODUCTION IN SLICES OF RAT CEREBRAL CORTEX.
202777 02-03

EVIDENCE AGAINST A CAUSAL RELATIONSHIP BETWEEN INCREASE IN C-AMP AND INDUCTION OF TYROSINE-HYDROXYLASE IN THE RAT ADRENAL MEDULLA.
202795 02-03

PHARMACOKINETICS IN THE RAT OF THE HALLUCINOGENIC ALKALOIDS HARMINE AND HARMALINE.
202796 02-03

EFFECT OF NOMIFENSINE (HOE-984), A NEW ANTIDEPRESSANT, ON UPTAKE OF NORADRENALINE AND SEROTONIN AND ON RELEASE OF NORADRENALINE IN RAT BRAIN SYNAPTOSOMES.
202807 02-03

AFFERENTS TO THE SEPTAL AREA OF THE RAT STUDIED WITH THE METHOD OF RETROGRADE AXONAL TRANSPORT OF HORSERADISH PEROXIDASE.
203573 02-03

THE RELATIVE SIGNIFICANCE OF NOREPINEPHRINE DOPAMINE AND 5-HYDROXYTRYPTAMINE IN THE ELECTROSHOCK SEIZURE IN THE RAT.
204339 02-03

HYDROXYLATION OF AMPHETAMINE TO P-HYDROXYAMPHETAMINE BY RAT LIVER MICROSOMES.
205433 02-03

EFFECTS OF PSYCHOACTIVE TRICYCLIC DRUGS ON THE EEG OF THE ISOLATED PERFUSED RAT BRAIN.
205492 02-03

SHORT-TERM EFFECT OF PERPHENAZINE ENANTHATE ON THE RAT BRAIN.
206359 03-03

INFLUENCE OF IPRONIAZID ON THE CONTENT OF NORADRENALINE IN VARIOUS PARTS OF THE RAT BRAIN BEFORE AND AFTER STIMULATION OF THE RECEPTORS.
206404 03-03

AGE RELATED RESPONSIVENESS OF THE RAT TO DRUGS AFFECTING THE CENTRAL NERVOUS SYSTEM.
206912 03-03

METABOLISM OF DOPAMINE AND NOREPINEPHRINE IN RAT BRAIN AFTER SINGLE AND REPEATED ADMINISTRATION OF HALOPERIDOL, LOXAPINE AND CLOZAPINE.
206973 03-03

SIGNIFICANCE OF CATECHOLAMINES FOR THE MANIFESTATION OF MORPHINE WITHDRAWAL IN THE RAT.
206988 03-03

TRICYCLIC ANTIDEPRESSANT DRUGS AND DOPAMINE SENSITIVE ADENYLCYCLASE FROM RAT CAUDATE NUCLEI.
206990 03-03

EFFECT OF STRESS UPON SEROTONIN METABOLISM IN VARIOUS REGIONS OF THE RAT BRAIN.
206993 03-03

EFFECTS OF AMPHETAMINES ON THE METABOLISM OF CATECHOLAMINES IN THE RAT BRAIN.
207288 03-03

A MASS FRAGMENTOGRAPHIC STUDY OF AMPHETAMINE AND METABOLITES IN RAT BRAIN.
207289 03-06

THE EFFECT OF CLOZAPINE AND ACETYLCHOLINE TURNOVER RATE IN RAT STRIATUM. (UNPUBLISHED PAPER).
207500 03-03

THE PHARMACOLOGICAL AND ANATOMICAL SUBSTRATES OF THE AMPHETAMINE RESPONSE IN THE RAT.
207794 03-04

ADENOSINE-3-5-MONOPHOSPHATE CONTENT IN RAT CAUDATE NUCLEUS: DEMONSTRATION OF DOPAMINERGIC AND ADRENERGIC RECEPTORS.
208300 03-03

THE INFLUENCE OF INTRAPERITONEAL INJECTION OF IPRAZIDE AND TRANSAMINE ON THE DISTRIBUTION OF BIOGENIC AMINES IN CORTICAL AND SUBCORTICAL WHITE MATTER OF THE RAT BRAIN.
209032 03-03

INFLUENCE OF NONCHOLINERGIC DRUGS ON RAT STRIATAL ACETYLCHOLINE LEVELS.
210658 03-03

SEROTONIN CONTENT OF THE BRAINSTEM NUCLEI IN THE RAT.
210661 03-03

HIPPOCAMPUS: SELECTIVE CONCENTRATIONS OF LEAD IN THE NORMAL RAT BRAIN.
210665 03-03

CORRELATIONS BETWEEN CIRCADIAN CHANGES IN SERUM AMINO ACIDS OR BRAIN TRYPTOPHAN AND THE CONTENTS OF SEROTONIN AND 5-HYDROXYINDOLEACETIC ACID IN REGIONS OF THE RAT BRAIN.
210673 03-03

AMPHETAMINE: POSSIBLE SITE AND MODE OF ACTION FOR PRODUCING ANOREXIA IN THE RAT.
210675 03-03

POSTNATAL DEVELOPMENT OF CHOLINE UPTAKE BY CHOLINERGIC TERMINALS IN RAT BRAIN.
210713 03-03

SEROTONERGIC INVOLVEMENT WITH THE STEREOTYPY/CATALEPSY INDUCED BY MORPHINE-LIKE AGENTS IN THE RAT.
210754 03-04

EXTRAPINEAL N-ACETYLTRANSFERASE ACTIVITY IN RAT BRAIN.
210760 03-03

CHANGED EATING AND LOCOMOTOR BEHAVIOUR IN THE RAT AFTER 6-HYDROXYDOPAMINE LESIONS TO THE SUBSTANTIA-NIGRA.
210763 03-04

CATECHOLAMINES IN SYMPATHETIC GANGLIA OF RAT: EFFECTS OF DEXAMETHASONE AND RESERPINE.
210766 03-03

EFFECT OF DELTA9-TETRAHYDROCANNABINOL ADMINISTRATION ON THE LIPID CONSTITUENTS OF RAT BRAIN SUBCELLULAR FRACTIONS.
210769 03-03

INHIBITION BY APOMORPHINE OF DOPAMINE DEAMINATION IN THE RAT BRAIN.
210776 03-03

ACCUMULATION OF LITHIUM IN THE PARTICULATE FRACTION OF RAT BRAIN FOLLOWING ITS LONG-TERM ADMINISTRATION.
210782 03-03

EFFECTS OF NALORPHINE ON AVOIDANCE BEHAVIOR AND LOCOMOTOR ACTIVITY IN THE RAT.
210783 03-04

EFFECTS OF PSYCHOACTIVE DRUGS ON RESPONSES OF THE RAT TO AVERSIVE STIMULATION.
210784 03-04

BLOOD-BRAIN BARRIER: I. KINETICS OF DISTRIBUTION OF 3H-AMPHETAMINE IN THE RAT BRAIN AFTER INTRAVENOUS ADMINISTRATION.
210788 03-03

THE EFFECTS OF RUBIDIUM ON THE DURATION OF SLEEP ELICITED BY PENTOBARBITAL IN THE RAT.
210791 03-03

REGIONAL AND SUBCELLULAR DISTRIBUTION AND KINETIC PROPERTIES OF RAT BRAIN CHOLINE ACETYLTRANSFERASE -- SOME FUNCTIONAL CONSIDERATIONS.
210816 03-03

EVIDENCE THAT 5-METHOXYDIMETHYLTRYPTAMINE IS A SPECIFIC SUBSTRATE FOR MAO-A IN THE RAT: IMPLICATIONS FOR THE INDOLEAMINE DEPENDENT BEHAVIORAL SYNDROME.
210817 03-04

PHARMACOKINETIC INTERACTION BETWEEN NEUROLEPTICS AND TRICYCLIC ANTIDEPRESSANTS IN THE RAT.
210834 03-03

TRICYCLIC ANTIDEPRESSIVE DRUGS AND DOPAMINE SENSITIVE ADENYLATE-CYCLASE FROM RAT BRAIN STRIATUM.
210856 03-03

NEUROTRANSMITTER CONTROL OF THYROTROPIN SECRETION IN THE RAT.
210858 03-03

DIFFERENTIAL EFFECTS OF D- AND L-AMPHETAMINE AND METHYLPHENIDATE ON RAT STRIATAL DOPAMINE BIOSYNTHESIS.
210859 03-03

EFFECT OF ANTIPSYCHOTIC DRUGS ON HOMOVANILLIC ACID LEVELS IN STRIATUM AND OLFACTORY TUBERCLE OF THE RAT.
210864 03-03

THE EFFECT OF TWO SYNTHETIC ACTH ANALOGUES ON THE METABOLISM OF BIOGENIC AMINES IN THE RAT BRAIN.
210875 03-03

DELTA9-TETRAHYDROCANNABINOL AND SOME CNS DEPRESSANTS: EVIDENCE FOR CROSS-TOLERANCE IN THE RAT.
210876 03-03

EFFECTS OF METHAMPHETAMINE ON THE ISOLATED RAT PHRENIC NERVE DIAPHRAM PREPARATION.
210900 03-03

THE EFFECTS OF ACUTE AND CHRONIC MORPHINE ADMINISTRATION ON THE LEVELS OF 3-METHOXY-4-HYDROXYPHENYLGLYCOL SULFATE IN RAT BRAIN.
210927 03-03

METABOLISM OF 4-CHLOROAMPHETAMINE TO 3-CHLORO-4-HYDROXYAMPHETAMINE IN RAT: EVIDENCE FOR AN IN VIVO NIH SHIFT OF CHOLINE.
210929 03-03

COMPARISON OF STRUCTURAL AND STEREOISOMERS OF APOMORPHINE ON STEREOTYPED SNIFFING BEHAVIOUR OF THE RAT.
210930 03-04

EFFECT OF THYROXINE AND CORTISOL ON BRAIN ORNITHINE DECARBOXYLASE ACTIVITY AND SWIMMING BEHAVIOR IN DEVELOPING RAT.
210933 03-03

HIGH AFFINITY UPTAKE OF GABA IN PRESUMED GABA-ERGIC NERVE ENDINGS IN RAT BRAIN.
211062 03-03

DIFFERENTIAL EFFECTS OF THE OPTICAL ISOMERS OF AMPHETAMINE ON NEURONAL ACTIVITY IN THE RETICULAR FORMATION AND CAUDATE NUCLEUS OF THE RAT.
211063 03-03

INHIBITION OF DELTA1-TETRAHYDROCANNABINOL OF NA+-K+ TRANSPORT ATPASE FROM RAT ILEUM. PRELIMINARY REPORT.
211099 03-03

THE EFFECT OF RESERPINE AND CHLORIMIPRAMINE ON GLYCOGEN CONTENT IN DIFFERENT BRAIN STRUCTURES OF RAT.
211106 03-03

THE EFFECT OF CERTAIN TRANQUILISERS, CHLORPROMAZINE METABOLITES AND DIETHYLDITHIOCARBAMATE ON TISSUE AMPHETAMINE LEVELS IN THE RAT.
211111 03-03

METABOLISM OF DELTA1-TETRAHYDROCANNABINOL BY THE RAT IN VIVO AND IN VITRO.
211112 03-03

NEUROCHEMICAL REGULATION OF FEEDING IN THE RAT: FACILITATION BY ALPHA-NORADRENERGIC, BUT NOT DOPAMINERGIC RECEPTOR STIMULANTS.
211538 03-04

INTRAVENTRICULAR AMPHETAMINE SELF-ADMINISTRATION IN THE ALBINO RAT. (PH.D. DISSERTATION).
211899 03-04

SELECTIVE DESTRUCTION OF SEROTONIN TERMINALS IN RAT FOREBRAIN BY HIGH DOSES OF 5,7 DIHYDROXYTRYPTAMINE.
213401 04-03

INHIBITORY EFFECT OF NEONATAL ESTROGENIZATION ON THE INCORPORATION OF (3H)LYSINE IN THE PURKINJE CELLS OF THE ADULT MALE AND FEMALE RAT.
213478 04-03

IN VIVO IDENTIFICATION OF MUSCARINIC CHOLINERGIC RECEPTOR BINDING IN RAT BRAIN.
213480 04-03

THE EFFECT OF PROLONGED LITHIUM INGESTION ON MORPHINE ACTIONS IN THE RAT.
213482 04-03

CATECHOLAMINE NEUROTRANSMITTERS AND SYNTHETIC ENZYMES IN THE SPINAL CORD OF THE RAT.
213987 04-03

NORADRENERGIC CONTROL OF SPONTANEOUS MEAL SIZE IN THE RAT. (PH.D. DISSERTATION).
214206 04-04

RAT BRAIN REGIONAL UPTAKE AND DECARBOXYLATION OF L-DOPA FOLLOWING CAROTID INJECTION.
214323 04-03

UPTAKE OF 3H-NORADRENALINE AND 3H-5-HYDROXYTRYPTAMINE IN CULTURED RAT BRAINSTEM.
215159 04-03

LYSERGIC ACID DIETHYLAMIDE AFFECTS BLOOD FLOW TO SPECIFIC AREAS OF THE CONSCIOUS RAT BRAIN.
215161 04-03

RAT PINEAL CYCLIC ADENOSINE-3-5-MONOPHOSPHATE PHOSPHODIESTERASE ACTIVITY: IN VIVO MODULATION BY A BETA ADRENERGIC RECEPTOR.
215600 04-03

THE IN VIVO REGULATION OF CGMP CONTENT IN RAT CEREBELLUM: A STUDY OF THE ACTION OF TAURINE.
215654 04-03

ANTINOCICEPTIVE ACTION OF OXOTREMORINE AND REGIONAL TURNOVER OF RAT BRAIN NORADRENALINE, DOPAMINE AND 5-HT.
215683 04-03

METHYLPHENIDATE EFFECTS ON AVOIDANCE LEARNING AT TWO AGES IN THE RAT.
215685 04-04

BLOOD PRESSURE AND HEART RATE RESPONSES EVOKED BY D- AND L-AMPHETAMINE IN THE PITHED RAT PREPARATION.
215687 04-03

EFFECT OF ALPHA-METHYLDOPA ON DOPAMINE SYNTHESIS AND RELEASE IN RAT STRIATUM IN VITRO.
215690 04-03

EFFECTS OF 6-HYDROXYDOPAMINE AND RESERPINE ON AMPHETAMINE-INDUCED RELEASE OF NOREPINEPHRINE IN RAT CEREBRAL CORTEX.
215691 04-03

THE EFFECT OF CHRONIC LITHIUM APPLICATION ON THE MINERAL CONTENT OF RAT BONE AND SOFT TISSUES.
215695 04-05

HOMOVANILLIC ACID CONCENTRATION IN RAT BRAIN: EFFECT OF A CHOLINE ACETYLTRANSFERASE INHIBITOR AND COMPARISON WITH CHOLINERGIC AND DOPAMINERGIC AGENTS.
215711 04-03

STUDIES ON THE DISTINCTION BETWEEN UPTAKE INHIBITION AND RELEASE OF H3-DOPAMINE IN RAT BRAIN TISSUE SLICES.
215756 04-03

MASS FRAGMENTOGRAPHY OF PICOMOLE QUANTITIES OF BIOGENIC AMINE METABOLITES IN HUMAN CEREBROSPINAL FLUID AS WELL AS WHOLE RAT BRAINS. (UNPUBLISHED PAPER).
217219 04-06

SEROTONIN SENSITIVE ADENYLCYCLASE ACTIVITY IN IMMATURE RAT BRAIN.
217355 04-03

INHIBITION OF D-AMPHETAMINE INDUCED LOCOMOTOR ACTIVITY BY INJECTION OF HALOPERIDOL INTO THE NUCLEUS-ACCUMBENS OF THE RAT.
217461 04-04

NEUROLEPTIC-INDUCED HYPERSENSITIVITY OF STRIATAL DOPAMINE RECEPTORS IN THE RAT AS A MODEL OF TARDIVE DYSKINESIAS. EFFECTS OF CLOZAPINE, HALOPERIDOL, LOXAPINE AND CHLORPROMAZINE.
217462 04-03

EFFECTS OF CLOZAPINE, THIORIDAZINE, PERLAPINE AND HALOPERIDOL ON THE METABOLISM OF THE BIOGENIC AMINES IN THE BRAIN OF THE RAT.
217543 04-03

THE EFFECT OF HEMICHOLINIUM ON BEHAVIOR AND ON BRAIN ACETYLCHOLINE AND CHOLINE IN THE RAT.
217551 04-04

CHLORPROMAZINE-INDUCED HYPERPHAGIA IN THE RAT.
217552 04-04

A DEVELOPMENTAL STUDY OF THE EFFECTS OF 5,7 DIHYDROXYTRYPTAMINE ON REGIONAL TRYPTOPHAN-HYDROXYLASE IN RAT BRAIN.
217555 04-03

EFFECTS OF HALOTHANE AND NITROUS OXIDE ANESTHESIA ON 5-HT TURN-OVER IN THE RAT BRAIN.
217655 04-03

ONTOGENESIS OF NEOSTRIATAL CHOLINERGIC NEURONES IN THE RAT AND DEVELOPMENT OF THEIR SENSITIVITY TO NEUROLEPTIC DRUGS.
217658 04-03

EVIDENCE AGAINST THE INVOLVEMENT OF FALSE NEUROTRANSMITTERS IN TOLERANCE TO AMPHETAMINE-INDUCED HYPERTHERMIA IN THE RAT.
217690 04-03

ON THE MECHANISM OF THE HYPERTHERMIA INDUCED BY AMPHETAMINE IN THE RAT.
217691 04-03

INFLUENCE OF SOME TRICYCLIC ANTIDEPRESSIVE DRUGS ON THE UPTAKE OF 5-HYDROXYTRYPTAMINE BY RAT BLOOD PLATELETS.
217693 04-03

AGE DIFFERENCES AFFECTING INDUCTION OF HEPATIC DRUG METABOLIZING ENZYMES BY METHAQUALONE AND PHENOBARBITAL IN THE RAT.
217793 04-03

A COMPARISON OF THE INDUCTIVE EFFECTS OF PHENOBARBITAL, METHAQUALONE, AND METHYPRYLON ON HEPATIC MIXED FUNCTION OXIDASE ENZYMES IN THE RAT.
217794 04-03

THE EFFECT OF CHLORDIAZEPOXIDE HYDROCHLORIDE ON THE ISOLATED PERFUSED RAT LIVER (38786).
217796 04-03

STUDIES ON THE SYNTHESIS AND SUBCELLULAR DISTRIBUTION OF DOPAMINE IN THE RAT ADRENAL MEDULLA.
217797 04-03

THE INFLUENCE OF APOMORPHINE AND TRICYCLIC ANTIDEPRESSANT DRUGS ON THE LEVEL OF SEROTONIN AND ITS METABOLITE IN RAT BRAIN.
217815 04-03

LACK OF EFFECT OF PROTRIPTYLINE ON THE 6-HYDROXYDOPAMINE INDUCED NORADRENALINE DEPLETION IN THE RAT SPINAL CORD.
217824 04-03

MIDBRAIN RAPHE NEURONS: SENSITIVITY TO GLUCOCORTICOIDS AND ACTH IN THE RAT.
217863 04-03

6-HYDROXYDOPA DURING DEVELOPMENT OF CENTRAL ADRENERGIC NEURONS PRODUCES DIFFERENT LONG-TERM CHANGES IN RAT BRAIN NORADRENALINE.
217867 04-03

REGIONAL DISTRIBUTION OF TYROSINE-HYDROXYLASE, NOREPINEPHRINE AND DOPAMINE WITHIN THE AMYGDALOID COMPLEX OF THE RAT.
217872 04-03

EFFECTS OF THE DOPAMINE-BETA-HYDROXYLASE INHIBITOR FLA-63 ON THE KINETICS OF ELIMINATION OF AMPHETAMINE IN THE RAT.
217881 04-03

EFFECT OF CHRONIC PHENOBARBITAL ADMINISTRATION UPON BRAIN GROWTH OF THE INFANT RAT.
217885 04-03

THE EFFECT OF AMANTADINE ON THE TURNOVER OF CATECHOLAMINES IN THE RAT BRAIN.
217961 04-03

SOME INTERACTIONS BETWEEN FENFLURAMINE AND ANTIDEPRESSANT DRUGS: EFFECTS ON 5-HYDROXYINDOLE CONCENTRATIONS IN RAT BRAIN.
217962 04-03

CHANGES IN THE CONCENTRATIONS OF 5-HYDROXYTRYPTAMINE AND NORADRENALINE IN SIX AREAS OF RAT BRAIN DURING RECOVERY FROM CHRONIC METHYLAMPHETAMINE ADMINISTRATION.
217963 04-03

DEXTROMETHORPHAN INHIBITS 5-HYDROXYTRYPTAMINE UPTAKE BY HUMAN BLOOD PLATELETS AND DECREASES 5-HYDROXYINDOLEACETIC ACID CONTENT IN RAT BRAIN.
217964 04-03

THE EFFECT OF 6-HYDROXYDOPAMINE ON THE TOLERANCE DEVELOPMENT TO THE HYPERTHERMIC EFFECT OF (+) AMPHETAMINE IN THE RAT.
217965 04-03

THE INFLUENCE OF DESIPRAMINE AND AMITRIPTYLINE ON THE ACCUMULATION OF (3H)NORADRENALINE AND ITS TWO MAJOR METABOLITES FORMED FROM (3H)TYROSINE IN THE RAT BRAIN.
217966 04-03

PHYSIOLOGICAL MECHANISMS FOR CARDIAC CONTROL BY NUTRITIONAL INTAKE AFTER EARLY MATERNAL SEPARATION IN THE YOUNG RAT.
218047 04-03

ANTIDEPRESSANT AGENTS AND REVERSAL OF DIURNAL ACTIVITY CYCLES IN THE RAT.
218954 04-04

ACTION OF SEROTONIN MICROINJECTED INTO HYPOTHALAMIC SITES AT WHICH ELECTRICAL STIMULATION PRODUCED AVERSIVE RESPONSES IN THE RAT.
219075 04-04

EFFECTS OF PREVIOUS CURARE IMMOBILIZATION ON PAVLOVIAN CONDITIONED HEART DECELERATIONS IN THE CURARIZED RAT.
219083 04-04

THE METABOLISM OF INDIVIDUAL PHOSPHOLIPID FRACTIONS IN THE RAT BRAIN DURING THIOPENTAL SLEEP AND AMPHETAMINE EXCITATION.
219747 04-03

DETERMINANTS OF AMPHETAMINE PRODUCED STEREOTYPED BEHAVIOR IN THE RAT. (PH.D. DISSERTATION).
220687 04-04

BEHAVIORAL EFFECTS OF LOCAL INJECTION OF 6-HYDROXYDOPAMINE IN THE MEDIAL VENTRAL TEGMENTUM IN THE RAT. POSSIBLE ROLE OF THE MESOLIMBIC DOPAMINERGIC SYSTEM.
220946 04-04

THE BLOOD-BRAIN BARRIER II: DISTRIBUTION KINETICS OF H3-P-HYDROXYAMPHETAMINE IN BRAIN STRUCTURES OF THE RAT AFTER INTRAVENOUS ADMINISTRATION.
220977 04-03

DOES CHRONIC MORPHINE TREATMENT INDUCE A SUPERSENSITIVITY OF DOPAMINE RECEPTORS IN RAT BRAIN
221038 04-03

EFFECTS OF HEROIN ON LEVER PRESSING FOR INTRACRANIAL SELF-STIMULATION, FOOD AND WATER IN THE RAT.
221039 04-04

RELATIONSHIPS BETWEEN TRICYCLIC ANTIDEPRESSANT CONCENTRATIONS, 1-3H-NORAFRENALINE UPTAKE AND CHRONOTROPIC EFFECT IN ISOLATED RAT ATRIA.
221188 04-03

THE EFFECT OF SEROTONIN ON THE FETUS AND FETAL MATERNAL RELATIONS IN THE RAT.
221743 04-03

ROLE OF MONOAMINES IN THE CONTROL BY HORMONES OF SEXUAL RECEPTIVITY IN THE FEMALE RAT.
222263 04-04

CENTRAL NERVOUS SYSTEM PHARMACOLOGY OF CHOLINERGICALLY ELICITED EATING AND DRINKING BEHAVIOR IN THE ALBINO RAT. (PH.D. DISSERTATION).
222638 04-04

FACILITATORY AND INHIBITORY INFLUENCES OF PROGESTERONE, 20ALPHA-HYDROXYPROGESTERONE AND METHYSERGIDE ON THE RECEPTIVE BEHAVIOR OF THE FEMALE RAT. (PH.D. DISSERTATION).
222739 04-04

THE EFFECT OF AUTONOMIC AND PSYCHOTROPIC DRUGS ON ADRENALINE REVERSAL IN THE RAT UTERUS.
222803 04-03

AMPHETAMINE-INDUCED INHIBITION OF TYROSINE HYDROXYLATION IN HOMOGENATES OF RAT CORPUS-STRIATUM.
222813 04-03

A DIRECT EFFECT OF DIBUTYRYL CYCLIC-AMP ON THE DURATION OF NARCOSIS INDUCED BY SEDATIVE, HYPNOTIC, TRANQUILISER AND ANESTHETIC DRUGS IN THE RAT.
222814 04-04

ACCUMULATION OF 4-HYDROXYAMPHETAMINE BY RAT STRIATAL HOMOGENATES.
222822 04-03

THE CORRELATION BETWEEN TRIFTAZINE DISTRIBUTION IN SOME RAT ORGANS AND ITS PHARMACOLOGICAL EFFECTS WITH DIFFERENT TYPES OF ADMINISTRATION.
223016 04-03

REGIONAL DISTRIBUTION OF MONOAMINEOXIDASE ACTIVITY FOR 5-HYDROXYTRYPTAMINE AND TYRAMINE IN THE HYPOTHALAMUS OF THE RAT.
223049 04-03

THE EFFECT OF THE PSYCHOTROPIC AGENTS (CHLORPROMAZINE, MAJEPTIL, TRICEDIL) ON PROTEIN SYNTHESIS IN VARIOUS PORTIONS OF THE RAT BRAIN.
223063 04-03

INTERACTIONS BETWEEN LYSERGIC ACID DIETHYLAMIDE AND DOPAMINE SENSITIVE ADENYLCYCLASE SYSTEMS IN RAT BRAIN.
223175 04-03
THE EFFECT OF NEUROLEPTICS AND ANTIDEPRESSANTS ON THE UPTAKE OF 3H-GAMMA-AMINOBUTYRIC ACID BY ISOLATED NERVE ENDINGS OF THE RAT BRAIN.
224114 04-03
NEONATAL LOCOMOTOR AND LONG-TERM BEHAVIORAL EFFECTS OF D-AMPHETAMINE IN THE RAT.
225077 04-04
PRENATAL MATERNAL D-AMPHETAMINE EFFECTS ON EMOTIONALITY AND AUDIOGENIC SEIZURE SUSCEPTIBILITY OF RAT OFFSPRING.
225079 04-04
THE RELATION BETWEEN CEREBRAL SEROTONIN LEVELS AND CONDITIONED BEHAVIOUR IN THE RAT FOLLOWING THE ADMINISTRATION OF LSD-25 AND UML.
225564 04-04
THE EFFECT OF AMITRIPTYLINE, DESIPRAMINE AND IMIPRAMINE ON THE IN VIVO BRAIN SYNTHESIS OF 3H-NORADRENALINE FROM 3H-L-DOPA IN THE RAT.
225565 04-03

RATE
DIFFERENTIAL EFFECTS ON LEVER CHOICE AND RESPONSE RATE PRODUCED BY D-AMPHETAMINE.
194178 01-04
CHANGES IN ACID-BASE BALANCE, RESPIRATION RATE AND HEART RATE UPON REPEATED ORAL ADMINISTRATION OF BENZOCTAMINE AND DIAZEPAM TO CONSCIOUS DOGS.
197460 01-03
EFFECTS OF CHLORDIAZEPOXIDE UPON DIFFERENTIAL HEART RATE CONDITIONING IN RATS.
201323 02-03
THE EFFECT OF VARYING THE DOSAGE OF SODIUM PENTOBARBITAL ON THE BARPRESS RATE OF RATS.
201843 02-04
MEASUREMENT OF ACETYLCHOLINE TURNOVER RATE IN DISCRETE AREAS OF RAT BRAIN.
202465 02-06
HEART RATE AND GALVANIC SKIN RESPONSE VARIATIONS DURING THE REM AND NON-REM SLEEP PHASES IN MAN.
205443 02-13
THE EFFECT OF CLOZAPINE AND ACETYLCHOLINE TURNOVER RATE IN RAT STRIATUM. (UNPUBLISHED PAPER).
207500 03-03
EXPLICIT SOLUTION TO PHARMACOKINETIC FIRST-ORDER RATE CONSTANTS OF MAPROTILIN.
208919 03-17
APPLICATION OF PRINCIPLES OF STEADY-STATE KINETICS TO THE IN VIVO ESTIMATION OF ACETYLCHOLINE TURNOVER RATE IN MOUSE BRAIN.
210885 03-06
STRUCTURE-ACTIVITY RELATIONSHIPS BETWEEN META-SUBSTITUTED N-ETHYLAMPHETAMINES AND ISOLATED GUINEA-PIG ATRIAL RATE.
210887 03-03
MARIJUANA: HEART RATE AND EEG RESPONSE.
210895 03-01
PRELIMINARY STUDY OF A BETA-BLOCKER (PINDOLOL) IN THREE SCHIZOPHRENICS AND THREE NONPSYCHOTIC PSYCHIATRIC PATIENTS: DIFFERENTIAL SENSITIVITY IN HEART RATE.
212164 03-13
OPERANT CONDITIONING OF HEART RATE IN CURARIZED RATS: HEMODYNAMIC CHANGES.
213275 03-04
BLOOD PRESSURE AND HEART RATE RESPONSES EVOKED BY D- AND L-AMPHETAMINE IN THE PITHED RAT PREPARATION.
215687 04-03
RATE DEPENDENT EFFECTS OF DRUGS. II. EFFECTS OF SOME MAJOR TRANQUILIZERS ON MULTIPLE FIXED-RATIO, FIXED-INTERVAL SCHEDULE PERFORMANCE.
217458 04-04
PHARMACOLOGICAL - CLINICAL INTEREST IN THE STUDY OF 24 HOUR LITHIUM RATE CYCLES.
221667 04-09
TRICYCLIC ANTIDEPRESSANTS: EFFECTS ON THE FIRING RATE OF BRAIN NORADRENERGIC NEURONS.
222805 04-03
EFFECT OF ACTH4-10 ON THE RATE OF SYNTHESIS OF (3H)CATECHOLAMINES IN THE BRAINS OF INTACT, HYPOPHYSECTOMIZED AND ADRENALECTOMIZED RATS.
223050 04-03

RATE-FREE
COMPARATIVE INVOLVEMENT OF DOPAMINE AND NORADRENALINE IN RATE-FREE SELF-STIMULATION IN SUBSTANTIA-NIGRA, LATERAL HYPOTHALAMUS, AND MESENCEPHALIC CENTRAL GRAY.
193303 01-03

RATES
CHROMOSOMAL ABERRATION RATES AND INTRAVENOUSLY GIVEN DIAZEPAM: A NEGATIVE STUDY.
195949 01-13
DRUG AND SOCIOTHERAPY IN THE AFTERCARE OF SCHIZOPHRENIC PATIENTS: II. TWO-YEAR RELAPSE RATES.
199625 02-08
A DOUBLE-BLIND STUDY ON THE EFFECTS OF PIRACETAM UPON PERCEPTUAL AND PSYCHOMOTOR PERFORMANCE AT VARIED HEART RATES IN PATIENTS TREATED WITH ARTIFICIAL PACEMAKERS.
201328 02-13
CODEINE AND COCAINE REINFORCED RESPONDING IN RHESUS MONKEYS: EFFECTS OF DOSE ON RESPONSE RATES UNDER A FIXED-RATIO SCHEDULE.
202667 02-04
EFFECT OF PHENOBARBITAL ADMINISTRATION ON ETHANOL OXIDIZING ENZYMES AND ON RATES OF ETHANOL DEGRADATION.
204386 02-03
EFFECTS OF D-AMPHETAMINE AND SECOBARBITAL ON KEY PRESS RATES IN NORMAL HUMANS.
210879 03-14
DIFFERENTIAL RATES OF INCREASE IN PONTINE TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE ACTIVITIES AFTER RESERPINE.
217854 04-03
CHIRAL 1,4 BENZODIAZEPINE: VII. CYCLIZATION RATES OF 2-N-ALPHA-AMMONIUMACYL-AMINO-5-CHLOROBENZOPHENONES IN THE CHIRAL 1,4 BENZODIAZEPIN-2-ONES.
221858 04-01

RATING
THE USE OF ANALOGUE SCALES IN RATING SUBJECTIVE FEELINGS.
193851 01-14
RATING THE BEHAVIORAL EFFECTS OF AMPHETAMINE.
197863 01-04

RATIO
INTRA-EXTRACELLULAR LITHIUM RATIO: CLINICAL AND EXPERIMENTAL FINDINGS ON THROMBOCYTES AND ERYTHROCYTES.
204393 02-13

RATIONAL
RATIONAL USE OF PSYCHOTROPIC DRUGS. II. ANTIANXIETY AGENTS.
193192 01-17
A SIMPLIFIED GUIDE TO THE RATIONAL USE OF PSYCHOTROPIC DRUGS.
196231 01-17
RATIONAL USE OF PSYCHOTROPIC DRUGS. III. MAJOR TRANQUILIZERS.
198823 02-17
RATIONAL USE OF PSYCHOTROPIC DRUGS. IV. ANTIDEPRESSANTS.
200584 02-09

RATIOS
THE LEVELS OF LITHIUM IN SERUM AND IN RED BLOOD CELLS AND ITS RATIOS IN MANIC-DEPRESSIVE PATIENTS.
205607 03-09
RELATIONSHIPS AMONG CLINICAL RESPONSE, EPS, AND PLASMA CPZ AND CPZ METABOLITE RATIOS.
224831 04-08

RATS
SUPPRESSION OF CONDITIONED HYPERTHERMIC RESPONSE BY L- AND D-OXPRENOLOL IN RATS.
192937 01-03
DRUG-INDUCED ROTATION IN RATS AFTER UNILATERAL INTRACEREBRAL INJECTION OF 5,6 DIHYDROXYTRYPTAMINE (5-6-DHT).
192940 01-03
SEROTONIN AND THE AVERSIVE THRESHOLD IN RATS.
193157 01-04
ABSENCE OF TOLERANCE TO THE HYPOTENSIVE EFFECTS OF DELTA9-TETRAHYDROCANNABINOL IN HYPERTENSIVE RATS.
193419 01-03
EFFECT OF ACUTE AND CHRONIC DIELDRIN EXPOSURE ON BRAIN BIOGENIC AMINES OF MALE AND FEMALE RATS.
193428 01-03
DIFFERENTIAL EFFECTS OF D-AMPHETAMINE ON BRAIN ACETYLCHOLINE IN YOUNG, ADULT, AND GERIATRIC RATS.
193457 01-03
THE ANTAGONISTIC EFFECTS OF ASPARTIC ACID ON SOME EFFECTS OF MORPHINE ON RATS.
193458 01-03
BEHAVIOURAL INTERACTIONS BETWEEN IMIDAZOLEACETIC ACID AND GAMMA-HYDROXYBUTYRIC ACID IN RATS AND MICE.
193545 01-04
EFFECT OF TWO DOPAMINE RECEPTOR BLOCKERS ON A SEROTONIN MEDIATED BEHAVIORAL SYNDROME IN RATS.
193548 01-04
EFFECTS OF L-DOPA ON THE HETEROSEXUAL COPULATORY BEHAVIOR OF MALE RATS.
193549 01-04
A PHARMACOLOGICAL AND NEUROANATOMICAL ANALYSIS OF DOPAMINERGIC AND NORADRENERGIC PATHWAYS INVOLVED IN SELF-STIMULATION IN RATS. (PH. D. DISSERTATION).
193582 01-04
DIFFERENTIAL EFFECTS OF EPINEPHRINE AND PROPRANOLOL ON SHUTTLEBOX AVOIDANCE LEARNING IN RATS OF DIFFERENT AGES. (PH.D. DISSERTATION).
193745 01-04

EFFECTS OF CENTRAL ACTING DRUGS AND ERGOT DERIVATIVES ON PROLACTIN AND GROWTH HORMONE SECRETION, ON GROWTH OF PITUITARY AND MAMMARY TUMORS AND ON REPRODUCTION IN OLD RATS. (PH.D. DISSERTATION).
194571 01-03

DOSE EFFECTS OF CHLORDIAZEPOXIDE UPON HABITUATION OF OPEN-FIELD BEHAVIOR IN WHITE RATS.
194736 01-04

LONG-TERM LITHIUM ADMINISTRATION TO RATS. LITHIUM AND SODIUM DOSAGE AND ADMINISTRATION, AVOIDANCE OF INTOXICATION, POLYURIC CONTROL RATS.
195042 01-03

BRAIN ACETYLCHOLINE AND CHOLINESTERASE: EFFECT OF PHENOTHIAZINES AND PHYSOSTIGMINE INTERACTION IN RATS.
195046 01-03

EFFECT OF INDOLEALKYLAMINE MANIPULATIONS ON LOCOMOTOR ACTIVITY IN RATS.
195087 01-04

THE EFFECTS OF HASHISH INJECTIONS ON FEEDING AND DRINKING IN RATS.
195113 01-04

EFFECTS OF WITHDRAWAL FROM CHRONIC AMPHETAMINE ADMINISTRATION ON ACTIVITY LEVELS OF ALBINO RATS.
195223 01-04

EFFECTS OF PSYCHOTROPIC DRUGS ON HYPEREMOTIONALITY OF RATS WITH BILATERAL ABLATIONS OF THE OLFACTORY BULBS AND OLFACTORY TUBERCLES.
195231 01-04

EFFECT OF LITHIUM ON SERUM TRYPTOPHAN AND BRAIN SEROTONIN IN RATS.
195232 01-03

BRAIN SEROTONIN METABOLISM IN LITHIUM TREATED RATS.
195235 01-03

CHANGES IN BRAIN CONCENTRATION OF BIOGENIC AMINES AND THE ANTINOCICEPTIVE EFFECT OF MORPHINE IN RATS.
195246 01-03

THE EFFECT OF CHLORPROMAZINE AND IMIPRAMINE ON THE AVERSIVE THRESHOLD OF RATS.
195294 01-04

EFFECTS OF D-AMPHETAMINE ON ACQUISITION OF LEVERPRESS SIDMAN AVOIDANCE IN RATS.
195305 01-04

PROGRAMMED SELF-ADMINISTRATION OF POTENTIALLY ADDICTIVE DRUGS IN YOUNG RATS AND ITS EFFECTS ON LEARNING.
195430 01-04

EFFECTS OF REPEATED DOSES OF 1-DELTA8-TRANS-TETRAHYDROCANNABINOL ON SCHEDULE-CONTROLLED TEMPORALLY SPACED RESPONDING OF RATS.
195431 01-04

THE INEFFECTIVENESS OF DESIPRAMINE PRETREATMENT ON BEHAVIORAL EFFECTS OF 6-HYDROXYDOPAMINE IN NIALAMIDE PRETREATED RATS.
195434 01-04

PHYSOSTIGMINE ATTENUATION OF DELTA9-TETRAHYDROCANNABINOL INDUCED HYPERTHERMIA IN RATS.
195539 01-03

POTENTIATION OF AMYGDALOID KINDLING AND METRAZOL-INDUCED SEIZURES BY 6-HYDROXYDOPAMINE IN RATS.
195907 01-03

THE EFFECTS OF SODIUM AMOBARBITAL ON ODOR-BASED RESPONDING IN RATS.
195995 01-04

SOCIAL INTERACTION BETWEEN DRUGGED AND UNDRUGGED RATS.
196206 01-04

PROLONGED PENTOBARBITAL SLEEPING TIME IN ADJUVANT INDUCED POLYARTHRITIC RATS.
196228 01-04

AGE RELATED ENHANCED RESPONSIVENESS TO CENTRAL NERVOUS SYSTEM DRUGS IN RATS. (PH.D. DISSERTATION).
196256 01-03

THE INFLUENCE OF CEREBROLYSINE ON HIGHER NERVOUS ACTIVITY IN ADULT RATS.
196758 01-04

RELATIONSHIP BETWEEN ANALGESIC ACTION OF PETHIDINE AND ITS EFFECT ON THE BRAIN 5-HYDROXYTRYPTAMINE CONCENTRATION IN THE RATS OF DIFFERENT AGE.
196782 01-03

ALTERATIONS IN THE TURNOVER OF BRAIN NOREPINEPHRINE AND DOPAMINE IN ALCOHOL DEPENDENT RATS.
196805 01-03

ON THE BIOTRANSFORMATION OF AMPHETAMINE IN ADULT AND OLD RATS.
197292 01-03

CATALEPSY, STEREOTYPED BEHAVIOUR AND STRIATAL HOMOVANILLIC ACID CONTENT IN RATS TREATED WITH METHADONE.
197299 01-03

THE SENSITIVITY OF BARBITONE DEPENDENT AND WITHDRAWN RATS TO TREMORGENIC DRUGS.
197303 01-03

EFFECT OF 6-HYDROXYDOPAMINE ON THE LEVEL OF THE CATECHOLAMINES IN THE BRAIN OF DEVELOPING RATS.
197449 01-03

SEIZURES IN RATS INDUCED BY PINEALECTOMY: INFLUENCE OF DIAZEPAM, CHLORDIAZEPOXIDE, AND DIPHENYLHYDANTOIN AND PINEAL SUBSTANCES.
197465 01-03

ENHANCED LOCOMOTOR ACTIVITY FOLLOWING AMPHETAMINE IN MOUSE-KILLING RATS.
197482 01-04

INHIBITORY EFFECT OF AMPHETAMINE, L-DOPA AND APOMORPHINE ON MORPHINE-INDUCED BEHAVIOURAL EXCITATION OF RATS.
197483 01-04

THE EFFECTS OF LSD, PSILOCYBIN, HARMALINE AND AMPHETAMINE ON THE BODY TEMPERATURE OF P-CHLOROPHENYLALANINE PRETREATED RATS.
197484 01-03

PREVENTION OF SEROTONIN ABORTION BY SEROTONIN ANTAGONISTS IN RATS.
197489 01-03

PHARMACOLOGICAL STUDIES ON TETRABENAZINE-INDUCED EXCITED BEHAVIOUR OF RATS PRETREATED WITH AMPHETAMINE OR NIALAMIDE.
197490 01-04

RELATIONSHIP BETWEEN THE CHANGES ON BLOOD PRESSURE RESPONSE AND THE CARDIAC CATECHOLAMINE LEVEL AFTER SINGLE AND REPEATED ADMINISTRATIONS OF TYRAMINE AND METHAMPHETAMINE IN RATS.
197491 01-03

THE EFFECT OF 6-HYDROXYDOPAMINE ADMINISTRATION TO NEONATAL RATS ON SOME ENDOCRINE AND BEHAVIORAL PARAMETERS.
197498 01-03

EFFECTS OF PSYCHOTROPIC DRUGS ON THE EMOTIONAL REACTIVITY OF RATS.
197499 01-04

MEASUREMENT OF SEROTONIN TURNOVER IN RATS WITH THE HELP OF MONOAMINEOXIDASE INHIBITORS.
197580 01-03

THE EFFECTS OF SOME CNS DEPRESSANTS ON RATS EXPOSED TO IONIZING IRRADIATION.
197581 01-03

CADMIUM-INDUCED POTENTIATION OF HEXOBARBITAL SLEEP TIME IN RATS.
197684 01-04

EFFECT OF PROLONGED LITHIUM INGESTION ON GLUCAGON AND PARATHYROID HORMONE RESPONSES IN RATS.
197744 01-03

CENTRAL ACTION OF ANOREXIC AGENTS: EFFECTS OF AMPHETAMINE AND FENFLURAMINE IN RATS WITH LATERAL HYPOTHALAMIC LESIONS.
197865 01-04

EFFECT OF SEROTONIN ON WATER INTAKE AND RENIN ANGIOTENSIN SYSTEM IN RATS.
197963 01-03

TURNOVER OF BIOGENIC AMINES AFTER ACUTE AND CHRONIC MORPHINE TREATMENT IN RATS.
197974 01-03

TASTE PHENOMENA INFLUENCES ON STIMULATION OF DEPRIVATION INDUCED FLUID CONSUMPTION OF RATS.
197991 01-03

EFFECTS OF PHYSOSTIGMINE ON THE ACCURACY AND ACTIVITY OF DISCRIMINATION BEHAVIOUR IN RATS.
197995 01-04

INTRACRANIAL SELF-STIMULATION IN RATS AS A FUNCTION OF VARIOUS STIMULUS PARAMETERS: V. INFLUENCE OF COCAINE ON MEDIAL FOREBRAIN BUNDLE STIMULATION WITH MONOPOLAR ELECTRODES.
198223 02-03

RESISTANCE TO EXTINCTION OF AN AVOIDANCE RESPONSE IN RATS FOLLOWING THE ADMINISTRATION OF CHLORDIAZEPOXIDE (LIBRIUM) AND DIAZEPAM (VALIUM).
198226 02-04

ON THE METABOLISM OF A NEW ANTIDEPRESSANT, AZAPHEN, IN RATS.
198484 02-01

THE EFFECT OF L-DOPA ON THE DEVELOPMENT OF RESERPINE INDUCED PARKINSONISM AND CATECHOLAMINE METABOLISM IN RATS.
198486 02-03

THE EFFECT OF DIFFERENTIAL SALINE AND CYCLOHEXIMIDE STATES ON THE ACQUISITION OF A SPATIAL REVERSAL TASK IN MICE AND RATS. (PH.D. DISSERTATION
198897 02-04

ACTION OF RESERPINE IN MORPHINE TOLERANT RATS: ABSENCE OF AN ANTAGONISM OF CATECHOLAMINE DEPLETION.
199277 02-03

SYMPATHOMIMETIC AMINES AND GASTRIC SECRETION IN RATS.
199622 02-03

LITHIUM INDUCED LOSS OF BODY SODIUM AND THE DEVELOPMENT OF SEVERE INTOXICATION IN RATS.
199623 02-03

REDUCED BEHAVIOURAL EFFECTS OF INTRAHIPPOCAMPALLY ADMINISTERED CARBACHOL IN RATS WITH LOW CHOLINESTERASE ACTIVITY.
199956 02-04

THE INTERACTION OF DOPAMINE ANTAGONISTS AND AMANTADINE HYDROCHLORIDE ON THE ACQUISITION OF THE CONDITIONED AVOIDANCE RESPONSE IN RATS.
199959 02-04

THE ROLE OF BRAIN DOPAMINE IN THE HYPERACTIVITY SYNDROME PRODUCED BY INCREASED 5-HYDROXYTRYPTAMINE SYNTHESIS IN RATS.
199960 02-04

INHIBITORY ROLE OF DOPAMINE AND 5-HYDROXYTRYPTAMINE IN THE SEXUAL BEHAVIOUR OF FEMALE RATS.
199968 02-04

ACUTE AND CHRONIC EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON FOOD INTAKE BY RATS.
200043 02-04

DECREASED ANTINOCICEPTIVE EFFECT OF MORPHINE IN RATS TREATED INTRAVENTRICULARLY WITH PROSTAGLANDIN-E1.
200045 02-03

ROLE OF CATECHOLAMINERGIC MECHANISMS IN THE EXPRESSION OF THE MORPHINE ABSTINENCE SYNDROME IN RATS.
200053 02-03

THE EFFECTS OF CHLORPROMAZINE, ATROPINE, MORPHINE AND PENTOBARBITAL ON INDUCED GASTRIC ULCERATION IN RATS. (PH.D. DISSERTATION).
200405 02-02

THE INFLUENCE OF CATECHOLAMINES, SEROTONIN, AND SOME AMINO ACIDS ADMINISTERED INTO THE AMYGDALOID COMPLEX ON CONDITIONED REFLEXES OF AVOIDANCE AND MOTOR ACTIVITY IN RATS.
200566 02-03

AGGRESSIVE BEHAVIORS INDUCED BY CHRONIC ADMINISTRATION OF THEOPHYLLINE, WITH PARTICULAR REFERENCE TO ALTERATIONS IN BEHAVIORS OF IMMATURE RATS.
200748 02-04

CONDITIONED SUPPRESSION OF MOUSE-KILLING IN RATS FOLLOWING RADIATION OR LITHIUM CHLORIDE INJECTIONS. (PH.D. DISSERTATION).
201153 02-04

LITHIUM TREATMENT REDUCES MORPHINE SELF-ADMINISTRATION IN ADDICT RATS.
201293 02-04

A COMPARATIVE STUDY OF D- AND L-AMPHETAMINE ON THE OPEN-FIELD PERFORMANCE OF RATS.
201322 02-04

EFFECTS OF CHLORDIAZEPOXIDE UPON DIFFERENTIAL HEART RATE CONDITIONING IN RATS.
201323 02-03

PHARMACOLOGICAL MODULATION OF PHOTICALLY EVOKED AFTERDISCHARGE PATTERNS IN HOODED LONG-EVANS RATS.
201409 02-03

NEURONAL ACTIVITY OF NUCLEUS CAUDATES AND THALAMUS DURING BARBITURATE SPINDLES IN RATS.
201479 02-03

THE EFFECT OF VARYING THE DOSAGE OF SODIUM PENTOBARBITAL ON THE BARPRESS RATE OF RATS.
201843 02-04

EFFECTS ON THE ACQUISITION OF CONDITIONED AVOIDANCE RESPONSES AND SEIZURE THRESHOLD IN THE OFFSPRING OF AMPHETAMINE TREATED GRAVID RATS.
202722 02-05

MORPHINE-INDUCED STEREOTYPIC BEHAVIOR IN RATS.
202740 02-04

DEFICIENT BRIGHTNESS DISCRIMINATION ACQUISITION PRODUCED BY DAILY INTRACRANIAL INJECTIONS OF PENICILLIN IN RATS.
202758 02-04

LIPIDOSIS LIKE ALTERATIONS IN SPINAL CORD AND CEREBELLAR CORTEX OF RATS TREATED WITH CHLORPHENTERMINE OR TRICYCLIC ANTIDEPRESSANTS.
202767 02-03

INTRASPECIES AGGRESSION IN RATS: EFFECTS OF D-AMPHETAMINE AND CHLORDIAZEPOXIDE.
202768 02-04

ACTION OF A NEW PSYCHOTROPIC DRUG (SULPIRIDE) ON AVOIDANCE BEHAVIOR IN RATS.
202770 02-04

INFLUENCE OF MIDBRAIN RAPHE LESION ON SOME PHARMACOLOGICAL AND BIOCHEMICAL EFFECTS OF APOMORPHINE IN RATS.
202771 02-03

THE EFFECTS OF L-DOPA, CLONIDINE, AND APOMORPHINE ON THE ACOUSTIC STARTLE REACTION IN RATS.
202773 02-04

6-HYDROXYDOPAMINE LESIONS OF OLFACTORY TUBERCLES AND CAUDATE NUCLEI: EFFECT ON AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR IN RATS.
202788 02-04

EFFECTS OF PSYCHOTROPIC DRUGS ON HYPOTHALAMIC SELF-STIMULATION BEHAVIOR IN RATS.
202802 02-04

A PRELIMINARY REPORT ON THE ACTION OF IMIPRAMINE AND ANTIPARKINSONIAN AGENTS ON THE OPEN-FIELD BEHAVIOUR OF RATS.
202803 02-04

RIGIDITY IN RATS DUE TO ANEMIC DECEREBRATION AND THE EFFECT OF CHLORPROMAZINE.
202804 02-03

EFFECTS OF DELTA8-THC ON DISSOCIATION OF CONDITIONED AVOIDANCE RESPONDING IN TOLERANT AND NONTOLERANT RATS.
202969 02-04

EFFECTS OF NICOTINE ON SPONTANEOUS LOCOMOTOR ACTIVITY IN RATS HAVING HIGH AND LOW BASAL ACTIVITY LEVELS.
202980 02-04

EFFECTS OF AMPHETAMINE AND AND CHLORPROMAZINE UPON OBSERVING RESPONSES IN RATS. (PH.D. DISSERTATION).
203166 02-04

AMPHETAMINE-INDUCED CHANGES IN STRIATAL DOPAMINE AND ACETYLCHOLINE LEVELS AND RELATIONSHIP TO ROTATION (CIRCLING BEHAVIOR) IN RATS.
205432 02-04

CARDIOTOXIC EFFECTS OF TRICYCLIC ANTIDEPRESSANTS IMIPRAMINE, AMITRIPTYLINE AND DOSULEPIN (PROTHIADEN-SPOFA) IN AN ACUTE EXPERIMENT IN RATS.
205597 02-15

THE EFFECT OF MAPROTILIN ON BRAIN SEROTONIN METABOLISM IN RATS.
205604 03-03

EFFECTS OF SCOPOLAMINE ON THE EEG OF CORTEX AND HIPPOCAMPUS DURING SPONTANEOUS BEHAVIOUR IN RATS.
205628 03-04

SOME FACTORS DETERMINING THE RESPONSE OF SEPTAL RATS TO ANTICHOLINERGIC DRUGS.
205632 03-03

SUPPRESSION OF MOUSE-KILLING AND APOMORPHINE-INDUCED SOCIAL AGGRESSION IN RATS BY LOCAL ANESTHESIA OF THE MYSTACIAL-VIBRISSAE.
206714 03-04

ELECTROPHYSIOLOGICAL AND BEHAVIORAL REACTIVITY TO PHOTIC STIMULI FOLLOWING SEPTAL LESIONS AND PHARMACOLOGICAL TREATMENTS IN RATS.
206724 03-04

ROLE OF PITUITARY ADRENOCORTICAL SYSTEM IN MEDIATING AVOIDANCE BEHAVIOR OF RATS WITH SEPTAL LESIONS.
206739 03-04

EFFECTS OF HIPPOCAMPAL MICROINJECTIONS OF D-AMPHETAMINE AND SCOPOLAMINE ON ACTIVE AVOIDANCE BEHAVIOR IN RATS.
206741 03-04

TIME-DEPENDENT CHANGES IN AMPHETAMINE SELF-ADMINISTRATION FOLLOWING FRONTAL CORTEX ABLATIONS IN RATS.
206747 03-04

LONG-TERM TRIAL OF FLUPHENAZINE DECANOATE AND FLUPENTHIXOL DECANOATE FOR CATALEPTIC ACTIVITY AND EFFECT ON MOTOR ACTIVITY IN RATS.
206787 03-04

THE DISPOSITION OF BUTRIPTYLINE IN RATS, DOGS AND MAN.
206806 03-13

THE EFFECT OF DIAZEPAM AND NITRAZEPAM ON INTRACELLULAR AND EXTRACELLULAR DISTRIBUTION OF SODIUM AND POTASSIUM IONS IN INDIVIDUAL STRUCTURES OF RATS BRAINS.
207199 03-03

THE INFLUENCE OF ETHYMISOL ON THE ACTIVITY OF ADENYLCYCLASE AND 3,5 AMP-PHOSPHODIESTERASE OF RATS BRAINS.
208973 03-03

AN ANALYSIS OF MONOAMINERGIC MECHANISMS OF THE DORSAL HIPPOCAMPUS WHICH MEDIATE THE CONDITIONED ESCAPE REACTION IN RATS.
208991 03-04

ENDOCRINE EFFECTS OF CHRONIC ADMINISTRATION OF PSYCHOACTIVE DRUGS TO PREPUBERAL MALE RATS. I: DELTA9-TETRAHYDROCANNABINOL.
209840 03-03

EFFECTS OF OVERTRAINING UPON DRUG STATE DEPENDENCY IN DISCRIMINATION LEARNING IN WHITE RATS.
209866 03-04

D-AMPHETAMINE AND THE SENSORY ROLE OF A RATS TAIL IN THERMOREGULATION OR WHAT THE RATS TAIL TELLS THE RATS BRAIN.
209961 03-03

RECOVERY OF FUNCTION AND CHANGES IN SENSITIVITY TO AMPHETAMINE FOLLOWING CAUDATE LESIONS IN RATS.
209962 03-03

MORPHINE-DEPENDENT RATS: BLOCKADE OF PRECIPITATED ABSTINENCE BY TETRAHYDROCANNABINOL.
210221 03-13

PHARMACOLOGICAL MANIPULATIONS OF BRAIN CATECHOLAMINES AND THE AGGRESSIVE BEHAVIOR INDUCED BY MARIHUANA IN REM SLEEP DEPRIVED RATS.
210325 03-04

EFFECT OF STRESS AND DIAZEPAM TREATMENT DURING INFANCY ON THE CORTICOSTERONE REGULATION AND ANDROGENIC ACTIVITY IN ADULT MALE RATS.
210348 03-03

STIMULATION OF SEXUAL BEHAVIOUR IN RATS BY A BENZODIOXANE DERIVATIVE.
210351 03-04

QUANTITATIVE RELATIONSHIP OF CATECHOLAMINE CONTENT AND HISTOFLUORESCENCE IN BRAIN OF RATS.
210660 03-03

THE EFFECTS OF PSYCHOMOTOR STIMULANTS ON STEREOTYPY AND LOCOMOTOR ACTIVITY IN SOCIALLY DEPRIVED AND CONTROL RATS.
210666 03-04

THE EFFECT OF SODIUM CHLORIDE ON KIDNEY FUNCTION IN RATS WITH LITHIUM INTOXICATION.
210696 03-03

SOME PHARMACOLOGICAL ACTIONS OF 2,5 DIMETHOXY-4-ETHYLAMPHETAMINE (DOET) IN RATS AND MICE.
210747 03-03

CANNABIS AND AMPHETAMINE-INDUCED STEREOTYPY IN RATS.
210752 03-04

NEONATAL 6-HYDROXYDOPAMINE TREATMENT: NORADRENALINE LEVELS AND IN VITRO 3H-CATECHOLAMINE SYNTHESIS IN DISCRETE BRAIN REGIONS OF ADULT RATS.
210759 03-03

EFFECTS OF DELTA9-TETRAHYDROCANNABINOL AND CANNABINOL ON OPERANT PERFORMANCE IN RATS.
210785 03-04

THE EFFECT OF ANTIDEPRESSANTS ON UNIT ACTIVITY IN THE MIDBRAIN RAPHE OF RATS.
210789 03-03

SOME EVIDENCE FOR LONG-TERM MEMORY RETENTION BY OROTIC ACID IN RATS BAR PRESSING FOR WATER.
210790 03-04

EFFECTS OF WATER DEPRIVATION IN RATS WITH POLYDIPSIA AND POLYURIA DUE TO LONG-TERM ADMINISTRATION OF LITHIUM.
210833 03-05

6-CHLORO-2-AMINOTETRALIN, A RIGID CONFORMATIONAL ANALOG OF 4-CHLOROAMPHETAMINE: PHARMACOLOGIC PROPERTIES OF IT AND RELATED COMPOUNDS IN RATS.
210870 03-02

LACK OF TOLERANCE TO THE BRADYCARDIC EFFECT OF DELTA9-TRANS-TETRAHYDROCANNABINOL IN RATS.
210873 03-05

THE EFFECT OF DOPAMINE AND NORADRENALINE ANTAGONISTS ON AMPHETAMINE-INDUCED LOCOMOTOR ACTIVITY IN MICE AND RATS.
210894 03-04

A FURTHER STUDY ON THE EFFECT OF PHYSOSTIGMINE ON MEMORY IN RATS.
210916 03-04

EFFECT OF PHENOBARBITAL ON THE METABOLISM AND SEROTONIN DEPLETING ACTION OF 4-CHLORODIFLUOROAMPHETAMINE IN RATS.
210922 03-03

EFFECT OF MIDBRAIN RAPHE LESION AND OF 6-HYDROXYDOPAMINE ON THE ANTINOCICEPTIVE ACTION OF BUPRENORPHINE IN RATS.
210923 03-03

METABOLISM OF DELTA1-TETRAHYDROCANNABINOL BY RATS TOLERANT TO CANNABIS.
211100 03-03

POTENTIATION OF THE L-5-HYDROXYTRYPTOPHAN INDUCED ELEVATION OF PLASMA CORTICOSTERONE LEVELS IN RATS BY A SPECIFIC INHIBITOR OF SEROTONIN UPTAKE.
211104 03-03

HYPOTHALAMIC SELF-STIMULATION IN RATS FOLLOWING IMMUNOSYMPATHECTOMY OR CENTRAL NERVE GROWTH FACTOR ANTISERUM INJECTION.
211512 03-04

EFFECTS OF D-AMPHETAMINE AND PRESESSION SHOCKS ON SIDMAN AVOIDANCE WITH A TONE IN RATS. (PH.D. DISSERTATION).
212677 03-04

THE ROLE OF SEROTONIN IN THE SEPTAL BEHAVIOR SYNDROME OF RATS. (PH.D. DISSERTATION).
213128 03-03

OPERANT CONDITIONING OF HEART RATE IN CURARIZED RATS: HEMODYNAMIC CHANGES.
213275 03-04

INCREASED LEVEL PRESSING FOR AMPHETAMINE AFTER PIMOZIDE IN RATS: IMPLICATIONS FOR A DOPAMINE THEORY OF REWARD.
213350 03-04

THE ROLE OF MONOAMINES IN AVOIDANCE BEHAVIOUR IN RATS.
213422 04-04

THE INFLUENCE OF ACTH4-10 ON HIPPOCAMPAL AND THALAMIC SYNCHRONISED ACTIVITY IN RATS.
213430 04-03

THE EFFECTS OF PSYCHOMOTOR STIMULATION ON STEREOTYPY AND LOCOMOTOR ACTIVITY IN SOCIALLY DEPRIVED AND CONTROL RATS.
213433 04-03

ROLE OF THE STRIO-PALLIDAL SYSTEM AND MOTOR CORTEX IN INDUCED CIRCUS MOVEMENTS IN RATS AND CATS.
213450 04-03

EFFECT OF LITHIUM ON GLUCAGON STIMULATED CYCLIC-AMP EXCRETION IN RATS.
213481 04-03

THE EFFECT OF LITHIUM ON BLOOD PRESSURE AND ON PLASMA RENIN SUBSTRATE AND RENIN IN RATS.
213483 04-03

THE BEHAVIORAL EFFECTS OF L-METHIONINE AND RELATED COMPOUNDS IN RATS AND MICE.
213528 04-04

APOMORPHINE-INDUCED ROTATION IN NORMAL RATS AND INTERACTION WITH UNILATERAL CAUDATE LESIONS.
214012 04-04

THE EFFECTS OF AMPHETAMINE, IMIPRAMINE AND ICI-58834 (VIVALAN), A POTENTIAL ANTIDEPRESSANT, ON UNCONDITIONED BEHAVIOUR IN RATS.
214016 04-04

COMPARATIVE ANALGESIC ACTIVITY OF VARIOUS NATURALLY OCCURRING CANNABINOIDS IN MICE AND RATS.
214017 04-04

BLOCKING OF STRESS BY PENTOBARBITAL MORPHINE AS RELATED TO TRAINING AND AGE OF RATS.
214056 04-04

THE EFFECT OF ACTH AND DIAZEPAM, ADMINISTERED TO INFANT RATS ON THE BODY GROWTH CURVE AND SOME ENDOCRINE PARAMETERS MEASURED IN ADULT AGE.
215066 04-03

THE EFFECT OF SODIUM GAMMA-HYDROXYBUTYRATE ON THE CNS OF RATS AND MICE.
215069 04-03

THE BIPHASIC EFFECT OF SMALL DOSES OF TRANYLCYPROMINE ON THE SPONTANEOUS MOTOR ACTIVITY AND LEARNED CONDITIONED BEHAVIOUR IN RATS.
215665 04-04

ACTIONS OF ACETYLCHOLINE AND ATROPINE ON CEREBRAL CORTICAL NEURONS IN CHRONICALLY MORPHINE TREATED RATS.
215733 04-03

A RELATION BETWEEN DRUG CONCENTRATIONS IN BRAIN AND STRIATAL HOMOVANILLIC ACID LEVELS IN CHLORPROMAZINE TREATED RATS.
215734 04-03

NEUROLEPTIC ACTION OF CLOZAPINE INJECTED INTO VARIOUS BRAIN AREAS IN RATS.
217451 04-04

CONDITIONED LEARNING IN YOUNG RATS BORN OF DRUG ADDICTED PARENTS AND RAISED ON ADDICTIVE DRUGS.
217465 04-04

THE INHIBITION OF A AND B FORMS OF MAO IN THE PRODUCTION OF A CHARACTERISTIC BEHAVIOURAL SYNDROME IN RATS AFTER L-TRYPTOPHAN LOADING.
217471 04-03

EFFECTS OF ANTAGONISTS UPON LOCOMOTOR STIMULATION INDUCED BY INJECTION OF DOPAMINE AND NORADRENALINE INTO THE NUCLEUS-ACCUMBENS OF NIALAMIDE PRETREATED RATS.
217475 04-04

ORAL DELTA9-TETRAHYDROCANNABINOL TOXICITY IN RATS TREATED UP TO SIX MONTHS.
217518 04-05

DIFFERENTIAL NEUROCHEMISTRY AND TEMPORAL PATTERN IN RATS TREATED ORALLY WITH DELTA9-TETRAHYDROCANNABINOL FOR PERIODS UP TO SIX MONTHS.
217519 04-04

DIETARY TRYPTOPHAN AND THE SELECTION OF ETHYL ALCOHOL IN DIFFERENT STRAINS OF RATS.
217520 04-03

THE EFFECTS OF NICOTINE ON TWO-WAY AVOIDANCE CONDITIONING IN BIDIRECTIONALLY SELECTED STRAINS OF RATS.
217525 04-04

DOPAMINERGIC MEDIATION OF THE INTEROCEPTIVE CUE PRODUCED BY D-AMPHETAMINE IN RATS.
217531 04-04

THE EFFECTS OF CHRONIC CANNABIS TREATMENT UPON BRAIN 5-HYDROXYTRYPTAMINE, PLASMA CORTICOSTERONE AND AGGRESSIVE BEHAVIOR IN FEMALE RATS WITH DIFFERENT HORMONAL STATUS.
217532 04-04

ANTAGONISM BY D-AMPHETAMINE OF LEARNING DEFICITS IN RATS INDUCED BY EXPOSURE TO ANTIPSYCHOTIC DRUGS DURING EARLY POSTNATAL LIFE.
217656 04-04

EFFECTS OF VARIOUS PSYCHOACTIVE DRUGS ON THE METABOLISM OF DELTA1-TETRAHYDROCANNABINOL BY RATS IN VITRO AND IN VIVO.
217672 04-03

POTENTIATION OF LOCOMOTOR ACTIVITY AND MODIFICATION OF STEREOTYPY BY STARVATION IN APOMORPHINE TREATED RATS.
217675 04-04

INHIBITION OF STRIATAL DOPAMINE SYNTHESIS IN RATS INJECTED CHRONICALLY WITH NEUROLEPTICS IN THEIR EARLY LIFE.
217687 04-03

MODIFICATION OF THE PUNISHING EFFECTS OF PSYCHOACTIVE DRUGS IN RATS BY PREVIOUS DRUG EXPERIENCE.
217765 04-04

GENETICALLY SELECTED WINNER AND LOSER RATS IN THE TUNNEL COMPETITION: INFLUENCE OF APOMORPHINE AND DOPA.
217829 04-04

LONG-LASTING REDUCTION OF BRAIN 5-HYDROXYTRYPTAMINE CONCENTRATION BY 3-CHLOROAMPHETAMINE AND 4-CHLOROAMPHETAMINE IN IPRINDOLE TREATED RATS.
217879 04-03

INTERACTIVE EFFECT OF (PLUS/MINUS) FENFLURAMINE AND (+) AMPHETAMINE ON FEEDING IN RATS.
217883 04-04

EFFECT OF SOME ANORECTIC AGENTS ON THE UPTAKE AND RELEASE OF 5-HYDROXYTRYPTAMINE BY BLOOD PLATELETS OF RATS.
217890 04-03

EFFECTS OF PROCAINE HYDROCHLORIDE, DIAZEPAM, AND DIPHENYLHYDANTOIN ON SEIZURE DEVELOPMENT IN CORTICAL AND SUBCORTICAL STRUCTURES IN RATS.
218191 04-03

THE INFLUENCE OF LITHIUM AND CESIUM IONS ON THE EFFECTS OF CATECHOLAMINES AND SEROTONIN INTRODUCED INTO THE HIPPOCAMPUS OF RATS.
218470 04-04

SEX DIFFERENCES IN THE EFFECTS OF DEXAMETHASONE PHOSPHATE ON BEHAVIOR IN RATS.
218492 04-04

ON NEUROCHEMICAL MECHANISMS OF SEPTUM INFLUENCE ON THE CONDITIONED AVOIDANCE REACTION IN RATS.
218803 04-04

METHYLATED DERIVATIVES OF NOREPINEPHRINE AND THE CONDITIONED AVOIDANCE RESPONSE IN RATS.
218958 04-02

NALOXONE-INDUCED AVERSION TO SUCROSE IN MORPHINE-DEPENDENT RATS.
219031 04-04

INDUCED PREFERENCE FOR MORPHINE IN RATS.
219033 04-04

CONDITIONED AVERSION TO MORPHINE WITH LITHIUM CHLORIDE IN MORPHINE-DEPENDENT RATS.
219039 04-04

ESTROGEN INDUCED MATERNAL BEHAVIOR IN HYSTERECTOMIZED OVARIECTOMIZED VIRGIN RATS.
219069 04-04

LATENCY AND DURATION OF ESTROGEN INDUCTION OF MATERNAL BEHAVIOR IN HYSTERECTOMIZED OVARIECTOMIZED VIRGIN RATS: EFFECTS OF PUP STIMULATION.
219070 04-04

THE INFLUENCE OF HYDROCORTISONE ON THE ELABORATION OF EXTINCTION INHIBITION IN RATS.
219327 04-04

THE ROLE OF THE AMYGDALA IN THE DEPRESSIVE ACTION OF SEROTONIN AND 5-HYDROXYTRYPTOPHAN ON THE CONDITIONED ACTIVITY OF WHITE RATS.
219328 04-04

THE EFFECT OF CATECHOLAMINERGIC DRUGS ON THE BEHAVIOR AND EEG OF RATS DURING CORAZOL SEIZURES.
219332 04-04

THE EFFECT OF DIAZEPAM ON THE BEHAVIOR OF RATS ADAPTED TO HIGH ALTITUDE HYPOXIA IN CONFLICTING SITUATIONS.
219502 04-04

THE EFFECT OF 6-HYDROXYDOPAMINE AND RESERPINE ON THE MOBILIZATION OF CARBOHYDRATES AND FATS IN STIMULATED RATS.
219504 04-03

THE EFFECT OF TRANSAMINE ON PSYCHONERVOUS AND CONDITIONED MEMORY IN RATS.
219745 04-04

THE EFFECT OF PSYCHOTROPIC AGENTS ON THE MENTAL AND PHYSICAL WORKING CAPACITY IN RATS.
219748 04-04

THE EFFECT OF LITHIUM ON THE CONTENT OF CATECHOLAMINES IN THE BRAIN OF RABBITS AND RATS.
219749 04-03

THE DISTRIBUTION KINETICS AND TURNOVER OF CHOLINE AND ACETYLCHOLINE IN PLASMA AND BRAIN OF RATS. (PH.D. DISSERTATION).
220472 04-03

POSSIBLE ROLE OF ADENOSINE-3-5-MONOPHOSPHATE AND BIOGENIC AMINES IN MORPHINE AND COCAINE TREATED RATS. (PH.D. DISSERTATION).
220475 04-03

SCHEDULE INDUCED AGGRESSION IN LABORATORY RATS: DEMONSTRATION AND CONTROL THROUGH SODIUM AMOBARBITAL. (PH.D. DISSERTATION).
220644 04-04

EFFECTS OF RESERPINE AND L-DOPA IN THE GLOBUS-PALLIDUS OF FREELY BEHAVING RATS.
220975 04-03

STIMULATION OF ESTROGEN INDUCED COPULATORY BEHAVIOR IN CASTRATE MALE RATS WITH THE SEROTONIN BIOSYNTHESIS INHIBITOR P-CHLOROPHENYLALANINE.
221010 04-04

EFFECTS OF SCOPOLAMINE, PHYSOSTIGMINE AND CHLORDIAZEPOXIDE ON PUNISHED AND EXTINGUISHED WATER CONSUMPTION IN RATS.
221043 04-04

INFLUENCE OF CHEMICAL STIMULATION OF CENTRAL DOPAMINERGIC SYSTEM ON THE OPEN-FIELD BEHAVIOR OF RATS.
221308 04-03

EFFECTS OF ACTH, DEXAMETHASONE AND DEOXYCORTICOSTERONE ON AVERSIVE THRESHOLD OF RATS.
221766 04-04

PHARMACOLOGICAL ACTION OF FD-008, A NEW DOPAMINE-BETA-HYDROXYLASE INHIBITOR: II. EFFECTS ON CENTRAL NERVOUS SYSTEM IN MICE AND RATS.
221823 04-02

PHARMACOLOGICAL ACTION OF FD-008, A NEW DOPAMINE-BETA-HYDROXYLASE INHIBITOR: III. EFFECTS ON ENDOGENOUS BIOGENIC AMINE LEVELS IN RATS.
221859 04-03

EFFECTS OF ANALGETICS ON CENTRALLY INDUCED PAIN IN RATS. (PH.D. DISSERTATION).
222640 04-03

BEHAVIORAL EFFECTS OF 2,5 DIMETHOXY-4-METHYLAMPHETAMINE (DOM) IN RATS AND MICE.
222801 04-04

APOMORPHINE: FACILITATION OF SEXUAL BEHAVIOUR IN FEMALE RATS.
222807 04-04

THE EFFECTS OF THYROTROPIN-RELEASING HORMONE ON THE BEHAVIOUR OF RATS PRETREATED WITH ALPHA-METHYLTYROSINE.
222815 04-04

NEUROTRANSMITTER CONTENT IN SYNAPTIC VESICLES OF THE ADRENERGIC NERVES OF RATS UNDER PHARMACOLOGICAL INFLUENCE.
223017 04-03

EFFECTS OF SCOPOLAMINE ON RETENTION OF TASTE AVERSION LEARNING IN RATS.
223033 04-04

LONG-LASTING EFFECTS OF PRENATAL 2,4,5 TRICHLOROPHENOXYACETIC ACID ON OPEN-FIELD BEHAVIOR IN RATS: PRE- AND POSTNATAL MEDIATION.
223044 04-04

EFFECT OF ACTH4-10 ON THE RATE OF SYNTHESIS OF (3H)CATECHOLAMINES IN THE BRAINS OF INTACT, HYPOPHYSECTOMIZED AND ADRENALECTOMIZED RATS.
223050 04-03

POISON INDUCED NEOPHOBIA IN RATS: ROLE OF STIMULUS GENERALIZATION OF CONDITIONED TASTE AVERSIONS.
223254 04-04

THE EFFECT OF STIMULANTS AND OPIOIDS ON SENSORY REINFORCEMENT IN RATS. (PH.D. DISSERTATION).
223711 04-04

THE INFLUENCE OF PHENAMINE AND CAFFEINE ON THE CAPACITY FOR EXTRAPOLATION IN RATS.
224466 04-04

THE INFLUENCE OF PHENAMINE ON THE AVOIDANCE REACTION IN INTACT AND STRIATECTOMIZED RATS.
224467 04-04

THE EFFECTS OF CHLORDIAZEPOXIDE ON THE DEVELOPMENT OF ADJUNCTIVE DRINKING IN RATS.
225149 04-04

THE EFFECT OF INTRAVENTRICULAR ADMINISTRATION OF SEROTONIN ON SPONTANEOUS MOTOR ACTIVITY OF RATS. (UNPUBLISHED PAPER).
225287 04-04

FORMATION OF NOREPINEPHRINE IN THE BRAIN OF RATS AFTER ADMINISTRATION OF (+) ERYTHRO 3,4 DIHYDROXYPHENYLSERINE.
225558 04-03

NICOTINE INDUCED HYPOPHAGIA AND HYPODIPSIA IN DEPRIVED AND IN HYPOTHALAMICALLY STIMULATED RATS.
225559 04-04

CHANGES IN MORPHINE SELF-ADMINISTRATION AND MORPHINE-DEPENDENCE AFTER LESIONS OF THE CAUDATE NUCLEUS IN RATS.
225560 04-04

FAILURE OF ANTISEROTONERGIC AGENTS TO MODIFY LEVALLORPHAN INDUCED STEREOTYPY IN RATS.
225567 04-03

EFFECT OF LOPERAMIDE, HALOPERIDOL AND METHADONE IN RATS TRAINED TO DISCRIMINATE MORPHINE FROM SALINE.
225568 04-04

RAUWOLFIA

RETROSPECTIVE STUDY OF THE ASSOCIATION BETWEEN USE OF RAUWOLFIA DERIVATIVES AND BREAST CANCER IN ENGLISH WOMEN.
194063 01-13

RAUWOLFIA DERIVATIVES AND CANCER.
194065 01-13

REACTION

IATROGENIC DYSKINESIA: A UNIQUE REACTION TO PARENTERAL METHYLPHENIDATE.
193087 01-15

REACTION OF CATIONIC GROUPS OF CHLORPROMAZINE WITH ANIONIC MACROMOLECULES: COMPLEXES WITH DNA, RNA, HYALURONIC ACID AND HEPARIN.
199897 02-03

THE EFFECTS OF L-DOPA, CLONIDINE, AND APOMORPHINE ON THE ACOUSTIC STARTLE REACTION IN RATS.
202773 02-04

INFLUENCE OF STRIATAL DOPAMINE RECEPTOR BLOCKADE ON A BULBAR MOTOR REACTION.
202778 02-03

AN ANALYSIS OF MONOAMINERGIC MECHANISMS OF THE DORSAL HIPPOCAMPUS WHICH MEDIATE THE CONDITIONED ESCAPE REACTION IN RATS.
208991 03-04

THE EFFECTS OF A NEW SEDATIVE (LEXOTAN) ON REACTION TIMES AND ON ATTENTIVE CAPACITY OF A GROUP OF ATHLETES.
209857 03-14

ACTION AND REACTION: BIOPHYSIOLOGICAL AND NEUROPHYSIOLOGICAL MECHANISMS.
210419 03-13

A COMPARISON BETWEEN MAPROTILINE (LUDIOMIL) AND AMITRIPTYLINE IN THE TREATMENT OF DEPRESSIVE REACTION IN GENERAL PRACTICE.
215058 04-14

THE USE OF LITHIUM IN THE TREATMENT OF THE DRUG-INDUCED PSYCHOTIC REACTION.
216183 04-11

SOME EFFECTS OF ACTH4-10 ON PERFORMANCE DURING A SERIAL REACTION TASK.
217533 04-04

ON NEUROCHEMICAL MECHANISMS OF SEPTUM INFLUENCE ON THE CONDITIONED AVOIDANCE REACTION IN RATS.
218803 04-04

THE INFLUENCE OF PHENAMINE ON THE AVOIDANCE REACTION IN INTACT AND STRIATECTOMIZED RATS.
224467 04-04

REACTIONS

DEPRESSIVE REACTIONS ASSOCIATED WITH RESERPINE.
194511 01-15

ALCOHOL WITHDRAWAL REACTIONS AND RESERPINE EFFECTS IN INBRED STRAINS OF MICE.
197821 01-03

ADVERSE REACTIONS TO CHLORPROMAZINE IN PSYCHIATRIC PATIENTS.
197923 01-01

THE INFLUENCE OF ANTIDEPRESSANTS AND NEUROLEPTICS ON BEHAVIORAL REACTIONS ELICITED BY LESION AND EXCITATION OF THE HIPPOCAMPUS.
198483 02-04

COMPARATIVE EFFECT OF PHENAMINE (AMPHETAMINE) AND CAFFEINE ON THE BACKGROUND ACTIVITY OF CORTICAL SENSORIMOTOR NEURONS AND THEIR REACTIONS DURING STIMULATION OF THE CAUDATE NUCLEUS.
198835 02-03

UNUSUAL REACTIONS TO ISONIAZIDE.
203495 02-15

EXTRAPYRAMIDAL REACTIONS AND AMINE METABOLITES IN CEREBROSPINAL FLUID DURING HALOPERIDOL AND CLOZAPINE TREATMENT OF SCHIZOPHRENIC PATIENTS.
214010 04-15

DEPRESSIVE REACTIONS IN THE COURSE OF CLOMIPRAMINE THERAPY USED IN THE TREATMENT OF OBSESSIONAL CONDITIONS.
214834 04-15

A NEUROPHARMACOLOGICAL ANALYSIS OF CHOLINERGIC MECHANISMS OF SELF-STIMULATION REACTIONS.
215497 04-04

CHLORDIAZEPOXIDE EFFECTS ON REACTIONS TO NOVELTY AND ACTIVITY WITH AND WITHOUT PRIOR DRUG EXPERIENCE.
221047 04-04

IDIOSYNCRATIC REACTIONS TO THE ANTIEPILEPTIC DRUGS.
225538 04-15

REACTIVE

WORK CAPABILITY AND TREATMENT OF REACTIVE DEPRESSIONS.
198354 02-10

THE INFLUENCE OF RESERPINE ON THE SEROTONIN METABOLISM IN PATIENTS WITH SCHIZOPHRENIA AND REACTIVE CONDITIONS.
200013 02-08

REACTIVE BRAINSTEM LOCI FOR ELICITING ELECTRODERMAL RESPONSES.
206250 03-03

THE PARTICIPATION OF SEROTONIN REACTIVE BRAIN STRUCTURES IN SOME FORMS OF BEHAVIORAL PATTERNS IN HAMSTERS.
218472 04-04

A DOUBLE-BLIND GENERAL PRACTICE TRIAL OF MAPROTILINE (LUDIOMIL) AGAINST AMITRIPTYLINE IN THE TREATMENT OF REACTIVE DEPRESSION.
221658 04-09

A COMPARISON BETWEEN DAILY AND NIGHTLY DOSE REGIMEN OF AMITRIPTYLINE AND MAPROTILINE (LUDIOMIL) IN THE TREATMENT OF REACTIVE DEPRESSION IN GENERAL PRACTICE.
221662 04-09

REACTIVITY

EFFECTS OF PSYCHOTROPIC DRUGS ON THE EMOTIONAL REACTIVITY OF RATS.
197499 01-04

ALTERATION OF PSYCHOSOMATIC REACTIVITY AFTER A SINGLE THERAPEUTIC DOSE OF PENTOBARBITAL IN RELATION TO THE SEX OF PROBANDS.
205627 03-14

ELECTROPHYSIOLOGICAL AND BEHAVIORAL REACTIVITY TO PHOTIC STIMULI FOLLOWING SEPTAL LESIONS AND PHARMACOLOGICAL TREATMENTS IN RATS.
206724 03-04

REACTIVITY OF VARIOUS PHENOTHIAZINE DERIVATIVES WITH OXYGEN AND OXYGEN RADICALS.
210882 03-02

THE LEVEL OF BLOOD NEUROMEDIATORS AFTER THE USE OF SEDUXEN AS AN INDEX OF NERVOUS SYSTEM REACTIVITY.
212432 03-13

EFFECTS OF EARLY EXPERIENCE AND DEXAMETHASONE ON ADRENOCORTICAL REACTIVITY.
225078 04-03

READING

ANALYSIS OF EYE MOVEMENTS AND BLINKS DURING READING: EFFECTS OF VALIUM.
206360 03-14

REAPPRAISAL

THE DEPOT FLUPHENAZINES: A REAPPRAISAL AFTER 10 YEARS CLINICAL EXPERIENCE.
225325 04-08

REASONS

ANTAGONISM OF NICOTINIC ACID AND OTHER KYNURENINES TO ANTIDEPRESSANTS: ONE OF THE PROBABLE REASONS FOR THE THERAPY-RESISTANCE IN DEPRESSION?.
215074 04-17

RECEIVING

GALVANIC SKIN RESISTANCE (GSR) MEASUREMENTS ON VOLUNTEERS RECEIVING FENFLURAMINE OR D-AMPHETAMINE.
225062 04-13

ELECTROCARDIOGRAPHIC MONITORING OF ENURETIC CHILDREN RECEIVING THERAPEUTIC DOSES OF IMIPRAMINE.
225336 04-15

RECEPTIVE

FACILITATORY AND INHIBITORY INFLUENCES OF PROGESTERONE, 20ALPHA-HYDROXYPROGESTERONE AND METHYSERGIDE ON THE RECEPTIVE BEHAVIOR OF THE FEMALE RAT. (PH.D. DISSERTATION).
222739 04-04

RECEPTIVITY

5-HYDROXYTRYPTAMINE IN THE CENTRAL NERVOUS SYSTEM AND SEXUAL RECEPTIVITY OF FEMALE RHESUS MONKEYS.
217856 04-04

ROLE OF MONOAMINES IN THE CONTROL BY HORMONES OF SEXUAL RECEPTIVITY IN THE FEMALE RAT.
222263 04-04

RECEPTOR

THYROXINE AND BRAIN CATECHOLAMINES: INCREASED TRANSMITTER SYNTHESIS AND INCREASED RECEPTOR SENSITIVITY.
193541 01-03

EFFECT OF TWO DOPAMINE RECEPTOR BLOCKERS ON A SEROTONIN MEDIATED BEHAVIORAL SYNDROME IN RATS.
193548 01-04

SOME STUDIES OF ADRENERGIC AMINES: PART I. ROLE OF THE AROMATIC RING IN RECEPTOR BINDING. PART II. BETA ADRENERGIC BLOCKADE. (PH.D. DISSERTATION).
194564 01-01

A TRANSIENT STATE CONCEPT OF DRUG RECEPTOR INTERACTION.
195240 01-17

ADRENERGIC RECEPTOR BLOCKING AGENTS: EFFECTS ON CENTRAL NORADRENALINE AND DOPAMINE RECEPTORS AND ON MOTOR ACTIVITY.
195429 01-03

ADENYLCYCLASE IN RAT STRIATUM AND NUCLEUS-ACCUMBENS: STIMULATION BY DOPAMINE RECEPTOR AGONISTS. (UNPUBLISHED PAPER).
197124 01-03

PSYCHOPHARMACOLOGICAL EVIDENCE FOR INCREASE IN RECEPTOR SENSITIVITY FOLLOWING CHRONIC MORPHINE TREATMENT.
197855 01-04

THE RELATIVE ATTENUATION OF SELF-STIMULATION, EATING AND DRINKING PRODUCED BY DOPAMINE RECEPTOR BLOCKADE.
198225 02-04

BETA-ADRENERGIC RECEPTOR BLOCKING DRUGS IN PSYCHIATRY.
199636 02-17

MODIFICATION OF THE RECEPTOR COMPONENT OF ADENYLATE-CYCLASE IN THE RAT BRAIN BY PHENOTHIAZINE DERIVATIVES.
199771 02-03

COMPARISON OF THE EFFECTS OF THE INTRANIGRAL INJECTIONS OF CHOLINOMIMETICS WITH SYSTEMIC INJECTIONS OF THE DOPAMINE RECEPTOR STIMULATING AND BLOCKING AGENTS IN THE RABBIT.
199772 02-03

AN ONTOGENIC STUDY ON THE EFFECT OF CATECHOLAMINE RECEPTOR STIMULATING AGENTS ON THE TURNOVER OF NORADRENALINE AND DOPAMINE IN THE BRAIN.
202715 02-03

INFLUENCE OF STRIATAL DOPAMINE RECEPTOR BLOCKADE ON A BULBAR MOTOR REACTION.
202778 02-03

USE OF BETA-ADRENERGIC RECEPTOR BLOCKING DRUGS IN PSYCHIATRY.
202797 02-17

STUDIES ON THE TIME COURSE AND THE EFFECT OF CHOLINERGIC AND ADRENERGIC RECEPTOR BLOCKERS ON THE STIMULUS EFFECT OF NICOTINE.
206353 03-03

BIOCHEMICAL CHARACTERIZATION OF THE DOPAMINE RECEPTOR IN THE MAMMALIAN CAUDATE NUCLEUS.
207297 03-03

ANTISCHIZOPHRENIC DRUGS: AFFINITY FOR MUSCARINIC CHOLINERGIC RECEPTOR SITES IN THE BRAIN PREDICTS EXTRAPYRAMIDAL EFFECTS.
207298 03-03

DOPAMINE RECEPTOR BLOCKADE BY NEUROLEPTIC DRUGS IN APLYSIA NEURONES.
210599 03-03

EFFECTS OF DOPAMINERGIC RECEPTOR AGONISTS AND ANTAGONISTS ON THE ACTIVITY OF THE NEOSTRIATAL CHOLINERGIC SYSTEM.
210669 03-03

EFFECT OF ERGOT DRUGS ON CENTRAL 5-HYDROXYTRYPTAMINE NEURONS: EVIDENCE FOR 5-HYDROXYTRYPTAMINE RELEASE OR 5-HYDROXYTRYPTAMINE RECEPTOR STIMULATION.
210857 03-03

THE DOPAMINE VASCULAR RECEPTOR.
210902 03-03

PREFERRED CONFORMATIONS OF SEROTONIN IN RELATION TO RECEPTOR SITES.
210928 03-03

NEUROCHEMICAL REGULATION OF FEEDING IN THE RAT: FACILITATION BY ALPHA-NORADRENERGIC, BUT NOT DOPAMINERGIC RECEPTOR STIMULANTS.
211538 03-04

IN VIVO IDENTIFICATION OF MUSCARINIC CHOLINERGIC RECEPTOR BINDING IN RAT BRAIN.
213480 04-03

5-HYDROXYTRYPTAMINE-14C AND DEXAMPHETAMINE-14C UPTAKE BY FUNDAL SARCOLEMMA PREPARATIONS AND THE PROBLEM OF THE COMMON RECEPTOR.
213591 04-03

RAT PINEAL CYCLIC ADENOSINE-3-5-MONOPHOSPHATE PHOSPHODIESTERASE ACTIVITY: IN VIVO MODULATION BY A BETA ADRENERGIC RECEPTOR.
215600 04-03

INDUCTION OF TYROSINE-HYDROXYLASE ELICITED BY BETA ADRENERGIC RECEPTOR AGONISTS IN NORMAL AND DECENTRALIZED SYMPATHETIC GANGLIA: ROLE OF CYCLIC 3,5 ADENOSINE-MONOPHOSPHATE.
215688 04-03

STRATEGIES FOR THE SYSTEMATIC STUDY OF NEUROTRANSMITTER RECEPTOR FUNCTION IN MAN.
215860 04-16

SLEEP AND BEHAVIORAL CHANGES REFLECTING CENTRAL RECEPTOR HYPERSENSITIVITY FOLLOWING CATECHOLAMINE SYNTHESIS INHIBITION IN MAN. (UNPUBLISHED PAPER).
216373 04-09

BEHAVIOURAL EVIDENCE OF DOPAMINE RECEPTOR STIMULATION BY PIRIBEDIL (ET495) AND ITS METABOLITE S584.
217152 04-04

PHARMACOLOGICAL EVIDENCE FOR CEREBRAL DOPAMINE RECEPTOR BLOCKADE BY METOCLOPRAMIDE IN RODENTS.
217469 04-03

CENTRAL CATECHOLAMINE RECEPTOR BLOCKING ACTIONS OF BE-2254 (HEAT): COMPARISON WITH CHLORPROMAZINE AND HALOPERIDOL.
222804 04-03

PINEAL BETA-ADRENERGIC RECEPTOR: CORRELATION OF BINDING OF H3-1-ALPRENOLOL WITH STIMULATION OF ADENYLCYCLASE. (UNPUBLISHED PAPER).
224096 04-03

RECEPTORS

CENTRAL NERVOUS SYSTEM ALPHA-ADRENERGIC RECEPTORS AND THE MODE OF ACTION OF ALPHA-METHYLDOPA.
195237 01-03

ADRENERGIC RECEPTOR BLOCKING AGENTS: EFFECTS ON CENTRAL NORADRENALINE AND DOPAMINE RECEPTORS AND ON MOTOR ACTIVITY.
195429 01-03

PRESSOR RESPONSES TO HYPOTHALAMIC STIMULATION AS INFLUENCED BY DRUGS AFFECTING ADRENERGIC RECEPTORS.
197290 01-03

EFFECTS OF D-ISOMERS AND L-AMPHETAMINE ON 5-HYDROXYTRYPTAMINE RECEPTORS.
197481 01-04

D-LSD BINDING TO BRAIN HOMOGENATES: POSSIBLE RELATIONSHIP TO SEROTONIN RECEPTORS.
202464 02-03

CHANGES OF KINETIC CONSTANT OF STRIATAL TYROSINE-HYDROXYLASE ELICITED BY NEUROLEPTICS THAT IMPAIR THE FUNCTION OF DOPAMINE RECEPTORS.
202716 02-03

LSD AS AN AGONIST OF DOPAMINE RECEPTORS IN THE STRIATUM.
204183 02-03

LSD AS AN AGONIST AND ANTAGONIST AT CENTRAL DOPAMINE RECEPTORS.
204184 02-03

INFLUENCE OF IPRONIAZID ON THE CONTENT OF NORADRENALINE IN VARIOUS PARTS OF THE RAT BRAIN BEFORE AND AFTER STIMULATION OF THE RECEPTORS.
206404 03-03

ADENOSINE-3-5-MONOPHOSPHATE CONTENT IN RAT CAUDATE NUCLEUS: DEMONSTRATION OF DOPAMINERGIC AND ADRENERGIC RECEPTORS.
208300 03-03

CHOLINERGIC AGENTS AFFECT TWO RECEPTORS THAT MODULATE TRANSMITTER RELEASE AT A CENTRAL SYNAPSE IN APLYSIA-CALIFORNICA.
215705 04-03

NEUROLEPTIC-INDUCED HYPERSENSITIVITY OF STRIATAL DOPAMINE RECEPTORS IN THE RAT AS A MODEL OF TARDIVE DYSKINESIAS. EFFECTS OF CLOZAPINE, HALOPERIDOL, LOXAPINE AND CHLORPROMAZINE.
217462 04-03

STEREOSPECIFICITY OF DOPAMINE RECEPTORS INVOLVED IN THE REGULATION OF THE KINETIC STATE OF TYROSINE-HYDROXYLASE IN STRIATUM AND NUCLEUS-ACCUMBENS.
217888 04-03

DOPAMINE RECEPTORS IN THE BRAIN.
220311 04-17

DOES CHRONIC MORPHINE TREATMENT INDUCE A SUPERSENSITIVITY OF DOPAMINE RECEPTORS IN RAT BRAIN
221038 04-03

BETA-PHENYLETHYLAMINE AND LOCOMOTOR ACTIVITY IN MICE: INTERACTION WITH CATECHOLAMINERGIC NEURONES AND RECEPTORS.
221742 04-03

LYSERGIC ACID DIETHYLAMIDE: EVIDENCE FOR STIMULATION OF CEREBRAL DOPAMINE RECEPTORS.
223174 04-03

ROLE FOR POSTSYNAPTIC DOPAMINE RECEPTORS IN THE REGULATION OF THE KINETIC STATE OF STRIATAL TYROSINE-HYDROXYLASE. (UNPUBLISHED PAPER).
225307 04-03

RECIDIVISM

THE CURRENT STATUS OF LITHIUM RECIDIVISM PROPHYLAXIS IN ENDOGENOUS AFFECTIVE ILLNESSES.
200568 02-09

PREVENTION OF RECIDIVISM OF SCHIZOPHRENICS TREATED WITH FLUPHENAZINE ENANTHATE.
211436 03-08

RECIPROCAL

RECIPROCAL (PUSH-PULL) EFFECTS OF MORPHINE ON SINGLE UNITS IN THE VENTROMEDIAN AND LATERAL HYPOTHALAMUS AND INFLUENCES ON OTHER NUCLEI: WITH COMMENT ON METHADONE EFFECTS DURING WITHDRAWAL FROM MORPHINE.
210700 03-03

RECOGNIZED

AKINESIA: A POORLY RECOGNIZED DRUG-INDUCED EXTRAPYRAMIDAL BEHAVIORAL DISORDER.
218773 04-15

RECOMMENDING

SUIT AGAINST RECOMMENDING DOCTOR AND PSYCHIATRIST -- REJECTED. STOVALL V. HARMS, 522 P.2D 353, (KANSAS) SUPREME COURT OF KANSAS. MAY 11, 1974.
200438 02-17

RECORDING

PSYCHOPHARMACOLOGIC MANAGEMENT OF PATIENTS: A METHOD FOR RECORDING TREATMENT DECISIONS.
207683 03-17

RECORDINGS

SERIAL EEG RECORDINGS IN PSYCHOTROPIC DRUG TREATMENT.
196144 01-08

ALL-NIGHT POLYGRAPHIC RECORDINGS ON THE HYPNOTIC EFFECTS OF A NEW BENZODIAZEPINE: FLUNITRAZEPAM (RO-5-4200, ROHYPNOL).
202272 02-11

EFFECTS OF LITHIUM ON ELECTROMYOGRAPHIC RECORDINGS IN MAN: STUDIES IN MANIC-DEPRESSIVE PATIENTS AND NORMAL VOLUNTEERS.
215697 04-13

SPECIFICITY OF BENZODIAZEPINE ACTION ON HUMAN SLEEP CONFIRMED. ANOTHER CONTRIBUTION OF AUTOMATIC ANALYSIS OF POLYGRAPH RECORDINGS.
218953 04-14

THE INFLUENCE OF SULPIRIDE ON SLEEP: RESULTS OF POLYGRAPHIC NIGHT SLEEP RECORDINGS.
221339 04-14

RECOVERED

A CASE OF PHENOTHIAZINE ILEUS RECOVERED FROM SHOCK.
193828 01-15

RECOVERY

ANALYSIS OF ACETYLCHOLINESTERASE SYNTHESIS AND TRANSPORT IN THE RAT HIPPOCAMPUS: RECOVERY OF ACETYLCHOLINESTERASE ACTIVITY IN THE SEPTUM AND HIPPOCAMPUS AFTER ADMINISTRATION OF DIISOPROPYLFLUOROPHOSPHATE.
199805 02-03

RECOVERY OF FUNCTION AND CHANGES IN SENSITIVITY TO AMPHETAMINE FOLLOWING CAUDATE LESIONS IN RATS.
209962 03-03

CHANGES IN THE CONCENTRATIONS OF 5-HYDROXYTRYPTAMINE AND NORADRENALINE IN SIX AREAS OF RAT BRAIN DURING RECOVERY FROM CHRONIC METHYLAMPHETAMINE ADMINISTRATION.
217963 04-03

RECOVERY OF FUNCTION: SOME NEW THOUGHTS ON AN OLD PROBLEM. (PH.D. DISSERTATION).
219268 04-04

THE EFFECTS OF METHYLPHENIDATE DURING REST, EXERCISE, AND RECOVERY UPON THE CIRCULORESPIRATORY RESPONSES OF HYPERACTIVE CHILDREN. (PH.D. DISSERTATION).
221934 04-11

RECURRENT

LITHIUM PROPHYLAXIS IN RECURRENT AFFECTIVE DISORDERS.
197532 01-09

THE LITHIUM PROPHYLACTIC TREATMENT OF RECURRENT ENDOGENOUS AFFECTIVE DISORDERS.
209392 03-09

FURTHER REPORT ON PROPHYLACTIC LITHIUM IN RECURRENT AFFECTIVE DISORDERS.
218556 04-09

RELATIONSHIP BETWEEN DOSAGE AND RESPONSE TO LITHIUM PROPHYLAXIS IN RECURRENT DEPRESSION.
224872 04-09

RED

EFFECT OF ALCOHOLS, CHLORPROMAZINE AND DIPHENYLHYDANTOIN ON (CA2+) ATPASE OF HUMAN RED BLOOD CELLS.
197976 01-13

RED BLOOD CELL LITHIUM INDEX IN PATIENTS WITH AFFECTIVE DISORDERS IN THE COURSE OF LITHIUM PROPHYLAXIS.
202786 02-09

THE LEVELS OF LITHIUM IN SERUM AND IN RED BLOOD CELLS AND ITS RATIOS IN MANIC-DEPRESSIVE PATIENTS.
205607 03-09

RED CELL FOLATE AND MACROCYTOSIS DURING LONG-TERM ANTICONVULSANT THERAPY IN NONANAEMIC MENTALLY RETARDED EPILEPTICS.
218553 04-11

LITHIUM IN NONMANIC DEPRESSIVES: ANTIAGGRESSIVE EFFECT AND RED BLOOD CELL LITHIUM VALUES.
222604 04-09

REDUCED

REDUCED BEHAVIOURAL EFFECTS OF INTRAHIPPOCAMPALLY ADMINISTERED CARBACHOL IN RATS WITH LOW CHOLINESTERASE ACTIVITY.
199956 02-04

APONEURON TREATMENT OF CHRONIC SCHIZOPHRENICS WITH REDUCED DRIVE.
203666 02-08

REDUCES

LITHIUM TREATMENT REDUCES MORPHINE SELF-ADMINISTRATION IN ADDICT RATS.
201293 02-04

REDUCING

THE COMBINED EFFECTS OF METHYLPHENIDATE (RITALIN) AND A CLASSROOM BEHAVIOR MODIFICATION PROGRAM IN REDUCING THE HYPERKINETIC BEHAVIORS OF INSTITUTIONALIZED MENTAL RETARDATES. (PH.D. DISSERTATION).
202356 02-11

REDUCTION

REDUCTION OF STIMULUS BOUND FOOD CONSUMPTION IN THE RAT FOLLOWING AMPHETAMINE ADMINISTRATION.
195081 01-04

REDUCTION BY DIAZEPAM OF REPETITIVE ELECTRICAL ACTIVITY AND TOXICITY RESULTING FROM SOMAN.
199861 02-03

RAPIDITY OF SYMPTOM REDUCTION IN DEPRESSIONS TREATED WITH AMITRIPTYLINE.
209437 03-09

LONG-LASTING REDUCTION OF BRAIN 5-HYDROXYTRYPTAMINE CONCENTRATION BY 3-CHLOROAMPHETAMINE AND 4-CHLOROAMPHETAMINE IN IPRINDOLE TREATED RATS.
217879 04-03

REM SLEEP REDUCTION EFFECTS ON DEPRESSION SYNDROMES.
218120 04-09

CYCLIC-GMP: REDUCTION OF CEREBELLAR CONCENTRATIONS IN NERVOUS MUTANT MICE.
221031 04-03

REDUCTIONS

PERFORMANCES UNDER CERUTIL OF NORMALLY INTELLIGENT CHILDREN AFFECTED BY CEREBROORGANIC REDUCTIONS IN EFFICIENCY.
203742 02-11

REEVALUATION

THE PENTOBARBITAL TEST DOSE FOR DEPRESSANT DRUG DEPENDENCE: A REEVALUATION IN TERMS OF ALCOHOL CONSUMPTION.
202883 02-17

REEXAMINATION

EFFECT OF P-CHLOROAMPHETAMINE ON CEREBRAL TRYPTOPHAN-5-HYDROXYLASE IN VIVO: A REEXAMINATION.
210826 03-03

REFERRED

DRUG TREATMENT OF CHRONIC INTRACTABLE PAIN IN PATIENTS REFERRED TO A PSYCHIATRY CLINIC.
196090 01-14

REFLECTING

SLEEP AND BEHAVIORAL CHANGES REFLECTING CENTRAL RECEPTOR HYPERSENSITIVITY FOLLOWING CATECHOLAMINE SYNTHESIS INHIBITION IN MAN. (UNPUBLISHED PAPER).
216373 04-09

REFLEX

THE USE OF THE IMMOBILITY REFLEX (ANIMAL HYPNOSIS) AS A POSSIBLE PROCEDURE FOR DETECTING SEDATIVE ACTIVITY.
196066 01-04

POTENTIATION WITH TRICYCLIC ANTIDEPRESSANTS OF THE INHIBITORY ACTION OF APOMORPHINE ON THE ATTITUDINAL REFLEX IN FROGS.
201919 02-04

THE BLINK REFLEX TO LIGHT: ITS COURSE AND ITS FACILITATION BY RESERPINE.
204220 02-03

RELATIONSHIP BETWEEN THE LATE REFLEX DISCHARGE AND LOCOMOTOR MOVEMENTS IN ACUTE SPINAL CATS AND RABBITS WITH DOPA.
209728 03-03

A STUDY OF AN ANIMAL MODEL OF DEPRESSION BY THE CONDITIONED REFLEX TECHNIQUE.
210853 03-04

THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL PRETREATMENT ON KETAMINE, THIOPENTAL OR CT-1341 -- INDUCED LOSS OF RIGHTING REFLEX IN MICE.
210878 03-02

REFLEXES

THE EFFECT OF TWO BARBITURATE ANTIPODES ON SPINAL REFLEXES AND SINGLE MOTONEURONS.
197297 01-03

STUDIES OF TRYPTAMINE AND LYSERGIC ACID DIETHYLAMIDE (LSD) ON CUTANEOUS C-FIBER AND POLYSYNAPTIC REFLEXES IN THE CAT.
197814 01-03

THE INFLUENCE OF TYROCALCITONIN ON CONDITIONAL REFLEXES AND THE ELECTRICAL ACTIVITY OF THE BRAIN IN ANIMALS.
198479 02-02

THE INFLUENCE OF CATECHOLAMINES, SEROTONIN, AND SOME AMINO ACIDS ADMINISTERED INTO THE AMYGDALOID COMPLEX ON CONDITIONED REFLEXES OF AVOIDANCE AND MOTOR ACTIVITY IN RATS.
200566 02-03

COMPARISON OF THE EFFECTS OF ATROPINE AND CANNABIS UPON THE FIXED CONDITIONED ALIMENTARY MOTOR REFLEXES IN CATS AFFECTED BY NICOTINE.
205623 03-14

DIFFERENTIAL ATTENUATION OF SOMATOVISCERAL AND VISCEROSOMATIC REFLEXES BY DIAZEPAM, PHENOBARBITAL AND DIPHENYLHYDANTOIN.
222818 04-04

ABSENT VESTIBULO-OCULAR REFLEXES AND ACUTE SUPRATENTORIAL LESIONS.
225323 04-13

REGIME

A COMPARISON OF A DIVIDED AND A SINGLE DOSE REGIME OF CLOMIPRAMINE (ANAFRANIL).
215149 04-09

A COMPARISON OF A LOW AND HIGH DOSAGE REGIME OF CLOMIPRAMINE (ANAFRANIL).
215150 04-09

OBSERVATIONS ON THE DOSE REGIME OF FLUPHENAZINE DECANOATE IN MAINTENANCE THERAPY OF SCHIZOPHRENIA.
222602 04-17

REGIMEN
PRESENILE DEMENTIA: FURTHER EXPERIENCE WITH AN ANTICOAGULANT PSYCHOTHERAPY REGIMEN.
195601 01-14
A COMPARISON BETWEEN DAILY AND NIGHTLY DOSE REGIMEN OF AMITRIPTYLINE AND MAPROTILINE (LUDIOMIL) IN THE TREATMENT OF REACTIVE DEPRESSION IN GENERAL PRACTICE.
221662 04-09

REGULATING
THE EFFECTS OF DRUGS REGULATING AUTONOMIC RESPONSES DURING CONDITIONING ON SUBSEQUENT AVOIDANCE BEHAVIOR. (PH.D. DISSERTATION).
193777 01-03

REGULATION
THE EFFECTS OF P-SUBSTITUTED AMPHETAMINES ON THE TRANSMITTER REGULATION IN RAT BRAIN.
197571 01-03
METHODS TO STUDY THE IN VIVO REGULATION OF CYCLIC NUCLEOTIDES IN HYPOTHALAMIC NUCLEI, PITUITARY AND PINEAL. (UNPUBLISHED PAPER).
201491 02-06
THE REGULATION OF CYCLIC GUANOSINE MONOPHOSPHATE IN RAT CEREBELLUM: POSSIBLE INVOLVEMENT OF PUTATIVE AMINO ACID NEUROTRANSMITTERS.
202717 02-03
THEORETICAL IMPLICATIONS OF DRUG-INDUCED ADAPTIVE REGULATION FOR A BIOGENIC AMINE HYPOTHESIS OF AFFECTIVE DISORDER.
206335 03-03
THE ROLE OF ADAPTIVE REGULATION IN THE PATHOPHYSIOLOGY OF PSYCHIATRIC DISEASE.
207307 03-03
THE REGULATION OF THE NORADRENERGIC NEURON.
207331 03-17
POSSIBLE ROLE OF CATECHOLAMINES (CA) IN THE REGULATION OF ADRENAL TYROSINE-HYDROXYLASE (TH).
207333 03-03
ON THE REGULATION OF CYCLIC-AMP PHOSPHODIESTERASE BY A SPECIFIC PROTEIN ACTIVATOR. (UNPUBLISHED PAPER).
208735 03-03
EFFECT OF STRESS AND DIAZEPAM TREATMENT DURING INFANCY ON THE CORTICOSTERONE REGULATION AND ANDROGENIC ACTIVITY IN ADULT MALE RATS.
210348 03-03
NEUROCHEMICAL REGULATION OF FEEDING IN THE RAT: FACILITATION BY ALPHA-NORADRENERGIC, BUT NOT DOPAMINERGIC-RECEPTOR STIMULANTS.
211538 03-04
THE IN VIVO REGULATION OF CGMP CONTENT IN RAT CEREBELLUM: A STUDY OF THE ACTION OF TAURINE.
215654 04-03
STEREOSPECIFICITY OF DOPAMINE RECEPTORS INVOLVED IN THE REGULATION OF THE KINETIC STATE OF TYROSINE-HYDROXYLASE IN STRIATUM AND NUCLEUS-ACCUMBENS.
217888 04-03
THE ACTION OF DELTA9-TETRAHYDROCANNABINOL ON CENTRAL CARDIOVASCULAR REGULATION: MECHANISM AND LOCALIZATION.
221669 04-03
ROLE FOR POSTSYNAPTIC DOPAMINE RECEPTORS IN THE REGULATION OF THE KINETIC STATE OF STRIATAL TYROSINE-HYDROXYLASE. (UNPUBLISHED PAPER).
225307 04-03

REHABILITATING
CLINICAL - PSYCHOPATHOLOGICAL CRITERIA FOR THE SELECTION OF PSYCHOTROPIC DRUGS ACCORDING TO THE STAGE OF ILLNESS AND THE EFFECTIVENESS OF REHABILITATING SCHIZOPHRENICS.
220403 04-17
AN ASPECT OF BIOLOGICAL THERAPY IN THE SYSTEM OF REHABILITATING EPILEPTIC PATIENTS WITH MENTAL DISORDERS.
220420 04-11
PSYCHOPHARMACOLOGICAL PRINCIPLES OF REHABILITATING MENTAL PATIENTS.
220425 04-08

REHABILITATION
EXAMINATION OF THE EFFECTS OF CLOXAZOLAM BY A DOUBLE-BLIND STUDY OF MENTAL PATIENTS BEFORE REHABILITATION.
194474 01-08
CLINICAL TRIAL OF FLUPENTHIXOL IN PATIENTS WITH CHRONIC SCHIZOPHRENIA: ESPECIALLY IN PATIENTS HAVING DIFFICULTY IN REHABILITATION OWING TO DECREASED EXPRESSION, APATHY AND DISTURBANCE OF RAPPORT.
202603 02-08
THE SIGNIFICANCE OF PSYCHOPHARMACOLOGY FOR PSYCHIATRIC REHABILITATION.
220367 04-09

REINFORCED
CODEINE AND COCAINE REINFORCED RESPONDING IN RHESUS MONKEYS: EFFECTS OF DOSE ON RESPONSE RATES UNDER A FIXED-RATIO SCHEDULE.
202667 02-04
OPIOID REINFORCED OPERANT BEHAVIOR: SELECTIVE SUPPRESSION BY ALPHA-METHYL-P-TYROSINE.
211511 03-04

REINFORCEMENT
DIFFERENTIAL EFFECTS OF CHLORDIAZEPOXIDE AND D-AMPHETAMINE ON RESPONDING MAINTAINED BY A DRL SCHEDULE OF REINFORCEMENT.
195433 01-04
THE EFFECTS OF REINFORCEMENT CONTINGENCIES AND CAFFEINE ON HYPERACTIVE CHILDREN. (PH.D. DISSERTATION).
220523 04-14
THE EFFECT OF ALPHA-METHYL-P-TYROSINE METHYLESTER ON TEMPORAL SUMMATION IN THE NEURAL SUBSTRATE FOR THE REINFORCEMENT EFFECT IN SELF-STIMULATION. (PH.D. DISSERTATION).
222090 04-04
THE EFFECT OF STIMULANTS AND OPIOIDS ON SENSORY REINFORCEMENT IN RATS. (PH.D. DISSERTATION).
223711 04-04
REINFORCEMENT SCHEDULES AND EXTRAPOLATIONS TO HUMANS FROM ANIMALS IN BEHAVIORAL PHARMACOLOGY.
225171 04-04

REINFORCING
NEGATIVE REINFORCING PROPERTIES OF MORPHINE ANTAGONISTS IN NAIVE RHESUS MONKEYS.
197284 01-04
NEGATIVE REINFORCING PROPERTIES OF SOME PSYCHOTROPIC DRUGS IN DRUG NAIVE RHESUS MONKEYS.
210889 03-04
RELATIONSHIPS BETWEEN THE STRUCTURE AND THE CHRONOTROPIC, LOCOMOTOR STIMULANT AND REINFORCING ACTIONS OF SEVERAL FENFLURAMINE ANALOGS. (PH.D. DISSERTATION).
223563 04-04

REJECTED
SUIT AGAINST RECOMMENDING DOCTOR AND PSYCHIATRIST -- REJECTED. STOVALL V. HARMS, 522 P.2D 353, (KANSAS) SUPREME COURT OF KANSAS. MAY 11, 1974.
200438 02-17

RELAPSE
DRUG AND SOCIOTHERAPY IN THE AFTERCARE OF SCHIZOPHRENIC PATIENTS: II. TWO-YEAR RELAPSE RATES.
199625 02-08
DOSAGE OF A PSYCHOTROPIC DRUG TO PREVENT RELAPSE IN A CURED SCHIZOPHRENIC PATIENT.
209402 03-08

RELEASE
IN VIVO RELEASE OF ENDOGENOUSLY SYNTHESIZED CATECHOLAMINES FROM THE CAT BRAIN EVOKED BY ELECTRICAL STIMULATION AND BY D-AMPHETAMINE.
195049 01-03
EFFECTS OF THEOPHYLLINE AND PROPRANOLOL ON ACETYLCHOLINE-INDUCED RELEASE OF ADRENAL MEDULLARY CATECHOLAMINES.
195591 01-03
THE INHIBITORY EFFECT OF DOPAMINE ON ACETYLCHOLINE RELEASE.
197566 01-03
EFFECT OF MORPHINE ON SEROTONIN RELEASE FROM MYENTERIC PLEXUS OF THE GUINEA-PIG.
197811 01-03
CORRELATION OF THE RELEASE OF AMINES AND ANTAGONISTS WITH THEIR EFFECTS.
197829 01-03
D-AMPHETAMINE AND THE RELEASE OF 3H-NOREPINEPHRINE FROM SYNAPTOSOMES.
197871 01-03
GLUCOSE RELEASE OF THE RAT KIDNEY IN VIVO AFTER BETA-ADRENERGIC STIMULATION AND BLOCKADE.
197946 01-03
INFLUENCE OF MORPHINE ON THE RELEASE OF NORADRENALINE FROM BRAIN SLICES.
197964 01-03
INFLUENCE OF OXYMETAZOLINE AND PHENTOLAMINE ON NORADRENALINE (NA) RELEASE CAUSED BY ELECTRICAL STIMULATION, POTASSIUM, TYRAMINE AND DIMETHYLPHENYLPIPERAZINE (DMPP).
197973 01-03
EFFECT OF NICOTINE AND OTHER DRUGS ON THE RELEASE OF 3H-NOREPINEPHRINE AND 3H-DOPAMINE FROM RAT BRAIN SLICES.
197985 01-03
UPTAKE AND RELEASE OF POSSIBLE FALSE TRANSMITTER AMINO ACIDS BY RAT BRAIN TISSUE.
199788 02-03
EFFECT OF LIMBIC SYSTEM LESIONS ON ACETYLCHOLINE RELEASE FROM THE CEREBRAL CORTEX OF THE RAT.
200044 02-03
THE IN VIVO RELEASE OF ENDOGENOUSLY SYNTHESIZED CATECHOLAMINES FROM THE CAT BRAIN BY LATERAL HYPOTHALAMIC STIMULATION AND BY D-AMPHETAMINE ADMINISTRATION. (PH.D. DISSERTATION).
200313 02-03

THE IMPORTANCE OF NEURONAL UPTAKE OF AMINES FOR AMPHETAMINE-INDUCED RELEASE OF 3H-NOREPINEPHRINE FROM ISOLATED BRAIN TISSUE.
202191 02-03

THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON THE UPTAKE AND RELEASE OF 14C-DOPAMINE FROM CRUDE STRIATAL SYNAPTOSOMAL PREPARATIONS.
202775 02-03

ALPHA-RECEPTOR MEDIATED MODULATION OF TRANSMITTER RELEASE FROM CENTRAL NORADRENERGIC NEURONES.
202805 02-03

EFFECT OF NOMIFENSINE (HOE-984), A NEW ANTIDEPRESSANT, ON UPTAKE OF NORADRENALINE AND SEROTONIN AND ON RELEASE OF NORADRENALINE IN RAT BRAIN SYNAPTOSOMES.
202807 02-03

RELEASE OF NOREPINEPHRINE AND DOPAMINE-BETA-HYDROXYLASE BY NERVE STIMULATION: II. EFFECTS OF PAPAVERINE.
204485 02-03

LACK OF EFFECT OF AMANTADINE ON D-AMPHETAMINE INDUCED RELEASE OF DOPAMINE FROM CAT BRAIN IN VIVO.
204865 02-02

ANTIPSYCHOTIC DRUGS STIMULATE PROLACTIN RELEASE.
206354 03-03

EFFECTS OF INTRAVENTRICULAR INFUSIONS OF ACTH1-24 AND ACTH4-10 ON LH RELEASE, OVULATION AND BEHAVIOR IN THE RABBIT.
210662 03-03

5-HT AND NOREPINEPHRINE-INDUCED RELEASE OF ACH FROM THE THALAMUS AND MESENCEPHALON OF THE MONKEY DURING THERMOREGULATION.
210672 03-03

EFFECT OF ERGOT DRUGS ON CENTRAL 5-HYDROXYTRYPTAMINE NEURONS: EVIDENCE FOR 5-HYDROXYTRYPTAMINE RELEASE OR 5-HYDROXYTRYPTAMINE RECEPTOR STIMULATION.
210857 03-03

L-DOPA HYPOTENSION IN DOGS: EVIDENCE FOR MEDIATION THROUGH 5-HT RELEASE.
210868 03-05

NERVE IMPULSE ENHANCED RELEASE OF AMINO ACIDS FROM NONSYNAPTIC REGIONS OF PERIPHERAL AND CENTRAL NERVE TRUNKS OF BULLFROG.
213277 03-03

MECHANISMS OF STORAGE AND RELEASE OF AMINES.
213632 04-03

D-AMPHETAMINE INDUCED RELEASE OF NEWLY SYNTHESIZED AND STORED DOPAMINE FROM THE CAUDATE NUCLEUS IN VIVO.
214110 04-03

GROWTH HORMONE AND PROLACTIN RELEASE AFTER INJECTION OF THYROTROPIN-RELEASING HORMONE IN PATIENTS WITH DEPRESSION.
214885 04-13

EFFECT OF ALPHA-METHYLDOPA ON DOPAMINE SYNTHESIS AND RELEASE IN RAT STRIATUM IN VITRO.
215690 04-03

EFFECTS OF 6-HYDROXYDOPAMINE AND RESERPINE ON AMPHETAMINE-INDUCED RELEASE OF NOREPINEPHRINE IN RAT CEREBRAL CORTEX.
215691 04-03

CHOLINERGIC AGENTS AFFECT TWO RECEPTORS THAT MODULATE TRANSMITTER RELEASE AT A CENTRAL SYNAPSE IN APLYSIA-CALIFORNICA.
215705 04-03

STUDIES ON THE DISTINCTION BETWEEN UPTAKE INHIBITION AND RELEASE OF H3-DOPAMINE IN RAT BRAIN TISSUE SLICES.
215756 04-03

CLINICAL EXPERIMENTATION WITH A SUSTAINED RELEASE LITHIUM CARBONATE.
216769 04-09

BLOCKADE OF RESERPINE OF METHYLPHENIDATE-INDUCED RELEASE OF BRAIN DOPAMINE.
217456 04-03

NOREPINEPHRINE AND SEROTONIN: SPECIFICITY OF RELEASE WITH REWARDING ELECTRICAL STIMULATION OF THE BRAIN.
217522 04-03

IN VIVO RELEASE OF ENDOGENOUS NEUROTRANSMITTERS IN CAT LIMBIC REGIONS: EFFECT OF CHLORPROMAZINE AND OF ELECTRICAL STIMULATION.
217685 04-03

FURTHER STUDIES OF METHAMPHETAMINE-INDUCED INSULIN RELEASE.
217695 04-03

EFFECT OF SOME ANORECTIC AGENTS ON THE UPTAKE AND RELEASE OF 5-HYDROXYTRYPTAMINE BY BLOOD PLATELETS OF RATS.
217890 04-03

THE EFFECT OF DRUGS ON THE RELEASE OF ENDOGENOUS CATECHOLAMINES INTO THE PERFUSATE OF DISCRETE BRAIN AREAS OF THE CAT IN VIVO.
219631 04-06

NEUROTRANSMITTERS AFFECTING PITUITARY HORMONE RELEASE. (UNPUBLISHED PAPER).
219633 04-03

A SINGLE DAILY DOSE OF A SUSTAINED RELEASE FORM OF AMITRIPTYLINE IN DEPRESSIVE ILLNESS.
219961 04-09

GROWTH HORMONE RELEASE AND CATECHOLAMINES IN AFFECTIVE DISEASE.
224773 04-13

RELEASERS

THE EFFECT OF PSYCHOPHARMACOLOGIC PROLACTIN RELEASERS ON LACTATION IN SHEEP.
210793 03-03

RELEASING

EFFECTS OF CATECHOLAMINE RELEASING AGENTS ON SYNAPTOSOMAL DOPAMINE BIOSYNTHESIS: MULTIPLE POOLS OF DOPAMINE OR MULTIPLE FORMS OF TYROSINE-HYDROXYLASE?.
210825 03-03

UPTAKE AND DISAPPEARANCE OF 4-METHYL-ALPHA-ETHYLMETATYRAMINE IN RELATION TO ITS RELEASING ACTION ON 5-HYDROXYTRYPTAMINE IN THE BRAIN.
217897 04-03

RELIABILITY

RELIABILITY AND VALIDITY OF A PLACEBO TEST.
224894 04-16

RELIEF

MAJOR OR MINOR TRANQUILIZERS FOR RELIEF OF COMMON SYMPTOMS OF PSYCHONEUROSIS
193412 01-10

RELIEVING

RELIEVING SELECT SYMPTOMS OF THE ELDERLY.
213353 03-11

REM

SOME AMPHETAMINE EFFECTS ON REM SLEEP.
195923 01-14

HEART RATE AND GALVANIC SKIN RESPONSE VARIATIONS DURING THE REM AND NON-REM SLEEP PHASES IN MAN.
205443 02-13

PHARMACOLOGICAL MANIPULATIONS OF BRAIN CATECHOLAMINES AND THE AGGRESSIVE BEHAVIOR INDUCED BY MARIHUANA IN REM SLEEP DEPRIVED RATS.
210325 03-04

REM INHIBITORY EFFECT OF L-DOPA INFUSION DURING HUMAN SLEEP.
210602 03-14

EFFECTS OF AMITRIPTYLINE ON HUMAN REM SLEEP AS EVALUATED BY USING PARTIAL DIFFERENTIAL REM SLEEP DEPRIVATION (PDRD).
214750 04-14

DIFFERENTIAL EFFECTS OF CHLORPROMAZINE, IMIPRAMINE, NITRAZEPAM AND AMOBARBITAL ON REM SLEEP AND REM DENSITY IN MAN.
215955 04-14

REM SLEEP REDUCTION EFFECTS ON DEPRESSION SYNDROMES.
218120 04-09

REMEDIAL

COMPARISON OF THE REMEDIAL RESULTS OF CLOFLUPEROL AND HALOPERIDOL FOR SCHIZOPHRENIA BY DOUBLE-BLIND TEST METHOD.
224549 04-08

REMEDIATION

WILL THE REAL HYPERACTIVE CHILD PLEASE SIT DOWN? PROBLEMS OF DIAGNOSIS AND REMEDIATION.
212811 03-11

RENAL

ELIMINATION OF LITHIUM DEPENDENT ON AGE IN HEALTHY PEOPLE AND PATIENTS SUFFERING FROM RENAL INSUFFICIENCY.
205043 02-13

RENAL TUBULAR FUNCTION IN PATIENTS ON LONG-TERM LITHIUM THERAPY.
207043 03-13

THE EFFECT OF PSYCHOTROPIC AND ANTICONVULSIVE DRUGS ON THE TRANSPORT OF ATPASE IN THE RENAL TUBES OF A GUINEA-PIG.
223015 04-05

THE INFLUENCE OF SOME PHENOTHIAZINE DERIVATIVES ON RENAL FUNCTION.
223019 04-05

RENIN

INFLUENCE OF CATECHOLAMINE UPTAKE BLOCKING DRUGS ON THE INCREASE IN WATER INTAKE AND PLASMA RENIN CONCENTRATION INDUCED BY SOME HYPOTENSIVE DRUGS.
197288 01-03

EFFECT OF SEROTONIN ON WATER INTAKE AND RENIN ANGIOTENSIN SYSTEM IN RATS.
197963 01-03

THE EFFECT OF LITHIUM ON BLOOD PRESSURE AND ON PLASMA RENIN SUBSTRATE AND RENIN IN RATS.
213483 04-03

REPEATED

EFFECTS OF REPEATED DOSES OF 1-DELTA8-TRANS-TETRAHYDROCANNABINOL ON SCHEDULE-CONTROLLED TEMPORALLY SPACED RESPONDING OF RATS.
195431 01-04

CHANGES IN ACID-BASE BALANCE, RESPIRATION RATE AND HEART RATE UPON REPEATED ORAL ADMINISTRATION OF BENZOCTAMINE AND DIAZEPAM TO CONSCIOUS DOGS.
197460 01-03

RELATIONSHIP BETWEEN THE CHANGES ON BLOOD PRESSURE RESPONSE AND THE CARDIAC CATECHOLAMINE LEVEL AFTER SINGLE AND REPEATED ADMINISTRATIONS OF TYRAMINE AND METHAMPHETAMINE IN RATS.
197491 01-03

METHAMPHETAMINES EFFECT ON REPEATED ACQUISITIONS WITH SERIAL DISCRIMINATION REVERSALS.
202769 02-04

EFFECTS OF SINGLE AND REPEATED ADMINISTRATION OF MAPROTILINE AND ITS RELATION TO PLASMA LEVELS IN HEALTHY TEST SUBJECTS.
204403 02-15

PHARMACOLOGICAL PROPERTIES OF A POTENTIAL TRANQUILISING AGENT MESYLPHENACYRAZINE: II. CHANGES RELATED TO ITS REPEATED ADMINISTRATION.
205579 02-03

METABOLISM OF DOPAMINE AND NOREPINEPHRINE IN RAT BRAIN AFTER SINGLE AND REPEATED ADMINISTRATION OF HALOPERIDOL, LOXAPINE AND CLOZAPINE.
206973 03-03

PERMANENT EFFECTS OF REPEATED ADMINISTRATION OF ACTH AND DIAZEPAM IN EARLY POSTNATAL PERIOD UPON THE DYNAMICS OF EXCITATION AND INHIBITION DURING HABITUATION.
215068 04-04

INFLUENCE OF TEMPIDON ON THE EEG OF CATS AT A SINGLE AND REPEATED APPLICATION.
215076 04-03

REPEATED ACQUISITION OF RESPONSE SEQUENCES: STIMULUS CONTROL AND DRUGS.
215969 04-04

FEEDING IN RESPONSE TO REPEATED PROTAMINE ZINC INSULIN INJECTIONS.
219073 04-04

REPETITIVE

REDUCTION BY DIAZEPAM OF REPETITIVE ELECTRICAL ACTIVITY AND TOXICITY RESULTING FROM SOMAN.
199861 02-03

REPLICATION

METHAMPHETAMINES EFFECT ON SDR: REPLICATION AND EXTENSION.
194133 01-04

REPRESSION

THE USE OF FREE IMAGERY, NONDIRECTIVE INTERVIEWING, AND SELECTED DRUGS TO LIFT POSTHYPNOTIC REPRESSION. (PH.D. DISSERTATION).
222060 04-14

REPRODUCTION

TERATOLOGIC AND REPRODUCTION STUDIES WITH CYCLAZOCINE.
193429 01-03

EFFECTS OF CENTRAL ACTING DRUGS AND ERGOT DERIVATIVES ON PROLACTIN AND GROWTH HORMONE SECRETION, ON GROWTH OF PITUITARY AND MAMMARY TUMORS AND ON REPRODUCTION IN OLD RATS. (PH.D. DISSERTATION).
194571 01-03

BENZODIAZEPINES, REPRODUCTION, AND DEVELOPMENT.
213605 04-03

REQUIRED

MINIMUM DURATION OF TRANS-SYNAPTIC STIMULATION REQUIRED FOR THE INDUCTION OF TYROSINE-HYDROXYLASE BY RESERPINE IN THE RAT SUPERIOR CERVICAL GANGLION.
199999 02-03

ADRENAL GLUCOCORTICOIDS AS A REQUIRED FACTOR IN THE DEVELOPMENT OF ETHANOL WITHDRAWAL SEIZURES IN MICE.
213479 04-03

REQUIREMENTS

NEUROLEPTIC AGENTS OF THE BENZOCYCLOHEPTAPYRIDOISOQUINOLINE SERIES. 1.SYNTHESES AND STEREOCHEMICAL AND STRUCTURAL REQUIREMENTS FOR ACTIVITY OF BUTACLAMOL AND RELATED COMPOUNDS.
208592 03-01

RESEARCH

PATTERN ANALYSIS OF PSYCHIATRIC RESEARCH DATA.
195940 01-11

PERSONALITY TRAIT STABILITY LABILITY AND ITS SIGNIFICANCE FOR PHARMACOLOGICAL RESEARCH.
196776 01-16

METHODOLOGY OF OUTPATIENT DRUG RESEARCH.
198106 02-07

PSYCHOPHARMACOLOGY COMPUTER RESEARCH.
198107 02-17

BASIC CONCEPTS OF PSYCHOPHARMACOLOGICAL RESEARCH AS APPLIED TO THE PSYCHOPHARMACOLOGICAL ANALYSIS OF THE AMYGDALA.
200980 02-17

CLONAZEPAM (RO-5-4023). FOUR YEARS OF CLINICAL RESEARCH.
205505 02-13

THE MANAGEMENT OF SCHIZOPHRENIA OUTSIDE THE HOSPITAL: RESEARCH FINDINGS AND UNDERLYING PRINCIPLES.
206044 03-08

FRONTIERS IN CATECHOLAMINE RESEARCH. PROCEEDINGS OF THE THIRD INTERNATIONAL CATECHOLAMINE SYMPOSIUM.
206437 03-17

NEUROLEPTICS AS A GUIDELINE TO BIOLOGICAL RESEARCH IN PSYCHOTIC DISORDERS.
207765 03-17

PSYCHOPHARMACOLOGY IN THE AGED: RESEARCH CONSIDERATIONS IN GERIATRIC PSYCHOPHARMACOLOGY.
208573 03-11

THE USE OF CLOMIPRAMINE IN PHOBIC PATIENTS; PRELIMINARY RESEARCH REPORT.
209488 03-10

RESEARCH ON PSYCHIATRIC INDICATIONS OF A POWERFUL ANXIOLYTIC, LORAZEPAM.
210088 03-14

THE PLACEBO EFFECT: AN INTEGRATED ANALYSIS OF THEORETICAL AND RESEARCH PERSPECTIVES. (PH.D. DISSERTATION).
212593 03-17

NEW PSYCHOTROPIC DRUG RESEARCH IN JAPAN.
213596 04-07

DRUG THERAPY FOR STUTTERERS: A REVIEW OF RESEARCH.
213786 04-11

ETHICS IN MEDICAL RESEARCH AS VIEWED BY THE CLINICAL INVESTIGATOR.
214341 04-17

PSYCHOPHARMACOLOGIC INVESTIGATIONS IN HEALTHY ELDERLY VOLUNTEERS: EFFECTS OF PIPRADROL - VITAMIN (ALERTONIC) ELIXIR AND PLACEBO IN RELATION TO RESEARCH DESIGN.
218217 04-11

THE ASSESSMENT OF NEUROLEPTOGENIC EXTRAPYRAMIDAL SYNDROMES IN PSYCHOPHARMACOLOGICAL RESEARCH.
221307 04-15

RESEARCH INTO THE INTERACTION BETWEEN NORTRIPTYLINE AND PERPHENAZINE -- CLINICAL EVALUATION.
221632 04-13

RESERPINE

DEPRESSION BY AMANTADINE OF TREMOR INDUCED BY RESERPINE AND OXOTREMORINE IN THE RAT.
193282 01-04

ROLE OF NORADRENALINE IN LEVODOPA REVERSAL OF RESERPINE AKINESIA.
193544 01-03

RESERPINE AND BREAST CANCER.
194062 01-13

RESERPINE USE IN RELATION TO BREAST CANCER.
194064 01-13

DEPRESSIVE REACTIONS ASSOCIATED WITH RESERPINE.
194511 01-15

EFFECTS ON SHOCK-ELICITED AGGRESSION IN MICE OF PREFERENTIALLY PROTECTING BRAIN MONOAMINES AGAINST THE DEPLETING ACTION OF RESERPINE.
195452 01-04

EFFECTS OF RESERPINE AND CHLORPROMAZINE ON 5-HYDROXYTRYPTAMINE UPTAKE OF PLATELETS FROM MIGRAINOUS AND CONTROL SUBJECTS.
196926 01-13

EFFECTS OF RESERPINE AND PRENYLAMINE ON THE NORADRENALINE FLUXES OF ISOLATED SPLENIC NERVE GRANULES.
197280 01-03

EFFECTS OF RESERPINE, 6-HYDROXYDOPAMINE, P-CHLOROPHENYLALANINE AND A COMBINATION OF THESE SUBSTANCES ON THE GROOMING BEHAVIOUR OF MICE.
197291 01-04

INVESTIGATIONS ON THE ACTION AND MECHANISM OF ACTION OF DIPHENYLHYDANTOIN AS AN ANTAGONIST OF TETRABENAZINE AND RESERPINE.
197471 01-03

THE INFLUENCE OF CHLORPROMAZINE AND RESERPINE ON THE METABOLISM OF CEREBRAL PHOSPHOLIPIDS IN THE RAT IN VIVO.
197477 01-03

THE RELATIONSHIP BETWEEN RIGIDITY AND CHANGE IN WHOLE BRAIN ACETYLCHOLINE CONCENTRATION PRODUCED BY INJECTION OF RESERPINE IN THE RAT.
197569 01-03

ALCOHOL WITHDRAWAL REACTIONS AND RESERPINE EFFECTS IN INBRED STRAINS OF MICE.
197821 01-03

EFFECTS OF L-DOPA ON CONDITIONED AVOIDANCE RESPONDING AFTER BEHAVIOURAL SUPPRESSION BY ALPHA-METHYLTYROSINE OR RESERPINE IN MICE.
197987 01-04

REVERSAL OF THE RESERPINE ELECTROENCEPHALOGRAPHIC SYNCHRONIZATION IN THE RABBIT BY P-CHLOROPHENYLALANINE.
197994 01-03

EFFECT OF RESERPINE ON CATIONIC CONTENTS OF RAT BRAIN.
198196 02-03

THE EFFECT OF L-DOPA ON THE DEVELOPMENT OF RESERPINE INDUCED PARKINSONISM AND CATECHOLAMINE METABOLISM IN RATS.
198486 02-03

ACTION OF RESERPINE IN MORPHINE TOLERANT RATS: ABSENCE OF AN ANTAGONISM OF CATECHOLAMINE DEPLETION.
199277 02-03

MINIMUM DURATION OF TRANS-SYNAPTIC STIMULATION REQUIRED FOR THE INDUCTION OF TYROSINE-HYDROXYLASE BY RESERPINE IN THE RAT SUPERIOR CERVICAL GANGLION.
199999 02-03

THE INFLUENCE OF RESERPINE ON THE SEROTONIN METABOLISM IN PATIENTS WITH SCHIZOPHRENIA AND REACTIVE CONDITIONS.
200013 02-08

RESERPINE THERAPY FOR MENOPAUSAL TROUBLE.
201694 02-11

REVERSAL OF RESERPINE INDUCED BRADYKINESIA BY ALPHA-METHYLDOPA -- NEW LIGHT ON ITS MODUS-OPERANDI.
202281 02-03

SUBCELLULAR DISTRIBUTION OF RESERPINE IN BLOOD PLATELETS: EVIDENCE FOR MULTIPLE POOLS.
202665 02-03

STUDIES ON THE INTERACTION OF RESERPINE, D-AMPHETAMINE, APOMORPHINE AND 5-HYDROXYTRYPTOPHAN.
203885 02-03

THE BLINK REFLEX TO LIGHT: ITS COURSE AND ITS FACILITATION BY RESERPINE.
204220 02-03

INTERACTIONS OF SOME ANALGESICS AND ANTIDEPRESSANTS WITH PHENELZINE OR RESERPINE IN THE MOUSE.
204879 02-05

INFLUENCE OF RESERPINE ON HEMODYNAMICS IN DOGS.
206415 03-03

ONTOGENY OF THE INDUCTION OF TYROSINE-HYDROXYLASE BY RESERPINE IN THE SUPERIOR CERVICAL GANGLION, NUCLEUS LOCUS-COERULEUS AND ADRENAL GLAND.
210670 03-03

CATECHOLAMINES IN SYMPATHETIC GANGLIA OF RAT: EFFECTS OF DEXAMETHASONE AND RESERPINE.
210766 03-03

ELECTROCONVULSIVE SHOCK: SUSTAINED DECREASE IN NOREPINEPHRINE UPTAKE AFFINITY IN A RESERPINE MODEL OF DEPRESSION.
210830 03-03

COMPARISON OF THE EFFECTS OF D-AMPHETAMINE AND L-AMPHETAMINE IN REVERSING DEPRESSION OF MOUSE LOCOMOTOR ACTIVITY CAUSED BY RESERPINE.
210869 03-03

THE EFFECT OF RESERPINE AND CHLORIMIPRAMINE ON GLYCOGEN CONTENT IN DIFFERENT BRAIN STRUCTURES OF RAT.
211106 03-03

INFLUENCE OF RESERPINE ON ALL-NIGHT SLEEP PATTERN IN NONLOBOTOMIZED AND LOBOTOMIZED CHRONIC SCHIZOPHRENIC PATIENTS.
213530 04-08

EFFECTS OF 6-HYDROXYDOPAMINE AND RESERPINE ON AMPHETAMINE-INDUCED RELEASE OF NOREPINEPHRINE IN RAT CEREBRAL CORTEX.
215691 04-03

BLOCKADE OF RESERPINE OF METHYLPHENIDATE-INDUCED RELEASE OF BRAIN DOPAMINE.
217456 04-03

LOSS OF BODY WEIGHT AS A PREDICTOR OF RESERPINE INDUCED AMINE DEPLETION.
217661 04-03

DIFFERENTIAL RATES OF INCREASE IN PONTINE TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE ACTIVITIES AFTER RESERPINE.
217854 04-03

SIMILARITIES OF THE INFLUENCE OF SECONDARY AND TERTIARY TRICYCLIC ANTIDEPRESSANTS ON THE EFFECT OF RESERPINE IN FROGS AND ON THE SEROTONIN UPTAKE OF HUMAN THROMBOCYTES.
219503 04-13

THE EFFECT OF 6-HYDROXYDOPAMINE AND RESERPINE ON THE MOBILIZATION OF CARBOHYDRATES AND FATS IN STIMULATED RATS.
219504 04-03

EFFECTS OF RESERPINE AND L-DOPA IN THE GLOBUS-PALLIDUS OF FREELY BEHAVING RATS.
220975 04-03

INFLUENCE OF RESERPINE ON THE POTENCY OF ALPHA-ADRENOCEPTOR BLOCKING AGENTS.
221860 04-03

RESIDUAL

N-DESMETHYLDIAZEPAM AND AMYLOBARBITONE SODIUM AS HYPNOTICS IN ANXIOUS PATIENTS. PLASMA LEVELS, CLINICAL EFFICACY AND RESIDUAL EFFECTS.
217460 04-10

RESISTANCE

CLINICAL ASPECTS OF RESISTANCE TO IMIPRAMINE THERAPY.
196039 01-11

RESISTANCE TO EXTINCTION OF AN AVOIDANCE RESPONSE IN RATS FOLLOWING THE ADMINISTRATION OF CHLORDIAZEPOXIDE (LIBRIUM) AND DIAZEPAM (VALIUM).
198226 02-04

EXPERIMENTAL STUDY INTO IMMUNOLOGICAL FACTORS OF RESISTANCE TO CHLORPROMAZINE.
201920 02-03

THERAPEUTIC-RESISTANT DEPRESSIONS: SYMPTOMS, RESISTANCE AND THERAPY.
202854 02-09

GALVANIC SKIN RESISTANCE (GSR) MEASUREMENTS ON VOLUNTEERS RECEIVING FENFLURAMINE OR D-AMPHETAMINE.
225062 04-13

RESISTANT

THE PSYCHIATRIST ATTITUDES AND THERAPEUTIC MEANS WHEN FACED WITH RESISTANT DEPRESSIONS.
196035 01-17

TREATMENT OF RESISTANT DEPRESSION.
196036 01-17

5-HYDROXYTRYPTOPHAN IN COMBINATION WITH CLOMIPRAMINE IN THERAPY RESISTANT DEPRESSIONS.
198229 02-09

TREATMENT OF RESISTANT DEPRESSION: CONTRIBUTIONS TO GENETIC ASPECTS.
203596 02-09

RESISTIVENESS

PREDICTING TREATMENT RESPONSIVENESS RESISTIVENESS IN A POPULATION OF DEPRESSED PATIENTS.
196040 01-17

RESPIRATION

CHANGES IN ACID-BASE BALANCE, RESPIRATION RATE AND HEART RATE UPON REPEATED ORAL ADMINISTRATION OF BENZOCTAMINE AND DIAZEPAM TO CONSCIOUS DOGS.
197460 01-03

RESPIRATORY

EFFECTS OF CHLORDIAZEPOXIDE IN RESPIRATORY FAILURE DUE TO CHRONIC BRONCHITIS.
194854 01-13

THE SITE OF THE RESPIRATORY STIMULANT ACTION OF IMIDAZOLE IN CATS.
196582 01-03

MODULATION OF THE RESPIRATORY DEPRESSANT EFFECT OF ETHANOL BY 5-HYDROXYTRYPTAMINE.
210751 03-03

RESPIRATORY EFFECTS OF DELTA9-TETRAHYDROCANNABINOL.
215669 04-13

RESPONSE

SUPPRESSION OF CONDITIONED HYPERTHERMIC RESPONSE BY L- AND D-OXPRENOLOL IN RATS.
192937 01-03

AGE SEX DIFFERENCES IN RESPONSE TO ANTIDEPRESSANT DRUGS.
193093 01-11

DIFFERENTIAL EFFECTS ON LEVER CHOICE AND RESPONSE RATE PRODUCED BY D-AMPHETAMINE.
194178 01-04

AFFECTIVE DISEASE HEALTH MAINTENANCE ORGANIZATION: PATTERNS OF LITHIUM RESPONSE.
194746 01-09

SOMATOSENSORY EVOKED RESPONSE WAVE SHAPE STABILITY: RELATIONSHIPS TO PSYCHIATRIC DIAGNOSIS AND EFFECTS OF PSYCHOACTIVE DRUGS.
195935 01-17

DRUG-RESISTANT DEPRESSIONS: RESPONSE TO ECT.
196037 01-17

THE ROLE OF BRAIN CATECHOLAMINES IN THE ANORECTIC RESPONSE TO AMPHETAMINE. (PH.D. DISSERTATION).
196370 01-04

SUBTYPE OF AFFECTIVE PSYCHOSES CLASSIFIED BY RESPONSE ON AMINE PRECURSORS AND MONOAMINE METABOLISM.
197209 01-09

THE EFFECTS OF CORD SECTION UNDER ETHER OR HALOTHANE ON THE ABILITY OF CHLORPROMAZINE TO AFFECT THE JAW-JERK RESPONSE TO TOOTH PULP STIMULATION IN THE ENCEPHALE ISOLE PREPARATION.
197451 01-03

THE EFFECTS OF AMPHETAMINE AND COCAINE ON THE RESPONSE OF THE ISOLATED GUINEA-PIG VAS-DEFERENS TO NORADRENALINE, TYRAMINE AND NERVE STIMULATION.
197463 01-03

RELATIONSHIP BETWEEN THE CHANGES ON BLOOD PRESSURE RESPONSE AND THE CARDIAC CATECHOLAMINE LEVEL AFTER SINGLE AND REPEATED ADMINISTRATIONS OF TYRAMINE AND METHAMPHETAMINE IN RATS.
197491 01-03

PLASMA NORTRIPTYLINE AND CLINICAL RESPONSE.
198029 01-09

PATIENT PROFILES AND DIFFERENTIAL RESPONSE TO DRUGS.
198087 02-10

PSYCHOACTIVE DRUG BLOOD LEVELS AND CLINICAL RESPONSE.
198095 02-07

RESISTANCE TO EXTINCTION OF AN AVOIDANCE RESPONSE IN RATS FOLLOWING THE ADMINISTRATION OF CHLORDIAZEPOXIDE (LIBRIUM) AND DIAZEPAM (VALIUM).
198226 02-04

ENHANCEMENT OF THE CHLORPROMAZINE-INDUCED SUPPRESSION OF THE CONDITIONED AVOIDANCE RESPONSE BY CARBONIC ANHYDRASE INHIBITION.
199770 02-03

THE INTERACTION OF DOPAMINE ANTAGONISTS AND AMANTADINE HYDROCHLORIDE ON THE ACQUISITION OF THE CONDITIONED AVOIDANCE RESPONSE IN RATS.
199959 02-04

EFFECTS OF ALCOHOL, UNCERTAINTY AND NOVELTY UPON RESPONSE SELECTION.
200048 02-14

LITHIUM RESPONSE IN DEPRESSION AS PREDICTED BY UNIPOLAR/BIPOLAR ILLNESS, AVERAGE EVOKED RESPONSE, CATECHOL-O-METHYLTRANSFERASE AND FAMILY HISTORY. (UNPUBLISHED PAPER).
201000 02-09

CODEINE AND COCAINE REINFORCED RESPONDING IN RHESUS MONKEYS: EFFECTS OF DOSE ON RESPONSE RATES UNDER A FIXED-RATIO SCHEDULE.
202667 02-04

DISCRIMINATIVE RESPONSE CONTROL PRODUCED WITH HASHISH, TETRAHYDROCANNABINOLS (DELTA8-THC AND DELTA9-THC), AND OTHER DRUGS.
202720 02-12

THE ROLE OF SEX AND NOVELTY IN DETERMINING THE SOCIAL RESPONSE TO LITHIUM CHLORIDE.
202721 02-04

CHRONIC AMPHETAMINE TREATMENT: VAST INDIVIDUAL DIFFERENCES IN PERFORMING A LEARNED RESPONSE.
202794 02-04

SPECIES DIFFERENCES IN ANTAGONISTIC EFFECT OF MORPHINE AGAINST DEPRESSOR RESPONSE TO DOPAMINE.
202800 02-03

DIVALENT CATIONS IN PREDICTING ANTIDEPRESSANT RESPONSE TO LITHIUM.
202886 02-14

METHODS OF DECONDITIONING PERSISTING AVOIDANCE: AMPHETAMINE, CHLORPROMAZINE, AND CHLORDIAZEPOXIDE AS ADJUNCTS TO RESPONSE PREVENTION.
202987 02-04

PHARMACOKINETIC DETERMINANTS OF THE RESPONSE TO SINGLE DOSES OF CHLORDIAZEPOXIDE.
203005 02-13

COMPUTER NYSTAGMOGRAPHY, A NEW METHOD OF DETERMINING CHANGES IN VIGILANCE AS A RESPONSE TO PSYCHOTROPIC DRUGS.
204395 02-16

RESPONSE OF DEPRESSED PATIENTS TO METHYLAMPHETAMINE.
205318 02-09

THE RELATIONSHIP BETWEEN THE EEG DRIVING RESPONSE TO LIGHT AND PLASMA MONOAMINEOXIDASE (MAO) LEVELS.
205437 02-03

HEART RATE AND GALVANIC SKIN RESPONSE VARIATIONS DURING THE REM AND NON-REM SLEEP PHASES IN MAN.
205443 02-13

INFLUENCE OF SOME BIOGRAPHIC FACTORS ON THE THERAPEUTIC DRUG RESPONSE.
205622 03-14

SOME FACTORS DETERMINING THE RESPONSE OF SEPTAL RATS TO ANTICHOLINERGIC DRUGS.
205632 03-03

EFFECT OF INCREASED AROUSAL ON RESPONSE TO STIMULUS CHANGE IN A COMPLEX MAZE.
206187 03-04

REGIONAL DIFFERENCES IN RESPONSE TO DISPLACEMENT AND INHIBITION OF SYNTHESIS OF CATECHOLAMINES IN THE CAT BRAIN.
206334 03-03

THE RELATIONSHIP BETWEEN RESPONSE TO PHENELZINE AND ACETYLATOR STATUS IN DEPRESSED PATIENTS.
206366 03-09

DIFFERENT URINARY EXCRETIONS OF 3-METHOXY-4-HYDROXYPHENYLGLYCOL AND RESPONSE TO TRICYCLIC ANTIDEPRESSIVE DRUGS.
206985 03-13

ANTIDEPRESSANT RESPONSE TO TRICYCLICS AND URINARY MHPG IN UNIPOLAR PATIENTS: CLINICAL RESPONSE TO IMIPRAMINE OR AMITRIPTYLINE.
207443 03-13

RELATIONSHIP BETWEEN SERUM LITHIUM LEVEL AND CLINICAL RESPONSE TO DEPRESSION TREATED WITH LITHIUM CARBONATE.
207719 03-09

THE PHARMACOLOGICAL AND ANATOMICAL SUBSTRATES OF THE AMPHETAMINE RESPONSE IN THE RAT.
207794 03-04

INFANTILE AUDITORY EXPOSURE AND UNUSUAL RESPONSE TO ANTIPSYCHOTIC DRUGS.
208617 03-04

THE ROLE OF DOPAMINE AND NOREPINEPHRINE IN CHANGING THE DIRECT CORTICAL RESPONSE TO PHENAMINE.
208971 03-03

METHODS OF DECONDITIONING PERSISTING AVOIDANCE: AMPHETAMINE AND AMOBARBITAL AS ADJUNCTS TO RESPONSE PREVENTION.
209897 03-04

THE EFFECTS OF NUCLEOTIDES AND GABA IN LARGE DOSES ON THE RESPONSE TO A PAINFUL STIMULUS WITH RETARDATES.
210296 03-14

DRUG-RESISTANCE AND BIOCLINICAL FACTORS IN THE RESPONSE OF SCHIZOPHRENIC PATIENTS TO CHLORPROMAZINE.
210500 03-08

POSSIBLE MECHANISMS INVOLVED IN THE DEPRESSOR RESPONSE TO DOPAMINE.
210787 03-03

EFFECTS OF HYPERBARIC CONDITIONS ON THE RESPONSE OF ANIMALS TO CENTRAL NERVOUS SYSTEM STIMULANTS AND DEPRESSANTS.
210877 03-03

MARIJUANA: HEART RATE AND EEG RESPONSE.
210895 03-01

THE EFFECT OF CHLORPROMAZINE AND STIMULATION OF THE MESENCEPHALIC RETICULAR FORMATION ON CENTRAL AROUSAL AND ON THE VISUAL EVOKED RESPONSE. (PH.D. DISSERTATION).
212547 03-03

THE COMPARATIVE EFFECTS OF MORPHINE AND CHLORPROMAZINE ON THE ACQUISITION OF CONDITIONED AVOIDANCE RESPONSE. (PH.D. DISSERTATION).
212963 03-04

HUMAN GROWTH HORMONE RESPONSE TO LEVODOPA: RELATION TO MENOPAUSE, DEPRESSION, AND PLASMA DOPA CONCENTRATION.
213918 04-09

THE ELECTRODERMAL RESPONSE: NEUROPHYSIOLOGICAL AND NEUROPHARMACOLOGICAL CHARACTERISTICS. (PH.D. DISSERTATION).
214203 04-03

DRUGS AND PUNISHED RESPONDING. V. EFFECTS OF DRUGS ON RESPONDING SUPPRESSED BY RESPONSE DEPENDENT AND RESPONSE INDEPENDENT ELECTRIC SHOCK.
215722 04-04

REPEATED ACQUISITION OF RESPONSE SEQUENCES: STIMULUS CONTROL AND DRUGS.
215969 04-04

EFFECT OF WITHDRAWAL FROM CHRONIC ETHANOL INGESTION ON THE CAMP RESPONSE OF CEREBRAL CORTICAL SLICES USING THE AGONISTS HISTAMINE, SEROTONIN, AND OTHER NEUROTRANSMITTERS.
215980 04-03

RESPONSE TO METHYLPHENIDATE IN LOW SOCIOECONOMIC HYPERACTIVE CHILDREN.
217181 04-14

RELATIONSHIP BETWEEN SERUM LITHIUM LEVEL AND CLINICAL RESPONSE ON DEPRESSION TREATED WITH LITHIUM CARBONATE.
217354 04-09

INFLUENCE OF RESPONSE TOPOGRAPHY ON THE EFFECT OF APOMORPHINE AND AMPHETAMINE ON OPERANT BEHAVIOR OF PIGEONS.
217468 04-04

EFFECT OF MORPHINE, HYDROMORPHONE, METHADONE, MESCALINE, TRYPAN-BLUE, VITAMIN-A, SODIUM SALICYLATE AND CAFFEINE ON THE SERUM INTERFERON LEVEL IN RESPONSE TO VIRAL INFECTION.
217654 04-03

ANTIDEPRESSANTS IN BLACK AND WHITE INPATIENTS: DIFFERENTIAL RESPONSE TO A CONTROLLED TRIAL OF CHLORPROMAZINE AND IMIPRAMINE.
218770 04-09

METHYLATED DERIVATIVES OF NOREPINEPHRINE AND THE CONDITIONED AVOIDANCE RESPONSE IN RATS.
218958 04-02

FEEDING IN RESPONSE TO REPEATED PROTAMINE ZINC INSULIN INJECTIONS.
219073 04-04

BEHAVIORALLY EVOKED HIPPOCAMPAL THETA WAVES: A CHOLINERGIC RESPONSE.
220312 04-03

A GENETIC ANALYSIS OF THE RESPONSE TO MORPHINE IN MICE: ANALGESIA AND RUNNING.
221042 04-03

THE EFFECTS OF SHOCK INTENSITY, D-AMPHETAMINE, AND PENTOBARBITAL ON THE FREQUENCY AND RESPONSE DYNAMICS OF BITING ATTACK IN THE SQUIRREL MONKEY. (PH.D. DISSERTATION).
222114 04-04

THE EFFECT OF AN ADRENAL DEMEDULLATION AND CHEMICAL SYMPATHECTOMY (2,4,5 TRIHYDROXYPHENYLETHYLAMINE) ON THE ACQUISITION OF A ONE-WAY ACTIVE AVOIDANCE RESPONSE. (PH.D. DISSERTATION).
222736 04-04

PHARMACOKINETICS OF CHLORDIAZEPOXIDE, MEPERIDINE, THIORIDAZINE, AND MESORIDAZINE AND CLINICAL RESPONSE.
224830 04-13

RELATIONSHIPS AMONG CLINICAL RESPONSE, EPS, AND PLASMA CPZ AND CPZ METABOLITE RATIOS.
224831 04-08

RELATIONSHIP BETWEEN DOSAGE AND RESPONSE TO LITHIUM PROPHYLAXIS IN RECURRENT DEPRESSION.
224872 04-09

SCHEDULE-CONTROLLED BEHAVIORS AS DETERMINANTS OF DRUG RESPONSE.
225168 04-06

THE EFFECTS OF CHRONIC MORPHINE ADMINISTRATION UPON A MODIFIED SIDMAN AVOIDANCE SCHEDULE THAT UTILIZES RESPONSE INDEPENDENT SHOCK.
225566 04-04

RESPONSES

THE EFFECTS OF DRUGS REGULATING AUTONOMIC RESPONSES DURING CONDITIONING ON SUBSEQUENT AVOIDANCE BEHAVIOR. (PH.D. DISSERTATION).
193777 01-03

ALTERATIONS BY ANESTHETIC AGENTS OF THE RESPONSES OF RAT STRIATAL NEURONS TO IONTOPHORETICALLY APPLIED AMPHETAMINE, ACETYLCHOLINE, NORADRENALINE, AND DOPAMINE.
193803 01-03

TRYPTAMINERGIC AND DOPAMINERGIC RESPONSES OF SCHISTOSOMA-MANSONI.
194155 01-03

EFFECTS OF ADRENERGIC DRUGS ON PRESSOR RESPONSES TO HYPOTHALAMIC STIMULATION.
195441 01-03

PRESSOR RESPONSES TO HYPOTHALAMIC STIMULATION AS INFLUENCED BY DRUGS AFFECTING ADRENERGIC RECEPTORS.
197290 01-03

RESPONSES OF MOLLUSCAN NEURONS TO CATECHOLAMINES.
197445 01-03

A COMPARISON OF THE EFFECTS OF (+) AMPHETAMINE, COCAINE AND DENERVATION ON THE RESPONSES OF THE ISOLATED VAS-DEFERENS OF THE GUINEA-PIG TO NOREPINEPHRINE AND ACETYLCHOLINE.
197495 01-03

CHANGES IN THE ACQUISITION OF CONDITIONED AVOIDANCE RESPONSES FOLLOWING MIDBRAIN RAPHE LESIONS IN TH
197574 01-04

EFFECT OF PROLONGED LITHIUM INGESTION ON GLUCAGON AND PARATHYROID HORMONE RESPONSES IN RATS.
197744 01-03

EFFECTS OF MESCALINE, DELTA9-TETRAHYDROCANNABINOL AND PENTOBARBITAL ON THE AUDITORY EVOKED RESPONSES IN THE CAT.
197990 01-03

RESPONSES OF DYSPHORIC PATIENTS TO PHARMACOTHERAPIES.
198074 01-11

DEPRESSION, ELATION, AND LITHIUM CARBONATE RESPONSES IN MANIC PATIENT SUBGROUPS.
199631 02-09

MATURATION OF VISUAL ELECTROCORTICAL RESPONSES IN UNANESTHETIZED KITTENS: EFFECTS OF BARBITURATE ANESTHESIA.
199765 02-03

EFFECTS OF LITHIUM CHLORIDE ON CARDIOVASCULAR RESPONSES INDUCED BY CHOLINERGIC AND ADRENERGIC STIMULATIONS.
199870 02-03

CONTRACTILE RESPONSES OF GUINEA-PIG UMBILICAL ARTERIES TO VARIOUS HALLUCINOGENIC AGENTS.
200037 02-03

EFFECTS OF ALPHA-ADRENERGIC BLOCKERS ON VISUAL EVOKED RESPONSES IN RABBITS.
200064 02-03

THE CURRENT STATUS OF BIOLOGICAL CRITERIA FOR CLASSIFYING THE DEPRESSIVE DISORDERS AND PREDICTING RESPONSES TO TREATMENT.
202380 02-17

THE EFFECT OF INHIBITORS OF CATECHOLAMINE SYNTHESIS (ALPHA-METHYLTYROSINE AND DISULFIRAM) ON THE BACKGROUND ACTIVITY OF SENSORIMOTOR CORTEX NEURONS AND THEIR RESPONSES TO AFFERENT CAUDATE AND RETICULAR STIMULATION.
202598 02-04

EFFECTS ON THE ACQUISITION OF CONDITIONED AVOIDANCE RESPONSES AND SEIZURE THRESHOLD IN THE OFFSPRING OF AMPHETAMINE TREATED GRAVID RATS.
202722 02-05

EFFECTS OF AMPHETAMINE AND AND CHLORPROMAZINE UPON OBSERVING RESPONSES IN RATS. (PH.D. DISSERTATION).
203166 02-04

BIOCHEMICAL CRITERIA FOR CLASSIFYING DEPRESSIVE DISORDERS AND PREDICTING RESPONSES TO PHARMACOTHERAPY: PRELIMINARY FINDINGS FROM STUDIES OF NOREPINEPHRINE METABOLISM. CONTRIBUTIONS TO BIOCHEMISTRY.
203594 02-09

REACTIVE BRAINSTEM LOCI FOR ELICITING ELECTRODERMAL RESPONSES.
206250 03-03

THE ROLE OF THE RETICULAR FORMATION IN ACTION EXERTED BY CHLORPROMAZINE AND BENACTYZINE ON PRIMARY RESPONSES OF THE BRAIN-CORTEX.
206440 03-04

SOME EFFECTS OF PILOCARPINE AND ACETYLCHOLINE ON THE RESPONSES OF THE GUINEA-PIG VAS-DEFERENS TO HYPOGASTRIC NERVE STIMULATION AND TRANSMURAL STIMULATION AND APPLIED (-) NORADRENALINE.
210770 03-03

EFFECTS OF PSYCHOACTIVE DRUGS ON RESPONSES OF THE RAT TO AVERSIVE STIMULATION.
210784 03-04

MODIFICATION BY L-DOPA METHYLESTER (H-19-61) OF AMPHETAMINE-INDUCED BRAIN CATECHOLAMINE CHANGES, THERMAL RESPONSES AND TOXICITY IN DEVELOPING MICE.
210891 03-03

THE EFFECTS OF (+) AMPHETAMINE ON THE CHRONOTROPIC RESPONSES OF THE ISOLATED GUINEA-PIG PACEMAKER TO NOREPINEPHRINE AND ISOPROTERENOL.
211066 03-03

RESPONSES OF CULTURED CEREBELLAR NEURONS TO IONTOPHORETICALLY APPLIED AMINO ACIDS.
213279 03-03

RESPONSES OF CENTRAL NEURONES TO AMANTADINE: COMPARISON WITH DOPAMINE AND AMPHETAMINE.
213398 04-03

BLOOD PRESSURE AND HEART RATE RESPONSES EVOKED BY D- AND L-AMPHETAMINE IN THE PITHED RAT PREPARATION.
215687 04-03

ROLE OF BRAIN SEROTONIN IN THE INTEGRATION OF BEHAVIORAL RESPONSES AND PITUITARY ADRENOCORTICAL FUNCTIONS UNDER EMOTION.
218364 04-04

ACTION OF SEROTONIN MICROINJECTED INTO HYPOTHALAMIC SITES AT WHICH ELECTRICAL STIMULATION PRODUCED AVERSIVE RESPONSES IN THE RAT.
219075 04-04

MODIFICATIONS BY LITHIUM OF BEHAVIORAL RESPONSES TO METHAMPHETAMINE AND TETRABENAZINE.
221041 04-04

AVERAGE EVOKED RESPONSES (AER) AND HOMOVANILLIC ACID (HVA) IN CEREBROSPINAL FLUID (CSF) IN A PSYCHOTIC PATIENT WITH ADDISONS DISEASE.
221310 04-09

THE EFFECTS OF METHYLPHENIDATE DURING REST, EXERCISE, AND RECOVERY UPON THE CIRCULORESPIRATORY RESPONSES OF HYPERACTIVE CHILDREN. (PH.D. DISSERTATION).
221934 04-11

RESPONSIBLE

TYROSINE-HYDROXYLASE INHIBITION BY CYCLOHEXIMIDE AND ANISOMYCIN IS NOT RESPONSIBLE FOR THEIR AMNESIC EFFECT.
203572 02-04

RESPONSIVE

WITHDRAWN, APATHETIC GERIATRIC PATIENTS RESPONSIVE TO METHYLPHENIDATE.
218216 04-11

LITHIUM RESPONSIVE HYPERALDOSTERONISM IN MANIC PATIENTS.
221718 04-09

RESPONSIVENESS

PREDICTING TREATMENT RESPONSIVENESS RESISTIVENESS IN A POPULATION OF DEPRESSED PATIENTS.
196040 01-17

AGE RELATED ENHANCED RESPONSIVENESS TO CENTRAL NERVOUS SYSTEM DRUGS IN RATS. (PH.D. DISSERTATION).
196256 01-03

DEPRESSIVE ILLNESS: ADRENERGIC RESPONSIVENESS AND THE EFFECT OF LITHIUM ON PLATELET ADENYLCYCLASE. (PH.D. DISSERTATION).
196260 01-13

AGE RELATED RESPONSIVENESS OF THE RAT TO DRUGS AFFECTING THE CENTRAL NERVOUS SYSTEM.
206912 03-03

POSTCASTRATION DECLINE IN BEHAVIOURAL RESPONSIVENESS TO INTRAHYPOTHALAMIC ANDROGEN IN DOVES.
210918 03-03

REST

THE EFFECTS OF METHYLPHENIDATE DURING REST, EXERCISE, AND RECOVERY UPON THE CIRCULORESPIRATORY RESPONSES OF HYPERACTIVE CHILDREN. (PH.D. DISSERTATION).
221934 04-11

RESTLESS

SULPIRIDE VERSUS CHLORPROMAZINE AND PLACEBO IN THE TREATMENT OF RESTLESS MENTALLY SUBNORMAL PATIENTS -- A DOUBLE-BLIND CROSSOVER STUDY.
209702 03-11

RESTORATION

PARTIAL RESTORATION BY AN A NEUROLEPTIC (SPIRAMIDE) OF ITEMS OF GROOMING BEHAVIOUR SUPPRESSED BY AMPHETAMINE.
213590 04-04

RETARD
EVENTUAL DEVELOPMENTS OF 64 CHRONIC PSYCHOTICS ON MODITEN RETARD OR MODECATE TREATMENT.
202514 02-09

RETARDATES
THE COMBINED EFFECTS OF METHYLPHENIDATE (RITALIN) AND A CLASSROOM BEHAVIOR MODIFICATION PROGRAM IN REDUCING THE HYPERKINETIC BEHAVIORS OF INSTITUTIONALIZED MENTAL RETARDATES. (PH.D. DISSERTATION).
202356 02-11
THE PASSATIZATION INDEX OF RETARDATES TREATED WITH HIGH DOSES OF GABA AND NUCLEOTIDES.
210288 03-11
TEMPORAL DISCRIMINATION TESTS IN MENTAL RETARDATES TREATED WITH NUCLEOTIDES AND GABA IN HIGH DOSES.
210293 03-14
THE EFFECTS OF NUCLEOTIDES AND GABA IN LARGE DOSES ON THE RESPONSE TO A PAINFUL STIMULUS WITH RETARDATES.
210296 03-14

RETARDED
EFFECTS OF PSYCHOTROPIC DRUGS ON THE SHORT-TERM MEMORY OF RETARDED CHILDREN. (PH.D. DISSERTATION).
194655 01-14
MNEMONIC CAPACITY OF MENTALLY RETARDED BOYS TREATED WITH HIGH DOSES OF NUCLEOTIDES AND GABA.
210291 03-14
RED CELL FOLATE AND MACROCYTOSIS DURING LONG-TERM ANTICONVULSANT THERAPY IN NONANAEMIC MENTALLY RETARDED EPILEPTICS.
218553 04-11
RESULTS OF A SURVEY (1966-1967) OF DRUG USAGE IN INSTITUTIONS FOR THE MENTALLY RETARDED. (UNPUBLISHED PAPER).
222411 04-17

RETENTION
SOME EVIDENCE FOR LONG-TERM MEMORY RETENTION BY OROTIC ACID IN RATS BAR PRESSING FOR WATER.
210790 03-04
6-METHOXYTETRAHYDRO-BETA-CARBOLINE PRODUCES A RETENTION DEFICIT FOR ONE-TRIAL PASSIVE AVOIDANCE IN MICE.
217833 04-04
EFFECTS OF SCOPOLAMINE ON RETENTION OF TASTE AVERSION LEARNING IN RATS.
223033 04-04

RETESTING
RETESTING WITH GRAPHIC PRODUCTION: RESOLUTION OF A DIAGNOSTIC DILEMMA.
197600 01-09

RETICULAR
THE INFLUENCE OF TRIFLUOPERAZINE, CARBIDINE AND IMIZINE ON EVOKED POTENTIALS IN DIFFERENT STRUCTURES OF THE LIMBIC RETICULAR COMPLEX.
200564 02-02
THE EFFECT OF INHIBITORS OF CATECHOLAMINE SYNTHESIS (ALPHA-METHYLTYROSINE AND DISULFIRAM) ON THE BACKGROUND ACTIVITY OF SENSORIMOTOR CORTEX NEURONS AND THEIR RESPONSES TO AFFERENT CAUDATE AND RETICULAR STIMULATION.
202598 02-04
THE ROLE OF THE RETICULAR FORMATION IN ACTION EXERTED BY CHLORPROMAZINE AND BENACTYZINE ON PRIMARY RESPONSES OF THE BRAIN-CORTEX.
206440 03-04
ELECTROCORTICAL CHANGES INDUCED BY PERFUSION OF CATECHOLAMINES INTO THE BRAINSTEM RETICULAR FORMATION.
210827 03-03
DIFFERENTIAL EFFECTS OF THE OPTICAL ISOMERS OF AMPHETAMINE ON NEURONAL ACTIVITY IN THE RETICULAR FORMATION AND CAUDATE NUCLEUS OF THE RAT.
211063 03-03
THE EFFECT OF CHLORPROMAZINE AND STIMULATION OF THE MESENCEPHALIC RETICULAR FORMATION ON CENTRAL AROUSAL AND ON THE VISUAL EVOKED RESPONSE. (PH.D. DISSERTATION).
212547 03-03
THE INFLUENCE OF ALKYLATE PHERPACET DERIVATIVES ON NEURON POPULATIONS IN THE MIDBRAIN RETICULAR FORMATION.
219501 04-03

RETICULUM
DIFFERENTIAL EFFECTS OF CHLORPROMAZINE AND CHLORPROMAZINE FREE-RADICAL ON CALCIUM TRANSPORT IN SARCOPLASMIC RETICULUM VESICLES.
210812 03-03

RETINA
SELECTIVE STIMULATION BY DOPAMINE OF ADENYLATE-CYCLASE IN HOMOGENATES OF RABBIT RETINA.
192936 01-03

RETIRED
EFFECT OF FIGHTING AND DIPHENYLHYDANTOIN ON THE UPTAKE OF H3-L-NOREPINEPHRINE IN VITRO IN SYNAPTOSOMES ISOLATED FROM RETIRED MALE BREEDING MICE.
222821 04-03

RETRANSPLANTABLE
BIOGENIC AMINES IN A RETRANSPLANTABLE NEUROGENIC TERATOCARCINOMA.
192925 01-03

RETRIEVAL
TIME-DEPENDENT, MEMORY RETRIEVAL EFFECTS FOLLOWING PERIPHERAL AND HIPPOCAMPAL TREATMENTS TO INCREASE SYNAPTIC BIOGENIC AMINES. (PH.D. DISSERTATION).
194677 01-04
DISRUPTION OF STATE-DEPENDENT LEARNING (MEMORY RETRIEVAL) BY EMOTIONALLY IMPORTANT STIMULI.
217470 04-04

RETROGRADE
PENTYLENETETRAZOL INDUCED RETROGRADE AMNESIA AND BRAIN SEIZURES IN MICE.
202724 02-04
AFFERENTS TO THE SEPTAL AREA OF THE RAT STUDIED WITH THE METHOD OF RETROGRADE AXONAL TRANSPORT OF HORSERADISH PEROXIDASE.
203573 02-03
ANTEROGRADE AND RETROGRADE EFFECTS OF ELECTROCONVULSIVE SHOCK AND OF PUROMYCIN ON MEMORY FORMATION IN THE GOLDFISH.
213853 04-04

RETROSPECTIVE
RETROSPECTIVE STUDY OF THE ASSOCIATION BETWEEN USE OF RAUWOLFIA DERIVATIVES AND BREAST CANCER IN ENGLISH WOMEN.
194063 01-13

REUPTAKE
MECHANISM OF ANTIDEPRESSANT EFFICACY OF MONOAMINEOXIDASE INHIBITORS: INHIBITION OF MONOAMINE OXIDASE OR OF CATECHOLAMINE REUPTAKE.
195925 01-17

REVERSAL
ANTIANESTHETIC EFFECTS OF CYCLIC-AMP AND ANALEPTIC DRUGS AS DETERMINED BY REVERSAL OF AMOBARBITAL INDUCED NARCOSIS.
193426 01-03
ROLE OF NORADRENALINE IN LEVODOPA REVERSAL OF RESERPINE AKINESIA.
193544 01-03
REVERSAL BY L-DOPA OF IMPAIRED LEARNING DUE TO DESTRUCTION OF THE DOPAMINERGIC NIGRO-NEOSTRIATAL PROJECTION.
193578 01-04
REVERSAL OF THE RESERPINE ELECTROENCEPHALOGRAPHIC SYNCHRONIZATION IN THE RABBIT BY P-CHLOROPHENYLALANINE.
197994 01-03
THE EFFECT OF DIFFERENTIAL SALINE AND CYCLOHEXIMIDE STATES ON THE ACQUISITION OF A SPATIAL REVERSAL TASK IN MICE AND RATS. (PH.D. DISSERTATION
198897 02-04
THE INHIBITORY EFFECT OF TOLUIDINE BLUE AND METHYLENE BLUE ON RAT MAST CELL DAMAGE BY PROMETHAZINE, CHLORPROMETHAZINE AND CHLORPROMAZINE. ITS REVERSAL BY GLUCOSE.
199255 02-05
REVERSAL OF RESERPINE INDUCED BRADYKINESIA BY ALPHA-METHYLDOPA -- NEW LIGHT ON ITS MODUS-OPERANDI.
202281 02-03
TRICYCLIC ANTIDEPRESSANT POISONING: REVERSAL OF COMA, CHOREOATHETOSIS, AND MYOCLONUS BY PHYSOSTIGMINE.
202919 02-15
REVERSAL OF AMITRIPTYLINE INTOXICATION BY PHYSOSTIGMINE.
202922 02-15
RAPID REVERSAL OF INTERNAL NA+ AND K+ CONTENTS OF SYNAPTOSOMES BY OUABAIN.
204185 02-03
ROLE OF THE BIOGENIC AMINES IN THE REVERSAL OF CYCLOHEXIMIDE INDUCED AMNESIA.
206752 03-04
REVERSAL OF DELIRIUM INDUCED BY TRICYCLIC ANTIDEPRESSANT DRUGS WITH PHYSOSTIGMINE.
213708 04-15
THERAPEUTIC REVERSAL WITH BENZTROPINE IN SCHIZOPHRENICS: PRACTICAL AND THEORETICAL SIGNIFICANCE.
213726 04-08
ANTIDEPRESSANT AGENTS AND REVERSAL OF DIURNAL ACTIVITY CYCLES IN THE RAT.
218954 04-04
THE EFFECT OF AUTONOMIC AND PSYCHOTROPIC DRUGS ON ADRENALINE REVERSAL IN THE RAT UTERUS.
222803 04-03
PHYSOSTIGMINE INDUCED REVERSAL OF EEG AND BEHAVIORAL EFFECTS OF DELTA9-TETRAHYDROCANNABINOL.
223093 04-04

REVERSALS
METHAMPHETAMINES EFFECT ON REPEATED ACQUISITIONS WITH SERIAL DISCRIMINATION REVERSALS.
202769 02-04

REVERSIBLE
EVIDENCE FOR REVERSIBLE INHIBITION OF BRAIN DOPAMINE-BETA-HYDROXYLASE ACTIVITY IN VIVO BY AMPHETAMINE ANALOGUES.
210821 03-03
REVERSIBLE INHIBITION OF MAMMALIAN BRAIN ACETYLCHOLINESTERASE AND SODIUM POTASSIUM STIMULATED ADENOSINE-TRIPHOSPHATASE BY CYCLOPROPANE.
210903 03-03
THE REVERSIBLE INHIBITION OF STEROID INDUCED SEXUAL BEHAVIOR BY INTRACRANIAL CYCLOHEXIMIDE.
213685 04-03

REVERSING
COMPARISON OF THE EFFECTS OF D-AMPHETAMINE AND L-AMPHETAMINE IN REVERSING DEPRESSION OF MOUSE LOCOMOTOR ACTIVITY CAUSED BY RESERPINE.
210869 03-03

REVIBOL
REVIBOL IN CHILDRENS PSYCHIATRY.
198395 02-11

REVIEW
LITHIUM PROPHYLAXIS -- A CRITICAL REVIEW.
194355 01-09
LITHIUM PROPHYLAXIS: A CRITICAL REVIEW.
197531 01-09
NIACIN THERAPY IN SCHIZOPHRENIA: A REVIEW.
200898 02-08
BENZODIAZEPINES IN THE TREATMENT OF EPILEPSY: A REVIEW.
201870 02-11
CANNABIS: A PSYCHOPHARMACOLOGICAL REVIEW.
205931 03-12
PHARMACOTHERAPY OF DEPRESSION -- A CRITICAL REVIEW.
211432 03-09
DRUG THERAPY FOR STUTTERERS: A REVIEW OF RESEARCH.
213786 04-11
ASPECTS OF LONG-TERM TREATMENT WITH NEUROLEPTICS: HISTORICAL AND LITERATURE REVIEW -- PERSONAL EXPERIENCE WITH FLUSPIRILENE AND PENFLURIDOL.
215059 04-14
A CRITICAL REVIEW OF OXAZEPAM: EFFICACY AND SPECIFICITY.
218154 04-17
HYPOTHYROIDISM DURING LITHIUM TREATMENT: A REVIEW OF 49 CASES.
221988 04-15
PEER REVIEW OF PRESCRIBING PATTERNS IN A CMHC.
224742 04-17

REWARD
ROLE OF DOPAMINE AND NOREPINEPHRINE IN THE CHEMISTRY OF REWARD.
207302 03-04
ACTIONS AND INTERACTIONS OF ABUSED DRUGS OF THE REWARD SYSTEM. (PH.D. DISSERTATION).
212964 03-04
INCREASED LEVEL PRESSING FOR AMPHETAMINE AFTER PIMOZIDE IN RATS: IMPLICATIONS FOR A DOPAMINE THEORY OF REWARD.
213350 03-04
ENHANCEMENT OF SELF-STIMULATION BY DEPRENIL: EVIDENCE FOR A ROLE OF DOPAMINE NEURONES IN REWARD.
213432 04-04
INTRACRANIAL REWARD AFTER 5,6 DIHYDROXYTRYPTAMINE: FURTHER EVIDENCE FOR SEROTONINS INHIBITORY ROLE.
215732 04-04
THE EFFECTS OF A DEXAMPHETAMINE AMYLOBARBITONE SODIUM MIXTURE ON THE REWARD VALUE OF DIFFERENT SENSORY CHANGES.
217476 04-03

REWARDING
NOREPINEPHRINE AND SEROTONIN: SPECIFICITY OF RELEASE WITH REWARDING ELECTRICAL STIMULATION OF THE BRAIN.
217522 04-03

RHESUS
FENFLURAMINE: AMPHETAMINE CONGENER THAT FAILS TO MAINTAIN DRUG-TAKING BEHAVIOR IN THE RHESUS MONKEY.
193137 01-04
CANNABINOL-7-OIC ACID: A METABOLITE OF DELTA1-TETRAHYDROCANNABINOL IN THE RHESUS MONKEY.
195114 01-03
NEGATIVE REINFORCING PROPERTIES OF MORPHINE ANTAGONISTS IN NAIVE RHESUS MONKEYS.
197284 01-04
CODEINE AND COCAINE REINFORCED RESPONDING IN RHESUS MONKEYS: EFFECTS OF DOSE ON RESPONSE RATES UNDER A FIXED-RATIO SCHEDULE.
202667 02-04
CEREBRAL FUNCTIONAL EFFECTS OF 2-DEOXY-D-GLUCOSE AND 3-O-METHYLGLUCOSE IN RHESUS MONKEYS.
210355 03-03
NEGATIVE REINFORCING PROPERTIES OF SOME PSYCHOTROPIC DRUGS IN DRUG NAIVE RHESUS MONKEYS.
210889 03-04
5-HYDROXYTRYPTAMINE IN THE CENTRAL NERVOUS SYSTEM AND SEXUAL RECEPTIVITY OF FEMALE RHESUS MONKEYS.
217856 04-04
SERUM ERYTHROCYTE AND CNS LEVELS IN RHESUS MONKEYS OF ORALLY AND INTRAVENOUSLY ADMINISTERED RUBIDIUM SALTS.
218956 04-02

RHYTHMS
DECREASED TEMPORAL VARIABILITY IN HIPPOCAMPAL THETA RHYTHMS OF CATS ADMINISTERED METHYLPHENIDATE.
213855 04-03
A STUDY OF THE RELATIONSHIP BETWEEN CIRCADIAN RHYTHMS IN DRUG ACTION AND METABOLISM IN THE MOUSE. (PH.D. DISSERTATION).
223562 04-03

RIBOSOMAL
MESCALINE-INDUCED CHANGES OF BRAIN CORTEX RIBOSOMES: EFFECT OF MESCALINE ON RIBOSOMAL SYNTHESIS OF POLYURIDINE DIRECTED POLYPHENYLALANINE.
194153 01-03

RIBOSOMES
MESCALINE-INDUCED CHANGES OF BRAIN CORTEX RIBOSOMES: EFFECT OF MESCALINE ON RIBOSOMAL SYNTHESIS OF POLYURIDINE DIRECTED POLYPHENYLALANINE.
194153 01-03
MESCALINE-INDUCED CHANGES OF BRAIN-CORTEX RIBOSOMES: EFFECT OF MESCALINE ON TRNA AND AMINOACYL-TRNA SYNTHETASE.
195242 01-03
FREE AND MEMBRANE BOUND RIBOSOMES AND POLYSOMES IN HIPPOCAMPAL NEURONS DURING A LEARNING EXPERIMENT.
210674 03-04

RIGHT
NEGATIVE INOTROPIC EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON THE ISOLATED RIGHT VENTRICULAR PAPILLARY MUSCLE OF THE CAT.
204400 02-05

RIGHTING
THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL PRETREATMENT ON KETAMINE, THIOPENTAL OR CT-1341 -- INDUCED LOSS OF RIGHTING REFLEX IN MICE.
210878 03-02

RIGID
POTENTIAL PSYCHOTOMIMETICS. 2. RIGID ANALOGS OF 2,5 DIMETHOXY-4-METHYLPHENYLISOPROPYLAMINE (DOM, STP).
202109 02-02
6-CHLORO-2-AMINOTETRALIN, A RIGID CONFORMATIONAL ANALOG OF 4-CHLOROAMPHETAMINE: PHARMACOLOGIC PROPERTIES OF IT AND RELATED COMPOUNDS IN RATS.
210870 03-02
EFFECTS OF RIGID AMPHETAMINE ANALOGS ON VASCULAR STRIPS: STUDIES OF 2-AMINOTETRAHYDRONAPHTHALENE AND 2-AMINOINDAN DERIVATIVES.
210921 03-03

RIGIDITY
THE RELATIONSHIP BETWEEN RIGIDITY AND CHANGE IN WHOLE BRAIN ACETYLCHOLINE CONCENTRATION PRODUCED BY INJECTION OF RESERPINE IN THE RAT.
197569 01-03
RIGIDITY IN RATS DUE TO ANEMIC DECEREBRATION AND THE EFFECT OF CHLORPROMAZINE.
202804 02-03
COGWHEEL RIGIDITY RELATED TO LITHIUM MAINTENANCE.
225334 04-15

RIGOR
QUANTITATIVE MEASUREMENT OF PARKINSON DISEASE RIGOR. MYOINTEGRATIVE DRUG TRIAL IN COMBINATION WITH THE DECARBOXYLASE INHIBITING DRUG RO-8-0576.
220829 04-11

RISK
THE TERATOGENIC RISK OF ANTIEPILEPTIC DRUGS.
225537 04-15

RITALIN
THE COMBINED EFFECTS OF METHYLPHENIDATE (RITALIN) AND A CLASSROOM BEHAVIOR MODIFICATION PROGRAM IN REDUCING THE HYPERKINETIC BEHAVIORS OF INSTITUTIONALIZED MENTAL RETARDATES. (PH.D. DISSERTATION).
202356 02-11
THE DIFFERENTIATION OF TWO TYPES OF HYPERACTIVE CHILDREN BY ACTIVITY LEVEL AND TASK PERFORMANCE WITH METHYLPHENIDATE (RITALIN) AND PLACEBO. (PH.D. DISSERTATION).
204688 02-11
THE EFFECTIVENESS OF RITALIN AND TOKEN ECONOMY IN INCREASING HYPERKINETIC CHILDRENS COLORING BEHAVIOR. (PH.D. DISSERTATION).
220510 04-14
RITALIN VERSUS BEHAVIOR THERAPY IN HYPERACTIVE CHILDREN.
224855 04-11

RITUAL
EFFECT OF DRUG RITUAL CHANGES ON SCHIZOPHRENICS.
224908 04-08

RNA

THE EFFECT OF PSYCHOPHARMACOLOGICAL DRUGS ON PUFFING AND ON RNA AND DNA SYNTHESES IN THE SALIVARY GLAND CHROMOSOMES OF DROSOPHILA-MELANOGASTER. (PH.D. DISSERTATION).
196250 01-03

RNA TREATMENT OF DEMENTIA: A DOUBLE-BLIND STUDY.
197841 01-11

REACTION OF CATIONIC GROUPS OF CHLORPROMAZINE WITH ANIONIC MACROMOLECULES: COMPLEXES WITH DNA, RNA, HYALURONIC ACID AND HEPARIN.
199897 02-03

BETA-ADRENERGIC STIMULATION OF PINEAL N-ACETYLTRANSFERASE: CYCLIC-AMP STIMULATES BOTH RNA AND PROTEIN SYNTHESIS.
215601 04-03

RO-4-4602

ACTION OF PROBENECID ON THE CENTRAL NERVOUS SYSTEM OF THE RABBIT: II. POTENTIATION OF 5-HYDROXYTRYPTOPHAN-INDUCED HYPERTHERMIA AND SUPPRESSION OF THIS EFFECT BY A DECARBOXYLASE INHIBITOR (RO-4-4602).
196580 01-03

RO-5-3350

A COMPARATIVE STUDY ON THE EFFECT OF INTRAVENOUS DIAZEPAM AND RO-5-3350 ON PYRAMIDAL SPASTICITY.
205575 02-13

DOUBLE-BLIND EXAMINATION OF BROMAZEPAM (RO-5-3350) FOR THE TREATMENT OF PSYCHONEUROSIS.
213293 03-10

A COMPARISON BETWEEN BROMAZEPAM (RO-5-3350, LEXOTAN) AND DIAZEPAM (VALIUM) IN ANXIETY NEUROSIS: A CONTROLLED, DOUBLE-BLIND CLINICAL TRIAL.
217455 04-10

RO-5-4023

CLONAZEPAM (RO-5-4023). FOUR YEARS OF CLINICAL RESEARCH.
205505 02-13

RO-5-4200

ALL-NIGHT POLYGRAPHIC RECORDINGS ON THE HYPNOTIC EFFECTS OF A NEW BENZODIAZEPINE: FLUNITRAZEPAM (RO-5-4200, ROHYPNOL).
202272 02-11

EEG EVALUATION OF HYPNOTIC DRUGS: MOGADON V. RO-5-4200, USING THE DOUBLE-BLIND METHOD.
205435 02-13

RO-8-0576

QUANTITATIVE MEASUREMENT OF PARKINSON DISEASE RIGOR. MYOINTEGRATIVE DRUG TRIAL IN COMBINATION WITH THE DECARBOXYLASE INHIBITING DRUG RO-8-0576.
220829 04-11

RODENTS

PHARMACOLOGICAL EVIDENCE FOR CEREBRAL DOPAMINE RECEPTOR BLOCKADE BY METOCLOPRAMIDE IN RODENTS.
217469 04-03

ROHYPNOL

ALL-NIGHT POLYGRAPHIC RECORDINGS ON THE HYPNOTIC EFFECTS OF A NEW BENZODIAZEPINE: FLUNITRAZEPAM (RO-5-4200, ROHYPNOL).
202272 02-11

ROLE

ROLE OF NORADRENALINE IN LEVODOPA REVERSAL OF RESERPINE AKINESIA.
193544 01-03

ROLE OF MONOAMINES IN THE ANOREXIGENIC ACTIONS OF FENFLURAMINE, AMPHETAMINE AND P-CHLOROMETHAMPHETAMINE.
193546 01-04

SOME STUDIES OF ADRENERGIC AMINES: PART I. ROLE OF THE AROMATIC RING IN RECEPTOR BINDING. PART II. BETA ADRENERGIC BLOCKADE. (PH.D. DISSERTATION).
194564 01-01

THE ROLE OF BRAIN CATECHOLAMINES IN THE ANORECTIC RESPONSE TO AMPHETAMINE. (PH.D. DISSERTATION).
196370 01-04

THE ROLE OF BRAIN DOPAMINE IN THE HYPERACTIVITY SYNDROME PRODUCED BY INCREASED 5-HYDROXYTRYPTAMINE SYNTHESIS IN RATS.
199960 02-04

INHIBITORY ROLE OF DOPAMINE AND 5-HYDROXYTRYPTAMINE IN THE SEXUAL BEHAVIOUR OF FEMALE RATS.
199968 02-04

ROLE OF CATECHOLAMINERGIC MECHANISMS IN THE EXPRESSION OF THE MORPHINE ABSTINENCE SYNDROME IN RATS.
200053 02-03

THE ROLE OF SEROTONIN IN THE PATHOPHYSIOLOGY OF MYOCLONIC SEIZURES ASSOCIATED WITH ACUTE IMIPRAMINE TOXICITY.
200088 02-03

THE ROLE OF SEX AND NOVELTY IN DETERMINING THE SOCIAL RESPONSE TO LITHIUM CHLORIDE.
202721 02-04

THE ROLE OF FOREBRAIN DOPAMINE SYSTEMS IN AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR IN THE RAT.
202774 02-04

THE PERIPHERAL AND CENTRAL ROLE OF THE CATECHOLAMINES IN THE MECHANISMS OF ANXIETY.
202783 02-17

THE ROLE OF CEREBRAL CYCLIC-AMP IN THE ACTION OF PSYCHOTROPIC DRUGS: IN VIVO AND IN VITRO STUDIES. (PH.D. DISSERTATION).
203032 02-03

THE ROLE OF THE RETICULAR FORMATION IN ACTION EXERTED BY CHLORPROMAZINE AND BENACTYZINE ON PRIMARY RESPONSES OF THE BRAIN-CORTEX.
206440 03-04

ROLE OF PITUITARY ADRENOCORTICAL SYSTEM IN MEDIATING AVOIDANCE BEHAVIOR OF RATS WITH SEPTAL LESIONS.
206739 03-04

ROLE OF THE BIOGENIC AMINES IN THE REVERSAL OF CYCLOHEXIMIDE INDUCED AMNESIA.
206752 03-04

ROLE OF DOPAMINE AND NOREPINEPHRINE IN THE CHEMISTRY OF REWARD.
207302 03-04

THE ROLE OF ADAPTIVE REGULATION IN THE PATHOPHYSIOLOGY OF PSYCHIATRIC DISEASE.
207307 03-03

POSSIBLE ROLE OF CATECHOLAMINES (CA) IN THE REGULATION OF ADRENAL TYROSINE-HYDROXYLASE (TH).
207333 03-03

THE ROLE OF DOPAMINE AND NOREPINEPHRINE IN CHANGING THE DIRECT CORTICAL RESPONSE TO PHENAMINE.
208971 03-03

D-AMPHETAMINE AND THE SENSORY ROLE OF A RATS TAIL IN THERMOREGULATION OR WHAT THE RATS TAIL TELLS THE RATS BRAIN.
209961 03-03

FROM PSYCHOPHARMACOLOGY TO PSYCHOPHARMACOGENETICS: DETERMINANTS OF THE EFFECTS OF DRUGS ON BEHAVIOR, ROLE OF GENETIC FACTORS.
210530 03-14

THE ROLE OF P-HYDROXYLATION OF AMPHETAMINE IN ITS PERIPHERAL MODE OF ACTION.
210749 03-03

BLOCKADE BY PIMOZIDE OF A NORADRENALINE SENSITIVE ADENYLATE-CYCLASE IN THE LIMBIC FOREBRAIN: POSSIBLE ROLE OF LIMBIC NORADRENERGIC MECHANISMS IN THE MODE OF ACTION OF ANTIPSYCHOTICS.
210771 03-03

COMPARATIVE STUDIES ON THE MEMBRANE ACTIONS OF DEPRESSANT DRUGS: THE ROLE OF LIPOPHILICITY IN INHIBITION OF BRAIN SODIUM AND POTASSIUM STIMULATED ATPASE.
210818 03-03

ON A PRIME ROLE FOR NEWLY SYNTHESIZED DOPAMINE IN STRIATAL FUNCTION.
210862 03-03

THE ROLE OF 5-HYDROXYTRYPTAMINE IN THE CONTROL OF ALPHA AND GAMMA MOTONEURONS. (PH.D. DISSERTATION).
212522 03-03

THE ROLE OF SEROTONIN IN THE SEPTAL BEHAVIOR SYNDROME OF RATS. (PH.D. DISSERTATION).
213128 03-03

THE ROLE OF MONOAMINES IN AVOIDANCE BEHAVIOUR IN RATS.
213422 04-04

ENHANCEMENT OF SELF-STIMULATION BY DEPRENIL: EVIDENCE FOR A ROLE OF DOPAMINE NEURONES IN REWARD.
213432 04-04

ROLE OF THE STRIO-PALLIDAL SYSTEM AND MOTOR CORTEX IN INDUCED CIRCUS MOVEMENTS IN RATS AND CATS.
213450 04-03

THE ROLE OF TYROSINE TRANSAMINASE IN BRAIN FUNCTION.
213607 04-03

NEUROPHYSIOLOGICAL ROLE OF SEROTONIN.
213621 04-03

THE ROLE OF INTRAVENOUS CLOMIPRAMINE IN THE TREATMENT OF OBSESSIONAL AND PHOBIC DISORDERS.
214835 04-10

THE MECHANISM OF THE POTENTIATING EFFECT OF ANTIDEPRESSANT DRUGS ON THE PROTECTIVE INFLUENCE OF DIPHENHYDRAMINE IN EXPERIMENTAL CATATONIA. THE ROLE OF HISTAMINE.
215664 04-03

INDUCTION OF TYROSINE-HYDROXYLASE ELICITED BY BETA ADRENERGIC RECEPTOR AGONISTS IN NORMAL AND DECENTRALIZED SYMPATHETIC GANGLIA: ROLE OF CYCLIC 3,5 ADENOSINE-MONOPHOSPHATE.
215688 04-03

TOLERANCE DEVELOPMENT TO THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON CONDITIONED BEHAVIOR: ROLE OF TREATMENT INTERVAL AND INFLUENCE OF MICROSOMAL METABOLISM.
215726 04-03

INTRACRANIAL REWARD AFTER 5,6 DIHYDROXYTRYPTAMINE: FURTHER EVIDENCE FOR SEROTONINS INHIBITORY ROLE.
215732 04-04

THE ROLE OF CATECHOLAMINES IN THE ACTION OF AMPHETAMINE AND L-DOPA ON CEREBRAL ENERGY METABOLISM.
217677 04-03

NEUROLEPTICS: RELATION BETWEEN CATALEPTIC AND ANTITURNING ACTIONS, AND ROLE OF THE CHOLINERGIC SYSTEM.
217826 04-04

ROLE OF BRAIN SEROTONIN IN THE INTEGRATION OF BEHAVIORAL RESPONSES AND PITUITARY ADRENOCORTICAL FUNCTIONS UNDER EMOTION.
218364 04-04

ON THE ROLE OF SEROTONIN IN PREDATORY AGGRESSION.
219110 04-04

EXAMINATION OF THE ROLE OF BRAIN AMINES AND CYCLIC-AMP IN BENZODIAZEPINE INDUCED SUPPRESSION OF AGGRESSION. (PH.D. DISSERTATION).
219278 04-04

THE ROLE OF THE AMYGDALA IN THE DEPRESSIVE ACTION OF SEROTONIN AND 5-HYDROXYTRYPTOPHAN ON THE CONDITIONED ACTIVITY OF WHITE RATS.
219328 04-04

POSSIBLE ROLE OF ADENOSINE-3-5-MONOPHOSPHATE AND BIOGENIC AMINES IN MORPHINE AND COCAINE TREATED RATS. (PH.D. DISSERTATION).
220475 04-03

BEHAVIORAL EFFECTS OF LOCAL INJECTION OF 6-HYDROXYDOPAMINE IN THE MEDIAL VENTRAL TEGMENTUM IN THE RAT. POSSIBLE ROLE OF THE MESOLIMBIC DOPAMINERGIC SYSTEM.
220946 04-04

ROLE OF MONOAMINES IN THE CONTROL BY HORMONES OF SEXUAL RECEPTIVITY IN THE FEMALE RAT.
222263 04-04

POISON INDUCED NEOPHOBIA IN RATS: ROLE OF STIMULUS GENERALIZATION OF CONDITIONED TASTE AVERSIONS.
223254 04-04

THE ROLE OF DISCRIMINATIVE STIMULI IN MODULATING DRUG ACTION.
225170 04-04

ROLE FOR POSTSYNAPTIC DOPAMINE RECEPTORS IN THE REGULATION OF THE KINETIC STATE OF STRIATAL TYROSINE-HYDROXYLASE. (UNPUBLISHED PAPER).
225307 04-03

ROLES
THERAPEUTIC ROLES OF DRUGS AND MORITA THERAPY PROCESS.
204428 02-10

ANTIPSYCHOTIC DRUGS: ROLES OF CYCLIC-AMP.
213609 04-03

EFFECTS OF MARIHUANA (DELTA9-THC) ON BEHAVIOR PATTERNS AND SOCIAL ROLES IN COLONIES OF CBA MICE.
216494 04-04

ROOT
CHANGES IN THE DORSAL ROOT POTENTIAL WITH DIAZEPAM AND WITH THE ANALGESICS ASPIRIN, NITROUS OXIDE, MORPHINE AND MEPERIDINE.
195248 01-03

ROTATION
DRUG-INDUCED ROTATION IN RATS AFTER UNILATERAL INTRACEREBRAL INJECTION OF 5,6 DIHYDROXYTRYPTAMINE (5-6-DHT).
192940 01-03

AMPHETAMINE-INDUCED CHANGES IN STRIATAL DOPAMINE AND ACETYLCHOLINE LEVELS AND RELATIONSHIP TO ROTATION (CIRCLING BEHAVIOR) IN RATS.
205432 02-04

APOMORPHINE-INDUCED ROTATION IN NORMAL RATS AND INTERACTION WITH UNILATERAL CAUDATE LESIONS.
214012 04-04

ROUTE
CYANOGEN CONDENSATIONS AS A ROUTE TO 3-AMINO-2-IMINOBENZOTHIAZIN-4-ONES WITH CNS DEPRESSANT POTENTIAL.
222870 04-02

ROUTES
EFFECT OF ORAL AND INTRAMUSCULAR ROUTES OF ADMINISTRATION ON SERUM CHLORDIAZEPOXIDE LEVELS AND THE PREDICTION OF THESE LEVELS FROM PREDRUG FASTING SERUM GLUCOSE CONCENTRATIONS.
195055 01-13

A COMPARISON OF THE LOCOMOTOR EFFECTS OF 5-HYDROXYTRYPTAMINE AND 5-HYDROXYTRYPTOPHAN ADMINISTERED VIA TWO SYSTEMIC ROUTES.
206086 03-04

RUBIDIUM
THE EFFECTS OF RUBIDIUM ON THE DURATION OF SLEEP ELICITED BY PENTOBARBITAL IN THE RAT.
210791 03-03

SERUM ERYTHROCYTE AND CNS LEVELS IN RHESUS MONKEYS OF ORALLY AND INTRAVENOUSLY ADMINISTERED RUBIDIUM SALTS.
218956 04-02

RULES
MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 1. COMMUNICATION: SETTING A GOAL AND METHODOLOGICAL GROUND RULES.
203839 02-13

RUMINANT
THE DISPOSITION KINETICS OF AMPHETAMINE IN THE RUMINANT ANIMAL.
197456 01-03

RUN
A SOCIETY ON THE RUN: A PSYCHOLOGY OF NORTHERN-IRELAND.
194054 01-17

S-ADENOSYL-L-METHIONINE
THERAPEUTIC EFFECTS AND MECHANISM OF ACTION OF S-ADENOSYL-L-METHIONINE (SAM) IN DEPRESSIVE SYNDROMES.
210213 03-09

S-1530
ELECTROENCEPHALOGRAPHIC AND BEHAVIORAL STUDIES ON THE CENTRAL ACTION OF NIMETAZEPAM (S-1530) IN CATS.
199910 02-04

S-804
THE EFFECTS OF MEDAZEPAM (S-804) ON ALL-NIGHT SLEEP.
211361 03-14

SACRAL
INHIBITION OF SACRAL PARASYMPATHETIC PREGANGLIONIC NEURONS BY GABA, GLYCIN, 5-HYDROXYTRYPTAMINE AND NOREPINEPHRINE. (PH.D. DISSERTATION).
212524 03-03

SAD
FROM SAD TO GLAD: KLINE ON DEPRESSION.
216706 04-17

SAFETY
SAFETY EVALUATION OF PENFLURIDOL.
198047 01-08

VOLATILE SOLVENT ADDICTION AND TRAFFIC SAFETY.
205596 02-15

RELATIVE SAFETY OF AMITRIPTYLINE IN MAINTENANCE TREATMENT OF DEPRESSION.
209438 03-15

BENZODIAZEPINES: SAFETY AND TOXICITY.
218155 04-15

SAH-42-548
THE EFFECTS OF 5-HYDROXY-5-4-CHLOROPHENYL 2,3 DIHYDRO-5H-IMIDAZOISOINDOLE (MAZINDOL, SAH-42-548) ON THE METABOLISM OF BRAIN NOREPINEPHRINE.
217653 04-03

SAIMIRI-SCIUREUS
A COMPARISON BETWEEN CAUDATE, AMYGDALOID AND HYPOTHALAMIC SELF-STIMULATION IN SQUIRREL MONKEYS (SAIMIRI-SCIUREUS). (PH.D. DISSERTATION).
214207 04-04

SALICYLATE
THE EFFECT OF BENZODIAZEPINES ON THE ANALGESIC EFFECT OF MORPHINE AND SODIUM SALICYLATE.
197480 01-03

PHYSOSTIGMINE SALICYLATE IN THE TREATMENT OF TRICYCLIC ANTIDEPRESSANT OVERDOSAGE.
212265 03-15

EFFECT OF MORPHINE, HYDROMORPHONE, METHADONE, MESCALINE, TRYPAN-BLUE, VITAMIN-A, SODIUM SALICYLATE AND CAFFEINE ON THE SERUM INTERFERON LEVEL IN RESPONSE TO VIRAL INFECTION.
217654 04-03

SALINE
THE EFFECT OF DIFFERENTIAL SALINE AND CYCLOHEXIMIDE STATES ON THE ACQUISITION OF A SPATIAL REVERSAL TASK IN MICE AND RATS. (PH.D. DISSERTATION
198897 02-04

EFFECT OF LOPERAMIDE, HALOPERIDOL AND METHADONE IN RATS TRAINED TO DISCRIMINATE MORPHINE FROM SALINE.
225568 04-04

SALIVA
ESTIMATION OF PHARMACOKINETIC PARAMETERS OF LITHIUM FROM SALIVA AND URINE.
195446 01-13

SALIVA LITHIUM LEVELS: CLINICAL APPLICATIONS.
207042 03-16

SALIVARY
THE EFFECT OF PSYCHOPHARMACOLOGICAL DRUGS ON PUFFING AND ON RNA AND DNA SYNTHESES IN THE SALIVARY GLAND CHROMOSOMES OF DROSOPHILA-MELANOGASTER. (PH.D. DISSERTATION).
196250 01-03

SALIVARY SCINTOGRAPHY: INTEREST IN TREATMENT OF DRY MOUTH PROVOKED BY PSYCHOTROPIC MEDICATION.
212493 03-15

SALT
LITHIUM SALT POISONING IN AN 8-YEAR-OLD CHILD.
219827 04-15

SALTS
PROBLEMS OF CLINICAL EFFECTIVENESS AND USE OF LITHIUM SALTS IN PSYCHIATRIC PRACTICE.
200072 02-09
CHANGES IN THE PSYCHODYNAMICS OF MANIC-DEPRESSIVES THROUGH LONG-TERM ADMINISTRATION OF LITHIUM SALTS.
203601 02-14
TO THE INCOMPATIBILITY OF HALOPERIDOL WITH LITHIUM SALTS.
205612 03-15
THERAPY WITH LITHIUM SALTS IN MANIC-DEPRESSIVE ILLNESSES.
209070 03-09
PRELIMINARY RESULTS ON THE CLINICAL USE OF A SLOW-RELEASE PREPARATION OF LITHIUM SALTS.
209122 03-09
SERUM ERYTHROCYTE AND CNS LEVELS IN RHESUS MONKEYS OF ORALLY AND INTRAVENOUSLY ADMINISTERED RUBIDIUM SALTS.
218956 04-02

SAM
THERAPEUTIC EFFECTS AND MECHANISM OF ACTION OF S-ADENOSYL-L-METHIONINE (SAM) IN DEPRESSIVE SYNDROMES.
210213 03-09

SAN-DIEGO
ANXIETY NEUROSIS, DEPRESSIVE DISORDER AND MEPROBAMATE ADDICTION -- PSYCHIATRIC GRAND-ROUNDS, UNIV. OF CALIFORNIA, SAN-DIEGO.
222772 04-10

SANDOMIGRAN
THE ANTIDEPRESSIVE EFFECT OF SANDOMIGRAN.
209019 03-11

SARCOLEMMA
5-HYDROXYTRYPTAMINE-14C AND DEXAMPHETAMINE-14C UPTAKE BY FUNDAL SARCOLEMMA PREPARATIONS AND THE PROBLEM OF THE COMMON RECEPTOR.
213591 04-03

SARCOPLASMIC
DIFFERENTIAL EFFECTS OF CHLORPROMAZINE AND CHLORPROMAZINE FREE-RADICAL ON CALCIUM TRANSPORT IN SARCOPLASMIC RETICULUM VESICLES.
210812 03-03

SB-5833
EFFECT OF CAMAZEPAM (SB-5833), A NEW ANTIANXIOUS DRUG, ON CARDIAC CONTRACTILITY AND CORONARY HEMODYNAMICS.
206785 03-03
NEUROPHARMACOLOGICAL STUDIES ON SB-5833, A NEW PSYCHOTHERAPEUTIC AGENT OF THE BENZODIAZEPINE CLASS.
221268 04-02
A PRELIMINARY DOUBLE-BLIND STUDY WITH SB-5833 (CAMAZEPAM), A NEW BENZODIAZEPINE DERIVATIVE.
221269 04-10

SC-13504
A NEUROPHARMACOLOGICAL EVALUATION OF SC-13504 -- A NEW ANTICONVULSANT. (PH.D. DISSERTATION).
222639 04-03

SCALE
THE SHAPIRO CARDS SCALE AS A METHOD OF ASSESSMENT OF OBSESSIONAL SYMPTOMS IN CLOMIPRAMINE THERAPY.
214829 04-10
DOUBLE-BLIND TEST OF THREE ANTIDEPRESSANTS, FOURTH COMMUNICATION; RESULTS WITH THE HAMBURG DEPRESSION SCALE.
221289 04-11

SCALES
THE USE OF ANALOGUE SCALES IN RATING SUBJECTIVE FEELINGS.
193851 01-14
THE SIGNIFICANCE OF STANDARDIZED EVALUATION SCALES IN PSYCHIATRIC DIAGNOSIS AS EXEMPLIFIED BY THE THERAPEUTIC INTERVENTION WITH DESMETHYLOXAPINE.
221337 04-10

SCALING
MULTIDIMENSIONAL SCALING TO RELATE ANIMAL PHARMACOLOGY AND CLINICAL SYMPTOMS OF PSYCHOPHARMACOLOGIC AGENTS.
198058 01-02
AN EXTENSION OF MULTIDIMENSIONAL SCALING TO FACILITATE CLINICAL INTERPRETATION OF ANIMAL TEST MODELS.
198059 01-02

SCH-10595
EFFECTS OF 5-(N-BUTYL) PICOLINAMIDE (SCH-10595), A DOPAMINE-BETA-HYDROXYLASE INHIBITOR, ON SEROTONIN AND CATECHOLAMINE METABOLITES IN BRAIN.
197813 01-03

SCHEDULE
DIFFERENTIAL EFFECTS OF CHLORDIAZEPOXIDE AND D-AMPHETAMINE ON RESPONDING MAINTAINED BY A DRL SCHEDULE OF REINFORCEMENT.
195433 01-04
POTENTIATION OF TETRABENAZINE-INDUCED BEHAVIOURAL DEPRESSION BY IMIPRAMINE ON A DISCRETE TRIAL AVOIDANCE ESCAPE SCHEDULE.
197859 01-04
CODEINE AND COCAINE REINFORCED RESPONDING IN RHESUS MONKEYS: EFFECTS OF DOSE ON RESPONSE RATES UNDER A FIXED-RATIO SCHEDULE.
202667 02-04
OXYPERTINE IN THE TREATMENT OF MORBID ANXIETY. REPORT OF A NEW LOW DOSAGE SCHEDULE.
207532 03-10
EFFECTS OF CHLORDIAZEPOXIDE ON SCHEDULE INDUCED WATER AND ALCOHOL CONSUMPTION IN THE SQUIRREL MONKEY.
214013 04-04
RATE DEPENDENT EFFECTS OF DRUGS. II. EFFECTS OF SOME MAJOR TRANQUILIZERS ON MULTIPLE FIXED-RATIO, FIXED-INTERVAL SCHEDULE PERFORMANCE.
217458 04-04
SCHEDULE INDUCED AGGRESSION IN LABORATORY RATS: DEMONSTRATION AND CONTROL THROUGH SODIUM AMOBARBITAL. (PH.D. DISSERTATION).
220644 04-04
THE EFFECTS OF CHRONIC MORPHINE ADMINISTRATION UPON A MODIFIED SIDMAN AVOIDANCE SCHEDULE THAT UTILIZES RESPONSE INDEPENDENT SHOCK.
225566 04-04

SCHEDULE-CONTROLLED
EFFECTS OF REPEATED DOSES OF 1-DELTA8-TRANS-TETRAHYDROCANNABINOL ON SCHEDULE-CONTROLLED TEMPORALLY SPACED RESPONDING OF RATS.
195431 01-04
NEUROCHEMICAL CHANGES ASSOCIATED WITH SCHEDULE-CONTROLLED BEHAVIOR.
225160 04-04
SCHEDULE-CONTROLLED BEHAVIORS AS DETERMINANTS OF DRUG RESPONSE.
225168 04-06

SCHEDULES
STEADY-STATE PLASMA CONCENTRATIONS DURING SINGLE AND MULTIPLE DOSAGE SCHEDULES OF AMITRIPTYLINE.
202699 02-13
SECOND-ORDER SCHEDULES OF DRUG INJECTION.
225157 04-04
REINFORCEMENT SCHEDULES AND EXTRAPOLATIONS TO HUMANS FROM ANIMALS IN BEHAVIORAL PHARMACOLOGY.
225171 04-04

SCHISTOSOMA-MANSONI
TRYPTAMINERGIC AND DOPAMINERGIC RESPONSES OF SCHISTOSOMA-MANSONI.
194155 01-03

SCHIZOAFFECTIVE
THE EFFECTIVENESS OF LITHIUM IN AFFECTIVE AND SCHIZOAFFECTIVE PSYCHOSES.
194043 01-11
CLINICAL BIOLOGICAL CORRELATIONS IN SCHIZOAFFECTIVE PATIENTS TREATED WITH LITHIUM CARBONATE AND HALOPERIDOL.
210501 03-09

SCHIZOPHRENIA
CLINICAL EXPERIENCE OF THE USE OF PENFLURIDOL (TLP-609) FOR THE TREATMENT OF SCHIZOPHRENIA.
194457 01-08
OUTPATIENT TREATMENT OF SCHIZOPHRENIA BY A LONG-LASTING STRONG TRANQUILIZER: USE OF FLUPHENAZINE ENANTHATE.
194460 01-08
TREATMENT OF SCHIZOPHRENIA BY THE ADMINISTRATION OF A SMALL DOSE OF FORIT FOR COMPARATIVELY LONG PERIODS OF TIME.
194476 01-08
USE OF SULPIRIDE IN THE TREATMENT OF SCHIZOPHRENIA.
194512 01-08
DIAGNOSING AND TREATING CHRONIC SCHIZOPHRENIA.
196601 01-08
PIMOZIDE (R-6238) IN SCHIZOPHRENIA (A PILOT STUDY).
196707 01-08
PATTERNS OF PSYCHOTROPIC DRUG USE FOR SCHIZOPHRENIA.
198052 01-08
SCHIZOPHRENIA FOLLOWUP: A CONTROLLED TREATMENT STUDY.
198076 02-08
CHLORPROMAZINE METABOLISM IN ACUTE SCHIZOPHRENIA.
198094 02-08
BEHAVIORAL MECHANISMS OF DRUG ACTION IN SCHIZOPHRENIA.
198103 02-08
CLINICAL EXPERIENCE WITH FORIT: ITS ACTIVATING EFFECT ON CHRONIC SCHIZOPHRENIA.
198710 02-08
A DOUBLE-BLIND CLINICAL EVALUATION OF PENFLURIDOL (R-16341) AS A MAINTENANCE THERAPY IN SCHIZOPHRENIA.
199993 02-08
THE INFLUENCE OF RESERPINE ON THE SEROTONIN METABOLISM IN PATIENTS WITH SCHIZOPHRENIA AND REACTIVE CONDITIONS.
200013 02-08
GABA BLOCKADE, DOPAMINE AND SCHIZOPHRENIA: EXPERIMENTAL STUDIES IN THE CAT.
200052 02-03

MAINTENANCE TREATMENT OF CHRONIC SCHIZOPHRENIA WITH NEUROLEPTIC DRUGS.
200636 02-08

CLOZAPINE AND HALOPERIDOL IN A SINGLE-BLIND CROSSOVER TRIAL: THERAPEUTIC AND BIOCHEMICAL ASPECTS IN THE TREATMENT OF SCHIZOPHRENIA.
200803 02-08

NIACIN THERAPY IN SCHIZOPHRENIA: A REVIEW.
200898 02-08

SEROTONIN AND SCHIZOPHRENIA. (UNPUBLISHED PAPER).
201002 02-08

REMARKS ON THE USE OF FLUPENTHIXOL IN TREATING CHRONIC SCHIZOPHRENIA.
201669 02-08

SOME CHARACTERISTICS OF PATHOLOGY IN SCHIZOPHRENIA DURING THE TWO STAGES OF PSYCHOPHARMACOLOGICAL DEVELOPMENT.
201908 02-08

CLINICAL TRIAL OF FLUPENTHIXOL IN PATIENTS WITH CHRONIC SCHIZOPHRENIA: ESPECIALLY IN PATIENTS HAVING DIFFICULTY IN REHABILITATION OWING TO DECREASED EXPRESSION, APATHY AND DISTURBANCE OF RAPPORT.
202603 02-08

HALLUCINOGENIC DRUGS AS PRECIPITANTS OF SCHIZOPHRENIA.
202693 02-08

SCHNEIDERIAN FIRST RANK SYMPTOMS AND CLINICAL FEATURES OF SCHIZOPHRENIA.
205179 02-08

EEG AND SCHIZOPHRENIA: EXPERIMENTAL STUDIES, SPECTRAL ANALYSIS AND SEPTAL SPIKES.
205455 02-03

OXYPROTHEPINE IN SCHIZOPHRENIA.
205581 02-08

MAINTENANCE TREATMENT OF SCHIZOPHRENIA WITH LONG-ACTING FLUPHENAZINE.
205585 02-08

CLOZAPINE IN THE MAINTENANCE THERAPY OF SCHIZOPHRENIA.
205618 03-08

THE MANAGEMENT OF SCHIZOPHRENIA OUTSIDE THE HOSPITAL: RESEARCH FINDINGS AND UNDERLYING PRINCIPLES.
206044 03-08

A TWO-FACTOR BIOCHEMICAL THEORY OF SCHIZOPHRENIA.
206542 03-03

PHARMACOTHERAPY OF SCHIZOPHRENIA: FACTS, SPECULATIONS, HYPOTHESES AND THEORIES.
206603 03-08

CLOZAPINE IN LONG-TERM THERAPY OF CHRONIC SCHIZOPHRENIA.
206975 03-08

A TWO FACTOR THEORY OF SCHIZOPHRENIA.
207286 03-14

A PILOT STUDY OF PIMOZIDE IN SCHIZOPHRENIA.
207293 03-08

DOPAMINE AND THE PHARMACOLOGY OF SCHIZOPHRENIA: THE STATE OF THE EVIDENCE.
207300 03-03

CENTRAL CATECHOLAMINE NEURONS, BEHAVIOR AND NEUROLEPTIC DRUGS: AN ANALYSIS TO UNDERSTAND THE INVOLVEMENT OF CATECHOLAMINES IN SCHIZOPHRENIA.
207305 03-03

CLINICAL USE OF CLOCAPRAMINE FOR THE TREATMENT OF CHRONIC SCHIZOPHRENIA -- SPECIAL EMPHASIS ON ITS COMPARISON WITH PERPHENAZINE.
207534 03-08

DOSE LEVEL AND EFFECTS OF TRIFLUPERIDOL IN CLINICAL USE FOR SCHIZOPHRENIA.
207643 03-08

THOUGHT DISORDERS IN SCHIZOPHRENIA BEFORE AND AFTER PHARMACOLOGICAL TREATMENT.
207767 03-17

DRUGS, MEDIATORS, AND SCHIZOPHRENIA.
208631 03-08

TREATMENT OF SCHIZOPHRENIA.
209002 03-13

PERSONAL EXPERIENCE IN THE USE OF SULPIRIDE (FK-880) ON SCHIZOPHRENIA.
209405 03-08

EFFECTIVENESS OF LOXAPINE SUCCINATE IN ACUTE SCHIZOPHRENIA: A COMPARATIVE STUDY WITH THIOTHIXENE.
209484 03-08

SULPIRIDE VERSUS HALOPERIDOL IN SCHIZOPHRENIA: A DOUBLE-BLIND COMPARATIVE TRIAL.
209701 03-08

TREATMENT OF ACUTE SCHIZOPHRENIA WITH A NEW BUTYROPHENONE - - LENPERONE.
209791 03-07

A CASE OF PHEOCHROMOCYTOMA WITH SCHIZOPHRENIA LIKE SYMPTOMS.
210794 03-17

THE EFFECT OF L-DOPA ON SCHIZOPHRENIA.
211339 03-08

DOPAMINE ANTAGONISM BY THIORIDAZINE IN SCHIZOPHRENIA.
213527 04-08

SCHIZOPHRENIA AND EVOKED POTENTIALS: MAXIMUM AMPLITUDE, FREQUENCY OF PEAKS, VARIABILITY, AND PHENOTHIAZINE EFFECTS.
213764 04-08

COMPUTERIZED EEG: PREDICTOR OF OUTCOME IN SCHIZOPHRENIA.
213863 04-08

A COMPARISON OF THE THERAPEUTIC EFFECT OF OXYPERTINE AND THIORIDAZINE IN CHRONIC SCHIZOPHRENIA (A CONTROLLED TRIAL).
215075 04-08

TREATMENT OF ACUTE SCHIZOPHRENIA WITH ULTRA-HIGH-DOSE FLUPHENAZINE: A FAILURE AT SHORTENING TIME ON A CRISIS INTERVENTION UNIT.
215456 04-08

EFFECTS OF PHENOTHIAZINES ON ANXIETY AND COGNITION IN SCHIZOPHRENIA.
216190 04-08

SCHIZOPHRENIA -- 5: PHYSICAL TREATMENTS AND DRUGS.
216403 04-08

AMPHETAMINE PSYCHOSIS OR PARANOID SCHIZOPHRENIA?
216965 04-15

COMPARATIVE STUDY OF CLOTHIAPINE AND TRIFLUOPERAZINE IN EPISODES OF ACUTE PARANOID SCHIZOPHRENIA.
217025 04-08

A PHARMACOLOGICAL MODEL OF THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA.
218213 04-08

BACLOFEN IN THE TREATMENT OF SCHIZOPHRENIA.
218254 04-08

SOME NEUROCHEMICAL EFFECTS OF N,N DIMETHYLTRYPTAMINE AND THEIR POSSIBLE RELATION TO ACUTE SCHIZOPHRENIA. (PH.D. DISSERTATION).
219179 04-03

MEGAVITAMIN AND ORTHOMOLECULAR THERAPY OF SCHIZOPHRENIA.
219536 04-08

CHLORIMIPRAMINE IN SCHIZOPHRENIA.
220267 04-08

PERPHENAZINE ENANTHATE IN TREATING CHRONIC SCHIZOPHRENIA.
221558 04-08

LITHIUM TREATMENT OF SCHIZOPHRENIA: A CONTROLLED EXPERIMENT.
221635 04-08

CLOZAPINE AND HALOPERIDOL: CLINICAL AND BIOCHEMICAL ASPECTS IN THE TREATMENT OF SCHIZOPHRENIA.
221637 04-08

COMPARATIVE STUDY OF CLOCAPRAMINE AND PERPHENAZINE ON CHRONIC SCHIZOPHRENIA BY A DOUBLE-BLIND METHOD.
222158 04-08

OBSERVATIONS ON THE DOSE REGIME OF FLUPHENAZINE DECANOATE IN MAINTENANCE THERAPY OF SCHIZOPHRENIA.
222602 04-17

THE USE OF AN ORGAL LONG-ACTING ANTIPSYCHOTIC AGENT, PENFLURIDOL, IN SCHIZOPHRENIA.
223165 04-08

TREATMENT RESULTS OF L-DOPA ON SCHIZOPHRENIA.
223202 04-08

METHYLATION & SCHIZOPHRENIA.
224353 04-17

TREATING PATIENTS WITH A SLUGGISH FORM OF SCHIZOPHRENIA.
224383 04-08

TREATMENT EXPERIENCE OF CHRONIC SCHIZOPHRENIA WITH PENFLURIDOL.
224548 04-08

COMPARISON OF THE REMEDIAL RESULTS OF CLOFLUPEROL AND HALOPERIDOL FOR SCHIZOPHRENIA BY DOUBLE-BLIND TEST METHOD.
224549 04-08

PSYCHOSOCIAL TREATMENT OF ACUTE SCHIZOPHRENIA.
224790 04-17

SCHIZOPHRENIAS

PROFILE-BASED-THERAPY (PBT) IN SCHIZOPHRENIAS: A PRECLINICAL INDICATION FOR THE USE OF DIHYDROXYPHENYLSERINE (DOPS).
195115 01-08

NEGATIVE FINDINGS WITH NICOTINIC ACID IN THE TREATMENT OF SCHIZOPHRENIAS.
202787 02-08

NICOTINIC ACID IN THE TREATMENT OF SCHIZOPHRENIAS: CANADIAN MENTAL HEALTH ASSOCIATION COLLABORATIVE STUDY PROGRESS REPORT II.
219537 04-08

SCHIZOPHRENIC

ONCE VERSUS THRICE DAILY THIOTHIXENE IN THE TREATMENT OF SCHIZOPHRENIC INPATIENTS.
194044 01-08

EFFECT OF CHRONIC ADMINISTRATION OF CENTRALLY ACTING COMPOUNDS ON CHLORAMPHENICOL METABOLISM IN SCHIZOPHRENIC PATIENTS.
194157 01-08

PAMELA -- A PARANOID SCHIZOPHRENIC.
197142 01-08

THE COURSE AND PROGNOSIS OF SCHIZOPHRENIC PSYCHOSES IN HELSINKI: A COMPARATIVE STUDY OF FIRST ADMISSIONS IN 1950, 1960 AND 1965.
197276 01-17

NIMH-PRB COLLABORATIVE OUTPATIENT SCHIZOPHRENIC STUDY.
198075 02-08

PHENOTHIAZINE AND SCHIZOPHRENIC THOUGHT DISORDER.
198102 02-08

CLINICAL EXPERIENCE WITH CLOCAPRAMINE (CLOFEKTON) FOR THE TREATMENT OF SCHIZOPHRENIC PATIENTS.
198709 02-08

DRUG AND SOCIOTHERAPY IN THE AFTERCARE OF SCHIZOPHRENIC PATIENTS: II. TWO-YEAR RELAPSE RATES.
199625 02-08

DRUG AND SOCIOTHERAPY IN THE AFTERCARE OF SCHIZOPHRENIC PATIENTS: III. ADJUSTMENT OF NONRELAPSED PATIENTS.
199626 02-08

PRELIMINARY RESULTS OF A CONTROLLED TRIAL WITH SULPIRIDE VERSUS CHLORIMIPRAMINE IN CHRONIC SCHIZOPHRENIC PATIENTS WITH MARKED IDEO-EMOTIONAL POVERTY.
200445 02-08

PLASMA TRYPTOPHAN TOLERANCE CURVES IN DRUG-FREE NORMAL CONTROLS, SCHIZOPHRENIC PATIENTS AND PRISONER VOLUNTEERS.
200773 02-13

COMPARATIVE RESULTS OF A PHARMACOLOGICAL LOADING WITH AMINAZINE AND HALOPERIDOL IN SCHIZOPHRENIC PATIENTS.
201910 02-08

MONTHLY INTERMITTENT CHEMOTHERAPY OF CHRONIC SCHIZOPHRENIC OUTPATIENTS WITH PIPOTHIAZINE PALMITATE.
204169 02-08

EEG STATISTICAL SPECTRAL ANALYSIS OF SCHIZOPHRENIC PATIENTS.
205448 02-08

A CONTROLLED COMPARISON OF OXYPERTINE AND PERPHENAZINE IN SCHIZOPHRENIC PSYCHOSES.
205582 02-08

MG++ DEPENDENT ADENOSINE-TRIPHOSPHATASE ACTIVITY IN ERYTHROCYTE GHOSTS OF SCHIZOPHRENIC PATIENTS.
206332 03-08

CLINICAL STUDY ON SULPIRIDE IN LONG-TERM HOSPITALIZED SCHIZOPHRENIC PATIENTS.
206978 03-08

THE INFLUENCE OF HALOPERIDOL AND PENFLURIDOL ON THE LEARNING CAPACITY OF THE SCHIZOPHRENIC.
207000 03-14

MASS FRAGMENTOMETRIC DETERMINATION OF HOMOVANILLIC ACID IN LUMBAR CEREBROSPINAL FLUID OF SCHIZOPHRENIC PATIENTS DURING TREATMENT WITH ANTIPSYCHOTIC DRUGS.
207295 03-08

A CROSSOVER STUDY OF ALLOPURINOL ADMINISTRATION TO A SCHIZOPHRENIC CHILD.
207788 03-08

TWO DECADES OF PSYCHOPHARMACOLOGY AND COMMUNITY MENTAL HEALTH: OLD AND NEW PROBLEMS OF THE SCHIZOPHRENIC PATIENT.
207921 03-17

PSYCHOPHARMACOLOGY, COMMUNITY MENTAL HEALTH AND THE SCHIZOPHRENIC PATIENT.
207922 03-17

RESULTS OF THERAPY WITH LYOGEN DEPOT IN SCHIZOPHRENIC ILLNESS.
208622 03-08

DOSAGE OF A PSYCHOTROPIC DRUG TO PREVENT RELAPSE IN A CURED SCHIZOPHRENIC PATIENT.
209402 03-08

PROPRANOLOL IN THE CONTROL OF SCHIZOPHRENIC SYMPTOMS.
209830 03-08

PIMOZIDE IN CHRONIC SCHIZOPHRENIC OUTPATIENTS.
209905 03-08

DRUG-RESISTANCE AND BIOCLINICAL FACTORS IN THE RESPONSE OF SCHIZOPHRENIC PATIENTS TO CHLORPROMAZINE.
210500 03-08

USE OF A NEW PSYCHOTROPIC DRUG, CLOFLUPEROL FOR THE TREATMENT OF CHRONIC SCHIZOPHRENIC PATIENTS.
211304 03-08

THE LONG-TERM MAINTENANCE TREATMENT OF SCHIZOPHRENIC OUTPATIENTS WITH DEPOT FLUPENTHIXOL.
212491 03-08

CLINICAL EXPERIENCE OF FLUPHENAZINE ENANTHATE IN TREATMENT OF SCHIZOPHRENIC PATIENTS.
213294 03-08

INFLUENCE OF RESERPINE ON ALL-NIGHT SLEEP PATTERN IN NONLOBOTOMIZED AND LOBOTOMIZED CHRONIC SCHIZOPHRENIC PATIENTS.
213530 04-08

EXTRAPYRAMIDAL REACTIONS AND AMINE METABOLITES IN CEREBROSPINAL FLUID DURING HALOPERIDOL AND CLOZAPINE TREATMENT OF SCHIZOPHRENIC PATIENTS.
214010 04-15

PIPOTHIAZINE PALMITATE: AN EVALUATION OF A NEW LONG-ACTING INTRAMUSCULAR ANTIPSYCHOTIC AGENT IN SEVERELY ILL SCHIZOPHRENIC PATIENTS.
216188 04-08

LOXAPINE IN NEWLY ADMITTED CHRONIC SCHIZOPHRENIC PATIENTS.
217810 04-08

DOPAMINE SENSITIVE ADENYLCYCLASE IN HUMAN CAUDATE NUCLEUS: A STUDY IN CONTROL SUBJECTS AND SCHIZOPHRENIC PATIENTS.
221732 04-13

RESULTS OF A COMPARATIVE DOUBLE-BLIND STUDY WITH CLOZAPINE AND CHLORPROMAZINE IN THE TREATMENT OF SCHIZOPHRENIC PATIENTS.
221989 04-08

ATROPINE COMA TREATMENT OF SCHIZOPHRENIC PATIENTS WITH A SLUGGISH DEVELOPMENT AND OBSESSIVE SYNDROMES.
224085 04-08

A COMPARISON OF PHENOTHIAZINES IN MANAGING AGGRESSIVE EPISODES IN SCHIZOPHRENIC PATIENTS.
224955 04-08

SCHIZOPHRENICS

GROUP THERAPY AND MAINTENANCE TREATMENT OF SCHIZOPHRENICS.
194860 01-08

A CLINICAL NEUROLEPTIC INVESTIGATION OF N-(1-ETHYL-PYRROLIDIN-2-YL) 2-METHOXY-5-SULFAMOYL-BENZAMIDE NEUROLEPTIC SULPIRIDE (DOGMATIL) IN ACUTELY ILL SCHIZOPHRENICS.
195038 01-11

EFFECT OF THIOTHIXENE UPON THE HIGHER NERVOUS ACTIVITY IN CHRONIC SCHIZOPHRENICS.
195041 01-09

CLINICAL EFFICACY OF PIMOZIDE IN HOSPITALISED CHRONIC SCHIZOPHRENICS.
195615 01-08

DRUG-SCREENING PROGRAM FOR DRUG-RESISTANT SCHIZOPHRENICS.
198072 01-02

APONEURON TREATMENT OF CHRONIC SCHIZOPHRENICS WITH REDUCED DRIVE.
203666 02-08

DIFFERENTIAL EFFECTS OF NEUROLEPTIC DRUGS IN CHRONIC SCHIZOPHRENICS: A CONFIGURATION ANALYTICAL EVOLUTION.
204415 02-08

A POLYGRAPHIC STUDY OF TOLERANCE OF SCHIZOPHRENICS TO CHLORPROMAZINE.
204430 02-08

BUTACLAMOL HYDROCHLORIDE (AY-23028): AN EARLY EVALUATION IN SEVERELY ILL SCHIZOPHRENICS.
206933 03-08

EFFECTS OF PHENOTHIAZINE WITHDRAWAL ON PROVERB INTERPRETATION BY CHRONIC SCHIZOPHRENICS.
208325 03-08

CLINICAL TRENDS AND PSYCHOMETRIC APPRAISAL OF A GROUP OF SCHIZOPHRENICS TREATED WITH THIOTHIXENE (NAVANE).
208981 03-08

A CLINICAL EXPERIMENTAL STUDY ON THE USE OF SULPIRIDE IN A GROUP OF CHRONIC SCHIZOPHRENICS (FIRST NOTE).
210510 03-08

COMPARISON OF 3,4 DIMETHOXYPHENYLETHYLAMINE TREATED PLASMA FROM CHRONIC SCHIZOPHRENICS AND CONTROLS.
210897 03-08

PREVENTION OF RECIDIVISM OF SCHIZOPHRENICS TREATED WITH FLUPHENAZINE ENANTHATE.
211436 03-08

PRELIMINARY STUDY OF A BETA-BLOCKER (PINDOLOL) IN THREE SCHIZOPHRENICS AND THREE NONPSYCHOTIC PSYCHIATRIC PATIENTS: DIFFERENTIAL SENSITIVITY IN HEART RATE.
212164 03-13

A STUDY OF FLUPENTHIXOL DECANOATE AND PIPOTIAZINE UNDECYLENATE IN SCHIZOPHRENICS.
212238 03-08

THERAPEUTIC REVERSAL WITH BENZTROPINE IN SCHIZOPHRENICS: PRACTICAL AND THEORETICAL SIGNIFICANCE.
213726 04-08

PHENOTHIAZINE EFFECTS ON CEREBRAL EVOKED POTENTIALS AND EYE MOVEMENTS IN ACUTE SCHIZOPHRENICS.
217454 04-08

CLINICAL - PSYCHOPATHOLOGICAL CRITERIA FOR THE SELECTION OF PSYCHOTROPIC DRUGS ACCORDING TO THE STAGE OF ILLNESS AND THE EFFECTIVENESS OF REHABILITATING SCHIZOPHRENICS.
220403 04-17

EFFECT OF DRUG RITUAL CHANGES ON SCHIZOPHRENICS.
224908 04-08

SCHIZOPHRENIFORM

A SCHIZOPHRENIFORM BEHAVIORAL PSYCHOSIS MEDIATED BY DOPAMINE.
207035 03-04

SCHNEIDERIAN

SCHNEIDERIAN FIRST RANK SYMPTOMS AND CLINICAL FEATURES OF SCHIZOPHRENIA.
205179 02-08

SCHOOL-AGE
PLATELET SEROTONIN OF HYPERACTIVE SCHOOL-AGE BOYS.
194397 01-13

SCINTOGRAPHY
SALIVARY SCINTOGRAPHY: INTEREST IN TREATMENT OF DRY MOUTH PROVOKED BY PSYCHOTROPIC MEDICATION.
212493 03-15

SCOPE
SCOPE AND LIMITATION IN DOPAMINE BETA-HYDROXYLASE MEASUREMENT.
210811 03-02

SCOPOLAMINE
THE EFFECTS OF SCOPOLAMINE ON A TWO-CUE DISCRIMINATION.
192952 01-04
INHIBITION OF SCOPOLAMINE INDUCED STIMULATION OF Y-MAZE ACTIVITY BY ALPHA-METHYL-P-TYROSINE AND BY LITHIUM.
199866 02-04
THE EFFECTS OF SCOPOLAMINE AND PHYSOSTIGMINE ON FIXED-INTERVAL BEHAVIOUR IN THE RAT.
200046 02-04
EFFECTS OF SCOPOLAMINE ON THE EEG OF CORTEX AND HIPPOCAMPUS DURING SPONTANEOUS BEHAVIOUR IN RATS.
205628 03-04
SCOPOLAMINE AND AMPHETAMINE EFFECTS ON DISCRIMINATION.
206109 03-04
EFFECTS OF HIPPOCAMPAL MICROINJECTIONS OF D-AMPHETAMINE AND SCOPOLAMINE ON ACTIVE AVOIDANCE BEHAVIOR IN RATS.
206741 03-04
ATTENUATION OF ACUTE HABITUATION BY SCOPOLAMINE IN THE BLACK-TAILED PRAIRIE DOG (CYNOMYS-LUDOVICIANUS).
206745 03-04
THE EFFECTS OF SCOPOLAMINE (0.6 MG) AND PHYSOSTIGMINE (1.0 MG) ON HIGHER NERVOUS ACTIVITY IN MAN, FOLLOWED-UP DURING 5 HOURS AFTER APPLICATION.
217205 04-14
EFFECTS OF SCOPOLAMINE AND ALPHA-METHYL-P-TYROSINE UPON PREDATORY ATTACK IN CATS.
217526 04-04
EFFECTS OF SCOPOLAMINE, PHYSOSTIGMINE AND CHLORDIAZEPOXIDE ON PUNISHED AND EXTINGUISHED WATER CONSUMPTION IN RATS.
221043 04-04
EFFECTS OF SCOPOLAMINE ON RETENTION OF TASTE AVERSION LEARNING IN RATS.
223033 04-04
SPONTANEOUS ALTERNATION IN FERRETS FOLLOWING TREATMENT WITH SCOPOLAMINE, CHLORDIAZEPOXIDE, AND CAFFEINE.
223039 04-04
SIZE OF THE ENVIRONMENT AS A DETERMINER OF EFFECTS OF SCOPOLAMINE.
223849 04-04

SCORBUTIC
6-HYDROXYDOPAMINE INDUCED DEGENERATION OF NORADRENALINE NEURONS IN THE SCORBUTIC GUINEA-PIG.
195449 01-03

SCOTTISH
INVOLVEMENT OF SEROTONIN IN HYPERKINETIC EPISODES IN SCOTTISH TERRIER DOGS. (PH.D. DISSERTATION).
196261 01-03

SCREENED
A NEW BENZODIAZEPINE, SCREENED BY A PARALLEL DOUBLE-BLIND TEST.
212167 03-10

SCREENING
THE SCREENING OF BENZODIAZEPINES.
198056 01-06
COOPERATIVE CLINICAL SCREENING OF PSYCHOTROPIC DRUGS.
198066 01-07
URINARY SCREENING FOR DRUGS IN A HOSPITAL FOR THE MENTALLY SUBNORMAL.
210437 03-17
SCREENING HALLUCINOGENIC DRUGS: SYSTEMIC STUDY OF THREE BEHAVIORAL TESTS.
217528 04-06
RAPID MASS SCREENING AND CONFIRMATION OF URINARY AMPHETAMINE AND METHAMPHETAMINE BY GAS CHROMATOGRAPHY.
222829 04-06

SDR
METHAMPHETAMINES EFFECT ON SDR: REPLICATION AND EXTENSION.
194133 01-04

SEARCH
SEARCH FOR NEW HALLUCINOGENIC CACTI.
202382 02-01

SECOBARBITAL
A COMPARATIVE STUDY OF THE HYPNOTIC PROPERTIES OF FLURAZEPAM (30 MG), SECOBARBITAL (100 MG), AND OF PLACEBO AMONG FOUR TYPES OF PSYCHOTIC INSOMNIACS.
203204 02-04
EFFECTS OF D-AMPHETAMINE AND SECOBARBITAL ON KEY PRESS RATES IN NORMAL HUMANS.
210879 03-14
EEG CORRELATES OF IMPAIRED ATTENTION PERFORMANCE UNDER SECOBARBITAL AND CHLORPROMAZINE IN THE MONKEY.
217544 04-03

SECOND-ORDER
SECOND-ORDER SCHEDULES OF DRUG INJECTION.
225157 04-04

SECONDARY
DIFFERENTIAL SENSITIVITY OF PRIMARY AND SECONDARY SPINDLE AFFERENTS TO DEPRESSANT DRUGS.
210801 03-03
SIMILARITIES OF THE INFLUENCE OF SECONDARY AND TERTIARY TRICYCLIC ANTIDEPRESSANTS ON THE EFFECT OF RESERPINE IN FROGS AND ON THE SEROTONIN UPTAKE OF HUMAN THROMBOCYTES.
219503 04-13

SECRETION
EFFECTS OF CENTRAL ACTING DRUGS AND ERGOT DERIVATIVES ON PROLACTIN AND GROWTH HORMONE SECRETION, ON GROWTH OF PITUITARY AND MAMMARY TUMORS AND ON REPRODUCTION IN OLD RATS. (PH.D. DISSERTATION).
194571 01-03
SYMPATHOMIMETIC AMINES AND GASTRIC SECRETION IN RATS.
199622 02-03
SUPPRESSION BY NORADRENALINE OF CATECHOLAMINE SECRETION FROM ADRENAL MEDULLA.
199869 02-03
NEUROTRANSMITTER CONTROL OF THYROTROPIN SECRETION IN THE RAT.
210858 03-03
INHIBITION OF CATECHOLAMINE AND 5-HYDROXYTRYPTAMINE INDUCED ENZYME SECRETION FROM THE GUINEA-PIG SUBMANDIBULAR GLAND BY 2-BROMO-D-LYSERGIC ACID DIETHYLAMIDE.
216968 04-03

SECTION
THE EFFECTS OF CORD SECTION UNDER ETHER OR HALOTHANE ON THE ABILITY OF CHLORPROMAZINE TO AFFECT THE JAW-JERK RESPONSE TO TOOTH PULP STIMULATION IN THE ENCEPHALE ISOLE PREPARATION.
197451 01-03
THE EEG EFFECTS OF DOPA IN THE RABBIT DEPENDING UPON THE LEVEL OF BRAINSTEM SECTION.
210880 03-03

SECTIONS
PROTEINASE ACTIVITY OF DIFFERENT SECTIONS OF THE BRAIN DURING CORAZOL (PENTYLENETETRAZOL) INDUCED CONVULSIONS.
198485 02-03

SEDATIVE
THE USE OF THE IMMOBILITY REFLEX (ANIMAL HYPNOSIS) AS A POSSIBLE PROCEDURE FOR DETECTING SEDATIVE ACTIVITY.
196066 01-04
HMO ANALYSIS OF STRUCTURE-ACTIVITY RELATIONS IN SEDATIVE AND HYPNOTIC DRUGS AND ANALYSIS OF POTENTIAL SEDATIVES BY MEANS OF HOMOLOGOUS COMPOUNDS.
199208 02-01
AZAPERONE, A SEDATIVE NEUROLEPTIC OF THE BUTYROPHENONE SERIES WITH PRONOUNCED ANTIAGGRESSIVE AND ANTISHOCK ACTIVITY IN ANIMALS.
206786 03-04
SEDATIVE EFFECTS ON PHYSIOLOGICAL AND PSYCHOLOGICAL MEASURES IN ANXIOUS PATIENTS.
209079 03-10
THE EFFECTS OF A NEW SEDATIVE (LEXOTAN) ON REACTION TIMES AND ON ATTENTIVE CAPACITY OF A GROUP OF ATHLETES.
209857 03-14
CLOZAPINE AS A SEDATIVE.
221537 04-11
A DIRECT EFFECT OF DIBUTYRYL CYCLIC-AMP ON THE DURATION OF NARCOSIS INDUCED BY SEDATIVE, HYPNOTIC, TRANQUILISER AND ANESTHETIC DRUGS IN THE RAT.
222814 04-04

SEDATIVES
HMO ANALYSIS OF STRUCTURE-ACTIVITY RELATIONS IN SEDATIVE AND HYPNOTIC DRUGS AND ANALYSIS OF POTENTIAL SEDATIVES BY MEANS OF HOMOLOGOUS COMPOUNDS.
199208 02-01
SEDATIVES, HYPNOTICS AND TRANQUILLIZERS.
202458 02-17
MICROMETHODS FOR QUANTITATIVE DETERMINATION OF SEDATIVES AND ANTIPYRETICS BY THERMO-GAS CHROMATOGRAPHY.
206807 03-06
A DOUBLE-BLIND TRIAL OF NITRAZEPAM AND FLURAZEPAM AS SEDATIVES.
217041 04-14

SEDUXEN
A DIFFERENTIATED USE OF ELENIUM AND SEDUXEN IN YOUNG PATIENTS IN THE POST-INFARCTIONAL PERIOD.
200104 02-11

THE EFFECT OF SEDUXEN ON THE PERCEPTIVE AND SOME OTHER FUNCTIONS OF THE CENTRAL NERVOUS SYSTEM UNDER EMOTIONAL STRESS IN MAN.
201916 02-14

THE LEVEL OF BLOOD NEUROMEDIATORS AFTER THE USE OF SEDUXEN AS AN INDEX OF NERVOUS SYSTEM REACTIVITY.
212432 03-13

SEIZURE

EFFECT OF BENZODIAZEPINE DERIVATIVES ON SOMAN INDUCED SEIZURE ACTIVITY AND CONVULSIONS IN THE MONKEY.
197466 01-03

PROTECTIVE EFFECT OF ADENOSINE AND NICOTINAMIDE AGAINST AUDIOGENIC SEIZURE.
198135 02-03

EFFECTS OF DIAZEPAM AND PHENOBARBITAL ON ELECTRICALLY-INDUCED AMYGDALOID SEIZURES AND SEIZURE DEVELOPMENT.
198612 02-04

EFFECTS OF 5-HYDROXYTRYPTOPHAN, IPRONIAZID AND P-CHLOROPHENYLALANINE ON LIDOCAINE SEIZURE THRESHOLD OF MICE.
199962 02-03

EFFECTS ON THE ACQUISITION OF CONDITIONED AVOIDANCE RESPONSES AND SEIZURE THRESHOLD IN THE OFFSPRING OF AMPHETAMINE TREATED GRAVID RATS.
202722 02-05

EFFECT OF DIAZEPAM UPON SOMAN INDUCED SEIZURE ACTIVITY AND CONVULSIONS.
204192 02-02

THE RELATIVE SIGNIFICANCE OF NOREPINEPHRINE DOPAMINE AND 5-HYDROXYTRYPTAMINE IN THE ELECTROSHOCK SEIZURE IN THE RAT.
204339 02-03

5-HYDROXYTRYPTAMINE AS AN INHIBITORY MODULATOR IN AUDIOGENIC SEIZURE. (PH.D. DISSERTATION).
212521 03-03

THE PSYCHOPHARMACOLOGY OF AUDIOGENIC SEIZURE.
213629 04-03

EFFECTS OF PROCAINE HYDROCHLORIDE, DIAZEPAM, AND DIPHENYLHYDANTOIN ON SEIZURE DEVELOPMENT IN CORTICAL AND SUBCORTICAL STRUCTURES IN RATS.
218191 04-03

PRENATAL MATERNAL D-AMPHETAMINE EFFECTS ON EMOTIONALITY AND AUDIOGENIC SEIZURE SUSCEPTIBILITY OF RAT OFFSPRING.
225079 04-04

SEIZURES

POTENTIATION OF AMYGDALOID KINDLING AND METRAZOL-INDUCED SEIZURES BY 6-HYDROXYDOPAMINE IN RATS.
195907 01-03

SEIZURES OF CHOREOATHETIC TYPE INDUCED BY SUDDEN MOVEMENT: CORRELATION TO THE BIOGENIC AMINES.
196146 01-14

SEIZURES IN RATS INDUCED BY PINEALECTOMY: INFLUENCE OF DIAZEPAM, CHLORDIAZEPOXIDE, AND DIPHENYLHYDANTOIN AND PINEAL SUBSTANCES.
197465 01-03

EEG SEIZURES PRODUCED BY INTRAVENTRICULAR QUATERNARY AMMONIUM COMPOUNDS IN THE RAT.
197475 01-03

EPILEPTIFORM SEIZURES IN DOMESTIC FOWL. IV. THE EFFECTS OF ANTICONVULSANT DRUGS.
197742 01-03

ON THE PROBLEM OF DIPHENYLHYDANTOIN-INDUCED SEIZURES: AN EXPERIMENTAL APPROACH.
197815 01-05

EFFECTS OF DIAZEPAM AND PHENOBARBITAL ON ELECTRICALLY-INDUCED AMYGDALOID SEIZURES AND SEIZURE DEVELOPMENT.
198612 02-04

THE ROLE OF SEROTONIN IN THE PATHOPHYSIOLOGY OF MYOCLONIC SEIZURES ASSOCIATED WITH ACUTE IMIPRAMINE TOXICITY.
200088 02-03

PENTYLENETETRAZOL INDUCED RETROGRADE AMNESIA AND BRAIN SEIZURES IN MICE.
202724 02-04

A CASE OF NONSPECIFIC PSYCHOSES WHICH MANIFESTED CONVULSIVE SEIZURES DURING LITHIUM THERAPY.
209324 03-15

SERUM CLONAZEPAM CONCENTRATIONS IN CHILDREN WITH ABSENCE SEIZURES.
211064 03-13

ADRENAL GLUCOCORTICOIDS AS A REQUIRED FACTOR IN THE DEVELOPMENT OF ETHANOL WITHDRAWAL SEIZURES IN MICE.
213479 04-03

ACUTE AND CHRONIC EFFECTS OF DELTA9-TETRAHYDROCANNABINOL ON SEIZURES IN THE GERBIL.
217673 04-03

THE EFFECT OF CATECHOLAMINERGIC DRUGS ON THE BEHAVIOR AND EEG OF RATS DURING CORAZOL SEIZURES.
219332 04-04

IMIPRAMINE AND SEIZURES.
225335 04-15

EFFECTS OF AMINERGIC DRUGS AND GLUTAMIC ACID ON AUDIOGENIC SEIZURES INDUCED BY EARLY EXPOSURE TO ETHANOL.
225527 04-03

SELECTING

THE USE OF DRUG INTERACTIONS IN ANIMALS FOR SELECTING PSYCHOTROPIC DRUGS.
198057 01-02

SELECTION

EFFECTS OF ALCOHOL, UNCERTAINTY AND NOVELTY UPON RESPONSE SELECTION.
200048 02-14

DIETARY TRYPTOPHAN AND THE SELECTION OF ETHYL ALCOHOL IN DIFFERENT STRAINS OF RATS.
217520 04-03

CLINICAL - PSYCHOPATHOLOGICAL CRITERIA FOR THE SELECTION OF PSYCHOTROPIC DRUGS ACCORDING TO THE STAGE OF ILLNESS AND THE EFFECTIVENESS OF REHABILITATING SCHIZOPHRENICS.
220403 04-17

SELECTIVE

SELECTIVE STIMULATION BY DOPAMINE OF ADENYLATE-CYCLASE IN HOMOGENATES OF RABBIT RETINA.
192936 01-03

EVIDENCE THAT PUNCTUATE INTRACEREBRAL ADMINISTRATION OF 6-HYDROXYDOPAMINE FAILS TO PRODUCE SELECTIVE NEURONAL DEGENERATION: COMPARISON WITH COPPER SULFATE AND FACTORS GOVERNING THE DEPORTMENT OF FLUIDS INJECTED INTO BRAIN.
197931 01-03

SELECTIVE DIPHENYLHYDANTOIN SUPPRESSION OF AUDITORY EVOKED POTENTIALS IN THE CAT CEREBELLAR CORTEX.
197989 01-03

SELECTIVE INHIBITION OF DOPAMINE-BETA-HYDROXYLASE IN THE PERIPHERAL TISSUES BY 5-DIMETHYLDITHIOCARBAMYLPICOLINIC ACID; ITS EFFECT ON STRESS INDUCED ULCER, ETHANOL INDUCED SLEEP AND BLOOD PRESSURE.
204484 02-03

HIPPOCAMPUS: SELECTIVE CONCENTRATIONS OF LEAD IN THE NORMAL RAT BRAIN.
210665 03-03

P-CHLOROAMPHETAMINE: SELECTIVE NEUROTOXIC ACTION IN BRAIN.
211494 03-05

OPIOID REINFORCED OPERANT BEHAVIOR: SELECTIVE SUPPRESSION BY ALPHA-METHYL-P-TYROSINE.
211511 03-04

SELECTIVE DESTRUCTION OF SEROTONIN TERMINALS IN RAT FOREBRAIN BY HIGH DOSES OF 5,7 DIHYDROXYTRYPTAMINE.
213401 04-03

MONOAMINERGIC NEUROTOXINS: ARE THEY SELECTIVE? SOME PERSPECTIVES ON THE SYMPOSIUM HELD AT THE FOURTH ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, OCTOBER, 1974. (UNPUBLISHED PAPER).
222353 04-06

SELF-ADMINISTRATION

PROGRAMMED SELF-ADMINISTRATION OF POTENTIALLY ADDICTIVE DRUGS IN YOUNG RATS AND ITS EFFECTS ON LEARNING.
195430 01-04

LITHIUM TREATMENT REDUCES MORPHINE SELF-ADMINISTRATION IN ADDICT RATS.
201293 02-04

CENTRAL CHOLINERGIC INFLUENCE ON SELF-ADMINISTRATION OF MORPHINE AND AMPHETAMINE.
205889 03-04

TIME-DEPENDENT CHANGES IN AMPHETAMINE SELF-ADMINISTRATION FOLLOWING FRONTAL CORTEX ABLATIONS IN RATS.
206747 03-04

INTRAVENTRICULAR AMPHETAMINE SELF-ADMINISTRATION IN THE ALBINO RAT. (PH.D. DISSERTATION).
211899 03-04

INTRAVENOUS SELF-ADMINISTRATION OF D-AMPHETAMINE AND L-AMPHETAMINE BY DOG.
222806 04-04

CHANGES IN MORPHINE SELF-ADMINISTRATION AND MORPHINE-DEPENDENCE AFTER LESIONS OF THE CAUDATE NUCLEUS IN RATS.
225560 04-04

SELF-PUNITIVE

CHLORPROMAZINE EFFECTS ON SELF-PUNITIVE BEHAVIOR.
198457 02-04

SELF-RATING

ARBITERS AND SELF-RATING OF MOMENTARY MOOD IN PSYCHOPHARMACOLOGICAL LONGITUDINAL STUDIES.
206980 03-16

SELF-STIMULATION

COMPARATIVE INVOLVEMENT OF DOPAMINE AND NORADRENALINE IN RATE-FREE SELF-STIMULATION IN SUBSTANTIA-NIGRA, LATERAL HYPOTHALAMUS, AND MESENCEPHALIC CENTRAL GRAY.
193303 01-03

A PHARMACOLOGICAL AND NEUROANATOMICAL ANALYSIS OF DOPAMINERGIC AND NORADRENERGIC PATHWAYS INVOLVED IN SELF-STIMULATION IN RATS. (PH. D. DISSERTATION).
193582 01-04

EFFECTS OF SELF-STIMULATION BEHAVIOR OF DRUGS INFLUENCING DOPAMINERGIC NEUROTRANSMISSION MECHANISMS.
194152 01-04

EFFECTS OF ANTICHOLINERGIC AGENTS ON SELF-STIMULATION.
197446 01-03

INTRACRANIAL SELF-STIMULATION IN RATS AS A FUNCTION OF VARIOUS STIMULUS PARAMETERS: V. INFLUENCE OF COCAINE ON MEDIAL FOREBRAIN BUNDLE STIMULATION WITH MONOPOLAR ELECTRODES.
198223 02-03

THE RELATIVE ATTENUATION OF SELF-STIMULATION, EATING AND DRINKING PRODUCED BY DOPAMINE RECEPTOR BLOCKADE.
198225 02-04

EFFECTS OF PSYCHOTROPIC DRUGS ON HYPOTHALAMIC SELF-STIMULATION BEHAVIOR IN RATS.
202802 02-04

DIFFERENTIAL EFFECTS OF AMPHETAMINE AND FOOD DEPRIVATION ON SELF-STIMULATION OF THE LATERAL HYPOTHALAMUS AND MEDIAL FRONTAL CORTEX.
206733 03-04

EFFECT OF INTRAVENTRICULAR NOREPINEPHRINE ON NEURON ACTIVITY IN THE MEDIAL FOREBRAIN BUNDLE DURING SELF-STIMULATION BEHAVIOR.
210704 03-04

HYPOTHALAMIC SELF-STIMULATION IN RATS FOLLOWING IMMUNOSYMPATHECTOMY OR CENTRAL NERVE GROWTH FACTOR ANTISERUM INJECTION.
211512 03-04

EFFECTS OF AMPHETAMINE ISOMERS AND NEUROLEPTICS ON SELF-STIMULATION FROM THE NUCLEUS-ACCUMBENS AND DORSAL NORADRENERGIC BUNDLE.
213394 04-03

EFFECT OF VARIOUS INHIBITORS OF TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE ON SELF-STIMULATION BEHAVIOUR.
213431 04-04

ENHANCEMENT OF SELF-STIMULATION BY DEPRENIL: EVIDENCE FOR A ROLE OF DOPAMINE NEURONES IN REWARD.
213432 04-04

A COMPARISON BETWEEN CAUDATE, AMYGDALOID AND HYPOTHALAMIC SELF-STIMULATION IN SQUIRREL MONKEYS (SAIMIRI-SCIUREUS). (PH.D. DISSERTATION).
214207 04-04

A NEUROPHARMACOLOGICAL ANALYSIS OF CHOLINERGIC MECHANISMS OF SELF-STIMULATION REACTIONS.
215497 04-04

THE EFFECT OF MICROINJECTIONS OF AMPHETAMINE INTO THE NEOSTRIATUM AND THE NUCLEUS-ACCUMBENS ON SELF-STIMULATION BEHAVIOUR.
217530 04-04

CATECHOLAMINES AND SELF-STIMULATION: PHARMACOLOGICAL DIFFERENCES BETWEEN NEAR-LATERAL AND FAR-LATERAL HYPOTHALAMIC SITES.
221030 04-03

EFFECTS OF HEROIN ON LEVER PRESSING FOR INTRACRANIAL SELF-STIMULATION, FOOD AND WATER IN THE RAT.
221039 04-04

THE EFFECT OF ALPHA-METHYL-P-TYROSINE METHYLESTER ON TEMPORAL SUMMATION IN THE NEURAL SUBSTRATE FOR THE REINFORCEMENT EFFECT IN SELF-STIMULATION. (PH.D. DISSERTATION).
222090 04-04

DIFFERENTIAL ANTAGONISM BY THE ANTICHOLINERGIC DEXETIMIDE OF INHIBITORY EFFECTS OF HALOPERIDOL AND FENTANYL ON BRAIN SELF-STIMULATION.
225562 04-03

SENEGALESE

BEHAVIOURAL AND ELECTROGRAPHIC EFFECTS OF L-5-HYDROXYTRYPTOPHAN AND D,L-PARA-CHLOROPHENYLALANINE ON EPILEPTIC SENEGALESE BABOON (PAPIO-PAPIO).
199764 02-03

SENESCENCE

PSYCHOPHARMACOLOGICAL TREATMENT OF DISORDERS OF SENESCENCE.
203470 02-11

CONSIDERATIONS ABOUT THE TREATMENT OF SENESCENCE.
211202 03-11

SENILE

CLINICAL TRIAL WITH FLUPENTHIXOL (FLUANXOL) IN THE TREATMENT OF SENILE DEMENTIA.
225281 04-11

SENIOR

DRUG STUDIES IN NORMAL FEMALES, SENIOR CITIZENS, AND IN EXPERIMENTAL GROUPS.
198071 01-07

SENSITIVE

THE NUCLEUS LINEARIS INTERMEDIUS RAPHE AND BEHAVIOUR EVOKED BY DIRECT AND INDIRECT STIMULATION OF DOPAMINE SENSITIVE SITES WITHIN THE CAUDATE NUCLEUS OF CATS.
199864 02-04

AMANTADINE AND D-145, AN AMANTADINE DERIVATIVE, DO NOT EFFECT DOPAMINE SENSITIVE ADENYLATE-CYCLASE FROM THE CAUDATE PUTAMEN OF THE RAT BRAIN.
199867 02-03

TRICYCLIC ANTIDEPRESSANT DRUGS AND DOPAMINE SENSITIVE ADENYLCYCLASE FROM RAT CAUDATE NUCLEI.
206990 03-03

BLOCKADE BY PIMOZIDE OF A NORADRENALINE SENSITIVE ADENYLATE-CYCLASE IN THE LIMBIC FOREBRAIN: POSSIBLE ROLE OF LIMBIC NORADRENERGIC MECHANISMS IN THE MODE OF ACTION OF ANTIPSYCHOTICS.
210771 03-03

TRICYCLIC ANTIDEPRESSIVE DRUGS AND DOPAMINE SENSITIVE ADENYLATE-CYCLASE FROM RAT BRAIN STRIATUM.
210856 03-03

SEROTONIN SENSITIVE ADENYLCYCLASE ACTIVITY IN IMMATURE RAT BRAIN.
217355 04-03

A RAPID, SIMPLE AND MORE SENSITIVE METHOD FOR THE DEMONSTRATION OF CENTRAL CATECHOLAMINE CONTAINING NEURONS AND AXONS BY GLYOXYLIC ACID INDUCED FLUORESCENCE: I. SPECIFICITY.
217550 04-16

DOPAMINE SENSITIVE ADENYLCYCLASE IN HUMAN CAUDATE NUCLEUS: A STUDY IN CONTROL SUBJECTS AND SCHIZOPHRENIC PATIENTS.
221732 04-13

INTERACTIONS BETWEEN LYSERGIC ACID DIETHYLAMIDE AND DOPAMINE SENSITIVE ADENYLCYCLASE SYSTEMS IN RAT BRAIN.
223175 04-03

SENSITIVITY

COMPARISON BETWEEN THE EFFECTS PRODUCED BY CHRONIC DENERVATION AND BY COCAINE ON THE SENSITIVITY TO, AND ON THE DISPOSITION OF, NORADRENALINE IN ISOLATED SPLEEN STRIPS.
193139 01-03

THYROXINE AND BRAIN CATECHOLAMINES: INCREASED TRANSMITTER SYNTHESIS AND INCREASED RECEPTOR SENSITIVITY.
193541 01-03

THE SENSITIVITY OF BARBITONE DEPENDENT AND WITHDRAWN RATS TO TREMORGENIC DRUGS.
197303 01-03

MODIFICATION BY DESIPRAMINE OF THE ADRENERGIC SENSITIVITY OF PYROGALLOL IN THE RAT.
197461 01-03

PSYCHOPHARMACOLOGICAL EVIDENCE FOR INCREASE IN RECEPTOR SENSITIVITY FOLLOWING CHRONIC MORPHINE TREATMENT.
197855 01-04

THEOPHYLLINE INCREASED SENSITIVITY TO NOCICEPTIVE STIMULATION AND REGIONAL TURNOVER OF RAT BRAIN 5-HT, NORADRENALINE AND DOPAMINE.
197926 01-03

SENSITIVITY OF DENERVATED CEREBRAL CORTEX TO CHOLINOMIMETICS.
199769 02-03

RECOVERY OF FUNCTION AND CHANGES IN SENSITIVITY TO AMPHETAMINE FOLLOWING CAUDATE LESIONS IN RATS.
209962 03-03

DIFFERENTIAL SENSITIVITY OF PRIMARY AND SECONDARY SPINDLE AFFERENTS TO DEPRESSANT DRUGS.
210801 03-03

COMPARATIVE TIME-DEPENDENT CHANGES IN SENSITIVITY TO LOCOMOTOR EFFECTS OF D-AMPHETAMINE IN MICE WITH CAUDATE, HIPPOCAMPAL OR FRONTAL CORTICAL LESIONS.
210926 03-03

PRELIMINARY STUDY OF A BETA-BLOCKER (PINDOLOL) IN THREE SCHIZOPHRENICS AND THREE NONPSYCHOTIC PSYCHIATRIC PATIENTS: DIFFERENTIAL SENSITIVITY IN HEART RATE.
212164 03-13

INCREASED SENSITIVITY TO DOPAMINERGIC AGENTS AFTER CHRONIC NEUROLEPTIC TREATMENT.
215689 04-04

ONTOGENESIS OF NEOSTRIATAL CHOLINERGIC NEURONES IN THE RAT AND DEVELOPMENT OF THEIR SENSITIVITY TO NEUROLEPTIC DRUGS.
217658 04-03

MIDBRAIN RAPHE NEURONS: SENSITIVITY TO GLUCOCORTICOIDS AND ACTH IN THE RAT.
217863 04-03

MORPHINE SENSITIVITY AND TOLERANCE: A GENETIC INVESTIGATION IN THE MOUSE.
221037 04-03

SENSITIZATION

THE SPECIFICITY OF ACTION EXERTED BY NEUROTROPIC AGENTS DURING SENSITIZATION.
219508 04-03

SENSORIMOTOR

COMPARATIVE EFFECT OF PHENAMINE (AMPHETAMINE) AND CAFFEINE ON THE BACKGROUND ACTIVITY OF CORTICAL SENSORIMOTOR NEURONS AND THEIR REACTIONS DURING STIMULATION OF THE CAUDATE NUCLEUS.
198835 02-03

THE EFFECT OF INHIBITORS OF CATECHOLAMINE SYNTHESIS (ALPHA-METHYLTYROSINE AND DISULFIRAM) ON THE BACKGROUND ACTIVITY OF SENSORIMOTOR CORTEX NEURONS AND THEIR RESPONSES TO AFFERENT CAUDATE AND RETICULAR STIMULATION.
202598 02-04

THE EFFECTS OF ACETYLCHOLINE AND SYNAPTIC STIMULATION ON THE NEURONS IN THE SENSORIMOTOR CORTEX.
205510 02-03

SENSORY

CENTRAL DOPAMINE NEURONS AND SENSORY PROCESSING.
207304 03-03

THE EFFECT OF METHYLPHENIDATE ON SENSORY PERCEPTION AND INTEGRATION IN HYPERACTIVE CHILDREN.
208920 03-14

D-AMPHETAMINE AND THE SENSORY ROLE OF A RATS TAIL IN THERMOREGULATION OR WHAT THE RATS TAIL TELLS THE RATS BRAIN.
209961 03-03

COGNITIVE AND MOTOR SENSORY PERFORMANCES IN TOXIC AND NONTOXIC EPILEPTIC SUBJECTS.
210824 03-15

EFFECT OF SENSORY STIMULATION ON THE POTENCY OF CATALEPTOGENS.
217473 04-03

THE EFFECTS OF A DEXAMPHETAMINE AMYLOBARBITONE SODIUM MIXTURE ON THE REWARD VALUE OF DIFFERENT SENSORY CHANGES.
217476 04-03

COMMISSURAL AND SENSORY EVOKED POTENTIALS OF THE HIPPOCAMPUS FOLLOWING MICROIONTOPHORESIS OF SOME DRUGS.
219111 04-03

THE EFFECT OF STIMULANTS AND OPIOIDS ON SENSORY REINFORCEMENT IN RATS. (PH.D. DISSERTATION).
223711 04-04

PSYCHOPHYSICAL EVALUATION OF TOXIC EFFECTS ON SENSORY SYSTEMS.
225166 04-03

SEPARATION

MARIHUANA METABOLITES IN URINE OF MAN: V. CHARACTERISTICS AND SEPARATION OF POLAR METABOLITES OF DELTA9-TETRAHYDROCANNABINOL.
210896 03-16

PHYSIOLOGICAL MECHANISMS FOR CARDIAC CONTROL BY NUTRITIONAL INTAKE AFTER EARLY MATERNAL SEPARATION IN THE YOUNG RAT.
218047 04-03

SEPTAL

GENOTYPE DEPENDENT ELECTROENCEPHALOGRAPHIC, BEHAVIORAL AND ANALGESIC CORRELATES OF MORPHINE: AN ANALYSIS IN NORMAL MICE AND IN MICE WITH SEPTAL LESIONS.
203520 02-04

AFFERENTS TO THE SEPTAL AREA OF THE RAT STUDIED WITH THE METHOD OF RETROGRADE AXONAL TRANSPORT OF HORSERADISH PEROXIDASE.
203573 02-03

EEG AND SCHIZOPHRENIA: EXPERIMENTAL STUDIES, SPECTRAL ANALYSIS AND SEPTAL SPIKES.
205455 02-03

SOME FACTORS DETERMINING THE RESPONSE OF SEPTAL RATS TO ANTICHOLINERGIC DRUGS.
205632 03-03

ELECTROPHYSIOLOGICAL AND BEHAVIORAL REACTIVITY TO PHOTIC STIMULI FOLLOWING SEPTAL LESIONS AND PHARMACOLOGICAL TREATMENTS IN RATS.
206724 03-04

ROLE OF PITUITARY ADRENOCORTICAL SYSTEM IN MEDIATING AVOIDANCE BEHAVIOR OF RATS WITH SEPTAL LESIONS.
206739 03-04

THE ROLE OF SEROTONIN IN THE SEPTAL BEHAVIOR SYNDROME OF RATS. (PH.D. DISSERTATION).
213128 03-03

SEPTUM

ANALYSIS OF ACETYLCHOLINESTERASE SYNTHESIS AND TRANSPORT IN THE RAT HIPPOCAMPUS: RECOVERY OF ACETYLCHOLINESTERASE ACTIVITY IN THE SEPTUM AND HIPPOCAMPUS AFTER ADMINISTRATION OF DIISOPROPYLFLUOROPHOSPHATE.
199805 02-03

ON NEUROCHEMICAL MECHANISMS OF SEPTUM INFLUENCE ON THE CONDITIONED AVOIDANCE REACTION IN RATS.
218803 04-04

SEQUENCES

REPEATED ACQUISITION OF RESPONSE SEQUENCES: STIMULUS CONTROL AND DRUGS.
215969 04-04

SERIAL

SERIAL EEG RECORDINGS IN PSYCHOTROPIC DRUG TREATMENT.
196144 01-08

METHAMPHETAMINES EFFECT ON REPEATED ACQUISITIONS WITH SERIAL DISCRIMINATION REVERSALS.
202769 02-04

SOME EFFECTS OF ACTH4-10 ON PERFORMANCE DURING A SERIAL REACTION TASK.
217533 04-04

SEROTONERGIC

LONG-TERM EFFECTS OF P-CHLOROAMPHETAMINE AND RELATED DRUGS ON CENTRAL SEROTONERGIC MECHANISMS.
208553 03-03

SEROTONERGIC INVOLVEMENT WITH THE STEREOTYPY/CATALEPSY INDUCED BY MORPHINE-LIKE AGENTS IN THE RAT.
210754 03-04

EFFECTS OF 5,7 DIHYDROXYTRYPTAMINE ON TRANSMISSION AT SEROTONERGIC SYNAPSE.
217638 04-03

INHIBITION OF BOTH NORADRENERGIC AND SEROTONERGIC NEURONS IN BRAIN BY THE ALPHA-ADRENERGIC AGONIST CLONIDINE.
221131 04-03

PHYSIOLOGICAL AND PHARMACOLOGICAL EVIDENCE FOR A SEROTONERGIC PROJECTION TO THE HIPPOCAMPUS.
223171 04-03

SEROTONERGIC AND CHOLINERGIC MECHANISMS DURING DISRUPTION OF APPROACH AND AVOIDANCE BEHAVIOR.
225161 04-04

SEROTONIN

DOES MAPROTILINE (LUDIOMIL) INFLUENCE SEROTONIN UPTAKE AND FREE TRYPTOPHAN CONCENTRATION IN HUMAN PLASMA
192943 01-13

SEROTONIN AND THE AVERSIVE THRESHOLD IN RATS.
193157 01-04

EFFECT OF TWO DOPAMINE RECEPTOR BLOCKERS ON A SEROTONIN MEDIATED BEHAVIORAL SYNDROME IN RATS.
193548 01-04

PLATELET SEROTONIN OF HYPERACTIVE SCHOOL-AGE BOYS.
194397 01-13

EFFECTS OF SOME HOMOLOGUES OF 4-CHLOROAMPHETAMINE ON BRAIN SEROTONIN METABOLISM.
195092 01-02

INTERACTION OF PENTYLENETETRAZOL AND TRIMETHADIONE ON THE METABOLISM OF SEROTONIN IN BRAIN AND ITS RELATION TO THE ANTICONVULSANT ACTION OF TRIMETHADIONE.
195093 01-03

EFFECT OF LITHIUM ON SERUM TRYPTOPHAN AND BRAIN SEROTONIN IN RATS.
195232 01-03

BRAIN SEROTONIN METABOLISM IN LITHIUM TREATED RATS.
195235 01-03

CLINICAL MEASUREMENT OF CENTRAL DOPAMINE AND SEROTONIN METABOLISM IN ACUTE PSYCHOTIC DISORDERS.
195924 01-09

THE MULTIPLICITY OF INTERACTIONS OF PSYCHOTROPIC DRUGS WITH THE BRAIN SEROTONIN BIOSYNTHETIC UNIT.
195926 01-17

INVOLVEMENT OF SEROTONIN IN HYPERKINETIC EPISODES IN SCOTTISH TERRIER DOGS. (PH.D. DISSERTATION).
196261 01-03

EVIDENCE FOR A PERIPHERAL EFFECT OF FUSARIC ACID, A DOPAMINE-BETA-HYDROXYLASE INHIBITOR, ON SEROTONIN METABOLISM.
196593 01-03

THE EFFECTS OF PARENTERAL ADMINISTRATION OF CATECHOLAMINES, SEROTONIN AND HISTAMINE ON BEHAVIOR AND LEVELS OF THESE AMINES IN THE BRAIN OF THE NEONATE CHICK.
197457 01-03

PREVENTION OF SEROTONIN ABORTION BY SEROTONIN ANTAGONISTS IN RATS.
197489 01-03

THE EFFECT OF A NEW TETRACYCLIC ANTIDEPRESSANT COMPOUND, ORG-GB94, ON THE TURNOVER OF DOPAMINE, NORADRENALIN AND SEROTONIN IN THE RAT BRAIN.
197496 01-03

MEASUREMENT OF SEROTONIN TURNOVER IN RATS WITH THE HELP OF MONOAMINEOXIDASE INHIBITORS.
197580 01-03

EFFECT OF ANGIOTENSIN II ON SEROTONIN ACCUMULATION IN THE RAT BRAIN.
197582 01-03

EFFECT OF MORPHINE ON SEROTONIN RELEASE FROM MYENTERIC PLEXUS OF THE GUINEA-PIG.
197811 01-03

EFFECTS OF 5-(N-BUTYL) PICOLINAMIDE (SCH-10595), A DOPAMINE-BETA-HYDROXYLASE INHIBITOR, ON SEROTONIN AND CATECHOLAMINE METABOLITES IN BRAIN.
197813 01-03

EFFECT OF SEROTONIN ON WATER INTAKE AND RENIN ANGIOTENSIN SYSTEM IN RATS.
197963 01-03

DETERMINATION OF NORADRENALINE, DOPAMINE, SEROTONIN, 5-HYDROXYINDOLEACETIC ACID, TYROSINE AND TRYPTOPHANE IN THE ISOLATED PERFUSED RAT BRAIN.
197967 01-06

SEROTONIN IN DOWNS SYNDROME.
198423 02-11

CHRONIC LYSERGIC ACID DIETHYLAMIDE ADMINISTRATION AND SEROTONIN TURNOVER IN VARIOUS REGIONS OF RAT BRAIN.
199783 02-03

THE INFLUENCE OF RESERPINE ON THE SEROTONIN METABOLISM IN PATIENTS WITH SCHIZOPHRENIA AND REACTIVE CONDITIONS.
200013 02-08

THE ROLE OF SEROTONIN IN THE PATHOPHYSIOLOGY OF MYOCLONIC SEIZURES ASSOCIATED WITH ACUTE IMIPRAMINE TOXICITY.
200088 02-03

THE INFLUENCE OF CATECHOLAMINES, SEROTONIN, AND SOME AMINO ACIDS ADMINISTERED INTO THE AMYGDALOID COMPLEX ON CONDITIONED REFLEXES OF AVOIDANCE AND MOTOR ACTIVITY IN RATS.
200566 02-03

SEROTONIN AND SCHIZOPHRENIA. (UNPUBLISHED PAPER).
201002 02-08

EFFECT OF LITHIUM ON THE EEG AND SEROTONIN CONTENT IN THE BRAIN.
201888 02-03

D-LSD BINDING TO BRAIN HOMOGENATES: POSSIBLE RELATIONSHIP TO SEROTONIN RECEPTORS.
202464 02-03

EFFECT OF NOMIFENSINE (HOE-984), A NEW ANTIDEPRESSANT, ON UPTAKE OF NORADRENALINE AND SEROTONIN AND ON RELEASE OF NORADRENALINE IN RAT BRAIN SYNAPTOSOMES.
202807 02-03

LONG-LASTING DEPLETION OF BRAIN SEROTONIN BY 4-CHLOROAMPHETAMINE IN GUINEA-PIGS.
203580 02-03

THE EFFECT OF MAPROTILIN ON BRAIN SEROTONIN METABOLISM IN RATS.
205604 03-03

SEROTONIN AND DOPAMINE TURNOVER AFTER ACUTE AND CHRONIC MORPHINE ADMINISTRATION.
206989 03-03

EFFECT OF STRESS UPON SEROTONIN METABOLISM IN VARIOUS REGIONS OF THE RAT BRAIN.
206993 03-03

SEROTONIN CONTENT OF THE BRAINSTEM NUCLEI IN THE RAT.
210661 03-03

CORRELATIONS BETWEEN CIRCADIAN CHANGES IN SERUM AMINO ACIDS OR BRAIN TRYPTOPHAN AND THE CONTENTS OF SEROTONIN AND 5-HYDROXYINDOLEACETIC ACID IN REGIONS OF THE RAT BRAIN.
210673 03-03

EFFECT OF PERIPHERALLY ADMINISTERED SEROTONIN ON THE NEURONAL ACTIVITY OF MIDBRAIN RAPHE NEURONS.
210710 03-03

EFFECT OF PHENOBARBITAL ON THE METABOLISM AND SEROTONIN DEPLETING ACTION OF 4-CHLORODIFLUOROAMPHETAMINE IN RATS.
210922 03-03

PREFERRED CONFORMATIONS OF SEROTONIN IN RELATION TO RECEPTOR SITES.
210928 03-03

POTENTIATION OF THE L-5-HYDROXYTRYPTOPHAN INDUCED ELEVATION OF PLASMA CORTICOSTERONE LEVELS IN RATS BY A SPECIFIC INHIBITOR OF SEROTONIN UPTAKE.
211104 03-03

EFFECTS OF DRUG ALTERED SEROTONIN LEVELS ON THE ACQUISITION OF A SHUTTLEBOX AVOIDANCE TASK. (PH.D. DISSERTATION).
211781 03-04

THE ROLE OF SEROTONIN IN THE SEPTAL BEHAVIOR SYNDROME OF RATS. (PH.D. DISSERTATION).
213128 03-03

SELECTIVE DESTRUCTION OF SEROTONIN TERMINALS IN RAT FOREBRAIN BY HIGH DOSES OF 5,7 DIHYDROXYTRYPTAMINE.
213401 04-03

NEUROPHYSIOLOGICAL ROLE OF SEROTONIN.
213621 04-03

SEROTONIN -- NEW VISTAS: HISTOCHEMISTRY AND PHARMACOLOGY.
213715 04-17

SEROTONIN -- NEW VISTAS: BIOCHEMISTRY AND BEHAVIORAL AND CLINICAL STUDIES.
213716 04-17

FENFLURAMINE IN MAN: HYPOPHAGIA ASSOCIATED WITH DIMINISHED SEROTONIN TURNOVER.
215674 04-13

EFFECTS OF TACLAMINE (AY-22214), A NEW PSYCHOACTIVE AGENT, ON CATECHOLAMINE AND SEROTONIN METABOLISM.
215725 04-03

EFFECT OF WITHDRAWAL FROM CHRONIC ETHANOL INGESTION ON THE CAMP RESPONSE OF CEREBRAL CORTICAL SLICES USING THE AGONISTS HISTAMINE, SEROTONIN, AND OTHER NEUROTRANSMITTERS.
215980 04-03

THE PROTECTIVE EFFECT OF SEROTONIN AGAINST THE INHIBITORY ACTION OF CHLORPROMAZINE ON THE MEMBRANE POTENTIAL OF STAGE 2 BLASTOMERES OF MOUSE EMBRYOS IN VITRO.
217005 04-03

THE INFLUENCE OF TRICYCLIC ANTIDEPRESSANTS, AZAPHEN AND IMIZINE ON BLOOD SUGAR CONCENTRATION CHANGES PRODUCED BY EPINEPHRINE AND SEROTONIN.
217214 04-03

COMPARISON OF THE EFFECTS OF TETRACYCLIC AND TRICYCLIC ANTIDEPRESSANTS ON THE SEROTONIN UPTAKE BY HUMAN THROMBOCYTES IN VITRO.
217258 04-13

SEROTONIN SENSITIVE ADENYLCYCLASE ACTIVITY IN IMMATURE RAT BRAIN.
217355 04-03

NOREPINEPHRINE AND SEROTONIN: SPECIFICITY OF RELEASE WITH REWARDING ELECTRICAL STIMULATION OF THE BRAIN.
217522 04-03

BLOCKADE OF THE STIMULUS PROPERTIES OF MESCALINE BY A SEROTONIN ANTAGONIST.
217650 04-03

INHIBITION OF SEROTONIN UPTAKE AND THE TOXIC INTERACTION BETWEEN MEPERIDINE AND MONOAMINEOXIDASE INHIBITORS.
217696 04-03

THE INFLUENCE OF APOMORPHINE AND TRICYCLIC ANTIDEPRESSANT DRUGS ON THE LEVEL OF SEROTONIN AND ITS METABOLITE IN RAT BRAIN.
217815 04-03

EFFECT OF ANESTHETIC DOSAGES OF PENTOBARBITAL ON THE CONTENT AND TURNOVER OF SEROTONIN IN BRAIN AREAS.
217816 04-03

ROLE OF BRAIN SEROTONIN IN THE INTEGRATION OF BEHAVIORAL RESPONSES AND PITUITARY ADRENOCORTICAL FUNCTIONS UNDER EMOTION.
218364 04-04

THE INFLUENCE OF LITHIUM AND CESIUM IONS ON THE EFFECTS OF CATECHOLAMINES AND SEROTONIN INTRODUCED INTO THE HIPPOCAMPUS OF RATS.
218470 04-04

THE PARTICIPATION OF SEROTONIN REACTIVE BRAIN STRUCTURES IN SOME FORMS OF BEHAVIORAL PATTERNS IN HAMSTERS.
218472 04-04

SEROTONIN IN THE LATERAL GENICULATE.
218499 04-03

ACTION OF SEROTONIN MICROINJECTED INTO HYPOTHALAMIC SITES AT WHICH ELECTRICAL STIMULATION PRODUCED AVERSIVE RESPONSES IN THE RAT.
219075 04-04

ON THE ROLE OF SEROTONIN IN PREDATORY AGGRESSION.
219110 04-04

THE ROLE OF THE AMYGDALA IN THE DEPRESSIVE ACTION OF SEROTONIN AND 5-HYDROXYTRYPTOPHAN ON THE CONDITIONED ACTIVITY OF WHITE RATS.
219328 04-04

SIMILARITIES OF THE INFLUENCE OF SECONDARY AND TERTIARY TRICYCLIC ANTIDEPRESSANTS ON THE EFFECT OF RESERPINE IN FROGS AND ON THE SEROTONIN UPTAKE OF HUMAN THROMBOCYTES.
219503 04-13

ON THE MECHANISM OF THE DEFENSIVE ACTION OF ACETYLCHOLINE AND SEROTONIN AGAINST THEIR CYTOTOXIC ANTAGONISTS.
219663 04-03

STIMULATION OF ESTROGEN INDUCED COPULATORY BEHAVIOR IN CASTRATE MALE RATS WITH THE SEROTONIN BIOSYNTHESIS INHIBITOR P-CHLOROPHENYLALANINE.
221010 04-04

ANTAGONISM OF PSYCHOSTIMULANT 2 PHENYLDIMETHYLTETRAHYDROOXAZINE HYDROCHLORIDE (G-130) TO CENTRAL NERVOUS SYSTEM DEPRESSING DRUGS: MONOAMINEOXIDASE INHIBITORY ACTIVITY AND NOREPINEPHRINE AND SEROTONIN INDUCED CHANGES, COMPARISON WITH DL-AMPHETAMINE.
221267 04-03

THE EFFECT OF SEROTONIN ON THE FETUS AND FETAL MATERNAL RELATIONS IN THE RAT.
221743 04-03

IS THERE A CATECHOLAMINE SEROTONIN INTERACTION IN THE CONTROL OF LOCOMOTOR ACTIVITY?
222816 04-04

BEHAVIORAL CORRELATES OF SEROTONIN DEPLETION.
225159 04-04

THE EFFECT OF INTRAVENTRICULAR ADMINISTRATION OF SEROTONIN ON SPONTANEOUS MOTOR ACTIVITY OF RATS. (UNPUBLISHED PAPER).
225287 04-04

THE RELATION BETWEEN CEREBRAL SEROTONIN LEVELS AND CONDITIONED BEHAVIOUR IN THE RAT FOLLOWING THE ADMINISTRATION OF LSD-25 AND UML.
225564 04-04

SEROTONINERGIC
THE EFFECT OF SEROTONINERGIC AND ADRENERGIC PREPARATIONS UPON ALCOHOLIINDUCED EXCITATION IN MICE.
201915 02-04

SEROTONINS
INTRACRANIAL REWARD AFTER 5,6 DIHYDROXYTRYPTAMINE: FURTHER EVIDENCE FOR SEROTONINS INHIBITORY ROLE.
215732 04-04

SERUM
CHARACTERIZATION OF THE BINDING OF BENZODIAZEPINES TO HUMAN SERUM ALBUMIN.
193278 01-01
INTERACTIONS OF BENZODIAZEPINES WITH HUMAN SERUM ALBUMIN: CIRCULAR DICHROISM STUDIES.
194148 01-01
EFFECT OF ORAL AND INTRAMUSCULAR ROUTES OF ADMINISTRATION ON SERUM CHLORDIAZEPOXIDE LEVELS AND THE PREDICTION OF THESE LEVELS FROM PREDRUG FASTING SERUM GLUCOSE CONCENTRATIONS.
195055 01-13
EFFECT OF LITHIUM ON SERUM TRYPTOPHAN AND BRAIN SEROTONIN IN RATS.
195232 01-03
DIAZEPAM METABOLISM IN NORMAL MAN: I. SERUM CONCENTRATIONS AND CLINICAL EFFECTS AFTER INTRAVENOUS, INTRAMUSCULAR, AND ORAL ADMINISTRATION.
195444 01-15
DIAZEPAM METABOLISM IN NORMAL MAN: II. SERUM CONCENTRATION AND CLINICAL EFFECT AFTER ORAL ADMINISTRATION AND CUMULATION.
195445 01-13
BRAIN AND SERUM CONCENTRATIONS OF DIAZEPAM IN EXPERIMENTAL EPILEPSY.
195494 01-04
COLORIMETRIC, ULTRAVIOLET SPECTROPHOTOMETRIC, AND SPECTROPHOTOFLUOROMETRIC DETERMINATION OF DOXEPIN AND SOME OF ITS METABOLITES IN SERUM AND IN URINE.
199214 02-16
BINDING OF D-OXAZEPAM AND L-OXAZEPAM HEMISUCCINATE TO BOVINE SERUM ALBUMIN.
200033 02-03
THE EFFECTS OF LITHIUM CARBONATE ON SERUM GASTRIN IN PSYCHIATRIC PATIENTS.
200637 02-04
STUDY OF LITHIUM INTOXICATION UNDER THERAPEUTIC LITHIUM SERUM CONCENTRATION.
200952 02-15
THE SERUM GONADOTROPIN LEVEL UNDER THE MEDICATION OF L-DOPA.
204394 02-13
THE LEVELS OF LITHIUM IN SERUM AND IN RED BLOOD CELLS AND ITS RATIOS IN MANIC-DEPRESSIVE PATIENTS.
205607 03-09
THE EFFECT OF LYSERGIC ACID DIETHYLAMIDE ON SERUM CREATINE KINASE LEVELS.
206361 03-12
LEUKOCYTOSIS DURING LITHIUM TREATMENT AND ITS CORRELATION TO SERUM LITHIUM LEVEL.
207718 03-15
RELATIONSHIP BETWEEN SERUM LITHIUM LEVEL AND CLINICAL RESPONSE TO DEPRESSION TREATED WITH LITHIUM CARBONATE.
207719 03-09
CORRELATIONS BETWEEN CIRCADIAN CHANGES IN SERUM AMINO ACIDS OR BRAIN TRYPTOPHAN AND THE CONTENTS OF SEROTONIN AND 5-HYDROXYINDOLEACETIC ACID IN REGIONS OF THE RAT BRAIN.
210673 03-03
COMPARATIVE STUDIES ABOUT SERUM ELECTROLYTES DURING LITHIUM PROPHYLAXIS OF AFFECTIVE DISORDERS.
210807 03-09
SERUM CLONAZEPAM CONCENTRATIONS IN CHILDREN WITH ABSENCE SEIZURES.
211064 03-13
RELATIONSHIP BETWEEN SERUM LITHIUM LEVEL AND CLINICAL RESPONSE ON DEPRESSION TREATED WITH LITHIUM CARBONATE.
217354 04-09
EFFECT OF MORPHINE, HYDROMORPHONE, METHADONE, MESCALINE, TRYPAN-BLUE, VITAMIN-A, SODIUM SALICYLATE AND CAFFEINE ON THE SERUM INTERFERON LEVEL IN RESPONSE TO VIRAL INFECTION.
217654 04-03
BENZODIAZEPINES: SPECIFIC COMPETITORS FOR THE BINDING OF L-TRYPTOPHAN TO HUMAN SERUM ALBUMIN.
217686 04-01
SERUM CONCENTRATIONS OF PHENOBARBITAL AND DIPHENYLHYDANTOIN (PRELIMINARY REPORT).
218011 04-11
SERUM ERYTHROCYTE AND CNS LEVELS IN RHESUS MONKEYS OF ORALLY AND INTRAVENOUSLY ADMINISTERED RUBIDIUM SALTS.
218956 04-02
TETRAHYDROCANNABINOLS AND SERUM PROLACTIN LEVELS IN MAN.
220973 04-13
A CLINICAL STUDY OF SERUM CONCENTRATION LEVELS OF PHENOBARBITAL DERIVED FROM PRIMIDONE (MUSOLINE).
224644 04-13

SEX
AGE SEX DIFFERENCES IN RESPONSE TO ANTIDEPRESSANT DRUGS.
193093 01-11
THE ROLE OF SEX AND NOVELTY IN DETERMINING THE SOCIAL RESPONSE TO LITHIUM CHLORIDE.
202721 02-04
ALTERATION OF PSYCHOSOMATIC REACTIVITY AFTER A SINGLE THERAPEUTIC DOSE OF PENTOBARBITAL IN RELATION TO THE SEX OF PROBANDS.
205627 03-14
PSYCHOTOMIMETIC SUBSTANCES DURING PREGNANCY AND SEX OF OFFSPRING MICE. (PH.D. DISSERTATION).
213050 03-03
SEX DIFFERENCES IN THE EFFECTS OF DEXAMETHASONE PHOSPHATE ON BEHAVIOR IN RATS.
218492 04-04

SEXUAL
THE CONTROL OF DEVIANT SEXUAL BEHAVIOUR BY DRUGS: I. BEHAVIOURAL CHANGES FOLLOWING ESTROGENS AND ANTIANDROGENS.
196958 01-14
INHIBITORY ROLE OF DOPAMINE AND 5-HYDROXYTRYPTAMINE IN THE SEXUAL BEHAVIOUR OF FEMALE RATS.
199968 02-04
TREATMENT OF SEXUAL DELINQUENCY WITH ANDROCUR (CYPROTERONE ACETATE).
203496 02-17
STIMULATION OF SEXUAL BEHAVIOUR IN RATS BY A BENZODIOXANE DERIVATIVE.
210351 03-04
THE REVERSIBLE INHIBITION OF STEROID INDUCED SEXUAL BEHAVIOR BY INTRACRANIAL CYCLOHEXIMIDE.
213685 04-03
5-HYDROXYTRYPTAMINE IN THE CENTRAL NERVOUS SYSTEM AND SEXUAL RECEPTIVITY OF FEMALE RHESUS MONKEYS.
217856 04-04
ROLE OF MONOAMINES IN THE CONTROL BY HORMONES OF SEXUAL RECEPTIVITY IN THE FEMALE RAT.
222263 04-04
APOMORPHINE: FACILITATION OF SEXUAL BEHAVIOUR IN FEMALE RATS.
222807 04-04

SEXUALITY
EXPERIENCE WITH CYPROTERONE ACETATE INFLUENCE ON HUMAN SEXUALITY.
195037 01-11
SEXUALITY AND GILLES-DE-LA-TOURETTES SYNDROME.
207957 03-11

SHANGRI-LA
THE ROAD TO SHANGRI-LA IS PAVED WITH VITAMIN AND PSYCHOTHERAPEUTIC FADDISM.
209010 03-17

SHAPE
SOMATOSENSORY EVOKED RESPONSE WAVE SHAPE STABILITY: RELATIONSHIPS TO PSYCHIATRIC DIAGNOSIS AND EFFECTS OF PSYCHOACTIVE DRUGS.
195935 01-17

SHAPIRO
THE SHAPIRO CARDS SCALE AS A METHOD OF ASSESSMENT OF OBSESSIONAL SYMPTOMS IN CLOMIPRAMINE THERAPY.
214829 04-10

SHEEP
NEUROCHEMICAL CODING FOR FEEDING IN SHEEP AND STEERS.
206727 03-04
FEEDING BEHAVIOR IN SHEEP: EFFECTS OF NIALAMIDE AND 6-HYDROXYDOPAMINE.
210743 03-04
THE EFFECT OF PSYCHOPHARMACOLOGIC PROLACTIN RELEASERS ON LACTATION IN SHEEP.
210793 03-03

SHIFT
METABOLISM OF 4-CHLOROAMPHETAMINE TO 3-CHLORO-4-HYDROXYAMPHETAMINE IN RAT: EVIDENCE FOR AN IN VIVO NIH SHIFT OF CHOLINE.
210929 03-03
THE EFFECTS OF D-AMPHETAMINE MONOPHOSPHATE ON THE PEAK SHIFT. (PH.D. DISSERTATION).
213153 03-04

SHOCK
A CASE OF PHENOTHIAZINE ILEUS RECOVERED FROM SHOCK.
193828 01-15
INTERACTION BETWEEN MASSED ELECTROCONVULSIVE SHOCK AND P-BROMOMETHYLAMPHETAMINE (V-111) TREATMENT.
197579 01-03
ELECTROCONVULSIVE SHOCK: SUSTAINED DECREASE IN NOREPINEPHRINE UPTAKE AFFINITY IN A RESERPINE MODEL OF DEPRESSION.
210830 03-03

ANTEROGRADE AND RETROGRADE EFFECTS OF ELECTROCONVULSIVE SHOCK AND OF PUROMYCIN ON MEMORY FORMATION IN THE GOLDFISH.
213853 04-04

DRUGS AND PUNISHED RESPONDING. V. EFFECTS OF DRUGS ON RESPONDING SUPPRESSED BY RESPONSE DEPENDENT AND RESPONSE INDEPENDENT ELECTRIC SHOCK.
215722 04-04

THE EFFECTS OF SHOCK INTENSITY, D-AMPHETAMINE, AND PENTOBARBITAL ON THE FREQUENCY AND RESPONSE DYNAMICS OF BITING ATTACK IN THE SQUIRREL MONKEY. (PH.D. DISSERTATION).
222114 04-04

U-SHAPED FUNCTIONS IN A SHOCK ESCAPE TASK.
222265 04-04

THE EFFECTS OF CHRONIC MORPHINE ADMINISTRATION UPON A MODIFIED SIDMAN AVOIDANCE SCHEDULE THAT UTILIZES RESPONSE INDEPENDENT SHOCK.
225566 04-04

SHOCK-ELICITED
EFFECTS ON SHOCK-ELICITED AGGRESSION IN MICE OF PREFERENTIALLY PROTECTING BRAIN MONOAMINES AGAINST THE DEPLETING ACTION OF RESERPINE.
195452 01-04

SHOCKS
EFFECTS OF D-AMPHETAMINE AND PRESESSION SHOCKS ON SIDMAN AVOIDANCE WITH A TONE IN RATS. (PH.D. DISSERTATION).
212677 03-04

SHORT-TERM
EFFECTS OF PSYCHOTROPIC DRUGS ON THE SHORT-TERM MEMORY OF RETARDED CHILDREN. (PH.D. DISSERTATION).
194655 01-14

SHORT-TERM EFFECTS OF TESTOSTERONE PROPIONATE ON THE BEHAVIOUR OF YOUNG INTACT MALE DOMESTIC DUCKS (ANAS-PLATYRHYNCHOS).
199461 02-04

THE THERAPEUTIC EFFECT OF SHORT-TERM ORAL DIAZEPAM TREATMENT ON ACUTE CLINICAL ANXIETY IN A CRISIS CENTRE.
199991 02-10

AN ATTEMPT TO CLASSIFY NEUROLEPTIC DRUGS ON THE BASIS OF SHORT-TERM CLINICAL COMPARATIVE STUDIES.
205591 02-08

SHORT-TERM EFFECT OF PERPHENAZINE ENANTHATE ON THE RAT BRAIN.
206359 03-03

LONG-TERM AND SHORT-TERM EFFECTS OF SULPIRIDE ON SLEEP EEG IN MAN.
206977 03-14

THE EFFECT OF CHOLINERGICS ON SHORT-TERM MEMORY AND THE EXCITABILITY LEVEL OF HIPPOCAMPUS CIRCLE STRUCTURES.
208972 03-03

ADRENERGIC AND CHOLINERGIC DRUG EFFECTS UPON SHORT-TERM MEMORY IN MICE. (PH.D. DISSERTATION).
214205 04-04

THE CORRELATION BETWEEN THE VENTRAL AND DORSAL HIPPOCAMPUS DURING IMPROVEMENT OR DETERIORATION OF SHORT-TERM MEMORY.
215487 04-04

GENETIC, BIOCHEMICAL, AND ENVIRONMENTAL VARIABLES IN THE EXPRESSION OF SHORT-TERM MEMORY IN THE MOUSE. (PH.D. DISSERTATION).
222749 04-04

SHORTENING
DURATION OF EXPERIENCED LENGTHENING AND SHORTENING OF STRAIGHT LINES.
205135 02-14

TREATMENT OF ACUTE SCHIZOPHRENIA WITH ULTRA-HIGH-DOSE FLUPHENAZINE: A FAILURE AT SHORTENING TIME ON A CRISIS INTERVENTION UNIT.
215456 04-08

SHUTTLE
SHUTTLE AVOIDANCE LEARNING OF MICE: EFFECTS OF POSTTRIAL PENTYLENETETRAZOL, STRAIN AND AGE.
195226 01-04

SHUTTLEBOX
DIFFERENTIAL EFFECTS OF EPINEPHRINE AND PROPRANOLOL ON SHUTTLEBOX AVOIDANCE LEARNING IN RATS OF DIFFERENT AGES. (PH.D. DISSERTATION).
193745 01-04

DIETHYLDITHIOCARBAMATE (ANTABUSE): DECREASE OF BRAIN HEAVY METAL STAINING PATTERN AND IMPROVED CONSOLIDATION OF SHUTTLEBOX AVOIDANCE IN GOLDFISH.
203521 02-04

NORMAL SHUTTLEBOX AVOIDANCE LEARNING AFTER CHRONIC PHENOBARBITAL INTOXICATION IN MICE.
210737 03-04

EFFECTS OF DRUG ALTERED SEROTONIN LEVELS ON THE ACQUISITION OF A SHUTTLEBOX AVOIDANCE TASK. (PH.D. DISSERTATION).
211781 03-04

SIAMESE
CHLORDIAZEPOXIDE (LIBRIUM) INDUCED CHANGES IN INTRASPECIFIC ATTACK AND SELECTED NONAGONISTIC BEHAVIORS IN MALE SIAMESE FIGHTING FISH.
217524 04-04

SIDE-EFFECT
HEAVY INTOXICATION AS A SIDE-EFFECT OF CARBROMAL IN TWO CHILDREN.
203882 02-15

SIDE-EFFECTS
SIDE-EFFECTS OF BREVITAL AIDED DESENSITIZATION: SOME CLINICAL IMPRESSIONS.
193986 01-15

PLASMA LITHIUM LEVELS AND SIDE-EFFECTS DURING ADMINISTRATION OF A SLOW-RELEASE LITHIUM SULPHATE PREPARATION (LITHIUM LIPETT-C) AND LITHIUM CARBONATE LEVELS.
197029 01-15

TRUE AND APPARENT SIDE-EFFECTS IN A CONTROLLED TRIAL OF CHLORPROMAZINE AND IMIPRAMINE IN DEPRESSION.
197856 01-09

SIDE-EFFECTS OF PSYCHOTROPIC DRUGS -- AN ANALYSIS OF DATA OBTAINED FROM DOUBLE-BLIND COMPARATIVE STUDIES IN JAPAN.
201260 02-15

SIDE-EFFECTS OF METHYLPERONE IN LONG-TERM THERAPY UP TO 8 YEARS.
204406 02-15

THE PROBLEM OF SIDE-EFFECTS OF THYMOLEPTICS.
205620 03-15

SIDE-EFFECTS OF IMIPRAMINE AND AMITRIPTYLINE.
207519 03-15

DEPRESSIONS AND ANTIDEPRESSANTS DURING TREATMENT WITH LONG-ACTING NEUROLEPTIC DRUGS: SIDE-EFFECTS AND THE EMERGENT METATHERAPEUTIC SYNDROME.
219694 04-15

PLACEBO INDUCED SIDE-EFFECTS.
221165 04-15

OBJECTIVE ASSESSMENT OF ANTICHOLINERGIC SIDE-EFFECTS OF TRICYCLIC ANTIDEPRESSANTS A CONTROLLED STUDY OF IMIPRAMINE AND IMIPRAMINE-N-OXIDE.
221633 04-15

MAPROTILINE (LUDIOMIL): SIDE-EFFECTS AND OVERDOSAGE.
221663 04-15

SIDMAN
EFFECTS OF D-AMPHETAMINE ON ACQUISITION OF LEVERPRESS SIDMAN AVOIDANCE IN RATS.
195305 01-04

EFFECTS OF D-AMPHETAMINE AND PRESESSION SHOCKS ON SIDMAN AVOIDANCE WITH A TONE IN RATS. (PH.D. DISSERTATION).
212677 03-04

THE EFFECTS OF CHRONIC MORPHINE ADMINISTRATION UPON A MODIFIED SIDMAN AVOIDANCE SCHEDULE THAT UTILIZES RESPONSE INDEPENDENT SHOCK.
225566 04-04

SIDNOCARB
A THERAPEUTIC STUDY OF SIDNOCARB.
217000 04-14

THE USE OF SIDNOCARB IN CHILD PSYCHIATRY.
217001 04-11

SIDNOKARB
THE ACTION OF PSYCHOSTIMULANT SIDNOKARB ON METABOLISM OF BIOGENIC AMINES IN THE BRAIN.
197573 01-03

SIGNAL
EFFECTS OF MARIHUANA ON AUDITORY SIGNAL DETECTION.
206356 03-12

SIGNIFICANCE
PERSONALITY TRAIT STABILITY LABILITY AND ITS SIGNIFICANCE FOR PHARMACOLOGICAL RESEARCH.
196776 01-16

THE SIGNIFICANCE OF NORADRENALINE AND ADRENALINE AS ADRENERGIC TRANSMITTERS IN THE CHICKEN.
197958 01-03

SOCIOPSYCHIATRIC SIGNIFICANCE OF THE APPLICATION OF PSYCHOTROPICS IN GERIATRICS.
198394 02-11

THE RELATIVE SIGNIFICANCE OF NOREPINEPHRINE DOPAMINE AND 5-HYDROXYTRYPTAMINE IN THE ELECTROSHOCK SEIZURE IN THE RAT.
204339 02-03

SIGNIFICANCE OF PSYCHOTHERAPY USED WITH DRUGS.
204426 02-17

SIGNIFICANCE OF CATECHOLAMINES FOR THE MANIFESTATION OF MORPHINE WITHDRAWAL IN THE RAT.
206988 03-03

A CRYSTALLOGRAPHIC AND THEORETICAL STUDY OF THE CONFORMATION OF DOET AND ITS SIGNIFICANCE FOR THE HALLUCINOGENIC AMPHETAMINES.
210746 03-01

THERAPEUTIC REVERSAL WITH BENZTROPINE IN SCHIZOPHRENICS: PRACTICAL AND THEORETICAL SIGNIFICANCE.
213726 04-08
THE SIGNIFICANCE OF PSYCHOPHARMACOLOGY FOR PSYCHIATRIC REHABILITATION.
220367 04-09
THE SIGNIFICANCE OF STANDARDIZED EVALUATION SCALES IN PSYCHIATRIC DIAGNOSIS AS EXEMPLIFIED BY THE THERAPEUTIC INTERVENTION WITH DESMETHYLOXAPINE.
221337 04-10
SIGNIFICANCE OF PLASMA CHLORPROMAZINE IN MANAGEMENT OF PSYCHIATRIC PATIENTS.
224832 04-13

SIGNS
SIGNS, COURSE AND PROGNOSIS OF TICS IN CHILDREN AND JUVENILES.
203881 02-14

SIMILARITIES
SIMILARITIES OF THE INFLUENCE OF SECONDARY AND TERTIARY TRICYCLIC ANTIDEPRESSANTS ON THE EFFECT OF RESERPINE IN FROGS AND ON THE SEROTONIN UPTAKE OF HUMAN THROMBOCYTES.
219503 04-13
SIMILARITIES IN THE EFFECTS OF LITHIUM CARBONATE, LITAREX AND LITHIONITE DURETTER: PRELIMINARY STUDY.
221634 04-14

SIMPLE
A SIMPLE AND RAPID SPECTROPHOTOMETRIC DETERMINATION OF MONOAMINEOXIDASE ACTIVITY.
197281 01-01
SIMPLE METHOD FOR DETECTION OF THE DRUG CHEATERS IN PSYCHIATRY.
205586 02-17
A RAPID, SIMPLE AND MORE SENSITIVE METHOD FOR THE DEMONSTRATION OF CENTRAL CATECHOLAMINE CONTAINING NEURONS AND AXONS BY GLYOXYLIC ACID INDUCED FLUORESCENCE: I. SPECIFICITY.
217550 04-16
A SIMPLE AVOIDANCE PROCEDURE FOR TESTING PSYCHOTROPIC DRUGS IN MICE.
220903 04-04

SIMPLIFIED
DISTRIBUTION OF CHLORPROMAZINE IN A SIMPLIFIED BLOOD INFLUENCED BY VARIOUS DRUGS.
195245 01-03
A SIMPLIFIED GUIDE TO THE RATIONAL USE OF PSYCHOTROPIC DRUGS.
196231 01-17

SIMULATED
EFFECT OF SIMULATED ALTITUDE ON THE DISPOSITION OF CHLORPROMAZINE IN MOUSE BRAIN AND LIVER.
197455 01-05

SINEQUAN
MAINTENANCE DOXEPIN (SINEQUAN) THERAPY FOR DEPRESSIVE ILLNESS.
209901 03-09

SINGAPORE
HEAD INJURY, HYPOPITUITARISM AND PARANOID PSYCHOSIS: CIRCUMCISION FOR THE SINGAPORE VIRUS.
200581 02-09

SINGLE
EFFECT OF SINGLE AND DAILY INJECTIONS OF PHENOBARBITAL ON OVULATION IN HAMSTERS.
193421 01-03
DOXEPIN IN A SINGLE BEDTIME DOSE IN PSYCHONEUROTIC OUTPATIENTS.
194834 01-10
THE EFFECT OF TWO BARBITURATE ANTIPODES ON SPINAL REFLEXES AND SINGLE MOTONEURONS.
197297 01-03
RELATIONSHIP BETWEEN THE CHANGES ON BLOOD PRESSURE RESPONSE AND THE CARDIAC CATECHOLAMINE LEVEL AFTER SINGLE AND REPEATED ADMINISTRATIONS OF TYRAMINE AND METHAMPHETAMINE IN RATS.
197491 01-03
EFFECTS OF DIAZEPAM ON DISCHARGE PATTERN IN SINGLE FIBRES OF PHRENIC NERVE.
197577 01-03
STEADY-STATE PLASMA CONCENTRATIONS DURING SINGLE AND MULTIPLE DOSAGE SCHEDULES OF AMITRIPTYLINE.
202699 02-13
PHARMACOKINETIC DETERMINANTS OF THE RESPONSE TO SINGLE DOSES OF CHLORDIAZEPOXIDE.
203005 02-13
EFFECTS OF SINGLE AND REPEATED ADMINISTRATION OF MAPROTILINE AND ITS RELATION TO PLASMA LEVELS IN HEALTHY TEST SUBJECTS.
204403 02-15
EFFECTS OF D-AMPHETAMINE ON SINGLE VESTIBULAR NEURONS.
204483 02-03
ALTERATION OF PSYCHOSOMATIC REACTIVITY AFTER A SINGLE THERAPEUTIC DOSE OF PENTOBARBITAL IN RELATION TO THE SEX OF PROBANDS.
205627 03-14
PLASMA AND CEREBROSPINAL FLUID CONCENTRATIONS OF PHENOBARBITAL IN INFANTS GIVEN SINGLE DOSES.
206057 03-13
METABOLISM OF DOPAMINE AND NOREPINEPHRINE IN RAT BRAIN AFTER SINGLE AND REPEATED ADMINISTRATION OF HALOPERIDOL, LOXAPINE AND CLOZAPINE.
206973 03-03
RECIPROCAL (PUSH-PULL) EFFECTS OF MORPHINE ON SINGLE UNITS IN THE VENTROMEDIAN AND LATERAL HYPOTHALAMUS AND INFLUENCES ON OTHER NUCLEI: WITH COMMENT ON METHADONE EFFECTS DURING WITHDRAWAL FROM MORPHINE.
210700 03-03
INFLUENCE OF TEMPIDON ON THE EEG OF CATS AT A SINGLE AND REPEATED APPLICATION.
215076 04-03
A COMPARISON OF A DIVIDED AND A SINGLE DOSE REGIME OF CLOMIPRAMINE (ANAFRANIL).
215149 04-09
POLYGRAPHIC NIGHT SLEEP PATTERN DURING CHRONIC SINGLE AND MULTIPLE NEUROLEPTIC DOSE ADMINISTRATION.
215701 04-08
A DOUBLE-BLIND COMPARISON OF THREE TIMES DAILY AND SINGLE NIGHT DOSAGE OF THE TRICYCLIC ANTIDEPRESSANT DOTHIEPIN.
216463 04-09
A SINGLE DAILY DOSE OF A SUSTAINED RELEASE FORM OF AMITRIPTYLINE IN DEPRESSIVE ILLNESS.
219961 04-09
EFFECTS OF SINGLE AND MULTIPLE DOSE LSD ON ENDOGENOUS LEVELS OF BRAIN TYROSINE-HYDROXYLASE AND CATECHOLAMINES.
221044 04-12

SINGLE-BLIND
CLOZAPINE AND HALOPERIDOL IN A SINGLE-BLIND CROSSOVER TRIAL: THERAPEUTIC AND BIOCHEMICAL ASPECTS IN THE TREATMENT OF SCHIZOPHRENIA.
200803 02-08

SINTAMIL
DOUBLE-BLIND TRIAL OF SINTAMIL IN DEPRESSION.
206043 03-10

SINUS
SYMPTOMATIC SINUS NODE ABNORMALITIES FOLLOWING LITHIUM CARBONATE THERAPY.
223120 04-15

SITES
EFFECTS OF TRANSMITTER MIMICKERS AT SITES OF ANGIOTENSIN INDUCED DRINKING IN THE CAT.
193434 01-04
THE EFFECT OF DIAZEPAM ON SPINAL CORD ACTIVITIES: POSSIBLE SITES AND MECHANISMS OF ACTION.
197585 01-03
THE NUCLEUS LINEARIS INTERMEDIUS RAPHE AND BEHAVIOUR EVOKED BY DIRECT AND INDIRECT STIMULATION OF DOPAMINE SENSITIVE SITES WITHIN THE CAUDATE NUCLEUS OF CATS.
199864 02-04
ANTISCHIZOPHRENIC DRUGS: AFFINITY FOR MUSCARINIC CHOLINERGIC RECEPTOR SITES IN THE BRAIN PREDICTS EXTRAPYRAMIDAL EFFECTS.
207298 03-03
PREFERRED CONFORMATIONS OF SEROTONIN IN RELATION TO RECEPTOR SITES.
210928 03-03
COMPETITION FOR PLASMA PROTEIN BINDING SITES BETWEEN PHENOTHIAZINE TRANQUILIZERS AND IMINODIBENZYL ANTIDEPRESSANTS.
217891 04-03
ACTION OF SEROTONIN MICROINJECTED INTO HYPOTHALAMIC SITES AT WHICH ELECTRICAL STIMULATION PRODUCED AVERSIVE RESPONSES IN THE RAT.
219075 04-04
CATECHOLAMINES AND SELF-STIMULATION: PHARMACOLOGICAL DIFFERENCES BETWEEN NEAR-LATERAL AND FAR-LATERAL HYPOTHALAMIC SITES.
221030 04-03

SITUATION
CHLORDIAZEPOXIDE AND PHENOBARBITAL IN A MODEL ANXIETY INDUCING SITUATION.
207775 03-14

SITUATIONS
THE EFFECT OF DIAZEPAM ON THE BEHAVIOR OF RATS ADAPTED TO HIGH ALTITUDE HYPOXIA IN CONFLICTING SITUATIONS.
219502 04-04

SIZE
NORADRENERGIC CONTROL OF SPONTANEOUS MEAL SIZE IN THE RAT. (PH.D. DISSERTATION).
214206 04-04
SIZE OF THE ENVIRONMENT AS A DETERMINER OF EFFECTS OF SCOPOLAMINE.
223849 04-04

SKED
SKED PROGRAM FOR A MODIFIED STERNBERG PROCEDURE.
214812 04-16

SKELETAL
DEPOLARIZATION, DESENSITIZATION AND THE EFFECTS OF TUBOCURARINE AND NEOSTIGMINE IN CULTURED SKELETAL MUSCLE.
193447 01-03
THE ACTION OF DIAZEPAM ON HUMAN SKELETAL MUSCLE.
193800 01-13

SKF-525A
THE INFLUENCE OF SKF-525A ON THE ACUTE PHARMACOLOGICAL PROPERTIES OF CHLORDIAZEPOXIDE.
197478 01-03

SKILLS
EFFECT OF TRICYCLIC ANTIDEPRESSANTS AND ALCOHOL ON PSYCHOMOTOR SKILLS RELATED TO DRIVING.
215667 04-14

SKIN
HEART RATE AND GALVANIC SKIN RESPONSE VARIATIONS DURING THE REM AND NON-REM SLEEP PHASES IN MAN.
205443 02-13
INFLUENCE OF MEPROBAMATE, CARISPRODOL, OXAZEPAM AND PHENOBARBITAL ON NA+ TRANSPORT IN THE ISOLATED FROG SKIN.
206781 03-03
ON THE USE OF SULPIRIDE WITH SOME SKIN DISEASES.
209044 03-11
GALVANIC SKIN RESISTANCE (GSR) MEASUREMENTS ON VOLUNTEERS RECEIVING FENFLURAMINE OR D-AMPHETAMINE.
225062 04-13

SLEEP
THE EFFECTS OF NICOTINAMIDE ON MOUSE SLEEP.
194929 01-03
SLEEP IN PATIENTS WITH PARKINSONS DISEASE AND ITS INFLUENCE BY L-DOPA.
195155 01-11
EFFECTS OF LITHIUM CARBONATE ON SLEEP.
195918 01-09
SOME AMPHETAMINE EFFECTS ON REM SLEEP.
195923 01-14
CADMIUM-INDUCED POTENTIATION OF HEXOBARBITAL SLEEP TIME IN RATS.
197684 01-04
CHLORDIAZEPOXIDE AND ITS EFFECT ON SLEEP WAKEFULNESS BEHAVIOR IN UNRESTRAINED CATS.
199213 02-04
SLEEP AMPHETAMINE EFFECTS IN MBDS AND NORMAL SUBJECTS.
199640 02-11
EFFECTS OF 5-HYDROXYTRYPTOPHAN ON SLEEP OF A PATIENT WITH A BRAINSTEM LESION.
199757 02-13
THE RELATIONSHIP OF CENTRAL MONOAMINES TO DRUG-INDUCED SLEEP IN THE RAT, EXAMINED ON A 24-HOUR BASIS. (PH.D. DISSERTATION).
201005 02-03
DETERMINATION OF DRUG-INDUCED CHANGES IN SLEEP QUALITY BASED ON DIGITAL COMPUTER SLEEP PRINTS.
203603 02-14
SLEEP - EEG TESTS OF NONSPECIFIC CASES OF PAROXYSM AND EPISODIC BEHAVIORAL DISTURBANCES: A PRELIMINARY REPORT.
203704 02-14
SELECTIVE INHIBITION OF DOPAMINE-BETA-HYDROXYLASE IN THE PERIPHERAL TISSUES BY 5-DIMETHYLDITHIOCARBAMYLPICOLINIC ACID; ITS EFFECT ON STRESS INDUCED ULCER, ETHANOL INDUCED SLEEP AND BLOOD PRESSURE.
204484 02-03
HEART RATE AND GALVANIC SKIN RESPONSE VARIATIONS DURING THE REM AND NON-REM SLEEP PHASES IN MAN.
205443 02-13
INFLUENCE OF MELATONIN ON EEG AND HUMAN SLEEP: AUTOMATIC EEG ANALYSES AND POLYGRAPHIC NIGHT SLEEP INVESTIGATIONS.
205446 02-13
STUDY ON AMITRIPTYLINE-INDUCED SLEEP IN EPILEPTIC PATIENTS.
205470 02-13
COMPARATIVE STUDY OF THE ELECTRONEUROPHYSIOLOGICAL PARAMETERS OF SLEEP INDUCED BY SEVERAL HYPNOTIC DRUGS.
205520 02-13
THE EFFECTS OF LITHIUM CARBONATE ON SLEEP AND WAKEFULNESS IN THE CAT.
205546 02-03
SLEEP DEPRIVATION AS A POTENTIATION OF ANTIDEPRESSIVE PHARMACOTHERAPY?
205602 03-09
CATEGORIES OF PSYCHOTROPIC DRUG EFFECTS ON SLEEP EEG AND EOG.
205621 03-13
LONGITUDINAL STUDY OF THE EFFECTS OF LITHIUM CARBONATE ON THE SLEEP OF HOSPITALIZED DEPRESSED PATIENTS.
206333 03-09
MOOD AND SLEEP CHANGES WITH MONOAMINEOXIDASE INHIBITORS.
206369 03-14
EFFECT OF FLURAZEPAM ON SLEEP IN THE LABORATORY.
206450 03-14
LONG-TERM AND SHORT-TERM EFFECTS OF SULPIRIDE ON SLEEP EEG IN MAN.
206977 03-14
CLINICAL STUDIES OF D-40TA (TRIAZOLOBENZODIAZEPINE) -- CROSSOVER TRIAL ON SLEEP DISTURBANCES AND SLEEP EEG IN NORMAL ADULTS.
209412 03-10
THE EFFECTS OF HYPNOTIC DRUGS ON SLEEP.
209981 03-14
PHARMACOLOGICAL MANIPULATIONS OF BRAIN CATECHOLAMINES AND THE AGGRESSIVE BEHAVIOR INDUCED BY MARIHUANA IN REM SLEEP DEPRIVED RATS.
210325 03-04
REM INHIBITORY EFFECT OF L-DOPA INFUSION DURING HUMAN SLEEP.
210602 03-14
THE EFFECTS OF RUBIDIUM ON THE DURATION OF SLEEP ELICITED BY PENTOBARBITAL IN THE RAT.
210791 03-03
THE EFFECT OF COCA-COLA, CAFFEINE, ANTIDEPRESSANTS AND CHLORPROMAZINE ON OBJECTIVE AND SUBJECTIVE SLEEP PARAMETERS.
210808 03-14
THE EFFECTS OF MEDAZEPAM (S-804) ON ALL-NIGHT SLEEP.
211361 03-14
INFLUENCE OF RESERPINE ON ALL-NIGHT SLEEP PATTERN IN NONLOBOTOMIZED AND LOBOTOMIZED CHRONIC SCHIZOPHRENIC PATIENTS.
213530 04-08
PHARMACOLOGICAL STUDIES OF SLEEP.
213610 04-03
EFFECTS OF AMITRIPTYLINE ON HUMAN REM SLEEP AS EVALUATED BY USING PARTIAL DIFFERENTIAL REM SLEEP DEPRIVATION (PDRD).
214750 04-14
POLYGRAPHIC NIGHT SLEEP PATTERN DURING CHRONIC SINGLE AND MULTIPLE NEUROLEPTIC DOSE ADMINISTRATION.
215701 04-08
EFFECTS OF HIGH DOSAGE DELTA9-TETRAHYDROCANNABINOL ON SLEEP PATTERNS IN MAN.
215740 04-14
DIFFERENTIAL EFFECTS OF CHLORPROMAZINE, IMIPRAMINE, NITRAZEPAM AND AMOBARBITAL ON REM SLEEP AND REM DENSITY IN MAN.
215955 04-14
SLEEP AND BEHAVIORAL CHANGES REFLECTING CENTRAL RECEPTOR HYPERSENSITIVITY FOLLOWING CATECHOLAMINE SYNTHESIS INHIBITION IN MAN. (UNPUBLISHED PAPER).
216373 04-09
DIFFERENTIAL DIAGNOSIS AND THERAPY OF SLEEP DISTURBANCES.
217193 04-11
CORRELATION OF BRAIN LEVELS OF BARBITURATE ENANTIOMERS WITH REPORTED DIFFERENCES IN DURATION OF SLEEP.
217457 04-03
EFFECTS OF CENTRAL DOPAMINERGIC BLOCKADE WITH PIMOZIDE UPON THE EEG STAGES OF SLEEP IN MAN.
217546 04-14
THE EFFECT OF TRIAZOLAM ON THE SLEEP OF INSOMNIACS.
217548 04-14
REM SLEEP REDUCTION EFFECTS ON DEPRESSION SYNDROMES.
218120 04-09
EFFECTS OF HEXAPROPYMATE ON THE SLEEP OF THE NORMAL MAN MEASURED BY A POLYGRAPHIC METHOD.
218166 04-14
SPECIFICITY OF BENZODIAZEPINE ACTION ON HUMAN SLEEP CONFIRMED. ANOTHER CONTRIBUTION OF AUTOMATIC ANALYSIS OF POLYGRAPH RECORDINGS.
218953 04-14
THE EFFECT OF ALCOHOL AND BARBITURATE ON THE FREQUENCY OF ATRIAL AND VENTRICULAR PREMATURE BEATS DURING SLEEP.
218971 04-13
THE METABOLISM OF INDIVIDUAL PHOSPHOLIPID FRACTIONS IN THE RAT BRAIN DURING THIOPENTAL SLEEP AND AMPHETAMINE EXCITATION.
219747 04-03
SLEEP INDUCING EFFECT OF PIPERIDINE.
220945 04-03
EFFECTS OF ALPHA-METHYLDOPA ON NEWBORN KITTEN SLEEP. BEHAVIORAL EVOLUTION DURING THE FIRST MONTH AFTERBIRTH.
221049 04-04
ELECTROENCEPHALOGRAPHIC STUDY FOR THE EVALUATION OF THE EFFECTS OF 7-CHLORO-5-PHENYLBENZODIAZEPIN-2-ONE (N-DEMETHYLDIAZEPAM) ON SLEEP DISTURBANCES IN A GROUP OF MENTAL PATIENTS.
221272 04-14
THE INFLUENCE OF SULPIRIDE ON SLEEP: RESULTS OF POLYGRAPHIC NIGHT SLEEP RECORDINGS.
221339 04-14
EEG SLEEP PATTERNS AND DRUG ABUSE.
224719 04-15

EEG SLEEP CHANGES AS PREDICTORS IN DEPRESSION.
224769 04-09

SLEEP-WAKEFULNESS
EFFECT OF CHRONIC MARIJUANA ADMINISTRATION ON STAGES OF PRIMATE SLEEP-WAKEFULNESS.
225520 04-14

SLEEP-WAKING
EFFECTS OF 2-DEOXY-D-GLUCOSE ON SLEEP-WAKING PATTERNS.
206253 03-04
L-HISTIDINE: FAILURE TO AFFECT THE SLEEP-WAKING CYCLE IN MAN.
214015 04-14

SLEEPING
PROLONGED PENTOBARBITAL SLEEPING TIME IN ADJUVANT INDUCED POLYARTHRITIC RATS.
196228 01-04
THE EFFECT OF BETA-THIAMINOKETONES ON THE AMINOPYRINE-N-DEMETHYLATION IN VITRO AND IN VIVA SUCH AS THE HEXOBARBITAL SLEEPING TIME AND L-ASCORBIC ACID EXCRETION IN THE RAT.
197469 01-03
EFFECT OF DELTA8-THC ON ALCOHOL-INDUCED SLEEPING TIME IN THE RAT.
200041 02-03
THE EFFECT OF OZONE ON PENTOBARBITAL SLEEPING TIME IN MICE.
204862 02-02
THE EFFECT OF CAFFEINE ON BARBITURATE SLEEPING TIME AND BRAIN LEVEL.
214109 04-03
ON THE MECHANISM OF POTENTIATION BY MORPHINE OF THIOPENTAL SLEEPING TIME.
215666 04-03

SLICES
ADENOSINE-3-5-MONOPHOSPHATE IN CEREBRAL CORTICAL SLICES FROM GUINEA-PIG AND RAT: EFFECT OF ALPHA-ADRENERGIC AND BETA-ADRENERGIC COMPOUNDS.
197293 01-03
STUDIES ON THE UPTAKE OF D-AMPHETAMINE BY RAT CEREBRAL CORTEX SLICES.
197961 01-03
INFLUENCE OF MORPHINE ON THE RELEASE OF NORADRENALINE FROM BRAIN SLICES.
197964 01-03
ADENOSINE-3-5-MONOPHOSPHATE IN CEREBRAL CORTICAL SLICES FROM GUINEA-PIG AND RAT: EFFECT OF BENZODIAZEPINES.
197972 01-03
EFFECT OF NICOTINE AND OTHER DRUGS ON THE RELEASE OF 3H-NOREPINEPHRINE AND 3H-DOPAMINE FROM RAT BRAIN SLICES.
197985 01-03
THE EFFECT OF TRIIODOTHYRONINE IN COMBINATION WITH IMIPRAMINE ON (3H) CYCLIC-AMP PRODUCTION IN SLICES OF RAT CEREBRAL CORTEX.
202777 02-03
STUDIES ON THE DISTINCTION BETWEEN UPTAKE INHIBITION AND RELEASE OF H3-DOPAMINE IN RAT BRAIN TISSUE SLICES.
215756 04-03
EFFECT OF WITHDRAWAL FROM CHRONIC ETHANOL INGESTION ON THE CAMP RESPONSE OF CEREBRAL CORTICAL SLICES USING THE AGONISTS HISTAMINE, SEROTONIN, AND OTHER NEUROTRANSMITTERS.
215980 04-03

SLOW
PSYCHOTROPIC DRUGS AND SLOW POTENTIALS IN MAN.
198101 02-13
POLYGRAPHIC EXAMINATION DURING FAST AND SLOW INTRAVENOUS INJECTION OF THE SAME DOSE OF DIAZEPAM.
205508 02-13

SLOW-RELEASE
PLASMA LITHIUM LEVELS AND SIDE-EFFECTS DURING ADMINISTRATION OF A SLOW-RELEASE LITHIUM SULPHATE PREPARATION (LITHIUM LIPETT-C) AND LITHIUM CARBONATE LEVELS.
197029 01-15
PRELIMINARY RESULTS ON THE CLINICAL USE OF A SLOW-RELEASE PREPARATION OF LITHIUM SALTS.
209122 03-09

SLUGGISH
ATROPINE COMA TREATMENT OF SCHIZOPHRENIC PATIENTS WITH A SLUGGISH DEVELOPMENT AND OBSESSIVE SYNDROMES.
224085 04-08
TREATING PATIENTS WITH A SLUGGISH FORM OF SCHIZOPHRENIA.
224383 04-08

SMOKED
DOSE EFFECTS OF SMOKED MARIHUANA ON HUMAN COGNITIVE AND MOTOR FUNCTIONS.
221036 04-01

SMOKING
DROWSINESS DUE TO CHLORPROMAZINE IN RELATION TO CIGARETTE SMOKING: A REPORT FROM THE BOSTON COLLABORATIVE DRUG SURVEILLANCE PROGRAM.
193072 01-15
EFFECT OF SMOKING MARIHUANA AND OF A HIGH NICOTINE CIGARETTE ON ANGINA-PECTORIS.
215670 04-15

SNIFFING
COMPARISON OF STRUCTURAL AND STEREOISOMERS OF APOMORPHINE ON STEREOTYPED SNIFFING BEHAVIOUR OF THE RAT.
210930 03-04

SOCIAL
SOCIAL INTERACTION BETWEEN DRUGGED AND UNDRUGGED RATS.
196206 01-04
EFFECTS OF SOCIAL STRESS ON THE TURNOVER OF BRAIN CATECHOLAMINES AND 5-HYDROXYTRYPTAMINE IN MICE.
198025 01-03
SOCIAL ASPECTS OF PSYCHOPHARMACOTHERAPY.
198327 02-17
SOCIAL AND PSYCHOLOGICAL ASPECTS OF MEDICAL PRACTICE: DRUG TREATMENT IN PSYCHIATRY.
201270 02-17
THE ROLE OF SEX AND NOVELTY IN DETERMINING THE SOCIAL RESPONSE TO LITHIUM CHLORIDE.
202721 02-04
SUPPRESSION OF MOUSE-KILLING AND APOMORPHINE-INDUCED SOCIAL AGGRESSION IN RATS BY LOCAL ANESTHESIA OF THE MYSTACIAL-VIBRISSAE.
206714 03-04
EFFECTS OF MARIHUANA (DELTA9-THC) ON BEHAVIOR PATTERNS AND SOCIAL ROLES IN COLONIES OF CBA MICE.
216494 04-04

SOCIALLY
THE EFFECTS OF PSYCHOMOTOR STIMULANTS ON STEREOTYPY AND LOCOMOTOR ACTIVITY IN SOCIALLY DEPRIVED AND CONTROL RATS.
210666 03-04
THE EFFECTS OF PSYCHOMOTOR STIMULATION ON STEREOTYPY AND LOCOMOTOR ACTIVITY IN SOCIALLY DEPRIVED AND CONTROL RATS.
213433 04-03
DIAZEPAM TREATMENT OF SOCIALLY ISOLATED MONKEYS.
224776 04-04

SOCIETY
A SOCIETY ON THE RUN: A PSYCHOLOGY OF NORTHERN-IRELAND.
194054 01-17
MONOAMINERGIC NEUROTOXINS: ARE THEY SELECTIVE? SOME PERSPECTIVES ON THE SYMPOSIUM HELD AT THE FOURTH ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, OCTOBER, 1974. (UNPUBLISHED PAPER).
222353 04-06

SOCIOECONOMIC
RESPONSE TO METHYLPHENIDATE IN LOW SOCIOECONOMIC HYPERACTIVE CHILDREN.
217181 04-14

SOCIOLOGICAL
A CONTROLLED SERIES OF EXPERIMENTS INVESTIGATING SOME SOCIOLOGICAL EFFECTS OF TWO DOSAGES OF CHLORDIAZEPOXIDE (LIBRIUM) UPON INDIVIDUALS AND SMALL GROUPS. (PH.D. DISSERTATION).
195145 01-14

SOCIOPSYCHIATRIC
SOCIOPSYCHIATRIC ASPECTS OF PSYCHOPHARMACOLOGY.
198393 02-17
SOCIOPSYCHIATRIC SIGNIFICANCE OF THE APPLICATION OF PSYCHOTROPICS IN GERIATRICS.
198394 02-11

SOCIOTHERAPY
DRUG AND SOCIOTHERAPY IN THE AFTERCARE OF SCHIZOPHRENIC PATIENTS: II. TWO-YEAR RELAPSE RATES.
199625 02-08
DRUG AND SOCIOTHERAPY IN THE AFTERCARE OF SCHIZOPHRENIC PATIENTS: III. ADJUSTMENT OF NONRELAPSED PATIENTS.
199626 02-08

SODIUM
LONG-TERM LITHIUM ADMINISTRATION TO RATS. LITHIUM AND SODIUM DOSAGE AND ADMINISTRATION, AVOIDANCE OF INTOXICATION, POLYURIC CONTROL RATS.
195042 01-03
SODIUM AND LITHIUM ERYTHROCYTE CONCENTRATION IN AFFECTIVE DISORDERS.
195931 01-09
THE EFFECTS OF SODIUM AMOBARBITAL ON ODOR-BASED RESPONDING IN RATS.
195995 01-04
THE EFFECT OF BENZODIAZEPINES ON THE ANALGESIC EFFECT OF MORPHINE AND SODIUM SALICYLATE.
197480 01-03
EFFECTS OF SODIUM, OUABAIN AND DMPP ON THE NEURONAL EFFLUX OF NORADRENALINE.
197959 01-03
THE INFLUENCE OF SODIUM OXYBUTYRATE ON INTERNEURONAL TRANSMISSION OF EXCITATION AT VARIOUS LEVELS OF THE CENTRAL NERVOUS SYSTEM.
198435 02-03

LITHIUM INDUCED LOSS OF BODY SODIUM AND THE DEVELOPMENT OF SEVERE INTOXICATION IN RATS.
199623 02-03

THE EFFECT OF VARYING THE DOSAGE OF SODIUM PENTOBARBITAL ON THE BARPRESS RATE OF RATS.
201843 02-04

EFFECT OF SODIUM GAMMA-HYDROXYBUTYRATE ON ISOLATION INDUCED AGGRESSIVITY IN MICE.
205588 02-04

THE EFFECT OF DIAZEPAM AND NITRAZEPAM ON INTRACELLULAR AND EXTRACELLULAR DISTRIBUTION OF SODIUM AND POTASSIUM IONS IN INDIVIDUAL STRUCTURES OF RATS BRAINS.
207199 03-03

THE EFFECT OF SODIUM CHLORIDE ON KIDNEY FUNCTION IN RATS WITH LITHIUM INTOXICATION.
210696 03-03

COMPARATIVE STUDIES ON THE MEMBRANE ACTIONS OF DEPRESSANT DRUGS: THE ROLE OF LIPOPHILICITY IN INHIBITION OF BRAIN SODIUM AND POTASSIUM STIMULATED ATPASE.
210818 03-03

REVERSIBLE INHIBITION OF MAMMALIAN BRAIN ACETYLCHOLINESTERASE AND SODIUM POTASSIUM STIMULATED ADENOSINE-TRIPHOSPHATASE BY CYCLOPROPANE.
210903 03-03

THE EFFECT OF SODIUM GAMMA-HYDROXYBUTYRATE ON THE CNS OF RATS AND MICE.
215069 04-03

N-DESMETHYLDIAZEPAM AND AMYLOBARBITONE SODIUM AS HYPNOTICS IN ANXIOUS PATIENTS. PLASMA LEVELS, CLINICAL EFFICACY AND RESIDUAL EFFECTS.
217460 04-10

THE EFFECTS OF A DEXAMPHETAMINE AMYLOBARBITONE SODIUM MIXTURE ON THE REWARD VALUE OF DIFFERENT SENSORY CHANGES.
217476 04-03

EFFECT OF MORPHINE, HYDROMORPHONE, METHADONE, MESCALINE, TRYPAN-BLUE, VITAMIN-A, SODIUM SALICYLATE AND CAFFEINE ON THE SERUM INTERFERON LEVEL IN RESPONSE TO VIRAL INFECTION.
217654 04-03

SCHEDULE INDUCED AGGRESSION IN LABORATORY RATS: DEMONSTRATION AND CONTROL THROUGH SODIUM AMOBARBITAL. (PH.D. DISSERTATION).
220644 04-04

THE PARTIAL PUNISHMENT EFFECT FOLLOWING MINIMAL ACQUISITION TRAINING: SODIUM AMOBARBITAL AND THE STIMULUS PROPERTIES OF EARLY PUNISHED TRIALS.
224504 04-04

SOFT

THE EFFECT OF CHRONIC LITHIUM APPLICATION ON THE MINERAL CONTENT OF RAT BONE AND SOFT TISSUES.
215695 04-05

SOLUBILITY

LIPID SOLUBILITY AND DRUG PENETRATION OF THE BLOOD-BRAIN BARRIER.
206913 03-03

SOLUBLE

WATER SOLUBLE DERIVATIVES OF 3-OXY-SUBSTITUTED 1,4 BENZODIAZEPINES.
200739 02-01

SOLUTION

EXPLICIT SOLUTION TO PHARMACOKINETIC FIRST-ORDER RATE CONSTANTS OF MAPROTILIN.
208919 03-17

SOLVENT

VOLATILE SOLVENT ADDICTION AND TRAFFIC SAFETY.
205596 02-15

SOMAN

EFFECT OF BENZODIAZEPINE DERIVATIVES ON SOMAN INDUCED SEIZURE ACTIVITY AND CONVULSIONS IN THE MONKEY.
197466 01-03

REDUCTION BY DIAZEPAM OF REPETITIVE ELECTRICAL ACTIVITY AND TOXICITY RESULTING FROM SOMAN.
199861 02-03

EFFECT OF DIAZEPAM UPON SOMAN INDUCED SEIZURE ACTIVITY AND CONVULSIONS.
204192 02-02

SOMATIC

MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 2. COMMUNICATION: PSYCHOPATHOLOGICAL COURSE PROFILE AND SOMATIC CHARACTERISTICS (STUDIES WITH THE AMP SYSTEM).
203840 02-14

SOMATOSENSORY

SOMATOSENSORY EVOKED RESPONSE WAVE SHAPE STABILITY: RELATIONSHIPS TO PSYCHIATRIC DIAGNOSIS AND EFFECTS OF PSYCHOACTIVE DRUGS.
195935 01-17

HALLUCINOGENIC DRUG ACTION ON THE SOMATOSENSORY SYSTEM.
213634 04-04

SOMATOVISCERAL

DIFFERENTIAL ATTENUATION OF SOMATOVISCERAL AND VISCEROSOMATIC REFLEXES BY DIAZEPAM, PHENOBARBITAL AND DIPHENYLHYDANTOIN.
222818 04-04

SOPORIFICS

UNEXPECTED COMPLICATIONS BY ANTICHOLINERGICS CONTAINED IN SOPORIFICS AND ANALGESIC DRUGS.
204404 02-15

SPACED

EFFECTS OF REPEATED DOSES OF 1-DELTA8-TRANS-TETRAHYDROCANNABINOL ON SCHEDULE-CONTROLLED TEMPORALLY SPACED RESPONDING OF RATS.
195431 01-04

SPARING

THE SPARING TECHNIQUE IN ELECTROCONVULSIVE THERAPY.
200071 02-13

SPASTICITY

A COMPARATIVE STUDY ON THE EFFECT OF INTRAVENOUS DIAZEPAM AND RO-5-3350 ON PYRAMIDAL SPASTICITY.
205575 02-13

SPATIAL

THE EFFECT OF DIFFERENTIAL SALINE AND CYCLOHEXIMIDE STATES ON THE ACQUISITION OF A SPATIAL REVERSAL TASK IN MICE AND RATS. (PH.D. DISSERTATION
198897 02-04

SPATIAL DISTRIBUTION OF THE EEG OF DYSLEXIC CHILDREN.
205504 02-13

SPECIES

SPECIES DIFFERENCES IN ANTAGONISTIC EFFECT OF MORPHINE AGAINST DEPRESSOR RESPONSE TO DOPAMINE.
202800 02-03

FACTORS INFLUENCING BRAIN AND TISSUE LEVELS OF TRYPTAMINE: SPECIES, DRUGS AND LESIONS.
210850 03-03

SPECIFIC

SPECIFIC ASYMMETRIC BEHAVIOUR INDUCED BY THE DIRECT CHEMICAL STIMULATION OF NEOSTRIATAL DOPAMINERGIC MECHANISMS.
197929 01-04

STIMULATION OF A SPECIFIC DRIVE (PREDATORY BEHAVIOR) BY P-CHLOROPHENYLALANINE (PCPA) IN THE RAT.
197952 01-04

AN MAOI SPECIFIC AFFECTIVE DISORDER. THE TOO MUCH SYNDROME.
202705 02-09

ON THE REGULATION OF CYCLIC-AMP PHOSPHODIESTERASE BY A SPECIFIC PROTEIN ACTIVATOR. (UNPUBLISHED PAPER).
208735 03-03

EVIDENCE THAT 5-METHOXYDIMETHYLTRYPTAMINE IS A SPECIFIC SUBSTRATE FOR MAO-A IN THE RAT: IMPLICATIONS FOR THE INDOLEAMINE DEPENDENT BEHAVIORAL SYNDROME.
210817 03-04

DOPAMINERGIC NEURONS IN THE NIGROSTRIATAL AND MESOLIMBIC PATHWAYS: MEDIATION OF SPECIFIC EFFECTS OF D-AMPHETAMINE.
210855 03-03

POTENTIATION OF THE L-5-HYDROXYTRYPTOPHAN INDUCED ELEVATION OF PLASMA CORTICOSTERONE LEVELS IN RATS BY A SPECIFIC INHIBITOR OF SEROTONIN UPTAKE.
211104 03-03

CHLORPROMAZINE: SPECIFIC INHIBITION OF L-NORADRENALINE AND 5-HYDROXYTRYPTAMINE UPTAKE IN SYNAPTOSOMES FROM SQUID BRAIN.
213395 04-03

LYSERGIC ACID DIETHYLAMIDE AFFECTS BLOOD FLOW TO SPECIFIC AREAS OF THE CONSCIOUS RAT BRAIN.
215161 04-03

BENZODIAZEPINES: SPECIFIC COMPETITORS FOR THE BINDING OF L-TRYPTOPHAN TO HUMAN SERUM ALBUMIN.
217686 04-01

AN APPLICATION OF LONG-TERM FREQUENCY ANALYSIS IN MEASURING DRUG SPECIFIC ALTERATIONS IN THE EEG OF THE CAT.
218190 04-03

SPECIFICITIES

SOME SPECIFICITIES IN THE COURSE OF MANIOMELANCHOLIC PSYCHOSIS DURING LITHIUM THERAPY.
205609 03-09

SPECIFICITY

COMPARISON OF THE SPECIFICITY OF 3-(P-TRIFLUOROMETHYLPHENOXY)-N-METHYL-3 PHENYLPROPYLAMINE AND CHLORIMIPRAMINE AS AMINE UPTAKE INHIBITORS IN MICE.
197870 01-03

ON THE SPECIFICITY OF NEUROCHEMICAL MECHANISMS DEALING WITH NOCICEPTIVE STIMULATION OF NEURONS IN VARIOUS BRAIN FORMATIONS OF RABBITS.
198436 02-03

BEHAVIORAL SPECIFICITY OF CHLORALOSE INDUCED FEEDING IN THE RAT.
200054 02-04

NOREPINEPHRINE AND SEROTONIN: SPECIFICITY OF RELEASE WITH REWARDING ELECTRICAL STIMULATION OF THE BRAIN.
217522 04-03

A RAPID, SIMPLE AND MORE SENSITIVE METHOD FOR THE DEMONSTRATION OF CENTRAL CATECHOLAMINE CONTAINING NEURONS AND AXONS BY GLYOXYLIC ACID INDUCED FLUORESCENCE: I. SPECIFICITY.
217550 04-16

A CRITICAL REVIEW OF OXAZEPAM: EFFICACY AND SPECIFICITY.
218154 04-17

SPECIFICITY OF BENZODIAZEPINE ACTION ON HUMAN SLEEP CONFIRMED. ANOTHER CONTRIBUTION OF AUTOMATIC ANALYSIS OF POLYGRAPH RECORDINGS.
218953 04-14

THE SPECIFICITY OF ACTION EXERTED BY NEUROTROPIC AGENTS DURING SENSITIZATION.
219508 04-03

SPECTRA

COMPARISON OF THE ACTION OF DIAZEPAM AND PHENOBARBITAL USING EEG DERIVED POWER SPECTRA OBTAINED FROM TEMPORAL LOBE EPILEPTICS.
197992 01-13

STUDIES ON CLINICAL AND PHARMACOLOGICAL SPECTRA OF THE TETRACYCLIC COMPOUND MIANSERIN.
204412 02-14

SPECTRAL

EEG STATISTICAL SPECTRAL ANALYSIS OF SCHIZOPHRENIC PATIENTS.
205448 02-08

EEG AND SCHIZOPHRENIA: EXPERIMENTAL STUDIES, SPECTRAL ANALYSIS AND SEPTAL SPIKES.
205455 02-03

EEG CHANGES AFTER PSYCHOACTIVE DRUGS (SPECTRAL ANALYTIC STUDY).
205472 02-13

EEG SPECTRAL ANALYSIS FOR THE EVALUATION OF THE CENTRAL EFFECTS OF DELTA6-TETRAHYDROCANNABINOL IN RABBITS.
217467 04-03

SPECTRAL ANALYSIS OF HUMAN EEG CHANGES INDUCED BY ETIFOXIN.
221724 04-13

SPECTROFLUORODENSITOMETRIC

SPECTROFLUORODENSITOMETRIC DETERMINATION OF FLURAZEPAM AND ITS MAJOR METABOLITES IN BLOOD.
200737 02-16

SPECTROMETRY

RAPID ANALYSIS OF THE CENTRAL NERVOUS SYSTEM STIMULANTS, AMPHETAMINES, VIA GAS CHROMATOGRAPHY MASS SPECTROMETRY: RAPID ACYLATION IN THE PRESENCE OF A MERCURY CATALYST.
222830 04-06

SPECTROPHOTOFLUOROMETRIC

COLORIMETRIC, ULTRAVIOLET SPECTROPHOTOMETRIC, AND SPECTROPHOTOFLUOROMETRIC DETERMINATION OF DOXEPIN AND SOME OF ITS METABOLITES IN SERUM AND IN URINE.
199214 02-16

SPECTROPHOTOMETRIC

A SIMPLE AND RAPID SPECTROPHOTOMETRIC DETERMINATION OF MONOAMINEOXIDASE ACTIVITY.
197281 01-01

COLORIMETRIC, ULTRAVIOLET SPECTROPHOTOMETRIC, AND SPECTROPHOTOFLUOROMETRIC DETERMINATION OF DOXEPIN AND SOME OF ITS METABOLITES IN SERUM AND IN URINE.
199214 02-16

SPECULATIONS

PHARMACOTHERAPY OF SCHIZOPHRENIA: FACTS, SPECULATIONS, HYPOTHESES AND THEORIES.
206603 03-08

SPIKES

EEG AND SCHIZOPHRENIA: EXPERIMENTAL STUDIES, SPECTRAL ANALYSIS AND SEPTAL SPIKES.
205455 02-03

SPINAL

ACETYLCHOLINE LEVELS IN THE FROG SPINAL CORD FOLLOWING THE ADMINISTRATION OF DIFFERENT CONVULSANTS.
193550 01-03

EFFECT OF CHRONIC TRANSECTION ON DOPAMINE, NORADRENALINE AND 5-HYDROXYTRYPTAMINE IN THE RAT SPINAL CORD.
195244 01-03

THE EFFECT OF TWO BARBITURATE ANTIPODES ON SPINAL REFLEXES AND SINGLE MOTONEURONS.
197297 01-03

THE EFFECT OF DIAZEPAM ON SPINAL CORD ACTIVITIES: POSSIBLE SITES AND MECHANISMS OF ACTION.
197585 01-03

DIAZEPAM INCREASES 5-HYDROXYINDOLE CONCENTRATIONS IN RAT BRAIN AND SPINAL CORD.
200081 02-03

LIPIDOSIS LIKE ALTERATIONS IN SPINAL CORD AND CEREBELLAR CORTEX OF RATS TREATED WITH CHLORPHENTERMINE OR TRICYCLIC ANTIDEPRESSANTS.
202767 02-03

THE EFFECT OF L-DOPA AND L-DOPA COMBINED WITH CHLORPROMAZINE ON SPINAL CORD ACTIVITY DURING DISTURBED INHIBITION BY TETANUS TOXOID.
207200 03-03

RELATIONSHIP BETWEEN THE LATE REFLEX DISCHARGE AND LOCOMOTOR MOVEMENTS IN ACUTE SPINAL CATS AND RABBITS WITH DOPA.
209728 03-03

NORADRENALINE MEDIATED INHIBITION BY LOCUS-COERULEUS OF SPINAL TRIGEMINAL NEURONS.
210703 03-03

CATECHOLAMINE NEUROTRANSMITTERS AND SYNTHETIC ENZYMES IN THE SPINAL CORD OF THE RAT.
213987 04-03

LACK OF EFFECT OF PROTRIPTYLINE ON THE 6-HYDROXYDOPAMINE INDUCED NORADRENALINE DEPLETION IN THE RAT SPINAL CORD.
217824 04-03

SPINALISED

THE LIPOLYTIC ACTIVITY OF AMPHETAMINE IN THE SPINALISED CAT.
195118 01-03

SPINDLE

PERSISTENT THALAMIC AND CORTICAL BARBITURATE SPINDLE ACTIVITY AFTER ABLATION OF THE ORBITAL CORTEX IN CATS.
199763 02-03

DIFFERENTIAL SENSITIVITY OF PRIMARY AND SECONDARY SPINDLE AFFERENTS TO DEPRESSANT DRUGS.
210801 03-03

SPINDLES

NEURONAL ACTIVITY OF NUCLEUS CAUDATES AND THALAMUS DURING BARBITURATE SPINDLES IN RATS.
201479 02-03

SPIRAMIDE

PARTIAL RESTORATION BY AN A NEUROLEPTIC (SPIRAMIDE) OF ITEMS OF GROOMING BEHAVIOUR SUPPRESSED BY AMPHETAMINE.
213590 04-04

SPLEEN

COMPARISON BETWEEN THE EFFECTS PRODUCED BY CHRONIC DENERVATION AND BY COCAINE ON THE SENSITIVITY TO, AND ON THE DISPOSITION OF, NORADRENALINE IN ISOLATED SPLEEN STRIPS.
193139 01-03

SPLENIC

EFFECTS OF RESERPINE AND PRENYLAMINE ON THE NORADRENALINE FLUXES OF ISOLATED SPLENIC NERVE GRANULES.
197280 01-03

SPONTANEOUS

SPONTANEOUS ORAL DYSKINESIA: RESULTS OF TREATMENT WITH TETRABENAZINE, PIMOZIDE, OR BOTH.
196600 01-11

THE EFFECT OF CYCLOHEXIMIDE AND ACTINOMYCIN-D ON THE SPONTANEOUS AND OPERATIVE BEHAVIORS OF THE PIGEON. PRELIMINARY NOTE.
199381 02-04

ONTOGENETIC ASPECTS OF CENTRAL CHOLINERGIC INVOLVEMENT IN SPONTANEOUS ALTERNATION BEHAVIOR.
199550 02-04

EFFECTS OF NICOTINE ON SPONTANEOUS LOCOMOTOR ACTIVITY IN RATS HAVING HIGH AND LOW BASAL ACTIVITY LEVELS.
202980 02-04

EFFECTS OF SCOPOLAMINE ON THE EEG OF CORTEX AND HIPPOCAMPUS DURING SPONTANEOUS BEHAVIOUR IN RATS.
205628 03-04

NORADRENERGIC CONTROL OF SPONTANEOUS MEAL SIZE IN THE RAT. (PH.D. DISSERTATION).
214206 04-04

THE BIPHASIC EFFECT OF SMALL DOSES OF TRANYLCYPROMINE ON THE SPONTANEOUS MOTOR ACTIVITY AND LEARNED CONDITIONED BEHAVIOUR IN RATS.
215665 04-04

SPONTANEOUS ALTERNATION IN FERRETS FOLLOWING TREATMENT WITH SCOPOLAMINE, CHLORDIAZEPOXIDE, AND CAFFEINE.
223039 04-04

THE EFFECT OF INTRAVENTRICULAR ADMINISTRATION OF SEROTONIN ON SPONTANEOUS MOTOR ACTIVITY OF RATS. (UNPUBLISHED PAPER).
225287 04-04

SPREADING

CHANGES IN THE NEURONAL PROTEIN LABELLING INDUCED BY POTASSIUM IONS IN VIVO (SPREADING DEPRESSION).
210779 03-03

EFFECT OF OUABAIN AND PHENOBARBITAL ON OXIDATIVE METABOLIC ACTIVITY ASSOCIATED WITH SPREADING CORTICAL DEPRESSION IN CATS.
220944 04-03

SQ-10996

NEUROPHARMACOLOGY OF SQ-10996, A COMPOUND WITH SEVERAL THERAPEUTIC INDICATIONS.
197459 01-13

SQUID

INEFFECTIVENESS OF LYSERGIC ACID DIETHYL AMIDE 25 (LSD) ON ALTERING NA-K CURRENTS IN SQUID GIANT AXON.
194927 01-03

CHLORPROMAZINE: SPECIFIC INHIBITION OF L-NORADRENALINE AND 5-HYDROXYTRYPTAMINE UPTAKE IN SYNAPTOSOMES FROM SQUID BRAIN.
213395 04-03

COMPARISON OF THE ACTION OF DIFFERENT BARBITURATES ON SQUID AXON MEMBRANES.
217662 04-03

SQUIRREL

BEHAVIORAL EFFECTS OF D-AMPHETAMINE AND CAFFEINE IN THE SQUIRREL MONKEY.
210860 03-04

EFFECTS OF CHLORDIAZEPOXIDE ON SCHEDULE INDUCED WATER AND ALCOHOL CONSUMPTION IN THE SQUIRREL MONKEY.
214013 04-04

A COMPARISON BETWEEN CAUDATE, AMYGDALOID AND HYPOTHALAMIC SELF-STIMULATION IN SQUIRREL MONKEYS (SAIMIRI-SCIUREUS). (PH.D. DISSERTATION).
214207 04-04

EFFECTS OF CHRONIC ADMINISTRATION AND WITHDRAWAL OF D-AMPHETAMINE UPON DAILY ACTIVITY LEVELS OF SQUIRREL MONKEYS.
219032 04-04

THE EFFECTS OF SHOCK INTENSITY, D-AMPHETAMINE, AND PENTOBARBITAL ON THE FREQUENCY AND RESPONSE DYNAMICS OF BITING ATTACK IN THE SQUIRREL MONKEY. (PH.D. DISSERTATION).
222114 04-04

THE EFFECTS OF DELTA9-TETRAHYDROCANNABINOL UPON FEAR-MOTIVATED BEHAVIOR IN SQUIRREL MONKEYS.
223040 04-04

STABILITY

SOMATOSENSORY EVOKED RESPONSE WAVE SHAPE STABILITY: RELATIONSHIPS TO PSYCHIATRIC DIAGNOSIS AND EFFECTS OF PSYCHOACTIVE DRUGS.
195935 01-17

PERSONALITY TRAIT STABILITY LABILITY AND ITS SIGNIFICANCE FOR PHARMACOLOGICAL RESEARCH.
196776 01-16

PRACTICAL KINETICS I: QUANTITATION OF BARBITURATE STABILITY BY TLC.
211007 03-06

CONSTITUENTS OF CANNABIS-SATIVA L. IX: STABILITY OF SYNTHETIC AND NATURALLY OCCURRING CANNABINOIDS IN CHLOROFORM.
211010 03-06

STAGE

THE PROTECTIVE EFFECT OF SEROTONIN AGAINST THE INHIBITORY ACTION OF CHLORPROMAZINE ON THE MEMBRANE POTENTIAL OF STAGE 2 BLASTOMERES OF MOUSE EMBRYOS IN VITRO.
217005 04-03

CLINICAL - PSYCHOPATHOLOGICAL CRITERIA FOR THE SELECTION OF PSYCHOTROPIC DRUGS ACCORDING TO THE STAGE OF ILLNESS AND THE EFFECTIVENESS OF REHABILITATING SCHIZOPHRENICS.
220403 04-17

STAGES

SOME CHARACTERISTICS OF PATHOLOGY IN SCHIZOPHRENIA DURING THE TWO STAGES OF PSYCHOPHARMACOLOGICAL DEVELOPMENT.
201908 02-08

EFFECTS OF CENTRAL DOPAMINERGIC BLOCKADE WITH PIMOZIDE UPON THE EEG STAGES OF SLEEP IN MAN.
217546 04-14

EFFECT OF CHRONIC MARIJUANA ADMINISTRATION ON STAGES OF PRIMATE SLEEP-WAKEFULNESS.
225520 04-14

STAINING

DIETHYLDITHIOCARBAMATE (ANTABUSE): DECREASE OF BRAIN HEAVY METAL STAINING PATTERN AND IMPROVED CONSOLIDATION OF SHUTTLEBOX AVOIDANCE IN GOLDFISH.
203521 02-04

STANDARD

COMPARATIVE PHARMACOLOGICAL STUDIES ON BUTRIPTYLINE AND SOME RELATED STANDARD TRICYCLIC ANTIDEPRESSANTS.
211101 03-03

STANDARDIZED

THE SIGNIFICANCE OF STANDARDIZED EVALUATION SCALES IN PSYCHIATRIC DIAGNOSIS AS EXEMPLIFIED BY THE THERAPEUTIC INTERVENTION WITH DESMETHYLOXAPINE.
221337 04-10

STARTLE

THE EFFECTS OF L-DOPA, CLONIDINE, AND APOMORPHINE ON THE ACOUSTIC STARTLE REACTION IN RATS.
202773 02-04

STARVATION

POTENTIATION OF LOCOMOTOR ACTIVITY AND MODIFICATION OF STEREOTYPY BY STARVATION IN APOMORPHINE TREATED RATS.
217675 04-04

STATE

A TRANSIENT STATE CONCEPT OF DRUG RECEPTOR INTERACTION.
195240 01-17

EFFECTS OF NIKETHAMIDE, PICROTOXIN AND STRYCHNINE ON AMPHETAMINE STATE.
199967 02-03

PIPERACETAZINE STUDY IN STATE HOSPITAL PATIENTS.
203423 02-11

DOPAMINE AND THE PHARMACOLOGY OF SCHIZOPHRENIA: THE STATE OF THE EVIDENCE.
207300 03-03

ARE AUTORECEPTORS IN DOPAMINERGIC NEURONS INVOLVED IN THE CHANGE OF THE KINETIC STATE OF STRIATAL TYROSINE-HYDROXYLASE ELICITED BY ANTIPSYCHOTICS? (UNPUBLISHED PAPER).
208636 03-03

APPLICATION OF LOPRAMINE (DB-2182) FOR THE TREATMENT OF DEPRESSIVE STATE.
209395 03-11

EFFECTS OF OVERTRAINING UPON DRUG STATE DEPENDENCY IN DISCRIMINATION LEARNING IN WHITE RATS.
209866 03-04

CLOMIPRAMINE IN THE TREATMENT OF THE TRUE OBSESSIONAL STATE: A REPORT ON FOUR PATIENTS.
211433 03-10

STEREOSPECIFICITY OF DOPAMINE RECEPTORS INVOLVED IN THE REGULATION OF THE KINETIC STATE OF TYROSINE-HYDROXYLASE IN STRIATUM AND NUCLEUS-ACCUMBENS.
217888 04-03

THE INTOXICATION: STATE OF CONSCIOUSNESS.
224757 04-14

ROLE FOR POSTSYNAPTIC DOPAMINE RECEPTORS IN THE REGULATION OF THE KINETIC STATE OF STRIATAL TYROSINE-HYDROXYLASE. (UNPUBLISHED PAPER).
225307 04-03

STATE-DEPENDENT

ANALYSIS OF CUE USE IN STATE-DEPENDENT LEARNING. (PH.D. DISSERTATION).
196409 01-04

DISRUPTION OF STATE-DEPENDENT LEARNING (MEMORY RETRIEVAL) BY EMOTIONALLY IMPORTANT STIMULI.
217470 04-04

STATE-DEPENDENT LEARNING WITH CENTRALLY AND NONCENTRALLY ACTIVE DRUGS.
219020 04-04

STATISTICAL

EEG STATISTICAL SPECTRAL ANALYSIS OF SCHIZOPHRENIC PATIENTS.
205448 02-08

A STATISTICAL ANALYSIS OF THE COMPARATIVE DOUBLE-BLIND STUDY OF THE ACTIVITY OF LOXAPINE AND THIORIDAZINE.
221671 04-11

PROGNOSIS OF THE THERAPEUTIC EFFECT OF SUXILEP AND TRIMETIN USING A SUCCESSIONAL STATISTICAL PROCEDURE.
224086 04-11

STATUS-EPILEPTICUS

SURVIVAL IN LITHIUM INTOXICATION, STATUS-EPILEPTICUS, AND PROLONGED COMA.
208536 03-15

STEADY-STATE

STEADY-STATE PLASMA CONCENTRATIONS DURING SINGLE AND MULTIPLE DOSAGE SCHEDULES OF AMITRIPTYLINE.
202699 02-13

APPLICATION OF PRINCIPLES OF STEADY-STATE KINETICS TO THE IN VIVO ESTIMATION OF ACETYLCHOLINE TURNOVER RATE IN MOUSE BRAIN.
210885 03-06

STEERS

NEUROCHEMICAL CODING FOR FEEDING IN SHEEP AND STEERS.
206727 03-04

STELAZINE

THE NEURON ULTRASTRUCTURE IN SOME BRAIN AREAS DURING A LONG-TERM ADMINISTRATION OF AMINAZINE AND STELAZINE.
200021 02-03

STENIN

INHIBITION OF SYNAPTIC VESICULAR MG++ DEPENDENT ATPASE (STENIN) BY ANTIPSYCHOTIC PHENOTHIAZINES.
195054 01-03

STEREOCHEMICAL

STEREOCHEMICAL DEPENDENCE OF PHARMACOLOGICAL ACTIVITY IN A SERIES OF OPTICALLY ACTIVE N-METHYLATED BARBITURATES.
193140 01-01

STEREOCHEMICAL STUDIES ON POTENTIAL CENTRAL NERVOUS SYSTEM ACTIVE AGENTS AND STUDIES ON THE CHEMISTRY OF SOME 3-BENZOYLPIPERIDINES. (PH.D. DISSERTATION).
193586 01-01

STEREOCHEMICAL APPROACHES TO TRICYCLIC PSYCHOACTIVE AGENTS. (PH.D. DISSERTATION).
194565 01-01

NEUROLEPTIC AGENTS OF THE BENZOCYCLOHEPTAPYRIDOISOQUINOLINE SERIES. 1.SYNTHESES AND STEREOCHEMICAL AND STRUCTURAL REQUIREMENTS FOR ACTIVITY OF BUTACLAMOL AND RELATED COMPOUNDS.
208592 03-01

STEREOCHEMISTRY
A DUAL STUDY. PART I: SYNTHESIS AND STEREOCHEMISTRY OF SOME 1 SUBSTITUTED QUINOLIZIDINES AS ANALOGS OF BIOLOGICALLY ACTIVE COMPOUNDS. PART II: AMINO DERIVATIVES OF THIOPHENE FUSED CYCLIC KETONES AS POTENTIAL CNS. (PH.D. DISSERTATION).
196252 01-01

STEREOISOMERS
COMPARISON OF STRUCTURAL AND STEREOISOMERS OF APOMORPHINE ON STEREOTYPED SNIFFING BEHAVIOUR OF THE RAT.
210930 03-04

STEREOSELECTIVE
THE STEREOSELECTIVE INHIBITION OF LIPOLYSIS BY NONPHENOLIC PHENETHYLAMINES.
193456 01-03
STEREOSELECTIVE FEATURES OF CATECHOLAMINE DISPOSITION AND THEIR BEHAVIORAL IMPLICATIONS.
207287 03-04

STEREOSPECIFICITY
STEREOSPECIFICITY OF DOPAMINE RECEPTORS INVOLVED IN THE REGULATION OF THE KINETIC STATE OF TYROSINE-HYDROXYLASE IN STRIATUM AND NUCLEUS-ACCUMBENS.
217888 04-03

STEREOTYPED
THE SITE OF AND MODE OF ACTION OF ET495 FOR THE MEDIATION OF STEREOTYPED BEHAVIOUR IN THE RAT.
195252 01-03
CATALEPSY, STEREOTYPED BEHAVIOUR AND STRIATAL HOMOVANILLIC ACID CONTENT IN RATS TREATED WITH METHADONE.
197299 01-03
ONTOGENY OF STEREOTYPED BEHAVIOUR INDUCED BY APOMORPHINE AND AMPHETAMINE IN THE RAT.
197462 01-04
A COMPARISON OF PIMOZIDE AND THIORIDAZINE AS ANTAGONISTS OF AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR IN DOGS.
197470 01-04
THE ROLE OF FOREBRAIN DOPAMINE SYSTEMS IN AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR IN THE RAT.
202774 02-04
6-HYDROXYDOPAMINE LESIONS OF OLFACTORY TUBERCLES AND CAUDATE NUCLEI: EFFECT ON AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR IN RATS.
202788 02-04
STEREOTYPED AND CIRCLING BEHAVIOUR INDUCED BY DOPAMINERGIC AGONISTS AFTER LESIONS OF THE MIDBRAIN RAPHE NUCLEI.
202792 02-04
PHARMACOLOGY AND PHYSIOLOGY OF STEREOTYPED BEHAVIOR.
207284 03-04
COMPARISON OF STRUCTURAL AND STEREOISOMERS OF APOMORPHINE ON STEREOTYPED SNIFFING BEHAVIOUR OF THE RAT.
210930 03-04
EFFECTS OF PENFLURIDOL AND OTHER DRUGS ON APOMORPHINE-INDUCED STEREOTYPED BEHAVIOR IN MONKEYS.
215684 04-04
DETERMINANTS OF AMPHETAMINE PRODUCED STEREOTYPED BEHAVIOR IN THE RAT. (PH.D. DISSERTATION).
220687 04-04

STEREOTYPIC
MORPHINE-INDUCED STEREOTYPIC BEHAVIOR IN RATS.
202740 02-04

STEREOTYPY
APOMORPHINE AND AMPHETAMINE STEREOTYPY AFTER 6-HYDROXYDOPAMINE LESIONS OF THE SUBSTANTIA-NIGRA.
202793 02-04
THE EFFECTS OF PSYCHOMOTOR STIMULANTS ON STEREOTYPY AND LOCOMOTOR ACTIVITY IN SOCIALLY DEPRIVED AND CONTROL RATS.
210666 03-04
COMPARISON BETWEEN BEHAVIOURS ELICITED BY HIGH DOSES OF AMPHETAMINE AND FENFLURAMINE: IMPLICATIONS FOR THE CONCEPT OF STEREOTYPY.
210742 03-04
CANNABIS AND AMPHETAMINE-INDUCED STEREOTYPY IN RATS.
210752 03-04
SEROTONERGIC INVOLVEMENT WITH THE STEREOTYPY/CATALEPSY INDUCED BY MORPHINE-LIKE AGENTS IN THE RAT.
210754 03-04
THE EFFECTS OF PSYCHOMOTOR STIMULATION ON STEREOTYPY AND LOCOMOTOR ACTIVITY IN SOCIALLY DEPRIVED AND CONTROL RATS.
213433 04-03
AMPHETAMINE STEREOTYPY: THE INFLUENCE OF ENVIRONMENTAL FACTORS AND PREPOTENT BEHAVIORAL PATTERNS ON ITS TOPOGRAPHY AND DEVELOPMENT.
213531 04-04
POTENTIATION OF LOCOMOTOR ACTIVITY AND MODIFICATION OF STEREOTYPY BY STARVATION IN APOMORPHINE TREATED RATS.
217675 04-04
FAILURE OF ANTISEROTONERGIC AGENTS TO MODIFY LEVALLORPHAN INDUCED STEREOTYPY IN RATS.
225567 04-03

STERNBERG
SKED PROGRAM FOR A MODIFIED STERNBERG PROCEDURE.
214812 04-16

STEROID
THE REVERSIBLE INHIBITION OF STEROID INDUCED SEXUAL BEHAVIOR BY INTRACRANIAL CYCLOHEXIMIDE.
213685 04-03

STIMULANT
THE SITE OF THE RESPIRATORY STIMULANT ACTION OF IMIDAZOLE IN CATS.
196582 01-03
PHARMACOLOGICAL AND TOXICOLOGICAL STUDY OF A NEW PSYCHOTROPIC STIMULANT: THE 2-PHENYLDIMETHYL-TETRAHYDROOXAZINE, IN COMPARISON WITH D,L-AMPHETAMINE, PHENMETRAZINE AND PEMOLINE-MG.
199211 02-04
TOLERANCE TO THE STIMULANT EFFECTS OF MORPHINE AND PENTAZOCINE ON AVOIDANCE RESPONDING IN THE RAT.
201319 02-04
HYPERKINETIC CHILDREN: THE USE OF STIMULANT DRUGS EVALUATED.
205263 02-14
THE EFFECTS OF STIMULANT AND DEPRESSANT DRUGS ON VERBAL CONDITIONING.
209260 03-14
OBSERVATIONS ON EFFECTS OF A CENTRAL STIMULANT DRUG (METHYLPHENIDATE) IN CHILDREN WITH HYPERACTIVE BEHAVIOR.
219354 04-14
USE OF CNS STIMULANT MEDICATION IN AVERAGED ELECTROENCEPHALIC AUDIOMETRY WITH CHILDREN WITH MBD.
221103 04-11
RELATIONSHIPS BETWEEN THE STRUCTURE AND THE CHRONOTROPIC, LOCOMOTOR STIMULANT AND REINFORCING ACTIONS OF SEVERAL FENFLURAMINE ANALOGS. (PH.D. DISSERTATION).
223563 04-04
STIMULANT DRUG TREATMENT OF HYPERACTIVE ADOLESCENTS.
224379 04-14

STIMULANTS
ELECTROENCEPHALOGRAPHIC STUDY OF THE LOCAL TRANSPORT OF CENTRAL NERVOUS STIMULANTS INTO THE BRAIN.
202165 02-03
THE EFFECTS OF PSYCHOMOTOR STIMULANTS ON STEREOTYPY AND LOCOMOTOR ACTIVITY IN SOCIALLY DEPRIVED AND CONTROL RATS.
210666 03-04
EFFECTS OF HYPERBARIC CONDITIONS ON THE RESPONSE OF ANIMALS TO CENTRAL NERVOUS SYSTEM STIMULANTS AND DEPRESSANTS.
210877 03-03
NEUROCHEMICAL REGULATION OF FEEDING IN THE RAT: FACILITATION BY ALPHA-NORADRENERGIC, BUT NOT DOPAMINERGIC RECEPTOR STIMULANTS.
211538 03-04
THE EFFECTS OF AGE AND ILLUMINATION ON THE DOSE-RESPONSE CURVES FOR THREE STIMULANTS.
214014 04-04
RAPID ANALYSIS OF THE CENTRAL NERVOUS SYSTEM STIMULANTS, AMPHETAMINES, VIA GAS CHROMATOGRAPHY MASS SPECTROMETRY: RAPID ACYLATION IN THE PRESENCE OF A MERCURY CATALYST.
222830 04-06
THE EFFECT OF STIMULANTS AND OPIOIDS ON SENSORY REINFORCEMENT IN RATS. (PH.D. DISSERTATION).
223711 04-04
USING CEREBRAL STIMULANTS TO TREAT MINIMAL-BRAIN-DYSFUNCTION.
224359 04-17

STIMULATE
ANTIPSYCHOTIC DRUGS STIMULATE PROLACTIN RELEASE.
206354 03-03

STIMULATED
PSYCHOTROPIC DRUGS AND DIFFERENTLY STIMULATED ATPASE IN CNS.
205629 03-03
COMPARATIVE STUDIES ON THE MEMBRANE ACTIONS OF DEPRESSANT DRUGS: THE ROLE OF LIPOPHILICITY IN INHIBITION OF BRAIN SODIUM AND POTASSIUM STIMULATED ATPASE.
210818 03-03
REVERSIBLE INHIBITION OF MAMMALIAN BRAIN ACETYLCHOLINESTERASE AND SODIUM POTASSIUM STIMULATED ADENOSINE-TRIPHOSPHATASE BY CYCLOPROPANE.
210903 03-03
EFFECT OF LITHIUM ON GLUCAGON STIMULATED CYCLIC-AMP EXCRETION IN RATS.
213481 04-03
THE EFFECT OF 6-HYDROXYDOPAMINE AND RESERPINE ON THE MOBILIZATION OF CARBOHYDRATES AND FATS IN STIMULATED RATS.
219504 04-03
NICOTINE INDUCED HYPOPHAGIA AND HYPODIPSIA IN DEPRIVED AND IN HYPOTHALAMICALLY STIMULATED RATS.
225559 04-04

STIMULATES
BETA-ADRENERGIC STIMULATION OF PINEAL N-ACETYLTRANSFERASE: CYCLIC-AMP STIMULATES BOTH RNA AND PROTEIN SYNTHESIS.
215601 04-03

STIMULATING
COMPARISON OF THE EFFECTS OF THE INTRANIGRAL INJECTIONS OF CHOLINOMIMETICS WITH SYSTEMIC INJECTIONS OF THE DOPAMINE RECEPTOR STIMULATING AND BLOCKING AGENTS IN THE RABBIT.
199772 02-03

AN ONTOGENIC STUDY ON THE EFFECT OF CATECHOLAMINE RECEPTOR STIMULATING AGENTS ON THE TURNOVER OF NORADRENALINE AND DOPAMINE IN THE BRAIN.
202715 02-03

MELANOCYTE STIMULATING HORMONE: SOME BEHAVIORAL EFFECTS. (PH.D. DISSERTATION).
213030 03-04

CENTRAL STIMULATING AGENTS AND POPULATION GROWTH IN MICE.
221052 04-04

STIMULATION
SELECTIVE STIMULATION BY DOPAMINE OF ADENYLATE-CYCLASE IN HOMOGENATES OF RABBIT RETINA.
192936 01-03

IN VIVO RELEASE OF ENDOGENOUSLY SYNTHESIZED CATECHOLAMINES FROM THE CAT BRAIN EVOKED BY ELECTRICAL STIMULATION AND BY D-AMPHETAMINE.
195049 01-03

EFFECTS OF ADRENERGIC DRUGS ON PRESSOR RESPONSES TO HYPOTHALAMIC STIMULATION.
195441 01-03

ADENYLCYCLASE IN RAT STRIATUM AND NUCLEUS-ACCUMBENS: STIMULATION BY DOPAMINE RECEPTOR AGONISTS. (UNPUBLISHED PAPER).
197124 01-03

PRESSOR RESPONSES TO HYPOTHALAMIC STIMULATION AS INFLUENCED BY DRUGS AFFECTING ADRENERGIC RECEPTORS.
197290 01-03

THE EFFECTS OF CORD SECTION UNDER ETHER OR HALOTHANE ON THE ABILITY OF CHLORPROMAZINE TO AFFECT THE JAW-JERK RESPONSE TO TOOTH PULP STIMULATION IN THE ENCEPHALE ISOLE PREPARATION.
197451 01-03

THE EFFECTS OF AMPHETAMINE AND COCAINE ON THE RESPONSE OF THE ISOLATED GUINEA-PIG VAS-DEFERENS TO NORADRENALINE, TYRAMINE AND NERVE STIMULATION.
197463 01-03

THE INHIBITION OF THE EFFECT OF NERVE STIMULATION BY PHENOTHIAZINES ON ISOLATED INNERVATED ORGANS.
197576 01-03

THEOPHYLLINE INCREASED SENSITIVITY TO NOCICEPTIVE STIMULATION AND REGIONAL TURNOVER OF RAT BRAIN 5-HT, NORADRENALINE AND DOPAMINE.
197926 01-03

SPECIFIC ASYMMETRIC BEHAVIOUR INDUCED BY THE DIRECT CHEMICAL STIMULATION OF NEOSTRIATAL DOPAMINERGIC MECHANISMS.
197929 01-04

GLUCOSE RELEASE OF THE RAT KIDNEY IN VIVO AFTER BETA-ADRENERGIC STIMULATION AND BLOCKADE.
197946 01-03

STIMULATION OF A SPECIFIC DRIVE (PREDATORY BEHAVIOR) BY P-CHLOROPHENYLALANINE (PCPA) IN THE RAT.
197952 01-04

INHIBITION OF EFFECTS OF ACCELERATOR NERVE STIMULATION IN CATS AND RABBITS BY BS-100-141 AND GUANABENZ.
197971 01-03

INFLUENCE OF OXYMETAZOLINE AND PHENTOLAMINE ON NORADRENALINE (NA) RELEASE CAUSED BY ELECTRICAL STIMULATION, POTASSIUM, TYRAMINE AND DIMETHYLPHENYLPIPERAZINE (DMPP).
197973 01-03

TASTE PHENOMENA INFLUENCES ON STIMULATION OF DEPRIVATION INDUCED FLUID CONSUMPTION OF RATS.
197991 01-03

INTRACRANIAL SELF-STIMULATION IN RATS AS A FUNCTION OF VARIOUS STIMULUS PARAMETERS: V. INFLUENCE OF COCAINE ON MEDIAL FOREBRAIN BUNDLE STIMULATION WITH MONOPOLAR ELECTRODES.
198223 02-03

ON THE SPECIFICITY OF NEUROCHEMICAL MECHANISMS DEALING WITH NOCICEPTIVE STIMULATION OF NEURONS IN VARIOUS BRAIN FORMATIONS OF RABBITS.
198436 02-03

COMPARATIVE EFFECT OF PHENAMINE (AMPHETAMINE) AND CAFFEINE ON THE BACKGROUND ACTIVITY OF CORTICAL SENSORIMOTOR NEURONS AND THEIR REACTIONS DURING STIMULATION OF THE CAUDATE NUCLEUS.
198835 02-03

THE NUCLEUS LINEARIS INTERMEDIUS RAPHE AND BEHAVIOUR EVOKED BY DIRECT AND INDIRECT STIMULATION OF DOPAMINE SENSITIVE SITES WITHIN THE CAUDATE NUCLEUS OF CATS.
199864 02-04

INHIBITION OF SCOPOLAMINE INDUCED STIMULATION OF Y-MAZE ACTIVITY BY ALPHA-METHYL-P-TYROSINE AND BY LITHIUM.
199866 02-04

MINIMUM DURATION OF TRANS-SYNAPTIC STIMULATION REQUIRED FOR THE INDUCTION OF TYROSINE-HYDROXYLASE BY RESERPINE IN THE RAT SUPERIOR CERVICAL GANGLION.
199999 02-03

THE IN VIVO RELEASE OF ENDOGENOUSLY SYNTHESIZED CATECHOLAMINES FROM THE CAT BRAIN BY LATERAL HYPOTHALAMIC STIMULATION AND BY D-AMPHETAMINE ADMINISTRATION. (PH.D. DISSERTATION).
200313 02-03

THE EFFECT OF INHIBITORS OF CATECHOLAMINE SYNTHESIS (ALPHA-METHYLTYROSINE AND DISULFIRAM) ON THE BACKGROUND ACTIVITY OF SENSORIMOTOR CORTEX NEURONS AND THEIR RESPONSES TO AFFERENT CAUDATE AND RETICULAR STIMULATION.
202598 02-04

CHEMICAL STIMULATION OF THE AMYGDALA WITH SPECIAL REGARD TO INFLUENCE ON THE HYPOTHALAMUS.
202779 02-04

RELEASE OF NOREPINEPHRINE AND DOPAMINE-BETA-HYDROXYLASE BY NERVE STIMULATION: II. EFFECTS OF PAPAVERINE.
204485 02-03

THE EFFECTS OF ACETYLCHOLINE AND SYNAPTIC STIMULATION ON THE NEURONS IN THE SENSORIMOTOR CORTEX.
205510 02-03

INFLUENCE OF IPRONIAZID ON THE CONTENT OF NORADRENALINE IN VARIOUS PARTS OF THE RAT BRAIN BEFORE AND AFTER STIMULATION OF THE RECEPTORS.
206404 03-03

STIMULATION OF SEXUAL BEHAVIOUR IN RATS BY A BENZODIOXANE DERIVATIVE.
210351 03-04

THE EFFECTS OF CHLORPROMAZINE AND D-AMPHETAMINE SULFATE ON THE VISUAL STIMULATION PREFERENCE OF EXTRAVERTS AND INTROVERTS.
210680 03-14

SOME EFFECTS OF PILOCARPINE AND ACETYLCHOLINE ON THE RESPONSES OF THE GUINEA-PIG VAS-DEFERENS TO HYPOGASTRIC NERVE STIMULATION AND TRANSMURAL STIMULATION AND APPLIED (-) NORADRENALINE.
210770 03-03

EFFECTS OF PSYCHOACTIVE DRUGS ON RESPONSES OF THE RAT TO AVERSIVE STIMULATION.
210784 03-04

EFFECT OF ERGOT DRUGS ON CENTRAL 5-HYDROXYTRYPTAMINE NEURONS: EVIDENCE FOR 5-HYDROXYTRYPTAMINE RELEASE OR 5-HYDROXYTRYPTAMINE RECEPTOR STIMULATION.
210857 03-03

THE EFFECT OF CHLORPROMAZINE AND STIMULATION OF THE MESENCEPHALIC RETICULAR FORMATION ON CENTRAL AROUSAL AND ON THE VISUAL EVOKED RESPONSE. (PH.D. DISSERTATION).
212547 03-03

THE EFFECTS OF PSYCHOMOTOR STIMULATION ON STEREOTYPY AND LOCOMOTOR ACTIVITY IN SOCIALLY DEPRIVED AND CONTROL RATS.
213433 04-03

TOWARD THE QUESTION OF THE INFLUENCE OF STIMULATION OF THE THALAMIC ASSOCIATIVE NUCLEI ON THE BEHAVIOR OF CATS.
215498 04-04

BETA-ADRENERGIC STIMULATION OF PINEAL N-ACETYLTRANSFERASE: CYCLIC-AMP STIMULATES BOTH RNA AND PROTEIN SYNTHESIS.
215601 04-03

THE EFFECT OF SOME NEUROTROPIC DRUGS ON THE PHASIC CHANGES OF ARTERIAL PRESSURE EVOKED BY STIMULATION OF THE CEREBELLAR FASTIGAL NUCLEUS.
217067 04-03

BEHAVIOURAL EVIDENCE OF DOPAMINE RECEPTOR STIMULATION BY PIRIBEDIL (ET495) AND ITS METABOLITE S584.
217152 04-04

EFFECT OF SENSORY STIMULATION ON THE POTENCY OF CATALEPTOGENS.
217473 04-03

EFFECTS OF ANTAGONISTS UPON LOCOMOTOR STIMULATION INDUCED BY INJECTION OF DOPAMINE AND NORADRENALINE INTO THE NUCLEUS-ACCUMBENS OF NIALAMIDE PRETREATED RATS.
217475 04-04

NOREPINEPHRINE AND SEROTONIN: SPECIFICITY OF RELEASE WITH REWARDING ELECTRICAL STIMULATION OF THE BRAIN.
217522 04-03

IN VIVO RELEASE OF ENDOGENOUS NEUROTRANSMITTERS IN CAT LIMBIC REGIONS: EFFECT OF CHLORPROMAZINE AND OF ELECTRICAL STIMULATION.
217685 04-03

DISCRIMINATIVE CONTROL OF BEHAVIOR BY ELECTRICAL STIMULATION OF THE DORSAL RAPHE NUCLEUS: GENERALIZATION TO LYSERGIC ACID DIETHYLAMIDE (LSD).
217821 04-12

THE EFFECT OF DOPAMINE AND OF APOMORPHINE ON DB-CAMP INDUCED STIMULATION OF SYNAPTOSOMAL TYROSINE-HYDROXYLASE. 217823 04-03

LATENCY AND DURATION OF ESTROGEN INDUCTION OF MATERNAL BEHAVIOR IN HYSTERECTOMIZED OVARIECTOMIZED VIRGIN RATS: EFFECTS OF PUP STIMULATION. 219070 04-04

ACTION OF SEROTONIN MICROINJECTED INTO HYPOTHALAMIC SITES AT WHICH ELECTRICAL STIMULATION PRODUCED AVERSIVE RESPONSES IN THE RAT. 219075 04-04

STIMULATION OF ESTROGEN INDUCED COPULATORY BEHAVIOR IN CASTRATE MALE RATS WITH THE SEROTONIN BIOSYNTHESIS INHIBITOR P-CHLOROPHENYLALANINE. 221010 04-04

INFLUENCE OF CHEMICAL STIMULATION OF CENTRAL DOPAMINERGIC SYSTEM ON THE OPEN-FIELD BEHAVIOR OF RATS. 221308 04-03

LYSERGIC ACID DIETHYLAMIDE: EVIDENCE FOR STIMULATION OF CEREBRAL DOPAMINE RECEPTORS. 223174 04-03

PINEAL BETA-ADRENERGIC RECEPTOR: CORRELATION OF BINDING OF H3-1-ALPRENOLOL WITH STIMULATION OF ADENYLCYCLASE. (UNPUBLISHED PAPER). 224096 04-03

STIMULATIONS

EFFECTS OF LITHIUM CHLORIDE ON CARDIOVASCULAR RESPONSES INDUCED BY CHOLINERGIC AND ADRENERGIC STIMULATIONS. 199870 02-03

ESTROGEN STIMULATIONS DURING NEONATAL PERIOD AND THEIR EFFECTS ON EMOTIONAL AND OPERATIVE BEHAVIOR IN THE ADULT. 211219 03-04

STIMULATORY

POLYETHYLENE GLYCOL INDUCED THIRST: A DUAL STIMULATORY MECHANISM? 219071 04-04

STIMULI

ELECTROPHYSIOLOGICAL AND BEHAVIORAL REACTIVITY TO PHOTIC STIMULI FOLLOWING SEPTAL LESIONS AND PHARMACOLOGICAL TREATMENTS IN RATS. 206724 03-04

DISRUPTION OF STATE-DEPENDENT LEARNING (MEMORY RETRIEVAL) BY EMOTIONALLY IMPORTANT STIMULI. 217470 04-04

OVERCOMING OBSTACLES TO DESENSITIZATION USING IN VIVO STIMULI AND BREVITAL. 224984 04-10

THE ROLE OF DISCRIMINATIVE STIMULI IN MODULATING DRUG ACTION. 225170 04-04

STIMULUS

REDUCTION OF STIMULUS BOUND FOOD CONSUMPTION IN THE RAT FOLLOWING AMPHETAMINE ADMINISTRATION. 195081 01-04

INFLUENCE OF AN ANTICHOLINERGIC PSYCHOTOMIMETIC AGENT ON BEHAVIOUR IN CATS CONTROLLED BY AN AUDITORY STIMULUS. 197996 01-04

INTRACRANIAL SELF-STIMULATION IN RATS AS A FUNCTION OF VARIOUS STIMULUS PARAMETERS: V. INFLUENCE OF COCAINE ON MEDIAL FOREBRAIN BUNDLE STIMULATION WITH MONOPOLAR ELECTRODES. 198223 02-03

STIMULUS PROPERTIES OF MESCALINE AND N-METHYLATED DERIVATIVES: DIFFERENCE IN PERIPHERAL AND DIRECT CENTRAL ADMINISTRATION. 201320 02-02

BREAKDOWN OF STIMULUS CONTROL BY D-AMPHETAMINE. 202968 02-04

STIMULUS PROPERTIES OF SYMPATHOMIMETIC AND SYMPATHOLYTIC DRUGS. 205335 02-04

EFFECT OF INCREASED AROUSAL ON RESPONSE TO STIMULUS CHANGE IN A COMPLEX MAZE. 206187 03-04

STUDIES ON THE TIME COURSE AND THE EFFECT OF CHOLINERGIC AND ADRENERGIC RECEPTOR BLOCKERS ON THE STIMULUS EFFECT OF NICOTINE. 206353 03-03

THE EFFECTS OF NUCLEOTIDES AND GABA IN LARGE DOSES ON THE RESPONSE TO A PAINFUL STIMULUS WITH RETARDATES. 210296 03-14

NALOXONE-INDUCED JUMPING IN MORPHINE-DEPENDENT MICE: STIMULUS CONTROL AND MOTIVATION. 215696 04-04

REPEATED ACQUISITION OF RESPONSE SEQUENCES: STIMULUS CONTROL AND DRUGS. 215969 04-04

BLOCKADE OF THE STIMULUS PROPERTIES OF MESCALINE BY A SEROTONIN ANTAGONIST. 217650 04-03

POISON INDUCED NEOPHOBIA IN RATS: ROLE OF STIMULUS GENERALIZATION OF CONDITIONED TASTE AVERSIONS. 223254 04-04

THE PARTIAL PUNISHMENT EFFECT FOLLOWING MINIMAL ACQUISITION TRAINING: SODIUM AMOBARBITAL AND THE STIMULUS PROPERTIES OF EARLY PUNISHED TRIALS. 224504 04-04

STORAGE

FURTHER EVIDENCE FOR THE HETEROGENEOUS STORAGE OF NORADRENALINE IN CENTRAL NORADRENERGIC TERMINALS. 195239 01-03

MECHANISMS OF STORAGE AND RELEASE OF AMINES. 213632 04-03

STORE

NICOTINE AND CAFFEINE: DISRUPTION OF THE LONG-TERM STORE MEMORY AND PROACTIVE FACILITATION OF LEARNING IN MICE. 198222 02-04

STORED

D-AMPHETAMINE INDUCED RELEASE OF NEWLY SYNTHESIZED AND STORED DOPAMINE FROM THE CAUDATE NUCLEUS IN VIVO. 214110 04-03

STOVALL

SUIT AGAINST RECOMMENDING DOCTOR AND PSYCHIATRIST -- REJECTED. STOVALL V. HARMS, 522 P.2D 353, (KANSAS) SUPREME COURT OF KANSAS. MAY 11, 1974. 200438 02-17

STP

POTENTIAL PSYCHOTOMIMETICS. 2. RIGID ANALOGS OF 2,5 DIMETHOXY-4-METHYLPHENYLISOPROPYLAMINE (DOM, STP). 202109 02-02

STRAIGHT

DURATION OF EXPERIENCED LENGTHENING AND SHORTENING OF STRAIGHT LINES. 205135 02-14

STRAIN

SHUTTLE AVOIDANCE LEARNING OF MICE: EFFECTS OF POSTTRIAL PENTYLENETETRAZOL, STRAIN AND AGE. 195226 01-04

THE EFFECTS OF STRAIN, DRUG, AND DOSE LEVEL ON GENERAL ACTIVITY AND EXPLORATORY BEHAVIOR IN MICE. (PH.D. DISSERTATION). 211883 03-04

STRAINS

ALCOHOL WITHDRAWAL REACTIONS AND RESERPINE EFFECTS IN INBRED STRAINS OF MICE. 197821 01-03

COMPARISON OF THE EFFECTS OF ANISOMYCIN ON MEMORY ACROSS SIX STRAINS OF MICE. 202202 02-04

DIETARY TRYPTOPHAN AND THE SELECTION OF ETHYL ALCOHOL IN DIFFERENT STRAINS OF RATS. 217520 04-03

THE EFFECTS OF NICOTINE ON TWO-WAY AVOIDANCE CONDITIONING IN BIDIRECTIONALLY SELECTED STRAINS OF RATS. 217525 04-04

EARLY LIFE UNDERNUTRITION AND AGGRESSION IN TWO MOUSE STRAINS. 225081 04-04

STRATEGIC

CHLORDIAZEPOXIDE (LIBRIUM): THE EFFECTS OF A MINOR TRANQUILIZER ON STRATEGIC CHOICE BEHAVIOR IN THE PRISONERS DILEMMA. 199609 02-14

STRATEGIES

STRATEGIES FOR THE SYSTEMATIC STUDY OF NEUROTRANSMITTER RECEPTOR FUNCTION IN MAN. 215860 04-16

STRESS

EFFECTS OF SOCIAL STRESS ON THE TURNOVER OF BRAIN CATECHOLAMINES AND 5-HYDROXYTRYPTAMINE IN MICE. 198025 01-03

A CORRELATION BETWEEN THE INFLUENCE OF PSYCHOTROPIC DRUGS AND EMOTIONAL STRESS. 200103 02-09

THE EFFECT OF SEDUXEN ON THE PERCEPTIVE AND SOME OTHER FUNCTIONS OF THE CENTRAL NERVOUS SYSTEM UNDER EMOTIONAL STRESS IN MAN. 201916 02-14

SELECTIVE INHIBITION OF DOPAMINE-BETA-HYDROXYLASE IN THE PERIPHERAL TISSUES BY 5-DIMETHYLDITHIOCARBAMYLPICOLINIC ACID; ITS EFFECT ON STRESS INDUCED ULCER, ETHANOL INDUCED SLEEP AND BLOOD PRESSURE. 204484 02-03

EFFECT OF STRESS UPON SEROTONIN METABOLISM IN VARIOUS REGIONS OF THE RAT BRAIN. 206993 03-03

EFFECT OF STRESS ON CATECHOLAMINES AND TYROSINE-HYDROXYLASE ACTIVITY OF INDIVIDUAL HYPOTHALAMIC NUCLEI. 208994 03-03

EFFECT OF STRESS AND DIAZEPAM TREATMENT DURING INFANCY ON THE CORTICOSTERONE REGULATION AND ANDROGENIC ACTIVITY IN ADULT MALE RATS.
210348 03-03

BLOCKING OF STRESS BY PENTOBARBITAL MORPHINE AS RELATED TO TRAINING AND AGE OF RATS.
214056 04-04

THE EFFECTS OF CHLORDIAZEPOXIDE ON AVOIDANCE PERFORMANCE OF MICE SUBJECTED TO UNDERNUTRITION OR HANDLING STRESS IN EARLY LIFE.
217463 04-04

URBAN ECOLOGICAL AND HOUSEHOLD CORRELATES OF STRESS ALLEVIATIVE DRUG USE.
223949 04-17

STRIATAL

ALTERATIONS BY ANESTHETIC AGENTS OF THE RESPONSES OF RAT STRIATAL NEURONS TO IONTOPHORETICALLY APPLIED AMPHETAMINE, ACETYLCHOLINE, NORADRENALINE, AND DOPAMINE.
193803 01-03

CATALEPSY, STEREOTYPED BEHAVIOUR AND STRIATAL HOMOVANILLIC ACID CONTENT IN RATS TREATED WITH METHADONE.
197299 01-03

KINETICS OF 14C-DOPAMINE IN ISOLATED RAT STRIATAL TISSUE UNDER THE INFLUENCE OF MORPHINE.
197954 01-03

CHANGES OF KINETIC CONSTANT OF STRIATAL TYROSINE-HYDROXYLASE ELICITED BY NEUROLEPTICS THAT IMPAIR THE FUNCTION OF DOPAMINE RECEPTORS.
202716 02-03

THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON THE UPTAKE AND RELEASE OF 14C-DOPAMINE FROM CRUDE STRIATAL SYNAPTOSOMAL PREPARATIONS.
202775 02-03

INFLUENCE OF STRIATAL DOPAMINE RECEPTOR BLOCKADE ON A BULBAR MOTOR REACTION.
202778 02-03

CANNABINOID INDUCED CHANGES IN MOUSE STRIATAL HOMOVANILLIC ACID AND DIHYDROXYPHENYLACETIC ACID: THE EFFECTS OF AMPHETAMINE AND L-DOPA.
204866 02-03

AMPHETAMINE-INDUCED CHANGES IN STRIATAL DOPAMINE AND ACETYLCHOLINE LEVELS AND RELATIONSHIP TO ROTATION (CIRCLING BEHAVIOR) IN RATS.
205432 02-04

SUPERSENSITIVITY TO DOPAMINE AGONISTS FOLLOWING UNILATERAL, 6-HYDROXYDOPAMINE INDUCED STRIATAL LESIONS IN MICE.
208552 03-03

ARE AUTORECEPTORS IN DOPAMINERGIC NEURONS INVOLVED IN THE CHANGE OF THE KINETIC STATE OF STRIATAL TYROSINE-HYDROXYLASE ELICITED BY ANTIPSYCHOTICS? (UNPUBLISHED PAPER).
208636 03-03

INFLUENCE OF NONCHOLINERGIC DRUGS ON RAT STRIATAL ACETYLCHOLINE LEVELS.
210658 03-03

CHOLINERGIC DOPAMINERGIC INTERACTION IN THE STRIATUM: THE EFFECT OF 6-HYDROXYDOPAMINE OR PIMOZIDE TREATMENT ON THE INCREASED STRIATAL ACETYLCHOLINE LEVELS INDUCED BY APOMORPHINE, PIRIBEDIL AND D-AMPHETAMINE.
210668 03-03

ENHANCEMENT OF APOMORPHINE-INDUCED INHIBITION OF STRIATAL DOPAMINE TURNOVER FOLLOWING CHRONIC HALOPERIDOL.
210814 03-03

EFFECTS OF DOPAMINERGIC DRUGS AND ACUTE MEDIAL FOREBRAIN BUNDLE LESIONS ON STRIATAL ACETYLCHOLINE LEVELS.
210831 03-03

DIFFERENTIAL EFFECTS OF D- AND L-AMPHETAMINE AND METHYLPHENIDATE ON RAT STRIATAL DOPAMINE BIOSYNTHESIS.
210859 03-03

ON A PRIME ROLE FOR NEWLY SYNTHESIZED DOPAMINE IN STRIATAL FUNCTION.
210862 03-03

IN VIVO INHIBITION OF STRIATAL ACETYLCHOLINE TURNOVER BY L-DOPA, APOMORPHINE AND (+) AMPHETAMINE.
213399 04-03

A RELATION BETWEEN DRUG CONCENTRATIONS IN BRAIN AND STRIATAL HOMOVANILLIC ACID LEVELS IN CHLORPROMAZINE TREATED RATS.
215734 04-03

NEUROLEPTIC-INDUCED HYPERSENSITIVITY OF STRIATAL DOPAMINE RECEPTORS IN THE RAT AS A MODEL OF TARDIVE DYSKINESIAS. EFFECTS OF CLOZAPINE, HALOPERIDOL, LOXAPINE AND CHLORPROMAZINE.
217462 04-03

INHIBITION OF STRIATAL DOPAMINE SYNTHESIS IN RATS INJECTED CHRONICALLY WITH NEUROLEPTICS IN THEIR EARLY LIFE.
217687 04-03

6-HYDROXYDOPAMINE AND STRIATAL ACETYLCHOLINE LEVELS.
217842 04-03

ACCUMULATION OF 4-HYDROXYAMPHETAMINE BY RAT STRIATAL HOMOGENATES.
222822 04-03

ROLE FOR POSTSYNAPTIC DOPAMINE RECEPTORS IN THE REGULATION OF THE KINETIC STATE OF STRIATAL TYROSINE-HYDROXYLASE. (UNPUBLISHED PAPER).
225307 04-03

STRIATECTOMIZED

THE INFLUENCE OF PHENAMINE ON THE AVOIDANCE REACTION IN INTACT AND STRIATECTOMIZED RATS.
224467 04-04

STRIATUM

CHANGES IN ACTIVATION OF ADENYLATE-CYCLASE AND OF DOPAMINE TURNOVER IN RAT STRIATUM DURING PROLONGED HALOPERIDOL TREATMENT.
192933 01-03

A COMPARISON OF THE INHIBITORY EFFECTS OF CERTAIN ANTIPARKINSONIAN AGENTS ON DOPAMINE ACCUMULATION INTO THE RAT STRIATUM.
195234 01-03

TYROSINE-HYDROXYLASE (TH) IN NUCLEUS-ACCUMBENS AND STRIATUM: EFFECTS OF NEUROLEPTICS ON THE AFFINITY FOR PTERIDINE COFACTOR. (UNPUBLISHED PAPER).
196588 01-03

ADENYLCYCLASE IN RAT STRIATUM AND NUCLEUS-ACCUMBENS: STIMULATION BY DOPAMINE RECEPTOR AGONISTS. (UNPUBLISHED PAPER).
197124 01-03

LSD AS AN AGONIST OF DOPAMINE RECEPTORS IN THE STRIATUM.
204183 02-03

THE EFFECT OF CLOZAPINE AND ACETYLCHOLINE TURNOVER RATE IN RAT STRIATUM. (UNPUBLISHED PAPER).
207500 03-03

CHOLINERGIC DOPAMINERGIC INTERACTION IN THE STRIATUM: THE EFFECT OF 6-HYDROXYDOPAMINE OR PIMOZIDE TREATMENT ON THE INCREASED STRIATAL ACETYLCHOLINE LEVELS INDUCED BY APOMORPHINE, PIRIBEDIL AND D-AMPHETAMINE.
210668 03-03

TRICYCLIC ANTIDEPRESSIVE DRUGS AND DOPAMINE SENSITIVE ADENYLATE-CYCLASE FROM RAT BRAIN STRIATUM.
210856 03-03

EFFECT OF ANTIPSYCHOTIC DRUGS ON HOMOVANILLIC ACID LEVELS IN STRIATUM AND OLFACTORY TUBERCLE OF THE RAT.
210864 03-03

EFFECT OF ALPHA-METHYLDOPA ON DOPAMINE SYNTHESIS AND RELEASE IN RAT STRIATUM IN VITRO.
215690 04-03

STEREOSPECIFICITY OF DOPAMINE RECEPTORS INVOLVED IN THE REGULATION OF THE KINETIC STATE OF TYROSINE-HYDROXYLASE IN STRIATUM AND NUCLEUS-ACCUMBENS.
217888 04-03

STRIO-PALLIDAL

ROLE OF THE STRIO-PALLIDAL SYSTEM AND MOTOR CORTEX IN INDUCED CIRCUS MOVEMENTS IN RATS AND CATS.
213450 04-03

STRIPS

COMPARISON BETWEEN THE EFFECTS PRODUCED BY CHRONIC DENERVATION AND BY COCAINE ON THE SENSITIVITY TO, AND ON THE DISPOSITION OF, NORADRENALINE IN ISOLATED SPLEEN STRIPS.
193139 01-03

EFFECTS OF RIGID AMPHETAMINE ANALOGS ON VASCULAR STRIPS: STUDIES OF 2-AMINOTETRAHYDRONAPHTHALENE AND 2-AMINOINDAN DERIVATIVES.
210921 03-03

STRONG

OUTPATIENT TREATMENT OF SCHIZOPHRENIA BY A LONG-LASTING STRONG TRANQUILIZER: USE OF FLUPHENAZINE ENANTHATE.
194460 01-08

CLINICAL APPLICATION OF OXYPERTINE -- ITS CHARACTERISTICS AS A STRONG TRANQUILIZER.
209394 03-08

STROPHANTHIN

HEAT PRODUCTION AND OXYGEN CONSUMPTION OF THE ISOLATED RABBIT HEART UNDER THE INFLUENCE OF STROPHANTHIN VERAPAMIL, AND GLYCERYL TRINITRATE.
197567 01-03

STRUCTURAL

IDENTIFICATION AND STRUCTURAL CHARACTERIZATION OF AN INHIBITOR OF CATECHOLAMINE INDUCED FREE FATTY ACID MOBILIZATION FROM THE CALF MIDBRAIN.
200006 02-01

THE STRUCTURAL CHEMISTRY OF ADRENERGIC NEURAL TRANSMISSION SYSTEMS. (PH.D. DISSERTATION).
203027 02-01

NEUROLEPTIC AGENTS OF THE BENZOCYCLOHEPTAPYRIDOISOQUINOLINE SERIES. 1.SYNTHESES AND STEREOCHEMICAL AND STRUCTURAL REQUIREMENTS FOR ACTIVITY OF BUTACLAMOL AND RELATED COMPOUNDS.
208592 03-01

COMPARISON OF STRUCTURAL AND STEREOISOMERS OF APOMORPHINE ON STEREOTYPED SNIFFING BEHAVIOUR OF THE RAT.
210930 03-04

STRUCTURALLY
A CLINICAL TRIAL OF A STRUCTURALLY UNIQUE NEUROLEPTIC (SU-23397).
225065 04-14
PHENOTHIAZINES AND STRUCTURALLY RELATED DRUGS. ADVANCES IN BIOCHEMICAL PSYCHOPHARMACOLOGY.
225399 04-17

STRUCTURE
A QUANTUM CHEMICAL INVESTIGATION OF THE PI-ELECTRONIC STRUCTURE OF THE HALLUCINOGENIC N,N-DIMETHYLTRYPTAMINES.
195119 01-01
CRYSTAL STRUCTURE DETERMINATIONS OF THE DONOR ACCEPTOR COMPLEXES OF PHENOTHIAZINE AND PHENOXAZINE WITH NICKEL THIETE. (PH.D. DISSERTATION).
201003 02-01
POSSIBLE PHARMACOLOGICAL AND THEORETICAL IMPLICATIONS OF X-RAY STRUCTURE OF THE TRICYCLIC ANTIDEPRESSANT IMIPRAMINE.
205029 02-01
THE INFLUENCE OF SEVERAL PSYCHOTROPIC DRUGS ON THE STRUCTURE OF THE BRAIN.
222889 04-03
RELATIONSHIPS BETWEEN THE STRUCTURE AND THE CHRONOTROPIC, LOCOMOTOR STIMULANT AND REINFORCING ACTIONS OF SEVERAL FENFLURAMINE ANALOGS. (PH.D. DISSERTATION).
223563 04-04

STRUCTURE-ACTIVITY
STRUCTURE-ACTIVITY RELATIONSHIPS IN PSYCHOTOMIMETIC PHENYLALKYLAMINES.
196437 01-01
HMO ANALYSIS OF STRUCTURE-ACTIVITY RELATIONS IN SEDATIVE AND HYPNOTIC DRUGS AND ANALYSIS OF POTENTIAL SEDATIVES BY MEANS OF HOMOLOGOUS COMPOUNDS.
199208 02-01
STRUCTURE-ACTIVITY RELATIONSHIPS IN MAN OF CANNABIS CONSTITUENTS, AND HOMOLOGS AND METABOLITES OF DELTA9-TETRAHYDROCANNABINOL.
202192 02-02
STRUCTURE-ACTIVITY RELATIONSHIPS BETWEEN META-SUBSTITUTED N-ETHYLAMPHETAMINES AND LOCOMOTOR ACTIVITY IN MICE.
210886 03-04
STRUCTURE-ACTIVITY RELATIONSHIPS BETWEEN META-SUBSTITUTED N-ETHYLAMPHETAMINES AND ISOLATED GUINEA-PIG ATRIAL RATE.
210887 03-03
NEUROLEPTIC PIPERAZINYLDIBENZOAZEPINES: CHEMISTRY AND STRUCTURE-ACTIVITY RELATIONSHIPS.
221734 04-01

STRUCTURES
INHIBITION OF BEHAVIOURAL AND EEG ACTIVATION INDUCED BY MORPHINE ACTING ON LOWER BRAINSTEM STRUCTURES.
200078 02-03
THE INFLUENCE OF TRIFLUOPERAZINE, CARBIDINE AND IMIZINE ON EVOKED POTENTIALS IN DIFFERENT STRUCTURES OF THE LIMBIC RETICULAR COMPLEX.
200564 02-02
THE EFFECT OF DIAZEPAM AND NITRAZEPAM ON INTRACELLULAR AND EXTRACELLULAR DISTRIBUTION OF SODIUM AND POTASSIUM IONS IN INDIVIDUAL STRUCTURES OF RATS BRAINS.
207199 03-03
AMITRIPTYLINE AND DEPRESSIVE STRUCTURES (ON 100 OBSERVATIONS).
207579 03-14
THE EFFECT OF CHOLINERGICS ON SHORT-TERM MEMORY AND THE EXCITABILITY LEVEL OF HIPPOCAMPUS CIRCLE STRUCTURES.
208972 03-03
THE EFFECT OF RESERPINE AND CHLORIMIPRAMINE ON GLYCOGEN CONTENT IN DIFFERENT BRAIN STRUCTURES OF RAT.
211106 03-03
EFFECTS OF PROCAINE HYDROCHLORIDE, DIAZEPAM, AND DIPHENYLHYDANTOIN ON SEIZURE DEVELOPMENT IN CORTICAL AND SUBCORTICAL STRUCTURES IN RATS.
218191 04-03
THE PARTICIPATION OF SEROTONIN REACTIVE BRAIN STRUCTURES IN SOME FORMS OF BEHAVIORAL PATTERNS IN HAMSTERS.
218472 04-04
A HISTOCHEMICAL ANALYSIS OF THE INFLUENCE OF SOME PSYCHOTROPIC SUBSTANCES ON THE DEHYDROGENASE ACTIVITY OF VARIOUS BRAIN STRUCTURES.
219498 04-03
THE BLOOD-BRAIN BARRIER II: DISTRIBUTION KINETICS OF H3-P-HYDROXYAMPHETAMINE IN BRAIN STRUCTURES OF THE RAT AFTER INTRAVENOUS ADMINISTRATION.
220977 04-03

STRYCHNINE
EFFECTS OF NIKETHAMIDE, PICROTOXIN AND STRYCHNINE ON AMPHETAMINE STATE.
199967 02-03
BEHAVIOURAL AND ELECTROGRAPHIC OBSERVATIONS DURING EPILEPTIC CONVULSIONS INDUCED BY STRYCHNINE AND PENTYLENETETRAZOL IN CONSCIOUS YOUNG AND ADULT CHICKENS.
205459 02-03
ACTION OF STRYCHNINE AND CENTRAL DEPRESSANTS ON THE CEREBELLO-RUBRAL SYSTEM.
210881 03-03

STUDYING
ASPECTS OF USING PSYCHOLOGICAL METHODS IN STUDYING THE EFFECTS OF PSYCHOTROPIC DRUGS.
204401 02-16

STUTTERERS
DRUG THERAPY FOR STUTTERERS: A REVIEW OF RESEARCH.
213786 04-11

STUTTERING
HALOPERIDOL AS A TREATMENT FOR ADULT STUTTERING.
207771 03-14

SU-23397
A CLINICAL TRIAL OF A STRUCTURALLY UNIQUE NEUROLEPTIC (SU-23397).
225065 04-14

SUBACUTE
ACUTE, SUBACUTE AND 23-DAY CHRONIC MARIHUANA INHALATION TOXICITIES IN THE RAT.
193576 01-04

SUBCELLULAR
THE SUBCELLULAR DISTRIBUTION OF INTRAVENTRICULARLY ADMINISTERED 3H-METARAMINOL IN INTACT AND RAT BRAIN PRETREATED WITH P-CHLOROAMPHETAMINE.
197289 01-03
UPTAKE OF NEUROTRANSMITTERS INTO SUBCELLULAR PARTICLES OF THE CAUDATE NUCLEUS.
197962 01-03
SUBCELLULAR DISTRIBUTION OF RESERPINE IN BLOOD PLATELETS: EVIDENCE FOR MULTIPLE POOLS.
202665 02-03
EFFECT OF DELTA9-TETRAHYDROCANNABINOL ADMINISTRATION ON THE LIPID CONSTITUENTS OF RAT BRAIN SUBCELLULAR FRACTIONS.
210769 03-03
REGIONAL AND SUBCELLULAR DISTRIBUTION AND KINETIC PROPERTIES OF RAT BRAIN CHOLINE ACETYLTRANSFERASE -- SOME FUNCTIONAL CONSIDERATIONS.
210816 03-03
STUDIES ON THE SYNTHESIS AND SUBCELLULAR DISTRIBUTION OF DOPAMINE IN THE RAT ADRENAL MEDULLA.
217797 04-03

SUBCORTICAL
THE INFLUENCE OF INTRAPERITONEAL INJECTION OF IPRAZIDE AND TRANSAMINE ON THE DISTRIBUTION OF BIOGENIC AMINES IN CORTICAL AND SUBCORTICAL WHITE MATTER OF THE RAT BRAIN.
209032 03-03
EFFECTS OF PROCAINE HYDROCHLORIDE, DIAZEPAM, AND DIPHENYLHYDANTOIN ON SEIZURE DEVELOPMENT IN CORTICAL AND SUBCORTICAL STRUCTURES IN RATS.
218191 04-03

SUBCUTANEOUS
EFFECTS OF DIETHYLPROPION AND D-AMPHETAMINE AFTER SUBCUTANEOUS AND ORAL ADMINISTRATION.
198030 01-14
THE EFFECTS OF INTRAVENOUS AND SUBCUTANEOUS EPINEPHRINE ADMINISTRATION ON CONDITIONED SUPPRESSION. (PH.D. DISSERTATION).
213131 03-04

SUBFORNICAL
SUBFORNICAL ORGAN: ACETYLCHOLINE APPLICATION ELICITS DRINKING.
210804 03-03

SUBGROUPS
DEPRESSION, ELATION, AND LITHIUM CARBONATE RESPONSES IN MANIC PATIENT SUBGROUPS.
199631 02-09

SUBJECTED
TRANQUILIZING EFFECTS OF DIAZEPAM IN PIGS SUBJECTED TO A PUNISHMENT PROCEDURE.
210741 03-04
THE EFFECTS OF CHLORDIAZEPOXIDE ON AVOIDANCE PERFORMANCE OF MICE SUBJECTED TO UNDERNUTRITION OR HANDLING STRESS IN EARLY LIFE.
217463 04-04

SUBJECTIVE
THE USE OF ANALOGUE SCALES IN RATING SUBJECTIVE FEELINGS.
193851 01-14
SUBJECTIVE CHANGES IN VOLUNTEERS WITHOUT PRIOR EXPERIENCE OF CANNABIS INDUCED BY (-)DELTA9-TRANS-TETRAHYDROCANNABINOL.
202784 02-14
THE EFFECT OF COCA-COLA, CAFFEINE, ANTIDEPRESSANTS AND CHLORPROMAZINE ON OBJECTIVE AND SUBJECTIVE SLEEP PARAMETERS.
210808 03-14

SUBJECTS
THE ACUTE EFFECTS OF INTRAVENOUS INFUSION OF L-TRYPTOPHAN IN NORMAL SUBJECTS.
195443 01-15
EFFECTS OF RESERPINE AND CHLORPROMAZINE ON 5-HYDROXYTRYPTAMINE UPTAKE OF PLATELETS FROM MIGRAINOUS AND CONTROL SUBJECTS.
196926 01-13
BLOOD AND URINE LEVELS OF N,N DIMETHYLTRYPTAMINE FOLLOWING ADMINISTRATION OF PSYCHOACTIVE DOSAGES TO HUMAN SUBJECTS.
198230 02-12
SLEEP AMPHETAMINE EFFECTS IN MBDS AND NORMAL SUBJECTS.
199640 02-11
THE EFFECT OF CHLORPROMAZINE ON VISUAL INFORMATION PROCESSING IN NORMAL SUBJECTS.
199663 02-14
EFFECTS OF SINGLE AND REPEATED ADMINISTRATION OF MAPROTILINE AND ITS RELATION TO PLASMA LEVELS IN HEALTHY TEST SUBJECTS.
204403 02-15
COMPARATIVE STUDIES OF VERBAL INTERACTIONS IN A GROUP OF HEALTHY SUBJECTS UNDER THE INFLUENCE OF PSYCHOPHARMACOLOGICAL AGENTS: WITH SPECIAL CONSIDERATION OF YG-19256, CHLORDIAZEPOXIDE AND PLACEBO.
207140 03-14
COGNITIVE AND MOTOR SENSORY PERFORMANCES IN TOXIC AND NONTOXIC EPILEPTIC SUBJECTS.
210824 03-15
FACTOR ANALYSIS OF EEG OF HEALTHY SUBJECTS GIVEN NO DRUGS AND A COMBINATION OF DIAZEPAM AND METHYLPHENIDATE.
215071 04-13
DOPAMINE SENSITIVE ADENYLCYCLASE IN HUMAN CAUDATE NUCLEUS: A STUDY IN CONTROL SUBJECTS AND SCHIZOPHRENIC PATIENTS.
221732 04-13

SUBMANDIBULAR
INHIBITION OF CATECHOLAMINE AND 5-HYDROXYTRYPTAMINE INDUCED ENZYME SECRETION FROM THE GUINEA-PIG SUBMANDIBULAR GLAND BY 2-BROMO-D-LYSERGIC ACID DIETHYLAMIDE.
216968 04-03

SUBMAXIMUM
MILD ANALGESICS EVALUATED WITH THE SUBMAXIMUM EFFORT TOURNIQUET TECHNIQUE. I. THE INFLUENCE OF PSYCHOLOGICAL FACTORS ON THEIR EFFECT.
197861 01-14
MILD ANALGESICS EVALUATED WITH THE SUBMAXIMUM EFFORT TOURNIQUET TECHNIQUE: II. THE INFLUENCE OF A TRANQUILLIZER ON THEIR EFFECT.
197862 01-13

SUBMICROGRAM
ANALYSIS OF AMPHETAMINES AND OTHER PSYCHOACTIVE DRUGS: A COLORIMETRIC ASSAY OF (S)-(+) AMPHETAMINE IN THE SUBMICROGRAM RANGE. (PH.D. DISSERTATION).
222633 04-01

SUBNORMAL
SULPIRIDE VERSUS CHLORPROMAZINE AND PLACEBO IN THE TREATMENT OF RESTLESS MENTALLY SUBNORMAL PATIENTS -- A DOUBLE-BLIND CROSSOVER STUDY.
209702 03-11
CHANGES IN MENTAL AGE WITH SUBNORMAL CHILDREN TREATED WITH DOSES OF GABA AND NUCLEOTIDES.
210286 03-14
URINARY SCREENING FOR DRUGS IN A HOSPITAL FOR THE MENTALLY SUBNORMAL.
210437 03-17

SUBSEQUENT
THE EFFECTS OF DRUGS REGULATING AUTONOMIC RESPONSES DURING CONDITIONING ON SUBSEQUENT AVOIDANCE BEHAVIOR. (PH.D. DISSERTATION).
193777 01-03
PRESLEEP INGESTION OF TWO HYPNOTIC DRUGS AND SUBSEQUENT PERFORMANCE.
206362 03-14
IN VIVO BINDING OF ANTIBODY TO DOPAMINE-BETA-HYDROXYLASE IN ADRENERGIC NERVES AND SUBSEQUENT ANTIDROMIC TRANSPORT (UNPUBLISHED PAPER).
218147 04-03

SUBSTANCE
INFLUENCE OF NEUROLEPTIC SUBSTANCE ON NEUROPHYSIOLOGICAL PARAMETERS IN EXPERIMENTAL ANIMALS.
206998 03-06
PHARMACOLOGICAL ANALYSIS OF A NEW ANOREXIC SUBSTANCE: 5-HYDROXY-5-4-CHLOROPHENYL 2,3 DIHYDRO-5H-IMIDAZOISOINDOLE (MAZINDOL).
217652 04-04

SUBSTANTIA-NIGRA
COMPARATIVE INVOLVEMENT OF DOPAMINE AND NORADRENALINE IN RATE-FREE SELF-STIMULATION IN SUBSTANTIA-NIGRA, LATERAL HYPOTHALAMUS, AND MESENCEPHALIC CENTRAL GRAY.
193303 01-03
APOMORPHINE AND AMPHETAMINE STEREOTYPY AFTER 6-HYDROXYDOPAMINE LESIONS OF THE SUBSTANTIA-NIGRA.
202793 02-04
CHEMICAL OR ELECTROLYTIC LESION OF THE SUBSTANTIA-NIGRA: EARLY EFFECTS ON NEOSTRIATAL DOPAMINE METABOLISM.
210699 03-03
CHANGED EATING AND LOCOMOTOR BEHAVIOUR IN THE RAT AFTER 6-HYDROXYDOPAMINE LESIONS TO THE SUBSTANTIA-NIGRA.
210763 03-04
APPARENT FEEDBACK FROM THE CAUDATE NUCLEUS TO THE SUBSTANTIA-NIGRA FOLLOWING AMPHETAMINE ADMINISTRATION.
217676 04-03

SUBSTITUTED
A DUAL STUDY. PART I: SYNTHESIS AND STEREOCHEMISTRY OF SOME 1 SUBSTITUTED QUINOLIZIDINES AS ANALOGS OF BIOLOGICALLY ACTIVE COMPOUNDS. PART II: AMINO DERIVATIVES OF THIOPHENE FUSED CYCLIC KETONES AS POTENTIAL CNS. (PH.D. DISSERTATION).
196252 01-01
SYNTHESIS OF SUBSTITUTED BENZYLIDINOHYDRAZINES AND THEIR MONOAMINEOXIDASE INHIBITORY AND ANTICONVULSANT PROPERTIES.
206461 03-02
A NEW SUBSTITUTED BENZAMIDE WITH NEUROLEPTIC EFFECTS: LIN-14-18 OR SULTOPRIDE.
216759 04-08

SUBSTRATE
EVIDENCE THAT 5-METHOXYDIMETHYLTRYPTAMINE IS A SPECIFIC SUBSTRATE FOR MAO-A IN THE RAT: IMPLICATIONS FOR THE INDOLEAMINE DEPENDENT BEHAVIORAL SYNDROME.
210817 03-04
THE EFFECT OF LITHIUM ON BLOOD PRESSURE AND ON PLASMA RENIN SUBSTRATE AND RENIN IN RATS.
213483 04-03
THE EFFECT OF ALPHA-METHYL-P-TYROSINE METHYLESTER ON TEMPORAL SUMMATION IN THE NEURAL SUBSTRATE FOR THE REINFORCEMENT EFFECT IN SELF-STIMULATION. (PH.D. DISSERTATION).
222090 04-04

SUBSTRATES
THE PHARMACOLOGICAL AND ANATOMICAL SUBSTRATES OF THE AMPHETAMINE RESPONSE IN THE RAT.
207794 03-04

SUBTYPE
SUBTYPE OF AFFECTIVE PSYCHOSES CLASSIFIED BY RESPONSE ON AMINE PRECURSORS AND MONOAMINE METABOLISM.
197209 01-09

SUBTYPES
LITHIUM PROPHYLAXIS OF THREE DEPRESSION SUBTYPES.
224874 04-09

SUCCESSIONAL
PROGNOSIS OF THE THERAPEUTIC EFFECT OF SUXILEP AND TRIMETIN USING A SUCCESSIONAL STATISTICAL PROCEDURE.
224086 04-11

SUCCESSIVE
EFFECTS OF LOW AND HIGH DOSES OF L-DOPA ON THE TETRABENAZINE OR ALPHA-METHYLTYROSINE-INDUCED SUPPRESSION OF BEHAVIOUR IN A SUCCESSIVE DISCRIMINATION TASK.
200042 02-04

SUCCINATE
EFFECTIVENESS OF LOXAPINE SUCCINATE IN ACUTE SCHIZOPHRENIA: A COMPARATIVE STUDY WITH THIOTHIXENE.
209484 03-08
METABOLIC COMPARTMENTATION IN THE BRAIN: METABOLISM OF A TRICARBOXYLIC ACID CYCLE INTERMEDIATE, (1,4-14C)SUCCINATE, AFTER INTRACEREBRAL ADMINISTRATION.
210780 03-03

SUCKLING
EFFECTS IN THE SUCKLING RAT OF CHRONIC TREATMENT WITH TRYPTOPHAN AND A MONOAMINE OXIDASE INHIBITOR.
195906 01-04

SUCROSE
THE EFFECT OF DIFFERENT LEVELS OF PRE-EXPOSURE TO SUCROSE ON THE ACQUISITION AND EXTINCTION OF A CONDITIONED AVERSION.
217807 04-04
NALOXONE-INDUCED AVERSION TO SUCROSE IN MORPHINE-DEPENDENT RATS.
219031 04-04

SUDDEN
SEIZURES OF CHOREOATHETIC TYPE INDUCED BY SUDDEN MOVEMENT: CORRELATION TO THE BIOGENIC AMINES.
196146 01-14

SUFFERING
ELIMINATION OF LITHIUM DEPENDENT ON AGE IN HEALTHY PEOPLE AND PATIENTS SUFFERING FROM RENAL INSUFFICIENCY.
205043 02-13
CEREBRAL AND PERIPHERAL CONSUMPTION OF L-5-HTP BY PATIENTS SUFFERING FROM MANIACAL, DEPRESSIVE OR PSYCHOTIC SYMPTOMS.
206834 03-10

SUGAR
THE INFLUENCE OF TRICYCLIC ANTIDEPRESSANTS, AZAPHEN AND IMIZINE ON BLOOD SUGAR CONCENTRATION CHANGES PRODUCED BY EPINEPHRINE AND SEROTONIN.
217214 04-03

SUGGESTIBILITY
THE EFFECTS OF CANNABIS INTOXICATION ON PRIMARY SUGGESTIBILITY. (PH.D. DISSERTATION).
211831 03-14

SUICIDE
SUICIDE IN BRISBANE, 1956 TO 1973: THE DRUG DEATH EPIDEMIC.
224491 04-17

SULFATE
EFFECTS OF D-AMPHETAMINE SULFATE GIVEN TO PREGNANT MICE ON ACTIVITY AND ON CATECHOLAMINES IN THE BRAINS OF OFFSPRING.
196025 01-03
EVIDENCE THAT PUNCTUATE INTRACEREBRAL ADMINISTRATION OF 6-HYDROXYDOPAMINE FAILS TO PRODUCE SELECTIVE NEURONAL DEGENERATION: COMPARISON WITH COPPER SULFATE AND FACTORS GOVERNING THE DEPORTMENT OF FLUIDS INJECTED INTO BRAIN.
197931 01-03
THE EFFECTS OF CHLORPROMAZINE AND D-AMPHETAMINE SULFATE ON THE VISUAL STIMULATION PREFERENCE OF EXTRAVERTS AND INTROVERTS.
210680 03-14
THE EFFECTS OF ACUTE AND CHRONIC MORPHINE ADMINISTRATION ON THE LEVELS OF 3-METHOXY-4-HYDROXYPHENYLGLYCOL SULFATE IN RAT BRAIN.
210927 03-03
POSTTRIAL D-AMPHETAMINE SULFATE AND ONE-TRIAL LEARNING IN MICE.
222268 04-04

SULPHATE
PLASMA LITHIUM LEVELS AND SIDE-EFFECTS DURING ADMINISTRATION OF A SLOW-RELEASE LITHIUM SULPHATE PREPARATION (LITHIUM LIPETT-C) AND LITHIUM CARBONATE LEVELS.
197029 01-15
URINARY EXCRETION OF THE SULPHATE AND GLUCURONIDE OF 3-METHOXY-4-HYDROXYPHENYLETHYLENEGLYCOL IN A MANIC-DEPRESSIVE PATIENT.
224424 04-09

SULPIRIDE
SMALL DOSES OF SULPIRIDE IN THE TREATMENT OF PSYCHONEUROTIC SYNDROMES.
194071 01-09
EXAMINATION OF THE NEW PSYCHOTROPIC DRUG, DOGMATYL (FK-880 SULPIRIDE).
194509 01-11
USE OF SULPIRIDE IN THE TREATMENT OF SCHIZOPHRENIA.
194512 01-08
A CLINICAL NEUROLEPTIC INVESTIGATION OF N-(1-ETHYL-PYRROLIDIN-2-YL) 2-METHOXY-5-SULFAMOYL-BENZAMIDE NEUROLEPTIC SULPIRIDE (DOGMATIL) IN ACUTELY ILL SCHIZOPHRENICS.
195038 01-11
EXPERIMENTATION WITH SULPIRIDE IN CASES OF PSYCHONEUROSIS.
195532 01-10
CLINICAL OBSERVATIONS ON SULPIRIDE TREATMENT IN PSYCHIATRY.
200170 02-11
PRELIMINARY RESULTS OF A CONTROLLED TRIAL WITH SULPIRIDE VERSUS CHLORIMIPRAMINE IN CHRONIC SCHIZOPHRENIC PATIENTS WITH MARKED IDEO-EMOTIONAL POVERTY.
200445 02-08
INTEREST OF SULPIRIDE IN KINETIC DISTURBANCES.
202069 02-11
ACTION OF A NEW PSYCHOTROPIC DRUG (SULPIRIDE) ON AVOIDANCE BEHAVIOR IN RATS.
202770 02-04
CLINICAL TRIAL WITH SULPIRIDE.
205945 03-14
CLINICOSTATISTICAL STUDY OF THE EFFECTS OF SULPIRIDE, A NEW NEUROLEPTIC DRUG.
206805 03-07
LONG-TERM AND SHORT-TERM EFFECTS OF SULPIRIDE ON SLEEP EEG IN MAN.
206977 03-14
CLINICAL STUDY ON SULPIRIDE IN LONG-TERM HOSPITALIZED SCHIZOPHRENIC PATIENTS.
206978 03-08
INVESTIGATION OF CLINICAL EFFECTS OF FK-880 (SULPIRIDE) ON MANIC-DEPRESSIVE ILLNESS.
207535 03-09
ON THE USE OF SULPIRIDE WITH SOME SKIN DISEASES.
209044 03-11
REFLECTIONS ON THE EFFICACY OF NEW DRUG THERAPIES ON THE OCCASION OF USING AN ORIGINAL MEDICATION: SULPIRIDE (DOGMATIL).
209123 03-11
PERSONAL EXPERIENCE IN THE USE OF SULPIRIDE (FK-880) ON SCHIZOPHRENIA.
209405 03-08
THE DISINHIBITING EFFECT OF N(1-ETHYL-2-PYRROLIDINYL-METHYL-2-METHOXY-5-SULFAMIDE BENZAMIDE (SULPIRIDE).
209527 03-14
SULPIRIDE IN AMBULATORY TREATMENT OF CHRONIC PSYCHOTICS.
209533 03-14
SULPIRIDE VERSUS HALOPERIDOL IN SCHIZOPHRENIA: A DOUBLE-BLIND COMPARATIVE TRIAL.
209701 03-08
SULPIRIDE VERSUS CHLORPROMAZINE AND PLACEBO IN THE TREATMENT OF RESTLESS MENTALLY SUBNORMAL PATIENTS -- A DOUBLE-BLIND CROSSOVER STUDY.
209702 03-11
A COMPARISON OF A NEW TRANQUILIZER, SULPIRIDE AND OXAZOLAM ON PSYCHOSOMATIC DISEASES, NEUROSIS AND MASKED DEPRESSION USING DOUBLE-BLIND METHOD.
210180 03-11
A CLINICAL EXPERIMENTAL STUDY ON THE USE OF SULPIRIDE IN A GROUP OF CHRONIC SCHIZOPHRENICS (FIRST NOTE).
210510 03-08
CLINICAL EXPERIMENTS WITH A NEW PSYCHOTROPIC DRUG (SULPIRIDE).
211203 03-14
THE ACTION OF SULPIRIDE IN PURE INTERPRETIVE DELIRIUM.
212492 03-09
SULPIRIDE AND DRUG ADDICTION.
216764 04-11
SULPIRIDE AND HYPERKINETIC SYNDROMES.
218564 04-11
THE INFLUENCE OF SULPIRIDE ON VIGILANCE: OBJECTIVE MEASUREMENTS OF THE VISUOMOTOR SYSTEM.
221271 04-14
THE INFLUENCE OF SULPIRIDE ON SLEEP: RESULTS OF POLYGRAPHIC NIGHT SLEEP RECORDINGS.
221339 04-14
CLINICAL TRAILS OF SULPIRIDE WITH EMPHASIS ON NEUROTIC OUTPATIENTS.
224194 04-10
CLINICAL EXPERIENCE OF THE USE OF FK-880 (SULPIRIDE) FOR DEPRESSION AND NEUROSIS.
224195 04-14
SULPIRIDE TRIAL IN CHILD PSYCHIATRY.
224585 04-11

SULTOPRIDE
A NEW SUBSTITUTED BENZAMIDE WITH NEUROLEPTIC EFFECTS: LIN-14-18 OR SULTOPRIDE.
216759 04-08
AN ATTEMPT TO CLASSIFY SULTOPRIDE AMONG CURRENT NEUROLEPTICS.
216760 04-09

SUMMATION
THE EFFECT OF ALPHA-METHYL-P-TYROSINE METHYLESTER ON TEMPORAL SUMMATION IN THE NEURAL SUBSTRATE FOR THE REINFORCEMENT EFFECT IN SELF-STIMULATION. (PH.D. DISSERTATION).
222090 04-04

SUMMATIONAL
THE INFLUENCE OF PROLONGED APPLICATION OF TRANQUILIZERS AND ANTIDEPRESSANTS ON THE SUMMATIONAL CAPACITY OF THE CENTRAL NERVOUS SYSTEM.
201913 02-03

SUPERIOR
MINIMUM DURATION OF TRANS-SYNAPTIC STIMULATION REQUIRED FOR THE INDUCTION OF TYROSINE-HYDROXYLASE BY RESERPINE IN THE RAT SUPERIOR CERVICAL GANGLION.
199999 02-03
ONTOGENY OF THE INDUCTION OF TYROSINE-HYDROXYLASE BY RESERPINE IN THE SUPERIOR CERVICAL GANGLION, NUCLEUS LOCUS-COERULEUS AND ADRENAL GLAND.
210670 03-03

SUPERSENSITIVITY
HYDROCORTISONE-INDUCED SUPERSENSITIVITY TO NORADRENALINE IN THE ISOLATED NICTITATING MEMBRANE AS A CONSEQUENCE OF AN IMPAIRMENT OF AN O-METHYLATING SYSTEM WITH HIGH AFFINITY.
197944 01-03
BEHAVIOURAL SUPERSENSITIVITY TO APOMORPHINE FOLLOWING CHRONIC TREATMENT WITH DRUGS WHICH INTERFERE WITH THE SYNAPTIC FUNCTION OF CATECHOLAMINES.
199958 02-04
SUPERSENSITIVITY TO DOPAMINE AGONISTS FOLLOWING UNILATERAL, 6-HYDROXYDOPAMINE INDUCED STRIATAL LESIONS IN MICE.
208552 03-03
BEHAVIOURAL SUPERSENSITIVITY TO APOMORPHINE FOLLOWING CEREBRAL DOPAMINERGIC DENERVATION BY 6-HYDROXYDOPAMINE.
217527 04-03
BLOCKADE OF ALPHA-METHYLTYROSINE-INDUCED SUPERSENSITIVITY TO APOMORPHINE BY CHRONIC ADMINISTRATION OF L-DOPA.
220974 04-03

DOES CHRONIC MORPHINE TREATMENT INDUCE A SUPERSENSITIVITY OF DOPAMINE RECEPTORS IN RAT BRAIN
221038 04-03

SUPPORTED
A SURVEY OF DRUG TREATMENT IN PSYCHIATRY: SPECIAL EMPHASIS ON INPATIENTS ON MEDICAL WELFARE SUPPORTED BY YOKOHAMA CITY.
200447 02-17

SUPPRESSED
COMPARISON OF MORPHINE AND CHLORPROMAZINE EFFECTS ON MODERATELY AND SEVERELY SUPPRESSED PUNISHED RESPONDING IN THE PIGEON.
202666 02-04

PARTIAL RESTORATION BY AN A NEUROLEPTIC (SPIRAMIDE) OF ITEMS OF GROOMING BEHAVIOUR SUPPRESSED BY AMPHETAMINE.
213590 04-04

DRUGS AND PUNISHED RESPONDING. V. EFFECTS OF DRUGS ON RESPONDING SUPPRESSED BY RESPONSE DEPENDENT AND RESPONSE INDEPENDENT ELECTRIC SHOCK.
215722 04-04

SUPPRESSION
SUPPRESSION OF CONDITIONED HYPERTHERMIC RESPONSE BY L- AND D-OXPRENOLOL IN RATS.
192937 01-03

ACTION OF PROBENECID ON THE CENTRAL NERVOUS SYSTEM OF THE RABBIT: II. POTENTIATION OF 5-HYDROXYTRYPTOPHAN-INDUCED HYPERTHERMIA AND SUPPRESSION OF THIS EFFECT BY A DECARBOXYLASE INHIBITOR (RO-4-4602).
196580 01-03

EFFECTS OF L-DOPA ON CONDITIONED AVOIDANCE RESPONDING AFTER BEHAVIOURAL SUPPRESSION BY ALPHA-METHYLTYROSINE OR RESERPINE IN MICE.
197987 01-04

SELECTIVE DIPHENYLHYDANTOIN SUPPRESSION OF AUDITORY EVOKED POTENTIALS IN THE CAT CEREBELLAR CORTEX.
197989 01-03

ENHANCEMENT OF THE CHLORPROMAZINE-INDUCED SUPPRESSION OF THE CONDITIONED AVOIDANCE RESPONSE BY CARBONIC ANHYDRASE INHIBITION.
199770 02-03

SUPPRESSION BY NORADRENALINE OF CATECHOLAMINE SECRETION FROM ADRENAL MEDULLA.
199869 02-03

EFFECTS OF LOW AND HIGH DOSES OF L-DOPA ON THE TETRABENAZINE OR ALPHA-METHYLTYROSINE-INDUCED SUPPRESSION OF BEHAVIOUR IN A SUCCESSIVE DISCRIMINATION TASK.
200042 02-04

CONDITIONED SUPPRESSION OF MOUSE-KILLING IN RATS FOLLOWING RADIATION OR LITHIUM CHLORIDE INJECTIONS. (PH.D. DISSERTATION).
201153 02-04

SUPPRESSION OF MOUSE-KILLING AND APOMORPHINE-INDUCED SOCIAL AGGRESSION IN RATS BY LOCAL ANESTHESIA OF THE MYSTACIAL-VIBRISSAE.
206714 03-04

OPIOID REINFORCED OPERANT BEHAVIOR: SELECTIVE SUPPRESSION BY ALPHA-METHYL-P-TYROSINE.
211511 03-04

THE EFFECTS OF INTRAVENOUS AND SUBCUTANEOUS EPINEPHRINE ADMINISTRATION ON CONDITIONED SUPPRESSION. (PH.D. DISSERTATION).
213131 03-04

EXAMINATION OF THE ROLE OF BRAIN AMINES AND CYCLIC-AMP IN BENZODIAZEPINE INDUCED SUPPRESSION OF AGGRESSION. (PH.D. DISSERTATION).
219278 04-04

SUPRATENTORIAL
ABSENT VESTIBULO-OCULAR REFLEXES AND ACUTE SUPRATENTORIAL LESIONS.
225323 04-13

SUPREME
SUIT AGAINST RECOMMENDING DOCTOR AND PSYCHIATRIST -- REJECTED. STOVALL V. HARMS, 522 P.2D 353, (KANSAS) SUPREME COURT OF KANSAS. MAY 11, 1974.
200438 02-17

SURGERY
MENTAL DISORDERS SEEN AFTER OPEN HEART SURGERY.
214304 04-11

SURGICAL
PSYCHOTROPIC DRUGS ON GENERAL MEDICAL AND SURGICAL WARDS OF A TEACHING HOSPITAL.
213919 04-17

SURMONTIL
SURMONTIL -- IN DEPRESSION
195616 01-10

TRIMIPRAMINE (SURMONTIL) -- CLINICAL EVALUATION IN DEPRESSION.
195617 01-09

SURMONTIL (TRIMIPRAMINE) -- A CLINICAL TRIAL.
195620 01-10

CLINICAL TRIAL OF TRIMIPRAMINE (SURMONTIL).
198119 02-07

A DOUBLE-BLIND CLINICAL TRIAL OF NEW ANTIDEPRESSANT, SURMONTIL.
200922 02-09

SURVEILLANCE
DROWSINESS DUE TO CHLORPROMAZINE IN RELATION TO CIGARETTE SMOKING: A REPORT FROM THE BOSTON COLLABORATIVE DRUG SURVEILLANCE PROGRAM.
193072 01-15

PSYCHOTROPIC DRUG USE IN THE BOSTON AREA: A REPORT FROM THE BOSTON COLLABORATIVE DRUG SURVEILLANCE PROGRAM.
213920 04-17

SURVEY
PSYCHOACTIVE DRUG USE IN ELDERLY PATIENTS WITH PSYCHIATRIC DISORDERS: A SURVEY OF 12 VETERANS ADMINISTRATION HOSPITALS.
193291 01-11

ONCE-A-DAY DOSAGE TRICYCLIC ANTIDEPRESSANT DRUG THERAPY: A SURVEY.
196679 01-09

SURVEY OF HEALTH AND ILLNESS IN FAMILY PRACTICE.
198049 01-17

A SURVEY OF DRUG TREATMENT IN PSYCHIATRY: SPECIAL EMPHASIS ON INPATIENTS ON MEDICAL WELFARE SUPPORTED BY YOKOHAMA CITY.
200447 02-17

SURVEY ON AND EVALUATION OF THE CONTRIBUTIONS OF METHODOLOGICAL ASPECTS IN THE INVESTIGATION OF LONG-TERM PSYCHOPHARMACOLOGICAL DRUG ACTION.
206984 03-16

THE USE OF PSYCHOACTIVE DRUGS IN ELDERLY PATIENTS WITH PSYCHIATRIC DISORDERS: SURVEY CONDUCTED IN TWELVE VETERANS ADMINISTRATION HOSPITALS.
215009 04-11

NEUROLEPTICS OF PROLONGED ACTION (A SURVEY OF FOREIGN LITERATURE).
217003 04-14

RESULTS OF A SURVEY (1966-1967) OF DRUG USAGE IN INSTITUTIONS FOR THE MENTALLY RETARDED. (UNPUBLISHED PAPER).
222411 04-17

SURVIVAL
SURVIVAL IN LITHIUM INTOXICATION, STATUS-EPILEPTICUS, AND PROLONGED COMA.
208536 03-15

SUSCEPTIBILITY
PRENATAL MATERNAL D-AMPHETAMINE EFFECTS ON EMOTIONALITY AND AUDIOGENIC SEIZURE SUSCEPTIBILITY OF RAT OFFSPRING.
225079 04-04

SUSTAINED
ELECTROCONVULSIVE SHOCK: SUSTAINED DECREASE IN NOREPINEPHRINE UPTAKE AFFINITY IN A RESERPINE MODEL OF DEPRESSION.
210830 03-03

CLINICAL EXPERIMENTATION WITH A SUSTAINED RELEASE LITHIUM CARBONATE.
216769 04-09

A SINGLE DAILY DOSE OF A SUSTAINED RELEASE FORM OF AMITRIPTYLINE IN DEPRESSIVE ILLNESS.
219961 04-09

SUXILEP
PROGNOSIS OF THE THERAPEUTIC EFFECT OF SUXILEP AND TRIMETIN USING A SUCCESSIONAL STATISTICAL PROCEDURE.
224086 04-11

SWIMMING
EFFECT OF THYROXINE AND CORTISOL ON BRAIN ORNITHINE DECARBOXYLASE ACTIVITY AND SWIMMING BEHAVIOR IN DEVELOPING RAT.
210933 03-03

SYDNOCARB
THE EFFECT OF SYDNOCARB ON SOME PSYCHOLOGICAL AND AUTONOMIC TESTS: A PILOT STUDY.
205599 02-13

ON THE USE OF SYDNOCARB FOR PSYCHOPHARMACOLOGICAL CORRECTION OF BEHAVIORAL DISORDERS OF THE CYCLOID TYPE OF ACCENTUATED PERSONALITY IN ADOLESCENTS.
207271 03-11

COMPARATIVE EFFECTS OF SYDNOCARB AND AMPHETAMINE ON THE BIOELECTRICAL ACTIVITY OF THE BRAIN.
223012 04-03

AN EXPERIMENTAL ANALYSIS ON THE EFFECTS OF THE PSYCHOSTIMULATOR SYDNOCARB.
223013 04-04

SYMMETREL
VISUAL HALLUCINATIONS AND DELIRIUM DURING TREATMENT WITH AMANTADINE (SYMMETREL).
215858 04-11

SYMPATHECTOMY
NEONATAL CHEMICAL SYMPATHECTOMY: FUNCTIONAL CONTROL OF DENERVATION OF THE VASCULAR SYSTEM AND TISSUE NORADRENALINE LEVEL IN THE RAT AFTER 6-HYDROXYDOPAMINE.
197584 01-03
THE EFFECT OF AN ADRENAL DEMEDULLATION AND CHEMICAL SYMPATHECTOMY (2,4,5 TRIHYDROXYPHENYLETHYLAMINE) ON THE ACQUISITION OF A ONE-WAY ACTIVE AVOIDANCE RESPONSE. (PH.D. DISSERTATION).
222736 04-04

SYMPATHETIC
MECHANISM OF ACTION OF PHENCYCLIDINE ON THE PERIPHERAL SYMPATHETIC NERVOUS SYSTEM.
193425 01-03
NEUROPHARMACOLOGICAL STUDIES OF EFFECT OF NEW CENTRAL DEPRESSANT, 8-CHLOR-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D40TA) ON EEG AND CENTRAL SYMPATHETIC ACTIVATING MECHANISM IN CATS.
195549 01-03
INFLUENCE OF HALOTHANE ON PERIPHERAL SYMPATHETIC NERVES AND ON THE EFFECTS OF NORADRENALINE ON MYOCARDIUM.
197945 01-03
SYMPATHETIC NERVE ACTIVITY AFTER NORADRENALINE DEPLETION AND ITS ALTERATION BY CLONIDINE.
197947 01-03
EFFECT OF TROPOLONE ON VASCULAR SYMPATHETIC NEUROEFFECTOR TRANSMISSION.
197970 01-03
INHIBITION OF SYMPATHETIC ACTIVITY FOLLOWING CHRONIC ADMINISTRATION OF 2-AMINO-4-(3,4 DICHLOROPHENYL) 2-IMIDAZOLINE (MJ-10459-2).
199863 02-03
CATECHOLAMINES IN SYMPATHETIC GANGLIA OF RAT: EFFECTS OF DEXAMETHASONE AND RESERPINE.
210766 03-03
INHIBITION OF THE SYMPATHETIC NERVOUS SYSTEM BY 5,6 DIHYDROXY-2-DIMETHYLAMINOTETRALIN (M-7), APOMORPHINE AND DOPAMINE.
210888 03-03
A PROLONGED AFTEREFFECT OF INTENSE SYNAPTIC ACTIVITY ON ACETYLCHOLINE IN A SYMPATHETIC GANGLION.
211102 03-03
INDUCTION OF TYROSINE-HYDROXYLASE ELICITED BY BETA ADRENERGIC RECEPTOR AGONISTS IN NORMAL AND DECENTRALIZED SYMPATHETIC GANGLIA: ROLE OF CYCLIC 3,5 ADENOSINE-MONOPHOSPHATE.
215688 04-03
INHIBITION OF EFFERENT SYMPATHETIC NERVE ACTIVITY BY 5-HYDROXYTRYPTOPHAN AND CENTRALLY ADMINISTERED 5-HYDROXYTRYPTAMINE.
215712 04-03
DEVELOPMENTAL VARIATIONS OF CHOLINE ACETYLTRANSFERASE, DOPAMINE-BETA-HYDROXYLASE AND MONOAMINEOXIDASE IN CHICKEN EMBRYO AND CHICKEN SYMPATHETIC GANGLIA.
217840 04-03
IN VIVO UPTAKE OF ANTIBODY TO DOPAMINE-BETA-HYDROXYLASE INTO SYMPATHETIC ELEMENTS.
217848 04-03
DEXAMETHASONE INDUCES TYROSINE-HYDROXYLASE IN SYMPATHETIC GANGLIA BUT NOT IN ADRENAL MEDULLA.
217853 04-03
ACTION OF DIAZEPAM, DIBUTYRYL-CGMP, AND GABA ON PRESYNAPTIC NERVE TERMINALS IN BULLFROG SYMPATHETIC GANGLIA.
217873 04-03
INTERACTIONS BETWEEN POSTGANGLIONIC SYMPATHETIC BLOCKING DRUGS AND ANTIDEPRESSANTS.
221650 04-09

SYMPATHOLYTIC
STIMULUS PROPERTIES OF SYMPATHOMIMETIC AND SYMPATHOLYTIC DRUGS.
205335 02-04

SYMPATHOMIMETIC
SYMPATHOMIMETIC AMINES AND GASTRIC SECRETION IN RATS.
199622 02-03
STIMULUS PROPERTIES OF SYMPATHOMIMETIC AND SYMPATHOLYTIC DRUGS.
205335 02-04

SYMPOSIUM
FRONTIERS IN CATECHOLAMINE RESEARCH. PROCEEDINGS OF THE THIRD INTERNATIONAL CATECHOLAMINE SYMPOSIUM.
206437 03-17
THE DIPHENYLBUTYLPIPERIDINES: FIRST NORTH AMERICAN SYMPOSIUM, 1972.
207052 03-17
MONOAMINERGIC NEUROTOXINS: ARE THEY SELECTIVE? SOME PERSPECTIVES ON THE SYMPOSIUM HELD AT THE FOURTH ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, OCTOBER, 1974. (UNPUBLISHED PAPER).
222353 04-06

SYMPTOM
RAPIDITY OF SYMPTOM REDUCTION IN DEPRESSIONS TREATED WITH AMITRIPTYLINE.
209437 03-09
PATTERNS OF SYMPTOM CHANGE IN ANXIOUS DEPRESSED OUTPATIENTS TREATED WITH DIFFERENT DRUGS.
209904 03-10

SYMPTOMATIC
THE ACTIVITY PROFILE OF PIRACETAM IN PSYCHOSYNDROMES AND SYMPTOMATIC PSYCHOSES.
204411 02-09
SYMPTOMATIC SINUS NODE ABNORMALITIES FOLLOWING LITHIUM CARBONATE THERAPY.
223120 04-15

SYMPTOMATOLOGICAL
PHARMACOLOGICAL TREATMENT OF PHOBIC - OBSESSIVE PSYCHONEUROSES: PSYCHODYNAMIC AND SYMPTOMATOLOGICAL ASPECTS.
210506 03-10
COMPARATIVE SYMPTOMATOLOGICAL AND EVOKED POTENTIAL STUDIES WITH D-AMPHETAMINE, THIORIDAZINE, AND PLACEBO IN HYPERKINETIC CHILDREN.
225516 04-10

SYMPTOMS
A DOUBLE-BLIND CROSSOVER COMPARISON BETWEEN CLOTHIAPINE AND DIAZEPAM IN THE TREATMENT OF MENTAL SYMPTOMS IN CHRONIC ALCOHOLICS.
192988 01-11
MAJOR OR MINOR TRANQUILIZERS FOR RELIEF OF COMMON SYMPTOMS OF PSYCHONEUROSIS
193412 01-10
MULTIDIMENSIONAL SCALING TO RELATE ANIMAL PHARMACOLOGY AND CLINICAL SYMPTOMS OF PSYCHOPHARMACOLOGIC AGENTS.
198058 01-02
THERAPEUTIC-RESISTANT DEPRESSIONS: SYMPTOMS, RESISTANCE AND THERAPY.
202854 02-09
TREATMENT OF WITHDRAWAL SYMPTOMS WITH APOMORPHINE.
204407 02-15
SCHNEIDERIAN FIRST RANK SYMPTOMS AND CLINICAL FEATURES OF SCHIZOPHRENIA.
205179 02-08
CEREBRAL AND PERIPHERAL CONSUMPTION OF L-5-HTP BY PATIENTS SUFFERING FROM MANIACAL, DEPRESSIVE OR PSYCHOTIC SYMPTOMS.
206834 03-10
PROPRANOLOL IN THE CONTROL OF SCHIZOPHRENIC SYMPTOMS.
209830 03-08
A CASE OF PHEOCHROMOCYTOMA WITH SCHIZOPHRENIA LIKE SYMPTOMS.
210794 03-17
THREE CASES OF CHRONIC CHLORDIAZEPOXIDE INTOXICATION AND THEIR WITHDRAWAL SYMPTOMS.
211360 03-15
AFFECTS OF L-DOPA ON THE PSYCHOLOGICAL SYMPTOMS OF PICKS DISEASE.
211365 03-11
RELIEVING SELECT SYMPTOMS OF THE ELDERLY.
213353 03-11
THE SHAPIRO CARDS SCALE AS A METHOD OF ASSESSMENT OF OBSESSIONAL SYMPTOMS IN CLOMIPRAMINE THERAPY.
214829 04-10
THE RELATIONSHIP OF DIAGNOSIS AND TARGET SYMPTOMS TO PSYCHOTROPIC DRUG ASSIGNMENT.
215251 04-17
EFFECTS OF MAINTENANCE AMITRIPTYLINE AND PSYCHOTHERAPY ON SYMPTOMS OF DEPRESSION.
218041 04-09

SYNAPSE
CHOLINERGIC AGENTS AFFECT TWO RECEPTORS THAT MODULATE TRANSMITTER RELEASE AT A CENTRAL SYNAPSE IN APLYSIA-CALIFORNICA.
215705 04-03
EFFECTS OF 5,7 DIHYDROXYTRYPTAMINE ON TRANSMISSION AT SEROTONERGIC SYNAPSE.
217638 04-03

SYNAPSES
ANTIPSYCHOTIC DRUGS AND CATECHOLAMINE SYNAPSES.
207290 03-03
ANTIPSYCHOTIC DRUGS AND CATECHOLAMINE SYNAPSES: SUMMARY OF THE SESSION.
207299 03-03

SYNAPTIC
TIME-DEPENDENT, MEMORY RETRIEVAL EFFECTS FOLLOWING PERIPHERAL AND HIPPOCAMPAL TREATMENTS TO INCREASE SYNAPTIC BIOGENIC AMINES. (PH.D. DISSERTATION).
194677 01-04

INHIBITION OF SYNAPTIC VESICULAR MG++ DEPENDENT ATPASE (STENIN) BY ANTIPSYCHOTIC PHENOTHIAZINES.
195054 01-03

BEHAVIOURAL SUPERSENSITIVITY TO APOMORPHINE FOLLOWING CHRONIC TREATMENT WITH DRUGS WHICH INTERFERE WITH THE SYNAPTIC FUNCTION OF CATECHOLAMINES.
199958 02-04

THE EFFECTS OF ACETYLCHOLINE AND SYNAPTIC STIMULATION ON THE NEURONS IN THE SENSORIMOTOR CORTEX.
205510 02-03

NEURAMINIDASE: ITS EFFECT ON SYNAPTIC TRANSMISSION.
210664 03-03

A PROLONGED AFTEREFFECT OF INTENSE SYNAPTIC ACTIVITY ON ACETYLCHOLINE IN A SYMPATHETIC GANGLION.
211102 03-03

COCAINE, AMPHETAMINE, AND TRICYCLIC ANTIDEPRESSANTS AND SYNAPTIC TRANSMISSION.
221386 04-13

NEUROTRANSMITTER CONTENT IN SYNAPTIC VESICLES OF THE ADRENERGIC NERVES OF RATS UNDER PHARMACOLOGICAL INFLUENCE.
223017 04-03

SYNAPTOSOMAL

ANTAGONISTIC EFFECTS OF NEUROLEPTICS AND APOMORPHINE ON SYNAPTOSOMAL TYROSINE-HYDROXYLASE IN VITRO.
198209 02-03

THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON THE UPTAKE AND RELEASE OF 14C-DOPAMINE FROM CRUDE STRIATAL SYNAPTOSOMAL PREPARATIONS.
202775 02-03

EFFECTS OF CATECHOLAMINE RELEASING AGENTS ON SYNAPTOSOMAL DOPAMINE BIOSYNTHESIS: MULTIPLE POOLS OF DOPAMINE OR MULTIPLE FORMS OF TYROSINE-HYDROXYLASE?.
210825 03-03

THE EFFECT OF DOPAMINE AND OF APOMORPHINE ON DB-CAMP INDUCED STIMULATION OF SYNAPTOSOMAL TYROSINE-HYDROXYLASE.
217823 04-03

SYNAPTOSOMES

D-AMPHETAMINE AND THE RELEASE OF 3H-NOREPINEPHRINE FROM SYNAPTOSOMES.
197871 01-03

UPTAKE OF CATECHOLAMINES BY HUMAN SYNAPTOSOMES.
202719 02-03

EFFECT OF NOMIFENSINE (HOE-984), A NEW ANTIDEPRESSANT, ON UPTAKE OF NORADRENALINE AND SEROTONIN AND ON RELEASE OF NORADRENALINE IN RAT BRAIN SYNAPTOSOMES.
202807 02-03

RAPID REVERSAL OF INTERNAL NA+ AND K+ CONTENTS OF SYNAPTOSOMES BY OUABAIN.
204185 02-03

THE NATURE OF (3H)IMIPRAMINE BINDING TO SYNAPTOSOMES.
210904 03-03

CHLORPROMAZINE: SPECIFIC INHIBITION OF L-NORADRENALINE AND 5-HYDROXYTRYPTAMINE UPTAKE IN SYNAPTOSOMES FROM SQUID BRAIN.
213395 04-03

COMPARATIVE STUDIES ON SYNAPTOSOMES: HIGH-AFFINITY UPTAKE AND ACETYLATION OF N-H3-ME-CHOLINE AND N-H3-ME-HYDROXYETHYLPYRROLIDINIUM.
217869 04-03

EFFECT OF FIGHTING AND DIPHENYLHYDANTOIN ON THE UPTAKE OF H3-L-NOREPINEPHRINE IN VITRO IN SYNAPTOSOMES ISOLATED FROM RETIRED MALE BREEDING MICE.
222821 04-03

SYNCHRONISED

THE INFLUENCE OF ACTH4-10 ON HIPPOCAMPAL AND THALAMIC SYNCHRONISED ACTIVITY IN RATS.
213430 04-03

SYNCHRONIZATION

REVERSAL OF THE RESERPINE ELECTROENCEPHALOGRAPHIC SYNCHRONIZATION IN THE RABBIT BY P-CHLOROPHENYLALANINE.
197994 01-03

ANALYSIS OF VARIOUS FACTORS INVOLVED IN EEG SYNCHRONIZATION DURING MILK DRINKING IN THE CAT.
217846 04-04

SYNDROME

EFFECT OF TWO DOPAMINE RECEPTOR BLOCKERS ON A SEROTONIN MEDIATED BEHAVIORAL SYNDROME IN RATS.
193548 01-04

ADMINISTRATION OF PG-501 FOR THE TREATMENT OF EXTRAPYRAMIDAL SYNDROME CAUSED BY THE ADMINISTRATION OF A PSYCHOTROPIC DRUG.
194475 01-11

EFFECTS OF PHENOXYBENZAMINE ON THE NARCOTIC WITHDRAWAL SYNDROME IN THE RAT.
195091 01-03

THE EFFECT OF DAILY ORAL DOSAGE OF DIAZEPAM, PLASMA CONCENTRATIONS AND METABOLIC CLEARANCE OF DIAZEPAM AND DEMETHYLDIAZEPAM ON VARIOUS CONSTITUENTS OF THE ACUTE CLINICAL ANXIETY SYNDROME.
196191 01-10

SEROTONIN IN DOWNS SYNDROME.
198423 02-11

MULTIPLE TIC SYNDROME (GILLES-DE-LA-TOURETTES SYNDROME): CLINICAL, BIOLOGICAL, AND PSYCHOSOCIAL VARIABLES AND THEIR INFLUENCE WITH HALOPERIDOL.
199473 02-11

THE ROLE OF BRAIN DOPAMINE IN THE HYPERACTIVITY SYNDROME PRODUCED BY INCREASED 5-HYDROXYTRYPTAMINE SYNTHESIS IN RATS.
199960 02-04

ROLE OF CATECHOLAMINERGIC MECHANISMS IN THE EXPRESSION OF THE MORPHINE ABSTINENCE SYNDROME IN RATS.
200053 02-03

THE EXTRAPYRAMIDAL SYNDROME INDUCED BY NEUROLEPTICS.
202445 02-15

AN MAOI SPECIFIC AFFECTIVE DISORDER. THE TOO MUCH SYNDROME.
202705 02-09

PSYCHOPHARMACOLOGICAL TREATMENT OF OBSESSIVE SYNDROME.
204408 02-09

GILLES-DE-LA-TOURETTES SYNDROME AND DEPRESSION: A CASE REPORT.
206939 03-09

SEXUALITY AND GILLES-DE-LA-TOURETTES SYNDROME.
207957 03-11

THE TREATMENT OF NIGHT TERRORS ASSOCIATED WITH THE POSTTRAUMATIC SYNDROME.
209750 03-11

EVIDENCE THAT 5-METHOXYDIMETHYLTRYPTAMINE IS A SPECIFIC SUBSTRATE FOR MAO-A IN THE RAT: IMPLICATIONS FOR THE INDOLEAMINE DEPENDENT BEHAVIORAL SYNDROME.
210817 03-04

PHYSOSTIGMINE: ITS USE IN ACUTE ANTICHOLINERGIC SYNDROME WITH ANTIDEPRESSANT AND ANTIPARKINSON DRUGS.
211416 03-15

THE CENTRAL ANTICHOLINERGIC SYNDROME: MANAGEMENT WITH PHYSOSTIGMINE.
211427 03-15

CAFFEINE IN THE TREATMENT OF CHILDREN WITH MINIMAL BRAIN DYSFUNCTION OR HYPERKINETIC SYNDROME.
211434 03-11

THE ROLE OF SEROTONIN IN THE SEPTAL BEHAVIOR SYNDROME OF RATS. (PH.D. DISSERTATION).
213128 03-03

NEUROLEPTIC-INDUCED KLUVER-BUCY SYNDROME.
213532 04-15

ACUTE ORGANIC BRAIN SYNDROME: A COMPLICATION OF DISULFIRAM THERAPY.
213710 04-15

A CLINICAL STUDY OF A NEW NEUROLEPTIC EXTRAPYRAMIDAL SYNDROME CORRECTOR WITH ACUTE PSYCHOTIC STATES.
216766 04-15

THE INHIBITION OF A AND B FORMS OF MAO IN THE PRODUCTION OF A CHARACTERISTIC BEHAVIOURAL SYNDROME IN RATS AFTER L-TRYPTOPHAN LOADING.
217471 04-03

DEPRESSIONS AND ANTIDEPRESSANTS DURING TREATMENT WITH LONG-ACTING NEUROLEPTIC DRUGS: SIDE-EFFECTS AND THE EMERGENT METATHERAPEUTIC SYNDROME.
219694 04-15

TETRAHYDROCANNABINOL INDUCED MANIFESTATIONS OF THE MARIHUANA SYNDROME IN GROUP LIVING MACAQUES.
221340 04-04

STUDIES ON MICROVIBRATION OF UNIDENTIFIED CLINICAL SYNDROME.
221664 04-14

ON SYNDROME MALIN INDUCED BY NEUROLEPTICS.
224507 04-15

A FOLLOWUP OF TOURETTES SYNDROME IN SEVENTY-SEVEN PATIENTS.
224910 04-11

SYNDROMES

SMALL DOSES OF SULPIRIDE IN THE TREATMENT OF PSYCHONEUROTIC SYNDROMES.
194071 01-09

LUMBAR CSF 5-HYDROXYINDOLEACETIC ACID AND HOMOVANILLIC ACID IN AFFECTIVE SYNDROMES.
202248 02-09

EXPERIENCE WITH OXYPROTHEPINE IN THE TREATMENT OF MANIC SYNDROMES.
205580 02-09

PSYCHOPATHOGENIC ASPECTS IN ACUTE PSYCHOORGANIC SYNDROMES (RELATIONSHIPS BETWEEN DRUG DEPENDENCE AND DELIRIUM-TREMENS TYPE SYNDROMES).
209063 03-15

THERAPEUTIC EFFECTS AND MECHANISM OF ACTION OF S-ADENOSYL-L-METHIONINE (SAM) IN DEPRESSIVE SYNDROMES.
210213 03-09

NONPHARMACOLOGICAL FACTORS IN DRUG THERAPY: THE INTERACTION OF DOCTOR, PATIENT, AND TABLET APPEARANCE IN THE TREATMENT OF ANXIETY/DEPRESSIVE SYNDROMES.
215060 04-10

REM SLEEP REDUCTION EFFECTS ON DEPRESSION SYNDROMES.
218120 04-09

SULPIRIDE AND HYPERKINETIC SYNDROMES.
218564 04-11

DETERIORATION SYNDROMES IN THE ELDERLY.
220284 04-11

THE ASSESSMENT OF NEUROLEPTOGENIC EXTRAPYRAMIDAL SYNDROMES IN PSYCHOPHARMACOLOGICAL RESEARCH.
221307 04-15

ATROPINE COMA TREATMENT OF SCHIZOPHRENIC PATIENTS WITH A SLUGGISH DEVELOPMENT AND OBSESSIVE SYNDROMES.
224085 04-08

SYNERGISM

SYNERGISM BETWEEN GAMMA-AMINOBUTYRIC ACID AND BUTYROPHENONES ADMINISTERED MICROELECTROPHORETICALLY IN THE PURKINJE CELLS OF THE CAT CEREBELLUM.
220904 04-03

SYNTHESES

THE EFFECT OF PSYCHOPHARMACOLOGICAL DRUGS ON PUFFING AND ON RNA AND DNA SYNTHESES IN THE SALIVARY GLAND CHROMOSOMES OF DROSOPHILA-MELANOGASTER. (PH.D. DISSERTATION).
196250 01-03

NEUROLEPTIC AGENTS OF THE BENZOCYCLOHEPTAPYRIDOISOQUINOLINE SERIES. 1.SYNTHESES AND STEREOCHEMICAL AND STRUCTURAL REQUIREMENTS FOR ACTIVITY OF BUTACLAMOL AND RELATED COMPOUNDS.
208592 03-01

SYNTHESIS

THYROXINE AND BRAIN CATECHOLAMINES: INCREASED TRANSMITTER SYNTHESIS AND INCREASED RECEPTOR SENSITIVITY.
193541 01-03

MESCALINE-INDUCED CHANGES OF BRAIN CORTEX RIBOSOMES: EFFECT OF MESCALINE ON RIBOSOMAL SYNTHESIS OF POLYURIDINE DIRECTED POLYPHENYLALANINE.
194153 01-03

EFFECT OF PENTOBARBITONE AND DIETHYL ETHER ON THE SYNTHESIS OF MONOAMINES IN RAT BRAIN.
195950 01-03

A DUAL STUDY. PART I: SYNTHESIS AND STEREOCHEMISTRY OF SOME 1 SUBSTITUTED QUINOLIZIDINES AS ANALOGS OF BIOLOGICALLY ACTIVE COMPOUNDS. PART II: AMINO DERIVATIVES OF THIOPHENE FUSED CYCLIC KETONES AS POTENTIAL CNS. (PH.D. DISSERTATION).
196252 01-01

PROTRIPTYLINE INDUCED INHIBITION OF THE IN VIVO 3H-NORADRENALINE SYNTHESIS FROM 3H-L-DOPA IN THE RAT BRAIN.
197928 01-03

ANALYSIS OF ACETYLCHOLINESTERASE SYNTHESIS AND TRANSPORT IN THE RAT HIPPOCAMPUS: RECOVERY OF ACETYLCHOLINESTERASE ACTIVITY IN THE SEPTUM AND HIPPOCAMPUS AFTER ADMINISTRATION OF DIISOPROPYLFLUOROPHOSPHATE.
199805 02-03

THE ROLE OF BRAIN DOPAMINE IN THE HYPERACTIVITY SYNDROME PRODUCED BY INCREASED 5-HYDROXYTRYPTAMINE SYNTHESIS IN RATS.
199960 02-04

TISSUE METABOLITES OF TRIFLUOPERAZINE, FLUPHENAZINE, PROCHLORPERAZINE, AND PERPHENAZINE IN THE RAT: IDENTIFICATION AND SYNTHESIS.
200738 02-01

THE EFFECT OF INHIBITORS OF CATECHOLAMINE SYNTHESIS (ALPHA-METHYLTYROSINE AND DISULFIRAM) ON THE BACKGROUND ACTIVITY OF SENSORIMOTOR CORTEX NEURONS AND THEIR RESPONSES TO AFFERENT CAUDATE AND RETICULAR STIMULATION.
202598 02-04

SYNTHESIS AND PRELIMINARY PHARMACOLOGY OF A NOVEL BUTYROPHENONE DERIVATIVE, ID-4708.
202862 02-02

REGIONAL DIFFERENCES IN RESPONSE TO DISPLACEMENT AND INHIBITION OF SYNTHESIS OF CATECHOLAMINES IN THE CAT BRAIN.
206334 03-03

SYNTHESIS OF SUBSTITUTED BENZYLIDINOHYDRAZINES AND THEIR MONOAMINEOXIDASE INHIBITORY AND ANTICONVULSANT PROPERTIES.
206461 03-02

THE SYNTHESIS AND PHARMACOLOGY OF A NOVEL BENZODIAZEPINE DERIVATIVE, 1-METHYL-5-O-FLUOROPHENYL 7-CHLORODIHYDROBENZODIAZEPIN-2-ONE (ID-540).
206780 03-02

1 N-METHYLATED TRYPTAMINE DERIVATIVES: SYNTHESIS AND PROPERTIES.
207496 03-01

NEONATAL 6-HYDROXYDOPAMINE TREATMENT: NORADRENALINE LEVELS AND IN VITRO 3H-CATECHOLAMINE SYNTHESIS IN DISCRETE BRAIN REGIONS OF ADULT RATS.
210759 03-03

CHLORPROMAZINE AND BRAIN CATECHOLAMINE SYNTHESIS.
213630 04-03

BETA-ADRENERGIC STIMULATION OF PINEAL N-ACETYLTRANSFERASE: CYCLIC-AMP STIMULATES BOTH RNA AND PROTEIN SYNTHESIS.
215601 04-03

HEPATIC CHOLESTEROL SYNTHESIS IN MAN: EFFECT OF DIAZEPAM AND OTHER DRUGS.
215681 04-15

EFFECT OF ALPHA-METHYLDOPA ON DOPAMINE SYNTHESIS AND RELEASE IN RAT STRIATUM IN VITRO.
215690 04-03

SLEEP AND BEHAVIORAL CHANGES REFLECTING CENTRAL RECEPTOR HYPERSENSITIVITY FOLLOWING CATECHOLAMINE SYNTHESIS INHIBITION IN MAN. (UNPUBLISHED PAPER).
216373 04-09

INHIBITION OF STRIATAL DOPAMINE SYNTHESIS IN RATS INJECTED CHRONICALLY WITH NEUROLEPTICS IN THEIR EARLY LIFE.
217687 04-03

STUDIES ON THE SYNTHESIS AND SUBCELLULAR DISTRIBUTION OF DOPAMINE IN THE RAT ADRENAL MEDULLA.
217797 04-03

INTERACTIONS OF IMIPRAMINE AND SYNTHESIS INHIBITORS ON BIOGENIC AMINES.
217827 04-03

MONOAMINEOXIDASE INHIBITORS ANTAGONIZE THE ACCELERATION OF BRAIN DOPAMINE SYNTHESIS INDUCED BY NEUROLEPTIC DRUGS IN VIVO: IMPLICATIONS FOR THE TREATMENT OF TARDIVE DYSKINESIA.
220948 04-03

INHIBITORS OF CEREBRAL PROTEIN SYNTHESIS: DISSOCIATION OF AVERSIVE AND AMNESIC EFFECTS.
221005 04-04

THE SYNTHESIS AND PHARMACOLOGY OF A NOVEL BENZODIAZEPINE DERIVATIVE, 1-BETA-METHYLSULFONYLETHYL-5-O-FLUOROPHENYL 7-CHLORODIHYDROBENZODIAZEPIN-2-ONE (ID-622).
221741 04-02

EFFECT OF ACTH4-10 ON THE RATE OF SYNTHESIS OF (3H)CATECHOLAMINES IN THE BRAINS OF INTACT, HYPOPHYSECTOMIZED AND ADRENALECTOMIZED RATS.
223050 04-03

THE EFFECT OF THE PSYCHOTROPIC AGENTS (CHLORPROMAZINE, MAJEPTIL, TRICEDIL) ON PROTEIN SYNTHESIS IN VARIOUS PORTIONS OF THE RAT BRAIN.
223063 04-03

THE EFFECT OF AMITRIPTYLINE, DESIPRAMINE AND IMIPRAMINE ON THE IN VIVO BRAIN SYNTHESIS OF 3H-NORADRENALINE FROM 3H-L-DOPA IN THE RAT.
225565 04-03

SYNTHESIZED

IN VIVO RELEASE OF ENDOGENOUSLY SYNTHESIZED CATECHOLAMINES FROM THE CAT BRAIN EVOKED BY ELECTRICAL STIMULATION AND BY D-AMPHETAMINE.
195049 01-03

THE IN VIVO RELEASE OF ENDOGENOUSLY SYNTHESIZED CATECHOLAMINES FROM THE CAT BRAIN BY LATERAL HYPOTHALAMIC STIMULATION AND BY D-AMPHETAMINE ADMINISTRATION. (PH.D. DISSERTATION).
200313 02-03

ON A PRIME ROLE FOR NEWLY SYNTHESIZED DOPAMINE IN STRIATAL FUNCTION.
210862 03-03

EFFECTS OF AMPHETAMINE AND ITS HYDROXYLATED DERIVATIVES ON NEWLY SYNTHESIZED HYPOTHALAMIC NOREPINEPHRINE; STUDY IN VITRO.
210884 03-03

D-AMPHETAMINE INDUCED RELEASE OF NEWLY SYNTHESIZED AND STORED DOPAMINE FROM THE CAUDATE NUCLEUS IN VIVO.
214110 04-03

SYNTHETASE

MESCALINE-INDUCED CHANGES OF BRAIN-CORTEX RIBOSOMES: EFFECT OF MESCALINE ON TRNA AND AMINOACYL-TRNA SYNTHETASE.
195242 01-03

THE INCORPORATION OF GLUCOSE INTO BRAIN GLYCOGEN AND THE ACTIVITIES OF CEREBRAL GLYCOGEN PHOSPHORYLASE AND SYNTHETASE: SOME EFFECTS OF AMPHETAMINE.
196808 01-03

SYNTHETIC

THE EFFECT OF TWO SYNTHETIC ACTH ANALOGUES ON THE METABOLISM OF BIOGENIC AMINES IN THE RAT BRAIN.
210875 03-03

CONSTITUENTS OF CANNABIS-SATIVA L. IX: STABILITY OF SYNTHETIC AND NATURALLY OCCURRING CANNABINOIDS IN CHLOROFORM.
211010 03-06

ON THE PARTICIPATION OF BIOGENIC AMINES AND THEIR SYNTHETIC ENZYMES IN THE MECHANISMS OF IMAGE MEMORY.
213469 04-04

CATECHOLAMINE NEUROTRANSMITTERS AND SYNTHETIC ENZYMES IN THE SPINAL CORD OF THE RAT.
213987 04-03

SYSTEMATIC
SYSTEMATIC CLINICAL STUDIES WITH TRAZODONE.
198053 01-07
LITHIUM GLUCONATE: SYSTEMATIC AND FACTORIAL ANALYSIS OF 104 OBSERVATIONS OVER 2.5-3 YEARS IN PATIENTS PRESENTING CYCLOTHYMIC OR DYSTHYMIC DISORDERS.
210126 03-09
STRATEGIES FOR THE SYSTEMATIC STUDY OF NEUROTRANSMITTER RECEPTOR FUNCTION IN MAN.
215860 04-16

SYSTEMIC
PSYCHOSIS IN SYSTEMIC LUPUS-ERYTHEMATOSUS.
196088 01-08
COMPARISON OF THE EFFECTS OF THE INTRANIGRAL INJECTIONS OF CHOLINOMIMETICS WITH SYSTEMIC INJECTIONS OF THE DOPAMINE RECEPTOR STIMULATING AND BLOCKING AGENTS IN THE RABBIT.
199772 02-03
A COMPARISON OF THE LOCOMOTOR EFFECTS OF 5-HYDROXYTRYPTAMINE AND 5-HYDROXYTRYPTOPHAN ADMINISTERED VIA TWO SYSTEMIC ROUTES.
206086 03-04
BRAIN ACETYLCHOLINE: INCREASE AFTER SYSTEMIC CHOLINE ADMINISTRATION.
217399 04-03
SCREENING HALLUCINOGENIC DRUGS: SYSTEMIC STUDY OF THREE BEHAVIORAL TESTS.
217528 04-06

SYSTEMS
THE APPLICATION OF ELECTROANALYTICAL TECHNIQUES TO BIOCHEMICAL SYSTEMS. (PH.D. DISSERTATION).
194561 01-16
THE IMPORTANCE OF THE ASCENDING DOPAMINERGIC SYSTEMS TO THE EXTRAPYRAMIDAL AND MESOLIMBIC BRAIN AREAS FOR THE CATALEPTIC ACTION OF THE NEUROLEPTIC AND CHOLINERGIC AGENTS.
195250 01-03
THE ROLE OF FOREBRAIN DOPAMINE SYSTEMS IN AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR IN THE RAT.
202774 02-04
THE STRUCTURAL CHEMISTRY OF ADRENERGIC NEURAL TRANSMISSION SYSTEMS. (PH.D. DISSERTATION).
203027 02-01
ELECTROENCEPHALOGRAPHIC STUDY ON THE ACTION OF THE COMBINATION MEPROBAMATE ACEPROMETAZINE ON VARIOUS CEREBRAL SYSTEMS.
221286 04-03
INTERACTIONS BETWEEN LYSERGIC ACID DIETHYLAMIDE AND DOPAMINE SENSITIVE ADENYLCYCLASE SYSTEMS IN RAT BRAIN.
223175 04-03
PSYCHOPHYSICAL EVALUATION OF TOXIC EFFECTS ON SENSORY SYSTEMS.
225166 04-03

S584
BEHAVIOURAL EVIDENCE OF DOPAMINE RECEPTOR STIMULATION BY PIRIBEDIL (ET495) AND ITS METABOLITE S584.
217152 04-04

TABLET
NONPHARMACOLOGICAL FACTORS IN DRUG THERAPY: THE INTERACTION OF DOCTOR, PATIENT, AND TABLET APPEARANCE IN THE TREATMENT OF ANXIETY/DEPRESSIVE SYNDROMES.
215060 04-10

TABLETS
A COMPARATIVE STUDY OF CLOMIPRAMINE (ANAFRANIL) CAPSULES AND TABLETS.
215148 04-09

TACHYPHYLAXIS
CROSS-TOLERANCE OR TACHYPHYLAXIS AMONG VARIOUS PSYCHOTOMIMETIC AGENTS ON CATS.
199965 02-03

TACITIN
PHARMACOLOGICAL INVESTIGATIONS WITH BENZOCTAMINE (TACITIN), A NEW PSYCHOACTIVE AGENT.
197447 01-03
TACITIN AND APONAL IN THE TREATMENT OF NEUROSES.
198396 02-10
BENZOCTAMINE (TACITIN) VERSUS PLACEBO: A DOUBLE-BLIND CROSSOVER STUDY IN ANXIETY NEUROTICS.
225064 04-10

TACLAMINE
EFFECTS OF TACLAMINE (AY-22214), A NEW PSYCHOACTIVE AGENT, ON CATECHOLAMINE AND SEROTONIN METABOLISM.
215725 04-03

TAIL
D-AMPHETAMINE AND THE SENSORY ROLE OF A RATS TAIL IN THERMOREGULATION OR WHAT THE RATS TAIL TELLS THE RATS BRAIN.
209961 03-03

TARDINE
ATYPICAL TARDINE DYSKINESIA.
225333 04-15

TARDIVE
EFFECT OF CHOLINERGIC AND ANTICHOLINERGIC AGENTS ON TARDIVE DYSKINESIA.
200086 02-13
LITHIUM AND MRIH IN TARDIVE DYSKINESIA.
202887 02-14
TARDIVE DYSKINESIA: AN EVALUATION OF THE ETIOLOGIC ASSOCIATION WITH NEUROLEPTIC THERAPY.
204164 02-15
NEUROLEPTIC-INDUCED HYPERSENSITIVITY OF STRIATAL DOPAMINE RECEPTORS IN THE RAT AS A MODEL OF TARDIVE DYSKINESIAS. EFFECTS OF CLOZAPINE, HALOPERIDOL, LOXAPINE AND CHLORPROMAZINE.
217462 04-03
DEANOL IN TARDIVE DYSKINESIA: A PRELIMINARY REPORT.
217523 04-11
MONOAMINEOXIDASE INHIBITORS ANTAGONIZE THE ACCELERATION OF BRAIN DOPAMINE SYNTHESIS INDUCED BY NEUROLEPTIC DRUGS IN VIVO: IMPLICATIONS FOR THE TREATMENT OF TARDIVE DYSKINESIA.
220948 04-03
EFFECT OF LITHIUM ON NEUROLEPTIC-INDUCED TARDIVE DYSKINESIA COMPARED WITH PLACEBO IN A DOUBLE-BLIND CROSSOVER TRIAL.
221335 04-15
LITHIUM CARBONATE IN THE TREATMENT OF TARDIVE DYSKINESIA.
225343 04-15

TARGET
THE RELATIONSHIP OF DIAGNOSIS AND TARGET SYMPTOMS TO PSYCHOTROPIC DRUG ASSIGNMENT.
215251 04-17

TASK
THE EFFECT OF DIFFERENTIAL SALINE AND CYCLOHEXIMIDE STATES ON THE ACQUISITION OF A SPATIAL REVERSAL TASK IN MICE AND RATS. (PH.D. DISSERTATION
198897 02-04
EFFECTS OF LOW AND HIGH DOSES OF L-DOPA ON THE TETRABENAZINE OR ALPHA-METHYLTYROSINE-INDUCED SUPPRESSION OF BEHAVIOUR IN A SUCCESSIVE DISCRIMINATION TASK.
200042 02-04
THE DIFFERENTIATION OF TWO TYPES OF HYPERACTIVE CHILDREN BY ACTIVITY LEVEL AND TASK PERFORMANCE WITH METHYLPHENIDATE (RITALIN) AND PLACEBO. (PH.D. DISSERTATION).
204688 02-11
EFFECTS OF DRUG ALTERED SEROTONIN LEVELS ON THE ACQUISITION OF A SHUTTLEBOX AVOIDANCE TASK. (PH.D. DISSERTATION).
211781 03-04
SOME EFFECTS OF ACTH4-10 ON PERFORMANCE DURING A SERIAL REACTION TASK.
217533 04-04
U-SHAPED FUNCTIONS IN A SHOCK ESCAPE TASK.
222265 04-04

TASTE
A CONDITIONED TASTE AVERSION INDUCED BY ALPHA-METHYL-P-TYROSINE.
195090 01-04
TASTE PHENOMENA INFLUENCES ON STIMULATION OF DEPRIVATION INDUCED FLUID CONSUMPTION OF RATS.
197991 01-03
INVESTIGATIONS OF UCS-CS MEDIATION IN RADIATION INDUCED CONDITIONED TASTE AVERSION. (PH.D. DISSERTATION).
220681 04-04
EFFECTS OF SCOPOLAMINE ON RETENTION OF TASTE AVERSION LEARNING IN RATS.
223033 04-04
POISON INDUCED NEOPHOBIA IN RATS: ROLE OF STIMULUS GENERALIZATION OF CONDITIONED TASTE AVERSIONS.
223254 04-04
TEGRETOL DEPENDENCY AND DIVERSION OF THE SENSE OF TASTE.
225486 04-14

TAURINE
EFFECTS OF TAURINE ON PSYCHOMOTOR ACTIVITY IN THE RAT.
195089 01-04
THE IN VIVO REGULATION OF CGMP CONTENT IN RAT CEREBELLUM: A STUDY OF THE ACTION OF TAURINE.
215654 04-03

TEACHING
PSYCHOTROPIC DRUGS ON GENERAL MEDICAL AND SURGICAL WARDS OF A TEACHING HOSPITAL.
213919 04-17

TECHNIQUE
MILD ANALGESICS EVALUATED WITH THE SUBMAXIMUM EFFORT TOURNIQUET TECHNIQUE. I. THE INFLUENCE OF PSYCHOLOGICAL FACTORS ON THEIR EFFECT.
197861 01-14

MILD ANALGESICS EVALUATED WITH THE SUBMAXIMUM EFFORT TOURNIQUET TECHNIQUE: II. THE INFLUENCE OF A TRANQUILLIZER ON THEIR EFFECT.
197862 01-13
THE SPARING TECHNIQUE IN ELECTROCONVULSIVE THERAPY.
200071 02-13
A STUDY OF AN ANIMAL MODEL OF DEPRESSION BY THE CONDITIONED REFLEX TECHNIQUE.
210853 03-04

TECHNIQUES
THE APPLICATION OF ELECTROANALYTICAL TECHNIQUES TO BIOCHEMICAL SYSTEMS. (PH.D. DISSERTATION).
194561 01-16
CLINICAL STUDY OF HALOPERIDOL. I. TECHNIQUES AND THEORY OF PARENTERAL THERAPY.
220156 04-08

TEGMENTAL
A HISTOCHEMICAL STUDY OF VENTRAL TEGMENTAL ACETYLCHOLINESTERASE CONTAINING PATHWAY FOLLOWING DESTRUCTIVE LESIONS.
210919 03-03

TEGMENTUM
BEHAVIORAL EFFECTS OF LOCAL INJECTION OF 6-HYDROXYDOPAMINE IN THE MEDIAL VENTRAL TEGMENTUM IN THE RAT. POSSIBLE ROLE OF THE MESOLIMBIC DOPAMINERGIC SYSTEM.
220946 04-04

TEGRETOL
ANTIMANIC AND PROPHYLACTIC EFFECTS OF CARBAMAZEPINE (TEGRETOL) ON MANIC-DEPRESSIVE PSYCHOSIS.
225086 04-09
TEGRETOL DEPENDENCY AND DIVERSION OF THE SENSE OF TASTE.
225486 04-14

TEHERAN
STUDY OF 220 OBSERVATIONS OF LITHIUM THERAPY IN DEPRESSION CASES IN TEHERAN.
212211 03-09

TELLENBACHS
CRITICAL REMARKS ON TELLENBACHS CONCEPT OF TYPUS-MELANCHOLICUS.
206696 03-09

TEMESTA
INJECTABLE TEMESTA, ANXIETY AND ANGUISH.
212163 03-10

TEMPERATURE
THE INFLUENCE OF CYPROHEPTADINE AND OF D-LYSERGAMIDE ON THE RISE IN TEMPERATURE INDUCED BY INTRACEREBROVENTRICULAR 5-HYDROXYTRYPTAMINE, NORADRENALINE AND DOPAMINE IN CONSCIOUS RABBITS.
193451 01-03
THE EFFECTS OF LSD, PSILOCYBIN, HARMALINE AND AMPHETAMINE ON THE BODY TEMPERATURE OF P-CHLOROPHENYLALANINE PRETREATED RATS.
197484 01-03
EFFECT OF ACUTE ADMINISTRATION OF L-DOPA ON BODY TEMPERATURE IN MAN.
197831 01-13
THE EFFECT OF LSD, PSILOCYBIN, HARMALINE AND AMPHETAMINE ON THE BODY TEMPERATURE OF P-CHLOROPHENYLALANINE PRETREATED RABBITS.
210920 03-05
PLASMA CATECHOLAMINES: ARTERIAL VENOUS DIFFERENCES AND THE INFLUENCE OF BODY TEMPERATURE.
215655 04-06
EFFECTS OF IPRONIAZID, CHLORPROMAZINE AND METHIOTHEPIN ON DMT INDUCED CHANGES IN BODY TEMPERATURE, PUPILLARY DILATATION, BLOOD PRESSURE AND EEG IN THE RABBIT.
215724 04-03
ABSENCE OF INTERACTION BETWEEN DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) AND CANNABIDIOL (CBD) IN AGGRESSION, MUSCLE CONTROL AND BODY TEMPERATURE EXPERIMENTS IN MICE.
217474 04-04

TEMPIDON
INFLUENCE OF TEMPIDON ON THE EEG OF CATS AT A SINGLE AND REPEATED APPLICATION.
215076 04-03

TEMPORAL
COMPARISON OF THE ACTION OF DIAZEPAM AND PHENOBARBITAL USING EEG DERIVED POWER SPECTRA OBTAINED FROM TEMPORAL LOBE EPILEPTICS.
197992 01-13
TEMPORAL DISCRIMINATION TESTS IN MENTAL RETARDATES TREATED WITH NUCLEOTIDES AND GABA IN HIGH DOSES.
210293 03-14
DECREASED TEMPORAL VARIABILITY IN HIPPOCAMPAL THETA RHYTHMS OF CATS ADMINISTERED METHYLPHENIDATE.
213855 04-03
DIFFERENTIAL NEUROCHEMISTRY AND TEMPORAL PATTERN IN RATS TREATED ORALLY WITH DELTA9-TETRAHYDROCANNABINOL FOR PERIODS UP TO SIX MONTHS.
217519 04-04
THE EFFECT OF ALPHA-METHYL-P-TYROSINE METHYLESTER ON TEMPORAL SUMMATION IN THE NEURAL SUBSTRATE FOR THE REINFORCEMENT EFFECT IN SELF-STIMULATION. (PH.D. DISSERTATION).
222090 04-04

TENSION
HEPTAMINOL AND TENSION DISTURBANCES INDUCED BY PSYCHOTROPIC DRUG THERAPY: CLINICAL STUDY.
210089 03-13
A COMPARISON BETWEEN DIAZEPAM AND HALOPERIDOL IN NEUROTIC ANXIETY AND TENSION STATES IN PATIENTS IN A OPEN WARD.
221638 04-10

TENTATIVE
TENTATIVE DOUBLE-BLIND TREATMENT OF ANXIETY WITH B-5833.
212166 03-10

TERATOCARCINOMA
BIOGENIC AMINES IN A RETRANSPLANTABLE NEUROGENIC TERATOCARCINOMA.
192925 01-03

TERATOGENIC
A TERATOGENIC STUDY OF HALOPERIDOL.
206014 03-03
THE TERATOGENIC RISK OF ANTIEPILEPTIC DRUGS.
225537 04-15

TERATOGENICITY
TERATOGENICITY OF ORAL DIAZEPAM AND DIPHENYLHYDANTOIN IN MICE.
217694 04-05

TERATOLOGIC
TERATOLOGIC AND REPRODUCTION STUDIES WITH CYCLAZOCINE.
193429 01-03
THE TOXICOLOGIC AND TERATOLOGIC EFFECTS OF DELTA9-TETRAHYDROCANNABINOL IN THE ZEBRAFISH EMBRYO.
217697 04-05

TERATOLOGICAL
TOXICOLOGICAL AND TERATOLOGICAL STUDY OF 2-PHENYLDIMETHYLTETRAHYDROOXAZINE HYDROCHLORIDE (G-130), A PSYCHOSTIMULANT DRUG.
206783 03-05

TERMINALS
FURTHER EVIDENCE FOR THE HETEROGENEOUS STORAGE OF NORADRENALINE IN CENTRAL NORADRENERGIC TERMINALS.
195239 01-03
POSTNATAL DEVELOPMENT OF CHOLINE UPTAKE BY CHOLINERGIC TERMINALS IN RAT BRAIN.
210713 03-03
PRESENCE OF DOPAMINERGIC TERMINALS AND ABSENCE OF DOPAMINERGIC CELL BODIES IN THE CEREBRAL CORTEX OF THE CAT.
210800 03-03
SELECTIVE DESTRUCTION OF SEROTONIN TERMINALS IN RAT FOREBRAIN BY HIGH DOSES OF 5,7 DIHYDROXYTRYPTAMINE.
213401 04-03
ACTION OF DIAZEPAM, DIBUTYRYL-CGMP, AND GABA ON PRESYNAPTIC NERVE TERMINALS IN BULLFROG SYMPATHETIC GANGLIA.
217873 04-03

TERMS
THE PENTOBARBITAL TEST DOSE FOR DEPRESSANT DRUG DEPENDENCE: A REEVALUATION IN TERMS OF ALCOHOL CONSUMPTION.
202883 02-17

TERRIER
INVOLVEMENT OF SEROTONIN IN HYPERKINETIC EPISODES IN SCOTTISH TERRIER DOGS. (PH.D. DISSERTATION).
196261 01-03

TERRORS
THE TREATMENT OF NIGHT TERRORS ASSOCIATED WITH THE POSTTRAUMATIC SYNDROME.
209750 03-11

TERTIARY
CHLORPROMAZINE METABOLISM IV: QUATERNIZATION AS A KEY TO DETERMINATION OF PICOMOLES OF CHLORPROMAZINE AND OTHER TERTIARY AMINE DRUGS.
217667 04-06
SIMILARITIES OF THE INFLUENCE OF SECONDARY AND TERTIARY TRICYCLIC ANTIDEPRESSANTS ON THE EFFECT OF RESERPINE IN FROGS AND ON THE SEROTONIN UPTAKE OF HUMAN THROMBOCYTES.
219503 04-13

TEST
EVALUATION OF CLINICAL PREDICTION OF ANTIDEPRESSANT ACTIVITY USING VARIOUS ANIMAL TEST MODELS.
198055 01-02
AN EXTENSION OF MULTIDIMENSIONAL SCALING TO FACILITATE CLINICAL INTERPRETATION OF ANIMAL TEST MODELS.
198059 01-02
THE PENTOBARBITAL TEST DOSE FOR DEPRESSANT DRUG DEPENDENCE: A REEVALUATION IN TERMS OF ALCOHOL CONSUMPTION.
202883 02-17

PROTECTION AGAINST EFFECTS OF BRAIN DAMAGE BY CATECHOLAMINE DEPLETION IS TEST DEPENDENT.
203579 02-04

EFFECTS OF SINGLE AND REPEATED ADMINISTRATION OF MAPROTILINE AND ITS RELATION TO PLASMA LEVELS IN HEALTHY TEST SUBJECTS.
204403 02-15

POTENTIATION OF CATALEPSY INDUCED BY NARCOTIC AGENTS DURING HAFFNERS TEST FOR ANALGESIA.
206358 03-04

A NEW BENZODIAZEPINE, SCREENED BY A PARALLEL DOUBLE-BLIND TEST.
212167 03-10

A COMPARISON OF THE ACTION OF THE TRICYCLIC ANTIDEPRESSANTS, AZAPHEN AND IMIPRAMINE, ON THE GASTROINTESTINAL TRACT OF TEST ANIMALS.
219505 04-03

AN ANIMAL TEST MODEL FOR EVALUATING DRUGS WITH ANTIMASS PSYCHOTIC ACTIVITY.
221273 04-06

DOUBLE-BLIND TEST OF THREE ANTIDEPRESSANTS, THIRD COMMUNICATIONS: METHODOLOGICAL PROBLEMS.
221288 04-16

DOUBLE-BLIND TEST OF THREE ANTIDEPRESSANTS, FOURTH COMMUNICATION; RESULTS WITH THE HAMBURG DEPRESSION SCALE.
221289 04-11

COMPARISON OF THE REMEDIAL RESULTS OF CLOFLUPEROL AND HALOPERIDOL FOR SCHIZOPHRENIA BY DOUBLE-BLIND TEST METHOD.
224549 04-08

RELIABILITY AND VALIDITY OF A PLACEBO TEST.
224894 04-16

ELEVATION OF PLASMA DOPAMINE-BETA-HYDROXYLASE ACTIVITY DURING MECHOLYL TEST.
225523 04-13

TESTED

THE EFFECT OF ALAMON (HYDROXYZINE HYDROCHLORIDE) AND MEDAZEPAM ON NEUROSIS TESTED BY A DOUBLE-BLIND METHOD.
211344 03-10

TESTING

PHARMACOKINETIC EVALUATION OF ANTICONVULSANTS PRIOR TO EFFICACY TESTING EXEMPLIFIED BY CARBAMAZEPINE IN EPILEPTIC MONKEY MODEL.
195492 01-04

TESTING ANATENSOL DECANOATE, A MAJOR NEUROLEPTIC, AT THE IXELLES GUIDANCE CENTER.
212165 03-09

A SIMPLE AVOIDANCE PROCEDURE FOR TESTING PSYCHOTROPIC DRUGS IN MICE.
220903 04-04

TESTOSTERONE

THE INTERACTION OF BARBITAL AND TESTOSTERONE RELATIVE TO THEIR HYPNOTIC EFFECTS.
197448 01-03

SHORT-TERM EFFECTS OF TESTOSTERONE PROPIONATE ON THE BEHAVIOUR OF YOUNG INTACT MALE DOMESTIC DUCKS (ANAS-PLATYRHYNCHOS).
199461 02-04

PLASMA TESTOSTERONE LEVELS DURING CHRONIC HEROIN USE AND PROTRACTED ABSTINENCE.
202307 02-13

TESTS

NEW HOT PLATE TESTS TO QUANTIFY ANTINOCICEPTIVE AND NARCOTIC ANTAGONIST ACTIVITIES.
193446 01-04

LONG-TERM TREATMENT OF PSYCHIATRIC PATIENTS WITH CLOPENTHIXOL: ANALYSIS OF LABORATORY TESTS WITH A VIEW TO LONG-TERM THERAPY.
199989 02-14

SLEEP - EEG TESTS OF NONSPECIFIC CASES OF PAROXYSM AND EPISODIC BEHAVIORAL DISTURBANCES: A PRELIMINARY REPORT.
203704 02-14

THE EFFECT OF SYDNOCARB ON SOME PSYCHOLOGICAL AND AUTONOMIC TESTS: A PILOT STUDY.
205599 02-13

THE EFFECT OF MEFEXAMIDE ON SOME AUTONOMIC AND PSYCHOLOGICAL TESTS.
205605 03-13

EXPERIMENTAL TESTS OF HYPOTHESES ABOUT NEUROCHEMICAL MECHANISMS UNDERLYING BEHAVIORAL TOLERANCE TO THE ANTICHOLINESTERASE, DIISOPROPYLFLUOROPHOSPHATE.
208555 03-03

TEMPORAL DISCRIMINATION TESTS IN MENTAL RETARDATES TREATED WITH NUCLEOTIDES AND GABA IN HIGH DOSES.
210293 03-14

EFFECTS OF (-)DELTA9-TRANS-TETRAHYDROCANNABINOL (DELTA9-THC) ON TESTS OF PSYCHOTICISM: A STUDY OF EYSENCKS DRUG POSTULATE ON THE EFFECTS OF HALLUCINOGENS IN RELATION TO PSYCHOTICISM.
214009 04-09

SCREENING HALLUCINOGENIC DRUGS: SYSTEMIC STUDY OF THREE BEHAVIORAL TESTS.
217528 04-06

EFFECT OF MARIJUANA ON DIVERGENT AND CONVERGENT PRODUCTION COGNITIVE TESTS.
223394 04-14

TETANUS

THE EFFECT OF L-DOPA AND L-DOPA COMBINED WITH CHLORPROMAZINE ON SPINAL CORD ACTIVITY DURING DISTURBED INHIBITION BY TETANUS TOXOID.
207200 03-03

TETRABENAZINE

SPONTANEOUS ORAL DYSKINESIA: RESULTS OF TREATMENT WITH TETRABENAZINE, PIMOZIDE, OR BOTH.
196600 01-11

INVESTIGATIONS ON THE ACTION AND MECHANISM OF ACTION OF DIPHENYLHYDANTOIN AS AN ANTAGONIST OF TETRABENAZINE AND RESERPINE.
197471 01-03

EFFECTS OF LOW AND HIGH DOSES OF L-DOPA ON THE TETRABENAZINE OR ALPHA-METHYLTYROSINE-INDUCED SUPPRESSION OF BEHAVIOUR IN A SUCCESSIVE DISCRIMINATION TASK.
200042 02-04

THE ACCUMULATION OF NORADRENALINE AND 5-HYDROXYTRYPTAMINE IN THREE REGIONS OF MOUSE BRAIN AFTER TETRABENAZINE AND IPRONIAZID: EFFECTS OF ETHINYLESTRADIOL AND PROGESTERONE.
200058 02-03

MODIFICATIONS BY LITHIUM OF BEHAVIORAL RESPONSES TO METHAMPHETAMINE AND TETRABENAZINE.
221041 04-04

TETRABENAZINE-INDUCED

PHARMACOLOGICAL STUDIES ON TETRABENAZINE-INDUCED EXCITED BEHAVIOUR OF RATS PRETREATED WITH AMPHETAMINE OR NIALAMIDE.
197490 01-04

POTENTIATION OF TETRABENAZINE-INDUCED BEHAVIOURAL DEPRESSION BY IMIPRAMINE ON A DISCRETE TRIAL AVOIDANCE ESCAPE SCHEDULE.
197859 01-04

TETRACYCLIC

THE EFFECT OF A NEW TETRACYCLIC ANTIDEPRESSANT COMPOUND, ORG-GB94, ON THE TURNOVER OF DOPAMINE, NORADRENALIN AND SEROTONIN IN THE RAT BRAIN.
197496 01-03

STUDIES ON CLINICAL AND PHARMACOLOGICAL SPECTRA OF THE TETRACYCLIC COMPOUND MIANSERIN.
204412 02-14

REPORT ON A PRELIMINARY CLINICAL STUDY OF MIANSERIN (GB-94), A TETRACYCLIC ANTIDEPRESSANT, AN OPEN TRIAL.
207283 03-03

COMPARISON OF THE EFFECTS OF TETRACYCLIC AND TRICYCLIC ANTIDEPRESSANTS ON THE SEROTONIN UPTAKE BY HUMAN THROMBOCYTES IN VITRO.
217258 04-13

A CONTROLLED STUDY OF A TETRACYCLIC ANTIDEPRESSANT -- MAPROTILINE (LUDIOMIL).
224486 04-09

TETRAETHYLAMMONIUM

AN ANALYSIS OF THE GROSS BEHAVIOURAL CHANGES INDUCED BY TETRAETHYLAMMONIUM AND A COMPARISON WITH OTHER SUBSTANCES AFFECTING THE AUTONOMIC AND CENTRAL NERVOUS SYSTEM AFTER INTRAVENTRICULAR INJECTIONS TO CONSCIOUS CATS.
202781 02-04

TETRAHYDROCANNABINOL

THE EFFECTS OF DEXTROAMPHETAMINE, DIMETHYLTRYPTAMINE, LYSERGIC ACID DIETHYLAMIDE AND TETRAHYDROCANNABINOL UPON PREGNANCY AND THE OFFSPRING. (PH.D. DISSERTATION).
194568 01-04

MORPHINE-DEPENDENT RATS: BLOCKADE OF PRECIPITATED ABSTINENCE BY TETRAHYDROCANNABINOL.
210221 03-13

TETRAHYDROCANNABINOL INDUCED MANIFESTATIONS OF THE MARIHUANA SYNDROME IN GROUP LIVING MACAQUES.
221340 04-04

DIFFERENTIAL EFFECTS OF A TETRAHYDROCANNABINOL AND PENTOBARBITAL ON CEREBRAL CORTICAL NEURONES.
222819 04-03

TETRAHYDROCANNABINOLS

EFFECTS OF TETRAHYDROCANNABINOLS ON CYCLIC-AMP LEVELS IN RAT BRAIN AREAS.
194925 01-03

DISCRIMINATIVE RESPONSE CONTROL PRODUCED WITH HASHISH, TETRAHYDROCANNABINOLS (DELTA8-THC AND DELTA9-THC), AND OTHER DRUGS.
202720 02-12

HASHISH. IMPORTANCE OF THE PHENOLIC HYDROXYL GROUP IN TETRAHYDROCANNABINOLS.
208594 03-02

TETRAHYDROCANNABINOLS AND SERUM PROLACTIN LEVELS IN MAN.
220973 04-13

TETRAHYDROISOQUINOLINE
DYSKINETIC PHENOMENA CAUSED BY THE INTRASTRIATAL INJECTION OF PHENYLETHYLAMINE, PHENYLPIPERAZINE, TETRAHYDROISOQUINOLINE AND TETRAHYDRONAPTHALENE DERIVATIVES IN THE GUINEA-PIG.
217671 04-04

TETRAHYDRONAPTHALENE
DYSKINETIC PHENOMENA CAUSED BY THE INTRASTRIATAL INJECTION OF PHENYLETHYLAMINE, PHENYLPIPERAZINE, TETRAHYDROISOQUINOLINE AND TETRAHYDRONAPTHALENE DERIVATIVES IN THE GUINEA-PIG.
217671 04-04

TETRAMETHYLENE-5-PHENYL-1-2-DIHYDRO
PHARMACOLOGICAL PROPERTIES OF 6,7 TETRAMETHYLENE-5-PHENYL-1-2-DIHYDRO 3H THIENODIAZEPIN-2-ONE (QM-6008), THIADIPONE), A NEW PSYCHOTROPIC DRUG.
221722 04-02

THALAMIC
PERSISTENT THALAMIC AND CORTICAL BARBITURATE SPINDLE ACTIVITY AFTER ABLATION OF THE ORBITAL CORTEX IN CATS.
199763 02-03

THE INFLUENCE OF ACTH4-10 ON HIPPOCAMPAL AND THALAMIC SYNCHRONISED ACTIVITY IN RATS.
213430 04-03

TOWARD THE QUESTION OF THE INFLUENCE OF STIMULATION OF THE THALAMIC ASSOCIATIVE NUCLEI ON THE BEHAVIOR OF CATS.
215498 04-04

THALAMUS
NEURONAL ACTIVITY OF NUCLEUS CAUDATES AND THALAMUS DURING BARBITURATE SPINDLES IN RATS.
201479 02-03

5-HT AND NOREPINEPHRINE-INDUCED RELEASE OF ACH FROM THE THALAMUS AND MESENCEPHALON OF THE MONKEY DURING THERMOREGULATION.
210672 03-03

THALIDOMIDE
THALIDOMIDE AND THE POWER OF THE PHARMACEUTICAL INDUSTRY.
210077 03-15

THC
IN VITRO NEUROMUSCULAR EFFECTS OF DELTA9-TETRAHYDROCANNABINOL (THC).
210866 03-03

TRANSFORMATION OF DELTA1-TETRAHYDROCANNABINOL (THC) BY RABBIT LIVER MICROSOMES.
217817 04-03

THEOPHYLLINE
EFFECTS OF THEOPHYLLINE AND PROPRANOLOL ON ACETYLCHOLINE-INDUCED RELEASE OF ADRENAL MEDULLARY CATECHOLAMINES.
195591 01-03

THEOPHYLLINE INCREASED SENSITIVITY TO NOCICEPTIVE STIMULATION AND REGIONAL TURNOVER OF RAT BRAIN 5-HT, NORADRENALINE AND DOPAMINE.
197926 01-03

AGGRESSIVE BEHAVIORS INDUCED BY CHRONIC ADMINISTRATION OF THEOPHYLLINE, WITH PARTICULAR REFERENCE TO ALTERATIONS IN BEHAVIORS OF IMMATURE RATS.
200748 02-04

THEORETICAL
EFFECT OF BETA-RECEPTOR BLOCKERS (PINDOLOL AND PRACTOLOL) ON LITHIUM INDUCED TREMOR -- CLINICAL TRIAL AND THEORETICAL CONSIDERATIONS.
204409 02-15

POSSIBLE PHARMACOLOGICAL AND THEORETICAL IMPLICATIONS OF X-RAY STRUCTURE OF THE TRICYCLIC ANTIDEPRESSANT IMIPRAMINE.
205029 02-01

MATURATION OF THE ADRENAL MEDULLA -- III: PRACTICAL AND THEORETICAL CONSIDERATIONS OF AGE DEPENDENT ALTERATIONS IN KINETICS OF INCORPORATION OF CATECHOLAMINES AND NONCATECHOLAMINES.
205852 03-03

THEORETICAL IMPLICATIONS OF DRUG-INDUCED ADAPTIVE REGULATION FOR A BIOGENIC AMINE HYPOTHESIS OF AFFECTIVE DISORDER.
206335 03-03

A CRYSTALLOGRAPHIC AND THEORETICAL STUDY OF THE CONFORMATION OF DOET AND ITS SIGNIFICANCE FOR THE HALLUCINOGENIC AMPHETAMINES.
210746 03-01

THE PLACEBO EFFECT: AN INTEGRATED ANALYSIS OF THEORETICAL AND RESEARCH PERSPECTIVES. (PH.D. DISSERTATION).
212593 03-17

THERAPEUTIC REVERSAL WITH BENZTROPINE IN SCHIZOPHRENICS: PRACTICAL AND THEORETICAL SIGNIFICANCE.
213726 04-08

THEORIES
PHARMACOTHERAPY OF SCHIZOPHRENIA: FACTS, SPECULATIONS, HYPOTHESES AND THEORIES.
206603 03-08

THEORY
A TWO-FACTOR BIOCHEMICAL THEORY OF SCHIZOPHRENIA.
206542 03-03

A TWO FACTOR THEORY OF SCHIZOPHRENIA.
207286 03-14

AMENORRHEA AND BEHAVIORAL DISTURBANCES: CLINICAL CASE TREATED WITH A PSYCHOTHERAPEUTIC METHOD BASED ON ELEMENTS OF THE CYBERNETIC THEORY OF G. CIPOLLINA MANGIAMELI.
210418 03-14

INCREASED LEVEL PRESSING FOR AMPHETAMINE AFTER PIMOZIDE IN RATS: IMPLICATIONS FOR A DOPAMINE THEORY OF REWARD.
213350 03-04

PSYCHOPHARMACOLOGICAL TREATMENT: THEORY AND PRACTICE.
213392 04-17

ON THE ORTHOMOLECULAR ENVIRONMENT OF THE MIND: ORTHOMOLECULAR THEORY.
213703 04-13

COMMENT ON LINUS PAULINGS THEORY OF ORTHOMOLECULAR PSYCHIATRY.
213704 04-08

COMMENT ON LINUS PAULINGS THEORY OF ORTHOMOLECULAR PSYCHIATRY.
213705 04-13

COMMENT ON LINUS PAULINGS THEORY OF ORTHOMOLECULAR PSYCHIATRY.
213706 04-15

CLINICAL STUDY OF HALOPERIDOL. I. TECHNIQUES AND THEORY OF PARENTERAL THERAPY.
220156 04-08

THERAPEUTIC
INFLUENCE OF THERAPEUTIC AND TOXIC DOSES OF NEUROLEPTICS AND ANTIDEPRESSANTS ON ENERGY METABOLISM OF THE ISOLATED PERFUSED RAT BRAIN.
195236 01-03

THE PSYCHIATRIST ATTITUDES AND THERAPEUTIC MEANS WHEN FACED WITH RESISTANT DEPRESSIONS.
196035 01-17

RECENT THERAPEUTIC ASPECTS OF DEPRESSION ESPECIALLY ON THE DRUG THERAPY.
196149 01-09

NEUROPHARMACOLOGY OF SQ-10996, A COMPOUND WITH SEVERAL THERAPEUTIC INDICATIONS.
197459 01-13

THE THERAPEUTIC EFFECT OF SHORT-TERM ORAL DIAZEPAM TREATMENT ON ACUTE CLINICAL ANXIETY IN A CRISIS CENTRE.
199991 02-10

CLOZAPINE AND HALOPERIDOL IN A SINGLE-BLIND CROSSOVER TRIAL: THERAPEUTIC AND BIOCHEMICAL ASPECTS IN THE TREATMENT OF SCHIZOPHRENIA.
200803 02-08

STUDY OF LITHIUM INTOXICATION UNDER THERAPEUTIC LITHIUM SERUM CONCENTRATION.
200952 02-15

MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 6. COMMUNICATION: RELATIONSHIP BETWEEN NEUROLEPTIC HYPOKINESIS AND ANTIPSYCHOTIC THERAPEUTIC RESULTS.
203844 02-13

THERAPEUTIC ROLES OF DRUGS AND MORITA THERAPY PROCESS.
204428 02-10

INFLUENCE OF SOME BIOGRAPHIC FACTORS ON THE THERAPEUTIC DRUG RESPONSE.
205622 03-14

ALTERATION OF PSYCHOSOMATIC REACTIVITY AFTER A SINGLE THERAPEUTIC DOSE OF PENTOBARBITAL IN RELATION TO THE SEX OF PROBANDS.
205627 03-14

BRAIN DOPAMINE AND BEHAVIOUR: A CRITICAL ANALYSIS OF THE RELATIONSHIP BETWEEN DOPAMINE ANTAGONISM AND THERAPEUTIC EFFICACY OF NEUROLEPTIC DRUGS.
207306 03-04

THERAPEUTIC EFFECTS AND MECHANISM OF ACTION OF S-ADENOSYL-L-METHIONINE (SAM) IN DEPRESSIVE SYNDROMES.
210213 03-09

SOME OBSERVATIONS ON THE CORRELATIONS BETWEEN PLASMA LEVELS OF MONOMETHYLATED TRICYCLIC ANTIDEPRESSANTS AND THERAPEUTIC EFFECTS.
210507 03-09

TYPOLOGY OF DEPRESSIONS AND THERAPEUTIC BEHAVIOR OF PSYCHIATRISTS.
212215 03-17

THERAPEUTIC STUDIES OF DEPRESSION WITH L-DOPA.
212947 03-09

THERAPEUTIC REVERSAL WITH BENZTROPINE IN SCHIZOPHRENICS: PRACTICAL AND THEORETICAL SIGNIFICANCE.
213726 04-08

DRUG METABOLISM AND THERAPEUTIC MONITORING.
214337 04-17

A COMPARISON OF THE THERAPEUTIC EFFECT OF OXYPERTINE AND THIORIDAZINE IN CHRONIC SCHIZOPHRENIA (A CONTROLLED TRIAL). 215075 04-08

A THERAPEUTIC STUDY OF SIDNOCARB. 217000 04-14

INSOMNIA: OFTEN A THERAPEUTIC CHALLENGE. 218214 04-14

THE SIGNIFICANCE OF STANDARDIZED EVALUATION SCALES IN PSYCHIATRIC DIAGNOSIS AS EXEMPLIFIED BY THE THERAPEUTIC INTERVENTION WITH DESMETHYLOXAPINE. 221337 04-10

TOXICOLOGICAL AND PHARMACOLOGICAL INVESTIGATIONS OF PINAZEPAM (7-CHLORO-1-PROPARGYL-5-PHENYLBENZODIAZEPIN-2-ONE): A NEW THERAPEUTIC AGENT. 221723 04-02

PROGNOSIS OF THE THERAPEUTIC EFFECT OF SUXILEP AND TRIMETIN USING A SUCCESSIONAL STATISTICAL PROCEDURE. 224086 04-11

A STUDY OF THERAPEUTIC INNOVATION. 224972 04-17

ELECTROCARDIOGRAPHIC MONITORING OF ENURETIC CHILDREN RECEIVING THERAPEUTIC DOSES OF IMIPRAMINE. 225336 04-15

CASE PRESENTATION OF AN ALTERNATIVE THERAPEUTIC APPROACH FOR THE BORDERLINE PSYCHOTIC HEROIN ADDICT: DIPHENYLHYDANTOIN. 225512 04-09

THERAPEUTIC-RESISTANT

THERAPEUTIC-RESISTANT DEPRESSIONS: SYMPTOMS, RESISTANCE AND THERAPY. 202854 02-09

THERAPIES

REFLECTIONS ON THE EFFICACY OF NEW DRUG THERAPIES ON THE OCCASION OF USING AN ORIGINAL MEDICATION: SULPIRIDE (DOGMATIL). 209123 03-11

THERAPY

ASSESSMENT OF THERAPY IN PSYCHOGERIATRIC ILLNESS. 194244 01-11

EVALUATION OF LITHIUM THERAPY IN CHRONIC AND PERIODIC ALCOHOLISM. 194758 01-11

GROUP THERAPY AND MAINTENANCE TREATMENT OF SCHIZOPHRENICS. 194860 01-08

NEUROPSYCHOLOGIC MECHANISMS OF LITHIUM THERAPY. 195932 01-09

THERAPY POSSIBILITIES FOR THERAPY-RESISTANT DEPRESSIONS. 196034 01-17

CLINICAL ASPECTS OF RESISTANCE TO IMIPRAMINE THERAPY. 196039 01-11

RECENT THERAPEUTIC ASPECTS OF DEPRESSION ESPECIALLY ON THE DRUG THERAPY. 196149 01-09

ONCE-A-DAY DOSAGE TRICYCLIC ANTIDEPRESSANT DRUG THERAPY: A SURVEY. 196679 01-09

PENFLURIDOL (R-16341) AS A MAINTENANCE THERAPY IN CHRONIC PSYCHOTIC PATIENTS: A DOUBLE-BLIND CLINICAL EVALUATION. 197033 01-09

DRUG THERAPY OF DEPRESSED OUTPATIENTS. 198079 02-10

DRUG THERAPY IN DEPRESSION. 198084 02-09

CLINICAL CHEMICAL CORRELATES OF CPZ THERAPY. 198098 02-08

BIOCHEMICAL MONITORING IN THE THERAPY OF DEPRESSIONS. 198099 02-10

5-HYDROXYTRYPTOPHAN IN COMBINATION WITH CLOMIPRAMINE IN THERAPY RESISTANT DEPRESSIONS. 198229 02-09

A COMPARISON OF THE RELATIVE EFFICACY OF SPECIAL CLASS EDUCATION AND DRUG THERAPY FOR CHILDREN WITH SELECTED LEARNING DISABILITIES. (ED.D. DISSERTATION). 198662 02-11

DRUG THERAPY: BENZODIAZEPINES (FIRST OF TWO PARTS). 199515 02-14

LONG-TERM TREATMENT OF PSYCHIATRIC PATIENTS WITH CLOPENTHIXOL: ANALYSIS OF LABORATORY TESTS WITH A VIEW TO LONG-TERM THERAPY. 199989 02-14

A DOUBLE-BLIND CLINICAL EVALUATION OF PENFLURIDOL (R-16341) AS A MAINTENANCE THERAPY IN SCHIZOPHRENIA. 199993 02-08

THE SPARING TECHNIQUE IN ELECTROCONVULSIVE THERAPY. 200071 02-13

EEG VARIATIONS UNDER ANTABUSE (DISULFIRAM) AND ANTABUSE PLUS ALCOHOL EXPOSITION: A STUDY OF PATHOGENESIS FROM ANTABUSE THERAPY COMPLICATIONS. 200572 02-15

NIACIN THERAPY IN SCHIZOPHRENIA: A REVIEW. 200898 02-08

RESERPINE THERAPY FOR MENOPAUSAL TROUBLE. 201694 02-11

POSSIBILITIES AND LIMITATIONS OF PSYCHOTROPIC THERAPY IN PATIENTS WITH GLAUCOMA. 201911 02-15

ASPECTS OF NEUROLEPTIC DEPOT THERAPY WITH SPECIAL CONSIDERATION OF CLINICAL EXPERIENCE WITH THE PERORAL DEPOT PREPARATION PENFLURIDOL (R-16341 - JANSSEN). 202785 02-07

THERAPEUTIC-RESISTANT DEPRESSIONS: SYMPTOMS, RESISTANCE AND THERAPY. 202854 02-09

LITHIUM THERAPY IN CYCLOTHYMIA. 203600 02-09

TARDIVE DYSKINESIA: AN EVALUATION OF THE ETIOLOGIC ASSOCIATION WITH NEUROLEPTIC THERAPY. 204164 02-15

SIDE-EFFECTS OF METHYLPERONE IN LONG-TERM THERAPY UP TO 8 YEARS. 204406 02-15

FURTHER OBSERVATIONS ON AUTOMATON LIKE EXISTENCE UNDER LONG-TERM LITHIUM THERAPY. 204410 02-15

THERAPEUTIC ROLES OF DRUGS AND MORITA THERAPY PROCESS. 204428 02-10

DRUG THERAPY: BENZODIAZEPINES (SECOND OF TWO PARTS). 205299 02-17

EEG CHANGES BEFORE AND AFTER L-DOPA THERAPY IN PARKINSON PATIENTS. 205569 02-13

PILOT CLINICAL STUDY WITH TRIFLUPERIDOL (TRISEDYL) THERAPY IN PSYCHOTIC PATIENTS. 205589 02-09

SOME SPECIFICITIES IN THE COURSE OF MANIOMELANCHOLIC PSYCHOSIS DURING LITHIUM THERAPY. 205609 03-09

CLOZAPINE IN THE MAINTENANCE THERAPY OF SCHIZOPHRENIA. 205618 03-08

CLOZAPINE IN LONG-TERM THERAPY OF CHRONIC SCHIZOPHRENIA. 206975 03-08

ENHANCED DRUG HYDROXYLATION IN MAN UNDER DIPHENYLHYDANTOIN THERAPY. 206992 03-13

RENAL TUBULAR FUNCTION IN PATIENTS ON LONG-TERM LITHIUM THERAPY. 207043 03-13

RESULTS OF THERAPY WITH LYOGEN DEPOT IN SCHIZOPHRENIC ILLNESS. 208622 03-08

THE CONTROVERSY OVER ORTHOMOLECULAR THERAPY. 208862 03-08

THERAPY WITH LITHIUM SALTS IN MANIC-DEPRESSIVE ILLNESSES. 209070 03-09

CLINICAL COMPARISON OF ANXIOLYTIC DRUG THERAPY. 209080 03-10

A CASE OF NONSPECIFIC PSYCHOSES WHICH MANIFESTED CONVULSIVE SEIZURES DURING LITHIUM THERAPY. 209324 03-15

PLASMA LEVELS OF A NEW PELLETIZED FORM OF AMITRIPTYLINE FOR MAINTENANCE THERAPY. 209789 03-13

MAINTENANCE DOXEPIN (SINEQUAN) THERAPY FOR DEPRESSIVE ILLNESS. 209901 03-09

HEPTAMINOL AND TENSION DISTURBANCES INDUCED BY PSYCHOTROPIC DRUG THERAPY: CLINICAL STUDY. 210089 03-13

THERAPY WITH PSYCHOPHARMACEUTIC AND OTHER PSYCHOTROPIC DRUGS. 210511 03-17

STUDY OF 220 OBSERVATIONS OF LITHIUM THERAPY IN DEPRESSION CASES IN TEHERAN. 212211 03-09

ATYPICAL INDICATION OF LITHIUM THERAPY. 212213 03-09

PSYCHOPHARMACOLOGICAL THERAPY AND THE PROBLEMS OF DELINEATING BORDERLINE FORMS OF NEUROPSYCHIC DISORDERS. 212431 03-17

THERAPY AND LONG-ACTING NEUROLEPTICS. 212774 03-14

PHYSIOLOGIC FACTORS IN PSYCHOTROPIC DRUG THERAPY. 213616 04-03

ACUTE ORGANIC BRAIN SYNDROME: A COMPLICATION OF DISULFIRAM THERAPY. 213710 04-15

DRUG THERAPY FOR STUTTERERS: A REVIEW OF RESEARCH. 213786 04-11

THE SHAPIRO CARDS SCALE AS A METHOD OF ASSESSMENT OF OBSESSIONAL SYMPTOMS IN CLOMIPRAMINE THERAPY.
214829 04-10

DEPRESSIVE REACTIONS IN THE COURSE OF CLOMIPRAMINE THERAPY USED IN THE TREATMENT OF OBSESSIONAL CONDITIONS.
214834 04-15

NONPHARMACOLOGICAL FACTORS IN DRUG THERAPY: THE INTERACTION OF DOCTOR, PATIENT, AND TABLET APPEARANCE IN THE TREATMENT OF ANXIETY/DEPRESSIVE SYNDROMES.
215060 04-10

PSYCHOTROPIC DRUG THERAPY IN A MENTAL HOSPITAL.
215291 04-17

CLINICAL TRIAL OF 3-METHYL-5-BETA-N-N-M-CHLOROPHENYLPIPERAZINOETHYL PYRAZOLE DIHYDROCHLORIDE (MEPIPRAZOL) IN THE THERAPY OF PSYCHOVEGETATIVE DISORDERS.
215694 04-10

PROS AND CONS OF DRUG THERAPY IN THE MANAGEMENT OF THE HYPERACTIVE CHILD.
216966 04-11

DIFFERENTIAL DIAGNOSIS AND THERAPY OF SLEEP DISTURBANCES.
217193 04-11

PLASMA LEVELS OF IMIPRAMINE AND DESMETHYLIMIPRAMINE AND ANTIDEPRESSANT EFFECT DURING CONTROLLED THERAPY.
217477 04-09

TREATING DEPRESSION WITH TRANQUILIZERS: WITH DISSENTING VIEW OF LITHIUM CARBONATE THERAPY.
218123 04-09

RED CELL FOLATE AND MACROCYTOSIS DURING LONG-TERM ANTICONVULSANT THERAPY IN NONANAEMIC MENTALLY RETARDED EPILEPTICS.
218553 04-11

INTERACTION OF DRUG THERAPY WITH MARITAL THERAPY IN DEPRESSIVE PATIENTS.
218769 04-10

CARDIAC ARRHYTHMIA AND IMIPRAMINE THERAPY.
219517 04-15

MEGAVITAMIN AND ORTHOMOLECULAR THERAPY OF SCHIZOPHRENIA.
219536 04-08

CLINICAL STUDY OF HALOPERIDOL. I. TECHNIQUES AND THEORY OF PARENTERAL THERAPY.
220156 04-08

AN ASPECT OF BIOLOGICAL THERAPY IN THE SYSTEM OF REHABILITATING EPILEPTIC PATIENTS WITH MENTAL DISORDERS.
220420 04-11

COMBINATION DRUG THERAPY IN PSYCHOPHARMACOLOGY.
221075 04-17

ANTIDEPRESSIVE THERAPY IN GENERAL PRACTICE.
221348 04-09

NYSTAGMUS AND DISTURBANCES IN PSYCHOMOTOR FUNCTIONS INDUCED BY PSYCHOTROPIC DRUG THERAPY.
221990 04-15

OBSERVATIONS ON THE DOSE REGIME OF FLUPHENAZINE DECANOATE IN MAINTENANCE THERAPY OF SCHIZOPHRENIA.
222602 04-17

SYMPTOMATIC SINUS NODE ABNORMALITIES FOLLOWING LITHIUM CARBONATE THERAPY.
223120 04-15

THE EFFECT OF LONG-TERM PHENOTHIAZINE THERAPY ON PLASMA PROLACTIN.
223777 04-15

DEPRESSED WOMEN ONE YEAR AFTER MAINTENANCE THERAPY.
224766 04-09

RITALIN VERSUS BEHAVIOR THERAPY IN HYPERACTIVE CHILDREN.
224855 04-11

THERAPY-RESISTANCE

ANTAGONISM OF NICOTINIC ACID AND OTHER KYNURENINES TO ANTIDEPRESSANTS: ONE OF THE PROBABLE REASONS FOR THE THERAPY-RESISTANCE IN DEPRESSION?.
215074 04-17

THERAPY-RESISTANT

THERAPY POSSIBILITIES FOR THERAPY-RESISTANT DEPRESSIONS.
196034 01-17

INFLUENCE POSSIBILITIES ON THERAPY-RESISTANT LATE DEPRESSIONS.
196038 01-17

THERAPY-RESISTANT DEPRESSIONS: METHODOLOGICAL PROBLEMS. CONTRIBUTIONS TO METHODICAL QUESTIONS AND ANIMAL EXPERIMENTAL ASPECTS.
203591 02-09

THE BIOCHEMISTRY OF THERAPY-RESISTANT DEPRESSION: CONTRIBUTIONS TO BIOCHEMISTRY.
203592 02-09

THERAPY-RESISTANT DEPRESSIONS. BIOCHEMICAL AND PHARMACOLOGICAL CONSIDERATIONS: CONTRIBUTIONS TO BIOCHEMISTRY.
203593 02-09

THERMAL

MODIFICATION BY L-DOPA METHYLESTER (H-19-61) OF AMPHETAMINE-INDUCED BRAIN CATECHOLAMINE CHANGES, THERMAL RESPONSES AND TOXICITY IN DEVELOPING MICE.
210891 03-03

THERMO-GAS

MICROMETHODS FOR QUANTITATIVE DETERMINATION OF SEDATIVES AND ANTIPYRETICS BY THERMO-GAS CHROMATOGRAPHY.
206807 03-06

THERMOREGULATION

D-AMPHETAMINE AND THE SENSORY ROLE OF A RATS TAIL IN THERMOREGULATION OR WHAT THE RATS TAIL TELLS THE RATS BRAIN.
209961 03-03

5-HT AND NOREPINEPHRINE-INDUCED RELEASE OF ACH FROM THE THALAMUS AND MESENCEPHALON OF THE MONKEY DURING THERMOREGULATION.
210672 03-03

THERMOREGULATORY

INTERRELATION BETWEEN MONOAMINERGIC AND CHOLINERGIC MECHANISMS IN THE HYPOTHALAMIC THERMOREGULATORY CENTRE OF RABBITS.
195249 01-03

THETA

DECREASED TEMPORAL VARIABILITY IN HIPPOCAMPAL THETA RHYTHMS OF CATS ADMINISTERED METHYLPHENIDATE.
213855 04-03

BEHAVIORALLY EVOKED HIPPOCAMPAL THETA WAVES: A CHOLINERGIC RESPONSE.
220312 04-03

THIADIPONE

PHARMACOLOGICAL PROPERTIES OF 6,7 TETRAMETHYLENE-5-PHENYL-1-2-DIHYDRO 3H THIENODIAZEPIN-2-ONE (QM-6008), THIADIPONE), A NEW PSYCHOTROPIC DRUG.
221722 04-02

THIENODIAZEPIN-2-ONE

PHARMACOLOGICAL PROPERTIES OF 6,7 TETRAMETHYLENE-5-PHENYL-1-2-DIHYDRO 3H THIENODIAZEPIN-2-ONE (QM-6008), THIADIPONE), A NEW PSYCHOTROPIC DRUG.
221722 04-02

THIENODIAZEPINE

A DOUBLE-BLIND CONTROLLED STUDY OF THE THIENODIAZEPINE DERIVATIVE (Y-6047) ON NEUROTICS AND PSYCHOSOMATIC DISORDERS.
210559 03-14

THIETANES

THIETANES AS POTENTIAL MAO INHIBITORS AND ANALGETICS. (PH.D. DISSERTATION).
194563 01-01

THIETE

CRYSTAL STRUCTURE DETERMINATIONS OF THE DONOR ACCEPTOR COMPLEXES OF PHENOTHIAZINE AND PHENOXAZINE WITH NICKEL THIETE. (PH.D. DISSERTATION).
201003 02-01

THINKING

THE EFFECTS OF THIORIDAZINE ON LANGUAGE AND THINKING.
198104 02-08

THIOPENTAL

ALTERATIONS IN ACID-BASE BALANCE IN THE DOG AFTER INTRAVENOUS ADMINISTRATION OF BENZOCTAMINE AND DIAZEPAM, COMPARED WITH THOSE INDUCED BY THIOPENTAL.
197485 01-03

THE ACTIVATION OF THE KININ FORMING SYSTEM AND THE EFFECTS OF THIOPENTAL.
210744 03-03

THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL PRETREATMENT ON KETAMINE, THIOPENTAL OR CT-1341 -- INDUCED LOSS OF RIGHTING REFLEX IN MICE.
210878 03-02

ON THE MECHANISM OF POTENTIATION BY MORPHINE OF THIOPENTAL SLEEPING TIME.
215666 04-03

THE METABOLISM OF INDIVIDUAL PHOSPHOLIPID FRACTIONS IN THE RAT BRAIN DURING THIOPENTAL SLEEP AND AMPHETAMINE EXCITATION.
219747 04-03

THIOPHENE

A DUAL STUDY. PART I: SYNTHESIS AND STEREOCHEMISTRY OF SOME 1 SUBSTITUTED QUINOLIZIDINES AS ANALOGS OF BIOLOGICALLY ACTIVE COMPOUNDS. PART II: AMINO DERIVATIVES OF THIOPHENE FUSED CYCLIC KETONES AS POTENTIAL CNS. (PH.D. DISSERTATION).
196252 01-01

THIOPROPERAZINE

A CLINICAL TRIAL WITH THIOPROPERAZINE (MAJEPTIL M & B) -- A COMPARISON WITH CHLORPROMAZINE.
194311 01-11

THIORIDAZINE

THIOTHIXENE AND THIORIDAZINE IN ANXIETY.
194045 01-10

A COMPARISON OF PIMOZIDE AND THIORIDAZINE AS ANTAGONISTS OF AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR IN DOGS.
197470 01-04

THE EFFECTS OF THIORIDAZINE ON LANGUAGE AND THINKING.
198104 02-08

THIORIDAZINE: CENTRAL DOPAMINE TURNOVER AND CLINICAL EFFECTS OF ANTIPSYCHOTIC DRUGS.
204852 02-08

HYDERGINE THIORIDAZINE COMBINATION IN THE TREATMENT OF PSYCHOPATHOLOGICAL STATES IN OLD AGE.
205637 03-11

PLASMA LEVELS AND CLINICAL EFFECTS OF THIORIDAZINE AND THIOTHIXENE.
209790 03-08

DOPAMINE ANTAGONISM BY THIORIDAZINE IN SCHIZOPHRENIA.
213527 04-08

A COMPARISON OF THE THERAPEUTIC EFFECT OF OXYPERTINE AND THIORIDAZINE IN CHRONIC SCHIZOPHRENIA (A CONTROLLED TRIAL).
215075 04-08

ABSORPTION AND EXCRETION OF THIORIDAZINE AND MESORIDAZINE IN MAN.
217154 04-08

EFFECTS OF CLOZAPINE, THIORIDAZINE, PERLAPINE AND HALOPERIDOL ON THE METABOLISM OF THE BIOGENIC AMINES IN THE BRAIN OF THE RAT.
217543 04-03

ON THE PHARMACOKINETICS OF THIORIDAZINE.
221629 04-13

A STATISTICAL ANALYSIS OF THE COMPARATIVE DOUBLE-BLIND STUDY OF THE ACTIVITY OF LOXAPINE AND THIORIDAZINE.
221671 04-11

PHARMACOKINETICS OF CHLORDIAZEPOXIDE, MEPERIDINE, THIORIDAZINE, AND MESORIDAZINE AND CLINICAL RESPONSE.
224830 04-13

COMPARATIVE SYMPTOMATOLOGICAL AND EVOKED POTENTIAL STUDIES WITH D-AMPHETAMINE, THIORIDAZINE, AND PLACEBO IN HYPERKINETIC CHILDREN.
225516 04-10

THIOTHIXENE

ONCE VERSUS THRICE DAILY THIOTHIXENE IN THE TREATMENT OF SCHIZOPHRENIC INPATIENTS.
194044 01-08

THIOTHIXENE AND THIORIDAZINE IN ANXIETY.
194045 01-10

EFFECT OF THIOTHIXENE UPON THE HIGHER NERVOUS ACTIVITY IN CHRONIC SCHIZOPHRENICS.
195041 01-09

HALOPERIDOL FOR CHRONICALLY HOSPITALIZED PSYCHOTICS: A DOUBLE-BLIND COMPARISON WITH THIOTHIXENE AND PLACEBO: A FOLLOWUP OPEN EVALUATION.
196676 01-14

CLINICAL TRENDS AND PSYCHOMETRIC APPRAISAL OF A GROUP OF SCHIZOPHRENICS TREATED WITH THIOTHIXENE (NAVANE).
208981 03-08

EFFECTIVENESS OF LOXAPINE SUCCINATE IN ACUTE SCHIZOPHRENIA: A COMPARATIVE STUDY WITH THIOTHIXENE.
209484 03-08

PLASMA LEVELS AND CLINICAL EFFECTS OF THIORIDAZINE AND THIOTHIXENE.
209790 03-08

THIRST

POLYETHYLENE GLYCOL INDUCED THIRST: A DUAL STIMULATORY MECHANISM?
219071 04-04

THOUGHT

PHENOTHIAZINE AND SCHIZOPHRENIC THOUGHT DISORDER.
198102 02-08

THOUGHT DISORDERS IN SCHIZOPHRENIA BEFORE AND AFTER PHARMACOLOGICAL TREATMENT.
207767 03-17

THOUGHTS

RECOVERY OF FUNCTION: SOME NEW THOUGHTS ON AN OLD PROBLEM. (PH.D. DISSERTATION).
219268 04-04

THRESHOLD

SEROTONIN AND THE AVERSIVE THRESHOLD IN RATS.
193157 01-04

THE EFFECT OF CHLORPROMAZINE AND IMIPRAMINE ON THE AVERSIVE THRESHOLD OF RATS.
195294 01-04

EFFECTS OF 5-HYDROXYTRYPTOPHAN, IPRONIAZID AND P-CHLOROPHENYLALANINE ON LIDOCAINE SEIZURE THRESHOLD OF MICE.
199962 02-03

POTENTIATION OF JUMPING BEHAVIOR BY AMINOPHYLLINE IN MICE TREATED WITH THRESHOLD DOSES OF AMPHETAMINE AND DOPA.
200039 02-04

EFFECTS ON THE ACQUISITION OF CONDITIONED AVOIDANCE RESPONSES AND SEIZURE THRESHOLD IN THE OFFSPRING OF AMPHETAMINE TREATED GRAVID RATS.
202722 02-05

THE EFFECT OF WITHDRAWAL FROM CANNABIS ON PENTYLENETETRAZOL CONVULSIVE THRESHOLD IN MICE.
206355 03-04

EFFECTS OF ACTH, DEXAMETHASONE AND DEOXYCORTICOSTERONE ON AVERSIVE THRESHOLD OF RATS.
221766 04-04

THRESHOLDS

THE ALTERATION OF AVERSIVE THRESHOLDS AFTER CHRONIC ADMINISTRATION OF TWO TRANQUILIZING AGENTS.
205418 02-04

THRICE

ONCE VERSUS THRICE DAILY THIOTHIXENE IN THE TREATMENT OF SCHIZOPHRENIC INPATIENTS.
194044 01-08

AN INTERIM REPORT OF A DOUBLE-BLIND STUDY COMPARING A ONCE DAILY DOSAGE OF MAPROTILINE (LUDIOMIL) WITH AMITRIPTYLINE THRICE DAILY.
221661 04-09

THROMBOCYTES

INTRA-EXTRACELLULAR LITHIUM RATIO: CLINICAL AND EXPERIMENTAL FINDINGS ON THROMBOCYTES AND ERYTHROCYTES.
204393 02-13

COMPARISON OF THE EFFECTS OF TETRACYCLIC AND TRICYCLIC ANTIDEPRESSANTS ON THE SEROTONIN UPTAKE BY HUMAN THROMBOCYTES IN VITRO.
217258 04-13

SIMILARITIES OF THE INFLUENCE OF SECONDARY AND TERTIARY TRICYCLIC ANTIDEPRESSANTS ON THE EFFECT OF RESERPINE IN FROGS AND ON THE SEROTONIN UPTAKE OF HUMAN THROMBOCYTES.
219503 04-13

THYMOLEPTIC

EXPERIMENTAL PSYCHOLOGIC AND PSYCHOPHYSIOLOGIC LONGITUDINAL PROFILE STUDIES ON DEPRESSIVE PATIENTS UNDER THYMOLEPTIC MEDICATION.
204413 02-15

THYMOLEPTICS

THE PROBLEM OF SIDE-EFFECTS OF THYMOLEPTICS.
205620 03-15

COMPARATIVE STUDIES OF A NEW 5-HT UPTAKE INHIBITOR AND SOME TRICYCLIC THYMOLEPTICS.
217663 04-03

THYROID

THE EFFECT OF LITHIUM ON THYROID FUNCTIONING: A CONTROLLED STUDY.
195916 01-09

ACCELERATION OF ANTIDEPRESSANTS BY THYROID HORMONE.
198082 02-07

THYROID AXIS -- DRUGS AND BEHAVIOR.
198592 02-14

LITHIUM TREATMENT AND THYROID FUNCTION IN MAN.
205611 03-15

COMBINED THYROID (TRIIODOTHYRONINE) TRICYCLIC ANTIDEPRESSANT TREATMENT IN DEPRESSIVE STATES.
207720 03-09

CLINICAL EXPERIENCES IN TREATING DEPRESSED PATIENTS WITH A COMBINATION OF TRICYCLIC DRUGS AND THYROID EXTRACT.
209144 03-09

THYROSTIMULIN

AN ATTEMPT TO VERIFY THE ANTIDEPRESSANT ACTION OF THE HYPOTHALAMIC THYROSTIMULIN (THYROTROPIN-RELEASING FACTOR OR TRF) IN MELANCHOLIC STATES.
216758 04-09

THYROTROPIN

NEUROTRANSMITTER CONTROL OF THYROTROPIN SECRETION IN THE RAT.
210858 03-03

THYROTROPIN-RELEASING

THYROTROPIN-RELEASING HORMONE (TRH) IN DEPRESSION: A PRELIMINARY REPORT.
195929 01-10

A POSSIBLE MECHANISM FOR THE ANTIDEPRESSANT ACTIVITY OF THYROTROPIN-RELEASING HORMONE.
196836 01-13

THYROTROPIN-RELEASING HORMONE: ACTIVATION OF CEREBRAL NORADRENALINE TURNOVER.
197950 01-03

NEUROTROPIC EFFECTS OF THYROTROPIN-RELEASING HORMONE (TRH).
197953 01-04

GROWTH HORMONE AND PROLACTIN RELEASE AFTER INJECTION OF THYROTROPIN-RELEASING HORMONE IN PATIENTS WITH DEPRESSION.
214885 04-13

EFFECTS OF THYROTROPIN-RELEASING HORMONE (TRH) ON THE ACTIONS OF PENTOBARBITAL AND OTHER CENTRALLY ACTING DRUGS.
215692 04-03

AN ATTEMPT TO VERIFY THE ANTIDEPRESSANT ACTION OF THE HYPOTHALAMIC THYROSTIMULIN (THYROTROPIN-RELEASING FACTOR OR TRF) IN MELANCHOLIC STATES.
216758 04-09

THYROTROPIN-RELEASING HORMONE IN DEPRESSION.
219521 04-09

THE EFFECTS OF THYROTROPIN-RELEASING HORMONE ON THE BEHAVIOUR OF RATS PRETREATED WITH ALPHA-METHYLTYROSINE.
222815 04-04

THYROXINE

THYROXINE AND BRAIN CATECHOLAMINES: INCREASED TRANSMITTER SYNTHESIS AND INCREASED RECEPTOR SENSITIVITY.
193541 01-03

EFFECT OF THYROXINE AND CORTISOL ON BRAIN ORNITHINE DECARBOXYLASE ACTIVITY AND SWIMMING BEHAVIOR IN DEVELOPING RAT.
210933 03-03

FREE THYROXINE INDEX AND ABSOLUTE FREE THYROXINE IN PATIENTS WITH AFFECTIVE DISORDERS TREATED WITH LITHIUM CARBONATE.
216747 04-09

THYROXINE-LIKE

THYROXINE-LIKE EFFECTS OF ZINC ON BRAIN AND BEHAVIOUR WITH FIRM DEPENDENCE ON SEVERAL HORMONES.
213434 04-04

TIC

MULTIPLE TIC SYNDROME (GILLES-DE-LA-TOURETTES SYNDROME): CLINICAL, BIOLOGICAL, AND PSYCHOSOCIAL VARIABLES AND THEIR INFLUENCE WITH HALOPERIDOL.
199473 02-11

TICS

THE USE OF HALOPERIDOL IN THE TREATMENT OF A PSYCHOTIC CHILD WITH MULTIPLE TICS: A CASE REPORT.
194710 01-11

SIGNS, COURSE AND PROGNOSIS OF TICS IN CHILDREN AND JUVENILES.
203881 02-14

TIME

TREATMENT OF SCHIZOPHRENIA BY THE ADMINISTRATION OF A SMALL DOSE OF FORIT FOR COMPARATIVELY LONG PERIODS OF TIME.
194476 01-08

PROLONGED PENTOBARBITAL SLEEPING TIME IN ADJUVANT INDUCED POLYARTHRITIC RATS.
196228 01-04

THE EFFECT OF BETA-THIAMINOKETONES ON THE AMINOPYRINE-N-DEMETHYLATION IN VITRO AND IN VIVA SUCH AS THE HEXOBARBITAL SLEEPING TIME AND L-ASCORBIC ACID EXCRETION IN THE RAT.
197469 01-03

CADMIUM-INDUCED POTENTIATION OF HEXOBARBITAL SLEEP TIME IN RATS.
197684 01-04

EFFECT OF DELTA8-THC ON ALCOHOL-INDUCED SLEEPING TIME IN THE RAT.
200041 02-03

THE EFFECT OF OZONE ON PENTOBARBITAL SLEEPING TIME IN MICE.
204862 02-02

STUDIES ON THE TIME COURSE AND THE EFFECT OF CHOLINERGIC AND ADRENERGIC RECEPTOR BLOCKERS ON THE STIMULUS EFFECT OF NICOTINE.
206353 03-03

THE EFFECT OF CAFFEINE ON BARBITURATE SLEEPING TIME AND BRAIN LEVEL.
214109 04-03

TREATMENT OF ACUTE SCHIZOPHRENIA WITH ULTRA-HIGH-DOSE FLUPHENAZINE: A FAILURE AT SHORTENING TIME ON A CRISIS INTERVENTION UNIT.
215456 04-08

ON THE MECHANISM OF POTENTIATION BY MORPHINE OF THIOPENTAL SLEEPING TIME.
215666 04-03

INTERRESPONSE TIME CHANGES AS A FUNCTION OF WATER DEPRIVATION AND AMPHETAMINE.
217459 04-04

TIME TO EVALUATE LONG-ACTING NEUROLEPTICS?
224417 04-08

TIME-DEPENDENT

TIME-DEPENDENT, MEMORY RETRIEVAL EFFECTS FOLLOWING PERIPHERAL AND HIPPOCAMPAL TREATMENTS TO INCREASE SYNAPTIC BIOGENIC AMINES. (PH.D. DISSERTATION).
194677 01-04

TIME-DEPENDENT EFFECTS OF PHENOTHIAZINES ON DOPAMINE TURNOVER IN PSYCHIATRIC PATIENTS. (UNPUBLISHED PAPER).
196087 01-13

EFFECTS OF CENTRAL AND PERIPHERAL ADRENERGIC AND CHOLINERGIC MODIFICATION ON TIME-DEPENDENT PROCESSES IN AVOIDANCE PERFORMANCE.
202203 02-03

TIME-DEPENDENT CHANGES IN AMPHETAMINE SELF-ADMINISTRATION FOLLOWING FRONTAL CORTEX ABLATIONS IN RATS.
206747 03-04

FACILITATION OF TIME-DEPENDENT MEMORY PROCESSES WITH POSTTRIAL EPINEPHRINE INJECTIONS.
209951 03-04

COMPARATIVE TIME-DEPENDENT CHANGES IN SENSITIVITY TO LOCOMOTOR EFFECTS OF D-AMPHETAMINE IN MICE WITH CAUDATE, HIPPOCAMPAL OR FRONTAL CORTICAL LESIONS.
210926 03-03

TIMES

THE EFFECTS OF A NEW SEDATIVE (LEXOTAN) ON REACTION TIMES AND ON ATTENTIVE CAPACITY OF A GROUP OF ATHLETES.
209857 03-14

A DOUBLE-BLIND COMPARISON OF THREE TIMES DAILY AND SINGLE NIGHT DOSAGE OF THE TRICYCLIC ANTIDEPRESSANT DOTHIEPIN.
216463 04-09

TIMIDITY

ISOLATION INDUCED TIMIDITY IN MICE AS A MEASURE OF ANXIOLYTIC ACTIVITY OF DRUGS.
215063 04-04

TISSUE

A METHOD FOR THE ISOLATION AND DETERMINATION OF 3-METHOXYTYRAMINE IN BRAIN TISSUE.
193302 01-03

EFFECT OF COPPER LOADING ON VARIOUS TISSUE ENZYMES AND BRAIN MONOAMINES IN THE RAT.
193577 01-03

PERIPHERAL TISSUE DISTRIBUTION, BRAIN DISTRIBUTION AND METABOLISM OF MESCALINE-14C IN MONKEYS.
197458 01-03

NEONATAL CHEMICAL SYMPATHECTOMY: FUNCTIONAL CONTROL OF DENERVATION OF THE VASCULAR SYSTEM AND TISSUE NORADRENALINE LEVEL IN THE RAT AFTER 6-HYDROXYDOPAMINE.
197584 01-03

MORPHOLOGICAL, BIOCHEMICAL, AND FUNCTIONAL CHANGES IN CHICK EMBRYONIC BRAIN TISSUE AFTER INTRACEREBRAL ADMINISTRATION OF OUABAIN.
197788 01-03

KINETICS OF 14C-DOPAMINE IN ISOLATED RAT STRIATAL TISSUE UNDER THE INFLUENCE OF MORPHINE.
197954 01-03

UPTAKE AND RELEASE OF POSSIBLE FALSE TRANSMITTER AMINO ACIDS BY RAT BRAIN TISSUE.
199788 02-03

TISSUE METABOLITES OF TRIFLUOPERAZINE, FLUPHENAZINE, PROCHLORPERAZINE, AND PERPHENAZINE IN THE RAT: IDENTIFICATION AND SYNTHESIS.
200738 02-01

THE IMPORTANCE OF NEURONAL UPTAKE OF AMINES FOR AMPHETAMINE-INDUCED RELEASE OF 3H-NOREPINEPHRINE FROM ISOLATED BRAIN TISSUE.
202191 02-03

FACTORS INFLUENCING BRAIN AND TISSUE LEVELS OF TRYPTAMINE: SPECIES, DRUGS AND LESIONS.
210850 03-03

THE EFFECT OF CERTAIN TRANQUILISERS, CHLORPROMAZINE METABOLITES AND DIETHYLDITHIOCARBAMATE ON TISSUE AMPHETAMINE LEVELS IN THE RAT.
211111 03-03

STUDIES ON THE DISTINCTION BETWEEN UPTAKE INHIBITION AND RELEASE OF H3-DOPAMINE IN RAT BRAIN TISSUE SLICES.
215756 04-03

THE EFFECT OF ETHYMIZOL ON THE CONTENT OF CYCLIC 3,5 ADENOSINE-MONOPHOSPHATE IN BRAIN TISSUE.
217065 04-03

3H-NORTRIPTYLINE UPTAKE AND TISSUE BINDING IN VITRO AND ITS EFFECT ON 3H-NORADRENALINE UPTAKE.
220949 04-03

TISSUES

GLC DETERMINATION OF PROPRANOLOL, OTHER BETA-BLOCKING DRUGS, AND METABOLITES IN BIOLOGICAL FLUIDS AND TISSUES.
200740 02-16

SELECTIVE INHIBITION OF DOPAMINE-BETA-HYDROXYLASE IN THE PERIPHERAL TISSUES BY 5-DIMETHYLDITHIOCARBAMYLPICOLINIC ACID; ITS EFFECT ON STRESS INDUCED ULCER, ETHANOL INDUCED SLEEP AND BLOOD PRESSURE.
204484 02-03

THE EFFECT OF CHRONIC LITHIUM APPLICATION ON THE MINERAL CONTENT OF RAT BONE AND SOFT TISSUES.
215695 04-05

THE EFFECT OF CATECHOLAMINES ON THE NOREPINEPHRINE LEVEL IN THE TISSUES.
219506 04-03

TITRATION

CHEMISTRY OF NONAQUEOUS TITRATION OF CHLORPROMAZINE.
206460 03-01

TLC

PRACTICAL KINETICS I: QUANTITATION OF BARBITURATE STABILITY BY TLC.
211007 03-06

TLP-609
CLINICAL EXPERIENCE OF THE USE OF PENFLURIDOL (TLP-609) FOR THE TREATMENT OF SCHIZOPHRENIA.
194457 01-08

TOKEN
THE EFFECTIVENESS OF RITALIN AND TOKEN ECONOMY IN INCREASING HYPERKINETIC CHILDRENS COLORING BEHAVIOR. (PH.D. DISSERTATION).
220510 04-14

TOLERANCE
ABSENCE OF TOLERANCE TO THE HYPOTENSIVE EFFECTS OF DELTA9-TETRAHYDROCANNABINOL IN HYPERTENSIVE RATS.
193419 01-03
TOLERANCE DEVELOPMENT TO THE ANTINOCICEPTIVE ACTIONS OF MORPHINE, AMPHETAMINE, PHYSOSTIGMINE AND 2-AMINOINDANE IN THE MOUSE.
194930 01-03
A STUDY OF THE DEVELOPMENT OF TOLERANCE TO AN ANTICONVULSANT EFFECT OF DELTA9-TETRAHYDROCANNABINOL AND CANNABIDIOL.
195117 01-03
ACUTE TOLERANCE, AND DEPENDENCE IN GUINEA-PIG ILEUM.
197304 01-03
STUDIES ON EEG TOLERANCE TO MARIJUANA IN THE RAT.
197473 01-03
TOLERANCE TO THE HYPOTHERMIC AND AGGRESSION ATTENUATING EFFECT OF DELTA8- AND DELTA9-TETRAHYDROCANNABINOL IN MICE.
197866 01-04
PLASMA TRYPTOPHAN TOLERANCE CURVES IN DRUG-FREE NORMAL CONTROLS, SCHIZOPHRENIC PATIENTS AND PRISONER VOLUNTEERS.
200773 02-13
TOLERANCE TO THE STIMULANT EFFECTS OF MORPHINE AND PENTAZOCINE ON AVOIDANCE RESPONDING IN THE RAT.
201319 02-04
INHIBITION OF AMPHETAMINE TOLERANCE AND METABOLISM BY PROPRANOLOL.
202662 02-03
A POLYGRAPHIC STUDY OF TOLERANCE OF SCHIZOPHRENICS TO CHLORPROMAZINE.
204430 02-08
EXPERIMENTAL TESTS OF HYPOTHESES ABOUT NEUROCHEMICAL MECHANISMS UNDERLYING BEHAVIORAL TOLERANCE TO THE ANTICHOLINESTERASE, DIISOPROPYLFLUOROPHOSPHATE.
208555 03-03
LACK OF TOLERANCE TO THE BRADYCARDIC EFFECT OF DELTA9-TRANS-TETRAHYDROCANNABINOL IN RATS.
210873 03-05
TOLERANCE DEVELOPMENT WITH CHLORDIAZEPOXIDE IN RELATION TO THE PLASMA LEVELS OF THE PARENT COMPOUND AND ITS MAIN METABOLITES IN MICE.
210973 03-03
TOLERANCE DEVELOPMENT TO THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON CONDITIONED BEHAVIOR: ROLE OF TREATMENT INTERVAL AND INFLUENCE OF MICROSOMAL METABOLISM.
215726 04-03
EVIDENCE AGAINST THE INVOLVEMENT OF FALSE NEUROTRANSMITTERS IN TOLERANCE TO AMPHETAMINE-INDUCED HYPERTHERMIA IN THE RAT.
217690 04-03
THE EFFECT OF 6-HYDROXYDOPAMINE ON THE TOLERANCE DEVELOPMENT TO THE HYPERTHERMIC EFFECT OF (+) AMPHETAMINE IN THE RAT.
217965 04-03
MORPHINE SENSITIVITY AND TOLERANCE: A GENETIC INVESTIGATION IN THE MOUSE.
221037 04-03
ASSESSMENT OF TOLERANCE TO BARBITAL BY MEANS OF DRUG DISCRIMINATION PROCEDURES.
221046 04-02

TOLERANT
EFFECTS OF MORPHINE, CHOLINERGIC AGENTS AND COLD EXPOSURE ON MIDBRAIN DOPAMINE (DA) NERVE CELLS OF MORPHINE TOLERANT AND NONTOLERANT MICE.
197287 01-03
ACTION OF RESERPINE IN MORPHINE TOLERANT RATS: ABSENCE OF AN ANTAGONISM OF CATECHOLAMINE DEPLETION.
199277 02-03
EFFECTS OF DELTA8-THC ON DISSOCIATION OF CONDITIONED AVOIDANCE RESPONDING IN TOLERANT AND NONTOLERANT RATS.
202969 02-04
METABOLISM OF DELTA1-TETRAHYDROCANNABINOL BY RATS TOLERANT TO CANNABIS.
211100 03-03

TOLUIDINE
THE INHIBITORY EFFECT OF TOLUIDINE BLUE AND METHYLENE BLUE ON RAT MAST CELL DAMAGE BY PROMETHAZINE, CHLORPROMETHAZINE AND CHLORPROMAZINE. ITS REVERSAL BY GLUCOSE.
199255 02-05

TONE
EFFECTS OF D-AMPHETAMINE AND PRESESSION SHOCKS ON SIDMAN AVOIDANCE WITH A TONE IN RATS. (PH.D. DISSERTATION).
212677 03-04

TONIC
TONIC IMMOBILITY IN CHICKENS: POSSIBLE INVOLVEMENT OF MONOAMINES.
217762 04-03

TOOTH
THE EFFECTS OF CORD SECTION UNDER ETHER OR HALOTHANE ON THE ABILITY OF CHLORPROMAZINE TO AFFECT THE JAW-JERK RESPONSE TO TOOTH PULP STIMULATION IN THE ENCEPHALE ISOLE PREPARATION.
197451 01-03

TOPOGRAPHY
AMPHETAMINE STEREOTYPY: THE INFLUENCE OF ENVIRONMENTAL FACTORS AND PREPOTENT BEHAVIORAL PATTERNS ON ITS TOPOGRAPHY AND DEVELOPMENT.
213531 04-04
INFLUENCE OF RESPONSE TOPOGRAPHY ON THE EFFECT OF APOMORPHINE AND AMPHETAMINE ON OPERANT BEHAVIOR OF PIGEONS.
217468 04-04

TOURETTES
A FOLLOWUP OF TOURETTES SYNDROME IN SEVENTY-SEVEN PATIENTS.
224910 04-11

TOURNIQUET
MILD ANALGESICS EVALUATED WITH THE SUBMAXIMUM EFFORT TOURNIQUET TECHNIQUE. I. THE INFLUENCE OF PSYCHOLOGICAL FACTORS ON THEIR EFFECT.
197861 01-14
MILD ANALGESICS EVALUATED WITH THE SUBMAXIMUM EFFORT TOURNIQUET TECHNIQUE: II. THE INFLUENCE OF A TRANQUILLIZER ON THEIR EFFECT.
197862 01-13

TOXIC
INFLUENCE OF THERAPEUTIC AND TOXIC DOSES OF NEUROLEPTICS AND ANTIDEPRESSANTS ON ENERGY METABOLISM OF THE ISOLATED PERFUSED RAT BRAIN.
195236 01-03
ANTICHOLINERGIC TOXIC PSYCHOSIS IN DRUG ABUSERS TREATED WITH BENZTROPINE.
197539 01-15
ACUTE TOXIC PSYCHOSIS IN TWO CHILDREN TREATED WITH BENZHEXOL HYDROCHLORIDE (ARTANE).
205315 02-15
COGNITIVE AND MOTOR SENSORY PERFORMANCES IN TOXIC AND NONTOXIC EPILEPTIC SUBJECTS.
210824 03-15
COMPARISON OF CARDIOVASCULAR, HYPERTHERMIC, AND TOXIC EFFECTS OF P-METHOXYAMPHETAMINE (PMA) AND 3,4 METHYLENEDIOXYAMPHETAMINE (MDA).
217578 04-05
INHIBITION OF SEROTONIN UPTAKE AND THE TOXIC INTERACTION BETWEEN MEPERIDINE AND MONOAMINEOXIDASE INHIBITORS.
217696 04-03
PSYCHOPHYSICAL EVALUATION OF TOXIC EFFECTS ON SENSORY SYSTEMS.
225166 04-03

TOXICITIES
ACUTE, SUBACUTE AND 23-DAY CHRONIC MARIHUANA INHALATION TOXICITIES IN THE RAT.
193576 01-04

TOXICITY
CHRONIC ORAL TOXICITY OF CANNABINOIDS IN MONKEYS.
193417 01-05
REDUCTION BY DIAZEPAM OF REPETITIVE ELECTRICAL ACTIVITY AND TOXICITY RESULTING FROM SOMAN.
199861 02-03
DUAL MECHANISM OF AMPHETAMINE TOXICITY IN MICE: RELATIONSHIP TO BRAIN CATECHOLAMINES.
199898 02-05
THE ROLE OF SEROTONIN IN THE PATHOPHYSIOLOGY OF MYOCLONIC SEIZURES ASSOCIATED WITH ACUTE IMIPRAMINE TOXICITY.
200088 02-03
THE TOXICITY OF CHLORPROMAZINE AND MESCALINE ON MOUSE CEREBELLUM AND FIBROBLAST CELLS IN CULTURE.
210890 03-03
MODIFICATION BY L-DOPA METHYLESTER (H-19-61) OF AMPHETAMINE-INDUCED BRAIN CATECHOLAMINE CHANGES, THERMAL RESPONSES AND TOXICITY IN DEVELOPING MICE.
210891 03-03
CARDIOPULMONARY TOXICITY OF DELTA9-TETRAHYDROCANNABINOL IN THE ANESTHETIZED DOG.
211015 03-05
THE EFFECT OF COLD AND DIAZEPAM ON THE TOXICITY OF FENFLURAMINE IN MICE.
215160 04-05

ORAL DELTA9-TETRAHYDROCANNABINOL TOXICITY IN RATS TREATED UP TO SIX MONTHS.
217518 04-05

BENZODIAZEPINES: SAFETY AND TOXICITY.
218155 04-15

LITHIUM TOXICITY PRECIPITATED BY DIURETICS.
219353 04-15

EFFECT OF ETHANOL ON TOXICITY AND METABOLISM OF AMPHETAMINE IN THE MOUSE.
220950 04-05

AMPHETAMINE TOXICITY: BEHAVIORAL AND NEUROPATHOLOGICAL INDEXES.
225165 04-05

ACUTE TOXICITY OF ANTIEPILEPTIC DRUGS.
225539 04-15

TOXICOLOGIC

THE TOXICOLOGIC AND TERATOLOGIC EFFECTS OF DELTA9-TETRAHYDROCANNABINOL IN THE ZEBRAFISH EMBRYO.
217697 04-05

TOXICOLOGICAL

PHARMACOLOGICAL AND TOXICOLOGICAL STUDY OF A NEW PSYCHOTROPIC STIMULANT: THE 2-PHENYLDIMETHYL-TETRAHYDROOXAZINE, IN COMPARISON WITH D,L-AMPHETAMINE, PHENMETRAZINE AND PEMOLINE-MG.
199211 02-04

PHARMACOLOGICAL AND TOXICOLOGICAL PROPERTIES OF CLOBAZAM (1-PHENYL-5-METHYL-8-CHLORO 1,2,4,5-TETRAHYDRO-2,4-DIKETO-3H-1,5 BENZODIAZEPINE), A NEW PSYCHOTHERAPEUTIC AGENT.
199912 02-05

TOXICOLOGICAL AND TERATOLOGICAL STUDY OF 2-PHENYLDIMETHYLTETRAHYDROOXAZINE HYDROCHLORIDE (G-130), A PSYCHOSTIMULANT DRUG.
206783 03-05

TOXICOLOGICAL AND PHARMACOLOGICAL INVESTIGATIONS OF PINAZEPAM (7-CHLORO-1-PROPARGYL-5-PHENYLBENZODIAZEPIN-2-ONE): A NEW THERAPEUTIC AGENT.
221723 04-02

TOXICOMANIA

FUTURE DEVELOPMENT OF PHARMACOTHERAPY AND TOXICOMANIA.
207100 03-17

TOXOID

THE EFFECT OF L-DOPA AND L-DOPA COMBINED WITH CHLORPROMAZINE ON SPINAL CORD ACTIVITY DURING DISTURBED INHIBITION BY TETANUS TOXOID.
207200 03-03

TRACE

THE INFLUENCE OF CHOLINOMIMETICS ON THE AFTEREFFECTS OF TRACE DISCHARGES AND THE ACTIVITY OF EPILEPTOGENIC FOCI IN THE RABBIT HIPPOCAMPUS.
219499 04-03

TRACT

PHARMACOLOGY OF PYRAMIDAL TRACT CELLS IN THE CEREBRAL CORTEX: NORADRENALINE AND RELATED SUBSTANCES.
195438 01-03

A COMPARISON OF THE ACTION OF THE TRICYCLIC ANTIDEPRESSANTS, AZAPHEN AND IMIPRAMINE, ON THE GASTROINTESTINAL TRACT OF TEST ANIMALS.
219505 04-03

TRAFFIC

VOLATILE SOLVENT ADDICTION AND TRAFFIC SAFETY.
205596 02-15

TRAILS

CLINICAL TRAILS OF SULPIRIDE WITH EMPHASIS ON NEUROTIC OUTPATIENTS.
224194 04-10

TRAINED

EFFECT OF LOPERAMIDE, HALOPERIDOL AND METHADONE IN RATS TRAINED TO DISCRIMINATE MORPHINE FROM SALINE.
225568 04-04

TRAINING

HALOPERIDOL INDUCED DISRUPTION OF CONDITIONED AVOIDANCE RESPONDING: ATTENUATION BY PRIOR TRAINING OR BY ANTICHOLINERGIC DRUGS.
210861 03-04

BLOCKING OF STRESS BY PENTOBARBITAL MORPHINE AS RELATED TO TRAINING AND AGE OF RATS.
214056 04-04

THE PARTIAL PUNISHMENT EFFECT FOLLOWING MINIMAL ACQUISITION TRAINING: SODIUM AMOBARBITAL AND THE STIMULUS PROPERTIES OF EARLY PUNISHED TRIALS.
224504 04-04

TRAIT

PERSONALITY TRAIT STABILITY LABILITY AND ITS SIGNIFICANCE FOR PHARMACOLOGICAL RESEARCH.
196776 01-16

TRANQUILISER

A DIRECT EFFECT OF DIBUTYRYL CYCLIC-AMP ON THE DURATION OF NARCOSIS INDUCED BY SEDATIVE, HYPNOTIC, TRANQUILISER AND ANESTHETIC DRUGS IN THE RAT.
222814 04-04

TRANQUILISERS

THE EFFECT OF CERTAIN TRANQUILISERS, CHLORPROMAZINE METABOLITES AND DIETHYLDITHIOCARBAMATE ON TISSUE AMPHETAMINE LEVELS IN THE RAT.
211111 03-03

TRANQUILISING

PHARMACOLOGICAL PROPERTIES OF A POTENTIAL TRANQUILISING AGENT MESYLPHENACYRAZINE: I. INTERACTION WITH DRUGS INFLUENCING THE NERVOUS SYSTEM.
205578 02-03

PHARMACOLOGICAL PROPERTIES OF A POTENTIAL TRANQUILISING AGENT MESYLPHENACYRAZINE: II. CHANGES RELATED TO ITS REPEATED ADMINISTRATION.
205579 02-03

TRANQUILIZER

PHENOTHIAZINE TRANQUILIZER PD-50S EXERTED AGAINST AMPHETAMINE EFFECT IN AGGREGATED MICE.
193422 01-03

OUTPATIENT TREATMENT OF SCHIZOPHRENIA BY A LONG-LASTING STRONG TRANQUILIZER: USE OF FLUPHENAZINE ENANTHATE.
194460 01-08

MY EXPERIENCE WITH THE USE OF A TRANQUILIZER, NORITREN, IN THE DEPARTMENT OF INTERNAL MEDICINE PSYCHOSOMATICS.
194510 01-11

PHARMACOLOGY OF MAGNESIUM GLUTAMATE HYDROBROMIDE (PS-042), A NEW TRANQUILIZER: THIRD PART, PSYCHOPHARMACOLOGICAL STUDIES.
196444 01-02

USE OF THE MAUDSLEY PERSONALITY INVENTORY IN EVALUATING THE EFFECTIVENESS OF A MINOR TRANQUILIZER IN PSYCHOSOMATIC DISEASES (THE FIRST REPORT).
198518 02-14

CHLORDIAZEPOXIDE (LIBRIUM): THE EFFECTS OF A MINOR TRANQUILIZER ON STRATEGIC CHOICE BEHAVIOR IN THE PRISONERS DILEMMA.
199609 02-14

THE DETECTION OF PRAZEPAM, A NEW BENZODIAZEPINE TRANQUILIZER.
204196 02-01

CLINICAL APPLICATION OF OXYPERTINE -- ITS CHARACTERISTICS AS A STRONG TRANQUILIZER.
209394 03-08

A COMPARISON OF A NEW TRANQUILIZER, SULPIRIDE AND OXAZOLAM ON PSYCHOSOMATIC DISEASES, NEUROSIS AND MASKED DEPRESSION USING DOUBLE-BLIND METHOD.
210180 03-11

THE TREATMENT OF ANXIETY IN THE ELDERLY WITH A NEW TRANQUILIZER COMPOUND.
210211 03-11

EXPERIENCE OF USING LORAZEPAM, A NEW TRANQUILIZER.
224394 04-11

CLINICAL STUDY OF A NEW TRANQUILIZER, LEXOTAN, IN NEUROTIC DISTURBANCES.
224583 04-10

TRANQUILIZERS

MAJOR OR MINOR TRANQUILIZERS FOR RELIEF OF COMMON SYMPTOMS OF PSYCHONEUROSIS
193412 01-10

THE INFLUENCE OF BENZODIAZEPINE SERIES TRANQUILIZERS ON VARIOUS FORMS OF OPERANT ANIMAL BEHAVIOR.
198482 02-04

RATIONAL USE OF PSYCHOTROPIC DRUGS. III. MAJOR TRANQUILIZERS.
198823 02-17

COMPARATIVE CHARACTERISTICS OF THE CLINICAL ACTION OF TRANQUILIZERS.
201909 02-14

THE INFLUENCE OF PROLONGED APPLICATION OF TRANQUILIZERS AND ANTIDEPRESSANTS ON THE SUMMATIONAL CAPACITY OF THE CENTRAL NERVOUS SYSTEM.
201913 02-03

TREATMENT OF HUMAN AGGRESSION WITH MAJOR TRANQUILIZERS, ANTIDEPRESSANTS, AND NEWER PSYCHOTROPIC DRUGS.
209127 03-11

MINOR TRANQUILIZERS IN THE TREATMENT OF AGGRESSION.
209128 03-11

TRANQUILIZERS CAUSING AGGRESSION.
210220 03-17

MINOR TRANQUILIZERS: USE, MISUSE OR OVERUSE
211435 03-17

RATE DEPENDENT EFFECTS OF DRUGS. II. EFFECTS OF SOME MAJOR TRANQUILIZERS ON MULTIPLE FIXED-RATIO, FIXED-INTERVAL SCHEDULE PERFORMANCE.
217458 04-04

COMPETITION FOR PLASMA PROTEIN BINDING SITES BETWEEN PHENOTHIAZINE TRANQUILIZERS AND IMINODIBENZYL ANTIDEPRESSANTS.
217891 04-03

TREATING DEPRESSION WITH TRANQUILIZERS: WITH DISSENTING VIEW OF LITHIUM CARBONATE THERAPY.
218123 04-09

A MULTICENTRIC EVALUATION OF PIMOZIDE (ORAP) IN PATIENTS WHO USUALLY WOULD TAKE TRANQUILIZERS.
218750 04-10

INHIBITION OF CELLULAR ATP HYDROLYZING ACTIVITY BY TRICYCLIC ANTIDEPRESSANTS AND PHENOTHIAZINE TRANQUILIZERS.
221053 04-03

THE EFFECT OF TRANQUILIZERS (DIAZEPAM AND CHLORDIAZEPOXIDE) ON THE BLOOD SUPPLY AND CARDIAC ACTIVITY.
223018 04-03

TRANQUILIZING

THE ALTERATION OF AVERSIVE THRESHOLDS AFTER CHRONIC ADMINISTRATION OF TWO TRANQUILIZING AGENTS.
205418 02-04

PHARMACOLOGIC EFFECTS OF MH-9022-1, A POTENTIAL TRANQUILIZING AGENT.
206808 03-02

TRANQUILIZING EFFECTS OF DIAZEPAM IN PIGS SUBJECTED TO A PUNISHMENT PROCEDURE.
210741 03-04

TRANQUILLIZER

MILD ANALGESICS EVALUATED WITH THE SUBMAXIMUM EFFORT TOURNIQUET TECHNIQUE: II. THE INFLUENCE OF A TRANQUILLIZER ON THEIR EFFECT.
197862 01-13

TRANQUILLIZERS

SEDATIVES, HYPNOTICS AND TRANQUILLIZERS.
202458 02-17

TRANQUILLIZING

TRANQUILLIZING ACTION OF A CRYSTALLINE FRACTION OF PASPALUM-SCROBICULATUM EXTRACT IN FOURTEEN PSYCHOTIC PATIENTS.
194711 01-08

TRANS-DELTA9-TETRAHYDROCANNABINOL

ANTIHISTAMINIC ACTION OF (-) TRANS-DELTA9-TETRAHYDROCANNABINOL.
217651 04-03

TRANS-SYNAPTIC

MINIMUM DURATION OF TRANS-SYNAPTIC STIMULATION REQUIRED FOR THE INDUCTION OF TYROSINE-HYDROXYLASE BY RESERPINE IN THE RAT SUPERIOR CERVICAL GANGLION.
199999 02-03

TRANSAMINASE

THE ROLE OF TYROSINE TRANSAMINASE IN BRAIN FUNCTION.
213607 04-03

TRANSAMINE

THE INFLUENCE OF INTRAPERITONEAL INJECTION OF IPRAZIDE AND TRANSAMINE ON THE DISTRIBUTION OF BIOGENIC AMINES IN CORTICAL AND SUBCORTICAL WHITE MATTER OF THE RAT BRAIN.
209032 03-03

THE EFFECT OF TRANSAMINE ON PSYCHONERVOUS AND CONDITIONED MEMORY IN RATS.
219745 04-04

TRANSECTION

EFFECT OF CHRONIC TRANSECTION ON DOPAMINE, NORADRENALINE AND 5-HYDROXYTRYPTAMINE IN THE RAT SPINAL CORD.
195244 01-03

TRANSFER

PLACENTAL TRANSFER OF DIAZEPAM AND ITS DISPOSITION IN THE NEWBORN.
215672 04-13

TRANSFORMATION

TRANSFORMATION OF DELTA1-TETRAHYDROCANNABINOL (THC) BY RABBIT LIVER MICROSOMES.
217817 04-03

TRANSIENT

A TRANSIENT STATE CONCEPT OF DRUG RECEPTOR INTERACTION.
195240 01-17

TRANSIENTS

EFFECT OF OUABAIN AND PHENOBARBITAL ON THE KINETICS OF CORTICAL METABOLIC TRANSIENTS ASSOCIATED WITH EVOKED POTENTIALS.
210820 03-03

TRANSMETHYLATION

A MECHANISTIC STUDY OF BIOLOGICAL TRANSMETHYLATION.
213604 04-03

TRANSMISSION

THE EFFECT OF PGE1, PGE2 AND PGF2ALPHA ON PARASYMPATHETIC TRANSMISSION.
197941 01-03

EFFECT OF NICOTINE AND NICOTINE MONOMETHIODIDE ON VASCULAR ADRENERGIC NEUROEFFECTOR TRANSMISSION.
197966 01-03

EFFECT OF TROPOLONE ON VASCULAR SYMPATHETIC NEUROEFFECTOR TRANSMISSION.
197970 01-03

THE INFLUENCE OF SODIUM OXYBUTYRATE ON INTERNEURONAL TRANSMISSION OF EXCITATION AT VARIOUS LEVELS OF THE CENTRAL NERVOUS SYSTEM.
198435 02-03

THE STRUCTURAL CHEMISTRY OF ADRENERGIC NEURAL TRANSMISSION SYSTEMS. (PH.D. DISSERTATION).
203027 02-01

NEURAMINIDASE: ITS EFFECT ON SYNAPTIC TRANSMISSION.
210664 03-03

THE EFFECTS OF AMPHETAMINE ISOMERS ON NEUROMUSCULAR TRANSMISSION.
210765 03-03

PHARMACOLOGY OF NEURAL MODULATION AND TRANSMISSION.
213627 04-03

EFFECTS OF 5,7 DIHYDROXYTRYPTAMINE ON TRANSMISSION AT SEROTONERGIC SYNAPSE.
217638 04-03

COCAINE, AMPHETAMINE, AND TRICYCLIC ANTIDEPRESSANTS AND SYNAPTIC TRANSMISSION.
221386 04-13

THE EFFECT OF CARBIDINE ON ADRENERGIC TRANSMISSION.
224115 04-03

DOXEPIN AND IMIPRAMINE: EFFECT ON CATECHOLAMINE INHIBITION OF GANGLIONIC TRANSMISSION.
225059 04-03

TRANSMITTER

EFFECTS OF TRANSMITTER MIMICKERS AT SITES OF ANGIOTENSIN INDUCED DRINKING IN THE CAT.
193434 01-04

THYROXINE AND BRAIN CATECHOLAMINES: INCREASED TRANSMITTER SYNTHESIS AND INCREASED RECEPTOR SENSITIVITY.
193541 01-03

THE EFFECTS OF P-SUBSTITUTED AMPHETAMINES ON THE TRANSMITTER REGULATION IN RAT BRAIN.
197571 01-03

UPTAKE AND RELEASE OF POSSIBLE FALSE TRANSMITTER AMINO ACIDS BY RAT BRAIN TISSUE.
199788 02-03

ALPHA-RECEPTOR MEDIATED MODULATION OF TRANSMITTER RELEASE FROM CENTRAL NORADRENERGIC NEURONES.
202805 02-03

CHOLINERGIC AGENTS AFFECT TWO RECEPTORS THAT MODULATE TRANSMITTER RELEASE AT A CENTRAL SYNAPSE IN APLYSIA-CALIFORNICA.
215705 04-03

TRANSMITTERS

THE SIGNIFICANCE OF NORADRENALINE AND ADRENALINE AS ADRENERGIC TRANSMITTERS IN THE CHICKEN.
197958 01-03

CATECHOLAMINES AS CENTRAL NERVOUS TRANSMITTERS.
213620 04-03

TRANSMURAL

SOME EFFECTS OF PILOCARPINE AND ACETYLCHOLINE ON THE RESPONSES OF THE GUINEA-PIG VAS-DEFERENS TO HYPOGASTRIC NERVE STIMULATION AND TRANSMURAL STIMULATION AND APPLIED (-) NORADRENALINE.
210770 03-03

TRANSPORT

THE EFFECT OF DIPYRIDAMOLE ON THE NORADRENALINE TRANSPORT INTO NERVE GRANULES.
197942 01-03

ANALYSIS OF ACETYLCHOLINESTERASE SYNTHESIS AND TRANSPORT IN THE RAT HIPPOCAMPUS: RECOVERY OF ACETYLCHOLINESTERASE ACTIVITY IN THE SEPTUM AND HIPPOCAMPUS AFTER ADMINISTRATION OF DIISOPROPYLFLUOROPHOSPHATE.
199805 02-03

ELECTROENCEPHALOGRAPHIC STUDY OF THE LOCAL TRANSPORT OF CENTRAL NERVOUS STIMULANTS INTO THE BRAIN.
202165 02-03

EFFECT OF IPRINDOLE ON NOREPINEPHRINE TURNOVER AND TRANSPORT.
202723 02-03

AFFERENTS TO THE SEPTAL AREA OF THE RAT STUDIED WITH THE METHOD OF RETROGRADE AXONAL TRANSPORT OF HORSERADISH PEROXIDASE.
203573 02-03

INFLUENCE OF MEPROBAMATE, CARISPRODOL, OXAZEPAM AND PHENOBARBITAL ON NA+ TRANSPORT IN THE ISOLATED FROG SKIN.
206781 03-03

DIFFERENTIAL EFFECTS OF CHLORPROMAZINE AND CHLORPROMAZINE FREE-RADICAL ON CALCIUM TRANSPORT IN SARCOPLASMIC RETICULUM VESICLES.
210812 03-03

INHIBITION OF DELTA1-TETRAHYDROCANNABINOL OF NA+-K+ TRANSPORT ATPASE FROM RAT ILEUM. PRELIMINARY REPORT.
211099 03-03

IN VIVO BINDING OF ANTIBODY TO DOPAMINE-BETA-HYDROXYLASE IN ADRENERGIC NERVES AND SUBSEQUENT ANTIDROMIC TRANSPORT (UNPUBLISHED PAPER).
218147 04-03

THE EFFECT OF PSYCHOTROPIC AND ANTICONVULSIVE DRUGS ON THE TRANSPORT OF ATPASE IN THE RENAL TUBES OF A GUINEA-PIG.
223015 04-05

PUTRESCINE: EFFECT ON AXOPLASMIC TRANSPORT.
223051 04-03

TRANYLCYPROMINE

THE BIPHASIC EFFECT OF SMALL DOSES OF TRANYLCYPROMINE ON THE SPONTANEOUS MOTOR ACTIVITY AND LEARNED CONDITIONED BEHAVIOUR IN RATS.
215665 04-04

TRASYLOL

ON THE INFLUENCE OF APROTINIUM (TRASYLOL) IN THE TREATMENT OF ALCOHOL DELIRIUM.
215698 04-11

TRAZODONE

THE USE OF TRAZODONE IN PSYCHOSOMATIC MEDICINE.
196197 01-14

SYSTEMATIC CLINICAL STUDIES WITH TRAZODONE.
198053 01-07

PSYCHOTHERAPEUTIC PROFILE OF A NEW PSYCHOACTIVE DRUG TRAZODONE (AF-1161).
215699 04-09

TREAT

USING CEREBRAL STIMULANTS TO TREAT MINIMAL-BRAIN-DYSFUNCTION.
224359 04-17

TREATED

5-HYDROXYTRYPTAMINE IN PLATELETS AND BRAIN OF RABBITS TREATED CHRONICALLY WITH IMIPRAMINE, MORPHINE OR METHADONE.
194744 01-03

BRAIN SEROTONIN METABOLISM IN LITHIUM TREATED RATS.
195235 01-03

CATALEPSY, STEREOTYPED BEHAVIOUR AND STRIATAL HOMOVANILLIC ACID CONTENT IN RATS TREATED WITH METHADONE.
197299 01-03

ANTICHOLINERGIC TOXIC PSYCHOSIS IN DRUG ABUSERS TREATED WITH BENZTROPINE.
197539 01-15

DEPRESSION TREATED WITH CHLORIMIPRAMINE WITH SPECIAL ANALYSIS OF CHANGE IN BLOOD PRESSURE BY INFUSION.
199212 02-09

POTENTIATION OF JUMPING BEHAVIOR BY AMINOPHYLLINE IN MICE TREATED WITH THRESHOLD DOSES OF AMPHETAMINE AND DOPA.
200039 02-04

DECREASED ANTINOCICEPTIVE EFFECT OF MORPHINE IN RATS TREATED INTRAVENTRICULARLY WITH PROSTAGLANDIN-E1.
200045 02-03

A DOUBLE-BLIND STUDY ON THE EFFECTS OF PIRACETAM UPON PERCEPTUAL AND PSYCHOMOTOR PERFORMANCE AT VARIED HEART RATES IN PATIENTS TREATED WITH ARTIFICIAL PACEMAKERS.
201328 02-13

CLINICAL STUDY OF GERDAXYL 10MG WITH 40 PATIENTS TREATED IN A PSYCHIATRIC OUTPATIENT FACILITY.
202037 02-11

EFFECTS ON THE ACQUISITION OF CONDITIONED AVOIDANCE RESPONSES AND SEIZURE THRESHOLD IN THE OFFSPRING OF AMPHETAMINE TREATED GRAVID RATS.
202722 02-05

LIPIDOSIS LIKE ALTERATIONS IN SPINAL CORD AND CEREBELLAR CORTEX OF RATS TREATED WITH CHLORPHENTERMINE OR TRICYCLIC ANTIDEPRESSANTS.
202767 02-03

LEARNING DEFICITS IN 4 WEEKS OLD OFFSPRING OF THE NURSING MOTHERS TREATED WITH THE NEUROLEPTIC DRUG PENFLURIDOL.
202806 02-04

ACUTE TOXIC PSYCHOSIS IN TWO CHILDREN TREATED WITH BENZHEXOL HYDROCHLORIDE (ARTANE).
205315 02-15

CONFUSIONAL STATES IN ELDERLY MENTAL PATIENTS TREATED WITH ANTIDEPRESSANTS.
205603 03-15

FOUR CASES OF DEPRESSION TREATED BY INDOLEACETIC ACID.
207554 03-09

RELATIONSHIP BETWEEN SERUM LITHIUM LEVEL AND CLINICAL RESPONSE TO DEPRESSION TREATED WITH LITHIUM CARBONATE.
207719 03-09

CLINICAL TRENDS AND PSYCHOMETRIC APPRAISAL OF A GROUP OF SCHIZOPHRENICS TREATED WITH THIOTHIXENE (NAVANE).
208981 03-08

CLINICAL ELECTROENCEPHALOGRAPHIC DATA IN DEPRESSED PATIENTS TREATED WITH ANAFRANIL.
209148 03-09

RAPIDITY OF SYMPTOM REDUCTION IN DEPRESSIONS TREATED WITH AMITRIPTYLINE.
209437 03-09

ONE-YEAR FOLLOWUP OF HYPERACTIVE BOYS TREATED WITH IMIPRAMINE OR METHYLPHENIDATE.
209736 03-11

PATTERNS OF SYMPTOM CHANGE IN ANXIOUS DEPRESSED OUTPATIENTS TREATED WITH DIFFERENT DRUGS.
209904 03-10

THREE CASES OF ANEJACULATION IN PATIENTS TREATED WITH CLOMIPRAMINE.
210136 03-15

CHANGES IN MENTAL AGE WITH SUBNORMAL CHILDREN TREATED WITH DOSES OF GABA AND NUCLEOTIDES.
210286 03-14

THE PASSATIZATION INDEX OF RETARDATES TREATED WITH HIGH DOSES OF GABA AND NUCLEOTIDES.
210288 03-11

MNEMONIC CAPACITY OF MENTALLY RETARDED BOYS TREATED WITH HIGH DOSES OF NUCLEOTIDES AND GABA.
210291 03-14

TEMPORAL DISCRIMINATION TESTS IN MENTAL RETARDATES TREATED WITH NUCLEOTIDES AND GABA IN HIGH DOSES.
210293 03-14

AMENORRHEA AND BEHAVIORAL DISTURBANCES: CLINICAL CASE TREATED WITH A PSYCHOTHERAPEUTIC METHOD BASED ON ELEMENTS OF THE CYBERNETIC THEORY OF G. CIPOLLINA MANGIAMELI.
210418 03-14

CLINICAL BIOLOGICAL CORRELATIONS IN SCHIZOAFFECTIVE PATIENTS TREATED WITH LITHIUM CARBONATE AND HALOPERIDOL.
210501 03-09

COMPARISON OF 3,4 DIMETHOXYPHENYLETHYLAMINE TREATED PLASMA FROM CHRONIC SCHIZOPHRENICS AND CONTROLS.
210897 03-08

PREVENTION OF RECIDIVISM OF SCHIZOPHRENICS TREATED WITH FLUPHENAZINE ENANTHATE.
211436 03-08

EVALUATION OF BENAPRYZINE IN PSYCHOTIC PATIENTS TREATED WITH PHENOTHIAZINES.
213387 04-07

ACTIONS OF ACETYLCHOLINE AND ATROPINE ON CEREBRAL CORTICAL NEURONS IN CHRONICALLY MORPHINE TREATED RATS.
215733 04-03

A RELATION BETWEEN DRUG CONCENTRATIONS IN BRAIN AND STRIATAL HOMOVANILLIC ACID LEVELS IN CHLORPROMAZINE TREATED RATS.
215734 04-03

FREE THYROXINE INDEX AND ABSOLUTE FREE THYROXINE IN PATIENTS WITH AFFECTIVE DISORDERS TREATED WITH LITHIUM CARBONATE.
216747 04-09

RELATIONSHIP BETWEEN SERUM LITHIUM LEVEL AND CLINICAL RESPONSE ON DEPRESSION TREATED WITH LITHIUM CARBONATE.
217354 04-09

ORAL DELTA9-TETRAHYDROCANNABINOL TOXICITY IN RATS TREATED UP TO SIX MONTHS.
217518 04-05

DIFFERENTIAL NEUROCHEMISTRY AND TEMPORAL PATTERN IN RATS TREATED ORALLY WITH DELTA9-TETRAHYDROCANNABINOL FOR PERIODS UP TO SIX MONTHS.
217519 04-04

POTENTIATION OF LOCOMOTOR ACTIVITY AND MODIFICATION OF STEREOTYPY BY STARVATION IN APOMORPHINE TREATED RATS.
217675 04-04

LONG-LASTING REDUCTION OF BRAIN 5-HYDROXYTRYPTAMINE CONCENTRATION BY 3-CHLOROAMPHETAMINE AND 4-CHLOROAMPHETAMINE IN IPRINDOLE TREATED RATS.
217879 04-03

EXPERIENCE WITH 20 PATIENTS TREATED WITH LITHIUM CARBONATE.
218682 04-09

POSSIBLE ROLE OF ADENOSINE-3-5-MONOPHOSPHATE AND BIOGENIC AMINES IN MORPHINE AND COCAINE TREATED RATS. (PH.D. DISSERTATION).
220475 04-03

ATTENTION AND THE AUDITORY EVOKED POTENTIAL IN HYPERKINETIC CHILDREN TREATED WITH METHYLPHENIDATE AND IN NORMAL CHILDREN. (PH.D. DISSERTATION).
222747 04-11

TREATING

RESULTS OF TREATING CHILDREN WITH NOCTURNAL ENURESIS WITH IMIPRAMINE (PSYCHOFORIN).
194208 01-11

DIAGNOSING AND TREATING CHRONIC SCHIZOPHRENIA.
196601 01-08

REMARKS ON THE USE OF FLUPENTHIXOL IN TREATING CHRONIC SCHIZOPHRENIA.
201669 02-08

BROMAZEPAM IN TREATING DYSTHYMIC ELDERLY PATIENTS.
201690 02-11

CLINICAL EXPERIENCES IN TREATING DEPRESSED PATIENTS WITH A COMBINATION OF TRICYCLIC DRUGS AND THYROID EXTRACT.
209144 03-09

DIPROPYLACETAMIDE IN TREATING MANIC-DEPRESSIVE PSYCHOSIS.
216761 04-09

TREATING DEPRESSION WITH TRANQUILIZERS: WITH DISSENTING VIEW OF LITHIUM CARBONATE THERAPY.
218123 04-09

EXPERIENCE WITH IMIPRAMINE-N-OXIDE (IPNO) IN TREATING DEPRESSIVE STATES.
221209 04-09

PERPHENAZINE ENANTHATE IN TREATING CHRONIC SCHIZOPHRENIA.
221558 04-08

TREATING PATIENTS WITH A SLUGGISH FORM OF SCHIZOPHRENIA.
224383 04-08

TREATMENT

CHANGES IN ACTIVATION OF ADENYLATE-CYCLASE AND OF DOPAMINE TURNOVER IN RAT STRIATUM DURING PROLONGED HALOPERIDOL TREATMENT.
192933 01-03

A DOUBLE-BLIND CROSSOVER COMPARISON BETWEEN CLOTHIAPINE AND DIAZEPAM IN THE TREATMENT OF MENTAL SYMPTOMS IN CHRONIC ALCOHOLICS.
192988 01-11

THE CURRENT STATUS OF LITHIUM TREATMENT.
193040 01-09

FACTORS ASSOCIATED WITH TREATMENT SUCCESS IN LITHIUM CARBONATE PROPHYLAXIS: REPORT OF THE NIMH-VA COLLABORATIVE STUDY GROUP.
193068 01-09

ONCE VERSUS THRICE DAILY THIOTHIXENE IN THE TREATMENT OF SCHIZOPHRENIC INPATIENTS.
194044 01-08

SMALL DOSES OF SULPIRIDE IN THE TREATMENT OF PSYCHONEUROTIC SYNDROMES.
194071 01-09

CLINICAL EXPERIENCE OF THE USE OF PENFLURIDOL (TLP-609) FOR THE TREATMENT OF SCHIZOPHRENIA.
194457 01-08

OUTPATIENT TREATMENT OF SCHIZOPHRENIA BY A LONG-LASTING STRONG TRANQUILIZER: USE OF FLUPHENAZINE ENANTHATE.
194460 01-08

ADMINISTRATION OF PG-501 FOR THE TREATMENT OF EXTRAPYRAMIDAL SYNDROME CAUSED BY THE ADMINISTRATION OF A PSYCHOTROPIC DRUG.
194475 01-11

TREATMENT OF SCHIZOPHRENIA BY THE ADMINISTRATION OF A SMALL DOSE OF FORIT FOR COMPARATIVELY LONG PERIODS OF TIME.
194476 01-08

USE OF SULPIRIDE IN THE TREATMENT OF SCHIZOPHRENIA.
194512 01-08

TREATMENT OF ANXIOUS PATIENTS WITH NEALBARBITONE -- (CENSEDAL).
194556 01-10

THE USE OF HALOPERIDOL IN THE TREATMENT OF A PSYCHOTIC CHILD WITH MULTIPLE TICS: A CASE REPORT.
194710 01-11

COMMENTS ON TREATMENT: EYE CHANGES FOLLOWING PHENOTHIAZINE ADMINISTRATION.
194749 01-15

GROUP THERAPY AND MAINTENANCE TREATMENT OF SCHIZOPHRENICS.
194860 01-08

INCREASE IN BRAIN DOPAMINE AFTER AXOTOMY OR TREATMENT WITH GAMMA-HYDROXYBUTYRIC ACID DUE TO ELIMINATION OF THE NERVE IMPULSE FLOW.
195439 01-03

EFFECTS OF DRUGS INFLUENCING MONOAMINE MECHANISMS ON THE INCREASE IN BRAIN DOPAMINE PRODUCED BY AXOTOMY OR TREATMENT WITH GAMMA-HYDROXYBUTYRIC ACID.
195440 01-03

EFFECTS IN THE SUCKLING RAT OF CHRONIC TREATMENT WITH TRYPTOPHAN AND A MONOAMINE OXIDASE INHIBITOR.
195906 01-04

TREATMENT OF RESISTANT DEPRESSION.
196036 01-17

PREDICTING TREATMENT RESPONSIVENESS RESISTIVENESS IN A POPULATION OF DEPRESSED PATIENTS.
196040 01-17

DRUG TREATMENT OF CHRONIC INTRACTABLE PAIN IN PATIENTS REFERRED TO A PSYCHIATRY CLINIC.
196090 01-14

SERIAL EEG RECORDINGS IN PSYCHOTROPIC DRUG TREATMENT.
196144 01-08

SPONTANEOUS ORAL DYSKINESIA: RESULTS OF TREATMENT WITH TETRABENAZINE, PIMOZIDE, OR BOTH.
196600 01-11

INTERMITTENT TREATMENT WITH ANORECTIC DRUGS.
197137 01-11

THE EFFECTS OF EARLY ALPHA-METHYLDOPA TREATMENT ON BEHAVIOUR IN THE RAT.
197578 01-04

INTERACTION BETWEEN MASSED ELECTROCONVULSIVE SHOCK AND P-BROMOMETHYLAMPHETAMINE (V-111) TREATMENT.
197579 01-03

RNA TREATMENT OF DEMENTIA: A DOUBLE-BLIND STUDY.
197841 01-11

PSYCHOPHARMACOLOGICAL EVIDENCE FOR INCREASE IN RECEPTOR SENSITIVITY FOLLOWING CHRONIC MORPHINE TREATMENT.
197855 01-04

TREATMENT OF EXPERIMENTAL IMIPRAMINE INTOXICATION BY INTERRUPTING ENTERAL CYCLES WITH ACTIVATED CHARCOAL.
197969 01-03

TURNOVER OF BIOGENIC AMINES AFTER ACUTE AND CHRONIC MORPHINE TREATMENT IN RATS.
197974 01-03

A COMPARATIVE STUDY OF AMPHETAMINE, EPHEDRINE ATROPINE MIXTURE, PLACEBO AND BEHAVIORAL CONDITIONING IN THE TREATMENT OF NOCTURNAL ENURESIS.
198020 01-11

SOME NEW APPROACHES TO THE TREATMENT OF ANXIETY.
198046 01-10

SCHIZOPHRENIA FOLLOWUP: A CONTROLLED TREATMENT STUDY.
198076 02-08

NIMH-PRB OUTPATIENT TREATMENT OF DEPRESSION.
198078 02-10

DRUG TREATMENT OF DEPRESSED OUTPATIENTS.
198083 02-10

COMPARATIVE DRUG TREATMENT OF HYPERACTIVE CHILDREN.
198090 02-11

WORK CAPABILITY AND TREATMENT OF REACTIVE DEPRESSIONS.
198354 02-10

TACITIN AND APONAL IN THE TREATMENT OF NEUROSES.
198396 02-10

COMPARATIVE STUDY OF Y-6047 AND DIAZEPAM BY A DOUBLE-BLIND METHOD FOR THE TREATMENT OF PSYCHOSOMATIC DISEASES AND NEUROSIS.
198705 02-11

CLINICAL EXPERIENCE WITH CLOCAPRAMINE (CLOFEKTON) FOR THE TREATMENT OF SCHIZOPHRENIC PATIENTS.
198709 02-08

LSD TREATMENT OF PIERIS-BRASSICAE AND CONSEQUENCES ON THE PROGENY.
199425 02-04

BEHAVIOURAL SUPERSENSITIVITY TO APOMORPHINE FOLLOWING CHRONIC TREATMENT WITH DRUGS WHICH INTERFERE WITH THE SYNAPTIC FUNCTION OF CATECHOLAMINES.
199958 02-04

LONG-TERM TREATMENT OF PSYCHIATRIC PATIENTS WITH CLOPENTHIXOL: ANALYSIS OF LABORATORY TESTS WITH A VIEW TO LONG-TERM THERAPY.
199989 02-14

THE THERAPEUTIC EFFECT OF SHORT-TERM ORAL DIAZEPAM TREATMENT ON ACUTE CLINICAL ANXIETY IN A CRISIS CENTRE.
199991 02-10

THE EFFECTS OF HYPNOTICS ON IMIPRAMINE TREATMENT.
200049 02-13

EFFECT OF TWO WEEKS TREATMENT WITH CHLORIMIPRAMINE AND NORTRIPTYLINE, ALONE OR IN COMBINATION WITH ALCOHOL, ON LEARNING AND MEMORY.
200057 02-14

CLINICAL OBSERVATIONS ON SULPIRIDE TREATMENT IN PSYCHIATRY.
200170 02-11

PSYCHOPHARMACOLOGIC TREATMENT OF AFFECTIVE DISORDERS.
200237 02-09

A SURVEY OF DRUG TREATMENT IN PSYCHIATRY: SPECIAL EMPHASIS ON INPATIENTS ON MEDICAL WELFARE SUPPORTED BY YOKOHAMA CITY.
200447 02-17

OBSERVATIONS ON THE TREATMENT OF DEPRESSIONS.
200481 02-09

MAINTENANCE TREATMENT OF CHRONIC SCHIZOPHRENIA WITH NEUROLEPTIC DRUGS.
200636 02-08

EFFECT OF LONG-TERM LITHIUM TREATMENT ON BRAIN FUMARASE ACTIVITY.
200751 02-03

CLOZAPINE AND HALOPERIDOL IN A SINGLE-BLIND CROSSOVER TRIAL: THERAPEUTIC AND BIOCHEMICAL ASPECTS IN THE TREATMENT OF SCHIZOPHRENIA.
200803 02-08

SOCIAL AND PSYCHOLOGICAL ASPECTS OF MEDICAL PRACTICE: DRUG TREATMENT IN PSYCHIATRY.
201270 02-17

LITHIUM TREATMENT REDUCES MORPHINE SELF-ADMINISTRATION IN ADDICT RATS.
201293 02-04

TREATMENT OF MASKED DEPRESSION.
201655 02-09

BENZODIAZEPINES IN THE TREATMENT OF EPILEPSY: A REVIEW.
201870 02-11

KETAMIN HYDROCHLORIDE AS A PREANESTHESIA DRUG FOR AN ELECTROSHOCK TREATMENT.
202121 02-11
BROMAZEPAM, MEDAZEPAM, CHLORDIAZEPOXIDE IN TREATMENT OF NEUROTIC ANXIETY.
202219 02-10
TREATMENT AND COUNTERMEASURES FOR PATIENTS WITH INSOMNIA IN THE DEPARTMENT OF INTERNAL MEDICINE -- SPECIAL EMPHASIS ON THE CLINICAL APPLICATION OF FLURAZEPAM.
202285 02-14
THE CURRENT STATUS OF BIOLOGICAL CRITERIA FOR CLASSIFYING THE DEPRESSIVE DISORDERS AND PREDICTING RESPONSES TO TREATMENT.
202380 02-17
RECENT ADVANCES IN THE TREATMENT OF DEPRESSION.
202390 02-10
THE PRESENT CONDITIONS OF PSYCHOPHARMACOLOGICAL TREATMENT FOR CHILDREN IN JAPAN: OPINIONS FROM THIRTY-SEVEN WELL-KNOWN CHILD NEUROPSYCHIATRISTS AND NEUROPSYCHIATRIC PEDIATRICIANS.
202500 02-17
EVENTUAL DEVELOPMENTS OF 64 CHRONIC PSYCHOTICS ON MODITEN RETARD OR MODECATE TREATMENT.
202514 02-09
NEGATIVE FINDINGS WITH NICOTINIC ACID IN THE TREATMENT OF SCHIZOPHRENIAS.
202787 02-08
CHRONIC AMPHETAMINE TREATMENT: VAST INDIVIDUAL DIFFERENCES IN PERFORMING A LEARNED RESPONSE.
202794 02-04
PEMOLINE (CYLERT) IN THE TREATMENT OF CHILDHOOD HYPERKINESIS.
202824 02-11
PSYCHOPHARMACOLOGICAL TREATMENT OF DISORDERS OF SENESCENCE.
203470 02-11
CONTRIBUTION OF TREATMENT BY LEVODOPA TO THE NEUROPHARMACOLOGY OF AKINESIA.
203494 02-15
TREATMENT OF SEXUAL DELINQUENCY WITH ANDROCUR (CYPROTERONE ACETATE).
203496 02-17
BLOOD LEVELS AND MANAGEMENT OF LITHIUM TREATMENT.
203546 02-15
TREATMENT OF RESISTANT DEPRESSION: CONTRIBUTIONS TO GENETIC ASPECTS.
203596 02-09
THE TREATMENT OF BEHAVIOR DISORDERS IN IDIOCY AND IMBECILITY WITH CLOZAPINE.
203598 02-11
APONEURON TREATMENT OF CHRONIC SCHIZOPHRENICS WITH REDUCED DRIVE.
203666 02-08
EEG EXAMINATIONS DURING LITHIUM TREATMENT.
203701 02-13
POSSIBLE TREATMENT OF PSYCHONEUROSES WITH MEDAZEPAM (NOBRIUM).
203705 02-07
TREATMENT OF PARKINSONS DISEASE BY COMBINING L-DOPA WITH A DECARBOXYLASE INHIBITOR.
204372 02-07
TREATMENT OF WITHDRAWAL SYMPTOMS WITH APOMORPHINE.
204407 02-15
PSYCHOPHARMACOLOGICAL TREATMENT OF OBSESSIVE SYNDROME.
204408 02-09
RECENT ADVANCES IN THE TREATMENT OF DEPRESSION.
205155 02-09
EXPERIENCE WITH OXYPROTHEPINE IN THE TREATMENT OF MANIC SYNDROMES.
205580 02-09
MAINTENANCE TREATMENT OF SCHIZOPHRENIA WITH LONG-ACTING FLUPHENAZINE.
205585 02-08
PRIAPISM AS A POSSIBLE COMPLICATION OF THE CHLORPROMAZINE TREATMENT.
205594 02-15
PAPAVERIN IN THE TREATMENT OF GERIATRIC PATIENTS.
205606 03-11
FAMILY HISTORY OF MANIC-DEPRESSIVE AND ENDOGENOUS DEPRESSIVE PATIENTS AND CLINICAL EFFECT OF TREATMENT WITH LITHIUM.
205608 03-09
LITHIUM TREATMENT OF BEHAVIOURAL DISTURBANCES IN PATIENTS WITH DEFECTIVE INTELLECT.
205610 03-09
LITHIUM TREATMENT AND THYROID FUNCTION IN MAN.
205611 03-15
OUR EXPERIENCE WITH CLOZAPINE TREATMENT.
205613 03-08
RESULTS ACHIEVED WITH CLOZAPINE (LEPONEX) IN THE TREATMENT OF NEUROSES.
205614 03-10
HYDERGINE THIORIDAZINE COMBINATION IN THE TREATMENT OF PSYCHOPATHOLOGICAL STATES IN OLD AGE.
205637 03-11
OUR EXPERIENCE WITH THE TREATMENT OF DELIRIUM-TREMENS WITH DIAZEPAM.
205639 03-11
THE EFFECTS OF CHRONIC PHENOTHIAZINE TREATMENT ON ADRENAL PITUITARY FUNCTION IN MAN.
205765 03-13
DIPHENYLHYDANTOIN IN THE TREATMENT OF LSD FLASHBACKS: A CASE STUDY.
205766 03-12
LITHIUM TREATMENT OF DEPRESSION.
206146 03-09
CLINICAL FEATURES, ETIOLOGY AND TREATMENT OF FACIAL DYSKINESIAS IN THE ELDERLY.
206926 03-14
URGENT CHEMICAL TREATMENT OF STATES OF AGITATION.
207151 03-11
MASS FRAGMENTOMETRIC DETERMINATION OF HOMOVANILLIC ACID IN LUMBAR CEREBROSPINAL FLUID OF SCHIZOPHRENIC PATIENTS DURING TREATMENT WITH ANTIPSYCHOTIC DRUGS.
207295 03-08
OXYPERTINE IN THE TREATMENT OF MORBID ANXIETY. REPORT OF A NEW LOW DOSAGE SCHEDULE.
207532 03-10
CLINICAL USE OF CLOCAPRAMINE FOR THE TREATMENT OF CHRONIC SCHIZOPHRENIA -- SPECIAL EMPHASIS ON ITS COMPARISON WITH PERPHENAZINE.
207534 03-08
EFFECT OF LONG-TERM TREATMENT OF HYPERACTIVE CHILDREN WITH METHYLPHENIDATE.
207580 03-11
PSYCHOPHARMACOLOGIC MANAGEMENT OF PATIENTS: A METHOD FOR RECORDING TREATMENT DECISIONS.
207683 03-17
LEUKOCYTOSIS DURING LITHIUM TREATMENT AND ITS CORRELATION TO SERUM LITHIUM LEVEL.
207718 03-15
COMBINED THYROID (TRIIODOTHYRONINE) TRICYCLIC ANTIDEPRESSANT TREATMENT IN DEPRESSIVE STATES.
207720 03-09
THOUGHT DISORDERS IN SCHIZOPHRENIA BEFORE AND AFTER PHARMACOLOGICAL TREATMENT.
207767 03-17
HALOPERIDOL AS A TREATMENT FOR ADULT STUTTERING.
207771 03-14
PSYCHOPHARMACOLOGY IN THE AGED: USE OF MAJOR PSYCHOTROPIC MEDICATIONS IN TREATMENT OF THE ELDERLY: CASE EXAMPLES.
208575 03-11
FROM HOSPITAL TREATMENT TO COMMUNITY PSYCHIATRY -- SECOND REPORT -- OUTPATIENT EMERGENCY TREATMENT OF MENTAL PATIENTS WITH THE USE OF HALOPERIDOL.
208723 03-11
TREATMENT OF INTRACTABLE DEPRESSION.
208918 03-17
TREATMENT OF SCHIZOPHRENIA.
209002 03-13
CONCEPTUAL ISSUES IN THE USE OF DRUGS FOR THE TREATMENT OF AGGRESSION IN MAN.
209126 03-17
TREATMENT OF HUMAN AGGRESSION WITH MAJOR TRANQUILIZERS, ANTIDEPRESSANTS, AND NEWER PSYCHOTROPIC DRUGS.
209127 03-11
MINOR TRANQUILIZERS IN THE TREATMENT OF AGGRESSION.
209128 03-11
LITHIUM IN THE TREATMENT OF AGGRESSION.
209129 03-11
ANTICONVULSANTS IN THE TREATMENT OF AGGRESSION.
209130 03-11
HORMONE AND HORMONAL AGENTS IN THE TREATMENT OF AGGRESSION.
209131 03-11
DEPRESSIVE CONDITION. PERCEPTION, EVALUATION, TREATMENT.
209332 03-09
THE LITHIUM PROPHYLACTIC TREATMENT OF RECURRENT ENDOGENOUS AFFECTIVE DISORDERS.
209392 03-09
APPLICATION OF LOPRAMINE (DB-2182) FOR THE TREATMENT OF DEPRESSIVE STATE.
209395 03-11
RELATIVE SAFETY OF AMITRIPTYLINE IN MAINTENANCE TREATMENT OF DEPRESSION.
209438 03-15
SULPIRIDE IN AMBULATORY TREATMENT OF CHRONIC PSYCHOTICS.
209533 03-14

SULPIRIDE VERSUS CHLORPROMAZINE AND PLACEBO IN THE TREATMENT OF RESTLESS MENTALLY SUBNORMAL PATIENTS -- A DOUBLE-BLIND CROSSOVER STUDY.
209702 03-11

THE TREATMENT OF NIGHT TERRORS ASSOCIATED WITH THE POSTTRAUMATIC SYNDROME.
209750 03-11

TREATMENT OF ACUTE SCHIZOPHRENIA WITH A NEW BUTYROPHENONE - - LENPERONE.
209791 03-07

THE APPEARANCE OF EXOPHTHALMIA IN THE COURSE OF LITHIUM CARBONATE TREATMENT: BIOLOGICAL HYPERTHYROIDISM.
209998 03-15

TREATMENT OF PHENOTHIAZINE INDUCED BULBAR PERSISTENT DYSKINESIA WITH DEANOL ACETAMIDOBENZOATE.
210209 03-13

THE TREATMENT OF ANXIETY IN THE ELDERLY WITH A NEW TRANQUILIZER COMPOUND.
210211 03-11

A DOUBLE-BLIND COMPARISON OF LITHIUM CARBONATE AND IMIPRAMINE IN THE TREATMENT OF DEPRESSION.
210241 03-09

EFFECT OF STRESS AND DIAZEPAM TREATMENT DURING INFANCY ON THE CORTICOSTERONE REGULATION AND ANDROGENIC ACTIVITY IN ADULT MALE RATS.
210348 03-03

PHARMACOLOGICAL TREATMENT OF PHOBIC - OBSESSIVE PSYCHONEUROSES: PSYCHODYNAMIC AND SYMPTOMATOLOGICAL ASPECTS.
210506 03-10

TREATMENT OF PSYCHOSOMATIC GASTROINTESTINAL DISORDERS IN OUTPATIENTS.
210513 03-11

CHOLINERGIC DOPAMINERGIC INTERACTION IN THE STRIATUM: THE EFFECT OF 6-HYDROXYDOPAMINE OR PIMOZIDE TREATMENT ON THE INCREASED STRIATAL ACETYLCHOLINE LEVELS INDUCED BY APOMORPHINE, PIRIBEDIL AND D-AMPHETAMINE.
210668 03-03

NEONATAL 6-HYDROXYDOPAMINE TREATMENT: NORADRENALINE LEVELS AND IN VITRO 3H-CATECHOLAMINE SYNTHESIS IN DISCRETE BRAIN REGIONS OF ADULT RATS.
210759 03-03

AMPHETAMINE TREATMENT OF PARANOID OBSESSIONS: CASE REPORT AND BIOCHEMICAL IMPLICATIONS.
210809 03-09

CONSIDERATIONS ABOUT THE TREATMENT OF SENESCENCE.
211202 03-11

USE OF A NEW PSYCHOTROPIC DRUG, CLOFLUPEROL FOR THE TREATMENT OF CHRONIC SCHIZOPHRENIC PATIENTS.
211304 03-08

THE USE OF ANTICONVULSANT TREATMENT OF BEHAVIORALLY DISTURBED CHILDREN WITH BIOELECTRIC EPILEPSY: A CATAMNESTIC STUDY OF 76 CASES.
211355 03-11

CLOMIPRAMINE IN THE TREATMENT OF THE TRUE OBSESSIONAL STATE: A REPORT ON FOUR PATIENTS.
211433 03-10

CAFFEINE IN THE TREATMENT OF CHILDREN WITH MINIMAL BRAIN DYSFUNCTION OR HYPERKINETIC SYNDROME.
211434 03-11

TENTATIVE DOUBLE-BLIND TREATMENT OF ANXIETY WITH B-5833.
212166 03-10

PHYSOSTIGMINE SALICYLATE IN THE TREATMENT OF TRICYCLIC ANTIDEPRESSANT OVERDOSAGE.
212265 03-15

THE LONG-TERM MAINTENANCE TREATMENT OF SCHIZOPHRENIC OUTPATIENTS WITH DEPOT FLUPENTHIXOL.
212491 03-08

SALIVARY SCINTOGRAPHY: INTEREST IN TREATMENT OF DRY MOUTH PROVOKED BY PSYCHOTROPIC MEDICATION.
212493 03-15

DRUG TREATMENT IN PSYCHIATRY.
212888 03-17

DOUBLE-BLIND EXAMINATION OF BROMAZEPAM (RO-5-3350) FOR THE TREATMENT OF PSYCHONEUROSIS.
213293 03-10

CLINICAL EXPERIENCE OF FLUPHENAZINE ENANTHATE IN TREATMENT OF SCHIZOPHRENIC PATIENTS.
213294 03-08

PSYCHOPHARMACOLOGICAL TREATMENT: THEORY AND PRACTICE.
213392 04-17

PEYOTE IN THE TREATMENT OF ALCOHOLISM AMONG AMERICAN-INDIANS.
213702 04-12

EXTRAPYRAMIDAL REACTIONS AND AMINE METABOLITES IN CEREBROSPINAL FLUID DURING HALOPERIDOL AND CLOZAPINE TREATMENT OF SCHIZOPHRENIC PATIENTS.
214010 04-15

ORTHOMOLECULAR TREATMENT IN DISTURBANCES INVOLVING BRAIN FUNCTION.
214719 04-11

CHANGES IN OBSESSIVE/COMPULSIVE PATIENTS AS MEASURED BY THE LEYTON INVENTORY BEFORE AND AFTER TREATMENT WITH CLOMIPRAMINE.
214833 04-10

DEPRESSIVE REACTIONS IN THE COURSE OF CLOMIPRAMINE THERAPY USED IN THE TREATMENT OF OBSESSIONAL CONDITIONS.
214834 04-15

THE ROLE OF INTRAVENOUS CLOMIPRAMINE IN THE TREATMENT OF OBSESSIONAL AND PHOBIC DISORDERS.
214835 04-10

A PILOT STUDY OF ANAFRANIL IN THE TREATMENT OF PHOBIC STATES.
214836 04-10

A COMPARISON BETWEEN MAPROTILINE (LUDIOMIL) AND AMITRIPTYLINE IN THE TREATMENT OF DEPRESSIVE REACTION IN GENERAL PRACTICE.
215058 04-14

ASPECTS OF LONG-TERM TREATMENT WITH NEUROLEPTICS: HISTORICAL AND LITERATURE REVIEW -- PERSONAL EXPERIENCE WITH FLUSPIRILENE AND PENFLURIDOL.
215059 04-14

NONPHARMACOLOGICAL FACTORS IN DRUG THERAPY: THE INTERACTION OF DOCTOR, PATIENT, AND TABLET APPEARANCE IN THE TREATMENT OF ANXIETY/DEPRESSIVE SYNDROMES.
215060 04-10

EEG CHANGES IN THE TREATMENT WITH OCTOCLOTHEPINE IN VERY HIGH DOSES.
215064 04-13

CLOMIPRAMINE (ANAFRANIL) IN THE TREATMENT OF OBSESSIONAL STATES: A PSYCHIATRISTS VIEW.
215155 04-10

CLOMIPRAMINE (ANAFRANIL) IN THE TREATMENT OF PHOBIC STATES: A PSYCHIATRISTS VIEW.
215156 04-10

EXPERIENCES WITH CLOMIPRAMINE (ANAFRANIL) IN THE TREATMENT OF THE PHOBIC ANXIETY STATES IN GENERAL PRACTICE.
215158 04-10

FLUPHENAZINE TREATMENT IN THE PSYCHOTIC CHILD: CLINICAL EVOKED POTENTIAL CORRELATIONS.
215455 04-09

TREATMENT OF ACUTE SCHIZOPHRENIA WITH ULTRA-HIGH-DOSE FLUPHENAZINE: A FAILURE AT SHORTENING TIME ON A CRISIS INTERVENTION UNIT.
215456 04-08

INCREASED SENSITIVITY TO DOPAMINERGIC AGENTS AFTER CHRONIC NEUROLEPTIC TREATMENT.
215689 04-04

ON THE INFLUENCE OF APROTINIUM (TRASYLOL) IN THE TREATMENT OF ALCOHOL DELIRIUM.
215698 04-11

THE OUTCOME OF DOTHIEPIN TREATMENT IN 1,900 DEPRESSED PATIENTS.
215700 04-09

TOLERANCE DEVELOPMENT TO THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON CONDITIONED BEHAVIOR: ROLE OF TREATMENT INTERVAL AND INFLUENCE OF MICROSOMAL METABOLISM.
215726 04-03

METHYSERGIDE IN THE TREATMENT OF NARCOLEPSY.
215738 04-11

THE USE OF CYAMEPROMAZINE IN SMALL DOSES IN TREATMENT OF NONPSYCHOTIC DISTURBANCES.
215798 04-04

VISUAL HALLUCINATIONS AND DELIRIUM DURING TREATMENT WITH AMANTADINE (SYMMETREL).
215858 04-11

THE USE OF LITHIUM IN THE TREATMENT OF THE DRUG-INDUCED PSYCHOTIC REACTION.
216183 04-11

REPORT ON THREE CASES OF CARDIAC CHANGES DURING TREATMENT WITH FLOROPIPAMIDE (PROPITAN).
216391 04-15

TRIAL INTERRUPTION OF ANTIPARKINSONIANS IN LONG-TERM NEUROLEPTIC TREATMENT.
216767 04-15

THE EFFECTS OF CHRONIC CANNABIS TREATMENT UPON BRAIN 5-HYDROXYTRYPTAMINE, PLASMA CORTICOSTERONE AND AGGRESSIVE BEHAVIOR IN FEMALE RATS WITH DIFFERENT HORMONAL STATUS.
217532 04-04

PROPRANOLOL IN THE TREATMENT OF OPIATE DEPENDENCE -- A CONTROLLED STUDY.
217549 04-14

BACLOFEN IN THE TREATMENT OF SCHIZOPHRENIA.
218254 04-08

BROM-ERGOCRYPTINE IN THE TREATMENT OF PHENOTHIAZINE INDUCED GALACTORRHOEA.
218557 04-15

DOUBLE-BLIND COMPARISON OF LITHIUM CARBONATE AND IMIPRAMINE IN TREATMENT OF DEPRESSION.
218772 04-09
NICOTINIC ACID IN THE TREATMENT OF SCHIZOPHRENIAS: CANADIAN MENTAL HEALTH ASSOCIATION COLLABORATIVE STUDY PROGRESS REPORT II.
219537 04-08
DEPRESSIONS AND ANTIDEPRESSANTS DURING TREATMENT WITH LONG-ACTING NEUROLEPTIC DRUGS: SIDE-EFFECTS AND THE EMERGENT METATHERAPEUTIC SYNDROME.
219694 04-15
MONOAMINEOXIDASE INHIBITORS ANTAGONIZE THE ACCELERATION OF BRAIN DOPAMINE SYNTHESIS INDUCED BY NEUROLEPTIC DRUGS IN VIVO: IMPLICATIONS FOR THE TREATMENT OF TARDIVE DYSKINESIA.
220948 04-03
DOXEPIN-I.M. IN THE TREATMENT OF DEPRESSION AND ANXIETY.
221035 04-10
DOES CHRONIC MORPHINE TREATMENT INDUCE A SUPERSENSITIVITY OF DOPAMINE RECEPTORS IN RAT BRAIN
221038 04-03
AMITRIPTYLINE TREATMENT OF PATIENTS WITH MIGRAINE.
221561 04-11
LITHIUM TREATMENT OF SCHIZOPHRENIA: A CONTROLLED EXPERIMENT.
221635 04-03
CLOZAPINE AND HALOPERIDOL: CLINICAL AND BIOCHEMICAL ASPECTS IN THE TREATMENT OF SCHIZOPHRENIA.
221637 04-08
DOUBLE-BLIND COMPARISON OF MAPROTILINE (LUDIOMIL) WITH AMITRIPTYLINE IN THE TREATMENT OF DEPRESSIVE ILLNESS.
221652 04-09
A COMPARISON BETWEEN MAPROTILINE (LUDIOMIL) AND IMIPRAMINE IN THE TREATMENT OF DEPRESSIVE ILLNESS IN THE ELDERLY.
221655 04-09
A COMPARISON OF MAPROTILINE (LUDIOMIL) AND PLACEBO IN THE TREATMENT OF DEPRESSION.
221656 04-09
A CLINICAL TRIAL OF MAPROTILINE (LUDIOMIL) IN THE TREATMENT OF DEPRESSIVE PATIENTS IN GENERAL PRACTICE AND THE PSYCHIATRIC CLINIC.
221657 04-09
A DOUBLE-BLIND GENERAL PRACTICE TRIAL OF MAPROTILINE (LUDIOMIL) AGAINST AMITRIPTYLINE IN THE TREATMENT OF REACTIVE DEPRESSION.
221658 04-09
A COMPARISON BETWEEN DAILY AND NIGHTLY DOSE REGIMEN OF AMITRIPTYLINE AND MAPROTILINE (LUDIOMIL) IN THE TREATMENT OF REACTIVE DEPRESSION IN GENERAL PRACTICE.
221662 04-09
LONG-ACTING DRUGS IN PSYCHIATRIC TREATMENT: LACUNAE AND NEEDS.
221672 04-17
METFORMIN (GLUCOPHAGE) IN THE TREATMENT OF DRUG-INDUCED OBESITY.
221821 04-13
NEW PROSPECTS OF TREATMENT OF PARKINSONS DISEASE WITH PARKS-PLUS.
221885 04-11
HYPOTHYROIDISM DURING LITHIUM TREATMENT: A REVIEW OF 49 CASES.
221988 04-15
RESULTS OF A COMPARATIVE DOUBLE-BLIND STUDY WITH CLOZAPINE AND CHLORPROMAZINE IN THE TREATMENT OF SCHIZOPHRENIC PATIENTS.
221989 04-08
ACCIDENTS AND DRUG TREATMENT IN A PSYCHIATRIC HOSPITAL.
222603 04-15
PARKINSONISM: EFFECTS OF LEVODOPA TREATMENT ON CONCEPT FORMATION.
222871 04-14
SPONTANEOUS ALTERNATION IN FERRETS FOLLOWING TREATMENT WITH SCOPOLAMINE, CHLORDIAZEPOXIDE, AND CAFFEINE.
223039 04-04
TREATMENT RESULTS OF L-DOPA ON SCHIZOPHRENIA.
223202 04-08
TREATMENT OF DEPRESSION WITH PIRAZIDOL.
224083 04-09
ATROPINE COMA TREATMENT OF SCHIZOPHRENIC PATIENTS WITH A SLUGGISH DEVELOPMENT AND OBSESSIVE SYNDROMES.
224085 04-08
CLINICAL TRIAL OF OXYPERTINE IN THE TREATMENT OF PSYCHOSOMATIC DISORDERS, NEUROSIS AND DEPRESSION.
224193 04-14
DEPRESSIONS CAUSED BY ORAL CONTRACEPTIVES AND THEIR TREATMENT WITH ORIGEN.
224347 04-09
STIMULANT DRUG TREATMENT OF HYPERACTIVE ADOLESCENTS.
224379 04-14
TREATMENT OF ANXIETY BY LORAZEPAM.
224393 04-09
TREATMENT EXPERIENCE OF CHRONIC SCHIZOPHRENIA WITH PENFLURIDOL.
224548 04-08
DIAZEPAM TREATMENT OF SOCIALLY ISOLATED MONKEYS.
224776 04-04
PSYCHOSOCIAL TREATMENT OF ACUTE SCHIZOPHRENIA.
224790 04-17
LITHIUM IN THE TREATMENT OF DEPRESSION.
224871 04-09
THE MISUSE OF DRUGS IN THE TREATMENT OF THE CHRONIC PSYCHOSES.
225055 04-17
A COMPARATIVE CLINICAL TRIAL OF ORG-GB-94 AND IMIPRAMINE IN THE TREATMENT OF DEPRESSION IN GENERAL PRACTICE.
225107 04-09
CLINICAL TRIAL WITH FLUPENTHIXOL (FLUANXOL) IN THE TREATMENT OF SENILE DEMENTIA.
225281 04-11
LITHIUM CARBONATE IN THE TREATMENT OF TARDIVE DYSKINESIA.
225343 04-15

TREATMENTS
TIME-DEPENDENT, MEMORY RETRIEVAL EFFECTS FOLLOWING PERIPHERAL AND HIPPOCAMPAL TREATMENTS TO INCREASE SYNAPTIC BIOGENIC AMINES. (PH.D. DISSERTATION).
194677 01-04
ELECTROPHYSIOLOGICAL AND BEHAVIORAL REACTIVITY TO PHOTIC STIMULI FOLLOWING SEPTAL LESIONS AND PHARMACOLOGICAL TREATMENTS IN RATS.
206724 03-04
SCHIZOPHRENIA -- 5: PHYSICAL TREATMENTS AND DRUGS.
216403 04-08

TREMOR
DEPRESSION BY AMANTADINE OF TREMOR INDUCED BY RESERPINE AND OXOTREMORINE IN THE RAT.
193282 01-04
MECHANISMS OF TREMOR INDUCTION BY HARMINE.
193448 01-03
EFFECT OF BETA-RECEPTOR BLOCKERS (PINDOLOL AND PRACTOLOL) ON LITHIUM INDUCED TREMOR -- CLINICAL TRIAL AND THEORETICAL CONSIDERATIONS.
204409 02-15
INHIBITION BY DIAZEPAM OF THE TREMOR AND THE INCREASE OF CEREBELLAR CGMP CONTENT ELICITED BY HARMALINE.
207798 03-03
PARKINSONIAN TYPE TREMOR AND THE ACTION OF HARMALINE: EXPERIMENTAL FACTS AND HYPOTHETICAL MECHANISMS.
212182 03-03
STUDIES OF LITHIUM INDUCED TREMOR BY MEANS OF DIFFERENT MEASUREMENT METHODS.
217453 04-15
CONTRASTING LOCAL EFFECTS OF MAO INHIBITORS ON CAUDATE TREMOR ACTIVITIES.
217669 04-03

TREMORGENIC
THE SENSITIVITY OF BARBITONE DEPENDENT AND WITHDRAWN RATS TO TREMORGENIC DRUGS.
197303 01-03

TREMORIGEN
A NOVEL TREMORIGEN ANTAGONIZED BY D-AMPHETAMINE.
217874 04-03

TREND
LONGITUDINAL TREND IN PRESCRIBING PSYCHOTROPIC DRUGS.
205633 03-17

TRENDS
CLINICAL TRENDS AND PSYCHOMETRIC APPRAISAL OF A GROUP OF SCHIZOPHRENICS TREATED WITH THIOTHIXENE (NAVANE).
208981 03-08

TRF
AN ATTEMPT TO VERIFY THE ANTIDEPRESSANT ACTION OF THE HYPOTHALAMIC THYROSTIMULIN (THYROTROPIN-RELEASING FACTOR OR TRF) IN MELANCHOLIC STATES.
216758 04-09

TRH
PROTIRELIN (TRH) IN DEPRESSION.
194827 01-14
THYROTROPIN-RELEASING HORMONE (TRH) IN DEPRESSION: A PRELIMINARY REPORT.
195929 01-10
NEUROTROPIC EFFECTS OF THYROTROPIN-RELEASING HORMONE (TRH).
197953 01-04
CLINICAL AND NEUROENDOCRINOLOGICAL STUDY OF TRH IN MELANCHOLIA.
212162 03-09
EFFECTS OF THYROTROPIN-RELEASING HORMONE (TRH) ON THE ACTIONS OF PENTOBARBITAL AND OTHER CENTRALLY ACTING DRUGS.
215692 04-03

TRIAZOLAM
COMPARISON OF THE HYPNOTIC ACTIVITY OF TRIAZOLAM, FLURAZEPAM HYDROCHLORIDE, AND PLACEBO.
215673 04-14
THE EFFECT OF TRIAZOLAM ON THE SLEEP OF INSOMNIACS.
217548 04-14

TRIAZOLOBENZODIAZEPINE
CLINICAL STUDIES OF D-40TA (TRIAZOLOBENZODIAZEPINE) -- CROSSOVER TRIAL ON SLEEP DISTURBANCES AND SLEEP EEG IN NORMAL ADULTS.
209412 03-10

TRICARBOXYLIC
METABOLIC COMPARTMENTATION IN THE BRAIN: METABOLISM OF A TRICARBOXYLIC ACID CYCLE INTERMEDIATE, (1,4-14C)SUCCINATE, AFTER INTRACEREBRAL ADMINISTRATION.
210780 03-03

TRICEDIL
THE EFFECT OF THE PSYCHOTROPIC AGENTS (CHLORPROMAZINE, MAJEPTIL, TRICEDIL) ON PROTEIN SYNTHESIS IN VARIOUS PORTIONS OF THE RAT BRAIN.
223063 04-03

TRICHLOROETHANOL
COMPARATIVE STUDY OF THE EFFECTS OF CHLORAL HYDRATE AND TRICHLOROETHANOL ON CEREBRAL METABOLISM.
194742 01-03
COMPARISON OF THE EFFECTS OF CHLORAL HYDRATE AND TRICHLOROETHANOL ON THE EEG OF THE ISOLATED PERFUSED RAT BRAIN.
194743 01-03

TRICHLOROPHENOXYACETIC
LONG-LASTING EFFECTS OF PRENATAL 2,4,5 TRICHLOROPHENOXYACETIC ACID ON OPEN-FIELD BEHAVIOR IN RATS: PRE- AND POSTNATAL MEDIATION.
223044 04-04

TRICLORYL
CLINICAL PHARMACOLOGICAL STUDY OF A HYPNOTIC DRUG, TRICLORYL.
200009 02-11

TRICYCLIC
STEREOCHEMICAL APPROACHES TO TRICYCLIC PSYCHOACTIVE AGENTS. (PH.D. DISSERTATION).
194565 01-01
CARDIOVASCULAR ABNORMALITIES FOLLOWING TRICYCLIC ANTIDEPRESSANT DRUG OVERDOSAGE.
195847 01-15
ONCE-A-DAY DOSAGE TRICYCLIC ANTIDEPRESSANT DRUG THERAPY: A SURVEY.
196679 01-09
THE EFFECT OF LITHIUM CARBONATE IN COMBINATION WITH TRICYCLIC ANTIDEPRESSANTS IN ENDOGENOUS DEPRESSION: A DOUBLE-BLIND, MULTICENTER TRIAL.
197035 01-09
THE EFFECTS OF THE TRICYCLIC ANTIDEPRESSANTS DESMETHYLIMIPRAMINE, DOXEPIN AND IPRINDOLE ON THE ISOLATED PERFUSED RABBIT HEART.
197277 01-03
ARRHYTHMIAS EVOKED BY INFUSION OF TRICYCLIC ANTIDEPRESSANTS AND NORADRENALINE ON ISOLATED RABBIT HEARTS.
197939 01-03
POTENTIAL CARDIOTOXICITY FROM PHENOTHIAZINES AND TRICYCLIC ANTIDEPRESSANTS.
198044 01-15
POTENTIATION WITH TRICYCLIC ANTIDEPRESSANTS OF THE INHIBITORY ACTION OF APOMORPHINE ON THE ATTITUDINAL REFLEX IN FROGS.
201919 02-04
LIPIDOSIS LIKE ALTERATIONS IN SPINAL CORD AND CEREBELLAR CORTEX OF RATS TREATED WITH CHLORPHENTERMINE OR TRICYCLIC ANTIDEPRESSANTS.
202767 02-03
TRICYCLIC ANTIDEPRESSANT POISONING: REVERSAL OF COMA, CHOREOATHETOSIS, AND MYOCLONUS BY PHYSOSTIGMINE.
202919 02-15
NEGATIVE INOTROPIC EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON THE ISOLATED RIGHT VENTRICULAR PAPILLARY MUSCLE OF THE CAT.
204400 02-05
POSSIBLE PHARMACOLOGICAL AND THEORETICAL IMPLICATIONS OF X-RAY STRUCTURE OF THE TRICYCLIC ANTIDEPRESSANT IMIPRAMINE.
205029 02-01
EFFECTS OF PSYCHOACTIVE TRICYCLIC DRUGS ON THE EEG OF THE ISOLATED PERFUSED RAT BRAIN.
205492 02-03
CARDIOTOXIC EFFECTS OF TRICYCLIC ANTIDEPRESSANTS IMIPRAMINE, AMITRIPTYLINE AND DOSULEPIN (PROTHIADEN-SPOFA) IN AN ACUTE EXPERIMENT IN RATS.
205597 02-15
L-DOPA AND TRICYCLIC ANTIDEPRESSANTS IN AFFECTIVE DISORDERS. A PILOT STUDY.
205601 03-09
DIFFERENT URINARY EXCRETIONS OF 3-METHOXY-4-HYDROXYPHENYLGLYCOL AND RESPONSE TO TRICYCLIC ANTIDEPRESSIVE DRUGS.
206985 03-13
TRICYCLIC ANTIDEPRESSANT DRUGS AND DOPAMINE SENSITIVE ADENYLCYCLASE FROM RAT CAUDATE NUCLEI.
206990 03-03
COMBINED THYROID (TRIIODOTHYRONINE) TRICYCLIC ANTIDEPRESSANT TREATMENT IN DEPRESSIVE STATES.
207720 03-09
CLINICAL EXPERIENCES IN TREATING DEPRESSED PATIENTS WITH A COMBINATION OF TRICYCLIC DRUGS AND THYROID EXTRACT.
209144 03-09
CARDIOVASCULAR COMPLICATIONS OF TRICYCLIC ANTIDEPRESSANT OVERDOSAGE.
209234 03-15
SOME OBSERVATIONS ON THE CORRELATIONS BETWEEN PLASMA LEVELS OF MONOMETHYLATED TRICYCLIC ANTIDEPRESSANTS AND THERAPEUTIC EFFECTS.
210507 03-09
PHARMACOKINETIC INTERACTION BETWEEN NEUROLEPTICS AND TRICYCLIC ANTIDEPRESSANTS IN THE RAT.
210834 03-03
TRICYCLIC ANTIDEPRESSIVE DRUGS AND DOPAMINE SENSITIVE ADENYLATE-CYCLASE FROM RAT BRAIN STRIATUM.
210856 03-03
COMPARATIVE PHARMACOLOGICAL STUDIES ON BUTRIPTYLINE AND SOME RELATED STANDARD TRICYCLIC ANTIDEPRESSANTS.
211101 03-03
PHYSOSTIGMINE SALICYLATE IN THE TREATMENT OF TRICYCLIC ANTIDEPRESSANT OVERDOSAGE.
212265 03-15
REVERSAL OF DELIRIUM INDUCED BY TRICYCLIC ANTIDEPRESSANT DRUGS WITH PHYSOSTIGMINE.
213708 04-15
EFFECT OF TRICYCLIC ANTIDEPRESSANTS AND ALCOHOL ON PSYCHOMOTOR SKILLS RELATED TO DRIVING.
215667 04-14
A DOUBLE-BLIND COMPARISON OF THREE TIMES DAILY AND SINGLE NIGHT DOSAGE OF THE TRICYCLIC ANTIDEPRESSANT DOTHIEPIN.
216463 04-09
THE INFLUENCE OF TRICYCLIC ANTIDEPRESSANTS, AZAPHEN AND IMIZINE ON BLOOD SUGAR CONCENTRATION CHANGES PRODUCED BY EPINEPHRINE AND SEROTONIN.
217214 04-03
COMPARISON OF THE EFFECTS OF TETRACYCLIC AND TRICYCLIC ANTIDEPRESSANTS ON THE SEROTONIN UPTAKE BY HUMAN THROMBOCYTES IN VITRO.
217258 04-13
EFFECTS OF TRICYCLIC ANTIDEPRESSANTS UPON HUMAN PLATELET MONOAMINEOXIDASE.
217356 04-13
INTERACTION BETWEEN CENTRALLY ACTING HYPOTENSIVE DRUGS AND TRICYCLIC ANTIDEPRESSANTS.
217575 04-03
ARRHYTHMIAS AND INHIBITION OF NORADRENALINE UPTAKE CAUSED BY TRICYCLIC ANTIDEPRESSANTS AND CHLORPROMAZINE ON THE ISOLATED PERFUSED RABBIT HEART.
217657 04-03
COMPARATIVE STUDIES OF A NEW 5-HT UPTAKE INHIBITOR AND SOME TRICYCLIC THYMOLEPTICS.
217663 04-03
INFLUENCE OF SOME TRICYCLIC ANTIDEPRESSIVE DRUGS ON THE UPTAKE OF 5-HYDROXYTRYPTAMINE BY RAT BLOOD PLATELETS.
217693 04-03
THE INFLUENCE OF APOMORPHINE AND TRICYCLIC ANTIDEPRESSANT DRUGS ON THE LEVEL OF SEROTONIN AND ITS METABOLITE IN RAT BRAIN.
217815 04-03
SIMILARITIES OF THE INFLUENCE OF SECONDARY AND TERTIARY TRICYCLIC ANTIDEPRESSANTS ON THE EFFECT OF RESERPINE IN FROGS AND ON THE SEROTONIN UPTAKE OF HUMAN THROMBOCYTES.
219503 04-13
A COMPARISON OF THE ACTION OF THE TRICYCLIC ANTIDEPRESSANTS, AZAPHEN AND IMIPRAMINE, ON THE GASTROINTESTINAL TRACT OF TEST ANIMALS.
219505 04-03
INHIBITION OF CELLULAR ATP HYDROLYZING ACTIVITY BY TRICYCLIC ANTIDEPRESSANTS AND PHENOTHIAZINE TRANQUILIZERS.
221053 04-03
RELATIONSHIPS BETWEEN TRICYCLIC ANTIDEPRESSANT CONCENTRATIONS, 1-3H-NORAFRENALINE UPTAKE AND CHRONOTROPIC EFFECT IN ISOLATED RAT ATRIA.
221188 04-03
NOXIPTILIN (AGEDAL) -- A NEW TRICYCLIC ANTIDEPRESSANT WITH A FASTER ONSET OF ACTION? A DOUBLE-BLIND, MULTICENTRE COMPARISON WITH AMITRIPTYLINE.
221306 04-09

COCAINE, AMPHETAMINE, AND TRICYCLIC ANTIDEPRESSANTS AND SYNAPTIC TRANSMISSION.
221386 04-13
OBJECTIVE ASSESSMENT OF ANTICHOLINERGIC SIDE-EFFECTS OF TRICYCLIC ANTIDEPRESSANTS A CONTROLLED STUDY OF IMIPRAMINE AND IMIPRAMINE-N-OXIDE.
221633 04-15
TRICYCLIC ANTIDEPRESSANTS: EFFECTS ON THE FIRING RATE OF BRAIN NORADRENERGIC NEURONS.
222805 04-03
TRICYCLIC ANTIDEPRESSANTS AND TRYPTOPHAN IN UNIPOLAR DEPRESSION.
224423 04-09
TRICYCLIC EFFECT ON BUTAPERAZINE PLASMA LEVEL.
224909 04-13

TRICYCLICS
ANTIDEPRESSANT RESPONSE TO TRICYCLICS AND URINARY MHPG IN UNIPOLAR PATIENTS: CLINICAL RESPONSE TO IMIPRAMINE OR AMITRIPTYLINE.
207443 03-13

TRIFLUOPERAZINE
A COMPARATIVE STUDY OF DOXEPIN VERSUS TRIFLUOPERAZINE IN ANXIETY NEUROSIS.
194276 01-10
A CONTROLLED TRIAL OF TRIFLUPERIDOL WITH TRIFLUOPERAZINE.
196069 01-08
THE INFLUENCE OF TRIFLUOPERAZINE, CARBIDINE AND IMIZINE ON EVOKED POTENTIALS IN DIFFERENT STRUCTURES OF THE LIMBIC RETICULAR COMPLEX.
200564 02-02
TISSUE METABOLITES OF TRIFLUOPERAZINE, FLUPHENAZINE, PROCHLORPERAZINE, AND PERPHENAZINE IN THE RAT: IDENTIFICATION AND SYNTHESIS.
200738 02-01
COMPARATIVE STUDY OF CLOTHIAPINE AND TRIFLUOPERAZINE IN EPISODES OF ACUTE PARANOID SCHIZOPHRENIA.
217025 04-08

TRIFLUPERIDOL
A CONTROLLED TRIAL OF TRIFLUPERIDOL WITH TRIFLUOPERAZINE.
196069 01-08
PILOT CLINICAL STUDY WITH TRIFLUPERIDOL (TRISEDYL) THERAPY IN PSYCHOTIC PATIENTS.
205589 02-09
DOSE LEVEL AND EFFECTS OF TRIFLUPERIDOL IN CLINICAL USE FOR SCHIZOPHRENIA.
207643 03-08

TRIFTAZINE
THE ACTION OF CHLORPROMAZINE AND TRIFTAZINE ON DISCHARGES OF CORTICAL NEURONS IN RABBITS AFTER CHRONIC ADMINISTRATION OF THE DRUGS.
215499 04-03
THE CORRELATION BETWEEN TRIFTAZINE DISTRIBUTION IN SOME RAT ORGANS AND ITS PHARMACOLOGICAL EFFECTS WITH DIFFERENT TYPES OF ADMINISTRATION.
223016 04-03

TRIGEMINAL
NORADRENALINE MEDIATED INHIBITION BY LOCUS-COERULEUS OF SPINAL TRIGEMINAL NEURONS.
210703 03-03

TRIHYDROXYPHENYLETHYLAMINE
THE EFFECT OF AN ADRENAL DEMEDULLATION AND CHEMICAL SYMPATHECTOMY (2,4,5 TRIHYDROXYPHENYLETHYLAMINE) ON THE ACQUISITION OF A ONE-WAY ACTIVE AVOIDANCE RESPONSE. (PH.D. DISSERTATION).
222736 04-04

TRIIODOTHYRONINE
THE EFFECT OF TRIIODOTHYRONINE IN COMBINATION WITH IMIPRAMINE ON (3H) CYCLIC-AMP PRODUCTION IN SLICES OF RAT CEREBRAL CORTEX.
202777 02-03
COMBINED THYROID (TRIIODOTHYRONINE) TRICYCLIC ANTIDEPRESSANT TREATMENT IN DEPRESSIVE STATES.
207720 03-09

TRIMETHADIONE
INTERACTION OF PENTYLENETETRAZOL AND TRIMETHADIONE ON THE METABOLISM OF SEROTONIN IN BRAIN AND ITS RELATION TO THE ANTICONVULSANT ACTION OF TRIMETHADIONE.
195093 01-03

TRIMETHOXYBENZOIC
OXIDATIVE METABOLISM OF MESCALINE IN THE CENTRAL NERVOUS SYSTEM -- V. IN VITRO DEAMINATION OF MESCALINE TO 3,4,5 TRIMETHOXYBENZOIC ACID.
210813 03-03

TRIMETIN
PROGNOSIS OF THE THERAPEUTIC EFFECT OF SUXILEP AND TRIMETIN USING A SUCCESSIONAL STATISTICAL PROCEDURE.
224086 04-11

TRIMIPRAMINE
TRIMIPRAMINE (SURMONTIL) -- CLINICAL EVALUATION IN DEPRESSION.
195617 01-09
SURMONTIL (TRIMIPRAMINE) -- A CLINICAL TRIAL.
195620 01-10
CLINICAL TRIAL OF TRIMIPRAMINE (SURMONTIL).
198119 02-07

TRINITRATE
HEAT PRODUCTION AND OXYGEN CONSUMPTION OF THE ISOLATED RABBIT HEART UNDER THE INFLUENCE OF STROPHANTHIN VERAPAMIL, AND GLYCERYL TRINITRATE.
197567 01-03

TRISEDYL
PILOT CLINICAL STUDY WITH TRIFLUPERIDOL (TRISEDYL) THERAPY IN PSYCHOTIC PATIENTS.
205589 02-09

TRISUBSTITUTED
MONOAMINEOXIDASE INHIBITORY AND ANTICONVULSANT PROPERTIES OF 1,2,4 TRISUBSTITUTED 5-IMIDAZOLONES.
225105 04-01

TRNA
MESCALINE-INDUCED CHANGES OF BRAIN-CORTEX RIBOSOMES: EFFECT OF MESCALINE ON TRNA AND AMINOACYL-TRNA SYNTHETASE.
195242 01-03

TROPOLONE
EFFECT OF TROPOLONE ON VASCULAR SYMPATHETIC NEUROEFFECTOR TRANSMISSION.
197970 01-03

TROUBLE
RESERPINE THERAPY FOR MENOPAUSAL TROUBLE.
201694 02-11

TROUBLES
CLINICAL TRIAL OF CLOCAPRAMINE IN NEUROTIC PATIENTS WHO HAD TROUBLES IN EVERYDAY LIFE OWING TO SEVERE ANXIETY, IRRITABILITY AND DEPRESSION.
204464 02-10

TRUNKS
NERVE IMPULSE ENHANCED RELEASE OF AMINO ACIDS FROM NONSYNAPTIC REGIONS OF PERIPHERAL AND CENTRAL NERVE TRUNKS OF BULLFROG.
213277 03-03

TRYPAN-BLUE
EFFECT OF MORPHINE, HYDROMORPHONE, METHADONE, MESCALINE, TRYPAN-BLUE, VITAMIN-A, SODIUM SALICYLATE AND CAFFEINE ON THE SERUM INTERFERON LEVEL IN RESPONSE TO VIRAL INFECTION.
217654 04-03

TRYPTAMINE
STUDIES OF TRYPTAMINE AND LYSERGIC ACID DIETHYLAMIDE (LSD) ON CUTANEOUS C-FIBER AND POLYSYNAPTIC REFLEXES IN THE CAT.
197814 01-03
1 N-METHYLATED TRYPTAMINE DERIVATIVES: SYNTHESIS AND PROPERTIES.
207496 03-01
FACTORS INFLUENCING BRAIN AND TISSUE LEVELS OF TRYPTAMINE: SPECIES, DRUGS AND LESIONS.
210850 03-03

TRYPTAMINERGIC
TRYPTAMINERGIC AND DOPAMINERGIC RESPONSES OF SCHISTOSOMA-MANSONI.
194155 01-03

TRYPTAMINES
ON THE PHARMACOLOGY OF SOME BETA-HYDROXYLATED TRYPTAMINES.
197568 01-03
BIOCHEMICAL EFFECTS OF DIHYDROXYLATED TRYPTAMINES ON CENTRAL INDOLEAMINE NEURONES.
204340 02-03

TRYPTOPHAN
DOES MAPROTILINE (LUDIOMIL) INFLUENCE SEROTONIN UPTAKE AND FREE TRYPTOPHAN CONCENTRATION IN HUMAN PLASMA
192943 01-13
ANTIDEPRESSANT ACTION OF TRYPTOPHAN.
194857 01-13
EFFECT OF LITHIUM ON SERUM TRYPTOPHAN AND BRAIN SEROTONIN IN RATS.
195232 01-03
EFFECTS IN THE SUCKLING RAT OF CHRONIC TREATMENT WITH TRYPTOPHAN AND A MONOAMINE OXIDASE INHIBITOR.
195906 01-04
A PATTERN OF ANTIDEPRESSIVE EFFECT OF TRYPTOPHAN & IMIPRAMINE IN MALES & FEMALES.
196680 01-09
PLASMA TRYPTOPHAN TOLERANCE CURVES IN DRUG-FREE NORMAL CONTROLS, SCHIZOPHRENIC PATIENTS AND PRISONER VOLUNTEERS.
200773 02-13
TRYPTOPHAN METABOLISM EXAMINATIONS IN OLIGOPHRENIC CHILDREN. FIRST REPORT: RESULTS OF THE EXCRETION OF KYNURENINE AND XANTHURENIC ACID AFTER TRYPTOPHAN LOADING AND THEIR DEPENDENCE UPON THE SUPPLY.
203645 02-13

CEREBRAL HEMODYNAMIC EFFECTS OF CHRONIC TRYPTOPHAN FEEDING IN MAN AS MEASURED BY QUANTIFIED CEREBRAL IMPEDANCE PLETHYSMOGRAPHY.
206337 03-08

CORRELATIONS BETWEEN CIRCADIAN CHANGES IN SERUM AMINO ACIDS OR BRAIN TRYPTOPHAN AND THE CONTENTS OF SEROTONIN AND 5-HYDROXYINDOLEACETIC ACID IN REGIONS OF THE RAT BRAIN.
210673 03-03

DIETARY TRYPTOPHAN AND THE SELECTION OF ETHYL ALCOHOL IN DIFFERENT STRAINS OF RATS.
217520 04-03

TRYPTOPHAN PLUS A PYRROLASE INHIBITOR FOR DEPRESSION?.
219522 04-03

INHIBITORY ACTION OF NOREPINEPHRINE ON THE INDUCTION OF TRYPTOPHAN 2,3 DIOXYGENASE BY CORTISOL: MEDIATION BY THE ALPHA-RECEPTOR.
221051 04-03

POTENTIATION OF ANTIDEPRESSANT ACTION OF CLOMIPRAMINE BY TRYPTOPHAN.
221385 04-09

TRYPTOPHAN METABOLISM IN DEVELOPING CHICK BRAIN.
223053 04-03

TRICYCLIC ANTIDEPRESSANTS AND TRYPTOPHAN IN UNIPOLAR DEPRESSION.
224423 04-09

TRYPTOPHAN-HYDROXYLASE

ACTION OF (S)- AND (R) P-SUBSTITUTED AMPHETAMINE HYDROCHLORIDES AND (ALPHA S)- AND (ALPHA R) P-CHLORONOREPHEDRINE AND (ALPHA S)- AND (ALPHA R) P-CHLORONORPSEUDOEPHEDRINE HYDROCHLORIDES ON THE LEVEL OF 5-HYDROXYTRYPTAMINE AND THE ACTIVITY OF TRYPTOPHAN-HYDROXYLASE IN RAT BRAIN.
202417 02-03

A DEVELOPMENTAL STUDY OF THE EFFECTS OF 5,7 DIHYDROXYTRYPTAMINE ON REGIONAL TRYPTOPHAN-HYDROXYLASE IN RAT BRAIN.
217555 04-03

TRYPTOPHAN-5-HYDROXYLASE

EFFECT OF P-CHLOROAMPHETAMINE ON CEREBRAL TRYPTOPHAN-5-HYDROXYLASE IN VIVO: A REEXAMINATION.
210826 03-03

TRYPTOPHANE

DETERMINATION OF NORADRENALINE, DOPAMINE, SEROTONIN, 5-HYDROXYINDOLEACETIC ACID, TYROSINE AND TRYPTOPHANE IN THE ISOLATED PERFUSED RAT BRAIN.
197967 01-06

TUBERCLE

EFFECT OF ANTIPSYCHOTIC DRUGS ON HOMOVANILLIC ACID LEVELS IN STRIATUM AND OLFACTORY TUBERCLE OF THE RAT.
210864 03-03

TUBERCLES

EFFECTS OF PSYCHOTROPIC DRUGS ON HYPEREMOTIONALITY OF RATS WITH BILATERAL ABLATIONS OF THE OLFACTORY BULBS AND OLFACTORY TUBERCLES.
195231 01-04

6-HYDROXYDOPAMINE LESIONS OF OLFACTORY TUBERCLES AND CAUDATE NUCLEI: EFFECT ON AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR IN RATS.
202788 02-04

TUBES

THE EFFECT OF PSYCHOTROPIC AND ANTICONVULSIVE DRUGS ON THE TRANSPORT OF ATPASE IN THE RENAL TUBES OF A GUINEA-PIG.
223015 04-05

TUBOCURARINE

DEPOLARIZATION, DESENSITIZATION AND THE EFFECTS OF TUBOCURARINE AND NEOSTIGMINE IN CULTURED SKELETAL MUSCLE.
193447 01-03

TUBULAR

RENAL TUBULAR FUNCTION IN PATIENTS ON LONG-TERM LITHIUM THERAPY.
207043 03-13

TUMORS

EFFECTS OF CENTRAL ACTING DRUGS AND ERGOT DERIVATIVES ON PROLACTIN AND GROWTH HORMONE SECRETION, ON GROWTH OF PITUITARY AND MAMMARY TUMORS AND ON REPRODUCTION IN OLD RATS. (PH.D. DISSERTATION).
194571 01-03

TUNNEL

GENETICALLY SELECTED WINNER AND LOSER RATS IN THE TUNNEL COMPETITION: INFLUENCE OF APOMORPHINE AND DOPA.
217829 04-04

TURKEY

NEW PSYCHOTROPIC DRUG TRIALS IN TURKEY.
213594 04-11

TURN-OVER

EFFECTS OF HALOTHANE AND NITROUS OXIDE ANESTHESIA ON 5-HT TURN-OVER IN THE RAT BRAIN.
217655 04-03

TWIN

GENETIC DETERMINANT OF LITHIUM ION DISTRIBUTION. I. AN IN VITRO MONOZYGOTIC DIZYGOTIC TWIN STUDY.
194826 01-13

TWO-CUE

THE EFFECTS OF SCOPOLAMINE ON A TWO-CUE DISCRIMINATION.
192952 01-04

TWO-DAY

CHROMOSOMAL DAMAGE IN CHRONICAL USERS OF CANNABIS: IN VIVO INVESTIGATION WITH TWO-DAY LEUKOCYTE CULTURES.
210810 03-15

TWO-FACTOR

A TWO-FACTOR BIOCHEMICAL THEORY OF SCHIZOPHRENIA.
206542 03-03

TWO-WAY

THE EFFECTS OF NICOTINE ON TWO-WAY AVOIDANCE CONDITIONING IN BIDIRECTIONALLY SELECTED STRAINS OF RATS.
217525 04-04

TYPOLOGY

TYPOLOGY OF DEPRESSIONS AND THERAPEUTIC BEHAVIOR OF PSYCHIATRISTS.
212215 03-17

PLASMA LEVEL, DEPRESSIVE TYPOLOGY, CLINICAL OUTCOME.
224836 04-09

TYPUS-MELANCHOLICUS

CRITICAL REMARKS ON TELLENBACHS CONCEPT OF TYPUS-MELANCHOLICUS.
206696 03-09

TYRAMINE

THE EFFECTS OF AMPHETAMINE AND COCAINE ON THE RESPONSE OF THE ISOLATED GUINEA-PIG VAS-DEFERENS TO NORADRENALINE, TYRAMINE AND NERVE STIMULATION.
197463 01-03

RELATIONSHIP BETWEEN THE CHANGES ON BLOOD PRESSURE RESPONSE AND THE CARDIAC CATECHOLAMINE LEVEL AFTER SINGLE AND REPEATED ADMINISTRATIONS OF TYRAMINE AND METHAMPHETAMINE IN RATS.
197491 01-03

INFLUENCE OF OXYMETAZOLINE AND PHENTOLAMINE ON NORADRENALINE (NA) RELEASE CAUSED BY ELECTRICAL STIMULATION, POTASSIUM, TYRAMINE AND DIMETHYLPHENYLPIPERAZINE (DMPP).
197973 01-03

TWO CONTROLLED TRIALS OF TYRAMINE IN CHILDREN WITH MIGRAINE.
206058 03-13

REGIONAL DISTRIBUTION OF MONOAMINEOXIDASE ACTIVITY FOR 5-HYDROXYTRYPTAMINE AND TYRAMINE IN THE HYPOTHALAMUS OF THE RAT.
223049 04-03

TYROCALCITONIN

THE INFLUENCE OF TYROCALCITONIN ON CONDITIONAL REFLEXES AND THE ELECTRICAL ACTIVITY OF THE BRAIN IN ANIMALS.
198479 02-02

TYROSINE

DETERMINATION OF NORADRENALINE, DOPAMINE, SEROTONIN, 5-HYDROXYINDOLEACETIC ACID, TYROSINE AND TRYPTOPHANE IN THE ISOLATED PERFUSED RAT BRAIN.
197967 01-06

COMPARISON OF THE EFFECTS OF LITHIUM, BETA-PHENYLETHYLAMINE AND TYROSINE ON XENOPUS EMBRYOS.
200752 02-03

THE ROLE OF TYROSINE TRANSAMINASE IN BRAIN FUNCTION.
213607 04-03

THE INFLUENCE OF DESIPRAMINE AND AMITRIPTYLINE ON THE ACCUMULATION OF (3H)NORADRENALINE AND ITS TWO MAJOR METABOLITES FORMED FROM (3H)TYROSINE IN THE RAT BRAIN.
217966 04-03

AMPHETAMINE-INDUCED INHIBITION OF TYROSINE HYDROXYLATION IN HOMOGENATES OF RAT CORPUS-STRIATUM.
222813 04-03

TYROSINE-HYDROXYLASE

EFFECTS OF THE NORADRENALINE METABOLITES ON TYROSINE-HYDROXYLASE ACTIVITY IN GUINEA-PIG ATRIA.
193279 01-02

POTENTIATION OF DRUG INITIATED ADRENAL TYROSINE-HYDROXYLASE INDUCTION BY DIAZEPAM.
193304 01-03

TYROSINE-HYDROXYLASE (TH) IN NUCLEUS-ACCUMBENS AND STRIATUM: EFFECTS OF NEUROLEPTICS ON THE AFFINITY FOR PTERIDINE COFACTOR. (UNPUBLISHED PAPER).
196588 01-03

INVOLVEMENT OF CYCLIC NUCLEOTIDES IN THE LONG-TERM INDUCTION OF TYROSINE-HYDROXYLASE. (UNPUBLISHED PAPER).
196590 01-03

ANTAGONISTIC EFFECTS OF NEUROLEPTICS AND APOMORPHINE ON SYNAPTOSOMAL TYROSINE-HYDROXYLASE IN VITRO.
198209 02-03

MINIMUM DURATION OF TRANS-SYNAPTIC STIMULATION REQUIRED FOR THE INDUCTION OF TYROSINE-HYDROXYLASE BY RESERPINE IN THE RAT SUPERIOR CERVICAL GANGLION.
199999 02-03

DOPAMINERGIC NEURONS: DRUG-INDUCED ANTAGONISM OF THE INCREASE IN TYROSINE-HYDROXYLASE ACTIVITY PRODUCED BY CESSATION OF IMPULSE FLOW.
202664 02-03

CHANGES OF KINETIC CONSTANT OF STRIATAL TYROSINE-HYDROXYLASE ELICITED BY NEUROLEPTICS THAT IMPAIR THE FUNCTION OF DOPAMINE RECEPTORS.
202716 02-03

EVIDENCE AGAINST A CAUSAL RELATIONSHIP BETWEEN INCREASE IN C-AMP AND INDUCTION OF TYROSINE-HYDROXYLASE IN THE RAT ADRENAL MEDULLA.
202795 02-03

TYROSINE-HYDROXYLASE INHIBITION BY CYCLOHEXIMIDE AND ANISOMYCIN IS NOT RESPONSIBLE FOR THEIR AMNESIC EFFECT.
203572 02-04

POSSIBLE ROLE OF CATECHOLAMINES (CA) IN THE REGULATION OF ADRENAL TYROSINE-HYDROXYLASE (TH).
207333 03-03

ARE AUTORECEPTORS IN DOPAMINERGIC NEURONS INVOLVED IN THE CHANGE OF THE KINETIC STATE OF STRIATAL TYROSINE-HYDROXYLASE ELICITED BY ANTIPSYCHOTICS? (UNPUBLISHED PAPER).
208636 03-03

EFFECT OF STRESS ON CATECHOLAMINES AND TYROSINE-HYDROXYLASE ACTIVITY OF INDIVIDUAL HYPOTHALAMIC NUCLEI.
208994 03-03

ONTOGENY OF THE INDUCTION OF TYROSINE-HYDROXYLASE BY RESERPINE IN THE SUPERIOR CERVICAL GANGLION, NUCLEUS LOCUS-COERULEUS AND ADRENAL GLAND.
210670 03-03

EFFECTS OF CATECHOLAMINE RELEASING AGENTS ON SYNAPTOSOMAL DOPAMINE BIOSYNTHESIS: MULTIPLE POOLS OF DOPAMINE OR MULTIPLE FORMS OF TYROSINE-HYDROXYLASE?.
210825 03-03

EFFECT OF VARIOUS INHIBITORS OF TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE ON SELF-STIMULATION BEHAVIOUR.
213431 04-04

INDUCTION OF TYROSINE-HYDROXYLASE ELICITED BY BETA ADRENERGIC RECEPTOR AGONISTS IN NORMAL AND DECENTRALIZED SYMPATHETIC GANGLIA: ROLE OF CYCLIC 3,5 ADENOSINE-MONOPHOSPHATE.
215688 04-03

THE EFFECT OF DOPAMINE AND OF APOMORPHINE ON DB-CAMP INDUCED STIMULATION OF SYNAPTOSOMAL TYROSINE-HYDROXYLASE.
217823 04-03

DEXAMETHASONE INDUCES TYROSINE-HYDROXYLASE IN SYMPATHETIC GANGLIA BUT NOT IN ADRENAL MEDULLA.
217853 04-03

DIFFERENTIAL RATES OF INCREASE IN PONTINE TYROSINE-HYDROXYLASE AND DOPAMINE-BETA-HYDROXYLASE ACTIVITIES AFTER RESERPINE.
217854 04-03

REGIONAL DISTRIBUTION OF TYROSINE-HYDROXYLASE, NOREPINEPHRINE AND DOPAMINE WITHIN THE AMYGDALOID COMPLEX OF THE RAT.
217872 04-03

STEREOSPECIFICITY OF DOPAMINE RECEPTORS INVOLVED IN THE REGULATION OF THE KINETIC STATE OF TYROSINE-HYDROXYLASE IN STRIATUM AND NUCLEUS-ACCUMBENS.
217888 04-03

EFFECTS OF SINGLE AND MULTIPLE DOSE LSD ON ENDOGENOUS LEVELS OF BRAIN TYROSINE-HYDROXYLASE AND CATECHOLAMINES.
221044 04-12

ROLE FOR POSTSYNAPTIC DOPAMINE RECEPTORS IN THE REGULATION OF THE KINETIC STATE OF STRIATAL TYROSINE-HYDROXYLASE. (UNPUBLISHED PAPER).
225307 04-03

U-SHAPED
U-SHAPED FUNCTIONS IN A SHOCK ESCAPE TASK.
222265 04-04

UCS-CS
INVESTIGATIONS OF UCS-CS MEDIATION IN RADIATION INDUCED CONDITIONED TASTE AVERSION. (PH.D. DISSERTATION).
220681 04-04

ULCER
SELECTIVE INHIBITION OF DOPAMINE-BETA-HYDROXYLASE IN THE PERIPHERAL TISSUES BY 5-DIMETHYLDITHIOCARBAMYLPICOLINIC ACID; ITS EFFECT ON STRESS INDUCED ULCER, ETHANOL INDUCED SLEEP AND BLOOD PRESSURE.
204484 02-03

ULCERATION
THE EFFECTS OF CHLORPROMAZINE, ATROPINE, MORPHINE AND PENTOBARBITAL ON INDUCED GASTRIC ULCERATION IN RATS. (PH.D. DISSERTATION).
200405 02-02

ULCUS
PHARMACOLOGICAL EXAMINATIONS BY AN ULCUS INHIBITING AGENT (L-S-519).
197955 01-03

ULTRA-HIGH-DOSE
TREATMENT OF ACUTE SCHIZOPHRENIA WITH ULTRA-HIGH-DOSE FLUPHENAZINE: A FAILURE AT SHORTENING TIME ON A CRISIS INTERVENTION UNIT.
215456 04-08

ULTRASTRUCTURAL
DOSE-DEPENDENCE OF CHLORPHENTERMINE-INDUCED ULTRASTRUCTURAL ALTERATIONS IN RAT.
197960 01-03

ULTRASTRUCTURE
EFFECT OF 6-HYDROXYDOPAMINE ON HYPOTHALAMIC NOREPINEPHRINE AND DOPAMINE CONTENT, ULTRASTRUCTURE OF THE MEDIAN EMINENCE, AND PLASMA CORTICOSTERONE.
193050 01-03

THE NEURON ULTRASTRUCTURE IN SOME BRAIN AREAS DURING A LONG-TERM ADMINISTRATION OF AMINAZINE AND STELAZINE.
200021 02-03

THE EFFECT OF NEUROLEPTICS OF THE PHENOTHIAZINE SERIES ON PULSE ACTIVITY AND THE ULTRASTRUCTURE OF RABBIT CORTICAL NEURONS.
219606 04-03

SOME PECULIARITIES OF THE NEURON ULTRASTRUCTURE IN THE BRAIN-CORTEX MOTOR AREA UNDER THE INFLUENCE OF LYSERGIC ACID DIETHYLAMIDE (LSD) AND HALOPERIDOL.
222890 04-03

ULTRAVIOLET
COLORIMETRIC, ULTRAVIOLET SPECTROPHOTOMETRIC, AND SPECTROPHOTOFLUOROMETRIC DETERMINATION OF DOXEPIN AND SOME OF ITS METABOLITES IN SERUM AND IN URINE.
199214 02-16

UMBILICAL
CONTRACTILE RESPONSES OF GUINEA-PIG UMBILICAL ARTERIES TO VARIOUS HALLUCINOGENIC AGENTS.
200037 02-03

UML
THE RELATION BETWEEN CEREBRAL SEROTONIN LEVELS AND CONDITIONED BEHAVIOUR IN THE RAT FOLLOWING THE ADMINISTRATION OF LSD-25 AND UML.
225564 04-04

UNANAESTHETIZED
THE PHARMACOLOGY OF GROSS BEHAVIOURAL EFFECTS OF CHOLINOMIMETIC SUBSTANCES INJECTED INTO THE CEREBRAL VENTRICLES OF UNANAESTHETIZED CATS: EVIDENCE FOR CENTRAL MUSCARINIC MEDIATION.
202780 02-04

UNANESTHETIZED
MATURATION OF VISUAL ELECTROCORTICAL RESPONSES IN UNANESTHETIZED KITTENS: EFFECTS OF BARBITURATE ANESTHESIA.
199765 02-03

UNCERTAINTY
EFFECTS OF ALCOHOL, UNCERTAINTY AND NOVELTY UPON RESPONSE SELECTION.
200048 02-14

UNCHANGED
MARIHUANA METABOLITES IN URINE OF MAN: III. UNCHANGED DELTA9-TETRAHYDROCANNABINOL.
195053 01-13

UNCONDITIONED
THE EFFECTS OF AMPHETAMINE, IMIPRAMINE AND ICI-58834 (VIVALAN), A POTENTIAL ANTIDEPRESSANT, ON UNCONDITIONED BEHAVIOUR IN RATS.
214016 04-04

UNDECYLENATE
A STUDY OF FLUPENTHIXOL DECANOATE AND PIPOTIAZINE UNDECYLENATE IN SCHIZOPHRENICS.
212238 03-08

UNDERNUTRITION
THE EFFECTS OF CHLORDIAZEPOXIDE ON AVOIDANCE PERFORMANCE OF MICE SUBJECTED TO UNDERNUTRITION OR HANDLING STRESS IN EARLY LIFE.
217463 04-04

EARLY LIFE UNDERNUTRITION AND AGGRESSION IN TWO MOUSE STRAINS.
225081 04-04

UNDRUGGED
SOCIAL INTERACTION BETWEEN DRUGGED AND UNDRUGGED RATS.
196206 01-04

UNEXPECTED
UNEXPECTED COMPLICATIONS BY ANTICHOLINERGICS CONTAINED IN SOPORIFICS AND ANALGESIC DRUGS.
204404 02-15

UNIDENTIFIED
STUDIES ON MICROVIBRATION OF UNIDENTIFIED CLINICAL SYNDROME.
221664 04-14

UNIFIED
THE PROPOSAL OF AN UNIFIED MODEL FOR THE INTERPRETATION OF THE ACTIVITY OF DIFFERENT CLASSES OF BETA-ADRENERGIC AGENTS.
220951 04-01

UNILATERAL

DRUG-INDUCED ROTATION IN RATS AFTER UNILATERAL INTRACEREBRAL INJECTION OF 5,6 DIHYDROXYTRYPTAMINE (5-6-DHT).
192940 01-03

SUPERSENSITIVITY TO DOPAMINE AGONISTS FOLLOWING UNILATERAL, 6-HYDROXYDOPAMINE INDUCED STRIATAL LESIONS IN MICE.
208552 03-03

APOMORPHINE-INDUCED ROTATION IN NORMAL RATS AND INTERACTION WITH UNILATERAL CAUDATE LESIONS.
214012 04-04

UNIPOLAR

THE EFFECT OF LITHIUM ON URINARY MHPG IN UNIPOLAR AND BIPOLAR DEPRESSED PATIENTS. (UNPUBLISHED PAPER).
196042 01-09

LITHIUM RESPONSE IN DEPRESSION AS PREDICTED BY UNIPOLAR/BIPOLAR ILLNESS, AVERAGE EVOKED RESPONSE, CATECHOL-O-METHYLTRANSFERASE AND FAMILY HISTORY. (UNPUBLISHED PAPER).
201000 02-09

ANTIDEPRESSANT RESPONSE TO TRICYCLICS AND URINARY MHPG IN UNIPOLAR PATIENTS: CLINICAL RESPONSE TO IMIPRAMINE OR AMITRIPTYLINE.
207443 03-13

THE EFFECT OF LITHIUM ON URINARY MHPG IN UNIPOLAR AND BIPOLAR DEPRESSED PATIENTS.
221045 04-09

TRICYCLIC ANTIDEPRESSANTS AND TRYPTOPHAN IN UNIPOLAR DEPRESSION.
224423 04-09

UNIT

THE MULTIPLICITY OF INTERACTIONS OF PSYCHOTROPIC DRUGS WITH THE BRAIN SEROTONIN BIOSYNTHETIC UNIT.
195926 01-17

REPORT OF EARLY CLINICAL DRUG EVALUATION UNIT '11.
198041 01-07

REPORT ON THE EARLY CLINICAL DRUG EVALUATION UNIT.
198043 01-07

CHILDRENS PSYCHOPHARMACOLOGY UNIT.
198061 01-07

EARLY CLINICAL DRUG EVALUATION UNIT.
198062 01-07

NIMH-PRB EARLY CLINICAL DRUG EVALUATION UNIT.
198068 01-07

EARLY CLINICAL DRUG EVALUATION UNIT.
198070 01-07

NIMH-PRB EARLY CLINICAL DRUG EVALUATION UNIT.
198073 01-07

THE EFFECT OF ANTIDEPRESSANTS ON UNIT ACTIVITY IN THE MIDBRAIN RAPHE OF RATS.
210789 03-03

TREATMENT OF ACUTE SCHIZOPHRENIA WITH ULTRA-HIGH-DOSE FLUPHENAZINE: A FAILURE AT SHORTENING TIME ON A CRISIS INTERVENTION UNIT.
215456 04-08

UNITED-STATES

TWENTY-THREE PSYCHOTROPIC DRUGS USED IN CHILDREN ABROAD WHICH ARE NOT RECOMMENDED IN THE UNITED-STATES.
213600 04-17

UNITS

RECIPROCAL (PUSH-PULL) EFFECTS OF MORPHINE ON SINGLE UNITS IN THE VENTROMEDIAN AND LATERAL HYPOTHALAMUS AND INFLUENCES ON OTHER NUCLEI: WITH COMMENT ON METHADONE EFFECTS DURING WITHDRAWAL FROM MORPHINE.
210700 03-03

UNRESTRAINED

CHLORDIAZEPOXIDE AND ITS EFFECT ON SLEEP WAKEFULNESS BEHAVIOR IN UNRESTRAINED CATS.
199213 02-04

AN OBSERVATIONAL STUDY OF HALLUCINOGEN INDUCED BEHAVIOR IN UNRESTRAINED MACACA-MULATTA.
210739 03-04

UPTAKE

DOES MAPROTILINE (LUDIOMIL) INFLUENCE SEROTONIN UPTAKE AND FREE TRYPTOPHAN CONCENTRATION IN HUMAN PLASMA
192943 01-13

EFFECTS OF RESERPINE AND CHLORPROMAZINE ON 5-HYDROXYTRYPTAMINE UPTAKE OF PLATELETS FROM MIGRAINOUS AND CONTROL SUBJECTS.
196926 01-13

INFLUENCE OF CATECHOLAMINE UPTAKE BLOCKING DRUGS ON THE INCREASE IN WATER INTAKE AND PLASMA RENIN CONCENTRATION INDUCED BY SOME HYPOTENSIVE DRUGS.
197288 01-03

COMPARISON OF THE SPECIFICITY OF 3-(P-TRIFLUOROMETHYLPHENOXY)-N-METHYL-3 PHENYLPROPYLAMINE AND CHLORIMIPRAMINE AS AMINE UPTAKE INHIBITORS IN MICE.
197870 01-03

STUDIES ON THE UPTAKE OF D-AMPHETAMINE BY RAT CEREBRAL CORTEX SLICES.
197961 01-03

UPTAKE OF NEUROTRANSMITTERS INTO SUBCELLULAR PARTICLES OF THE CAUDATE NUCLEUS.
197962 01-03

UPTAKE AND RELEASE OF POSSIBLE FALSE TRANSMITTER AMINO ACIDS BY RAT BRAIN TISSUE.
199788 02-03

EFFECTS OF BENAPRYZINE, A NEW ANTIPARKINSON DRUG, ON DOPAMINE UPTAKE INTO CORPUS-STRIATUM.
199868 02-03

THE IMPORTANCE OF NEURONAL UPTAKE OF AMINES FOR AMPHETAMINE-INDUCED RELEASE OF 3H-NOREPINEPHRINE FROM ISOLATED BRAIN TISSUE.
202191 02-03

UPTAKE OF CATECHOLAMINES BY HUMAN SYNAPTOSOMES.
202719 02-03

THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON THE UPTAKE AND RELEASE OF 14C-DOPAMINE FROM CRUDE STRIATAL SYNAPTOSOMAL PREPARATIONS.
202775 02-03

EFFECT OF NOMIFENSINE (HOE-984), A NEW ANTIDEPRESSANT, ON UPTAKE OF NORADRENALINE AND SEROTONIN AND ON RELEASE OF NORADRENALINE IN RAT BRAIN SYNAPTOSOMES.
202807 02-03

POSTNATAL DEVELOPMENT OF CHOLINE UPTAKE BY CHOLINERGIC TERMINALS IN RAT BRAIN.
210713 03-03

ELECTROCONVULSIVE SHOCK: SUSTAINED DECREASE IN NOREPINEPHRINE UPTAKE AFFINITY IN A RESERPINE MODEL OF DEPRESSION.
210830 03-03

HIGH AFFINITY UPTAKE OF GABA IN PRESUMED GABA-ERGIC NERVE ENDINGS IN RAT BRAIN.
211062 03-03

POTENTIATION OF THE L-5-HYDROXYTRYPTOPHAN INDUCED ELEVATION OF PLASMA CORTICOSTERONE LEVELS IN RATS BY A SPECIFIC INHIBITOR OF SEROTONIN UPTAKE.
211104 03-03

CHLORPROMAZINE: SPECIFIC INHIBITION OF L-NORADRENALINE AND 5-HYDROXYTRYPTAMINE UPTAKE IN SYNAPTOSOMES FROM SQUID BRAIN.
213395 04-03

(3H)GLUTAMATE UPTAKE AT INSECT NEUROMUSCULAR JUNCTIONS: EFFECT OF CHLORPROMAZINE.
213474 04-03

5-HYDROXYTRYPTAMINE-14C AND DEXAMPHETAMINE-14C UPTAKE BY FUNDAL SARCOLEMMA PREPARATIONS AND THE PROBLEM OF THE COMMON RECEPTOR.
213591 04-03

RAT BRAIN REGIONAL UPTAKE AND DECARBOXYLATION OF L-DOPA FOLLOWING CAROTID INJECTION.
214323 04-03

UPTAKE OF 3H-NORADRENALINE AND 3H-5-HYDROXYTRYPTAMINE IN CULTURED RAT BRAINSTEM.
215159 04-03

STUDIES ON THE DISTINCTION BETWEEN UPTAKE INHIBITION AND RELEASE OF H3-DOPAMINE IN RAT BRAIN TISSUE SLICES.
215756 04-03

COMPARISON OF THE EFFECTS OF TETRACYCLIC AND TRICYCLIC ANTIDEPRESSANTS ON THE SEROTONIN UPTAKE BY HUMAN THROMBOCYTES IN VITRO.
217258 04-13

ARRHYTHMIAS AND INHIBITION OF NORADRENALINE UPTAKE CAUSED BY TRICYCLIC ANTIDEPRESSANTS AND CHLORPROMAZINE ON THE ISOLATED PERFUSED RABBIT HEART.
217657 04-03

COMPARATIVE STUDIES OF A NEW 5-HT UPTAKE INHIBITOR AND SOME TRICYCLIC THYMOLEPTICS.
217663 04-03

EFFECT OF BUTRIPTYLINE ON THE BRAIN UPTAKE MECHANISMS FOR NORADRENALINE AND 5-HYDROXYTRYPTAMINE.
217688 04-03

INHIBITION OF HUMAN PLATELET 5-HYDROXYTRYPTAMINE UPTAKE BY BETA-PHENETHYLAMINE DERIVATIVES.
217689 04-13

INFLUENCE OF SOME TRICYCLIC ANTIDEPRESSIVE DRUGS ON THE UPTAKE OF 5-HYDROXYTRYPTAMINE BY RAT BLOOD PLATELETS.
217693 04-03

INHIBITION OF SEROTONIN UPTAKE AND THE TOXIC INTERACTION BETWEEN MEPERIDINE AND MONOAMINEOXIDASE INHIBITORS.
217696 04-03

IN VIVO UPTAKE OF ANTIBODY TO DOPAMINE-BETA-HYDROXYLASE INTO SYMPATHETIC ELEMENTS.
217848 04-03

AMINO ACID UPTAKE IN VIVO BY THE MOUSE BRAIN AND BY VARIOUS REGIONS OF THE RABBIT BRAIN AFTER DRUG-INDUCED CONVULSIONS.
217858 04-03

COMPARATIVE STUDIES ON SYNAPTOSOMES: HIGH-AFFINITY UPTAKE AND ACETYLATION OF N-H3-ME-CHOLINE AND N-H3-ME-HYDROXYETHYLPYRROLIDINIUM.
217869 04-03

EFFECT OF AMPHETAMINE, 3,4 METHYLENEDIOXYAMPHETAMINE, P-METHOXYAMPHETAMINE AND RELATED AMPHETAMINES ON UPTAKE OF METARAMINOL AND EFFLUX OF NORADRENALINE IN ADRENERGIC NERVES OF RABBIT ATRIA.
217889 04-03

EFFECT OF SOME ANORECTIC AGENTS ON THE UPTAKE AND RELEASE OF 5-HYDROXYTRYPTAMINE BY BLOOD PLATELETS OF RATS.
217890 04-03

UPTAKE AND DISAPPEARANCE OF 4-METHYL-ALPHA-ETHYLMETATYRAMINE IN RELATION TO ITS RELEASING ACTION ON 5-HYDROXYTRYPTAMINE IN THE BRAIN.
217897 04-03

DEXTROMETHORPHAN INHIBITS 5-HYDROXYTRYPTAMINE UPTAKE BY HUMAN BLOOD PLATELETS AND DECREASES 5-HYDROXYINDOLEACETIC ACID CONTENT IN RAT BRAIN.
217964 04-03

SIMILARITIES OF THE INFLUENCE OF SECONDARY AND TERTIARY TRICYCLIC ANTIDEPRESSANTS ON THE EFFECT OF RESERPINE IN FROGS AND ON THE SEROTONIN UPTAKE OF HUMAN THROMBOCYTES.
219503 04-13

3H-NORTRIPTYLINE UPTAKE AND TISSUE BINDING IN VITRO AND ITS EFFECT ON 3H-NORADRENALINE UPTAKE.
220949 04-03

RELATIONSHIPS BETWEEN TRICYCLIC ANTIDEPRESSANT CONCENTRATIONS, 1-3H-NORAFRENALINE UPTAKE AND CHRONOTROPIC EFFECT IN ISOLATED RAT ATRIA.
221188 04-03

EFFECT OF FIGHTING AND DIPHENYLHYDANTOIN ON THE UPTAKE OF H3-L-NOREPINEPHRINE IN VITRO IN SYNAPTOSOMES ISOLATED FROM RETIRED MALE BREEDING MICE.
222821 04-03

THE EFFECT OF NEUROLEPTICS AND ANTIDEPRESSANTS ON THE UPTAKE OF 3H-GAMMA-AMINOBUTYRIC ACID BY ISOLATED NERVE ENDINGS OF THE RAT BRAIN.
224114 04-03

URACIL
IMPRINTING: CORRELATIONS BETWEEN BEHAVIOUR AND INCORPORATION OF (14C)URACIL INTO CHICK BRAIN.
210667 03-04

URBAN
URBAN ECOLOGICAL AND HOUSEHOLD CORRELATES OF STRESS ALLEVIATIVE DRUG USE.
223949 04-17

URETHANE
THE INFLUENCE OF NEMBUTAL, CHLORALOSE AND URETHANE ON INHIBITORY POSTSYNAPTIC POTENTIALS OF CORTICAL NEURONS.
199443 02-03

URGENT
URGENT CHEMICAL TREATMENT OF STATES OF AGITATION.
207151 03-11

URIDINE
ANTICONVULSANT ACTIVITIES OF DELTA8-THC AND DELTA9-TETRAHYDROCANNABINOL AND URIDINE.
213374 04-03

URINARY
THE EFFECT OF LITHIUM ON URINARY MHPG IN UNIPOLAR AND BIPOLAR DEPRESSED PATIENTS. (UNPUBLISHED PAPER).
196042 01-09

DIFFERENT URINARY EXCRETIONS OF 3-METHOXY-4-HYDROXYPHENYLGLYCOL AND RESPONSE TO TRICYCLIC ANTIDEPRESSIVE DRUGS.
206985 03-13

ANTIDEPRESSANT RESPONSE TO TRICYCLICS AND URINARY MHPG IN UNIPOLAR PATIENTS: CLINICAL RESPONSE TO IMIPRAMINE OR AMITRIPTYLINE.
207443 03-13

URINARY SCREENING FOR DRUGS IN A HOSPITAL FOR THE MENTALLY SUBNORMAL.
210437 03-17

PATHOPHYSIOLOGICAL STUDIES OF MANIC-DEPRESSIVE PSYCHOSES: RELATIONSHIP BETWEEN ANXIETY AND EXCRETION OF URINARY CATECHOLAMINES.
212938 03-10

THE EFFECT OF LITHIUM ON URINARY MHPG IN UNIPOLAR AND BIPOLAR DEPRESSED PATIENTS.
221045 04-09

RAPID MASS SCREENING AND CONFIRMATION OF URINARY AMPHETAMINE AND METHAMPHETAMINE BY GAS CHROMATOGRAPHY.
222829 04-06

URINARY EXCRETION OF THE SULPHATE AND GLUCURONIDE OF 3-METHOXY-4-HYDROXYPHENYLETHYLENEGLYCOL IN A MANIC-DEPRESSIVE PATIENT.
224424 04-09

URINE
MARIHUANA METABOLITES IN URINE OF MAN: III. UNCHANGED DELTA9-TETRAHYDROCANNABINOL.
195053 01-13

ESTIMATION OF PHARMACOKINETIC PARAMETERS OF LITHIUM FROM SALIVA AND URINE.
195446 01-13

BLOOD AND URINE LEVELS OF N,N DIMETHYLTRYPTAMINE FOLLOWING ADMINISTRATION OF PSYCHOACTIVE DOSAGES TO HUMAN SUBJECTS.
198230 02-12

COLORIMETRIC, ULTRAVIOLET SPECTROPHOTOMETRIC, AND SPECTROPHOTOFLUOROMETRIC DETERMINATION OF DOXEPIN AND SOME OF ITS METABOLITES IN SERUM AND IN URINE.
199214 02-16

THE INFLUENCE OF CLOZAPINE ON THE EXCRETION OF MHPG, HVA, AND 5-HIAA IN URINE AND CEREBROSPINAL FLUID.
206974 03-13

MARIHUANA METABOLITES IN URINE OF MAN: V. CHARACTERISTICS AND SEPARATION OF POLAR METABOLITES OF DELTA9-TETRAHYDROCANNABINOL.
210896 03-16

PHENETHYLAMINE IN NORMAL URINE: FAILURE TO VERIFY HIGH VALUES.
225517 04-16

UROPEPTIC
THE EFFECT OF PSYCHOPHARMACA ON UROPEPTIC ACTIVITY.
196188 01-13

USAGE
PSYCHOTHERAPEUTIC DRUGS: STUDIES OF USAGE PATTERNS AND STUDIES OF PRESCRIBING PRACTICES.
198048 01-17

RESULTS OF A SURVEY (1966-1967) OF DRUG USAGE IN INSTITUTIONS FOR THE MENTALLY RETARDED. (UNPUBLISHED PAPER).
222411 04-17

USERS
CHROMOSOMAL DAMAGE IN CHRONICAL USERS OF CANNABIS: IN VIVO INVESTIGATION WITH TWO-DAY LEUKOCYTE CULTURES.
210810 03-15

USSR
NEW PSYCHOTROPIC DRUG DEVELOPMENTS IN THE USSR AND OTHER EASTERN EUROPEAN COUNTRIES.
213598 04-07

UTERUS
THE EFFECT OF AUTONOMIC AND PSYCHOTROPIC DRUGS ON ADRENALINE REVERSAL IN THE RAT UTERUS.
222803 04-03

UTILIZES
THE EFFECTS OF CHRONIC MORPHINE ADMINISTRATION UPON A MODIFIED SIDMAN AVOIDANCE SCHEDULE THAT UTILIZES RESPONSE INDEPENDENT SHOCK.
225566 04-04

VALIDITY
THE VALIDITY OF IDENTICAL MATCHING PLACEBOS.
193073 01-16

RELIABILITY AND VALIDITY OF A PLACEBO TEST.
224894 04-16

VALIUM
RESISTANCE TO EXTINCTION OF AN AVOIDANCE RESPONSE IN RATS FOLLOWING THE ADMINISTRATION OF CHLORDIAZEPOXIDE (LIBRIUM) AND DIAZEPAM (VALIUM).
198226 02-04

ANALYSIS OF EYE MOVEMENTS AND BLINKS DURING READING: EFFECTS OF VALIUM.
206360 03-14

A COMPARISON BETWEEN BROMAZEPAM (RO-5-3350, LEXOTAN) AND DIAZEPAM (VALIUM) IN ANXIETY NEUROSIS: A CONTROLLED, DOUBLE-BLIND CLINICAL TRIAL.
217455 04-10

VALUE
THE EFFECTS OF A DEXAMPHETAMINE AMYLOBARBITONE SODIUM MIXTURE ON THE REWARD VALUE OF DIFFERENT SENSORY CHANGES.
217476 04-03

VALUES
LITHIUM IN NONMANIC DEPRESSIVES: ANTIAGGRESSIVE EFFECT AND RED BLOOD CELL LITHIUM VALUES.
222604 04-09

PHENETHYLAMINE IN NORMAL URINE: FAILURE TO VERIFY HIGH VALUES.
225517 04-16

VARIABILITY
SCHIZOPHRENIA AND EVOKED POTENTIALS: MAXIMUM AMPLITUDE, FREQUENCY OF PEAKS, VARIABILITY, AND PHENOTHIAZINE EFFECTS.
213764 04-08

DECREASED TEMPORAL VARIABILITY IN HIPPOCAMPAL THETA RHYTHMS OF CATS ADMINISTERED METHYLPHENIDATE.
213855 04-03

VARIABLES
MULTIPLE TIC SYNDROME (GILLES-DE-LA-TOURETTES SYNDROME): CLINICAL, BIOLOGICAL, AND PSYCHOSOCIAL VARIABLES AND THEIR INFLUENCE WITH HALOPERIDOL.
199473 02-11

MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 4. COMMUNICATION: CONNECTION BETWEEN EEG CHANGES, CONCENTRATION IN BLOOD, AND OTHER CLINICAL VARIABLES.
203842 02-13

GENETIC, BIOCHEMICAL, AND ENVIRONMENTAL VARIABLES IN THE EXPRESSION OF SHORT-TERM MEMORY IN THE MOUSE. (PH.D. DISSERTATION).
222749 04-04

VARIATIONS

EEG VARIATIONS UNDER ANTABUSE (DISULFIRAM) AND ANTABUSE PLUS ALCOHOL EXPOSITION: A STUDY OF PATHOGENESIS FROM ANTABUSE THERAPY COMPLICATIONS.
200572 02-15

HEART RATE AND GALVANIC SKIN RESPONSE VARIATIONS DURING THE REM AND NON-REM SLEEP PHASES IN MAN.
205443 02-13

VARIATIONS IN THE AUTONOMIC NERVOUS SYSTEM AFTER ADMINISTRATION OF DIHYDROERGOTAMINE IN PSYCHOSOMATIC PATIENTS.
209045 03-11

DEVELOPMENTAL VARIATIONS OF CHOLINE ACETYLTRANSFERASE, DOPAMINE-BETA-HYDROXYLASE AND MONOAMINEOXIDASE IN CHICKEN EMBRYO AND CHICKEN SYMPATHETIC GANGLIA.
217840 04-03

VAS-DEFERENS

POTENTIATION BY 3,4 DIMETHOXYPHENYLETHYLAMINE (DMPEA) AND COCAINE OF NOREPINEPHRINE-INDUCED CONTRACTION OF GUINEA-PIG VAS-DEFERENS.
194156 01-03

THE EFFECTS OF AMPHETAMINE AND COCAINE ON THE RESPONSE OF THE ISOLATED GUINEA-PIG VAS-DEFERENS TO NORADRENALINE, TYRAMINE AND NERVE STIMULATION.
197463 01-03

A COMPARISON OF THE EFFECTS OF (+) AMPHETAMINE, COCAINE AND DENERVATION ON THE RESPONSES OF THE ISOLATED VAS-DEFERENS OF THE GUINEA-PIG TO NOREPINEPHRINE AND ACETYLCHOLINE.
197495 01-03

SOME EFFECTS OF PILOCARPINE AND ACETYLCHOLINE ON THE RESPONSES OF THE GUINEA-PIG VAS-DEFERENS TO HYPOGASTRIC NERVE STIMULATION AND TRANSMURAL STIMULATION AND APPLIED (-) NORADRENALINE.
210770 03-03

VASCULAR

NEONATAL CHEMICAL SYMPATHECTOMY: FUNCTIONAL CONTROL OF DENERVATION OF THE VASCULAR SYSTEM AND TISSUE NORADRENALINE LEVEL IN THE RAT AFTER 6-HYDROXYDOPAMINE.
197584 01-03

EFFECT OF NICOTINE AND NICOTINE MONOMETHIODIDE ON VASCULAR ADRENERGIC NEUROEFFECTOR TRANSMISSION.
197966 01-03

EFFECT OF TROPOLONE ON VASCULAR SYMPATHETIC NEUROEFFECTOR TRANSMISSION.
197970 01-03

THE DOPAMINE VASCULAR RECEPTOR.
210902 03-03

EFFECTS OF RIGID AMPHETAMINE ANALOGS ON VASCULAR STRIPS: STUDIES OF 2-AMINOTETRAHYDRONAPHTHALENE AND 2-AMINOINDAN DERIVATIVES.
210921 03-03

VAST

CHRONIC AMPHETAMINE TREATMENT: VAST INDIVIDUAL DIFFERENCES IN PERFORMING A LEARNED RESPONSE.
202794 02-04

VENOUS

THE EFFECT OF (-) DELTA9-TRANS-TETRAHYDROCANNABINOL ON MYOCARDIAL CONTRACTILITY AND VENOUS RETURN IN ANESTHETIZED DOGS.
199964 02-03

PLASMA CATECHOLAMINES: ARTERIAL VENOUS DIFFERENCES AND THE INFLUENCE OF BODY TEMPERATURE.
215655 04-06

VENTRAL

A HISTOCHEMICAL STUDY OF VENTRAL TEGMENTAL ACETYLCHOLINESTERASE CONTAINING PATHWAY FOLLOWING DESTRUCTIVE LESIONS.
210919 03-03

THE CORRELATION BETWEEN THE VENTRAL AND DORSAL HIPPOCAMPUS DURING IMPROVEMENT OR DETERIORATION OF SHORT-TERM MEMORY.
215487 04-04

BEHAVIORAL EFFECTS OF LOCAL INJECTION OF 6-HYDROXYDOPAMINE IN THE MEDIAL VENTRAL TEGMENTUM IN THE RAT. POSSIBLE ROLE OF THE MESOLIMBIC DOPAMINERGIC SYSTEM.
220946 04-04

VENTRICLES

THE PHARMACOLOGY OF GROSS BEHAVIOURAL EFFECTS OF CHOLINOMIMETIC SUBSTANCES INJECTED INTO THE CEREBRAL VENTRICLES OF UNANAESTHETIZED CATS: EVIDENCE FOR CENTRAL MUSCARINIC MEDIATION.
202780 02-04

VENTRICULAR

BETA-ADRENOCEPTORS AND/OR ALPHA-ADRENOCEPTORS IN THE VENTRICULAR MUSCLE OF THE RABBIT
197943 01-03

MULTIDIMENSIONAL PSYCHOPHARMACOTHERAPEUTIC TRIALS WITH THE NEUROLEPTIC PERAZINE. 5. COMMUNICATION: INFLUENCE ON VENTRICULAR EXCITATION IN THE ELECTROCARDIOGRAM.
203843 02-13

NEGATIVE INOTROPIC EFFECTS OF TRICYCLIC ANTIDEPRESSANTS ON THE ISOLATED RIGHT VENTRICULAR PAPILLARY MUSCLE OF THE CAT.
204400 02-05

THE EFFECT OF ALCOHOL AND BARBITURATE ON THE FREQUENCY OF ATRIAL AND VENTRICULAR PREMATURE BEATS DURING SLEEP.
218971 04-13

VENTROMEDIAN

RECIPROCAL (PUSH-PULL) EFFECTS OF MORPHINE ON SINGLE UNITS IN THE VENTROMEDIAN AND LATERAL HYPOTHALAMUS AND INFLUENCES ON OTHER NUCLEI: WITH COMMENT ON METHADONE EFFECTS DURING WITHDRAWAL FROM MORPHINE.
210700 03-03

VERAPAMIL

HEAT PRODUCTION AND OXYGEN CONSUMPTION OF THE ISOLATED RABBIT HEART UNDER THE INFLUENCE OF STROPHANTHIN VERAPAMIL, AND GLYCERYL TRINITRATE.
197567 01-03

VERBAL

MARKOV CHAIN AS A MODEL OF VERBAL LEARNING.
205624 03-14

COMPARATIVE STUDIES OF VERBAL INTERACTIONS IN A GROUP OF HEALTHY SUBJECTS UNDER THE INFLUENCE OF PSYCHOPHARMACOLOGICAL AGENTS: WITH SPECIAL CONSIDERATION OF YG-19256, CHLORDIAZEPOXIDE AND PLACEBO.
207140 03-14

THE EFFECTS OF STIMULANT AND DEPRESSANT DRUGS ON VERBAL CONDITIONING.
209260 03-14

VERIFY

AN ATTEMPT TO VERIFY THE ANTIDEPRESSANT ACTION OF THE HYPOTHALAMIC THYROSTIMULIN (THYROTROPIN-RELEASING FACTOR OR TRF) IN MELANCHOLIC STATES.
216758 04-09

PHENETHYLAMINE IN NORMAL URINE: FAILURE TO VERIFY HIGH VALUES.
225517 04-16

VESICLES

DIFFERENTIAL EFFECTS OF CHLORPROMAZINE AND CHLORPROMAZINE FREE-RADICAL ON CALCIUM TRANSPORT IN SARCOPLASMIC RETICULUM VESICLES.
210812 03-03

NEUROTRANSMITTER CONTENT IN SYNAPTIC VESICLES OF THE ADRENERGIC NERVES OF RATS UNDER PHARMACOLOGICAL INFLUENCE.
223017 04-03

VESICULAR

INHIBITION OF SYNAPTIC VESICULAR MG++ DEPENDENT ATPASE (STENIN) BY ANTIPSYCHOTIC PHENOTHIAZINES.
195054 01-03

VESTIBULAR

EFFECTS OF D-AMPHETAMINE ON SINGLE VESTIBULAR NEURONS.
204483 02-03

VESTIBULO-OCULAR

ABSENT VESTIBULO-OCULAR REFLEXES AND ACUTE SUPRATENTORIAL LESIONS.
225323 04-13

VETERANS

PSYCHOACTIVE DRUG USE IN ELDERLY PATIENTS WITH PSYCHIATRIC DISORDERS: A SURVEY OF 12 VETERANS ADMINISTRATION HOSPITALS.
193291 01-11

THE USE OF PSYCHOACTIVE DRUGS IN ELDERLY PATIENTS WITH PSYCHIATRIC DISORDERS: SURVEY CONDUCTED IN TWELVE VETERANS ADMINISTRATION HOSPITALS.
215009 04-11

VIEWED

ETHICS IN MEDICAL RESEARCH AS VIEWED BY THE CLINICAL INVESTIGATOR.
214341 04-17

VIEWPOINTS

LONGITUDINAL PROFILES OF THE EFFECTS OF PSYCHOTROPIC DRUGS FROM CLINICOMETHODOLOGICAL VIEWPOINTS.
206971 03-16

VIGILANCE

COMPUTER NYSTAGMOGRAPHY, A NEW METHOD OF DETERMINING CHANGES IN VIGILANCE AS A RESPONSE TO PSYCHOTROPIC DRUGS.
204395 02-16

THE INFLUENCE OF SULPIRIDE ON VIGILANCE: OBJECTIVE MEASUREMENTS OF THE VISUOMOTOR SYSTEM.
221271 04-14

VINCAMIN
CLINICAL AND PSYCHOMETRIC EVALUATION OF THE ACTION OF VINCAMIN IN CEREBRAL ARTERIOSCLEROSIS.
211226 03-11

VIRAL
EFFECT OF MORPHINE, HYDROMORPHONE, METHADONE, MESCALINE, TRYPAN-BLUE, VITAMIN-A, SODIUM SALICYLATE AND CAFFEINE ON THE SERUM INTERFERON LEVEL IN RESPONSE TO VIRAL INFECTION.
217654 04-03

VIRGIN
ESTROGEN INDUCED MATERNAL BEHAVIOR IN HYSTERECTOMIZED OVARIECTOMIZED VIRGIN RATS.
219069 04-04

LATENCY AND DURATION OF ESTROGEN INDUCTION OF MATERNAL BEHAVIOR IN HYSTERECTOMIZED OVARIECTOMIZED VIRGIN RATS: EFFECTS OF PUP STIMULATION.
219070 04-04

VIRUS
HEAD INJURY, HYPOPITUITARISM AND PARANOID PSYCHOSIS: CIRCUMCISION FOR THE SINGAPORE VIRUS.
200581 02-09

VISCEROSOMATIC
DIFFERENTIAL ATTENUATION OF SOMATOVISCERAL AND VISCEROSOMATIC REFLEXES BY DIAZEPAM, PHENOBARBITAL AND DIPHENYLHYDANTOIN.
222818 04-04

VISUAL
THE EFFECT OF CHLORPROMAZINE ON VISUAL INFORMATION PROCESSING IN NORMAL SUBJECTS.
199663 02-14

MATURATION OF VISUAL ELECTROCORTICAL RESPONSES IN UNANESTHETIZED KITTENS: EFFECTS OF BARBITURATE ANESTHESIA.
199765 02-03

EFFECTS OF ALPHA-ADRENERGIC BLOCKERS ON VISUAL EVOKED RESPONSES IN RABBITS.
200064 02-03

EFFECTS OF CHOLINESTERASE INHIBITION ON THE VISUAL EVOKED POTENTIALS IN THE RABBIT AND THEIR MODIFICATION WITH VARIOUS DRUGS.
205631 03-03

MICROIONTOPHORETIC STUDIES ON THE EFFECT OF NOREPINEPHRINE ON THE ACTIVITY OF THE VISUAL CORTEX NEURONS IN RABBITS.
206441 03-03

THE EFFECTS OF DOPA ON THE VISUAL EVOKED POTENTIALS IN RABBIT AND ON MOUSE MOTOR BEHAVIOR FOLLOWING INHIBITION OF DOPAMINE-BETA-HYDROXYLASE.
206768 03-03

THE EFFECTS OF CHLORPROMAZINE AND D-AMPHETAMINE SULFATE ON THE VISUAL STIMULATION PREFERENCE OF EXTRAVERTS AND INTROVERTS.
210680 03-14

THE EFFECT OF CHLORPROMAZINE AND STIMULATION OF THE MESENCEPHALIC RETICULAR FORMATION ON CENTRAL AROUSAL AND ON THE VISUAL EVOKED RESPONSE. (PH.D. DISSERTATION).
212547 03-03

VISUAL HALLUCINATIONS AND PROPRANOLOL.
213522 04-15

VISUAL HALLUCINATIONS AND DELIRIUM DURING TREATMENT WITH AMANTADINE (SYMMETREL).
215858 04-11

THE EFFECTS OF METHYLPHENIDATE HYDROCHLORIDE ON PSYCHOLINGUISTIC, MOTOR AND VISUAL PERCEPTUAL ABILITIES OF HYPERKINETIC CHILDREN WITH LEARNING DISABILITIES. (PH.D. DISSERTATION).
222725 04-14

VISUOMOTOR
THE INFLUENCE OF SULPIRIDE ON VIGILANCE: OBJECTIVE MEASUREMENTS OF THE VISUOMOTOR SYSTEM.
221271 04-14

VITAMIN
THE ROAD TO SHANGRI-LA IS PAVED WITH VITAMIN AND PSYCHOTHERAPEUTIC FADDISM.
209010 03-17

PSYCHOPHARMACOLOGIC INVESTIGATIONS IN HEALTHY ELDERLY VOLUNTEERS: EFFECTS OF PIPRADROL - VITAMIN (ALERTONIC) ELIXIR AND PLACEBO IN RELATION TO RESEARCH DESIGN.
218217 04-11

VITAMIN-A
EFFECT OF MORPHINE, HYDROMORPHONE, METHADONE, MESCALINE, TRYPAN-BLUE, VITAMIN-A, SODIUM SALICYLATE AND CAFFEINE ON THE SERUM INTERFERON LEVEL IN RESPONSE TO VIRAL INFECTION.
217654 04-03

VIVALAN
THE EFFECTS OF AMPHETAMINE, IMIPRAMINE AND ICI-58834 (VIVALAN), A POTENTIAL ANTIDEPRESSANT, ON UNCONDITIONED BEHAVIOUR IN RATS.
214016 04-04

VOLATILE
VOLATILE SOLVENT ADDICTION AND TRAFFIC SAFETY.
205596 02-15

VOLUNTARY
ACUTE VOLUNTARY POISONING BY DOXEPIN.
210141 03-15

ENVIRONMENTAL INFLUENCES AFFECTING THE VOLUNTARY INTAKE OF DRUGS: AN OVERVIEW.
225155 04-04

VOLUNTEERS
A CONTROLLED COMPARISON OF THE EFFECTS OF DIPHENYLHYDANTOIN AND PLACEBO ON MOOD AND PSYCHOMOTOR FUNCTIONING IN NORMAL VOLUNTEERS.
199518 02-14

PLASMA TRYPTOPHAN TOLERANCE CURVES IN DRUG-FREE NORMAL CONTROLS, SCHIZOPHRENIC PATIENTS AND PRISONER VOLUNTEERS.
200773 02-13

SUBJECTIVE CHANGES IN VOLUNTEERS WITHOUT PRIOR EXPERIENCE OF CANNABIS INDUCED BY (-)DELTA9-TRANS-TETRAHYDROCANNABINOL.
202784 02-14

EFFECTS OF LITHIUM ON ELECTROMYOGRAPHIC RECORDINGS IN MAN: STUDIES IN MANIC-DEPRESSIVE PATIENTS AND NORMAL VOLUNTEERS.
215697 04-13

PSYCHOPHARMACOLOGIC INVESTIGATIONS IN HEALTHY ELDERLY VOLUNTEERS: EFFECTS OF PIPRADROL - VITAMIN (ALERTONIC) ELIXIR AND PLACEBO IN RELATION TO RESEARCH DESIGN.
218217 04-11

GALVANIC SKIN RESISTANCE (GSR) MEASUREMENTS ON VOLUNTEERS RECEIVING FENFLURAMINE OR D-AMPHETAMINE.
225062 04-13

VUFB-9977
LONG-ACTING NEUROLEPTICS OF PERATHIEPINE GROUP: VUFB-9977 (OXYPROTHEPINE DECANOATE).
205583 02-03

WAKEFULNESS
CHLORDIAZEPOXIDE AND ITS EFFECT ON SLEEP WAKEFULNESS BEHAVIOR IN UNRESTRAINED CATS.
199213 02-04

THE EFFECTS OF LITHIUM CARBONATE ON SLEEP AND WAKEFULNESS IN THE CAT.
205546 02-03

WARD
A COMPARISON BETWEEN DIAZEPAM AND HALOPERIDOL IN NEUROTIC ANXIETY AND TENSION STATES IN PATIENTS IN A OPEN WARD.
221638 04-10

WARDS
PSYCHOTROPIC DRUGS ON GENERAL MEDICAL AND SURGICAL WARDS OF A TEACHING HOSPITAL.
213919 04-17

WATER
DOES LITHIUM IN DRINKING WATER PREVENT MENTAL DISORDER?
195933 01-17

INFLUENCE OF CATECHOLAMINE UPTAKE BLOCKING DRUGS ON THE INCREASE IN WATER INTAKE AND PLASMA RENIN CONCENTRATION INDUCED BY SOME HYPOTENSIVE DRUGS.
197288 01-03

EFFECT OF SEROTONIN ON WATER INTAKE AND RENIN ANGIOTENSIN SYSTEM IN RATS.
197963 01-03

WATER SOLUBLE DERIVATIVES OF 3-OXY-SUBSTITUTED 1,4 BENZODIAZEPINES.
200739 02-01

CORRELATION OF PSYCHOTOMIMETIC ACTIVITY OF PHENETHYLAMINES AND AMPHETAMINES WITH 1-OCTANOL WATER PARTITION COEFFICIENTS.
208593 03-12

SOME EVIDENCE FOR LONG-TERM MEMORY RETENTION BY OROTIC ACID IN RATS BAR PRESSING FOR WATER.
210790 03-04

EFFECTS OF WATER DEPRIVATION IN RATS WITH POLYDIPSIA AND POLYURIA DUE TO LONG-TERM ADMINISTRATION OF LITHIUM.
210833 03-05

EFFECTS OF CHLORDIAZEPOXIDE ON SCHEDULE INDUCED WATER AND ALCOHOL CONSUMPTION IN THE SQUIRREL MONKEY.
214013 04-04

INTERRESPONSE TIME CHANGES AS A FUNCTION OF WATER DEPRIVATION AND AMPHETAMINE.
217459 04-04

EFFECTS OF HEROIN ON LEVER PRESSING FOR INTRACRANIAL SELF-STIMULATION, FOOD AND WATER IN THE RAT.
221039 04-04

EFFECTS OF SCOPOLAMINE, PHYSOSTIGMINE AND CHLORDIAZEPOXIDE ON PUNISHED AND EXTINGUISHED WATER CONSUMPTION IN RATS.
221043 04-04

WAVE
SOMATOSENSORY EVOKED RESPONSE WAVE SHAPE STABILITY: RELATIONSHIPS TO PSYCHIATRIC DIAGNOSIS AND EFFECTS OF PSYCHOACTIVE DRUGS.
195935 01-17

WAVES
BEHAVIORALLY EVOKED HIPPOCAMPAL THETA WAVES: A CHOLINERGIC RESPONSE.
220312 04-03

WEIGHT
THE EFFECT OF CYPROHEPTADINE ON HUNGER, CALORIE INTAKE AND BODY WEIGHT IN MAN.
214011 04-13

LOSS OF BODY WEIGHT AS A PREDICTOR OF RESERPINE INDUCED AMINE DEPLETION.
217661 04-03

WELFARE
A SURVEY OF DRUG TREATMENT IN PSYCHIATRY: SPECIAL EMPHASIS ON INPATIENTS ON MEDICAL WELFARE SUPPORTED BY YOKOHAMA CITY.
200447 02-17

WINNER
GENETICALLY SELECTED WINNER AND LOSER RATS IN THE TUNNEL COMPETITION: INFLUENCE OF APOMORPHINE AND DOPA.
217829 04-04

WITHDRAWAL
FAILURE OF DIPHENYLHYDANTOIN TO PREVENT ALCOHOL WITHDRAWAL CONVULSIONS IN MICE.
193454 01-03

EFFECTS OF PHENOXYBENZAMINE ON THE NARCOTIC WITHDRAWAL SYNDROME IN THE RAT.
195091 01-03

EFFECTS OF WITHDRAWAL FROM CHRONIC AMPHETAMINE ADMINISTRATION ON ACTIVITY LEVELS OF ALBINO RATS.
195223 01-04

ALCOHOL WITHDRAWAL REACTIONS AND RESERPINE EFFECTS IN INBRED STRAINS OF MICE.
197821 01-03

TREATMENT OF WITHDRAWAL SYMPTOMS WITH APOMORPHINE.
204407 02-15

THE EFFECT OF WITHDRAWAL FROM CANNABIS ON PENTYLENETETRAZOL CONVULSIVE THRESHOLD IN MICE.
206355 03-04

SIGNIFICANCE OF CATECHOLAMINES FOR THE MANIFESTATION OF MORPHINE WITHDRAWAL IN THE RAT.
206988 03-03

EFFECTS OF PHENOTHIAZINE WITHDRAWAL ON PROVERB INTERPRETATION BY CHRONIC SCHIZOPHRENICS.
208325 03-08

RECIPROCAL (PUSH-PULL) EFFECTS OF MORPHINE ON SINGLE UNITS IN THE VENTROMEDIAN AND LATERAL HYPOTHALAMUS AND INFLUENCES ON OTHER NUCLEI: WITH COMMENT ON METHADONE EFFECTS DURING WITHDRAWAL FROM MORPHINE.
210700 03-03

NARCOTIC WITHDRAWAL LIKE MOUSE JUMPING PRODUCED BY AMPHETAMINE AND L-DOPA.
210931 03-04

THREE CASES OF CHRONIC CHLORDIAZEPOXIDE INTOXICATION AND THEIR WITHDRAWAL SYMPTOMS.
211360 03-15

ADRENAL GLUCOCORTICOIDS AS A REQUIRED FACTOR IN THE DEVELOPMENT OF ETHANOL WITHDRAWAL SEIZURES IN MICE.
213479 04-03

EFFECT OF WITHDRAWAL FROM CHRONIC ETHANOL INGESTION ON THE CAMP RESPONSE OF CEREBRAL CORTICAL SLICES USING THE AGONISTS HISTAMINE, SEROTONIN, AND OTHER NEUROTRANSMITTERS.
215980 04-03

EFFECT OF MESORIDAZINE ADMINISTRATION AND WITHDRAWAL ON PERFORMANCE IN AN OLDER AGE GROUP.
217452 04-11

EFFECTS OF CHRONIC ADMINISTRATION AND WITHDRAWAL OF D-AMPHETAMINE UPON DAILY ACTIVITY LEVELS OF SQUIRREL MONKEYS.
219032 04-04

WITHDRAWN
THE SENSITIVITY OF BARBITONE DEPENDENT AND WITHDRAWN RATS TO TREMORGENIC DRUGS.
197303 01-03

WITHDRAWN, APATHETIC GERIATRIC PATIENTS RESPONSIVE TO METHYLPHENIDATE.
218216 04-11

WOMEN
RETROSPECTIVE STUDY OF THE ASSOCIATION BETWEEN USE OF RAUWOLFIA DERIVATIVES AND BREAST CANCER IN ENGLISH WOMEN.
194063 01-13

DEPRESSED WOMEN ONE YEAR AFTER MAINTENANCE THERAPY.
224766 04-09

WORD
WHATS IN A WORD? OR GUILT BY DEFINITION.
221563 04-17

WORK
WORK CAPABILITY AND TREATMENT OF REACTIVE DEPRESSIONS.
198354 02-10

WORKERS
LIVER FUNCTION IN WORKERS OCCUPATIONALLY DEALING WITH CHLORPROMAZINE AND SOME OTHER COMPOUNDS.
202925 02-13

WORKING
THE EFFECT OF PSYCHOTROPIC AGENTS ON THE MENTAL AND PHYSICAL WORKING CAPACITY IN RATS.
219748 04-04

WY-23409
THE PHARMACOLOGY OF WY-23409, A NEW ANTIDEPRESSANT.
197305 01-03

WY-4036
EXPERIENCE OF USING LORAZEPAM (WY-4036) IN PSYCHIATRY.
224395 04-11

X-RAY
POSSIBLE PHARMACOLOGICAL AND THEORETICAL IMPLICATIONS OF X-RAY STRUCTURE OF THE TRICYCLIC ANTIDEPRESSANT IMIPRAMINE.
205029 02-01

XANTHURENIC
TRYPTOPHAN METABOLISM EXAMINATIONS IN OLIGOPHRENIC CHILDREN. FIRST REPORT: RESULTS OF THE EXCRETION OF KYNURENINE AND XANTHURENIC ACID AFTER TRYPTOPHAN LOADING AND THEIR DEPENDENCE UPON THE SUPPLY.
203645 02-13

XENOPUS
COMPARISON OF THE EFFECTS OF LITHIUM, BETA-PHENYLETHYLAMINE AND TYROSINE ON XENOPUS EMBRYOS.
200752 02-03

Y-MAZE
INHIBITION OF SCOPOLAMINE INDUCED STIMULATION OF Y-MAZE ACTIVITY BY ALPHA-METHYL-P-TYROSINE AND BY LITHIUM.
199866 02-04

Y-4153
STUDIES ON PSYCHOTROPIC DRUGS: XVII. EFFECTS OF 3-CHLORO-5-(3-(4 PIPERIDINO-4-CARBAMOYL-PIPERIDINO)PROPYL) 10,11-DIHYDRO-5(H) DIBENZAZEPINE DIHYDROCHLORIDE MONOHYDRATE (Y-4153) ON THE METABOLISM OF BIOGENIC AMINES.
199210 02-03

Y-6047
COMPARATIVE STUDY OF Y-6047 AND DIAZEPAM BY A DOUBLE-BLIND METHOD FOR THE TREATMENT OF PSYCHOSOMATIC DISEASES AND NEUROSIS.
198705 02-11

A DOUBLE-BLIND CONTROLLED STUDY OF THE THIENODIAZEPINE DERIVATIVE (Y-6047) ON NEUROTICS AND PSYCHOSOMATIC DISORDERS.
210559 03-14

YG-19256
COMPARATIVE STUDIES OF VERBAL INTERACTIONS IN A GROUP OF HEALTHY SUBJECTS UNDER THE INFLUENCE OF PSYCHOPHARMACOLOGICAL AGENTS: WITH SPECIAL CONSIDERATION OF YG-19256, CHLORDIAZEPOXIDE AND PLACEBO.
207140 03-14

YOHIMBINE
AN INVESTIGATION ON THE BEHAVIORAL AND HYPOTHERMIC EFFECTS OF YOHIMBINE: INTERACTION WITH DRUGS AFFECTING CENTRAL AND PERIPHERAL MONOAMINES.
211068 03-04

YOHIMBINE: BEHAVIORAL AND BIOCHEMICAL EFFECTS IN MICE.
213592 04-04

YOKOHAMA
A SURVEY OF DRUG TREATMENT IN PSYCHIATRY: SPECIAL EMPHASIS ON INPATIENTS ON MEDICAL WELFARE SUPPORTED BY YOKOHAMA CITY.
200447 02-17

YOUNG
DIFFERENTIAL EFFECTS OF D-AMPHETAMINE ON BRAIN ACETYLCHOLINE IN YOUNG, ADULT, AND GERIATRIC RATS.
193457 01-03

PROGRAMMED SELF-ADMINISTRATION OF POTENTIALLY ADDICTIVE DRUGS IN YOUNG RATS AND ITS EFFECTS ON LEARNING.
195430 01-04

SHORT-TERM EFFECTS OF TESTOSTERONE PROPIONATE ON THE BEHAVIOUR OF YOUNG INTACT MALE DOMESTIC DUCKS (ANAS-PLATYRHYNCHOS).
199461 02-04

A DIFFERENTIATED USE OF ELENIUM AND SEDUXEN IN YOUNG PATIENTS IN THE POST-INFARCTIONAL PERIOD.
200104 02-11

BEHAVIOURAL AND ELECTROGRAPHIC OBSERVATIONS DURING EPILEPTIC CONVULSIONS INDUCED BY STRYCHNINE AND PENTYLENETETRAZOL IN CONSCIOUS YOUNG AND ADULT CHICKENS.
205459 02-03

INHIBITION OF MEMORY FORMATION IN THE IMPRINTING PERIOD: IRREVERSIBLE ACTION OF CYCLOHEXIMIDE IN YOUNG CHICKENS.
210708 03-04

CONDITIONED LEARNING IN YOUNG RATS BORN OF DRUG ADDICTED PARENTS AND RAISED ON ADDICTIVE DRUGS.
217465 04-04

PHYSIOLOGICAL MECHANISMS FOR CARDIAC CONTROL BY NUTRITIONAL INTAKE AFTER EARLY MATERNAL SEPARATION IN THE YOUNG RAT.
218047 04-03

YOUTH
MORE EVIDENCE FAVORS YOUTH DRUG: FIRST DOUBLE-BLIND TRIALS SHOW GEROVITAL HAS SOME EFFECT ON AGING.
221352 04-11

YOUTHS
PRETREATMENT OF PROBLEM YOUTHS WITH CLOZAPINE IN PREPARATION FOR GROUP PSYCHOTHERAPY.
203599 02-14

ZEBRAFISH
THE TOXICOLOGIC AND TERATOLOGIC EFFECTS OF DELTA9-TETRAHYDROCANNABINOL IN THE ZEBRAFISH EMBRYO.
217697 04-05

ZINC
THE EEG EFFECTS OF ZINC IN GERIATRIC PSYCHIATRIC PATIENTS.
195039 01-13

THYROXINE-LIKE EFFECTS OF ZINC ON BRAIN AND BEHAVIOUR WITH FIRM DEPENDENCE ON SEVERAL HORMONES.
213434 04-04

ZINC AND HIPPOCAMPAL FUNCTION.
214716 04-03

FEEDING IN RESPONSE TO REPEATED PROTAMINE ZINC INSULIN INJECTIONS.
219073 04-04

1-BETA-METHYLSULFONYLETHYL-5-O-FLUOROPHENYL
THE SYNTHESIS AND PHARMACOLOGY OF A NOVEL BENZODIAZEPINE DERIVATIVE, 1-BETA-METHYLSULFONYLETHYL-5-O-FLUOROPHENYL 7-CHLORODIHYDROBENZODIAZEPIN-2-ONE (ID-622).
221741 04-02

1-DELTA8-TRANS-TETRAHYDROCANNABINOL
EFFECTS OF REPEATED DOSES OF 1-DELTA8-TRANS-TETRAHYDROCANNABINOL ON SCHEDULE-CONTROLLED TEMPORALLY SPACED RESPONDING OF RATS.
195431 01-04

1-ETHYL-PYRROLIDIN-2-YL
A CLINICAL NEUROLEPTIC INVESTIGATION OF N-(1-ETHYL-PYRROLIDIN-2-YL) 2-METHOXY-5-SULFAMOYL-BENZAMIDE NEUROLEPTIC SULPIRIDE (DOGMATIL) IN ACUTELY ILL SCHIZOPHRENICS.
195038 01-11

1-ETHYL-2-PYRROLIDINYL-METHYL-2-METHOXY-5-SULFAMIDE
THE DISINHIBITING EFFECT OF N(1-ETHYL-2-PYRROLIDINYL-METHYL-2-METHOXY-5-SULFAMIDE BENZAMIDE (SULPIRIDE).
209527 03-14

1-METHYL-5-O-FLUOROPHENYL
THE SYNTHESIS AND PHARMACOLOGY OF A NOVEL BENZODIAZEPINE DERIVATIVE, 1-METHYL-5-O-FLUOROPHENYL 7-CHLORODIHYDROBENZODIAZEPIN-2-ONE (ID-540).
206780 03-02

ELECTROPHYSIOLOGICAL AND BEHAVIORAL EFFECTS OF 1-METHYL-5-O-FLUOROPHENYL 7-CHLORODIHYDROBENZODIAZEPIN-2-ONE (ID-540) IN CATS AND RABBITS.
221736 04-03

1-METHYLINDOLE
CHEMICAL PHARMACOLOGY OF THE BENZOTHIOPHENE AND 1-METHYLINDOLE ANALOGS OF N,N-DIMETHYLTRYPTAMINE. (PH.D. DISSERTATION).
193590 01-12

1-OCTANOL
CORRELATION OF PSYCHOTOMIMETIC ACTIVITY OF PHENETHYLAMINES AND AMPHETAMINES WITH 1-OCTANOL WATER PARTITION COEFFICIENTS.
208593 03-12

1-3H-NORAFRENALINE
RELATIONSHIPS BETWEEN TRICYCLIC ANTIDEPRESSANT CONCENTRATIONS, 1-3H-NORAFRENALINE UPTAKE AND CHRONOTROPIC EFFECT IN ISOLATED RAT ATRIA.
221188 04-03

1035-MD
A YEAR OF INVESTIGATIONS ON 1035-MD IN CHILD AND JUVENILE NEUROPSYCHIATRY: CLINICAL AND EEG FINDINGS FROM 46 CASES.
209784 03-11

14C-CATECHOLAMINES
EFFECT OF PHENCYCLIDINE ON THE ACCUMULATION OF 14C-CATECHOLAMINES FORMED FROM 14C-TYROSINE.
197467 01-03

14C-DOPAMINE
KINETICS OF 14C-DOPAMINE IN ISOLATED RAT STRIATAL TISSUE UNDER THE INFLUENCE OF MORPHINE.
197954 01-03

THE EFFECT OF DELTA9-TETRAHYDROCANNABINOL ON THE UPTAKE AND RELEASE OF 14C-DOPAMINE FROM CRUDE STRIATAL SYNAPTOSOMAL PREPARATIONS.
202775 02-03

14C-HISTAMINE
EFFECT OF PSYCHOACTIVE DRUGS ON IN VIVO METABOLISM OF 14C-HISTAMINE IN MOUSE BRAIN.
197472 01-03

14C-TRIFLUBAZAM
BLOOD LEVEL, EXCRETION, DISTRIBUTION AND METABOLISM OF 14C-TRIFLUBAZAM, A NEW 1,5 BENZODIAZEPINE, IN MICE AND DOGS.
197940 01-03

14C-TYROSINE
EFFECT OF PHENCYCLIDINE ON THE ACCUMULATION OF 14C-CATECHOLAMINES FORMED FROM 14C-TYROSINE.
197467 01-03

1766-CERM
PHARMACOLOGICAL PROFILE OF A NEW NONTRICYCLIC ANTIDEPRESSANT: OXAFLOZANE (1766-CERM).
199385 02-02

PRELIMINARY CLINICAL RESULTS OF A NEW NONTRICYCLIC ANTIDEPRESSANT: OXAFLOZANE (1766-CERM).
199386 02-07

19560-RP
A TRUE ANTIDEPRESSANT: 19560-RP.
212392 03-09

2-AMINOINDAN
EFFECTS OF RIGID AMPHETAMINE ANALOGS ON VASCULAR STRIPS: STUDIES OF 2-AMINOTETRAHYDRONAPHTHALENE AND 2-AMINOINDAN DERIVATIVES.
210921 03-03

2-AMINOINDANE
TOLERANCE DEVELOPMENT TO THE ANTINOCICEPTIVE ACTIONS OF MORPHINE, AMPHETAMINE, PHYSOSTIGMINE AND 2-AMINOINDANE IN THE MOUSE.
194930 01-03

2-AMINOTETRAHYDRONAPHTHALENE
EFFECTS OF RIGID AMPHETAMINE ANALOGS ON VASCULAR STRIPS: STUDIES OF 2-AMINOTETRAHYDRONAPHTHALENE AND 2-AMINOINDAN DERIVATIVES.
210921 03-03

2-BROMO-ALPHA-ERGOKRYPTINE
CB-154 (2-BROMO-ALPHA-ERGOKRYPTINE, BROMOCRIPTIN), A POTENTIAL ANTIPARKINSON AGENT.
197949 01-04

2-BROMO-D-LYSERGIC
INHIBITION OF CATECHOLAMINE AND 5-HYDROXYTRYPTAMINE INDUCED ENZYME SECRETION FROM THE GUINEA-PIG SUBMANDIBULAR GLAND BY 2-BROMO-D-LYSERGIC ACID DIETHYLAMIDE.
216968 04-03

2-BROMOLSD
THE EFFECT OF LSD AND 2-BROMOLSD ON THE DOPA ACCUMULATION AFTER CENTRAL AND PERIPHERAL DECARBOXYLASE INHIBITION.
217674 04-03

2-DEOXY-D-GLUCOSE
EFFECTS OF 2-DEOXY-D-GLUCOSE ON SLEEP-WAKING PATTERNS.
206253 03-04

CEREBRAL FUNCTIONAL EFFECTS OF 2-DEOXY-D-GLUCOSE AND 3-O-METHYLGLUCOSE IN RHESUS MONKEYS.
210355 03-03

2-IMIDAZOLINE
INHIBITION OF SYMPATHETIC ACTIVITY FOLLOWING CHRONIC ADMINISTRATION OF 2-AMINO-4-(3,4 DICHLOROPHENYL) 2-IMIDAZOLINE (MJ-10459-2).
199863 02-03

2-METHOXY-5-SULFAMOYL-BENZAMIDE
A CLINICAL NEUROLEPTIC INVESTIGATION OF N-(1-ETHYL-PYRROLIDIN-2-YL) 2-METHOXY-5-SULFAMOYL-BENZAMIDE NEUROLEPTIC SULPIRIDE (DOGMATIL) IN ACUTELY ILL SCHIZOPHRENICS.
195038 01-11

2-N-ALPHA-AMMONIUMACYL-AMINO-5-CHLOROBENZOPHENONES
CHIRAL 1,4 BENZODIAZEPINE: VII. CYCLIZATION RATES OF 2-N-ALPHA-AMMONIUMACYL-AMINO-5-CHLOROBENZOPHENONES IN THE CHIRAL 1,4 BENZODIAZEPIN-2-ONES.
221858 04-01

2-PHENYLDIMETHYL-TETRAHYDROOXAZINE
PHARMACOLOGICAL AND TOXICOLOGICAL STUDY OF A NEW PSYCHOTROPIC STIMULANT: THE 2-PHENYLDIMETHYL-TETRAHYDROOXAZINE, IN COMPARISON WITH D,L-AMPHETAMINE, PHENMETRAZINE AND PEMOLINE-MG.
199211 02-04

2-PHENYLDIMETHYLTETRAHYDROOXAZINE
TOXICOLOGICAL AND TERATOLOGICAL STUDY OF 2-PHENYLDIMETHYLTETRAHYDROOXAZINE HYDROCHLORIDE (G-130), A PSYCHOSTIMULANT DRUG.
206783 03-05

2-PHENYLETHYLAMINE
BEHAVIORAL AND ELECTROPHYSIOLOGICAL EFFECTS OF PHENYLETHANOLAMINE AND 2-PHENYLETHYLAMINE.
217521 04-04

2-PYRIMIDINYLSULFONYL-PHENYLACETAMIDES
NEW HYPOGLYCEMIC BENZENESULFONAMIDO PYRIMIDINES: N-SUBSTITUTED 4-(N-(2-PYRIMIDINYLSULFONYL-PHENYLACETAMIDES.
206994 03-02

2-PYRROLIDON
PILOT STUDY OF 2-PYRROLIDON ACETAMIDE (GENERIC NAME: PIRACETAM).
221338 04-08

20ALPHA-HYDROXYPROGESTERONE
FACILITATORY AND INHIBITORY INFLUENCES OF PROGESTERONE, 20ALPHA-HYDROXYPROGESTERONE AND METHYSERGIDE ON THE RECEPTIVE BEHAVIOR OF THE FEMALE RAT. (PH.D. DISSERTATION).
222739 04-04

3-AMINO-2-IMINOBENZOTHIAZIN-4-ONES
CYANOGEN CONDENSATIONS AS A ROUTE TO 3-AMINO-2-IMINOBENZOTHIAZIN-4-ONES WITH CNS DEPRESSANT POTENTIAL.
222870 04-02

3-BENZOYLPIPERIDINES
STEREOCHEMICAL STUDIES ON POTENTIAL CENTRAL NERVOUS SYSTEM ACTIVE AGENTS AND STUDIES ON THE CHEMISTRY OF SOME 3-BENZOYLPIPERIDINES. (PH.D. DISSERTATION).
193586 01-01

3-CHLORO-4-HYDROXYAMPHETAMINE
METABOLISM OF 4-CHLOROAMPHETAMINE TO 3-CHLORO-4-HYDROXYAMPHETAMINE IN RAT: EVIDENCE FOR AN IN VIVO NIH SHIFT OF CHOLINE.
210929 03-03

3-CHLOROAMPHETAMINE
LONG-LASTING REDUCTION OF BRAIN 5-HYDROXYTRYPTAMINE CONCENTRATION BY 3-CHLOROAMPHETAMINE AND 4-CHLOROAMPHETAMINE IN IPRINDOLE TREATED RATS.
217879 04-03

3-HYDROXY-DL-PHENYLALANINE
THE FORMATION IN VIVO OF 3,4 DIHYDROXYPHENYLALANINE (DOPA) FROM 3-HYDROXY-DL-PHENYLALANINE (M-TYROSINE).
198015 01-03

3-METHOXY-4-HYDROXYPHENYLETHYLENEGLYCOL
URINARY EXCRETION OF THE SULPHATE AND GLUCURONIDE OF 3-METHOXY-4-HYDROXYPHENYLETHYLENEGLYCOL IN A MANIC-DEPRESSIVE PATIENT.
224424 04-09

3-METHOXY-4-HYDROXYPHENYLGLYCOL
DIFFERENT URINARY EXCRETIONS OF 3-METHOXY-4-HYDROXYPHENYLGLYCOL AND RESPONSE TO TRICYCLIC ANTIDEPRESSIVE DRUGS.
206985 03-13
THE EFFECTS OF ACUTE AND CHRONIC MORPHINE ADMINISTRATION ON THE LEVELS OF 3-METHOXY-4-HYDROXYPHENYLGLYCOL SULFATE IN RAT BRAIN.
210927 03-03

3-METHOXYTYRAMINE
A METHOD FOR THE ISOLATION AND DETERMINATION OF 3-METHOXYTYRAMINE IN BRAIN TISSUE.
193302 01-03
POSTMORTAL ACCUMULATION OF 3-METHOXYTYRAMINE IN BRAIN.
197583 01-03

3-METHYL-5-BETA-N-N-M-CHLOROPHENYLPIPERAZINOETHYL
CLINICAL TRIAL OF 3-METHYL-5-BETA-N-N-M-CHLOROPHENYLPIPERAZINOETHYL PYRAZOLE DIHYDROCHLORIDE (MEPIPRAZOL) IN THE THERAPY OF PSYCHOVEGETATIVE DISORDERS.
215694 04-10

3-O-METHYLGLUCOSE
CEREBRAL FUNCTIONAL EFFECTS OF 2-DEOXY-D-GLUCOSE AND 3-O-METHYLGLUCOSE IN RHESUS MONKEYS.
210355 03-03

3-OXY-SUBSTITUTED
WATER SOLUBLE DERIVATIVES OF 3-OXY-SUBSTITUTED 1,4 BENZODIAZEPINES.
200739 02-01

3H-AMPHETAMINE
BLOOD-BRAIN BARRIER: I. KINETICS OF DISTRIBUTION OF 3H-AMPHETAMINE IN THE RAT BRAIN AFTER INTRAVENOUS ADMINISTRATION.
210788 03-03

3H-CATECHOLAMINE
NEONATAL 6-HYDROXYDOPAMINE TREATMENT: NORADRENALINE LEVELS AND IN VITRO 3H-CATECHOLAMINE SYNTHESIS IN DISCRETE BRAIN REGIONS OF ADULT RATS.
210759 03-03

3H-DELTA8-TETRAHYDROCANNABINOL
INTRACELLULAR DISTRIBUTION OF 3H-DELTA8-TETRAHYDROCANNABINOL IN RAT ORGANS AFTER I.V. ADMINISTRATION.
195112 01-03

3H-DOPAMINE
EFFECT OF NICOTINE AND OTHER DRUGS ON THE RELEASE OF 3H-NOREPINEPHRINE AND 3H-DOPAMINE FROM RAT BRAIN SLICES.
197985 01-03

3H-GAMMA-AMINOBUTYRIC
THE EFFECT OF NEUROLEPTICS AND ANTIDEPRESSANTS ON THE UPTAKE OF 3H-GAMMA-AMINOBUTYRIC ACID BY ISOLATED NERVE ENDINGS OF THE RAT BRAIN.
224114 04-03

3H-HOMOVANILLIC
ACCUMULATION OF 3H-HOMOVANILLIC ACID IN RABBIT BRAIN AND CEREBROSPINAL FLUID FOLLOWING INTRAVENOUS 3H-L-DOPA.
206336 03-03

3H-L-DOPA
PROTRIPTYLINE INDUCED INHIBITION OF THE IN VIVO 3H-NORADRENALINE SYNTHESIS FROM 3H-L-DOPA IN THE RAT BRAIN.
197928 01-03
ACCUMULATION OF 3H-HOMOVANILLIC ACID IN RABBIT BRAIN AND CEREBROSPINAL FLUID FOLLOWING INTRAVENOUS 3H-L-DOPA.
206336 03-03
THE EFFECT OF AMITRIPTYLINE, DESIPRAMINE AND IMIPRAMINE ON THE IN VIVO BRAIN SYNTHESIS OF 3H-NORADRENALINE FROM 3H-L-DOPA IN THE RAT.
225565 04-03

3H-METARAMINOL
THE SUBCELLULAR DISTRIBUTION OF INTRAVENTRICULARLY ADMINISTERED 3H-METARAMINOL IN INTACT AND RAT BRAIN PRETREATED WITH P-CHLOROAMPHETAMINE.
197289 01-03

3H-NORADRENALINE
PROTRIPTYLINE INDUCED INHIBITION OF THE IN VIVO 3H-NORADRENALINE SYNTHESIS FROM 3H-L-DOPA IN THE RAT BRAIN.
197928 01-03
UPTAKE OF 3H-NORADRENALINE AND 3H-5-HYDROXYTRYPTAMINE IN CULTURED RAT BRAINSTEM.
215159 04-03
3H-NORTRIPTYLINE UPTAKE AND TISSUE BINDING IN VITRO AND ITS EFFECT ON 3H-NORADRENALINE UPTAKE.
220949 04-03
THE EFFECT OF AMITRIPTYLINE, DESIPRAMINE AND IMIPRAMINE ON THE IN VIVO BRAIN SYNTHESIS OF 3H-NORADRENALINE FROM 3H-L-DOPA IN THE RAT.
225565 04-03

3H-NOREPINEPHRINE
D-AMPHETAMINE AND THE RELEASE OF 3H-NOREPINEPHRINE FROM SYNAPTOSOMES.
197871 01-03
EFFECT OF NICOTINE AND OTHER DRUGS ON THE RELEASE OF 3H-NOREPINEPHRINE AND 3H-DOPAMINE FROM RAT BRAIN SLICES.
197985 01-03
THE IMPORTANCE OF NEURONAL UPTAKE OF AMINES FOR AMPHETAMINE-INDUCED RELEASE OF 3H-NOREPINEPHRINE FROM ISOLATED BRAIN TISSUE.
202191 02-03

3H-NORTRIPTYLINE
3H-NORTRIPTYLINE UPTAKE AND TISSUE BINDING IN VITRO AND ITS EFFECT ON 3H-NORADRENALINE UPTAKE.
220949 04-03

3H-5-HYDROXYTRYPTAMINE
UPTAKE OF 3H-NORADRENALINE AND 3H-5-HYDROXYTRYPTAMINE IN CULTURED RAT BRAINSTEM.
215159 04-03

38640
ANTAGONISM OF DEPRESSANT ACTIVITY OF ETHANOL BY DH-524; A COMPARATIVE STUDY WITH BEMEGRIDE, DOXAPRAM AND D-AMPHETAMINE (38640).
213282 03-03

4-BR-DIMETHOXYPHENYLISOPROPYLAMINE
IN VIVO HUMAN PHARMACODYNAMICS OF THE PSYCHODYSLEPTIC 4-BR-DIMETHOXYPHENYLISOPROPYLAMINE LABELLED WITH 82BR OR 77BR.
215710 04-13

4-CHLOROAMPHETAMINE
EFFECTS OF SOME HOMOLOGUES OF 4-CHLOROAMPHETAMINE ON BRAIN SEROTONIN METABOLISM.
195092 01-02
COMPARISON OF THE OXIME AND THE HYDROXYLAMINE DERIVATIVES OF 4-CHLOROAMPHETAMINE AS DEPLETORS OF BRAIN 5-HYDROXYINDOLES.
200004 02-03
LONG-LASTING DEPLETION OF BRAIN SEROTONIN BY 4-CHLOROAMPHETAMINE IN GUINEA-PIGS.
203580 02-03
6-CHLORO-2-AMINOTETRALIN, A RIGID CONFORMATIONAL ANALOG OF 4-CHLOROAMPHETAMINE: PHARMACOLOGIC PROPERTIES OF IT AND RELATED COMPOUNDS IN RATS.
210870 03-02

METABOLISM OF 4-CHLOROAMPHETAMINE TO 3-CHLORO-4-HYDROXYAMPHETAMINE IN RAT: EVIDENCE FOR AN IN VIVO NIH SHIFT OF CHOLINE.
210929 03-03

LONG-LASTING REDUCTION OF BRAIN 5-HYDROXYTRYPTAMINE CONCENTRATION BY 3-CHLOROAMPHETAMINE AND 4-CHLOROAMPHETAMINE IN IPRINDOLE TREATED RATS.
217879 04-03

4-CHLORODIFLUOROAMPHETAMINE
EFFECT OF PHENOBARBITAL ON THE METABOLISM AND SEROTONIN DEPLETING ACTION OF 4-CHLORODIFLUOROAMPHETAMINE IN RATS.
210922 03-03

4-HYDROXYAMPHETAMINE
ACCUMULATION OF 4-HYDROXYAMPHETAMINE BY RAT STRIATAL HOMOGENATES.
222822 04-03

4-METHYL-ALPHA-ETHYLMETATYRAMINE
UPTAKE AND DISAPPEARANCE OF 4-METHYL-ALPHA-ETHYLMETATYRAMINE IN RELATION TO ITS RELEASING ACTION ON 5-HYDROXYTRYPTAMINE IN THE BRAIN.
217897 04-03

5-DIMETHYLDITHIOCARBAMYLPICOLINIC
SELECTIVE INHIBITION OF DOPAMINE-BETA-HYDROXYLASE IN THE PERIPHERAL TISSUES BY 5-DIMETHYLDITHIOCARBAMYLPICOLINIC ACID; ITS EFFECT ON STRESS INDUCED ULCER, ETHANOL INDUCED SLEEP AND BLOOD PRESSURE.
204484 02-03

5-FERROCENYLBENZODIAZEPIN-2-ONES
QUINAZOLINES AND 1,4 BENZODIAZEPINES. 67. 5-FERROCENYLBENZODIAZEPIN-2-ONES.
208595 03-01

5-FLUOURACIL
DEVELOPMENTAL DISTURBANCE OF THE BRAIN IN RAT OFFSPRING FOLLOWING MATERNAL ADMINISTRATION OF 5-FLUOURACIL DURING PREGNANCY.
202422 02-03

5-HIAA
THE INFLUENCE OF CLOZAPINE ON THE EXCRETION OF MHPG, HVA, AND 5-HIAA IN URINE AND CEREBROSPINAL FLUID.
206974 03-13

THE ORIGIN OF BLOOD 5-HYDROXYINDOLEACETIC (5-HIAA) ACID FOLLOWING L-HYDRAZINO-ALPHA-METHYLDOPA (MK-486).
217665 04-03

5-HT
D,L P-CHLORO-N-METHYLAMPHETAMINE (P) INDUCED ACCUMULATION OF 5-HT IN NONTERMINAL AXONS.
192944 01-03

EFFECTS OF THE HIGH DOSES OF L-DOPA ON ELECTRICAL ACTIVITY IN THE BRAIN OF THE RABBIT: INTERACTION WITH THE METABOLISM OF 5-HT.
197468 01-03

THEOPHYLLINE INCREASED SENSITIVITY TO NOCICEPTIVE STIMULATION AND REGIONAL TURNOVER OF RAT BRAIN 5-HT, NORADRENALINE AND DOPAMINE.
197926 01-03

SIMILAR ACTIONS OF INTRAHYPOTHALAMIC 5-6-DHT AND 5-HT IN EVOKING HYPERTHERMIA IN THE MONKEY.
200034 02-03

FACTORS AFFECTING THE ACTIVITY OF 5-HT CONTAINING NEURONES.
202718 02-03

5-HT AND NOREPINEPHRINE-INDUCED RELEASE OF ACH FROM THE THALAMUS AND MESENCEPHALON OF THE MONKEY DURING THERMOREGULATION.
210672 03-03

L-DOPA HYPOTENSION IN DOGS: EVIDENCE FOR MEDIATION THROUGH 5-HT RELEASE.
210868 03-05

ANTINOCICEPTIVE ACTION OF OXOTREMORINE AND REGIONAL TURNOVER OF RAT BRAIN NORADRENALINE, DOPAMINE AND 5-HT.
215683 04-03

EFFECTS OF HALOTHANE AND NITROUS OXIDE ANESTHESIA ON 5-HT TURN-OVER IN THE RAT BRAIN.
217655 04-03

COMPARATIVE STUDIES OF A NEW 5-HT UPTAKE INHIBITOR AND SOME TRICYCLIC THYMOLEPTICS.
217663 04-03

5-HTP
BRAIN DOPA/5-HTP DECARBOXYLASE ACTIVITY AFTER THE CHRONIC ADMINISTRATION OF L-DOPA OR 5-HYDROXY-L-TRYPTOPHAN IN NORMAL AND LESIONED CATS.
194483 01-05

EFFECTS OF A DECARBOXYLASE INHIBITOR ON THE DOPA AND 5-HTP INDUCED CHANGES IN THE LOCOMOTOR LIKE DISCHARGE PATTERN OF RABBIT HIND LIMB NERVES.
210740 03-03

5-HYDROXY-L-TRYPTOPHAN
BRAIN DOPA/5-HTP DECARBOXYLASE ACTIVITY AFTER THE CHRONIC ADMINISTRATION OF L-DOPA OR 5-HYDROXY-L-TRYPTOPHAN IN NORMAL AND LESIONED CATS.
194483 01-05

5-HYDROXY-5-4-CHLOROPHENYL
PHARMACOLOGICAL ANALYSIS OF A NEW ANOREXIC SUBSTANCE: 5-HYDROXY-5-4-CHLOROPHENYL 2,3 DIHYDRO-5H-IMIDAZOISOINDOLE (MAZINDOL).
217652 04-04

THE EFFECTS OF 5-HYDROXY-5-4-CHLOROPHENYL 2,3 DIHYDRO-5H-IMIDAZOISOINDOLE (MAZINDOL, SAH-42-548) ON THE METABOLISM OF BRAIN NOREPINEPHRINE.
217653 04-03

5-HYDROXYDOPA
DETAILED NORADRENALINE PATHWAYS OF LOCUS-COERULEUS NEURON TO THE CEREBRAL CORTEX WITH THE USE OF 5-HYDROXYDOPA.
210803 03-03

5-HYDROXYINDOLE
DIAZEPAM INCREASES 5-HYDROXYINDOLE CONCENTRATIONS IN RAT BRAIN AND SPINAL CORD.
200081 02-03

SOME INTERACTIONS BETWEEN FENFLURAMINE AND ANTIDEPRESSANT DRUGS: EFFECTS ON 5-HYDROXYINDOLE CONCENTRATIONS IN RAT BRAIN.
217962 04-03

5-HYDROXYINDOLEACETIC
DETERMINATION OF NORADRENALINE, DOPAMINE, SEROTONIN, 5-HYDROXYINDOLEACETIC ACID, TYROSINE AND TRYPTOPHANE IN THE ISOLATED PERFUSED RAT BRAIN.
197967 01-06

LUMBAR CSF 5-HYDROXYINDOLEACETIC ACID AND HOMOVANILLIC ACID IN AFFECTIVE SYNDROMES.
202248 02-09

EFFECTS OF 5-HYDROXYINDOLEACETIC ACID ON ISOLATED CANINE CEREBRAL ARTERIES.
202799 02-03

CORRELATIONS BETWEEN CIRCADIAN CHANGES IN SERUM AMINO ACIDS OR BRAIN TRYPTOPHAN AND THE CONTENTS OF SEROTONIN AND 5-HYDROXYINDOLEACETIC ACID IN REGIONS OF THE RAT BRAIN.
210673 03-03

THE ORIGIN OF BLOOD 5-HYDROXYINDOLEACETIC (5-HIAA) ACID FOLLOWING L-HYDRAZINO-ALPHA-METHYLDOPA (MK-486).
217665 04-03

DEXTROMETHORPHAN INHIBITS 5-HYDROXYTRYPTAMINE UPTAKE BY HUMAN BLOOD PLATELETS AND DECREASES 5-HYDROXYINDOLEACETIC ACID CONTENT IN RAT BRAIN.
217964 04-03

5-HYDROXYINDOLES
CONJOINT NATIVE AND ORTHOPHTHALDIALDEHYDE CONDENSATE ASSAYS FOR THE FLUORIMETRIC DETERMINATION OF 5-HYDROXYINDOLES IN BRAIN.
195238 01-01

EFFECTS OF CHLORIMIPRAMINE ON EXPERIMENTALLY INDUCED CHANGES IN FOREBRAIN 5-HYDROXYINDOLES.
199966 02-03

COMPARISON OF THE OXIME AND THE HYDROXYLAMINE DERIVATIVES OF 4-CHLOROAMPHETAMINE AS DEPLETORS OF BRAIN 5-HYDROXYINDOLES.
200004 02-03

5-HYDROXYTRYPTAMINE
THE INFLUENCE OF CYPROHEPTADINE AND OF D-LYSERGAMIDE ON THE RISE IN TEMPERATURE INDUCED BY INTRACEREBROVENTRICULAR 5-HYDROXYTRYPTAMINE, NORADRENALINE AND DOPAMINE IN CONSCIOUS RABBITS.
193451 01-03

5-HYDROXYTRYPTAMINE IN PLATELETS AND BRAIN OF RABBITS TREATED CHRONICALLY WITH IMIPRAMINE, MORPHINE OR METHADONE.
194744 01-03

EFFECT OF CHRONIC TRANSECTION ON DOPAMINE, NORADRENALINE AND 5-HYDROXYTRYPTAMINE IN THE RAT SPINAL CORD.
195244 01-03

NORADRENALINE AND 5-HYDROXYTRYPTAMINE METABOLISM IN SIX AREAS OF RAT BRAIN DURING POST-AMPHETAMINE DEPRESSION.
195437 01-03

RELATIONSHIP BETWEEN ANALGESIC ACTION OF PETHIDINE AND ITS EFFECT ON THE BRAIN 5-HYDROXYTRYPTAMINE CONCENTRATION IN THE RATS OF DIFFERENT AGE.
196782 01-03

EFFECTS OF RESERPINE AND CHLORPROMAZINE ON 5-HYDROXYTRYPTAMINE UPTAKE OF PLATELETS FROM MIGRAINOUS AND CONTROL SUBJECTS.
196926 01-13

EFFECTS OF 5-HYDROXYTRYPTAMINE ON THE CEREBRAL BLOOD FLOW IN THE DOG.
197215 01-03

EFFECTS OF D-ISOMERS AND L-AMPHETAMINE ON 5-HYDROXYTRYPTAMINE RECEPTORS.
197481 01-04

LONG-TERM EFFECTS OF N-HYDROXY-4-CHLOROAMPHETAMINE ON THE LEVEL AND ACCUMULATION OF 5-HYDROXYTRYPTAMINE IN THE RAT BRAIN.
197869 01-03

EFFECTS OF SOCIAL STRESS ON THE TURNOVER OF BRAIN CATECHOLAMINES AND 5-HYDROXYTRYPTAMINE IN MICE.
198025 01-03

EFFECT OF PROGESTERONE ON REGIONAL 5-HYDROXYTRYPTAMINE METABOLISM IN THE RAT BRAIN.
199773 02-03

THE ROLE OF BRAIN DOPAMINE IN THE HYPERACTIVITY SYNDROME PRODUCED BY INCREASED 5-HYDROXYTRYPTAMINE SYNTHESIS IN RATS.
199960 02-04

INHIBITORY ROLE OF DOPAMINE AND 5-HYDROXYTRYPTAMINE IN THE SEXUAL BEHAVIOUR OF FEMALE RATS.
199968 02-04

THE ACCUMULATION OF NORADRENALINE AND 5-HYDROXYTRYPTAMINE IN THREE REGIONS OF MOUSE BRAIN AFTER TETRABENAZINE AND IPRONIAZID: EFFECTS OF ETHINYLESTRADIOL AND PROGESTERONE.
200058 02-03

ACTION OF (S)- AND (R) P-SUBSTITUTED AMPHETAMINE HYDROCHLORIDES AND (ALPHA S)- AND (ALPHA R) P-CHLORONOREPHEDRINE AND (ALPHA S)- AND (ALPHA R) P-CHLORONORPSEUDOEPHEDRINE HYDROCHLORIDES ON THE LEVEL OF 5-HYDROXYTRYPTAMINE AND THE ACTIVITY OF TRYPTOPHAN-HYDROXYLASE IN RAT BRAIN.
202417 02-03

THE RELATIVE SIGNIFICANCE OF NOREPINEPHRINE DOPAMINE AND 5-HYDROXYTRYPTAMINE IN THE ELECTROSHOCK SEIZURE IN THE RAT.
204339 02-03

A COMPARISON OF THE LOCOMOTOR EFFECTS OF 5-HYDROXYTRYPTAMINE AND 5-HYDROXYTRYPTOPHAN ADMINISTERED VIA TWO SYSTEMIC ROUTES.
206086 03-04

MODULATION OF THE RESPIRATORY DEPRESSANT EFFECT OF ETHANOL BY 5-HYDROXYTRYPTAMINE.
210751 03-03

POSSIBLE INVOLVEMENT OF 5-HYDROXYTRYPTAMINE IN THE ANTIDEPRESSANT ACTIVITY OF NARCOTIC ANALGESICS.
210761 03-03

THE EFFECT OF DIPHENYLHYDANTOIN ON BRAIN 5-HYDROXYTRYPTAMINE METABOLISM AND FUNCTION.
210764 03-03

EFFECT OF ERGOT DRUGS ON CENTRAL 5-HYDROXYTRYPTAMINE NEURONS: EVIDENCE FOR 5-HYDROXYTRYPTAMINE RELEASE OR 5-HYDROXYTRYPTAMINE RECEPTOR STIMULATION.
210857 03-03

5-HYDROXYTRYPTAMINE AS AN INHIBITORY MODULATOR IN AUDIOGENIC SEIZURE. (PH.D. DISSERTATION).
212521 03-03

THE ROLE OF 5-HYDROXYTRYPTAMINE IN THE CONTROL OF ALPHA AND GAMMA MOTONEURONS. (PH.D. DISSERTATION).
212522 03-03

INHIBITION OF SACRAL PARASYMPATHETIC PREGANGLIONIC NEURONS BY GABA, GLYCIN, 5-HYDROXYTRYPTAMINE AND NOREPINEPHRINE. (PH.D. DISSERTATION).
212524 03-03

CHLORPROMAZINE: SPECIFIC INHIBITION OF L-NORADRENALINE AND 5-HYDROXYTRYPTAMINE UPTAKE IN SYNAPTOSOMES FROM SQUID BRAIN.
213395 04-03

INHIBITION OF EFFERENT SYMPATHETIC NERVE ACTIVITY BY 5-HYDROXYTRYPTOPHAN AND CENTRALLY ADMINISTERED 5-HYDROXYTRYPTAMINE.
215712 04-03

INHIBITION OF CATECHOLAMINE AND 5-HYDROXYTRYPTAMINE INDUCED ENZYME SECRETION FROM THE GUINEA-PIG SUBMANDIBULAR GLAND BY 2-BROMO-D-LYSERGIC ACID DIETHYLAMIDE.
216968 04-03

THE EFFECTS OF CHRONIC CANNABIS TREATMENT UPON BRAIN 5-HYDROXYTRYPTAMINE, PLASMA CORTICOSTERONE AND AGGRESSIVE BEHAVIOR IN FEMALE RATS WITH DIFFERENT HORMONAL STATUS.
217532 04-04

EFFECT OF BUTRIPTYLINE ON THE BRAIN UPTAKE MECHANISMS FOR NORADRENALINE AND 5-HYDROXYTRYPTAMINE.
217688 04-03

INHIBITION OF HUMAN PLATELET 5-HYDROXYTRYPTAMINE UPTAKE BY BETA-PHENETHYLAMINE DERIVATIVES.
217689 04-13

INFLUENCE OF SOME TRICYCLIC ANTIDEPRESSIVE DRUGS ON THE UPTAKE OF 5-HYDROXYTRYPTAMINE BY RAT BLOOD PLATELETS.
217693 04-03

ACETYLCHOLINE ACTIVITY IN AN IDENTIFIED 5-HYDROXYTRYPTAMINE CONTAINING NEURON.
217825 04-03

5-HYDROXYTRYPTAMINE IN THE CENTRAL NERVOUS SYSTEM AND SEXUAL RECEPTIVITY OF FEMALE RHESUS MONKEYS.
217856 04-04

LONG-LASTING REDUCTION OF BRAIN 5-HYDROXYTRYPTAMINE CONCENTRATION BY 3-CHLOROAMPHETAMINE AND 4-CHLOROAMPHETAMINE IN IPRINDOLE TREATED RATS.
217879 04-03

EFFECT OF SOME ANORECTIC AGENTS ON THE UPTAKE AND RELEASE OF 5-HYDROXYTRYPTAMINE BY BLOOD PLATELETS OF RATS.
217890 04-03

UPTAKE AND DISAPPEARANCE OF 4-METHYL-ALPHA-ETHYLMETATYRAMINE IN RELATION TO ITS RELEASING ACTION ON 5-HYDROXYTRYPTAMINE IN THE BRAIN.
217897 04-03

CHANGES IN THE CONCENTRATIONS OF 5-HYDROXYTRYPTAMINE AND NORADRENALINE IN SIX AREAS OF RAT BRAIN DURING RECOVERY FROM CHRONIC METHYLAMPHETAMINE ADMINISTRATION.
217963 04-03

DEXTROMETHORPHAN INHIBITS 5-HYDROXYTRYPTAMINE UPTAKE BY HUMAN BLOOD PLATELETS AND DECREASES 5-HYDROXYINDOLEACETIC ACID CONTENT IN RAT BRAIN.
217964 04-03

REGIONAL DISTRIBUTION OF MONOAMINEOXIDASE ACTIVITY FOR 5-HYDROXYTRYPTAMINE AND TYRAMINE IN THE HYPOTHALAMUS OF THE RAT.
223049 04-03

5-HYDROXYTRYPTAMINE-14C

5-HYDROXYTRYPTAMINE-14C AND DEXAMPHETAMINE-14C UPTAKE BY FUNDAL SARCOLEMMA PREPARATIONS AND THE PROBLEM OF THE COMMON RECEPTOR.
213591 04-03

5-HYDROXYTRYPTOPHAN

MURICIDAL BLOCK INDUCED BY 5-HYDROXYTRYPTOPHAN IN THE RAT.
197454 01-04

5-HYDROXYTRYPTOPHAN IN COMBINATION WITH CLOMIPRAMINE IN THERAPY RESISTANT DEPRESSIONS.
198229 02-09

EFFECTS OF 5-HYDROXYTRYPTOPHAN ON SLEEP OF A PATIENT WITH A BRAINSTEM LESION.
199757 02-13

EFFECTS OF 5-HYDROXYTRYPTOPHAN, IPRONIAZID AND P-CHLOROPHENYLALANINE ON LIDOCAINE SEIZURE THRESHOLD OF MICE.
199962 02-03

STUDIES ON THE INTERACTION OF RESERPINE, D-AMPHETAMINE, APOMORPHINE AND 5-HYDROXYTRYPTOPHAN.
203885 02-03

A COMPARISON OF THE LOCOMOTOR EFFECTS OF 5-HYDROXYTRYPTAMINE AND 5-HYDROXYTRYPTOPHAN ADMINISTERED VIA TWO SYSTEMIC ROUTES.
206086 03-04

THE EFFECT OF 5-HYDROXYTRYPTOPHAN ON FOOD INTAKE AND ON THE ANOREXIC ACTION OF AMPHETAMINE AND FENFLURAMINE.
210748 03-04

INHIBITION OF EFFERENT SYMPATHETIC NERVE ACTIVITY BY 5-HYDROXYTRYPTOPHAN AND CENTRALLY ADMINISTERED 5-HYDROXYTRYPTAMINE.
215712 04-03

CENTRALLY MEDIATED CARDIOVASCULAR EFFECTS OF 5-HYDROXYTRYPTOPHAN IN MAO INHIBITED DOGS: MODIFICATION BY AUTONOMIC ANTAGONISTS.
215757 04-03

THE ROLE OF THE AMYGDALA IN THE DEPRESSIVE ACTION OF SEROTONIN AND 5-HYDROXYTRYPTOPHAN ON THE CONDITIONED ACTIVITY OF WHITE RATS.
219328 04-04

5-HYDROXYTRYPTOPHAN-INDUCED

ACTION OF PROBENECID ON THE CENTRAL NERVOUS SYSTEM OF THE RABBIT: II. POTENTIATION OF 5-HYDROXYTRYPTOPHAN-INDUCED HYPERTHERMIA AND SUPPRESSION OF THIS EFFECT BY A DECARBOXYLASE INHIBITOR (RO-4-4602).
196580 01-03

5-IMIDAZOLONES

MONOAMINEOXIDASE INHIBITORY AND ANTICONVULSANT PROPERTIES OF 1,2,4 TRISUBSTITUTED 5-IMIDAZOLONES.
225105 04-01

5-METHOXYDIMETHYLTRYPTAMINE

EVIDENCE THAT 5-METHOXYDIMETHYLTRYPTAMINE IS A SPECIFIC SUBSTRATE FOR MAO-A IN THE RAT: IMPLICATIONS FOR THE INDOLEAMINE DEPENDENT BEHAVIORAL SYNDROME.
210817 03-04

5-6-DHT

DRUG-INDUCED ROTATION IN RATS AFTER UNILATERAL INTRACEREBRAL INJECTION OF 5,6 DIHYDROXYTRYPTAMINE (5-6-DHT).
192940 01-03

SIMILAR ACTIONS OF INTRAHYPOTHALAMIC 5-6-DHT AND 5-HT IN EVOKING HYPERTHERMIA IN THE MONKEY.
200034 02-03

6-CHLORO-2-AMINOTETRALIN

6-CHLORO-2-AMINOTETRALIN, A RIGID CONFORMATIONAL ANALOG OF 4-CHLOROAMPHETAMINE: PHARMACOLOGIC PROPERTIES OF IT AND RELATED COMPOUNDS IN RATS.
210870 03-02

6-HYDROXYDOPA
6-HYDROXYDOPA DURING DEVELOPMENT OF CENTRAL ADRENERGIC NEURONS PRODUCES DIFFERENT LONG-TERM CHANGES IN RAT BRAIN NORADRENALINE.
217867 04-03

6-HYDROXYDOPAMINE
EFFECT OF 6-HYDROXYDOPAMINE ON HYPOTHALAMIC NOREPINEPHRINE AND DOPAMINE CONTENT, ULTRASTRUCTURE OF THE MEDIAN EMINENCE, AND PLASMA CORTICOSTERONE.
193050 01-03
THE INEFFECTIVENESS OF DESIPRAMINE PRETREATMENT ON BEHAVIORAL EFFECTS OF 6-HYDROXYDOPAMINE IN NIALAMIDE PRETREATED RATS.
195434 01-04
6-HYDROXYDOPAMINE INDUCED DEGENERATION OF NORADRENALINE NEURONS IN THE SCORBUTIC GUINEA-PIG.
195449 01-03
POTENTIATION OF AMYGDALOID KINDLING AND METRAZOL-INDUCED SEIZURES BY 6-HYDROXYDOPAMINE IN RATS.
195907 01-03
EFFECTS OF RESERPINE, 6-HYDROXYDOPAMINE, P-CHLOROPHENYLALANINE AND A COMBINATION OF THESE SUBSTANCES ON THE GROOMING BEHAVIOUR OF MICE.
197291 01-04
EFFECT OF 6-HYDROXYDOPAMINE ON THE LEVEL OF THE CATECHOLAMINES IN THE BRAIN OF DEVELOPING RATS.
197449 01-03
THE EFFECT OF 6-HYDROXYDOPAMINE ADMINISTRATION TO NEONATAL RATS ON SOME ENDOCRINE AND BEHAVIORAL PARAMETERS.
197498 01-03
NEONATAL CHEMICAL SYMPATHECTOMY: FUNCTIONAL CONTROL OF DENERVATION OF THE VASCULAR SYSTEM AND TISSUE NORADRENALINE LEVEL IN THE RAT AFTER 6-HYDROXYDOPAMINE.
197584 01-03
EVIDENCE THAT PUNCTUATE INTRACEREBRAL ADMINISTRATION OF 6-HYDROXYDOPAMINE FAILS TO PRODUCE SELECTIVE NEURONAL DEGENERATION: COMPARISON WITH COPPER SULFATE AND FACTORS GOVERNING THE DEPORTMENT OF FLUIDS INJECTED INTO BRAIN.
197931 01-03
THE EFFECTS OF 6-HYDROXYDOPAMINE AND GUANETHIDINE ON PERIPHERAL ADRENERGIC NERVES IN THE GUINEA-PIG.
199862 02-03
6-HYDROXYDOPAMINE LESIONS OF OLFACTORY TUBERCLES AND CAUDATE NUCLEI: EFFECT ON AMPHETAMINE-INDUCED STEREOTYPED BEHAVIOR IN RATS.
202788 02-04
APOMORPHINE AND AMPHETAMINE STEREOTYPY AFTER 6-HYDROXYDOPAMINE LESIONS OF THE SUBSTANTIA-NIGRA.
202793 02-04
INCREASED FIXED-RATIO PERFORMANCE AND DIFFERENTIAL D- AND L-AMPHETAMINE ACTION FOLLOWING NOREPINEPHRINE DEPLETION BY INTRAVENTRICULAR 6-HYDROXYDOPAMINE.
204482 02-04
SUPERSENSITIVITY TO DOPAMINE AGONISTS FOLLOWING UNILATERAL, 6-HYDROXYDOPAMINE INDUCED STRIATAL LESIONS IN MICE.
208552 03-03
CHOLINERGIC DOPAMINERGIC INTERACTION IN THE STRIATUM: THE EFFECT OF 6-HYDROXYDOPAMINE OR PIMOZIDE TREATMENT ON THE INCREASED STRIATAL ACETYLCHOLINE LEVELS INDUCED BY APOMORPHINE, PIRIBEDIL AND D-AMPHETAMINE.
210668 03-03
FEEDING BEHAVIOR IN SHEEP: EFFECTS OF NIALAMIDE AND 6-HYDROXYDOPAMINE.
210743 03-04
NEONATAL 6-HYDROXYDOPAMINE TREATMENT: NORADRENALINE LEVELS AND IN VITRO 3H-CATECHOLAMINE SYNTHESIS IN DISCRETE BRAIN REGIONS OF ADULT RATS.
210759 03-03
CHANGED EATING AND LOCOMOTOR BEHAVIOUR IN THE RAT AFTER 6-HYDROXYDOPAMINE LESIONS TO THE SUBSTANTIA-NIGRA.
210763 03-04
EFFECT OF MIDBRAIN RAPHE LESION AND OF 6-HYDROXYDOPAMINE ON THE ANTINOCICEPTIVE ACTION OF BUPRENORPHINE IN RATS.
210923 03-03
EFFECTS OF 6-HYDROXYDOPAMINE AND RESERPINE ON AMPHETAMINE-INDUCED RELEASE OF NOREPINEPHRINE IN RAT CEREBRAL CORTEX.
215691 04-03
LOSS OF ACTIVE AVOIDANCE RESPONDING AFTER LATERAL HYPOTHALAMIC INJECTIONS OF 6-HYDROXYDOPAMINE.
215704 04-04
BEHAVIOURAL SUPERSENSITIVITY TO APOMORPHINE FOLLOWING CEREBRAL DOPAMINERGIC DENERVATION BY 6-HYDROXYDOPAMINE.
217527 04-03
LACK OF EFFECT OF PROTRIPTYLINE ON THE 6-HYDROXYDOPAMINE INDUCED NORADRENALINE DEPLETION IN THE RAT SPINAL CORD.
217824 04-03
6-HYDROXYDOPAMINE AND STRIATAL ACETYLCHOLINE LEVELS.
217842 04-03
THE EFFECT OF 6-HYDROXYDOPAMINE ON THE TOLERANCE DEVELOPMENT TO THE HYPERTHERMIC EFFECT OF (+) AMPHETAMINE IN THE RAT.
217965 04-03
THE EFFECT OF 6-HYDROXYDOPAMINE AND RESERPINE ON THE MOBILIZATION OF CARBOHYDRATES AND FATS IN STIMULATED RATS.
219504 04-03
6-HYDROXYDOPAMINE AND AVOIDANCE: A BEHAVIORAL AND PHARMACOLOGICAL ANALYSIS. (PH.D. DISSERTATION).
220674 04-04
BEHAVIORAL EFFECTS OF LOCAL INJECTION OF 6-HYDROXYDOPAMINE IN THE MEDIAL VENTRAL TEGMENTUM IN THE RAT. POSSIBLE ROLE OF THE MESOLIMBIC DOPAMINERGIC SYSTEM.
220946 04-04

6-METHOXYTETRAHYDRO-BETA-CARBOLINE
6-METHOXYTETRAHYDRO-BETA-CARBOLINE PRODUCES A RETENTION DEFICIT FOR ONE-TRIAL PASSIVE AVOIDANCE IN MICE.
217833 04-04

7-CHLORO-1-PROPARGYL-5-PHENYLBENZODIAZEPIN-2-ONE
TOXICOLOGICAL AND PHARMACOLOGICAL INVESTIGATIONS OF PINAZEPAM (7-CHLORO-1-PROPARGYL-5-PHENYLBENZODIAZEPIN-2-ONE): A NEW THERAPEUTIC AGENT.
221723 04-02

7-CHLORO-5-PHENYLBENZODIAZEPIN-2-ONE
ELECTROENCEPHALOGRAPHIC STUDY FOR THE EVALUATION OF THE EFFECTS OF 7-CHLORO-5-PHENYLBENZODIAZEPIN-2-ONE (N-DEMETHYLDIAZEPAM) ON SLEEP DISTURBANCES IN A GROUP OF MENTAL PATIENTS.
221272 04-14

7-CHLORODIHYDROBENZODIAZEPIN-2-ONE
THE SYNTHESIS AND PHARMACOLOGY OF A NOVEL BENZODIAZEPINE DERIVATIVE, 1-METHYL-5-O-FLUOROPHENYL 7-CHLORODIHYDROBENZODIAZEPIN-2-ONE (ID-540).
206780 03-02
ELECTROPHYSIOLOGICAL AND BEHAVIORAL EFFECTS OF 1-METHYL-5-O-FLUOROPHENYL 7-CHLORODIHYDROBENZODIAZEPIN-2-ONE (ID-540) IN CATS AND RABBITS.
221736 04-03
THE SYNTHESIS AND PHARMACOLOGY OF A NOVEL BENZODIAZEPINE DERIVATIVE, 1-BETA-METHYLSULFONYLETHYL-5-O-FLUOROPHENYL 7-CHLORODIHYDROBENZODIAZEPIN-2-ONE (ID-622).
221741 04-02

7-HYDROXY-DELTA1-TETRAHYDROCANNBINOL
BINDING OF (+) AMPHETAMINE AND (-) DELTA1-TETRAHYDROCANNABINOLS AND (-) 7-HYDROXY-DELTA1-TETRAHYDROCANNBINOL TO BLOOD CELLS AND PLASMA PROTEINS IN MAN.
217878 04-13

77BR
IN VIVO HUMAN PHARMACODYNAMICS OF THE PSYCHODYSLEPTIC 4-BR-DIMETHOXYPHENYLISOPROPYLAMINE LABELLED WITH 82BR OR 77BR.
215710 04-13

8-CHLOR-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE
NEUROPHARMACOLOGICAL STUDIES OF EFFECT OF NEW CENTRAL DEPRESSANT, 8-CHLOR-6-PHENYL-4H-S-TRIAZOLOBENZODIAZEPINE (D40TA) ON EEG AND CENTRAL SYMPATHETIC ACTIVATING MECHANISM IN CATS.
195549 01-03

82BR
IN VIVO HUMAN PHARMACODYNAMICS OF THE PSYCHODYSLEPTIC 4-BR-DIMETHOXYPHENYLISOPROPYLAMINE LABELLED WITH 82BR OR 77BR.
215710 04-13

Computer Information Services of the National Clearinghouse for Mental Health Information

Searches of the NCMHI computer-based information system will be done on request. These reader-generated bibliographies are available without charge to anyone within the mental health community.

Requests for a printout on a topic not covered by the abstracts in this issue or other NCMHI publications should be sent directly to the Clearinghouse. The request should include the inquirer's name, address, professional affiliation, and phone number, along with a clear and specific statement of the information desired. Either a letter or the order blank below should be sent to the following address:

National Clearinghouse for Mental
Health Information
Alcohol, Drug Abuse, and
Mental Health Administration
5600 Fishers Lane
Rockville, Maryland 20852

Date _____

Name of requester _____

Address _____

Organization _____

Phone number (include area code) _____

Information requested (please be as specific as possible) _____

_____

_____

_____

_____

*U.S. GOVERNMENT PRINTING OFFICE: 1976 627-220/570 1-3

DEPARTMENT OF
HEALTH, EDUCATION, AND WELFARE
PUBLIC HEALTH SERVICE
ALCOHOL, DRUG ABUSE, AND
MENTAL HEALTH ADMINISTRATION
5600 FISHERS LANE
ROCKVILLE, MARYLAND 20852

OFFICIAL BUSINESS
Penalty for private use, $300

POSTAGE AND FEES PAID
U.S. DEPARTMENT OF H.E.W.
HEW 389

Special 4th class
rate book

U.S. MAIL

NOTICE OF MAILING CHANGE

☐ Check here if you wish to discontinue receiving this type of publication.

☐ Check here if your address has changed and you wish to continue receiving this type of publication. (Be sure to furnish your complete address including zip code.)

Tear off cover with address label still affixed and send to:

Alcohol, Drug Abuse, and Mental Health Administration
Printing and Publications Management Section
5600 Fishers Lane (Rm. 6-105)
Rockville, Maryland 20852

DHEW Publication No. (ADM) 76-150
Printed 1976